<SEC-DOCUMENT>0001140361-20-004500.txt : 20200302
<SEC-HEADER>0001140361-20-004500.hdr.sgml : 20200302
<ACCEPTANCE-DATETIME>20200302140447
ACCESSION NUMBER:		0001140361-20-004500
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		120
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200302
DATE AS OF CHANGE:		20200302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IONIS PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000874015
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330336973
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19125
		FILM NUMBER:		20676005

	BUSINESS ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010
		BUSINESS PHONE:		7609319200

	MAIL ADDRESS:	
		STREET 1:		2855 GAZELLE COURT
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ISIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10k.htm
<DESCRIPTION>IONIS PHARMACEUTICALS, INC. 10-K 12-31-2019
<TEXT>
<XBRL>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:ions="http://isispharm.com/20191231" xmlns="http://www.w3.org/1999/xhtml">
<head>
  <title></title>
  <meta http-equiv="Content-Type" content="text/html" />
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_6104fbc79d0047928ce0530c29121038" contextRef="c20190101to20191231">0000874015</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" id="Fact_f736aac1be9d44d8a7c970cdeb69b081" contextRef="c20190101to20191231" format="ixt:datemonthday">12-31</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_8a77f6f4ebb346e7ac84078a365dacec" contextRef="c20190101to20191231" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" id="Fact_51bbeb4c096d4ab2a5fb40142600a2e8" contextRef="c20190101to20191231">2019</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" id="Fact_89ca9da358684bde912e758d7d33270c" contextRef="c20190101to20191231">FY</ix:nonNumeric><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" id="Fact_814732dbfffb4dbbb487265b1d09e7b7" contextRef="c20170101to20170630_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="U003" decimals="INF">0.06</ix:nonFraction><ix:nonNumeric name="ions:PeriodAfterBillingWhenPaymentIsReceived" id="Fact_5acf7b3d4ee04d009d32a31d9e4ded77" contextRef="c20190101to20191231">P3M</ix:nonNumeric><ix:nonFraction name="us-gaap:InventoryWriteDown" id="Fact_1261d93c836d4d94bba4bd8c45f1e569" contextRef="c20190101to20191231" unitRef="U001" xsi:nil="true"></ix:nonFraction><ix:nonNumeric name="ions:MaximumContractMaturityPeriodRange3" id="Fact_5b50da2d62974df399b2ebfcfccf0c30" contextRef="c20190101to20191231">P3Y6M</ix:nonNumeric><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_5720e35e625f4851a419d661f07222c0" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes275PercentMember" unitRef="U003" decimals="INF">0.0275</ix:nonFraction><ix:nonNumeric name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="Fact_f81ca57385a04657b8ecd0f06d505159" contextRef="c20191231">us-gaap:OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Fact_530181678e9244af8b37885d3ba85980" contextRef="c20191231">us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="Fact_9c37cb3853f74a4f821bbe4ed37a06ba" contextRef="c20191231">ions:LongTermObligationsNoncurrent</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ions-20191231.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c20190101to20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0125PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0125PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ProductOrServiceAxis_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ProductOrServiceAxis_SPINRAZARoyaltiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ProductOrServiceAxis_CommercialMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ProductOrServiceAxis_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ProductOrServiceAxis_CommercialMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ProductOrServiceAxis_CommercialMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ProductOrServiceAxis_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ProductOrServiceAxis_SPINRAZARoyaltiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ProductOrServiceAxis_SPINRAZARoyaltiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20161231_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20161231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20161231_StatementEquityComponentsAxis_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20161231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20161231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20161231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_StatementEquityComponentsAxis_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_StatementEquityComponentsAxis_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_StatementEquityComponentsAxis_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:NovartisInternationalAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:NovartisInternationalAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:BiogenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:BiogenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:BiogenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:NovartisInternationalAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:BiogenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:BiogenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:NovartisInternationalAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:NovartisInternationalAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:BiogenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:NovartisInternationalAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:NovartisInternationalAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:BiogenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_StatementEquityComponentsAxis_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20171231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_StatementEquityComponentsAxis_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20171231_StatementEquityComponentsAxis_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_StatementEquityComponentsAxis_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20171231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_MajorCustomersAxis_BiogenIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ions:BiogenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_MajorCustomersAxis_NovartisInternationalAGMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ions:NovartisInternationalAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_MajorCustomersAxis_NovartisInternationalAGMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ions:NovartisInternationalAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_MajorCustomersAxis_NovartisInternationalAGMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ions:NovartisInternationalAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_MajorCustomersAxis_BiogenIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ions:BiogenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_MajorCustomersAxis_BiogenIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ions:BiogenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsRocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_OwnershipAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_OwnershipAxis_AkceaTherapeuticsIncMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_OwnershipAxis_AkceaTherapeuticsIncMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20170630_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_ConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_ConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_StatementClassOfStockAxis_ConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190701to20190930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181001to20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170201to20170228_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-01</xbrli:startDate><xbrli:endDate>2017-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20150501to20150531_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-05-01</xbrli:startDate><xbrli:endDate>2015-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190401to20190630_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170701to20170930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170228_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20170228_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20180401to20180630_MajorCustomersAxis_BiogenIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ions:BiogenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170630_OwnershipAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190101to20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181231_PublicUtilitiesInventoryAxis_ClinicalRawMaterialsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">ions:ClinicalRawMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_PublicUtilitiesInventoryAxis_ClinicalRawMaterialsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">ions:ClinicalRawMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_PublicUtilitiesInventoryAxis_CommercialRawMaterialsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">ions:CommercialRawMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_PublicUtilitiesInventoryAxis_CommercialRawMaterialsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">ions:CommercialRawMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_PropertyPlantAndEquipmentByTypeAxis_LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentExcludingLandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:PropertyPlantAndEquipmentExcludingLandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_PropertyPlantAndEquipmentByTypeAxis_LandImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_PropertyPlantAndEquipmentByTypeAxis_LandImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndComputerSoftwareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:EquipmentAndComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_PropertyPlantAndEquipmentByTypeAxis_LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentExcludingLandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:PropertyPlantAndEquipmentExcludingLandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndComputerSoftwareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:EquipmentAndComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndComputerSoftwareMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:EquipmentAndComputerSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndComputerSoftwareMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:EquipmentAndComputerSoftwareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_LandImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201602Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20161231_StatementEquityComponentsAxis_AociIncludingPortionAttributableToNoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20171231_StatementEquityComponentsAxis_AociIncludingPortionAttributableToNoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_StatementEquityComponentsAxis_AociIncludingPortionAttributableToNoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_StatementEquityComponentsAxis_AociIncludingPortionAttributableToNoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_BalanceSheetLocationAxis_CashAndCashEquivalentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_BalanceSheetLocationAxis_CashAndCashEquivalentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_BalanceSheetLocationAxis_CashAndCashEquivalentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_BalanceSheetLocationAxis_CashAndCashEquivalentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_InvestmentTypeAxis_DebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfMoreThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_DebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfMoreThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_DebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfMoreThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfMoreThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfMoreThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfMoreThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfMoreThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_InvestmentTypeAxis_DebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfMoreThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_DebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfMoreThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_DebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfMoreThanOneYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_InvestmentTypeAxis_EquitySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_BalanceSheetLocationAxis_DepositsAndOtherAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ions:DepositsAndOtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_BalanceSheetLocationAxis_OtherCurrentAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_BalanceSheetLocationAxis_OtherCurrentAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_InvestmentSecondaryCategorizationAxis_IncludedInOtherCurrentAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:IncludedInOtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_InvestmentTypeAxis_EquitySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_InvestmentTypeAxis_EquitySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_InvestmentSecondaryCategorizationAxis_IncludedInDepositsAndOtherAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:IncludedInDepositsAndOtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_InvestmentSecondaryCategorizationAxis_IncludedInOtherCurrentAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:IncludedInOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_InvestmentSecondaryCategorizationAxis_IncludedInDepositsAndOtherAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:IncludedInDepositsAndOtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_InvestmentTypeAxis_EquitySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_InvestmentTypeAxis_USTreasurySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_InvestmentTypeAxis_CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_DebtInstrumentAxis_LongTermMortgageDebtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:LongTermMortgageDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_DebtInstrumentAxis_FixedRateNoteWithMorganStanleyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:FixedRateNoteWithMorganStanleyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_DebtInstrumentAxis_FixedRateNoteWithMorganStanleyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:FixedRateNoteWithMorganStanleyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_DebtInstrumentAxis_LeasesAndOtherObligationsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:LeasesAndOtherObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_DebtInstrumentAxis_LeasesAndOtherObligationsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:LeasesAndOtherObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_DebtInstrumentAxis_LongTermMortgageDebtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:LongTermMortgageDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20141130_DebtInstrumentAxis_ConvertibleSeniorNotes275PercentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes275PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20161231_DebtInstrumentAxis_ConvertibleSeniorNotes275PercentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes275PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20161231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20141130_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191201to20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0125PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes275PercentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes275PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0125PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191201to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0125PercentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_CreditFacilityAxis_RevolvingCreditFacilityMember_LineOfCreditFacilityAxis_MorganStanleyPrivateBankNationalAssociationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ions:MorganStanleyPrivateBankNationalAssociationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_CreditFacilityAxis_RevolvingCreditFacilityMember_LineOfCreditFacilityAxis_MorganStanleyPrivateBankNationalAssociationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ions:MorganStanleyPrivateBankNationalAssociationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190701to20190930_DebtInstrumentAxis_FixedRateNoteWithMorganStanleyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:FixedRateNoteWithMorganStanleyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170701to20170731_PropertyPlantAndEquipmentByTypeAxis_PrimaryResearchAndDevelopmentFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:PrimaryResearchAndDevelopmentFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170701to20170731_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170731_DebtInstrumentAxis_LongTermMortgageDebtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:LongTermMortgageDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20170731_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20170731_PropertyPlantAndEquipmentByTypeAxis_PrimaryResearchAndDevelopmentFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:PrimaryResearchAndDevelopmentFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_PrimaryResearchAndDevelopmentFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:PrimaryResearchAndDevelopmentFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170701to20170930_PropertyPlantAndEquipmentByTypeAxis_PrimaryResearchAndDevelopmentFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:PrimaryResearchAndDevelopmentFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:OfficeSpaceSubleasedToAkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceForCorporateHeadquartersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:OfficeSpaceForCorporateHeadquartersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_PropertyPlantAndEquipmentByTypeAxis_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:OfficeSpaceSubleasedToAkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceForCorporateHeadquartersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:OfficeSpaceForCorporateHeadquartersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_StatementClassOfStockAxis_PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_StatementClassOfStockAxis_SeriesCPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_StatementClassOfStockAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_StatementClassOfStockAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_StatementClassOfStockAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_StatementClassOfStockAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_StatementClassOfStockAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200302_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20150630_PlanNameAxis_EquityIncentivePlan2011Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EquityIncentivePlan2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20170531_PlanNameAxis_EquityIncentivePlan2011Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EquityIncentivePlan2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_PlanNameAxis_StockOptionPlan1989Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:StockOptionPlan1989Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20150531_PlanNameAxis_EquityIncentivePlan2011Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EquityIncentivePlan2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190630_PlanNameAxis_EquityIncentivePlan2011Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EquityIncentivePlan2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20150630_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:NonemployeeDirectorsStockOptionPlan2002Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20150531_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:NonemployeeDirectorsStockOptionPlan2002Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_PlanNameAxis_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_PlanNameAxis_StockOptionPlan1989Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:StockOptionPlan1989Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2011Member_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EquityIncentivePlan2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2011Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EquityIncentivePlan2011Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_AwardTypeAxis_StockOptionMember_PlanNameAxis_EquityIncentivePlan2011Member_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EquityIncentivePlan2011Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_AwardTypeAxis_StockOptionMember_PlanNameAxis_StockOptionPlan1989Member_VestingAxis_ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:StockOptionPlan1989Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_AwardTypeAxis_StockOptionMember_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member_VestingAxis_ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:NonemployeeDirectorsStockOptionPlan2002Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:NonemployeeDirectorsStockOptionPlan2002Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:NonemployeeDirectorsStockOptionPlan2002Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_PlanNameAxis_EquityIncentivePlan2011Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EquityIncentivePlan2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_PlanNameAxis_EquityIncentivePlan2011Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EquityIncentivePlan2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member_VestingAxis_ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:NonemployeeDirectorsStockOptionPlan2002Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_PlanNameAxis_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20090601to20090630_PlanNameAxis_EmployeeStockPurchasePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-06-01</xbrli:startDate><xbrli:endDate>2009-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181231_AwardTypeAxis_StockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_AwardTypeAxis_StockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_AwardTypeAxis_StockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_AwardTypeAxis_StockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_AwardTypeAxis_StockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_IncomeStatementLocationAxis_ResearchDevelopmentAndPatentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ions:ResearchDevelopmentAndPatentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190701to20190930_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_IncomeStatementLocationAxis_ResearchDevelopmentAndPatentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ions:ResearchDevelopmentAndPatentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_IncomeStatementLocationAxis_ResearchDevelopmentAndPatentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ions:ResearchDevelopmentAndPatentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_IncomeStatementLocationAxis_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_IncomeStatementLocationAxis_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_IncomeStatementLocationAxis_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_AwardTypeAxis_BoardOfDirectorStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ions:BoardOfDirectorStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ions:BoardOfDirectorStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_AwardTypeAxis_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ions:BoardOfDirectorStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_AwardTypeAxis_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ions:BoardOfDirectorStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_AwardTypeAxis_BoardOfDirectorStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ions:BoardOfDirectorStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_AwardTypeAxis_EmployeeStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_AwardTypeAxis_BoardOfDirectorStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ions:BoardOfDirectorStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181001to20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_IncomeTaxAuthorityNameAxis_CaliforniaFranchiseTaxBoardMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_IncomeTaxAuthorityNameAxis_InternalRevenueServiceIRSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_IncomeTaxAuthorityNameAxis_InternalRevenueServiceIRSMember_TaxCreditCarryforwardAxis_ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_IncomeTaxAuthorityNameAxis_CaliforniaFranchiseTaxBoardMember_TaxCreditCarryforwardAxis_ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20180401to20180630_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_ProductOrServiceAxis_SPINRAZARoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_RangeAxis_MaximumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20130901to20130930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-09-01</xbrli:startDate><xbrli:endDate>2013-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20121201to20121231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-12-01</xbrli:startDate><xbrli:endDate>2012-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20171201to20171231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20180430_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20130930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20171231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_ProductOrServiceAxis_IONISMAPTMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:IONISMAPTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_ProductOrServiceAxis_MedicinesForUndisclosedTargetsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:MedicinesForUndisclosedTargetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_ProductOrServiceAxis_MedicinesForAmyotrophicLateralSclerosisMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:MedicinesForAmyotrophicLateralSclerosisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191201to20191231_ProductOrServiceAxis_MedicinesForAmyotrophicLateralSclerosisMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:MedicinesForAmyotrophicLateralSclerosisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_ProductOrServiceAxis_AntisenseMoleculeMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:AntisenseMoleculeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20121231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190401to20190630_ProductOrServiceAxis_IONISMAPTMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:IONISMAPTMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181001to20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191231_ProductOrServiceAxis_IONISMAPTMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:IONISMAPTMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181001to20181231_ProductOrServiceAxis_TofersenMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:TofersenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ProductOrServiceAxis_SPINRAZARoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191231_ProductOrServiceAxis_ION581Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ION581Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180701to20180930_ProductOrServiceAxis_IONISC9Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:IONISC9Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ProductOrServiceAxis_SPINRAZARoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181001to20181231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191231_ProductOrServiceAxis_IONISC9Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:IONISC9Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190701to20190930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20200101to20200226_SubsequentEventTypeAxis_SubsequentEventMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-02-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ProductOrServiceAxis_SPINRAZARoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190701to20190930_ProductOrServiceAxis_ION859Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ION859Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20150701to20150731_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-07-01</xbrli:startDate><xbrli:endDate>2015-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20121201to20121231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-12-01</xbrli:startDate><xbrli:endDate>2012-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_RangeAxis_MaximumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20121231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20150731_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20180101to20180331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20140331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181001to20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181001to20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181001to20181231_ProductOrServiceAxis_ION736Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ION736Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181001to20181231_ProductOrServiceAxis_DanvatirsenMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:DanvatirsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20180331_ProductOrServiceAxis_ION532Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ION532Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20180331_ProductOrServiceAxis_ION839Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ION839Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180701to20180930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20150401to20150630_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-04-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20150531_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20170201to20170228_ProductOrServiceAxis_ResearchAndDevelopmentServicesForIONISFXILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentServicesForIONISFXILMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-01</xbrli:startDate><xbrli:endDate>2017-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170201to20170228_ProductOrServiceAxis_IONISFXILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:IONISFXILMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-01</xbrli:startDate><xbrli:endDate>2017-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170228_ProductOrServiceAxis_IONISFXILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:IONISFXILMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20170228_ProductOrServiceAxis_ResearchAndDevelopmentServicesForIONISFXILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentServicesForIONISFXILMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20100301to20100331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-03-01</xbrli:startDate><xbrli:endDate>2010-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190701to20190930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20141231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20141201to20141231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-12-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20171101to20171130_ProductOrServiceAxis_IONISJBI225Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:IONISJBI225Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20130401to20130430_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-04-01</xbrli:startDate><xbrli:endDate>2013-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181001to20181031_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20190331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181031_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20130430_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsRocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsRocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20171001to20171231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsRocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsRocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsRocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsRocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsRocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsRocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20170101to20170331_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190201to20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:AKCEAAPOALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:AKCEAAPOALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20170331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170331_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20170701to20170731_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20170331_ProductOrServiceAxis_DeliveryOfAKCEAAPOCIIILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:DeliveryOfAKCEAAPOCIIILMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20170331_ProductOrServiceAxis_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20170331_ProductOrServiceAxis_DeliveryOfAKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:DeliveryOfAKCEAAPOALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20170331_ProductOrServiceAxis_ResearchAndDevelopmentServicesForAKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentServicesForAKCEAAPOALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190201to20190228_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_LicenseMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_ResearchAndDevelopmentServicesForMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentServicesForMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAANGPTL3LActivePharmaceuticalIngredientMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:AKCEAANGPTL3LActivePharmaceuticalIngredientMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAANGPTL3LMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:AKCEAANGPTL3LMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAANGPTL3LMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:AKCEAANGPTL3LMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190401to20190630_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180701to20180930_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180831_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_TegsediMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:TegsediMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190401to20190630_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_WaylivraMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:WaylivraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180701to20180930_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_LicenseMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ProductMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_CommercialMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ProductMember_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_CommercialMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_CommercialMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ProductMember_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ProductMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191231_ConsolidationItemsAxis_IntersegmentEliminationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20181231_ConsolidationItemsAxis_IntersegmentEliminationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CreditConcentrationRiskMember_MajorCustomersAxis_SignificantPartnersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ions:SignificantPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CreditConcentrationRiskMember_MajorCustomersAxis_SignificantPartnersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ions:SignificantPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190401to20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180701to20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180401to20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190701to20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20190331_OwnershipAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190701to20190930_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20190331_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181001to20181231_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180701to20180930_OwnershipAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180401to20180630_OwnershipAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190401to20190630_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191231_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180701to20180930_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180401to20180630_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191231_OwnershipAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20180331_OwnershipAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20180101to20180331_StatementBusinessSegmentsAxis_IonisCoreMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181001to20181231_OwnershipAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190701to20190930_OwnershipAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190401to20190630_OwnershipAxis_AkceaTherapeuticsIncMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190930_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20190331_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20190331_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0125PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190701to20190930_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181001to20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20190331_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181001to20181231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190101to20190331_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191231_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20191001to20191231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190701to20190930_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20181001to20181231_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190701to20190930_AwardTypeAxis_RestrictedStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000874015</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U001"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U002"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U003"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U004"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U005"><xbrli:measure>ions:PerformanceObligation</xbrli:measure></xbrli:unit><xbrli:unit id="U006"><xbrli:measure>ions:Payment</xbrli:measure></xbrli:unit><xbrli:unit id="U007"><xbrli:measure>ions:Target</xbrli:measure></xbrli:unit><xbrli:unit id="U008"><xbrli:measure>ions:Agreement</xbrli:measure></xbrli:unit><xbrli:unit id="U009"><xbrli:measure>ions:Company</xbrli:measure></xbrli:unit><xbrli:unit id="U010"><xbrli:measure>ions:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U011"><xbrli:measure>ions:Investment</xbrli:measure></xbrli:unit><xbrli:unit id="U012"><xbrli:measure>ions:Option</xbrli:measure></xbrli:unit><xbrli:unit id="U013"><xbrli:measure>ions:Officer</xbrli:measure></xbrli:unit><xbrli:unit id="U014"><xbrli:measure>ions:Installment</xbrli:measure></xbrli:unit><xbrli:unit id="U015"><xbrli:measure>ions:Drug</xbrli:measure></xbrli:unit><xbrli:unit id="U016"><xbrli:measure>ions:Country</xbrli:measure></xbrli:unit><xbrli:unit id="U017"><xbrli:measure>ions:Program</xbrli:measure></xbrli:unit><xbrli:unit id="U018"><xbrli:measure>ions:LicenseFee</xbrli:measure></xbrli:unit><xbrli:unit id="U019"><xbrli:measure>ions:Partner</xbrli:measure></xbrli:unit><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_8caafd476a3541b9aef7c098cc041e94" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_90b66da8071a4a14ae79ae20e35a4725" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_bc9e70d55b674cc9b6be541478de94e8" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_06b37f3d76b24645b428aed40ef7519d" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_4ae16ba11af3451383afc794f381425b" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_be05404e83c643348777fa91b0e1b9ba" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_e4c79d28e0dd438c896e0c5148cdbae0" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_627bd1dd191a4e2aa0ffcac3c093515e" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_160b2612c5ff403daa0b23ecdd2866db" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_da1b311c89004135b55ecee7befa549d" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_1a4e37f7b16f498caa99b193ac3977d1" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_267f46317f0b40caa2f037611c038a1e" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_f17e37bd45aa4fdbae4827a34aa7dac9" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_a5e37551797746d7832fc5653898ad64" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_3b50fc36268c472c83543a498f74c6a3" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_f91f4bf7895e4255b6fb1606547e04c4" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_c9d17af33c554c64ac738dfbdb48494c" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_68c90e44ae7142faa5c935422fe6ca01" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_f00bcd75b4b842ec98fdc045c48c2576" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_2665cd241db44217ad8643b9ae2a63da" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_b71803caad4d4886ad41f6bbc5e209f5" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_8ea119980dc64034994a6b7ad86f848c" toRefs="Foot_41dc381daf5c41bb92e06d06481bf7a5" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_bc9e70d55b674cc9b6be541478de94e8" toRefs="Foot_88fe67a8cca841eaa8660167eec626fe" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_f00bcd75b4b842ec98fdc045c48c2576" toRefs="Foot_88fe67a8cca841eaa8660167eec626fe" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_2665cd241db44217ad8643b9ae2a63da" toRefs="Foot_88fe67a8cca841eaa8660167eec626fe" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_8ea119980dc64034994a6b7ad86f848c" toRefs="Foot_88fe67a8cca841eaa8660167eec626fe" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_d0fdecfde0594969b57923784dc22c4e" toRefs="Foot_cc6012bb3041434399bdb287399a913a" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_476f612dfc4a4ddc8171ae7717eec530" toRefs="Foot_7f9ebb5194d04d4294eb3dd811ff49fa" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_2306dcbd35634a0485a18bef2da7300e" toRefs="Foot_f0e1d58ea08e4b55a4c7703dd1e397d3" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_21a61427c87a455b8534f57a12968f6a" toRefs="Foot_f0e1d58ea08e4b55a4c7703dd1e397d3" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_25150245f8544078baf644d29cdc825a" toRefs="Foot_f0e1d58ea08e4b55a4c7703dd1e397d3" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_bfc11b60b8204c22927b5f6205cfe9b4" toRefs="Foot_f0e1d58ea08e4b55a4c7703dd1e397d3" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_373fed9ce3ba443a8feb7284438f4bb6" toRefs="Foot_e11deb538669403f9b23668e7ec77e3b" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_a48bf0d7ba1349e58e4936fc5037bb76" toRefs="Foot_77eb85d4142a44a68a7c6b25a7169d1c" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_c119be8fc8d4422e8e8714cae28a1b7d" toRefs="Foot_ad43559c353f456eac7c04729a412d6f" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_c019e6ae06e64200907ceaf6cd9642e2" toRefs="Foot_ad43559c353f456eac7c04729a412d6f" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_04d37423456f431eae8b542d5d3b0213" toRefs="Foot_4e4fe8e547864dd797e4a2e01acbee32" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_af905ebe97f14c108dd0f43f627bb6f0" toRefs="Foot_260ceacf638c4b6691c7c678cfe81725" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_2d4ca33cff2c472890862928fc3e81b2" toRefs="Foot_260ceacf638c4b6691c7c678cfe81725" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_8a292b5b2fc640eaaa6c9eddb9c04d14" toRefs="Foot_260ceacf638c4b6691c7c678cfe81725" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_55abe2d19d6a42c689a6863e846a7fea" toRefs="Foot_260ceacf638c4b6691c7c678cfe81725" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_08e18485edd442aeb6ea55cb7dc5a055" toRefs="Foot_260ceacf638c4b6691c7c678cfe81725" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_16eafacc8b6c4c46b58136f0b68b2937" toRefs="Foot_260ceacf638c4b6691c7c678cfe81725" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_68f4a8f3d2df47cfa8896e2ea15ab759" toRefs="Foot_260ceacf638c4b6691c7c678cfe81725" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_f969201be6664a8ba8da16dedbdfffc9" toRefs="Foot_260ceacf638c4b6691c7c678cfe81725" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_66c12e16e5ef41b7be87c24864ef5483" toRefs="Foot_260ceacf638c4b6691c7c678cfe81725" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_8e3aff85017d49ac81262282323b3438" toRefs="Foot_260ceacf638c4b6691c7c678cfe81725" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_d19a2d112d904b8bb9b627ad113e904f" toRefs="Foot_260ceacf638c4b6691c7c678cfe81725" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_313f67285e0f464192314b8ac770adc7" toRefs="Foot_260ceacf638c4b6691c7c678cfe81725" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_c12cf7abb66848b497c1b0fdca78f316" toRefs="Foot_260ceacf638c4b6691c7c678cfe81725" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_0ce5ff94fbd3419d928cd3c0d9de8ba9" toRefs="Foot_260ceacf638c4b6691c7c678cfe81725" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_763576c71cab41fb95dcbba53d8fc8b3" toRefs="Foot_260ceacf638c4b6691c7c678cfe81725" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_ab7ddc03812d45bba8a6590bbdaa6412" toRefs="Foot_260ceacf638c4b6691c7c678cfe81725" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_af905ebe97f14c108dd0f43f627bb6f0" toRefs="Foot_f63ff29e56764f3485555958bff3cab9" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_2d4ca33cff2c472890862928fc3e81b2" toRefs="Foot_f63ff29e56764f3485555958bff3cab9" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_68f4a8f3d2df47cfa8896e2ea15ab759" toRefs="Foot_f63ff29e56764f3485555958bff3cab9" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_f969201be6664a8ba8da16dedbdfffc9" toRefs="Foot_f63ff29e56764f3485555958bff3cab9" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_2d4ca33cff2c472890862928fc3e81b2" toRefs="Foot_3d79790158204fcc95642c2ca83c4b8f" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_68f4a8f3d2df47cfa8896e2ea15ab759" toRefs="Foot_3d79790158204fcc95642c2ca83c4b8f" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_66c12e16e5ef41b7be87c24864ef5483" toRefs="Foot_94f9411e48574896ba56a419ae90ffb3" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_8e3aff85017d49ac81262282323b3438" toRefs="Foot_94f9411e48574896ba56a419ae90ffb3" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_d19a2d112d904b8bb9b627ad113e904f" toRefs="Foot_94f9411e48574896ba56a419ae90ffb3" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_313f67285e0f464192314b8ac770adc7" toRefs="Foot_94f9411e48574896ba56a419ae90ffb3" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_c12cf7abb66848b497c1b0fdca78f316" toRefs="Foot_94f9411e48574896ba56a419ae90ffb3" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_0ce5ff94fbd3419d928cd3c0d9de8ba9" toRefs="Foot_94f9411e48574896ba56a419ae90ffb3" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_763576c71cab41fb95dcbba53d8fc8b3" toRefs="Foot_94f9411e48574896ba56a419ae90ffb3" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_ab7ddc03812d45bba8a6590bbdaa6412" toRefs="Foot_94f9411e48574896ba56a419ae90ffb3" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_9ebd36323e384809b15acae0a3551932" toRefs="Foot_92f3ab0ee45a44b9baf44a6e4c6792b4" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_ddb646a5d0f1447b92caf9f07a627fcd" toRefs="Foot_33f87045331d4d29a03153170558d0a1" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_cef09f69ddec4b3dabee2b4ce3e2377b" toRefs="Foot_33f87045331d4d29a03153170558d0a1" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_2b37972d666b46d1ac6f9e2f013208f4" toRefs="Foot_c498c367d1f949d4a789172bf48c4121" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_3ad78e1baf8a45d8baedda5ec0ee15d5" toRefs="Foot_c498c367d1f949d4a789172bf48c4121" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_cc2b624b002347aca5b376689005c704" toRefs="Foot_c173053f21eb48f2baac71e2bf36f606" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_f4bc7becd02b4abe8419122ceb5ec217" toRefs="Foot_c173053f21eb48f2baac71e2bf36f606" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_8f26788799e14b9bb1344435140f818a" toRefs="Foot_c173053f21eb48f2baac71e2bf36f606" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_dd04e3efb270478489cafc35f9191531" toRefs="Foot_9a970986ba874d05b3ae45569fb070a7" linkRole="http://www.xbrl.org/2003/role/link"></ix:relationship></ix:resources></ix:header></div>
<div></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;"><hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" />UNITED STATES</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Washington, DC 20549</div>
<div style="text-align: center;"><br /></div>
<table cellpadding="0" cellspacing="0" id="zdf69700a1f684572831fa77a71456d10" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">
  <tr>
    <td style="width: 31.95%; vertical-align: top;">&#160;</td>
    <td style="width: 34.77%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>
    <td style="width: 33.28%; vertical-align: top;">&#160;</td>
  </tr>
</table>
<div style="text-align: center;"><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_6777d74751794fff96b76ff5cb8c6aab" contextRef="c20190101to20191231">10-K</ix:nonNumeric></div>
<div style="text-align: center;"><br /></div>
<div style="text-align: left;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="za3b071c2f2df4de78a0ff6275da9ca18">
  <tr>
    <td style="width: 36pt; vertical-align: top; align: right; font-family: 'Segoe UI Symbol'; font-size: 10pt;"><ix:nonNumeric name="dei:DocumentAnnualReport" id="Fact_3626099ee72a4966a03bb040aef4b1f9" contextRef="c20190101to20191231" format="ixt-sec:boolballotbox">&#x2612;</ix:nonNumeric></td>
    <td style="width: auto; vertical-align: top; text-align: left;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_1b51dcb448964fa491ed107ca7bfc303" contextRef="c20190101to20191231" format="ixt:datemonthdayyearen">December 31, 2019</ix:nonNumeric></div>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z0e0bb020d3d642578e9835c974c1c5bd">
  <tr>
    <td style="width: 36pt; vertical-align: top; align: right; font-family: 'Segoe UI Symbol'; font-size: 10pt;"><ix:nonNumeric name="dei:DocumentTransitionReport" id="Fact_5400abf97a83450e9302ff61e30117ca" contextRef="c20190101to20191231" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">TRANSITION</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For the transition period from ___________ to ___________</div>
<div style="text-align: center;"><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Commission file number <ix:nonNumeric name="dei:EntityFileNumber" id="Fact_8426a2008b4146659670559a9fdbbda1" contextRef="c20190101to20191231">000-19125</ix:nonNumeric></div>
<table cellpadding="0" cellspacing="0" id="zf3dc4b7420a6468499e0c793cd9c3260" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">
  <tr>
    <td style="width: 32.84%; vertical-align: top;">&#160;</td>
    <td style="width: 34.31%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>
    <td style="width: 32.84%; vertical-align: top;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 18pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_df7bd26e86ee40cc818e648190a37ffd" contextRef="c20190101to20191231">Ionis Pharmaceuticals, Inc.</ix:nonNumeric></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Exact name of Registrant as specified in its charter)</div>
<div style="text-align: center;"><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z3e785aee04f34235af920afff4a2781d">
  <tr>
    <td style="width: 48.93%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_aa094870de6141069767c3ab99f91e41" contextRef="c20190101to20191231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></div></td>
    <td style="width: 2.14%; vertical-align: bottom;">&#160;</td>
    <td style="width: 48.93%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_b473b5882d1549c2a9731e5e943607f3" contextRef="c20190101to20191231">33-0336973</ix:nonNumeric></div></td>
  </tr>
  <tr>
    <td style="width: 48.93%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(State or other jurisdiction of incorporation or organization)</div></td>
    <td style="width: 2.14%; vertical-align: bottom;">&#160;</td>
    <td style="width: 48.93%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(IRS Employer Identification No.)</div></td>
  </tr>
</table>
<div style="text-align: center;"><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zd6a02d502a8c4fa784494cd6cfe30ba0">
  <tr>
    <td style="width: 49%; vertical-align: bottom;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_834011ed8dca4521bd3d00bf9c0e66da" contextRef="c20190101to20191231">2855 Gazelle Court</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_69c1e23277f54a1f9c28e4b77162da21" contextRef="c20190101to20191231">Carlsbad</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_66e4abe2440141a1b06886bd81011085" contextRef="c20190101to20191231">CA</ix:nonNumeric></div></td>
    <td style="width: 2%; vertical-align: bottom;">&#160;</td>
    <td style="width: 49%; vertical-align: bottom;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_ddd3f0d34aef45c6bc8e86d2d2e74d11" contextRef="c20190101to20191231">92010</ix:nonNumeric></div></td>
  </tr>
  <tr>
    <td style="width: 49%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Address of Principal Executive Offices)</div></td>
    <td style="width: 2%; vertical-align: bottom;">&#160;</td>
    <td style="width: 49%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Zip Code)</div></td>
  </tr>
</table>
<div style="text-align: center;"><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonNumeric name="dei:CityAreaCode" id="Fact_3200624fb12245debf1cdc11d91ac9b9" contextRef="c20190101to20191231">760</ix:nonNumeric>-<ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_055ebb5973ce4ad4950bf287b17f0cd5" contextRef="c20190101to20191231">931-9200</ix:nonNumeric></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Registrant&#8217;s telephone number, including area code)</div>
<div><br /></div>
<div style="text-align: center; margin-top: 6pt; margin-bottom: 6pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Securities registered pursuant to Section 12(b) of the Act:</div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="ze23aa774dfcc48b59094390fec2daa58">
  <tr>
    <td style="width: 39.77%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Title of each class</div></td>
    <td style="width: 1.82%; vertical-align: top;">&#160;</td>
    <td style="width: 15.83%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Trading symbol</div></td>
    <td style="width: 1.39%; vertical-align: bottom;">&#160;</td>
    <td style="width: 41.19%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Name of each exchange on which registered</div></td>
  </tr>
  <tr>
    <td style="width: 39.77%; vertical-align: top; border-top: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_6ea276f4924047d5abdf6678bee3cf9d" contextRef="c20190101to20191231">Common Stock, $.001 Par Value</ix:nonNumeric></div></td>
    <td style="width: 1.82%; vertical-align: top;">&#160;</td>
    <td style="width: 15.83%; vertical-align: top; border-top: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="background-color: #FFFFFF; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8220;</span><ix:nonNumeric name="dei:TradingSymbol" id="Fact_6e531f880d474706b6d8ca0da3d2fd9a" contextRef="c20190101to20191231">IONS</ix:nonNumeric><span style="background-color: #FFFFFF; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#8221;</span></div></td>
    <td style="width: 1.39%; vertical-align: top;">&#160;</td>
    <td style="width: 41.19%; vertical-align: top; border-top: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_3d1cdb1ee844484fa5c20d21f415a997" contextRef="c20190101to20191231" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></div></td>
  </tr>
</table>
<div style="text-align: left; text-indent: 18pt;"><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Securities registered pursuant to Section 12(g) of the Act: <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">None</span></div>
<table cellpadding="0" cellspacing="0" id="zde873103f4f84d1194ad9da4a524ae7e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">
  <tr>
    <td style="width: 32.84%; vertical-align: top;">&#160;</td>
    <td style="width: 34.31%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>
    <td style="width: 32.84%; vertical-align: top;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" id="Fact_175f9c28e466467f9ad35cba6fcb2164" contextRef="c20190101to20191231">Yes</ix:nonNumeric>&#160;<span style="font-size: 10pt; font-family: 'Segoe UI Symbol';">&#x2612;&#160; </span>No <span style="font-size: 10pt; font-family: 'Segoe UI Symbol';">&#x2610;</span></div>
<div style="text-align: justify; text-indent: 18pt;"><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indicate by check if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes <span style="font-size: 10pt; font-family: 'Segoe UI Symbol';">&#x2610;&#160; </span><ix:nonNumeric name="dei:EntityVoluntaryFilers" id="Fact_e74a2fcd4f3a4426a40ae17a7612bbef" contextRef="c20190101to20191231">No</ix:nonNumeric>&#160;<span style="font-size: 10pt; font-family: 'Segoe UI Symbol';">&#x2612;</span></div>
<div style="text-align: justify; text-indent: 18pt;"><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" id="Fact_2097594455434eeb869fc101a26ce6da" contextRef="c20190101to20191231">Yes</ix:nonNumeric>&#160;<span style="font-size: 10pt; font-family: 'Segoe UI Symbol';">&#x2612;&#160; </span>No <span style="font-size: 10pt; font-family: 'Segoe UI Symbol';">&#x2610;</span></div>
<div style="text-align: justify; text-indent: 18pt;"><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" id="Fact_8b6f444a07694a15821e67f80f290670" contextRef="c20190101to20191231">Yes</ix:nonNumeric>&#160;<span style="font-size: 10pt; font-family: 'Segoe UI Symbol';">&#x2612;&#160; </span>No <span style="font-size: 10pt; font-family: 'Segoe UI Symbol';">&#x2610;</span></div>
<div style="text-align: left; text-indent: 18pt;"><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</div>
<div style="text-align: center;"><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z8d8ab3d4b1cf47618b109f950a9b0b25">
  <tr>
    <td style="width: 48.93%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="dei:EntityFilerCategory" id="Fact_95c89a5712094ebaa070a91099973a53" contextRef="c20190101to20191231">Large Accelerated Filer</ix:nonNumeric>&#160;<span style="font-size: 10pt; font-family: 'Segoe UI Symbol';">&#x2612;</span></div></td>
    <td style="width: 2.14%; vertical-align: bottom;">&#160;</td>
    <td style="width: 48.93%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Accelerated Filer <span style="font-size: 10pt; font-family: 'Segoe UI Symbol';">&#x2610;</span></div></td>
  </tr>
  <tr>
    <td style="width: 48.93%; vertical-align: top;">&#160;</td>
    <td style="width: 2.14%; vertical-align: bottom;">&#160;</td>
    <td style="width: 48.93%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 48.93%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-accelerated Filer <span style="font-size: 10pt; font-family: 'Segoe UI Symbol';">&#x2610;</span></div></td>
    <td style="width: 2.14%; vertical-align: bottom;">&#160;</td>
    <td style="width: 48.93%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Smaller Reporting Company <span style="font-size: 10pt; font-family: 'Segoe UI Symbol';"><ix:nonNumeric name="dei:EntitySmallBusiness" id="Fact_f3251c66fd9b436a8ef6a23f77e3d6f1" contextRef="c20190101to20191231" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></span></div></td>
  </tr>
  <tr>
    <td style="width: 48.93%; vertical-align: top;">&#160;</td>
    <td style="width: 2.14%; vertical-align: bottom;">&#160;</td>
    <td style="width: 48.93%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Emerging Growth Company <span style="font-size: 10pt; font-family: 'Segoe UI Symbol';"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_5c10ae56e71043aeaa41bbc825971bea" contextRef="c20190101to20191231" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></span></div></td>
  </tr>
</table>
<div style="text-align: center;"><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Act. </span><span style="font-size: 10pt; font-family: 'Segoe UI Symbol';">&#x2610;</span></div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes </span><span style="font-size: 10pt; font-family: 'Segoe UI Symbol';"><ix:nonNumeric name="dei:EntityShellCompany" id="Fact_fb99b76b7ba14e8a9b1cee262ebe4ab2" contextRef="c20190101to20191231" format="ixt-sec:boolballotbox">&#x2610;</ix:nonNumeric></span><span style="font-size: 12pt; font-family: 'Segoe UI Symbol';">&#160; </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">No </span><span style="font-size: 10pt; font-family: 'Segoe UI Symbol';">&#x2612;</span></div>
<div style="text-align: left; text-indent: 18pt;"><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The approximate aggregate market value of the voting common stock held by non-affiliates of the Registrant, based upon the last sale price of the common stock reported on The Nasdaq Global Select Market was $<ix:nonFraction name="dei:EntityPublicFloat" id="Fact_3093f45fbc13449d8907b516c6fba6ac" contextRef="c20190630" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">7,483,343,134</ix:nonFraction> as of June 30, 2019.*</div>
<div style="text-align: left; text-indent: 18pt;"><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The number of shares of voting common stock outstanding as of February 20, 2020 was <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" id="Fact_0fd2eda6fda6482ba4622abf15221ceb" contextRef="c20200220" unitRef="U002" decimals="INF" scale="0" format="ixt:numdotdecimal">139,219,800</ix:nonFraction>.</div>
<div><br /></div>
<div style="text-align: center; text-indent: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">DOCUMENTS INCORPORATED BY REFERENCE</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Portions of the Registrant&#8217;s definitive Proxy Statement to be filed on or about April 29, 2020 with the Securities and Exchange Commission in connection with the Registrant&#8217;s annual meeting of stockholders to be held on June 4, 2020 are incorporated by reference into Part III of this Report.</div>
<div style="text-align: left; text-indent: 18pt;"><br /></div>
<table cellpadding="0" cellspacing="0" id="z4af59dd2805c4fc3b5d162de2d34d88f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">
  <tr>
    <td style="width: 30.71%; vertical-align: top; border-bottom: #000000 2px solid;">&#160;</td>
    <td style="width: 69.29%; vertical-align: top;">&#160;</td>
  </tr>
</table>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z0d857ed2885e4e51bb325dbc438dd508">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">*</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Excludes 23,957,052 shares of common stock held by directors and officers and by stockholders whose beneficial ownership is known by the Registrant to exceed 10 percent of the common stock outstanding at June 30, 2019. Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the Registrant, or that such person is controlled by or under common control with the Registrant.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;" /></div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div><br /></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><!--PROfilePageNumberReset%Num%2%%%-->FORWARD-LOOKING STATEMENTS</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">This report on Form 10-K and the information incorporated herein by reference includes forward-looking statements regarding our business and the therapeutic and commercial potential of SPINRAZA (nusinersen), TEGSEDI (inotersen), WAYLIVRA (volanesorsen) and our technologies and products in development, including the business of Akcea Therapeutics, Inc., our majority-owned affiliate. Any statement describing our goals, expectations, financial or other projections, intentions or beliefs, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Our forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause our results to differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this report on Form 10-K, including those identified in Item 1A entitled &#8220;Risk Factors&#8221;. Although our forward-looking statements reflect the good faith judgment of our management, these statements are based only on facts and factors currently known by us. As a result, you are cautioned not to rely on these forward-looking statements.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In this report, unless the context requires otherwise, &#8220;Ionis,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; refers to Ionis Pharmaceuticals, Inc. and its subsidiaries.</div>
<div><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">TRADEMARKS</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</span>&#8220;Ionis,&#8221; the Ionis logo, and other trademarks or service marks of Ionis Pharmaceuticals, Inc. appearing in this report are the property of Ionis Pharmaceuticals, Inc. &#8220;Akcea,&#8221; the Akcea logo, and other trademarks or service marks of Akcea Therapeutics, Inc. appearing in this report are the property of Akcea Therapeutics, Inc. This report contains additional trade names, trademarks and service marks of others, which are the property of their respective owners. Solely for convenience, trademarks and trade names referred to in this report may appear without the &#174; or TM symbols.</div>
<div><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CORPORATE INFORMATION</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We incorporated in California in 1989 and in January 1991 we changed our state of incorporation to Delaware. In December 2015, we changed our name to Ionis Pharmaceuticals, Inc. from Isis Pharmaceuticals, Inc. Our principal offices are in Carlsbad, California. We make available, free of charge, on our website, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">www.ionispharma.com</span>, our reports on Forms 10-K, 10-Q, 8-K and amendments thereto, as soon as reasonably practical after we file such materials with the Securities and Exchange Commission. Any information that we include on or link to our website is not a part of this report or any registration statement that incorporates this report by reference.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In December 2014, we formed Akcea Therapeutics, Inc., as a Delaware corporation, with its principal office in Boston, Massachusetts. Prior to Akcea&#8217;s initial public offering, or IPO, in July 2017, we owned 100 percent of Akcea&#8217;s stock. At December 31, 2019, we owned approximately 76 percent of Akcea&#8217;s stock.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>2</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">IONIS PHARMACEUTICALS, INC.</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">FORM 10-K</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">For the Fiscal Year Ended December 31, 2019</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><a id="toc"><!--Anchor--></a>Table of Contents</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z42440a9be61e49b7921001f3bba68fd4">
  <tr>
    <td style="width: 10.51%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">PART I</div></td>
    <td style="width: 83.22%; vertical-align: top;">&#160;</td>
    <td style="width: 6.27%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top;">&#160;</td>
    <td style="width: 83.22%; vertical-align: top;">&#160;</td>
    <td style="width: 6.27%; vertical-align: top; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Page</div></td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Item 1.</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Business</div></td>
    <td style="width: 6.27%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4</div></td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Item 1A.</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Risk Factors</div></td>
    <td style="width: 6.27%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">40</div></td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Item 1B.</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Unresolved Staff Comments</div></td>
    <td style="width: 6.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">52</div></td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Item 2.</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Properties</div></td>
    <td style="width: 6.27%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">52</div></td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Item 3.</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Legal Proceedings</div></td>
    <td style="width: 6.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">52</div></td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Item 4.</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Mine Safety Disclosures</div></td>
    <td style="width: 6.27%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">52</div></td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 83.22%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 6.27%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">PART II</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 6.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 83.22%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 6.27%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Item 5.</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</div></td>
    <td style="width: 6.27%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">53</div></td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Item 6.</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Selected Financial Data</div></td>
    <td style="width: 6.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">55</div></td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Item 7.</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</div></td>
    <td style="width: 6.27%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">56</div></td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Item 7A.</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Quantitative and Qualitative Disclosures About Market Risk</div></td>
    <td style="width: 6.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">70</div></td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Item 8.</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Financial Statements and Supplementary Data</div></td>
    <td style="width: 6.27%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">70</div></td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Item 9.</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</div></td>
    <td style="width: 6.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">70</div></td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Item 9A.</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Controls and Procedures</div></td>
    <td style="width: 6.27%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">70</div></td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Item 9B.</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other Information</div></td>
    <td style="width: 6.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">73</div></td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 83.22%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 6.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">PART III</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 6.27%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 83.22%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 6.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Item 10.</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Directors, Executive Officers and Corporate Governance</div></td>
    <td style="width: 6.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">73</div></td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Item 11.</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Executive Compensation</div></td>
    <td style="width: 6.27%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">73</div></td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Item 12.</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</div></td>
    <td style="width: 6.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">73</div></td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Item 13.</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Certain Relationships and Related Transactions, and Director Independence</div></td>
    <td style="width: 6.27%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">73</div></td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Item 14.</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Principal Accounting Fees and Services</div></td>
    <td style="width: 6.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">73</div></td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 83.22%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 6.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">PART IV</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 6.27%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 83.22%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 6.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Item 15.</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Exhibits, Financial Statement Schedules</div></td>
    <td style="width: 6.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">74</div></td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 83.22%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 6.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 10.51%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Signatures</div></td>
    <td style="width: 83.22%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 6.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">82</div></td>
  </tr>
</table>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>3</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">PART I</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 1. Business</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Overview</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are a leader in discovering and developing RNA-targeted therapeutics. We have created an efficient and broadly applicable drug discovery platform leveraging our expertise in antisense oligonucleotide therapeutics that we believe has fundamentally changed medicine and transformed the lives of people with devastating diseases. Our large, diverse and advancing pipeline has over 40 potential first-in-class and/or best-in-class medicines designed to <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">address a broad spectrum of therapeutic areas, such as neurodegenerative diseases, cardiometabolic diseases, cancer and others. The medicines in our pipeline address patients with diseases ranging from rare to common.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In 2019, we achieved important goals across our business, including advancing four new medicines into pivotal studies. We also reported positive clinical proof-of-concept results from five medicines, four of which were LICA medicines. We advanced and grew our pipeline of unpartnered medicines, which we call our Ionis-owned pipeline. In addition, we made significant progress across the rest of our pipeline by advancing numerous medicines into earlier stages of development, six of which were Ionis-owned medicines. In 2019, we also broadened the scope of our antisense technology by investing in complementary technologies such as<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> new LICA strategies to address more organ systems and cell types and technologies to potentially identify novel targets to ensure continued pipeline growth. These accomplishments enabled us to achieve revenues in excess of $1.1 billion, net income of nearly $300 million and a year-end cash balance of $2.5 billion.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">This year we plan to use our financial strength to invest fully in those areas of the business that we believe have the greatest potential to create value for patients and shareholders. By the end of this year, we plan to have six pivotal studies underway and report clinical proof-of-concept data for six or more medicines. We also plan to expand the reach of our antisense technology by optimizing additional routes of administration, such as oral and pulmonary for which we expect clinical data this year. Additionally, this year, we are continuing to prioritize the growth and advancement of our Ionis-owned pipeline.</span>&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Building on our achievements in 2019, we believe that continued advances in our pipeline and technology will enable us to achieve our goal of 10 or more new drug applications through the end of 2025.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our goal is to determine the optimal development and commercialization strategy for each medicine in our pipeline, while ensuring we remain focused on innovation and delivering substantial value for patients in need and shareholders. With this goal firmly in mind, this year we plan to <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">further develop our commercial strategy and capabilities to ensure we maximize the value of each of our medicines.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By building on our strong foundation and continuing to focus on our strategic priorities, we believe we are achieving our vision of becoming one of the most successful and innovative companies in the healthcare industry. We intend to continue to pursue our vision by executing on our strategic priorities: advancing our Ionis-owned pipeline, further developing our commercial strategies and capabilities, and expanding the reach of our antisense technology.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have three commercial medicines approved in major markets around the world, SPINRAZA, TEGSEDI and WAYLIVRA. We have four drugs in pivotal studies, tominersen (formerly IONIS-HTT<sub>Rx</sub>) for Huntington&#8217;s disease, tofersen for SOD1-ALS, AKCEA-APO(a)-L<sub>Rx</sub> for cardiovascular disease, or CVD, and AKCEA-TTR-L<sub>Rx</sub> for all forms of TTR amyloidosis, or ATTR. Our goal is to start up to five additional pivotal studies before the end of 2021.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SPINRAZA is a global foundation-of-care for the treatment of patients of all ages with spinal muscular atrophy, or SMA, a progressive, debilitating and often fatal genetic disease. Biogen, our partner responsible for commercializing SPINRAZA worldwide, reported that as of December 31, 2019, more than 10,000 patients were on SPINRAZA therapy in markets around the world. Additionally, as of December 31, 2019, SPINRAZA is approved in over 50 countries with formal reimbursement in 40 countries. Through December 31, 2019, we have earned more than $1 billion in revenues from our SPINRAZA collaboration, including more than $640 million in royalties on sales of SPINRAZA.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">TEGSEDI, a once weekly, self-administered subcutaneous medicine, was approved in 2018 in the U.S., EU and Canada for the treatment of patients with polyneuropathy caused by hereditary TTR amyloidosis, or hATTR, a debilitating, progressive, and fatal disease. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Akcea, our majority-owned affiliate focused on developing and commercializing medicines to treat patients with serious and rare diseases, </span>launched TEGSEDI in the U.S. and EU in late 2018. TEGSEDI is commercially available in more than 10 countries. Akcea plans to expand the global launch of TEGSEDI by launching in additional countries. In Latin America, PTC Therapeutics, or PTC, through its exclusive license from Akcea, is launching TEGSEDI in Brazil and is working towards access in additional Latin American countries.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>4</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">WAYLIVRA, a once weekly, self-administered, </span>subcutaneous medicine,<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> received conditional marketing authorization in May 2019 from the European Commission, or EC, as an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome, or FCS, and at high risk for pancreatitis. Akcea launched WAYLIVRA in the EU in the third quarter of 2019 and is leveraging its existing commercial infrastructure in Europe to market WAYLIVRA. PTC through its exclusive license agreement with Akcea is working to expand access to WAYLIVRA across Latin America, beginning in Brazil with potential approval in 2020.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As a result of our business achievements, we generated more than $1 billion in revenues in 2019 and $294 million of net income. We earned $352 million of commercial revenue and $770 million in research and development revenue, including significant license fees for two LICA medicines. First, we earned a $150 million license fee from Novartis when Akcea licensed AKCEA-APO(a)-L<sub>Rx</sub> in the first quarter of 2019. Additionally, in the fourth quarter of 2019, Akcea initiated a collaboration with Pfizer for the license of AKCEA<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-ANGPTL3-L</span><sub>Rx</sub> to treat people with cardiovascular and metabolic diseases. Akcea received a $250 million upfront license fee, of which we recognized nearly all into revenue in the fourth quarter of 2019.</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Our Marketed Medicines &#8211; Transformational Medicines Bringing Value to Patients Today</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">SPINRAZA </span>&#8211; SPINRAZA (nusinersen) injection for intrathecal use is a survival motor neuron-2, or SMN2, directed antisense medicine indicated for the treatment of SMA in pediatric and adult patients.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SPINRAZA is a global foundation-of-care for the treatment of patients of all ages with SMA. Biogen, our partner responsible for commercializing SPINRAZA worldwide, reported that as of December 31, 2019, more than 10,000 patients were on SPINRAZA therapy in markets around the world. Additionally, as of December 31, 2019, SPINRAZA is approved in over 50 countries with formal reimbursement in 40 countries.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SMA is characterized by loss of motor neu<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">rons in the spinal cord and lower brain stem, resulting in severe and progressive muscular atrophy and weakness. Ultimately, if untreated, individuals with the most severe type of SMA, infantile-onset, or Type 1, SMA, can become paralyzed and have difficulty performing the basic functions of life, like breathing and swallowing. Due to a loss of, or defect in, the </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">SMN1</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> gene, people with SMA do not produce enough SMN protein, which is critical for the maintenance of motor neurons. The severity of SMA correlates with the amount of SMN protein a patient can produce on his/her own. Patients with Type 1 SMA produce very little SMN protein and do not achieve the ability to sit without support or live beyond two years without respiratory support. Patients with later-onset, or Type 2 or Type 3 SMA, suffer from less severe forms of the disease. These patients produce greater amounts of SMN protein, but also experience progressive degeneration due to the disease.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The approval of SPINRAZA was based on safety and efficacy data from multiple clinical studies, including two randomized, placebo-controlled Phase 3 studies, ENDEAR, in patients with infantile-onset SMA, and CHERISH, in patients with later-onset SMA as well as from SHINE, an ongoing OLE study for patients with SMA who participated in prior SPINRAZA studies.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For over five years, Biogen has been conducting the Phase 2 open-label NURTURE study, the first study investigating a treatment targeting the underlying cause of SMA in infants with the genetic diagnosis of SMA (most likely to develop SMA Type 1 or 2) treated pre-symptomatically.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Biogen is also conducting DEVOTE, a Phase 2/3 study evaluating the safety and potential to achieve increased efficacy with a higher dose of SPINRAZA compared to the currently approved dose. We and Biogen believe that the favorable safety and tolerability profile of SPINRAZA that has been observed in over 10,000 patients now on SPINRAZA treatment supports the potential to evaluate higher dosing. Biogen plans to enroll SMA patients of all ages, including adults, in the DEVOTE study.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In all clinical studies, SPINRAZA demonstrated a favorable safety profile. The most common side effects of SPINRAZA included lower respiratory infection, fever, constipation, headache, vomiting, back pain, and post-lumbar puncture syndrome. For additional safety information, please see </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">www.spinraza.com</span></span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> (Any information that is included on or linked to this website is not part of this report or any registration statement or report that incorporates this report by reference).</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">TEGSEDI &#8211; </span>TEGSEDI (inotersen) injection is an RNA-targeted medicine designed to reduce the production of TTR protein that we licensed to Akcea in March 2018.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">TEGSEDI is commercially available in more than 10 countries. Akcea plans to expand the global launch of TEGSEDI, by launching in additional countries. In Latin America PTC is launching TEGSEDI in Brazil and is working towards access in additional Latin American countries. The FDA approved TEGSEDI for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults in October 2018. TEGSEDI is also approved in the EU, Canada and Brazil for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>5</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">TTR amyloidosis that is the result of inherited mutations in the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">TTR </span>gene is referred to as hereditary ATTR, or hATTR. There are an estimated 50,000 people worldwide with hATTR. There are two primary manifestations of hATTR: polyneuropathy and cardiomyopathy. Many people with hATTR often experience both manifestations, but often one manifestation or the other is diagnosed first and is more pronounced.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In people with hATTR, both the mutant and wild type, or wt, TTR protein builds up as fibrils in the tissues, such as peripheral nerves, heart, gastrointestinal system, eyes, kidneys, central nervous system, thyroid and bone marrow. The presence of TTR fibrils interferes with the normal function of these tissues. As the TTR protein fibrils enlarge, more tissue damage occurs and the disease worsens, resulting in poor quality of life and eventually death. We designed TEGSEDI to reduce the production of the TTR protein, the underlying cause of hATTR.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Polyneuropathy due to hATTR is caused by the accumulation of misfolded mutated TTR protein in the peripheral nerves. People with polyneuropathy due to hATTR experience ongoing debilitating nerve damage throughout their body resulting in the progressive loss of sensation in the extremities that advances centrally, and loss of motor functions, such as walking. These people also accumulate TTR in other major organs, which progressively compromises their function and eventually leads to death within five to 15 years of disease onset.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">People without mutations in the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">TTR</span> gene can also develop ATTR, often referred to as wild-type, or wt-ATTR. This non-hereditary form of the disease results from normal, non-mutant, TTR protein forming fibrils, primarily in the heart. It is estimated that more than 200,000 people worldwide have wt-ATTR. People with hATTR cardiomyopathy and wt-ATTR experience ongoing debilitating heart damage resulting in progressive heart failure, which results in death within three to five years from disease onset.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The approvals of TEGSEDI were based on results from the Phase 3 NEURO-TTR study in patients with hATTR amyloidosis with stage 1 and stage 2 polyneuropathy. Results from that study demonstrated that patients treated with TEGSEDI experienced significant benefit compared to patients treated with placebo across both co-primary endpoints: the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy, or Norfolk QoL-DN, and modified Neuropathy Impairment Score +7, or mNIS+7, a measure of neuropathic disease progression.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> In July 2018, the final results from the NEURO-TTR pivotal study were published in </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">The New England Journal of Medicine.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We identified thrombocytopenia and safety signals related to renal function during the study. We implemented enhanced monitoring during the study to support early detection and management of these issues. Serious platelet and renal events were infrequent and manageable with routine monitoring, which has proven effective since implementation.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are also conducting an ongoing OLE study in patients with hATTR treated with TEGSEDI. This study is intended to evaluate the long-term efficacy and safety profile of TEGSEDI. We have observed that the benefits TEGSEDI demonstrated in the NEURO-TTR study continued in the OLE.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The product label for TEGSEDI in the U.S. has a boxed warning for thrombocytopenia and glomerulonephritis and requires periodic blood and urine monitoring. TEGSEDI has a Risk Evaluation and Mitigation Strategy, or REMS, program. </span>For TEGSEDI&#8217;s full prescribing information, including boxed warnings, please see <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">www.tegsedi.com</span></span> (Any information that is included on or linked to this website is not part of this report or any registration statement or report that incorporates this report by reference).</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">WAYLIVRA &#8211; </span>WAYLIVRA (volanesorsen) is an antisense medicine designed to treat people with rare, hereditary diseases characterized by extremely elevated triglyceride levels and a high risk of life-threatening pancreatitis, such as FCS and familial partial lipodystrophy, or FPL, that we licensed to Akcea.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Akcea launched WAYLIVRA in the EU in the third quarter of 2019 and is leveraging its existing commercial infrastructure in Europe to market WAYLIVRA. Akcea also plans to launch WAYLIVRA in Latin America through its exclusive license agreement with PTC if WAYLIVRA is approved by ANVISA.</span> WAYLIVRA<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> received conditional marketing authorization from the EC in May 2019 as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for pancreatitis. </span>In August 2019, Akcea launched WAYLIVRA in Germany and preparations are underway to launch in additional countries this year.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In August 2018, we received a complete response letter, or CRL, from the Division of Metabolism and Endocrinology Products of the FDA regarding the NDA for WAYLIVRA. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In November 2018, we received a Notice of Noncompliance withdrawal letter, or NON-W, from Heath Canada for WAYLIVRA. </span><a id="_Hlk33788989"><!--Anchor--></a>Our goal is to refile the NDA for WAYLIVRA with the FDA this year.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">FCS and FPL, are each estimated to affect 3,000 to 5,000 people worldwide. FCS can lead to many chronic health issues including severe, recurrent abdominal pain, fatigue, high risk of life-threatening pancreatitis and abnormal enlargement of the liver or spleen as a result of these patients&#8217; severely elevated blood triglyceride levels. In addition, people with FCS are often unable to work, adding to their disease. In severe cases, patients can have bleeding into the pancreas, serious tissue damage, infection and cyst formation, as well as damage to other vital organs such as the heart, lungs and kidneys.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> People with FPL typically have diabetes and other metabolic abnormalities, including elevated triglycerides, which increases their risk of pancreatitis.</span></div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>6</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">WAYLIVRA acts to reduce triglyceride levels by inhibiting the production of apolipoprotein C-III, or apoC-III, a protein that is a key regulator of triglyceride levels. People who have low levels of apoC-III or reduced apoC-III function have lower levels of triglycerides and a lower incidence of CVD. By inhibiting the production of apoC-III, WAYLIVRA is able to reduce triglyceride levels in people with high levels of triglycerides.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The conditional marketing authorization for WAYLIVRA <span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">is based on results from the Phase 3 APPROACH study and the ongoing APPROACH OLE study and supported by results from the Phase 3 COMPASS study.</span> The pivotal APPROACH study was a one-year, randomized, placebo-controlled study in 66 patients with FCS (average baseline triglycerides of 2,209 mg/dL, or 25.0 mmol/L). The study achieved its primary endpoint of reduction in triglycerides at three months, with a 77 percent mean reduction in triglycerides, which translated into a 1,712 mg/dL (19.3 mmol/L) mean absolute triglyceride reduction in WAYLIVRA-treated patients. We observed 50 percent of treated patients achieved triglyceride levels below 500 mg/dL, a commonly accepted threshold for pancreatitis risk. In addition, treatment with WAYLIVRA was associated with a statistically significant reduced rate of pancreatitis attacks in the group of patients who had the highest incidence of pre-study pancreatitis and reduced abdominal pain in patients reporting pain before treatment in the study. In August 2019, the final results from the APPROACH <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">pivotal study were published in </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">The New England Journal of Medicine.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The most common adverse events in the APPROACH study were injection site reactions and reductions in platelet levels. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">For important safety information for WAYLIVRA, including method of administration, special warnings, drug interactions and adverse drug reactions, please see the European Summary of Product Characteristics at: </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">www.waylivra.eu</span></span>. (Any information that is included on or linked to this website is not part of this report or any registration statement or report that incorporates this report by reference).</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In August 2019, we reported top line results from the BROADEN study of WAYLIVRA in FPL. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">BROADEN is a randomized, double blind, placebo-controlled study of 300mg of WAYLIVRA administered by a subcutaneous injection in patients with FPL. In the study, WAYLIVRA met its primary endpoint demonstrating a statistically significant reduction in triglyceride levels. WAYLIVRA also met a key secondary endpoint with a statistically significant reduction in liver fat. The most common adverse events observed in WAYLIVRA-treated patients were mild or moderate in severity and included injection site reactions, cold-like symptoms, urinary tract infection, and reductions in platelet levels.</span> Patients in the BROADEN study were also eligible to enroll into an OLE study upon completing dosing in the pivotal study.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">An OLE study is ongoing for patients with FCS who have completed or meet the study criteria for the APPROACH and COMPASS studies. Additionally, we have expanded access programs, or EAPs, for WAYLIVRA.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">See our separate section below where we further discuss Akcea, our majority-owned affiliate focused on developing and commercializing medicines to treat people with serious and rare diseases.</div>
<div><br /></div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Drug Discovery and Development</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Introduction to Drug Discovery</div>
<div style="text-align: justify; text-indent: 35.3pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Proteins are essential working molecules in a cell. Almost all human diseases result from inappropriate protein production, improper protein activity or loss of a protein. Antisense medicines can modify the production of proteins by targeting RNAs. In this way, antisense medicines can inhibit the production of a disease-causing protein, modify the protein produced or increase the production of a protein that, when absent, causes diseases. Antisense medicines also can treat diseases by targeting and reducing RNAs that may be causing diseases (so called &#8220;toxic RNAs&#8221;). RNAs are naturally occurring molecules in the body that primarily act as messengers that carry the information the cell needs to produce proteins from the DNA/genes to the protein making complex in the cell. When our antisense medicines bind to the specific RNAs of a particular gene, they will ultimately alter the production of the protein encoded in the target gene or, in the case of disease-causing RNAs, degrade the toxic RNAs.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Our Development Projects</div>
<div style="text-align: justify; text-indent: 35.3pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We are a leader in the discovery and development of an exciting class of RNA-targeted medicines called antisense oligonucleotide, or ASO, medicines, or just antisense medicines. With our proprietary drug discovery platform, we can rapidly identify medicines from a wealth of potential targets to treat a broad range of diseases. We focus our efforts in therapeutic areas in which our medicines will work best, efficiently screening many targets in parallel and carefully selecting the best candidates. By combining this efficiency with our rational approach to selecting disease targets, we have built a large and diverse portfolio of medicines we designed to treat a variety of health conditions, such as cardiometabolic diseases, neurodegenerative diseases, cancer, rare diseases and others.</span>&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We are developing antisense medicines for systemic and local delivery (e.g., subcutaneous, intrathecal, intraocular, oral and aerosol).</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We plan to continue to add new investigational medicines to our pipeline, building a broad proprietary portfolio of medicines to treat many diseases and creating opportunities to continue to generate substantial revenue. We also continue to improve our scientific understanding of our medicines, including how our medicines impact the biological processes of the diseases we target.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>7</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">With our expertise in discovering and characterizing novel antisense medicines, our scientists can optimize the properties of our antisense medicines against each particular target. Our scientists have made significant advances in chemical modifications we use in our antisense medicines, such as with our Generation 2+ antisense medicines, which have increased potency and an improved side effect profile over our earlier generation medicines. Our scientists have further improved upon our second-generation chemistry with our Generation 2.5 chemistry, an advancement that further increases the potency of our medicines, which broadens the organs and tissues in which our medicines can work. We currently have 19 Generation 2.5 medicines in development, and we anticipate that more of our future medicines will incorporate our Generation 2.5 chemistry.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In addition to improving the chemical foundation of our medicines, we have also created LIgand-Conjugated Antisense, or LICA, technology, which we design to enhance the effective uptake and activity of our medicines in particular tissues. With our LICA technology we attach specific chemical structures or molecules to our antisense medicines. With our first LICA conjugate, a complex sugar-like molecule called N-acetylgalactosamine, or GalNac, we have shown an increase in medicinal potency of up to 30-fold for liver targets, compared to non-conjugated antisense medicines. We currently have 16 LICA medicines in development, including two LICA medicines currently in Phase 3 studies, AKCEA-APO(a)-L<sub>Rx</sub>, for CVD and AKCEA-TTR-L<sub>Rx</sub>, for all forms of ATTR. We also have four investigational medicines that combine our Generation 2.5 chemistry and LICA technology.</div>
<div style="text-align: justify; text-indent: 35.3pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have utilized our chemistry advancements, such as Generation 2.5 and LICA, to expand the therapeutic and commercial opportunities of our pipeline. These advancements, along with the manufacturing and analytical processes that are the same for all of our medicines, shorten our timeline from initial concept to the first human dose, when compared to early development timelines for other drug modalities like small molecule and antibody medicines.</div>
<div><br /></div>
<div style="text-align: center;"><img src="image15.jpg" width="624" height="705" alt="graphic" /></div>
<div style="text-align: center;"><img src="image1.jpg" width="615" height="31" alt="graphic" /></div>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zba4241f165f94fd28b75a32e80993ce3">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">*</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">China rights only</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>8</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The above table lists the medicines in our clinical pipeline. The table includes the disease indication, a partner (if the medicine is partnered), and the development status of each medicine.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Focusing on our key fundamental strategies has created a deep and broad pipeline of over 40 potentially first-in-class and/or best-in-class medicines that we believe have the potential to deliver significant value to patients affected by the devastating diseases each medicine addresses, many of which have limited or no treatment options. With a pipeline as large and advanced as ours, we have a number of clinical events each year as we initiate new clinical studies, complete and report data from clinical studies, and add numerous new medicines to our pipeline.</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Our Phase 3 Medicines</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As of the end of 2019, we have four medicines in pivotal Phase 3 studies: tominersen, tofersen, AKCEA-APO(a)-L<sub>Rx</sub> and AKCEA-TTR-L<sub>Rx</sub>.</div>
<div><br /></div>
<div style="text-align: center;"><img src="image16.jpg" width="627" height="140" alt="graphic" /></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Tominersen (</span>IONIS-HTT<sub>Rx </sub>or RG6042<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">) &#8211; </span>Tominersen is an antisense medicine we designed to target the underlying cause of Huntington&#8217;s Disease, or HD, by reducing the production of the toxic mutant huntingtin protein, or mHTT. HD is a rare, inherited, genetic brain disorder that results in the progressive deterioration of mental abilities and physical control. In the U.S., there are approximately 30,000 individuals with symptomatic HD and more than 200,000 people at risk of inheriting HD. The prevalence of HD is similar in other parts of the world. HD is a triplet repeat disorder and is one of a large family of genetic diseases in which the body mistakenly repeats certain gene sequences. The resulting mHTT protein is toxic and gradually damages neurons in the brain. Symptoms of HD usually appear between the ages of 30 to 50 years and continually worsen over a 10 to 25-year period. Ultimately, the weakened individual succumbs to pneumonia, heart failure or other complications. Presently, there are no disease-modifying treatments available for HD patients, with current medicines only managing some disease symptoms.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We completed a randomized, placebo-controlled, dose escalation, Phase 1/2 clinical study of tominersen in patients with early stage HD. In this study, we observed dose-dependent reductions of mHTT among patients treated with tominersen and tominersen demonstrated a favorable safety and tolerability profile. In March 2018, we reported data from the study that demonstrated substantial reductions in the mHTT as observed in the cerebral spinal fluid, or CSF. The reductions in mHTT were in the target range that produced disease reversal in preclinical models of HD. The results from this study were the first to demonstrate disease-modifying potential by lowering the root cause of HD, the mHTT protein. There were no serious adverse events reported and no participants discontinued from the study. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The data from this study were published in </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">The New England Journal of Medicine</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in May 2019.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Following the results from the Phase 1/2 study, Roche initiated a broad clinical program including multiple studies of tominersen. Roche initiated a Phase 3 GENERATION HD1 study of tominersen. GENERATION HD1 is a randomized, multicenter, double-blind, placebo-controlled study in approximately 800 patients with HD. The GENERATION HD1 study is evaluating the efficacy and safety of bi-monthly and tri-annual dosing regimens of tominersen for 25 months of dosing. The global primary endpoint is the change from baseline in the composite Unified Huntington Disease Rating Scale, or cUHDRS, and the U.S. primary endpoint is the change from baseline in the Total Functional Capacity, or TFC.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In addition to the Phase 3 study, all participants who took part in the Phase 1/2 study continued to receive tominersen as part of an OLE study to assess the safety and tolerability of tominersen. In parallel with the OLE, Roche initiated a natural history study in a similar patient population to the OLE. The natural history study is planned as a 15-month natural study aimed at further understanding the role of mHTT in disease progression and includes approximately 100 participants. There is no drug treatment in the natural history study, as the goal is to understand the natural progression of HD.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In August 2018, the European Medicines Agency, or EMA, granted PRIority MEdicines scheme, or PRIME, designation to tominersen. EMA PRIME status is granted to medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment options. The FDA and EMA granted Orphan Medicine Designation for tominersen to treat people with HD.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>9</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We entered into a collaboration with Roche to develop and commercialize antisense medicines to treat HD in April 2013. In December 2017, Roche exercised its licensing option to develop and commercialize tominersen following the completion of a Phase 1/2 randomized, placebo-controlled, dose escalation study of tominersen in people with HD. Roche is responsible for all tominersen development, regulatory and commercialization activities and costs.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Tofersen (</span>IONIS-SOD1<sub>Rx </sub>or BIIB067<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">) &#8211; </span>Tofersen is an antisense medicine we designed to inhibit the production of superoxide dismutase 1, or SOD1, which is a well understood genetic cause of familial amyotrophic lateral sclerosis, or ALS. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">ALS is a rare, fatal, neurodegenerative disorder. People with ALS suffer progressive degeneration of the motor neurons, which results in a declining quality of life and ultimately death. The second most common familial form of ALS is SOD1-ALS, in which people have a mutation in the </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">SOD1</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> gene that causes a progressive loss of motor neurons. As a result, people with SOD1-ALS experience muscle weakness, loss of movement, difficulty breathing and swallowing and eventually succumb to the disease. Currently, treatment options for people with ALS are extremely limited, with no medicines that significantly slow disease progression.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our partner Biogen conducted a Phase 1/2 study that demonstrated proof-of-biology and proof-of-concept. At the highest dose tested, treatment with tofersen over a three month period resulted in a statistically significant lowering of SOD1 protein levels in the CSF and positive numerical trends across three efficacy endpoints: slowing of clinical decline as measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale, or ALSFRS, slowing of decline in respiratory function as measured by vital capacity and slowing of decline in muscle strength as measured by a handheld device, all compared to placebo. The safety and tolerability profile in this study supported the continued development of tofersen in ALS.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In March 2019, Biogen initiated and dosed the first patient in the VALOR Phase 3 clinical study of tofersen. VALOR is assessing the efficacy and safety of tofersen versus placebo. The primary endpoint of this study is an analysis based on the ALSFRS, which is a validated rating instrument that monitors the progression of disability in patients with ALS.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In December 2018, Biogen exercised its licensing option to develop and commercialize tofersen based on the positive interim analysis from the Phase 1/2 study. Following its licensing, Biogen is responsible for all tofersen development, regulatory and commercialization activities and costs.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">AKCEA-TTR-L</span><sub style="font-weight: bold;">Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#8211; </span>AKCEA-TTR-L<sub>Rx</sub>&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">is a LICA medicine we designed </span>to inhibit the production of transthyretin, the same protein inhibited by TEGSEDI (inotersen). There are two types of ATTR amyloidosis: hATTR amyloidosis and wt-ATTR amyloidosis. We are co-developing AKCEA-TTR-L<sub>Rx</sub> with Akcea for the treatment of people with all forms of TTR amyloidosis as a once monthly self-administered subcutaneous injection. See the TEGSEDI summary under &#8220;Our Marketed Medicines&#8221; section for more information about hATTR amyloidosis and wt-ATTR amyloidosis.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In September 2019, we reported results from the Phase 1 study with AKCEA-TTR-L<sub>Rx</sub> in healthy volunteers at the Heart Failure Society of America Annual Meeting. In this study, subjects treated with AKCEA-TTR-L<sub>Rx</sub> achieved dose-dependent reductions of TTR protein of up to 94 percent and AKCEA-TTR-L<sub>Rx</sub> demonstrated a favorable safety and tolerability profile, consistent with our other liver LICA medicines. There were no serious adverse events in AKCEA-TTR-L<sub>Rx</sub> treated-subjects and no dosing interruptions due to an adverse event.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We and Akcea are evaluating AKCEA-TTR-L<sub>Rx</sub> in a broad Phase 3 program. The first of two indications we are pursuing is for the treatment of patients with polyneuropathy caused by hATTR amyloidosis. We initiated the global NEURO-TTRansform Phase 3 study for AKCEA-TTR-L<sub>Rx</sub> in November 2019. NEURO-TTRansform is <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">a multi-center, randomized, open-label study designed to evaluate the efficacy and safety of AKCEA-TTR-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in up to 140 patients with polyneuropathy due to hATTR amyloidosis. The current study will be compared to the historical placebo arm from the TEGSEDI (inotersen) NEURO-TTR Phase 3 study that was completed in 2017. The NEURO-TTRansform study includes multiple primary endpoints, including the percent change from baseline in serum TTR concentration, the change from baseline in the modified Neuropathy Impairment Score +7 (mNIS+7), and the change from baseline in Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (Norfolk QoL-DN).</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The second indication we and Akcea are pursuing is for the treatment of patients with cardiomyopathy caused by hereditary or wild-type TTR amyloidosis. In January 2020, we and Akcea initiated the global CARDIO-TTRansform Phase 3 cardiovascular outcome study. CARDIO-TTRansform i<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">s </span>a randomized, double-blinded, placebo-controlled study in up to 750 patients with cardiomyopathy caused by hereditary or wild-type TTR amyloidosis. The CARDIO-TTRansform study includes<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> co-</span>primary outcome measures of cardiovascular death and frequency of cardiovascular clinical events.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>10</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">AKCEA-APO(a)-L</span><sub style="font-weight: bold;">Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</span>(TQJ230)<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> &#8211; </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">AKCEA-APO(a)-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">is a LICA medicine we designed to inhibit the production of apolipoprotein(a), or Apo(a), protein in the liver to offer a direct approach for reducing lipoprotein(a), or Lp(a). AKCEA-APO(a)-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> inhibits the production of the Apo(a) protein, thereby reducing Lp(a). Elevated Lp(a) is recognized as an independent, genetic cause of CVD. It is estimated that there are more than eight million people living with CVD and elevated levels of Lp(a). Inhibiting the production of Apo(a) in the liver reduces the level of Lp(a) in blood, potentially slowing down or reversing cardiovascular disease in people with hyperlipoproteinemia(a), a condition in which individuals have levels of Lp(a) greater than 50 mg/dL.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Lp(a) is difficult to inhibit using other technologies, such as small molecules and antibodies. There are multiple genetically determined forms of the Apo(a) molecule and creating a small molecule or antibody that can interact with multiple targets is difficult. We believe antisense technology is well suited to address hyperlipoproteinemia(a) because antisense technology specifically targets the RNA that codes for all forms of the Apo(a) molecule. Furthermore, we believe addressing elevated Lp(a) is the next important horizon in lipid-focused treatment.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We reported results of the Phase 2 study with AKCEA-APO(a)-L<sub>Rx</sub> in patients with hyperlipoproteinemia(a) at the American Heart Association, or AHA, annual meeting in November 2018. In this clinical study, we observed statistically significant and dose dependent reductions from baseline in Lp(a) levels. Approximately 98 percent of patients who received the highest dose in the study demonstrated a reduction in Lp(a) levels to below 50 mg/dL, the recognized threshold for risk of CVD. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">This study of AKCEA-APO(a)-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> was </span>the longest and largest clinical study in patients with established CVD and elevated levels of Lp(a). This study was also the longest and largest clinical study of any of our LICA medicines. AKCEA-APO(a)-L<sub>Rx</sub> demonstrated a favorable safety and tolerability profile in the study. Compliance in the study was almost 90 percent, which was higher than what we observed in the placebo group.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea initiated a collaboration with Novartis in January 2017 to advance AKCEA-APO(a)-L<sub>Rx</sub>.<span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>In February 2019, Novartis exercised its licensing option to develop and commercialize AKCEA-APO(a)-L<sub>Rx</sub>. Following its licensing, Novartis is responsible for all AKCEA-APO(a)-L<sub>Rx</sub> development, regulatory and commercialization activities and costs.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In December 2019,<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>Novartis initiated the Phase 3 Lp(a)HORIZON study of AKCEA-APO(a)-L<sub>Rx</sub>, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">a global, randomized, double-blinded, placebo-controlled outcomes study in approximately 7,500 patients with </span>elevated Lp(a) levels and a prior cardiovascular event. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Patients will be treated with </span>80 mg of AKCEA-APO(a)-L<sub>Rx</sub> administered monthly by subcutaneous injection. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The primary endpoint in Lp(a)HORIZON is the time to occurrence of first major adverse cardiovascular event, or MACE.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Neurological Disease Medicines in Development</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are discovering and developing antisense medicines to treat people with inadequate treatment options for neurological diseases. Our antisense medicines aim to address both large and rare patient populations. We are currently investigating potential disease-modifying treatments for common neurological diseases including, Alzheimer&#8217;s disease and Parkinson&#8217;s disease. We have multiple investigational medicines in clinical trials for rare neurological diseases. According to the National Institute of Neurological Disorders and Stroke, or NINDS, at the National Institutes of Health, or NIH, a third of the 7,000 known rare diseases are neurological disorders or thought to include a neurological component.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">IONIS</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Neurological Disease Clinical Pipeline</span></div>
<div><br /></div>
<div style="text-align: center;"><img src="image13.jpg" width="611" height="188" alt="graphic" /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Tominersen</span> &#8211; See the medicine description under &#8220;Our Phase 3 Medicines&#8221; section above.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Tofersen</span> &#8211; See the medicine description under &#8220;Our Phase 3 Medicines&#8221; section above.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">IONIS-MAPT</span><sub style="font-weight: bold;">Rx</sub> (BIIB080) &#8211; IONIS-MAPT<sub>Rx</sub> is an antisense medicine we designed to selectively inhibit production of the microtubule-associated protein tau, or tau, protein in the brain. We are collaborating with Biogen to develop IONIS-MAPT<sub>Rx</sub> to treat people with Alzheimer&#8217;s disease, or AD, and potentially other neurodegenerative disorders characterized by the deposition of abnormal tau protein in the brain, such as certain forms of frontotemporal degeneration, or FTD.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>11</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The tau protein is a contributor or cause of certain neurodegenerative diseases, known as tauopathies, characterized by the deposition of abnormal tau protein in neurons and non-neuronal cells in the brain. AD and FTD are characterized predominantly by memory impairment and behavioral changes, resulting in a person&#8217;s inability to independently perform daily activities. AD generally occurs late in life and may progress to death in five to 20 years after the onset of the disease. FTD has a more rapid disease progression. There are approximately five million people living with AD in the U.S. and approximately 55,000 people affected by FTD in the U.S.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We and Biogen are evaluating IONIS-MAPT<sub>Rx</sub> in a Phase 1/2 double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the safety and activity of once-monthly intrathecal injections of IONIS-MAPT<sub>Rx</sub> in patients with mild AD. In January 2020, we completed enrollment in the Phase 1/2 study of IONIS-MAPT<sub>Rx</sub>.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In December 2019, Biogen exercised its licensing option to develop and commercialize IONIS-MAPT<sub>Rx</sub>. We are responsible for completing the Phase 1/2 in study patients with mild AD that we initiated in 2017 and a one-year long-term extension study that began in 2019. Biogen will have responsibility for all other studies and any further development, including regulatory and commercialization activities and costs.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">IONIS-C9</span><sub style="font-weight: bold;">Rx</sub> (BIIB078) &#8211; IONIS-C9<sub>Rx</sub> is an antisense medicine we designed to selectively inhibit the production of the mutated chromosome 9 open reading frame 72, or <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">C9ORF72</span>, gene. A mutation in this gene results in an inherited form of ALS, referred to as C9ORF72-ALS, the most prevalent genetic cause of ALS worldwide. There is substantial evidence that this mutation can lead to rapid progressive loss of motor neurons in people with C9ORF72-ALS. This is a fatal disease characterized by muscle weakness, loss of movement, and difficulty breathing and swallowing.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We and Biogen are collaborating to develop IONIS-C9<sub>Rx</sub> to treat patients with this genetic form of ALS. In August 2018, Biogen initiated a Phase 1/2 clinical study evaluating IONIS-C9<sub>Rx</sub> in adult patients with C9ORF72-ALS. The current study is a randomized, blinded, placebo-controlled study designed to assess the safety, tolerability, and pharmacokinetics of multiple ascending doses of IONIS-C9<sub>Rx</sub> administered intrathecally. IONIS-C9<sub>Rx</sub> is the second medicine from our Biogen collaboration targeting a familial form of ALS. The first is tofersen, designed to treat SOD1 related ALS, caused by a mutation in the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">SOD1</span> gene.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">ION859 </span>(BIIB094) &#8211; ION859 is an antisense medicine we designed to inhibit the production of the Leucine Rich Repeat Kinase 2, or LRRK2, protein as a potential therapy for Parkinson&#8217;s disease, or PD. The exact cause of PD is unknown, but it is believed to be a combination of genetics and environmental factors. There are known hereditary mutations in the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">LRRK2</span> gene that cause Parkinson&#8217;s disease. The most common genetic mutation associated with PD is found in the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">LRRK2 </span>gene. It is believed that increased LRRK2 protein activity could be one of the key drivers for developing PD.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">PD is a progressive neurodegenerative disease characterized by loss of neurons in the motor system. Patient&#8217;s with PD can experience tremors, loss of balance and coordination, stiffness, slowing of movement, changes in speech and in some cases cognitive decline. PD is ultimately fatal. There are treatments that can relieve symptoms, but there is no disease modifying therapy.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We and Biogen are collaborating to develop ION859 to treat patients with PD. In August 2019, we initiated a Phase 1/2 clinical study evaluating ION859 in adult patients with PD. The current study is a randomized, blinded, placebo-controlled study designed to assess the safety, tolerability and pharmacokinetics of multiple ascending doses of ION859 administered intrathecally.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">IONIS-DNM2-2.5</span><sub style="font-weight: bold;">Rx</sub> (DYN101) &#8211; IONIS-DNM2-2.5<sub>Rx</sub> is a Generation 2.5 antisense medicine we designed to inhibit the production of Dynamin 2, or DNM2, protein for the treatment of centronuclear myopathy, or CNM. CNM is a group of rare congenital myopathies where cell nuclei are abnormally located in the center of the skeletal muscle cells. It is characterized by muscle weakness, decreased muscle tone and muscle atrophy, ranging from severe to mild.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a id="_Hlk33163079"><!--Anchor--></a>DNM2 reduction demonstrated improved muscle mass and muscle force, and extended lifespan in animal models of the most severe form of CNM.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We and Dynacure are collaborating to develop IONIS-DNM2-2.5<sub>Rx</sub> to treat patients with CNM. In November 2019, Dynacure initiated a Phase 1/2 clinical study evaluating IONIS-DNM2-2.5<sub>Rx</sub> in patients with CNM. The current study is an open-label study in 18 patients who are 16 years of age or older and is designed to assess the safety and tolerability of multiple doses of IONIS-DNM2-2.5<sub>Rx</sub> administered intravenously.</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Cardiometabolic and Renal Disease Medicines in Development</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">CVD is an important area of focus for us. According to the World Health Organization, or WHO, CVD was the number one cause of death globally. An estimated 17.9 million people died from CVD in 2016, representing approximately 30 percent of all deaths globally. Our cardiovascular medicines target the key components of cardiovascular disease, including various atherogenic lipids, inflammation and thrombosis. Metabolic disorders, such as diabetes and nonalcoholic steatohepatitis, or NASH, are chronic diseases that affect tens of millions of people. According to the Centers for Disease Control and Prevention, diabetes affects more than 30 million people in the U.S., or nine percent of the population, with type 2 diabetes constituting 90 percent of those cases. There is a significant need for new therapies for these people. According to the American Liver Foundation, nonalcoholic fatty liver disease, or NAFLD, is the most common chronic liver condition in the U.S. It is estimated that about 25 percent of adults in the U.S. have NAFLD. Of those with NAFLD, about 20 percent have NASH or about 5% of adults in the U.S.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>12</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">IONIS</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Cardiometabolic and Renal Disease Clinical Pipeline</span></div>
<div><br /></div>
<div style="text-align: center;"><img src="image17.jpg" width="626" height="264" alt="graphic" /></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">AKCEA-TTR-L</span><sub style="font-weight: bold;">Rx</sub> &#8211; See the medicine description under &#8220;Our Phase 3 Medicines&#8221; section above.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">AKCEA-APO(a)-L</span><sub style="font-weight: bold;">Rx</sub> &#8211; See the medicine description under &#8220;Our Phase 3 Medicines&#8221; section above.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">AKCEA-ANGPTL3-L</span><sub style="font-weight: bold;">Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</span><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">&#8211; </span>AKCEA-ANGPTL3-L<sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</span>is a LICA medicine we designed to inhibit the production of the angiopoietin-like 3, or ANGPTL3, protein. People with elevated levels of the ANGPTL3, protein have high LDL-C and triglyceride levels. Studies show people with elevated levels of ANGPTL3 protein have an increased risk of premature heart attacks, increased arterial wall thickness and multiple metabolic disorders such as diseases resulting from increased liver fat. In contrast, people with lower levels of ANGPTL3 have lower LDL-C and triglyceride levels, and thus lower risk of heart attacks, lower prevalence of fatty liver and lower incidence of metabolic disorders.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a id="_Hlk33163150"><!--Anchor--></a>In preclinical studies, treatment with an antisense medicine designed to inhibit the production of the ANGPTL3 protein in the liver resulted in lower liver fat accumulation and lower blood levels of LDL-C, triglycerides and very low-density lipoprotein cholesterol, or VLDL-C.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Results from a Phase 1/2 study of AKCEA-ANGPTL3-L<sub>Rx</sub> in healthy volunteers with elevated triglycerides were published in <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">The</span>&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">New England Journal of Medicine</span>. In the study, we observed that the people with elevated triglycerides achieved dose-dependent, statistically significant mean reductions in ANGPTL3 of up to 83 percent. Treatment with AKCEA-ANGPTL3-L<sub>Rx</sub> was also associated with statistically significant mean reductions in triglycerides of up to 66 percent, in LDL-C of up to 35 percent and in total cholesterol of up to 36 percent. In this study, AKCEA-ANGPTL3-L<sub>Rx</sub> demonstrated a favorable safety and tolerability profile.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In January 2020, we reported positive results from a Phase 2 clinical study in patients</span> with elevated levels of triglycerides, or hypertriglyceridemia, type 2 diabetes and NAFLD. Patients were treated with multiple doses of AKCEA-ANGPTL3-L<sub>Rx</sub> administered weekly and monthly. AKCEA-ANGPTL3-L<sub>Rx</sub> achieved statistically significant, dose-dependent reductions in the study&#8217;s primary endpoint of fasting triglycerides compared to placebo at all dose levels. AKCEA-ANGPTL3-L<sub>Rx</sub> also achieved statistical significance in multiple secondary endpoints, including dose-dependent reductions in angptl3, apoC-III, very low-density lipoprotein (VLDL-C), non-HDL cholesterol and total cholesterol compared to placebo. AKCEA-ANGPTL3-L<sub>Rx</sub> demonstrated a favorable safety and tolerability profile in the study.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In October 2019, we exclusively licensed </span>AKCEA-ANGPTL3-L<sub>Rx</sub>&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">to Pfizer. Pfizer is </span>responsible for all development and regulatory activities and costs beyond those associated with the above Phase 2 study. Akcea has the option prior to regulatory filing for marketing approval, to participate in certain commercialization activities in the future with Pfizer in the U.S. and certain additional markets on pre-defined terms and based on meeting pre-defined criteria.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">AKCEA-APOCIII-L</span><sub style="font-weight: bold;">Rx </sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#8211; </span>AKCEA-APOCIII-L<sub>Rx</sub> is a LICA medicine we designed to inhibit the production of apoC-III for patients who are at risk of disease due to elevated triglyceride levels. ApoC-III is a protein produced in the liver that regulates triglyceride metabolism in the blood. People with severely elevated triglycerides, such as people with FCS, a rare, hereditary disease characterized by extremely elevated triglyceride levels, are at high risk for acute pancreatitis and other serious conditions. ApoC-III is also the target of WAYLIVRA, the only medicine approved for the treatment of people with FCS. See the WAYLIVRA summary under &#8220;Our Marketed Medicines&#8221; section for more information about FCS.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>13</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We and Akcea plan to initiate a Phase 3 study this year in patients with FCS based on the Phase 2 data described below. We believe that the enhancements offered by our LICA technology can provide greater reductions in triglycerides and patient convenience by allowing for significantly lower doses and less frequent administration, compared to WAYLIVRA.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In October 2017, we reported positive results of a Phase 1/2 clinical study in healthy volunteers with elevated triglyceride levels. Patients in the study were treated with multiple doses at either weekly or monthly dosing intervals. Patients treated with AKCEA-APOCIII-L<sub>Rx</sub> demonstrated significant dose-dependent reductions in apoC-III protein and triglycerides. In this study, AKCEA-APOCIII-L<sub>Rx</sub> demonstrated a favorable safety and tolerability profile. No serious adverse events, platelet count reductions, changes in liver function or adverse events leading to treatment discontinuation were observed.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In January 2020, we reported positive results from a Phase 2 clinical study in patients</span> with hypertriglyceridemia and at high risk of or with established CVD. Patients were treated with multiple doses of AKCEA-APOCIII-L<sub>Rx</sub> administered weekly, bi-weekly, or monthly. AKCEA-APOCIII-L<sub>Rx</sub> achieved statistically significant, dose-dependent reductions in fasting triglycerides compared to placebo at all dose levels. Additionally, at the highest monthly dose, more than 90 percent of patients achieved serum triglycerides of &#8804; 150 mg/dL, the recognized threshold for cardiovascular risk, compared to less than 5 percent of patients in the placebo group. AKCEA-APOCIII-L<sub>Rx</sub> also achieved statistical significance in numerous key secondary endpoints, including significant reductions in apoC-III, very low-density lipoprotein cholesterol, or VLDL-C, and remnant cholesterol, and a statistically significant increase in high-density lipoprotein cholesterol, or HDL-C. AKCEA-APOCIII-L<sub>Rx</sub> demonstrated a favorable safety and tolerability profile in the study.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">IONIS-GCGR</span><sub style="font-weight: bold;">Rx</sub> &#8211; IONIS-GCGR<sub>Rx</sub> is an antisense medicine designed to inhibit the production of the glucagon receptor, or GCGR, to treat patients with type 2 diabetes. GCGR is a receptor for the hormone glucagon. Glucagon is a hormone that opposes the action of insulin and stimulates the liver to produce glucose, particularly in type 2 diabetes. In patients with advanced diabetes, uncontrolled glucagon action can lead to significant increase in blood glucose level. In addition, reducing GCGR produces more active glucagon-like peptide, or GLP-1, a hormone that preserves pancreatic function and enhances insulin secretion.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Diabetes is a chronic disease in which the blood glucose levels are too high. Although glucose is an important source of energy for your body and is vital to your health, uncontrolled increases in glucose can lead to serious health problems, such as diabetes. Diabetes is separated into type 1 and type 2. In type 1 diabetes, the body does not make insulin. In type 2 diabetes, the more common type, the body does not respond properly to insulin and, therefore, blood glucose levels are not adequately controlled.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We and Suzhou-Ribo are collaborating to develop IONIS-GCGR<sub>Rx</sub> to treat patients with type 2 diabetes. In October 2019, Suzhou-Ribo initiated a Phase 2 clinical study evaluating IONIS-GCGR<sub>Rx</sub> in patients with type 2 diabetes.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">IONIS-AGT-L</span><sub style="font-weight: bold;">Rx</sub>&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#8211;</span> IONIS-AGT-L<sub>Rx</sub> is a LICA medicine we designed to inhibit the production of angiotensinogen to decrease blood pressure in people with treatment resistant hypertension, or TRH. Despite the availability of antihypertensive agents, TRH is still a major contributor to cardiovascular and renal disease.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Approximately 75 million adults in the U.S. have hypertension, half of whom have uncontrolled hypertension. About 12-15 percent of patients with uncontrolled hypertension have resistant hypertension, defined as failure to achieve a blood pressure goal of 140/90 (systolic/diastolic) despite the use of three or more antihypertensive medications. People with TRH have been found to have a three-fold higher chance of having fatal and non-fatal cardiovascular events relative to those with controlled hypertension.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We are evaluating IONIS-AGT-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in a double-blinded, randomized, placebo-controlled, Phase 2 study in people with mild hypertension and in a second Phase 2 study in patients with TRH.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">IONIS-AZ4-2.5-L</span><sub style="font-weight: bold;">Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> &#8211; IONIS-AZ4-2.5-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>is a Generation 2.5 LICA antisense medicine we designed to treat patients with CVD. We and AstraZeneca are collaborating to develop IONIS-AZ4-2.5-L<sub>Rx</sub> to treat patients with CVD.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">IONIS-FXI-L</span><sub style="font-weight: bold;">Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> &#8211; </span>IONIS-FXI-L<sub>Rx</sub> is a LICA medicine we designed to inhibit the production of Factor XI. Factor XI is a clotting factor produced in the liver that is important in the growth of blood clots. High levels of Factor XI increase the risk of thrombosis. Thrombosis, characterized by the formation of a blood clot inside blood vessels, can cause heart attacks and strokes. People who are deficient in Factor XI have a lower incidence of thromboembolic events with minimal increase in bleeding risk. Although currently available anticoagulants reduce the risk of thrombosis, physicians associate these anticoagulants with increased bleeding, which can be fatal. By inhibiting Factor XI production, we believe that IONIS-FXI-L<sub>Rx</sub> can be used broadly as an anti-thrombotic in many different therapeutic settings for which additional safe and well tolerated anti-thrombotic medicines are needed.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In November 2016, we completed a Phase 2 double-blinded, randomized, placebo-controlled study of the parent medicine, IONIS-FXI<sub>Rx</sub>, in people with end-stage renal disease on hemodialysis. In this Phase 2 study, patients treated with IONIS-FXI<sub>Rx</sub> achieved statistically significant, dose-dependent reductions in Factor XI activity. In this study, IONIS-FXI<sub>Rx</sub> demonstrated a favorable safety and tolerability profile. There were no treatment-related major or clinically relevant non-major bleeding events.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>14</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We conducted a Phase 1, double-blind, randomized, placebo-controlled, dose-escalation study of IONIS-FXI-L<sub>Rx </sub>in healthy volunteers. In this study, IONIS-FXI-L<sub>Rx</sub> produced significant reductions in FXI activity and FXI antigen, without evidence of increased bleeding. Additionally, IONIS-FXI-L<sub>Rx</sub> demonstrated a favorable safety and tolerability profile in this study. We and Bayer are planning to report the data from this Phase 1 study this year.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In February 2017, we licensed IONIS-FXI-L<sub>Rx </sub>to Bayer. In October 2019, Bayer opted to continue to develop and commercialize IONIS-FXI-L<sub>Rx</sub> following positive clinical results. Bayer plans to advance IONIS-FXI-L<sub>Rx</sub> into a Phase 2 clinical trial. Bayer is responsible for all IONIS-FXI-L<sub>Rx</sub> development, regulatory and commercialization activities and costs.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">ION839</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> &#8211; ION839 (formerly IONIS-AZ6-2.5-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">) is a Generation 2.5 LICA antisense medicine we designed to inhibit an undisclosed target</span>. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We and AstraZeneca </span>are collaborating to develop <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">ION839</span> to treat patients with NASH.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In October 2019, we initiated a Phase 1 clinical study evaluating <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">ION839</span> in healthy volunteers. The current study is a randomized, blinded, placebo-controlled study designed to assess the safety and tolerability of multiple doses of <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">ION839</span>.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Rare Disease Medicines in Development</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are discovering and developing antisense medicines to treat people with rare diseases who have limited or no treatment options. We believe our antisense technology could offer effective therapies for these people. According to the NIH there are approximately 7,000 rare diseases, many life-threatening or fatal. Unfortunately, people with many of these severe and rare diseases have few or no effective therapies available. Since most of these diseases are genetic or have a genetic component, parents often pass the disease to their children resulting in profound impacts through multiple generations. Due to the severe nature of these diseases and the lack of available treatments, there is often an opportunity for more flexible and efficient development paths to the market. For example, SPINRAZA received FDA approval within five years following the start of its first Phase 1 study.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">IONIS</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Rare Disease Clinical Pipeline</span></div>
<div><br /></div>
<div style="text-align: center;"><img src="image4.jpg" width="614" height="214" alt="graphic" /></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">AKCEA-TTR-L</span><sub style="font-weight: bold;">Rx</sub> &#8211; See the medicine description under &#8220;Our Phase 3 Medicines&#8221; section above.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">AKCEA-APOCIII-L</span><sub style="font-weight: bold;">Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</span>&#8211; See the medicine description under &#8220;Ionis&#8217; Cardiometabolic and Renal Disease Clinical Pipeline&#8221; section above.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">IONIS-GHR-L</span><sub style="font-weight: bold;">Rx</sub> &#8211; IONIS-GHR-L<sub>Rx</sub> is a LICA medicine we designed to inhibit the production of the growth hormone receptor, or GHr, to decrease the circulating level of insulin-like growth factor-1, or IGF-1. IGF-1 is a hormone primarily produced in the liver that plays an important role in childhood growth and has anabolic effects in adults. Several different diseases result from abnormally low or high levels of IGF-1, or an inappropriate response to this hormone.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">High levels of circulating GH and IGF-1 lead to multiple diseases characterized by organ overgrowth and physical disfigurement, such as enlarged hands, feet, and facial features. Patients with acromegaly also experience multiple chronic conditions, such as type 2 diabetes, hypertension, and respiratory complications, as well as premature mortality. Because IGF-1 mediates the majority of the growth-promoting action of GH, reducing GHr production could in turn decrease levels of IGF-1 and provide a potential treatment to patients with acromegaly. Current treatments to block IGF-1 include surgical removal of the pituitary gland, which is often unsuccessful. Drug treatments to normalize IGF-1 levels are also available but are associated with potentially serious side effects.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>15</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We completed a Phase 1, double-blind, placebo-controlled, dose-escalation study of IONIS-GHR-L<sub>Rx</sub> in healthy volunteers. In this study, IONIS-GHR-L<sub>Rx</sub> demonstrated a favorable safety and tolerability profile.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In November 2018, we initiated the Phase 2 proof-of-concept clinical study of IONIS-GHR-L<sub>Rx</sub> in acromegaly patients. The study is a randomized, double-blind, placebo-controlled, multi-center study in acromegaly patients uncontrolled on select long-acting somatostatin receptor ligands.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a id="_Hlk33777473"><!--Anchor--></a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">IONIS-PKK-L</span><sub style="font-weight: bold;">Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> &#8211; </span>IONIS-PKK-L<sub>Rx</sub> is a LICA medicine we designed to inhibit the production of prekallikrein, or PKK, to treat people with hereditary angioedema, or HAE. It is a rare genetic disease that is characterized by rapid and painful attacks of inflammation in the hands, feet, limbs, face, abdomen, larynx and trachea and can be fatal if swelling occurs in the larynx. PKK plays an important role in the activation of inflammatory mediators associated with acute attacks of HAE. By inhibiting the production of PKK, IONIS-PKK-L<sub>Rx</sub> could be an effective prophylactic approach to preventing HAE attacks. In patients with frequent or severe attacks, doctors may use prophylactic treatment approaches to prevent or reduce the severity of HAE attacks.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In August 2019, we initiated a Phase 2 study evaluating </span>IONIS-PKK-L<sub>Rx</sub>&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">in patients with HAE. The current study is a randomized, double-blinded, placebo-controlled study designed to assess the clinical efficacy, safety and tolerability of </span>IONIS-PKK-L<sub>Rx</sub>&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">administered subcutaneously.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">IONIS-TMPRSS6-L</span><sub style="font-weight: bold;">Rx</sub> &#8211; IONIS-TMPRSS6-L<sub>Rx</sub> is a LICA medicine we designed to inhibit the production of transmembrane protease, serine 6, or TMPRSS6, to treat anemia and iron toxicity in people with &#946;-thalassemia, a disease caused by mutations in the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">beta globin</span> gene. TMPRSS6 is a protein produced in the liver that is important in the regulation of the body&#8217;s iron homeostasis through the control of the iron regulatory protein hepcidin. Inhibition of TMPRSS6 leads to increased production of hepcidin, which results in more effective red blood cell production in the bone marrow and reduced iron toxicity in the liver as a result of improved control of iron availability.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Patients with &#946;-thalassemia can experience severe anemia, marrow expansion, bone deformities, as well as iron toxicity. While the severity of anemia varies between patients, iron toxicity is a common complication leading to high rates of mortality as a result of iron accumulation in major organs, such as the heart and liver. The current standard of care is managing patients&#8217; symptoms with blood transfusions, and iron chelation medicines designed to remove extra iron from blood.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#946;-thalassemia can be further subdivided into patients with transfusion-dependent thalassemia, or TDT, and non-transfusion dependent thalassemia, or NTDT, including &#946;-thalassemia intermedia. Although transfusions are not needed to support life in patients with NTDT, the associated complications of the disease are severe and often fatal.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Results from preclinical and clinical studies suggest that reducing levels of TMPRSS6 may be an effective strategy to control iron availability, reduce liver iron toxicity and increase red blood cell production under conditions of &#946;-thalassemia. In December 2018, we presented positive Phase 1 data at the ASH Annual Meeting. In a randomized, double-blind, placebo-controlled, dose-escalation Phase 1 study in healthy volunteers, we demonstrated dose-dependent reductions of serum iron and serum transferrin saturation. Additionally, we observed an increase in serum hepcidin and predicted changes in hemoglobin. IONIS-TMPRSS6-L<sub>Rx</sub> demonstrated a favorable safety and tolerability profile.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a id="_Hlk33777721"><!--Anchor--></a>We are planning to begin a Phase 2 study of IONIS-TMPRSS6-L<sub>Rx</sub> in 2020 in patients with NTDT &#946;-thalassemia.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">IONIS-ENAC-2.5</span><sub style="font-weight: bold;">Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> &#8211; </span>IONIS-ENAC-2.5<sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</span>is a Generation 2.5 antisense medicine we designed to selectively reduce epithelial sodium channel, or ENaC, to treat people with cystic fibrosis, or CF. CF is an autosomal recessive disorder caused by mutations in the gene that encodes the cystic fibrosis transmembrane conductance regulator, or CFTR. CFTR is a chloride channel expressed in epithelial cells, including those in the lung. Targeting ENaC may enable treatment of all forms of CF due to various CFTR mutations, unlike existing therapeutics. CF is a multisystem disease that mostly affects the lungs, clogging airways due to mucus build-up and resulting in inflammation and infection. This disease is characterized by a progressive decline in lung function with acute periods of worsened symptoms, known as pulmonary exacerbations. Despite progress with other treatments, there remains a need for additional effective treatment options.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In preclinical studies in transgenic rodents, treatment with ENaC-targeting antisense medicines specifically suppressed ENaC expression, resulting in the reduction of markers of CF mucus pathology and improved lung function. Treatment not only prevented manifestations of the disease from occurring but also reversed existing manifestations of CF in the animal model.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In December 2018, we initiated a Phase 1/2 double-blinded, placebo-controlled, dose-escalation study to evaluate the safety and efficacy of IONIS-ENAC-2.5<sub>Rx</sub>. The study consists of three parts: a single ascending dose, or SAD, regimen and a multiple ascending dose, or MAD, regimen in healthy volunteers, followed by a MAD regimen in patients with CF.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>16</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">ION357 &#8211; </span>ION357 (formerly IONIS-RHO-2.5<sub>Rx</sub>), is a Generation 2.5 antisense medicine we designed to treat patients with a genetic form of autosomal dominant retinitis pigmentosa by inhibiting the production of the rhodopsin P23H mutant protein in the eye while allowing normal protein to be expressed.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Retinitis pigmentosa, or RP, is a group of rare inherited eye disorders causing photoreceptor degeneration that leads to progressive vision loss. Photoreceptors are cells in the eye&#8217;s retina responsible for converting light into signals that are sent to the brain. Photoreceptors provide us our color and night vision. Affected patients first experience defective dark adaptation during adolescence or young adulthood, followed by loss of peripheral visual field when rod photoreceptor function declines. Patients eventually have limited residual central vision, which ultimately leads to complete blindness around the age of 60.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We and ProQR </span>are collaborating to develop <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">ION357 </span>to treat patients with RP. In November 2019, ProQR initiated a Phase 1/2 clinical study evaluating <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">ION357</span> in patients with RP. The current study is a randomized, masked, placebo-controlled study designed to assess the safety and tolerability of <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">ION357</span> in adult patients with RP.</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Anti-Cancer and Other Medicines in Development</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a id="_Hlk33163274"><!--Anchor--></a>Cancer is an area of significant unmet medical need. Cancer is an extremely complex disease that involves a large number of targets. Using our antisense technology, we can validate multiple potential cancer targets for a variety of different cancers, and rapidly identify anti-cancer medicines. We preferentially select anti-cancer targets that can potentially provide a multi-faceted approach to treating cancer.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our anti-cancer pipeline consists of antisense medicines that act upon biological targets associated with cancer progression, treatment resistance, and/or the tumor immune environment. Our alliances with AstraZeneca include an anti-cancer collaboration that expands our efforts. AstraZeneca brings significant experience that enables the identification of novel genetic and epigenetic targets for cancer. We also have collaboration agreements with University of Texas MD Anderson Cancer Center and Oregon Health and Science University Knight Cancer Institute to identify cancer targets and create novel antisense medicines to treat cancer.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In addition to oncology programs, we continue to advance other medicines in development that are outside of our core therapeutic areas, including IONIS-FB-L<sub>Rx</sub> for complement-mediated diseases we and Roche are developing, and antiviral medicines IONIS-HBV<sub>Rx</sub> and IONIS-HBV-L<sub>Rx</sub> GSK is developing.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our Generation 2.5 chemistry enhances the potency and effectiveness of our antisense medicines, and potentially allows us to extend the applicability of our technology to cancers that are difficult to treat. For instance, STAT3 is a protein known to be important in the formation of cancer, however, it has been difficult to approach with traditional drug modalities. Data from a Phase 1b/2 clinical study of danvatirsen in combination with durvalumab, AstraZeneca&#8217;s programmed death ligand, or PD-L1, blocking antibody showed evidence of antitumor activity in people with advanced solid tumors and recurrent metastatic head and neck cancer.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">IONIS</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Oncology/Other Clinical Pipeline</span></div>
<div><br /></div>
<div style="text-align: center;"><img src="image5.jpg" width="610" height="138" alt="graphic" /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zc9417fb4d7464feeb58914918c3be3ec">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">*</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">China rights only</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">IONIS-AR-2.5</span><sub style="font-weight: bold;">Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> &#8211;</span> IONIS-AR-2.5<sub>Rx</sub> is a Generation 2.5 antisense medicine we designed to treat people with prostate cancer by reducing the production of all known forms of androgen receptor, or AR, including variants of the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">AR</span> gene. Prostate cancer is the second leading cause of cancer deaths in American men. Prostate cancer growth, proliferation and progression are all androgen-dependent and AR function is involved in disease progression at all stages of prostate cancer. For patients diagnosed with metastatic prostate cancer, current treatments largely involve opposing the action of androgens by blocking the androgen receptor or removing circulating androgens. Resistance to current therapies is frequent and can occur through a variety of mechanisms including the activation of AR signaling in tumor cells through the amplification, overexpression and mutation of the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">AR </span>gene.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">An open-label, dose-escalation, Phase 1/2 clinical study of IONIS-AR-2.5<sub>Rx</sub> was completed in people with advanced tumors for which the androgen receptor pathway is potentially a contributing factor. The study was primarily conducted in prostate cancer patients and it showed durable responses in a number of those patients. Results from this study demonstrated a safety and tolerability profile supportive of continued development.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In March 2017, we licensed IONIS-AR-2.5<sub>Rx</sub> to Suzhou-Ribo to develop and commercialize the medicine in China.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>17</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Danvatirsen&#8211; </span>Danvatirsen (formerly IONIS-STAT3-2.5<sub>Rx</sub>) is a Generation 2.5 antisense medicine we designed to inhibit the production of signal transducer and activator of transcription 3, or STAT3, to treat people with cancer. STAT3 is a protein involved in the translation of key factors critical for tumor cell growth and survival. STAT3 is over-active in a variety of cancers, including brain, lung, breast, bone, liver and multiple myeloma. Physicians believe that overactivity in STAT3 prevents cancer cell death and promotes tumor cell growth.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In October 2018, we and AstraZeneca announced data from a Phase 1/2 study of danvatirsen in combination with durvalumab in recurrent metastatic head and neck cancer. The combination treatment resulted in seven percent of patients achieving a complete tumor response and 23 percent achieving either a partial or complete tumor response. This response rate is estimated to be double that with durvalumab alone, based on previous studies in this difficult to treat patient population. Results from this study demonstrated a safety and tolerability profile supportive of continued development.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">AstraZeneca is evaluating danvatirsen in a range of cancer types as part of a broader oncology partnership evaluating Generation 2.5 antisense therapies against undruggable targets either alone or in combination with immuno-oncology agents, including in non-small cell lung cancer, bladder cancer and head and neck cancer.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">IONIS-HBV</span><sub style="font-weight: bold;">Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> and IONIS-HBV-L</span><sub style="font-weight: bold;">Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> &#8211; </span>IONIS-HBV<sub>Rx</sub> and IONIS-HBV-L<sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</span>are antisense medicines we designed to inhibit the production of viral proteins associated with hepatitis B virus, or HBV. These include proteins associated with infection and replication, including the hepatitis B surface antigen, or HBsAg, which is present in both acute and chronic infections and is associated with a poor prognosis in people with chronic HBV infection.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">HBV infection is a serious health problem that can lead to significant and potentially fatal health conditions, including cirrhosis, liver failure and liver cancer. Chronic HBV infection is one of the most common persistent viral infections in the world. Currently available therapies, although effective in reducing circulating HBV in the blood, do not effectively inhibit HBV antigen production and secretion, which are associated with poor prognosis and increased risk of liver cancer.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">GSK reported results of the Phase 2 studies with IONIS-HBV<sub>Rx</sub> and IONIS-HBV-L<sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</span>in patients with chronic hepatitis B virus infection at the American Association for the Study of Liver Diseases annual meeting in November 2019. In the Phase 2 study with IONIS-HBV<sub>Rx</sub>, the medicine demonstrated target engagement with dose dependent declines in HBsAg with up to 3-log reductions in HBsAg at 1 month, including two patients who achieved reductions in HBsAg and HBV DNA below levels of detection. In the Phase 2 study with IONIS-HBV-L<sub>Rx</sub>, the medicine demonstrated efficacy similar to IONIS-HBV<sub>Rx</sub>. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In these studies, both </span>IONIS-HBV<sub>Rx</sub> and IONIS-HBV-L<sub>Rx</sub>&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">demonstrated favorable safety and tolerability profiles.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In August 2019, GSK exercised its option to license our HBV program following the positive Phase 2 results described above. Following the licensing, GSK is responsible for all development, regulatory and commercialization activities and costs.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">IONIS-FB-L</span><sub style="font-weight: bold;">Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>&#8211; <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">IONIS-FB-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> is a LICA medicine we designed to inhibit the production of complement factor B, or FB. FB is produced predominantly in the liver and circulates at high levels throughout the vascular system where it plays a pivotal role in an innate immunogenic cascade. Genetic association studies have shown that overactivity of this cascade has been associated with the development of several complement-mediated diseases, including dry age-related macular degeneration, or AMD, and IgA nephropathy, or IgAN.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">AMD is the leading cause of central vision loss in developed countries. It is estimated that the disease will affect more than three million people in the U.S. by 2026. AMD is believed to be a systemic disease with local disease manifestation at the aging retinal macula. AMD gradually destroys vision in the center of the visual field due to progressive damage of the retina.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a id="_Hlk33777794"><!--Anchor--></a>IgAN is one of the most common causes of inflammation that impairs the filtering ability of kidneys worldwide and is an important cause of chronic kidney disease and renal failure. Also known as Berger&#8217;s disease, IgAN is characterized by immunodeposits of IgA in the kidneys, resulting in inflammation and tissue damage. The clinical presentation, disease progression and histologic findings are highly variable.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In May 2017, we reported data from a randomized, placebo-controlled, dose-escalation Phase 1 study evaluating IONIS-FB-L<sub>Rx</sub> in 54 healthy volunteers. Subjects treated with a single dose of IONIS-FB-L<sub>Rx</sub> achieved dose-dependent reductions in plasma FB of up to 50 percent. Treatment with multiple doses of IONIS-FB-L<sub>Rx</sub> during a six-week period resulted in greater reductions in circulating FB levels. In this study, IONIS-FB-L<sub>Rx</sub> demonstrated a favorable safety and tolerability profile.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We and Roche are collaborating to develop IONIS-FB-L<sub>Rx</sub> for the treatment of complement-mediated diseases. In June 2019, we initiated a Phase 2 study evaluating IONIS-FB-L<sub>Rx</sub> in patients with geographic atrophy secondary to age-related macular degeneration. The current study is a randomized, blinded, placebo-controlled study designed to assess the safety, tolerability and pharmacokinetics of multiple ascending doses of IONIS-FB-L<sub>Rx</sub> administered subcutaneously in adults with geographic atrophy.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>18</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In September 2019, we initiated a Phase 2 study of IONIS-FB-L<sub>Rx</sub> in patients with IgA nephropathy. The current study is a single-arm, open-label study designed to assess the safety, tolerability and pharmacokinetics of IONIS-FB-L<sub>Rx</sub> administered subcutaneously in adults with primary IgA nephropathy.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Preclinical Medicines in Development</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The efficiency and broad applicability of our technology enables us to develop medicines for a broad range of diseases. On average, it takes approximately 1-2 years to complete the preclinical studies necessary to support clinical development. In 2019, we added 10 new medicines to our preclinical pipeline.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">IONIS</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Preclinical Pipeline</span></div>
<div><br /></div>
<div style="text-align: center;"><img src="image14.jpg" width="719" height="429" alt="graphic" /></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Akcea Therapeutics: Our Majority Owned Affiliate Focused on Developing and Commercializing Medicines to Treat People with Serious and Rare Diseases</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We formed Akcea Therapeutics and Akcea began operations in 2015. Akcea is focused on developing and commercializing medicines to treat people with serious and rare diseases. As of December 31, 2019, we owned approximately 76 percent of Akcea.</span>&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Akcea is commercializing TEGSEDI and WAYLIVRA, medicines we discovered and developed using our proprietary antisense technology. Additionally, Akcea has a mature pipeline of four of our novel medicines, including AKCEA-APO(a)-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, AKCEA-ANGPTL3-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, AKCEA-APOCIII-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, and AKCEA-TTR-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, with the potential to treat rare and common diseases. Akcea is co-developing these four medicines with us.</span></div>
<div style="background-color: #FFFFFF;">
<div><br /></div>
</div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This report includes financial information for Akcea as a separate business segment. See Note 7, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Segment Information and Concentration of Business Risk,</span> in the Notes to the Consolidated Financial Statements for additional information.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">TEGSEDI</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> &#8211; </span>See the medicine description under &#8220;Our Marketed Medicines&#8221; section above.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">WAYLIVRA &#8211;</span>See the medicine description under &#8220;Our Marketed Medicines&#8221; section above</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">AKCEA-APO(a)-L</span><sub style="font-weight: bold;">Rx</sub> &#8211; See the medicine description under &#8220;Our Phase 3 Medicines&#8221; section above.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">AKCEA-TTR-L</span><sub style="font-weight: bold;">Rx</sub> &#8211; See the medicine description under &#8220;Our Phase 3 Medicines&#8221; section above.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">AKCEA-ANGPTL3-L</span><sub style="font-weight: bold;">Rx</sub> &#8211; See the medicine description under &#8220;Cardiometabolic and Renal Disease Pipeline&#8221; section above.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">AKCEA-APOCIII-L</span><sub style="font-weight: bold;">Rx</sub> &#8211; See the medicine description under &#8220;Cardiometabolic and Renal Disease Pipeline&#8221; section above.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>19</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Antisense Technology</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our antisense technology is an innovative platform for discovering first-in-class and/or best-in-class medicines for treating disease. We believe this technology represents an important advance in the way we treat disease. Unlike most other drug technologies that work by affecting existing proteins in the body, antisense medicines target RNA, the intermediary that conveys genetic information from a gene to the protein synthesis machinery in the cell. By targeting RNA instead of proteins, we can use antisense technology to increase, decrease or alter the production of specific proteins. The unique properties of antisense technology provide several advantages over traditional drug discovery technologies.</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">These advantages include:</div>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zc89fa21bd32f4365be7722ae263d099a">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Direct intervention in the disease process at the genetic level by targeting RNA: antisense technology represents a direct route from gene to drug. The explosion in genomic information and RNA biology has led to the discovery of many new disease-causing proteins and RNAs and has created new opportunities that are uniquely accessible to antisense technology.</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z59155cde61b74d87b897ba75574b7511">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Precise specificity: we design antisense medicines to target a single RNA, which minimizes or eliminates the possibility our medicines will bind to unintended targets, which can cause unwanted side effects.</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z940ed64ee11d46aabc89ab1f0d949689">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Good drug properties: antisense medicines distribute well throughout the body without the need for special formulations or vehicles. They also have a relatively long half-life in the range of weeks to months, which means patients and/or healthcare providers can dose our medicines weekly, monthly or even less frequently depending on the medicine and target tissue.</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z622aff28136d49d497bb108713c986f5">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ability to combine with other medicines: because antisense medicines do not interact with the enzymes that metabolize or break down other medicines, physicians can use our medicines in combination with other medicines.</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z193db6ec84a245be81c74c45be1a6f54">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Broad applications to multiple disease targets, multiple tissues and multiple mechanisms: there are virtually no &#8220;undruggable&#8221; targets with antisense technology.</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zf2cabc64302c4e278eabb1fde4baf4ac">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Efficient discovery and early development: because of the efficiency of our antisense technology, our drug discovery and early development costs and success rates compare favorably to small molecule or antibody drug discovery and development.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We develop antisense medicines to potentially treat a wide range of diseases in a number of different therapeutic areas from severe and rare diseases to diseases that affect large patient populations. We focus our efforts on diseases in which there is a large unmet medical need with limited or no current treatments or in diseases for which we believe our medicines have a competitive advantage over existing therapies.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Technology Overview</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We use our core technology platform to discover and develop medicines that affect targets in the body at the genetic level. Genes contain the information necessary to produce proteins. A gene is made up of nucleotides containing the nucleoside bases: adenine, thymine, guanine, and cytosine, commonly known as A, T, G and C, which are linked together to form a two-stranded structure that resembles a twisted ladder, known as deoxyribonucleic acid, or DNA. The nucleotides on one side of the ladder bind weakly to complementary nucleotides on the other strand according to specific rules; for example, A pairs with T and G pairs with C, creating the ladder&#8217;s rungs (Figure 1). Scientists call this highly specific nucleotide pairing hybridization. The sequence or order of these nucleotides establishes the cell&#8217;s recipes for making proteins. Each protein&#8217;s instructions reside in a corresponding segment of DNA known as a gene.</div>
<div><br /></div>
<div style="text-align: center;"><img src="image6.jpg" width="561" height="468" alt="graphic" /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Figure 1: Illustration of DNA.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>20</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The instructions for making a protein are transcribed from a gene, or DNA into a different genetic molecule called messenger RNA. This process starts with the partial uncoiling of the two complementary strands of the DNA. One strand acts as a template and information stored in the DNA template strand is copied into a complementary RNA (Figure 2) by an enzyme called RNA polymerase, or RNAP. Messenger RNA, or mRNA, are mature, fully processed RNA that code for proteins.</div>
<div><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><img src="image7.jpg" width="716" height="252" alt="graphic" /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Figure 2: Transcription of information contained in a gene, or DNA, to RNA.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ribosomes, the cell&#8217;s factories for manufacturing proteins, translate mRNA into proteins. The ribosome reads the encoded information, the mRNA&#8217;s nucleotide sequence, and in doing so, strings together amino acids to form a specific protein (Figure 3).</div>
<div><br /></div>
<div style="text-align: center;"><img src="image8.jpg" width="497" height="427" alt="graphic" /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Figure 3: Translation of the protein-coding information contained in mRNA to protein.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We primarily use our antisense technology to interrupt the cell&#8217;s protein production process by preventing the mRNA instructions from reaching the ribosome, thus inhibiting the production of the protein. We can also design antisense medicines to increase protein production for diseases caused by the lack of a particular protein or modify the processing (or splicing) of the mRNA, which can alter the composition of the protein. The mRNA sequence of nucleotides that carries the information for protein production is called the &#8216;sense&#8217; strand. Scientists call the complementary nucleotide chain that binds specifically to the sense strand the &#8220;antisense&#8221; strand. We use the information contained in mRNA to design chemical structures, that we call antisense oligonucleotides, or ASOs, or antisense medicines, which resemble DNA and RNA and are the complement of RNA. Our antisense medicines bind with high selectivity to the mRNA they were designed to target. Since each mRNA codes for a specific protein, this selectivity provides a level of specificity that is better than traditional medicines. As a result, we can design antisense medicines that selectively inhibit the disease-causing member of a protein family without interfering with other members of the protein family that might be necessary for normal cellular or bodily functions. This unique specificity means that antisense medicines may be less toxic than traditional medicines because we can design them to minimize the impact on unintended targets.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>21</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have developed the majority of the medicines in our pipeline using our advanced screens to produce medicines with what we believe have the best possible safety and tolerability profiles. We refer to our medicines that have passed these advanced screens as Generation 2+ medicines. We continue to advance our antisense technology to create even more potent medicines that we can use in more tissues and against more targets. These advances allow us to expand the mechanisms through which we can use our medicines and provide us with greater opportunities to use our antisense medicines to treat a greater number of diseases and reach more patient populations. Today several of our early stage medicines and those entering our pipeline use our most advanced antisense technology, including our next generation chemistries, Generation 2.5, and our LICA technology.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Generation 2.5 chemistry is an advancement that we have demonstrated increases the potency of our medicines by up to 10-fold over our Generation 2+ medicines. This increase in potency enables our medicines to engage targets in a broader array of tissues. We have published data demonstrating that our Generation 2.5 medicines generally have enhanced potency over our Generation 2+ medicines and are broadly distributed throughout the body to multiple tissues including liver, kidney, lung, muscle, adipose, adrenal gland, peripheral nerves and tumor tissues. Our Generation 2.5 medicines constitute some of our recently added new medicines to our pipeline.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">LICA is a chemical technology we developed that involves attaching a molecule called a ligand that binds with receptors on the surfaces of cells in a highly specific manner. Because these receptors are often found only on certain cell types, LICA allows us to increase effective delivery of our antisense medicines with higher specificity to certain cell types that express these receptors relative to non-conjugated antisense medicines. As of December 2019, we have an integrated assessment of data from multiple LICA medicines and over 1,100 subjects who have been treated with our LICA medicines. Our integrated assessment includes a substantial number of subjects on treatment for one year from randomized placebo-controlled dose-ranging studies. Our integrated assessment demonstrated that our LICA technology for liver targets can increase potency by up to 30-fold over our non-LICA antisense medicines.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In addition to the increase in potency, a favorable safety and tolerability profile was observed and was consistent across the LICA platform. For example, AKCEA-APO(a)-L<sub>Rx</sub> exemplifies these improvements. We designed this medicine to reduce the production of Apo(a), protein in the liver to offer a direct approach for reducing Lp(a). In the Phase 2 AKCEA-APO(a)-L<sub>Rx </sub>study, AKCEA-APO(a)-L<sub>Rx</sub> was the first and only medicine to selectively and robustly reduce Lp(a) levels below threshold levels associated with CVD in nearly all patients. This study included more than 280 patients, with 98 percent of patients in the high dose group achieving levels below 50 mg/dL, the recognized risk threshold for CVD. The safety and tolerability profile from this study was favorable and there were no safety concerns related to platelets, liver or kidney function.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We can also combine our LICA technology with our Generation 2.5 chemistry, further increasing potency. This increase in potency may enable oral delivery of our antisense medicines. In addition to the LICA technology for liver targets, we are also developing LICA conjugation technology that we can use to target other tissues, such as the pancreas, and initial results are promising.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Antisense Targets and Mechanisms</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">There are more than a dozen different antisense mechanisms that we can exploit with our antisense technology. The majority of the medicines in our pipeline bind to mRNAs and inhibit the production of disease-causing proteins. However, our antisense technology is broadly applicable to many different antisense mechanisms, including modulation of RNA splicing, RNA interference, or RNAi, and enhancing protein translation to increase protein production.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;When using antisense technology to inhibit the production of disease-causing proteins or reduce levels of harmful RNAs, our antisense medicines bind to the target RNA via highly specific nucleotide pairing, or hybridization, and recruit a cellular enzyme called ribonuclease H1, or RNase H1, to degrade the target RNA. The antisense medicine itself remains intact during this process, so it can remain active against additional target RNA molecules and repeatedly trigger their degradation (Figure 4). Examples of our antisense medicines that use the RNase H1 mechanism to reduce disease protein production include, TEGSEDI, WAYLIVRA, tominersen, AKCEA-APO(a)-L<sub>Rx</sub>, IONIS-FXI-L<sub>Rx,</sub>, and others.</div>
<div><br /></div>
<div style="text-align: center;"><img src="image9.jpg" width="449" height="414" alt="graphic" /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Figure 4: Antisense medicine using the RNase H mechanism of action.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>22</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SPINRAZA is an example of an antisense medicine that modulates RNA splicing to increase protein production of the SMN protein (Figure 5), which is critical to the health and survival of nerve cells in the spinal cord that are responsible for neuro-muscular function. The SMN protein is deficient in people with SMA. There are a number of other diseases, including cystic fibrosis and Duchenne muscular dystrophy, which may be treated by modulating splicing using antisense technology.</div>
<div><br /></div>
<div style="text-align: center;"><img src="image10.jpg" width="579" height="354" alt="graphic" /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Figure 5: Antisense medicine altering splicing of the SMN2 mRNA.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are also making progress in designing antisense medicines to target long, non-coding RNAs, or lncRNAs and RNAs that possess a toxic function in human diseases. Many of these RNAs, such as lncRNAs, do not make proteins but often cause disease by regulating the function of other genes or proteins. In 2014, we published a paper in <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Nature</span> in which we were the first to show that targeted reduction of a lncRNA with an antisense compound can ameliorate certain cognitive deficits in a mouse model of Angelman syndrome, or AS. Moreover, these studies demonstrate the potential therapeutic benefits of antisense medicines for the treatment of AS.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 35.3pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Because the efficiency of our core technology platform can support multiple target-based antisense research programs, we can develop antisense medicines to target a broad range of diseases, efficiently producing a large and broad proprietary portfolio of medicines. We are currently pursuing antisense drug discovery programs focused on various rare diseases, cardiometabolic diseases, neurologic diseases, cancer and other diseases.</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Collaborative Arrangements</div>
<div><br /></div>
<div style="background-color: #FFFFFF;">
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We strive to find the optimum organization to develop and commercialize each of our antisense medicines. We have established alliances with a cadre of leading global pharmaceutical companies that are working alongside us in developing our medicines, advancing our technology, preparing to commercialize our medicines and selling our medicines. Our partners include the following companies, among others: AstraZeneca, Bayer, Biogen, GSK, Janssen, Novartis, Pfizer and Roche. Our partners bring resources and expertise that augment and build upon our internal capabilities and in many cases, add value by conducting development and regulatory activities and paying for these activities. The depth of our knowledge and expertise with antisense technology together with our strong financial position enables us to partner our medicines at what we believe is the optimal time to maximize the value of our medicines. We have distinct partnering strategies that we employ based on the specific program, therapeutic area and the expertise and resources our potential partners may bring to the collaboration.</div>
<div><br /></div>
</div>
<div style="text-align: justify; text-indent: 39.6pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Through our partnerships, we have earned both commercial revenue and a broad and sustaining base of R&amp;D revenue in the form of license fees, upfront payments and milestone payments. In 2019, we recognized more than $1.1 billion in revenue, primarily from our partnerships. We have the potential to earn more than $20 billion in future milestone payments, licensing fees and other payments from our current partnerships, not including potential royalties. Below, we include the significant terms of our collaboration agreements. For additional details, including other financial information, see Note 6, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Collaborative Arrangements and Licensing Agreements,</span> in the Notes to the Consolidated Financial Statements.</div>
<div style="background-color: #FFFFFF;">
<div><br /></div>
</div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>23</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Strategic Partnership</div>
<div><br /></div>
<div style="background-color: #FFFFFF;">
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Biogen</div>
</div>
<div style="background-color: #FFFFFF;">
<div><br /></div>
</div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We have several strategic collaborations with Biogen focused on using antisense technology to advance the treatment of neurological disorders. These collaborations combine our expertise in creating antisense medicines with Biogen&#8217;s expertise in developing therapies for neurological disorders. We developed and licensed to Biogen SPINRAZA, our approved medicine to treat people with spinal muscular atrophy, or SMA. In</span> December 2017, we entered into a collaboration with Biogen to identify <span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">new antisense medicines for the treatment of SMA</span>. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We and Biogen are currently developing eight medicines under our collaborations, including medicines to treat people with ALS, Alzheimer&#8217;s disease</span><sub>&#160;</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">and Parkinson&#8217;s disease. In addition to these medicines, our collaborations with Biogen include a substantial research pipeline that addresses a broad range of neurological diseases. From inception through February 2020, we have generated more than $2.5 billion from our Biogen collaborations, including $1 billion we received from Biogen in the second quarter of 2018 for our 2018 strategic neurology collaboration.</span></div>
<div style="background-color: #FFFFFF;">
<div><br /></div>
</div>
<div style="background-color: #FFFFFF;">
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Spinal Muscular Atrophy Collaborations</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">SPINRAZA</div>
<div><br /></div>
</div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In January 2012, we entered into a collaboration agreement with Biogen to develop and commercialize SPINRAZA, an RNA-targeted therapy for the treatment of SMA. Biogen reported in </span>January 2020 that SPINRAZA was approved in over 50 countries around the world. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">From inception through December 2019, we generated more than $1 billion in total revenue under our SPINRAZA collaboration, including more than $640 million in revenue from SPINRAZA royalties and more than $435 million in R&amp;D revenue. We are receiving tiered royalties ranging from 11 percent to 15 percent on sales of SPINRAZA. We have exclusively in-licensed patents related to SPINRAZA from Cold Spring Harbor Laboratory and the University of Massachusetts. We pay Cold Spring Harbor Laboratory and the University of Massachusetts a low single digit royalty on net sales of SPINRAZA. Biogen is responsible for global development, regulatory and commercialization activities and costs for SPINRAZA.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">New antisense medicines for the treatment of SMA</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In December 2017, we entered into a collaboration agreement with Biogen to </span>identify <span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">new antisense medicines for the treatment of SMA</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. </span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Biogen has the option to license therapies arising out of this collaboration following the completion of preclinical studies. Upon licensing, Biogen </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">will be responsible for all further global development, regulatory and commercialization activities and costs for such therapies</span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. Under the collaboration agreement, we received a </span>$25 million<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> upfront payment in December 2017. We will receive development and regulatory milestone payments from Biogen if new medicines advance towards marketing approval. </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In total over the term of our collaboration, we are eligible to receive up to $1.2 billion in license fees, milestone payments and other payments. In addition, we are eligible to receive tiered royalties </span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">from the mid-teens to </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">mid-20 percent range </span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">on net sales.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Neurology Collaborations</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">2018 Strategic Neurology</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In April 2018, we and Biogen entered into a strategic collaboration to develop novel antisense medicines for a broad range of neurological diseases and entered into a Stock Purchase Agreement, or SPA. As part of the collaboration, Biogen gained exclusive rights to the use of our antisense technology to develop therapies for these diseases for 10 years. We are responsible for the identification of antisense drug candidates based on selected targets</span>. Biogen is responsible for conducting IND-enabling toxicology studies for the selected target. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Biogen will have the option to license the selected target </span>after it completes the IND-enabling toxicology study. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">If Biogen exercises its option to license a medicine, it will assume </span>all <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">further global development, regulatory and commercialization responsibilities and costs for that medicine. </span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In the second quarter of 2018, we received </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$1 billion from Biogen, comprised of $</span>625<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million to purchase our stock at an approximately 25 percent cash premium and $375 million in an upfront payment. </span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We are eligible to receive up to $</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">270</span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in milestone payments for each medicine that achieves marketing approval. </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In addition, we are eligible to receive tiered royalties </span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">up to the </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">20 percent range </span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">on net sales.</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Through December 2019, w</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">e have advanced six targets under this collaboration, including two new targets we advanced in the fourth quarter of 2019. </span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">W</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">e have generated over $1.05 billion in payments through February 2020, including $15 million we generated in the fourth quarter of 2019 for advancing two targets under this collaboration.</span></div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">2013 Strategic Neurology</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In September 2013, we and Biogen entered into a long-term strategic relationship focused on applying antisense technology to advance the treatment of neurodegenerative diseases. As part of the collaboration, Biogen gained exclusive rights to the use of our antisense technology to develop therapies for neurological diseases and has the option to license medicines resulting from this collaboration. We will usually be responsible for drug discovery and early development of antisense medicines and Biogen will have the option to license antisense medicines after Phase 2 proof-of-concept. In October 2016, we expanded our collaboration to include additional research activities we will perform. If Biogen exercises its option to license a medicine, it will assume all further global development, regulatory and commercialization responsibilities and costs for that medicine. We are currently advancing five medicines in development under this collaboration, including a medicine for Parkinson&#8217;s disease, two medicines for ALS and two medicines for undisclosed targets. In December 2018, Biogen exercised its option to license one of our ALS medicines, tofersen, and as a result Biogen is now responsible for all further global development, regulatory and commercialization activities and costs for tofersen.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>24</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under the terms of the agreement, we received an upfront payment of $100 million and are eligible to receive milestone payments, license fees and royalty payments for all medicines developed under this collaboration, with the specific amounts dependent upon the modality of the molecule advanced by Biogen. For each antisense molecule that is chosen for drug discovery and development under this collaboration, we are eligible to receive up to approximately $260 million in a license fee and milestone payments per program. In addition, we are eligible to receive tiered royalties up to the mid-teens on net sales from any antisense medicines developed under this collaboration. We have generated over $240 million through February 2020, including $10 million we earned in the fourth quarter of 2019 when Biogen advanced IONIS-C9<sub>Rx</sub> in development.</div>
<div style="background-color: #FFFFFF;">
<div><br /></div>
</div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">2012 Neurology</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In December 2012, we and Biogen entered into a collaboration agreement to develop and commercialize up to three novel antisense medicines to treat neurodegenerative diseases. We are responsible for the development of each of the medicines through the completion of the initial Phase 2 clinical study for such medicine. Biogen has the option to license a medicine from each of the programs through the completion of the first Phase 2 study for each program. Under this collaboration, we are currently advancing IONIS-MAPT<sub>Rx</sub> for Alzheimer&#8217;s disease and ION581 for Angelman syndrome. If Biogen exercises its option to license a medicine, it will assume all further global development, regulatory and commercialization responsibilities and costs for that medicine. In December 2019, Biogen exercised its option to license IONIS-MAPT<sub>Rx</sub> and as a result Biogen is now responsible for all further global development, regulatory and commercialization activities and costs for IONIS-MAPT<sub>Rx</sub>.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under the terms of the agreement, we received an upfront payment of $30 million. Over the term of the collaboration, we are eligible to receive up to $210 million in a license fee and milestone payments per program, plus a mark-up on the cost estimate of the Phase 1 and 2 studies. In addition, we are eligible to receive tiered royalties up to the mid-teens on net sales of any medicines resulting from each program under the agreement. We have generated over $130 million through February 2020, including $45 million we earned when Biogen licensed IONIS-MAPT<sub>Rx </sub>and $10 million when Biogen advanced ION581, both of which occurred in the fourth quarter of 2019. We also achieved a $7.5 million milestone payment in the first quarter of 2020 for advancing IONIS-MAPT<sub>Rx</sub>.</div>
<div style="background-color: #FFFFFF;">
<div><br /></div>
</div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Research, Development and Commercialization Partners</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">AstraZeneca</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Cardiovascular, Renal and Metabolic Diseases Collaboration</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In July 2015, we and AstraZeneca formed a collaboration to discover and develop antisense therapies for treating cardiovascular, renal and metabolic diseases. Under our collaboration, AstraZeneca has licensed three medicines from us: IONIS-AZ4-2.5-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, a medicine we designed to treat cardiovascular disease and our first </span>medicine that combines our Generation 2.5 and<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> LICA technology, ION532, a medicine we designed to </span>treat a genetically associated form of kidney disease and <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">ION839, a medicine we designed to </span>inhibit an undisclosed to treat patients with NASH<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. AstraZeneca is responsible for all further global development, regulatory and commercialization activities and costs for each of the medicines it has licensed and any medicines AstraZeneca licenses in the future.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under the terms of the agreement, we received a $65 million upfront payment. We are eligible to receive license fees and milestone payments of up to more than $4 billion as medicines under this collaboration advance. In addition, we are eligible to receive tiered royalties up to the low teens on net sales from any product that AstraZeneca successfully commercializes under this collaboration agreement. We have generated over $175 million in payments through February 2020, including a $10 million milestone payment we earned in the fourth quarter of 2019 when AstraZeneca initiated a Phase 1 trial for ION839.</div>
<div style="background-color: #FFFFFF;">
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Oncology Collaboration</div>
<div><br /></div>
</div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In December 2012, we entered into a collaboration agreement with AstraZeneca to discover and develop antisense medicines to treat cancer. As part of the agreement, we granted AstraZeneca an exclusive license to develop and commercialize </span>danvatirsen <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">for the treatment of cancer. AstraZeneca is responsible for all global development, regulatory and commercialization activities for </span>danvatirsen<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. We and AstraZeneca have evaluated </span>danvatirsen<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in people with head and neck cancer, advanced lymphoma and advanced metastatic hepatocellular carcinoma. AstraZeneca is evaluating </span>danvatirsen<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in combination with durvalumab, AstraZeneca&#8217;s PD-L1, blocking medicine, in people with head and neck cancer, metastatic bladder cancer and metastatic non-small cell lung cancer. We and AstraZeneca also established an oncology research program. AstraZeneca has the option to license medicines resulting from the program, and if AstraZeneca exercises its option to license a medicine, it will be responsible for all further global development, regulatory and commercialization activities and costs for such medicine. In the fourth quarter of 2018, we added </span>a second medicine under our oncology collaboration,<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>ION736, (formerly IONIS-AZ7-2.5<sub>Rx</sub>) to our preclinical pipeline,.</div>
<div style="background-color: #FFFFFF;">
<div><br /></div>
</div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Under the terms of this agreement, we received $31 million in upfront payments. We are eligible to receive milestone payments and license fees from AstraZeneca as programs advance in development. If AstraZeneca successfully develops </span>danvatirsen<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and ION736 under the research program, we could receive license fees and milestone payments of up to more than $450 million. In addition, we are eligible to receive tiered royalties up to the mid-teens on net sales from any medicines resulting from these programs. We have generated over $125 million in payments through February 2020, including nearly $30 million in milestone payments we achieved when AstraZeneca advanced</span> danvatirsen and ION736 in the fourth quarter of 2018.</div>
<div style="background-color: #FFFFFF;">
<div><br /></div>
</div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>25</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="background-color: #FFFFFF;">
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Bayer</div>
</div>
<div style="background-color: #FFFFFF;">
<div><br /></div>
</div>
<div style="background-color: #FFFFFF;">
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In May 2015, we entered into an exclusive license agreement with Bayer to develop and commercialize IONIS-FXI<sub>Rx</sub> for the prevention of thrombosis. We were responsible for completing a Phase 2 study of IONIS-FXI<sub>Rx</sub> in people with end-stage renal disease on hemodialysis. Under the terms of the agreement, we received a $100 million upfront payment in the second quarter of 2015. In February 2017, we amended our agreement with Bayer to advance IONIS-FXI<sub>Rx</sub> and to initiate development of IONIS-FXI-L<sub>Rx</sub>, which Bayer licensed. In conjunction with the decision to advance these programs, we received a $75 million payment from Bayer. In October 2019, Bayer decided it would advance IONIS-FXI-L<sub>Rx</sub> following positive clinical results. Bayer is now responsible for all global development, regulatory and commercialization activities and costs for the FXI program. We are eligible to receive additional milestone payments as the FXI program advances toward the market. Over the term of the collaboration, we are eligible to receive up to $385 million in license fees, milestone payments and other payments. In addition, we are eligible to receive tiered royalties in the low to high 20 percent range on gross margins of both medicines combined. We have generated over $185 million through February 2020, including a $10 million milestone payment we earned in the fourth quarter of 2019 when Bayer decided it would advance IONIS-FXI-L<sub>Rx</sub>.</div>
</div>
<div style="background-color: #FFFFFF;">
<div><br /></div>
</div>
<div style="background-color: #FFFFFF;">
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">GSK</div>
<div><br /></div>
</div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In March 2010, we entered into an alliance with GSK using our antisense drug discovery platform to discover and develop new medicines against targets for rare and serious diseases, including infectious diseases and some conditions causing blindness. Under the collaboration, we received upfront payments of $35 million. Our collaboration with GSK includes two medicines targeting hepatitis B virus, or HBV: IONIS-HBV<sub>Rx</sub> and IONIS-HBV-L<sub>Rx</sub>, which we designed to reduce the production of viral proteins associated with HBV infection. In the third quarter of 2019, following positive Phase 2 results, GSK licensed our HBV program. GSK is responsible for all global development, regulatory and commercialization activities and costs for the HBV program. Under our agreement, if GSK successfully develops these medicines and achieves pre-agreed sales targets, we could receive license fees and milestone payments of up to $262 million. In addition, we are eligible to receive tiered royalties up to the mid-teens on net sales from any product that GSK successfully commercializes under this alliance. We have generated over $185 million in payments through February 2020, including a $25 million license fee we earned in the third quarter of 2019 when GSK licensed the HBV program.</div>
<div style="background-color: #FFFFFF;">
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Janssen Biotech, Inc.</div>
</div>
<div style="background-color: #FFFFFF;">
<div><br /></div>
</div>
<div style="background-color: #FFFFFF;">
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In December 2014, we entered into a collaboration agreement with Janssen Biotech, Inc. to discover and develop antisense medicines that can be locally administered, including oral delivery, to treat autoimmune disorders of the GI tract. Janssen had the option to license medicines from us through the designation of development candidates for up to three programs. Under our collaboration, Janssen licensed ION253 in November 2017, which is currently in preclinical development. Prior to Janssen&#8217;s license of ION253, we were responsible for the discovery activities to identify development candidates. Under the license, Janssen is responsible for the global development, regulatory and commercial activities for ION253. Under the terms of the agreement, we received $35 million in upfront payments. In addition, we are eligible to receive tiered royalties up to the near teens on net sales from any medicines resulting from this collaboration. We are eligible to receive up to $285 million in <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">milestone payments and license fees </span>for ION253. We have generated over $75 million through February 2020.</div>
<div><br /></div>
</div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Roche</div>
<div style="background-color: #FFFFFF;">
<div><br /></div>
</div>
<div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Huntington&#8217;s Disease</div>
<div style="background-color: #FFFFFF;">
<div><br /></div>
</div>
<div style="background-color: #FFFFFF;">
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In April 2013, we formed an alliance with Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd., collectively Roche, to develop treatments for HD based on our antisense technology. Under the agreement, we discovered and developed tominersen, an antisense medicine targeting HTT protein. We developed tominersen through completion of our Phase 1/2 clinical study in people with early stage HD. In December 2017, upon completion of the Phase 1/2 study, Roche exercised its option to license tominersen<sub>&#160;</sub>and is now responsible for the global development, regulatory and commercialization activities and costs for tominersen. Under the terms of the agreement, we received an upfront payment of $30 million in April 2013. We are eligible to receive up to $365 million in a license fee and milestone payments as tominersen advances. In addition, we are eligible to receive up to $136.5 million in milestone payments for each additional medicine successfully developed. We are also eligible to receive tiered royalties up to the mid-teens on net sales from any product resulting from this alliance. We have generated over $145 million through February 2020, including $35 million in milestone payments we generated in the first quarter of 2019 when Roche dosed the first patient in a Phase 3 study for tominersen.</div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">IONIS-FB-L</span><sub><span style="background-color: #FBFBFB;">Rx</span></sub><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for Complement-Mediated Diseases</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In October 2018, we entered into a collaboration agreement with Roche to</span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> develop IONIS-FB-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for the treatment of complement-mediated diseases. We are currently conducting Phase 2 studies in two disease indications for </span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">IONIS-FB-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, one for the treatment of patients with GA, the advanced stage of dry AMD, and a second for the treatment of patients with IgA nephropathy. </span>Roche<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> has the option to license IONIS-FB-L</span><sub><span style="background-color: #FBFBFB;">Rx</span></sub><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> at the completion of these studies. Upon licensing, </span>Roche <span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">will be responsible for all further global development, regulatory and commercialization activities and costs.</span>&#160;<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Under the terms of this agreement, we received a </span>$75 million<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> upfront payment in October 2018. We are eligible to receive up to </span>$684 million<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in milestone payments and license fees. In addition, we are also eligible to receive tiered royalties from the high teens to </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">twenty percent</span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> on net sales.</span></div>
<div style="background-color: #FFFFFF;">
<div><br /></div>
</div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>26</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Akcea Collaborations</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following collaboration agreements relate to Akcea, our majority owned affiliate. Our consolidated results include all the revenue earned, cash received and expenses incurred under these collaboration agreements. We reflect the noncontrolling interest attributable to other owners of Akcea&#8217;s common stock in a separate line on the statement of operations and a separate line within stockholders&#8217; equity on our consolidated balance sheet.</div>
<div style="background-color: #FFFFFF;">
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Novartis</div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In January 2017, we and Akcea initiated a collaboration with Novartis to develop and commercialize AKCEA-APO(a)-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and AKCEA-APOCIII-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</span><sub>&#160;</sub>Akcea received a $75 million upfront payment in the first quarter of 2017. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In February 2019, Novartis licensed AKCEA-APO(a)-L</span><sub>Rx</sub> and we earned a $150 million license fee. Novartis is responsible for conducting and funding all future development, regulatory and commercialization activities for AKCEA-APO(a)-L<sub>Rx</sub>, including a global Phase 3 cardiovascular outcomes study, which Novartis initiated in December 2019.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>In connection with Novartis&#8217; license of AKCEA-APO(a)-L<sub>Rx</sub>, Akcea and Novartis established a more definitive framework under which the companies would negotiate the co-commercialization of AKCEA-APO(a)-L<sub>Rx</sub> in selected markets. Included in this framework is an option by which Novartis could solely commercialize AKCEA-APO(a)-L<sub>Rx</sub> in exchange for Novartis paying Akcea increased commercial milestone payments based on sales of AKCEA-APO(a)-L<sub>Rx</sub>. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">When Novartis decided to not exercise its option for </span>AKCEA-APOCIII-L<sub>Rx</sub>, Akcea retained rights to develop and commercial AKCEA-APOCIII-L<sub>Rx</sub>.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under the collaboration, Akcea is eligible to receive up to $675 million in milestone payments related to AKCEA-APO(a)-L<sub>Rx</sub>. Akcea is also eligible to receive tiered royalties in the mid-teens to low 20 percent range on net sales of AKCEA-APO(a)-L<sub>Rx</sub>. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We have generated approximately $345 million through February 2020 under this collaboration. </span>Akcea paid us a portion of the upfront payment it received from Novartis in 2017 and 50 percent of the license fee it received from Novartis in 2019 and will pay 50 percent of milestone payments and royalties to us as sublicense fees.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In conjunction with this collaboration, we entered into a SPA with Novartis. As part of the SPA, Novartis purchased 1.6 million shares of our common stock for $100 million in the first quarter of 2017 and purchased $50 million of Akcea&#8217;s common stock at the IPO price concurrent with the IPO in July 2017.</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Pfizer</div>
<div style="text-align: justify; text-indent: 36pt;"><a id="_Hlk33099596"><!--Anchor--></a><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In October 2019, Akcea initiated a collaboration with Pfizer for the license of AKCEA<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-ANGPTL3-L</span><sub>Rx</sub> to treat people with cardiovascular and metabolic diseases. Akcea conducted a Phase 2 study of AKCEA<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-ANGPTL3-L</span><sub>Rx</sub> for the treatment of non-alcoholic fatty liver disease, or NAFLD. Pfizer is responsible for all development and regulatory activities and costs beyond those associated with this recently completed Phase 2 study.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Under the terms of the agreement, Akcea received a $250 million upfront license fee. Akcea is also eligible to receive development, regulatory and sales milestone payments of up to $1.3 billion and tiered royalties in the mid-teens to low 20 percent range on annual worldwide net sales. Akcea has retained the rights to co-commercialize AKCEA</span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-ANGPTL3-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in the U.S. and certain additional markets. The license fee, milestone payments and royalties will be split equally between us and Akcea. During the fourth quarter of 2019, we received </span>6.9 million shares of Akcea common stock for <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">payment of the </span>$125 million sublicense fee Akcea owed us.</div>
<div style="text-align: justify; text-indent: 36pt;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">PTC Therapeutics</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In August 2018, Akcea entered into an exclusive license agreement with PTC Therapeutics to commercialize TEGSEDI and WAYLIVRA in Latin America. Under the license agreement, Akcea is eligible to receive up to $26 million in payments. Akcea is eligible to receive royalties from PTC in the mid-20 percent range on net sales in Latin America for each medicine. PTC&#8217;s obligation to pay Akcea royalties begins on the earlier of 12 months after the first commercial sale of a product in Brazil or the date that PTC recognizes revenue of at least $10 million in Latin America. Consistent with the agreements between Ionis and Akcea, the companies will share all payments, including royalties. We have generated over $20 million through February 2020, including $6 million when WAYLIVRA was approved in the EU in the second quarter of 2019 and $4 million when PTC received approval for TEGSEDI in Brazil in the fourth quarter of 2019.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>27</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="background-color: #FFFFFF;">
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Other Agreements</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Alnylam Pharmaceuticals, Inc.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under the terms of our agreement with Alnylam, we exclusively licensed to Alnylam our patent estate relating to antisense motifs and mechanisms and oligonucleotide chemistry for double-stranded RNAi therapeutics in exchange for a technology access fee, participation in fees from Alnylam&#8217;s partnering programs, as well as future milestone and royalty payments from Alnylam. We also have the potential to earn a portion of payments that Alnylam receives from licenses of our technology it grants to its partners, plus royalties. We retained rights to a limited number of double-stranded RNAi therapeutic targets and all rights to single-stranded RNAi, or ssRNAi, therapeutics. In turn, Alnylam nonexclusively licensed to us its patent estate relating to antisense motifs and mechanisms and oligonucleotide chemistry to research, develop and commercialize single-stranded antisense therapeutics, ssRNAi therapeutics, and to research double-stranded RNAi compounds. We also received a license to develop and commercialize double-stranded RNAi medicines targeting a limited number of therapeutic targets on a nonexclusive basis. Additionally, in 2015, we and Alnylam entered into an alliance in which we cross-licensed intellectual property. Under this alliance, we and Alnylam each obtained exclusive license rights to four therapeutic programs. Alnylam granted us an exclusive, royalty-bearing license to its chemistry, RNA targeting mechanism and target-specific intellectual property for oligonucleotides against four targets, including FXI and Apo(a) and two other targets. In exchange, we granted Alnylam an exclusive, royalty-bearing license to our chemistry, RNA targeting mechanism and target-specific intellectual property for oligonucleotides against four other targets. Alnylam also granted us a royalty-bearing, non-exclusive license to new platform technology arising from May 2014 through April 2019 for single-stranded antisense therapeutics. In turn, we granted Alnylam a royalty-bearing, non-exclusive license to new platform technology arising from May 2014 through April 2019 for double-stranded RNAi therapeutics.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">The Ludwig Institute; Center for Neurological Studies</div>
</div>
<div style="background-color: #FFFFFF;">
<div><br /></div>
</div>
<div style="background-color: #FFFFFF;">
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have a collaboration with the Ludwig Institute, the Center for Neurological Studies and researchers to discover and develop antisense medicines for ALS and other neurodegenerative diseases. Under this agreement, we agreed to pay the Ludwig Institute and the Center for Neurological Studies modest milestone payments and royalties on any antisense medicines resulting from the collaboration.</div>
</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Manufacturing</div>
<div style="text-align: justify;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have internal capabilities to manufacture our medicines. We have dedicated significant resources to develop ways to improve manufacturing efficiency and capacity. Since we can use variants of the same nucleotide building blocks and the same type of equipment to produce our oligonucleotide medicines, we found that the same techniques we used to efficiently manufacture one oligonucleotide medicine could help improve the manufacturing processes for many other oligonucleotide medicines. By developing several proprietary chemical processes to scale up our manufacturing capabilities, we have greatly reduced the cost of producing oligonucleotide medicines. For example, we have significantly reduced the cost of raw materials through improved yield efficiency, while at the same time increasing our capacity to make the medicines. Through both our internal research and development programs and collaborations with outside vendors we may achieve even greater efficiency and further cost reductions.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our manufacturing facility is located in a 28,700 square foot building in Carlsbad, California. We purchased this building in 2017. In addition, we have a 25,800 square foot building that houses support functions for our manufacturing activities. We lease this facility under a lease that has an initial term ending in June 2021 with an option to extend the lease for up to two additional five-year periods. Our manufacturing facility is subject to periodic inspections by the FDA and foreign equivalents to ensure that it is operating in compliance with current Good Manufacturing Practices, or cGMP, requirements.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As part of our collaborations we may agree to manufacture clinical trial materials and/or commercial supply for our partners. For example, in the past we have manufactured clinical supply materials for AstraZeneca, Bayer, Biogen, GSK and Novartis and commercial supply materials for Biogen.</div>
<div style="text-align: justify; text-indent: 36pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We believe we have sufficient manufacturing capacity at our own facility or at contract manufacturing organizations, or CMOs, to meet our current internal research, development and potential commercial needs, as well as our obligations under existing agreements with our partners for research, development and commercial needs. We believe our current network of CMO partners are capable of providing sufficient quantities to meet anticipated commercial demands. Additionally, we continue to evaluate relationships with additional suppliers to increase overall capacity and diversify our supply chain. While we believe that there are alternate sources of supply that can satisfy our commercial requirements, it is possible that identifying and establishing relationships with such sources, if necessary, would not result in significant delay or material additional costs. We also could experience a disruption in supply from our current CMO partners.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">CMOs are subject to the FDA&#8217;s cGMP requirements and other rules and regulations prescribed by foreign regulatory authorities. We depend on our CMO partners for continued compliance with cGMP requirements and applicable foreign standards.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Specifically, we have the following in place for our approved medicines, SPINRAZA, TEGSEDI and WAYLIVRA and our medicines in Phase 3 development: tominersen, tofersen, AKCEA-APO(a)-L<sub>Rx</sub> and AKCEA-TTR-L<sub>Rx</sub>:</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>28</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">SPINRAZA</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to our collaboration with Biogen, Biogen is responsible for SPINRAZA drug supply. We provided Biogen with API for SPINRAZA in 2018 under our manufacturing agreement with Biogen, which ended in September 2018. Biogen has an oligonucleotide synthesis manufacturing facility that gives it the capability to manufacture SPINRAZA.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">TEGSEDI</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For TEGSEDI&#8217;s commercial drug supply, Akcea is using CMOs to produce custom raw materials, API and finished goods. Akcea&#8217;s CMO partners have extensive technical expertise and cGMP experience. We believe Akcea&#8217;s current network of CMO partners are capable of providing sufficient quantities to meet anticipated commercial demands.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">WAYLIVRA</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have supplied the API and the finished drug product for WAYLIVRA&#8217;s commercial launch. We believe Akcea has sufficient API and drug product for at least the first two years of WAYLIVRA&#8217;s commercial launch. Akcea plans to leverage its relationships with CMOs to procure its own long-term raw material and drug supplies at competitive prices in the future.</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Tominersen</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to our collaboration with Roche, Roche is responsible for tominersen drug supply.</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Tofersen</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to our collaboration with Biogen, Biogen is responsible for tofersen drug supply. We provided Biogen with the first batch of API for tofersen in 2015 to support the first in human studies under our collaboration agreement with Biogen. Biogen has an oligonucleotide synthesis manufacturing facility that gives it the capability to manufacture tofersen for all subsequent clinical studies and potential commercialization, including providing the API for the current Phase 3 study.</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">AKCEA-APO(a)-L<sub>Rx</sub></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have supplied the API and the finished drug product for AKCEA-APO(a)-L<sub>Rx</sub> which Akcea sold to Novartis to use in its Phase 3 study. Pursuant to our collaboration with Novartis, Novartis is responsible for any further AKCEA-APO(a)-L<sub>Rx</sub> drug supply.</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">AKCEA-TTR-L<sub>Rx</sub></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We have supplied the API and the finished drug product for </span>AKCEA-TTR-L<sub>Rx </sub>that we believe will be <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">sufficient through the completion of the Phase 3 program for AKCEA-TTR-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. Akcea plans to leverage its relationships with CMOs to procure its own long-term raw material and drug supplies at competitive prices in the future.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">LICA Medicines</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have manufactured limited supplies of our LICA medicines for our preclinical and clinical studies. We have also used CMOs to manufacture our LICA medicines. LICA enables lower doses than unconjugated oligonucleotides. With our expertise in optimizing manufacturing of oligonucleotides, we believe we can develop new processes to scale up manufacturing of our LICA medicines at commercially competitive prices or use CMO&#8217;s.</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Patents and Proprietary Rights</div>
<div style="text-align: justify;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our success depends, in part, on our ability to obtain patent protection for our products in the U.S. and other countries. We own or have exclusively licensed a substantial patent estate with numerous issued patents worldwide protecting our products and, more generally, our platform for development and commercialization of oligonucleotide therapeutics. We focus our resources on patents and new patent applications that drive value for our company.</div>
<div style="text-align: left; text-indent: 36pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We own or control patents that provide exclusivity for products in our pipeline and patents that provide exclusivity for our core technology in the field of antisense more generally. Our core technology patents include claims to chemically modified nucleosides and oligonucleotides as well as antisense medicine designs utilizing these chemically modified nucleosides. These core claims are independent of specific therapeutic target, nucleic acid sequence, or clinical indication. We also own a large number of patents claiming antisense compounds having nucleic acid sequences complementary to therapeutic target nucleic acids, independent of the particular chemical modifications incorporated into the antisense compound. Most importantly, we seek and obtain issued patent claims to specifically protect each of our medicines. For example, we file and seek to obtain claims covering each drug&#8217;s nucleic acid sequence and precise drug design. In sum, we maintain our competitive advantage in the field of antisense technology by protecting our core platform technology and by creating multiple layers of patent protection for each of our specific medicines in development.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>29</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zf1acea27b4ba4bb4ac0a9e663a557191">
  <tr>
    <td style="width: 74.42%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Type of Patent Claim</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Broadly Applicable to Specific)</div></td>
    <td style="width: 2.49%; vertical-align: top;">&#160;</td>
    <td style="width: 23.09%; vertical-align: bottom;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 74.42%; vertical-align: top; border-top: #000000 2px solid;"><div style="text-align: left; text-indent: -18pt; margin-left: 52.8pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#9679;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Chemically Modified Nucleosides and Oligonucleotides (target and sequence independent)</span></div><div style="text-align: left; text-indent: -18pt; margin-left: 52.8pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#9679;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Antisense Drug Design Motifs (target and sequence independent)</span></div><div style="text-align: left; text-indent: -18pt; margin-left: 52.8pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#9679;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Therapeutic Methods (sequence and chemistry independent)</span></div><div style="text-align: left; text-indent: -18pt; margin-left: 52.8pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#9679;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Antisense Sequence (chemistry independent)</span></div><div style="text-align: left; text-indent: -18pt; margin-left: 52.8pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#9679;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Drug Composition</span></div></td>
    <td style="width: 2.49%; vertical-align: top;">&#160;</td>
    <td style="width: 23.09%; vertical-align: top;"><div style="text-align: center;"><img src="image11.jpg" width="115" height="129" alt="graphic" /></div></td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="text-decoration: underline;">Chemically Modified Nucleosides and Oligonucleotides</span></div>
<div style="text-align: justify; text-indent: 36pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The most broadly applicable of our patents are those that claim modified nucleosides and oligonucleotides comprising the modified nucleosides that we incorporate into our antisense medicines to increase their therapeutic efficacy. Nucleosides and chemically modified nucleosides are the basic building blocks of our antisense medicines, therefore claims that cover any oligonucleotide incorporating one of our proprietary modified nucleosides can apply to a wide array of antisense mechanisms of action as well as several therapeutic targets. Of particular note are our patents covering our proprietary 2&#8217;-O-(2-methoxy) ethyl, or &#8220;MOE,&#8221; modified nucleosides, incorporated into many of our second generation development compounds, as well as our constrained-ethyl nucleosides, or &#8220;cEt&#8221; nucleosides incorporated into our Generation 2.5 compounds.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following are some of our patents in this category in key jurisdictions (U.S., Europe and Japan):</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zec031f4d49714e61932643c53a7c1abe">
  <tr>
    <td style="width: 9.96%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Jurisdiction</div></td>
    <td style="width: 1.71%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.5%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Patent No.</div></td>
    <td style="width: 1.67%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.68%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Title</div></td>
    <td style="width: 1.67%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.76%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Expiration</div></td>
    <td style="width: 1.67%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.39%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description of Claims</div></td>
  </tr>
  <tr>
    <td style="width: 9.96%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.71%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.5%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7,101,993</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.68%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">OLIGONUCLEOTIDES CONTAINING 2&#8217;O-MODIFIED PURINES</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.76%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2023</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.39%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Covers certain MOE nucleosides and oligonucleotides containing these nucleotides.</div></td>
  </tr>
  <tr>
    <td style="width: 9.96%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.71%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.5%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7,399,845</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.68%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.76%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2027</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.39%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Covers our cEt nucleosides and oligonucleotides containing these nucleoside analogs.</div></td>
  </tr>
  <tr>
    <td style="width: 9.96%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.71%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.5%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7,741,457</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.68%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.76%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2027</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.39%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Covers our cEt nucleosides and oligonucleotides containing these nucleoside analogs.</div></td>
  </tr>
  <tr>
    <td style="width: 9.96%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.71%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.5%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,022,193</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.68%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.76%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2027</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.39%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Covers oligonucleotides containing cEt nucleoside analogs.</div></td>
  </tr>
  <tr>
    <td style="width: 9.96%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.71%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.5%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7,569,686</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.68%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">COMPOUNDS AND METHODS FOR SYNTHESIS OF BICYCLIC NUCLEIC ACID ANALOGS</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.76%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2027</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.39%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Covers methods of synthesizing our cEt nucleosides.</div></td>
  </tr>
  <tr>
    <td style="width: 9.96%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Europe</div></td>
    <td style="width: 1.71%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.5%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1984381</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.68%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.76%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2027</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.39%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Covers our cEt nucleosides and oligonucleotides containing these nucleoside analogs.</div></td>
  </tr>
  <tr>
    <td style="width: 9.96%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Europe</div></td>
    <td style="width: 1.71%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.5%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2314594</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.68%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.76%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2027</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.39%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Covers our cEt oligonucleotides and methods of use.</div></td>
  </tr>
  <tr>
    <td style="width: 9.96%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Japan</div></td>
    <td style="width: 1.71%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.5%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5342881</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.68%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.76%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2027</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.39%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Covers our cEt nucleosides and oligonucleotides containing these nucleoside analogs.</div></td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="text-decoration: underline;">Antisense Drug Design Motifs</span></div>
<div style="text-align: justify; text-indent: 36pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We also have patents that claim oligonucleotides comprising antisense drug design motifs, or patterns of nucleoside modifications at specified positions in the oligonucleotide. Patent claims covering our antisense drug design motifs are independent of nucleic acid sequence, so they cover oligonucleotides having the recited motif, regardless of cellular target or clinical indication. The claimed motifs generally confer properties that optimize oligonucleotides for a particular antisense mechanism of action, such as ribonuclease H(RNase H), RNAi, or splicing. We have designed oligonucleotides incorporating motifs, which we refer to as chimeric compounds or gapmers, to exploit the RNase H mechanism to achieve target RNA reduction. Almost all of our medicines, including TEGSEDI and WAYLIVRA, but excluding SPINRAZA, contain this gapmer antisense drug design motif. We own a U.S. patent that covers all of our second generation MOE gapmer antisense medicines until March of 2023.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In addition, we have pursued patent claims to antisense drug design motifs incorporating bicyclic nucleoside analogs, which include both locked nucleic acids, or &#8220;LNA&#8221; and cEt. In Europe, we have been granted claims drawn to certain short gapmer oligonucleotides with bicyclic nucleosides, which include locked nucleic acids, in the wings for the treatment of cardiovascular or metabolic disorders. We have also successfully obtained issued patent claims covering our Generation 2.5 gapmer antisense drug design motifs that incorporate our cEt modified nucleosides. The following patents are some examples of our issued patents in this category in key jurisdictions:</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>30</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z376a7f71346d440991b75eb34552ed2e">
  <tr>
    <td style="width: 9.96%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Jurisdiction</div></td>
    <td style="width: 1.71%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.5%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Patent No.</div></td>
    <td style="width: 1.67%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.68%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Title</div></td>
    <td style="width: 1.67%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.76%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Expiration</div></td>
    <td style="width: 1.67%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.39%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description of Claims</div></td>
  </tr>
  <tr>
    <td style="width: 9.96%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.71%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.5%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7,015,315</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.68%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">GAPPED OLIGONUCLEOTIDES</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.76%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2023</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.39%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2&#8217;-O-alkyl-O-alkyl gapmer oligonucleotides.</div></td>
  </tr>
  <tr>
    <td style="width: 9.96%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Europe</div></td>
    <td style="width: 1.71%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.5%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2021472</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.68%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">COMPOUNDS AND METHODS FOR MODULATING GENE EXPRESSION</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.76%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2027</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.39%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Short gapmer oligonucleotides, having wings of 2 bicyclic nucleosides, and a gap of 10 deoxynucleotides for the treatment of cardiovascular or metabolic disorders</div></td>
  </tr>
  <tr>
    <td style="width: 9.96%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.71%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.5%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7,750,131</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.68%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5&#8217;-MODIFIED BICYCLIC NUCLEIC ACID ANALOGS</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.76%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2027</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.39%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5&#8217;-Methyl BNA containing gapmer compounds</div></td>
  </tr>
  <tr>
    <td style="width: 9.96%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.71%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.5%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,550,988</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.68%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ANTISENSE COMPOUNDS</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.76%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2028</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.39%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Gapmer oligonucleotides having BNA nucleosides and 2&#8217;-MOE nucleosides</div></td>
  </tr>
  <tr>
    <td style="width: 9.96%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.71%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.5%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,493,092</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.68%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ANTISENSE COMPOUNDS</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.76%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2028</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.39%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Gapmer oligonucleotides having BNA nucleosides and 2&#8217;-MOE nucleosides and/or 2&#8217;-OMe nucleosides</div></td>
  </tr>
  <tr>
    <td style="width: 9.96%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Europe</div></td>
    <td style="width: 1.71%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.5%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2092065</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.68%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ANTISENSE COMPOUNDS</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.76%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2027</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.39%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Gapmer compounds having 2&#8217;-modifed and LNA nucleosides</div></td>
  </tr>
  <tr>
    <td style="width: 9.96%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Europe</div></td>
    <td style="width: 1.71%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.5%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2410053</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.68%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ANTISENSE COMPOUNDS</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.76%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2027</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.39%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Gapmer compounds having wings comprised of 2&#8217;-MOE and bicyclic nucleosides</div></td>
  </tr>
  <tr>
    <td style="width: 9.96%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Europe</div></td>
    <td style="width: 1.71%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.5%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2410054</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.68%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ANTISENSE COMPOUNDS</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.76%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2027</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.39%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Gapmer compounds having a 2&#8217;-modifed nucleoside in the 5&#8217;-wing and a bicyclic nucleoside in the 3&#8217;-wing</div></td>
  </tr>
  <tr>
    <td style="width: 9.96%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Japan</div></td>
    <td style="width: 1.71%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.5%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5665317</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.68%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ANTISENSE COMPOUNDS</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.76%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2027</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.39%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Gapmer oligonucleotides having wings comprised of 2&#8217;-MOE and bicyclic nucleosides</div></td>
  </tr>
  <tr>
    <td style="width: 9.96%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Europe</div></td>
    <td style="width: 1.71%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.5%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3067421</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.68%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">OLIGOMERIC COMPOUNDS COMPRISING BICYCLIC NUCLEOTIDES AND USES THEREOF</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.76%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2032</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.39%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Gapmer oligonucleotides having at least one bicyclic, one 2&#8217;-modified nucleoside and on 2&#8217;-deoxynucleoside</div></td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="text-decoration: underline;">LIgand-Conjugated Antisense (LICA) Technology</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have also pursued patent claims to new chemistries created to enhance targeting of antisense medicines to specific tissues and cells to improve a drug&#8217;s properties. We designed our N-acetyl-galactosamine, or GalNAc, LICA medicines to provide an increase in potency for targets in the liver. We have successfully obtained issued patent claims covering our LICA technology conjugated to any modified oligonucleotide, including gapmers, double-stranded siRNA compounds, and fully modified oligonucleotides. The following patents are some examples of our issued patents in this category:</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z0f1b3b6fae294efc86322aee1e82c093">
  <tr>
    <td style="width: 10%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Jurisdiction</div></td>
    <td style="width: 1.67%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Patent</div></td>
    <td style="width: 1.67%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.74%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Title</div></td>
    <td style="width: 1.67%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.79%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Expiration</div></td>
    <td style="width: 1.67%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.47%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description of Claims</div></td>
  </tr>
  <tr>
    <td style="width: 10%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,127,276</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.74%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.79%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2034</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.47%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Preferred THA LICA conjugated to any group of nucleosides, including gapmers, double-stranded siRNA compounds, and fully modified oligonucleotides</div></td>
  </tr>
  <tr>
    <td style="width: 10%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,181,549</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.74%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.79%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2034</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.47%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Preferred THA conjugate having our preferred linker and cleavable moiety conjugated to any oligomeric compound or any nucleoside having a 2&#8217;-MOE modification or a cEt modification</div></td>
  </tr>
  <tr>
    <td style="width: 10%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Europe</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2991661</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.74%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.79%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2034</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.47%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Preferred THA LICA conjugated to any group of nucleosides, including gapmers, double-stranded siRNA compounds, and fully modified oligonucleotides</div></td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="text-decoration: underline;">Therapeutic Methods of Treatment and Antisense Drug Sequences</span></div>
<div style="text-align: justify; text-indent: 36pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In addition to our broad core patents, we also own hundreds of patents, worldwide, with claims to antisense compounds having particular sequences and compounds directed to particular therapeutically important targets or methods of achieving cellular or clinical endpoints using these antisense compounds. These &#8220;Target&#8221; patents also include claims reciting the specific nucleic acid sequences utilized by our products, independent of chemical modifications and motifs. In addition, our product-specific patents typically include claims combining specific nucleic acid sequences with nucleoside modifications and motifs. In this way, we seek patent claims narrowly tailored to protect our product&#8217;s specifically, in addition to the broader core antisense patents described above.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>31</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">SPINRAZA and Survival Motor Neuron</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We believe SPINRAZA is protected from generic competition in the U.S. and Europe until at least 2030 by a suite of patents. These issued patents include: (i) patents licensed from the University of Massachusetts drawn to antisense compounds having the sequence of SPINRAZA, independent of chemical modification and uses of such compounds for treating SMA, and (ii) joint patents with Cold Spring Harbor Laboratory claiming fully modified 2&#8217;MOE compositions targeting SMN2, including the precise composition of matter of SPINRAZA and methods of using such compositions. We have filed for patent term extension, to potentially extend the term beyond 2030. With Biogen&#8217;s license of SPINRAZA, we assigned our interest in these patents to Biogen. The table below lists some key issued patents protecting SPINRAZA in the U.S. and European:</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z284bbc454afd4f198dc881ba88c81da5">
  <tr>
    <td style="width: 10%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Jurisdiction</div></td>
    <td style="width: 1.67%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Patent No.</div></td>
    <td style="width: 1.67%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.74%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Title</div></td>
    <td style="width: 1.67%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.79%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Expiration</div></td>
    <td style="width: 1.67%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.47%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description of Claims</div></td>
  </tr>
  <tr>
    <td style="width: 10%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,361,977</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.74%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.79%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2030</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.47%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Sequence and chemistry (full 2&#8217;-MOE) of SPINRAZA</div></td>
  </tr>
  <tr>
    <td style="width: 10%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Europe</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1910395</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.74%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.79%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2026</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.47%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Sequence and chemistry (full 2&#8217;-MOE) of SPINRAZA</div></td>
  </tr>
  <tr>
    <td style="width: 10%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Europe</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3308788</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.74%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.79%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2026</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.47%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pharmaceutical compositions that include SPINRAZA</div></td>
  </tr>
  <tr>
    <td style="width: 10%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7,838,657</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.74%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.79%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2027</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.47%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Oligonucleotides having sequence of SPINRAZA</div></td>
  </tr>
  <tr>
    <td style="width: 10%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,266,822</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.74%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.79%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2025</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.47%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Methods of increasing exon-7 containing SMN2 mRNA in a cell using an oligonucleotide having the sequence of SPINRAZA</div></td>
  </tr>
  <tr>
    <td style="width: 10%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,110,560</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.74%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SPINAL MUSCULAR ATROPHY (SMA) TREATMENT VIA TARGETING OF SMN2 SPLICE SITE INHIBITORY SEQUENCES</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.79%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2025</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.47%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Methods of using antisense oligonucleotides having sequence of SPINRAZA to alter splicing of SMN2 and/or to treat SMA</div></td>
  </tr>
  <tr>
    <td style="width: 10%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,980,853</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.74%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING IN A SUBJECT</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.79%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2030</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.47%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Methods of administering SPINRAZA</div></td>
  </tr>
  <tr>
    <td style="width: 10%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,717,750</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.74%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING IN A SUBJECT</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.79%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2030</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.47%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Methods of administering SPINRAZA to a patient</div></td>
  </tr>
  <tr>
    <td style="width: 10%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Europe</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3449926</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.74%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING IN A SUBJECT</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.79%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2030</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.47%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Antisense compounds including SPINRAZA for treating SMA</div></td>
  </tr>
</table>
<div style="text-align: left;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">TEGSEDI and Transthyretin</div>
<div style="text-align: justify;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We obtained issued claims covering TEGSEDI in the U.S. and Europe. We believe the issued U.S. claims protect TEGSEDI from generic competition in the U.S. and Europe until at least 2031. We are also pursuing additional patent applications designed to protect TEGSEDI in other foreign jurisdictions. The table below lists some key issued patents protecting TEGSEDI<sub>&#160;</sub>in the U.S. and Europe:</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zb8534930a2664f0189d1c3bed436d403">
  <tr>
    <td style="width: 10.01%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Jurisdiction</div></td>
    <td style="width: 1.67%; vertical-align: bottom;">&#160;</td>
    <td style="width: 8.35%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Patent No.</div></td>
    <td style="width: 1.67%; vertical-align: bottom;">&#160;</td>
    <td style="width: 30.72%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Title</div></td>
    <td style="width: 1.67%; vertical-align: bottom;">&#160;</td>
    <td style="width: 8.81%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Expiration</div></td>
    <td style="width: 1.67%; vertical-align: bottom;">&#160;</td>
    <td style="width: 35.44%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description of Claims</div></td>
  </tr>
  <tr>
    <td style="width: 10.01%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.35%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,101,743</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.72%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">MODULATION OF TRANSTHYRETIN EXPRESSION</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.81%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2025</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.44%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Antisense sequence and chemistry of TEGSEDI</div></td>
  </tr>
  <tr>
    <td style="width: 10.01%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.35%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,697,860</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.72%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">DIAGNOSIS AND TREATMENT OF DISEASE</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.81%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2031</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.44%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Composition of TEGSEDI</div></td>
  </tr>
  <tr>
    <td style="width: 10.01%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.35%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,061,044</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.72%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">MODULATION OF TRANSTHYRETIN EXPRESSION</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.81%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2031</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.44%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Sodium salt composition of TEGSEDI</div></td>
  </tr>
  <tr>
    <td style="width: 10.01%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.35%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,399,774</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.72%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">MODULATION OF TRANSTHYRETIN EXPRESSION</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.81%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2031</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.44%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Methods of treating transthyretin amyloidosis by administering TEGSEDI</div></td>
  </tr>
  <tr>
    <td style="width: 10.01%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Europe</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.35%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2563920</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.72%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">MODULATION OF TRANSTHYRETIN EXPRESSION</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.81%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2031</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.44%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Composition of TEGSEDI</div></td>
  </tr>
</table>
<div style="text-align: left; text-indent: 36pt;"><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>32</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">WAYLIVRA and Apolipoprotein C-III</div>
<div style="text-align: justify; text-indent: 36pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have obtained patent claims in the U.S. and Europe drawn to the use of antisense compounds complementary to a broad active region of human ApoC-III, including the site targeted by WAYLIVRA. We have also obtained an issued patent claiming the specific sequence and chemical composition of WAYLIVRA in the U.S. and Europe. We believe the issued U.S. and Europe claims protect WAYLIVRA from generic competition in the U.S. and Europe until at least 2023 and 2024, respectively. We are pursuing additional patent applications designed to protect WAYLIVRA worldwide. The table below lists some key issued patents protecting WAYLIVRA in the U.S. and Europe:</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="za128ca9fb22b4728bc3c09c1ba99a418">
  <tr>
    <td style="width: 10%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Jurisdiction</div></td>
    <td style="width: 1.67%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Patent No.</div></td>
    <td style="width: 1.67%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.39%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Title</div></td>
    <td style="width: 1.67%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.86%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Expiration</div></td>
    <td style="width: 1.67%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.75%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description of Claims</div></td>
  </tr>
  <tr>
    <td style="width: 10%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,624,496</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.39%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">MODULATION OF APOLIPOPROTEIN C-III EXPRESSION</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.86%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2023</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.75%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Antisense compounds specifically hybridizable within the nucleotide region of apoCIII targeted by WAYLIVRA</div></td>
  </tr>
  <tr>
    <td style="width: 10%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7,598,227</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.39%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">MODULATION OF APOLIPOPROTEIN C-III EXPRESSION</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.86%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2023</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.75%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Methods of treating hyperlipidemia, lowering cholesterol levels or lowering triglyceride levels with WAYLIVRA</div></td>
  </tr>
  <tr>
    <td style="width: 10%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7,750,141</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.39%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">MODULATION OF APOLIPOPROTEIN C-III EXPRESSION</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.86%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2023</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.75%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Antisense sequence and chemistry of WAYLIVRA</div></td>
  </tr>
  <tr>
    <td style="width: 10%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Europe</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1622597</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.39%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">MODULATION OF APOLIPOPROTEIN C-III EXPRESSION</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.86%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2024</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.75%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Antisense sequence and chemistry of WAYLIVRA</div></td>
  </tr>
  <tr>
    <td style="width: 10%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Europe</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2441449</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.39%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">MODULATION OF APOLIPOPROTEIN C-III EXPRESSION</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.86%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2024</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.75%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Antisense compounds specifically hybridizable within the nucleotide region of apoCIII targeted by WAYLIVRA</div></td>
  </tr>
  <tr>
    <td style="width: 10%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Europe</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3002007</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.39%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">MODULATION OF APOLIPOPROTEIN C-III EXPRESSION</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.86%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2024</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.75%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Compounds complementary to an apoCIII nucleic acid for use in therapy</div></td>
  </tr>
  <tr>
    <td style="width: 10%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.33%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,157,082</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.39%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.86%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2032</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.75%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Methods of using APOCIII antisense oligonucleotides for reducing pancreatitis and chylomicronemia and increasing HDL</div></td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Tominersen and Huntingtin</div>
<div style="text-align: justify;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We obtained issued claims covering tominersen in the U.S. and Europe. We believe the issued U.S. and Europe claims protect tominersen from generic competition in the U.S. until at least 2030. We are also pursuing additional patent applications designed to protect tominersen in foreign jurisdictions. The table below lists some key issued patents protecting tominersen<sub>&#160;</sub>in U.S. and Europe:</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zbb4f7de5abe447ec8102eb1d326f5cfb">
  <tr>
    <td style="width: 10.01%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Jurisdiction</div></td>
    <td style="width: 1.67%; vertical-align: bottom;">&#160;</td>
    <td style="width: 8.35%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Patent No.</div></td>
    <td style="width: 1.67%; vertical-align: bottom;">&#160;</td>
    <td style="width: 30.72%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Title</div></td>
    <td style="width: 1.67%; vertical-align: bottom;">&#160;</td>
    <td style="width: 8.81%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Expiration</div></td>
    <td style="width: 1.67%; vertical-align: bottom;">&#160;</td>
    <td style="width: 35.44%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description of Claims</div></td>
  </tr>
  <tr>
    <td style="width: 10.01%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.35%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,273,315</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.72%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">MODULATION OF HUNTINGTIN EXPRESSION</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.81%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2030</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.44%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Composition of tominersen</div></td>
  </tr>
  <tr>
    <td style="width: 10.01%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.35%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,906,873</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.72%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">MODULATION OF HUNTINGTIN EXPRESSION</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.81%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2030</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.44%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Methods of treating Huntington&#8217;s disease by administering tominersen</div></td>
  </tr>
  <tr>
    <td style="width: 10.01%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Europe</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.35%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2475675</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.72%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">MODULATION OF HUNTINGTIN EXPRESSION</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.81%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2030</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.44%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Composition of tominersen</div></td>
  </tr>
  <tr>
    <td style="width: 10.01%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.35%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7,951,934</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.72%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.81%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2027</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.44%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Antisense sequence of tominersen</div></td>
  </tr>
  <tr>
    <td style="width: 10.01%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.35%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,952,145</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.72%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.81%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2027</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.44%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Antisense compound specifically hybridizable within the nucleotide region of HTT targeted by tominersen</div></td>
  </tr>
  <tr>
    <td style="width: 10.01%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Europe</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.35%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2161038</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.72%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">COMPOSITIONS AND THEIR USES DIRECTED TO HUNTINGTIN</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.81%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2027</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.44%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Antisense sequence of tominersen</div></td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Tofersen and SOD-1</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We believe tofersen is protected from generic competition in the U.S. until at least 2036. Additional patent protection designed to protect tofersen is being pursued in foreign jurisdictions. With Biogen&#8217;s license of tofersen, we assigned our interest in these patents to Biogen. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The table below lists some key issued patents protecting t</span>ofersen in the U.S. and Europe:</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z5bd29c53b35a4389abb7c3a516597c1e">
  <tr>
    <td style="width: 10.01%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Jurisdiction</div></td>
    <td style="width: 1.67%; vertical-align: bottom;">&#160;</td>
    <td style="width: 8.35%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Patent No.</div></td>
    <td style="width: 1.67%; vertical-align: bottom;">&#160;</td>
    <td style="width: 30.72%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Title</div></td>
    <td style="width: 1.67%; vertical-align: bottom;">&#160;</td>
    <td style="width: 8.81%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Expiration</div></td>
    <td style="width: 1.67%; vertical-align: bottom;">&#160;</td>
    <td style="width: 35.44%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description of Claims</div></td>
  </tr>
  <tr>
    <td style="width: 10.01%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.35%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,385,341</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.72%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">COMPOSITIONS FOR MODULATING SOD-1 EXPRESSION</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.81%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2036</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.44%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Composition of tofersen</div></td>
  </tr>
  <tr>
    <td style="width: 10.01%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.35%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,993,529</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.72%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.81%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2021</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.44%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Antisense compound specifically hybridizable within nucleotide region of SOD-1 targeted by tofersen</div></td>
  </tr>
  <tr>
    <td style="width: 10.01%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Europe</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.35%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">EP2270024</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.72%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ANTISENSE MODULATION OF SUPEROXIDE DISMUTASE 1, SOLUBLE EXPRESSION</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.81%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2022</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.44%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Antisense compound specifically hybridizable within nucleotide region of SOD-1 targeted by tofersen</div></td>
  </tr>
</table>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>33</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">AKCEA-APO(a)-L<sub>Rx</sub></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We believe AKCEA-APO(a)-L<sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> is protected from generic competition in the U.S. until at least 2034. In addition, if </span>AKCEA-APO(a)-L<sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> is approved by the FDA, we will seek patent term extension to recapture a portion of the term lost during FDA regulatory review, extending the term of this patent beyond 2034. We are pursuing additional patent applications designed to protect </span>AKCEA-APO(a)-L<sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> worldwide. The table below lists some key issued patents protecting </span>AKCEA-APO(a)-L<sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in the U.S.:</span></div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z4b5e3920286842a1ae6ebe25a50eb1d2">
  <tr>
    <td style="width: 10.01%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Jurisdiction</div></td>
    <td style="width: 1.67%; vertical-align: bottom;">&#160;</td>
    <td style="width: 8.35%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Patent No.</div></td>
    <td style="width: 1.67%; vertical-align: bottom;">&#160;</td>
    <td style="width: 30.72%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Title</div></td>
    <td style="width: 1.67%; vertical-align: bottom;">&#160;</td>
    <td style="width: 8.81%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Expiration</div></td>
    <td style="width: 1.67%; vertical-align: bottom;">&#160;</td>
    <td style="width: 35.44%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description of Claims</div></td>
  </tr>
  <tr>
    <td style="width: 10.01%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.35%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,574,193</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.72%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.81%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2033</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.44%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Compounds that include an oligonucleotide complementary to the region of the Apo(a) transcript where </span>AKCEA-APO(a)-L<sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> binds</span></div></td>
  </tr>
  <tr>
    <td style="width: 10.01%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.35%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,478,448</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 30.72%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">METHODS AND COMPOSITIONS FOR MODULATING APOLIPOPROTEIN (A) EXPRESSION</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 8.81%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2033</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 35.44%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Methods of treating hyberlipidemia using oligonucleotide complementary to the region of the Apo(a) transcript where </span>AKCEA-APO(a)-L<sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> binds</span></div></td>
  </tr>
  <tr>
    <td style="width: 10.01%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.35%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,181,550</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 30.72%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">COMPOSITIONS AND METHODS FOR MODULATING APOLIPOPROTEIN (a) EXPRESSION</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 8.81%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2034</div></td>
    <td style="width: 1.67%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 35.44%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The composition of </span>AKCEA-APO(a)-L<sub>Rx</sub></div></td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic;">AKCEA-TTR-L</span><sub style="font-style: italic; font-weight: bold;">Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold; font-style: italic;"> and Transthyretin</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are pursuing claims covering AKCEA-TTR-L<sub>Rx</sub> in the U.S. We believe the claims when granted will protect AKCEA-TTR-L<sub>Rx</sub> from generic competition in the U.S. until at least 2034. We are also pursuing additional patent applications to protect AKCEA-TTR-L<sub>Rx</sub> in foreign jurisdictions.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We seek patent protection in significant markets and/or countries for each medicine in development. We also seek to maximize patent term. In some cases, the patent term can be extended to recapture a portion of the term lost during FDA regulatory review. The patent exclusivity period for a medicine will prevent generic medicines from entering the market. Patent exclusivity depends on a number of factors including initial patent term and available patent term extensions based upon delays caused by the regulatory approval process.</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="text-decoration: underline;">Manufacturing Patents</span></div>
<div style="text-align: justify; text-indent: 36pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We also own patents claiming methods of manufacturing and purifying oligonucleotides. These patents claim methods for improving oligonucleotide drug manufacturing, including processes for large-scale oligonucleotide synthesis and purification. These methods allow us to manufacture oligonucleotides at lower cost by, for example, eliminating expensive manufacturing steps.</div>
<div style="text-align: justify; text-indent: 36pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We also rely on trade secrets, proprietary know-how and continuing technological innovation to develop and maintain a competitive position in antisense therapeutics.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Government Regulation</div>
<div style="text-align: justify;"><br /></div>
<div style="text-align: justify; text-indent: 35pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Regulation by government authorities in the U.S. and other countries is a significant component in the development, manufacture and commercialization of pharmaceutical products and services. In addition to regulations enforced by the FDA and relevant foreign regulatory authorities, we are also subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act and other present and potential future federal, state and local regulations.</div>
<div style="text-align: justify; text-indent: 35pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Extensive regulation by the U.S. and foreign governmental authorities governs the development, manufacture and sale of our medicines. In particular, our medicines are subject to a number of approval requirements by the FDA in the U.S. under the Federal Food, Drug and Cosmetic Act, or FDCA, and other laws and by comparable agencies in those foreign countries in which we conduct business. The FDCA and other various federal, state and foreign statutes govern or influence the research, testing, manufacture, safety, labeling, storage, recordkeeping, approval, promotion, marketing, distribution, post-approval monitoring and reporting, sampling, quality, and import and export of our medicines. State, local, and other authorities also regulate pharmaceutical manufacturing facilities and procedures.</div>
<div style="text-align: justify; text-indent: 36pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;Our manufacturing facility and our CMOs are subject to periodic inspection by the FDA and other foreign equivalents to ensure that they are operating in compliance with cGMP requirements. In addition, marketing authorization for each new medicine may require a rigorous manufacturing pre-approval inspection by regulatory authorities. Post approval, there are strict regulations regarding changes to the manufacturing process, and, depending on the significance of the change, changes may require prior FDA approval. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide to use.</div>
<div style="text-align: justify; text-indent: 36pt;"><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>34</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The FDA must approve any new medicine before a manufacturer can market it in the U.S.. In order to obtain approval, we and our partners must complete clinical studies and prepare and submit an NDA to the FDA. If the FDA approves a medicine, it will issue an approval letter authorizing commercial marketing of the medicine and may require a risk evaluation and mitigation strategy, or REMS, to help ensure the benefits of the medicine outweigh the potential risks. For example, TEGSEDI has a REMS program. The requirements for REMS can materially affect the potential market and profitability of our medicines. In foreign jurisdictions, the drug approval process is similarly demanding.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Numerous regulatory authorities in addition to the FDA, including, in the U.S., the Centers for Medicare &amp; Medicaid Services, other divisions of the U.S. Department of Health and Human Services, the U.S. Department of Justice, and similar foreign, state and local government authorities, regulate sales, promotion and other activities following drug approval. Only those claims relating to safety and efficacy that the FDA has approved may be used in labeling. We are only allowed to use promotional communications regarding a drug that are consistent with the information in the drug&#8217;s approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For any approved medicine, domestic and foreign sales of the medicine depend, in part, on the availability and amount of reimbursement by third party payors, including governments and private health plans. Private health plans may seek to manage cost and use of our medicines by implementing coverage and reimbursement limitations. Governments may also regulate or influence coverage, reimbursement and/or pricing of our medicines to control cost or affect use. Within the EU a variety of payors pay for medicines, with governments being the primary source of payment. Negotiating pricing with governmental authorities can delay commercialization. Such pricing and reimbursement factors could impact our ability, including Akcea, and that of our commercial partners to successfully commercialize approved medicines.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the U.S. and foreign jurisdictions, the legislative landscape continues to evolve. There have been a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels and by foreign governments that seek to reduce healthcare costs. There has also been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in efforts to bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for medicines.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other healthcare laws that may affect our ability to operate include the following:</div>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z8095dd0d41034ff8a2a6aa5c7f66aca5">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zdb9fb7a9af4248959cd0ffa4113f5941">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Foreign and state laws governing the privacy and security of health information, such as the General Data Protection Regulation, or GDPR, in the EU;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zfb39f9df927c40e5a1e1e4553e39d5b8">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The California Consumer Privacy Act, or CCPA, in California, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect; and</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z10206162902944a4af93a3efa842c765">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Physician Payments Sunshine Act, which requires manufacturers of medicines, devices, biologics, and medical supplies to report annually to the U.S. Department of Health and Human Services information related to payments and other transfers of value to physicians and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our operations may be directly, or indirectly through our customers, distributors, or other business partners, subject to various federal and state fraud and abuse laws, including, without limitation, anti-kickback statutes and false claims statutes. These laws may impact, among other things, our, Akcea&#8217;s, and our partners&#8217; proposed sales, marketing and education programs.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The U.S. Foreign Corrupt Practices Act, or FCPA, prohibits certain individuals and entities, including us, from promising, paying, offering to pay, or authorizing the payment of anything of value to any foreign government official, directly or indirectly, to obtain or retain business or an improper advantage. If we violate the FCPA, it could result in large civil and criminal penalties as well as an adverse effect on our reputation, operations, and financial condition. We could also face collateral consequences such as debarment and the loss of export privileges.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Competition</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 39.6pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Our Business in General</div>
<div style="text-align: justify; text-indent: 39.6pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Some of our medicines may compete with existing therapies for market share and some of our medicines in development may compete for patients in study trials. In addition, there are a number of companies pursuing the development of oligonucleotide-based technologies and the development of pharmaceuticals utilizing these technologies. These companies include biopharmaceutical companies and large pharmaceutical companies acting either independently or together. Our medicines are differentiated from traditional small molecule medicines by their chemistry, how they move in the body, how they act in the body, delivery technology, and formulations.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>35</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our approved products and our products under development address numerous markets. The diseases our medicines target for which we have or may receive marketing authorization will determine our competition. For some of our products, an important factor may be the timing of market introduction of competitive products. Accordingly, the relative speed with which we can develop products, complete the clinical trials and marketing authorization processes and supply commercial quantities of the products to the market are important competitive factors. We expect to compete with products approved for sale based on a variety of factors, including, among other things, product efficacy, safety, mechanism of action, dosing convenience, marketing and sales strategy and tactics, availability, price, and reimbursement.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Below we have included what we believe to be the competitive landscape for our marketed medicines and for the medicines we currently have in Phase 3 trials. We included competitors, potential competitors that are past Phase 1 development or potential competitors that plan to start a pivotal study this year. We do not b<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">elieve that any medicines meet these criteria to compete with AKCEA-APO(a)-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</span></div>
<div><br /></div>
<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">SPINRAZA</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We consider the following medicines as competitors and potential future competitors to SPINRAZA:</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z71557a12a8d8491389261a2ca6d72b38">
  <tr>
    <td style="width: 10.19%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Medicine</div></td>
    <td style="width: 2.23%; vertical-align: top;">&#160;</td>
    <td style="width: 12.25%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Company</div></td>
    <td style="width: 2.45%; vertical-align: top;">&#160;</td>
    <td style="width: 17.97%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Medicine Description</span><sup> (1)</sup></div></td>
    <td style="width: 2.25%; vertical-align: top;">&#160;</td>
    <td style="width: 12.45%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Phase</span><sup> (1)</sup></div></td>
    <td style="width: 2.45%; vertical-align: top;">&#160;</td>
    <td style="width: 15.67%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Route of Administration</span><sup> (1)</sup></div></td>
    <td style="width: 2.31%; vertical-align: top;">&#160;</td>
    <td style="width: 19.77%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Next Milestones</span><sup> (1)</sup></div></td>
  </tr>
  <tr>
    <td style="width: 10.19%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Zolgensma</div><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(AVXS-101)</div></td>
    <td style="width: 2.23%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 12.25%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Novartis</div></td>
    <td style="width: 2.45%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 17.97%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Gene therapy designed to target the genetic root cause of SMA by replacing the function of the missing or nonworking SMN1 gene</div></td>
    <td style="width: 2.25%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 12.45%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Approved (U.S.)</div></td>
    <td style="width: 2.45%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 15.67%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Infusion</div></td>
    <td style="width: 2.31%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 19.77%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">- Approval decision for EU expected in the first quarter of 2020</div><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">- Approval decision for Japan expected in the first half of 2020</div></td>
  </tr>
  <tr>
    <td style="width: 10.19%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Risdiplam</div><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(RG7916)</div></td>
    <td style="width: 2.23%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 12.25%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">PTC Therapeutics/ Roche/ SMA Foundation</div></td>
    <td style="width: 2.45%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 17.97%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A small molecule medicine that modulates splicing of the SMN2 gene</div></td>
    <td style="width: 2.25%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 12.45%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">NDA Submitted</div></td>
    <td style="width: 2.45%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 15.67%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Oral</div></td>
    <td style="width: 2.31%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 19.77%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Prescription Drug User Fee Act, or PDUFA, date set for May 2020</div></td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z6e79b4a7056d423a87078d1628d69ff4">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 8pt;">Taken from public documents including respective company press releases, company presentations, and scientific presentations.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In May 2019, Zolgensma was approved for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy including those who are presymptomatic at diagnosis, becoming the first approved medicine to compete with SPINRAZA. In November 2019, the FDA accepted Roche and PTC&#8217;s NDA and granted priority review for risdiplam. The filing submission includes 12-month data from pivotal FIREFISH and SUNFISH trials in a broad population of people living with Type 1, 2, or 3 SMA.</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">TEGSEDI and AKCEA-TTR-L<sub>Rx</sub></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We consider the following medicines as competitors and potential future competitors to TEGSEDI and AKCEA-TTR-L<sub>Rx</sub> for the indication of hATTR amyloidosis and/or ATTR cardiomyopathy:</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z53a435c0f67542e38cb4c9f1ab3565ab">
  <tr>
    <td style="width: 10.54%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Medicine</div></td>
    <td style="width: 2.21%; vertical-align: top;">&#160;</td>
    <td style="width: 11.96%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Company</div></td>
    <td style="width: 2.4%; vertical-align: top;">&#160;</td>
    <td style="width: 17.22%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Medicine Description</span><sup> (1)</sup></div></td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 13.76%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Phase</span><sup> (1)</sup></div></td>
    <td style="width: 2.18%; vertical-align: top;">&#160;</td>
    <td style="width: 16.54%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Route of Administration</span><sup> (1)</sup></div></td>
    <td style="width: 2.28%; vertical-align: top;">&#160;</td>
    <td style="width: 18.69%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Next Milestones</span><sup> (1)</sup></div></td>
  </tr>
  <tr>
    <td style="width: 10.54%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Onpattro</div></td>
    <td style="width: 2.21%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 11.96%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Alnylam</div></td>
    <td style="width: 2.4%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 17.22%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">An RNAi medicine formulated with lipid nanoparticles to inhibit TTR mRNA</div></td>
    <td style="width: 2.22%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 13.76%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Approved (hATTR)/</div><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Phase 3 (ATTR)</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 16.54%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Intravenous infusion with pre-treatment with steroids</div></td>
    <td style="width: 2.28%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 18.69%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Topline data for the APOLLO-B (Phase 3 study) is expected in 2021</div></td>
  </tr>
  <tr>
    <td style="width: 10.54%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Vyndaqel &amp;</div><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Vyndamax</div><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Tafamidis)</div></td>
    <td style="width: 2.21%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 11.96%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pfizer</div></td>
    <td style="width: 2.4%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 17.22%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A small molecule medicine to stabilize TTR protein</div></td>
    <td style="width: 2.22%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 13.76%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Commercially available in the U.S. for cardiomyopathy and in the EU for stage 1 polyneuropathy and cardiomyopathy</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 16.54%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Oral</div></td>
    <td style="width: 2.28%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 18.69%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">None reported</div></td>
  </tr>
  <tr>
    <td style="width: 10.54%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Vutrisiran</div></td>
    <td style="width: 2.21%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 11.96%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Alnylam</div></td>
    <td style="width: 2.4%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 17.22%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">An RNAi medicine conjugated with GalNAC to inhibit TTR mRNA</div></td>
    <td style="width: 2.22%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 13.76%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 16.54%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Subcutaneous Injections</div></td>
    <td style="width: 2.28%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 18.69%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Topline data expected for HELIOS-A (Phase 3) study in 2021</div></td>
  </tr>
  <tr>
    <td style="width: 10.54%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">AG10</div></td>
    <td style="width: 2.21%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 11.96%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Eidos</div></td>
    <td style="width: 2.4%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 17.22%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Small molecule that binds and stabilizes TTR in the blood</div></td>
    <td style="width: 2.22%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 13.76%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 16.54%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Oral</div></td>
    <td style="width: 2.28%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 18.69%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Phase 3 study planned to begin in the first quarter of 2020</div></td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zdb5299892a94449ab735843f08fc8850">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 8pt;">Taken from public documents including respective company press releases, company presentations, and scientific presentations.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>36</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our main competition for Tegsedi is Onpattro (patisiran), marketed by Alnylam Pharmaceuticals. Although ONPATTRO requires intravenous administration by a healthcare provider in a clinical setting every three weeks and pre-treatment with steroids, it does not have a boxed warning or REMS as TEGSEDI does.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We believe that Alnylam&#8217;s Onpattro and vutrisiran could compete directly against AKCEA-TTR-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, given their transthyretin-silencing profile. Vyndaqel and Vyndamax, marketed by Pfizer, were approved in the U.S. and in the EU. They are two oral formulations of the transthyretin stabilizer, and currently the only medicines approved by the FDA to treat ATTR-CM.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">WAYLIVRA</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We believe that the following medicines could compete with WAYLIVRA:</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z76443cf6d666485e8a41fd68a66c4324">
  <tr>
    <td style="width: 11.44%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Medicine</div></td>
    <td style="width: 2.19%; vertical-align: top;">&#160;</td>
    <td style="width: 13.86%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Company</div></td>
    <td style="width: 2.4%; vertical-align: top;">&#160;</td>
    <td style="width: 17.08%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Medicine Description</span><sup> (1)</sup></div></td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 11.43%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Phase</span><sup> (1)</sup></div></td>
    <td style="width: 2.45%; vertical-align: top;">&#160;</td>
    <td style="width: 16.03%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Route of Administration</span><sup> (1)</sup></div></td>
    <td style="width: 2.27%; vertical-align: top;">&#160;</td>
    <td style="width: 18.63%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Next Milestones</span><sup> (1)</sup></div></td>
  </tr>
  <tr>
    <td style="width: 11.44%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Gemcabene</div></td>
    <td style="width: 2.19%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 13.86%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">NeuroBo Pharmaceuticals</div></td>
    <td style="width: 2.4%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 17.08%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Monocalcium salt of a dialkyl ether dicarboxylic acid</div></td>
    <td style="width: 2.22%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 11.43%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2</div></td>
    <td style="width: 2.45%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 16.03%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Oral</div></td>
    <td style="width: 2.27%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 18.63%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Currently on partial clinical hold, which was issued by the FDA in 2004</div></td>
  </tr>
  <tr>
    <td style="width: 11.44%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Myalept (metreleptin)</div></td>
    <td style="width: 2.19%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 13.86%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amryt Pharma</div></td>
    <td style="width: 2.4%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 17.08%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Leptin replacement therapy</div></td>
    <td style="width: 2.22%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 11.43%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2</div></td>
    <td style="width: 2.45%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 16.03%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Subcutaneous Injections</div></td>
    <td style="width: 2.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 18.63%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">None reported</div></td>
  </tr>
  <tr>
    <td style="width: 11.44%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ARO-APOC3</div></td>
    <td style="width: 2.19%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 13.86%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Arrowhead Pharmaceuticals</div></td>
    <td style="width: 2.4%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 17.08%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Targets APOCIII by utilizing Targeted RNAi Molecule Platform</div></td>
    <td style="width: 2.22%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 11.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1</div></td>
    <td style="width: 2.45%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 16.03%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Subcutaneous Injections</div></td>
    <td style="width: 2.27%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 18.63%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Plans to initiate pivotal (Phase 3) study in 2020</div></td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z76060618094e4ef9bafd0f7b1392b280">
  <tr>
    <td style="width: 36pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">&#160;(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 8pt;">Taken from public documents including respective company press releases, company presentations, and scientific presentations.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Tominersen</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We believe that the following medicines could compete with tominersen:</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z2be6dc435be24d439a4c3c7b150acad9">
  <tr>
    <td style="width: 11.44%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">C</div></td>
    <td style="width: 2.19%; vertical-align: top;">&#160;</td>
    <td style="width: 13.86%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Company</div></td>
    <td style="width: 2.4%; vertical-align: top;">&#160;</td>
    <td style="width: 17.08%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Medicine Description</span><sup> (1)</sup></div></td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 11.43%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Phase</span><sup> (1)</sup></div></td>
    <td style="width: 2.45%; vertical-align: top;">&#160;</td>
    <td style="width: 16.03%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Route of Administration</span><sup> (1)</sup></div></td>
    <td style="width: 2.27%; vertical-align: top;">&#160;</td>
    <td style="width: 18.63%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Next Milestones</span><sup> (1)</sup></div></td>
  </tr>
  <tr>
    <td style="width: 11.44%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">WVE-120101/ WVE-120102</div></td>
    <td style="width: 2.19%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 13.86%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Wave Life Sciences</div></td>
    <td style="width: 2.4%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 17.08%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Antisense medicines targeting mHTT SNP-1 and SNP-2</div></td>
    <td style="width: 2.22%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 11.43%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1b/2a</div></td>
    <td style="width: 2.45%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 16.03%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Intrathecal</div><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Infusion</div></td>
    <td style="width: 2.27%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 18.63%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Topline data from PRECISION-HD1 is expected in the second half of 2020</div></td>
  </tr>
  <tr>
    <td style="width: 11.44%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Selisistat</div></td>
    <td style="width: 2.19%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 13.86%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">AOP Orphan</div></td>
    <td style="width: 2.4%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 17.08%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">An orally active, selective SIRT1 inhibitor</div></td>
    <td style="width: 2.22%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 11.43%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2</div></td>
    <td style="width: 2.45%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 16.03%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Oral</div></td>
    <td style="width: 2.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 18.63%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">None reported</div></td>
  </tr>
  <tr>
    <td style="width: 11.44%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">VX15</div></td>
    <td style="width: 2.19%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 13.86%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Vaccinex</div></td>
    <td style="width: 2.4%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 17.08%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A monoclonal antibody that blocks the activity of SEMA4D</div></td>
    <td style="width: 2.22%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 11.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2</div></td>
    <td style="width: 2.45%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 16.03%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Intravenous</div><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Infusion</div></td>
    <td style="width: 2.27%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 18.63%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Phase 2 (SIGNAL) topline data is anticipated in second half of 2020</div></td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z2dfe98e78e79430e8acb5c7ae9fa5e36">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 8pt;">Taken from public documents including respective company press releases, company presentations, and scientific presentations.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Tofersen</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We believe that the following medicine could compete with tofersen:</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zb4bb72aa39e74673887814a3e3fe71bf">
  <tr>
    <td style="width: 11.76%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">C</div></td>
    <td style="width: 2.19%; vertical-align: top;">&#160;</td>
    <td style="width: 13.81%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Company</div></td>
    <td style="width: 2.39%; vertical-align: top;">&#160;</td>
    <td style="width: 17.01%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Medicine Description</span><sup> (1)</sup></div></td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 11.37%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Phase</span><sup> (1)</sup></div></td>
    <td style="width: 2.44%; vertical-align: top;">&#160;</td>
    <td style="width: 16%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Route of Administration</span><sup> (1)</sup></div></td>
    <td style="width: 2.27%; vertical-align: top;">&#160;</td>
    <td style="width: 18.55%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Next Milestones</span><sup> (1)</sup></div></td>
  </tr>
  <tr>
    <td style="width: 11.76%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Arimoclomol</div></td>
    <td style="width: 2.19%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 13.81%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Orphazyme</div></td>
    <td style="width: 2.39%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 17.01%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Provides cellular protection from abnormal proteins by activating molecular &#8220;chaperone&#8221; proteins that can repair or degrade the damaged proteins</div></td>
    <td style="width: 2.22%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 11.37%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3</div></td>
    <td style="width: 2.44%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 16%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Oral</div></td>
    <td style="width: 2.27%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 18.55%; vertical-align: top; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Results of the Phase 3 trial in ALS are expected in the first half of 2021</div></td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z26276a21e058413ab925fb78be00fbdb">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 8pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 8pt;">Taken from public documents including respective company press releases, company presentations, and scientific presentations.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>37</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Employees</div>
<div style="text-align: justify; text-indent: 36pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As of February 20, 2020, we employed 817 people, including 294 Akcea employees. A significant number of our management and professional employees have had prior experience with pharmaceutical, biotechnology or medical product companies. Collective bargaining agreements do not cover any of our employees, and management considers relations with our employees to be good.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Information about our Executive Officers</div>
<div style="text-align: justify; text-indent: 36pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following sets forth certain information regarding our executive officers as of February 20, 2020:</div>
<div style="text-align: left;"><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="ze42f0e2a928540c692492db3e97d8c69">
  <tr>
    <td style="width: 29.29%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Name</div></td>
    <td style="width: 2.46%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 6.68%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Age</div></td>
    <td style="width: 2.46%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 59.11%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Position</div></td>
  </tr>
  <tr>
    <td style="width: 29.29%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stanley T. Crooke, M.D., Ph.D.</div></td>
    <td style="width: 2.46%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 6.68%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">74</div></td>
    <td style="width: 2.46%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 59.11%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Executive Chairman of the Board of Directors</div></td>
  </tr>
  <tr>
    <td style="width: 29.29%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Brett P. Monia, Ph.D.</div></td>
    <td style="width: 2.46%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 6.68%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">58</div></td>
    <td style="width: 2.46%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 59.11%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Chief Executive Officer</div></td>
  </tr>
  <tr>
    <td style="width: 29.29%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">C. Frank Bennett, Ph.D.</div></td>
    <td style="width: 2.46%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 6.68%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">63</div></td>
    <td style="width: 2.46%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 59.11%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Chief Scientific Officer</div></td>
  </tr>
  <tr>
    <td style="width: 29.29%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Onaiza Cadoret-Manier</div></td>
    <td style="width: 2.46%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 6.68%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">55</div></td>
    <td style="width: 2.46%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 59.11%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Chief Corporate Development and Commercial Officer</div></td>
  </tr>
  <tr>
    <td style="width: 29.29%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Richard S. Geary, Ph.D.</div></td>
    <td style="width: 2.46%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 6.68%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">62</div></td>
    <td style="width: 2.46%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 59.11%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Senior Vice President, Development</div></td>
  </tr>
  <tr>
    <td style="width: 29.29%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Elizabeth L. Hougen</div></td>
    <td style="width: 2.46%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 6.68%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">58</div></td>
    <td style="width: 2.46%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 59.11%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Senior Vice President, Finance and Chief Financial Officer</div></td>
  </tr>
  <tr>
    <td style="width: 29.29%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Patrick R. O&#8217;Neil, Esq.</div></td>
    <td style="width: 2.46%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 6.68%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">46</div></td>
    <td style="width: 2.46%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 59.11%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary</div></td>
  </tr>
  <tr>
    <td style="width: 29.29%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Eric E. Swayze, Ph.D.</div></td>
    <td style="width: 2.46%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 6.68%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">54</div></td>
    <td style="width: 2.46%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 59.11%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Senior Vice President, Research</div></td>
  </tr>
</table>
<div style="text-align: left;"><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;">Management Transitions</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In January 2020, Dr. Crooke, our founder and Chief Executive Officer, transitioned from Chief Executive Officer to Executive Chairman of our Board of Directors. As Executive Chairman, Dr. Crooke is responsible for the activities of the board and will remain active in the company, providing strategic advice and continuing to participate in the scientific activities. Dr. Monia, who was our Chief Operating Officer and a member of our team since our founding over 30 years ago, began serving as our Chief Executive Officer in January 2020.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">STANLEY T. CROOKE, M.D., Ph.D.</div>
<div style="text-align: justify;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Executive Chairman of Ionis&#8217; Board of Directors</div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dr. Crooke is a founder of Ionis and became Executive Chairman of our board of directors in January 2020. Dr. Crooke served as Chief Executive Officer and a Director from January 1989 to January 2020. He was elected Chairman of the Board in February 1991. Prior to founding Ionis, from 1980 until January 1989, Dr. Crooke was employed by SmithKline Beckman Corporation, a pharmaceutical company, where his titles included President of Research and Development of SmithKline and French Laboratories.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">BRETT P. MONIA, Ph.D.</div>
<div style="text-align: justify;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Chief Executive Officer</div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt;"><br /></div>
<div style="text-align: justify; text-indent: 38.15pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dr. Monia was promoted to Chief Executive Officer in January 2020. From January 2019 to December 2019, Dr. Monia served as Chief Operating Officer. From January 2012 to January 2019, Dr. Monia served as Senior Vice President. From February 2009 to January 2012, Dr. Monia served as our Vice President, Drug Discovery and Corporate Development and from October 2000 to February 2009, he served as our Vice President, Preclinical Drug Discovery. From October 1989 to October 2000 he held various positions within our Molecular Pharmacology department.</div>
<div style="text-align: justify; text-indent: 36pt;"><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">C. FRANK BENNETT, Ph.D.</div>
<div style="text-align: justify;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Chief Scientific Officer</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dr. Bennett was promoted to Chief Scientific Officer in January 2020. From January 2006 to December 2019, Dr. Bennett served as Senior Vice President, Antisense Research. From June 1995 to January 2006, Dr. Bennett served as our Vice President, Research. From March 1993 to June 1995, he was Director, Molecular Pharmacology, and from May 1992 to March 1993, he was an Associate Director in our Molecular and Cellular Biology department. Prior to joining Ionis in 1989, Dr. Bennett was employed by SmithKline and French Laboratories in various research positions. He is an external member of the Scientific Advisory Board of Experimental Therapeutics Center in Singapore and the Hereditary Disease Foundation.</div>
<div style="text-align: justify; text-indent: 36pt;"><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>38</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ONAIZA CADORET-MANIER</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Chief Corporate Development and Commercial Officer</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ms. Cadoret-Manier joined Ionis as Chief Corporate Development and Commercial Officer in January 2020. Prior to joining Ionis, from 2018 to 2019 Ms. Cadoret-Manier was the chief commercial officer for Grail Biosciences, an early detection genomics company. Prior to Grail, Ms. Cadoret-Manier was vice president of the Respiratory Franchise at Genentech where she worked from 2011 to 2018. Ms. Cadoret-Manier also has held multiple senior management positions overseeing corporate strategy, alliances, and marketing and sales for numerous disease areas for Genentech, Pfizer and Amylin Pharmaceuticals.</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">RICHARD S. GEARY, Ph.D.</div>
<div style="text-align: justify;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Senior Vice President, Development</div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dr. Geary has served as Ionis&#8217; Senior Vice President, Development since August 2008. From August 2003 to August 2008, Dr. Geary served as our Vice President, Preclinical Development. From November 1995 to August 2003, he held various positions within the Preclinical Development department. Prior to joining Ionis in 1995, Dr. Geary was Senior Research Scientist and Group Leader for the bioanalytical and preclinical pharmacokinetics group in the Applied Chemistry Department at Southwest Research Institute.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ELIZABETH L. HOUGEN</div>
<div style="text-align: justify;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Senior Vice President, Finance and Chief Financial Officer</div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ms. Hougen has served as Ionis&#8217; Senior Vice President, Finance and Chief Financial Officer since January 2013. From January 2007 to December 2012, Ms. Hougen served as our Vice President, Finance and Chief Accounting Officer and from May 2000 to January 2007, she served as our Vice President, Finance. Prior to joining Ionis in 2000, Ms. Hougen was Executive Director, Finance and Chief Financial Officer for Molecular Biosystems, Inc., a public biotechnology company.</div>
<div style="text-align: justify; text-indent: 36pt;"><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">PATRICK R. O&#8217;NEIL, Esq.</div>
<div style="text-align: justify;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary</div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Mr. O&#8217;Neil has served as Ionis&#8217; Senior Vice President, Legal and General Counsel since January 2013. Mr. O&#8217;Neil also serves as our Chief Compliance Officer and Corporate Secretary. From September 2010 to January 2013, Mr. O&#8217;Neil served as our Vice President, Legal and General Counsel and from January 2009 to September 2010, he served as our Vice President, Legal and Senior Transactions Counsel. From October 2001 to January 2009 he held various positions within our Legal department. Prior to joining Ionis, Mr. O&#8217;Neil was an associate at Cooley LLP.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ERIC E. SWAYZE, Ph.D.</div>
<div style="text-align: justify;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Senior Vice President, Research</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Dr. Swayze was promoted to Senior Vice President of Research at Ionis Pharmaceuticals in January 2020. He is responsible for leading preclinical antisense drug discovery and antisense technology research.</span>&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Previously, Dr. Swayze was Vice President of Chemistry and Neuroscience Drug Discovery at Ionis, overseeing the advancement of multiple programs to clinical development. He joined Ionis in 1994 and has contributed to key technology advancements, including Ionis' Generation 2.5 chemistry and LICA technology.</span></div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>39</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 1A. RISK FACTORS</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Investing in our securities involves a high degree of risk. You should consider carefully the following information about the risks described below, together with the other information contained in this report and in our other public filings in evaluating our business. If any of the following risks actually occur, our business could be materially harmed, and our financial condition and results of operations could be materially and adversely affected. As a result, the trading price of our securities could decline, and you might lose all or part of your investment.</div>
<div><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Risks Associated with our Ionis Core and Akcea Therapeutics Businesses</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">If the market does not accept our medicines, including SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development, we are not likely to generate substantial revenues or become consistently profitable.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Even if our medicines are authorized for marketing, including SPINRAZA, TEGSEDI and WAYLIVRA, our success will depend upon the medical community, patients and third-party payors accepting our medicines as medically useful, cost-effective, safe and convenient. Even when the FDA or foreign regulatory authorities authorize our or our partners&#8217; medicines for commercialization, doctors may not prescribe our medicines to treat patients. We and our partners may not successfully commercialize additional medicines.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Additionally, in many of the markets where we or our partners may sell our medicines in the future, if we or our partners cannot agree with the government or other third-party payors regarding the price we can charge for our medicines, then we may not be able to sell our medicines in that market. Similarly, cost control initiatives by governments or third-party payors could decrease the price received for our medicines or increase patient coinsurance to a level that makes our medicines, including SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development, economically unviable.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The degree of market acceptance for our medicines, including SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development, depends upon a number of factors, including the:</div>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zea2682b46480419b9f2265b8f01b6e39">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">receipt and scope of marketing authorizations;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z13276de8a40248dd916cd4460fbbc20b">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">establishment and demonstration in the medical and patient community of the efficacy and safety of our medicines and their potential advantages over competing products;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z9484f34c36494fabb9faa56662641335">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">cost and effectiveness of our medicines compared to other available therapies;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zc47a44ddf02f4c6e81b8bfa722251e68">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">patient convenience of the dosing regimen for our medicines; and</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z623785be1d8a44d9924efb522d3d3689">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">reimbursement policies of government and third-party payors.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Based on the profile of our medicines, physicians, patients, patient advocates, payors or the medical community in general may not accept or use any medicines that we may develop.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">For example, the product label for TEGSEDI in the U.S. has a boxed warning for thrombocytopenia and glomerulonephritis, requires periodic blood and urine monitoring, and TEGSEDI is only available through a Risk Evaluation and Mitigation Strategy, or REMS, program. </span>Our main competition in the U.S. market for TEGSEDI is ONPATTRO (patisiran), marketed by Alnylam Pharmaceuticals, Inc. Although ONPATTRO requires intravenous administration and pre-treatment with steroids, it does not have a boxed warning or REMS. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Additionally, the product label for WAYLIVRA in the EU requires regular blood monitoring. In each case, these label requirements could negatively affect our ability to attract and retain patients for these medicines. We believe that the enhanced monitoring we have implemented to support early detection and management of these issues can help manage these safety issues so that patients can continue treatment. Since implementation of the enhanced monitoring, serious platelet events have been infrequent. While we believe we and Akcea can better maintain patients on TEGSEDI and WAYLIVRA through our patient-centric commercial approach where we plan to have greater involvement with physicians and patients, if we cannot effectively maintain patients on TEGSEDI or WAYLIVRA, we may not be able to generate substantial revenue from TEGSEDI or WAYLIVRA sales.</span></div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">If we or our partners fail to compete effectively, our medicines, including SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development, will not contribute significant revenues.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our competitors engage in drug discovery throughout the world, are numerous, and include, among others, major pharmaceutical companies and specialized biopharmaceutical firms. Other companies engage in developing antisense technology. Our competitors may succeed in developing medicines that are:</div>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z078d236d8fd64f80aaf109cce4e71563">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">priced lower than our medicines;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z19726f9ec6154b81898bf12a37a22ebb">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">reimbursed more favorably by government and other third-party payors than our medicines;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z998d40022dc24bd39dca83834d62ace7">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">safer than our medicines;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zaa9f5fcfd7fd4933af42d03a745ff9b3">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">more effective than our medicines; or</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z68e769c49aa3409dbe0dd6a8b2acbff5">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">more convenient to use than our medicines.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>40</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">These competitive developments could make our medicines, including SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development, obsolete or non-competitive.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Certain of our partners are pursuing other technologies or developing other medicines either on their own or in collaboration with others, including our competitors, to treat the same diseases our own collaborative programs target. Competition may negatively impact a partner&#8217;s focus on and commitment to our medicines and, as a result, could delay or otherwise negatively affect the commercialization of our medicines, including SPINRAZA, TEGSEDI and WAYLIVRA.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Many of our competitors have substantially greater financial, technical and human resources than we do. In addition, many of these competitors have significantly greater experience than we do in conducting preclinical testing and human clinical studies of new pharmaceutical products, in obtaining FDA and other regulatory authorizations of such products and in commercializing such products. Accordingly, our competitors may succeed in obtaining regulatory authorization for products earlier than we do. Marketing and sales capability is another factor relevant to the competitive position of our medicines, and we will primarily rely on our partners and Akcea to provide this capability.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">There are several pharmaceutical and biotechnology companies engaged in the development or commercialization of products against targets that are also targets of products in our development pipeline. For example:</div>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z3325ced3c10540088fb04e130d4564a2">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ZOLGENSMA (approved in the U.S. for the treatment of pediatric patients less than two years of age with SMA) and risdiplam (RG7916) could compete with SPINRAZA;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="ze9aea69928c34b8b947ad0757dfeeba1">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ONPATTRO (approved in the U.S., Europe and Brazil for a similar indication as TEGSEDI), VYNDAQEL and VYNDAMAX (approved in the U.S. for patients with both hereditary and wild type ATTR cardiomyopathy and in the EU for stage 1 hATTR amyloidosis with polyneuropathy and cardiomyopathy), AG10 and vutrisiran could compete with TEGSEDI;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z92e61c2bb0a140e6a6e4a1ae0d18a471">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">ARO-APOC3, </span>Myalept<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and gemcabene could compete with WAYLIVRA;</span></div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z749c91827b8d4e5bbd60711845af9de2">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">WVE-120101/WVE-120102, Selistat and VX15 could compete with tominersen;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zf1fe69f06fcc446f94db53f2d6cd1434">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Arimoclomol could compete with tofersen; and</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z0c93e1287c624461bfd7d85478f87e89">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">ONPATTRO, VYNDAQEL and VYNDAMAX, vutrisiran and AG10 could complete with AKCEA-TTR-L<sub>Rx;</sub>.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Certain of our medicines may compete with our other medicines, which could reduce our expected revenues.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Certain of our medicines inhibit the production of the same protein. For example, WAYLIVRA inhibits the production of the same protein as AKCEA-APOCIII-L<sub>Rx</sub> and TEGSEDI inhibits the production of the same protein as <a id="_Hlk31961917"><!--Anchor--></a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">AKCEA-TTR-L</span><sub>Rx</sub>. We believe the enhancements we incorporated into <a id="_Hlk31961656"><!--Anchor--></a>AKCEA-APOCIII-L<sub>Rx</sub> and <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">AKCEA-TTR-L</span><sub>Rx</sub> can provide greater patient convenience by allowing for significantly lower doses and less frequent administration compared to WAYLIVRA and TEGSEDI, respectively. As such, to the extent physicians and patients elect to use AKCEA-APOCIII-L<sub>Rx</sub> or <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">AKCEA-TTR-L</span><sub>Rx</sub> instead of WAYLIVRA or TEGSEDI, respectively, it will reduce the revenue we derive from those medicines. In addition, while AKCEA-ANGPTL3-L<sub>Rx</sub>, AKCEA-APOCIII-L<sub>Rx</sub> and WAYLIVRA use different mechanisms of action, if AKCEA-ANGPTL3-L<sub>Rx</sub> can effectively lower triglyceride levels in FCS patients, it may likewise reduce the revenue we derive from WAYLIVRA and AKCEA-APOCIII-L<sub>Rx</sub>.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Our medicines could be subject to regulatory limitations following approval.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Following approval of a medicine, we and our partners must comply with comprehensive government regulations regarding the manufacture, marketing and distribution of medicines. Promotional communications regarding prescription medicines must be consistent with the information in the product&#8217;s approved labeling. We or our partners may not obtain the labeling claims necessary or desirable to successfully commercialize our medicines, including SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The FDA and foreign regulatory bodies have the authority to impose significant restrictions on an approved medicine through the product label and on advertising, promotional and distribution activities. For example:</div>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zbf370d94bef248c9b52897d42d8593dc">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">in the U.S., TEGSEDI&#8217;s label contains a boxed warning for thrombocytopenia and glomerulonephritis;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zb2ac1c1de2674bad8063ce8accc4f9ca">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">TEGSEDI requires periodic blood and urine monitoring;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z02c544f7f6d84060a6eddef230fc4b5f">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">in the U.S., TEGSEDI is available only through a Risk Evaluation and Mitigation Strategy, or REMS, program; and</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="za6bd4a52858d4d6689fca0b728d8b455">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">we expect WAYLIVRA will require periodic blood monitoring if approved in the U.S.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Prescription medicines may be promoted only for the approved indications in accordance with the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label may be subject to significant liability.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>41</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In addition, when approved, the FDA or a foreign regulatory authority may condition approval on the performance of post-approval clinical studies or patient monitoring, which could be time consuming and expensive. For example, in connection with the conditional marketing approval for WAYLIVRA in the EU, we are required to conduct a post-authorization safety study to evaluate the safety of WAYLIVRA on thrombocytopenia and bleeding in FCS patients taking WAYLIVRA. If the results of such post-marketing studies are not satisfactory, the FDA, EC or other foreign regulatory authority may withdraw marketing authorization or may condition continued marketing on commitments from us or our partners that may be expensive and time consuming to fulfill.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 39.6pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If we or others identify side effects after any of our medicines are on the market, or if manufacturing problems occur subsequent to regulatory approval, or if we, our manufacturers or our partners fail to comply with regulatory requirements, we or our partners may, among other things, lose regulatory approval and be forced to withdraw products from the market, need to conduct additional clinical studies, incur restrictions on the marketing, distribution or manufacturing of the product, and/or change the labeling of our medicines, including <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">SPINRAZA, TEGSEDI and WAYLIVRA.</span></div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">We depend on our collaboration with Biogen for the development and commercialization of SPINRAZA.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have entered into a collaborative arrangement with Biogen to develop and commercialize SPINRAZA. We entered into this collaboration primarily to:</div>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z55ba5069bddc4480a1f784705dcfc29e">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">fund our development activities for SPINRAZA;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zfa6f7b74e43443e7875d65e35dc7f7d9">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">seek and obtain regulatory approvals for SPINRAZA; and</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z7bea126f4a86488894a576245462c66b">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">successfully commercialize SPINRAZA.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are relying on Biogen to obtain additional regulatory approvals for SPINRAZA, and successfully commercialize SPINRAZA. In general, we cannot control the amount and timing of resources that Biogen devotes to our collaboration. If Biogen fails to further develop SPINRAZA, obtain additional regulatory approvals for SPINRAZA, or commercialize SPINRAZA, or if Biogen&#8217;s efforts are not effective, our business may be negatively affected.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our collaboration with Biogen may not continue for various reasons. Biogen can terminate our collaboration at any time. If Biogen stops developing or commercializing SPINRAZA, we would have to seek or spend additional funding, and SPINRAZA&#8217;s commercialization may be harmed or delayed.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our collaboration with Biogen may not result in the continued successful commercialization of SPINRAZA. If Biogen does not continue to successfully commercialize SPINRAZA, we will receive limited revenues for SPINRAZA.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">If Akcea cannot optimize and maintain effective marketing and sales capabilities or enter into agreements with third parties to market and sell TEGSEDI and WAYLIVRA, we may not generate significant product revenue from TEGSEDI or WAYLIVRA.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">To successfully commercialize TEGSEDI and WAYLIVRA, Akcea must effectively manage its marketing, sales and distribution capabilities or make arrangements with third parties to perform these services. Akcea may not be successful in doing so. To commercialize WAYLIVRA in the initial indications Akcea is planning to pursue and to continue the commercialization of TEGSEDI, Akcea will need to optimize and maintain specialty sales forces in the global regions where it currently markets or expects to market TEGSEDI and WAYLIVRA, supported by case managers, reimbursement specialists, partnerships with specialty pharmacies, injection training, routine blood and urine monitoring and a medical affairs team.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Even though certain members of Akcea&#8217;s management team and other employees have experience commercializing medicines, as a company Akcea has limited experience marketing, selling and distributing medicines, and there are significant risks involved in building, tailoring, optimizing and managing a commercial infrastructure. Beginning in September 2019, Akcea announced several changes to its senior leadership team, including the departure of its Chief Executive Officer, its President, and its Chief Operating Officer and the recent resignation of its Chief Financial Officer, whose resignation is to become effective on April 1, 2020, and the appointment of an interim Chief Executive Officer, a new Chief Commercial Officer and a new Chief Operating Officer. The effectiveness of the senior leadership team following these transitions, new leaders as they fill in these roles, and any further transition as a result of these changes could impair Akcea&#8217;s ability to manage its business.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">It is expensive and time consuming for Akcea to maintain its own sales forces and related compliance protocols to market TEGSEDI and WAYLIVRA, and it will be increasingly expensive and time consuming when Akcea commercially launches additional medicines, if approved. Akcea may never successfully optimize or manage this capability and any failure could harm the commercial launch of WAYLIVRA or adversely affect TEGSEDI sales. Additionally, Akcea and its partners, if any, will have to compete with other companies to recruit, hire, train, manage and retain marketing and sales personnel. As a result of Akcea&#8217;s receipt of a CRL from the FDA regarding the new drug application for WAYLIVRA, on September 6, 2018, Akcea enacted a plan to reorganize its workforce to better align with the immediate needs of the business. In connection with this reorganization plan, Akcea reduced its workforce by approximately 12% and will need to increase its operations and expand its use of third -party contractors if WAYLIVRA is approved in the United States.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>42</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea incurred expenses launching TEGSEDI in the EU, Canada and the U.S. and launching WAYLIVRA in the EU and building and managing the marketing and sales infrastructure. If regulatory requirements or other factors cause the commercialization of TEGSEDI or WAYLIVRA to be less successful than expected in important markets, Akcea would incur additional expenses for having invested in these capabilities prior to realizing any significant revenue from sales of TEGSEDI or WAYLIVRA. Akcea&#8217;s sales force and marketing teams may not successfully commercialize TEGSEDI or WAYLIVRA.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">To the extent we and Akcea decide to rely on third parties to commercialize TEGSEDI or WAYLIVRA in a particular geographic market, we may receive less revenue than if Akcea commercialized TEGSEDI or WAYLIVRA by itself. For example, in August 2018, Akcea granted PTC Therapeutics International Limited, or PTC Therapeutics, the exclusive right to commercialize TEGSEDI and WAYLIVRA in Latin America and certain Caribbean countries, and Akcea will continue to rely on PTC Therapeutics to commercialize TEGSEDI and WAYLIVRA in those geographic markets. In addition, in August 2018 Akcea entered into an agreement with Accredo Health Group, Inc., or Accredo, a subsidiary of Express Scripts, to be Akcea&#8217;s specialty pharmacy partner for distribution of TEGSEDI in the U.S. Further, Akcea has less control over the sales efforts of other third parties, </span>including PTC Therapeutics and Accredo,<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> involved in commercializing TEGSEDI or WAYLIVRA.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If Akcea cannot effectively build and manage its distribution, medical affairs, market access, marketing and sales infrastructure, or find a suitable third party to perform such functions, the sales of TEGSEDI and WAYLIVRA may be adversely affected. Any such events may result in decreased sales and lower revenue, which could have a material adverse effect on our business, prospects, financial condition and results of operations.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">If government or other third-party payors fail to provide adequate coverage and payment rates for our medicines, including SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development, our revenue will be limited.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In both domestic and foreign markets, sales of our current and future products will depend in part upon the availability of coverage and reimbursement from third-party payors. The majority of patients in the U.S. who would fit within our target patient populations for our medicines have their healthcare supported by a combination of Medicare coverage, other government health programs such as Medicaid, managed care providers, private health insurers and other organizations. Coverage decisions may depend upon clinical and economic standards that disfavor new medicines when more established or lower cost therapeutic alternatives are already available or subsequently become available. Assuming coverage is approved, the resulting reimbursement payment rates might not be enough to make our medicines affordable. Accordingly, SPINRAZA, TEGSEDI and WAYLIVRA for FCS in the EU and, if approved, WAYLIVRA in the United States or Canada and for additional indications, and our medicines in development, will face competition from other therapies and medicines for limited financial resources. We or our partners may need to conduct post-marketing studies to demonstrate the cost-effectiveness of any future products to satisfy third-party payors. These studies might require us to commit a significant amount of management time and financial and other resources. Third-party payors may never consider our future products as cost-effective. Adequate third-party coverage and reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in product development.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In addition, in the U.S., no uniform policy of coverage and reimbursement for medicines exists among third-party payors. Therefore, coverage and reimbursement for medicines can differ significantly from payor to payor. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the PPACA, was passed in March 2010, and substantially changed the way healthcare is financed by both governmental and private insurers, and continues to significantly impact the U.S. pharmaceutical industry. There remain judicial and Congressional challenges to certain aspects of the Affordable Care Act, as well as efforts by the Trump administration to repeal or replace certain aspects of the Affordable Care Act. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act are invalid as well. It is unclear how this decision, future decisions, subsequent appeals, and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act and our business.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Further, we believe that future coverage and reimbursement will likely be subject to increased restrictions both in the United States and in international markets. For example, in the United States, recent health reform measures have resulted in reductions in Medicare and other healthcare funding, and there have been several recent U.S. Congressional inquiries and legislation designed to, among other things, reform government program reimbursement methodologies for medicines and bring more transparency to drug pricing. At the federal level, the Trump administration&#8217;s budget proposal for fiscal year 2020 contains further drug price control measures that could be enacted during the budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain medicines under Medicare Part B, to allow some states to negotiate prices under Medicaid, and to eliminate cost sharing for generic medicines for low-income patients. Further, the Trump administration released a &#8220;Blueprint&#8221; to lower medicine prices and reduce out of pocket costs of medicines that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out of pocket costs of medicines paid by consumers. The Department of Health and Human Services has solicited feedback on some of these measures and, at the same time, has implemented others under its existing authority. While some of these and other measures may require additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and administrative measures to control drug costs. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Third-party coverage and reimbursement for medicines may not be available or adequate in either the United States or international markets, which would negatively affect the potential commercial success of our products, our revenue and our profits.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>43</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">If Biogen cannot manufacture finished drug product for SPINRAZA or the post-launch supply of the active drug substance for SPINRAZA, SPINRAZA may not maintain commercial success.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Biogen is responsible for the long-term supply of both SPINRAZA drug substance and finished drug product. Biogen may not be able to reliably manufacture SPINRAZA drug substance and drug product to support the long-term commercialization of SPINRAZA. If Biogen cannot reliably manufacture SPINRAZA drug substance and drug product, SPINRAZA may not maintain commercial success, which will harm our ability to generate revenue.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">If we or our partners fail to obtain regulatory approval for our medicines and additional approvals for SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development, we or our partners cannot sell them in the applicable markets.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We cannot guarantee that any of our medicines will be considered safe and effective, or will be approved for commercialization. In addition, it is possible that SPINRAZA, TEGSEDI and WAYLIVRA may not be approved in additional markets or for additional indications. We and our partners must conduct time-consuming, extensive and costly clinical studies to demonstrate the safety and efficacy of each of our medicines before they can be approved or receive additional approvals for sale. We and our partners must conduct these studies in compliance with FDA regulations and with comparable regulations in other countries.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We and our partners may not obtain necessary regulatory approvals on a timely basis, if at all, for our medicines. It is possible that regulatory agencies will not approve our medicines for marketing or SPINRAZA, TEGSEDI or WAYLIVRA in additional markets or for additional indications. If the FDA or another regulatory agency believes that we or our partners have not sufficiently demonstrated the safety or efficacy of any of our medicines, including SPINRAZA, TEGSEDI and WAYLIVRA, or our medicines in development, the agency will not approve the specific medicine or will require additional studies, which can be time consuming and expensive and which will delay or harm commercialization of the medicine. For example, in August 2018 Akcea received a CRL from the FDA regarding the new drug application for WAYLIVRA in which the FDA determined that the safety concerns identified with WAYLIVRA in Akcea&#8217;s clinical development program outweighed the expected benefits of triglyceride lowering in patients with FCS. Akcea also received a Non-W from Health Canada for WAYLIVRA in November 2018. We and Akcea are engaged with the FDA and plan to work with Health Canada to confirm a path forward for WAYLIVRA.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The FDA or other comparable foreign regulatory authorities can delay, limit or deny approval of a medicine for many reasons, including:</div>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z169b5c55310c4631ad50890eb14debf2">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">such authorities may disagree with the design or implementation of our clinical studies;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z35d3649bfa684a6dbf1d4736933f4eb6">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">we or our partners may be unable to demonstrate to the satisfaction of the FDA or other regulatory authorities that a medicine is safe and effective for any indication;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zcafdda5a414f4bb78718b56b20d372b7">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">such authorities may not accept clinical data from studies conducted at clinical facilities that have deficient clinical practices or that are in countries where the standard of care is potentially different from the United States;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zb59f675fb76e4dad833f8d21531236ed">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">we or our partners may be unable to demonstrate that our medicine's clinical and other benefits outweigh its safety risks to support approval;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z8407fd65dba34b3197a8fda43fb168b5">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">such authorities may disagree with the interpretation of data from preclinical or clinical studies;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z90421073209b49568215a5f1cb0bfc5a">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">such authorities may find deficiencies in the manufacturing processes or facilities of third-party manufacturers who manufacture clinical and commercial supplies for our medicines; and</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z5b0d4f729a314214b526474b73e042c3">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the approval policies or regulations of such authorities or their prior guidance to us or our partners during clinical development may significantly change in a manner rendering our clinical data insufficient for approval.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Failure to receive marketing authorization for our medicines, or failure to receive additional marketing authorizations for SPINRAZA, TEGSEDI or WAYLIVRA, and our medicines in development, or delays in these authorizations could prevent or delay commercial introduction of the medicine, and, as a result, could negatively impact our ability to generate revenue from product sales.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">If the results of clinical testing indicate that any of our medicines are not suitable for commercial use, we may need to abandon one or more of our drug development programs.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Drug discovery and development has inherent risks and the historical failure rate for drugs is high. Antisense medicines are a relatively new approach to therapeutics. If we cannot demonstrate that our medicines are safe and effective for human use in the intended indication, we may need to abandon one or more of our drug development programs.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the past, we have invested in clinical studies of medicines that have not met the primary clinical end points in their Phase 3 studies. Similar results could occur in clinical studies for our medicines, including the studies of tominersen, tofersen, AKCEA-APO(a)-L<sub>Rx</sub> and AKCEA<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">-</span>TTR-L<sub>Rx</sub>. If any of our medicines in clinical studies, including tominersen, tofersen, AKCEA-APO(a)-L<sub>Rx,</sub> and AKCEA<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">-</span>TTR-L<sub>Rx</sub>, do not show sufficient efficacy in patients with the targeted indication, it could negatively impact our development and commercialization goals for these medicines and our stock price could decline.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>44</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Even if our medicines are successful in preclinical and human clinical studies, the medicines may not be successful in late-stage clinical studies.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Successful results in preclinical or initial human clinical studies, including the Phase 2 results for some of our medicines in development, may not predict the results of subsequent clinical studies, including the studies of tominersen<sub>,</sub>, tofersen, AKCEA-APO(a)-L<sub>Rx</sub> and AKCEA<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">-</span>TTR-L<sub>Rx</sub>. There are a number of factors that could cause a clinical study to fail or be delayed, including:</div>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z9fcdb354c9cd4ccc8a27ce11aa1c122d">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the clinical study may produce negative or inconclusive results;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z2ac300a795f048b39ce00457c8a85934">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">regulators may require that we hold, suspend or terminate clinical research for noncompliance with regulatory requirements;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z92c343adc19443ab986cc6b26071fd68">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">we, our partners, the FDA or foreign regulatory authorities could suspend or terminate a clinical study due to adverse side effects of a medicine on subjects in the trial;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="za69ae37dee694d1899a27924bd098612">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">we, or our partners, may decide, or regulators may require us, to conduct additional preclinical testing or clinical studies;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z646e9bc9e02542648e5bc99c1b0dea30">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">enrollment in our clinical studies may be slower than we anticipate;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z2f4f57efa85f420c834dead81c9de4ef">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">we or our partners, including our independent clinical investigators, contract research organizations and other third-party service providers on which we rely, may not identify, recruit and train suitable clinical investigators at a sufficient number of study sites or timely enroll a sufficient number of study subjects in the clinical study;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z4c4a048422534812b871001947c6b935">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the institutional review board for a prospective site might withhold or delay its approval for the study;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z9d2fea0ebbfe4e6294468edb1f050534">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">enrollment in our clinical studies may be slower than we anticipate;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zf959473a7c5a4ca89aa4786fc497ed6a">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">people who enroll in the clinical study may later drop out due to adverse events, a perception they are not benefiting from participating in the study, fatigue with the clinical study process or personal issues;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zdb6c47de55fa4b5c89b2241bba73878e">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">a clinical study site may deviate from the protocol for the study;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z72123a34e729479dbd57e8ef863e8eaf">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the cost of our clinical studies may be greater than we anticipate;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zc50dfda807a141efa598a16e9d22d48d">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">our partners may decide not to exercise any existing options to license and conduct additional clinical studies for our medicines; and</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z05fa6bd1c95743079a6b5673a757df17">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the supply or quality of our medicines or other materials necessary to conduct our clinical studies may be insufficient, inadequate or delayed.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In addition, our current medicines, including SPINRAZA, TEGSEDI and WAYLIVRA, are chemically similar to each other. As a result, a safety observation we encounter with one of our medicines could have, or be perceived by a regulatory authority to have, an impact on a different medicine we are developing. This could cause the FDA and other regulators to ask questions or take actions that could harm or delay our ability to develop and commercialize our medicines or increase our costs. For example, the FDA or other regulatory agencies could request, among other things, any of the following regarding one of our medicines: additional information or commitments before we can start or continue a clinical study, protocol amendments, increased safety monitoring, additional product labeling information, and post-approval commitments. This happened in connection with the conditional marketing approval for WAYLIVRA in the EU, as the EC is requiring Akcea to conduct a post-authorization safety study to evaluate the safety of WAYLIVRA on thrombocytopenia and bleeding in FCS patients taking WAYLIVRA. Akcea has an ongoing OLE extension study of WAYLIVRA in patients with FCS and an OLE study of TEGSEDI in patients with hATTR, and an early access program, or EAP, for both WAYLIVRA and TEGSEDI. Adverse events or results from these studies or the EAPs could negatively impact Akcea&#8217;s pending or future marketing approval applications for WAYLIVRA and TEGSEDI in patients with FCS or hATTR amyloidosis or the commercial opportunity for WAYLIVRA or TEGSEDI.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Any failure or delay in the clinical studies, including the studies of tominersen, tofersen, AKCEA-APO(a)-L<sub>Rx</sub> and AKCEA<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">-</span>TTR-L<sub>Rx</sub>, could reduce the commercial potential or viability of our medicines.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">If we cannot manufacture our medicines or contract with a third party to manufacture our medicines at costs that allow us to charge competitive prices to buyers, we cannot market our products profitably.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">To successfully commercialize any of our medicines, we or our partner would need to optimize and manage large-scale commercial manufacturing capabilities either on our own or through a third-party manufacturer. We and Akcea will rely on third-party manufacturers to supply the drug substance and drug product for TEGSEDI and WAYLIVRA. In addition, as our drug development pipeline increases and matures, we will have a greater need for clinical trial and commercial manufacturing capacity. We have limited experience manufacturing pharmaceutical products of the chemical class represented by our medicines, called oligonucleotides, on a commercial scale for the systemic administration of a medicine. There are a small number of suppliers for certain capital equipment and raw materials that we use to manufacture our medicines, and some of these suppliers will need to increase their scale of production to meet our projected needs for commercial manufacturing. Further, we must continue to improve our manufacturing processes to allow us to reduce our drug costs. We may not be able to manufacture our medicines at a cost or in quantities necessary to make commercially successful products.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Also, manufacturers, including us, must adhere to the FDA&#8217;s current Good Manufacturing Practices regulations and similar regulations in foreign countries, which the applicable regulatory authorities enforce through facilities inspection programs. We, our partners and our contract manufacturers may not comply or maintain compliance with Good Manufacturing Practices, or similar foreign regulations. Non-compliance could significantly delay or prevent receipt of marketing authorizations for our medicines, including authorizations for SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development, or result in enforcement action after authorization that could limit the commercial success of our medicines, including SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>45</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">We depend on third parties to conduct our clinical studies for our medicines and any failure of those parties to fulfill their obligations could adversely affect our development and commercialization plans.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We depend on independent clinical investigators, contract research organizations and other third-party service providers to conduct our clinical studies for our medicines and expect to continue to do so in the future. For example, we use clinical research organizations, such as Pharmaceutical Research Associates, Inc., Icon Clinical Research Limited, Syneos Health, Inc., PPD and Medpace for the clinical studies for our medicines, including tominersen, tofersen, AKCEA-APO(a)-L<sub>Rx</sub> and AKCEA<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">-</span>TTR-L<sub>Rx</sub>. We rely heavily on these parties for successful execution of our clinical studies, but do not control many aspects of their activities. For example, the investigators are not our employees. However, we are responsible for ensuring that these third parties conduct each of our clinical studies in accordance with the general investigational plan and approved protocols for the study. Third parties may not complete activities on schedule or may not conduct our clinical studies in accordance with regulatory requirements or our stated protocols. The failure of these third parties to carry out their obligations or a termination of our relationship with these third parties could delay or prevent the development, marketing authorization and commercialization of our medicines or additional marketing authorizations for SPINRAZA, TEGSEDI and WAYLIVRA.</div>
<div><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Risks Associated with our Businesses as a Whole</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">We have incurred losses, and our business will suffer if we fail to consistently achieve profitability in the future.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Because drug discovery and development requires substantial lead-time and money prior to commercialization, our expenses have generally exceeded our revenue since we were founded in January 1989. As of December 31, 2019, we had an accumulated deficit of approximately $0.7 billion and stockholders&#8217; equity of approximately $1.7 billion. Most of our historical losses resulted from costs incurred in connection with our research and development programs and from selling, general and administrative costs associated with our operations. Most of our income has come from collaborative arrangements, including commercial revenue from royalties and R&amp;D revenue, with additional income from research grants and the sale or licensing of our patents, as well as interest income. If we do not continue to earn substantial revenue, we may incur additional operating losses in the future. We may not successfully develop any additional products or achieve or sustain future profitability.</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Our ability to use our net operating loss carryovers and certain other tax attributes may be limited.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under the Internal Revenue Code of 1986, as amended, or the Code, a corporation is generally allowed a deduction for net operating losses, or NOLs, carried over from a prior taxable year. Under that provision, we can carryforward our NOLs to offset our future taxable income, if any, until such NOLs are used or expire. The same is true of other unused tax attributes, such as tax credits.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under the Tax Cut and Jobs Act of 2017, or the Tax Act, federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. It is uncertain if and to what extent various states will conform to the federal Tax Act.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In addition, under Section 382 of the Code, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50 percent change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. If an ownership change occurs and our ability to use our net operating loss carryforwards or other tax attributes is materially limited, it would harm our future operating results by effectively increasing our future tax obligations.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Since corporate partnering is a significant part of our strategy to fund the development and commercialization of our development programs, if any of our collaborative partners fail to fund our collaborative programs, or if we cannot obtain additional partners, we may have to delay or stop progress on our drug development programs.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">To date, corporate partnering has played a significant role in our strategy to fund our development programs and to add key development resources. We plan to continue to rely on additional collaborative arrangements to develop and commercialize our unpartnered medicines. However, we may not be able to negotiate favorable collaborative arrangements for these drug programs. If we cannot continue to secure additional collaborative partners, our revenues could decrease and the development of our medicines could suffer.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our corporate partners are developing and/or funding many of the medicines in our development pipeline. For example, we are relying on:</div>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z6a2fd99f67a24fac8d56530cb9bfe4c2">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Roche for development and funding of tominersen;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zed4a3159992944b4bad16156927e11d3">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Novartis for development and funding of AKCEA-APO(a)-L<sub>Rx</sub>; and</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zd879a9d0dc574ea1815588eb1538ec4c">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Biogen for development and funding of tofersen.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If any of these pharmaceutical companies stops developing and/or funding these medicines, our business could suffer and we may not have, or be willing to dedicate, the resources available to develop these medicines on our own. Our collaborators can terminate their relationships with us under certain circumstances, many of which are outside of our control. For example, as part of a reprioritization of its pipeline and strategic review of its rare disease business, GSK declined its option to license TEGSEDI and IONIS-FB-L<sub>Rx</sub>.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>46</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Even with funding from corporate partners, if our partners do not effectively perform their obligations under our agreements with them, it would delay or stop the progress of our drug development and commercial programs.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In addition to receiving funding, we enter into collaborative arrangements with third parties to:</div>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z2754a3585bb348348f128838796c4022">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">conduct clinical studies;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zd2ea2d3d165641c7b68a795541551bc3">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">seek and obtain marketing authorization; and</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z3d826e129cba4490a1d5506f54287273">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">manufacture, market and sell our medicines.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Once we have secured a collaborative arrangement to further develop and commercialize one of our drug development programs, such as our collaborations with AstraZeneca, Bayer, Biogen, GSK, Janssen, Novartis, Pfizer and Roche, these collaborations may not continue or result in commercialized medicines, or may not progress as quickly as we first anticipated.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For example, a collaborator such as AstraZeneca, Bayer, Biogen, GSK, Janssen, Novartis, Pfizer or Roche, could determine that it is in its financial interest to:</div>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z899a25d72b4b4627882357800685d400">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">pursue alternative technologies or develop alternative products that may be competitive with the medicine that is part of the collaboration with us;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="ze6ea47b88a094b82a99d3325f7b93da7">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">pursue higher-priority programs or change the focus of its own development programs; or</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z7896556e9be249d98d64a390976839ab">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">choose to devote fewer resources to our medicines than it does for its own medicines.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If any of these occur, it could affect our partner&#8217;s commitment to the collaboration with us and could delay or otherwise negatively affect the commercialization of our medicines, including SPINRAZA, tominersen, AKCEA-APO(a)-L<sub>Rx</sub> and tofersen.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">If we do not progress in our programs as anticipated, the price of our securities could decrease.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For planning purposes, we estimate and may disclose the timing of a variety of clinical, regulatory and other milestones, such as when we anticipate a certain medicine will enter clinical trials, when we anticipate completing a clinical study, or when we anticipate filing an application for, or obtaining, marketing authorization, or when our partners plan to commercially launch a medicine. We base our estimates on present facts and a variety of assumptions. Many underlying assumptions are outside of our control. If we do not achieve milestones in accordance with our or our investors&#8217; or securities analysts&#8217; expectations, including milestones related to SPINRAZA, TEGSEDI, WAYLIVRA, tominersen, tofersen, AKCEA-APO(a)-L<sub>Rx</sub> and AKCEA<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">-</span>TTR-L<sub>Rx</sub>, the price of our securities could decrease.</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">If we cannot protect our patent rights or our other proprietary rights, others may compete more effectively against us.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our success depends to a significant degree upon whether we can continue to develop, secure and maintain intellectual property rights to proprietary products and services. However, we may not receive issued patents on any of our pending patent applications in the U.S. or in other countries and we may not be able to obtain, maintain or enforce our patents and other intellectual property rights which could impact our ability to compete effectively. In addition, the scope of any of our issued patents may not be sufficiently broad to provide us with a competitive advantage. Furthermore, other parties may successfully challenge, invalidate or circumvent our issued patents or patents licensed to us so that our patent rights do not create an effective competitive barrier or revenue source.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We cannot be certain that the U.S. Patent and Trademark Office, or U.S. PTO, and courts in the United States or the patent offices and courts in foreign countries will consider the claims in our patents and applications covering SPINRAZA, TEGSEDI, WAYLIVRA, or any of our medicines in development as patentable. Method-of-use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products off-label. Although off-label prescriptions may infringe or contribute to the infringement of method-of-use patents, the practice is common and such infringement is difficult to prevent, including through legal action.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If we or any licensor partner loses or cannot obtain patent protection for SPINRAZA, TEGSEDI, WAYLIVRA, or any of our other medicines in development, it could have a material adverse impact on our business.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intellectual property litigation could be expensive and prevent us from pursuing our programs.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">From time to time we have to defend our intellectual property rights. If we are involved in an intellectual property dispute, we may need to litigate to defend our rights or assert them against others. Disputes can involve arbitration, litigation or proceedings declared by the U.S. PTO or the International Trade Commission or foreign patent authorities. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If a third party claims that our medicines or technology infringe its patents or other intellectual property rights, we may have to discontinue an important product or product line, alter our products and processes, pay license fees or cease certain activities. We may not be able to obtain a license to needed intellectual property on favorable terms, if at all. There are many patents issued or applied for in the biotechnology industry, and we may not be aware of patents or patent applications held by others that relate to our business. This is especially true since patent applications in the U.S. are filed confidentially for the first 18 months. Moreover, the validity and breadth of biotechnology patents involve complex legal and factual questions for which important legal issues remain.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>47</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">If we fail to obtain timely funding, we may need to curtail or abandon some of our programs.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Many of our medicines are undergoing clinical studies or are in the early stages of research and development. Most of our drug programs will require significant additional research, development, manufacturing, preclinical and clinical testing, marketing authorization, preclinical activities and commitment of significant additional resources prior to their successful commercialization. These activities will require significant cash. As of December 31, 2019, we had cash, cash equivalents and short-term investments equal to $2.5 billion. If we or our partners do not meet our goals to successfully commercialize our medicines, including SPINRAZA, TEGSEDI and WAYLIVRA, or to license certain medicines and proprietary technologies, we will need additional funding in the future. Our future capital requirements will depend on many factors, such as the following:</div>
<div><br /></div>
<div style="text-align: left;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z415b5cf22ad64dd883b106f03cd012d8">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: left;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">successful commercialization of SPINRAZA, TEGSEDI and WAYLIVRA;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: left;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zb3ed6a775f88423f896252475b443a82">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: left;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">additional marketing approvals for WAYLIVRA and TEGSEDI;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z72422f5a90b24cd9a706eafcf792e63a">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the profile and launch timing of our medicines, including TEGSEDI and WAYLIVRA;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z13331b00863e4868bf2a4d8bf0c196ef">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">changes in existing collaborative relationships and our ability to establish and maintain additional collaborative arrangements;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zd638bc14f0f74b3f92763638996abd1f">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">continued scientific progress in our research, drug discovery and development programs;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z6cda7a6a2e2b42f094f00520ec40f616">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the size of our programs and progress with preclinical and clinical studies;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zc6f54347c55140a49e0636a0552c009f">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">the time and costs involved in obtaining marketing authorizations; and</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zb05d74df0e8848afbfcfda88e1b882b3">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">competing technological and market developments, including the introduction by others of new therapies that address our markets.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If we need additional funds, we may need to raise them through public or private financing. Additional financing may not be available at all or on acceptable terms. If we raise additional funds by issuing equity securities, the shares of existing stockholders will be diluted and the price, as well as the price of our other securities, may decline. If adequate funds are not available or not available on acceptable terms, we may have to cut back on one or more of our research, drug discovery or development programs. Alternatively, we may obtain funds through arrangements with collaborative partners or others, which could require us to give up rights to certain of our technologies or medicines.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">If our planned management transition is not successful our business could suffer.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In January 2020, Dr. Crooke, our founder and Chief Executive Officer, transitioned from Chief Executive Officer to Executive Chairman of our Board of Directors. As Executive Chairman, Dr. Crooke will continue to be responsible for the activities of the board and will remain active in the company, providing strategic advice and continuing to participate in the scientific activities. Starting in January 2020, Dr. Monia, who had been our Chief Operating Officer for the last year and has been a member of our team since our founding over 30 years ago, serves as our Chief Executive Officer. If this transition is not successful, our business could suffer.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">The loss of key personnel, or the inability to attract and retain highly skilled personnel, could make it more difficult to run our business and reduce our likelihood of success.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We are dependent on the principal members of our management and scientific staff. We do not have employment agreements with any of our executive officers that would prevent them from leaving us. The loss of our management and key scientific employees might slow the achievement of important research and development goals. It is also critical to our success that we recruit and retain qualified scientific personnel to perform research and development work. We may not be able to attract and retain skilled and experienced scientific personnel on acceptable terms because of intense competition for experienced scientists among many pharmaceutical and health care companies, universities and non-profit research institutions. In addition, failure to succeed in clinical studies may make it more challenging to recruit and retain qualified scientific personnel. Similarly, Akcea is dependent on the principal members of its staff responsible for marketing, sales and distribution activities. If Akcea is not able to recruit and retain qualified </span>marketing and sales personnel, the sales of TEGSEDI and WAYLIVRA may be adversely affected.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">If the price of our securities continues to be highly volatile, this could make it harder for you to liquidate your investment and could increase your risk of suffering a loss.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The market price of our common stock, like that of the securities of many other biopharmaceutical companies, has been and is likely to continue to be highly volatile. These fluctuations in our common stock price may significantly affect the trading price of our securities. During the 12 months preceding December 31, 2019, the market price of our common stock ranged from $86.58 to $52.45 per share. Many factors can affect the market price of our securities, including, for example, fluctuations in our operating results, announcements of collaborations, clinical study results, technological innovations or new products being developed by us or our competitors, the commercial success of our approved medicines, governmental regulation, marketing authorizations, changes in payors&#8217; reimbursement policies, developments in patent or other proprietary rights and public concern regarding the safety of our medicines.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>48</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Additionally, broad market and industry factors may materially harm the market price of our common stock irrespective of our operating performance. The stock market in general, and NASDAQ and the market for biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of the particular companies affected. The trading prices and valuations of these stocks, and of ours, may not be predictable. A loss of investor confidence in the market for biotechnology or pharmaceutical stocks or the stocks of other companies which investors perceive to be similar to us, the opportunities in the biotechnology and pharmaceutical market or the stock market in general, could depress our stock price regardless of our business, prospects, financial conditions or results of operations.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">We are exposed to potential product liability claims, and insurance against these claims may not be available to us at a reasonable rate in the future or at all.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our business exposes us to potential product liability risks that are inherent in the testing, manufacturing, marketing and sale of therapeutic products, including potential product liability claims related to SPINRAZA, TEGSEDI and WAYLIVRA, and our medicines in development. We have clinical study insurance coverage and commercial product liability insurance coverage. However, this insurance coverage may not be adequate to cover claims against us, or be available to us at an acceptable cost, if at all. Regardless of their merit or eventual outcome, product liability claims may result in decreased demand for our medicines, injury to our reputation, withdrawal of clinical study volunteers and loss of revenues. Thus, whether or not we are insured, a product liability claim or product recall may result in losses that could be material.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">We are dependent on information technology systems, infrastructure and data, which exposes us to data security risks.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are dependent upon our own and third-party information technology systems, infrastructure and data, including mobile technologies, to operate our business. The multitude and complexity of our computer systems may make them vulnerable to service interruption or destruction, disruption of data integrity, malicious intrusion, or random attacks. Likewise, data privacy or security incidents or breaches by employees or others may pose a risk that sensitive data, including our intellectual property, trade secrets or personal information of our employees, patients, customers or other business partners may be exposed to unauthorized persons or to the public. Cyber-attacks are increasing in their frequency, sophistication and intensity. Cyber-attacks could include the deployment of harmful malware, denial-of-service, social engineering and other means to affect service reliability and threaten data confidentiality, integrity and availability. Our business partners face similar risks and any security breach of their systems could adversely affect our security posture. A security breach or privacy violation that leads to disclosure or modification of or prevents access to patient information, including personally identifiable information or protected health information, could harm our reputation, compel us to comply with federal and state breach notification laws and foreign law equivalents, subject us to financial penalties and mandatory and costly corrective action, require us to verify the correctness of database contents and otherwise subject us to litigation or other liability under laws and regulations that protect personal data, any of which could disrupt our business and result in increased costs or loss of revenue. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property. While we have invested, and continue to invest, in the protection of our data and information technology infrastructure, our efforts may not prevent service interruptions, or identify breaches in our systems, that could adversely affect our business and operations and result in the loss of critical or sensitive information, which could result in financial, legal, business or reputational harm to us. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Because we use biological materials, hazardous materials, chemicals and radioactive compounds, if we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our research, development and manufacturing activities involve the use of potentially harmful biological materials as well as materials, chemicals and various radioactive compounds that could be hazardous to human health and safety or the environment. We store most of these materials and various wastes resulting from their use at our facilities in Carlsbad, California pending ultimate use and disposal. We cannot completely eliminate the risk of contamination, which could cause:</div>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z72eda2cc8b724ddcaa269273645d9f1a">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">interruption of our research, development and manufacturing efforts;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z0187618c199d447e82edad7076b140fd">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">injury to our employees and others;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zd77ae09b65d54f859284286ca33756f2">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">environmental damage resulting in costly clean up; and</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zdf75506f506e47e1b215f78b524731a0">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">liabilities under federal, state and local laws and regulations governing health and human safety, as well as the use, storage, handling and disposal of these materials and resultant waste products.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In such an event, we may be held liable for any resulting damages, and any liability could exceed our resources. Although we carry insurance in amounts and types that we consider commercially reasonable, we do not have insurance coverage for losses relating to an interruption of our research, development or manufacturing efforts caused by contamination, and the coverage or coverage limits of our insurance policies may not be adequate. If our losses exceed our insurance coverage, our financial condition would be adversely affected.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>49</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">If a natural or man-made disaster strikes our research, development or manufacturing facilities or otherwise affects our business, it could delay our progress developing and commercializing our medicines.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We manufacture most of our research and clinical supplies in a manufacturing facility located in Carlsbad, California. We manufacture the finished drug product for TEGSEDI and WAYLIVRA at third-party contract manufacturers. Biogen manufactures the finished drug product for SPINRAZA. The facilities and the equipment we, our partners and our contract manufacturers use to research, develop and manufacture our medicines would be costly to replace and could require substantial lead time to repair or replace. Our facilities or those of our partners or contract manufacturers may be harmed by natural or man-made disasters, including, without limitation, earthquakes, floods, fires, acts of terrorism and pandemics; and if such facilities are affected by a disaster, our development and commercialization efforts would be delayed. Although we possess property damage and business interruption insurance coverage, this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. In addition, our development and commercialization activities could be harmed or delayed by a shutdown of the U.S. government, including the FDA.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Provisions in our certificate of incorporation, convertible notes documents, call spread hedge transaction documents and Delaware law may prevent stockholders from receiving a premium for their shares.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our certificate of incorporation provides for classified terms for the members of our board of directors. Our certificate also includes a provision that requires at least 66 2/3 percent of our voting stockholders to approve a merger or certain other business transactions with, or proposed by, any holder of 15 percent or more of our voting stock, except in cases where certain directors approve the transaction or certain minimum price criteria and other procedural requirements are met.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our certificate of incorporation also requires that any action required or permitted to be taken by our stockholders must be taken at a duly called annual or special meeting of stockholders and may not be taken by written consent. In addition, only our board of directors, chairman of the board or chief executive officer can call special meetings of our stockholders. We have in the past, and may in the future, implement a stockholders&#8217; rights plan, also called a poison pill, which could make it uneconomical for a third party to acquire our company on a hostile basis. In addition, our board of directors has the authority to fix the rights and preferences of, and issue shares of preferred stock, which may have the effect of delaying or preventing a change in control of our company without action by our stockholders.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The provisions of our convertible senior notes could make it more difficult or more expensive for a third party to acquire us. Upon the occurrence of certain transactions constituting a fundamental change, holders of the notes will have the right, at their option, to require us to repurchase all of their notes or a portion of their notes, which may discourage certain types of transactions in which our stockholders might otherwise receive a premium for their shares over the then current market prices.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In December 2019, we entered into privately negotiated exchange and/or subscription agreements with certain new investors and certain holders of our existing 1% Notes to exchange $375.6 million of our 1% Notes for $439.3 million of our 0.125% Notes, and to issue $109.5 million of our 0.125% Notes. Additionally, in connection with the pricing of our 0.125% Notes, we entered into call spread transactions in which we purchased note hedges and sold warrants. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Terminating or unwinding the call spread transactions could require us to make substantial payments to the counterparties under those agreements or may increase our stock price. The costs or any increase in stock price that may arise from terminating or unwinding such agreements could make an acquisition of our company significantly more expensive to the purchaser.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">These provisions, as well as Delaware law, including Section 203 of the Delaware General Corporation Law, and other of our agreements, may discourage certain types of transactions in which our stockholders might otherwise receive a premium for their shares over then current market prices, and may limit the ability of our stockholders to approve transactions that they think may be in their best interests.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Future sales of our common stock in the public market could adversely affect the trading price of our securities.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Future sales of substantial amounts of our common stock in the public market, or the perception that such sales could occur, could adversely affect trading prices of our securities. For example, we may issue approximately 11.2 million shares of our common stock upon conversion of our convertible senior notes and up to 6.6 million shares may be issued in connection with the warrant transactions we entered into in connection with the issuance of our 0.125 percent convertible senior notes, in each case subject to customary anti-dilution adjustments. The addition of any of these shares into the public market may have an adverse effect on the price of our securities.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In addition, pursuant to the call spread transactions we entered into in connection with the pricing of our 0.125% notes, the counterparties are likely to modify their hedge positions from time to time at or prior to the conversion or maturity of the notes by purchasing and selling shares of our common stock, other of our securities, or other instruments, including over-the-counter derivative instruments, that they may wish to use in connection with such hedging, which may have a negative effect on the conversion value of those notes and an adverse impact on the trading price of our common stock. The call spread transactions are expected generally to reduce potential dilution to holders of our common stock upon any conversion of our 0.125% notes or offset any cash payments we are required to make in excess of the principal amount of the converted 0.125% notes, as the case may be. However, the warrant transactions could separately have a dilutive effect to the extent that the market value per share of our common stock exceeds the applicable strike price of the warrants.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>50</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Our business is subject to changing regulations for corporate governance and public disclosure that has increased both our costs and the risk of noncompliance.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Each year we are required to evaluate our internal controls systems in order to allow management to report on and our Independent Registered Public Accounting Firm to attest to, our internal controls as required by Section 404 of the Sarbanes-Oxley Act. As a result, we continue to incur additional expenses and divert our management&#8217;s time to comply with these regulations. In addition, if we cannot continue to comply with the requirements of Section 404 in a timely manner, we might be subject to sanctions or investigation by regulatory authorities, such as the SEC, the Public Company Accounting Oversight Board, or PCAOB, or The Nasdaq Global Select Market. Any such action could adversely affect our financial results and the market price of our common stock.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The SEC and other regulators have continued to adopt new rules and regulations and make additional changes to existing regulations that require our compliance. On July 21, 2010, the Dodd-Frank Wall Street Reform and Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation-related provisions in the Dodd-Frank Act that require the SEC to adopt, or where the SEC has adopted, additional rules and regulations in these areas such as &#8220;say on pay&#8221; and proxy access. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business.</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Changes in tax laws, regulations and treaties could affect our future taxable income.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A change in tax laws, treaties or regulations, or their interpretation, of any country in which we operate could materially affect us.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">We could be subject to additional tax liabilities.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are subject to U.S. federal, state, local and sales taxes in the U.S. and foreign income taxes, withholding taxes and transaction taxes in foreign jurisdictions. Significant judgment is required in evaluating our tax positions and our worldwide provision for taxes. During the ordinary course of business, there are many activities and transactions for which the ultimate tax determination is uncertain. In addition, our tax obligations and effective tax rates could be adversely affected by changes in the relevant tax, accounting and other laws, regulations, principles and interpretations, including those relating to income tax nexus, by recognizing tax losses or lower than anticipated earnings in jurisdictions where we have lower statutory rates and higher than anticipated earnings in jurisdictions where we have higher statutory rates, by changes in foreign currency exchange rates, or by changes in the valuation of our deferred tax assets and liabilities. We may be audited in various jurisdictions, and such jurisdictions may assess additional taxes, sales taxes and value-added taxes against us. Although we believe our tax estimates are reasonable, the final determination of any tax audits or litigation could be materially different from our historical tax provisions and accruals, which could have a material adverse effect on our operating results or cash flows in the period for which a determination is made.</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Negative conditions in the global credit markets and financial services and other industries may adversely affect our business.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The global credit markets, the financial services industry, the U.S. capital markets, and the U.S. economy as a whole have in the past experienced periods of substantial turmoil and uncertainty characterized by unprecedented intervention by the U.S. federal government and the failure, bankruptcy, or sale of various financial and other institutions. It is possible that a crisis in the global credit markets, the U.S. capital markets, the financial services industry or the U.S. economy may adversely affect our business, vendors and prospects, as well as our liquidity and financial condition. More specifically, our insurance carriers and insurance policies covering all aspects of our business may become financially unstable or may not be sufficient to cover any or all of our losses and may not continue to be available to us on acceptable terms, or at all.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><a id="_Hlk2098045"><!--Anchor--></a>The impact on us of the vote by the United Kingdom to leave the European Union cannot be predicted.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On June 23, 2016, the United Kingdom, or the U.K., voted to leave the EU in an advisory referendum, which is generally referred to as Brexit. In January 2020, the U.K. and the EU entered into a withdrawal agreement pursuant to which the U.K. formally withdrew from the EU on January 31, 2020. Following such withdrawal, the U.K. entered into a transition period scheduled to end on December 31, 2020, or the Transition Period. During the Transition Period, the U.K. will remain subject to EU law and maintain access to the EU single market and to the global trade deals negotiated by the EU on behalf of its members. Negotiations are expected to continue in relation to the customs and trading relationship between the U.K. and the EU following the expiry of the Transition Period.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>51</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In addition, as a result of Brexit, the EMA, formerly situated in London, relocated to Amsterdam. Following the Transition Period, there is a risk that the relocation will interrupt current administrative routines and occupy resources, which may generally adversely affect our dealings with the EMA. Further, there is considerable uncertainty resulting from a lack of precedent and the complexity of the U.K. and EU&#8217;s intertwined legal regimes as to how Brexit (following the Transition Period) will impact the life sciences industry in Europe, including our company, including with respect to ongoing or future clinical trials. The impact will largely depend on the model and means by which the U.K.&#8217;s relationship with the EU is governed post-Brexit. For example, following the Transition Period, the U.K. will no longer be covered by the centralized procedures for obtaining EU-wide marketing authorization from the EMA and, unless a specific agreement is entered into, a separate process for authorization of drug products, including our product candidates, will be required in the UK, the potential process for which is currently unclear. Brexit may adversely affect and delay our ability to commercialize, market and sell our product candidates in the U.K.</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 1B. Unresolved Staff Comments</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Not applicable.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 2. Properties</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As of February 20, 2020, the following are the primary facilities in which we operate:</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z1302bbf857114ec194df86f112a0bd0c">
  <tr>
    <td style="width: 19.66%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Property Description</div></td>
    <td style="width: 2.18%; vertical-align: top;">&#160;</td>
    <td style="width: 12.55%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Location</div></td>
    <td style="width: 2.18%; vertical-align: top;">&#160;</td>
    <td style="width: 9.77%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Square</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Footage</div></td>
    <td style="width: 2.18%; vertical-align: top;">&#160;</td>
    <td style="width: 10.38%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">or Leased</div></td>
    <td style="width: 2.18%; vertical-align: top;">&#160;</td>
    <td style="width: 14.52%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Initial Lease</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Term End Date</div></td>
    <td style="width: 2.18%; vertical-align: top;">&#160;</td>
    <td style="width: 22.22%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Lease</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Extension Options</div></td>
  </tr>
  <tr>
    <td style="width: 19.66%; vertical-align: bottom; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis laboratory and office space facility</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 12.55%; vertical-align: bottom; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Carlsbad, CA</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 9.77%; vertical-align: bottom; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">176,000</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 10.38%; vertical-align: bottom; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Owned</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 14.52%; vertical-align: bottom; border-top: #000000 2px solid; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 22.22%; vertical-align: bottom; border-top: #000000 2px solid; background-color: #CCEEFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 19.66%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis manufacturing facility</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 12.55%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Carlsbad, CA</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 9.77%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">28,700</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 10.38%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Owned</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 14.52%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.18%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 22.22%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 19.66%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis manufacturing support facility</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 12.55%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Carlsbad, CA</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 9.77%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">25,800</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 10.38%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Leased</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 14.52%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2021</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 22.22%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Two, five-year options to extend</div></td>
  </tr>
  <tr>
    <td style="width: 19.66%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis office space facility</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 12.55%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Carlsbad, CA</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 9.77%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,800</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 10.38%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Leased</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 14.52%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2023</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 22.22%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">One, five-year option to extend</div></td>
  </tr>
  <tr>
    <td style="width: 19.66%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea office space facility</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 12.55%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Boston, MA</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 9.77%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">30,175</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 10.38%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Leased</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 14.52%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2028</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 22.22%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">One, five-year option to extend</div></td>
  </tr>
  <tr>
    <td style="width: 19.66%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea office and Ionis storage space facility</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 12.55%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Carlsbad, CA</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 9.77%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,700</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 10.38%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Leased</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 14.52%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2023</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 22.22%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">One, five-year option to extend</div></td>
  </tr>
  <tr>
    <td style="width: 19.66%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 12.55%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 9.77%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 4px double; background-color: #CCEEFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">285,175</div></td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 10.38%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 14.52%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 2.18%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 22.22%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 3. Legal Proceedings</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In November 2019, a purported stockholder of Akcea filed an action in the Delaware Court of Chancery, captioned <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">City of Cambridge Retirement System v. Crooke, et al.</span>, C.A. No. 2019-0905, or the Delaware Action. The plaintiff in the Delaware Action asserts claims against (i) current and former members of Akcea&#8217;s Board of Directors, and (ii) Ionis, or collectively, the Defendants. The plaintiff asserts derivative claims on behalf of Akcea, which is a nominal defendant in the Delaware Action, as well as putatively direct claims on behalf of a purported class of Akcea stockholders. The plaintiff in the Delaware Action asserts that the Defendants breached their fiduciary duties in connection with the licensing transaction that Akcea and Ionis entered into regarding TEGSEDI and AKCEA-TTR-<span style="background-color: #FFFFFF; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">L</span><sub><span style="background-color: #FFFFFF;">Rx</span></sub>. The plaintiff also asserts an unjust enrichment claim against Ionis. We and Akcea have moved to dismiss the plaintiff&#8217;s complaint. We believe that the claims asserted in the Delaware Action are without merit. The results of litigation are uncertain and entail risk of adverse outcomes, and litigation is usually expensive and can be distracting to management.</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 4. Mine Safety Disclosures</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Not applicable.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>52</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">PART II</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Item 5. Market for Registrant</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Market Information and Dividends</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our common stock is traded publicly through The Nasdaq Global Select Market under the symbol &#8220;IONS.&#8221; As of February 20, 2020, there were approximately 516 stockholders of record of our common stock. Because many of our shares are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have never paid dividends and do not anticipate paying any dividends in the foreseeable future.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Purchases of Equity Securities</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In September 2019, our board of directors approved an initial share repurchase program of up to $125 million of our common stock. Our stock repurchase program has no expiration date. We repurchased the following amounts of our common stock during the fourth quarter of 2019 (in thousands, except per share amounts). All of our repurchases were made under a 10b5-1 plan:</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="z71036d0eee7a486eb7b08579bc9ddd18" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Number of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares Purchased</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Price Paid</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share (1)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Approximate Dollar Value</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">of Shares that May Yet Be</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Purchased under our Stock</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Repurchase Program</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">October 2019</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">125,000</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">November 2019</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">75</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">63.57</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">120,230</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 2019</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">460</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">64.40</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">90,593</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">535</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: left;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z2899d3fc776e4d5f99a0bd1ddb6ff287">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: left;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Average Price Paid Per Share excludes cash paid for commissions.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the first quarter of 2020, we used the remaining $90.6 million approved under the plan to repurchase additional shares.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>53</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Performance Graph (1)</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Set forth below is a table and chart comparing the total return on an indexed basis of $100 invested on December 31, 2014 in our common stock, the Nasdaq Composite Index (total return) and the Nasdaq Biotechnology Index. The total return assumes reinvestment of dividends.</div>
<div><br /></div>
<div style="text-align: center;"><img src="image12.jpg" width="524" height="421" alt="graphic" /></div>
<div><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">*&#160; $100 invested on December 31, 2014 in stock or index, including reinvestment of dividends. Fiscal year ending December 31.</div>
<div><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Among Ionis Pharmaceuticals, Inc., the Nasdaq Composite Index,</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">and the Nasdaq Biotechnology Index</div>
<div style="text-align: center;"><br /></div>
<table cellpadding="0" cellspacing="0" id="z588a065a93134e5d840d60ea61c2c9e0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Dec-14</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Dec-15</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Dec-16</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Dec-17</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Dec-18</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Dec-19</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis Pharmaceuticals, Inc.</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">100.00</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">100.31</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">77.47</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">81.47</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">87.56</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">97.85</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Nasdaq Composite Index</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">100.00</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">106.96</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">116.45</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">150.96</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">146.67</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">200.49</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Nasdaq Biotechnology Index</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">100.00</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">111.77</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">87.91</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">106.92</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">97.45</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">121.92</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zaab5feb6dad6469783c5816bb6ab2eb5">
  <tr>
    <td style="width: 36pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This section is not &#8220;soliciting material,&#8221; is not deemed &#8220;filed&#8221; with the SEC, is not subject to the liabilities of Section 18 of the Exchange Act and is not to be incorporated by reference in any of our filings under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>54</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 6. Selected Financial Data</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This selected financial data should be read in conjunction with our audited consolidated financial statements and accompanying notes and Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included elsewhere in this Annual Report on Form 10-K. Our historical consolidated financial information may not be indicative of our future performance. Set forth below are our selected consolidated financial data (in millions, except per share amounts):</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="z58c301e3423f49869911182a693eda38" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="18" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Years Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2016</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2015 (1)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Consolidated Statement of Operations Data:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,122.6</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">599.7</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">514.2</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">372.8</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">283.7</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Research, development and patent expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">465.7</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">414.6</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">374.6</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">344.3</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">322.3</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Selling, general and administrative expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">286.6</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">244.6</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">108.5</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">48.6</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">37.2</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">294.1</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">273.7</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.3</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(60.4</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(88.3</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income (loss) per share attributable to Ionis Pharmaceuticals, Inc. common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.12</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.09</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.15</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.50</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.74</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Diluted net income (loss) per share attributable to Ionis Pharmaceuticals, Inc. common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.08</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.07</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.15</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.50</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.74</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares used in computing basic net income (loss) per share</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">140.0</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">132.3</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">124.0</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">120.9</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">119.7</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares used in computing diluted net income (loss) per share</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">142.9</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">134.1</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">126.1</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">120.9</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">119.7</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="z7f135b57bbd1405a96be2fbe57f8104a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="18" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">As of December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2016 (1)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2015 (1)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Consolidated Balance Sheet Data:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cash, cash equivalents and short-term investments</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,499.5</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,084.1</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,022.7</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">665.2</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">779.2</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Working capital</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,447.6</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,927.6</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">925.1</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">664.1</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">688.1</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total assets</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,233.1</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,667.8</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,322.8</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">912.5</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">947.9</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Long-term debt and other obligations, less current portion</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,275.6</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,200.3</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">713.9</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">679.1</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">598.2</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Accumulated deficit</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(707.5</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(967.3</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,241.0</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,181.4</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,094.9</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stockholders&#8217; equity</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,684.5</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,187.2</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">365.3</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">99.6</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">200.8</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="background-color: #FFFFFF;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z4bb6e10ac6c647bfaebf31d3277c9c38">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</div></td>
    <td style="width: auto; vertical-align: top;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We adopted the new revenue recognition accounting standard in 2018 (Topic 606) and adjusted our 2017 results for the adoption. This change is not reflected in our consolidated statement of operations data for 2015 or in our consolidated balance sheet data for 2016 and 2015.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>55</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Item 7. Management</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Discussion and Analysis of Financial Condition and Results of Operations</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This financial review presents our operating results for each of the three years in the period ended December 31, 2019, and our financial condition at December 31, 2019. Except for the historical information contained herein, the following discussion contains forward-looking statements that are subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements. We discuss such risks, uncertainties and other factors throughout this report and specifically under Item 1A of Part I of this report, &#8220;Risk Factors.&#8221; In addition, the following review should be read in conjunction with the information presented in our consolidated financial statements and the related notes to our consolidated financial statements as indexed on page F-1.</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Overview</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are a leader in discovering and developing RNA-targeted therapeutics. We have created an efficient and broadly applicable drug discovery platform leveraging our expertise in antisense oligonucleotide therapeutics that we believe has fundamentally changed medicine and transformed the lives of people with devastating diseases. Our large, diverse and advancing pipeline has over 40 potential first-in-class and/or best-in-class medicines designed to <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">address a broad spectrum of therapeutic areas, such as neurodegenerative diseases, cardiometabolic diseases, cancer and others. The medicines in our pipeline address patients with diseases ranging from rare to common.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In 2019, we achieved important goals across our business, including advancing four new medicines into pivotal studies. We also reported positive clinical proof-of-concept results from five medicines, four of which were LICA medicines. We advanced and grew our pipeline of unpartnered medicines, which we call our Ionis-owned pipeline. In addition, we made significant progress across the rest of our pipeline by advancing numerous medicines into earlier stages of development, six of which were Ionis-owned medicines. In 2019, we also broadened the scope of our antisense technology by investing in complementary technologies such as<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> new LICA strategies to address more organ systems and cell types and technologies to potentially identify novel targets to ensure continued pipeline growth. These accomplishments enabled us to achieve revenues in excess of $1.1 billion, net income of nearly $300 million and a year-end cash balance of $2.5 billion.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">This year we plan to use our financial strength to invest fully in those areas of the business that we believe have the greatest potential to create value for patients and shareholders. By the end of this year, we plan to have six pivotal studies underway and report clinical proof-of-concept data for six or more medicines. We also plan to expand the reach of our antisense technology by optimizing additional routes of administration, such as oral and pulmonary for which we expect clinical data this year. Additionally, this year, we are continuing to prioritize the growth and advancement of our Ionis-owned pipeline.</span>&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Building on our achievements in 2019, we believe that continued advances in our pipeline and technology will enable us to achieve our goal of 10 or more new drug applications through the end of 2025.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our goal is to determine the optimal development and commercialization strategy for each medicine in our pipeline, while ensuring we remain focused on innovation and delivering substantial value for patients in need and shareholders. With this goal firmly in mind, this year we plan to <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">further develop our commercial strategy and capabilities to ensure we maximize the value of each of our medicines.</span></div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>56</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By building on our strong foundation and continuing to focus on our strategic priorities, we believe we are achieving our vision of becoming one of the most successful and innovative companies in the healthcare industry. We intend to continue to pursue our vision by executing on our strategic priorities: advancing our Ionis-owned pipeline, further developing our commercial strategies and capabilities, and expanding the reach of our antisense technology.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have three commercial medicines approved in major markets around the world, SPINRAZA, TEGSEDI and WAYLIVRA. We have four drugs in pivotal studies, tominersen (formerly IONIS-HTT<sub>Rx</sub>) for Huntington&#8217;s disease, tofersen for SOD1-ALS, AKCEA-APO(a)-L<sub>Rx</sub> for cardiovascular disease, or CVD, and AKCEA-TTR-L<sub>Rx</sub> for all forms of TTR amyloidosis, or ATTR. Our goal is to start up to five additional pivotal studies before the end of 2021.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SPINRAZA is a global foundation-of-care for the treatment of patients of all ages with spinal muscular atrophy, or SMA, a progressive, debilitating and often fatal genetic disease. Biogen, our partner responsible for commercializing SPINRAZA worldwide, reported that as of December 31, 2019, more than 10,000 patients were on SPINRAZA therapy in markets around the world. Additionally, as of December 31, 2019, SPINRAZA is approved in over 50 countries with formal reimbursement in 40 countries. Through December 31, 2019, we have earned more than $1 billion in revenues from our SPINRAZA collaboration, including more than $640 million in royalties on sales of SPINRAZA.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">TEGSEDI, a once weekly, self-administered subcutaneous medicine, was approved in 2018 in the U.S., EU and Canada for the treatment of patients with polyneuropathy caused by hereditary TTR amyloidosis, or hATTR, a debilitating, progressive, and fatal disease. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Akcea, our majority-owned affiliate focused on developing and commercializing medicines to treat patients with serious and rare diseases, </span>launched TEGSEDI in the U.S. and EU in late 2018. TEGSEDI is commercially available in more than 10 countries. Akcea plans to expand the global launch of TEGSEDI by launching in additional countries. In Latin America, PTC Therapeutics, or PTC, through its exclusive license from Akcea, is launching TEGSEDI in Brazil and is working towards access in additional Latin American countries.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">WAYLIVRA, a once weekly, self-administered, </span>subcutaneous medicine,<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> received conditional marketing authorization in May 2019 from the European Commission, or EC, as an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome, or FCS, and at high risk for pancreatitis. Akcea launched WAYLIVRA in the EU in the third quarter of 2019 and is leveraging its existing commercial infrastructure in Europe to market WAYLIVRA. PTC through its exclusive license agreement with Akcea is working to expand access to WAYLIVRA across Latin America, beginning in Brazil with potential approval in 2020.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Financial Highlights</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">The following is a summary of our financial results (in millions):</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="zb5f0dc33101447f5a64dcda24bf1fde6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,122.6</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">599.7</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">514.2</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total operating expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">756.7</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">661.0</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">483.1</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) from operations</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">365.9</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(61.4</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">31.0</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income (loss)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">303.3</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">215.0</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(10.8</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -8.85pt; margin-left: 8.85pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income attributable to Ionis Pharmaceuticals, Inc. common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">294.1</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">273.7</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.3</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cash, cash equivalents and short-term investments</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,499.5</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,084.1</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$1,022.7</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our revenue in 2019 nearly doubled, compared to 2018, primarily due to more than doubling our R&amp;D revenues including nearly $490 million in license fees we earned during 2019. Additionally, commercial revenue increased more than 35 percent compared to 2018 primarily from increases in SPINRAZA royalties and TEGSEDI product sales, along with the addition of WAYLIVRA product sales in 2019.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>57</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our operating expenses for 2019 increased compared to 2018, principally due to our investments in the global launches of <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">TEGSEDI and WAYLIVRA and </span>advancing and expanding our pipeline.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We believe we have the financial resources to execute on our strategic priorities for 2020 and beyond. During 2019 we received more than $900 million in payments from our partners.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Business Segments</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We have two operating segments, our Ionis Core segment and Akcea Therapeutics, our majority-owned affiliate. Akcea is </span>a biopharmaceutical company focused on developing and commercializing medicines to treat patients with serious and rare diseases<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. We provide segment financial information and results for our Ionis Core segment and our Akcea Therapeutics segment based on the segregation of revenues and expenses that our chief decision maker reviews to assess operating performance and to make operating decisions. We allocate a portion of Ionis&#8217; development, R&amp;D support and general and administrative expenses to Akcea for work Ionis performs on behalf of Akcea and we bill Akcea for these expenses.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Critical Accounting Estimates</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>We prepare our consolidated financial statements in conformity with accounting principles generally accepted in the United States. As such, we make certain estimates, judgments and assumptions that we believe are reasonable, based upon the information available to us. These judgments involve making estimates about the effect of matters that are inherently uncertain and may significantly impact our quarterly or annual results of operations and financial condition. Each quarter, our senior management reviews the development, selection and disclosure of such estimates with the audit committee of our board of directors. In the following paragraphs, we describe the specific risks associated with these critical accounting estimates and we caution that future events rarely develop exactly as one may expect, and that best estimates may require adjustment. Our significant accounting policies are outlined in Note 1, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Organization and Significant Accounting Policies</span>, in the Notes to the Consolidated Financial Statements.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following are our significant accounting estimates, which we believe are the most critical to aid in fully understanding and evaluating our reported financial results:</div>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zbec957126032456d94380fba99118378">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Assessing the propriety of revenue recognition and associated deferred revenue;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zbfa4d2850b274c9497d67ad1bb583810">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Determining the appropriate cost estimates for unbilled preclinical studies and clinical development activities;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z11fa33c76b8344d8a4d78a41a1aa124e">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income taxes; and</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zdc4e52b838e140a686b6a3b93a26dc05">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Estimating the fair value of convertible debt without the conversion feature.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following are descriptions of our critical accounting estimates.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Revenue Recognition</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We earn revenue from several sources. The judgements and estimates we make vary between each source of our revenue. The following is a summary of the critical accounting estimates we make with respect to each of our significant revenue sources.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Commercial Revenue: SPINRAZA royalties and Licensing and other royalty revenue</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We estimate our commercial revenue from SPINRAZA royalties based on reporting we receive from Biogen each quarter. We use this reporting to calculate our royalty revenue based on our tiered contractual royalty rate for the given period based on annual cumulative net sales. We record our royalty revenue in the same period in which Biogen sells SPINRAZA.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Commercial Revenue: Product sales, net</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We added product sales from TEGSEDI to our commercial revenue in the fourth quarter of 2018 and we added product sales from WAYLIVRA to our commercial revenue in the third quarter of 2019. We recognize product sales in the period when our customer obtains control of our products. We record product sales at our net sales price, which includes estimated reserves for discounts, returns, chargebacks, rebates, co-pay assistance and other allowances that we offer under contracts between us and our customers, wholesalers, health care providers and other indirect customers. Actual amounts may vary from our estimates. Our historical reserve estimates have not been materially different from our actual amounts. The total reserves we estimated during 2018 and 2019 are not material to our financial results.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>58</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Research and development revenue under collaborative agreements</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We recognize R&amp;D revenue from numerous collaboration agreements. Our collaboration agreements typically contain multiple elements, or performance obligations, including technology licenses or options to obtain technology licenses, R&amp;D services, and manufacturing services. Upon entering into a collaboration agreement, we are required to make the following judgements:</div>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z263e60d16d2d460d901db1451bed9e6a">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Identifying the performance obligations contained in the agreement</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: justify; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our assessment of what constitutes a separate performance obligation requires us to apply judgement.</span> Specifically, we have to identify which goods and services we are required to provide under the contract are distinct.</div>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z8232d052f0cd41a38937a64e1bb4d1d9">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Determining the transaction price, including any variable consideration</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: justify; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">To determine the transaction price, we review the amount of consideration we are eligible to earn under the agreement. We do not typically include any payments we may receive in the future in our initial transaction price since the payments are typically not probable because they are contingent upon certain future events.</div>
<div><br /></div>
<div style="text-align: justify; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are required to reassess the total transaction price at each reporting period to determine if we should include additional payments in the transaction price that have become probable. For example, in the fourth quarter of 2019, we achieved two milestone payments for $7.5 million each under our 2018 strategic neurology collaboration with Biogen. Prior to achieving these milestone payments, we did not consider the payments probable. Upon achieving these milestone payments, we reassessed the total transaction price of our 2018 strategic neurology collaboration. We added these two milestone payments to our total transaction price under our collaboration.</div>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z07ab7f801c7b4cba90a64d282c135ea4">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Allocating the transaction price to each of our performance obligations</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: justify; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">When we allocate the transaction price to more than one performance obligation, we make estimates of the relative stand-alone selling price of each performance obligation because we do not typically sell our goods or services on a stand-alone basis. The estimate of the relative stand-alone selling price requires us in some cases to make significant judgements. For example, when we deliver a license at the start of an agreement, we use valuation methodologies, such as the relief from royalty method, to value the license. Under this method we are required to make estimates including: future sales, royalties on future product sales, contractual milestones, expenses, income taxes and discount rates. Additionally, when we estimate the selling price for R&amp;D services, we make estimates, including: the number of internal hours we will spend on the services, the cost of work we and third parties will perform and the cost of API we will use.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The R&amp;D revenue we recognize each period is comprised of several types of revenue, including amortization from upfront payments, milestone payments, license fees and other services. Each of these types of revenue require us to make various judgements and estimates.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Amortization from Upfront Payments</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We recognize revenue from the amortization of upfront payments as we perform R&amp;D services. We use an input method to estimate the amount of revenue to recognize each period. This method requires us to make estimates of the total costs we expect to incur to complete our R&amp;D services performance obligation or the total length of time it will take us to complete our R&amp;D services performance obligation. If we change our estimates, we may have to adjust our revenue. For example, in the fourth quarter of 2019, we completed our R&amp;D services performance obligation under our collaboration with Biogen for new antisense medicines for the treatment of SMA sooner than we anticipated. We were recognizing revenue as we performed services based on our effort to satisfy our performance obligation relative to the total effort expected to satisfy our performance obligation. As a result of completing our performance obligation earlier than our previous estimate, we recognized $8.3 million of additional revenue in the fourth quarter of 2019.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Milestone Payments</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">When recognizing revenue related to milestone payments we typically make the following judgements and estimates:</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Whether the milestone payment is probable (discussed in detail above under &#8220;Determining the<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> transaction price, including any variable consideration&#8221;</span>); and</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Whether the milestone payment relates to services we are performing or if our partner is performing the services:</div>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z3c43bbc99a4145b0a6b5f4adfef4f0f1">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If we are performing services, we recognize revenue over our estimated period of performance in a similar manner to the amortization of upfront payments (discussed above under &#8220;Amortization of Upfront payments&#8221;).</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z3eccb965d50e423790f8507073320561">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Conversely, we recognize in full those milestone payments that we earn based on our partners&#8217; activities when our partner achieves the milestone event and we do not have a performance obligation.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>59</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">License Fees</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We generally recognize as revenue the total amount we determine to be the relative stand-alone selling price of a license when we deliver the license to our partner. We discuss the estimates we make related to the relative stand-alone selling price of a license in detail above under &#8220;Allocating the transaction price to each of our performance obligations&#8221;.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Estimated Liability for Clinical Development Costs</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have numerous medicines in preclinical studies and/or clinical trials at clinical sites throughout the world. On at least a quarterly basis, we estimate our liability for preclinical and clinical development costs we have incurred and services that we have received but for which we have not yet been billed and maintain an accrual to cover these costs. These costs primarily relate to third-party clinical management costs, laboratory and analysis costs, toxicology studies and investigator grants. We estimate our liability using assumptions about study and patient activities and the related expected expenses for those activities determined based on the contracted fees with our service providers. The assumptions we use represent our best estimates of the activity and expenses at the time of our accrual and involve inherent uncertainties and the application of our judgment. Upon settlement, these costs may differ materially from the amounts accrued in our consolidated financial statements. Our historical accrual estimates have not been materially different from our actual amounts.</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Income Taxes</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For U.S. federal income tax purposes, we are required to file separate U.S. federal income tax returns for Ionis and Akcea. We began deconsolidating Akcea for U.S. federal income tax purposes upon Akcea&#8217;s IPO. As a result, we are required to assess our Ionis stand-alone and Akcea&#8217;s valuation allowances separately even though we consolidate Akcea&#8217;s financial results in our consolidated financial statements. We continue to file combined state tax returns in most jurisdictions. As a result, we continue to assess the state portion of our valuation allowance for those jurisdictions on a consolidated basis.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We have historically recorded a valuation allowance against all our net deferred tax assets due to cumulative financial statement losses. However, in the fourth quarter of 2018, we reversed the valuation allowance previously recorded against our Ionis stand-alone U.S. federal net deferred tax assets, resulting in a one-time non-cash tax benefit of $</span>332.1<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million. We reversed this valuation allowance in 2018 based on Ionis&#8217; stand-alone pre-tax income in that period and our expectation to generate sufficient stand-alone pre-tax income in future years to fully utilize our U.S. federal net operating loss carryforwards and our R&amp; D and Orphan Drug tax credit carryforwards over the next three years. </span>We utilized a significant portion of these carryforwards in 2019 to reduce our estimated federal tax liability for the year.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We continue to maintain a full valuation allowance of $</span>197.0<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million against all of Akcea&#8217;s net deferred tax assets and the net state deferred tax assets of Ionis at December 31, </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> due to uncertainties related to our ability to realize the tax benefits associated with these assets. We maintain a full valuation allowance against Akcea's stand-alone net deferred tax assets primarily due to Akcea&#8217;s history of financial statement losses and the uncertainty of generating sufficient pre-tax income in future periods to realize the deferred tax benefits. We maintain a full valuation allowance against the net state deferred tax assets of Ionis as we file combined state tax returns with Akcea in most jurisdictions, which includes the impact of Akcea&#8217;s historical losses.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We generated combined state taxable income and recognized a combined state tax liability in 2019. We utilized Ionis&#8217; state deferred tax assets, primarily California net operating loss carry forwards, to reduce our combined state tax liability by $59.1 million, which resulted in a corresponding reduction to our combined state valuation allowance. We have historically generated combined state net operating losses due primarily to Akcea&#8217;s net operating losses. However, Akcea generated net income in 2019. This was due to an increase in their research and development and license revenue, primarily related to non-recurring transactions in the first and fourth quarter from Novartis&#8217; exercise of its option to license AKCEA-APO(a)-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and Pfizer&#8217;s license of AKCEA-ANGPTL3-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, respectively. </span>Although Akcea generated net income in 2019, given their history of losses, there can be no assurance that they will achieve profitability in future periods. We expect Akcea to incur additional operating losses for the foreseeable future and therefore we continue to maintain a full valuation allowance against our remaining net deferred state tax assets.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We evaluate our deferred tax assets quarterly to determine whether adjustments to the valuation allowance are appropriate due to changes in facts or circumstances, such as changes in expected future pre-tax earnings, tax law, interactions with taxing authorities and developments in case law. In making this evaluation, we rely on our recent history of pre-tax earnings. Our material assumptions are our forecasts of future pre-tax earnings and the nature and timing of future deductions and income represented by the deferred tax assets and liabilities, all of which involve the exercise of significant judgment. Although we believe our estimates are reasonable, we are required to use significant judgment in determining the appropriate amount of valuation allowance recorded against our deferred tax assets.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>60</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Estimating the Fair Value of Convertible Debt Without the Conversion Feature</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In December 2019, we issued new convertible senior notes, which we refer to as our 0.125% Notes. To account for the issuance of the </span>0.125% Notes<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, which may be settled in cash upon conversion (including partial cash settlement), we are required to separate the liability and equity components of the 0.125% Notes in a manner that reflects our nonconvertible debt borrowing rate at issuance. In reviewing recent debt issuances, we were not able to identify any comparable companies that recently issued non-convertible debt instruments. Therefore, we estimated the fair value of the liability component of our 0.125% Notes by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities. We used the average of our estimated underlying credit rate and observable credit spreads for comparable companies with similar debt outstanding plus the London Inter-Bank Offered Rate, or LIBOR, swap rate for the same maturity time period as our 0.125% Notes (five years). These estimates and assumptions were judgmental in nature and had a significant impact on the determination of the liability component and the associated non-cash interest expense. For additional information, see Note 3, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Long-Term Obligations and Commitments</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, in the Notes to the Consolidated Financial Statements.</span></div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Results of Operations</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Below we have included our results of operations for 2019 compared to 2018. Refer to our 2018 Form 10-K for our results of operations for 2018 compared to 2017.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Years Ended December 31, 2019 and December 31, 2018</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Revenue</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total revenue for 2019 was $1.1 billion, compared to $599.7 million in 2018 and was comprised of the following (amounts in thousands):</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="z8e6d7866eca049178ea3ac8f57a19c78" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Revenue:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Commercial revenue:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -27pt; margin-left: 45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SPINRAZA royalties</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">292,992</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">237,930</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -27pt; margin-left: 45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Product sales, net</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">42,253</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,237</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -27pt; margin-left: 45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Licensing and other royalty revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">17,205</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14,755</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total commercial revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">352,450</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">254,922</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amortization from upfront payments</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">146,246</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">124,695</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Milestone payments</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">114,906</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">82,771</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">License fees</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">489,708</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">102,053</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other services</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">19,289</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">35,233</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total R&amp;D revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">770,149</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">344,752</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 81pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,122,599</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">599,674</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We significantly increased both commercial and R&amp;D revenue in 2019, compared to 2018. Commercial revenue increased over 35 percent primarily due to increased SPINRAZA royalties and TEGSEDI product sales. We launched WAYLIVRA in the third quarter of 2019.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our R&amp;D revenue more than doubled in 2019 compared to 2018. The most significant components were:</div>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z335b13967b4b494a8deccf212b4bab4c">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$246 million we earned from Pfizer when Pfizer licensed AKCEA-ANGPTL3-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">;</span></div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="ze2ef3ede02c848da81aa66427780bfbb">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$150 million we earned from Novartis when Novartis licensed AKCEA-APO(a)-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">;</span></div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z8a5aae134c134aa5b92124499823fc96">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$136 million we earned from Biogen for advancing several programs under our collaborations, including adding four targets under our 2018 strategic neurology collaboration;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z0104c0adace24af190fb66fcd901c804">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$45 million we earned from Biogen when Biogen licensed IONIS-MAPT</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">;</span></div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z5d81fe2b02f242cea65723b9879f7560">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$35 million we earned from Roche when Roche enrolled the first patient in the Phase 3 study of tominersen in patients with Huntington's disease;</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zaf770cfc19b647689d824a23a1100acc">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$25 million we earned from GSK when GSK licensed our HBV program; and</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zb1041ec4504a4e1a8fb39ccdbc1c5988">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$20 million we earned from Alnylam when Alnylam licensed our technology to Regeneron.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>61</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Operating Expenses</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Operating expenses for </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> were $</span>756.7<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million, and increased compared to $</span>661.0<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for </span>2018<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. R&amp;D expenses for 2019 increased compared to 2018 primarily from </span>investments we made in our technology and advancing and expanding our pipeline. Additionally, our SG&amp;A expenses increased in 2019 compared to 2018<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> principally due to our investment in the global launches of TEGSEDI and WAYLIVRA and various SG&amp;A expenses we incurred related to the growth in our business.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our operating expenses by segment were as follows (in thousands):</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="zbf21c47b0ffe4c90b9d23ace0816b5b7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis Core</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">374,014</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">293,175</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea Therapeutics</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">450,688</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">251,408</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Elimination of intercompany activity</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(214,560</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(14,849</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Subtotal</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">610,142</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">529,734</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-cash compensation expense related to equity awards</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">146,574</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">131,312</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total operating expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">756,716</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">661,046</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s operating expenses included $200 million of intercompany drug development expenses consisting of the $75 million sublicense fee for Novartis&#8217; license of AKCEA-APO(a)-L<sub>Rx</sub> and the $125 million sublicense fee for Pfizer&#8217;s license of AKCEA-ANGPTL3-L<sub>Rx</sub>. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We eliminated these expenses in our consolidated results.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In order to analyze and compare our results of operations to other similar companies, we believe it is important to exclude non-cash compensation expense related to equity awards from our operating expenses. We believe non-cash compensation expense related to equity awards is not indicative of our operating results or cash flows from our operations. Further, we internally evaluate the performance of our operations excluding it.</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Cost of Products Sold</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our cost of products sold consisted of manufacturing costs, including certain fixed costs, transportation and freight, indirect overhead costs associated with the manufacturing and distribution of TEGSEDI and WAYLIVRA (beginning in the third quarter of 2019) and certain associated period costs. We do not expect our fixed costs will increase in direct correlation to TEGSEDI and WAYLIVRA product sales. Prior to the regulatory approval of TEGSEDI and WAYLIVRA, we expensed as R&amp;D expense a significant portion of the cost of producing TEGSEDI and WAYLIVRA that Akcea is using in the commercial launches. We expect cost of products sold to increase as we deplete these inventories.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our cost of products sold by segment were as follows (in thousands):</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="z6538e1f395b642a7a07f022f5d7b566b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis Core</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea Therapeutics</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12,820</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11,573</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Elimination of intercompany activity</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(8,873</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(9,913</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Subtotal</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,947</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,660</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-cash compensation expense related to equity awards</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">437</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">160</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total cost of products sold</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,384</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,820</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We began recognizing cost of products sold for TEGSEDI in the third quarter of 2018 when TEGSEDI was approved and for WAYLIVRA in the second quarter of 2019 when WAYLIVRA was approved. Our cost of products sold increased in 2019 compared to 2018 primarily due to the increase in commercial product sales. We previously expensed $0.7 million and $0.1 million of costs to produce the TEGSEDI and WAYLIVRA we sold in 2019 and 2018, respectively. We recognized these costs in prior periods because we incurred these costs before we obtained regulatory approval. In its cost of products sold Akcea includes the amortization for milestone payments it made to us related to the U.S. and European approvals of TEGSEDI. Akcea is recognizing this amortization over TEGSEDI&#8217;s remaining estimated patent life. We eliminate this amortization in our consolidated results. All amounts exclude non-cash compensation expense related to equity awards.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>62</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Research, Development and Patent Expenses</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our research, development and patent expenses consist of expenses for antisense drug discovery, antisense drug development, manufacturing and developmental chemistry and R&amp;D support expenses.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table sets forth information on research, development and patent expenses (in thousands):</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="za511c6ebc13c44deba2aac076f213c62" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Research, development and patent expenses, excluding non-cash compensation expense related to equity awards</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">370,340</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">338,047</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-cash compensation expense related to equity awards</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">95,348</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">76,557</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total research, development and patent expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">465,688</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">414,604</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our research, development and patent expenses by segment were as follows (in thousands):</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="zf4c2308e7bc345749487ef68089f15e6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis Core</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">295,071</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">222,528</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea Therapeutics</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">280,956</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">120,905</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Elimination of intercompany activity</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(205,687</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5,386</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Subtotal</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">370,340</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">338,047</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-cash compensation expense related to equity awards</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">95,348</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">76,557</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total research, development and patent expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">465,688</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">414,604</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;">Antisense Drug Discovery</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We use our proprietary antisense technology to generate information about the function of genes and to determine the value of genes as drug discovery targets. We use this information to direct our own antisense drug discovery research, and that of our partners. Antisense drug discovery is also the function that is responsible for advancing our antisense core technology. This function is also responsible for making investments in complementary technologies to expand the reach of antisense technology.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As we continue to advance our antisense technology, we are investing in our drug discovery programs to expand our and our partners&#8217; drug pipelines.</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our antisense drug discovery expenses are part of our Ionis Core business segment and were as follows (in thousands):</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="z66a0e121e0024ceeb5316b3183ea6dfe" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Antisense drug discovery expenses, excluding non-cash compensation expense related to equity awards</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">83,506</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">61,387</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-cash compensation expense related to equity awards</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20,913</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">17,530</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total antisense drug discovery expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104,419</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">78,917</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Antisense drug discovery expenses were higher in 2019, compared to 2018, due to expenses we incurred related to advancing our research programs and investments we made in complementary technologies to expand the reach of antisense technology. All amounts exclude non-cash compensation expense related to equity awards.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;">Antisense Drug Development</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table sets forth drug development expenses, including expenses for our medicines in Phase 3 development and/or commercialization for which we have incurred significant costs (in thousands):</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="zfaa4eab3fd684def9540455595ab619c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">AKCEA-TTR-L<sub>Rx</sub></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14,061</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,204</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">WAYLIVRA</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7,435</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">19,397</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">TEGSEDI</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">16,830</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">19,204</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other antisense development projects</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">94,188</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">98,546</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Development overhead expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">74,006</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">63,940</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total antisense drug development, excluding non-cash compensation expense related to equity awards</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">206,520</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">204,291</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-cash compensation expense related to equity awards</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">45,898</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">34,845</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total antisense drug development expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">252,418</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">239,136</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>63</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our development expenses were essentially flat in 2019 compared to 2018. In 2019, we had increased expenses related to AKCEA-TTR-L<sub>Rx </sub>and overhead expenses to support the investments we are making in advancing our pipeline, including our Ionis-owned pipeline. These increases were mostly offset by decreases in expenses from WAYLIVRA, TEGSEDI and AKCEA-APO(a)-L<sub>Rx</sub>. Expenses related to AKCEA-APO(a)-L<sub>Rx</sub> decreased because we completed our Phase 2 study and Novartis is responsible for all further development activities. All amounts exclude non-cash compensation expense related to equity awards.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our antisense drug development expenses by segment were as follows (in thousands):</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="za392e7a18e9e4e5aa57460dd363939b4" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis Core</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">145,062</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">100,090</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea Therapeutics</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">261,458</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104,201</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Elimination of intercompany activity</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(200,000</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Subtotal</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">206,520</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">204,291</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-cash compensation expense related to equity awards</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">45,898</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">34,845</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total antisense drug development expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">252,418</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">239,136</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s development expenses included $200 million of intercompany drug development expenses consisting of the $75 million sublicense fee for Novartis&#8217; license of AKCEA-APO(a)-L<sub>Rx</sub> and the $125 million sublicense fee for Pfizer&#8217;s license of AKCEA-ANGPTL3-L<sub>Rx</sub>. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We eliminated these expenses in our consolidated results. Excluding these fees, Akcea's development expenses decreased primarily because Akcea transitioned all further development of AKCEA-APO(a)-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> to Novartis.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We may conduct multiple clinical trials on a drug candidate, including multiple clinical trials for the various indications we may be studying. Furthermore, as we obtain results from trials we may elect to discontinue clinical trials for certain drug candidates in certain indications in order to focus our resources on more promising drug candidates or indications. Our Phase 1 and Phase 2 programs are clinical research programs that fuel our Phase 3 pipeline. When our medicines are in Phase 1 or Phase 2 clinical trials, they are in a dynamic state in which we may adjust the development strategy for each medicine. Although we may characterize a medicine as &#8220;in Phase 1&#8221; or &#8220;in Phase 2,&#8221; it does not mean that we are conducting a single, well-defined study with dedicated resources. Instead, we allocate our internal resources on a shared basis across numerous medicines based on each medicine&#8217;s particular needs at that time. This means we are constantly shifting resources among medicines. Therefore, what we spend on each medicine during a particular period is usually a function of what is required to keep the medicines progressing in clinical development, not what medicines we think are most important. For example, the number of people required to start a new study is large, the number of people required to keep a study going is modest and the number of people required to finish a study is large. However, such fluctuations are not indicative of a shift in our emphasis from one medicine to another and cannot be used to accurately predict future costs for each medicine. And, because we always have numerous medicines in preclinical and early stage clinical research, the fluctuations in expenses from medicine to medicine, in large part, offset one another. If we partner a medicine, it may affect the size of a trial, its timing, its total cost and the timing of the related costs.</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;">Manufacturing and Developmental Chemistry</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expenditures in our manufacturing and developmental chemistry function consist primarily of personnel costs, specialized chemicals for oligonucleotide manufacturing, laboratory supplies and outside services. Our manufacturing and developmental chemistry function is responsible for providing drug supplies to antisense drug development, Akcea and our collaboration partners. Our manufacturing procedures include testing to satisfy good laboratory and good manufacturing practice requirements.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our manufacturing and developmental chemistry expenses were as follows (in thousands):</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="z338538d5b5a8427a9c0f22300c4be0d2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Manufacturing and developmental chemistry expenses, excluding non-cash compensation expense related to equity awards</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">42,507</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">39,806</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-cash compensation expense related to equity awards</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,569</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,036</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total manufacturing and developmental chemistry expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">52,076</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">48,842</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our manufacturing and developmental chemistry expenses by segment were as follows (in thousands):</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="z20fce823ecfd43e1a924779213d46f00" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis Core</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">36,847</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">32,277</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea Therapeutics</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11,174</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12,758</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Elimination of intercompany activity</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5,515</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5,229</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Subtotal</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">42,507</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">39,806</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-cash compensation expense related to equity awards</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,569</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,036</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total manufacturing and developmental chemistry expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">52,076</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">48,842</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>64</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="text-decoration: underline;">R&amp;D Support</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In our research, development and patent expenses, we include support costs such as rent, repair and maintenance for buildings and equipment, utilities, depreciation of laboratory equipment and facilities, amortization of our intellectual property, informatics costs, procurement costs and waste disposal costs. We call these costs R&amp;D support expenses.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table sets forth information on R&amp;D support expenses (in thousands):</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="zd437851fb0d04f1fa406eb6f360b051a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Personnel costs</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15,165</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12,968</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Occupancy</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,351</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,567</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Patent expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,209</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,744</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Depreciation and amortization</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">519</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">439</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Insurance</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,861</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,622</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,703</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,223</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total R&amp;D support expenses, excluding non-cash compensation expense related to equity awards</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">37,808</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">32,563</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-cash compensation expense related to equity awards</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,968</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15,146</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total R&amp;D support expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">56,776</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">47,709</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D support expenses for 2019 were slightly higher compared to 2018 primarily due to costs from the growth of Akcea&#8217;s business as they continued to expand. All amounts exclude non-cash compensation expense related to equity awards.</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our R&amp;D support expenses by segment were as follows (in thousands):</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="z660cde6516b84a18a3241ff8d1ba1691" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis Core</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">29,656</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">28,774</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea Therapeutics</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,324</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,946</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Elimination of intercompany activity</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(172</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(157</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Subtotal</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">37,808</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">32,563</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-cash compensation expense related to equity awards</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,968</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15,146</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total R&amp;D support expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">56,776</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">47,709</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Selling, General and Administrative Expenses</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Selling, general and administrative, or SG&amp;A, expenses include personnel and outside costs associated with the pre-commercialization and commercialization activities for our medicines and costs to support our company, our employees and our stockholders including, legal, human resources, investor relations, and finance. Additionally, we include in selling, general and administrative expenses such costs as rent, repair and maintenance of buildings and equipment, depreciation and utilities costs that we need to support the corporate functions listed above. We also include fees we owe under our in-licensing agreements related to SPINRAZA.</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table sets forth information on SG&amp;A expenses (in thousands):</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="z5501d7738c25421ea412be779a31c302" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Selling, general and administrative expenses, excluding non-cash compensation expense related to equity awards</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">235,856</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">190,027</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-cash compensation expense related to equity awards</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">50,788</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">54,595</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total selling, general and administrative expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">286,644</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">244,622</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SG&amp;A expenses <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">were higher for </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> compared to </span>2018 principally due to the cost of commercializing <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">TEGSEDI and WAYLIVRA and various other expenses related to the growth in our business. All amounts exclude non-cash compensation expense related to equity awards.</span></div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>65</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our selling, general and administrative expenses by segment were as follows (in thousands):</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="z795108006d30408b8d932731aa1137fa" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis Core</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">78,943</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">70,647</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea Therapeutics</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">156,912</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">118,930</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Elimination of intercompany activity</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">450</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Subtotal</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">235,855</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">190,027</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-cash compensation expense related to equity awards</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">50,789</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">54,595</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total selling general and administrative expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">286,644</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">244,622</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Akcea Therapeutics, Inc.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table sets forth information on operating expenses (in thousands) for our Akcea Therapeutics business segment:</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="z2d9808686e1848a887168c885d68aaa4" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cost of products sold</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12,819</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11,573</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Development and patent expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">80,956</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">120,905</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Sublicense fees to Ionis</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">200,000</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Selling, general and administrative expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">156,912</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">118,930</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Profit (loss) share for TEGSEDI commercialization activities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(37,332</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total operating expenses, excluding non-cash compensation expense related to equity awards</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">413,355</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">251,408</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-cash compensation expense related to equity awards</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">37,111</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">44,275</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total Akcea Therapeutics operating expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">450,466</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">295,683</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s development and patent expenses increased in 2019 compared to 2018 as a result of sublicense fees totaling $200 million Akcea paid to Ionis in Akcea common stock for Ionis' portion of the license fee Akcea received from Novartis in the first quarter of 2019 and from Pfizer in the fourth quarter of 2019. We eliminated the sublicense fees Akcea paid Ionis in our consolidated results. Excluding these fees, Akcea's development expenses decreased primarily because Akcea transitioned all further development of AKCEA-APO(a)-L<sub>Rx</sub> to Novartis.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s SG&amp;A expenses increased in 2019, compared to 2018, primarily due to Akcea&#8217;s commercialization of TEGSEDI and WAYLIVRA. For each period presented, we allocated a portion of Ionis&#8217; SG&amp;A expenses to Akcea for work we performed on Akcea&#8217;s behalf and we bill Akcea for these expenses. We included these allocated expenses in Akcea&#8217;s SG&amp;A expenses in the table above. All amounts exclude non-cash compensation expense related to equity awards.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the first quarter of 2019, we began sharing profits and losses for TEGSEDI with Akcea under our TTR licensing agreement. As Akcea is the principal for all commercial activities related to the TTR License Agreement, Akcea records all activities related to TEGSEDI on a gross basis in its statement of operations based on the nature of the activity, including revenues, cost of products sold and sales and marketing expenses. Ionis&#8217; share of the net profit/loss from commercializing TEGSEDI is separately presented on Akcea&#8217;s statement of operations on the line titled &#8220;Profit (loss) share for TEGSEDI commercialization activities&#8221;. Since TEGSEDI is currently generating a loss, this represents the amount Ionis owes Akcea under the licensing agreement for Ionis&#8217; share of the net loss of TEGSEDI commercialization activities during the period. In 2019, Ionis&#8217; share of losses for TEGSEDI commercialization activities was $37 million. With the launch of WAYLIVRA in the third quarter of 2019, Akcea began paying Ionis royalties on WAYLIVRA product sales. We eliminate these amounts in our consolidated results.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">All amounts exclude non-cash compensation expense related to equity awards.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Investment Income</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investment income for 2019 was $52.2 million compared to $30.2 million for 2018. Investment income increased primarily due to a significantly higher average cash balance and higher average returns.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>66</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Interest Expense</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table sets forth information on interest expense (in thousands):</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="z3c7b73aa97d74242b4fe7773bfe25db1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Convertible senior notes:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-cash amortization of the debt discounts and debt issuance costs</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">39,280</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">35,173</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: 9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Interest expense payable in cash</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,727</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,855</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Interest on mortgage for primary R&amp;D and manufacturing facilities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,397</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,409</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">364</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">352</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: 9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total interest expense</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">48,768</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">44,789</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Early Retirement of Debt</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As a result of the debt exchange we completed in December 2019, we recorded a $21.9 million non-cash loss on early retirement of debt, reflecting the early retirement of a portion of our 1% Notes. The non-cash loss on the early retirement of our debt is the difference between the amount paid to exchange our 1% Notes that we attributed to the liability component and the net carrying balance of the liability component at the time that we completed the debt exchange.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Income Tax Expense (Benefit)</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We had income tax expense of $43.5 million for 2019, compared to an income tax benefit of $291.1 million for 2018<span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">. </span>Our income tax expense in 2019 relates primarily to our estimated U.S. federal and state tax liabilities for the year. We recognized a significant tax benefit in 2018 due largely to a one-time, non-cash tax benefit from the reversal of the valuation allowance previously recorded against Ionis&#8217; stand-alone U.S. federal net deferred tax assets of $332.1 million. We reversed the valuation allowance in 2018 as we determined it was more likely than not that we would utilize our deferred federal income tax assets, primarily net operating loss carryforwards and research and development and orphan drug credit carryforwards, in future years. We utilized a significant portion of these carryforwards in 2019 to reduce our estimated federal tax liability for the year. We continue to maintain a full valuation allowance against all of Akcea&#8217;s net deferred tax assets and the net state deferred tax assets of Ionis at December 31, 2019 due to uncertainties related to our ability to realize the tax benefits associated with these assets. See discussion of our valuation allowance under the section titled, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Income Taxes</span>, above in our discussion of our critical accounting estimates.</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Net Income</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We had net income of $303.3 million for 2019, compared to $215.0 million for 2018. The increase in our net income in 2019, compared to 2018 was primarily due to our increasing revenues. Somewhat offsetting this increase was income tax expense we recognized in 2019 compared to a one-time non-cash tax benefit recognized in 2018 related to our deferred income taxes.</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Net Income (Loss) Attributable to Noncontrolling Interest in Akcea Therapeutics, Inc.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At December 31, 2019, we owned approximately 76 percent of Akcea. The shares of Akcea third parties own represent an interest in Akcea's equity that we do not control. However, because we continue to maintain overall control of Akcea through our voting interest, we reflect the assets, liabilities and results of operations of Akcea in our consolidated financial statements. We reflect the noncontrolling interest attributable to other owners of Akcea's common stock in a separate line called &#8220;Net income attributable to noncontrolling interest in Akcea&#8221; on our statement of operations. Our noncontrolling interest in Akcea on our statement of operations for 2019 was net income of $9.1 million, compared to a net loss of $58.8 million for 2018.<span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>Akcea generated net income in 2019 primarily because it earned significant license fee revenue from Novartis and Pfizer.</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Net Income Attributable to Ionis Pharmaceuticals, Inc. Common Stockholders<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and Net Income per Share</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We had net income attributable to our common stockholders of $294.1 million for 2019, compared $273.7 million in 2018. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Basic and diluted net income per share for </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> was $</span>2.12<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and $</span>2.08<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, respectively compared to $</span>2.09<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and $</span>2.07<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for </span>2018<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. The increase in our net income attributable to</span> our common stockholders in 2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, compared to </span>2018<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, was primarily due to our increasing revenues. Somewhat offsetting this increase was income tax expense we recognized in 2019 compared to a one-time non-cash tax benefit recognized in 2018 related to our deferred income taxes.</span></div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>67</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Liquidity and Capital Resources</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We have financed our operations primarily from research and development collaborative agreements. </span>We also finance our operations from commercial revenue from SPINRAZA royalties and product sales. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">From our inception through December 31, </span>2019, we had earned approximately $4.3 billion<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in revenue. We also financed our operations through the sale of our equity securities and the issuance of long-term debt. From the time we were founded through December 31, </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, we had raised net proceeds of approximately $</span>1.8&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">billion from the sale of our equity securities, not including the $182.4 million Akcea received in net proceeds from its IPO in July 2017. Additionally, we borrowed approximately $</span>1.5<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> billion under long-term debt arrangements to finance a portion of our operations over the same time period.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At December 31, 2019, we had cash, cash equivalents and short-term investments of $2.5 billion and stockholders&#8217; equity of $1.7 billion. In comparison, we had cash, cash equivalents and short-term investments of $2.1 billion and stockholders&#8217; equity of $1.2 billion at December 31, 2018. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our cash, cash equivalents and short-term investments increased in</span>&#160;2019&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">primarily from payments we received from Biogen, Pfizer, Novartis and Roche. Our stockholders' equity increased in 2019 primarily from our net income and our stock-based compensation expense.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In September 2019, our board of directors approved an initial share repurchase program of up to $125 million of our common stock. Our stock repurchase program has no expiration date. Through December 31, 2019, we had repurchased 535,000 shares for $34.4 million in open market transactions. See </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for details of the purchases we made in 2019.</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">During the first quarter of 2020, we repurchased the remaining amount authorized under our stock repurchase program. </span>We may consider additional share repurchases in the future as part of our overall capital allocation strategy.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At December 31, 2019, we had consolidated working capital of $2.4 billion compared to $1.9 billion at December 31, 2018. As of December 31, 2019, our debt and other obligations totaled $936.2 million compared to $764.0 million at December 31, 2018. In December 2019, we exchanged $375.6 million of our 1% notes for $439.3 million of new 0.125% notes and issued an additional $109.5 million of new 0.125% notes. Additionally, during 2019 our debt and other obligations increased from the operating lease liability we added to our balance sheet when we adopted the new accounting guidance for leases on January 1, 2019.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes our contractual obligations as of December 31, 2019. The table provides a breakdown of when obligations become due. We provide a more detailed description of the major components of our debt in the paragraphs following the table:</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="z272932285b124dc8b4397270c6dd7c45" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="18" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Payments Due by Period (in millions)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Contractual Obligations</div><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(selected balances described below)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Less than</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1 year</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1-3 years</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3-5 years</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">After</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5 years</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1% Notes (principal and interest payable)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">316.1</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.1</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">313.0</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.125% Notes (principal and interest payable)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">552.3</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.7</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.4</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">550.2</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Building mortgage payments</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">78.2</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.4</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.1</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.9</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">63.8</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other obligations (principal and interest payable)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.0</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.1</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.1</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.1</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.7</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating leases</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23.5</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.3</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.8</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.9</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.5</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">971.1</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9.6</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">325.4</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">562.1</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">74.0</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our contractual obligations consist primarily of our convertible debt. In addition, we also have facility mortgages, facility leases, equipment financing arrangements and other obligations. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Due to the uncertainty with respect to the timing of future cash flows associated with our unrecognized tax benefits, we are unable to make reasonably reliable estimates of the period of cash settlement with the respective taxing authorities. Therefore, we have excluded our gross unrecognized tax benefits from our contractual obligations table above.</span></div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">0.125 Percent Convertible Senior Notes and Call Spread</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In December 2019, we entered into privately negotiated exchange and/or subscription agreements with certain new investors and certain holders of our existing 1% Notes to exchange $375.6 million of our 1% Notes for $439.3 million of our 0.125% Notes, and to issue $109.5 million of our 0.125% Notes. We completed this exchange to reduce our cash interest payments, increase our conversion price and extend our maturity for a large portion of our debt. Additionally, i<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">n conjunction with the December 2019 exchange, we entered into a call spread transaction, which was comprised of purchasing note hedges and selling warrants, to minimize the impact of potential economic dilution upon conversion of our </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.125% Notes by increasing the conversion price on our 0.125% even further</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</span></div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>68</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The call spread cost us $52.6 million, of which $108.7 million was for the note hedge purchase, offset by $56.1 million we received for selling the warrants. We increased our effective conversion price to $123.38 with the same number of underlying shares as our 0.125% Notes.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Similar to our </span>0.125% Notes<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, our note hedges are subject to adjustment. Additionally, our note hedges are exercisable upon conversion of the </span>0.125% Notes<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. The note hedges will expire upon maturity of </span>0.125% Notes<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, or December 2024. The note hedges and warrants are separate transactions and are not part of the terms of our </span>0.125% Notes<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. The holders of the </span>0.125% Notes<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> do not have any rights with respect to the note hedges and warrants.</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We recorded the aggregate amount paid for the note hedges and the aggregate amount received for the warrants in additional paid-in capital in our consolidated balance sheet. We excluded shares under the note hedges from our calculation of diluted earnings per share as they were antidilutive. We will include the shares issuable under the warrants in our calculation of diluted earnings per share when the average market price per share of our common stock for the reporting period exceeds the strike price of the warrants.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At December 31, 2019, we had the following 0.125% Notes outstanding (amounts in millions except price per share data):</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="z8829c38ba964418d86d319f864b2891e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">0.125% Notes</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Outstanding principal balance</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">548.8</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; background-color: #FFFFFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Maturity date</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: top; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 2024</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Interest rate</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: top; background-color: #CCEEFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.125 percent</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #FFFFFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Conversion price per share</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">83.28</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total shares of common stock subject to conversion</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.6</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Interest is payable semi-annually for the 0.125% Notes. The 0.125% Notes are convertible under certain conditions, at the option of the note holders. We can settle conversions of the 0.125% Notes, at our election, in cash, shares of our common stock or a combination of both. We may not redeem the 0.125% Notes prior to maturity, and no sinking fund is provided for them. Holders of the 0.125% Notes may require us to purchase some or all of their notes upon the occurrence of certain fundamental changes, as set forth in the indenture governing the 0.125% Notes, at a purchase price equal to 100 percent of the principal amount of the notes to be purchased, plus accrued and unpaid interest.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">1 Percent Convertible Senior Notes</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In November 2014, we completed a $500 million offering of convertible senior notes, which mature in 2021 and bear interest at 1 percent. </span>We used a substantial portion of the net proceeds from the issuance of the 1% Notes to repurchase $140 million in principal of our 2&#190; percent convertible senior notes, or 2&#190;% Notes. In December 2016, we issued an additional $185.5 million of 1% Notes in exchange for the redemption of $61.1 million of our 2&#190;% Notes. In December 2019, we exchanged a portion of our 1% Notes for new 0.125% Notes. As a result, the principal balance of the 1% Notes following the exchange was $309.9 million.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At December 31, 2019, we had the following 1% Notes outstanding (amounts in millions except price per share data):</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="z592aa756d834450f958ba03b23f89ac6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: top; padding-bottom: 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1% Notes</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Outstanding principal balance</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">309.9</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; background-color: #FFFFFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Maturity date</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: top; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">November 2021</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Interest rate</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: top; background-color: #CCEEFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1 percent</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #FFFFFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Conversion price per share</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">66.81</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total shares of common stock subject to conversion</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.6</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Interest is payable semi-annually for the 1% Notes. The 1% Notes are convertible under certain conditions, at the option of the note holders. We settle conversions of the 1% Notes, at our election, in cash, shares of our common stock or a combination of both. We may not redeem the 1% Notes prior to maturity, and no sinking fund is provided for them. Holders of the 1% Notes may require us to purchase some or all of their notes upon the occurrence of certain fundamental changes, as set forth in the indenture governing the 1% Notes, at a purchase price equal to 100 percent of the principal amount of the notes to be purchased, plus accrued and unpaid interest.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Financing Arrangement</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In June 2015, we entered into a five-year revolving line of credit agreement with Morgan Stanley Private Bank, National Association, or Morgan Stanley, which we amended in February 2016. Under the amended credit agreement, Morgan Stanley provided a maximum of $30 million of revolving credit for general working capital purposes. During the third quarter of 2019, we paid off our total outstanding borrowings of $12.5 million under the agreement and subsequently terminated the agreement.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>69</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Research and Development and Manufacturing Facilities</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In July 2017, we purchased the building that houses our primary R&amp;D facility for $79.4 million and our manufacturing facility for $14.0 million. We financed the purchase of these two facilities with mortgage debt of $60.4 million in total. Our primary R&amp;D facility mortgage has an interest rate of 3.88 percent. Our manufacturing facility mortgage has an interest rate of 4.20 percent. During the first five years of both mortgages, we are only required to make interest payments. Both mortgages mature in August 2027.</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Other Obligations</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In addition to contractual obligations, we had outstanding purchase orders as of December 31, 2019 for the purchase of services, capital equipment and materials as part of our normal course of business.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We may enter into additional collaborations with partners which could provide for additional revenue to us and we may incur additional cash expenditures related to our obligations under any of the new agreements we may enter into. We currently intend to use our cash, cash equivalents and short-term investments to finance our activities. However, we may also pursue other financing alternatives, like issuing additional shares of our common stock, issuing debt instruments, refinancing our existing debt, or securing lines of credit. Whether we use our existing capital resources or choose to obtain financing will depend on various factors, including the future success of our business, the prevailing interest rate environment and the condition of financial markets generally.</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Off-Balance Sheet Arrangements</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have not entered into, nor do we currently have, any off-balance sheet arrangements (as defined under SEC rules).</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are exposed to changes in interest rates primarily from our long-term debt arrangements and, secondarily, investments in certain short-term investments. We primarily invest our excess cash in highly liquid short-term investments of the U.S. Treasury and reputable financial institutions, corporations, and U.S. government agencies with strong credit ratings. We typically hold our investments for the duration of the term of the respective instrument. We do not utilize derivative financial instruments, derivative commodity instruments or other market risk sensitive instruments, positions or transactions to manage exposure to interest rate changes. Accordingly, we believe that, while the securities we hold are subject to changes in the financial standing of the issuer of such securities, we are not subject to any material risks arising from changes in interest rates, foreign currency exchange rates, commodity prices, equity prices or other market changes that affect market risk sensitive instruments.</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 8. Financial Statements and Supplementary Data</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We filed our consolidated financial statements and supplementary data required by this item as exhibits hereto, and listed them under Item 15(a)(1) and (2), and incorporate them herein by reference.</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</div>
<div><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">None.</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 9A. Controls and Procedures</div>
<div><br /></div>
<div style="text-align: left; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Disclosure Controls and Procedures</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or Exchange Act) that are designed to ensure that information we are required to disclose in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. We designed and evaluate our disclosure controls and procedures recognizing that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance and not absolute assurance of achieving the desired control objectives.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As of the end of the period covered by this report on Form 10-K, we carried out an evaluation of our disclosure controls and procedures under the supervision of, and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer. Based on our evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2019.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>70</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Management</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Report on Internal Control over Financial Reporting</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Exchange Act Rules 13a-15(f). Our internal control over financial reporting is a process designed under the supervision of our Chief Executive Officer and Chief Financial Officer to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our financial statements for external purposes in accordance with U.S. generally accepted accounting principles.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As of December 31, 2019, we assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting under the 2013 &#8220;Internal Control&#8212;Integrated Framework,&#8221; issued by the Committee of Sponsoring Organizations, or COSO, of the Treadway Commission, under the supervision of, and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer. Based on that assessment, our management concluded that we maintained effective internal control over financial reporting as of December 31, 2019.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ernst &amp; Young LLP, an independent registered public accounting firm, audited the effectiveness of our internal control over financial reporting as of December 31, 2019, as stated in their attestation report, which is included elsewhere herein.</div>
<div><br /></div>
<div style="text-align: left; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Changes in Internal Control over Financial Reporting</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The above assessment did not identify any change in our internal control over financial reporting that occurred during our latest fiscal quarter and that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>71</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">To the Stockholders and Board of Directors of Ionis Pharmaceuticals, Inc.</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Opinion on Internal Control over Financial Reporting</div>
<div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have audited Ionis Pharmaceuticals, Inc.&#8217;s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control &#8212; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Ionis Pharmaceuticals, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on the COSO criteria.</div>
<div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2019 and 2018, and the related consolidated statements of operations, comprehensive loss, stockholders&#8217; equity, and cash flows for each of the three years in the period ended December 31, 2019, and the related notes and our report dated March 2, 2020 expressed an unqualified opinion thereon.</div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Basis for Opinion</div>
<div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the US federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div>
<div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</div>
<div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Definition and Limitations of Internal Control Over Financial Reporting</div>
<div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</div>
<div style="text-align: justify; margin-bottom: 8pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Ernst &amp; Young LLP</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">San Diego, California</div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">March 2, 2020</div>
<div><br /></div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>72</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 9B. Other Information</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Not applicable.</div>
<div><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">PART III</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 10. Directors, Executive Officers and Corporate Governance</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We incorporate by reference the information required by this Item with respect to directors and the Audit Committee from the information under the caption &#8220;ELECTION OF DIRECTORS,&#8221; including in particular the information under &#8220;Nominating, Governance and Review Committee&#8221; and &#8220;Audit Committee,&#8221; contained in our definitive Proxy Statement, which we will file with the Securities and Exchange Commission within 120 days after the end of the fiscal year ended </span>December 31, 2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> (the &#8220;Proxy Statement&#8221;).</span></div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We incorporate by reference the required information concerning our Code of Ethics from the information under the caption &#8220;Code of Ethics and Business Conduct&#8221; contained in the Proxy Statement. Our Code of Ethics and Business Conduct is posted on our website at www.ionispharma.com<sup>(1)</sup>. We intend to disclose future amendments to, or waivers from, our Code of Ethics and Business Conduct on our website.</div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">________________</div>
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zdadf5c7c379c4ceba3603247fed840a1">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</div></td>
    <td style="width: auto; vertical-align: top;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Any information that is included on or linked to our website is not part of this Form 10-K.</div></td>
  </tr>
</table>
</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 11. Executive Compensation</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We incorporate by reference the information required by this item to the information under the caption &#8220;EXECUTIVE COMPENSATION,&#8221; &#8220;Compensation Committee Interlocks and Insider Participation&#8221; and &#8220;COMPENSATION COMMITTEE REPORT&#8221; contained in the Proxy Statement.</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We incorporate by reference the information required by this item to the information under the captions &#8220;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT&#8221; contained in the Proxy Statement.</div>
<div><br /></div>
<div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Securities Authorized for Issuance under Equity Compensation Plans</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table sets forth information regarding outstanding options and shares reserved for future issuance under our equity compensation plans as of December 31, 2019.</div>
<div style="text-align: left;"><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="ze2f105c8d57d4d56963983305ae681f6">
  <tr>
    <td style="width: 41.45%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Plan Category</div></td>
    <td style="width: 1%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 19.85%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Number of Shares to</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">be Issued Upon Exercise</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">of Outstanding Options</div></td>
    <td style="width: 0.75%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" style="width: 17.48%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted Average</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exercise Price of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Outstanding Options</div></td>
    <td style="width: 0.87%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 16.36%; vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Number of Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Remaining Available</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">for Future Issuance</div></td>
    <td style="width: 2.24%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 41.45%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Equity compensation plans approved by stockholders (a)</div></td>
    <td style="width: 1%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 19.85%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11,001,241</div></td>
    <td style="width: 0.75%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 2.87%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td style="width: 14.61%; vertical-align: bottom; border-top: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">51.48</div></td>
    <td style="width: 0.87%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 16.36%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 2px solid; background-color: #CCEEFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,335,635</div></td>
    <td style="width: 2.24%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)</div></td>
  </tr>
  <tr>
    <td style="width: 41.45%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td style="width: 1%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 19.85%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11,001,241</div></td>
    <td style="width: 0.75%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.87%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td style="width: 14.61%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">51.48</div></td>
    <td style="width: 0.87%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 16.36%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,335,635</div></td>
    <td style="width: 2.24%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
  </tr>
</table>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">________________</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zc6455579df84479f87de45ab1ed21c2e">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(a)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Consists of four Ionis plans: 1989 Stock Option Plan, Amended and Restated 2002 Non-Employee Directors&#8217; Stock Option Plan, 2011 Equity Incentive Plan and Employee Stock Purchase Plan, or ESPP.</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: left; text-indent: -36pt; margin-left: 36pt;"><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="za6a8fc9e058d486ebf718b247cfb4c68">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(b)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Of these shares, 725,930 remained available for purchase under the ESPP as of December 31, 2019.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For additional details about our equity compensation plans, including a description of each plan, see Note 4, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Stockholders&#8217; Equity</span>, in the Notes to the Consolidated Financial Statements.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 13. Certain Relationships and Related Transactions, and Director Independence</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We incorporate by reference the information required by this item to the information under the captions &#8220;Independence of the Board of Directors&#8221; and &#8220;Certain Relationships and Related Transactions&#8221; contained in the Proxy Statement.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 14. Principal Accounting Fees and Services</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We incorporate by reference the information required by this item to the information under the caption &#8220;Ratification of Selection of Independent Auditors&#8221; contained in the Proxy Statement.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>73</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">PART IV</div>
<div style="text-align: center;"><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Item 15. Exhibits, Financial Statement Schedules</div>
<div style="text-align: left;"><br /></div>
<div style="text-align: left; text-indent: -36pt; margin-left: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(a)(1) Index to Financial Statements</div>
<div style="text-align: justify; text-indent: -36pt; margin-left: 72pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We submitted the consolidated financial statements required by this item in a separate section beginning on page F-1 of this Report.</div>
<div style="text-align: left; text-indent: 36pt;"><br /></div>
<div style="text-align: left; text-indent: -36pt; margin-left: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(a)(2) Index to Financial Statement Schedules</div>
<div style="text-align: left; text-indent: -36pt; margin-left: 72pt;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We omitted these schedules because they are not required, or are not applicable, or the required information is shown in the consolidated financial statements or notes thereto.</div>
<div style="text-align: left; text-indent: 36pt;"><br /></div>
<div style="text-align: left; text-indent: -36pt; margin-left: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(a)(3) Index to Exhibits</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>74</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">INDEX TO EXHIBITS</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z29c4159b540c40c9aa9ee34f3726e7dd">
  <tr>
    <td style="width: 7.41%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit Number</div></td>
    <td style="width: 2.17%; vertical-align: bottom;">&#160;</td>
    <td style="width: 90.43%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description of Document</div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.1</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401518000047/exhibit3_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amended and Restated Certificate of Incorporation filed June 19, 1991</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2017 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.2</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036114017588/formdef14a.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Certificate of Amendment to Restated Certificate of Incorporation</a><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">filed June 17, 2014. - Filed as an exhibit to the Registrant&#8217;s Notice of Annual Meeting and Proxy Statement, for the 2014 Annual Meeting of Stockholders, filed with the SEC on April 25, 2014, and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.3</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036115045083/ex3_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Certificate of Amendment to Restated Certificate of Incorporation</a><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;">, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">filed December 18, 2015. - Filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed December 18, 2015 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.4</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036115045083/ex3_2.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amended and Restated Bylaws</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed December 18, 2015 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.1</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000091205700053343/a2032851zex-4_2.txt" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Certificate of Designation of the Series C Junior Participating Preferred Stock</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to Registrant&#8217;s Report on Form 8-K filed December 13, 2000 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.2</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401518000047/exhibit4_2.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Specimen Common Stock Certificate</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2017 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.3</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000110465912057327/a12-17479_3ex4d1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indenture, dated as of August 13, 2012, between the Registrant and Wells Fargo Bank, National Association, as trustee, including Form of 2&#190; percent Convertible Senior Note due 2019</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Report on Form 8-K filed August 13, 2012 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.4</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000110465914082750/a14-24885_1ex4d1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indenture, dated as of November 17, 2014, between the Registrant and Wells Fargo Bank, National Association, as trustee, including Form of 1.00 percent Convertible Senior Note due 2021</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed November 21, 2014 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.5</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036119023019/ex4_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indenture, dated as of December 19, 2019, by and between Ionis Pharmaceuticals, Inc. and U.S. Bank National Association, as trustee, including Form of 0.125 percent Convertible Senior Note due 2024</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed December 23, 2019 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.6</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036119022393/ex99_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Form of Exchange and/or Subscription Agreement for Ionis Pharmaceuticals, Inc. Convertible Senior Notes due 2024</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed December 12, 2019 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.7</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036119022393/ex99_2.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Form of Convertible Note Hedge Transactions Confirmation</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed December 12, 2019 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.8</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036119022393/ex99_3.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Form of Warrant Transactions Confirmation</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed December 12, 2019 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit4_9.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.9</a></div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Description of the Registrant&#8217;s Securities.</div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.1</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000110465913016208/a12-28450_1ex10d1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Form of Indemnity Agreement entered into between the Registrant and its Directors and Officers with related schedule</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2012 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.2*</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000110465912025639/a12-1729_1def14a.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Registrant&#8217;s 1989 Stock Option Plan, as amended</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to Registrant&#8217;s Notice of Annual Meeting and Proxy Statement for the 2012 Annual Meeting of Stockholders, filed with the SEC on April 16, 2012, and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.3*</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036119005627/ex10_2.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Registrant&#8217;s Amended and Restated 2000 Employee Stock Purchase Plan</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to Registrant&#8217;s Current Report on Form8-K filed with the SEC on March 26, 2019, and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.4</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401518000047/exhibit10_4.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Form of Employee Confidential Information and Inventions Agreement</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2017 and incorporated herein by reference.</span></div></td>
  </tr>
</table>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>75</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z5d59b71d6eec4a4db6431ea98121f369">
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.5</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000091205701527777/a2056057zex-10_2.txt" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Collaboration and License Agreement between the Registrant and Hybridon, Inc., dated May 24, 2001</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s report on Form 10-Q as amended for the quarter ended June 30, 2001 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.6</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000110465911044376/a11-13864_1ex10d1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amendment #1 to the Research, Development and License Agreement dated May 11, 2011 by and between the Registrant and Glaxo Group Limited</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.7</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000110465908032466/a08-11587_1ex10d2.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amended and Restated Collaboration and License Agreement between the Registrant and Antisense Therapeutics Ltd dated February 8, 2008</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2008 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.8</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401517000033/ex10_2.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stock Purchase Agreement among the Registrant, Akcea Therapeutics, Inc. and Novartis Pharma AG</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> dated January 5, 2017, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.9</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401517000033/ex10_3.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amendment #1 between the Registrant and Bayer AG dated February 10, 2017</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.10</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000110465913081234/a13-19600_1ex10d4.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Registrant&#8217;s Amended and Restated 10b5-1 Trading Plan dated September 12, 2013</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.41%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.11*</div></td>
    <td style="width: 2.17%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.43%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036114017588/formdef14a.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Registrant&#8217;s Amended and Restated 2002 Non-Employee Directors&#8217; Stock Option Plan, as amended</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Notice of Annual Meeting and Proxy Statement, for the 2014 Annual Meeting of Stockholders, filed with the SEC on April 25, 2014, and incorporated herein by reference.</span></div></td>
  </tr>
</table>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zfe12f628bdf34e2cbef08ae19ae98f55">
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.12*</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000110465912054509/a12-13652_1ex10d3.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Form of Restricted Stock Unit Agreement for Restricted Stock Units granted under the Ionis Pharmaceuticals, Inc. Amended and Restated 2002 Non-Employee Directors&#8217; Stock Option Plan</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.13</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401518000047/exhibit10_17.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Research Collaboration, Option and License Agreement between the Registrant and Biogen MA Inc.</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> dated December 19, 2017, filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2017 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.14*</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036119007625/nc10001158x1_def14a.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Notice of 2019 Annual Meeting of Stockholders and Proxy Statement filed with the SEC on April 26, 2019, and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.15*</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401515000082/ex10_4.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Form of Option Agreement under the 2011 Equity Incentive Plan</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.16*</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000110465911044856/a11-23763_1ex99d3.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Form of Time-Vested Restricted Stock Unit Agreement for Restricted Stock Units granted under the 2011 Equity Incentive Plan</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Registration Statement on Form S-8 filed with the SEC on August 8, 2011, and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.17</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036117028398/ex10_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Loan Agreement between Ionis Gazelle, LLC and UBS AG dated July 18, 2017</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed July 21, 2017 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.18*</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401515000082/ex10_5.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Form of Option Agreement under the 1989 Stock Option Plan</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.19*</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000104746905006784/a2153640zex-10_57.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Form of Option Agreement for Options Granted after March 8, 2005 under the 2002 Non-Employee Director&#8217;s Stock Option Plan</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2004 and incorporated herein by reference.</span></div></td>
  </tr>
</table>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>76</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zc56368e71fe941b9bf7b7f19792cb9b7">
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.20</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000110465910026849/a10-5958_1ex10d5.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Research, Development and License Agreement between the Registrant and Glaxo Group Limited dated March 30, 2010</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2010 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.21</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036117028398/ex10_2.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Loan Agreement between Ionis Faraday, LLC and UBS AG</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> dated July 18, 2017, filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed July 21, 2017 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.22</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000110465911061713/a11-25667_1ex10d1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Research Agreement dated August 10, 2011 between the Registrant and CHDI Foundation, Inc</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.23</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036117028398/ex10_3.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Guaranty between the Registrant and UBS AG</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> dated July 18, 2017, filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed July 21, 2017 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.24</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000110465912034636/a12-6491_1ex10d1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Development, Option and License Agreement between the Registrant and Biogen Idec International Holding Ltd. dated January 3, 2012</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.25</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000110465912054509/a12-13652_1ex10d1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">DMPK Research, Development, Option and License Agreement between the Registrant and Biogen Idec MA Inc. dated June 27, 2012</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.26</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000110465913016208/a12-28450_1ex10d44.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amendment #2 to Research, Development and License Agreement between the Registrant and Glaxo Group Limited dated October 30, 2012</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2012 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.27</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000110465913016208/a12-28450_1ex10d45.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Collaboration, License and Development Agreement between the Registrant and AstraZeneca AB dated December 7, 2012</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2012 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
</table>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z252f963650a14044b5df0e5cc833d73d">
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.28</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000110465913016208/a12-28450_1ex10d46.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Neurology Drug Discovery and Development Collaboration, Option and License Agreement between the Registrant and Biogen Idec MA Inc. dated December 10, 2012</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2012 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.29</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000110465913060361/a13-13715_1ex10d1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">HTT Research, Development, Option and License Agreement among the Registrant, F. Hoffmann-La Roche Ltd and Hoffman-La Roche Inc. dated April 8, 2013</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2013 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.30</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000110465913060361/a13-13715_1ex10d2.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Letter Agreement between the Registrant and CHDI Foundation, Inc. dated April 8, 2013</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2013 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.31</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000110465913081234/a13-19600_1ex10d2.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amendment #1 to Collaboration, License and Development Agreement between the Registrant and AstraZeneca AB dated August 13, 2013</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.32</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036114018974/ex10_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Letter Agreement Amendment between the Registrant and Biogen Idec International Holding Ltd dated January 27, 2014</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
</table>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>77</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zcc0eac26475041f0a7aa19c01bea0389">
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.33</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036114030549/ex10_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amendment No. 3 to the Research, Development and License Agreement between the Registrant and Glaxo Group Limited dated July 10, 2013</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.34</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036114030549/ex10_2.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amendment #4 to the Research, Development and License Agreement between the Registrant and Glaxo Group Limited dated April 10, 2014</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.35</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036114030549/ex10_3.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amendment #5 to the Research, Development and License Agreement among the Registrant, Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited dated June 27, 2014</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.36</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401514000095/ex10_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Exclusive License Agreement between the Registrant and the University of Massachusetts dated January 14, 2010</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.37</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401514000095/ex10_2.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amended and Restated Collaboration and License Agreement between the Registrant and Cold Spring Harbor Laboratory dated October 26, 2011</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.38</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401514000095/ex10_3.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amendment to Amended and Restated Collaboration and License Agreement between the Registrant and Cold Spring Harbor Laboratory dated March 14, 2014</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.39</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036115009498/exhibit10_59.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amendment #1 to the Development, Option and License Agreement between the Registrant and Biogen Idec International Holding Ltd. dated December 15, 2014</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.40</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036115009498/exhibit10_60.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Research Collaboration, Option and License Agreement between the Registrant and Janssen Biotech Inc. dated December 22, 2014</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.41</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036115009498/exhibit10_61.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amendment No.2 to the Collaboration, License and Development Agreement between the Registrant and AstraZeneca AB dated October 15, 2014</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.42</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401515000082/ex10_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Strategic Collaboration Agreement between the Registrant and AstraZeneca AB dated July 31, 2015</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.43</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401515000082/ex10_2.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amendment #6 to Research, Development and License Agreement between the Registrant, Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited dated September 2, 2015</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.44</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401515000082/ex10_3.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amendment Number One to the Second Amended and Restated Strategic Collaboration and License Agreement between the Registrant and Alnylam Pharmaceuticals, Inc. dated July 13, 2015</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
</table>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>78</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z96606bbe7a644524bd6b1805e4f58192">
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.45</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401515000077/ex10_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">License Agreement between the Registrant and Bayer Pharma AG dated May 1, 2015. Portions of this exhibit have been omitted and separately filed with the SEC</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.46</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401515000057/ex10_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Second Amended and Restated Strategic Collaboration and License Agreement between the Registrant and Alnylam Pharmaceuticals, Inc. dated January 8, 2015</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.47</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401515000057/ex10_2.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amendment #1 to HTT Research, Development, Option and License Agreement between the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. dated January 9, 2015</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2015 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.48</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401516000118/ex10_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amendment No.3 to the Collaboration, License and Development Agreement between the Registrant and AstraZeneca AB dated January 18, 2016</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.49</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401516000118/ex10_2.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amendment #7 to the Research, Development and License Agreement among the Registrant, Glaxo Group Limited and GlaxoSmithKline Intellectual Property Development Limited dated March 4, 2016</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.50</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036117009823/exhibit10_60.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">First Amendment to Research Collaboration, Option and License Agreement between the Registrant and Janssen Biotech Inc. dated December 21, 2016</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2016 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.51</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036117009823/exhibit10_61.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Letter Agreement between the Registrant and Biogen MA Inc. dated October 28, 2016</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2016 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.52</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036117028398/ex10_4.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Guaranty between the Registrant and UBS AG dated July 18, 2017</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed July 21, 2017 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.53</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036117028398/ex10_5.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Environmental Indemnity Agreement among the Registrant, Ionis Gazelle, LLC and UBS AG</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> dated July 18, 2017, filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed July 21, 2017 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.54</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036117028398/ex10_6.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Environmental Indemnity Agreement among the Registrant, Ionis Faraday, LLC and UBS AG</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> dated July 18, 2017, filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed July 21, 2017 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.55*</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036118040955/ex10_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Registrant&#8217;s Severance Benefit Plan and Summary Plan Description dated October 18, 2018</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, - filed as an exhibit to the Registrant&#8217;s Current Report on form 8-K filed October 18, 2018 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.56</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036120000641/ex10_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Second Amended and Restated Strategic Advisory Services Agreement by and between the Registrant and B. Lynne Parshall, dated January 9, 2020</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Current Report on Form 8-K filed January 10, 2020 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.57</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401518000060/ex10_2.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Development, Commercialization, Collaboration, and License Agreement by and between the Registrant and Akcea Therapeutics, Inc.</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, dated March 14, 2018, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.58</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401518000060/ex10_3.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amended and Restated Services Agreement by and between the Registrant and Akcea Therapeutics, Inc.</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, dated March 14, 2018, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.64%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.59</div></td>
    <td style="width: 2.09%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.27%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401518000105/ex10_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">New Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement by and between the Registrant and Biogen MA Inc.</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, dated April 19, 2018, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
</table>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>79</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z04190945ecf14359a08bdd03fde2d2a0">
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.60</div></td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401518000105/ex10_2.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stock Purchase Agreement by and between the Registrant and Biogen MA Inc.</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, dated April 19, 2018, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 and incorporated herein by reference.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.61</div></td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401518000128/ex10_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Second Amendment to Research, Collaboration, Option and License Agreement by and between the Registrant and Janssen Biotech Inc.</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, dated August 7, 2018, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.62</div></td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401519000045/exhibit10_67.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Factor B Development Collaboration, Option and License Agreement by and between the Registrant, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., dated October 9, 2018,</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018 and incorporated herein by reference. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.63</div></td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401519000045/exhibit10_68.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Second Amended and Restated Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement by and between the Registrant and Biogen MA Inc.,</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> dated October 17, 2018, filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.64</div></td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401519000045/exhibit10_69.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amendment #1 to the Strategic Collaboration Agreement by and between the Registrant and AstraZeneca AB, dated October 18, 2018</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.65</div></td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401519000045/exhibit10_70.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amendment #4 to the Collaboration, License and Development Agreement by and between the Registrant and AstraZeneca AB, dated October 18, 2018</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2018. Portions of this exhibit have been omitted and separately filed with the SEC with a request for confidential treatment.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.66</div></td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000114036119014492/ex10_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amendment #1 to Second Amended and Restated Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement by and between the Registrant and Biogen MA Inc., dated May 2, 2019</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2019.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.67</div></td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401519000130/ex10_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amendment #1 to the New Strategic Neurology Drug Discovery and Development Collaboration, Option and License Agreement between the Registrant and Biogen MA Inc., dated August 16, 2019</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019. Portions of this exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.68</div></td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401519000130/ex10_2.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amendment #8 to the Research, Development and License Agreement between the Registrant, Glaxo Group Limited and Glaxosmithkline Intellectual Property Development Limited, dated July 29, 2019</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019. Portions of this exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.69</div></td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/874015/000087401519000130/ex10_3.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Consent to Collateral Addition and Amendment to Loan Documents between the Registrant, Ionis Gazelle, LLC, Wells Fargo Bank, National Association, as Trustee for the Benefit of the Registered Holders of UBS Commercial Mortgage Trust 2017-C3, Commercial Mortgage Pass-Through Certificates, Series 2017-C3, dated August 1, 2019</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, filed as an exhibit to the Registrant&#8217;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019.</span></div></td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit10_70.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.70</a></div></td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Letter Agreement between the Registrant, Akcea Therapeutics, Inc., and Pfizer Inc., dated October 4, 2019. Portions of this exhibit have been omitted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed.</div></td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit21_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21.1</a></div></td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">List of Subsidiaries for the Registrant.</div></td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit23_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23.1</a></div></td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Consent of Independent Registered Public Accounting Firm.</div></td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">24.1</div></td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Power of Attorney &#8211; Included on the signature page of this Annual Report on Form 10-K.</div></td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit31_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">31.1</a></div></td>
    <td style="width: 1.94%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.28%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Certification by Chief Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</div></td>
  </tr>
</table>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>80</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z5070c5be42b041f3a3bf9c83e5dbc3c4">
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit31_2.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">31.2</a></div></td>
    <td style="width: 2.04%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.19%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Certification by Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</div></td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.04%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.19%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a href="exhibit32_1.htm" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">32.1</a><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">+</span></div></td>
    <td style="width: 2.04%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.19%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Certification Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</div></td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.04%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.19%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">101</div></td>
    <td style="width: 2.04%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.19%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following financial statements from the Ionis Pharmaceuticals, Inc. Annual Report on Form 10-K for the year ended December 31, 2019, formatted in Extensive Business Reporting Language (XBRL): (i) consolidated balance sheets, (ii) consolidated statements of operations, (iii) consolidated statements of comprehensive income (loss), (iv) consolidated statements of stockholders&#8217; equity (v) consolidated statements of cash flows, and (vi) notes to consolidated financial statements (detail tagged)</div></td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 2.04%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 90.19%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 7.78%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104</div></td>
    <td style="width: 2.04%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 90.19%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cover Page Interactive Data File (formatted in iXBRL and included in exhibit 101)</div></td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z5ec72872d9314987bfd3f2868d7dca4b">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">*</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Indicates management compensatory plans and arrangements as required to be filed as exhibits to this Report pursuant to Item 14(c).</div></td>
  </tr>
</table>
</div>
</div>
<div style="text-align: justify;">
<div>
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zb97876ec0bc24e57b4566d5620b0dbea">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">+</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This certification is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 133, as amended, or the Securities Exchange Act of 1934, as amended.</div></td>
  </tr>
</table>
</div>
</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>81</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">SIGNATURES</div>
<div style="text-align: justify;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized on the 2<sup>nd</sup> day of March, 2020.</div>
<div style="text-align: center;"><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z33f25e06e05d4230bcfa2e9467757996">
  <tr>
    <td style="width: 49.81%; vertical-align: top;">&#160;</td>
    <td colspan="2" style="width: 50.19%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">IONIS PHARMACEUTICALS, INC.</div></td>
  </tr>
  <tr>
    <td style="width: 49.81%; vertical-align: top;">&#160;</td>
    <td style="width: 4.63%; vertical-align: top;">&#160;</td>
    <td style="width: 45.56%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 49.81%; vertical-align: top;">&#160;</td>
    <td style="width: 4.63%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">By:</div></td>
    <td style="width: 45.56%; vertical-align: top; border-bottom: #000000 2px solid;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ BRETT P. MONIA</div></td>
  </tr>
  <tr>
    <td style="width: 49.81%; vertical-align: top;">&#160;</td>
    <td style="width: 4.63%; vertical-align: top;">&#160;</td>
    <td style="width: 45.56%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Brett P. Monia., Ph.D.</div></td>
  </tr>
  <tr>
    <td style="width: 49.81%; vertical-align: top;">&#160;</td>
    <td style="width: 4.63%; vertical-align: top;">&#160;</td>
    <td style="width: 45.56%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Chief Executive Officer (Principal executive officer)</div></td>
  </tr>
</table>
<div style="text-align: center;"><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">POWER OF ATTORNEY</div>
<div style="text-align: center;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Brett P. Monia and Elizabeth L. Hougen, or any of them, his or her attorney-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Report, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his or her substitute or substitutes, may do or cause to be done by virtue hereof.</div>
<div><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</div>
<div style="text-align: left;"><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z133811699bf64c66a3e9c8e98e3e70a0">
  <tr>
    <td style="width: 30.39%; vertical-align: top; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">Signatures</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">Title</div></td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 8pt; font-weight: bold;">Date</div></td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;">&#160;</td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ BRETT P. MONIA</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Director and Chief Executive Officer</div></td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">March 2, 2020</div></td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Brett P. MONIA, Ph.D.</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Principal executive officer)</div></td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;">&#160;</td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ ELIZABETH L. HOUGEN</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Senior Vice President, Finance and Chief Financial Officer</div></td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">March 2, 2020</div></td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Elizabeth L. Hougen</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(Principal financial and accounting officer)</div></td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;">&#160;</td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ STANLEY T. CROOKE</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Executive Chairman of the Board</div></td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">March 2, 2020</div></td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stanley T. Crooke, M.D., Ph.D.</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;">&#160;</td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ B. LYNNE PARSHALL</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Director and Senior Strategic Advisor</div></td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">March 2, 2020</div></td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">B. Lynne Parshall, J.D.</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;">&#160;</td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ SPENCER R. BERTHELSEN</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Director</div></td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">March 2, 2020</div></td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Spencer R. Berthelsen, M.D.</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;">&#160;</td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ BREAUX CASTLEMAN</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Director</div></td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">March 2, 2020</div></td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Breaux Castleman</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;">&#160;</td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ MICHAEL HAYDEN</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Director</div></td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">March 2, 2020</div></td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top; border-top: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Michael Hayden, CM OBC MB ChB PhD FRCP(C) FRSC</div><div>&#160;</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ JOAN E. HERMAN</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Director</div></td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">March 2, 2020</div></td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top; border-top: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Joan E. Herman</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;">&#160;</td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ JOSEPH KLEIN</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Director</div></td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">March 2, 2020</div></td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Joseph Klein, III</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;">&#160;</td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ JOSEPH LOSCALZO</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Director</div></td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">March 2, 2020</div></td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Joseph Loscalzo, M.D., Ph.D.</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;">&#160;</td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ FREDERICK T. MUTO</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Director</div></td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">March 2, 2020</div></td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Frederick T. Muto, Esq.</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;">&#160;</td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ PETER N. REIKES</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Director</div></td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">March 2, 2020</div></td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Peter N. Reikes</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top;">&#160;</td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ JOSEPH H. WENDER</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Director</div></td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">March 2, 2020</div></td>
  </tr>
  <tr>
    <td style="width: 30.39%; vertical-align: top; border-top: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Joseph H. Wender</div></td>
    <td style="width: 2.04%; vertical-align: top;">&#160;</td>
    <td style="width: 49.28%; vertical-align: top;">&#160;</td>
    <td style="width: 2.22%; vertical-align: top;">&#160;</td>
    <td style="width: 16.07%; vertical-align: top;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span>82</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><!--PROfilePageNumberReset%Num%1%%%-->IONIS PHARMACEUTICALS, INC.</div>
<div><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</div>
<div style="text-align: center;"><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z92528cc930f647b7a1b9109e9b47fd83">
  <tr>
    <td style="width: 93.33%; vertical-align: bottom;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"></div></td>
    <td style="width: 6.67%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Page</div></td>
  </tr>
  <tr>
    <td style="width: 93.33%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Report of Independent Registered Public Accounting Firm</div></td>
    <td style="width: 6.67%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-2</div></td>
  </tr>
  <tr>
    <td style="width: 93.33%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Consolidated Balance Sheets at December 31, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2019</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2018</span></div></td>
    <td style="width: 6.67%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-4</div></td>
  </tr>
  <tr>
    <td style="width: 93.33%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Consolidated Statements of Operations for the years ended December 31, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2019</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2018</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2017</span></div></td>
    <td style="width: 6.67%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-5</div></td>
  </tr>
  <tr>
    <td style="width: 93.33%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2019</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2018</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2017</span></div></td>
    <td style="width: 6.67%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-6</div></td>
  </tr>
  <tr>
    <td style="width: 93.33%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Consolidated Statements of Stockholders&#8217; Equity for the years ended December 31, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2019</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2018</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2017</span></div></td>
    <td style="width: 6.67%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-7</div></td>
  </tr>
  <tr>
    <td style="width: 93.33%; vertical-align: top; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Consolidated Statements of Cash Flows for the years ended December 31, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2019</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2018</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2017</span></div></td>
    <td style="width: 6.67%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-8</div></td>
  </tr>
  <tr>
    <td style="width: 93.33%; vertical-align: top; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Notes to Consolidated Financial Statements</div></td>
    <td style="width: 6.67%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-10</div></td>
  </tr>
</table>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>1</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>
<div style="text-align: center;"><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">To the Stockholders and Board of Directors of Ionis Pharmaceuticals, Inc.</div>
<div style="text-align: left;"><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Opinion on the Financial Statements</div>
<div><br /></div>
<div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have audited the accompanying consolidated balance sheets of Ionis Pharmaceuticals, Inc. (the &#8220;Company&#8220;) as of December 31, 2019 and 2018, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity, and cash flows, for each of the three years in the period ended December 31, 2019 and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019, in conformity with US generally accepted accounting principles.</div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated March 2, 2020 expressed an unqualified opinion thereon.</div>
<div><br /></div>
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Basis for Opinion</div>
<div><br /></div>
<div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div>
<div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Critical Audit Matters</div>
<div><br /></div>
<div style="text-align: justify; margin-bottom: 12pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matters or on the accounts or disclosures to which they relate.</div>
<div><a id="_Hlk32858616"><!--Anchor--></a></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z4831e5d422214cbd9916c89ef45e0e36">
  <tr>
    <td style="width: 15.43%; vertical-align: top;">&#160;</td>
    <td style="width: 2.85%; vertical-align: top;">&#160;</td>
    <td style="width: 81.72%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Revenue recognition for collaboration agreements</div></td>
  </tr>
  <tr>
    <td style="width: 15.43%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Description of the Matter</div></td>
    <td style="width: 2.85%; vertical-align: top;">&#160;</td>
    <td style="width: 81.72%; vertical-align: top;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For the year ended December 31, 2019, the Company&#8217;s reported research and development revenue under collaborative agreements was $770.1 million. As discussed in Note 1 to the consolidated financial statements, the Company enters into collaboration agreements that are often comprised of multiple performance obligations, including technology licenses or options to obtain technology licenses, research and development services, and manufacturing services.</div><div>&#160;</div><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Auditing the Company&#8217;s revenue recognition for collaboration agreements is complex because significant judgment may be required to apply the authoritative accounting guidance at the outset of the arrangement, including the determination of performance obligations and transaction price, as well as the allocation of the transaction price among the performance obligations. For example, the allocation of the transaction price among the performance obligations involves the estimation of the standalone selling price of each performance obligation which is based upon various assumptions, which may include projected income, estimated costs and discount rate.</div></td>
  </tr>
  <tr>
    <td style="width: 15.43%; vertical-align: top;">&#160;</td>
    <td style="width: 2.85%; vertical-align: top;">&#160;</td>
    <td style="width: 81.72%; vertical-align: top;">&#160;</td>
  </tr>
</table>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>2</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z346de4d9d02f481b862f96becb6c8b56">
  <tr>
    <td style="width: 15.43%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">How We Addressed the Matter in Our Audit</div></td>
    <td style="width: 2.85%; vertical-align: top;">&#160;</td>
    <td style="width: 81.72%; vertical-align: top;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We evaluated and tested the design and operating effectiveness of key controls over the risks of material misstatement relating to the accounting for revenue recognition of collaboration agreements with multiple performance obligations. For example, we tested management&#8217;s controls over the allocation of the transaction price, particularly the review of the methodology and assumptions used in the valuation of standalone selling price mentioned above.</div><div>&#160;</div><div style="text-align: justify; margin-right: 3.6pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our audit procedures included, among others, <span style="background-color: #FFFFFF; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">evaluating the Company&#8217;s assessment of the authoritative guidance to its contracts, inspecting contracts entered into during the period, and evaluating management&#8217;s interpretation of certain contract provisions when identifying performance obligations and allocating the transaction price to the performance obligations. We also evaluated the Company&#8217;s key assumptions and judgments and tested the completeness and accuracy of the underlying data used to determine the standalone selling price of each performance obligation. In addition, we compared the significant assumptions mentioned above to current industry and market trends and performed sensitivity analyses to evaluate the changes to revenue recognized that would result from changes in the assumptions.</span></div></td>
  </tr>
  <tr>
    <td style="width: 15.43%; vertical-align: top;">&#160;</td>
    <td style="width: 2.85%; vertical-align: top;">&#160;</td>
    <td style="width: 81.72%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 15.43%; vertical-align: top;">&#160;</td>
    <td style="width: 2.85%; vertical-align: top;">&#160;</td>
    <td style="width: 81.72%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Realizability of Deferred Tax Assets</div></td>
  </tr>
  <tr>
    <td style="width: 15.43%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Description of the Matter</div></td>
    <td style="width: 2.85%; vertical-align: top;">&#160;</td>
    <td style="width: 81.72%; vertical-align: top;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As discussed in Note 1 to the consolidated financial statements, the Company records a valuation allowance based on the assessment of the realizability of the Company&#8217;s deferred tax assets. Deferred tax assets are reduced by a valuation allowance if, based on the weight of all available evidence, in management&#8217;s judgment it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. For the year ended December 31, 2019, the Company had gross deferred tax assets of $514.5 million and a related valuation allowance of&#160; $197.0 million as described in Note 5.</div><div>&#160;</div><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Auditing management&#8217;s assessment of the realizability of its deferred tax assets involved significant judgment because the assessment process is complex and is based upon assumptions that may be affected by future market or economic conditions.</div></td>
  </tr>
  <tr>
    <td style="width: 15.43%; vertical-align: top;">&#160;</td>
    <td style="width: 2.85%; vertical-align: top;">&#160;</td>
    <td style="width: 81.72%; vertical-align: top;">&#160;</td>
  </tr>
  <tr>
    <td style="width: 15.43%; vertical-align: top;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">How We Addressed the Matter in Our Audit</div></td>
    <td style="width: 2.85%; vertical-align: top;">&#160;</td>
    <td style="width: 81.72%; vertical-align: top;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We evaluated and tested the design and operating effectiveness of controls over the Company&#8217;s income tax process, including controls over management&#8217;s scheduling of the future reversal of existing taxable temporary differences, identification and use of available tax planning strategies and projections of future taxable income.</div><div>&#160;</div><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Among other audit procedures performed, we evaluated the assumptions used by the Company to develop the scheduling of the future reversal of existing taxable temporary differences, tax planning strategies, as well as current earnings and anticipated future earnings used in the Company&#8217;s analysis in determining the valuation allowance on a jurisdiction by jurisdiction basis. We tested the completeness and accuracy of the underlying data used in the Company&#8217;s projections. For example, we compared management&#8217;s forecasts to actual results for the current and historical periods. Furthermore, we evaluated the appropriateness of the assumptions underlying the future projected financial information, as well as management&#8217;s consideration of current operating, industry and economic trends. We also compared the projections of future taxable income with other forecasted financial information prepared by the Company. In addition, we involved our tax specialists to evaluate the application of tax law in the projections of future taxable income.</div></td>
  </tr>
</table>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ Ernst &amp; Young LLP</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have served as the Company&#8217;s auditor since 1989</div>
<div><br /></div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">San Diego, California</div>
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">March 2, 2020</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>3</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">IONIS PHARMACEUTICALS, INC.</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CONSOLIDATED BALANCE SHEETS</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(In thousands, except share data)</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="z710eaf1b8f81455b9cde887751886282" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom;"><div style="text-align: center; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">ASSETS</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Current assets:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cash and cash equivalents</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_bc9174e7fd1b46998715a48e884958d3" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">683,287</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_7d7f77575df24801aeb6d430b5e2aea9" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">278,820</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Short-term investments</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" id="Fact_f2286909ac5641e29bb72849f613afb8" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,816,257</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" id="Fact_a1df8a4ae5fb4f9d95e154d2c09e0e03" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,805,252</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Contracts receivable</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNetCurrent" id="Fact_09ccd7c4554b495cb3b69ab0dd4c6353" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">63,034</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ContractWithCustomerAssetNetCurrent" id="Fact_264161db8a37477daa1cb9fc9575e8fb" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">12,759</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Inventories</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_ef71bc5f67e14616981b9564f38cbdf9" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">18,180</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_dac3eca6a6f24f2b88d7f80946b830f6" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">8,582</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other current assets</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" id="Fact_ea0ef4e752a74ed2b3d6cfb2d9a33c46" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">139,839</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" id="Fact_05664ce5755b408da83f5e1ff62a18ee" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">102,473</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total current assets</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_c50a2906bf9c489fa10f03522ee0777f" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,720,597</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_37c6bfa1615e424e9cc12fd7d5941e85" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,207,886</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Property, plant and equipment, net</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_e673fd22a5d44fc98ce04c462d2a135c" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">153,651</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_d4aed8b852744ba8a28d733722dfa3e7" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">132,160</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Patents, net</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_35383fdfc944499d99481f4236a96589" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">25,674</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_bd7406d09bb34cd38fa8036df5735589" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">24,032</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Long-term deferred tax assets</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" id="Fact_5f2a655af2b4494588eb9fd1c7927ce1" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">305,557</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" id="Fact_d5da495aeeca4464978a569391184ebe" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">290,796</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deposits and other assets</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" id="Fact_028d5e12b53d44efafc7fc6259a8c677" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">27,633</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" id="Fact_0c76b4574810464783e04a0b5fcd3d22" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">12,910</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total assets</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:Assets" id="Fact_e7755fa54d8645189ca7a38afb274c32" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,233,112</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:Assets" id="Fact_bbc96043d6b84ad0a64609e7e45001dd" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,667,784</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: center; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">LIABILITIES AND STOCKHOLDERS</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> EQUITY</span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Current liabilities:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Accounts payable</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_d2f4209896534c34b236247e2f014047" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">16,067</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_4a77a0a95bc24ec9879730f3c54c5767" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">28,660</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Accrued compensation</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_6757e467d4ca4989a92e1b0146882726" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">37,357</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" id="Fact_e13f67f862ed4bf9b0ccd8241eabef36" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">29,268</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Accrued liabilities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_70b781ca48864bb9b31bb2272f1c75fd" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">66,769</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_969294300c9b472f89e106ba0b60bd69" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">47,503</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income taxes payable</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" id="Fact_0ac97222f6364543b31753077f08b8f9" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">32,514</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" id="Fact_924182cca560478288901c6e2b93dbec" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">858</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Current portion of long-term obligations</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" id="Fact_c3dd012ae5014734b3edfded476645f1" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,026</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" id="Fact_b637339218424d74ba82205fd72c11a5" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">13,749</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Current portion of deferred contract revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" id="Fact_dde59dcefdfc41a5aece21fc7e36d234" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">118,272</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" id="Fact_b5c48cb25c964d7c97633d915cafdb42" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">160,256</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total current liabilities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_6dd286ee152042f78be1fe86c4b53e7b" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">273,005</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_324dbdee5a4a42159831822bf6b85720" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">280,294</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Long-term deferred contract revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" id="Fact_e76b53d24abc4ce98f4c0bd7bb5c4ee7" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">490,060</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityNoncurrent" id="Fact_4f3a8b90ab234988bb31ecd484021c4b" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">567,359</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_2d12bb6f256d41509009bc5bd3a0c195" contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_75004fb19a054dbb96df3227e79bee4c" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction></ix:nonFraction> percent convertible senior notes</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConvertibleDebtNoncurrent" id="Fact_4eab47dc0a1d4b1c9a9acd7ab3519611" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">434,711</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConvertibleDebtNoncurrent" id="Fact_20d7bf53e413467294f1b30f5e5ea0f9" contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_4d6ff05e689748ac82559327ae5d49e0" contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_1396e02f45a24349a9a81454882364d5" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></ix:nonFraction> percent convertible senior notes</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConvertibleDebtNoncurrent" id="Fact_fa9ddcff26e244deb6af4ff717c2ed72" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">275,333</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConvertibleDebtNoncurrent" id="Fact_b81d968939c04aae8ac13f6ad19d2814" contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">568,215</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Long-term obligations, less current portion</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:LongTermObligationsNoncurrent" id="Fact_4c526f7e2df4476ea452dc42e08d921b" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">15,543</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:LongTermObligationsNoncurrent" id="Fact_59cacc1d32984d6198584f93759863e0" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">4,914</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -36pt; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Long-term mortgage debt</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:LongTermLoansFromBank" id="Fact_d0bdde965a494bd1967c669121c18b69" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">59,913</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:LongTermLoansFromBank" id="Fact_b1093c295a3e4d8980c112cd144aa095" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">59,842</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total liabilities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:Liabilities" id="Fact_72e72fa97a344884ae45c7d1457d4c58" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,548,565</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:Liabilities" id="Fact_e80cd271efab4a4c8c3d5beb70de894b" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,480,624</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stockholders&#8217; equity:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_633d3f736e2247d291880fed08c8de60" contextRef="c20181231" unitRef="U004" decimals="3" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_3582d99df2904a4ab26bce510bf362eb" contextRef="c20191231" unitRef="U004" decimals="3" scale="0" format="ixt:numdotdecimal">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_9a0912d45871495e9d5ffb48117b86ac" contextRef="c20181231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_7cf23bc0b3da4da3818fa69653f089c6" contextRef="c20191231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_6b03136461bc406ab4ea599c454895bc" contextRef="c20191231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_83959e73ecef45b7bf3b111575f95c72" contextRef="c20191231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">140,339,615</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_ae85ba7613de4a38acdf354791b136fa" contextRef="c20181231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_2e7ea39c8d104a0ca5cf2a5f9cdbc016" contextRef="c20181231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">137,928,828</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_5f48063ae846417a85a50e82db398716" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">140</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_942a957fd1a642b4a9846b941b383984" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">138</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Additional paid-in capital</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" id="Fact_3f85039492a3477ba262bbaf1e3a9940" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,203,778</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" id="Fact_a0bd160ae16c4b96869235d0b1952ae3" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,047,250</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Accumulated other comprehensive loss</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" id="Fact_7f6094dad8014d18a90ab96ded5f7902" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">25,290</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" id="Fact_3e9ce1fe826144aea3422b89b11598b2" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">32,016</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Accumulated deficit</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_6946ee9e730b46ca9324cbc783ed82e1" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">707,534</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_37e824371589479e8ba1817b0f9ad53a" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">967,293</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total Ionis stockholders&#8217; equity</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_1ebcc837b8984805befb132fd95881a8" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,471,094</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_2815f025bebb4872b942adb7491ee5b7" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,048,079</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -18.15pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Noncontrolling interest in Akcea Therapeutics, Inc.</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:MinorityInterest" id="Fact_15a602087f334617867a83b5dd1b29aa" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">213,453</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:MinorityInterest" id="Fact_689780f0068e47e98756616aa52d94d0" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">139,081</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total stockholders&#8217; equity</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_d61c237c2816416e9904b633d30916b8" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,684,547</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_0f68a4db9f9b47ad8afdba3a4483a05e" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,187,160</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total liabilities and stockholders&#8217; equity</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_801588c240bd4ed6bb876453863968da" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,233,112</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_52b3ab3e91024ab988399c759f32bda8" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,667,784</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">See accompanying notes.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>4</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">IONIS PHARMACEUTICALS, INC.</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CONSOLIDATED STATEMENTS OF OPERATIONS</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(In thousands, except for per share amounts)</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="z154526b9b8d445a0a3629bd8d883f551" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Revenue:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Commercial revenue:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: 8.85pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SPINRAZA royalties</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_fdaf4e7de3e14bc88036b45f358b0bc2" contextRef="c20190101to20191231_ProductOrServiceAxis_SPINRAZARoyaltiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">292,992</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_7043d15f95394ffe96f0662fa9fad2fa" contextRef="c20180101to20181231_ProductOrServiceAxis_SPINRAZARoyaltiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">237,930</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_ac6e240eca5848d5badb78f0ca60c1a3" contextRef="c20170101to20171231_ProductOrServiceAxis_SPINRAZARoyaltiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">112,540</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: 8.85pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Product sales, net</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_e82af709616c487887988783c2c8d9c7" contextRef="c20190101to20191231_ProductOrServiceAxis_ProductMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">42,253</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_a83fa126a57b41d599f30e7cad218b6c" contextRef="c20180101to20181231_ProductOrServiceAxis_ProductMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,237</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_ad9a698af9f24b05865de462af852631" contextRef="c20170101to20171231_ProductOrServiceAxis_ProductMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: 8.85pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Licensing and other royalty revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_573e884a4bdb425aa0b05fe6b144961b" contextRef="c20190101to20191231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">17,205</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_f85a761fec13470182f51d2856db9e79" contextRef="c20180101to20181231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">14,755</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_b54fd83200b746189af9f22a352eed08" contextRef="c20170101to20171231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">7,474</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: 17.75pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total commercial revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_fd9bb6ab6005461abb18649530165b23" contextRef="c20190101to20191231_ProductOrServiceAxis_CommercialMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">352,450</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_22602d3c8dbb4cce84585819b2a51d20" contextRef="c20180101to20181231_ProductOrServiceAxis_CommercialMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">254,922</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_00a0f7dfe1fe42f2a3f0f34b4024aee6" contextRef="c20170101to20171231_ProductOrServiceAxis_CommercialMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">120,014</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Research and development revenue under collaborative agreements</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_1620967f6acc42749745d5ae96e21c91" contextRef="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">770,149</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_0b96d8115fb4483dbc8311aafd1be7ec" contextRef="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">344,752</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_e3059784aae44cb6910ec96b251c7c0c" contextRef="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">394,165</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_00980b8be4a74f4fbdcc3edafc17198f" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,122,599</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_538efe69e72243699e94c3aa305b19c1" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">599,674</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_32e9022328524875ac203ea1d35a74e1" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">514,179</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expenses:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cost of products sold</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" id="Fact_284d13f3b0c542e2be15e9d709d0fa47" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">4,384</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" id="Fact_5c8f71079d0c4bab89afb5b5cd4f517d" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,820</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" id="Fact_c74a16886992472e8e1ef9e3f198eae8" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Research, development and patent</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:ResearchDevelopmentAndPatentExpense" id="Fact_deeed41a015f43ddb12f6865983ea8df" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">465,688</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:ResearchDevelopmentAndPatentExpense" id="Fact_9c3cab4b5389427ba74e69009ea765e5" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">414,604</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:ResearchDevelopmentAndPatentExpense" id="Fact_b91da5a5400f4a60b02409b9d698857d" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">374,644</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Selling, general and administrative</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_45acc2391f3d437c94c32375af3fd727" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">286,644</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_4b516d97f3e644e3bebe35a3e962a2d3" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">244,622</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_91e5528c46124f72a2837c37daf9ab0b" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">108,488</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total operating expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_209b855f67a840c5adfd7d6d2132674f" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">756,716</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_9583df6f11bd43278907171ed427d4ec" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">661,046</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_710cbcd2ece544baa561093e1ebc3db4" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">483,132</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) from operations</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_a29afc3ae1f74d74a4369f8ed00932b6" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">365,883</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_a89db9808ad84853b7f4af5bb8f658a1" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">61,372</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_c14f627556d1404e9df00ec104e525ef" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">31,047</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other income (expense):</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investment income</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" id="Fact_8190f0450b994481b761b63a19fa2db0" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">52,205</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" id="Fact_8c0f1b356e8a463e92d88c8d35f410bc" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">30,187</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:InvestmentIncomeNet" id="Fact_4cafde1786854b4a831f3771fe519f13" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">8,179</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Interest expense</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_47eb0551e96b4a789a0b721ce64eef0f" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">48,768</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_6c26daacbb594ef5a5eafb7e6d90e3cb" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">44,789</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:InterestExpense" id="Fact_97c245353bc447c096bb628d4d02557c" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">44,752</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Loss on extinguishment of financing liability for leased facility</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:GainLossOnExtinguishmentOfFinancingLiability" id="Fact_1b6947bfaba548758e64566b848f59cb" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:GainLossOnExtinguishmentOfFinancingLiability" id="Fact_a5937e22a494466284df196fbd0fcb71" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:GainLossOnExtinguishmentOfFinancingLiability" id="Fact_58a1a8d5100146e5ad352c095b159c25" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,689</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Loss on early retirement of debt</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_c3a4479d5bc24c12bbb3654f2b59fba2" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">21,865</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_1e981ccfec9e4e77bdb93b732ca6bb87" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_db456fea13e442f58dc87cedc52ba432" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_516792b864244fea81a047aaeb6a86f7" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">686</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_df31a318f46e40c0bad155f92c7bffb9" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">182</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_95a44b06b165497c90c92f0ecb837d5d" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,548</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) before income tax benefit (expense)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" id="Fact_786ffe6ab1c44b428a4fc9133fa1fb21" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">346,769</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" id="Fact_d3bdd0f2404d4109ab52a26b4122517d" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">76,156</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" id="Fact_abea68078429482298990eda2a273682" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,763</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income tax benefit (expense)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_25eb94c1a44848a4ae8038f050bdb154" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">43,507</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_5b1c8e20abb84c34b626e66d15f639fe" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">291,141</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_4e00bc85f9de44bc9fae3e310059dd54" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,980</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income (loss)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_eed2832b2f23443a8a7b6a11b3b5c8be" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">303,262</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_17fba83bb5c645feab5192b45331713f" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">214,985</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_1b16a95e7fa948b78f84194e8da4f693" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,783</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net (income) loss attributable to noncontrolling interest in Akcea Therapeutics, Inc.</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" id="Fact_39c266b37a4b4b75807a14eb73538310" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">9,116</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" id="Fact_498b97278bb645e598fad5c547449f5f" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">58,756</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" id="Fact_2924ba1e6c0449e68559e8bfbf1fff33" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">11,129</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income attributable to Ionis Pharmaceuticals, Inc. common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_d67d140ccc41433e809a30cd81e184e2" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">294,146</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_41f8afe988ab4add8c88a8e7caefd925" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">273,741</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_bb9a33cf051a47359fe47c04a4566435" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">346</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_ad4c690aa177438c98b7e63bbcd61da7" contextRef="c20190101to20191231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">2.12</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_2c847af7934d4aee8d1e75c8c45eaaed" contextRef="c20180101to20181231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">2.09</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_dc69ad9fdaac456cb95135c896add9e4" contextRef="c20170101to20171231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">0.15</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares used in computing basic net income per share</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_974483869c87424686f8a9d8ad9407f8" contextRef="c20190101to20191231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">139,998</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_57a007ce704b4b8e9d16bf5187758b1a" contextRef="c20180101to20181231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">132,320</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_24585fd306204e04ac047eefaae344a7" contextRef="c20170101to20171231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">124,016</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Diluted net income per share</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_7912333792fd463c8e34f1de8bd9f9e6" contextRef="c20190101to20191231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">2.08</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_be3545ea33e8465ea31dcf5f8cde1413" contextRef="c20180101to20181231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">2.07</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_1c75266fa9c242d78bbf9c06298d1fe8" contextRef="c20170101to20171231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">0.15</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares used in computing diluted net income per share</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_2e175ab1f4b4430c94110075de726551" contextRef="c20190101to20191231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">142,872</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_2bfa48d5ab3a400f9f083d57c473a574" contextRef="c20180101to20181231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">134,056</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_5a8e2e89a8854d18b716d51e6be5e33a" contextRef="c20170101to20171231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">126,098</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">See accompanying notes.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>5</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">I<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">ONIS PHARMACEUTICALS, INC.</span></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(In thousands)</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="z215203d716884f2c98d8af3b9606083c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income (loss)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_ca9d6b6e811d4d90a3511939ceaffd35" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">303,262</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_0f152c7175c442d096186ccdac7163b8" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">214,985</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_e9347ab362a94c8f9fec26b2321644a8" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,783</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Unrealized gains (losses) on investments, net of tax</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" id="Fact_33ff3ee28c9b4c45b1a904711a9fffdb" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">6,633</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" id="Fact_7ada2fcd89584f6e9d084b26c02bad37" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">280</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" id="Fact_48783ec4c4a4439782c377df7893c03c" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">960</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Reclassification adjustment for realized gains included in net income (loss)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" id="Fact_3b86bd0eff5744bea0c1168aa475edc1" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" id="Fact_4956a7b49b104a6a89c4a25a21e22e91" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" id="Fact_5ebf1d568f17475db6e7caa910125a6d" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">374</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Currency translation adjustment</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_0118d01a0fc0483d942b9e51407b4717" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">93</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_e0cf23c629544136a3b19d99634a49a6" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">23</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_107faab7668f4901940b3c076c0c0ec6" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">67</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Comprehensive income (loss)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" id="Fact_88990aa910f44465b514db16de1b6797" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">309,988</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" id="Fact_a94a014398884db3aad264a9afa0f0b9" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">214,728</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" id="Fact_952a61bbba0241e4b821f51c3f0cbaf0" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">12,184</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Comprehensive income (loss) attributable to noncontrolling interest in Akcea Therapeutics, Inc.</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" id="Fact_0a2ffbf7523a40bfb67425a2f824fdda" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">9,118</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" id="Fact_835fc2d29a554273b86faf6556c423be" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">58,781</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" id="Fact_7354d55541b84356989b29706bcadb0e" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">11,224</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Comprehensive income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_c084b014906646ef8b8e0d1564259a56" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">300,870</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_a5f2d997e0854eb2bac6beedf43dbdc0" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">273,509</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" id="Fact_8a473722becb41bd9bc5a5fa8d670a5c" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">960</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>
<div><br /></div>
<div><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">See accompanying notes.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>6</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">IONIS PHARMACEUTICALS, INC.</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> EQUITY</span></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Years Ended December 31, 2019, 2018 and 2017</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(In thousands)</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="z86b08c63681741a49f8b74a20f52752d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Common Stock</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Additional</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Accumulated Other</div><div> </div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Accumulated</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total Ionis</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Stockholders</span>&#8217;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Noncontrolling</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Interest in Akcea</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Stockholders</span>&#8217;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Description</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Paid in Capital</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Comprehensive Loss</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Deficit</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Equity</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Therapeutics, Inc.</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Equity</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Balance at December 31, 2016</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:SharesIssued" id="Fact_fd68097e538c4b81b9bd4921620080f6" contextRef="c20161231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">121,636</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_64d1adea22c6400d899f50eacb6b29e2" contextRef="c20161231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">122</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_92deefa3c28e47c5b979d2b7658c7619" contextRef="c20161231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,311,229</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_c3741346678549d58e3408ca523e7a1c" contextRef="c20161231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">30,358</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_ea62c55770e44c1daacc2df30d4795b7" contextRef="c20161231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,241,380</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_ad4ccb7a094841f58d036cd173beda7a" contextRef="c20161231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">39,613</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_a952a188c419434fb7ec7098f2b9950c" contextRef="c20161231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_c686bc8629764f71b2253b35cf2412e0" contextRef="c20161231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">39,613</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_f57535e622164f339a6c82bba63e4428" contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_1743253c1bf14efab032700eb36bdf42" contextRef="c20170101to20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_020443c416a44ec388ce65759f2a445c" contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_6c410bcb824948a88f2e5504a60e6c63" contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">346</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_56d476ab6a104072b642175b9bd8b013" contextRef="c20170101to20171231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">346</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_17081bb682174af2af61b2f9f5397c43" contextRef="c20170101to20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_4afb0261ba344f83b0def222fca29e14" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">346</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Change in unrealized gains, net of tax</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_0e3bd928ac7848c387c696f2f40dbe60" contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_a90097243bde4406b124f7551e1fc054" contextRef="c20170101to20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_051ca26e3c29447889e52b45ae827ab0" contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,334</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_7d3018f98130431dbce35431bd18a168" contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_93d42dc646f3414ea4f28746f0f079c2" contextRef="c20170101to20171231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,334</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_1ebfaf794acb4bc4859d0aa04832df0e" contextRef="c20170101to20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_f36378ab4b5a4c85a76002fd8dbe422b" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,334</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Foreign currency translation</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_120b3e829cca4d3db38746d14dcea9cf" contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_6ea42c0ff7e0453a95bed2efa16563d0" contextRef="c20170101to20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_760886ee213a4f1086e1fa353c55ac27" contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">67</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_b2f243cad35940a69fd750813e0b9005" contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_dc848cf7789b4c529df5f6778ad65a0c" contextRef="c20170101to20171231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">67</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_02e237697f4b43d69464b572b00bb889" contextRef="c20170101to20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_5d654a3d46b34c72818ae5f97336adfc" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">67</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Novartis stock purchase</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_ab01054e09164a8b86ed8a056a2a40bc" contextRef="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">1,631</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_48f92edc119349c392868b97532a1a7e" contextRef="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_a11acc6903c6429690c33297ae69a98b" contextRef="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">71,737</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_64057ec289eb4423b8dd2ef0ceb00709" contextRef="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_5353448487fb4a49836e592fb3b985f1" contextRef="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_95c240029be54d83a8e53b879da39f7b" contextRef="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">71,739</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_0eb705d35b9f467ab511c84f357ce263" contextRef="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_d7a6aabe82c747d9a58860a3f2d5280b" contextRef="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">71,739</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Issuance of common stock in connection with employee stock plans</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" id="Fact_e57de8a5f40049fb875ab0d99a0da99a" contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">1,709</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" id="Fact_074d7b5874874ed09f1da1463212087a" contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" id="Fact_8d03d0db70d14bf9ac1b58473ad4c657" contextRef="c20170101to20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">22,931</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" id="Fact_a55a166958544405abb544f64c2dbc62" contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" id="Fact_7d5c129eb6824cd9aa9d7fb088cdcddc" contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" id="Fact_7edee4630923452abd6ae5450469a239" contextRef="c20170101to20171231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">22,932</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" id="Fact_33279df145c44dd2b8899acc707a2958" contextRef="c20170101to20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" id="Fact_44948b5450a74c80b499a91d44ff8887" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">22,932</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stock-based compensation expense</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_e2b28030b5914cbf88c54ac00cc4576f" contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_001c6ca7907842f98ac9aef5630fcf80" contextRef="c20170101to20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">85,975</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_5771dc32ee084269a6710bd19e393b9f" contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_6604eb2d4df04aa6810504a074bfa450" contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_99b5694fc4174f9781d435577fcd4f05" contextRef="c20170101to20171231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">85,975</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_8591421a040646408b49f831181765f5" contextRef="c20170101to20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_a0e7f202280747dc8f747551ebd633bb" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">85,975</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Issuance of Akcea Therapeutics, Inc. common stock in conjunction with initial public offering</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:StockIssuedDuringPeriodSharesNewIssuesBySubsidiary" id="Fact_2565e2b8fd63455e811028466b2e6f8b" contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:StockIssuedDuringPeriodValueNewIssuesBySubsidiary" id="Fact_ade3d650cd164279ab40871e21547b9b" contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:StockIssuedDuringPeriodValueNewIssuesBySubsidiary" id="Fact_9a85d1991e2a4b7b8111903a160c684e" contextRef="c20170101to20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">157,270</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:StockIssuedDuringPeriodValueNewIssuesBySubsidiary" id="Fact_0bf0f8a752094c6a802223a55b51f861" contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:StockIssuedDuringPeriodValueNewIssuesBySubsidiary" id="Fact_d5894fd6fe8d4a0e8be4122b860d9dc9" contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:StockIssuedDuringPeriodValueNewIssuesBySubsidiary" id="Fact_167168c44c79462c85f9a5954f3f40d5" contextRef="c20170101to20171231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">157,270</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:StockIssuedDuringPeriodValueNewIssuesBySubsidiary" id="Fact_21434565ba214cbf8ebbdf2fd33571c0" contextRef="c20170101to20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:StockIssuedDuringPeriodValueNewIssuesBySubsidiary" id="Fact_0c7fb6d2206c4f1bb29dba4c01188835" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">157,270</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Noncontrolling interest in Akcea Therapeutics, Inc. in conjunction with initial public offering</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" id="Fact_c2efaca8fa6a45a7a69b6d8520c0f455" contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" id="Fact_6cec2ceb83354bd7acbed0f8425163e5" contextRef="c20170101to20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">90,351</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" id="Fact_a7e9a2348e4f46198a4a5ebb155e570d" contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" id="Fact_22e15779c5de4e7c8f4fef6cb91a190a" contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" id="Fact_f303f512554042ce87e1f6f40a816984" contextRef="c20170101to20171231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">90,351</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" id="Fact_f461e3ac014041d788dd481fc6aed056" contextRef="c20170101to20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">90,381</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" id="Fact_37f880c732844e9bad324aafba1a49d5" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">30</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Noncontrolling interest in Akcea Therapeutics, Inc.</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:MinorityInterestPeriodIncreaseDecrease" id="Fact_35741777134841d7a1d294b1ff07b5c2" contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:MinorityInterestPeriodIncreaseDecrease" id="Fact_d001dff9df0e4f0b9610194daa5aa057" contextRef="c20170101to20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,110</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:MinorityInterestPeriodIncreaseDecrease" id="Fact_a041c2cab55e4ef899c87ce42e0cea35" contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:MinorityInterestPeriodIncreaseDecrease" id="Fact_4e9d2a3a7f454b9e8fcec454f09f4f63" contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:MinorityInterestPeriodIncreaseDecrease" id="Fact_cbb62b66e5fa4370989862794a4e53ee" contextRef="c20170101to20171231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,110</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:MinorityInterestPeriodIncreaseDecrease" id="Fact_5f98725aad6343fc92d3aa055a631ba0" contextRef="c20170101to20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,114</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:MinorityInterestPeriodIncreaseDecrease" id="Fact_9877998ce4fe403fbb49607c40dc5dd1" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">11,224</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Balance at December 31, 2017</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:SharesIssued" id="Fact_6fe590d22b42475cb2ab499952418720" contextRef="c20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">124,976</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_0b2e87ee326e4b829343f9178b718248" contextRef="c20171231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">125</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_71af73b6843e4908bff33ed3bb3f81dc" contextRef="c20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,553,681</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_506ef91fee2e48aaae45a93b7ba31557" contextRef="c20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">31,759</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_e7473abf9eef44dd831973c3e99d4a9c" contextRef="c20171231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,241,034</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_1df4c5d4bf1e4c5fbb614f3dfa6fcd49" contextRef="c20171231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">281,013</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_8ad5daed766d41658a6facb3d89a1cd8" contextRef="c20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">84,267</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_03abc9126e214857b1c975f0d8b154cb" contextRef="c20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">365,280</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_c84e3d7df2744ac490f2ece90238084c" contextRef="c20180101to20181231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_a05d8d9d09c34d3aa0b85cc78675563d" contextRef="c20180101to20181231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_0f5d62d23bc047e2a3dc1c0f774b9020" contextRef="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_aecdfc9e7f3b4d8181fc8ead9202c0bf" contextRef="c20180101to20181231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">273,741</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_9e86184a3845435c956f280f8d01667b" contextRef="c20180101to20181231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">273,741</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_b254521696fb4e05a0eb787bdb22422a" contextRef="c20180101to20181231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_8ff18ce23015476190e74edcd530b87d" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">273,741</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Change in unrealized losses, net of tax</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_7ba08b22b1b540d6aeb73d182a28608d" contextRef="c20180101to20181231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_9c3d7ef70b634be98d60773f8b79aaf0" contextRef="c20180101to20181231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_3e64e9de93f64f50802c77e8a55ac347" contextRef="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">280</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_8de1eaa5c2ee4ab3b60cc78f1890b129" contextRef="c20180101to20181231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_930a0caf475345729a1ee26892965811" contextRef="c20180101to20181231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">280</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_eb2f7611b4dc405193a092337b144d42" contextRef="c20180101to20181231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_48c7584a84da4c90803e9757f9b399cc" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">280</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Foreign currency translation</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_90ccf61964db4d16a531dc7d86992d0a" contextRef="c20180101to20181231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_fd28d183cbe944178e688ea98f385c3c" contextRef="c20180101to20181231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_d9b7477e2efe498582984e21cc3cbeb0" contextRef="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">23</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_8d4fdd4f7f7f438cbb9dc1ad836fdec1" contextRef="c20180101to20181231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_d68b268e678f471ab3112b50cbac1193" contextRef="c20180101to20181231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">23</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_9929043870fc465fb02ef438606c0838" contextRef="c20180101to20181231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_82fc623119a8449f8f2a8a7bb05278a1" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">23</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Biogen stock purchase</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_422d1342431843698c70e9e3e6a7d970" contextRef="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">11,502</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_2815369ff411484dafeb907944063272" contextRef="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">11</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_f81af2efa9704103bcb9323e1a5f10a0" contextRef="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">447,954</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_af988eeb5f914d178b4f60d05fcf8139" contextRef="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_7999e83bb836472b9fb91450d2febc65" contextRef="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_348f46d0add04c708f65b3df0bb57858" contextRef="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">447,965</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_5aeda03bfc9940e3979be51056cd44d1" contextRef="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_da1f3831ed924137a6c6e12ae46c56d6" contextRef="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">447,965</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Issuance of common stock in connection with employee stock plans</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" id="Fact_9d30603d6cfd4749bcdd89daaf10dd65" contextRef="c20180101to20181231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">1,451</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" id="Fact_f826cd8d24a94dcd96107584163a2fdc" contextRef="c20180101to20181231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" id="Fact_2dc6f4f1933f49daaca7de2c77136413" contextRef="c20180101to20181231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">27,898</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" id="Fact_bcc4a6182a964efeac1f24893ac74c31" contextRef="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" id="Fact_a243a22d6fc3446a8f3886c10c6effad" contextRef="c20180101to20181231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" id="Fact_700a04df12a14eb6a230b1964cc684b2" contextRef="c20180101to20181231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">27,900</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" id="Fact_69b8eb05b0ef4453b060ffd6599f20a6" contextRef="c20180101to20181231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" id="Fact_3783a73ce7344d1bbda2d31237e63c46" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">27,900</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stock-based compensation expense</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_db045d548f2240a286157e5143cd5467" contextRef="c20180101to20181231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_78d7b7e3c1f74195a84f5fcc6da41363" contextRef="c20180101to20181231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">131,312</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_da8349e873094998b27c1da80326bb76" contextRef="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_f03b2cdadbfd478cac32496466c3e7c5" contextRef="c20180101to20181231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_f7b362873c854477ba81148bc17282ab" contextRef="c20180101to20181231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">131,312</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_9453fe6b0add4f3a99b3bb84b26f63dd" contextRef="c20180101to20181231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_17be3f01639941beb54bf488fbc8f610" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">131,312</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Noncontrolling interest in Akcea Therapeutics, Inc.</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:MinorityInterestPeriodIncreaseDecrease" id="Fact_666c40a4a122403cae72b21e8817611b" contextRef="c20180101to20181231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:MinorityInterestPeriodIncreaseDecrease" id="Fact_47a91296bf2945758c0363e1d81f40a4" contextRef="c20180101to20181231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">113,595</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:MinorityInterestPeriodIncreaseDecrease" id="Fact_94729224298b458b8079f3c8596d65ae" contextRef="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:MinorityInterestPeriodIncreaseDecrease" id="Fact_91c3d721cec84f3a8abc4a8a4938d37f" contextRef="c20180101to20181231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:MinorityInterestPeriodIncreaseDecrease" id="Fact_7d69dd60ea324bb889f6533ca7de9328" contextRef="c20180101to20181231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">113,595</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:MinorityInterestPeriodIncreaseDecrease" id="Fact_d388d05f36b24606903d69f5ffdc3ed4" contextRef="c20180101to20181231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">54,814</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:MinorityInterestPeriodIncreaseDecrease" id="Fact_01d5d052ad874a94a27a0b66cccb1b73" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">58,781</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Balance at December 31, 2018</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:SharesIssued" id="Fact_ddcaee8d8e4e415f99603d60fbe0130c" contextRef="c20181231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">137,929</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_b05da05da7fe41bda5bf6ada927a792d" contextRef="c20181231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">138</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_6ab9978b577d43178d568aee326b7826" contextRef="c20181231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,047,250</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_a41d9ba2c9a34eac96b94876d458700e" contextRef="c20181231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">32,016</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_84f539e326a64ec0ab408c09645014b1" contextRef="c20181231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">967,293</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_d7840211f9204d4e84bda2551d44d0c2" contextRef="c20181231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,048,079</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_ec7256f1e9984d82a2ceccc0c5cc83d5" contextRef="c20181231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">139,081</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_12ff567b84a548acaed74dc483a0acc8" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,187,160</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_a67f9527449c47eeb32f69118f686b2f" contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_8f3162784e6545a6924bc32c7733346c" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_a350a139c53d4d6fb396ed04590e6ce5" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_b3a2447b1d834cd0a3ceaa4817d99a93" contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">294,146</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_1a865e1176c546ef9bb829e8888bea17" contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">294,146</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_8ae3f201424a47eda14b0dc5e7c87f15" contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_de8d2f53ac6d4d879added5a5aa1dcc9" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">294,146</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Change in unrealized gains, net of tax</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_091acbdc3d82400b856fb543039fff06" contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_cb0a0c71133844d3813cf48f84db8653" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_ccafcb363fac48a1894ab9d43abd6205" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">6,633</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_783f4fab8a7a406b9f621eff4771df67" contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_452ae92e05a247dd8ff31928b367fbc8" contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">6,633</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_a40693ecba5b4be18cf4bf78c9877442" contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" id="Fact_1bb43560b5e5484e943ecb8f677e0578" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">6,633</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Foreign currency translation</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_57e0d1697c8e4a479de822431d02ddcb" contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_ac7228222b1b49dcb8f72098da3a2fc5" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_1fc757414d054332964615bbdf74bef5" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">93</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_f0d212544aec4c4a9786a02a41de4f60" contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_ea09c80cfd634d45bab908ab4ec28c80" contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">93</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_72802d9709534b28aab5c5cde6356875" contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" id="Fact_87403d54e17c49d7b817a60049b06375" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">93</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Issuance of common stock in connection with employee stock plans</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" id="Fact_c24c54602c144726bfa552f8a73e19cb" contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">3,100</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" id="Fact_8e7958f907ad494caf864e34d07a6a23" contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" id="Fact_2147c10da0b64b7e9ecab30181a3380f" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">119,654</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" id="Fact_f09f40a13c0a49e7bb263437412ae0fa" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" id="Fact_e64b1e9c032f43b69df459e05bc70d0d" contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" id="Fact_50a3d26ac1f5441697cb3978958677f5" contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">119,657</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" id="Fact_35227d58ddcd4fd5a24c7e200027ed14" contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross" id="Fact_a9610c4a050040a1b9d134486721c73b" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">119,657</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_83a3e2736f2143ada2faad90731539af" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction> percent convertible senior notes retirement, equity portion, net of tax</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" id="Fact_953662494e8042ca9a0656b07a91bf1c" contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" id="Fact_d8369e5fb5e64dd88bad2b718fbc5a05" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">77,331</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" id="Fact_8b3a83dca8ec4f0989e5a8a7a373b923" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" id="Fact_69b685a069454aada5e59edce9c03386" contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" id="Fact_ccc3b06011914242998f1f6fc5a86f5e" contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">77,331</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" id="Fact_90b27e956e1341d88497f039672d94bf" contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" id="Fact_724720b280a44a0ba9fb326d292189c3" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">77,331</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_48a58ec03ee9478c94ed56dd8e46cc7d" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction> percent convertible senior notes, equity portion, net of issuance costs and tax</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" id="Fact_65e36c24f0894b40853b9eeb75338a47" contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" id="Fact_83f8530c6b384ae98925066d03454ef3" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">81,877</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" id="Fact_dfeb6a4b1c284a3b93d79cf3a45a07ac" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" id="Fact_8888f84bb0a14310ae386fb181379ef5" contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" id="Fact_49bc1c5ebc0548fcb8fcda6bac4779e5" contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">81,877</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" id="Fact_4e13fb008b184d2ca173a0e726662a02" contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" id="Fact_69bcc9ef38b04a3f9c599f8d1788c1c8" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">81,877</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Issuance of warrants</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_e50a4f4665d04c8c948a7c4ed8b11a23" contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_9030e03e300141b7a4c3684d6640bb69" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">56,110</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_69d1c1a3e263405db0d40fc651f9eee0" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_4d037abc26f04f29babe19cdcdf1e842" contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_bdc639c44a0045d6aeb936229afd02b6" contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">56,110</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_6fd6745266c64d4ba944fd94daf65883" contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_3d495ff92a534f91aa5cba742ef4998d" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">56,110</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Purchase of note hedges, net of tax</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" id="Fact_e79a280b4f0648d4b31f376e0c7b6a73" contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" id="Fact_b588eded63ab4563bbe0ece09adcb1a8" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">85,860</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" id="Fact_11e3e8eb23cc49358654b3257ee72ae0" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" id="Fact_b8fcdd9317c54a3faf946784ada255fd" contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" id="Fact_888f566bee434121b979e85a24d8d253" contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">85,860</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" id="Fact_d3315b42b16c424b8b2915ebba587dd6" contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" id="Fact_3d45fdaeb6cb42af88cdd003e9d475c9" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">85,860</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Repurchases and retirements of common stock</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" id="Fact_6d0509a3a49e4fd79186aba88fdfe7cc" contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">535</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" id="Fact_3e2d452fbb8e42f6a34ac114784ab9a3" contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" id="Fact_c2c06cb20c284344b197268932c18253" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" id="Fact_e4b1fe1d06444bfd96807b9c900fe8c4" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" id="Fact_c29b6427e7554a4180120463ed6cd6f4" contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">34,387</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" id="Fact_bb78398196024e879afbff00d3335ff8" contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">34,388</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" id="Fact_caf4b9bf5c8041a1a878141b4db37ad9" contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" id="Fact_f181e719466440b694f0c0c4e9e5e3cf" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">34,388</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stock-based compensation expense</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_8814916665504ddc88722078a6a2074f" contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_251a778792bc4574921239d96e2cc76b" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">146,574</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_72ff720ee9954b8e8e3dd43fd9fb1c97" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_1d0ce5c99690477898d58d2270f91119" contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_3bbe99e715fc4f75ad0ccd0a8564a13a" contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">146,574</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_aa9f51446a9947dfa4afad89a4c87329" contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" id="Fact_ecddf625db5e4ae8b44436f78790413a" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">146,574</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" id="Fact_a3235a69b98240b697dda8695b530e9b" contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">154</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" id="Fact_b6558edaae9a4bc19dc54b131b2b7dbd" contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" id="Fact_4e435cadfcab475db76df4d24e337ba4" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">19,242</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" id="Fact_1dd896112023423b82db73b8a21630fa" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" id="Fact_f7f9adce2f554b4da4e8e972e171e084" contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" id="Fact_4fc01f2664c9469caeed47d3bd7593a9" contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">19,242</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" id="Fact_4d1d40b3aa7e4e0eba01947bddbee8e4" contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" id="Fact_20b2a9e912cc45ad89b6a659c11d0af7" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">19,242</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Noncontrolling interest in Akcea Therapeutics, Inc.</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:MinorityInterestPeriodIncreaseDecrease" id="Fact_9019973e46e44654bc6d5693a64d8d54" contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:MinorityInterestPeriodIncreaseDecrease" id="Fact_fa0e947eab2649f98fdad98a4fc5b5cb" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">65,254</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:MinorityInterestPeriodIncreaseDecrease" id="Fact_45ed5950a192470bb0c6f36e87ee64eb" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:MinorityInterestPeriodIncreaseDecrease" id="Fact_b914f08f78a044f782f44be3ed9b15fd" contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:MinorityInterestPeriodIncreaseDecrease" id="Fact_fe58258522784128b04dece32d36d4c2" contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">65,254</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:MinorityInterestPeriodIncreaseDecrease" id="Fact_eec4affdb73243209fa0da61997ada6b" contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">74,372</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:MinorityInterestPeriodIncreaseDecrease" id="Fact_6a88f675be4b4fbdaa04b195da7e5eaf" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">9,118</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 20%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Balance at December 31, 2019</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:SharesIssued" id="Fact_746edf0b2d594dc1bfff28688790aadb" contextRef="c20191231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">140,340</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_dd95823efc6d48629085e2df2a2df03f" contextRef="c20191231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">140</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_7926590c4ac846588194c66ff4c2550a" contextRef="c20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,203,778</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_e2257cbf08d94c6bb70d24097bf49d5d" contextRef="c20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">25,290</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_73eb2d116b2544438ca47b4bc3166000" contextRef="c20191231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">707,534</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_2257e7f227984d2080fa75bfdcc1445e" contextRef="c20191231_StatementEquityComponentsAxis_ParentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,471,094</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_a6af661e63ee4803aa097fa82936e2c0" contextRef="c20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">213,453</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 7%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_f192a399801f4e43be246c6b0b0043d5" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,684,547</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">See accompanying notes.</div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>7</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">IONIS PHARMACEUTICALS, INC.</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(In thousands)</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="z9e4f71cfd4614c3cb13c95e093e4e0d2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating activities:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income (loss)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_74418700e541478eadc5aced379a124b" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">303,262</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_3fb9b4a0ea3c4f27a1399c4165b5801f" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">214,985</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_39b8baae321b42f7a5f4fa01fd0016cc" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,783</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Depreciation</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:Depreciation" id="Fact_9783424161d0448dad5051ce77601a96" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">12,540</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:Depreciation" id="Fact_6e647886642547db938d5dd7ac6cb6ac" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">10,706</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:Depreciation" id="Fact_c043d99cc86a49da958b7b3be663c1e1" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">6,708</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amortization of right-of-use operating lease assets</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:OperatingLeaseRightOfUseAssetAmortization" id="Fact_187fd18217c9402ba4a18dc3da990453" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,542</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:OperatingLeaseRightOfUseAssetAmortization" id="Fact_97e6d2268c574e3d8f29df4998aec6d6" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:OperatingLeaseRightOfUseAssetAmortization" id="Fact_215c70afe4f549f890056ebd2c3be83f" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amortization of patents</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_c4419687fb464fe5bdc6e0d2984bef36" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,912</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_2510d199eca04ba290db4822e474a069" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,822</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_dfcf2be324b646d9bb90e538cfcfa5d7" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,641</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amortization of premium (discount) on investments, net</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" id="Fact_19b1a8aca8b7454d8d920b65112f9717" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">7,485</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" id="Fact_1d483a94eb99484aaf16db7faa11b937" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,013</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" id="Fact_a3256c7afeb0459b896a0c3caee0e2f8" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,752</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amortization of debt issuance costs</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" id="Fact_b85286437b974418ba977d6f06debc76" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,942</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" id="Fact_a644e66590634fa5857536f88b90ec7a" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,810</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" id="Fact_8299ca7b84184a219ca22bdd8885ded6" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,616</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amortization of convertible senior notes discount</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_c6a08bf487994614bcb0094e8c8ffdb8" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">37,338</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_1705faed1556409b8a834d130ee3edae" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">33,363</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_a26c3943aee0441994aee8f5be710103" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">30,920</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amortization of long-term financing liability for leased facility</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AmortizationOfLeasedAsset" id="Fact_0f0686824c2d4ba5bbe71d8816dab0f9" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AmortizationOfLeasedAsset" id="Fact_c63e45e30bb84c4ab3194b7e56e8eb76" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AmortizationOfLeasedAsset" id="Fact_17752f9064a34f5b816cc4fae67422b9" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,659</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stock-based compensation expense</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_de86964f1c204681a24953a828812433" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">146,574</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_b7ce371b025e4c42b0adacb5ab3929a4" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">131,312</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_1639ac5ab8ad4f01b5b69c5287ccb579" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">85,975</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Gain on investment in Regulus Therapeutics, Inc.</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:GainOnSaleOfInvestments" id="Fact_4d1595e63af04abea4966fe86708ced5" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:GainOnSaleOfInvestments" id="Fact_6c6ff75931a54728a59ae998477a38a1" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:GainOnSaleOfInvestments" id="Fact_4636e938136d4cdfa6bfecf49a1f916d" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">374</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Loss on extinguishment of financing liability for leased facility</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:GainLossOnExtinguishmentOfFinancingLiability" id="Fact_0c14da2f172b4616bda58edd7c204d69" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:GainLossOnExtinguishmentOfFinancingLiability" id="Fact_5938268a07c646f2b101d782daafc456" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:GainLossOnExtinguishmentOfFinancingLiability" id="Fact_9ef4a7dd516e42f787c64d7e55cc44ab" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,689</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Loss on early retirement of debt</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_e867493ef4ff4d3ebe904b6d5afd0509" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">21,865</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_746295e1c66f4d83896cdde464856584" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_92b9752085fc414faf69a3c81e0bfb45" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deferred income taxes (including benefit from valuation allowance release)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndTaxCredits" id="Fact_1d37213306b346a2a2c697ca032c3d0e" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,096</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndTaxCredits" id="Fact_5c2bc7d8b78d4b099c1e6ade218bd61f" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">290,516</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxesAndTaxCredits" id="Fact_2a9eba50a072476bbfd8481cf925c9b4" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-cash losses related to patents, licensing, property, plant and equipment and investments</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" id="Fact_291cde2cb61241079f0d07a1773ddce6" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,034</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" id="Fact_41bc9d424e104261a082087cb455e2a0" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,012</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" id="Fact_3670e160c2544d3d9cbe6b16b6a00e35" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,302</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Changes in operating assets and liabilities:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Contracts receivable</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" id="Fact_f68a004f44a6458192f1daa14c3a54bb" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">47,674</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" id="Fact_e61ccb4ba21a4ee397258365ed72f449" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">47,595</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" id="Fact_d476ac7c7da448f6a23a134d6afa1da6" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">45,088</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Inventories</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" id="Fact_085c28a5897b4fdc902bd3eb96b38cfe" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">5,411</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" id="Fact_721b959345b1466b92ba324d3da7222a" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,400</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" id="Fact_f0c18d8f1c034754aa7043aeea9887ef" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,493</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other current and long-term assets</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" id="Fact_864803efe0c94dcc8ef6304a526731c5" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">44,659</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" id="Fact_9c22cd95e9714742b7353b0030bbba8e" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">29,348</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" id="Fact_6e52fd98d6cb4429b89f68777b6ce49d" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">58,367</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Long-term income tax receivable</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" id="Fact_f85089599ebd420ab0dfeb4f295cfc60" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">8,418</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" id="Fact_39986573e52c4b22a4e7523064d4a2b9" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">223</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" id="Fact_5e5b325268ae444f9a6564725f633244" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">9,114</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Accounts payable</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" id="Fact_a2882fd1ebf24bd894bdd232be12bb88" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,343</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" id="Fact_19037c392df44ffaa87bb0e8fa58cb64" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">655</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" id="Fact_fdf8edb884a5467dbfa35ec370b22a73" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,784</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income taxes</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" id="Fact_cbe5d4f72a7b47b6bbf20a734efa0ff9" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">31,656</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" id="Fact_928bf4ded5484066ada8046ae256e5bd" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">710</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" id="Fact_35b11d3a61584178b39dbfdaa63e5d23" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">435</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Accrued compensation</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherEmployeeRelatedLiabilities" id="Fact_be8c0f046cfa423dbf8943de92eacba3" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">8,089</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherEmployeeRelatedLiabilities" id="Fact_c2e1e6792bbf4d45bb9581a0838da942" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">4,117</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherEmployeeRelatedLiabilities" id="Fact_1610f4d30b0d484693cb2ccb1dd531cd" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">965</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Accrued liabilities and deferred rent</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" id="Fact_c2d76681eaf6401eb0820fac87914240" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">16,499</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" id="Fact_46fb0027cc774970b1e33fe73a8d0134" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">17,023</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" id="Fact_fd2ee65b38e940ef8147608e66310a1d" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">28,564</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deferred contract revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" id="Fact_6eed7a6f16674d629d60401fee845c19" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">119,283</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" id="Fact_860c87bb13ca432ab6413fcb41ab7d48" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">494,254</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" id="Fact_9c03c531ef514d558aa7fca25bb6b718" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">30,182</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net cash provided by operating activities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_19c256c737ca49a4a82b43e1d4907fd7" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">345,720</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_6ac8228472434c89928ff5906d8cdfa8" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">602,888</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_39199cc3649f4be29630e4d9f60a5e3f" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">174,149</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investing activities:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Purchases of short-term investments</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" id="Fact_e72b6b733f32469391537642ed9f915f" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,946,726</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" id="Fact_dade26c6f20f4b60a4feec4e181794e8" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,794,735</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" id="Fact_67fd6ba04f7343b8835d000a36955a72" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">877,810</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Proceeds from the sale of short-term investments</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" id="Fact_4c7538b4bbdc45c8b0632c5597958d34" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,951,734</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" id="Fact_38e7752c94b34c97a1435e616eb5db40" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">882,824</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" id="Fact_80d5593638ef4ce1981649265ba744b9" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">557,369</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Purchases of property, plant and equipment</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_af7f2fbf99644b83883250b2765bc5ae" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">30,905</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_28d3f3d53dd04a84a5b65fcacb820e59" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">13,608</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_77a9b1f4ce9d4712ac162eef39cf7ca1" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">34,764</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Acquisition of licenses and other assets, net</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:PaymentsToAcquireLicensesAndOtherAssets" id="Fact_c4ddbc47fdde42a994020ac78cea3e4d" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">5,377</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:PaymentsToAcquireLicensesAndOtherAssets" id="Fact_dff874e0a9d440f2b2291df63ce33c1c" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">4,044</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:PaymentsToAcquireLicensesAndOtherAssets" id="Fact_83d9fabba44a4c58856c75295f25be39" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,093</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Purchase of strategic investments</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:PaymentsToAcquireCostMethodInvestments" id="Fact_80fc4ad369ea4266aa819342e5a274f3" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">10,000</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:PaymentsToAcquireCostMethodInvestments" id="Fact_2dd3f9b1b98e487c90386a8b5c2e7dbd" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:PaymentsToAcquireCostMethodInvestments" id="Fact_62fe3844a7e8414ea863aff8f888c1ce" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,500</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Proceeds from the sale of Regulus Therapeutics, Inc.</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" id="Fact_7edd2db69de6496994b65033d5aa0d88" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" id="Fact_e41dc87c481d4131aff70bf715ac57c7" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" id="Fact_27c69f80f41e411ba9543311f05e58f7" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,507</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net cash (used in) provided by investing activities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_f34b0cc23b5d447c95919927abae52a5" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">41,274</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_dc86ed420ba74326be5713c12aa09032" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">929,563</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_25c5a36f9c66441bbadcb049e1be0f09" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">358,291</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Financing activities:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Proceeds from equity, net</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" id="Fact_9766979c83c547faaf9db39fd1ec8b13" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">119,657</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" id="Fact_e8614ff277e9476fabd71fcec8d4876c" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">27,900</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" id="Fact_847a8383a3104ae19857ffdfc7350136" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">22,931</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" id="Fact_d0c63549a159422d8925dbeac4505a02" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">19,242</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" id="Fact_4420366a0a5648d6bb96c8031145c0f8" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" id="Fact_0355270d749349ec8d585f6e041767cc" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Proceeds from the issuance of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_d059c5d1572341c7b1665fabcbd30820" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction> percent convertible senior notes</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" id="Fact_225e1862aa0445a6b71d0471dfa6b546" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">109,500</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" id="Fact_b7eedb2ae11b4edb9d5e14441f8c7798" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" id="Fact_fc4f30f07d0c493098e146a7aead7848" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_70f588014d3e4b30baa726f0da2418a1" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction> percent convertible senior notes issuance costs</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" id="Fact_64ba705f156e4145a902a5899027210e" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">10,428</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" id="Fact_f313f339843849879880343bb3a88792" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" id="Fact_9e7cba35e2b34b3294529c9f00b291fc" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Proceeds from issuance of warrants</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" id="Fact_495d0e1c772f477aa4b69187144a2acc" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">56,110</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" id="Fact_fd3083678ca946bc8c04d46f0ed04911" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" id="Fact_6a2730d1fb4e46bfbf665ffb2a8cec4f" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Purchase of note hedges</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:PaymentsForHedgeFinancingActivities" id="Fact_93476033a0d54173bc9010c262c485d1" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">108,684</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PaymentsForHedgeFinancingActivities" id="Fact_f5757aa8a1b84931b13cb7b1821bd15a" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PaymentsForHedgeFinancingActivities" id="Fact_18ed7373cfed41688772a16bc1938cfc" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Repurchases and retirements of common stock</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" id="Fact_4ea9107410344f6ea56e07ac99f40f7d" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">34,392</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" id="Fact_a877c68b655745d9b6bc70655c9025d0" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" id="Fact_95cb066a3d5548738b8c9564f1c73b6c" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Principal payments on debt and capital lease obligations</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities" id="Fact_557667a97fa84b1f8a6a354d828e462f" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">12,500</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities" id="Fact_06f41cbbdf604c0c83ffd872ca84b5a4" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities" id="Fact_15ae921ec787447894e64ba1af89992c" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,599</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Proceeds from issuance of common stock in Akcea Therapeutics, Inc. from its initial public offering, net of underwriters&#8217; discount</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" id="Fact_33886d091bd74c3b81ba8a961010aafc" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" id="Fact_9e405ad35d8347d982a4eab76b7f513b" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" id="Fact_311cba869100479c9bc1af6662d37d2b" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">110,438</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Proceeds from building mortgage debt, net of issuance costs</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" id="Fact_40fecba1abf94eb3933e63602d8d200c" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" id="Fact_a737854ff328444db888566f0555afd4" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" id="Fact_64402f2028b048fc9a02f9274727ae4f" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">59,750</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Proceeds from the issuance of common stock to Biogen</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_31f2a6013f174a42875e8adb4bd9553d" contextRef="c20190101to20191231_MajorCustomersAxis_BiogenIncMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_a6d6cf7497d14ddabf086f00d2d6b9f7" contextRef="c20180101to20181231_MajorCustomersAxis_BiogenIncMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">447,965</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_d21338aa254a4785a08c74f7957900df" contextRef="c20170101to20171231_MajorCustomersAxis_BiogenIncMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Proceeds from the issuance of common stock to Novartis</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_b2a0da660cd14042b4297bcbdf082081" contextRef="c20190101to20191231_MajorCustomersAxis_NovartisInternationalAGMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_62098e4ea30d4e17870220459736b7ff" contextRef="c20180101to20181231_MajorCustomersAxis_NovartisInternationalAGMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_7356470850824c2ba37d8f507541acda" contextRef="c20170101to20171231_MajorCustomersAxis_NovartisInternationalAGMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">71,737</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Proceeds from the sale of Akcea Therapeutics, Inc. common stock to Novartis in a private placement</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" id="Fact_2ce8896b663c496391a7345690647e9c" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" id="Fact_bb4d2886dfbe4912bae7a8e421b3bebe" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" id="Fact_8005a235884a48568575462880dd3388" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">50,000</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Offering costs paid</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" id="Fact_b24671f684db4b548dd971d0d518995e" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" id="Fact_b29ef4a3029c4beab233a01aaa773f2f" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" id="Fact_8b71bc7ef66240c8bd938cb5a0e51095" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,037</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Payment to settle financing liability for leased facility</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:PaymentToSettleFinancingLiabilityForLeasedFacility" id="Fact_5944b73e0a664cadad2799749f6cfce6" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:PaymentToSettleFinancingLiabilityForLeasedFacility" id="Fact_d1f4073d220243ed9ca2c6c80e5df1da" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:PaymentToSettleFinancingLiabilityForLeasedFacility" id="Fact_519835b941674b2f959525ccdeabc30f" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">80,133</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net cash provided by financing activities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_d0b81d4107734a99947e72b9ef08fd52" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">100,021</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_695577047908479aa462291bcf511bc0" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">475,865</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_51741218780e4456a9f34ed2578e6cb5" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">229,087</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net increase in cash and cash equivalents</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" id="Fact_424bfa231a4440118755b82c9de508d0" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">404,467</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" id="Fact_95d8220f6f2d45ba950a407056745ec4" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">149,190</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" id="Fact_9335e820abb445728b10d591aaa919e2" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">44,945</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cash and cash equivalents at beginning of year</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_2fe11c4a0552452c9ee5a7c3aac47705" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">278,820</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_38e0d74e03924dde80c877dfd5b295d0" contextRef="c20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">129,630</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_f274cb6e3cd045b38892b34d9be46c38" contextRef="c20161231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">84,685</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cash and cash equivalents at end of year</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_802558b256f940a8a9f59915d51c438b" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">683,287</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_463b7126048f497ca4901d977f5c2ac9" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">278,820</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_b29066047a884910867fa584b8145295" contextRef="c20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">129,630</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>8</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">IONIS PHARMACEUTICALS, INC.</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(In thousands)</div>
<div><br /></div>
<table cellpadding="0" cellspacing="0" id="zfebc6666473542b5b66a4b98737d5f6b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Supplemental disclosures of cash flow information:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Interest paid</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_b47f47ad7adc4ae2a63c5b2b958e5986" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">9,870</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_365634aaa3f54c4e87b568166b422025" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">9,592</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_777216b0c9fd41a0868d458c42358f8f" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">8,035</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income taxes paid</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" id="Fact_ecaed007242544d4875e2a8394cda8a9" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">9,041</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" id="Fact_8ba0df8b170c45d9b7cc4f3eb3758c73" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" id="Fact_4fcf50f2783540e1ab2ce456a89dac23" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Supplemental disclosures of non-cash investing and financing activities:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Right-of-use assets obtained in exchange for lease liabilities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" id="Fact_9fb6e06d97424d029e274cd992868d40" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">14,178</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" id="Fact_f9435009c20c4e1286dedbf877ee8a0d" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" id="Fact_7ee9fe8123e4431f9d154d9f5bfe7e4b" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amounts accrued for capital and patent expenditures</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:NonCashCapitalAndPatentExpenditures" id="Fact_2e1171bfaa9c4beb805687ac979a648e" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,126</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:NonCashCapitalAndPatentExpenditures" id="Fact_b651f1c7ed9545389caa3fee850fcf78" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">4,428</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:NonCashCapitalAndPatentExpenditures" id="Fact_13b925f99e774581bb9380f16b558158" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,983</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Purchases of property, plant and equipment included in long-term obligations</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" id="Fact_c9258d5b61324343bc87d4c7de8a4f80" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" id="Fact_36807bb56a004428912cae04b722058b" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,350</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" id="Fact_16d4c75aad684ff0b03a47e44f07a03d" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_85b2c604ea1643578611fc5d1efde99f" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction> percent convertible senior notes principal issued related to our December 2019 debt exchange/issuance</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NotesIssued1" id="Fact_2631a61142764254850409ae81f33c49" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">439,326</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NotesIssued1" id="Fact_a433da4a48564dd69284d9856e9c3deb" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NotesIssued1" id="Fact_fbe82c691e6c437781dfb207e079037c" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_0fb7afd855e24e069c48f8df5ed96d3d" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction> percent convertible senior notes principal extinguished related to our December 2019 debt exchange</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NotesReduction" id="Fact_cee29604c1c5449fbe8073a349e9224b" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">375,590</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NotesReduction" id="Fact_8210f62b70dc4bd3a67ec6dd974850eb" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NotesReduction" id="Fact_9a4cd310e1fd4b579017d09f17982879" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
<div><br /></div>
<div><br /></div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">See accompanying notes.</div>
<div><br /></div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>9</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">IONIS PHARMACEUTICALS, INC.</div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>
<div><br /></div>
<div><ix:nonNumeric name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="Text_86f14b4beea94d60902ec7fb792ab655" contextRef="c20190101to20191231" escape="true" continuedAt="Text_46b341a9e8d644a8b79909b44816a3221">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1. Organization and Significant Accounting Policies</div>
</ix:nonNumeric><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a3221" continuedAt="Text_46b341a9e8d644a8b79909b44816a3222">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a3222" continuedAt="Text_46b341a9e8d644a8b79909b44816a3223"><ix:nonNumeric name="us-gaap:ConsolidationPolicyTextBlock" id="Text_2b199108265b4c4198b7da63e8c89a7b" contextRef="c20190101to20191231" escape="true" continuedAt="Text_90ebf819d56b4d33883cc5a70b62fbe81">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Basis of Presentation</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a3223" continuedAt="Text_46b341a9e8d644a8b79909b44816a3224"><ix:continuation id="Text_90ebf819d56b4d33883cc5a70b62fbe81" continuedAt="Text_90ebf819d56b4d33883cc5a70b62fbe82">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a3224" continuedAt="Text_46b341a9e8d644a8b79909b44816a3225"><ix:continuation id="Text_90ebf819d56b4d33883cc5a70b62fbe82">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In our consolidated financial statements we included the accounts of Ionis Pharmaceuticals, Inc. (&#8220;we&#8221;, &#8220;us&#8221; or &#8220;our&#8221;) and the consolidated results of our majority-owned affiliate, Akcea Therapeutics, Inc., which we formed in December 2014. In July 2017, Akcea completed an initial public offering, or IPO. Since Akcea&#8217;s IPO, our ownership has ranged from </span><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" id="Fact_1c52629d5af4464eb05fbdfeead6d0a1" contextRef="c20191231_OwnershipAxis_AkceaTherapeuticsIncMember_RangeAxis_MinimumMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">68</ix:nonFraction> percent<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> to </span><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" id="Fact_6d7f1e25827e4935a7cab4cc683ece59" contextRef="c20191231_OwnershipAxis_AkceaTherapeuticsIncMember_RangeAxis_MaximumMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">77</ix:nonFraction> percent<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. At December 31, 2019, o</span>ur ownership was approximately <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" id="Fact_a67cffe7b85b4003bd09a2f4a26d72d3" contextRef="c20191231_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">76</ix:nonFraction> percent. We reflect changes in our ownership of Akcea in our financial statements in the period the change occurs. For example, we reflected an increase in our ownership when we received <ix:nonFraction name="ions:SharesReceivedFromSubsidiaryForLicenseOfDrug" id="Fact_df5ee0c42b2442929cc860f2dfd73ba5" contextRef="c20191001to20191231" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">6.9</ix:nonFraction> million shares of Akcea common stock as payment for the sublicense fee Akcea owed us for Pfizer&#8217;s license of AKCEA-ANGPTL3-L<sub>Rx</sub> in the fourth quarter of 2019. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Refer to the section titled &#8220;Noncontrolling Interest in Akcea&#8221; in Note 2, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Significant Accounting Policies,</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for further information related to our accounting for our investment in Akcea.</span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a3225" continuedAt="Text_46b341a9e8d644a8b79909b44816a3226">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a3226" continuedAt="Text_46b341a9e8d644a8b79909b44816a3227">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Organization and Business Activity</div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a3227" continuedAt="Text_46b341a9e8d644a8b79909b44816a3228">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a3228" continuedAt="Text_46b341a9e8d644a8b79909b44816a3229">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We incorporated in California on January 10, 1989. In conjunction with our IPO, we reorganized as a Delaware corporation in April 1991. We were organized principally to develop human therapeutic medicines using antisense technology. In December 2015, we changed our name from Isis Pharmaceuticals, Inc. to Ionis Pharmaceuticals, Inc.</div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a3229" continuedAt="Text_46b341a9e8d644a8b79909b44816a32210">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32210" continuedAt="Text_46b341a9e8d644a8b79909b44816a32211"><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" id="Text_2da7bfa9547f4a7dbb2f9930781fb07b" contextRef="c20190101to20191231" escape="true" continuedAt="Text_929536832613473d8746e4525403255a1">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Basic and Diluted Net Income per Share</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32211" continuedAt="Text_46b341a9e8d644a8b79909b44816a32212"><ix:continuation id="Text_929536832613473d8746e4525403255a1" continuedAt="Text_929536832613473d8746e4525403255a2">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32212" continuedAt="Text_46b341a9e8d644a8b79909b44816a32213"><ix:continuation id="Text_929536832613473d8746e4525403255a2" continuedAt="Text_929536832613473d8746e4525403255a3">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Basic net income per share</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32213" continuedAt="Text_46b341a9e8d644a8b79909b44816a32214"><ix:continuation id="Text_929536832613473d8746e4525403255a3" continuedAt="Text_929536832613473d8746e4525403255a4">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32214" continuedAt="Text_46b341a9e8d644a8b79909b44816a32215"><ix:continuation id="Text_929536832613473d8746e4525403255a4" continuedAt="Text_929536832613473d8746e4525403255a5">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We compute basic net income per share by dividing the total net income attributable to our common stockholders by our weighted-average number of common shares outstanding during the period.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32215" continuedAt="Text_46b341a9e8d644a8b79909b44816a32216"><ix:continuation id="Text_929536832613473d8746e4525403255a5" continuedAt="Text_929536832613473d8746e4525403255a6">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32216" continuedAt="Text_46b341a9e8d644a8b79909b44816a32217"><ix:continuation id="Text_929536832613473d8746e4525403255a6" continuedAt="Text_929536832613473d8746e4525403255a7">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The calculation of total net income attributable to our common stockholders for each year considered our net income for Ionis on a stand-alone basis plus our share of Akcea&#8217;s net income (loss) for the period. To calculate the portion of Akcea&#8217;s net income (loss) attributable to our ownership for each year, we multiplied Akcea&#8217;s income (loss) per share by the weighted average shares we owned in Akcea during the period. As a result of this calculation, our total net income available to Ionis common stockholders for the calculation of net income per share is different than net income attributable to Ionis Pharmaceuticals, Inc. common stockholders in our consolidated statements of operations for each year.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32217" continuedAt="Text_46b341a9e8d644a8b79909b44816a32218"><ix:continuation id="Text_929536832613473d8746e4525403255a7" continuedAt="Text_929536832613473d8746e4525403255a8">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32218" continuedAt="Text_46b341a9e8d644a8b79909b44816a32219"><ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" id="Text_c28282748cc547e59916832cd89fb4c8" contextRef="c20190101to20191231" escape="true" continuedAt="Text_d409dd760a2042a68fb7c5fa948352171"><ix:continuation id="Text_929536832613473d8746e4525403255a8" continuedAt="Text_929536832613473d8746e4525403255a9">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our basic net income per share, was calculated as follows (in thousands, except per share amounts):</div>
</ix:continuation></ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32219" continuedAt="Text_46b341a9e8d644a8b79909b44816a32220"><ix:continuation id="Text_d409dd760a2042a68fb7c5fa948352171" continuedAt="Text_d409dd760a2042a68fb7c5fa948352172"><ix:continuation id="Text_929536832613473d8746e4525403255a9" continuedAt="Text_929536832613473d8746e4525403255a10">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32220" continuedAt="Text_46b341a9e8d644a8b79909b44816a32221"><ix:continuation id="Text_d409dd760a2042a68fb7c5fa948352172" continuedAt="Text_d409dd760a2042a68fb7c5fa948352173"><ix:continuation id="Text_929536832613473d8746e4525403255a10" continuedAt="Text_929536832613473d8746e4525403255a11">
<table cellpadding="0" cellspacing="0" id="z104b454b266445eaac9eed834835145f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2019</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Portion of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Income</span></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:WeightedAverageNumberOfSharesOwnedInSubsidiary" id="Fact_15287ca1da7a4e18a9ee8972a4823021" contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">70,100</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_9814ec36723d489dbd4e4c74f8b91687" contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">0.49</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_343d7b1e02e240df812b3efbadfc402c" contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">34,073</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net income attributable to our ownership</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_9de17ffd9b104577a708d4d8f1509e01" contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">34,073</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_5c7b0518904e47418483341709852d64" contextRef="c20190101to20191231_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">262,490</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_7e491f4aadd94c68abfd6a19ddac90ad" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">296,563</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_683ae782f7fe4a82918f22dea02d9d01" contextRef="c20190101to20191231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">139,998</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_025896a7df2b41838c7449c76fed8d09" contextRef="c20190101to20191231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">2.12</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32221" continuedAt="Text_46b341a9e8d644a8b79909b44816a32222"><ix:continuation id="Text_d409dd760a2042a68fb7c5fa948352173" continuedAt="Text_d409dd760a2042a68fb7c5fa948352174"><ix:continuation id="Text_929536832613473d8746e4525403255a11" continuedAt="Text_929536832613473d8746e4525403255a12">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32222" continuedAt="Text_46b341a9e8d644a8b79909b44816a32223"><ix:continuation id="Text_d409dd760a2042a68fb7c5fa948352174" continuedAt="Text_d409dd760a2042a68fb7c5fa948352175"><ix:continuation id="Text_929536832613473d8746e4525403255a12" continuedAt="Text_929536832613473d8746e4525403255a13">
<table cellpadding="0" cellspacing="0" id="zfe21e6fd0158439f854dad365e54a58d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2018</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Portion of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:WeightedAverageNumberOfSharesOwnedInSubsidiary" id="Fact_940b4a03fe6f4389949b2cdbec92c4e0" contextRef="c20180101to20181231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">59,812</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_0332420a922344dbb39388360df6e41d" contextRef="c20180101to20181231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember" unitRef="U004" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">2.74</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_16fac149fc8a42eb8215243e61e0851d" contextRef="c20180101to20181231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">163,938</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_3ee347bdde47445b90efca086e479676" contextRef="c20180101to20181231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">163,938</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_e9ea76d10eaf4d52892351487043b0f0" contextRef="c20180101to20181231_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">440,806</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_cb1ed57e97fa41f88c3b82ffabc4e03c" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">276,868</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_30220b3f42ac486f9c7b81691c93d62b" contextRef="c20180101to20181231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">132,320</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_94e75adb0d50429696d61fb3a1db7bb4" contextRef="c20180101to20181231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">2.09</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32223" continuedAt="Text_46b341a9e8d644a8b79909b44816a32224"><ix:continuation id="Text_d409dd760a2042a68fb7c5fa948352175" continuedAt="Text_d409dd760a2042a68fb7c5fa948352176"><ix:continuation id="Text_929536832613473d8746e4525403255a13" continuedAt="Text_929536832613473d8746e4525403255a14">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>10</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32224" continuedAt="Text_46b341a9e8d644a8b79909b44816a32225"><ix:continuation id="Text_d409dd760a2042a68fb7c5fa948352176" continuedAt="Text_d409dd760a2042a68fb7c5fa948352177"><ix:continuation id="Text_929536832613473d8746e4525403255a14" continuedAt="Text_929536832613473d8746e4525403255a15">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We calculated our basic net income per share for 2017 as follows (in thousands, except per share amounts):</div>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32225" continuedAt="Text_46b341a9e8d644a8b79909b44816a32226"><ix:continuation id="Text_d409dd760a2042a68fb7c5fa948352177" continuedAt="Text_d409dd760a2042a68fb7c5fa948352178"><ix:continuation id="Text_929536832613473d8746e4525403255a15" continuedAt="Text_929536832613473d8746e4525403255a16">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32226" continuedAt="Text_46b341a9e8d644a8b79909b44816a32227"><ix:continuation id="Text_d409dd760a2042a68fb7c5fa948352178"><ix:continuation id="Text_929536832613473d8746e4525403255a16" continuedAt="Text_929536832613473d8746e4525403255a17">
<table cellpadding="0" cellspacing="0" id="z7f02aeb560ee40bd982c44713ab0a2ac" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2017</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Portion of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:WeightedAverageNumberOfSharesOwnedInSubsidiary" id="Fact_7f3e78d8ab30451e8241ca0e38eee153" contextRef="c20170101to20171231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">20,669</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_c8212e5603a14371bc8cfbb9954ade3f" contextRef="c20170101to20171231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember" unitRef="U004" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">3.08</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_f558eef64fe94b50b7701b347d41b454" contextRef="c20170101to20171231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">63,638</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Preferred shares</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:WeightedAverageNumberOfSharesOwnedInSubsidiary" id="Fact_4f96c03ae3ce4ff787733bc0b5ec5544" contextRef="c20170101to20171231_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">15,748</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_746a8867994d42d29ca41bf1fef558d7" contextRef="c20170101to20171231_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="U004" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">1.80</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_63e92a44c759484cb7272d40998b6eeb" contextRef="c20170101to20171231_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,346</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_2ce538bf55324fddb82784f3b5823d97" contextRef="c20170101to20171231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">91,984</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_baffdf3fbb9c415ab2b08db707345d3f" contextRef="c20170101to20171231_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">110,776</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_3e2e4d46fb4d4c759780855b07483e3f" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">18,792</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_b84b45d5c04845a4b15143efc6c0dec6" contextRef="c20170101to20171231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">124,016</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_aa49435657a645e0abbdf698dd72f613" contextRef="c20170101to20171231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">0.15</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32227" continuedAt="Text_46b341a9e8d644a8b79909b44816a32228"><ix:continuation id="Text_929536832613473d8746e4525403255a17" continuedAt="Text_929536832613473d8746e4525403255a18">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32228" continuedAt="Text_46b341a9e8d644a8b79909b44816a32229"><ix:continuation id="Text_929536832613473d8746e4525403255a18" continuedAt="Text_929536832613473d8746e4525403255a19">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Prior to Akcea&#8217;s IPO in July 2017, we owned Akcea series A convertible preferred stock, which included a <span style="-sec-ix-hidden:Fact_814732dbfffb4dbbb487265b1d09e7b7">six percent</span> cumulative dividend. Upon completion of Akcea&#8217;s IPO in July 2017, our preferred stock was <ix:nonNumeric name="us-gaap:ConvertiblePreferredStockTermsOfConversion" id="Fact_ecb896b7a1c74750abf1bb5e217f0fe8" contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_ConvertiblePreferredStockMember">converted into common stock on a 1:1 basis</ix:nonNumeric>. The preferred stock dividend was not paid at the IPO because the IPO was not a liquidation event or a change in control. During 2017, Akcea used a two-class method to compute its net loss per share because it had both common and preferred shares outstanding during the periods. The two-class method required Akcea to calculate its net loss per share for each class of stock by dividing total distributable losses applicable to preferred and common stock, including the six percent cumulative dividend contractually due to series A convertible preferred shareholders, by the weighted-average of preferred and common shares outstanding during the requisite period. Since Akcea used the two-class method, accounting rules required us to include our portion of Akcea&#8217;s net loss per share for both Akcea&#8217;s common and preferred shares that we owned in our calculation of basic and diluted net income per share for the year ended December 31, 2017.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32229" continuedAt="Text_46b341a9e8d644a8b79909b44816a32230"><ix:continuation id="Text_929536832613473d8746e4525403255a19" continuedAt="Text_929536832613473d8746e4525403255a20">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32230" continuedAt="Text_46b341a9e8d644a8b79909b44816a32231"><ix:continuation id="Text_929536832613473d8746e4525403255a20" continuedAt="Text_929536832613473d8746e4525403255a21">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Diluted net income per share</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32231" continuedAt="Text_46b341a9e8d644a8b79909b44816a32232"><ix:continuation id="Text_929536832613473d8746e4525403255a21" continuedAt="Text_929536832613473d8746e4525403255a22">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32232" continuedAt="Text_46b341a9e8d644a8b79909b44816a32233"><ix:continuation id="Text_929536832613473d8746e4525403255a22" continuedAt="Text_929536832613473d8746e4525403255a23"><ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Text_c5b95a77a3674760bd9dde0a5ba42e29" contextRef="c20190101to20191231" escape="true" continuedAt="Text_2522603c4aa644d8a65cd49bea3afcc31">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We calculated our diluted net income per share as follows <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(in thousands except per share amounts):</span></div>
</ix:nonNumeric></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32233" continuedAt="Text_46b341a9e8d644a8b79909b44816a32234"><ix:continuation id="Text_929536832613473d8746e4525403255a23" continuedAt="Text_929536832613473d8746e4525403255a24"><ix:continuation id="Text_2522603c4aa644d8a65cd49bea3afcc31" continuedAt="Text_2522603c4aa644d8a65cd49bea3afcc32">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32234" continuedAt="Text_46b341a9e8d644a8b79909b44816a32235"><ix:continuation id="Text_929536832613473d8746e4525403255a24" continuedAt="Text_929536832613473d8746e4525403255a25"><ix:continuation id="Text_2522603c4aa644d8a65cd49bea3afcc32" continuedAt="Text_2522603c4aa644d8a65cd49bea3afcc33">
<table cellpadding="0" cellspacing="0" id="zb0e4b49c2e274df0b9950bc8e8004fbd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2019</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_928ebff2305241a187a9702bd859ffdc" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">296,563</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_8c42ec6f83704cb0b72cd914336afac6" contextRef="c20190101to20191231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">139,998</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_db74783fdc8d4155ba634e6a502e8c66" contextRef="c20190101to20191231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">2.12</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -8.9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" id="Fact_fb4b7906279d467fb31bf97c42314d00" contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">2,090</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: 0.1pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" id="Fact_6fda8655aebe48fcb0075da625a15701" contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">766</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our Employee Stock Purchase Plan</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" id="Fact_c0b638de467b4fa3899ed822f610c542" contextRef="c20190101to20191231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">18</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" id="Fact_48a3337692f14bbdad665c341beadbc3" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">296,563</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_afcf6e9e7dd24cc4870bf41943d9e76d" contextRef="c20190101to20191231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">142,872</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_1c2916338e004b83b9a89b2346d1a77d" contextRef="c20190101to20191231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">2.08</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32235" continuedAt="Text_46b341a9e8d644a8b79909b44816a32236"><ix:continuation id="Text_929536832613473d8746e4525403255a25" continuedAt="Text_929536832613473d8746e4525403255a26"><ix:continuation id="Text_2522603c4aa644d8a65cd49bea3afcc33" continuedAt="Text_2522603c4aa644d8a65cd49bea3afcc34">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32236" continuedAt="Text_46b341a9e8d644a8b79909b44816a32237"><ix:continuation id="Text_929536832613473d8746e4525403255a26" continuedAt="Text_929536832613473d8746e4525403255a27"><ix:continuation id="Text_2522603c4aa644d8a65cd49bea3afcc34" continuedAt="Text_2522603c4aa644d8a65cd49bea3afcc35">
<table cellpadding="0" cellspacing="0" id="z01b775cd675848508a1d52bc1c4cff37" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2018</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_a26ab11884634d9d8cbfbe2f762fd122" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">276,868</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_82557aeb9c3c4b78bc24813f9172640c" contextRef="c20180101to20181231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">132,320</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_5f9331686a4747708db2903e2436826a" contextRef="c20180101to20181231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">2.09</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -8.9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" id="Fact_54681ee48ba34ad68a5424d80a225e34" contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">1,216</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: 0.1pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" id="Fact_91caa39b33724bef87c48867cfa27c77" contextRef="c20180101to20181231_AwardTypeAxis_RestrictedStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">514</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our Employee Stock Purchase Plan</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" id="Fact_63435561706d411bada0a6048a8b479f" contextRef="c20180101to20181231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" id="Fact_a61d1113740f4208a4f729d24f0e5aa6" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">276,868</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_3fde4743a5254c2e9d1db7eaa0ba1e5d" contextRef="c20180101to20181231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">134,056</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_c2d9fb4d375f42e6a6330aada4be5e62" contextRef="c20180101to20181231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">2.07</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32237" continuedAt="Text_46b341a9e8d644a8b79909b44816a32238"><ix:continuation id="Text_929536832613473d8746e4525403255a27" continuedAt="Text_929536832613473d8746e4525403255a28"><ix:continuation id="Text_2522603c4aa644d8a65cd49bea3afcc35" continuedAt="Text_2522603c4aa644d8a65cd49bea3afcc36">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32238" continuedAt="Text_46b341a9e8d644a8b79909b44816a32239"><ix:continuation id="Text_929536832613473d8746e4525403255a28" continuedAt="Text_929536832613473d8746e4525403255a29"><ix:continuation id="Text_2522603c4aa644d8a65cd49bea3afcc36">
<table cellpadding="0" cellspacing="0" id="zd8deeaecb9c64cd89c8fc8806b7a193d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2017</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_7770bc95f08f4485a43bbc0a7ccb1d48" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">18,792</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_16f6d335b2e94b91842456b8650b64e7" contextRef="c20170101to20171231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">124,016</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_dac2ceb88209472f9ee8b0435b40e522" contextRef="c20170101to20171231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">0.15</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -8.9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" id="Fact_2bdc136d0eae478587248dd71970987b" contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">1,619</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: 0.1pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" id="Fact_16f130a3cbc4456fb8a66929f97a1363" contextRef="c20170101to20171231_AwardTypeAxis_RestrictedStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">459</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our Employee Stock Purchase Plan</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" id="Fact_b5b936017ef040e4a73ecb6f10bcccf2" contextRef="c20170101to20171231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">4</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" id="Fact_19cdca1d19fd4b0aaa3c90ca895f3626" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">18,792</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_8f4199f02a7c4375b1908349b2e11384" contextRef="c20170101to20171231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">126,098</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_6c4277c20e034a4c9fdf6030aba39c8c" contextRef="c20170101to20171231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">0.15</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32239" continuedAt="Text_46b341a9e8d644a8b79909b44816a32240"><ix:continuation id="Text_929536832613473d8746e4525403255a29" continuedAt="Text_929536832613473d8746e4525403255a30">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>11</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32240" continuedAt="Text_46b341a9e8d644a8b79909b44816a32241"><ix:continuation id="Text_929536832613473d8746e4525403255a30">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For each year presented, the calculation excluded our convertible senior notes because the effect on diluted earnings per share was anti-dilutive.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32241" continuedAt="Text_46b341a9e8d644a8b79909b44816a32242">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32242" continuedAt="Text_46b341a9e8d644a8b79909b44816a32243"><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Text_a7941b74efeb4884837e75cd6f25191b" contextRef="c20190101to20191231" escape="true" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc191">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Revenue Recognition</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32243" continuedAt="Text_46b341a9e8d644a8b79909b44816a32244"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc191" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc192">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32244" continuedAt="Text_46b341a9e8d644a8b79909b44816a32245"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc192" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc193">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Our Revenue Sources</span></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32245" continuedAt="Text_46b341a9e8d644a8b79909b44816a32246"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc193" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc194">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32246" continuedAt="Text_46b341a9e8d644a8b79909b44816a32247"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc194" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc195">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We generally recognize revenue when we have satisfied all contractual obligations and are reasonably assured of collecting the resulting receivable. We are often entitled to bill our customers and receive payment from our customers in advance of recognizing the revenue. In the instances in which we have received payment from our customers in advance of recognizing revenue, we include the amounts in deferred revenue on our consolidated balance sheet.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32247" continuedAt="Text_46b341a9e8d644a8b79909b44816a32248"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc195" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc196">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32248" continuedAt="Text_46b341a9e8d644a8b79909b44816a32249"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc196" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc197">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Commercial Revenue: SPINRAZA royalties and Licensing and other royalty revenue</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32249" continuedAt="Text_46b341a9e8d644a8b79909b44816a32250"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc197" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc198">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32250" continuedAt="Text_46b341a9e8d644a8b79909b44816a32251"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc198" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc199">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We earn commercial revenue primarily in the form of royalty payments on net sales of SPINRAZA. We will also recognize as commercial revenue future sales milestone payments and royalties we earn under our partnerships.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32251" continuedAt="Text_46b341a9e8d644a8b79909b44816a32252"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc199" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1910">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32252" continuedAt="Text_46b341a9e8d644a8b79909b44816a32253"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1910" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1911">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Commercial Revenue: Product sales, net</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32253" continuedAt="Text_46b341a9e8d644a8b79909b44816a32254"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1911" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1912">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32254" continuedAt="Text_46b341a9e8d644a8b79909b44816a32255"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1912" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1913">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We added product sales from TEGSEDI to our commercial revenue in the fourth quarter of 2018 and we added product sales from WAYLIVRA to our commercial revenue in the third quarter of 2019. </span>In the U.S., we distribute TEGSEDI through an exclusive distribution agreement with a third-party logistics company, or 3PL, that takes title to TEGSEDI. The 3PL is our sole customer in the U.S. The 3PL then distributes TEGSEDI to a specialty pharmacy and a specialty distributor, which we collectively refer to as wholesalers, who then distribute TEGSEDI to health care providers and patients. In Europe, prior to the third quarter of 2019 we distributed TEGSEDI through a non-exclusive distribution model with a 3PL that took title to TEGSEDI. The 3PL was our sole customer in Europe. The 3PL in Europe then distributed TEGSEDI to hospitals and pharmacies. In the third quarter of 2019, we entered into a distribution arrangement with a 3PL and began to sell both TEGSEDI and WAYLIVRA directly to hospitals and pharmacies in Europe.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32255" continuedAt="Text_46b341a9e8d644a8b79909b44816a32256"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1913" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1914">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32256" continuedAt="Text_46b341a9e8d644a8b79909b44816a32257"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1914" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1915">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Research and development revenue under collaborative agreements</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32257" continuedAt="Text_46b341a9e8d644a8b79909b44816a32258"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1915" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1916">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32258" continuedAt="Text_46b341a9e8d644a8b79909b44816a32259"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1916" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1917">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We often enter into collaboration agreements to license and sell our technology on an exclusive or non-exclusive basis. Our collaboration agreements typically contain multiple elements, or performance obligations, including technology licenses or options to obtain technology licenses, research and development, or R&amp;D, services, and manufacturing services.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32259" continuedAt="Text_46b341a9e8d644a8b79909b44816a32260"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1917" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1918">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32260" continuedAt="Text_46b341a9e8d644a8b79909b44816a32261"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1918" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1919">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our collaboration agreements are detailed in Note 6, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Collaborative Arrangements and Licensing Agreements.</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Under each collaboration note we discuss our specific revenue recognition conclusions, including our significant performance obligations under each collaboration.</span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32261" continuedAt="Text_46b341a9e8d644a8b79909b44816a32262"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1919" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1920">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32262" continuedAt="Text_46b341a9e8d644a8b79909b44816a32263"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1920" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1921">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Steps to Recognize Revenue</span></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32263" continuedAt="Text_46b341a9e8d644a8b79909b44816a32264"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1921" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1922">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32264" continuedAt="Text_46b341a9e8d644a8b79909b44816a32265"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1922" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1923">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We use a five-step process to determine the amount of revenue we should recognize and when we should recognize it. The five step process is as follows:</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32265" continuedAt="Text_46b341a9e8d644a8b79909b44816a32266"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1923" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1924">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="text-align: left;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1924" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1925"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32266" continuedAt="Text_46b341a9e8d644a8b79909b44816a32267">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zb9f70b6bc634422f82831b9476ae8444">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">1.</td>
    <td style="width: auto; vertical-align: top; text-align: left;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Identify the contract</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32267" continuedAt="Text_46b341a9e8d644a8b79909b44816a32268"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1925" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1926">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32268" continuedAt="Text_46b341a9e8d644a8b79909b44816a32269"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1926" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1927">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Accounting rules require us to first determine if we have a contract with our partner, including confirming that we have met each of the following criteria:</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32269" continuedAt="Text_46b341a9e8d644a8b79909b44816a32270"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1927" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1928">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="text-align: left;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1928" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1929"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32270" continuedAt="Text_46b341a9e8d644a8b79909b44816a32271">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z32abea7f3b454dedb5d275fcd69bfc41">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: left;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We and our partner approved the contract and we are both committed to perform our obligations;</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div style="text-align: left;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1929" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1930"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32271" continuedAt="Text_46b341a9e8d644a8b79909b44816a32272">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z2fef2cbf4007441595d4245add81d46d">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: left;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have identified our rights, our partner&#8217;s rights and the payment terms;</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1930" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1931"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32272" continuedAt="Text_46b341a9e8d644a8b79909b44816a32273">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="ze8401d5278b84ee1953ba4283b1f9851">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have concluded that the contract has commercial substance, meaning that the risk, timing, or amount of our future cash flows is expected to change as a result of the contract; and</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div style="text-align: left;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1931" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1932"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32273" continuedAt="Text_46b341a9e8d644a8b79909b44816a32274">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z7c8deb873be94db28e11c93fd5b094f0">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: left;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We believe collectability is probable. </div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32274" continuedAt="Text_46b341a9e8d644a8b79909b44816a32275"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1932" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1933">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: -18pt; margin-left: 54pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="text-align: left;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1933" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1934"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32275" continuedAt="Text_46b341a9e8d644a8b79909b44816a32276">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zac78659984944d66a7d6f7f05a5a6181">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"><span style="background-color: #FFFFFF;">2.</span></td>
    <td style="width: auto; vertical-align: top; text-align: left;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"><span style="background-color: #FFFFFF; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Identify the performance obligations</span></div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32276" continuedAt="Text_46b341a9e8d644a8b79909b44816a32277"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1934" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1935">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32277" continuedAt="Text_46b341a9e8d644a8b79909b44816a32278"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1935" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1936">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We next identify the distinct goods and services we are required to provide under the contract. Accounting rules refer to these as our performance obligations. We typically have only <ix:nonFraction name="ions:RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract" id="Fact_916eaa51598549fa924e925f66d1a329" contextRef="c20190101to20191231" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> performance obligation at the inception of a contract, which is to perform R&amp;D services.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32278" continuedAt="Text_46b341a9e8d644a8b79909b44816a32279"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1936" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1937">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>12</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32279" continuedAt="Text_46b341a9e8d644a8b79909b44816a32280"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1937" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1938">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Often times we enter into a collaboration agreement in which we provide our partner with an option to license a medicine in the future. We may also provide our partner with an option to request that we provide additional goods or services in the future, such as active pharmaceutical ingredient, or API. We evaluate whether these options are material rights at the inception of the agreement. If we determine an option is a material right, we will consider the option a separate performance obligation. Historically, we have concluded that the options we grant to license a medicine in the future or to provide additional goods and services as requested by our partner are not material rights. These items are contingent upon future events that may not occur. When a partner exercises its option to license a medicine or requests additional goods or services, then we identify a new performance obligation for that item.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32280" continuedAt="Text_46b341a9e8d644a8b79909b44816a32281"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1938" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1939">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32281" continuedAt="Text_46b341a9e8d644a8b79909b44816a32282"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1939" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1940">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In some cases, we deliver a license at the start of an agreement. If we determine that our partner has full use of the license and we do not have any additional material performance obligations related to the license after delivery, then we consider the license to be a separate performance obligation.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32282" continuedAt="Text_46b341a9e8d644a8b79909b44816a32283"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1940" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1941">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1941" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1942"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32283" continuedAt="Text_46b341a9e8d644a8b79909b44816a32284">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zf1f446d282dd4e1b832e3c09c5f82c88">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">3.</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Determine the transaction price</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32284" continuedAt="Text_46b341a9e8d644a8b79909b44816a32285"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1942" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1943">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32285" continuedAt="Text_46b341a9e8d644a8b79909b44816a32286"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1943" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1944">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We then determine the transaction price by reviewing the amount of consideration we are eligible to earn under the collaboration agreement, including any variable consideration. Under our collaboration agreements, consideration typically includes fixed consideration in the form of an upfront payment and variable consideration in the form of potential milestone payments, license fees and royalties. At the start of an agreement, our transaction price usually consists of only the upfront payment. We do not typically include any payments we may receive in the future in our initial transaction price because the payments are not probable and are contingent on certain future events. We reassess the total transaction price at each reporting period to determine if we should include additional payments in the transaction price.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32286" continuedAt="Text_46b341a9e8d644a8b79909b44816a32287"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1944" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1945">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32287" continuedAt="Text_46b341a9e8d644a8b79909b44816a32288"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1945" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1946">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Milestone payments are our most common type of variable consideration. We recognize milestone payments using the most likely amount method because we will either receive the milestone payment or we will not, which makes the potential milestone payment a binary event. The most likely amount method requires us to determine the likelihood of earning the milestone payment. We include a milestone payment in the transaction price once it is probable we will achieve the milestone event. Most often, we do not consider our milestone payments probable until we or our partner achieve the milestone event because the majority of our milestone payments are contingent upon events that are not within our control and are usually based on scientific progress. For example, in the fourth quarter of 2019, we earned a $<ix:nonFraction name="ions:UpfrontPaymentReceived" id="Fact_e7341a58c10044d89181f318ab768870" contextRef="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million milestone payment from AstraZeneca when AstraZeneca initiated a Phase 1 trial for ION839. We did not consider the milestone payments probable until AstraZeneca achieved the milestone event because the initiation of the Phase 1 trial was a contingent event that was not within our control. We recognized the milestone payments in full in the period the milestone event was achieved because we did not have any remaining performance obligations related to the milestone payment.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32288" continuedAt="Text_46b341a9e8d644a8b79909b44816a32289"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1946" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1947">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1947" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1948"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32289" continuedAt="Text_46b341a9e8d644a8b79909b44816a32290">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z61f3f8aec88b4866a2bbc6540840c7b9">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">4.</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Allocate the transaction price</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32290" continuedAt="Text_46b341a9e8d644a8b79909b44816a32291"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1948" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1949">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32291" continuedAt="Text_46b341a9e8d644a8b79909b44816a32292"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1949" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1950">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Next, we allocate the transaction price to each of our performance obligations. When we have to allocate the transaction price to more than one performance obligation, we make estimates of the relative stand-alone selling price of each performance obligation because we do not typically sell our goods or services on a stand-alone basis. We then allocate the transaction price to each performance obligation based on the relative stand-alone selling price.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32292" continuedAt="Text_46b341a9e8d644a8b79909b44816a32293"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1950" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1951">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32293" continuedAt="Text_46b341a9e8d644a8b79909b44816a32294"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1951" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1952">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We may engage a third party, independent valuation specialist to assist us with determining a stand-alone selling price for collaborations in which we deliver a license at the start of an agreement. We estimate the stand-alone selling price of these licenses using valuation methodologies, such as the relief from royalty method. Under this method, we estimate the amount of income, net of taxes, for the license. We then discount the projected income to present value. The significant inputs we use to determine the projected income of a license could include:</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32294" continuedAt="Text_46b341a9e8d644a8b79909b44816a32295"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1952" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1953">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1953" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1954"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32295" continuedAt="Text_46b341a9e8d644a8b79909b44816a32296">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zd0332dc311ad49d5aebb0b0dcec49da1">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Estimated future product sales;</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1954" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1955"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32296" continuedAt="Text_46b341a9e8d644a8b79909b44816a32297">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zbafbea8c82a44de19538caf8c4d34c17">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Estimated royalties on future product sales;</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1955" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1956"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32297" continuedAt="Text_46b341a9e8d644a8b79909b44816a32298">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zc5914eb350eb4288913df6b658f90445">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Contractual milestone payments;</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1956" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1957"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32298" continuedAt="Text_46b341a9e8d644a8b79909b44816a32299">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z23f53850cb2e499c87cc78fc51b878db">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expenses we expect to incur;</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1957" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1958"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a32299" continuedAt="Text_46b341a9e8d644a8b79909b44816a322100">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zba5b48ea375f49caad917f1f137ff6cf">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income taxes; and</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1958" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1959"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322100" continuedAt="Text_46b341a9e8d644a8b79909b44816a322101">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zc80b99fe0b894aecb56282f28ddea0a9">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A discount rate.</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322101" continuedAt="Text_46b341a9e8d644a8b79909b44816a322102"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1959" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1960">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322102" continuedAt="Text_46b341a9e8d644a8b79909b44816a322103"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1960" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1961">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We typically estimate the selling price of R&amp;D services by using our internal estimates of the cost to perform the specific services. The significant inputs we use to determine the selling price of our R&amp;D services include:</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322103" continuedAt="Text_46b341a9e8d644a8b79909b44816a322104"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1961" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1962">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1962" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1963"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322104" continuedAt="Text_46b341a9e8d644a8b79909b44816a322105">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z2a27bbd1916f4ee3b3441ed762a2c2b3">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The number of internal hours we estimate we will spend performing these services;</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1963" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1964"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322105" continuedAt="Text_46b341a9e8d644a8b79909b44816a322106">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z3d50f6d0709c44f89b5262ca45319fbe">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The estimated cost of work we will perform;</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1964" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1965"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322106" continuedAt="Text_46b341a9e8d644a8b79909b44816a322107">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zf1df7de1efb647f3a758705c8216c76d">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The estimated cost of work that we will contract with third parties to perform; and</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1965" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1966"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322107" continuedAt="Text_46b341a9e8d644a8b79909b44816a322108">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zcc18420c84464778ad67ecdb5155e530">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The estimated cost of API we will use. </div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322108" continuedAt="Text_46b341a9e8d644a8b79909b44816a322109"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1966" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1967">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>13</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322109" continuedAt="Text_46b341a9e8d644a8b79909b44816a322110"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1967" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1968">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For purposes of determining the stand-alone selling price of the R&amp;D services we perform and the API we will deliver, accounting guidance requires us to include a markup for a reasonable profit margin.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322110" continuedAt="Text_46b341a9e8d644a8b79909b44816a322111"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1968" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1969">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322111" continuedAt="Text_46b341a9e8d644a8b79909b44816a322112"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1969" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1970">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We do not reallocate the transaction price after the start of an agreement to reflect subsequent changes in stand-alone selling prices.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322112" continuedAt="Text_46b341a9e8d644a8b79909b44816a322113"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1970" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1971">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1971" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1972"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322113" continuedAt="Text_46b341a9e8d644a8b79909b44816a322114">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zaa2a29a440094a6385db6db34fe05178">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">5.</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Recognize revenue</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322114" continuedAt="Text_46b341a9e8d644a8b79909b44816a322115"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1972" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1973">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -54pt; margin-left: 54pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322115" continuedAt="Text_46b341a9e8d644a8b79909b44816a322116"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1973" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1974">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We recognize revenue in one of two ways, over time or at a point in time. We recognize revenue over time when we are executing on our performance obligation over time and our partner receives benefit over time. For example, we recognize revenue over time when we provide R&amp;D services. We recognize revenue at a point in time when our partner receives full use of an item at a specific point in time. For example, we recognize revenue at a point in time when we deliver a license or API to a partner.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322116" continuedAt="Text_46b341a9e8d644a8b79909b44816a322117"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1974" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1975">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322117" continuedAt="Text_46b341a9e8d644a8b79909b44816a322118"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1975" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1976">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For R&amp;D services that we recognize over time, we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time we estimate it will take us to complete the activities, or costs we incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates and use significant judgement. If our estimates or judgements <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods. For example, </span>in the third quarter of 2019, we updated our estimate of the total effort we expected to expend to satisfy our performance obligation under our<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> 2013 Strategic Neurology collaboration with Biogen</span>. As of September 30, 2019, we had completed a<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> significant portion of the research and development services. We expect to complete the remainder of our services in 2020. As a result of our change in estimate, in the third quarter of 2019, we recorded a cumulative catch up adjustment of $</span><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_35fadf63788d44d1bb8722e81096991c" contextRef="c20190701to20190930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" unitRef="U001" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">16.5</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million to decrease revenue. Refer to Note 7, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Collaborative Arrangements and Licensing Agreements</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, for further discussion of the cumulative catch up adjustment we made.</span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322118" continuedAt="Text_46b341a9e8d644a8b79909b44816a322119"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1976" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1977">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322119" continuedAt="Text_46b341a9e8d644a8b79909b44816a322120"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1977" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1978">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following are examples of when we typically recognize revenue based on the types of payments we receive.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322120" continuedAt="Text_46b341a9e8d644a8b79909b44816a322121"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1978" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1979">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322121" continuedAt="Text_46b341a9e8d644a8b79909b44816a322122"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1979" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1980">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Commercial Revenue: SPINRAZA royalties and Licensing and other royalty revenue</span></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322122" continuedAt="Text_46b341a9e8d644a8b79909b44816a322123"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1980" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1981">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322123" continuedAt="Text_46b341a9e8d644a8b79909b44816a322124"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1981" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1982">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We recognize royalty revenue, including royalties from SPINRAZA sales, in the period in which the counterparty sells the related product and recognizes the related revenue, which in certain cases may require us to estimate our royalty revenue.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322124" continuedAt="Text_46b341a9e8d644a8b79909b44816a322125"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1982" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1983">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322125" continuedAt="Text_46b341a9e8d644a8b79909b44816a322126"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1983" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1984">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Commercial Revenue: Product sales, net</span></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322126" continuedAt="Text_46b341a9e8d644a8b79909b44816a322127"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1984" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1985">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322127" continuedAt="Text_46b341a9e8d644a8b79909b44816a322128"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1985" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1986">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We recognize product sales in the period </span>when our customer obtains control of our products, which occurs at a point in time upon transfer of title to the customer. We classify payments to customers or other parties in the distribution channel for services that are distinct and priced at fair value as selling, general and administrative expenses in our consolidated statements of operations. Otherwise, payments to customers or other parties in the distribution channel that do not meet those criteria are classified as a reduction of revenue, as discussed further below. We exclude from revenues taxes collected from customers relating to product sales and remitted to governmental authorities.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322128" continuedAt="Text_46b341a9e8d644a8b79909b44816a322129"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1986" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1987">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322129" continuedAt="Text_46b341a9e8d644a8b79909b44816a322130"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1987" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1988">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Reserves for Product sales</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322130" continuedAt="Text_46b341a9e8d644a8b79909b44816a322131"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1988" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1989">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322131" continuedAt="Text_46b341a9e8d644a8b79909b44816a322132"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1989" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1990">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We record product sales at our net sales price, or transaction price. We include in our transaction price estimated reserves for discounts, returns, chargebacks, rebates, co-pay assistance and other allowances that we offer within contracts between us and our customers, wholesalers, health care providers and other indirect customers. We estimate our reserves using the amounts we have earned or what we can claim on the associated sales. We classify our reserves as a reduction of accounts receivable when we are not required to make a payment or as a current liability when we are required to make a payment. In certain cases, our estimates include a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, our reserves reflect our best estimates under the terms of our respective contracts. When calculating our reserves and related product sales, we only recognize amounts to the extent that we consider it probable that we would not have to reverse in a future period a significant amount of the cumulative sales we previously recognized. The actual amounts we receive may ultimately differ from our reserve estimates. If actual amounts in the future vary from our estimates, we will adjust these estimates, which would affect our net product sales in the respective period.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322132" continuedAt="Text_46b341a9e8d644a8b79909b44816a322133"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1990" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1991">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>14</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322133" continuedAt="Text_46b341a9e8d644a8b79909b44816a322134"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1991" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1992">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following are the components of variable consideration related to product sales:</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322134" continuedAt="Text_46b341a9e8d644a8b79909b44816a322135"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1992" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1993">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322135" continuedAt="Text_46b341a9e8d644a8b79909b44816a322136"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1993" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1994">
<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Chargebacks: </span>In the U.S., we estimate obligations resulting from contractual commitments with the government and other entities to sell products to qualified healthcare providers at prices lower than the list prices charged to our U.S. customer. Our U.S. customer charges us for the difference between what it pays for the product and the selling price to the qualified healthcare providers. We also estimate the amount of chargebacks related to our estimated product remaining in the distribution channel at the end of the reporting period that we expect our customer to sell to healthcare providers in future periods. We record these reserves as an accrued liability on our consolidated balance sheet for the chargebacks related to product sales to our U.S. customer during the reporting period.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322136" continuedAt="Text_46b341a9e8d644a8b79909b44816a322137"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1994" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1995">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322137" continuedAt="Text_46b341a9e8d644a8b79909b44816a322138"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1995" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1996">
<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Government rebates</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">: We are subject t</span>o discount obligations under government programs, including Medicaid and Medicare programs in the U.S. and we record reserves for government rebates based on statutory discount rates and estimated utilization. We estimate Medicaid and Medicare rebates based on a range of possible outcomes that are probability-weighted for the estimated payer mix. We record these reserves as an accrued liability on our consolidated balance sheet with a corresponding offset reducing our product sales in the same period we recognize the related sale. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program. On a quarterly basis, we update our estimates and record any adjustments in the period that we identify the adjustments.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322138" continuedAt="Text_46b341a9e8d644a8b79909b44816a322139"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1996" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1997">
<div style="text-align: justify; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322139" continuedAt="Text_46b341a9e8d644a8b79909b44816a322140"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1997" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1998">
<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Managed care rebates: </span>We are subject to rebates in connection with a value-based agreement with one of our commercial payer&#8217;s. We record these rebates as an accrual on our consolidated balance sheet in the same period we recognize the related revenue. We estimate our managed care rebates based on our estimated payer mix and the applicable contractual rebate rate.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322140" continuedAt="Text_46b341a9e8d644a8b79909b44816a322141"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1998" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc1999">
<div style="text-align: justify; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322141" continuedAt="Text_46b341a9e8d644a8b79909b44816a322142"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc1999" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19100">
<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Trade discounts: </span>We provide customary invoice discounts on product sales to our U.S. customer for prompt payment. We record this discount as a reduction of product sales in the period in which we recognize the related product revenue.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322142" continuedAt="Text_46b341a9e8d644a8b79909b44816a322143"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19100" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19101">
<div style="text-align: justify; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322143" continuedAt="Text_46b341a9e8d644a8b79909b44816a322144"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19101" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19102">
<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Distribution services</span>: We receive and pay for various distribution services from our U.S. and EU customers and wholesalers in the U.S.. We classify the costs for services we receive that are either not distinct from the sale of the product or for which we cannot reasonably estimate the fair value as a reduction of product sales. To the extent that the services we receive are distinct from the sale of the product, we classify the costs for such services as selling, general and administration, or SG&amp;A, expenses.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322144" continuedAt="Text_46b341a9e8d644a8b79909b44816a322145"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19102" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19103">
<div style="text-align: justify; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322145" continuedAt="Text_46b341a9e8d644a8b79909b44816a322146"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19103" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19104">
<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Product returns: </span>Our U.S. customer has return rights and the wholesalers have limited return rights primarily related to the product&#8217;s expiration date. We estimate the amount of product sales that our customer may return. We record our return estimate as an accrued refund liability on our consolidated balance sheet with a corresponding offset reducing our product sales in the same period we recognize the related sale. Based on our distribution model for product sales, contractual inventory limits with our customer and wholesalers and the price of the product, we have had minimal returns to date and we believe we will continue to have minimal returns. Our EU customers only take title to the product after they receive an order from a hospital or pharmacy and therefore they do not maintain excess inventory levels of our products. Accordingly, we have limited return risk in the EU and we do not estimate returns in the EU.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322146" continuedAt="Text_46b341a9e8d644a8b79909b44816a322147"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19104" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19105">
<div style="text-align: justify; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322147" continuedAt="Text_46b341a9e8d644a8b79909b44816a322148"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19105" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19106">
<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Other incentives: </span>In the U.S., we estimate reserves for other incentives including co-payment assistance we provide to patients with commercial insurance who have coverage and reside in states that allow co-payment assistance. We record a reserve for the amount we estimate we will pay for co-payment assistance. We base our reserve on the number of estimated claims and our estimate of the cost per claim related to product sales that we have recognized as revenue. We record our other incentive reserve estimates as an accrued liability on our consolidated balance sheet with a corresponding offset reducing our product sales in the same period we recognize the related sale.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322148" continuedAt="Text_46b341a9e8d644a8b79909b44816a322149"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19106" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19107">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322149" continuedAt="Text_46b341a9e8d644a8b79909b44816a322150"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19107" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19108">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Research and development revenue under collaboration agreements:</span></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322150" continuedAt="Text_46b341a9e8d644a8b79909b44816a322151"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19108" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19109">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322151" continuedAt="Text_46b341a9e8d644a8b79909b44816a322152"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19109" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19110">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Upfront payments</span></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322152" continuedAt="Text_46b341a9e8d644a8b79909b44816a322153"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19110" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19111">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322153" continuedAt="Text_46b341a9e8d644a8b79909b44816a322154"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19111" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19112">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">When we enter into a collaboration agreement with an upfront payment, we typically record the entire upfront payment as deferred revenue if our only performance obligation is for R&amp;D services we will provide in the future. We amortize the upfront payment into revenue as we perform the R&amp;D services. For example, under our <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">collaboration agreement with Roche to</span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> develop IONIS-FB-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for the treatment of complement-mediated diseases</span>, we received a $<ix:nonFraction name="ions:UpfrontPaymentReceived" id="Fact_f3341a779cd4477b9ed549b3598e413c" contextRef="c20181001to20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million upfront payment in the fourth quarter of 2018. We allocated the upfront payment to our single performance obligation, R&amp;D services. We are amortizing the $<ix:nonFraction name="ions:UpfrontPaymentReceived" id="Fact_d7a5d9320f994613bb599013781aff1f" contextRef="c20181001to20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million upfront payment using an input method over the estimated period of time we are providing R&amp;D services.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322154" continuedAt="Text_46b341a9e8d644a8b79909b44816a322155"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19112" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19113">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>15</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322155" continuedAt="Text_46b341a9e8d644a8b79909b44816a322156"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19113" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19114">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Milestone payments</span></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322156" continuedAt="Text_46b341a9e8d644a8b79909b44816a322157"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19114" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19115">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322157" continuedAt="Text_46b341a9e8d644a8b79909b44816a322158"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19115" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19116">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are required to include additional consideration in the transaction price when it is probable. We typically include milestone payments for R&amp;D services in the transaction price when they are achieved. We include these milestone payments when they are achieved because there is considerable uncertainty in the research and development processes that trigger these payments. Similarly, we include approval milestone payments in the transaction price once the medicine is approved by the applicable regulatory agency. We will recognize sales-based milestone payments in the period in which we achieve the milestone under the sales-based royalty exception allowed under accounting rules.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322158" continuedAt="Text_46b341a9e8d644a8b79909b44816a322159"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19116" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19117">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322159" continuedAt="Text_46b341a9e8d644a8b79909b44816a322160"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19117" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19118">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We recognize milestone payments that relate to an ongoing performance obligation over our period of performance. For example, in the fourth quarter of 2019, we achieved <ix:nonFraction name="ions:NumberOfMilestonePaymentsAchieved" id="Fact_2f4c3cdec64d4ebab74fa61267369768" contextRef="c20170701to20170930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> $<ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPriceAdditions" id="Fact_67b6c98cd0b04a499399e7c1949be7e0" contextRef="c20170701to20170930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">7.5</ix:nonFraction> million milestone payments from Biogen when we advanced <ix:nonFraction name="ions:NumberOfNewTargetsAdvanced" id="Fact_b795fee01141433db219e12877341375" contextRef="c20170701to20170930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U007" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> new targets for undisclosed neurological diseases under our 2018 strategic neurology collaboration. We added these payments to the transaction price and allocated it to our R&amp;D services performance obligation. We are recognizing revenue related to these milestone payments over our estimated period of performance.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322160" continuedAt="Text_46b341a9e8d644a8b79909b44816a322161"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19118" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19119">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322161" continuedAt="Text_46b341a9e8d644a8b79909b44816a322162"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19119" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19120">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Conversely, we recognize in full those milestone payments that we earn based on our partners&#8217; activities when our partner achieves the milestone event and we do not have a performance obligation. For example, in the fourth quarter of 2019, we recognized a $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_dc0f5410578c4b3caf3ed28f1705b5dc" contextRef="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million milestone payment <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">when Biogen advanced the development candidate for an undisclosed target under our 2012 neurology collaboration agreement</span>. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We concluded that the milestone payment was not related to our R&amp;D services performance obligation. Therefore, we recognized the milestone payment in full in the fourth quarter of 2019.</span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322162" continuedAt="Text_46b341a9e8d644a8b79909b44816a322163"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19120" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19121">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322163" continuedAt="Text_46b341a9e8d644a8b79909b44816a322164"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19121" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19122">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">License fees</span></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322164" continuedAt="Text_46b341a9e8d644a8b79909b44816a322165"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19122" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19123">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322165" continuedAt="Text_46b341a9e8d644a8b79909b44816a322166"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19123" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19124">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We generally recognize as revenue the total amount we determine to be the relative stand-alone selling price of a license when we deliver the license to our partner. This is because our partner has full use of the license and we do not have any additional performance obligations related to the license after delivery. </span>For example, in the fourth quarter of 2019, we earned a $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_10644c4cd74c4270aa654dc8e76ab934" contextRef="c20191001to20191231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction> million license fee when Biogen licensed IONIS-MAPT<sub>Rx</sub> from us. We also recognized $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_83765ee3444f4da28551fd1252bdbdff" contextRef="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">246</ix:nonFraction> million of license fee revenue related to Akcea&#8217;s license of AKCEA-ANGPTL3-L<sub>Rx</sub> to Pfizer in the fourth quarter of 2019.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322166" continuedAt="Text_46b341a9e8d644a8b79909b44816a322167"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19124" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19125">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322167" continuedAt="Text_46b341a9e8d644a8b79909b44816a322168"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19125" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19126">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Sublicense fees</span></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322168" continuedAt="Text_46b341a9e8d644a8b79909b44816a322169"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19126" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19127">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322169" continuedAt="Text_46b341a9e8d644a8b79909b44816a322170"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19127" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19128">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We recognize sublicense fee revenue in the period in which a party, who has already licensed our technology, further licenses the technology to another party because we do not have any performance obligations related to the sublicense. </span>For example, in the second quarter of 2019, we earned a $<ix:nonFraction name="ions:UpfrontPaymentReceived" id="Fact_3fe0a292e07f47b2a1337dab39a323b4" contextRef="c20190401to20190630_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction> million sublicense fee when Alnylam Pharmaceuticals sublicensed our technology to Regeneron Pharmaceuticals.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322170" continuedAt="Text_46b341a9e8d644a8b79909b44816a322171"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19128" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19129">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322171" continuedAt="Text_46b341a9e8d644a8b79909b44816a322172"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19129" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19130">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Amendments to Agreements</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322172" continuedAt="Text_46b341a9e8d644a8b79909b44816a322173"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19130" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19131">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322173" continuedAt="Text_46b341a9e8d644a8b79909b44816a322174"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19131" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19132">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">From time to time we amend our collaboration agreements. When this occurs, we are required to assess the following items to determine the accounting for the amendment:</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322174" continuedAt="Text_46b341a9e8d644a8b79909b44816a322175"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19132" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19133">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19133" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19134"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322175" continuedAt="Text_46b341a9e8d644a8b79909b44816a322176">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z4d3009374a5e478e8122026b5e139b45">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If the additional goods and/or services are distinct from the other performance obligations in the original agreement; and</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19134" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19135"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322176" continuedAt="Text_46b341a9e8d644a8b79909b44816a322177">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zf0f366c375b94c81a0b52ddbbfa1f51e">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If the goods and/or services are at a stand-alone selling price. </div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322177" continuedAt="Text_46b341a9e8d644a8b79909b44816a322178"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19135" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19136">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322178" continuedAt="Text_46b341a9e8d644a8b79909b44816a322179"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19136" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19137">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If we conclude the goods and/or services in the amendment are distinct from the performance obligations in the original agreement and at a stand-alone selling price, we account for the amendment as a separate agreement. If we conclude the goods and/or services are not distinct and at their stand-alone selling price, we then assess whether the remaining goods or services are distinct from those already provided. If the goods and/or services are distinct from what we have already provided, then we allocate the remaining transaction price from the original agreement and the additional transaction price from the amendment to the remaining goods and/or services. If the goods and/or services are not distinct from what we have already provided, we update the transaction price for our single performance obligation and recognize any change in our estimated revenue as a cumulative adjustment.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322179" continuedAt="Text_46b341a9e8d644a8b79909b44816a322180"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19137" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19138">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322180" continuedAt="Text_46b341a9e8d644a8b79909b44816a322181"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19138" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19139">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">For example, in May 2015, we entered into an exclusive license agreement with Bayer to develop and commercialize IONIS-FXI</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for the prevention of thrombosis. As part of the agreement, Bayer paid us a $</span><ix:nonFraction name="ions:UpfrontPaymentReceived" id="Fact_6ea18e5a463d43b3b68db4829c2434ab" contextRef="c20150501to20150531_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million upfront payment. At the onset of the agreement, we were responsible for completing a Phase 2 study of IONIS-FXI</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in people with end-stage renal disease on hemodialysis and for providing an initial supply of API. In February 2017, we amended our agreement with Bayer to advance IONIS-FXI</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and to initiate development of IONIS-FXI-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, which Bayer licensed. As part of the 2017 amendment, Bayer paid us $</span><ix:nonFraction name="ions:UpfrontPaymentReceived" id="Fact_b224b3d9e0104fcb9d25e5b648e59cd5" contextRef="c20170201to20170228_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million. We are also eligible to receive milestone payments and tiered royalties on gross margins of IONIS-FXI</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and IONIS-FXI-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. Under the 2017 amendment, we concluded we had a new agreement with </span><ix:nonFraction name="ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" id="Fact_a813007ed00d44ddb1de4e340c0c1d20" contextRef="c20170228_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> performance obligations. These performance obligations were to deliver the license of IONIS-FXI-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, to provide R&amp;D services and to deliver API. We allocated the $</span><ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPrice" id="Fact_aee59b0b43254954a5491abf5bd715ef" contextRef="c20170228_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million transaction price to these performance obligations. </span>Refer to <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Note 7, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Collaborative Arrangements and Licensing Agreements</span>, for further discussion <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">of our accounting treatment for our Bayer collaboration.</span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322181" continuedAt="Text_46b341a9e8d644a8b79909b44816a322182"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19139" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19140">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>16</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322182" continuedAt="Text_46b341a9e8d644a8b79909b44816a322183"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19140" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19141">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Multiple agreements</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322183" continuedAt="Text_46b341a9e8d644a8b79909b44816a322184"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19141" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19142">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322184" continuedAt="Text_46b341a9e8d644a8b79909b44816a322185"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19142" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19143">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">From time to time, we may enter into separate agreements at or near the same time with the same partner. We evaluate such agreements to determine whether we should account for them individually as distinct arrangements or whether the separate agreements should be combined and accounted for together. We evaluate the following to determine the accounting for the agreements:</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322185" continuedAt="Text_46b341a9e8d644a8b79909b44816a322186"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19143" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19144">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19144" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19145"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322186" continuedAt="Text_46b341a9e8d644a8b79909b44816a322187">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z5a22915e59694cedaf8815e2feb45467">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Whether the agreements were negotiated together with a single objective;</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19145" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19146"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322187" continuedAt="Text_46b341a9e8d644a8b79909b44816a322188">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z4c6b305fcd854a51950b2b0c8b9ff86f">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Whether the amount of consideration in one contract depends on the price or performance of the other agreement; or</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19146" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19147"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322188" continuedAt="Text_46b341a9e8d644a8b79909b44816a322189">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z82b56ef158ea487c94fc2daddd0e9546">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Whether the goods and/or services promised under the agreements are a single performance obligation. </div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322189" continuedAt="Text_46b341a9e8d644a8b79909b44816a322190"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19147" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19148">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322190" continuedAt="Text_46b341a9e8d644a8b79909b44816a322191"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19148" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19149">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our evaluation involves significant judgment to determine whether a group of agreements might be so closely related that accounting guidance requires us to account for them as a combined arrangement.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322191" continuedAt="Text_46b341a9e8d644a8b79909b44816a322192"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19149" continuedAt="Text_71a760b180af4a65b11ec3a6e932fc19150">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322192" continuedAt="Text_46b341a9e8d644a8b79909b44816a322193"><ix:continuation id="Text_71a760b180af4a65b11ec3a6e932fc19150">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For example, in the second quarter of 2018, we entered into <ix:nonFraction name="ions:NumberOfAgreementsWithCollaborationPartner" id="Fact_794974dbb1c34381ac6981b5758714d7" contextRef="c20180401to20180630_MajorCustomersAxis_BiogenIncMember" unitRef="U008" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> separate agreements with Biogen at the same time: a new strategic neurology collaboration agreement and a stock purchase agreement, or SPA. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We evaluated the Biogen agreements to determine whether we should treat the agreements separately or combine them. We considered that the agreements were negotiated concurrently and in contemplation of one another. Based on these facts and circumstances, we concluded that we should evaluate the provisions of the agreements on a combined basis.</span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322193" continuedAt="Text_46b341a9e8d644a8b79909b44816a322194">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322194" continuedAt="Text_46b341a9e8d644a8b79909b44816a322195"><ix:nonNumeric name="us-gaap:ReceivablesPolicyTextBlock" id="Text_70a8fbc7cd8d478a96621d57f162a36c" contextRef="c20190101to20191231" escape="true" continuedAt="Text_8b75c4596ab7427ba7cfc6ce328784141">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: -54pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Contracts Receivable</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322195" continuedAt="Text_46b341a9e8d644a8b79909b44816a322196"><ix:continuation id="Text_8b75c4596ab7427ba7cfc6ce328784141" continuedAt="Text_8b75c4596ab7427ba7cfc6ce328784142">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: -18pt; margin-left: 54pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322196" continuedAt="Text_46b341a9e8d644a8b79909b44816a322197"><ix:continuation id="Text_8b75c4596ab7427ba7cfc6ce328784142">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our contracts receivable balance represents the amounts we have billed our partners or customers and that are due to us unconditionally for goods we have delivered or services we have performed. When we bill our partners or customers with payment terms based on the passage of time, we consider the contract receivable to be unconditional. We typically receive payment within one </span><span style="-sec-ix-hidden:Fact_5acf7b3d4ee04d009d32a31d9e4ded77">quarter</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> of billing our partner or customer</span>.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322197" continuedAt="Text_46b341a9e8d644a8b79909b44816a322198">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322198" continuedAt="Text_46b341a9e8d644a8b79909b44816a322199"><ix:nonNumeric name="us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" id="Text_faac8b93fbf747a0b879d9b6b5712192" contextRef="c20190101to20191231" escape="true" continuedAt="Text_9f78c7d36b264b25b1b88cdfd4c5b0d71">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -54pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Unbilled SPINRAZA Royalties</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322199" continuedAt="Text_46b341a9e8d644a8b79909b44816a322200"><ix:continuation id="Text_9f78c7d36b264b25b1b88cdfd4c5b0d71" continuedAt="Text_9f78c7d36b264b25b1b88cdfd4c5b0d72">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322200" continuedAt="Text_46b341a9e8d644a8b79909b44816a322201"><ix:continuation id="Text_9f78c7d36b264b25b1b88cdfd4c5b0d72">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our unbilled SPINRAZA royalties represent our right to receive consideration from Biogen in advance of when we are eligible to bill Biogen for SPINRAZA royalties. We include these unbilled amounts in other current assets on our consolidated balance sheet.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322201" continuedAt="Text_46b341a9e8d644a8b79909b44816a322202">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322202" continuedAt="Text_46b341a9e8d644a8b79909b44816a322203"><ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Text_823cc816d6d44936960102525ecec2ea" contextRef="c20190101to20191231" escape="true" continuedAt="Text_b33d3975595d46dcb032f264742ff0bc1">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: -54pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Deferred Revenue</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322203" continuedAt="Text_46b341a9e8d644a8b79909b44816a322204"><ix:continuation id="Text_b33d3975595d46dcb032f264742ff0bc1" continuedAt="Text_b33d3975595d46dcb032f264742ff0bc2">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322204" continuedAt="Text_46b341a9e8d644a8b79909b44816a322205"><ix:continuation id="Text_b33d3975595d46dcb032f264742ff0bc2">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We are often entitled to bill our customers and receive payment from our customers in advance of our obligation to provide services or transfer goods to our partners. In these instances, we include the amounts in deferred revenue on our consolidated balance sheet.</span> During the years ended December 31, 2019 and 2018, we recognized $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" id="Fact_7a9ec3bea8ad464ca6e12c6aa16435cd" contextRef="c20190101to20191231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">159.5</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" id="Fact_ced6b030f6d146bb91eabbce81e6f413" contextRef="c20180101to20181231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">105.3</ix:nonFraction> million of revenue from amounts that were in our beginning deferred revenue balance for each respective period. For further discussion, refer to our revenue recognition policy above.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322205" continuedAt="Text_46b341a9e8d644a8b79909b44816a322206">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322206" continuedAt="Text_46b341a9e8d644a8b79909b44816a322207"><ix:nonNumeric name="us-gaap:CostOfSalesPolicyTextBlock" id="Text_254afeb786aa436f810cc6424e22ff9f" contextRef="c20190101to20191231" escape="true" continuedAt="Text_cb83ea307c30443881ce6fd29e81d6cc1">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Cost of Products Sold</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322207" continuedAt="Text_46b341a9e8d644a8b79909b44816a322208"><ix:continuation id="Text_cb83ea307c30443881ce6fd29e81d6cc1" continuedAt="Text_cb83ea307c30443881ce6fd29e81d6cc2">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322208" continuedAt="Text_46b341a9e8d644a8b79909b44816a322209"><ix:continuation id="Text_cb83ea307c30443881ce6fd29e81d6cc2">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our cost of products sold includes manufacturing costs, transportation and freight costs and indirect overhead costs associated with the manufacturing and distribution of our products. We also may include certain period costs related to manufacturing services and inventory adjustments in cost of products sold. Prior to obtaining regulatory approval of TEGSEDI in July 2018 and WAYLIVRA in May 2019, we expensed as research and development expenses a significant portion of the costs we incurred to produce the initial commercial launch supply for each medicine. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We previously expensed $</span><ix:nonFraction name="ions:CostOfProductsSoldPreviouslyRecognized" id="Fact_0bfe661a777b42c0be8e4a6111928739" contextRef="c20190101to20191231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million and $</span><ix:nonFraction name="ions:CostOfProductsSoldPreviouslyRecognized" id="Fact_6fbce6aca9464ccb92df280b96eebb3c" contextRef="c20180101to20181231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million of costs to produce our products related to the product sales revenue we recognized in 2019 and 2018, respectively.</span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322209" continuedAt="Text_46b341a9e8d644a8b79909b44816a322210">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322210" continuedAt="Text_46b341a9e8d644a8b79909b44816a322211">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Research, Development and Patent Expenses</div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322211" continuedAt="Text_46b341a9e8d644a8b79909b44816a322212">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322212" continuedAt="Text_46b341a9e8d644a8b79909b44816a322213"><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Text_28c5a2071783403e9a962d2e005cb136" contextRef="c20190101to20191231" escape="true">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our research and development expenses include wages, benefits, facilities, supplies, external services, clinical trial and manufacturing costs and other expenses that are directly related to our research and development operations. We expense research and development costs as we incur them. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. For the years ended December 31, 2019, 2018 and 2017, research and development expenses were $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_d0c1565159a044b595630e050bb43a4e" contextRef="c20190101to20191231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">461.5</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_0114d1a3cfd445bbb2a6b5bc9fba079f" contextRef="c20180101to20181231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">411.9</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_203e9d3fa0b14eca9d0edbb437f4f325" contextRef="c20170101to20171231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">372.5</ix:nonFraction> million, respectively. A portion of the costs included in research and development expenses are costs associated with our partner agreements. For the years ended December 31, 2019, 2018 and 2017, research and development costs of approximately $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_802d7e1d88dd4400b573e6ee2246659a" contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">83.2</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_216c3f8ce5e44d2c80d7b536e2b7febb" contextRef="c20180101to20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">58.7</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_f19630c62fc04ac590d8f34e449d0135" contextRef="c20170101to20171231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">59.5</ix:nonFraction> million, respectively, were related to our partner agreements.</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322213" continuedAt="Text_46b341a9e8d644a8b79909b44816a322214">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>17</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322214" continuedAt="Text_46b341a9e8d644a8b79909b44816a322215"><ix:nonNumeric name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="Text_3d51b0b184354eea966e871ef92d8650" contextRef="c20190101to20191231" escape="true" continuedAt="Text_b9dc1b210c23406fbf16e7ff6a647def1">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We capitalize costs consisting principally of outside legal costs and filing fees related to obtaining patents. We amortize patent costs over the useful life of the patent, beginning with the date the U.S. Patent and Trademark Office, or foreign equivalent, issues the patent. The weighted average remaining amortizable life of our issued patents was <ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Fact_0743de364414479fa413c5d659ce3213" contextRef="c20190101to20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" format="ixt-sec:duryear">10.3</ix:nonNumeric> years at December 31, 2019.</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322215" continuedAt="Text_46b341a9e8d644a8b79909b44816a322216"><ix:continuation id="Text_b9dc1b210c23406fbf16e7ff6a647def1" continuedAt="Text_b9dc1b210c23406fbf16e7ff6a647def2">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322216" continuedAt="Text_46b341a9e8d644a8b79909b44816a322217"><ix:continuation id="Text_b9dc1b210c23406fbf16e7ff6a647def2" continuedAt="Text_b9dc1b210c23406fbf16e7ff6a647def3">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The cost of our patents capitalized on our consolidated balance sheet at December 31, 2019 and 2018 was $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_df1e6fe595054242bd56601d34e950e2" contextRef="c20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">34.0</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_421e79a98335467eb99a9cba6857377d" contextRef="c20181231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">32.7</ix:nonFraction> million, respectively. Accumulated amortization related to patents was $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_414dd9c96ebb45a28f493a17da9dec2e" contextRef="c20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">8.3</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_91380e7cfc944a1e8053aef43d6d897f" contextRef="c20181231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">8.7</ix:nonFraction> million at December 31, 2019 and 2018, respectively.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322217" continuedAt="Text_46b341a9e8d644a8b79909b44816a322218"><ix:continuation id="Text_b9dc1b210c23406fbf16e7ff6a647def3" continuedAt="Text_b9dc1b210c23406fbf16e7ff6a647def4">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322218" continuedAt="Text_46b341a9e8d644a8b79909b44816a322219"><ix:nonNumeric name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="Text_369ccc0519494b209f2f7c69b835cf77" contextRef="c20190101to20191231" escape="true" continuedAt="Text_65805ffb43234ff3a915ba111b9af82f1"><ix:continuation id="Text_b9dc1b210c23406fbf16e7ff6a647def4" continuedAt="Text_b9dc1b210c23406fbf16e7ff6a647def5">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Based on our existing patents, we estimate amortization expense related to patents in each of the next five years to be the following:</div>
</ix:continuation></ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322219" continuedAt="Text_46b341a9e8d644a8b79909b44816a322220"><ix:continuation id="Text_65805ffb43234ff3a915ba111b9af82f1" continuedAt="Text_65805ffb43234ff3a915ba111b9af82f2"><ix:continuation id="Text_b9dc1b210c23406fbf16e7ff6a647def5" continuedAt="Text_b9dc1b210c23406fbf16e7ff6a647def6">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322220" continuedAt="Text_46b341a9e8d644a8b79909b44816a322221"><ix:continuation id="Text_65805ffb43234ff3a915ba111b9af82f2"><ix:continuation id="Text_b9dc1b210c23406fbf16e7ff6a647def6" continuedAt="Text_b9dc1b210c23406fbf16e7ff6a647def7">
<table cellpadding="0" cellspacing="0" id="z3b4746089ec94fcf825148a7e478c941" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ending December 31,</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amortization</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(in millions)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" id="Fact_8b4595506d5b46448ab97fdee1240d0f" contextRef="c20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2021</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" id="Fact_e44494ea589f4fd6bf584443ca16bfcc" contextRef="c20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2022</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" id="Fact_5f35096f0bcf43fb92b147de0bf72462" contextRef="c20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2023</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" id="Fact_7b3245e6bc5b4426819c1fb6dc13148c" contextRef="c20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2024</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" id="Fact_f6ccdf05d6a5463584227257d28f4a82" contextRef="c20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322221" continuedAt="Text_46b341a9e8d644a8b79909b44816a322222"><ix:continuation id="Text_b9dc1b210c23406fbf16e7ff6a647def7" continuedAt="Text_b9dc1b210c23406fbf16e7ff6a647def8">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322222" continuedAt="Text_46b341a9e8d644a8b79909b44816a322223"><ix:continuation id="Text_b9dc1b210c23406fbf16e7ff6a647def8">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We review our capitalized patent costs regularly to ensure that they include costs for patents and patent applications that have future value. When we identify patents and patent applications that we are not actively pursuing, we write off any associated costs. In 2019, 2018 and 2017, patent expenses were $<ix:nonFraction name="ions:PatentExpenses" id="Fact_57ea08b5d1894948b17ad9f00140ea03" contextRef="c20190101to20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">4.2</ix:nonFraction> million, $<ix:nonFraction name="ions:PatentExpenses" id="Fact_9907ec92e4dd4419b5a9f4fb46f56330" contextRef="c20180101to20181231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">2.6</ix:nonFraction> million and $<ix:nonFraction name="ions:PatentExpenses" id="Fact_3201b72effcf4c0c8e0d51523e32d64f" contextRef="c20170101to20171231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">2.1</ix:nonFraction> million, respectively, and included non-cash charges related to the write-down of our patent costs to their estimated net realizable values of $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" id="Fact_acdbb50a6f92446b87e379e817f900c3" contextRef="c20190101to20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" id="Fact_3029299725d54805be6165d35d2050b9" contextRef="c20180101to20181231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" id="Fact_1057b62f0867480b862004e4e8b9e9ed" contextRef="c20170101to20171231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction> million, respectively.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322223" continuedAt="Text_46b341a9e8d644a8b79909b44816a322224">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322224" continuedAt="Text_46b341a9e8d644a8b79909b44816a322225">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Accrued Liabilities</div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322225" continuedAt="Text_46b341a9e8d644a8b79909b44816a322226">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322226" continuedAt="Text_46b341a9e8d644a8b79909b44816a322227"><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Text_87bf2c631a3c4ead881ada96127f2237" contextRef="c20190101to20191231" escape="true" continuedAt="Text_960de44ff5f742adbd648b4b1b7b78611">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our accrued liabilities consisted of the following (in thousands):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322227" continuedAt="Text_46b341a9e8d644a8b79909b44816a322228"><ix:continuation id="Text_960de44ff5f742adbd648b4b1b7b78611" continuedAt="Text_960de44ff5f742adbd648b4b1b7b78612">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322228" continuedAt="Text_46b341a9e8d644a8b79909b44816a322229"><ix:continuation id="Text_960de44ff5f742adbd648b4b1b7b78612">
<table cellpadding="0" cellspacing="0" id="z3a44c21e41964165973dff87ef753698" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Clinical expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:AccruedClinicalExpenses" id="Fact_dd19e9b42ea648b5a66ad1c40729f204" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">24,461</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:AccruedClinicalExpenses" id="Fact_fac7f03b039f4f02a05228c036fc1f3c" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">22,125</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -18pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In-licensing expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:AccruedInLicensingFeesCurrent" id="Fact_4a54e14632b04a9cb08ecbd7c4f7b264" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">10,289</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:AccruedInLicensingFeesCurrent" id="Fact_a1182bff6aa841d1b17861b49376378a" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">12,298</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -18pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other miscellaneous expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" id="Fact_962c481f08204a1f938ac3ce6088c025" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">32,019</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" id="Fact_558a2514ca9d46d38ef6431a99ec3875" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">13,080</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total accrued liabilities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_d3d4336195b54976b7bcea8d3b30b7ac" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">66,769</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" id="Fact_e91e73e81dd74acab89c06a66144eab3" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">47,503</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322229" continuedAt="Text_46b341a9e8d644a8b79909b44816a322230">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322230" continuedAt="Text_46b341a9e8d644a8b79909b44816a322231"><ix:nonNumeric name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="Text_ece58b8638f04f80b592393388f33955" contextRef="c20190101to20191231" escape="true" continuedAt="Text_6193b31ac13a4aa2ab8f0ee15bb793b61">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Noncontrolling Interest in Akcea Therapeutics, Inc.</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322231" continuedAt="Text_46b341a9e8d644a8b79909b44816a322232"><ix:continuation id="Text_6193b31ac13a4aa2ab8f0ee15bb793b61" continuedAt="Text_6193b31ac13a4aa2ab8f0ee15bb793b62">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322232" continuedAt="Text_46b341a9e8d644a8b79909b44816a322233"><ix:continuation id="Text_6193b31ac13a4aa2ab8f0ee15bb793b62" continuedAt="Text_6193b31ac13a4aa2ab8f0ee15bb793b63">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Prior to Akcea&#8217;s IPO in July 2017, we owned <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" id="Fact_769029e542944bf999e422df3b90efc5" contextRef="c20170630_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction> percent of Akcea. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Since Akcea&#8217;s IPO, our ownership has ranged from </span><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" id="Fact_58b26cdf07c24edeadfa19650b871e33" contextRef="c20191231_OwnershipAxis_AkceaTherapeuticsIncMember_RangeAxis_MinimumMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">68</ix:nonFraction> percent<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> to </span><ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" id="Fact_77ecfee62c304b829d327b3441b4f57e" contextRef="c20191231_OwnershipAxis_AkceaTherapeuticsIncMember_RangeAxis_MaximumMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">77</ix:nonFraction> percent<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. At December 31, </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, o</span>ur ownership was approximately <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" id="Fact_6b6bb01bbc794527a344f19aa39625a5" contextRef="c20191231_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">76</ix:nonFraction> percent. We reflect changes in our ownership percentage in our financial statements as an adjustment to noncontrolling interest in the period the change occurs. During 2019, we received the following additional shares of Akcea common stock:</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322233" continuedAt="Text_46b341a9e8d644a8b79909b44816a322234"><ix:continuation id="Text_6193b31ac13a4aa2ab8f0ee15bb793b63" continuedAt="Text_6193b31ac13a4aa2ab8f0ee15bb793b64">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_6193b31ac13a4aa2ab8f0ee15bb793b64" continuedAt="Text_6193b31ac13a4aa2ab8f0ee15bb793b65"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322234" continuedAt="Text_46b341a9e8d644a8b79909b44816a322235">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zb8e73bce7e5949779fde18c99941a249">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:SharesReceivedFromSubsidiaryForLicenseOfDrug" id="Fact_5c33394e61a94d3aa8de15383f87fe0d" contextRef="c20190101to20190331" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction> million shares in the first quarter of 2019 as payment for the sublicense fee Akcea owed us for Novartis&#8217;s license of AKCEA-APO(a)-L<sub>Rx</sub>, and;</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_6193b31ac13a4aa2ab8f0ee15bb793b65" continuedAt="Text_6193b31ac13a4aa2ab8f0ee15bb793b66"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322235" continuedAt="Text_46b341a9e8d644a8b79909b44816a322236">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zb8be43d6e4c14352bda3fb7b936ad303">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:SharesReceivedFromSubsidiaryForLicenseOfDrug" id="Fact_55cba755dbc541409905ee410a39c915" contextRef="c20191001to20191231" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">6.9</ix:nonFraction> million shares in the fourth quarter of 2019 as payment for the sublicense fee Akcea owed us for Pfizer&#8217;s license of AKCEA-ANGPTL3-L<sub>Rx</sub>.</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322236" continuedAt="Text_46b341a9e8d644a8b79909b44816a322237"><ix:continuation id="Text_6193b31ac13a4aa2ab8f0ee15bb793b66" continuedAt="Text_6193b31ac13a4aa2ab8f0ee15bb793b67">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322237" continuedAt="Text_46b341a9e8d644a8b79909b44816a322238"><ix:continuation id="Text_6193b31ac13a4aa2ab8f0ee15bb793b67">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The shares third parties own represent an interest in Akcea&#8217;s equity that we do control. However, as we continue to maintain overall control of Akcea through our voting interest, we reflect the assets, liabilities and results of operations of Akcea in our consolidated financial statements. We reflect the noncontrolling interest attributable to other owners of Akcea&#8217;s common stock in a separate line on the statement of operations and a separate line within stockholders&#8217; equity in our consolidated balance sheet. In addition, we record a noncontrolling interest adjustment to account for the stock options Akcea grants, which if exercised, will dilute our ownership in Akcea. This adjustment is a reclassification within stockholders&#8217; equity from additional paid-in capital to noncontrolling interest in Akcea equal to the amount of stock-based compensation expense Akcea had recognized.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322238" continuedAt="Text_46b341a9e8d644a8b79909b44816a322239">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>18</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322239" continuedAt="Text_46b341a9e8d644a8b79909b44816a322240"><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" id="Text_f2cb3c34c3c943679b79190d82dff1f7" contextRef="c20190101to20191231" escape="true" continuedAt="Text_304daa6515d049cb927386fb0ac8dcad1">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Concentration of Credit Risk</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322240" continuedAt="Text_46b341a9e8d644a8b79909b44816a322241"><ix:continuation id="Text_304daa6515d049cb927386fb0ac8dcad1" continuedAt="Text_304daa6515d049cb927386fb0ac8dcad2">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322241" continuedAt="Text_46b341a9e8d644a8b79909b44816a322242"><ix:continuation id="Text_304daa6515d049cb927386fb0ac8dcad2">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, short-term investments and receivables. We place our cash equivalents and short-term investments with reputable financial institutions. We primarily invest our excess cash in commercial paper and debt instruments of the U.S. Treasury, financial institutions, corporations, and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1, P-1 or F-1 by Moody&#8217;s, Standard &amp; Poor&#8217;s, or S&amp;P, or Fitch, respectively. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322242" continuedAt="Text_46b341a9e8d644a8b79909b44816a322243">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322243" continuedAt="Text_46b341a9e8d644a8b79909b44816a322244"><ix:nonNumeric name="ions:CashCashEquivalentsAndInvestmentsPolicyTextBlock" id="Text_b61476ba09e2462e89e8f87c1ed0938a" contextRef="c20190101to20191231" escape="true" continuedAt="Text_8aec887a54a941ec86e5630912a3b8e01">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Cash, Cash Equivalents and Investments</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322244" continuedAt="Text_46b341a9e8d644a8b79909b44816a322245"><ix:continuation id="Text_8aec887a54a941ec86e5630912a3b8e01" continuedAt="Text_8aec887a54a941ec86e5630912a3b8e02">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322245" continuedAt="Text_46b341a9e8d644a8b79909b44816a322246"><ix:continuation id="Text_8aec887a54a941ec86e5630912a3b8e02" continuedAt="Text_8aec887a54a941ec86e5630912a3b8e03">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We consider all liquid investments with maturities of three months or less when we purchase them to be cash equivalents. Our short-term investments have initial maturities of greater than three months from date of purchase. We classify our short-term debt investments as &#8220;available-for-sale&#8221; and carry them at fair market value based upon prices on the last day of the fiscal period for identical or similar items. We record unrealized gains and losses on debt securities as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments. We use the specific identification method to determine the cost of securities sold.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322246" continuedAt="Text_46b341a9e8d644a8b79909b44816a322247"><ix:continuation id="Text_8aec887a54a941ec86e5630912a3b8e03" continuedAt="Text_8aec887a54a941ec86e5630912a3b8e04">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="background-color: #FFFFFF;"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322247" continuedAt="Text_46b341a9e8d644a8b79909b44816a322248"><ix:continuation id="Text_8aec887a54a941ec86e5630912a3b8e04" continuedAt="Text_8aec887a54a941ec86e5630912a3b8e05">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We also have equity investments of less than 20 percent ownership in publicly and privately held biotechnology companies that we received as part of a technology license or partner agreement. At December 31, 2019, we held equity investments in <ix:nonFraction name="ions:NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" id="Fact_b448547c88c7434cbc329f97a4b3ea28" contextRef="c20191231" unitRef="U009" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> publicly held companies, ProQR Therapeutics N.V., or ProQR, and Antisense Therapeutics Limited, or ATL. We also held equity investments in <ix:nonFraction name="ions:NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" id="Fact_5091e6339b9e4e85943dd42b9d332383" contextRef="c20191231" unitRef="U009" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction> privately-held companies, Atlantic Pharmaceuticals Limited, Dynacure SAS, Empirico, Inc., Seventh Sense Biosystems and Suzhou Ribo Life Science Co, Ltd.</div>
</ix:continuation></ix:continuation></div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322248" continuedAt="Text_46b341a9e8d644a8b79909b44816a322249"><ix:continuation id="Text_8aec887a54a941ec86e5630912a3b8e05" continuedAt="Text_8aec887a54a941ec86e5630912a3b8e06">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322249" continuedAt="Text_46b341a9e8d644a8b79909b44816a322250"><ix:continuation id="Text_8aec887a54a941ec86e5630912a3b8e06">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In January 2018, we adopted the amended accounting guidance related to the recognition, measurement, presentation, and disclosure of certain financial instruments. The amended guidance requires us to measure and record our equity investments at fair value. Additionally, the amended accounting guidance requires us to recognize the changes in fair value in our consolidated statement of operations, instead of through accumulated other comprehensive income. Prior to 2018, we accounted for our equity investments in privately held companies under the cost method of accounting. Under the amended guidance we account for our equity investments in privately held companies at their cost minus impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Our adoption of this guidance did not have an impact on our results.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322250" continuedAt="Text_46b341a9e8d644a8b79909b44816a322251">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322251" continuedAt="Text_46b341a9e8d644a8b79909b44816a322252"><ix:nonNumeric name="us-gaap:InventoryPolicyTextBlock" id="Text_7e9cc48265cd42a19ccef33d81370017" contextRef="c20190101to20191231" escape="true" continuedAt="Text_6202ea7207ff44f59a670ff7d3fa5d281">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Inventory Valuation</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322252" continuedAt="Text_46b341a9e8d644a8b79909b44816a322253"><ix:continuation id="Text_6202ea7207ff44f59a670ff7d3fa5d281" continuedAt="Text_6202ea7207ff44f59a670ff7d3fa5d282">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322253" continuedAt="Text_46b341a9e8d644a8b79909b44816a322254"><ix:continuation id="Text_6202ea7207ff44f59a670ff7d3fa5d282" continuedAt="Text_6202ea7207ff44f59a670ff7d3fa5d283">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We reflect our inventory on our consolidated balance sheet at the lower of cost or market value under the first-in, first-out method, or FIFO. We capitalize the costs of raw materials that we purchase for use in producing our medicines because until we use these raw materials, they have alternative future uses, which we refer to as clinical raw materials. We include in inventory raw material costs for medicines that we manufacture for our partners under contractual terms and that we use primarily in our clinical development activities and drug products. We can use each of our raw materials in multiple products and, as a result, each raw material has future economic value independent of the development status of any single medicine. For example, if one of our medicines failed, we could use the raw materials for that medicine to manufacture our other medicines. We expense these costs as R&amp;D expenses when we begin to manufacture API for a particular medicine if the medicine has not been approved for marketing by a regulatory agency.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322254" continuedAt="Text_46b341a9e8d644a8b79909b44816a322255"><ix:continuation id="Text_6202ea7207ff44f59a670ff7d3fa5d283" continuedAt="Text_6202ea7207ff44f59a670ff7d3fa5d284">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322255" continuedAt="Text_46b341a9e8d644a8b79909b44816a322256"><ix:continuation id="Text_6202ea7207ff44f59a670ff7d3fa5d284" continuedAt="Text_6202ea7207ff44f59a670ff7d3fa5d285">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We obtained the first regulatory approval for TEGSEDI in July 2018 and for WAYLIVRA in May 2019. At December 31, 2019, our physical inventory for TEGSEDI and WAYLIVRA included API that we produced prior to when we obtained regulatory approval. As such, this API has no cost basis as we had previously expensed the costs as R&amp;D expenses.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322256" continuedAt="Text_46b341a9e8d644a8b79909b44816a322257"><ix:continuation id="Text_6202ea7207ff44f59a670ff7d3fa5d285" continuedAt="Text_6202ea7207ff44f59a670ff7d3fa5d286">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322257" continuedAt="Text_46b341a9e8d644a8b79909b44816a322258"><ix:continuation id="Text_6202ea7207ff44f59a670ff7d3fa5d286" continuedAt="Text_6202ea7207ff44f59a670ff7d3fa5d287">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We review our inventory periodically and reduce the carrying value of items we consider to be slow moving or obsolete to their estimated net realizable value based on forecasted demand compared to quantities on hand. We consider several factors in estimating the net realizable value, including shelf life of our inventory, alternative uses for our medicines in development and historical write-offs. We recorded an <span style="-sec-ix-hidden:Fact_1261d93c836d4d94bba4bd8c45f1e569">insignificant</span> amount of inventory write-offs during the year ended December 31, 2019. We did <ix:nonFraction name="us-gaap:InventoryWriteDown" id="Fact_2004f9d82c16414ba69bf4dd2f384800" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:InventoryWriteDown" id="Fact_e7c66e14d5e9439da7f69eb299318ade" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t record any inventory write-offs for the years ended December 31, 2018 or 2017.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322258" continuedAt="Text_46b341a9e8d644a8b79909b44816a322259"><ix:continuation id="Text_6202ea7207ff44f59a670ff7d3fa5d287" continuedAt="Text_6202ea7207ff44f59a670ff7d3fa5d288">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322259" continuedAt="Text_46b341a9e8d644a8b79909b44816a322260"><ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Text_5fd58eb42e4748f1b0cb4bfcfebadc48" contextRef="c20190101to20191231" escape="true" continuedAt="Text_be4a9f6b9b584143ac3636123936cf631"><ix:continuation id="Text_6202ea7207ff44f59a670ff7d3fa5d288" continuedAt="Text_6202ea7207ff44f59a670ff7d3fa5d289">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our inventory consisted of the following (in thousands):</div>
</ix:continuation></ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322260" continuedAt="Text_46b341a9e8d644a8b79909b44816a322261"><ix:continuation id="Text_be4a9f6b9b584143ac3636123936cf631" continuedAt="Text_be4a9f6b9b584143ac3636123936cf632"><ix:continuation id="Text_6202ea7207ff44f59a670ff7d3fa5d289" continuedAt="Text_6202ea7207ff44f59a670ff7d3fa5d2810">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322261" continuedAt="Text_46b341a9e8d644a8b79909b44816a322262"><ix:continuation id="Text_be4a9f6b9b584143ac3636123936cf632"><ix:continuation id="Text_6202ea7207ff44f59a670ff7d3fa5d2810">
<table cellpadding="0" cellspacing="0" id="z1ee494cca3ec409c868c744c6428df49" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Raw materials:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 19.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Raw materials- clinical</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:InventoryRawMaterials" id="Fact_607597dd540146e09e590486dfbfd332" contextRef="c20191231_PublicUtilitiesInventoryAxis_ClinicalRawMaterialsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">9,363</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:InventoryRawMaterials" id="Fact_7cb2d5b100c4460fa603ceb958dfa363" contextRef="c20181231_PublicUtilitiesInventoryAxis_ClinicalRawMaterialsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">8,497</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -18pt; margin-left: 28.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Raw materials- commercial</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:InventoryRawMaterials" id="Fact_7ce8ae9ab80f4c6b893833f04a2e1b3a" contextRef="c20191231_PublicUtilitiesInventoryAxis_CommercialRawMaterialsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">6,520</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:InventoryRawMaterials" id="Fact_de29fe59994e4eedaaf0e505fe2fa8ce" contextRef="c20181231_PublicUtilitiesInventoryAxis_CommercialRawMaterialsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 28.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total raw materials</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:InventoryRawMaterials" id="Fact_128d62d036e2429290b412a68bb359e3" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">15,883</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:InventoryRawMaterials" id="Fact_2a47aa942a2943ed97036570c8b25890" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">8,497</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Work in process</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" id="Fact_85d7f4970a574d26939ed8575266e7f1" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,039</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" id="Fact_84044948dea84b95bf0906aa87b24ba3" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Finished goods</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" id="Fact_e5ad76dbdb1441b68871a7035a59c0b3" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">258</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" id="Fact_518f7488f3314fafb99fe4a5c96254f0" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">85</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: justify; margin-left: 28.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total inventory</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_ed1f9a6ae98d4c7cba25f90cb15577f3" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">18,180</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_d2b4370b0072452b9c9faa8459b51794" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">8,582</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322262" continuedAt="Text_46b341a9e8d644a8b79909b44816a322263">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>19</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322263" continuedAt="Text_46b341a9e8d644a8b79909b44816a322264"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Text_3ca961ffb1204250b6e485d9fbf46b51" contextRef="c20190101to20191231" escape="true" continuedAt="Text_b480c0912bba43efb4eb976d9635ed971">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Property, Plant and Equipment</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322264" continuedAt="Text_46b341a9e8d644a8b79909b44816a322265"><ix:continuation id="Text_b480c0912bba43efb4eb976d9635ed971" continuedAt="Text_b480c0912bba43efb4eb976d9635ed972">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322265" continuedAt="Text_46b341a9e8d644a8b79909b44816a322266"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Text_ec7145f67b8740268c4191ee25a68742" contextRef="c20190101to20191231" escape="true" continuedAt="Text_321d449b4ae342b6b7976fb78ecd31811"><ix:continuation id="Text_b480c0912bba43efb4eb976d9635ed972" continuedAt="Text_b480c0912bba43efb4eb976d9635ed973">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We carry our property, plant and equipment at cost and depreciate it on the straight-line method over its estimated useful life, which consists of the following (in thousands):</div>
</ix:continuation></ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322266" continuedAt="Text_46b341a9e8d644a8b79909b44816a322267"><ix:continuation id="Text_321d449b4ae342b6b7976fb78ecd31811" continuedAt="Text_321d449b4ae342b6b7976fb78ecd31812"><ix:continuation id="Text_b480c0912bba43efb4eb976d9635ed973" continuedAt="Text_b480c0912bba43efb4eb976d9635ed974">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322267" continuedAt="Text_46b341a9e8d644a8b79909b44816a322268"><ix:continuation id="Text_321d449b4ae342b6b7976fb78ecd31812"><ix:continuation id="Text_b480c0912bba43efb4eb976d9635ed974" continuedAt="Text_b480c0912bba43efb4eb976d9635ed975">
<table cellpadding="0" cellspacing="0" id="z6b8fa4917b344088b2fa85d6aab08f8c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Estimated Useful Lives</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(in years)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Computer software, laboratory, manufacturing and other equipment</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_bee2828c703f419991ca5e4f981c6bfb" contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndComputerSoftwareMember_RangeAxis_MinimumMember" format="ixt-sec:duryear">3</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_5570d89b49ca4d3bbc122f34e561c666" contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndComputerSoftwareMember_RangeAxis_MaximumMember" format="ixt-sec:duryear">10</ix:nonNumeric></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_a358b86f59e5426781124e8c9288e3bd" contextRef="c20191231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndComputerSoftwareMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">60,965</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_32583aa3a38b4549871afd68f63cda1e" contextRef="c20181231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndComputerSoftwareMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">53,496</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Building, building improvements and building systems</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_af3476af11bf463db8625923d46c44ce" contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember_RangeAxis_MinimumMember" format="ixt-sec:duryear">15</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_86510f26269445ae8f1cd2bd97d35737" contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember_RangeAxis_MaximumMember" format="ixt-sec:duryear">40</ix:nonNumeric></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_36283464a0474949b8398ef74fa87f78" contextRef="c20191231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">119,830</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_babb21fe699d4456ba2a90a494e8f764" contextRef="c20181231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">97,528</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Land improvements</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_c74c578c9a114415ba62e9a933b22bc1" contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_LandImprovementsMember" format="ixt-sec:duryear">20</ix:nonNumeric></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_56a2f9f0147240f0bd015bba6bf7acb2" contextRef="c20191231_PropertyPlantAndEquipmentByTypeAxis_LandImprovementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,853</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_48464f6662f34caab0d0adfeb2d1483a" contextRef="c20181231_PropertyPlantAndEquipmentByTypeAxis_LandImprovementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,853</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Leasehold improvements</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_8e57e819a7024b98844132cc9cdf317f" contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember_RangeAxis_MinimumMember" format="ixt-sec:duryear">5</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_09061fd932d049ef9bf84842b438b1c8" contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember_RangeAxis_MaximumMember" format="ixt-sec:duryear">15</ix:nonNumeric></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_9274143ded5b4f0ba33136edf1a5c107" contextRef="c20191231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">13,600</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_a69d39db65ac49c7a52d11122d390f52" contextRef="c20181231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">18,981</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Furniture and fixtures</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_c9e81d98bca94d41b8a299e5e0e5d8a8" contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember_RangeAxis_MinimumMember" format="ixt-sec:duryear">5</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_4ace8e2987224a629f4296698241a73c" contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember_RangeAxis_MaximumMember" format="ixt-sec:duryear">10</ix:nonNumeric></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_4cc9147a7cbc4ee49795347f0fb5a079" contextRef="c20191231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">7,354</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_94b40916e0474421a05f751c4a6948c3" contextRef="c20181231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">6,283</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_e24786e819c34f2797962439fcf6ce74" contextRef="c20191231_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentExcludingLandMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">204,602</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_191a9c51a9564c86b6ddbb7016ec7e8d" contextRef="c20181231_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentExcludingLandMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">179,141</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less accumulated depreciation</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact_c8c6a3d838c64434aeb0fd3c8a6f6727" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">74,013</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact_35a3e65d6be441349ebb2cee7ffa8cd5" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">61,474</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_b19aa12690254ebfbb74e114f415ba73" contextRef="c20191231_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentExcludingLandMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">130,589</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_43f79740c06f430d802eb80d4aee36c7" contextRef="c20181231_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentExcludingLandMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">117,667</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Land</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_34379c34064b4008bd443f086b5b56d2" contextRef="c20191231_PropertyPlantAndEquipmentByTypeAxis_LandMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">23,062</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_640721fc5bba475f8612db62b456d80b" contextRef="c20181231_PropertyPlantAndEquipmentByTypeAxis_LandMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">14,493</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;Total</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_845ce990f2174f7bafb81c35eb3d8604" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">153,651</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_c1ac0d6f145b41659e8c734c98f6f1c8" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">132,160</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322268" continuedAt="Text_46b341a9e8d644a8b79909b44816a322269"><ix:continuation id="Text_b480c0912bba43efb4eb976d9635ed975" continuedAt="Text_b480c0912bba43efb4eb976d9635ed976">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322269" continuedAt="Text_46b341a9e8d644a8b79909b44816a322270"><ix:continuation id="Text_b480c0912bba43efb4eb976d9635ed976">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We depreciate our leasehold improvements using the shorter of the estimated useful life or remaining lease term.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322270" continuedAt="Text_46b341a9e8d644a8b79909b44816a322271">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322271" continuedAt="Text_46b341a9e8d644a8b79909b44816a322272"><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Text_c824b2789e934753b736b5a6841fbd43" contextRef="c20190101to20191231" escape="true" continuedAt="Text_f162ec735a5a40978746c7bf8786b4cb1">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value of Financial Instruments</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322272" continuedAt="Text_46b341a9e8d644a8b79909b44816a322273"><ix:continuation id="Text_f162ec735a5a40978746c7bf8786b4cb1" continuedAt="Text_f162ec735a5a40978746c7bf8786b4cb2">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322273" continuedAt="Text_46b341a9e8d644a8b79909b44816a322274"><ix:continuation id="Text_f162ec735a5a40978746c7bf8786b4cb2">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have estimated the fair value of our financial instruments. The amounts reported for cash, accounts receivable, accounts payable and accrued expenses approximate the fair value because of their short maturities. We report our investment securities at their estimated fair value based on quoted market prices for identical or similar instruments.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322274" continuedAt="Text_46b341a9e8d644a8b79909b44816a322275">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322275" continuedAt="Text_46b341a9e8d644a8b79909b44816a322276"><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" id="Text_ae074b5998d54afa844354162eb3317e" contextRef="c20190101to20191231" escape="true" continuedAt="Text_7aa42d18fb2e4e849ef8eb5965837b361">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Leases</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322276" continuedAt="Text_46b341a9e8d644a8b79909b44816a322277"><ix:continuation id="Text_7aa42d18fb2e4e849ef8eb5965837b361" continuedAt="Text_7aa42d18fb2e4e849ef8eb5965837b362">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322277" continuedAt="Text_46b341a9e8d644a8b79909b44816a322278"><ix:continuation id="Text_7aa42d18fb2e4e849ef8eb5965837b362" continuedAt="Text_7aa42d18fb2e4e849ef8eb5965837b363">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Topic 842 Adoption</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322278" continuedAt="Text_46b341a9e8d644a8b79909b44816a322279"><ix:continuation id="Text_7aa42d18fb2e4e849ef8eb5965837b363" continuedAt="Text_7aa42d18fb2e4e849ef8eb5965837b364">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322279" continuedAt="Text_46b341a9e8d644a8b79909b44816a322280"><ix:continuation id="Text_7aa42d18fb2e4e849ef8eb5965837b364" continuedAt="Text_7aa42d18fb2e4e849ef8eb5965837b365">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In February 2016, the Financial Accounting Standards Board, or FASB, issued amended accounting guidance related to lease accounting. This guidance supersedes the lease requirements we previously followed in Accounting Standards Codification, or ASC, Topic 840, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Leases</span>, or Topic 840, and created a new lease accounting standard, Topic 842, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Leases</span>, or Topic 842. Under Topic 842, an entity will record on its balance sheet all leases with a term longer than one year. Further, an entity will record a liability with a value equal to the present value of payments it will make over the life of the lease (lease liability) and an asset representing the underlying leased asset (right-of-use asset). The new accounting guidance requires entities to determine if its leases are operating or financing leases. Entities will recognize expense for operating leases on a straight-line basis as an operating expense. If an entity determines a lease is a financing lease, it will record both interest and amortization expense and generally the expense will be higher in the earlier periods of the lease. We adopted Topic 842 on January 1, 2019 and adjusted our opening balance sheet on that date for our right-of-use operating lease assets and operating lease liabilities. At adoption, we recorded $<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_791b97c772ad4257ae769911c654eae9" contextRef="c20181231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201602Member" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">13.5</ix:nonFraction> million in right-of-use operating lease assets and $<ix:nonFraction name="us-gaap:OperatingLeaseLiability" id="Fact_dafb303ce0f34188b19899dba00a8508" contextRef="c20181231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201602Member" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">18.5</ix:nonFraction> million in operating lease liabilities, of which we classified $<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_cfa70eddbff644b78e96e7f036178408" contextRef="c20181231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201602Member" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction> million as a current liability. We adopted Topic 842 using the available practical expedients<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification of those leases we had in place as of January 1, 2019. </span>The adoption did not have an impact on our consolidated statement of operations.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322280" continuedAt="Text_46b341a9e8d644a8b79909b44816a322281"><ix:continuation id="Text_7aa42d18fb2e4e849ef8eb5965837b365" continuedAt="Text_7aa42d18fb2e4e849ef8eb5965837b366">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322281" continuedAt="Text_46b341a9e8d644a8b79909b44816a322282"><ix:continuation id="Text_7aa42d18fb2e4e849ef8eb5965837b366" continuedAt="Text_7aa42d18fb2e4e849ef8eb5965837b367">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Leases</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322282" continuedAt="Text_46b341a9e8d644a8b79909b44816a322283"><ix:continuation id="Text_7aa42d18fb2e4e849ef8eb5965837b367" continuedAt="Text_7aa42d18fb2e4e849ef8eb5965837b368">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322283" continuedAt="Text_46b341a9e8d644a8b79909b44816a322284"><ix:continuation id="Text_7aa42d18fb2e4e849ef8eb5965837b368" continuedAt="Text_7aa42d18fb2e4e849ef8eb5965837b369">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We determine if an arrangement contains a lease at inception. We currently only have operating leases. We recognize a right-of-use operating lease asset and associated short- and long-term operating lease liability on our consolidated balance sheet for operating leases greater than one year. Our right-of-use assets represent our right to use an underlying asset for the lease term and our lease liabilities represent our obligation to make lease payments arising from the lease arrangement. We recognize our right-of-use operating lease assets and lease liabilities based on the present value of the future minimum lease payments we will pay over the lease term.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</span>We determined the lease term at the inception of the lease, and in certain cases our lease term could include renewal options if we concluded we were reasonably certain that we will exercise the renewal option.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322284" continuedAt="Text_46b341a9e8d644a8b79909b44816a322285"><ix:continuation id="Text_7aa42d18fb2e4e849ef8eb5965837b369" continuedAt="Text_7aa42d18fb2e4e849ef8eb5965837b3610">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322285" continuedAt="Text_46b341a9e8d644a8b79909b44816a322286"><ix:continuation id="Text_7aa42d18fb2e4e849ef8eb5965837b3610">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As our current leases do not provide an interest rate implicit in the lease, we used our or Akcea&#8217;s incremental borrowing rate, based on the information available on the date we adopted Topic 842 or as of the lease inception date in determining the present value of future payments. Our right-of-use operating lease asset also includes any lease payments we made and excludes any tenant improvement allowances we received. We recognize rent expense for our minimum lease payments on a straight-line basis over the expected term of our lease. We recognize period expenses, such as common area maintenance expenses, in the period we incur the expense.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322286" continuedAt="Text_46b341a9e8d644a8b79909b44816a322287">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>20</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322287" continuedAt="Text_46b341a9e8d644a8b79909b44816a322288"><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="Text_ccc9e6e3414f4ec8a6fb102c6bd6da0b" contextRef="c20190101to20191231" escape="true" continuedAt="Text_91407218dee045a8b2d173f806d187691">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Long-Lived Assets</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322288" continuedAt="Text_46b341a9e8d644a8b79909b44816a322289"><ix:continuation id="Text_91407218dee045a8b2d173f806d187691" continuedAt="Text_91407218dee045a8b2d173f806d187692">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322289" continuedAt="Text_46b341a9e8d644a8b79909b44816a322290"><ix:continuation id="Text_91407218dee045a8b2d173f806d187692">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We evaluate long-lived assets, which include property, plant and equipment and patent costs, for impairment on at least a quarterly basis and whenever events or changes in circumstances indicate that we may not be able to recover the carrying amount of such assets. We recorded charges of $<ix:nonFraction name="us-gaap:AssetImpairmentCharges" id="Fact_1f00325938654d8aaa92961967dd4fe1" contextRef="c20190101to20191231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:AssetImpairmentCharges" id="Fact_d4bb9e72c83944a891eb6db91aae4474" contextRef="c20180101to20181231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:AssetImpairmentCharges" id="Fact_42a5e2e524a746bebd539b59be5602e1" contextRef="c20170101to20171231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction> million for the years ended December 31, 2019, 2018 and 2017, respectively, related primarily to the write-down of intangible assets.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322290" continuedAt="Text_46b341a9e8d644a8b79909b44816a322291">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322291" continuedAt="Text_46b341a9e8d644a8b79909b44816a322292"><ix:nonNumeric name="us-gaap:UseOfEstimates" id="Text_fa52b57cc0c34e458f80bc4eb239131d" contextRef="c20190101to20191231" escape="true" continuedAt="Text_7b354b9c8cf04c7c8d08d67b5a9ed8da1">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Use of Estimates</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322292" continuedAt="Text_46b341a9e8d644a8b79909b44816a322293"><ix:continuation id="Text_7b354b9c8cf04c7c8d08d67b5a9ed8da1" continuedAt="Text_7b354b9c8cf04c7c8d08d67b5a9ed8da2">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322293" continuedAt="Text_46b341a9e8d644a8b79909b44816a322294"><ix:continuation id="Text_7b354b9c8cf04c7c8d08d67b5a9ed8da2">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322294" continuedAt="Text_46b341a9e8d644a8b79909b44816a322295">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322295" continuedAt="Text_46b341a9e8d644a8b79909b44816a322296"><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Text_ea6ca4b7f7044d6782f4b675d057249a" contextRef="c20190101to20191231" escape="true" continuedAt="Text_44113e72eb8746dd94b3b057361a5b6b1">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Stock-Based Compensation Expense</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322296" continuedAt="Text_46b341a9e8d644a8b79909b44816a322297"><ix:continuation id="Text_44113e72eb8746dd94b3b057361a5b6b1" continuedAt="Text_44113e72eb8746dd94b3b057361a5b6b2">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322297" continuedAt="Text_46b341a9e8d644a8b79909b44816a322298"><ix:continuation id="Text_44113e72eb8746dd94b3b057361a5b6b2" continuedAt="Text_44113e72eb8746dd94b3b057361a5b6b3">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We measure stock-based compensation expense for equity-classified awards, principally related to stock options, restricted stock units, or RSUs, and stock purchase rights under our ESPP based on the estimated fair value of the award on the date of grant. We recognize the value of the portion of the award that we ultimately expect to vest as stock-based compensation expense over the requisite service period in our consolidated statements of operations. We reduce stock-based compensation expense for estimated forfeitures at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322298" continuedAt="Text_46b341a9e8d644a8b79909b44816a322299"><ix:continuation id="Text_44113e72eb8746dd94b3b057361a5b6b3" continuedAt="Text_44113e72eb8746dd94b3b057361a5b6b4">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322299" continuedAt="Text_46b341a9e8d644a8b79909b44816a322300"><ix:continuation id="Text_44113e72eb8746dd94b3b057361a5b6b4" continuedAt="Text_44113e72eb8746dd94b3b057361a5b6b5">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We use the Black-Scholes model to estimate the fair value of stock options granted and stock purchase rights under our ESPP. On the grant date, we use our stock price and assumptions regarding a number of variables to determine the estimated fair value of stock-based payment awards. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322300" continuedAt="Text_46b341a9e8d644a8b79909b44816a322301"><ix:continuation id="Text_44113e72eb8746dd94b3b057361a5b6b5" continuedAt="Text_44113e72eb8746dd94b3b057361a5b6b6">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322301" continuedAt="Text_46b341a9e8d644a8b79909b44816a322302"><ix:continuation id="Text_44113e72eb8746dd94b3b057361a5b6b6" continuedAt="Text_44113e72eb8746dd94b3b057361a5b6b7">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We recognize compensation expense for option awards and RSUs using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award were in substance multiple awards, which results in the expense being front-loaded over the vesting period.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322302" continuedAt="Text_46b341a9e8d644a8b79909b44816a322303"><ix:continuation id="Text_44113e72eb8746dd94b3b057361a5b6b7" continuedAt="Text_44113e72eb8746dd94b3b057361a5b6b8">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322303" continuedAt="Text_46b341a9e8d644a8b79909b44816a322304"><ix:continuation id="Text_44113e72eb8746dd94b3b057361a5b6b8" continuedAt="Text_44113e72eb8746dd94b3b057361a5b6b9">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The fair value of RSUs is based on the market price of our common stock on the date of grant. The RSUs we have granted vest annually over a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_9c07a9a996a942cfa5196c4e73d65a5f" contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember" format="ixt-sec:durwordsen">four-year</ix:nonNumeric> period.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322304" continuedAt="Text_46b341a9e8d644a8b79909b44816a322305"><ix:continuation id="Text_44113e72eb8746dd94b3b057361a5b6b9" continuedAt="Text_44113e72eb8746dd94b3b057361a5b6b10">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322305" continuedAt="Text_46b341a9e8d644a8b79909b44816a322306"><ix:continuation id="Text_44113e72eb8746dd94b3b057361a5b6b10">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">See Note 4, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Stockholders&#8217; Equity,</span> for additional information regarding our stock-based compensation plans.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322306" continuedAt="Text_46b341a9e8d644a8b79909b44816a322307">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322307" continuedAt="Text_46b341a9e8d644a8b79909b44816a322308"><ix:nonNumeric name="us-gaap:StockholdersEquityPolicyTextBlock" id="Text_d27c5c60b02f4df9826e0031d2963802" contextRef="c20190101to20191231" escape="true" continuedAt="Text_0d951b9bb0ca4620b2ec2e86d1b2edb21">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Accumulated Other Comprehensive Loss</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322308" continuedAt="Text_46b341a9e8d644a8b79909b44816a322309"><ix:continuation id="Text_0d951b9bb0ca4620b2ec2e86d1b2edb21" continuedAt="Text_0d951b9bb0ca4620b2ec2e86d1b2edb22">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322309" continuedAt="Text_46b341a9e8d644a8b79909b44816a322310"><ix:nonNumeric name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="Text_d8df1a2b2dc24317bc8c70d8750aae0c" contextRef="c20190101to20191231" escape="true" continuedAt="Text_a46b2d78c52147a79e7e58cbdcf42fd11"><ix:continuation id="Text_0d951b9bb0ca4620b2ec2e86d1b2edb22" continuedAt="Text_0d951b9bb0ca4620b2ec2e86d1b2edb23">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Accumulated other comprehensive loss is primarily comprised of unrealized gains and losses on investments, net of taxes and adjustments we made to reclassify realized gains and losses on investments from other accumulated comprehensive loss to our Consolidated Statement of Operations. The following table summarizes changes in accumulated other comprehensive loss for the years ended December 31, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2019</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2018</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2017</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> (in thousands):</span></div>
</ix:continuation></ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322310" continuedAt="Text_46b341a9e8d644a8b79909b44816a322311"><ix:continuation id="Text_a46b2d78c52147a79e7e58cbdcf42fd11" continuedAt="Text_a46b2d78c52147a79e7e58cbdcf42fd12"><ix:continuation id="Text_0d951b9bb0ca4620b2ec2e86d1b2edb23" continuedAt="Text_0d951b9bb0ca4620b2ec2e86d1b2edb24">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322311" continuedAt="Text_46b341a9e8d644a8b79909b44816a322312"><ix:continuation id="Text_a46b2d78c52147a79e7e58cbdcf42fd12" continuedAt="Text_a46b2d78c52147a79e7e58cbdcf42fd13"><ix:continuation id="Text_0d951b9bb0ca4620b2ec2e86d1b2edb24" continuedAt="Text_0d951b9bb0ca4620b2ec2e86d1b2edb25">
<table cellpadding="0" cellspacing="0" id="zf8dcaf0ca45440bba49fa3a29bc22bb5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Beginning balance accumulated other comprehensive loss</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_6f30e6b32fc54ac29484f539ce291bdb" contextRef="c20181231_StatementEquityComponentsAxis_AociIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">32,016</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_19707e9f0bad40fbb1dba6349904c9f1" contextRef="c20171231_StatementEquityComponentsAxis_AociIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">31,759</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_1a98a410f1db4d8f8fc817d58996446f" contextRef="c20161231_StatementEquityComponentsAxis_AociIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">30,358</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Unrealized gains (losses) on securities, net of tax (1)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" id="Fact_cc2b624b002347aca5b376689005c704" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">6,633</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" id="Fact_f4bc7becd02b4abe8419122ceb5ec217" contextRef="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">280</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" id="Fact_8f26788799e14b9bb1344435140f818a" contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">960</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amounts reclassified from accumulated other comprehensive loss</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" id="Fact_0b7e13fbfd214cd4a51d0949e3a3d4e3" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" id="Fact_a8d24fdb304f411ebbfbd80312597613" contextRef="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" id="Fact_3e832d296129439b9c7c04d0ac7ce585" contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">374</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Currency translation adjustment</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" id="Fact_0a2161241cf748ad98c7b5a37ef210e4" contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">93</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" id="Fact_ad85fd5199354df78b105b0532f640eb" contextRef="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">23</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" id="Fact_2cf95908fea8415aa5b562ff94646094" contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">67</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net other comprehensive loss for the period</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" id="Fact_2ce128cedcb64e06a3c8d4d1586e4c6e" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">6,726</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" id="Fact_a2223b8bb7e44f6f89e44f7a99d65ec1" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">257</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" id="Fact_15d14efe39a949dabe720e0cc4f8a8d2" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,401</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ending balance accumulated other comprehensive loss</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_47d26dc5eb544c51b35c31726e80cf7c" contextRef="c20191231_StatementEquityComponentsAxis_AociIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">25,290</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_92c6a81d4cc548c79c16aa702d293bfc" contextRef="c20181231_StatementEquityComponentsAxis_AociIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">32,016</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" id="Fact_d50f6f2316fb42a59ada44dcc1e3f6fc" contextRef="c20171231_StatementEquityComponentsAxis_AociIncludingPortionAttributableToNoncontrollingInterestMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">31,759</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_0d951b9bb0ca4620b2ec2e86d1b2edb25" continuedAt="Text_0d951b9bb0ca4620b2ec2e86d1b2edb26"><ix:continuation id="Text_a46b2d78c52147a79e7e58cbdcf42fd13" continuedAt="Text_a46b2d78c52147a79e7e58cbdcf42fd14"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322312" continuedAt="Text_46b341a9e8d644a8b79909b44816a322313">
<div style="text-align: justify;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>
</ix:continuation></ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_a46b2d78c52147a79e7e58cbdcf42fd14"><ix:continuation id="Text_0d951b9bb0ca4620b2ec2e86d1b2edb26"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322313" continuedAt="Text_46b341a9e8d644a8b79909b44816a322314">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z11d622af5d604f70bd2be3051942ec9a">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:footnote id="Foot_c173053f21eb48f2baac71e2bf36f606" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="Foot_4f28a60e3e41493b92119fa64d10a40d1">A tax benefit of $<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTax" id="Fact_94347ad5e6d2462b8cc18ca1ddce90e2" contextRef="c20190101to20191231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">1.4</ix:nonFraction></ix:footnote><ix:continuation id="Foot_4f28a60e3e41493b92119fa64d10a40d1" continuedAt="Foot_4f28a60e3e41493b92119fa64d10a40d2"> million and $<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTax" id="Fact_b4c227fd58254a14b4a1aab9ae5a2738" contextRef="c20180101to20181231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">0.3</ix:nonFraction></ix:continuation><ix:continuation id="Foot_4f28a60e3e41493b92119fa64d10a40d2" continuedAt="Foot_4f28a60e3e41493b92119fa64d10a40d3"> million was included in other comprehensive loss for the years ended December 31, 2019</ix:continuation><ix:continuation id="Foot_4f28a60e3e41493b92119fa64d10a40d3" continuedAt="Foot_4f28a60e3e41493b92119fa64d10a40d4"> and 2018</ix:continuation><ix:continuation id="Foot_4f28a60e3e41493b92119fa64d10a40d4" continuedAt="Foot_4f28a60e3e41493b92119fa64d10a40d5">, respectively. There was <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossTax" id="Fact_d03ca52bed96438596b3ef0a600a4819" contextRef="c20170101to20171231" unitRef="U001" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:continuation><ix:continuation id="Foot_4f28a60e3e41493b92119fa64d10a40d5" continuedAt="Foot_4f28a60e3e41493b92119fa64d10a40d6"> tax benefit or expense for other comprehensive loss for the year ended December 31, 2017</ix:continuation><ix:continuation id="Foot_4f28a60e3e41493b92119fa64d10a40d6">.</ix:continuation>&#160;</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322314" continuedAt="Text_46b341a9e8d644a8b79909b44816a322315">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322315" continuedAt="Text_46b341a9e8d644a8b79909b44816a322316"><ix:nonNumeric name="us-gaap:DebtPolicyTextBlock" id="Text_da81473855ab4b1397ab41e0c02ea04c" contextRef="c20190101to20191231" escape="true" continuedAt="Text_dbe8043ec614432d96e02c5e8a6293c51">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Convertible Debt</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322316" continuedAt="Text_46b341a9e8d644a8b79909b44816a322317"><ix:continuation id="Text_dbe8043ec614432d96e02c5e8a6293c51" continuedAt="Text_dbe8043ec614432d96e02c5e8a6293c52">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322317" continuedAt="Text_46b341a9e8d644a8b79909b44816a322318"><ix:continuation id="Text_dbe8043ec614432d96e02c5e8a6293c52" continuedAt="Text_dbe8043ec614432d96e02c5e8a6293c53">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At issuance, we accounted for our convertible debt instruments, including our <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_9dac22281bdf451a940008eda1d7a823" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction> percent senior convertible notes, or <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_21cdbefcddab46039805db2aaa0c4339" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>% Notes and <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_d2044d977d4a415c9cadeaa7e187ed54" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction> percent senior convertible notes, or <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_b10b14bf0679415f909b7c584e5b9db5" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>% Notes, that may be settled in cash upon conversion (including partial cash settlement) by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate on the date the notes were issued. In reviewing debt issuances, we were not able to identify any comparable companies that recently issued non-convertible debt instruments. Therefore, we estimated the fair value of the liability component of our notes by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322318" continuedAt="Text_46b341a9e8d644a8b79909b44816a322319"><ix:continuation id="Text_dbe8043ec614432d96e02c5e8a6293c53" continuedAt="Text_dbe8043ec614432d96e02c5e8a6293c54">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322319" continuedAt="Text_46b341a9e8d644a8b79909b44816a322320"><ix:continuation id="Text_dbe8043ec614432d96e02c5e8a6293c54">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We assigned a value to the debt component of our convertible notes equal to the estimated fair value of similar debt instruments without the conversion feature, which resulted in us recording our debt at a discount. We are amortizing our debt issuance costs and debt discount over the life of the convertible notes as additional non-cash interest expense utilizing the effective interest method. For additional information, see Note 3, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Long-Term Obligations and Commitments</span>.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322320" continuedAt="Text_46b341a9e8d644a8b79909b44816a322321">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>21</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322321" continuedAt="Text_46b341a9e8d644a8b79909b44816a322322"><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Text_6d9fef6cc7d04259a699ad6740c48d10" contextRef="c20190101to20191231" escape="true" continuedAt="Text_3b66d09220354022b1c6338d75ca91a21">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Segment Information</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322322" continuedAt="Text_46b341a9e8d644a8b79909b44816a322323"><ix:continuation id="Text_3b66d09220354022b1c6338d75ca91a21" continuedAt="Text_3b66d09220354022b1c6338d75ca91a22">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322323" continuedAt="Text_46b341a9e8d644a8b79909b44816a322324"><ix:continuation id="Text_3b66d09220354022b1c6338d75ca91a22">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We have </span><ix:nonFraction name="us-gaap:NumberOfOperatingSegments" id="Fact_419f6aaf7f954198a58ab39bfb5080c8" contextRef="c20190101to20191231" unitRef="U010" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> operating segments, our Ionis Core segment and Akcea Therapeutics, our majority-owned affiliate. Akcea is </span>a biopharmaceutical company focused on developing and commercializing medicines to treat patients with serious and rare diseases<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. We provide segment financial information and results for our Ionis Core segment and our Akcea Therapeutics segment based on the segregation of revenues and expenses that our chief decision maker reviews to assess operating performance and to make operating decisions. We allocate a portion of Ionis&#8217; development, R&amp;D support and general and administrative expenses to Akcea for work Ionis performs on behalf of Akcea and we bill Akcea for these expenses.</span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322324" continuedAt="Text_46b341a9e8d644a8b79909b44816a322325">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322325" continuedAt="Text_46b341a9e8d644a8b79909b44816a322326"><ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Text_d1e487930af14a5b9c0da0458c9a0a80" contextRef="c20190101to20191231" escape="true" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc173441">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value Measurements</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322326" continuedAt="Text_46b341a9e8d644a8b79909b44816a322327"><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc173441" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc173442">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322327" continuedAt="Text_46b341a9e8d644a8b79909b44816a322328"><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc173442" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc173443">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We use a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets, which includes our money market funds and treasury securities classified as available-for-sale securities and our investment in equity securities in publicly-held biotechnology companies; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable, which includes our fixed income securities and commercial paper classified as available-for-sale securities; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring us to develop our own assumptions. We classify the majority of our securities as Level 2. We obtain the fair value of our Level 2 investments from our custodian bank or from a professional pricing service. We validate the fair value of our Level 2 investments by understanding the pricing model used by the custodian banks or professional pricing service provider and comparing that fair value to the fair value based on observable market prices.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322328" continuedAt="Text_46b341a9e8d644a8b79909b44816a322329"><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc173443" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc173444">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322329" continuedAt="Text_46b341a9e8d644a8b79909b44816a322330"><ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="Text_3b110457f29542f28d1e0eea27b2d971" contextRef="c20190101to20191231" escape="true" continuedAt="Text_ef5c492663ae43cc9b131e5a3b228dad1"><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc173444" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc173445">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following tables present the major security types we held at December 31, 2019 and 2018&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">that we regularly measure and carry at fair value</span>. At December 31, 2019, a portion of our ProQR investment was <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">subject to trading restrictions through the fourth quarter of 2020, as a result we</span> included a lack of marketability discount in valuing this investment, which is a Level 3 input. At December 31, 2018, our ProQR investment was <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">subject to trading restrictions through the fourth quarter of 2019, as a result we</span> included a lack of marketability discount in valuing this investment, which is a Level 3 input. The tables segregate each security type by the level within the fair value hierarchy of the valuation techniques we utilized to determine the respective securities&#8217; fair value (in thousands):</div>
</ix:continuation></ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322330" continuedAt="Text_46b341a9e8d644a8b79909b44816a322331"><ix:continuation id="Text_ef5c492663ae43cc9b131e5a3b228dad1" continuedAt="Text_ef5c492663ae43cc9b131e5a3b228dad2"><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc173445" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc173446">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322331" continuedAt="Text_46b341a9e8d644a8b79909b44816a322332"><ix:continuation id="Text_ef5c492663ae43cc9b131e5a3b228dad2" continuedAt="Text_ef5c492663ae43cc9b131e5a3b228dad3"><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc173446" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc173447">
<table cellpadding="0" cellspacing="0" id="z0cec2f41ef46437e96b40a502fd19a06" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 8pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">At</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quoted Prices in</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Active Markets</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 1)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Significant Other</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Observable Inputs</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 2)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Significant</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Unobservable Inputs</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 3)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cash equivalents (1)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_c019e6ae06e64200907ceaf6cd9642e2" contextRef="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">418,406</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_e16b0ecf33a545d1b4a712e4f2efae2f" contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">418,406</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_eefa2800e09b4d348fe4eea3ed73e20e" contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_3309e6a041b04ac8b0c2bc0e51a2b7af" contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities (2)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_a48bf0d7ba1349e58e4936fc5037bb76" contextRef="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,102,568</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_0690adcb15b64af0b0c13842098e9b68" contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_372fce9620ea4fcb92674a9744117a0f" contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,102,568</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_dcdce4930680418c9c6723d59d0766bf" contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies (3)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_d0fdecfde0594969b57923784dc22c4e" contextRef="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">329,404</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_2d496c63e7fc4f4db6d3d96def177b93" contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_94fd62b1449442d198bd1ba1536e68d9" contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">329,404</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_2265bd19815f4068a52086a7da4852fb" contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury (4)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_bfc11b60b8204c22927b5f6205cfe9b4" contextRef="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">363,694</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_929a4b0adc4b4b7e8aff38356715510b" contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">363,694</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_6e86df31823f42aaa223f9a0dce513f0" contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_972a7f7ceab649b8beac4628d113d401" contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states (4)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_21a61427c87a455b8534f57a12968f6a" contextRef="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">40,407</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_dd6b67a198574e04be9fb121cc80987c" contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_d9174d81bf52404fb4871b9adc8c39ad" contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">40,407</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div></div><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_4e6f9b5b003344d79d80feeaea24381e" contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;"><div><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investment in ProQR Therapeutics N.V. (5)</div></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" id="Fact_3ad78e1baf8a45d8baedda5ec0ee15d5" contextRef="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">4,506</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" id="Fact_be5ad974e87249c580a06f47230219d6" contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" id="Fact_8c4ee761b3584039949879598e5ff4dd" contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" id="Fact_0e852cc477c6465290c90b9918bf4e1e" contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">4,506</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -8.9pt; margin-left: 22.55pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_b383f6d599984bd3b51295d6cb0bc979" contextRef="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,258,985</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_29f2efb673634f019fe1212835028f33" contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">782,100</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_8c28d864022a4a0e91e10d4036681a05" contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,472,379</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_b35385dc7d67458392cde51a59fa3e67" contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">4,506</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322332" continuedAt="Text_46b341a9e8d644a8b79909b44816a322333"><ix:continuation id="Text_ef5c492663ae43cc9b131e5a3b228dad3" continuedAt="Text_ef5c492663ae43cc9b131e5a3b228dad4"><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc173447" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc173448">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322333" continuedAt="Text_46b341a9e8d644a8b79909b44816a322334"><ix:continuation id="Text_ef5c492663ae43cc9b131e5a3b228dad4" continuedAt="Text_ef5c492663ae43cc9b131e5a3b228dad5"><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc173448" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc173449">
<table cellpadding="0" cellspacing="0" id="z6dbe183adeca4fdb81898fb0f23d867c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 8pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">At</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quoted Prices in</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Active Markets</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 1)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Significant Other</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Observable Inputs</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 2)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Significant</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Unobservable Inputs</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 3)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cash equivalents (1)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_c119be8fc8d4422e8e8714cae28a1b7d" contextRef="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">146,281</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_64a733b40fb74b518fbb1f69987bfa71" contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">146,281</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_adeed04e01c04759ab4b5d9eef7ee8b4" contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" id="Fact_02fa0aa5d92f4ff5a0ad5e5c16bc3364" contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities (6)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_476f612dfc4a4ddc8171ae7717eec530" contextRef="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,252,960</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_fc99a9820d3a456aaffbfe4b6e153744" contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_6c1a2a160c664221a7242dfab67b3575" contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,252,960</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_93a97d3b0bc14ef699aa0469026c016a" contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies (4)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_25150245f8544078baf644d29cdc825a" contextRef="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">276,612</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_d58fb10abb6b47a5ace8828f366b7446" contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_b8cc5e04c3774039a93ccc6034f74cdc" contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">276,612</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_4c086c2c3c3e4b11867fb21e86ee9bfa" contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury (7)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_373fed9ce3ba443a8feb7284438f4bb6" contextRef="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">260,154</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_e7e3e68358c94a6991f9bc9a67ba0a25" contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">260,154</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_be401c09516e46dab13e6a290c4e0f85" contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_1eaad4e0aba3488cb7490a9c85c3f710" contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states (4)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_2306dcbd35634a0485a18bef2da7300e" contextRef="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">79,942</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_466914000cd34e929809ae3a3d1dd4e1" contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_b4cbb2969a654ce8975e05064b68c183" contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">79,942</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_bfc230aff26841d7b6cef430106fd85f" contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;"><div><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investment in ProQR Therapeutics N.V. (5)</div></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" id="Fact_2b37972d666b46d1ac6f9e2f013208f4" contextRef="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,349</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" id="Fact_cd8848724d3a4b7c8f698a98cfad6ef8" contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" id="Fact_51a776a3c3724c5da2107bd7882086d5" contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" id="Fact_0e5d97a4f5634458a86e73a8df42af50" contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,349</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -8.9pt; margin-left: 22.55pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_58c677dbf6914befb31c51c42a5f9de8" contextRef="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,017,298</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_eea07a2d8e9d46a790284fc98f7de43b" contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">406,435</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_dc11b10a350e43f09509ec7adfbe3fb1" contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,609,514</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" id="Fact_efc7bd319e6048baa4c12bac36ead8a2" contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,349</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322334" continuedAt="Text_46b341a9e8d644a8b79909b44816a322335"><ix:continuation id="Text_ef5c492663ae43cc9b131e5a3b228dad5" continuedAt="Text_ef5c492663ae43cc9b131e5a3b228dad6"><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc173449" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc1734410">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">________________</div>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322335" continuedAt="Text_46b341a9e8d644a8b79909b44816a322336"><ix:continuation id="Text_ef5c492663ae43cc9b131e5a3b228dad6" continuedAt="Text_ef5c492663ae43cc9b131e5a3b228dad7"><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc1734410" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc1734411">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc1734411" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc1734412"><ix:continuation id="Text_ef5c492663ae43cc9b131e5a3b228dad7" continuedAt="Text_ef5c492663ae43cc9b131e5a3b228dad8"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322336" continuedAt="Text_46b341a9e8d644a8b79909b44816a322337">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zcc6c856321964d22a7f08198e22558a3">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:footnote id="Foot_ad43559c353f456eac7c04729a412d6f" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Included in cash and cash equivalents on our consolidated balance sheet.</ix:footnote></div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322337" continuedAt="Text_46b341a9e8d644a8b79909b44816a322338"><ix:continuation id="Text_ef5c492663ae43cc9b131e5a3b228dad8" continuedAt="Text_ef5c492663ae43cc9b131e5a3b228dad9"><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc1734412" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc1734413">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -36pt; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc1734413" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc1734414"><ix:continuation id="Text_ef5c492663ae43cc9b131e5a3b228dad9" continuedAt="Text_ef5c492663ae43cc9b131e5a3b228dad10"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322338" continuedAt="Text_46b341a9e8d644a8b79909b44816a322339">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z3bb7cbd9edf34eea8445b9bb699f5225">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:footnote id="Foot_77eb85d4142a44a68a7c6b25a7169d1c" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="Foot_058a0362a5144ec592322c844008875b1">$<ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_ce470ce0da684fc0965a0abdbc5bdb8f" contextRef="c20191231_BalanceSheetLocationAxis_CashAndCashEquivalentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">19.0</ix:nonFraction></ix:footnote><ix:continuation id="Foot_058a0362a5144ec592322c844008875b1"> million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</ix:continuation></div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322339" continuedAt="Text_46b341a9e8d644a8b79909b44816a322340"><ix:continuation id="Text_ef5c492663ae43cc9b131e5a3b228dad10" continuedAt="Text_ef5c492663ae43cc9b131e5a3b228dad11"><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc1734414" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc1734415">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc1734415" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc1734416"><ix:continuation id="Text_ef5c492663ae43cc9b131e5a3b228dad11" continuedAt="Text_ef5c492663ae43cc9b131e5a3b228dad12"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322340" continuedAt="Text_46b341a9e8d644a8b79909b44816a322341">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z9302b49ff4924d45b72f0ef80173e32d">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:footnote id="Foot_cc6012bb3041434399bdb287399a913a" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="Foot_805c4ac544b046f1994850f8bf13a7de1">$<ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_94f64bff77254ab4850b08f2bbbd1572" contextRef="c20191231_BalanceSheetLocationAxis_CashAndCashEquivalentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction></ix:footnote><ix:continuation id="Foot_805c4ac544b046f1994850f8bf13a7de1"> million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</ix:continuation></div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322341" continuedAt="Text_46b341a9e8d644a8b79909b44816a322342"><ix:continuation id="Text_ef5c492663ae43cc9b131e5a3b228dad12" continuedAt="Text_ef5c492663ae43cc9b131e5a3b228dad13"><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc1734416" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc1734417">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc1734417" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc1734418"><ix:continuation id="Text_ef5c492663ae43cc9b131e5a3b228dad13" continuedAt="Text_ef5c492663ae43cc9b131e5a3b228dad14"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322342" continuedAt="Text_46b341a9e8d644a8b79909b44816a322343">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zcc7cb538270446d19a63ff93630b2e26">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:footnote id="Foot_f0e1d58ea08e4b55a4c7703dd1e397d3" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Included in short-term investments.</ix:footnote></div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322343" continuedAt="Text_46b341a9e8d644a8b79909b44816a322344"><ix:continuation id="Text_ef5c492663ae43cc9b131e5a3b228dad14" continuedAt="Text_ef5c492663ae43cc9b131e5a3b228dad15"><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc1734418" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc1734419">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc1734419" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc1734420"><ix:continuation id="Text_ef5c492663ae43cc9b131e5a3b228dad15" continuedAt="Text_ef5c492663ae43cc9b131e5a3b228dad16"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322344" continuedAt="Text_46b341a9e8d644a8b79909b44816a322345">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z0a497b435bb34da0940d397a2ee925d1">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:footnote id="Foot_c498c367d1f949d4a789172bf48c4121" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Included in other current assets on our consolidated balance sheet.</ix:footnote>&#160;</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322345" continuedAt="Text_46b341a9e8d644a8b79909b44816a322346"><ix:continuation id="Text_ef5c492663ae43cc9b131e5a3b228dad16" continuedAt="Text_ef5c492663ae43cc9b131e5a3b228dad17"><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc1734420" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc1734421">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc1734421" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc1734422"><ix:continuation id="Text_ef5c492663ae43cc9b131e5a3b228dad17" continuedAt="Text_ef5c492663ae43cc9b131e5a3b228dad18"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322346" continuedAt="Text_46b341a9e8d644a8b79909b44816a322347">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="ze53e73690894408ba98ca5e5e87ae494">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(6)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:footnote id="Foot_7f9ebb5194d04d4294eb3dd811ff49fa" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="Foot_ed17a5115c9c4e638668df77485fdef71">$<ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_901bc85a32f541369ef5a8de46f7eb74" contextRef="c20181231_BalanceSheetLocationAxis_CashAndCashEquivalentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">50.2</ix:nonFraction></ix:footnote><ix:continuation id="Foot_ed17a5115c9c4e638668df77485fdef71"> million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</ix:continuation></div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322347" continuedAt="Text_46b341a9e8d644a8b79909b44816a322348"><ix:continuation id="Text_ef5c492663ae43cc9b131e5a3b228dad18" continuedAt="Text_ef5c492663ae43cc9b131e5a3b228dad19"><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc1734422" continuedAt="Text_8113d6f4626b44a08cb22a2a5bc1734423">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_ef5c492663ae43cc9b131e5a3b228dad19"><ix:continuation id="Text_8113d6f4626b44a08cb22a2a5bc1734423"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322348" continuedAt="Text_46b341a9e8d644a8b79909b44816a322349">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z9da9f51ab1ce4cf8b13bf7b591532750">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(7)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:footnote id="Foot_e11deb538669403f9b23668e7ec77e3b" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="Foot_118a41ae9a55481f8693cb340888b6371">$<ix:nonFraction name="us-gaap:AvailableForSaleSecurities" id="Fact_0be87ae2076b4d75a7c41aba90d2f514" contextRef="c20181231_BalanceSheetLocationAxis_CashAndCashEquivalentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-5" scale="6">14.2</ix:nonFraction></ix:footnote><ix:continuation id="Foot_118a41ae9a55481f8693cb340888b6371"> million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</ix:continuation></div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322349" continuedAt="Text_46b341a9e8d644a8b79909b44816a322350">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>22</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322350" continuedAt="Text_46b341a9e8d644a8b79909b44816a322351"><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" id="Text_757da07036b745328cb726e2edccfa35" contextRef="c20190101to20191231" escape="true" continuedAt="Text_510312cb03ec46b89ae38a6eb14008461">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income Taxes</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322351" continuedAt="Text_46b341a9e8d644a8b79909b44816a322352"><ix:continuation id="Text_510312cb03ec46b89ae38a6eb14008461" continuedAt="Text_510312cb03ec46b89ae38a6eb14008462">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322352" continuedAt="Text_46b341a9e8d644a8b79909b44816a322353"><ix:continuation id="Text_510312cb03ec46b89ae38a6eb14008462" continuedAt="Text_510312cb03ec46b89ae38a6eb14008463">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We account for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. We record a valuation allowance when necessary to reduce our net deferred tax assets to the amount expected to be realized.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322353" continuedAt="Text_46b341a9e8d644a8b79909b44816a322354"><ix:continuation id="Text_510312cb03ec46b89ae38a6eb14008463" continuedAt="Text_510312cb03ec46b89ae38a6eb14008464">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322354" continuedAt="Text_46b341a9e8d644a8b79909b44816a322355"><ix:continuation id="Text_510312cb03ec46b89ae38a6eb14008464" continuedAt="Text_510312cb03ec46b89ae38a6eb14008465">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act of 2017, or the Tax Act. The Tax Act created a new requirement on global intangible low-taxed income, or GILTI, earned by foreign subsidiaries for tax years beginning on or after January 1, 2018. The GILTI provisions require foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#8217;s assets to be included in our U.S. income tax return. Under U.S. GAAP, we are permitted to make an accounting policy election to either treat taxes due on future inclusions in U.S. taxable income related to GILTI as a current-period expense when incurred or to factor such amounts into our measurement of deferred taxes. We have made the election to account for GILTI as a component of current taxes incurred rather than as a component of deferred taxes.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322355" continuedAt="Text_46b341a9e8d644a8b79909b44816a322356"><ix:continuation id="Text_510312cb03ec46b89ae38a6eb14008465" continuedAt="Text_510312cb03ec46b89ae38a6eb14008466">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322356" continuedAt="Text_46b341a9e8d644a8b79909b44816a322357"><ix:continuation id="Text_510312cb03ec46b89ae38a6eb14008466" continuedAt="Text_510312cb03ec46b89ae38a6eb14008467">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We apply the authoritative accounting guidance prescribing a threshold and measurement attribute for the financial recognition and measurement of a tax position taken or expected to be taken in a tax return. We recognize liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step requires us to estimate and measure the tax benefit as the largest amount that is more than 50 percent likely to be realized upon ultimate settlement.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322357" continuedAt="Text_46b341a9e8d644a8b79909b44816a322358"><ix:continuation id="Text_510312cb03ec46b89ae38a6eb14008467" continuedAt="Text_510312cb03ec46b89ae38a6eb14008468">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322358" continuedAt="Text_46b341a9e8d644a8b79909b44816a322359"><ix:continuation id="Text_510312cb03ec46b89ae38a6eb14008468" continuedAt="Text_510312cb03ec46b89ae38a6eb14008469">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are required to use significant judgment in evaluating our uncertain tax positions and determining our provision for income taxes. Although we believe our reserves are reasonable, no assurance can be given that the final tax outcome of these matters will not be different from that which is reflected in our historical income tax provisions and accruals. We adjust these reserves for changing facts and circumstances, such as the closing of a tax audit or the refinement of an estimate. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences may impact the provision for income taxes in the period in which such determination is made.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322359" continuedAt="Text_46b341a9e8d644a8b79909b44816a322360"><ix:continuation id="Text_510312cb03ec46b89ae38a6eb14008469" continuedAt="Text_510312cb03ec46b89ae38a6eb140084610">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322360" continuedAt="Text_46b341a9e8d644a8b79909b44816a322361"><ix:continuation id="Text_510312cb03ec46b89ae38a6eb140084610" continuedAt="Text_510312cb03ec46b89ae38a6eb140084611">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are also required to use significant judgment in determining any valuation allowance recorded against our deferred tax assets. In assessing the need for a valuation allowance, we consider all available evidence, including scheduled reversal of deferred tax liabilities, past operating results, the feasibility of tax planning strategies and estimates of future taxable income. We base our estimates of future taxable income on assumptions that are consistent with our plans. The assumptions we use represent our best estimates and involve inherent uncertainties and the application of our judgment. Should actual amounts differ from our estimates, the amount of our tax expense and liabilities we recognize could be materially impacted.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> We record a valuation allowance to reduce the balance of our net deferred tax assets to the amount we believe is more-likely-than-not to be realized.</span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322361" continuedAt="Text_46b341a9e8d644a8b79909b44816a322362"><ix:continuation id="Text_510312cb03ec46b89ae38a6eb140084611" continuedAt="Text_510312cb03ec46b89ae38a6eb140084612">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322362" continuedAt="Text_46b341a9e8d644a8b79909b44816a322363"><ix:continuation id="Text_510312cb03ec46b89ae38a6eb140084612">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We do not provide for a U.S. income tax liability and foreign withholding taxes on undistributed foreign earnings of our foreign subsidiaries.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322363" continuedAt="Text_46b341a9e8d644a8b79909b44816a322364">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322364" continuedAt="Text_46b341a9e8d644a8b79909b44816a322365"><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Text_bc384ef6d5a446c59da5885dc5771bd9" contextRef="c20190101to20191231" escape="true" continuedAt="Text_b85727dc9f6e416eb2bf563e4b6b475c1">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Impact of Recently Issued Accounting Standards</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322365" continuedAt="Text_46b341a9e8d644a8b79909b44816a322366"><ix:continuation id="Text_b85727dc9f6e416eb2bf563e4b6b475c1" continuedAt="Text_b85727dc9f6e416eb2bf563e4b6b475c2">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322366" continuedAt="Text_46b341a9e8d644a8b79909b44816a322367"><ix:continuation id="Text_b85727dc9f6e416eb2bf563e4b6b475c2" continuedAt="Text_b85727dc9f6e416eb2bf563e4b6b475c3">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In June 2016, the FASB issued guidance that changes the measurement of credit losses for most financial assets and certain other instruments. If we have credit losses, this updated guidance requires us to record allowances for these instruments under a new expected credit loss model. This model requires us to estimate the expected credit loss of an instrument over its lifetime, which represents the portion of the amortized cost basis we do not expect to collect. The new guidance requires us to remeasure our allowance in each reporting period we have credit losses. We adopted this the new guidance on January 1, 2020. We do not expect this guidance will have an impact on our consolidated financial statements.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322367" continuedAt="Text_46b341a9e8d644a8b79909b44816a322368"><ix:continuation id="Text_b85727dc9f6e416eb2bf563e4b6b475c3" continuedAt="Text_b85727dc9f6e416eb2bf563e4b6b475c4">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322368" continuedAt="Text_46b341a9e8d644a8b79909b44816a322369"><ix:continuation id="Text_b85727dc9f6e416eb2bf563e4b6b475c4" continuedAt="Text_b85727dc9f6e416eb2bf563e4b6b475c5">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In August 2018, the FASB issued clarifying guidance on how to account for implementation costs related to cloud-servicing arrangements. The guidance states that if these fees qualify to be capitalized and amortized over the service period, they need to be expensed in the same line item as the service expense and recognized in the same balance sheet category. The update can be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We adopted this guidance on January 1, 2020 on a prospective basis. We do not expect this guidance will have an impact on our consolidated financial statements.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322369" continuedAt="Text_46b341a9e8d644a8b79909b44816a322370"><ix:continuation id="Text_b85727dc9f6e416eb2bf563e4b6b475c5" continuedAt="Text_b85727dc9f6e416eb2bf563e4b6b475c6">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322370" continuedAt="Text_46b341a9e8d644a8b79909b44816a322371"><ix:continuation id="Text_b85727dc9f6e416eb2bf563e4b6b475c6" continuedAt="Text_b85727dc9f6e416eb2bf563e4b6b475c7">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In August 2018, the FASB updated its disclosure requirements related to Level 1, 2 and 3 fair value measurements. The update included deletion and modification of certain disclosure requirements and additional disclosure related to Level 3 measurements. The guidance is effective for fiscal years beginning after December 31, 2019 and early adoption is permitted. We adopted this updated guidance on January 1, 2019 and it did not have a significant impact on our disclosures.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322371" continuedAt="Text_46b341a9e8d644a8b79909b44816a322372"><ix:continuation id="Text_b85727dc9f6e416eb2bf563e4b6b475c7" continuedAt="Text_b85727dc9f6e416eb2bf563e4b6b475c8">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>23</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322372" continuedAt="Text_46b341a9e8d644a8b79909b44816a322373"><ix:continuation id="Text_b85727dc9f6e416eb2bf563e4b6b475c8" continuedAt="Text_b85727dc9f6e416eb2bf563e4b6b475c9">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In November 2018, the FASB issued clarifying guidance of the interaction between the collaboration accounting guidance and the new revenue recognition guidance we adopted on January 1, 2018 (Topic 606). Below is the clarifying guidance and how we will implement it (in italics):</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322373" continuedAt="Text_46b341a9e8d644a8b79909b44816a322374"><ix:continuation id="Text_b85727dc9f6e416eb2bf563e4b6b475c9" continuedAt="Text_b85727dc9f6e416eb2bf563e4b6b475c10">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_b85727dc9f6e416eb2bf563e4b6b475c10" continuedAt="Text_b85727dc9f6e416eb2bf563e4b6b475c11"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322374" continuedAt="Text_46b341a9e8d644a8b79909b44816a322375">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z6b37abcc28844ec1995be6ea3287fde1">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">When a participant is considered a customer in a collaborative arrangement, all of the associated accounting under Topic 606 should be applied</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_b85727dc9f6e416eb2bf563e4b6b475c11" continuedAt="Text_b85727dc9f6e416eb2bf563e4b6b475c12"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322375" continuedAt="Text_46b341a9e8d644a8b79909b44816a322376">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z568b757cadfb43b88346ae2bdab57f19">
  <tr>
    <td style="width: 72pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">We will apply all of the associated accounting under Topic 606 when we determine a participant in a collaborative arrangement is a customer </div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_b85727dc9f6e416eb2bf563e4b6b475c12" continuedAt="Text_b85727dc9f6e416eb2bf563e4b6b475c13"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322376" continuedAt="Text_46b341a9e8d644a8b79909b44816a322377">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z729d51441c36453d9dd29ff6baaa5429">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Adds &#8220;unit of account&#8221; concept to collaboration accounting guidance to align with Topic 606. The &#8220;unit of account&#8221; concept is used to determine if revenue is recognized or if a contra expense is recognized from consideration received under a collaboration</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_b85727dc9f6e416eb2bf563e4b6b475c13" continuedAt="Text_b85727dc9f6e416eb2bf563e4b6b475c14"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322377" continuedAt="Text_46b341a9e8d644a8b79909b44816a322378">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z36356b76546d4b1b9df6a54de364a594">
  <tr>
    <td style="width: 72pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">We will use the &#8220;unit of account&#8221; concept when we receive consideration under a collaborative arrangement to determine when we recognize revenue or a contra expense</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_b85727dc9f6e416eb2bf563e4b6b475c14" continuedAt="Text_b85727dc9f6e416eb2bf563e4b6b475c15"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322378" continuedAt="Text_46b341a9e8d644a8b79909b44816a322379">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="ze5669a8c7b084090bd8ad32061dcc5d9">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The clarifying guidance precludes us from recognizing revenue under Topic 606 when we determine a transaction with a collaborative partner is not a customer and is not directly related to the sales to third parties</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_b85727dc9f6e416eb2bf563e4b6b475c15" continuedAt="Text_b85727dc9f6e416eb2bf563e4b6b475c16"><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322379" continuedAt="Text_46b341a9e8d644a8b79909b44816a322380">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="ze5279de5f245498da7e1f9b7cb96a4f7">
  <tr>
    <td style="width: 72pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">When we conclude a collaboration partner is not a customer and is not directly related to the sales to third parties, we will not recognize revenue for the transaction </div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322380" continuedAt="Text_46b341a9e8d644a8b79909b44816a322381"><ix:continuation id="Text_b85727dc9f6e416eb2bf563e4b6b475c16" continuedAt="Text_b85727dc9f6e416eb2bf563e4b6b475c17">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322381" continuedAt="Text_46b341a9e8d644a8b79909b44816a322382"><ix:continuation id="Text_b85727dc9f6e416eb2bf563e4b6b475c17" continuedAt="Text_b85727dc9f6e416eb2bf563e4b6b475c18">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We adopted this new guidance on January 1, 2020. We do not expect this guidance will have a significant impact on our consolidated financial statements.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322382" continuedAt="Text_46b341a9e8d644a8b79909b44816a322383"><ix:continuation id="Text_b85727dc9f6e416eb2bf563e4b6b475c18" continuedAt="Text_b85727dc9f6e416eb2bf563e4b6b475c19">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_46b341a9e8d644a8b79909b44816a322383"><ix:continuation id="Text_b85727dc9f6e416eb2bf563e4b6b475c19">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In December 2019, the FASB issued guidance to simplify the accounting for income taxes. The update includes removing several exceptions under the existing guidance and includes several simplification updates, none of which apply to our current accounting for income taxes. The guidance is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted. We adopted this updated guidance in the fourth quarter of 2019 and it did not have an impact on our consolidated financial statements or disclosures.</div>
</ix:continuation></ix:continuation></div>
<div><br /></div>
<div><ix:nonNumeric name="us-gaap:InvestmentTextBlock" id="Text_33b4e7480c98452daf1f231b92b474a1" contextRef="c20190101to20191231" escape="true" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e1">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2. Investments</div>
</ix:nonNumeric><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e1" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e2">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e2" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e3"><ix:nonNumeric name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="Text_277e9831a1824875a68a5502ea289e18" contextRef="c20190101to20191231" escape="true" continuedAt="Text_8a2ca77007b948d49e0a5b61629b5b0e1">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes the contract maturity of the available-for-sale securities we held as of December 31, 2019:</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e3" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e4"><ix:continuation id="Text_8a2ca77007b948d49e0a5b61629b5b0e1" continuedAt="Text_8a2ca77007b948d49e0a5b61629b5b0e2">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e4" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e5"><ix:continuation id="Text_8a2ca77007b948d49e0a5b61629b5b0e2">
<table cellpadding="0" cellspacing="0" id="z6c0f78857c00481b9a2fe8abae31c196" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="ions:MaximumContractMaturityPeriodRange1" id="Fact_a0389bbbc04d444aa9945a16f2f77b47" contextRef="c20190101to20191231" format="ixt-sec:durwordsen">One year</ix:nonNumeric> or less</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" id="Fact_e1a84f7ba1234915827448c633c10e96" contextRef="c20191231" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">70</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">After <ix:nonNumeric name="ions:MaximumContractMaturityPeriodRange1" id="Fact_a9a809b245674eb5912c14df728dc0f0" contextRef="c20190101to20191231" format="ixt-sec:durwordsen">one year</ix:nonNumeric> but within <ix:nonNumeric name="ions:MaximumContractMaturityPeriodRange2" id="Fact_d1dd3aa1c3444cc8babea1f02c42cb74" contextRef="c20190101to20191231" format="ixt-sec:durwordsen">two years</ix:nonNumeric></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" id="Fact_54f16a3082454b16a1368f8660393627" contextRef="c20191231" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">After <ix:nonNumeric name="ions:MaximumContractMaturityPeriodRange2" id="Fact_649df9025a904bcfad6dc6ab6bd4c304" contextRef="c20190101to20191231" format="ixt-sec:durwordsen">two years</ix:nonNumeric> but within <span style="-sec-ix-hidden:Fact_5b50da2d62974df399b2ebfcfccf0c30">three and a half years</span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" id="Fact_d60e9c8e586b428c886b9d9653ac0f6e" contextRef="c20191231" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" id="Fact_298fc5ad20a2442399af2cd8e8215ece" contextRef="c20191231" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e5" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e6">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e6" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e7">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As illustrated above, at December 31, 2019, <ix:nonFraction name="ions:AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" id="Fact_971b070bcf6846b8970847cdbaef1457" contextRef="c20191231" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">90</ix:nonFraction> percent of our available-for-sale securities had a maturity of less than <ix:nonNumeric name="ions:MaximumContractMaturityPeriodRange2" id="Fact_e4aa3be8fcd040d0bcd0def824af337d" contextRef="c20190101to20191231" format="ixt-sec:durwordsen">two years</ix:nonNumeric>.</div>
</ix:continuation><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e7" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e8">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e8" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e9">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">All of our available-for-sale securities are available to us for use in our current operations. As a result, we categorize all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</div>
</ix:continuation><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e9" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e10">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e10" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e11">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At December 31, 2019, we had an ownership interest of less than 20 percent <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">in </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:nonFraction name="ions:NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" id="Fact_c487d989afb240aaae9be0536d4b8656" contextRef="c20191231" unitRef="U009" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction></span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> private companies and </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:nonFraction name="ions:NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" id="Fact_cc8fa179d30548a7b52fcdc75fe7eeee" contextRef="c20191231" unitRef="U009" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> public companies with which we conduct business. The privately-held companies are </span>Atlantic Pharmaceuticals Limited, Dynacure SAS, Empirico, Inc., Seventh Sense Biosystems and Suzhou Ribo Life Science Co, Ltd.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The publicly traded companies are ATL and ProQR. </span></div>
</ix:continuation><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e11" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e12">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>24</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e12" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e13"><ix:nonNumeric name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="Text_25f9d7aa00504b8ca3d76245ab5a2ce0" contextRef="c20190101to20191231" escape="true" continuedAt="Text_6b7043123d7040528aacf680d1654cf21">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following is a summary of our investments (in thousands):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e13" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e14"><ix:continuation id="Text_6b7043123d7040528aacf680d1654cf21" continuedAt="Text_6b7043123d7040528aacf680d1654cf22">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e14" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e15"><ix:continuation id="Text_6b7043123d7040528aacf680d1654cf22" continuedAt="Text_6b7043123d7040528aacf680d1654cf23">
<table cellpadding="0" cellspacing="0" id="zf9b6c17e2c154c6ab71c1ee67da358d6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gross Unrealized</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Estimated</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2019</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Cost </span>(1)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gains</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Losses</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Available-for-sale securities:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities (2)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_bc9e70d55b674cc9b6be541478de94e8" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">669,665</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_0c24393396f14a5fadd7e6d9dd062834" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,451</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_615e6981ef5c43e4afa6a302941c0754" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">43</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_0a185c2049a6469e81e8e4df671bb2f5" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">671,073</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_c9d17af33c554c64ac738dfbdb48494c" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">188,216</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_e61b3c1e7a7a45d7a7ce7d512404dfea" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">303</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_8cd5ebaff4ff47b59a6f49c94f90f5e4" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">43</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_dc66d2f463f54767abee4fc4f62595f6" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">188,476</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury (2)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_f00bcd75b4b842ec98fdc045c48c2576" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">327,670</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_d6b1880a34fc425f848f593694e21d3b" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">232</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_52ee12eba4604cd6beb6d916ef074d49" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">27</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_93f61f2dcaf249fe8c2941b0bedb2ad6" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">327,875</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_f17e37bd45aa4fdbae4827a34aa7dac9" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">21,065</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_8da02b683fe94c99ae3334fe0583bcbf" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">26</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_f5548b5e22d64358b14bff13c4cde745" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_5215ece6e8674be582ac13fad8e0e02f" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">21,086</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total securities with a maturity of one year or less</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_06b37f3d76b24645b428aed40ef7519d" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,206,616</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_868aecd154b3411fad39ee7f067ae085" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,012</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_27ce74de3a8d48ed86f8ce84429f7f33" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">118</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_7cbbbf68a23c4d05acea3eb703650eb7" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,208,510</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_68c90e44ae7142faa5c935422fe6ca01" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">428,627</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_0ecb6c8cead3473f9be6b9fc2b15d79f" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,911</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_4f2e99491c92483882c5013894e5a3b4" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">43</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_8078467ba1d947589f274b1470ccc8c7" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">431,495</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_e4c79d28e0dd438c896e0c5148cdbae0" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">140,988</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_c3fb53b35b5e4f0a801fb17377bbe452" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">57</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_f20247b6d2f84ccbbb1dbab68b9cd3d6" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">117</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_a656c02b450b4ae39000dbd1d10a2d67" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">140,928</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_160b2612c5ff403daa0b23ecdd2866db" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">35,822</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_b1272ac8ac42497ba65853e630ea020a" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">9</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_803581e2009f4b95bf2af6ab10413c74" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">12</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_32fdcfaa188c4467a9bc336b98ee4765" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">35,819</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_4ae16ba11af3451383afc794f381425b" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">19,309</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_fee237831c094d6db8d66deaea062f6b" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">18</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_b46d7b7d41284f92910e48dd0d37da98" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_072a76897a5042d8befaddf252441541" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">19,321</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total securities with a maturity of more than one year</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_b71803caad4d4886ad41f6bbc5e209f5" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">624,746</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_8a0a49d9cc1e4c129249d0be27e415f2" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,995</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_0ca92b9c73b2492aadcfbe4f82a50cb4" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">178</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_91167061047b48f4b8610c1a21447584" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">627,563</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total available-for-sale securities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_a5e37551797746d7832fc5653898ad64" contextRef="c20191231_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,831,362</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_5784263002924b25aff1cb14f626bf7f" contextRef="c20191231_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">5,007</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_7654b51ce0a5448fa1c5723b77e4a3cd" contextRef="c20191231_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">296</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_fb3ebfc0325446129501360d15bf62ff" contextRef="c20191231_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,836,073</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Equity securities:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total equity securities included in other current assets (3)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiCost" id="Fact_cef09f69ddec4b3dabee2b4ce3e2377b" contextRef="c20191231_BalanceSheetLocationAxis_OtherCurrentAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">4,712</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" id="Fact_3f654be6d96e41e4b4713c77ccf1c8e3" contextRef="c20190101to20191231_InvestmentSecondaryCategorizationAxis_IncludedInOtherCurrentAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" id="Fact_3d2a388042994347ab5102d669861a7d" contextRef="c20190101to20191231_InvestmentSecondaryCategorizationAxis_IncludedInOtherCurrentAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">870</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" id="Fact_2d87969d9ae34d49b910e43cebb1d676" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_IncludedInOtherCurrentAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,842</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total equity securities included in deposits and other assets (4)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiCost" id="Fact_9ebd36323e384809b15acae0a3551932" contextRef="c20191231_BalanceSheetLocationAxis_DepositsAndOtherAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">10,000</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" id="Fact_aed73c2c4de9479b940ffa549e9fedd0" contextRef="c20190101to20191231_InvestmentSecondaryCategorizationAxis_IncludedInDepositsAndOtherAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" id="Fact_1f1394dc79044e9197f515e0b7bca042" contextRef="c20190101to20191231_InvestmentSecondaryCategorizationAxis_IncludedInDepositsAndOtherAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" id="Fact_acab1218ec2e41199e1b320128741143" contextRef="c20191231_InvestmentSecondaryCategorizationAxis_IncludedInDepositsAndOtherAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">10,000</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total equity securities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiCost" id="Fact_1f62fdc7a62342f68a33d50b3bde0a58" contextRef="c20191231_InvestmentTypeAxis_EquitySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">14,712</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" id="Fact_c2b1f14b00d941b6b317ee97742c8d96" contextRef="c20190101to20191231_InvestmentTypeAxis_EquitySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">-</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" id="Fact_9d1928afc7224324b66d25fddff38253" contextRef="c20190101to20191231_InvestmentTypeAxis_EquitySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">870</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" id="Fact_594521b1bd6241bea5eaec95f58271c0" contextRef="c20191231_InvestmentTypeAxis_EquitySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">13,842</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total available-for-sale and equity securities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" id="Fact_afee4ce7ef954363a1010e810f1ae960" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,846,074</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" id="Fact_a346c4f456874316909407a757ecc1b7" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">5,007</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" id="Fact_0bd6c064edff43c09905fc28e289473e" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,166</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" id="Fact_f35d561e61484f2295cadeeb2d03bdbd" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,849,915</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e15" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e16"><ix:continuation id="Text_6b7043123d7040528aacf680d1654cf23" continuedAt="Text_6b7043123d7040528aacf680d1654cf24">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e16" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e17"><ix:continuation id="Text_6b7043123d7040528aacf680d1654cf24" continuedAt="Text_6b7043123d7040528aacf680d1654cf25">
<table cellpadding="0" cellspacing="0" id="z13827f1de67a455a9892b6f4cd0857a7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gross Unrealized</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Estimated</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2018</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Cost </span>(1)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gains</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Losses</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Available-for-sale securities:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities (2)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_8ea119980dc64034994a6b7ad86f848c" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">956,879</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_6df2fbe2752e4bd0bb77abf8abe0ae29" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">13</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_73421ff544c5487b9e733e95b060b569" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,858</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_c85091a5a55a45a881f09b4c8c70a29c" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">955,034</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_da1b311c89004135b55ecee7befa549d" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">168,839</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_6c6ca7c3257b46848b5da442e9d2b424" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_f8696120bd5749f081186004728dcfec" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">104</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_ba83c8acf52443779871f0f7f21e0f69" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">168,738</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_267f46317f0b40caa2f037611c038a1e" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">244,640</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_2d25c6a792494377addd272a5b8dded6" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">15</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_f56cc4d0d90d4e7fbb8f72585969858c" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">77</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_0c7a5d61dae34de8a30b14b8802b8785" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">244,578</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states (2)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_2665cd241db44217ad8643b9ae2a63da" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">63,572</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_5244a18f7849464e8277366dd5790037" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_703babc31466440681b56330914ed672" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">323</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_8732df0d6eac436fa8da11aab067289a" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">63,249</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total securities with a maturity of one year or less</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_f91f4bf7895e4255b6fb1606547e04c4" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,433,930</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_58f014330e0d46f68ac56681d9bcc775" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">31</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_4d687e924d2549c292e3b98c471a8b1c" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,362</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_5b653caa5875494f883c075c43b1bf5c" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,431,599</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_90b66da8071a4a14ae79ae20e35a4725" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">299,018</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_6969869c8ab34390a5923698c47c72bb" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">194</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_fa5a358807714f81a4468c02e061a381" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,286</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_c8341442a25e450b8c2a53f28afa5bbb" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">297,926</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_627bd1dd191a4e2aa0ffcac3c093515e" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">107,789</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_de7b01c6aeff4c67be7342b578227fe7" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">194</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_6dd609ef5c9d4c5abd47201f2f3c3971" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">109</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_01ade62c43ae4d1d9d121b813ab06110" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">107,874</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_1a4e37f7b16f498caa99b193ac3977d1" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">15,600</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_9e774f36b3824b5da1f596ef542f70e8" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_fcf3826f90e44039b289f8286697222d" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">24</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_3834f60c806146fdb57604df4ca44d5f" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">15,576</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_3b50fc36268c472c83543a498f74c6a3" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">16,980</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_3cc6fe9c6c684eabbb359b5b57a83381" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_f9f79be238454b459039ee2cf29f6635" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">287</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_285a93f311de42a8b8b01192c7d0cee6" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">16,693</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total securities with a maturity of more than one year</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_be05404e83c643348777fa91b0e1b9ba" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">439,387</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_80c5acbabb8c4f0bb30f07636779a6ef" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">388</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_2d2b1cb797c643148d37d334e933eeb2" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,706</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_2bbc29a667a94cb99ff6c9f040ebeea6" contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">438,069</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total available-for-sale securities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" id="Fact_8caafd476a3541b9aef7c098cc041e94" contextRef="c20181231_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,873,317</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" id="Fact_609132a66d2f4130b140a88c2fb0c89d" contextRef="c20181231_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">419</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" id="Fact_b09e4761e6054b25a622ed40b8db284e" contextRef="c20181231_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">4,068</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="Fact_4de7d9b3be6d447db4b3c3fe0b8f036b" contextRef="c20181231_InvestmentTypeAxis_DebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,869,668</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Equity securities:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total equity securities included in other current assets (3)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiCost" id="Fact_ddb646a5d0f1447b92caf9f07a627fcd" contextRef="c20181231_BalanceSheetLocationAxis_OtherCurrentAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,212</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" id="Fact_88ed4a2745c54e14a622755a003ef7d5" contextRef="c20180101to20181231_InvestmentTypeAxis_EquitySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">137</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" id="Fact_b4cdd38512ef47d9b5d3df0de25143e1" contextRef="c20180101to20181231_InvestmentTypeAxis_EquitySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EquitySecuritiesFvNi" id="Fact_c71d4b805e374b9696b1907d0c3b8708" contextRef="c20181231_InvestmentTypeAxis_EquitySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,349</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total available-for-sale and equity securities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" id="Fact_fd07a2a1606f48d78bc5fb285d90a137" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,874,529</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" id="Fact_f166a5e138d3457b82d04bfee0b2aaa8" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">556</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" id="Fact_377148fd543d4bcd9b069e1883f63342" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">4,068</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" id="Fact_250e88ec455a48818d6c542e743f1801" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,871,017</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e17" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e18"><ix:continuation id="Text_6b7043123d7040528aacf680d1654cf25" continuedAt="Text_6b7043123d7040528aacf680d1654cf26">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_6b7043123d7040528aacf680d1654cf26" continuedAt="Text_6b7043123d7040528aacf680d1654cf27"><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e18" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e19">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z784ee7f1d4b643169b5db132e0df44a0">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:footnote id="Foot_41dc381daf5c41bb92e06d06481bf7a5" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">We hold our available-for-sale securities at amortized cost.</ix:footnote></div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e19" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e20"><ix:continuation id="Text_6b7043123d7040528aacf680d1654cf27" continuedAt="Text_6b7043123d7040528aacf680d1654cf28">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_6b7043123d7040528aacf680d1654cf28" continuedAt="Text_6b7043123d7040528aacf680d1654cf29"><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e20" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e21">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z0db8278eb43646f79139982440394852">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:footnote id="Foot_88fe67a8cca841eaa8660167eec626fe" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Includes investments classified as cash equivalents on our consolidated balance sheet.</ix:footnote></div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e21" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e22"><ix:continuation id="Text_6b7043123d7040528aacf680d1654cf29" continuedAt="Text_6b7043123d7040528aacf680d1654cf210">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_6b7043123d7040528aacf680d1654cf210" continuedAt="Text_6b7043123d7040528aacf680d1654cf211"><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e22" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e23">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z72201901808a45b9b3f1774f8add5ea2">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:footnote id="Foot_33f87045331d4d29a03153170558d0a1" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="Foot_c3f135792d8a4093a361a8c10382a34c1">Our equity securities included in other current assets consisted of our investment in ProQR, which is a public company. We recognize our public company equity securities at</ix:footnote></span><ix:continuation id="Foot_c3f135792d8a4093a361a8c10382a34c1"> fair value.</ix:continuation></div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e23" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e24"><ix:continuation id="Text_6b7043123d7040528aacf680d1654cf211" continuedAt="Text_6b7043123d7040528aacf680d1654cf212">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_6b7043123d7040528aacf680d1654cf212"><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e24" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e25">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z3d706207d5ac4b169c0cbd627c904d24">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:footnote id="Foot_92f3ab0ee45a44b9baf44a6e4c6792b4" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="Foot_2df91347c84449a8938ca0631276400d1">Our equity securities included in deposits and other assets consisted of our investment in Empirico, which is a private company. We recognize our private company equity securities at</ix:footnote></span><ix:continuation id="Foot_2df91347c84449a8938ca0631276400d1" continuedAt="Foot_2df91347c84449a8938ca0631276400d2"> cost minus impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer</ix:continuation><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:continuation id="Foot_2df91347c84449a8938ca0631276400d2"> on our consolidated balance sheet.</ix:continuation></span></div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e25" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e26">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>25</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e26" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e27"><ix:nonNumeric name="us-gaap:ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock" id="Text_cba310dfefea46e783635573366c8a41" contextRef="c20190101to20191231" escape="true" continuedAt="Text_549101c081ac404ea0541646858af9131">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investments we consider to be temporarily impaired at December 31, 2019 are as follows (in thousands):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e27" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e28"><ix:continuation id="Text_549101c081ac404ea0541646858af9131" continuedAt="Text_549101c081ac404ea0541646858af9132">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e28" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e29"><ix:continuation id="Text_549101c081ac404ea0541646858af9132">
<table cellpadding="0" cellspacing="0" id="zc70ed2d8b7b040eaa431c9f6deed2462" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Less than 12 Months of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Temporary Impairment</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">More than 12 Months of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Temporary Impairment</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total Temporary</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Impairment</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Number of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Investments</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Estimated</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Unrealized</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Losses</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Estimated</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Unrealized</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Losses</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Estimated</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Unrealized</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Losses</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" id="Fact_f9618b2492ae44b9b2470cf733ce4b89" contextRef="c20191231_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U011" decimals="0" scale="0" format="ixt:numdotdecimal">49</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" id="Fact_8a4ee48acfb249da93ed76eb27590389" contextRef="c20191231_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">131,702</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" id="Fact_c22fdf6c8a284c929edd1d1e31715069" contextRef="c20191231_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">75</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" id="Fact_ae913f21594f4e35afd8a76532ae424d" contextRef="c20191231_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">11,840</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" id="Fact_43ae0d4a4c054ce9ac7eda928a66f3ce" contextRef="c20191231_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">11</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" id="Fact_ec87642bcf1e414893317ddf8e9a318b" contextRef="c20191231_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">143,542</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" id="Fact_78ffaf6a2e0a4600a0863fb17ff1167b" contextRef="c20191231_InvestmentTypeAxis_CorporateDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">86</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" id="Fact_f0a1839edcc7432e98746bb64c9ee469" contextRef="c20191231_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U011" decimals="0" scale="0" format="ixt:numdotdecimal">43</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" id="Fact_b304ca8379be480192f74af7587a8091" contextRef="c20191231_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">149,731</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" id="Fact_301a9ca5e351446b9207bca35ae755e0" contextRef="c20191231_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">136</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" id="Fact_9b1b03fbb4cf4eecac345367db167657" contextRef="c20191231_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">37,041</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" id="Fact_9d6b816f7b4142c18af47ff9cfd9f58f" contextRef="c20191231_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">24</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" id="Fact_3e15c3eb96834a428a8667e2fb4e22b1" contextRef="c20191231_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">186,772</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" id="Fact_6e0af781bd10431daa022f5cd9efe3b5" contextRef="c20191231_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">160</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 16%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" id="Fact_c1029e647fba4541b4d7263304fd79cc" contextRef="c20191231_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U011" decimals="0" scale="0" format="ixt:numdotdecimal">10</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" id="Fact_d716f3ced7e84d1798d4c4fa34d6a57d" contextRef="c20191231_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">84,270</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" id="Fact_f5f5355986bb47ef8a1ca8923caf0a85" contextRef="c20191231_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">39</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" id="Fact_9b9a73b628f344808c7ab85c6a75d8d1" contextRef="c20191231_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" id="Fact_174a3baf01714eeeb108a54a57ca43f7" contextRef="c20191231_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" id="Fact_ed030e10b084484a9b80a80825ca4cb5" contextRef="c20191231_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">84,270</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" id="Fact_58dcc7edf31940d68b9dd446115a1dfd" contextRef="c20191231_InvestmentTypeAxis_USTreasurySecuritiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">39</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 16%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" id="Fact_6a4598e27cbb4ce3834c5c94e2c9c9ef" contextRef="c20191231_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U011" decimals="0" scale="0" format="ixt:numdotdecimal">11</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" id="Fact_d2cb2e04792f444ca946c37374eeb936" contextRef="c20191231_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">10,241</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" id="Fact_0766a8e2b98249298b9034c82546a6aa" contextRef="c20191231_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">5</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" id="Fact_6be64d751387431f8ba145348542de66" contextRef="c20191231_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">10,303</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" id="Fact_8324ced774214cbd90bb510a612d290b" contextRef="c20191231_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">6</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" id="Fact_504113a73418469ebd7cef470ea4110b" contextRef="c20191231_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">20,544</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" id="Fact_ab7ea417914c4216add9d8b5bcfc1435" contextRef="c20191231_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">11</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 16%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total temporarily impaired securities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" id="Fact_38afc72bdce54d76994f6fb7a69caed9" contextRef="c20191231" unitRef="U011" decimals="0" scale="0" format="ixt:numdotdecimal">113</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" id="Fact_74871fb2d35c495cbb8413d5c53f03ee" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">375,944</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" id="Fact_7c6e399d14d947288451729c35801e95" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">255</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" id="Fact_87f419c8d84b49258b687bc0e4069426" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">59,184</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" id="Fact_093fdc7dd87f4ffb94e8b8f388a333f4" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">41</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" id="Fact_c04e62a976624d76bc5f1b3453b01bc4" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">435,128</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" id="Fact_80adec327e3b4b73825cd52dd312f579" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">296</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e29" continuedAt="Text_0ffbb3ba420741b3a42f3f5c63171b2e30">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_0ffbb3ba420741b3a42f3f5c63171b2e30">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We believe that the decline in value of our debt securities is temporary and primarily related to the change in market interest rates since purchase. We believe it is more likely than not that we will be able to hold these securities to maturity. Therefore, we anticipate full recovery of our debt securities&#8217; amortized cost basis at maturity.</div>
</ix:continuation></div>
<div><br /></div>
<div><ix:nonNumeric name="us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock" id="Text_a58b6e796bad49fe998eefa2a578a4e7" contextRef="c20190101to20191231" escape="true" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c1">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3. Long-Term Obligations and Commitments</div>
</ix:nonNumeric><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c1" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c2">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c2" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c3"><ix:nonNumeric name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="Text_208586d6f378473eabd791ddd2021443" contextRef="c20190101to20191231" escape="true" continuedAt="Text_d9ef03c2aa184069852371c0d9d125cd1">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The carrying value of our long-term obligations was as follows (in thousands):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c3" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c4"><ix:continuation id="Text_d9ef03c2aa184069852371c0d9d125cd1" continuedAt="Text_d9ef03c2aa184069852371c0d9d125cd2">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c4" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c5"><ix:continuation id="Text_d9ef03c2aa184069852371c0d9d125cd2" continuedAt="Text_d9ef03c2aa184069852371c0d9d125cd3">
<table cellpadding="0" cellspacing="0" id="z3479120fb70c49dfbea272f920706f19" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_e8724a5b059d4f8799a8feaa202dd539" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction> percent convertible senior notes</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:LongTermDebtAndOtherObligations" id="Fact_cc24fb43c0744f1c98325749d3d1c0eb" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">434,711</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:LongTermDebtAndOtherObligations" id="Fact_65be5fa6a2434040beb0d9ae2a2ca4aa" contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_678c9c8d08e84bc49b41f282f783fa1e" contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_d0d025675d994c9489fb7c521ed3ca93" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></ix:nonFraction> percent convertible senior notes</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:LongTermDebtAndOtherObligations" id="Fact_cab8c72e622844b2bff548c7151f9645" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">275,333</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:LongTermDebtAndOtherObligations" id="Fact_263762c2879f49e19df48df907a46cf1" contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">568,215</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Long-term mortgage debt</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:LongTermDebtAndOtherObligations" id="Fact_7526ddee5b884532b24be01e4d495612" contextRef="c20191231_DebtInstrumentAxis_LongTermMortgageDebtMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">59,913</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:LongTermDebtAndOtherObligations" id="Fact_1a31cb06bce14608b6b4bc53c537a2e8" contextRef="c20181231_DebtInstrumentAxis_LongTermMortgageDebtMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">59,842</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Principal balance of fixed rate note with Morgan Stanley (1)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:LongTermDebtAndOtherObligations" id="Fact_e8de7b5791e54d49b936fa0044b283a0" contextRef="c20191231_DebtInstrumentAxis_FixedRateNoteWithMorganStanleyMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:LongTermDebtAndOtherObligations" id="Fact_dd04e3efb270478489cafc35f9191531" contextRef="c20181231_DebtInstrumentAxis_FixedRateNoteWithMorganStanleyMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">12,500</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Leases and other obligations</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:LongTermDebtAndOtherObligations" id="Fact_4f4ce1cf534445a182bc4dc79c4da3ed" contextRef="c20191231_DebtInstrumentAxis_LeasesAndOtherObligationsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">17,569</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:LongTermDebtAndOtherObligations" id="Fact_14ee837947184542bf24c811e63d710b" contextRef="c20181231_DebtInstrumentAxis_LeasesAndOtherObligationsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">6,163</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:LongTermDebtAndOtherObligations" id="Fact_67f1e8de33db4b3ba71a251d6969a0e4" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">787,526</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:LongTermDebtAndOtherObligations" id="Fact_0db6c0acf39c4704b8b7fb0682124be0" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">646,720</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less: current portion</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" id="Fact_66f728e151b74fe99d367269b42506b7" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,026</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" id="Fact_6b303576d07b435ebdc0b94cf229a5a7" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">13,749</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total Long-Term Obligations</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:LongTermDebtAndOtherObligationsNoncurrent" id="Fact_147209ef0e4d4ccf9a6541966995a76b" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">785,500</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:LongTermDebtAndOtherObligationsNoncurrent" id="Fact_85488b1118b143d68b8dce7fa49d282e" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">632,971</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c5" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c6"><ix:continuation id="Text_d9ef03c2aa184069852371c0d9d125cd3" continuedAt="Text_d9ef03c2aa184069852371c0d9d125cd4">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_d9ef03c2aa184069852371c0d9d125cd4"><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c6" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c7">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z2d1da80f1e1b4c8fb24d5d884387f78e">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:footnote id="Foot_9a970986ba874d05b3ae45569fb070a7" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="Foot_b1dc963afbb64d67a50bbb1fb3ec169e1">Our $<ix:nonFraction name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" id="Fact_85c8de06d6504ef7b8e7379132dfcceb" contextRef="c20181231_DebtInstrumentAxis_FixedRateNoteWithMorganStanleyMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">12.5</ix:nonFraction></ix:footnote><ix:continuation id="Foot_b1dc963afbb64d67a50bbb1fb3ec169e1"> million fixed rate note with Morgan Stanley was included in our current portion of long-term obligations on our consolidated balance sheet at December 31, 2018. We paid off our fixed rate note in the third quarter of 2019.</ix:continuation></div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c7" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c8">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c8" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c9">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Convertible Notes and Call Spread</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c9" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c10">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c10" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c11">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_4bea2f4a817c43a9a04ad1e23ed64460" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction> Percent</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Convertible Senior Notes</span></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c11" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c12">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c12" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c13">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In December 2019, we entered into privately negotiated exchange and/or subscription agreements with certain new investors and certain holders of our existing <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_1870776015794dfc8ef5f8b1e447336c" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>%</span> Notes to exchange $<ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" id="Fact_c20e03a6b29c48f297e64a4679fa9c5f" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">375.6</ix:nonFraction> million of our <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_b16e24609ee743c7bc4f5ff336547c52" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>%</span> Notes for $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_712a7e9c20e2446687234da15c55574b" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">439.3</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>million of our <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_ee88310c4297461c9e36d233141d8e6d" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>% Notes, and to issue $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_4fb2d114d9054ec1ab34d5bc942df800" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">109.5</ix:nonFraction> million of our <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_91e74186c76c4d6f9f3b0792c25a8126" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>% Notes. We completed this exchange to reduce our cash interest payments, increase our conversion price and extend our maturity for a large portion of our debt. Additionally, i<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">n conjunction with the December 2019 exchange, we entered into a call spread transaction, which was comprised of purchasing note hedges and selling warrants, to minimize the impact of potential economic dilution upon conversion of our </span><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_b678b3b287184ce883f541de9b3318b0" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>% Notes<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> by increasing the effective conversion price even further.</span></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c13" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c14">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c14" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c15">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Interest is payable semi-annually on June 15 and December 15 of each year for the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_243b14e84d1842d5a1561cbadfdc7501" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>%</span> Notes. The <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_aca37e6592634dfea9eef91832500545" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>%</span> Notes are convertible at the option of the note holders prior to August 1, 2024 only under certain conditions. On or after August 1, 2024, the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_93e447d776f44e03b6def90e87589945" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>%</span> Notes are initially convertible into approximately <ix:nonFraction name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" id="Fact_bdb0f6e71c464c07a7fcbc83441b7a3d" contextRef="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">6.6</ix:nonFraction> million shares of common stock at a conversion price of approximately $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" id="Fact_11e47b80c0ea4c0b84c2b33098b7b371" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">83.28</ix:nonFraction> per share. We will settle conversions of the notes, at our election, in cash, shares of our common stock or a combination of both. We may not redeem the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_1853ce4f8b7b48fd95ac8e504bc98be7" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>%</span> Notes prior to maturity, and no sinking fund is provided for them. If we undergo a fundamental change, holders may require us to purchase for cash all or any portion of their <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_dfcecee6bd19487eaf70edea7c8f81ca" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>%</span> Notes at a purchase price equal to <ix:nonFraction name="ions:DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" id="Fact_c714ec93e83942c5ab6d1b22a0ca3d32" contextRef="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction> percent of the principal amount of the notes to be purchased, plus accrued and unpaid interest to, but excluding, the fundamental change purchase date.</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c15" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c16">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>26</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c16" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c17"><ix:nonNumeric name="us-gaap:ConvertibleDebtTableTextBlock" id="Text_a71fb8ccb76643209283717603f36b68" contextRef="c20190101to20191231" escape="true" continuedAt="Text_a39aa6c3194d4f8da6630e3328609d401">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At December 31, 2019, we had the following <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_0e5fc93e472946cc9732114aaf09fe86" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>%</span> Notes outstanding (amounts in millions except price per share data):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c17" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c18"><ix:continuation id="Text_a39aa6c3194d4f8da6630e3328609d401" continuedAt="Text_a39aa6c3194d4f8da6630e3328609d402">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c18" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c19"><ix:continuation id="Text_a39aa6c3194d4f8da6630e3328609d402" continuedAt="Text_a39aa6c3194d4f8da6630e3328609d403">
<table cellpadding="0" cellspacing="0" id="za16edea38bc54e628301a72484af85b3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: top; padding-bottom: 2px; white-space: nowrap;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_b355bf734b4d4619b79d46bb66e07d75" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>% <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Notes</span></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Outstanding principal balance</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" id="Fact_57777fe91a8e4f29a6ef267206ee9a82" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">548.8</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Maturity date</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: top; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_717eebd3862f421ca0587a6d283178c9" contextRef="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" format="ixt:datemonthdayyearen">December 15, 2024</ix:nonNumeric></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Interest rate</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_f57c2bf3954e4b06bdb6e73d241258c0" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Conversion price per share</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" id="Fact_a265121c183843bd982ee24779b2a3e1" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">83.28</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total shares of common stock subject to conversion</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" id="Fact_a8446d3306204ee4841e3d9e1f0b0e88" contextRef="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">6.6</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c19" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c20"><ix:continuation id="Text_a39aa6c3194d4f8da6630e3328609d403" continuedAt="Text_a39aa6c3194d4f8da6630e3328609d404">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c20" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c21"><ix:continuation id="Text_a39aa6c3194d4f8da6630e3328609d404" continuedAt="Text_a39aa6c3194d4f8da6630e3328609d405">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The following table summarizes information about the equity and liability components of our outstanding </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_6b7a3e820d8b4273b11b894d2ba67007" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>%</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes (in millions). We measured the fair values of the convertible notes outstanding based on quoted market prices, which is a Level 2 measurement at December 31, </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">:</span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c21" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c22"><ix:continuation id="Text_a39aa6c3194d4f8da6630e3328609d405" continuedAt="Text_a39aa6c3194d4f8da6630e3328609d406">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c22" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c23"><ix:continuation id="Text_a39aa6c3194d4f8da6630e3328609d406" continuedAt="Text_a39aa6c3194d4f8da6630e3328609d407">
<table cellpadding="0" cellspacing="0" id="z7dc44d0a9b0443dda7f99ab1d70efbdf" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-indent: 3pt;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_36c017cad1564114b1df3b506c8236f1" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>% <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Notes</span></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Fair value of outstanding notes</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:LongTermDebtFairValue" id="Fact_2f64fb9997454976b38c6e2b417f5aec" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">558.7</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Principal amount of convertible notes outstanding</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" id="Fact_3403814cbf0745fd98f50890c7c3cf9e" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">548.8</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Unamortized portion of debt discount</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" id="Fact_832aa30f085e43a8865c2e2d32fd5473" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">105.2</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Long-term debt</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConvertibleDebtNoncurrent" id="Fact_889e7ec833e44e569fb87f9f739bbe7b" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">434.7</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Carrying value of equity component</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" id="Fact_63d1f0908e44402a9baa9b04f5053aab" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">105.8</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c23" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c24"><ix:continuation id="Text_a39aa6c3194d4f8da6630e3328609d407" continuedAt="Text_a39aa6c3194d4f8da6630e3328609d408">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 27pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c24" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c25">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Call Spread</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c25" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c26">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c26" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c27">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Additionally, i</span>n conjunction with the December 2019 exchange, we entered into a call spread transaction, which was comprised of purchasing note hedges and selling warrants, to minimize the impact of potential economic dilution upon conversion of our <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_1eb86644c97d419d93743b0512053bf1" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>%</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes</span> by increasing the conversion price even further. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The call spread cost us $</span><ix:nonFraction name="ions:CallSpread" id="Fact_e9d4aad460e644458ec285d77482089c" contextRef="c20191201to20191231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">52.6</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million, of which $</span><ix:nonFraction name="us-gaap:PaymentsForHedgeFinancingActivities" id="Fact_0994e1dc04004d2382a34c5e13628fa1" contextRef="c20191201to20191231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">108.7</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million was for the note hedge purchase, offset by $</span><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" id="Fact_129b374a00b44cc89defdbe6353d570e" contextRef="c20191201to20191231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">56.1</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million we received for selling the warrants. We increased our effective conversion price to $</span><ix:nonFraction name="ions:DebtInstrumentConvertibleConversionPriceIncludingCallSpread" id="Fact_47a59f154aa241e092e3cb2ff63ce803" contextRef="c20191231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">123.38</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> with the same number of underlying shares as our </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_d2c7414fb1da467f803bda3bed07ee1b" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>%</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</span></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c27" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c28">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c28" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c29">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Similar to our </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_7b8ba4a02a954d6599d6024b18243e28" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>%</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, our note hedges are subject to adjustment. Additionally, our note hedges are exercisable upon conversion of the </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_7a8ce4e67bd54f9a987fa4ed687d2240" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>%</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. The note hedges will expire upon maturity of </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_3d6dde904f90445d93305af76cf6eda2" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>%</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, or December 2024. The note hedges and warrants are separate transactions and are not part of the terms of our </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_9bb8ca84262b41cdb2763e3d9fb4239f" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>%</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. The holders of the </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_4451c7a7d9d84d2780c91b575f56d194" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>%</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> do not have any rights with respect to the note hedges and warrants.</span></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c29" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c30">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c30" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c31">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We recorded the aggregate amount paid for the note hedges and the aggregate amount received for the warrants in additional paid-in capital in our consolidated balance sheet. We excluded shares under the note hedges from our calculation of diluted earnings per share as they were antidilutive. We will include the shares issuable under the warrants in our calculation of diluted earnings per share when the average market price per share of our common stock for the reporting period exceeds the strike price of the warrants.</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c31" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c32">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c32" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c33">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_a138942c9a354318adbd51f712f26e3a" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction> Percent Convertible Senior Notes</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c33" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c34">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c34" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c35">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In November 2014, we completed a $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_ae69fb3096d04ec386cf18bda382f2ac" contextRef="c20141130_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction> million offering of convertible senior notes, which mature in 2021 and bear interest at <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_5aa11ec0f17e45ff8bae60179009c497" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction> percent. We used a substantial portion of the net proceeds from the issuance of the <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_eb07200e0d7e47e8980856189249c81b" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>% Notes to repurchase $<ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" id="Fact_a7cfea2321f84b2196ac4f1c44ae3c68" contextRef="c20141130_DebtInstrumentAxis_ConvertibleSeniorNotes275PercentMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction> million in principal of our 2&#190; percent convertible senior notes, or 2&#190;% Notes. In December 2016, we issued an additional $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_40b369e59fd54938a3c76d88c97539ee" contextRef="c20161231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">185.5</ix:nonFraction> million of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_8ed18eaff8004156b3c13189a20eab93" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>% Notes in exchange for the redemption of $<ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" id="Fact_c377503f2bbe44b488a9c42e68e820e1" contextRef="c20161231_DebtInstrumentAxis_ConvertibleSeniorNotes275PercentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">61.1</ix:nonFraction> million of our <span style="-sec-ix-hidden:Fact_5720e35e625f4851a419d661f07222c0">2&#190;</span>% Notes. In December 2019, we exchanged a portion of our <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_72efeb8706804393b794e69da1859ca9" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>% Notes for <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_52a80f2cfee04eb587e3582cda96ceb8" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>%</span> Notes. As a result, the principal balance of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_7f4517d888a848e8aa549382b1f663fa" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>% Notes was $<ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" id="Fact_73cc83fd51084b739e29305c9bcf6432" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">309.9</ix:nonFraction> million. Additionally, we recorded a $<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_e56c4f7d46164e5682b05b11e5a76ff0" contextRef="c20191201to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">21.9</ix:nonFraction> million non-cash loss on early retirement of debt, reflecting the early retirement of a significant portion of our <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_21ae763200804eda89d695f565a9b421" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>% Notes in December 2019.</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c35" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c36">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c36" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c37"><ix:continuation id="Text_a39aa6c3194d4f8da6630e3328609d408" continuedAt="Text_a39aa6c3194d4f8da6630e3328609d409">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At December 31, 2019, we had the following <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_351f7a4cc22d4c609a76582f7cafaced" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>% Notes outstanding (amounts in millions except price per share data):</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c37" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c38"><ix:continuation id="Text_a39aa6c3194d4f8da6630e3328609d409" continuedAt="Text_a39aa6c3194d4f8da6630e3328609d4010">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c38" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c39"><ix:continuation id="Text_a39aa6c3194d4f8da6630e3328609d4010" continuedAt="Text_a39aa6c3194d4f8da6630e3328609d4011">
<table cellpadding="0" cellspacing="0" id="zb43006877680441c81f9bc23fb14ec3e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: top; padding-bottom: 2px; white-space: nowrap;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_d9759ef53cf341c89d402861e03cffa5" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>% Notes</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Outstanding principal balance</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" id="Fact_4c0a1cf7da584572b5539e94887de88d" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">309.9</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Maturity date</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: top; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_e4ab161cf8e14dac8e510129236b076a" contextRef="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" format="ixt:datemonthdayyearen">November 30, 2021</ix:nonNumeric></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Interest rate</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: top; background-color: #CCEEFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_3e00958972ef4dd78ced0398e546c3e7" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction> percent</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Conversion price per share</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" id="Fact_95d9dc164aba4bc4906d223af6cce4cd" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">66.81</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total shares of common stock subject to conversion</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" id="Fact_c84bb6217a084a41ad136652cc09e03d" contextRef="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c39" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c40"><ix:continuation id="Text_a39aa6c3194d4f8da6630e3328609d4011" continuedAt="Text_a39aa6c3194d4f8da6630e3328609d4012">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>27</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c40" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c41">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Interest is payable semi-annually in arrears on May 15 and November 15 of each year for the <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_f0bd4c0c0e7f4e15a243cf31a30d5fe3" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>% Notes. The <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_5195a53072b24193b8693cceb851285c" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>% Notes are convertible at the option of the note holders prior to July 1, 2021 only under certain conditions. On or after July 1, 2021, the <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_599a6c650ba949af823e3721d1dcc7ab" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>% Notes are initially convertible into approximately <ix:nonFraction name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" id="Fact_c3b8a56b35774f09a683069e7da23a49" contextRef="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">4.6</ix:nonFraction> million shares of common stock at a conversion price of approximately $<ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" id="Fact_1e3f531b50ce45a78f352059a2aabe03" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">66.81</ix:nonFraction> per share. We will settle conversions of the notes, at our election, in cash, shares of our common stock or a combination of both. We may not redeem the <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_fef53aa8a8f64806813c1c9401c10e7c" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>% Notes prior to maturity, and no sinking fund is provided for them. If we undergo a fundamental change, holders may require us to purchase for cash all or any portion of their <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_8147e405f341494fba590f9fd7e1adbe" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>% Notes at a purchase price equal to <ix:nonFraction name="ions:DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" id="Fact_fdfc68a3935a465f936cbb5325d0f693" contextRef="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction> percent of the principal amount of the notes to be purchased, plus accrued and unpaid interest to, but excluding, the fundamental change purchase date.</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c41" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c42">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c42" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c43"><ix:continuation id="Text_a39aa6c3194d4f8da6630e3328609d4012" continuedAt="Text_a39aa6c3194d4f8da6630e3328609d4013">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The following table summarizes information about the equity and liability components of our outstanding </span><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_6957f3faaf5447e0a8c23e16d21eb4cd" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>%<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes (in millions). We measured the fair values of the convertible notes outstanding based on quoted market prices, which is a Level 2 measurement at December 31, </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">:</span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c43" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c44"><ix:continuation id="Text_a39aa6c3194d4f8da6630e3328609d4013" continuedAt="Text_a39aa6c3194d4f8da6630e3328609d4014">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c44" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c45"><ix:continuation id="Text_a39aa6c3194d4f8da6630e3328609d4014" continuedAt="Text_a39aa6c3194d4f8da6630e3328609d4015">
<table cellpadding="0" cellspacing="0" id="zabdbc8437c344a2893cd480c7c4bf557" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-indent: 16pt;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Fair value of outstanding notes</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:LongTermDebtFairValue" id="Fact_b112bc86a62a40879d379e5de93d9d13" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">354.8</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:LongTermDebtFairValue" id="Fact_19578032f14c46009a660da235b4a752" contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">725.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Principal amount of convertible notes outstanding</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" id="Fact_77697145541a4cb3a1de5998960249dc" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">309.9</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" id="Fact_37a87f48cea1468dbabf7142062c1fde" contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">685.5</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Unamortized portion of debt discount</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" id="Fact_692ce55b49e842f39e92b6574d933927" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">32.8</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet" id="Fact_927ea0104b9648739f8cadf26fe8c648" contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">110.8</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Long-term debt</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConvertibleDebtNoncurrent" id="Fact_4eefe8c5ad4f45dab9f8431005a68c88" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">275.3</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConvertibleDebtNoncurrent" id="Fact_394e50c3174b419995a848e3ad315d86" contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">568.2</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Carrying value of equity component</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" id="Fact_615b424156904461b65ab8fba56baf57" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">33.5</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" id="Fact_275ed98d8a534881b164a506f08888da" contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">219.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c45" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c46"><ix:continuation id="Text_a39aa6c3194d4f8da6630e3328609d4015" continuedAt="Text_a39aa6c3194d4f8da6630e3328609d4016">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c46" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c47"><ix:continuation id="Text_a39aa6c3194d4f8da6630e3328609d4016" continuedAt="Text_a39aa6c3194d4f8da6630e3328609d4017">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We account for our convertible notes using an accounting standard that requires us to assign a value to our convertible debt equal to the estimated fair value of similar debt instruments without the conversion feature and to record the remaining portion in equity. As a result, we recorded our convertible notes at a discount, which we are amortizing as additional non-cash interest expense over the expected life of the respective debt. We determined our nonconvertible debt borrowing rate using a combination of the present value of the debt&#8217;s cash flows and a Black-Scholes valuation model. The following table summarizes the nonconvertible borrowing rate, effective interest rate and amortization period of our debt discount for our convertible notes:</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c47" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c48"><ix:continuation id="Text_a39aa6c3194d4f8da6630e3328609d4017" continuedAt="Text_a39aa6c3194d4f8da6630e3328609d4018">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c48" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c49"><ix:continuation id="Text_a39aa6c3194d4f8da6630e3328609d4018" continuedAt="Text_a39aa6c3194d4f8da6630e3328609d4019">
<table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z42f3873bea834b268c1005c0970cb12c">
  <tr>
    <td style="width: 39.53%; vertical-align: bottom;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td style="width: 2.25%; vertical-align: bottom;">&#160;</td>
    <td style="width: 28.83%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_54d20492d3454961ab50976a25101d84" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction>% Notes</div></td>
    <td style="width: 1.39%; vertical-align: top;">&#160;</td>
    <td style="width: 28%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_4b335b7942d14e2abc8562afa2e5f0ec" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction>%<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes</span></div></td>
  </tr>
  <tr>
    <td style="width: 39.53%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Nonconvertible debt borrowing rate</div></td>
    <td style="width: 2.25%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 28.83%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" id="Fact_ad2c1bc1c1f846a1affa31c79be4b69c" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">7.4</ix:nonFraction> percent</div></td>
    <td style="width: 1.39%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 28%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentMeasurementInput" id="Fact_596bdc839a504047b97a479e25a26ff8" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">4.4</ix:nonFraction> percent</div></td>
  </tr>
  <tr>
    <td style="width: 39.53%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effective interest rate (1)</div></td>
    <td style="width: 2.25%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 28.83%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_04d37423456f431eae8b542d5d3b0213" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">7.5</ix:nonFraction> percent</div></td>
    <td style="width: 1.39%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 28%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_6ac68bb7b1894b778d0cc3db62132135" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">4.9</ix:nonFraction> percent</div></td>
  </tr>
  <tr>
    <td style="width: 39.53%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amortization period of debt discount</div></td>
    <td style="width: 2.25%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 28.83%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" id="Fact_5e9b605d305346328ae877fed8602d67" contextRef="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" format="ixt-sec:durwordsen">7 years</ix:nonNumeric></div></td>
    <td style="width: 1.39%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 28%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" id="Fact_0958d84136bc4152acbe44cfeef2d965" contextRef="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" format="ixt-sec:durwordsen">5 years</ix:nonNumeric></div></td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c49" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c50"><ix:continuation id="Text_a39aa6c3194d4f8da6630e3328609d4019" continuedAt="Text_a39aa6c3194d4f8da6630e3328609d4020">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_a39aa6c3194d4f8da6630e3328609d4020"><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c50" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c51">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z644a31acdd52488c97d7adc5c94171fd">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:footnote id="Foot_4e4fe8e547864dd797e4a2e01acbee32" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="Foot_f0fc64d15b8d439996fb09b6ac894e481">For our <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_e30378472c6741629087ed2375181d83" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></ix:footnote><ix:continuation id="Foot_f0fc64d15b8d439996fb09b6ac894e481">% Notes, our effective interest rate represents our effective interest rate after our December 2019 debt exchange.</ix:continuation>&#160;</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c51" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c52">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c52" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c53">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our total interest expense for our outstanding senior convertible notes for the years ended December 31, 2019, 2018 and 2017 included $<ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" id="Fact_9c53099ee180469b94aa9696977d2880" contextRef="c20190101to20191231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">39.3</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" id="Fact_bdbef3ccc85649118ae89b354a641e27" contextRef="c20180101to20181231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">35.2</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" id="Fact_08ed41e893e1431f80a65f44ee96fab5" contextRef="c20170101to20171231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">32.5</ix:nonFraction> million, respectively, of non-cash interest expense related to the amortization of the debt discount and debt issuance costs for our convertible notes.</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c53" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c54">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c54" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c55">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Financing Arrangements</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c55" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c56">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c56" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c57">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Line of Credit Arrangement</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c57" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c58">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c58" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c59">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In June 2015, we entered into a <ix:nonNumeric name="us-gaap:DebtInstrumentTerm" id="Fact_a08d8b007c144c47ba522cd66c16754b" contextRef="c20190101to20191231_CreditFacilityAxis_RevolvingCreditFacilityMember_LineOfCreditFacilityAxis_MorganStanleyPrivateBankNationalAssociationMember" format="ixt-sec:durwordsen">five-year</ix:nonNumeric> revolving line of credit agreement with Morgan Stanley Private Bank, National Association, or Morgan Stanley, which we amended in February 2016. Under the amended credit agreement, Morgan Stanley provided a maximum of $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" id="Fact_89fd661deb0b4c3fa02f86026008098b" contextRef="c20191231_CreditFacilityAxis_RevolvingCreditFacilityMember_LineOfCreditFacilityAxis_MorganStanleyPrivateBankNationalAssociationMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction> million of revolving credit for general working capital purposes. During the third quarter of 2019, we paid off our total outstanding borrowings of $<ix:nonFraction name="us-gaap:RepaymentsOfLongTermLinesOfCredit" id="Fact_df1b80118efc4ee18a12e9720dbc121d" contextRef="c20190701to20190930_DebtInstrumentAxis_FixedRateNoteWithMorganStanleyMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">12.5</ix:nonFraction> million under the agreement and subsequently terminated the agreement.</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c59" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c60">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c60" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c61">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Research and Development and Manufacturing Facilities</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c61" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c62">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c62" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c63">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In July 2017, we purchased the building that houses our primary R&amp;D facility for $<ix:nonFraction name="us-gaap:PaymentsToAcquireBuildings" id="Fact_4a0c024b965c4f51b897f9cf5bc80424" contextRef="c20170701to20170731_PropertyPlantAndEquipmentByTypeAxis_PrimaryResearchAndDevelopmentFacilityMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">79.4</ix:nonFraction> million and our manufacturing facility for $<ix:nonFraction name="us-gaap:PaymentsToAcquireBuildings" id="Fact_06974c574f644e5baacbd3f8e2c599a6" contextRef="c20170701to20170731_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">14.0</ix:nonFraction> million. We financed the purchase of these two facilities with mortgage debt of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" id="Fact_1c1b0d341f0d4a39b8dd7164eab2e39d" contextRef="c20170731_DebtInstrumentAxis_LongTermMortgageDebtMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">60.4</ix:nonFraction> million in total. Our primary R&amp;D facility mortgage has an interest rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_2e21e0a6347e447a8991607c0227050a" contextRef="c20170731_PropertyPlantAndEquipmentByTypeAxis_PrimaryResearchAndDevelopmentFacilityMember" unitRef="U003" decimals="4" scale="-2" format="ixt:numdotdecimal">3.88</ix:nonFraction> percent. Our manufacturing facility mortgage has an interest rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_b8df62c274f14f0499a84c79aa3dd4f9" contextRef="c20170731_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember" unitRef="U003" decimals="4" scale="-2" format="ixt:numdotdecimal">4.20</ix:nonFraction> percent. During the first <ix:nonNumeric name="ions:PeriodToMakeInterestOnlyPaymentsOnMortgageLoan" id="Fact_cec9dfdd051e4462bf766547d85be9b4" contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember" format="ixt-sec:durwordsen"><ix:nonNumeric name="ions:PeriodToMakeInterestOnlyPaymentsOnMortgageLoan" id="Fact_885a5330a5d64c1ca25849873c2df457" contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_PrimaryResearchAndDevelopmentFacilityMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric></ix:nonNumeric> of both mortgages, we are only required to make interest payments. Both mortgages mature in August 2027.</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c63" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c64">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c64" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c65">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As a result of the purchase, we extinguished the financing liability we had previously recorded on our balance sheet for our primary R&amp;D facility. The difference between the purchase price of our primary R&amp;D facility and the carrying value of our financing liability at the time of the purchase was $<ix:nonFraction name="ions:GainLossOnExtinguishmentOfFinancingLiability" id="Fact_91f1c941f9ad432eb652599a51fbba84" contextRef="c20170701to20170930_PropertyPlantAndEquipmentByTypeAxis_PrimaryResearchAndDevelopmentFacilityMember" unitRef="U001" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">7.7</ix:nonFraction> million. We recognized this amount as a non-cash loss on extinguishment of financing liability for leased facility in our consolidated results of operations in the third quarter of 2017. We previously accounted for the lease of our manufacturing facility as an operating lease. We capitalized the purchase price of the manufacturing facility as a fixed asset in the third quarter of 2017.</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c65" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c66">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>28</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c66" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c67">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Maturity Schedules</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c67" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c68">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c68" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c69"><ix:nonNumeric name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="Text_73b31c6480504477b1a7dc3c319a40db" contextRef="c20190101to20191231" escape="true" continuedAt="Text_763869976b214d608e31533d3511af9b1">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Annual debt and other obligation maturities, including fixed and determinable interest, at December 31, 2019 are as follows (in thousands):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c69" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c70"><ix:continuation id="Text_763869976b214d608e31533d3511af9b1" continuedAt="Text_763869976b214d608e31533d3511af9b2">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c70" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c71"><ix:continuation id="Text_763869976b214d608e31533d3511af9b2">
<table cellpadding="0" cellspacing="0" id="zbf1bb99a34ec45e78be045fb2e06c256" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ContractualObligationDueInNextTwelveMonths" id="Fact_d2eb54062a6d4f188ef1dbae3b8653d3" contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">6,260</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2021</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ContractualObligationDueInSecondYear" id="Fact_c42e928b65cd45aa923675e567769ac7" contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">316,114</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2022</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ContractualObligationDueInThirdYear" id="Fact_6b7eb3455bef4825bec5934f0ca8a9f2" contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,495</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2023</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ContractualObligationDueInFourthYear" id="Fact_5163088d8dfb4bd8afb6a945c3e15b83" contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">4,180</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2024</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ContractualObligationDueInFifthYear" id="Fact_04194527fb664e52a3ac79595e34b654" contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">553,006</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Thereafter</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ContractualObligationDueAfterFifthYear" id="Fact_74f3f2a83bb64af5b0b4b21df7d35ef0" contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">64,429</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Subtotal</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ContractualObligation" id="Fact_41f58f8c96774a38af7b7c1cc41eabb9" contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">947,484</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less: current portion</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" id="Fact_6f4d80245c92479cb52c2337f5f2441b" contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,026</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less: fixed and determinable interest</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:InterestPayableCurrentAndNoncurrent" id="Fact_53dcce35c24c453fbe6ca8ac55743624" contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">28,014</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less: unamortized portion of debt discount</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" id="Fact_dd49b690e0844ab6ae886462d160f033" contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">137,975</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Plus: lease liabilities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredRentCredit" id="Fact_59ceb438da8a4afa9f9b8d13af3dfa2f" contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">17,235</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:LongTermDebtAndOtherObligationsNoncurrent" id="Fact_e4222f3c3fbf48189f3454e1d53ce42c" contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">796,704</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c71" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c72">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c72" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c73">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Operating Leases</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c73" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c74">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c74" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c75">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Ionis Leases</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c75" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c76">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c76" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c77">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We lease a facility adjacent to our manufacturing facility that has laboratory and office space that we use to support our manufacturing facility. We lease this space under a non-cancelable operating lease with an initial term ending in June 2021 and an option to extend the lease for up to <ix:nonFraction name="ions:LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease" id="Fact_1404db7a5a0e4be8b2654e7362b1b46b" contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember" unitRef="U012" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction>&#160;<ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Fact_3fa1c2318c4d4b2f8088992fbf02bb6d" contextRef="c20191231_PropertyPlantAndEquipmentByTypeAxis_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember" format="ixt-sec:durwordsen">five-year</ix:nonNumeric> periods.</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c77" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c78">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c78" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c79">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We also lease additional office spaces. We sublease a portion of one of these spaces to Akcea. We lease these spaces under non-cancelable operating leases with initial terms ending in 2023 with options to extend the leases for <ix:nonFraction name="ions:LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease" id="Fact_cb77855b95994f0488becac7637cd2b1" contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember" unitRef="U012" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction>&#160;<ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Fact_5cb70db62bdc4486992b4feba32be9c4" contextRef="c20191231_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember" format="ixt-sec:durwordsen">five-year</ix:nonNumeric> period. The sublease with Akcea is eliminated in our consolidated financial statements.</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c79" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c80">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c80" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c81">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Akcea Lease</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c81" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c82">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c82" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c83">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea entered into an operating lease agreement for office space located in Boston, Massachusetts for its new corporate headquarters in the second quarter of 2018. The lease commencement date was in August 2018 and Akcea took occupancy in September 2018. Akcea is leasing this space under a non-cancelable operating lease with an initial term ending after <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Fact_1cf767bfa2604645b03665b44c8069bb" contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceForCorporateHeadquartersMember" format="ixt-sec:durmonth">123</ix:nonNumeric> months and an option to extend the lease for an additional <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Fact_a817cf4e10ab4fdc88a9eaaa0d2f61a5" contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceForCorporateHeadquartersMember" format="ixt-sec:durwordsen">five-year</ix:nonNumeric> term. Under the lease agreement, Akcea received a <ix:nonNumeric name="ions:LesseeOperatingLeasePeriodOfFreeRent" id="Fact_ba6fa8c8bcc140258a36c6828c2ab217" contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceForCorporateHeadquartersMember" format="ixt-sec:durwordsen">three-month</ix:nonNumeric> free rent period, which commenced on August 15, 2018, and a tenant improvement allowance up to $<ix:nonFraction name="ions:LesseeOperatingLeaseAllowanceForTenantImprovements" id="Fact_4d5ed2a157b248b29eab88a7bb6399b9" contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceForCorporateHeadquartersMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">3.8</ix:nonFraction> million. Akcea provided the lessor with a letter of credit to secure its obligations under the lease in the initial amount of $<ix:nonFraction name="ions:LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation" id="Fact_4ea76f481ee94befba9ffed4fb541c89" contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceForCorporateHeadquartersMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">2.4</ix:nonFraction> million, to be reduced to $<ix:nonFraction name="ions:LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate" id="Fact_5cd8770ef41646968466e8170f8df26c" contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceForCorporateHeadquartersMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">1.8</ix:nonFraction> million on the third anniversary of the rent commencement date and to $<ix:nonFraction name="ions:LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate" id="Fact_1ff3895264114d1abecd3d9873549a39" contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceForCorporateHeadquartersMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million on the fifth anniversary of the rent commencement date if Akcea meets certain conditions set forth in the lease at each such time.</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c83" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c84">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c84" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c85">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">When we determined our lease term for our operating lease right-of-use assets and lease liabilities for these leases, we did not include the extension options for these leases.</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c85" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c86">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c86" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c87"><ix:nonNumeric name="ions:LesseeOperatingLeaseInformationTableTextBlock" id="Text_617aaf4bea8246bc99dc65dcafe47f72" contextRef="c20190101to20191231" escape="true" continuedAt="Text_0dff9229ec3b452f8cbc5f98707030a31">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amounts related to our operating leases were as follows (dollar amounts in millions):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c87" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c88"><ix:continuation id="Text_0dff9229ec3b452f8cbc5f98707030a31" continuedAt="Text_0dff9229ec3b452f8cbc5f98707030a32">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c88" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c89"><ix:continuation id="Text_0dff9229ec3b452f8cbc5f98707030a32" continuedAt="Text_0dff9229ec3b452f8cbc5f98707030a33">
<table cellpadding="0" cellspacing="0" id="z3d2e84cc75f74373b53127abdaff1269" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">At December 31, 2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Right-of-use operating lease assets (1)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_23749203f9514c17a3eb9047effcbc3f" contextRef="c20191231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">12.6</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating lease liabilities (2)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" id="Fact_0bcc1def02bf4a9fae57dfb5f4021412" contextRef="c20191231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">17.2</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average remaining lease term</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Fact_ccfd1bbd8568445fb43b6a1d85973cc7" contextRef="c20191231" format="ixt-sec:duryear">8.1</ix:nonNumeric> years</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average discount rate</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" id="Fact_0f6726aa9c174130a3010b4dad4799ef" contextRef="c20191231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">7.6</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c89" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c90"><ix:continuation id="Text_0dff9229ec3b452f8cbc5f98707030a33" continuedAt="Text_0dff9229ec3b452f8cbc5f98707030a34">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_0dff9229ec3b452f8cbc5f98707030a34" continuedAt="Text_0dff9229ec3b452f8cbc5f98707030a35"><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c90" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c91">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z49deda5f82f74fe1af4f88874881e5f9">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Included in <span style="-sec-ix-hidden:Fact_f81ca57385a04657b8ecd0f06d505159">deposits and other assets</span> on our consolidated balance sheet.</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c91" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c92"><ix:continuation id="Text_0dff9229ec3b452f8cbc5f98707030a35" continuedAt="Text_0dff9229ec3b452f8cbc5f98707030a36">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_0dff9229ec3b452f8cbc5f98707030a36"><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c92" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c93">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z26af2e3421ce4117a512d5aa97d68ee7">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Current portion of $<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_9b0c762d64a740078d7920512d9fd9e9" contextRef="c20191231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction> million was included in <span style="-sec-ix-hidden:Fact_530181678e9244af8b37885d3ba85980">current portion of long-term obligations</span> on our consolidated balance sheet, with the difference included in <span style="-sec-ix-hidden:Fact_9c37cb3853f74a4f821bbe4ed37a06ba">long-term obligations</span>.</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c93" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c94">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c94" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c95">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the year ended December 31, 2019, we paid $<ix:nonFraction name="us-gaap:OperatingLeasePayments" id="Fact_0b0968d7b6d44d43b94d14127e7b0391" contextRef="c20190101to20191231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">3.9</ix:nonFraction> million of lease payments, which was included in operating activities in our consolidated statement of cash flows.</div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c95" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c96">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>29</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c96" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c97"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Text_2cefc4cc8d6748129c33abcec77c053a" contextRef="c20190101to20191231" escape="true" continuedAt="Text_4d63c5e5a9a842ea96226c9d522bf6351">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As of December 31, 2019, the future payments for our operating lease liabilities are as follows (in thousands):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c97" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c98"><ix:continuation id="Text_4d63c5e5a9a842ea96226c9d522bf6351" continuedAt="Text_4d63c5e5a9a842ea96226c9d522bf6352">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c98" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c99"><ix:continuation id="Text_4d63c5e5a9a842ea96226c9d522bf6352">
<table cellpadding="0" cellspacing="0" id="z21d6f95567c944849963a4017490880d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Operating</span> <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Leases</span></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Year ending December 31,</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">$</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;"><div style="text-align: justify; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" id="Fact_46f76b117a04494ca6a17beb53f570c7" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,285</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -0.2pt; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2021</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" id="Fact_a0c5aec014324c7cb0c840fa0ba4f4fd" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,022</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -0.2pt; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2022</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" id="Fact_60d8f92c9a0245da92a6e5b3703538f4" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,781</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;"><div style="text-align: justify; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2023</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" id="Fact_06719e85aaa649a793c4a758dc24108b" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,520</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;"><div style="text-align: justify; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2024</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" id="Fact_a234894a94604af3851d9a9b9a7e0368" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,396</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Thereafter</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" id="Fact_9dfbcc29769149b7a7275bc1e34d886d" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">9,465</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;"><div style="text-align: left; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total minimum lease payments</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" id="Fact_1c01baaf54874ba59a14a7ef68852b77" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">23,469</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Imputed interest</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" id="Fact_f5bf1724933445328ccdc1f5bcee5d01" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">6,234</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; margin-left: 36.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total operating lease liabilities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" id="Fact_4b3b9da6657742a4adb29f8c455266b5" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">17,235</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c99" continuedAt="Text_8c0b3c7ac16f487186b53c3db694de1c100">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8c0b3c7ac16f487186b53c3db694de1c100">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Rent expense was $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" id="Fact_c4dae47efc26426db76344c3495d0867" contextRef="c20190101to20191231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">3.6</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" id="Fact_3fece8ea1f464d25a5ccc06fa0fb6da2" contextRef="c20180101to20181231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">2.6</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" id="Fact_aa216fc8e41f4f6586b6e1b074494d8d" contextRef="c20170101to20171231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction> million for the years ended December 31, 2019, 2018 and 2017, respectively.</div>
</ix:continuation></div>
<div><br /></div>
<div><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Text_6d42e24e9e4a40f2b1346af8b0d12a02" contextRef="c20190101to20191231" escape="true" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf21">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">4. Stockholders</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Equity</span></div>
</ix:nonNumeric><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf21" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf22">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf22" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf23">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Preferred Stock</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf23" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf24">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf24" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf25">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are authorized to issue up to <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_cdf2c784100f453c85b910f7ffa74a1e" contextRef="c20191231_StatementClassOfStockAxis_PreferredStockMember" unitRef="U002" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction> million shares of &#8220;blank check&#8221; Preferred Stock. As of December 31, 2019, there were <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_9e3c83d35b1a4ad9bb5804db20a70950" contextRef="c20191231_StatementClassOfStockAxis_PreferredStockMember" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> shares of Preferred Stock outstanding. We have designated Series C Junior Participating Preferred Stock but have <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_56071bcb2d56480397a630e97def5c32" contextRef="c20191231_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_5fe1b66991274e8cbc8b7286eae05354" contextRef="c20191231_StatementClassOfStockAxis_SeriesCPreferredStockMember" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> issued or outstanding shares as of December 31, 2019.</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf25" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf26">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf26" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf27">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Common Stock</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf27" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf28">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf28" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf29">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At December 31, 2019 and 2018, we had <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_292edcba897f40209ed42c14feed0f2e" contextRef="c20181231_StatementClassOfStockAxis_CommonStockMember" unitRef="U002" decimals="-6" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_10c668f50b664401a30c1bb6a51edb5a" contextRef="c20191231_StatementClassOfStockAxis_CommonStockMember" unitRef="U002" decimals="-6" scale="6" format="ixt:numdotdecimal">300</ix:nonFraction></ix:nonFraction> million shares of common stock authorized, of which <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_6d69412111c94f649e3bc6185a645456" contextRef="c20191231_StatementClassOfStockAxis_CommonStockMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_5f23b4a620974ffa9ac1338867c08a09" contextRef="c20191231_StatementClassOfStockAxis_CommonStockMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">140.3</ix:nonFraction></ix:nonFraction> million and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_eba69077d17e4204b64b00ee384f8ab0" contextRef="c20181231_StatementClassOfStockAxis_CommonStockMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_7461dbbf5e58485bbd613618075e0ee5" contextRef="c20181231_StatementClassOfStockAxis_CommonStockMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">137.9</ix:nonFraction></ix:nonFraction> million were issued and outstanding, respectively. As of December 31, 2019, total common shares reserved for future issuance were <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_47e88bfdb1664c48a2b1ff64f80389f5" contextRef="c20191231_StatementClassOfStockAxis_CommonStockMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">26.2</ix:nonFraction> million.</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf29" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf210">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf210" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf211">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019, 2018 and 2017, we issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" id="Fact_0ee4b00a77834001bc604428d95159c5" contextRef="c20190101to20191231_StatementClassOfStockAxis_CommonStockMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">3.1</ix:nonFraction> million, <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" id="Fact_6d8eb059ce834187b603ca07d5abb207" contextRef="c20180101to20181231_StatementClassOfStockAxis_CommonStockMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross" id="Fact_edd10ce23a74492e8176afb94a7abdb0" contextRef="c20170101to20171231_StatementClassOfStockAxis_CommonStockMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction> million shares of common stock, respectively, for stock option exercises, vesting of restricted stock units, and ESPP purchases. We received net proceeds from these transactions of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" id="Fact_d6943984a2cd41b0a8cb3b1deb1f9fc2" contextRef="c20190101to20191231_StatementClassOfStockAxis_CommonStockMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">119.7</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" id="Fact_5fbad294b6304ae4a8a72a7d07384a09" contextRef="c20180101to20181231_StatementClassOfStockAxis_CommonStockMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">27.9</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" id="Fact_4af5fbc849034e59b7d2901adc45af29" contextRef="c20170101to20171231_StatementClassOfStockAxis_CommonStockMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">22.9</ix:nonFraction> million in 2019, 2018 and 2017, respectively.</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf211" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf212">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf212" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf213">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Share Repurchase Program</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf213" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf214">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf214" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf215">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In September 2019, our board of directors approved an initial share repurchase program of up to $<ix:nonFraction name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" id="Fact_44310671d1664bfca3445b963a157027" contextRef="c20190930" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction> million of our common stock. Our stock repurchase program has no expiration date. Through December 31, 2019, we repurchased <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" id="Fact_a0ec8c80989241c28567434e9da68f95" contextRef="c20191001to20191231" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">535,000</ix:nonFraction> shares for $<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" id="Fact_b3c70b4e95ca4205b78bd5e2e50aeeab" contextRef="c20191001to20191231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">34.4</ix:nonFraction> million. In the first quarter of 2020, we repurchased an additional <ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" id="Fact_e459a3912815439c8077106b57fb5880" contextRef="c20200101to20200302_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction> million shares for $<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfCommonStock" id="Fact_2b769cf5ebe543ef91ba7139fec3a4d2" contextRef="c20200101to20200302_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">90.6</ix:nonFraction> million.</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf215" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf216">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf216" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf217">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Stock Plans</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf217" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf218">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf218" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf219">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">1989 Stock Option Plan</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf219" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf220">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf220" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf221">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In June 1989, our Board of Directors adopted, and the stockholders subsequently approved, a stock option plan that, as amended, provides for the issuance of non-qualified and incentive stock options for the purchase of up to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_2a82263b39a7474ba2b3298ff2f3a349" contextRef="c20191231_PlanNameAxis_StockOptionPlan1989Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction> million shares of common stock to our employees, directors, and consultants. The plan expires in January 2024. The 1989 Plan does not allow us to grant stock bonuses or restricted stock awards and prohibits us from repricing any options outstanding under the plan unless our stockholders approve the repricing. Options vest over a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_300b6e73bf984f4ba7b411e09fd8ac0a" contextRef="c20190101to20191231_PlanNameAxis_StockOptionPlan1989Member" format="ixt-sec:durwordsen">four-year</ix:nonNumeric> period, with <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" id="Fact_f9de77fe0ed4406e89bc6cca403c951f" contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember_PlanNameAxis_StockOptionPlan1989Member_VestingAxis_ShareBasedCompensationAwardTrancheOneMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">25 </ix:nonFraction>percent exercisable at the end of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Fact_8c42e3e31eb04afc9a1a6d089d774313" contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember_PlanNameAxis_StockOptionPlan1989Member_VestingAxis_ShareBasedCompensationAwardTrancheOneMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric> from the date of the grant and the balance vesting ratably, on a monthly basis, thereafter and have a term of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Fact_7077ae6833184dee85f5278742d25b56" contextRef="c20190101to20191231_PlanNameAxis_StockOptionPlan1989Member" format="ixt-sec:durwordsen">seven years</ix:nonNumeric>. At December 31, 2019, a total of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_add8de5b32ae49bb87473e4eddedffb6" contextRef="c20191231_PlanNameAxis_StockOptionPlan1989Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million options were outstanding, of which options to purchase <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" id="Fact_803cbfb1dea74d34930f47cade7a9b19" contextRef="c20191231_PlanNameAxis_StockOptionPlan1989Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million shares were exercisable, and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" id="Fact_8c931ba74e0d4e5c8d57ed4b294c4a22" contextRef="c20191231_PlanNameAxis_StockOptionPlan1989Member" unitRef="U002" decimals="-4" scale="6" format="ixt:numdotdecimal">0.04</ix:nonFraction> million shares were available for future grant under the 1989 Plan.</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf221" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf222">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>30</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf222" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf223">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">2011 Equity Incentive Plan</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf223" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf224">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf224" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf225">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In March 2011, our Board of Directors adopted, and the stockholders subsequently approved, a stock option plan that provides for the issuance of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and performance cash awards to our employees, directors, and consultants. In June 2015, May 2017 and June 2019, after receiving approval from our stockholders, we amended our 2011 Equity Incentive Plan to increase the total number of shares reserved for issuance. We increased the shares available under our 2011 Equity Incentive Plan from <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_5882aa832aa646c6b635e3bfe41d5f81" contextRef="c20150531_PlanNameAxis_EquityIncentivePlan2011Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">5.5</ix:nonFraction> million to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_1f00ba80dcbf4591a6c03449d0ff3e6e" contextRef="c20150630_PlanNameAxis_EquityIncentivePlan2011Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction> million in June 2015, from <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_b4182e47d22e4ab1b6c25c3beae739b7" contextRef="c20150630_PlanNameAxis_EquityIncentivePlan2011Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">11.0</ix:nonFraction> million to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_73b32b7412144ae2844353056c2328ce" contextRef="c20170531_PlanNameAxis_EquityIncentivePlan2011Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">16.0</ix:nonFraction> million in May 2017 and from <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_67f1d774e8d34fbbbdcb82cbb830d91a" contextRef="c20170531_PlanNameAxis_EquityIncentivePlan2011Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">16.0</ix:nonFraction> million to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_dd1127c8a7ec4eedb63afb7ca6169e93" contextRef="c20190630_PlanNameAxis_EquityIncentivePlan2011Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">23.0</ix:nonFraction> million in June 2019. The plan expires in June 2021. The 2011 Plan does not allow us to reduce the exercise price of any outstanding stock options or stock appreciation rights or cancel any outstanding stock options or stock appreciation rights that have an exercise price or strike price greater than the current fair market value of the common stock in exchange for cash or other stock awards unless our stockholders approve such action. Currently we anticipate awarding only options and restricted stock unit awards to our employees, directors and consultants. Under the 2011 Plan, stock options cannot vest in a period of less than <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_0537bd173d9041859f6644b1acb57f77" contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember_PlanNameAxis_EquityIncentivePlan2011Member_RangeAxis_MinimumMember" format="ixt-sec:durwordsen">two years</ix:nonNumeric> and restricted stock unit awards cannot vest in a period of less than <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_a9447454bff64390b3b86709206cd065" contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2011Member_RangeAxis_MinimumMember" format="ixt-sec:durwordsen">three years</ix:nonNumeric>. We have granted restricted stock unit awards to our employees under the 2011 Plan which vest annually over a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_323dc3ca223441ed8cae26677d80920d" contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2011Member" format="ixt-sec:durwordsen">four-year</ix:nonNumeric> period. At December 31, 2019, a total of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_f6eb4ef69d9549b79f43b5ca7f3d3f65" contextRef="c20191231_PlanNameAxis_EquityIncentivePlan2011Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million options were outstanding, of which <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" id="Fact_c37dd0f781d649a5bc97d2c87bbaeacf" contextRef="c20191231_PlanNameAxis_EquityIncentivePlan2011Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">5.4</ix:nonFraction> million were exercisable, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" id="Fact_f19dff70c85e4b53ab5b44f7e4b872f2" contextRef="c20191231_PlanNameAxis_EquityIncentivePlan2011Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction> million restricted stock unit awards were outstanding, and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" id="Fact_f121d278af9942b4ba6d23912dbef6db" contextRef="c20191231_PlanNameAxis_EquityIncentivePlan2011Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">7.4</ix:nonFraction> million shares were available for future grant under the 2011 Plan.</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf225" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf226">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf226" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf227">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under the 2011 Plan, we may issue a stock award with additional acceleration of vesting and exercisability upon or after a change in control. In the absence of such provisions, no such acceleration will occur. The stock options and restricted stock unit awards we issue to Dr. Stanley T. Crooke in his former role as chief executive officer and issued to B. Lynne Parshall in her former role as chief operating officer will accelerate upon a change of control, as defined in the 2011 Plan. In addition, we implemented a change of control and severance benefit plan that provides for change of control and severance benefits to our executive officers, including our chief executive officer and chief financial officer. If we terminate <ix:nonFraction name="ions:NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" id="Fact_8f959a059fb340fc9f6dfdc4cbdfc6d9" contextRef="c20190101to20191231_PlanNameAxis_EquityIncentivePlan2011Member" unitRef="U013" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> of our executive officers or if an executive officer resigns for good reason during the period that begins <ix:nonNumeric name="ions:PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" id="Fact_5cf8f8a57af249d4a6cce115597f8861" contextRef="c20190101to20191231_PlanNameAxis_EquityIncentivePlan2011Member" format="ixt-sec:durwordsen">three months</ix:nonNumeric> before and ends <ix:nonNumeric name="ions:PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" id="Fact_4b4db5c64d7f42eca6f341535cd62db4" contextRef="c20190101to20191231_PlanNameAxis_EquityIncentivePlan2011Member" format="ixt-sec:durwordsen">twelve months</ix:nonNumeric> following a change in control of the company, the impacted executive officers&#8217; stock options and RSUs vesting will accelerate for options and RSUs outstanding as of the termination date.</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf227" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf228">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf228" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf229">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Corporate Transactions and Change in Control under 2011 Plan</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf229" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf230">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf230" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf231">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the event of certain significant corporate transactions, our Board of Directors has the discretion to take one or more of the following actions with respect to outstanding stock awards under the 2011 Plan:</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf231" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf232">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf232" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf233">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zcb34c7d1e4c048899e93ebb5a7d68318">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">arrange for assumption, continuation, or substitution of a stock award by a surviving or acquiring entity (or its parent company);</div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf233" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf234">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z6e451eac07ec40ea8f4b2469d382252a">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">arrange for the assignment of any reacquisition or repurchase rights applicable to any shares of our common stock issued pursuant to a stock award to the surviving or acquiring corporation (or its parent company);</div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf234" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf235">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z1804c283807648828a63435f4451acd3">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">accelerate the vesting and exercisability of a stock award followed by the termination of the stock award;</div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf235" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf236">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z5f80dab3f5b546fd8cc4ecce3150f3af">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">arrange for the lapse of any reacquisition or repurchase rights applicable to any shares of our common stock issued pursuant to a stock award;</div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf236" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf237">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="za9fb373834d54a3a900c0043acd5e180">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">cancel or arrange for the cancellation of a stock award, to the extent not vested or not exercised prior to the effective date of the corporate transaction, in exchange for cash consideration, if any, as the Board, in its sole discretion, may consider appropriate; and</div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf237" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf238">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z166bbc44488d4829b2be0e17a4e293e6">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">arrange for the surrender of a stock award in exchange for a payment equal to the excess of (a) the value of the property the holder of the stock award would have received upon the exercise of the stock award, over (b) any exercise price payable by such holder in connection with such exercise.</div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf238" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf239">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf239" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf240">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">2002 Non-Employee Directors&#8217; Stock Option Plan</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf240" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf241">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf241" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf242">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In September 2001, our Board of Directors adopted, and the stockholders subsequently approved, an amendment and restatement of the 1992 Non-Employee Directors&#8217; Stock Option Plan, which provides for the issuance of non-qualified stock options and restricted stock units to our non-employee directors. The name of the resulting plan is the 2002 Non-Employee Directors&#8217; Stock Option Plan, or the 2002 Plan. In June 2015, after receiving approval from our stockholders, we amended our 2002 Non-Employee Directors Stock Option Plan to increase the total number of shares reserved for issuance. We increased the shares available under our 2002 Non-Employee Directors Stock Option Plan from <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_0e9dea3a9bb44f258d4a6a1eeffbb1b0" contextRef="c20150531_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">1.2</ix:nonFraction> million to <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_e55c20e37dc6464eb74bde99a3d220dc" contextRef="c20150630_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">2.0</ix:nonFraction> million. Options under this plan expire <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Fact_e6b00753880241348e596a82fa22bab2" contextRef="c20190101to20191231_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member" format="ixt-sec:durwordsen">10 years</ix:nonNumeric> from the date of grant. Options granted become exercisable in <ix:nonFraction name="ions:NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable" id="Fact_ecf5143f6da4476497ba61d7ea1d3cf7" contextRef="c20190101to20191231_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member_VestingAxis_ShareBasedCompensationAwardTrancheOneMember" unitRef="U014" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction> equal annual installments beginning <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Fact_21760feab1df457580b254deda24e758" contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member_VestingAxis_ShareBasedCompensationAwardTrancheOneMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric> after the date of grant. At December 31, 2019, a total of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_28beff5bd3d14e0c9936c3a0e4bfd184" contextRef="c20191231_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction> million options were outstanding, of which <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" id="Fact_5c3c554e640546a481c2968b37014870" contextRef="c20191231_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.5</ix:nonFraction> million were exercisable, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" id="Fact_d025b834777346cfa313dfb503dafd03" contextRef="c20191231_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million restricted stock unit awards were outstanding, and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" id="Fact_03da27efb55141628520731fb9e70ab8" contextRef="c20191231_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction> million shares were available for future grant under the 2002 Plan.</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf242" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf243">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>31</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf243" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf244">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Employee Stock Purchase Plan</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf244" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf245">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf245" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf246">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In June 2009, our Board of Directors adopted, and the stockholders subsequently approved, the amendment and restatement of the ESPP and we reserved an additional <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" id="Fact_3b40f4cda8e040fdba6be624573711c9" contextRef="c20090601to20090630_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">150,000</ix:nonFraction> shares of common stock for issuance thereunder. In each of the subsequent years, we reserved an additional <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" id="Fact_627f300828104f14b873bf05eda50f67" contextRef="c20190101to20191231_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U002" decimals="0" scale="0" format="ixt:numdotdecimal">150,000</ix:nonFraction> shares of common stock for the ESPP resulting in a total of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" id="Fact_e19efe7ddb5143df982e961a832ee9c5" contextRef="c20191231_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">3.7</ix:nonFraction> million shares authorized under the plan as of December 31, 2019. The ESPP permits full-time employees to purchase common stock through payroll deductions (which cannot exceed <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" id="Fact_ad7d5d970b7445cb891d0cfb579417b5" contextRef="c20191231_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">10 </ix:nonFraction>percent of each employee&#8217;s compensation) at the lower of <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" id="Fact_f1124fb149ea4ba28036505d69fad8f3" contextRef="c20190101to20191231_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">85 </ix:nonFraction>percent of fair market value at the beginning of the purchase period or the end of each purchase period. Under the amended and restated ESPP, employees must hold the stock they purchase for a minimum of <ix:nonNumeric name="ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod" id="Fact_f085e44a32534bbd8486ce10fc828657" contextRef="c20190101to20191231_PlanNameAxis_EmployeeStockPurchasePlanMember" format="ixt-sec:durwordsen">six months</ix:nonNumeric> from the date of purchase. During 2019, employees purchased and we issued to employees <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" id="Fact_36267c2abcb644b69eb45aceda22f69b" contextRef="c20190101to20191231_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U002" decimals="-4" scale="6" format="ixt:numdotdecimal">0.05</ix:nonFraction> million shares under the ESPP at a weighted average price of $<ix:nonFraction name="us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" id="Fact_2c284719dc094a59851d962ad33aacae" contextRef="c20190101to20191231_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">40.95</ix:nonFraction> per share. At December 31, 2019, there were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" id="Fact_9bcf03b844ab41c1a8fbd64333e01f0e" contextRef="c20191231_PlanNameAxis_EmployeeStockPurchasePlanMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">0.7</ix:nonFraction> million shares available for purchase under the ESPP.</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf246" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf247">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf247" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf248">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Stock Option Activity</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf248" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf249">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf249" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf250"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Text_7b10324fbe6d4c7b8c7ce61a7cf34482" contextRef="c20190101to20191231" escape="true" continuedAt="Text_15bf27c4991e4701a66ecd6f78003c241">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes the stock option activity under our stock plans for the year ended December 31, 2019 (in thousands, except per share and contractual life data):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf250" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf251"><ix:continuation id="Text_15bf27c4991e4701a66ecd6f78003c241" continuedAt="Text_15bf27c4991e4701a66ecd6f78003c242">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf251" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf252"><ix:continuation id="Text_15bf27c4991e4701a66ecd6f78003c242">
<table cellpadding="0" cellspacing="0" id="z9b50c63317624dd0af7fdc21a2a7bfb8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Number</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">of Shares</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Exercise</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Price Per Share</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Remaining</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Contractual Term</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Years)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Aggregate</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intrinsic</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Value</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Outstanding at December 31, 2018</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_de361e6a303f48689eff997a4c7a9e18" contextRef="c20181231_AwardTypeAxis_StockOptionMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">11,311</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_013443363d8b4eb7aa061c464dc7a3dd" contextRef="c20181231_AwardTypeAxis_StockOptionMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">47.85</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Granted</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_c363e628c500466b86c02f00df87e45d" contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">2,543</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" id="Fact_147bf3d775c544d39301adb1493fa05e" contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">56.19</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Exercised</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_65fe49e661654c6fadd66c3158cb37e5" contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">2,617</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" id="Fact_645eac997a48446a8364fedf6f9b00a2" contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">40.48</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cancelled/forfeited/expired</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" id="Fact_d7093d8852d44af280644f5b3f4724f8" contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">236</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; padding-bottom: 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" id="Fact_b2d99eaaf66c4310b3826984e917430d" contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">50.11</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Outstanding at December 31, 2019</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" id="Fact_ac7cb8c9588948168b54c219f469e752" contextRef="c20191231_AwardTypeAxis_StockOptionMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">11,001</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="Fact_3a779dec16434ab39ded18c995252583" contextRef="c20191231_AwardTypeAxis_StockOptionMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">51.48</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_8a97634ee0de48ab9bba7815890a31ce" contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember" format="ixt-sec:duryear">4.41</ix:nonNumeric></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" id="Fact_c25c76c1a9f94691b856964b458fadef" contextRef="c20191231_AwardTypeAxis_StockOptionMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">104,029</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Exercisable at December 31, 2019</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" id="Fact_f87605af70314ee88af627c71f1097ba" contextRef="c20191231_AwardTypeAxis_StockOptionMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">6,004</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" id="Fact_385eca89102d4e9587c5000cc39964b4" contextRef="c20191231_AwardTypeAxis_StockOptionMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">50.95</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Fact_7314f310e53045fd9d6e985a8a4eb55d" contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember" format="ixt-sec:duryear">3.34</ix:nonNumeric></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" id="Fact_bb850db7a9184d57b61549c6a8eeacca" contextRef="c20191231_AwardTypeAxis_StockOptionMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">59,780</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf252" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf253">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf253" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf254">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The weighted-average estimated fair values of options granted were $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_bd436c790ccc47e68cd7e2153d0e63dd" contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">28.76</ix:nonFraction>, $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_4dd2a593ab554175bbb0a93d55390a88" contextRef="c20180101to20181231_AwardTypeAxis_StockOptionMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">25.49</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_a3befa246b7c4d03aced2b483085120f" contextRef="c20170101to20171231_AwardTypeAxis_StockOptionMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">25.42</ix:nonFraction> for the years ended December 31, 2019, 2018 and 2017, respectively. The total intrinsic value of options exercised during the years ended December 31, 2019, 2018 and 2017 were $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" id="Fact_1218d40eea68418bb4f00f1ad78f4cff" contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">83.8</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" id="Fact_bde2c92764604d8497b0668d13fb888b" contextRef="c20180101to20181231_AwardTypeAxis_StockOptionMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">34.8</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" id="Fact_8cc0e16daa8e4b2382fc554cc98ddf99" contextRef="c20170101to20171231_AwardTypeAxis_StockOptionMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">49.5</ix:nonFraction> million, respectively, which we determined as of the date of exercise. The amount of cash received from the exercise of stock options was $<ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_83423df31a3f436fab220d64f20b3ada" contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">105.9</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_9199ba163c904e0aaa3d539cccdda650" contextRef="c20180101to20181231_AwardTypeAxis_StockOptionMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">18.9</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_6cc972e2025849d8a6820145ab793c87" contextRef="c20170101to20171231_AwardTypeAxis_StockOptionMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">21.2</ix:nonFraction> million for the years ended December 31, 2019, 2018 and 2017, respectively. For the year ended December 31, 2019, the weighted-average fair value of options exercised was $<ix:nonFraction name="ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue" id="Fact_2b17593a26f3421991429bedce8b1c41" contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">72.52</ix:nonFraction>. As of December 31, 2019, total unrecognized compensation cost related to non-vested stock options was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" id="Fact_72c37b7b47114b45a9abf8d6722faa52" contextRef="c20191231_AwardTypeAxis_StockOptionMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">97.5</ix:nonFraction> million. We will adjust the total unrecognized compensation cost for future changes in estimated forfeitures. We expect to recognize this cost over a weighted average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_b3913cf410e541fe90a6f1003271ba18" contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember" format="ixt-sec:duryear">1.3</ix:nonNumeric> years.</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf254" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf255">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf255" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf256">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Restricted Stock Unit Activity</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf256" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf257">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf257" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf258"><ix:nonNumeric name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="Text_079cd073de4a49889e073e44695cbbe1" contextRef="c20190101to20191231" escape="true" continuedAt="Text_4b30aa803d7441b78d5d7ee8cb7aea9c1">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes the RSU activity for the year ended December 31, 2019 (in thousands, except per share data):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf258" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf259"><ix:continuation id="Text_4b30aa803d7441b78d5d7ee8cb7aea9c1" continuedAt="Text_4b30aa803d7441b78d5d7ee8cb7aea9c2">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf259" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf260"><ix:continuation id="Text_4b30aa803d7441b78d5d7ee8cb7aea9c2">
<table cellpadding="0" cellspacing="0" id="zc0f5e4e23b714ab09d3ea5e085c1013f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Number</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">of Shares</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted Average</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Grant Date Fair</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Value Per Share</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-vested at December 31, 2018</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_9b79ad26dfed4644a99778a07c2788e7" contextRef="c20181231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">1,246</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_7b0c381469384de4a83c2d06c591c7e0" contextRef="c20181231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">50.20</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Granted</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_1bdc071fcc1b43c49a958a8b0de0d593" contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">1,114</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_029b251fe1ed4825bb24ef350c208693" contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">60.23</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Vested</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_32f1bead9c704269b614ad1cd037ad04" contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">422</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" id="Fact_df38f96941f0458f9ca876b79bbed1b6" contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">51.36</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cancelled/forfeited</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" id="Fact_22694e1383774415bf4c78c2ec3ee1f6" contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">72</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" id="Fact_d3684b8ecd434d79a0c627293baaf219" contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">53.39</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-vested at December 31, 2019</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_28559434ff5b402683a66fe056752875" contextRef="c20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">1,866</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_5d0497b5899240c48adeef1f11e34ed4" contextRef="c20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">55.80</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf260" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf261">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf261" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf262">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For the years ended December 31, 2019, 2018 and 2017, the weighted-average grant date fair value of RSUs granted was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_6c1a06db93094900a762b6eb164c546f" contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U004" decimals="2">60.23</ix:nonFraction>, $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_43f43b5a78cc4be1918b46bdde39a8d8" contextRef="c20180101to20181231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">51.06</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_57cca4b8f1044664988a96c292d978d1" contextRef="c20170101to20171231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">48.88</ix:nonFraction> per RSU, respectively. As of December 31, 2019, total unrecognized compensation cost related to RSUs was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" id="Fact_87ca3f2ec59f473aaf7df5ff01d27232" contextRef="c20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">56.5</ix:nonFraction> million. We will adjust the total unrecognized compensation cost for future changes in estimated forfeitures. We expect to recognize this cost over a weighted average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_18e1a1c706d54df78d64da3820fb50b9" contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear">1.5</ix:nonNumeric> years.</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf262" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf263">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>32</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf263" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf264">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Stock-based Compensation Expense and Valuation Information</span></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf264" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf265">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf265" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf266"><ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Text_73294d497dea4c4fbe6e3dffff002cbe" contextRef="c20190101to20191231" escape="true" continuedAt="Text_ac159db61cdb4fd9977fd084c4824d981">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes stock-based compensation expense for the years ended December 31, 2019, 2018 and 2017 (in thousands), which was allocated as follows and includes $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_f10b8b42e6244f988aaf4fd5de10cafc" contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">37.1</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_1f1c1f94efad47beb6afa69146eccaa6" contextRef="c20180101to20181231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">44.3</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_afb09cb91b5c4c60ac3218bdcff80a83" contextRef="c20170101to20171231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6">17.5</ix:nonFraction> million of stock-based compensation expense for Akcea employees in 2019, 2018 and 2017, respectively:</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf266" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf267"><ix:continuation id="Text_ac159db61cdb4fd9977fd084c4824d981" continuedAt="Text_ac159db61cdb4fd9977fd084c4824d982">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf267" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf268"><ix:continuation id="Text_ac159db61cdb4fd9977fd084c4824d982">
<table cellpadding="0" cellspacing="0" id="ze0f1f82608a349d9975520506247db45" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cost of products sold</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_c65bd9300b1849b09ce0cf552755ec1d" contextRef="c20190101to20191231_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">438</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_5192811678f84304b2c63cedee948433" contextRef="c20180101to20181231_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">160</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_a370ff2076d840e78591c1b614a65c61" contextRef="c20170101to20171231_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Research, development and patent</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_082a856e25ff4c6c87bb43e07011a3a0" contextRef="c20190101to20191231_IncomeStatementLocationAxis_ResearchDevelopmentAndPatentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">95,348</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_fbf019d0d38c4d20951785656bdfb76e" contextRef="c20180101to20181231_IncomeStatementLocationAxis_ResearchDevelopmentAndPatentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">76,557</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_590dd7d3580e4ce79e0bd853a27c60e2" contextRef="c20170101to20171231_IncomeStatementLocationAxis_ResearchDevelopmentAndPatentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">64,521</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Selling, general and administrative</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_faf4608623c94854a015ec45e8a2e44a" contextRef="c20190101to20191231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">50,788</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_e2891cabb204471380d6c8707ca7c311" contextRef="c20180101to20181231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">54,595</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_1d43b8c463a34284a11803d822ccf283" contextRef="c20170101to20171231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">21,454</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_e526ced9a8ee48df88cdbb0fe414de86" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">146,574</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_e09ed4e35f1149ffade548f4d1e3dd6a" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">131,312</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_14e48c9e15754897b6ddb6e8ce984ffb" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">85,975</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf268" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf269">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf269" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf270">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the third quarter of 2019, <ix:nonFraction name="ions:NumberOfExecutiveOfficersTerminatingEmployment" id="Fact_cb6c6555dd4d4b54a68986c39eb04125" contextRef="c20190701to20190930_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U013" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> Akcea executive officers terminated their employment and entered into separation agreements with Akcea. As a result, in the third quarter of 2019, Akcea reversed $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_e366f8294e7a416091e1112d5e7b1895" contextRef="c20190701to20190930_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">19.1</ix:nonFraction> million of stock-based compensation expense it had previously recognized related to the executive officers&#8217; stock options and RSUs that were no longer going to vest. In the fourth quarter of 2019, Akcea adjusted its stock-based compensation expense for an additional executive officer who will terminate his employment in April 2020.</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf270" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf271">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf271" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf272">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Determining Fair Value</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf272" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf273">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf273" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf274">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Valuation.</span> We measure stock-based compensation expense for equity-classified awards, principally related to stock options, RSUs, and stock purchase rights under the ESPP at the grant date, based on the estimated fair value of the award and we recognize the expense over the employee&#8217;s requisite service period. We value RSUs based on the market price of our common stock on the date of grant.</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf274" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf275">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf275" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf276">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We use the Black-Scholes model to estimate the fair value of stock options granted and stock purchase rights under our ESPP. The expected term of stock options granted represents the period of time that we expect them to be outstanding. We estimate the expected term of options granted based on actual and projected exercise patterns. We recognize compensation expense for stock options granted, RSUs, and stock purchase rights under the ESPP using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award were in substance multiple awards, which results in the expense being front-loaded over the vesting period.</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf276" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf277">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf277" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf278">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For the years ended December 31, 2019, 2018 and 2017, we used the following weighted-average assumptions in our Black-Scholes calculations:</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf278" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf279">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf279" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf280"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Text_eed5d49b2291458dab9b93c467ee0710" contextRef="c20190101to20191231" escape="true" continuedAt="Text_c2ec69c1f6ee440a83a2810b7bf899451">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Ionis Employee Stock Options:</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf280" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf281"><ix:continuation id="Text_c2ec69c1f6ee440a83a2810b7bf899451" continuedAt="Text_c2ec69c1f6ee440a83a2810b7bf899452">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf281" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf282"><ix:continuation id="Text_c2ec69c1f6ee440a83a2810b7bf899452" continuedAt="Text_c2ec69c1f6ee440a83a2810b7bf899453">
<table cellpadding="0" cellspacing="0" id="z1a22f5901f3944f2be1e317aad3cab4b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Risk-free interest rate</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_39e4c82810704489bfbb65ee776e5a18" contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">2.3</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_a907f9f67ed94038aa87ea5dbd343610" contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">2.4</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_d5a55e05e6ab431680a0d9086b9e0bb9" contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">1.8</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dividend yield</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_ac7a468c8e8141e5a6b44a4226e17623" contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_6f0bd71680af49fe8c31973636909b08" contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_467f22edbb03445faa1bf91c44625ca8" contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Volatility</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" id="Fact_e343e701b7bb4973a553dcb0d627618e" contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">60.3</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" id="Fact_cf083492bd334305a8d635507396630c" contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">63.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" id="Fact_b479bbaa6e5942498c2c6ef23bade12e" contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">65.9</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expected life</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_aeba017ee0304164a606372e31b4d36e" contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">4.8</ix:nonNumeric> years</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_4ff009d529b14f28a67b413d0aa72b8a" contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">4.6</ix:nonNumeric> years</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_17b6c1af49ea4548aea7024e13340b1f" contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">4.5</ix:nonNumeric> years</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf282" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf283"><ix:continuation id="Text_c2ec69c1f6ee440a83a2810b7bf899453" continuedAt="Text_c2ec69c1f6ee440a83a2810b7bf899454">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf283" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf284"><ix:continuation id="Text_c2ec69c1f6ee440a83a2810b7bf899454" continuedAt="Text_c2ec69c1f6ee440a83a2810b7bf899455">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Ionis Board of Director Stock Options:</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf284" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf285"><ix:continuation id="Text_c2ec69c1f6ee440a83a2810b7bf899455" continuedAt="Text_c2ec69c1f6ee440a83a2810b7bf899456">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf285" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf286"><ix:continuation id="Text_c2ec69c1f6ee440a83a2810b7bf899456">
<table cellpadding="0" cellspacing="0" id="zc7e20a324c544bf6af7f8bb69517a4b2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Risk-free interest rate</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_59c5b44210f64e2ba5300762080b28cb" contextRef="c20190101to20191231_AwardTypeAxis_BoardOfDirectorStockOptionMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">1.9</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_5cd81543aca54eeaa0061cb4901bcea7" contextRef="c20180101to20181231_AwardTypeAxis_BoardOfDirectorStockOptionMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">2.8</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_b27308a354da40f7bb7eb1590023fe41" contextRef="c20170101to20171231_AwardTypeAxis_BoardOfDirectorStockOptionMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">2.2</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dividend yield</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_836ca23d34bf40d1ad317bbd7b996732" contextRef="c20190101to20191231_AwardTypeAxis_BoardOfDirectorStockOptionMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_dd7841189e61468984dd257450ed86fa" contextRef="c20180101to20181231_AwardTypeAxis_BoardOfDirectorStockOptionMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_f6175c15b7104058bdf6a42169341ab4" contextRef="c20170101to20171231_AwardTypeAxis_BoardOfDirectorStockOptionMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Volatility</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" id="Fact_570fb2702c0c4104ab71032ea3a96785" contextRef="c20190101to20191231_AwardTypeAxis_BoardOfDirectorStockOptionMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">60.7</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" id="Fact_71af5aa64f46473c820a7539b3bcc84e" contextRef="c20180101to20181231_AwardTypeAxis_BoardOfDirectorStockOptionMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">61.5</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" id="Fact_9d88dfeaff20416a8bed01fc37947c33" contextRef="c20170101to20171231_AwardTypeAxis_BoardOfDirectorStockOptionMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">61.2</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expected life</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_bdcda0ba9a7942588e74e26d29bbb33b" contextRef="c20190101to20191231_AwardTypeAxis_BoardOfDirectorStockOptionMember" format="ixt-sec:duryear">6.6</ix:nonNumeric> years</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_42adbfd09267470aaddb1b451dd3ec51" contextRef="c20180101to20181231_AwardTypeAxis_BoardOfDirectorStockOptionMember" format="ixt-sec:duryear">6.6</ix:nonNumeric> years</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_a0b7e9b5bba44f52abc599d09c3c6813" contextRef="c20170101to20171231_AwardTypeAxis_BoardOfDirectorStockOptionMember" format="ixt-sec:duryear">6.6</ix:nonNumeric> years</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf286" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf287">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf287" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf288"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="Text_ad4e550d1cc64418b2227fa2fb6f6a90" contextRef="c20190101to20191231" escape="true" continuedAt="Text_95c1cb3c812c43a2a610109805895cea1">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Ionis ESPP:</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf288" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf289"><ix:continuation id="Text_95c1cb3c812c43a2a610109805895cea1" continuedAt="Text_95c1cb3c812c43a2a610109805895cea2">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf289" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf290"><ix:continuation id="Text_95c1cb3c812c43a2a610109805895cea2">
<table cellpadding="0" cellspacing="0" id="zaf6dcfd7dd86499dbd414c26e0657d2f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Risk-free interest rate</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_3c0b7d8f83f04a1eb86c0d26a34847de" contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">2.4</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_d445da93ea354d4a8bd3403324c38b1b" contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">1.8</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_7e683d90439c433b952d511d85e1a926" contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.8</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dividend yield</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_99b71834e6e0477dbdfc7e3f693daeaa" contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_0eb7e7fbc4304fdf9099a8b950d12dde" contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_34e237d15deb4d56bee7e4f7c1e34d34" contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Volatility</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" id="Fact_6518e8ff94e84bee8887d5c801654559" contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">45.6</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" id="Fact_9ae61ebbc4da40a487b4fb949bf8e04a" contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">47.3</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" id="Fact_46d7ebf746c644dbab44800478c4bf2c" contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">59.9</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expected life</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_6cb5a0bf099e40cc864c264a7ce21cef" contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockMember" format="ixt-sec:durwordsen">6 months</ix:nonNumeric></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_f4dc66b6347f46f7b1f589a4102dcbc3" contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockMember" format="ixt-sec:durwordsen">6 months</ix:nonNumeric></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_b50f67a3f15a4f28a7f815371d6feb14" contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockMember" format="ixt-sec:durwordsen">6 months</ix:nonNumeric></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf290" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf291">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>33</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf291" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf292">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Risk-Free Interest Rate.</span> We base the risk-free interest rate assumption on observed interest rates appropriate for the term of our stock option plans or ESPP.</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf292" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf293">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf293" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf294">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Dividend Yield.</span> We base the dividend yield assumption on our history and expectation of dividend payouts. We have not paid dividends in the past and do not expect to in the future.</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf294" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf295">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf295" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf296">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Volatility.</span> We use an average of the historical stock price volatility of our stock for the Black-Scholes model. We computed the historical stock volatility based on the expected term of the awards.</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf296" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf297">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf297" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf298">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Expected Life. </span>The expected term of stock options we have granted represents the period of time that we expect them to be outstanding. We estimated the expected term of options we have granted based on actual and projected exercise patterns.</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf298" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf299">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf299" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf2100">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Forfeitures.</span> We reduce stock-based compensation expense for estimated forfeitures. We estimate forfeitures at the time of grant and revise, if necessary, in subsequent periods if actual forfeitures differ from those estimates. We estimate forfeitures based on historical experience.</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf2100" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf2101">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf2101" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf2102">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In addition to our stock plans, Akcea has its own stock plan under which it grants options and RSUs and under which it derives its stock-based compensation expense. The following are the weighted-average Black-Scholes assumptions Akcea used under its plan for the years ended December 31, 2019, 2018 and 2017:</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf2102" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf2103">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf2103" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf2104"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Text_9a47228854db40e58bb10bf8df4c7de5" contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" escape="true" continuedAt="Text_7804727e037b4cda82e95e7674272c141">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Akcea Employee Stock Options:</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf2104" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf2105"><ix:continuation id="Text_7804727e037b4cda82e95e7674272c141" continuedAt="Text_7804727e037b4cda82e95e7674272c142">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf2105" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf2106"><ix:continuation id="Text_7804727e037b4cda82e95e7674272c142" continuedAt="Text_7804727e037b4cda82e95e7674272c143">
<table cellpadding="0" cellspacing="0" id="z6d0f71f781114c2796697bdc6544ea2f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Risk-free interest rate</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_9427990941124c8d84b21942b7851dc1" contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">2.2</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_7f37e862c77a4dfa88dbb42f1f7df3b5" contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">2.8</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_65f69e859fe64c2f8567e04d83d27ad2" contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">1.9</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dividend yield</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_ad69dda9779c4411a946438aa548dc66" contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_63f6046c55da44619e30077b4b23e13d" contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_8afdde2a0f4d4c508212cbba4de5d73f" contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Volatility</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" id="Fact_a81b171ee24a461b80fe013b4fafde03" contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">75.4</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" id="Fact_e1c6279157a942a5a72f291eb095018e" contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">77.1</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" id="Fact_14142d560c124e338be9ccae1fc251d6" contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">79.5</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expected life</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_e33d45f84350409ca60b5e11bee0862b" contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" format="ixt-sec:duryear">6.09</ix:nonNumeric> years</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_32a1e1728de345a992537bc600ef3217" contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" format="ixt-sec:duryear">6.08</ix:nonNumeric> years</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_d7baac71895f4870b794ceabe6ec6861" contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" format="ixt-sec:duryear">6.06</ix:nonNumeric> years</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf2106" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf2107"><ix:continuation id="Text_7804727e037b4cda82e95e7674272c143" continuedAt="Text_7804727e037b4cda82e95e7674272c144">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf2107" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf2108"><ix:continuation id="Text_7804727e037b4cda82e95e7674272c144" continuedAt="Text_7804727e037b4cda82e95e7674272c145">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Akcea Board of Director Stock Options:</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf2108" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf2109"><ix:continuation id="Text_7804727e037b4cda82e95e7674272c145" continuedAt="Text_7804727e037b4cda82e95e7674272c146">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf2109" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf2110"><ix:continuation id="Text_7804727e037b4cda82e95e7674272c146">
<table cellpadding="0" cellspacing="0" id="zbbe3118c00004f9f91eb04676b0aef23" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Risk-free interest rate</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_32bfb362dea94deaabe530ccc1ebb41b" contextRef="c20190101to20191231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">1.8</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_787fd132ce504f22badee12fa1cd9add" contextRef="c20180101to20181231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">2.9</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_598e1a9e2c4f479297eac501bde974c7" contextRef="c20170101to20171231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">1.9</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dividend yield</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_7d00f24631834ad59d867d14e7f8f474" contextRef="c20190101to20191231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_b92024a4a63c4472980707f550677db7" contextRef="c20180101to20181231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_310662f660c1405196f21feb60d767ad" contextRef="c20170101to20171231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Volatility</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" id="Fact_20e6c9e5c43d4b0abfb9f1f0f43fdd00" contextRef="c20190101to20191231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">73.8</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" id="Fact_a2007326872f4bdcbd5f3bd17302d57b" contextRef="c20180101to20181231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">78.2</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" id="Fact_ff076db6ae4745cbbeb3c378e621b02d" contextRef="c20170101to20171231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">79.4</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expected life</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_d65dbad630614b6686dc737ed2dbf318" contextRef="c20190101to20191231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" format="ixt-sec:duryear">6.25</ix:nonNumeric> years</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_33083c5e681a431aa5caf47692ebc8cd" contextRef="c20180101to20181231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" format="ixt-sec:duryear">6.42</ix:nonNumeric> years</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_5e855268ef484ae090049da9c0a5494c" contextRef="c20170101to20171231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" format="ixt-sec:duryear">6.25</ix:nonNumeric> years</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf2110" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf2111">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf2111" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf2112"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="Text_ac97a0fcee594c8c8f377c30d4f5daf1" contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" escape="true" continuedAt="Text_c5f85afd4a78415daabc92cf300f63721">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Akcea ESPP:</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf2112" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf2113"><ix:continuation id="Text_c5f85afd4a78415daabc92cf300f63721" continuedAt="Text_c5f85afd4a78415daabc92cf300f63722">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf2113" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf2114"><ix:continuation id="Text_c5f85afd4a78415daabc92cf300f63722">
<table cellpadding="0" cellspacing="0" id="z274cc299456642c993f118c12d22a0fd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Risk-free interest rate</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_bf5ecf8a64054fae95c4804511ce6aec" contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">2.4</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_72db8e8c6e314a68b21ff5ca9daa8795" contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">1.9</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_441c829cbbd14005ae76633c08dbb58d" contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">1.1</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dividend yield</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_410ad5b69a2248319707dd8c8030cb6e" contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_d4a69058792f4aafa70899b5b9ee410b" contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_300a88498bfa41528eaf68769e20db52" contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Volatility</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" id="Fact_637662f604f74eff9088c6c132d5f729" contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">60.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" id="Fact_b2759e0179794c4ea710cb01fde6ffad" contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">64.2</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" id="Fact_e83cd4f6e0e542deaa111fc2184cb9c3" contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">73.3</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expected life</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_6867f5f4f3d6472898e752108981a60e" contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" format="ixt-sec:durwordsen">6 months</ix:nonNumeric></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_ecab4ddbcf9d44d2bd9ac9d2163912b1" contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" format="ixt-sec:durwordsen">6 months</ix:nonNumeric></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_c36b27cba34d4c6e9e05233761bbebdb" contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember" format="ixt-sec:durwordsen">6 months</ix:nonNumeric></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf2114" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf2115">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf2115" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf2116">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following summarizes the Black-Scholes input methodology for Akcea options that differs from the methodology we use for Ionis options:</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf2116" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf2117">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf2117" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf2118">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Volatility.</span> Since Akcea does not have sufficient history to estimate the volatility of its common stock, Akcea calculates its expected volatility based on a blend of its historical volatility and reported data from selected publicly traded peer companies for which historical information is available. Akcea plans to continue to use this blend to calculate its volatility until the historical volatility of its common stock is sufficient to measure expected volatility for future option grants.</div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf2118" continuedAt="Text_a9ed7838ac904580bea7f1ad3c673cf2119">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_a9ed7838ac904580bea7f1ad3c673cf2119">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Expected Life. </span>Since Akcea does not have sufficient historical information, it uses the simplified method for estimating its expected term. Under the simplified method Akcea calculates its expected term as the average time-to-vesting and the contractual life of the options. As Akcea gains additional historical information, it will transition to calculating its expected term based on its exercise patterns.</div>
</ix:continuation></div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>34</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" id="Text_c0b4f25af9504e6a8c2960620b85c78d" contextRef="c20190101to20191231" escape="true" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d61">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5. Income Taxes</div>
</ix:nonNumeric><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d61" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d62">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d62" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d63"><ix:nonNumeric name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="Text_c607f452c64f473bb9c5dde69c499108" contextRef="c20190101to20191231" escape="true" continuedAt="Text_30a54670ab2c4ed59261cad036aad03a1">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) before income taxes is comprised of (in thousands):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d63" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d64"><ix:continuation id="Text_30a54670ab2c4ed59261cad036aad03a1" continuedAt="Text_30a54670ab2c4ed59261cad036aad03a2">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d64" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d65"><ix:continuation id="Text_30a54670ab2c4ed59261cad036aad03a2">
<table cellpadding="0" cellspacing="0" id="z4092c9a5a2814eb28f48de6d2a9e9058" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" id="Fact_1154d9477ea5403c89bcaba61b591e79" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">344,280</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" id="Fact_74d3abad4f744e0aa68801acc3a6ed6b" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">69,576</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" id="Fact_8977ca2c8272434794efd8259c5f22b7" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,289</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Foreign</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" id="Fact_70ca994a31be49619caefe5e71de1587" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,489</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" id="Fact_8425f2adaf6948cdb4db61cdf7def1fc" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,580</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" id="Fact_15eeca6092a14a5c9b839eb716ea8ae4" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">11,474</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) before income taxes</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" id="Fact_317564d38d3f4684aaa47f65a5d386e8" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">346,769</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" id="Fact_9fd05fd89e164623ad7d51c758cf30c6" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">76,156</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" id="Fact_225bd758b4d047a9b56b2a1266e8768e" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,763</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d65" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d66">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d66" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d67"><ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Text_75ef1dbd0a5841a5acf583bb7ca67f64" contextRef="c20190101to20191231" escape="true" continuedAt="Text_c2d7a586330644dbaa882a22bf50eda11">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our income tax expense (benefit) was as follows (in thousands):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d67" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d68"><ix:continuation id="Text_c2d7a586330644dbaa882a22bf50eda11" continuedAt="Text_c2d7a586330644dbaa882a22bf50eda12">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d68" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d69"><ix:continuation id="Text_c2d7a586330644dbaa882a22bf50eda12">
<table cellpadding="0" cellspacing="0" id="z713025753cca4d42a8b28f2a7fba9d21" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Current:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Federal</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" id="Fact_f7d1c022ad9f48ddaa94094db5e10a09" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">35,861</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" id="Fact_3b8dd023e1f647b8a3ac8d6daa73c20c" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">438</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" id="Fact_7390edee7ebc486d8f38622d5c52bcc1" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,460</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">State</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" id="Fact_29cdf46cccf847508b045e7ee750b157" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">14,329</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" id="Fact_18598915ff304ad69c4f603530fa17ba" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,442</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" id="Fact_b16b487bd08b4f16b0833b9f760c9124" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,246</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Foreign</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" id="Fact_ca5d84cba52a406991333d46438a92be" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">413</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" id="Fact_7ac2061535c24653b193dc9c25179163" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">374</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CurrentForeignTaxExpenseBenefit" id="Fact_94c31631758a4c52bc819107405e16bf" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">234</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total current income tax expense (benefit)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" id="Fact_273269185dee42eb91195045f6449fc7" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">50,603</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" id="Fact_33a16e765b9c499ba27c595254ef3547" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">630</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" id="Fact_2d44830595d442f082fda176f5b4c723" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,980</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deferred:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Federal</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" id="Fact_87cec1e54272412b8aa84293213da2a9" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,096</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" id="Fact_3fdf75baf2f34ebb8e8ae479ea28b0dc" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">290,511</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" id="Fact_c00a5eec073e447cab0567a91678c321" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">State</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" id="Fact_e78064ae2d4443f18407baa35f73bf2f" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" id="Fact_989cd3ae4b8346399913987c81866608" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" id="Fact_d254df8f11b14f8594ca47e6a7f95134" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total deferred income tax benefit</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" id="Fact_be2ed18e2072458bba8c88d0a45981b5" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,096</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" id="Fact_499db25413694d1996ce63465160cf19" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">290,511</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" id="Fact_b02665644bb848b5b79ed1b9b7aba937" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total income tax expense (benefit)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_39aa3556afa54b90a94840a97eb5b995" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">43,507</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_d3a17d5cbd604f2eaffbec171dab238a" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">291,141</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_72e6d39ff1da4d90b52e886f5e5ff672" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,980</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d69" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d610">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d610" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d611"><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Text_2c8e7d31275c4be7ad6a80198f6bab7d" contextRef="c20190101to20191231" escape="true" continuedAt="Text_42daf5616a2a4812b8851814d76645211">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our expense (benefit) for income taxes differs from the amount computed by applying the U.S. federal statutory rate to income (loss) before taxes. The sources and tax effects of the differences are as follows (in thousands):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d611" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d612"><ix:continuation id="Text_42daf5616a2a4812b8851814d76645211" continuedAt="Text_42daf5616a2a4812b8851814d76645212">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d612" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d613"><ix:continuation id="Text_42daf5616a2a4812b8851814d76645212">
<table cellpadding="0" cellspacing="0" id="zb11f654ab51c478685d3b34848ff0f2f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="22" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pre-tax income (loss)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" id="Fact_48c8db752dd847f894945e665263db28" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">346,769</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" id="Fact_d90962261a1d4e50b88595c178ff0d7d" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">76,156</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" id="Fact_82f7c2373f9d4876bd0497532436a6c4" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,763</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Statutory rate</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" id="Fact_b85170cf40184efb99422514dde69ba0" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">72,822</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" id="Fact_ba5c266bc6c041669acb634b40fe9801" contextRef="c20190101to20191231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" id="Fact_a4b904e0d10e47ab8481b786c1abe1ef" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">15,993</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" id="Fact_a77137cc5cdc428e9742bd1fec8ff6f2" contextRef="c20180101to20181231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" id="Fact_9224cc00ae254362861b845404083000" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,867</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" id="Fact_0e74348c85d9419b92dc858bfbfb8651" contextRef="c20170101to20171231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">35.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">State income tax net of federal benefit</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" id="Fact_2b7c3633170a40ae9be93f62ef0241a6" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">49,119</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" id="Fact_0598ed64f7924d5fbe52079c56929f59" contextRef="c20190101to20191231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">14.2</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" id="Fact_e3b34f93e7f9416ca458d23851dae3c9" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,202</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" id="Fact_196a7e14a0f4404891352f10b96f74b4" contextRef="c20180101to20181231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">2.9</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" id="Fact_69b8ebd3294b4be8ba8b457bfcaa8715" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">820</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" id="Fact_35da4fb5e1034b3e8483e03f47ce73c3" contextRef="c20170101to20171231" unitRef="U003" decimals="3" sign="-" scale="-2" format="ixt:numdotdecimal">4.9</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Foreign</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" id="Fact_7f4040ef5d7b4da7a7f650bc5150bcee" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">340</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" id="Fact_f0ada95d66be46c484ea33c6988ff8cf" contextRef="c20190101to20191231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.1</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" id="Fact_bb56315ea61941fa9334b20db313a392" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,735</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" id="Fact_1b666959322542018da1ab6a3fcdd0d0" contextRef="c20180101to20181231" unitRef="U003" decimals="3" sign="-" scale="-2" format="ixt:numdotdecimal">2.3</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" id="Fact_a8b08aa07f334b19ae749ec79bb4c2f8" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">4,299</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" id="Fact_3073dd31dd784f6199bcbd4645c6a2c9" contextRef="c20170101to20171231" unitRef="U003" decimals="3" sign="-" scale="-2" format="ixt:numdotdecimal">25.6</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net change in valuation allowance</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_9efc559699e843b7949b61578198c52e" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">37,765</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_44c537cfa23648abad9df1629e8ef953" contextRef="c20190101to20191231" unitRef="U003" decimals="3" sign="-" scale="-2" format="ixt:numdotdecimal">10.9</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_3089c505758644759fb7e8c5ad5478fe" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">277,924</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_110d265d3b7b40408f9b513e9a9ba4c6" contextRef="c20180101to20181231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">364.9</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_add03b8c1f5c42b8ae930d79a66e2d9b" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">86,296</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_6ec22dc5b4fd41c6ad55f9ed00a9676e" contextRef="c20170101to20171231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">514.8</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net operating loss expiration</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount" id="Fact_037b68149f514240b571e4b057b7d37d" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent" id="Fact_892196abe1a5452f8f1fadd574e7d5b0" contextRef="c20190101to20191231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount" id="Fact_a63a31c01b6f498aa2504bf9fa0220ff" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">8,864</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent" id="Fact_3994e2dcfb154b47a855adea0299a9fc" contextRef="c20180101to20181231" unitRef="U003" decimals="3" sign="-" scale="-2" format="ixt:numdotdecimal">11.6</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount" id="Fact_cd496ddabe66446f915c56d43b20262d" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,987</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent" id="Fact_5574c2ce2b434d8c849853df85a0f198" contextRef="c20170101to20171231" unitRef="U003" decimals="3" sign="-" scale="-2" format="ixt:numdotdecimal">23.8</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">TEGSEDI licensing gain</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount" id="Fact_e91cdb5920254d0b9c8644ea0bd6b31e" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent" id="Fact_7baff2ad883145ecacbb955908ebe106" contextRef="c20190101to20191231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount" id="Fact_f125a9429aed4ba59cb4535943b4d39f" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">59,583</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent" id="Fact_c9f5186ca7d84f9f98618eeb48a5a9b9" contextRef="c20180101to20181231" unitRef="U003" decimals="3" sign="-" scale="-2" format="ixt:numdotdecimal">78.2</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount" id="Fact_9c59a15f67874cbf89823f5147894005" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent" id="Fact_b1173bf1f8de49f08e0e02bf8437d58c" contextRef="c20170101to20171231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Impact from outside basis differences</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount" id="Fact_9fb2790ff3c94f178f4d09b6102d0adf" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">16,344</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent" id="Fact_9f26347de83849108790ac9dfef08ef7" contextRef="c20190101to20191231" unitRef="U003" decimals="3" sign="-" scale="-2" format="ixt:numdotdecimal">4.7</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount" id="Fact_f59a48753b43436a810d954a9d62028a" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent" id="Fact_170526424df144d6b3a5c7ad2df709ad" contextRef="c20180101to20181231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount" id="Fact_b0ac595eec344cd89ecac62ed010fd34" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent" id="Fact_79be2841c00041e7af11e17a17380101" contextRef="c20170101to20171231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Tax credits</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCredits" id="Fact_8a24b678d3fe4184bb737b9b5173599f" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">22,296</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" id="Fact_4a7a563d6d234cd58bc7137fba77ff75" contextRef="c20190101to20191231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">6.4</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCredits" id="Fact_ba2fef410ac44e2f8481b601dcf4397d" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">73,362</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" id="Fact_3fbd7800b7924295bc76f61b343a21a8" contextRef="c20180101to20181231" unitRef="U003" decimals="3" sign="-" scale="-2" format="ixt:numdotdecimal">96.3</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationTaxCredits" id="Fact_c945210ff20b45cd8c7dba081d43d2d5" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">32,769</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" id="Fact_d1bcf2d2993f400c81d80c35f297056d" contextRef="c20170101to20171231" unitRef="U003" decimals="3" sign="-" scale="-2" format="ixt:numdotdecimal">195.5</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deferred tax true-up</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" id="Fact_fdfb05c1990c464695261107a860feeb" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">646</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" id="Fact_b964d6aa6a524c4b8d521e92d44ddf1c" contextRef="c20190101to20191231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.2</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" id="Fact_ba7b1884b12a4e2abb5526f4674a1b50" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">9,947</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" id="Fact_7b8114439ec74d04b71a3c5bf7cc21bb" contextRef="c20180101to20181231" unitRef="U003" decimals="3" sign="-" scale="-2" format="ixt:numdotdecimal">13.1</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" id="Fact_ad3c883eceee40a88935de84f632b61b" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">4,848</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" id="Fact_37390301d0c64a41907cda1fe77196a4" contextRef="c20170101to20171231" unitRef="U003" decimals="3" sign="-" scale="-2" format="ixt:numdotdecimal">28.9</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Tax rate change</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" id="Fact_d8e127114141478db3fce29187653ab8" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,811</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" id="Fact_ff5dfbc4b41e4ba2b6268cabc8800f1d" contextRef="c20190101to20191231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.5</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" id="Fact_aa8f48cff99340d4a3fed8f3b3cbf779" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,808</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" id="Fact_52d9c63f1ecc41e1a17a8fbee6d6d2b0" contextRef="c20180101to20181231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">2.4</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" id="Fact_120334d23e2248fa94f0a8b3a47a38ec" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">114,832</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" id="Fact_ff0c8b5e461b4e889743179d12b8fc63" contextRef="c20170101to20171231" unitRef="U003" decimals="3" sign="-" scale="-2" format="ixt:numdotdecimal">685.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-deductible compensation</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount" id="Fact_b9e8226b9cd642a1885a669f1e3ff8e8" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,361</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" id="Fact_8a1f4cfd47914ffdbf619fcbc8052f31" contextRef="c20190101to20191231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">1.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount" id="Fact_c63d7e7b9487406bac497ca46a6fc820" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,154</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" id="Fact_d641767da49f48b0857103834131b687" contextRef="c20180101to20181231" unitRef="U003" decimals="3" sign="-" scale="-2" format="ixt:numdotdecimal">4.1</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount" id="Fact_c2fa1635eae94d73911269398d313a08" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,575</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" id="Fact_5755b6fed27041f187a7d0f88f7107ea" contextRef="c20170101to20171231" unitRef="U003" decimals="3" sign="-" scale="-2" format="ixt:numdotdecimal">9.4</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other non-deductible items</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" id="Fact_bce0197e78cd4cc7ba3eb11921c32b36" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">329</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" id="Fact_d3f365ea019845c7bf004cde11c47f07" contextRef="c20190101to20191231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.1</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" id="Fact_28cb54a2c81c4c359a6868e4d9ab80be" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">569</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" id="Fact_b6b2ce59821f49c5809c638e96706e58" contextRef="c20180101to20181231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.7</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" id="Fact_6a6dcd4f9b944b1e858d646ec40c72b7" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,548</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" id="Fact_be635adead3e46bd8c975057753892db" contextRef="c20170101to20171231" unitRef="U003" decimals="3" sign="-" scale="-2" format="ixt:numdotdecimal">15.2</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea deconsolidation adjustment at IPO</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount" id="Fact_14125e9710be4f4990c31c44ce937c5d" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent" id="Fact_f46ab7265f39434b85df84146b99602c" contextRef="c20190101to20191231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount" id="Fact_67cc5470c2dd4915bb82242964974990" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent" id="Fact_cc5abb17ae784ef596f7eb9f04c0a0fd" contextRef="c20180101to20181231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount" id="Fact_d6efdf4265814896844d64b589018989" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">469</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent" id="Fact_146b3877cfb84c5c905ff82c19d29d16" contextRef="c20170101to20171231" unitRef="U003" decimals="3" sign="-" scale="-2" format="ixt:numdotdecimal">2.8</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stock-based compensation</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" id="Fact_f07a2c7215d74a90a5f9d4a42053e134" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,837</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" id="Fact_896722cf23bd46bd892c4514b440f82b" contextRef="c20190101to20191231" unitRef="U003" decimals="3" sign="-" scale="-2" format="ixt:numdotdecimal">1.4</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" id="Fact_4ace56cd661941dda164a7b4d1dbc5d5" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,199</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" id="Fact_883950498a674a698da46bd68262d2a9" contextRef="c20180101to20181231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">5.5</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" id="Fact_72b2dcbbe49449748e7c9c75562444f6" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">14,337</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" id="Fact_9e38310d67c54659ba2147167a59a001" contextRef="c20170101to20171231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">85.5</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Foreign-derived intangible income benefit</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount" id="Fact_dfb8b37eb49f4805811f12f4b8c7ce05" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,071</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent" id="Fact_17e44038245847de86fe6b3f39ef47bd" contextRef="c20190101to20191231" unitRef="U003" decimals="3" sign="-" scale="-2" format="ixt:numdotdecimal">0.6</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount" id="Fact_282ef35eb1654b2f8cb0e93c44ba382f" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent" id="Fact_09164a15a1544ccf853826dd0b3550ba" contextRef="c20180101to20181231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount" id="Fact_7e6cff3559a04bcb99869ca1d4ef489c" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent" id="Fact_417843ce4b3c41b7a5882fd6f8e31e98" contextRef="c20170101to20171231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 28%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" id="Fact_579c7a65442043da929eea96c26a5f30" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,608</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" id="Fact_d4daf54210844f62bbb1a04059ef74aa" contextRef="c20190101to20191231" unitRef="U003" decimals="3" sign="-" scale="-2" format="ixt:numdotdecimal">0.5</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" id="Fact_a992f73d15204a0081e6aa41357a8de5" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,633</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" id="Fact_4c434cf931ee4c45825ee90aa9c5caf0" contextRef="c20180101to20181231" unitRef="U003" decimals="3" sign="-" scale="-2" format="ixt:numdotdecimal">2.1</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" id="Fact_bc52c68679ef48cab49f85908463be0f" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">89</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" id="Fact_4d88b363955f43e1a07814eb57337204" contextRef="c20170101to20171231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">0.5</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 28%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effective rate</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_deca3f5e839941f4a90d3b8031b558aa" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">43,507</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Fact_5b3403b4768d4be492d67b3c92d9483d" contextRef="c20190101to20191231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">12.6</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_9706d35248bb454c8a3a3c80240bc33f" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">291,141</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Fact_f0cc7188c05e4808b694a7a38a1291cc" contextRef="c20180101to20181231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">382.3</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_05f18d362e2441e2a636fa371d9e87f0" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,980</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Fact_b6d022290a824526a58ab495c81c8422" contextRef="c20170101to20171231" unitRef="U003" decimals="3" scale="-2" format="ixt:numdotdecimal">35.7</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d613" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d614">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d614" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d615">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d615" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d616">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>35</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d616" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d617"><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Text_7bc059be0d5b40b885611b777029a315" contextRef="c20190101to20191231" escape="true" continuedAt="Text_87a024c24a314994bf6cbb7699934a201">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Significant components of our deferred tax assets and liabilities as of December 31, 2019 and 2018 are as follows (in thousands):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d617" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d618"><ix:continuation id="Text_87a024c24a314994bf6cbb7699934a201" continuedAt="Text_87a024c24a314994bf6cbb7699934a202">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d618" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d619"><ix:continuation id="Text_87a024c24a314994bf6cbb7699934a202">
<table cellpadding="0" cellspacing="0" id="z6ce9a811fab143898ba48d74d51fe77e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deferred Tax Assets:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net operating loss carryovers</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" id="Fact_f6113dec90244be7a15feeec0e7f99b3" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">20,191</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" id="Fact_de531fc8054a467eb0d8ebe192e75809" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">89,717</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D credits</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" id="Fact_6e4434c808b24cdd8e98c8c527eccd87" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">210,455</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" id="Fact_8cae73daf0c14e699722d8495d504e3f" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">313,652</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deferred revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" id="Fact_3161a0571c2d40cfa484d6df3f0587b3" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">127,763</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsDeferredIncome" id="Fact_8e7b04eb5d41408cb9a2aae8c76b704c" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">27,381</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stock-based compensation</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" id="Fact_cf4d0af63f314ebebc4008a2387ff7ba" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">65,703</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" id="Fact_616f9b6b59aa4b9b83a42abbfc396399" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">61,027</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Intangible and capital assets</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" id="Fact_1eb4e0ee7798484c84a06c938cd4969a" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">77,861</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" id="Fact_5dbb3a06f1ce4e86bcf8b0b23175d4c6" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">49,007</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" id="Fact_68255c3bd980428f8ac1596cf0f40278" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">12,510</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" id="Fact_8fd4dba767ea4fb1ad2e077d22dd1144" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">8,275</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total deferred tax assets</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" id="Fact_db490d6be6234997ab204f135fae4219" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">514,483</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" id="Fact_0e07da67ce43444f913fc9c18171c638" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">549,059</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deferred Tax Liabilities:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Convertible debt</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" id="Fact_33b89af7fd6c46f9863e3c4ca73a50d0" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">6,110</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesFinancingArrangements" id="Fact_0c45383ac12549f6ae51268c42c2cd6f" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">24,018</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Fixed assets</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" id="Fact_e25b4841ea8643daaead657546cec52e" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,958</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" id="Fact_9878485dcb08467684a2d157588eeafd" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" id="Fact_1b5703c2c4764515a3e8ad2afeea59cf" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,884</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" id="Fact_1b2f279a0c764ac6861cf53127c15459" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net deferred tax asset</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" id="Fact_2aed2e8242ea4d2a953befcd5fd869ee" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">502,531</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" id="Fact_079ce9450c7a4660ba7391c5cb7a50dc" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">525,041</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Valuation allowance</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" id="Fact_972868dc5873412980ceca72fd836c11" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">196,974</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" id="Fact_2c9b12b4481545a7ba60367cdb421919" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">234,245</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total net deferred tax assets and liabilities</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" id="Fact_57658da53796431d95347a5ae91df615" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">305,557</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" id="Fact_b0ad9b5a1bcf4171839877e1f6c48962" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">290,796</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d619" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d620">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d620" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d621">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We evaluate our deferred tax assets regularly to determine whether adjustments to the valuation allowance are appropriate due to changes in facts or circumstances, such as changes in expected future pre-tax earnings, tax law, interactions with taxing authorities and developments in case law. In making this evaluation, we rely on our recent history of pre-tax earnings. Our material assumptions are our forecasts of future pre-tax earnings and the nature and timing of future deductions and income represented by the deferred tax assets and liabilities, all of which involve the exercise of significant judgment. Although we believe our estimates are reasonable, we are required to use significant judgment in determining the appropriate amount of valuation allowance recorded against our deferred tax assets.</div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d621" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d622">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d622" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d623">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We have historically recorded a valuation allowance against all our net deferred tax assets due to cumulative financial statement losses. However, in the fourth quarter of 2018, we reversed the valuation allowance previously recorded against Ionis&#8217; stand-alone U.S. federal net deferred tax assets, resulting in a one-time non-cash tax benefit of $</span><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_5822bb0dcd3341c7a8c11324ef6b029b" contextRef="c20181001to20181231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">332.1</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million. </span>We reversed the valuation allowance in 2018 as<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> we expected to generate U.S. pre-tax income on an Ionis standalone basis in future periods at a level that would result in us fully utilizing our U.S. federal net operating loss carryforwards and our Research and Development and Orphan Drug tax credit carryforwards. </span>We utilized a significant portion of these carryforwards in 2019 to partially offset our estimated federal tax liability for the year.</div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d623" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d624">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d624" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d625">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our valuation allowance decreased by $<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" id="Fact_54269da909f44affbb474d26a98ef345" contextRef="c20190101to20191231" unitRef="U001" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">37.3</ix:nonFraction> million from December 31, 2018 to December 31, 2019. The decrease relates primarily to the current year utilization of a portion of our net deferred state tax assets, primarily California net operating loss carryovers, that had been fully reserved by the valuation allowance.</div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d625" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d626">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d626" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d627">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We continue to maintain a full valuation allowance of $<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" id="Fact_79bb4d4f42da4e4cb9634ca58cbeb45a" contextRef="c20191231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">197.0</ix:nonFraction> million against all of Akcea&#8217;s net deferred tax assets and the net state deferred tax assets of Ionis at December 31, 2019 due to uncertainties related to our ability to realize the tax benefits associated with these assets.</div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d627" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d628">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d628" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d629">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We generated combined state taxable income and recognized a combined state tax liability in 2019. We utilized Ionis&#8217; state deferred tax assets, primarily California net operating loss carry forwards, to reduce our combined state tax liability for the year by $<ix:nonFraction name="ions:IncreaseDecreaseInStateTaxLiability" id="Fact_32218318699447e786a482dfc0bf3f88" contextRef="c20190101to20191231" unitRef="U001" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">59.1</ix:nonFraction> million, which resulted in a corresponding reduction to our combined state valuation allowance. We have historically generated combined state net operating losses due primarily to Akcea&#8217;s net operating losses. However, Akcea generated net income in 2019. This was due to an increase in their research and development and license revenue, primarily related to non-recurring transactions in the first and fourth quarter from Novartis&#8217; exercise of its option to license AKCEA-APO(a)-L<sub>Rx</sub> and Pfizer&#8217;s license of AKCEA-ANGPTL3-L<sub>Rx</sub>, respectively. Although Akcea generated net income in 2019, given their history of losses, there can be no assurance that they will achieve profitability in future periods. We expect Akcea to incur additional operating losses for the foreseeable future and therefore we continue to maintain a full valuation allowance against our remaining net deferred state tax assets.</div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d629" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d630">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d630" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d631">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At December 31, 2019, we had federal and state, primarily California, tax net operating loss carryforwards of $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_d9f8be4484bf4eb29dfdbd375c201523" contextRef="c20191231_IncomeTaxAuthorityNameAxis_InternalRevenueServiceIRSMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">99.5</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_ad3cae48e06445f7aefbd80a218590f4" contextRef="c20191231_IncomeTaxAuthorityNameAxis_CaliforniaFranchiseTaxBoardMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">117.9</ix:nonFraction> million, respectively. Our federal tax loss carryforwards are available indefinitely. Our California tax loss carryforwards will begin to expire in 2033. At December 31, 2019, we also had federal and California research and development tax credit carryforwards of $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" id="Fact_895e697c597d405a96e760deb75e2c01" contextRef="c20191231_IncomeTaxAuthorityNameAxis_InternalRevenueServiceIRSMember_TaxCreditCarryforwardAxis_ResearchMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">198.8</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" id="Fact_8191e961253a4f2faaff06f7920ca14f" contextRef="c20191231_IncomeTaxAuthorityNameAxis_CaliforniaFranchiseTaxBoardMember_TaxCreditCarryforwardAxis_ResearchMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">74.1</ix:nonFraction> million, respectively. Our Federal research and development tax credit carryforwards will begin to expire in 2034. Our California research and development tax credit carryforwards are available indefinitely.</div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d631" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d632">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>36</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d632" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d633">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Utilization of the net operating loss and tax credit carryforwards may be subject to an annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization.</div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d633" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d634">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d634" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d635">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act of 2017, or the Tax Act. The Tax Act made broad and complex changes to the U.S. tax code, including, but not limited to, reducing the U.S. federal corporate income tax rate to <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" id="Fact_5d85031df258433ba61dbc8dc13d4b85" contextRef="c20180101to20181231" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction> percent, imposing a mandatory one-time transition tax on certain unrepatriated earnings of foreign subsidiaries <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">subjecting certain foreign earnings to U.S. taxation through base erosion anti-abuse tax, or BEAT, and global intangible low-taxed income, or GILTI, </span>eliminating the corporate alternative minimum tax, or AMT, and changing how existing AMT credits can be realized. We were required to recognize the tax effect of the tax law changes in the year of enactment. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our accounting for the elements of the Tax Act is complete. We have made an accounting policy election to treat taxes due on the GILTI inclusion as a current period expense.</span></div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d635" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d636">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d636" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d637">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We analyze filing positions in all U.S. federal, state and foreign jurisdictions where we file income tax returns, and all open tax years in these jurisdictions to determine if we have any uncertain tax positions on any of our income tax returns. We recognize the impact of an uncertain tax position on an income tax return at the largest amount that the relevant taxing authority is more-likely-than not to sustain upon audit. We do not recognize uncertain income tax positions if they have less than 50 percent likelihood of the applicable tax authority sustaining our position.</div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d637" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d638">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d638" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d639"><ix:nonNumeric name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="Text_6436d4f50bda4b63bd641448eb6cb0d4" contextRef="c20190101to20191231" escape="true" continuedAt="Text_876abf3a45b245d1b3d6fdcef9f06c181">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes our gross unrecognized tax benefits (in thousands):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d639" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d640"><ix:continuation id="Text_876abf3a45b245d1b3d6fdcef9f06c181" continuedAt="Text_876abf3a45b245d1b3d6fdcef9f06c182">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d640" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d641"><ix:continuation id="Text_876abf3a45b245d1b3d6fdcef9f06c182">
<table cellpadding="0" cellspacing="0" id="z4b3b1be351044041904f4aadda12afa8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Beginning balance of unrecognized tax benefits</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_6f5ba375963f47a19fbb04fed7232165" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">68,301</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_0f12ba3f88584d21bf0b87b613d47847" contextRef="c20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">78,014</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_67e334d942db4ea29c0cbe3ffcea2715" contextRef="c20161231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">66,999</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Decrease for prior period tax positions</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" id="Fact_3f06e5d0f5b747c280280e9fcf69a448" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">867</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" id="Fact_39287cd4b49c44a4a617144fa53df1bf" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">12,814</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" id="Fact_0bb19795798b4cca8d22978a26340bd0" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Increase for prior period tax positions</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" id="Fact_ecf1724d9d65437ab5ccd486d8ab6ebd" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">736</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" id="Fact_0ad407c0955648c48850ba2d8d052462" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" id="Fact_7d0ea3f6a325421b85ab3cbb04eb12fa" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,520</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Increase for current period tax positions</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" id="Fact_6119186f5d854118b836ddc5c481ef2d" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,614</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" id="Fact_f3e7b13433a84e72a642c54ecc6a02b3" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,101</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" id="Fact_809af95107674a60b9a6aa50165e5ba7" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">9,495</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ending balance of unrecognized tax benefits</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_c2747640a25a483791181f56caf8bc45" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">69,784</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_58382ea6463045ef8f7cefb3fdbf3dd7" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">68,301</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_ed1574437d194d92b955e24fdec9efce" contextRef="c20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">78,014</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d641" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d642">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d642" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d643">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Included in the balance of unrecognized tax benefits at December 31, 2019, is $<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" id="Fact_d79b3530a3b2429e9ee130d62e49ab36" contextRef="c20191231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">21.7</ix:nonFraction> million that could impact our effective tax rate, subject to our remaining valuation allowance.</div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d643" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d644">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d644" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d645">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We do not foresee any material changes to our gross unrecognized tax benefits within the next twelve months.</div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d645" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d646">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d646" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d647">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We recognize interest and/or penalties related to income tax matters in income tax expense. We did <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" id="Fact_f621fb3495a94bc1ae99ec0bc3395bdf" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction>t recognize any accrued interest and penalties related to gross unrecognized tax benefits during the year ended December 31, 2019.</div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d647" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d648">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d648" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d649">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are subject to taxation in the U.S. and various state and foreign jurisdictions. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our tax years for 1999 through 2018 are subject to examination by the U.S. federal, state and foreign tax authorities.</span></div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d649" continuedAt="Text_7e0eacb91e2e4e68ac0b31899003d0d650">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7e0eacb91e2e4e68ac0b31899003d0d650">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We do not provide for a U.S. income tax liability and foreign withholding taxes on undistributed foreign earnings of our foreign subsidiaries as we consider those earnings to be permanently reinvested. It is not practicable for us to calculate the amount of unrecognized deferred tax liabilities associated with these earnings.</div>
</ix:continuation></div>
<div><br /></div>
<div><ix:nonNumeric name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Text_6e702f22370b442ca4e36ca2335e2018" contextRef="c20190101to20191231" escape="true" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e301">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">6. Collaborative Arrangements and Licensing Agreements</div>
</ix:nonNumeric><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e301" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e302">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e302" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e303">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Strategic Partnership</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e303" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e304">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e304" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e305">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Biogen</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e305" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e306">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e306" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e307">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We have several strategic collaborations with Biogen focused on using antisense technology to advance the treatment of neurological disorders. These collaborations combine our expertise in creating antisense medicines with Biogen&#8217;s expertise in developing therapies for neurological disorders. We developed and licensed to Biogen SPINRAZA, our approved medicine to treat people with spinal muscular atrophy, or SMA. In</span> December 2017, we entered into a collaboration with Biogen to identify <span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">new antisense medicines for the treatment of SMA</span>. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We and Biogen are currently developing </span><ix:nonFraction name="ions:NumberOfDrugsBeingDeveloped" id="Fact_7af8e6ccc5734a52b212b2cb39251c85" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" unitRef="U015" decimals="INF" scale="0" format="ixt-sec:numwordsen">eight</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> medicines to treat neurodegenerative diseases under these collaborations, including medicines to treat people with ALS, Alzheimer&#8217;s disease</span><sub>&#160;</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">and Parkinson&#8217;s disease. In addition to these medicines, our collaborations with Biogen include a substantial research pipeline that addresses a broad range of neurological diseases. From inception through December 2019, we have received more than $</span><ix:nonFraction name="ions:CumulativePaymentsReceived" id="Fact_2c7f6368c67b460ea001466f23a85954" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" unitRef="U001" decimals="-8" scale="9" format="ixt:numdotdecimal">2.4</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> billion from our Biogen collaborations, including $</span><ix:nonFraction name="ions:UpfrontPaymentReceivedIncludingPurchaseOfStock" id="Fact_1d11244e9c01430c90e4f6051ed9a9c0" contextRef="c20180401to20180630_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U001" decimals="-9" scale="9" format="ixt:numdotdecimal">1</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> billion we received from Biogen in the second quarter of 2018 for our 2018 strategic neurology collaboration.</span></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e307" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e308">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>37</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e308" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e309">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Spinal Muscular Atrophy Collaborations</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e309" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3010">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3010" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3011">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">SPINRAZA</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3011" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3012">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3012" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3013">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In January 2012, we entered into a collaboration agreement with Biogen to develop and commercialize SPINRAZA, an RNA-targeted therapy for the treatment of SMA. Biogen reported in </span>January 2020 that SPINRAZA was approved in over <ix:nonFraction name="ions:NumberOfCountriesWhereDrugIsApprovedForUse" id="Fact_36f52e68092e46448c21ed2babef24c8" contextRef="c20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" unitRef="U016" decimals="0" scale="0" format="ixt:numdotdecimal">50</ix:nonFraction> countries around the world. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">From inception through December 2019, we earned more than $</span><ix:nonFraction name="ions:CumulativeRevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_80c48219eb9e4393b8569e87d9780e38" contextRef="c20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" unitRef="U001" decimals="-9" scale="9" format="ixt:numdotdecimal">1</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> billion in total revenue under our SPINRAZA collaboration, including more than $</span><ix:nonFraction name="ions:CumulativeRevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_6cef645a43bf4562909cf1040246fa31" contextRef="c20191231_ProductOrServiceAxis_SPINRAZARoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">640</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in revenue from SPINRAZA royalties and more than $</span><ix:nonFraction name="ions:CumulativeRevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_4f6bdc7d5939403c952ca9aeb8c58deb" contextRef="c20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">435</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in R&amp;D revenue. We are receiving tiered royalties ranging from </span><ix:nonFraction name="ions:RoyaltyPercentageReceivedOnNetSalesOfDrug" id="Fact_61c6432e61694a50bab0c763baf066d7" contextRef="c20190101to20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction> percent<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> to </span><ix:nonFraction name="ions:RoyaltyPercentageReceivedOnNetSalesOfDrug" id="Fact_1823d09bb3e44264ad0c1a26037d2ae5" contextRef="c20190101to20191231_RangeAxis_MaximumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction> percent<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> on net sales of SPINRAZA. We have exclusively in-licensed patents related to SPINRAZA from Cold Spring Harbor Laboratory and the University of Massachusetts. We pay Cold Spring Harbor Laboratory and the University of Massachusetts a low single digit royalty on net sales of SPINRAZA. Biogen is responsible for global development, regulatory and commercialization activities and costs for SPINRAZA.</span></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3013" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3014">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3014" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3015">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We completed our performance obligations under our collaboration in 2016, including delivering the license to Biogen in July 2016. </span>We also earned additional milestone payments subsequent to delivering the license to Biogen that we recognized in full in the period each milestone payment became probable because we did not have a performance obligation related to each milestone payment. For example, we received $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_d2b23e45f5f74edbb0a88c4534bcf757" contextRef="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction> million of milestone payments for the approval of SPINRAZA in the EU and Japan in 2017 and recognized the full amounts into revenue in the period Biogen achieved the milestone events.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3015" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3016">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3016" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3017">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">New antisense medicines for the treatment of SMA</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3017" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3018">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3018" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3019">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In December 2017, we entered into a collaboration agreement with Biogen to </span>identify <span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">new antisense medicines for the treatment of SMA</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. </span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Biogen has the option to license therapies arising out of this collaboration following the completion of preclinical studies. Upon licensing, Biogen </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">will be responsible for all further global development, regulatory and commercialization activities and costs for such therapies</span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. Under the collaboration agreement, we received a </span>$<ix:nonFraction name="ions:UpfrontPaymentReceived" id="Fact_d0f059efca0b4cb78eead790f4fa19ae" contextRef="c20171201to20171231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction> million<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> upfront payment in December 2017. We will receive development and regulatory milestone payments from Biogen if new medicines advance towards marketing approval. </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In total over the term of our collaboration, we are eligible to receive up to $</span><ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" id="Fact_8fa42de141e3407c99bbfa2f29113c53" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" unitRef="U001" decimals="-8" scale="9" format="ixt:numdotdecimal">1.2</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> billion in license fees, milestone payments and other payments, including up to $</span><ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" id="Fact_e38aa26f41814546bda50548960b0e5e" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for the achievement of development milestones, up to $</span><ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForCommercializationMilestones" id="Fact_6b3fbb9794124e4184ca605383c0149b" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for the achievement of commercialization milestones and up to $</span><ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForSalesMilestones" id="Fact_322a430335cd4f42adcade119ecaa19b" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">800</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for the achievement of sales milestones. In addition, we are eligible to receive tiered royalties </span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">from the mid-teens to </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">mid-</span><ix:nonFraction name="ions:RoyaltyPercentageReceivedOnNetSalesOfDrug" id="Fact_febbc9e4755e4074b3a325f2dacf1e28" contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction> percent<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> range </span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">on net sales.</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> We will achieve the next payment of up to $</span><ix:nonFraction name="ions:NextPotentialPayment" id="Fact_7d01c2380f624d1fb49986067438d3ed" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">for the license of a medicine under this collaboration. </span></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3019" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3020">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3020" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3021">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of this collaboration, we identified <ix:nonFraction name="ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" id="Fact_d072d638eb714ba6a26876ea2bbbb72a" contextRef="c20171231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> performance obligation, which was to perform R&amp;D services for Biogen. We determined the transaction price to be the $<ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPrice" id="Fact_e3683f7ee88940418d4cb28dad798342" contextRef="c20171231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" unitRef="U001" decimals="-6" scale="6">25</ix:nonFraction> million upfront payment we received when we entered into the collaboration. We allocated the transaction price to our single performance obligation. In the fourth quarter of 2019, we completed our R&amp;D services performance obligation under this collaboration. We were recognizing revenue as we performed services based on our effort to satisfy our performance obligation relative to the total effort expected to satisfy our performance obligation. We completed our performance obligation earlier than we previously estimated, as a result, we recognized $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_4edfbf91e3db4c149d8f7c6de6cfd7f2" contextRef="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">8.3</ix:nonFraction> million of additional revenue in the fourth quarter of 2019. We do not have any remaining performance obligations under this collaboration. We will receive development and regulatory milestone payments from Biogen if Biogen advances the development candidate under this collaboration toward marketing approval.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3021" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3022">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3022" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3023">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Neurology Collaborations</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3023" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3024">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3024" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3025">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">2018 Strategic Neurology</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3025" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3026">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3026" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3027">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In April 2018, we and Biogen entered into a strategic collaboration to develop novel antisense medicines for a broad range of neurological diseases and entered into a SPA. As part of the collaboration, Biogen gained exclusive rights to the use of our antisense technology to develop therapies for these diseases for </span><ix:nonNumeric name="ions:TermOfCollaborationAgreement" id="Fact_3d01100b8b54487eb5650d892b0313da" contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" format="ixt-sec:duryear">10</ix:nonNumeric><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> years. We are responsible for the identification of antisense drug candidates based on selected targets</span>. Biogen is responsible for conducting IND-enabling toxicology studies for the selected target. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Biogen will have the option to license the selected target </span>after it completes the IND-enabling toxicology study. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">If Biogen exercises its option to license a medicine, it will assume </span>all <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">further global development, regulatory and commercialization responsibilities and costs for that medicine.</span></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3027" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3028">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3028" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3029">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In the second quarter of 2018, we received </span>$<ix:nonFraction name="ions:UpfrontPaymentReceivedIncludingPurchaseOfStock" id="Fact_976237d61b074e5e9b91af22b9df351f" contextRef="c20180401to20180630_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U001" decimals="-9" scale="9" format="ixt:numdotdecimal">1</ix:nonFraction> billion from Biogen, comprised of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_271dd8aced544c41be19b5a818ba4058" contextRef="c20180401to20180630_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">625</ix:nonFraction> million to purchase our stock at an approximately <ix:nonFraction name="ions:PercentageCashPremiumPaidOnSharesPurchased" id="Fact_c96d0cb6c7e643c7b9c75b57384aa601" contextRef="c20180401to20180630_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction> percent cash premium and $<ix:nonFraction name="ions:UpfrontPaymentReceived" id="Fact_755b026d1fee41558d1dc2c5b62ee556" contextRef="c20180401to20180630_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">375</ix:nonFraction> million in an upfront payment. <span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We are eligible to receive up to $</span><ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments" id="Fact_62648637171d42169a691df96b84fa12" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">270</ix:nonFraction><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in milestone payments for each medicine that achieves marketing approval. </span>In addition, we are eligible to receive tiered royalties <span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">up to the </span><ix:nonFraction name="ions:RoyaltyPercentageReceivedOnNetSalesOfDrug" id="Fact_210a08ece63647968230838a5127deb6" contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction> percent range <span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">on net sales.</span> From inception through December 2019, we have received over $<ix:nonFraction name="ions:CumulativePaymentsReceived" id="Fact_da56d1dc03c24e66a27cff951a361cbb" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U001" decimals="-9" scale="9" format="ixt:numdotdecimal">1</ix:nonFraction> billion in payments under this collaboration, excluding $<ix:nonFraction name="ions:MilestonePaymentAchieved" id="Fact_5f11f4f0f6ca486ba3c59c4c2ec9f3a8" contextRef="c20181001to20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U001" decimals="-6" scale="6">15</ix:nonFraction> million we generated in the fourth quarter of 2019 for advancing <ix:nonFraction name="ions:NumberOfTargetsAdvanced" id="Fact_dad6ba19467e4eae98084a3e57d833ca" contextRef="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U007" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> targets under this collaboration. We will achieve the next payment of $<ix:nonFraction name="ions:NextPotentialPayment" id="Fact_2ccf74adb28c46398e26d42924be60cb" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">7.5</ix:nonFraction> million if Biogen designates another target<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> under this collaboration. </span></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3029" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3030">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>38</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3030" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3031">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">At the commencement of this collaboration, </span>we identified <ix:nonFraction name="ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" id="Fact_5e47f934a68347d89f25d91842517b61" contextRef="c20180430_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> performance obligation, which was to perform R&amp;D services for Biogen.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> We determined our transaction price to be $</span><ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPrice" id="Fact_295623a84e6d476bb91ebff3bfed5858" contextRef="c20180430_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">552</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million, comprised of $</span><ix:nonFraction name="ions:UpfrontPaymentReceived" id="Fact_141e7593cbf740c7a6acd7c7ace28ee3" contextRef="c20180401to20180630_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">375</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million from the upfront payment and $</span><ix:nonFraction name="ions:PremiumPaidOnSharesPurchased" id="Fact_90cf8273bd7a479187f0efa5fa9c8263" contextRef="c20180401to20180630_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">177</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for the premium paid by Biogen for its purchase of our common stock.</span> We determined the fair value of the premium we received by using the stated premium in the SPA and applying a lack of marketability discount. We included a lack of marketability discount in our valuation of the premium because Biogen received restricted shares of our common stock. We allocated the transaction price to our single performance obligation. From inception through December 2019, we have included $<ix:nonFraction name="ions:CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" id="Fact_20ba18c7432f48b692b7d780c2e643aa" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">597</ix:nonFraction> million in payments in the transaction price for our R&amp;D services performance obligation under this collaboration, including <ix:nonFraction name="ions:NumberOfMilestonePaymentsAchieved" id="Fact_0a1037bc6a4143f29676e6da2baeec61" contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction> $<ix:nonFraction name="ions:PaymentsIncludedInTransactionPriceForPerformanceObligation" id="Fact_c2e9e0d69612487ab5f5ec8cb0d9ef7c" contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">7.5</ix:nonFraction> million milestone payments we achieved in 2019 for advancing <ix:nonFraction name="ions:NumberOfTargetsAdvanced" id="Fact_dedcae59a32644a79cca2aa4b477e4b2" contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" unitRef="U007" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>targets under this collaboration. These milestone payments did not create new performance obligations because they are part of our original R&amp;D services performance obligation. Therefore, we included these amounts in our transaction price for our R&amp;D services performance obligation in the period we achieved the milestone payment. We are recognizing revenue for our R&amp;D services performance obligation as we perform services based on our effort to satisfy our performance obligation relative to our total effort expected to satisfy our performance obligation. We<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> currently estimate we will satisfy our performance obligation in </span>June 2028.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3031" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3032">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3032" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3033">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">2013 Strategic Neurology</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3033" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3034">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3034" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3035">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In September 2013, we and Biogen entered into a long-term strategic relationship focused on applying antisense technology to advance the treatment of neurodegenerative diseases. As part of the collaboration, Biogen gained exclusive rights to the use of our antisense technology to develop therapies for neurological diseases and has the option to license medicines resulting from this collaboration. We will usually be responsible for drug discovery and early development of antisense medicines and Biogen will have the option to license antisense medicines after Phase 2 proof-of-concept. In October 2016, we expanded our collaboration to include additional research activities we will perform. If Biogen exercises its option to license a medicine, it will assume all further global development, regulatory and commercialization responsibilities and costs for that medicine. We are currently advancing <ix:nonFraction name="ions:NumberOfDrugsCurrentlyBeingAdvanced" id="Fact_eb09908f5c9a48cc93d43f56069f13ca" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" unitRef="U015" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction> medicines in development under this collaboration, including a medicine for Parkinson&#8217;s disease, <ix:nonFraction name="ions:NumberOfDrugsCurrentlyBeingAdvanced" id="Fact_996f95d3d4dd49e39ee68fd344ce391e" contextRef="c20191231_ProductOrServiceAxis_MedicinesForAmyotrophicLateralSclerosisMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" unitRef="U015" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> medicines for ALS and <ix:nonFraction name="ions:NumberOfDrugsCurrentlyBeingAdvanced" id="Fact_d29b91083ea1419fb33ff60bf441130f" contextRef="c20191231_ProductOrServiceAxis_MedicinesForUndisclosedTargetsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" unitRef="U015" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> medicines for undisclosed targets. In December 2018, Biogen exercised its option to license <ix:nonFraction name="ions:NumberOfDrugsLicensedUnderOptionInCollaborationAgreement" id="Fact_45b8fdc1551143b7b267f69ae4b242c5" contextRef="c20191201to20191231_ProductOrServiceAxis_MedicinesForAmyotrophicLateralSclerosisMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" unitRef="U015" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> of our ALS medicines, tofersen, and as a result Biogen is now responsible for all further global development, regulatory and commercialization activities and costs for tofersen.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3035" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3036">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3036" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3037">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under the terms of the agreement, we received an upfront payment of $<ix:nonFraction name="ions:UpfrontPaymentReceived" id="Fact_df6e4e7a86a541f1926d3e828e7efea5" contextRef="c20130901to20130930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction> million and are eligible to receive milestone payments, license fees and royalty payments for all medicines developed under this collaboration, with the specific amounts dependent upon the modality of the molecule advanced by Biogen. For each antisense molecule that is chosen for drug discovery and development under this collaboration, we are eligible to receive up to approximately $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" id="Fact_e29891c91d1a456e9cb73201cb58d5f4" contextRef="c20191231_ProductOrServiceAxis_AntisenseMoleculeMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">260</ix:nonFraction> million in a license fee and milestone payments per program. The $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" id="Fact_0dfbd8128b624f969b95f7ef71d4d44f" contextRef="c20191231_ProductOrServiceAxis_AntisenseMoleculeMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">260</ix:nonFraction> million per program consists of approximately $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones" id="Fact_245f4587f74e4be8b4a2a97ac77ea0f6" contextRef="c20191231_ProductOrServiceAxis_AntisenseMoleculeMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction> million in development milestones, including amounts related to the cost of clinical trials, and up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" id="Fact_c1d1f25511534235862a7aa4449afd2d" contextRef="c20191231_ProductOrServiceAxis_AntisenseMoleculeMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">130</ix:nonFraction> million in milestone payments if Biogen achieves pre-specified regulatory milestones. In addition, we are eligible to receive tiered royalties up to the mid-teens on net sales from any antisense medicines developed under this collaboration. From inception through December 2019, we have received over $<ix:nonFraction name="ions:CumulativePaymentsReceived" id="Fact_43252364b31243cf9fe665618b7d0d4d" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">240</ix:nonFraction> million in upfront fees, milestone payments and other payments under this collaboration. We will achieve the next payment of up to $<ix:nonFraction name="ions:NextPotentialPayment" id="Fact_531e5e06da924c38a4eddf832276baff" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million if we advance a program under this collaboration.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3037" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3038">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3038" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3039">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of our strategic neurology collaboration, we identified <ix:nonFraction name="ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" id="Fact_5f22f24c59d44580af822992d7804572" contextRef="c20130930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> performance obligation, which was to perform R&amp;D services for Biogen. At inception, we determined the transaction price to be the $<ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPrice" id="Fact_bcce97a700fa470ea25912768f89b9f3" contextRef="c20130930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction> million upfront payment we received and allocated it to our single performance obligation. As we achieve milestone payments for our R&amp;D services, we include these amounts in our transaction price for our R&amp;D services performance obligation. We are recognizing revenue for our R&amp;D services performance obligation based on our effort to satisfy our performance obligation relative to our total effort expected to satisfy our performance obligation<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. </span>In the third quarter of 2019, we updated our estimate of the total effort we expect to expend to satisfy our performance obligation. As of September 30, 2019, we had completed a<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> significant portion of the research and development services. We expect to complete the remainder of our services in 2020. </span>As a result, we recorded a cumulative catch up adjustment of $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_b62f5dd4cf444635b5e8c1a45181319c" contextRef="c20190701to20190930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" unitRef="U001" decimals="-5" scale="6" sign="-" format="ixt:numdotdecimal">16.5</ix:nonFraction> million to decrease revenue in the third quarter of 2019. We will recognize this amount over the estimated remaining period we will perform services. From inception through December <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2019</span>, we have included $<ix:nonFraction name="ions:CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" id="Fact_8e6bac473c9a4873a7bb0e87fa0b76df" contextRef="c20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonFraction> million in total payments in the transaction price for our R&amp;D services performance obligation.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3039" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3040">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3040" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3041">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under this collaboration, we have also generated additional payments that we concluded were not part of our R&amp;D services performance obligation. We recognized each of these payments in full in the respective quarter we generated the payment because we did not have any performance obligations for the respective payment. The following are the payments we generated in 2018 and 2019:</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3041" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3042">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3042" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3043">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zf702cef10ad9420fbb18fe4148806ca7">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the third quarter of 2018, we earned a $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_63dec559cce845c6b0ef765a3708692b" contextRef="c20180701to20180930_ProductOrServiceAxis_IONISC9Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million milestone payment when Biogen initiated a Phase 1 study of IONIS-C9<sub>Rx</sub>. </div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3043" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3044">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zd8bea4369b954832b61973bbc3eb6b4b">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the fourth quarter of 2018, we earned a $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_81e42ca6272446b1b4943add62dab9b1" contextRef="c20181001to20181231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction> million license fee when Biogen licensed tofersen from us because Biogen had full use of the licenses without any continuing involvement from us.</div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3044" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3045">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z0d772d1d1a5a49d0bbf4e2f24aeb9608">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the fourth quarter of 2018, we earned <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">a $</span><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_006f69b7a4444911a0f6769b45a080a9" contextRef="c20181001to20181231_ProductOrServiceAxis_TofersenMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million milestone when Biogen initiated a Proof-of-Concept study for tofersen</span></div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3045" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3046">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z7067decd235e4169aa6e8ded911dd106">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the third quarter of 2019, we earned an $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_ccce677ba0b14a499d2ffb36507cc46d" contextRef="c20190701to20190930_ProductOrServiceAxis_ION859Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction> million milestone payment when Biogen initiated a Phase 1/2 study of ION859 (IONIS-LRRK2<sub>Rx</sub>) <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">for the treatment of people with Parkinson&#8217;s disease </span>under this collaboration. </div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3046" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3047">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="ze7ef725125ba4d91b9d7e95ae4eb1fa0">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the fourth quarter of 2019, we earned a $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_c73bcf5effca436fa5cef751e9a6c8ca" contextRef="c20191001to20191231_ProductOrServiceAxis_IONISC9Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million milestone payment when Biogen advanced IONIS-C9<sub>Rx</sub>. </div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3047" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3048">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>39</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3048" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3049">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">2012 Neurology</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3049" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3050">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3050" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3051">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In December 2012, we and Biogen entered into a collaboration agreement to develop and commercialize novel antisense medicines to up to <ix:nonFraction name="ions:NumberOfTargetsToBeDevelopedAndCommercialized" id="Fact_150fabe1273b434dbedbd63b5b43038c" contextRef="c20121231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" unitRef="U007" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> targets to treat neurodegenerative diseases. We are responsible for the development of each of the medicines through the completion of the initial Phase 2 clinical study for such medicine. Biogen has the option to license a medicine from each of the programs through the completion of the first Phase 2 study for each program. We are currently advancing IONIS-MAPT<sub>Rx</sub> for Alzheimer&#8217;s disease and ION581 for Angelman syndrome under this collaboration. If Biogen exercises its option to license a medicine, it will assume all further global development, regulatory and commercialization responsibilities and costs for that medicine. In December 2019, Biogen exercised its option to license IONIS-MAPT<sub>Rx</sub> and as a result Biogen is now responsible for all further global development, regulatory and commercialization activities and costs for IONIS-MAPT<sub>Rx</sub>.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3051" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3052">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3052" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3053">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Under the terms of the agreement, we received an upfront payment of $</span><ix:nonFraction name="ions:UpfrontPaymentReceived" id="Fact_96e0bfc66c13486cb77a67ff0bc02893" contextRef="c20121201to20121231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million. Over the term of the collaboration, we are eligible to receive up to $</span><ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" id="Fact_ca3ece52a6764f27b53aa658420e1e3c" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">210</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in a license fee and milestone payments per program, plus a mark-up on the cost estimate of the Phase 1 and 2 studies. The $</span><ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" id="Fact_0bbe193efceb411386581d3674a65290" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">210</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million per program consists of up to $</span><ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones" id="Fact_75f24e61b9f94c949ecc39419626d788" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in development milestone payments, plus a mark-up on the cost estimate of the Phase 1 and 2 studies and up to $</span><ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" id="Fact_12ca19bdf13e48ffb87ff55a87528661" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">130</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in milestone payments if Biogen achieves pre-specified regulatory milestones. In addition, we are eligible to receive tiered royalties up to the mid-teens on net sales of any medicines resulting from each of the </span><ix:nonFraction name="ions:NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" id="Fact_a9dc5fc90fff488ab419c13f5bd3df17" contextRef="c20121231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" unitRef="U017" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> programs. From inception through December 2019, we have received $</span><ix:nonFraction name="ions:CumulativePaymentsReceived" id="Fact_7a4c67230f974ba9bfd049a2c63e615a" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">130</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in payments under this collaboration, including $</span><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_975c2c7408d7426c81c8a83cec34024b" contextRef="c20191001to20191231_ProductOrServiceAxis_IONISMAPTMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million we earned when Biogen licensed IONIS-MAPT</span><sub>Rx </sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">and $</span><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_b3c0f29705e748919da1c85bbb7a6e6f" contextRef="c20191001to20191231_ProductOrServiceAxis_ION581Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million when Biogen advanced ION581, both of which occurred in the fourth quarter of 2019. We also achieved a $</span><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_820c16ce7d3640a1a6c86987f712b3ab" contextRef="c20200101to20200226_SubsequentEventTypeAxis_SubsequentEventMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">7.5</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million milestone payment in the first quarter of 2020 when we advanced IONIS-MAPT</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. We will achieve the next payment of $</span><ix:nonFraction name="ions:NextPotentialPayment" id="Fact_7bc80b0e8adf47ca8dd64914ace6d170" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>million if we continue to advance IONIS-MAPT<sub>Rx</sub>.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3053" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3054">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3054" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3055">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under our collaboration, we determined we had a performance obligation to perform R&amp;D services. We allocated $<ix:nonFraction name="ions:CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" id="Fact_1381ecc294394ea081d42cec69196f2b" contextRef="c20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction> million in total payments to the transaction price for our R&amp;D services performance obligation. In the third quarter of 2019, we completed our R&amp;D services performance obligation when we designated a development candidate and Biogen accepted the development candidate. Biogen&#8217;s decision to accept the development candidate was not within our control. We were recognizing revenue as we performed services based on our effort to satisfy our performance obligation relative to the total effort expected to satisfy our performance obligation. Because Biogen accepted the development candidate earlier than when we were previously estimating, we recognized $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_6edc31f3d40d48f3944b9cbb4ebd25f4" contextRef="c20190701to20190930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">6.3</ix:nonFraction> million of accelerated revenue in the third quarter of 2019.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3055" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3056">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3056" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3057">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">When we commenced development for IONIS-MAPT<sub>Rx</sub> we identified our development work as a separate performance obligation. We are recognizing for our IONIS-MAPT<sub>Rx</sub> development performance obligation based on the percentage of completion. From inception through December 2019, we have included $<ix:nonFraction name="ions:CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" id="Fact_65c25865c5cb46d88f766f99f72dcb07" contextRef="c20191231_ProductOrServiceAxis_IONISMAPTMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">37.5</ix:nonFraction> million in the transaction price for our IONIS-MAPT<sub>Rx</sub> development performance obligation. We currently estimate we will satisfy our performance obligation in September 2020. Our total transaction price for our IONIS-MAPT<sub>Rx </sub>development performance obligation includes the following payments we achieved in 2019 related to our development work:</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3057" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3058">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3058" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3059">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zb049489b4a5f433bbe2ed2024d5f35c3">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the second quarter of 2019, we achieved a $<ix:nonFraction name="ions:MilestonePaymentAchieved" id="Fact_501adc29c4e44efd9ab1593ae3a999b3" contextRef="c20190401to20190630_ProductOrServiceAxis_IONISMAPTMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">7.5</ix:nonFraction> million milestone payment from Biogen when we advanced IONIS-MAPT<sub>Rx </sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">for Alzheimer&#8217;s disease</span> under this collaboration. </div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3059" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3060">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z635746e4788a4facb52952eeb34cfca2">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the fourth quarter of 2019, we achieved a $<ix:nonFraction name="ions:MilestonePaymentAchieved" id="Fact_e3916157cd464b41935844d1547678d0" contextRef="c20191001to20191231_ProductOrServiceAxis_IONISMAPTMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction> million milestone payment from Biogen when we entered into an agreement to conduct a long-term extension study for IONIS-MAPT<sub>Rx</sub>. </div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3060" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3061">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3061" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3062">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the fourth quarter of 2019, we identified another performance obligation upon Biogen&#8217;s license of IONIS-MAPT<sub>Rx</sub> because the license we granted to Biogen is distinct from our other performance obligations. We recognized the $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_15e8499c99b84633ab63c1a97bb470f3" contextRef="c20191001to20191231_ProductOrServiceAxis_IONISMAPTMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction> million license fee for IONIS-MAPT<sub>Rx</sub> as revenue at that time because Biogen had full use of the license without any continuing involvement from us. Additionally, we did not have any further performance obligations related to the license after we delivered it to Biogen.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3062" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3063">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3063" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3064">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the fourth quarter of 2019, we <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">earned a $</span><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_68b4f122e6a446cf9ecf4f8f9556c677" contextRef="c20191001to20191231_ProductOrServiceAxis_ION581Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million milestone payment when Biogen advanced ION581. We recognized this milestone payment in full in the fourth quarter of 2019 because we do not have any performance obligations related to this milestone payment.</span></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3064" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3065">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3065" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3066"><ix:nonNumeric name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="Text_d8f9c34f572b4ed39b43785ed86e06a1" contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" escape="true" continuedAt="Text_3bf6eb1f109241838b6db84262cc787a1">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with Biogen (in millions, except percentage amounts):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3066" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3067"><ix:continuation id="Text_3bf6eb1f109241838b6db84262cc787a1" continuedAt="Text_3bf6eb1f109241838b6db84262cc787a2">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3067" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3068"><ix:continuation id="Text_3bf6eb1f109241838b6db84262cc787a2">
<table cellpadding="0" cellspacing="0" id="z0380747c43454884ab39653ff62a443c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SPINRAZA royalties (commercial revenue)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_146a11e1cc3848fa846dfa10b6ca4fac" contextRef="c20190101to20191231_ProductOrServiceAxis_SPINRAZARoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">293.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_14a41acf19b5433ca4e106a13b3a92ec" contextRef="c20180101to20181231_ProductOrServiceAxis_SPINRAZARoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">237.9</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_ebf6a7c4d4d642cb8445cc41028dbc4f" contextRef="c20170101to20171231_ProductOrServiceAxis_SPINRAZARoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">112.5</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_d521219505d14ed8ba28900af2b4eef0" contextRef="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">180.6</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_9cfd5dd6b460430ca49c4c87b102810e" contextRef="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">137.1</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_0be9c7e59ca144e3bbe8fe61671d767b" contextRef="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">150.6</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total revenue from our relationship with Biogen</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_1fd9f9b2ff4242a8ba5d5dc97a5064da" contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">473.6</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_73c0a219d58348498ce8dc987fd9d27e" contextRef="c20180101to20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">375.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_542df45308ad4ee9a37c56efe7fa18d1" contextRef="c20170101to20171231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">263.1</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_b18b889b350941048d2231c689a9f351" contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">42</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_33938ec04f5e40b889d8fcae645d637a" contextRef="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">63</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_6c809afdaa814005b1f6b0887bff71f2" contextRef="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">51</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3068" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3069">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3069" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3070">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our </span>consolidated balance sheet at <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">December 31, </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and </span>2018<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> included deferred revenue of $</span><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" id="Fact_f8f7b974cb2a433882a0fd53fe341a83" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">525.8</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million and $</span><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" id="Fact_35c30aecc55949b1afd1112082165450" contextRef="c20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">580.9</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million, respectively, related to our relationship with Biogen.</span></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3070" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3071">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>40</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3071" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3072">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Research, Development and Commercialization Partners</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3072" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3073">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3073" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3074">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">AstraZeneca</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3074" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3075">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3075" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3076">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Cardiovascular, Renal and Metabolic Diseases Collaboration</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3076" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3077">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3077" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3078">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In July 2015, we and AstraZeneca formed a collaboration to discover and develop antisense therapies for treating cardiovascular, renal and metabolic diseases. Under our collaboration, AstraZeneca has licensed </span><ix:nonFraction name="ions:NumberOfLicensedDrugs" id="Fact_b682e7d57d3a45c18d753ca8d347beeb" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" unitRef="U015" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> medicines from us: IONIS-AZ4-2.5-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, a medicine we designed to treat cardiovascular disease and our first </span>medicine that combines our Generation 2.5 and<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> LICA technology, ION532, a medicine we designed to </span>treat a genetically associated form of kidney disease and <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">ION839, a medicine we designed to </span>inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis, or NASH<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. AstraZeneca is responsible for all further global development, regulatory and commercialization activities and costs for each of the medicines it has licensed and any medicines AstraZeneca licenses in the future.</span></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3078" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3079">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3079" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3080">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under the terms of the agreement, we received a $<ix:nonFraction name="ions:UpfrontPaymentReceived" id="Fact_afe0e303f52c47de8fef2665adbb52f3" contextRef="c20150701to20150731_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">65</ix:nonFraction> million upfront payment. We are eligible to receive license fees and milestone payments of up to more than $<ix:nonFraction name="ions:MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" id="Fact_681cbdadca67472d9b022f4711037c7f" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" unitRef="U001" decimals="-9" scale="9" format="ixt:numdotdecimal">4</ix:nonFraction> billion as medicines under this collaboration advance, including up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" id="Fact_8bf17f1115c642a893b55340a0970cea" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" unitRef="U001" decimals="-8" scale="9" format="ixt:numdotdecimal">1.1</ix:nonFraction> billion for the achievement of development milestones and up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" id="Fact_efb4704088a04a6e826d67ea5c2f326d" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" unitRef="U001" decimals="-8" scale="9" format="ixt:numdotdecimal">2.9</ix:nonFraction> billion for regulatory milestones. In addition, we are eligible to receive tiered royalties up to the low teens on net sales from any product that AstraZeneca successfully commercializes under this collaboration agreement. We will achieve the next payment of $<ix:nonFraction name="ions:NextPotentialPayment" id="Fact_cf47c653ca844b46ba8588a2a589a194" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million under this collaboration if we advance a medicine under this collaboration<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</span> From inception through December 2019, we have received over $<ix:nonFraction name="ions:CumulativePaymentsReceived" id="Fact_b46d3be360f94ea788b2b83ce6c73f6f" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">175</ix:nonFraction> million in upfront fees, license fees, milestone payments, and other payments under this collaboration, including a $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_48047624f3d64ef8ab735f9f354d1afb" contextRef="c20180701to20180930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million milestone payment we earned in the fourth quarter of 2019 when AstraZeneca initiated a Phase 1 trial for ION839.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3080" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3081">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3081" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3082">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of this collaboration, we identified <ix:nonFraction name="ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" id="Fact_12852f4c3cee4a69b4f4fee5d29498e6" contextRef="c20150731_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> performance obligation, which was to perform R&amp;D services for AstraZeneca. We determined the transaction price to be the $<ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPrice" id="Fact_321f6d91fea64a57a4103c135ba57bd1" contextRef="c20150731_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">65</ix:nonFraction> million upfront payment we received and we allocated it to our single performance obligation. We are recognizing revenue for our R&amp;D services performance obligation as we perform services based on our effort to satisfy this performance obligation relative to our total effort expected to satisfy our performance obligation. We<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> currently estimate we will satisfy this performance obligation in</span> August 2021. As we achieve milestone payments for our R&amp;D services, we include these amounts in our transaction price for our R&amp;D services performance obligation. From inception through December<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> 2019</span>, we have included $<ix:nonFraction name="ions:CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" id="Fact_ec77e25e50654249ba1ef8f5f9e4a1d1" contextRef="c20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction> million in payments in the transaction price for our R&amp;D services performance obligation.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3082" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3083">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3083" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3084">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under this collaboration, we have also generated additional payments that we concluded were not part of our R&amp;D services performance obligation. We recognized each of these payments in full in the respective quarter we generated the payment because the payments were distinct and we did not have any performance obligations for the respective payment. The following are the payments we have earned:</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3084" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3085">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3085" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3086">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z4e81e175835f49a2a473992532fd14cc">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In the first quarter of 2018, we earned </span><ix:nonFraction name="ions:NumberOfLicenseFeesEarned" id="Fact_cae7641b707f452289941fceefd520c1" contextRef="c20180101to20180331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" unitRef="U018" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>$<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_e5a7b501073741939fc54a02add83b3a" contextRef="c20180101to20180331_ProductOrServiceAxis_ION839Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_e85c6c9e30914bd0a8087a5b903ad7e9" contextRef="c20180101to20180331_ProductOrServiceAxis_ION532Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction></ix:nonFraction> million license fees when AstraZeneca licensed ION532 and ION839 because AstraZeneca had full use of the licenses without any continuing involvement from us. </div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3086" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3087">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z984f9fae8d6743d1acd0c178a6cbc814">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the third quarter of 2018, we earned a $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_b354e861c2bd46999901a4505b256e38" contextRef="c20180701to20180930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million milestone payment when AstraZeneca initiated a Phase 1 study of IONIS-AZ4-2.5-L<sub>Rx</sub>. </div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3087" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3088">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z6311690ca5444922891b858eebbeb95b">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the fourth quarter of 2019, we earned a $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_344416977fa842688cb3eb2ccbfc49f5" contextRef="c20181001to20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million milestone payment when AstraZeneca initiated a Phase 1 study of ION839. </div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3088" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3089">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3089" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3090">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Oncology Collaboration</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3090" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3091">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3091" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3092">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In December 2012, we entered into a collaboration agreement with AstraZeneca to discover and develop antisense medicines to treat cancer. As part of the agreement, we granted AstraZeneca an exclusive license to develop and commercialize </span>danvatirsen <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">for the treatment of cancer. AstraZeneca is responsible for all global development, regulatory and commercialization activities for </span>danvatirsen<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. We and AstraZeneca have evaluated </span>danvatirsen<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in people with head and neck cancer, advanced lymphoma and advanced metastatic hepatocellular carcinoma. AstraZeneca is evaluating </span>danvatirsen<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in combination with durvalumab, AstraZeneca&#8217;s PD-L1, blocking medicine, in people with head and neck cancer, metastatic bladder cancer and metastatic non-small cell lung cancer. We and AstraZeneca also established an oncology research program. AstraZeneca has the option to license medicines resulting from the program, and if AstraZeneca exercises its option to license a medicine, it will be responsible for all further global development, regulatory and commercialization activities and costs for such medicine. In the fourth quarter of 2018, we added </span>ION736 (formerly IONIS-AZ7-2.5<sub>Rx</sub>) to our preclinical pipeline, a second medicine under our oncology collaboration.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3092" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3093">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3093" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3094">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Under the terms of this agreement, we received $</span><ix:nonFraction name="ions:UpfrontPaymentReceived" id="Fact_2cd1bc1d00e14c1d84b80c4ee6e222db" contextRef="c20121201to20121231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in upfront payments. We are eligible to receive milestone payments and license fees from AstraZeneca as programs advance in development. If AstraZeneca successfully develops </span>danvatirsen<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and ION736 under the research program, we could receive license fees and milestone payments of up to more than $</span><ix:nonFraction name="ions:MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" id="Fact_7408146d87de4593b6dc9b03dacc64e6" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">450</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million, including up to $</span><ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" id="Fact_484e8f6f1dd242f5996c00b362124558" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">152</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for the achievement of development milestones and up to $</span><ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" id="Fact_20c0e0a8259e44148a7d32d9c9881c8c" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">275</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for the achievement of regulatory milestones. In addition, we are eligible to receive tiered royalties up to the mid-teens on net sales from any medicines resulting from these programs. From inception through December 2019, we have received over $</span><ix:nonFraction name="ions:CumulativePaymentsReceived" id="Fact_ec695803788a443b8addc8655e99aaa7" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in upfront fees, milestone payments, and other payments under this oncology collaboration, including nearly $</span><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_546bc7b5d7b641e0842361b086374c17" contextRef="c20181001to20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in milestone payments we achieved when AstraZeneca advanced </span>danvatirsen and ION736, in the fourth quarter of 2018. We <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">will achieve the next payment of up to $</span><ix:nonFraction name="ions:NextPotentialPayment" id="Fact_9d85706b0d4c4c5dbc82e0700a25253c" contextRef="c20191231_RangeAxis_MaximumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">if we advance a medicine under our cancer research program with AstraZeneca.</span></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3094" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3095">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>41</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3095" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3096">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of this collaboration, we identified <ix:nonFraction name="ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" id="Fact_9659e33cf0f045a18ddfbc6af3bd7186" contextRef="c20121231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction> performance obligations, <ix:nonFraction name="ions:NumberOfPerformanceObligationsCompleted" id="Fact_98902606606a46b192b6aa219b7c20cb" contextRef="c20140331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> of which we completed in March 2014 and we completed the remaining R&amp;D services performance obligation in February 2018. In the fourth quarter of 2018, we earned a $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_2c2750daedb84d4285c346d6c1676448" contextRef="c20181001to20181231_ProductOrServiceAxis_DanvatirsenMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">17.5</ix:nonFraction> million milestone payment and a $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_c12e1cf9eef04dedbdefabddee95ccee" contextRef="c20181001to20181231_ProductOrServiceAxis_ION736Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million milestone payment when AstraZeneca advanced <ix:nonFraction name="ions:NumberOfProgramsAdvanced" id="Fact_869d672b0b0d4547ab0774a9a808f2d8" contextRef="c20181001to20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" unitRef="U017" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> programs under our collaboration. We recognized these milestone payments in full in the fourth quarter because we do not have any performance obligations related to these milestone payments.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3096" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3097">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3097" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3098"><ix:nonNumeric name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="Text_f400bcb381b745faa5a030abbe973471" contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" escape="true" continuedAt="Text_a05acba47f364da085725362ceca56fa1">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with AstraZeneca (in millions, except percentage amounts):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3098" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e3099"><ix:continuation id="Text_a05acba47f364da085725362ceca56fa1" continuedAt="Text_a05acba47f364da085725362ceca56fa2">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e3099" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30100"><ix:continuation id="Text_a05acba47f364da085725362ceca56fa2">
<table cellpadding="0" cellspacing="0" id="z3e98572cb7a74e948b59d5a9feec5657" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_77009387bc654006989ae141c96c8496" contextRef="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">28.1</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_b4bc1487977543468f0c2592f732bfb0" contextRef="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">120.7</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_6f993bce8b8f4c7aa2348aedba4438cf" contextRef="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">21.6</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_146be9f3b2bd4a1390bcfa5173d38d88" contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_dd338796e71247f6bc131ed50f37ef36" contextRef="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_aa247af696394bd6806e0b89dffcff91" contextRef="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">4</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30100" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30101">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30101" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30102">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our </span>consolidated balance sheet at <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">December 31, </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and </span>2018<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> included deferred revenue of $</span><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" id="Fact_c0d98582c04c40f885040e43e3e95697" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">25.0</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million and $</span><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" id="Fact_29e93280d0e245d79babbeeaf1bba43f" contextRef="c20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">40.1</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million, respectively, related to our relationship with AstraZeneca.</span></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30102" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30103">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30103" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30104">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Bayer</div>
</ix:continuation></div>
<div style="background-color: #FFFFFF;"><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30104" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30105">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30105" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30106">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In May 2015, we entered into an exclusive license agreement with Bayer to develop and commercialize IONIS-FXI<sub>Rx</sub> for the prevention of thrombosis. We were responsible for completing a Phase 2 study of IONIS-FXI<sub>Rx</sub> in people with end-stage renal disease on hemodialysis. Under the terms of the agreement, we received a $<ix:nonFraction name="ions:UpfrontPaymentReceived" id="Fact_1ecc831150824141bd76a92d58b3f591" contextRef="c20150401to20150630_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction> million upfront payment in the second quarter of 2015. In February 2017, we amended our agreement with Bayer to advance IONIS-FXI<sub>Rx</sub> and to initiate development of IONIS-FXI-L<sub>Rx</sub>, which Bayer licensed. In conjunction with the decision to advance these programs, we received a $<ix:nonFraction name="ions:PaymentReceivedForAdvancingPrograms" id="Fact_27a5975c2c5d4ed98e446e999c953f35" contextRef="c20170201to20170228_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million payment from Bayer. In October 2019, Bayer decided it would advance IONIS-FXI-L<sub>Rx</sub> following positive clinical results. Bayer is now responsible for all global development, regulatory and commercialization activities and costs for the FXI program.</div>
</ix:continuation></div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30106" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30107">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30107" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30108">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are eligible to receive up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" id="Fact_1ea7b17e0fd54a53ba9ea212e481602c" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">385</ix:nonFraction> million in license fees, milestone payments and other payments, including up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" id="Fact_e03c5e12d8dc4479948a18adba98b88c" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction> million for the achievement of development milestones and up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForCommercializationMilestones" id="Fact_ab70c484782f41e4acf44792bd373694" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">110</ix:nonFraction> million for the achievement of commercialization milestones. In addition, we are eligible to receive tiered royalties in the low to high <ix:nonFraction name="ions:RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement" id="Fact_fb2e5156c6b544b98419218e7a28691b" contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction> percent range on gross margins of both medicines combined. From inception through December 2019, we have received over $<ix:nonFraction name="ions:CumulativePaymentsReceived" id="Fact_55c7b99eec38441eb299ea5fe41b3ea2" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">185</ix:nonFraction> million from our Bayer collaboration, including a $10 million milestone payment we earned in the fourth quarter of 2019 when Bayer decided it would advance IONIS-FXI-L<sub>Rx</sub>. We will achieve the next payment of $<ix:nonFraction name="ions:NextPotentialMilestonePayment" id="Fact_abb5e5bfab0742a594537d03e99e580c" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction> million if Bayer initiates a Phase 3 study for the FXI program.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30108" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30109">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30109" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30110">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of this collaboration, we identified <ix:nonFraction name="ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" id="Fact_1279bd3e4793428181ec1aad1e8b44ba" contextRef="c20150531_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> performance obligations, the license of IONIS-FXI<sub>Rx</sub>, which we delivered in May 2016, R&amp;D services and delivery of API, both of which we completed in November 2016.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30110" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30111">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30111" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30112">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In February 2017, when we amended our collaboration with Bayer, we identified <ix:nonFraction name="ions:RevenueFromContractWithCustomerNumberOfNewPerformanceObligations" id="Fact_88bf8c1f8dfc4704bd5e5ef69d1688f0" contextRef="c20170201to20170228_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> new performance obligations<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, </span><ix:nonFraction name="ions:RevenueFromContractWithCustomerNumberOfNewPerformanceObligations" id="Fact_036ca3d6a65a45808b611cf2f29cf18c" contextRef="c20170201to20170228_ProductOrServiceAxis_IONISFXILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for the license of IONIS-FXI-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and </span><ix:nonFraction name="ions:RevenueFromContractWithCustomerNumberOfNewPerformanceObligations" id="Fact_84ed394b95dc4b689089483bec9ee81d" contextRef="c20170201to20170228_ProductOrServiceAxis_ResearchAndDevelopmentServicesForIONISFXILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for R&amp;D services</span>. We determined the transaction price to be the $<ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPrice" id="Fact_c9e8f99e0b5547cfa910d6da0c7fa156" contextRef="c20170228_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million payment. We allocated $<ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPrice" id="Fact_671c15f958d449e1b0996ae26fb02f7f" contextRef="c20170228_ProductOrServiceAxis_IONISFXILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">64.9</ix:nonFraction> million to <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">the license of IONIS-FXI-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> based on its estimated relative stand-alone selling price and recognized the associated revenue upon our delivery of the license in the first quarter of 2017. We allocated $</span><ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPrice" id="Fact_66e51b39565d4d5491b40a7ff56ff227" contextRef="c20170228_ProductOrServiceAxis_ResearchAndDevelopmentServicesForIONISFXILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">10.1</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million to our R&amp;D services performance obligation based on an estimated relative stand-alone selling price. </span>We recognized revenue for our R&amp;D services performance obligation as we performed services based on our effort to satisfy our performance obligation relative to our total effort expected to satisfy our performance obligation which we completed in the third quarter of 2019.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30112" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30113">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30113" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30114">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the fourth quarter of 2019, we earned a $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_9fa6b92a37764bc4ad97b1ac44dab174" contextRef="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million milestone payment when Bayer decided it would advance IONIS-FXI-L<sub>Rx</sub>. We recognized this milestone payment in full in the fourth quarter of 2019 because we do not have any performance obligations related to this milestone payment.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30114" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30115">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30115" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30116"><ix:nonNumeric name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="Text_3e44851f40134046bc9f808677661e83" contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember" escape="true" continuedAt="Text_6c395dbab0f549dc8625646a3ab6ce841">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with Bayer (in millions, except percentage amounts):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30116" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30117"><ix:continuation id="Text_6c395dbab0f549dc8625646a3ab6ce841" continuedAt="Text_6c395dbab0f549dc8625646a3ab6ce842">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30117" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30118"><ix:continuation id="Text_6c395dbab0f549dc8625646a3ab6ce842">
<table cellpadding="0" cellspacing="0" id="zb1073dc32a5e4c66a2a664b0634da7c6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_f99969488acc436791df63a07499be6d" contextRef="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">14.3</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_9fe9de20486147f8955d5c734eb9d8b3" contextRef="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_59362cd04b3741fd938d03dcb0e698f6" contextRef="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">67.1</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_4046e641eafa4ddcb89c308b055c2ce2" contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_babedde018f446ab8478453fdfd8dcc9" contextRef="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_abdecb8fff3747c8aca189e9a145033d" contextRef="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">13</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30118" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30119">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30119" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30120">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our </span>consolidated balance sheet at <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">December 31, 2019 and 2019 included deferred revenue of $</span><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" id="Fact_739fa714d0af4d74849dd6f1cadcd0d8" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">2.4</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million and $</span><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" id="Fact_64e74248337d43bd85c81ec53ac919fa" contextRef="c20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">4.3</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million, respectively, related to our relationship with Bayer.</span></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30120" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30121">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>42</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30121" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30122">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">GSK</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30122" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30123">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30123" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30124">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In March 2010, we entered into an alliance with GSK using our antisense drug discovery platform to discover and develop new medicines against targets for rare and serious diseases, including infectious diseases and some conditions causing blindness. Under the terms of the agreement, we received upfront payments of $<ix:nonFraction name="ions:UpfrontPaymentReceived" id="Fact_7283fa5013cc4c8f8847969829246bd2" contextRef="c20100301to20100331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction> million. Our collaboration with GSK currently includes <ix:nonFraction name="ions:NumberOfDrugsBeingDeveloped" id="Fact_34359473758b4342a786a2bfd26d9b28" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" unitRef="U015" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> medicines targeting hepatitis B virus, or HBV: IONIS-HBV<sub>Rx</sub> and IONIS-HBV-L<sub>Rx</sub>, which we designed to reduce the production of viral proteins associated with HBV infection. In the third quarter of 2019, following positive Phase 2 results, GSK licensed our HBV program. GSK is responsible for all global development, regulatory and commercialization activities and costs for the HBV program.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30124" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30125">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30125" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30126">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under our agreement, if GSK successfully develops these medicines and achieves pre-agreed sales targets, we could receive license fees and milestone payments of up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" id="Fact_4efd385d112840afad0e4faa46214870" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">262</ix:nonFraction> million, including up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" id="Fact_229776738d884ce8aee54ac341784a2d" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">47.5</ix:nonFraction> million for the achievement of development milestones, up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" id="Fact_131e23080dcc40398152b2bd4d048056" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">120</ix:nonFraction> million for the achievement of regulatory milestones and up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForCommercializationMilestones" id="Fact_a5c67dd2e09b4b708ea1ffa029688a59" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction> million for the achievement of commercialization milestones. In addition, we are eligible to receive tiered royalties up to the mid-teens on net sales from any product that GSK successfully commercializes under this alliance. From inception through December 2019, we have received more than $<ix:nonFraction name="ions:CumulativePaymentsReceived" id="Fact_80b40aad4e4f428d854cce06e968dea2" contextRef="c20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">189</ix:nonFraction> million in payments under this alliance with GSK, including a $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_157814dcf79c45a780af9420a88abc80" contextRef="c20190701to20190930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction> million license fee we earned in the third quarter of 2019 when GSK licensed the HBV program. We will achieve the next payment of $<ix:nonFraction name="ions:NextPotentialMilestonePayment" id="Fact_5f7e1c8f371048a4aa050ce4806c0edf" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction> million when GSK initiates a Phase 3 study of a medicine under this program.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30126" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30127">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30127" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30128">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We completed our R&amp;D services performance obligations under our collaboration in March 2015. </span>We identified a new performance obligation when we granted GSK the license of the HBV program and assignment of related intellectual property rights in the third quarter of 2019 because the license is distinct from our other performance obligations. We recognized the $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_eaf6203cfa224f3791cb9bffe7977090" contextRef="c20190701to20190930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction> million license fee for the HBV program as revenue at that time because GSK had full use of the license without any continuing involvement from us. Additionally, we did not have any further performance obligations related to the license after we delivered it to GSK.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30128" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30129">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30129" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30130">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We do not have any remaining performance obligations under our collaboration with GSK; however, we can still earn additional payments and royalties as GSK advances the HBV program.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30130" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30131">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30131" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30132"><ix:nonNumeric name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="Text_4f8ce91d37794e73ae312862eb75a78e" contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" escape="true" continuedAt="Text_fe6efa6b042a4f17a3dd9b99f763096c1">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with GSK (in millions, except percentage amounts):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30132" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30133"><ix:continuation id="Text_fe6efa6b042a4f17a3dd9b99f763096c1" continuedAt="Text_fe6efa6b042a4f17a3dd9b99f763096c2">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30133" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30134"><ix:continuation id="Text_fe6efa6b042a4f17a3dd9b99f763096c2">
<table cellpadding="0" cellspacing="0" id="zfc1697a2c45e4e5d9ba00caf3a13ead3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_1efa0cc60e004562b4e6a6c7879c789d" contextRef="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">25.4</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_56e66bccc3624645bcb22750e41916dd" contextRef="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_ec6cf4febb2f49e683915746e6801969" contextRef="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">14.8</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_fcadd36b6cbc4c4796ae789c7805b00f" contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_ff3be5276ecf4d51a2514c2feff18233" contextRef="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_64cbaaeaf4c249c28f7644f151cd8a75" contextRef="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30134" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30135">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30135" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30136">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We did <ix:nonFraction name="us-gaap:ContractWithCustomerLiability" id="Fact_b211069271df4c4a802417ef5e7b0d32" contextRef="c20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" unitRef="U001" decimals="-6" scale="6" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" id="Fact_59e8ee0b0973416987e4c07862acaea5" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" unitRef="U001" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t have any deferred revenue from our relationship with GSK at December 31, 2019 and 2018.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30136" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30137">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30137" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30138">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Janssen Biotech, Inc.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30138" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30139">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="background-color: #FFFFFF;"><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30139" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30140">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In December 2014, we entered into a collaboration agreement with Janssen Biotech, Inc. to discover and develop antisense medicines that can be locally administered, including oral delivery, to treat autoimmune disorders of the GI tract. Janssen had the option to license medicines from us through the designation of development candidates for up to <ix:nonFraction name="ions:NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" id="Fact_26aef289b10143debb8dca041c8ee779" contextRef="c20141231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" unitRef="U017" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> programs. Under our collaboration, Janssen licensed ION253 in November 2017, which is currently in preclinical development. Prior Janssen&#8217;s license of ION253, we were responsible for the discovery activities to identify development candidates. Under the license, Janssen is responsible for the global development, regulatory and commercial activities for ION253.</div>
</ix:continuation></div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30140" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30141">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30141" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30142">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under the terms of the agreement, we received $<ix:nonFraction name="ions:UpfrontPaymentReceived" id="Fact_7f98b32d298b42688c37d988ab2909b8" contextRef="c20141201to20141231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction> million in upfront payments. We are eligible to receive up to more than $<ix:nonFraction name="ions:MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" id="Fact_a564066b38e84d2595cdfbfc276b1eba" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">285</ix:nonFraction> million in license fees and milestone payments for these programs, including up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" id="Fact_c2e87dcc7db149c7bef875e445a5c48c" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">65</ix:nonFraction> million for the achievement of development milestones, up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" id="Fact_8be6f9afea8a40139feecb8a0aa84941" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">160</ix:nonFraction> million for the achievement of regulatory milestones and up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForCommercializationMilestones" id="Fact_e21d01127a2247a9ba21d6eafa2cdea6" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction> million for the achievement of commercialization milestones. From inception through December 2019, we have received over $<ix:nonFraction name="ions:CumulativePaymentsReceived" id="Fact_9ad34bef7ccb4d00b82f1650470dc23d" contextRef="c20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million. In addition, we are eligible to receive tiered royalties up to the near teens on net sales from any medicines resulting from this collaboration. We will achieve the next payment of $<ix:nonFraction name="ions:NextPotentialMilestonePayment" id="Fact_608263f8b813452282c49861d04ce4b7" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction> million if Janssen continues to advance a target under this collaboration.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30142" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30143">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30143" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30144">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of this collaboration, we identified <ix:nonFraction name="ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" id="Fact_f68fbf09b9ae48f4837c1876e49a8d0f" contextRef="c20141231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> performance obligation, which was to perform R&amp;D services for Janssen. We determined the transaction price to be the $<ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPrice" id="Fact_6b929259ee5b4b7da8a05540eca83d56" contextRef="c20141231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction> million upfront payments we received. We allocated the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</span><ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPrice" id="Fact_a00a77fdd643486b8ca7e353ece96e57" contextRef="c20141231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million</span> to our single performance obligation. As we achieved milestone payments for our R&amp;D services, we included these amounts in our transaction price for our R&amp;D services performance obligation. We recognized revenue for our R&amp;D services performance obligation over our period of performance, which ended in November 2017.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30144" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30145">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>43</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30145" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30146">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We identified separate performance obligation when Janssen licensed ION253 under our collaboration because the license we granted to Janssen was distinct from our other performance obligations. We recognized the $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_a198ddc9a96f4e258029eddad08021db" contextRef="c20171101to20171130_ProductOrServiceAxis_IONISJBI225Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction> million license fee for ION253 in November 2017, because Janssen had full use of the licenses without any continuing involvement from us. Additionally, we did not have any further performance obligations related to the license after we delivered it to Janssen.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30146" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30147">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30147" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30148"><ix:nonNumeric name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="Text_f54f5d999716490c9cb36e7ed99e0d8d" contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" escape="true" continuedAt="Text_99eae8605f7a4ce583617178eba8d3c91">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with Janssen (in millions, except percentage amounts):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30148" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30149"><ix:continuation id="Text_99eae8605f7a4ce583617178eba8d3c91" continuedAt="Text_99eae8605f7a4ce583617178eba8d3c92">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30149" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30150"><ix:continuation id="Text_99eae8605f7a4ce583617178eba8d3c92">
<table cellpadding="0" cellspacing="0" id="zf8941280a0a94e81bb425341b948878a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_e6fb7a6986bb4a6dabf275cd43de3142" contextRef="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">0.1</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_d2a35f12eb3c4819acf4b38b9b44e610" contextRef="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">6.6</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_fb1097993d3640f5978bde9ecba258fb" contextRef="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">36.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_fba485fa0402455c87b77af7362e351f" contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_84de48daf8514dcaa02ab54da0a048a0" contextRef="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_d89ed37737544e2aac9c1cd3c8d8ab99" contextRef="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30150" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30151">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30151" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30152">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We did <ix:nonFraction name="us-gaap:ContractWithCustomerLiability" id="Fact_e6090aaddd3944d880fb682755e83a3b" contextRef="c20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" unitRef="U001" decimals="-6" scale="6" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" id="Fact_365ae9af3d38401eb562eea4ba20c9d2" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" unitRef="U001" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t have any deferred revenue from our relationship with Janssen at December 31, 2019 and 2018.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30152" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30153">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30153" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30154">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Roche</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30154" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30155">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30155" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30156">
<div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Huntington&#8217;s Disease</span></div>
</ix:continuation></div>
<div style="background-color: #FFFFFF;"><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30156" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30157">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30157" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30158">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In April 2013, we formed an alliance with Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd., collectively Roche, to develop treatments for HD based on our antisense technology. Under the agreement, we discovered and developed tominersen, an antisense medicine targeting HTT protein. We developed tominersen through completion of our Phase 1/2 clinical study in people with early stage HD. In December 2017, upon completion of the Phase 1/2 study, Roche exercised its option to license tominersen<sub>&#160;</sub>and is now responsible for the global development, regulatory and commercialization activities and costs for tominersen.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30158" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30159">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30159" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30160">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under the terms of the agreement, we received an upfront payment of $<ix:nonFraction name="ions:UpfrontPaymentReceived" id="Fact_9f09a173393d49bc818e79aacee84764" contextRef="c20130401to20130430_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction> million in April 2013 and an additional $<ix:nonFraction name="ions:MilestonePaymentsReceived" id="Fact_8432cd12b85e48c6b111a7bdcb5f2ac8" contextRef="c20170101to20171231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction> million payment in 2017. We are eligible to receive up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" id="Fact_d8d42ebb32dc46b7895c83156cf73607" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">365</ix:nonFraction> million in a license fee and milestone payments including up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" id="Fact_70a5f7bc239446719e9285ed2ff78c07" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction> million for the achievement of development milestones, up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" id="Fact_884490256579410c93629768255d304a" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">170</ix:nonFraction> million for the achievement of regulatory milestones and up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForCommercializationMilestones" id="Fact_a9fce437f8684220b259d8408d43875f" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction> million for the achievement of commercialization milestones. In addition, we are eligible to receive up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped" id="Fact_67793d8d7c8843aba2b236e8d909758e" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">136.5</ix:nonFraction> million in milestone payments for each additional medicine successfully developed. We are also eligible to receive tiered royalties up to the mid-teens on any net sales of any product resulting from this alliance. From inception through December 2019, we have received over $<ix:nonFraction name="ions:CumulativePaymentsReceived" id="Fact_3aa74885781e415aa4fe5dd8e04e1eda" contextRef="c20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonFraction> million in upfront fees, milestone payments and license fees for advancing tominersen, including $<ix:nonFraction name="ions:MilestonePaymentsReceived" id="Fact_18ad29df344a4c9e9dc00cbac3e23532" contextRef="c20190101to20190331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction> million in milestone payments we earned in the first quarter of 2019 when Roche dosed the first patient in a Phase 3 study for tominersen. We will achieve the next payment of $<ix:nonFraction name="ions:NextPotentialMilestonePayment" id="Fact_cb403b59db80408fb4a9b96e8393b762" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction> million if Roche advances tominersen.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30160" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30161">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30161" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30162">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of this collaboration, we identified <ix:nonFraction name="ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" id="Fact_efae3e04708b4937bacd7fa2bb5963f7" contextRef="c20130430_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> performance obligation, which was to perform R&amp;D services for Roche. We determined the transaction price to be the $<ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPrice" id="Fact_872b6a5c29be484ca3beb5fa683f1784" contextRef="c20130430_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction> million upfront payment we received and allocated it to our single performance obligation. As we achieved milestone payments for our R&amp;D services, we included these amounts in our transaction price for our R&amp;D services performance obligation. We recognized revenue for our R&amp;D services performance obligation over our period of performance, which ended in September 2017.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30162" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30163">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30163" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30164">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under this collaboration, we have also generated additional payments that we concluded were not part of our R&amp;D services performance obligation. We recognized each of these payments in full in the respective quarter we generated the payment because the payments were distinct and we did not have any performance obligations for the respective payment. The following are the payments we have earned:</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30164" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30165">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30165" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30166">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z2cb9bd0d8147431e8242225e5734bea8">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the fourth quarter of 2017, we earned a $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_bc4e255dadbd4cddaaf6cf364d7f60a2" contextRef="c20171001to20171231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction> million license fee when Roche licensed tominersen because Roche had full use of the license without any continuing involvement from us. </div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30166" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30167">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z3ba97b8a23374e16b9cd8bc689285c53">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the first quarter of 2019, we earned $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_7314f04e9d0e40a49fbaacf4f47109de" contextRef="c20190101to20190331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction> million in milestone payments when Roche dosed the first patient in the Phase 3 study of tominersen in the first quarter of 2019. </div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30167" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30168">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30168" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30169">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We do not have any remaining performance obligations related to tominersen under this collaboration with Roche; however, we can still earn additional payments and royalties as Roche advances tominersen.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30169" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30170">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30170" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30171">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">IONIS-FB-L</span><sub><span style="background-color: #FBFBFB;">Rx</span></sub><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for Complement-Mediated Diseases</span></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30171" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30172">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30172" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30173">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In October 2018, we entered into a collaboration agreement with Roche to</span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> develop IONIS-FB-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for the treatment of complement-mediated diseases. We are currently conducting Phase 2 studies in two disease indications for </span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">IONIS-FB-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, one for the treatment of patients with geographic atrophy, or GA, the advanced stage of dry age-related macular degeneration, or AMD, and a second for the treatment of patients with IgA nephropathy. </span>Roche<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> has the option to license IONIS-FB-L</span><sub><span style="background-color: #FBFBFB;">Rx</span></sub><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> at the completion of these studies. Upon licensing, </span>Roche <span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">will be responsible for all further global development, regulatory and commercialization activities and costs.</span></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30173" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30174">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>44</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30174" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30175">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Under the terms of this agreement, we received a </span>$<ix:nonFraction name="ions:UpfrontPaymentReceived" id="Fact_dc2c32a9c1124cddb9ed5ff336ece731" contextRef="c20181001to20181031_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> upfront payment in October 2018. We are eligible to receive up to </span>$<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" id="Fact_06d83477fcf046bbabd2d4017da3a520" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">684</ix:nonFraction> million<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in development, regulatory and sales milestone payments and license fees. In addition, we are also eligible to receive tiered royalties from the high teens to </span><ix:nonFraction name="ions:RoyaltyPercentageReceivedOnNetSalesOfDrug" id="Fact_63fb5f4decbb426a9cd241023b3ecd39" contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction> percent<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> on net sales. We will achieve the next payment of $</span><ix:nonFraction name="ions:NextPotentialMilestonePayment" id="Fact_5128247561064475b51c4c5bf62130be" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million when we advance </span>the Phase 2 study in patients with dry AMD<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</span></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30175" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30176">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30176" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30177">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of this collaboration, we identified <ix:nonFraction name="ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" id="Fact_468a8db7e8de46a69b5ee7a0575f664d" contextRef="c20181031_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> performance obligation, which was to perform R&amp;D services for Roche. We determined the transaction price to be the $<ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPrice" id="Fact_64f9009b51e54bc8a818455d38bda2ae" contextRef="c20181031_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million upfront payment we received and allocated it to our single performance obligation. We are recognizing revenue for our R&amp;D services performance obligation as we perform services based on our effort to satisfy our performance obligation relative to our total effort expected to satisfy our performance obligation. We<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> currently estimate we will satisfy our performance obligation in </span>December 2022.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30177" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30178">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30178" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30179"><ix:nonNumeric name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="Text_468e27558b254e0daccd0fff5ff71edd" contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember" escape="true" continuedAt="Text_50461ff1b78a4c388e80c22f475df00f1">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with Roche (in millions, except percentage amounts):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30179" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30180"><ix:continuation id="Text_50461ff1b78a4c388e80c22f475df00f1" continuedAt="Text_50461ff1b78a4c388e80c22f475df00f2">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30180" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30181"><ix:continuation id="Text_50461ff1b78a4c388e80c22f475df00f2">
<table cellpadding="0" cellspacing="0" id="z3751bf5f787c451499c06571891a9800" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_fb8913807e664ded9db727de95b93bfc" contextRef="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">57.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_43d5265cf6164fce9ca88f18b5897dc3" contextRef="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">8.3</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_20872827ad6c4817bcf759078e23498f" contextRef="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">55.7</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_50cff48cda6946bc87457fee3925e81c" contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_cf5ca05dc07c4448bdda2353f8ed8769" contextRef="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_6490dfcad60e494083f50ae6646f73e4" contextRef="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30181" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30182">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30182" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30183">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our </span>consolidated balance sheet at <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">December 31, </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and 2018 included deferred revenue of $</span><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" id="Fact_5ff4d7b8efd14d4a81981ea0cfa0cf58" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">52.3</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million and $</span><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" id="Fact_a38902f403274142aedd7c7ed42e8214" contextRef="c20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">72.6</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million related to our relationship with Roche, respectively.</span></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30183" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30184">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30184" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30185">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Akcea Collaborations</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30185" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30186">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30186" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30187">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following collaboration agreements relate to Akcea, our majority owned affiliate. Akcea is responsible for the development activities under these collaborations. As such, Akcea recognizes the associated revenue earned, cash received and expenses incurred in its statement of operations, which we reflect in our consolidated results. We also reflect the noncontrolling interest attributable to other owners of Akcea&#8217;s common stock in a separate line on our statement of operations and a separate line within stockholders&#8217; equity on our consolidated balance sheet.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30187" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30188">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30188" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30189">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For each of Akcea's collaborations Akcea pays us sublicense fees for payments that it receives and we recognize those fees as revenue in our Ionis Core operating segment results and Akcea recognizes the fees as R&amp;D expense. In our consolidated results, we eliminate any sublicense revenue and expense.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30189" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30190">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30190" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30191">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Novartis</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30191" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30192">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30192" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30193">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In January 2017, we and Akcea initiated a collaboration with Novartis to develop and commercialize AKCEA-APO(a)-L<sub>Rx</sub> and AKCEA-APOCIII-L<sub>Rx</sub>.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30193" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30194">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30194" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30195">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea received a $<ix:nonFraction name="ions:UpfrontPaymentReceived" id="Fact_f101e92127dd43ef9f460e172673d2f2" contextRef="c20170101to20170331_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million upfront payment in the first quarter of 2017, of which it retained $<ix:nonFraction name="ions:PortionOfUpfrontPaymentRetained" id="Fact_22075448bf51400dbf0c07e88efac495" contextRef="c20170101to20170331_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction> million and paid us $<ix:nonFraction name="ions:PortionOfUpfrontPaymentPaidAsSublicenseFee" id="Fact_658dc7b342f34e4fb8aea7a4183d5bd5" contextRef="c20170101to20170331_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction> million as a sublicense fee. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In February 2019, Novartis licensed AKCEA-APO(a)-L</span><sub>Rx</sub> and Akcea earned a $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_0515b2fff4b64bc6b94f554c3b656d06" contextRef="c20190201to20190228_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_LicenseMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction> million license fee. Akcea paid us $<ix:nonFraction name="ions:SublicenseFeePaidForLicenseOfDrug" id="Fact_7496596603f7476a91badebb2a672dea" contextRef="c20190201to20190228" unitRef="U001" decimals="-6" scale="6">75</ix:nonFraction> million as a sublicense fee in <ix:nonFraction name="ions:ReceiptOfSharesInSubsidiary" id="Fact_e7462e9427f94afe949ed71375352f81" contextRef="c20190201to20190228" unitRef="U002" decimals="-5" scale="6">2.8</ix:nonFraction> million shares of Akcea common stock. Novartis is responsible for conducting and funding all future development, regulatory and commercialization activities for AKCEA-APO(a)-L<sub>Rx</sub>, including a global Phase 3 cardiovascular outcomes study, which Novartis initiated in December 2019.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>In connection with Novartis&#8217; license of AKCEA-APO(a)-L<sub>Rx</sub>, Akcea and Novartis established a more definitive framework under which the companies would negotiate the co-commercialization of AKCEA-APO(a)-L<sub>Rx</sub> in selected markets. Included in this framework is an option by which Novartis could solely commercialize AKCEA-APO(a)-L<sub>Rx</sub> in exchange for Novartis paying Akcea increased commercial milestone payments based on sales of AKCEA-APO(a)-L<sub>Rx</sub>.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> When Novartis decided to not exercise its option for </span>AKCEA-APOCIII-L<sub>Rx</sub>, Akcea retained rights to develop and commercial AKCEA-APOCIII-L<sub>Rx</sub>.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30195" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30196">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30196" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30197">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under the collaboration, Akcea is eligible to receive up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForMilestones" id="Fact_d2d27d33e1b24ff79741dbb8504b3a12" contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">675</ix:nonFraction> million in milestone payments, including $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" id="Fact_b0160b60708f4f9cac5ee7648f0ee321" contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction> million for the achievement of a development milestone, up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" id="Fact_788a557118454c209aecf3914c029c91" contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">290</ix:nonFraction> million for the achievement of regulatory milestones and up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForCommercializationMilestones" id="Fact_b32f437673cc4aac8bfcce020d51b7b0" contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">360</ix:nonFraction> million for the achievement of commercialization milestones. Akcea is also eligible to receive tiered royalties in the mid-teens to low <ix:nonFraction name="ions:RoyaltyPercentageReceivedOnSalesOfDrug" id="Fact_016f76af44eb49289c02150198f2a523" contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction> percent range on net sales of AKCEA-APO(a)-L<sub>Rx</sub>. Akcea will pay <ix:nonFraction name="ions:PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee" id="Fact_2f358346f22a4389b8b1dd0527408054" contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction> percent of these license fees, milestone payments and royalties to us as sublicense fees.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30197" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30198">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30198" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30199">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In conjunction with this collaboration, we entered into a SPA with Novartis. As part of the SPA, Novartis purchased <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_21e55b070897453d838adbfcb2e0f867" contextRef="c20170101to20170331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">1.6</ix:nonFraction> million shares of our common stock for $<ix:nonFraction name="ions:ProceedsFromSaleOfCommonStockIncludingPremiumPaid" id="Fact_3a1b3a249b30451fa1ce1c491bcb7999" contextRef="c20170101to20170331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction> million in the first quarter of 2017. As part of the SPA, Novartis was required to purchase $<ix:nonFraction name="ions:AdditionalAmountOfCommonStockRequiredToBePurchased" id="Fact_f8120f81bc5b4216ac3b0e47eb07b856" contextRef="c20170331_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction> million of Akcea&#8217;s common stock at the IPO price or our common stock at a premium if an IPO did not occur by April 2018. Under the SPA, in July 2017, Novartis purchased $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" id="Fact_47ca08bac8744acbb92fb035975c1a5d" contextRef="c20170701to20170731_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction> million of Akcea&#8217;s common stock in a separate private placement concurrent with the completion of Akcea's IPO at a price per share equal to the IPO price.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30199" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30200">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30200" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30201">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of this collaboration, Akcea identified <ix:nonFraction name="ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" id="Fact_45dfae68b384426d9e7f35800c5ee5da" contextRef="c20170331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction> separate performance obligations:</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30201" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30202">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30202" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30203">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="za92dcc9ca554450dbde079edd52a748b">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D services for AKCEA-APO(a)-L<sub>Rx</sub>;</div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30203" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30204">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z969c1fbd3a7d4bceb111d5b8034e0da7">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D services for AKCEA-APOCIII-L<sub>Rx</sub>;<sub>&#160;</sub></div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30204" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30205">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z7a53186ffac14cde8f9dafbcae98b1ee">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">API for AKCEA-APO(a)-L<sub>Rx</sub>; and </div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30205" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30206">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z5c9cb7188be64f6fa8629693209b9498">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">API for AKCEA-APOCIII-L<sub>Rx</sub>. </div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30206" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30207">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>45</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30207" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30208">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea determined that the R&amp;D services for each medicine and the API for each medicine were distinct from its other performance obligations.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30208" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30209">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30209" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30210">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea determined our transaction price to be $<ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPrice" id="Fact_6dbe3e18253b42678289e91bfc07aa2b" contextRef="c20170331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">108.4</ix:nonFraction> million, comprised of the following:</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30210" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30211">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30211" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30212">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z95c64f6ac223413087c92b4e7148ad52">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$<ix:nonFraction name="ions:UpfrontPaymentReceived" id="Fact_5578c7a91e964f86994ba7891b038b6c" contextRef="c20170101to20170331_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million from the upfront payment;</div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30212" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30213">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z5fda1af0585f4b50aece02928629da77">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$<ix:nonFraction name="ions:PremiumReceivedOnSharesIssued" id="Fact_a374896a5baf4a14a92524dbf907cb65" contextRef="c20170101to20170331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">28.4</ix:nonFraction> million for the premium paid by Novartis for its purchase of our common stock at a premium in the first quarter of 2017; and </div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30213" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30214">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zd1af860b61eb4d06adc195cc22f1eefa">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$<ix:nonFraction name="ions:PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture" id="Fact_844ad8b58c81489eb92908f6d9b9a1e0" contextRef="c20170331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">5.0</ix:nonFraction> million for the potential premium Novartis would have paid if they purchased our common stock in the future.</div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30214" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30215">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -36pt; margin-left: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30215" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30216">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea allocated the transaction price based on the estimated stand-alone selling price of each performance obligation as follows:</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30216" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30217">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30217" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30218">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zf1ec8c14e9fd4097a634d42230b5ed2d">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</span><ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPrice" id="Fact_40c2b997e5d94404a5664d9c274e413e" contextRef="c20170331_ProductOrServiceAxis_ResearchAndDevelopmentServicesForAKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">64.0</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for the R&amp;D services for </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">AKCEA-APO(a)-L</span><sub style="font-family: 'Times New Roman';">Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">;</span></div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30218" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30219">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z4d65be2b97bf4dc992b6d7f8890d35fe">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$<ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPrice" id="Fact_051befe7d00048df8a2b3cb0405d5ae3" contextRef="c20170331_ProductOrServiceAxis_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">40.1</ix:nonFraction> million for the R&amp;D services for <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">AKCEA-APOCIII-L</span><sub style="font-family: 'Times New Roman';">Rx</sub>; </div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30219" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30220">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z4a5a892931aa46dcbb360dd2c2da8d07">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPrice" id="Fact_b3744373869c4288908b09e14ce88277" contextRef="c20170331_ProductOrServiceAxis_DeliveryOfAKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">1.5</ix:nonFraction></span> million for the delivery of AKCEA-APO(a)-L<sub>Rx</sub> API; and</div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30220" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30221">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z70a24658629e48879924f550d9d26261">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPrice" id="Fact_060f939deb0d4433a9dd740934afd81c" contextRef="c20170331_ProductOrServiceAxis_DeliveryOfAKCEAAPOCIIILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">2.8</ix:nonFraction></span> million for the delivery of AKCEA-APOCIII-L<sub>Rx</sub> API.</div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30221" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30222">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30222" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30223">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea recognized revenue related to each of the performance obligations as follows:</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30223" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30224">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30224" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30225">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z4ad445a40aac4d02b766c98537df051b">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea completed its R&amp;D services performance obligation for AKCEA-APO(a)-L<sub>Rx </sub>in second quarter of 2019. As such, Akcea recognized all revenue it allocated to its AKCEA-APO(a)-L<sub>Rx </sub>R&amp;D services as of the end of the second quarter of 2019;</div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30225" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30226">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z9bc63efdf0e1423fa47eb9c79e9a847f">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea completed its R&amp;D services performance obligation for AKCEA-APOCIII-L<sub>Rx</sub> in the fourth quarter of 2019 because Novartis elected to terminate the strategic collaboration for AKCEA-APOCIII-L<sub>Rx</sub> during the period. As a result, Akcea was not required to provide any further R&amp;D services, as such, Akcea recognized all revenue it allocated to its AKCEA-APOCIII-L<sub>Rx</sub> L<sub>Rx </sub>R&amp;D services as of the end of the fourth quarter of 2019;</div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30226" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30227">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z2eb463986cc148edaab3f8c0fc340615">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea recognized the amount attributed to AKCEA-APO(a)-L<sub>Rx</sub> API when Akcea delivered it to Novartis in 2017; and</div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30227" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30228">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zc57903c50d3a443fb4070a41db918de4">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea recognized the amount attributed to AKCEA-APOCIII-L<sub>Rx</sub> API when Akcea delivered it to Novartis in May 2018.</div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30228" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30229">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30229" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30230">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Akcea recognized revenue related to the R&amp;D services for the AKCEA-APO(a)-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and AKCEA-APOCIII-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> performance obligations as Akcea performed services </span>based on its effort to satisfy its performance obligation relative to Akcea's total effort expected to satisfy its performance obligation<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</span></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30230" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30231">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30231" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30232"><ix:nonNumeric name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="Text_a6f89095bf0e47fc874b96fd205b9809" contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" escape="true" continuedAt="Text_7998a643f1244e8eb656ce7c9067c2211">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019 and 2018, Akcea earned the following revenue from its relationship with Novartis (in millions, except percentage amounts):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30232" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30233"><ix:continuation id="Text_7998a643f1244e8eb656ce7c9067c2211" continuedAt="Text_7998a643f1244e8eb656ce7c9067c2212">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30233" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30234"><ix:continuation id="Text_7998a643f1244e8eb656ce7c9067c2212">
<table cellpadding="0" cellspacing="0" id="z69ce748cda9640099c4155d9ea42f332" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="10" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_34a7cbc53ddb475aaaa8bcec238b44ce" contextRef="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">187.4</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_cd2c4f63152b45998731917ab0309ed1" contextRef="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">50.6</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_4ff5f9c394c349349b7bc24fd95d7574" contextRef="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">43.4</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_1f40d9d87ee4435c83ab9656d281b655" contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">17</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_130e18fe0f0c441186a0e17a58f664d9" contextRef="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_3cbf0264fff04ba19d7c857cee72d9f4" contextRef="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30234" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30235">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30235" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30236">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our </span>consolidated balance sheet at <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">December 31, </span>2018<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> included deferred revenue of $</span><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" id="Fact_c157a7a68eec446e886b129749c3f931" contextRef="c20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">28.8</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million related to Akcea's relationship with Novartis. We did </span><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" id="Fact_4a63767109a742c69dad59da07813ba7" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" unitRef="U001" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">t have any deferred revenue from our relationship with Novartis at December 31, 2019.</span></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30236" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30237">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30237" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30238">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Pfizer</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30238" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30239">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30239" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30240">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">AKCEA<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-ANGPTL3-L</span><sub>Rx</sub></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30240" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30241">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30241" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30242">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In October 2019, Akcea initiated a collaboration with Pfizer for the license of AKCEA</span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-ANGPTL3-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, a medicine to treat people with cardiovascular and metabolic diseases. Akcea recently completed a Phase 2 study of AKCEA</span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-ANGPTL3-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in patients</span> with elevated levels of triglycerides, or hypertriglyceridemia, type 2 diabetes and <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">non-alcoholic fatty liver disease, or NAFLD. Pfizer is responsible for all development and regulatory activities and costs beyond those associated with this study.</span></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30242" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30243">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30243" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30244">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Under the terms of the agreement, Akcea received a $</span><ix:nonFraction name="ions:UpfrontPaymentReceived" id="Fact_cb6f652ab8d440198d3fd9d76dec5102" contextRef="c20191001to20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million upfront payment. Akcea is also eligible to receive development, regulatory and sales milestone payments of up to $</span><ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones" id="Fact_6b53e3b0d55a43dc810b7552f975ad24" contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" unitRef="U001" decimals="-8" scale="9" format="ixt:numdotdecimal">1.3</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> billion</span>, including up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" id="Fact_4843a345b1a94a5c9754fd3131d466f1" contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">205</ix:nonFraction> million for the achievement of development milestones, up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" id="Fact_65c6ae0a577449888f0854e765cc3fca" contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction> million for the achievement of regulatory milestones and up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivableForCommercializationMilestones" id="Fact_1e2a222db3b0433380bd4a8b285d7a81" contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">850</ix:nonFraction> million for the achievement of commercialization milestones. Akcea is<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> also eligible to earn tiered royalties in the mid-teens to low </span><ix:nonFraction name="ions:RoyaltyPercentageReceivedOnNetSalesOfDrug" id="Fact_087ef4b100ca43ee9a37508169ca8d55" contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction> percent<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> range on annual worldwide net sales. Akcea has retained the rights to co-commercialize AKCEA</span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-ANGPTL3-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in the U.S. and certain additional markets. Akcea</span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> will achieve the next payment of $</span><ix:nonFraction name="ions:NextPotentialMilestonePayment" id="Fact_ba59193a12cb4ecfa5c7841f81370632" contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million when Pfizer advances AKCEA-ANGPTL3-L</span><sub><span style="background-color: #FBFBFB;">Rx</span></sub><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</span></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30244" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30245">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30245" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30246">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of this collaboration, Akcea identified <ix:nonFraction name="ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" id="Fact_a8154dd63afb404880837533d573e4e5" contextRef="c20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> separate performance obligations:</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30246" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30247">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30247" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30248">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="ze99c6a33b95947ed81c68654c16d319e">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">License of AKCEA-ANGPTL3-L<sub>Rx</sub>;</div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30248" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30249">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z9f82745b2a734ec181ae05f3d3c17dfb">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D services for AKCEA-ANGPTL3-L<sub>Rx</sub>; and</div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30249" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30250">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="ze279fcd45eb041eab8e90392a384799d">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">API for AKCEA-ANGPTL3-L<sub>Rx</sub>.</div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30250" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30251">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>46</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30251" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30252">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea determined the transaction price to be $<ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPrice" id="Fact_0a949aa4d4bd4639afc9cb68a2386c63" contextRef="c20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction> million, the upfront payment it received.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Akcea</span> allocated the transaction price based on the estimated stand-alone selling price of each performance obligation as follows:</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30252" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30253">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30253" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30254">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="ze54e7b0fe6964ad482f1ea90cb1e8d4f">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$<ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPrice" id="Fact_3df59de76eec44fb982aa66ddb7bf65b" contextRef="c20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAANGPTL3LMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">245.6</ix:nonFraction> million for the license of AKCEA-ANGPTL3-L<sub>Rx</sub>;</div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30254" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30255">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z8172b430e2874deb85b9c47a783a932f">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</span><ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPrice" id="Fact_2ee33180ebd4466188789fc4e1ca515e" contextRef="c20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_ResearchAndDevelopmentServicesForMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for the R&amp;D services for </span>AKCEA-ANGPTL3-L<sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">; and</span></div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30255" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30256">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z7c560cb48d85427a9f66c095b4b29f24">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</span><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_ccb177feb237400896c77bdba3d1032a" contextRef="c20191001to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal"><ix:nonFraction name="ions:RevenueFromContractWithCustomerTransactionPrice" id="Fact_faca94cd7ae3413ba6ba103ff64de86a" contextRef="c20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAANGPTL3LActivePharmaceuticalIngredientMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">2.2</ix:nonFraction></ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for the delivery of </span>AKCEA-ANGPTL3-L<sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> API.</span></div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30256" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30257">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30257" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30258">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea is recognizing revenue related to each of its performance obligations as follows:</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30258" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30259">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30259" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30260">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zeb2eff08d272446d9de8fac3d324e9bb">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 22.5pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea recognized $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_a58f0662a0494f9fbe63a6f7245c7574" contextRef="c20191001to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAANGPTL3LMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">245.6</ix:nonFraction> million for the license of AKCEA-ANGPTL3-L<sub>Rx</sub> in the fourth quarter of 2019 because Akcea determined the license Akcea granted to Pfizer was distinct from its other performance obligations and Pfizer had full use of the license without any continuing involvement from Akcea. </div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30260" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30261">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z06340fd0be4446e4add1b4fab2760135">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 22.5pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea is<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> recognizing revenue related to the R&amp;D services for </span>AKCEA-ANGPTL3-L<sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> as Akcea performs services </span>based on Akcea's effort to satisfy its performance obligation relative to Akcea's total effort expected to satisfy its performance obligation<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. Akcea</span> expects to satisfy its R&amp;D services performance obligation by mid-2020<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. </span></div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30261" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30262">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z7f59c7ed1f0c4a5bb58495efb32b1f25">
  <tr>
    <td style="width: 36pt;"></td>
    <td style="width: 22.5pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> recognized the amount attributed to the API supply for </span>AKCEA-ANGPTL3-L<sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> when it delivered it to Pfizer in the fourth quarter of 2019. </span></div></td>
  </tr>
</table>
</ix:continuation></div>
</div>
<div><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30262" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30263">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30263" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30264">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">During the fourth quarter of 2019, we received </span><ix:nonFraction name="ions:ReceiptOfSharesInSubsidiary" id="Fact_931ab7e2e5ce499b803bf647570b165c" contextRef="c20191001to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" unitRef="U002" decimals="-5" scale="6" format="ixt:numdotdecimal">6.9</ix:nonFraction> million shares of Akcea common stock for <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">payment of the </span>$<ix:nonFraction name="ions:SublicenseFeePaidForLicenseOfDrug" id="Fact_09e1434df8f644f6b9c95d432101ab61" contextRef="c20191001to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction> million sublicense fee Akcea owed us.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30264" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30265">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30265" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30266"><ix:nonNumeric name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="Text_a4a2e7f817664c90a16e230b1467d77c" contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" escape="true" continuedAt="Text_89ba22ef26984468a2acbc1fd5b31d421">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the year ended December 31, 2019, Akcea earned the following revenue from its relationship with Pfizer (in millions, except percentage amounts):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30266" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30267"><ix:continuation id="Text_89ba22ef26984468a2acbc1fd5b31d421" continuedAt="Text_89ba22ef26984468a2acbc1fd5b31d422">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30267" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30268"><ix:continuation id="Text_89ba22ef26984468a2acbc1fd5b31d422">
<table cellpadding="0" cellspacing="0" id="z6a52ad3f4f4548a28b37262fe935a7dc" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_1d17b5c018944937b8cbeb29dd0891c5" contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">248.7</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_a3245c2e2713458bb84324eb997a0b67" contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">22</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30268" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30269">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30269" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30270">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our </span>consolidated balance sheet at <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">December 31, </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> included deferred revenue of $</span><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" id="Fact_cd5471bf55444af8bd2d42a2cd8ec423" contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million related to Akcea&#8217;s relationship with Pfizer.</span></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30270" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30271">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30271" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30272">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">PTC Therapeutics</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30272" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30273">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30273" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30274">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In August 2018, Akcea entered into an exclusive license agreement with PTC Therapeutics to commercialize TEGSEDI and WAYLIVRA in Latin America. Under the license agreement, Akcea is eligible to receive up to $<ix:nonFraction name="ions:MaximumPaymentReceivableUnderLicenseAgreement" id="Fact_7e14ae5c11c740c6831238a4f01ae711" contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction> million in payments, including $<ix:nonFraction name="us-gaap:ProceedsFromLicenseFeesReceived" id="Fact_7f4ceca23bae42a69715fca5095f560d" contextRef="c20180701to20180930_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction> million it received in the third quarter of 2018, $<ix:nonFraction name="us-gaap:ProceedsFromLicenseFeesReceived" id="Fact_b2771ded298b402da7a83f7e5fa44114" contextRef="c20190401to20190630_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction> million it received in the second quarter of 2019 following European Medicines Agency, or EMA, approval of WAYLIVRA, $<ix:nonFraction name="us-gaap:ProceedsFromLicenseFeesReceived" id="Fact_11672b26a18f4223bfa5b297211ae00b" contextRef="c20191001to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction> million it received in the fourth quarter of 2019 when PTC received approval for TEGSEDI in Brazil, and up to $<ix:nonFraction name="ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" id="Fact_e9b4a2226bef410b9424e419209f30ed" contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction> million in an additional regulatory milestone payment. Akcea is eligible to receive royalties from PTC in the mid-<ix:nonFraction name="ions:RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner" id="Fact_570d071a48d248dbb4cd460b720cd572" contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">20</ix:nonFraction> percent range on net sales in Latin America for each medicine. PTC&#8217;s obligation to pay Akcea royalties begins on the earlier of <ix:nonNumeric name="ions:PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil" id="Fact_bccc4622e6f241879d241b2230aae36c" contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" format="ixt-sec:durmonth">12</ix:nonNumeric> months after the first commercial sale of a product in Brazil or the date that PTC recognizes revenue of at least $<ix:nonFraction name="ions:RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties" id="Fact_bc71f4a0dda144cc9da7727f9004032f" contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million in Latin America. Consistent with the agreements between Ionis and Akcea, the companies will share all payments, including royalties.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30274" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30275">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30275" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30276">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of this collaboration, Akcea identified <ix:nonFraction name="ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" id="Fact_7cdf5da28b2f42cbb5b3b1e421c304b3" contextRef="c20180831_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> performance obligations, which were the licenses Akcea granted to PTC to commercialize TEGSEDI and WAYLIVRA in Latin America in the third quarter of 2018. Akcea recognized $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_cca90ebf4c4e4f7eb1bd74a11a6216ea" contextRef="c20180701to20180930_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_LicenseMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction> million in license fee revenue at that time because PTC had full use of both licenses without any continuing involvement from Akcea. Akcea does not have any remaining performance obligations under its collaboration with PTC. Akcea can still earn additional payments and royalties as PTC commercializes the medicines.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30276" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30277">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30277" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30278">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the second quarter of 2019, Akcea earned a $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_9adc484ca5df48ce9cc85dc768b8a6da" contextRef="c20190401to20190630_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_WaylivraMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction> million payment when WAYLIVRA was approved by the EMA. Akcea recognized this payment in full in the second quarter of 2019 because it does not have any performance obligations related to this payment. Additionally, in the fourth quarter of 2019, Akcea earned $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_444bcde53d3e43399eefaef07d545127" contextRef="c20191001to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_TegsediMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" unitRef="U001" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction> million when TEGSEDI was approved in Brazil. Akcea recognized this payment in full in the fourth quarter of 2019 because it does not have any performance obligations related to this payment.</div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30278" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30279">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30279" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30280"><ix:nonNumeric name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="Text_06f7674d78514b5abc8204e089e60c94" contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" escape="true" continuedAt="Text_14ce2222139a45b0a3f41a09d5bb550f1">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019 and 2018, Akcea earned the following revenue from its relationship with PTC (in millions, except percentage amounts):</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30280" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30281"><ix:continuation id="Text_14ce2222139a45b0a3f41a09d5bb550f1" continuedAt="Text_14ce2222139a45b0a3f41a09d5bb550f2">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30281" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30282"><ix:continuation id="Text_14ce2222139a45b0a3f41a09d5bb550f2">
<table cellpadding="0" cellspacing="0" id="zf3ce81334bbb4ee983c75acc2b6feb6c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="6" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Licensing and other royalty revenue (commercial revenue)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_9891ac1c164742aa9f336a16f8769e38" contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">10.2</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_6133400e71034c1d812fdb9519ceeeb6" contextRef="c20180101to20181231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_9a2a82c451d248319bd6f1123ba4776c" contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_a7a775b1695d4dfbb7cc3ab3a3a9eae7" contextRef="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">2</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30282" continuedAt="Text_8bc9ec7a99ee444986ef202ed5c32e30283">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_8bc9ec7a99ee444986ef202ed5c32e30283">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our consolidated balance sheet at December 31, 2019 and 2018 did <ix:nonFraction name="us-gaap:ContractWithCustomerLiability" id="Fact_dd80a9f419024a63bbffa3c2e2888698" contextRef="c20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" unitRef="U001" decimals="-6" scale="6" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ContractWithCustomerLiability" id="Fact_81d977bc02a14b74be1bb00b1a4c83a5" contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" unitRef="U001" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t include any deferred revenue related to Akcea&#8217;s relationship with PTC.</div>
</ix:continuation></div>
<div><br /></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>47</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" id="Text_e344b0f2337949b4b280461dffbd966f" contextRef="c20190101to20191231" escape="true" continuedAt="Text_7078b7729d744076b19fa095c5c4fe3f1">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">7. Segment Information and Concentration of Business Risk</div>
</ix:nonNumeric><ix:continuation id="Text_7078b7729d744076b19fa095c5c4fe3f1" continuedAt="Text_7078b7729d744076b19fa095c5c4fe3f2">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7078b7729d744076b19fa095c5c4fe3f2" continuedAt="Text_7078b7729d744076b19fa095c5c4fe3f3">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We have </span><ix:nonFraction name="us-gaap:NumberOfReportableSegments" id="Fact_7b6216c3ebc44b518de52c3d575b97de" contextRef="c20190101to20191231" unitRef="U010" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> reportable segments Ionis Core and Akcea Therapeutics. </span>At December 31, 2019, we owned approximately <ix:nonFraction name="us-gaap:MinorityInterestOwnershipPercentageByParent" id="Fact_7579292414fd4edcae095d48a9e69f1b" contextRef="c20191231_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">76</ix:nonFraction> percent of Akcea.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Segment income (loss) from operations includes revenue less operating expenses attributable to each segment.</span></div>
</ix:continuation><ix:continuation id="Text_7078b7729d744076b19fa095c5c4fe3f3" continuedAt="Text_7078b7729d744076b19fa095c5c4fe3f4">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7078b7729d744076b19fa095c5c4fe3f4" continuedAt="Text_7078b7729d744076b19fa095c5c4fe3f5">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In our Ionis Core segment we are exploiting our antisense technology to generate a broad pipeline of first-in-class and/or best-in-class medicines for us and our partners. Our Ionis Core segment generates revenue from a multifaceted partnering strategy.</div>
</ix:continuation><ix:continuation id="Text_7078b7729d744076b19fa095c5c4fe3f5" continuedAt="Text_7078b7729d744076b19fa095c5c4fe3f6">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7078b7729d744076b19fa095c5c4fe3f6" continuedAt="Text_7078b7729d744076b19fa095c5c4fe3f7">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Akcea is </span>a biopharmaceutical company focused on developing and commercializing medicines to treat patients with serious and rare diseases<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. Akcea generates revenue from TEGSEDI and WAYLIVRA product sales and from its collaborations.</span></div>
</ix:continuation><ix:continuation id="Text_7078b7729d744076b19fa095c5c4fe3f7" continuedAt="Text_7078b7729d744076b19fa095c5c4fe3f8">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7078b7729d744076b19fa095c5c4fe3f8" continuedAt="Text_7078b7729d744076b19fa095c5c4fe3f9"><ix:nonNumeric name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Text_22aa02140d1544bb91cfa2bb9e2b5708" contextRef="c20190101to20191231" escape="true" continuedAt="Text_a9361adee888469bb7779f0897c02e1c1">
<div style="display:none;"><br /></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The following tables show our segment revenue and income (loss) from operations for </span>2019, 2018 and 2017<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> (in thousands), respectively.</span></div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_7078b7729d744076b19fa095c5c4fe3f9" continuedAt="Text_7078b7729d744076b19fa095c5c4fe3f10"><ix:continuation id="Text_a9361adee888469bb7779f0897c02e1c1" continuedAt="Text_a9361adee888469bb7779f0897c02e1c2">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_7078b7729d744076b19fa095c5c4fe3f10" continuedAt="Text_7078b7729d744076b19fa095c5c4fe3f11"><ix:continuation id="Text_a9361adee888469bb7779f0897c02e1c2" continuedAt="Text_a9361adee888469bb7779f0897c02e1c3">
<table cellpadding="0" cellspacing="0" id="ze030c5e389c640c2991886f2f6ba40f4" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Ionis Core</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Akcea Therapeutics</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Elimination of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intercompany Activity</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Revenue:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; white-space: nowrap;"><div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Commercial revenue:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SPINRAZA royalties</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_6afe8e8668b04c5fb57325d4b93bb23d" contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">292,992</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_4f418fb55533484c9b94b8ee10ef7898" contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_e90aac00ba9f4b74bfa7df527a4402e7" contextRef="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_33b6132cd6d149bcb21f15b948504473" contextRef="c20190101to20191231_ProductOrServiceAxis_SPINRAZARoyaltiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">292,992</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Product sales, net</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_825dd68f3b244ab980fcb381b502335e" contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ProductMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_4253d66893b544a0b98945eeff82e360" contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ProductMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">42,253</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_48b2d3d7430c48faa4f514df069b8308" contextRef="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_ProductMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_236e4517c52741819047698a87bd8f57" contextRef="c20190101to20191231_ProductOrServiceAxis_ProductMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">42,253</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Licensing and other royalty revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_b9dfeeef44b447bdb8495f56c12d23ae" contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">12,616</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_3628beb8cd0440aa9c4e2b743f6115fc" contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">10,172</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_5eeb113cac5e42f9aa002efebb601358" contextRef="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,583</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_b42c7a2cbe7c4bdeac16fe7876deace0" contextRef="c20190101to20191231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">17,205</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; margin-left: 43.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total commercial revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_c44a9fae3b504834badbba6952229a72" contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">305,608</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_00ea3970f91f4a2ca51524fd6e5d8c5a" contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">52,425</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_21b636a466964e9a96a4e4276b023022" contextRef="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_CommercialMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">5,583</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_c262df0828a44f0ca600f2d34ecf59cd" contextRef="c20190101to20191231_ProductOrServiceAxis_CommercialMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">352,450</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue under collaborative agreements</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_4a04a60c9cea4630a3974e9237779741" contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">553,038</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_c500cc672e4e4a61bdc98605f5ad035f" contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">436,118</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_30890e9b395041aab244b05eaa9bfc1c" contextRef="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">219,007</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_49f0bd2b45984a46a61dd06f40a3a248" contextRef="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">770,149</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total segment revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_780e562acba94b9db1a44fb8db4d391a" contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">858,646</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_17dccbb558b94ce893b8e12b7a220935" contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">488,543</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_7133b18e64924d3f97f374bef01929e8" contextRef="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">224,590</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_5938281f23ba489da69fb9de8ddb93c4" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">1,122,599</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total operating expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_fd90bb8f1c014004a60938ffe5512b22" contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">523,207</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_b608e9a60f0746ba87e457b693f95589" contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">450,469</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_18e0bbe264124c5da106c621ebd8b0de" contextRef="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">216,960</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_2f29c1009e9f454eaa686cf5f03a4f1f" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">756,716</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) from operations</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_c70bdd1280d04e33928f8f67b27d342d" contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">335,439</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_97c27fd2cd8746c4bff11763fab60a9c" contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">38,074</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_13c0b92f5c334cd79fe21d76465bbe72" contextRef="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">7,630</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_1e7c02d8f21b4997a7d5799940f1f5c7" contextRef="c20190101to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">365,883</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_7078b7729d744076b19fa095c5c4fe3f11" continuedAt="Text_7078b7729d744076b19fa095c5c4fe3f12"><ix:continuation id="Text_a9361adee888469bb7779f0897c02e1c3" continuedAt="Text_a9361adee888469bb7779f0897c02e1c4">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_7078b7729d744076b19fa095c5c4fe3f12" continuedAt="Text_7078b7729d744076b19fa095c5c4fe3f13"><ix:continuation id="Text_a9361adee888469bb7779f0897c02e1c4" continuedAt="Text_a9361adee888469bb7779f0897c02e1c5">
<table cellpadding="0" cellspacing="0" id="zb93ba8fe3f024f1fa4d3f61c84b60bad" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Ionis Core</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Akcea Therapeutics</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Elimination of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intercompany Activity</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Revenue:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; white-space: nowrap;"><div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Commercial revenue:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SPINRAZA royalties</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_318542b6e43041b7a35f38b86729d651" contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">237,930</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_ce8a3e7546c743fd992f9ed83ba36bc1" contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_5716fcd14cd247f0af30c52d8a2c8746" contextRef="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_aca9c4384cb2417fb4477bb426020a57" contextRef="c20180101to20181231_ProductOrServiceAxis_SPINRAZARoyaltiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">237,930</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">TEGSEDI product sales, net</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_a8cad1b246414eae888b966f9439fd96" contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ProductMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_a472da0eb90b474fb01235eab69bc338" contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ProductMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,237</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_569d3f5cedb341479573c9f00ad5065a" contextRef="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_ProductMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_bc0c5a8aed6242cf9507f59667b0b095" contextRef="c20180101to20181231_ProductOrServiceAxis_ProductMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,237</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Licensing and other royalty revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_108299dc3f78432cbeda93345157c390" contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,755</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_4198a0c44e4d4c119e3bba3f27762740" contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">12,000</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_44436caf046a4b41a0411d5af56dfd9d" contextRef="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_86539ea247ab47c58125baeeffd8bf77" contextRef="c20180101to20181231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">14,755</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; margin-left: 43.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total commercial revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_a74b1519a21d4f6392d89d778544c1d7" contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">240,685</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_3d84626bae4f4617b6271858829afef2" contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">14,237</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_d09fd63c25564e329244f14aa77aa9a0" contextRef="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_CommercialMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_389f7e0d63054fb39d19dc6da506f8e7" contextRef="c20180101to20181231_ProductOrServiceAxis_CommercialMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">254,922</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue under collaborative agreements</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_8270d7f5f6c744bb92a2004a7c28da0b" contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">401,259</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_7e3dbc256f6c48fabac7999367080c21" contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">50,630</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_110d4a8b116f419b977be52cd7010d44" contextRef="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">107,137</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_2904d0e875bc4fea942e1a7a98101b32" contextRef="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">344,752</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total segment revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_4398da70003540029d0d7605e03b67dc" contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">641,944</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_c4c389db39494e34bcc70f18ed8ca66c" contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">64,867</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_88b7466081ca436b95e9eceb5f7eaf60" contextRef="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">107,137</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_2abe38c85e084b75a9fea72a3d7a0970" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">599,674</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total operating expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_df004b537cda4ce88886e4777d7ee02a" contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">380,212</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_a885c7bc128e4998a6d7e9c76b52ddb6" contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">295,683</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_8954dd602fd8409282de2096ddd23aa4" contextRef="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">14,849</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_3ab6506defab44cc8c1a14f909cdc1a9" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">661,046</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) from operations</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_9f1ec2a8feac4ffb8941b0d7e2a02108" contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">261,732</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_b8ae4f5fab1b4c8fafcc8d016c245441" contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">230,816</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_cce557a5eabd4144bab77f9bcdca4655" contextRef="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">92,288</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_81b2472c287a477cb0cbfdf02ba82947" contextRef="c20180101to20181231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">61,372</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_7078b7729d744076b19fa095c5c4fe3f13" continuedAt="Text_7078b7729d744076b19fa095c5c4fe3f14"><ix:continuation id="Text_a9361adee888469bb7779f0897c02e1c5" continuedAt="Text_a9361adee888469bb7779f0897c02e1c6">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_7078b7729d744076b19fa095c5c4fe3f14" continuedAt="Text_7078b7729d744076b19fa095c5c4fe3f15"><ix:continuation id="Text_a9361adee888469bb7779f0897c02e1c6" continuedAt="Text_a9361adee888469bb7779f0897c02e1c7">
<table cellpadding="0" cellspacing="0" id="z4d329b28bc324ba3bbf9eb96d75066a3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Ionis Core</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Akcea Therapeutics</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Elimination of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intercompany Activity</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Revenue:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; white-space: nowrap;"><div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Commercial revenue:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SPINRAZA royalties</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_643bfff6e6454546a0eafa6003d06593" contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">112,540</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_48d5fd71182c4dec9a297759f5cc32c9" contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_a7072df96aa24aecbf3b3f722277f21e" contextRef="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_efeda3f0d1e84d4cbf7c9d49e2f64bcf" contextRef="c20170101to20171231_ProductOrServiceAxis_SPINRAZARoyaltiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">112,540</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Licensing and other royalty revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_509142df716d47c0b8878dd24fd11c1c" contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">7,474</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_400c68af61a142ad9505e01a2a1bcb4f" contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_40dc99a7994848b491aacc3da206e693" contextRef="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_83ce62cd8a594ab0a0fa82f5001c8135" contextRef="c20170101to20171231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">7,474</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; margin-left: 43.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total commercial revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_e3523e77e4d5401d9e93bf5f4b6f5d0e" contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">120,014</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_341d4848206f4e3cbec9234fb7359cfc" contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_2d85ea774425454f8294e974309e0f99" contextRef="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_CommercialMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_d0c68b66db7b4a07a14ec99c249724a3" contextRef="c20170101to20171231_ProductOrServiceAxis_CommercialMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">120,014</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue under collaborative agreements</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_df95ee27ac7f462cb96345455905d8f8" contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">405,171</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_472a27771e2c41b1952c38b51a763990" contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">43,401</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_1fa27f1eb4b54d72bb91032b29ffb598" contextRef="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">54,407</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_b4ea2826218e4568bef4c392942b28dc" contextRef="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">394,165</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total segment revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_24a4a2bacce9474ca9a3cd3ce053902e" contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">525,185</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_f3149f9bfb8a4644bb11a55b9d5abd25" contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">43,401</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_15cdc207e58b4f26bc58ff17b1e5c225" contextRef="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">54,407</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_537a36a3fb2c4240830bf14f1fc0e530" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">514,179</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total operating expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_1b8dc8f1f1354498ac3cb49477328548" contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">373,788</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_eeb2dc8a1acc47b3bee47d336d5e9f2b" contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">163,871</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_25a14b8a961e4d22b16608d8fbd24489" contextRef="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">54,527</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_3e4d0b646d914517b93860165a8d9dd7" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">483,132</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) from operations</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_b6f49d0ddfea4cae8b24ef0506b19dd5" contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">151,397</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_feefc7d2d3b94cfaa86963033e8da9a4" contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">120,470</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_0972534fc7674f2ca0c2113c30bc8e26" contextRef="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">120</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_ec70297ab4244463a24824848df2246f" contextRef="c20170101to20171231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">31,047</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_7078b7729d744076b19fa095c5c4fe3f15" continuedAt="Text_7078b7729d744076b19fa095c5c4fe3f16"><ix:continuation id="Text_a9361adee888469bb7779f0897c02e1c7" continuedAt="Text_a9361adee888469bb7779f0897c02e1c8">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>48</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_7078b7729d744076b19fa095c5c4fe3f16" continuedAt="Text_7078b7729d744076b19fa095c5c4fe3f17"><ix:continuation id="Text_a9361adee888469bb7779f0897c02e1c8" continuedAt="Text_a9361adee888469bb7779f0897c02e1c9">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table shows our total assets by segment at December 31, 2019 and 2018 (in thousands), respectively.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_7078b7729d744076b19fa095c5c4fe3f17" continuedAt="Text_7078b7729d744076b19fa095c5c4fe3f18"><ix:continuation id="Text_a9361adee888469bb7779f0897c02e1c9" continuedAt="Text_a9361adee888469bb7779f0897c02e1c10">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_7078b7729d744076b19fa095c5c4fe3f18" continuedAt="Text_7078b7729d744076b19fa095c5c4fe3f19"><ix:continuation id="Text_a9361adee888469bb7779f0897c02e1c10">
<table cellpadding="0" cellspacing="0" id="z4b7b08804da24aa49b1b8bfdb2287736" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total Assets</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Ionis Core</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Akcea Therapeutics</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Elimination of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intercompany Activity</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2019</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:Assets" id="Fact_4393e21bf23041519f08cf012a684ef4" contextRef="c20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,478,081</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:Assets" id="Fact_41da19f8f16940fc8503d30961a583e9" contextRef="c20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">599,250</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:Assets" id="Fact_e878b5b1327943bf9fe8329a61b7ca25" contextRef="c20191231_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">844,219</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:Assets" id="Fact_bd3cd73399c64f20b57693c66dc37ab9" contextRef="c20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">3,233,112</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2018</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:Assets" id="Fact_165a2783f8ad4636aa05337476ec6f11" contextRef="c20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,975,491</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:Assets" id="Fact_0c0f2ea58e66476ea656ccf108f71566" contextRef="c20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">365,261</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:Assets" id="Fact_474f897008694a98a304e7242c4bd91b" contextRef="c20181231_ConsolidationItemsAxis_IntersegmentEliminationMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">672,968</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:Assets" id="Fact_72af7c7066294da4883e92aa73bfecde" contextRef="c20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,667,784</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_7078b7729d744076b19fa095c5c4fe3f19" continuedAt="Text_7078b7729d744076b19fa095c5c4fe3f20">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_7078b7729d744076b19fa095c5c4fe3f20">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Contracts receivables at December 31, 2019 and December 31, 2018 were comprised of approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_28f0adbb41bc491dba19be13a5d7e43d" contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CreditConcentrationRiskMember_MajorCustomersAxis_SignificantPartnersMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">75 </ix:nonFraction>percent and <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_65b613fed44d4106b07531e197665bfb" contextRef="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CreditConcentrationRiskMember_MajorCustomersAxis_SignificantPartnersMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">99 </ix:nonFraction> percent for each year from <ix:nonFraction name="ions:NumberOfSignificantPartners" id="Fact_f77b5cfe2f944a15983b965d2dedff4b" contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CreditConcentrationRiskMember_MajorCustomersAxis_SignificantPartnersMember" unitRef="U019" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> and <ix:nonFraction name="ions:NumberOfSignificantPartners" id="Fact_4c28cf57e67b421f9e33d6b9fe701b2c" contextRef="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CreditConcentrationRiskMember_MajorCustomersAxis_SignificantPartnersMember" unitRef="U019" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction> significant partners, respectively.</div>
</ix:continuation></div>
<div><br /></div>
<div><ix:nonNumeric name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Text_4828029eb0b0493f99454748bc595924" contextRef="c20190101to20191231" escape="true" continuedAt="Text_5303483789a34538b56e7974687f37c51">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">8. Employment Benefits</div>
</ix:nonNumeric><ix:continuation id="Text_5303483789a34538b56e7974687f37c51" continuedAt="Text_5303483789a34538b56e7974687f37c52">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_5303483789a34538b56e7974687f37c52">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have an employee 401(k) salary deferral plan, covering all employees. Employees could make contributions by withholding a percentage of their salary up to the IRS annual limit $<ix:nonFraction name="ions:DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge" id="Fact_06c142c7ec1040e0b05c4b2596dfe112" contextRef="c20190101to20191231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">19,000</ix:nonFraction> and $<ix:nonFraction name="ions:DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge" id="Fact_2703ad6213db4e249c38d0794a2c6418" contextRef="c20190101to20191231" unitRef="U001" decimals="0" scale="0" format="ixt:numdotdecimal">25,000</ix:nonFraction> in 2019 for employees under 50 years old and employees 50 years old or over, respectively. We made approximately $<ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" id="Fact_345fd7748408424580894d7cb0e0e108" contextRef="c20190101to20191231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">6.4</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" id="Fact_47a2898dc66b4221ba3a2d92c2c0643a" contextRef="c20180101to20181231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">5.7</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" id="Fact_0c0b367e1550466b886c0390a13e1e0f" contextRef="c20170101to20171231" unitRef="U001" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction> million in matching contributions for the years ended December 31, 2019, 2018 and 2017, respectively.</div>
</ix:continuation></div>
<div><br /></div>
<div><ix:nonNumeric name="us-gaap:LegalMattersAndContingenciesTextBlock" id="Text_8889b34573874aeeb1e3093442528ca9" contextRef="c20190101to20191231" escape="true" continuedAt="Text_e047054a74b14cb9b283ccbe0b866fcd1">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">9. Legal Proceedings</div>
</ix:nonNumeric><ix:continuation id="Text_e047054a74b14cb9b283ccbe0b866fcd1" continuedAt="Text_e047054a74b14cb9b283ccbe0b866fcd2">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_e047054a74b14cb9b283ccbe0b866fcd2" continuedAt="Text_e047054a74b14cb9b283ccbe0b866fcd3">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">From time to time, we are involved in legal proceedings arising in the ordinary course of our business. Periodically, we evaluate the status of each legal matter and assess our potential financial exposure. If the potential loss from any legal proceeding is considered probable and the amount can be reasonably estimated, we accrue a liability for the estimated loss. Significant judgment is required to determine the probability of a loss and whether the amount of the loss is reasonably estimable. The outcome of any proceeding is not determinable in advance. As a result, the assessment of a potential liability and the amount of accruals recorded are based only on the information available to us at the time. As additional information becomes available, we reassess the potential liability related to the legal proceeding, and may revise our estimates.</div>
</ix:continuation><ix:continuation id="Text_e047054a74b14cb9b283ccbe0b866fcd3" continuedAt="Text_e047054a74b14cb9b283ccbe0b866fcd4">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_e047054a74b14cb9b283ccbe0b866fcd4">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In November 2019, a purported stockholder of Akcea filed an action in the Delaware Court of Chancery, captioned <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">City of Cambridge Retirement System v. Crooke, et al.</span>, C.A. No. 2019-0905, or the Delaware Action. The plaintiff in the Delaware Action asserts claims against (i) current and former members of Akcea&#8217;s Board of Directors, and (ii) Ionis, or collectively, the Defendants. The plaintiff asserts derivative claims on behalf of Akcea, which is a nominal defendant in the Delaware Action, as well as putatively direct claims on behalf of a purported class of Akcea stockholders. The plaintiff in the Delaware Action asserts that the Defendants breached their fiduciary duties in connection with the licensing transaction that Akcea and Ionis entered into regarding TEGSEDI and AKCEA-TTR-<span style="background-color: #FFFFFF; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">L</span><sub><span style="background-color: #FFFFFF;">Rx</span></sub>. The plaintiff also asserts an unjust enrichment claim against Ionis. We and Akcea have moved to dismiss the plaintiff&#8217;s complaint. We believe that the claims asserted in the Delaware Action are without merit.</div>
</ix:continuation></div>
<div><br /></div>
<div><ix:nonNumeric name="us-gaap:QuarterlyFinancialInformationTextBlock" id="Text_c2c3e6e9a4d542cf8c6f1350eb5450ef" contextRef="c20190101to20191231" escape="true" continuedAt="Text_297f60bfa5364fd38dee2c2748f287541">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">10. Quarterly Financial Data (Unaudited)</div>
</ix:nonNumeric><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f287541" continuedAt="Text_297f60bfa5364fd38dee2c2748f287542">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br /></div>
</ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f287542" continuedAt="Text_297f60bfa5364fd38dee2c2748f287543"><ix:nonNumeric name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="Text_b65c0b3c5ab243bd949bc3d66e4ac1df" contextRef="c20190101to20191231" escape="true" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd31911">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Summarized quarterly data for the years ended December 31, 2019 and 2018 are as follows (in thousands, except per share data).</div>
</ix:nonNumeric></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f287543" continuedAt="Text_297f60bfa5364fd38dee2c2748f287544"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd31911" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd31912">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f287544" continuedAt="Text_297f60bfa5364fd38dee2c2748f287545"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd31912" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd31913">
<table cellpadding="0" cellspacing="0" id="zbbded80230f54883844977a2db5dd5f5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019 Quarters</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">First</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Second</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Third</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fourth</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:Revenues" id="Fact_405935fc1a234f9693c9e050d5d1faf6" contextRef="c20190101to20190331" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">297,214</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:Revenues" id="Fact_e1ea1a2285c44c159fc7940b53b1eca8" contextRef="c20190401to20190630" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">163,813</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:Revenues" id="Fact_b0f53fcdeb5149d4a00f45cc69091373" contextRef="c20190701to20190930" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">167,892</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:Revenues" id="Fact_e4523a99204b47479a6578ee1ea5c227" contextRef="c20191001to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">493,680</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_aa23b0f93153488597551e03eb288034" contextRef="c20190101to20190331" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">175,679</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_ba0545722fa749958bc91a3467210be7" contextRef="c20190401to20190630" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">182,640</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_b19b91ad3aed407aabf139e529e9fa66" contextRef="c20190701to20190930" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">165,369</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_ef90677def3140d98ac71d198d622906" contextRef="c20191001to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">233,028</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) from operations</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_01f1a808e8df4e62a878cf07afa7ed37" contextRef="c20190101to20190331" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">121,535</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_deef4502b31f41688adecd82c0c515de" contextRef="c20190401to20190630" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,827</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_0a8576bd68274551b54937a3c64dfcd7" contextRef="c20190701to20190930" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">2,523</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_923dc71a6c8946569992db56c25448e0" contextRef="c20191001to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">260,652</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income (loss)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_ef4e35c29e504ecda7c36c96c1aee8e8" contextRef="c20190101to20190331" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">90,884</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_4a9a55aede9e4d679715875d6e3584b3" contextRef="c20190401to20190630" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,012</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_28285e71fbae42529e40f2f9e7c6ac1c" contextRef="c20190701to20190930" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">18,432</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_c6bc921d748440ee8a2149a0046d16dd" contextRef="c20191001to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">203,957</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_70191f1596d046aab1549b8741bbb263" contextRef="c20190101to20190331" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">84,443</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_c32a43869a1b46e2a6d4c6675431dd9c" contextRef="c20190401to20190630" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">876</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_fb7803ccdeda4e7199d2a1be79da9830" contextRef="c20190701to20190930" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">26,163</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_33e716eff34a4b7b8689e954b0810f18" contextRef="c20191001to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">184,415</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income (loss) per share (1) (2)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_c12cf7abb66848b497c1b0fdca78f316" contextRef="c20190101to20190331" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">0.63</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_ab7ddc03812d45bba8a6590bbdaa6412" contextRef="c20190401to20190630" unitRef="U004" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_8e3aff85017d49ac81262282323b3438" contextRef="c20190701to20190930" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">0.19</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_d19a2d112d904b8bb9b627ad113e904f" contextRef="c20191001to20191231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">1.31</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Diluted net income (loss) per share (1) (3)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_68f4a8f3d2df47cfa8896e2ea15ab759" contextRef="c20190101to20190331" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">0.62</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_16eafacc8b6c4c46b58136f0b68b2937" contextRef="c20190401to20190630" unitRef="U004" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_2d4ca33cff2c472890862928fc3e81b2" contextRef="c20190701to20190930" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">0.18</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_af905ebe97f14c108dd0f43f627bb6f0" contextRef="c20191001to20191231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">1.28</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f287545" continuedAt="Text_297f60bfa5364fd38dee2c2748f287546"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd31913" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd31914">
<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f287546" continuedAt="Text_297f60bfa5364fd38dee2c2748f287547"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd31914" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd31915">
<table cellpadding="0" cellspacing="0" id="z6dcd313bcba54fcbbfd2063358483afb" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018 Quarters</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">First</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Second</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Third</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fourth</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Revenue</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:Revenues" id="Fact_5204880f63b443bd81fa12e49662e39e" contextRef="c20180101to20180331" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">144,419</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:Revenues" id="Fact_5691cb1907b145f6b282b80ef5adf3e7" contextRef="c20180401to20180630" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">117,747</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:Revenues" id="Fact_580cdc588a9a45d787156f145dfd6e74" contextRef="c20180701to20180930" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">145,395</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:Revenues" id="Fact_d0af4ac96aec47cfb0e22e39e38be43d" contextRef="c20181001to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">192,113</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating expenses</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_faeea64b036241e0b02cf5560667b6d0" contextRef="c20180101to20180331" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">147,720</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_b89203e619464a8a8d711634dd2a54a4" contextRef="c20180401to20180630" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">168,028</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_6e09fbd1ee99419186761cf8063c181c" contextRef="c20180701to20180930" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">163,967</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:CostsAndExpenses" id="Fact_2ef12b0b1e934c82b2b4fd872862b4b8" contextRef="c20181001to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">181,331</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) from operations</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_ddde75d1e32c4bc8ad8f3d53e587dd94" contextRef="c20180101to20180331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,301</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_c88f114e993d41aaac8521254f951167" contextRef="c20180401to20180630" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">50,281</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_78f6c5253c2c44d7a296c84d2dd8ba33" contextRef="c20180701to20180930" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">18,572</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_08ef991a056947b487e3906f5e0841c0" contextRef="c20181001to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">10,782</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income (loss)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_e61281c101e64429aca3f789e110d674" contextRef="c20180101to20180331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">10,812</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_5b34ea9293b84685a8158429326c6f14" contextRef="c20180401to20180630" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">56,573</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_a32ea718553e43b19f110a461acdad46" contextRef="c20180701to20180930" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">20,365</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:ProfitLoss" id="Fact_6d0055893f9641e3866eed897c5a7c63" contextRef="c20181001to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">302,735</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_4a0c58ce78ec4910902158c4525e452d" contextRef="c20180101to20180331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,420</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_8c845df7689446e29d1c1bf0a37fab2e" contextRef="c20180401to20180630" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">40,358</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_12dac20c747c4975a7f4f1577e69ec61" contextRef="c20180701to20180930" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,559</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_ba9e92a5bd4e4e859856117256f50207" contextRef="c20181001to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">320,078</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income (loss) per share (1) (2)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_763576c71cab41fb95dcbba53d8fc8b3" contextRef="c20180101to20180331" unitRef="U004" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_66c12e16e5ef41b7be87c24864ef5483" contextRef="c20180401to20180630" unitRef="U004" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.29</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_313f67285e0f464192314b8ac770adc7" contextRef="c20180701to20180930" unitRef="U004" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.03</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_0ce5ff94fbd3419d928cd3c0d9de8ba9" contextRef="c20181001to20181231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">2.32</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Diluted net income (loss) per share (1) (3)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_08e18485edd442aeb6ea55cb7dc5a055" contextRef="c20180101to20180331" unitRef="U004" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_8a292b5b2fc640eaaa6c9eddb9c04d14" contextRef="c20180401to20180630" unitRef="U004" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.29</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_55abe2d19d6a42c689a6863e846a7fea" contextRef="c20180701to20180930" unitRef="U004" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.03</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_f969201be6664a8ba8da16dedbdfffc9" contextRef="c20181001to20181231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">2.21</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f287547" continuedAt="Text_297f60bfa5364fd38dee2c2748f287548"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd31915" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd31916">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">________________</div>
</ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd31916" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd31917"><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f287548" continuedAt="Text_297f60bfa5364fd38dee2c2748f287549">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z238c61f0c45341568e1fd63ba558f508">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:footnote id="Foot_260ceacf638c4b6691c7c678cfe81725" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">We computed net income (loss) per share independently for each of the quarters presented. Therefore, the sum of the quarterly net income (loss) per share will not necessarily equal the total for the year.</ix:footnote></div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f287549" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875410"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd31917" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd31918">
<div style="text-align: justify; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>49</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd31918" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd31919"><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875410" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875411">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="z4b10092c7ee94951986f14bc378411d6">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:footnote id="Foot_94f9411e48574896ba56a419ae90ffb3" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="Foot_171c32667bf34a32aea672842662caf31">As discussed in Note 1, </ix:footnote><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"><ix:continuation id="Foot_171c32667bf34a32aea672842662caf31" continuedAt="Foot_171c32667bf34a32aea672842662caf32">Organization and Significant Accounting Policies, </ix:continuation></span><ix:continuation id="Foot_171c32667bf34a32aea672842662caf32">we compute basic net income (loss) per share by dividing the total net income (loss) attributable to our common stockholders by our weighted-average number of common shares outstanding during the period. Our basic net income (loss) per share calculation for each of the quarters in 2019 and 2018 considered our net income for Ionis on a stand-alone basis plus our share of Akcea&#8217;s net loss for the period. To calculate the portion of Akcea&#8217;s net loss attributable to our ownership, we multiplied Akcea&#8217;s loss per share by the weighted average shares we owned in Akcea during the period. As a result of this calculation, our total net income (loss) available to Ionis common stockholders for the calculation of net income (loss) per share is different than net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders in the consolidated statements of operations.</ix:continuation></div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875411" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875412"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd31919" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319110">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875412" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875413"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319110" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319111">
<div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our basic net income (loss) per share for each quarter in 2019 was calculated as follows (in thousands, except per share amounts):</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875413" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875414"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319111" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319112">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875414" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875415"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319112" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319113">
<table cellpadding="0" cellspacing="0" id="z66d226e9f1e04c068da73924c4bbb872" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended March 31 , 2019</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Income</span></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:WeightedAverageNumberOfSharesOwnedInSubsidiary" id="Fact_1216b48327b7477bb2f422d217a18307" contextRef="c20190101to20190331_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">68,582</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_799d1133f85c49f39362cc2c835becca" contextRef="c20190101to20190331_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">0.35</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_e604af170ed04b548deb692cc50b66fc" contextRef="c20190101to20190331_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">23,846</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net income attributable to our ownership</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_26f856a46c2b4e5fb50866b8cb04b29a" contextRef="c20190101to20190331_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">23,846</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_c81e9f3e122941018b434df23f66b4c5" contextRef="c20190101to20190331_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">63,697</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_e87ae36d3520424eab9b68ccefbc3f46" contextRef="c20190101to20190331" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">87,543</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_58327dafdbed4b9eab67dcc9582fe38c" contextRef="c20190101to20190331" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">138,582</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_cded1266b5a742518086dee9fdfb3f1b" contextRef="c20190101to20190331" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">0.63</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875415" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875416"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319113" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319114">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875416" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875417"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319114" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319115">
<table cellpadding="0" cellspacing="0" id="z0a7c3905d3e645b7bf1d61ed99b81aa3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended June 30 , 2019</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:WeightedAverageNumberOfSharesOwnedInSubsidiary" id="Fact_88c7772a2b124614b9620340a1db2410" contextRef="c20190401to20190630_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">70,221</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_ce8420ec05674c74b45524f8397e6947" contextRef="c20190401to20190630_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U004" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.40</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_6fc555d704cc45e083ec6dcb21be4625" contextRef="c20190401to20190630_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,244</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_f1532d4f7130494696c9301fe4a4605c" contextRef="c20190401to20190630_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">28,244</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_9d2998f4fb82407fb38c3c6cae74551e" contextRef="c20190401to20190630_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">27,311</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net loss available to Ionis common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_5d807d32331041009e14eaf1335c36f7" contextRef="c20190401to20190630" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">933</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_a97a88f6b028439b8b03672135ee2b40" contextRef="c20190401to20190630" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">140,247</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net loss per share</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_9ded035640c84b8089eeec1dac09cd5f" contextRef="c20190401to20190630" unitRef="U004" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875417" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875418"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319115" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319116">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875418" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875419"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319116" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319117">
<table cellpadding="0" cellspacing="0" id="z63a88a9296e2466eaad9bc93a89393ce" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended September 30 , 2019</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:WeightedAverageNumberOfSharesOwnedInSubsidiary" id="Fact_83edf38f53a24b64b8b6bd94a8ca5658" contextRef="c20190701to20190930_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">70,221</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_368309363def4642ac46f2434cabc9d0" contextRef="c20190701to20190930_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U004" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.34</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_087e07deab0440bebdc73de289324d1a" contextRef="c20190701to20190930_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">23,772</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_20b89649d34e48249b8e5adb928d2712" contextRef="c20190701to20190930_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">23,772</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_72a432341a4d489ea5258e3ad45a4601" contextRef="c20190701to20190930_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">49,930</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_8ec47d7cc67d4462b0ba87428e68c1d1" contextRef="c20190701to20190930" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">26,158</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_b4532452076740d5a6203a0b217e9329" contextRef="c20190701to20190930" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">140,551</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_46edfb3c0a6b49ffb1bbef370451f895" contextRef="c20190701to20190930" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">0.19</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875419" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875420"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319117" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319118">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875420" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875421"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319118" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319119">
<table cellpadding="0" cellspacing="0" id="zd25327371fce44efae3b5570b907c56d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended December 31 , 2019</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Income</span></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:WeightedAverageNumberOfSharesOwnedInSubsidiary" id="Fact_2e9fe85ccab349ca8d5506c348e2a62a" contextRef="c20191001to20191231_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">71,342</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_a903c30771cf4bd5b62eebe86cd6fd6d" contextRef="c20191001to20191231_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">0.87</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_caa5b7b2a4a24544990e8d31e09125a6" contextRef="c20191001to20191231_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">62,243</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net income attributable to our ownership</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_884e7d77348346b49e5227d5ed057f9b" contextRef="c20191001to20191231_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">62,243</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_46f6f7a9b6234ec19d304e746c55815c" contextRef="c20191001to20191231_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">121,552</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_f9a948d9257f437e994aec65b62081e8" contextRef="c20191001to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">183,795</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_815dfe6768684e6290e270f2d79702f8" contextRef="c20191001to20191231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">140,583</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_2977dc798d184957ade439c2afeb14e0" contextRef="c20191001to20191231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">1.31</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875421" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875422"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319119" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319120">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>50</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><br /></div>
<div><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875422" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875423"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319120" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319121">
<div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our basic net income (loss) per share for each quarter in 2018 was calculated as follows (in thousands, except per share amounts):</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875423" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875424"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319121" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319122">
<div style="text-align: left; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875424" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875425"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319122" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319123">
<table cellpadding="0" cellspacing="0" id="zbbcbf397131340ad9566b5428b09a107" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended March 31 , 2018</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:WeightedAverageNumberOfSharesOwnedInSubsidiary" id="Fact_8db77bf79d71403d84e4278b7edb8914" contextRef="c20180101to20180331_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">45,448</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_4c9782a2610c438fb25085c943cc0693" contextRef="c20180101to20180331_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U004" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.44</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_6dd56f27f2784d41868ec6fb9bf431fc" contextRef="c20180101to20180331_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">19,997</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_bf06aa234c5341cdb35faf00ae495b70" contextRef="c20180101to20180331_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">19,997</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_475d550bccca407f9b58b0755d00eb46" contextRef="c20180101to20180331_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">18,785</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net loss available to Ionis common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_9a795de9784940e9aad1ae90b4114c56" contextRef="c20180101to20180331" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,212</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_e6d6605951b845078ca1ce96ceea6a96" contextRef="c20180101to20180331" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">125,330</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net loss per share</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_93036c39f03143c9a31348e606869fed" contextRef="c20180101to20180331" unitRef="U004" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.01</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875425" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875426"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319123" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319124">
<div style="text-align: justify; margin-left: 31.5pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875426" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875427"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319124" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319125">
<table cellpadding="0" cellspacing="0" id="z2b8e94f57db4490c82a68c1ff759a0e3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended June 30 , 2018</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:WeightedAverageNumberOfSharesOwnedInSubsidiary" id="Fact_52794ae9c4b2481d805373d5dcf5b4b3" contextRef="c20180401to20180630_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">60,832</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_5cbce9b960094b6ca3b5dfc348800e11" contextRef="c20180401to20180630_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U004" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.72</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_35b7599a33924bd29ec74c40b127eed0" contextRef="c20180401to20180630_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">43,814</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_7ce183bea5544ce99568eb14a97b35d2" contextRef="c20180401to20180630_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">43,814</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_58af2114d636404e96f20c6fc372e1d9" contextRef="c20180401to20180630_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">5,882</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net loss available to Ionis common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_9e438608dee94fc99a32689cd2d5a726" contextRef="c20180401to20180630" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">37,932</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_607e907eaed84e20a757c60b736ce5b9" contextRef="c20180401to20180630" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">128,712</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net loss per share</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_2b07a0dfa1f546f480946f41747c98e2" contextRef="c20180401to20180630" unitRef="U004" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.29</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875427" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875428"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319125" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319126">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875428" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875429"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319126" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319127">
<table cellpadding="0" cellspacing="0" id="z2549de914d904e2a82162394a6946bc2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended September 30 , 2018</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:WeightedAverageNumberOfSharesOwnedInSubsidiary" id="Fact_fe01f2e6ba89433c8ebe0f79d8de626e" contextRef="c20180701to20180930_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">65,538</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_cf9cf896ab094238bfb8de8a475025f3" contextRef="c20180701to20180930_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U004" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.73</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_57bdfb4cd4bb4987930f793ddf853745" contextRef="c20180701to20180930_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">47,789</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_c42298ded5ea4e20aa09715c73219c96" contextRef="c20180701to20180930_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">47,789</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_93736b7449dd479bb8bf1d62fc201ad1" contextRef="c20180701to20180930_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">43,226</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net loss available to Ionis common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_2eb7d38e7b1e4acc9014b6a612a983ae" contextRef="c20180701to20180930" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">4,563</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_0361de674f3b416ba6083f36403670d3" contextRef="c20180701to20180930" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">137,346</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net loss per share</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_8c347451d45b432291da57ff527bbe07" contextRef="c20180701to20180930" unitRef="U004" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.03</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875429" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875430"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319127" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319128">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875430" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875431"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319128" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319129">
<table cellpadding="0" cellspacing="0" id="z0b1244fa792d4e2f89c46e4a73ab2036" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended December 31 , 2018</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:WeightedAverageNumberOfSharesOwnedInSubsidiary" id="Fact_223fbd8edec84d22a431d075f6b021e9" contextRef="c20181001to20181231_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">67,130</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_480a35ceb8ec4bdab6ad6de10c208d51" contextRef="c20181001to20181231_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U004" decimals="2" sign="-" scale="0" format="ixt:numdotdecimal">0.79</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_4b6b562b1b444738b46963f7ab22ab83" contextRef="c20181001to20181231_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">53,219</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_da4a53325773454293ff741fac8e7648" contextRef="c20181001to20181231_OwnershipAxis_AkceaTherapeuticsIncMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">53,219</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_f4ccced4fb204e50861835e5f147707f" contextRef="c20181001to20181231_StatementBusinessSegmentsAxis_IonisCoreMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">372,913</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_ba94acd702cc4643a3b677508da8ad40" contextRef="c20181001to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">319,694</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_933e80e19a314141afb2843f6937af37" contextRef="c20181001to20181231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">137,699</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_3d352e6ec8fa4346a84762440947b384" contextRef="c20181001to20181231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">2.32</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
<div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>51</span></div>
</div>
<div style="page-break-after:always;"><hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;" /></div>
<div></div>
</div>
<div><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875431" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875432"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319129" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319130">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation></div>
<div style="text-align: justify;">
<div><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319130" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319131"><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875432" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875433">
<table style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" cellpadding="0" cellspacing="0" id="zc5ec9a701b644f2192ef4fd51a353c9b">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:footnote id="Foot_f63ff29e56764f3485555958bff3cab9" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">We had net income available to Ionis common stockholders for the following periods. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during those periods.</ix:footnote></div></td>
  </tr>
</table>
</ix:continuation></ix:continuation></div>
</div>
<div><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875433" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875434"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319131" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319132">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875434" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875435"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319132" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319133">
<div style="text-align: justify; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Diluted common equivalent shares for each of the periods consisted of the following (in thousands except per share amounts):</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875435" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875436"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319133" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319134">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875436" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875437"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319134" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319135">
<table cellpadding="0" cellspacing="0" id="zf822f8c87ab4452683b2466a81529563" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended March 31, 2019</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_4ac638415d964b8b93c21f45fdb098cc" contextRef="c20190101to20190331" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">87,543</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_c9da96157a1b4395969239ff01cb2920" contextRef="c20190101to20190331" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">138,582</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_903d4771485b4358bc027428ec706f85" contextRef="c20190101to20190331" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">0.63</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -6pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" id="Fact_31b7afe977814a36919731ca9237457f" contextRef="c20190101to20190331_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">2,252</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" id="Fact_1ff39f911f734fb5875ed8bbed315591" contextRef="c20190101to20190331_AwardTypeAxis_RestrictedStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">665</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our ESPP</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" id="Fact_c7044d0277ca498b8e2dfbc5a2ddc1fd" contextRef="c20190101to20190331" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">38</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_7a05d15db4e54c92a623574937d6183e" contextRef="c20190331_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction> percent convertible notes</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" id="Fact_936ef83a91964ac3aa661bb2b577b835" contextRef="c20190101to20190331_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" id="Fact_4437f69579374ad38f076343b0900c91" contextRef="c20190101to20190331_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" id="Fact_0587e06300254e20a4d0a0207ac53329" contextRef="c20190101to20190331" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">87,543</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_eb9d746b433448fd88352d2be3f4668f" contextRef="c20190101to20190331" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">141,537</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_acf19f9f2a2d454f806cb8c67c3f1221" contextRef="c20190101to20190331" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">0.62</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875437" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875438"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319135" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319136">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875438" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875439"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319136" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319137">
<table cellpadding="0" cellspacing="0" id="zcafdd1c50c0b47bea13bfdef22787b0b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended September 30, 2019</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_a2e7db14af714d97b8fcb9e454ffad59" contextRef="c20190701to20190930" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">26,158</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_37c357f8a90640b0835dd699bddc6b7c" contextRef="c20190701to20190930" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">140,551</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_5dc13a1ebb204497a09727c28e16985a" contextRef="c20190701to20190930" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">0.19</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" id="Fact_380ff50e306d4522903deb7f48356023" contextRef="c20190701to20190930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">1,993</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" id="Fact_9bd54d740942472a961376ed64002fab" contextRef="c20190701to20190930_AwardTypeAxis_RestrictedStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">844</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our ESPP</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" id="Fact_a76a0ba8954044e2bfd6db1397a2240b" contextRef="c20190701to20190930" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">20</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_04e82bb0d1424192a81e9920608ff298" contextRef="c20190930_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction> percent convertible notes</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" id="Fact_de2d5c0a4048495cb76d4a395a2b5599" contextRef="c20190701to20190930_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" id="Fact_0bc2c40501dd48c2a51a6f433946a3f4" contextRef="c20190701to20190930_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" id="Fact_c443cf59a91a4df2961be7e6bd2e98ed" contextRef="c20190701to20190930" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">26,158</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_280a96ed03d247af953c06d965812719" contextRef="c20190701to20190930" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">143,408</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_c6bda12260a24486afece5222821d5c7" contextRef="c20190701to20190930" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">0.18</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875439" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875440"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319137" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319138">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875440" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875441"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319138" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319139">
<table cellpadding="0" cellspacing="0" id="z43f9157d9e1242ac8e62d24c49d3a75f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended December 31, 2019</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_cceaef2c22204a908414bc2f28045442" contextRef="c20191001to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">183,795</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_b83d923230294453aea541f0cd433d52" contextRef="c20191001to20191231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">140,583</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_26fc347439824bad93dea56901589229" contextRef="c20191001to20191231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">1.31</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" id="Fact_261405a64e7b42a2864075242c35b9fd" contextRef="c20191001to20191231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">1,467</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" id="Fact_81007694e2e844bd86c089aa743141ba" contextRef="c20191001to20191231_AwardTypeAxis_RestrictedStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">848</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our ESPP</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" id="Fact_a73965154bf34010a7ae7aff58d873a7" contextRef="c20191001to20191231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">18</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_1fcaca39a2db4ce499e9fb5e7b7659cb" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U003" decimals="5" scale="-2" format="ixt:numdotdecimal">0.125</ix:nonFraction> percent convertible notes</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" id="Fact_cbef44e0f5a9433baad60d1521f098d0" contextRef="c20191001to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">644</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" id="Fact_2a64057c1222473ba4bddd213c182709" contextRef="c20191001to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">860</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_65762f29027f42468a0a3c7099b3f5c1" contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction> percent convertible notes</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" id="Fact_02848174582845b899cba8c3ac468ebf" contextRef="c20191001to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">12,046</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" id="Fact_4dff535f8d4c4acfb4ecc1cf03fcc02a" contextRef="c20191001to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">9,527</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" id="Fact_ce3cbc4dcd6347a28e0ee3cc46fa7443" contextRef="c20191001to20191231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">196,485</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_984bf13bbf9044a691a42dd3eb008c11" contextRef="c20191001to20191231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">153,303</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_92fcf919d3694b338ecfefc170097220" contextRef="c20191001to20191231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">1.28</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875441" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875442"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319139" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319140">
<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875442" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875443"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319140" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319141">
<table cellpadding="0" cellspacing="0" id="z2edbbee13c264fed8062982b71bf6ef3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended December 31, 2018</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
    <td colspan="2" valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" id="Fact_a711b3e4209a4addafefd5ba790e3924" contextRef="c20181001to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">319,694</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_dcae11cbbf09411c82064edb89209cc1" contextRef="c20181001to20181231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">137,699</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_d607a38fcd0f417c91a9e8770288fd33" contextRef="c20181001to20181231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">2.32</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" id="Fact_66c0753e21d048c1916338f168e89337" contextRef="c20181001to20181231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">1,254</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" id="Fact_7ee0340cd65a4528bbced1df496993e7" contextRef="c20181001to20181231_AwardTypeAxis_RestrictedStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">636</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our ESPP</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="ions:IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" id="Fact_03b69728caff4c708fea2f9df8ab9c22" contextRef="c20181001to20181231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">7</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_9e657f6f4338497084c4f62d902e54e3" contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction> percent convertible notes</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" id="Fact_6ae71e31117549879ba639a42ec356ca" contextRef="c20181001to20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">10,745</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" id="Fact_04589a9e03a84687950244aecc7e00f3" contextRef="c20181001to20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">10,260</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;">&#160;</td>
  </tr>
  <tr>
    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" id="Fact_43f2a0fff211482c90108a69c1a23e52" contextRef="c20181001to20181231" unitRef="U001" decimals="-3" scale="3" format="ixt:numdotdecimal">330,439</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_79d79ed66e074edfb7ef753c4bf456b7" contextRef="c20181001to20181231" unitRef="U002" decimals="-3" scale="3" format="ixt:numdotdecimal">149,856</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_8779796f76214f59b2a0c11ee7a79cac" contextRef="c20181001to20181231" unitRef="U004" decimals="2" scale="0" format="ixt:numdotdecimal">2.21</ix:nonFraction></div></td>
    <td colspan="1" valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>
  </tr>
</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875443" continuedAt="Text_297f60bfa5364fd38dee2c2748f2875444"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319141" continuedAt="Text_7b79e0a10231457ca0bc6ed6a1dd319142">
<div style="display:none;"><br /></div>
<div style="text-align: justify; text-indent: -36pt; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br /></span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_297f60bfa5364fd38dee2c2748f2875444"><ix:continuation id="Text_7b79e0a10231457ca0bc6ed6a1dd319142">
<div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><ix:footnote id="Foot_3d79790158204fcc95642c2ca83c4b8f" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="Foot_b337714bdf38487d95df61fbf8881a561">For the three months ended March 31, 2019 and September 30, 2019, the calculation excluded the <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_02416fb2919c4c8b9c6e5dc81b9d57d7" contextRef="c20190930_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_f11ae7226fa64dc9adde56548c8d6e8e" contextRef="c20190331_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember" unitRef="U003" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></ix:nonFraction> percent</ix:footnote><ix:continuation id="Foot_b337714bdf38487d95df61fbf8881a561"> notes because the effect on diluted earnings per share was anti-dilutive.</ix:continuation></div>
</ix:continuation></ix:continuation></div>
<div><br /></div>
<div>
<div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">F-<span>52</span></div>
</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.9
<SEQUENCE>2
<FILENAME>exhibit4_9.htm
<DESCRIPTION>EXHIBIT 4.9
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using EDGARfilings PROfile 6.5.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-weight: bold;">Exhibit 4.9</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</div>
      <div style="text-align: center; font-weight: bold;">REGISTERED PURSUANT TO SECTION 12 OF THE</div>
      <div style="text-align: center; font-weight: bold;">SECURITIES EXCHANGE ACT OF 1934</div>
      <div><br>
      </div>
      <div style="text-indent: 36pt;">As of December 31, 2019, Ionis Pharmaceuticals, Inc. (the &#8220;Company&#8221;) had one class of securities, its Common Stock, registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</div>
      <div><br>
      </div>
      <div style="text-align: center; font-weight: bold;">Description of Common Stock</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">General</div>
      <div><br>
      </div>
      <div>The following description of our Common Stock is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our Amended and Restated Certificate of Incorporation, as amended (the &#8220;Certificate of
        Incorporation&#8221;), and our Amended and Restated Bylaws (the &#8220;Bylaws&#8221;), each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.4 is a part. We encourage you to read our Certificate of
        Incorporation, Bylaws and the applicable provisions of the General Corporation Law of Delaware (the &#8220;DGCL&#8221;) for additional information.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Authorized Capital Stock</div>
      <div><br>
      </div>
      <div style="background-color: #FFFFFF;">
        <div>Our authorized capital stock consists of 300,000,000 shares of Common Stock, par value $0.001 per share, and 15,000,000 shares of Preferred Stock, par value $0.001 per share.<font style="color: #000000;"> Our board of directors has the
            authority, without stockholder approval, except as required by the listing standards of The Nasdaq Stock Market LLC, to issue additional shares of our capital stock. In addition, our board of directors has the authority, without further action
            by our stockholders, to designate the rights, preferences, privileges and restrictions of our Preferred Stock in one or more series.</font></div>
        <div><br>
        </div>
      </div>
      <div style="font-weight: bold;">Voting Rights</div>
      <div><br>
      </div>
      <div style="background-color: #FFFFFF;">
        <div>Holders of Common Stock are entitled to one vote per share on all matters to be voted upon by the stockholders, including the election of directors. Our Common Stock does not have cumulative voting rights.</div>
        <div><br>
        </div>
      </div>
      <div style="font-weight: bold;">Dividend Rights</div>
      <div><br>
      </div>
      <div>Subject to the preferential rights of outstanding shares of Preferred Stock, if any, the holders of Common Stock are entitled to receive dividends out of assets legally available at the times and in the amounts that our board of directors may
        determine from time to time in its discretion.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Classification of the Board of Directors</div>
      <div><br>
      </div>
      <div>Our Certificate of Incorporation provides for classified terms for the members of our board of directors. The board of directors is divided into three classes, and each director serves a three-year term.</div>
      <div style="font-weight: bold;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageFooter"></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div id="DSPFPageHeader"></div>
      </div>
      <br>
      <div style="font-weight: bold;">Liquidation, Dissolution or Winding Up</div>
      <div><br>
      </div>
      <div><a name="z_Hlk33602782"></a>Subject to the preferential rights of outstanding shares of Preferred Stock, if any, holders of Common Stock will share equally in all assets legally available for distribution, after payment of all liabilities, to
        our stockholders in the event of liquidation, dissolution or winding up of the Company.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Other Rights and Preferences</div>
      <div><br>
      </div>
      <div>Our Common Stock has no sinking fund or redemption provisions or preemptive, conversion or exchange rights.</div>
      <div><br>
      </div>
      <div style="font-weight: bold;">Anti-Takeover Provisions</div>
      <div><br>
      </div>
      <div style="font-style: italic; font-weight: bold;">Delaware Anti-takeover Law</div>
      <div><br>
      </div>
      <div>We are subject to Section 203 of the DGCL, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such stockholder became an interested
        stockholder, unless:</div>
      <div><br>
      </div>
      <div>
        <div>
          <table cellspacing="0" cellpadding="0" id="z8745744eaf064df6bde74fd8e6732dd4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 18pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
                <td style="width: auto; vertical-align: top;">
                  <div>the transaction is approved by the board of directors before the date the interested stockholder attained that status;</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div>
        <div>
          <table cellspacing="0" cellpadding="0" id="zbd762e1c3bd046b789a84377d8f8dd70" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 18pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
                <td style="width: auto; vertical-align: top;">
                  <div>upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction
                    commenced; or</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div>
        <div>
          <table cellspacing="0" cellpadding="0" id="z98b291b96ae54c44a41cb1ed23fd65ec" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 18pt;"><br>
                </td>
                <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
                <td style="width: auto; vertical-align: top;">
                  <div>on or after the date the business combination is approved by the board and authorized at a meeting of stockholders by at least 66-2/3% of the outstanding voting stock that is not owned by the interested stockholder.</div>
                </td>
              </tr>

          </table>
        </div>
      </div>
      <div><br>
      </div>
      <div>A &#8220;business combination&#8221; is defined to include any merger or consolidation involving a corporation and the interested stockholder; any sale, transfer,<font style="color: #000000;"> pledge or other disposition involving the interested stockholder
          of 10% or more of the assets of the </font>corporation<font style="color: #000000;">; subject to exceptions, any transaction involving the </font>corporation <font style="color: #000000;">that has the effect of increasing the proportionate
          share of the stock of any class or series of the </font>corporation <font style="color: #000000;">beneficially owned by the interested stockholder; subject to exceptions, any transaction that results in the issuance or transfer by the </font>corporation


        <font style="color: #000000;">of any stock of the corporation to the interested stockholder; and the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through
          the </font>corporation<font style="color: #000000;">.</font></div>
      <div><br>
      </div>
      <div>In general, an &#8220;interested stockholder&#8221; is an entity or person who, together with affiliates and associates, owns (or within three years prior to the determination of interested stockholder status, did own) 15% or more of a corporation&#8217;s voting
        stock.</div>
      <div><br>
      </div>
      <div>The fair price provision and Section 203 of the DGCL could prohibit or delay mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage attempts to acquire us even though such a transaction may
        offer our stockholders the opportunity to sell their stock at a price above the prevailing market price.</div>
      <div><br>
      </div>
      <div style="font-style: italic; font-weight: bold;">Certificate of Incorporation and Bylaws Provisions</div>
      <div><br>
      </div>
      <div>Our Certificate of Incorporation includes a provision that requires at least 66-2/3% of our voting stockholders to approve a merger or certain other business transactions with, or proposed by, any holder of 15 percent or more of our voting
        stock, except in cases where certain directors approve the transaction or certain minimum price criteria and other procedural requirements are met.</div>
      <div><br>
      </div>
      <div style="background-color: #FFFFFF;">
        <div>Provisions of our Certificate of Incorporation and Bylaws may delay or discourage transactions involving an actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise
          receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our Certificate of
          Incorporation and Bylaws:</div>
      </div>
      <div>&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageFooter"></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div id="DSPFPageHeader"></div>
      </div>
      <div><br>
      </div>
      <div style="background-color: #FFFFFF;">
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" id="z74b26221d45844959e7277cf9d279bce" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 36pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right; color: #000000;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div>permit our board of directors to issue up to 15,000,000 shares of Preferred Stock, with a<font style="color: #000000;">ny rights, preferences and privileges as they may designate;</font></div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div style="background-color: #FFFFFF;">
        <div><br>
        </div>
      </div>
      <div style="background-color: #FFFFFF;">
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" id="zc1aa7cd68e6e48ba91f91bdb4f32ffe8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 36pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right; color: #000000;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="color: #000000;">provide that the authorized number of directors shall be fixed exclusively by the board of directors;</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div style="background-color: #FFFFFF;">
        <div><br>
        </div>
      </div>
      <div style="background-color: #FFFFFF;">
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" id="ze723e6869c83432fb64879b70c99e612" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 36pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right; color: #000000;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="color: #000000;">provide that the board of directors or any individual director may only be removed with cause by the affirmative vote of the holders of at least a majority of the outstanding common stock or without cause by
                      the affirmative vote of the holders of at least 66-2/3% of the voting power of all of our then outstanding common stock;</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div><br>
        </div>
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" id="z146be5c8293042d491df012d87d4fae6" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 36pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right; color: #000000;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="color: #000000;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law or subject to the rights of holders of preferred stock as designated from time to time, be filled
                      by the affirmative vote of a majority of directors then in office, even if less than a quorum, unless the board of directors determines by resolution that any such vacancies or newly created directorships shall be filled by
                      stockholders;</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div style="background-color: #FFFFFF;">
        <div><br>
        </div>
      </div>
      <div style="background-color: #FFFFFF;">
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" id="zeccaf6d4035d4aa4a40d16dd685c32af" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 36pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right; color: #000000;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="color: #000000;">classifies our board of directors into three classes;</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div style="background-color: #FFFFFF;">
        <div><br>
        </div>
      </div>
      <div style="background-color: #FFFFFF;">
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" id="za5dc832ce1074cc9ac7acb520833cd38" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 36pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right; color: #000000;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="color: #000000;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent or electronic transmission;</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div style="background-color: #FFFFFF;">
        <div><br>
        </div>
      </div>
      <div style="background-color: #FFFFFF;">
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" id="zec81751bb0ce458da1b6cda8265829ad" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 36pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right; color: #000000;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="color: #000000;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a
                      timely manner and also specify requirements as to the form and content of a stockholder&#8217;s notice;</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div style="background-color: #FFFFFF;">
        <div><br>
        </div>
      </div>
      <div style="background-color: #FFFFFF;">
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" id="z58ea70f93317404b8f0c09c015223fd9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 36pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right; color: #000000;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="color: #000000;">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of Common Stock entitled to vote in any election of directors to elect all of the directors standing
                      for election, if they should so choose); and</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div style="background-color: #FFFFFF;">
        <div><br>
        </div>
      </div>
      <div style="background-color: #FFFFFF;">
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" id="z401497cc5494436090bd1d98bee19ac8" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 36pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top; align: right;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div><font style="color: #000000;">provide that special meetings of our stockholders may be called only by the ch</font>airman of the board, our Chief Executive Officer or by the board of directors pursuant to a resolution adopted by a
                      majority of the total number of authorized directors (whether or not there exists any vacancies).</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
      </div>
      <div style="background-color: #FFFFFF;">
        <div><br>
        </div>
        <div style="color: #000000;">The foregoing provisions may make it more difficult for our existing stockholders to replace our board of directors as well as for another party to obtain control of us by replacing our board of directors. Since our
          board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in management. In addition, the authorization of undesignated
          Preferred Stock makes it possible for our board of directors to issue Preferred Stock with voting or other rights or preferences that could impede the success of any attempt to change our control.</div>
        <div><br>
        </div>
        <div style="color: #000000;">These provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies and to discourage certain types of transactions that may involve an actual or
          threatened acquisition of us. These provisions are also designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect
          of discouraging others from making tender offers for our shares and may have the effect of deterring hostile takeovers or delaying changes in our control or management. As a consequence, these provisions also may inhibit fluctuations in the
          market price of our stock that could result from actual or rumored takeover attempts.</div>
      </div>
      <div style="color: #000000;">&#160;</div>
      <div id="DSPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div id="DSPFPageFooter"></div>
        <div id="DSPFPageBreak" style="page-break-after:always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        <div id="DSPFPageHeader"></div>
      </div>
      <br>
      <div style="background-color: #FFFFFF;">
        <div style="color: #000000; font-weight: bold;">Choice of Forum</div>
        <div><br>
        </div>
        <div style="color: #000000;">Our Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another state
          court located within the State of Delaware or, if no state court located within the State of Delaware has jurisdiction, the federal district court for the District of Delaware) shall, to the fullest extent permitted by law, be the sole and
          exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company; (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the
          Company&#8217;s stockholders; (iii) any action asserting a claim against the Company or any director or officer or other employee of the Company arising pursuant to any provision of the DGCL, the Certificate of Incorporation (as may be amended from
          time to time) or the Bylaws (as may be amended from time to time); and (iv) any action asserting a claim against the Company or any director or officer or other employee of the Company governed by the internal affairs doctrine. This choice of
          forum provision does not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended, or the Exchange Act, as amended, or any claim for which the federal courts have exclusive jurisdiction. Any person
          or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Company shall be deemed to have notice of and consented to the provisions of Article XV of the Bylaws.</div>
        <div style="color: #000000;"> <br>
        </div>
        <div style="color: #000000;"> <br>
        </div>
        <div style="color: #000000;">
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.70
<SEQUENCE>3
<FILENAME>exhibit10_70.htm
<DESCRIPTION>EXHIBIT 10.70
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using EDGARfilings PROfile 6.5.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  <div>
    <div style="text-align: right; font-weight: bold;"> Exhibit 10.70 </div>
    <div style="text-align: right; font-weight: bold;"> <br>
    </div>
    <div style="text-align: justify; font-weight: bold;"> <img src="image3.jpg"></div>
    <div style="text-align: justify; font-weight: bold;"> <br>
    </div>
    <div style="text-align: justify; font-weight: bold;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION HAS BEEN
      MARKED WITH &#8220;[***]&#8221;.</div>
    <div><br>
    </div>
    <div>October 4, 2019</div>
    <div><br>
    </div>
    <div>Pfizer Inc.</div>
    <div>235 East 42<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">nd</sup> Street</div>
    <div>New York, NY&#160; 10017</div>
    <div>Attention: Morris J. Birnbaum, M.D., Ph.D.</div>
    <div><br>
    </div>
    <div>Akcea Therapeutics, Inc.</div>
    <div>22 Boston Wharf Road</div>
    <div>9<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor</div>
    <div>Boston, MA 02210</div>
    <div>Attention: Damien McDevitt, Ph.D.</div>
    <div><br>
    </div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8c7893f15a8d4c75b911eaf7ca95a530">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top; align: right; font-weight: bold;">Re:</td>
              <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">AKCEA-ANGPTL3-L<sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">Rx</sub> License Agreement</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div>Dear Dr. Birnbaum and Dr. McDevitt:</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">This letter agreement (&#8220;<font style="font-weight: bold; font-style: italic;">Letter Agreement</font>&#8221;) is in reference to the License Agreement (the &#8220;<font style="font-weight: bold; font-style: italic;">Agreement</font>&#8221;),




      dated October 4, 2019, by and between Akcea Therapeutics, Inc. (&#8220;<font style="font-weight: bold; font-style: italic;">Akcea</font>&#8221;) and Pfizer Inc. (&#8220;<font style="font-weight: bold; font-style: italic;">Pfizer</font>&#8221;), which Agreement includes a
      sublicense of certain rights licensed by Akcea from its Affiliate, Ionis Pharmaceuticals, Inc. (&#8220;<font style="font-weight: bold; font-style: italic;">Ionis</font>&#8221;), under the Development, Commercialization and License Agreement, dated December 18,
      2015, by and between Ionis (formerly known as Isis Pharmaceuticals, Inc.) and Akcea (the &#8220;<font style="font-weight: bold; font-style: italic;">Ionis/Akcea License Agreement</font>&#8221;).&#160; Any capitalized terms not defined in this Letter Agreement will
      have the meanings set forth in the Agreement, unless expressly specified otherwise.&#160; This Letter Agreement will become effective on the Closing Date of the Agreement.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <u>Consent</u>.&#160; Pursuant to <u>Section 4.2</u> of the Ionis/Akcea License Agreement, Ionis hereby consents to Akcea entering into the Agreement.</div>
    <div>&#160;</div>
    <div><img src="image2.jpg"> </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div>
      <div>Morris J. Birnbaum, M.D., Ph.D.</div>
      <div>Damien McDevitt, Ph.D.</div>
      <div>October 4, 2019</div>
      <div>Page 2</div>
    </div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <u>Potential Follow-On Compounds</u>.&#160; After the Execution Date, subject to <u>Article 6</u> (Exclusivity) of the Agreement and the terms of this Letter Agreement, Ionis may conduct discovery activities on
      any compound, other than AKCEA-ANGPTL3-L<sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">Rx</sub>,<sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">&#160;</sub>that is designed to bind to the RNA that encodes
      ANGPTL3 (each such compound, a &#8220;<font style="font-weight: bold; font-style: italic;">Potential Follow-On Compound</font>&#8221;), and may conduct pre-clinical research and pre-clinical development on each such Potential Follow-On Compound.&#160; Ionis will
      provide written notice identifying and disclosing each Potential Follow-On Compound to Pfizer at each Development Update Meeting or sooner if a Potential Follow-On Compound has otherwise been identified.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <u>ROFN for Potential Follow-On Compound Collaboration</u>.&#160; At any time on or after the Closing Date through the expiration of the Exclusivity Period<sub style="vertical-align: bottom; line-height: 1; font-size: smaller;">&#160;</sub>(the &#8220;<font style="font-weight: bold; font-style: italic;">ROFN Period</font>&#8221;), Pfizer may, on a one-time basis for each Potential Follow-On Compound, send written notice to Ionis requesting that Ionis and Pfizer enter
      into a collaboration to conduct research to discover, identify and Exploit a Potential Follow-On Compound (such notice the &#8220;<font style="font-weight: bold; font-style: italic;">Collaboration Request Notice</font>&#8221;).&#160; Upon Ionis&#8217; receipt of the
      Collaboration Request Notice, Pfizer and Ionis will negotiate in good faith commercially reasonable terms for such collaboration for a period of not less than [***] days (the &#8220;<font style="font-weight: bold; font-style: italic;">Collaboration
        Negotiation Period</font>&#8221;).&#160; If Pfizer and Ionis cannot reach agreement during the Collaboration Negotiation Period, or if Pfizer does not exercise its right to negotiate under this paragraph 3 of this Letter Agreement before the expiration of the
      ROFN Period, then Ionis will have no further obligation to Pfizer under this paragraph 3 with respect to such Potential Follow-On Compound. For clarity, except as set forth in <u>Section 6.2.1</u> and <u>Section 6.2.2</u> of the Agreement, Ionis
      will not work independently or for or with any Third Party (including the grant of any license to any Third Party) with respect to the clinical development or Commercialization of a Potential Follow-On Compound until the Exclusivity Period expires.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <u>Attendance at Meetings between Akcea and Pfizer</u>.&#160; Ionis has the right, but not the obligation, to attend any meetings between Akcea and Pfizer described in <u>Schedule 4.1</u> (Project Management
      Activities) of the Agreement.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <u>Pfizer Designee to the Ionis/Akcea Joint Patent Committee</u>.&#160; Pfizer hereby designates [***], as Pfizer&#8217;s initial designee to the JPC (as such term is defined in the Ionis/Akcea License Agreement)
      solely with respect to the Product, pursuant to the last sentence of <u>Section 9.1.2</u> of the Ionis/Akcea License Agreement. Pfizer may replace its designee to the JPC (as such term is defined in the Ionis/Akcea License Agreement) at any time by
      written notice to Ionis and Akcea. For clarity, Pfizer&#8217;s designee to the JPC will not have any right to attend those portions of JPC meetings that do not concern the Product.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">6.&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <u>Ionis Covenants between Execution and Closing</u>.&#160; From the Execution Date and until the Closing Date or the earlier termination of the Agreement in accordance with <u>Article 13</u> (Term and
      Termination) of the Agreement, except as consented to in writing by Pfizer, (a) Ionis will conduct its business in the ordinary course of business consistent with past practice and in accordance with all applicable Laws with respect to the
      performance of its obligations under this Letter Agreement, and (b) Ionis will not (i) [***], and, in addition, will not [***]; (ii) [***]; and (iii) enter into, modify, extend, renew or amend any contract that by its terms expressly limits or
      impairs in any material manner the ability of Ionis to carry out its obligations under this Letter Agreement or the ability of Akcea to carry out its obligations under the License Agreement.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div>
      <div>
        <div>Morris J. Birnbaum, M.D., Ph.D.</div>
        <div>Damien McDevitt, Ph.D.</div>
        <div>October 4, 2019</div>
        <div>Page 3</div>
      </div>
    </div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <u>Intellectual Property</u>.&#160; Ionis will fulfill the obligations of Akcea as set forth in <u>Article 9</u> (Intellectual Property) of the Agreement, to the extent that Ionis, rather than Akcea, has the
      requisite rights to fulfill such obligations under the Ionis/Akcea License Agreement.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">8.&#160;&#160;&#160;&#160;&#160; &#160; &#160;&#160; <u>New Agreements</u>. Ionis will not enter into any new agreement or other obligation with any Third Party, or amend an existing agreement with any Third Party, in each case that restricts, limits or
      encumbers the rights granted to Pfizer under the Agreement.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">9.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Formulation or Delivery Technology</u>. If, after the Closing Date, Ionis or its Affiliates becomes the owner or otherwise acquires Control of any formulation or delivery technology that would be
      necessary or useful in order for Pfizer to further Develop, Commercialize or Exploit the Product, Ionis will make such technology available to Pfizer on commercially reasonable terms.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">10.&#160;&#160;&#160;&#160;&#160;&#160; &#160; <u>Application of Additional Provisions of the Agreement to Ionis</u>.</div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To the extent that Ionis is expressly referenced or is referenced in its capacity as an Affiliate of Akcea in the Additional Provisions, Ionis hereby agrees to be bound by and to comply with such provisions
      as if it was a Party to the Agreement for such purposes. Additionally, to the extent that Ionis is not expressly referenced in the Additional Provisions, Ionis hereby agrees to be bound by and to comply with such Additional Provisions as if it was a
      Party to the Agreement for such purposes.</div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;<font style="font-weight: bold; font-style: italic;">Additional Provisions</font>&#8221; means the following provisions of the Agreement: <u>Section 2.8.2</u> (Akcea Regulatory Transfer Cooperation), <u>Section
        2.9</u> (Technology Transfer), <u>Section 2.10</u> (Class Generic Claims for the Product), <u>Section 2.11.3</u> (Ionis&#8217; Internal Antisense Safety Database), <u>Section 3.2</u> (Manufacturing Transition Assistance), <u>Section 3.3</u> (Transfer
      of Existing Inventory), <u>Section 5.1</u> (License Grant), <u>Section 5.2</u> (Pfizer&#8217;s Sublicensing Rights), <u>Section 5.3</u> (Requests to Grant Sublicense to CMOs), <u>Article 6</u> (Exclusivity Provisions), <u>Article 10</u>
      (Confidentiality) and <u>Article 11</u> (Representations and Warranties), <font style="font-style: italic;">provided, however</font>, that the [***] hours of no-cost manufacturing transition assistance set forth in <u>Section 3.2</u>
      (Manufacturing Transition Assistance) of the Agreement and the [***] hours of no-cost regulatory transfer assistance set forth in <u>Section 2.8.2</u> (Akcea Regulatory Transfer Cooperation) of the Agreement are aggregate caps such that hours
      contributed by Ionis or Akcea will count toward each such cap, as applicable.</div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Article 14</u> (Miscellaneous) and <u>Section 13.4</u> of the Agreement shall apply to this Letter Agreement <font style="font-style: italic;">mutatis mutandis</font>.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">11.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Indemnification</u>.</div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Ionis is an intended third party beneficiary with respect to <u>Section 12.1</u> (Indemnification by Pfizer) of the Agreement.</div>
    <div><br>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div>
      <div>
        <div>
          <div>Morris J. Birnbaum, M.D., Ph.D.</div>
          <div>Damien McDevitt, Ph.D.</div>
          <div>October 4, 2019</div>
          <div>Page 4<br>
          </div>
        </div>
      </div>
    </div>
    <div>&#160;</div>
    <div style="text-indent: 72pt;">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Ionis hereby agrees to defend, and indemnify and hold harmless, the Pfizer Indemnified Parties from and against any and all Losses, to the extent arising out of or resulting from any Third Party Claims to
      the extent based upon:</div>
    <div><br>
    </div>
    <div style="text-indent: 108pt;">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;any breach of any representation, warranty or covenant made by Ionis in this Letter Agreement;</div>
    <div><br>
    </div>
    <div style="text-indent: 108pt;">(ii)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; the Exploitation of the Product by Ionis or its Affiliates, subcontractors or Sublicensees, to the extent applicable; or</div>
    <div><br>
    </div>
    <div style="text-indent: 108pt;">(iii)&#160;&#160;&#160;&#160;&#160;&#160;&#160; the gross negligence or willful misconduct by Ionis in the exercise of its rights or performance of its obligations hereunder;</div>
    <div><br>
    </div>
    <div><font style="font-style: italic;">provided</font> that, in the case of each of paragraph 11(b)(i) through 11(b)(iii) above, Ionis will not be obligated to so defend, and indemnify and hold harmless, the Pfizer Indemnified Parties for any Third
      Party Claims to the extent that Pfizer has an obligation to indemnify the Akcea Indemnified Parties under <u>Section 12.1</u> (Indemnification by Pfizer) of the Agreement.</div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Section 12.3</u> (Procedure) and <u>Section 12.5</u> (Damages Waiver) of the Agreement shall apply to this Letter Agreement <font style="font-style: italic;">mutatis mutandis</font>.</div>
    <div><br>
    </div>
    <div style="text-indent: 72pt;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in the Agreement or this Letter Agreement, Pfizer&#8217;s obligation to indemnify Ionis pursuant to paragraph 11(a) of this Letter Agreement is not duplicative of or in
      addition to Pfizer&#8217;s indemnification obligation pursuant to <u>Section 12.1</u> (Indemnification by Pfizer) of the Agreement. For the avoidance of doubt, neither this Letter Agreement nor the Agreement shall permit a duplicate claim for
      indemnification or a duplicate payment of Losses arising from the same facts and circumstances giving rise to a pending or previously made claim for indemnification as a claim for indemnification pursuant to either paragraph 11(a) of this Letter
      Agreement or <u>Section 12.1</u> (Indemnification by Pfizer) of the Agreement.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">12.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Incorporation by Reference</u>.&#160; <u>Article 1</u> (Definitions) is hereby incorporated herein by reference with the same force and effect as though fully set forth herein.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">13.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Term</u>.&#160; The term of this Side Letter Agreement will be the Term under the Agreement.</div>
    <div><br>
    </div>
    <div style="text-indent: 36pt;">14.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <u>Effect of Termination of the Agreement</u>. If the Agreement terminates for any reason, Pfizer will, from the effective date of such termination, automatically become a direct licensee of Ionis with
      respect to the rights licensed to Pfizer by Akcea on the terms substantially the same as the terms set forth in the Agreement.</div>
    <div><br>
    </div>
    <div style="text-align: center; font-style: italic;"><font style="font-weight: bold;">[</font>Signature page to follow<font style="font-weight: bold;">]</font></div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" id="DSPFPageBreakArea">
      <div style="page-break-after:always;" id="DSPFPageBreak">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div>
      <div>Morris J. Birnbaum, M.D., Ph.D.</div>
      <div>Damien McDevitt, Ph.D.</div>
      <div>October 4, 2019</div>
      <div>Page 5<br>
      </div>
    </div>
    <div>&#160;</div>
    <div style="text-indent: 36pt;">If the terms of this Letter Agreement are acceptable, please so indicate by executing a copy of this Letter Agreement and returning it to Ionis.</div>
    <div><br>
    </div>
    <div>Very truly yours,</div>
    <div><br>
    </div>
    <div>/s/Brett Monia</div>
    <div>Brett Monia</div>
    <div>Chief Operating Officer</div>
    <div>IONIS PHARMACEUTICALS, INC.</div>
    <div><br>
    </div>
    <div style="font-weight: bold;"><u>AGREED TO AND CONFIRMED BY AKCEA THERAPEUTICS, INC.</u>:</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z92b307332e444bb6ab074970bd0f6c34">

        <tr>
          <td rowspan="1" style="width: 50%; vertical-align: top;">
            <div>By:<u>/s/Damien McDevitt</u></div>
          </td>
          <td style="width: 50%; vertical-align: top;"><br>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>Name:</div>
          </td>
          <td style="width: 45%; vertical-align: top;">
            <div>Damien McDevitt</div>
          </td>
          <td style="width: 50%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>Title:</div>
          </td>
          <td style="width: 45%; vertical-align: top;">
            <div>Interim Chief Executive Officer</div>
          </td>
          <td style="width: 50%; vertical-align: top;"><br>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="font-weight: bold;"><u>AGREED TO AND CONFIRMED BY PFIZER INC.</u>:</div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);" id="z5ec82eceef1f484881d5b6fb02cf99c6">

        <tr>
          <td rowspan="1" style="width: 50%; vertical-align: top;">
            <div>By:<u>/s/Morris J. Birnbaum</u></div>
          </td>
          <td style="width: 50%; vertical-align: top;"><br>
          </td>
        </tr>

    </table>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">

        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>Name:</div>
          </td>
          <td style="width: 45%; vertical-align: top;">
            <div>Morris J. Birnbaum</div>
          </td>
          <td style="width: 50%; vertical-align: top;"><br>
          </td>
        </tr>
        <tr>
          <td style="width: 5%; vertical-align: top;">
            <div>Title:</div>
          </td>
          <td style="width: 45%; vertical-align: top;">
            <div>SVP-CSO, Internal Medicine</div>
          </td>
          <td style="width: 50%; vertical-align: top;"><br>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
    <div><br>
    </div>
    <div>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>exhibit21_1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<html>
  <head>
    <title>&#160;</title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using EDGARfilings PROfile 6.5.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
  <div id="TRGRSegment:f499a0ae-02f9-48a9-add8-20f1dcaf844d"><br>
    <div>
      <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit&#160;21.1</div>
      <div style="text-align: right;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </font><br>
      </div>
      <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">LIST OF SUBSIDIARIES FOR THE REGISTRANT</div>
      <div><br>
      </div>
      <div style="text-align: center;"><font style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> </font><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea Therapeutics, Inc., a Delaware Corporation</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea Therapeutics Canada Inc., a Canadian Corporation</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea Therapeutics France SAS, a French Company</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea Therapeutics Germany GmbH, a German Corporation</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea Therapeutics UK Limited, a United Kingdom Limited Private Company</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea Securities Corporation., a Massachusetts Corporation</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea Therapeutics Ireland Limited, an Irish Private Company</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea Therapeutics Portugal, Unipessoal Lda, a Portuguese Company</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea Therapeutics Spain SL, a Spanish Company</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea Therapeutics Italia SRL, an Italian Company</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Isis USA Limited, a United Kingdom Limited Private Company</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Osprey Therapeutics, Inc., a Delaware Corporation</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">PerIsis I Development Corporation, a Delaware Corporation</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Symphony GenIsis,&#160;Inc., a Delaware Corporation</div>
      <div><br>
      </div>
      <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis Development (Ireland) Limited, an Irish Private Company</div>
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>exhibit23_1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title>&#160;</title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using EDGARfilings PROfile 6.5.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
  <div id="TRGRSegment:b8cd2a2a-2f7b-470b-8887-e5b31a337448">
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit&#160;23.1</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We consent to the incorporation by reference in the Registration Statements on Form&#160;S-3 (Nos.&#160;333-71911, 333-90811, 333-38844, 333-71116, 333-71176,
      333-89066, 333-89626, 333-128156, 333-130639, 333-134380, 333-141447, 333-151076, 333-188407 and 333-217422) and in the related Prospectuses, as applicable, and in the Registration Statements on Form&#160;S-8 (Nos.333-05825, 333-55683, 333-40336,
      333-59296, 333-91572, 333-106859, 333-116962, 333-125911, 333-133853, 333-142777, 333-151996, 333-160269, 333-168674, 333-176136, 333-184788, 333-190408, 333-207900, 333-219801 and 333-233143) of Ionis Pharmaceuticals,&#160;Inc. of our reports dated
      February 26, 2020, with respect to the consolidated financial statements of Ionis Pharmaceuticals,&#160;Inc. and the effectiveness of internal control over financial reporting of Ionis Pharmaceuticals,&#160;Inc. included in this Annual Report (Form&#160;10-K) for
      the year ended December&#160;31, 2019.</div>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z6a67acf6d0bc4e098a2d1ab09e8dc180" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50.57%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 1pt;">&#160;</div>
          </td>
          <td style="width: 49.43%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ ERNST&#160;&amp; YOUNG LLP</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50.57%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 49.43%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50.57%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">San Diego, California</div>
          </td>
          <td style="width: 49.43%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 1pt;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50.57%; vertical-align: top;">March 2, 2020<br>
          </td>
          <td style="width: 49.43%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 1pt;">&#160;</div>
          </td>
        </tr>

    </table>
    <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>exhibit31_1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
  <head>
    <title>&#160;</title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using EDGARfilings PROfile 6.5.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
  <div id="TRGRSegment:27688458-8a95-448c-9822-a3a5e0da6065">
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit 31.1</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">CERTIFICATION</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">I, Brett P. Monia, certify that:</div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc704652642144c9c9ebcef736d4a3104">

          <tr>
            <td style="width: 27pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">I have reviewed this Annual Report on Form 10-K of Ionis Pharmaceuticals, Inc.;</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z32880994535447bbacc0613221b0384f">

          <tr>
            <td style="width: 27pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
                make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z7a8b8d16a0c048b0a841d6a2450131da">

          <tr>
            <td style="width: 27pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Based on my knowledge, the consolidated financial statements, and other financial information included in this annual report, fairly present in
                all material respects the financial condition, consolidated results of operations and consolidated cash flows of the registrant as of, and for, the periods presented in this annual report;</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc2b1383339594fe58e1309e91b578aaf">

          <tr>
            <td style="width: 27pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
                in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z006ba4704cdc4f32acce3be2d5211c1d">

          <tr>
            <td style="width: 45pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">a)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
                ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z22f2a6249bf749238c0ed91dc5a3fa4c">

          <tr>
            <td style="width: 45pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">b)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
                supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za9dc216f15bc49efab18ecb6e31f8119">

          <tr>
            <td style="width: 45pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">c)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the
                effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze78e3515ffa941b897bad5585d95ce02">

          <tr>
            <td style="width: 45pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">d)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most
                recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0ba8f108766844199832b71012e746d6">

          <tr>
            <td style="width: 27pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
                to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zfb8fe5cd3bfb450797f9e654eb0baea2">

          <tr>
            <td style="width: 45pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">a)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
                likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd90a2ca131bb45ce8a1e439147ca2121">

          <tr>
            <td style="width: 45pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">b)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control
                over financial reporting.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zbb2c9594bc8c45c98b5cd97034dc94ca">

        <tr>
          <td style="width: 41.41%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dated: March 2, 2020</div>
          </td>
          <td style="width: 58.59%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 41.41%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 58.59%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 41.41%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ BRETT P. MONIA<br>
            </div>
          </td>
          <td style="width: 58.59%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 41.41%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Brett P. Monia, Ph.D.</div>
          </td>
          <td style="width: 58.59%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 41.41%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Chief Executive Officer</div>
          </td>
          <td style="width: 58.59%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>exhibit31_2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
  <head>
    <title>&#160;</title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using EDGARfilings PROfile 6.5.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
  <div id="TRGRSegment:f325a129-9b94-442a-a705-509884803066">
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit 31.2</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">CERTIFICATION</div>
    <div><br>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">I, Elizabeth L. Hougen, certify that:</div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="ze28ff8054b97421a8d95ac64b8b11406">

          <tr>
            <td style="width: 27pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">I have reviewed this Annual Report on Form 10-K of Ionis Pharmaceuticals, Inc.;</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z242d60040f2645ea9dca8608726d68db">

          <tr>
            <td style="width: 27pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to
                make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd301adfa538d47f38a3df8bca8a163b1">

          <tr>
            <td style="width: 27pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Based on my knowledge, the consolidated financial statements, and other financial information included in this annual report, fairly present in
                all material respects the financial condition, consolidated results of operations and consolidated cash flows of the registrant as of, and for, the periods presented in this annual report;</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd85364f1dc5a40c6a8fc5f2d1ad37386">

          <tr>
            <td style="width: 27pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
                in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zea7bfa9c004840a7939f5aa9e5924995">

          <tr>
            <td style="width: 45pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">a)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
                ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z9b59769a5896469cad8e9bdf482d78d7">

          <tr>
            <td style="width: 45pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">b)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
                supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z1feda61f15cf49ce9dc40f242c58dede">

          <tr>
            <td style="width: 45pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">c)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the
                effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zeb1871a334cb475eba81333b85083186">

          <tr>
            <td style="width: 45pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">d)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most
                recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3740e14d55074afdbc1df77e993b2b91">

          <tr>
            <td style="width: 27pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
                to the registrant&#8217;s auditors and the audit committee of registrant&#8217;s board of directors (or persons performing the equivalent functions):</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zc1974665462e45c1bea9834fe75724d5">

          <tr>
            <td style="width: 45pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">a)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
                likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</div>
            </td>
          </tr>

      </table>
    </div>
    <div><br>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd2cc9e8bb4a44ea6b73d4ccb6c7834d2">

          <tr>
            <td style="width: 45pt; vertical-align: top; align: right;">
              <div style="text-align: left; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">b)</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control
                over financial reporting.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;&#160;</div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z606152edc4bf450f8ba4fbfea05c0a0d">

        <tr>
          <td style="width: 41.23%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dated: March 2, 2020</div>
          </td>
          <td style="width: 58.77%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 41.23%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 58.77%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 41.23%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ ELIZABETH L. HOUGEN</div>
          </td>
          <td style="width: 58.77%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 41.23%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Elizabeth L. Hougen</div>
          </td>
          <td style="width: 58.77%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 41.23%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Chief Financial Officer</div>
          </td>
          <td style="width: 58.77%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
        </tr>

    </table>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>8
<FILENAME>exhibit32_1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
  <head>
    <title>&#160;</title>
    <!-- Licensed to: Summit, a Broadridge Company
         Document created using EDGARfilings PROfile 6.5.1.0
         Copyright 1995 - 2020 Broadridge -->
  </head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
  <div id="TRGRSegment:6efc6d20-d43f-45b4-aa04-090d35475d75">
    <div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Exhibit 32.1</div>
    <div><br>
    </div>
    <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">CERTIFICATION</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pursuant to the requirement set forth in Rule&#160;13a-14(b)&#160;of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and
      Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18&#160;U.S.C. &#167;1350),&#160; Brett P. Monia, the Chief Executive Officer of Ionis Pharmaceuticals, Inc., (the &#8220;Company&#8221;), and Elizabeth L. Hougen, the Chief Financial Officer of the Company,
      each hereby certifies that, to the best of his or her knowledge:</div>
    <div><br>
    </div>
    <div style="text-align: justify;">
      <div>
        <table cellspacing="0" cellpadding="0" id="z027d6370a1cb477ead0cf34502433e26" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt;"></td>
              <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2019, to which this Certification is attached as Exhibit 32.1 (the &#8220;Annual Report&#8221;), fully
                  complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div style="text-align: justify;">
      <div>
        <table cellspacing="0" cellpadding="0" id="zf7eb4ec57f3641a6a822cbe4c4ac1971" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 18pt;"></td>
              <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The information contained in the Annual Report fairly presents, in all material respects, the financial condition of the Company at the end of the period covered by
                  the Annual Report and the results of operations of the Company for the period covered by the Annual Report.</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <table cellspacing="0" cellpadding="0" id="z667bf9e09b47421ebd0eb954f419aa9f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 40.1%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><a name="z67c7d4b1a5524f7095e3a56b8ca645e7"><!--Anchor--></a>Dated: March 2, 2020</div>
          </td>
          <td style="width: 9.69%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 40.28%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 9.92%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 40.1%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 9.69%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 40.28%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 9.92%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 40.1%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ BRETT P. MONIA<br>
            </div>
          </td>
          <td style="width: 9.69%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 40.28%; vertical-align: top; border-bottom: #000000 2px solid;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">/s/ ELIZABETH L. HOUGEN</div>
          </td>
          <td style="width: 9.92%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 40.1%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Brett P. Monia, Ph.D.</div>
          </td>
          <td style="width: 9.69%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 40.28%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Elizabeth L. Hougen</div>
          </td>
          <td style="width: 9.92%; vertical-align: top;">&#160;</td>
        </tr>
        <tr>
          <td style="width: 40.1%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Chief Executive Officer</div>
          </td>
          <td style="width: 9.69%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;</div>
          </td>
          <td style="width: 40.28%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Chief Financial Officer</div>
          </td>
          <td style="width: 9.92%; vertical-align: top;">&#160;</td>
        </tr>

    </table>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A signed original of this written statement required by Section 906 has been provided to Ionis Pharmaceuticals, Inc. and will be
      retained by Ionis Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</div>
    <div><br>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">This certification accompanies the Form&#160;10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is
      not to be incorporated by reference into any filing of Ionis Pharmaceuticals,&#160;Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form&#160;10-K), irrespective
      of any general incorporation language contained in such filing.</div>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>ions-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 6.2.0.0 Broadridge-->
<xs:schema targetNamespace="http://isispharm.com/20191231" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:ions="http://isispharm.com/20191231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ions-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://isispharm.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>010000 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
        <!--Parent Role: CONSOLIDATED BALANCE SHEETS-->
        <link:definition>010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
        <link:definition>020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" id="ConsolidatedStatementsOfComprehensiveIncomeLoss">
        <link:definition>030000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity" id="ConsolidatedStatementsOfStockholdersEquity">
        <link:definition>040000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" id="ConsolidatedStatementsOfStockholdersEquityParenthetical">
        <!--Parent Role: CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY-->
        <link:definition>040100 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>050000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" id="ConsolidatedStatementsOfCashFlowsParenthetical">
        <!--Parent Role: CONSOLIDATED STATEMENTS OF CASH FLOWS-->
        <link:definition>050100 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPolicies" id="OrganizationAndSignificantAccountingPolicies">
        <link:definition>060100 - Disclosure - Organization and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/Investments" id="Investments">
        <link:definition>060200 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/LongtermObligationsAndCommitments" id="LongtermObligationsAndCommitments">
        <link:definition>060300 - Disclosure - Long-Term Obligations and Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>060400 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>060500 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreements" id="CollaborativeArrangementsAndLicensingAgreements">
        <link:definition>060600 - Disclosure - Collaborative Arrangements and Licensing Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRisk" id="SegmentInformationAndConcentrationOfBusinessRisk">
        <link:definition>060700 - Disclosure - Segment Information and Concentration of Business Risk</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/EmploymentBenefits" id="EmploymentBenefits">
        <link:definition>060800 - Disclosure - Employment Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/LegalProceedings" id="LegalProceedings">
        <link:definition>060900 - Disclosure - Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/QuarterlyFinancialDataUnaudited" id="QuarterlyFinancialDataUnaudited">
        <link:definition>061000 - Disclosure - Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" id="OrganizationAndSignificantAccountingPoliciesPolicies">
        <!--Parent Role: Organization and Significant Accounting Policies-->
        <link:definition>070100 - Disclosure - Organization and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesTables" id="OrganizationAndSignificantAccountingPoliciesTables">
        <!--Parent Role: Organization and Significant Accounting Policies-->
        <link:definition>080100 - Disclosure - Organization and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/InvestmentsTables" id="InvestmentsTables">
        <!--Parent Role: Investments-->
        <link:definition>080200 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsTables" id="LongtermObligationsAndCommitmentsTables">
        <!--Parent Role: Long-Term Obligations and Commitments-->
        <link:definition>080300 - Disclosure - Long-Term Obligations and Commitments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
        <!--Parent Role: Stockholders' Equity-->
        <link:definition>080400 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <!--Parent Role: Income Taxes-->
        <link:definition>080500 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables" id="CollaborativeArrangementsAndLicensingAgreementsTables">
        <!--Parent Role: Collaborative Arrangements and Licensing Agreements-->
        <link:definition>080600 - Disclosure - Collaborative Arrangements and Licensing Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskTables" id="SegmentInformationAndConcentrationOfBusinessRiskTables">
        <!--Parent Role: Segment Information and Concentration of Business Risk-->
        <link:definition>080700 - Disclosure - Segment Information and Concentration of Business Risk (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/QuarterlyFinancialDataUnauditedTables" id="QuarterlyFinancialDataUnauditedTables">
        <!--Parent Role: Quarterly Financial Data (Unaudited)-->
        <link:definition>081000 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails" id="OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails">
        <!--Parent Role: Organization and Significant Accounting Policies-->
        <link:definition>090100 - Disclosure - Organization and Significant Accounting Policies, Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails" id="OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails">
        <!--Parent Role: Organization and Significant Accounting Policies-->
        <link:definition>090102 - Disclosure - Organization and Significant Accounting Policies, Basic and Diluted Net Income per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails" id="OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails">
        <!--Parent Role: Organization and Significant Accounting Policies-->
        <link:definition>090104 - Disclosure - Organization and Significant Accounting Policies, Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesContractsReceivableDetails" id="OrganizationAndSignificantAccountingPoliciesContractsReceivableDetails">
        <!--Parent Role: Organization and Significant Accounting Policies-->
        <link:definition>090106 - Disclosure - Organization and Significant Accounting Policies, Contracts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesDeferredRevenueDetails" id="OrganizationAndSignificantAccountingPoliciesDeferredRevenueDetails">
        <!--Parent Role: Organization and Significant Accounting Policies-->
        <link:definition>090108 - Disclosure - Organization and Significant Accounting Policies, Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesCostOfProductsSoldDetails" id="OrganizationAndSignificantAccountingPoliciesCostOfProductsSoldDetails">
        <!--Parent Role: Organization and Significant Accounting Policies-->
        <link:definition>090110 - Disclosure - Organization and Significant Accounting Policies, Cost of Products Sold (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails" id="OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails">
        <!--Parent Role: Organization and Significant Accounting Policies-->
        <link:definition>090112 - Disclosure - Organization and Significant Accounting Policies, Research, Development and Patent Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails" id="OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails">
        <!--Parent Role: Organization and Significant Accounting Policies-->
        <link:definition>090114 - Disclosure - Organization and Significant Accounting Policies, Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails" id="OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails">
        <!--Parent Role: Organization and Significant Accounting Policies-->
        <link:definition>090116 - Disclosure - Organization and Significant Accounting Policies, Noncontrolling Interest in Akcea Therapeutics, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndInvestmentsDetails" id="OrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndInvestmentsDetails">
        <!--Parent Role: Organization and Significant Accounting Policies-->
        <link:definition>090118 - Disclosure - Organization and Significant Accounting Policies, Cash, Cash Equivalents and Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails" id="OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails">
        <!--Parent Role: Organization and Significant Accounting Policies-->
        <link:definition>090120 - Disclosure - Organization and Significant Accounting Policies, Inventory Valuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" id="OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails">
        <!--Parent Role: Organization and Significant Accounting Policies-->
        <link:definition>090122 - Disclosure - Organization and Significant Accounting Policies, Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLeasesDetails" id="OrganizationAndSignificantAccountingPoliciesLeasesDetails">
        <!--Parent Role: Organization and Significant Accounting Policies-->
        <link:definition>090124 - Disclosure - Organization and Significant Accounting Policies, Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLonglivedAssetsDetails" id="OrganizationAndSignificantAccountingPoliciesLonglivedAssetsDetails">
        <!--Parent Role: Organization and Significant Accounting Policies-->
        <link:definition>090126 - Disclosure - Organization and Significant Accounting Policies, Long-Lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesStockbasedCompensationExpenseDetails" id="OrganizationAndSignificantAccountingPoliciesStockbasedCompensationExpenseDetails">
        <!--Parent Role: Organization and Significant Accounting Policies-->
        <link:definition>090128 - Disclosure - Organization and Significant Accounting Policies, Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails" id="OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails">
        <!--Parent Role: Organization and Significant Accounting Policies-->
        <link:definition>090130 - Disclosure - Organization and Significant Accounting Policies, Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesConvertibleDebtDetails" id="OrganizationAndSignificantAccountingPoliciesConvertibleDebtDetails">
        <!--Parent Role: Organization and Significant Accounting Policies-->
        <link:definition>090132 - Disclosure - Organization and Significant Accounting Policies, Convertible Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesSegmentInformationDetails" id="OrganizationAndSignificantAccountingPoliciesSegmentInformationDetails">
        <!--Parent Role: Organization and Significant Accounting Policies-->
        <link:definition>090134 - Disclosure - Organization and Significant Accounting Policies, Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails" id="OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails">
        <!--Parent Role: Organization and Significant Accounting Policies-->
        <link:definition>090136 - Disclosure - Organization and Significant Accounting Policies, Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails" id="InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails">
        <!--Parent Role: Investments-->
        <link:definition>090200 - Disclosure - Investments, Contract Maturity of Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails" id="InvestmentsSummaryOfInvestmentsDetails">
        <!--Parent Role: Investments-->
        <link:definition>090202 - Disclosure - Investments, Summary of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails" id="InvestmentsInvestmentsTemporarilyImpairedDetails">
        <!--Parent Role: Investments-->
        <link:definition>090204 - Disclosure - Investments, Investments Temporarily Impaired (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetailsCalc2" id="InvestmentsSummaryOfInvestmentsDetailsCalc2">
        <!--Parent Role: Investments, Summary of Investments (Details)-->
        <link:definition>090204 - Disclosure - Investments, Summary of Investments (Details) Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails" id="LongtermObligationsAndCommitmentsLongtermObligationsDetails">
        <!--Parent Role: Long-Term Obligations and Commitments-->
        <link:definition>090300 - Disclosure - Long-Term Obligations and Commitments, Long-Term Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsDetailsCalc2" id="LongtermObligationsAndCommitmentsDetailsCalc2">
        <!--Parent Role: Long-Term Obligations and Commitments, Long-Term Obligations (Details)-->
        <link:definition>090302 - Disclosure - Long-Term Obligations and Commitments (Details) Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails" id="LongtermObligationsAndCommitmentsConvertibleNotesDetails">
        <!--Parent Role: Long-Term Obligations and Commitments-->
        <link:definition>090302 - Disclosure - Long-Term Obligations and Commitments, Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails" id="LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails">
        <!--Parent Role: Long-Term Obligations and Commitments-->
        <link:definition>090304 - Disclosure - Long-Term Obligations and Commitments, Line of Credit Arrangement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails" id="LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails">
        <!--Parent Role: Long-Term Obligations and Commitments-->
        <link:definition>090306 - Disclosure - Long-Term Obligations and Commitments, Research and Development and Manufacturing Facilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails" id="LongtermObligationsAndCommitmentsMaturitySchedulesDetails">
        <!--Parent Role: Long-Term Obligations and Commitments-->
        <link:definition>090308 - Disclosure - Long-Term Obligations and Commitments, Maturity Schedules (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails" id="LongtermObligationsAndCommitmentsOperatingLeasesDetails">
        <!--Parent Role: Long-Term Obligations and Commitments-->
        <link:definition>090310 - Disclosure - Long-Term Obligations and Commitments, Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/OperatingLeasesDetailsCalc01" id="OperatingLeasesDetailsCalc01">
        <!--Parent Role: Long-Term Obligations and Commitments, Operating Leases (Details)-->
        <link:definition>090312 - Disclosure - Operating Leases (Details) CALC 01</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails" id="StockholdersEquityPreferredAndCommonStockDetails">
        <!--Parent Role: Stockholders' Equity-->
        <link:definition>090400 - Disclosure - Stockholders' Equity, Preferred and Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/StockholdersEquityShareRepurchaseProgramDetails" id="StockholdersEquityShareRepurchaseProgramDetails">
        <!--Parent Role: Stockholders' Equity-->
        <link:definition>090402 - Disclosure - Stockholders' Equity, Share Repurchase Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/StockholdersEquityStockPlansDetails" id="StockholdersEquityStockPlansDetails">
        <!--Parent Role: Stockholders' Equity-->
        <link:definition>090404 - Disclosure - Stockholders' Equity, Stock Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails" id="StockholdersEquityStockOptionActivityDetails">
        <!--Parent Role: Stockholders' Equity-->
        <link:definition>090406 - Disclosure - Stockholders' Equity, Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails" id="StockholdersEquityRestrictedStockUnitActivityDetails">
        <!--Parent Role: Stockholders' Equity-->
        <link:definition>090408 - Disclosure - Stockholders' Equity, Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" id="StockholdersEquityStockbasedCompensationExpenseDetails">
        <!--Parent Role: Stockholders' Equity-->
        <link:definition>090410 - Disclosure - Stockholders' Equity, Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails" id="StockholdersEquityStockbasedValuationInformationDetails">
        <!--Parent Role: Stockholders' Equity-->
        <link:definition>090412 - Disclosure - Stockholders' Equity, Stock-based Valuation Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" id="IncomeTaxesIncomeLossBeforeIncomeTaxesDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>090500 - Disclosure - Income Taxes, Income (Loss) Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" id="IncomeTaxesIncomeTaxExpenseBenefitDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>090502 - Disclosure - Income Taxes, Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails" id="IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>090504 - Disclosure - Income Taxes, Reconciliation of Statutory to Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" id="IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>090506 - Disclosure - Income Taxes, Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/IncomeTaxesTaxCreditCarryforwardsDetails" id="IncomeTaxesTaxCreditCarryforwardsDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>090508 - Disclosure - Income Taxes, Tax Credit Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/IncomeTaxesTaxActDetails" id="IncomeTaxesTaxActDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>090510 - Disclosure - Income Taxes, Tax Act (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails" id="IncomeTaxesGrossUnrecognizedTaxBenefitsDetails">
        <!--Parent Role: Income Taxes-->
        <link:definition>090512 - Disclosure - Income Taxes, Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails" id="CollaborativeArrangementsAndLicensingAgreementsBiogenDetails">
        <!--Parent Role: Collaborative Arrangements and Licensing Agreements-->
        <link:definition>090600 - Disclosure - Collaborative Arrangements and Licensing Agreements, Biogen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails" id="CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails">
        <!--Parent Role: Collaborative Arrangements and Licensing Agreements-->
        <link:definition>090602 - Disclosure - Collaborative Arrangements and Licensing Agreements, AstraZeneca (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails" id="CollaborativeArrangementsAndLicensingAgreementsBayerDetails">
        <!--Parent Role: Collaborative Arrangements and Licensing Agreements-->
        <link:definition>090604 - Disclosure - Collaborative Arrangements and Licensing Agreements, Bayer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails" id="CollaborativeArrangementsAndLicensingAgreementsGskDetails">
        <!--Parent Role: Collaborative Arrangements and Licensing Agreements-->
        <link:definition>090606 - Disclosure - Collaborative Arrangements and Licensing Agreements, GSK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails" id="CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails">
        <!--Parent Role: Collaborative Arrangements and Licensing Agreements-->
        <link:definition>090608 - Disclosure - Collaborative Arrangements and Licensing Agreements, Janssen Biotech, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails" id="CollaborativeArrangementsAndLicensingAgreementsRocheDetails">
        <!--Parent Role: Collaborative Arrangements and Licensing Agreements-->
        <link:definition>090610 - Disclosure - Collaborative Arrangements and Licensing Agreements, Roche (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails" id="CollaborativeArrangementsAndLicensingAgreementsNovartisDetails">
        <!--Parent Role: Collaborative Arrangements and Licensing Agreements-->
        <link:definition>090612 - Disclosure - Collaborative Arrangements and Licensing Agreements, Novartis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails" id="CollaborativeArrangementsAndLicensingAgreementsPfizerDetails">
        <!--Parent Role: Collaborative Arrangements and Licensing Agreements-->
        <link:definition>090614 - Disclosure - Collaborative Arrangements and Licensing Agreements, Pfizer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails" id="CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails">
        <!--Parent Role: Collaborative Arrangements and Licensing Agreements-->
        <link:definition>090616 - Disclosure - Collaborative Arrangements and Licensing Agreements, PTC Therapeutics (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails" id="SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails">
        <!--Parent Role: Segment Information and Concentration of Business Risk-->
        <link:definition>090700 - Disclosure - Segment Information and Concentration of Business Risk, Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails" id="SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails">
        <!--Parent Role: Segment Information and Concentration of Business Risk-->
        <link:definition>090702 - Disclosure - Segment Information and Concentration of Business Risk, Contracts Receivable from Significant Partners (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/EmploymentBenefitsDetails" id="EmploymentBenefitsDetails">
        <!--Parent Role: Employment Benefits-->
        <link:definition>090800 - Disclosure - Employment Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails" id="QuarterlyFinancialDataUnauditedDetails">
        <!--Parent Role: Quarterly Financial Data (Unaudited)-->
        <link:definition>091000 - Disclosure - Quarterly Financial Data (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xs:element name="CollaborativeArrangementsAndLicensingAgreementsAbstract" id="ions_CollaborativeArrangementsAndLicensingAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LongTermDebtAndOtherObligationsNoncurrent" id="ions_LongTermDebtAndOtherObligationsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="LeasesAndOtherObligationsMember" id="ions_LeasesAndOtherObligationsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FixedRateNoteWithMorganStanleyMember" id="ions_FixedRateNoteWithMorganStanleyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LongTermMortgageDebtMember" id="ions_LongTermMortgageDebtMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LongTermDebtAndOtherObligations" id="ions_LongTermDebtAndOtherObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ConvertibleSeniorNotes1PercentMember" id="ions_ConvertibleSeniorNotes1PercentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ConvertibleSeniorNotes0125PercentMember" id="ions_ConvertibleSeniorNotes0125PercentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MorganStanleyPrivateBankNationalAssociationMember" id="ions_MorganStanleyPrivateBankNationalAssociationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SharesReceivedFromSubsidiaryForLicenseOfDrug" id="ions_SharesReceivedFromSubsidiaryForLicenseOfDrug" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AkceaTherapeuticsIncMember" id="ions_AkceaTherapeuticsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OfficeSpaceSubleasedToAkceaTherapeuticsIncMember" id="ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LesseeOperatingLeasePeriodOfFreeRent" id="ions_LesseeOperatingLeasePeriodOfFreeRent" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LesseeOperatingLeaseAllowanceForTenantImprovements" id="ions_LesseeOperatingLeaseAllowanceForTenantImprovements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="OfficeSpaceForCorporateHeadquartersMember" id="ions_OfficeSpaceForCorporateHeadquartersMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate" id="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate" id="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember" id="ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease" id="ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation" id="ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="LongTermObligationsNoncurrent" id="ions_LongTermObligationsNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborativeArrangementAndLicensingAgreementAbstract" id="ions_CollaborativeArrangementAndLicensingAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones" id="ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="ReceiptOfSharesInSubsidiary" id="ions_ReceiptOfSharesInSubsidiary" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="RoyaltyPercentageReceivedOnNetSalesOfDrug" id="ions_RoyaltyPercentageReceivedOnNetSalesOfDrug" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" id="ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="AKCEAANGPTL3LActivePharmaceuticalIngredientMember" id="ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AKCEAANGPTL3LMember" id="ions_AKCEAANGPTL3LMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" id="ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SublicenseFeePaidForLicenseOfDrug" id="ions_SublicenseFeePaidForLicenseOfDrug" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="UpfrontPaymentReceived" id="ions_UpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" id="ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" id="ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="NextPotentialMilestonePayment" id="ions_NextPotentialMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" id="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="RevenueFromContractWithCustomerTransactionPrice" id="ions_RevenueFromContractWithCustomerTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ResearchAndDevelopmentServicesForMember" id="ions_ResearchAndDevelopmentServicesForMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CostOfProductsSoldPreviouslyRecognized" id="ions_CostOfProductsSoldPreviouslyRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ResearchDevelopmentAndPatentExpense" id="ions_ResearchDevelopmentAndPatentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="GainLossOnExtinguishmentOfFinancingLiability" id="ions_GainLossOnExtinguishmentOfFinancingLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="CommercialMember" id="ions_CommercialMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SPINRAZARoyaltiesMember" id="ions_SPINRAZARoyaltiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LicensingAndOtherRoyaltiesMember" id="ions_LicensingAndOtherRoyaltiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PeriodAfterBillingWhenPaymentIsReceived" id="ions_PeriodAfterBillingWhenPaymentIsReceived" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" id="ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="IncreaseDecreaseInStateTaxLiability" id="ions_IncreaseDecreaseInStateTaxLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount" id="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent" id="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount" id="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount" id="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent" id="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent" id="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount" id="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" id="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent" id="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount" id="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount" id="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent" id="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" id="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ConvertibleSeniorNotes275PercentMember" id="ions_ConvertibleSeniorNotes275PercentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember" id="ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember" id="ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CallSpread" id="ions_CallSpread" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="DebtInstrumentConvertibleConversionPriceIncludingCallSpread" id="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" id="ions_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PropertyPlantAndEquipmentExcludingLandMember" id="ions_PropertyPlantAndEquipmentExcludingLandMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquipmentAndComputerSoftwareMember" id="ions_EquipmentAndComputerSoftwareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PeriodToMakeInterestOnlyPaymentsOnMortgageLoan" id="ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PrimaryResearchAndDevelopmentFacilityMember" id="ions_PrimaryResearchAndDevelopmentFacilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationTable" id="ions_ShareBasedCompensationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationLineItems" id="ions_ShareBasedCompensationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="BoardOfDirectorStockOptionMember" id="ions_BoardOfDirectorStockOptionMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AkceaTherapeuticsMember" id="ions_AkceaTherapeuticsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="IonisCoreMember" id="ions_IonisCoreMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue" id="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue" type="num:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PaymentsToAcquireCostMethodInvestments" id="ions_PaymentsToAcquireCostMethodInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="PaymentsToAcquireLicensesAndOtherAssets" id="ions_PaymentsToAcquireLicensesAndOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="NonCashCapitalAndPatentExpenditures" id="ions_NonCashCapitalAndPatentExpenditures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="PaymentToSettleFinancingLiabilityForLeasedFacility" id="ions_PaymentToSettleFinancingLiabilityForLeasedFacility" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" id="ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" id="ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="OperatingLeaseRightOfUseAssetAmortization" id="ions_OperatingLeaseRightOfUseAssetAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="NovartisInternationalAGMember" id="ions_NovartisInternationalAGMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="BiogenIncMember" id="ions_BiogenIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" id="ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="WeightedAverageNumberOfSharesOwnedInSubsidiary" id="ions_WeightedAverageNumberOfSharesOwnedInSubsidiary" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ClinicalRawMaterialsMember" id="ions_ClinicalRawMaterialsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CommercialRawMaterialsMember" id="ions_CommercialRawMaterialsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CashCashEquivalentsAndInvestmentsPolicyTextBlock" id="ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfExecutiveOfficersTerminatingEmployment" id="ions_NumberOfExecutiveOfficersTerminatingEmployment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ResearchDevelopmentAndPatentMember" id="ions_ResearchDevelopmentAndPatentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" id="ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" id="ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" id="ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod" id="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable" id="ions_NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NonemployeeDirectorsStockOptionPlan2002Member" id="ions_NonemployeeDirectorsStockOptionPlan2002Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquityIncentivePlan2011Member" id="ions_EquityIncentivePlan2011Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StockOptionPlan1989Member" id="ions_StockOptionPlan1989Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EmployeeStockPurchasePlanMember" id="ions_EmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LesseeOperatingLeaseInformationTableTextBlock" id="ions_LesseeOperatingLeaseInformationTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" id="ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="StockIssuedDuringPeriodValueNewIssuesBySubsidiary" id="ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" id="ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSharesNewIssuesBySubsidiary" id="ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PatentAbstract" id="ions_PatentAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PatentExpenses" id="ions_PatentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="CollaborativeArrangementsAndLicensingAgreementsMember" id="ions_CollaborativeArrangementsAndLicensingAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DepositsAndOtherAssetsMember" id="ions_DepositsAndOtherAssetsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SecuritiesWithMaturityOfOneYearOrLessMember" id="ions_SecuritiesWithMaturityOfOneYearOrLessMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SecuritiesWithMaturityOfMoreThanOneYearMember" id="ions_SecuritiesWithMaturityOfMoreThanOneYearMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" id="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" id="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" id="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" id="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="IncludedInOtherCurrentAssetsMember" id="ions_IncludedInOtherCurrentAssetsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="IncludedInDepositsAndOtherAssetsMember" id="ions_IncludedInDepositsAndOtherAssetsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MaximumContractMaturityPeriodRange2" id="ions_MaximumContractMaturityPeriodRange2" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="MaximumContractMaturityPeriodRange1" id="ions_MaximumContractMaturityPeriodRange1" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="MaximumContractMaturityPeriodRange3" id="ions_MaximumContractMaturityPeriodRange3" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" id="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" id="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" id="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" id="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" id="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" id="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" id="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" id="ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge" id="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge" id="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="SignificantPartnersAbstract" id="ions_SignificantPartnersAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfSignificantPartners" id="ions_NumberOfSignificantPartners" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SignificantPartnersMember" id="ions_SignificantPartnersMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AccruedClinicalExpenses" id="ions_AccruedClinicalExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="AccruedInLicensingFeesCurrent" id="ions_AccruedInLicensingFeesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable" id="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems" id="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborativeArrangementsAndLicensingAgreementsRocheMember" id="ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborativeArrangementsAndLicensingAgreementsBayerMember" id="ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" id="ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" id="ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped" id="ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="CumulativePaymentsReceived" id="ions_CumulativePaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" id="ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="MilestonePaymentsReceived" id="ions_MilestonePaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PaymentReceivedForAdvancingPrograms" id="ions_PaymentReceivedForAdvancingPrograms" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" id="ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="IONISFXILMember" id="ions_IONISFXILMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ResearchAndDevelopmentServicesForIONISFXILMember" id="ions_ResearchAndDevelopmentServicesForIONISFXILMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement" id="ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="RevenueFromContractWithCustomerNumberOfNewPerformanceObligations" id="ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="IONISJBI225Member" id="ions_IONISJBI225Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" id="ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="IONISJBI125Member" id="ions_IONISJBI125Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" id="ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="IONISMAPTMember" id="ions_IONISMAPTMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PaymentsIncludedInTransactionPriceForPerformanceObligation" id="ions_PaymentsIncludedInTransactionPriceForPerformanceObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="NumberOfMilestonePaymentsAchieved" id="ions_NumberOfMilestonePaymentsAchieved" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="MedicinesForUndisclosedTargetsMember" id="ions_MedicinesForUndisclosedTargetsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments" id="ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="MedicinesForAmyotrophicLateralSclerosisMember" id="ions_MedicinesForAmyotrophicLateralSclerosisMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfDrugsLicensedUnderOptionInCollaborationAgreement" id="ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="IONISC9Member" id="ions_IONISC9Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfTargetsToBeDevelopedAndCommercialized" id="ions_NumberOfTargetsToBeDevelopedAndCommercialized" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="TofersenMember" id="ions_TofersenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ION581Member" id="ions_ION581Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ION859Member" id="ions_ION859Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MilestonePaymentAchieved" id="ions_MilestonePaymentAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="NextPotentialPayment" id="ions_NextPotentialPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="PercentageCashPremiumPaidOnSharesPurchased" id="ions_PercentageCashPremiumPaidOnSharesPurchased" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfDrugsCurrentlyBeingAdvanced" id="ions_NumberOfDrugsCurrentlyBeingAdvanced" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="PremiumPaidOnSharesPurchased" id="ions_PremiumPaidOnSharesPurchased" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones" id="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="NumberOfTargetsAdvanced" id="ions_NumberOfTargetsAdvanced" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AntisenseMoleculeMember" id="ions_AntisenseMoleculeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MaximumAmountOfPaymentsReceivableForSalesMilestones" id="ions_MaximumAmountOfPaymentsReceivableForSalesMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="UpfrontPaymentReceivedIncludingPurchaseOfStock" id="ions_UpfrontPaymentReceivedIncludingPurchaseOfStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" id="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TermOfCollaborationAgreement" id="ions_TermOfCollaborationAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" id="ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="NumberOfDrugsBeingDeveloped" id="ions_NumberOfDrugsBeingDeveloped" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" id="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="CumulativeRevenueFromContractWithCustomerExcludingAssessedTax" id="ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="NumberOfCountriesWhereDrugIsApprovedForUse" id="ions_NumberOfCountriesWhereDrugIsApprovedForUse" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ION736Member" id="ions_ION736Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DanvatirsenMember" id="ions_DanvatirsenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfLicenseFeesEarned" id="ions_NumberOfLicenseFeesEarned" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ION839Member" id="ions_ION839Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfProgramsAdvanced" id="ions_NumberOfProgramsAdvanced" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfLicensedDrugs" id="ions_NumberOfLicensedDrugs" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="NumberOfPerformanceObligationsCompleted" id="ions_NumberOfPerformanceObligationsCompleted" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ION532Member" id="ions_ION532Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AKCEAAPOALMember" id="ions_AKCEAAPOALMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ResearchAndDevelopmentServicesForAKCEAAPOALMember" id="ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ProceedsFromSaleOfCommonStockIncludingPremiumPaid" id="ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="RoyaltyPercentageReceivedOnSalesOfDrug" id="ions_RoyaltyPercentageReceivedOnSalesOfDrug" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PortionOfUpfrontPaymentPaidAsSublicenseFee" id="ions_PortionOfUpfrontPaymentPaidAsSublicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="AKCEAAPOCIIILMember" id="ions_AKCEAAPOCIIILMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DeliveryOfAKCEAAPOCIIILMember" id="ions_DeliveryOfAKCEAAPOCIIILMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember" id="ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee" id="ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AdditionalAmountOfCommonStockRequiredToBePurchased" id="ions_AdditionalAmountOfCommonStockRequiredToBePurchased" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="DeliveryOfAKCEAAPOALMember" id="ions_DeliveryOfAKCEAAPOALMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MaximumAmountOfPaymentsReceivableForMilestones" id="ions_MaximumAmountOfPaymentsReceivableForMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="PremiumReceivedOnSharesIssued" id="ions_PremiumReceivedOnSharesIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="PortionOfUpfrontPaymentRetained" id="ions_PortionOfUpfrontPaymentRetained" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture" id="ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties" id="ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner" id="ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil" id="ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="WaylivraMember" id="ions_WaylivraMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="MaximumPaymentReceivableUnderLicenseAgreement" id="ions_MaximumPaymentReceivableUnderLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="TegsediMember" id="ions_TegsediMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract" id="ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfNewTargetsAdvanced" id="ions_NumberOfNewTargetsAdvanced" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="RevenueFromContractWithCustomerTransactionPriceAdditions" id="ions_RevenueFromContractWithCustomerTransactionPriceAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="NumberOfAgreementsWithCollaborationPartner" id="ions_NumberOfAgreementsWithCollaborationPartner" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>ions-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 6.2.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#QuarterlyFinancialDataUnauditedDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxesIncomeTaxExpenseBenefitDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OperatingLeasesDetailsCalc01" xlink:type="simple" xlink:href="ions-20191231.xsd#OperatingLeasesDetailsCalc01" />
  <link:roleRef roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#LongtermObligationsAndCommitmentsOperatingLeasesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#LongtermObligationsAndCommitmentsMaturitySchedulesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#LongtermObligationsAndCommitmentsLongtermObligationsDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetailsCalc2" xlink:type="simple" xlink:href="ions-20191231.xsd#InvestmentsSummaryOfInvestmentsDetailsCalc2" />
  <link:roleRef roleURI="http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#InvestmentsInvestmentsTemporarilyImpairedDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#InvestmentsSummaryOfInvestmentsDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="ions-20191231.xsd#ConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ions-20191231.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" />
  <link:roleRef roleURI="http://isispharm.com/role/ConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="ions-20191231.xsd#ConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://isispharm.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ions-20191231.xsd#ConsolidatedBalanceSheets" />
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="calculation: StockholdersEquity to AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="AdditionalPaidInCapitalCommonStock" xlink:title="AdditionalPaidInCapitalCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapitalCommonStock" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapitalCommonStock" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="StockholdersEquity" xlink:title="calculation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to StockholdersEquity" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="MinorityInterest" xlink:title="MinorityInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="MinorityInterest" xlink:title="calculation: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to MinorityInterest" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="ContractWithCustomerLiabilityNoncurrent" xlink:title="ContractWithCustomerLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="ContractWithCustomerLiabilityNoncurrent" xlink:title="calculation: Liabilities to ContractWithCustomerLiabilityNoncurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccruedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to AccruedLiabilitiesCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="LongTermDebtAndCapitalLeaseObligationsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="calculation: LiabilitiesCurrent to LongTermDebtAndCapitalLeaseObligationsCurrent" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="calculation: LiabilitiesCurrent to EmployeeRelatedLiabilitiesCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="ContractWithCustomerLiabilityCurrent" xlink:title="calculation: LiabilitiesCurrent to ContractWithCustomerLiabilityCurrent" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="AccruedIncomeTaxesCurrent" xlink:title="AccruedIncomeTaxesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccruedIncomeTaxesCurrent" xlink:title="calculation: LiabilitiesCurrent to AccruedIncomeTaxesCurrent" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermObligationsNoncurrent" xlink:label="LongTermObligationsNoncurrent" xlink:title="LongTermObligationsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LongTermObligationsNoncurrent" xlink:title="calculation: Liabilities to LongTermObligationsNoncurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermLoansFromBank" xlink:label="LongTermLoansFromBank" xlink:title="LongTermLoansFromBank" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LongTermLoansFromBank" xlink:title="calculation: Liabilities to LongTermLoansFromBank" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="ConvertibleDebtNoncurrent" xlink:title="ConvertibleDebtNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Liabilities" xlink:to="ConvertibleDebtNoncurrent" xlink:title="calculation: Liabilities to ConvertibleDebtNoncurrent" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="ContractWithCustomerAssetNetCurrent" xlink:title="ContractWithCustomerAssetNetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="ContractWithCustomerAssetNetCurrent" xlink:title="calculation: AssetsCurrent to ContractWithCustomerAssetNetCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="InventoryNet" xlink:title="calculation: AssetsCurrent to InventoryNet" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="OtherAssetsCurrent" xlink:title="OtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="OtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to OtherAssetsCurrent" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:title="AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:title="calculation: AssetsCurrent to AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="OtherAssetsNoncurrent" xlink:title="calculation: Assets to OtherAssetsNoncurrent" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="FiniteLivedIntangibleAssetsNet" xlink:title="calculation: Assets to FiniteLivedIntangibleAssetsNet" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="DeferredIncomeTaxAssetsNet" xlink:title="DeferredIncomeTaxAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="DeferredIncomeTaxAssetsNet" xlink:title="calculation: Assets to DeferredIncomeTaxAssetsNet" order="5.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/ConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="calculation: NetIncomeLoss to NetIncomeLossAttributableToNoncontrollingInterest" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="calculation: OperatingIncomeLoss to RevenueFromContractWithCustomerExcludingAssessedTax" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="CostOfGoodsAndServicesSold" xlink:title="CostOfGoodsAndServicesSold" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CostsAndExpenses" xlink:to="CostOfGoodsAndServicesSold" xlink:title="calculation: CostsAndExpenses to CostOfGoodsAndServicesSold" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchDevelopmentAndPatentExpense" xlink:label="ResearchDevelopmentAndPatentExpense" xlink:title="ResearchDevelopmentAndPatentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CostsAndExpenses" xlink:to="ResearchDevelopmentAndPatentExpense" xlink:title="calculation: CostsAndExpenses to ResearchDevelopmentAndPatentExpense" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CostsAndExpenses" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="calculation: CostsAndExpenses to SellingGeneralAndAdministrativeExpense" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="CostsAndExpenses" xlink:title="calculation: OperatingIncomeLoss to CostsAndExpenses" order="3.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="OperatingIncomeLoss" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to OperatingIncomeLoss" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to GainsLossesOnExtinguishmentOfDebt" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_GainLossOnExtinguishmentOfFinancingLiability" xlink:label="GainLossOnExtinguishmentOfFinancingLiability" xlink:title="GainLossOnExtinguishmentOfFinancingLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="GainLossOnExtinguishmentOfFinancingLiability" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to GainLossOnExtinguishmentOfFinancingLiability" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="InterestExpense" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to InterestExpense" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="InvestmentIncomeNet" xlink:title="InvestmentIncomeNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="InvestmentIncomeNet" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to InvestmentIncomeNet" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to OtherNonoperatingIncomeExpense" order="8.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLoss" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="calculation: ProfitLoss to IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLoss" xlink:to="IncomeTaxExpenseBenefit" xlink:title="calculation: ProfitLoss to IncomeTaxExpenseBenefit" order="1.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="ProfitLoss" xlink:title="calculation: NetIncomeLoss to ProfitLoss" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:title="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="ProfitLoss" xlink:title="calculation: ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest to ProfitLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:title="OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:title="calculation: ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest to OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="calculation: ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest to OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="calculation: ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:title="calculation: ComprehensiveIncomeNetOfTax to ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:title="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:title="calculation: ComprehensiveIncomeNetOfTax to ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="1.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/ConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="IncreaseDecreaseInIncomeTaxesReceivable" xlink:title="IncreaseDecreaseInIncomeTaxesReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInIncomeTaxesReceivable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInIncomeTaxesReceivable" order="20.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_OperatingLeaseRightOfUseAssetAmortization" xlink:label="OperatingLeaseRightOfUseAssetAmortization" xlink:title="OperatingLeaseRightOfUseAssetAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="OperatingLeaseRightOfUseAssetAmortization" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to OperatingLeaseRightOfUseAssetAmortization" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ShareBasedCompensation" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ProfitLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ProfitLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="IncreaseDecreaseInContractWithCustomerLiability" xlink:title="IncreaseDecreaseInContractWithCustomerLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInContractWithCustomerLiability" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInContractWithCustomerLiability" order="26.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" order="24.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="AmortizationOfFinancingCosts" xlink:title="AmortizationOfFinancingCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfFinancingCosts" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfFinancingCosts" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfIntangibleAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfIntangibleAssets" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="GainOnSaleOfInvestments" xlink:title="GainOnSaleOfInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="GainOnSaleOfInvestments" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to GainOnSaleOfInvestments" order="10.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInInventories" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInInventories" order="18.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_GainLossOnExtinguishmentOfFinancingLiability" xlink:label="GainLossOnExtinguishmentOfFinancingLiability" xlink:title="GainLossOnExtinguishmentOfFinancingLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="GainLossOnExtinguishmentOfFinancingLiability" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to GainLossOnExtinguishmentOfFinancingLiability" order="11.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="Depreciation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to Depreciation" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:label="IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:title="IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" order="22.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsPayable" order="21.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to GainsLossesOnExtinguishmentOfDebt" order="12.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="IncreaseDecreaseInContractWithCustomerAsset" xlink:title="IncreaseDecreaseInContractWithCustomerAsset" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInContractWithCustomerAsset" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInContractWithCustomerAsset" order="17.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:title="AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="5.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfLeasedAsset" xlink:label="AmortizationOfLeasedAsset" xlink:title="AmortizationOfLeasedAsset" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfLeasedAsset" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfLeasedAsset" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities" xlink:label="IncreaseDecreaseInOtherEmployeeRelatedLiabilities" xlink:title="IncreaseDecreaseInOtherEmployeeRelatedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInOtherEmployeeRelatedLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInOtherEmployeeRelatedLiabilities" order="23.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" xlink:label="AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" xlink:title="AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" order="15.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfDebtDiscountPremium" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="IncreaseDecreaseInOtherOperatingAssets" xlink:title="IncreaseDecreaseInOtherOperatingAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInOtherOperatingAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInOtherOperatingAssets" order="19.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="DeferredIncomeTaxesAndTaxCredits" xlink:title="DeferredIncomeTaxesAndTaxCredits" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="DeferredIncomeTaxesAndTaxCredits" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to DeferredIncomeTaxesAndTaxCredits" order="14.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInOperatingActivities" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:title="RepaymentsOfLongTermDebtAndCapitalSecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to RepaymentsOfLongTermDebtAndCapitalSecurities" order="17.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="ProceedsFromIssuanceOfPrivatePlacement" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfPrivatePlacement" order="13.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentsOfDebtIssuanceCosts" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentsOfDebtIssuanceCosts" order="4.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:title="ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities" xlink:label="PaymentsForHedgeFinancingActivities" xlink:title="PaymentsForHedgeFinancingActivities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentsForHedgeFinancingActivities" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentsForHedgeFinancingActivities" order="6.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="ProceedsFromIssuanceOfWarrants" xlink:title="ProceedsFromIssuanceOfWarrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfWarrants" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfWarrants" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="ProceedsFromConvertibleDebt" xlink:title="ProceedsFromConvertibleDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromConvertibleDebt" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromConvertibleDebt" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="ProceedsFromIssuanceInitialPublicOffering" xlink:title="ProceedsFromIssuanceInitialPublicOffering" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceInitialPublicOffering" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceInitialPublicOffering" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfCommonStock" order="11.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="ProceedsFromDebtNetOfIssuanceCosts" xlink:title="ProceedsFromDebtNetOfIssuanceCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromDebtNetOfIssuanceCosts" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromDebtNetOfIssuanceCosts" order="10.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentsOfStockIssuanceCosts" order="14.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PaymentToSettleFinancingLiabilityForLeasedFacility" xlink:label="PaymentToSettleFinancingLiabilityForLeasedFacility" xlink:title="PaymentToSettleFinancingLiabilityForLeasedFacility" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentToSettleFinancingLiabilityForLeasedFacility" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentToSettleFinancingLiabilityForLeasedFacility" order="15.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="PaymentsForRepurchaseOfCommonStock" xlink:title="PaymentsForRepurchaseOfCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentsForRepurchaseOfCommonStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentsForRepurchaseOfCommonStock" order="7.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInFinancingActivities" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:title="ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="ProceedsFromSaleOfEquityMethodInvestments" xlink:title="ProceedsFromSaleOfEquityMethodInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="ProceedsFromSaleOfEquityMethodInvestments" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to ProceedsFromSaleOfEquityMethodInvestments" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PaymentsToAcquireLicensesAndOtherAssets" xlink:label="PaymentsToAcquireLicensesAndOtherAssets" xlink:title="PaymentsToAcquireLicensesAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquireLicensesAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquireLicensesAndOtherAssets" order="6.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:title="PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquirePropertyPlantAndEquipment" order="5.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PaymentsToAcquireCostMethodInvestments" xlink:label="PaymentsToAcquireCostMethodInvestments" xlink:title="PaymentsToAcquireCostMethodInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquireCostMethodInvestments" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquireCostMethodInvestments" order="8.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to NetCashProvidedByUsedInInvestingActivities" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:title="NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersDiluted to NetIncomeLossAvailableToCommonStockholdersBasic" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="calculation: WeightedAverageNumberOfDilutedSharesOutstanding to WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" xlink:label="IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" xlink:title="IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" xlink:title="calculation: WeightedAverageNumberOfDilutedSharesOutstanding to IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="calculation: WeightedAverageNumberOfDilutedSharesOutstanding to IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="OtherAccruedLiabilitiesCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to OtherAccruedLiabilitiesCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AccruedClinicalExpenses" xlink:label="AccruedClinicalExpenses" xlink:title="AccruedClinicalExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedClinicalExpenses" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedClinicalExpenses" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AccruedInLicensingFeesCurrent" xlink:label="AccruedInLicensingFeesCurrent" xlink:title="AccruedInLicensingFeesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AccruedLiabilitiesCurrent" xlink:to="AccruedInLicensingFeesCurrent" xlink:title="calculation: AccruedLiabilitiesCurrent to AccruedInLicensingFeesCurrent" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="InventoryRawMaterials" xlink:title="InventoryRawMaterials" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InventoryNet" xlink:to="InventoryRawMaterials" xlink:title="calculation: InventoryNet to InventoryRawMaterials" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="InventoryWorkInProcess" xlink:title="InventoryWorkInProcess" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InventoryNet" xlink:to="InventoryWorkInProcess" xlink:title="calculation: InventoryNet to InventoryWorkInProcess" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="InventoryFinishedGoods" xlink:title="InventoryFinishedGoods" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="InventoryNet" xlink:to="InventoryFinishedGoods" xlink:title="calculation: InventoryNet to InventoryFinishedGoods" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="calculation: PropertyPlantAndEquipmentNet to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="calculation: PropertyPlantAndEquipmentNet to PropertyPlantAndEquipmentGross" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="OtherComprehensiveIncomeLossNetOfTax" xlink:title="OtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:title="OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherComprehensiveIncomeLossNetOfTax" xlink:to="OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:title="calculation: OtherComprehensiveIncomeLossNetOfTax to OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:title="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OtherComprehensiveIncomeLossNetOfTax" xlink:to="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:title="calculation: OtherComprehensiveIncomeLossNetOfTax to ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" order="2.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="AvailableForSaleSecurities" xlink:title="AvailableForSaleSecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsFairValueDisclosure" xlink:to="AvailableForSaleSecurities" xlink:title="calculation: AssetsFairValueDisclosure to AvailableForSaleSecurities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="EquitySecuritiesFvNi" xlink:title="EquitySecuritiesFvNi" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsFairValueDisclosure" xlink:to="EquitySecuritiesFvNi" xlink:title="calculation: AssetsFairValueDisclosure to EquitySecuritiesFvNi" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AssetsFairValueDisclosure" xlink:to="CashAndCashEquivalentsFairValueDisclosure" xlink:title="calculation: AssetsFairValueDisclosure to CashAndCashEquivalentsFairValueDisclosure" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:title="AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" xlink:title="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:to="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" xlink:title="calculation: AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage to AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" xlink:title="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:to="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" xlink:title="calculation: AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage to AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" xlink:title="AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:to="AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" xlink:title="calculation: AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage to AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:title="AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="AvailableForSaleSecuritiesDebtSecurities" xlink:title="AvailableForSaleSecuritiesDebtSecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="AvailableForSaleSecuritiesDebtSecurities" xlink:title="calculation: AvailableForSaleDebtSecuritiesAmortizedCostBasis to AvailableForSaleSecuritiesDebtSecurities" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:title="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:title="calculation: AvailableForSaleDebtSecuritiesAmortizedCostBasis to AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:title="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:title="calculation: AvailableForSaleDebtSecuritiesAmortizedCostBasis to AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:label="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:title="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:label="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:title="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:to="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:title="calculation: DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost to DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" order="0.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:label="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:title="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:to="AvailableForSaleSecuritiesDebtSecurities" xlink:title="calculation: DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi to AvailableForSaleSecuritiesDebtSecurities" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="EquitySecuritiesFvNi" xlink:title="EquitySecuritiesFvNi" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:to="EquitySecuritiesFvNi" xlink:title="calculation: DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi to EquitySecuritiesFvNi" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:to="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:title="calculation: DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost to DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:label="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:title="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:to="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:title="calculation: DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost to DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:to="AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:title="calculation: AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss to AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:to="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:title="calculation: AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss to AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:to="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:title="calculation: AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue to AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:to="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:title="calculation: AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue to AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetailsCalc2">
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:label="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:title="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:title="AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:to="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:title="calculation: DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost to AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:label="EquitySecuritiesFvNiCost" xlink:title="EquitySecuritiesFvNiCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:to="EquitySecuritiesFvNiCost" xlink:title="calculation: DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost to EquitySecuritiesFvNiCost" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails">
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermDebtAndOtherObligations" xlink:label="LongTermDebtAndOtherObligations" xlink:title="LongTermDebtAndOtherObligations" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermDebtAndOtherObligationsNoncurrent" xlink:label="LongTermDebtAndOtherObligationsNoncurrent" xlink:title="LongTermDebtAndOtherObligationsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LongTermDebtAndOtherObligations" xlink:to="LongTermDebtAndOtherObligationsNoncurrent" xlink:title="calculation: LongTermDebtAndOtherObligations to LongTermDebtAndOtherObligationsNoncurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="LongTermDebtAndCapitalLeaseObligationsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LongTermDebtAndOtherObligations" xlink:to="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="calculation: LongTermDebtAndOtherObligations to LongTermDebtAndCapitalLeaseObligationsCurrent" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation" xlink:label="ContractualObligation" xlink:title="ContractualObligation" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="ContractualObligationDueInFifthYear" xlink:title="ContractualObligationDueInFifthYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ContractualObligation" xlink:to="ContractualObligationDueInFifthYear" xlink:title="calculation: ContractualObligation to ContractualObligationDueInFifthYear" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="ContractualObligationDueInSecondYear" xlink:title="ContractualObligationDueInSecondYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ContractualObligation" xlink:to="ContractualObligationDueInSecondYear" xlink:title="calculation: ContractualObligation to ContractualObligationDueInSecondYear" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="ContractualObligationDueInThirdYear" xlink:title="ContractualObligationDueInThirdYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ContractualObligation" xlink:to="ContractualObligationDueInThirdYear" xlink:title="calculation: ContractualObligation to ContractualObligationDueInThirdYear" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="ContractualObligationDueAfterFifthYear" xlink:title="ContractualObligationDueAfterFifthYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ContractualObligation" xlink:to="ContractualObligationDueAfterFifthYear" xlink:title="calculation: ContractualObligation to ContractualObligationDueAfterFifthYear" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="ContractualObligationDueInFourthYear" xlink:title="ContractualObligationDueInFourthYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ContractualObligation" xlink:to="ContractualObligationDueInFourthYear" xlink:title="calculation: ContractualObligation to ContractualObligationDueInFourthYear" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="ContractualObligationDueInNextTwelveMonths" xlink:title="ContractualObligationDueInNextTwelveMonths" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ContractualObligation" xlink:to="ContractualObligationDueInNextTwelveMonths" xlink:title="calculation: ContractualObligation to ContractualObligationDueInNextTwelveMonths" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="7.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OperatingLeasesDetailsCalc01">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="OperatingLeaseLiability" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to OperatingLeaseLiability" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="DeferredIncomeTaxExpenseBenefit" xlink:title="DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="DeferredFederalIncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredIncomeTaxExpenseBenefit" xlink:to="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="calculation: DeferredIncomeTaxExpenseBenefit to DeferredFederalIncomeTaxExpenseBenefit" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredIncomeTaxExpenseBenefit" xlink:to="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="calculation: DeferredIncomeTaxExpenseBenefit to DeferredStateAndLocalIncomeTaxExpenseBenefit" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="DeferredIncomeTaxExpenseBenefit" xlink:title="calculation: IncomeTaxExpenseBenefit to DeferredIncomeTaxExpenseBenefit" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="CurrentIncomeTaxExpenseBenefit" xlink:title="CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="CurrentStateAndLocalTaxExpenseBenefit" xlink:title="CurrentStateAndLocalTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentIncomeTaxExpenseBenefit" xlink:to="CurrentStateAndLocalTaxExpenseBenefit" xlink:title="calculation: CurrentIncomeTaxExpenseBenefit to CurrentStateAndLocalTaxExpenseBenefit" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="CurrentFederalTaxExpenseBenefit" xlink:title="CurrentFederalTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentIncomeTaxExpenseBenefit" xlink:to="CurrentFederalTaxExpenseBenefit" xlink:title="calculation: CurrentIncomeTaxExpenseBenefit to CurrentFederalTaxExpenseBenefit" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="CurrentForeignTaxExpenseBenefit" xlink:title="CurrentForeignTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CurrentIncomeTaxExpenseBenefit" xlink:to="CurrentForeignTaxExpenseBenefit" xlink:title="calculation: CurrentIncomeTaxExpenseBenefit to CurrentForeignTaxExpenseBenefit" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="CurrentIncomeTaxExpenseBenefit" xlink:title="calculation: IncomeTaxExpenseBenefit to CurrentIncomeTaxExpenseBenefit" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent" xlink:label="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent" xlink:title="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" order="11.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationTaxCredits" order="8.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent" xlink:label="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent" xlink:title="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent" order="13.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:title="EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="12.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:title="EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="17.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="14.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent" xlink:label="EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent" xlink:title="EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="10.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent" xlink:label="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent" xlink:title="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent" xlink:label="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent" xlink:title="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent" xlink:title="calculation: EffectiveIncomeTaxRateContinuingOperations to EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent" order="16.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:title="IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount" xlink:title="calculation: IncomeTaxExpenseBenefit to EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount" order="14.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount" xlink:label="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount" xlink:title="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount" xlink:title="calculation: IncomeTaxExpenseBenefit to EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount" xlink:label="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount" xlink:title="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount" xlink:title="calculation: IncomeTaxExpenseBenefit to EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="IncomeTaxReconciliationTaxCredits" xlink:title="IncomeTaxReconciliationTaxCredits" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationTaxCredits" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationTaxCredits" order="9.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="IncomeTaxReconciliationOtherAdjustments" xlink:title="IncomeTaxReconciliationOtherAdjustments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationOtherAdjustments" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationOtherAdjustments" order="19.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount" xlink:label="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount" xlink:title="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount" xlink:title="calculation: IncomeTaxExpenseBenefit to EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount" order="16.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:title="IncomeTaxReconciliationPriorYearIncomeTaxes" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationPriorYearIncomeTaxes" order="12.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:title="IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:title="IncomeTaxReconciliationChangeInEnactedTaxRate" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationChangeInEnactedTaxRate" order="13.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="17.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="IncomeTaxReconciliationNondeductibleExpenseOther" xlink:title="IncomeTaxReconciliationNondeductibleExpenseOther" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationNondeductibleExpenseOther" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationNondeductibleExpenseOther" order="15.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount" xlink:label="EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount" xlink:title="EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount" xlink:title="calculation: IncomeTaxExpenseBenefit to EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount" xlink:label="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount" xlink:title="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount" xlink:title="calculation: IncomeTaxExpenseBenefit to EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount" order="18.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" xlink:title="DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:label="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:title="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:label="DeferredTaxLiabilitiesFinancingArrangements" xlink:title="DeferredTaxLiabilitiesFinancingArrangements" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:to="DeferredTaxLiabilitiesFinancingArrangements" xlink:title="calculation: DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance to DeferredTaxLiabilitiesFinancingArrangements" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsOperatingLossCarryforwards" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="DeferredTaxAssetsOther" xlink:title="DeferredTaxAssetsOther" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsOther" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsOther" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="DeferredTaxAssetsDeferredIncome" xlink:title="DeferredTaxAssetsDeferredIncome" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsDeferredIncome" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsDeferredIncome" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:title="DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsGoodwillAndIntangibleAssets" order="6.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:to="DeferredTaxAssetsGross" xlink:title="calculation: DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance to DeferredTaxAssetsGross" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:title="DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:to="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:title="calculation: DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance to DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="DeferredTaxLiabilitiesOther" xlink:title="DeferredTaxLiabilitiesOther" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:to="DeferredTaxLiabilitiesOther" xlink:title="calculation: DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance to DeferredTaxLiabilitiesOther" order="4.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:title="calculation: DeferredTaxAssetsLiabilitiesNet to DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="DeferredTaxAssetsValuationAllowance" xlink:title="calculation: DeferredTaxAssetsLiabilitiesNet to DeferredTaxAssetsValuationAllowance" order="2.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:title="NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersDiluted to NetIncomeLossAvailableToCommonStockholdersBasic" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:label="DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:title="DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:title="calculation: NetIncomeLossAvailableToCommonStockholdersDiluted to DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="calculation: WeightedAverageNumberOfDilutedSharesOutstanding to WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="calculation: WeightedAverageNumberOfDilutedSharesOutstanding to IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" xlink:label="IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" xlink:title="IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" xlink:title="calculation: WeightedAverageNumberOfDilutedSharesOutstanding to IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:title="IncrementalCommonSharesAttributableToConversionOfDebtSecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:title="calculation: WeightedAverageNumberOfDilutedSharesOutstanding to IncrementalCommonSharesAttributableToConversionOfDebtSecurities" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="Revenues" xlink:title="Revenues" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="Revenues" xlink:title="calculation: OperatingIncomeLoss to Revenues" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="CostsAndExpenses" xlink:title="calculation: OperatingIncomeLoss to CostsAndExpenses" order="1.0" weight="-1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>ions-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 6.2.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#QuarterlyFinancialDataUnauditedDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/EmploymentBenefitsDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#EmploymentBenefitsDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreementsPfizerDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreementsNovartisDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreementsRocheDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreementsGskDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreementsBayerDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreementsBiogenDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxesGrossUnrecognizedTaxBenefitsDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxesTaxActDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxesTaxActDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxesTaxCreditCarryforwardsDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxesTaxCreditCarryforwardsDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxesIncomeTaxExpenseBenefitDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#StockholdersEquityStockbasedValuationInformationDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#StockholdersEquityStockbasedCompensationExpenseDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#StockholdersEquityRestrictedStockUnitActivityDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#StockholdersEquityStockOptionActivityDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/StockholdersEquityStockPlansDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#StockholdersEquityStockPlansDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/StockholdersEquityShareRepurchaseProgramDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#StockholdersEquityShareRepurchaseProgramDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#StockholdersEquityPreferredAndCommonStockDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OperatingLeasesDetailsCalc01" xlink:type="simple" xlink:href="ions-20191231.xsd#OperatingLeasesDetailsCalc01" />
  <link:roleRef roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#LongtermObligationsAndCommitmentsOperatingLeasesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#LongtermObligationsAndCommitmentsMaturitySchedulesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#LongtermObligationsAndCommitmentsConvertibleNotesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsDetailsCalc2" xlink:type="simple" xlink:href="ions-20191231.xsd#LongtermObligationsAndCommitmentsDetailsCalc2" />
  <link:roleRef roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#LongtermObligationsAndCommitmentsLongtermObligationsDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetailsCalc2" xlink:type="simple" xlink:href="ions-20191231.xsd#InvestmentsSummaryOfInvestmentsDetailsCalc2" />
  <link:roleRef roleURI="http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#InvestmentsInvestmentsTemporarilyImpairedDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#InvestmentsSummaryOfInvestmentsDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesSegmentInformationDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesConvertibleDebtDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesConvertibleDebtDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesStockbasedCompensationExpenseDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLonglivedAssetsDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesLonglivedAssetsDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLeasesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesLeasesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndInvestmentsDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndInvestmentsDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesCostOfProductsSoldDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesCostOfProductsSoldDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesDeferredRevenueDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesDeferredRevenueDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesContractsReceivableDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesContractsReceivableDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="ions-20191231.xsd#QuarterlyFinancialDataUnauditedTables" />
  <link:roleRef roleURI="http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskTables" xlink:type="simple" xlink:href="ions-20191231.xsd#SegmentInformationAndConcentrationOfBusinessRiskTables" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreementsTables" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxesTables" />
  <link:roleRef roleURI="http://isispharm.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="ions-20191231.xsd#StockholdersEquityTables" />
  <link:roleRef roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsTables" xlink:type="simple" xlink:href="ions-20191231.xsd#LongtermObligationsAndCommitmentsTables" />
  <link:roleRef roleURI="http://isispharm.com/role/InvestmentsTables" xlink:type="simple" xlink:href="ions-20191231.xsd#InvestmentsTables" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://isispharm.com/role/QuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="ions-20191231.xsd#QuarterlyFinancialDataUnaudited" />
  <link:roleRef roleURI="http://isispharm.com/role/LegalProceedings" xlink:type="simple" xlink:href="ions-20191231.xsd#LegalProceedings" />
  <link:roleRef roleURI="http://isispharm.com/role/EmploymentBenefits" xlink:type="simple" xlink:href="ions-20191231.xsd#EmploymentBenefits" />
  <link:roleRef roleURI="http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRisk" xlink:type="simple" xlink:href="ions-20191231.xsd#SegmentInformationAndConcentrationOfBusinessRisk" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreements" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreements" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://isispharm.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ions-20191231.xsd#StockholdersEquity" />
  <link:roleRef roleURI="http://isispharm.com/role/LongtermObligationsAndCommitments" xlink:type="simple" xlink:href="ions-20191231.xsd#LongtermObligationsAndCommitments" />
  <link:roleRef roleURI="http://isispharm.com/role/Investments" xlink:type="simple" xlink:href="ions-20191231.xsd#Investments" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPolicies" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://isispharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" xlink:href="ions-20191231.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" />
  <link:roleRef roleURI="http://isispharm.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="ions-20191231.xsd#ConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" xlink:href="ions-20191231.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" />
  <link:roleRef roleURI="http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" xlink:href="ions-20191231.xsd#ConsolidatedStatementsOfStockholdersEquity" />
  <link:roleRef roleURI="http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ions-20191231.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" />
  <link:roleRef roleURI="http://isispharm.com/role/ConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="ions-20191231.xsd#ConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://isispharm.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ions-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://isispharm.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ions-20191231.xsd#ConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://isispharm.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="ions-20191231.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/DocumentAndEntityInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AssetsAbstract" xlink:title="definition: StatementLineItems to AssetsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="definition: StatementLineItems to LiabilitiesAndStockholdersEquityAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LiabilitiesCurrentAbstract" xlink:title="definition: StatementLineItems to LiabilitiesCurrentAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="ContractWithCustomerLiabilityNoncurrent" xlink:title="ContractWithCustomerLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ContractWithCustomerLiabilityNoncurrent" xlink:title="definition: StatementLineItems to ContractWithCustomerLiabilityNoncurrent" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="ConvertibleDebtNoncurrent" xlink:title="ConvertibleDebtNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ConvertibleDebtNoncurrent" xlink:title="definition: StatementLineItems to ConvertibleDebtNoncurrent" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermObligationsNoncurrent" xlink:label="LongTermObligationsNoncurrent" xlink:title="LongTermObligationsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LongTermObligationsNoncurrent" xlink:title="definition: StatementLineItems to LongTermObligationsNoncurrent" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermLoansFromBank" xlink:label="LongTermLoansFromBank" xlink:title="LongTermLoansFromBank" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LongTermLoansFromBank" xlink:title="definition: StatementLineItems to LongTermLoansFromBank" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="Liabilities" xlink:title="definition: StatementLineItems to Liabilities" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquityAbstract" xlink:title="definition: StatementLineItems to StockholdersEquityAbstract" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="definition: StatementLineItems to LiabilitiesAndStockholdersEquity" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockValue" xlink:title="definition: StatementLineItems to CommonStockValue" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="AdditionalPaidInCapitalCommonStock" xlink:title="AdditionalPaidInCapitalCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdditionalPaidInCapitalCommonStock" xlink:title="definition: StatementLineItems to AdditionalPaidInCapitalCommonStock" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="definition: StatementLineItems to AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="definition: StatementLineItems to RetainedEarningsAccumulatedDeficit" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="definition: StatementLineItems to StockholdersEquity" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="MinorityInterest" xlink:title="MinorityInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="MinorityInterest" xlink:title="definition: StatementLineItems to MinorityInterest" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="definition: StatementLineItems to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AccountsPayableCurrent" xlink:title="definition: StatementLineItems to AccountsPayableCurrent" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="definition: StatementLineItems to EmployeeRelatedLiabilitiesCurrent" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AccruedLiabilitiesCurrent" xlink:title="definition: StatementLineItems to AccruedLiabilitiesCurrent" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="AccruedIncomeTaxesCurrent" xlink:title="AccruedIncomeTaxesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AccruedIncomeTaxesCurrent" xlink:title="definition: StatementLineItems to AccruedIncomeTaxesCurrent" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="LongTermDebtAndCapitalLeaseObligationsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="definition: StatementLineItems to LongTermDebtAndCapitalLeaseObligationsCurrent" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ContractWithCustomerLiabilityCurrent" xlink:title="definition: StatementLineItems to ContractWithCustomerLiabilityCurrent" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LiabilitiesCurrent" xlink:title="definition: StatementLineItems to LiabilitiesCurrent" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AssetsCurrentAbstract" xlink:title="definition: StatementLineItems to AssetsCurrentAbstract" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="definition: StatementLineItems to PropertyPlantAndEquipmentNet" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="FiniteLivedIntangibleAssetsNet" xlink:title="definition: StatementLineItems to FiniteLivedIntangibleAssetsNet" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="DeferredIncomeTaxAssetsNet" xlink:title="DeferredIncomeTaxAssetsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DeferredIncomeTaxAssetsNet" xlink:title="definition: StatementLineItems to DeferredIncomeTaxAssetsNet" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OtherAssetsNoncurrent" xlink:title="definition: StatementLineItems to OtherAssetsNoncurrent" order="29.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="Assets" xlink:title="definition: StatementLineItems to Assets" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="definition: StatementLineItems to CashAndCashEquivalentsAtCarryingValue" order="31.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:title="AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:title="definition: StatementLineItems to AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="32.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="ContractWithCustomerAssetNetCurrent" xlink:title="ContractWithCustomerAssetNetCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ContractWithCustomerAssetNetCurrent" xlink:title="definition: StatementLineItems to ContractWithCustomerAssetNetCurrent" order="33.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="InventoryNet" xlink:title="definition: StatementLineItems to InventoryNet" order="34.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="OtherAssetsCurrent" xlink:title="OtherAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OtherAssetsCurrent" xlink:title="definition: StatementLineItems to OtherAssetsCurrent" order="35.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AssetsCurrent" xlink:title="definition: StatementLineItems to AssetsCurrent" order="36.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="37.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: StatementTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentMember" xlink:label="ConvertibleSeniorNotes0125PercentMember" xlink:title="ConvertibleSeniorNotes0125PercentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes0125PercentMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleSeniorNotes0125PercentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes1PercentMember" xlink:label="ConvertibleSeniorNotes1PercentMember" xlink:title="ConvertibleSeniorNotes1PercentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes1PercentMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleSeniorNotes1PercentMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/ConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="definition: StatementLineItems to LiabilitiesAndStockholdersEquityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: StatementLineItems to DebtInstrumentInterestRateStatedPercentage" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquityAbstract" xlink:title="definition: StatementLineItems to StockholdersEquityAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="definition: StatementLineItems to CommonStockParOrStatedValuePerShare" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockSharesAuthorized" xlink:title="definition: StatementLineItems to CommonStockSharesAuthorized" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockSharesIssued" xlink:title="definition: StatementLineItems to CommonStockSharesIssued" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CommonStockSharesOutstanding" xlink:title="definition: StatementLineItems to CommonStockSharesOutstanding" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: StatementTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentMember" xlink:label="ConvertibleSeniorNotes0125PercentMember" xlink:title="ConvertibleSeniorNotes0125PercentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes0125PercentMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleSeniorNotes0125PercentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes1PercentMember" xlink:label="ConvertibleSeniorNotes1PercentMember" xlink:title="ConvertibleSeniorNotes1PercentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes1PercentMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleSeniorNotes1PercentMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/ConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="RevenuesAbstract" xlink:title="RevenuesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="RevenuesAbstract" xlink:title="definition: StatementLineItems to RevenuesAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CostsAndExpensesAbstract" xlink:title="definition: StatementLineItems to CostsAndExpensesAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OperatingIncomeLoss" xlink:title="definition: StatementLineItems to OperatingIncomeLoss" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="definition: StatementLineItems to NonoperatingIncomeExpenseAbstract" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="definition: StatementLineItems to IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncomeTaxExpenseBenefit" xlink:title="definition: StatementLineItems to IncomeTaxExpenseBenefit" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProfitLoss" xlink:title="definition: StatementLineItems to ProfitLoss" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="definition: StatementLineItems to NetIncomeLossAttributableToNoncontrollingInterest" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EarningsPerShareBasic" xlink:title="definition: StatementLineItems to EarningsPerShareBasic" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="definition: StatementLineItems to WeightedAverageNumberOfSharesOutstandingBasic" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="EarningsPerShareDiluted" xlink:title="definition: StatementLineItems to EarningsPerShareDiluted" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="definition: StatementLineItems to WeightedAverageNumberOfDilutedSharesOutstanding" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="InvestmentIncomeNet" xlink:title="InvestmentIncomeNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="InvestmentIncomeNet" xlink:title="definition: StatementLineItems to InvestmentIncomeNet" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="InterestExpense" xlink:title="definition: StatementLineItems to InterestExpense" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_GainLossOnExtinguishmentOfFinancingLiability" xlink:label="GainLossOnExtinguishmentOfFinancingLiability" xlink:title="GainLossOnExtinguishmentOfFinancingLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="GainLossOnExtinguishmentOfFinancingLiability" xlink:title="definition: StatementLineItems to GainLossOnExtinguishmentOfFinancingLiability" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="definition: StatementLineItems to GainsLossesOnExtinguishmentOfDebt" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="definition: StatementLineItems to OtherNonoperatingIncomeExpense" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="CostOfGoodsAndServicesSold" xlink:title="CostOfGoodsAndServicesSold" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CostOfGoodsAndServicesSold" xlink:title="definition: StatementLineItems to CostOfGoodsAndServicesSold" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchDevelopmentAndPatentExpense" xlink:label="ResearchDevelopmentAndPatentExpense" xlink:title="ResearchDevelopmentAndPatentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ResearchDevelopmentAndPatentExpense" xlink:title="definition: StatementLineItems to ResearchDevelopmentAndPatentExpense" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="definition: StatementLineItems to SellingGeneralAndAdministrativeExpense" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CostsAndExpenses" xlink:title="definition: StatementLineItems to CostsAndExpenses" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: StatementLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="24.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="ProductOrServiceAxis" xlink:title="definition: StatementTable to ProductOrServiceAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain_2" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain_2" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CommercialMember" xlink:label="CommercialMember" xlink:title="CommercialMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="CommercialMember" xlink:title="definition: ProductsAndServicesDomain to CommercialMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:label="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="definition: ProductsAndServicesDomain to ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SPINRAZARoyaltiesMember" xlink:label="SPINRAZARoyaltiesMember" xlink:title="SPINRAZARoyaltiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CommercialMember" xlink:to="SPINRAZARoyaltiesMember" xlink:title="definition: CommercialMember to SPINRAZARoyaltiesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="ProductMember" xlink:title="ProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CommercialMember" xlink:to="ProductMember" xlink:title="definition: CommercialMember to ProductMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LicensingAndOtherRoyaltiesMember" xlink:label="LicensingAndOtherRoyaltiesMember" xlink:title="LicensingAndOtherRoyaltiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CommercialMember" xlink:to="LicensingAndOtherRoyaltiesMember" xlink:title="definition: CommercialMember to LicensingAndOtherRoyaltiesMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="definition: StatementLineItems to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="SharesIssued" xlink:title="SharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharesIssued" xlink:title="definition: StatementLineItems to SharesIssued" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="definition: StatementLineItems to OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="definition: StatementLineItems to OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueNewIssues" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesNewIssues" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:title="StockIssuedDuringPeriodValueShareBasedCompensationGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueShareBasedCompensationGross" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesShareBasedCompensation" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" xlink:label="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" xlink:title="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:title="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="AdjustmentsToAdditionalPaidInCapitalOther" xlink:title="AdjustmentsToAdditionalPaidInCapitalOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalOther" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalOther" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="StockRepurchasedAndRetiredDuringPeriodValue" xlink:title="StockRepurchasedAndRetiredDuringPeriodValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockRepurchasedAndRetiredDuringPeriodValue" xlink:title="definition: StatementLineItems to StockRepurchasedAndRetiredDuringPeriodValue" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="StockRepurchasedAndRetiredDuringPeriodShares" xlink:title="StockRepurchasedAndRetiredDuringPeriodShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockRepurchasedAndRetiredDuringPeriodShares" xlink:title="definition: StatementLineItems to StockRepurchasedAndRetiredDuringPeriodShares" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary" xlink:label="StockIssuedDuringPeriodValueNewIssuesBySubsidiary" xlink:title="StockIssuedDuringPeriodValueNewIssuesBySubsidiary" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssuesBySubsidiary" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueNewIssuesBySubsidiary" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary" xlink:label="StockIssuedDuringPeriodSharesNewIssuesBySubsidiary" xlink:title="StockIssuedDuringPeriodSharesNewIssuesBySubsidiary" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssuesBySubsidiary" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesNewIssuesBySubsidiary" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" xlink:label="NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" xlink:title="NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" xlink:title="definition: StatementLineItems to NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="definition: StatementLineItems to SharesPaidForTaxWithholdingForShareBasedCompensation" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="MinorityInterestPeriodIncreaseDecrease" xlink:title="MinorityInterestPeriodIncreaseDecrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="MinorityInterestPeriodIncreaseDecrease" xlink:title="definition: StatementLineItems to MinorityInterestPeriodIncreaseDecrease" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="24.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="definition: EquityComponentDomain to AdditionalPaidInCapitalMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AccumulatedOtherComprehensiveIncomeMember" xlink:title="definition: EquityComponentDomain to AccumulatedOtherComprehensiveIncomeMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="ParentMember" xlink:title="ParentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="ParentMember" xlink:title="definition: EquityComponentDomain to ParentMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="NoncontrollingInterestMember" xlink:title="NoncontrollingInterestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="NoncontrollingInterestMember" xlink:title="definition: EquityComponentDomain to NoncontrollingInterestMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="CounterpartyNameAxis" xlink:title="definition: StatementTable to CounterpartyNameAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NovartisInternationalAGMember" xlink:label="NovartisInternationalAGMember" xlink:title="NovartisInternationalAGMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="NovartisInternationalAGMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to NovartisInternationalAGMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_BiogenIncMember" xlink:label="BiogenIncMember" xlink:title="BiogenIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="BiogenIncMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to BiogenIncMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: StatementLineItems to DebtInstrumentInterestRateStatedPercentage" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: StatementTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes1PercentMember" xlink:label="ConvertibleSeniorNotes1PercentMember" xlink:title="ConvertibleSeniorNotes1PercentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes1PercentMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleSeniorNotes1PercentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentMember" xlink:label="ConvertibleSeniorNotes0125PercentMember" xlink:title="ConvertibleSeniorNotes0125PercentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes0125PercentMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleSeniorNotes0125PercentMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/ConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="definition: StatementLineItems to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="definition: StatementLineItems to NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="definition: StatementLineItems to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="definition: StatementLineItems to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="definition: StatementLineItems to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="definition: StatementLineItems to SupplementalCashFlowInformationAbstract" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="definition: StatementLineItems to CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="definition: StatementLineItems to RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NonCashCapitalAndPatentExpenditures" xlink:label="NonCashCapitalAndPatentExpenditures" xlink:title="NonCashCapitalAndPatentExpenditures" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NonCashCapitalAndPatentExpenditures" xlink:title="definition: StatementLineItems to NonCashCapitalAndPatentExpenditures" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="CapitalExpendituresIncurredButNotYetPaid" xlink:title="CapitalExpendituresIncurredButNotYetPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CapitalExpendituresIncurredButNotYetPaid" xlink:title="definition: StatementLineItems to CapitalExpendituresIncurredButNotYetPaid" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesIssued1" xlink:label="NotesIssued1" xlink:title="NotesIssued1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NotesIssued1" xlink:title="definition: StatementLineItems to NotesIssued1" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesReduction" xlink:label="NotesReduction" xlink:title="NotesReduction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NotesReduction" xlink:title="definition: StatementLineItems to NotesReduction" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="InterestPaidNet" xlink:title="definition: StatementLineItems to InterestPaidNet" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="IncomeTaxesPaidNet" xlink:title="IncomeTaxesPaidNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncomeTaxesPaidNet" xlink:title="definition: StatementLineItems to IncomeTaxesPaidNet" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:title="ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:title="definition: StatementLineItems to ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="definition: StatementLineItems to PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="ProceedsFromConvertibleDebt" xlink:title="ProceedsFromConvertibleDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProceedsFromConvertibleDebt" xlink:title="definition: StatementLineItems to ProceedsFromConvertibleDebt" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PaymentsOfDebtIssuanceCosts" xlink:title="definition: StatementLineItems to PaymentsOfDebtIssuanceCosts" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="ProceedsFromIssuanceOfWarrants" xlink:title="ProceedsFromIssuanceOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProceedsFromIssuanceOfWarrants" xlink:title="definition: StatementLineItems to ProceedsFromIssuanceOfWarrants" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities" xlink:label="PaymentsForHedgeFinancingActivities" xlink:title="PaymentsForHedgeFinancingActivities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PaymentsForHedgeFinancingActivities" xlink:title="definition: StatementLineItems to PaymentsForHedgeFinancingActivities" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="PaymentsForRepurchaseOfCommonStock" xlink:title="PaymentsForRepurchaseOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PaymentsForRepurchaseOfCommonStock" xlink:title="definition: StatementLineItems to PaymentsForRepurchaseOfCommonStock" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:title="RepaymentsOfLongTermDebtAndCapitalSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:title="definition: StatementLineItems to RepaymentsOfLongTermDebtAndCapitalSecurities" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="ProceedsFromIssuanceInitialPublicOffering" xlink:title="ProceedsFromIssuanceInitialPublicOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProceedsFromIssuanceInitialPublicOffering" xlink:title="definition: StatementLineItems to ProceedsFromIssuanceInitialPublicOffering" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="ProceedsFromDebtNetOfIssuanceCosts" xlink:title="ProceedsFromDebtNetOfIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProceedsFromDebtNetOfIssuanceCosts" xlink:title="definition: StatementLineItems to ProceedsFromDebtNetOfIssuanceCosts" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: StatementLineItems to ProceedsFromIssuanceOfCommonStock" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="ProceedsFromIssuanceOfPrivatePlacement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="definition: StatementLineItems to ProceedsFromIssuanceOfPrivatePlacement" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="definition: StatementLineItems to PaymentsOfStockIssuanceCosts" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PaymentToSettleFinancingLiabilityForLeasedFacility" xlink:label="PaymentToSettleFinancingLiabilityForLeasedFacility" xlink:title="PaymentToSettleFinancingLiabilityForLeasedFacility" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PaymentToSettleFinancingLiabilityForLeasedFacility" xlink:title="definition: StatementLineItems to PaymentToSettleFinancingLiabilityForLeasedFacility" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="definition: StatementLineItems to NetCashProvidedByUsedInFinancingActivities" order="29.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:title="PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:title="definition: StatementLineItems to PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:title="ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:title="definition: StatementLineItems to ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="31.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="definition: StatementLineItems to PaymentsToAcquirePropertyPlantAndEquipment" order="32.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PaymentsToAcquireLicensesAndOtherAssets" xlink:label="PaymentsToAcquireLicensesAndOtherAssets" xlink:title="PaymentsToAcquireLicensesAndOtherAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PaymentsToAcquireLicensesAndOtherAssets" xlink:title="definition: StatementLineItems to PaymentsToAcquireLicensesAndOtherAssets" order="33.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PaymentsToAcquireCostMethodInvestments" xlink:label="PaymentsToAcquireCostMethodInvestments" xlink:title="PaymentsToAcquireCostMethodInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="PaymentsToAcquireCostMethodInvestments" xlink:title="definition: StatementLineItems to PaymentsToAcquireCostMethodInvestments" order="34.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="ProceedsFromSaleOfEquityMethodInvestments" xlink:title="ProceedsFromSaleOfEquityMethodInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProceedsFromSaleOfEquityMethodInvestments" xlink:title="definition: StatementLineItems to ProceedsFromSaleOfEquityMethodInvestments" order="35.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="definition: StatementLineItems to NetCashProvidedByUsedInInvestingActivities" order="36.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ProfitLoss" xlink:title="definition: StatementLineItems to ProfitLoss" order="37.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="definition: StatementLineItems to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="38.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="definition: StatementLineItems to NetCashProvidedByUsedInOperatingActivities" order="39.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="Depreciation" xlink:title="definition: StatementLineItems to Depreciation" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_OperatingLeaseRightOfUseAssetAmortization" xlink:label="OperatingLeaseRightOfUseAssetAmortization" xlink:title="OperatingLeaseRightOfUseAssetAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="OperatingLeaseRightOfUseAssetAmortization" xlink:title="definition: StatementLineItems to OperatingLeaseRightOfUseAssetAmortization" order="41.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AmortizationOfIntangibleAssets" xlink:title="definition: StatementLineItems to AmortizationOfIntangibleAssets" order="42.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:title="AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:title="definition: StatementLineItems to AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="43.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="AmortizationOfFinancingCosts" xlink:title="AmortizationOfFinancingCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AmortizationOfFinancingCosts" xlink:title="definition: StatementLineItems to AmortizationOfFinancingCosts" order="44.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="definition: StatementLineItems to AmortizationOfDebtDiscountPremium" order="45.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfLeasedAsset" xlink:label="AmortizationOfLeasedAsset" xlink:title="AmortizationOfLeasedAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AmortizationOfLeasedAsset" xlink:title="definition: StatementLineItems to AmortizationOfLeasedAsset" order="46.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="ShareBasedCompensation" xlink:title="definition: StatementLineItems to ShareBasedCompensation" order="47.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="GainOnSaleOfInvestments" xlink:title="GainOnSaleOfInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="GainOnSaleOfInvestments" xlink:title="definition: StatementLineItems to GainOnSaleOfInvestments" order="48.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_GainLossOnExtinguishmentOfFinancingLiability" xlink:label="GainLossOnExtinguishmentOfFinancingLiability" xlink:title="GainLossOnExtinguishmentOfFinancingLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="GainLossOnExtinguishmentOfFinancingLiability" xlink:title="definition: StatementLineItems to GainLossOnExtinguishmentOfFinancingLiability" order="49.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="definition: StatementLineItems to GainsLossesOnExtinguishmentOfDebt" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="DeferredIncomeTaxesAndTaxCredits" xlink:title="DeferredIncomeTaxesAndTaxCredits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DeferredIncomeTaxesAndTaxCredits" xlink:title="definition: StatementLineItems to DeferredIncomeTaxesAndTaxCredits" order="51.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" xlink:label="AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" xlink:title="AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" xlink:title="definition: StatementLineItems to AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" order="52.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="definition: StatementLineItems to IncreaseDecreaseInOperatingCapitalAbstract" order="53.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="IncreaseDecreaseInContractWithCustomerAsset" xlink:title="IncreaseDecreaseInContractWithCustomerAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInContractWithCustomerAsset" xlink:title="definition: StatementLineItems to IncreaseDecreaseInContractWithCustomerAsset" order="54.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInInventories" xlink:title="definition: StatementLineItems to IncreaseDecreaseInInventories" order="55.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="IncreaseDecreaseInOtherOperatingAssets" xlink:title="IncreaseDecreaseInOtherOperatingAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInOtherOperatingAssets" xlink:title="definition: StatementLineItems to IncreaseDecreaseInOtherOperatingAssets" order="56.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="IncreaseDecreaseInIncomeTaxesReceivable" xlink:title="IncreaseDecreaseInIncomeTaxesReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInIncomeTaxesReceivable" xlink:title="definition: StatementLineItems to IncreaseDecreaseInIncomeTaxesReceivable" order="57.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="definition: StatementLineItems to IncreaseDecreaseInAccountsPayable" order="58.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:label="IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:title="IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:title="definition: StatementLineItems to IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" order="59.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities" xlink:label="IncreaseDecreaseInOtherEmployeeRelatedLiabilities" xlink:title="IncreaseDecreaseInOtherEmployeeRelatedLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInOtherEmployeeRelatedLiabilities" xlink:title="definition: StatementLineItems to IncreaseDecreaseInOtherEmployeeRelatedLiabilities" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" xlink:title="definition: StatementLineItems to IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" order="61.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="IncreaseDecreaseInContractWithCustomerLiability" xlink:title="IncreaseDecreaseInContractWithCustomerLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInContractWithCustomerLiability" xlink:title="definition: StatementLineItems to IncreaseDecreaseInContractWithCustomerLiability" order="62.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="63.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="MajorCustomersAxis" xlink:title="definition: StatementTable to MajorCustomersAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain_2" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain_2" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_BiogenIncMember" xlink:label="BiogenIncMember" xlink:title="BiogenIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="BiogenIncMember" xlink:title="definition: NameOfMajorCustomerDomain to BiogenIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NovartisInternationalAGMember" xlink:label="NovartisInternationalAGMember" xlink:title="NovartisInternationalAGMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="NovartisInternationalAGMember" xlink:title="definition: NameOfMajorCustomerDomain to NovartisInternationalAGMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="definition: StatementLineItems to CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: StatementLineItems to DebtInstrumentInterestRateStatedPercentage" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: StatementTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentMember" xlink:label="ConvertibleSeniorNotes0125PercentMember" xlink:title="ConvertibleSeniorNotes0125PercentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes0125PercentMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleSeniorNotes0125PercentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes1PercentMember" xlink:label="ConvertibleSeniorNotes1PercentMember" xlink:title="ConvertibleSeniorNotes1PercentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes1PercentMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleSeniorNotes1PercentMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/Investments" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/LongtermObligationsAndCommitments" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/StockholdersEquity" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxes" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreements" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRisk" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/EmploymentBenefits" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/LegalProceedings" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/QuarterlyFinancialDataUnaudited" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/InvestmentsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/LongtermObligationsAndCommitmentsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/StockholdersEquityTables">
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ShareBasedCompensationLineItems" xlink:label="ShareBasedCompensationLineItems" xlink:title="ShareBasedCompensationLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationLineItems" xlink:to="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="definition: ShareBasedCompensationLineItems to ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationLineItems" xlink:to="ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:title="definition: ShareBasedCompensationLineItems to ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ShareBasedCompensationTable" xlink:label="ShareBasedCompensationTable" xlink:title="ShareBasedCompensationTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationLineItems" xlink:to="ShareBasedCompensationTable" xlink:title="definition: ShareBasedCompensationLineItems to ShareBasedCompensationTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ShareBasedCompensationTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="definition: ShareBasedCompensationTable to ConsolidatedEntitiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain_2" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain_2" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidatedEntitiesDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="definition: ConsolidatedEntitiesDomain to AkceaTherapeuticsIncMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables">
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems" xlink:label="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems" xlink:title="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:title="SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems" xlink:to="SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:title="definition: CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems to SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable" xlink:label="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable" xlink:title="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems" xlink:to="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable" xlink:title="definition: CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems to CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementsAndLicensingAgreementsBiogenMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsBayerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementsAndLicensingAgreementsBayerMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsRocheMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsRocheMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementsAndLicensingAgreementsRocheMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementsAndLicensingAgreementsRocheMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" order="9.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/QuarterlyFinancialDataUnauditedTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="MinorityInterestLineItems" xlink:title="MinorityInterestLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:label="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="ProceedsFromIssuanceOrSaleOfEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MinorityInterestLineItems" xlink:to="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="definition: MinorityInterestLineItems to ProceedsFromIssuanceOrSaleOfEquityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MinorityInterestLineItems" xlink:to="MinorityInterestOwnershipPercentageByParent" xlink:title="definition: MinorityInterestLineItems to MinorityInterestOwnershipPercentageByParent" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SharesReceivedFromSubsidiaryForLicenseOfDrug" xlink:label="SharesReceivedFromSubsidiaryForLicenseOfDrug" xlink:title="SharesReceivedFromSubsidiaryForLicenseOfDrug" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MinorityInterestLineItems" xlink:to="SharesReceivedFromSubsidiaryForLicenseOfDrug" xlink:title="definition: MinorityInterestLineItems to SharesReceivedFromSubsidiaryForLicenseOfDrug" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="MinorityInterestTable" xlink:title="MinorityInterestTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="MinorityInterestLineItems" xlink:to="MinorityInterestTable" xlink:title="definition: MinorityInterestLineItems to MinorityInterestTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="MinorityInterestTable" xlink:to="OwnershipAxis" xlink:title="definition: MinorityInterestTable to OwnershipAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="definition: OwnershipAxis to OwnershipDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain_2" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain_2" xlink:title="definition: OwnershipAxis to OwnershipDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OwnershipDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="definition: OwnershipDomain to AkceaTherapeuticsIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="MinorityInterestTable" xlink:to="RangeAxis" xlink:title="definition: MinorityInterestTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="EarningsPerShareBasicLineItems" xlink:title="EarningsPerShareBasicLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="EarningsPerShareBasicAbstract" xlink:title="EarningsPerShareBasicAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="EarningsPerShareBasicAbstract" xlink:title="definition: EarningsPerShareBasicLineItems to EarningsPerShareBasicAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="PreferredStockDividendRatePercentage" xlink:title="PreferredStockDividendRatePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="PreferredStockDividendRatePercentage" xlink:title="definition: EarningsPerShareBasicLineItems to PreferredStockDividendRatePercentage" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="ConvertiblePreferredStockTermsOfConversion" xlink:title="ConvertiblePreferredStockTermsOfConversion" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="ConvertiblePreferredStockTermsOfConversion" xlink:title="definition: EarningsPerShareBasicLineItems to ConvertiblePreferredStockTermsOfConversion" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_WeightedAverageNumberOfSharesOwnedInSubsidiary" xlink:label="WeightedAverageNumberOfSharesOwnedInSubsidiary" xlink:title="WeightedAverageNumberOfSharesOwnedInSubsidiary" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="WeightedAverageNumberOfSharesOwnedInSubsidiary" xlink:title="definition: EarningsPerShareBasicLineItems to WeightedAverageNumberOfSharesOwnedInSubsidiary" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="EarningsPerShareBasic" xlink:title="definition: EarningsPerShareBasicLineItems to EarningsPerShareBasic" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: EarningsPerShareBasicLineItems to NetIncomeLoss" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="definition: EarningsPerShareBasicLineItems to NetIncomeLossAvailableToCommonStockholdersBasic" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="definition: EarningsPerShareBasicLineItems to WeightedAverageNumberOfSharesOutstandingBasic" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:title="NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:title="definition: EarningsPerShareBasicLineItems to NetIncomeLossAvailableToCommonStockholdersDiluted" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="definition: EarningsPerShareBasicLineItems to IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" xlink:label="IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" xlink:title="IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" xlink:title="definition: EarningsPerShareBasicLineItems to IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="definition: EarningsPerShareBasicLineItems to WeightedAverageNumberOfDilutedSharesOutstanding" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="EarningsPerShareDiluted" xlink:title="definition: EarningsPerShareBasicLineItems to EarningsPerShareDiluted" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:title="ScheduleOfEarningsPerShareBasicByCommonClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EarningsPerShareBasicLineItems" xlink:to="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:title="definition: EarningsPerShareBasicLineItems to ScheduleOfEarningsPerShareBasicByCommonClassTable" order="14.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="definition: ScheduleOfEarningsPerShareBasicByCommonClassTable to ConsolidatedEntitiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain_2" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain_2" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidatedEntitiesDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="definition: ConsolidatedEntitiesDomain to AkceaTherapeuticsIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: ScheduleOfEarningsPerShareBasicByCommonClassTable to StatementClassOfStockAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="definition: ClassOfStockDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="ConvertiblePreferredStockMember" xlink:title="definition: ClassOfStockDomain to ConvertiblePreferredStockMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="definition: ScheduleOfEarningsPerShareBasicByCommonClassTable to StatementBusinessSegmentsAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain_2" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain_2" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IonisCoreMember" xlink:label="IonisCoreMember" xlink:title="IonisCoreMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="IonisCoreMember" xlink:title="definition: SegmentDomain to IonisCoreMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfEarningsPerShareBasicByCommonClassTable to AwardTypeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="DisaggregationOfRevenueLineItems" xlink:title="DisaggregationOfRevenueLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" xlink:title="RevenueFromContractWithCustomerAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisaggregationOfRevenueLineItems" xlink:to="RevenueFromContractWithCustomerAbstract" xlink:title="definition: DisaggregationOfRevenueLineItems to RevenueFromContractWithCustomerAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract" xlink:label="RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract" xlink:title="RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisaggregationOfRevenueLineItems" xlink:to="RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract" xlink:title="definition: DisaggregationOfRevenueLineItems to RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisaggregationOfRevenueLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: DisaggregationOfRevenueLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceived" xlink:label="UpfrontPaymentReceived" xlink:title="UpfrontPaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisaggregationOfRevenueLineItems" xlink:to="UpfrontPaymentReceived" xlink:title="definition: DisaggregationOfRevenueLineItems to UpfrontPaymentReceived" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfMilestonePaymentsAchieved" xlink:label="NumberOfMilestonePaymentsAchieved" xlink:title="NumberOfMilestonePaymentsAchieved" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisaggregationOfRevenueLineItems" xlink:to="NumberOfMilestonePaymentsAchieved" xlink:title="definition: DisaggregationOfRevenueLineItems to NumberOfMilestonePaymentsAchieved" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerTransactionPriceAdditions" xlink:label="RevenueFromContractWithCustomerTransactionPriceAdditions" xlink:title="RevenueFromContractWithCustomerTransactionPriceAdditions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisaggregationOfRevenueLineItems" xlink:to="RevenueFromContractWithCustomerTransactionPriceAdditions" xlink:title="definition: DisaggregationOfRevenueLineItems to RevenueFromContractWithCustomerTransactionPriceAdditions" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfNewTargetsAdvanced" xlink:label="NumberOfNewTargetsAdvanced" xlink:title="NumberOfNewTargetsAdvanced" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisaggregationOfRevenueLineItems" xlink:to="NumberOfNewTargetsAdvanced" xlink:title="definition: DisaggregationOfRevenueLineItems to NumberOfNewTargetsAdvanced" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisaggregationOfRevenueLineItems" xlink:to="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="definition: DisaggregationOfRevenueLineItems to RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerTransactionPrice" xlink:label="RevenueFromContractWithCustomerTransactionPrice" xlink:title="RevenueFromContractWithCustomerTransactionPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisaggregationOfRevenueLineItems" xlink:to="RevenueFromContractWithCustomerTransactionPrice" xlink:title="definition: DisaggregationOfRevenueLineItems to RevenueFromContractWithCustomerTransactionPrice" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfAgreementsWithCollaborationPartner" xlink:label="NumberOfAgreementsWithCollaborationPartner" xlink:title="NumberOfAgreementsWithCollaborationPartner" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DisaggregationOfRevenueLineItems" xlink:to="NumberOfAgreementsWithCollaborationPartner" xlink:title="definition: DisaggregationOfRevenueLineItems to NumberOfAgreementsWithCollaborationPartner" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="DisaggregationOfRevenueTable" xlink:title="DisaggregationOfRevenueTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DisaggregationOfRevenueLineItems" xlink:to="DisaggregationOfRevenueTable" xlink:title="definition: DisaggregationOfRevenueLineItems to DisaggregationOfRevenueTable" order="11.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisaggregationOfRevenueTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: DisaggregationOfRevenueTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsBayerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementsAndLicensingAgreementsBayerMember" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" xlink:title="definition: CollaborativeArrangementsAndLicensingAgreementsBayerMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" xlink:label="CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" xlink:title="CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:to="CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" xlink:title="definition: CollaborativeArrangementsAndLicensingAgreementsBayerMember to CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisaggregationOfRevenueTable" xlink:to="ProductOrServiceAxis" xlink:title="definition: DisaggregationOfRevenueTable to ProductOrServiceAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain_2" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain_2" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LicensingAndOtherRoyaltiesMember" xlink:label="LicensingAndOtherRoyaltiesMember" xlink:title="LicensingAndOtherRoyaltiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="LicensingAndOtherRoyaltiesMember" xlink:title="definition: ProductsAndServicesDomain to LicensingAndOtherRoyaltiesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DisaggregationOfRevenueTable" xlink:to="MajorCustomersAxis" xlink:title="definition: DisaggregationOfRevenueTable to MajorCustomersAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain_2" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain_2" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_BiogenIncMember" xlink:label="BiogenIncMember" xlink:title="BiogenIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="BiogenIncMember" xlink:title="definition: NameOfMajorCustomerDomain to BiogenIncMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesContractsReceivableDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesDeferredRevenueDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesCostOfProductsSoldDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="ResearchAndDevelopmentExpenseAbstract" xlink:title="ResearchAndDevelopmentExpenseAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="ResearchAndDevelopmentExpenseAbstract" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to ResearchAndDevelopmentExpenseAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="ResearchAndDevelopmentExpense" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to ResearchAndDevelopmentExpense" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PatentAbstract" xlink:label="PatentAbstract" xlink:title="PatentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="PatentAbstract" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to PatentAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetUsefulLife" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetUsefulLife" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsGross" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsGross" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsAccumulatedAmortization" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PatentExpenses" xlink:label="PatentExpenses" xlink:title="PatentExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="PatentExpenses" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to PatentExpenses" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="ImpairmentOfIntangibleAssetsFinitelived" xlink:title="ImpairmentOfIntangibleAssetsFinitelived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="ImpairmentOfIntangibleAssetsFinitelived" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to ImpairmentOfIntangibleAssetsFinitelived" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to ScheduleOfFiniteLivedIntangibleAssetsTable" order="15.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ScheduleOfFiniteLivedIntangibleAssetsTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementsAndLicensingAgreementsMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementsAndLicensingAgreementsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="definition: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PatentsMember" xlink:label="PatentsMember" xlink:title="PatentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="PatentsMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to PatentsMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="MinorityInterestLineItems" xlink:title="MinorityInterestLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:label="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="ProceedsFromIssuanceOrSaleOfEquityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MinorityInterestLineItems" xlink:to="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="definition: MinorityInterestLineItems to ProceedsFromIssuanceOrSaleOfEquityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MinorityInterestLineItems" xlink:to="MinorityInterestOwnershipPercentageByParent" xlink:title="definition: MinorityInterestLineItems to MinorityInterestOwnershipPercentageByParent" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SharesReceivedFromSubsidiaryForLicenseOfDrug" xlink:label="SharesReceivedFromSubsidiaryForLicenseOfDrug" xlink:title="SharesReceivedFromSubsidiaryForLicenseOfDrug" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MinorityInterestLineItems" xlink:to="SharesReceivedFromSubsidiaryForLicenseOfDrug" xlink:title="definition: MinorityInterestLineItems to SharesReceivedFromSubsidiaryForLicenseOfDrug" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="MinorityInterestTable" xlink:title="MinorityInterestTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="MinorityInterestLineItems" xlink:to="MinorityInterestTable" xlink:title="definition: MinorityInterestLineItems to MinorityInterestTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="MinorityInterestTable" xlink:to="OwnershipAxis" xlink:title="definition: MinorityInterestTable to OwnershipAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="definition: OwnershipAxis to OwnershipDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain_2" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain_2" xlink:title="definition: OwnershipAxis to OwnershipDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OwnershipDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="definition: OwnershipDomain to AkceaTherapeuticsIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="MinorityInterestTable" xlink:to="RangeAxis" xlink:title="definition: MinorityInterestTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndInvestmentsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="InventoryLineItems" xlink:title="InventoryLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="InventoryNetAbstract" xlink:title="InventoryNetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InventoryLineItems" xlink:to="InventoryNetAbstract" xlink:title="definition: InventoryLineItems to InventoryNetAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="InventoryWriteDown" xlink:title="InventoryWriteDown" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InventoryLineItems" xlink:to="InventoryWriteDown" xlink:title="definition: InventoryLineItems to InventoryWriteDown" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="InventoryRawMaterials" xlink:title="InventoryRawMaterials" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InventoryLineItems" xlink:to="InventoryRawMaterials" xlink:title="definition: InventoryLineItems to InventoryRawMaterials" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="InventoryWorkInProcess" xlink:title="InventoryWorkInProcess" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InventoryLineItems" xlink:to="InventoryWorkInProcess" xlink:title="definition: InventoryLineItems to InventoryWorkInProcess" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="InventoryFinishedGoods" xlink:title="InventoryFinishedGoods" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InventoryLineItems" xlink:to="InventoryFinishedGoods" xlink:title="definition: InventoryLineItems to InventoryFinishedGoods" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InventoryLineItems" xlink:to="InventoryNet" xlink:title="definition: InventoryLineItems to InventoryNet" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="InventoryCurrentTable" xlink:title="InventoryCurrentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="InventoryLineItems" xlink:to="InventoryCurrentTable" xlink:title="definition: InventoryLineItems to InventoryCurrentTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="PublicUtilitiesInventoryAxis" xlink:title="PublicUtilitiesInventoryAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="InventoryCurrentTable" xlink:to="PublicUtilitiesInventoryAxis" xlink:title="definition: InventoryCurrentTable to PublicUtilitiesInventoryAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="PublicUtilitiesInventoryTypeDomain" xlink:title="PublicUtilitiesInventoryTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PublicUtilitiesInventoryAxis" xlink:to="PublicUtilitiesInventoryTypeDomain" xlink:title="definition: PublicUtilitiesInventoryAxis to PublicUtilitiesInventoryTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="PublicUtilitiesInventoryTypeDomain_2" xlink:title="PublicUtilitiesInventoryTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PublicUtilitiesInventoryAxis" xlink:to="PublicUtilitiesInventoryTypeDomain_2" xlink:title="definition: PublicUtilitiesInventoryAxis to PublicUtilitiesInventoryTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ClinicalRawMaterialsMember" xlink:label="ClinicalRawMaterialsMember" xlink:title="ClinicalRawMaterialsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PublicUtilitiesInventoryTypeDomain" xlink:to="ClinicalRawMaterialsMember" xlink:title="definition: PublicUtilitiesInventoryTypeDomain to ClinicalRawMaterialsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CommercialRawMaterialsMember" xlink:label="CommercialRawMaterialsMember" xlink:title="CommercialRawMaterialsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PublicUtilitiesInventoryTypeDomain" xlink:to="CommercialRawMaterialsMember" xlink:title="definition: PublicUtilitiesInventoryTypeDomain to CommercialRawMaterialsMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentAbstract" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentGross" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="definition: PropertyPlantAndEquipmentLineItems to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNet" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentUsefulLife" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ScheduleOfPropertyPlantAndEquipmentTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PropertyPlantAndEquipmentExcludingLandMember" xlink:label="PropertyPlantAndEquipmentExcludingLandMember" xlink:title="PropertyPlantAndEquipmentExcludingLandMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="PropertyPlantAndEquipmentExcludingLandMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to PropertyPlantAndEquipmentExcludingLandMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandMember" xlink:label="LandMember" xlink:title="LandMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LandMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LandMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EquipmentAndComputerSoftwareMember" xlink:label="EquipmentAndComputerSoftwareMember" xlink:title="EquipmentAndComputerSoftwareMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentExcludingLandMember" xlink:to="EquipmentAndComputerSoftwareMember" xlink:title="definition: PropertyPlantAndEquipmentExcludingLandMember to EquipmentAndComputerSoftwareMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="BuildingAndBuildingImprovementsMember" xlink:title="BuildingAndBuildingImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentExcludingLandMember" xlink:to="BuildingAndBuildingImprovementsMember" xlink:title="definition: PropertyPlantAndEquipmentExcludingLandMember to BuildingAndBuildingImprovementsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandImprovementsMember" xlink:label="LandImprovementsMember" xlink:title="LandImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentExcludingLandMember" xlink:to="LandImprovementsMember" xlink:title="definition: PropertyPlantAndEquipmentExcludingLandMember to LandImprovementsMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentExcludingLandMember" xlink:to="LeaseholdImprovementsMember" xlink:title="definition: PropertyPlantAndEquipmentExcludingLandMember to LeaseholdImprovementsMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentExcludingLandMember" xlink:to="FurnitureAndFixturesMember" xlink:title="definition: PropertyPlantAndEquipmentExcludingLandMember to FurnitureAndFixturesMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLeasesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:title="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="LesseeDisclosureAbstract" xlink:title="LesseeDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="LesseeDisclosureAbstract" xlink:title="definition: NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems to LesseeDisclosureAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="definition: NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems to OperatingLeaseRightOfUseAsset" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="OperatingLeaseLiability" xlink:title="definition: NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems to OperatingLeaseLiability" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="definition: NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems to OperatingLeaseLiabilityCurrent" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:title="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:title="definition: NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems to NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="definition: NewAccountingPronouncementsOrChangeInAccountingPrincipleTable to AdjustmentsForNewAccountingPronouncementsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember" xlink:title="definition: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember_2" xlink:title="TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember_2" xlink:title="definition: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="AccountingStandardsUpdate201602Member" xlink:title="AccountingStandardsUpdate201602Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TypeOfAdoptionMember" xlink:to="AccountingStandardsUpdate201602Member" xlink:title="definition: TypeOfAdoptionMember to AccountingStandardsUpdate201602Member" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLonglivedAssetsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:title="AccumulatedOtherComprehensiveIncomeLossLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:label="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:title="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:title="definition: AccumulatedOtherComprehensiveIncomeLossLineItems to ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="definition: AccumulatedOtherComprehensiveIncomeLossLineItems to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:title="OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:title="definition: AccumulatedOtherComprehensiveIncomeLossLineItems to OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:title="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:title="definition: AccumulatedOtherComprehensiveIncomeLossLineItems to ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="OtherComprehensiveIncomeLossNetOfTax" xlink:title="OtherComprehensiveIncomeLossNetOfTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="OtherComprehensiveIncomeLossNetOfTax" xlink:title="definition: AccumulatedOtherComprehensiveIncomeLossLineItems to OtherComprehensiveIncomeLossNetOfTax" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="OtherComprehensiveIncomeLossTax" xlink:title="OtherComprehensiveIncomeLossTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="OtherComprehensiveIncomeLossTax" xlink:title="definition: AccumulatedOtherComprehensiveIncomeLossLineItems to OtherComprehensiveIncomeLossTax" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="AccumulatedOtherComprehensiveIncomeLossTable" xlink:title="AccumulatedOtherComprehensiveIncomeLossTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="AccumulatedOtherComprehensiveIncomeLossTable" xlink:title="definition: AccumulatedOtherComprehensiveIncomeLossLineItems to AccumulatedOtherComprehensiveIncomeLossTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: AccumulatedOtherComprehensiveIncomeLossTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:title="AociIncludingPortionAttributableToNoncontrollingInterestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:title="definition: EquityComponentDomain to AociIncludingPortionAttributableToNoncontrollingInterestMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:title="AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:title="definition: AociIncludingPortionAttributableToNoncontrollingInterestMember to AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:title="AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:title="definition: AociIncludingPortionAttributableToNoncontrollingInterestMember to AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesConvertibleDebtDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:title="LongtermConvertibleDebtCurrentAndNoncurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:title="definition: DebtInstrumentLineItems to LongtermConvertibleDebtCurrentAndNoncurrentAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateStatedPercentage" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentMember" xlink:label="ConvertibleSeniorNotes0125PercentMember" xlink:title="ConvertibleSeniorNotes0125PercentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes0125PercentMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleSeniorNotes0125PercentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes1PercentMember" xlink:label="ConvertibleSeniorNotes1PercentMember" xlink:title="ConvertibleSeniorNotes1PercentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes1PercentMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleSeniorNotes1PercentMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesSegmentInformationDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueNetAssetLiabilityAbstract" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueNetAssetLiabilityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="CashAndCashEquivalentsFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to CashAndCashEquivalentsFairValueDisclosure" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="AvailableForSaleSecurities" xlink:title="AvailableForSaleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="AvailableForSaleSecurities" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to AvailableForSaleSecurities" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="EquitySecuritiesFvNi" xlink:title="EquitySecuritiesFvNi" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="EquitySecuritiesFvNi" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to EquitySecuritiesFvNi" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="AssetsFairValueDisclosure" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to AssetsFairValueDisclosure" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain_2" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain_2" xlink:title="definition: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="definition: FairValueMeasurementFrequencyDomain to FairValueMeasurementsRecurringMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FinancialInstrumentAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FinancialInstrumentAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" xlink:title="definition: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="CorporateDebtSecuritiesMember" xlink:title="CorporateDebtSecuritiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="CorporateDebtSecuritiesMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to CorporateDebtSecuritiesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="USGovernmentAgenciesDebtSecuritiesMember" xlink:title="USGovernmentAgenciesDebtSecuritiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="USGovernmentAgenciesDebtSecuritiesMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to USGovernmentAgenciesDebtSecuritiesMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="USTreasurySecuritiesMember" xlink:title="USTreasurySecuritiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="USTreasurySecuritiesMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to USTreasurySecuritiesMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="USStatesAndPoliticalSubdivisionsMember" xlink:title="USStatesAndPoliticalSubdivisionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="USStatesAndPoliticalSubdivisionsMember" xlink:title="definition: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to USStatesAndPoliticalSubdivisionsMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="BalanceSheetLocationAxis" xlink:title="BalanceSheetLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="BalanceSheetLocationAxis" xlink:title="definition: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to BalanceSheetLocationAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="BalanceSheetLocationDomain" xlink:title="BalanceSheetLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BalanceSheetLocationAxis" xlink:to="BalanceSheetLocationDomain" xlink:title="definition: BalanceSheetLocationAxis to BalanceSheetLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="BalanceSheetLocationDomain_2" xlink:title="BalanceSheetLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BalanceSheetLocationAxis" xlink:to="BalanceSheetLocationDomain_2" xlink:title="definition: BalanceSheetLocationAxis to BalanceSheetLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="CashAndCashEquivalentsMember" xlink:title="CashAndCashEquivalentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BalanceSheetLocationDomain" xlink:to="CashAndCashEquivalentsMember" xlink:title="definition: BalanceSheetLocationDomain to CashAndCashEquivalentsMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsLineItems" xlink:label="InvestmentHoldingsLineItems" xlink:title="InvestmentHoldingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:title="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentHoldingsLineItems" xlink:to="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:title="definition: InvestmentHoldingsLineItems to AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:title="AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentHoldingsLineItems" xlink:to="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:title="definition: InvestmentHoldingsLineItems to AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:title="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentHoldingsLineItems" xlink:to="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:title="definition: InvestmentHoldingsLineItems to AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:title="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentHoldingsLineItems" xlink:to="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:title="definition: InvestmentHoldingsLineItems to AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="AvailableForSaleSecuritiesDebtSecurities" xlink:title="AvailableForSaleSecuritiesDebtSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentHoldingsLineItems" xlink:to="AvailableForSaleSecuritiesDebtSecurities" xlink:title="definition: InvestmentHoldingsLineItems to AvailableForSaleSecuritiesDebtSecurities" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:label="EquitySecuritiesFvNiCost" xlink:title="EquitySecuritiesFvNiCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentHoldingsLineItems" xlink:to="EquitySecuritiesFvNiCost" xlink:title="definition: InvestmentHoldingsLineItems to EquitySecuritiesFvNiCost" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="EquitySecuritiesFvNiUnrealizedGain" xlink:title="EquitySecuritiesFvNiUnrealizedGain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentHoldingsLineItems" xlink:to="EquitySecuritiesFvNiUnrealizedGain" xlink:title="definition: InvestmentHoldingsLineItems to EquitySecuritiesFvNiUnrealizedGain" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="EquitySecuritiesFvNiUnrealizedLoss" xlink:title="EquitySecuritiesFvNiUnrealizedLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentHoldingsLineItems" xlink:to="EquitySecuritiesFvNiUnrealizedLoss" xlink:title="definition: InvestmentHoldingsLineItems to EquitySecuritiesFvNiUnrealizedLoss" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="EquitySecuritiesFvNi" xlink:title="EquitySecuritiesFvNi" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentHoldingsLineItems" xlink:to="EquitySecuritiesFvNi" xlink:title="definition: InvestmentHoldingsLineItems to EquitySecuritiesFvNi" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:label="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:title="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentHoldingsLineItems" xlink:to="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:title="definition: InvestmentHoldingsLineItems to DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:label="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:title="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentHoldingsLineItems" xlink:to="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:title="definition: InvestmentHoldingsLineItems to DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:label="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:title="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentHoldingsLineItems" xlink:to="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:title="definition: InvestmentHoldingsLineItems to DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:label="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:title="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentHoldingsLineItems" xlink:to="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:title="definition: InvestmentHoldingsLineItems to DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsTable" xlink:label="InvestmentHoldingsTable" xlink:title="InvestmentHoldingsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="InvestmentHoldingsLineItems" xlink:to="InvestmentHoldingsTable" xlink:title="definition: InvestmentHoldingsLineItems to InvestmentHoldingsTable" order="14.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="InvestmentTypeAxis" xlink:title="InvestmentTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="InvestmentHoldingsTable" xlink:to="InvestmentTypeAxis" xlink:title="definition: InvestmentHoldingsTable to InvestmentTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember" xlink:title="InvestmentTypeCategorizationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="InvestmentTypeAxis" xlink:to="InvestmentTypeCategorizationMember" xlink:title="definition: InvestmentTypeAxis to InvestmentTypeCategorizationMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember_2" xlink:title="InvestmentTypeCategorizationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="InvestmentTypeAxis" xlink:to="InvestmentTypeCategorizationMember_2" xlink:title="definition: InvestmentTypeAxis to InvestmentTypeCategorizationMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="DebtSecuritiesMember" xlink:title="DebtSecuritiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentTypeCategorizationMember" xlink:to="DebtSecuritiesMember" xlink:title="definition: InvestmentTypeCategorizationMember to DebtSecuritiesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="EquitySecuritiesMember" xlink:title="EquitySecuritiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentTypeCategorizationMember" xlink:to="EquitySecuritiesMember" xlink:title="definition: InvestmentTypeCategorizationMember to EquitySecuritiesMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="CorporateDebtSecuritiesMember" xlink:title="CorporateDebtSecuritiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtSecuritiesMember" xlink:to="CorporateDebtSecuritiesMember" xlink:title="definition: DebtSecuritiesMember to CorporateDebtSecuritiesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="USGovernmentAgenciesDebtSecuritiesMember" xlink:title="USGovernmentAgenciesDebtSecuritiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtSecuritiesMember" xlink:to="USGovernmentAgenciesDebtSecuritiesMember" xlink:title="definition: DebtSecuritiesMember to USGovernmentAgenciesDebtSecuritiesMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="USTreasurySecuritiesMember" xlink:title="USTreasurySecuritiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtSecuritiesMember" xlink:to="USTreasurySecuritiesMember" xlink:title="definition: DebtSecuritiesMember to USTreasurySecuritiesMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="USStatesAndPoliticalSubdivisionsMember" xlink:title="USStatesAndPoliticalSubdivisionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtSecuritiesMember" xlink:to="USStatesAndPoliticalSubdivisionsMember" xlink:title="definition: DebtSecuritiesMember to USStatesAndPoliticalSubdivisionsMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentSecondaryCategorizationAxis" xlink:label="InvestmentSecondaryCategorizationAxis" xlink:title="InvestmentSecondaryCategorizationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="InvestmentHoldingsTable" xlink:to="InvestmentSecondaryCategorizationAxis" xlink:title="definition: InvestmentHoldingsTable to InvestmentSecondaryCategorizationAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsBySecondaryCategorizationDomain" xlink:label="InvestmentsBySecondaryCategorizationDomain" xlink:title="InvestmentsBySecondaryCategorizationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="InvestmentSecondaryCategorizationAxis" xlink:to="InvestmentsBySecondaryCategorizationDomain" xlink:title="definition: InvestmentSecondaryCategorizationAxis to InvestmentsBySecondaryCategorizationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsBySecondaryCategorizationDomain" xlink:label="InvestmentsBySecondaryCategorizationDomain_2" xlink:title="InvestmentsBySecondaryCategorizationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="InvestmentSecondaryCategorizationAxis" xlink:to="InvestmentsBySecondaryCategorizationDomain_2" xlink:title="definition: InvestmentSecondaryCategorizationAxis to InvestmentsBySecondaryCategorizationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SecuritiesWithMaturityOfOneYearOrLessMember" xlink:label="SecuritiesWithMaturityOfOneYearOrLessMember" xlink:title="SecuritiesWithMaturityOfOneYearOrLessMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentsBySecondaryCategorizationDomain" xlink:to="SecuritiesWithMaturityOfOneYearOrLessMember" xlink:title="definition: InvestmentsBySecondaryCategorizationDomain to SecuritiesWithMaturityOfOneYearOrLessMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SecuritiesWithMaturityOfMoreThanOneYearMember" xlink:label="SecuritiesWithMaturityOfMoreThanOneYearMember" xlink:title="SecuritiesWithMaturityOfMoreThanOneYearMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentsBySecondaryCategorizationDomain" xlink:to="SecuritiesWithMaturityOfMoreThanOneYearMember" xlink:title="definition: InvestmentsBySecondaryCategorizationDomain to SecuritiesWithMaturityOfMoreThanOneYearMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IncludedInOtherCurrentAssetsMember" xlink:label="IncludedInOtherCurrentAssetsMember" xlink:title="IncludedInOtherCurrentAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentsBySecondaryCategorizationDomain" xlink:to="IncludedInOtherCurrentAssetsMember" xlink:title="definition: InvestmentsBySecondaryCategorizationDomain to IncludedInOtherCurrentAssetsMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IncludedInDepositsAndOtherAssetsMember" xlink:label="IncludedInDepositsAndOtherAssetsMember" xlink:title="IncludedInDepositsAndOtherAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentsBySecondaryCategorizationDomain" xlink:to="IncludedInDepositsAndOtherAssetsMember" xlink:title="definition: InvestmentsBySecondaryCategorizationDomain to IncludedInDepositsAndOtherAssetsMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="BalanceSheetLocationAxis" xlink:title="BalanceSheetLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="InvestmentHoldingsTable" xlink:to="BalanceSheetLocationAxis" xlink:title="definition: InvestmentHoldingsTable to BalanceSheetLocationAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="BalanceSheetLocationDomain" xlink:title="BalanceSheetLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="BalanceSheetLocationAxis" xlink:to="BalanceSheetLocationDomain" xlink:title="definition: BalanceSheetLocationAxis to BalanceSheetLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="BalanceSheetLocationDomain_2" xlink:title="BalanceSheetLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BalanceSheetLocationAxis" xlink:to="BalanceSheetLocationDomain_2" xlink:title="definition: BalanceSheetLocationAxis to BalanceSheetLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="OtherCurrentAssetsMember" xlink:title="OtherCurrentAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BalanceSheetLocationDomain" xlink:to="OtherCurrentAssetsMember" xlink:title="definition: BalanceSheetLocationDomain to OtherCurrentAssetsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DepositsAndOtherAssetsMember" xlink:label="DepositsAndOtherAssetsMember" xlink:title="DepositsAndOtherAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="BalanceSheetLocationDomain" xlink:to="DepositsAndOtherAssetsMember" xlink:title="definition: BalanceSheetLocationDomain to DepositsAndOtherAssetsMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsLineItems" xlink:label="InvestmentHoldingsLineItems" xlink:title="InvestmentHoldingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="AvailableForSaleSecuritiesAbstract" xlink:title="AvailableForSaleSecuritiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentHoldingsLineItems" xlink:to="AvailableForSaleSecuritiesAbstract" xlink:title="definition: InvestmentHoldingsLineItems to AvailableForSaleSecuritiesAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:label="AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:title="AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentHoldingsLineItems" xlink:to="AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:title="definition: InvestmentHoldingsLineItems to AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentHoldingsLineItems" xlink:to="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:title="definition: InvestmentHoldingsLineItems to AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentHoldingsLineItems" xlink:to="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:title="definition: InvestmentHoldingsLineItems to AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentHoldingsLineItems" xlink:to="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:title="definition: InvestmentHoldingsLineItems to AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentHoldingsLineItems" xlink:to="AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:title="definition: InvestmentHoldingsLineItems to AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentHoldingsLineItems" xlink:to="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:title="definition: InvestmentHoldingsLineItems to AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentHoldingsLineItems" xlink:to="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:title="definition: InvestmentHoldingsLineItems to AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsTable" xlink:label="InvestmentHoldingsTable" xlink:title="InvestmentHoldingsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="InvestmentHoldingsLineItems" xlink:to="InvestmentHoldingsTable" xlink:title="definition: InvestmentHoldingsLineItems to InvestmentHoldingsTable" order="9.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="InvestmentTypeAxis" xlink:title="InvestmentTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="InvestmentHoldingsTable" xlink:to="InvestmentTypeAxis" xlink:title="definition: InvestmentHoldingsTable to InvestmentTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember" xlink:title="InvestmentTypeCategorizationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="InvestmentTypeAxis" xlink:to="InvestmentTypeCategorizationMember" xlink:title="definition: InvestmentTypeAxis to InvestmentTypeCategorizationMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember_2" xlink:title="InvestmentTypeCategorizationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="InvestmentTypeAxis" xlink:to="InvestmentTypeCategorizationMember_2" xlink:title="definition: InvestmentTypeAxis to InvestmentTypeCategorizationMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="DebtSecuritiesMember" xlink:title="DebtSecuritiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="InvestmentTypeCategorizationMember" xlink:to="DebtSecuritiesMember" xlink:title="definition: InvestmentTypeCategorizationMember to DebtSecuritiesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="CorporateDebtSecuritiesMember" xlink:title="CorporateDebtSecuritiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtSecuritiesMember" xlink:to="CorporateDebtSecuritiesMember" xlink:title="definition: DebtSecuritiesMember to CorporateDebtSecuritiesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="USGovernmentAgenciesDebtSecuritiesMember" xlink:title="USGovernmentAgenciesDebtSecuritiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtSecuritiesMember" xlink:to="USGovernmentAgenciesDebtSecuritiesMember" xlink:title="definition: DebtSecuritiesMember to USGovernmentAgenciesDebtSecuritiesMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="USTreasurySecuritiesMember" xlink:title="USTreasurySecuritiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtSecuritiesMember" xlink:to="USTreasurySecuritiesMember" xlink:title="definition: DebtSecuritiesMember to USTreasurySecuritiesMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="USStatesAndPoliticalSubdivisionsMember" xlink:title="USStatesAndPoliticalSubdivisionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtSecuritiesMember" xlink:to="USStatesAndPoliticalSubdivisionsMember" xlink:title="definition: DebtSecuritiesMember to USStatesAndPoliticalSubdivisionsMember" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetailsCalc2" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtCurrentAndNoncurrentAbstract" xlink:label="LongtermDebtCurrentAndNoncurrentAbstract" xlink:title="LongtermDebtCurrentAndNoncurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongtermDebtCurrentAndNoncurrentAbstract" xlink:title="definition: DebtInstrumentLineItems to LongtermDebtCurrentAndNoncurrentAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermDebtAndOtherObligations" xlink:label="LongTermDebtAndOtherObligations" xlink:title="LongTermDebtAndOtherObligations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtAndOtherObligations" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtAndOtherObligations" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="LongTermDebtAndCapitalLeaseObligationsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtAndCapitalLeaseObligationsCurrent" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermDebtAndOtherObligationsNoncurrent" xlink:label="LongTermDebtAndOtherObligationsNoncurrent" xlink:title="LongTermDebtAndOtherObligationsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtAndOtherObligationsNoncurrent" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtAndOtherObligationsNoncurrent" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateStatedPercentage" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentMember" xlink:label="ConvertibleSeniorNotes0125PercentMember" xlink:title="ConvertibleSeniorNotes0125PercentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes0125PercentMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleSeniorNotes0125PercentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes1PercentMember" xlink:label="ConvertibleSeniorNotes1PercentMember" xlink:title="ConvertibleSeniorNotes1PercentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes1PercentMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleSeniorNotes1PercentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermMortgageDebtMember" xlink:label="LongTermMortgageDebtMember" xlink:title="LongTermMortgageDebtMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="LongTermMortgageDebtMember" xlink:title="definition: DebtInstrumentNameDomain to LongTermMortgageDebtMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_FixedRateNoteWithMorganStanleyMember" xlink:label="FixedRateNoteWithMorganStanleyMember" xlink:title="FixedRateNoteWithMorganStanleyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="FixedRateNoteWithMorganStanleyMember" xlink:title="definition: DebtInstrumentNameDomain to FixedRateNoteWithMorganStanleyMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LeasesAndOtherObligationsMember" xlink:label="LeasesAndOtherObligationsMember" xlink:title="LeasesAndOtherObligationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="LeasesAndOtherObligationsMember" xlink:title="definition: DebtInstrumentNameDomain to LeasesAndOtherObligationsMember" order="5.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/LongtermObligationsAndCommitmentsDetailsCalc2" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:title="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:title="definition: DebtInstrumentLineItems to ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="DebtInstrumentRepurchasedFaceAmount" xlink:title="DebtInstrumentRepurchasedFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentRepurchasedFaceAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentRepurchasedFaceAmount" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFaceAmount" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CallSpread" xlink:label="CallSpread" xlink:title="CallSpread" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="CallSpread" xlink:title="definition: DebtInstrumentLineItems to CallSpread" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities" xlink:label="PaymentsForHedgeFinancingActivities" xlink:title="PaymentsForHedgeFinancingActivities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="PaymentsForHedgeFinancingActivities" xlink:title="definition: DebtInstrumentLineItems to PaymentsForHedgeFinancingActivities" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="ProceedsFromIssuanceOfWarrants" xlink:title="ProceedsFromIssuanceOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ProceedsFromIssuanceOfWarrants" xlink:title="definition: DebtInstrumentLineItems to ProceedsFromIssuanceOfWarrants" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread" xlink:label="DebtInstrumentConvertibleConversionPriceIncludingCallSpread" xlink:title="DebtInstrumentConvertibleConversionPriceIncludingCallSpread" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentConvertibleConversionPriceIncludingCallSpread" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentConvertibleConversionPriceIncludingCallSpread" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentMaturityDate" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentMaturityDate" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateStatedPercentage" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentConvertibleConversionPrice1" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentConvertibleConversionPrice1" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:title="DebtInstrumentConvertibleNumberOfEquityInstruments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentConvertibleNumberOfEquityInstruments" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" xlink:label="DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" xlink:title="DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="LongTermDebtFairValue" xlink:title="LongTermDebtFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtFairValue" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtFairValue" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentCarryingAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentCarryingAmount" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="DebtInstrumentUnamortizedDiscountPremiumNet" xlink:title="DebtInstrumentUnamortizedDiscountPremiumNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentUnamortizedDiscountPremiumNet" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentUnamortizedDiscountPremiumNet" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="ConvertibleDebtNoncurrent" xlink:title="ConvertibleDebtNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ConvertibleDebtNoncurrent" xlink:title="definition: DebtInstrumentLineItems to ConvertibleDebtNoncurrent" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:title="DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="definition: DebtInstrumentLineItems to GainsLossesOnExtinguishmentOfDebt" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="DebtInstrumentMeasurementInput" xlink:title="DebtInstrumentMeasurementInput" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentMeasurementInput" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentMeasurementInput" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateEffectivePercentage" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateEffectivePercentage" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:title="DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="AmortizationOfFinancingCostsAndDiscounts" xlink:title="definition: DebtInstrumentLineItems to AmortizationOfFinancingCostsAndDiscounts" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="23.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentMember" xlink:label="ConvertibleSeniorNotes0125PercentMember" xlink:title="ConvertibleSeniorNotes0125PercentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes0125PercentMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleSeniorNotes0125PercentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes1PercentMember" xlink:label="ConvertibleSeniorNotes1PercentMember" xlink:title="ConvertibleSeniorNotes1PercentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes1PercentMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleSeniorNotes1PercentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes275PercentMember" xlink:label="ConvertibleSeniorNotes275PercentMember" xlink:title="ConvertibleSeniorNotes275PercentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes275PercentMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleSeniorNotes275PercentMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember" xlink:label="ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember" xlink:title="ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConvertibleSeniorNotes0125PercentMember" xlink:to="ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember" xlink:title="definition: ConvertibleSeniorNotes0125PercentMember to ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember" xlink:label="ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember" xlink:title="ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConvertibleSeniorNotes0125PercentMember" xlink:to="ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember" xlink:title="definition: ConvertibleSeniorNotes0125PercentMember to ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="MeasurementInputTypeAxis" xlink:title="definition: DebtInstrumentTable to MeasurementInputTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain_2" xlink:title="MeasurementInputTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain_2" xlink:title="definition: MeasurementInputTypeAxis to MeasurementInputTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="MeasurementInputDiscountRateMember" xlink:title="MeasurementInputDiscountRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputDiscountRateMember" xlink:title="definition: MeasurementInputTypeDomain to MeasurementInputDiscountRateMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="definition: DebtInstrumentTable to FairValueByFairValueHierarchyLevelAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain_2" xlink:title="definition: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="definition: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="LineOfCreditFacilityLineItems" xlink:title="LineOfCreditFacilityLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="LineOfCreditFacilityAbstract" xlink:title="LineOfCreditFacilityAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="LineOfCreditFacilityAbstract" xlink:title="definition: LineOfCreditFacilityLineItems to LineOfCreditFacilityAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="DebtInstrumentTerm" xlink:title="definition: LineOfCreditFacilityLineItems to DebtInstrumentTerm" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="definition: LineOfCreditFacilityLineItems to LineOfCreditFacilityMaximumBorrowingCapacity" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="RepaymentsOfLongTermLinesOfCredit" xlink:title="RepaymentsOfLongTermLinesOfCredit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLineItems" xlink:to="RepaymentsOfLongTermLinesOfCredit" xlink:title="definition: LineOfCreditFacilityLineItems to RepaymentsOfLongTermLinesOfCredit" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="LineOfCreditFacilityTable" xlink:title="LineOfCreditFacilityTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LineOfCreditFacilityLineItems" xlink:to="LineOfCreditFacilityTable" xlink:title="definition: LineOfCreditFacilityLineItems to LineOfCreditFacilityTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LineOfCreditFacilityTable" xlink:to="LineOfCreditFacilityAxis" xlink:title="definition: LineOfCreditFacilityTable to LineOfCreditFacilityAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain" xlink:title="definition: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain_2" xlink:title="LineOfCreditFacilityLenderDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain_2" xlink:title="definition: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MorganStanleyPrivateBankNationalAssociationMember" xlink:label="MorganStanleyPrivateBankNationalAssociationMember" xlink:title="MorganStanleyPrivateBankNationalAssociationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="MorganStanleyPrivateBankNationalAssociationMember" xlink:title="definition: LineOfCreditFacilityLenderDomain to MorganStanleyPrivateBankNationalAssociationMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LineOfCreditFacilityTable" xlink:to="CreditFacilityAxis" xlink:title="definition: LineOfCreditFacilityTable to CreditFacilityAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain" xlink:title="definition: CreditFacilityAxis to CreditFacilityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain_2" xlink:title="CreditFacilityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain_2" xlink:title="definition: CreditFacilityAxis to CreditFacilityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="RevolvingCreditFacilityMember" xlink:title="RevolvingCreditFacilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CreditFacilityDomain" xlink:to="RevolvingCreditFacilityMember" xlink:title="definition: CreditFacilityDomain to RevolvingCreditFacilityMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LineOfCreditFacilityTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: LineOfCreditFacilityTable to DebtInstrumentAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_FixedRateNoteWithMorganStanleyMember" xlink:label="FixedRateNoteWithMorganStanleyMember" xlink:title="FixedRateNoteWithMorganStanleyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="FixedRateNoteWithMorganStanleyMember" xlink:title="definition: DebtInstrumentNameDomain to FixedRateNoteWithMorganStanleyMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipmentAbstract" xlink:label="PaymentsToAcquirePropertyPlantAndEquipmentAbstract" xlink:title="PaymentsToAcquirePropertyPlantAndEquipmentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PaymentsToAcquirePropertyPlantAndEquipmentAbstract" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PaymentsToAcquirePropertyPlantAndEquipmentAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBuildings" xlink:label="PaymentsToAcquireBuildings" xlink:title="PaymentsToAcquireBuildings" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PaymentsToAcquireBuildings" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PaymentsToAcquireBuildings" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="DebtInstrumentFaceAmount" xlink:title="definition: PropertyPlantAndEquipmentLineItems to DebtInstrumentFaceAmount" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: PropertyPlantAndEquipmentLineItems to DebtInstrumentInterestRateStatedPercentage" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan" xlink:label="PeriodToMakeInterestOnlyPaymentsOnMortgageLoan" xlink:title="PeriodToMakeInterestOnlyPaymentsOnMortgageLoan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PeriodToMakeInterestOnlyPaymentsOnMortgageLoan" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PeriodToMakeInterestOnlyPaymentsOnMortgageLoan" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_GainLossOnExtinguishmentOfFinancingLiability" xlink:label="GainLossOnExtinguishmentOfFinancingLiability" xlink:title="GainLossOnExtinguishmentOfFinancingLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="GainLossOnExtinguishmentOfFinancingLiability" xlink:title="definition: PropertyPlantAndEquipmentLineItems to GainLossOnExtinguishmentOfFinancingLiability" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ScheduleOfPropertyPlantAndEquipmentTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PrimaryResearchAndDevelopmentFacilityMember" xlink:label="PrimaryResearchAndDevelopmentFacilityMember" xlink:title="PrimaryResearchAndDevelopmentFacilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="PrimaryResearchAndDevelopmentFacilityMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to PrimaryResearchAndDevelopmentFacilityMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="ManufacturingFacilityMember" xlink:title="ManufacturingFacilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ManufacturingFacilityMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to ManufacturingFacilityMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to DebtInstrumentAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermMortgageDebtMember" xlink:label="LongTermMortgageDebtMember" xlink:title="LongTermMortgageDebtMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="LongTermMortgageDebtMember" xlink:title="definition: DebtInstrumentNameDomain to LongTermMortgageDebtMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:label="MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:title="MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:title="definition: DebtInstrumentLineItems to MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="ContractualObligationDueInNextTwelveMonths" xlink:title="ContractualObligationDueInNextTwelveMonths" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ContractualObligationDueInNextTwelveMonths" xlink:title="definition: DebtInstrumentLineItems to ContractualObligationDueInNextTwelveMonths" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="ContractualObligationDueInSecondYear" xlink:title="ContractualObligationDueInSecondYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ContractualObligationDueInSecondYear" xlink:title="definition: DebtInstrumentLineItems to ContractualObligationDueInSecondYear" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="ContractualObligationDueInThirdYear" xlink:title="ContractualObligationDueInThirdYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ContractualObligationDueInThirdYear" xlink:title="definition: DebtInstrumentLineItems to ContractualObligationDueInThirdYear" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="ContractualObligationDueInFourthYear" xlink:title="ContractualObligationDueInFourthYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ContractualObligationDueInFourthYear" xlink:title="definition: DebtInstrumentLineItems to ContractualObligationDueInFourthYear" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="ContractualObligationDueInFifthYear" xlink:title="ContractualObligationDueInFifthYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ContractualObligationDueInFifthYear" xlink:title="definition: DebtInstrumentLineItems to ContractualObligationDueInFifthYear" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="ContractualObligationDueAfterFifthYear" xlink:title="ContractualObligationDueAfterFifthYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ContractualObligationDueAfterFifthYear" xlink:title="definition: DebtInstrumentLineItems to ContractualObligationDueAfterFifthYear" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation" xlink:label="ContractualObligation" xlink:title="ContractualObligation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ContractualObligation" xlink:title="definition: DebtInstrumentLineItems to ContractualObligation" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="LongTermDebtAndCapitalLeaseObligationsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtAndCapitalLeaseObligationsCurrent" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="InterestPayableCurrentAndNoncurrent" xlink:title="InterestPayableCurrentAndNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="InterestPayableCurrentAndNoncurrent" xlink:title="definition: DebtInstrumentLineItems to InterestPayableCurrentAndNoncurrent" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentUnamortizedDiscount" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="DeferredRentCredit" xlink:title="DeferredRentCredit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DeferredRentCredit" xlink:title="definition: DebtInstrumentLineItems to DeferredRentCredit" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermDebtAndOtherObligationsNoncurrent" xlink:label="LongTermDebtAndOtherObligationsNoncurrent" xlink:title="LongTermDebtAndOtherObligationsNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtAndOtherObligationsNoncurrent" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtAndOtherObligationsNoncurrent" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="14.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" xlink:label="LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" xlink:title="LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" xlink:title="definition: DebtInstrumentNameDomain to LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="LesseeDisclosureAbstract" xlink:title="LesseeDisclosureAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeDisclosureAbstract" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeDisclosureAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease" xlink:label="LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease" xlink:title="LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="LesseeOperatingLeaseRenewalTerm" xlink:title="LesseeOperatingLeaseRenewalTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseRenewalTerm" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseRenewalTerm" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseTermOfContract" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseTermOfContract" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LesseeOperatingLeasePeriodOfFreeRent" xlink:label="LesseeOperatingLeasePeriodOfFreeRent" xlink:title="LesseeOperatingLeasePeriodOfFreeRent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeasePeriodOfFreeRent" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeasePeriodOfFreeRent" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LesseeOperatingLeaseAllowanceForTenantImprovements" xlink:label="LesseeOperatingLeaseAllowanceForTenantImprovements" xlink:title="LesseeOperatingLeaseAllowanceForTenantImprovements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseAllowanceForTenantImprovements" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseAllowanceForTenantImprovements" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation" xlink:label="LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation" xlink:title="LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate" xlink:label="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate" xlink:title="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate" xlink:label="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate" xlink:title="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseRightOfUseAsset" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiability" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseLiability" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:title="OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseWeightedAverageDiscountRatePercent" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseLiabilityCurrent" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="OperatingLeasePayments" xlink:title="OperatingLeasePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeasePayments" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeasePayments" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseLiabilitiesPaymentsDueAbstract" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="OperatingLeaseExpense" xlink:title="OperatingLeaseExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="OperatingLeaseExpense" xlink:title="definition: LesseeLeaseDescriptionLineItems to OperatingLeaseExpense" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityPaymentsDue" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeLeaseDescriptionTable" xlink:title="definition: LesseeLeaseDescriptionLineItems to LesseeLeaseDescriptionTable" order="29.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LesseeLeaseDescriptionTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="definition: LesseeLeaseDescriptionTable to ConsolidatedEntitiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain_2" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain_2" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidatedEntitiesDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="definition: ConsolidatedEntitiesDomain to AkceaTherapeuticsIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LesseeLeaseDescriptionTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: LesseeLeaseDescriptionTable to PropertyPlantAndEquipmentByTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember" xlink:label="OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember" xlink:title="OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember" xlink:label="OfficeSpaceSubleasedToAkceaTherapeuticsIncMember" xlink:title="OfficeSpaceSubleasedToAkceaTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeSpaceSubleasedToAkceaTherapeuticsIncMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to OfficeSpaceSubleasedToAkceaTherapeuticsIncMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_OfficeSpaceForCorporateHeadquartersMember" xlink:label="OfficeSpaceForCorporateHeadquartersMember" xlink:title="OfficeSpaceForCorporateHeadquartersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeSpaceForCorporateHeadquartersMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to OfficeSpaceForCorporateHeadquartersMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/OperatingLeasesDetailsCalc01" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="definition: ClassOfStockLineItems to PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="definition: ClassOfStockLineItems to CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockSharesAuthorized" xlink:title="definition: ClassOfStockLineItems to CommonStockSharesAuthorized" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockSharesIssued" xlink:title="definition: ClassOfStockLineItems to CommonStockSharesIssued" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockSharesOutstanding" xlink:title="definition: ClassOfStockLineItems to CommonStockSharesOutstanding" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="definition: ClassOfStockLineItems to CommonStockCapitalSharesReservedForFutureIssuance" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:title="StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:title="definition: ClassOfStockLineItems to StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:title="ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:title="definition: ClassOfStockLineItems to ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockSharesAuthorized" xlink:title="definition: ClassOfStockLineItems to PreferredStockSharesAuthorized" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockSharesIssued" xlink:title="definition: ClassOfStockLineItems to PreferredStockSharesIssued" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockSharesOutstanding" xlink:title="definition: ClassOfStockLineItems to PreferredStockSharesOutstanding" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfStockLineItems" xlink:to="ScheduleOfStockByClassTable" xlink:title="definition: ClassOfStockLineItems to ScheduleOfStockByClassTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain_2" xlink:title="ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain_2" xlink:title="definition: StatementClassOfStockAxis to ClassOfStockDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="PreferredStockMember" xlink:title="definition: ClassOfStockDomain to PreferredStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="definition: ClassOfStockDomain to CommonStockMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="SeriesCPreferredStockMember" xlink:title="SeriesCPreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PreferredStockMember" xlink:to="SeriesCPreferredStockMember" xlink:title="definition: PreferredStockMember to SeriesCPreferredStockMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/StockholdersEquityShareRepurchaseProgramDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems" xlink:label="EquityClassOfTreasuryStockLineItems" xlink:title="EquityClassOfTreasuryStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="ClassOfStockDisclosuresAbstract" xlink:title="ClassOfStockDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityClassOfTreasuryStockLineItems" xlink:to="ClassOfStockDisclosuresAbstract" xlink:title="definition: EquityClassOfTreasuryStockLineItems to ClassOfStockDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="StockRepurchaseProgramAuthorizedAmount1" xlink:title="StockRepurchaseProgramAuthorizedAmount1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityClassOfTreasuryStockLineItems" xlink:to="StockRepurchaseProgramAuthorizedAmount1" xlink:title="definition: EquityClassOfTreasuryStockLineItems to StockRepurchaseProgramAuthorizedAmount1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="StockRepurchasedDuringPeriodShares" xlink:title="StockRepurchasedDuringPeriodShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityClassOfTreasuryStockLineItems" xlink:to="StockRepurchasedDuringPeriodShares" xlink:title="definition: EquityClassOfTreasuryStockLineItems to StockRepurchasedDuringPeriodShares" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="PaymentsForRepurchaseOfCommonStock" xlink:title="PaymentsForRepurchaseOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityClassOfTreasuryStockLineItems" xlink:to="PaymentsForRepurchaseOfCommonStock" xlink:title="definition: EquityClassOfTreasuryStockLineItems to PaymentsForRepurchaseOfCommonStock" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="ClassOfTreasuryStockTable" xlink:title="ClassOfTreasuryStockTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EquityClassOfTreasuryStockLineItems" xlink:to="ClassOfTreasuryStockTable" xlink:title="definition: EquityClassOfTreasuryStockLineItems to ClassOfTreasuryStockTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ClassOfTreasuryStockTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: ClassOfTreasuryStockTable to SubsequentEventTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/StockholdersEquityStockPlansDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:title="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedArrangementsToObtainGoodsAndServicesAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:label="NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:title="NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:label="PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:title="PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:label="PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:title="PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable" xlink:label="NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable" xlink:title="NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:label="EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:title="EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="21.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_StockOptionPlan1989Member" xlink:label="StockOptionPlan1989Member" xlink:title="StockOptionPlan1989Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="StockOptionPlan1989Member" xlink:title="definition: PlanNameDomain to StockOptionPlan1989Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EquityIncentivePlan2011Member" xlink:label="EquityIncentivePlan2011Member" xlink:title="EquityIncentivePlan2011Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2011Member" xlink:title="definition: PlanNameDomain to EquityIncentivePlan2011Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NonemployeeDirectorsStockOptionPlan2002Member" xlink:label="NonemployeeDirectorsStockOptionPlan2002Member" xlink:title="NonemployeeDirectorsStockOptionPlan2002Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="NonemployeeDirectorsStockOptionPlan2002Member" xlink:title="definition: PlanNameDomain to NonemployeeDirectorsStockOptionPlan2002Member" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EmployeeStockPurchasePlanMember" xlink:label="EmployeeStockPurchasePlanMember" xlink:title="EmployeeStockPurchasePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EmployeeStockPurchasePlanMember" xlink:title="definition: PlanNameDomain to EmployeeStockPurchasePlanMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="StockOptionMember" xlink:title="StockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="StockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to StockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="VestingAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to VestingAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="VestingAxis" xlink:to="VestingDomain" xlink:title="definition: VestingAxis to VestingDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain_2" xlink:title="VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VestingAxis" xlink:to="VestingDomain_2" xlink:title="definition: VestingAxis to VestingDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="ShareBasedCompensationAwardTrancheOneMember" xlink:title="ShareBasedCompensationAwardTrancheOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="VestingDomain" xlink:to="ShareBasedCompensationAwardTrancheOneMember" xlink:title="definition: VestingDomain to ShareBasedCompensationAwardTrancheOneMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ProceedsFromStockOptionsExercised" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="25.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="StockOptionMember" xlink:title="StockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="StockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to StockOptionMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="14.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/StockholdersEquityStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to AllocatedShareBasedCompensationExpense" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfExecutiveOfficersTerminatingEmployment" xlink:label="NumberOfExecutiveOfficersTerminatingEmployment" xlink:title="NumberOfExecutiveOfficersTerminatingEmployment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="NumberOfExecutiveOfficersTerminatingEmployment" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to NumberOfExecutiveOfficersTerminatingEmployment" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="definition: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="definition: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to ConsolidatedEntitiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain_2" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain_2" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidatedEntitiesDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="definition: ConsolidatedEntitiesDomain to AkceaTherapeuticsIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to IncomeStatementLocationAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="CostOfSalesMember" xlink:title="CostOfSalesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="CostOfSalesMember" xlink:title="definition: IncomeStatementLocationDomain to CostOfSalesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchDevelopmentAndPatentMember" xlink:label="ResearchDevelopmentAndPatentMember" xlink:title="ResearchDevelopmentAndPatentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchDevelopmentAndPatentMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchDevelopmentAndPatentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="SellingGeneralAndAdministrativeExpensesMember" xlink:title="SellingGeneralAndAdministrativeExpensesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="SellingGeneralAndAdministrativeExpensesMember" xlink:title="definition: IncomeStatementLocationDomain to SellingGeneralAndAdministrativeExpensesMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ConsolidatedEntitiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain_2" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain_2" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidatedEntitiesDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="definition: ConsolidatedEntitiesDomain to AkceaTherapeuticsIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_BoardOfDirectorStockOptionMember" xlink:label="BoardOfDirectorStockOptionMember" xlink:title="BoardOfDirectorStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="BoardOfDirectorStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to BoardOfDirectorStockOptionMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="EmployeeStockMember" xlink:title="EmployeeStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxesTaxCreditCarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="TaxCreditCarryforwardLineItems" xlink:title="TaxCreditCarryforwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="TaxCreditCarryforwardAmount" xlink:title="TaxCreditCarryforwardAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxCreditCarryforwardLineItems" xlink:to="TaxCreditCarryforwardAmount" xlink:title="definition: TaxCreditCarryforwardLineItems to TaxCreditCarryforwardAmount" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="TaxCreditCarryforwardTable" xlink:title="TaxCreditCarryforwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="TaxCreditCarryforwardLineItems" xlink:to="TaxCreditCarryforwardTable" xlink:title="definition: TaxCreditCarryforwardLineItems to TaxCreditCarryforwardTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="TaxCreditCarryforwardTable" xlink:to="TaxCreditCarryforwardAxis" xlink:title="definition: TaxCreditCarryforwardTable to TaxCreditCarryforwardAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain_2" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain_2" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="ResearchMember" xlink:title="ResearchMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxCreditCarryforwardNameDomain" xlink:to="ResearchMember" xlink:title="definition: TaxCreditCarryforwardNameDomain to ResearchMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="IncomeTaxAuthorityNameAxis" xlink:title="IncomeTaxAuthorityNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="TaxCreditCarryforwardTable" xlink:to="IncomeTaxAuthorityNameAxis" xlink:title="definition: TaxCreditCarryforwardTable to IncomeTaxAuthorityNameAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="IncomeTaxAuthorityNameDomain" xlink:title="IncomeTaxAuthorityNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeTaxAuthorityNameAxis" xlink:to="IncomeTaxAuthorityNameDomain" xlink:title="definition: IncomeTaxAuthorityNameAxis to IncomeTaxAuthorityNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="IncomeTaxAuthorityNameDomain_2" xlink:title="IncomeTaxAuthorityNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityNameAxis" xlink:to="IncomeTaxAuthorityNameDomain_2" xlink:title="definition: IncomeTaxAuthorityNameAxis to IncomeTaxAuthorityNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="InternalRevenueServiceIRSMember" xlink:title="InternalRevenueServiceIRSMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxAuthorityNameDomain" xlink:to="InternalRevenueServiceIRSMember" xlink:title="definition: IncomeTaxAuthorityNameDomain to InternalRevenueServiceIRSMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="CaliforniaFranchiseTaxBoardMember" xlink:title="CaliforniaFranchiseTaxBoardMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxAuthorityNameDomain" xlink:to="CaliforniaFranchiseTaxBoardMember" xlink:title="definition: IncomeTaxAuthorityNameDomain to CaliforniaFranchiseTaxBoardMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwards" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwards" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwardsTable" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwardsTable" order="2.0" t1:closed="true" t1:contextElement="segment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OperatingLossCarryforwardsTable" xlink:to="IncomeTaxAuthorityNameAxis" xlink:title="definition: OperatingLossCarryforwardsTable to IncomeTaxAuthorityNameAxis" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxesTaxActDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAbstract" xlink:label="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="CollaborativeArrangementAndLicensingAgreementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborativeArrangementAndLicensingAgreementAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfDrugsBeingDeveloped" xlink:label="NumberOfDrugsBeingDeveloped" xlink:title="NumberOfDrugsBeingDeveloped" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NumberOfDrugsBeingDeveloped" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NumberOfDrugsBeingDeveloped" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CumulativePaymentsReceived" xlink:label="CumulativePaymentsReceived" xlink:title="CumulativePaymentsReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CumulativePaymentsReceived" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CumulativePaymentsReceived" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceivedIncludingPurchaseOfStock" xlink:label="UpfrontPaymentReceivedIncludingPurchaseOfStock" xlink:title="UpfrontPaymentReceivedIncludingPurchaseOfStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="UpfrontPaymentReceivedIncludingPurchaseOfStock" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to UpfrontPaymentReceivedIncludingPurchaseOfStock" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfCountriesWhereDrugIsApprovedForUse" xlink:label="NumberOfCountriesWhereDrugIsApprovedForUse" xlink:title="NumberOfCountriesWhereDrugIsApprovedForUse" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NumberOfCountriesWhereDrugIsApprovedForUse" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NumberOfCountriesWhereDrugIsApprovedForUse" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="CumulativeRevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="CumulativeRevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CumulativeRevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CumulativeRevenueFromContractWithCustomerExcludingAssessedTax" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:label="RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:title="RoyaltyPercentageReceivedOnNetSalesOfDrug" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RoyaltyPercentageReceivedOnNetSalesOfDrug" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceived" xlink:label="UpfrontPaymentReceived" xlink:title="UpfrontPaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="UpfrontPaymentReceived" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to UpfrontPaymentReceived" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForCommercializationMilestones" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForSalesMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForSalesMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForSalesMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForSalesMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForSalesMilestones" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NextPotentialPayment" xlink:label="NextPotentialPayment" xlink:title="NextPotentialPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NextPotentialPayment" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NextPotentialPayment" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerTransactionPrice" xlink:label="RevenueFromContractWithCustomerTransactionPrice" xlink:title="RevenueFromContractWithCustomerTransactionPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerTransactionPrice" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerTransactionPrice" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_TermOfCollaborationAgreement" xlink:label="TermOfCollaborationAgreement" xlink:title="TermOfCollaborationAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="TermOfCollaborationAgreement" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to TermOfCollaborationAgreement" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ProceedsFromIssuanceOfCommonStock" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PercentageCashPremiumPaidOnSharesPurchased" xlink:label="PercentageCashPremiumPaidOnSharesPurchased" xlink:title="PercentageCashPremiumPaidOnSharesPurchased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PercentageCashPremiumPaidOnSharesPurchased" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PercentageCashPremiumPaidOnSharesPurchased" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments" xlink:label="MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments" xlink:title="MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfTargetsAdvanced" xlink:label="NumberOfTargetsAdvanced" xlink:title="NumberOfTargetsAdvanced" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NumberOfTargetsAdvanced" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NumberOfTargetsAdvanced" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PremiumPaidOnSharesPurchased" xlink:label="PremiumPaidOnSharesPurchased" xlink:title="PremiumPaidOnSharesPurchased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PremiumPaidOnSharesPurchased" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PremiumPaidOnSharesPurchased" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfMilestonePaymentsAchieved" xlink:label="NumberOfMilestonePaymentsAchieved" xlink:title="NumberOfMilestonePaymentsAchieved" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NumberOfMilestonePaymentsAchieved" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NumberOfMilestonePaymentsAchieved" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:label="CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:title="CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:label="PaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:title="PaymentsIncludedInTransactionPriceForPerformanceObligation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PaymentsIncludedInTransactionPriceForPerformanceObligation" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfDrugsCurrentlyBeingAdvanced" xlink:label="NumberOfDrugsCurrentlyBeingAdvanced" xlink:title="NumberOfDrugsCurrentlyBeingAdvanced" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NumberOfDrugsCurrentlyBeingAdvanced" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NumberOfDrugsCurrentlyBeingAdvanced" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement" xlink:label="NumberOfDrugsLicensedUnderOptionInCollaborationAgreement" xlink:title="NumberOfDrugsLicensedUnderOptionInCollaborationAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NumberOfDrugsLicensedUnderOptionInCollaborationAgreement" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NumberOfDrugsLicensedUnderOptionInCollaborationAgreement" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" xlink:label="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" xlink:title="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones" xlink:label="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones" xlink:title="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" xlink:label="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" xlink:title="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" order="29.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfTargetsToBeDevelopedAndCommercialized" xlink:label="NumberOfTargetsToBeDevelopedAndCommercialized" xlink:title="NumberOfTargetsToBeDevelopedAndCommercialized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NumberOfTargetsToBeDevelopedAndCommercialized" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NumberOfTargetsToBeDevelopedAndCommercialized" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" xlink:label="NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" xlink:title="NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" order="31.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MilestonePaymentAchieved" xlink:label="MilestonePaymentAchieved" xlink:title="MilestonePaymentAchieved" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MilestonePaymentAchieved" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MilestonePaymentAchieved" order="32.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="33.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ConcentrationRiskPercentage1" order="34.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="ContractWithCustomerLiability" xlink:title="ContractWithCustomerLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ContractWithCustomerLiability" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ContractWithCustomerLiability" order="35.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="36.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementsAndLicensingAgreementsBiogenMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" xlink:title="definition: CollaborativeArrangementsAndLicensingAgreementsBiogenMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" xlink:title="definition: CollaborativeArrangementsAndLicensingAgreementsBiogenMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" xlink:title="definition: CollaborativeArrangementsAndLicensingAgreementsBiogenMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" xlink:title="definition: CollaborativeArrangementsAndLicensingAgreementsBiogenMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" xlink:title="definition: CollaborativeArrangementsAndLicensingAgreementsBiogenMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ProductOrServiceAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ProductOrServiceAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain_2" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain_2" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SPINRAZARoyaltiesMember" xlink:label="SPINRAZARoyaltiesMember" xlink:title="SPINRAZARoyaltiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="SPINRAZARoyaltiesMember" xlink:title="definition: ProductsAndServicesDomain to SPINRAZARoyaltiesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LicensingAndOtherRoyaltiesMember" xlink:label="LicensingAndOtherRoyaltiesMember" xlink:title="LicensingAndOtherRoyaltiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="LicensingAndOtherRoyaltiesMember" xlink:title="definition: ProductsAndServicesDomain to LicensingAndOtherRoyaltiesMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:label="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="definition: ProductsAndServicesDomain to ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MedicinesForAmyotrophicLateralSclerosisMember" xlink:label="MedicinesForAmyotrophicLateralSclerosisMember" xlink:title="MedicinesForAmyotrophicLateralSclerosisMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="MedicinesForAmyotrophicLateralSclerosisMember" xlink:title="definition: ProductsAndServicesDomain to MedicinesForAmyotrophicLateralSclerosisMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MedicinesForUndisclosedTargetsMember" xlink:label="MedicinesForUndisclosedTargetsMember" xlink:title="MedicinesForUndisclosedTargetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="MedicinesForUndisclosedTargetsMember" xlink:title="definition: ProductsAndServicesDomain to MedicinesForUndisclosedTargetsMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AntisenseMoleculeMember" xlink:label="AntisenseMoleculeMember" xlink:title="AntisenseMoleculeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="AntisenseMoleculeMember" xlink:title="definition: ProductsAndServicesDomain to AntisenseMoleculeMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IONISC9Member" xlink:label="IONISC9Member" xlink:title="IONISC9Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="IONISC9Member" xlink:title="definition: ProductsAndServicesDomain to IONISC9Member" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_TofersenMember" xlink:label="TofersenMember" xlink:title="TofersenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="TofersenMember" xlink:title="definition: ProductsAndServicesDomain to TofersenMember" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ION859Member" xlink:label="ION859Member" xlink:title="ION859Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ION859Member" xlink:title="definition: ProductsAndServicesDomain to ION859Member" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IONISMAPTMember" xlink:label="IONISMAPTMember" xlink:title="IONISMAPTMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="IONISMAPTMember" xlink:title="definition: ProductsAndServicesDomain to IONISMAPTMember" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ION581Member" xlink:label="ION581Member" xlink:title="ION581Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ION581Member" xlink:title="definition: ProductsAndServicesDomain to ION581Member" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to SubsequentEventTypeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByBenchmarkAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByTypeAxis" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAbstract" xlink:label="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="CollaborativeArrangementAndLicensingAgreementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborativeArrangementAndLicensingAgreementAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfLicensedDrugs" xlink:label="NumberOfLicensedDrugs" xlink:title="NumberOfLicensedDrugs" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NumberOfLicensedDrugs" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NumberOfLicensedDrugs" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceived" xlink:label="UpfrontPaymentReceived" xlink:title="UpfrontPaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="UpfrontPaymentReceived" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to UpfrontPaymentReceived" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:label="MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NextPotentialPayment" xlink:label="NextPotentialPayment" xlink:title="NextPotentialPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NextPotentialPayment" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NextPotentialPayment" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CumulativePaymentsReceived" xlink:label="CumulativePaymentsReceived" xlink:title="CumulativePaymentsReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CumulativePaymentsReceived" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CumulativePaymentsReceived" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerTransactionPrice" xlink:label="RevenueFromContractWithCustomerTransactionPrice" xlink:title="RevenueFromContractWithCustomerTransactionPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerTransactionPrice" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerTransactionPrice" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:label="CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:title="CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfLicenseFeesEarned" xlink:label="NumberOfLicenseFeesEarned" xlink:title="NumberOfLicenseFeesEarned" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NumberOfLicenseFeesEarned" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NumberOfLicenseFeesEarned" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfPerformanceObligationsCompleted" xlink:label="NumberOfPerformanceObligationsCompleted" xlink:title="NumberOfPerformanceObligationsCompleted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NumberOfPerformanceObligationsCompleted" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NumberOfPerformanceObligationsCompleted" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfProgramsAdvanced" xlink:label="NumberOfProgramsAdvanced" xlink:title="NumberOfProgramsAdvanced" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NumberOfProgramsAdvanced" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NumberOfProgramsAdvanced" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ConcentrationRiskPercentage1" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="ContractWithCustomerLiability" xlink:title="ContractWithCustomerLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ContractWithCustomerLiability" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ContractWithCustomerLiability" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="18.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" xlink:title="definition: CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" xlink:title="definition: CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ProductOrServiceAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ProductOrServiceAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain_2" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain_2" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ION532Member" xlink:label="ION532Member" xlink:title="ION532Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ION532Member" xlink:title="definition: ProductsAndServicesDomain to ION532Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ION839Member" xlink:label="ION839Member" xlink:title="ION839Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ION839Member" xlink:title="definition: ProductsAndServicesDomain to ION839Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DanvatirsenMember" xlink:label="DanvatirsenMember" xlink:title="DanvatirsenMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="DanvatirsenMember" xlink:title="definition: ProductsAndServicesDomain to DanvatirsenMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ION736Member" xlink:label="ION736Member" xlink:title="ION736Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ION736Member" xlink:title="definition: ProductsAndServicesDomain to ION736Member" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:label="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="definition: ProductsAndServicesDomain to ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByBenchmarkAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByTypeAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAbstract" xlink:label="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="CollaborativeArrangementAndLicensingAgreementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborativeArrangementAndLicensingAgreementAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceived" xlink:label="UpfrontPaymentReceived" xlink:title="UpfrontPaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="UpfrontPaymentReceived" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to UpfrontPaymentReceived" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PaymentReceivedForAdvancingPrograms" xlink:label="PaymentReceivedForAdvancingPrograms" xlink:title="PaymentReceivedForAdvancingPrograms" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PaymentReceivedForAdvancingPrograms" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PaymentReceivedForAdvancingPrograms" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForCommercializationMilestones" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement" xlink:label="RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement" xlink:title="RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CumulativePaymentsReceived" xlink:label="CumulativePaymentsReceived" xlink:title="CumulativePaymentsReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CumulativePaymentsReceived" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CumulativePaymentsReceived" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NextPotentialMilestonePayment" xlink:label="NextPotentialMilestonePayment" xlink:title="NextPotentialMilestonePayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NextPotentialMilestonePayment" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NextPotentialMilestonePayment" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfNewPerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfNewPerformanceObligations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerNumberOfNewPerformanceObligations" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerNumberOfNewPerformanceObligations" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerTransactionPrice" xlink:label="RevenueFromContractWithCustomerTransactionPrice" xlink:title="RevenueFromContractWithCustomerTransactionPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerTransactionPrice" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerTransactionPrice" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ConcentrationRiskPercentage1" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="ContractWithCustomerLiability" xlink:title="ContractWithCustomerLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ContractWithCustomerLiability" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ContractWithCustomerLiability" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="16.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsBayerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementsAndLicensingAgreementsBayerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" xlink:title="definition: CollaborativeArrangementsAndLicensingAgreementsBayerMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" xlink:label="CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" xlink:title="CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:to="CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" xlink:title="definition: CollaborativeArrangementsAndLicensingAgreementsBayerMember to CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ProductOrServiceAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ProductOrServiceAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain_2" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain_2" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IONISFXILMember" xlink:label="IONISFXILMember" xlink:title="IONISFXILMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="IONISFXILMember" xlink:title="definition: ProductsAndServicesDomain to IONISFXILMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:label="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="definition: ProductsAndServicesDomain to ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentServicesForIONISFXILMember" xlink:label="ResearchAndDevelopmentServicesForIONISFXILMember" xlink:title="ResearchAndDevelopmentServicesForIONISFXILMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:to="ResearchAndDevelopmentServicesForIONISFXILMember" xlink:title="definition: ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember to ResearchAndDevelopmentServicesForIONISFXILMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByBenchmarkAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByTypeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAbstract" xlink:label="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="CollaborativeArrangementAndLicensingAgreementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborativeArrangementAndLicensingAgreementAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceived" xlink:label="UpfrontPaymentReceived" xlink:title="UpfrontPaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="UpfrontPaymentReceived" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to UpfrontPaymentReceived" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfDrugsBeingDeveloped" xlink:label="NumberOfDrugsBeingDeveloped" xlink:title="NumberOfDrugsBeingDeveloped" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NumberOfDrugsBeingDeveloped" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NumberOfDrugsBeingDeveloped" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForCommercializationMilestones" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CumulativePaymentsReceived" xlink:label="CumulativePaymentsReceived" xlink:title="CumulativePaymentsReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CumulativePaymentsReceived" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CumulativePaymentsReceived" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NextPotentialMilestonePayment" xlink:label="NextPotentialMilestonePayment" xlink:title="NextPotentialMilestonePayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NextPotentialMilestonePayment" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NextPotentialMilestonePayment" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ConcentrationRiskPercentage1" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="ContractWithCustomerLiability" xlink:title="ContractWithCustomerLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ContractWithCustomerLiability" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ContractWithCustomerLiability" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="13.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ProductOrServiceAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ProductOrServiceAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain_2" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain_2" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:label="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="definition: ProductsAndServicesDomain to ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByBenchmarkAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByTypeAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAbstract" xlink:label="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="CollaborativeArrangementAndLicensingAgreementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborativeArrangementAndLicensingAgreementAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" xlink:label="NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" xlink:title="NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceived" xlink:label="UpfrontPaymentReceived" xlink:title="UpfrontPaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="UpfrontPaymentReceived" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to UpfrontPaymentReceived" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:label="MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForCommercializationMilestones" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CumulativePaymentsReceived" xlink:label="CumulativePaymentsReceived" xlink:title="CumulativePaymentsReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CumulativePaymentsReceived" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CumulativePaymentsReceived" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NextPotentialMilestonePayment" xlink:label="NextPotentialMilestonePayment" xlink:title="NextPotentialMilestonePayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NextPotentialMilestonePayment" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NextPotentialMilestonePayment" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerTransactionPrice" xlink:label="RevenueFromContractWithCustomerTransactionPrice" xlink:title="RevenueFromContractWithCustomerTransactionPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerTransactionPrice" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerTransactionPrice" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ConcentrationRiskPercentage1" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="ContractWithCustomerLiability" xlink:title="ContractWithCustomerLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ContractWithCustomerLiability" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ContractWithCustomerLiability" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="15.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ProductOrServiceAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ProductOrServiceAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain_2" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain_2" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LicensingAndOtherRoyaltiesMember" xlink:label="LicensingAndOtherRoyaltiesMember" xlink:title="LicensingAndOtherRoyaltiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="LicensingAndOtherRoyaltiesMember" xlink:title="definition: ProductsAndServicesDomain to LicensingAndOtherRoyaltiesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:label="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="definition: ProductsAndServicesDomain to ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IONISJBI125Member" xlink:label="IONISJBI125Member" xlink:title="IONISJBI125Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LicensingAndOtherRoyaltiesMember" xlink:to="IONISJBI125Member" xlink:title="definition: LicensingAndOtherRoyaltiesMember to IONISJBI125Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IONISJBI225Member" xlink:label="IONISJBI225Member" xlink:title="IONISJBI225Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LicensingAndOtherRoyaltiesMember" xlink:to="IONISJBI225Member" xlink:title="definition: LicensingAndOtherRoyaltiesMember to IONISJBI225Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByBenchmarkAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByTypeAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAbstract" xlink:label="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="CollaborativeArrangementAndLicensingAgreementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborativeArrangementAndLicensingAgreementAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceived" xlink:label="UpfrontPaymentReceived" xlink:title="UpfrontPaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="UpfrontPaymentReceived" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to UpfrontPaymentReceived" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MilestonePaymentsReceived" xlink:label="MilestonePaymentsReceived" xlink:title="MilestonePaymentsReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MilestonePaymentsReceived" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MilestonePaymentsReceived" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForCommercializationMilestones" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped" xlink:label="MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped" xlink:title="MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CumulativePaymentsReceived" xlink:label="CumulativePaymentsReceived" xlink:title="CumulativePaymentsReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CumulativePaymentsReceived" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CumulativePaymentsReceived" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NextPotentialMilestonePayment" xlink:label="NextPotentialMilestonePayment" xlink:title="NextPotentialMilestonePayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NextPotentialMilestonePayment" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NextPotentialMilestonePayment" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerTransactionPrice" xlink:label="RevenueFromContractWithCustomerTransactionPrice" xlink:title="RevenueFromContractWithCustomerTransactionPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerTransactionPrice" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerTransactionPrice" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:label="RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:title="RoyaltyPercentageReceivedOnNetSalesOfDrug" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RoyaltyPercentageReceivedOnNetSalesOfDrug" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ConcentrationRiskPercentage1" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="ContractWithCustomerLiability" xlink:title="ContractWithCustomerLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ContractWithCustomerLiability" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ContractWithCustomerLiability" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="17.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsRocheMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsRocheMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementsAndLicensingAgreementsRocheMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementsAndLicensingAgreementsRocheMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndLicensingAgreementsRocheMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" xlink:title="definition: CollaborativeArrangementsAndLicensingAgreementsRocheMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndLicensingAgreementsRocheMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" xlink:title="definition: CollaborativeArrangementsAndLicensingAgreementsRocheMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ProductOrServiceAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ProductOrServiceAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain_2" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain_2" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:label="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="definition: ProductsAndServicesDomain to ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByBenchmarkAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByTypeAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAbstract" xlink:label="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="CollaborativeArrangementAndLicensingAgreementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborativeArrangementAndLicensingAgreementAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceived" xlink:label="UpfrontPaymentReceived" xlink:title="UpfrontPaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="UpfrontPaymentReceived" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to UpfrontPaymentReceived" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PortionOfUpfrontPaymentRetained" xlink:label="PortionOfUpfrontPaymentRetained" xlink:title="PortionOfUpfrontPaymentRetained" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PortionOfUpfrontPaymentRetained" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PortionOfUpfrontPaymentRetained" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PortionOfUpfrontPaymentPaidAsSublicenseFee" xlink:label="PortionOfUpfrontPaymentPaidAsSublicenseFee" xlink:title="PortionOfUpfrontPaymentPaidAsSublicenseFee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PortionOfUpfrontPaymentPaidAsSublicenseFee" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PortionOfUpfrontPaymentPaidAsSublicenseFee" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SublicenseFeePaidForLicenseOfDrug" xlink:label="SublicenseFeePaidForLicenseOfDrug" xlink:title="SublicenseFeePaidForLicenseOfDrug" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="SublicenseFeePaidForLicenseOfDrug" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to SublicenseFeePaidForLicenseOfDrug" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ReceiptOfSharesInSubsidiary" xlink:label="ReceiptOfSharesInSubsidiary" xlink:title="ReceiptOfSharesInSubsidiary" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ReceiptOfSharesInSubsidiary" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ReceiptOfSharesInSubsidiary" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForMilestones" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForCommercializationMilestones" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RoyaltyPercentageReceivedOnSalesOfDrug" xlink:label="RoyaltyPercentageReceivedOnSalesOfDrug" xlink:title="RoyaltyPercentageReceivedOnSalesOfDrug" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RoyaltyPercentageReceivedOnSalesOfDrug" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RoyaltyPercentageReceivedOnSalesOfDrug" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee" xlink:label="PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee" xlink:title="PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to StockIssuedDuringPeriodSharesNewIssues" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid" xlink:label="ProceedsFromSaleOfCommonStockIncludingPremiumPaid" xlink:title="ProceedsFromSaleOfCommonStockIncludingPremiumPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ProceedsFromSaleOfCommonStockIncludingPremiumPaid" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ProceedsFromSaleOfCommonStockIncludingPremiumPaid" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AdditionalAmountOfCommonStockRequiredToBePurchased" xlink:label="AdditionalAmountOfCommonStockRequiredToBePurchased" xlink:title="AdditionalAmountOfCommonStockRequiredToBePurchased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="AdditionalAmountOfCommonStockRequiredToBePurchased" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to AdditionalAmountOfCommonStockRequiredToBePurchased" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="ProceedsFromIssuanceOfPrivatePlacement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ProceedsFromIssuanceOfPrivatePlacement" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerTransactionPrice" xlink:label="RevenueFromContractWithCustomerTransactionPrice" xlink:title="RevenueFromContractWithCustomerTransactionPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerTransactionPrice" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerTransactionPrice" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PremiumReceivedOnSharesIssued" xlink:label="PremiumReceivedOnSharesIssued" xlink:title="PremiumReceivedOnSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PremiumReceivedOnSharesIssued" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PremiumReceivedOnSharesIssued" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture" xlink:label="PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture" xlink:title="PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ConcentrationRiskPercentage1" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="ContractWithCustomerLiability" xlink:title="ContractWithCustomerLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ContractWithCustomerLiability" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ContractWithCustomerLiability" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="24.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConsolidatedEntitiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain_2" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain_2" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidatedEntitiesDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="definition: ConsolidatedEntitiesDomain to AkceaTherapeuticsIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ProductOrServiceAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ProductOrServiceAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain_2" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain_2" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember" xlink:label="LicenseMember" xlink:title="LicenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="LicenseMember" xlink:title="definition: ProductsAndServicesDomain to LicenseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AKCEAAPOALMember" xlink:label="AKCEAAPOALMember" xlink:title="AKCEAAPOALMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="AKCEAAPOALMember" xlink:title="definition: ProductsAndServicesDomain to AKCEAAPOALMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AKCEAAPOCIIILMember" xlink:label="AKCEAAPOCIIILMember" xlink:title="AKCEAAPOCIIILMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="AKCEAAPOCIIILMember" xlink:title="definition: ProductsAndServicesDomain to AKCEAAPOCIIILMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:label="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="definition: ProductsAndServicesDomain to ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember" xlink:label="ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember" xlink:title="ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AKCEAAPOCIIILMember" xlink:to="ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember" xlink:title="definition: AKCEAAPOCIIILMember to ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DeliveryOfAKCEAAPOCIIILMember" xlink:label="DeliveryOfAKCEAAPOCIIILMember" xlink:title="DeliveryOfAKCEAAPOCIIILMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AKCEAAPOCIIILMember" xlink:to="DeliveryOfAKCEAAPOCIIILMember" xlink:title="definition: AKCEAAPOCIIILMember to DeliveryOfAKCEAAPOCIIILMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember" xlink:label="ResearchAndDevelopmentServicesForAKCEAAPOALMember" xlink:title="ResearchAndDevelopmentServicesForAKCEAAPOALMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AKCEAAPOALMember" xlink:to="ResearchAndDevelopmentServicesForAKCEAAPOALMember" xlink:title="definition: AKCEAAPOALMember to ResearchAndDevelopmentServicesForAKCEAAPOALMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DeliveryOfAKCEAAPOALMember" xlink:label="DeliveryOfAKCEAAPOALMember" xlink:title="DeliveryOfAKCEAAPOALMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AKCEAAPOALMember" xlink:to="DeliveryOfAKCEAAPOALMember" xlink:title="definition: AKCEAAPOALMember to DeliveryOfAKCEAAPOALMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to RangeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByBenchmarkAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByTypeAxis" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAbstract" xlink:label="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="CollaborativeArrangementAndLicensingAgreementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborativeArrangementAndLicensingAgreementAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceived" xlink:label="UpfrontPaymentReceived" xlink:title="UpfrontPaymentReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="UpfrontPaymentReceived" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to UpfrontPaymentReceived" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivableForCommercializationMilestones" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:label="RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:title="RoyaltyPercentageReceivedOnNetSalesOfDrug" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RoyaltyPercentageReceivedOnNetSalesOfDrug" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NextPotentialMilestonePayment" xlink:label="NextPotentialMilestonePayment" xlink:title="NextPotentialMilestonePayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NextPotentialMilestonePayment" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to NextPotentialMilestonePayment" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerTransactionPrice" xlink:label="RevenueFromContractWithCustomerTransactionPrice" xlink:title="RevenueFromContractWithCustomerTransactionPrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerTransactionPrice" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerTransactionPrice" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ReceiptOfSharesInSubsidiary" xlink:label="ReceiptOfSharesInSubsidiary" xlink:title="ReceiptOfSharesInSubsidiary" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ReceiptOfSharesInSubsidiary" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ReceiptOfSharesInSubsidiary" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SublicenseFeePaidForLicenseOfDrug" xlink:label="SublicenseFeePaidForLicenseOfDrug" xlink:title="SublicenseFeePaidForLicenseOfDrug" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="SublicenseFeePaidForLicenseOfDrug" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to SublicenseFeePaidForLicenseOfDrug" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ConcentrationRiskPercentage1" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="ContractWithCustomerLiability" xlink:title="ContractWithCustomerLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ContractWithCustomerLiability" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ContractWithCustomerLiability" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="16.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConsolidatedEntitiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain_2" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain_2" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidatedEntitiesDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="definition: ConsolidatedEntitiesDomain to AkceaTherapeuticsIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ProductOrServiceAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ProductOrServiceAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain_2" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain_2" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AKCEAANGPTL3LMember" xlink:label="AKCEAANGPTL3LMember" xlink:title="AKCEAANGPTL3LMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="AKCEAANGPTL3LMember" xlink:title="definition: ProductsAndServicesDomain to AKCEAANGPTL3LMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentServicesForMember" xlink:label="ResearchAndDevelopmentServicesForMember" xlink:title="ResearchAndDevelopmentServicesForMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentServicesForMember" xlink:title="definition: ProductsAndServicesDomain to ResearchAndDevelopmentServicesForMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember" xlink:label="AKCEAANGPTL3LActivePharmaceuticalIngredientMember" xlink:title="AKCEAANGPTL3LActivePharmaceuticalIngredientMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="AKCEAANGPTL3LActivePharmaceuticalIngredientMember" xlink:title="definition: ProductsAndServicesDomain to AKCEAANGPTL3LActivePharmaceuticalIngredientMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:label="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="definition: ProductsAndServicesDomain to ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByBenchmarkAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByTypeAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAbstract" xlink:label="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="CollaborativeArrangementAndLicensingAgreementAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborativeArrangementAndLicensingAgreementAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumPaymentReceivableUnderLicenseAgreement" xlink:label="MaximumPaymentReceivableUnderLicenseAgreement" xlink:title="MaximumPaymentReceivableUnderLicenseAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumPaymentReceivableUnderLicenseAgreement" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumPaymentReceivableUnderLicenseAgreement" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="ProceedsFromLicenseFeesReceived" xlink:title="ProceedsFromLicenseFeesReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ProceedsFromLicenseFeesReceived" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ProceedsFromLicenseFeesReceived" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" xlink:label="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" xlink:title="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner" xlink:label="RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner" xlink:title="RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil" xlink:label="PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil" xlink:title="PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties" xlink:label="RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties" xlink:title="RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ConcentrationRiskPercentage1" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="ContractWithCustomerLiability" xlink:title="ContractWithCustomerLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ContractWithCustomerLiability" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ContractWithCustomerLiability" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="definition: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConsolidatedEntitiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain_2" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain_2" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidatedEntitiesDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="definition: ConsolidatedEntitiesDomain to AkceaTherapeuticsIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ProductOrServiceAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ProductOrServiceAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain_2" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain_2" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LicensingAndOtherRoyaltiesMember" xlink:label="LicensingAndOtherRoyaltiesMember" xlink:title="LicensingAndOtherRoyaltiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="LicensingAndOtherRoyaltiesMember" xlink:title="definition: ProductsAndServicesDomain to LicensingAndOtherRoyaltiesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_WaylivraMember" xlink:label="WaylivraMember" xlink:title="WaylivraMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="WaylivraMember" xlink:title="definition: ProductsAndServicesDomain to WaylivraMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_TegsediMember" xlink:label="TegsediMember" xlink:title="TegsediMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="TegsediMember" xlink:title="definition: ProductsAndServicesDomain to TegsediMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember" xlink:label="LicenseMember" xlink:title="LicenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LicensingAndOtherRoyaltiesMember" xlink:to="LicenseMember" xlink:title="definition: LicensingAndOtherRoyaltiesMember to LicenseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByBenchmarkAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByTypeAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:title="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:title="definition: SegmentReportingInformationLineItems to SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: SegmentReportingInformationLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="CostsAndExpenses" xlink:title="definition: SegmentReportingInformationLineItems to CostsAndExpenses" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="OperatingIncomeLoss" xlink:title="definition: SegmentReportingInformationLineItems to OperatingIncomeLoss" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="Assets" xlink:title="definition: SegmentReportingInformationLineItems to Assets" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SegmentReportingInformationLineItems" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="definition: SegmentReportingInformationLineItems to ScheduleOfSegmentReportingInformationBySegmentTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="ConsolidationItemsAxis" xlink:title="ConsolidationItemsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="ConsolidationItemsAxis" xlink:title="definition: ScheduleOfSegmentReportingInformationBySegmentTable to ConsolidationItemsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain" xlink:title="ConsolidationItemsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidationItemsAxis" xlink:to="ConsolidationItemsDomain" xlink:title="definition: ConsolidationItemsAxis to ConsolidationItemsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain_2" xlink:title="ConsolidationItemsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidationItemsAxis" xlink:to="ConsolidationItemsDomain_2" xlink:title="definition: ConsolidationItemsAxis to ConsolidationItemsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="OperatingSegmentsMember" xlink:title="OperatingSegmentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidationItemsDomain" xlink:to="OperatingSegmentsMember" xlink:title="definition: ConsolidationItemsDomain to OperatingSegmentsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntersegmentEliminationMember" xlink:label="IntersegmentEliminationMember" xlink:title="IntersegmentEliminationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidationItemsDomain" xlink:to="IntersegmentEliminationMember" xlink:title="definition: ConsolidationItemsDomain to IntersegmentEliminationMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="definition: ScheduleOfSegmentReportingInformationBySegmentTable to StatementBusinessSegmentsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain_2" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain_2" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IonisCoreMember" xlink:label="IonisCoreMember" xlink:title="IonisCoreMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="IonisCoreMember" xlink:title="definition: SegmentDomain to IonisCoreMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsMember" xlink:label="AkceaTherapeuticsMember" xlink:title="AkceaTherapeuticsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="AkceaTherapeuticsMember" xlink:title="definition: SegmentDomain to AkceaTherapeuticsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="ProductOrServiceAxis" xlink:title="definition: ScheduleOfSegmentReportingInformationBySegmentTable to ProductOrServiceAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain_2" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain_2" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CommercialMember" xlink:label="CommercialMember" xlink:title="CommercialMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="CommercialMember" xlink:title="definition: ProductsAndServicesDomain to CommercialMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:label="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="definition: ProductsAndServicesDomain to ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SPINRAZARoyaltiesMember" xlink:label="SPINRAZARoyaltiesMember" xlink:title="SPINRAZARoyaltiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CommercialMember" xlink:to="SPINRAZARoyaltiesMember" xlink:title="definition: CommercialMember to SPINRAZARoyaltiesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="ProductMember" xlink:title="ProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CommercialMember" xlink:to="ProductMember" xlink:title="definition: CommercialMember to ProductMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LicensingAndOtherRoyaltiesMember" xlink:label="LicensingAndOtherRoyaltiesMember" xlink:title="LicensingAndOtherRoyaltiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CommercialMember" xlink:to="LicensingAndOtherRoyaltiesMember" xlink:title="definition: CommercialMember to LicensingAndOtherRoyaltiesMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="MinorityInterestLineItems" xlink:title="MinorityInterestLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="NoncontrollingInterestAbstract" xlink:title="NoncontrollingInterestAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MinorityInterestLineItems" xlink:to="NoncontrollingInterestAbstract" xlink:title="definition: MinorityInterestLineItems to NoncontrollingInterestAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="MinorityInterestLineItems" xlink:to="MinorityInterestOwnershipPercentageByParent" xlink:title="definition: MinorityInterestLineItems to MinorityInterestOwnershipPercentageByParent" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="MinorityInterestTable" xlink:title="MinorityInterestTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="MinorityInterestLineItems" xlink:to="MinorityInterestTable" xlink:title="definition: MinorityInterestLineItems to MinorityInterestTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="MinorityInterestTable" xlink:to="OwnershipAxis" xlink:title="definition: MinorityInterestTable to OwnershipAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="definition: OwnershipAxis to OwnershipDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain_2" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain_2" xlink:title="definition: OwnershipAxis to OwnershipDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OwnershipDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="definition: OwnershipDomain to AkceaTherapeuticsIncMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="EntityWideRevenueMajorCustomerLineItems" xlink:title="EntityWideRevenueMajorCustomerLineItems" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SignificantPartnersAbstract" xlink:label="SignificantPartnersAbstract" xlink:title="SignificantPartnersAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityWideRevenueMajorCustomerLineItems" xlink:to="SignificantPartnersAbstract" xlink:title="definition: EntityWideRevenueMajorCustomerLineItems to SignificantPartnersAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityWideRevenueMajorCustomerLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: EntityWideRevenueMajorCustomerLineItems to ConcentrationRiskPercentage1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfSignificantPartners" xlink:label="NumberOfSignificantPartners" xlink:title="NumberOfSignificantPartners" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EntityWideRevenueMajorCustomerLineItems" xlink:to="NumberOfSignificantPartners" xlink:title="definition: EntityWideRevenueMajorCustomerLineItems to NumberOfSignificantPartners" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:title="ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EntityWideRevenueMajorCustomerLineItems" xlink:to="ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:title="definition: EntityWideRevenueMajorCustomerLineItems to ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable to ConcentrationRiskByBenchmarkAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="AccountsReceivableMember" xlink:title="AccountsReceivableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="AccountsReceivableMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to AccountsReceivableMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable to ConcentrationRiskByTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="CreditConcentrationRiskMember" xlink:title="CreditConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CreditConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to CreditConcentrationRiskMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="MajorCustomersAxis" xlink:title="definition: ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable to MajorCustomersAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain_2" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain_2" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SignificantPartnersMember" xlink:label="SignificantPartnersMember" xlink:title="SignificantPartnersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="SignificantPartnersMember" xlink:title="definition: NameOfMajorCustomerDomain to SignificantPartnersMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/EmploymentBenefitsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="EarningsPerShareBasicLineItems" xlink:title="EarningsPerShareBasicLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="SelectedQuarterlyFinancialInformationAbstract" xlink:title="SelectedQuarterlyFinancialInformationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="SelectedQuarterlyFinancialInformationAbstract" xlink:title="definition: EarningsPerShareBasicLineItems to SelectedQuarterlyFinancialInformationAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:title="NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:title="definition: EarningsPerShareBasicLineItems to NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:title="definition: EarningsPerShareBasicLineItems to WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="definition: EarningsPerShareBasicLineItems to WeightedAverageNumberOfSharesOutstandingBasic" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:title="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:title="definition: EarningsPerShareBasicLineItems to WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="definition: EarningsPerShareBasicLineItems to WeightedAverageNumberOfDilutedSharesOutstanding" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="definition: EarningsPerShareBasicLineItems to IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" xlink:label="IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" xlink:title="IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" xlink:title="definition: EarningsPerShareBasicLineItems to IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:title="IncrementalCommonSharesAttributableToConversionOfDebtSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:title="definition: EarningsPerShareBasicLineItems to IncrementalCommonSharesAttributableToConversionOfDebtSecurities" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="definition: EarningsPerShareBasicLineItems to NetIncomeLossAvailableToCommonStockholdersBasic" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:title="NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:title="definition: EarningsPerShareBasicLineItems to NetIncomeLossAvailableToCommonStockholdersDiluted" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:label="DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:title="DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:title="definition: EarningsPerShareBasicLineItems to DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="Revenues" xlink:title="Revenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="Revenues" xlink:title="definition: EarningsPerShareBasicLineItems to Revenues" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="CostsAndExpenses" xlink:title="definition: EarningsPerShareBasicLineItems to CostsAndExpenses" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="OperatingIncomeLoss" xlink:title="definition: EarningsPerShareBasicLineItems to OperatingIncomeLoss" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="ProfitLoss" xlink:title="definition: EarningsPerShareBasicLineItems to ProfitLoss" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: EarningsPerShareBasicLineItems to NetIncomeLoss" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="EarningsPerShareBasic" xlink:title="definition: EarningsPerShareBasicLineItems to EarningsPerShareBasic" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="EarningsPerShareDiluted" xlink:title="definition: EarningsPerShareBasicLineItems to EarningsPerShareDiluted" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_WeightedAverageNumberOfSharesOwnedInSubsidiary" xlink:label="WeightedAverageNumberOfSharesOwnedInSubsidiary" xlink:title="WeightedAverageNumberOfSharesOwnedInSubsidiary" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="WeightedAverageNumberOfSharesOwnedInSubsidiary" xlink:title="definition: EarningsPerShareBasicLineItems to WeightedAverageNumberOfSharesOwnedInSubsidiary" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EarningsPerShareBasicLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: EarningsPerShareBasicLineItems to DebtInstrumentInterestRateStatedPercentage" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:title="ScheduleOfEarningsPerShareBasicByCommonClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="EarningsPerShareBasicLineItems" xlink:to="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:title="definition: EarningsPerShareBasicLineItems to ScheduleOfEarningsPerShareBasicByCommonClassTable" order="22.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="OwnershipAxis" xlink:title="definition: ScheduleOfEarningsPerShareBasicByCommonClassTable to OwnershipAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="definition: OwnershipAxis to OwnershipDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain_2" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain_2" xlink:title="definition: OwnershipAxis to OwnershipDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OwnershipDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="definition: OwnershipDomain to AkceaTherapeuticsIncMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="definition: ScheduleOfEarningsPerShareBasicByCommonClassTable to StatementBusinessSegmentsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain_2" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain_2" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IonisCoreMember" xlink:label="IonisCoreMember" xlink:title="IonisCoreMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="IonisCoreMember" xlink:title="definition: SegmentDomain to IonisCoreMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfEarningsPerShareBasicByCommonClassTable to AwardTypeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: ScheduleOfEarningsPerShareBasicByCommonClassTable to DebtInstrumentAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentMember" xlink:label="ConvertibleSeniorNotes0125PercentMember" xlink:title="ConvertibleSeniorNotes0125PercentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes0125PercentMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleSeniorNotes0125PercentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes1PercentMember" xlink:label="ConvertibleSeniorNotes1PercentMember" xlink:title="ConvertibleSeniorNotes1PercentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes1PercentMember" xlink:title="definition: DebtInstrumentNameDomain to ConvertibleSeniorNotes1PercentMember" order="2.0" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>ions-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 6.2.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract_lbl" xml:lang="en-US" id="dei_CoverAbstract_lbl">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:title="label: CoverAbstract to dei_CoverAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" id="dei_EntityAddressAddressLine1_lbl">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag_lbl" xml:lang="en-US" id="dei_AmendmentFlag_lbl">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:title="label: AmendmentFlag to dei_AmendmentFlag_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode_lbl" xml:lang="en-US" id="dei_CityAreaCode_lbl">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:title="label: CityAreaCode to dei_CityAreaCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" id="dei_EntityAddressCityOrTown_lbl">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="dei_CurrentFiscalYearEndDate_lbl">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:title="label: CurrentFiscalYearEndDate to dei_CurrentFiscalYearEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="dei_DocumentPeriodEndDate_lbl">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode_lbl">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber_lbl" xml:lang="en-US" id="dei_LocalPhoneNumber_lbl">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" id="dei_EntityAddressPostalZipCode_lbl">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" id="dei_EntityAddressStateOrProvince_lbl">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle_lbl" xml:lang="en-US" id="dei_Security12bTitle_lbl">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:title="label: Security12bTitle to dei_Security12bTitle_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol_lbl" xml:lang="en-US" id="dei_TradingSymbol_lbl">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:title="label: TradingSymbol to dei_TradingSymbol_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName_lbl" xml:lang="en-US" id="dei_SecurityExchangeName_lbl">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:label xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="dei_EntityWellKnownSeasonedIssuer_lbl">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:title="label: EntityWellKnownSeasonedIssuer to dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:label xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="dei_EntityVoluntaryFilers_lbl">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:title="label: EntityVoluntaryFilers to dei_EntityVoluntaryFilers_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="dei_EntityCurrentReportingStatus_lbl">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:title="label: EntityCurrentReportingStatus to dei_EntityCurrentReportingStatus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="dei_EntityFilerCategory_lbl">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:label xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="dei_EntityPublicFloat_lbl">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:title="label: EntityPublicFloat to dei_EntityPublicFloat_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="dei_EntityRegistrantName_lbl">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="dei_EntityCentralIndexKey_lbl">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber_lbl">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="dei_EntityCommonStockSharesOutstanding_lbl">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:title="label: EntityCommonStockSharesOutstanding to dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalYearFocus_lbl">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus_lbl">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType_lbl" xml:lang="en-US" id="dei_DocumentType_lbl">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType_lbl" xlink:title="label: DocumentType to dei_DocumentType_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="DocumentAnnualReport" xlink:title="DocumentAnnualReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentAnnualReport_lbl" xml:lang="en-US" id="dei_DocumentAnnualReport_lbl">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:title="label: DocumentAnnualReport to dei_DocumentAnnualReport_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentTransitionReport_lbl" xml:lang="en-US" id="dei_DocumentTransitionReport_lbl">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:title="label: DocumentTransitionReport to dei_DocumentTransitionReport_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:label xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" id="dei_EntityInteractiveDataCurrent_lbl">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:title="label: EntityInteractiveDataCurrent to dei_EntityInteractiveDataCurrent_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber_lbl" xml:lang="en-US" id="dei_EntityFileNumber_lbl">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:title="label: EntityFileNumber to dei_EntityFileNumber_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityShellCompany_lbl" xml:lang="en-US" id="dei_EntityShellCompany_lbl">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:title="label: EntityShellCompany to dei_EntityShellCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany_lbl">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany_lbl" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:label xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntitySmallBusiness_lbl" xml:lang="en-US" id="dei_EntitySmallBusiness_lbl">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:title="label: EntitySmallBusiness to dei_EntitySmallBusiness_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:title="AociIncludingPortionAttributableToNoncontrollingInterestMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xml:lang="en-US" id="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl">Accumulated Other Comprehensive Loss [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xlink:title="label: AociIncludingPortionAttributableToNoncontrollingInterestMember to us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl1" xml:lang="en-US" id="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl1">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl1" xlink:title="label: AociIncludingPortionAttributableToNoncontrollingInterestMember to us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="us-gaap_AwardTypeAxis_lbl">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:title="label: AwardTypeAxis to us-gaap_AwardTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:title="label: ArrangementsAndNonarrangementTransactionsMember to us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:label="AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:title="AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_lbl" xml:lang="en-US" id="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_lbl">Number of investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:to="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_lbl" xlink:title="label: AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1 to us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_lbl1" xml:lang="en-US" id="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_lbl1">Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:to="us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_lbl1" xlink:title="label: AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1 to us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="AccountingStandardsUpdate201602Member" xlink:title="AccountingStandardsUpdate201602Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US" id="us-gaap_AccountingStandardsUpdate201602Member_lbl">Topic 842 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:title="label: AccountingStandardsUpdate201602Member to us-gaap_AccountingStandardsUpdate201602Member_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountingStandardsUpdate201602Member_lbl1" xml:lang="en-US" id="us-gaap_AccountingStandardsUpdate201602Member_lbl1">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl1" xlink:title="label: AccountingStandardsUpdate201602Member to us-gaap_AccountingStandardsUpdate201602Member_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent_lbl">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent_lbl1">Accounts Payable, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl1" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="AccountsReceivableMember" xlink:title="AccountsReceivableMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" id="us-gaap_AccountsReceivableMember_lbl">Contracts Receivables [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:title="label: AccountsReceivableMember to us-gaap_AccountsReceivableMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsReceivableMember_lbl1" xml:lang="en-US" id="us-gaap_AccountsReceivableMember_lbl1">Accounts Receivable [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl1" xlink:title="label: AccountsReceivableMember to us-gaap_AccountsReceivableMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:title="AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US" id="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl">Amortization of premium (discount) on investments, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:title="label: AccretionAmortizationOfDiscountsAndPremiumsInvestments to us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl1" xml:lang="en-US" id="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl1">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl1" xlink:title="label: AccretionAmortizationOfDiscountsAndPremiumsInvestments to us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl">Accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl1">Total accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl1" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesCurrent_lbl2" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrent_lbl2">Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl2" xlink:title="label: AccruedLiabilitiesCurrent to us-gaap_AccruedLiabilitiesCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="AccruedLiabilitiesCurrentAbstract" xlink:title="AccruedLiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl">Accrued Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:title="label: AccruedLiabilitiesCurrentAbstract to us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl1">Accrued Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl1" xlink:title="label: AccruedLiabilitiesCurrentAbstract to us-gaap_AccruedLiabilitiesCurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="AccruedIncomeTaxesCurrent" xlink:title="AccruedIncomeTaxesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US" id="us-gaap_AccruedIncomeTaxesCurrent_lbl">Income taxes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:title="label: AccruedIncomeTaxesCurrent to us-gaap_AccruedIncomeTaxesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedIncomeTaxesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AccruedIncomeTaxesCurrent_lbl1">Accrued Income Taxes, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl1" xlink:title="label: AccruedIncomeTaxesCurrent to us-gaap_AccruedIncomeTaxesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:title="AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xml:lang="en-US" id="us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_lbl">Currency Translation Adjustment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xlink:title="label: AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember to us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="AccumulatedOtherComprehensiveIncomeLossTable" xlink:title="AccumulatedOtherComprehensiveIncomeLossTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US" id="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:title="label: AccumulatedOtherComprehensiveIncomeLossTable to us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl">Less accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:title="AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xml:lang="en-US" id="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_lbl">Unrealized Gains (Losses) on Securities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_lbl" xlink:title="label: AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember to us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_lbl1" xml:lang="en-US" id="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_lbl1">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_lbl1" xlink:title="label: AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember to us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:title="AccumulatedOtherComprehensiveIncomeLossLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US" id="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:title="label: AccumulatedOtherComprehensiveIncomeLossLineItems to us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:title="label: AccumulatedOtherComprehensiveIncomeLossNetOfTax to us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl1">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl1" xlink:title="label: AccumulatedOtherComprehensiveIncomeLossNetOfTax to us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" id="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl">Accumulated Other Comprehensive Loss [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:title="label: AccumulatedOtherComprehensiveIncomeMember to us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalMember_lbl">Additional Paid In Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:title="label: AdditionalPaidInCapitalMember to us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="AdditionalPaidInCapitalCommonStock" xlink:title="AdditionalPaidInCapitalCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalCommonStock_lbl">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:title="label: AdditionalPaidInCapitalCommonStock to us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapitalCommonStock_lbl1" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalCommonStock_lbl1">Additional Paid in Capital, Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl1" xlink:title="label: AdditionalPaidInCapitalCommonStock to us-gaap_AdditionalPaidInCapitalCommonStock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:title="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl">0.125 percent convertible senior notes, equity portion, net of issuance costs and tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt to us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl1">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt to us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Adjustments to reconcile net income (loss) to net cash provided by operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="AdjustmentsToAdditionalPaidInCapitalOther" xlink:title="AdjustmentsToAdditionalPaidInCapitalOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl">Purchase of note hedges, net of tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalOther to us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl1">Adjustments to Additional Paid in Capital, Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalOther to us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl">Issuance of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalWarrantIssued to us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalWarrantIssued to us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl">Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl1">APIC, Share-based Payment Arrangement, Recognition and Exercise</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:title="label: AdjustmentsForNewAccountingPronouncementsAxis to us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue to us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense_lbl1">Share-based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl">Amortization of debt discount and debt issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:title="label: AmortizationOfFinancingCostsAndDiscounts to us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl1" xml:lang="en-US" id="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl1">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl1" xlink:title="label: AmortizationOfFinancingCostsAndDiscounts to us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfIntangibleAssets_lbl">Amortization of patents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:title="label: AmortizationOfIntangibleAssets to us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfIntangibleAssets_lbl1" xml:lang="en-US" id="us-gaap_AmortizationOfIntangibleAssets_lbl1">Amortization of Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl1" xlink:title="label: AmortizationOfIntangibleAssets to us-gaap_AmortizationOfIntangibleAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="AmortizationOfFinancingCosts" xlink:title="AmortizationOfFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfFinancingCosts_lbl">Amortization of debt issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:title="label: AmortizationOfFinancingCosts to us-gaap_AmortizationOfFinancingCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfFinancingCosts_lbl1" xml:lang="en-US" id="us-gaap_AmortizationOfFinancingCosts_lbl1">Amortization of Debt Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl1" xlink:title="label: AmortizationOfFinancingCosts to us-gaap_AmortizationOfFinancingCosts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfLeasedAsset" xlink:label="AmortizationOfLeasedAsset" xlink:title="AmortizationOfLeasedAsset" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfLeasedAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AmortizationOfLeasedAsset_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfLeasedAsset_lbl">Amortization of long-term financing liability for leased facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfLeasedAsset" xlink:to="us-gaap_AmortizationOfLeasedAsset_lbl" xlink:title="label: AmortizationOfLeasedAsset to us-gaap_AmortizationOfLeasedAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfLeasedAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfLeasedAsset_lbl1" xml:lang="en-US" id="us-gaap_AmortizationOfLeasedAsset_lbl1">Amortization of Leased Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfLeasedAsset" xlink:to="us-gaap_AmortizationOfLeasedAsset_lbl1" xlink:title="label: AmortizationOfLeasedAsset to us-gaap_AmortizationOfLeasedAsset_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" id="us-gaap_AmortizationOfDebtDiscountPremium_lbl">Amortization of convertible senior notes discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:title="label: AmortizationOfDebtDiscountPremium to us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfDebtDiscountPremium_lbl1" xml:lang="en-US" id="us-gaap_AmortizationOfDebtDiscountPremium_lbl1">Amortization of Debt Discount (Premium)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl1" xlink:title="label: AmortizationOfDebtDiscountPremium to us-gaap_AmortizationOfDebtDiscountPremium_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="AssetImpairmentChargesAbstract" xlink:title="AssetImpairmentChargesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetImpairmentChargesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetImpairmentChargesAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetImpairmentChargesAbstract_lbl">Long-Lived Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetImpairmentChargesAbstract" xlink:to="us-gaap_AssetImpairmentChargesAbstract_lbl" xlink:title="label: AssetImpairmentChargesAbstract to us-gaap_AssetImpairmentChargesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetImpairmentChargesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetImpairmentChargesAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetImpairmentChargesAbstract_lbl1">Asset Impairment Charges [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetImpairmentChargesAbstract" xlink:to="us-gaap_AssetImpairmentChargesAbstract_lbl1" xlink:title="label: AssetImpairmentChargesAbstract to us-gaap_AssetImpairmentChargesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" id="us-gaap_AssetImpairmentCharges_lbl">Charges related to write-down of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:title="label: AssetImpairmentCharges to us-gaap_AssetImpairmentCharges_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetImpairmentCharges_lbl1" xml:lang="en-US" id="us-gaap_AssetImpairmentCharges_lbl1">Asset Impairment Charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl1" xlink:title="label: AssetImpairmentCharges to us-gaap_AssetImpairmentCharges_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="us-gaap_AssetsFairValueDisclosure_lbl">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:title="label: AssetsFairValueDisclosure to us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_AssetsFairValueDisclosure_lbl1">Assets, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl1" xlink:title="label: AssetsFairValueDisclosure to us-gaap_AssetsFairValueDisclosure_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Assets_lbl" xml:lang="en-US" id="us-gaap_Assets_lbl">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl" xlink:title="label: Assets to us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Assets_lbl1" xml:lang="en-US" id="us-gaap_Assets_lbl1">Total assets as of current period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets_lbl1" xlink:title="label: Assets to us-gaap_Assets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract_lbl1">Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl1" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:title="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" id="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl">Gross unrealized gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:title="label: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax to us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl1" xml:lang="en-US" id="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl1">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl1" xlink:title="label: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax to us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:title="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl">Summary of Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl" xlink:title="label: AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract to us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:title="AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" id="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl">Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:title="label: AvailableForSaleDebtSecuritiesAmortizedCostBasis to us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl1" xml:lang="en-US" id="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl1">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl1" xlink:title="label: AvailableForSaleDebtSecuritiesAmortizedCostBasis to us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:title="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_lbl" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_lbl">Unrealized losses, total temporary impairment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_lbl" xlink:title="label: AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss to us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_lbl1" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_lbl1">Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_lbl1" xlink:title="label: AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss to us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="AvailableForSaleSecuritiesAbstract" xlink:title="AvailableForSaleSecuritiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AvailableForSaleSecuritiesAbstract_lbl" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesAbstract_lbl">Temporarily Impaired Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract_lbl" xlink:title="label: AvailableForSaleSecuritiesAbstract to us-gaap_AvailableForSaleSecuritiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleSecuritiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesAbstract_lbl1">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesAbstract_lbl1" xlink:title="label: AvailableForSaleSecuritiesAbstract to us-gaap_AvailableForSaleSecuritiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl">Unrealized losses, more than 12 months of temporary impairment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" xlink:title="label: AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss to us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl1" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl1">Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl1" xlink:title="label: AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss to us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:title="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" id="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl">Gross unrealized losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:title="label: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax to us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl1" xml:lang="en-US" id="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl1">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl1" xlink:title="label: AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax to us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl">Unrealized losses, less than 12 months of temporary impairment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" xlink:title="label: AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss to us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl1" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl1">Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl1" xlink:title="label: AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss to us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="AvailableForSaleSecurities" xlink:title="AvailableForSaleSecurities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AvailableForSaleSecurities_lbl" xml:lang="en-US" id="us-gaap_AvailableForSaleSecurities_lbl">Available-for-sale securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities_lbl" xlink:title="label: AvailableForSaleSecurities to us-gaap_AvailableForSaleSecurities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecurities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleSecurities_lbl1" xml:lang="en-US" id="us-gaap_AvailableForSaleSecurities_lbl1">Available-for-sale Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecurities_lbl1" xlink:title="label: AvailableForSaleSecurities to us-gaap_AvailableForSaleSecurities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:title="AvailableForSaleSecuritiesDebtMaturitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl">Contract Maturity of Available-for-Sale Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl" xlink:title="label: AvailableForSaleSecuritiesDebtMaturitiesAbstract to us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl1">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl1" xlink:title="label: AvailableForSaleSecuritiesDebtMaturitiesAbstract to us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_lbl" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_lbl">Estimated fair value, total temporary impairment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_lbl" xlink:title="label: AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue to us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_lbl1" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_lbl1">Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_lbl1" xlink:title="label: AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue to us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_lbl" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_lbl">Estimated fair value, more than 12 months of temporary impairment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_lbl" xlink:title="label: AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue to us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_lbl1" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_lbl1">Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_lbl1" xlink:title="label: AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue to us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_lbl" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_lbl">Estimated fair value, less than 12 months of temporary impairment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_lbl" xlink:title="label: AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue to us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_lbl1" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_lbl1">Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_lbl1" xlink:title="label: AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue to us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:title="AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl">Short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:title="label: AvailableForSaleSecuritiesDebtSecuritiesCurrent to us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl1">Debt Securities, Available-for-sale, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl1" xlink:title="label: AvailableForSaleSecuritiesDebtSecuritiesCurrent to us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="AvailableForSaleSecuritiesDebtSecurities" xlink:title="AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl">Estimated fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:title="label: AvailableForSaleSecuritiesDebtSecurities to us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl1" xml:lang="en-US" id="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl1">Debt Securities, Available-for-sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl1" xlink:title="label: AvailableForSaleSecuritiesDebtSecurities to us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="BalanceSheetLocationDomain" xlink:title="BalanceSheetLocationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" id="us-gaap_BalanceSheetLocationDomain_lbl">Balance Sheet Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xlink:title="label: BalanceSheetLocationDomain to us-gaap_BalanceSheetLocationDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="BalanceSheetLocationAxis" xlink:title="BalanceSheetLocationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" id="us-gaap_BalanceSheetLocationAxis_lbl">Balance Sheet Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xlink:title="label: BalanceSheetLocationAxis to us-gaap_BalanceSheetLocationAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="BuildingAndBuildingImprovementsMember" xlink:title="BuildingAndBuildingImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_BuildingAndBuildingImprovementsMember_lbl" xml:lang="en-US" id="us-gaap_BuildingAndBuildingImprovementsMember_lbl">Building, Building Improvements and Building Systems [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BuildingAndBuildingImprovementsMember" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_lbl" xlink:title="label: BuildingAndBuildingImprovementsMember to us-gaap_BuildingAndBuildingImprovementsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BuildingAndBuildingImprovementsMember_lbl1" xml:lang="en-US" id="us-gaap_BuildingAndBuildingImprovementsMember_lbl1">Building and Building Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BuildingAndBuildingImprovementsMember" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_lbl1" xlink:title="label: BuildingAndBuildingImprovementsMember to us-gaap_BuildingAndBuildingImprovementsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="CaliforniaFranchiseTaxBoardMember" xlink:title="CaliforniaFranchiseTaxBoardMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xml:lang="en-US" id="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl">California [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CaliforniaFranchiseTaxBoardMember" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" xlink:title="label: CaliforniaFranchiseTaxBoardMember to us-gaap_CaliforniaFranchiseTaxBoardMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl1" xml:lang="en-US" id="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl1">California Franchise Tax Board [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CaliforniaFranchiseTaxBoardMember" xlink:to="us-gaap_CaliforniaFranchiseTaxBoardMember_lbl1" xlink:title="label: CaliforniaFranchiseTaxBoardMember to us-gaap_CaliforniaFranchiseTaxBoardMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="CapitalExpendituresIncurredButNotYetPaid" xlink:title="CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US" id="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl">Purchases of property, plant and equipment included in long-term obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:title="label: CapitalExpendituresIncurredButNotYetPaid to us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl1" xml:lang="en-US" id="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl1">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl1" xlink:title="label: CapitalExpendituresIncurredButNotYetPaid to us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl">Cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:title="label: CashAndCashEquivalentsFairValueDisclosure to us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1" xlink:title="label: CashAndCashEquivalentsFairValueDisclosure to us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl">Net increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl">Cash and cash equivalents at end of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1">Cash and cash equivalents at beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="CashAndCashEquivalentsMember" xlink:title="CashAndCashEquivalentsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsMember_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsMember_lbl">Cash and Cash Equivalents [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:title="label: CashAndCashEquivalentsMember to us-gaap_CashAndCashEquivalentsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl">Supplemental disclosures of non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:title="label: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl1" xml:lang="en-US" id="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl1">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl1" xlink:title="label: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:title="CashCashEquivalentsAndShortTermInvestmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl" xml:lang="en-US" id="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl">Cash, Cash Equivalents and Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl" xlink:title="label: CashCashEquivalentsAndShortTermInvestmentsAbstract to us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl1">Cash, Cash Equivalents, and Short-term Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl1" xlink:title="label: CashCashEquivalentsAndShortTermInvestmentsAbstract to us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="ClassOfTreasuryStockTable" xlink:title="ClassOfTreasuryStockTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfTreasuryStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfTreasuryStockTable_lbl" xml:lang="en-US" id="us-gaap_ClassOfTreasuryStockTable_lbl">Class of Treasury Stock [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfTreasuryStockTable" xlink:to="us-gaap_ClassOfTreasuryStockTable_lbl" xlink:title="label: ClassOfTreasuryStockTable to us-gaap_ClassOfTreasuryStockTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockLineItems_lbl">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:title="label: ClassOfStockLineItems to us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockLineItems_lbl1" xml:lang="en-US" id="us-gaap_ClassOfStockLineItems_lbl1">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl1" xlink:title="label: ClassOfStockLineItems to us-gaap_ClassOfStockLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockDomain_lbl">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xlink:title="label: ClassOfStockDomain to us-gaap_ClassOfStockDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="ClassOfStockDisclosuresAbstract" xlink:title="ClassOfStockDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_ClassOfStockDisclosuresAbstract_lbl">Share Repurchase Program [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xlink:title="label: ClassOfStockDisclosuresAbstract to us-gaap_ClassOfStockDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_ClassOfStockDisclosuresAbstract_lbl1">Class of Stock Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_lbl1" xlink:title="label: ClassOfStockDisclosuresAbstract to us-gaap_ClassOfStockDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" id="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:title="label: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="CollaborativeArrangementDisclosureTextBlock" xlink:title="CollaborativeArrangementDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl">Collaborative Arrangements and Licensing Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:title="label: CollaborativeArrangementDisclosureTextBlock to us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl1">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl1" xlink:title="label: CollaborativeArrangementDisclosureTextBlock to us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl">Legal Proceedings [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl">Common shares reserved for future issuance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:title="label: CommonStockCapitalSharesReservedForFutureIssuance to us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1" xml:lang="en-US" id="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1" xlink:title="label: CommonStockCapitalSharesReservedForFutureIssuance to us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="us-gaap_CommonStockMember_lbl">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl">Common Stock [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:title="label: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare_lbl">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare_lbl1">Common Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl1">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesIssued_lbl2" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued_lbl2">Common Stock, Shares, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl2" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl1">Common stock, shares authorized to issue (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesAuthorized_lbl2" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized_lbl2">Common Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl2" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl1">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesOutstanding_lbl2" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding_lbl2">Common Stock, Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl2" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="us-gaap_CommonStockValue_lbl">Common stock, $0.001 par value; 300,000,000 shares authorized, 140,339,615 and 137,928,828 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl">Employment Benefits [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:title="label: CompensationAndRetirementDisclosureAbstract to us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl">Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:title="label: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl1">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl1" xlink:title="label: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTax_lbl">Comprehensive income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:title="label: ComprehensiveIncomeNetOfTax to us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComprehensiveIncomeNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTax_lbl1">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl1" xlink:title="label: ComprehensiveIncomeNetOfTax to us-gaap_ComprehensiveIncomeNetOfTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:title="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl">Comprehensive income (loss) attributable to noncontrolling interest in Akcea Therapeutics, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" xlink:title="label: ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest to us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl1">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl1" xlink:title="label: ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest to us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:title="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl">Comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:title="label: ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest to us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl1">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl1" xlink:title="label: ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest to us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskTypeDomain_lbl">Concentration Risk Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:title="label: ConcentrationRiskTypeDomain to us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl">Concentration Risk Benchmark [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:title="label: ConcentrationRiskByBenchmarkAxis to us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskPercentage1_lbl">Concentration percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:title="label: ConcentrationRiskPercentage1 to us-gaap_ConcentrationRiskPercentage1_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskBenchmarkDomain_lbl">Concentration Risk Benchmark [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:title="label: ConcentrationRiskBenchmarkDomain to us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskCreditRisk_lbl">Concentration of Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:title="label: ConcentrationRiskCreditRisk to us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskCreditRisk_lbl1" xml:lang="en-US" id="us-gaap_ConcentrationRiskCreditRisk_lbl1">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl1" xlink:title="label: ConcentrationRiskCreditRisk to us-gaap_ConcentrationRiskCreditRisk_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" id="us-gaap_ConcentrationRiskByTypeAxis_lbl">Concentration Risk Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:title="label: ConcentrationRiskByTypeAxis to us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:label="ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:title="ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_lbl" xml:lang="en-US" id="us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_lbl">Noncontrolling Interest in Akcea Therapeutics, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_lbl" xlink:title="label: ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy to us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_lbl1" xml:lang="en-US" id="us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_lbl1">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_lbl1" xlink:title="label: ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy to us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="ConsolidationPolicyTextBlock" xlink:title="ConsolidationPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_ConsolidationPolicyTextBlock_lbl">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:title="label: ConsolidationPolicyTextBlock to us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConsolidationPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ConsolidationPolicyTextBlock_lbl1">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl1" xlink:title="label: ConsolidationPolicyTextBlock to us-gaap_ConsolidationPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="ContractWithCustomerLiabilityNoncurrent" xlink:title="ContractWithCustomerLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xml:lang="en-US" id="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl">Long-term deferred contract revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:title="label: ContractWithCustomerLiabilityNoncurrent to us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl1">Contract with Customer, Liability, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl1" xlink:title="label: ContractWithCustomerLiabilityNoncurrent to us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="ContractWithCustomerLiability" xlink:title="ContractWithCustomerLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ContractWithCustomerLiability_lbl" xml:lang="en-US" id="us-gaap_ContractWithCustomerLiability_lbl">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" xlink:title="label: ContractWithCustomerLiability to us-gaap_ContractWithCustomerLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContractWithCustomerLiability_lbl1" xml:lang="en-US" id="us-gaap_ContractWithCustomerLiability_lbl1">Contract with Customer, Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl1" xlink:title="label: ContractWithCustomerLiability to us-gaap_ContractWithCustomerLiability_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="ContractWithCustomerLiabilityRevenueRecognized" xlink:title="ContractWithCustomerLiabilityRevenueRecognized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US" id="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl">Revenue recognized from amounts in beginning deferred revenue balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:title="label: ContractWithCustomerLiabilityRevenueRecognized to us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl1" xml:lang="en-US" id="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl1">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl1" xlink:title="label: ContractWithCustomerLiabilityRevenueRecognized to us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="ContractWithCustomerLiabilityAbstract" xlink:title="ContractWithCustomerLiabilityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ContractWithCustomerLiabilityAbstract_lbl" xml:lang="en-US" id="us-gaap_ContractWithCustomerLiabilityAbstract_lbl">Deferred Revenue [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityAbstract_lbl" xlink:title="label: ContractWithCustomerLiabilityAbstract to us-gaap_ContractWithCustomerLiabilityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContractWithCustomerLiabilityAbstract_lbl1" xml:lang="en-US" id="us-gaap_ContractWithCustomerLiabilityAbstract_lbl1">Contract with Customer, Liability [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractWithCustomerLiabilityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityAbstract_lbl1" xlink:title="label: ContractWithCustomerLiabilityAbstract to us-gaap_ContractWithCustomerLiabilityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="ContractWithCustomerAssetNetCurrent" xlink:title="ContractWithCustomerAssetNetCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US" id="us-gaap_ContractWithCustomerAssetNetCurrent_lbl">Contracts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xlink:title="label: ContractWithCustomerAssetNetCurrent to us-gaap_ContractWithCustomerAssetNetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContractWithCustomerAssetNetCurrent_lbl1" xml:lang="en-US" id="us-gaap_ContractWithCustomerAssetNetCurrent_lbl1">Contract with Customer, Asset, Net, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl1" xlink:title="label: ContractWithCustomerAssetNetCurrent to us-gaap_ContractWithCustomerAssetNetCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" id="us-gaap_ContractWithCustomerLiabilityCurrent_lbl">Current portion of deferred contract revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:title="label: ContractWithCustomerLiabilityCurrent to us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContractWithCustomerLiabilityCurrent_lbl1" xml:lang="en-US" id="us-gaap_ContractWithCustomerLiabilityCurrent_lbl1">Contract with Customer, Liability, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl1" xlink:title="label: ContractWithCustomerLiabilityCurrent to us-gaap_ContractWithCustomerLiabilityCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractReceivablesAbstract" xlink:label="ContractReceivablesAbstract" xlink:title="ContractReceivablesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractReceivablesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ContractReceivablesAbstract_lbl" xml:lang="en-US" id="us-gaap_ContractReceivablesAbstract_lbl">Contracts Receivable [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractReceivablesAbstract" xlink:to="us-gaap_ContractReceivablesAbstract_lbl" xlink:title="label: ContractReceivablesAbstract to us-gaap_ContractReceivablesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractReceivablesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContractReceivablesAbstract_lbl1" xml:lang="en-US" id="us-gaap_ContractReceivablesAbstract_lbl1">Contracts Receivable [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractReceivablesAbstract" xlink:to="us-gaap_ContractReceivablesAbstract_lbl1" xlink:title="label: ContractReceivablesAbstract to us-gaap_ContractReceivablesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="ContractualObligationDueInFifthYear" xlink:title="ContractualObligationDueInFifthYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInFifthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ContractualObligationDueInFifthYear_lbl" xml:lang="en-US" id="us-gaap_ContractualObligationDueInFifthYear_lbl">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractualObligationDueInFifthYear" xlink:to="us-gaap_ContractualObligationDueInFifthYear_lbl" xlink:title="label: ContractualObligationDueInFifthYear to us-gaap_ContractualObligationDueInFifthYear_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInFifthYear_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContractualObligationDueInFifthYear_lbl1" xml:lang="en-US" id="us-gaap_ContractualObligationDueInFifthYear_lbl1">Contractual Obligation, Due in Fifth Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractualObligationDueInFifthYear" xlink:to="us-gaap_ContractualObligationDueInFifthYear_lbl1" xlink:title="label: ContractualObligationDueInFifthYear to us-gaap_ContractualObligationDueInFifthYear_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="ContractualObligationDueInNextTwelveMonths" xlink:title="ContractualObligationDueInNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US" id="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl">2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xlink:title="label: ContractualObligationDueInNextTwelveMonths to us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl1" xml:lang="en-US" id="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl1">Contractual Obligation, Due in Next Fiscal Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl1" xlink:title="label: ContractualObligationDueInNextTwelveMonths to us-gaap_ContractualObligationDueInNextTwelveMonths_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="ContractualObligationDueAfterFifthYear" xlink:title="ContractualObligationDueAfterFifthYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ContractualObligationDueAfterFifthYear_lbl" xml:lang="en-US" id="us-gaap_ContractualObligationDueAfterFifthYear_lbl">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractualObligationDueAfterFifthYear" xlink:to="us-gaap_ContractualObligationDueAfterFifthYear_lbl" xlink:title="label: ContractualObligationDueAfterFifthYear to us-gaap_ContractualObligationDueAfterFifthYear_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContractualObligationDueAfterFifthYear_lbl1" xml:lang="en-US" id="us-gaap_ContractualObligationDueAfterFifthYear_lbl1">Contractual Obligation, Due after Fifth Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractualObligationDueAfterFifthYear" xlink:to="us-gaap_ContractualObligationDueAfterFifthYear_lbl1" xlink:title="label: ContractualObligationDueAfterFifthYear to us-gaap_ContractualObligationDueAfterFifthYear_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="ContractualObligationDueInThirdYear" xlink:title="ContractualObligationDueInThirdYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInThirdYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ContractualObligationDueInThirdYear_lbl" xml:lang="en-US" id="us-gaap_ContractualObligationDueInThirdYear_lbl">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractualObligationDueInThirdYear" xlink:to="us-gaap_ContractualObligationDueInThirdYear_lbl" xlink:title="label: ContractualObligationDueInThirdYear to us-gaap_ContractualObligationDueInThirdYear_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInThirdYear_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContractualObligationDueInThirdYear_lbl1" xml:lang="en-US" id="us-gaap_ContractualObligationDueInThirdYear_lbl1">Contractual Obligation, Due in Third Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractualObligationDueInThirdYear" xlink:to="us-gaap_ContractualObligationDueInThirdYear_lbl1" xlink:title="label: ContractualObligationDueInThirdYear to us-gaap_ContractualObligationDueInThirdYear_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="ContractualObligationDueInFourthYear" xlink:title="ContractualObligationDueInFourthYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInFourthYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ContractualObligationDueInFourthYear_lbl" xml:lang="en-US" id="us-gaap_ContractualObligationDueInFourthYear_lbl">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractualObligationDueInFourthYear" xlink:to="us-gaap_ContractualObligationDueInFourthYear_lbl" xlink:title="label: ContractualObligationDueInFourthYear to us-gaap_ContractualObligationDueInFourthYear_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInFourthYear_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContractualObligationDueInFourthYear_lbl1" xml:lang="en-US" id="us-gaap_ContractualObligationDueInFourthYear_lbl1">Contractual Obligation, Due in Fourth Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractualObligationDueInFourthYear" xlink:to="us-gaap_ContractualObligationDueInFourthYear_lbl1" xlink:title="label: ContractualObligationDueInFourthYear to us-gaap_ContractualObligationDueInFourthYear_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="ContractualObligationDueInSecondYear" xlink:title="ContractualObligationDueInSecondYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US" id="us-gaap_ContractualObligationDueInSecondYear_lbl">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear_lbl" xlink:title="label: ContractualObligationDueInSecondYear to us-gaap_ContractualObligationDueInSecondYear_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContractualObligationDueInSecondYear_lbl1" xml:lang="en-US" id="us-gaap_ContractualObligationDueInSecondYear_lbl1">Contractual Obligation, Due in Second Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear_lbl1" xlink:title="label: ContractualObligationDueInSecondYear to us-gaap_ContractualObligationDueInSecondYear_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation" xlink:label="ContractualObligation" xlink:title="ContractualObligation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_ContractualObligation_lbl" xml:lang="en-US" id="us-gaap_ContractualObligation_lbl">Subtotal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" xlink:title="label: ContractualObligation to us-gaap_ContractualObligation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractualObligation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContractualObligation_lbl1" xml:lang="en-US" id="us-gaap_ContractualObligation_lbl1">Contractual Obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl1" xlink:title="label: ContractualObligation to us-gaap_ContractualObligation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="us-gaap_ConvertiblePreferredStockMember_lbl">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:title="label: ConvertiblePreferredStockMember to us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConvertiblePreferredStockMember_lbl1" xml:lang="en-US" id="us-gaap_ConvertiblePreferredStockMember_lbl1">Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl1" xlink:title="label: ConvertiblePreferredStockMember to us-gaap_ConvertiblePreferredStockMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="ConvertibleDebtNoncurrent" xlink:title="ConvertibleDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConvertibleDebtNoncurrent_lbl" xml:lang="en-US" id="us-gaap_ConvertibleDebtNoncurrent_lbl">Convertible senior notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl" xlink:title="label: ConvertibleDebtNoncurrent to us-gaap_ConvertibleDebtNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ConvertibleDebtNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_ConvertibleDebtNoncurrent_lbl1">Long-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl1" xlink:title="label: ConvertibleDebtNoncurrent to us-gaap_ConvertibleDebtNoncurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtNoncurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConvertibleDebtNoncurrent_lbl2" xml:lang="en-US" id="us-gaap_ConvertibleDebtNoncurrent_lbl2">Convertible Debt, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent_lbl2" xlink:title="label: ConvertibleDebtNoncurrent to us-gaap_ConvertibleDebtNoncurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:title="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_lbl">Convertible Notes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_lbl" xlink:title="label: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="ConvertibleDebtTableTextBlock" xlink:title="ConvertibleDebtTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConvertibleDebtTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ConvertibleDebtTableTextBlock_lbl">Convertible Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl" xlink:title="label: ConvertibleDebtTableTextBlock to us-gaap_ConvertibleDebtTableTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="ConvertiblePreferredStockTermsOfConversion" xlink:title="ConvertiblePreferredStockTermsOfConversion" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xml:lang="en-US" id="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl">Conversion ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:title="label: ConvertiblePreferredStockTermsOfConversion to us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="CorporateDebtSecuritiesMember" xlink:title="CorporateDebtSecuritiesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" id="us-gaap_CorporateDebtSecuritiesMember_lbl">Corporate Debt Securities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:title="label: CorporateDebtSecuritiesMember to us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CorporateDebtSecuritiesMember_lbl1" xml:lang="en-US" id="us-gaap_CorporateDebtSecuritiesMember_lbl1">Corporate Debt Securities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl1" xlink:title="label: CorporateDebtSecuritiesMember to us-gaap_CorporateDebtSecuritiesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:label="CostOfGoodsAndServicesSoldAbstract" xlink:title="CostOfGoodsAndServicesSoldAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CostOfGoodsAndServicesSoldAbstract_lbl" xml:lang="en-US" id="us-gaap_CostOfGoodsAndServicesSoldAbstract_lbl">Cost of Products Sold [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfGoodsAndServicesSoldAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAbstract_lbl" xlink:title="label: CostOfGoodsAndServicesSoldAbstract to us-gaap_CostOfGoodsAndServicesSoldAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSoldAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfGoodsAndServicesSoldAbstract_lbl1" xml:lang="en-US" id="us-gaap_CostOfGoodsAndServicesSoldAbstract_lbl1">Cost of Goods and Services Sold [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfGoodsAndServicesSoldAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSoldAbstract_lbl1" xlink:title="label: CostOfGoodsAndServicesSoldAbstract to us-gaap_CostOfGoodsAndServicesSoldAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="CostOfGoodsAndServicesSold" xlink:title="CostOfGoodsAndServicesSold" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US" id="us-gaap_CostOfGoodsAndServicesSold_lbl">Cost of products sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:title="label: CostOfGoodsAndServicesSold to us-gaap_CostOfGoodsAndServicesSold_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfGoodsAndServicesSold_lbl1" xml:lang="en-US" id="us-gaap_CostOfGoodsAndServicesSold_lbl1">Cost of Goods and Services Sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl1" xlink:title="label: CostOfGoodsAndServicesSold to us-gaap_CostOfGoodsAndServicesSold_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="CostOfSalesPolicyTextBlock" xlink:title="CostOfSalesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_CostOfSalesPolicyTextBlock_lbl">Cost of Products Sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:title="label: CostOfSalesPolicyTextBlock to us-gaap_CostOfSalesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfSalesPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CostOfSalesPolicyTextBlock_lbl1">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl1" xlink:title="label: CostOfSalesPolicyTextBlock to us-gaap_CostOfSalesPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="CostOfSalesMember" xlink:title="CostOfSalesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CostOfSalesMember_lbl" xml:lang="en-US" id="us-gaap_CostOfSalesMember_lbl">Cost of Products Sold [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" xlink:title="label: CostOfSalesMember to us-gaap_CostOfSalesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfSalesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfSalesMember_lbl1" xml:lang="en-US" id="us-gaap_CostOfSalesMember_lbl1">Cost of Sales [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl1" xlink:title="label: CostOfSalesMember to us-gaap_CostOfSalesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" id="us-gaap_CostsAndExpenses_lbl">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl" xlink:title="label: CostsAndExpenses to us-gaap_CostsAndExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CostsAndExpenses_lbl1" xml:lang="en-US" id="us-gaap_CostsAndExpenses_lbl1">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl1" xlink:title="label: CostsAndExpenses to us-gaap_CostsAndExpenses_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CostsAndExpenses_lbl2" xml:lang="en-US" id="us-gaap_CostsAndExpenses_lbl2">Operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl2" xlink:title="label: CostsAndExpenses to us-gaap_CostsAndExpenses_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostsAndExpenses_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostsAndExpenses_lbl3" xml:lang="en-US" id="us-gaap_CostsAndExpenses_lbl3">Costs and Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl3" xlink:title="label: CostsAndExpenses to us-gaap_CostsAndExpenses_lbl3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" id="us-gaap_CostsAndExpensesAbstract_lbl">Expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl" xlink:title="label: CostsAndExpensesAbstract to us-gaap_CostsAndExpensesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostsAndExpensesAbstract_lbl1" xml:lang="en-US" id="us-gaap_CostsAndExpensesAbstract_lbl1">Costs and Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl1" xlink:title="label: CostsAndExpensesAbstract to us-gaap_CostsAndExpensesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CreditFacilityDomain_lbl" xml:lang="en-US" id="us-gaap_CreditFacilityDomain_lbl">Credit Facility [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" xlink:title="label: CreditFacilityDomain to us-gaap_CreditFacilityDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US" id="us-gaap_CreditFacilityAxis_lbl">Credit Facility [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xlink:title="label: CreditFacilityAxis to us-gaap_CreditFacilityAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="CreditConcentrationRiskMember" xlink:title="CreditConcentrationRiskMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CreditConcentrationRiskMember_lbl" xml:lang="en-US" id="us-gaap_CreditConcentrationRiskMember_lbl">Credit Concentration [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CreditConcentrationRiskMember" xlink:to="us-gaap_CreditConcentrationRiskMember_lbl" xlink:title="label: CreditConcentrationRiskMember to us-gaap_CreditConcentrationRiskMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="CurrentIncomeTaxExpenseBenefit" xlink:title="CurrentIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl">Total current income tax expense (benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:title="label: CurrentIncomeTaxExpenseBenefit to us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1">Current Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1" xlink:title="label: CurrentIncomeTaxExpenseBenefit to us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="CurrentStateAndLocalTaxExpenseBenefit" xlink:title="CurrentStateAndLocalTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:title="label: CurrentStateAndLocalTaxExpenseBenefit to us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl1">Current State and Local Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl1" xlink:title="label: CurrentStateAndLocalTaxExpenseBenefit to us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="CurrentForeignTaxExpenseBenefit" xlink:title="CurrentForeignTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_CurrentForeignTaxExpenseBenefit_lbl">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:title="label: CurrentForeignTaxExpenseBenefit to us-gaap_CurrentForeignTaxExpenseBenefit_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="CurrentFederalTaxExpenseBenefit" xlink:title="CurrentFederalTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_CurrentFederalTaxExpenseBenefit_lbl">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:title="label: CurrentFederalTaxExpenseBenefit to us-gaap_CurrentFederalTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentFederalTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_CurrentFederalTaxExpenseBenefit_lbl1">Current Federal Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl1" xlink:title="label: CurrentFederalTaxExpenseBenefit to us-gaap_CurrentFederalTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl">Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:title="label: CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract to us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" xml:lang="en-US" id="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" xlink:title="label: CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract to us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" id="us-gaap_CustomerConcentrationRiskMember_lbl">Strategic Partner [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:title="label: CustomerConcentrationRiskMember to us-gaap_CustomerConcentrationRiskMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CustomerConcentrationRiskMember_lbl1" xml:lang="en-US" id="us-gaap_CustomerConcentrationRiskMember_lbl1">Customer Concentration Risk [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl1" xlink:title="label: CustomerConcentrationRiskMember to us-gaap_CustomerConcentrationRiskMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="DisaggregationOfRevenueLineItems" xlink:title="DisaggregationOfRevenueLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisaggregationOfRevenueLineItems_lbl" xml:lang="en-US" id="us-gaap_DisaggregationOfRevenueLineItems_lbl">Disaggregation of Revenue [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:title="label: DisaggregationOfRevenueLineItems to us-gaap_DisaggregationOfRevenueLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="DisaggregationOfRevenueTable" xlink:title="DisaggregationOfRevenueTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DisaggregationOfRevenueTable_lbl" xml:lang="en-US" id="us-gaap_DisaggregationOfRevenueTable_lbl">Disaggregation of Revenue [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:title="label: DisaggregationOfRevenueTable to us-gaap_DisaggregationOfRevenueTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:title="DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_lbl">Amortization period of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_lbl" xlink:title="label: DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1 to us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="DebtInstrumentRepurchasedFaceAmount" xlink:title="DebtInstrumentRepurchasedFaceAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl">Principal amount repurchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentRepurchasedFaceAmount" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl" xlink:title="label: DebtInstrumentRepurchasedFaceAmount to us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentTerm_lbl">Term of agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:title="label: DebtInstrumentTerm to us-gaap_DebtInstrumentTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentTerm_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentTerm_lbl1">Debt Instrument, Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl1" xlink:title="label: DebtInstrumentTerm to us-gaap_DebtInstrumentTerm_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="DebtInstrumentMeasurementInput" xlink:title="DebtInstrumentMeasurementInput" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentMeasurementInput_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentMeasurementInput_lbl">Nonconvertible debt measurement input rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl" xlink:title="label: DebtInstrumentMeasurementInput to us-gaap_DebtInstrumentMeasurementInput_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMeasurementInput_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentMeasurementInput_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentMeasurementInput_lbl1">Debt Instrument, Measurement Input</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentMeasurementInput" xlink:to="us-gaap_DebtInstrumentMeasurementInput_lbl1" xlink:title="label: DebtInstrumentMeasurementInput to us-gaap_DebtInstrumentMeasurementInput_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_DebtDisclosureAbstract_lbl">Long-Term Obligations and Commitments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:title="label: DebtDisclosureAbstract to us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl">Conversion price per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:title="label: DebtInstrumentConvertibleConversionPrice1 to us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentTable_lbl">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:title="label: DebtInstrumentTable to us-gaap_DebtInstrumentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentAxis_lbl">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:title="label: DebtInstrumentAxis to us-gaap_DebtInstrumentAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentCarryingAmount_lbl">Principal amount of convertible notes outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:title="label: DebtInstrumentCarryingAmount to us-gaap_DebtInstrumentCarryingAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentCarryingAmount_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentCarryingAmount_lbl1">Long-term Debt, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl1" xlink:title="label: DebtInstrumentCarryingAmount to us-gaap_DebtInstrumentCarryingAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock" xlink:label="DebtAndCapitalLeasesDisclosuresTextBlock" xlink:title="DebtAndCapitalLeasesDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock_lbl" xml:lang="en-US" id="us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock_lbl">Long-Term Obligations and Commitments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtAndCapitalLeasesDisclosuresTextBlock" xlink:to="us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock_lbl" xlink:title="label: DebtAndCapitalLeasesDisclosuresTextBlock to us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock_lbl1" xml:lang="en-US" id="us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock_lbl1">Debt and Capital Leases Disclosures [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtAndCapitalLeasesDisclosuresTextBlock" xlink:to="us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock_lbl1" xlink:title="label: DebtAndCapitalLeasesDisclosuresTextBlock to us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentLineItems_lbl">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:title="label: DebtInstrumentLineItems to us-gaap_DebtInstrumentLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentNameDomain_lbl">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xlink:title="label: DebtInstrumentNameDomain to us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentFaceAmount_lbl">Face amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:title="label: DebtInstrumentFaceAmount to us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DebtInstrumentFaceAmount_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentFaceAmount_lbl1">Face amount of offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl1" xlink:title="label: DebtInstrumentFaceAmount to us-gaap_DebtInstrumentFaceAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentFaceAmount_lbl2" xml:lang="en-US" id="us-gaap_DebtInstrumentFaceAmount_lbl2">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl2" xlink:title="label: DebtInstrumentFaceAmount to us-gaap_DebtInstrumentFaceAmount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl">Interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1">Interest rate on convertible senior notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentMaturityDate_lbl">Maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:title="label: DebtInstrumentMaturityDate to us-gaap_DebtInstrumentMaturityDate_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:title="DebtInstrumentConvertibleNumberOfEquityInstruments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl">Total shares of common stock subject to conversion (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl" xlink:title="label: DebtInstrumentConvertibleNumberOfEquityInstruments to us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl1">Debt Instrument, Convertible, Number of Equity Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl1" xlink:title="label: DebtInstrumentConvertibleNumberOfEquityInstruments to us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl">Effective interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:title="label: DebtInstrumentInterestRateEffectivePercentage to us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="DebtInstrumentUnamortizedDiscountPremiumNet" xlink:title="DebtInstrumentUnamortizedDiscountPremiumNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl">Unamortized portion of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" xlink:title="label: DebtInstrumentUnamortizedDiscountPremiumNet to us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl1">Debt Instrument, Unamortized Discount (Premium), Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscountPremiumNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl1" xlink:title="label: DebtInstrumentUnamortizedDiscountPremiumNet to us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:title="DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl">Carrying value of equity component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl" xlink:title="label: DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent to us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl1">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl1" xlink:title="label: DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent to us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedDiscount_lbl">Less: unamortized portion of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:title="label: DebtInstrumentUnamortizedDiscount to us-gaap_DebtInstrumentUnamortizedDiscount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1">Debt Instrument, Unamortized Discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" xlink:title="label: DebtInstrumentUnamortizedDiscount to us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="DebtPolicyTextBlock" xlink:title="DebtPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_DebtPolicyTextBlock_lbl">Convertible Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xlink:title="label: DebtPolicyTextBlock to us-gaap_DebtPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_DebtPolicyTextBlock_lbl1">Debt, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl1" xlink:title="label: DebtPolicyTextBlock to us-gaap_DebtPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="DebtSecuritiesMember" xlink:title="DebtSecuritiesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtSecuritiesMember_lbl" xml:lang="en-US" id="us-gaap_DebtSecuritiesMember_lbl">Available-for-sale Securities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtSecuritiesMember" xlink:to="us-gaap_DebtSecuritiesMember_lbl" xlink:title="label: DebtSecuritiesMember to us-gaap_DebtSecuritiesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtSecuritiesMember_lbl1" xml:lang="en-US" id="us-gaap_DebtSecuritiesMember_lbl1">Debt Securities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtSecuritiesMember" xlink:to="us-gaap_DebtSecuritiesMember_lbl1" xlink:title="label: DebtSecuritiesMember to us-gaap_DebtSecuritiesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="DeferredIncomeTaxAssetsNet" xlink:title="DeferredIncomeTaxAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxAssetsNet_lbl">Long-term deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:title="label: DeferredIncomeTaxAssetsNet to us-gaap_DeferredIncomeTaxAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredIncomeTaxAssetsNet_lbl1" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxAssetsNet_lbl1">Deferred Income Tax Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl1" xlink:title="label: DeferredIncomeTaxAssetsNet to us-gaap_DeferredIncomeTaxAssetsNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:title="DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl">Intangible and capital assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:title="label: DeferredTaxAssetsGoodwillAndIntangibleAssets to us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl1">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl1" xlink:title="label: DeferredTaxAssetsGoodwillAndIntangibleAssets to us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="DeferredFederalIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:title="label: DeferredFederalIncomeTaxExpenseBenefit to us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl1">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl1" xlink:title="label: DeferredFederalIncomeTaxExpenseBenefit to us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="DeferredIncomeTaxExpenseBenefit" xlink:title="DeferredIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl">Total deferred income benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:title="label: DeferredIncomeTaxExpenseBenefit to us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1">Deferred Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1" xlink:title="label: DeferredIncomeTaxExpenseBenefit to us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="DeferredIncomeTaxesAndTaxCredits" xlink:title="DeferredIncomeTaxesAndTaxCredits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl">Deferred income taxes (including benefit from valuation allowance release)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxesAndTaxCredits" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" xlink:title="label: DeferredIncomeTaxesAndTaxCredits to us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl1" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl1">Deferred Income Taxes and Tax Credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxesAndTaxCredits" xlink:to="us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl1" xlink:title="label: DeferredIncomeTaxesAndTaxCredits to us-gaap_DeferredIncomeTaxesAndTaxCredits_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl">Deferred [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:title="label: DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract to us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" xlink:title="label: DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract to us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="DeferredRentCredit" xlink:title="DeferredRentCredit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRentCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DeferredRentCredit_lbl" xml:lang="en-US" id="us-gaap_DeferredRentCredit_lbl">Plus: lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRentCredit" xlink:to="us-gaap_DeferredRentCredit_lbl" xlink:title="label: DeferredRentCredit to us-gaap_DeferredRentCredit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRentCredit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredRentCredit_lbl1" xml:lang="en-US" id="us-gaap_DeferredRentCredit_lbl1">Deferred Rent Credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRentCredit" xlink:to="us-gaap_DeferredRentCredit_lbl1" xlink:title="label: DeferredRentCredit to us-gaap_DeferredRentCredit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="DeferredTaxAssetsDeferredIncome" xlink:title="DeferredTaxAssetsDeferredIncome" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsDeferredIncome_lbl">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:title="label: DeferredTaxAssetsDeferredIncome to us-gaap_DeferredTaxAssetsDeferredIncome_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsDeferredIncome_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsDeferredIncome_lbl1">Deferred Tax Assets, Deferred Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl1" xlink:title="label: DeferredTaxAssetsDeferredIncome to us-gaap_DeferredTaxAssetsDeferredIncome_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGross_lbl">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:title="label: DeferredTaxAssetsGross to us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsGross_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGross_lbl1">Deferred Tax Assets, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl1" xlink:title="label: DeferredTaxAssetsGross to us-gaap_DeferredTaxAssetsGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" xlink:title="DeferredTaxAssetsLiabilitiesNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl">Total net deferred tax assets and liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:title="label: DeferredTaxAssetsLiabilitiesNet to us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1">Deferred Tax Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" xlink:title="label: DeferredTaxAssetsLiabilitiesNet to us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="DeferredTaxAssetsGrossAbstract" xlink:title="DeferredTaxAssetsGrossAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGrossAbstract_lbl">Deferred Tax Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:title="label: DeferredTaxAssetsGrossAbstract to us-gaap_DeferredTaxAssetsGrossAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsGrossAbstract_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGrossAbstract_lbl1">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl1" xlink:title="label: DeferredTaxAssetsGrossAbstract to us-gaap_DeferredTaxAssetsGrossAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:title="label: DeferredStateAndLocalIncomeTaxExpenseBenefit to us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl1">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl1" xlink:title="label: DeferredStateAndLocalIncomeTaxExpenseBenefit to us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl">Net operating loss carryovers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwards to us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwards to us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl">R&amp;D credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:title="label: DeferredTaxAssetsTaxCreditCarryforwardsResearch to us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl1">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl1" xlink:title="label: DeferredTaxAssetsTaxCreditCarryforwardsResearch to us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="DeferredTaxAssetsOther" xlink:title="DeferredTaxAssetsOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOther_lbl">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:title="label: DeferredTaxAssetsOther to us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsOther_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOther_lbl1">Deferred Tax Assets, Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl1" xlink:title="label: DeferredTaxAssetsOther to us-gaap_DeferredTaxAssetsOther_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost to us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost to us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="DeferredTaxLiabilitiesAbstract" xlink:title="DeferredTaxLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesAbstract_lbl">Deferred Tax Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:title="label: DeferredTaxLiabilitiesAbstract to us-gaap_DeferredTaxLiabilitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxLiabilitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesAbstract_lbl1">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl1" xlink:title="label: DeferredTaxLiabilitiesAbstract to us-gaap_DeferredTaxLiabilitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsValuationAllowance_lbl">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:title="label: DeferredTaxAssetsValuationAllowance to us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xlink:title="label: DeferredTaxAssetsValuationAllowance to us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:title="DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl">Fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:title="label: DeferredTaxLiabilitiesPropertyPlantAndEquipment to us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl1">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl1" xlink:title="label: DeferredTaxLiabilitiesPropertyPlantAndEquipment to us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:label="DeferredTaxLiabilitiesFinancingArrangements" xlink:title="DeferredTaxLiabilitiesFinancingArrangements" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesFinancingArrangements_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DeferredTaxLiabilitiesFinancingArrangements_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesFinancingArrangements_lbl">Convertible debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesFinancingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesFinancingArrangements_lbl" xlink:title="label: DeferredTaxLiabilitiesFinancingArrangements to us-gaap_DeferredTaxLiabilitiesFinancingArrangements_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesFinancingArrangements_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxLiabilitiesFinancingArrangements_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesFinancingArrangements_lbl1">Deferred Tax Liabilities, Financing Arrangements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesFinancingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesFinancingArrangements_lbl1" xlink:title="label: DeferredTaxLiabilitiesFinancingArrangements to us-gaap_DeferredTaxLiabilitiesFinancingArrangements_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="DeferredTaxLiabilitiesOther" xlink:title="DeferredTaxLiabilitiesOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DeferredTaxLiabilitiesOther_lbl" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesOther_lbl">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:title="label: DeferredTaxLiabilitiesOther to us-gaap_DeferredTaxLiabilitiesOther_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxLiabilitiesOther_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesOther_lbl1">Deferred Tax Liabilities, Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl1" xlink:title="label: DeferredTaxLiabilitiesOther to us-gaap_DeferredTaxLiabilitiesOther_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="DefinedContributionPlanCostRecognized" xlink:title="DefinedContributionPlanCostRecognized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" id="us-gaap_DefinedContributionPlanCostRecognized_lbl">Matching contributions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:title="label: DefinedContributionPlanCostRecognized to us-gaap_DefinedContributionPlanCostRecognized_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DefinedContributionPlanCostRecognized_lbl1" xml:lang="en-US" id="us-gaap_DefinedContributionPlanCostRecognized_lbl1">Defined Contribution Plan, Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl1" xlink:title="label: DefinedContributionPlanCostRecognized to us-gaap_DefinedContributionPlanCostRecognized_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_Depreciation_lbl" xml:lang="en-US" id="us-gaap_Depreciation_lbl">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:title="label: Depreciation to us-gaap_Depreciation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Depreciation_lbl1" xml:lang="en-US" id="us-gaap_Depreciation_lbl1">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="us-gaap_Depreciation_lbl1" xlink:title="label: Depreciation to us-gaap_Depreciation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:label="DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:title="DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl" xml:lang="en-US" id="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl">Shares issuable related to our convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:to="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl" xlink:title="label: DilutiveSecuritiesEffectOnBasicEarningsPerShareOther to us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl1" xml:lang="en-US" id="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl1">Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:to="us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl1" xlink:title="label: DilutiveSecuritiesEffectOnBasicEarningsPerShareOther to us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted_lbl">Diluted net income per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDiluted_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted_lbl1">Diluted net income (loss) per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl1" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic_lbl">Basic net income per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareBasic_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic_lbl1">Basic net income (loss) per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl1" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock_lbl">Basic and Diluted Net Income per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="EarningsPerShareBasicAbstract" xlink:title="EarningsPerShareBasicAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareBasicAbstract_lbl">Basic Net Income per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" xlink:title="label: EarningsPerShareBasicAbstract to us-gaap_EarningsPerShareBasicAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasicAbstract_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerShareBasicAbstract_lbl1">Earnings Per Share, Basic [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl1" xlink:title="label: EarningsPerShareBasicAbstract to us-gaap_EarningsPerShareBasicAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="EarningsPerShareBasicLineItems" xlink:title="EarningsPerShareBasicLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasicLineItems_lbl" xml:lang="en-US" id="us-gaap_EarningsPerShareBasicLineItems_lbl">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:title="label: EarningsPerShareBasicLineItems to us-gaap_EarningsPerShareBasicLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:title="EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential to us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl1">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential to us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl">Net change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl">U.S. federal corporate tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate to us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1">Statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate to us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl">Tax rate change</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate to us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl1">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate to us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl">State income tax net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes to us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl1">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes to us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl">Other nondeductible items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther to us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost to us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost to us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationOtherAdjustments to us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl1">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationOtherAdjustments to us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:title="EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl">Deferred tax true-up</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes to us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl1">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes to us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl">Tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationTaxCredits to us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl1">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationTaxCredits to us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl">Effective rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:title="label: EffectiveIncomeTaxRateContinuingOperations to us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" xlink:title="label: EffectiveIncomeTaxRateContinuingOperations to us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl">Reconciliation Between Effective and Statutory Tax Rate Percentage [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:title="label: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl1" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl1">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl1" xlink:title="label: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl">Unrecognized Compensation Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="EmployeeStockMember" xlink:title="EmployeeStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" id="us-gaap_EmployeeStockMember_lbl">ESPP [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xlink:title="label: EmployeeStockMember to us-gaap_EmployeeStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeStockMember_lbl1" xml:lang="en-US" id="us-gaap_EmployeeStockMember_lbl1">Employee Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl1" xlink:title="label: EmployeeStockMember to us-gaap_EmployeeStockMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:label="EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:title="EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl" xml:lang="en-US" id="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl">Purchase price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl" xlink:title="label: EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased to us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl1" xml:lang="en-US" id="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl1">Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl1" xlink:title="label: EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased to us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl">Unrecognized compensation cost related to non-vested RSUs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl1">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl">Unrecognized compensation expense related to non-vested stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl">Weighted average period for recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1">Weighted average period for recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl2" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl2">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl2" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:title="label: EmployeeRelatedLiabilitiesCurrent to us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl1">Employee-related Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl1" xlink:title="label: EmployeeRelatedLiabilitiesCurrent to us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeStockOptionMember_lbl1" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl1">Employee Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl1" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeStockOptionMember_lbl2" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember_lbl2">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl2" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:title="label: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="EntityWideRevenueMajorCustomerLineItems" xlink:title="EntityWideRevenueMajorCustomerLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl" xml:lang="en-US" id="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl">Revenue, Major Customer [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityWideRevenueMajorCustomerLineItems" xlink:to="us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl" xlink:title="label: EntityWideRevenueMajorCustomerLineItems to us-gaap_EntityWideRevenueMajorCustomerLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:label="EquitySecuritiesFvNiCost" xlink:title="EquitySecuritiesFvNiCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EquitySecuritiesFvNiCost_lbl" xml:lang="en-US" id="us-gaap_EquitySecuritiesFvNiCost_lbl">Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquitySecuritiesFvNiCost" xlink:to="us-gaap_EquitySecuritiesFvNiCost_lbl" xlink:title="label: EquitySecuritiesFvNiCost to us-gaap_EquitySecuritiesFvNiCost_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquitySecuritiesFvNiCost_lbl1" xml:lang="en-US" id="us-gaap_EquitySecuritiesFvNiCost_lbl1">Equity Securities, FV-NI, Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquitySecuritiesFvNiCost" xlink:to="us-gaap_EquitySecuritiesFvNiCost_lbl1" xlink:title="label: EquitySecuritiesFvNiCost to us-gaap_EquitySecuritiesFvNiCost_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="EquitySecuritiesFvNi" xlink:title="EquitySecuritiesFvNi" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EquitySecuritiesFvNi_lbl" xml:lang="en-US" id="us-gaap_EquitySecuritiesFvNi_lbl">Investment in ProQR Therapeutics N.V.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl" xlink:title="label: EquitySecuritiesFvNi to us-gaap_EquitySecuritiesFvNi_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EquitySecuritiesFvNi_lbl1" xml:lang="en-US" id="us-gaap_EquitySecuritiesFvNi_lbl1">Estimated fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl1" xlink:title="label: EquitySecuritiesFvNi to us-gaap_EquitySecuritiesFvNi_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquitySecuritiesFvNi_lbl2" xml:lang="en-US" id="us-gaap_EquitySecuritiesFvNi_lbl2">Equity Securities, FV-NI</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl2" xlink:title="label: EquitySecuritiesFvNi to us-gaap_EquitySecuritiesFvNi_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="EquitySecuritiesFvNiUnrealizedGain" xlink:title="EquitySecuritiesFvNiUnrealizedGain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl" xml:lang="en-US" id="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl">Gross unrealized gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquitySecuritiesFvNiUnrealizedGain" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl" xlink:title="label: EquitySecuritiesFvNiUnrealizedGain to us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl1" xml:lang="en-US" id="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl1">Equity Securities, FV-NI, Unrealized Gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquitySecuritiesFvNiUnrealizedGain" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl1" xlink:title="label: EquitySecuritiesFvNiUnrealizedGain to us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="us-gaap_EquityComponentDomain_lbl">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xlink:title="label: EquityComponentDomain to us-gaap_EquityComponentDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="EquitySecuritiesFvNiUnrealizedLoss" xlink:title="EquitySecuritiesFvNiUnrealizedLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl" xml:lang="en-US" id="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl">Gross unrealized losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquitySecuritiesFvNiUnrealizedLoss" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl" xlink:title="label: EquitySecuritiesFvNiUnrealizedLoss to us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl1" xml:lang="en-US" id="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl1">Equity Securities, FV-NI, Unrealized Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquitySecuritiesFvNiUnrealizedLoss" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl1" xlink:title="label: EquitySecuritiesFvNiUnrealizedLoss to us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="EquitySecuritiesMember" xlink:title="EquitySecuritiesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EquitySecuritiesMember_lbl" xml:lang="en-US" id="us-gaap_EquitySecuritiesMember_lbl">Equity Securities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquitySecuritiesMember" xlink:to="us-gaap_EquitySecuritiesMember_lbl" xlink:title="label: EquitySecuritiesMember to us-gaap_EquitySecuritiesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquitySecuritiesMember_lbl1" xml:lang="en-US" id="us-gaap_EquitySecuritiesMember_lbl1">Equity Securities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquitySecuritiesMember" xlink:to="us-gaap_EquitySecuritiesMember_lbl1" xlink:title="label: EquitySecuritiesMember to us-gaap_EquitySecuritiesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems" xlink:label="EquityClassOfTreasuryStockLineItems" xlink:title="EquityClassOfTreasuryStockLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityClassOfTreasuryStockLineItems_lbl" xml:lang="en-US" id="us-gaap_EquityClassOfTreasuryStockLineItems_lbl">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_EquityClassOfTreasuryStockLineItems_lbl" xlink:title="label: EquityClassOfTreasuryStockLineItems to us-gaap_EquityClassOfTreasuryStockLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xml:lang="en-US" id="us-gaap_FairValueNetAssetLiabilityAbstract_lbl">Fair Value Measurements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="us-gaap_FairValueNetAssetLiabilityAbstract_lbl" xlink:title="label: FairValueNetAssetLiabilityAbstract to us-gaap_FairValueNetAssetLiabilityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueNetAssetLiabilityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueNetAssetLiabilityAbstract_lbl1" xml:lang="en-US" id="us-gaap_FairValueNetAssetLiabilityAbstract_lbl1">Fair Value, Net Asset (Liability) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="us-gaap_FairValueNetAssetLiabilityAbstract_lbl1" xlink:title="label: FairValueNetAssetLiabilityAbstract to us-gaap_FairValueNetAssetLiabilityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="FairValueMeasurementPolicyPolicyTextBlock" xlink:title="FairValueMeasurementPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:title="label: FairValueMeasurementPolicyPolicyTextBlock to us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl1">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl1" xlink:title="label: FairValueMeasurementPolicyPolicyTextBlock to us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:title="label: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementsRecurringMember_lbl">Recurring Basis [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:title="label: FairValueMeasurementsRecurringMember to us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementsRecurringMember_lbl1" xml:lang="en-US" id="us-gaap_FairValueMeasurementsRecurringMember_lbl1">Fair Value, Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl1" xlink:title="label: FairValueMeasurementsRecurringMember to us-gaap_FairValueMeasurementsRecurringMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementFrequencyDomain_lbl">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:title="label: FairValueMeasurementFrequencyDomain to us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl">Fair Value Hierarchy [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:title="label: FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl">Fair Value, Hierarchy [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:title="label: FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" id="us-gaap_FairValueByMeasurementFrequencyAxis_lbl">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:title="label: FairValueByMeasurementFrequencyAxis to us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xml:lang="en-US" id="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:title="FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US" id="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl">Assets Measured at Fair Value on a Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:title="label: FairValueAssetsMeasuredOnRecurringBasisTextBlock to us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl1" xml:lang="en-US" id="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl1">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl1" xlink:title="label: FairValueAssetsMeasuredOnRecurringBasisTextBlock to us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel1Member_lbl">Quoted Prices in Active Markets (Level 1) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:title="label: FairValueInputsLevel1Member to us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel1Member_lbl1" xml:lang="en-US" id="us-gaap_FairValueInputsLevel1Member_lbl1">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl1" xlink:title="label: FairValueInputsLevel1Member to us-gaap_FairValueInputsLevel1Member_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel3Member_lbl">Significant Unobservable Inputs (Level 3) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:title="label: FairValueInputsLevel3Member to us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel3Member_lbl1" xml:lang="en-US" id="us-gaap_FairValueInputsLevel3Member_lbl1">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl1" xlink:title="label: FairValueInputsLevel3Member to us-gaap_FairValueInputsLevel3Member_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="us-gaap_FairValueInputsLevel2Member_lbl">Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:title="label: FairValueInputsLevel2Member to us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FairValueInputsLevel2Member_lbl1" xml:lang="en-US" id="us-gaap_FairValueInputsLevel2Member_lbl1">Significant Other Observable Inputs (Level 2) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl1" xlink:title="label: FairValueInputsLevel2Member to us-gaap_FairValueInputsLevel2Member_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" id="us-gaap_FinancialInstrumentAxis_lbl">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:title="label: FinancialInstrumentAxis to us-gaap_FinancialInstrumentAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsGross_lbl">Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:title="label: FiniteLivedIntangibleAssetsGross to us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1">Finite-Lived Intangible Assets, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsGross to us-gaap_FiniteLivedIntangibleAssetsGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNet_lbl">Patents, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:title="label: FiniteLivedIntangibleAssetsNet to us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1">Finite-Lived Intangible Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsNet to us-gaap_FiniteLivedIntangibleAssetsNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:title="label: FiniteLivedIntangibleAssetsMajorClassNameDomain to us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl">Accumulated amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAccumulatedAmortization to us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAccumulatedAmortization to us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:title="label: FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:title="label: FiniteLivedIntangibleAssetsByMajorClassAxis to us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl">2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl1">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl">Estimated Amortization Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xlink:title="label: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl">Estimated useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:title="label: FiniteLivedIntangibleAssetUsefulLife to us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1" xlink:title="label: FiniteLivedIntangibleAssetUsefulLife to us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl1">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearFive to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl1">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearFive to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearThree to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl1">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearThree to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearFour to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl1">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseYearFour to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" id="us-gaap_FurnitureAndFixturesMember_lbl">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:title="label: FurnitureAndFixturesMember to us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FurnitureAndFixturesMember_lbl1" xml:lang="en-US" id="us-gaap_FurnitureAndFixturesMember_lbl1">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl1" xlink:title="label: FurnitureAndFixturesMember to us-gaap_FurnitureAndFixturesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="GainOnSaleOfInvestments" xlink:title="GainOnSaleOfInvestments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainOnSaleOfInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_GainOnSaleOfInvestments_lbl" xml:lang="en-US" id="us-gaap_GainOnSaleOfInvestments_lbl">Gain on investment in Regulus Therapeutics, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainOnSaleOfInvestments" xlink:to="us-gaap_GainOnSaleOfInvestments_lbl" xlink:title="label: GainOnSaleOfInvestments to us-gaap_GainOnSaleOfInvestments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainOnSaleOfInvestments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GainOnSaleOfInvestments_lbl1" xml:lang="en-US" id="us-gaap_GainOnSaleOfInvestments_lbl1">Gain on Sale of Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainOnSaleOfInvestments" xlink:to="us-gaap_GainOnSaleOfInvestments_lbl1" xlink:title="label: GainOnSaleOfInvestments to us-gaap_GainOnSaleOfInvestments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US" id="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl">Loss on early retirement of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:title="label: GainsLossesOnExtinguishmentOfDebt to us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:title="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1" xml:lang="en-US" id="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1">Loss on early retirement of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1" xlink:title="label: GainsLossesOnExtinguishmentOfDebt to us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl2" xml:lang="en-US" id="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl2">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl2" xlink:title="label: GainsLossesOnExtinguishmentOfDebt to us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntersegmentEliminationMember" xlink:label="IntersegmentEliminationMember" xlink:title="IntersegmentEliminationMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntersegmentEliminationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IntersegmentEliminationMember_lbl" xml:lang="en-US" id="us-gaap_IntersegmentEliminationMember_lbl">Elimination of Intercompany Activity [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntersegmentEliminationMember" xlink:to="us-gaap_IntersegmentEliminationMember_lbl" xlink:title="label: IntersegmentEliminationMember to us-gaap_IntersegmentEliminationMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="ImpairmentOfIntangibleAssetsFinitelived" xlink:title="ImpairmentOfIntangibleAssetsFinitelived" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xml:lang="en-US" id="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl">Non-cash charges related to write-down</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" xlink:title="label: ImpairmentOfIntangibleAssetsFinitelived to us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl1" xml:lang="en-US" id="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl1">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfIntangibleAssetsFinitelived" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl1" xlink:title="label: ImpairmentOfIntangibleAssetsFinitelived to us-gaap_ImpairmentOfIntangibleAssetsFinitelived_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl">Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" xlink:title="label: ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock to us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl1">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl1" xlink:title="label: ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock to us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="IncomeTaxAuthorityNameDomain" xlink:title="IncomeTaxAuthorityNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxAuthorityNameDomain_lbl">Income Tax Authority, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:title="label: IncomeTaxAuthorityNameDomain to us-gaap_IncomeTaxAuthorityNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureAbstract_lbl">Income Taxes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:title="label: IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementLocationAxis_lbl">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:title="label: IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementLocationDomain_lbl">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xlink:title="label: IncomeStatementLocationDomain to us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="IncomeTaxAuthorityNameAxis" xlink:title="IncomeTaxAuthorityNameAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxAuthorityNameAxis_lbl">Income Tax Authority, Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:title="label: IncomeTaxAuthorityNameAxis to us-gaap_IncomeTaxAuthorityNameAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeStatementAbstract_lbl">CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:title="label: IncomeStatementAbstract to us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl1" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl1">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl1" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl">United States</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl1" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl1">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl1" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock_lbl">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock_lbl1">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl">Income (loss) before income tax benefit (expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl1" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl1">Pre-tax income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl1" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl2" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl2">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl2" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl">Income tax expense (benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl1">Income tax benefit (expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl1" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExpenseBenefit_lbl2" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit_lbl2">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl2" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl">Statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:title="label: IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate to us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl1">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl1" xlink:title="label: IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate to us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:title="IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:title="label: IncomeTaxReconciliationForeignIncomeTaxRateDifferential to us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl1">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl1" xlink:title="label: IncomeTaxReconciliationForeignIncomeTaxRateDifferential to us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl">One-time non-cash tax benefit related to reversal of valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:title="label: IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1">Net change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xlink:title="label: IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl2" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl2">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl2" xlink:title="label: IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:title="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl">Reconciliation Between Effective and Statutory Tax Rate [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:title="label: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl1">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl1" xlink:title="label: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:title="IncomeTaxReconciliationChangeInEnactedTaxRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl">Tax rate change</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:title="label: IncomeTaxReconciliationChangeInEnactedTaxRate to us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl1">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl1" xlink:title="label: IncomeTaxReconciliationChangeInEnactedTaxRate to us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:title="IncomeTaxReconciliationPriorYearIncomeTaxes" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl">Deferred tax true-up</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xlink:title="label: IncomeTaxReconciliationPriorYearIncomeTaxes to us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl1">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl1" xlink:title="label: IncomeTaxReconciliationPriorYearIncomeTaxes to us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:title="label: IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost to us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1" xlink:title="label: IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost to us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:title="IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl">State income tax net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:title="label: IncomeTaxReconciliationStateAndLocalIncomeTaxes to us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl1">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl1" xlink:title="label: IncomeTaxReconciliationStateAndLocalIncomeTaxes to us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl1">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="IncomeTaxReconciliationOtherAdjustments" xlink:title="IncomeTaxReconciliationOtherAdjustments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:title="label: IncomeTaxReconciliationOtherAdjustments to us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl1">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl1" xlink:title="label: IncomeTaxReconciliationOtherAdjustments to us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="IncomeTaxReconciliationTaxCredits" xlink:title="IncomeTaxReconciliationTaxCredits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationTaxCredits_lbl">Tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl" xlink:title="label: IncomeTaxReconciliationTaxCredits to us-gaap_IncomeTaxReconciliationTaxCredits_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCredits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationTaxCredits_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationTaxCredits_lbl1">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationTaxCredits" xlink:to="us-gaap_IncomeTaxReconciliationTaxCredits_lbl1" xlink:title="label: IncomeTaxReconciliationTaxCredits to us-gaap_IncomeTaxReconciliationTaxCredits_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="IncomeTaxReconciliationNondeductibleExpenseOther" xlink:title="IncomeTaxReconciliationNondeductibleExpenseOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl">Other non-deductible items</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" xlink:title="label: IncomeTaxReconciliationNondeductibleExpenseOther to us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl1">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl1" xlink:title="label: IncomeTaxReconciliationNondeductibleExpenseOther to us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="IncomeTaxesPaidNet" xlink:title="IncomeTaxesPaidNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" id="us-gaap_IncomeTaxesPaidNet_lbl">Income taxes paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:title="label: IncomeTaxesPaidNet to us-gaap_IncomeTaxesPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxesPaidNet_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxesPaidNet_lbl1">Income Taxes Paid, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl1" xlink:title="label: IncomeTaxesPaidNet to us-gaap_IncomeTaxesPaidNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:label="IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:title="IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_lbl">Income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_lbl" xlink:title="label: IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable to us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="IncreaseDecreaseInContractWithCustomerLiability" xlink:title="IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl">Deferred contract revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:title="label: IncreaseDecreaseInContractWithCustomerLiability to us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl1">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl1" xlink:title="label: IncreaseDecreaseInContractWithCustomerLiability to us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="IncreaseDecreaseInContractWithCustomerAsset" xlink:title="IncreaseDecreaseInContractWithCustomerAsset" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl">Contracts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInContractWithCustomerAsset" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl" xlink:title="label: IncreaseDecreaseInContractWithCustomerAsset to us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl1">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInContractWithCustomerAsset" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl1" xlink:title="label: IncreaseDecreaseInContractWithCustomerAsset to us-gaap_IncreaseDecreaseInContractWithCustomerAsset_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayable_lbl">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:title="label: IncreaseDecreaseInAccountsPayable to us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1">Increase (Decrease) in Accounts Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xlink:title="label: IncreaseDecreaseInAccountsPayable to us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="IncreaseDecreaseInIncomeTaxesReceivable" xlink:title="IncreaseDecreaseInIncomeTaxesReceivable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl">Long-term income tax receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:title="label: IncreaseDecreaseInIncomeTaxesReceivable to us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl1">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl1" xlink:title="label: IncreaseDecreaseInIncomeTaxesReceivable to us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="IncreaseDecreaseInOtherOperatingAssets" xlink:title="IncreaseDecreaseInOtherOperatingAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl">Other current and long-term assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:title="label: IncreaseDecreaseInOtherOperatingAssets to us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl1">Increase (Decrease) in Other Operating Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl1" xlink:title="label: IncreaseDecreaseInOtherOperatingAssets to us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInInventories_lbl">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:title="label: IncreaseDecreaseInInventories to us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInInventories_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInInventories_lbl1">Increase (Decrease) in Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl1" xlink:title="label: IncreaseDecreaseInInventories to us-gaap_IncreaseDecreaseInInventories_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities" xlink:label="IncreaseDecreaseInOtherEmployeeRelatedLiabilities" xlink:title="IncreaseDecreaseInOtherEmployeeRelatedLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities_lbl">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities_lbl" xlink:title="label: IncreaseDecreaseInOtherEmployeeRelatedLiabilities to us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities_lbl1">Increase (Decrease) in Other Employee-Related Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities_lbl1" xlink:title="label: IncreaseDecreaseInOtherEmployeeRelatedLiabilities to us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl1">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl1" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US" id="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl">Shares issuable related to stock-based compensation (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:title="label: IncrementalCommonSharesAttributableToShareBasedPaymentArrangements to us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:title="IncrementalCommonSharesAttributableToConversionOfDebtSecurities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xml:lang="en-US" id="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl">Shares issuable related to our convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xlink:title="label: IncrementalCommonSharesAttributableToConversionOfDebtSecurities to us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl1" xml:lang="en-US" id="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl1">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl1" xlink:title="label: IncrementalCommonSharesAttributableToConversionOfDebtSecurities to us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="IntangibleAssetsFiniteLivedPolicy" xlink:title="IntangibleAssetsFiniteLivedPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US" id="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl">Patent Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:title="label: IntangibleAssetsFiniteLivedPolicy to us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl1" xml:lang="en-US" id="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl1">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl1" xlink:title="label: IntangibleAssetsFiniteLivedPolicy to us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="InterestPayableCurrentAndNoncurrent" xlink:title="InterestPayableCurrentAndNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xml:lang="en-US" id="us-gaap_InterestPayableCurrentAndNoncurrent_lbl">Less: fixed and determinable interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl" xlink:title="label: InterestPayableCurrentAndNoncurrent to us-gaap_InterestPayableCurrentAndNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPayableCurrentAndNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_InterestPayableCurrentAndNoncurrent_lbl1">Interest Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent_lbl1" xlink:title="label: InterestPayableCurrentAndNoncurrent to us-gaap_InterestPayableCurrentAndNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="us-gaap_InterestExpense_lbl">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:title="label: InterestExpense to us-gaap_InterestExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpense_lbl1" xml:lang="en-US" id="us-gaap_InterestExpense_lbl1">Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpense" xlink:to="us-gaap_InterestExpense_lbl1" xlink:title="label: InterestExpense to us-gaap_InterestExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" id="us-gaap_InterestPaidNet_lbl">Interest paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:title="label: InterestPaidNet to us-gaap_InterestPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPaidNet_lbl1" xml:lang="en-US" id="us-gaap_InterestPaidNet_lbl1">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl1" xlink:title="label: InterestPaidNet to us-gaap_InterestPaidNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="InternalRevenueServiceIRSMember" xlink:title="InternalRevenueServiceIRSMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InternalRevenueServiceIRSMember_lbl" xml:lang="en-US" id="us-gaap_InternalRevenueServiceIRSMember_lbl">Federal [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:title="label: InternalRevenueServiceIRSMember to us-gaap_InternalRevenueServiceIRSMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="InventoryFinishedGoods" xlink:title="InventoryFinishedGoods" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US" id="us-gaap_InventoryFinishedGoods_lbl">Finished goods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:title="label: InventoryFinishedGoods to us-gaap_InventoryFinishedGoods_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoods_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryFinishedGoods_lbl1" xml:lang="en-US" id="us-gaap_InventoryFinishedGoods_lbl1">Inventory, Finished Goods, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl1" xlink:title="label: InventoryFinishedGoods to us-gaap_InventoryFinishedGoods_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="InventoryWriteDown" xlink:title="InventoryWriteDown" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryWriteDown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US" id="us-gaap_InventoryWriteDown_lbl">Inventory write-off</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xlink:title="label: InventoryWriteDown to us-gaap_InventoryWriteDown_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryWriteDown_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryWriteDown_lbl1" xml:lang="en-US" id="us-gaap_InventoryWriteDown_lbl1">Inventory Write-down</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl1" xlink:title="label: InventoryWriteDown to us-gaap_InventoryWriteDown_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="InventoryLineItems" xlink:title="InventoryLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryLineItems_lbl" xml:lang="en-US" id="us-gaap_InventoryLineItems_lbl">Inventory [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryLineItems" xlink:to="us-gaap_InventoryLineItems_lbl" xlink:title="label: InventoryLineItems to us-gaap_InventoryLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="InventoryCurrentTable" xlink:title="InventoryCurrentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryCurrentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryCurrentTable_lbl" xml:lang="en-US" id="us-gaap_InventoryCurrentTable_lbl">Inventory, Current [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryCurrentTable" xlink:to="us-gaap_InventoryCurrentTable_lbl" xlink:title="label: InventoryCurrentTable to us-gaap_InventoryCurrentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="InventoryRawMaterials" xlink:title="InventoryRawMaterials" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterials_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US" id="us-gaap_InventoryRawMaterials_lbl">Raw materials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xlink:title="label: InventoryRawMaterials to us-gaap_InventoryRawMaterials_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterials_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryRawMaterials_lbl1" xml:lang="en-US" id="us-gaap_InventoryRawMaterials_lbl1">Inventory, Raw Materials, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl1" xlink:title="label: InventoryRawMaterials to us-gaap_InventoryRawMaterials_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="InventoryPolicyTextBlock" xlink:title="InventoryPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_InventoryPolicyTextBlock_lbl">Inventory Valuation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:title="label: InventoryPolicyTextBlock to us-gaap_InventoryPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_InventoryPolicyTextBlock_lbl1">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl1" xlink:title="label: InventoryPolicyTextBlock to us-gaap_InventoryPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InventoryNet_lbl" xml:lang="en-US" id="us-gaap_InventoryNet_lbl">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:title="label: InventoryNet to us-gaap_InventoryNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_InventoryNet_lbl1" xml:lang="en-US" id="us-gaap_InventoryNet_lbl1">Total inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="us-gaap_InventoryNet_lbl1" xlink:title="label: InventoryNet to us-gaap_InventoryNet_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryNet_lbl2" xml:lang="en-US" id="us-gaap_InventoryNet_lbl2">Inventory, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="us-gaap_InventoryNet_lbl2" xlink:title="label: InventoryNet to us-gaap_InventoryNet_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="InventoryWorkInProcess" xlink:title="InventoryWorkInProcess" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US" id="us-gaap_InventoryWorkInProcess_lbl">Work-in-process</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xlink:title="label: InventoryWorkInProcess to us-gaap_InventoryWorkInProcess_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcess_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryWorkInProcess_lbl1" xml:lang="en-US" id="us-gaap_InventoryWorkInProcess_lbl1">Inventory, Work in Process, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl1" xlink:title="label: InventoryWorkInProcess to us-gaap_InventoryWorkInProcess_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="InventoryNetAbstract" xlink:title="InventoryNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US" id="us-gaap_InventoryNetAbstract_lbl">Inventory Valuation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl" xlink:title="label: InventoryNetAbstract to us-gaap_InventoryNetAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryNetAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryNetAbstract_lbl1" xml:lang="en-US" id="us-gaap_InventoryNetAbstract_lbl1">Inventory, Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl1" xlink:title="label: InventoryNetAbstract to us-gaap_InventoryNetAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTextBlock" xlink:label="InvestmentTextBlock" xlink:title="InvestmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentTextBlock_lbl" xml:lang="en-US" id="us-gaap_InvestmentTextBlock_lbl">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentTextBlock" xlink:to="us-gaap_InvestmentTextBlock_lbl" xlink:title="label: InvestmentTextBlock to us-gaap_InvestmentTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember" xlink:title="InvestmentTypeCategorizationMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US" id="us-gaap_InvestmentTypeCategorizationMember_lbl">Investments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:title="label: InvestmentTypeCategorizationMember to us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsLineItems" xlink:label="InvestmentHoldingsLineItems" xlink:title="InvestmentHoldingsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentHoldingsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentHoldingsLineItems_lbl" xml:lang="en-US" id="us-gaap_InvestmentHoldingsLineItems_lbl">Investment Holdings [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentHoldingsLineItems" xlink:to="us-gaap_InvestmentHoldingsLineItems_lbl" xlink:title="label: InvestmentHoldingsLineItems to us-gaap_InvestmentHoldingsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="InvestmentIncomeNet" xlink:title="InvestmentIncomeNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InvestmentIncomeNet_lbl" xml:lang="en-US" id="us-gaap_InvestmentIncomeNet_lbl">Investment income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl" xlink:title="label: InvestmentIncomeNet to us-gaap_InvestmentIncomeNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentIncomeNet_lbl1" xml:lang="en-US" id="us-gaap_InvestmentIncomeNet_lbl1">Investment Income, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl1" xlink:title="label: InvestmentIncomeNet to us-gaap_InvestmentIncomeNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentSecondaryCategorizationAxis" xlink:label="InvestmentSecondaryCategorizationAxis" xlink:title="InvestmentSecondaryCategorizationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentSecondaryCategorizationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentSecondaryCategorizationAxis_lbl" xml:lang="en-US" id="us-gaap_InvestmentSecondaryCategorizationAxis_lbl">Investment Secondary Categorization [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentSecondaryCategorizationAxis" xlink:to="us-gaap_InvestmentSecondaryCategorizationAxis_lbl" xlink:title="label: InvestmentSecondaryCategorizationAxis to us-gaap_InvestmentSecondaryCategorizationAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsTable" xlink:label="InvestmentHoldingsTable" xlink:title="InvestmentHoldingsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentHoldingsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentHoldingsTable_lbl" xml:lang="en-US" id="us-gaap_InvestmentHoldingsTable_lbl">Investment Holdings [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentHoldingsTable" xlink:to="us-gaap_InvestmentHoldingsTable_lbl" xlink:title="label: InvestmentHoldingsTable to us-gaap_InvestmentHoldingsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="InvestmentTypeAxis" xlink:title="InvestmentTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US" id="us-gaap_InvestmentTypeAxis_lbl">Investment Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:title="label: InvestmentTypeAxis to us-gaap_InvestmentTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsBySecondaryCategorizationDomain" xlink:label="InvestmentsBySecondaryCategorizationDomain" xlink:title="InvestmentsBySecondaryCategorizationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsBySecondaryCategorizationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentsBySecondaryCategorizationDomain_lbl" xml:lang="en-US" id="us-gaap_InvestmentsBySecondaryCategorizationDomain_lbl">Investments by Secondary Categorization [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsBySecondaryCategorizationDomain" xlink:to="us-gaap_InvestmentsBySecondaryCategorizationDomain_lbl" xlink:title="label: InvestmentsBySecondaryCategorizationDomain to us-gaap_InvestmentsBySecondaryCategorizationDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:title="InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl">Contract Maturity of Available-for-Sale Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:title="label: InvestmentsClassifiedByContractualMaturityDateTableTextBlock to us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl1">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl1" xlink:title="label: InvestmentsClassifiedByContractualMaturityDateTableTextBlock to us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAbstract" xlink:label="InvestmentsAbstract" xlink:title="InvestmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentsAbstract_lbl" xml:lang="en-US" id="us-gaap_InvestmentsAbstract_lbl">Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsAbstract" xlink:to="us-gaap_InvestmentsAbstract_lbl" xlink:title="label: InvestmentsAbstract to us-gaap_InvestmentsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="InvestmentsAllOtherInvestmentsAbstract" xlink:title="InvestmentsAllOtherInvestmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xml:lang="en-US" id="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl">Ownership Interests in Private and Public Companies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:title="label: InvestmentsAllOtherInvestmentsAbstract to us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl1" xml:lang="en-US" id="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl1">Investments, All Other Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl1" xlink:title="label: InvestmentsAllOtherInvestmentsAbstract to us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" id="us-gaap_LesseeLeaseDescriptionLineItems_lbl">Operating Leased Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:title="label: LesseeLeaseDescriptionLineItems to us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl1">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl">2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearFour to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl1">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearFour to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearFive to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl1">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearFive to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl">Total minimum lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="LesseeOperatingLeaseRenewalTerm" xlink:title="LesseeOperatingLeaseRenewalTerm" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl">Term of lease extension</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:title="label: LesseeOperatingLeaseRenewalTerm to us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl1">Lessee, Operating Lease, Renewal Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl1" xlink:title="label: LesseeOperatingLeaseRenewalTerm to us-gaap_LesseeOperatingLeaseRenewalTerm_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl">Future Payments for Operating Lease Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityMaturityTableTextBlock to us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl1">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityMaturityTableTextBlock to us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" id="us-gaap_LesseeLeaseDescriptionTable_lbl">Schedule of Operating Leased Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:title="label: LesseeLeaseDescriptionTable to us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl">Imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount to us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount to us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="LesseeLeasesPolicyTextBlock" xlink:title="LesseeLeasesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_LesseeLeasesPolicyTextBlock_lbl">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:title="label: LesseeLeasesPolicyTextBlock to us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeLeasesPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_LesseeLeasesPolicyTextBlock_lbl1">Lessee, Leases [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl1" xlink:title="label: LesseeLeasesPolicyTextBlock to us-gaap_LesseeLeasesPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearThree to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearThree to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearTwo to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearTwo to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseTermOfContract_lbl">Term of lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:title="label: LesseeOperatingLeaseTermOfContract to us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseTermOfContract_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseTermOfContract_lbl1">Lessee, Operating Lease, Term of Contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl1" xlink:title="label: LesseeOperatingLeaseTermOfContract to us-gaap_LesseeOperatingLeaseTermOfContract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="LesseeDisclosureAbstract" xlink:title="LesseeDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_LesseeDisclosureAbstract_lbl">Operating Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl" xlink:title="label: LesseeDisclosureAbstract to us-gaap_LesseeDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeDisclosureAbstract_lbl1" xml:lang="en-US" id="us-gaap_LesseeDisclosureAbstract_lbl1">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl1" xlink:title="label: LesseeDisclosureAbstract to us-gaap_LesseeDisclosureAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:title="LongtermConvertibleDebtCurrentAndNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_lbl">Convertible Debt [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_lbl" xlink:title="label: LongtermConvertibleDebtCurrentAndNoncurrentAbstract to us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_lbl1">Convertible Debt [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_lbl1" xlink:title="label: LongtermConvertibleDebtCurrentAndNoncurrentAbstract to us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtCurrentAndNoncurrentAbstract" xlink:label="LongtermDebtCurrentAndNoncurrentAbstract" xlink:title="LongtermDebtCurrentAndNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_lbl">Long-Term Obligations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongtermDebtCurrentAndNoncurrentAbstract" xlink:to="us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_lbl" xlink:title="label: LongtermDebtCurrentAndNoncurrentAbstract to us-gaap_LongtermDebtCurrentAndNoncurrentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandMember" xlink:label="LandMember" xlink:title="LandMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LandMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LandMember_lbl" xml:lang="en-US" id="us-gaap_LandMember_lbl">Land [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LandMember" xlink:to="us-gaap_LandMember_lbl" xlink:title="label: LandMember to us-gaap_LandMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandImprovementsMember" xlink:label="LandImprovementsMember" xlink:title="LandImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LandImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LandImprovementsMember_lbl" xml:lang="en-US" id="us-gaap_LandImprovementsMember_lbl">Land Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LandImprovementsMember" xlink:to="us-gaap_LandImprovementsMember_lbl" xlink:title="label: LandImprovementsMember to us-gaap_LandImprovementsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LandImprovementsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LandImprovementsMember_lbl1" xml:lang="en-US" id="us-gaap_LandImprovementsMember_lbl1">Land Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LandImprovementsMember" xlink:to="us-gaap_LandImprovementsMember_lbl1" xlink:title="label: LandImprovementsMember to us-gaap_LandImprovementsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="us-gaap_LeaseholdImprovementsMember_lbl">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:title="label: LeaseholdImprovementsMember to us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeaseholdImprovementsMember_lbl1" xml:lang="en-US" id="us-gaap_LeaseholdImprovementsMember_lbl1">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl1" xlink:title="label: LeaseholdImprovementsMember to us-gaap_LeaseholdImprovementsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="LegalMattersAndContingenciesTextBlock" xlink:title="LegalMattersAndContingenciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xml:lang="en-US" id="us-gaap_LegalMattersAndContingenciesTextBlock_lbl">Legal Proceedings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LegalMattersAndContingenciesTextBlock" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock_lbl" xlink:title="label: LegalMattersAndContingenciesTextBlock to us-gaap_LegalMattersAndContingenciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LegalMattersAndContingenciesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LegalMattersAndContingenciesTextBlock_lbl1" xml:lang="en-US" id="us-gaap_LegalMattersAndContingenciesTextBlock_lbl1">Legal Matters and Contingencies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LegalMattersAndContingenciesTextBlock" xlink:to="us-gaap_LegalMattersAndContingenciesTextBlock_lbl1" xlink:title="label: LegalMattersAndContingenciesTextBlock to us-gaap_LegalMattersAndContingenciesTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Liabilities_lbl" xml:lang="en-US" id="us-gaap_Liabilities_lbl">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Liabilities_lbl1" xml:lang="en-US" id="us-gaap_Liabilities_lbl1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl1" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract_lbl">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrentAbstract_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract_lbl1">Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl1" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember" xlink:label="LicenseMember" xlink:title="LicenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LicenseMember_lbl" xml:lang="en-US" id="us-gaap_LicenseMember_lbl">License Fees [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" xlink:title="label: LicenseMember to us-gaap_LicenseMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LicenseMember_lbl1" xml:lang="en-US" id="us-gaap_LicenseMember_lbl1">License [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicenseMember" xlink:to="us-gaap_LicenseMember_lbl1" xlink:title="label: LicenseMember to us-gaap_LicenseMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="LineOfCreditFacilityTable" xlink:title="LineOfCreditFacilityTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityTable_lbl" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityTable_lbl">Line of Credit Facility [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityTable" xlink:to="us-gaap_LineOfCreditFacilityTable_lbl" xlink:title="label: LineOfCreditFacilityTable to us-gaap_LineOfCreditFacilityTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="LineOfCreditFacilityLineItems" xlink:title="LineOfCreditFacilityLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityLineItems_lbl" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityLineItems_lbl">Line of Credit Facility [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityLineItems" xlink:to="us-gaap_LineOfCreditFacilityLineItems_lbl" xlink:title="label: LineOfCreditFacilityLineItems to us-gaap_LineOfCreditFacilityLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="LineOfCreditFacilityAbstract" xlink:title="LineOfCreditFacilityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LineOfCreditFacilityAbstract_lbl" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityAbstract_lbl">Line of Credit Arrangement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityAbstract" xlink:to="us-gaap_LineOfCreditFacilityAbstract_lbl" xlink:title="label: LineOfCreditFacilityAbstract to us-gaap_LineOfCreditFacilityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityAbstract_lbl1" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityAbstract_lbl1">Line of Credit Facility [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityAbstract" xlink:to="us-gaap_LineOfCreditFacilityAbstract_lbl1" xlink:title="label: LineOfCreditFacilityAbstract to us-gaap_LineOfCreditFacilityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityAxis_lbl" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityAxis_lbl">Lender Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:title="label: LineOfCreditFacilityAxis to us-gaap_LineOfCreditFacilityAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl">Maximum borrowing capacity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:title="label: LineOfCreditFacilityMaximumBorrowingCapacity to us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityLenderDomain_lbl">Line of Credit Facility, Lender [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain_lbl" xlink:title="label: LineOfCreditFacilityLenderDomain to us-gaap_LineOfCreditFacilityLenderDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="LongTermDebtFairValue" xlink:title="LongTermDebtFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtFairValue_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtFairValue_lbl">Fair value of outstanding notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue_lbl" xlink:title="label: LongTermDebtFairValue to us-gaap_LongTermDebtFairValue_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="LongTermDebtAndCapitalLeaseObligationsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xml:lang="en-US" id="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl">LongTermDebtAndCapitalLeaseObligationsCurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" xlink:title="label: LongTermDebtAndCapitalLeaseObligationsCurrent to us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl1" xml:lang="en-US" id="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl1">Current portion of long-term obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl1" xlink:title="label: LongTermDebtAndCapitalLeaseObligationsCurrent to us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl2" xml:lang="en-US" id="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl2">Less: current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl2" xlink:title="label: LongTermDebtAndCapitalLeaseObligationsCurrent to us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermLoansFromBank" xlink:label="LongTermLoansFromBank" xlink:title="LongTermLoansFromBank" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermLoansFromBank_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermLoansFromBank_lbl" xml:lang="en-US" id="us-gaap_LongTermLoansFromBank_lbl">Long-term mortgage debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermLoansFromBank" xlink:to="us-gaap_LongTermLoansFromBank_lbl" xlink:title="label: LongTermLoansFromBank to us-gaap_LongTermLoansFromBank_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="ManufacturingFacilityMember" xlink:title="ManufacturingFacilityMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ManufacturingFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ManufacturingFacilityMember_lbl" xml:lang="en-US" id="us-gaap_ManufacturingFacilityMember_lbl">Manufacturing Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember_lbl" xlink:title="label: ManufacturingFacilityMember to us-gaap_ManufacturingFacilityMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:label="MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:title="MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract_lbl" xml:lang="en-US" id="us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract_lbl">Annual Debt and Other Obligation Maturities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:to="us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract_lbl" xlink:title="label: MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract to us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputTypeDomain_lbl">Measurement Input Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xlink:title="label: MeasurementInputTypeDomain to us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="MeasurementInputDiscountRateMember" xlink:title="MeasurementInputDiscountRateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_MeasurementInputDiscountRateMember_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputDiscountRateMember_lbl">Borrowing Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:title="label: MeasurementInputDiscountRateMember to us-gaap_MeasurementInputDiscountRateMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputDiscountRateMember_lbl1" xml:lang="en-US" id="us-gaap_MeasurementInputDiscountRateMember_lbl1">Measurement Input, Discount Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl1" xlink:title="label: MeasurementInputDiscountRateMember to us-gaap_MeasurementInputDiscountRateMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" id="us-gaap_MeasurementInputTypeAxis_lbl">Measurement Input Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:title="label: MeasurementInputTypeAxis to us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="MinorityInterestPeriodIncreaseDecrease" xlink:title="MinorityInterestPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterestPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_MinorityInterestPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="us-gaap_MinorityInterestPeriodIncreaseDecrease_lbl">Noncontrolling interest in Akcea Therapeutics, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterestPeriodIncreaseDecrease" xlink:to="us-gaap_MinorityInterestPeriodIncreaseDecrease_lbl" xlink:title="label: MinorityInterestPeriodIncreaseDecrease to us-gaap_MinorityInterestPeriodIncreaseDecrease_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterestPeriodIncreaseDecrease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinorityInterestPeriodIncreaseDecrease_lbl1" xml:lang="en-US" id="us-gaap_MinorityInterestPeriodIncreaseDecrease_lbl1">Noncontrolling Interest, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterestPeriodIncreaseDecrease" xlink:to="us-gaap_MinorityInterestPeriodIncreaseDecrease_lbl1" xlink:title="label: MinorityInterestPeriodIncreaseDecrease to us-gaap_MinorityInterestPeriodIncreaseDecrease_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="MinorityInterest" xlink:title="MinorityInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinorityInterest_lbl" xml:lang="en-US" id="us-gaap_MinorityInterest_lbl">Noncontrolling interest in Akcea Therapeutics, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl" xlink:title="label: MinorityInterest to us-gaap_MinorityInterest_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="MinorityInterestLineItems" xlink:title="MinorityInterestLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterestLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinorityInterestLineItems_lbl" xml:lang="en-US" id="us-gaap_MinorityInterestLineItems_lbl">Noncontrolling Interest [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterestLineItems" xlink:to="us-gaap_MinorityInterestLineItems_lbl" xlink:title="label: MinorityInterestLineItems to us-gaap_MinorityInterestLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" id="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl">Percentage ownership</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xlink:title="label: MinorityInterestOwnershipPercentageByParent to us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl1" xml:lang="en-US" id="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl1">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl1" xlink:title="label: MinorityInterestOwnershipPercentageByParent to us-gaap_MinorityInterestOwnershipPercentageByParent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="MinorityInterestTable" xlink:title="MinorityInterestTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MinorityInterestTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MinorityInterestTable_lbl" xml:lang="en-US" id="us-gaap_MinorityInterestTable_lbl">Noncontrolling Interest [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterestTable" xlink:to="us-gaap_MinorityInterestTable_lbl" xlink:title="label: MinorityInterestTable to us-gaap_MinorityInterestTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl">Net cash provided by operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl">Net cash (used in) provided by investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl">Investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl1">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl1" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl">Operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl">Net income attributable to Ionis Pharmaceuticals, Inc. common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl1">Net income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl2">Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetIncomeLoss_lbl3" xml:lang="en-US" id="us-gaap_NetIncomeLoss_lbl3">Net income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl3" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss_lbl3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl">Income (loss) available to Ionis common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1">Net income available to Ionis common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl2" xml:lang="en-US" id="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl2">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl2" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersBasic to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl">Financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:title="NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl">Income (Numerator) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersDilutedAbstract to us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:title="NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl">Income available to Ionis common shareholders, plus assumed conversions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersDiluted to us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl1">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl1" xlink:title="label: NetIncomeLossAvailableToCommonStockholdersDiluted to us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" id="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl">Net (income) loss attributable to noncontrolling interest in Akcea Therapeutics, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" xlink:title="label: NetIncomeLossAttributableToNoncontrollingInterest to us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl1">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl1" xlink:title="label: NetIncomeLossAttributableToNoncontrollingInterest to us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:title="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:title="label: NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems to us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl">Impact of Recently Issued Accounting Standards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:title="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:title="label: NewAccountingPronouncementsOrChangeInAccountingPrincipleTable to us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpenseAbstract_lbl">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:title="label: NonoperatingIncomeExpenseAbstract to us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpenseAbstract_lbl1" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpenseAbstract_lbl1">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl1" xlink:title="label: NonoperatingIncomeExpenseAbstract to us-gaap_NonoperatingIncomeExpenseAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesReduction" xlink:label="NotesReduction" xlink:title="NotesReduction" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NotesReduction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NotesReduction_lbl" xml:lang="en-US" id="us-gaap_NotesReduction_lbl">1 percent convertible senior notes principal extinguished related to our December 2019 debt exchange</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesReduction" xlink:to="us-gaap_NotesReduction_lbl" xlink:title="label: NotesReduction to us-gaap_NotesReduction_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NotesReduction_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NotesReduction_lbl1" xml:lang="en-US" id="us-gaap_NotesReduction_lbl1">Notes Reduction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesReduction" xlink:to="us-gaap_NotesReduction_lbl1" xlink:title="label: NotesReduction to us-gaap_NotesReduction_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesIssued1" xlink:label="NotesIssued1" xlink:title="NotesIssued1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NotesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NotesIssued1_lbl" xml:lang="en-US" id="us-gaap_NotesIssued1_lbl">0.125 percent convertible senior notes principal issued related to our December 2019 debt exchange/issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl" xlink:title="label: NotesIssued1 to us-gaap_NotesIssued1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NotesIssued1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NotesIssued1_lbl1" xml:lang="en-US" id="us-gaap_NotesIssued1_lbl1">Notes Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl1" xlink:title="label: NotesIssued1 to us-gaap_NotesIssued1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="NumberOfReportableSegments" xlink:title="NumberOfReportableSegments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" id="us-gaap_NumberOfReportableSegments_lbl">Number of reportable segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" xlink:title="label: NumberOfReportableSegments to us-gaap_NumberOfReportableSegments_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="us-gaap_NumberOfOperatingSegments_lbl">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:title="label: NumberOfOperatingSegments to us-gaap_NumberOfOperatingSegments_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="NoncontrollingInterestAbstract" xlink:title="NoncontrollingInterestAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncontrollingInterestAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NoncontrollingInterestAbstract_lbl" xml:lang="en-US" id="us-gaap_NoncontrollingInterestAbstract_lbl">Segment Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncontrollingInterestAbstract" xlink:to="us-gaap_NoncontrollingInterestAbstract_lbl" xlink:title="label: NoncontrollingInterestAbstract to us-gaap_NoncontrollingInterestAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncontrollingInterestAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NoncontrollingInterestAbstract_lbl1" xml:lang="en-US" id="us-gaap_NoncontrollingInterestAbstract_lbl1">Noncontrolling Interest [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncontrollingInterestAbstract" xlink:to="us-gaap_NoncontrollingInterestAbstract_lbl1" xlink:title="label: NoncontrollingInterestAbstract to us-gaap_NoncontrollingInterestAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="NoncontrollingInterestMember" xlink:title="NoncontrollingInterestMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US" id="us-gaap_NoncontrollingInterestMember_lbl">Noncontrolling Interest in Akcea Therapeutics, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl" xlink:title="label: NoncontrollingInterestMember to us-gaap_NoncontrollingInterestMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl">Annual Future Payments for Operating Lease Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:title="label: OperatingLeaseLiabilitiesPaymentsDueAbstract to us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl1">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl1" xlink:title="label: OperatingLeaseLiabilitiesPaymentsDueAbstract to us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:title="label: OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList to us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl">Weighted average remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:title="label: OperatingLeaseWeightedAverageRemainingLeaseTerm1 to us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl1">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl1" xlink:title="label: OperatingLeaseWeightedAverageRemainingLeaseTerm1 to us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset_lbl">Right-of-use operating lease assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset_lbl1">Operating Lease, Right-of-Use Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl1" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:title="label: OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList to us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="OperatingLeaseExpense" xlink:title="OperatingLeaseExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseExpense_lbl">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:title="label: OperatingLeaseExpense to us-gaap_OperatingLeaseExpense_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="OperatingSegmentsMember" xlink:title="OperatingSegmentsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingSegmentsMember_lbl" xml:lang="en-US" id="us-gaap_OperatingSegmentsMember_lbl">Operating Segments [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl" xlink:title="label: OperatingSegmentsMember to us-gaap_OperatingSegmentsMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:title="OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl">Weighted average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:title="label: OperatingLeaseWeightedAverageDiscountRatePercent to us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl1">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl1" xlink:title="label: OperatingLeaseWeightedAverageDiscountRatePercent to us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl">Income (loss) from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl1">Income (loss) from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingIncomeLoss_lbl2" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl2">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl2" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:title="label: OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList to us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent_lbl">Current portion of operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent_lbl1">Operating Lease, Liability, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="OperatingLeasePayments" xlink:title="OperatingLeasePayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" id="us-gaap_OperatingLeasePayments_lbl">Operating lease cash payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:title="label: OperatingLeasePayments to us-gaap_OperatingLeasePayments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeasePayments_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeasePayments_lbl1">Operating Lease, Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl1" xlink:title="label: OperatingLeasePayments to us-gaap_OperatingLeasePayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" id="us-gaap_OperatingLeaseLiability_lbl">Operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:title="label: OperatingLeaseLiability to us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseLiability_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiability_lbl1">Total operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl1" xlink:title="label: OperatingLeaseLiability to us-gaap_OperatingLeaseLiability_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiability_lbl2" xml:lang="en-US" id="us-gaap_OperatingLeaseLiability_lbl2">Operating Lease, Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl2" xlink:title="label: OperatingLeaseLiability to us-gaap_OperatingLeaseLiability_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwardsLineItems_lbl">Operating Loss Carryforwards [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:title="label: OperatingLossCarryforwardsLineItems to us-gaap_OperatingLossCarryforwardsLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwards_lbl">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:title="label: OperatingLossCarryforwards to us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwards_lbl1" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwards_lbl1">Operating Loss Carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl1" xlink:title="label: OperatingLossCarryforwards to us-gaap_OperatingLossCarryforwards_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwardsTable_lbl">Operating Loss Carryforwards [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:title="label: OperatingLossCarryforwardsTable to us-gaap_OperatingLossCarryforwardsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:title="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl">Organization and Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" xlink:title="label: OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock to us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl1" xml:lang="en-US" id="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl1">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl1" xlink:title="label: OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock to us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl">Organization and Significant Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:title="OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_lbl">Other comprehensive loss before reclassifications, net of tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_lbl" xlink:title="label: OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax to us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_lbl1">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_lbl1" xlink:title="label: OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax to us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:title="OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl">Reclassification adjustment for realized gains included in net income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" xlink:title="label: OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax to us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl1">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl1" xlink:title="label: OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax to us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="OtherCurrentAssetsMember" xlink:title="OtherCurrentAssetsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherCurrentAssetsMember_lbl" xml:lang="en-US" id="us-gaap_OtherCurrentAssetsMember_lbl">Other Current Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCurrentAssetsMember" xlink:to="us-gaap_OtherCurrentAssetsMember_lbl" xlink:title="label: OtherCurrentAssetsMember to us-gaap_OtherCurrentAssetsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCurrentAssetsMember_lbl1" xml:lang="en-US" id="us-gaap_OtherCurrentAssetsMember_lbl1">Other Current Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCurrentAssetsMember" xlink:to="us-gaap_OtherCurrentAssetsMember_lbl1" xlink:title="label: OtherCurrentAssetsMember to us-gaap_OtherCurrentAssetsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="OtherComprehensiveIncomeLossNetOfTax" xlink:title="OtherComprehensiveIncomeLossNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl">Net other comprehensive loss for the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:title="label: OtherComprehensiveIncomeLossNetOfTax to us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl1">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl1" xlink:title="label: OtherComprehensiveIncomeLossNetOfTax to us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="OtherComprehensiveIncomeLossTax" xlink:title="OtherComprehensiveIncomeLossTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherComprehensiveIncomeLossTax_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeLossTax_lbl">Income tax expense included in other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax_lbl" xlink:title="label: OtherComprehensiveIncomeLossTax to us-gaap_OtherComprehensiveIncomeLossTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeLossTax_lbl1" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeLossTax_lbl1">Other Comprehensive Income (Loss), Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax_lbl1" xlink:title="label: OtherComprehensiveIncomeLossTax to us-gaap_OtherComprehensiveIncomeLossTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="OtherAssetsCurrent" xlink:title="OtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" id="us-gaap_OtherAssetsCurrent_lbl">Other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:title="label: OtherAssetsCurrent to us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherAssetsCurrent_lbl1">Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl1" xlink:title="label: OtherAssetsCurrent to us-gaap_OtherAssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="us-gaap_OtherAssetsNoncurrent_lbl">OtherAssetsNoncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:title="label: OtherAssetsNoncurrent to us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherAssetsNoncurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherAssetsNoncurrent_lbl1">Deposits and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl1" xlink:title="label: OtherAssetsNoncurrent to us-gaap_OtherAssetsNoncurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl">Currency translation adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" xlink:title="label: OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax to us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1">Foreign currency translation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1" xlink:title="label: OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax to us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl">Unrealized gains (losses) on investments, net of tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:title="label: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax to us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl1">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl1" xlink:title="label: OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax to us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncomeExpense_lbl">Other expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:title="label: OtherNonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherNonoperatingIncomeExpense_lbl1" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncomeExpense_lbl1">Other Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl1" xlink:title="label: OtherNonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncomeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="us-gaap_OtherAccruedLiabilitiesCurrent_lbl">Other miscellaneous expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:title="label: OtherAccruedLiabilitiesCurrent to us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1">Other Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" xlink:title="label: OtherAccruedLiabilitiesCurrent to us-gaap_OtherAccruedLiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl">Change in unrealized gains (losses), net of tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" xlink:title="label: OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent to us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl1" xml:lang="en-US" id="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl1">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl1" xlink:title="label: OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent to us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="ParentMember" xlink:title="ParentMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ParentMember_lbl" xml:lang="en-US" id="us-gaap_ParentMember_lbl">Total Ionis Stockholders' Equity [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ParentMember" xlink:to="us-gaap_ParentMember_lbl" xlink:title="label: ParentMember to us-gaap_ParentMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PatentsMember" xlink:label="PatentsMember" xlink:title="PatentsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PatentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PatentsMember_lbl" xml:lang="en-US" id="us-gaap_PatentsMember_lbl">Patents [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xlink:title="label: PatentsMember to us-gaap_PatentsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PatentsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PatentsMember_lbl1" xml:lang="en-US" id="us-gaap_PatentsMember_lbl1">Patents [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PatentsMember" xlink:to="us-gaap_PatentsMember_lbl1" xlink:title="label: PatentsMember to us-gaap_PatentsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl">Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:title="label: PaymentsRelatedToTaxWithholdingForShareBasedCompensation to us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl1">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl1" xlink:title="label: PaymentsRelatedToTaxWithholdingForShareBasedCompensation to us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities" xlink:label="PaymentsForHedgeFinancingActivities" xlink:title="PaymentsForHedgeFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsForHedgeFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsForHedgeFinancingActivities_lbl" xml:lang="en-US" id="us-gaap_PaymentsForHedgeFinancingActivities_lbl">Purchase of note hedges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForHedgeFinancingActivities" xlink:to="us-gaap_PaymentsForHedgeFinancingActivities_lbl" xlink:title="label: PaymentsForHedgeFinancingActivities to us-gaap_PaymentsForHedgeFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsForHedgeFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PaymentsForHedgeFinancingActivities_lbl1" xml:lang="en-US" id="us-gaap_PaymentsForHedgeFinancingActivities_lbl1">Purchase of note hedges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForHedgeFinancingActivities" xlink:to="us-gaap_PaymentsForHedgeFinancingActivities_lbl1" xlink:title="label: PaymentsForHedgeFinancingActivities to us-gaap_PaymentsForHedgeFinancingActivities_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsForHedgeFinancingActivities_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsForHedgeFinancingActivities_lbl2" xml:lang="en-US" id="us-gaap_PaymentsForHedgeFinancingActivities_lbl2">Payments for Hedge, Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForHedgeFinancingActivities" xlink:to="us-gaap_PaymentsForHedgeFinancingActivities_lbl2" xlink:title="label: PaymentsForHedgeFinancingActivities to us-gaap_PaymentsForHedgeFinancingActivities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="PaymentsForRepurchaseOfCommonStock" xlink:title="PaymentsForRepurchaseOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US" id="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl">Repurchases and retirements of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:title="label: PaymentsForRepurchaseOfCommonStock to us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl1" xml:lang="en-US" id="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl1">Shares repurchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl1" xlink:title="label: PaymentsForRepurchaseOfCommonStock to us-gaap_PaymentsForRepurchaseOfCommonStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl2" xml:lang="en-US" id="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl2">Payments for Repurchase of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl2" xlink:title="label: PaymentsForRepurchaseOfCommonStock to us-gaap_PaymentsForRepurchaseOfCommonStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:title="PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US" id="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl">Purchases of short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:title="label: PaymentsToAcquireAvailableForSaleSecuritiesDebt to us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl1">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl1" xlink:title="label: PaymentsToAcquireAvailableForSaleSecuritiesDebt to us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US" id="us-gaap_PaymentsOfDebtIssuanceCosts_lbl">0.125 percent convertible senior notes issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:title="label: PaymentsOfDebtIssuanceCosts to us-gaap_PaymentsOfDebtIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" xml:lang="en-US" id="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1">Payments of Debt Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" xlink:title="label: PaymentsOfDebtIssuanceCosts to us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="us-gaap_PaymentsOfStockIssuanceCosts_lbl">Offering costs paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:title="label: PaymentsOfStockIssuanceCosts to us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsOfStockIssuanceCosts_lbl1" xml:lang="en-US" id="us-gaap_PaymentsOfStockIssuanceCosts_lbl1">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl1" xlink:title="label: PaymentsOfStockIssuanceCosts to us-gaap_PaymentsOfStockIssuanceCosts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBuildings" xlink:label="PaymentsToAcquireBuildings" xlink:title="PaymentsToAcquireBuildings" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBuildings_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquireBuildings_lbl" xml:lang="en-US" id="us-gaap_PaymentsToAcquireBuildings_lbl">Payment to acquire building</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireBuildings" xlink:to="us-gaap_PaymentsToAcquireBuildings_lbl" xlink:title="label: PaymentsToAcquireBuildings to us-gaap_PaymentsToAcquireBuildings_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl">Purchases of property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipmentAbstract" xlink:label="PaymentsToAcquirePropertyPlantAndEquipmentAbstract" xlink:title="PaymentsToAcquirePropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipmentAbstract_lbl">Research and Development and Manufacturing Facilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipmentAbstract_lbl" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipmentAbstract to us-gaap_PaymentsToAcquirePropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl">Employment Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:title="label: PensionAndOtherPostretirementBenefitsDisclosureTextBlock to us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl1">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl1" xlink:title="label: PensionAndOtherPostretirementBenefitsDisclosureTextBlock to us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="us-gaap_PlanNameAxis_lbl">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:title="label: PlanNameAxis to us-gaap_PlanNameAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_PlanNameDomain_lbl">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xlink:title="label: PlanNameDomain to us-gaap_PlanNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="PreferredStockDividendRatePercentage" xlink:title="PreferredStockDividendRatePercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" id="us-gaap_PreferredStockDividendRatePercentage_lbl">Dividend rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:title="label: PreferredStockDividendRatePercentage to us-gaap_PreferredStockDividendRatePercentage_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockMember_lbl" xml:lang="en-US" id="us-gaap_PreferredStockMember_lbl">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:title="label: PreferredStockMember to us-gaap_PreferredStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl">Preferred Stock [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:title="label: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesIssued_lbl">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:title="label: PreferredStockSharesIssued to us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesIssued_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockSharesIssued_lbl1">Preferred Stock, Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl1" xlink:title="label: PreferredStockSharesIssued to us-gaap_PreferredStockSharesIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding_lbl">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding_lbl1">Preferred Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl1" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized_lbl">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="ProceedsFromDebtNetOfIssuanceCosts" xlink:title="ProceedsFromDebtNetOfIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl">Proceeds from building mortgage debt, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:title="label: ProceedsFromDebtNetOfIssuanceCosts to us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl">Proceeds from the issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="ProceedsFromConvertibleDebt" xlink:title="ProceedsFromConvertibleDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromConvertibleDebt_lbl">Proceeds from the issuance of 0.125 percent convertible senior notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:title="label: ProceedsFromConvertibleDebt to us-gaap_ProceedsFromConvertibleDebt_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromConvertibleDebt_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromConvertibleDebt_lbl1">Proceeds from Convertible Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl1" xlink:title="label: ProceedsFromConvertibleDebt to us-gaap_ProceedsFromConvertibleDebt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="ProceedsFromIssuanceInitialPublicOffering" xlink:title="ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl">Proceeds from issuance of common stock in Akcea Therapeutics, Inc. from its initial public offering, net of underwriters' discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:title="label: ProceedsFromIssuanceInitialPublicOffering to us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl1">Proceeds from Issuance Initial Public Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl1" xlink:title="label: ProceedsFromIssuanceInitialPublicOffering to us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:label="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="ProceedsFromIssuanceOrSaleOfEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl">Noncontrolling Interest in Akcea Therapeutics, Inc. [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl" xlink:title="label: ProceedsFromIssuanceOrSaleOfEquityAbstract to us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1">Basis of Presentation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1" xlink:title="label: ProceedsFromIssuanceOrSaleOfEquityAbstract to us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl2" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl2">Proceeds from Issuance or Sale of Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl2" xlink:title="label: ProceedsFromIssuanceOrSaleOfEquityAbstract to us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="ProceedsFromLicenseFeesReceived" xlink:title="ProceedsFromLicenseFeesReceived" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromLicenseFeesReceived_lbl">Payment received under license agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:title="label: ProceedsFromLicenseFeesReceived to us-gaap_ProceedsFromLicenseFeesReceived_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromLicenseFeesReceived_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromLicenseFeesReceived_lbl1">Proceeds from License Fees Received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl1" xlink:title="label: ProceedsFromLicenseFeesReceived to us-gaap_ProceedsFromLicenseFeesReceived_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="ProceedsFromIssuanceOfPrivatePlacement" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl">Proceeds from the sale of Akcea Therapeutics, Inc. common stock to Novartis in a private placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:title="label: ProceedsFromIssuanceOfPrivatePlacement to us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1">Proceeds from sale of common stock to Novartis in a private placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1" xlink:title="label: ProceedsFromIssuanceOfPrivatePlacement to us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="ProceedsFromIssuanceOfWarrants" xlink:title="ProceedsFromIssuanceOfWarrants" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfWarrants_lbl">Proceeds from issuance of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:title="label: ProceedsFromIssuanceOfWarrants to us-gaap_ProceedsFromIssuanceOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfWarrants_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfWarrants_lbl1">Proceeds from Issuance of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl1" xlink:title="label: ProceedsFromIssuanceOfWarrants to us-gaap_ProceedsFromIssuanceOfWarrants_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="ProceedsFromSaleOfEquityMethodInvestments" xlink:title="ProceedsFromSaleOfEquityMethodInvestments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl">Proceeds from the sale of Regulus Therapeutics, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfEquityMethodInvestments" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl" xlink:title="label: ProceedsFromSaleOfEquityMethodInvestments to us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl1">Proceeds from Sale of Equity Method Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfEquityMethodInvestments" xlink:to="us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl1" xlink:title="label: ProceedsFromSaleOfEquityMethodInvestments to us-gaap_ProceedsFromSaleOfEquityMethodInvestments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:title="ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl">Proceeds from sale of short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:title="label: ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities to us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl1">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl1" xlink:title="label: ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities to us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised_lbl">Cash received from exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromStockOptionsExercised_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised_lbl1">Proceeds from Stock Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl1" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:title="ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl">Net proceeds from stock option exercises, vesting of restricted stock units, and ESPP purchases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:title="label: ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions to us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl1">Proceeds from equity, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl1" xlink:title="label: ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions to us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="ProductMember" xlink:title="ProductMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProductMember_lbl" xml:lang="en-US" id="us-gaap_ProductMember_lbl">Product Sales, Net [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductMember" xlink:to="us-gaap_ProductMember_lbl" xlink:title="label: ProductMember to us-gaap_ProductMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProductMember_lbl1" xml:lang="en-US" id="us-gaap_ProductMember_lbl1">Product [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductMember" xlink:to="us-gaap_ProductMember_lbl1" xlink:title="label: ProductMember to us-gaap_ProductMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_ProfitLoss_lbl" xml:lang="en-US" id="us-gaap_ProfitLoss_lbl">Net income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:title="label: ProfitLoss to us-gaap_ProfitLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ProfitLoss_lbl1" xml:lang="en-US" id="us-gaap_ProfitLoss_lbl1">Net income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl1" xlink:title="label: ProfitLoss to us-gaap_ProfitLoss_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProfitLoss_lbl2" xml:lang="en-US" id="us-gaap_ProfitLoss_lbl2">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl2" xlink:title="label: ProfitLoss to us-gaap_ProfitLoss_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl">Estimated useful lives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentGross_lbl">Property, plant and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:title="label: PropertyPlantAndEquipmentGross to us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentGross_lbl1">Property, Plant and Equipment, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl1" xlink:title="label: PropertyPlantAndEquipmentGross to us-gaap_PropertyPlantAndEquipmentGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentLineItems_lbl">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:title="label: PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl">Property, Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentAbstract_lbl">Property, Plant and Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:title="label: PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentAbstract_lbl1">Property, Plant and Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl1" xlink:title="label: PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:title="label: PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:title="label: PropertyPlantAndEquipmentTypeDomain to us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl">Property, plant and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl1">Property, plant and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNet_lbl2" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet_lbl2">Property, Plant and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl2" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl">Property, Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="PublicUtilitiesInventoryAxis" xlink:title="PublicUtilitiesInventoryAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PublicUtilitiesInventoryAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PublicUtilitiesInventoryAxis_lbl" xml:lang="en-US" id="us-gaap_PublicUtilitiesInventoryAxis_lbl">Inventory [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PublicUtilitiesInventoryAxis" xlink:to="us-gaap_PublicUtilitiesInventoryAxis_lbl" xlink:title="label: PublicUtilitiesInventoryAxis to us-gaap_PublicUtilitiesInventoryAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="PublicUtilitiesInventoryTypeDomain" xlink:title="PublicUtilitiesInventoryTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PublicUtilitiesInventoryTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PublicUtilitiesInventoryTypeDomain_lbl" xml:lang="en-US" id="us-gaap_PublicUtilitiesInventoryTypeDomain_lbl">Inventory [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PublicUtilitiesInventoryTypeDomain" xlink:to="us-gaap_PublicUtilitiesInventoryTypeDomain_lbl" xlink:title="label: PublicUtilitiesInventoryTypeDomain to us-gaap_PublicUtilitiesInventoryTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="QuarterlyFinancialInformationTextBlock" xlink:title="QuarterlyFinancialInformationTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US" id="us-gaap_QuarterlyFinancialInformationTextBlock_lbl">Quarterly Financial Data (Unaudited)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:title="label: QuarterlyFinancialInformationTextBlock to us-gaap_QuarterlyFinancialInformationTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_QuarterlyFinancialInformationTextBlock_lbl1" xml:lang="en-US" id="us-gaap_QuarterlyFinancialInformationTextBlock_lbl1">Quarterly Financial Information [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl1" xlink:title="label: QuarterlyFinancialInformationTextBlock to us-gaap_QuarterlyFinancialInformationTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="QuarterlyFinancialInformationDisclosureAbstract" xlink:title="QuarterlyFinancialInformationDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US" id="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl">Quarterly Financial Data (Unaudited) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:title="label: QuarterlyFinancialInformationDisclosureAbstract to us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" id="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl">Right-of-use assets obtained in exchange for lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:title="label: RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability to us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1" xml:lang="en-US" id="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1" xlink:title="label: RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability to us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="ReceivablesPolicyTextBlock" xlink:title="ReceivablesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ReceivablesPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_ReceivablesPolicyTextBlock_lbl">Contracts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl" xlink:title="label: ReceivablesPolicyTextBlock to us-gaap_ReceivablesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ReceivablesPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ReceivablesPolicyTextBlock_lbl1">Receivable [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl1" xlink:title="label: ReceivablesPolicyTextBlock to us-gaap_ReceivablesPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:label="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:title="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_lbl" xml:lang="en-US" id="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_lbl">Accumulated Other Comprehensive Loss [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_lbl" xlink:title="label: ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract to us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_lbl1" xml:lang="en-US" id="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_lbl1">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_lbl1" xlink:title="label: ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract to us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:title="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_lbl" xml:lang="en-US" id="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_lbl">Amounts reclassified from accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_lbl" xlink:title="label: ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax to us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_lbl1" xml:lang="en-US" id="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_lbl1">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_lbl1" xlink:title="label: ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax to us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:title="ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xml:lang="en-US" id="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl">Gross Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:title="label: ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward to us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl1" xml:lang="en-US" id="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl1">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl1" xlink:title="label: ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward to us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="RepaymentsOfLongTermLinesOfCredit" xlink:title="RepaymentsOfLongTermLinesOfCredit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermLinesOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RepaymentsOfLongTermLinesOfCredit_lbl" xml:lang="en-US" id="us-gaap_RepaymentsOfLongTermLinesOfCredit_lbl">Payment of outstanding borrowings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongTermLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLongTermLinesOfCredit_lbl" xlink:title="label: RepaymentsOfLongTermLinesOfCredit to us-gaap_RepaymentsOfLongTermLinesOfCredit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermLinesOfCredit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RepaymentsOfLongTermLinesOfCredit_lbl1" xml:lang="en-US" id="us-gaap_RepaymentsOfLongTermLinesOfCredit_lbl1">Repayments of Long-term Lines of Credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongTermLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLongTermLinesOfCredit_lbl1" xlink:title="label: RepaymentsOfLongTermLinesOfCredit to us-gaap_RepaymentsOfLongTermLinesOfCredit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:title="RepaymentsOfLongTermDebtAndCapitalSecurities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl" xml:lang="en-US" id="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl">Principal payments on debt and capital lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:to="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl" xlink:title="label: RepaymentsOfLongTermDebtAndCapitalSecurities to us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl1" xml:lang="en-US" id="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl1">Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:to="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl1" xlink:title="label: RepaymentsOfLongTermDebtAndCapitalSecurities to us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="ResearchAndDevelopmentExpenseAbstract" xlink:title="ResearchAndDevelopmentExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl">Research, Development and Patent Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" xlink:title="label: ResearchAndDevelopmentExpenseAbstract to us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl1">Research and Development Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl1" xlink:title="label: ResearchAndDevelopmentExpenseAbstract to us-gaap_ResearchAndDevelopmentExpenseAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="ResearchMember" xlink:title="ResearchMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchMember_lbl" xml:lang="en-US" id="us-gaap_ResearchMember_lbl">Research and Development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xlink:title="label: ResearchMember to us-gaap_ResearchMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchMember_lbl1" xml:lang="en-US" id="us-gaap_ResearchMember_lbl1">Research Tax Credit Carryforward [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchMember" xlink:to="us-gaap_ResearchMember_lbl1" xlink:title="label: ResearchMember to us-gaap_ResearchMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense_lbl">Research and development expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpense_lbl1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense_lbl1">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl1" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="us-gaap_RestrictedStockMember_lbl">Restricted Stock Awards [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:title="label: RestrictedStockMember to us-gaap_RestrictedStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestrictedStockMember_lbl1" xml:lang="en-US" id="us-gaap_RestrictedStockMember_lbl1">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl1" xlink:title="label: RestrictedStockMember to us-gaap_RestrictedStockMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember_lbl">Restricted Stock Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember_lbl1">RSUs [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestrictedStockUnitsRSUMember_lbl2" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember_lbl2">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl2" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsMember_lbl">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsMember_lbl1" xml:lang="en-US" id="us-gaap_RetainedEarningsMember_lbl1">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl1" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RevenueFromContractWithCustomerMember_lbl" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerMember_lbl">Revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerMember" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_lbl" xlink:title="label: RevenueFromContractWithCustomerMember to us-gaap_RevenueFromContractWithCustomerMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerMember_lbl1" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerMember_lbl1">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerMember" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_lbl1" xlink:title="label: RevenueFromContractWithCustomerMember to us-gaap_RevenueFromContractWithCustomerMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="RevenueFromContractWithCustomerPolicyTextBlock" xlink:title="RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:title="label: RevenueFromContractWithCustomerPolicyTextBlock to us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl1">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl1" xlink:title="label: RevenueFromContractWithCustomerPolicyTextBlock to us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" xlink:title="RevenueFromContractWithCustomerAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerAbstract_lbl">Revenue Recognition [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:title="label: RevenueFromContractWithCustomerAbstract to us-gaap_RevenueFromContractWithCustomerAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerAbstract_lbl1" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerAbstract_lbl1">Revenue from Contract with Customer [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl1" xlink:title="label: RevenueFromContractWithCustomerAbstract to us-gaap_RevenueFromContractWithCustomerAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:title="label: RevenueFromContractWithCustomerExcludingAssessedTax to us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1" xlink:title="label: RevenueFromContractWithCustomerExcludingAssessedTax to us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="RevenueRecognitionPolicyTextBlock" xlink:title="RevenueRecognitionPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_RevenueRecognitionPolicyTextBlock_lbl">Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:title="label: RevenueRecognitionPolicyTextBlock to us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueRecognitionPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_RevenueRecognitionPolicyTextBlock_lbl1">Revenue [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl1" xlink:title="label: RevenueRecognitionPolicyTextBlock to us-gaap_RevenueRecognitionPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="RevenuesAbstract" xlink:title="RevenuesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="us-gaap_RevenuesAbstract_lbl">Revenue:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:title="label: RevenuesAbstract to us-gaap_RevenuesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenuesAbstract_lbl1" xml:lang="en-US" id="us-gaap_RevenuesAbstract_lbl1">Revenues [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl1" xlink:title="label: RevenuesAbstract to us-gaap_RevenuesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="Revenues" xlink:title="Revenues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_Revenues_lbl" xml:lang="en-US" id="us-gaap_Revenues_lbl">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:title="label: Revenues to us-gaap_Revenues_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Revenues_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Revenues_lbl1" xml:lang="en-US" id="us-gaap_Revenues_lbl1">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Revenues" xlink:to="us-gaap_Revenues_lbl1" xlink:title="label: Revenues to us-gaap_Revenues_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="RevolvingCreditFacilityMember" xlink:title="RevolvingCreditFacilityMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevolvingCreditFacilityMember_lbl" xml:lang="en-US" id="us-gaap_RevolvingCreditFacilityMember_lbl">Revolving Line of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:title="label: RevolvingCreditFacilityMember to us-gaap_RevolvingCreditFacilityMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl">Average remaining contractual term, exercisable at end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl">Award term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl">Expected life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl">Percentage of fair market value used to determine purchase price of stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl">Aggregate intrinsic value, exercisable at end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl">Vesting percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl">Average remaining contractual term, outstanding at end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:title="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl">Amortization Expense for Patents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:title="label: ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock to us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl1">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl1" xlink:title="label: ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock to us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock" xlink:label="ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock" xlink:title="ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock_lbl">Temporarily Impaired Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock_lbl" xlink:title="label: ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock to us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock_lbl1">Schedule of Temporary Impairment Losses, Investments [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock_lbl1" xlink:title="label: ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock to us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:title="ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl">RSU Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:title="label: ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock to us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl1">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl1" xlink:title="label: ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock to us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="ScheduleOfInventoryCurrentTableTextBlock" xlink:title="ScheduleOfInventoryCurrentTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:title="label: ScheduleOfInventoryCurrentTableTextBlock to us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl1">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl1" xlink:title="label: ScheduleOfInventoryCurrentTableTextBlock to us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl">Weighted-Average Assumptions for Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl">Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl1">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl1" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl">Weighted-Average Assumptions for ESPP</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:title="label: ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl1">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl1" xlink:title="label: ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:title="ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl">Gross Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:title="label: ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock to us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl1">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl1" xlink:title="label: ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock to us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:title="ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl">Quarterly Financial Data</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:title="label: ScheduleOfQuarterlyFinancialInformationTableTextBlock to us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl1">Quarterly Financial Information [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl1" xlink:title="label: ScheduleOfQuarterlyFinancialInformationTableTextBlock to us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:title="label: ScheduleOfFiniteLivedIntangibleAssetsTable to us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:title="ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl">Income (Loss) Before Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:title="label: ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock to us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl1">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl1" xlink:title="label: ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock to us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:title="label: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:title="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:title="label: ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock to us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl1">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl1" xlink:title="label: ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock to us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl">Deferred Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:title="label: ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock to us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl1">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl1" xlink:title="label: ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock to us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl">Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl">Basic and Diluted Net Income Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:title="label: ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock to us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl1">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl1" xlink:title="label: ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock to us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl">Reconciliation of Statutory to Effective Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:title="label: ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock to us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl1">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl1" xlink:title="label: ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock to us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:title="ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl">Changes in Accumulated Other Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl" xlink:title="label: ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock to us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl1">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl1" xlink:title="label: ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock to us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="ScheduleOfDebtInstrumentsTextBlock" xlink:title="ScheduleOfDebtInstrumentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl">Long-Term Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:title="label: ScheduleOfDebtInstrumentsTextBlock to us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl1">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl1" xlink:title="label: ScheduleOfDebtInstrumentsTextBlock to us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:title="ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" xlink:title="label: ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable to us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:title="ScheduleOfEarningsPerShareBasicByCommonClassTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:title="label: ScheduleOfEarningsPerShareBasicByCommonClassTable to us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl">Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" xlink:title="label: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:label="ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:title="ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl">Basic Net Income per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl" xlink:title="label: ScheduleOfEarningsPerShareBasicByCommonClassTextBlock to us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl1">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl1" xlink:title="label: ScheduleOfEarningsPerShareBasicByCommonClassTextBlock to us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl">Property, Plant and Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:title="label: ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl">Segment Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xlink:title="label: ScheduleOfSegmentReportingInformationBySegmentTextBlock to us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xlink:title="label: ScheduleOfSegmentReportingInformationBySegmentTable to us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl1" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="us-gaap_ScheduleOfStockByClassTable_lbl">Schedule of Stock by Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:title="label: ScheduleOfStockByClassTable to us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:title="SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US" id="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl">Revenue from Collaborative Relationship</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:title="label: SchedulesOfConcentrationOfRiskByRiskFactorTextBlock to us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl1">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl1" xlink:title="label: SchedulesOfConcentrationOfRiskByRiskFactorTextBlock to us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="SegmentReportingDisclosureTextBlock" xlink:title="SegmentReportingDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingDisclosureTextBlock_lbl">Segment Information and Concentration of Business Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:title="label: SegmentReportingDisclosureTextBlock to us-gaap_SegmentReportingDisclosureTextBlock_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingInformationLineItems_lbl">Segment Reporting Information [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xlink:title="label: SegmentReportingInformationLineItems to us-gaap_SegmentReportingInformationLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" xlink:label="SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" xlink:title="SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract_lbl">Segment Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" xlink:to="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract_lbl" xlink:title="label: SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract to us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract_lbl1" xml:lang="en-US" id="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract_lbl1">Segment Reporting, Disclosure of Other Information about Entity's Reportable Segments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" xlink:to="us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract_lbl1" xlink:title="label: SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract to us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="SegmentReportingPolicyPolicyTextBlock" xlink:title="SegmentReportingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl">Segment Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:title="label: SegmentReportingPolicyPolicyTextBlock to us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl1">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl1" xlink:title="label: SegmentReportingPolicyPolicyTextBlock to us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentDomain_lbl" xml:lang="en-US" id="us-gaap_SegmentDomain_lbl">Segments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl" xlink:title="label: SegmentDomain to us-gaap_SegmentDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingAbstract_lbl">Segment Information and Concentration of Business Risk [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xlink:title="label: SegmentReportingAbstract to us-gaap_SegmentReportingAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:title="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" xml:lang="en-US" id="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl">Segment Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" xlink:title="label: SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract to us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl1" xml:lang="en-US" id="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl1">Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl1" xlink:title="label: SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract to us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="SelectedQuarterlyFinancialInformationAbstract" xlink:title="SelectedQuarterlyFinancialInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SelectedQuarterlyFinancialInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SelectedQuarterlyFinancialInformationAbstract_lbl" xml:lang="en-US" id="us-gaap_SelectedQuarterlyFinancialInformationAbstract_lbl">Quarterly Financial Data (Unaudited) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SelectedQuarterlyFinancialInformationAbstract" xlink:to="us-gaap_SelectedQuarterlyFinancialInformationAbstract_lbl" xlink:title="label: SelectedQuarterlyFinancialInformationAbstract to us-gaap_SelectedQuarterlyFinancialInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SelectedQuarterlyFinancialInformationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SelectedQuarterlyFinancialInformationAbstract_lbl1" xml:lang="en-US" id="us-gaap_SelectedQuarterlyFinancialInformationAbstract_lbl1">Selected Quarterly Financial Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SelectedQuarterlyFinancialInformationAbstract" xlink:to="us-gaap_SelectedQuarterlyFinancialInformationAbstract_lbl1" xlink:title="label: SelectedQuarterlyFinancialInformationAbstract to us-gaap_SelectedQuarterlyFinancialInformationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="SellingGeneralAndAdministrativeExpensesMember" xlink:title="SellingGeneralAndAdministrativeExpensesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl">Selling, General and Administrative [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:title="label: SellingGeneralAndAdministrativeExpensesMember to us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl1" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl1">Selling, General and Administrative Expenses [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl1" xlink:title="label: SellingGeneralAndAdministrativeExpensesMember to us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpense_lbl">Selling, general and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:title="label: SellingGeneralAndAdministrativeExpense to us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpense_lbl1" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpense_lbl1">Selling, General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl1" xlink:title="label: SellingGeneralAndAdministrativeExpense to us-gaap_SellingGeneralAndAdministrativeExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="SeriesCPreferredStockMember" xlink:title="SeriesCPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US" id="us-gaap_SeriesCPreferredStockMember_lbl">Series C Junior Participating Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl" xlink:title="label: SeriesCPreferredStockMember to us-gaap_SeriesCPreferredStockMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl">Exercised (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl">Weighted Average Exercise Price Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract_lbl">Stock-Based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationAbstract_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract_lbl1">Stock-Based Compensation Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl1" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAbstract_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract_lbl2">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl2" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl">Weighted Average Grant Date Fair Value per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl1">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="ShareBasedCompensationAwardTrancheOneMember" xlink:title="ShareBasedCompensationAwardTrancheOneMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl">One Year from Date of Grant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:title="label: ShareBasedCompensationAwardTrancheOneMember to us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl">Vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl">Number of additional shares reserved for issuance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:title="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl">Stock Plans [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" xlink:title="label: ShareBasedArrangementsToObtainGoodsAndServicesAbstract to us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl1">Share-based Payment Arrangement, Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl1" xlink:title="label: ShareBasedArrangementsToObtainGoodsAndServicesAbstract to us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl">Cancelled/forfeited (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl">Cancelled/forfeited/expired (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl">Number of awards outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl">Period before options are exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl">Cancelled/forfeited (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl">Vested (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl">Number of Shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl">Non-vested at end of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1">Non-vested at beginning of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl">Non-vested at beginning of period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1">Non-vested at end of period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl">Vested (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl">Weighted-Average Assumptions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl">Number of shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl">Weighted average fair value of options granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl">Number of shares available for grant (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl">Maximum percentage of employee compensation used to purchase shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl">Intrinsic value of options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl">Exercisable at end of period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl">Exercisable at end of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1">Number of options exercisable (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl">Number of Shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl">Average Remaining Contractual Term, Aggregate Intrinsic Value and Other [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl">Cancelled/forfeited/expired (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl">Equity Award [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl">Outstanding at end of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1">Outstanding at beginning of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2">Number of options outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl3" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl3">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl3" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl">Outstanding at end of period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl">Aggregate intrinsic value, outstanding at end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl">Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl">Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:title="label: SharesPaidForTaxWithholdingForShareBasedCompensation to us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl1">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl1" xlink:title="label: SharesPaidForTaxWithholdingForShareBasedCompensation to us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="SharesIssued" xlink:title="SharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_SharesIssued_lbl" xml:lang="en-US" id="us-gaap_SharesIssued_lbl">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:title="label: SharesIssued to us-gaap_SharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_SharesIssued_lbl1" xml:lang="en-US" id="us-gaap_SharesIssued_lbl1">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1" xlink:title="label: SharesIssued to us-gaap_SharesIssued_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesIssued_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesIssued_lbl2" xml:lang="en-US" id="us-gaap_SharesIssued_lbl2">Shares, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssued" xlink:to="us-gaap_SharesIssued_lbl2" xlink:title="label: SharesIssued to us-gaap_SharesIssued_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfFinancialPositionAbstract_lbl">CONSOLIDATED BALANCE SHEETS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:title="label: StatementOfFinancialPositionAbstract to us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="us-gaap_StatementClassOfStockAxis_lbl">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:title="label: StatementClassOfStockAxis to us-gaap_StatementClassOfStockAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:title="StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:title="label: StatementOfIncomeAndComprehensiveIncomeAbstract to us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="us-gaap_StatementEquityComponentsAxis_lbl">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:title="label: StatementEquityComponentsAxis to us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="us-gaap_StatementLineItems_lbl">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:title="label: StatementLineItems to us-gaap_StatementLineItems_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementTable_lbl" xml:lang="en-US" id="us-gaap_StatementTable_lbl">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:title="label: StatementTable to us-gaap_StatementTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US" id="us-gaap_StatementBusinessSegmentsAxis_lbl">Segments [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xlink:title="label: StatementBusinessSegmentsAxis to us-gaap_StatementBusinessSegmentsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfCashFlowsAbstract_lbl">CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:title="label: StatementOfCashFlowsAbstract to us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StatementOfStockholdersEquityAbstract_lbl">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:title="label: StatementOfStockholdersEquityAbstract to us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl">Exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:title="StockIssuedDuringPeriodValueShareBasedCompensationGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl">Issuance of common stock in connection with employee stock plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xlink:title="label: StockIssuedDuringPeriodValueShareBasedCompensationGross to us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl1">Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl1" xlink:title="label: StockIssuedDuringPeriodValueShareBasedCompensationGross to us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl">Issuance of common stock in connection with employee stock plans (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:title="label: StockIssuedDuringPeriodSharesShareBasedCompensation to us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl1">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesShareBasedCompensation to us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="StockRepurchaseProgramAuthorizedAmount1" xlink:title="StockRepurchaseProgramAuthorizedAmount1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xml:lang="en-US" id="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl">Authorized amount of share repurchase program</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockRepurchaseProgramAuthorizedAmount1" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xlink:title="label: StockRepurchaseProgramAuthorizedAmount1 to us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl1" xml:lang="en-US" id="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl1">Stock Repurchase Program, Authorized Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockRepurchaseProgramAuthorizedAmount1" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl1" xlink:title="label: StockRepurchaseProgramAuthorizedAmount1 to us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl">Shares purchased and issued under ESPP (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:title="label: StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans to us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl1">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans to us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl">Stock purchase (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1">Shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:title="StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl">Number of shares issued for stock option exercises, vesting of restricted stock units, and ESPP purchases (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xlink:title="label: StockIssuedDuringPeriodSharesShareBasedCompensationGross to us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl1">Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesShareBasedCompensationGross to us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="StockRepurchasedAndRetiredDuringPeriodValue" xlink:title="StockRepurchasedAndRetiredDuringPeriodValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xml:lang="en-US" id="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl">Repurchases and retirements of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:title="label: StockRepurchasedAndRetiredDuringPeriodValue to us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl1" xml:lang="en-US" id="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl1">Stock Repurchased and Retired During Period, Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl1" xlink:title="label: StockRepurchasedAndRetiredDuringPeriodValue to us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl">Stock purchase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="StockRepurchasedAndRetiredDuringPeriodShares" xlink:title="StockRepurchasedAndRetiredDuringPeriodShares" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xml:lang="en-US" id="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl">Repurchases and retirements of common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:title="label: StockRepurchasedAndRetiredDuringPeriodShares to us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl1" xml:lang="en-US" id="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl1">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl1" xlink:title="label: StockRepurchasedAndRetiredDuringPeriodShares to us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="StockOptionMember" xlink:title="StockOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockOptionMember_lbl" xml:lang="en-US" id="us-gaap_StockOptionMember_lbl">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:title="label: StockOptionMember to us-gaap_StockOptionMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockOptionMember_lbl1" xml:lang="en-US" id="us-gaap_StockOptionMember_lbl1">Equity Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl1" xlink:title="label: StockOptionMember to us-gaap_StockOptionMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="StockRepurchasedDuringPeriodShares" xlink:title="StockRepurchasedDuringPeriodShares" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US" id="us-gaap_StockRepurchasedDuringPeriodShares_lbl">Shares repurchased (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:title="label: StockRepurchasedDuringPeriodShares to us-gaap_StockRepurchasedDuringPeriodShares_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockRepurchasedDuringPeriodShares_lbl1" xml:lang="en-US" id="us-gaap_StockRepurchasedDuringPeriodShares_lbl1">Stock Repurchased During Period, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl1" xlink:title="label: StockRepurchasedDuringPeriodShares to us-gaap_StockRepurchasedDuringPeriodShares_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl">Stockholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl">Total Ionis stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl1">Stockholders' Equity Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="StockholdersEquityPolicyTextBlock" xlink:title="StockholdersEquityPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityPolicyTextBlock_lbl">Accumulated Other Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:title="label: StockholdersEquityPolicyTextBlock to us-gaap_StockholdersEquityPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityPolicyTextBlock_lbl1">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl1" xlink:title="label: StockholdersEquityPolicyTextBlock to us-gaap_StockholdersEquityPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl">Total stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:title="label: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xlink:title="label: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" xml:lang="en-US" id="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" xlink:title="label: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl3" xml:lang="en-US" id="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl3">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl3" xlink:title="label: StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl">Stockholders' equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl1">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl1" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteAbstract_lbl">Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:title="label: StockholdersEquityNoteAbstract to us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventMember_lbl">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:title="label: SubsequentEventMember to us-gaap_SubsequentEventMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeDomain_lbl">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xlink:title="label: SubsequentEventTypeDomain to us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="us-gaap_SubsequentEventTypeAxis_lbl">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:title="label: SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="us-gaap_SupplementalCashFlowInformationAbstract_lbl">Supplemental disclosures of cash flow information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:title="label: SupplementalCashFlowInformationAbstract to us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract_lbl1" xml:lang="en-US" id="us-gaap_SupplementalCashFlowInformationAbstract_lbl1">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl1" xlink:title="label: SupplementalCashFlowInformationAbstract to us-gaap_SupplementalCashFlowInformationAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="TaxCreditCarryforwardLineItems" xlink:title="TaxCreditCarryforwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_TaxCreditCarryforwardLineItems_lbl" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardLineItems_lbl">Tax Credit Carryforwards [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_lbl" xlink:title="label: TaxCreditCarryforwardLineItems to us-gaap_TaxCreditCarryforwardLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardLineItems_lbl1" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardLineItems_lbl1">Tax Credit Carryforward [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardLineItems" xlink:to="us-gaap_TaxCreditCarryforwardLineItems_lbl1" xlink:title="label: TaxCreditCarryforwardLineItems to us-gaap_TaxCreditCarryforwardLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="TaxCreditCarryforwardAmount" xlink:title="TaxCreditCarryforwardAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardAmount_lbl">Tax credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:title="label: TaxCreditCarryforwardAmount to us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardAmount_lbl1" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardAmount_lbl1">Tax Credit Carryforward, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl1" xlink:title="label: TaxCreditCarryforwardAmount to us-gaap_TaxCreditCarryforwardAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="TaxCreditCarryforwardTable" xlink:title="TaxCreditCarryforwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardTable_lbl" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardTable_lbl">Tax Credit Carryforward [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardTable" xlink:to="us-gaap_TaxCreditCarryforwardTable_lbl" xlink:title="label: TaxCreditCarryforwardTable to us-gaap_TaxCreditCarryforwardTable_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardNameDomain_lbl">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:title="label: TaxCreditCarryforwardNameDomain to us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardAxis_lbl">Tax Credit Carryforward [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:title="label: TaxCreditCarryforwardAxis to us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:label="TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:title="TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_lbl" xml:lang="en-US" id="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_lbl">Unbilled SPINRAZA Royalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_lbl" xlink:title="label: TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy to us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_lbl1" xml:lang="en-US" id="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_lbl1">Trade and Other Accounts Receivable, Unbilled Receivables, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_lbl1" xlink:title="label: TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy to us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" id="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:title="label: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US" id="us-gaap_TypeOfAdoptionMember_lbl">Type of Adoption [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" xlink:title="label: TypeOfAdoptionMember to us-gaap_TypeOfAdoptionMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="us-gaap_TypeOfArrangementAxis_lbl">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:title="label: TypeOfArrangementAxis to us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_TypeOfArrangementAxis_lbl1" xml:lang="en-US" id="us-gaap_TypeOfArrangementAxis_lbl1">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl1" xlink:title="label: TypeOfArrangementAxis to us-gaap_TypeOfArrangementAxis_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:title="UnrealizedGainLossOnInvestmentsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl" xml:lang="en-US" id="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl">Summary of Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl" xlink:title="label: UnrealizedGainLossOnInvestmentsTableTextBlock to us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl1">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl1" xlink:title="label: UnrealizedGainLossOnInvestmentsTableTextBlock to us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:title="UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl">Increase for prior period tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:title="label: UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions to us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl1" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl1">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl1" xlink:title="label: UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions to us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefits_lbl">Ending balance of unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:title="label: UnrecognizedTaxBenefits to us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_UnrecognizedTaxBenefits_lbl1" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefits_lbl1">Beginning balance of unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl1" xlink:title="label: UnrecognizedTaxBenefits to us-gaap_UnrecognizedTaxBenefits_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrecognizedTaxBenefits_lbl2" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefits_lbl2">Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl2" xlink:title="label: UnrecognizedTaxBenefits to us-gaap_UnrecognizedTaxBenefits_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:title="UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl">Unrecognized tax benefits that could impact effective tax rate, if recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:title="label: UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate to us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:title="UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl">Decrease for prior period tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:title="label: UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions to us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl1" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl1">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl1" xlink:title="label: UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions to us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:title="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl">Interest and penalties on unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:title="label: UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense to us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl1" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl1">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl1" xlink:title="label: UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense to us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:title="UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl">Increase for current period tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:title="label: UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions to us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl1" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl1">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl1" xlink:title="label: UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions to us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="us-gaap_UseOfEstimates_lbl">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UseOfEstimates_lbl1" xml:lang="en-US" id="us-gaap_UseOfEstimates_lbl1">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl1" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="USGovernmentAgenciesDebtSecuritiesMember" xlink:title="USGovernmentAgenciesDebtSecuritiesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xml:lang="en-US" id="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl">Debt Securities issued by U.S. Government Agencies [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:title="label: USGovernmentAgenciesDebtSecuritiesMember to us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl1" xml:lang="en-US" id="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl1">US Government Agencies Debt Securities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl1" xlink:title="label: USGovernmentAgenciesDebtSecuritiesMember to us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="USStatesAndPoliticalSubdivisionsMember" xlink:title="USStatesAndPoliticalSubdivisionsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl" xml:lang="en-US" id="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl">Debt Securities issued by States of the U.S. and Political Subdivisions of the States [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="USStatesAndPoliticalSubdivisionsMember" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl" xlink:title="label: USStatesAndPoliticalSubdivisionsMember to us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl1" xml:lang="en-US" id="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl1">US States and Political Subdivisions Debt Securities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="USStatesAndPoliticalSubdivisionsMember" xlink:to="us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl1" xlink:title="label: USStatesAndPoliticalSubdivisionsMember to us-gaap_USStatesAndPoliticalSubdivisionsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="USTreasurySecuritiesMember" xlink:title="USTreasurySecuritiesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_USTreasurySecuritiesMember_lbl" xml:lang="en-US" id="us-gaap_USTreasurySecuritiesMember_lbl">Debt Securities issued by the U.S. Treasury [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl" xlink:title="label: USTreasurySecuritiesMember to us-gaap_USTreasurySecuritiesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_USTreasurySecuritiesMember_lbl1" xml:lang="en-US" id="us-gaap_USTreasurySecuritiesMember_lbl1">US Treasury Securities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl1" xlink:title="label: USTreasurySecuritiesMember to us-gaap_USTreasurySecuritiesMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_VestingAxis_lbl" xml:lang="en-US" id="us-gaap_VestingAxis_lbl">Vesting [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xlink:title="label: VestingAxis to us-gaap_VestingAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_VestingDomain_lbl" xml:lang="en-US" id="us-gaap_VestingDomain_lbl">Vesting [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xlink:title="label: VestingDomain to us-gaap_VestingDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:label="ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:title="ValuationAllowancesAndReservesPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl">Decrease in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:to="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl" xlink:title="label: ValuationAllowancesAndReservesPeriodIncreaseDecrease to us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl1" xml:lang="en-US" id="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl1">SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:to="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl1" xlink:title="label: ValuationAllowancesAndReservesPeriodIncreaseDecrease to us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl">Shares used in computing basic net income per share (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1">Shares used in computing basic net income (loss) per share (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl">Shares used in computing diluted net income per share (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1">Shares used in computing diluted net income per share (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl2" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl2">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl2" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:title="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl">Effect of Diluted Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl" xlink:title="label: WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract to us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl">Shares (Denominator) [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xlink:title="label: WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract to us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl1" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl1">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl1" xlink:title="label: WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract to us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:label xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" id="srt_CounterpartyNameAxis_lbl">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xlink:title="label: CounterpartyNameAxis to srt_CounterpartyNameAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ConsolidatedEntitiesDomain_lbl" xml:lang="en-US" id="srt_ConsolidatedEntitiesDomain_lbl">Consolidated Entities [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl" xlink:title="label: ConsolidatedEntitiesDomain to srt_ConsolidatedEntitiesDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:label xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US" id="srt_ConsolidatedEntitiesAxis_lbl">Consolidated Entities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" xlink:title="label: ConsolidatedEntitiesAxis to srt_ConsolidatedEntitiesAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain" xlink:title="ConsolidationItemsDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ConsolidationItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ConsolidationItemsDomain_lbl" xml:lang="en-US" id="srt_ConsolidationItemsDomain_lbl">Consolidation Items [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl" xlink:title="label: ConsolidationItemsDomain to srt_ConsolidationItemsDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="ConsolidationItemsAxis" xlink:title="ConsolidationItemsAxis" />
    <link:label xlink:type="resource" xlink:label="srt_ConsolidationItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ConsolidationItemsAxis_lbl" xml:lang="en-US" id="srt_ConsolidationItemsAxis_lbl">Consolidation Items [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl" xlink:title="label: ConsolidationItemsAxis to srt_ConsolidationItemsAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:title="ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xml:lang="en-US" id="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl">Maturity Schedules</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" xlink:title="label: ContractualObligationFiscalYearMaturityScheduleTableTextBlock to srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl1" xml:lang="en-US" id="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl1">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl1" xlink:title="label: ContractualObligationFiscalYearMaturityScheduleTableTextBlock to srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:label xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MajorCustomersAxis_lbl" xml:lang="en-US" id="srt_MajorCustomersAxis_lbl">Customer [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:title="label: MajorCustomersAxis to srt_MajorCustomersAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="srt_MaximumMember_lbl" xml:lang="en-US" id="srt_MaximumMember_lbl">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:title="label: MaximumMember to srt_MaximumMember_lbl" />
    <link:label xlink:type="resource" xlink:label="srt_MaximumMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MaximumMember_lbl1" xml:lang="en-US" id="srt_MaximumMember_lbl1">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="srt_MaximumMember_lbl1" xlink:title="label: MaximumMember to srt_MaximumMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="srt_MinimumMember_lbl" xml:lang="en-US" id="srt_MinimumMember_lbl">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:title="label: MinimumMember to srt_MinimumMember_lbl" />
    <link:label xlink:type="resource" xlink:label="srt_MinimumMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MinimumMember_lbl1" xml:lang="en-US" id="srt_MinimumMember_lbl1">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="srt_MinimumMember_lbl1" xlink:title="label: MinimumMember to srt_MinimumMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:label xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" id="srt_NameOfMajorCustomerDomain_lbl">Customer [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" xlink:title="label: NameOfMajorCustomerDomain to srt_NameOfMajorCustomerDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:label xlink:type="resource" xlink:label="srt_OwnershipAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_OwnershipAxis_lbl" xml:lang="en-US" id="srt_OwnershipAxis_lbl">Ownership [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xlink:title="label: OwnershipAxis to srt_OwnershipAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:label xlink:type="resource" xlink:label="srt_OwnershipDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_OwnershipDomain_lbl" xml:lang="en-US" id="srt_OwnershipDomain_lbl">Ownership [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" xlink:title="label: OwnershipDomain to srt_OwnershipDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US" id="srt_ProductsAndServicesDomain_lbl">Products and Services [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" xlink:title="label: ProductsAndServicesDomain to srt_ProductsAndServicesDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:label xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ProductOrServiceAxis_lbl" xml:lang="en-US" id="srt_ProductOrServiceAxis_lbl">Products and Services [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:title="label: ProductOrServiceAxis to srt_ProductOrServiceAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeMember_lbl" xml:lang="en-US" id="srt_RangeMember_lbl">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="srt_RangeMember_lbl" xlink:title="label: RangeMember to srt_RangeMember_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeAxis_lbl" xml:lang="en-US" id="srt_RangeAxis_lbl">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:title="label: RangeAxis to srt_RangeAxis_lbl" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" id="srt_RepurchaseAgreementCounterpartyNameDomain_lbl">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:title="label: RepurchaseAgreementCounterpartyNameDomain to srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:title="CollaborativeArrangementsAndLicensingAgreementsAbstract" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementsAndLicensingAgreementsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementsAndLicensingAgreementsAbstract_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementsAndLicensingAgreementsAbstract_lbl1">Collaborative Arrangements and Licensing Agreements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:to="ions_CollaborativeArrangementsAndLicensingAgreementsAbstract_lbl1" xlink:title="label: CollaborativeArrangementsAndLicensingAgreementsAbstract to ions_CollaborativeArrangementsAndLicensingAgreementsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermDebtAndOtherObligationsNoncurrent" xlink:label="LongTermDebtAndOtherObligationsNoncurrent" xlink:title="LongTermDebtAndOtherObligationsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="ions_LongTermDebtAndOtherObligationsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_LongTermDebtAndOtherObligationsNoncurrent_lbl" xml:lang="en-US" id="ions_LongTermDebtAndOtherObligationsNoncurrent_lbl">Amount of long-term debt, capital lease and other obligations due after one year or beyond the normal operating cycle, if longer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtAndOtherObligationsNoncurrent" xlink:to="ions_LongTermDebtAndOtherObligationsNoncurrent_lbl" xlink:title="label: LongTermDebtAndOtherObligationsNoncurrent to ions_LongTermDebtAndOtherObligationsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_LongTermDebtAndOtherObligationsNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_LongTermDebtAndOtherObligationsNoncurrent_lbl1" xml:lang="en-US" id="ions_LongTermDebtAndOtherObligationsNoncurrent_lbl1">Long-term Debt and Other Obligations, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtAndOtherObligationsNoncurrent" xlink:to="ions_LongTermDebtAndOtherObligationsNoncurrent_lbl1" xlink:title="label: LongTermDebtAndOtherObligationsNoncurrent to ions_LongTermDebtAndOtherObligationsNoncurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_LongTermDebtAndOtherObligationsNoncurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_LongTermDebtAndOtherObligationsNoncurrent_lbl2" xml:lang="en-US" id="ions_LongTermDebtAndOtherObligationsNoncurrent_lbl2">Total Long-Term Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtAndOtherObligationsNoncurrent" xlink:to="ions_LongTermDebtAndOtherObligationsNoncurrent_lbl2" xlink:title="label: LongTermDebtAndOtherObligationsNoncurrent to ions_LongTermDebtAndOtherObligationsNoncurrent_lbl2" />
    <link:label xlink:type="resource" xlink:label="ions_LongTermDebtAndOtherObligationsNoncurrent_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ions_LongTermDebtAndOtherObligationsNoncurrent_lbl3" xml:lang="en-US" id="ions_LongTermDebtAndOtherObligationsNoncurrent_lbl3">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtAndOtherObligationsNoncurrent" xlink:to="ions_LongTermDebtAndOtherObligationsNoncurrent_lbl3" xlink:title="label: LongTermDebtAndOtherObligationsNoncurrent to ions_LongTermDebtAndOtherObligationsNoncurrent_lbl3" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LeasesAndOtherObligationsMember" xlink:label="LeasesAndOtherObligationsMember" xlink:title="LeasesAndOtherObligationsMember" />
    <link:label xlink:type="resource" xlink:label="ions_LeasesAndOtherObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_LeasesAndOtherObligationsMember_lbl" xml:lang="en-US" id="ions_LeasesAndOtherObligationsMember_lbl">Details pertaining to leases and other obligations not separately disclosed in the financial statements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeasesAndOtherObligationsMember" xlink:to="ions_LeasesAndOtherObligationsMember_lbl" xlink:title="label: LeasesAndOtherObligationsMember to ions_LeasesAndOtherObligationsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_LeasesAndOtherObligationsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_LeasesAndOtherObligationsMember_lbl1" xml:lang="en-US" id="ions_LeasesAndOtherObligationsMember_lbl1">Leases and Other Obligations [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeasesAndOtherObligationsMember" xlink:to="ions_LeasesAndOtherObligationsMember_lbl1" xlink:title="label: LeasesAndOtherObligationsMember to ions_LeasesAndOtherObligationsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_FixedRateNoteWithMorganStanleyMember" xlink:label="FixedRateNoteWithMorganStanleyMember" xlink:title="FixedRateNoteWithMorganStanleyMember" />
    <link:label xlink:type="resource" xlink:label="ions_FixedRateNoteWithMorganStanleyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_FixedRateNoteWithMorganStanleyMember_lbl" xml:lang="en-US" id="ions_FixedRateNoteWithMorganStanleyMember_lbl">Fixed rate note with Morgan Stanley Private Bank, National Association under a five-year revolving credit agreement dated June 16, 2015 and amended February 24, 2016.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FixedRateNoteWithMorganStanleyMember" xlink:to="ions_FixedRateNoteWithMorganStanleyMember_lbl" xlink:title="label: FixedRateNoteWithMorganStanleyMember to ions_FixedRateNoteWithMorganStanleyMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_FixedRateNoteWithMorganStanleyMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_FixedRateNoteWithMorganStanleyMember_lbl1" xml:lang="en-US" id="ions_FixedRateNoteWithMorganStanleyMember_lbl1">Fixed Rate Note with Morgan Stanley [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FixedRateNoteWithMorganStanleyMember" xlink:to="ions_FixedRateNoteWithMorganStanleyMember_lbl1" xlink:title="label: FixedRateNoteWithMorganStanleyMember to ions_FixedRateNoteWithMorganStanleyMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_FixedRateNoteWithMorganStanleyMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_FixedRateNoteWithMorganStanleyMember_lbl2" xml:lang="en-US" id="ions_FixedRateNoteWithMorganStanleyMember_lbl2">Fixed Rate Note with Morgan Stanley [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FixedRateNoteWithMorganStanleyMember" xlink:to="ions_FixedRateNoteWithMorganStanleyMember_lbl2" xlink:title="label: FixedRateNoteWithMorganStanleyMember to ions_FixedRateNoteWithMorganStanleyMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermMortgageDebtMember" xlink:label="LongTermMortgageDebtMember" xlink:title="LongTermMortgageDebtMember" />
    <link:label xlink:type="resource" xlink:label="ions_LongTermMortgageDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_LongTermMortgageDebtMember_lbl" xml:lang="en-US" id="ions_LongTermMortgageDebtMember_lbl">Two loan agreements with UBS AG entered into on July 18, 2017 to partially finance the purchase of the Company's research and development and manufacturing facilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermMortgageDebtMember" xlink:to="ions_LongTermMortgageDebtMember_lbl" xlink:title="label: LongTermMortgageDebtMember to ions_LongTermMortgageDebtMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_LongTermMortgageDebtMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_LongTermMortgageDebtMember_lbl1" xml:lang="en-US" id="ions_LongTermMortgageDebtMember_lbl1">Long-term Mortgage Debt [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermMortgageDebtMember" xlink:to="ions_LongTermMortgageDebtMember_lbl1" xlink:title="label: LongTermMortgageDebtMember to ions_LongTermMortgageDebtMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_LongTermMortgageDebtMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_LongTermMortgageDebtMember_lbl2" xml:lang="en-US" id="ions_LongTermMortgageDebtMember_lbl2">Long-term Mortgage Debt [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermMortgageDebtMember" xlink:to="ions_LongTermMortgageDebtMember_lbl2" xlink:title="label: LongTermMortgageDebtMember to ions_LongTermMortgageDebtMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermDebtAndOtherObligations" xlink:label="LongTermDebtAndOtherObligations" xlink:title="LongTermDebtAndOtherObligations" />
    <link:label xlink:type="resource" xlink:label="ions_LongTermDebtAndOtherObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_LongTermDebtAndOtherObligations_lbl" xml:lang="en-US" id="ions_LongTermDebtAndOtherObligations_lbl">Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of long-term debt, capital lease and other obligations (with maturities initially due after one year or beyond the operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtAndOtherObligations" xlink:to="ions_LongTermDebtAndOtherObligations_lbl" xlink:title="label: LongTermDebtAndOtherObligations to ions_LongTermDebtAndOtherObligations_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_LongTermDebtAndOtherObligations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_LongTermDebtAndOtherObligations_lbl1" xml:lang="en-US" id="ions_LongTermDebtAndOtherObligations_lbl1">Long-term Debt and Other Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtAndOtherObligations" xlink:to="ions_LongTermDebtAndOtherObligations_lbl1" xlink:title="label: LongTermDebtAndOtherObligations to ions_LongTermDebtAndOtherObligations_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_LongTermDebtAndOtherObligations_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ions_LongTermDebtAndOtherObligations_lbl2" xml:lang="en-US" id="ions_LongTermDebtAndOtherObligations_lbl2">Total long-term obligations, including current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtAndOtherObligations" xlink:to="ions_LongTermDebtAndOtherObligations_lbl2" xlink:title="label: LongTermDebtAndOtherObligations to ions_LongTermDebtAndOtherObligations_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes1PercentMember" xlink:label="ConvertibleSeniorNotes1PercentMember" xlink:title="ConvertibleSeniorNotes1PercentMember" />
    <link:label xlink:type="resource" xlink:label="ions_ConvertibleSeniorNotes1PercentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ConvertibleSeniorNotes1PercentMember_lbl" xml:lang="en-US" id="ions_ConvertibleSeniorNotes1PercentMember_lbl">1 percent convertible senior notes due November 2021.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes1PercentMember" xlink:to="ions_ConvertibleSeniorNotes1PercentMember_lbl" xlink:title="label: ConvertibleSeniorNotes1PercentMember to ions_ConvertibleSeniorNotes1PercentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ConvertibleSeniorNotes1PercentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ConvertibleSeniorNotes1PercentMember_lbl1" xml:lang="en-US" id="ions_ConvertibleSeniorNotes1PercentMember_lbl1">Convertible Senior Notes 1 Percent [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes1PercentMember" xlink:to="ions_ConvertibleSeniorNotes1PercentMember_lbl1" xlink:title="label: ConvertibleSeniorNotes1PercentMember to ions_ConvertibleSeniorNotes1PercentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ConvertibleSeniorNotes1PercentMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ConvertibleSeniorNotes1PercentMember_lbl2" xml:lang="en-US" id="ions_ConvertibleSeniorNotes1PercentMember_lbl2">1 Percent Convertible Senior Notes [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes1PercentMember" xlink:to="ions_ConvertibleSeniorNotes1PercentMember_lbl2" xlink:title="label: ConvertibleSeniorNotes1PercentMember to ions_ConvertibleSeniorNotes1PercentMember_lbl2" />
    <link:label xlink:type="resource" xlink:label="ions_ConvertibleSeniorNotes1PercentMember_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ions_ConvertibleSeniorNotes1PercentMember_lbl3" xml:lang="en-US" id="ions_ConvertibleSeniorNotes1PercentMember_lbl3">1% Convertible Senior Notes [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes1PercentMember" xlink:to="ions_ConvertibleSeniorNotes1PercentMember_lbl3" xlink:title="label: ConvertibleSeniorNotes1PercentMember to ions_ConvertibleSeniorNotes1PercentMember_lbl3" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentMember" xlink:label="ConvertibleSeniorNotes0125PercentMember" xlink:title="ConvertibleSeniorNotes0125PercentMember" />
    <link:label xlink:type="resource" xlink:label="ions_ConvertibleSeniorNotes0125PercentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ConvertibleSeniorNotes0125PercentMember_lbl" xml:lang="en-US" id="ions_ConvertibleSeniorNotes0125PercentMember_lbl">0.125 percent convertible senior notes due December 2024.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes0125PercentMember" xlink:to="ions_ConvertibleSeniorNotes0125PercentMember_lbl" xlink:title="label: ConvertibleSeniorNotes0125PercentMember to ions_ConvertibleSeniorNotes0125PercentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ConvertibleSeniorNotes0125PercentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ConvertibleSeniorNotes0125PercentMember_lbl1" xml:lang="en-US" id="ions_ConvertibleSeniorNotes0125PercentMember_lbl1">Convertible Senior Notes 0.125 Percent [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes0125PercentMember" xlink:to="ions_ConvertibleSeniorNotes0125PercentMember_lbl1" xlink:title="label: ConvertibleSeniorNotes0125PercentMember to ions_ConvertibleSeniorNotes0125PercentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ConvertibleSeniorNotes0125PercentMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ConvertibleSeniorNotes0125PercentMember_lbl2" xml:lang="en-US" id="ions_ConvertibleSeniorNotes0125PercentMember_lbl2">0.125 Percent Convertible Senior Notes [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes0125PercentMember" xlink:to="ions_ConvertibleSeniorNotes0125PercentMember_lbl2" xlink:title="label: ConvertibleSeniorNotes0125PercentMember to ions_ConvertibleSeniorNotes0125PercentMember_lbl2" />
    <link:label xlink:type="resource" xlink:label="ions_ConvertibleSeniorNotes0125PercentMember_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ions_ConvertibleSeniorNotes0125PercentMember_lbl3" xml:lang="en-US" id="ions_ConvertibleSeniorNotes0125PercentMember_lbl3">0.125% Convertible Senior Notes [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes0125PercentMember" xlink:to="ions_ConvertibleSeniorNotes0125PercentMember_lbl3" xlink:title="label: ConvertibleSeniorNotes0125PercentMember to ions_ConvertibleSeniorNotes0125PercentMember_lbl3" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MorganStanleyPrivateBankNationalAssociationMember" xlink:label="MorganStanleyPrivateBankNationalAssociationMember" xlink:title="MorganStanleyPrivateBankNationalAssociationMember" />
    <link:label xlink:type="resource" xlink:label="ions_MorganStanleyPrivateBankNationalAssociationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MorganStanleyPrivateBankNationalAssociationMember_lbl" xml:lang="en-US" id="ions_MorganStanleyPrivateBankNationalAssociationMember_lbl">Morgan Stanley Private Bank, National Association offers banking and credit products and services. The company was founded in 1996 and is based in Purchase, New York. Morgan Stanley Private Bank, National Association operates as a subsidiary of Morgan Stanley.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MorganStanleyPrivateBankNationalAssociationMember" xlink:to="ions_MorganStanleyPrivateBankNationalAssociationMember_lbl" xlink:title="label: MorganStanleyPrivateBankNationalAssociationMember to ions_MorganStanleyPrivateBankNationalAssociationMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MorganStanleyPrivateBankNationalAssociationMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MorganStanleyPrivateBankNationalAssociationMember_lbl1" xml:lang="en-US" id="ions_MorganStanleyPrivateBankNationalAssociationMember_lbl1">Morgan Stanley Private Bank, National Association [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MorganStanleyPrivateBankNationalAssociationMember" xlink:to="ions_MorganStanleyPrivateBankNationalAssociationMember_lbl1" xlink:title="label: MorganStanleyPrivateBankNationalAssociationMember to ions_MorganStanleyPrivateBankNationalAssociationMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_MorganStanleyPrivateBankNationalAssociationMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_MorganStanleyPrivateBankNationalAssociationMember_lbl2" xml:lang="en-US" id="ions_MorganStanleyPrivateBankNationalAssociationMember_lbl2">Morgan Stanley [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MorganStanleyPrivateBankNationalAssociationMember" xlink:to="ions_MorganStanleyPrivateBankNationalAssociationMember_lbl2" xlink:title="label: MorganStanleyPrivateBankNationalAssociationMember to ions_MorganStanleyPrivateBankNationalAssociationMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SharesReceivedFromSubsidiaryForLicenseOfDrug" xlink:label="SharesReceivedFromSubsidiaryForLicenseOfDrug" xlink:title="SharesReceivedFromSubsidiaryForLicenseOfDrug" />
    <link:label xlink:type="resource" xlink:label="ions_SharesReceivedFromSubsidiaryForLicenseOfDrug_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_SharesReceivedFromSubsidiaryForLicenseOfDrug_lbl" xml:lang="en-US" id="ions_SharesReceivedFromSubsidiaryForLicenseOfDrug_lbl">The number of additional shares of stock received from Akcea Therapeutics, Inc. as a sublicense fee in connection with Pfizer licensing AKCEA-ANGPTL3-L.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesReceivedFromSubsidiaryForLicenseOfDrug" xlink:to="ions_SharesReceivedFromSubsidiaryForLicenseOfDrug_lbl" xlink:title="label: SharesReceivedFromSubsidiaryForLicenseOfDrug to ions_SharesReceivedFromSubsidiaryForLicenseOfDrug_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_SharesReceivedFromSubsidiaryForLicenseOfDrug_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_SharesReceivedFromSubsidiaryForLicenseOfDrug_lbl1" xml:lang="en-US" id="ions_SharesReceivedFromSubsidiaryForLicenseOfDrug_lbl1">Shares received from subsidiary for license of drug</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesReceivedFromSubsidiaryForLicenseOfDrug" xlink:to="ions_SharesReceivedFromSubsidiaryForLicenseOfDrug_lbl1" xlink:title="label: SharesReceivedFromSubsidiaryForLicenseOfDrug to ions_SharesReceivedFromSubsidiaryForLicenseOfDrug_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_SharesReceivedFromSubsidiaryForLicenseOfDrug_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_SharesReceivedFromSubsidiaryForLicenseOfDrug_lbl2" xml:lang="en-US" id="ions_SharesReceivedFromSubsidiaryForLicenseOfDrug_lbl2">Additional shares of Akcea stock received for license of AKCEA-ANGPTL3-L</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesReceivedFromSubsidiaryForLicenseOfDrug" xlink:to="ions_SharesReceivedFromSubsidiaryForLicenseOfDrug_lbl2" xlink:title="label: SharesReceivedFromSubsidiaryForLicenseOfDrug to ions_SharesReceivedFromSubsidiaryForLicenseOfDrug_lbl2" />
    <link:label xlink:type="resource" xlink:label="ions_SharesReceivedFromSubsidiaryForLicenseOfDrug_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ions_SharesReceivedFromSubsidiaryForLicenseOfDrug_lbl3" xml:lang="en-US" id="ions_SharesReceivedFromSubsidiaryForLicenseOfDrug_lbl3">Additional shares of Akcea stock received for license of drug</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesReceivedFromSubsidiaryForLicenseOfDrug" xlink:to="ions_SharesReceivedFromSubsidiaryForLicenseOfDrug_lbl3" xlink:title="label: SharesReceivedFromSubsidiaryForLicenseOfDrug to ions_SharesReceivedFromSubsidiaryForLicenseOfDrug_lbl3" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:label xlink:type="resource" xlink:label="ions_AkceaTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_AkceaTherapeuticsIncMember_lbl" xml:lang="en-US" id="ions_AkceaTherapeuticsIncMember_lbl">Akcea Therapeutics, Inc. is a subsidiary of the Company and was formed to develop and commercialize drugs for cardiometabolic disorders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AkceaTherapeuticsIncMember" xlink:to="ions_AkceaTherapeuticsIncMember_lbl" xlink:title="label: AkceaTherapeuticsIncMember to ions_AkceaTherapeuticsIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_AkceaTherapeuticsIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_AkceaTherapeuticsIncMember_lbl1" xml:lang="en-US" id="ions_AkceaTherapeuticsIncMember_lbl1">Akcea Therapeutics, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AkceaTherapeuticsIncMember" xlink:to="ions_AkceaTherapeuticsIncMember_lbl1" xlink:title="label: AkceaTherapeuticsIncMember to ions_AkceaTherapeuticsIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_AkceaTherapeuticsIncMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_AkceaTherapeuticsIncMember_lbl2" xml:lang="en-US" id="ions_AkceaTherapeuticsIncMember_lbl2">Akcea [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AkceaTherapeuticsIncMember" xlink:to="ions_AkceaTherapeuticsIncMember_lbl2" xlink:title="label: AkceaTherapeuticsIncMember to ions_AkceaTherapeuticsIncMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember" xlink:label="OfficeSpaceSubleasedToAkceaTherapeuticsIncMember" xlink:title="OfficeSpaceSubleasedToAkceaTherapeuticsIncMember" />
    <link:label xlink:type="resource" xlink:label="ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember_lbl" xml:lang="en-US" id="ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember_lbl">Office space subleased to Akcea Therapeutics, Inc. (Akcea) leased under non-cancelable operating leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OfficeSpaceSubleasedToAkceaTherapeuticsIncMember" xlink:to="ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember_lbl" xlink:title="label: OfficeSpaceSubleasedToAkceaTherapeuticsIncMember to ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember_lbl1" xml:lang="en-US" id="ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember_lbl1">Office Space Subleased to Akcea Therapeutics, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OfficeSpaceSubleasedToAkceaTherapeuticsIncMember" xlink:to="ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember_lbl1" xlink:title="label: OfficeSpaceSubleasedToAkceaTherapeuticsIncMember to ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember_lbl2" xml:lang="en-US" id="ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember_lbl2">Office Space Subleased to Akcea [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OfficeSpaceSubleasedToAkceaTherapeuticsIncMember" xlink:to="ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember_lbl2" xlink:title="label: OfficeSpaceSubleasedToAkceaTherapeuticsIncMember to ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LesseeOperatingLeasePeriodOfFreeRent" xlink:label="LesseeOperatingLeasePeriodOfFreeRent" xlink:title="LesseeOperatingLeasePeriodOfFreeRent" />
    <link:label xlink:type="resource" xlink:label="ions_LesseeOperatingLeasePeriodOfFreeRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_LesseeOperatingLeasePeriodOfFreeRent_lbl" xml:lang="en-US" id="ions_LesseeOperatingLeasePeriodOfFreeRent_lbl">Period of time in which the rent is free under operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeasePeriodOfFreeRent" xlink:to="ions_LesseeOperatingLeasePeriodOfFreeRent_lbl" xlink:title="label: LesseeOperatingLeasePeriodOfFreeRent to ions_LesseeOperatingLeasePeriodOfFreeRent_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_LesseeOperatingLeasePeriodOfFreeRent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_LesseeOperatingLeasePeriodOfFreeRent_lbl1" xml:lang="en-US" id="ions_LesseeOperatingLeasePeriodOfFreeRent_lbl1">Lessee, Operating Lease, Period of Free Rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeasePeriodOfFreeRent" xlink:to="ions_LesseeOperatingLeasePeriodOfFreeRent_lbl1" xlink:title="label: LesseeOperatingLeasePeriodOfFreeRent to ions_LesseeOperatingLeasePeriodOfFreeRent_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_LesseeOperatingLeasePeriodOfFreeRent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_LesseeOperatingLeasePeriodOfFreeRent_lbl2" xml:lang="en-US" id="ions_LesseeOperatingLeasePeriodOfFreeRent_lbl2">Period of free rent under lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeasePeriodOfFreeRent" xlink:to="ions_LesseeOperatingLeasePeriodOfFreeRent_lbl2" xlink:title="label: LesseeOperatingLeasePeriodOfFreeRent to ions_LesseeOperatingLeasePeriodOfFreeRent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LesseeOperatingLeaseAllowanceForTenantImprovements" xlink:label="LesseeOperatingLeaseAllowanceForTenantImprovements" xlink:title="LesseeOperatingLeaseAllowanceForTenantImprovements" />
    <link:label xlink:type="resource" xlink:label="ions_LesseeOperatingLeaseAllowanceForTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_LesseeOperatingLeaseAllowanceForTenantImprovements_lbl" xml:lang="en-US" id="ions_LesseeOperatingLeaseAllowanceForTenantImprovements_lbl">Allowance for tenant improvements to the office space included in the lessee's operating lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseAllowanceForTenantImprovements" xlink:to="ions_LesseeOperatingLeaseAllowanceForTenantImprovements_lbl" xlink:title="label: LesseeOperatingLeaseAllowanceForTenantImprovements to ions_LesseeOperatingLeaseAllowanceForTenantImprovements_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_LesseeOperatingLeaseAllowanceForTenantImprovements_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_LesseeOperatingLeaseAllowanceForTenantImprovements_lbl1" xml:lang="en-US" id="ions_LesseeOperatingLeaseAllowanceForTenantImprovements_lbl1">Lessee, Operating Lease, Allowance for Tenant Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseAllowanceForTenantImprovements" xlink:to="ions_LesseeOperatingLeaseAllowanceForTenantImprovements_lbl1" xlink:title="label: LesseeOperatingLeaseAllowanceForTenantImprovements to ions_LesseeOperatingLeaseAllowanceForTenantImprovements_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_LesseeOperatingLeaseAllowanceForTenantImprovements_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_LesseeOperatingLeaseAllowanceForTenantImprovements_lbl2" xml:lang="en-US" id="ions_LesseeOperatingLeaseAllowanceForTenantImprovements_lbl2">Tenant improvement allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseAllowanceForTenantImprovements" xlink:to="ions_LesseeOperatingLeaseAllowanceForTenantImprovements_lbl2" xlink:title="label: LesseeOperatingLeaseAllowanceForTenantImprovements to ions_LesseeOperatingLeaseAllowanceForTenantImprovements_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_OfficeSpaceForCorporateHeadquartersMember" xlink:label="OfficeSpaceForCorporateHeadquartersMember" xlink:title="OfficeSpaceForCorporateHeadquartersMember" />
    <link:label xlink:type="resource" xlink:label="ions_OfficeSpaceForCorporateHeadquartersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_OfficeSpaceForCorporateHeadquartersMember_lbl" xml:lang="en-US" id="ions_OfficeSpaceForCorporateHeadquartersMember_lbl">Office space located in Boston, Massachusetts for Akcea Therapeutics, Inc.'s corporate headquarters leased under non-cancelable operating leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OfficeSpaceForCorporateHeadquartersMember" xlink:to="ions_OfficeSpaceForCorporateHeadquartersMember_lbl" xlink:title="label: OfficeSpaceForCorporateHeadquartersMember to ions_OfficeSpaceForCorporateHeadquartersMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_OfficeSpaceForCorporateHeadquartersMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_OfficeSpaceForCorporateHeadquartersMember_lbl1" xml:lang="en-US" id="ions_OfficeSpaceForCorporateHeadquartersMember_lbl1">Office Space for Corporate Headquarters [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OfficeSpaceForCorporateHeadquartersMember" xlink:to="ions_OfficeSpaceForCorporateHeadquartersMember_lbl1" xlink:title="label: OfficeSpaceForCorporateHeadquartersMember to ions_OfficeSpaceForCorporateHeadquartersMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate" xlink:label="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate" xlink:title="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate" />
    <link:label xlink:type="resource" xlink:label="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate_lbl" xml:lang="en-US" id="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate_lbl">Letter of credit provided to lessor to secure lease obligation under lessee's operating lease on the fifth anniversary of the rent commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate" xlink:to="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate_lbl" xlink:title="label: LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate to ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate_lbl1" xml:lang="en-US" id="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate_lbl1">Lessee, Operating Lease, Letter of Credit to Secure Lease Obligation on Fifth Anniversary of Rent Commencement Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate" xlink:to="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate_lbl1" xlink:title="label: LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate to ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate_lbl2" xml:lang="en-US" id="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate_lbl2">Letter of credit on fifth anniversary of rent commencement date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate" xlink:to="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate_lbl2" xlink:title="label: LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate to ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate" xlink:label="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate" xlink:title="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate" />
    <link:label xlink:type="resource" xlink:label="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate_lbl" xml:lang="en-US" id="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate_lbl">Letter of credit provided to lessor to secure lease obligation under lessee's operating lease on the third anniversary of the rent commencement date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate" xlink:to="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate_lbl" xlink:title="label: LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate to ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate_lbl1" xml:lang="en-US" id="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate_lbl1">Lessee, Operating Lease, Letter of Credit to Secure Lease Obligation on Third Anniversary of Rent Commencement Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate" xlink:to="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate_lbl1" xlink:title="label: LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate to ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate_lbl2" xml:lang="en-US" id="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate_lbl2">Letter of credit on third anniversary of rent commencement date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate" xlink:to="ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate_lbl2" xlink:title="label: LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate to ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember" xlink:label="OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember" xlink:title="OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember" />
    <link:label xlink:type="resource" xlink:label="ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember_lbl" xml:lang="en-US" id="ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember_lbl">Office and laboratory space in a facility adjacent to the Company's manufacturing facility leased under non-cancelable operating leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember" xlink:to="ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember_lbl" xlink:title="label: OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember to ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember_lbl1" xml:lang="en-US" id="ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember_lbl1">Office and Laboratory Space Adjacent to Manufacturing Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember" xlink:to="ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember_lbl1" xlink:title="label: OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember to ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember_lbl2" xml:lang="en-US" id="ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember_lbl2">Office and Laboratory Space Adjacent to Manufacturing Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember" xlink:to="ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember_lbl2" xlink:title="label: OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember to ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease" xlink:label="LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease" xlink:title="LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease" />
    <link:label xlink:type="resource" xlink:label="ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease_lbl" xml:lang="en-US" id="ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease_lbl">The number of options to extend the lease under the lessee's operating leasing arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease" xlink:to="ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease_lbl" xlink:title="label: LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease to ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease_lbl1" xml:lang="en-US" id="ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease_lbl1">Lessee, Leasing Arrangements, Operating Leases, Number of options to extend lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease" xlink:to="ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease_lbl1" xlink:title="label: LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease to ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease_lbl2" xml:lang="en-US" id="ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease_lbl2">Number of options to extend lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease" xlink:to="ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease_lbl2" xlink:title="label: LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease to ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation" xlink:label="LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation" xlink:title="LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation" />
    <link:label xlink:type="resource" xlink:label="ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation_lbl" xml:lang="en-US" id="ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation_lbl">Initial letter of credit provided to lessor to secure lease obligation under lessee's operating lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation" xlink:to="ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation_lbl" xlink:title="label: LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation to ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation_lbl1" xml:lang="en-US" id="ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation_lbl1">Lessee, Operating Lease, Initial Letter of Credit to Secure Lease Obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation" xlink:to="ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation_lbl1" xlink:title="label: LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation to ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation_lbl2" xml:lang="en-US" id="ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation_lbl2">Initial amount of letter of credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation" xlink:to="ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation_lbl2" xlink:title="label: LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation to ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermObligationsNoncurrent" xlink:label="LongTermObligationsNoncurrent" xlink:title="LongTermObligationsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="ions_LongTermObligationsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_LongTermObligationsNoncurrent_lbl" xml:lang="en-US" id="ions_LongTermObligationsNoncurrent_lbl">Amount of long-term debt and lease obligation, classified as noncurrent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermObligationsNoncurrent" xlink:to="ions_LongTermObligationsNoncurrent_lbl" xlink:title="label: LongTermObligationsNoncurrent to ions_LongTermObligationsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_LongTermObligationsNoncurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_LongTermObligationsNoncurrent_lbl1" xml:lang="en-US" id="ions_LongTermObligationsNoncurrent_lbl1">Long-term Obligations, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermObligationsNoncurrent" xlink:to="ions_LongTermObligationsNoncurrent_lbl1" xlink:title="label: LongTermObligationsNoncurrent to ions_LongTermObligationsNoncurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_LongTermObligationsNoncurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_LongTermObligationsNoncurrent_lbl2" xml:lang="en-US" id="ions_LongTermObligationsNoncurrent_lbl2">Long-term obligations, less current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermObligationsNoncurrent" xlink:to="ions_LongTermObligationsNoncurrent_lbl2" xlink:title="label: LongTermObligationsNoncurrent to ions_LongTermObligationsNoncurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember_lbl">Represents information pertaining to the collaborative arrangements and licensing agreements entered into with Pfizer for the license of AKCEA-ANGPTL3-LR to treat people with cardiovascular and metabolic diseases..</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember_lbl" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember_lbl1">Collaborative Arrangement and Licensing Agreement Entered Into in October 2019 with Pfizer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember_lbl1" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember_lbl2">Pfizer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember_lbl2" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAbstract" xlink:label="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="CollaborativeArrangementAndLicensingAgreementAbstract" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementAbstract_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementAbstract_lbl1">Collaborative Arrangement and Licensing Agreement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementAbstract_lbl1" xlink:title="label: CollaborativeArrangementAndLicensingAgreementAbstract to ions_CollaborativeArrangementAndLicensingAgreementAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones_lbl" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones_lbl">The maximum amount of payments receivable for development, regulatory and sales milestones under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones_lbl" xlink:title="label: MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones to ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones_lbl1" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones_lbl1">Maximum amount of payments receivable for development, regulatory and sales milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones_lbl1" xlink:title="label: MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones to ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones_lbl2" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones_lbl2">Maximum amount of payments receivable for development, regulatory and sales milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones_lbl2" xlink:title="label: MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones to ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ReceiptOfSharesInSubsidiary" xlink:label="ReceiptOfSharesInSubsidiary" xlink:title="ReceiptOfSharesInSubsidiary" />
    <link:label xlink:type="resource" xlink:label="ions_ReceiptOfSharesInSubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ReceiptOfSharesInSubsidiary_lbl" xml:lang="en-US" id="ions_ReceiptOfSharesInSubsidiary_lbl">The number of shares received from the subsidiary during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceiptOfSharesInSubsidiary" xlink:to="ions_ReceiptOfSharesInSubsidiary_lbl" xlink:title="label: ReceiptOfSharesInSubsidiary to ions_ReceiptOfSharesInSubsidiary_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ReceiptOfSharesInSubsidiary_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ReceiptOfSharesInSubsidiary_lbl1" xml:lang="en-US" id="ions_ReceiptOfSharesInSubsidiary_lbl1">Receipt of shares in subsidiary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceiptOfSharesInSubsidiary" xlink:to="ions_ReceiptOfSharesInSubsidiary_lbl1" xlink:title="label: ReceiptOfSharesInSubsidiary to ions_ReceiptOfSharesInSubsidiary_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ReceiptOfSharesInSubsidiary_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ReceiptOfSharesInSubsidiary_lbl2" xml:lang="en-US" id="ions_ReceiptOfSharesInSubsidiary_lbl2">Additional shares of Akcea stock received (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceiptOfSharesInSubsidiary" xlink:to="ions_ReceiptOfSharesInSubsidiary_lbl2" xlink:title="label: ReceiptOfSharesInSubsidiary to ions_ReceiptOfSharesInSubsidiary_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:label="RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:title="RoyaltyPercentageReceivedOnNetSalesOfDrug" />
    <link:label xlink:type="resource" xlink:label="ions_RoyaltyPercentageReceivedOnNetSalesOfDrug_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_RoyaltyPercentageReceivedOnNetSalesOfDrug_lbl" xml:lang="en-US" id="ions_RoyaltyPercentageReceivedOnNetSalesOfDrug_lbl">Royalty percentage received on the net sales of a drug by a collaboration partner under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:to="ions_RoyaltyPercentageReceivedOnNetSalesOfDrug_lbl" xlink:title="label: RoyaltyPercentageReceivedOnNetSalesOfDrug to ions_RoyaltyPercentageReceivedOnNetSalesOfDrug_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_RoyaltyPercentageReceivedOnNetSalesOfDrug_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_RoyaltyPercentageReceivedOnNetSalesOfDrug_lbl1" xml:lang="en-US" id="ions_RoyaltyPercentageReceivedOnNetSalesOfDrug_lbl1">Royalty percentage received on net sales of drug</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:to="ions_RoyaltyPercentageReceivedOnNetSalesOfDrug_lbl1" xlink:title="label: RoyaltyPercentageReceivedOnNetSalesOfDrug to ions_RoyaltyPercentageReceivedOnNetSalesOfDrug_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_RoyaltyPercentageReceivedOnNetSalesOfDrug_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_RoyaltyPercentageReceivedOnNetSalesOfDrug_lbl2" xml:lang="en-US" id="ions_RoyaltyPercentageReceivedOnNetSalesOfDrug_lbl2">Royalty percentage received on net sales of drug</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:to="ions_RoyaltyPercentageReceivedOnNetSalesOfDrug_lbl2" xlink:title="label: RoyaltyPercentageReceivedOnNetSalesOfDrug to ions_RoyaltyPercentageReceivedOnNetSalesOfDrug_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones_lbl" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones_lbl">The maximum amount of payments receivable for development milestones under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones_lbl" xlink:title="label: MaximumAmountOfPaymentsReceivableForDevelopmentMilestones to ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones_lbl1" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones_lbl1">Maximum amount of payments receivable for development milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones_lbl1" xlink:title="label: MaximumAmountOfPaymentsReceivableForDevelopmentMilestones to ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones_lbl2" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones_lbl2">Maximum amount of payments receivable for development milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones_lbl2" xlink:title="label: MaximumAmountOfPaymentsReceivableForDevelopmentMilestones to ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember" xlink:label="AKCEAANGPTL3LActivePharmaceuticalIngredientMember" xlink:title="AKCEAANGPTL3LActivePharmaceuticalIngredientMember" />
    <link:label xlink:type="resource" xlink:label="ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember_lbl" xml:lang="en-US" id="ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember_lbl">The active pharmaceutical ingredient, or API, for AKCEA-ANGPTL3-L, a LIgand-Conjugated Antisense, or LICA, medicine designed to inhibit the production of the angiopoietin-like 3, or ANGPTL3, protein.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AKCEAANGPTL3LActivePharmaceuticalIngredientMember" xlink:to="ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember_lbl" xlink:title="label: AKCEAANGPTL3LActivePharmaceuticalIngredientMember to ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember_lbl1" xml:lang="en-US" id="ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember_lbl1">AKCEA-ANGPTL3-L Active Pharmaceutical Ingredient [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AKCEAANGPTL3LActivePharmaceuticalIngredientMember" xlink:to="ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember_lbl1" xlink:title="label: AKCEAANGPTL3LActivePharmaceuticalIngredientMember to ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember_lbl2" xml:lang="en-US" id="ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember_lbl2">AKCEA-ANGPTL3-L API [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AKCEAANGPTL3LActivePharmaceuticalIngredientMember" xlink:to="ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember_lbl2" xlink:title="label: AKCEAANGPTL3LActivePharmaceuticalIngredientMember to ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AKCEAANGPTL3LMember" xlink:label="AKCEAANGPTL3LMember" xlink:title="AKCEAANGPTL3LMember" />
    <link:label xlink:type="resource" xlink:label="ions_AKCEAANGPTL3LMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_AKCEAANGPTL3LMember_lbl" xml:lang="en-US" id="ions_AKCEAANGPTL3LMember_lbl">AKCEA-ANGPTL3-L is a LIgand-Conjugated Antisense, or LICA, medicine designed to inhibit the production of the angiopoietin-like 3, or ANGPTL3, protein.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AKCEAANGPTL3LMember" xlink:to="ions_AKCEAANGPTL3LMember_lbl" xlink:title="label: AKCEAANGPTL3LMember to ions_AKCEAANGPTL3LMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_AKCEAANGPTL3LMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_AKCEAANGPTL3LMember_lbl1" xml:lang="en-US" id="ions_AKCEAANGPTL3LMember_lbl1">AKCEA-ANGPTL3-L [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AKCEAANGPTL3LMember" xlink:to="ions_AKCEAANGPTL3LMember_lbl1" xlink:title="label: AKCEAANGPTL3LMember to ions_AKCEAANGPTL3LMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:label="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_lbl" xml:lang="en-US" id="ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_lbl">Revenue from research and development services performed under a collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:to="ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_lbl" xlink:title="label: ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember to ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_lbl1" xml:lang="en-US" id="ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_lbl1">Research and Development Revenue Under Collaborative Agreements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:to="ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_lbl1" xlink:title="label: ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember to ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_lbl2" xml:lang="en-US" id="ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_lbl2">R&amp;D Revenue Under Collaborative Agreements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:to="ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_lbl2" xlink:title="label: ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember to ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_lbl2" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_lbl3" xml:lang="en-US" id="ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_lbl3">R&amp;D Revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:to="ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_lbl3" xlink:title="label: ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember to ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_lbl3" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SublicenseFeePaidForLicenseOfDrug" xlink:label="SublicenseFeePaidForLicenseOfDrug" xlink:title="SublicenseFeePaidForLicenseOfDrug" />
    <link:label xlink:type="resource" xlink:label="ions_SublicenseFeePaidForLicenseOfDrug_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_SublicenseFeePaidForLicenseOfDrug_lbl" xml:lang="en-US" id="ions_SublicenseFeePaidForLicenseOfDrug_lbl">The amount of the sublicense fee paid in common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SublicenseFeePaidForLicenseOfDrug" xlink:to="ions_SublicenseFeePaidForLicenseOfDrug_lbl" xlink:title="label: SublicenseFeePaidForLicenseOfDrug to ions_SublicenseFeePaidForLicenseOfDrug_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_SublicenseFeePaidForLicenseOfDrug_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_SublicenseFeePaidForLicenseOfDrug_lbl1" xml:lang="en-US" id="ions_SublicenseFeePaidForLicenseOfDrug_lbl1">Sublicense fee paid for license of drug</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SublicenseFeePaidForLicenseOfDrug" xlink:to="ions_SublicenseFeePaidForLicenseOfDrug_lbl1" xlink:title="label: SublicenseFeePaidForLicenseOfDrug to ions_SublicenseFeePaidForLicenseOfDrug_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_SublicenseFeePaidForLicenseOfDrug_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_SublicenseFeePaidForLicenseOfDrug_lbl2" xml:lang="en-US" id="ions_SublicenseFeePaidForLicenseOfDrug_lbl2">Sublicense fee paid in stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SublicenseFeePaidForLicenseOfDrug" xlink:to="ions_SublicenseFeePaidForLicenseOfDrug_lbl2" xlink:title="label: SublicenseFeePaidForLicenseOfDrug to ions_SublicenseFeePaidForLicenseOfDrug_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceived" xlink:label="UpfrontPaymentReceived" xlink:title="UpfrontPaymentReceived" />
    <link:label xlink:type="resource" xlink:label="ions_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_UpfrontPaymentReceived_lbl" xml:lang="en-US" id="ions_UpfrontPaymentReceived_lbl">The amount of upfront payments received during the period under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UpfrontPaymentReceived" xlink:to="ions_UpfrontPaymentReceived_lbl" xlink:title="label: UpfrontPaymentReceived to ions_UpfrontPaymentReceived_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_UpfrontPaymentReceived_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_UpfrontPaymentReceived_lbl1" xml:lang="en-US" id="ions_UpfrontPaymentReceived_lbl1">Upfront payment received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UpfrontPaymentReceived" xlink:to="ions_UpfrontPaymentReceived_lbl1" xlink:title="label: UpfrontPaymentReceived to ions_UpfrontPaymentReceived_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_UpfrontPaymentReceived_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_UpfrontPaymentReceived_lbl2" xml:lang="en-US" id="ions_UpfrontPaymentReceived_lbl2">Upfront payment received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UpfrontPaymentReceived" xlink:to="ions_UpfrontPaymentReceived_lbl2" xlink:title="label: UpfrontPaymentReceived to ions_UpfrontPaymentReceived_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones_lbl" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones_lbl">The maximum amount of payments receivable for regulatory milestones under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones_lbl" xlink:title="label: MaximumAmountOfPaymentsReceivableForRegulatoryMilestones to ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones_lbl1" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones_lbl1">Maximum amount of payments receivable for regulatory milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones_lbl1" xlink:title="label: MaximumAmountOfPaymentsReceivableForRegulatoryMilestones to ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones_lbl2" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones_lbl2">Maximum amount of payments receivable for regulatory milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones_lbl2" xlink:title="label: MaximumAmountOfPaymentsReceivableForRegulatoryMilestones to ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones_lbl" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones_lbl">The maximum amount of payments receivable for commercialization milestones under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones_lbl" xlink:title="label: MaximumAmountOfPaymentsReceivableForCommercializationMilestones to ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones_lbl1" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones_lbl1">Maximum amount of payments receivable for commercialization milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones_lbl1" xlink:title="label: MaximumAmountOfPaymentsReceivableForCommercializationMilestones to ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones_lbl2" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones_lbl2">Maximum amount of payments receivable for commercialization milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones_lbl2" xlink:title="label: MaximumAmountOfPaymentsReceivableForCommercializationMilestones to ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NextPotentialMilestonePayment" xlink:label="NextPotentialMilestonePayment" xlink:title="NextPotentialMilestonePayment" />
    <link:label xlink:type="resource" xlink:label="ions_NextPotentialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NextPotentialMilestonePayment_lbl" xml:lang="en-US" id="ions_NextPotentialMilestonePayment_lbl">The next potential milestone payment to be earned under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NextPotentialMilestonePayment" xlink:to="ions_NextPotentialMilestonePayment_lbl" xlink:title="label: NextPotentialMilestonePayment to ions_NextPotentialMilestonePayment_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NextPotentialMilestonePayment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NextPotentialMilestonePayment_lbl1" xml:lang="en-US" id="ions_NextPotentialMilestonePayment_lbl1">Next potential milestone payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NextPotentialMilestonePayment" xlink:to="ions_NextPotentialMilestonePayment_lbl1" xlink:title="label: NextPotentialMilestonePayment to ions_NextPotentialMilestonePayment_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NextPotentialMilestonePayment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NextPotentialMilestonePayment_lbl2" xml:lang="en-US" id="ions_NextPotentialMilestonePayment_lbl2">Next prospective milestone</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NextPotentialMilestonePayment" xlink:to="ions_NextPotentialMilestonePayment_lbl2" xlink:title="label: NextPotentialMilestonePayment to ions_NextPotentialMilestonePayment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" />
    <link:label xlink:type="resource" xlink:label="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations_lbl" xml:lang="en-US" id="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations_lbl">The number of separate performance obligations under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:to="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations_lbl" xlink:title="label: RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations to ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations_lbl1" xml:lang="en-US" id="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations_lbl1">Revenue from Contract with Customer, Number of separate performance obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:to="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations_lbl1" xlink:title="label: RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations to ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations_lbl2" xml:lang="en-US" id="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations_lbl2">Number of separate performance obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:to="ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations_lbl2" xlink:title="label: RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations to ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerTransactionPrice" xlink:label="RevenueFromContractWithCustomerTransactionPrice" xlink:title="RevenueFromContractWithCustomerTransactionPrice" />
    <link:label xlink:type="resource" xlink:label="ions_RevenueFromContractWithCustomerTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_RevenueFromContractWithCustomerTransactionPrice_lbl" xml:lang="en-US" id="ions_RevenueFromContractWithCustomerTransactionPrice_lbl">The amount of consideration the Company earned or is eligible to earn under the collaboration agreement, including any variable consideration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerTransactionPrice" xlink:to="ions_RevenueFromContractWithCustomerTransactionPrice_lbl" xlink:title="label: RevenueFromContractWithCustomerTransactionPrice to ions_RevenueFromContractWithCustomerTransactionPrice_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_RevenueFromContractWithCustomerTransactionPrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_RevenueFromContractWithCustomerTransactionPrice_lbl1" xml:lang="en-US" id="ions_RevenueFromContractWithCustomerTransactionPrice_lbl1">Revenue from Contract with Customer, Transaction Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerTransactionPrice" xlink:to="ions_RevenueFromContractWithCustomerTransactionPrice_lbl1" xlink:title="label: RevenueFromContractWithCustomerTransactionPrice to ions_RevenueFromContractWithCustomerTransactionPrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_RevenueFromContractWithCustomerTransactionPrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_RevenueFromContractWithCustomerTransactionPrice_lbl2" xml:lang="en-US" id="ions_RevenueFromContractWithCustomerTransactionPrice_lbl2">Transaction price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerTransactionPrice" xlink:to="ions_RevenueFromContractWithCustomerTransactionPrice_lbl2" xlink:title="label: RevenueFromContractWithCustomerTransactionPrice to ions_RevenueFromContractWithCustomerTransactionPrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentServicesForMember" xlink:label="ResearchAndDevelopmentServicesForMember" xlink:title="ResearchAndDevelopmentServicesForMember" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchAndDevelopmentServicesForMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ResearchAndDevelopmentServicesForMember_lbl" xml:lang="en-US" id="ions_ResearchAndDevelopmentServicesForMember_lbl">Research and development (R&amp;D) services for AKCEA-ANGPTL3-L, a LIgand-Conjugated Antisense, or LICA, medicine designed to inhibit the production of the angiopoietin-like 3, or ANGPTL3, protein.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentServicesForMember" xlink:to="ions_ResearchAndDevelopmentServicesForMember_lbl" xlink:title="label: ResearchAndDevelopmentServicesForMember to ions_ResearchAndDevelopmentServicesForMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchAndDevelopmentServicesForMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ResearchAndDevelopmentServicesForMember_lbl1" xml:lang="en-US" id="ions_ResearchAndDevelopmentServicesForMember_lbl1">Research and Development Services for AKCEA-ANGPTL3-L [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentServicesForMember" xlink:to="ions_ResearchAndDevelopmentServicesForMember_lbl1" xlink:title="label: ResearchAndDevelopmentServicesForMember to ions_ResearchAndDevelopmentServicesForMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchAndDevelopmentServicesForMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ResearchAndDevelopmentServicesForMember_lbl2" xml:lang="en-US" id="ions_ResearchAndDevelopmentServicesForMember_lbl2">R&amp;D Services for AKCEA-ANGPTL3-L [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentServicesForMember" xlink:to="ions_ResearchAndDevelopmentServicesForMember_lbl2" xlink:title="label: ResearchAndDevelopmentServicesForMember to ions_ResearchAndDevelopmentServicesForMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CostOfProductsSoldPreviouslyRecognized" xlink:label="CostOfProductsSoldPreviouslyRecognized" xlink:title="CostOfProductsSoldPreviouslyRecognized" />
    <link:label xlink:type="resource" xlink:label="ions_CostOfProductsSoldPreviouslyRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CostOfProductsSoldPreviouslyRecognized_lbl" xml:lang="en-US" id="ions_CostOfProductsSoldPreviouslyRecognized_lbl">The costs related to goods produced and sold that were previously recognized as expense and are related to the commercial revenue recognized during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfProductsSoldPreviouslyRecognized" xlink:to="ions_CostOfProductsSoldPreviouslyRecognized_lbl" xlink:title="label: CostOfProductsSoldPreviouslyRecognized to ions_CostOfProductsSoldPreviouslyRecognized_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CostOfProductsSoldPreviouslyRecognized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CostOfProductsSoldPreviouslyRecognized_lbl1" xml:lang="en-US" id="ions_CostOfProductsSoldPreviouslyRecognized_lbl1">Cost of Products Sold Previously Recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfProductsSoldPreviouslyRecognized" xlink:to="ions_CostOfProductsSoldPreviouslyRecognized_lbl1" xlink:title="label: CostOfProductsSoldPreviouslyRecognized to ions_CostOfProductsSoldPreviouslyRecognized_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CostOfProductsSoldPreviouslyRecognized_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CostOfProductsSoldPreviouslyRecognized_lbl2" xml:lang="en-US" id="ions_CostOfProductsSoldPreviouslyRecognized_lbl2">Previously expensed costs to produce TEGSEDI related to TEGSEDI commercial revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfProductsSoldPreviouslyRecognized" xlink:to="ions_CostOfProductsSoldPreviouslyRecognized_lbl2" xlink:title="label: CostOfProductsSoldPreviouslyRecognized to ions_CostOfProductsSoldPreviouslyRecognized_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchDevelopmentAndPatentExpense" xlink:label="ResearchDevelopmentAndPatentExpense" xlink:title="ResearchDevelopmentAndPatentExpense" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchDevelopmentAndPatentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ResearchDevelopmentAndPatentExpense_lbl" xml:lang="en-US" id="ions_ResearchDevelopmentAndPatentExpense_lbl">The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects. Also includes charges for amortization and write-downs of capitalized patent costs, as well as legal fees for patent litigation and patent defense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchDevelopmentAndPatentExpense" xlink:to="ions_ResearchDevelopmentAndPatentExpense_lbl" xlink:title="label: ResearchDevelopmentAndPatentExpense to ions_ResearchDevelopmentAndPatentExpense_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchDevelopmentAndPatentExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ResearchDevelopmentAndPatentExpense_lbl1" xml:lang="en-US" id="ions_ResearchDevelopmentAndPatentExpense_lbl1">Research, Development and Patent Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchDevelopmentAndPatentExpense" xlink:to="ions_ResearchDevelopmentAndPatentExpense_lbl1" xlink:title="label: ResearchDevelopmentAndPatentExpense to ions_ResearchDevelopmentAndPatentExpense_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchDevelopmentAndPatentExpense_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ResearchDevelopmentAndPatentExpense_lbl2" xml:lang="en-US" id="ions_ResearchDevelopmentAndPatentExpense_lbl2">Research, development and patent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchDevelopmentAndPatentExpense" xlink:to="ions_ResearchDevelopmentAndPatentExpense_lbl2" xlink:title="label: ResearchDevelopmentAndPatentExpense to ions_ResearchDevelopmentAndPatentExpense_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_GainLossOnExtinguishmentOfFinancingLiability" xlink:label="GainLossOnExtinguishmentOfFinancingLiability" xlink:title="GainLossOnExtinguishmentOfFinancingLiability" />
    <link:label xlink:type="resource" xlink:label="ions_GainLossOnExtinguishmentOfFinancingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_GainLossOnExtinguishmentOfFinancingLiability_lbl" xml:lang="en-US" id="ions_GainLossOnExtinguishmentOfFinancingLiability_lbl">Difference between the purchase price of the facility and the carrying value of our financing liability at the time of the purchase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnExtinguishmentOfFinancingLiability" xlink:to="ions_GainLossOnExtinguishmentOfFinancingLiability_lbl" xlink:title="label: GainLossOnExtinguishmentOfFinancingLiability to ions_GainLossOnExtinguishmentOfFinancingLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_GainLossOnExtinguishmentOfFinancingLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_GainLossOnExtinguishmentOfFinancingLiability_lbl1" xml:lang="en-US" id="ions_GainLossOnExtinguishmentOfFinancingLiability_lbl1">Gain (Loss) on Extinguishment of Financing Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnExtinguishmentOfFinancingLiability" xlink:to="ions_GainLossOnExtinguishmentOfFinancingLiability_lbl1" xlink:title="label: GainLossOnExtinguishmentOfFinancingLiability to ions_GainLossOnExtinguishmentOfFinancingLiability_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_GainLossOnExtinguishmentOfFinancingLiability_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_GainLossOnExtinguishmentOfFinancingLiability_lbl2" xml:lang="en-US" id="ions_GainLossOnExtinguishmentOfFinancingLiability_lbl2">Loss on extinguishment of financing liability for leased facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnExtinguishmentOfFinancingLiability" xlink:to="ions_GainLossOnExtinguishmentOfFinancingLiability_lbl2" xlink:title="label: GainLossOnExtinguishmentOfFinancingLiability to ions_GainLossOnExtinguishmentOfFinancingLiability_lbl2" />
    <link:label xlink:type="resource" xlink:label="ions_GainLossOnExtinguishmentOfFinancingLiability_lbl3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ions_GainLossOnExtinguishmentOfFinancingLiability_lbl3" xml:lang="en-US" id="ions_GainLossOnExtinguishmentOfFinancingLiability_lbl3">Loss on extinguishment of financing liability for leased facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnExtinguishmentOfFinancingLiability" xlink:to="ions_GainLossOnExtinguishmentOfFinancingLiability_lbl3" xlink:title="label: GainLossOnExtinguishmentOfFinancingLiability to ions_GainLossOnExtinguishmentOfFinancingLiability_lbl3" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CommercialMember" xlink:label="CommercialMember" xlink:title="CommercialMember" />
    <link:label xlink:type="resource" xlink:label="ions_CommercialMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CommercialMember_lbl1" xml:lang="en-US" id="ions_CommercialMember_lbl1">Commercial [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommercialMember" xlink:to="ions_CommercialMember_lbl1" xlink:title="label: CommercialMember to ions_CommercialMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CommercialMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CommercialMember_lbl2" xml:lang="en-US" id="ions_CommercialMember_lbl2">Commercial Revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommercialMember" xlink:to="ions_CommercialMember_lbl2" xlink:title="label: CommercialMember to ions_CommercialMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SPINRAZARoyaltiesMember" xlink:label="SPINRAZARoyaltiesMember" xlink:title="SPINRAZARoyaltiesMember" />
    <link:label xlink:type="resource" xlink:label="ions_SPINRAZARoyaltiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_SPINRAZARoyaltiesMember_lbl" xml:lang="en-US" id="ions_SPINRAZARoyaltiesMember_lbl">Royalty revenues from the sale of SPINRAZA (nusinersen).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SPINRAZARoyaltiesMember" xlink:to="ions_SPINRAZARoyaltiesMember_lbl" xlink:title="label: SPINRAZARoyaltiesMember to ions_SPINRAZARoyaltiesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_SPINRAZARoyaltiesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_SPINRAZARoyaltiesMember_lbl1" xml:lang="en-US" id="ions_SPINRAZARoyaltiesMember_lbl1">SPINRAZA Royalties [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SPINRAZARoyaltiesMember" xlink:to="ions_SPINRAZARoyaltiesMember_lbl1" xlink:title="label: SPINRAZARoyaltiesMember to ions_SPINRAZARoyaltiesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_SPINRAZARoyaltiesMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_SPINRAZARoyaltiesMember_lbl2" xml:lang="en-US" id="ions_SPINRAZARoyaltiesMember_lbl2">SPINRAZA Royalties [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SPINRAZARoyaltiesMember" xlink:to="ions_SPINRAZARoyaltiesMember_lbl2" xlink:title="label: SPINRAZARoyaltiesMember to ions_SPINRAZARoyaltiesMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LicensingAndOtherRoyaltiesMember" xlink:label="LicensingAndOtherRoyaltiesMember" xlink:title="LicensingAndOtherRoyaltiesMember" />
    <link:label xlink:type="resource" xlink:label="ions_LicensingAndOtherRoyaltiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_LicensingAndOtherRoyaltiesMember_lbl" xml:lang="en-US" id="ions_LicensingAndOtherRoyaltiesMember_lbl">Revenue from license fees and other royalties, excluding royalties from the sale of SPINRAZA.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicensingAndOtherRoyaltiesMember" xlink:to="ions_LicensingAndOtherRoyaltiesMember_lbl" xlink:title="label: LicensingAndOtherRoyaltiesMember to ions_LicensingAndOtherRoyaltiesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_LicensingAndOtherRoyaltiesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_LicensingAndOtherRoyaltiesMember_lbl1" xml:lang="en-US" id="ions_LicensingAndOtherRoyaltiesMember_lbl1">Licensing and Other Royalties [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicensingAndOtherRoyaltiesMember" xlink:to="ions_LicensingAndOtherRoyaltiesMember_lbl1" xlink:title="label: LicensingAndOtherRoyaltiesMember to ions_LicensingAndOtherRoyaltiesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_LicensingAndOtherRoyaltiesMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ions_LicensingAndOtherRoyaltiesMember_lbl2" xml:lang="en-US" id="ions_LicensingAndOtherRoyaltiesMember_lbl2">Licensing and Other Royalty Revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicensingAndOtherRoyaltiesMember" xlink:to="ions_LicensingAndOtherRoyaltiesMember_lbl2" xlink:title="label: LicensingAndOtherRoyaltiesMember to ions_LicensingAndOtherRoyaltiesMember_lbl2" />
    <link:label xlink:type="resource" xlink:label="ions_LicensingAndOtherRoyaltiesMember_lbl3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_LicensingAndOtherRoyaltiesMember_lbl3" xml:lang="en-US" id="ions_LicensingAndOtherRoyaltiesMember_lbl3">Licensing and Other Royalties [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicensingAndOtherRoyaltiesMember" xlink:to="ions_LicensingAndOtherRoyaltiesMember_lbl3" xlink:title="label: LicensingAndOtherRoyaltiesMember to ions_LicensingAndOtherRoyaltiesMember_lbl3" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PeriodAfterBillingWhenPaymentIsReceived" xlink:label="PeriodAfterBillingWhenPaymentIsReceived" xlink:title="PeriodAfterBillingWhenPaymentIsReceived" />
    <link:label xlink:type="resource" xlink:label="ions_PeriodAfterBillingWhenPaymentIsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_PeriodAfterBillingWhenPaymentIsReceived_lbl" xml:lang="en-US" id="ions_PeriodAfterBillingWhenPaymentIsReceived_lbl">The time period between billing a collaboration partner for goods delivered or services performed that are due unconditionally and payment is received from the collaboration partner, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodAfterBillingWhenPaymentIsReceived" xlink:to="ions_PeriodAfterBillingWhenPaymentIsReceived_lbl" xlink:title="label: PeriodAfterBillingWhenPaymentIsReceived to ions_PeriodAfterBillingWhenPaymentIsReceived_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_PeriodAfterBillingWhenPaymentIsReceived_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_PeriodAfterBillingWhenPaymentIsReceived_lbl1" xml:lang="en-US" id="ions_PeriodAfterBillingWhenPaymentIsReceived_lbl1">Period after billing when payment is received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodAfterBillingWhenPaymentIsReceived" xlink:to="ions_PeriodAfterBillingWhenPaymentIsReceived_lbl1" xlink:title="label: PeriodAfterBillingWhenPaymentIsReceived to ions_PeriodAfterBillingWhenPaymentIsReceived_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_PeriodAfterBillingWhenPaymentIsReceived_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_PeriodAfterBillingWhenPaymentIsReceived_lbl2" xml:lang="en-US" id="ions_PeriodAfterBillingWhenPaymentIsReceived_lbl2">Period of time after billing when payment is received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodAfterBillingWhenPaymentIsReceived" xlink:to="ions_PeriodAfterBillingWhenPaymentIsReceived_lbl2" xlink:title="label: PeriodAfterBillingWhenPaymentIsReceived to ions_PeriodAfterBillingWhenPaymentIsReceived_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:label="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:title="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl" xml:lang="en-US" id="ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl">Represents the net amount of deferred tax assets (before reduction for valuation allowance) and liabilities as of the balance sheet date, which result from applying the applicable enacted tax rate to net temporary differences and carryforwards pertaining to assets or liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:to="ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl" xlink:title="label: DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance to ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl1" xml:lang="en-US" id="ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl1">Deferred Tax Assets (Liabilities), Net, before Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:to="ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl1" xlink:title="label: DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance to ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl2" xml:lang="en-US" id="ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl2">Net deferred tax asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:to="ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl2" xlink:title="label: DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance to ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IncreaseDecreaseInStateTaxLiability" xlink:label="IncreaseDecreaseInStateTaxLiability" xlink:title="IncreaseDecreaseInStateTaxLiability" />
    <link:label xlink:type="resource" xlink:label="ions_IncreaseDecreaseInStateTaxLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_IncreaseDecreaseInStateTaxLiability_lbl" xml:lang="en-US" id="ions_IncreaseDecreaseInStateTaxLiability_lbl">Amount of increase (decrease) in state tax liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStateTaxLiability" xlink:to="ions_IncreaseDecreaseInStateTaxLiability_lbl" xlink:title="label: IncreaseDecreaseInStateTaxLiability to ions_IncreaseDecreaseInStateTaxLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_IncreaseDecreaseInStateTaxLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_IncreaseDecreaseInStateTaxLiability_lbl1" xml:lang="en-US" id="ions_IncreaseDecreaseInStateTaxLiability_lbl1">Increase (Decrease) in State Tax Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStateTaxLiability" xlink:to="ions_IncreaseDecreaseInStateTaxLiability_lbl1" xlink:title="label: IncreaseDecreaseInStateTaxLiability to ions_IncreaseDecreaseInStateTaxLiability_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_IncreaseDecreaseInStateTaxLiability_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_IncreaseDecreaseInStateTaxLiability_lbl2" xml:lang="en-US" id="ions_IncreaseDecreaseInStateTaxLiability_lbl2">Decrease in combined state tax liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStateTaxLiability" xlink:to="ions_IncreaseDecreaseInStateTaxLiability_lbl2" xlink:title="label: IncreaseDecreaseInStateTaxLiability to ions_IncreaseDecreaseInStateTaxLiability_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount" xlink:label="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount" xlink:title="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount_lbl" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount_lbl">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the impact from outside basis differences.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount" xlink:to="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount to ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount_lbl1" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount_lbl1">Effective Income Tax Rate Reconciliation, Impact from outside basis differences, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount" xlink:to="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount to ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount_lbl2" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount_lbl2">Impact from outside basis differences</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount" xlink:to="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount_lbl2" xlink:title="label: EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount to ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent" xlink:label="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent" xlink:title="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent_lbl" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent_lbl">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the impact from outside basis differences.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent" xlink:to="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent to ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent_lbl1" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent_lbl1">Effective Income Tax Rate Reconciliation, Impact from outside basis differences, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent" xlink:to="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent to ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent_lbl2" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent_lbl2">Impact from outside basis differences</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent" xlink:to="ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent_lbl2" xlink:title="label: EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent to ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount" xlink:label="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount" xlink:title="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount_lbl" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount_lbl">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the expiration of net operating loss carryforwards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount" xlink:to="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount to ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount_lbl1" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount_lbl1">Effective Income Tax Rate Reconciliation, Expiration of Net Operating Loss, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount" xlink:to="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount to ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount_lbl2" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount_lbl2">Net operating loss expiration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount" xlink:to="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount_lbl2" xlink:title="label: EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount to ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount" xlink:label="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount" xlink:title="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount_lbl" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount_lbl">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to an adjustment for the deconsolidation of a subsidiary from the consolidated federal income tax return on the date of the subsidiary's Initial Public Offering (IPO).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount" xlink:to="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount to ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount_lbl1" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount_lbl1">Effective Income Tax Rate Reconciliation, Deconsolidation Adjustment for Subsidiary at IPO, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount" xlink:to="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount to ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount_lbl2" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount_lbl2">Akcea deconsolidation adjustment at IPO</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount" xlink:to="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount_lbl2" xlink:title="label: EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount to ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent" xlink:label="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent" xlink:title="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent_lbl" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent_lbl">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to an adjustment for the deconsolidation of a subsidiary from the consolidated federal income tax return on the date of the subsidiary's Initial Public Offering (IPO).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent" xlink:to="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent to ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent_lbl1" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent_lbl1">Effective Income Tax Rate Reconciliation, Deconsolidation Adjustment for Subsidiary at IPO, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent" xlink:to="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent to ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent_lbl2" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent_lbl2">Akcea deconsolidation adjustment at IPO</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent" xlink:to="ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent_lbl2" xlink:title="label: EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent to ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent" xlink:label="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent" xlink:title="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent_lbl" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent_lbl">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the expiration of net operating loss carryforwards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent" xlink:to="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent to ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent_lbl1" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent_lbl1">Effective Income Tax Rate Reconciliation, Expiration of Net Operating Loss, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent" xlink:to="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent to ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent_lbl2" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent_lbl2">Net operating loss expiration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent" xlink:to="ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent_lbl2" xlink:title="label: EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent to ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount" xlink:label="EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount" xlink:title="EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount_lbl" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount_lbl">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to licensing gain on TEGSEDI.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount" xlink:to="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount to ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount_lbl1" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount_lbl1">Effective Income Tax Rate Reconciliation, Drug Licensing Gain, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount" xlink:to="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount to ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount_lbl2" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount_lbl2">TEGSEDI licensing gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount" xlink:to="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount_lbl2" xlink:title="label: EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount to ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_lbl" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_lbl">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to compensation in excess of $1 million paid to any "covered employee" of the corporation under Section 162(m) of the Tax Act.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:to="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent to ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_lbl1" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_lbl1">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Excess Compensation, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:to="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent to ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_lbl2" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_lbl2">Non-deductible compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:to="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_lbl2" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent to ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent" xlink:label="EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent" xlink:title="EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent_lbl" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent_lbl">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to licensing gain on TEGSEDI.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent" xlink:to="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent to ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent_lbl1" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent_lbl1">Effective Income Tax Rate Reconciliation, Drug Licensing Gain, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent" xlink:to="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent to ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent_lbl2" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent_lbl2">TEGSEDI licensing gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent" xlink:to="ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent_lbl2" xlink:title="label: EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent to ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount_lbl" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount_lbl">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to compensation in excess of $1 million paid to any "covered employee" of the corporation under Section 162(m) of the Tax Act.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount" xlink:to="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount to ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount_lbl1" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount_lbl1">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Excess Compensation, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount" xlink:to="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount to ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount_lbl2" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount_lbl2">Non-deductible compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount" xlink:to="ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount_lbl2" xlink:title="label: EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount to ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount" xlink:label="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount" xlink:title="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount_lbl" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount_lbl">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign-derived intangible income benefit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount" xlink:to="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount to ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount_lbl1" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount_lbl1">Effective Income Tax Rate Reconciliation, Foreign-derived intangible income benefit, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount" xlink:to="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount to ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount_lbl2" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount_lbl2">Foreign-derived intangible income benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount" xlink:to="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount_lbl2" xlink:title="label: EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount to ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent" xlink:label="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent" xlink:title="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent_lbl" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent_lbl">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign-derived intangible income benefit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent" xlink:to="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent_lbl" xlink:title="label: EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent to ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent_lbl1" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent_lbl1">Effective Income Tax Rate Reconciliation, Foreign-derived intangible income benefit, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent" xlink:to="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent_lbl1" xlink:title="label: EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent to ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent_lbl2" xml:lang="en-US" id="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent_lbl2">Foreign-derived intangible income benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent" xlink:to="ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent_lbl2" xlink:title="label: EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent to ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" xlink:label="DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" xlink:title="DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" />
    <link:label xlink:type="resource" xlink:label="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange_lbl" xml:lang="en-US" id="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange_lbl">The percentage of the principal amount of the notes to be purchased, plus accrued and unpaid interest, upon the occurrence of certain fundamental changes, as set forth in the indenture governing the convertible notes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" xlink:to="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange_lbl" xlink:title="label: DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange to ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange_lbl1" xml:lang="en-US" id="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange_lbl1">Debt Instrument, Convertible, Percentage of principal amount used as purchase price upon occurrence of fundamental change</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" xlink:to="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange_lbl1" xlink:title="label: DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange to ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange_lbl2" xml:lang="en-US" id="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange_lbl2">Percentage of principal amount used as purchase price upon occurrence of fundamental change</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" xlink:to="ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange_lbl2" xlink:title="label: DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange to ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes275PercentMember" xlink:label="ConvertibleSeniorNotes275PercentMember" xlink:title="ConvertibleSeniorNotes275PercentMember" />
    <link:label xlink:type="resource" xlink:label="ions_ConvertibleSeniorNotes275PercentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ConvertibleSeniorNotes275PercentMember_lbl" xml:lang="en-US" id="ions_ConvertibleSeniorNotes275PercentMember_lbl">2 3/4 percent convertible senior notes due October 2019.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes275PercentMember" xlink:to="ions_ConvertibleSeniorNotes275PercentMember_lbl" xlink:title="label: ConvertibleSeniorNotes275PercentMember to ions_ConvertibleSeniorNotes275PercentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ConvertibleSeniorNotes275PercentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ConvertibleSeniorNotes275PercentMember_lbl1" xml:lang="en-US" id="ions_ConvertibleSeniorNotes275PercentMember_lbl1">Convertible Senior Notes 2.75 Percent [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes275PercentMember" xlink:to="ions_ConvertibleSeniorNotes275PercentMember_lbl1" xlink:title="label: ConvertibleSeniorNotes275PercentMember to ions_ConvertibleSeniorNotes275PercentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ConvertibleSeniorNotes275PercentMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ConvertibleSeniorNotes275PercentMember_lbl2" xml:lang="en-US" id="ions_ConvertibleSeniorNotes275PercentMember_lbl2">2 3/4 Percent Convertible Senior Notes [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes275PercentMember" xlink:to="ions_ConvertibleSeniorNotes275PercentMember_lbl2" xlink:title="label: ConvertibleSeniorNotes275PercentMember to ions_ConvertibleSeniorNotes275PercentMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember" xlink:label="ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember" xlink:title="ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember" />
    <link:label xlink:type="resource" xlink:label="ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember_lbl" xml:lang="en-US" id="ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember_lbl">0.125 percent convertible senior notes due December 2024 that were issued in exchange for 1 percent notes in December 2019.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember" xlink:to="ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember_lbl" xlink:title="label: ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember to ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember_lbl1" xml:lang="en-US" id="ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember_lbl1">Convertible Senior Notes 0.125 Percent, Issued in Exchange for 1 Percent Notes [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember" xlink:to="ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember_lbl1" xlink:title="label: ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember to ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember_lbl2" xml:lang="en-US" id="ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember_lbl2">0.125 Percent Convertible Senior Notes Issued in Exchange for 1 Percent Notes [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember" xlink:to="ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember_lbl2" xlink:title="label: ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember to ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember" xlink:label="ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember" xlink:title="ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember" />
    <link:label xlink:type="resource" xlink:label="ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember_lbl" xml:lang="en-US" id="ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember_lbl">0.125 percent convertible senior notes due December 2024 that were issued under subscription agreements in December 2019.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember" xlink:to="ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember_lbl" xlink:title="label: ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember to ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember_lbl1" xml:lang="en-US" id="ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember_lbl1">Convertible Senior Notes 0.125 Percent, Issued under Subscription Agreements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember" xlink:to="ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember_lbl1" xlink:title="label: ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember to ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember_lbl2" xml:lang="en-US" id="ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember_lbl2">0.125 Percent Convertible Senior Notes Issued under Subscription Agreements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember" xlink:to="ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember_lbl2" xlink:title="label: ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember to ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CallSpread" xlink:label="CallSpread" xlink:title="CallSpread" />
    <link:label xlink:type="resource" xlink:label="ions_CallSpread_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CallSpread_lbl" xml:lang="en-US" id="ions_CallSpread_lbl">The net cash outflow from payments for hedge transactions and proceeds from the issuance of warrants. The call spread transaction was entered into to minimize the impact of potential economic dilution upon conversion of the 0.125% notes issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CallSpread" xlink:to="ions_CallSpread_lbl" xlink:title="label: CallSpread to ions_CallSpread_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CallSpread_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CallSpread_lbl1" xml:lang="en-US" id="ions_CallSpread_lbl1">Call Spread</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CallSpread" xlink:to="ions_CallSpread_lbl1" xlink:title="label: CallSpread to ions_CallSpread_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CallSpread_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CallSpread_lbl2" xml:lang="en-US" id="ions_CallSpread_lbl2">Cost of call spread</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CallSpread" xlink:to="ions_CallSpread_lbl2" xlink:title="label: CallSpread to ions_CallSpread_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread" xlink:label="DebtInstrumentConvertibleConversionPriceIncludingCallSpread" xlink:title="DebtInstrumentConvertibleConversionPriceIncludingCallSpread" />
    <link:label xlink:type="resource" xlink:label="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl" xml:lang="en-US" id="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl">The computed conversion price per share of the debt instrument based on the the conversion feature embedded in the debt instrument and the impact of the purchased hedges in the call spread transaction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleConversionPriceIncludingCallSpread" xlink:to="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl" xlink:title="label: DebtInstrumentConvertibleConversionPriceIncludingCallSpread to ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl1" xml:lang="en-US" id="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl1">Debt Instrument, Convertible, Conversion Price including call spread</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleConversionPriceIncludingCallSpread" xlink:to="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl1" xlink:title="label: DebtInstrumentConvertibleConversionPriceIncludingCallSpread to ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl2" xml:lang="en-US" id="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl2">Conversion price per share, including note hedges (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentConvertibleConversionPriceIncludingCallSpread" xlink:to="ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl2" xlink:title="label: DebtInstrumentConvertibleConversionPriceIncludingCallSpread to ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" xlink:label="LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" xlink:title="LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" />
    <link:label xlink:type="resource" xlink:label="ions_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember_lbl" xml:lang="en-US" id="ions_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember_lbl">Represents the aggregate of all long-term obligations of the entity, including capital leases and other financing arrangements, excluding the long-term financing liability for the entity's leased research and development facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" xlink:to="ions_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember_lbl" xlink:title="label: LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember to ions_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember_lbl1" xml:lang="en-US" id="ions_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember_lbl1">Long-Term Obligations, Excluding Financing Liability for Leased Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" xlink:to="ions_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember_lbl1" xlink:title="label: LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember to ions_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PropertyPlantAndEquipmentExcludingLandMember" xlink:label="PropertyPlantAndEquipmentExcludingLandMember" xlink:title="PropertyPlantAndEquipmentExcludingLandMember" />
    <link:label xlink:type="resource" xlink:label="ions_PropertyPlantAndEquipmentExcludingLandMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_PropertyPlantAndEquipmentExcludingLandMember_lbl" xml:lang="en-US" id="ions_PropertyPlantAndEquipmentExcludingLandMember_lbl">Physical assets used in the normal conduct of business and not intended for resale, excluding land. Examples include, but are not limited to, buildings, land and leasehold improvements, machinery and equipment, office equipment, and furniture and fixtures.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentExcludingLandMember" xlink:to="ions_PropertyPlantAndEquipmentExcludingLandMember_lbl" xlink:title="label: PropertyPlantAndEquipmentExcludingLandMember to ions_PropertyPlantAndEquipmentExcludingLandMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_PropertyPlantAndEquipmentExcludingLandMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_PropertyPlantAndEquipmentExcludingLandMember_lbl1" xml:lang="en-US" id="ions_PropertyPlantAndEquipmentExcludingLandMember_lbl1">Property, Plant and Equipment, Excluding Land [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentExcludingLandMember" xlink:to="ions_PropertyPlantAndEquipmentExcludingLandMember_lbl1" xlink:title="label: PropertyPlantAndEquipmentExcludingLandMember to ions_PropertyPlantAndEquipmentExcludingLandMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EquipmentAndComputerSoftwareMember" xlink:label="EquipmentAndComputerSoftwareMember" xlink:title="EquipmentAndComputerSoftwareMember" />
    <link:label xlink:type="resource" xlink:label="ions_EquipmentAndComputerSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_EquipmentAndComputerSoftwareMember_lbl" xml:lang="en-US" id="ions_EquipmentAndComputerSoftwareMember_lbl">Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and purchased software applications and internally developed software for long-term internal use. Includes other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services, such as laboratory, manufacturing and other equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentAndComputerSoftwareMember" xlink:to="ions_EquipmentAndComputerSoftwareMember_lbl" xlink:title="label: EquipmentAndComputerSoftwareMember to ions_EquipmentAndComputerSoftwareMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_EquipmentAndComputerSoftwareMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_EquipmentAndComputerSoftwareMember_lbl1" xml:lang="en-US" id="ions_EquipmentAndComputerSoftwareMember_lbl1">Equipment and Computer Software [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentAndComputerSoftwareMember" xlink:to="ions_EquipmentAndComputerSoftwareMember_lbl1" xlink:title="label: EquipmentAndComputerSoftwareMember to ions_EquipmentAndComputerSoftwareMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_EquipmentAndComputerSoftwareMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_EquipmentAndComputerSoftwareMember_lbl2" xml:lang="en-US" id="ions_EquipmentAndComputerSoftwareMember_lbl2">Computer Software, Laboratory, Manufacturing and Other Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentAndComputerSoftwareMember" xlink:to="ions_EquipmentAndComputerSoftwareMember_lbl2" xlink:title="label: EquipmentAndComputerSoftwareMember to ions_EquipmentAndComputerSoftwareMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan" xlink:label="PeriodToMakeInterestOnlyPaymentsOnMortgageLoan" xlink:title="PeriodToMakeInterestOnlyPaymentsOnMortgageLoan" />
    <link:label xlink:type="resource" xlink:label="ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan_lbl" xml:lang="en-US" id="ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan_lbl">Period of time to make only payments of interest on the mortgage loan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodToMakeInterestOnlyPaymentsOnMortgageLoan" xlink:to="ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan_lbl" xlink:title="label: PeriodToMakeInterestOnlyPaymentsOnMortgageLoan to ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan_lbl1" xml:lang="en-US" id="ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan_lbl1">Period to make interest only payments on mortgage loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodToMakeInterestOnlyPaymentsOnMortgageLoan" xlink:to="ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan_lbl1" xlink:title="label: PeriodToMakeInterestOnlyPaymentsOnMortgageLoan to ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan_lbl2" xml:lang="en-US" id="ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan_lbl2">Period to make interest only payments on mortgage loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodToMakeInterestOnlyPaymentsOnMortgageLoan" xlink:to="ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan_lbl2" xlink:title="label: PeriodToMakeInterestOnlyPaymentsOnMortgageLoan to ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PrimaryResearchAndDevelopmentFacilityMember" xlink:label="PrimaryResearchAndDevelopmentFacilityMember" xlink:title="PrimaryResearchAndDevelopmentFacilityMember" />
    <link:label xlink:type="resource" xlink:label="ions_PrimaryResearchAndDevelopmentFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_PrimaryResearchAndDevelopmentFacilityMember_lbl" xml:lang="en-US" id="ions_PrimaryResearchAndDevelopmentFacilityMember_lbl">Facility constructed for the entity's primary research and development activities under a lease agreement with an affiliate of BioMed Realty, L.P.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrimaryResearchAndDevelopmentFacilityMember" xlink:to="ions_PrimaryResearchAndDevelopmentFacilityMember_lbl" xlink:title="label: PrimaryResearchAndDevelopmentFacilityMember to ions_PrimaryResearchAndDevelopmentFacilityMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_PrimaryResearchAndDevelopmentFacilityMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_PrimaryResearchAndDevelopmentFacilityMember_lbl1" xml:lang="en-US" id="ions_PrimaryResearchAndDevelopmentFacilityMember_lbl1">Primary Research and Development Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrimaryResearchAndDevelopmentFacilityMember" xlink:to="ions_PrimaryResearchAndDevelopmentFacilityMember_lbl1" xlink:title="label: PrimaryResearchAndDevelopmentFacilityMember to ions_PrimaryResearchAndDevelopmentFacilityMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_PrimaryResearchAndDevelopmentFacilityMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_PrimaryResearchAndDevelopmentFacilityMember_lbl2" xml:lang="en-US" id="ions_PrimaryResearchAndDevelopmentFacilityMember_lbl2">Primary R&amp;D Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrimaryResearchAndDevelopmentFacilityMember" xlink:to="ions_PrimaryResearchAndDevelopmentFacilityMember_lbl2" xlink:title="label: PrimaryResearchAndDevelopmentFacilityMember to ions_PrimaryResearchAndDevelopmentFacilityMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ShareBasedCompensationTable" xlink:label="ShareBasedCompensationTable" xlink:title="ShareBasedCompensationTable" />
    <link:label xlink:type="resource" xlink:label="ions_ShareBasedCompensationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ShareBasedCompensationTable_lbl" xml:lang="en-US" id="ions_ShareBasedCompensationTable_lbl">Disclosure of information about share-based compensation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationTable" xlink:to="ions_ShareBasedCompensationTable_lbl" xlink:title="label: ShareBasedCompensationTable to ions_ShareBasedCompensationTable_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ShareBasedCompensationTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ShareBasedCompensationTable_lbl1" xml:lang="en-US" id="ions_ShareBasedCompensationTable_lbl1">Share-based Compensation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationTable" xlink:to="ions_ShareBasedCompensationTable_lbl1" xlink:title="label: ShareBasedCompensationTable to ions_ShareBasedCompensationTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ShareBasedCompensationLineItems" xlink:label="ShareBasedCompensationLineItems" xlink:title="ShareBasedCompensationLineItems" />
    <link:label xlink:type="resource" xlink:label="ions_ShareBasedCompensationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ShareBasedCompensationLineItems_lbl" xml:lang="en-US" id="ions_ShareBasedCompensationLineItems_lbl">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationLineItems" xlink:to="ions_ShareBasedCompensationLineItems_lbl" xlink:title="label: ShareBasedCompensationLineItems to ions_ShareBasedCompensationLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ShareBasedCompensationLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ShareBasedCompensationLineItems_lbl1" xml:lang="en-US" id="ions_ShareBasedCompensationLineItems_lbl1">Share-based Compensation [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationLineItems" xlink:to="ions_ShareBasedCompensationLineItems_lbl1" xlink:title="label: ShareBasedCompensationLineItems to ions_ShareBasedCompensationLineItems_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ShareBasedCompensationLineItems_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ShareBasedCompensationLineItems_lbl2" xml:lang="en-US" id="ions_ShareBasedCompensationLineItems_lbl2">Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationLineItems" xlink:to="ions_ShareBasedCompensationLineItems_lbl2" xlink:title="label: ShareBasedCompensationLineItems to ions_ShareBasedCompensationLineItems_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_BoardOfDirectorStockOptionMember" xlink:label="BoardOfDirectorStockOptionMember" xlink:title="BoardOfDirectorStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="ions_BoardOfDirectorStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_BoardOfDirectorStockOptionMember_lbl" xml:lang="en-US" id="ions_BoardOfDirectorStockOptionMember_lbl">An arrangement whereby a member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, as a form of compensation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorStockOptionMember" xlink:to="ions_BoardOfDirectorStockOptionMember_lbl" xlink:title="label: BoardOfDirectorStockOptionMember to ions_BoardOfDirectorStockOptionMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_BoardOfDirectorStockOptionMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_BoardOfDirectorStockOptionMember_lbl1" xml:lang="en-US" id="ions_BoardOfDirectorStockOptionMember_lbl1">Board of Director Stock Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorStockOptionMember" xlink:to="ions_BoardOfDirectorStockOptionMember_lbl1" xlink:title="label: BoardOfDirectorStockOptionMember to ions_BoardOfDirectorStockOptionMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_BoardOfDirectorStockOptionMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_BoardOfDirectorStockOptionMember_lbl2" xml:lang="en-US" id="ions_BoardOfDirectorStockOptionMember_lbl2">Board of Director Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorStockOptionMember" xlink:to="ions_BoardOfDirectorStockOptionMember_lbl2" xlink:title="label: BoardOfDirectorStockOptionMember to ions_BoardOfDirectorStockOptionMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsMember" xlink:label="AkceaTherapeuticsMember" xlink:title="AkceaTherapeuticsMember" />
    <link:label xlink:type="resource" xlink:label="ions_AkceaTherapeuticsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_AkceaTherapeuticsMember_lbl" xml:lang="en-US" id="ions_AkceaTherapeuticsMember_lbl">Reportable segment which includes the operations of the Company's wholly-owned subsidiary, Akcea Therapeutics, Inc., which was formed to develop and commercialize drugs for cardiometabolic disorders.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AkceaTherapeuticsMember" xlink:to="ions_AkceaTherapeuticsMember_lbl" xlink:title="label: AkceaTherapeuticsMember to ions_AkceaTherapeuticsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_AkceaTherapeuticsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_AkceaTherapeuticsMember_lbl1" xml:lang="en-US" id="ions_AkceaTherapeuticsMember_lbl1">Akcea Therapeutics [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AkceaTherapeuticsMember" xlink:to="ions_AkceaTherapeuticsMember_lbl1" xlink:title="label: AkceaTherapeuticsMember to ions_AkceaTherapeuticsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IonisCoreMember" xlink:label="IonisCoreMember" xlink:title="IonisCoreMember" />
    <link:label xlink:type="resource" xlink:label="ions_IonisCoreMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_IonisCoreMember_lbl" xml:lang="en-US" id="ions_IonisCoreMember_lbl">Reportable segment in which the Company is exploiting a novel drug discovery platform created to generate a broad pipeline of first-in-class or best-in-class drugs for the Company and its partners. This segment generates revenue from a multifaceted partnering strategy. This strategy includes revenue from collaborations with preferred partners, traditional alliances and working with a consortium of companies that can exploit the Company's drugs and technology. Revenue from collaborations with preferred partners and traditional alliances may consist of upfront payments, milestone payments, licensing fees and royalties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IonisCoreMember" xlink:to="ions_IonisCoreMember_lbl" xlink:title="label: IonisCoreMember to ions_IonisCoreMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_IonisCoreMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_IonisCoreMember_lbl1" xml:lang="en-US" id="ions_IonisCoreMember_lbl1">Ionis Core [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IonisCoreMember" xlink:to="ions_IonisCoreMember_lbl1" xlink:title="label: IonisCoreMember to ions_IonisCoreMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_IonisCoreMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_IonisCoreMember_lbl2" xml:lang="en-US" id="ions_IonisCoreMember_lbl2">Ionis [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IonisCoreMember" xlink:to="ions_IonisCoreMember_lbl2" xlink:title="label: IonisCoreMember to ions_IonisCoreMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue" />
    <link:label xlink:type="resource" xlink:label="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue_lbl" xml:lang="en-US" id="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue_lbl">The weighted average grant-date fair value of options exercised during the reporting period as calculated by applying the disclosed option pricing methodology.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue" xlink:to="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue to ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue_lbl1" xml:lang="en-US" id="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue" xlink:to="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue to ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue_lbl2" xml:lang="en-US" id="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue_lbl2">Weighted-average fair value of options exercised (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue" xlink:to="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue to ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PaymentsToAcquireCostMethodInvestments" xlink:label="PaymentsToAcquireCostMethodInvestments" xlink:title="PaymentsToAcquireCostMethodInvestments" />
    <link:label xlink:type="resource" xlink:label="ions_PaymentsToAcquireCostMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_PaymentsToAcquireCostMethodInvestments_lbl" xml:lang="en-US" id="ions_PaymentsToAcquireCostMethodInvestments_lbl">The cash outflow associated with the purchase of investments accounted for under the cost method of accounting.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireCostMethodInvestments" xlink:to="ions_PaymentsToAcquireCostMethodInvestments_lbl" xlink:title="label: PaymentsToAcquireCostMethodInvestments to ions_PaymentsToAcquireCostMethodInvestments_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_PaymentsToAcquireCostMethodInvestments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_PaymentsToAcquireCostMethodInvestments_lbl1" xml:lang="en-US" id="ions_PaymentsToAcquireCostMethodInvestments_lbl1">Payments to Acquire Cost Method Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireCostMethodInvestments" xlink:to="ions_PaymentsToAcquireCostMethodInvestments_lbl1" xlink:title="label: PaymentsToAcquireCostMethodInvestments to ions_PaymentsToAcquireCostMethodInvestments_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_PaymentsToAcquireCostMethodInvestments_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ions_PaymentsToAcquireCostMethodInvestments_lbl2" xml:lang="en-US" id="ions_PaymentsToAcquireCostMethodInvestments_lbl2">Purchase of strategic investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireCostMethodInvestments" xlink:to="ions_PaymentsToAcquireCostMethodInvestments_lbl2" xlink:title="label: PaymentsToAcquireCostMethodInvestments to ions_PaymentsToAcquireCostMethodInvestments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PaymentsToAcquireLicensesAndOtherAssets" xlink:label="PaymentsToAcquireLicensesAndOtherAssets" xlink:title="PaymentsToAcquireLicensesAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="ions_PaymentsToAcquireLicensesAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_PaymentsToAcquireLicensesAndOtherAssets_lbl" xml:lang="en-US" id="ions_PaymentsToAcquireLicensesAndOtherAssets_lbl">The cash outflow for acquisition of licenses and other assets not otherwise defined in the taxonomy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireLicensesAndOtherAssets" xlink:to="ions_PaymentsToAcquireLicensesAndOtherAssets_lbl" xlink:title="label: PaymentsToAcquireLicensesAndOtherAssets to ions_PaymentsToAcquireLicensesAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_PaymentsToAcquireLicensesAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_PaymentsToAcquireLicensesAndOtherAssets_lbl1" xml:lang="en-US" id="ions_PaymentsToAcquireLicensesAndOtherAssets_lbl1">Payments to Acquire Licenses and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireLicensesAndOtherAssets" xlink:to="ions_PaymentsToAcquireLicensesAndOtherAssets_lbl1" xlink:title="label: PaymentsToAcquireLicensesAndOtherAssets to ions_PaymentsToAcquireLicensesAndOtherAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_PaymentsToAcquireLicensesAndOtherAssets_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ions_PaymentsToAcquireLicensesAndOtherAssets_lbl2" xml:lang="en-US" id="ions_PaymentsToAcquireLicensesAndOtherAssets_lbl2">Acquisition of licenses and other assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireLicensesAndOtherAssets" xlink:to="ions_PaymentsToAcquireLicensesAndOtherAssets_lbl2" xlink:title="label: PaymentsToAcquireLicensesAndOtherAssets to ions_PaymentsToAcquireLicensesAndOtherAssets_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NonCashCapitalAndPatentExpenditures" xlink:label="NonCashCapitalAndPatentExpenditures" xlink:title="NonCashCapitalAndPatentExpenditures" />
    <link:label xlink:type="resource" xlink:label="ions_NonCashCapitalAndPatentExpenditures_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NonCashCapitalAndPatentExpenditures_lbl" xml:lang="en-US" id="ions_NonCashCapitalAndPatentExpenditures_lbl">Future cash outflow to pay for purchases of fixed assets and patents that have been incurred.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonCashCapitalAndPatentExpenditures" xlink:to="ions_NonCashCapitalAndPatentExpenditures_lbl" xlink:title="label: NonCashCapitalAndPatentExpenditures to ions_NonCashCapitalAndPatentExpenditures_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NonCashCapitalAndPatentExpenditures_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NonCashCapitalAndPatentExpenditures_lbl1" xml:lang="en-US" id="ions_NonCashCapitalAndPatentExpenditures_lbl1">Non-cash Capital and Patent Expenditures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonCashCapitalAndPatentExpenditures" xlink:to="ions_NonCashCapitalAndPatentExpenditures_lbl1" xlink:title="label: NonCashCapitalAndPatentExpenditures to ions_NonCashCapitalAndPatentExpenditures_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NonCashCapitalAndPatentExpenditures_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NonCashCapitalAndPatentExpenditures_lbl2" xml:lang="en-US" id="ions_NonCashCapitalAndPatentExpenditures_lbl2">Amounts accrued for capital and patent expenditures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonCashCapitalAndPatentExpenditures" xlink:to="ions_NonCashCapitalAndPatentExpenditures_lbl2" xlink:title="label: NonCashCapitalAndPatentExpenditures to ions_NonCashCapitalAndPatentExpenditures_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PaymentToSettleFinancingLiabilityForLeasedFacility" xlink:label="PaymentToSettleFinancingLiabilityForLeasedFacility" xlink:title="PaymentToSettleFinancingLiabilityForLeasedFacility" />
    <link:label xlink:type="resource" xlink:label="ions_PaymentToSettleFinancingLiabilityForLeasedFacility_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_PaymentToSettleFinancingLiabilityForLeasedFacility_lbl" xml:lang="en-US" id="ions_PaymentToSettleFinancingLiabilityForLeasedFacility_lbl">The cash outflow paid to settle financing liability for leased facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentToSettleFinancingLiabilityForLeasedFacility" xlink:to="ions_PaymentToSettleFinancingLiabilityForLeasedFacility_lbl" xlink:title="label: PaymentToSettleFinancingLiabilityForLeasedFacility to ions_PaymentToSettleFinancingLiabilityForLeasedFacility_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_PaymentToSettleFinancingLiabilityForLeasedFacility_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_PaymentToSettleFinancingLiabilityForLeasedFacility_lbl1" xml:lang="en-US" id="ions_PaymentToSettleFinancingLiabilityForLeasedFacility_lbl1">Payment to settle financing liability for leased facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentToSettleFinancingLiabilityForLeasedFacility" xlink:to="ions_PaymentToSettleFinancingLiabilityForLeasedFacility_lbl1" xlink:title="label: PaymentToSettleFinancingLiabilityForLeasedFacility to ions_PaymentToSettleFinancingLiabilityForLeasedFacility_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_PaymentToSettleFinancingLiabilityForLeasedFacility_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ions_PaymentToSettleFinancingLiabilityForLeasedFacility_lbl2" xml:lang="en-US" id="ions_PaymentToSettleFinancingLiabilityForLeasedFacility_lbl2">Payment to settle financing liability for leased facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentToSettleFinancingLiabilityForLeasedFacility" xlink:to="ions_PaymentToSettleFinancingLiabilityForLeasedFacility_lbl2" xlink:title="label: PaymentToSettleFinancingLiabilityForLeasedFacility to ions_PaymentToSettleFinancingLiabilityForLeasedFacility_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" />
    <link:label xlink:type="resource" xlink:label="ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities_lbl" xml:lang="en-US" id="ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities_lbl">The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and the change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" xlink:to="ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities_lbl" xlink:title="label: IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities to ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities_lbl1" xml:lang="en-US" id="ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities_lbl1">Increase (Decrease) in Accrued Liabilities and Deferred Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" xlink:to="ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities_lbl1" xlink:title="label: IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities to ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities_lbl2" xml:lang="en-US" id="ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities_lbl2">Accrued liabilities and deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" xlink:to="ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities_lbl2" xlink:title="label: IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities to ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" xlink:label="AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" xlink:title="AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" />
    <link:label xlink:type="resource" xlink:label="ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments_lbl" xml:lang="en-US" id="ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments_lbl">Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill and an other than temporary decline in value that has been recognized against investments accounted for under the cost method of accounting.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" xlink:to="ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments_lbl" xlink:title="label: AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments to ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments_lbl1" xml:lang="en-US" id="ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments_lbl1">Asset Impairment Charges, including other than temporary impairment in Cost-method Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" xlink:to="ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments_lbl1" xlink:title="label: AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments to ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments_lbl2" xml:lang="en-US" id="ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments_lbl2">Non-cash losses related to patents, licensing, property, plant and equipment and investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" xlink:to="ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments_lbl2" xlink:title="label: AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments to ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_OperatingLeaseRightOfUseAssetAmortization" xlink:label="OperatingLeaseRightOfUseAssetAmortization" xlink:title="OperatingLeaseRightOfUseAssetAmortization" />
    <link:label xlink:type="resource" xlink:label="ions_OperatingLeaseRightOfUseAssetAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_OperatingLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US" id="ions_OperatingLeaseRightOfUseAssetAmortization_lbl">Amount of amortization expense attributable to right-of-use asset from operating lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetAmortization" xlink:to="ions_OperatingLeaseRightOfUseAssetAmortization_lbl" xlink:title="label: OperatingLeaseRightOfUseAssetAmortization to ions_OperatingLeaseRightOfUseAssetAmortization_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_OperatingLeaseRightOfUseAssetAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_OperatingLeaseRightOfUseAssetAmortization_lbl1" xml:lang="en-US" id="ions_OperatingLeaseRightOfUseAssetAmortization_lbl1">Operating Lease, Right-of-Use Asset, Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetAmortization" xlink:to="ions_OperatingLeaseRightOfUseAssetAmortization_lbl1" xlink:title="label: OperatingLeaseRightOfUseAssetAmortization to ions_OperatingLeaseRightOfUseAssetAmortization_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_OperatingLeaseRightOfUseAssetAmortization_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_OperatingLeaseRightOfUseAssetAmortization_lbl2" xml:lang="en-US" id="ions_OperatingLeaseRightOfUseAssetAmortization_lbl2">Amortization of right-of-use operating lease assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetAmortization" xlink:to="ions_OperatingLeaseRightOfUseAssetAmortization_lbl2" xlink:title="label: OperatingLeaseRightOfUseAssetAmortization to ions_OperatingLeaseRightOfUseAssetAmortization_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NovartisInternationalAGMember" xlink:label="NovartisInternationalAGMember" xlink:title="NovartisInternationalAGMember" />
    <link:label xlink:type="resource" xlink:label="ions_NovartisInternationalAGMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NovartisInternationalAGMember_lbl" xml:lang="en-US" id="ions_NovartisInternationalAGMember_lbl">Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NovartisInternationalAGMember" xlink:to="ions_NovartisInternationalAGMember_lbl" xlink:title="label: NovartisInternationalAGMember to ions_NovartisInternationalAGMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NovartisInternationalAGMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NovartisInternationalAGMember_lbl1" xml:lang="en-US" id="ions_NovartisInternationalAGMember_lbl1">Novartis International AG [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NovartisInternationalAGMember" xlink:to="ions_NovartisInternationalAGMember_lbl1" xlink:title="label: NovartisInternationalAGMember to ions_NovartisInternationalAGMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NovartisInternationalAGMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NovartisInternationalAGMember_lbl2" xml:lang="en-US" id="ions_NovartisInternationalAGMember_lbl2">Novartis [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NovartisInternationalAGMember" xlink:to="ions_NovartisInternationalAGMember_lbl2" xlink:title="label: NovartisInternationalAGMember to ions_NovartisInternationalAGMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_BiogenIncMember" xlink:label="BiogenIncMember" xlink:title="BiogenIncMember" />
    <link:label xlink:type="resource" xlink:label="ions_BiogenIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_BiogenIncMember_lbl" xml:lang="en-US" id="ions_BiogenIncMember_lbl">Biogen Inc. is an American multinational biotechnology company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BiogenIncMember" xlink:to="ions_BiogenIncMember_lbl" xlink:title="label: BiogenIncMember to ions_BiogenIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_BiogenIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_BiogenIncMember_lbl1" xml:lang="en-US" id="ions_BiogenIncMember_lbl1">Biogen Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BiogenIncMember" xlink:to="ions_BiogenIncMember_lbl1" xlink:title="label: BiogenIncMember to ions_BiogenIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_BiogenIncMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_BiogenIncMember_lbl2" xml:lang="en-US" id="ions_BiogenIncMember_lbl2">Biogen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BiogenIncMember" xlink:to="ions_BiogenIncMember_lbl2" xlink:title="label: BiogenIncMember to ions_BiogenIncMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" xlink:label="IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" xlink:title="IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" />
    <link:label xlink:type="resource" xlink:label="ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan_lbl" xml:lang="en-US" id="ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan_lbl">Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of shares issuable related to employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" xlink:to="ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan_lbl" xlink:title="label: IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan to ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan_lbl1" xml:lang="en-US" id="ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan_lbl1">Incremental Common Shares Attributable to Employee Stock Purchase Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" xlink:to="ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan_lbl1" xlink:title="label: IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan to ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan_lbl2" xml:lang="en-US" id="ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan_lbl2">Shares issuable related to our Employee Stock Purchase Plan (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" xlink:to="ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan_lbl2" xlink:title="label: IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan to ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_WeightedAverageNumberOfSharesOwnedInSubsidiary" xlink:label="WeightedAverageNumberOfSharesOwnedInSubsidiary" xlink:title="WeightedAverageNumberOfSharesOwnedInSubsidiary" />
    <link:label xlink:type="resource" xlink:label="ions_WeightedAverageNumberOfSharesOwnedInSubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_WeightedAverageNumberOfSharesOwnedInSubsidiary_lbl" xml:lang="en-US" id="ions_WeightedAverageNumberOfSharesOwnedInSubsidiary_lbl">Number of shares owned in the subsidiary during the reporting period determined by relating the portion of time within a reporting period that shares have been owned to the total time in that period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOwnedInSubsidiary" xlink:to="ions_WeightedAverageNumberOfSharesOwnedInSubsidiary_lbl" xlink:title="label: WeightedAverageNumberOfSharesOwnedInSubsidiary to ions_WeightedAverageNumberOfSharesOwnedInSubsidiary_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_WeightedAverageNumberOfSharesOwnedInSubsidiary_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_WeightedAverageNumberOfSharesOwnedInSubsidiary_lbl1" xml:lang="en-US" id="ions_WeightedAverageNumberOfSharesOwnedInSubsidiary_lbl1">Weighted average number of shares owned in subsidiary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOwnedInSubsidiary" xlink:to="ions_WeightedAverageNumberOfSharesOwnedInSubsidiary_lbl1" xlink:title="label: WeightedAverageNumberOfSharesOwnedInSubsidiary to ions_WeightedAverageNumberOfSharesOwnedInSubsidiary_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_WeightedAverageNumberOfSharesOwnedInSubsidiary_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_WeightedAverageNumberOfSharesOwnedInSubsidiary_lbl2" xml:lang="en-US" id="ions_WeightedAverageNumberOfSharesOwnedInSubsidiary_lbl2">Weighted average shares owned in Akcea (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOwnedInSubsidiary" xlink:to="ions_WeightedAverageNumberOfSharesOwnedInSubsidiary_lbl2" xlink:title="label: WeightedAverageNumberOfSharesOwnedInSubsidiary to ions_WeightedAverageNumberOfSharesOwnedInSubsidiary_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ClinicalRawMaterialsMember" xlink:label="ClinicalRawMaterialsMember" xlink:title="ClinicalRawMaterialsMember" />
    <link:label xlink:type="resource" xlink:label="ions_ClinicalRawMaterialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ClinicalRawMaterialsMember_lbl" xml:lang="en-US" id="ions_ClinicalRawMaterialsMember_lbl">Raw materials purchased for use in producing medicines that have alternative future uses until they are used.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClinicalRawMaterialsMember" xlink:to="ions_ClinicalRawMaterialsMember_lbl" xlink:title="label: ClinicalRawMaterialsMember to ions_ClinicalRawMaterialsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ClinicalRawMaterialsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ClinicalRawMaterialsMember_lbl1" xml:lang="en-US" id="ions_ClinicalRawMaterialsMember_lbl1">Clinical Raw Materials [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClinicalRawMaterialsMember" xlink:to="ions_ClinicalRawMaterialsMember_lbl1" xlink:title="label: ClinicalRawMaterialsMember to ions_ClinicalRawMaterialsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ClinicalRawMaterialsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ClinicalRawMaterialsMember_lbl2" xml:lang="en-US" id="ions_ClinicalRawMaterialsMember_lbl2">Clinical Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClinicalRawMaterialsMember" xlink:to="ions_ClinicalRawMaterialsMember_lbl2" xlink:title="label: ClinicalRawMaterialsMember to ions_ClinicalRawMaterialsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CommercialRawMaterialsMember" xlink:label="CommercialRawMaterialsMember" xlink:title="CommercialRawMaterialsMember" />
    <link:label xlink:type="resource" xlink:label="ions_CommercialRawMaterialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CommercialRawMaterialsMember_lbl" xml:lang="en-US" id="ions_CommercialRawMaterialsMember_lbl">Raw materials purchased for manufacturing medicines for commercial production.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommercialRawMaterialsMember" xlink:to="ions_CommercialRawMaterialsMember_lbl" xlink:title="label: CommercialRawMaterialsMember to ions_CommercialRawMaterialsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CommercialRawMaterialsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CommercialRawMaterialsMember_lbl1" xml:lang="en-US" id="ions_CommercialRawMaterialsMember_lbl1">Commercial Raw Materials [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommercialRawMaterialsMember" xlink:to="ions_CommercialRawMaterialsMember_lbl1" xlink:title="label: CommercialRawMaterialsMember to ions_CommercialRawMaterialsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CommercialRawMaterialsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CommercialRawMaterialsMember_lbl2" xml:lang="en-US" id="ions_CommercialRawMaterialsMember_lbl2">Commercial [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommercialRawMaterialsMember" xlink:to="ions_CommercialRawMaterialsMember_lbl2" xlink:title="label: CommercialRawMaterialsMember to ions_CommercialRawMaterialsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock" xlink:label="CashCashEquivalentsAndInvestmentsPolicyTextBlock" xlink:title="CashCashEquivalentsAndInvestmentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock_lbl" xml:lang="en-US" id="ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock_lbl">Disclosure of accounting policy for cash, cash equivalents and investments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsAndInvestmentsPolicyTextBlock" xlink:to="ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock_lbl" xlink:title="label: CashCashEquivalentsAndInvestmentsPolicyTextBlock to ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock_lbl1" xml:lang="en-US" id="ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock_lbl1">Cash, Cash Equivalents and Investments [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsAndInvestmentsPolicyTextBlock" xlink:to="ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock_lbl1" xlink:title="label: CashCashEquivalentsAndInvestmentsPolicyTextBlock to ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock_lbl2" xml:lang="en-US" id="ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock_lbl2">Cash, Cash Equivalents and Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsAndInvestmentsPolicyTextBlock" xlink:to="ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock_lbl2" xlink:title="label: CashCashEquivalentsAndInvestmentsPolicyTextBlock to ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfExecutiveOfficersTerminatingEmployment" xlink:label="NumberOfExecutiveOfficersTerminatingEmployment" xlink:title="NumberOfExecutiveOfficersTerminatingEmployment" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfExecutiveOfficersTerminatingEmployment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NumberOfExecutiveOfficersTerminatingEmployment_lbl" xml:lang="en-US" id="ions_NumberOfExecutiveOfficersTerminatingEmployment_lbl">The number of executive officers terminating employment with the company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfExecutiveOfficersTerminatingEmployment" xlink:to="ions_NumberOfExecutiveOfficersTerminatingEmployment_lbl" xlink:title="label: NumberOfExecutiveOfficersTerminatingEmployment to ions_NumberOfExecutiveOfficersTerminatingEmployment_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfExecutiveOfficersTerminatingEmployment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NumberOfExecutiveOfficersTerminatingEmployment_lbl1" xml:lang="en-US" id="ions_NumberOfExecutiveOfficersTerminatingEmployment_lbl1">Number of executive officers terminating employment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfExecutiveOfficersTerminatingEmployment" xlink:to="ions_NumberOfExecutiveOfficersTerminatingEmployment_lbl1" xlink:title="label: NumberOfExecutiveOfficersTerminatingEmployment to ions_NumberOfExecutiveOfficersTerminatingEmployment_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfExecutiveOfficersTerminatingEmployment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NumberOfExecutiveOfficersTerminatingEmployment_lbl2" xml:lang="en-US" id="ions_NumberOfExecutiveOfficersTerminatingEmployment_lbl2">Number of executive officers terminating employment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfExecutiveOfficersTerminatingEmployment" xlink:to="ions_NumberOfExecutiveOfficersTerminatingEmployment_lbl2" xlink:title="label: NumberOfExecutiveOfficersTerminatingEmployment to ions_NumberOfExecutiveOfficersTerminatingEmployment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchDevelopmentAndPatentMember" xlink:label="ResearchDevelopmentAndPatentMember" xlink:title="ResearchDevelopmentAndPatentMember" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchDevelopmentAndPatentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ResearchDevelopmentAndPatentMember_lbl" xml:lang="en-US" id="ions_ResearchDevelopmentAndPatentMember_lbl">Primary financial statement caption encompassing research, development and patent expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchDevelopmentAndPatentMember" xlink:to="ions_ResearchDevelopmentAndPatentMember_lbl" xlink:title="label: ResearchDevelopmentAndPatentMember to ions_ResearchDevelopmentAndPatentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchDevelopmentAndPatentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ResearchDevelopmentAndPatentMember_lbl1" xml:lang="en-US" id="ions_ResearchDevelopmentAndPatentMember_lbl1">Research, Development and Patent [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchDevelopmentAndPatentMember" xlink:to="ions_ResearchDevelopmentAndPatentMember_lbl1" xlink:title="label: ResearchDevelopmentAndPatentMember to ions_ResearchDevelopmentAndPatentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchDevelopmentAndPatentMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ResearchDevelopmentAndPatentMember_lbl2" xml:lang="en-US" id="ions_ResearchDevelopmentAndPatentMember_lbl2">Research, Development and Patent [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchDevelopmentAndPatentMember" xlink:to="ions_ResearchDevelopmentAndPatentMember_lbl2" xlink:title="label: ResearchDevelopmentAndPatentMember to ions_ResearchDevelopmentAndPatentMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:label="NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:title="NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl" xml:lang="en-US" id="ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl">The number of executive officers terminated by the Company during the period that begins three months before and ends twelve months following a change in control of the Company when vesting will accelerate for options and RSUs outstanding as of the termination date for executive officers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:to="ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl" xlink:title="label: NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers to ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl1" xml:lang="en-US" id="ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl1">Number of executive officers terminated before change in control when vesting will accelerate for executive officers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:to="ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl1" xlink:title="label: NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers to ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl2" xml:lang="en-US" id="ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl2">Number of executive officers terminated before change in control when vesting will accelerate for executive officers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:to="ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl2" xlink:title="label: NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers to ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:label="PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:title="PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" />
    <link:label xlink:type="resource" xlink:label="ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl" xml:lang="en-US" id="ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl">Period of time before a change in control of the Company when vesting will accelerate for options and RSUs outstanding as of the termination date for executive officers, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:to="ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl" xlink:title="label: PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers to ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl1" xml:lang="en-US" id="ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl1">Period before change in control when vesting will accelerate for executive officers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:to="ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl1" xlink:title="label: PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers to ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl2" xml:lang="en-US" id="ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl2">Period before change in control when vesting will accelerate for executive officers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:to="ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl2" xlink:title="label: PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers to ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:label="PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:title="PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" />
    <link:label xlink:type="resource" xlink:label="ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl" xml:lang="en-US" id="ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl">Period of time after a change in control of the Company when vesting will accelerate for options and RSUs outstanding as of the termination date for executive officers, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:to="ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl" xlink:title="label: PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers to ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl1" xml:lang="en-US" id="ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl1">Period after change in control when vesting will accelerate for executive officers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:to="ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl1" xlink:title="label: PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers to ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl2" xml:lang="en-US" id="ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl2">Period after change in control when vesting will accelerate for executive officers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:to="ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl2" xlink:title="label: PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers to ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod" />
    <link:label xlink:type="resource" xlink:label="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod_lbl" xml:lang="en-US" id="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod_lbl">Represents the holding period from the date of purchase for stock purchased under the plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod" xlink:to="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod to ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod_lbl1" xml:lang="en-US" id="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Holding Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod" xlink:to="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod to ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod_lbl2" xml:lang="en-US" id="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod_lbl2">Holding period for purchased stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod" xlink:to="ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod to ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable" xlink:label="NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable" xlink:title="NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable_lbl" xml:lang="en-US" id="ions_NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable_lbl">Number of equal annual installments over which options become exercisable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable" xlink:to="ions_NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable_lbl" xlink:title="label: NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable to ions_NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable_lbl1" xml:lang="en-US" id="ions_NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable_lbl1">Number of equal annual installments over which options become exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable" xlink:to="ions_NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable_lbl1" xlink:title="label: NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable to ions_NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NonemployeeDirectorsStockOptionPlan2002Member" xlink:label="NonemployeeDirectorsStockOptionPlan2002Member" xlink:title="NonemployeeDirectorsStockOptionPlan2002Member" />
    <link:label xlink:type="resource" xlink:label="ions_NonemployeeDirectorsStockOptionPlan2002Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NonemployeeDirectorsStockOptionPlan2002Member_lbl" xml:lang="en-US" id="ions_NonemployeeDirectorsStockOptionPlan2002Member_lbl">Represents the 2002 Non-Employee Directors Stock Option Plan, which provided for the issuance of stock options to the entity's non-employee directors for the purchase of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonemployeeDirectorsStockOptionPlan2002Member" xlink:to="ions_NonemployeeDirectorsStockOptionPlan2002Member_lbl" xlink:title="label: NonemployeeDirectorsStockOptionPlan2002Member to ions_NonemployeeDirectorsStockOptionPlan2002Member_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NonemployeeDirectorsStockOptionPlan2002Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NonemployeeDirectorsStockOptionPlan2002Member_lbl1" xml:lang="en-US" id="ions_NonemployeeDirectorsStockOptionPlan2002Member_lbl1">Nonemployee Directors' Stock Option Plan 2002 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonemployeeDirectorsStockOptionPlan2002Member" xlink:to="ions_NonemployeeDirectorsStockOptionPlan2002Member_lbl1" xlink:title="label: NonemployeeDirectorsStockOptionPlan2002Member to ions_NonemployeeDirectorsStockOptionPlan2002Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NonemployeeDirectorsStockOptionPlan2002Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NonemployeeDirectorsStockOptionPlan2002Member_lbl2" xml:lang="en-US" id="ions_NonemployeeDirectorsStockOptionPlan2002Member_lbl2">2002 Non-Employee Directors' Stock Option Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonemployeeDirectorsStockOptionPlan2002Member" xlink:to="ions_NonemployeeDirectorsStockOptionPlan2002Member_lbl2" xlink:title="label: NonemployeeDirectorsStockOptionPlan2002Member to ions_NonemployeeDirectorsStockOptionPlan2002Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EquityIncentivePlan2011Member" xlink:label="EquityIncentivePlan2011Member" xlink:title="EquityIncentivePlan2011Member" />
    <link:label xlink:type="resource" xlink:label="ions_EquityIncentivePlan2011Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_EquityIncentivePlan2011Member_lbl" xml:lang="en-US" id="ions_EquityIncentivePlan2011Member_lbl">Represents the stock option plan that provides for the issuance of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and performance cash awards to employees, directors, and consultants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2011Member" xlink:to="ions_EquityIncentivePlan2011Member_lbl" xlink:title="label: EquityIncentivePlan2011Member to ions_EquityIncentivePlan2011Member_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_EquityIncentivePlan2011Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_EquityIncentivePlan2011Member_lbl1" xml:lang="en-US" id="ions_EquityIncentivePlan2011Member_lbl1">Equity Incentive Plan 2011 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2011Member" xlink:to="ions_EquityIncentivePlan2011Member_lbl1" xlink:title="label: EquityIncentivePlan2011Member to ions_EquityIncentivePlan2011Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_EquityIncentivePlan2011Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_EquityIncentivePlan2011Member_lbl2" xml:lang="en-US" id="ions_EquityIncentivePlan2011Member_lbl2">2011 Equity Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlan2011Member" xlink:to="ions_EquityIncentivePlan2011Member_lbl2" xlink:title="label: EquityIncentivePlan2011Member to ions_EquityIncentivePlan2011Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_StockOptionPlan1989Member" xlink:label="StockOptionPlan1989Member" xlink:title="StockOptionPlan1989Member" />
    <link:label xlink:type="resource" xlink:label="ions_StockOptionPlan1989Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_StockOptionPlan1989Member_lbl" xml:lang="en-US" id="ions_StockOptionPlan1989Member_lbl">Represents the 1989 Stock Option Plan, which provides the issuance of non-qualified and incentive stock options for the purchase of common stock to the entity's employees, directors and consultants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlan1989Member" xlink:to="ions_StockOptionPlan1989Member_lbl" xlink:title="label: StockOptionPlan1989Member to ions_StockOptionPlan1989Member_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_StockOptionPlan1989Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_StockOptionPlan1989Member_lbl1" xml:lang="en-US" id="ions_StockOptionPlan1989Member_lbl1">Stock Option Plan 1989 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlan1989Member" xlink:to="ions_StockOptionPlan1989Member_lbl1" xlink:title="label: StockOptionPlan1989Member to ions_StockOptionPlan1989Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_StockOptionPlan1989Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_StockOptionPlan1989Member_lbl2" xml:lang="en-US" id="ions_StockOptionPlan1989Member_lbl2">1989 Stock Option Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionPlan1989Member" xlink:to="ions_StockOptionPlan1989Member_lbl2" xlink:title="label: StockOptionPlan1989Member to ions_StockOptionPlan1989Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EmployeeStockPurchasePlanMember" xlink:label="EmployeeStockPurchasePlanMember" xlink:title="EmployeeStockPurchasePlanMember" />
    <link:label xlink:type="resource" xlink:label="ions_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" id="ions_EmployeeStockPurchasePlanMember_lbl">Represents the 2009 Employee Stock Purchase Plan, as amended and restated, which permits full-time employees to purchase common stock through payroll deductions at a percentage of the fair market value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanMember" xlink:to="ions_EmployeeStockPurchasePlanMember_lbl" xlink:title="label: EmployeeStockPurchasePlanMember to ions_EmployeeStockPurchasePlanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_EmployeeStockPurchasePlanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_EmployeeStockPurchasePlanMember_lbl1" xml:lang="en-US" id="ions_EmployeeStockPurchasePlanMember_lbl1">Employee Stock Purchase Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanMember" xlink:to="ions_EmployeeStockPurchasePlanMember_lbl1" xlink:title="label: EmployeeStockPurchasePlanMember to ions_EmployeeStockPurchasePlanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_EmployeeStockPurchasePlanMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_EmployeeStockPurchasePlanMember_lbl2" xml:lang="en-US" id="ions_EmployeeStockPurchasePlanMember_lbl2">Employee Stock Purchase Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockPurchasePlanMember" xlink:to="ions_EmployeeStockPurchasePlanMember_lbl2" xlink:title="label: EmployeeStockPurchasePlanMember to ions_EmployeeStockPurchasePlanMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LesseeOperatingLeaseInformationTableTextBlock" xlink:label="LesseeOperatingLeaseInformationTableTextBlock" xlink:title="LesseeOperatingLeaseInformationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="ions_LesseeOperatingLeaseInformationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_LesseeOperatingLeaseInformationTableTextBlock_lbl" xml:lang="en-US" id="ions_LesseeOperatingLeaseInformationTableTextBlock_lbl">Tabular disclosure of information on lessee's operating leases, including carrying value of right-of-use assets and lease liabilities, weighted-average remaining term and weighted-average discount rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseInformationTableTextBlock" xlink:to="ions_LesseeOperatingLeaseInformationTableTextBlock_lbl" xlink:title="label: LesseeOperatingLeaseInformationTableTextBlock to ions_LesseeOperatingLeaseInformationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_LesseeOperatingLeaseInformationTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_LesseeOperatingLeaseInformationTableTextBlock_lbl1" xml:lang="en-US" id="ions_LesseeOperatingLeaseInformationTableTextBlock_lbl1">Lessee, Operating Lease Information [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseInformationTableTextBlock" xlink:to="ions_LesseeOperatingLeaseInformationTableTextBlock_lbl1" xlink:title="label: LesseeOperatingLeaseInformationTableTextBlock to ions_LesseeOperatingLeaseInformationTableTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_LesseeOperatingLeaseInformationTableTextBlock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_LesseeOperatingLeaseInformationTableTextBlock_lbl2" xml:lang="en-US" id="ions_LesseeOperatingLeaseInformationTableTextBlock_lbl2">Amounts Related to Operating Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseInformationTableTextBlock" xlink:to="ions_LesseeOperatingLeaseInformationTableTextBlock_lbl2" xlink:title="label: LesseeOperatingLeaseInformationTableTextBlock to ions_LesseeOperatingLeaseInformationTableTextBlock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" xlink:label="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" xlink:title="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" />
    <link:label xlink:type="resource" xlink:label="ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption_lbl" xml:lang="en-US" id="ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption_lbl">Adjustment to additional paid in capital resulting from the redemption of convertible debt instruments as two separate components - a debt component and an equity component.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" xlink:to="ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption_lbl" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption to ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption_lbl1" xml:lang="en-US" id="ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption_lbl1">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Redemption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" xlink:to="ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption to ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption_lbl2" xml:lang="en-US" id="ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption_lbl2">1 percent convertible senior notes retirement, equity portion, net of tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" xlink:to="ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption_lbl2" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption to ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary" xlink:label="StockIssuedDuringPeriodValueNewIssuesBySubsidiary" xlink:title="StockIssuedDuringPeriodValueNewIssuesBySubsidiary" />
    <link:label xlink:type="resource" xlink:label="ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary_lbl" xml:lang="en-US" id="ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary_lbl">Equity impact of the value of new stock issued during the period by a subsidiary. Includes shares issued in an initial public offering or a secondary public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssuesBySubsidiary" xlink:to="ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary_lbl" xlink:title="label: StockIssuedDuringPeriodValueNewIssuesBySubsidiary to ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary_lbl1" xml:lang="en-US" id="ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary_lbl1">Stock Issued During Period, Value, New Issues by Subsidiary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssuesBySubsidiary" xlink:to="ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary_lbl1" xlink:title="label: StockIssuedDuringPeriodValueNewIssuesBySubsidiary to ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary_lbl2" xml:lang="en-US" id="ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary_lbl2">Issuance of Akcea Therapeutics, Inc. common stock in conjunction with intial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssuesBySubsidiary" xlink:to="ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary_lbl2" xlink:title="label: StockIssuedDuringPeriodValueNewIssuesBySubsidiary to ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" xlink:label="NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" xlink:title="NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" />
    <link:label xlink:type="resource" xlink:label="ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary_lbl" xml:lang="en-US" id="ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary_lbl">Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders in an initial public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" xlink:to="ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary_lbl" xlink:title="label: NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary to ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary_lbl1" xml:lang="en-US" id="ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary_lbl1">Noncontrolling Interest, Increase from New Issues by Subsidiary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" xlink:to="ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary_lbl1" xlink:title="label: NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary to ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary_lbl2" xml:lang="en-US" id="ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary_lbl2">Noncontrolling interest in Akcea Therapeutics, Inc. in conjunction with initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" xlink:to="ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary_lbl2" xlink:title="label: NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary to ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary" xlink:label="StockIssuedDuringPeriodSharesNewIssuesBySubsidiary" xlink:title="StockIssuedDuringPeriodSharesNewIssuesBySubsidiary" />
    <link:label xlink:type="resource" xlink:label="ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary_lbl" xml:lang="en-US" id="ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary_lbl">Number of new stock issued by subsidiary during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssuesBySubsidiary" xlink:to="ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary_lbl" xlink:title="label: StockIssuedDuringPeriodSharesNewIssuesBySubsidiary to ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary_lbl1" xml:lang="en-US" id="ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary_lbl1">Stock Issued During Period, Shares, New Issues by Subsidiary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssuesBySubsidiary" xlink:to="ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesNewIssuesBySubsidiary to ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary_lbl2" xml:lang="en-US" id="ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary_lbl2">Issuance of Akcea Therapeutics, Inc. common stock in conjunction with intial public offering (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssuesBySubsidiary" xlink:to="ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary_lbl2" xlink:title="label: StockIssuedDuringPeriodSharesNewIssuesBySubsidiary to ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PatentAbstract" xlink:label="PatentAbstract" xlink:title="PatentAbstract" />
    <link:label xlink:type="resource" xlink:label="ions_PatentAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_PatentAbstract_lbl1" xml:lang="en-US" id="ions_PatentAbstract_lbl1">Patent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PatentAbstract" xlink:to="ions_PatentAbstract_lbl1" xlink:title="label: PatentAbstract to ions_PatentAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_PatentAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_PatentAbstract_lbl2" xml:lang="en-US" id="ions_PatentAbstract_lbl2">Patents [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PatentAbstract" xlink:to="ions_PatentAbstract_lbl2" xlink:title="label: PatentAbstract to ions_PatentAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PatentExpenses" xlink:label="PatentExpenses" xlink:title="PatentExpenses" />
    <link:label xlink:type="resource" xlink:label="ions_PatentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_PatentExpenses_lbl" xml:lang="en-US" id="ions_PatentExpenses_lbl">Includes charges for amortization and write-downs of capitalized patent costs as well as legal fees for patent litigation and patent defense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PatentExpenses" xlink:to="ions_PatentExpenses_lbl" xlink:title="label: PatentExpenses to ions_PatentExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_PatentExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_PatentExpenses_lbl1" xml:lang="en-US" id="ions_PatentExpenses_lbl1">Patent Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PatentExpenses" xlink:to="ions_PatentExpenses_lbl1" xlink:title="label: PatentExpenses to ions_PatentExpenses_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_PatentExpenses_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_PatentExpenses_lbl2" xml:lang="en-US" id="ions_PatentExpenses_lbl2">Patent expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PatentExpenses" xlink:to="ions_PatentExpenses_lbl2" xlink:title="label: PatentExpenses to ions_PatentExpenses_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementsAndLicensingAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementsAndLicensingAgreementsMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementsAndLicensingAgreementsMember_lbl">Represents collaborative arrangements and licensing agreements to which the entity is party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndLicensingAgreementsMember" xlink:to="ions_CollaborativeArrangementsAndLicensingAgreementsMember_lbl" xlink:title="label: CollaborativeArrangementsAndLicensingAgreementsMember to ions_CollaborativeArrangementsAndLicensingAgreementsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementsAndLicensingAgreementsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementsAndLicensingAgreementsMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementsAndLicensingAgreementsMember_lbl1">Collaborative Arrangements and Licensing Agreements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndLicensingAgreementsMember" xlink:to="ions_CollaborativeArrangementsAndLicensingAgreementsMember_lbl1" xlink:title="label: CollaborativeArrangementsAndLicensingAgreementsMember to ions_CollaborativeArrangementsAndLicensingAgreementsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementsAndLicensingAgreementsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ions_CollaborativeArrangementsAndLicensingAgreementsMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementsAndLicensingAgreementsMember_lbl2">Collaborative Agreements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndLicensingAgreementsMember" xlink:to="ions_CollaborativeArrangementsAndLicensingAgreementsMember_lbl2" xlink:title="label: CollaborativeArrangementsAndLicensingAgreementsMember to ions_CollaborativeArrangementsAndLicensingAgreementsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DepositsAndOtherAssetsMember" xlink:label="DepositsAndOtherAssetsMember" xlink:title="DepositsAndOtherAssetsMember" />
    <link:label xlink:type="resource" xlink:label="ions_DepositsAndOtherAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_DepositsAndOtherAssetsMember_lbl" xml:lang="en-US" id="ions_DepositsAndOtherAssetsMember_lbl">Primary financial statement caption encompassing deposits and other noncurrent assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAndOtherAssetsMember" xlink:to="ions_DepositsAndOtherAssetsMember_lbl" xlink:title="label: DepositsAndOtherAssetsMember to ions_DepositsAndOtherAssetsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_DepositsAndOtherAssetsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_DepositsAndOtherAssetsMember_lbl1" xml:lang="en-US" id="ions_DepositsAndOtherAssetsMember_lbl1">Deposits and Other Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAndOtherAssetsMember" xlink:to="ions_DepositsAndOtherAssetsMember_lbl1" xlink:title="label: DepositsAndOtherAssetsMember to ions_DepositsAndOtherAssetsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SecuritiesWithMaturityOfOneYearOrLessMember" xlink:label="SecuritiesWithMaturityOfOneYearOrLessMember" xlink:title="SecuritiesWithMaturityOfOneYearOrLessMember" />
    <link:label xlink:type="resource" xlink:label="ions_SecuritiesWithMaturityOfOneYearOrLessMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_SecuritiesWithMaturityOfOneYearOrLessMember_lbl" xml:lang="en-US" id="ions_SecuritiesWithMaturityOfOneYearOrLessMember_lbl">Represents investment securities with an expected maturity of one year or less.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuritiesWithMaturityOfOneYearOrLessMember" xlink:to="ions_SecuritiesWithMaturityOfOneYearOrLessMember_lbl" xlink:title="label: SecuritiesWithMaturityOfOneYearOrLessMember to ions_SecuritiesWithMaturityOfOneYearOrLessMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_SecuritiesWithMaturityOfOneYearOrLessMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_SecuritiesWithMaturityOfOneYearOrLessMember_lbl1" xml:lang="en-US" id="ions_SecuritiesWithMaturityOfOneYearOrLessMember_lbl1">Securities with Maturity of One Year or Less [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuritiesWithMaturityOfOneYearOrLessMember" xlink:to="ions_SecuritiesWithMaturityOfOneYearOrLessMember_lbl1" xlink:title="label: SecuritiesWithMaturityOfOneYearOrLessMember to ions_SecuritiesWithMaturityOfOneYearOrLessMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SecuritiesWithMaturityOfMoreThanOneYearMember" xlink:label="SecuritiesWithMaturityOfMoreThanOneYearMember" xlink:title="SecuritiesWithMaturityOfMoreThanOneYearMember" />
    <link:label xlink:type="resource" xlink:label="ions_SecuritiesWithMaturityOfMoreThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_SecuritiesWithMaturityOfMoreThanOneYearMember_lbl" xml:lang="en-US" id="ions_SecuritiesWithMaturityOfMoreThanOneYearMember_lbl">Represents investment securities with an expected maturity of more than one year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuritiesWithMaturityOfMoreThanOneYearMember" xlink:to="ions_SecuritiesWithMaturityOfMoreThanOneYearMember_lbl" xlink:title="label: SecuritiesWithMaturityOfMoreThanOneYearMember to ions_SecuritiesWithMaturityOfMoreThanOneYearMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_SecuritiesWithMaturityOfMoreThanOneYearMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_SecuritiesWithMaturityOfMoreThanOneYearMember_lbl1" xml:lang="en-US" id="ions_SecuritiesWithMaturityOfMoreThanOneYearMember_lbl1">Securities with Maturity of More than One Year [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuritiesWithMaturityOfMoreThanOneYearMember" xlink:to="ions_SecuritiesWithMaturityOfMoreThanOneYearMember_lbl1" xlink:title="label: SecuritiesWithMaturityOfMoreThanOneYearMember to ions_SecuritiesWithMaturityOfMoreThanOneYearMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:label="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:title="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" />
    <link:label xlink:type="resource" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain_lbl" xml:lang="en-US" id="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain_lbl">Total of (1) unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain_lbl" xlink:title="label: DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain to ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain_lbl1" xml:lang="en-US" id="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain_lbl1">Debt Securities, Available-for-sale and Equity Securities, FV-NI, Gross Unrealized Gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain_lbl1" xlink:title="label: DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain to ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain_lbl2" xml:lang="en-US" id="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain_lbl2">Gross unrealized gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain_lbl2" xlink:title="label: DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain to ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:label="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:title="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" />
    <link:label xlink:type="resource" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost_lbl" xml:lang="en-US" id="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost_lbl">Total of (1) amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost_lbl" xlink:title="label: DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost to ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost_lbl1" xml:lang="en-US" id="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost_lbl1">Debt Securities, Available-for-sale and Equity Securities, FV-NI, Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost_lbl1" xlink:title="label: DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost to ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost_lbl2" xml:lang="en-US" id="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost_lbl2">Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost_lbl2" xlink:title="label: DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost to ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:label="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:title="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" />
    <link:label xlink:type="resource" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss_lbl" xml:lang="en-US" id="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss_lbl">Total of (1) unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss_lbl" xlink:title="label: DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss to ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss_lbl1" xml:lang="en-US" id="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss_lbl1">Debt Securities, Available-for-sale and Equity Securities, FV-NI, Gross Unrealized Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss_lbl1" xlink:title="label: DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss to ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss_lbl2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss_lbl2" xml:lang="en-US" id="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss_lbl2">Gross unrealized losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss_lbl2" xlink:title="label: DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss to ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:label="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:title="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" />
    <link:label xlink:type="resource" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi_lbl" xml:lang="en-US" id="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi_lbl">Total of (1) investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi_lbl" xlink:title="label: DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi to ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi_lbl1" xml:lang="en-US" id="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi_lbl1">Debt Securities, Available-for-sale and Equity Securities, FV-NI</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi_lbl1" xlink:title="label: DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi to ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi_lbl2" xml:lang="en-US" id="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi_lbl2">Estimated fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:to="ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi_lbl2" xlink:title="label: DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi to ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IncludedInOtherCurrentAssetsMember" xlink:label="IncludedInOtherCurrentAssetsMember" xlink:title="IncludedInOtherCurrentAssetsMember" />
    <link:label xlink:type="resource" xlink:label="ions_IncludedInOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_IncludedInOtherCurrentAssetsMember_lbl" xml:lang="en-US" id="ions_IncludedInOtherCurrentAssetsMember_lbl">Amount related to amortized cost balance included in Other current assets on the statement of financial position.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncludedInOtherCurrentAssetsMember" xlink:to="ions_IncludedInOtherCurrentAssetsMember_lbl" xlink:title="label: IncludedInOtherCurrentAssetsMember to ions_IncludedInOtherCurrentAssetsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_IncludedInOtherCurrentAssetsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_IncludedInOtherCurrentAssetsMember_lbl1" xml:lang="en-US" id="ions_IncludedInOtherCurrentAssetsMember_lbl1">Included in Other Current Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncludedInOtherCurrentAssetsMember" xlink:to="ions_IncludedInOtherCurrentAssetsMember_lbl1" xlink:title="label: IncludedInOtherCurrentAssetsMember to ions_IncludedInOtherCurrentAssetsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_IncludedInOtherCurrentAssetsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_IncludedInOtherCurrentAssetsMember_lbl2" xml:lang="en-US" id="ions_IncludedInOtherCurrentAssetsMember_lbl2">Included in Other Current Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncludedInOtherCurrentAssetsMember" xlink:to="ions_IncludedInOtherCurrentAssetsMember_lbl2" xlink:title="label: IncludedInOtherCurrentAssetsMember to ions_IncludedInOtherCurrentAssetsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IncludedInDepositsAndOtherAssetsMember" xlink:label="IncludedInDepositsAndOtherAssetsMember" xlink:title="IncludedInDepositsAndOtherAssetsMember" />
    <link:label xlink:type="resource" xlink:label="ions_IncludedInDepositsAndOtherAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_IncludedInDepositsAndOtherAssetsMember_lbl" xml:lang="en-US" id="ions_IncludedInDepositsAndOtherAssetsMember_lbl">Amount related to amortized cost balance included in Deposits and other assets on the statement of financial position.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncludedInDepositsAndOtherAssetsMember" xlink:to="ions_IncludedInDepositsAndOtherAssetsMember_lbl" xlink:title="label: IncludedInDepositsAndOtherAssetsMember to ions_IncludedInDepositsAndOtherAssetsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_IncludedInDepositsAndOtherAssetsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_IncludedInDepositsAndOtherAssetsMember_lbl1" xml:lang="en-US" id="ions_IncludedInDepositsAndOtherAssetsMember_lbl1">Included in Deposits and Other Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncludedInDepositsAndOtherAssetsMember" xlink:to="ions_IncludedInDepositsAndOtherAssetsMember_lbl1" xlink:title="label: IncludedInDepositsAndOtherAssetsMember to ions_IncludedInDepositsAndOtherAssetsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_IncludedInDepositsAndOtherAssetsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_IncludedInDepositsAndOtherAssetsMember_lbl2" xml:lang="en-US" id="ions_IncludedInDepositsAndOtherAssetsMember_lbl2">Included in Deposits and Other Assets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncludedInDepositsAndOtherAssetsMember" xlink:to="ions_IncludedInDepositsAndOtherAssetsMember_lbl2" xlink:title="label: IncludedInDepositsAndOtherAssetsMember to ions_IncludedInDepositsAndOtherAssetsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumContractMaturityPeriodRange2" xlink:label="MaximumContractMaturityPeriodRange2" xlink:title="MaximumContractMaturityPeriodRange2" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumContractMaturityPeriodRange2_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MaximumContractMaturityPeriodRange2_lbl" xml:lang="en-US" id="ions_MaximumContractMaturityPeriodRange2_lbl">The maximum contract maturity period for the second range of available-for-sale securities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumContractMaturityPeriodRange2" xlink:to="ions_MaximumContractMaturityPeriodRange2_lbl" xlink:title="label: MaximumContractMaturityPeriodRange2 to ions_MaximumContractMaturityPeriodRange2_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumContractMaturityPeriodRange2_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MaximumContractMaturityPeriodRange2_lbl1" xml:lang="en-US" id="ions_MaximumContractMaturityPeriodRange2_lbl1">Maximum contract maturity period, range 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumContractMaturityPeriodRange2" xlink:to="ions_MaximumContractMaturityPeriodRange2_lbl1" xlink:title="label: MaximumContractMaturityPeriodRange2 to ions_MaximumContractMaturityPeriodRange2_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumContractMaturityPeriodRange2_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_MaximumContractMaturityPeriodRange2_lbl2" xml:lang="en-US" id="ions_MaximumContractMaturityPeriodRange2_lbl2">Maximum contract maturity period, range 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumContractMaturityPeriodRange2" xlink:to="ions_MaximumContractMaturityPeriodRange2_lbl2" xlink:title="label: MaximumContractMaturityPeriodRange2 to ions_MaximumContractMaturityPeriodRange2_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumContractMaturityPeriodRange1" xlink:label="MaximumContractMaturityPeriodRange1" xlink:title="MaximumContractMaturityPeriodRange1" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumContractMaturityPeriodRange1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MaximumContractMaturityPeriodRange1_lbl" xml:lang="en-US" id="ions_MaximumContractMaturityPeriodRange1_lbl">The maximum contract maturity period for the first range of available-for-sale securities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumContractMaturityPeriodRange1" xlink:to="ions_MaximumContractMaturityPeriodRange1_lbl" xlink:title="label: MaximumContractMaturityPeriodRange1 to ions_MaximumContractMaturityPeriodRange1_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumContractMaturityPeriodRange1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MaximumContractMaturityPeriodRange1_lbl1" xml:lang="en-US" id="ions_MaximumContractMaturityPeriodRange1_lbl1">Maximum contract maturity period, range 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumContractMaturityPeriodRange1" xlink:to="ions_MaximumContractMaturityPeriodRange1_lbl1" xlink:title="label: MaximumContractMaturityPeriodRange1 to ions_MaximumContractMaturityPeriodRange1_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumContractMaturityPeriodRange1_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_MaximumContractMaturityPeriodRange1_lbl2" xml:lang="en-US" id="ions_MaximumContractMaturityPeriodRange1_lbl2">Maximum contract maturity period, range 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumContractMaturityPeriodRange1" xlink:to="ions_MaximumContractMaturityPeriodRange1_lbl2" xlink:title="label: MaximumContractMaturityPeriodRange1 to ions_MaximumContractMaturityPeriodRange1_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumContractMaturityPeriodRange3" xlink:label="MaximumContractMaturityPeriodRange3" xlink:title="MaximumContractMaturityPeriodRange3" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumContractMaturityPeriodRange3_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MaximumContractMaturityPeriodRange3_lbl" xml:lang="en-US" id="ions_MaximumContractMaturityPeriodRange3_lbl">The maximum contract maturity period for the third range of available-for-sale securities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumContractMaturityPeriodRange3" xlink:to="ions_MaximumContractMaturityPeriodRange3_lbl" xlink:title="label: MaximumContractMaturityPeriodRange3 to ions_MaximumContractMaturityPeriodRange3_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumContractMaturityPeriodRange3_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MaximumContractMaturityPeriodRange3_lbl1" xml:lang="en-US" id="ions_MaximumContractMaturityPeriodRange3_lbl1">Maximum contract maturity period, range 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumContractMaturityPeriodRange3" xlink:to="ions_MaximumContractMaturityPeriodRange3_lbl1" xlink:title="label: MaximumContractMaturityPeriodRange3 to ions_MaximumContractMaturityPeriodRange3_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumContractMaturityPeriodRange3_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_MaximumContractMaturityPeriodRange3_lbl2" xml:lang="en-US" id="ions_MaximumContractMaturityPeriodRange3_lbl2">Maximum contract maturity period, range 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumContractMaturityPeriodRange3" xlink:to="ions_MaximumContractMaturityPeriodRange3_lbl2" xlink:title="label: MaximumContractMaturityPeriodRange3 to ions_MaximumContractMaturityPeriodRange3_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" xlink:title="AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" />
    <link:label xlink:type="resource" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage_lbl" xml:lang="en-US" id="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage_lbl">The percentage of available-for-sale debt securities that mature beyond two years but within three and one-half years of the balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage_lbl" xlink:title="label: AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage to ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage_lbl1" xml:lang="en-US" id="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage_lbl1">Available-for-sale Securities, Debt Maturities, after Two Through Three and One Half Years, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage_lbl1" xlink:title="label: AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage to ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage_lbl2" xml:lang="en-US" id="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage_lbl2">After two years but within three and a half years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage_lbl2" xlink:title="label: AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage to ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" xlink:title="AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" />
    <link:label xlink:type="resource" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage_lbl" xml:lang="en-US" id="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage_lbl">The percentage of available-for-sale debt securities that mature within two years of the balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage_lbl" xlink:title="label: AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage to ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage_lbl1" xml:lang="en-US" id="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage_lbl1">Available-for-sale Securities, Debt Maturities, within Two Years, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage_lbl1" xlink:title="label: AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage to ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage_lbl2" xml:lang="en-US" id="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage_lbl2">Percentage of available-for-sale securities with a maturity of less than two years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage_lbl2" xlink:title="label: AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage to ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:label="NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:title="NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment_lbl" xml:lang="en-US" id="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment_lbl">Number of privately-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for under the cost method.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:to="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment_lbl" xlink:title="label: NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment to ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment_lbl1" xml:lang="en-US" id="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment_lbl1">Number of Privately-Held Companies in which Entity has Equity Investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:to="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment_lbl1" xlink:title="label: NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment to ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment_lbl2" xml:lang="en-US" id="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment_lbl2">Number of privately-held companies in which there is an equity ownership interest of less than 20%</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:to="ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment_lbl2" xlink:title="label: NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment to ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:title="AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" />
    <link:label xlink:type="resource" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage_lbl" xml:lang="en-US" id="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage_lbl">The aggregate percentage of all available-for-sale debt securities, regardless of maturity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage_lbl" xlink:title="label: AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage to ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage_lbl1" xml:lang="en-US" id="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage_lbl1">Available-for-sale Securities, Debt Maturities, Total, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage_lbl1" xlink:title="label: AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage to ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage_lbl2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage_lbl2" xml:lang="en-US" id="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage_lbl2">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage_lbl2" xlink:title="label: AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage to ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" xlink:title="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" />
    <link:label xlink:type="resource" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage_lbl" xml:lang="en-US" id="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage_lbl">The percentage of available-for-sale debt securities that mature within one year of the balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage_lbl" xlink:title="label: AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage to ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage_lbl1" xml:lang="en-US" id="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage_lbl1">Available-for-sale Securities, Debt Maturities, within One Year, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage_lbl1" xlink:title="label: AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage to ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage_lbl2" xml:lang="en-US" id="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage_lbl2">One year or less</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage_lbl2" xlink:title="label: AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage to ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:label="NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:title="NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment_lbl" xml:lang="en-US" id="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment_lbl">Number of publicly-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for at fair value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:to="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment_lbl" xlink:title="label: NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment to ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment_lbl1" xml:lang="en-US" id="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment_lbl1">Number of Publicly-Held Companies in which Entity has Equity Investment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:to="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment_lbl1" xlink:title="label: NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment to ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment_lbl2" xml:lang="en-US" id="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment_lbl2">Number of publicly-held companies in which there is an equity ownership interest of less than 20%</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:to="ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment_lbl2" xlink:title="label: NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment to ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" xlink:title="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" />
    <link:label xlink:type="resource" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage_lbl" xml:lang="en-US" id="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage_lbl">The percentage of available-for-sale debt securities that mature beyond one year but within two years of the balance sheet date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage_lbl" xlink:title="label: AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage to ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage_lbl1" xml:lang="en-US" id="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage_lbl1">Available-for-sale Securities, Debt Maturities, after One Through Two Years, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage_lbl1" xlink:title="label: AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage to ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage_lbl2" xml:lang="en-US" id="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage_lbl2">After one year but within two years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" xlink:to="ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage_lbl2" xlink:title="label: AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage to ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" xlink:label="IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" xlink:title="IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" />
    <link:label xlink:type="resource" xlink:label="ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan_lbl" xml:lang="en-US" id="ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan_lbl">Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of shares issuable under the Company's employee stock purchase plan (ESPP).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" xlink:to="ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan_lbl" xlink:title="label: IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan to ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan_lbl1" xml:lang="en-US" id="ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan_lbl1">Incremental Common Shares Attributable to Dilutive Effect of Employee Stock Purchase Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" xlink:to="ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan_lbl1" xlink:title="label: IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan to ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan_lbl2" xml:lang="en-US" id="ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan_lbl2">Shares issuable related to our ESPP (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" xlink:to="ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan_lbl2" xlink:title="label: IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan to ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge" xlink:label="DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge" xlink:title="DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge" />
    <link:label xlink:type="resource" xlink:label="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge_lbl" xml:lang="en-US" id="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge_lbl">The limit of annual employee contributions to the plan per calendar year by eligible employees who are under 50 years of age.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge" xlink:to="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge_lbl" xlink:title="label: DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge to ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge_lbl1" xml:lang="en-US" id="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge_lbl1">Defined Contribution Plan, Employee Contribution Limit by Plan Participants under Fifty Years Age</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge" xlink:to="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge_lbl1" xlink:title="label: DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge to ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge_lbl2" xml:lang="en-US" id="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge_lbl2">Employee contribution limit per calendar year for employees under 50 years of age</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge" xlink:to="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge_lbl2" xlink:title="label: DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge to ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge" xlink:label="DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge" xlink:title="DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge" />
    <link:label xlink:type="resource" xlink:label="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge_lbl" xml:lang="en-US" id="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge_lbl">The limit of annual employee contributions to the plan per calendar year by eligible employees who are over 50 years of age.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge" xlink:to="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge_lbl" xlink:title="label: DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge to ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge_lbl1" xml:lang="en-US" id="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge_lbl1">Defined Contribution Plan, Employee Contribution Limit by Plan Participants over Fifty Years Age</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge" xlink:to="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge_lbl1" xlink:title="label: DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge to ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge_lbl2" xml:lang="en-US" id="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge_lbl2">Employee contribution limit per calendar year for employees over 50 years of age</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge" xlink:to="ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge_lbl2" xlink:title="label: DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge to ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SignificantPartnersAbstract" xlink:label="SignificantPartnersAbstract" xlink:title="SignificantPartnersAbstract" />
    <link:label xlink:type="resource" xlink:label="ions_SignificantPartnersAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_SignificantPartnersAbstract_lbl1" xml:lang="en-US" id="ions_SignificantPartnersAbstract_lbl1">Significant Partners [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantPartnersAbstract" xlink:to="ions_SignificantPartnersAbstract_lbl1" xlink:title="label: SignificantPartnersAbstract to ions_SignificantPartnersAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfSignificantPartners" xlink:label="NumberOfSignificantPartners" xlink:title="NumberOfSignificantPartners" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfSignificantPartners_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NumberOfSignificantPartners_lbl" xml:lang="en-US" id="ions_NumberOfSignificantPartners_lbl">Represents the number of significant partners.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSignificantPartners" xlink:to="ions_NumberOfSignificantPartners_lbl" xlink:title="label: NumberOfSignificantPartners to ions_NumberOfSignificantPartners_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfSignificantPartners_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NumberOfSignificantPartners_lbl1" xml:lang="en-US" id="ions_NumberOfSignificantPartners_lbl1">Number of Significant Partners</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSignificantPartners" xlink:to="ions_NumberOfSignificantPartners_lbl1" xlink:title="label: NumberOfSignificantPartners to ions_NumberOfSignificantPartners_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfSignificantPartners_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NumberOfSignificantPartners_lbl2" xml:lang="en-US" id="ions_NumberOfSignificantPartners_lbl2">Number of significant partners</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfSignificantPartners" xlink:to="ions_NumberOfSignificantPartners_lbl2" xlink:title="label: NumberOfSignificantPartners to ions_NumberOfSignificantPartners_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SignificantPartnersMember" xlink:label="SignificantPartnersMember" xlink:title="SignificantPartnersMember" />
    <link:label xlink:type="resource" xlink:label="ions_SignificantPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_SignificantPartnersMember_lbl" xml:lang="en-US" id="ions_SignificantPartnersMember_lbl">Significant corporate partners and leading global pharmaceutical companies that are working alongside the Company to develop the Company's drugs, advance the Company's technology, and prepare to commercialize and sell the Company's drugs under collaborative arrangement and licensing agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantPartnersMember" xlink:to="ions_SignificantPartnersMember_lbl" xlink:title="label: SignificantPartnersMember to ions_SignificantPartnersMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_SignificantPartnersMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_SignificantPartnersMember_lbl1" xml:lang="en-US" id="ions_SignificantPartnersMember_lbl1">Significant Partners [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantPartnersMember" xlink:to="ions_SignificantPartnersMember_lbl1" xlink:title="label: SignificantPartnersMember to ions_SignificantPartnersMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_SignificantPartnersMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_SignificantPartnersMember_lbl2" xml:lang="en-US" id="ions_SignificantPartnersMember_lbl2">Significant Partners [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantPartnersMember" xlink:to="ions_SignificantPartnersMember_lbl2" xlink:title="label: SignificantPartnersMember to ions_SignificantPartnersMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AccruedClinicalExpenses" xlink:label="AccruedClinicalExpenses" xlink:title="AccruedClinicalExpenses" />
    <link:label xlink:type="resource" xlink:label="ions_AccruedClinicalExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_AccruedClinicalExpenses_lbl" xml:lang="en-US" id="ions_AccruedClinicalExpenses_lbl">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedClinicalExpenses" xlink:to="ions_AccruedClinicalExpenses_lbl" xlink:title="label: AccruedClinicalExpenses to ions_AccruedClinicalExpenses_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_AccruedClinicalExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_AccruedClinicalExpenses_lbl1" xml:lang="en-US" id="ions_AccruedClinicalExpenses_lbl1">Accrued clinical expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedClinicalExpenses" xlink:to="ions_AccruedClinicalExpenses_lbl1" xlink:title="label: AccruedClinicalExpenses to ions_AccruedClinicalExpenses_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_AccruedClinicalExpenses_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_AccruedClinicalExpenses_lbl2" xml:lang="en-US" id="ions_AccruedClinicalExpenses_lbl2">Clincial expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedClinicalExpenses" xlink:to="ions_AccruedClinicalExpenses_lbl2" xlink:title="label: AccruedClinicalExpenses to ions_AccruedClinicalExpenses_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AccruedInLicensingFeesCurrent" xlink:label="AccruedInLicensingFeesCurrent" xlink:title="AccruedInLicensingFeesCurrent" />
    <link:label xlink:type="resource" xlink:label="ions_AccruedInLicensingFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_AccruedInLicensingFeesCurrent_lbl" xml:lang="en-US" id="ions_AccruedInLicensingFeesCurrent_lbl">Carrying value as of the balance sheet date of obligations incurred through that date and payable for in-licensing fees under collaboration agreements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedInLicensingFeesCurrent" xlink:to="ions_AccruedInLicensingFeesCurrent_lbl" xlink:title="label: AccruedInLicensingFeesCurrent to ions_AccruedInLicensingFeesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_AccruedInLicensingFeesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_AccruedInLicensingFeesCurrent_lbl1" xml:lang="en-US" id="ions_AccruedInLicensingFeesCurrent_lbl1">Accrued in-licensing fees, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedInLicensingFeesCurrent" xlink:to="ions_AccruedInLicensingFeesCurrent_lbl1" xlink:title="label: AccruedInLicensingFeesCurrent to ions_AccruedInLicensingFeesCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_AccruedInLicensingFeesCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_AccruedInLicensingFeesCurrent_lbl2" xml:lang="en-US" id="ions_AccruedInLicensingFeesCurrent_lbl2">In-licensing expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedInLicensingFeesCurrent" xlink:to="ions_AccruedInLicensingFeesCurrent_lbl2" xlink:title="label: AccruedInLicensingFeesCurrent to ions_AccruedInLicensingFeesCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable" xlink:label="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable" xlink:title="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable_lbl">Disclosure of information about collaborative arrangements and non-collaborative arrangement transactions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable" xlink:to="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable_lbl" xlink:title="label: CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable to ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable_lbl1">Collaborative Arrangements and Non-collaborative Arrangement Transactions Disclosure [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable" xlink:to="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable_lbl1" xlink:title="label: CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable to ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems" xlink:label="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems" xlink:title="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems_lbl">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems" xlink:to="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems_lbl" xlink:title="label: CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems to ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems_lbl1">Collaborative Arrangements and Non-collaborative Arrangement Transactions Disclosure [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems" xlink:to="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems_lbl1" xlink:title="label: CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems to ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems_lbl2">Collaborative Arrangements and Licensing Agreements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems" xlink:to="ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems_lbl2" xlink:title="label: CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems to ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember_lbl">Represents information pertaining to the collaborative arrangements and licensing agreements entered into with Novartis to develop and commercialize AKCEA-APO(a)-L and AKCEA-APOCIII-L.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember_lbl" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember_lbl1">Collaborative Arrangement and Licensing Agreement Entered Into in January 2017 with Novartis [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember_lbl1" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember_lbl2">Novartis [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember_lbl2" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember_lbl">Represents information pertaining to the collaborative arrangement and licensing agreement entered into with GlaxoSmithKline (GSK) in March 2010 to discover and develop new drugs against targets for rare and serious diseases, including infectious diseases and some conditions causing blindness.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember_lbl" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember_lbl1">Collaborative Arrangement and Licensing Agreement Entered Into in March 2010 with GSK [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember_lbl1" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember_lbl2">GSK [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember_lbl2" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsRocheMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsRocheMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember_lbl">Represents information pertaining to the collaborative arrangements and licensing agreements entered into with Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd., collectively Roche.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndLicensingAgreementsRocheMember" xlink:to="ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember_lbl" xlink:title="label: CollaborativeArrangementsAndLicensingAgreementsRocheMember to ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember_lbl1">Collaborative Arrangements and Licensing Agreements, Roche [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndLicensingAgreementsRocheMember" xlink:to="ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember_lbl1" xlink:title="label: CollaborativeArrangementsAndLicensingAgreementsRocheMember to ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember_lbl2">Roche [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndLicensingAgreementsRocheMember" xlink:to="ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember_lbl2" xlink:title="label: CollaborativeArrangementsAndLicensingAgreementsRocheMember to ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsBayerMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember_lbl">Represents information pertaining to the collaborative arrangements and licensing agreements entered into with Bayer HealthCare.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:to="ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember_lbl" xlink:title="label: CollaborativeArrangementsAndLicensingAgreementsBayerMember to ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember_lbl1">Collaborative Arrangements and Licensing Agreements, Bayer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:to="ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember_lbl1" xlink:title="label: CollaborativeArrangementsAndLicensingAgreementsBayerMember to ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember_lbl2">Bayer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:to="ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember_lbl2" xlink:title="label: CollaborativeArrangementsAndLicensingAgreementsBayerMember to ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember_lbl">Represents information pertaining to the collaborative arrangements and licensing agreements entered into with Biogen Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:to="ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember_lbl" xlink:title="label: CollaborativeArrangementsAndLicensingAgreementsBiogenMember to ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember_lbl1">Collaborative Arrangements and Licensing Agreements, Biogen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:to="ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember_lbl1" xlink:title="label: CollaborativeArrangementsAndLicensingAgreementsBiogenMember to ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember_lbl2">Biogen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:to="ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember_lbl2" xlink:title="label: CollaborativeArrangementsAndLicensingAgreementsBiogenMember to ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember_lbl">Represents information pertaining to the collaborative arrangement entered into with Janssen Biotech, Inc. in December 2014 to discover and develop antisense drugs that can be locally administered, including oral delivery, to treat autoimmune disorders of the gastrointestinal tract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember_lbl" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember_lbl1">Collaborative Arrangement and Licensing Agreement Entered Into in December 2014 with Janssen Biotech, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember_lbl1" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember_lbl2">Janssen Biotech, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember_lbl2" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember_lbl">Represents information pertaining to the collaborative arrangements and licensing agreements entered into with AstraZeneca PLC.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" xlink:to="ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember_lbl" xlink:title="label: CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember to ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember_lbl1">Collaborative Arrangements and Licensing Agreements, AstraZeneca [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" xlink:to="ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember_lbl1" xlink:title="label: CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember to ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember_lbl2">AstraZeneca [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" xlink:to="ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember_lbl2" xlink:title="label: CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember to ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember_lbl">Represents information pertaining to the collaborative arrangement entered into with PTC Therapeutics by Akcea Therapeutics, Inc. in August 2018 to commercialize TEGSEDI and WAYLIVRA in Latin America.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember_lbl" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember_lbl1">Collaborative Arrangement and Licensing Agreement Entered Into in August 2018 with PTC Therapeutics [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember_lbl1" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember_lbl2">PTC Therapeutics [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember_lbl2" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped" xlink:label="MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped" xlink:title="MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped_lbl" xml:lang="en-US" id="ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped_lbl">The maximum amount of payments receivable for each additional drug developed under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped" xlink:to="ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped_lbl" xlink:title="label: MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped to ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped_lbl1" xml:lang="en-US" id="ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped_lbl1">Maximum amount of payment receivable for each additional drug developed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped" xlink:to="ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped_lbl1" xlink:title="label: MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped to ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped_lbl2" xml:lang="en-US" id="ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped_lbl2">Maximum amount of payment receivable for each additional drug developed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped" xlink:to="ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped_lbl2" xlink:title="label: MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped to ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CumulativePaymentsReceived" xlink:label="CumulativePaymentsReceived" xlink:title="CumulativePaymentsReceived" />
    <link:label xlink:type="resource" xlink:label="ions_CumulativePaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CumulativePaymentsReceived_lbl" xml:lang="en-US" id="ions_CumulativePaymentsReceived_lbl">Cumulative amount of payments received under the collaboration agreement as of the end of the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CumulativePaymentsReceived" xlink:to="ions_CumulativePaymentsReceived_lbl" xlink:title="label: CumulativePaymentsReceived to ions_CumulativePaymentsReceived_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CumulativePaymentsReceived_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CumulativePaymentsReceived_lbl1" xml:lang="en-US" id="ions_CumulativePaymentsReceived_lbl1">Cumulative payments received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CumulativePaymentsReceived" xlink:to="ions_CumulativePaymentsReceived_lbl1" xlink:title="label: CumulativePaymentsReceived to ions_CumulativePaymentsReceived_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CumulativePaymentsReceived_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CumulativePaymentsReceived_lbl2" xml:lang="en-US" id="ions_CumulativePaymentsReceived_lbl2">Cumulative payments received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CumulativePaymentsReceived" xlink:to="ions_CumulativePaymentsReceived_lbl2" xlink:title="label: CumulativePaymentsReceived to ions_CumulativePaymentsReceived_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl">The maximum amount of payments receivable for license fees and substantive milestones under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl" xlink:title="label: MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones to ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl1" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl1">Maximum amount of payments receivable for license fees and substantive milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl1" xlink:title="label: MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones to ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl2" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl2">Maximum amount of payments receivable for license fees and milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl2" xlink:title="label: MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones to ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MilestonePaymentsReceived" xlink:label="MilestonePaymentsReceived" xlink:title="MilestonePaymentsReceived" />
    <link:label xlink:type="resource" xlink:label="ions_MilestonePaymentsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MilestonePaymentsReceived_lbl" xml:lang="en-US" id="ions_MilestonePaymentsReceived_lbl">The amount of milestone payments received during the period under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsReceived" xlink:to="ions_MilestonePaymentsReceived_lbl" xlink:title="label: MilestonePaymentsReceived to ions_MilestonePaymentsReceived_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MilestonePaymentsReceived_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MilestonePaymentsReceived_lbl1" xml:lang="en-US" id="ions_MilestonePaymentsReceived_lbl1">Milestone payments received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsReceived" xlink:to="ions_MilestonePaymentsReceived_lbl1" xlink:title="label: MilestonePaymentsReceived to ions_MilestonePaymentsReceived_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_MilestonePaymentsReceived_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_MilestonePaymentsReceived_lbl2" xml:lang="en-US" id="ions_MilestonePaymentsReceived_lbl2">Milestone payments received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentsReceived" xlink:to="ions_MilestonePaymentsReceived_lbl2" xlink:title="label: MilestonePaymentsReceived to ions_MilestonePaymentsReceived_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember_lbl">Represents information pertaining to the collaborative arrangement entered into with Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd., collectively Roche, in October 2018 to develop IONIS-FB-LRx for the treatment of complement-mediated diseases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember_lbl" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember_lbl1">Collaborative Arrangement and Licensing Agreement Entered Into in October 2018 with Roche [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember_lbl1" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember_lbl2">IONIS-FB-L for Complement-Mediated Diseases [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember_lbl2" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember_lbl">Represents information pertaining to the collaborative arrangement entered into with Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd., collectively Roche, in April 2013 to develop treatments for Huntington's disease, or HD, based on the Company's antisense technology.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember_lbl" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember_lbl1">Collaborative Arrangement and Licensing Agreement Entered Into in April 2013 with Roche [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember_lbl1" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember_lbl2">Huntington's Disease [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember_lbl2" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PaymentReceivedForAdvancingPrograms" xlink:label="PaymentReceivedForAdvancingPrograms" xlink:title="PaymentReceivedForAdvancingPrograms" />
    <link:label xlink:type="resource" xlink:label="ions_PaymentReceivedForAdvancingPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_PaymentReceivedForAdvancingPrograms_lbl" xml:lang="en-US" id="ions_PaymentReceivedForAdvancingPrograms_lbl">The amount of payments received during the period for advancing programs under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentReceivedForAdvancingPrograms" xlink:to="ions_PaymentReceivedForAdvancingPrograms_lbl" xlink:title="label: PaymentReceivedForAdvancingPrograms to ions_PaymentReceivedForAdvancingPrograms_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_PaymentReceivedForAdvancingPrograms_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_PaymentReceivedForAdvancingPrograms_lbl1" xml:lang="en-US" id="ions_PaymentReceivedForAdvancingPrograms_lbl1">Payment received for advancing programs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentReceivedForAdvancingPrograms" xlink:to="ions_PaymentReceivedForAdvancingPrograms_lbl1" xlink:title="label: PaymentReceivedForAdvancingPrograms to ions_PaymentReceivedForAdvancingPrograms_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_PaymentReceivedForAdvancingPrograms_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_PaymentReceivedForAdvancingPrograms_lbl2" xml:lang="en-US" id="ions_PaymentReceivedForAdvancingPrograms_lbl2">Payment received for advancing programs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentReceivedForAdvancingPrograms" xlink:to="ions_PaymentReceivedForAdvancingPrograms_lbl2" xlink:title="label: PaymentReceivedForAdvancingPrograms to ions_PaymentReceivedForAdvancingPrograms_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember_lbl">Represents information pertaining to collaborative arrangement entered into with Bayer HealthCare in May 2015 to develop and commercialize IONIS-FXI for the prevention of thrombosis.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember_lbl" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember_lbl1">Collaborative Arrangement and Licensing Agreement Entered Into in May 2015 with Bayer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember_lbl1" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember_lbl2">Bayer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember_lbl2" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" xlink:label="CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" xlink:title="CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember_lbl">Represents information pertaining to collaborative arrangement with Bayer HealthCare amended in February 2017 to advance IONIS-FXIRx for the prevention of thrombosis and to initiate development of IONIS-FXI-LRx.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember_lbl" xlink:title="label: CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember to ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember_lbl1">Collaborative Arrangement and Licensing Agreement Amended in February 2017 with Bayer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember_lbl1" xlink:title="label: CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember to ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember_lbl2">Bayer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember_lbl2" xlink:title="label: CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember to ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IONISFXILMember" xlink:label="IONISFXILMember" xlink:title="IONISFXILMember" />
    <link:label xlink:type="resource" xlink:label="ions_IONISFXILMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_IONISFXILMember_lbl1" xml:lang="en-US" id="ions_IONISFXILMember_lbl1">IONIS-FXI-L [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IONISFXILMember" xlink:to="ions_IONISFXILMember_lbl1" xlink:title="label: IONISFXILMember to ions_IONISFXILMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_IONISFXILMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_IONISFXILMember_lbl2" xml:lang="en-US" id="ions_IONISFXILMember_lbl2">IONIS-FXI-L [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IONISFXILMember" xlink:to="ions_IONISFXILMember_lbl2" xlink:title="label: IONISFXILMember to ions_IONISFXILMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentServicesForIONISFXILMember" xlink:label="ResearchAndDevelopmentServicesForIONISFXILMember" xlink:title="ResearchAndDevelopmentServicesForIONISFXILMember" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchAndDevelopmentServicesForIONISFXILMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ResearchAndDevelopmentServicesForIONISFXILMember_lbl" xml:lang="en-US" id="ions_ResearchAndDevelopmentServicesForIONISFXILMember_lbl">Research and development (R&amp;D) services for IONIS-FXI-L.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentServicesForIONISFXILMember" xlink:to="ions_ResearchAndDevelopmentServicesForIONISFXILMember_lbl" xlink:title="label: ResearchAndDevelopmentServicesForIONISFXILMember to ions_ResearchAndDevelopmentServicesForIONISFXILMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchAndDevelopmentServicesForIONISFXILMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ResearchAndDevelopmentServicesForIONISFXILMember_lbl1" xml:lang="en-US" id="ions_ResearchAndDevelopmentServicesForIONISFXILMember_lbl1">Research and Development Services for IONIS-FXI-L [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentServicesForIONISFXILMember" xlink:to="ions_ResearchAndDevelopmentServicesForIONISFXILMember_lbl1" xlink:title="label: ResearchAndDevelopmentServicesForIONISFXILMember to ions_ResearchAndDevelopmentServicesForIONISFXILMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchAndDevelopmentServicesForIONISFXILMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ResearchAndDevelopmentServicesForIONISFXILMember_lbl2" xml:lang="en-US" id="ions_ResearchAndDevelopmentServicesForIONISFXILMember_lbl2">R&amp;D Services for IONIS-FXI-L [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentServicesForIONISFXILMember" xlink:to="ions_ResearchAndDevelopmentServicesForIONISFXILMember_lbl2" xlink:title="label: ResearchAndDevelopmentServicesForIONISFXILMember to ions_ResearchAndDevelopmentServicesForIONISFXILMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement" xlink:label="RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement" xlink:title="RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement" />
    <link:label xlink:type="resource" xlink:label="ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement_lbl" xml:lang="en-US" id="ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement_lbl">The royalty percentage received on gross margins of drug(s) under the collaborative arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement" xlink:to="ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement_lbl" xlink:title="label: RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement to ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement_lbl1" xml:lang="en-US" id="ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement_lbl1">Royalty percentage received on gross margins of drugs under collaboration agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement" xlink:to="ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement_lbl1" xlink:title="label: RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement to ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement_lbl2" xml:lang="en-US" id="ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement_lbl2">Royalty percentage received on gross margins of both drugs combined</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement" xlink:to="ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement_lbl2" xlink:title="label: RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement to ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfNewPerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfNewPerformanceObligations" />
    <link:label xlink:type="resource" xlink:label="ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations_lbl" xml:lang="en-US" id="ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations_lbl">The number of new performance obligations identified under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerNumberOfNewPerformanceObligations" xlink:to="ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations_lbl" xlink:title="label: RevenueFromContractWithCustomerNumberOfNewPerformanceObligations to ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations_lbl1" xml:lang="en-US" id="ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations_lbl1">Revenue from Contract with Customer, Number of new performance obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerNumberOfNewPerformanceObligations" xlink:to="ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations_lbl1" xlink:title="label: RevenueFromContractWithCustomerNumberOfNewPerformanceObligations to ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations_lbl2" xml:lang="en-US" id="ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations_lbl2">Number of new performance obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerNumberOfNewPerformanceObligations" xlink:to="ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations_lbl2" xlink:title="label: RevenueFromContractWithCustomerNumberOfNewPerformanceObligations to ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IONISJBI225Member" xlink:label="IONISJBI225Member" xlink:title="IONISJBI225Member" />
    <link:label xlink:type="resource" xlink:label="ions_IONISJBI225Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_IONISJBI225Member_lbl1" xml:lang="en-US" id="ions_IONISJBI225Member_lbl1">IONIS-JBI2-2.5 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IONISJBI225Member" xlink:to="ions_IONISJBI225Member_lbl1" xlink:title="label: IONISJBI225Member to ions_IONISJBI225Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_IONISJBI225Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_IONISJBI225Member_lbl2" xml:lang="en-US" id="ions_IONISJBI225Member_lbl2">IONIS-JBI2-2.5 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IONISJBI225Member" xlink:to="ions_IONISJBI225Member_lbl2" xlink:title="label: IONISJBI225Member to ions_IONISJBI225Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:label="MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" />
    <link:label xlink:type="resource" xlink:label="ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl" xml:lang="en-US" id="ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl">The minimum amount of payments receivable for license fees and substantive milestones under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:to="ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl" xlink:title="label: MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones to ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl1" xml:lang="en-US" id="ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl1">Minimum amount of payments receivable for license fees and substantive milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:to="ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl1" xlink:title="label: MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones to ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl2" xml:lang="en-US" id="ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl2">Minimum amount of payments receivable for license fees and milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:to="ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl2" xlink:title="label: MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones to ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IONISJBI125Member" xlink:label="IONISJBI125Member" xlink:title="IONISJBI125Member" />
    <link:label xlink:type="resource" xlink:label="ions_IONISJBI125Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_IONISJBI125Member_lbl1" xml:lang="en-US" id="ions_IONISJBI125Member_lbl1">IONIS-JBI1-2.5 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IONISJBI125Member" xlink:to="ions_IONISJBI125Member_lbl1" xlink:title="label: IONISJBI125Member to ions_IONISJBI125Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_IONISJBI125Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_IONISJBI125Member_lbl2" xml:lang="en-US" id="ions_IONISJBI125Member_lbl2">IONIS-JBI1-2.5 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IONISJBI125Member" xlink:to="ions_IONISJBI125Member_lbl2" xlink:title="label: IONISJBI125Member to ions_IONISJBI125Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" xlink:label="NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" xlink:title="NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized_lbl" xml:lang="en-US" id="ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized_lbl">The number of programs under which drugs are to be developed and commercialized under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" xlink:to="ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized_lbl" xlink:title="label: NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized to ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized_lbl1" xml:lang="en-US" id="ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized_lbl1">Number of programs under which drugs are to be developed and commercialized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" xlink:to="ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized_lbl1" xlink:title="label: NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized to ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized_lbl2" xml:lang="en-US" id="ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized_lbl2">Number of programs under which drugs are to be developed and commercialized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" xlink:to="ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized_lbl2" xlink:title="label: NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized to ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IONISMAPTMember" xlink:label="IONISMAPTMember" xlink:title="IONISMAPTMember" />
    <link:label xlink:type="resource" xlink:label="ions_IONISMAPTMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_IONISMAPTMember_lbl" xml:lang="en-US" id="ions_IONISMAPTMember_lbl">IONIS-MAPT is an antisense drug designed to selectively reduce the production of microtubule-associated protein tau (MAPT), or tau protein, in the brain, for the treatment of Alzheimer's disease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IONISMAPTMember" xlink:to="ions_IONISMAPTMember_lbl" xlink:title="label: IONISMAPTMember to ions_IONISMAPTMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_IONISMAPTMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_IONISMAPTMember_lbl1" xml:lang="en-US" id="ions_IONISMAPTMember_lbl1">IONIS-MAPT [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IONISMAPTMember" xlink:to="ions_IONISMAPTMember_lbl1" xlink:title="label: IONISMAPTMember to ions_IONISMAPTMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_IONISMAPTMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_IONISMAPTMember_lbl2" xml:lang="en-US" id="ions_IONISMAPTMember_lbl2">IONIS-MAPT [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IONISMAPTMember" xlink:to="ions_IONISMAPTMember_lbl2" xlink:title="label: IONISMAPTMember to ions_IONISMAPTMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:label="PaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:title="PaymentsIncludedInTransactionPriceForPerformanceObligation" />
    <link:label xlink:type="resource" xlink:label="ions_PaymentsIncludedInTransactionPriceForPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_PaymentsIncludedInTransactionPriceForPerformanceObligation_lbl" xml:lang="en-US" id="ions_PaymentsIncludedInTransactionPriceForPerformanceObligation_lbl">Payments received under the collaboration agreement during the period included in the transaction price for the performance obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:to="ions_PaymentsIncludedInTransactionPriceForPerformanceObligation_lbl" xlink:title="label: PaymentsIncludedInTransactionPriceForPerformanceObligation to ions_PaymentsIncludedInTransactionPriceForPerformanceObligation_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_PaymentsIncludedInTransactionPriceForPerformanceObligation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_PaymentsIncludedInTransactionPriceForPerformanceObligation_lbl1" xml:lang="en-US" id="ions_PaymentsIncludedInTransactionPriceForPerformanceObligation_lbl1">Payments included in transaction price for performance obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:to="ions_PaymentsIncludedInTransactionPriceForPerformanceObligation_lbl1" xlink:title="label: PaymentsIncludedInTransactionPriceForPerformanceObligation to ions_PaymentsIncludedInTransactionPriceForPerformanceObligation_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_PaymentsIncludedInTransactionPriceForPerformanceObligation_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_PaymentsIncludedInTransactionPriceForPerformanceObligation_lbl2" xml:lang="en-US" id="ions_PaymentsIncludedInTransactionPriceForPerformanceObligation_lbl2">Payments included in transaction price for performance obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:to="ions_PaymentsIncludedInTransactionPriceForPerformanceObligation_lbl2" xlink:title="label: PaymentsIncludedInTransactionPriceForPerformanceObligation to ions_PaymentsIncludedInTransactionPriceForPerformanceObligation_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfMilestonePaymentsAchieved" xlink:label="NumberOfMilestonePaymentsAchieved" xlink:title="NumberOfMilestonePaymentsAchieved" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfMilestonePaymentsAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NumberOfMilestonePaymentsAchieved_lbl" xml:lang="en-US" id="ions_NumberOfMilestonePaymentsAchieved_lbl">The number of milestone payments achieved during the period under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfMilestonePaymentsAchieved" xlink:to="ions_NumberOfMilestonePaymentsAchieved_lbl" xlink:title="label: NumberOfMilestonePaymentsAchieved to ions_NumberOfMilestonePaymentsAchieved_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfMilestonePaymentsAchieved_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NumberOfMilestonePaymentsAchieved_lbl1" xml:lang="en-US" id="ions_NumberOfMilestonePaymentsAchieved_lbl1">Number of milestone payments achieved</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfMilestonePaymentsAchieved" xlink:to="ions_NumberOfMilestonePaymentsAchieved_lbl1" xlink:title="label: NumberOfMilestonePaymentsAchieved to ions_NumberOfMilestonePaymentsAchieved_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfMilestonePaymentsAchieved_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NumberOfMilestonePaymentsAchieved_lbl2" xml:lang="en-US" id="ions_NumberOfMilestonePaymentsAchieved_lbl2">Number of milestone payments achieved</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfMilestonePaymentsAchieved" xlink:to="ions_NumberOfMilestonePaymentsAchieved_lbl2" xlink:title="label: NumberOfMilestonePaymentsAchieved to ions_NumberOfMilestonePaymentsAchieved_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MedicinesForUndisclosedTargetsMember" xlink:label="MedicinesForUndisclosedTargetsMember" xlink:title="MedicinesForUndisclosedTargetsMember" />
    <link:label xlink:type="resource" xlink:label="ions_MedicinesForUndisclosedTargetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MedicinesForUndisclosedTargetsMember_lbl" xml:lang="en-US" id="ions_MedicinesForUndisclosedTargetsMember_lbl">Medicines to treat undisclosed targets under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MedicinesForUndisclosedTargetsMember" xlink:to="ions_MedicinesForUndisclosedTargetsMember_lbl" xlink:title="label: MedicinesForUndisclosedTargetsMember to ions_MedicinesForUndisclosedTargetsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MedicinesForUndisclosedTargetsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MedicinesForUndisclosedTargetsMember_lbl1" xml:lang="en-US" id="ions_MedicinesForUndisclosedTargetsMember_lbl1">Medicines for Undisclosed Targets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MedicinesForUndisclosedTargetsMember" xlink:to="ions_MedicinesForUndisclosedTargetsMember_lbl1" xlink:title="label: MedicinesForUndisclosedTargetsMember to ions_MedicinesForUndisclosedTargetsMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_MedicinesForUndisclosedTargetsMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_MedicinesForUndisclosedTargetsMember_lbl2" xml:lang="en-US" id="ions_MedicinesForUndisclosedTargetsMember_lbl2">Medicines for Undisclosed Targets [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MedicinesForUndisclosedTargetsMember" xlink:to="ions_MedicinesForUndisclosedTargetsMember_lbl2" xlink:title="label: MedicinesForUndisclosedTargetsMember to ions_MedicinesForUndisclosedTargetsMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments" xlink:label="MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments" xlink:title="MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments_lbl" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments_lbl">The maximum amount of payments receivable per drug for substantive milestone payments under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments" xlink:to="ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments_lbl" xlink:title="label: MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments to ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments_lbl1" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments_lbl1">Maximum amount of payments receivable per drug for substantive milestone payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments" xlink:to="ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments_lbl1" xlink:title="label: MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments to ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments_lbl2" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments_lbl2">Maximum amount of payments receivable per drug for substantive milestone payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments" xlink:to="ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments_lbl2" xlink:title="label: MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments to ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MedicinesForAmyotrophicLateralSclerosisMember" xlink:label="MedicinesForAmyotrophicLateralSclerosisMember" xlink:title="MedicinesForAmyotrophicLateralSclerosisMember" />
    <link:label xlink:type="resource" xlink:label="ions_MedicinesForAmyotrophicLateralSclerosisMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MedicinesForAmyotrophicLateralSclerosisMember_lbl" xml:lang="en-US" id="ions_MedicinesForAmyotrophicLateralSclerosisMember_lbl">Medicines to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, a nervous system disease that weakens muscles and impacts physical function.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MedicinesForAmyotrophicLateralSclerosisMember" xlink:to="ions_MedicinesForAmyotrophicLateralSclerosisMember_lbl" xlink:title="label: MedicinesForAmyotrophicLateralSclerosisMember to ions_MedicinesForAmyotrophicLateralSclerosisMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MedicinesForAmyotrophicLateralSclerosisMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MedicinesForAmyotrophicLateralSclerosisMember_lbl1" xml:lang="en-US" id="ions_MedicinesForAmyotrophicLateralSclerosisMember_lbl1">Medicines for Amyotrophic Lateral Sclerosis [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MedicinesForAmyotrophicLateralSclerosisMember" xlink:to="ions_MedicinesForAmyotrophicLateralSclerosisMember_lbl1" xlink:title="label: MedicinesForAmyotrophicLateralSclerosisMember to ions_MedicinesForAmyotrophicLateralSclerosisMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_MedicinesForAmyotrophicLateralSclerosisMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_MedicinesForAmyotrophicLateralSclerosisMember_lbl2" xml:lang="en-US" id="ions_MedicinesForAmyotrophicLateralSclerosisMember_lbl2">Medicines for ALS [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MedicinesForAmyotrophicLateralSclerosisMember" xlink:to="ions_MedicinesForAmyotrophicLateralSclerosisMember_lbl2" xlink:title="label: MedicinesForAmyotrophicLateralSclerosisMember to ions_MedicinesForAmyotrophicLateralSclerosisMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement" xlink:label="NumberOfDrugsLicensedUnderOptionInCollaborationAgreement" xlink:title="NumberOfDrugsLicensedUnderOptionInCollaborationAgreement" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement_lbl" xml:lang="en-US" id="ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement_lbl">The number of drugs licensed by the partner under option in the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDrugsLicensedUnderOptionInCollaborationAgreement" xlink:to="ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement_lbl" xlink:title="label: NumberOfDrugsLicensedUnderOptionInCollaborationAgreement to ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement_lbl1" xml:lang="en-US" id="ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement_lbl1">Number of drugs licensed under option in collaboration agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDrugsLicensedUnderOptionInCollaborationAgreement" xlink:to="ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement_lbl1" xlink:title="label: NumberOfDrugsLicensedUnderOptionInCollaborationAgreement to ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement_lbl2" xml:lang="en-US" id="ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement_lbl2">Number of drugs licensed under option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDrugsLicensedUnderOptionInCollaborationAgreement" xlink:to="ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement_lbl2" xlink:title="label: NumberOfDrugsLicensedUnderOptionInCollaborationAgreement to ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IONISC9Member" xlink:label="IONISC9Member" xlink:title="IONISC9Member" />
    <link:label xlink:type="resource" xlink:label="ions_IONISC9Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_IONISC9Member_lbl" xml:lang="en-US" id="ions_IONISC9Member_lbl">IONIS-C9Rx is an antisense medicine designed to selectively inhibit the production of the mutated chromosome 9 open reading frame 72, or C9ORF72, gene.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IONISC9Member" xlink:to="ions_IONISC9Member_lbl" xlink:title="label: IONISC9Member to ions_IONISC9Member_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_IONISC9Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_IONISC9Member_lbl1" xml:lang="en-US" id="ions_IONISC9Member_lbl1">IONIS-C9 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IONISC9Member" xlink:to="ions_IONISC9Member_lbl1" xlink:title="label: IONISC9Member to ions_IONISC9Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_IONISC9Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_IONISC9Member_lbl2" xml:lang="en-US" id="ions_IONISC9Member_lbl2">IONIS-C9 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IONISC9Member" xlink:to="ions_IONISC9Member_lbl2" xlink:title="label: IONISC9Member to ions_IONISC9Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfTargetsToBeDevelopedAndCommercialized" xlink:label="NumberOfTargetsToBeDevelopedAndCommercialized" xlink:title="NumberOfTargetsToBeDevelopedAndCommercialized" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfTargetsToBeDevelopedAndCommercialized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NumberOfTargetsToBeDevelopedAndCommercialized_lbl" xml:lang="en-US" id="ions_NumberOfTargetsToBeDevelopedAndCommercialized_lbl">The number of targets to be developed and commercialized under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTargetsToBeDevelopedAndCommercialized" xlink:to="ions_NumberOfTargetsToBeDevelopedAndCommercialized_lbl" xlink:title="label: NumberOfTargetsToBeDevelopedAndCommercialized to ions_NumberOfTargetsToBeDevelopedAndCommercialized_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfTargetsToBeDevelopedAndCommercialized_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NumberOfTargetsToBeDevelopedAndCommercialized_lbl1" xml:lang="en-US" id="ions_NumberOfTargetsToBeDevelopedAndCommercialized_lbl1">Number of targets to be developed and commercialized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTargetsToBeDevelopedAndCommercialized" xlink:to="ions_NumberOfTargetsToBeDevelopedAndCommercialized_lbl1" xlink:title="label: NumberOfTargetsToBeDevelopedAndCommercialized to ions_NumberOfTargetsToBeDevelopedAndCommercialized_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfTargetsToBeDevelopedAndCommercialized_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NumberOfTargetsToBeDevelopedAndCommercialized_lbl2" xml:lang="en-US" id="ions_NumberOfTargetsToBeDevelopedAndCommercialized_lbl2">Number of drugs to be developed and commercialized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTargetsToBeDevelopedAndCommercialized" xlink:to="ions_NumberOfTargetsToBeDevelopedAndCommercialized_lbl2" xlink:title="label: NumberOfTargetsToBeDevelopedAndCommercialized to ions_NumberOfTargetsToBeDevelopedAndCommercialized_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_TofersenMember" xlink:label="TofersenMember" xlink:title="TofersenMember" />
    <link:label xlink:type="resource" xlink:label="ions_TofersenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_TofersenMember_lbl" xml:lang="en-US" id="ions_TofersenMember_lbl">Tofersen (IONIS-SOD1Rx or BIIB067) is an antisense medicine designed to inhibit the production of superoxide dismutase 1, or SOD1, which is a well understood genetic cause of familial amyotrophic lateral sclerosis, or ALS.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TofersenMember" xlink:to="ions_TofersenMember_lbl" xlink:title="label: TofersenMember to ions_TofersenMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_TofersenMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_TofersenMember_lbl1" xml:lang="en-US" id="ions_TofersenMember_lbl1">Tofersen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TofersenMember" xlink:to="ions_TofersenMember_lbl1" xlink:title="label: TofersenMember to ions_TofersenMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_TofersenMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_TofersenMember_lbl2" xml:lang="en-US" id="ions_TofersenMember_lbl2">Tofersen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TofersenMember" xlink:to="ions_TofersenMember_lbl2" xlink:title="label: TofersenMember to ions_TofersenMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ION581Member" xlink:label="ION581Member" xlink:title="ION581Member" />
    <link:label xlink:type="resource" xlink:label="ions_ION581Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ION581Member_lbl" xml:lang="en-US" id="ions_ION581Member_lbl">ION581 is an antisense oligonucleotide (ASO) that targets Ubiquitin Protein Ligase E3A-Antisense Transcript (UBE3A-ATS), which is a long non-coding ribonucleic acid (lncRNA). ION581 reduces the levels of UBE3A-ATS and is being developed as a potential therapy for Angelman Syndrome (AS).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ION581Member" xlink:to="ions_ION581Member_lbl" xlink:title="label: ION581Member to ions_ION581Member_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ION581Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ION581Member_lbl1" xml:lang="en-US" id="ions_ION581Member_lbl1">ION581 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ION581Member" xlink:to="ions_ION581Member_lbl1" xlink:title="label: ION581Member to ions_ION581Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ION581Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ION581Member_lbl2" xml:lang="en-US" id="ions_ION581Member_lbl2">ION581 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ION581Member" xlink:to="ions_ION581Member_lbl2" xlink:title="label: ION581Member to ions_ION581Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ION859Member" xlink:label="ION859Member" xlink:title="ION859Member" />
    <link:label xlink:type="resource" xlink:label="ions_ION859Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ION859Member_lbl" xml:lang="en-US" id="ions_ION859Member_lbl">ION859 (BIIB094) is an antisense medicine designed to inhibit the production of the Leucine Rich Repeat Kinase 2, or LRRK2, protein as a potential therapy for Parkinson's disease, or PD.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ION859Member" xlink:to="ions_ION859Member_lbl" xlink:title="label: ION859Member to ions_ION859Member_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ION859Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ION859Member_lbl1" xml:lang="en-US" id="ions_ION859Member_lbl1">ION859 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ION859Member" xlink:to="ions_ION859Member_lbl1" xlink:title="label: ION859Member to ions_ION859Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ION859Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ION859Member_lbl2" xml:lang="en-US" id="ions_ION859Member_lbl2">ION859 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ION859Member" xlink:to="ions_ION859Member_lbl2" xlink:title="label: ION859Member to ions_ION859Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MilestonePaymentAchieved" xlink:label="MilestonePaymentAchieved" xlink:title="MilestonePaymentAchieved" />
    <link:label xlink:type="resource" xlink:label="ions_MilestonePaymentAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MilestonePaymentAchieved_lbl" xml:lang="en-US" id="ions_MilestonePaymentAchieved_lbl">Milestone payment achieved during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentAchieved" xlink:to="ions_MilestonePaymentAchieved_lbl" xlink:title="label: MilestonePaymentAchieved to ions_MilestonePaymentAchieved_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MilestonePaymentAchieved_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MilestonePaymentAchieved_lbl1" xml:lang="en-US" id="ions_MilestonePaymentAchieved_lbl1">Milestone payment achieved</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePaymentAchieved" xlink:to="ions_MilestonePaymentAchieved_lbl1" xlink:title="label: MilestonePaymentAchieved to ions_MilestonePaymentAchieved_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NextPotentialPayment" xlink:label="NextPotentialPayment" xlink:title="NextPotentialPayment" />
    <link:label xlink:type="resource" xlink:label="ions_NextPotentialPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NextPotentialPayment_lbl" xml:lang="en-US" id="ions_NextPotentialPayment_lbl">The next potential payment to be earned under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NextPotentialPayment" xlink:to="ions_NextPotentialPayment_lbl" xlink:title="label: NextPotentialPayment to ions_NextPotentialPayment_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NextPotentialPayment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NextPotentialPayment_lbl1" xml:lang="en-US" id="ions_NextPotentialPayment_lbl1">Next potential payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NextPotentialPayment" xlink:to="ions_NextPotentialPayment_lbl1" xlink:title="label: NextPotentialPayment to ions_NextPotentialPayment_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NextPotentialPayment_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NextPotentialPayment_lbl2" xml:lang="en-US" id="ions_NextPotentialPayment_lbl2">Next prospective payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NextPotentialPayment" xlink:to="ions_NextPotentialPayment_lbl2" xlink:title="label: NextPotentialPayment to ions_NextPotentialPayment_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PercentageCashPremiumPaidOnSharesPurchased" xlink:label="PercentageCashPremiumPaidOnSharesPurchased" xlink:title="PercentageCashPremiumPaidOnSharesPurchased" />
    <link:label xlink:type="resource" xlink:label="ions_PercentageCashPremiumPaidOnSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_PercentageCashPremiumPaidOnSharesPurchased_lbl" xml:lang="en-US" id="ions_PercentageCashPremiumPaidOnSharesPurchased_lbl">The percentage cash premium paid per share of the Company's common stock under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageCashPremiumPaidOnSharesPurchased" xlink:to="ions_PercentageCashPremiumPaidOnSharesPurchased_lbl" xlink:title="label: PercentageCashPremiumPaidOnSharesPurchased to ions_PercentageCashPremiumPaidOnSharesPurchased_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_PercentageCashPremiumPaidOnSharesPurchased_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_PercentageCashPremiumPaidOnSharesPurchased_lbl1" xml:lang="en-US" id="ions_PercentageCashPremiumPaidOnSharesPurchased_lbl1">Percentage cash premium paid on shares purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageCashPremiumPaidOnSharesPurchased" xlink:to="ions_PercentageCashPremiumPaidOnSharesPurchased_lbl1" xlink:title="label: PercentageCashPremiumPaidOnSharesPurchased to ions_PercentageCashPremiumPaidOnSharesPurchased_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_PercentageCashPremiumPaidOnSharesPurchased_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_PercentageCashPremiumPaidOnSharesPurchased_lbl2" xml:lang="en-US" id="ions_PercentageCashPremiumPaidOnSharesPurchased_lbl2">Percentage cash premium paid on shares purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageCashPremiumPaidOnSharesPurchased" xlink:to="ions_PercentageCashPremiumPaidOnSharesPurchased_lbl2" xlink:title="label: PercentageCashPremiumPaidOnSharesPurchased to ions_PercentageCashPremiumPaidOnSharesPurchased_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfDrugsCurrentlyBeingAdvanced" xlink:label="NumberOfDrugsCurrentlyBeingAdvanced" xlink:title="NumberOfDrugsCurrentlyBeingAdvanced" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfDrugsCurrentlyBeingAdvanced_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NumberOfDrugsCurrentlyBeingAdvanced_lbl" xml:lang="en-US" id="ions_NumberOfDrugsCurrentlyBeingAdvanced_lbl">The number of drugs currently being advanced under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDrugsCurrentlyBeingAdvanced" xlink:to="ions_NumberOfDrugsCurrentlyBeingAdvanced_lbl" xlink:title="label: NumberOfDrugsCurrentlyBeingAdvanced to ions_NumberOfDrugsCurrentlyBeingAdvanced_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfDrugsCurrentlyBeingAdvanced_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NumberOfDrugsCurrentlyBeingAdvanced_lbl1" xml:lang="en-US" id="ions_NumberOfDrugsCurrentlyBeingAdvanced_lbl1">Number of drugs currently being advanced</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDrugsCurrentlyBeingAdvanced" xlink:to="ions_NumberOfDrugsCurrentlyBeingAdvanced_lbl1" xlink:title="label: NumberOfDrugsCurrentlyBeingAdvanced to ions_NumberOfDrugsCurrentlyBeingAdvanced_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfDrugsCurrentlyBeingAdvanced_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NumberOfDrugsCurrentlyBeingAdvanced_lbl2" xml:lang="en-US" id="ions_NumberOfDrugsCurrentlyBeingAdvanced_lbl2">Number of drugs currently being advanced</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDrugsCurrentlyBeingAdvanced" xlink:to="ions_NumberOfDrugsCurrentlyBeingAdvanced_lbl2" xlink:title="label: NumberOfDrugsCurrentlyBeingAdvanced to ions_NumberOfDrugsCurrentlyBeingAdvanced_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PremiumPaidOnSharesPurchased" xlink:label="PremiumPaidOnSharesPurchased" xlink:title="PremiumPaidOnSharesPurchased" />
    <link:label xlink:type="resource" xlink:label="ions_PremiumPaidOnSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_PremiumPaidOnSharesPurchased_lbl" xml:lang="en-US" id="ions_PremiumPaidOnSharesPurchased_lbl">The cash premium paid on the purchase of the Company's common stock under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PremiumPaidOnSharesPurchased" xlink:to="ions_PremiumPaidOnSharesPurchased_lbl" xlink:title="label: PremiumPaidOnSharesPurchased to ions_PremiumPaidOnSharesPurchased_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_PremiumPaidOnSharesPurchased_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_PremiumPaidOnSharesPurchased_lbl1" xml:lang="en-US" id="ions_PremiumPaidOnSharesPurchased_lbl1">Premium paid on shares purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PremiumPaidOnSharesPurchased" xlink:to="ions_PremiumPaidOnSharesPurchased_lbl1" xlink:title="label: PremiumPaidOnSharesPurchased to ions_PremiumPaidOnSharesPurchased_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_PremiumPaidOnSharesPurchased_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_PremiumPaidOnSharesPurchased_lbl2" xml:lang="en-US" id="ions_PremiumPaidOnSharesPurchased_lbl2">Premium paid on shares purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PremiumPaidOnSharesPurchased" xlink:to="ions_PremiumPaidOnSharesPurchased_lbl2" xlink:title="label: PremiumPaidOnSharesPurchased to ions_PremiumPaidOnSharesPurchased_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones" xlink:label="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones" xlink:title="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones_lbl" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones_lbl">The maximum amount of payments receivable per drug or program for development milestone payments under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones_lbl" xlink:title="label: MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones to ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones_lbl1" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones_lbl1">Maximum amount of payments receivable per drug or program for development milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones_lbl1" xlink:title="label: MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones to ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones_lbl2" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones_lbl2">Maximum amount of payments receivable per program for development milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones_lbl2" xlink:title="label: MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones to ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfTargetsAdvanced" xlink:label="NumberOfTargetsAdvanced" xlink:title="NumberOfTargetsAdvanced" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfTargetsAdvanced_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NumberOfTargetsAdvanced_lbl" xml:lang="en-US" id="ions_NumberOfTargetsAdvanced_lbl">Number of targets advanced under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTargetsAdvanced" xlink:to="ions_NumberOfTargetsAdvanced_lbl" xlink:title="label: NumberOfTargetsAdvanced to ions_NumberOfTargetsAdvanced_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfTargetsAdvanced_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NumberOfTargetsAdvanced_lbl1" xml:lang="en-US" id="ions_NumberOfTargetsAdvanced_lbl1">Number of targets advanced</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTargetsAdvanced" xlink:to="ions_NumberOfTargetsAdvanced_lbl1" xlink:title="label: NumberOfTargetsAdvanced to ions_NumberOfTargetsAdvanced_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfTargetsAdvanced_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NumberOfTargetsAdvanced_lbl2" xml:lang="en-US" id="ions_NumberOfTargetsAdvanced_lbl2">Number of targets advanced</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfTargetsAdvanced" xlink:to="ions_NumberOfTargetsAdvanced_lbl2" xlink:title="label: NumberOfTargetsAdvanced to ions_NumberOfTargetsAdvanced_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AntisenseMoleculeMember" xlink:label="AntisenseMoleculeMember" xlink:title="AntisenseMoleculeMember" />
    <link:label xlink:type="resource" xlink:label="ions_AntisenseMoleculeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_AntisenseMoleculeMember_lbl" xml:lang="en-US" id="ions_AntisenseMoleculeMember_lbl">Each antisense molecule that is chosen for drug discovery and development to advance the treatment of neurological diseases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntisenseMoleculeMember" xlink:to="ions_AntisenseMoleculeMember_lbl" xlink:title="label: AntisenseMoleculeMember to ions_AntisenseMoleculeMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_AntisenseMoleculeMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_AntisenseMoleculeMember_lbl1" xml:lang="en-US" id="ions_AntisenseMoleculeMember_lbl1">Antisense Molecule [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntisenseMoleculeMember" xlink:to="ions_AntisenseMoleculeMember_lbl1" xlink:title="label: AntisenseMoleculeMember to ions_AntisenseMoleculeMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForSalesMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForSalesMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForSalesMilestones" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivableForSalesMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MaximumAmountOfPaymentsReceivableForSalesMilestones_lbl" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivableForSalesMilestones_lbl">The maximum amount of payments receivable for sales milestones under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForSalesMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForSalesMilestones_lbl" xlink:title="label: MaximumAmountOfPaymentsReceivableForSalesMilestones to ions_MaximumAmountOfPaymentsReceivableForSalesMilestones_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivableForSalesMilestones_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MaximumAmountOfPaymentsReceivableForSalesMilestones_lbl1" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivableForSalesMilestones_lbl1">Maximum amount of payments receivable for sales milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForSalesMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForSalesMilestones_lbl1" xlink:title="label: MaximumAmountOfPaymentsReceivableForSalesMilestones to ions_MaximumAmountOfPaymentsReceivableForSalesMilestones_lbl1" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceivedIncludingPurchaseOfStock" xlink:label="UpfrontPaymentReceivedIncludingPurchaseOfStock" xlink:title="UpfrontPaymentReceivedIncludingPurchaseOfStock" />
    <link:label xlink:type="resource" xlink:label="ions_UpfrontPaymentReceivedIncludingPurchaseOfStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_UpfrontPaymentReceivedIncludingPurchaseOfStock_lbl" xml:lang="en-US" id="ions_UpfrontPaymentReceivedIncludingPurchaseOfStock_lbl">The total amount of the upfront payment received, including the purchase of shares of the Company's stock, under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UpfrontPaymentReceivedIncludingPurchaseOfStock" xlink:to="ions_UpfrontPaymentReceivedIncludingPurchaseOfStock_lbl" xlink:title="label: UpfrontPaymentReceivedIncludingPurchaseOfStock to ions_UpfrontPaymentReceivedIncludingPurchaseOfStock_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_UpfrontPaymentReceivedIncludingPurchaseOfStock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_UpfrontPaymentReceivedIncludingPurchaseOfStock_lbl1" xml:lang="en-US" id="ions_UpfrontPaymentReceivedIncludingPurchaseOfStock_lbl1">Upfront payment received, including purchase of stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UpfrontPaymentReceivedIncludingPurchaseOfStock" xlink:to="ions_UpfrontPaymentReceivedIncludingPurchaseOfStock_lbl1" xlink:title="label: UpfrontPaymentReceivedIncludingPurchaseOfStock to ions_UpfrontPaymentReceivedIncludingPurchaseOfStock_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_UpfrontPaymentReceivedIncludingPurchaseOfStock_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_UpfrontPaymentReceivedIncludingPurchaseOfStock_lbl2" xml:lang="en-US" id="ions_UpfrontPaymentReceivedIncludingPurchaseOfStock_lbl2">Upfront payment received, including purchase of stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UpfrontPaymentReceivedIncludingPurchaseOfStock" xlink:to="ions_UpfrontPaymentReceivedIncludingPurchaseOfStock_lbl2" xlink:title="label: UpfrontPaymentReceivedIncludingPurchaseOfStock to ions_UpfrontPaymentReceivedIncludingPurchaseOfStock_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" xlink:label="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" xlink:title="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments_lbl" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments_lbl">The maximum amount of payments receivable per drug or program for license fees and/or substantive milestone payments under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" xlink:to="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments_lbl" xlink:title="label: MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments to ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments_lbl1" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments_lbl1">Maximum amount of payments receivable per drug or program for license fees and substantive milestone payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" xlink:to="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments_lbl1" xlink:title="label: MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments to ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments_lbl2" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments_lbl2">Maximum amount of payments receivable per program for license fee and milestone payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" xlink:to="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments_lbl2" xlink:title="label: MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments to ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember_lbl">Represents information pertaining to the collaborative arrangement entered into with Biogen Inc. in December 2012. This agreement is focused on developing and commercializing novel antisense drugs for up to three targets to treat neurological or neuromuscular diseases (Neurology).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember_lbl" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember_lbl1">Collaborative Arrangement and Licensing Agreement Entered Into in December 2012 with Biogen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember_lbl1" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember_lbl2">2012 Neurology [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember_lbl2" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember_lbl">Represents information pertaining to the expanded collaborative arrangement entered into with Biogen Inc. in April 2018 to develop novel antisense drug candidates for a broad range of neurological diseases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember_lbl" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember_lbl1">Collaborative Arrangement and Licensing Agreement Entered Into in April 2018 with Biogen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember_lbl1" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember_lbl2">2018 Strategic Neurology [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember_lbl2" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember_lbl">Represents information pertaining to the collaborative arrangement entered into with Biogen Inc. in September 2013. This agreement is a long-term strategic relationship focused on applying antisense technology to advance the treatment of neurodegenerative diseases (Strategic Neurology).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember_lbl" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember_lbl1">Collaborative Arrangement and Licensing Agreement Entered Into in September 2013 with Biogen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember_lbl1" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember_lbl2">2013 Strategic Neurology [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember_lbl2" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember_lbl">Represents information pertaining to the collaborative arrangement entered into with Biogen Inc. in January 2012 to develop and commercialize nusinersen for the treatment of spinal muscular atrophy, or SMA, a severe motor-neuron disease that is the leading genetic cause of infant mortality.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember_lbl" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember_lbl1">Collaborative Arrangement and Licensing Agreement Entered Into in January 2012 with Biogen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember_lbl1" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember_lbl2">SPINRAZA [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember_lbl2" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember_lbl">Represents information pertaining to the collaborative arrangement entered into with Biogen Inc. in December 2017 to identify new antisense oligonucleotide drug candidates for the treatment of spinal muscular atrophy, or SMA.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember_lbl" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember_lbl1">Collaborative Arrangement and Licensing Agreement Entered Into in December 2017 with Biogen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember_lbl1" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember_lbl2">New Antisense Medicines for the Treatment of SMA [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember_lbl2" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_TermOfCollaborationAgreement" xlink:label="TermOfCollaborationAgreement" xlink:title="TermOfCollaborationAgreement" />
    <link:label xlink:type="resource" xlink:label="ions_TermOfCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_TermOfCollaborationAgreement_lbl" xml:lang="en-US" id="ions_TermOfCollaborationAgreement_lbl">Term of the collaboration agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermOfCollaborationAgreement" xlink:to="ions_TermOfCollaborationAgreement_lbl" xlink:title="label: TermOfCollaborationAgreement to ions_TermOfCollaborationAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_TermOfCollaborationAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_TermOfCollaborationAgreement_lbl1" xml:lang="en-US" id="ions_TermOfCollaborationAgreement_lbl1">Term of collaboration agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermOfCollaborationAgreement" xlink:to="ions_TermOfCollaborationAgreement_lbl1" xlink:title="label: TermOfCollaborationAgreement to ions_TermOfCollaborationAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_TermOfCollaborationAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_TermOfCollaborationAgreement_lbl2" xml:lang="en-US" id="ions_TermOfCollaborationAgreement_lbl2">Term of collaboration agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermOfCollaborationAgreement" xlink:to="ions_TermOfCollaborationAgreement_lbl2" xlink:title="label: TermOfCollaborationAgreement to ions_TermOfCollaborationAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:label="CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:title="CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" />
    <link:label xlink:type="resource" xlink:label="ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation_lbl" xml:lang="en-US" id="ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation_lbl">Cumulative payments received since inception of the collaboration agreement included in the transaction price for the performance obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:to="ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation_lbl" xlink:title="label: CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation to ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation_lbl1" xml:lang="en-US" id="ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation_lbl1">Cumulative payments included in transaction price for performance obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:to="ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation_lbl1" xlink:title="label: CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation to ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation_lbl2" xml:lang="en-US" id="ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation_lbl2">Cumulative payments included in transaction price for performance obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:to="ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation_lbl2" xlink:title="label: CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation to ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfDrugsBeingDeveloped" xlink:label="NumberOfDrugsBeingDeveloped" xlink:title="NumberOfDrugsBeingDeveloped" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfDrugsBeingDeveloped_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NumberOfDrugsBeingDeveloped_lbl" xml:lang="en-US" id="ions_NumberOfDrugsBeingDeveloped_lbl">The number of drugs currently being developed under the collaboration agreement(s).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDrugsBeingDeveloped" xlink:to="ions_NumberOfDrugsBeingDeveloped_lbl" xlink:title="label: NumberOfDrugsBeingDeveloped to ions_NumberOfDrugsBeingDeveloped_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfDrugsBeingDeveloped_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NumberOfDrugsBeingDeveloped_lbl1" xml:lang="en-US" id="ions_NumberOfDrugsBeingDeveloped_lbl1">Number of drugs being developed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDrugsBeingDeveloped" xlink:to="ions_NumberOfDrugsBeingDeveloped_lbl1" xlink:title="label: NumberOfDrugsBeingDeveloped to ions_NumberOfDrugsBeingDeveloped_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfDrugsBeingDeveloped_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NumberOfDrugsBeingDeveloped_lbl2" xml:lang="en-US" id="ions_NumberOfDrugsBeingDeveloped_lbl2">Number of drugs currently being developed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDrugsBeingDeveloped" xlink:to="ions_NumberOfDrugsBeingDeveloped_lbl2" xlink:title="label: NumberOfDrugsBeingDeveloped to ions_NumberOfDrugsBeingDeveloped_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" xlink:label="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" xlink:title="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones_lbl" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones_lbl">The maximum amount of payments receivable per drug or program for regulatory milestone payments under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones_lbl" xlink:title="label: MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones to ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones_lbl1" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones_lbl1">Maximum amount of payments receivable per drug or program for regulatory milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones_lbl1" xlink:title="label: MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones to ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones_lbl2" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones_lbl2">Maximum amount of payments receivable per program for regulatory milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones_lbl2" xlink:title="label: MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones to ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones_lbl2" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones_lbl3" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones_lbl3">Maximum amount of payments receivable per drug for regulatory milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones_lbl3" xlink:title="label: MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones to ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones_lbl3" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="CumulativeRevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="CumulativeRevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xlink:type="resource" xlink:label="ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" id="ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax_lbl">Cumulative amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CumulativeRevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:title="label: CumulativeRevenueFromContractWithCustomerExcludingAssessedTax to ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax_lbl1" xml:lang="en-US" id="ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax_lbl1">Cumulative Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CumulativeRevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax_lbl1" xlink:title="label: CumulativeRevenueFromContractWithCustomerExcludingAssessedTax to ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax_lbl2" xml:lang="en-US" id="ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax_lbl2">Cumulative revenue earned</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CumulativeRevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax_lbl2" xlink:title="label: CumulativeRevenueFromContractWithCustomerExcludingAssessedTax to ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfCountriesWhereDrugIsApprovedForUse" xlink:label="NumberOfCountriesWhereDrugIsApprovedForUse" xlink:title="NumberOfCountriesWhereDrugIsApprovedForUse" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfCountriesWhereDrugIsApprovedForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NumberOfCountriesWhereDrugIsApprovedForUse_lbl" xml:lang="en-US" id="ions_NumberOfCountriesWhereDrugIsApprovedForUse_lbl">The number of countries where the drug is approved for treatment in patients.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCountriesWhereDrugIsApprovedForUse" xlink:to="ions_NumberOfCountriesWhereDrugIsApprovedForUse_lbl" xlink:title="label: NumberOfCountriesWhereDrugIsApprovedForUse to ions_NumberOfCountriesWhereDrugIsApprovedForUse_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfCountriesWhereDrugIsApprovedForUse_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NumberOfCountriesWhereDrugIsApprovedForUse_lbl1" xml:lang="en-US" id="ions_NumberOfCountriesWhereDrugIsApprovedForUse_lbl1">Number of countries where drug is approved for use</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCountriesWhereDrugIsApprovedForUse" xlink:to="ions_NumberOfCountriesWhereDrugIsApprovedForUse_lbl1" xlink:title="label: NumberOfCountriesWhereDrugIsApprovedForUse to ions_NumberOfCountriesWhereDrugIsApprovedForUse_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfCountriesWhereDrugIsApprovedForUse_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NumberOfCountriesWhereDrugIsApprovedForUse_lbl2" xml:lang="en-US" id="ions_NumberOfCountriesWhereDrugIsApprovedForUse_lbl2">Number of countries where SPINRAZA is approved for use</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCountriesWhereDrugIsApprovedForUse" xlink:to="ions_NumberOfCountriesWhereDrugIsApprovedForUse_lbl2" xlink:title="label: NumberOfCountriesWhereDrugIsApprovedForUse to ions_NumberOfCountriesWhereDrugIsApprovedForUse_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ION736Member" xlink:label="ION736Member" xlink:title="ION736Member" />
    <link:label xlink:type="resource" xlink:label="ions_ION736Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ION736Member_lbl" xml:lang="en-US" id="ions_ION736Member_lbl">ION736, formerly known as IONIS-AZ7-2.5, is a Generation 2.5 antisense drug.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ION736Member" xlink:to="ions_ION736Member_lbl" xlink:title="label: ION736Member to ions_ION736Member_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ION736Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ION736Member_lbl1" xml:lang="en-US" id="ions_ION736Member_lbl1">ION736 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ION736Member" xlink:to="ions_ION736Member_lbl1" xlink:title="label: ION736Member to ions_ION736Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ION736Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ION736Member_lbl2" xml:lang="en-US" id="ions_ION736Member_lbl2">ION736 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ION736Member" xlink:to="ions_ION736Member_lbl2" xlink:title="label: ION736Member to ions_ION736Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DanvatirsenMember" xlink:label="DanvatirsenMember" xlink:title="DanvatirsenMember" />
    <link:label xlink:type="resource" xlink:label="ions_DanvatirsenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_DanvatirsenMember_lbl" xml:lang="en-US" id="ions_DanvatirsenMember_lbl">Danvatirsen (formerly IONIS-STAT3-2.5, also known as AZD9150) was designed to treat cancer by inhibiting the production of a gene critical for tumor cell growth and survival. Signal transducer and activator of transcription 3, or STAT3, is over-active in a variety of cancers, including brain, lung, breast, bone, liver and multiple myeloma and promotes tumor cell growth and prevents cell death.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DanvatirsenMember" xlink:to="ions_DanvatirsenMember_lbl" xlink:title="label: DanvatirsenMember to ions_DanvatirsenMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_DanvatirsenMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_DanvatirsenMember_lbl1" xml:lang="en-US" id="ions_DanvatirsenMember_lbl1">Danvatirsen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DanvatirsenMember" xlink:to="ions_DanvatirsenMember_lbl1" xlink:title="label: DanvatirsenMember to ions_DanvatirsenMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_DanvatirsenMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_DanvatirsenMember_lbl2" xml:lang="en-US" id="ions_DanvatirsenMember_lbl2">Danvatirsen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DanvatirsenMember" xlink:to="ions_DanvatirsenMember_lbl2" xlink:title="label: DanvatirsenMember to ions_DanvatirsenMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfLicenseFeesEarned" xlink:label="NumberOfLicenseFeesEarned" xlink:title="NumberOfLicenseFeesEarned" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfLicenseFeesEarned_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NumberOfLicenseFeesEarned_lbl" xml:lang="en-US" id="ions_NumberOfLicenseFeesEarned_lbl">The number of license fees earned during the period under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfLicenseFeesEarned" xlink:to="ions_NumberOfLicenseFeesEarned_lbl" xlink:title="label: NumberOfLicenseFeesEarned to ions_NumberOfLicenseFeesEarned_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfLicenseFeesEarned_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NumberOfLicenseFeesEarned_lbl1" xml:lang="en-US" id="ions_NumberOfLicenseFeesEarned_lbl1">Number of license fees earned</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfLicenseFeesEarned" xlink:to="ions_NumberOfLicenseFeesEarned_lbl1" xlink:title="label: NumberOfLicenseFeesEarned to ions_NumberOfLicenseFeesEarned_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfLicenseFeesEarned_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NumberOfLicenseFeesEarned_lbl2" xml:lang="en-US" id="ions_NumberOfLicenseFeesEarned_lbl2">Number of license fees earned</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfLicenseFeesEarned" xlink:to="ions_NumberOfLicenseFeesEarned_lbl2" xlink:title="label: NumberOfLicenseFeesEarned to ions_NumberOfLicenseFeesEarned_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ION839Member" xlink:label="ION839Member" xlink:title="ION839Member" />
    <link:label xlink:type="resource" xlink:label="ions_ION839Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ION839Member_lbl" xml:lang="en-US" id="ions_ION839Member_lbl">A drug designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis, or NASH.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ION839Member" xlink:to="ions_ION839Member_lbl" xlink:title="label: ION839Member to ions_ION839Member_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ION839Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ION839Member_lbl1" xml:lang="en-US" id="ions_ION839Member_lbl1">ION839 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ION839Member" xlink:to="ions_ION839Member_lbl1" xlink:title="label: ION839Member to ions_ION839Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ION839Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ION839Member_lbl2" xml:lang="en-US" id="ions_ION839Member_lbl2">IOIN839 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ION839Member" xlink:to="ions_ION839Member_lbl2" xlink:title="label: ION839Member to ions_ION839Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfProgramsAdvanced" xlink:label="NumberOfProgramsAdvanced" xlink:title="NumberOfProgramsAdvanced" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfProgramsAdvanced_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NumberOfProgramsAdvanced_lbl" xml:lang="en-US" id="ions_NumberOfProgramsAdvanced_lbl">The number of programs advanced under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfProgramsAdvanced" xlink:to="ions_NumberOfProgramsAdvanced_lbl" xlink:title="label: NumberOfProgramsAdvanced to ions_NumberOfProgramsAdvanced_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfProgramsAdvanced_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NumberOfProgramsAdvanced_lbl1" xml:lang="en-US" id="ions_NumberOfProgramsAdvanced_lbl1">Number of programs advanced</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfProgramsAdvanced" xlink:to="ions_NumberOfProgramsAdvanced_lbl1" xlink:title="label: NumberOfProgramsAdvanced to ions_NumberOfProgramsAdvanced_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfProgramsAdvanced_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NumberOfProgramsAdvanced_lbl2" xml:lang="en-US" id="ions_NumberOfProgramsAdvanced_lbl2">Number of programs advanced</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfProgramsAdvanced" xlink:to="ions_NumberOfProgramsAdvanced_lbl2" xlink:title="label: NumberOfProgramsAdvanced to ions_NumberOfProgramsAdvanced_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfLicensedDrugs" xlink:label="NumberOfLicensedDrugs" xlink:title="NumberOfLicensedDrugs" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfLicensedDrugs_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NumberOfLicensedDrugs_lbl" xml:lang="en-US" id="ions_NumberOfLicensedDrugs_lbl">The number of drugs that have been licensed under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfLicensedDrugs" xlink:to="ions_NumberOfLicensedDrugs_lbl" xlink:title="label: NumberOfLicensedDrugs to ions_NumberOfLicensedDrugs_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfLicensedDrugs_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NumberOfLicensedDrugs_lbl1" xml:lang="en-US" id="ions_NumberOfLicensedDrugs_lbl1">Number of licensed drugs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfLicensedDrugs" xlink:to="ions_NumberOfLicensedDrugs_lbl1" xlink:title="label: NumberOfLicensedDrugs to ions_NumberOfLicensedDrugs_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfLicensedDrugs_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NumberOfLicensedDrugs_lbl2" xml:lang="en-US" id="ions_NumberOfLicensedDrugs_lbl2">Number of licensed drugs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfLicensedDrugs" xlink:to="ions_NumberOfLicensedDrugs_lbl2" xlink:title="label: NumberOfLicensedDrugs to ions_NumberOfLicensedDrugs_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfPerformanceObligationsCompleted" xlink:label="NumberOfPerformanceObligationsCompleted" xlink:title="NumberOfPerformanceObligationsCompleted" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfPerformanceObligationsCompleted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NumberOfPerformanceObligationsCompleted_lbl" xml:lang="en-US" id="ions_NumberOfPerformanceObligationsCompleted_lbl">The number of performance obligations completed under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPerformanceObligationsCompleted" xlink:to="ions_NumberOfPerformanceObligationsCompleted_lbl" xlink:title="label: NumberOfPerformanceObligationsCompleted to ions_NumberOfPerformanceObligationsCompleted_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfPerformanceObligationsCompleted_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NumberOfPerformanceObligationsCompleted_lbl1" xml:lang="en-US" id="ions_NumberOfPerformanceObligationsCompleted_lbl1">Number of performance obligations completed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPerformanceObligationsCompleted" xlink:to="ions_NumberOfPerformanceObligationsCompleted_lbl1" xlink:title="label: NumberOfPerformanceObligationsCompleted to ions_NumberOfPerformanceObligationsCompleted_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfPerformanceObligationsCompleted_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NumberOfPerformanceObligationsCompleted_lbl2" xml:lang="en-US" id="ions_NumberOfPerformanceObligationsCompleted_lbl2">Number of performance obligations completed</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPerformanceObligationsCompleted" xlink:to="ions_NumberOfPerformanceObligationsCompleted_lbl2" xlink:title="label: NumberOfPerformanceObligationsCompleted to ions_NumberOfPerformanceObligationsCompleted_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember_lbl">Represents information pertaining to the collaborative arrangement entered into with AstraZeneca PLC in December 2012 and amended in January 2016 to discover and develop antisense drugs for cancer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember_lbl" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember_lbl1">Collaborative Arrangement and Licensing Agreement Entered Into in December 2012 with AstraZeneca [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember_lbl1" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember_lbl2">Oncology [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember_lbl2" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember_lbl2" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember_lbl3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember_lbl3" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember_lbl3">AstraZeneca [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember_lbl3" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember_lbl3" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember_lbl">Represents information pertaining to the collaborative arrangement entered into with AstraZeneca PLC in July 2015 to discover and develop antisense therapies for treating cardiovascular and metabolic diseases primarily focused on targets in the kidney and renal diseases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember_lbl" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember_lbl1">Collaborative Arrangement and Licensing Agreement Entered Into in July 2015 with AstraZeneca [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember_lbl1" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember_lbl2">Cardiovascular, Renal and Metabolic Diseases [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember_lbl2" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ION532Member" xlink:label="ION532Member" xlink:title="ION532Member" />
    <link:label xlink:type="resource" xlink:label="ions_ION532Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ION532Member_lbl" xml:lang="en-US" id="ions_ION532Member_lbl">A drug designed to treat a genetically associated form of kidney disease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ION532Member" xlink:to="ions_ION532Member_lbl" xlink:title="label: ION532Member to ions_ION532Member_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ION532Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ION532Member_lbl1" xml:lang="en-US" id="ions_ION532Member_lbl1">ION532 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ION532Member" xlink:to="ions_ION532Member_lbl1" xlink:title="label: ION532Member to ions_ION532Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ION532Member_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ION532Member_lbl2" xml:lang="en-US" id="ions_ION532Member_lbl2">ION532 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ION532Member" xlink:to="ions_ION532Member_lbl2" xlink:title="label: ION532Member to ions_ION532Member_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AKCEAAPOALMember" xlink:label="AKCEAAPOALMember" xlink:title="AKCEAAPOALMember" />
    <link:label xlink:type="resource" xlink:label="ions_AKCEAAPOALMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_AKCEAAPOALMember_lbl" xml:lang="en-US" id="ions_AKCEAAPOALMember_lbl">An antisense therapy with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of the lipoprotein Lp(a).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AKCEAAPOALMember" xlink:to="ions_AKCEAAPOALMember_lbl" xlink:title="label: AKCEAAPOALMember to ions_AKCEAAPOALMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_AKCEAAPOALMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_AKCEAAPOALMember_lbl1" xml:lang="en-US" id="ions_AKCEAAPOALMember_lbl1">AKCEA-APO(a)-L [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AKCEAAPOALMember" xlink:to="ions_AKCEAAPOALMember_lbl1" xlink:title="label: AKCEAAPOALMember to ions_AKCEAAPOALMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_AKCEAAPOALMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_AKCEAAPOALMember_lbl2" xml:lang="en-US" id="ions_AKCEAAPOALMember_lbl2">AKCEA-APO(a)-L [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AKCEAAPOALMember" xlink:to="ions_AKCEAAPOALMember_lbl2" xlink:title="label: AKCEAAPOALMember to ions_AKCEAAPOALMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember" xlink:label="ResearchAndDevelopmentServicesForAKCEAAPOALMember" xlink:title="ResearchAndDevelopmentServicesForAKCEAAPOALMember" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember_lbl" xml:lang="en-US" id="ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember_lbl">Research and development (R&amp;D) services for AKCEA-APO(a)-L, an antisense therapy with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of the lipoprotein Lp(a).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentServicesForAKCEAAPOALMember" xlink:to="ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember_lbl" xlink:title="label: ResearchAndDevelopmentServicesForAKCEAAPOALMember to ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember_lbl1" xml:lang="en-US" id="ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember_lbl1">Research and Development Services for AKCEA-APO(a)-L [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentServicesForAKCEAAPOALMember" xlink:to="ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember_lbl1" xlink:title="label: ResearchAndDevelopmentServicesForAKCEAAPOALMember to ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember_lbl2" xml:lang="en-US" id="ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember_lbl2">R&amp;D Services for AKCEA-APO(a)-L [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentServicesForAKCEAAPOALMember" xlink:to="ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember_lbl2" xlink:title="label: ResearchAndDevelopmentServicesForAKCEAAPOALMember to ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid" xlink:label="ProceedsFromSaleOfCommonStockIncludingPremiumPaid" xlink:title="ProceedsFromSaleOfCommonStockIncludingPremiumPaid" />
    <link:label xlink:type="resource" xlink:label="ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid_lbl" xml:lang="en-US" id="ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid_lbl">The cash inflow from the sale of common stock, including the premium paid for the purchase of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfCommonStockIncludingPremiumPaid" xlink:to="ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid_lbl" xlink:title="label: ProceedsFromSaleOfCommonStockIncludingPremiumPaid to ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid_lbl1" xml:lang="en-US" id="ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid_lbl1">Proceeds from sale of common stock, including premium paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfCommonStockIncludingPremiumPaid" xlink:to="ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid_lbl1" xlink:title="label: ProceedsFromSaleOfCommonStockIncludingPremiumPaid to ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid_lbl2" xml:lang="en-US" id="ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid_lbl2">Proceeds from sale of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromSaleOfCommonStockIncludingPremiumPaid" xlink:to="ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid_lbl2" xlink:title="label: ProceedsFromSaleOfCommonStockIncludingPremiumPaid to ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RoyaltyPercentageReceivedOnSalesOfDrug" xlink:label="RoyaltyPercentageReceivedOnSalesOfDrug" xlink:title="RoyaltyPercentageReceivedOnSalesOfDrug" />
    <link:label xlink:type="resource" xlink:label="ions_RoyaltyPercentageReceivedOnSalesOfDrug_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_RoyaltyPercentageReceivedOnSalesOfDrug_lbl" xml:lang="en-US" id="ions_RoyaltyPercentageReceivedOnSalesOfDrug_lbl">Royalty percentage received on the sales of a drug by a collaboration partner under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentageReceivedOnSalesOfDrug" xlink:to="ions_RoyaltyPercentageReceivedOnSalesOfDrug_lbl" xlink:title="label: RoyaltyPercentageReceivedOnSalesOfDrug to ions_RoyaltyPercentageReceivedOnSalesOfDrug_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_RoyaltyPercentageReceivedOnSalesOfDrug_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_RoyaltyPercentageReceivedOnSalesOfDrug_lbl1" xml:lang="en-US" id="ions_RoyaltyPercentageReceivedOnSalesOfDrug_lbl1">Royalty percentage received on sales of drug</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentageReceivedOnSalesOfDrug" xlink:to="ions_RoyaltyPercentageReceivedOnSalesOfDrug_lbl1" xlink:title="label: RoyaltyPercentageReceivedOnSalesOfDrug to ions_RoyaltyPercentageReceivedOnSalesOfDrug_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_RoyaltyPercentageReceivedOnSalesOfDrug_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_RoyaltyPercentageReceivedOnSalesOfDrug_lbl2" xml:lang="en-US" id="ions_RoyaltyPercentageReceivedOnSalesOfDrug_lbl2">Royalty percentage received on sales of drug</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentageReceivedOnSalesOfDrug" xlink:to="ions_RoyaltyPercentageReceivedOnSalesOfDrug_lbl2" xlink:title="label: RoyaltyPercentageReceivedOnSalesOfDrug to ions_RoyaltyPercentageReceivedOnSalesOfDrug_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PortionOfUpfrontPaymentPaidAsSublicenseFee" xlink:label="PortionOfUpfrontPaymentPaidAsSublicenseFee" xlink:title="PortionOfUpfrontPaymentPaidAsSublicenseFee" />
    <link:label xlink:type="resource" xlink:label="ions_PortionOfUpfrontPaymentPaidAsSublicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_PortionOfUpfrontPaymentPaidAsSublicenseFee_lbl" xml:lang="en-US" id="ions_PortionOfUpfrontPaymentPaidAsSublicenseFee_lbl">The amount of the upfront payment received during the period under the collaboration agreement that was paid as a sublicense fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PortionOfUpfrontPaymentPaidAsSublicenseFee" xlink:to="ions_PortionOfUpfrontPaymentPaidAsSublicenseFee_lbl" xlink:title="label: PortionOfUpfrontPaymentPaidAsSublicenseFee to ions_PortionOfUpfrontPaymentPaidAsSublicenseFee_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_PortionOfUpfrontPaymentPaidAsSublicenseFee_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_PortionOfUpfrontPaymentPaidAsSublicenseFee_lbl1" xml:lang="en-US" id="ions_PortionOfUpfrontPaymentPaidAsSublicenseFee_lbl1">Portion of upfront payment paid as sublicense fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PortionOfUpfrontPaymentPaidAsSublicenseFee" xlink:to="ions_PortionOfUpfrontPaymentPaidAsSublicenseFee_lbl1" xlink:title="label: PortionOfUpfrontPaymentPaidAsSublicenseFee to ions_PortionOfUpfrontPaymentPaidAsSublicenseFee_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_PortionOfUpfrontPaymentPaidAsSublicenseFee_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_PortionOfUpfrontPaymentPaidAsSublicenseFee_lbl2" xml:lang="en-US" id="ions_PortionOfUpfrontPaymentPaidAsSublicenseFee_lbl2">Portion of upfront payment paid as sublicense fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PortionOfUpfrontPaymentPaidAsSublicenseFee" xlink:to="ions_PortionOfUpfrontPaymentPaidAsSublicenseFee_lbl2" xlink:title="label: PortionOfUpfrontPaymentPaidAsSublicenseFee to ions_PortionOfUpfrontPaymentPaidAsSublicenseFee_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AKCEAAPOCIIILMember" xlink:label="AKCEAAPOCIIILMember" xlink:title="AKCEAAPOCIIILMember" />
    <link:label xlink:type="resource" xlink:label="ions_AKCEAAPOCIIILMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_AKCEAAPOCIIILMember_lbl" xml:lang="en-US" id="ions_AKCEAAPOCIIILMember_lbl">An antisense therapy with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of the lipoprotein ApoCIII.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AKCEAAPOCIIILMember" xlink:to="ions_AKCEAAPOCIIILMember_lbl" xlink:title="label: AKCEAAPOCIIILMember to ions_AKCEAAPOCIIILMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_AKCEAAPOCIIILMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_AKCEAAPOCIIILMember_lbl1" xml:lang="en-US" id="ions_AKCEAAPOCIIILMember_lbl1">AKCEA-APOCIII-L [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AKCEAAPOCIIILMember" xlink:to="ions_AKCEAAPOCIIILMember_lbl1" xlink:title="label: AKCEAAPOCIIILMember to ions_AKCEAAPOCIIILMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_AKCEAAPOCIIILMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_AKCEAAPOCIIILMember_lbl2" xml:lang="en-US" id="ions_AKCEAAPOCIIILMember_lbl2">AKCEA-APOCIII-L [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AKCEAAPOCIIILMember" xlink:to="ions_AKCEAAPOCIIILMember_lbl2" xlink:title="label: AKCEAAPOCIIILMember to ions_AKCEAAPOCIIILMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DeliveryOfAKCEAAPOCIIILMember" xlink:label="DeliveryOfAKCEAAPOCIIILMember" xlink:title="DeliveryOfAKCEAAPOCIIILMember" />
    <link:label xlink:type="resource" xlink:label="ions_DeliveryOfAKCEAAPOCIIILMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_DeliveryOfAKCEAAPOCIIILMember_lbl" xml:lang="en-US" id="ions_DeliveryOfAKCEAAPOCIIILMember_lbl">Delivery of AKCEA-APOCIII-L, an antisense therapy with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of the lipoprotein ApoCIII.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeliveryOfAKCEAAPOCIIILMember" xlink:to="ions_DeliveryOfAKCEAAPOCIIILMember_lbl" xlink:title="label: DeliveryOfAKCEAAPOCIIILMember to ions_DeliveryOfAKCEAAPOCIIILMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_DeliveryOfAKCEAAPOCIIILMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_DeliveryOfAKCEAAPOCIIILMember_lbl1" xml:lang="en-US" id="ions_DeliveryOfAKCEAAPOCIIILMember_lbl1">Delivery of AKCEA-APOCIII-L [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeliveryOfAKCEAAPOCIIILMember" xlink:to="ions_DeliveryOfAKCEAAPOCIIILMember_lbl1" xlink:title="label: DeliveryOfAKCEAAPOCIIILMember to ions_DeliveryOfAKCEAAPOCIIILMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_DeliveryOfAKCEAAPOCIIILMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_DeliveryOfAKCEAAPOCIIILMember_lbl2" xml:lang="en-US" id="ions_DeliveryOfAKCEAAPOCIIILMember_lbl2">Delivery of AKCEA-APOCIII-L [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeliveryOfAKCEAAPOCIIILMember" xlink:to="ions_DeliveryOfAKCEAAPOCIIILMember_lbl2" xlink:title="label: DeliveryOfAKCEAAPOCIIILMember to ions_DeliveryOfAKCEAAPOCIIILMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember" xlink:label="ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember" xlink:title="ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember_lbl" xml:lang="en-US" id="ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember_lbl">Research and development (R&amp;D) services for AKCEA-APOCIII-L, an antisense therapy with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of the lipoprotein ApoCIII.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember" xlink:to="ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember_lbl" xlink:title="label: ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember to ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember_lbl1" xml:lang="en-US" id="ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember_lbl1">Research and Development Services for AKCEA-APOCIII-L [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember" xlink:to="ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember_lbl1" xlink:title="label: ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember to ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember_lbl2" xml:lang="en-US" id="ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember_lbl2">R&amp;D Services for AKCEA-APOCIII-L [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember" xlink:to="ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember_lbl2" xlink:title="label: ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember to ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee" xlink:label="PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee" xlink:title="PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee" />
    <link:label xlink:type="resource" xlink:label="ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee_lbl" xml:lang="en-US" id="ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee_lbl">The percentage of license fees, milestone payments and royalties paid as sublicense fee under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee" xlink:to="ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee_lbl" xlink:title="label: PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee to ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee_lbl1" xml:lang="en-US" id="ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee_lbl1">Percentage of license fees, milestone payments and royalties paid as sublicense fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee" xlink:to="ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee_lbl1" xlink:title="label: PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee to ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee_lbl2" xml:lang="en-US" id="ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee_lbl2">Percentage of license fees, milestone payments and royalties paid as sublicense fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee" xlink:to="ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee_lbl2" xlink:title="label: PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee to ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AdditionalAmountOfCommonStockRequiredToBePurchased" xlink:label="AdditionalAmountOfCommonStockRequiredToBePurchased" xlink:title="AdditionalAmountOfCommonStockRequiredToBePurchased" />
    <link:label xlink:type="resource" xlink:label="ions_AdditionalAmountOfCommonStockRequiredToBePurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_AdditionalAmountOfCommonStockRequiredToBePurchased_lbl" xml:lang="en-US" id="ions_AdditionalAmountOfCommonStockRequiredToBePurchased_lbl">The additional amount of common stock the collaboration partner is required to purchase under a Stock Purchase Agreement (SPA) in conjunction with the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalAmountOfCommonStockRequiredToBePurchased" xlink:to="ions_AdditionalAmountOfCommonStockRequiredToBePurchased_lbl" xlink:title="label: AdditionalAmountOfCommonStockRequiredToBePurchased to ions_AdditionalAmountOfCommonStockRequiredToBePurchased_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_AdditionalAmountOfCommonStockRequiredToBePurchased_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_AdditionalAmountOfCommonStockRequiredToBePurchased_lbl1" xml:lang="en-US" id="ions_AdditionalAmountOfCommonStockRequiredToBePurchased_lbl1">Additional amount of common stock required to be purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalAmountOfCommonStockRequiredToBePurchased" xlink:to="ions_AdditionalAmountOfCommonStockRequiredToBePurchased_lbl1" xlink:title="label: AdditionalAmountOfCommonStockRequiredToBePurchased to ions_AdditionalAmountOfCommonStockRequiredToBePurchased_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_AdditionalAmountOfCommonStockRequiredToBePurchased_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_AdditionalAmountOfCommonStockRequiredToBePurchased_lbl2" xml:lang="en-US" id="ions_AdditionalAmountOfCommonStockRequiredToBePurchased_lbl2">Additional amount of common stock required to be purchased</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalAmountOfCommonStockRequiredToBePurchased" xlink:to="ions_AdditionalAmountOfCommonStockRequiredToBePurchased_lbl2" xlink:title="label: AdditionalAmountOfCommonStockRequiredToBePurchased to ions_AdditionalAmountOfCommonStockRequiredToBePurchased_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DeliveryOfAKCEAAPOALMember" xlink:label="DeliveryOfAKCEAAPOALMember" xlink:title="DeliveryOfAKCEAAPOALMember" />
    <link:label xlink:type="resource" xlink:label="ions_DeliveryOfAKCEAAPOALMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_DeliveryOfAKCEAAPOALMember_lbl" xml:lang="en-US" id="ions_DeliveryOfAKCEAAPOALMember_lbl">Delivery of AKCEA-APO(a)-L, an antisense therapy with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of the lipoprotein Lp(a).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeliveryOfAKCEAAPOALMember" xlink:to="ions_DeliveryOfAKCEAAPOALMember_lbl" xlink:title="label: DeliveryOfAKCEAAPOALMember to ions_DeliveryOfAKCEAAPOALMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_DeliveryOfAKCEAAPOALMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_DeliveryOfAKCEAAPOALMember_lbl1" xml:lang="en-US" id="ions_DeliveryOfAKCEAAPOALMember_lbl1">Delivery of AKCEA-APO(a)-L [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeliveryOfAKCEAAPOALMember" xlink:to="ions_DeliveryOfAKCEAAPOALMember_lbl1" xlink:title="label: DeliveryOfAKCEAAPOALMember to ions_DeliveryOfAKCEAAPOALMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_DeliveryOfAKCEAAPOALMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_DeliveryOfAKCEAAPOALMember_lbl2" xml:lang="en-US" id="ions_DeliveryOfAKCEAAPOALMember_lbl2">Delivery of AKCEA-APO(a)-L [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeliveryOfAKCEAAPOALMember" xlink:to="ions_DeliveryOfAKCEAAPOALMember_lbl2" xlink:title="label: DeliveryOfAKCEAAPOALMember to ions_DeliveryOfAKCEAAPOALMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForMilestones" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivableForMilestones_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MaximumAmountOfPaymentsReceivableForMilestones_lbl" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivableForMilestones_lbl">The maximum amount of payments receivable for milestones under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForMilestones_lbl" xlink:title="label: MaximumAmountOfPaymentsReceivableForMilestones to ions_MaximumAmountOfPaymentsReceivableForMilestones_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivableForMilestones_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MaximumAmountOfPaymentsReceivableForMilestones_lbl1" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivableForMilestones_lbl1">Maximum amount of payments receivable for milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForMilestones_lbl1" xlink:title="label: MaximumAmountOfPaymentsReceivableForMilestones to ions_MaximumAmountOfPaymentsReceivableForMilestones_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumAmountOfPaymentsReceivableForMilestones_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_MaximumAmountOfPaymentsReceivableForMilestones_lbl2" xml:lang="en-US" id="ions_MaximumAmountOfPaymentsReceivableForMilestones_lbl2">Maximum amount of payments receivable for milestones</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumAmountOfPaymentsReceivableForMilestones" xlink:to="ions_MaximumAmountOfPaymentsReceivableForMilestones_lbl2" xlink:title="label: MaximumAmountOfPaymentsReceivableForMilestones to ions_MaximumAmountOfPaymentsReceivableForMilestones_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PremiumReceivedOnSharesIssued" xlink:label="PremiumReceivedOnSharesIssued" xlink:title="PremiumReceivedOnSharesIssued" />
    <link:label xlink:type="resource" xlink:label="ions_PremiumReceivedOnSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_PremiumReceivedOnSharesIssued_lbl" xml:lang="en-US" id="ions_PremiumReceivedOnSharesIssued_lbl">The total amount of the premium received over the trading price of common stock at the time of purchase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PremiumReceivedOnSharesIssued" xlink:to="ions_PremiumReceivedOnSharesIssued_lbl" xlink:title="label: PremiumReceivedOnSharesIssued to ions_PremiumReceivedOnSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_PremiumReceivedOnSharesIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_PremiumReceivedOnSharesIssued_lbl1" xml:lang="en-US" id="ions_PremiumReceivedOnSharesIssued_lbl1">Premium received on shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PremiumReceivedOnSharesIssued" xlink:to="ions_PremiumReceivedOnSharesIssued_lbl1" xlink:title="label: PremiumReceivedOnSharesIssued to ions_PremiumReceivedOnSharesIssued_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_PremiumReceivedOnSharesIssued_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_PremiumReceivedOnSharesIssued_lbl2" xml:lang="en-US" id="ions_PremiumReceivedOnSharesIssued_lbl2">Premium received on shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PremiumReceivedOnSharesIssued" xlink:to="ions_PremiumReceivedOnSharesIssued_lbl2" xlink:title="label: PremiumReceivedOnSharesIssued to ions_PremiumReceivedOnSharesIssued_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PortionOfUpfrontPaymentRetained" xlink:label="PortionOfUpfrontPaymentRetained" xlink:title="PortionOfUpfrontPaymentRetained" />
    <link:label xlink:type="resource" xlink:label="ions_PortionOfUpfrontPaymentRetained_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_PortionOfUpfrontPaymentRetained_lbl" xml:lang="en-US" id="ions_PortionOfUpfrontPaymentRetained_lbl">The amount of the upfront payment received during the period under the collaboration agreement that was retained by the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PortionOfUpfrontPaymentRetained" xlink:to="ions_PortionOfUpfrontPaymentRetained_lbl" xlink:title="label: PortionOfUpfrontPaymentRetained to ions_PortionOfUpfrontPaymentRetained_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_PortionOfUpfrontPaymentRetained_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_PortionOfUpfrontPaymentRetained_lbl1" xml:lang="en-US" id="ions_PortionOfUpfrontPaymentRetained_lbl1">Portion of upfront payment retained</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PortionOfUpfrontPaymentRetained" xlink:to="ions_PortionOfUpfrontPaymentRetained_lbl1" xlink:title="label: PortionOfUpfrontPaymentRetained to ions_PortionOfUpfrontPaymentRetained_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_PortionOfUpfrontPaymentRetained_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_PortionOfUpfrontPaymentRetained_lbl2" xml:lang="en-US" id="ions_PortionOfUpfrontPaymentRetained_lbl2">Portion of upfront payment retained</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PortionOfUpfrontPaymentRetained" xlink:to="ions_PortionOfUpfrontPaymentRetained_lbl2" xlink:title="label: PortionOfUpfrontPaymentRetained to ions_PortionOfUpfrontPaymentRetained_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture" xlink:label="PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture" xlink:title="PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture" />
    <link:label xlink:type="resource" xlink:label="ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture_lbl" xml:lang="en-US" id="ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture_lbl">The potential premium received if common stock is purchased in the future under a Stock Purchase Agreement (SPA) in conjunction with the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture" xlink:to="ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture_lbl" xlink:title="label: PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture to ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture_lbl1" xml:lang="en-US" id="ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture_lbl1">Potential premium received if common stock is purchased in future</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture" xlink:to="ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture_lbl1" xlink:title="label: PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture to ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture_lbl2" xml:lang="en-US" id="ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture_lbl2">Potential premium received if common stock is purchased in the future</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture" xlink:to="ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture_lbl2" xlink:title="label: PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture to ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties" xlink:label="RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties" xlink:title="RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties" />
    <link:label xlink:type="resource" xlink:label="ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties_lbl" xml:lang="en-US" id="ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties_lbl">The minimum amount of revenue recognized in Latin America by the collaboration partner before paying royalties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties" xlink:to="ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties_lbl" xlink:title="label: RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties to ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties_lbl1" xml:lang="en-US" id="ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties_lbl1">Revenue recognized by collaboration partner in Latin America before paying royalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties" xlink:to="ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties_lbl1" xlink:title="label: RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties to ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties_lbl2" xml:lang="en-US" id="ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties_lbl2">Minimum revenue recognized in Latin America by PTC before paying royalties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties" xlink:to="ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties_lbl2" xlink:title="label: RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties to ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner" xlink:label="RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner" xlink:title="RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner" />
    <link:label xlink:type="resource" xlink:label="ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner_lbl" xml:lang="en-US" id="ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner_lbl">Royalty percentage received on the net sales of each drug in Latin America from the collaboration partner under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner" xlink:to="ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner_lbl" xlink:title="label: RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner to ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner_lbl1" xml:lang="en-US" id="ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner_lbl1">Royalty percentage received on net sales of each drug in Latin America from collaboration partner</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner" xlink:to="ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner_lbl1" xlink:title="label: RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner to ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner_lbl2" xml:lang="en-US" id="ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner_lbl2">Royalty percentage received on net sales of each drug in Latin America from PTC</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner" xlink:to="ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner_lbl2" xlink:title="label: RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner to ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil" xlink:label="PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil" xlink:title="PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil" />
    <link:label xlink:type="resource" xlink:label="ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil_lbl" xml:lang="en-US" id="ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil_lbl">Period of time before collaboration partner pays royalties on net sales of product after first commercial sale in Brazil, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil" xlink:to="ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil_lbl" xlink:title="label: PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil to ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil_lbl1" xml:lang="en-US" id="ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil_lbl1">Period before collaboration partner pays royalties on net sales of product after first commercial sale in Brazil</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil" xlink:to="ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil_lbl1" xlink:title="label: PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil to ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil_lbl2" xml:lang="en-US" id="ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil_lbl2">Period before PTC pays royalties on net sales of product after first commercial sale in Brazil</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil" xlink:to="ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil_lbl2" xlink:title="label: PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil to ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_WaylivraMember" xlink:label="WaylivraMember" xlink:title="WaylivraMember" />
    <link:label xlink:type="resource" xlink:label="ions_WaylivraMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_WaylivraMember_lbl" xml:lang="en-US" id="ions_WaylivraMember_lbl">WAYLIVRA is a drug designed to treat two severe and rare, genetically defined diseases, familial chylomicronemia syndrome, or FCS, and familial partial lipodystrophy, or FPL.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WaylivraMember" xlink:to="ions_WaylivraMember_lbl" xlink:title="label: WaylivraMember to ions_WaylivraMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_WaylivraMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_WaylivraMember_lbl1" xml:lang="en-US" id="ions_WaylivraMember_lbl1">WAYLIVRA [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WaylivraMember" xlink:to="ions_WaylivraMember_lbl1" xlink:title="label: WaylivraMember to ions_WaylivraMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_WaylivraMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_WaylivraMember_lbl2" xml:lang="en-US" id="ions_WaylivraMember_lbl2">WAYLIVRA [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WaylivraMember" xlink:to="ions_WaylivraMember_lbl2" xlink:title="label: WaylivraMember to ions_WaylivraMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumPaymentReceivableUnderLicenseAgreement" xlink:label="MaximumPaymentReceivableUnderLicenseAgreement" xlink:title="MaximumPaymentReceivableUnderLicenseAgreement" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumPaymentReceivableUnderLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_MaximumPaymentReceivableUnderLicenseAgreement_lbl" xml:lang="en-US" id="ions_MaximumPaymentReceivableUnderLicenseAgreement_lbl">The maximum amount of payments expected to be received under the license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumPaymentReceivableUnderLicenseAgreement" xlink:to="ions_MaximumPaymentReceivableUnderLicenseAgreement_lbl" xlink:title="label: MaximumPaymentReceivableUnderLicenseAgreement to ions_MaximumPaymentReceivableUnderLicenseAgreement_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumPaymentReceivableUnderLicenseAgreement_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_MaximumPaymentReceivableUnderLicenseAgreement_lbl1" xml:lang="en-US" id="ions_MaximumPaymentReceivableUnderLicenseAgreement_lbl1">Maximum payment receivable under license agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumPaymentReceivableUnderLicenseAgreement" xlink:to="ions_MaximumPaymentReceivableUnderLicenseAgreement_lbl1" xlink:title="label: MaximumPaymentReceivableUnderLicenseAgreement to ions_MaximumPaymentReceivableUnderLicenseAgreement_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_MaximumPaymentReceivableUnderLicenseAgreement_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_MaximumPaymentReceivableUnderLicenseAgreement_lbl2" xml:lang="en-US" id="ions_MaximumPaymentReceivableUnderLicenseAgreement_lbl2">Maximum payment receivable under license agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumPaymentReceivableUnderLicenseAgreement" xlink:to="ions_MaximumPaymentReceivableUnderLicenseAgreement_lbl2" xlink:title="label: MaximumPaymentReceivableUnderLicenseAgreement to ions_MaximumPaymentReceivableUnderLicenseAgreement_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_TegsediMember" xlink:label="TegsediMember" xlink:title="TegsediMember" />
    <link:label xlink:type="resource" xlink:label="ions_TegsediMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_TegsediMember_lbl" xml:lang="en-US" id="ions_TegsediMember_lbl">TEGSEDI (inotersen) is a Generation 2+ antisense drug to treat people with hereditary TTR amyloidosis, or hATTR, a rare, progressive, fatal disease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TegsediMember" xlink:to="ions_TegsediMember_lbl" xlink:title="label: TegsediMember to ions_TegsediMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_TegsediMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_TegsediMember_lbl1" xml:lang="en-US" id="ions_TegsediMember_lbl1">TEGSEDI [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TegsediMember" xlink:to="ions_TegsediMember_lbl1" xlink:title="label: TegsediMember to ions_TegsediMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_TegsediMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_TegsediMember_lbl2" xml:lang="en-US" id="ions_TegsediMember_lbl2">TEGSEDI [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TegsediMember" xlink:to="ions_TegsediMember_lbl2" xlink:title="label: TegsediMember to ions_TegsediMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract" xlink:label="RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract" xlink:title="RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract" />
    <link:label xlink:type="resource" xlink:label="ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract_lbl" xml:lang="en-US" id="ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract_lbl">The number of performance obligations at the inception of a contract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract" xlink:to="ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract_lbl" xlink:title="label: RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract to ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract_lbl1" xml:lang="en-US" id="ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract_lbl1">Revenue from Contract with Customer, Number of performance obligations at inception of contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract" xlink:to="ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract_lbl1" xlink:title="label: RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract to ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract_lbl2" xml:lang="en-US" id="ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract_lbl2">Number of performance obligations at inception of contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract" xlink:to="ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract_lbl2" xlink:title="label: RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract to ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember_lbl" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember_lbl">Represents information pertaining to the collaborative arrangement entered into with Alnylam Pharmaceuticals, Inc. in March 2004 to develop and commercialize RNAi therapeutics.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember_lbl" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember_lbl1" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember_lbl1">Collaborative Arrangement and Licensing Agreement Entered Into in March 2004 with Alnylam Pharmaceuticals, Inc. [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember_lbl1" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember_lbl2" xml:lang="en-US" id="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember_lbl2">Alnylam [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember" xlink:to="ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember_lbl2" xlink:title="label: CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember to ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfNewTargetsAdvanced" xlink:label="NumberOfNewTargetsAdvanced" xlink:title="NumberOfNewTargetsAdvanced" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfNewTargetsAdvanced_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NumberOfNewTargetsAdvanced_lbl" xml:lang="en-US" id="ions_NumberOfNewTargetsAdvanced_lbl">The number of new targets advanced during the period under the collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfNewTargetsAdvanced" xlink:to="ions_NumberOfNewTargetsAdvanced_lbl" xlink:title="label: NumberOfNewTargetsAdvanced to ions_NumberOfNewTargetsAdvanced_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfNewTargetsAdvanced_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NumberOfNewTargetsAdvanced_lbl1" xml:lang="en-US" id="ions_NumberOfNewTargetsAdvanced_lbl1">Number of new targets advanced</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfNewTargetsAdvanced" xlink:to="ions_NumberOfNewTargetsAdvanced_lbl1" xlink:title="label: NumberOfNewTargetsAdvanced to ions_NumberOfNewTargetsAdvanced_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfNewTargetsAdvanced_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NumberOfNewTargetsAdvanced_lbl2" xml:lang="en-US" id="ions_NumberOfNewTargetsAdvanced_lbl2">Number of new targets advanced</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfNewTargetsAdvanced" xlink:to="ions_NumberOfNewTargetsAdvanced_lbl2" xlink:title="label: NumberOfNewTargetsAdvanced to ions_NumberOfNewTargetsAdvanced_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerTransactionPriceAdditions" xlink:label="RevenueFromContractWithCustomerTransactionPriceAdditions" xlink:title="RevenueFromContractWithCustomerTransactionPriceAdditions" />
    <link:label xlink:type="resource" xlink:label="ions_RevenueFromContractWithCustomerTransactionPriceAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_RevenueFromContractWithCustomerTransactionPriceAdditions_lbl" xml:lang="en-US" id="ions_RevenueFromContractWithCustomerTransactionPriceAdditions_lbl">The additional amount of consideration the Company earned under the collaboration agreement that is added to the transaction price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerTransactionPriceAdditions" xlink:to="ions_RevenueFromContractWithCustomerTransactionPriceAdditions_lbl" xlink:title="label: RevenueFromContractWithCustomerTransactionPriceAdditions to ions_RevenueFromContractWithCustomerTransactionPriceAdditions_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_RevenueFromContractWithCustomerTransactionPriceAdditions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_RevenueFromContractWithCustomerTransactionPriceAdditions_lbl1" xml:lang="en-US" id="ions_RevenueFromContractWithCustomerTransactionPriceAdditions_lbl1">Revenue from Contract with Customer, Transaction Price, Additions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerTransactionPriceAdditions" xlink:to="ions_RevenueFromContractWithCustomerTransactionPriceAdditions_lbl1" xlink:title="label: RevenueFromContractWithCustomerTransactionPriceAdditions to ions_RevenueFromContractWithCustomerTransactionPriceAdditions_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_RevenueFromContractWithCustomerTransactionPriceAdditions_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_RevenueFromContractWithCustomerTransactionPriceAdditions_lbl2" xml:lang="en-US" id="ions_RevenueFromContractWithCustomerTransactionPriceAdditions_lbl2">Milestone payments received and added to transaction price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerTransactionPriceAdditions" xlink:to="ions_RevenueFromContractWithCustomerTransactionPriceAdditions_lbl2" xlink:title="label: RevenueFromContractWithCustomerTransactionPriceAdditions to ions_RevenueFromContractWithCustomerTransactionPriceAdditions_lbl2" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfAgreementsWithCollaborationPartner" xlink:label="NumberOfAgreementsWithCollaborationPartner" xlink:title="NumberOfAgreementsWithCollaborationPartner" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfAgreementsWithCollaborationPartner_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="ions_NumberOfAgreementsWithCollaborationPartner_lbl" xml:lang="en-US" id="ions_NumberOfAgreementsWithCollaborationPartner_lbl">The number of agreements entered into with the collaboration partner.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfAgreementsWithCollaborationPartner" xlink:to="ions_NumberOfAgreementsWithCollaborationPartner_lbl" xlink:title="label: NumberOfAgreementsWithCollaborationPartner to ions_NumberOfAgreementsWithCollaborationPartner_lbl" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfAgreementsWithCollaborationPartner_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ions_NumberOfAgreementsWithCollaborationPartner_lbl1" xml:lang="en-US" id="ions_NumberOfAgreementsWithCollaborationPartner_lbl1">Number of agreements with collaboration partner</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfAgreementsWithCollaborationPartner" xlink:to="ions_NumberOfAgreementsWithCollaborationPartner_lbl1" xlink:title="label: NumberOfAgreementsWithCollaborationPartner to ions_NumberOfAgreementsWithCollaborationPartner_lbl1" />
    <link:label xlink:type="resource" xlink:label="ions_NumberOfAgreementsWithCollaborationPartner_lbl2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ions_NumberOfAgreementsWithCollaborationPartner_lbl2" xml:lang="en-US" id="ions_NumberOfAgreementsWithCollaborationPartner_lbl2">Number of agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfAgreementsWithCollaborationPartner" xlink:to="ions_NumberOfAgreementsWithCollaborationPartner_lbl2" xlink:title="label: NumberOfAgreementsWithCollaborationPartner to ions_NumberOfAgreementsWithCollaborationPartner_lbl2" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>ions-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by EDGARfilings PROfile 6.2.0.0 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#QuarterlyFinancialDataUnauditedDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/EmploymentBenefitsDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#EmploymentBenefitsDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreementsPfizerDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreementsNovartisDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreementsRocheDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreementsGskDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreementsBayerDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreementsBiogenDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxesGrossUnrecognizedTaxBenefitsDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxesTaxActDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxesTaxActDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxesTaxCreditCarryforwardsDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxesTaxCreditCarryforwardsDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxesIncomeTaxExpenseBenefitDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#StockholdersEquityStockbasedValuationInformationDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/StockholdersEquityStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#StockholdersEquityStockbasedCompensationExpenseDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#StockholdersEquityRestrictedStockUnitActivityDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#StockholdersEquityStockOptionActivityDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/StockholdersEquityStockPlansDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#StockholdersEquityStockPlansDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/StockholdersEquityShareRepurchaseProgramDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#StockholdersEquityShareRepurchaseProgramDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#StockholdersEquityPreferredAndCommonStockDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OperatingLeasesDetailsCalc01" xlink:type="simple" xlink:href="ions-20191231.xsd#OperatingLeasesDetailsCalc01" />
  <link:roleRef roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#LongtermObligationsAndCommitmentsOperatingLeasesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#LongtermObligationsAndCommitmentsMaturitySchedulesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#LongtermObligationsAndCommitmentsConvertibleNotesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsDetailsCalc2" xlink:type="simple" xlink:href="ions-20191231.xsd#LongtermObligationsAndCommitmentsDetailsCalc2" />
  <link:roleRef roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#LongtermObligationsAndCommitmentsLongtermObligationsDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetailsCalc2" xlink:type="simple" xlink:href="ions-20191231.xsd#InvestmentsSummaryOfInvestmentsDetailsCalc2" />
  <link:roleRef roleURI="http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#InvestmentsInvestmentsTemporarilyImpairedDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#InvestmentsSummaryOfInvestmentsDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesSegmentInformationDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesConvertibleDebtDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesConvertibleDebtDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesStockbasedCompensationExpenseDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLonglivedAssetsDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesLonglivedAssetsDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLeasesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesLeasesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndInvestmentsDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndInvestmentsDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesCostOfProductsSoldDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesCostOfProductsSoldDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesDeferredRevenueDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesDeferredRevenueDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesContractsReceivableDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesContractsReceivableDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails" />
  <link:roleRef roleURI="http://isispharm.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="ions-20191231.xsd#QuarterlyFinancialDataUnauditedTables" />
  <link:roleRef roleURI="http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskTables" xlink:type="simple" xlink:href="ions-20191231.xsd#SegmentInformationAndConcentrationOfBusinessRiskTables" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreementsTables" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxesTables" />
  <link:roleRef roleURI="http://isispharm.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="ions-20191231.xsd#StockholdersEquityTables" />
  <link:roleRef roleURI="http://isispharm.com/role/LongtermObligationsAndCommitmentsTables" xlink:type="simple" xlink:href="ions-20191231.xsd#LongtermObligationsAndCommitmentsTables" />
  <link:roleRef roleURI="http://isispharm.com/role/InvestmentsTables" xlink:type="simple" xlink:href="ions-20191231.xsd#InvestmentsTables" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://isispharm.com/role/QuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="ions-20191231.xsd#QuarterlyFinancialDataUnaudited" />
  <link:roleRef roleURI="http://isispharm.com/role/LegalProceedings" xlink:type="simple" xlink:href="ions-20191231.xsd#LegalProceedings" />
  <link:roleRef roleURI="http://isispharm.com/role/EmploymentBenefits" xlink:type="simple" xlink:href="ions-20191231.xsd#EmploymentBenefits" />
  <link:roleRef roleURI="http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRisk" xlink:type="simple" xlink:href="ions-20191231.xsd#SegmentInformationAndConcentrationOfBusinessRisk" />
  <link:roleRef roleURI="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreements" xlink:type="simple" xlink:href="ions-20191231.xsd#CollaborativeArrangementsAndLicensingAgreements" />
  <link:roleRef roleURI="http://isispharm.com/role/IncomeTaxes" xlink:type="simple" xlink:href="ions-20191231.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://isispharm.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ions-20191231.xsd#StockholdersEquity" />
  <link:roleRef roleURI="http://isispharm.com/role/LongtermObligationsAndCommitments" xlink:type="simple" xlink:href="ions-20191231.xsd#LongtermObligationsAndCommitments" />
  <link:roleRef roleURI="http://isispharm.com/role/Investments" xlink:type="simple" xlink:href="ions-20191231.xsd#Investments" />
  <link:roleRef roleURI="http://isispharm.com/role/OrganizationAndSignificantAccountingPolicies" xlink:type="simple" xlink:href="ions-20191231.xsd#OrganizationAndSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://isispharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" xlink:href="ions-20191231.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" />
  <link:roleRef roleURI="http://isispharm.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="ions-20191231.xsd#ConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" xlink:href="ions-20191231.xsd#ConsolidatedStatementsOfStockholdersEquityParenthetical" />
  <link:roleRef roleURI="http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" xlink:href="ions-20191231.xsd#ConsolidatedStatementsOfStockholdersEquity" />
  <link:roleRef roleURI="http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ions-20191231.xsd#ConsolidatedStatementsOfComprehensiveIncomeLoss" />
  <link:roleRef roleURI="http://isispharm.com/role/ConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="ions-20191231.xsd#ConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://isispharm.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ions-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://isispharm.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ions-20191231.xsd#ConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://isispharm.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="ions-20191231.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: CoverAbstract to CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityWellKnownSeasonedIssuer" xlink:title="presentation: CoverAbstract to EntityWellKnownSeasonedIssuer" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityVoluntaryFilers" xlink:title="presentation: CoverAbstract to EntityVoluntaryFilers" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: CoverAbstract to EntityCurrentReportingStatus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityInteractiveDataCurrent" xlink:title="presentation: CoverAbstract to EntityInteractiveDataCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityShellCompany" xlink:title="presentation: CoverAbstract to EntityShellCompany" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: CoverAbstract to EntityFilerCategory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntitySmallBusiness" xlink:title="presentation: CoverAbstract to EntitySmallBusiness" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityPublicFloat" xlink:title="presentation: CoverAbstract to EntityPublicFloat" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: CoverAbstract to EntityCommonStockSharesOutstanding" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="DocumentAnnualReport" xlink:title="DocumentAnnualReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentAnnualReport" xlink:title="presentation: CoverAbstract to DocumentAnnualReport" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentTransitionReport" xlink:title="presentation: CoverAbstract to DocumentTransitionReport" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentMember" xlink:label="ConvertibleSeniorNotes0125PercentMember" xlink:title="ConvertibleSeniorNotes0125PercentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes0125PercentMember" xlink:title="presentation: DebtInstrumentNameDomain to ConvertibleSeniorNotes0125PercentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes1PercentMember" xlink:label="ConvertibleSeniorNotes1PercentMember" xlink:title="ConvertibleSeniorNotes1PercentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes1PercentMember" xlink:title="presentation: DebtInstrumentNameDomain to ConvertibleSeniorNotes1PercentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: StatementTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:title="AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:title="presentation: AssetsCurrentAbstract to AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="ContractWithCustomerAssetNetCurrent" xlink:title="ContractWithCustomerAssetNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="ContractWithCustomerAssetNetCurrent" xlink:title="presentation: AssetsCurrentAbstract to ContractWithCustomerAssetNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="InventoryNet" xlink:title="presentation: AssetsCurrentAbstract to InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="OtherAssetsCurrent" xlink:title="OtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="OtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to OtherAssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsAbstract to PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="FiniteLivedIntangibleAssetsNet" xlink:title="presentation: AssetsAbstract to FiniteLivedIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="DeferredIncomeTaxAssetsNet" xlink:title="DeferredIncomeTaxAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="DeferredIncomeTaxAssetsNet" xlink:title="presentation: AssetsAbstract to DeferredIncomeTaxAssetsNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="OtherAssetsNoncurrent" xlink:title="presentation: AssetsAbstract to OtherAssetsNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="AssetsAbstract" xlink:title="presentation: StatementLineItems to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="EmployeeRelatedLiabilitiesCurrent" xlink:title="EmployeeRelatedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="EmployeeRelatedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to EmployeeRelatedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="AccruedIncomeTaxesCurrent" xlink:title="AccruedIncomeTaxesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedIncomeTaxesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedIncomeTaxesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="LongTermDebtAndCapitalLeaseObligationsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LongTermDebtAndCapitalLeaseObligationsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="ContractWithCustomerLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to ContractWithCustomerLiabilityCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="ContractWithCustomerLiabilityNoncurrent" xlink:title="ContractWithCustomerLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="ContractWithCustomerLiabilityNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to ContractWithCustomerLiabilityNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="ConvertibleDebtNoncurrent" xlink:title="ConvertibleDebtNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="ConvertibleDebtNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to ConvertibleDebtNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermObligationsNoncurrent" xlink:label="LongTermObligationsNoncurrent" xlink:title="LongTermObligationsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LongTermObligationsNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LongTermObligationsNoncurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermLoansFromBank" xlink:label="LongTermLoansFromBank" xlink:title="LongTermLoansFromBank" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LongTermLoansFromBank" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LongTermLoansFromBank" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to Liabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="AdditionalPaidInCapitalCommonStock" xlink:title="AdditionalPaidInCapitalCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapitalCommonStock" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapitalCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="presentation: StockholdersEquityAbstract to AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="MinorityInterest" xlink:title="MinorityInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="MinorityInterest" xlink:title="presentation: StockholdersEquityAbstract to MinorityInterest" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementLineItems to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfFinancialPositionAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/ConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentMember" xlink:label="ConvertibleSeniorNotes0125PercentMember" xlink:title="ConvertibleSeniorNotes0125PercentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes0125PercentMember" xlink:title="presentation: DebtInstrumentNameDomain to ConvertibleSeniorNotes0125PercentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes1PercentMember" xlink:label="ConvertibleSeniorNotes1PercentMember" xlink:title="ConvertibleSeniorNotes1PercentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes1PercentMember" xlink:title="presentation: DebtInstrumentNameDomain to ConvertibleSeniorNotes1PercentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: StatementTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to DebtInstrumentInterestRateStatedPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementLineItems to LiabilitiesAndStockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfFinancialPositionAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/ConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CommercialMember" xlink:label="CommercialMember" xlink:title="CommercialMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SPINRAZARoyaltiesMember" xlink:label="SPINRAZARoyaltiesMember" xlink:title="SPINRAZARoyaltiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommercialMember" xlink:to="SPINRAZARoyaltiesMember" xlink:title="presentation: CommercialMember to SPINRAZARoyaltiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="ProductMember" xlink:title="ProductMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommercialMember" xlink:to="ProductMember" xlink:title="presentation: CommercialMember to ProductMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LicensingAndOtherRoyaltiesMember" xlink:label="LicensingAndOtherRoyaltiesMember" xlink:title="LicensingAndOtherRoyaltiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommercialMember" xlink:to="LicensingAndOtherRoyaltiesMember" xlink:title="presentation: CommercialMember to LicensingAndOtherRoyaltiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="CommercialMember" xlink:title="presentation: ProductsAndServicesDomain to CommercialMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:label="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="presentation: ProductsAndServicesDomain to ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="presentation: ProductOrServiceAxis to ProductsAndServicesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="ProductOrServiceAxis" xlink:title="presentation: StatementTable to ProductOrServiceAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="RevenuesAbstract" xlink:title="RevenuesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: RevenuesAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="RevenuesAbstract" xlink:title="presentation: StatementLineItems to RevenuesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="CostOfGoodsAndServicesSold" xlink:title="CostOfGoodsAndServicesSold" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="CostOfGoodsAndServicesSold" xlink:title="presentation: CostsAndExpensesAbstract to CostOfGoodsAndServicesSold" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchDevelopmentAndPatentExpense" xlink:label="ResearchDevelopmentAndPatentExpense" xlink:title="ResearchDevelopmentAndPatentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="ResearchDevelopmentAndPatentExpense" xlink:title="presentation: CostsAndExpensesAbstract to ResearchDevelopmentAndPatentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="presentation: CostsAndExpensesAbstract to SellingGeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="CostsAndExpenses" xlink:title="presentation: CostsAndExpensesAbstract to CostsAndExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CostsAndExpensesAbstract" xlink:title="presentation: StatementLineItems to CostsAndExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="OperatingIncomeLoss" xlink:title="presentation: StatementLineItems to OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="InvestmentIncomeNet" xlink:title="InvestmentIncomeNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InvestmentIncomeNet" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InvestmentIncomeNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="InterestExpense" xlink:title="InterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_GainLossOnExtinguishmentOfFinancingLiability" xlink:label="GainLossOnExtinguishmentOfFinancingLiability" xlink:title="GainLossOnExtinguishmentOfFinancingLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="GainLossOnExtinguishmentOfFinancingLiability" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to GainLossOnExtinguishmentOfFinancingLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to GainsLossesOnExtinguishmentOfDebt" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to OtherNonoperatingIncomeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="presentation: StatementLineItems to NonoperatingIncomeExpenseAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="presentation: StatementLineItems to IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: StatementLineItems to IncomeTaxExpenseBenefit" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="ProfitLoss" xlink:title="presentation: StatementLineItems to ProfitLoss" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="presentation: StatementLineItems to NetIncomeLossAttributableToNoncontrollingInterest" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="presentation: StatementLineItems to NetIncomeLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EarningsPerShareBasic" xlink:title="presentation: StatementLineItems to EarningsPerShareBasic" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: StatementLineItems to WeightedAverageNumberOfSharesOutstandingBasic" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: StatementLineItems to EarningsPerShareDiluted" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: StatementLineItems to WeightedAverageNumberOfDilutedSharesOutstanding" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="StatementTable" xlink:title="presentation: IncomeStatementAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:title="StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="ProfitLoss" xlink:title="presentation: StatementOfIncomeAndComprehensiveIncomeAbstract to ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:title="presentation: StatementOfIncomeAndComprehensiveIncomeAbstract to OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:title="OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:title="presentation: StatementOfIncomeAndComprehensiveIncomeAbstract to OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="presentation: StatementOfIncomeAndComprehensiveIncomeAbstract to OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:title="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:title="presentation: StatementOfIncomeAndComprehensiveIncomeAbstract to ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:title="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:title="presentation: StatementOfIncomeAndComprehensiveIncomeAbstract to ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="ComprehensiveIncomeNetOfTax" xlink:title="presentation: StatementOfIncomeAndComprehensiveIncomeAbstract to ComprehensiveIncomeNetOfTax" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="CommonStockMember" xlink:title="presentation: StatementEquityComponentsAxis to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AdditionalPaidInCapitalMember" xlink:title="presentation: StatementEquityComponentsAxis to AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AccumulatedOtherComprehensiveIncomeMember" xlink:title="presentation: StatementEquityComponentsAxis to AccumulatedOtherComprehensiveIncomeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="RetainedEarningsMember" xlink:title="presentation: StatementEquityComponentsAxis to RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="ParentMember" xlink:title="ParentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="ParentMember" xlink:title="presentation: StatementEquityComponentsAxis to ParentMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="NoncontrollingInterestMember" xlink:title="NoncontrollingInterestMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="NoncontrollingInterestMember" xlink:title="presentation: StatementEquityComponentsAxis to NoncontrollingInterestMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NovartisInternationalAGMember" xlink:label="NovartisInternationalAGMember" xlink:title="NovartisInternationalAGMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="NovartisInternationalAGMember" xlink:title="presentation: RepurchaseAgreementCounterpartyNameDomain to NovartisInternationalAGMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_BiogenIncMember" xlink:label="BiogenIncMember" xlink:title="BiogenIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="BiogenIncMember" xlink:title="presentation: RepurchaseAgreementCounterpartyNameDomain to BiogenIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="presentation: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="CounterpartyNameAxis" xlink:title="presentation: StatementTable to CounterpartyNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="SharesIssued" xlink:title="SharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesIssued" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NetIncomeLoss" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:label="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesNewIssues" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:label="StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:title="StockIssuedDuringPeriodValueShareBasedCompensationGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueShareBasedCompensationGross" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesShareBasedCompensation" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" xlink:label="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" xlink:title="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:title="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="AdjustmentsToAdditionalPaidInCapitalOther" xlink:title="AdjustmentsToAdditionalPaidInCapitalOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalOther" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalOther" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="StockRepurchasedAndRetiredDuringPeriodValue" xlink:title="StockRepurchasedAndRetiredDuringPeriodValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockRepurchasedAndRetiredDuringPeriodValue" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockRepurchasedAndRetiredDuringPeriodValue" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="StockRepurchasedAndRetiredDuringPeriodShares" xlink:title="StockRepurchasedAndRetiredDuringPeriodShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockRepurchasedAndRetiredDuringPeriodShares" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockRepurchasedAndRetiredDuringPeriodShares" order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary" xlink:label="StockIssuedDuringPeriodValueNewIssuesBySubsidiary" xlink:title="StockIssuedDuringPeriodValueNewIssuesBySubsidiary" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueNewIssuesBySubsidiary" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueNewIssuesBySubsidiary" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary" xlink:label="StockIssuedDuringPeriodSharesNewIssuesBySubsidiary" xlink:title="StockIssuedDuringPeriodSharesNewIssuesBySubsidiary" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesNewIssuesBySubsidiary" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesNewIssuesBySubsidiary" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" xlink:label="NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" xlink:title="NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:title="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesPaidForTaxWithholdingForShareBasedCompensation" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestPeriodIncreaseDecrease" xlink:label="MinorityInterestPeriodIncreaseDecrease" xlink:title="MinorityInterestPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="MinorityInterestPeriodIncreaseDecrease" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to MinorityInterestPeriodIncreaseDecrease" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="SharesIssued_2" xlink:title="SharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesIssued_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesIssued" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes1PercentMember" xlink:label="ConvertibleSeniorNotes1PercentMember" xlink:title="ConvertibleSeniorNotes1PercentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes1PercentMember" xlink:title="presentation: DebtInstrumentNameDomain to ConvertibleSeniorNotes1PercentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentMember" xlink:label="ConvertibleSeniorNotes0125PercentMember" xlink:title="ConvertibleSeniorNotes0125PercentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes0125PercentMember" xlink:title="presentation: DebtInstrumentNameDomain to ConvertibleSeniorNotes0125PercentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: StatementTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to DebtInstrumentInterestRateStatedPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/ConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_BiogenIncMember" xlink:label="BiogenIncMember" xlink:title="BiogenIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfMajorCustomerDomain" xlink:to="BiogenIncMember" xlink:title="presentation: NameOfMajorCustomerDomain to BiogenIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NovartisInternationalAGMember" xlink:label="NovartisInternationalAGMember" xlink:title="NovartisInternationalAGMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfMajorCustomerDomain" xlink:to="NovartisInternationalAGMember" xlink:title="presentation: NameOfMajorCustomerDomain to NovartisInternationalAGMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="presentation: MajorCustomersAxis to NameOfMajorCustomerDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="MajorCustomersAxis" xlink:title="presentation: StatementTable to MajorCustomersAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ProfitLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="Depreciation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_OperatingLeaseRightOfUseAssetAmortization" xlink:label="OperatingLeaseRightOfUseAssetAmortization" xlink:title="OperatingLeaseRightOfUseAssetAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="OperatingLeaseRightOfUseAssetAmortization" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to OperatingLeaseRightOfUseAssetAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfIntangibleAssets" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfIntangibleAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:title="AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="AmortizationOfFinancingCosts" xlink:title="AmortizationOfFinancingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfFinancingCosts" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfFinancingCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfDebtDiscountPremium" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfLeasedAsset" xlink:label="AmortizationOfLeasedAsset" xlink:title="AmortizationOfLeasedAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfLeasedAsset" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfLeasedAsset" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainOnSaleOfInvestments" xlink:label="GainOnSaleOfInvestments" xlink:title="GainOnSaleOfInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainOnSaleOfInvestments" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainOnSaleOfInvestments" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_GainLossOnExtinguishmentOfFinancingLiability" xlink:label="GainLossOnExtinguishmentOfFinancingLiability" xlink:title="GainLossOnExtinguishmentOfFinancingLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnExtinguishmentOfFinancingLiability" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnExtinguishmentOfFinancingLiability" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainsLossesOnExtinguishmentOfDebt" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="DeferredIncomeTaxesAndTaxCredits" xlink:title="DeferredIncomeTaxesAndTaxCredits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DeferredIncomeTaxesAndTaxCredits" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DeferredIncomeTaxesAndTaxCredits" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" xlink:label="AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" xlink:title="AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="IncreaseDecreaseInContractWithCustomerAsset" xlink:title="IncreaseDecreaseInContractWithCustomerAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInContractWithCustomerAsset" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInContractWithCustomerAsset" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInInventories" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="IncreaseDecreaseInOtherOperatingAssets" xlink:title="IncreaseDecreaseInOtherOperatingAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherOperatingAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherOperatingAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="IncreaseDecreaseInIncomeTaxesReceivable" xlink:title="IncreaseDecreaseInIncomeTaxesReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInIncomeTaxesReceivable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInIncomeTaxesReceivable" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:label="IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:title="IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities" xlink:label="IncreaseDecreaseInOtherEmployeeRelatedLiabilities" xlink:title="IncreaseDecreaseInOtherEmployeeRelatedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherEmployeeRelatedLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherEmployeeRelatedLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="IncreaseDecreaseInContractWithCustomerLiability" xlink:title="IncreaseDecreaseInContractWithCustomerLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInContractWithCustomerLiability" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInContractWithCustomerLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementLineItems to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:title="PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:title="ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquirePropertyPlantAndEquipment" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PaymentsToAcquireLicensesAndOtherAssets" xlink:label="PaymentsToAcquireLicensesAndOtherAssets" xlink:title="PaymentsToAcquireLicensesAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquireLicensesAndOtherAssets" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquireLicensesAndOtherAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PaymentsToAcquireCostMethodInvestments" xlink:label="PaymentsToAcquireCostMethodInvestments" xlink:title="PaymentsToAcquireCostMethodInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquireCostMethodInvestments" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquireCostMethodInvestments" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="ProceedsFromSaleOfEquityMethodInvestments" xlink:title="ProceedsFromSaleOfEquityMethodInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ProceedsFromSaleOfEquityMethodInvestments" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to ProceedsFromSaleOfEquityMethodInvestments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to NetCashProvidedByUsedInInvestingActivities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="presentation: StatementLineItems to NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:title="ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="ProceedsFromConvertibleDebt" xlink:title="ProceedsFromConvertibleDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromConvertibleDebt" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromConvertibleDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentsOfDebtIssuanceCosts" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentsOfDebtIssuanceCosts" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="ProceedsFromIssuanceOfWarrants" xlink:title="ProceedsFromIssuanceOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfWarrants" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities" xlink:label="PaymentsForHedgeFinancingActivities" xlink:title="PaymentsForHedgeFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentsForHedgeFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentsForHedgeFinancingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="PaymentsForRepurchaseOfCommonStock" xlink:title="PaymentsForRepurchaseOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentsForRepurchaseOfCommonStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentsForRepurchaseOfCommonStock" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:title="RepaymentsOfLongTermDebtAndCapitalSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to RepaymentsOfLongTermDebtAndCapitalSecurities" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="ProceedsFromIssuanceInitialPublicOffering" xlink:title="ProceedsFromIssuanceInitialPublicOffering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceInitialPublicOffering" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceInitialPublicOffering" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="ProceedsFromDebtNetOfIssuanceCosts" xlink:title="ProceedsFromDebtNetOfIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromDebtNetOfIssuanceCosts" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromDebtNetOfIssuanceCosts" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfCommonStock" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="ProceedsFromIssuanceOfPrivatePlacement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfPrivatePlacement" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="PaymentsOfStockIssuanceCosts" xlink:title="PaymentsOfStockIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentsOfStockIssuanceCosts" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentsOfStockIssuanceCosts" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PaymentToSettleFinancingLiabilityForLeasedFacility" xlink:label="PaymentToSettleFinancingLiabilityForLeasedFacility" xlink:title="PaymentToSettleFinancingLiabilityForLeasedFacility" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentToSettleFinancingLiabilityForLeasedFacility" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentToSettleFinancingLiabilityForLeasedFacility" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to NetCashProvidedByUsedInFinancingActivities" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="presentation: StatementLineItems to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:title="presentation: StatementLineItems to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="presentation: StatementLineItems to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="presentation: StatementLineItems to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="InterestPaidNet" xlink:title="presentation: SupplementalCashFlowInformationAbstract to InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="IncomeTaxesPaidNet" xlink:title="IncomeTaxesPaidNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="IncomeTaxesPaidNet" xlink:title="presentation: SupplementalCashFlowInformationAbstract to IncomeTaxesPaidNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="presentation: StatementLineItems to SupplementalCashFlowInformationAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NonCashCapitalAndPatentExpenditures" xlink:label="NonCashCapitalAndPatentExpenditures" xlink:title="NonCashCapitalAndPatentExpenditures" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="NonCashCapitalAndPatentExpenditures" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to NonCashCapitalAndPatentExpenditures" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="CapitalExpendituresIncurredButNotYetPaid" xlink:title="CapitalExpendituresIncurredButNotYetPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="CapitalExpendituresIncurredButNotYetPaid" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to CapitalExpendituresIncurredButNotYetPaid" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesIssued1" xlink:label="NotesIssued1" xlink:title="NotesIssued1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="NotesIssued1" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to NotesIssued1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesReduction" xlink:label="NotesReduction" xlink:title="NotesReduction" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="NotesReduction" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to NotesReduction" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="presentation: StatementLineItems to CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfCashFlowsAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentMember" xlink:label="ConvertibleSeniorNotes0125PercentMember" xlink:title="ConvertibleSeniorNotes0125PercentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes0125PercentMember" xlink:title="presentation: DebtInstrumentNameDomain to ConvertibleSeniorNotes0125PercentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes1PercentMember" xlink:label="ConvertibleSeniorNotes1PercentMember" xlink:title="ConvertibleSeniorNotes1PercentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes1PercentMember" xlink:title="presentation: DebtInstrumentNameDomain to ConvertibleSeniorNotes1PercentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: StatementTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to DebtInstrumentInterestRateStatedPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="presentation: StatementLineItems to CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfCashFlowsAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:title="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/Investments">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAbstract" xlink:label="InvestmentsAbstract" xlink:title="InvestmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTextBlock" xlink:label="InvestmentTextBlock" xlink:title="InvestmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsAbstract" xlink:to="InvestmentTextBlock" xlink:title="presentation: InvestmentsAbstract to InvestmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/LongtermObligationsAndCommitments">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock" xlink:label="DebtAndCapitalLeasesDisclosuresTextBlock" xlink:title="DebtAndCapitalLeasesDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtAndCapitalLeasesDisclosuresTextBlock" xlink:title="presentation: DebtDisclosureAbstract to DebtAndCapitalLeasesDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/StockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityNoteDisclosureTextBlock" xlink:title="presentation: StockholdersEquityNoteAbstract to StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxes">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxDisclosureTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreements">
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:title="CollaborativeArrangementsAndLicensingAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="CollaborativeArrangementDisclosureTextBlock" xlink:title="CollaborativeArrangementDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:to="CollaborativeArrangementDisclosureTextBlock" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsAbstract to CollaborativeArrangementDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRisk">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="SegmentReportingDisclosureTextBlock" xlink:title="SegmentReportingDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="SegmentReportingDisclosureTextBlock" xlink:title="presentation: SegmentReportingAbstract to SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/EmploymentBenefits">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="presentation: CompensationAndRetirementDisclosureAbstract to PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/LegalProceedings">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock" xlink:label="LegalMattersAndContingenciesTextBlock" xlink:title="LegalMattersAndContingenciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="LegalMattersAndContingenciesTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to LegalMattersAndContingenciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/QuarterlyFinancialDataUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="QuarterlyFinancialInformationDisclosureAbstract" xlink:title="QuarterlyFinancialInformationDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="QuarterlyFinancialInformationTextBlock" xlink:title="QuarterlyFinancialInformationTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="QuarterlyFinancialInformationDisclosureAbstract" xlink:to="QuarterlyFinancialInformationTextBlock" xlink:title="presentation: QuarterlyFinancialInformationDisclosureAbstract to QuarterlyFinancialInformationTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="ConsolidationPolicyTextBlock" xlink:title="ConsolidationPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ConsolidationPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ConsolidationPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="EarningsPerSharePolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to EarningsPerSharePolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="RevenueFromContractWithCustomerPolicyTextBlock" xlink:title="RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="RevenueFromContractWithCustomerPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to RevenueFromContractWithCustomerPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="ReceivablesPolicyTextBlock" xlink:title="ReceivablesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ReceivablesPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ReceivablesPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:label="TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:title="TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="RevenueRecognitionPolicyTextBlock" xlink:title="RevenueRecognitionPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="RevenueRecognitionPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to RevenueRecognitionPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="CostOfSalesPolicyTextBlock" xlink:title="CostOfSalesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="CostOfSalesPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to CostOfSalesPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ResearchAndDevelopmentExpensePolicy" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ResearchAndDevelopmentExpensePolicy" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="IntangibleAssetsFiniteLivedPolicy" xlink:title="IntangibleAssetsFiniteLivedPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="IntangibleAssetsFiniteLivedPolicy" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to IntangibleAssetsFiniteLivedPolicy" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:label="ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:title="ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ConcentrationRiskCreditRisk" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ConcentrationRiskCreditRisk" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock" xlink:label="CashCashEquivalentsAndInvestmentsPolicyTextBlock" xlink:title="CashCashEquivalentsAndInvestmentsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="CashCashEquivalentsAndInvestmentsPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to CashCashEquivalentsAndInvestmentsPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="InventoryPolicyTextBlock" xlink:title="InventoryPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="InventoryPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to InventoryPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to PropertyPlantAndEquipmentPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="FairValueOfFinancialInstrumentsPolicy" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to FairValueOfFinancialInstrumentsPolicy" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="LesseeLeasesPolicyTextBlock" xlink:title="LesseeLeasesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="LesseeLeasesPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to LesseeLeasesPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="UseOfEstimates" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to UseOfEstimates" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ShareBasedCompensationOptionAndIncentivePlansPolicy" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="StockholdersEquityPolicyTextBlock" xlink:title="StockholdersEquityPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="StockholdersEquityPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to StockholdersEquityPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="DebtPolicyTextBlock" xlink:title="DebtPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="DebtPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to DebtPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="SegmentReportingPolicyPolicyTextBlock" xlink:title="SegmentReportingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="SegmentReportingPolicyPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to SegmentReportingPolicyPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="FairValueMeasurementPolicyPolicyTextBlock" xlink:title="FairValueMeasurementPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="FairValueMeasurementPolicyPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to FairValueMeasurementPolicyPolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="IncomeTaxPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to IncomeTaxPolicyTextBlock" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to NewAccountingPronouncementsPolicyPolicyTextBlock" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:label="ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:title="ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:title="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleOfAccruedLiabilitiesTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="ScheduleOfInventoryCurrentTableTextBlock" xlink:title="ScheduleOfInventoryCurrentTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleOfInventoryCurrentTableTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleOfInventoryCurrentTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="PropertyPlantAndEquipmentTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to PropertyPlantAndEquipmentTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:title="ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:title="FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/InvestmentsTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAbstract" xlink:label="InvestmentsAbstract" xlink:title="InvestmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:title="InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsAbstract" xlink:to="InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:title="presentation: InvestmentsAbstract to InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:title="UnrealizedGainLossOnInvestmentsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsAbstract" xlink:to="UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:title="presentation: InvestmentsAbstract to UnrealizedGainLossOnInvestmentsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock" xlink:label="ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock" xlink:title="ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsAbstract" xlink:to="ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock" xlink:title="presentation: InvestmentsAbstract to ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/LongtermObligationsAndCommitmentsTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="ScheduleOfDebtInstrumentsTextBlock" xlink:title="ScheduleOfDebtInstrumentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="ScheduleOfDebtInstrumentsTextBlock" xlink:title="presentation: DebtDisclosureAbstract to ScheduleOfDebtInstrumentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="ConvertibleDebtTableTextBlock" xlink:title="ConvertibleDebtTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="ConvertibleDebtTableTextBlock" xlink:title="presentation: DebtDisclosureAbstract to ConvertibleDebtTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:title="ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:title="presentation: DebtDisclosureAbstract to ContractualObligationFiscalYearMaturityScheduleTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LesseeOperatingLeaseInformationTableTextBlock" xlink:label="LesseeOperatingLeaseInformationTableTextBlock" xlink:title="LesseeOperatingLeaseInformationTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="LesseeOperatingLeaseInformationTableTextBlock" xlink:title="presentation: DebtDisclosureAbstract to LesseeOperatingLeaseInformationTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="presentation: DebtDisclosureAbstract to LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/StockholdersEquityTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="presentation: StockholdersEquityNoteAbstract to ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:title="ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:title="presentation: StockholdersEquityNoteAbstract to ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="presentation: StockholdersEquityNoteAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ShareBasedCompensationTable" xlink:label="ShareBasedCompensationTable" xlink:title="ShareBasedCompensationTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="presentation: ConsolidatedEntitiesDomain to AkceaTherapeuticsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="presentation: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="presentation: ShareBasedCompensationTable to ConsolidatedEntitiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ShareBasedCompensationLineItems" xlink:label="ShareBasedCompensationLineItems" xlink:title="ShareBasedCompensationLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationLineItems" xlink:to="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="presentation: ShareBasedCompensationLineItems to ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationLineItems" xlink:to="ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:title="presentation: ShareBasedCompensationLineItems to ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationTable" xlink:to="ShareBasedCompensationLineItems" xlink:title="presentation: ShareBasedCompensationTable to ShareBasedCompensationLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ShareBasedCompensationTable" xlink:title="presentation: StockholdersEquityNoteAbstract to ShareBasedCompensationTable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:title="ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:title="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:title="ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables">
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:title="CollaborativeArrangementsAndLicensingAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable" xlink:label="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable" xlink:title="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementsAndLicensingAgreementsBiogenMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsBayerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementsAndLicensingAgreementsBayerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsRocheMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsRocheMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementsAndLicensingAgreementsRocheMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementsAndLicensingAgreementsRocheMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems" xlink:label="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems" xlink:title="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:title="SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems" xlink:to="SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:title="presentation: CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems to SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable" xlink:to="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems" xlink:title="presentation: CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable to CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:to="CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsAbstract to CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="presentation: SegmentReportingAbstract to ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/QuarterlyFinancialDataUnauditedTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="QuarterlyFinancialInformationDisclosureAbstract" xlink:title="QuarterlyFinancialInformationDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:title="ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="QuarterlyFinancialInformationDisclosureAbstract" xlink:to="ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:title="presentation: QuarterlyFinancialInformationDisclosureAbstract to ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="MinorityInterestTable" xlink:title="MinorityInterestTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="presentation: OwnershipDomain to AkceaTherapeuticsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="presentation: OwnershipAxis to OwnershipDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestTable" xlink:to="OwnershipAxis" xlink:title="presentation: MinorityInterestTable to OwnershipAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestTable" xlink:to="RangeAxis" xlink:title="presentation: MinorityInterestTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="MinorityInterestLineItems" xlink:title="MinorityInterestLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:label="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="ProceedsFromIssuanceOrSaleOfEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="MinorityInterestOwnershipPercentageByParent" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to MinorityInterestOwnershipPercentageByParent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SharesReceivedFromSubsidiaryForLicenseOfDrug" xlink:label="SharesReceivedFromSubsidiaryForLicenseOfDrug" xlink:title="SharesReceivedFromSubsidiaryForLicenseOfDrug" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="SharesReceivedFromSubsidiaryForLicenseOfDrug" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to SharesReceivedFromSubsidiaryForLicenseOfDrug" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestLineItems" xlink:to="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="presentation: MinorityInterestLineItems to ProceedsFromIssuanceOrSaleOfEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestTable" xlink:to="MinorityInterestLineItems" xlink:title="presentation: MinorityInterestTable to MinorityInterestLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="MinorityInterestTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to MinorityInterestTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:title="ScheduleOfEarningsPerShareBasicByCommonClassTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="presentation: ConsolidatedEntitiesDomain to AkceaTherapeuticsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="presentation: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="presentation: ScheduleOfEarningsPerShareBasicByCommonClassTable to ConsolidatedEntitiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="presentation: ClassOfStockDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="ConvertiblePreferredStockMember" xlink:title="ConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="ConvertiblePreferredStockMember" xlink:title="presentation: ClassOfStockDomain to ConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: ScheduleOfEarningsPerShareBasicByCommonClassTable to StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IonisCoreMember" xlink:label="IonisCoreMember" xlink:title="IonisCoreMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="IonisCoreMember" xlink:title="presentation: SegmentDomain to IonisCoreMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="presentation: StatementBusinessSegmentsAxis to SegmentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="presentation: ScheduleOfEarningsPerShareBasicByCommonClassTable to StatementBusinessSegmentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfEarningsPerShareBasicByCommonClassTable to AwardTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="EarningsPerShareBasicLineItems" xlink:title="EarningsPerShareBasicLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="EarningsPerShareBasicAbstract" xlink:title="EarningsPerShareBasicAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="PreferredStockDividendRatePercentage" xlink:title="PreferredStockDividendRatePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAbstract" xlink:to="PreferredStockDividendRatePercentage" xlink:title="presentation: EarningsPerShareBasicAbstract to PreferredStockDividendRatePercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="ConvertiblePreferredStockTermsOfConversion" xlink:title="ConvertiblePreferredStockTermsOfConversion" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAbstract" xlink:to="ConvertiblePreferredStockTermsOfConversion" xlink:title="presentation: EarningsPerShareBasicAbstract to ConvertiblePreferredStockTermsOfConversion" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_WeightedAverageNumberOfSharesOwnedInSubsidiary" xlink:label="WeightedAverageNumberOfSharesOwnedInSubsidiary" xlink:title="WeightedAverageNumberOfSharesOwnedInSubsidiary" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAbstract" xlink:to="WeightedAverageNumberOfSharesOwnedInSubsidiary" xlink:title="presentation: EarningsPerShareBasicAbstract to WeightedAverageNumberOfSharesOwnedInSubsidiary" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: EarningsPerShareBasicAbstract to EarningsPerShareBasic" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: EarningsPerShareBasicAbstract to NetIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAbstract" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="presentation: EarningsPerShareBasicAbstract to NetIncomeLossAvailableToCommonStockholdersBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: EarningsPerShareBasicAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:title="NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAbstract" xlink:to="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:title="presentation: EarningsPerShareBasicAbstract to NetIncomeLossAvailableToCommonStockholdersDiluted" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAbstract" xlink:to="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="presentation: EarningsPerShareBasicAbstract to IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" xlink:label="IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" xlink:title="IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAbstract" xlink:to="IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" xlink:title="presentation: EarningsPerShareBasicAbstract to IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: EarningsPerShareBasicAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: EarningsPerShareBasicAbstract to EarningsPerShareDiluted" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicLineItems" xlink:to="EarningsPerShareBasicAbstract" xlink:title="presentation: EarningsPerShareBasicLineItems to EarningsPerShareBasicAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="EarningsPerShareBasicLineItems" xlink:title="presentation: ScheduleOfEarningsPerShareBasicByCommonClassTable to EarningsPerShareBasicLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleOfEarningsPerShareBasicByCommonClassTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="DisaggregationOfRevenueTable" xlink:title="DisaggregationOfRevenueTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsBayerMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsBayerMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" xlink:label="CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" xlink:title="CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:to="CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsBayerMember to CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementsAndLicensingAgreementsBayerMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisaggregationOfRevenueTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: DisaggregationOfRevenueTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LicensingAndOtherRoyaltiesMember" xlink:label="LicensingAndOtherRoyaltiesMember" xlink:title="LicensingAndOtherRoyaltiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="LicensingAndOtherRoyaltiesMember" xlink:title="presentation: ProductsAndServicesDomain to LicensingAndOtherRoyaltiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="presentation: ProductOrServiceAxis to ProductsAndServicesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisaggregationOfRevenueTable" xlink:to="ProductOrServiceAxis" xlink:title="presentation: DisaggregationOfRevenueTable to ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_BiogenIncMember" xlink:label="BiogenIncMember" xlink:title="BiogenIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfMajorCustomerDomain" xlink:to="BiogenIncMember" xlink:title="presentation: NameOfMajorCustomerDomain to BiogenIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="presentation: MajorCustomersAxis to NameOfMajorCustomerDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisaggregationOfRevenueTable" xlink:to="MajorCustomersAxis" xlink:title="presentation: DisaggregationOfRevenueTable to MajorCustomersAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="DisaggregationOfRevenueLineItems" xlink:title="DisaggregationOfRevenueLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" xlink:title="RevenueFromContractWithCustomerAbstract" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract" xlink:label="RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract" xlink:title="RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceived" xlink:label="UpfrontPaymentReceived" xlink:title="UpfrontPaymentReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="UpfrontPaymentReceived" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to UpfrontPaymentReceived" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfMilestonePaymentsAchieved" xlink:label="NumberOfMilestonePaymentsAchieved" xlink:title="NumberOfMilestonePaymentsAchieved" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="NumberOfMilestonePaymentsAchieved" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to NumberOfMilestonePaymentsAchieved" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerTransactionPriceAdditions" xlink:label="RevenueFromContractWithCustomerTransactionPriceAdditions" xlink:title="RevenueFromContractWithCustomerTransactionPriceAdditions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="RevenueFromContractWithCustomerTransactionPriceAdditions" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to RevenueFromContractWithCustomerTransactionPriceAdditions" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfNewTargetsAdvanced" xlink:label="NumberOfNewTargetsAdvanced" xlink:title="NumberOfNewTargetsAdvanced" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="NumberOfNewTargetsAdvanced" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to NumberOfNewTargetsAdvanced" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerTransactionPrice" xlink:label="RevenueFromContractWithCustomerTransactionPrice" xlink:title="RevenueFromContractWithCustomerTransactionPrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="RevenueFromContractWithCustomerTransactionPrice" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to RevenueFromContractWithCustomerTransactionPrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfAgreementsWithCollaborationPartner" xlink:label="NumberOfAgreementsWithCollaborationPartner" xlink:title="NumberOfAgreementsWithCollaborationPartner" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="NumberOfAgreementsWithCollaborationPartner" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to NumberOfAgreementsWithCollaborationPartner" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisaggregationOfRevenueLineItems" xlink:to="RevenueFromContractWithCustomerAbstract" xlink:title="presentation: DisaggregationOfRevenueLineItems to RevenueFromContractWithCustomerAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisaggregationOfRevenueTable" xlink:to="DisaggregationOfRevenueLineItems" xlink:title="presentation: DisaggregationOfRevenueTable to DisaggregationOfRevenueLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="DisaggregationOfRevenueTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to DisaggregationOfRevenueTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesContractsReceivableDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractReceivablesAbstract" xlink:label="ContractReceivablesAbstract" xlink:title="ContractReceivablesAbstract" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PeriodAfterBillingWhenPaymentIsReceived" xlink:label="PeriodAfterBillingWhenPaymentIsReceived" xlink:title="PeriodAfterBillingWhenPaymentIsReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContractReceivablesAbstract" xlink:to="PeriodAfterBillingWhenPaymentIsReceived" xlink:title="presentation: ContractReceivablesAbstract to PeriodAfterBillingWhenPaymentIsReceived" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ContractReceivablesAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ContractReceivablesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesDeferredRevenueDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityAbstract" xlink:label="ContractWithCustomerLiabilityAbstract" xlink:title="ContractWithCustomerLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="ContractWithCustomerLiabilityRevenueRecognized" xlink:title="ContractWithCustomerLiabilityRevenueRecognized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContractWithCustomerLiabilityAbstract" xlink:to="ContractWithCustomerLiabilityRevenueRecognized" xlink:title="presentation: ContractWithCustomerLiabilityAbstract to ContractWithCustomerLiabilityRevenueRecognized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ContractWithCustomerLiabilityAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ContractWithCustomerLiabilityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesCostOfProductsSoldDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAbstract" xlink:label="CostOfGoodsAndServicesSoldAbstract" xlink:title="CostOfGoodsAndServicesSoldAbstract" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CostOfProductsSoldPreviouslyRecognized" xlink:label="CostOfProductsSoldPreviouslyRecognized" xlink:title="CostOfProductsSoldPreviouslyRecognized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostOfGoodsAndServicesSoldAbstract" xlink:to="CostOfProductsSoldPreviouslyRecognized" xlink:title="presentation: CostOfGoodsAndServicesSoldAbstract to CostOfProductsSoldPreviouslyRecognized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="CostOfGoodsAndServicesSoldAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to CostOfGoodsAndServicesSoldAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementsAndLicensingAgreementsMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementsAndLicensingAgreementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PatentsMember" xlink:label="PatentsMember" xlink:title="PatentsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="PatentsMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to PatentsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="presentation: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseAbstract" xlink:label="ResearchAndDevelopmentExpenseAbstract" xlink:title="ResearchAndDevelopmentExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpenseAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: ResearchAndDevelopmentExpenseAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PatentAbstract" xlink:label="PatentAbstract" xlink:title="PatentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="FiniteLivedIntangibleAssetUsefulLife" xlink:title="FiniteLivedIntangibleAssetUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PatentAbstract" xlink:to="FiniteLivedIntangibleAssetUsefulLife" xlink:title="presentation: PatentAbstract to FiniteLivedIntangibleAssetUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PatentAbstract" xlink:to="FiniteLivedIntangibleAssetsGross" xlink:title="presentation: PatentAbstract to FiniteLivedIntangibleAssetsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PatentAbstract" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="presentation: PatentAbstract to FiniteLivedIntangibleAssetsAccumulatedAmortization" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PatentAbstract" xlink:to="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="presentation: PatentAbstract to FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PatentExpenses" xlink:label="PatentExpenses" xlink:title="PatentExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PatentAbstract" xlink:to="PatentExpenses" xlink:title="presentation: PatentAbstract to PatentExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:label="ImpairmentOfIntangibleAssetsFinitelived" xlink:title="ImpairmentOfIntangibleAssetsFinitelived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PatentAbstract" xlink:to="ImpairmentOfIntangibleAssetsFinitelived" xlink:title="presentation: PatentAbstract to ImpairmentOfIntangibleAssetsFinitelived" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentExpenseAbstract" xlink:to="PatentAbstract" xlink:title="presentation: ResearchAndDevelopmentExpenseAbstract to PatentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="ResearchAndDevelopmentExpenseAbstract" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to ResearchAndDevelopmentExpenseAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsLineItems" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleOfFiniteLivedIntangibleAssetsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="AccruedLiabilitiesCurrentAbstract" xlink:title="AccruedLiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AccruedClinicalExpenses" xlink:label="AccruedClinicalExpenses" xlink:title="AccruedClinicalExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="AccruedClinicalExpenses" xlink:title="presentation: AccruedLiabilitiesCurrentAbstract to AccruedClinicalExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AccruedInLicensingFeesCurrent" xlink:label="AccruedInLicensingFeesCurrent" xlink:title="AccruedInLicensingFeesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="AccruedInLicensingFeesCurrent" xlink:title="presentation: AccruedLiabilitiesCurrentAbstract to AccruedInLicensingFeesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="OtherAccruedLiabilitiesCurrent" xlink:title="presentation: AccruedLiabilitiesCurrentAbstract to OtherAccruedLiabilitiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="AccruedLiabilitiesCurrent" xlink:title="AccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesCurrent" xlink:title="presentation: AccruedLiabilitiesCurrentAbstract to AccruedLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="AccruedLiabilitiesCurrentAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to AccruedLiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="MinorityInterestTable" xlink:title="MinorityInterestTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="presentation: OwnershipDomain to AkceaTherapeuticsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="presentation: OwnershipAxis to OwnershipDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestTable" xlink:to="OwnershipAxis" xlink:title="presentation: MinorityInterestTable to OwnershipAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestTable" xlink:to="RangeAxis" xlink:title="presentation: MinorityInterestTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="MinorityInterestLineItems" xlink:title="MinorityInterestLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:label="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="ProceedsFromIssuanceOrSaleOfEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="MinorityInterestOwnershipPercentageByParent" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to MinorityInterestOwnershipPercentageByParent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SharesReceivedFromSubsidiaryForLicenseOfDrug" xlink:label="SharesReceivedFromSubsidiaryForLicenseOfDrug" xlink:title="SharesReceivedFromSubsidiaryForLicenseOfDrug" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="SharesReceivedFromSubsidiaryForLicenseOfDrug" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to SharesReceivedFromSubsidiaryForLicenseOfDrug" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestLineItems" xlink:to="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="presentation: MinorityInterestLineItems to ProceedsFromIssuanceOrSaleOfEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestTable" xlink:to="MinorityInterestLineItems" xlink:title="presentation: MinorityInterestTable to MinorityInterestLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="MinorityInterestTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to MinorityInterestTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:title="CashCashEquivalentsAndShortTermInvestmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:label="NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:title="NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:title="presentation: CashCashEquivalentsAndShortTermInvestmentsAbstract to NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:label="NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:title="NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:title="presentation: CashCashEquivalentsAndShortTermInvestmentsAbstract to NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to CashCashEquivalentsAndShortTermInvestmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="InventoryCurrentTable" xlink:title="InventoryCurrentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryAxis" xlink:label="PublicUtilitiesInventoryAxis" xlink:title="PublicUtilitiesInventoryAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:label="PublicUtilitiesInventoryTypeDomain" xlink:title="PublicUtilitiesInventoryTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ClinicalRawMaterialsMember" xlink:label="ClinicalRawMaterialsMember" xlink:title="ClinicalRawMaterialsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PublicUtilitiesInventoryTypeDomain" xlink:to="ClinicalRawMaterialsMember" xlink:title="presentation: PublicUtilitiesInventoryTypeDomain to ClinicalRawMaterialsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CommercialRawMaterialsMember" xlink:label="CommercialRawMaterialsMember" xlink:title="CommercialRawMaterialsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PublicUtilitiesInventoryTypeDomain" xlink:to="CommercialRawMaterialsMember" xlink:title="presentation: PublicUtilitiesInventoryTypeDomain to CommercialRawMaterialsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PublicUtilitiesInventoryAxis" xlink:to="PublicUtilitiesInventoryTypeDomain" xlink:title="presentation: PublicUtilitiesInventoryAxis to PublicUtilitiesInventoryTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryCurrentTable" xlink:to="PublicUtilitiesInventoryAxis" xlink:title="presentation: InventoryCurrentTable to PublicUtilitiesInventoryAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="InventoryLineItems" xlink:title="InventoryLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="InventoryNetAbstract" xlink:title="InventoryNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="InventoryWriteDown" xlink:title="InventoryWriteDown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryNetAbstract" xlink:to="InventoryWriteDown" xlink:title="presentation: InventoryNetAbstract to InventoryWriteDown" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="InventoryRawMaterials" xlink:title="InventoryRawMaterials" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryNetAbstract" xlink:to="InventoryRawMaterials" xlink:title="presentation: InventoryNetAbstract to InventoryRawMaterials" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="InventoryWorkInProcess" xlink:title="InventoryWorkInProcess" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryNetAbstract" xlink:to="InventoryWorkInProcess" xlink:title="presentation: InventoryNetAbstract to InventoryWorkInProcess" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="InventoryFinishedGoods" xlink:title="InventoryFinishedGoods" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryNetAbstract" xlink:to="InventoryFinishedGoods" xlink:title="presentation: InventoryNetAbstract to InventoryFinishedGoods" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryNetAbstract" xlink:to="InventoryNet" xlink:title="presentation: InventoryNetAbstract to InventoryNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryLineItems" xlink:to="InventoryNetAbstract" xlink:title="presentation: InventoryLineItems to InventoryNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryCurrentTable" xlink:to="InventoryLineItems" xlink:title="presentation: InventoryCurrentTable to InventoryLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="InventoryCurrentTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to InventoryCurrentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PropertyPlantAndEquipmentExcludingLandMember" xlink:label="PropertyPlantAndEquipmentExcludingLandMember" xlink:title="PropertyPlantAndEquipmentExcludingLandMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EquipmentAndComputerSoftwareMember" xlink:label="EquipmentAndComputerSoftwareMember" xlink:title="EquipmentAndComputerSoftwareMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentExcludingLandMember" xlink:to="EquipmentAndComputerSoftwareMember" xlink:title="presentation: PropertyPlantAndEquipmentExcludingLandMember to EquipmentAndComputerSoftwareMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="BuildingAndBuildingImprovementsMember" xlink:title="BuildingAndBuildingImprovementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentExcludingLandMember" xlink:to="BuildingAndBuildingImprovementsMember" xlink:title="presentation: PropertyPlantAndEquipmentExcludingLandMember to BuildingAndBuildingImprovementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandImprovementsMember" xlink:label="LandImprovementsMember" xlink:title="LandImprovementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentExcludingLandMember" xlink:to="LandImprovementsMember" xlink:title="presentation: PropertyPlantAndEquipmentExcludingLandMember to LandImprovementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentExcludingLandMember" xlink:to="LeaseholdImprovementsMember" xlink:title="presentation: PropertyPlantAndEquipmentExcludingLandMember to LeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentExcludingLandMember" xlink:to="FurnitureAndFixturesMember" xlink:title="presentation: PropertyPlantAndEquipmentExcludingLandMember to FurnitureAndFixturesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="PropertyPlantAndEquipmentExcludingLandMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to PropertyPlantAndEquipmentExcludingLandMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandMember" xlink:label="LandMember" xlink:title="LandMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LandMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to LandMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentUsefulLife" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentAbstract" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentLineItems" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleOfPropertyPlantAndEquipmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLeasesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:title="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="TypeOfAdoptionMember" xlink:title="TypeOfAdoptionMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="AccountingStandardsUpdate201602Member" xlink:title="AccountingStandardsUpdate201602Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfAdoptionMember" xlink:to="AccountingStandardsUpdate201602Member" xlink:title="presentation: TypeOfAdoptionMember to AccountingStandardsUpdate201602Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="TypeOfAdoptionMember" xlink:title="presentation: AdjustmentsForNewAccountingPronouncementsAxis to TypeOfAdoptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="AdjustmentsForNewAccountingPronouncementsAxis" xlink:title="presentation: NewAccountingPronouncementsOrChangeInAccountingPrincipleTable to AdjustmentsForNewAccountingPronouncementsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:title="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="LesseeDisclosureAbstract" xlink:title="LesseeDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="presentation: LesseeDisclosureAbstract to OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="OperatingLeaseLiability" xlink:title="presentation: LesseeDisclosureAbstract to OperatingLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: LesseeDisclosureAbstract to OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="LesseeDisclosureAbstract" xlink:title="presentation: NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems to LesseeDisclosureAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:title="presentation: NewAccountingPronouncementsOrChangeInAccountingPrincipleTable to NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLonglivedAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="AssetImpairmentChargesAbstract" xlink:title="AssetImpairmentChargesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="AssetImpairmentCharges" xlink:title="AssetImpairmentCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetImpairmentChargesAbstract" xlink:to="AssetImpairmentCharges" xlink:title="presentation: AssetImpairmentChargesAbstract to AssetImpairmentCharges" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="AssetImpairmentChargesAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to AssetImpairmentChargesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="presentation: ShareBasedCompensationAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="AccumulatedOtherComprehensiveIncomeLossTable" xlink:title="AccumulatedOtherComprehensiveIncomeLossTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:title="AociIncludingPortionAttributableToNoncontrollingInterestMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:title="AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:title="presentation: AociIncludingPortionAttributableToNoncontrollingInterestMember to AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:label="AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:title="AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:title="presentation: AociIncludingPortionAttributableToNoncontrollingInterestMember to AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:title="presentation: EquityComponentDomain to AociIncludingPortionAttributableToNoncontrollingInterestMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: AccumulatedOtherComprehensiveIncomeLossTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:title="AccumulatedOtherComprehensiveIncomeLossLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:label="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:title="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="presentation: ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:label="OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:title="OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:title="presentation: ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract to OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:label="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:title="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:title="presentation: ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract to ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="OtherComprehensiveIncomeLossNetOfTax" xlink:title="OtherComprehensiveIncomeLossNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="OtherComprehensiveIncomeLossNetOfTax" xlink:title="presentation: ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract to OtherComprehensiveIncomeLossNetOfTax" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:title="presentation: ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract to StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="OtherComprehensiveIncomeLossTax" xlink:title="OtherComprehensiveIncomeLossTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="OtherComprehensiveIncomeLossTax" xlink:title="presentation: ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract to OtherComprehensiveIncomeLossTax" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:title="presentation: AccumulatedOtherComprehensiveIncomeLossLineItems to ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:title="presentation: AccumulatedOtherComprehensiveIncomeLossTable to AccumulatedOtherComprehensiveIncomeLossLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="AccumulatedOtherComprehensiveIncomeLossTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to AccumulatedOtherComprehensiveIncomeLossTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesConvertibleDebtDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentMember" xlink:label="ConvertibleSeniorNotes0125PercentMember" xlink:title="ConvertibleSeniorNotes0125PercentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes0125PercentMember" xlink:title="presentation: DebtInstrumentNameDomain to ConvertibleSeniorNotes0125PercentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes1PercentMember" xlink:label="ConvertibleSeniorNotes1PercentMember" xlink:title="ConvertibleSeniorNotes1PercentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes1PercentMember" xlink:title="presentation: DebtInstrumentNameDomain to ConvertibleSeniorNotes1PercentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:label="LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:title="LongtermConvertibleDebtCurrentAndNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: LongtermConvertibleDebtCurrentAndNoncurrentAbstract to DebtInstrumentInterestRateStatedPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="LongtermConvertibleDebtCurrentAndNoncurrentAbstract" xlink:title="presentation: DebtInstrumentLineItems to LongtermConvertibleDebtCurrentAndNoncurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesSegmentInformationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:title="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="NumberOfOperatingSegments" xlink:title="presentation: SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract to NumberOfOperatingSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="FairValueMeasurementsRecurringMember" xlink:title="presentation: FairValueMeasurementFrequencyDomain to FairValueMeasurementsRecurringMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="FairValueMeasurementFrequencyDomain" xlink:title="presentation: FairValueByMeasurementFrequencyAxis to FairValueMeasurementFrequencyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByMeasurementFrequencyAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByMeasurementFrequencyAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel1Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel1Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel3Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel3Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="CorporateDebtSecuritiesMember" xlink:title="CorporateDebtSecuritiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="CorporateDebtSecuritiesMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to CorporateDebtSecuritiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="USGovernmentAgenciesDebtSecuritiesMember" xlink:title="USGovernmentAgenciesDebtSecuritiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="USGovernmentAgenciesDebtSecuritiesMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to USGovernmentAgenciesDebtSecuritiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="USTreasurySecuritiesMember" xlink:title="USTreasurySecuritiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="USTreasurySecuritiesMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to USTreasurySecuritiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="USStatesAndPoliticalSubdivisionsMember" xlink:title="USStatesAndPoliticalSubdivisionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="USStatesAndPoliticalSubdivisionsMember" xlink:title="presentation: TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to USStatesAndPoliticalSubdivisionsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentAxis" xlink:to="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="presentation: FinancialInstrumentAxis to TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FinancialInstrumentAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FinancialInstrumentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="BalanceSheetLocationAxis" xlink:title="BalanceSheetLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="BalanceSheetLocationDomain" xlink:title="BalanceSheetLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="CashAndCashEquivalentsMember" xlink:title="CashAndCashEquivalentsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetLocationDomain" xlink:to="CashAndCashEquivalentsMember" xlink:title="presentation: BalanceSheetLocationDomain to CashAndCashEquivalentsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetLocationAxis" xlink:to="BalanceSheetLocationDomain" xlink:title="presentation: BalanceSheetLocationAxis to BalanceSheetLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="BalanceSheetLocationAxis" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to BalanceSheetLocationAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueNetAssetLiabilityAbstract" xlink:label="FairValueNetAssetLiabilityAbstract" xlink:title="FairValueNetAssetLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="CashAndCashEquivalentsFairValueDisclosure" xlink:title="CashAndCashEquivalentsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="CashAndCashEquivalentsFairValueDisclosure" xlink:title="presentation: FairValueNetAssetLiabilityAbstract to CashAndCashEquivalentsFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="AvailableForSaleSecurities" xlink:title="AvailableForSaleSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="AvailableForSaleSecurities" xlink:title="presentation: FairValueNetAssetLiabilityAbstract to AvailableForSaleSecurities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="EquitySecuritiesFvNi" xlink:title="EquitySecuritiesFvNi" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="EquitySecuritiesFvNi" xlink:title="presentation: FairValueNetAssetLiabilityAbstract to EquitySecuritiesFvNi" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="AssetsFairValueDisclosure" xlink:title="AssetsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueNetAssetLiabilityAbstract" xlink:to="AssetsFairValueDisclosure" xlink:title="presentation: FairValueNetAssetLiabilityAbstract to AssetsFairValueDisclosure" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="FairValueNetAssetLiabilityAbstract" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to FairValueNetAssetLiabilityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="presentation: FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAbstract" xlink:label="InvestmentsAbstract" xlink:title="InvestmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:title="AvailableForSaleSecuritiesDebtMaturitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" xlink:title="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" xlink:title="presentation: AvailableForSaleSecuritiesDebtMaturitiesAbstract to AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" xlink:title="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" xlink:title="presentation: AvailableForSaleSecuritiesDebtMaturitiesAbstract to AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" xlink:title="AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" xlink:title="presentation: AvailableForSaleSecuritiesDebtMaturitiesAbstract to AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:title="AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" xlink:title="presentation: AvailableForSaleSecuritiesDebtMaturitiesAbstract to AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" xlink:label="AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" xlink:title="AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" xlink:title="presentation: AvailableForSaleSecuritiesDebtMaturitiesAbstract to AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumContractMaturityPeriodRange1" xlink:label="MaximumContractMaturityPeriodRange1" xlink:title="MaximumContractMaturityPeriodRange1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="MaximumContractMaturityPeriodRange1" xlink:title="presentation: AvailableForSaleSecuritiesDebtMaturitiesAbstract to MaximumContractMaturityPeriodRange1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumContractMaturityPeriodRange2" xlink:label="MaximumContractMaturityPeriodRange2" xlink:title="MaximumContractMaturityPeriodRange2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="MaximumContractMaturityPeriodRange2" xlink:title="presentation: AvailableForSaleSecuritiesDebtMaturitiesAbstract to MaximumContractMaturityPeriodRange2" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumContractMaturityPeriodRange3" xlink:label="MaximumContractMaturityPeriodRange3" xlink:title="MaximumContractMaturityPeriodRange3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="MaximumContractMaturityPeriodRange3" xlink:title="presentation: AvailableForSaleSecuritiesDebtMaturitiesAbstract to MaximumContractMaturityPeriodRange3" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsAbstract" xlink:to="AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:title="presentation: InvestmentsAbstract to AvailableForSaleSecuritiesDebtMaturitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:label="InvestmentsAllOtherInvestmentsAbstract" xlink:title="InvestmentsAllOtherInvestmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:label="NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:title="NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsAllOtherInvestmentsAbstract" xlink:to="NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:title="presentation: InvestmentsAllOtherInvestmentsAbstract to NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:label="NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:title="NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsAllOtherInvestmentsAbstract" xlink:to="NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" xlink:title="presentation: InvestmentsAllOtherInvestmentsAbstract to NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsAbstract" xlink:to="InvestmentsAllOtherInvestmentsAbstract" xlink:title="presentation: InvestmentsAbstract to InvestmentsAllOtherInvestmentsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAbstract" xlink:label="InvestmentsAbstract" xlink:title="InvestmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsTable" xlink:label="InvestmentHoldingsTable" xlink:title="InvestmentHoldingsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="InvestmentTypeAxis" xlink:title="InvestmentTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember" xlink:title="InvestmentTypeCategorizationMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="DebtSecuritiesMember" xlink:title="DebtSecuritiesMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="CorporateDebtSecuritiesMember" xlink:title="CorporateDebtSecuritiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtSecuritiesMember" xlink:to="CorporateDebtSecuritiesMember" xlink:title="presentation: DebtSecuritiesMember to CorporateDebtSecuritiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="USGovernmentAgenciesDebtSecuritiesMember" xlink:title="USGovernmentAgenciesDebtSecuritiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtSecuritiesMember" xlink:to="USGovernmentAgenciesDebtSecuritiesMember" xlink:title="presentation: DebtSecuritiesMember to USGovernmentAgenciesDebtSecuritiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="USTreasurySecuritiesMember" xlink:title="USTreasurySecuritiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtSecuritiesMember" xlink:to="USTreasurySecuritiesMember" xlink:title="presentation: DebtSecuritiesMember to USTreasurySecuritiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="USStatesAndPoliticalSubdivisionsMember" xlink:title="USStatesAndPoliticalSubdivisionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtSecuritiesMember" xlink:to="USStatesAndPoliticalSubdivisionsMember" xlink:title="presentation: DebtSecuritiesMember to USStatesAndPoliticalSubdivisionsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentTypeCategorizationMember" xlink:to="DebtSecuritiesMember" xlink:title="presentation: InvestmentTypeCategorizationMember to DebtSecuritiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="EquitySecuritiesMember" xlink:title="EquitySecuritiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentTypeCategorizationMember" xlink:to="EquitySecuritiesMember" xlink:title="presentation: InvestmentTypeCategorizationMember to EquitySecuritiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentTypeAxis" xlink:to="InvestmentTypeCategorizationMember" xlink:title="presentation: InvestmentTypeAxis to InvestmentTypeCategorizationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentHoldingsTable" xlink:to="InvestmentTypeAxis" xlink:title="presentation: InvestmentHoldingsTable to InvestmentTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentSecondaryCategorizationAxis" xlink:label="InvestmentSecondaryCategorizationAxis" xlink:title="InvestmentSecondaryCategorizationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsBySecondaryCategorizationDomain" xlink:label="InvestmentsBySecondaryCategorizationDomain" xlink:title="InvestmentsBySecondaryCategorizationDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SecuritiesWithMaturityOfOneYearOrLessMember" xlink:label="SecuritiesWithMaturityOfOneYearOrLessMember" xlink:title="SecuritiesWithMaturityOfOneYearOrLessMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsBySecondaryCategorizationDomain" xlink:to="SecuritiesWithMaturityOfOneYearOrLessMember" xlink:title="presentation: InvestmentsBySecondaryCategorizationDomain to SecuritiesWithMaturityOfOneYearOrLessMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SecuritiesWithMaturityOfMoreThanOneYearMember" xlink:label="SecuritiesWithMaturityOfMoreThanOneYearMember" xlink:title="SecuritiesWithMaturityOfMoreThanOneYearMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsBySecondaryCategorizationDomain" xlink:to="SecuritiesWithMaturityOfMoreThanOneYearMember" xlink:title="presentation: InvestmentsBySecondaryCategorizationDomain to SecuritiesWithMaturityOfMoreThanOneYearMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IncludedInOtherCurrentAssetsMember" xlink:label="IncludedInOtherCurrentAssetsMember" xlink:title="IncludedInOtherCurrentAssetsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsBySecondaryCategorizationDomain" xlink:to="IncludedInOtherCurrentAssetsMember" xlink:title="presentation: InvestmentsBySecondaryCategorizationDomain to IncludedInOtherCurrentAssetsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IncludedInDepositsAndOtherAssetsMember" xlink:label="IncludedInDepositsAndOtherAssetsMember" xlink:title="IncludedInDepositsAndOtherAssetsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsBySecondaryCategorizationDomain" xlink:to="IncludedInDepositsAndOtherAssetsMember" xlink:title="presentation: InvestmentsBySecondaryCategorizationDomain to IncludedInDepositsAndOtherAssetsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentSecondaryCategorizationAxis" xlink:to="InvestmentsBySecondaryCategorizationDomain" xlink:title="presentation: InvestmentSecondaryCategorizationAxis to InvestmentsBySecondaryCategorizationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentHoldingsTable" xlink:to="InvestmentSecondaryCategorizationAxis" xlink:title="presentation: InvestmentHoldingsTable to InvestmentSecondaryCategorizationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="BalanceSheetLocationAxis" xlink:title="BalanceSheetLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="BalanceSheetLocationDomain" xlink:title="BalanceSheetLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="OtherCurrentAssetsMember" xlink:title="OtherCurrentAssetsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetLocationDomain" xlink:to="OtherCurrentAssetsMember" xlink:title="presentation: BalanceSheetLocationDomain to OtherCurrentAssetsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DepositsAndOtherAssetsMember" xlink:label="DepositsAndOtherAssetsMember" xlink:title="DepositsAndOtherAssetsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetLocationDomain" xlink:to="DepositsAndOtherAssetsMember" xlink:title="presentation: BalanceSheetLocationDomain to DepositsAndOtherAssetsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BalanceSheetLocationAxis" xlink:to="BalanceSheetLocationDomain" xlink:title="presentation: BalanceSheetLocationAxis to BalanceSheetLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentHoldingsTable" xlink:to="BalanceSheetLocationAxis" xlink:title="presentation: InvestmentHoldingsTable to BalanceSheetLocationAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsLineItems" xlink:label="InvestmentHoldingsLineItems" xlink:title="InvestmentHoldingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:title="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:title="AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:title="presentation: AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract to AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:title="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:title="presentation: AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract to AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:title="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:title="presentation: AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract to AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="AvailableForSaleSecuritiesDebtSecurities" xlink:title="AvailableForSaleSecuritiesDebtSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="AvailableForSaleSecuritiesDebtSecurities" xlink:title="presentation: AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract to AvailableForSaleSecuritiesDebtSecurities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost" xlink:label="EquitySecuritiesFvNiCost" xlink:title="EquitySecuritiesFvNiCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="EquitySecuritiesFvNiCost" xlink:title="presentation: AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract to EquitySecuritiesFvNiCost" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="EquitySecuritiesFvNiUnrealizedGain" xlink:title="EquitySecuritiesFvNiUnrealizedGain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="EquitySecuritiesFvNiUnrealizedGain" xlink:title="presentation: AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract to EquitySecuritiesFvNiUnrealizedGain" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="EquitySecuritiesFvNiUnrealizedLoss" xlink:title="EquitySecuritiesFvNiUnrealizedLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="EquitySecuritiesFvNiUnrealizedLoss" xlink:title="presentation: AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract to EquitySecuritiesFvNiUnrealizedLoss" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="EquitySecuritiesFvNi" xlink:title="EquitySecuritiesFvNi" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="EquitySecuritiesFvNi" xlink:title="presentation: AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract to EquitySecuritiesFvNi" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:label="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:title="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" xlink:title="presentation: AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract to DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:label="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:title="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" xlink:title="presentation: AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract to DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:label="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:title="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" xlink:title="presentation: AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract to DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:label="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:title="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" xlink:title="presentation: AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract to DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentHoldingsLineItems" xlink:to="AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:title="presentation: InvestmentHoldingsLineItems to AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentHoldingsTable" xlink:to="InvestmentHoldingsLineItems" xlink:title="presentation: InvestmentHoldingsTable to InvestmentHoldingsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsAbstract" xlink:to="InvestmentHoldingsTable" xlink:title="presentation: InvestmentsAbstract to InvestmentHoldingsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsAbstract" xlink:label="InvestmentsAbstract" xlink:title="InvestmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsTable" xlink:label="InvestmentHoldingsTable" xlink:title="InvestmentHoldingsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="InvestmentTypeAxis" xlink:title="InvestmentTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="InvestmentTypeCategorizationMember" xlink:title="InvestmentTypeCategorizationMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="DebtSecuritiesMember" xlink:title="DebtSecuritiesMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="CorporateDebtSecuritiesMember" xlink:title="CorporateDebtSecuritiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtSecuritiesMember" xlink:to="CorporateDebtSecuritiesMember" xlink:title="presentation: DebtSecuritiesMember to CorporateDebtSecuritiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="USGovernmentAgenciesDebtSecuritiesMember" xlink:title="USGovernmentAgenciesDebtSecuritiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtSecuritiesMember" xlink:to="USGovernmentAgenciesDebtSecuritiesMember" xlink:title="presentation: DebtSecuritiesMember to USGovernmentAgenciesDebtSecuritiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="USTreasurySecuritiesMember" xlink:title="USTreasurySecuritiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtSecuritiesMember" xlink:to="USTreasurySecuritiesMember" xlink:title="presentation: DebtSecuritiesMember to USTreasurySecuritiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USStatesAndPoliticalSubdivisionsMember" xlink:label="USStatesAndPoliticalSubdivisionsMember" xlink:title="USStatesAndPoliticalSubdivisionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtSecuritiesMember" xlink:to="USStatesAndPoliticalSubdivisionsMember" xlink:title="presentation: DebtSecuritiesMember to USStatesAndPoliticalSubdivisionsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentTypeCategorizationMember" xlink:to="DebtSecuritiesMember" xlink:title="presentation: InvestmentTypeCategorizationMember to DebtSecuritiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentTypeAxis" xlink:to="InvestmentTypeCategorizationMember" xlink:title="presentation: InvestmentTypeAxis to InvestmentTypeCategorizationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentHoldingsTable" xlink:to="InvestmentTypeAxis" xlink:title="presentation: InvestmentHoldingsTable to InvestmentTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsLineItems" xlink:label="InvestmentHoldingsLineItems" xlink:title="InvestmentHoldingsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract" xlink:label="AvailableForSaleSecuritiesAbstract" xlink:title="AvailableForSaleSecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:label="AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:title="AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesAbstract" xlink:to="AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" xlink:title="presentation: AvailableForSaleSecuritiesAbstract to AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesAbstract" xlink:to="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" xlink:title="presentation: AvailableForSaleSecuritiesAbstract to AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesAbstract" xlink:to="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:title="presentation: AvailableForSaleSecuritiesAbstract to AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesAbstract" xlink:to="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" xlink:title="presentation: AvailableForSaleSecuritiesAbstract to AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesAbstract" xlink:to="AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:title="presentation: AvailableForSaleSecuritiesAbstract to AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesAbstract" xlink:to="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" xlink:title="presentation: AvailableForSaleSecuritiesAbstract to AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:label="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:title="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AvailableForSaleSecuritiesAbstract" xlink:to="AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" xlink:title="presentation: AvailableForSaleSecuritiesAbstract to AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentHoldingsLineItems" xlink:to="AvailableForSaleSecuritiesAbstract" xlink:title="presentation: InvestmentHoldingsLineItems to AvailableForSaleSecuritiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentHoldingsTable" xlink:to="InvestmentHoldingsLineItems" xlink:title="presentation: InvestmentHoldingsTable to InvestmentHoldingsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InvestmentsAbstract" xlink:to="InvestmentHoldingsTable" xlink:title="presentation: InvestmentsAbstract to InvestmentHoldingsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetailsCalc2" />
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentMember" xlink:label="ConvertibleSeniorNotes0125PercentMember" xlink:title="ConvertibleSeniorNotes0125PercentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes0125PercentMember" xlink:title="presentation: DebtInstrumentNameDomain to ConvertibleSeniorNotes0125PercentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes1PercentMember" xlink:label="ConvertibleSeniorNotes1PercentMember" xlink:title="ConvertibleSeniorNotes1PercentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes1PercentMember" xlink:title="presentation: DebtInstrumentNameDomain to ConvertibleSeniorNotes1PercentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermMortgageDebtMember" xlink:label="LongTermMortgageDebtMember" xlink:title="LongTermMortgageDebtMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="LongTermMortgageDebtMember" xlink:title="presentation: DebtInstrumentNameDomain to LongTermMortgageDebtMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_FixedRateNoteWithMorganStanleyMember" xlink:label="FixedRateNoteWithMorganStanleyMember" xlink:title="FixedRateNoteWithMorganStanleyMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="FixedRateNoteWithMorganStanleyMember" xlink:title="presentation: DebtInstrumentNameDomain to FixedRateNoteWithMorganStanleyMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LeasesAndOtherObligationsMember" xlink:label="LeasesAndOtherObligationsMember" xlink:title="LeasesAndOtherObligationsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="LeasesAndOtherObligationsMember" xlink:title="presentation: DebtInstrumentNameDomain to LeasesAndOtherObligationsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtCurrentAndNoncurrentAbstract" xlink:label="LongtermDebtCurrentAndNoncurrentAbstract" xlink:title="LongtermDebtCurrentAndNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermDebtAndOtherObligations" xlink:label="LongTermDebtAndOtherObligations" xlink:title="LongTermDebtAndOtherObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtCurrentAndNoncurrentAbstract" xlink:to="LongTermDebtAndOtherObligations" xlink:title="presentation: LongtermDebtCurrentAndNoncurrentAbstract to LongTermDebtAndOtherObligations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="LongTermDebtAndCapitalLeaseObligationsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtCurrentAndNoncurrentAbstract" xlink:to="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="presentation: LongtermDebtCurrentAndNoncurrentAbstract to LongTermDebtAndCapitalLeaseObligationsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermDebtAndOtherObligationsNoncurrent" xlink:label="LongTermDebtAndOtherObligationsNoncurrent" xlink:title="LongTermDebtAndOtherObligationsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtCurrentAndNoncurrentAbstract" xlink:to="LongTermDebtAndOtherObligationsNoncurrent" xlink:title="presentation: LongtermDebtCurrentAndNoncurrentAbstract to LongTermDebtAndOtherObligationsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LongtermDebtCurrentAndNoncurrentAbstract" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: LongtermDebtCurrentAndNoncurrentAbstract to DebtInstrumentInterestRateStatedPercentage" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="LongtermDebtCurrentAndNoncurrentAbstract" xlink:title="presentation: DebtInstrumentLineItems to LongtermDebtCurrentAndNoncurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtDisclosureAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/LongtermObligationsAndCommitmentsDetailsCalc2" />
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentMember" xlink:label="ConvertibleSeniorNotes0125PercentMember" xlink:title="ConvertibleSeniorNotes0125PercentMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember" xlink:label="ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember" xlink:title="ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleSeniorNotes0125PercentMember" xlink:to="ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember" xlink:title="presentation: ConvertibleSeniorNotes0125PercentMember to ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember" xlink:label="ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember" xlink:title="ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleSeniorNotes0125PercentMember" xlink:to="ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember" xlink:title="presentation: ConvertibleSeniorNotes0125PercentMember to ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes0125PercentMember" xlink:title="presentation: DebtInstrumentNameDomain to ConvertibleSeniorNotes0125PercentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes1PercentMember" xlink:label="ConvertibleSeniorNotes1PercentMember" xlink:title="ConvertibleSeniorNotes1PercentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes1PercentMember" xlink:title="presentation: DebtInstrumentNameDomain to ConvertibleSeniorNotes1PercentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes275PercentMember" xlink:label="ConvertibleSeniorNotes275PercentMember" xlink:title="ConvertibleSeniorNotes275PercentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes275PercentMember" xlink:title="presentation: DebtInstrumentNameDomain to ConvertibleSeniorNotes275PercentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="MeasurementInputTypeAxis" xlink:title="MeasurementInputTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="MeasurementInputTypeDomain" xlink:title="MeasurementInputTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="MeasurementInputDiscountRateMember" xlink:title="MeasurementInputDiscountRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeDomain" xlink:to="MeasurementInputDiscountRateMember" xlink:title="presentation: MeasurementInputTypeDomain to MeasurementInputDiscountRateMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MeasurementInputTypeAxis" xlink:to="MeasurementInputTypeDomain" xlink:title="presentation: MeasurementInputTypeAxis to MeasurementInputTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="MeasurementInputTypeAxis" xlink:title="presentation: DebtInstrumentTable to MeasurementInputTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="FairValueInputsLevel2Member" xlink:title="presentation: FairValueMeasurementsFairValueHierarchyDomain to FairValueInputsLevel2Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="presentation: FairValueByFairValueHierarchyLevelAxis to FairValueMeasurementsFairValueHierarchyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="FairValueByFairValueHierarchyLevelAxis" xlink:title="presentation: DebtInstrumentTable to FairValueByFairValueHierarchyLevelAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:label="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:title="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="DebtInstrumentRepurchasedFaceAmount" xlink:title="DebtInstrumentRepurchasedFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="DebtInstrumentRepurchasedFaceAmount" xlink:title="presentation: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to DebtInstrumentRepurchasedFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="DebtInstrumentFaceAmount" xlink:title="presentation: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to DebtInstrumentFaceAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CallSpread" xlink:label="CallSpread" xlink:title="CallSpread" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="CallSpread" xlink:title="presentation: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to CallSpread" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForHedgeFinancingActivities" xlink:label="PaymentsForHedgeFinancingActivities" xlink:title="PaymentsForHedgeFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="PaymentsForHedgeFinancingActivities" xlink:title="presentation: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to PaymentsForHedgeFinancingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="ProceedsFromIssuanceOfWarrants" xlink:title="ProceedsFromIssuanceOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="ProceedsFromIssuanceOfWarrants" xlink:title="presentation: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to ProceedsFromIssuanceOfWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread" xlink:label="DebtInstrumentConvertibleConversionPriceIncludingCallSpread" xlink:title="DebtInstrumentConvertibleConversionPriceIncludingCallSpread" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="DebtInstrumentConvertibleConversionPriceIncludingCallSpread" xlink:title="presentation: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to DebtInstrumentConvertibleConversionPriceIncludingCallSpread" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="DebtInstrumentMaturityDate" xlink:title="presentation: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to DebtInstrumentMaturityDate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to DebtInstrumentInterestRateStatedPercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="DebtInstrumentConvertibleConversionPrice1" xlink:title="DebtInstrumentConvertibleConversionPrice1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="DebtInstrumentConvertibleConversionPrice1" xlink:title="presentation: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to DebtInstrumentConvertibleConversionPrice1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:title="DebtInstrumentConvertibleNumberOfEquityInstruments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:title="presentation: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to DebtInstrumentConvertibleNumberOfEquityInstruments" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" xlink:label="DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" xlink:title="DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" xlink:title="presentation: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="LongTermDebtFairValue" xlink:title="LongTermDebtFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="LongTermDebtFairValue" xlink:title="presentation: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to LongTermDebtFairValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="DebtInstrumentCarryingAmount" xlink:title="presentation: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to DebtInstrumentCarryingAmount" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet" xlink:label="DebtInstrumentUnamortizedDiscountPremiumNet" xlink:title="DebtInstrumentUnamortizedDiscountPremiumNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="DebtInstrumentUnamortizedDiscountPremiumNet" xlink:title="presentation: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to DebtInstrumentUnamortizedDiscountPremiumNet" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="ConvertibleDebtNoncurrent" xlink:title="ConvertibleDebtNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="ConvertibleDebtNoncurrent" xlink:title="presentation: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to ConvertibleDebtNoncurrent" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:title="DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:title="presentation: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="presentation: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to GainsLossesOnExtinguishmentOfDebt" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentMeasurementInput" xlink:label="DebtInstrumentMeasurementInput" xlink:title="DebtInstrumentMeasurementInput" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="DebtInstrumentMeasurementInput" xlink:title="presentation: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to DebtInstrumentMeasurementInput" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="DebtInstrumentInterestRateEffectivePercentage" xlink:title="presentation: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to DebtInstrumentInterestRateEffectivePercentage" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:title="DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:title="presentation: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:to="AmortizationOfFinancingCostsAndDiscounts" xlink:title="presentation: ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract to AmortizationOfFinancingCostsAndDiscounts" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" xlink:title="presentation: DebtInstrumentLineItems to ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtDisclosureAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="LineOfCreditFacilityTable" xlink:title="LineOfCreditFacilityTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MorganStanleyPrivateBankNationalAssociationMember" xlink:label="MorganStanleyPrivateBankNationalAssociationMember" xlink:title="MorganStanleyPrivateBankNationalAssociationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="MorganStanleyPrivateBankNationalAssociationMember" xlink:title="presentation: LineOfCreditFacilityLenderDomain to MorganStanleyPrivateBankNationalAssociationMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain" xlink:title="presentation: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityTable" xlink:to="LineOfCreditFacilityAxis" xlink:title="presentation: LineOfCreditFacilityTable to LineOfCreditFacilityAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="RevolvingCreditFacilityMember" xlink:title="RevolvingCreditFacilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CreditFacilityDomain" xlink:to="RevolvingCreditFacilityMember" xlink:title="presentation: CreditFacilityDomain to RevolvingCreditFacilityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain" xlink:title="presentation: CreditFacilityAxis to CreditFacilityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityTable" xlink:to="CreditFacilityAxis" xlink:title="presentation: LineOfCreditFacilityTable to CreditFacilityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_FixedRateNoteWithMorganStanleyMember" xlink:label="FixedRateNoteWithMorganStanleyMember" xlink:title="FixedRateNoteWithMorganStanleyMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="FixedRateNoteWithMorganStanleyMember" xlink:title="presentation: DebtInstrumentNameDomain to FixedRateNoteWithMorganStanleyMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: LineOfCreditFacilityTable to DebtInstrumentAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="LineOfCreditFacilityLineItems" xlink:title="LineOfCreditFacilityLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityAbstract" xlink:label="LineOfCreditFacilityAbstract" xlink:title="LineOfCreditFacilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="DebtInstrumentTerm" xlink:title="DebtInstrumentTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAbstract" xlink:to="DebtInstrumentTerm" xlink:title="presentation: LineOfCreditFacilityAbstract to DebtInstrumentTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAbstract" xlink:to="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="presentation: LineOfCreditFacilityAbstract to LineOfCreditFacilityMaximumBorrowingCapacity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="RepaymentsOfLongTermLinesOfCredit" xlink:title="RepaymentsOfLongTermLinesOfCredit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAbstract" xlink:to="RepaymentsOfLongTermLinesOfCredit" xlink:title="presentation: LineOfCreditFacilityAbstract to RepaymentsOfLongTermLinesOfCredit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityLineItems" xlink:to="LineOfCreditFacilityAbstract" xlink:title="presentation: LineOfCreditFacilityLineItems to LineOfCreditFacilityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityTable" xlink:to="LineOfCreditFacilityLineItems" xlink:title="presentation: LineOfCreditFacilityTable to LineOfCreditFacilityLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="LineOfCreditFacilityTable" xlink:title="presentation: DebtDisclosureAbstract to LineOfCreditFacilityTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PrimaryResearchAndDevelopmentFacilityMember" xlink:label="PrimaryResearchAndDevelopmentFacilityMember" xlink:title="PrimaryResearchAndDevelopmentFacilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="PrimaryResearchAndDevelopmentFacilityMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to PrimaryResearchAndDevelopmentFacilityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="ManufacturingFacilityMember" xlink:title="ManufacturingFacilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ManufacturingFacilityMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to ManufacturingFacilityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermMortgageDebtMember" xlink:label="LongTermMortgageDebtMember" xlink:title="LongTermMortgageDebtMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="LongTermMortgageDebtMember" xlink:title="presentation: DebtInstrumentNameDomain to LongTermMortgageDebtMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to DebtInstrumentAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipmentAbstract" xlink:label="PaymentsToAcquirePropertyPlantAndEquipmentAbstract" xlink:title="PaymentsToAcquirePropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBuildings" xlink:label="PaymentsToAcquireBuildings" xlink:title="PaymentsToAcquireBuildings" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaymentsToAcquirePropertyPlantAndEquipmentAbstract" xlink:to="PaymentsToAcquireBuildings" xlink:title="presentation: PaymentsToAcquirePropertyPlantAndEquipmentAbstract to PaymentsToAcquireBuildings" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaymentsToAcquirePropertyPlantAndEquipmentAbstract" xlink:to="DebtInstrumentFaceAmount" xlink:title="presentation: PaymentsToAcquirePropertyPlantAndEquipmentAbstract to DebtInstrumentFaceAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaymentsToAcquirePropertyPlantAndEquipmentAbstract" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: PaymentsToAcquirePropertyPlantAndEquipmentAbstract to DebtInstrumentInterestRateStatedPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan" xlink:label="PeriodToMakeInterestOnlyPaymentsOnMortgageLoan" xlink:title="PeriodToMakeInterestOnlyPaymentsOnMortgageLoan" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaymentsToAcquirePropertyPlantAndEquipmentAbstract" xlink:to="PeriodToMakeInterestOnlyPaymentsOnMortgageLoan" xlink:title="presentation: PaymentsToAcquirePropertyPlantAndEquipmentAbstract to PeriodToMakeInterestOnlyPaymentsOnMortgageLoan" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_GainLossOnExtinguishmentOfFinancingLiability" xlink:label="GainLossOnExtinguishmentOfFinancingLiability" xlink:title="GainLossOnExtinguishmentOfFinancingLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PaymentsToAcquirePropertyPlantAndEquipmentAbstract" xlink:to="GainLossOnExtinguishmentOfFinancingLiability" xlink:title="presentation: PaymentsToAcquirePropertyPlantAndEquipmentAbstract to GainLossOnExtinguishmentOfFinancingLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PaymentsToAcquirePropertyPlantAndEquipmentAbstract" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PaymentsToAcquirePropertyPlantAndEquipmentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentLineItems" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="presentation: DebtDisclosureAbstract to ScheduleOfPropertyPlantAndEquipmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" xlink:label="LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" xlink:title="LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" xlink:title="presentation: DebtInstrumentNameDomain to LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:label="MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:title="MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="ContractualObligationDueInNextTwelveMonths" xlink:title="ContractualObligationDueInNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:to="ContractualObligationDueInNextTwelveMonths" xlink:title="presentation: MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract to ContractualObligationDueInNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="ContractualObligationDueInSecondYear" xlink:title="ContractualObligationDueInSecondYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:to="ContractualObligationDueInSecondYear" xlink:title="presentation: MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract to ContractualObligationDueInSecondYear" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="ContractualObligationDueInThirdYear" xlink:title="ContractualObligationDueInThirdYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:to="ContractualObligationDueInThirdYear" xlink:title="presentation: MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract to ContractualObligationDueInThirdYear" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInFourthYear" xlink:label="ContractualObligationDueInFourthYear" xlink:title="ContractualObligationDueInFourthYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:to="ContractualObligationDueInFourthYear" xlink:title="presentation: MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract to ContractualObligationDueInFourthYear" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueInFifthYear" xlink:label="ContractualObligationDueInFifthYear" xlink:title="ContractualObligationDueInFifthYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:to="ContractualObligationDueInFifthYear" xlink:title="presentation: MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract to ContractualObligationDueInFifthYear" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:label="ContractualObligationDueAfterFifthYear" xlink:title="ContractualObligationDueAfterFifthYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:to="ContractualObligationDueAfterFifthYear" xlink:title="presentation: MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract to ContractualObligationDueAfterFifthYear" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation" xlink:label="ContractualObligation" xlink:title="ContractualObligation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:to="ContractualObligation" xlink:title="presentation: MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract to ContractualObligation" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:label="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="LongTermDebtAndCapitalLeaseObligationsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:to="LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:title="presentation: MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract to LongTermDebtAndCapitalLeaseObligationsCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="InterestPayableCurrentAndNoncurrent" xlink:title="InterestPayableCurrentAndNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:to="InterestPayableCurrentAndNoncurrent" xlink:title="presentation: MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract to InterestPayableCurrentAndNoncurrent" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="presentation: MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract to DebtInstrumentUnamortizedDiscount" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="DeferredRentCredit" xlink:title="DeferredRentCredit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:to="DeferredRentCredit" xlink:title="presentation: MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract to DeferredRentCredit" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LongTermDebtAndOtherObligationsNoncurrent" xlink:label="LongTermDebtAndOtherObligationsNoncurrent" xlink:title="LongTermDebtAndOtherObligationsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:to="LongTermDebtAndOtherObligationsNoncurrent" xlink:title="presentation: MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract to LongTermDebtAndOtherObligationsNoncurrent" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" xlink:title="presentation: DebtInstrumentLineItems to MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtDisclosureAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="LesseeLeaseDescriptionTable" xlink:title="LesseeLeaseDescriptionTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="presentation: ConsolidatedEntitiesDomain to AkceaTherapeuticsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="presentation: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="presentation: LesseeLeaseDescriptionTable to ConsolidatedEntitiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember" xlink:label="OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember" xlink:title="OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember" xlink:label="OfficeSpaceSubleasedToAkceaTherapeuticsIncMember" xlink:title="OfficeSpaceSubleasedToAkceaTherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeSpaceSubleasedToAkceaTherapeuticsIncMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to OfficeSpaceSubleasedToAkceaTherapeuticsIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_OfficeSpaceForCorporateHeadquartersMember" xlink:label="OfficeSpaceForCorporateHeadquartersMember" xlink:title="OfficeSpaceForCorporateHeadquartersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeSpaceForCorporateHeadquartersMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to OfficeSpaceForCorporateHeadquartersMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: LesseeLeaseDescriptionTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="LesseeLeaseDescriptionLineItems" xlink:title="LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="LesseeDisclosureAbstract" xlink:title="LesseeDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease" xlink:label="LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease" xlink:title="LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease" xlink:title="presentation: LesseeDisclosureAbstract to LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="LesseeOperatingLeaseRenewalTerm" xlink:title="LesseeOperatingLeaseRenewalTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="LesseeOperatingLeaseRenewalTerm" xlink:title="presentation: LesseeDisclosureAbstract to LesseeOperatingLeaseRenewalTerm" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="LesseeOperatingLeaseTermOfContract" xlink:title="LesseeOperatingLeaseTermOfContract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="LesseeOperatingLeaseTermOfContract" xlink:title="presentation: LesseeDisclosureAbstract to LesseeOperatingLeaseTermOfContract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LesseeOperatingLeasePeriodOfFreeRent" xlink:label="LesseeOperatingLeasePeriodOfFreeRent" xlink:title="LesseeOperatingLeasePeriodOfFreeRent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="LesseeOperatingLeasePeriodOfFreeRent" xlink:title="presentation: LesseeDisclosureAbstract to LesseeOperatingLeasePeriodOfFreeRent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LesseeOperatingLeaseAllowanceForTenantImprovements" xlink:label="LesseeOperatingLeaseAllowanceForTenantImprovements" xlink:title="LesseeOperatingLeaseAllowanceForTenantImprovements" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="LesseeOperatingLeaseAllowanceForTenantImprovements" xlink:title="presentation: LesseeDisclosureAbstract to LesseeOperatingLeaseAllowanceForTenantImprovements" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation" xlink:label="LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation" xlink:title="LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation" xlink:title="presentation: LesseeDisclosureAbstract to LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate" xlink:label="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate" xlink:title="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate" xlink:title="presentation: LesseeDisclosureAbstract to LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate" xlink:label="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate" xlink:title="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate" xlink:title="presentation: LesseeDisclosureAbstract to LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="presentation: LesseeDisclosureAbstract to OperatingLeaseRightOfUseAsset" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:title="presentation: LesseeDisclosureAbstract to OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="OperatingLeaseLiability" xlink:title="OperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="OperatingLeaseLiability" xlink:title="presentation: LesseeDisclosureAbstract to OperatingLeaseLiability" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="presentation: LesseeDisclosureAbstract to OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:title="OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:title="presentation: LesseeDisclosureAbstract to OperatingLeaseWeightedAverageDiscountRatePercent" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: LesseeDisclosureAbstract to OperatingLeaseLiabilityCurrent" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:title="presentation: LesseeDisclosureAbstract to OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:title="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:title="presentation: LesseeDisclosureAbstract to OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="OperatingLeasePayments" xlink:title="OperatingLeasePayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="OperatingLeasePayments" xlink:title="presentation: LesseeDisclosureAbstract to OperatingLeasePayments" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="OperatingLeaseLiability" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to OperatingLeaseLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="presentation: LesseeDisclosureAbstract to OperatingLeaseLiabilitiesPaymentsDueAbstract" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="OperatingLeaseExpense" xlink:title="OperatingLeaseExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeDisclosureAbstract" xlink:to="OperatingLeaseExpense" xlink:title="presentation: LesseeDisclosureAbstract to OperatingLeaseExpense" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionLineItems" xlink:to="LesseeDisclosureAbstract" xlink:title="presentation: LesseeLeaseDescriptionLineItems to LesseeDisclosureAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeLeaseDescriptionTable" xlink:to="LesseeLeaseDescriptionLineItems" xlink:title="presentation: LesseeLeaseDescriptionTable to LesseeLeaseDescriptionLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="LesseeLeaseDescriptionTable" xlink:title="presentation: DebtDisclosureAbstract to LesseeLeaseDescriptionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/OperatingLeasesDetailsCalc01" />
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="SeriesCPreferredStockMember" xlink:title="SeriesCPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockMember" xlink:to="SeriesCPreferredStockMember" xlink:title="presentation: PreferredStockMember to SeriesCPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="PreferredStockMember" xlink:title="presentation: ClassOfStockDomain to PreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDomain" xlink:to="CommonStockMember" xlink:title="presentation: ClassOfStockDomain to CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementClassOfStockAxis" xlink:to="ClassOfStockDomain" xlink:title="presentation: StatementClassOfStockAxis to ClassOfStockDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementClassOfStockAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementClassOfStockAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="presentation: ClassOfStockLineItems to PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockCapitalSharesReservedForFutureIssuance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:label="StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:title="StockIssuedDuringPeriodSharesShareBasedCompensationGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:title="ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="presentation: ClassOfStockLineItems to CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ClassOfStockLineItems" xlink:title="presentation: ScheduleOfStockByClassTable to ClassOfStockLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ScheduleOfStockByClassTable" xlink:title="presentation: StockholdersEquityNoteAbstract to ScheduleOfStockByClassTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/StockholdersEquityShareRepurchaseProgramDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="ClassOfTreasuryStockTable" xlink:title="ClassOfTreasuryStockTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfTreasuryStockTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: ClassOfTreasuryStockTable to SubsequentEventTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems" xlink:label="EquityClassOfTreasuryStockLineItems" xlink:title="EquityClassOfTreasuryStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="ClassOfStockDisclosuresAbstract" xlink:title="ClassOfStockDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="StockRepurchaseProgramAuthorizedAmount1" xlink:title="StockRepurchaseProgramAuthorizedAmount1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDisclosuresAbstract" xlink:to="StockRepurchaseProgramAuthorizedAmount1" xlink:title="presentation: ClassOfStockDisclosuresAbstract to StockRepurchaseProgramAuthorizedAmount1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="StockRepurchasedDuringPeriodShares" xlink:title="StockRepurchasedDuringPeriodShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDisclosuresAbstract" xlink:to="StockRepurchasedDuringPeriodShares" xlink:title="presentation: ClassOfStockDisclosuresAbstract to StockRepurchasedDuringPeriodShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="PaymentsForRepurchaseOfCommonStock" xlink:title="PaymentsForRepurchaseOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockDisclosuresAbstract" xlink:to="PaymentsForRepurchaseOfCommonStock" xlink:title="presentation: ClassOfStockDisclosuresAbstract to PaymentsForRepurchaseOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityClassOfTreasuryStockLineItems" xlink:to="ClassOfStockDisclosuresAbstract" xlink:title="presentation: EquityClassOfTreasuryStockLineItems to ClassOfStockDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfTreasuryStockTable" xlink:to="EquityClassOfTreasuryStockLineItems" xlink:title="presentation: ClassOfTreasuryStockTable to EquityClassOfTreasuryStockLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ClassOfTreasuryStockTable" xlink:title="presentation: StockholdersEquityNoteAbstract to ClassOfTreasuryStockTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/StockholdersEquityStockPlansDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_StockOptionPlan1989Member" xlink:label="StockOptionPlan1989Member" xlink:title="StockOptionPlan1989Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="StockOptionPlan1989Member" xlink:title="presentation: PlanNameDomain to StockOptionPlan1989Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EquityIncentivePlan2011Member" xlink:label="EquityIncentivePlan2011Member" xlink:title="EquityIncentivePlan2011Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlan2011Member" xlink:title="presentation: PlanNameDomain to EquityIncentivePlan2011Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NonemployeeDirectorsStockOptionPlan2002Member" xlink:label="NonemployeeDirectorsStockOptionPlan2002Member" xlink:title="NonemployeeDirectorsStockOptionPlan2002Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="NonemployeeDirectorsStockOptionPlan2002Member" xlink:title="presentation: PlanNameDomain to NonemployeeDirectorsStockOptionPlan2002Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EmployeeStockPurchasePlanMember" xlink:label="EmployeeStockPurchasePlanMember" xlink:title="EmployeeStockPurchasePlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EmployeeStockPurchasePlanMember" xlink:title="presentation: PlanNameDomain to EmployeeStockPurchasePlanMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="StockOptionMember" xlink:title="StockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="StockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="ShareBasedCompensationAwardTrancheOneMember" xlink:title="ShareBasedCompensationAwardTrancheOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VestingDomain" xlink:to="ShareBasedCompensationAwardTrancheOneMember" xlink:title="presentation: VestingDomain to ShareBasedCompensationAwardTrancheOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VestingAxis" xlink:to="VestingDomain" xlink:title="presentation: VestingAxis to VestingDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="VestingAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to VestingAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:title="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="presentation: ShareBasedArrangementsToObtainGoodsAndServicesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="presentation: ShareBasedArrangementsToObtainGoodsAndServicesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="presentation: ShareBasedArrangementsToObtainGoodsAndServicesAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="presentation: ShareBasedArrangementsToObtainGoodsAndServicesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:title="presentation: ShareBasedArrangementsToObtainGoodsAndServicesAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="presentation: ShareBasedArrangementsToObtainGoodsAndServicesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="presentation: ShareBasedArrangementsToObtainGoodsAndServicesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:title="presentation: ShareBasedArrangementsToObtainGoodsAndServicesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="presentation: ShareBasedArrangementsToObtainGoodsAndServicesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:label="NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:title="NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:title="presentation: ShareBasedArrangementsToObtainGoodsAndServicesAbstract to NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:label="PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:title="PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:title="presentation: ShareBasedArrangementsToObtainGoodsAndServicesAbstract to PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:label="PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:title="PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" xlink:title="presentation: ShareBasedArrangementsToObtainGoodsAndServicesAbstract to PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable" xlink:label="NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable" xlink:title="NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable" xlink:title="presentation: ShareBasedArrangementsToObtainGoodsAndServicesAbstract to NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="presentation: ShareBasedArrangementsToObtainGoodsAndServicesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:title="presentation: ShareBasedArrangementsToObtainGoodsAndServicesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:title="presentation: ShareBasedArrangementsToObtainGoodsAndServicesAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod" xlink:title="presentation: ShareBasedArrangementsToObtainGoodsAndServicesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:title="presentation: ShareBasedArrangementsToObtainGoodsAndServicesAbstract to StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:label="EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:title="EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" xlink:title="presentation: ShareBasedArrangementsToObtainGoodsAndServicesAbstract to EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedArrangementsToObtainGoodsAndServicesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: StockholdersEquityNoteAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="StockOptionMember" xlink:title="StockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="StockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to ProceedsFromStockOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: StockholdersEquityNoteAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="presentation: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: StockholdersEquityNoteAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/StockholdersEquityStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="presentation: ConsolidatedEntitiesDomain to AkceaTherapeuticsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="presentation: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to ConsolidatedEntitiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="CostOfSalesMember" xlink:title="CostOfSalesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="CostOfSalesMember" xlink:title="presentation: IncomeStatementLocationDomain to CostOfSalesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchDevelopmentAndPatentMember" xlink:label="ResearchDevelopmentAndPatentMember" xlink:title="ResearchDevelopmentAndPatentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchDevelopmentAndPatentMember" xlink:title="presentation: IncomeStatementLocationDomain to ResearchDevelopmentAndPatentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="SellingGeneralAndAdministrativeExpensesMember" xlink:title="SellingGeneralAndAdministrativeExpensesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="SellingGeneralAndAdministrativeExpensesMember" xlink:title="presentation: IncomeStatementLocationDomain to SellingGeneralAndAdministrativeExpensesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: ShareBasedCompensationAbstract to AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfExecutiveOfficersTerminatingEmployment" xlink:label="NumberOfExecutiveOfficersTerminatingEmployment" xlink:title="NumberOfExecutiveOfficersTerminatingEmployment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="NumberOfExecutiveOfficersTerminatingEmployment" xlink:title="presentation: ShareBasedCompensationAbstract to NumberOfExecutiveOfficersTerminatingEmployment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="presentation: EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to ShareBasedCompensationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="presentation: ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="presentation: StockholdersEquityNoteAbstract to ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" xlink:title="StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="presentation: ConsolidatedEntitiesDomain to AkceaTherapeuticsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="presentation: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ConsolidatedEntitiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_BoardOfDirectorStockOptionMember" xlink:label="BoardOfDirectorStockOptionMember" xlink:title="BoardOfDirectorStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="BoardOfDirectorStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to BoardOfDirectorStockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="EmployeeStockMember" xlink:title="EmployeeStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: StockholdersEquityNoteAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="CurrentFederalTaxExpenseBenefit" xlink:title="CurrentFederalTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="CurrentFederalTaxExpenseBenefit" xlink:title="presentation: CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract to CurrentFederalTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="CurrentStateAndLocalTaxExpenseBenefit" xlink:title="CurrentStateAndLocalTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="CurrentStateAndLocalTaxExpenseBenefit" xlink:title="presentation: CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract to CurrentStateAndLocalTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="CurrentForeignTaxExpenseBenefit" xlink:title="CurrentForeignTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="CurrentForeignTaxExpenseBenefit" xlink:title="presentation: CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract to CurrentForeignTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="CurrentIncomeTaxExpenseBenefit" xlink:title="CurrentIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="CurrentIncomeTaxExpenseBenefit" xlink:title="presentation: CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract to CurrentIncomeTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="DeferredFederalIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="presentation: DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract to DeferredFederalIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="presentation: DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract to DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="DeferredIncomeTaxExpenseBenefit" xlink:title="DeferredIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="DeferredIncomeTaxExpenseBenefit" xlink:title="presentation: DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract to DeferredIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:title="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:title="IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:title="IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount" xlink:label="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount" xlink:title="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount" xlink:label="EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount" xlink:title="EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount" xlink:label="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount" xlink:title="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCredits" xlink:label="IncomeTaxReconciliationTaxCredits" xlink:title="IncomeTaxReconciliationTaxCredits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxReconciliationTaxCredits" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeTaxReconciliationTaxCredits" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:label="IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:title="IncomeTaxReconciliationPriorYearIncomeTaxes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeTaxReconciliationPriorYearIncomeTaxes" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:title="IncomeTaxReconciliationChangeInEnactedTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeTaxReconciliationChangeInEnactedTaxRate" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:label="IncomeTaxReconciliationNondeductibleExpenseOther" xlink:title="IncomeTaxReconciliationNondeductibleExpenseOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxReconciliationNondeductibleExpenseOther" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeTaxReconciliationNondeductibleExpenseOther" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount" xlink:label="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount" xlink:title="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount" xlink:label="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount" xlink:title="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="IncomeTaxReconciliationOtherAdjustments" xlink:title="IncomeTaxReconciliationOtherAdjustments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxReconciliationOtherAdjustments" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeTaxReconciliationOtherAdjustments" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract to IncomeTaxExpenseBenefit" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:title="EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent" xlink:label="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent" xlink:title="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent" xlink:label="EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent" xlink:title="EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent" xlink:label="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent" xlink:title="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:title="EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationTaxCredits" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:title="EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent" xlink:label="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent" xlink:title="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent" xlink:label="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent" xlink:title="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="EffectiveIncomeTaxRateContinuingOperations" xlink:title="presentation: EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract to EffectiveIncomeTaxRateContinuingOperations" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="DeferredTaxAssetsGrossAbstract" xlink:title="DeferredTaxAssetsGrossAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsOperatingLossCarryforwards" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="DeferredTaxAssetsDeferredIncome" xlink:title="DeferredTaxAssetsDeferredIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsDeferredIncome" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxAssetsDeferredIncome" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:title="DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxAssetsGoodwillAndIntangibleAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="DeferredTaxAssetsOther" xlink:title="DeferredTaxAssetsOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsOther" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxAssetsOther" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsGross" xlink:title="presentation: DeferredTaxAssetsGrossAbstract to DeferredTaxAssetsGross" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsGrossAbstract" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to DeferredTaxAssetsGrossAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="DeferredTaxLiabilitiesAbstract" xlink:title="DeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesFinancingArrangements" xlink:label="DeferredTaxLiabilitiesFinancingArrangements" xlink:title="DeferredTaxLiabilitiesFinancingArrangements" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxLiabilitiesAbstract" xlink:to="DeferredTaxLiabilitiesFinancingArrangements" xlink:title="presentation: DeferredTaxLiabilitiesAbstract to DeferredTaxLiabilitiesFinancingArrangements" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:title="DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxLiabilitiesAbstract" xlink:to="DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:title="presentation: DeferredTaxLiabilitiesAbstract to DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="DeferredTaxLiabilitiesOther" xlink:title="DeferredTaxLiabilitiesOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxLiabilitiesAbstract" xlink:to="DeferredTaxLiabilitiesOther" xlink:title="presentation: DeferredTaxLiabilitiesAbstract to DeferredTaxLiabilitiesOther" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxLiabilitiesAbstract" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to DeferredTaxLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:label="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:title="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsValuationAllowance" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to DeferredTaxAssetsValuationAllowance" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" xlink:title="DeferredTaxAssetsLiabilitiesNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsLiabilitiesNet" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to DeferredTaxAssetsLiabilitiesNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:label="ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:title="ValuationAllowancesAndReservesPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to ValuationAllowancesAndReservesPeriodIncreaseDecrease" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IncreaseDecreaseInStateTaxLiability" xlink:label="IncreaseDecreaseInStateTaxLiability" xlink:title="IncreaseDecreaseInStateTaxLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="IncreaseDecreaseInStateTaxLiability" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract to IncreaseDecreaseInStateTaxLiability" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxesTaxCreditCarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="IncomeTaxAuthorityNameAxis" xlink:title="IncomeTaxAuthorityNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="IncomeTaxAuthorityNameDomain" xlink:title="IncomeTaxAuthorityNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="InternalRevenueServiceIRSMember" xlink:title="InternalRevenueServiceIRSMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAuthorityNameDomain" xlink:to="InternalRevenueServiceIRSMember" xlink:title="presentation: IncomeTaxAuthorityNameDomain to InternalRevenueServiceIRSMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:label="CaliforniaFranchiseTaxBoardMember" xlink:title="CaliforniaFranchiseTaxBoardMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAuthorityNameDomain" xlink:to="CaliforniaFranchiseTaxBoardMember" xlink:title="presentation: IncomeTaxAuthorityNameDomain to CaliforniaFranchiseTaxBoardMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAuthorityNameAxis" xlink:to="IncomeTaxAuthorityNameDomain" xlink:title="presentation: IncomeTaxAuthorityNameAxis to IncomeTaxAuthorityNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="IncomeTaxAuthorityNameAxis" xlink:title="presentation: OperatingLossCarryforwardsTable to IncomeTaxAuthorityNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwards" xlink:title="presentation: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="OperatingLossCarryforwardsLineItems" xlink:title="presentation: OperatingLossCarryforwardsTable to OperatingLossCarryforwardsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="OperatingLossCarryforwardsTable" xlink:title="presentation: IncomeTaxDisclosureAbstract to OperatingLossCarryforwardsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="TaxCreditCarryforwardTable" xlink:title="TaxCreditCarryforwardTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="ResearchMember" xlink:title="ResearchMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardNameDomain" xlink:to="ResearchMember" xlink:title="presentation: TaxCreditCarryforwardNameDomain to ResearchMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="presentation: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardTable" xlink:to="TaxCreditCarryforwardAxis" xlink:title="presentation: TaxCreditCarryforwardTable to TaxCreditCarryforwardAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardTable" xlink:to="IncomeTaxAuthorityNameAxis" xlink:title="presentation: TaxCreditCarryforwardTable to IncomeTaxAuthorityNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="TaxCreditCarryforwardLineItems" xlink:title="TaxCreditCarryforwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="TaxCreditCarryforwardAmount" xlink:title="TaxCreditCarryforwardAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardLineItems" xlink:to="TaxCreditCarryforwardAmount" xlink:title="presentation: TaxCreditCarryforwardLineItems to TaxCreditCarryforwardAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardTable" xlink:to="TaxCreditCarryforwardLineItems" xlink:title="presentation: TaxCreditCarryforwardTable to TaxCreditCarryforwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="TaxCreditCarryforwardTable" xlink:title="presentation: IncomeTaxDisclosureAbstract to TaxCreditCarryforwardTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxesTaxActDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="presentation: IncomeTaxDisclosureAbstract to EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:title="ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="UnrecognizedTaxBenefits" xlink:title="presentation: ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward to UnrecognizedTaxBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:title="UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:title="presentation: ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward to UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:title="UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:title="presentation: ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward to UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:title="UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:title="presentation: ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward to UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits_2" xlink:title="UnrecognizedTaxBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="UnrecognizedTaxBenefits_2" xlink:title="presentation: ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward to UnrecognizedTaxBenefits" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:title="presentation: IncomeTaxDisclosureAbstract to ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:title="UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:title="presentation: IncomeTaxDisclosureAbstract to UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:title="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:title="presentation: IncomeTaxDisclosureAbstract to UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails">
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:title="CollaborativeArrangementsAndLicensingAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsBiogenMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsBiogenMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsBiogenMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsBiogenMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsBiogenMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementsAndLicensingAgreementsBiogenMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementsAndLicensingAgreementsBiogenMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SPINRAZARoyaltiesMember" xlink:label="SPINRAZARoyaltiesMember" xlink:title="SPINRAZARoyaltiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="SPINRAZARoyaltiesMember" xlink:title="presentation: ProductsAndServicesDomain to SPINRAZARoyaltiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LicensingAndOtherRoyaltiesMember" xlink:label="LicensingAndOtherRoyaltiesMember" xlink:title="LicensingAndOtherRoyaltiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="LicensingAndOtherRoyaltiesMember" xlink:title="presentation: ProductsAndServicesDomain to LicensingAndOtherRoyaltiesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:label="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="presentation: ProductsAndServicesDomain to ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MedicinesForAmyotrophicLateralSclerosisMember" xlink:label="MedicinesForAmyotrophicLateralSclerosisMember" xlink:title="MedicinesForAmyotrophicLateralSclerosisMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="MedicinesForAmyotrophicLateralSclerosisMember" xlink:title="presentation: ProductsAndServicesDomain to MedicinesForAmyotrophicLateralSclerosisMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MedicinesForUndisclosedTargetsMember" xlink:label="MedicinesForUndisclosedTargetsMember" xlink:title="MedicinesForUndisclosedTargetsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="MedicinesForUndisclosedTargetsMember" xlink:title="presentation: ProductsAndServicesDomain to MedicinesForUndisclosedTargetsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AntisenseMoleculeMember" xlink:label="AntisenseMoleculeMember" xlink:title="AntisenseMoleculeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="AntisenseMoleculeMember" xlink:title="presentation: ProductsAndServicesDomain to AntisenseMoleculeMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IONISC9Member" xlink:label="IONISC9Member" xlink:title="IONISC9Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="IONISC9Member" xlink:title="presentation: ProductsAndServicesDomain to IONISC9Member" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_TofersenMember" xlink:label="TofersenMember" xlink:title="TofersenMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="TofersenMember" xlink:title="presentation: ProductsAndServicesDomain to TofersenMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ION859Member" xlink:label="ION859Member" xlink:title="ION859Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ION859Member" xlink:title="presentation: ProductsAndServicesDomain to ION859Member" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IONISMAPTMember" xlink:label="IONISMAPTMember" xlink:title="IONISMAPTMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="IONISMAPTMember" xlink:title="presentation: ProductsAndServicesDomain to IONISMAPTMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ION581Member" xlink:label="ION581Member" xlink:title="ION581Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ION581Member" xlink:title="presentation: ProductsAndServicesDomain to ION581Member" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="presentation: ProductOrServiceAxis to ProductsAndServicesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ProductOrServiceAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="presentation: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByBenchmarkAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="presentation: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="presentation: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByTypeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAbstract" xlink:label="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="CollaborativeArrangementAndLicensingAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfDrugsBeingDeveloped" xlink:label="NumberOfDrugsBeingDeveloped" xlink:title="NumberOfDrugsBeingDeveloped" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="NumberOfDrugsBeingDeveloped" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to NumberOfDrugsBeingDeveloped" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CumulativePaymentsReceived" xlink:label="CumulativePaymentsReceived" xlink:title="CumulativePaymentsReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="CumulativePaymentsReceived" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to CumulativePaymentsReceived" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceivedIncludingPurchaseOfStock" xlink:label="UpfrontPaymentReceivedIncludingPurchaseOfStock" xlink:title="UpfrontPaymentReceivedIncludingPurchaseOfStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="UpfrontPaymentReceivedIncludingPurchaseOfStock" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to UpfrontPaymentReceivedIncludingPurchaseOfStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfCountriesWhereDrugIsApprovedForUse" xlink:label="NumberOfCountriesWhereDrugIsApprovedForUse" xlink:title="NumberOfCountriesWhereDrugIsApprovedForUse" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="NumberOfCountriesWhereDrugIsApprovedForUse" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to NumberOfCountriesWhereDrugIsApprovedForUse" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="CumulativeRevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="CumulativeRevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="CumulativeRevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to CumulativeRevenueFromContractWithCustomerExcludingAssessedTax" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:label="RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:title="RoyaltyPercentageReceivedOnNetSalesOfDrug" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RoyaltyPercentageReceivedOnNetSalesOfDrug" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceived" xlink:label="UpfrontPaymentReceived" xlink:title="UpfrontPaymentReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="UpfrontPaymentReceived" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to UpfrontPaymentReceived" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForCommercializationMilestones" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForSalesMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForSalesMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForSalesMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForSalesMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForSalesMilestones" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NextPotentialPayment" xlink:label="NextPotentialPayment" xlink:title="NextPotentialPayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="NextPotentialPayment" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to NextPotentialPayment" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerTransactionPrice" xlink:label="RevenueFromContractWithCustomerTransactionPrice" xlink:title="RevenueFromContractWithCustomerTransactionPrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerTransactionPrice" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerTransactionPrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_TermOfCollaborationAgreement" xlink:label="TermOfCollaborationAgreement" xlink:title="TermOfCollaborationAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="TermOfCollaborationAgreement" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to TermOfCollaborationAgreement" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ProceedsFromIssuanceOfCommonStock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PercentageCashPremiumPaidOnSharesPurchased" xlink:label="PercentageCashPremiumPaidOnSharesPurchased" xlink:title="PercentageCashPremiumPaidOnSharesPurchased" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="PercentageCashPremiumPaidOnSharesPurchased" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to PercentageCashPremiumPaidOnSharesPurchased" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments" xlink:label="MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments" xlink:title="MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfTargetsAdvanced" xlink:label="NumberOfTargetsAdvanced" xlink:title="NumberOfTargetsAdvanced" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="NumberOfTargetsAdvanced" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to NumberOfTargetsAdvanced" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PremiumPaidOnSharesPurchased" xlink:label="PremiumPaidOnSharesPurchased" xlink:title="PremiumPaidOnSharesPurchased" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="PremiumPaidOnSharesPurchased" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to PremiumPaidOnSharesPurchased" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfMilestonePaymentsAchieved" xlink:label="NumberOfMilestonePaymentsAchieved" xlink:title="NumberOfMilestonePaymentsAchieved" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="NumberOfMilestonePaymentsAchieved" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to NumberOfMilestonePaymentsAchieved" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:label="CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:title="CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:label="PaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:title="PaymentsIncludedInTransactionPriceForPerformanceObligation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="PaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to PaymentsIncludedInTransactionPriceForPerformanceObligation" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfDrugsCurrentlyBeingAdvanced" xlink:label="NumberOfDrugsCurrentlyBeingAdvanced" xlink:title="NumberOfDrugsCurrentlyBeingAdvanced" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="NumberOfDrugsCurrentlyBeingAdvanced" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to NumberOfDrugsCurrentlyBeingAdvanced" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement" xlink:label="NumberOfDrugsLicensedUnderOptionInCollaborationAgreement" xlink:title="NumberOfDrugsLicensedUnderOptionInCollaborationAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="NumberOfDrugsLicensedUnderOptionInCollaborationAgreement" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to NumberOfDrugsLicensedUnderOptionInCollaborationAgreement" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" xlink:label="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" xlink:title="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones" xlink:label="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones" xlink:title="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" xlink:label="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" xlink:title="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfTargetsToBeDevelopedAndCommercialized" xlink:label="NumberOfTargetsToBeDevelopedAndCommercialized" xlink:title="NumberOfTargetsToBeDevelopedAndCommercialized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="NumberOfTargetsToBeDevelopedAndCommercialized" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to NumberOfTargetsToBeDevelopedAndCommercialized" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" xlink:label="NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" xlink:title="NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MilestonePaymentAchieved" xlink:label="MilestonePaymentAchieved" xlink:title="MilestonePaymentAchieved" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MilestonePaymentAchieved" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MilestonePaymentAchieved" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ConcentrationRiskPercentage1" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ConcentrationRiskPercentage1" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="ContractWithCustomerLiability" xlink:title="ContractWithCustomerLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ContractWithCustomerLiability" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ContractWithCustomerLiability" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborativeArrangementAndLicensingAgreementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsAbstract to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails">
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:title="CollaborativeArrangementsAndLicensingAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ION532Member" xlink:label="ION532Member" xlink:title="ION532Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ION532Member" xlink:title="presentation: ProductsAndServicesDomain to ION532Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ION839Member" xlink:label="ION839Member" xlink:title="ION839Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ION839Member" xlink:title="presentation: ProductsAndServicesDomain to ION839Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DanvatirsenMember" xlink:label="DanvatirsenMember" xlink:title="DanvatirsenMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="DanvatirsenMember" xlink:title="presentation: ProductsAndServicesDomain to DanvatirsenMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ION736Member" xlink:label="ION736Member" xlink:title="ION736Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ION736Member" xlink:title="presentation: ProductsAndServicesDomain to ION736Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:label="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="presentation: ProductsAndServicesDomain to ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="presentation: ProductOrServiceAxis to ProductsAndServicesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ProductOrServiceAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="presentation: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByBenchmarkAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="presentation: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="presentation: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAbstract" xlink:label="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="CollaborativeArrangementAndLicensingAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfLicensedDrugs" xlink:label="NumberOfLicensedDrugs" xlink:title="NumberOfLicensedDrugs" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="NumberOfLicensedDrugs" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to NumberOfLicensedDrugs" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceived" xlink:label="UpfrontPaymentReceived" xlink:title="UpfrontPaymentReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="UpfrontPaymentReceived" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to UpfrontPaymentReceived" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:label="MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NextPotentialPayment" xlink:label="NextPotentialPayment" xlink:title="NextPotentialPayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="NextPotentialPayment" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to NextPotentialPayment" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CumulativePaymentsReceived" xlink:label="CumulativePaymentsReceived" xlink:title="CumulativePaymentsReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="CumulativePaymentsReceived" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to CumulativePaymentsReceived" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerTransactionPrice" xlink:label="RevenueFromContractWithCustomerTransactionPrice" xlink:title="RevenueFromContractWithCustomerTransactionPrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerTransactionPrice" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerTransactionPrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:label="CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:title="CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfLicenseFeesEarned" xlink:label="NumberOfLicenseFeesEarned" xlink:title="NumberOfLicenseFeesEarned" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="NumberOfLicenseFeesEarned" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to NumberOfLicenseFeesEarned" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfPerformanceObligationsCompleted" xlink:label="NumberOfPerformanceObligationsCompleted" xlink:title="NumberOfPerformanceObligationsCompleted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="NumberOfPerformanceObligationsCompleted" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to NumberOfPerformanceObligationsCompleted" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfProgramsAdvanced" xlink:label="NumberOfProgramsAdvanced" xlink:title="NumberOfProgramsAdvanced" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="NumberOfProgramsAdvanced" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to NumberOfProgramsAdvanced" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ConcentrationRiskPercentage1" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ConcentrationRiskPercentage1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="ContractWithCustomerLiability" xlink:title="ContractWithCustomerLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ContractWithCustomerLiability" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ContractWithCustomerLiability" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborativeArrangementAndLicensingAgreementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsAbstract to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails">
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:title="CollaborativeArrangementsAndLicensingAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsBayerMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsBayerMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" xlink:label="CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" xlink:title="CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:to="CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsBayerMember to CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementsAndLicensingAgreementsBayerMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementsAndLicensingAgreementsBayerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IONISFXILMember" xlink:label="IONISFXILMember" xlink:title="IONISFXILMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="IONISFXILMember" xlink:title="presentation: ProductsAndServicesDomain to IONISFXILMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:label="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentServicesForIONISFXILMember" xlink:label="ResearchAndDevelopmentServicesForIONISFXILMember" xlink:title="ResearchAndDevelopmentServicesForIONISFXILMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:to="ResearchAndDevelopmentServicesForIONISFXILMember" xlink:title="presentation: ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember to ResearchAndDevelopmentServicesForIONISFXILMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="presentation: ProductsAndServicesDomain to ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="presentation: ProductOrServiceAxis to ProductsAndServicesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ProductOrServiceAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="presentation: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByBenchmarkAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="presentation: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="presentation: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAbstract" xlink:label="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="CollaborativeArrangementAndLicensingAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceived" xlink:label="UpfrontPaymentReceived" xlink:title="UpfrontPaymentReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="UpfrontPaymentReceived" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to UpfrontPaymentReceived" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PaymentReceivedForAdvancingPrograms" xlink:label="PaymentReceivedForAdvancingPrograms" xlink:title="PaymentReceivedForAdvancingPrograms" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="PaymentReceivedForAdvancingPrograms" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to PaymentReceivedForAdvancingPrograms" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForCommercializationMilestones" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement" xlink:label="RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement" xlink:title="RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CumulativePaymentsReceived" xlink:label="CumulativePaymentsReceived" xlink:title="CumulativePaymentsReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="CumulativePaymentsReceived" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to CumulativePaymentsReceived" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NextPotentialMilestonePayment" xlink:label="NextPotentialMilestonePayment" xlink:title="NextPotentialMilestonePayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="NextPotentialMilestonePayment" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to NextPotentialMilestonePayment" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfNewPerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfNewPerformanceObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerNumberOfNewPerformanceObligations" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerNumberOfNewPerformanceObligations" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerTransactionPrice" xlink:label="RevenueFromContractWithCustomerTransactionPrice" xlink:title="RevenueFromContractWithCustomerTransactionPrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerTransactionPrice" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerTransactionPrice" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ConcentrationRiskPercentage1" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ConcentrationRiskPercentage1" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="ContractWithCustomerLiability" xlink:title="ContractWithCustomerLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ContractWithCustomerLiability" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ContractWithCustomerLiability" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborativeArrangementAndLicensingAgreementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsAbstract to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails">
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:title="CollaborativeArrangementsAndLicensingAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:label="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="presentation: ProductsAndServicesDomain to ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="presentation: ProductOrServiceAxis to ProductsAndServicesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ProductOrServiceAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="presentation: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByBenchmarkAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="presentation: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="presentation: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAbstract" xlink:label="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="CollaborativeArrangementAndLicensingAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceived" xlink:label="UpfrontPaymentReceived" xlink:title="UpfrontPaymentReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="UpfrontPaymentReceived" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to UpfrontPaymentReceived" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfDrugsBeingDeveloped" xlink:label="NumberOfDrugsBeingDeveloped" xlink:title="NumberOfDrugsBeingDeveloped" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="NumberOfDrugsBeingDeveloped" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to NumberOfDrugsBeingDeveloped" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForCommercializationMilestones" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CumulativePaymentsReceived" xlink:label="CumulativePaymentsReceived" xlink:title="CumulativePaymentsReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="CumulativePaymentsReceived" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to CumulativePaymentsReceived" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NextPotentialMilestonePayment" xlink:label="NextPotentialMilestonePayment" xlink:title="NextPotentialMilestonePayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="NextPotentialMilestonePayment" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to NextPotentialMilestonePayment" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ConcentrationRiskPercentage1" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ConcentrationRiskPercentage1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="ContractWithCustomerLiability" xlink:title="ContractWithCustomerLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ContractWithCustomerLiability" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ContractWithCustomerLiability" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborativeArrangementAndLicensingAgreementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsAbstract to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails">
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:title="CollaborativeArrangementsAndLicensingAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LicensingAndOtherRoyaltiesMember" xlink:label="LicensingAndOtherRoyaltiesMember" xlink:title="LicensingAndOtherRoyaltiesMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IONISJBI125Member" xlink:label="IONISJBI125Member" xlink:title="IONISJBI125Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherRoyaltiesMember" xlink:to="IONISJBI125Member" xlink:title="presentation: LicensingAndOtherRoyaltiesMember to IONISJBI125Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IONISJBI225Member" xlink:label="IONISJBI225Member" xlink:title="IONISJBI225Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherRoyaltiesMember" xlink:to="IONISJBI225Member" xlink:title="presentation: LicensingAndOtherRoyaltiesMember to IONISJBI225Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="LicensingAndOtherRoyaltiesMember" xlink:title="presentation: ProductsAndServicesDomain to LicensingAndOtherRoyaltiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:label="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="presentation: ProductsAndServicesDomain to ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="presentation: ProductOrServiceAxis to ProductsAndServicesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ProductOrServiceAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="presentation: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByBenchmarkAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="presentation: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="presentation: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAbstract" xlink:label="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="CollaborativeArrangementAndLicensingAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" xlink:label="NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" xlink:title="NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceived" xlink:label="UpfrontPaymentReceived" xlink:title="UpfrontPaymentReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="UpfrontPaymentReceived" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to UpfrontPaymentReceived" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:label="MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForCommercializationMilestones" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CumulativePaymentsReceived" xlink:label="CumulativePaymentsReceived" xlink:title="CumulativePaymentsReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="CumulativePaymentsReceived" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to CumulativePaymentsReceived" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NextPotentialMilestonePayment" xlink:label="NextPotentialMilestonePayment" xlink:title="NextPotentialMilestonePayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="NextPotentialMilestonePayment" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to NextPotentialMilestonePayment" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerTransactionPrice" xlink:label="RevenueFromContractWithCustomerTransactionPrice" xlink:title="RevenueFromContractWithCustomerTransactionPrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerTransactionPrice" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerTransactionPrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ConcentrationRiskPercentage1" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ConcentrationRiskPercentage1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="ContractWithCustomerLiability" xlink:title="ContractWithCustomerLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ContractWithCustomerLiability" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ContractWithCustomerLiability" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborativeArrangementAndLicensingAgreementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsAbstract to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails">
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:title="CollaborativeArrangementsAndLicensingAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember" xlink:label="CollaborativeArrangementsAndLicensingAgreementsRocheMember" xlink:title="CollaborativeArrangementsAndLicensingAgreementsRocheMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsRocheMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsRocheMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsRocheMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsRocheMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementsAndLicensingAgreementsRocheMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementsAndLicensingAgreementsRocheMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:label="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="presentation: ProductsAndServicesDomain to ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="presentation: ProductOrServiceAxis to ProductsAndServicesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ProductOrServiceAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="presentation: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByBenchmarkAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="presentation: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="presentation: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAbstract" xlink:label="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="CollaborativeArrangementAndLicensingAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceived" xlink:label="UpfrontPaymentReceived" xlink:title="UpfrontPaymentReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="UpfrontPaymentReceived" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to UpfrontPaymentReceived" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MilestonePaymentsReceived" xlink:label="MilestonePaymentsReceived" xlink:title="MilestonePaymentsReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MilestonePaymentsReceived" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MilestonePaymentsReceived" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForCommercializationMilestones" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped" xlink:label="MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped" xlink:title="MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CumulativePaymentsReceived" xlink:label="CumulativePaymentsReceived" xlink:title="CumulativePaymentsReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="CumulativePaymentsReceived" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to CumulativePaymentsReceived" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NextPotentialMilestonePayment" xlink:label="NextPotentialMilestonePayment" xlink:title="NextPotentialMilestonePayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="NextPotentialMilestonePayment" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to NextPotentialMilestonePayment" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerTransactionPrice" xlink:label="RevenueFromContractWithCustomerTransactionPrice" xlink:title="RevenueFromContractWithCustomerTransactionPrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerTransactionPrice" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerTransactionPrice" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:label="RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:title="RoyaltyPercentageReceivedOnNetSalesOfDrug" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RoyaltyPercentageReceivedOnNetSalesOfDrug" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ConcentrationRiskPercentage1" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ConcentrationRiskPercentage1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="ContractWithCustomerLiability" xlink:title="ContractWithCustomerLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ContractWithCustomerLiability" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ContractWithCustomerLiability" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborativeArrangementAndLicensingAgreementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsAbstract to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails">
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:title="CollaborativeArrangementsAndLicensingAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="presentation: ConsolidatedEntitiesDomain to AkceaTherapeuticsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="presentation: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConsolidatedEntitiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember" xlink:label="LicenseMember" xlink:title="LicenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="LicenseMember" xlink:title="presentation: ProductsAndServicesDomain to LicenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AKCEAAPOALMember" xlink:label="AKCEAAPOALMember" xlink:title="AKCEAAPOALMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember" xlink:label="ResearchAndDevelopmentServicesForAKCEAAPOALMember" xlink:title="ResearchAndDevelopmentServicesForAKCEAAPOALMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AKCEAAPOALMember" xlink:to="ResearchAndDevelopmentServicesForAKCEAAPOALMember" xlink:title="presentation: AKCEAAPOALMember to ResearchAndDevelopmentServicesForAKCEAAPOALMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DeliveryOfAKCEAAPOALMember" xlink:label="DeliveryOfAKCEAAPOALMember" xlink:title="DeliveryOfAKCEAAPOALMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AKCEAAPOALMember" xlink:to="DeliveryOfAKCEAAPOALMember" xlink:title="presentation: AKCEAAPOALMember to DeliveryOfAKCEAAPOALMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="AKCEAAPOALMember" xlink:title="presentation: ProductsAndServicesDomain to AKCEAAPOALMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AKCEAAPOCIIILMember" xlink:label="AKCEAAPOCIIILMember" xlink:title="AKCEAAPOCIIILMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember" xlink:label="ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember" xlink:title="ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AKCEAAPOCIIILMember" xlink:to="ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember" xlink:title="presentation: AKCEAAPOCIIILMember to ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DeliveryOfAKCEAAPOCIIILMember" xlink:label="DeliveryOfAKCEAAPOCIIILMember" xlink:title="DeliveryOfAKCEAAPOCIIILMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AKCEAAPOCIIILMember" xlink:to="DeliveryOfAKCEAAPOCIIILMember" xlink:title="presentation: AKCEAAPOCIIILMember to DeliveryOfAKCEAAPOCIIILMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="AKCEAAPOCIIILMember" xlink:title="presentation: ProductsAndServicesDomain to AKCEAAPOCIIILMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:label="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="presentation: ProductsAndServicesDomain to ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="presentation: ProductOrServiceAxis to ProductsAndServicesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ProductOrServiceAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ProductOrServiceAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="presentation: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByBenchmarkAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="presentation: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="presentation: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByTypeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAbstract" xlink:label="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="CollaborativeArrangementAndLicensingAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceived" xlink:label="UpfrontPaymentReceived" xlink:title="UpfrontPaymentReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="UpfrontPaymentReceived" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to UpfrontPaymentReceived" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PortionOfUpfrontPaymentRetained" xlink:label="PortionOfUpfrontPaymentRetained" xlink:title="PortionOfUpfrontPaymentRetained" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="PortionOfUpfrontPaymentRetained" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to PortionOfUpfrontPaymentRetained" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PortionOfUpfrontPaymentPaidAsSublicenseFee" xlink:label="PortionOfUpfrontPaymentPaidAsSublicenseFee" xlink:title="PortionOfUpfrontPaymentPaidAsSublicenseFee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="PortionOfUpfrontPaymentPaidAsSublicenseFee" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to PortionOfUpfrontPaymentPaidAsSublicenseFee" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SublicenseFeePaidForLicenseOfDrug" xlink:label="SublicenseFeePaidForLicenseOfDrug" xlink:title="SublicenseFeePaidForLicenseOfDrug" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="SublicenseFeePaidForLicenseOfDrug" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to SublicenseFeePaidForLicenseOfDrug" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ReceiptOfSharesInSubsidiary" xlink:label="ReceiptOfSharesInSubsidiary" xlink:title="ReceiptOfSharesInSubsidiary" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ReceiptOfSharesInSubsidiary" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ReceiptOfSharesInSubsidiary" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForMilestones" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForCommercializationMilestones" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RoyaltyPercentageReceivedOnSalesOfDrug" xlink:label="RoyaltyPercentageReceivedOnSalesOfDrug" xlink:title="RoyaltyPercentageReceivedOnSalesOfDrug" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RoyaltyPercentageReceivedOnSalesOfDrug" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RoyaltyPercentageReceivedOnSalesOfDrug" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee" xlink:label="PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee" xlink:title="PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to StockIssuedDuringPeriodSharesNewIssues" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid" xlink:label="ProceedsFromSaleOfCommonStockIncludingPremiumPaid" xlink:title="ProceedsFromSaleOfCommonStockIncludingPremiumPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ProceedsFromSaleOfCommonStockIncludingPremiumPaid" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ProceedsFromSaleOfCommonStockIncludingPremiumPaid" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AdditionalAmountOfCommonStockRequiredToBePurchased" xlink:label="AdditionalAmountOfCommonStockRequiredToBePurchased" xlink:title="AdditionalAmountOfCommonStockRequiredToBePurchased" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="AdditionalAmountOfCommonStockRequiredToBePurchased" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to AdditionalAmountOfCommonStockRequiredToBePurchased" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="ProceedsFromIssuanceOfPrivatePlacement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ProceedsFromIssuanceOfPrivatePlacement" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerTransactionPrice" xlink:label="RevenueFromContractWithCustomerTransactionPrice" xlink:title="RevenueFromContractWithCustomerTransactionPrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerTransactionPrice" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerTransactionPrice" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PremiumReceivedOnSharesIssued" xlink:label="PremiumReceivedOnSharesIssued" xlink:title="PremiumReceivedOnSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="PremiumReceivedOnSharesIssued" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to PremiumReceivedOnSharesIssued" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture" xlink:label="PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture" xlink:title="PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ConcentrationRiskPercentage1" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ConcentrationRiskPercentage1" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="ContractWithCustomerLiability" xlink:title="ContractWithCustomerLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ContractWithCustomerLiability" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ContractWithCustomerLiability" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborativeArrangementAndLicensingAgreementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsAbstract to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails">
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:title="CollaborativeArrangementsAndLicensingAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="presentation: ConsolidatedEntitiesDomain to AkceaTherapeuticsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="presentation: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConsolidatedEntitiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AKCEAANGPTL3LMember" xlink:label="AKCEAANGPTL3LMember" xlink:title="AKCEAANGPTL3LMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="AKCEAANGPTL3LMember" xlink:title="presentation: ProductsAndServicesDomain to AKCEAANGPTL3LMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentServicesForMember" xlink:label="ResearchAndDevelopmentServicesForMember" xlink:title="ResearchAndDevelopmentServicesForMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentServicesForMember" xlink:title="presentation: ProductsAndServicesDomain to ResearchAndDevelopmentServicesForMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember" xlink:label="AKCEAANGPTL3LActivePharmaceuticalIngredientMember" xlink:title="AKCEAANGPTL3LActivePharmaceuticalIngredientMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="AKCEAANGPTL3LActivePharmaceuticalIngredientMember" xlink:title="presentation: ProductsAndServicesDomain to AKCEAANGPTL3LActivePharmaceuticalIngredientMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:label="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="presentation: ProductsAndServicesDomain to ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="presentation: ProductOrServiceAxis to ProductsAndServicesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ProductOrServiceAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ProductOrServiceAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="presentation: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByBenchmarkAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="presentation: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="presentation: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAbstract" xlink:label="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="CollaborativeArrangementAndLicensingAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_UpfrontPaymentReceived" xlink:label="UpfrontPaymentReceived" xlink:title="UpfrontPaymentReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="UpfrontPaymentReceived" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to UpfrontPaymentReceived" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForDevelopmentMilestones" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForRegulatoryMilestones" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:label="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivableForCommercializationMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivableForCommercializationMilestones" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:label="RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:title="RoyaltyPercentageReceivedOnNetSalesOfDrug" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RoyaltyPercentageReceivedOnNetSalesOfDrug" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RoyaltyPercentageReceivedOnNetSalesOfDrug" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NextPotentialMilestonePayment" xlink:label="NextPotentialMilestonePayment" xlink:title="NextPotentialMilestonePayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="NextPotentialMilestonePayment" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to NextPotentialMilestonePayment" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerTransactionPrice" xlink:label="RevenueFromContractWithCustomerTransactionPrice" xlink:title="RevenueFromContractWithCustomerTransactionPrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerTransactionPrice" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerTransactionPrice" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ReceiptOfSharesInSubsidiary" xlink:label="ReceiptOfSharesInSubsidiary" xlink:title="ReceiptOfSharesInSubsidiary" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ReceiptOfSharesInSubsidiary" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ReceiptOfSharesInSubsidiary" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SublicenseFeePaidForLicenseOfDrug" xlink:label="SublicenseFeePaidForLicenseOfDrug" xlink:title="SublicenseFeePaidForLicenseOfDrug" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="SublicenseFeePaidForLicenseOfDrug" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to SublicenseFeePaidForLicenseOfDrug" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ConcentrationRiskPercentage1" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ConcentrationRiskPercentage1" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="ContractWithCustomerLiability" xlink:title="ContractWithCustomerLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ContractWithCustomerLiability" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ContractWithCustomerLiability" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborativeArrangementAndLicensingAgreementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsAbstract to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails">
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:label="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:title="CollaborativeArrangementsAndLicensingAgreementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="presentation: ConsolidatedEntitiesDomain to AkceaTherapeuticsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="presentation: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConsolidatedEntitiesAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConsolidatedEntitiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" xlink:label="CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" xlink:title="CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to TypeOfArrangementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LicensingAndOtherRoyaltiesMember" xlink:label="LicensingAndOtherRoyaltiesMember" xlink:title="LicensingAndOtherRoyaltiesMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember" xlink:label="LicenseMember" xlink:title="LicenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicensingAndOtherRoyaltiesMember" xlink:to="LicenseMember" xlink:title="presentation: LicensingAndOtherRoyaltiesMember to LicenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="LicensingAndOtherRoyaltiesMember" xlink:title="presentation: ProductsAndServicesDomain to LicensingAndOtherRoyaltiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_WaylivraMember" xlink:label="WaylivraMember" xlink:title="WaylivraMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="WaylivraMember" xlink:title="presentation: ProductsAndServicesDomain to WaylivraMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_TegsediMember" xlink:label="TegsediMember" xlink:title="TegsediMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="TegsediMember" xlink:title="presentation: ProductsAndServicesDomain to TegsediMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="presentation: ProductOrServiceAxis to ProductsAndServicesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ProductOrServiceAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ProductOrServiceAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="presentation: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByBenchmarkAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="presentation: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="presentation: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to ConcentrationRiskByTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CollaborativeArrangementAndLicensingAgreementAbstract" xlink:label="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="CollaborativeArrangementAndLicensingAgreementAbstract" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumPaymentReceivableUnderLicenseAgreement" xlink:label="MaximumPaymentReceivableUnderLicenseAgreement" xlink:title="MaximumPaymentReceivableUnderLicenseAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumPaymentReceivableUnderLicenseAgreement" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumPaymentReceivableUnderLicenseAgreement" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="ProceedsFromLicenseFeesReceived" xlink:title="ProceedsFromLicenseFeesReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ProceedsFromLicenseFeesReceived" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ProceedsFromLicenseFeesReceived" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" xlink:label="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" xlink:title="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner" xlink:label="RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner" xlink:title="RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil" xlink:label="PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil" xlink:title="PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties" xlink:label="RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties" xlink:title="RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:label="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ConcentrationRiskPercentage1" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ConcentrationRiskPercentage1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="ContractWithCustomerLiability" xlink:title="ContractWithCustomerLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:to="ContractWithCustomerLiability" xlink:title="presentation: CollaborativeArrangementAndLicensingAgreementAbstract to ContractWithCustomerLiability" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CollaborativeArrangementAndLicensingAgreementAbstract" xlink:title="presentation: CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to CollaborativeArrangementAndLicensingAgreementAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="presentation: ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable to CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CollaborativeArrangementsAndLicensingAgreementsAbstract" xlink:to="ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:title="presentation: CollaborativeArrangementsAndLicensingAgreementsAbstract to ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" xlink:label="SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" xlink:title="SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="NumberOfReportableSegments" xlink:title="NumberOfReportableSegments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" xlink:to="NumberOfReportableSegments" xlink:title="presentation: SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract to NumberOfReportableSegments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" xlink:title="presentation: SegmentReportingAbstract to SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestTable" xlink:label="MinorityInterestTable" xlink:title="MinorityInterestTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="presentation: OwnershipDomain to AkceaTherapeuticsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="presentation: OwnershipAxis to OwnershipDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestTable" xlink:to="OwnershipAxis" xlink:title="presentation: MinorityInterestTable to OwnershipAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestLineItems" xlink:label="MinorityInterestLineItems" xlink:title="MinorityInterestLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestAbstract" xlink:label="NoncontrollingInterestAbstract" xlink:title="NoncontrollingInterestAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="MinorityInterestOwnershipPercentageByParent" xlink:title="MinorityInterestOwnershipPercentageByParent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncontrollingInterestAbstract" xlink:to="MinorityInterestOwnershipPercentageByParent" xlink:title="presentation: NoncontrollingInterestAbstract to MinorityInterestOwnershipPercentageByParent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestLineItems" xlink:to="NoncontrollingInterestAbstract" xlink:title="presentation: MinorityInterestLineItems to NoncontrollingInterestAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MinorityInterestTable" xlink:to="MinorityInterestLineItems" xlink:title="presentation: MinorityInterestTable to MinorityInterestLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="MinorityInterestTable" xlink:title="presentation: SegmentReportingAbstract to MinorityInterestTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="ConsolidationItemsAxis" xlink:title="ConsolidationItemsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain" xlink:title="ConsolidationItemsDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="OperatingSegmentsMember" xlink:title="OperatingSegmentsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidationItemsDomain" xlink:to="OperatingSegmentsMember" xlink:title="presentation: ConsolidationItemsDomain to OperatingSegmentsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntersegmentEliminationMember" xlink:label="IntersegmentEliminationMember" xlink:title="IntersegmentEliminationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidationItemsDomain" xlink:to="IntersegmentEliminationMember" xlink:title="presentation: ConsolidationItemsDomain to IntersegmentEliminationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidationItemsAxis" xlink:to="ConsolidationItemsDomain" xlink:title="presentation: ConsolidationItemsAxis to ConsolidationItemsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="ConsolidationItemsAxis" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to ConsolidationItemsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IonisCoreMember" xlink:label="IonisCoreMember" xlink:title="IonisCoreMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="IonisCoreMember" xlink:title="presentation: SegmentDomain to IonisCoreMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsMember" xlink:label="AkceaTherapeuticsMember" xlink:title="AkceaTherapeuticsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="AkceaTherapeuticsMember" xlink:title="presentation: SegmentDomain to AkceaTherapeuticsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="presentation: StatementBusinessSegmentsAxis to SegmentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_CommercialMember" xlink:label="CommercialMember" xlink:title="CommercialMember" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SPINRAZARoyaltiesMember" xlink:label="SPINRAZARoyaltiesMember" xlink:title="SPINRAZARoyaltiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommercialMember" xlink:to="SPINRAZARoyaltiesMember" xlink:title="presentation: CommercialMember to SPINRAZARoyaltiesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="ProductMember" xlink:title="ProductMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommercialMember" xlink:to="ProductMember" xlink:title="presentation: CommercialMember to ProductMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_LicensingAndOtherRoyaltiesMember" xlink:label="LicensingAndOtherRoyaltiesMember" xlink:title="LicensingAndOtherRoyaltiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommercialMember" xlink:to="LicensingAndOtherRoyaltiesMember" xlink:title="presentation: CommercialMember to LicensingAndOtherRoyaltiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="CommercialMember" xlink:title="presentation: ProductsAndServicesDomain to CommercialMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:label="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" xlink:title="presentation: ProductsAndServicesDomain to ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="presentation: ProductOrServiceAxis to ProductsAndServicesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="ProductOrServiceAxis" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to ProductOrServiceAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:label="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:title="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="CostsAndExpenses" xlink:title="presentation: SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract to CostsAndExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract to OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="Assets" xlink:title="presentation: SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract to Assets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationLineItems" xlink:to="SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:title="presentation: SegmentReportingInformationLineItems to SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="SegmentReportingInformationLineItems" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to SegmentReportingInformationLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="presentation: SegmentReportingAbstract to ScheduleOfSegmentReportingInformationBySegmentTable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:title="ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="AccountsReceivableMember" xlink:title="AccountsReceivableMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="AccountsReceivableMember" xlink:title="presentation: ConcentrationRiskBenchmarkDomain to AccountsReceivableMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="presentation: ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable to ConcentrationRiskByBenchmarkAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="CreditConcentrationRiskMember" xlink:title="CreditConcentrationRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CreditConcentrationRiskMember" xlink:title="presentation: ConcentrationRiskTypeDomain to CreditConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="presentation: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="presentation: ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable to ConcentrationRiskByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SignificantPartnersMember" xlink:label="SignificantPartnersMember" xlink:title="SignificantPartnersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfMajorCustomerDomain" xlink:to="SignificantPartnersMember" xlink:title="presentation: NameOfMajorCustomerDomain to SignificantPartnersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="presentation: MajorCustomersAxis to NameOfMajorCustomerDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="MajorCustomersAxis" xlink:title="presentation: ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable to MajorCustomersAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="EntityWideRevenueMajorCustomerLineItems" xlink:title="EntityWideRevenueMajorCustomerLineItems" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_SignificantPartnersAbstract" xlink:label="SignificantPartnersAbstract" xlink:title="SignificantPartnersAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantPartnersAbstract" xlink:to="ConcentrationRiskPercentage1" xlink:title="presentation: SignificantPartnersAbstract to ConcentrationRiskPercentage1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_NumberOfSignificantPartners" xlink:label="NumberOfSignificantPartners" xlink:title="NumberOfSignificantPartners" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantPartnersAbstract" xlink:to="NumberOfSignificantPartners" xlink:title="presentation: SignificantPartnersAbstract to NumberOfSignificantPartners" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EntityWideRevenueMajorCustomerLineItems" xlink:to="SignificantPartnersAbstract" xlink:title="presentation: EntityWideRevenueMajorCustomerLineItems to SignificantPartnersAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="EntityWideRevenueMajorCustomerLineItems" xlink:title="presentation: ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable to EntityWideRevenueMajorCustomerLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:title="presentation: SegmentReportingAbstract to ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/EmploymentBenefitsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge" xlink:label="DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge" xlink:title="DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge" xlink:title="presentation: CompensationAndRetirementDisclosureAbstract to DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge" xlink:label="DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge" xlink:title="DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge" xlink:title="presentation: CompensationAndRetirementDisclosureAbstract to DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="DefinedContributionPlanCostRecognized" xlink:title="DefinedContributionPlanCostRecognized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="DefinedContributionPlanCostRecognized" xlink:title="presentation: CompensationAndRetirementDisclosureAbstract to DefinedContributionPlanCostRecognized" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="QuarterlyFinancialInformationDisclosureAbstract" xlink:title="QuarterlyFinancialInformationDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:title="ScheduleOfEarningsPerShareBasicByCommonClassTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_AkceaTherapeuticsIncMember" xlink:label="AkceaTherapeuticsIncMember" xlink:title="AkceaTherapeuticsIncMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipDomain" xlink:to="AkceaTherapeuticsIncMember" xlink:title="presentation: OwnershipDomain to AkceaTherapeuticsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="presentation: OwnershipAxis to OwnershipDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="OwnershipAxis" xlink:title="presentation: ScheduleOfEarningsPerShareBasicByCommonClassTable to OwnershipAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IonisCoreMember" xlink:label="IonisCoreMember" xlink:title="IonisCoreMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="IonisCoreMember" xlink:title="presentation: SegmentDomain to IonisCoreMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="presentation: StatementBusinessSegmentsAxis to SegmentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="presentation: ScheduleOfEarningsPerShareBasicByCommonClassTable to StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="RestrictedStockMember" xlink:title="RestrictedStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfEarningsPerShareBasicByCommonClassTable to AwardTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes0125PercentMember" xlink:label="ConvertibleSeniorNotes0125PercentMember" xlink:title="ConvertibleSeniorNotes0125PercentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes0125PercentMember" xlink:title="presentation: DebtInstrumentNameDomain to ConvertibleSeniorNotes0125PercentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_ConvertibleSeniorNotes1PercentMember" xlink:label="ConvertibleSeniorNotes1PercentMember" xlink:title="ConvertibleSeniorNotes1PercentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="ConvertibleSeniorNotes1PercentMember" xlink:title="presentation: DebtInstrumentNameDomain to ConvertibleSeniorNotes1PercentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: ScheduleOfEarningsPerShareBasicByCommonClassTable to DebtInstrumentAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="EarningsPerShareBasicLineItems" xlink:title="EarningsPerShareBasicLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:label="SelectedQuarterlyFinancialInformationAbstract" xlink:title="SelectedQuarterlyFinancialInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="Revenues" xlink:title="Revenues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SelectedQuarterlyFinancialInformationAbstract" xlink:to="Revenues" xlink:title="presentation: SelectedQuarterlyFinancialInformationAbstract to Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="CostsAndExpenses" xlink:title="CostsAndExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SelectedQuarterlyFinancialInformationAbstract" xlink:to="CostsAndExpenses" xlink:title="presentation: SelectedQuarterlyFinancialInformationAbstract to CostsAndExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SelectedQuarterlyFinancialInformationAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: SelectedQuarterlyFinancialInformationAbstract to OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SelectedQuarterlyFinancialInformationAbstract" xlink:to="ProfitLoss" xlink:title="presentation: SelectedQuarterlyFinancialInformationAbstract to ProfitLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SelectedQuarterlyFinancialInformationAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: SelectedQuarterlyFinancialInformationAbstract to NetIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SelectedQuarterlyFinancialInformationAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: SelectedQuarterlyFinancialInformationAbstract to EarningsPerShareBasic" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SelectedQuarterlyFinancialInformationAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: SelectedQuarterlyFinancialInformationAbstract to EarningsPerShareDiluted" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_WeightedAverageNumberOfSharesOwnedInSubsidiary" xlink:label="WeightedAverageNumberOfSharesOwnedInSubsidiary" xlink:title="WeightedAverageNumberOfSharesOwnedInSubsidiary" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SelectedQuarterlyFinancialInformationAbstract" xlink:to="WeightedAverageNumberOfSharesOwnedInSubsidiary" xlink:title="presentation: SelectedQuarterlyFinancialInformationAbstract to WeightedAverageNumberOfSharesOwnedInSubsidiary" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SelectedQuarterlyFinancialInformationAbstract" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: SelectedQuarterlyFinancialInformationAbstract to DebtInstrumentInterestRateStatedPercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicLineItems" xlink:to="SelectedQuarterlyFinancialInformationAbstract" xlink:title="presentation: EarningsPerShareBasicLineItems to SelectedQuarterlyFinancialInformationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:title="NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="presentation: NetIncomeLossAvailableToCommonStockholdersDilutedAbstract to NetIncomeLossAvailableToCommonStockholdersBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:title="NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:title="presentation: NetIncomeLossAvailableToCommonStockholdersDilutedAbstract to NetIncomeLossAvailableToCommonStockholdersDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:label="DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:title="DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" xlink:title="presentation: NetIncomeLossAvailableToCommonStockholdersDilutedAbstract to DilutiveSecuritiesEffectOnBasicEarningsPerShareOther" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicLineItems" xlink:to="NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:title="presentation: EarningsPerShareBasicLineItems to NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:title="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:title="presentation: WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract to IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ions-20191231.xsd#ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" xlink:label="IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" xlink:title="IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" xlink:title="presentation: WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract to IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:title="IncrementalCommonSharesAttributableToConversionOfDebtSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:title="presentation: WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract to IncrementalCommonSharesAttributableToConversionOfDebtSecurities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:title="presentation: WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract to WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareBasicLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:title="presentation: EarningsPerShareBasicLineItems to WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="EarningsPerShareBasicLineItems" xlink:title="presentation: ScheduleOfEarningsPerShareBasicByCommonClassTable to EarningsPerShareBasicLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="QuarterlyFinancialInformationDisclosureAbstract" xlink:to="ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:title="presentation: QuarterlyFinancialInformationDisclosureAbstract to ScheduleOfEarningsPerShareBasicByCommonClassTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image1.jpg
<TEXT>
begin 644 image1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R ^ # 2(  A$! Q$!_\0
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M\],_[]2?_%T?\+>\0?\ /GIG_?J3_P"+K@**.5!_9>#_ .?:._\ ^%O>(/\
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M2I=/T;4-4#-9VK2JIP6R%&?3)(%3&OC9-*,I.^VK"R+O_"8:]_S_ '_D%/\
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M_P"?[_R"G_Q-4[_1-2TR))+RU:)'. VX,,^G!XK/JIXG%P?+.<D_-L+(W/\
MA,->_P"?[_R"G_Q-'_"8:]_S_?\ D%/_ (FD7PCKCH&6QRK#(/FI_P#%53CT
M749=1:P2U;[4@R8V8+QZY)Q6CGCXVNYZ_P"(-"[_ ,)AKW_/]_Y!3_XFC_A,
M->_Y_O\ R"G_ ,33)O"NM00232V6V.-2S'S4. .3WJC<:9>6MG!=S0E;>?\
MU;[@<_D>/QI3J8Z'Q.:^\-#1_P"$PU[_ )_O_(*?_$T?\)AKW_/]_P"04_\
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M+C_T8U=&&W9[V1?Q)^ACT445UGTH45O^&?"L_B(W4[745EI]FF^YO)ONQ@]
M!W)]/_K9O:EX,@70YM8T'6H=8L[8XN0L#0R19Z$HV3CW_P#KU/,D[&$L13C/
MD;U_KKL<E17?:9X$\/:MI]W>6WC+='91"6Z_XED@\H8/JPST/3/2L^U\'Z?J
M0UN73->^U6VF6@N1+]C9/-."2N&;*XQUYI<\25BZ6N^F^C_R.1HK?T#PS_;F
MD:W?_:_(_LRW$VSR]WF_>XSD8^[[UL_\(1HMIH>EZEJ_BK[!_:$/FQQ_V>\N
M.F1E6[9'84.:6@YXFE"7*WKMLWTOT78X>BNRTKP9I6N^)UTG2_$?VFW^S-.]
MU]A9-K _=V,P)XP<Y[U8M? FCZPMS%H'BR*_OX8C*+9[%X-X'7#,?Z4<\4*6
M+I1=FW]ST]=-/F<+1115G2%%%% &S1117&=QZ_?:+'KOPNTR"/!U"WM!<P+W
M8* & ^H(_'%11?\ (4^'G_7LW_H JE>ZU)X?T[P/J"9*);LLJC^)#L##\OU
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M!17?_P#"H?$'_/YIG_?V3_XBC_A4/B#_ )_-,_[^R?\ Q%',@_M3!_\ /Q'
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MC?\ " Z5_P _%Y_WVO\ \31_P@.E?\_%Y_WVO_Q-']BXOLOO#F1YS17HW_"
MZ5_S\7G_ 'VO_P 31_P@.E?\_%Y_WVO_ ,31_8N+[+[PYD><T5Z-_P (#I7_
M #\7G_?:_P#Q-'_" Z5_S\7G_?:__$T?V+B^R^\.9'G-%>C?\(#I7_/Q>?\
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M]"]I/_@%'_A1_P (EX;_ .A>TG_P"C_PH^LKL']NT_Y&?*M%?57_  B7AO\
MZ%[2?_ */_"C_A$O#?\ T+VD_P#@%'_A1]978/[=I_R,^5:*^JO^$2\-_P#0
MO:3_ . 4?^%'_")>&_\ H7M)_P# */\ PH^LKL']NT_Y&?*M%?57_")>&_\
MH7M)_P# */\ PH_X1+PW_P!"]I/_ (!1_P"%'UE=@_MVG_(SY5HKZJ_X1+PW
M_P!"]I/_ (!1_P"%'_")>&_^A>TG_P  H_\ "CZRNP?V[3_D9\JT5]5?\(EX
M;_Z%[2?_  "C_P */^$2\-_]"]I/_@%'_A1]978/[=I_R,V****Y#YH****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image2.jpg
<TEXT>
begin 644 image2.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M2</*;=9KI65YWD'V=A&;==K$\AMY]1GKS2 ]'I#"@ H * "@ H * "@ H *
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M.1@\T =>JA %'0# _"D M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M@; I''< [VD,* "@ H * "@ QWH * #':@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
( * "@ H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image3.jpg
<TEXT>
begin 644 image3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  X )P# 2(  A$! Q$!_\0
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MPZ%XEG,K2G9;7;GYBW9'/?/8]<]>M>G_ !,_Y)_X@_Z\I/\ T&OCT^9:W/\
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M!XN2&XU$QYE!3&,G(##INX&?>NB4!5 '  P*6BLSY:<W-MG)?%K_ ))SKO\
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LA+F[\[4YT.5%Q@1@_P"X.OXDT44[LZ)YCB9KE<STL    8 X %%%%(XC_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image4.jpg
<TEXT>
begin 644 image4.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %]!$,# 2(  A$! Q$!_\0
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M>*_^>UI_WX%'_"WO%?\ SVM/^_ IV ^@Z*^?/^%O>*_^>UI_WX%'_"WO%?\
MSVM/^_ HL!]!T5\^?\+>\5_\]K3_ +\"C_A;WBO_ )[6G_?@46 ^@Z*^?/\
MA;WBO_GM:?\ ?@4?\+>\5_\ /:T_[\"BP'T'17SY_P +>\5_\]K3_OP*/^%O
M>*_^>UI_WX%%@/H.BOGS_A;WBO\ Y[6G_?@4?\+>\5_\]K3_ +\"BP'T'17S
MY_PM[Q7_ ,]K3_OP*/\ A;WBO_GM:?\ ?@46 ^@Z*^?/^%O>*_\ GM:?]^!1
M_P +>\5_\]K3_OP*+ ?0=%?/G_"WO%?_ #VM/^_ H_X6]XK_ .>UI_WX%%@/
MH.BOGS_A;WBO_GM:?]^!1_PM[Q7_ ,]K3_OP*+ ?0=%?/G_"WO%?_/:T_P"_
M H_X6]XK_P">UI_WX%%@/H.BOGS_ (6]XK_Y[6G_ 'X%'_"WO%?_ #VM/^_
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MUI_WX%%@/H.BOGS_ (6]XK_Y[6G_ 'X%'_"WO%?_ #VM/^_ HL!]!T5\^?\
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M!1_PM[Q7_P ]K3_OP*+ ?0=%?/G_  M[Q7_SVM/^_ H_X6]XK_Y[6G_?@46
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MBO(?^$ \5_\ 0#N_R'^--".;HKI/^$ \5_\ 0#N_R'^-'_" >*_^@'=_D/\
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M[_(?XT <W172?\(!XK_Z =W^0_QH_P"$ \5_] .[_(?XT <W172?\(!XK_Z
M=W^0_P :<GP\\6R$A=$N!C^\57^9H YFBNE/P_\ %BL0=#NN/0 _UI/^$ \5
M_P#0#N_R'^- '-T5TG_" >*_^@'=_D/\:/\ A /%?_0#N_R'^- '-T5TG_"
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MX1%OX=MKBYL]<52^IW$@;*J<^6  ,'/7('?KCBCJ?ASQ7J.B:/IW_"-7<?\
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MC_A /%?_ $ [O\A_C0!S=%=)_P (!XK_ .@'=_D/\:/^$ \5_P#0#N_R'^-
M'-T5TG_" >*_^@'=_D/\:/\ A /%?_0#N_R'^- '-T5TG_" >*_^@'=_D/\
M&C_A /%?_0#N_P A_C0!S=%=)_P@'BO_ * =W^0_QH_X0#Q7_P! .[_(?XT
M<W172?\ " >*_P#H!W?Y#_&E7X?>+&8*-#N<GUP!^IH YJBNF?X>^+(VPVAW
M)XS\I5OY&F_\(!XK_P"@'=_D/\: .;HKI/\ A /%?_0#N_R'^-'_  @'BO\
MZ =W^0_QH YNBND_X0#Q7_T [O\ (?XT?\(!XK_Z =W^0_QH YNBND_X0#Q7
M_P! .[_(?XT?\(!XK_Z =W^0_P : .;HKI/^$ \5_P#0#N_R'^-'_" >*_\
MH!W?Y#_&@#FZ*Z3_ (0#Q7_T [O\A_C1_P (!XK_ .@'=_D/\: .;HKI/^$
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M4+B:-/,9=\287(&<LX'<5YSI^D76A:/XWTV\7$T-O",CHP\SAA[$<UG^"?\
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M:ZD!*INB7.!D\LP'05T+Z]JT<;.WA/4B%&3MGMV/Y"3)KQ'X7 MX]LP.ICE
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MPNW1/^@9J'Y)_P#%5RWQK_Y'*S_[!Z?^C)*\WH&>X_\ "[=$_P"@9J'Y)_\
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MLW/E>2,'(]*SM NH;+Q'IEW</L@@NHI)&P3M4,"3@<]*^F_[!T+_ *!.G?\
M@,G^%']@Z%_T"=._\!D_PHYD%F?,^LWZS>*+[4+*4E7O'FAD (.-Y*GGD=JZ
M6]N/"?BZ;^T[_5)M"U.0#[4OV5KB*5L8W)MY7/?/_P!<^Y_V#H7_ $"=._\
M 9/\*/[!T+_H$Z=_X#)_A1=!9GS]K6LZ19Z!_P (]X>,\MO)*)KN\G7:T[+]
MT*O91UYY_K6TS5+.W\$:]ITLVV[NI;=H8]I.X*Q+<XP,>]?17]@Z%_T"=._\
M!D_PH_L'0O\ H$Z=_P" R?X47069XA\._&%CHTWV#7&_XEZR?:+>4J6-O*!C
M( !.&!(X_J:XBZ=9+N9T.5:1B#Z@FOJ;^P="_P"@3IW_ (#)_A1_8.A?] G3
MO_ 9/\*+H+,^4Z*^K/[!T+_H$Z=_X#)_A1_8.A?] G3O_ 9/\*.9!9GRG7N/
MP2_Y%K4/^OS_ -D6N[_L'0O^@3IW_@,G^%6K6TLK%&2TM[>W1CDK"BH"?7BB
MZ"S/DFNF\(ZK9:7#KRWDWE&ZTR6"'Y&;<YQ@<#CZGBOH;^P="_Z!.G?^ R?X
M4?V#H7_0)T[_ ,!D_P *.9!9GRG70^"[O2].\20ZAJTH6&T5IHTV%O-D ^1>
M <<\Y/'%?1?]@Z%_T"=._P# 9/\ "C^P="_Z!.G?^ R?X47069\X2^,_$DMT
M\XUS44+N7V+=.%&3G &<8]JM>.-1TS6M5M]7T^8&:[MT:\A",OE3  'DC!!]
ML]#7T+_8.A?] G3O_ 9/\*/[!T+_ *!.G?\ @,G^%%T%F?.OC#5+/5+K2WLI
MO-6#38()#M*[74'(Y _/I5_5];T[Q+X0M7U"Y\OQ#I_[I6:-C]JA[98# (]_
M?UKWO^P="_Z!.G?^ R?X4?V#H7_0)T[_ ,!D_P *+H+,^5!]X?6N@\<:G9ZQ
MXOO;ZPF\ZVEV;'VE<X10>" >H-?1?]@Z%_T"=._\!D_PH_L'0O\ H$Z=_P"
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M1<#P+_A'?!O_ $/?_E(F_P :Y6ZCABNYH[>?SX4<K'-L*[U!X;!Y&?2OJ?\
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M$>G7*:O:Q6FJVDBB>WC! ".H>,X))Y5L'W!H@\8PVT_B>769;>UL-'NDB24
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M9Y^U:SIT&V4P'S;I%Q( "4Y/WL$''7D46'<TZ*@N;VULK5KJZN88+=!EI99
MJ >I)XK.N?$%G+X;U#5=(O;.^6VMY)%>&42QEE4G!*GV]:0&Q161H&M1:MI=
M@\L]L-0GLHKJ6WC<;D#J#G;DD+G(!/I5AM<TA"0VJV*D/(AS<(,,@RXZ]5')
M';O0!?HJK8ZE8ZG:?:K"]MKNV)($UO*LB9'7D'%16.N:1JD\L&GZK8W<T/\
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MN>/5;NRM+^$0WEK#<Q!@X2:,.H8'(.#W![TL-I;6\LTL%O%%).P>9T0*9&
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M'<6\N&,(N2<DX'<DYH;TL"6MR>BBBI*"BBB@ HHHH **** "BBB@ KR#6?\
MD.:A_P!?,G_H1KU^O(-9_P"0YJ'_ %\R?^A&O%SK^''U/7RGXY>A2HHHKYX]
MT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M -G]:+0"\AGE/Z?K1Y3^GZT_S_\ 9_6CS_\ 9_6BT O(9Y3^GZT>4_I^M/\
M/_V?UH\__9_6BT O(9Y3^GZT>4_I^M/\_P#V?UH\_P#V?UHM +R&>4_I^M'E
M/Z?K3_/_ -G]://_ -G]:+0"\AGE/Z?K1Y3^GZT_S_\ 9_6CS_\ 9_6BT O(
M9Y3^GZT>4_I^M/\ /_V?UH\__9_6BT O(9Y3^GZT>4_I^M/\_P#V?UH\_P#V
M?UHM +R&>4_I^M'E/Z?K3_/_ -G]://_ -G]:+0"\AGE/Z?K1Y3^GZT_S_\
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M?^?9/^_J_P"-;7_"R/\ J$_^3/\ ]C1_PLC_ *A/_DS_ /8T>QRO_GX_Q_\
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M>US+^1?A_F8O_"$:[_S[)_W]7_&C_A"-=_Y]D_[^K_C6U_PLC_J$_P#DS_\
M8T?\+(_ZA/\ Y,__ &-'L<K_ .?C_'_Y$/:YE_(OP_S,7_A"-=_Y]D_[^K_C
M1_PA&N_\^R?]_5_QK:_X61_U"?\ R9_^QH_X61_U"?\ R9_^QH]CE?\ S\?X
M_P#R(>US+^1?A_F8O_"$:[_S[)_W]7_&C_A"-=_Y]D_[^K_C6U_PLC_J$_\
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M\(1KO_/LG_?U?\:/^$(UW_GV3_OZO^->K44_[$PW=_>O\A?VQB.R_KYGE/\
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M,CO-]HEE2=,C<DBLQW C/ISBK@_Y+'/_ -B^G_H]J5@N=E17CVE?\D\^'/\
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M**^>/="BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:]>^+[GQ5KFG6VD.]F+.*QAG$SL-P8O(XX)&,#'8G\>WHHN%@HHHI#"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#+\2/J<?AS4#H
MMN9]2,++;('5?G/ .6('&<]>U<9;?!'P4-*AANM+:2]$ 66Y%U,"TFWE\;L=
M><8Q7H]%--H5DSR]?!NJZ]9^$[#Q-I:SPZ<+JWO&:5"&3R]D4@P<Y. >.0>>
M*G'A[Q4?"UE:/%'-J?A[45FL)9Y5VZA"@(4$@DHQ5B.1U ]<UZ311<+'&V\?
MBCQ7I.KV6OZ3:Z':75JUM#"MP+F;>P(+EEPNW!&!C/7FO.K+X77'G6]A-\/-
M-AEC91+J[:U,\+ $;F6%7#Y(S@9'/M7N]%-2:#E/)_$?A36I?&FHWQ\(:?XD
MBNEC6RNKV]")9*$P4:)OO#=EOE'.>N3QU_PYTC4-!\"Z?I>J6ZP7=N9%=%<,
MN#(Q!!'8@@UU-%)O2P6U"BBBD,**** "BBB@ HHHH **** "O(-9_P"0YJ'_
M %\R?^A&O7Z\@UG_ )#FH?\ 7S)_Z$:\7.OX<?4]?*?CEZ%*BBBOGCW0HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH'_" :-_>NO^_@_PH_X0#1O[UU_W\'^%>?\ ]N:M_P!!2]_\"'_QH_MS5O\
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M]_\  A_\:/[<U;_H*7O_ ($/_C1]>P/_ #Y#ZGC/^?IZ!_P@&C?WKK_OX/\
M"C_A -&_O77_ '\'^%>?_P!N:M_T%+W_ ,"'_P :/[<U;_H*7O\ X$/_ (T?
M7L#_ ,^0^IXS_GZ>@?\ " :-_>NO^_@_PH_X0#1O[UU_W\'^%>?_ -N:M_T%
M+W_P(?\ QH_MS5O^@I>_^!#_ .-'U[ _\^0^IXS_ )^GLEM;I:6D-M'GRX46
M-<GG &!4M4M'=Y=$L))&9W:VC9F8Y))49)-7:^FIM.":/G9IJ33"BBBK)"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH BG^X/K6-J^MVVBOIZW*2L;^\2SB\L X=@2"V2./E/3/TK9G^
MX/K7#^/?]?X3_P"P_;_^@R5C+XC6/PFEXD\8:9X8,$5RMS=7MQGR+&RA,L\N
M.I"CM[G JMX?\=Z9KVH'36M=1TO4MN];/5+8P2NH_B49((^AS5/1O+_X6MXF
M^U8^V?9+7[)NZ_9\'=M]O,SG'?%)X_\ )^W>%-FW^TO[9A^S_P![9SYOOMV=
M>W2E9;%79L:5XMTO5_$6JZ% TB7^F,!-'( -X('S)@G(Y /2D?Q;8(_B%3#<
MYT&,276%7YP8S)\G// [XYK@6TVZ76?%'B728C)JNCZPTBQ*3_I,!@B\V(XZ
MY R/]H"DL=4M-:L?B=J5A*);6YL8Y(W'H;0]?0CH1V(HL*YW^I^+]*TCP[:Z
MU>-,L%V(_L\*1[Y96<95%49RQ_R:H:-\0=/U75(=-N=+UG1[NXS]G35;,P>>
M0,D(<D$X[5G7-K9:AX=\&V9U-M.UGR8YM,G$'FKYBPC<""-I!4G@D$]CQ1=:
MEKVCZGI2>+;'1=2L)[Z."UO+2-EEMYVR$<QON')XRK9&319!=G?5Q5Y\3=*A
MO9K;3M+UO6Q YCFFTJQ,T4;#J"V0#^&:+SQA=:C'K.E6/AWQ#:W<5M<""\N;
M'9;LZJ=NU\G.3C''-2>&KDV'PLTJX\-::FI2)9Q&.U6X6'S'./,R[< @[B<]
MP118=R\GCC19_"5YXDM99;BRLU8SQHF)49?O(5;&&'H<5J:CJT&F:%<ZO.DC
M6]O;M<.J %RH7<0 3C./>O,M4UB?4?!WCZWO?#*:%J,5LDMRBW:S^<SIPQ*@
M#.%%.\1_\+,_X0;4OMO_  B7]G_8'\WR?M/F^7L.=N>-V/7C-%A7.LUCX@V6
MDKI.S1]:U"34[8W,,.GVPE=4 4G<-PQ]X=,TFC?$33M6UF'2;C2M:TB\N%8V
MZ:K9F#SMHR0IR<D"N5O/[>_MKP-_PCG]F_;_ .PI/^0CO\K9MAS]SG/2IM&E
M\2^(/B#;V/B^XTZQGT4F\M[*RA?%WN4H)0[$Y4;B,#G/4"G96"[/4)9!%"\C
M E44L<>U4]$U>WU[1+/5K5)4@NXA+&LH 8 ^H!(S^-8</B_^T]0OM)_X1WQ!
M:>6DH^V75EY=NVW(R'W<Y[<<T[X;?\DV\/?]>4?\JFP[G4T5SMQXJ>.\U""U
M\/ZM?+8/Y<\UN;?;NV*^ 'E5C\K#HM;=E>0:C8V][:OYEO<1K+$^"-RL,@X/
ML:0R>BBB@ HHHH **** "BBB@ K"UCQ;I>B:[I6D7;2?:=28K$4 *IR "YSP
M"Q"CKDFMVO"M:UO_ (2"]\57(\.^)+YKC;::5>Z=8&6&-8')5P^1UE!)QG@"
MFE<3=CW6BO.+WQ5?:_X&\.OIUVVGW>LWD5C=3HOSVS8;S0N>C90@9YY]:TUT
M#4?"WAW7V7Q-JFHVYLG>W%\^^>"0(V6$HP2#QQCC'6BP7.THKR98M:T[P?H<
MJ>)M2?4O$LUI!+=7$V]+160L?)4C"D@8R>2><YK6MK#4/!?C'1+./Q%JNK6.
MKM+#+!JDXFDC=4+B1&P"!\N".G-.P7/0Z*\4_P"*A'@!O&*^*=3%Y8W,@M[4
MRYMW07!3$JGER>>2>!@ <5TJ6>K>&?'>BM+XDU+4X]6CN!=V]TP\H,D>\&)!
MQ&,]N?K18+GHU%?/MOXC\0:K:MKJ?\+!.JR%I+9+&Q#Z:!D[%V9^=<<%NOY5
MW=W)JOC7Q'9Z/)JFHZ!;1:5%J%Q%9.8+EY9"1MW$955P<C'4\^QRBYCT>BO)
M;*]U/P_I/C>UO/%%_/+8W,,%K>21?:9EWHNU$CW %SN"]0">3WJKX6NM?TOX
M@Z3:3OXG73]2BG#+KUXDQ<HF[*(O,>#COSGVHY0YCU+0M:MO$.CPZG:)*D$Q
M8*LH 8;6*G."1U![UI5Y-X;N+K2O#'@[5TN)EL4O9[2]B$A$96:5U1V7.#M?
M;SVW&NO\$7=SJ\.JZY-<2R6]]?.+*-G)1((_W:E1T&XJS''7(I-#3.JHHHI#
M"BBB@ HHHH **** "BBB@ HHHH ****  G S6;H&MVWB+0[75K-)4M[E2R+,
M &&"1R 2.WK6BWW3]*\DTJ_U"W^$GA.PTV\-C/JEXMD;L $PJSR$E<\;B%P/
MK32N)L]<HKSNWL-0\%^,-$M(_$6JZM8ZNTT,L&J3B:2-U0N)$; ('RX(Z<UR
MD,'B&'X>1^,_^$NUA[RUN"T=JTP-NT7GE"KJ1ESC/))QP.U.P7/8[>_^T:E>
M67V2[C^S!#Y\D>(I=PS\C?Q8Q@^E7*\YU.Y\1W6H^.K30[F5KV*"S^QQ&7B/
M<I+[-WRJQ&>?7%97@/59+/Q7#I][J/B^VDN8W7[%XBC\U9I ,YAFXQ@ \8PP
M-%@N>MT445(PHHHH **** "BBB@ HHHH **** "O(-9_Y#FH?]?,G_H1KU^O
M(-9_Y#FH?]?,G_H1KQ<Z_AQ]3U\I^.7H4J***^>/="BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /:=#_Y &F_]>L7_ *"*OU0T/_D :;_UZQ?^@BK]?H%'^''T1\/5_B2]6%%%
M%:&84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% $4_P!P?6L;5]$MM:?3VN7E4V%XEY%Y9 RZ@@!L@\?,
M>F/K6S-]P?6H,'TK&>YK#8P/$G@_3/$Q@FN6NK6]M\^1?64QBGBSU 8=O8YJ
MMX?\":9H.H'4FNM1U34MNQ;S5+DSRHI_A4X  ^@S748/I1@^E3=E61FZ9HEM
MI-WJ5S \K/J-S]IE$A!"MM5<+@#C"CKFLBQ\ :-IMOXAM[0W$4.N[OM*!UQ'
MN5@?+XX^\3SG\N*ZG!]*,'THU#0P=3\'Z1K'AVUT2^CDD@M506\H?;+$R#"N
MK#HWZ>U9NE?#G3=.U6WU*[U36M9N+8EK8ZK>F=8&]5& ,^YS788/I1@^E%V%
MD%<3>?##29;Z:[TS4];T-KAB\\>DWI@CD8_Q%<$ _3%=M@^E&#Z4*Z#0Y:'X
M?Z%;>'=2T:W2XC34EVW=R92\\I_O%VSS^&.3Q6UJ.DP:GH5SI$[R+;W%NUN[
M(0'"E=I()&,X]JOX/I1@^E&H:&+!X9LK?4-)O4EN#)IEFUG""PPR,%!+<<GY
M!TQWXIVK^'+/6-1TS4))9[>]TZ8R03V[ ,01AD;(.48=1[=16Q@^E&#Z4:AH
M,EC$L+QMD*ZE3CWK@+;X36]E;1VUKXS\8P01+MCBBU0*J#T "8 KT+!]*,'T
MH3:"R//WT#7VD\32:9JNH6LANT,,#I$([M1!"#\[1EP6PR[U; (SC(-5-0L1
M>P6TVCZ%J%M9PZ?&FI6SP/&]S;J1BV56&7< /R.QVY^?(]+P?2C!]*=PL16Q
MC-K"88S'$4&Q"A3:N.!M(!7Z8XJ6C!]*,'TJ1A11@^E&#Z4 %%&#Z48/I0 4
M48/I1@^E $5U ;FTFMQ+)#YJ,GF1XW)D8R,@C(]P:JZ)I%KH&B6>DV6_[/:Q
M"-"Y!9L=S@#DGD\=35_!]*,'TH Y>;P%HUQ8ZI92M=-!J%Y]NVB0*;:?CYXB
M "IR,]^<]CBF:5X!TW3+;44>_P!4U"ZOX#;37M_=>=.(B#\JL1@ 9)Z=>N:Z
MO!]*,'TIW8K(P[WPEI>H^%H/#MVDLMG!'''&V_;(I0#:P88PPQU%4- \ Z?H
M>J#5)-1U;5K](S'%<:I=F=H4/4)P ,_2NKP?2C!]*+L+(YS_ (0K3?\ A#Y?
M#/GW?V*5V=I-Z^9EI3(>=N.I].E:-YHEM?:OIFIRO*)M.,AA52-K;UVG=QD\
M=,$5I8/I1@^E&H:'#7'PLT::YF,6I:Y:Z?.[/-I=M?LEK(6.6R@&0#GH"*S/
MB%IT,5]ICIH'B+RK>W,4&I>&9,7,/_3$IC[F #G/MQW],P?2C!]*+L+(\O\
M!O@."[\-Z];:I87]G8ZM<I+#%=SYNU"*N)78='+@MCM]*W-+^&FFZ9KEGK3Z
MOKE_J%H6"3WUYYQ*,I4H<K]WDGC!SWKM,'THP?2B["R//O$^E?V/X&3P?I.E
M:EJ9U 20Q3!0R6[,V[?*XQM +9''\-=II&FPZ-HUEIEO_JK6%(5/J%&,_4]:
MNX/I1@^E%P"BC!]*,'TI#"BC!]*,'TH **,'THP?2@ HHP?2C!]* "BC!]*,
M'TH **,'THP?2@ HHP?2C!]*  \C%<T/ VCMX-A\+S">:PAYC=Y,2JP8L&#*
M!@@GL*Z7!]*,'TIZ@<IH/@'3]#U0:I)J.K:M?I&8HKC5+LSM"AZA. !GZ58_
MX0O3O^$-;POYUU]A;.9-Z^9S)YG7;CK[=*Z/!]*,'THNQ61S]WX-TF_EUA[L
M32KJRPK.A? 3RAA"A !!'7.3R*I:+\/M/TC5(=2GU76M6N;<'[,VJ7IF$&1@
ME!@ $CCG-=;@^E&#Z47860448/I1@^E(8448/I1@^E !11@^E&#Z4 %%&#Z4
M8/I0 448/I1@^E !11@^E&#Z4 %>0:S_ ,AS4/\ KYD_]"->OX/I7DFL0RG6
M[\B-R#<R?PG^\:\;.4_9Q]3ULI:YY>AG45)Y$W_/)_\ ODT>1-_SR?\ [Y-?
M/V9[MT1T5)Y$W_/)_P#ODT>1-_SR?_ODT6871'14GD3?\\G_ .^31Y$W_/)_
M^^319A=$=%2>1-_SR?\ [Y-'D3?\\G_[Y-%F%T1T5)Y$W_/)_P#ODT>1-_SR
M?_ODT6871'14GD3?\\G_ .^31Y$W_/)_^^319A=$=%2>1-_SR?\ [Y-'D3?\
M\G_[Y-%F%T1T5)Y$W_/)_P#ODT>1-_SR?_ODT6871'14GD3?\\G_ .^31Y$W
M_/)_^^319A=$=%2>1-_SR?\ [Y-'D3?\\G_[Y-%F%T1T5)Y$W_/)_P#ODT>1
M-_SR?_ODT6871'14GD3?\\G_ .^31Y$W_/)_^^319A=$=%2>1-_SR?\ [Y-'
MD3?\\G_[Y-%F%T1T5)Y$W_/)_P#ODT>1-_SR?_ODT6871'14GD3?\\G_ .^3
M1Y$W_/)_^^319A=$=%2>1-_SR?\ [Y-'D3?\\G_[Y-%F%T>RZ'_R --_Z]8O
M_015^J&B C0=.!&"+6+(_P" BK]??4?X<?1'Q%7^)+U84445H9A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR#^\0<FAK0$]3T>BBBI*$/W3]*Y+PGXG#_#BQ\0>(=0B3,;-/<RA4'WV4<
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M (JN2HKQ/[1Q7\[/7^H8;^1'6_\ "P]6_P"?>R_[X?\ ^*H_X6'JW_/O9?\
M?#__ !5<E11_:.*_G8?4,-_(CK?^%AZM_P ^]E_WP_\ \51_PL/5O^?>R_[X
M?_XJN2HH_M'%?SL/J&&_D1UO_"P]6_Y][+_OA_\ XJC_ (6'JW_/O9?]\/\
M_%5R5%']HXK^=A]0PW\B.M_X6'JW_/O9?]\/_P#%4?\ "P]6_P"?>R_[X?\
M^*KDJ*/[1Q7\[#ZAAOY$=;_PL/5O^?>R_P"^'_\ BJ/^%AZM_P ^]E_WP_\
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M7O\ A$M"_P"@<G_?;?XT?\(EH7_0.3_OMO\ &O+_ +"K_P R_'_(]'^V:/\
M*_P_S/(:*]>_X1+0O^@<G_?;?XT?\(EH7_0.3_OMO\:/["K_ ,R_'_(/[9H_
MRO\ #_,\AHKU[_A$M"_Z!R?]]M_C1_PB6A?] Y/^^V_QH_L*O_,OQ_R#^V:/
M\K_#_,\AHKU[_A$M"_Z!R?\ ?;?XT?\ "):%_P! Y/\ OMO\:/["K_S+\?\
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M-K$$\BY\X-Y^1\WRCE=IXYZYJY0 4444 %%%% !1110 4444 %%%% !1110
M5Y!K/_(<U#_KYD_]"->OUY!K/_(<U#_KYD_]"->+G7\./J>OE/QR]"E1117S
MQ[H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110![3H?_ " --_Z]8O\ T$5?JAH?_( TW_KUB_\
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M_A2_P_\ ^@!_Y.3_ /Q=":!IAXEL9&U+P18:K.NH.UU+%<RO$$$^;:0,2@X
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M6X[M+"'3-$\F.XD.U;:[G3=(Q/;8%4'TR:[9[$>%_#,D'A?0X9G@ ,%C'*L
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M^4@)4_*6[;ON\?WJS?!%JGA3QG8V5YX8N] FU!)(HS:ZI]JM;Q@-VYD8EE(
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M?\+#TG_GWO?^^$_^*H^IX#_G\'UO&_\ /HX?_A'=9_Z!EU_W[-'_  CNL_\
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MFAVD7A75=*.G7\5Y=7NHPB-8PF<I$<Y?<>,CMVJU>>(-0\.ZKK%I<>!+F_\
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M$S)H8W\>$3IWVS:WE>=N QNQ^G7%>@:#HEMX>TE-.M'E>%))) TI!;+N7/0
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MHHKYX]T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=Q17/_9>$_D_%_YF_P#:6*_G_!?Y'#_\*XA_Z"3_ /?D?XT?\*XA_P"@D_\
MWY'^-=Q11_9>$_D_%_YA_:6*_G_!?Y'#_P#"N(?^@D__ 'Y'^-'_  KB'_H)
M/_WY'^-=Q11_9>$_D_%_YA_:6*_G_!?Y'#_\*XA_Z"3_ /?D?XT?\*XA_P"@
MD_\ WY'^-=Q11_9>$_D_%_YA_:6*_G_!?Y'#_P#"N(?^@D__ 'Y'^-'_  KB
M'_H)/_WY'^-=Q11_9>$_D_%_YA_:6*_G_!?Y'#_\*XA_Z"3_ /?D?XT?\*XA
M_P"@D_\ WY'^-=Q11_9>$_D_%_YA_:6*_G_!?Y'#_P#"N(?^@D__ 'Y'^-'_
M  KB'_H)/_WY'^-=Q11_9>$_D_%_YA_:6*_G_!?Y'#_\*XA_Z"3_ /?D?XT?
M\*XA_P"@D_\ WY'^-=Q11_9>$_D_%_YA_:6*_G_!?Y'#_P#"N(?^@D__ 'Y'
M^-'_  KB'_H)/_WY'^-=Q11_9>$_D_%_YA_:6*_G_!?Y'#_\*XA_Z"3_ /?D
M?XT?\*XA_P"@D_\ WY'^-=Q11_9>$_D_%_YA_:6*_G_!?Y'#_P#"N(?^@D__
M 'Y'^-'_  KB'_H)/_WY'^-=Q11_9>$_D_%_YA_:6*_G_!?Y'#_\*XA_Z"3_
M /?D?XT?\*XA_P"@D_\ WY'^-=Q11_9>$_D_%_YA_:6*_G_!?Y'#_P#"N(?^
M@D__ 'Y'^-'_  KB'_H)/_WY'^-=Q11_9>$_D_%_YA_:6*_G_!?Y'#_\*XA_
MZ"3_ /?D?XT?\*XA_P"@D_\ WY'^-=Q11_9>$_D_%_YA_:6*_G_!?Y'#_P#"
MN(?^@D__ 'Y'^-'_  KB'_H)/_WY'^-=Q11_9>$_D_%_YA_:6*_G_!?Y'#_\
M*XA_Z"3_ /?D?XT?\*XA_P"@D_\ WY'^-=Q11_9>$_D_%_YA_:6*_G_!?Y$%
ME;"SL+>U#;A#$L8;&,X &?TJ>BBN]))61Q-MN["BBBF(**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image5.jpg
<TEXT>
begin 644 image5.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #\!%8# 2(  A$! Q$!_\0
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M>*_^>UI_WX%'_"WO%?\ SVM/^_ IV ^@Z*^?/^%O>*_^>UI_WX%'_"WO%?\
MSVM/^_ HL!]!T5\^?\+>\5_\]K3_ +\"C_A;WBO_ )[6G_?@46 ^@Z*^?/\
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M H_X6]XK_P">UI_WX%%@/H.BOGS_ (6]XK_Y[6G_ 'X%'_"WO%?_ #VM/^_
MHL!]!T5\^?\ "WO%?_/:T_[\"C_A;WBO_GM:?]^!18#Z#HKY\_X6]XK_ .>U
MI_WX%'_"WO%?_/:T_P"_ HL!]!T5\^?\+>\5_P#/:T_[\"C_ (6]XK_Y[6G_
M 'X%%@/H.BOGS_A;WBO_ )[6G_?@4?\ "WO%?_/:T_[\"BP'T'17SY_PM[Q7
M_P ]K3_OP*/^%O>*_P#GM:?]^!18#Z#HKY\_X6]XK_Y[6G_?@4?\+>\5_P#/
M:T_[\"BP'T'17SY_PM[Q7_SVM/\ OP*/^%O>*_\ GM:?]^!18#Z#HKY\_P"%
MO>*_^>UI_P!^!1_PM[Q7_P ]K3_OP*+ ?0=%?/G_  M[Q7_SVM/^_ H_X6]X
MK_Y[6G_?@46 ^@Z*^?/^%O>*_P#GM:?]^!1_PM[Q7_SVM/\ OP*+ ?0=%?/G
M_"WO%?\ SVM/^_ H_P"%O>*_^>UI_P!^!18#Z#HKY\_X6]XK_P">UI_WX%;'
MA_QWXV\0W,J0W6G6]O;IYEQ=7$06.%?4GW["BP'M=%>81^*M3U)VMM#\9Z5>
MZACY+:;3FMQ(?168X)]!7(O\5/&$-ZUI.UM%,DGENK6PRK9P012L![[17D7C
M/Q7XU\'WT,3WEI=6TZYCN!:! 2.JD9."/KWJA=_$+Q7:^&-.UG[=:-]MEEC\
MG[(!LV$<YSSG/H*+ >V45XWH'C7QAK-M/?W.I:;IVEV[!9;N>#C<?X54<LWM
M5^X\5Z]<Z;<WGAWQ-IVKM:(9)X/[/:"14'5E5C\P% 'JM%>"Z?\ $[QKJNH0
M6-E]FEN)VVH@@')_/@>]=6_BR\MIOL5YX[T>+40=K1IIS/$K>AER /?(XHL!
MZ?17AVN_$'QQX>U)K*]DLMVT/')'"&25#T93W!J?5OB!XKTO1=&U'[?:2_VE
M'))Y?V0+Y>UL8SDYS]!3L![517SY_P +>\5_\]K3_OP*ZJP\6^)!I4&IZ_X@
MTW1[6Y&;=6LC-+*/[PC4YV^_^(HL!ZS17D6L>,/%5GI7]KZ3K.FZOIBL$DFB
MM=CPD]-Z$Y4'M_\ JK*T3XA^./$&II86#6;2L"S,\("HHZLQ[ 4K >Y45Y@O
MB^X>7[(GC[2#?= ITUA"6]/-SMQ[US6I_$CQGHNLRZ;J4EK%)"X60I;AN.NY
M>1G(.1T_"BP'NE%>,^*/'/B[PY>VZ)?V=Y9W4*S6UTEJ%653[9."/3/<>M)X
M@\>>*_#T&GI<:A:-J%S#YTUI]C ^S@_=!;=R3Z8&*+ >ST5\^?\ "WO%?_/:
MT_[\"K%A\4?&.HZA;V4$EJTL\BQH/LXZDXIV ][HKQWQ?XT\7>%=2BMQJ%G>
M031[X[A;0*&()##&X\@CUJOX5^('BOQ-X@@THW]I;>:K'S?L@?&U2>F1Z>M*
MP'M5%>%ZU\1_&NA:O<:;>/:":%L9%N,,.S#V(YJQXE^(7BOP]JYL/MUI<8BC
MDW_9 GWE#8QD],T[ >V45YE/XLNK""S.J>-;2TN+FVCN1#_8KR;5<9'*M@]Z
MR]?\9^+=)L(=4L=5T[4])F<QK=0VVW:_]UU)RII >PT5\^?\+>\5_P#/:T_[
M\"M'1/B'XX\0:FEA8O9&1@69WA 2-1U9CV IV ]RHKS!/%MW/-]BMO'>CR:@
M3M$;Z<R0EO02YP1Z''-<OJ/Q+\:Z1JDNGZ@;:">%]L@-N#CW'J,<TK >[T5Y
MO8>*9=3^T?9/'=I)]F@:XF_XD<@VQKC)Y;GJ.!S7.ZY\3-0L(X3I/B6TU1G)
M$B_V6T'ECL?F/.: /:J*\3U/XA>*].T31]1^W6DG]HI(_E_9 /+V-MZYYS]!
M1I7Q"\5ZGI&KW_VZTC_LZ))-GV0'S-S;<9SQ^M.P'ME%>-^%?'?B3Q%<7JW.
MKVEA!9VS7,DOV'S?E!&> P/>M'_A/(/^B@VG_@@E_P#BJ5@/4Z*\-TWXE^)]
M3\16^EQ7]IY=Q<B%+C[)V+8#;<_CC-='/XT6UNY;6;Q_:)-$YC=3H4G# X(S
MNQUHL!Z?17BGB3Q[XQ\.:@EN][87,$T2S6]S% -LL9Z$<UC_ /"WO%?_ #VM
M/^_ IV ^@Z*^?/\ A;WBO_GM:?\ ?@4?\+>\5_\ /:T_[\"BP'T'17SY_P +
M>\5_\]K3_OP*/^%O>*_^>UI_WX%%@/H.BOGS_A;WBO\ Y[6G_?@4?\+>\5_\
M]K3_ +\"BP'T'17SY_PM[Q7_ ,]K3_OP*/\ A;WBO_GM:?\ ?@46 ^@Z*^?/
M^%O>*_\ GM:?]^!1_P +>\5_\]K3_OP*+ ?0=%?/G_"WO%?_ #VM/^_ H_X6
M]XK_ .>UI_WX%%@/H.BOGS_A;WBO_GM:?]^!1_PM[Q7_ ,]K3_OP*+ ?0=%?
M/G_"WO%?_/:T_P"_ H_X6]XK_P">UI_WX%%@/H.BOGS_ (6]XK_Y[6G_ 'X%
M'_"WO%?_ #VM/^_ HL!]!T5\^?\ "WO%?_/:T_[\"C_A;WBO_GM:?]^!18#Z
M#HKY\_X6]XK_ .>UI_WX%'_"WO%?_/:T_P"_ HL!]!T5\^?\+>\5_P#/:T_[
M\"C_ (6]XK_Y[6G_ 'X%%@/H.BOGS_A;WBO_ )[6G_?@4?\ "WO%?_/:T_[\
M"BP'T'17SY_PM[Q7_P ]K3_OP*/^%O>*_P#GM:?]^!18#Z#HKY\_X6]XK_Y[
M6G_?@4?\+>\5_P#/:T_[\"BP'T'17SY_PM[Q7_SVM/\ OP*/^%O>*_\ GM:?
M]^!18#Z#HKY\_P"%O>*_^>UI_P!^!1_PM[Q7_P ]K3_OP*+ ?0=%?/G_  M[
MQ7_SVM/^_ H_X6]XK_Y[6G_?@46 ^@Z*^?/^%O>*_P#GM:?]^!1_PM[Q7_SV
MM/\ OP*+ ?0=%?/G_"WO%?\ SVM/^_ H_P"%O>*_^>UI_P!^!18#Z#HKY\_X
M6]XK_P">UI_WX%'_  M[Q7_SVM/^_ HL!]!T5\^?\+>\5_\ /:T_[\"C_A;W
MBO\ Y[6G_?@46 ^@Z*^?/^%O>*_^>UI_WX%'_"WO%?\ SVM/^_ HL!]!T5\^
M?\+>\5_\]K3_ +\"M[P5\2/$.N>+[#3;V2W-O.7#A(0#PC$<_4"BP'LM%%%(
M#SKXS_\ (E6__7\G_H#UX+7T/\5-(O\ 6O"D-MIUK)<S+=HY2,<A0KC/ZBO'
M/^$ \5_] .[_ "'^--".;HKI/^$ \5_] .[_ "'^-'_" >*_^@'=_D/\:8'-
MT5TG_" >*_\ H!W?Y#_&C_A /%?_ $ [O\A_C0!S=%=)_P (!XK_ .@'=_D/
M\:/^$ \5_P#0#N_R'^- '-T5TG_" >*_^@'=_D/\:/\ A /%?_0#N_R'^- '
M-T5TG_" >*_^@'=_D/\ &C_A /%?_0#N_P A_C0!S=%=)_P@'BO_ * =W^0_
MQH_X0#Q7_P! .[_(?XT <W172?\ " >*_P#H!W?Y#_&C_A /%?\ T [O\A_C
M0!S=%=)_P@'BO_H!W?Y#_&C_ (0#Q7_T [O\A_C0!S=%=)_P@'BO_H!W?Y#_
M !H_X0#Q7_T [O\ (?XT <W172?\(!XK_P"@'=_D/\:/^$ \5_\ 0#N_R'^-
M '-T5TG_  @'BO\ Z =W^0_QH_X0#Q7_ - .[_(?XT <W172?\(!XK_Z =W^
M0_QH_P"$ \5D_P#(#NOR'^- '-T5T[_#OQ;&!NT2X.?[K*W\C3/^$ \5_P#0
M#N_R'^- '-T5TG_" >*_^@'=_D/\:/\ A /%?_0#N_R'^- '-T5TG_" >*_^
M@'=_D/\ &C_A /%?_0#N_P A_C0!S=%=)_P@'BO_ * =W^0_QH_X0#Q7_P!
M.[_(?XT <W172?\ " >*_P#H!W?Y#_&C_A /%?\ T [O\A_C0!S=%=)_P@'B
MO_H!W?Y#_&C_ (0#Q7_T [O\A_C0!S=%=)_P@'BO_H!W?Y#_ !H_X0#Q7_T
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M[AP,,.X//0CBKOBO0/%?B?7Y=4'ABZM?,15\K<'QM&.O'\J ,[X@?\?VB_\
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M./K63_P@'BO_ * =W^0_QI@='=?\(S_P@WA;_A(/[6W>5/Y/V#R\8\SG=O\
MPZ4MC_PC'_"&>*?[ _M?S/LT7F_;_+QCS.-NSOUZU2U/PYXKU'1-'T[_ (1J
M[C_LY)$\S<#YF]MW3MCZFC2O#GBO3-(U>P_X1J[D_M&)(]^X#R]K;LX[_I2
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M_C1_P@'BO_H!W?Y#_&@#FZ*Z3_A /%?_ $ [O\A_C1_P@'BO_H!W?Y#_ !H
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M - .[_(?XT?\(!XK_P"@'=_D/\: .;HKI/\ A /%?_0#N_R'^-'_  @'BO\
MZ =W^0_QH YNBND_X0#Q7_T [O\ (?XT?\(!XK_Z =W^0_QH YNBND_X0#Q7
M_P! .[_(?XT?\(!XK_Z =W^0_P : .;HKI/^$ \5_P#0#N_R'^-'_" >*_\
MH!W?Y#_&@#FZ*Z3_ (0#Q7_T [O\A_C1_P (!XK_ .@'=_D/\: .;HKI/^$
M\5_] .[_ "'^-'_" >*_^@'=_D/\: .;KK?AE_R432?]Z3_T6]5O^$ \5_\
M0#N_R'^-=)X!\'^(=,\;Z;>7NDW$%O&S[Y' PN8V _4BD![O1112&8?BKQ/:
M^$]*34+N"::-YA$%BQG)!.>2/2N-_P"%VZ)_T#-0_)/_ (JK/QG_ .1*M_\
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M6&S57?S+^?RD;]V!@'!R>: .\T[XLV.JRRQ66C:A*\433.-T2X1>2>6%4_\
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M_A=NB?\ 0,U#\D_^*H_X7;HG_0,U#\D_^*KPZBBPCW'_ (7;HG_0,U#\D_\
MBJ5?C7HSL%73-0))P/N?_%5X;4MO_P ?4/\ OC^=%@/IS^W-7_Z%34/_  )M
MO_CE<YJGQ6M-%O3::EH6J6TX&=KA.1Z@[L$>XKD_'/@'Q-K/C"^O[#3?.M9=
MFR3SXUSA%!X+ ]0:Q/'<GV?2?#^C75VEWJEA#(+IT??L#,"L9;N5 Q0,]&N?
MBS86=C9WEQHVH);WBLT#[HSO"G!X#9'/K1:_%FQO;.\N[?1M0>"S0/.VZ(;
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M3N+9 (8$].W\@9W?_"[=$_Z!FH?DG_Q5'_"[=$_Z!FH?DG_Q5>'446$>X_\
M"[=$_P"@9J'Y)_\ %4J_&S0]WS:;J('<@(?_ &:O#:*+ ?7]%%%(9YU\9_\
MD2K?_K^3_P! >O!:^N+NUM+R(1WEO#/&#D+,@89]<'O5+^PM!_Z!6F_^ Z?X
M4P/E2I(6"3QLQP P)_.OJ?\ L+0?^@5IO_@.G^%']A:#_P! K3?_  '3_"BX
MCQUO%>B2_$?5I[BY+Z#J=O\ 9YI!&_3RUP=N,Y##'3O5.#Q7I\WBCQ/?W$WD
MV]WIT]I9C8Q!X58UP!QPO? KV[^PM!_Z!6F_^ Z?X4?V%H/_ $"M-_\  =/\
M*!GSSX"U2QT;Q=:WNHS^1:HDBM)L9L90@<*">IJX?#W@TL3_ ,)WU/\ T")O
M\:]Z_L+0?^@5IO\ X#I_A1_86@_] K3?_ =/\*!'S'>PV5EK!CL;_P"W6D;J
M5N?):/>."?E/(P<C\*[7Q';^#/$'B"ZU4^,S!]H96,(TN9MN% QGCT]*]G_L
M+0?^@5IO_@.G^%']A:#_ - K3?\ P'3_  H&?/GB;6]-DTNQT#0EF.FV;M*T
M\PP]Q*W5L=@!P/K4/]IV?_"NO[*\[_3?[4^T>5M/^K\K;G.,=>V<U]$_V%H/
M_0*TW_P'3_"C^PM!_P"@5IO_ (#I_A0(^>O#.MZ=;V%]HFMQS-I=\5<R0??@
MD7HX!Z^AK6T]?!/AJZ_M5-9FURXA^:VLQ9-"N_L7+<$#CIZ=#TKV_P#L+0?^
M@5IO_@.G^%']A:#_ - K3?\ P'3_  H&?-6DZC&GBVRU.\98XQ?)/,54X4;P
MQP!VZ\"FZQ=P77BF^O(7W6\MX\J/@C*ER0<'GI7TO_86@_\ 0*TW_P !T_PH
M_L+0?^@5IO\ X#I_A1<1\]>*->2;Q]=:WH]T2HE22"8*5Y"J.A /4'K6KXX\
M3:1X@T#2?[/40W?FR37=N$8".1L9()&""03P>]>X?V%H/_0*TW_P'3_"C^PM
M!_Z!6F_^ Z?X4#/#-(N/#]_X"71=4UW^S+A-0-R#]DDFRNP*/N\>O?M5"[T+
MPG#9S2VWC/[1.B%HX?[+E3S&QPNXG SZU]!?V%H/_0*TW_P'3_"C^PM!_P"@
M5IO_ (#I_A0!\\>$]>LM,^WZ=JT$DNE:E$(KCROOQD'*NN>,@_Y[':TR/P3X
M=U./6(_$5UJ<ELWF06<=D\+%A]W<[<8]>G]*]M_L+0?^@5IO_@.G^%']A:#_
M - K3?\ P'3_  H ^7+^[;4-1N;QU57N)6E95Z L2<#\ZKU]5_V%H/\ T"M-
M_P# =/\ "C^PM!_Z!6F_^ Z?X47$?*E6=._Y"=I_UV3^8KZB_L+0?^@5IO\
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MKO/ ]YX=TO2KNZNM:CT_7)&\N":2R>?[.F.64 8W')&<\8]S7N/_  CVB?\
M0'T__P !D_PH_P"$>T3_ * ^G_\ @,G^%%P/G+Q!8:)#%]JL/%#:O=RRYE1[
M*2(\Y)8LQY.?YUS]?5O_  CVB?\ 0'T__P !D_PH_P"$>T3_ * ^G_\ @,G^
M%%P/E*O;O@C_ ,@#4_\ KZ'_ *"*[_\ X1[1/^@/I_\ X#)_A5NUL;2Q1DL[
M6"W5CEEAC" G\*+@?(]%?5O_  CVB?\ 0'T__P !D_PH_P"$>T3_ * ^G_\
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MA)5E#QG(V\C(."1TK9N-.\!:A=M?1>(KO3X96WM8O8L[ID\JKCY<>G6O=?\
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M&62PTU'"W$J[6F=SEFQV''%?0_\ PCVB?] ?3_\ P&3_  H_X1[1/^@/I_\
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M(CN(EE3=UPP!&?SKA(]:\?ZWJ&J/X?C\,KIMI>R6D9OQ/YC%, GY#@C.?RH
M]"HID7F>4GF[?,VC?LZ9[X]J?0 4444 %%%% !1110 4444 %%%<=XKUKQ-;
M^)-+T7PTFD&:[MYIY&U(2;0$*#@H?]KTH [&BN)TO7_%=AXDL='\5V>D%=16
M3[+=:8\FT.B[BC+)SDC)R*Z>VUS2;RY%O:ZI93SF,RB**X1FV X+8!SC/&:
M+]%9]EKVCZE<R6UAJUC=3Q_?B@N$=E^H!R*)]>T>UU!-/N-6L(;UR MM)<HL
MC9Z84G)S0!H45SMQXPTZV\;6_AJ2>V2>6V,VYKA00^Y0L>WKN8$D=\#I6BVO
MZ,FIC36U>P6_)VBU-R@E)]-F<_I0!HT5SMAXPTZ_\8:EX=2>V%Q9I&5Q<*6E
M8[BZA>N4VC/IGG%:<.NZ1<:B^G0:K8RWR9WVR7"-*N.N5!R/RH OT4$@#).
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MV8Y_V,YS^%<A>^+M)\;W4UA/XATS2O#44A2;S+Z-+G4-IY4*3F.(\Y)Y8=,
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M*6Q2.WHHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!C]:-0T&>1)Z#\Z/(D]!^=/^U?['ZT?:O]C]:-0T&>1)Z#\Z/(D]!^=/\
MM7^Q^M'VK_8_6C4-!GD2>@_.CR)/0?G3_M7^Q^M'VK_8_6C4-!GD2>@_.CR)
M/0?G3_M7^Q^M'VK_ &/UHU#09Y$GH/SH\B3T'YT_[5_L?K1]J_V/UHU#09Y$
MGH/SH\B3T'YT_P"U?['ZT?:O]C]:-0T&>1)Z#\Z/(D]!^=/^U?['ZT?:O]C]
M:-0T&>1)Z#\Z/(D]!^=/^U?['ZT?:O\ 8_6C4-!GD2>@_.CR)/0?G3_M7^Q^
MM'VK_8_6C4-!GD2>@_.CR)/0?G3_ +5_L?K1]J_V/UHU#09Y$GH/SH\B3T'Y
MT_[5_L?K1]J_V/UHU#09Y$GH/SH\B3T'YT_[5_L?K1]J_P!C]:-0T.%^*7A3
M5_$_AFVLM*@26=+Q965I%3Y0CC.2?5A7D?\ PIKQM_T#H?\ P*C_ ,:]P\<^
M./\ A#-$AU'^SOMGFW*P>7Y_EXRK-G.T_P!WICO7G_\ PT+_ -2O_P"5#_[7
M35Q:''_\*:\;?] Z'_P*C_QH_P"%->-O^@=#_P"!4?\ C78?\-"_]2O_ .5#
M_P"UT?\ #0O_ %*__E0_^UT]0T./_P"%->-O^@=#_P"!4?\ C1_PIKQM_P!
MZ'_P*C_QKL/^&A?^I7_\J'_VNC_AH7_J5_\ RH?_ &NC4-#C_P#A37C;_H'0
M_P#@5'_C1_PIKQM_T#H?_ J/_&NP_P"&A?\ J5__ "H?_:Z/^&A?^I7_ /*A
M_P#:Z-0T./\ ^%->-O\ H'0_^!4?^-'_  IKQM_T#H?_  *C_P :[#_AH7_J
M5_\ RH?_ &NC_AH7_J5__*A_]KHU#0X__A37C;_H'0_^!4?^-'_"FO&W_0.A
M_P# J/\ QKL/^&A?^I7_ /*A_P#:Z/\ AH7_ *E?_P J'_VNC4-#C_\ A37C
M;_H'0_\ @5'_ (T?\*:\;?\ 0.A_\"H_\:[#_AH7_J5__*A_]KH_X:%_ZE?_
M ,J'_P!KHU#0X_\ X4UXV_Z!T/\ X%1_XT?\*:\;?] Z'_P*C_QKL/\ AH7_
M *E?_P J'_VNC_AH7_J5_P#RH?\ VNC4-#C_ /A37C;_ *!T/_@5'_C1_P *
M:\;?] Z'_P "H_\ &NP_X:%_ZE?_ ,J'_P!KH_X:%_ZE?_RH?_:Z-0T./_X4
MUXV_Z!T/_@5'_C1_PIKQM_T#H?\ P*C_ ,:[#_AH7_J5_P#RH?\ VNC_ (:%
M_P"I7_\ *A_]KHU#0X__ (4UXV_Z!T/_ (%1_P"-'_"FO&W_ $#H?_ J/_&N
MP_X:%_ZE?_RH?_:Z/^&A?^I7_P#*A_\ :Z-0T./_ .%->-O^@=#_ .!4?^-'
M_"FO&W_0.A_\"H_\:[#_ (:%_P"I7_\ *A_]KH_X:%_ZE?\ \J'_ -KHU#0X
M_P#X4UXV_P"@=#_X%1_XT?\ "FO&W_0.A_\  J/_ !KL/^&A?^I7_P#*A_\
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M&D44@SO((Y(YPHR3@]*ZZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBN)\>QG7Y],\'12,HU*0S7C(>4MH^3]-S[!^= ';45R'A3Q&W_"#3
M76K%OM>C++;Z@%&6WPCYC[Y4!O\ @55?#OCO5M;NK1I_"=Q;Z9>G$%];WD=T
M!D$CS%3F,8'4]#P: .YHKRG1_'&NZ9:^,=3U?193:V-\2-U^K^6W[M?)4 '@
M [L@8YQUKHYO&.OP:5'</X+O/MMQ,RV]L+I-OE  ^9++C9%G.-IR<C% '9T5
MQ.AZY8_$?2M6T;6-)$#V[+%>6J7@F0AOF7$L9&>G..F,5PE[\-_"GB#Q8NA>
M&M)-M::?)G5=26XE?:W_ #PCW,5+^IQ\OUXI#/<:*X[5O%VH6FKR:+X;\-3:
MW<V<:&Z(NTMXX0P^5=S9RV!G'H:9??$.*T\,VFKQ:1=S2RWZV$UCD+-%*205
MQT8@C@9&<CD4Q':45QVD>.9Y=0U&P\1:))H5S96OVTB2Y297@R06W+QD$=.?
MK5.U^(6IM]GO[_PA>V/A^X9!'J+W,;,H<@*SPCYE4YZY..* .]HKC];\9ZC:
MZW/I6@^&KC6Y[-%DO62X6!80PRJ@L/G8CG:/;\+.J^*[VTT;3[O3_#>HWMW?
M+N6UD'V?R.,GSG;Y8\=.>IZ4 =/17+>#?&7_  E0OX9[ 6-]82*D\*727"#<
M,J1(G!Z'([5U- !1110 4444 %%%% !1110!YE\<O^1*L_\ L(I_Z+DKP"O?
M_CE_R)5G_P!A%/\ T7)7@%4A,****!!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5]2_"'_DEVC?]M__ $=)
M7RU7U+\(?^27:-_VW_\ 1TE*6Q2.WHHHJ"@HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"&Y_U8
M^M<+X[M-:EDT&_T32O[3GT^_\][?[0D.5\MU^\W'5AZUW5S_ *L?6JM-"9YW
M>0^,O&J0Z7JOAZ#0-)\Y)+QFU!;B2=%(;8@08&2!DGM6;XC\+:S-XTU&^/A'
M3_$<5V(Q9W-Y>A$LE"X*-$W4;LM\HYSUR>/5J*8'F?A3PKKFFV_@J*\L5B;2
MGO1=;94(0/NV$8/(.1TY'?%=!#X=ENO$7BTW]L/[.U6""&-BRGS (V5^,Y&,
M]Q7644"/.O#WA?Q(OAK7FU&9;?7[NV%C:S^8#LCCCV1MN7.W<Q9SCD;O6N7L
MO!6NK=:";?P#IVDC3K^":YN4OTFFG53ABISD+U8@DD\8KVVB@9Y?JGAWQ(]K
MXSTF'25FMM2N5O;2[6Y0;V)B!C*$@@@*3D\<5UFCZ7>VOC+Q'?S0[+:\2U%O
M)N!WE$(;@'(P2.N*Z2B@1XIJ?@77M0U9W@\&V&FZMYN5\06&J&&)3G.\0#+9
M(SGOGO5WQ=\/9IO%5WK#>$X?%,5ZL>5_M)K*6!U4*>X5E. ?7)->O44AGFEA
MX)OM.\-:-:6VDVMG(FN17\]K:W+R+#&#@Y>5B68 #.W )Z"NH.EWG_"QUU;R
M?]!&DFV,NX?ZSS0V,9ST[XQ71T4Q!1110 4444 %%%% !1110 4444 %%%%
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M* "BBB@ HHHH **** "BBB@ HHHH *^I?A#_ ,DNT;_MO_Z.DKY:KZE^$/\
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M_@;)_C1["7</["J?SH]>_P"%&>$O^>FI?]_U_P#B:/\ A1GA+_GIJ7_?]?\
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M+')P.[&OFC_A+?$G_0PZM_X&R?XU] ?#>[N;[P!IES>7$MQ._F[I9G+LV)7
MR3R> !45*3@KMG+C,MEA8*;E?6QU5%%%8GFA1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $%U_J
MA]:P=6UJVT9]/6X25C?7:6<7E@'#L"03DCCY3TS]*WKK_5#ZUPGCO_7^%?\
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MY_?:M%X\?PII< _T>\1=5U! ?NQ1](SZYEP/^ FNC?Q=L\3_ -B?\(]K[?O
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M1\)XV>?[NO7]&=C1117&?+!1110 4444 %%%% !1110 4444 %%%% !1110
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MBC_A:?@S_H,_^2LW_P 17S=11]7B']AX?N_P_P CZ1_X6GX,_P"@S_Y*S?\
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MBC_A:?@S_H,_^2LW_P 17S=11]7B']AX?N_P_P CZ1_X6GX,_P"@S_Y*S?\
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M6SR+J"T:,W"/_&83@[EP_ X.!BNIO?AQ+%'I\GAS79]%O;&T6R6<1+.LL*]
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MUI[6'<[?[1PO\Z/,**]/_P"%(ZW_ -!/3_\ Q_\ ^)H_X4CK?_03T_\ \?\
M_B:/:P[A_:.%_G1YA17I_P#PI'6_^@GI_P#X_P#_ !-'_"D=;_Z">G_^/_\
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M_P#X_P#_ !-'M8=P_M'"_P Z/,**]/\ ^%(ZW_T$]/\ _'__ (FC_A2.M_\
M03T__P ?_P#B:/:P[A_:.%_G1YA7TC\+/^2;Z3_VV_\ 1SUY[_PI'6_^@GI_
M_C__ ,37JW@[0Y_#GA2RTFYECEFM]^YX\[3N=FXS[&L:\XRC9,\S-L71K45&
MG*[O^C-VBBBN4^>"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image6.jpg
<TEXT>
begin 644 image6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (' E0# 2(  A$! Q$!_\0
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M ,31X$_Y)YX9_P"P5:_^BEKH* .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\
MT*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@
MNA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)KH*
M* .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)KH** .?_P"$
M$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)KH** .?_P"$$\'_ /0J
M:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_
M (FC_A!/!_\ T*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/
M!_\ T*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA
M_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^
M)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)KH** .?
M_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)KH** .?_P"$$\'_
M /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X
M+H?_ (FC_A!/!_\ T*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC
M_A!/!_\ T*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\
MT*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@
MNA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)KH*
M* .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)KH** .?_P"$
M$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)KH** .?_P"$$\'_ /0J
M:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_
M (FC_A!/!_\ T*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/
M!_\ T*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA
M_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^
M)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)KH** .?
M_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)KH** .?_P"$$\'_
M /0J:'_X+H?_ (FC_A!/!_\ T*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X
M+H?_ (FC_A!/!_\ T*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC
M_A!/!_\ T*FA_P#@NA_^)KH** .?_P"$$\'_ /0J:'_X+H?_ (FC_A!/!_\
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M,_\ 8*M?_12UT%<_X$_Y)YX9_P"P5:_^BEKH* "BBB@ HHHH **** "BBB@
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M@#Y@_:._Y*'I_P#V"H__ $;+11^T=_R4/3_^P5'_ .C9:* /?_ G_)//#/\
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M7I\YNIK<@[II%&(O8!3DT^9%<R//=1T0>'M*^'^F.0TT>L1M<.>=\K*[.?\
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\P?M'?\E#T_\
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MD,$_/;]16<I<KN93ER.[V+V!1CVH!! (.0:6M#4**** "BBB@ HHHH ****
M"L;6=0@2*2U8.)2 1QQ6S67K>G&^M"T8_?QC*?[7M6M%Q4US&E'EYUS&-9ZN
M]DCJD:N7(QD]*ZM-VQ=V-V!G'K7!:0INM7MX2.C;F'L.:[^NC&PC&22W-\9&
M,9)+<**I:=JEIJJ7+6CEUM[A[:0E2/WB'# >N#WJ[7$<@4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S!^T=_R4/3_^P5'_
M .C9:*/VCO\ DH>G_P#8*C_]&RT4 >_^!/\ DGGAG_L%6O\ Z*6N@KG_  )_
MR3SPS_V"K7_T4M=!0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'FEK>6FG>+;.#PUXAFOVOM4G.HZ6VQUA4[VDDX4-'M<
M#)P<XKO+73XM(T?[%IL6U8D;RE8YRQR<DGJ2QR3[U=$:*[.J*&;[S <FG4 >
M"Z8]R=,FO#K5A%J[:9>?;K:*6<WLTGDL2)58X4JXR#@ 8PO!K8U6UN- MP^B
M->Q27GAUI[MTEDD=F62$-)R2?,"/)@CG\J]@$:!V<(H=A@MCDTZ@#SKPC'X>
MC^(-U_PC4D<ME_9$>^2&5I%+^:W\1)R<8SS]>:]%IJ(L:A44*HZ # IU !17
M'?$/[1]@TI4>9K1]1C2[M;:X\F:Z0JV(T.5R=VTE002 :D\-CQ!I'@N/[587
M%[?+-(8;22Y0RI"7/EJ\C'!94QGD]* .MHJGIEU>7EF);[3GL)BQ!@>59"!V
M.5)'-7* "JE]%NB\Q1\R]?I5NH+IIDA)@0.WH:BHDXNYG52<'<IV5\B1LDK8
M"\@G^57X9EGB61,[3TS7+N_)!X.>16[H[[[!?9B*Y,-7<I<C.'!XF4Y>S?1%
M^BBBNX](***P/$'C#2O#-]IUKJ1E0WY<12*F44J!]XYXR6 'N: -^BN,@^)_
MAV>2"$23I/</:)%"ZJ'?[0 4(7=D@ C<>U=!+XATB'64T>34(%U%UW+;%OG8
M8SP/7 )QUH TZH:MK6FZ%9BZU.\CM82P16<_>8]  .2?84Y;Y[@*;6VD=&VG
MS'^1=K G(SR<<9'7FL;6_#NHZO-IM_'J$%KJ.G2^=;Y@,L09D*.&&06!#<'(
M(Q0!OV5[:ZE90WEE<1W%M,H>.6-MRL/4&IZ\RDU6\^&ATG1Q:2WNG-YCS7&P
M*UQ+(Y=O*P<!E))$9^\#\I)&#Z%INI6>KZ?#?Z?<)<6LR[DD0\'_  (Z$'D4
M 00Z1%!K4NH1X'F1[2F.C9Y/XU>N)TMK:6XE.(XD+L?0 9-25R/Q(UFVTSP5
MJ4#7D$-W>0FVMT>0*S-(=F0#Z;L^V*J4Y2W*E)RW)_AY \7@73)IAB:\5KV3
M/4M,YD_]FKIZ@L[>.SLH+6(8CAC6-/H!@5/4DA1110 445QOBW7M;T"ZBGMI
M]*DAEECCMM-='^TW9) <(V[ (SD?*1QSB@#LJ*R-/U"^O=<U6%[=(].M&CB@
MD((>63;N<\\;1E0,=]U5KCQCI=MJIL76[94F6WENDMV:WBE;&U&DZ DLH]BP
M!Q0!T%%<U:>.M'O=0@M(EO0L\[VL=R]JZPM,A;,8<C&[Y6]N.M4E\=Q7^OZ-
M9:7;W#V=[<RQ-=RVS+%*J1NV8GZ'YE'U&<>M '94444 %%%% !1110 4444
M%%%% !1110 4444 ?,'[1W_)0]/_ .P5'_Z-EHH_:._Y*'I__8*C_P#1LM%
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M-:1*_P!A-LWR3,F'<-NY;D@9! !/?FG_ !!_TC0;32_^@GJ-M:'_ '3('?\
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M=]10 4444 %%%% !1110 4444 %%%% !1110 4444 ?,'[1W_)0]/_[!4?\
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MB6GW@A2*?4(EOKD)G#32@.[ $G&6).*WZRO#*"+PIH\:G(2QA4'UP@K5KL,
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MW#>> =#:&59#%910R 'E)$4*RD=B"""#725[QYP4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'S!^T=_R4/3_P#L%1_^C9:*/VCO^2AZ?_V"H_\
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M=(!A6;>OT/-:G@ZZ\N^FM6/$J[E^H_\ K?RH [2BBB@ HHHH **** "BBB@
MKRR_U.T\'>-=7LKR1XK742NHVNV)W^9AME&%!_B4-_P.O4ZY+QH?[+NM%\3+
MPNG70ANC_P!.TV$?/LK>6W_ :QKT8UH<DBZ=1PES(P?^$^T+'_'W-_X"3?\
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M 'S!^T=_R4/3_P#L%1_^C9:*/VCO^2AZ?_V"H_\ T;+10![_ .!/^2>>&?\
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M(.#5G3I/(N-A^Y)Q^/:K5W!^]W@<-U^M5&CH VJ*AMI?-A!/WAPU34 %%%%
M'-^-[;7[_P .W.G>'XX1<7431M</<F$PYQRN%.2>1VQ6/X%\+3Z9JNH:G=Z-
M!I<<D<<=I9B<3F A?WK!OX0YV\#KL!/-=Y10 54U33;;6-*N]-O$+VUU$T,J
M@X)5A@X/:K=% '#^$=._L_QGK]O-=W-_<VMK9PK=W)7?Y9$A"84 <=<]23S7
M<5RGA_YO'GC!_1[2/\H<_P#LU=70 4444 %4]5OQI>D7FH-#),MK \QBB&6?
M:"<#WXJY2$ C! (/4&@#PWPWIE]KWB.;Q7KNQYI2LEJJMN0 KPR_[*J=J_\
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M%C0_,VS9NR 1GIFL35K_ %0Z'>+/>ZCJNC6]WISV]U>V)AG,GVA=\8&U3)@
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M"&PK,7P!NSA3TS6>/"6I_:M5U#3=#N+2*.\T^]L[6\N0TESY)?S%+%FVL=W
M8]<4 =+J?C#4&N-&B@M-0TQY=6@M[B.^MU7S(G5S\I!(_AYP<BJ^L^/7"Z/=
MZ5+<R6,NK_8Y7CMM_P!J4(Y(B[L-P W#'3KBH?$]G=^-[73[.70]3L[*/4HG
MN#<2)%(8MCARH5B0!D#/?-4)K'Q';6NAVD^ER7O]@ZHC)/;&-?M5J(G56"DC
M#C(!7C)Z=: .B/CZU2TNY;D7MK<6DL<$EE- //+R?ZL*H)W;NV#V/I4;_$&V
MMK.^GOEO[.2Q,8N+6:W'G*)&"HP"DA@2>H)Z&N;O=$U?5=8N/%$6GO!-#=VD
MEKI]RZI)-' '#;L$A6;S#M!/\(SC-1ZUHNLZ_)J>J#3)+5Y8[.UM[261#*RQ
MW E=VP2H]ADGB@#LH/'%L6ODOA>::]E;BZE6]A"$PDD!UP3D9&,=<\8JUI?B
MQ=1U#[!):ZA8730_:(H[V 1F:,$ LN">F1D'!&1Q7)^,?#&H>(=7U'[*BB*;
M1Q!'*S[5:9;A9 A[C(7KVS5[PWIUJ-;ANQX9UBQN8H'5KG4+PRK&6QE$S(V[
M./O  <4 =V)Y.,N:E61S_%57^&IXSE0: +*L3WJ&_L8-2LI;.Z5VAE&&"2,A
MZYX92".G8U*M24 <SI'@'P_H>HQWMC;SJT)=H(I+F22.%G&'9%8D!F[GW/K7
M3444 %<M<R-_PLW3K> ^6ATRXGN @ \T[XE3<>^/FQ74UREM^_\ BMJ#CI:Z
M/!'^+RR-_P"R"@#JZ*** "BBB@ KR2XTF'2/B9J8N(@\UZ#?6=R_+;&VK+'G
M_9*KC_98"O6ZX?XDP6_V/2+M;F"WU2&_1;+SGV"<O\KP[N@W+GKW45K0J<DT
MV:T9\DTV:5@Z@#-:TDL9AP,9KDK:\C-M'<V\ZSV[LRK(G0E25(_ @C\*LMJ0
MV_>KOG0YWS1.R5'G=T4_%UQ-;^'=3GLRXNH[:1H2B[FWA3C [G-<AH>H^+K/
M5Y+>VAC-T=2LX+AQ'MANOW$NZ1F53MR%CSCH1CBMK6=4NY9K;3-* ?5K]S';
M \B,#[TK?[*#GW.!WKT+P_H=KX<T2WTRT+,L0)>5SEY7)RSL>[,22:Y\5:-H
MW,<3[MHW,;P7J.NWG@ZQN=1MS-?.LIE,C>6=PF8!<;>FWH?8>M= UQ>C=BQ#
M8WX_?#G&-OY\_3%7**XSD/(M%O\ Q3JFMVFE>(DDN-$U$W[.9(0H,:L4$+\=
MMNX'C(?O7:V>GVED\D=I!%#&SEV$:A06/4\=ZL^,M'N-9\-3Q6+E-0MV6ZLV
M!Q^^0[E!]C]T^S&LG0-8BU;2;74(056>,,4/5&_B4^X.0?I7%BW9QOL>=CM'
M%O8Z6*W#+5:YA S3H[K"]:@GN >]9SE#E,YSI\AY5XQAD\,>,K/Q':HQAF)\
M]4'5E7$@_P"!1C/UB'K7:'Q;HMO$KRZQ81JP!!:Y09'YU2U9)O$FL1^&+%V1
M702ZE<(>;>W/&T'L\G*CT&XUVMGX6\/Z>B+9Z'IT 0  I:H#Q[XS13H.K%2;
ML%+#2K04F[?J>>:O\0[-888_#\UGJNI37,<,5MN)5]QY&X< ^G-=%\/-7T[6
MH+_6(8H[6YU&\D41LY#R1PX13M)X(&,XXR?>NR>TMI$1'MXF6-PZ*4!"L.A'
MH1ZUF:IX5T75K003V,<921IHI;<>5+#(>2Z.N"K$]3W[YKLI48TT=U&A&DM-
M6;-<?XRUJZ::'PUHTQCU2]3=-<+_ ,N=MT:3_>/W5'KSVJGJ.L^(_ NFW,^I
M0/X@TN"-FCO(0J7$6!P)EZ,OK(O3J5[T>%]-DMX9;Z^F2YU34&$]W<(<JQQ\
MJ)_L*.%_/O6>)K^RC9;O8[*5/G>NR*B^ ]%BBA^Q6TEA/ @2.ZLI6AFP/5E^
M\?\ >SFI&F\6Z3&T7VFT\063*5:"^403E>A D4;6X]5'UKM%@4Q9K-NT S7G
M2=;#QYHR^\ZDJ=5V:,SX7WT]QX/%E<P2PRZ9<R6.R5@S!$.4!(X)",HR/2NT
MKC/AP,Z9K4G_ #TUJZ/Y,%_]EKLZ]>G)R@F^IQ25I-(****LD**** "BBB@
MHHHH **** /F#]H[_DH>G_\ 8*C_ /1LM%'[1W_)0]/_ .P5'_Z-EHH ]_\
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M -&RT4?M'?\ )0]/_P"P5'_Z-EHH ]_\"?\ )//#/_8*M?\ T4M=!7/^!/\
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MW."1ST(KM8Y$E0/&ZNC<AE.0:Z(.ZN;\T9)..PZBBBJ **** "BBB@ HHHH
M**** "BBB@ HHHH **** (I6[51D?$BGT(JU<G#?45G3-P: -JBFQMNB1O4
MTZ@ HHHH **** "N7^($$K>$I[^W4M=:7)'J,('7,3!F'XJ&'XUU%4M8O;+3
M=%O;W4F"V,,+/.2,_(!SQW^E %BVN([NUAN86W13()$8=U(R#4M<?\/M2A_L
M6+0&%['>:7!&"E["(I#"V?*; )!&T8Z]5.<5V% !1110 4444 %%%% !1110
M 4444 %%%<#X^3Q#+K&G+H5W) IL;V.0A2ZM(44QK@,,.<-M8],&@#OJ*\X\
M3^(-2\->"?#V-76PUB6"*/R;N(2":4(N[S7)^15Y+-U].>#5^(L7B>745O-
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M2[(H!;(SR16W75"_*N;<ZJG+S/E044451 4444 %%%% !1110 4444 %%%%
M!1110!5O>$5O?%9,K5LWB[K5_89KGY'H WK!]]C$?08_*K-9NBR;[5T_NO\
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M-=;7+:TGDZ@_HX#"@"SH$W^E31$_>4,/P_\ UUT%<;I5QY.K0$GACL/XUV5
M!1110 5FSZ]IL37D274=S=VD32RV=NXDG  SCRP<Y_QJS?K>/92K82PQ71'[
MMYXRZ Y[@$$\>XK@?#OP_P!7TS6M.N+^]TV2'3[FYNUGMH&2XN'G#960DGY0
M6/<YPOI0!M>&]%OYKB?Q%K.8=4OE"I:ALK9P9RL0]6[L>Y]@*EUKPO-)=KK>
MB7"VFO0KM$CC]U<I_P \I@.J^AZJ>1Z'J**YHX2C&K[5+7^NFP^9VL<GX?\
M'VF:W<06,L-Q9:A(TD1BFC/EM+'D2(DH&QR,$\'I^-=97GP\.V6A^.-!M5N+
MVXMII[R\L[1F016DA7+MPNY@3(0 3QN->@UTB"BBB@ HHI&.U2V"<#/ S0 D
MDB11M)(ZI&@+,S' 4#J2:\2\1P0?$O7-:O/#U]''):V$=C#-*^U9]SN9 1R?
M+96X8CJH(XYJ'7->UOXFWXT^Q273_#H.6:1>90#C+C^(Y!Q'T'5L]*[K0?#%
MGI6G+:V,.Q!RS$Y9V[LQ[DUTTZ&G-/1";+O_  GVD:?J0TW5!-8* JQ7DR_Z
M/*<#C>.%.>/FQ76(ZR(KHP9&&593D$5PVIZ;'Y3QR(K(PPRL,@CW%>:ZM?WO
M@V]M+30M2O;"VO799;6 JZ*,J 8U<$(2S#I@=>*UG@[QYZ;T$I=SZ N+F"T@
M::YGC@B7[TDKA5'U)KRCXG^.]*U/PI<:7H-P^IW#RH9OL<32(D:'<27 V]5
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M<&!1L$$'(Q5FB@!D4,<,"0HH$:*%5?0"N6\1KI<$2B 01W5LPQ&!LSN' SC
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M9.AYQ@]>RMKB.ZM8KB(DQRH)$)&,@C(XK<S):*** "BBB@ HHHH ^8/VCO\
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MM3OH9+>.9--60I)'8&4Y8HI'S>F&)P.!BI=+\57%O?IH?B.W2TUAL^1)&?\
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M*X)1@5)!! /?@@BMRN\D**** /F#]H[_ )*'I_\ V"H__1LM%'[1W_)0]/\
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MTWN[[6OT\SL:***W, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(7,NMW>IZ7J<-FUZ$^TI/8I<#<HVAT)(VMM '.1P.*DE\&Q2Z7J=C]ND O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M).VUUC56&0A!P0>E:_\ PNWX>?\ 0P_^25Q_\;HHH /^%V_#S_H8?_)*X_\
MC='_  NWX>?]##_Y)7'_ ,;HHH /^%V_#S_H8?\ R2N/_C='_"[?AY_T,/\
MY)7'_P ;HHH /^%V_#S_ *&'_P DKC_XW1_PNWX>?]##_P"25Q_\;HHH /\
MA=OP\_Z&'_R2N/\ XW1_PNWX>?\ 0P_^25Q_\;HHH /^%V_#S_H8?_)*X_\
MC='_  NWX>?]##_Y)7'_ ,;HHH /^%V_#S_H8?\ R2N/_C='_"[?AY_T,/\
MY)7'_P ;HHH /^%V_#S_ *&'_P DKC_XW1_PNWX>?]##_P"25Q_\;HHH /\
MA=OP\_Z&'_R2N/\ XW1_PNWX>?\ 0P_^25Q_\;HHH /^%V_#S_H8?_)*X_\
MC='_  NWX>?]##_Y)7'_ ,;HHH /^%V_#S_H8?\ R2N/_C='_"[?AY_T,/\
MY)7'_P ;HHH /^%V_#S_ *&'_P DKC_XW1_PNWX>?]##_P"25Q_\;HHH /\
MA=OP\_Z&'_R2N/\ XW1_PNWX>?\ 0P_^25Q_\;HHH /^%V_#S_H8?_)*X_\
MC='_  NWX>?]##_Y)7'_ ,;HHH /^%V_#S_H8?\ R2N/_C='_"[?AY_T,/\
MY)7'_P ;HHH /^%V_#S_ *&'_P DKC_XW1_PNWX>?]##_P"25Q_\;HHH /\
MA=OP\_Z&'_R2N/\ XW1_PNWX>?\ 0P_^25Q_\;HHH /^%V_#S_H8?_)*X_\
MC='_  NWX>?]##_Y)7'_ ,;HHH /^%V_#S_H8?\ R2N/_C='_"[?AY_T,/\
MY)7'_P ;HHH /^%V_#S_ *&'_P DKC_XW1_PNWX>?]##_P"25Q_\;HHH /\
MA=OP\_Z&'_R2N/\ XW1_PNWX>?\ 0P_^25Q_\;HHH /^%V_#S_H8?_)*X_\
MC='_  NWX>?]##_Y)7'_ ,;HHH /^%V_#S_H8?\ R2N/_C='_"[?AY_T,/\
MY)7'_P ;HHH /^%V_#S_ *&'_P DKC_XW1_PNWX>?]##_P"25Q_\;HHH /\
MA=OP\_Z&'_R2N/\ XW1_PNWX>?\ 0P_^25Q_\;HHH /^%V_#S_H8?_)*X_\
MC='_  NWX>?]##_Y)7'_ ,;HHH /^%V_#S_H8?\ R2N/_C='_"[?AY_T,/\
MY)7'_P ;HHH /^%V_#S_ *&'_P DKC_XW1_PNWX>?]##_P"25Q_\;HHH /\
MA=OP\_Z&'_R2N/\ XW1_PNWX>?\ 0P_^25Q_\;HHH /^%V_#S_H8?_)*X_\
MC='_  NWX>?]##_Y)7'_ ,;HHH /^%V_#S_H8?\ R2N/_C='_"[?AY_T,/\
MY)7'_P ;HHH /^%V_#S_ *&'_P DKC_XW1_PNWX>?]##_P"25Q_\;HHH /\
MA=OP\_Z&'_R2N/\ XW1_PNWX>?\ 0P_^25Q_\;HHH /^%V_#S_H8?_)*X_\
MC='_  NWX>?]##_Y)7'_ ,;HHH /^%V_#S_H8?\ R2N/_C='_"[?AY_T,/\
MY)7'_P ;HHH /^%V_#S_ *&'_P DKC_XW1_PNWX>?]##_P"25Q_\;HHH /\
MA=OP\_Z&'_R2N/\ XW1_PNWX>?\ 0P_^25Q_\;HHH \*^-'B32/&'C&TU#0;
:O[7:QZ>D#R>6\>'$DC$8< ]&'YT444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image7.jpg
<TEXT>
begin 644 image7.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0T!WX# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?C;_ )[3?]]4 ?1/VZU_Y[Q_G1]NM?\ GO'^=?.W]A^-O^>TW_?5']A^-O\
MGM-_WU0!]$_;K7_GO'^='VZU_P">\?YU\[?V'XV_Y[3?]]4?V'XV_P">TW_?
M5 'T3]NM?^>\?YT?;K7_ )[Q_G7SM_8?C;_GM-_WU1_8?C;_ )[3?]]4 ?1/
MVZU_Y[Q_G1]NM?\ GO'^=?.W]A^-O^>TW_?5']A^-O\ GM-_WU0!]$_;K7_G
MO'^='VZU_P">\?YU\[?V'XV_Y[3?]]4?V'XV_P">TW_?5 'T3]NM?^>\?YT?
M;K7_ )[Q_G7SM_8?C;_GM-_WU1_8?C;_ )[3?]]4 ?1/VZU_Y[Q_G1]NM?\
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M?C;_ )[3?]]4 ?1/VZU_Y[Q_G1]NM?\ GO'^=?.W]A^-O^>TW_?5']A^-O\
MGM-_WU0!]$_;K7_GO'^='VZU_P">\?YU\[?V'XV_Y[3?]]4?V'XV_P">TW_?
M5 'T3]NM?^>\?YT?;K7_ )[Q_G7SM_8?C;_GM-_WU1_8?C;_ )[3?]]4 ?1/
MVZU_Y[Q_G1]NM?\ GO'^=?.W]A^-O^>TW_?5']A^-O\ GM-_WU0!]$_;K7_G
MO'^='VZU_P">\?YU\[?V'XV_Y[3?]]4?V'XV_P">TW_?5 'T3]NM?^>\?YT?
M;K7_ )[Q_G7SM_8?C;_GM-_WU1_8?C;_ )[3?]]4 ?1/VZU_Y[Q_G1]NM?\
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M#_GF*/L<'_/,5/10!!]C@_YYBC['!_SS%3T4 0?8X/\ GF*/L<'_ #S%3T4
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M#_GF*/L<'_/,5/10!!]C@_YYBC['!_SS%3T4 0?8X/\ GF*/L<'_ #S%3T4
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M#_GF*/L<'_/,5/10!!]C@_YYBC['!_SS%3T4 0?8X/\ GF*/L<'_ #S%3T4
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M#_GF*/L<'_/,5/10!!]C@_YYBC['!_SS%3T4 0?8X/\ GF*/L<'_ #S%3T4
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M#_GF*/L<'_/,5/10!!]C@_YYBC['!_SS%3T4 0?8X/\ GF*/L<'_ #S%3T4
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M#_GF*/L<'_/,5/10!!]C@_YYBC['!_SS%3T4 0?8X/\ GF*/L<'_ #S%3T4
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M'5_^05<?[M '!?!OG2]</_42>O2Z\T^#7_(*UO\ ["+UZ70 4444 %4=9_Y
ME]_UP?\ E5ZJ.L_\@2^_ZX/_ "H \^^"W_(N3_\ 75__ $(UZ?7F7P6 _P"$
M:F/_ $U?_P!"->FT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !5'5_^05<?[M7JHZO_ ,@JX_W: ."^
M#7_(*UO_ +"+UZ77FGP:_P"05K?_ &$7KTN@ HHHH *HZS_R!+[_ *X/_*KU
M4=9_Y E]_P!<'_E0!Y]\%?\ D7)_^NK_ /H1KT^O,O@L1_PC4W_75_\ T(UZ
M;0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% " Y.*6C%% !1110 4444 %%%% !1110 4444 (3BEHQFB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *HZO_R"KC_=J]5'5_\ D%7'^[0!P7P:_P"0
M5K?_ &$7KTNO-/@U_P @K6_^PB]>ET %%%% !5'6?^0)??\ 7!_Y5>JCK/\
MR!+[_K@_\J //O@M_P BY/\ ]=7_ /0C7I]>8_!8Y\-S#TE?_P!"->G4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK_\ (*N/]V@#@O@U_P @K6_^PB]>EUYI\&O^05K?_81>O2Z "BBB@ JCK/\
MR!+[_K@_\JO51UG_ ) E]_UP?^5 'G_P6'_%-S'UE?\ ]"->G5YC\%B?^$;F
M'I*__H1KTZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$M6-WI:V[/EE3IFO7ESSFOF7X):PUKK:VY/##;7TWVH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "J.K_\ (*N/]VKU4=7_ .05<?[M '!?!K_D%:W_ -A%Z]+K
MS3X-?\@K6_\ L(O7I= !1110 51UG_D"7W_7!_Y5>JCK/_($OO\ K@_\J .
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M-?9@"GS\5](?";7CJ>@0PO)N95[F@#T>O%?CI_QYQ\]C7M5>*_',?Z&A'H:
M.<_9[_Y"4_T-?1M?./[/8']J3G/.#7T=0 5R_P 0=1.F>#[VX5MK!< UU%>1
M_''53#X5EM5?!?M^- 'BW@F$ZSX_MG<;AYP8_G7TUXXTM;OP5=VH7("<"O"_
M@9IBW?B!IV7)1<Y_&OI:]A6:PFC89!0\'Z4 ?'G@N[DTOQM:H&VC[0 ?SK['
MMI1-;QN#G<,U\:>(+=]'\9^<!L5)MP/XU]7^#+W[?X<M9MV[,8.: .AHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU'5^N*]5^#^L+=>&[>W!R44*:R?C7H27.ERW>#N7YJY'X&:O(FI):,PV%NE
M'TG11VHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#'AN8^LK_P#H1KTZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZEXZ,.<J'P*]\^&>APVOAN-F3EAZ4 >(+\)]28CY!R:63X5:BF5V#WKZE%C
M,?(.#GI2-I]NQ)*#F@#Y;_X5/J(524%<?K_AZYT&^595P%.:^U38P$8*#\J\
M2^-^@P0Z>]U$AW 4 =;\(]8_M#0$4_PK@5Z37SU\#]9\I/LC'J<=:^A: "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "J.K_\ (*N/]VKU4=7_ .05<?[M '!?!K_D%:W_
M -A%Z]+KS3X-?\@K6_\ L(O7I= !1110 51UG_D"7W_7!_Y5>JCK/_($OO\
MK@_\J //_@L?^*<F'_35_P#T(UZ=7F/P6 _X1N8_]-7_ /0C7IU !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7S_ /M#H5.FN3P2V*^@*\ _:%@N
M;F73!%$S*N[)% &7\(/%EGH\D@G=4!3'->L'XG:0"1YZ?G7R;'::E$<Q1NO'
M:I#'J_4K)S[T ?4-W\5-*$9"S+D5YOXB^*V9)%@G.#G&,UY*+;5I.B.<^]:-
MCX2U;49%!MG.>] %">YO==ON=\A=N.]?1WPH\(-INF)/-%M9N>16+X%^$[01
MQW5UL#9SM->VVEJEI;)"@ "C'% $P& !Z55U/_D&7'^X:MU4U,$Z9< =2AH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK\,1>(8D60XV^U=$9D#[,C-/&"* .0\+^#+;0;@RQX)(QTKL*0#%+0 4444
M%-==R,OJ,4ZB@#SG5/AU;7MU]HX#$Y/RUW&D6"Z=IL-LAR$4"KV** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>G5YC\%C_P 4Y/\ ]=7_ /0C7IU !1110 4444 %%%% !1110 4444 %%%%
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD QFEH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "J.K_\ (*N/]VKU4=7_ .05<?[M '!?!K_D
M%:W_ -A%Z]+KS3X-?\@K6_\ L(O7I= !1110 51UG_D"7W_7!_Y5>JCK/_($
MOO\ K@_\J . ^"P'_"-S'OYK_P#H1KTVO,/@K_R+D_\ UU?_ -"->GT %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%5;R\CM8R6/:A %Q=) O)YK&N-8<OA3Q64\\^H7!()
M*9XK;MM-@:-=RC/>MN1)%V*W]JS#G/7K6C9:F)5PYYIZZ9 V05%9FIV#0%7M
MQC'7%+1Z"T.C5PXR*=7.Z/J)$IAF8Y/W<UT(.1FLVK":L+1112$%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4A&1BEHH R?$-FMYH\T;#.$/\ *OC;7X7TWQ+<
M$94K)Q^=?;<Z[K>1?52*^2?BYI_V+Q(6"X#L30![_P#"C4/MWA*+<VYE.*[N
MO$O@1J8G@DM5;A5)Q7MM !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%1RRK#&78@ 5S>L^,+*PMI#Y@#@<<T =++*L2[G
M.!7/:MXLM-/C+>:H(]Z\<\5_%*X^S&.WN&R>F&KRK4/%=_J&[S9G(]S0![MK
M7Q0C$<B1W S[&O+-<^(6H3LXCN7 /H:\],C22;F).:LQZ?--'YB*=M %JX\0
M7\YR]S*<^K&J#W,LV2TC$^YI40;MCCY@<5ZEX1^'L>MV"W8A#(P]* /*HT,I
M.22:GBL)),84U]$Z=\)-/!W/;)_WS70V7PPTJ)>;://^[0!\O#1)VZ(:J7=F
MUHVUP0:^Q8?A]I"J,V\>1_LUX%\8M'MM+UC9 @49/04 >:0VQG?:@R35S^R)
M<<H>.M=E\*='M]5U^..= R^X]Z^@W^'&CF0_Z/'@]?EH ^1WTR11]TU!]F=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTX)=1-NW-3<$%D=8"#TH!S6!8ZJXG\J7H>YK>1E=<J<BH:$T.HHHI""BBB@
MHHHH **** "BBD)P* &-((T9F[#-<5J>I/>7AA7[N<5M>(]1^RVC!#\QK TN
M)3%]HE&6;GFMZ<-+FD5U->R@CMT&*N)<A3Q65]I).!WJ6&7/7M5R0V;<-R=Q
M)JR DZD,.M8T4WSXK0A<[@,UC)6(9E:O8_976X@X*U?T:_\ M46&^\*O31+/
M&R.,Y%<PK/IFJHHXC8XHW5A[HZ^BFHX=0P[TZLR HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!",C%?.OQ\TP+>P7"CCFOHNO*OC/HZW>@/<XR5''M0!YK
M\#M4%EK;1_\ /0;:^GE.5!KXQ\!:@VF^*X%!X,@!K[%T^?[191R>HH M4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445!<7<-NC,[@8'>
M@"8D#J:S=3UNUTV%FD=3@=,UPGB3XG06&Z&(H6Z9KPOQ-\0-4U*[D5+EE3/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M06N8HPN]AT'M7OVGS+/IUO*IX= 17A_Q#O0_CN2W./E88_*@#VK0O^0%9?\
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M&MMK4"H2!)CUKL4.><Y%?%7A[Q7?>']129)R4 ^Z:^D_!'Q"AUZ.*.4HK$4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO929Y\I:^.M:M38ZO<PMV=OYU])?!O6TN]#@M<G<BA: /6>M-"X;-*!@8I:
M$8!E(/>L.W\-6T-[)<E$+.<]*W:* &1QK$FU1@4^BB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "D(SBEHH **** $SSBN!^*5R\.A.J Y9#T
MKOMOS9K(U[0(-<M_+F;  ]* /BVTM)+O6=A'S%\XK[!^'ML;7P98QLFU@IR*
M\[/PH2T\0"XB.5SGI[U['IUL+2PB@'15Q0 S4=/BU" Q2*#GUKQCXA_#%YX3
M/91J2,G"U[GCG--EB29&1U!!&.: /A;5-*GTVX,<ZE2/6KN@>(I]&O(Y$=L
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M2+R+2*+^XH%3444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5'5_\
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M:Q&N%=L9]:RY0YC<HJ""YCG7*L#^-3U)=PHHHH **** "BBB@ HHHH ****
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M*U2?2YDEC<K@YXKZ0^'7Q$MM2LHX9YQYB@ [C0QGK5%1PRK-$LB$%3T(J2D
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MG?Q@56\)2[O2O1*\\^+J[_!L[>@H ^=?!GBF?PWK1=6_=EL$9KZG\'^*(/$.
MFK(I <#GFOBN4E9VQV->E_#/QP=&U".">4B-B!0!]7T5GZ3JD&J6BS0R*P([
M&M"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&
M92#T-+10!2.E6K2;RGS5;1%C4*HP!3J* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *HZO_P @JX_W:O51U?\ Y!5Q_NT <%\&O^05K?\ V$7K
MTNO-/@U_R"M;_P"PB]>ET %%%% !5'6?^0)??]<'_E5ZJ.L_\@2^_P"N#_RH
M \_^"P_XIR?_ *ZO_P"A&O3J\Q^"QSX;F'I*_P#Z$:].H **** "BBB@ HHH
MH **** "BBB@!#7F'CBY^UW0A P4->GL<+FO'?$=P9-=D7T8UTX97D:TEJ4C
M/N4<=!55GPK+ZG-+(^.E57E)S7K<NATV)A)WIPDSSBJGFGIZ]:<LI%4E9 M'
M<MNY;8@KM- MO)L]_<\UQNG*;BZ"CMTKO[-/(M OM7FXJ5]#QL=4O/0G+%G!
MZ4\'#"H0QP/UIP8[N:XD<\66"VYMPXQV]:>N0F1S4"D[OY5+ _S8-%BMV.OK
MI8].;>,$K7!V"E6:7U)KH?$]T8[=D6N?LB?)_G7=AX61Z6'1:\W<Q8U$)B&Z
M=*A:7YR*;YF1D5TV.NQ<64Y]NM6HI^>E9:R$<58CDP>:AQ(:-R&;)K8M[C&T
MXS7-V\IW"M>VE_>+Z"L*L;HEKJ=+;N!A363XNL!>:7)\HSMZU;M7+/GM5Z[C
M%S92(>ZFN6+Y9(F]F?.L3F*X>%EZ'%6T<*2QIFMQ&PUF9&&/FJ" 2WDFR,=Z
M]V<ERG14DDB\L\DI"Q(6SZ5TFC>'Y[W#R+M'O5WP[X9(ACEE W'VKM(HX;2(
M1KUKSJM74\VI5[%'3_#\=I\Q936P(XMN-@J RD#COUI1*1UKF<KD1=U<MI'$
MHSM'%+$J ;2HJLLI_P *E5^14,HG>&.1"NT#-9,WA]I_G$@7VK563)J8R$D
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M#D$<5\.Z%KL^CW2O&3C/3-?2/PW^(=OJT"VMPQ#@8'- 'J@Y%+2*P9<@\4M
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M;JNF3:;<F*1"N#CFM7PWXBGT748F60[01QFO9/C#X,LTL'U"*)58<_+Q7SP
M0Y.?NU:(:/L_PAXH@UG38&WC<5&1FNKZU\:^#/&E[H5VB"9MA;.":^IO"GB>
M'7=.CE\P%R.<4".C4YS[&G444 %%%% $-Q;I<(5D4$>]5%TFW"@>6/RK1HH
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M<^).JPV6BS([@,5Z&J/P=?S?",9[$M_.@#TFBD' Q2T %%%% !1110 4444
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MB'4SIT)DW8XKS:?XBRK,RK*< ^M:+4SF^4]W6(*"21[U"P+L54\=Z\+/Q'F
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M@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO&TSQ7=6X.U<KQ3@KQL1+XN8]C20"5^/>O+_ (L2--';1K\H)(XKT8/G:_\
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M5:T\-5F[11FZB1W+S)&>2*JMJ<"D@L./>O)]0^)0E8^6,>G-<O>^.;UG)1P
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MNXW=OSI1\79><X_.@#Z3^W0_WA^='VZ+^\/SKYL?XN38!&/SI3\79<CZ<\T
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M<_NNG/6@#YF^QR_W33)(6B(#9&:^FU^$E@$;]UR3GK7E?Q/\)0:!=IY2[0:
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MMD$].E:.@6RWFK+"W(8@5Z=%X-MN&V=.*$!Y_P"#K>4:F-V>&KUK7WFCT(M
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M2HGN%[&JTD@SC\JKF0 Y[4*)O&):>XRA'YU$9PQJH9QGV[U$9P":M1-% O\
MGKZTT3#.,\#I6?YPSCUIIG&>*?*5R&G]H&[':G"<9*_G66LXSS4JS#=2Y27
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M%.8E*YU'A?4I;2VD6/."OKWJV3+>RYDSEZR_"Z">80#^(U[3X8\"Q7;H\H)
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M^V1]: -7X7X\R;\:]1P/2O+?AA_K)<>]>IT )@>E<[XQP-%E)]*Z.N:\9_\
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M6Y]30!UW[/9_XFMR.WE&OHBOGC]GO_D*7)[^6:^AZ "O/_C&<?#S4/HO\Z]
MK@/C%S\/;\>R_P Z /E+0/\ D8K'_KN/YU]NZ+_R!K3_ *YBOB+0?^1BL?\
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MQ_G7V=XB.-"NO]PU\8^*?^0[+_O'^= 'TG\&!_Q3Y/\ LBO3Z\Q^#39\/_\
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MS)*.G6O4Z "N;\9G_B22_2NDKFO&?_(&E/M0!XMI9_XG*\?Q5]":;_R#;?\
MW!7SWI9_XG"\?Q5]":;_ ,@VW_W!0!:ILG^K;Z4ZF2?ZMOI0!X=XY_Y#YX[U
MU_PS_P!1*/<UR'CD_P#$^/'>NO\ AF?]'DX[F@#T6BBB@#C_ !__ ,@EOI7E
M'AP_\3Q./XJ]6\?C_B5$^U>4^'#_ ,3U!C^(4#/H"T_X\XO]T5/4-I_QZ1?[
MHJ:@1%<_\>[\=C7@OBS_ )#DG^]7O5R<6[\=C7@OBT_\3N3CH:3&>C?#<_\
M$K8>]=S7#_#?_D%-_O5W%,05P7Q*.-.6N]K@OB4/] 3Z4,#S_P (_P#(>C_W
MA7O47^J7Z5X+X2.->C_WA7O47^J7Z4D ^BBBF 4F?FQ37F2/[S8J/[7!_?%
M$]%-217'RG-(TB@XSS0 ^BCK10 51U?_ )!5Q_NU>JCJ_P#R"KC_ ': ."^#
M7_(*UO\ ["+UZ77FGP:_Y!6M_P#81>O2Z "BBB@ JCK/_($OO^N#_P JO51U
MG_D"7W_7!_Y4 >?_  6!_P"$;F/K*_\ Z$:].KS'X+$_\(W,/25__0C7IU !
M1110 USMC9O0$U\Z>/\ Q%K&MZT^DPQX@+[0VZOHMQNC9?48KBD\#6IU?[9(
MI)W;NE 'SU=>!]8LQ]H#,53YNI[5[?\ "/Q0^KZ$D-QQ)%E>M=5K.G:8FEW
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M_:EKD#?U&:KWNIVALY5+]4/\J^9?^%I7N0=PX&.M1R_$^]EC=2PY&.M '/\
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M?[-6: "J.K_\@JX_W:O51U?_ )!5Q_NT <%\&O\ D%:W_P!A%Z]+KS3X-?\
M(*UO_L(O7I= !1110 51UG_D"7W_ %P?^57JHZS_ ,@2^_ZX/_*@#S_X+#'A
MN8^LK_\ H1KTZO,/@M_R+D__ %U?_P!"->GT %%%% !39#B-C[4[H,U!YL5S
M$Z1N#D8H ^;?&_CJ]C\07=E'))L60I@9KU3X50VJ>'(I49#(V2<'FLG6?A$M
M[>W-_P";&6<LV*YKX>:G+H'B%M#G8\2;10![#KN@)J\T4K("5QUK2EMU@TSR
M5& JXJX*9-'YL3)ZT ?/NO6<KZ_,P4[<XK,:QF60MM.*]LN?!B7%PTI9?FJ
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M4C?!V(*2)(^*"3YE%G,<_NVZ>E"VLNT_NF_*OIP?!J%E!\V,4H^#, )/FQ4
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MYI\&O^05K?\ V$7KTN@ HHHH *HZS_R!+[_K@_\ *KU4=9_Y E]_UP?^5 '
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/#NBI80*Q0!@/2N@'(KKIPY4>;7J\[LA:***U.8**** "BBB@ HHHH ****
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MV2JBNX[UYC\+=*ELK8,X(R*]/KPLPC!5WR;&E*_*KA24M%<3- HHHI@%%%%
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M1>H0F@"73]:M[^X:*)U9EZ@5J5XC\*M7FO?%-Y&Y) (KVTG&* %HI&.!FEH
M1@2.*H2:M;QWPM3(OF9QC-7STKQBXU>63XNSV:L?+CD7^5 'M%%%% !1110
M4444 %%%% !3)(Q(A5AD&GT4 >"?%;P9=QZA_:.GQ'+\G97!Z?X4U[5+V*"5
M)"@^8YKZMO+**\4+*@8#UJG::';6UP95C7ICI0!G^"M"71="AB*;9,<UTU(%
M"C &!2T %%%% !5'5_\ D%7'^[5ZJ.K_ /(*N/\ =H X+X-?\@K6_P#L(O7I
M=>:?!K_D%:W_ -A%Z]+H **** "J.L_\@2^_ZX/_ "J]5'6?^0)??]<'_E0!
MY_\ !8Y\-S#TE?\ ]"->G5YC\%@1X;F/K*__ *$:].H **** "BBB@ HHHH
M**** "BBB@ HHHH **** &2C=&P]J\2\0IY6L7!Q_&:]O/2O'/&T)AU9SC!;
MFKB>;F2_=G,3,<$^G2JC$YJS)NV<?A51B<UL?.P=DR2,_-]:N)R.E9\9)/\
M.KT;$C'>@<"[ 3FKD?WJIPY_PJ[%T%)G3 O1\C%74)$2_K5.+.*M)DQJ/SJ&
M=,2[*2+4-WKI_"BYTX2>M<K(3Y 4=<5U_A5"FCQ ^]0SMPJ]XWJ***D]0***
M* "BBB@"O=6L5U$R2(K CN*\9\8^&FL[UIH(R%)[5[=5#4]/COH"CJ#^%:TJ
MG*S"M2YT?.+.8I,$<TKJ"P8#J*[3Q1X1DMYFECB(7/&!7'O$\,NUP1BO1C4Y
MD>7*FXLC [D=:F1!3@5E_"I54'@=:O0C46-!N^G2K:'!]A4*1,#GTZ5;B3BD
MQHL1/GL*M1J,8'4U6C50.:M+\GS#\:S:1JKEN(-$-V*DFOVBCS%C>W&*J?:V
ME&Q3DUO^'] >YECGEC)3/<5A.5C>G&XSPYH3WUV+FY#<<C->CPQ+#&%50 /2
MFV]NEO$$0 "IJY9S<CMA340HHHJ#0**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBBA@%9.NZM'IFGR2E@& K0N;A+:W>5R %&3FO!/'/BM]0NIK6*4E
M"3@ UWX#"2Q-2RV(F[(YOQ1K=QJFI2GS&*@\<UD *(T/<')JUH]F]]>^4JEM
MQP*?XETBXT>4;T*J1Z5]GAO9PE[-[G&VSVOX6WT%UI+* F] .@KT/-?.'PMU
MXV&L) \F$D/()KZ+AE6:%9$.0:^2SC#NEB&^C.JG*Z'D9!![URNK>$K34+Z.
M5XE)5L]*ZL=:6O-H5IT]8FC5RM9V<5I L<:*N!V%6:**EMMW8)6"BBBD,***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "D/ XI:* (GC652KJ"/<5Q
MOB/P;:WVZ185W$=A7;T=:F<>96-:=64'='S)K7A.>RF?;&P7-<RR,I:*08Q7
MU=J&CV]\C!XU.1Z5Y?XE^'Y;=);P<Y[+VKEE2L>OAL?T9XR  #CG%+L;' X)
MK?U#PQ=V+-NB8>G%9!#P+L8$<USR3/4C6C)$!CP!BGJN!G%2QC+<_C4H1=V#
M4:E<S9& ?2ID''2I N.GX5*J<9HN)W8U!G'%31J>XZT;,#(_&I@&('ZU-R-4
M.0E>U2H<-0BDT]5XX_"E<AL>#S4BD$YIBCL>YJ4*J'!H6HK)ZL<O) /K4RDD
M$8Z=.*B)4'WQ2"=MZHN>>E:QB9RDD6H'4Y#&D\XHY1><U)'I-S,RE$;D\<5U
M^D>#7D57FA.?<5K&%V<\\1RHYZPTF>]D4E#@FO1_#_AF&V"R21@G'>MG3]'A
MM(U 0 CVK4 P,"NF%*VYYE;$<VB&Q1)$FU% 'M3Z**W.0**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>.P9#@*30!W/C'Q7)X=\G:0-Y&<BN3UOXJRV&D"YA=3(>V!57XZ[H[""8=F
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MXA-G_A:%B,\^>.?QKW3Q%SH5U_N'^5 'E?P:A9(V_P!]OYU[37CGPD.2X!P
MS?SKV.@#YR^+5NMWXZ,9&?F'\J]U\+0+;^&-/C48 A7^5>%_%B;[+X\\T]-P
M_E7N?AJX2X\-Z>ZMUA4\4 >/_%VW6W\0Q72C#$]:]+W[_AU$W<VU>6_&&_$G
MB>WLTPS9Y%>G\Q_#F($8/V;% 'GOPG0_\)9>L3W%>I>+YK>VT:664C.#UKRS
MX4.1XKN1ZFM'XQW]SYD5A#,8Q(0#B@#F+OQ]-/:26-F[!E&!@UYQ#->7/B**
M2Y+9,@SFO8_ _P *8[=8]1NIGE$@W$-7-_$&RT[3O%PCLT5!N  ':@#W[0L#
MP[9^@A'\J\<$QE^,ER5/'F+G\J]BT#_D6;'_ *X#^5>-6NU?B_> G_EHN/RH
M ];\7NR:#.5./E/\J^:_#7B<:!KEW,[?ZQSC\#7TGXOC,F@3!?[I_E7S?X?\
M MXLU6XC$[QLCGA?K0!T>H?$T7EK)#YAPW'6K'P8NC<>,;YL_*2,4DWP$DAB
M9S?3<<]O\*Z;X9>"E\.ZQ+*)VD;OGO0![!1110 4444 %%%% !1110 4444
M%%%% !5'5_\ D%7'^[5ZJ.K_ /(*N/\ =H X+X-?\@K6_P#L(O7I=>:?!K_D
M%:W_ -A%Z]+H **** "J.L_\@2^_ZX/_ "J]5'6?^0)??]<'_E0!Y]\%O^1<
MG_ZZO_Z$:]/KS+X+8_X1J;'7S7_]"->FT %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7(>.K?S-/W8Z5U]96OVZW&G.K#/!IQ>IAB8\U-G@G\1!]:AE
M49XJ]?1>3=RICHU4VK9'RDU:3&1J U6XEQ5=0,C]*MH ?I5"@7(0/6KD8YS5
M.#&?YU=CI,Z(%^+IFKMN,Y)J@G48K0B*K$/TJ6=,2SIL0GU(#TKT>%0L2@=A
M7!>%X3)=R.>S5WZ_='TK.1Z^%6EQ:***DZPHHHH **** "BBB@ I*6BDT 48
MHHI@)M'H*-H]!2T4"L'2BBB@84444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !112$X!- %.[U.WLR!*X4GU-5AXAL#_RV7\Z\&^*OB>__ .$I^QVD
MCX5.BFN&&LZZN/GE^\,\F@#[#@N([A=T;9%9NM&WO+&6R<C,@Z5S'PRN[JYT
M+S+HL6 [UR]]K]P?B59V0D;RW=AC-5%VDF)JZL<%XD\/S:?JKM&A$8;.:R;3
M5I-/UB&:-L*K &OI+7_#MM?:5,?+4OY>1QWKYBUFQ;3]4FMY!@;R:^RRW%+&
M1]F^AR5(\K/JSPUJ*ZEHMO,&RQ7FM9AN!^E>-?"/Q"7LQ:R2'C@ FO9@01D=
MZ^9S##/#XAQZ'33E=''W_@VSU'5Q=2Q*2#Z5T]E9Q6%LL,2A5'H*LT8R*YJM
M>=2-FQI68M)WI:*QL4%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M% !1110 51U?_D%7'^[5ZJ.K_P#(*N/]V@#@O@U_R"M;_P"PB]>EUYI\&O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "JNHS_ &:QDE]!5JLCQ*_EZ%<,3C H \=T?1K/Q)\1;J2]^XL9
M/7WKT5? GAF1R@7+?45X$?%%WI_B6[>R)WX*\5<T7Q[KL'B."6YD?R=WS CB
M@#Z4L-)M=*M&BME(3%>.ZC:!?BQI>,[G=B#^%>M^']8CUG3EF4@\<XKF+OPV
M9?'=C?\ .(RQ'MQ0-'>;0T(0]"N#7S]\5_#GV;47O8@=O4\5]!C@5R7CK0DU
M?1I1LR^.,5Z&68EX>NGW,JD>9'SYX*U.:RUF-80<;AFOJ?3Y3-80R'JR@UX[
MX*\!)#?F2:,G:V>:]HAB$,2QJ,*HP*ZLZKPK37+N*G&Q)1117BFH4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4A&:6B@!&4,,$<4H&!@444 %'7K110! ;6(ONV\U.!@8%%%
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M_P %A_Q3DQ_Z:O\ ^A&O3J\Q^"QSX;F'I*__ *$:].H **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHS10 4444 %%%% !1110 QHHV.612?<4
M\  8%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !5'5_P#D%7'^[5ZJ.K_\@JX_W: ."^#7_(*UO_L(O7I=>:?!
MK_D%:W_V$7KTN@ HHHH *HZS_P @2^_ZX/\ RJ]5'6?^0)??]<'_ )4 >?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M121+)#@(PXQ7E/QD\,17FE&^!_>*?3WH X?X.>(KAM4CLSN*,W6O7/B'K_\
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MNJ$D;?:N?^$#D:Q+'*3O63'ZT ?1E%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 51U?_ )!5Q_NU>JCJ_P#R"KC_ ': ."^#7_(*UO\ ["+UZ77F
MGP:_Y!6M_P#81>O2Z "BBB@ JCK/_($OO^N#_P JO51UG_D"7W_7!_Y4 <!\
M%L?\(U-CKYK_ /H1KTVO,/@M_P BY/\ ]=7_ /0C7I] !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%%  1FH)+6.0?,!4]% FDRF-.A!SM%6
ME4*,"G44!RH****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(RAE(/>EHH ^
M??C)X1N))OML$;%>Y KPB2-H9BC@@CUK[JU?38M3LG@D4-D<9KY4^*GADZ'J
MZD* KD]* //@&;+#M4UC\U[#Z[Q_.F(0BL/45-I*[M2@7U<?SH ^U?"&/^$;
MM<?W!_*MVL7PJNWP_;#&/D'\JVJ "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K,UC28-5M7CE4'(Q5^9MD$C>BDUX]I?Q$1?%;V%Q*5Q)M^;B@!
MVK?"N%HI6MX#N(/05Y'>:%K/@^Y:>2.2.'=U(Q7US%<PS1AED4AAV->9?&?[
M$GA.4;D\UON\\T =%\.=:&K^&X6+AG48/-4_BLQ7PN^.Y'\ZP_@C%)'H3%\[
M2<BMCXMD_P#"+,!ZC^= $7PK).EL.U8OQO"OIL&>@=<_G6U\*&5M(8A@3Z9K
M&^-TBC38%QU=?YT =WX,C2+P_;* !\@_E6KJMY;V=C)+.P"!3G-9OA'!T.W'
M_3,?RK!^)UTT.B2QKGE: /,-0^(A^W-9Z7+E68@!37#>(-+UF2Y-[=H^UFSD
MBO4OAGX)M+VQCU*01L68GJ..:M_%ZYL-/L(K5"F\CM0!U7PBV'P1;NO4@YKA
M?B!;K/\ $O3CC)&W^==G\&A_Q14(SGK_ #KCO':-'\3M.&>NT_K0![59QA-+
M"@<;#_*O$KBU"_$^S8#_ ):C^=>X0'_0 /5/Z5XO=?\ )3;3_?'\Z /9M6.-
M*N">R'^5>#_#NVBG\9271&6,AY_$U[QJH+:7.N,Y0C]*^?\ P9J,.D^.S8S,
M$8R]_<T ?05[$LUE,D@^4J?Y5XCX)LTMO'%VD(^02U[-K&H06NES2M*FT*>_
MM7B/@&_%]XUNIXLF-I.,"@#Z!HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "J.K_ /(*N/\ =J]5'5_^05<?[M '!?!K_D%:W_V$7KTNO-/@U_R"
MM;_["+UZ70 4444 %4=9_P"0)??]<'_E5ZJ.L_\ ($OO^N#_ ,J . ^"QSX;
MF'I*_P#Z$:]-KS'X+#_BG)C_ --7_P#0C7IU !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %(#D4M% %34KV.PLI)Y#A5%?*OQ8\31Z]JZQP@D1D\U[+\8O
M$G]E:%]GB?\ >.>1[5\S6,<NL:TB8+-(U %%K698?,*G;ZU:T%<ZS; ]W%>R
M7GPX8>%))1$?,5-PX]J\GT>V>#Q+;PR#!5\4 ?9GAS_D"6_&/D'\JU:S- /_
M !)[?_='\JTZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIU;5/%A^V+;R[!QS7L6K?"RWN-0>94^\<]*Z'2_AW9P:2T#(,GVH I_!'>/
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M** "BBB@ HZBBB@!,#TI<8HHH **** $VC=NQS2#.3FG44 %%%% !@>E%%%
M!1110 4444 %%%% "8%+110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !5'5_^05<?[M7JHZO_ ,@JX_W: ."^#7_(*UO_ +"+UZ77FGP:_P"0
M5K?_ &$7KTN@ HHHH *HZS_R!+[_ *X/_*KU4=9_Y E]_P!<'_E0!Y]\%O\
MD7)_^NK_ /H1KT^O,O@L!_PC<Q[^:_\ Z$:]-H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BB@G S0!0UB^CL-/EED8+\IQ7R#\0-:?6==E.XLJ,<5ZU\9O&,M
MO'_9\$I7UVFO%?#VF2:_JZ0X+Y;)H ].^"/A<W%XU[-'\JC@D5]&H@10JC %
M<]X+T.'1-!AACB56(R3CFNCH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZO_R"
MKC_=J]5'5_\ D%7'^[0!P7P:_P"05K?_ &$7KTNO-/@U_P @K6_^PB]>ET %
M%%% !5'6?^0)??\ 7!_Y5>JCK/\ R!+[_K@_\J //O@K_P BY/\ ]=7_ /0C
M7I]>9?!8C_A&IO\ KJ__ *$:]-H **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "J.K_P#(*N/]VKU4=7_Y!5Q_
MNT <%\&O^05K?_81>O2Z\T^#7_(*UO\ ["+UZ70 4444 %4=9_Y E]_UP?\
ME5ZJ.L_\@2^_ZX/_ "H \_\ @L/^*;F/K*__ *$:].KS'X+$_P#"-S#TE?\
M]"->G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %<9\0?$4>C:!< 2;79"!S777$RV]N
M\K'A1FOESXK^,GU74)K.%@$5O6@#SB[DEU+57<DLTCYKZ:^$?A:.QT2*ZDB
M9AD'%>(?#KPM+KVN0,P/E \\5];Z99QZ;I\-K&,*HP* +M%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 51U?_D%7'^[5ZJ.K_P#(*N/]V@#@O@U_R"M;
M_P"PB]>EUYI\&O\ D%:W_P!A%Z]+H **** "J.L_\@2^_P"N#_RJ]5'6?^0)
M??\ 7!_Y4 <!\%ACPW,?65__ $(UZ;7F'P6_Y%R?_KJ__H1KT^@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHI*3=@%HHHI@%%%,DSY;8ZXH X+XE^*ET;09DC<"1EP*^4!YVK:H=S%GD?&
M:]*^,ES>-J@C9W$>X\9XJC\*_"1U?6H+B6,M&C!N:$M /;/A;X2AT;1(9GC_
M 'S -DUZ-@5';0I;P+%&H"J,8%24-@+1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %4=7_Y!5Q_NU>JCJ_\ R"KC_=H X+X-?\@K6_\ L(O7I=>:?!K_
M )!6M_\ 81>O2Z "BBB@ JCK/_($OO\ K@_\JO51UG_D"7W_ %P?^5 ' ?!;
M'_"-S>OFO_Z$:]-KS#X*_P#(N3_]=7_]"->GT %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 44AI:0!1113 **04M)
M%(>1B@T=*2;; \R^(?@!->@,\>/,4\#%:_P^\*)X=TR-6 \S&.E=JRAQ@CBA
M54+@#BJN H&**6BD]0$I:**$@"BBBF 44E!I.]M %HI*6A7 ****8!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZO_P @JX_W
M:O51U?\ Y!5Q_NT <%\&O^05K?\ V$7KTNO-/@U_R"M;_P"PB]>ET %%%% !
M5'6?^0)??]<'_E5ZJ.L_\@2^_P"N#_RH \_^"QSX;F'I*_\ Z$:].KS'X+ C
MPW,?65__ $(UZ=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 076?L\O^Z:^8_$HW^+FB(^_)7T]=?\ 'K)_NFOF+Q%_R.H;
MTEKV\F;4VT95=CU#2/ L4^GQR,!EAZ5H#X?VY'./^^:ZOPX=VBP$_P!T?RK5
M-<V(S&NIN[",%8\FU7X;Q+&YC(Z<<5Y5J%E/X<U/C.T/FOJQXUD7:PZUXO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\9YYK>62*3<KA&I[I[_X@\8VUN&2&4'(]:\4NC/XF\1L1EE#\?G5.&9]2G5
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %4=7_P"05<?[M7JHZO\ \@JX_P!V@#@O@U_R"M;_ .PB]>EU
MYI\&O^05K?\ V$7KTN@ HHHH *HZS_R!+[_K@_\ *KU4=9_Y E]_UP?^5 'G
MWP6_Y%R?_KJ__H1KT^O,O@L<^&YAZ2O_ .A&O3: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %4=7_Y!5Q_NU>JCJ_\ R"KC_=H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JCJ_\
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M??']H5>HS7K-8WB'2$UBP:)QVP*Z<)6]E54B9*Z/E.63"Q*PY#@5])_#@_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM%%)*P!1113 3 (P12"- <A1GZ4ZDI7L M%%%, HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "DI:*0!1113 ****& 4AI:*5M $%+110E8 HHHI@%%%%) %%%%
M, I,\TM)CFD[] %HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 51U?_ )!5Q_NU>JCJ
M_P#R"KC_ ': ."^#7_(*UO\ ["+UZ77FGP:_Y!6M_P#81>O2Z "BBB@ JCK/
M_($OO^N#_P JO51UG_D"7W_7!_Y4 >?_  6.?#<P])7_ /0C7IU>8_!8'_A&
MYCZRO_Z$:].H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "J.K_\@JX_W:O51U?_ )!5Q_NT <%\&O\
MD%:W_P!A%Z]+KS3X-?\ (*UO_L(O7I= !1110 51UG_D"7W_ %P?^57JHZS_
M ,@2^_ZX/_*@#S_X+$_\(W,/25__ $(UZ=7F/P6&/#<Q]97_ /0C7IU !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 51U?\ Y!5Q_NU>JCJ__(*N/]V@#@O@U_R"M;_["+UZ77FGP:_Y
M!6M_]A%Z]+H **** "J.L_\ ($OO^N#_ ,JO51UG_D"7W_7!_P"5 'GWP6_Y
M%R?_ *ZO_P"A&O3Z\R^"V/\ A&YO7S7_ /0C7IM !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 51U?\
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M -,6_P * /?<CU%&1ZBO C\4+S/_ !YW?3_GBW^%'_"T+SY?]#N^/^F+?X4
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M>!?\+0O/^?.[Z?\ /%O\*!\4+SY?]#N^/^F+?X4 >^Y'J*,CU%> CXGWN/\
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M_P!#N^G_ #Q;_"@#WW(]11D>HKP'_A9][\O^AW?'_3%O\*#\3[W'_'G=]?\
MGBW^% 'OV1ZBC(]17@1^*%Y\W^AW?/\ TQ;_  H_X6A>?\^=WT_YXM_A0![[
MD>HHR/45X$/BA>?+_H=WQ_TQ;_"D'Q/O<?\ 'G=]?^>+?X4 >_9'J*,CU%>
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MTQ;_  H ]]R/449'J*\"_P"%GWN/^/.[Z_\ /%O\*#\4+SYO]#N^?^F+?X4
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M_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\
M".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!
ME_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6
MI10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ
M1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z
M7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'
M_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I
M'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I
M?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_
M\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I1
M0!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_
ME6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\
MSZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([
MI?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4
M?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^
MD?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7
M_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\
M".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!
ME_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6
MI10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ
M1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z
M7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'
M_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I
M'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I
M?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_
M\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I1
M0!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_
ME6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\
MSZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([
MI?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4
M?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^
MD?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7
M_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\
M".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!
ME_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6
MI10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ
M1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z
M7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'
M_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I
M'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I
M?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_
M\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I1
M0!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_
ME6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\
MSZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([
MI?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4
M?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^
MD?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7
M_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\
M".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!
ME_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ1_E6
MI10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z7_SZ
M1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'_".Z
M7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I'^5'
M_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I?_/I
M'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_\([I
M?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I10!E_
M\([I?_/I'^5'_".Z7_SZ1_E6I10!E_\ ".Z7_P ^D?Y4?\([I?\ SZ1_E6I1
M0!E_\([I?_/I'^5'_".Z7_SZ1_E6I10!6L[.WLHV2WB$:DYP*L$X%+2#.XB@
M!1THHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image8.jpg
<TEXT>
begin 644 image8.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &K ?8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W#6=3&CZ3
M/?F%IO*QB-" 6)8*!D\#DU0_M;7?^A9D_P# V+_&CQG_ ,BK=_[\7_HU*WJ
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MK>HH P?[6UW_ *%F3_P-B_QH_M;7?^A9D_\  V+_ !K>HH P?[6UW_H69/\
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M  -B_P :WJ* ,'^UM=_Z%F3_ ,#8O\:/[6UW_H69/_ V+_&MZB@#!_M;7?\
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M@U*UEM_MN@2P0S3QP&474;[2[!0< Y(R:Z&L/Q1_QY6'_82M?_1JT ;E%%%
M&#XS_P"15N_]^+_T:E;U8/C/_D5;O_?B_P#1J5O4 %%>8:+?"3Q8RZIJ>M)X
M@_M2:/[#%O,(MAN\O*$;!%LVG>.=QZ]JS)/&_B'6?#GB,2*EM)!;&15M\K-:
MR";8(S@DY*C.3M/7C!% 'L5%<UX;N+F;Q!XJCGEE>.*_185<G"+Y$9(7VR2>
M.^:Z6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHH 2BEHH **** "BBBF 4444 %%%+18!**** "BBB@ HHHI %)2T4 )12T4
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M**6B@!*6BEIBN)12T4 )12T46 2EQ11BBP!BC%&*,46 ,4E+BC%%@$HI:*+
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M .C5K<K#\4?\>5A_V$K7_P!&K0!N4444 8/C/_D5;O\ WXO_ $:E;U8/C/\
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M "BBB@ K#\4?\>5A_P!A*U_]&K6Y6'XH_P"/*P_["5K_ .C5H W**** .?\
M&[%/"%\ZH793&0H.-Q\Q>,U +2>ZNUO-3=99T.8H5_U4'^[ZM_M'\,58\:_\
MBE>?[T7_ *,6IF^^WUKFQ$FK)&]&*;NQ****Y#I"BEHH ****8!2T4M,0E+1
M2T"$I:*6F E+12XIV$)145U=VUC 9[N>."(?QR-@?0>IJB-0U"__ .09IY6(
M]+J^!C3ZJGWV_':/>KC!RV)<TMS4Q6==:[IEHVQKI99?^>4 \Q_R7./QI!H"
MW/S:M>3WY_YY$^5 /^ +U_X$365XBTZRTZ;3Y=-L5CO9IO+,%J@4S1;26RO
M(7@[CT_&MHT.YE*MV))?$%]-Q:6*0+_STNGRW_?"_P!35&4WEV#]KU"XD7ND
M9\I/R7G\S4\6E:K<<R-!9(>W^MD_HH_6KL7ANP&#<^=>-_T\/E?^^1A?TKIA
M0MT.:5?S,"*33K:0I;+&TO=8$\QS]=N3^=74AU.XYATV10?XKF01_IR?TKIH
MHHH(_+AC2)!_"BA1^E/K94EU,76?1'/)H>HR?ZZ^MX1W6&$N?S8_TJS9Z'-8
MVJ6MOK>I);ITC#1_+[ [<@>PZ5L4N*KDB1[23ZF6=!LY/^/F6]NC_P!-[N1A
M^0('Z4^+0M(A.8],M ?4PJ3^9K1Q1BJ44A-M]2..*.(8CC1!_L*!_*I-Q]3^
M=%%,0G/K12T4 )12T8H$&3ZG\Z:WS##?,/?FG48H IS:7I]Q_KM/M)/=H5)_
ME5;_ (1[2T.8;=[=O6WF>+_T$BM2BE9,=VMC.&G7</\ Q[:WJ">BS%)E_P#'
MAG]:K7FC7NHR0R7FLR,\#%HEBMT6,$C&XKSDX)YSQGBMJBER1*]I+N<X^DZM
M#RDEG=#T.Z)OZBJLLES; _:["ZA7NP3S$_-<_J*ZRCD=*ETET*5:2.+ABL+A
MS+:.J2]WMI"C#Z[<?K5Z*^U:UX2Z2Z0?P728;_OM?Z@UMW>F6-\<W5I%(W9R
MN&'_  (<UG2^'Y(^;&_D7TCN1YJ_GPP_,UE.A??4UCB+>1)%XD@'%_;S69_O
MD;X_^^EZ?B!6O#+'<1"6"1)8VZ/&P8'\17+2K>V9_P!,LG$?>:W/FI^('S#\
M14_AG0M(U/1QJ<\"SSW4CL[*[*(L,5"J%(VD =>I-<D\,NFAU0Q#?F=+16>V
MGZI8<V%T+Z$?\N]XV)!_NR@<_P# @?K2VNK6]Q<?995DM+W&?LUPNUS[KV8>
MZDUSSI2CN;QJ1D7Z2EHK(T$HHHH BN;:"[@:"XB62)NJM_/V/O4,&HW.B?)>
MO)=:<.ER>9(!_P!-/[R_[74=_6K=%7"HX/0B<%(V$D26-9(W5T895E.01Z@T
MZN6C%QHDC36$;2V3'=-9+U7U:+T/JO0]L'KT5G>6]_:QW-K*LD+C*L/Y>Q]J
M[H34U=')*+B[,GHHHJR0HHHH *P_%'_'E8?]A*U_]&K6Y6'XH_X\K#_L)6O_
M *-6@#<HHHH P/&O_(I7G^]%_P"C%J9OOM]:A\:_\BE>?[T7_HQ:F;[[?6N3
M$[HZ*'42EHHKF.@***6F 44M%,044M+3$)2T4M.PA,4N*7%9+:K-?2M!HL27
M+*=LEW(2+>(^F1R[>R_B15QBV]"7)+<T+JZM[&W:XNYXX85ZNYP/I[GVK/%S
MJFI_\>$'V&V/_+U=I\[#U2+K^+8^AJQ9Z)##<+=W<KWU^.D\P&$]HTZ(/ISZ
MDT7FNP07#6EK')?7R_>@@(^3_?<_*GX\^U=$**6YA*JQUGH=I;7 N7$EW>_\
M_-R=[C_=[*/90*;=:_9P7#6T/F7MXO6"U7>R_P"\?NK^)%4WLK[4AG5;O9"?
M^7.S8HGT=_O/^@]JO6]O!:0+!;0QPQ+T2-0H'X"NJ-)]3EE670IL=:O_ /6S
MQ:9"?^6=OB68_5V&T?@#]:EL]+M+&1Y8D9IW&'GE<R2./=CSCVZ5<I:V4$C&
M4Y2W$I:6C%.Y(E%+BEQ0 F*,4N*7% #<44[%&*0Q,48IV** &T8IV*,4 -I*
M?BDQ0 W%&*=BDQ0 VBG8HIB&T8I<447 ;12T4P&T4M% A*SYM+'VF2[L;F:Q
MNI#EWBP4D/JZ'Y6^O!]ZT**32>XTVMBBNLWE@,:O:9B'_+Y9J70>[I]Y?J-P
MK0EAT_6]/7>L%[:/RC AESZJ1T/N.:;TK.ETE5N&N].F:PNV.6>)04E/_32/
MHWUX/O64J78VC6_F%>SU/2OFM'?4K,=8)6'VA!_L.>'^C8/N:LV6H6VH1,]M
M)N*';(C*5>-O1E/*GZU'!KC02I;:Q"EG,YVQSJV;>8^@8_=/^RWX$U8U'1X;
MZ5;A7>UOD&$NH<!P/1AT=?8_ABN*I03VT9V4ZS7FB6DK.AU">VN8['5HTAN)
M#MAG3_4W'^Z3]UO]D\^F:TJXY1<79G5&2DKH2BBBI*"J+QW&G7;W^G)O+G-S
M:YP)_P#:7T?W[]#V-7J*<9.+NB914E9FE8WUOJ-HES;/OC?VP0>X([$="*L5
MR\@FTR[;4;)&D5^;NV7_ ):C^^O^V!_WT..N*Z.UN8;RUCN;>19(9%W(Z]"*
M]"$U-71QSBXNS):***LD*P_%'_'E8?\ 82M?_1JUN5A^*/\ CRL/^PE:_P#H
MU: -RBBB@# \:_\ (I7G^]%_Z,6IV^^WUJ#QK_R*5Y_O1?\ HQ:G;[[?6N3$
M[HZ*'42BBEKG.@*6BBF(*6BEIB"BEI:I(0E,N+B&TMWGN)4BA099W. *@U'4
MK?3+<2SEBS';'$@R\C>BC_..]<O/)<:A.+K42HV?-%;@YCA]_P#:;_:/3MBM
M84W(RG-1)+_6&U2\LK>93:Z+-<".<R$J\P(.T-_<0L%'J<\XS74WE[9:-:QB
M8K"GW(8(TRSGLJ(.3]!7)064VN1LJ?NM.<8>=ER9AW" ]O\ :/X>M;MAHVG:
M:0UI:I&X78)"2S[?3<237;3I::''.LKD;KJ6K_\ 'TSZ=9'_ )=H7_?2#_;<
M?='^RO/O5ZVM;>RMUM[6%(85Z(BX'_Z_>I:6NB,5$YI2<MQ*6BEIB&LP49.?
MP&2:S9/$>CPRO#-?QQ3(VUH75@X.,_=QG&.<]*OW,S6UK),MO+<,BY$4(!=S
MZ#/%<A_9VKZ7=P^++H/-J#R;;VTA^<0VQP B8ZE, D]SFM(1BTW(F3<5<Z^S
MN[:_M([JSGCN+>0926)MRL/8U+&RRC,;JX]4(/\ *O-(_L]IXHN='2[DM?"N
MH3&Y\THT2><%R\"N<!5;AC]"!1?JFHSGQ%IUBL7ANQ*0ND):(WT:M\[X7&47
MC&?O8/:M98:SNG[N]_7IZ^7D#DTN9+0].P1UXHK@WU*Z\)Z_]CMO-U#3=:C\
MW24:0L(Y^,Q[CR(R"&]NE/\ $%[KNF&VM-.U*XO=<,3W5U$D:&&.$#KM(XYX
M49R>:AT)723NFKW\O^!L_,<I6Z7.YI<5P=YK.HZ+::7XEM]4N=4\/2JJ:A',
MBEX@>/-7:!C!X*UHW.KW$FC76OW=[/IVF;,6,-NH\Z;/",<@Y+'&U!Z\TI4)
M))QU3T^?;U&WM;6YU8!/2CH"2< <DUY_ID.K>([?4-(UG5M1T_Q!$B20B*01
MK&N 0P"\/S][.?;%5]#\2IKEM.OBJ]MK>+0AMO8A*,7<@) D('WDXX ZL?I5
M?5FXMQ=[;I>>WKV]04N:-XGH^]-F_P Q-G3=N&/SIV/UKS-;$V>I6_BK5]+@
MBTF^F*M8O'Q9HP 25UZ;C_%QQNQ3K26XT/Q/-X)T[48TL;YA/9W'FAFM$()D
MA7_:XROH#FCZNFFD]5K_ )Z^7]>:4]T]T>E[&]#^5(5(ZY%>:ZO&;B>>Y\/)
M<?V3I"B._FANG#7AW NBD'DJ,EF]3CM5VZU9_">L6M]:RW%_X?UN,+:P&0N8
M;G&452QR%?ICL:2P[>E_>M>WX_?;6WZC4M6I:6.\Q1BN-US6]9\.65I+<74=
MWJMRY?\ LV.#*>6!EL$?, HZN?RJ];>*)XM2TJRU6U@1-5BW6EY:R%H7DQGR
MR& (..GK4*A-JZ_JVXXN[M8Z3%)65/XCM(S>&&"ZNHK+(N9K>,,D9'49)&XC
MN!G%51XUT7R[>=WNH[.XF\B*\DMV6%G]-QZ<\9(QP>:F-.<OA5P33=D;]&*K
M7FI6EA-%#<2XFESY<2*7=L=2%&3CWK-;QAX>6%I3JD6Q%W2$(Y\L9QE\#Y>?
M7%*,)2TBKA=7MU-K%)4$^HV=O8"^EN8A:E0RRALJP/3&.N>V.M9K^*=/6_&G
MI#>R7[8VVPMF5V!&=WS8 4#J2::C)NR0FTG:YLTF*RM+\2:=JUO>RHTENUBY
MCNXKI?+> C^\/3WJ&;Q;I-M##/<FZAMYP3#-);-MEQ_=QSD]ACFFZ<U+E:U$
MY):,VJ*SK+7]/U#49M.B>6*^BC$KVUQ"T;[#T8 ]1]*=-K>EV\[PS7T*/&P1
M\DX1CT!;H#[$T.$HNS0-I;EZBJEMJVFWDY@M=0M9IAGY(Y0Q..N!WQ[5<P<9
MH:<79C&T4M%(0R6*.:)XIHTDC<89'7(8>A%9J)>Z&,V8DO=.'6T+9EA'_3)C
M]X?[!_ ]JU**F45+<J,G%Z"H^GZ[IAQY=W9S#:RL.,CL0>58'Z$&LO=<:%-'
M#=2M<:;(XCANI#EX6/"I(>X/0/\ @?6G7%C-#=-J&ELD5XV/.C?B*Y [/CHW
MHXY'?(K+UW59M5C719M,DM%FVR3FX=6#HK E8]I.XY R>,#M7+5HW5F=E*MU
M1T])7.:;J;Z=(EI>2%[1SM@G<Y,1[(Y]/1OP-=)7FS@X.S.^$U)70E%%%04%
M44F_L&\:Y'_(-G?-R@Z0.?\ EH/]D_Q?GZU>I&4,I5@&4C!!&0150FX.Z)G%
M25C;!!&0<@T5SVC7#:==#1YF)A8%K*1C_".L1/JO;U7Z&NAKT8R4E='$TT[,
M*P_%'_'E8?\ 82M?_1JUN5A^*/\ CRL/^PE:_P#HU:8C<HHHH P/&O\ R*5Y
M_O1?^C%J=OOM]:@\:_\ (I7G^]%_Z,6K#??;ZURXC='10ZB4M%%<YN%+12TQ
M!2T4M4D(*I:IJ<.EVZNZF2:0[885/S2-Z>P]3VJ34+^'3+)KF?) (5$7[TC'
MHH]S7)/(YDFU'49$$Q7YCGY84_N+[>I[G\*VIT^8RG.P2.WF2:CJ,R-/M^9^
MB1+_ '4'8?J35RQTE]1VW&H1M':_>CM&X+^C2?T7\_2GZ7ICW,D=_?QE54[K
M:V8?<]'<?WO0=OK705Z%.GU9Y]2K?1"4M%+6QB%+12T@"EQ1BEI#"E'6C%.
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MRL/^PE:_^C5KM.4W**** ,#QK_R*5Y_O1?\ HQ:LM]]OK5;QK_R*5Y_O1?\
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MB=)X:!M?L0S;HV[]]]I5!(<C^YM)7_>!KIKG0-)O&G>YT^"5IYHYY2PY:2,
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M&F>*/^/*P_["5K_Z-6JEQ)_9^IVFI#B/(MKG_<8_*W_ 6Q^#&K?BC_CRL/\
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MRZCX8>VUB_N+C7)E$CZCYK;H9>H\OGA%/&!UK7+,K<H*O5JRBF]+?CIY=?\
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M_P"C5K4K+US_ %.G_P#82M?_ $:M73^-$S^%G74445Z)PF!XU_Y%.\_WHO\
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MX%;=%4Z4'NC..+K1ORRM=W?J5;;3K.RD:2VMHXF;=DH,8R02!Z D X%61@
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M$L9GV%4*,"0>AP2IQW /K7*:EX)\0MX1CL;7][J-Q=7$UW*]^X*YWB$J2<8
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M%V_Z#^M?]_T_^(H_X1=O^@_K7_?]/_B*WZ*.5=@NS _X1A_^A@UK_O\ I_\
M$4?\(P__ $,&M?\ ?]/_ (BM^BBR"[,#_A&'_P"A@UK_ +_I_P#$4?\ ",O_
M -#!K7_?]/\ XBM^BBR%=F#_ ,(R_P#T,&M?]_T_^(H_X1F3_H8-:_[_ *?_
M !%;U%%D%S!_X1F3_H8-:_[_ *?_ !%'_"-2?]#!K7_?]/\ XBMZBBR P?\
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M_P!/_B*/^$8?_H8-:_[_ *?_ !%;]%%D.[,#_A&'_P"A@UK_ +_I_P#$4?\
M"+M_T']:_P"_Z?\ Q%;]%'*NP79@?\(NW_0?UK_O^G_Q%)_PB[?]!_6O^_Z?
M_$5T%%'*NP79S_\ PBS?]!_6O^_Z?_$4?\(L?^@_K7_?]/\ XBN@HHY5V"[.
M?_X18_\ 0?UK_O\ I_\ $4?\(J?^@_K7_?\ 3_XBN@HI<L>P79SW_"*G_H/Z
MU_W_ $_^(H_X14_]!_6O^_Z?_$5T-%'+'L%V<]_PBI_Z#^M?]_T_^(H_X14_
M]!_6O^_Z?_$5T-%')'L',SGO^$5/_0>UK_O^G_Q%'_"*G_H/:U_W_3_XBNAH
MHY(]@YGW.>_X10_]![6O^_Z?_$4?\(I_U'M:_P"_Z?\ Q%=#11R1[!S/N<]_
MPBG_ %'M:_[_ *?_ !%'_"*?]1[6O^_Z?_$5T-%')'L',^YSW_"*?]1[6O\
MO^G_ ,11_P (I_U'M:_[_I_\170T4<D>P<S[G/?\(I_U'M:_[_I_\10/"4)G
B@DGU;5;A89DF6.6=2I93D9 4=ZZ&BCECV#F844450C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image9.jpg
<TEXT>
begin 644 image9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &B <4# 2(  A$! Q$!_\0
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M_<T3_ON7_"MZB@#!SXM_N:)_WW+_ (49\6_W-$_[[E_PK>HH P<^+?[FB?\
M?<O^%&?%O]S1/^^Y?\*WJ* ,'/BW^YHG_?<O^%&?%O\ <T3_ +[E_P *WJ*
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M#U[_ )"GA[_L('_T1+6Y6'KW_(4\/?\ 80/_ *(EK<H **** "BBB@ HHHH
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M51G*.S)<8O=#4UB_@XN[ 3+WDM'S_P".-@_D35ZTUBPO7\N&X43=XI 4<?\
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M[:IW*V-5_P"@C!_X"?\ V5'_ !-?^@A;GZVG_P!E5FBCV,.PO;5.Y6WZN/\
MEXL6^L#C^34OVC5UZQ6$GT=T_H:L44O84^Q2KU.Y7_M#4%^_I8;WBN5/_H0%
M+_:X7_7:??Q^XB#C_P =)J>BH>&@REB9HB76],9MK7B1-_=F!C/_ (\!5V-T
MF7=$ZR+ZHP(_2J[ ,,, P]#R*IOI.GR-N^R1H_\ ?B'EM^:XK.6$[,T6+[HU
M<4E98L[B+_CVU*Z3_9FQ,O\ X]S^M.%SJD/^LM[:Z7UA<QM^39'ZUA+#5$;Q
MQ--^1HT50&M6BD+<^;9L>URA4?\ ?7W?UJ\K*Z!T8,IZ,IR#^-82BUN;QDGL
M%)3J2H*$I*=24AB4E+12&-K(\5?\BIJ?_7 _TK8K'\5?\BIJ?_7 _P!*(_$A
M2V.PHHHKTCA.>\3?\?F@?]A _P#HF6K-5O$W_'[H'_80/_HF6K-<>(^(Z:/P
MA2T45B;!2T4M,04M%+5""BEI<4Q!5'4;)[E$DAQY\>=H)P&!ZBK]+BB=.-2+
MA):,2DT[HYI;@(_ER QR#JCC!%$MPB,LQ\MF3HKXPP[KSZ_X5T<D4<J[9(T<
M>C*#38[.VB;=';0JWJ$&:\R.5RA-2IU+6\O^";/$*2M*)6CT_3[F..=+8*K@
M.!@K[\BK]+2XKV(P2V1S7$Q2XI:7%6D3<2EQ2T55A7$Q2T52O-5M;.3R69I;
MDC(MX1N<_AV'N<"FD)NVY=JK>:E9V&!<SJKM]V, L[?11R:S7DU*]_UDHL83
M_P LX#NE/U?H/^ C\:=;6=O:;O(B"LWWGZLWU8\G\:VC1;W,)UTMASZEJ%SQ
M:VBVL9_Y:W9RWX(I_F1]*@;3Q<<W]S/>'^[(VV/_ +X7 _/-7**WC2BCGE5E
M+J-CC2&,1Q(L:#HJ* /R%.HI:LS$HI:* $I:*,4 %%+BB@!**6C H&)12\48
MH 2BEHH 2BEHQ0(;BBEHH 2BEHH 0\@@\@]0>]4CI5L'+V^^TD/5K9MF?JOW
M3^(J[12<4]&--K5%,2:I;=1%?1^W[J7_ .)/Z5-!JEK/*(2S07!_Y8SKL<_3
M/!_ FIJCG@AN8C%/$DL9_A=<BN:>%A+X=#HABIQWU+6**RQ:75IS871*#_EW
MN273\&^\OZCVJ2+58_,6&\C:SG8X592-CG_9?H?IP?:N*I0G#<[:=>$R_24Z
MDK W$K'\5?\ (J:G_P!<#_2MBL?Q5_R*FI_]<#_2B.Z%+8Z^BBBO1.(Y[Q-_
MQ^Z!_P!A _\ HF6K55O$O_'[H'_80/\ Z(EJS7)7^(Z:.P4M%+6)J%+24ZJ$
M%+24ZFB0I:*6K2$%+13L520A,4[%&*6J2);"EHI:JQ-PHHHI@%5[R^MK"(27
M,H0,<*,99SZ*!R3]*HW.K-+*]MIBI-(IVR3O_JHCZ<?>;V'XD5#!9I%,;B21
M[BZ88:>7[V/0#HH]A6L*3D8U*RCH@DGU#4.,MI]L?X5(,[CW/1/PR?<4^WM8
M+2,I;Q+&I.6QU8^I/4GW-345U1@H[''*<I;A112U1)2U2^_LZPDN!;W%P_W4
MBMX][DGV]*X*/Q'XL%K&KV&IF86,D;N+48-R6^23IT XQ^E>E4O/J:::6Z(G
M"3>DK'FT_B/Q2T5P(=/U1':"W6$FU'R2*1YK'CHW./Z5,_B;Q&;MW32]5$!U
M!953[*,BU ^:/IU)YS^M>AY/J:7)]33NNQ'LI_S'G$'B7Q,KVQFTW5759;@S
M 6H^=&'[D#C^$]?ZU$/$7BS[(J&PU3S_ .SS$7^RC'VK=D2=.F.,?I7IF3ZF
MER?4TN:/8?LI_P QYK<>)/%+K=>1IVJ(7%OY&;4?(5_UV>/XNW]*F_X2;Q']
MLW_V7JWV?^T?-V?91G[+M_U?3[V><_K77Z[JUQHMM%?"U-Q8QO\ Z:R$F2&/
M'^L5?X@#U'7'(K3BFCGACFAE62*10Z.C95E/((/<4N:.U@]E/?F/.(/$GBA1
M;>=IVJOM%QYV+4?.6SY../X>,_UIA\1^+?LC(+#5!.=/6(/]D&!=;LF3ITQQ
MC]*]-R?4T<^II\T>P>RG_.>;7'B7Q.S71@TW545Y+<P VH^15_UP/'\7;^E>
MBQL9(T<QM&6 .QNJY['WJ3)]324FT]D7"#CN[F39>(M,U'4)K*UED>2$N&<P
ML(R4.'"N1@E3P>:N'4+$0QS&^M1#(<))YR[7[<'.#7+'P1;W>IZK(VL@_;()
MX)4MHDCEQ+WE*G#E.BDJ#ZDTP_#BVDTE;*:\5F"70+BWXW3HJ;@&8X*A0>O)
M]*SO(VM$[#[3;FX>W%Q#YZ+N>+S!N4>I'4#WIT$L5S$LMO+'-&WW7C<,I^A'
M%<E/X"M[G5]3NCJ3QB_M'MYHH8P'^=%3<3D]-N1@#/0DXJ]H_A/^Q],%O%J$
MRW"RR3"6$LD9=E !:/<=P& <$]:+R%9&C8:[I>IQWDEI>1O'97#6UP[?*$D7
MJ,GMSUZ&EEUO3(9(8VOH&DGBDFA1'#&1$^\5QUQ7.6WPZMK/3KJPAU.Z>WN[
M>&*=;@"3<T3[PX],_,"/?VJPW@>$%?*NT10+]"/LXX2Z.2%Y^7:>GJ,],T7D
M.T3HXKVUF=8TN(C*T8E$6\;PI&02O4"FG4; 6ZSF^M1"Q(60S+M)'4 YQFN8
M7P!"-5ENQJ+HDUD;25(H@K/F$1;BV3R ,C !Z D@5#%\-[9=+BLIKQ9-C3N6
M^S\,9(/)!VEC@@8/N?2B\NPK1[G8_:+<W!MQ<1&<+N,0D&\+ZXZX]Z6&>&YB
M$MO-'-&20'C<,#CKR*Y3_A 8CJTU[_:,B+/9&TE6.+#/F(1;BQ)Y &1@ ]B2
M*U/"_AU/#.FR6BW G:23S&<(4'"A1P2>RCO5)NXFE8VJ*6BJ$-HI:*!"4V2.
M.:)HI462-AAD<9!_"G44 4!:W5CSI\OF0C_EUG8D#_<?JOT.1]*M6FH0W;M%
MAX;E!EX)1AQ[^X]QD5+4%U:07B*LR9*G*.IVLA]58<@US5<+&>L=&=-+$RAH
M]47*QO%7_(J:I_UP/]*E^UW.F\7Q,]J.ETJ_,@_Z:*.W^T/Q J+Q0RR>$=2=
M&#*UN2K*<@CCD&O.E3E"24CT(U(SC>)U]%%%=IRG/^)?^/W0/^P@?_1$M6JJ
M^)?^/[0/^P@?_1$M6JY*_P 1T4=A:**6LD:A2T4M4A"TM%+5)$A2T4HJTA"@
M4H% IU4D2PI:**NQ(445!=W<%C;-<7#[4' P,EB>@ [D^E,1)--%;PO--(L<
M2#+.QP *Q)9KC5^/WEKIY_AY66<>_=%]NI[XI/+GU"9+G4$VJAW06F<B/T9_
M[S_H.WK5RNBG2ZR.6K6OI$;'&D,2QQ(J1H,*JC  ]A3J**Z#F"EHHH **6B@
M844M+2 2BEHH *,4M+2&)7)#_BA[W'_,L74G'IILK'_T2Q/_  $GT-==4-W$
M)K*>)K>.Y$D;*8)#A9 1]TG!X-2QHEI<5XSX>U3Q#X?^).G:?KMI=6>F2QO8
M6<<LGFHB,=R 2]'P0 "><8%>SXHC*XY1L)0.H-+BC%,5CSZQ\+:I%JYFBTVW
ML98[N^N#J*RION$E#B-,+\V 65CNZ;>*AGB\81:?:+>+?>;->VD)BMKQ=[(M
MNPE.\<(&D&[)]1TKTC%95GJTFIW^-/B6338]RRWC$[9&'&V+^\ >K=.PR>D-
M(N[.2ET'Q:MO-<).IU&6RL(9Y8Y@KRF-Y#,H/&#AEYR,\\BKUKIWBI-8T.6X
MN9I;."W5-07[2H\V7YL-M YVY&[D;N.N*[/%&*?*3=B4E.Q251(E)BG44P&T
M4M% #:2G44Q#:*6DH 2BEI*8"44M)0(*YOQ-9/:>'-3>Q94A>(F6W;[G)&63
M^ZWMT/ZUTE9'BG_D5=3_ .N!_F*BI%2CJ7"3C+0[*BBBN4[#G_$O_']H'_80
M/_HB6K=5/$O_ !_:!_V$#_Z(EJW7+7^(Z*.PM+24M9(T8M+12U:$+2TE.%4B
M0%.%)3A5I$L*=2"EJT2PHHIDTT5O!)/,ZQQ1J6=VZ #O3$1W=W#8VS7%PQ"+
MQ@#)8GH .Y/85D113W5R+Z^&)1GR8,Y6W!_FY[G\!QU2/S=0N5O[E&15_P"/
M6!O^68/\;#^^1^0X]:N5TTJ=M6<=:K?1!1116Y@%+110 4M%% PI:*6D 44N
M*X35_$VM^&=;@@U8PS:9*^Y+J&':Q49RI&<9'&?TIQBY.R(J5%35Y;'=TM4-
M,U 7MM#O(\XV\4SD#"G>#C'Y&M#%2]#1--70E+45S<P65K+=7,BQ01*6=VZ
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M#P)H3)!'-%<W$-N28H9[EV12>3Q4%]\-O"]]J*Z@+!K6Z5@PDLYFAPPZ'"\
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M-+U"XEG^Q,AA,S9=%;(*DGG *_A7JXKP/X7ZK_8GB_Q''+"6C^8R$'YAME8
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ME>KYI:[:>98FG'E4OO2;^]E'$Z;\+?#>D)')90/]OC8NEY.?-</@@,0>.,Y
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M*_Q'11V'4M)162-1U+3:6J0AU.IE+5)B'TH--I:I,D>*7-,!IPJTR6C$\O\
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M_P#OB#_XW1_PCEY_T,FI_P#?$'_QNCVB#V4B[FC-4O\ A'+W_H9=3_[X@_\
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M3_A&[S_H9-3_ .^(/_C='_"-WG_0R:G_ -\0?_&Z?M$'LI%JDJK_ ,(W>?\
M0R:G_P!\0?\ QNC_ (1N\_Z&34_^^(/_ (W1[5![&1:J&YA2ZM9K>7/ES1M&
M^#@X88/\ZC_X1J\_Z&34_P#OB#_XW1_PC5W_ -#)J?\ WQ!_\;H]K$/8R,,>
M!M$477E)/"]U#;Q2/'+AOW!!C<<?>!5<GOCI4T/A+3[4VC07-_%);[QYB7!#
M2J\GFLKG'(+\\8[CH:UO^$:N_P#H9-3_ .^(/_C='_"-7?\ T,FI_P#?$'_Q
MNESP[![.?<PY?!&BS3V\S)-O@EEE!W@[O,D\UE.1]W?SQ@]LTX^#=,-Q>S&6
M\S=I*C)YWRQB5Q(^P8XRPSSGTZ5M?\(S=_\ 0R:G_P!\0?\ QNC_ (1F[_Z&
M34_^^(/_ (W3YX=@]E/N5]'TFUT/3(]/L_,\B,LP\QMQRQR?8#)Z  #M5;Q3
M_P BKJ?_ %P/\Q6A_P (S=_]#)J?_?$'_P ;J*Y\(2WEM);7/B#4Y()!MD3;
M"-P],B/-#JQM9 J4KW.GHHHK Z HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image10.jpg
<TEXT>
begin 644 image10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %E D(# 2(  A$! Q$!_\0
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MC?[R@U7;3;%CDVD(/JJ!3^E6J*$VA616%F(_]3<7</LD[$?D<BI5?4HO]7J
MD [3P@_JN*DHJU5FNI+IQ?05=4OX_P#76,<H[M!+@_DV/YU,FO660)S+:L?^
M?B,J/^^ON_K4%'M6BQ$EN0Z$>AKQRQS('BD5T/1E.0:?7.'3[;?YD:&"3^_
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M7/:9G2O$]_I;<6]Z#?VN>@8D"91_P(JW_ S0!MQVMO"L:Q01((U*H%0#:#U
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MO_V%+C^8H WJ*** ,/Q3_P @ZT_["-I_Z.2MRL/Q3_R#K3_L(VG_ *.2MR@
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MEHHJ#4**** "BBB@ HHHH **** "BBB@ K!\+_<U?_L*7'\Q6]6#X7^YJ_\
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M:)MT;C<IKQ\11]G+39GKX>M[2.NX^FR.D4;22.J1HI9F8X"@=23Z4ZN<N?\
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M_P#2(OQX<?\ ?7/_  *MFO2C+F5S@DK.P44450@HHHH **** "BBB@ HHHH
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M=4,NK5:?M*>IUYIAKF[OQE#':.\-M(9AC:),;<^^*ST\>2_\M-/0_P"[*?\
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MAU#'_P >+5%U>QK9VN:]%%%,05@^%_N:O_V%+C^8K>K!\+_<U?\ ["EQ_,4
M;U%%% &!XO\ ^01;_P#7_:_^CDJ<]:@\7_\ ((M_^O\ M?\ T<E3GK7)B/B1
MT4-F+2TE+6*-A:=3:<*I"8HIPIHIPJT2QU.%-IPJT0S-OQLU6S?_ )Z1R1G_
M ,=8?R-/HU@;8+>?_GC<(2?9OD/_ *%17H4'[IY^(5IA2TE+6Q@+2TE+2&+3
MJ;3J0Q13Q3*<*D:'BG"F"G"I92.8^(,-[/X5V6"W#2?;+<N(%=F\L2#?D(0Q
M&.H!!K':]U[3-&T2+1(+MHWG<7__ !+Y28X=XS(HE8ON&<!23D%B!Q7H0-.!
M/K4-&BEH<++K7C!=9U6.*SE:**.[,4?V3]VBHF;=TD_Y:,[<%>V3P,<T[W6/
M'=IHDY599KJ.YA*R+I_S/&UN'90 "!B0E<D=L$CK7H8NX/MGV/S5^T>7YOE]
M]F<9^F>*L U-BTR*SDEFL;>6:-HIGB5G1@ 58@9!QGD&IJ**!!1110 4444
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M]K:V;@<V>GLR1'M)/C#-]%&5^I;TK9J&UM8;*UBMK= D,2A44=A4U !1110
M5@^%_N:O_P!A2X_F*WJP?"_W-7_["EQ_,4 ;U%%% &!XO_Y!%O\ ]?\ :_\
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ME_X+I_\ XBES1[ARR[&K2UD_\)!9_P#/OJ7_ (+I_P#XBE_X2"S_ .>&I?\
M@NG_ /B*.:/<?++L:U%9/_"0V?\ SPU+_P %T_\ \11_PD-G_P \-2_\%T__
M ,12YEW#EEV->EK(_P"$ALO^>&I?^"Z?_P"(H_X2&S_YX:E_X+I__B*.9=PY
M9=C7HK)_X2&R_P">&I?^"Z?_ .(H_P"$BLO^>&I?^"Z?_P"(I<R'RR[&O161
M_P )%9?\\-2_\%T__P 11_PD5E_SPU+_ ,%T_P#\11S+N'++L:]%9/\ PD5E
M_P \-2_\%T__ ,12?\)%9?\ /#4O_!=/_P#$4<R[ARR[&OFBLC_A(K+_ )X:
ME_X+I_\ XBC_ (2*R_YX:E_X+I__ (BCF7<.678UZ2LG_A(K+_GAJ7_@NG_^
M(H_X2*R_YX:E_P""Z?\ ^(HYEW#EEV-:BLG_ (2&R_YX:E_X+I__ (BD_P"$
MAL_^>&I?^"Z?_P"(HYEW#EEV-:DK*_X2&R_YX:E_X+I__B*3_A(;/_GAJ7_@
MNG_^(I\R[BY9=C5KS?Q9XH\0:3XBU&&T8MIP-E CJ@+6TLC ECQRK*&4^AVU
MV?\ PD%G_P \-2_\%T__ ,12?V_9=[;43GK_ ,2V;_XBDVGU&DUT,*X\>&'4
M;^S6Q26:S^W,T$;GS-L 4IQCC?N/Y<9J+_A+;V0Z5<HUK<1EKSSX].<R)/Y<
M'F*H+#(.>.,\_E70_P!O66[<+;4 QZG^S9L_^@4#7;%0 MKJ "] --F&/I\E
M+YA9]CF+'XAR3Z5;7]W9VT$4EV;=Y1-F-1Y!E!SV.X!"#W/X5+IOCNXO=>TB
MPFL8(HM1M89@RR%G#O&7QCL!C&2,'U'2N@_MRPV[?LE_MSG;_9DV,_392_V[
M8[@WV74-P& ?[-FR!Z?<Z4[^86?\IJU5N9I&D6TM3BXD&2^,B)/[Q]_0=S]#
M5"X\10I"3!9ZE)*3A0=/G !]2=O04ZSU>PM(F!CU.2:0[I93ILX+M_WQP.P'
M85G6K<JM'<THT>9WEL;,$$=K D$0PB# R<D^I/J3UJ2LG_A(K+_GAJ7_ (+I
M_P#XBC_A(;+_ )X:E_X+I_\ XBO,<9/H>DI1[FI165_PD-G_ ,\-2_\ !=/_
M /$4G_"06?\ SPU+_P %T_\ \14\DNQ7/'N:M)67_P )!9_\^^I?^"Z?_P"(
MI/\ A(+/_GWU+_P73_\ Q%+DEV'SQ[FI167_ ,)!9_\ /OJ7_@NG_P#B*/\
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,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image11.jpg
<TEXT>
begin 644 image11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0Y!X(# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+5HK&2R>.R6WEA:0. PDD;*M@9&UEZ@<Y';)XN@ HHHH ^G_ -G'_DGFH?\
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M*D_]&Q5]/T %%%% !1110!\P?M'?\E#T_P#[!4?_ *-EKQ^O8/VCO^2AZ?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*1"A +LS!%&3T&YAD\X&>#TH U+Z_L],LY+R_NX+2UCQOFGD$:+D@#+'@9)
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M\/\ \:H_X9Q\'_\ 02US_O\ P_\ QJ@#Y@HKZ?\ ^&<?!_\ T$M<_P"_\/\
M\:H_X9Q\'_\ 02US_O\ P_\ QJ@#Y@JQ87UQIFHVU_9R>7=6LJS0OM!VNI!4
MX/!P0.M?2_\ PSCX/_Z"6N?]_P"'_P"-4?\ #./@_P#Z"6N?]_X?_C5 !HG[
M1/A:^\B/5K.^TN9]WF/M$\,>,X^9?G.0!T3@GT&:W)_CC\/H;>65-:DG=$++
M%'9S!G('W1N0#)Z<D#U(K#_X9Q\'_P#02US_ +_P_P#QJC_AG'P?_P!!+7/^
M_P##_P#&J (Y_P!I#PJMO*UOI6LR3A"8TDCB16;' +!R0,]\''H:XS6?VCO$
M%WO32-)L=/C>(INF9KB1'.?G4_*O'& 5/(YR#BNW_P"&<?!__02US_O_  __
M !JMBQ^!7@&TLXX)M+GO9%SF>>[D#ODD\A&5>.G '3UYH ^6-9US5/$.HO?Z
MO?SWMTV1OF?.T$D[5'15R3A1@#/ K/KZ_P#^%)?#S_H7O_)VX_\ CE;%C\./
M!6GV<=K#X7TIXTS@SVRS.<DGEW!8]>YXZ=* /BBNLTWX8^-]5N&@M_#&I(ZI
MO)NH3;KC('#2;03STSGKZ&OLNQL+/3+..SL+2"TM8\[(8(Q&BY))PHX&22?Q
MJQ0!\^:!^S9,763Q'KD:H'(,&G(6++MX/F.!M.[J-AX'7GCVOP]X5T+PI9M:
MZ'ID%E&WWR@)>3!)&YSEFQN.,DXS@<5L44 %%%% &?J>NZ/HGE?VMJMC8>=G
MR_M=PD6_&,XW$9QD=/45\T?'3QUI?BW7+&PT@^?;Z5YJM=JV4F=]F0GJHV?>
M[Y.. "?1_P#AG'P?_P!!+7/^_P##_P#&J/\ AG'P?_T$M<_[_P /_P :H ^8
M**^G_P#AG'P?_P!!+7/^_P##_P#&J/\ AG'P?_T$M<_[_P /_P :H ^8*]4^
M"?Q TCP3JFIV^M>9#::BD9^U*I<1-'OP&5020V\\C."!Q@DCTO\ X9Q\'_\
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M%%?7^M_!;P-K?GO_ &1]@N)MO[ZPD,6S&/NIS&,@8/R]R>O-<_\ \,X^#_\
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M_?\ A_\ C5=1X(^%7A_P%J-S?Z9+?3W4\7DE[N56V)D$@!54<D+US]T8QSD
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M!CP^@ K[_KX K[_H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M (.0'Z$ U\R:SXK\0>(=XU?6;Z]C:4S>5-.QC5SGE4SM7J0, 8!P.*^T]?\
M#FD>*=+;3=:L8[NT+A]C$J58="K*05/49!'!(Z$UY7K/[./A^[WOI&K7VGR/
M*7VS*MQ&B'/R*/E;CC!+'@<Y)S0!X1HGCGQ3X<\A=)UZ^MX8-WEV_FEX5W9S
M^Z;*'DD\CKSUKZK^%?BJ^\8> [/4]3AD6\5W@EE,7EI.5/\ K$[$$8!(P-P<
M  "N3T3]G;PM8^1)JUY?:I,F[S$W""&3.<?*OSC (Z/R1Z'%>L6-A9Z99QV=
MA:06EK'G9#!&(T7)).%' R23^- %BBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@".>9;:WEG<2%(T+L(XV=B ,
M\*H)8^P!)[5Y?J7[07@BQN%BMSJ6H(4W&6UM@J@Y/RGS&0YXSTQR.>M>J53L
M])TW3[BZN++3[2VGNWWW,D,*HTS9)RY RQRQY/J?6@#P#4OVEM2EMU72_#=I
M;3[\L]U<M.I7!X"J$(.<<Y['CGCC]5^-_CS4WN-FJQV,$Z;/)M+=%"#;@[78
M%P>^=V03QCC'U/X@\/Z;XGT:?2]4MHYH)48*S(K-$Q4KO3<"%<!C@XXKX4H
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M>X!]+T5\Z:;J?Q_U6W:>WCNT17V$75I:6[9P#PLBJ2.>N,=?0UE_\(;\<_\
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M$B^UF:+QAX?TW3]/%NS1RVL@9C+N7"G$K\;2QZ=AS0!WE%%% !1110 4444
M%%%% !1110 4444 %%%<OXZ\=:7X#T,W]^?-N),K:6B-A[AQV'HHR,MVSW)
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ME:K8ZWI=OJ>F7,=S9W";XI4/##^8(.00>000>15R@ HHHH *^ *^_P"O@"@
MKZ?_ &<?^2>:A_V%9/\ T5%7S!7T_P#LX_\ )/-0_P"PK)_Z*BH ]@HKC_%W
MQ-\+>"]T6I7WFWRX_P!!M ))OX>HR G#!OF(R,XS7C&L_M'>(+O>FD:38Z?&
M\13=,S7$B.<_.I^5>., J>1SD'% 'TO17QY/\9_B#<V\L#^(I DB%&,=M"C
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M+KX0\>:EI4$<BV>\36FY& \IQN 4DDL%)*;LG)0]\BOM.OF#]H[_ )*'I_\
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M !1110 5Y_XR^#WA;Q?YUS]F_LW4WRWVRT4+O8[CF1/NOEFR3PQP!N%>@44
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MP2+RF&P-Y?0$-L'R ??8D'J/GNOK_P"-O_)(==_[=_\ T?'7R!0 5]O^!/\
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MH)4*21R*&5U(P00>"".U 'PAJNJWVMZI<:GJ=S)<WEP^^65SRQ_D !@ #@
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M$/QE#X[\2KK,6D1Z:YMUBE191(964M\[-M7)VE5Y'11SZ<G0!ZA\!-9O-/\
MB9;:="_^BZE%)%<1DG!V(TBL #C<"N 3G 9O6OJ^OD#X)?\ )7M"_P"WC_T1
M)7U_0 4444 %? %??]? % !7HG@>3XD:CX:N-"\&0W<=@;A[B>YMR(2SXB&W
MSV( ("J=JD$AFSD=/.Z^G_V<?^2>:A_V%9/_ $5%0!@:)^S7_J)=>\0?WO.M
M["'Z[=LK_@3E/4>]=W!\#OA]#;Q1/HLD[H@5I9+R8,Y ^\=K@9/7@ >@%>B4
M4 >?_P#"DOAY_P!"]_Y.W'_QRL?6?V?/!VH;WTYK[2Y/**(L,WFQA^<.PDRQ
MZC(##('8\UZQ10!\D>.O@SX@\&Q&]MS_ &MI@R6N+:)@\0"[BTB<[5X;Y@2/
MEY(R!7F]??\ 7S)\;?AA#X;N%\1:#:2)I=PY%W#&H\NTD)&".X1B3QC"D8S\
MRJ #QNOH3X1?&6^U'5++POXD:.4RIY-IJ#-M=G&2%E).&+#"@CDD '<6)'SW
M10!]_P!%<O\ #KQ#<>*?A_H^L7BXNIHBDQR/G=&:-GX  W%2V .,X[5U% !1
M110!\0>._P#DH?B;_L*W7_HUJY^N@\=_\E#\3?\ 85NO_1K5S] 'T!^S+_S-
M/_;I_P"UJ]_KP#]F7_F:?^W3_P!K5[_0 4444 8_B?Q/I?A'0YM7U>?RK>/A
M57EY7/1$'=CC]"20 2/E#QU\4_$'CF4Q7$OV+3!D+86SL$8;MP,G/[QAA>2
M/ER ,G.Q\=/%W_"1^.6TVW;-CHVZV3C[TQ(\UN5!'("8R1^[R/O5Y?0!ZA\+
M?A#<>.-VIZJ\]EH2[E22/ DN7'&$R" H/5B#R-HYR5^E_#WA70O"EFUKH>F0
M64;??* EY,$D;G.6;&XXR3C.!Q7@GAN#XX6WAK34T&*.+23;H]HJ+8J#&PW
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M*C_]&RT >/UZ!\$O^2O:%_V\?^B)*\_KT#X)?\E>T+_MX_\ 1$E 'U_1110
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M%]0T.Z;9'=Q% ^"?+<'*/@$9VL%.,\XP>*^*-<T:\\/:Y>Z1?ILNK25HGP"
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MO8/^&9?^IN_\IO\ ]MH_X9E_ZF[_ ,IO_P!MH ^?Z*^@/^&9?^IN_P#*;_\
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M2.10RNI&""#P01VKP#Q1^SE<R:H\_A?4[2.SE=F^S7Q=3 .,*KJ&+C.[J 0
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MUZQ%Y7]D^(+&ZSGS/M<+V^WIC&W?N[]<8P.N>,__ (9Q\8?]!+0_^_\ -_\
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M_*;_ /;:/^&9?^IN_P#*;_\ ;: .7^ GBJS\/>+;ZUU34X+&POK3K.0J-,C
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M;6WBM[>*.&") D<<:A510,  #@ #M1!!#:V\5O;Q1PP1($CCC4*J*!@  <
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M10!X_P#\,X^#_P#H):Y_W_A_^-4?\,X^#_\ H):Y_P!_X?\ XU7L%% 'C_\
MPSCX/_Z"6N?]_P"'_P"-4?\ #./@_P#Z"6N?]_X?_C5>P44 >/\ _#./@_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKPCX[>+O&NB:C#8Z
M:T^G:))$A^VV@8-+(23M,NT;&&P_*IR5)))!VKXO_P )WXP_Z&O7/_!C-_\
M%4 ?;]%?$'_"=^,/^AKUS_P8S?\ Q5'_  G?C#_H:]<_\&,W_P 50!]OT5\0
M?\)WXP_Z&O7/_!C-_P#%4?\ "=^,/^AKUS_P8S?_ !5 'V_17Q!_PG?C#_H:
M]<_\&,W_ ,51_P )WXP_Z&O7/_!C-_\ %4 ?;]%?$'_"=^,/^AKUS_P8S?\
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MS?\ Q5'_  G?C#_H:]<_\&,W_P 50!]OT5\0?\)WXP_Z&O7/_!C-_P#%4?\
M"=^,/^AKUS_P8S?_ !5 'V_17Q!_PG?C#_H:]<_\&,W_ ,51_P )WXP_Z&O7
M/_!C-_\ %4 ?;]%?$'_"=^,/^AKUS_P8S?\ Q5'_  G?C#_H:]<_\&,W_P 5
M0!]OT5\0?\)WXP_Z&O7/_!C-_P#%4?\ "=^,/^AKUS_P8S?_ !5 'V_17Q!_
MPG?C#_H:]<_\&,W_ ,51_P )WXP_Z&O7/_!C-_\ %4 ?;]%?$'_"=^,/^AKU
MS_P8S?\ Q5'_  G?C#_H:]<_\&,W_P 50!]OT5\0?\)WXP_Z&O7/_!C-_P#%
M4?\ "=^,/^AKUS_P8S?_ !5 'V_17Q!_PG?C#_H:]<_\&,W_ ,51_P )WXP_
MZ&O7/_!C-_\ %4 ?;]%?$'_"=^,/^AKUS_P8S?\ Q5'_  G?C#_H:]<_\&,W
M_P 50!]OT5\0?\)WXP_Z&O7/_!C-_P#%4?\ "=^,/^AKUS_P8S?_ !5 'V_1
M7Q!_PG?C#_H:]<_\&,W_ ,51_P )WXP_Z&O7/_!C-_\ %4 ?;]%?$'_"=^,/
M^AKUS_P8S?\ Q5'_  G?C#_H:]<_\&,W_P 50!]OT5\0?\)WXP_Z&O7/_!C-
M_P#%4?\ "=^,/^AKUS_P8S?_ !5 'V_17Q!_PG?C#_H:]<_\&,W_ ,51_P )
MWXP_Z&O7/_!C-_\ %4 ?;]%?$'_"=^,/^AKUS_P8S?\ Q5'_  G?C#_H:]<_
M\&,W_P 50!]OT5\0?\)WXP_Z&O7/_!C-_P#%4?\ "=^,/^AKUS_P8S?_ !5
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MUS_P8S?_ !5 'V_17Q!_PG?C#_H:]<_\&,W_ ,51_P )WXP_Z&O7/_!C-_\
M%4 ?;]%?$'_"=^,/^AKUS_P8S?\ Q5'_  G?C#_H:]<_\&,W_P 50!]OT5\0
M?\)WXP_Z&O7/_!C-_P#%4?\ "=^,/^AKUS_P8S?_ !5 'V_17Q!_PG?C#_H:
M]<_\&,W_ ,51_P )WXP_Z&O7/_!C-_\ %4 ?;]%?$'_"=^,/^AKUS_P8S?\
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MS?\ Q5'_  G?C#_H:]<_\&,W_P 50!]OT5\0?\)WXP_Z&O7/_!C-_P#%4?\
M"=^,/^AKUS_P8S?_ !5 'V_17Q!_PG?C#_H:]<_\&,W_ ,51_P )WXP_Z&O7
M/_!C-_\ %4 ?;]%?$'_"=^,/^AKUS_P8S?\ Q5'_  G?C#_H:]<_\&,W_P 5
M0!]OT5\0?\)WXP_Z&O7/_!C-_P#%4?\ "=^,/^AKUS_P8S?_ !5 'V_17Q!_
MPG?C#_H:]<_\&,W_ ,51_P )WXP_Z&O7/_!C-_\ %4 ?;]%?$'_"=^,/^AKU
MS_P8S?\ Q5'_  G?C#_H:]<_\&,W_P 50!]OT5\0?\)WXP_Z&O7/_!C-_P#%
M4?\ "=^,/^AKUS_P8S?_ !5 'V_17Q!_PG?C#_H:]<_\&,W_ ,51_P )WXP_
MZ&O7/_!C-_\ %4 ?;]%?$'_"=^,/^AKUS_P8S?\ Q5'_  G?C#_H:]<_\&,W
M_P 50!]OT5\0?\)WXP_Z&O7/_!C-_P#%4?\ "=^,/^AKUS_P8S?_ !5 'V_1
M7Q!_PG?C#_H:]<_\&,W_ ,51_P )WXP_Z&O7/_!C-_\ %4 ?;]%?$'_"=^,/
M^AKUS_P8S?\ Q5'_  G?C#_H:]<_\&,W_P 50!]OT5\0?\)WXP_Z&O7/_!C-
M_P#%4?\ "=^,/^AKUS_P8S?_ !5 'V_17Q!_PG?C#_H:]<_\&,W_ ,51_P )
MWXP_Z&O7/_!C-_\ %4 ?;]%?$'_"=^,/^AKUS_P8S?\ Q5'_  G?C#_H:]<_
M\&,W_P 50!]OT5\0?\)WXP_Z&O7/_!C-_P#%4?\ "=^,/^AKUS_P8S?_ !5
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MUS_P8S?_ !5 'V_17Q!_PG?C#_H:]<_\&,W_ ,51_P )WXP_Z&O7/_!C-_\
M%4 ?;]%?$'_"=^,/^AKUS_P8S?\ Q5'_  G?C#_H:]<_\&,W_P 50!]OT5\0
M?\)WXP_Z&O7/_!C-_P#%4?\ "=^,/^AKUS_P8S?_ !5 'V_17Q!_PG?C#_H:
M]<_\&,W_ ,51_P )WXP_Z&O7/_!C-_\ %4 ?;]%?$'_"=^,/^AKUS_P8S?\
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MS?\ Q5'_  G?C#_H:]<_\&,W_P 50!]OT5\0?\)WXP_Z&O7/_!C-_P#%4?\
M"=^,/^AKUS_P8S?_ !5 'V_17Q!_PG?C#_H:]<_\&,W_ ,51_P )WXP_Z&O7
M/_!C-_\ %4 ?;]%?$'_"=^,/^AKUS_P8S?\ Q5'_  G?C#_H:]<_\&,W_P 5
M0!]OT5\0?\)WXP_Z&O7/_!C-_P#%4?\ "=^,/^AKUS_P8S?_ !5 'V_17Q!_
MPG?C#_H:]<_\&,W_ ,51_P )WXP_Z&O7/_!C-_\ %4 ?;]%?$'_"=^,/^AKU
MS_P8S?\ Q5'_  G?C#_H:]<_\&,W_P 50!]OT5\0?\)WXP_Z&O7/_!C-_P#%
M4?\ "=^,/^AKUS_P8S?_ !5 'V_17Q!_PG?C#_H:]<_\&,W_ ,51_P )WXP_
MZ&O7/_!C-_\ %4 ?;]%?$'_"=^,/^AKUS_P8S?\ Q5'_  G?C#_H:]<_\&,W
M_P 50!]OT5\0?\)WXP_Z&O7/_!C-_P#%4?\ "=^,/^AKUS_P8S?_ !5 'V_1
M7Q!_PG?C#_H:]<_\&,W_ ,51_P )WXP_Z&O7/_!C-_\ %4 ?;]%?$'_"=^,/
M^AKUS_P8S?\ Q5'_  G?C#_H:]<_\&,W_P 50!]OT5\0?\)WXP_Z&O7/_!C-
M_P#%4?\ "=^,/^AKUS_P8S?_ !5 'V_17Q!_PG?C#_H:]<_\&,W_ ,51_P )
MWXP_Z&O7/_!C-_\ %4 ?;]%?$'_"=^,/^AKUS_P8S?\ Q5'_  G?C#_H:]<_
M\&,W_P 50!]OT5\0?\)WXP_Z&O7/_!C-_P#%4?\ "=^,/^AKUS_P8S?_ !5
M'V_17Q!_PG?C#_H:]<_\&,W_ ,51_P )WXP_Z&O7/_!C-_\ %4 ?;]%?$'_"
M=^,/^AKUS_P8S?\ Q5'_  G?C#_H:]<_\&,W_P 50!]OT5\0?\)WXP_Z&O7/
M_!C-_P#%5]#_  .\0^,?$&AW$OB!?M&F1X2ROYCMFD*_*R\#]XHQRY.=V1EN
M=@!ZQ1110!7OK"SU.SDL[^T@N[63&^&>,2(V"",J>#@@'\*^>/B+\!KC3O\
MB9>#8I[RU^=I[!G#20]6!CS@NN/EV\OG'WLG'T?10!\ 5N>%_$8\.:HEQ-I6
MFZI:,ZF>UOK6.42*,\*S*2AY/*]P,A@,5]1^/_A)H7CG?>?\@_66V#[?$A;<
MJ\8=,@-P<9X;A><#!^8/%G@O7?!6HK9ZU:>5YNXP3(P:.95."58?@<'# $9
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M_0J:'_X+HO\ XFN@HH Y_P#X07PA_P!"KH?_ (+HO_B:3_A!?"'_ $*NA_\
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M .)KH#UI* ,#_A!O"/\ T*NA_P#@OB_^)H_X0;PC_P!"KH?_ (+XO_B:WZ*
M,#_A!O"/_0JZ'_X+XO\ XFC_ (0;PC_T*NA_^"^+_P")K?HH Y__ (0;PC_T
M*NA_^"^+_P")H_X0;PC_ -"KH?\ X+XO_B:WZ* ,#_A!O"/_ $*NA_\ @OB_
M^)H_X0;PC_T*NA_^"^+_ .)K?HH P/\ A!O"/_0JZ'_X+XO_ (FC_A!O"/\
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M?]"MHG_@OB_^)K>HH P?^$'\)?\ 0K:)_P""^+_XFC_A!_"7_0K:)_X+XO\
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M0!@?\(1X3_Z%?1?_  7Q?_$T?\(1X3_Z%?1?_!?%_P#$UO44 8/_  A'A/\
MZ%?1?_!?%_\ $T?\(1X3_P"A7T7_ ,%\7_Q-;U% &#_PA'A/_H5]%_\ !?%_
M\31_PA'A/_H5]%_\%\7_ ,36]10!@?\ "$^$_P#H5]%_\%\7_P 31_PA/A/_
M *%?1?\ P7Q?_$UO44 8/_"$^$_^A7T7_P %\7_Q-'_"$^$_^A7T7_P7Q?\
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M 1?_ !-'_"%^%?\ H6=&_P# "+_XFMRB@##_ .$+\*_]"SHW_@!%_P#$T?\
M"%^%?^A9T;_P B_^)K<HH P_^$+\*_\ 0LZ-_P" $7_Q-'_"%^%?^A9T;_P
MB_\ B:W** ,+_A"_"O\ T+.C?^ $7_Q-'_"%^%?^A9T;_P  (O\ XFMRB@##
M_P"$+\*_]"SHW_@!%_\ $T?\(7X5_P"A9T;_ , (O_B:W** ,/\ X0OPK_T+
M.C?^ $7_ ,31_P (7X5_Z%G1O_ "+_XFMRB@#"_X0OPK_P!"SHW_ ( 1?_$T
M?\(7X5_Z%G1O_ "+_P")K<HH P_^$+\*_P#0LZ-_X 1?_$T?\(7X5_Z%G1O_
M   B_P#B:W** ,/_ (0OPK_T+.C?^ $7_P 32'P7X5_Z%G1O_ "+_P")K=I#
MTH PO^$,\*_]"UHW_@!%_P#$T?\ "&>%?^A:T;_P B_^)K<HH P_^$,\*_\
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M_ &+_P")H_X0WPM_T+6C_P#@#%_\36W10!B?\(;X6_Z%K1__  !B_P#B:/\
MA#?"W_0M:/\ ^ ,7_P 36W10!A_\(;X6_P"A:T?_ , 8O_B:/^$-\+_]"WH_
M_@#%_P#$UN4E &)_PAOA?_H6]'_\ 8O_ (FC_A#?"_\ T+>C_P#@#%_\36W1
M0!B?\(;X7_Z%O1__  !B_P#B:/\ A#?"_P#T+>C_ /@#%_\ $UMT4 8?_"&^
M%_\ H6]'_P# &+_XFC_A#?"__0MZ/_X Q?\ Q-;=% &)_P (;X7_ .A;T?\
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M2?N_>/RC KVN@ HHHH *2EI* "BBB@ HHHH *2EI* "BBB@ HHHH #24II*
M"BBB@ HHHH 0]:2E/6DH **** "BBB@!**** "BBB@ HHHH 2BBB@ HHHH *
M*** $HHHH **** "D/6EI#UH 2BBB@ HHHH *2EI* "BBB@ HHHH *2EI* "
MBBB@ HHHH *2EI* "BBB@ HHHH 0TE*:2@ HHHH **** $HHHH **** "BBB
M@!**** "BBB@ HHHH 2BBB@ HHHH *0]*6D/2@!**** "BBB@ H-%!H 2BBB
M@ HHHH *2EI* "BBB@ HHHH *2EI* "BBB@ HHHH 0]*2E/2DH **** "BBB
M@!#10:* "BBB@ HHHH 2BBB@ HHHH **** $HHHH **** "BBB@!**** "BB
MB@ I#TI:0]* $HHHH **** "D-+2&@ HHHH **** "DI:2@ HHHH **** "D
MI:2@ HHHH ****  ]*;3CTIM !1110 4444 %)2TE !1110 4444 )1110 4
M444 %%%% "4444 %%%% !1110 VBBB@ HHHH **** $HHHH **** "@T4&@!
M**** "BBB@ I*6DH **** "BBB@ IO>G4WO0 4444 %%%% !24M)0 4444 %
M%,FFBMX))YY$BAC4N\CL%55 R22>@ KQ'QK\99;M)=/\,!X8'5DDOI%*R'G&
M8AGY1@=3\WS=%(S0!Z)XO^(>B^$8S'-)]KU Y"V<#@NIVY!D_N*<KR<GG(!P
M:^>O%/B[5?%^H)=ZG(@$:[8H(@5CC'?:"3R2,DDD].P &+--+<3R3SR/+-(Q
M=Y'8LS,3DDD]2372^#OA_P"(/'%YY6DVNVW7<)+V<,L$9 !VEP#EN5^4 GG.
M,9( .;@@FNKB*WMXI)IY7"1QQJ69V)P  .22>U>^> /V?_N:AXT_VP-*BD_!
M6>5&^IVK_LY;JM>C^!?A9X?\#1"6WB^VZF<%K^Y12ZG;M(CX_=J<MP"3\V"3
M@8[B@".""&UMXK>WBCA@B0)''&H544#   X  [5)110 4444 %%%% !1110
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M* "DI:2@ HHHH **** "DI:2@ HHHH **** $-)2FDH **** "BBB@!****
M"BBB@ HHHH 2BBB@ HHHH **** $HHHH **** "D/2EI#TH 2BBB@ HHHH *
M#10: $HHHH **** "DI:2@ HHHH **** "DI:2@ HHHH **** $/2DI3TI*
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M%%% !2'I2TAZ4 )1110 4444 %(:6D- !1110 4444 %)2TE !1110 4444
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MP\=GKY1O,LR"%DV@$M&QX((YVYW##=0-Q /0Z2EI* "BBB@ HHHH #24II*
M"BBB@ HHHH 0]:2E/6DH **** "BBB@!**** "BBB@ HHHH 2BBB@ HHHH *
M*** $HHHH **** "D/6EI#UH 2BBB@ HHHH *2EI* "BBB@ HHHH *2EI* "
MBBB@ HHHH *2EI* "BBB@ HHHH 0TE*:2@ HHHH **** $HHHH **** "BBB
M@!**** "BBB@ HHHH 2BBB@ HHHH *0]*6D/2@!**** "BBB@ H-%!H 2BBB
M@ HHHH *2EI* "BBB@ HHHH *2EI* "BBB@ HHHH 0]*2E/2DH **** "BBB
M@!#10:* "BBB@ HHHH 2BBB@ HHHH **** $HHHH **** "BBB@!**** "BB
MB@ I#TI:0]* $HHHH **** "D-+2&@ HHHH **** "DI:2@ HHHH **** "D
MI:2@ HHHH ****  ]*;3CTIM !1110 4444 %)2TE !1110 4444 )1110 4
M444 %%%% "4444 %%%% !1110 VBBB@ HHHH **** $HHHH **** "@T4&@!
M**** "BBB@ I*6DH **** "BBB@ IO>G4WO0 5D>(?$VE>&-/>\U2Z2(!2T<
M0(\R8C'"+_$<D>PSDD#FN(\9_&'3M&WV>@^3J-\-I,V=UL@/)&5.6;&.!P,]
M<@K7A6J:OJ.MWS7FIWDUU<-GYY6SM&2<*.BKDG & ,\4 =5XY^).I^+9YK2!
MWM=%+#9:X&Z3:>&D(ZDGG;G:,#J1N/$5H:-H>J>(=12PTBPGO;IL'9"F=H)
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M ****  ]*;3CTIM !1110 4444 %)2TE !1110 4444 )1110 4444 %%%%
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M@ HHHH **** $HHHH **** "BBB@!**** "BBB@ I#TI:0]* $HHHH ****
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MY))/4D]Z97MGP^^ M]J3PZGXM62QLU=773_^6MPFW/SD',0R0"/O?>'R'!H
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M1110 4E+24 %%%% !1110 AZ4E*>E)0 4444 %%%% "&B@T4 %%%% !1110
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M!;XV7;D< [64A%SGD\G;TPP:OH_1M#TOP]IR6&D6$%E:K@[(4QN( &YCU9L
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M<\'D;NN%"U]&Z/KFE^(-/2_TB^@O+9L#?"^=I(!VL.JM@C*G!&>10!>HHHH
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ME+24 %%%% !1110 E%%% !1110 4444 )1110 4444 %%%% #:*** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %1SP0W5O+;W$4<T$J%)(Y%#*ZD8((/!!':I** / /'_ .S_ /?U
M#P7_ + .E2R?@S)*[?0[6_VL-T6O YX)K6XEM[B*2&>)RDD<BE61@<$$'D$'
MM7WW7#^.OA9X?\<Q&6XB^Q:F,E;^V10[';M DX_>*,+P2#\N 1DY /EOP=XW
MUKP-JCWND2H1*FR:WF!:*4<XW $'()R""".1T)!^G_ _Q1T#QQ$(H)/L6IC
M:QN74.QV[B8^?WBC#<@ _+D@9&?F7QC\/_$'@>\\K5K7=;MM$=[ &:"0D$[0
MY PW#?*0#QG&,$\W!/-:W$=Q;RO#/$X>.2-BK(P.001R"#WH ^]**^=_A_\
M'F:Q2'3/%P>XMT18XM0B4M*/FQF89^<!3]Y1N^7D,3FOH2">&ZMX[BWE2:"5
M \<D;!E=2,@@C@@CO0 ^BBB@ HHHH **** $HHHH **** "D/6EI#UH 2BBB
M@ HHHH *2EI* "BBB@ HHHH *2EI* "BBB@ HHHH *2EI* "BBB@ HHHH 0T
ME*:2@ HHHH **** $HHHH **** "BBB@!**** "BBB@ HHHH 2BBB@ HHHH
M*0]*6D/2@!**** "BBB@ H-%!H 2BBB@ HHHH *2EI* "BBB@ HHHH *2EI*
M "BBB@ HHHH 0]*2E/2DH **** "BBB@!#10:* "BBB@ HHHH 2BBB@ HHHH
M **** $HHHH **** "BBB@!**** "BBB@ I#TI:0]* $HHHH **** "D-+2&
M@ HHHH **** "DI:2@ HHHH **** "DI:2@ HHHH ****  ]*;3CTIM !111
M0 4444 %)2TE !1110 4444 )1110 4444 %%%% "4444 %%%% !1110 VBJ
MNHZC9Z1IT^H:A<);VL"[I)'Z ?U)/  Y)( KP3QI\8]1UK?9:!YVFV!VDSYV
MW+D<D94X5<XX')QUP2M 'HWC?XJ:3X726SLF2_U;:P6.-@T<+@[<2D'@@Y^4
M<_+@[<@U\^^(/$&H^)]8EU/4YO,GDX51PD:]D4=E'^).22:RZ[CP+\+/$'CF
M42V\7V+3!@M?W*,$8;MI$?'[QAAN 0/EP2,C(!R>E:5?:WJEOIFF6TES>7#[
M(HD'+'^0 &22>  2>!7T/\/O@+8Z:D.I^+5COKQD5UT__EE;ONS\Y!Q*<  C
M[OWA\XP:]$\'?#_P_P"![/RM)M=UPVX27LX5IY 2#M+@#"\+\H '&<9R3U%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 5[ZPL]3LY+._M(+NUDQOAGC$B-@@C*G@X(!_"
MOGCXB_ :XT[_ (F7@V*>\M?G:>P9PTD/5@8\X+KCY=O+YQ][)Q]'T4 ? %==
MX'^(NN>!;L?89?.TZ2427-C)C9+Q@X."4;'<>BY# 8KZ1\?_  DT+QSOO/\
MD'ZRVP?;XD+;E7C#ID!N#C/#<+S@8/S!XL\%Z[X*U%;/6K3RO-W&"9&#1S*I
MP2K#\#@X8 C(&10!]4^!_B+H?CJT'V&7R=1CB$ES8R9WQ<X.#@!USW'JN0I.
M*ZZO@R">:UN([BWE>&>)P\<D;%61@<@@CD$'O7O_ ,.OCJESY6E>,9=MS)+M
MBU((J1D'/$H& N#@!@,8(SC!8@'NE%1P3PW5O'<6\J302H'CDC8,KJ1D$$<$
M$=ZDH **** $HHHH **** "D/6EI#UH 2BBB@ HHHH *2EI* "BBB@ HHHH
M*2EI* "BBB@ HHHH *2EI* "BBB@ HHHH 0TE*:2@ HHHH **** $HHHH **
M** "BBB@!**** "BBB@ HHHH 2BBB@ HHHH *0]*6D/2@!**** "BBB@ H-%
M!H 2BBB@ HHHH *2EI* "BBB@ HHHH *2EI* "BBB@ HHHH 0]*2E/2DH **
M** "BBB@!#10:* "BBB@ HHHH 2BBB@ HHHH **** $HHHH **** "BBB@!*
M*** "BBB@ I#TI:0]* $HHHH **** "D-+2&@ HHHH **** "DI:2@ HHHH
M**** "DI:2@ HHHH ****  ]*;3CTIM !1110 4444 %)2TE !1110 4444
M)1110 4444 %%%% "4444 %%%07=Y:Z?:O=7MS#;6Z8WRS2!$7)P,D\#D@?C
M0!/7$^-?B;H_@_?:_P#']JJ[3]CC;;M#<Y=\$+QSCD\KQ@YKSSQW\9I[[_0/
M"LDUK;_,LUXR!9)>HPG=%QSNX;./NXY\AH V_$OBS6/%M\MUJUSYGE[A#$B[
M8X@3G"C\ADY) &2<5D00375Q%;V\4DT\KA(XXU+,[$X  '))/:NL\"_#?7?'
MEX/L,/DZ;'*([F_DQLBXR<#(+MC^$?WER5!S7T_X%^&^A> [,?88?.U*2(1W
M-_)G?+SDX&2$7/\ "/[JY+$9H \X^&_P&2V\K5O&<6ZZCEW1:8'5XP!GF4C(
M?)P0H., ;LY*CW.""&UMXK>WBCA@B0)''&H544#   X  [5)10 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %4]5TJQUO2[C3-3MH[FSN$V2Q..&'\P0<$$<
M@@$<BKE% 'S!X_\ @1JF@;[_ ,->?JNFC8#;XWW:$\$[54!USCD<C=TPI:O'
MZ^_Z\S^(/P:T7Q@DU_IZQZ9K6QBLL2A8IW+;LS*!DDG=\XY^;)W8 H \"\#_
M !1U_P #RB*"3[;IAP&L;AV**-VXF/G]VQRW(!'S9(.!CZ:\'^/M \;6GFZ5
M=;;A=QDLIRJSH 0-Q0$Y7E?F!(YQG.0/D?Q/X8U3PCKDVD:O!Y5Q'RK+RDJ'
MHZ'NIQ^A! ((%/2]4OM$U.WU+3;E[:\MWWQ2H>5/\B",@@\$$@\&@#[KHKQ?
MP!\=K'4DATWQ8R6-XJ*BW_\ RRN&W8^8 8C.""3]W[Q^48%>T4 )1110 444
M4 %(>M+2'K0 E%%% !1110 4E+24 %%%% !1110 4E+24 %%%% !1110 4E+
M24 %%%% !1110 AI*4TE !1110 4444 )1110 4444 %%%% "4444 %%%% !
M1110 E%%% !1110 4AZ4M(>E "4444 %%%% !0:*#0 E%%% !1110 4E+24
M%%%% !1110 4E+24 %%%% !1110 AZ4E*>E)0 4444 %%%% "&B@T4 %%%%
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M%% !1110 AI*4TE !1110 4444 )1110 4444 %%%% "4444 %%%% !1110
ME%%% !1110 4AZ4M(>E "4444 %%%% !0:*#0 E%%% !1110 4E+24 %%%%
M!1110 4E+24 %%%% !1110 AZ4E*>E)0 4444 %%%% "&B@T4 %%%% !1110
M E%%% !1110 4444 )1110 4444 %%%% "4444 %%%% !2'I2TAZ4 )1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME !1110 4444 %)2TE !1110 4444 %)2TE !1110 4444 (:2E-)0 4444
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M''P^T7QUI<D%]!'#?A +?4$C!EA(R0,]63+'*$X.3C!P1UE% 'QAXZ^&^N^
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M% !24M)0 4444 %%%% "&DI324 %%%% !1110 E%%% !1110 4444 )1110
M4444 %%%% "4444 %%%% !2'I2TAZ4 )1110 4444 %!HH- "4444 %%%% !
M24M)0 4444 %%%% !24M)0 4444 %%%% "'I24IZ4E !1110 4444 (:*#10
M 4444 %%%% "4444 %%%% !1110 E%%% !1110 4444 )1110 4444 %(>E+
M2'I0 E%%% !1110 4AI:0T %%%% !1110 4E+24 %%%% !1110 4E+24 %%%
M% !1110 'I3:<>E-H **** "BBB@ I*6O/O''Q6TGPLDMG8LFH:MM8+'&P:*
M%P=N)2#P0<_*.?EP=N0: .OUO7=,\.:<;_5KQ+6V#!-[ DECT  !)/4X Z G
MH#7S]XX^+FI^)DEL-,5].TIU:.1,@RW"D_Q''RC  VJ>[ E@:Y#Q%XGU;Q3J
M+WFJW;RDL6CA!/E0@XX1<_*, >YQDDGFL^QL+S4[R.SL+2>[NI,[(8(S([8!
M)PHY. "?PH KUZ!X ^$FN^.=EY_R#]&;>/M\J!MS+QA$R"W)QGA>&YR,'U/X
M?? 6QTU(=3\6K'?7C(KKI_\ RRMWW9^<@XE.  1]W[P^<8->V4 <_P"$_!>A
M>"M.:ST6T\KS=IGF=BTDS*, LQ_$X&%!)P!DUT%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS_Q_\)-"\<[[S_D'ZRVP
M?;XD+;E7C#ID!N#C/#<+S@8/H%% 'Q!XL\%Z[X*U%;/6K3RO-W&"9&#1S*IP
M2K#\#@X8 C(&16'!/-:W$=Q;RO#-$X>.2-BK(P.001R"#WK[OU72K'6]+N-,
MU.VCN;.X39+$XX8?S!!P01R" 1R*^;/'_P "-4T#??\ AKS]5TT; ;?&^[0G
M@G:J@.N<<CD;NF%+4 =#\._CFESY6E>,)=MS)+MBU((J1D'/$H& N#@!@,8(
MSC!8^W03PW5O'<6\J30RH'CDC8,KJ1D$$<$$=Z^$*[7P1\3]?\$2B*"3[;II
MP&L;AV**-VXF/G]VQRW(!'S9(.!0!]?4E<UX0\>Z!XVM/-TJZVW"[O,LYRJS
MH 0-Q0$_+ROS D<XSG('2T %%%% !1110 4E+24 %%%% !1110 AI*4TE !1
M110 4444 )1110 4444 %%%% "4444 %%%% !1110 E%%% !1110 4AZ4M(>
ME "4444 %%%% !0:*#0 E%%% !1110 4E+24 %%%% !1110 4E+24 %%%% !
M1110 AZ4E*>E)0 4444 %%%% "&B@T4 %%%% !1110 E%%% !1110 4444 )
M1110 4444 %%%% "4444 %%%% !2'I2TAZ4 )1110 4444 %(:6D- !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/2EI#TH 2BBB@ HHHH *#10: $HHHH **** "DI:2@ HHHH **** "DI:2@
MHHHH **** $/2DI3TI* "BBB@ HHHH 0T4&B@ HHHH **** $HHHH **** "
MBBB@!**** "BBB@ HHHH 2BBB@ HHHH *0]*6D/2@!**** "BBB@ I#2TAH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME+24 %%%% !1110 4E+24 %%%% !1110 AZ4E*>E)0 4444 %%%% "&B@T4
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MG')H X/X??!K1?!Z0W^H+'J>M;%+2RJ&B@<-NS"I&00=OSGGY<C;DBO3***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q/
MX@_ 6QU))M3\)+'8WBHSMI__ "RN'W9^0DXB."0!]W[H^09-?/&JZ5?:)JEQ
MIFIVTEM>6[[)8G'*G^1!&"".""".#7WG7/\ BSP7H7C73EL]:M/-\K<8)D8K
M)"S#!*L/P.#E20,@X% 'QGH/B'5O#.IKJ.C7KVET$*;U 8,IZ@J00PZ'!!Y
M/4"OH_P#\9])\5/#IVJJFF:O(ZQQ)N)BN&(_A;'RDD$!6/=0"Q/'C/Q ^%6M
M>!+CS2)-0TDH&&H10E50Y *R#)V'<0!DX.1@YR!P= 'WC17S1X$^.&IZ%LL?
M$?GZIIPWD7&=]TA/(&YF =<YX/(W=< +7T1H^MZ9K^GI?:3?07ELV/GB;.TX
M!VL.JM@C*G!&>10!?HHHH 0TE*:2@ HHHH **** $HHHH **** "BBB@!***
M* "BBB@ HHHH 2BBB@ HHHH *0]*6D/2@!**** "BBB@ H-%!H 2BBB@ HHH
MH *2EI* "BBB@ HHHH *2EI* "BBB@ HHHH 0]*2E/2DH **** "BBB@!#10
M:* "BBB@ HHHH 2BBB@ HHHH **** $HHHH **** "BBB@!**** "BBB@ I#
MTI:0]* $HHHH **** "D-+2&@ HHHH **** "DI:2@ HHHH **RO$7B+3?"^
MC3:IJDWEP1\*J\O*YZ(@[L<?S)P 37SSXY^*^K^*GELK%GT_2-S!8XV*RS(1
MMQ*0<$$9^4<?-@[L T >B^/?C'8:3!/IWAR9+S4F4 7:%7@AR#D@YP[ 8XQM
MR>2<%:\"U+4KS6-1GU#4+A[B[G;?)*_4G^0 '  X   XJK7IGP^^#6M>,'AO
M]0633-%WJ6EE4K+.A7=F%2,$$;?G/'S9&[!% '#Z!X<U?Q3JBZ;HMC)=W90O
ML4A0JCJ69B HZ#)(Y('4BOI?X??!+2/";PZEJ[1ZIK$;K+$^TB*V8+_ N?G(
M8DAF'92 I'/>>&/#&E^$=#ATC2(/*MX^69N7E<]7<]V./T     V* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAZ4M(>E "4444 %%%% !0:*#0 E%%% !1110 4E+24 %%%% !1110 4E+24
M%%%% !1110 AZ4E*>E)0 4444 %%%% "&B@T4 %%%% !1110 E%%% !1110
M4444 )1110 4444 %%%% "4444 %%%% !2'I2TAZ4 )1110 4444 %(:6D-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGI24 %%%% !1110 AHH-% !1110 4444 )1110 4444 %%%% "4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,J!XY(V#*ZD9!!'!!'>GT %%%% !1110 E%%% !1110 4444 )1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-%!H 2BBB@ HHHH *2EI* "BBB@ HHHH *2EI* "BBB@ HHHH 0]*2E/2DH
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MBVGF^5M,\SL%CA5C@%F/XG RQ . <&@##@@FNKB*WMXI)IY7"1QQJ69V)P
M.22>U>X?#[X!37R0ZIXP,EO;NBR1:=$Q64_-G$QQ\@*C[JG=\W)4KBO2_ 'P
MDT+P-LO/^0AK*[Q]OE0KM5N,(F2%X&,\MRW.#@>@4 5[&PL],LX[.PM(+2UC
MSLA@C$:+DDG"C@9))_&K%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% &7K_ (<TCQ3I;:;K5C'=VA</
ML8E2K#H592"IZC((X)'0FOFCX@_!+5_":3:EI#2:IH\:-+*^T"6V4-_&N?G
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUY?F;A#"BEI)B!G"@?@,G !(R1FOG+QO\4-9\9[[7_CQTEMA^Q1L&W,O.7?
M+<\XX'"\9&:Y75M9U+7;]KW5;V:[N&S\\K9VC).U1T5<DX P!G@4[1M#U3Q#
MJ*6&D6$][=-@[(4SM!(&YCT5<D98X SR: ,^O5/A]\$M7\6)#J6KM)I>CR(L
ML3[09;E2W\"Y^0%02&8=U(# \>K_  ^^"6D>$WAU+5VCU36(W66)]I$5LP7^
M!<_.0Q)#,.RD!2.?5* ,O0/#FD>%M+73=%L8[2T#E]BDL68]2S,26/09)/
MZ 5J444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M44 %%%% !0:*#0 E%%% !1110 4E+24 %%%% !1110 4E+24 %%%% !1110
MAZ4E*>E)0 4444 %%%% "&B@T4 %%%% !1110 E%%% !1110 4444 )1110
M4444 %%%% "5FZYKVE^&]-;4-7O$M;4,$WL"2S'H H!)/4X Z GH#7#^.OC!
MI?AAY=/TM4U+5HV:.1-Q$5NP'\38^8@D JI[,"5(Y^>M<U[5/$FI-J&KWCW5
MT5";V  51T 4  #J< =23U)H ['QU\6=7\5/+96+/I^D;F"QQL5EG0C;B4@X
M((S\HX^;!W8!KSRKFE:5?:WJEOIFF6TES>7#[(HD'+'^0 &22>  2>!7T7\-
M_@79Z+Y6K>*D@O[YXOET]XP\-NQSG=U$C8P.FT'.-WRL #S3X??!K6O&#PW^
MH+)IFB[U+2RJ5EG0KNS"I&""-OSGCYLC=@BOI?POX1T7P?I:6&CV4<("*LLY
M4&6<C/S2-C+'+-[#.  .*W** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "N3\<?#[1?'6ER07T$<-^$ M]02,&6$C) S
MU9,L<H3@Y.,'!'644 ?&'CKX;Z[X#O#]NA\[39)3';7\>-DO&1D9)1L?PG^Z
MV"P&:X^OON>"&ZMY;>XBCF@E0I)'(H974C!!!X(([5X)X_\ V?\ [^H>"_\
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M%PCK)%IT3!HA\N<3''SD,?NJ=OR\E@V*]O@@AM;>*WMXHX8(D"1QQJ%5% P
M .  .U &'X3\%Z%X*TYK/1;3RO-VF>9V+23,HP"S'\3@84$G &370444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 </XZ^%GA_QS$9;B+[%J8R5O[9%#L=NT"3C]XHPO!(/RX!&3
MGY@\8_#_ ,0>![SRM6M=UNVT1WL 9H)"03M#D##<-\I /&<8P3]KU7OK"SU.
MSDL[^T@N[63&^&>,2(V"",J>#@@'\* /@R">:VN([BWE>*:)P\<D;%61@<@@
MCD$'O7L_@/XZ3620Z;XL#SVZ*L<=_&I:4<XS*,_, #]X#=\O(8G-2_$7X#7&
MG?\ $R\&Q3WEK\[3V#.&DAZL#'G!=<?+MY?./O9./#Z /NB">*YMX[BWE26&
M50\<D;!E=2,@@C@@CO3STKY \$_$+6_!%V/L4OG:>\HDN+&3&R7C!P<$HV.X
M]%R"!BOI/P5\0M$\;V@^Q2^3J"1"2XL9,[XN<'!P ZY[CU7(!.* .KHHHH *
M*** "@T4&@!**** "BBB@ I*6DH **** "BBB@ I*6DH **** "BBB@!#TI*
M4]*2@ HHHH **** $-%!HH **** "BBB@!**** "BBB@ HHHH 2JFIZG9:/I
ML^HZC<);VD"[Y)7Z ?S))P !R20!S7,^-/B5H7@R,Q3R?;-1.0ME;NI=3MW
MR?W%.5Y.3SD X-?-WBWQEJ_C34DO-5D0")=D-O""L40XSM!).21DDDD\=@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS_Q_\)-"\<[[
MS_D'ZRVP?;XD+;E7C#ID!N#C/#<+S@8/H%% 'Q!XL\%Z[X*U%;/6K3RO-W&"
M9&#1S*IP2K#\#@X8 C(&16'!/+;7$=Q;RO%-$P>.2-BK(P.001R"#WK[OU72
MK'6]+N-,U.VCN;.X39+$XX8?S!!P01R" 1R*^;/'_P "-4T#??\ AKS]5TT;
M ;?&^[0G@G:J@.N<<CD;NF%+4 ;GP]^-Z7'EZ7XOEVW+R[8M1"*D9!SQ*!@+
M@X 8#&",XP6/M4$\5S;QW%O*DL,JAXY(V#*ZD9!!'!!'>OAFNS\%?$S7O!4@
MB@D^V::<!K*X=BBC=N)CY^1CEN1D<Y(.!0!];T5S?A+QWH/C2T\W2[K;.N[?
M9SE5G0 @;BH)^7E?F&1SC.<@=)0 4&B@T )1110 4444 %)2TE !1110 444
M4 %)2TE !1110 4444 (>E)2GI24 %%%% !1110 AHH-% !1110 4444 )11
M10 445RGC3X@:+X*M3]ME\W4'B,EO91YWR\X&3@A%SW/HV 2,4 =1-/%;023
MSRI%#$I>221@JHH&223P !WKP;QU\;Y;Q)=-\*!X+=U:.2_D4K*><9B&?E!
M^\1N^;HI&:X/QI\0-:\:W1^VR^5IZ2F2WLH\;(N,#)P"[8[GU;  .*Y2@"2:
M>6YGDGGE>6:5B\DDC%F=B<DDGDDGO72>#OA_X@\<7GE:3:[;==PDO9PRP1D
M':7 .6Y7Y0"><XQDCTCX=? :XU'_ (F7C**>SM?D:"P5PLDW1B9,9*+CY=O#
MYS]W S]#V-A9Z99QV=A:06EK'G9#!&(T7)).%' R23^- ''^!?A9X?\  T0E
MMXOMNIG!:_N44NIV[2(^/W:G+< D_-@DX&.XHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7D_Q(^"FG>*O-U/01!IVMR2
M^9,SEA#<9P&W 9VMQG<HY).02=P]8HH ^$-9T/5/#VHO8:O83V5TN3LF3&X
MD;E/1ER#AAD''!I-(UK4]!OUOM*OIK.Y7'SQ-C<,@[6'1ER!E3D''(K[4\4>
M$=%\8:6]AK%E',"C+%.% E@)Q\T;8RIRJ^QQ@@CBOFCX@_!K6O![S7^GK)J>
MB[V*RQ*6E@0+NS,H&  -WSCCY<G;D"@#T;P-\;-,US98^(O)TS4#O(GSLM7
MY W,Q*-C/!X.WKDA:]7KX6KTGP!\7M3\)?Z#J8FU/2CL5$:7]Y; 8'[LGJNT
M?<.!D#!7G(!]045FZ%X@TKQ+IJZCH]XEU:EBF]0058=05(!!Z'!'0@]"*TJ
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MF%2,@@[?G//RY&W)%>F444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFG4-7O$M;4,$WL"2S'H H!)/4X Z GH#7SOXZ^,.J>)TET_2U?3=)D5HY$W
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M73D<D;E8A%SC@<G;UP2M>4T :6N:_JGB34FU#6+Q[JZ*A-[  *HZ *  !U.
M.I)ZDU#I6E7VMZI;Z9IEM)<WEP^R*)!RQ_D !DDG@ $G@5UG@7X6>(/',HEM
MXOL6F#!:_N48(PW;2(^/WC##< @?+@D9&?J?PGX+T+P5IS6>BVGE>;M,\SL6
MDF91@%F/XG PH). ,F@#S/X?? 6QTU(=3\6K'?7C(KKI_P#RRMWW9^<@XE.
M 1]W[P^<8->V444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5'/!#=6\MO<11S02H4DCD4,KJ1@@@\$$=JDHH \ \?_L__?U#P7_L Z5+
M)^#,DKM]#M;_ &L-T6O YX)K6XEM[B*2&>)RDD<BE61@<$$'D$'M7WW7#^.O
MA9X?\<Q&6XB^Q:F,E;^V10[';M DX_>*,+P2#\N 1DY /EGPCXSUCP5J3WFE
M2H1*NR:WF!:*4<XW $'()R""".>Q(/TIX*^)FA>-(Q%!)]CU(8#65PZAV.W<
M3'S\ZC#<C!XR0,BOG+QC\/\ Q!X'O/*U:UW6[;1'>P!F@D)!.T.0,-PWRD \
M9QC!/-P3RVUQ'<6\KQ31,'CDC8JR,#D$$<@@]Z /N2DKP'P)\<I;)(M-\5AY
M[=%6.._C4M*.<9E&?F !^\!N^7D,3FO>H)XKFWCG@E26&50\<D;!E=2,@@C@
M@CO0!)1110 4444 (>E)4-[>VFG6DEU?74-K;1XWS3R!$7) &2>!R0/QKP'Q
MW\;KW4'ET[PN7LK169&OO^6LZXQ\H(S&,DD'[WW3\IR* /2_''Q2T7P7OM?^
M/_5EV'[%&Q7:K<Y=\$+QSCD\KQ@YKYL\2>*=8\5ZD][JUV\I+%HX0Q\J$''R
MHN<*, >YQDDGFL:NP\"_#?7?'EX/L,/DZ;'*([F_DQLBXR<#(+MC^$?WER5!
MS0!R]C87FIWD=G86D]W=29V0P1F1VP"3A1R< $_A7T)\/O@%#8O#JGC QW%P
MCK)%IT3!HA\N<3''SD,?NJ=OR\E@V*]#\"_#?0O =F/L,/G:E)$([F_DSOEY
MR<#)"+G^$?W5R6(S784 1P00VMO%;V\4<,$2!(XXU"JB@8  '  ':I*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5/5=*L=;T
MNXTS4[:.YL[A-DL3CAA_,$'!!'((!'(JY10!\P>/_@1JF@;[_P ->?JNFC8#
M;XWW:$\$[54!USCD<C=TPI:O'Z^_ZY?6?ASX.U_>=1\.V+2/*9GEAC\F1W.<
MEGCVLV<DG)Y//6@#XHKVSX?? 6^U)X=3\6K)8V:NKKI__+6X3;GYR#F(9(!'
MWOO#Y#@U[GHG@;PMX<\AM)T&QMYH-WEW'E!YEW9S^];+G@D<GIQTKH* *>E:
M58Z)I=OIFF6T=M9VZ;(HD'"C^9).22>222>35RBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&"1D,<#)) /8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDG')K0KF_"GCSPYXSMP^C:C').$W26DGR3Q\+G*'D@%@-PRN> 3724 %%%%
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M 4444 %%%% 'SY\<_B?-]HF\(:%=QB )MU*XA8EBV2#!GH !C=@G.=IQA@?
MZZ#QW_R4/Q-_V%;K_P!&M7/T >\?LT6-O)J/B*_:/-U#%!#&^X_*CERPQTY,
M:?E[FOH>O /V9?\ F:?^W3_VM7O] !1110!R?C/X<^'/'2(VKVTBW<2;(KRW
M?9*B[@<9P0PZ\,#C<V,$YKS"?]F>%KB5K?Q7)' 7)C22P#LJYX!82 $X[X&?
M05[W10!Y'X4_9_\ #FB7 NM9N)-;G1]T:21^5 N"I&4!)8Y!ZL5(;!7O7HE]
MX3\-ZG>27E_X?TJ[NI,;YI[*.1VP !EB,G  'X5L44 <WI7P_P#"&BI;K8>'
M--1[9]\4SP"256W;@?,?+Y!Z'/'&.@KI*Q[[Q9X;TR\DL[_Q!I5I=1XWPSWL
M<;KD C*DY&00?QJYINK:;K-NUQI>H6E] K[&DM9EE4-@'!*DC."./<4 7***
M* "BBB@ HHHH **** "BN?\ ^$[\'_\ 0UZ'_P"#&'_XJKFF^)=!UFX:WTO6
M]-OIU3>T=K=)*P7(&2%).,D<^XH U**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KR_XI?"&W\<;=3TIX++75VJ\DF1'<H.,/@$A@.C
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M=@ \$+88*XQPQ8NV#DC< <$8 !Z!7!^/OBGIOP_N([6]TO4KB>XMVEMGB11
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO?\ [1KW^O /VFO^96_[>_\ VC0!\_T444 ??]%%% !1110 4444 ?$'CO\
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M%% !1110 445R^C_ !%\(Z_KCZ+I>MP7-^N_$:JX#[?O;&("OZ_*3D D<#-
M'44444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\@?&W_DKVN_\ ;O\
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MO0YX^8*,9Q\P7D#.?D2>":UN);>XBDAGB<I)'(I5D8'!!!Y!![5]]UY_X_\
MA)H7CG?>?\@_66V#[?$A;<J\8=,@-P<9X;A><#! /D"O5/A]\;=7\)I#INKK
M)JFCQHL42;@);90W\#8^<!20%8]E *@<\_XH^%7B_P *.[7>ER75HB,YO+$&
M:(*J@L6(&4 SU<+T.,@9KBZ /LOPO\5?"'BM$6TU2.UNW=4%G?$0REF8A0H)
MPY..B%NHS@G%=I7P!6IIOB77M&MVM]+UO4K&!GWM':W3Q*6P!DA2!G '/L*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MYOXI^"GAOQ=XCN]<O[W58[JZV;T@EC"#:BH, QD]%'>O2** (X((;6WBM[>*
M.&") D<<:A510,  #@ #M4E%% '+WWPX\%:A9R6LWA?2DC?&3!;+"XP0>'0!
MAT['GITKF]2^ W@.^MUBM[&[T]P^XRVMV[,1@_*?,WC'.>F>!SUKTRB@#Q__
M (9Q\'_]!+7/^_\ #_\ &J/^&<?!_P#T$M<_[_P__&J]@HH \?\ ^&<?!_\
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M@NC-SUY)Z^G%>L44 >/_ /#./@__ *"6N?\ ?^'_ .-4?\,X^#_^@EKG_?\
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A%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image12.jpg
<TEXT>
begin 644 image12.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (J G@# 2(  A$! Q$!_\0
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MUC,LKXS@#T'<^@KS[_A:FL06,6N7_@6_MO#$K;AJ(NT>58CG9(T &X \$\X
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M4-&P/8'IGT->XT4 >2? ^^N]3_X2R]U"'R;V;4]UQ'C&V3;\PQVYSQ7K=%%
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MJZ22E$)V+Y,HW''09(&3ZBO-KS1-0;0KV&VT:_&L_P!F:E'J\XM7'VR1\^6
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M4'.,C(ZU4?QCJW]B74]G>Z'J6V]M+:WU*S&^!C-*B.K1"4LKH&S]_!#+TY%
M&*FER!S(^C71\/\ VJR:[M/[/D_>0K:%0/(V[G"R^7E0IQC)& :H>,-.EOM,
MD@TGPO=0+%I6=-^TZ9-<S*=\AVQ$/MM64!6&?G(*+MRH6O1+36M0T[6KC3-?
MGL9 MDU]'=VL+PJ(T8+(&1G?!&5.=W(/08YS['QM=Q^'-3OM7L8X[ZT\J2.U
MC;;O2<*8022<'<Q1CTW(Q QB@#F=;TEII]4FN],N)D;5+F6&.YT:6^MY0UO
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** *&M_\ ( U'_KUE_P#035^J&M_\@#4?^O67_P!!-7Z "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** *&M_\@#4?^O67_T$U?JAK?\ R -1_P"O67_T$U?H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_7K+_P"@FK] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS;2(YD4YRV"5(QQD>_&>:6;Q!IMKYYNYI+5()5B>2Y@>)"QSC:[ *PXZ@D4
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M$NAN8(YK:ZW0RP.G[LLJ,5;"AD^?)RK'N#7=QQI%&L<:*B*,*JC  ] *=10
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M1DG)/U)Y)[U9H .@P**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@"AK?_ " -1_Z]9?\ T$U?JAK?_( U'_KUE_\ 035^
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ6Y10!PB^"-<BT.UTJWUK1H([9HI(IH]'E$H>,@JY;[3RQQR3U!(/6N[HHH
M**** "BBB@ HHHH **** "BD9E12SL%4#)). *HP:WIEW%=265[#>"U!,RVC
M><RG!.-J9.>#QU- %^BN(\0>)KB>&QMXK/5M,L;J\C@N=2EC2'RHVSP-S;E+
M-M7<5XW'!W8J"UOM5TGQE=:/I$%QJMD+03.MUJ7F&%\@ [VW,H;+?*Q/W,C'
M.0#OJ*S9[[4H=-AG31VGNF.)+:.X3*=>0S8![>G6C3=3NKUY%NM$O].V+D-<
MM"P?_=\N1S^8% &E16%%XQT-YHX9KJ6SED8(B7]M+:EF)P /-5<DGICK6[0
M4444 %%%% !1110 4444 %%%% !1110 44A(52S$  9)/:LVS\0Z5J-^]G8W
M8NI$!+M C/&A'8R ;0WL3F@#3JAJ>M:;HT:-J%Y% 9#B-"<O(?1%'S,?8 FJ
M/V7Q%?71-S?6VFVBN<162^;+( >"9'7"@^@3/^U6J+&T6^:]%K"+MD"-.(QO
M*CH-W7')H HW%QJ6HZ1#-HPBM99S]_4(7!B3GGR^"6] 2O7GTI^G:2]K#<+?
M:A<:E)<8\TW(78!C&U44!57\R>Y-:=% " !5"J  !@ =J6BB@ HHHH ****
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M,DMH<MM W%F)W9SSD5[17/GP9I'FS21OJL/G2O,Z0:Q=Q)O=B[$(LH499B>
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M(S*BEF(51R23P* %HK&N?%WARSD\J?7-/67_ )Y"X5G/_ 0<_I4'_"7V4O\
MQY6&KWA[&+3I54_1W55/YT =!17/_P!M:]/_ ,>OA:>/T-]>11#_ ,AF0_I1
MM\87'630[#/HDMWC]8J  ^,](\V:.--5F\F5X7>#1[N5-Z,48!UB*G#*1P3T
MK8L+ZWU/3K:_LY/,M;J)9H7VD;D8 J<'D9!'6N#T"+Q3H4TT=Y8:W>Q)>W<H
MCLUL$MYA)-(X;YY?,&=X;&1@\<@<]9X3LKC3/!NAV%Y'Y=U:Z?!#,FX':ZQJ
M&&1P<$'I0!L4444 %%%% !1110 4444 %%%% !1110 4444 4-;_ .0!J/\
MUZR_^@FK]4-;_P"0!J/_ %ZR_P#H)J_0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %4M2TC3M8@$.HV4%TBG*B5 2I]5/4'W'-7:* .=_L+5=,^;1-9
ME,8Z6>I9N(_HLF?,7\68>U)_PE+:?\OB'39],QUN5/GVI_[:*,J/=U2NCHH
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MN_;8\_EG- &Y17/_ /";>'F_U5^9_P#KW@DE_P#05-'_  F%B_\ J+#6YO\
M=TBY4'\70#]: .@HKG_^$DO7_P"/?PKK<ONPMXQ_X_*#^E']K>(Y/]3X85/^
MOG4$3_T!7H Z"BN?\[QA+_RY:';?]O<LV/\ R&E'V+Q9+_K-<TN >D&F.2/^
M!-,1_P".T =!6'?^(I+769-+M-$U+49XK>.XE:U:!519&D50?-E0DYB;H#VJ
M/^P-5E_X^/%NJ8[K!#;1C]8BWZUS][X+U2+Q#/?6LLVI6\]I#"WVK7KFSD#(
M\I.?)C(9<2# .,'=QS0!U>CZXNK)?;[&ZL)K*X^SSPW9CW*WEI(#F-V4C;(O
M?UIMUXJ\/6+;;O7=-A;^[)=(&/X9S7/^'_ &GQ2:E<Z[H>ERSW-V)H8VE:]$
M2"*-,;Y4!)W(S=/XAS776FG6-@NVSL[>W7TAB5/Y"@#(_P"$TT9_^/9KV\/;
M[)I\\P/_  )4(_6C_A([Z;_CS\+ZO*.SR^3 OX[Y W_CM=!10!S_ -J\67'^
MKTG2K1?[T]\\K?\ ?*Q@?^/4?V=XHG_U_B"SMP>UGIV"/^!22.#_ -\BN@HH
M Y__ (19YO\ C^\0ZY=>H%T+?_T0J&E7P3X;W!IM)@NV'(:]+7)_.0L:WZ*
M(+:SM;*/R[6VA@3^[%&%'Y"IZ** "BBB@ HHHH **** "BBB@ HHHH ****
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M>?#^VU.:)]5UB^U!$FCF:.XM;+$FQPX5BMN&VDJ 0",C([U?/@?PN#F+0;&
MGO;Q"$_^.8H Z"BN?_X0K0NT%T/]V^G'_L]'_"%Z+_=O\>G]IW./R\R@#H*:
M[K&I9V"J.I8X%8/_  A/AX_?T\R?]=9Y'_FQIR>"/"J,&_X1W2W8=&DM4<C\
M2": +=QXDT*SS]IUK3H,=?-ND7^9JE_PF_AQO]1J:7?I]CC>XS_W[#5IV^D:
M99X^S:=:08Z>5 J_R%7: .?_ .$LBD_X]=&URX]/^)>\.?\ O[LH_MO7)?\
MCW\*7:>AN[N"/_T!G-=!10!S_G^+YNFGZ):CU:\EG/Y"-/YT?8?%<O\ K-<T
MR$>D&F.2/Q:8_P JZ"B@#A]>\+^)[MM-N;/Q%)<7%G=F;RY!%;* 8I(R5802
M'=^\[@C!/0X(KV7@[7;OQ#!?:W?3QP06DT(-MK$DDC,[Q'^&"+:N(SG&<G;Z
M5Z!10!S_ /PAFD-_K7U2?_KMJUTX_(R8H_X0?PNW^MT.SG_Z^(_-_P#0LUT%
M% &3!X7\/VN/L^A:9#CIY=I&O\A6E%!# NV&)(U]$4#^5244 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 4-;_P"0!J/_ %ZR_P#H)J_5#6_^0!J/_7K+
M_P"@FK] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *S/$&C?V]H\UA]NN[)GP5GM9-K*1ZCHRGH5((()K3HH XR/
MX<6,6B+I<6KZM#!)%-'>"*9 MX)3F0NC*5!/(!0*0"0#5VU\"Z59:U'J$$ER
ML44YN8['<I@2<Q>5Y@&W=NV<8W8[XSS7344 4-;_ .0!J/\ UZR_^@FK]4-;
M_P"0!J/_ %ZR_P#H)J_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!0UO_D :C_UZ
MR_\ H)J_5#6_^0!J/_7K+_Z":OT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 4-;_
M .0!J/\ UZR_^@FK]4-;_P"0!J/_ %ZR_P#H)J_0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!0UO_D :C_UZR_\ H)J_5#6_^0!J/_7K+_Z":OT %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!Y_P#$7QAK/AG4='BL1:6ME<N1-?WL;M 'R L3LO\ JP<D[CGI
M[&I;?QMJ$OB>.%HK3^RI-6?2%5%8S"18/-\S?NVE205V[<XP<]JU/%O@N#Q<
M+=+C4[^UA0,DT$$@\N>-NH*L" W4!Q@@$CZ+;>!M*L];CU&&2Z6..<W4=D64
MP).8_*,@&W=NV<8W8SSC/- &GX@N((-"O5FFCC:2WD5 [ %CM/ ]34G]MZ3_
M -!2R_\  A/\:OT4 4/[;TG_ *"EE_X$)_C1_;>D_P#04LO_  (3_&K]% %#
M^V])_P"@I9?^!"?XT?VWI/\ T%++_P "$_QJ_10!0_MO2?\ H*67_@0G^-']
MMZ3_ -!2R_\  A/\:OT4 4/[;TG_ *"EE_X$)_C1_;>D_P#04LO_  (3_&K]
M% %#^V])_P"@I9?^!"?XT?VWI/\ T%++_P "$_QJ_10!0_MO2?\ H*67_@0G
M^-1R^(-*CDA47]HXD?:2LZX3Y2<GGIQCZD5IT4 4/[;TG_H*67_@0G^-']MZ
M3_T%++_P(3_&K]% %#^V])_Z"EE_X$)_C1_;>D_]!2R_\"$_QJ_10!0_MO2?
M^@I9?^!"?XT?VWI/_04LO_ A/\:OT4 4/[;TG_H*67_@0G^-']MZ3_T%++_P
M(3_&K]% %#^V])_Z"EE_X$)_C1_;>D_]!2R_\"$_QJ_10!0_MO2?^@I9?^!"
M?XT?VWI/_04LO_ A/\:OT4 9B^(-*-U)#]OM JHK"0SKM;)88'/4;?U%2?VW
MI/\ T%++_P "$_QJ_10!0_MO2?\ H*67_@0G^-']MZ3_ -!2R_\  A/\:OT4
M 4/[;TG_ *"EE_X$)_C1_;>D_P#04LO_  (3_&K]% %#^V])_P"@I9?^!"?X
MT?VWI/\ T%++_P "$_QJ_10!0_MO2?\ H*67_@0G^-']MZ3_ -!2R_\  A/\
M:OT4 4/[;TG_ *"EE_X$)_C1_;>D_P#04LO_  (3_&K]% %#^V])_P"@I9?^
M!"?XU'!X@TJ:,LU_:1D.ZX:=<G#$9Z]#C(]C6G10!0_MO2?^@I9?^!"?XT?V
MWI/_ $%++_P(3_&K]% %#^V])_Z"EE_X$)_C1_;>D_\ 04LO_ A/\:OT4 4/
M[;TG_H*67_@0G^-']MZ3_P!!2R_\"$_QJ_10!0_MO2?^@I9?^!"?XT?VWI/_
M $%++_P(3_&K]% %#^V])_Z"EE_X$)_C1_;>D_\ 04LO_ A/\:OT4 4/[;TG
M_H*67_@0G^-1W'B#2H+669;^TE:-"PC2=2S8&<#GJ:TZ* *']MZ3_P!!2R_\
M"$_QH_MO2?\ H*67_@0G^-7Z* *']MZ3_P!!2R_\"$_QH_MO2?\ H*67_@0G
M^-7Z* *']MZ3_P!!2R_\"$_QH_MO2?\ H*67_@0G^-7Z* *']MZ3_P!!2R_\
M"$_QH_MO2?\ H*67_@0G^-7Z* *']MZ3_P!!2R_\"$_QH_MO2?\ H*67_@0G
M^-7Z* *']MZ3_P!!2R_\"$_QH_MO2?\ H*67_@0G^-7Z* *"ZS8RW,$%M=07
M$DKE<12JQ4!2V2 >G&/Q%7Z** "BBB@ HHHH **** "BBB@ HHHH **** "N
M ^(ME.VJ^%+TW\ZVZ:W9Q"S7 C9BY)=N['   Z#GUX[^B@#QNZUW0HOBAJ%_
MI9L;9]%CNI;^62X!N=2N/*(,"*6WM&FT''0,N% QDZ3:'=:'XY\!B>_N;HK;
MW$0MOE"*R6WSL/5W<L2Q/<#C'/J5% 'E7@236V^*6NRZ[8W<%]=Z?!+*CR1-
M';C>X5$V.?EP  >I(8D+D5ZK110 4444 %%%% !1110 4444 >;2P)IOQ9U2
MZU75+B6UD\/33R,[%%MH1,ORIMY4!1DD<DY/ICG?!D^G:M%<)I"V-EI^KZE:
M1V^E6TR/)!! &D:295)VO*L1!SST&2>:]KHH \:O+"XM?^%F65UK#RR36]DL
MU[=HQ5%D5MYVQJ2J ,< #  Y(&6KM/AU<P3Z3J$5I9Z5%:6]\\4-SI4 AMKL
M!5_>*H+>NTG<V2AY[#L:* "BBB@ HHHH **** "BBB@"*Y266UFC@F\F9D*I
M+M#;&(X;!ZX/.*\;ANM&\-^!?%'_  D"R:Q'#XEEB@BO)@#>3A4V"0G"E<@L
MVX;0%)P< 5[310!Y;X2TR?4=,TW2[?7(2UAI;EKS3766.)[B<_+$W(S&D3Q@
M\[00<=*Y-0X^'WA!+N73QI.W4_/?5D:2W:8.WE!L.OSD>9M.<@Y(R<"O?J*
M,SPY,UQX8TF9[22T:2SA8V\KLS190?*2WS$CID\^O-:=%% !1110 4444 %%
M%% !7-^/+*>^\%ZI'!?SV02WDED:# >151CLR?N@G&2.<9'&<UTE% 'AWB:[
MT63PUX,T=VL8->NM)MC%J%]<"./38 $+3+N8 2$KA=O)VG)P,'3\=V<^I^!?
M$FMQZA/#;O?-^YBP!.D3I H8]=FY)'P.I<'IQ7KU% ' :QH6D:S\5M+@;2K,
M2V-O_:US<K HEFD#>5 K.!N(!#M@G!*+Z5W]%% !1110 4444 %%%% !1110
M!P'Q)LIWO/"][]OG6WBURQ3[(F CL9A\[=S@ 8'0<GZ<Y>ZWH$?Q3N[W3GL;
M631EN)]2N);D?:=0E\@KY$:EMQ1 H)&, KP!C)]BHH \M.AW>D>-OA[]JU">
M5ML\;6W C206KF1\#JS.6.3T' ]\[X8?9D\8NT*?Z1-97/VN-&_>6T@NC\MV
M<9DF/.UB%(4,,-G=7L=% !1110 4444 %%%% !1110 5YQ+ -.^,-W>:EJEQ
M);2>'KF9M[;%MHA-%PFWD8 R6ZD\^E>CT4 >)>#I],U6.\3118V.FZO?6=K;
M:5;S*\L<$.]Y)9E!.UY$C8'/. ,DGFK5YIDT%W\3;:[UN9G:RL99;NX1BH7]
MZQ0K&"5B(RI !PI)YYS['10!POPP\PZ=K+QQ6<6F/J<AL$L9?,ME3:FX0MM4
M%/,W\@ 9W8KNJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;#9&00,\=1I?A[6+?X>7&A:EJ9OM2EMIXA<3RM)C?NVAG*AFP"!N(!..@Z4
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M:H1PQ )WA>#C@@<@&S#XYTF[O[."SF69)UN=ZF*=;A&@QO00^5G<,\JQ5NF
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MM) 2=IPV/7!ZXZ47?A^UNM%&EFXU!(5!VR)J$XE!YZR;][=>C$CIZ"N-\/\
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MWVNRW>KO;6]U91Z=90VPC<"W1<@2&2,D$N2WR$?7.,6I?#/BF%[/5[&ZT_\
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MQQA[B26.1"$); E(92%SCAAUJY>_#:[8Z?9VMY"UC'X>ET.>65F65=VW$JJ
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&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image13.jpg
<TEXT>
begin 644 image13.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %6!%<# 2(  A$! Q$!_\0
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M_P#Y_P"+_P !T_PHL!]$T5\[?\+8\7_\_P#%_P" Z?X4?\+8\7_\_P#%_P"
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M%L>+_P#G_B_\!T_PHL!]$T5\[?\ "V/%_P#S_P 7_@.G^%'_  MCQ?\ \_\
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MX#I_A1_PMCQ?_P _\7_@.G^%%@/HFBOG;_A;'B__ )_XO_ =/\*/^%L>+_\
MG_B_\!T_PHL!]$T5\[?\+8\7_P#/_%_X#I_A1_PMCQ?_ ,_\7_@.G^%%@/HF
MBOG;_A;'B_\ Y_XO_ =/\*/^%L>+_P#G_B_\!T_PHL!]$T5\[?\ "V/%_P#S
M_P 7_@.G^%'_  MCQ?\ \_\ %_X#I_A18#Z)HKYV_P"%L>+_ /G_ (O_  '3
M_"C_ (6QXO\ ^?\ B_\  =/\*+ ?1-%?.W_"V/%__/\ Q?\ @.G^%'_"V/%_
M_/\ Q?\ @.G^%%@/HFBOG;_A;'B__G_B_P# =/\ "C_A;'B__G_B_P# =/\
M"BP'T317SM_PMCQ?_P _\7_@.G^%'_"V/%__ #_Q?^ Z?X46 ^B:*^=O^%L>
M+_\ G_B_\!T_PH_X6QXO_P"?^+_P'3_"BP'T317SM_PMCQ?_ ,_\7_@.G^%'
M_"V/%_\ S_Q?^ Z?X46 ^B:*^=O^%L>+_P#G_B_\!T_PH_X6QXO_ .?^+_P'
M3_"BP'T317SM_P +8\7_ //_ !?^ Z?X4?\ "V/%_P#S_P 7_@.G^%%@/HFB
MOG;_ (6QXO\ ^?\ B_\  =/\*/\ A;'B_P#Y_P"+_P !T_PHL!]$T5\[?\+8
M\7_\_P#%_P" Z?X4?\+8\7_\_P#%_P" Z?X46 ^B:*^=O^%L>+_^?^+_ ,!T
M_P */^%L>+_^?^+_ ,!T_P *+ ?1-%?.W_"V/%__ #_Q?^ Z?X4?\+8\7_\
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MPOX:\:^&=5-VGAY[F"2-HKBV>5 LJ'J"<G^5 S.@=Y/A1J<D1S,^K1FZV_\
M//9\N?;?^M<G9F<7UN;4L+@2+Y6SKNSQCWS7H&E>'?&>AZI=S:?X:)L+K*RV
M%S+'+&\>>%;D9QV-:T>EZOIK&YT/X<16.H8^6YEO?M C/JJL< ^] @U'R?\
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M*T5U7_"M_%__ $!9?^_B?_%4?\*W\7_] 67_ +^)_P#%4 <K175?\*W\7_\
M0%E_[^)_\51_PK?Q?_T!9?\ OXG_ ,50!RM%=8?AGXP";O[%?'_7://Y;J;_
M ,*W\7_] 67_ +^)_P#%4 <K175?\*W\7_\ 0%E_[^)_\51_PK?Q?_T!9?\
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M *&E8_Q-_P"2B:M_O1_^BTH&>HZ)\3V\174EMI7AV[N)HT\QE^T1IA<@9RQ
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MMS5U\)>(DTRXG\6_8IH+"&V>'^SI9,,HY^88'?\ 2O;O[/TG_GRL_P#ORO\
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M^(KK4Y+9O,@LX[)X6+#[NYVXQZ]/Z5ZW_;/@K_G[T;_R'1_;/@K_ )^]&_\
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M?\_>C?\ D.C4/JU;^1_<SYWU^YAO?$6I75N^^&:ZDDC;!&5+$@X/-9U?3/\
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MUHHHH+"BBB@ HHHH **** "BBB@ HHHH **** "BH+V9K:PN)T +1Q,X!Z9
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M:ZN[F&"W0;FFED"HH]23Q0!/15:QU&QU2V%SI]Y;W<!) EMY5D4D=1D$BK-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRA@?[1<33M+)=?(?*E1CSM/8=CUKU"&TMK>6:6&WBCDG8/,Z( 9& QEB.IP
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MWY8+9$9OJ0,FM"@<58****"@HHHH **** "BBB@ HHHH ^::***W/T4****
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M_<'YT!>8S[-)[?G1]FD]OSI_VL_W!^='VL_W!^= 7F,^S2>WYT?9I/;\Z?\
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M_/*V_P"_XH_X59XF_P">5M_W_%;7_"Y+C_H"Q?\ @0?_ (FC_A<EQ_T!8O\
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M%"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=/X.T*7PUX4L=)GF6::!6+L@(0%F+$+G^$9P/85NT4#2"BBB@84444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% '?\ PA_Y&RZ_Z\7_ /0XZ]JKQ7X0_P#(V77_ %XO_P"AQU[56,]SXC/O
M]\?H@HHHJ3Q@HHHH **** "BBB@ HHHH **** &NBR+ANE<YXKT"74+*UN]/
M0-J6FW*W=LI;'F8X>/)X&Y2RY/&2*W[DD1#!(Y[54WO_ 'F_.@TC%M:,:NAZ
M?_:_]K_9V6_:W%L9"Y_U>[=MQG'4]?UK)U_X<^$_%%RMSK&D1W%PHQYJR/&Q
M'H2A!/XUL;W_ +S?G1O?^\WYTRN1]R'3O#.CZ3I7]EZ?8QVUD5*F*/C.>"2>
MI)]>M/A\.Z7!HBZ,EJ/[.6#[.(&8L/+QC:2<D\>M/WO_ 'F_.C>_]YOSH#DE
MW*4'@S0;;3=-TZ*R*VNFS">TC\YSY;C.#G.3]X\'(YIOB#P1X<\51QIK6F1W
M?E?<8LRNOL&4@X]LU?WO_>;\Z-[_ -YOSH#D?<IZ!X.T#PO;/;Z+IT=I&YRY
M4EF?'3+,23^)K2NM+L[ZUEM;N!)[>52LD4@#*P/8@]:AWO\ WF_.C>_]YOSH
M#DEW.>TOX5>"=&U)-0L="B2Z1MR.\KR!#Z@,Q /N!6QKOA+0_$UD+36=/CNX
M5.5#D@J?56&"/P-6=[_WF_.C>_\ >;\Z0<C[F=X>\">&O"HD_L72X[5I.'?<
MSN1Z;F)./;.*S=6^$_@K7=4GU/4M',]Y.09)/M4R[B  .%< < =!71[W_O-^
M=&]_[S?G0'LWW(=&\,:-X>L19:1816EOG<5C'WCZD]6/N:FET+3IM5M]3D@)
MO+>-XHI-[?*KX+#&<'.T=1VHWO\ WF_.C>_]YOSIAR2[G)7?@2;49_$D_P!H
MO+.YN;I9+-DOI%AD40Q#$D2/M92RLK9&2/PJ#4M U764L;M- 33WTZU1FLVG
MCQ>,&#?9LHV!&-F06[E>,!@>TWO_ 'F_.C>_]YOSI!R/N9.E:-//XEO]=U"W
M>W+0QVEI [JS)&/F=CM)&6<XP">$%=#]FC]#^=5-[_WF_.C>_P#>;\Z8<DNY
M;^S1^A_.C[-'Z'\ZJ;W_ +S?G1O?^\WYT#Y9=RW]FC]#^='V:/T/YU4WO_>;
M\Z-[_P!YOSH#EEW+?V:/T/YT?9H_0_G53>_]YOSHWO\ WF_.@.67<M_9H_0_
MG1]FC]#^=5-[_P!YOSHWO_>;\Z Y9=RW]FC]#^='V:/T/YU4WO\ WF_.C>_]
MYOSH#EEW+?V:/T/YT?9H_0_G53>_]YOSHWO_ 'F_.@.67<M_9H_0_G1]FC]#
M^=5-[_WF_.C>_P#>;\Z Y9=RW]FC]#^='V:/T/YU4WO_ 'F_.C>_]YOSH#EE
MW+?V:/T/YT?9H_0_G53>_P#>;\Z-[_WF_.@.67<M_9H_0_G1]FC]#^=5-[_W
MF_.C>_\ >;\Z Y9=RW]FC]#^='V:/T/YU4WO_>;\Z-[_ -YOSH#EEW+?V:/T
M/YT?9H_0_G53>_\ >;\Z-[_WF_.@.67<M_9H_0_G1]FC]#^=5-[_ -YOSHWO
M_>;\Z Y9=RW]FC]#^='V:/T/YU4WO_>;\Z-[_P!YOSH#EEW+?V:/T/YT?9H_
M0_G53>_]YOSHWO\ WF_.@.67<M_9H_0_G1]FC]#^=5-[_P!YOSHWO_>;\Z Y
M9=RW]FC]#^='V:/T/YU4WO\ WF_.C>_]YOSH#EEW+?V:/T/YT?9H_0_G53>_
M]YOSHWO_ 'F_.@.67<M_9H_0_G1]FC]#^=5-[_WF_.C>_P#>;\Z Y9=RW]FC
M]#^='V:/T/YU4WO_ 'F_.C>_]YOSH#EEW+?V:/T/YT?9H_0_G53>_P#>;\Z-
M[_WF_.@.67<M_9H_0_G1]FC]#^=5-[_WF_.C>_\ >;\Z Y9=RW]FC]#^='V:
M/T/YU4WO_>;\Z-[_ -YOSH#EEW+?V:/T/YT?9H_0_G53>_\ >;\Z-[_WF_.@
M.67<M_9H_0_G1]FC]#^=5-[_ -YOSHWO_>;\Z Y9=RW]FC]#^='V:/T/YU4W
MO_>;\Z-[_P!YOSH#EEW+?V:/T/YT?9H_0_G53>_]YOSHWO\ WF_.@.67<YO_
M (59X9_YY7/_ '_-'_"K/#/_ #RN?^_YKQO^W=8_Z"M]_P"!#_XT?V[K'_05
MOO\ P(?_ !K3EEW/JO[-Q_\ T$/\3V3_ (59X9_YY7/_ '_-'_"K/#/_ #RN
M?^_YKQO^W=8_Z"M]_P"!#_XT?V[K'_05OO\ P(?_ !HY9=P_LW'_ /00_P 3
MV3_A5GAG_GE<_P#?\T?\*L\,_P#/*Y_[_FO&_P"W=8_Z"M]_X$/_ (T?V[K'
M_05OO_ A_P#&CEEW#^S<?_T$/\3V3_A5GAG_ )Y7/_?\T?\ "K/#/_/*Y_[_
M )KQO^W=8_Z"M]_X$/\ XT?V[K'_ $%;[_P(?_&CEEW#^S<?_P!!#_$]D_X5
M9X9_YY7/_?\ -'_"K/#/_/*Y_P"_YKQO^W=8_P"@K??^!#_XT?V[K'_05OO_
M  (?_&CEEW#^S<?_ -!#_$]D_P"%6>&?^>5S_P!_S1_PJSPS_P \KG_O^:\;
M_MW6/^@K??\ @0_^-']NZQ_T%;[_ ,"'_P :.67</[-Q_P#T$/\ $]D_X59X
M9_YY7/\ W_-'_"K/#/\ SRN?^_YKQO\ MW6/^@K??^!#_P"-']NZQ_T%;[_P
M(?\ QHY9=P_LW'_]!#_$]D_X59X9_P">5S_W_-'_  JSPS_SRN?^_P":\;_M
MW6/^@K??^!#_ .-']NZQ_P!!6^_\"'_QHY9=P_LW'_\ 00_Q/9/^%6>&?^>5
MS_W_ #1_PJSPS_SRN?\ O^:\;_MW6/\ H*WW_@0_^-']NZQ_T%;[_P "'_QH
MY9=P_LW'_P#00_Q/9/\ A5GAG_GE<_\ ?\T?\*L\,_\ /*Y_[_FO&_[=UC_H
M*WW_ ($/_C1_;NL?]!6^_P# A_\ &CEEW#^S<?\ ]!#_ !/9/^%6>&?^>5S_
M -_S1_PJSPS_ ,\KG_O^:\;_ +=UC_H*WW_@0_\ C1_;NL?]!6^_\"'_ ,:.
M67</[-Q__00_Q/9/^%6>&?\ GE<_]_S1_P *L\,_\\KG_O\ FO&_[=UC_H*W
MW_@0_P#C1_;NL?\ 05OO_ A_\:.67</[-Q__ $$/\3V3_A5GAG_GE<_]_P T
M?\*L\,_\\KG_ +_FO&_[=UC_ *"M]_X$/_C1_;NL?]!6^_\  A_\:.67</[-
MQ_\ T$/\3V3_ (59X9_YY7/_ '_-'_"K/#/_ #RN?^_YKQO^W=8_Z"M]_P"!
M#_XT?V[K'_05OO\ P(?_ !HY9=P_LW'_ /00_P 3V3_A5GAG_GE<_P#?\T?\
M*L\,_P#/*Y_[_FO&_P"W=8_Z"M]_X$/_ (T?V[K'_05OO_ A_P#&CEEW#^S<
M?_T$/\3V3_A5GAG_ )Y7/_?\T?\ "K/#/_/*Y_[_ )KQO^W=8_Z"M]_X$/\
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MX&.];GP^GOSI6I6&H7TM])INI36<=Q,<R/&N"NX]S@]:!WU.NHHHH*"BBB@
MHHHH **** "BBB@#YIHHHK<_10HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#W_ .&__(@Z9_VU
M_P#1KUU5<K\-_P#D0=,_[:_^C7KJJP>Y^<X[_>JG^)_F%%%%(Y0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,:"-$'0*!@#\JFVM_=/Y4;6_NG\J T.3M_ &FVEK8V\-[J")8FY^S$2KF,3
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M3;K_ %0^M4Z#6$$U<O?:8O4_E1]IB]3^54:*97LT7OM,7J?RH^TQ>I_*J-%
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M^?V7_P !W_PH_P"%G>%O^?V7_P !W_PKP6BCD0?ZOX7O+[U_D>]?\+.\+?\
M/[+_ . [_P"%'_"SO"W_ #^R_P#@._\ A7@M%'(@_P!7\+WE]Z_R/>O^%G>%
MO^?V7_P'?_"C_A9WA;_G]E_\!W_PKP6BCD0?ZOX7O+[U_D>]?\+.\+?\_LO_
M (#O_A1_PL[PM_S^R_\ @._^%>"T4<B#_5_"]Y?>O\CWK_A9WA;_ )_9?_ =
M_P#"C_A9WA;_ )_9?_ =_P#"O!:*.1!_J_A>\OO7^1[U_P +.\+?\_LO_@._
M^%'_  L[PM_S^R_^ [_X5X+11R(/]7\+WE]Z_P CWK_A9WA;_G]E_P# =_\
M"C_A9WA;_G]E_P# =_\ "O!:*.1!_J_A>\OO7^1[U_PL[PM_S^R_^ [_ .%'
M_"SO"W_/[+_X#O\ X5X+11R(/]7\+WE]Z_R/>O\ A9WA;_G]E_\  =_\*/\
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MO%&C3:;XJ3_70VUI-%<&?'5'C^]D_=);IC->C>"#JY\'::=<\W^T/+._SO\
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M@ HHHH ^::***W/T4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ_[\G_XJN%HHY4']FX3_ )]H[K_A;/B/^Y8_]^3_ /%4?\+9\1_W+'_OR?\
MXJN%HHY4']FX3_GVCNO^%L^(_P"Y8_\ ?D__ !5'_"V?$?\ <L?^_)_^*KA:
M*.5!_9N$_P"?:.Z_X6SXC_N6/_?D_P#Q5'_"V?$?]RQ_[\G_ .*KA:*.5!_9
MN$_Y]H[K_A;/B/\ N6/_ 'Y/_P 51_PMGQ'_ '+'_OR?_BJX6BCE0?V;A/\
MGVCNO^%L^(_[EC_WY/\ \51_PMGQ'_<L?^_)_P#BJX6BCE0?V;A/^?:.Z_X6
MSXC_ +EC_P!^3_\ %4?\+9\1_P!RQ_[\G_XJN%HHY4']FX3_ )]H[K_A;/B/
M^Y8_]^3_ /%4?\+9\1_W+'_OR?\ XJN%HHY4']FX3_GVCNO^%L^(_P"Y8_\
M?D__ !5'_"V?$?\ <L?^_)_^*KA:*.5!_9N$_P"?:.Z_X6SXC_N6/_?D_P#Q
M5'_"V?$?]RQ_[\G_ .*KA:*.5!_9N$_Y]H[K_A;/B/\ N6/_ 'Y/_P 51_PM
MGQ'_ '+'_OR?_BJX6BCE0?V;A/\ GVCZ-\(:M<ZYX6L]2NQ&)YM^X1C"\.RC
MCZ 5N5ROPW_Y$'3/^VO_ *->NJK%[GPN+BH8BI&.B3?YA1112.<**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+:WE  V*A.=A&0?KTXK1TWP_XJU'Q#8ZMXLO-*VZ<'-K:Z8DFQI'7:7=GYR
M2 !ZT!J8$/CWQI_PCT7B:;2-(_L6.<Q7"K)()Y%\W9O0<A0..#D\$]#75>(I
ME\(:;X@\5P0"YN)(HLQ*FT83Y06(Y.-Q)/\ = ':J7_"&ZC_ ,*N?PQYUK]M
M8MB3<WE\S>9UVYZ>W6NIU>UOKO2)[?3;T65XRCRIVB6100>A4\$'H?K0"3.2
M\%>+=;UW43!>S>'+^V:(R>?HUTQ: \862.0[N><$#C'-;OBW7[C0=.M_L%HM
MWJ-[<+:6D+MM0R-DY8]E !)^E<MH/@/6$\66>N:O!X<L&LR[*NAVSQM<%E*G
MS"V..<\ YKJO%>@SZ]I]O]ANUM-1LKA+JTF==RK(N1AE[@@D?C0"O8XV.;Q,
MWQ/\,1>);33TF2"\,5QI[N8I 47*X?Y@PP,]CGBH9O'UYI7@[0)+*TT73Y=2
MGN(_-N$>*RM]CMP0F2"WUZY-;5AX<\7W?B[2==\0WVE,+*.>,VUB) BAU #+
MN&6)/7) &!CO3!X1\267@RPTJQN='FF@:7[1:7\!FM;E7<L,G;N! /;@\T"U
M)+;QU>V7@?4==UB'39VM&"13:7=B2WNB<!=IR2GS'!W=,9K/T7XA:E_;=C:Z
MQ>^%;JWU"40Q+HU_YLUNY!V^8I)W G RO0TFF_"^9]$UVWU*73;2XU418@TN
MW(M8&C.58*_WLG&0<<<4[1/ >LQ:S9SZE8>#;6VM)1*)-+TH>?.1TR77"<X.
M5Y]"* ]XJ^+OB1K>@:I?+&_AJUM[1]HM;VZ>2[N  #N58LA-W8/SW-6O$?Q%
MU"UN-&M],.CZ>=1L%OOM.M/(L/S?\LU*?Q#J23CI5>Z\ ^*T;6[#3;O0$T_5
M)9Y6O9[9VO0)<DH3]TCG&3SC\!6EJ/A7Q0^@Z18VK^'KU+:SCM[FQU6V,MOY
MBC'F(P7=GM@\4![Q+?>.[S2_!%IJM[::>NH7=P+6#9>J;21B3B7S0<"/:"W/
M/:HO"OCF^O?$$6C:Q>>'+V:ZC=[>?0[LRJI49*.K$D'&2#TXQ52'X6RCPC)8
M27-@M^=0_M&.-;7=9QOMV^7Y;9RA&>O/.>U7/"O@W5;'7(M3U6Q\*60MT81Q
M:+IP5G9AC<TCKN7 SPN,YY]*!^]<[^BBB@L**** "BBB@#QV6]T6U\<>*EU/
MP/?^()#>QE9[;24NQ&/)3Y2S=#WQ[T[2-0M]/\"^+M0M-+MX;<:@&CT2^AR+
M8'RUQ)'QM+'+ #@<8KH9=%\>:9XDUJ\\/OX;:SU&X6<"_,YD4B-4_@&!]WWI
MDO@?7+_0/$#:E?V,FMZR8=_DATMX5C(VJN<L>,\D9Z4&=F7=3\0>*+_Q#>:/
MX4L]*_XEZ1FZNM3>39O<;@BJG.0,'/O5;_A/M1_X1_8-(3_A)3J!TO[%YG[K
MS\;M^[KY>SYOT]ZLZIX?\4V'B*\U?PI>:5C4$C%W:ZFDFP.@VAT*<YQ@8]JQ
M=8\.CP_X6CO-4\10VVNR:L+Y=2>%O(%RPVA& SMCV#;DX'?VH&[FEIGB+QC:
M^,;'0_$MGHZPW-O-.+G3S(0VP#Y0&.01GG(YR,=#6 ?BKJ<ZRZM:S^%4TF-F
M*V%SJ.R_E121D#.U6(&0I&>U+X?U#5=>^)VFRZCK.B:D;>QN-\>B,SPVZMM
M+.>K,>,=MOO2CX8:Q9%M.L+7P?-IQ9O+OK[2Q)>Q*2<=MCD>K=>] M>AT&J>
M*_$-UXAL=+\+6FG3I>Z6+])[YG58@6 !;;DD$$# &<G.<"MCP9KU]KVDW#:I
M:Q6VHV5W)9W*0L3&73&67/.#D>M-L_#<UEXLM=1C>#[%;Z2+ (JA&W!PV0J@
M*%P.V/IBI_#>BW.CMK!N'B;[;J4MW'Y9)PC!< Y YX]Z"E>YNT444%!1110
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M^ZM'E1?W5H#VB*%%7_*B_NK1Y47]U: ]HBA15_RHO[JT>5%_=6@/:(H45?\
M*B_NK1Y47]U: ]HBA15_RHO[JT>5%_=6@/:(H45?\J+^ZM'E1?W5H#VB*%%7
M_*B_NK1Y47]U: ]HBA15_P J+^ZM'E1?W5H#VB*%%7_*B_NK1Y47]U: ]HBA
M15_RHO[JT>5%_=6@/:(H45?\J+^ZM'E1?W5H#VB*%%7_ "HO[JT>5%_=6@/:
M(H45?\J+^ZM'E1?W5H#VB*%%7_*B_NK1Y47]U: ]HBA15_RHO[JT>5%_=6@/
M:(H45?\ *B_NK1Y47]U: ]HBA45S;07EO);W4$<\$@VO%*@96'H0>#6IY47]
MU:/*B_NK0+VB,33])TW2(FBTW3[2RC8[F2VA6,$^I"@5<J_Y47]U:/*B_NK0
M'M$4**O^5%_=6CRHO[JT#]HBA15_RHO[JT>5%_=6@/:(H45?\J+^ZM'E1?W5
MH#VB*%%7_*B_NK1Y47]U: ]HBA15_P J+^ZM'E1?W5H#VB*%%7_*B_NK1Y47
M]U: ]HCY:HKZ$_X1'PC_ - VQ_/_ .O1_P (CX1_Z!MC^?\ ]>M.='U7^L%'
M^27X?YGSW17T)_PB/A'_ *!MC^?_ ->C_A$?"/\ T#;'\_\ Z]'.@_U@H_R2
M_#_,^>Z*^A/^$1\(_P#0-L?S_P#KT?\ "(^$?^@;8_G_ /7HYT'^L%'^27X?
MYGSW17T)_P (CX1_Z!MC^?\ ]>C_ (1'PC_T#;'\_P#Z]'.@_P!8*/\ )+\/
M\SY[HKZ$_P"$1\(_] VQ_/\ ^O1_PB/A'_H&V/Y__7HYT'^L%'^27X?YGSW1
M7T)_PB/A'_H&V/Y__7IR^#_";L%32[)F/0 Y/\Z.=!_K#1_DE^'^9\\T5]$_
M\(1X9_Z UM^1_P :/^$(\,_] :V_(_XT<Z%_K%0_D?X?YGSM17T3_P (1X9_
MZ UM^1_QH_X0CPS_ - :V_(_XT<Z#_6*A_(_P_S/G:BOHG_A"/#/_0&MOR/^
M-'_"$>&?^@-;?D?\:.=!_K%0_D?X?YGSM17T3_PA'AG_ * UM^1_QH_X0CPS
M_P! :V_(_P"-'.@_UBH?R/\ #_,^=J*^B?\ A"/#/_0&MOR/^-'_  A'AG_H
M#6WY'_&CG0?ZQ4/Y'^'^9\[45]$_\(1X9_Z UM^1_P :/^$(\,_] :V_(_XT
M<Z#_ %BH?R/\/\SYVHKZ)_X0CPS_ - :V_(_XT?\(1X9_P"@-;?D?\:.=!_K
M%0_D?X?YGSM17T3_ ,(1X9_Z UM^1_QH_P"$(\,_] :V_(_XT<Z#_6*A_(_P
M_P SYVHKZ)_X0CPS_P! :V_(_P"-'_"$>&?^@-;?D?\ &CG0?ZQ4/Y'^'^9\
M[45]$_\ "$>&?^@-;?D?\:/^$(\,_P#0&MOR/^-'.@_UBH?R/\/\RK\-_P#D
M0=,_[:_^C7KJJKV5C;:;9QVEG"L-O'G9&O09))_4FK%9O<^5Q%15:TZBZMO[
MV%%%%(Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** (+K_5#ZU3JY=?ZH?6N;U[7/[$?2E^S>=]
MOOX[+[^WR]P8[NASC;TXZ]:9O3^$V**YKQ%XM;2+Z'2M,TJXUC6)H_-6TA<(
M$CSC>[MP@SP*K:/XTNIM7ATCQ%H,^A7]R";4/.L\4^!DJLB\;L<XH+NCKJ*Y
M?1_&UMJGC#5_#;VS6]U8-^Z<OE;A0 6(X&"-PR.>H-+)XOV2>*T^PY_L"(29
M\[_7YB,F/N_+TQWH"Z.GHKF=4\8QZ9X>TO4!I\]U>:F(UM;& @L[NN[&3C
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M=&T/PY_;-TUJ;J4?;DM_+3=M'W@0<GWK<T.\U*_TM)]6TK^R[LL0UK]H6?:
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M-Y#>83]IW9VXSTYZ>]6M4CO[7Q;XHA_LF_GBU?2$6WN8("\2O''("C$=&)(
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M** "BBB@ HHHH **** "BBB@ HHHH **** (+K_5#ZUPGCO_ %_A7_L/6_\
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M^);K4+VSO_"GV+3524)?_P!HQR;P,[3Y8&1N_2CX>R)#\--!DE=4C6Q0LS'
M QU)KJ'19(V1QE6!!'M7$Q_![P%%*LBZ I93D!KJ9A^(+X/XT!9G+F1;OPI=
M:C!G[%?>+HI[4XX9/.1=P]BRL:K>.0?"6F:AX;*%=)U&XBNM+(7Y8G\Y6E@]
MO[Z^Q([5ZS<Z'IEWI]O82V<8M+:2.2&&/,:HT9!3 7' (''2FZUH&E^(K-+3
M5;1;F&.5944L5*NO0@@@B@7*><^(U:#Q=XGUB)2TVD?V;? #NJ^8)!_W[9Z2
M61=5\0:;XB5@\=[XC2WMB#D>3!%*@(^K^8?QKTEM#TU[K4+EK8&;48EANF+M
M^\100!C.!PQZ8ZU!#X8T>WL=,LH;();Z9();-!(W[M@",YSEOO'KGK0'*S(U
MC7M0U34+CP]X70&[C^2\U.09AL<CH/[\N.BC@9!/<47 UCP=I&F:3X8\,-K-
MM#$4=VU".W*$8Y.\?,6))XJ"[^$O@B_O9[RZT0R7$\C2R.;N<;F8Y)X?'4UT
MVC:+I_A_2H=,TNW^SV<.[RX][/C))/+$GJ3WH'9]3%U?Q/>)<0Z-H^GBYU^:
M%9)(V?\ <V(;^*9QVZX4<MCC'6M'PUH0\/Z0+5KAKFYED>XNKEA@S3.<NV.P
MST'8 5E:O\,O!^O:I/J>IZ09[R<@R2?:IES@ #A7 ' '05;T_P "^&]+TK^R
M[/3?*L_M2WGE^?(W[U<%6R6)XVCC...E :W,#4_#MIXB\>:H4\6ZE87<-I#'
M+::>?L\B(,L&\P@[E.X_=X!ZFH_#7B?6(M+6R5X=;G_M>;3K6]GN/)6:-(S(
M'9E1\D;2O Y(KI?$/@CPYXKEBEUK2X[J6(;4DWNC >FY2"1R>#ZU6U7PM;R1
M^'M/T^U>WTVRNV=UM)V@,2>3( 0R,&Y9AG!R<G/>@5G<MV/B)Q>W=CK<-IIU
MS!Y)4I=^9%(LI(3#,J'<65AMV^F,YK8BN[:>::&&XBDE@(69$<%HR1D!AV)'
M/-<:=!U'3[;6M)BTXZG!?E3!?75P'8!CC;,SMYC"/[RXYQ@ @Y-;?A>PO-)L
M[C3KN)W,,[,E\S@F\#?-O89)#C.TY '''' !ILW:***"@HHHH **** "BJ]_
M=?8=.NKO9O\ (B>7;G&[:"<9_"N$C^)]RL>G7]UX5OXM&OU1(+Q)%D9YF7(0
M1 !L$\!CC/!QB@3:1Z'17$V/C?59KC5+&_\ "T]AJ=K9-?6UL]TL@N8QD8WJ
M"%;.!CGK6B/%\,\7AIK.V$[ZYAD7S,>5&(][N3CG;P,<9)[4!='2T5Y])\1]
M2DAGU/3O!][>^'H&</J"W,:LRH2&=(C\S+QUS5_5O'DEMJ5A8Z-HLVL2:C8?
M;+4PRA PR,!BPPBX.=Q/H,9- N9'945R.F^.)+K2]6DO-!O[?5M+*BXTN$>?
M(Q;[A0K]X'U]CVYK/TWXAZC<:Y_8NH^&A97\T$DEI$FIPSF5D7=M?;_J\]B:
M YD=]17B,'B'5[CP-H]_K6GW&+?Q#&T<HG$\ES^]DRH4<@J?D /7 QQ7<6'C
MC4YYM5L+_P ,36&K6=D;Z"T>[207,?(&'4?*21C&#B@%)';45S2^+XIXO#1L
M[;SWUTAD7S,>5&(][N>.=O QQDGM72T#N%%%% PHHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image14.jpg
<TEXT>
begin 644 image14.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )- ]D# 2(  A$! Q$!_\0
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M_L'7[S2_[#\_[,^SS?M>W=P#TV''7UK,_P"%Y_\ 4N?^3W_VNN&^(?\ R/\
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M$=]9Z3(]O(-R,TB(6'J S D>AQS0!W?_  O/_J7/_)[_ .UT?\+S_P"I<_\
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MK2V^VQNG9(9=ZG<5)!&,Y'0]16]%\,O&$T22QZ1E'4,I^TP\@]/XZ+ >L?\
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MUZX/H:;!X5UNYT"37(;!GTV/):8.O !P3MSN('THL![;_P +<\)_\_%S_P"
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M'4'SBIIHX+_A2NA_]!:^_-/\*/\ A2NA_P#06OOS3_"N]HH'[)'!?\*5T/\
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M.Z_\"#77T4!<Y#_A4WA#_GG=?^!!H_X5-X0_YYW7_@0:Z^B@+G(?\*F\(?\
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M$6OM$7_//]!1]HB_YY_H*JT4!R(M?:(O^>?Z"C[1%_SS_055HH#D1:^T1?\
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M%YH=R?B%HVJV]H@M(;:Y6YE3:O[Q]F"1G))V]>>E 79U-%%%!84444 %%%%
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MCXO?\DNUG_MA_P"CHZ^6J^I?B]_R2[6?^V'_ *.CKY:JX[$L****9)I^'?\
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M$%5!SQMQSL>'/#LNA7^H/N@^S31VT4"Q;OE$400Y#9('''S,<=33$=#1110
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MB7^Y^M'D2_W/UH#F7<CHJ3R)?[GZT>1+_<_6@.9=R.BI/(E_N?K1Y$O]S]:
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M-;^T+>@:;_:8U8V?D?/]I$>P'S-WW. VW;G/?'% >\=A11106%%%% !1110
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MY-VQQM9N#M;@X(QR!7.)\,[:*WO[:&;3X8KBUN;>*6/2XQ<+YP(S)+G+A0Q
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M_P#0)*[^N ^+W_(IVO\ U_)_Z!)3CN=^5_[Y3]3Q6NQT/4?$%MX7F=K2TN]
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M%6OLR?\ /2C[,G_/2@.=%6BK7V9/^>E'V9/^>E <Z*M%6OLR?\]*/LR?\]*
MYT5:*M?9D_YZ4?9D_P">E <Z*M%6OLR?\]*/LR?\]* YT5:*M?9D_P">E'V9
M/^>E <Z*M%6OLR?\]*/LR?\ /2@.=%6BK7V9/^>E'V9/^>E <Z*M%6OLR?\
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M/L5:*M>=!_SR_P#'11YT'_/+_P =% <S[%6BK7G0?\\O_'11YT'_ #R_\=%
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ME4GVE_1:/M+^BT 1^6_]QORH\M_[C?E4GVE_1:/M+^BT 1^6_P#<;\J/+?\
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MRO' JUKTUSJ7BS1H['2M06\L-1 EEN;8FV-L4)>1'YCW<@ @B0'(P 3GN**
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M9;*E<<$LW4YSQC;T;P^FC7]_<1S[X[I($6,1*GEB*,(/NX'.,X  '0"MFB@
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M"[TA9Q ;J2!/-*[MO[Y#G&1GIZUYA_PSW)_T,R_^ /\ ]LKT'XI<?#C5B/\
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M/S1CKNHN',>B45YS>>*-<EUJX>Q>5K2SDLU! MHK:9)51F:0RN)5+;R%"]U
M^8Y%3:!K6M3:II<UUJCW$%]J%_:-;-#&J(L32E""JAMP\O')P0>F>27#F1Z!
M1113&%%%% !5ZW_U"_C_ #JC5ZW_ -0OX_SJ69U?A):***DYPK@/B]_R*=K_
M -?R?^@25W]<!\7O^13M?^OY/_0)*<=SORO_ 'RGZGBM%%%;GZ"%;O@S_D<]
M(_Z^5K"K=\&?\CGI'_7RM)[&&*_@3]'^1[[/_KF^M1U)/_KF^M1UB? 1V"BB
MB@84444 9OB'2?[>\.ZAI/G^1]LMWA\W9NV;AC.,C/YUCKX4U#3[V6[T/5X;
M26YMHH;H7%F9T=HU")(H#J5;;P<E@>...>JHH%8XN/X<:;$=-A\YY;&SL[FU
MDAF0,T_GD%G+9&#G)Z=^V*HV?PFT^W\*2:1/?W$UV([F."^5Y(C&)NNY%<!Q
MP,@\-BO0J*!<J."NOAFDMFMG!JKQ6\]C!8Z@)(C*\Z1-N!1F?,;$%EYW  C
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MMN6OL@_YZ?I1]D'_ #T_2JM% [2[EK[(/^>GZ4?9!_ST_2JM% 6EW+7V0?\
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M4*>N"5)P:3^VM*_M&?3O[3LOMUO'YLUM]H7S(TP#N9<Y P0<GU% 79;\J/\
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MQ%D;@ Y+<_+P>>E N8]NHKPOQ)XDGUKP_P"''32[O2M*MWLKGRH+&0PS2-(
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M(KM:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *X#XO?\BG:_]?R?^@25W]<!\7O^13M?^OY/_0)*<=SORO\ WRGZ
MGBM%%%;GZ"%;O@S_ )'/2/\ KY6L*MWP9_R.>D?]?*TGL88K^!/T?Y'OL_\
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MC&<\]*T:* L1P016UO';V\210Q*$CCC4*J*!@  <  =JDHHH&%%%% !1110
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M@_*C,']P?E45%'M&'*68]G.Q<>O%/J&#^*IJUB[JYG+<****9(4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5R7Q#_ .0!!_U]+_Z"]=;7)?$/_D 0
M?]?2_P#H+UQ9C_NL_0Z\!_O,/4\TKO?#>EQ3Z)8DVLDHNGD$THD8>2!G!&#@
M<BN"KK/#^E_:M-$PU2Z8KG_0;24+(.>OS,![]*^7R[^+\-]/+NN__#GTF/\
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M5Z+'9Z5?I?:?J*B:6XMF-J;8H3)(C\Q[N0 <B0'(P 3E6079W5%%%24%%%%
M!1110 4444 %%%% !6!'XST26<Q+-=!1<&V,[6$ZP"4/LV^:4V??^7[W7BM^
MN$\.>%KBZT^<:E?ZG';?VM=7']G,D21,!=.Z$GR_,*DA6^_@_0XIH3.VNKF&
MRM)KJX?9!!&TDC8)VJHR3@<]!3H9H[B".>)MT<BAT;&,@C(KR5[+4/[-M])7
M2]1-Q:/K!E;[))Y>)1.8MKXVMN##&TGG@X.,I+X7FN;FYN)]'G>8ZKI2+(T#
M;A!Y,"3[3CA<;U?''!!Z<.PKGKU%>5MHR6C00:GHES<^&[>_U$+8163S*I9@
M866)03LQYH4@84N.G!%!?#.J2Z=J5QJ>EW$^K6NDZ;]DF>,R2).C2%MC#.7&
M$R02?4\\E@N>QT5Y=+9WDWQ!MKY-&,$D6L'S9UTV8S&'RF0.;HMM:-LC]VHP
MO&<8YJZ=H4VA>"?#,UE8-9:M>V_]EW8\L1RYF4?O&!P2R,BGGD+N[#%%AW/6
MZHVNKV=[.T-L\DC))+$Q$+[5>,@,"V, Y(QD\\XS@XQ/%VG#^PM.MHK)Y],M
MKR#[7:11&3?;+QMV#EP#L)7!R%/!Z5Q,6BRN#Y>DZK:Z<T>K;4BM&WI%(]N4
M 1L<%5;$?!(!4#(Q0D#9Z_17DT^EW;Z/ L6DP1:2FJ%YHTT2X\B9/( 5S8%P
MX42<;1P6428ZFJ6L:/J$WAFSTU])EO)%TJX%I-=Z/+,RL[MLB1!*5MF5-F'<
MEL;0>5*T6%<]FHKS>UL)!XRM+P:?<3W<DD3R2W>G2B2%?LX4M'=!@HCXYA89
M+%^.14/@#2-1L];@EO(Y(KQ+22/4F72Y(!/*74[I)WD(G;(8JZ*>"W*@@4K#
MN>G4444AA1110 4444 %%%% !5;4-0M=*T^>_O9?*MH$+R/M+;0.^ "35FN?
M\<V\]WX'UBWMH9)II+9E2.-2S,?0 <FA =!4<\RV]O).X<I&A=A'&SL0!GA5
M!+'V )/:O.M2TVZ;Q=<2?V;<R:T^K6LMAJ*V[&.&R"IYB>=C:@P)P4)!8N.#
MN%8;>&+JV\+)+:Z-<IJ%UI.KPW;);MYLI8?ND?C)Z#8#]!56)N>R*0RAAG!&
M>1BEKSNQTXP^.()TTV:6=IPTLUQI\B20IY&,I=!MCQ9 'E$$Y8G^'CT2DT-!
M1112&%%%% $T'\535#!_%4U;P^$QGN%%%%42%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW&DHHYY=P%W&C<:2BCGEW 7<:-QI**.>7<!=QHW&DHHYY=P%W&C<:2BCGEW
M7<:-QI**.>7<!=QHW&DHHYY=P%W&C<:2BCGEW 7<:-QI**.>7<!=QHW&DHHY
MY=P'J<TM-7O3JZ*;;CJ(****L HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KE?'W_ " H/^OE?_06KJJY7Q]_R H/^OE?_06KBS+_ '2?H-;GG-=!
MH*:$T/\ IY!O-_RK.S+%CZK_ %KGZZ_PM;1RV)>X72C"'/$T2M*WMDD8'YU\
MC@(N59))/U5T:/8S?$JSK<1 Q6J667^RFVV[67(YX[].M5?#O_(Q6'_785>\
M5JJW,'EVMA;Q8;:+5@2>G+8 _#\:H^'?^1BL/^NPK2HK8U+S7Z!T/6CUI*4]
M:2OJY;LS"BBBD 4444 8_BO5I]"\):MJUJD;SV=K)-&LH)4LHR,@$''XUA6G
MB+7O$.I7=EHKZ9:_V?;0-<RW<$DPEGEC$@155UVJ >6)8\XQP:Z+Q'I']O\
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MS746/AX6?BK4=<:Z:4W5M!;11,O,*Q[B?F));<6SVZ=Z5X] -NBBBI ****
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MQ"26W\Y&BD"[E*[EYRB$'/&.A!-<_:_#N6RTMK*/4[6X5K:TMY([[3EGAF6
M/]]"XSDN&&"""@Y(R*%:P&M>>,[>S@C=M)U5Y?LS7=Q L*B2UB4X+.&89Y!P
M$+%L$J".:DO?%UM97,*MIVH264LD$7]H)&GD!IB @^9@S#++DJK 9Y.0<8=U
M\,[>>WL LVG2SV]F;1GOM+2Y0*6+ Q(S?NRI9@H)8!< AL9I=0^&R7VLF_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXJ/LU977Z"Z'K1ZTE*>M)7U\MV9A1112 **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** '+WIU-7O3JZJ?P
MH044458!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7*^/O^0%!_U\
MK_Z"U=57*^/O^0%!_P!?*_\ H+5Q9E_ND_0:W/.:Z/2X/[0T/[$9+JVC$I=G
MCM6E27I@';SD8_6N<K;TNR\0SV>_3'NA;[B/W=QL&>_&17Q^$OSM<KEILO\
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MBCDL8'M[81Y5(XWQN4(/EP<#J*S%^'OA=-.M["+36@M[:226'R+J:-HS(,.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*K:CJ%KI6GSW][+Y5K A>1]I;:!WP 2?PH LT45'/,MO;RSN'*1H781QL[$
M9X502Q]@"3VH DHI%(90PS@C/(P:6@ HHHH **** '+WIU-7O3JZJ?PH0444
M58!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7*^/O^0%!_P!?*_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image15.jpg
<TEXT>
begin 644 image15.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 3S!&(# 2(  A$! Q$!_\0
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MA_X37PQ_T'M/_P"_ZT?\)KX8_P"@]I__ '_6OEZBBP'U#_PFOAC_ *#VG_\
M?]:/^$U\,?\ 0>T__O\ K7R]118#ZA_X37PQ_P!![3_^_P"M'_":^&/^@]I_
M_?\ 6OEZBBP'U#_PFOAC_H/:?_W_ %H_X37PQ_T'M/\ ^_ZU\O446 ^H?^$U
M\,?]![3_ /O^M'_":^&/^@]I_P#W_6OEZBBP'U#_ ,)KX8_Z#VG_ /?]:/\
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M_P"$U\,?]![3_P#O^M'_  FOAC_H/:?_ -_UKY>HHL!]0_\ ":^&/^@]I_\
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M^$U\,?\ 0>T__O\ K7R]118#ZA_X37PQ_P!![3_^_P"M'_":^&/^@]I__?\
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M[, 1D#C //-9EIITUYJ\.FQL@FFG$"LQ.T,6VY/&<9]J]$^"7_(PZE_UZ?\
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MZ52J>]@2VOKBWBF6>.*5D65>D@!P&'7@]>M04P"BBB@ HHHH **** "BBB@
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MZ&O-**0!6IX:EC@\4Z3--(D<4=Y"SN[850'&22>@K+HI@>S^,/#WAOQ9KO\
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M:LZBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW/QIN;*=H+OPK+!,OWHY;LJP^H,>:-0.0_X5/XO_ .?"+_P(3_&C_A4_B_\
MY\(O_ A/\:["U^,]U>NZ6GA.:X=$+LL5T6*J.I.(^@]:A_X7G_U+G_D]_P#:
MZ-0.5_X5/XO_ .?"+_P(3_&C_A4_B_\ Y\(O_ A/\:[RV^*&N7ENEQ:^ ]1G
MA<922*1V5OH1%@U7O?C#?Z9(L=_X/N;1V&56>X9"1[9CHU XO_A4_B__ )\(
MO_ A/\:/^%3^+_\ GPB_\"$_QKN[3XIZU?VZW%GX%O[B!L[9(9'=3CK@B+%%
MU\4]:L;=KB\\":A;P+C=)-(Z*,\#),6*-0.$_P"%3^+_ /GPB_\  A/\:/\
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M_D]_]KH&<K_PJ?Q?_P ^$7_@0G^-'_"I_%__ #X1?^!"?XUU7_"\_P#J7/\
MR>_^UT?\+S_ZES_R>_\ M=&HCE?^%3^+_P#GPB_\"$_QH_X5/XO_ .?"+_P(
M3_&NJ7XY%F"KX;)8G  O>3_Y#K7_ .%C^)/^B>:K^<G_ ,:HU \^_P"%3^+_
M /GPB_\  A/\:/\ A4_B_P#Y\(O_  (3_&NLE^-TD$K13>&6CD0X9'O,$'T(
M\NGW/QIN;.41W7A26"0J&"RW94D'H<&/H:-0.0_X5/XO_P"?"+_P(3_&C_A4
M_B__ )\(O_ A/\:Z^7XTW,$,,TWA66.*<%HG>[($@'!*DQ\C/I2VOQGNKUW2
MT\)S7#HA=EBNBQ51U)Q'T'K1J!Q__"I_%_\ SX1?^!"?XT?\*G\7_P#/A%_X
M$)_C75?\+S_ZES_R>_\ M=6['XO:CJ986'@VZNRGWA;W#2;?KB*C4#BO^%3^
M+_\ GPB_\"$_QH_X5/XO_P"?"+_P(3_&NONOC1<V4[07?A26WF7[T<MT48?@
M8\U:L_BMK&HP>?8^![ZZASM\R"5W7/ID14:@<-_PJ?Q?_P ^$7_@0G^-'_"I
M_%__ #X1?^!"?XUW5W\5-9T^W-Q>^!K^VA! ,DTKHH)Z<F+%9_\ PO/_ *ES
M_P GO_M=&H'*_P#"I_%__/A%_P"!"?XT?\*G\7_\^$7_ ($)_C75?\+S_P"I
M<_\ )[_[74@^-<YMFN1X6D-NKA#+]K.T,1D#/EXS@'BC4#D?^%3^+_\ GPB_
M\"$_QH_X5/XO_P"?"+_P(3_&NJ_X7G_U+G_D]_\ :Z/^%Y_]2Y_Y/?\ VNC4
M#E?^%3^+_P#GPB_\"$_QH_X5/XO_ .?"+_P(3_&NJ_X7G_U+G_D]_P#:Z/\
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MT6*J.I.(^@]:A_X7G_U+G_D]_P#:Z-0.5_X5/XO_ .?"+_P(3_&C_A4_B_\
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MBHD7U7,?(]Q1J!Q__"I_%_\ SX1?^!"?XT?\*G\7_P#/A%_X$)_C75#XY$D
M>',D] +W_P"UUH7'Q4UFTMC<W/@:_AMP,F625U7\S%BC4#A?^%3^+_\ GPB_
M\"$_QH_X5/XO_P"?"+_P(3_&NM@^-DUU.D%OX7>6:0[4CCO"S,?0 1\UJ?\
M"Q_$G_1/-5_.3_XU1J!Y]_PJ?Q?_ ,^$7_@0G^-'_"I_%_\ SX1?^!"?XUUU
MQ\:I[.X>WN?"TD$R'#QRW95E/N#'D5'_ ,+S_P"I<_\ )[_[71J!RO\ PJ?Q
M?_SX1?\ @0G^-'_"I_%__/A%_P"!"?XUVEC\8-0U-V2P\'7-VR#++;W#2%1[
MXCJ";XVRV\SPS^&'BE0[61[PAE/H08^*-0.2_P"%3^+_ /GPB_\  A/\:/\
MA4_B_P#Y\(O_  (3_&NJ_P"%Y_\ 4N?^3W_VNC_A>?\ U+G_ )/?_:Z-0.5_
MX5/XO_Y\(O\ P(3_ !J]H?PV\3Z7XBTJ^N[.-+>"]@>1A.AP!(O8&MS_ (7G
M_P!2Y_Y/?_:ZGL/B_P#VUJMAIG]A>3]INX8_,^U[MN9%YQL&?SHU&>L4444@
M. ^,/_(BG_KZC_K7S_7T!\8?^1%/_7U'_6OG^FA!1113 **** /6[V,:I\,=
M.TC;F9-,-_!QSF)\,/Q5C^51?#U%TWP].A4?:-5MKF;..1%$NT?FS-^58\7B
MK3K:;P<Z3[TLH&M[]"C85'.&'3YOE)/&:FMO$^BV_B^Z>.Y*:3;Z4]A9.8V)
M;Y1C(QD$L6/('6D,S?A@&/C2,+((V-M/AR<!3Y9YSVK6_LWQ)_T4W2O_  ?2
M?X5SG@34K#2O$Z7&I7/V:V,$L;2[&?:60@<*">]6_P#A'?!O_0]_^4B;_&@1
M1\&,[^/M(>1R[M>H6<G)8YY.>]3:CXO\1V?B&\,&N:@!%=2!$:X9D #' VDX
MQ[8JIX?N;'2/&UC<O=[["VNPWVCRV&Y ?O;>2,CG'6MR[TKP1/J5Q?2^,I9(
MY96E:"+3)%<Y).T,W&?<B@"EX_2&35-/U2*!(&U.PBO)8XQA1(V0Q'U(S2^.
MO^9<_P"P);?R-9GBG7(]>UCS[: V]E!$MO:PGJD2# !]^I_&K'BS4[/4_P"Q
M?L<WF?9M+@MY?E(VR+G(Y'/U'%,#:UO5;OPMX;T+2=&GELOM=FE]=3PMM>5W
MZ#<.< #'%8=]XMO-6\.KI>J*;V:*826]Y,^98QCYESC+ ^Y_IC4MM2\/^(]
MLM.U^]FTR^T]#%;WJ0F9'BSD*RCG([57U>Z\-Z9X>?2-$=M3NKB19)]1FM_+
M"A>BQJ>5]S_//" 7P_\ \D_\7?\ ;I_Z,:M'X;:E_9%KXBOS$LRPVB,\;#(=
M=X!'X@FL/1]3L[7P?XBL)IMMS>?9_(3:3OVN2W(&!@'O2^'=4L[#1/$5O<S;
M);RT6.!=I.]@P..!QQZT =7HFB0Z3\0(Y[%B^E7]A/<V4F#]PQM\I]UZ'\/6
ML/X8!CXTC"R"-C;3X<G 4^6><]JO> _&%AIEC<:=K3[88DDDLIMK,8W92K)P
M#PV<^F0:Q/ FI6&E>)TN-2N?LUL8)8VEV,^TLA X4$]Z .C_ +-\2?\ 13=*
M_P#!])_A7%Z+?06?B6ROM1#7$,5RLLV?F+@-DGGKZUN?\([X-_Z'O_RD3?XU
MBZ;=V6C>)H[AHHM3L()B"LL0VSQ\C.ULX)'(!Z&@#T"4^+-0UE]4\.^+K?5%
M:7S(K)+W8VSL&A; ''&/ZUYQK<UQ<:W>37=HEI<O*QE@1"@1NXP22.:ZD:;X
M#^VK?1>*+V" ,)!9_87\Y>^T2#Y0?>N>\4:ROB#Q)>ZHD/E).^40]0H  S[X
M'- &11113 **** "O;OBC_R3+2O^NT'_ **:O$:]N^*/_),M*_Z[0?\ HIJ0
M'B-%%%,#7\*_\C?HO_7]#_Z&*MZG_P E&NO^PJW_ *-K.T"ZALO$>F7=P^R"
M"ZBDD;!.U0P).!STJS?7]M-XTN-0CDS:OJ!F63:>4\S.<=>E '<?$.VA\1RZ
MK>VL874M%F,5TBCF6W)^5_JO(/M^%<W\0_\ D,:;_P!@JV_]!IUUXJCLOB/>
MZYI[?:+.:=@ZD%1-"W#*0>>1ZCJ!4/Q U32]6\0Q3:/,9;..TBA0E&7&T$8^
M8 \<4@-3QMKVL:=J&FP6.K7UM#_9=LWEP7#HN=O7 .*KZU>R^(OA[::OJ&)-
M1L[XV1N2/GEC*;QN/<@_YY-7=:3PCXB>QNYO%WV*6*RA@>'^S99,%5P?F&*Q
M/$6KZ4NCVGA_03-)86\K3S7,R[6N)2,9QV ' _\ K9(!+_S23_N-_P#M$59\
M/W3>'O 6H:]9#;J5Q>"PBGP"84V[V(ST)Z9K+_M.S_X5U_97G?Z;_:GVCRMI
M_P!7Y6W.<8Z]LYJ;PSK6F1Z;>Z!KHF&FWCK(L\(R]O*.C8[C'6@!+#QQJL4%
MY::I--JUE=1-&\%W,6VMV92<D$'GBLC0]+EUK7++380=UQ*$)'8=S^ R?PKJ
M+9O!WAF.XO+;4F\07S1M';PO9&**,L,;G#_>Q[?_ %QG>$-7L=!_M34YI<:B
MEJ8K",*>9'X+9 P-H]<=: .S\:65WK7AK4G;3+FU30[L"S\V!D#VI4(=I(YP
M5W?0UYA8ZKJ.EESI]_=6ADQO-O,T>['3.#S73^%O&=U%K0B\0ZK>W.DW,3P7
M*3S22J%9<9V\\YQT&>M<C<)''<RQPRB:)7(20 @.,\'!Y&?>@#N_&GB'6[8:
M"(-8U"(2Z/;R2>7<NN]B#EC@\D^M9W@7KXC_ .P)<?S6J?BS4[/4_P"Q?L<W
MF?9M+@MY?E(VR+G(Y'/U'%'A/4[/3/[:^V3>7]ITN:WB^4G=(VW X''0\GBF
M!8\ VUL^M75]=PK/'IME+>B)AD.R8V@_B<_A4)\?^*CJ7V[^VKH2;L^6'_=?
M3R_NX_"J?AG7/^$?UE;N2 7%LZ-#<0$X\R-AAA_GTK=_LKP 9OM?_"27ZVWW
MOL'V)O._W?,^[_GK2 J^/8+;^U;'4K6!(%U.QBO'B0857;(;'U(S^-=EXOMH
M?$MM_9,<8&KZ;8175J0.9XB@\R/W(/(__77GGBC7AX@U@W4<'V>UBC6"VASG
MRXU& /KW_&M3Q#XE3_A+K'6-&N=[6MO %?:RC<J@,I!P<=0?6@ \5?\ (I>$
M/^O27_T97(UVOC_7M'UR+1CI'R+%"YF@VL/)=VW%<D8/)/3BN*I@%:7A[_D9
M=*_Z_(?_ $,5FUI>'O\ D9=*_P"OR'_T,4 >G?'/_F _]O'_ +3KQ^O8/CG_
M ,P'_MX_]IUX_20!1113 ]>U[1O'5\VF3>'I;Y;'^SK<8@OQ"N[9S\N\>W:N
M9\?RS+8Z%9:I<Q76N6T,@O)4<.RJ6RB,PZD#/Y^^3E>,M4L]5U*QELIO-2+3
MX(7.TKAU7!'(%<Y2 ]+\!PW^A^'6UVTTVYNYKR]CMP((6D(MU.9#@ XS]W\*
MY+QGHA\/^*[ZQ"D0[_,ASWC;D?ET_"M3Q#XMD@_L_3/#6JW<.G6-JD7F6\DD
M/G2'EV(X/4]_>J_B36;/7_#FBW,MVTFMVRM;W2N&+2(#E'+$8/?/.>: .L6S
MU6[\&^&!IOBFTT;_ $>0&.;4&MS*3(<$!?O?_7JAXQ>?2/"2Z!KFLIJNM&Z6
M9<,TAMX\'^-ADD^AKF_$&J6=[X=\.6MO-OFL[>1)UVD;&+Y R1@\>E6KS6=/
MU[P5##J-P(]<TPB.VD:-B;B#^X6 X*]L_P!30!7\(:WJUOXAT>QAU.]CLVO8
ME-NEPXC(+C(V@XYR<T>+M<U:?7]7L9M4O9+07<BB![AS'@.<#:3C P*R] NH
M;+Q'IEW</L@@NHI)&P3M4,"3@<]*-?N8;WQ%J5U;OOAFNI)(VP1E2Q(.#S3
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MSZ#]GDCF2Z<LDSL/E2-3QNSZ=*\VKTCQ#)X:U^11)XZ2&S@&+:RAT>98H5[
M#/7WKS<]>.:0!1113 ]N^+7_ "3K2?\ KZA_]%/7B->W?%K_ ))UI/\ U]0_
M^BGKQ&D@"BBBF!Z)X'M-:O?!&O0: TRZ@;FW*F&<1-CYL_-D=O>K\=MXFT3P
M]KA\9WCM97%FT4%M=W8G>2<XV%.3C!YZ^_;(X_3]4LX/ FLZ;)-MN[FX@>*/
M:3N52<G.,#\37.4@.X\ V?\ :&E>)[3[3;VWFV2KYUR^R-/G'+-V%;'@WPG_
M &3KK7?_  D&@WFVUG'DV=[YDARA'"X%<EX=U2SL-$\16]S-LEO+18X%VD[V
M# XX'''K1X)U2STCQ%]JOIO*A^SS)NVEOF9" , $]30!F:'I<NM:Y9:;"#NN
M)0A([#N?P&3^%>E>-+*[UKPUJ3MIES:IH=V!9^; R![4J$.TD<X*[OH:XOP?
MJ]CH/]J:G++C44M3%81A6R9'X+9 P-H]2.M7/"WC.ZBUH1>(=5O;G2;F)X+E
M)YI)5"LN,[>><XZ#/6@#.\$ZI9:-XJM;W4#LA0.!+Y>_RF*D*^WO@G-=C;)X
MW@NVU'2O$5KXCC 9I+:.],JE3U#0L1CZ+SZ5Q6A7NDZ5KTPU&W74=,D62!F$
M8W;3P)$##AAP1T-=!IL'@K0M5AUB'Q/>7?V9_-BLX[)XY&(Z*7/RX]>F: ,7
MP<Q;X@:2QC6(F]4F-00%^;H ?2NNU'3O$+:G=M'\1]+A0S.5B;7)%*#<<*1C
MC'3%<?HVLP#Q[;:U>E;>$WWVB7:"P0%LG@<GK6M?:-X-O+^YNO\ A.=GG2M)
MM_LF8XR2<9S[T <GJGG_ -JW0N;T7LRR%7N5E,@E(XW!CRP..#52KFJ6]G:Z
MC+#I]]]NM5QLN/),6_@9^4\CGC\*ITP.HT'7=6>R@\/Z?J=KHT)E>9[MIF@+
MMC^-P3V&  !5_P")?FG4],>7-P?L*(=1&W9>$9RZE201R!Z_I6?I,'A/4M&2
MWU*\ET?4H7)-V(7G2X0] 5!^4CIQ@?7L>*M6TN>QTO1=&>>:QTU9,7$PVF5W
M(+$+V''%(#F****8!6QX3_Y'+0_^PA!_Z,6L>MCPG_R.6A_]A"#_ -&+0!]3
MT445(RCJNCV&N67V/4K9;BWW!]C$CD=#P:P_^%;^$/\ H"Q?]_'_ /BJZ2Z_
MU/XU2H+C#F5S(_X5OX0_Z L7_?Q__BJ/^%;^$/\ H"Q?]_'_ /BJPO&_AB2^
MM;[68O$?B#3Y+:S=DM[&^\J$E S E<=3WY[5%X)\/'3M,L?$%WXFU^\,UBLL
ML-_?^9 NY0Q.TCC'8YIC]GJ=%_PK?PA_T!8O^_C_ /Q5'_"M_"'_ $!8O^_C
M_P#Q5<];_%31+BYAS8:S!I\\@CAU2>R*6CDG PY/0GN0*NZSX_TW1M3N]--A
MJE[>VRH[06-MYKLC G< #PHQR3CJ,9H#D7<U/^%;^$/^@+%_W\?_ .*H_P"%
M;^$/^@+%_P!_'_\ BJYY_BMX='V66*+49[&<HLE_%:DV]LS8PLCG&&Y&0,XJ
MS>>)M,T&_P#$]_<3:I*M@ELUQ"65HD##"^2N1C.<MF@/9KN;'_"M_"'_ $!8
MO^_C_P#Q5'_"M_"'_0%B_P"_C_\ Q59>B_$#2];UM=*CL]4M)IHS+:R7MHT2
M72#JT9/)&.>0*J3?%#18;V5%L=8FL(9#%-JL5DS6D3 X.7] >X!% >S7<W_^
M%;^$/^@+%_W\?_XJC_A6_A#_ * L7_?Q_P#XJL_7?'-AH>IPZ<;'4K^[G@%Q
M#%I\ F,BEL<<CIU)Z8[U2O\ XF:587]S =,UN>VM)#'=7]O8F2VMV'W@S@_P
M]\ T![-=S=_X5OX0_P"@+%_W\?\ ^*H_X5OX0_Z L7_?Q_\ XJJ>O>-=-T'[
M)']GOM1NKQ#+!:Z=;F:5T&,OC@ <CJ:A'C[2/^$5O=?:*\2*Q8)=VLD.RXA;
M(^5D)&#\P/6@/9KN:7_"M_"'_0%B_P"_C_\ Q5'_  K?PA_T!8O^_C__ !59
M>B_$#2];UM=*CL]4M)IHS+:R7MHT272#JT9/)&.>0*ZN@:II]3(_X5OX0_Z
ML7_?Q_\ XJC_ (5OX0_Z L7_ '\?_P"*K7HH#V7F9'_"M_"'_0%B_P"_C_\
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M6_A#_H"Q?]_'_P#BJUZ* ]EYF1_PK?PA_P! 6+_OX_\ \51_PK?PA_T!8O\
MOX__ ,56O10'LO,R/^%;^$/^@+%_W\?_ .*H_P"%;^$/^@+%_P!_'_\ BJUZ
M* ]EYF1_PK?PA_T!8O\ OX__ ,54D'P^\*VUQ%<0Z/$DL3AT82/PP.0>M:=%
M >R\QNL^&](\0^1_:MDESY&[R]S,-N[&>A'H/RK*_P"%;^$/^@+%_P!_'_\
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M^$/^@+%_W\?_ .*H_P"%;^$/^@+%_P!_'_\ BJUZ* ]EYF1_PK?PA_T!8O\
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M 6+_ +^/_P#%4?\ "M_"'_0%B_[^/_\ %5U5% '*_P#"M_"'_0%B_P"_C_\
MQ5'_  K?PA_T!8O^_C__ !5=510!RO\ PK?PA_T!8O\ OX__ ,53H_A]X:M+
MB"YLM*BBN()HY4?S'^4JP/K[5U%% !1110!#=?ZG\:I5=NO]3^-4J9O3^$S?
M$44D_AG58HHVDD>SE5$09+$H< #N:RK?2;B_^&,.CL&M[F?2%MB) 5*.8MN"
M.HP>M=/1078\FO=4US7/!R^"U\&:K;:C)!':33S0J+.(+@%UDSAL 9 'ZXKK
M=%L+BW^('B.XD@F$$EI9)%.Z$+(55]V&Z$CC./6NLHH%8\O&DZ@/@;+IXT^Y
M%Z2Q^S"%O,.;DM]W&>G/TI/$^DZA<CQV(M/NI1=16 @"PLWG;?O!>/FQWQTK
MU&B@.4Y/7["XN/&?A6:*WD:*'[6LLJQDK$&BP-Q[9/KUKRR'PUJ>EV+:!<VW
MQ"ENE#Q)'IUXHTZ523C#D816'4$'&>:]_HH!QN<3I6CW%AXYTW-M.;>V\/+:
M^>_S@.)%^4N% +8'H,]<"N,\2:;/;^)-0ETW0O&.F:K-,SQSZ+()+.Z8_=DD
M)P%S_$O;G.:]IHH!Q/'O$^A:^FI:5KNICQ&\CZ7':WK>&9E6=)@2QW+CYE);
MMP"/I38O#U\_@+Q1/'8^)))-0, BCUB83W4RHPY**N4ZD8);@=J]CHH%RG*Z
MY9SR^-_"5S%;2/%;FZ\V58R5C#1 #<>V3ZUU5%%!04444#"BBB@ HHHH ***
M* "BBB@ HHHH **** "N,UO08-8^(VEOJ&DQWVGQZ;.&:XMA+$LA=,9R" V,
MX[]:[.B@35S@[GPQ9Z9\2/#=SH^AP6ELL-V+F6SM!&@)10N\J,>N,^]<G</X
M@A^'U_X.7PMJDEW;3-NNUB_</$9]X9""2[$$?*!QU)&,5[110+E.5T.SN(?'
M?BBZDMI4AGCM!%*T9"R;8VR%/?!/..E<=96FI:)H/@F_?1-1G73KVZ%Q;6]N
M3-&LGF*K;.#CD'Z5ZW10%CRY])U!A(#I]T0?&2W0S W^JX_>=/N_[72M3Q+H
M%YK7BW4888I(X[OPY+:+=%#L$C2<*6QC/.<>E=[4-U;0WMI-:W,8D@GC:.1#
MT92,$?E0'*>0>(_$VIW7A&ST2Y\(:I8RV\]I'=7$T06VCV2H,QOGY\D  #L?
M:NAU.POIO&?B?3?L%X(=>TI(;>^CB+01,B2 B1OX3EA@=ZOZ?\,M)L;VVFEU
M/6[ZWM9!);65[?&2WA9?NE4P/N]LDUVM DGU/)KW5-<USP<O@M?!FJVVHR01
MVDT\T*BSB"X!=9,X; &0!^N*ZW0;">V\<^)YY+>5898[-8IG0@2[8V!P>^#U
MQZUUE% ['+?#RSN+#P-8VUS;26\R--F*5"A&97(R"..,5YG+IFJ6.HR1^&-#
M\8:)J_FDK;12+)I6XGDEVX*D<]/PKW6B@''0:F[RUWXWX&['3-.HHH*"BBB@
M HHHH **** "BBB@ HHHH XW6_%^N6?B>71-$\*_VP\-M'<2R?V@EOM#E@!A
MEY^[V-3:!XOO[_7#HNN^'I]%U!H#<0JUPL\<J @-AUXR,CBL'5=,UW4OBGJ2
MZ'XA_L:1-+MS(WV)+CS!ODP/F^[CV]:;X(M]0/C#4CXJU.XO?$UA 8X8V1(X
M#;N01)$% !W$ $X!'0T$7=STRBO&M.\,:!KO@6Y\7ZM?W(UW;--)J/VMT:SE
M4G"*N["A>  1W]Q5^*UC\>:UH>G>*FE>W.@Q7PLA*T2SSL<,Y"D$D#'';- ^
M8[_7M<_L1=./V?SOME]%9_?V[-Y/S=#G&.G'UK7KS'Q)I=C#X4T+1])UFXG@
MCUZ&!;@7 ED@)9LH&'0KG SR.*KR:;'X"\1:]!X<\Z*%_#\E\+=Y7E7[0C$!
M_F).2* N>K45\]V6GZO8Z;8^(K+PK);Z@3%(=>F\3Q,+C)&0ZLP4ANFW@].:
M^A!TY&/:@$[A11104%%%% !1110 4444 %%%% !1110!X?\ $#_D=]1_[9_^
MBUKF:Z;X@?\ ([ZC_P!L_P#T6M<S6RV/O,'_ +M3_P *_(****9TA1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPSX@?\COJ/\ VS_]%K7,UW7C;PUK=[XOOKBUTJ[FA?R]KI$2#B-0>?J*Y_\
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MK_A$/$?_ $!+[_OR:/\ A$/$?_0$OO\ OR:+H/K-'^=?>C%HK:_X1#Q'_P!
M2^_[\FC_ (1#Q'_T!+[_ +\FBZ#ZS1_G7WHQ:*VO^$0\1_\ 0$OO^_)H_P"$
M0\1_] 2^_P"_)HN@^LT?YU]Z,6BMK_A$/$?_ $!+[_OR:/\ A$/$?_0$OO\
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MRQV<*.C#!5@@!!J)GSW$%6$Z4.62>II4445F?+!1110 4444 %%%% !1110
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M]3_[]1__ !='_"WO#_\ SYZG_P!^H_\ XNO%:*.1!_8.#[/[SVK_ (6]X?\
M^?/4_P#OU'_\71_PM[P__P ^>I_]^H__ (NO%:*.1!_8.#[/[SVK_A;WA_\
MY\]3_P"_4?\ \71_PM[P_P#\^>I_]^H__BZ\5HHY$']@X/L_O/:O^%O>'_\
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MN=_/!PPZ9H#0P=6\$ZY?W5W';>,[RWTF[9FFLIK2.X(W?>5)'Y5?08.*EO?
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MGEACD=L^N0-J@ HHJEIFJ0:K;230!T,4KPRQR##1NIP00,_7W!![T#+M%%%
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M*#/J=+/XVTO0M&T5!%J^IW-[:)+;VT,/GW<D849=P#C//)SUSBK>G>.M$O\
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M\CR6BO6O^%-V_P#T&I?_  ''_P 51_PINW_Z#4O_ (#C_P"*HYT']MX+^?\
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M+:!(0Y&-VU0,X_"HFT]CQ<ZQ^'Q-.*I2O9]F6J***@^>"BBB@ HHHH ****
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M+Q?_ !-'_"R/%O\ T%O_ "7B_P#B:Y6BBR#ZCA?^?<?N1U7_  LCQ;_T%O\
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M_P#"._%/49/[%UC4_.TNV7;IEKYQ3#R<L,C -=CXIT!/$V@3::9S;2LRR0W
M3<89%8,K 9'0CU%)9Z$]OXGN=;DNQ+)<64-JT8BV@%"Q+9R>N[IVQU- 69S_
M (:-YKWC>Z\3-H5[H]H+$6:K?1".:Y??NW,G) 4# )ZY_*XW_)7D_P"P&?\
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MHHHH&%%%% !1110 4444 %%%% !1110!X?\ $#_D=]1_[9_^BUKF:Z;X@?\
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M_D=]1_[9_P#HM:YFMEL?>8/_ ':G_A7Y!1113.D**** "BBB@ HHHH ****
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M\"$_QKI/^%S?]0#_ ,G/_L*/^%S?]0#_ ,G/_L*+R#V^<?\ /J/X?_)'-_\
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MG_A7Y!1113.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&R2,]"!D"MK3K+Q-X@\9:9K6LZ#!H,&F12J%6\6XEN"ZXVDH,!!UP>XKOJ*
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M7D*Y.. J@]P*Z*#PU9V]AK%FDLYCU6:6:<EAE3(NUMO' P.,YK:P?0T8/H:
M21QM_P##C3+TV,D&IZQIUQ:6B6?GV%WY+S1+T5\#!_ #K]*=:?#;0+/P]=Z&
MGVMK.XN?M2EYLR02X&&C?&005SSGDGL<5V&#Z&C!]#0*R.:T+P3IVAM=RO=Z
MAJEU=Q^3+<ZG<&>0Q?W <#"\GC%9EC\+=$L9;-UOM7F6QN5N+..XN_,2WVG.
MQ%(P%/&>_'6NXP?0T8/H: LC*T_0++3HM2B7?-'J-S)<3I-A@2X 90,#Y<#H
M<USEO\+M'@N(PVI:W-IT3AX]+FOV:T3:<J-G4@$="37<8/H:,'T- [(2BEP?
M0T8/H:!B44N#Z&C!]#0 E%+@^AHP?0T )12X/H:,'T- "44N#Z&C!]#0!X=\
M0/\ D=]1_P"V?_HM:YFNJ\?6\S^-M0989&!\O!"D_P#+-:YK[+<?\\)?^^#6
MRV/N\')?5Z?^%?D145+]EN/^>$O_ 'P:/LMQ_P \)?\ O@TSIYEW(J*E^RW'
M_/"7_O@T?9;C_GA+_P!\&@.9=R*BI?LMQ_SPE_[X-'V6X_YX2_\ ?!H#F7<B
MHJ7[+<?\\)?^^#1]EN/^>$O_ 'P: YEW(J*E^RW'_/"7_O@T?9;C_GA+_P!\
M&@.9=R*O:OA#_P BG=?]?S_^@1UXU]EN/^>$O_?!KV?X21O'X4N@Z,I^W.<,
M,?P1U$]CQL]:>#?JCO:***R/B0HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0L%&33?-3^]^E)-_J_P :
MKUG*;3+C%-%GS4_O?I1YJ?WOTJM14^T97(BSYJ?WOTH\U/[WZ56HH]HPY$6?
M-3^]^E'FI_>_2JU%'M&'(BSYJ?WOTH\U/[WZ56HH]HPY$6?-3^]^E'FI_>_2
MJU%'M&'(BSYJ?WOTH\U/[WZ56HH]HPY$6?-3^]^E'FI_>_2JU%'M&'(BSYJ?
MWOTH\U/[WZ56HH]HPY$6?-3^]^E'FI_>_2JU%'M&'(BSYJ?WOTH\U/[WZ56H
MH]HPY$6?-3^]^E'FI_>_2JU%'M&'(BSYJ?WOTH\U/[WZ56HH]HPY$6?-3^]^
ME'FI_>_2JU%'M&'(BSYJ?WOTH\U/[WZ56HH]HPY$6?-3^]^E0_VA9_;/L?VJ
M+[48_-\G>-^S.-VWKC/&:97G/B*XUN'XIPQ^'[2UGOY=%*J]X[+#$/.R6?;\
MQZ8 '<^U-3;$X)'I_FI_>_2N:NM&T7Q%XEMM6;5;BY?2I-AL8;O-NDRY(9XQ
M_P M!N[D=N*P[#QU<1>!=8UK7+6&WOM(EFMKB.%B8WE3 &W/(#%E Z]:Y;P+
MJ&G>'O%.F6<.N6&H/KUF6OOL]VDI6^4ERQP> P<K[E13YF'*CU*[\8^&=/NI
M+6]\0Z5;7$9P\,UY&CKQGD$Y'%5[CQ3X3U/2;Y/^$DTMK7RC'<2QWL9$8?Y1
MDYP,YXSWKEOBCX>T1O!NKZFVCZ>=0(C)NC;)YI.]1]_&>G'7I730^$?#45K+
M!'X>TE(9POFQK91A9,'(W#;@X/(S1SZ!R:E?2/%?@C1M&LM+M_%ND-!9P)!&
MTFH0EBJ@ $X(&>/2M:^\6>'-,F6&_P!>TRTE9!(J3W:1L5/1@">A]:X/0_"7
MAN7Q_P"*K:3P]I+P0+:>5$UE&5CW1L3M&,#/?%9GB6YTBP^*%Z-2\(W>OQ#2
MK<1Q6FFI=>1AY.2&^Z#T_"CG8N4]7T[7=)U>-I-,U.TO8T.&:VF60 ^Y4FKO
MFI_>_2O(/ ?V#7?&O_"1>&O#CZ)HL5G):SLT:0_:9=RD 1(2!MP?F]\=J]6I
M.;0U!,RM3\,Z?J_B+3]8N[R^8V.&BLQ.1;%P25D9,<N,\'/85O>:G][]*K44
MO:,?(BSYJ?WOTH\U/[WZ56HH]HPY$6?-3^]^E'FI_>_2JU%'M&'(BSYJ?WOT
MH\U/[WZ56HH]HPY$6?-3^]^E'FI_>_2JU%'M&'(BSYJ?WOTH\U/[WZ56HH]H
MPY$6?-3^]^E'FI_>_2JU%'M&'(BSYJ?WOTH\U/[WZ56HH]HPY$6?-3^]^E'F
MI_>_2JU%'M&'(BSYJ?WOTH\U/[WZ56HH]HPY$6?-3^]^E'FI_>_2JU%'M&'(
MBSYJ?WOTH\U/[WZ56HH]HPY$6?-3^]^E'FI_>_2JU%'M&'(BSYJ?WOTH\U/[
MWZ56HH]HPY$6?-3^]^E'FI_>_2JU%'M&'(BSYJ?WOTH\U/[WZ56HH]HPY$6?
M-3^]^E'FI_>_2JU%'M&'(BSYJ?WOTH\U/[WZ56HH]HPY$5+OQ1HUA=/;7-YL
MF3&Y?*<XR,CD#T-0?\)GX?\ ^?\ _P#(,G_Q-<!XN_Y&B\_X!_Z M8E?/ULY
MKPJR@DM&UU_S/<HY30G3C)MZI=O\CUK_ (3/P_\ \_\ _P"09/\ XFC_ (3/
MP_\ \_\ _P"09/\ XFO):*S_ +<Q'\L?Q_S-/[&H=W^'^1ZU_P )GX?_ .?_
M /\ (,G_ ,31_P )GX?_ .?_ /\ (,G_ ,37DM%']N8C^6/X_P"8?V-0[O\
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M,_#_ /S_ /\ Y!D_^)KR6BC^W,1_+'\?\P_L:AW?X?Y'K7_"9^'_ /G_ /\
MR#)_\31_PF?A_P#Y_P#_ ,@R?_$UY+11_;F(_EC^/^8?V-0[O\/\CUK_ (3/
MP_\ \_\ _P"09/\ XFC_ (3/P_\ \_\ _P"09/\ XFO):*/[<Q'\L?Q_S#^Q
MJ'=_A_D>M?\ "9^'_P#G_P#_ "#)_P#$T?\ "9^'_P#G_P#_ "#)_P#$UY+1
M1_;F(_EC^/\ F']C4.[_  _R/6O^$S\/_P#/_P#^09/_ (FC_A,_#_\ S_\
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MA_\ Y_\ _P @R?\ Q->2T4?VYB/Y8_C_ )A_8U#N_P /\CUK_A,_#_\ S_\
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M,OKD-W<);Z*!:MYNR9E2+RQ'YIW*HY#9YSFNQG\56UMJ$FG26EW]O$L<<5N
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M-*,7+5)''45V/_"N]1_Y_+7_ ,>_PH_X5WJ/_/Y:_P#CW^%8_P!FXK^1FO\
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MVG0_^0!IO_7K%_Z"*X?_ (5WJ/\ S^6O_CW^%=]I]NUGIEK:N0S0PI&2.A(
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M** "BBB@#K?AY_R'Y_\ KU;_ -"2O2Z\T^'G_(?G_P"O5O\ T)*]+KZ_)O\
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MV^;&K[<YQD9J6D,**** "BBB@ HHHH **** "BBB@ HHHH ***S/$.LP^'M
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M M8E;?B[_D:+S_@'_H"UB5\9BOX\_5_F?6X;^##T7Y!1117.;A1110 4444
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M5UJ=GJ,T.Z[LA(+>3<1L#@!N <'( Z@UG>(O!OA[Q6D:ZWI<5V8ON.2R.H]
MRD''MG%3<JQBZO=6^H?%+PW9V3K+=:?'<SWACY\F-DV!6/8EL<>U<MI-G<:?
MX9A\7Z9 TE]IE_>K<Q1KEKFT-PYD3W*_?7W!]:]*T'PSHOA>S:UT73XK.)CE
MMF2SG_:8Y)_$U:TW2K+2+-K2Q@\J!I'D*%BV6=BS'DGJ2:=Q6/'H[N"_^$/B
MB\MG\RWN-?:6-\8W*UQ$0?R-=UXH&D:AXJTS2[B]OM*UCR'FL-0MY$CW#(#Q
M MG<3\I*E>@R#6K#X,\/6^A3Z)#IRQZ;/-Y\D"RN 7W!L@YR!E1P"!Q5K7?#
MND>)K'[%K-A%>0 [E#Y!4^JL,%3]#1=!9G+VVJZ_X>\7Z?H&I:O!KR:E',\9
M\A(+BW*+N&X*=I0X(S@<U0\1W_BS7? VO6^I^$FTE8[=9%*ZA'<F=5<,Z84#
M'R _7-=9X=\$^&_"C2/HFE16LD@P\FYG<CTW,2<>V:WZ+CL<Q=:O?:MX9M[[
MP/=:),6*DM?,_DI'M.1^[Y# XX/3G-<%J&L:IXC^'TPFFTNVOXO$<-LESI<9
M>#>)4/F ,3O^9L\]:[2_^%?@C4M0:^N?#]N9V.YC&[QJ3ZE58*?RYK<D\.:/
M)IEOIHT^&.RMY4FB@A'EJCHVY2 N.XS[]Z+I"LSS'Q[X?\86/A.:XU7QQ_:=
MFL\&^U_LF&'?F50/G4Y&#@_A6MJVF:]J?Q5U)="\1?V-(FE6QD;[$EQYHWRX
M&&/RX]O6N_U;2+'7-/>PU&#S[9V5F3>RY*L&'*D'J!2QZ791:O-JJ0XO9X4@
MDEW'YD4DJ,9QP6/;O1S!8\\\#V^HGQAJA\5:G<7WBC3X#'!$RI' ;=R")(@H
M .X@ G QT-3^(-8\2:GX!\4)KGA7^Q8DTV4QR?VC'<^8=IR,(./K7<7.B:==
MZQ9ZM-;YO[-62&9792%;JIP0&'L<BI]1T^UU;3KC3[V+S;6YC,4L>XKN4C!&
M001^%%]1V&Z9_P @FS_ZX)_Z"*YE_%VKII=[K']B6;:59S3)*PU%O/\ +BD9
M'81F';GY20N_\:@MOA!X$L[J&Z@T+9-"ZR1M]KG.&!R#@OCK54^"[U=%FNHU
MN7U&/4+BZ_L^6^=K:[C,SL(VCW^6-RD$' PV">XHT%J=JVKZ:D4TCZA:JD$B
MQ3,TR@1N<85N>&.X<'GD5=KB+S2]5N?$:>(4T@HMO)$IL&E3?=#!!F)#[-T>
M_P"4$]%;U7;V])C04444AA1110 4444 %%%% !1110 5YU\0[_4[S7]%T+1M
M(.KR0.-3O+07*P HC 1@NW&"YSCG.RO1:HP:/8VVKW>JQ0D7UVB)-*79LJF=
MH )PHY/0#/4TT[">IP'@O4M8T[QKJ^GZSH3:,-8!U"SMC=).IE4 38=>,GY6
MQVY]:H^%/#?A_4]"L/&NK:M<0:Y)<>;/J1OO+V.),>20QV!> NW'3BO3;[1K
M#4;VQO+J#?<6$AEMI [*8V(P>A&01V.16.?AYX2;Q%_;QT2W.I>9YOFY;;O_
M +VS.W=GG.,YYZT[BL<]!X<T_6_BIXBN]0B>X.G&RFM8O,946782'(! 8\ #
M.1U]:Y[3?"^@:]X#NO&&KZA<C7MLTTNH_;)$:SE4G"*N["A>  1W]Q7KEOI=
MG:ZE>:A##MNKP()Y-Q._8,+P3@8![5@7GPS\&W^LMJUUH%M)>,^]VW,$=NY9
M =I)[Y'-',%CD8[#_A-/$?AR'7C-LN_#/GWD,;F+SSOCX8K@@9.< CH*S[?P
M3INH>%O$ZWL]_/%H5U=0Z5&UTX6S"+O4K@\G)ZMG@ 5ZY_9-C_:\>J^0!>QV
MYMDD#$8C+!BNW..H'.,U'%H6FPVNH6T=MMAU&226Z7S&_>,XPQSGC(],4<P<
MIX]K\VJ>)-2\.Z7<Z-+X@MFT*&[:Q_M060FE;[TC$G,A&!P.F<]ZFM[W7-#\
M$>)K$P/HEM;W%M'#&NIQWLFGQ2L%E^9264 ?, P!&>":],U;P1X;US2K33=2
MTJ*XM;-!';@NP:-0 ,!P0W0#//..:BD\+VVA^$+S2O"VE::C.AVV]VK-%,3@
M,)#G<V5R,DGMVI\R"S.%U'P9X8\+^*?!L^ARR13W.HKOB-VT@N%V,?-()/(.
M.1@?-[US_BS31KP\2>(K;34FCLKB9$U75-7=&A:/C9##'@* P^4-DDX)ZUO>
M&/ -S_PDNG7O_"$VGAF"RN/M,TO]I?:Y9V"L%1.2$7+9(]AZ5VM[\,_!NHZO
M-JMWH-O+>3$F1B[A6)ZDH#MS[XSGGK1>PK7.;T^V'B'7["VU!S+]O\'JD[MR
M6WNN3]><TSP[=S^(M7\,Z)=\R^'8I9M1'8SQDP1?G\SC\*[A-!L=&B6\TK3O
M,O+.P^QVL9N&&Z->5CRQ(&2!\Q!-9W@K1;VTDU;6]7LH;+5=8N!+-;Q2"00H
MB[44L.">I)'=J5QV.LHHHJ2@HHHH **** "BBB@ HHHH **** .-!(^,5P5&
M2/#Z8'K^_:N)TWPOH&O> [KQAJ^H7(U[;--+J/VR1&LY5)PBKNPH7@ $=_<5
MZX-*LAK+:N(?].:W%L9=Q_U8;=MQG'4YSC-8%Y\,_!M_K+:M=:!;27C/O=MS
M!';N60':2>^1S5)DM'&PZ1'XY\4Z!_PD0G99O#"3W,$<K1"9C(/O[2#C)SCU
MQZ57LX#8:-9Z4DTLEMIWC-+:V$CEBD0.57)[#->L#2;$:NNJB "]6W^S"0,>
M(]V[;MSCKWQFJA\+Z,<YL^M^-1/[U_\ CX_O]?TZ>U',%CR#Q'X>NCK^M:W/
MI*^(;=;F1TU;3=9,-SIRK_!L)V[DYP,'IS7M&B:A!JNA6&H6SRO#<6Z2(TP
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M_P! RZ_[]FC_ (1W6?\ H&77_?LUW'_"P])_Y][W_OA/_BJ/^%AZ3_S[WO\
MWPG_ ,51]3P'_/X/K>-_Y]'#_P#".ZS_ - RZ_[]FC_A'=9_Z!EU_P!^S7<?
M\+#TG_GWO?\ OA/_ (JC_A8>D_\ /O>_]\)_\51]3P'_ #^#ZWC?^?1P_P#P
MCNL_] RZ_P"_9H_X1W6?^@9=?]^S7<?\+#TG_GWO?^^$_P#BJ/\ A8>D_P#/
MO>_]\)_\51]3P'_/X/K>-_Y]'#_\([K/_0,NO^_9H_X1W6?^@9=?]^S7<?\
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M^][_ -\)_P#%4?4\!_S^#ZWC?^?1P_\ PCNL_P#0,NO^_9H_X1W6?^@9=?\
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M)R.>,UJUGZ;I$&E2W9MI)1!<R^<+<D>7"Q^]L &0&/S$9/))&,FM"I&%%%%
M!1110 4444 %%%% !1110 445YK\0;J]O/$-MI%A>^(W9+7SI+/00L+J2V%>
M6X8X53@@*!V)/:FE<3=CTJBO%++5O$MYX'M+-]5OK+48O$Z::)Y)A+,D>?NR
M,.)",\Y&#BMEKG5? >M:[;+K.HZQ:IH;ZG"NI2^:Z2JQ7 .!\IXX&*?*+F/4
MJIV]_P#:-2O++[)=Q_9@A\^2/$4NX9^1OXL8P?2O*-;T+7-(\+67B-?'&M3W
M<\UJUU$;C%O())$R(U&-@^;L>0".]:WB#Q%JFDWGCB2UNW#P+816OFL6CMVE
M^4N%/ QG)XYQS18+GIM%>9WND:IX'NM(U6+Q7K&IBYOX;2\M-0G$D<HE.TF-
M<?(03N 'I7,:CK^JZUK^KSS'Q\BVE[);V:^'K8-:H(SMRY_Y:$D9(/KBCE#F
M/<ZRTUZU?Q1)X?$<WVN.T%X7P/+V%BN,YSG(]/QK@WU3Q!XEL_"6BW5W?:%<
MZE%/)?RQQF"Y/DX&%!'R%L[N/PXZTHX[SP9XU\03/JD^KM9>&C/;O>,&E"B0
MD)(P'S<@G.,X/M18+GKM%>!V&N^(K=;35X(_B+>:JQC>>*YT_.GRJ2-X5%^Z
M,=&'/MS7;7FG:GXF\=^(-+7Q%JNF6%M;VDJK8S;'WLK]&.=J\<@ 9XR>*.4.
M8]&HKQ9CXDG^'=OXSG\5ZB+ZR8+';0D);R(LOEGS4_C9L$DD]^E7_&,^J:QX
MIOK/2[SQ5=?9(XU%OHDB6<,$A7<1+,Q.]B"#@ 8! ZT<H7/6J*Y;X<:K>ZUX
M TF_U&4RW<B,))#C+;7903CO@"NIJ64%%%% !1110 4444 %%%% !1110!R?
MV*Y;XJSW?D3"U;0UA$X0[-_G,=N[INQSBN1T_5=;\.^$I/!C>#-6O-0CCEMH
M+B"%39SJQ;:[29PN0<D'],UZU13N*QP'AS0+S1_%VCPS0R21V?AM+1[D(?+\
MP2+E0W3/&<>E91TC40) NG70!\:+=<0-_JN,R=/N_P"UTKU2BBX6/$_$NF3V
M_B749=,T'QEIFK33,\<^B2B2RNF/W9)"<!<_Q+VYSFO7=$&HC0K :N4.I"W3
M[44QCS,#=TXZ^G%7Z*&[@E8****0PHHHH **** "BBB@ HHHH **** "BBB@
M#R[Q=_R-%Y_P#_T!:Q*V_%W_ "-%Y_P#_P! 6L2OC,5_'GZO\SZW#?P8>B_(
M****YS<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#>_2CS7_O?I1S1#ED9OASPQ9^%]#@TBPEG>U@+F/SF#, S%L9 ' SQ6KY
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M@]AF/_/Q?U\CHO\ A7$/_02?_OR/\:/^%<0_]!)_^_(_QKG?^$S\0?\ /_\
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M(_QH_P"%<0_]!)_^_(_QKG?^$S\0?\__ /Y!C_\ B:/^$S\0?\__ /Y!C_\
MB:/K&5_\^W_7_;P>PS'_ )^+^OD=OH'A--!OWNEO&F+Q&/:8]N,D'/7VKHZX
M?P;X@U35=8F@O;KS8UMRX7RU7G<HSP!ZFNXKW,!*C*C>@K1_KS9XV-C5C5M6
M=W_7H%%%%=IR!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M** "BBB@#K?AY_R'Y_\ KU;_ -"2O2Z\T^'G_(?G_P"O5O\ T)*]+KZ_)O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** $.,?-C'O3<Q_[-)-_J_P :KUG*5F7&-T6<Q_[-&8_]FJU%+G\B
MN0LYC_V:,Q_[-5J*.?R#D+.8_P#9HS'_ +-5J*.?R#D+.8_]FC,?^S5:BCG\
M@Y"SF/\ V:,Q_P"S5:BCG\@Y"SF/_9HS'_LU6HHY_(.0LYC_ -FC,?\ LU6H
MHY_(.0LYC_V:,Q_[-5J*.?R#D+.8_P#9HS'_ +-5J*.?R#D+.8_]FC,?^S5:
MBCG\@Y"SF/\ V:,Q_P"S5:BCG\@Y"SF/_9HS'_LU6HHY_(.0LYC_ -FC,?\
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M^^HJ//\ #'_/72/^^HJ\AHH_ME_\^T']DK_GXSU[S_#'_/72/^^HJ//\,?\
M/72/^^HJ\AHH_ME_\^T']DK_ )^,]>\_PQ_SUTC_ +ZBH\_PQ_SUTC_OJ*O(
M:*/[9?\ S[0?V2O^?C/7O/\ #'_/72/^^HJ//\,?\]=(_P"^HJ\AHH_ME_\
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M;ZBNG3ZO817SD!;9[E%D.>F%)S7/#=_PN*XVXW?\(^F,^OGM7G^F_P#"OO\
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MZW#?P8>B_(****YS<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#K?AY_P A^?\ Z]6_]"2O2Z\T^'G_
M "'Y_P#KU;_T)*]+KZ_)O]U7JSY;-O\ >7Z(****]4\P**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH CF_U?XU7JS(I9,"H?*?T_6LIIMFD&K%:2TMI;J&YDMXGN( PBE9 7CW<
M-M/49P,XZU%J&E:=JT @U*PM;V$'(CN85D4'UPP-7O*?T_6CRG]/UJ>5EW14
MLK&STVV6VL;2"UMU^[%!&$4?0#BG6UI;64/E6MO%!&6+[(D"C<3DG [DDDU9
M\I_3]:/*?T_6CE871G#1=*6SELQIEF+6:3S9(! NQWR#N*XP3D Y]14]W96N
MH6SVU[;0W-N_WHIHPZM]0>*M>4_I^M'E/Z?K19A=&?IVD:9I$;1Z9IUI91N<
MLMM L8)]PH%6+BV@O+:2VN88YX)5*R12H&5P>H(/!%6/*?T_6CRG]/UHY6%T
M<]_P@_A+_H5M$_\ !?%_\36I%IMA;R020V5M&]O%Y$+)$H,<?'R+@<+P.!QP
M*N^4_I^M'E/Z?K1:0711NM*TZ^F6:[L+6XE6-H@\L*NP1AAER1T(X([U/!!#
M:V\=O;Q1PPQ*$CCC4*J*.  !P /2I_*?T_6CRG]/UHY6%T58+*TMIIYK>UAB
MEN&WS/'&%:5L8RQ'4X[FJ</AS0[;4#J$&C:=%>DDFYCM463)ZG<!FM;RG]/U
MH\I_3]:+,+H96)+X,\+3S/--X:T>261BSN]C$68GDDDKR:WO*?T_6CRG]/UH
MLPNC.@T;2[6*UBM]-LX8[1B]ND<"J(6.<E !\I.3G'J:;?:#H^J7$=QJ&DV-
MW/%_JY+BV21D^A()%:?E/Z?K1Y3^GZT6871S>L>%[37/$-A=ZC965Y8VUK/$
M8;F(2?.[1E6 ((X",,]>:S(_"6H)HA\,;[3^P1/B.0.WGK;?>$8&W&X-\H?=
MG;S][FNW\I_3]:/*?T_6BTA71DZ!:7NGZ1%8WIMV:VS#"\' >)>$++@!6VXR
M!QGIQP-.G^4_I^M'E/Z?K1RL=T,HI_E/Z?K1Y3^GZTN5AS(913_*?T_6CRG]
M/UHY6',AE%/\I_3]:/*?T_6CE8<R&5'/!#=0/!<11S0N-KQR*&5AZ$'K4_E/
MZ?K1Y3^GZT<K#F1FZ;H>DZ-YG]EZ796/F??^RVZ1;OKM S6+9:#J]QXTEUS6
MY[%X;1)(-+AM5<%$<C<\A;^/  XXZ]*ZSRG]/UH\I_3]:=F*Z,S4-"T?5Y(Y
M-3TJQO7BXC:YMTD*?0L#BI;S2M.U&U2UO;"UN;>,ADBGA5T4CH0", BKWE/Z
M?K1Y3^GZT68[HIKIUBL-Q"ME;B*Y9GG01+ME9N"6&/F)[YINGZ5IVD0&#3;"
MULH6;<8[:%8U)]<*!S5[RG]/UH\I_3]:+,+HK26EM-<0W$MO$\\&?)D9 6CR
M,':>HR.#BH3I.FE64Z?:$-.+D@PKS,.DG3[_  /FZU?\I_3]:/*?T_6CE871
M0L-(TW2S,=/TZTM/.;=+]G@6/S#ZMM R?K4UM9VUG;+;6MO#! N<11(%49.3
MP..235GRG]/UH\I_3]:.5A=&98Z#H^F7,EQI^DV-I/+_ *R6WMDC9^_) R:2
MZ\/Z+?7RWUWI%A<7B8VW$MLCR+CIAB,\5J>4_I^M'E/Z?K19A=%;[);?;/MG
MV>+[5Y?E>=L&_9G.W=UQGG%5+3P_HMA>O>V>D6%M=/G?/#;(CMGKE@,G-:GE
M/Z?K1Y3^GZT6870RBG^4_I^M'E/Z?K2Y6',AE%/\I_3]:/*?T_6CE8<R&44_
MRG]/UH\I_3]:.5AS(913_*?T_6CRG]/UHY6',AE%/\I_3]:/*?T_6CE8<R*W
MV2V^VF\^SQ?:C'Y1GV#?LSG;NZXSSBJDN@:-<:DNHS:1827RXVW+VR&48Z88
MC/ZUJ>4_I^M'E/Z?K3LPNBM]DMOMGVS[/%]J$?E>=L&_9G.W=UQGG%0_V3IO
M/_$OM.9_M)_<K_KO^>G3[_\ M=:O^4_I^M'E/Z?K1RL+HR[KP_HM]?+?7>D6
M%Q>)C;<2VR/(N.F&(SQ6C3_*?T_6CRG]/UHY6%T,HI_E/Z?K1Y3^GZTN5AS(
M913_ "G]/UH\I_3]:.5AS(913_*?T_6CRG]/UHY6',AE%/\ *?T_6CRG]/UH
MY6',AE%/\I_3]:/*?T_6CE8<R&44_P I_3]:/*?T_6CE8<R&44_RG]/UH\I_
M3]:.5AS(\K\7?\C1>?\  /\ T!:Q*[7Q#X4U?4-=N;JW@1HGV[29%'10/7U%
M9G_"$:[_ ,^R?]_5_P :^3Q.#Q$JTVH.UWT\SZ?#XJ@J44YK9=?(YVBNB_X0
MC7?^?9/^_J_XT?\ "$:[_P ^R?\ ?U?\:Q^I8G_GV_N9K];P_P#.OO.=HKHO
M^$(UW_GV3_OZO^-'_"$:[_S[)_W]7_&CZEB?^?;^YA];P_\ .OO.=HKHO^$(
MUW_GV3_OZO\ C1_PA&N_\^R?]_5_QH^I8G_GV_N8?6\/_.OO.=HKHO\ A"-=
M_P"?9/\ OZO^-'_"$:[_ ,^R?]_5_P :/J6)_P"?;^YA];P_\Z^\YVBNB_X0
MC7?^?9/^_J_XT?\ "$:[_P ^R?\ ?U?\:/J6)_Y]O[F'UO#_ ,Z^\YVBNB_X
M0C7?^?9/^_J_XT?\(1KO_/LG_?U?\:/J6)_Y]O[F'UO#_P Z^\YVBNB_X0C7
M?^?9/^_J_P"-'_"$:[_S[)_W]7_&CZEB?^?;^YA];P_\Z^\YVBNB_P"$(UW_
M )]D_P"_J_XT?\(1KO\ S[)_W]7_ !H^I8G_ )]O[F'UO#_SK[SG:*Z+_A"-
M=_Y]D_[^K_C1_P (1KO_ #[)_P!_5_QH^I8G_GV_N8?6\/\ SK[SG:*Z+_A"
M-=_Y]D_[^K_C1_PA&N_\^R?]_5_QH^I8G_GV_N8?6\/_ #K[SG:*Z+_A"-=_
MY]D_[^K_ (T?\(1KO_/LG_?U?\:/J6)_Y]O[F'UO#_SK[SG:*Z+_ (0C7?\
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MO/\ ]G]://\ ]G]:AHHYY!R(YS5_'']E:I-9?V=YOE[?G\_;G*@]-I]:I?\
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M "BBB@ HHHH **** "BBB@".;_5_C5>K$W^K_&J]8SW-8;'':_\ \E,\'?\
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MWIOA*P\6-KNH77BZQ+:C/IRP6US;LAA5!DLAP>)"Q!/8]L 4P/.?#G_"E_\
MA&=/_MG?_;'D+]HV?;-WFXYQM^7.?3BO8_AN+]?!%F+\7@.^3[/]M_U_D;SY
M>_WVXJ'2/""WGPRTSP]KEN8KB&T1"58%[>4#AT8$X8'D$&M7PD==31%M?$,.
M+ZU<P_: ZLMTB_=E&"2,CJ#@YS2;N"5C=HHHJ2@HHHH **** "BBB@ HHHH
M**** /+O%W_(T7G_  #_ - 6L2MOQ=_R-%Y_P#_T!:Q*^,Q7\>?J_P SZW#?
MP8>B_(****YS<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#K?AY_P A^?\ Z]6_]"2O2Z\T^'G_ "'Y
M_P#KU;_T)*]+KZ_)O]U7JSY;-O\ >7Z(****]4\P**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]JK?\(!HW]ZZ_P"_@_PKYVOE&)G5E-6LV^I[]'-,/"G&+OHET/,**]/_ .$
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MMSPV"BBBNXXPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC1_;6J_]!.\_[_M_C5&BCVU3^9_>%B]_;6J_]!.\_P"_[?XT?VUJO_03O/\
MO^W^-4:*/;5/YG]X6+W]M:K_ -!.\_[_ +?XT?VUJO\ T$[S_O\ M_C5&BCV
MU3^9_>%B]_;6J_\ 03O/^_[?XT?VUJO_ $$[S_O^W^-4:*/;5/YG]X6+W]M:
MK_T$[S_O^W^-']M:K_T$[S_O^W^-4:*/;5/YG]X6+W]M:K_T$[S_ +_M_C1_
M;6J_]!.\_P"_[?XU1HH]M4_F?WA8O?VUJO\ T$[S_O\ M_C1_;6J_P#03O/^
M_P"W^-4:*/;5/YG]X6+W]M:K_P!!.\_[_M_C1_;6J_\ 03O/^_[?XU1HH]M4
M_F?WA8O?VUJO_03O/^_[?XT?VUJO_03O/^_[?XU1HH]M4_F?WA8O?VUJO_03
MO/\ O^W^-']M:K_T$[S_ +_M_C5&BCVU3^9_>%B]_;6J_P#03O/^_P"W^-']
MM:K_ -!.\_[_ +?XU1HH]M4_F?WA8O?VUJO_ $$[S_O^W^->K:0[R:+8R2,S
MNUO&69CDDE1R:\;KV+1?^0%I_P#U[1_^@BO>R*<Y5)\SOH1,O4445]*0%%%%
M !1110 4444 %%%% !1110 C=*93VZ4RN:K\0SSCXHZV([G1=!73M1U*.>X%
MY?6VG0>=*;>)@0-O]UGVC.1P#4'PY\0!O%6O:,VEZII=O=R'4K&#4[8P2?-@
M3!1DC;OY&/[QKN;?0+6W\2WNO>;/)>74$=OB0KLBC3)VH  1DG)R3SZ4FI>'
M[74]8TK59)9XKK3'=H6B8 .'7:R-D'*GCICI4W5K >-PV&N76CW>HW5O%>>%
M=,UVZFN=+C)\R[03.7D;G!"'!"'AMISVKN_'EWI^I>%O#]ZLD4VA3:I9R7#X
M_=F G@MZ+NV9S76:)H5KH-C-:6SRR1S7$MRWG$$[I'+,. .,GBL_3?!.D:9I
M>IZ2BRSZ5?R/(UC.P:*'=]Y8P "JD\XR<'D8I\RN!K:O_9_]BWG]JB(Z<('-
MR)1E/+Q\V?;%>=>()]3NO&/A&?P5_9FZ32KAK?\ M%)4B\G,6/E4!@<8P"*T
MT^$>B;XXKG5M?O-,C8,FE7.H,]JN.@V8S@>A-:WB7P-:>)+RQN_[5U?2I[*-
MXHGTNX$!V-MR"=I./E' Q25D >'O^$]_M%O^$E_X1O[#Y9Q_9OG^;OR,??XQ
MC/Z5Y?K>N?\ "0WOBNY'ASQ+?-<;;/2;W3K RPQK Y*NKY'68$G&> *]$T_X
M='3[O[0/&7BZY^1T\NZU(2)\RE<[2F"1G(SW KI=#T>U\/Z)9Z39;_LUI$(T
M+D%FQU)( Y)R3QU-.Z0'*6GQ'!\):-JQT#6]2FO(V6>/2[/SC;RI@.KC(V_-
MG'TJ2Q^)'VV_M[3_ (0OQC;^?*L?G7&E[(X\G&YFW<*.I/I70Z-X?M="GU*2
MTEG*:A=-=O$[ I'(P&[8 !@'&3DGFM:I;0''>)/^2B>"_P#?O/\ T36WXI_Y
M%'6O^O&?_P! -27VB6U_K.EZI*\HGTTRF%5(VMYB[3NXR>.F"*M7]G'J.G75
MC,S+%<Q-"Y0X8!@0<9[\T7V Q?#G_).M*_[!47_HH5Y?HVL_$K0/AAI>HV-M
MX=FT>*T0A@D[W$4./]8ZY .T<G;GZ5[+9:9#8:+;Z5$TA@@MUMU9B-Q4+M!/
M&,X]JCT71K;0M!L]'MFDDMK6$0H9B"S*/[V  ?RIJ20'&:5J\7@;PMID4=AK
MGB8ZAYEX][I%@)49Y&WDD C:#NX'L:OZ3+Y_Q6U:;RY(_,T6S;9(N&7+RG!'
M8UO>'?#EIX8L)+"PFN&LVF>6*&5@5@#')1, $(#G .>O6L?7_A];:]KS:PNO
MZ_I=T\"0/_9EX(%=5)(S\I)^\>]%T!M:UK:Z-]C06%W>SWDY@AAM3&&+!&<Y
M,CJH&$/>DTG75U2ZNK26PO+"\M0C26]T$W;'SM<&-F4@[6'!SE3D"N5G\&W>
MF2Z':VFO^(KLG4VF>]NIEN9;=?L\J\%T*JI.!R#RWKBH;C3;B&+7-/U>RU#6
M-3G:(V6H)#CS5#'R?F10D+1.26.!Q\V#G%%D!Z-17->#[:>TAU"'4()/[7%P
M6O+PQ%4NR1E'1L8*A<+M'W<8]STM2P"BBB@ HHHH **** "BBB@ HHKF_$WC
M73_#-Q;6DEIJ&HZA<J7CLM-M_.F*#J^W(PH]<_R-"5P.DHKEW\?Z&GA2'Q#N
MN3;S2_9X[<0$SM/N*^4(^N_((Q[>E0:5\1--U--1673-8TVZL+9KN2TU&T\F
M5XAG+("<$9&.HYI\K Z^BN*M_B=HLVBW6L26>JVVGQ>6(9I[7:+MGZ)#R2YR
M,'''OCFL:W\;GQ!\2?#=I;PZQI>(+MKK3[^%K=F&P%'9,X8<-@\XP>E'*P/3
MJ*X:Q\:Z-HG@K3KYIM9OENYI(;6*9?/O+AP[94!>#C!QSTQ5_1?'VF:S#J'^
MAZE87FGPFXGL;^V\F<1X)#!2<$''KZ9QFCE8'545P<7Q<\./+;&:'4[:QN8]
MT>HSVI%LS[=QC#@G+CD8 (R, FK6G?$C3-1754&F:S;76G6QNVM+NT\J::$9
M^>-2W(..^*.5@=E16))XJT]8M"DC6:;^VW5;18PI."AD+-SPH4<XS^-<]=?%
MC0[:ZG"Z?K=SI]M(8I]4M[!GM(F4X;+YSP>X!HY6!WE%<IKOQ!TC0;ZULI(;
MV\N+NU-S:I8PB8W R %0 Y+$'/I@$YHL/B'H-YX?U#6)FN;&/36VWMO>0&.>
M!NRLG/)R,8SFCE8'5T5Q>F_$FPU"]:RDT/Q!87)ADFMXKZP,3780981<G<V.
MW'6N,M_B%?:AX,TO5-0;4[ P:]&ES<RPF%)H3))\B[?OA5 5ACJ,<T^5@>ST
M5QVF_$?3-2BU7&F:Q;76FVQNY+.[M/*FEB /SHI."#CC)%:TGBK3UBT*2-9I
MO[;=5M%C"DX*&0LW/"A1SC/XTK,#;HHHI %%%% !1110 4444 >7^.?$:CQ]
MI.GG1M7U>RTI#>W,.EVGV@B9PRQ!QD8 &]NO.153P?K!E^'WBGP_-:7UF^EP
M7'V:WU"(Q3BU=&:/<I].5XXP!7HVDZ!:Z/?:I>Q2SS7&IW'GSO,5)&%"JBX
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M':]BT7_D!:?_ ->T?_H(KW\@_B3]")EZBBBOJ" HHHH **** "BBB@ HHHH
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M  F&@_\ /]_Y!?\ ^)KP*V6X:524G72;;[?YE*3['EWDR_\ /)_^^31Y,O\
MSR?_ +Y->H_\)AH/_/\ ?^07_P#B:/\ A,-!_P"?[_R"_P#\36?]EX7_ *"%
M^'^8^9]CR[R9?^>3_P#?)H\F7_GD_P#WR:]1_P"$PT'_ )_O_(+_ /Q-'_"8
M:#_S_?\ D%__ (FC^R\+_P!!"_#_ ##F?8\N\F7_ )Y/_P!\FCR9?^>3_P#?
M)KU'_A,-!_Y_O_(+_P#Q-'_"8:#_ ,_W_D%__B:/[+PO_00OP_S#F?8\N\F7
M_GD__?)H\F7_ )Y/_P!\FO4?^$PT'_G^_P#(+_\ Q-'_  F&@_\ /]_Y!?\
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MPO\ T$+\/\PYGV/+O)E_YY/_ -\FCR9?^>3_ /?)KU'_ (3#0?\ G^_\@O\
M_$T?\)AH/_/]_P"07_\ B:/[+PO_ $$+\/\ ,.9]CR[R9?\ GD__ 'R:/)E_
MYY/_ -\FO4?^$PT'_G^_\@O_ /$T?\)AH/\ S_?^07_^)H_LO"_]!"_#_,.9
M]CR[R9?^>3_]\FCR9?\ GD__ 'R:]1_X3#0?^?[_ ,@O_P#$T?\ "8:#_P _
MW_D%_P#XFC^R\+_T$+\/\PYGV/+O)E_YY/\ ]\FCR9?^>3_]\FO4?^$PT'_G
M^_\ (+__ !-'_"8:#_S_ '_D%_\ XFC^R\+_ -!"_#_,.9]CR[R9?^>3_P#?
M)H\F7_GD_P#WR:]1_P"$PT'_ )_O_(+_ /Q-'_"8:#_S_?\ D%__ (FC^R\+
M_P!!"_#_ ##F?8\N\F7_ )Y/_P!\FCR9?^>3_P#?)KU'_A,-!_Y_O_(+_P#Q
M-'_"8:#_ ,_W_D%__B:/[+PO_00OP_S#F?8\N\F7_GD__?)H\F7_ )Y/_P!\
MFO4?^$PT'_G^_P#(+_\ Q-'_  F&@_\ /]_Y!?\ ^)H_LO"_]!"_#_,.9]CR
M[R9?^>3_ /?)H\F7_GD__?)KU'_A,-!_Y_O_ ""__P 31_PF&@_\_P!_Y!?_
M .)H_LO"_P#00OP_S#F?8\N\F7_GD_\ WR:/)E_YY/\ ]\FO4?\ A,-!_P"?
M[_R"_P#\31_PF&@_\_W_ )!?_P")H_LO"_\ 00OP_P PYGV/+O)E_P">3_\
M?)H\F7_GD_\ WR:]1_X3#0?^?[_R"_\ \31_PF&@_P#/]_Y!?_XFC^R\+_T$
M+\/\PYGV/+O)E_YY/_WR:/)E_P">3_\ ?)KU'_A,-!_Y_O\ R"__ ,31_P )
MAH/_ #_?^07_ /B:/[+PO_00OP_S#F?8\N\F7_GD_P#WR:/)E_YY/_WR:]1_
MX3#0?^?[_P @O_\ $T?\)AH/_/\ ?^07_P#B:/[+PO\ T$+\/\PYGV/+O)E_
MYY/_ -\FCR9?^>3_ /?)KU'_ (3#0?\ G^_\@O\ _$T?\)AH/_/]_P"07_\
MB:/[+PO_ $$+\/\ ,.9]CR[R9?\ GD__ 'R:/)E_YY/_ -\FO4?^$PT'_G^_
M\@O_ /$T?\)AH/\ S_?^07_^)H_LO"_]!"_#_,.9]CR[R9?^>3_]\FCR9?\
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M#C.TNIR/3-/E ]'HK(\+ZXOB3PS8:N(3 ;F/+Q$Y\MP2&7/?!!%:]2 4444
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M >7>+O\ D:+S_@'_ * M8E;?B[_D:+S_ (!_Z M8E?&8K^//U?YFJV"BBBL
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M3B\8_8M/M!K=A<V^HRV,5P(50 3RM@-%$"V=X9@-K8^\.<9(ZB-B\:LR,A8
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M?(I[\52LK?4/"+>+/#&KZDNH-J6G7&JVUT+<0AW*E9EV#(!^Z>#ZFO7J*KF
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M_P"%?ZA_S]VW_CW^%'_"O]0_Y^[;_P >_P *9_PGVJ_\^]G_ -\-_P#%4?\
M"?:K_P ^]G_WPW_Q5%\I[/\ $/>'_P#"O]0_Y^[;_P >_P */^%?ZA_S]VW_
M (]_A3/^$^U7_GWL_P#OAO\ XJC_ (3[5?\ GWL_^^&_^*HOE/9_B'O#_P#A
M7^H?\_=M_P"/?X4?\*_U#_G[MO\ Q[_"F?\ "?:K_P ^]G_WPW_Q5'_"?:K_
M ,^]G_WPW_Q5%\I[/\0]X?\ \*_U#_G[MO\ Q[_"C_A7^H?\_=M_X]_A3/\
MA/M5_P"?>S_[X;_XJC_A/M5_Y][/_OAO_BJ+Y3V?XA[P_P#X5_J'_/W;?^/?
MX4?\*_U#_G[MO_'O\*9_PGVJ_P#/O9_]\-_\51_PGVJ_\^]G_P!\-_\ %47R
MGL_Q#WA__"O]0_Y^[;_Q[_"C_A7^H?\ /W;?^/?X4S_A/M5_Y][/_OAO_BJ/
M^$^U7_GWL_\ OAO_ (JB^4]G^(>\/_X5_J'_ #]VW_CW^%'_  K_ %#_ )^[
M;_Q[_"F?\)]JO_/O9_\ ?#?_ !5'_"?:K_S[V?\ WPW_ ,51?*>S_$/>'_\
M"O\ 4/\ G[MO_'O\*/\ A7^H?\_=M_X]_A3/^$^U7_GWL_\ OAO_ (JC_A/M
M5_Y][/\ [X;_ .*HOE/9_B'O#_\ A7^H?\_=M_X]_A1_PK_4/^?NV_\ 'O\
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M 0:AI6G:M;?9M2L+:\@SN\JYB61<^N&!%/L["ST^U2ULK6&VMT&$BAC"(OT
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ME?<]7_X171/^@>G_ 'TW^-'_  BNB?\ 0/3_ +Z;_&O***/[5P__ $#K\/\
MY$.5]SU?_A%=$_Z!Z?\ ?3?XT?\ "*Z)_P! ]/\ OIO\:\HHH_M7#_\ 0.OP
M_P#D0Y7W/5_^$5T3_H'I_P!]-_C1_P (KHG_ $#T_P"^F_QKRBBC^U</_P!
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M%%% 'EWB[_D:+S_@'_H"UB5M^+O^1HO/^ ?^@+6)7QF*_CS]7^9JM@HHHK
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB3"YD+DY#@#.S&0W'/<L@.Z\0>/M/T'5/[+33=7U:_$8EEM]*M#.T2'.&?D
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M2M+;K&#\X8%54X11C[N#DDG-=?11S, HHHI %%%% !1110!Y=XN_Y&B\_P"
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MR ;13MOO1M]Z/9R ;13MOO1M]Z/9R ;13MOO1M]Z/9R \L\7?\C1>?\  /\
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MN-\87WCK3C<7V@#PZVF6UL9I!?B<S%E!+8V?+C &*[&LGQ3_ ,BCK7_7C/\
M^@&FIRON!S_A+5O&][!;ZMXC;PU#HLUH+C=:&994RH8;MYV@ 9SS746^O:3=
MFX%MJMC-]F4//Y=PC>4I&06P?E!'()KG(/\ DC<?_8!'_HBN!\2:-;Z7\(?#
M3:;9Z?;PW4MG)J<US&PBF&PD&X9!O*[R.??TJKMO<#V+3=;TS68WDTO4[.^1
M#M=K6=90I]"5)Q4;>(]%35!IC:SIZZ@3M%J;E!*3Z;,Y_2O)/!YFC^(-A+;W
M/@=<6LXGM_"_FEIHP,C> "F0VW&XJ>>,]*XC5YM+G\(+JL%]X6T^66Y66*PM
MH3/J()ER1+/(3(K#DEN!Q@<$4[.^X'OUIXXTNZ\7:KH!NK2.2PB1]YN4S(2&
M+C;VV!1GTSSBM>#7M)N;U+*#5;&6Z>(3)!'<(SLA&0P4')4CG/2O-Y+?1K;X
M@>-@\%C%J$NDQRVV4197)BE\UD[DGC<1^-94OA/0QX"\"72V$:7EY=6*7-TF
M5FE65/G5I!\Q!!QC/ X%&O<#U^PUG3=5,PT[4K2\\EMDOV>99/+;T;:3@_6F
M0^(-(N=2?38-6L);],[[5+A&E7'7* Y'Y5YQJVC0Z#XQUF'PO81V,\OA:5TB
MLHP@:4284A1QN]\9KSRR1O[!TK[%>?#FVN$D@-O/:FX_M(2;AC(52Y8G@@J1
MSTQ0KOJ!]$WGB+1M.,HOM8L+4PE5D$]RB;"PRH.3QD D9ZXK+USQOIFAZUHF
MGW%U:*-39OWLERJ") A97YZAB HZ<FN;M?#.BZ]\3_%TVKZ9:WSQP6D:"XC#
MA T9SM!Z'@<]>*Y+2[71H]*^&\^L0V1MH[F\MGFO$0KM42^6K,W&-V, ]Z$W
MW ]SEG2"%YII%CBC4L[N0%4#DDD]!5.WU[2;LW MM5L9OLRAY_+N$;RE(R"V
M#\H(Y!-<EJO_  G'V'7_ .UO^$>_L7[%=>5]D\[[3C8VS=N^7..N/PKB_$FC
M6^E_"'PTVFV>GV\-U+9R:G-<QL(IAL)!N&0;RN\CGW]*2OW ]BTW6],UF-Y-
M+U.SOD0[7:UG64*?0E2<4Q/$.C2:H=,36+!M0!(-JMRAE!'7Y,Y_2O)/!@E7
MXB:>\%WX&C!MIEG@\,><3+'C(+@*4X;;C<0>>,]*Y=_[+\/0"YMKGPAXAL(+
MH3(L@:UUC<),@9&'W!O7KCIBG9WW ^@+?49_[7U6*YO--^R6JQLB12'SH@5)
M8S \*#C*^V:=9>(]%U*&>:QUG3[J*W&Z9X+E'6(=<L0>!QWKS;7X+*_NOB)#
MJ-])IMK-!I^^Y\EI/*^7(W*.2N< ^Q-9'@^>TM?'.GZ?/9>#M2-[#-;K=>'6
MVLL>W<WVB)?D8-M Y'':C6VX'IOA?QMIOB70)=66YM8$@DD6=?M*MY*J[*K.
M?X=P7<,]C6K9>(-'U*UFNK'5["ZMX 3-+!<(Z1X&3N(.!QSS7B$$V@6GPSL[
M".TT3[5/KCP737C&."W9996C:Y$9!8!5PJO\O3L*30!:6_BKQ5!9ZIHUZK>&
MIFD_L:U2"W5L_= 7AR ?O<]<=J;3[@>X6_B#2+N]6RMM6L)KMHQ*L$=PC.4(
MR&V@YQ@@YK,\->--/\37^K6EK/;&2PNFA58[A9&E0!?W@ Z+N8CN..M>?#PO
MHFD>%OA[J.GZ;;V]\;^QWW,<8$DGF*=^YNK Y[_A70?#NVT:S\2^,+:V@L8-
M135),1QHBRK 4C(X'.S=GVS4W=MP/1-Q]:-Q]:2BHYI=P%W'UHW'UI**.:7<
M!=Q]:-Q]:HC5;(ZTVCB;_3UMQ<F+8W^K+;=V<8ZC&,YJ[3YI=P%W'UHW'UI*
MIZAJMEI0MC>S>4+FX2VA^5FW2-]U> <9]3Q1S2[@7=Q]:-Q]:2BES2[@+N/K
M1N/K244<TNX"[CZT;CZTE%'-+N NX^M&X^M)11S2[@+N/K1N/K244<TNX"[C
MZT;CZTE%'-+N NX^M&X^M)11S2[@+N/K1N/K244<TNX'!^(_$FK6&O7-M;7>
MR%-NU?+0XRH)Y(]367_PF&O?\_W_ )!3_P")I/%W_(T7G_ /_0%K$KY/$XO$
M*M-*;W?5]S1)6-S_ (3#7O\ G^_\@I_\31_PF&O?\_W_ )!3_P")K#HK'ZYB
M?^?DOO861N?\)AKW_/\ ?^04_P#B:/\ A,->_P"?[_R"G_Q-8=%'US$_\_)?
M>PLC<_X3#7O^?[_R"G_Q-'_"8:]_S_?^04_^)K#HH^N8G_GY+[V%D;G_  F&
MO?\ /]_Y!3_XFC_A,->_Y_O_ ""G_P 36'11]<Q/_/R7WL+(W/\ A,->_P"?
M[_R"G_Q-'_"8:]_S_?\ D%/_ (FL.BCZYB?^?DOO861N?\)AKW_/]_Y!3_XF
MC_A,->_Y_O\ R"G_ ,36'11]<Q/_ #\E]["R-S_A,->_Y_O_ ""G_P 31_PF
M&O?\_P!_Y!3_ .)K#HH^N8G_ )^2^]A9&Y_PF&O?\_W_ )!3_P")H_X3#7O^
M?[_R"G_Q-8=%'US$_P#/R7WL+(W/^$PU[_G^_P#(*?\ Q-'_  F&O?\ /]_Y
M!3_XFL.BCZYB?^?DOO861N?\)AKW_/\ ?^04_P#B:/\ A,->_P"?[_R"G_Q-
M8=%'US$_\_)?>PLC<_X3#7O^?[_R"G_Q-'_"8:]_S_?^04_^)K#HH^N8G_GY
M+[V%D;G_  F&O?\ /]_Y!3_XFC_A,->_Y_O_ ""G_P 36'11]<Q/_/R7WL+(
MW/\ A,->_P"?[_R"G_Q-'_"8:]_S_?\ D%/_ (FL.BCZYB?^?DOO861N?\)A
MKW_/]_Y!3_XFC_A,->_Y_O\ R"G_ ,36'11]<Q/_ #\E]["R-S_A,->_Y_O_
M ""G_P 31_PF&O?\_P!_Y!3_ .)K#HH^N8G_ )^2^]A9'=^$->U+5-6E@O+G
MS8U@+@>6J\[E'8#U-=K7G/@'_D.S_P#7LW_H2UZ-7U>45)U,,I3=W=[D2W"B
MBBO3)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** $;I3*>W2F5S5?B&<;X@_P"2G>#/^N5__P"B
MTJ#P1:V]YXA\5:S=1I)JBZK):"1P"T4,:J$5?0$'/'7/-=!J&@_;_$^C:S]I
MV?V:LZ^3Y>?,\U57KGC&/0Y]JR=<\%7=SK,NM>'?$%QH.I7"JETZ0+/%.%&%
M+1MQN X!J;JU@*NL6MOIWQ5\-7EC&L5UJ,=S!>"/CSHE3>K,.Y# <^]<?X4)
M\(QIXL4D:7>ZA<V6KKD;8_\ 27$4_P#P$G:?8CTKT#PYX.;2=2DUG5]7N-:U
MJ2/R?M<\:QK''G.V.->$!/)JSHWA2WT[PS<Z'=R+>V]S+</+NCVAEE=F*XR>
MF[&?:G=; >;3G/PK\8D?]#))_P"E,5=MXITN>\\5:5J6D3Z7/K6FPR,NG7\A
M&Z)R 9%VY9&!7 ;:1R15+3_ABNG?#^]\*1ZN[I<7@N5N7@RR .C!2-W)^3&<
MCKG':MKQ1X1;7;JTU+3]6N=(UBS5DAO(%#@HQ!*.AX=<@'![T-JX&19:O!+X
MRLG\3^&'T;7/(F6QNDNA/%/& "Z[DQDX&0KKQ@XJ]I_Q-\):O8ZE=:9JGVE=
M.MFN;@>1)'M0 _WU&>E-T3P5?V^N0:UXC\27&NWUJC):9MTMXH-PPS!$X+$<
M9]*U?%?AYO%&CKI;7?V>V>XB>Y'E[S-$K!C&.1MW8 SSQGBD[7 \3T/QUX;L
M-2T#78]65];N[Z;^V(1!(H\NX8'&XK@B,K'T/.#BO3]5M;;6/BUIEGJ,:2VU
MCI;WEK%( 5>8R!"V#U*J!CTS75:SI-OKFAWNE7*CR+J%H6XSC(QD>XZ_A6!>
M^!O[2T'2+:ZU>ZCUC2HPMOJUH/*D!P <KD@A@!E2>:?,F!C>/?$FB07BVFM>
M%?$5Q'I\\,\6IVMD/)B<%6!64L,<X4_B*U_BB<_#?5CZK'_Z,2J!^'VNZJHM
MO%'CB]U73@RL;2WLX[028.<.R9++QTXKI_%&A?\ "2>&[O1_M'V;[0%'F[-^
MW#!NF1GIZTKI- 2ZUKVF^&M'?5-7N?LUG%M#R>6SX)( X4$]3Z5QNK>(=*\4
M7O@G4M'NOM-HVM,@D\MDY$$N1A@#^E>B 8 'I7->,?#%]XDCTU]-UG^R;S3[
MK[3%<?95GYV,N-K$#HW?-)6 VM4U6TT:Q:\OG=(0ZI^[B>1BS,%4!4!8DD@<
M#O5;3?$>FZK>26ENUS'<I&)3#=V<ULY3.-RB55+#/!(SC(SU%<)K>@>,K"PA
MEU+QNFJ1F^LUCADTB.)5D-S%M<E&!(']W(SGJ*O74[6WB"]3QCJD=LZZ=(MA
M=V"O:J\+%3*5^=F$RLJ<!NA! .3A\JL!Z%17&^#+R]N+ZZBURXG76%@B9+61
MBJ_9L?+)L#%=Y;=O/4,-O0 GLJEJP!1110 4444 %%%% !1110 4444 %,EB
MCGA>&:-9(I%*NCKE6!X((/44^N)UWQG!X:\;F+5]3CM-&72?/970',OG!1C
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M^0%/_P!?+?\ H*UYS7HW@'_D!3_]?+?^@K7K9+_O:]&3+8ZJBBBOL3,****
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M0UOM,I;9Q\G#K@J<\>PJ"Y\)ZOK.C6>AZQ<V?V.TW8N8!F68J-L)*% J<'+
M$@D8^Z2*- .NLKR'4;*&\MBYAF4.A>-HR0>AVL 1^(JQ573OMW]G6_\ ::VZ
MWH0"86S%H]WJNX X/7!''3GK5JI **** "BBB@ HHHH *X/Q%J-OX6^(NGZ_
MJC&+2KRP;3FN2"4MY1)O7=Z!AD9]J[RHY[>&Z@>"XACFAD&UXY%#*P]"#P::
M=@.4NOB'H[ZKIVE:%<6VMW]Y,%:.SN ZPQ?QRNRA@ H['DUD>*-3C\!>,I?$
M<HQIVJV#QSCH&NH5+1<^K+N0>I KM]-T/2-&$@TK2K&Q\S&_[+;I%NQZ[0,U
M->Z?9:E$D5]9V]U&CB14GB#A6'1@".H]:=TF!Y[=Z-/HWP.UQ;WG4KRRN+V^
M;N9I06;\LA?^ ULK\1/".F>'([B7Q%I<C06RDPPW:22,0H^4*I))[5UMS;07
MEM);74$<\$JE)(I4#*ZGJ"#P167:>$?#5A<I<V?A[2;:X0Y26&RC1E/L0N11
M=/<"A\.K"YT[P)ID-Y$T-Q(KSM$W6/S'9POX!@,5U%%%2W=W **** "BBB@
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M *"M><UZ-X!_Y 4__7RW_H*UZV2_[VO1DRV.JHHHK[$S"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#R
M*;M-.)P*3=[5E-0OJ FTT;32[O:C=[5%J?<8FTT;32[O:C=[46I]P$VFC::7
M=[4;O:BU/N FTT;32[O:C=[46I]P$VFC::7=[4;O:BU/N FTT;32[O:C=[46
MI]P$VFC::7=[4;O:BU/N FTT;32[O:C=[46I]P$VFC::7=[4;O:BU/N FTT;
M32[O:C=[46I]P$VFC::7=[4;O:BU/N FTT;32[O:C=[46I]P$VFC::7=[4;O
M:BU/N FTT;32[O:C=[46I]P$VFC::7=[4;O:BU/N FTT;32[O:C=[46I]P$V
MFC::7=[4;O:BU/N FTT;32[O:C=[46I]P$VFC::7=[4;O:BU/N FTT;32[O:
MC=[46I]P$VFC::7=[4;O:BU/N FTT;32[O:C=[46I]P$VFC::7=[4;O:BU/N
M FTT;32[O:C=[46I]P$VFC::7=[4;O:BU/N FTT;32[O:C=[46I]P$VFC::7
M=[4;O:BU/N FTT;32[O:C=[46I]P$VFC::7=[4;O:BU/N FTT;32[O:C=[46
MI]P$VFC::7=[4;O:BU/N FTT;32[O:C=[46I]P$VFC::7=[4;O:BU/N FTT;
M32[O:C=[46I]P$VFC::7=[4;O:BU/N FTT;32[O:C=[46I]P$VFC::7=[4;O
M:BU/N!PGB'PQJNH:[<W5O K1/MVDR =% _F*R_\ A#-;_P"?9/\ OZO^-=-J
M_C/^RM4FLOL'F^7M^?SMN<J#TVGUJE_PL3_J%_\ DQ_]C7@5J66.I)SJ.]W?
M??[BDY&-_P (9K?_ #[)_P!_5_QH_P"$,UO_ )]D_P"_J_XUL_\ "Q/^H7_Y
M,?\ V-'_  L3_J%_^3'_ -C6?L<I_P"?C_'_ .1'>1C?\(9K?_/LG_?U?\:/
M^$,UO_GV3_OZO^-;/_"Q/^H7_P"3'_V-'_"Q/^H7_P"3'_V-'L<I_P"?C_'_
M .1"\C&_X0S6_P#GV3_OZO\ C1_PAFM_\^R?]_5_QK9_X6)_U"__ "8_^QH_
MX6)_U"__ "8_^QH]CE/_ #\?X_\ R(7D8W_"&:W_ ,^R?]_5_P :/^$,UO\
MY]D_[^K_ (UL_P#"Q/\ J%_^3'_V-'_"Q/\ J%_^3'_V-'L<I_Y^/\?_ )$+
MR,;_ (0S6_\ GV3_ +^K_C1_PAFM_P#/LG_?U?\ &MG_ (6)_P!0O_R8_P#L
M:/\ A8G_ %"__)C_ .QH]CE/_/Q_C_\ (A>1C?\ "&:W_P ^R?\ ?U?\:[/P
MEIEUI6E2P7:!)&G+@!@>-JCM]#6+_P +$_ZA?_DQ_P#8UT>@:S_;E@]S]G\C
M9*8]N_=G !SG ]:[<OIX"-:]";<O/_AD)WMJ:M%%%>\0%%%% !1110 4444
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M:K\0SF=8TJ]NO'?AG4H8=UI91W8N)-ZC8710O!.3D@] :R+RP\4^%-=U&_\
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MI[55_P"$$TC^]<_]_!_A7.>*-4U"W\1W<4-]<Q1KLPB3, /D7L#6/_;6J_\
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M2I\K[B:=CI:***]X@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?C&>^:X[0HW\-Z3%XVM$9HH;Z[MM7B3)\RU-R^),#JT9.?\ =+4^5- >A_\
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MSD>GXUPE^?%A^*FM'PI_8FXZ?:&?^U/-QC,FW;Y?XYS[4[PM_P )%_PMV_\
M^$F_LO[;_8B;?[,\SR]GG'&=_.<Y]NE'*!Z=1114@%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!D>)O$=CX4T.;5K]9GAC94$<"AI)&8X"J"1D_
MCV-:%E=P:A8V]Y;2"2WN(UEC<=&5AD'\C7FWCGQ&H\?:3IYT;5]7LM*0WMS#
MI=I]H(F<,L0<9& !O;KSD4?#G5[Z;PKKGAZSM;NQU+3#)_9T&IQ>5*L+AC!O
M4YZ'(], 57+I<#U"J=CJEGJ4MY':3"1K.<V\X"D;)  Q'/7AATKQOPOJFI:-
MXETV/7]1\9Z?>33"&Y75E%S87#L,;(G&-A+$$$9 QBF)IUWH'AOXA:E8:[JY
MNH=2-O'YMV2N<PGS#@ [SG:3_=XI\@'N=4M7U+^R-*N+_P"Q7E[Y*@_9[*+S
M)GY PJY&3S7F_B>RO-"L-.T6'Q+XKO[O4)Y;B:.RVR7<H"KG9(2%@B5B. #]
M['K4GPYUO4-._P"$HM/$ES?PVNDF*53JUTMQ/"CH6.^11@] 0.V<4N72X%F^
M^,EAI< GU'PCXOLX68()+C35C4L>@RS@9]J]&1M\:O@C< <,.17 :!IUUXVU
MV#QCK43Q:;;DG1-.D'W0?^7B0?WVZJ.PP>O-<SXOU[4=1\<ZIILG_";+I^G"
M*.)?"T()+LFYFE?K_$ %Z<9I\J>B ]GHKQ^76/$^H^!=)BDN=7TG4#K\5DEW
M=VQMYY(23M=T^ZW!P1RI*U=$^J> ]>UVU&M:CK-FFA2:I$NIS>8Z2HQ4@-@8
M4\<"ER@>IT5\_P"GZ]XCMEM-8MXOB1>ZLYC>>*ZT_.GS*2-X6-?NC'1AS[<U
MW5YI^I^-/&6N6G_"2:KH]GI'DQV\.G2B)G=XPY>0X.X<X"]./K0X6 ]&HKSC
MQO-J5IIN@Z(VM:U<:A,K>>NAVJI=7811E]Y;$*@D$]<D@"F?"N^UK[?XBT?5
MWU+%A)"T,>IW*W%P@D0L0TB@ YP"!VSBCETN!Z51114@%%%% !1110!Y=XN_
MY&B\_P" ?^@+6)6WXN_Y&B\_X!_Z M8E?&8K^//U?YFJV"BBBL "BBB@ HHH
MH **** "BBB@ KT;P#_R I_^OEO_ $%:\YKT;P#_ ,@*?_KY;_T%:];)?][7
MHR9;'54445]B9A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (S!!EC@
M4SSX_P"]^E)<?ZK\:J4Q7+GGQ_WOTH\^/^]^E4Z*+!<N>?'_ 'OTH\^/^]^E
M4Z*+!<N>?'_>_2CSX_[WZ53HHL%RYY\?][]*//C_ +WZ53HHL%RYY\?][]*/
M/C_O?I5.BBP7+GGQ_P![]*//C_O?I5.BBP7+GGQ_WOTH\^/^]^E4Z*+!<N>?
M'_>_2CSX_P"]^E4Z*+!<N>?'_>_2CSX_[WZ53HHL%RYY\?\ >_2CSX_[WZ53
MHHL%RYY\?][]*//C_O?I5.BBP7+GGQ_WOTH\^/\ O?I5.BBP7+GGQ_WOTH\^
M/^]^E4Z*+!<N>?'_ 'OTH\^/^]^E4Z*+!<N>?'_>_2CSX_[WZ53HHL%RYY\?
M][]*//C_ +WZ53HHL%RYY\?][]*//C_O?I5.BBP7+GGQ_P![]*//C_O?I5.B
MBP7+GGQ_WOTH\^/^]^E4Z*+!<N>?'_>_2CSX_P"]^E4Z*+!<N>?'_>_2CSX_
M[WZ53HHL%RYY\?\ >_2CSX_[WZ53HHL%RYY\?][]*//C_O?I5.BBP7+GGQ_W
MOTH\^/\ O?I5.BBP7+GGQ_WOTH\^/^]^E4Z*+!<N>?'_ 'OTH\^/^]^E4Z*+
M!<N>?'_>_2CSX_[WZ53HHL%R;^TK+[8;/[5%]J$?FF#<-^S.-VWKC/&:F\^/
M^]^E<&I ^,4Q)P!H"9/_ &W:L9/%OCG4M-E\1:1HVD-H2;WBMYY9!=W$2DC<
MI VKG&0#^O%%@N>J^?'_ 'OTJ&XU*RM!']INHH?-D$4?F,%WN>BC/4GTKSJ]
M\8Z_J6M:;8^%++3IH]0TH:@DVH,Z"'+ ?-MR3P0-HYR<YP*@B\77U_HVFOJF
ME:?_ &C#X@CTRY1D,D:.#S)%GE3R"#SBBP'J7GQ_WOTJ*?4+2U17N+B.%6=8
MU:1MH+,<*!GN20 .Y->1WWQ(UT^)M2L=//AN&.PN3;BPU*Z>"[NL=XV.(QN_
MAS^-=;K#MJ/B3PWIS1E K/J,\9(.WRU"J"1_MR#_ +YH Z*^\3Z!I=PMOJ&M
M:?:3N,K'<7"1LWT!(-:*W,+J&60,K#((Y!%>/?V%;^'[[57U_P "R^(?M=W)
M.NIV\$=W(ZL<A3&Q#)M''R@CCBM73-6T_0/#&CKX8N&NM/N]86T,=WN+6JNQ
MWQ@?*5*GH&SC/?BBP7/3?/C_ +WZ4>?'_>_2N-U+6M6'BJ;0],2R\PZ2UW ]
MR'QYWF;0&*G[GK@9]ZP-"\1>.KKQM_8FH1^';BTMDWW\VG"<^1D':FYSC>3@
MXP>,]*+!<]+M=1LKVW6XM+J*XA;.V2)@ZG!P<$<=014WGQ_WOTKPSP[XF\4Z
M!X'L]3M]*L'\/VD[QW'FR/\ :90T[ N@'RA06QSDG!-=EJGB#Q1?^([W1_"=
MGI1&GI&;J[U-Y-A=QN"*J<YVX)/O18#T'SX_[WZ4>?'_ 'OTKS>'QSJ,FF67
MGV$%MJ:ZW'I5_ Q+JA/)9"".JE2"?7O6U<^(FL_&;:7<O;0Z='I;7TD\IVE"
M)-O+$X"X]OQHL%SKO/C_ +WZ4>?'_>_2L;3M8TS6(WDTS4K.^2,[7:VG64*?
M0E2<5=HL%RYY\?\ >_2CSX_[WZ53HHL%RYY\?][]*//C_O?I5.BBP7,75OB1
MX2T/4YM.U'5O(NX=OF1_9I6QD!ARJD=".]4O^%O>!?\ H.?^2D__ ,17AOQ7
M_P"2EZO_ -L?_1*5QE5RH5SZE_X6]X%_Z#G_ )*3_P#Q%'_"WO O_0<_\E)_
M_B*^6J*.5!<^I?\ A;W@7_H.?^2D_P#\11_PM[P+_P!!S_R4G_\ B*^6J*.5
M!<^I?^%O>!?^@Y_Y*3__ !%'_"WO O\ T'/_ "4G_P#B*^6J*.5!<^I?^%O>
M!?\ H.?^2D__ ,11_P +>\"_]!S_ ,E)_P#XBOEJBCE07/J7_A;W@7_H.?\
MDI/_ /$4?\+>\"_]!S_R4G_^(KY:HHY4%SZE_P"%O>!?^@Y_Y*3_ /Q%'_"W
MO O_ $'/_)2?_P"(KY:HHY4%SZE_X6]X%_Z#G_DI/_\ $4?\+>\"_P#0<_\
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M_0<_\E)__B*^6J*.5!<^I?\ A;W@7_H.?^2D_P#\11_PM[P+_P!!S_R4G_\
MB*^6J*.5!<^I?^%O>!?^@Y_Y*3__ !%'_"WO O\ T'/_ "4G_P#B*^6J*.5!
M<^NM \=^&_$]\]EH^I?:;A(C*R>1(F$! )RR@=6'YUT5?.WP$_Y'F]_[!LG_
M *-BKZ)J6K#04444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% $5Q_JOQJI5NX_U7XU4IH3.;
MU?5+VU\<>&].AFVVEXEV;B/:#O*(I7DC(P2>A%9-Y?>)_%.MZA8^'-2@T;3M
M-E\B:_>V%Q)--@%E5&^4*N0"3WZ5:U__ )*7X/\ ^N5]_P"BTK*CU^U^'>LZ
MQ;:_'/!I5_>O?6FH)"TD>9 -\;;02K!AQQR#VH TM&U3Q!HWB2W\.^);F#45
MO8GDLM2AA$)=DY9)$' .#D$<5G^ /&6I:IJ=]I6N,&F>:>73IP@42PI*T;)P
M -R$#W(8&I+#5%\=>,M*U32[>?\ L/2%FD%[-$T8N)G78%C#8) !))Q6;H^A
MW&K_  _%QIK+'K&GZI=W5A(V<>8)WRAQ_"XRI^OM0!--XKUI? ?B/4EO<7EG
MK3VL$GE)\D0G1 N,8/RL1DC/-;'C/6=7@UC2-#TK4;32#J"RL^HW48<)LQA$
M5B%9SNZ'L*X.SO'U#X->)+R2!K>2?7#(T+]8R;B(E3[CI7=>-M7@TR\MH_$.
MCQ7WA6>(B>;[(9S;3@_*SCG"$$X(7(/?F@"SH5OXQTO6$M-8U"#7--FB9OMR
MVZ6TD#C&%9 <,I&<$#.>M=97DOA6;1KCQC9CX>&]31S%,=4;9*+0$K^[VK)T
MDW8^Z!QGWK3UG_A*?"OAO4)-0\5_VS=WX2QT^+[!';%)Y#M# J220"3C_9H
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M;?[*%!W;Y,KL7&5."?H:]!\!0QI<^*Y511))KDX9L<G 7% '94444Q!1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"V/_HE*XRO>/&GP?UCQ+XMOM7MM1L8H;CR]J2;]PVQJIS@>JU@?\*"U_\
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M $%M-_.3_P")H_X4%K__ $%M-_.3_P")HN@LSR:BO6?^%!:__P!!;3?SD_\
MB:/^%!:__P!!;3?SD_\ B:+H+,\FHKUG_A06O_\ 06TW\Y/_ (FC_A06O_\
M06TW\Y/_ (FBZ"S/)J*]9_X4%K__ $%M-_.3_P")H_X4%K__ $%M-_.3_P")
MHN@LSR:BO6?^%!:__P!!;3?SD_\ B:/^%!:__P!!;3?SD_\ B:+H+,\FHKUG
M_A06O_\ 06TW\Y/_ (FC_A06O_\ 06TW\Y/_ (FBZ"S/)J*]9_X4%K__ $%M
M-_.3_P")H_X4%K__ $%M-_.3_P")HN@LR'X"?\CS>_\ 8-D_]&Q5]$UY;\-O
MACJ?@OQ%<:E>WMI/'+:- %AW9!+HV>0./E->I5#W*04444AA1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% #)7*)D8_&H/M+^BU+<?ZK\:J4T)DWVE_1:/M+^BUDZEKNCZ,T:ZIJ
MMC8M*"8Q=7"1;\=<;B,]13].UG2]71GTS4K.]5/O&VG60+]=I- &G]I?T6C[
M2_HM0T4 3?:7]%H^TOZ+4-% $WVE_1:/M+^BU#4,]W;6HC-Q<10B6011^8X7
M>YZ*,]2?2@"Y]I?T6C[2_HM0T4 3?:7]%H^TOZ+4-% $WVE_1:/M+^BU#10!
M-]I?T6C[2_HM0T4 3?:7]%H^TOZ+4-% $WVE_1:/M+^BU#10!-]I?T6C[2_H
MM0T4 3?:7]%H^TOZ+4-% $WVE_1:/M+^BU#10!-]I?T6C[2_HM0T4 3?:7]%
MH^TOZ+4-1S3Q6T+S3RI%$@R[R,%51ZDGI0!:^TOZ+1]I?T6LK3M;TG6!(=+U
M2ROO+QO^RW"2[<^NTG%7Z )OM+^BT?:7]%J&B@";[2_HM'VE_1:AHH F^TOZ
M+1]I?T6H:* )OM+^BT?:7]%J&B@";[2_HM'VE_1:AHH F^TOZ+1]I?T6H:*
M)OM+^BT?:7]%J&B@";[2_HM'VE_1:AHH F^TOZ+1]I?T6H:* )OM+^BT?:7]
M%J&B@";[2_HM'VE_1:AHH F^TOZ+1]I?T6J=W>6UA:R75Y<0VUO&,O+,X1%^
MI/ J4$,H92"",@CO0!/]I?T6C[2_HM0T9'Y4 3?:7]%H^TOZ+4-0W=Y:V%K)
M=7ES#;6\8R\LSA$4>Y/ H N?:7]%H^TOZ+7-_P#";^$_^AHT7_P81?\ Q5;H
M(90RD$$9!'>@"?[2_HM'VE_1:AHH F^TOZ+1]I?T6H:* )OM+^BT?:7]%J&B
M@";[2_HM'VE_1:AHH F^TOZ+1]I?T6H:* )OM+^BT?:7]%J&B@#R7QM\7O$'
MAOQ??:19V>F26]OY>QIHI"QW1JQR0X'5CVK _P"%]^*?^?#1_P#OS+_\<KG_
M (K_ /)2]7_[8_\ HE*XRJLB;L]3_P"%]^*?^?#1_P#OS+_\<H_X7WXI_P"?
M#1_^_,O_ ,<KRRBG9!=GJ?\ POOQ3_SX:/\ ]^9?_CE'_"^_%/\ SX:/_P!^
M9?\ XY7EE%%D%V>I_P#"^_%/_/AH_P#WYE_^.4?\+[\4_P#/AH__ 'YE_P#C
ME>6446079ZG_ ,+[\4_\^&C_ /?F7_XY1_POOQ3_ ,^&C_\ ?F7_ ..5Y911
M9!=GJ?\ POOQ3_SX:/\ ]^9?_CE'_"^_%/\ SX:/_P!^9?\ XY7EE%%D%V>I
M_P#"^_%/_/AH_P#WYE_^.4?\+[\4_P#/AH__ 'YE_P#CE>6446079ZG_ ,+[
M\4_\^&C_ /?F7_XY1_POOQ3_ ,^&C_\ ?F7_ ..5Y9119!=GJ?\ POOQ3_SX
M:/\ ]^9?_CE'_"^_%/\ SX:/_P!^9?\ XY7EE%%D%V>I_P#"^_%/_/AH_P#W
MYE_^.4?\+[\4_P#/AH__ 'YE_P#CE>6446079ZG_ ,+[\4_\^&C_ /?F7_XY
M1_POOQ3_ ,^&C_\ ?F7_ ..5Y9119!=GJ?\ POOQ3_SX:/\ ]^9?_CE'_"^_
M%/\ SX:/_P!^9?\ XY7EE%%D%V>I_P#"^_%/_/AH_P#WYE_^.4?\+[\4_P#/
MAH__ 'YE_P#CE>6446079ZG_ ,+[\4_\^&C_ /?F7_XY1_POOQ3_ ,^&C_\
M?F7_ ..5Y9119!=GJ?\ POOQ3_SX:/\ ]^9?_CE'_"^_%/\ SX:/_P!^9?\
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M(!*?*%Z=!T[4P,CP_P#$?6M1\3KH,USX9OKBZ@E:WDTN29DAD52P$I;A@?\
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M@ HHHH **** "BBB@ HHHH ])^"?_(YWG_8/?_T9'7O->#?!/_D<[S_L'O\
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M!6>$?,JG/7)QQ5S6_&>H6NMSZ5H/AJXUJ>S19+UDN%@6$,,JH+#YV(YVCV_
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M%% !1110 4444 %%%% !1110 4444 ?/GQ+_ .2@ZI_VR_\ 125R==9\2_\
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M#_OPU'_"$^*/^@!J'_?AJ];_ .%V>&_^?'5O^_4?_P <H_X79X;_ .?'5O\
MOU'_ /'*/:5/Y0^N8_\ Y\GDG_"$^*/^@!J'_?AJ/^$)\4?] #4/^_#5ZW_P
MNSPW_P ^.K?]^H__ (Y1_P +L\-_\^.K?]^H_P#XY1[2I_*'US'_ //D\D_X
M0GQ1_P! #4/^_#4?\(3XH_Z &H?]^&KUO_A=GAO_ )\=6_[]1_\ QRC_ (79
MX;_Y\=6_[]1__'*/:5/Y0^N8_P#Y\GDG_"$^*/\ H :A_P!^&H_X0GQ1_P!
M#4/^_#5ZW_PNSPW_ ,^.K?\ ?J/_ ..4?\+L\-_\^.K?]^H__CE'M*G\H?7,
M?_SY/)/^$)\4?] #4/\ OPU'_"$^*/\ H :A_P!^&KUO_A=GAO\ Y\=6_P"_
M4?\ \<H_X79X;_Y\=6_[]1__ !RCVE3^4/KF/_Y\GDG_  A/BC_H :A_WX:C
M_A"?%'_0 U#_ +\-7K?_  NSPW_SXZM_WZC_ /CE'_"[/#?_ #XZM_WZC_\
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M'_\ '*/:5/Y0^N8__GR>2?\ "$^*/^@!J'_?AJ/^$)\4?] #4/\ OPU>M_\
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M9%< <YVY!S7'^)_LEG\1KN\U7P7J.OVDNG01PO;Z6+I8W#N6Y;@'!'2O4:*
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ])^"?_ ".=Y_V#W_\
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MK=%'MI]P_M3%_P _X+_(\D_X49;?]!Z7_P !A_\ %4?\*,MO^@]+_P" P_\
MBJ];HH]M/N']J8O^?\%_D>2?\*,MO^@]+_X##_XJC_A1EM_T'I?_  &'_P 5
M7K=%'MI]P_M3%_S_ (+_ ".&\&?#>'P?K$VH1ZF]T9+<P;&A"XRRMG.3_=_6
MNYHHK.4G)W9RUJTZTN>H[L****1D%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
( !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>image16.jpg
<TEXT>
begin 644 image16.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #V!$T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BN8\?ZS
M>Z#X0NM0T^01W,;QA690PY8 \'VKQW_A;'B__G_B_P# =/\ "@#Z)HKYV_X6
MQXO_ .?^+_P'3_"C_A;'B_\ Y_XO_ =/\*=@/HFBOG;_ (6QXO\ ^?\ B_\
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MPMCQ?_S_ ,7_ (#I_A1_PMCQ?_S_ ,7_ (#I_A18#Z)HKYV_X6QXO_Y_XO\
MP'3_  H_X6QXO_Y_XO\ P'3_  HL!]$T5\[?\+8\7_\ /_%_X#I_A1_PMCQ?
M_P _\7_@.G^%%@/HFBOG;_A;'B__ )_XO_ =/\*/^%L>+_\ G_B_\!T_PHL!
M]$T5\[?\+8\7_P#/_%_X#I_A1_PMCQ?_ ,_\7_@.G^%%@/HFBOG;_A;'B_\
MY_XO_ =/\*/^%L>+_P#G_B_\!T_PHL!]$T5\[?\ "V/%_P#S_P 7_@.G^%'_
M  MCQ?\ \_\ %_X#I_A18#Z)HKYV_P"%L>+_ /G_ (O_  '3_"C_ (6QXO\
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M_P +8\7_ //_ !?^ Z?X4?\ "V/%_P#S_P 7_@.G^%%@/HFBOG;_ (6QXO\
M^?\ B_\  =/\*/\ A;'B_P#Y_P"+_P !T_PHL!]$T5\[?\+8\7_\_P#%_P"
MZ?X4?\+8\7_\_P#%_P" Z?X46 ^B:*^=O^%L>+_^?^+_ ,!T_P */^%L>+_^
M?^+_ ,!T_P *+ ?1-%?.W_"V/%__ #_Q?^ Z?X4?\+8\7_\ /_%_X#I_A18#
MZ)HKYV_X6QXO_P"?^+_P'3_"C_A;'B__ )_XO_ =/\*+ ?1-%?.W_"V/%_\
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M_P"?^+_P'3_"BP'T317SM_PMCQ?_ ,_\7_@.G^%'_"V/%_\ S_Q?^ Z?X46
M^B:*^=O^%L>+_P#G_B_\!T_PH_X6QXO_ .?^+_P'3_"BP'T317SM_P +8\7_
M //_ !?^ Z?X4?\ "V/%_P#S_P 7_@.G^%%@/HFBOG;_ (6QXO\ ^?\ B_\
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MPMCQ?_S_ ,7_ (#I_A1_PMCQ?_S_ ,7_ (#I_A18#Z)HKYV_X6QXO_Y_XO\
MP'3_  H_X6QXO_Y_XO\ P'3_  HL!]$T5\[?\+8\7_\ /_%_X#I_A1_PMCQ?
M_P _\7_@.G^%%@/HFBOG;_A;'B__ )_XO_ =/\*/^%L>+_\ G_B_\!T_PHL!
M]$T5\[?\+8\7_P#/_%_X#I_A1_PMCQ?_ ,_\7_@.G^%%@/HFBOG;_A;'B_\
MY_XO_ =/\*/^%L>+_P#G_B_\!T_PHL!]$T5\[?\ "V/%_P#S_P 7_@.G^%'_
M  MCQ?\ \_\ %_X#I_A18#Z)HKYV_P"%L>+_ /G_ (O_  '3_"C_ (6QXO\
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M_P +8\7_ //_ !?^ Z?X4?\ "V/%_P#S_P 7_@.G^%%@/HFBOG;_ (6QXO\
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MG_Q5'_"M_%__ $!9?^_B?_%4 <K175?\*W\7_P#0%E_[^)_\51_PK?Q?_P!
M67_OXG_Q5 '*T5UC_#/Q@@R=%?GTFC/\FIO_  K?Q?\ ] 67_OXG_P 50!RM
M%=5_PK?Q?_T!9?\ OXG_ ,51_P *W\7_ /0%E_[^)_\ %4 <K175?\*W\7_]
M 67_ +^)_P#%4?\ "M_%_P#T!9?^_B?_ !5 '*T5U7_"M_%__0%E_P"_B?\
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ME_[^)_\ %4 <K175?\*W\7_] 67_ +^)_P#%4?\ "M_%_P#T!9?^_B?_ !5
M'*T5U0^&WB\D :++SZRQC_V:G/\ #3Q@AP=%D_":,_R:@#DZ*ZK_ (5OXO\
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MM?\ "GCCQ#JC7MSH;1@*(XH8W0)%&.BJ-W05E_\ "M_%_P#T!9?^_B?_ !5
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M_A6_B_\ Z LO_?Q/_BJ/^%;^+_\ H"R_]_$_^*H Y6OH_P"%O_).-)_[;?\
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MS72V7AR1M9CU7POXOL+^[$GF)'<RM!/*<YVE3RV>AR1F@#J?^%WZ;_T![O\
M[^+1_P +OTW_ * ]W_W\6O)->DNY=>OI+ZU2UNVF8S0HI54?/. 2>_O6=181
M[9_PN_3?^@/=_P#?Q:/^%WZ;_P! >[_[^+7B=%%@/;/^%WZ;_P! >[_[^+1_
MPN_3?^@/=_\ ?Q:\3HHL![9_PN_3?^@/=_\ ?Q:=%\:].EE2,:1= NP7/F+W
MKQ&IK3_C]@_ZZ+_.BP'TIXP\86_@^TMKBXM9;@3R% (V Q@9[UR/_"[]-_Z
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M_D :G_U]#_T$4#$;XVZ:KLO]CW?!Q_K%I/\ A=^F_P#0'N_^_BUXM+_KI/\
M>-,HL(]L_P"%WZ;_ - >[_[^+6QH?Q%N/$BS-I/AJ[N1 0)/])B3;G./O$>A
MKY[KOO!>E7NM>!?$]AI\/G74KVVQ-ZKG#$GDD#H*!GJ6H^+]7TFR>[O/"%^L
M$8R[)<12;1W)"DD#WK&TSXMPZQ?+9V&@W<UPRLP3SD7( R>20.@KEO"GAK6O
M!>J2:QK_ )>GZ9% XF1KA&-QE2 @52<G.#SZ5@_#0!_'=L 0H:*8 D\#]VU
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MS1%)XT>,]5=01^M5/[/TG_GRL_\ ORO^%""S9\GT5]8?V?I/_/E9_P#?E?\
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MVH64I*O>/-#( 0<;R5//([5].?V?I/\ SY6?_?E?\*/[/TG_ )\K/_ORO^%
M<K/"+VX\)^+IO[3O]4FT+4Y /M2_96N(I6QC<FWE<]\__7-'6M9TBST#_A'O
M#QGEMY)1-=WDZ[6G9?NA5[*.O//]?H7^S])_Y\K/_ORO^%']GZ3_ ,^5G_WY
M7_"@.5GSCIFJ6=OX(U[3I9MMW=2V[0Q[2=P5B6YQ@8]ZV_AWXPL=&F^P:XW_
M !+UD^T6\I4L;>4#&0 "<,"1Q_4U[G_9^D_\^5G_ -^5_P */[/TG_GRL_\
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M*22/@G:H().!S4&LW$5WKNH7,#;X9KF21&P1E2Q(//M7T7_;/@K_ )^]&_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#U3X,_\QO\
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M!'D23HH+SAHPF">K@9 QSCI27_@7Q9JEU<V]Y/X8D@N T3ZN=/QJ!B/!' "
M[?EX/2O0CHVFR)9+-8V\YL0/LSS1*[1$  %21D'@<CTI$J+/'M._X0#_ (5Y
M?_\ "0?V=_;^+C[;]HV?;?M&XYVY^?KC&WC]:V],T6'7/&'AU?$ME'>W,/AE
M))([I X\TN 2RG@GD]>YKT270='GU%=1FTFQDOEP5N7MD,@QTPQ&?UJU]DMO
MMGVS[/%]J$?E>=L&_9G.W=UQGG%.Q7*<C\.+6&PM/$%C;(([:WUJX2&,=$7Y
M3@>W-><>)+73;35_$%Q#?^$M3AENI9+JSUI#!?1-_$D3\.1_=(..F,U[K!:6
MUJ9?L]O%#YLAED\M N]SU8XZD^M5+K0-&O;Y;Z[TBPN+M,;9Y;9&D7'3#$9H
ML#C=6#0+T:CX=TV]6WDMUGMHY!#(Q9D!4'!)Y/U[UYE:KX*,_BI?& LCK)U"
M;<+O!N#%QY7D_P 7W<8V<UZ]5*YT?3+R\AO+K3K2>ZA_U4\L"L\?^ZQ&1^%
MVKGEO@_ L?AF?FQLONO7[K?K7*/_ &9H$ N;>X\)Z_8PW/G*L@:UU?<),@9&
M'W ^O7'3%>_0Z3IUN+40:?:Q"TW?9PD*KY.[[VS ^7/?'6HAH&C#4O[2&D6
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M6W_?\4?\*L\3?\\K;_O^*VO^%R7'_0%B_P# @_\ Q-'_  N2X_Z L7_@0?\
MXFB\B_:YQ_)'\/\ ,Q?^%6>)O^>5M_W_ !1_PJSQ-_SRMO\ O^*VO^%R7'_0
M%B_\"#_\31_PN2X_Z L7_@0?_B:+R#VN<?R1_#_,Q?\ A5GB;_GE;?\ ?\4?
M\*L\3?\ /*V_[_BMK_A<EQ_T!8O_  (/_P 31_PN2X_Z L7_ ($'_P")HO(/
M:YQ_)'\/\S%_X59XF_YY6W_?\4?\*L\3?\\K;_O^*VO^%R7'_0%B_P# @_\
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M:+R#VN<?R1_#_,Q?^%6>)O\ GE;?]_Q1_P *L\3?\\K;_O\ BMK_ (7)<?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6%PRO&T+[L$=1\H_*NTH$F%%%%,84444 %%%% !1110 4444 %%%% !1110
M5QWBSPS)XNU_2M/U&S:3P[;I)<W)\[:)9L;8T^5@_ +-GITYKL:*0-7/.I_A
MQ8>&-3TO6?!NE-'=V]T%NHA=,1+;L"KC]XQ&1D$?2CS/&/A[Q3XAFTWP=_:M
MG?W23QS_ -IPP<")%(VMD]5/7%>BT46%RKH<7?KXPU32M.UBSLETO6+.9VDT
MF:]\R&YC(QM9DPN>A4D<&L^6U\6^,-6TC^UO#MMH5IIUXEXTQO4N9I"O14V
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML:XIJL_Q.X_X59X9_P">5S_W_-'_  JSPS_SRN?^_P":X?\ M74?^?\ NO\
MO\W^-']JZC_S_P!U_P!_F_QI?V_'^1_>5]6QW_/]_B=Q_P *L\,_\\KG_O\
MFC_A5GAG_GE<_P#?\UP_]JZC_P _]U_W^;_&C^U=1_Y_[K_O\W^-']OQ_D?W
MA]6QW_/]_B=Q_P *L\,_\\KG_O\ FC_A5GAG_GE<_P#?\UP_]JZC_P _]U_W
M^;_&C^U=1_Y_[K_O\W^-']OQ_D?WA]6QW_/]_B=Q_P *L\,_\\KG_O\ FC_A
M5GAG_GE<_P#?\UP_]JZC_P _]U_W^;_&C^U=1_Y_[K_O\W^-']OQ_D?WA]6Q
MW_/]_B=Q_P *L\,_\\KG_O\ FC_A5GAG_GE<_P#?\UP_]JZC_P _]U_W^;_&
MC^U=1_Y_[K_O\W^-']OQ_D?WA]6QW_/]_B=Q_P *L\,_\\KG_O\ FC_A5GAG
M_GE<_P#?\UP_]JZC_P _]U_W^;_&C^U=1_Y_[K_O\W^-']OQ_D?WA]6QW_/]
M_B=Q_P *L\,_\\KG_O\ FC_A5GAG_GE<_P#?\UP_]JZC_P _]U_W^;_&C^U=
M1_Y_[K_O\W^-']OQ_D?WA]6QW_/]_B=Q_P *L\,_\\KG_O\ FC_A5GAG_GE<
M_P#?\UP_]JZC_P _]U_W^;_&C^U=1_Y_[K_O\W^-']OQ_D?WA]6QW_/]_B=Q
M_P *L\,_\\KG_O\ FC_A5GAG_GE<_P#?\UP_]JZC_P _]U_W^;_&C^U=1_Y_
M[K_O\W^-']OQ_D?WA]6QW_/]_B=Q_P *L\,_\\KG_O\ FC_A5GAG_GE<_P#?
M\UP_]JZC_P _]U_W^;_&C^U=1_Y_[K_O\W^-']OQ_D?WA]6QW_/]_B=Q_P *
ML\,_\\KG_O\ FC_A5GAG_GE<_P#?\UP_]JZC_P _]U_W^;_&C^U=1_Y_[K_O
M\W^-']OQ_D?WA]6QW_/]_B=Q_P *L\,_\\KG_O\ FC_A5GAG_GE<_P#?\UP_
M]JZC_P _]U_W^;_&C^U=1_Y_[K_O\W^-']OQ_D?WA]6QW_/]_B=Q_P *L\,_
M\\KG_O\ FC_A5GAG_GE<_P#?\UP_]JZC_P _]U_W^;_&C^U=1_Y_[K_O\W^-
M']OQ_D?WA]6QW_/]_B=Q_P *L\,_\\KG_O\ FC_A5GAG_GE<_P#?\UP_]JZC
M_P _]U_W^;_&C^U=1_Y_[K_O\W^-']OQ_D?WA]6QW_/]_B=Q_P *L\,_\\KG
M_O\ FC_A5GAG_GE<_P#?\UP_]JZC_P _]U_W^;_&C^U=1_Y_[K_O\W^-']OQ
M_D?WA]6QW_/]_B=Q_P *L\,_\\KG_O\ FC_A5GAG_GE<_P#?\UP_]JZC_P _
M]U_W^;_&C^U=1_Y_[K_O\W^-']OQ_D?WA]6QW_/]_B=Q_P *L\,_\\KG_O\
MFC_A5GAG_GE<_P#?\UP_]JZC_P _]U_W^;_&C^U=1_Y_[K_O\W^-']OQ_D?W
MA]6QW_/]_B=Q_P *L\,_\\KG_O\ FC_A5GAG_GE<_P#?\UP_]JZC_P _]U_W
M^;_&C^U=1_Y_[K_O\W^-']OQ_D?WA]6QW_/]_B=Q_P *L\,_\\KG_O\ FC_A
M5GAG_GE<_P#?\UP_]JZC_P _]U_W^;_&C^U=1_Y_[K_O\W^-']OQ_D?WA]6Q
MW_/]_B=Q_P *L\,_\\KG_O\ FC_A5GAG_GE<_P#?\UP_]JZC_P _]U_W^;_&
MC^U=1_Y_[K_O\W^-']OQ_D?WA]6QW_/]_B=Q_P *L\,_\\KG_O\ FC_A5GAG
M_GE<_P#?\UP_]JZC_P _]U_W^;_&C^U=1_Y_[K_O\W^-']OQ_D?WA]6QW_/]
M_B=Q_P *L\,_\\KG_O\ FC_A5GAG_GE<_P#?\UP_]JZC_P _]U_W^;_&C^U=
M1_Y_[K_O\W^-']OQ_D?WA]6QW_/]_B=Q_P *L\,_\\KG_O\ FC_A5GAG_GE<
M_P#?\UP_]JZC_P _]U_W^;_&C^U=1_Y_[K_O\W^-']OQ_D?WA]6QW_/]_B>I
M^'_"VF>&?M']G)*OVC;YF]]WW<X_]"-;5<3\/;JXN?[1^T3RR[?*V^8Y;'W_
M %KMJ];#8A8BDJJ5K_\ #'A8V,XUY1J2YGIK\@HHHK<Y0HHHH **** "BBB@
M HHHH 1NE,I[=*Y?Q]KTOAWP=?7EJCR7\@%O9QH-SO-(=JA1W()SCVKGJJ\K
M#)_#OB_2_$]SJ<&G-(7T^<PR;P 'Y(#I@G*$JP!X^Z:MPZY;3>)+K0U2875M
M;1W+N0-A5V8  YSGY3V]*\BT#7(/#_BCPR8/#OB/2[$VBZ1?3ZI8^1'(Q.8G
MW9(W>86SGLQK7\4V'B75OB-KFG>'+N"Q>?18//NI"=R@/+M1,="Q."W8 ]\5
M+BK@=]I_BBRU77[W2K"&XN!9?+<WB*OV>.3_ )Y;B<EQW ! [D&L*\^*.DPW
MDT&GZ1KVLQ6[F.>ZTNP,T,;#J"^1G'MFHO#]Y:W/PNO[/0;#^SKZQM9K66P&
M=]O<JAR">K$MR&_BSGK6UX ^P#P!H0TW9]F^QQXV?WL?/GWW;L^^:5D@([WQ
MYHUMX.3Q1;?:=0T^1T2-;./=*[,X0*%8CG<<8/-94?Q/\R5(_P#A!O&R;F W
M-I. ,]S\_2LSQO/I<G@?4(O# M1-#KD"2_NV6+[5Y\9;<<?-R1DKFM>S_P"%
MJ?;8/MO_  AOV3S%\[R?M6_9GYMN>,XSC-.RL!T/B;Q'8^%-#FU:_69X8V5!
M' H:21F. J@D9/X]C6A97<&H6-O>6T@DM[B-98W'1E89!_(UYMXY\1J/'VDZ
M>=&U?5[+2D-[<PZ7:?:")G#+$'&1@ ;VZ\Y%+\-_$IL_#6L:9-I>KH^B.\EM
M836Q%V]JV6C C)Y;JHP<<"ERZ7 [;Q)XA_X1RRBN?['U?5/,D\ORM,MO/=>"
M=Q&1@<8S[BN8T[XKVVJ78M[;PAXN.)Q;RR'31LA?(!#D.=N,Y.>E=+X;\2?\
M));SS?V+K&E^4X79JEKY#/D9RHR<BLGP#_K/%7_8>N?Y)1I;4"CJ?Q5MM)O&
MM[GPCXMXN/L\<JZ:-DSY(&PEQNSCCUJZWQ%MH?#-UKEWX>\0V<<$\< MKFR$
M<\K.0 44M\PRP'6E^(/^K\-_]AZT_F:A^*WVC_A"?]$\K[3]OL_*\W.S?YZ8
MW8YQG&<4TD[ 5S\6=/MRKZIX9\4Z5:%@K7E_IACACR<#<P8X_*N^!#*&4@@C
M(([UX]XFNOB!<S6OAKQ/<>']-TG66^ROJ-A#-)R?^67SG"LPR 2 /0YKN4\5
MK:>(HO#B>'/$3(C+"NH"RS:XV@Y\S=T[$XZTG'L!K:'KEMK]G-=6J3(D5S+;
M,)0 =T;E&(P3QD<5IUQOPU_Y%Z__ .PO??\ H]ZU;[Q&]MK,NEVFB:EJ,\,"
M3R-;- JHKE@O^LE0D_(W0&DUJ!NT5@VGBW3KI+.1DGMX[J.4AYU"B-XB1)$_
M/#C#>HPC8)Q6KI]X-0T^"\6":!9EWK', ' /3(!.,CG'7GG!XI6 LT444 %%
M%% !1110 4444 %%%% !1110 4444 %,EEC@A>65PD:*69F.  .233ZX3XKZ
MQ)8^%5TNVAN[BZU>46@ALH_,G,6,RE%[D("/^!"FE=V Z#PKXJT[QAH_]IZ:
M)EB$C1LDZA74C!Y )Z@AA[$5S>I_%6VTF\:WN?"/BWBX^SQRKIHV3/D@;"7&
M[../6L3PEXCAMOB3):Q:#K6C:;K%JB1QZI9F ?:85P-G)!S&!GOE174_$'_5
M^&_^P]:?S-59)@,_X6'_ ,2@ZA_PAWB[B?R/LW]F?OON[M^W=]SMGUJGIWQ7
MMM4NQ;VWA#Q<<3BWED.FC9"^0"'(<[<9R<]*] KCO /^L\5?]AZY_DE+2VP$
M.I?$NVL-;OM*@\,^)M2DLI!'-+I]@)HPQ4,!D-Z$=0*UO#'C'3O%7VN*V@O;
M.\LV47-E?0&*:+<,J2O/!QZUP\+^.(O&'C.3PI%H,L"WT9DCU R^8S^1'PFT
MA<8QU(YK6^&;7NM7&J>*-7O8)-6G*V4]E!"8EL?*+?NR&^8MEB<G\":;2L!Z
M'1114 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!D>)O$=CX4T.
M;5K]9GAC94$<"AI)&8X"J"1D_CV-6'UBT&@-K4;&6S%J;I3'@EDV[N.<=/>O
M/O'/B-1X^TG3SHVKZO9:4AO;F'2[3[01,X98@XR, #>W7G(JIX/U@R_#[Q3X
M?FM+ZS?2X+C[-;ZA$8IQ:NC-'N4^G*\<8 J^72X'J.FW\6J:7::A KK#=0I,
M@< ,%8 C.,\\U:KRGX;ZI=ZW>V\>H37MC_9&EV_V/2PQ1;B-HQ_I#X/[S)&
MIX7_ 'CQ8\)Z+KOB2QT_Q@_C'5(+RZE\\V2D-9+$'(\KRN.=HQNSG//6DXV
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#O/AO_ ,Q/_ME_[/7>5P?PW_YB?_;+_P!GKO*^SRG_ '.'S_-G
MR69_[U+Y?D@HHHKT3@"BBB@ HHHH **** "BBB@!&Z5CZKH%KK&I:5>74L__
M !+9S<10J5\MY-I4,P(R=N21@CD]ZV&Z4RN>K?F&9GB#0K3Q+H=SI-Z95@N
M 7B8!T(((920<$$ ]*;::!;6FO3ZR)[B2ZFM(K1_,92I6,L0W 'S$L<]O85J
MT5GJ!B)X8LH?%K^([>6XM[N: 07,43 17 'W6=<9++V((...E8-[\*](GO+B
M>PU;7='BN7+SVNF7YAAE8]24P>OM@5W-%%V!S%YX"T6X\'KX8MA<:?8(Z2(U
MG)ME5E<.&W,#SD9R>:R!\+<'/_"=^-__  ;_ /V%=]11>0&3I'A^UT:]U2\B
MFGGN-2N//GDG921A0JJ, ?* .,Y/)Y-#^'[5O%,7B%99X[Q+4VC(C#RY8RVX
M;AC)(/3!'6M:BC4 K-TC1+;16U VSRO]NNWO)?,(.';&0, <<=\_6M*BEJ!F
MZQHEMK:V(N7E3['=QWD?ED#+IG .0>.?_KTFNZ';>(-/6RNWF2-9XIP8B =T
M;AP.0>,J,UIT4]0,W7M#LO$FB7.DZ@A:WN%P2IPR'J&4]F!P0?:K=G;FTLH+
M9KB:X,2!#-,07? QEB !D_05/12U X!OA3;+<7,MKXN\6V27$\D[06FI".-6
M=BS84)QR:<GAC6(]>OH=.\0:O:&+2K:&&^FCBG^T2!IN9&DC.XC()VE3\W/:
MN]HJKL#SK^S;G7O#EEX>ATZYTV:)I+B\ENH6=!,K$X#L,2"21MQ(ZIN'&X5W
M.E7DFH:7;W4UK+:3.G[RWE4AHV'#+SU (.#T(P1P:N44G=@%%%%*P!11118
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MC!Y&*RO^%6:%_:?V@7>K"P,_V@Z0+PBR,F=V?*Q_>YQG'MCBNWHHNP.4\0>
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M^S1R2[!SQ[E>BK'V&[_Y]9_^_9H^PW?_ #ZS_P#?LT<DNP<\>Y7HJQ]AN_\
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M  FFB?\ /R__ 'Z;_"O+Z*/[=Q/9?<_\PY$>H?\ "::)_P _+_\ ?IO\*/\
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M_7S)_P"A&J57=9_Y#FH?]?,G_H1JE7Q%7^)+U-0HHHJ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#N/AW_S$O\ ME_[/7<5
MP_P[_P"8E_VR_P#9Z[BOM<H_W.'S_-F<MPHHHKTB0HHHH **** "BBB@ HHH
MH 1NE,IY&12;?>L*D6WH VBG;?>C;[U'LY=AC:*=M]Z-OO1[.78!M%.V^]&W
MWH]G+L VBG;?>C;[T>SEV ;13MOO1M]Z/9R[ -HIVWWHV^]'LY=@&U3U;2[;
M6M)NM-O%+6]S&8WVG! /<'L1U%7MOO1M]Z/9R[ 5;&&>WL+>&ZN!<SQQJLDP
M39YC 8+8R<9ZXS537M(&NZ6VG23F*WF=1< +DR1@Y9.O&[&">>":U=OO1M]Z
M.278!@ 50J@  8 ':EIVWWHV^]'LY=@,N?21-XAM=5,W$%K-;&$IG=YC1MG.
M>WE],<Y]JQU\&NMK)I/]H@Z ]QYOV#R/F$1&3!OW?ZO=SC;]WY>E=9M]Z-OO
M1R3 S=%T^XTO3ELI[TW:Q,5@=DPZQ9^16.3N('&[C..1G.8]#T9="@N;6"8M
M:/</-!$5QY <[F3.>1N+$=, X[5K;?>C;[T<D^P#:*=M]Z-OO1[.78")X8I'
MC=XT9HSN1F4$J<8R/3@D?C3Z=M]Z-OO1[.78!M%.V^]&WWH]G+L VBG;?>C;
M[T>SEV RET=3XDDUJ:7S)!;BVMX]F!"I.YSGN6(7)XX4#USIT[;[T;?>CDEV
M ;13MOO1M]Z/9R[ -HIVWWHV^]'LY=@&T4[;[T;?>CV<NP#:*=M]Z-OO1[.7
M8!M%.V^]&WWH]G+L VBG;?>C;[T>SEV ;13MOO1M]Z/9R[ -HIVWWHV^]'LY
M=@&T4[;[T;?>CV<NP#:*=M]Z-OO1[.78!M%.V^]&WWH]G+L VBG;?>C;[T>S
MEV ;13MOO1M]Z/9R[ -HIVWWHV^]'LY=@&T4[;[T;?>CV<NP#:*=M]Z-OO1[
M.78!M%.V^]&WWH]G+L VBG;?>C;[T>SEV ;13MOO1M]Z/9R[ -HIVWWHV^]'
MLY=@&T4[;[T;?>CV<NP#:*=M]Z-OO1[.78#Q[6?^0YJ'_7S)_P"A&J5=S?>!
MKF[U"YN5O(E6:5I "IXR2:K_ /"OKK_G^A_[X-?*5,LQ;FVH?D:<R..HKL?^
M%?77_/\ 0_\ ?!H_X5]=?\_T/_?!J/[+Q?\ )^0<R..HKL?^%?77_/\ 0_\
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DH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>image17.jpg
<TEXT>
begin 644 image17.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '6!%D# 2(  A$! Q$!_\0
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MC+_H,_\ DK#_ /$4?\+1\9?]!G_R5A_^(HL!]'T5\X?\+1\9?]!G_P E8?\
MXBC_ (6CXR_Z#/\ Y*P__$46 ^CZ*^</^%H^,O\ H,_^2L/_ ,11_P +1\9?
M]!G_ ,E8?_B*+ ?1]%?.'_"T?&7_ $&?_)6'_P"(H_X6CXR_Z#/_ )*P_P#Q
M%%@/H^BOG#_A:/C+_H,_^2L/_P 11_PM'QE_T&?_ "5A_P#B*+ ?1]%?.'_"
MT?&7_09_\E8?_B*/^%H^,O\ H,_^2L/_ ,118#Z/HKYP_P"%H^,O^@S_ .2L
M/_Q%'_"T?&7_ $&?_)6'_P"(HL!]'T5\X?\ "T?&7_09_P#)6'_XBK6F?$#Q
M[J^I06%CJ9EN9VVHHMH?S^YP .:+ ?0M%>2_V_JD<XL;CXG62:CG:8TTQ&B#
M^GF[<=>^*YC6/'7C[0M5GTZ^U4)<0G!Q;0D$'D$'9R"*+ ?0-%>,ZMK?CO2O
M"=EKC>(A(TP0S6WV*$&!7R4).WG./0=:J>%_&/BOQ!/?"Z\5?8+>SMFN9)O[
M/BE^4$ \!0>]%@/<:*\EMO$5[J-PEII_Q/BEO)3MACET41*[=AN*X&:H:)XD
M\97^JZK9:IXG_LT:9"\MQ)_9\4V-K '@*#WSQFE8#VFBO);?7]4U206NC?$J
MWNKY^(H)](6W#GT#,IY]L5C:9XL\<WMWJ]K<ZXUI/IMI+<2(UE"Q)0@%/NC'
M7KS18#W.BO#O#_BGQQK<%Q>S^)(-/TRV($UY<6T6T$_PJ-F6;V_Q%:9USQ)J
M-O,WAKQW!JUS"I=K5M-2WE8#KL#+\U%@/7J*\8\+:[XY\4V&HSP>)$AFM"H6
M)[*(^:6#<9V\'C'3O7.VWQ(\<7=Y#:0ZL6FFD$:+]EAY8G 'W/6G8#Z)HKQ[
M5=8\:Z5XITG0W\51RMJ"QDSQV,.U-S%>!CYNF>U3W7B::RNYK6X^*.R:%S'(
MO_"/@X8'!&0,4@/6J*\23QS?'69+9OB'ML5A#K>?V*IW/G[FS;D<<YK9N-<O
M+73[2_F^)VVVO-_D/_8(._:<-P!D8/K18#U2BO !X_\ &%UKRZ;IOB W:2SB
M&";[#$GF G ;:4R*T?%_BCQKX5U**W'B,7EO-'OCN%LH5#$$AAC:>01ZT[ >
MW45XWH_B;7[SPU_;>J^./[,A-R;91_9,<V6"AOX1GU[=J34O$GB5-%GU70O&
MT6K6]JRBY4:;'"\08X#;67D9[TK >RT5XIHWB7QE?:6=7U3Q9!I.E[RB3RV<
M3O*PZA$"9;'?_P"L:L7NO^*WTN?4?#_C2#68+8;KB-;".&:-?[VQER5'K18#
MV.BO"9?&GC*/PA!K_P#PD6?-O&M?(^Q0\87=NW;?TQ5'2OB)XRU/5[*P_MWR
M_M,Z0[_LD)V[F SC;SUIV ^A**\-M_%'C^^\476AV6MI(]M)(KSR6T*(J(<%
MV^4X'Y]:V(M=U:]G^PZ?\2[2XU-OE2!M+1(W;^Z)2N#GMZT@/6J*^=KOXC^.
M;"\FM+G5#'/"Y21#:P\$'!_@HM/B1XXO;R"T@U;=-/(L<:_9H1EB<#^#UIV
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MTO1=&U'_ (2+S?[2CDD\O[%"OE[6QC.TYS]!6-_PM'QE_P!!G_R5A_\ B*+
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M8#Z/HKYP_P"%H^,O^@S_ .2L/_Q%'_"T?&7_ $&?_)6'_P"(HL!]'T5\X?\
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M ,FH?_BZ/^%6^,O^@-_Y-0__ != ''T5V'_"K?&7_0&_\FH?_BZ/^%6^,O\
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M2L'7/AYKM_/$^D^#?[+C5<.G]J)/O.>N6;B@1YW178?\*M\9?] ;_P FH?\
MXNC_ (5;XR_Z W_DU#_\73 X^BNP_P"%6^,O^@-_Y-0__%T?\*M\9?\ 0&_\
MFH?_ (N@#CZ*[#_A5OC+_H#?^34/_P 71_PJWQE_T!O_ ":A_P#BZ ./HKL/
M^%6^,O\ H#?^34/_ ,71_P *M\9?] ;_ ,FH?_BZ ./HKL/^%6^,O^@-_P"3
M4/\ \71_PJWQE_T!O_)J'_XN@#CZ*[#_ (5;XR_Z W_DU#_\71_PJWQE_P!
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M+"/>-.^*5YJUG=7=AX5N+B&T ,Q2Z7* Y/3&3T/2LT?'"W8@#09B3P +D?\
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M &$5_P#0ZW=?\$?:O$6I7'_"4>&H?-NI'\N;4-KIEB<,-O!'<4 =KK'Q6N-
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M_H-'Q;_Y'^Y_ZXQ?^@T#.M_X7C;?] *7_P "1_\ $T?\+QMO^@%+_P"!(_\
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M.=R<\&K/@S1/^$@\5V5BR%H-_F3X_P">:\G\^GXT6$>L:I\4[K1$M7U'PO/
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MYMG<90M<J5;'7# $'\ZJ6/QC_M*^ALK/P[-+<3N$C072C)/N5Q7'^)89M#\
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M3[6JY &3R0!T%5/^%XVW_0"E_P# D?\ Q-<3\- '\=VP!"AHI@"3P/W;4?\
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MHKZX^RVO_/"'_O@4?9;7_GA#_P!\"CG06/ /A)_R/]M_UQE_]!H^+?\ R/\
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MGG>12C#!.TDYQG/X5SVKQV46KW::;<">R$A\B3:RY0\CA@#D=/PKZK^RVO\
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M2?VUX=_Y^;/_ +Y'^%']M>'?^?FS_P"^1_A1]:H?SK[T%F?+=%?4G]M>'?\
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M)&ZGAE(R#^5*VEP):**\T\1ZW\3-$NX2B>$GM+R_6SM=PN2XWD["_('0<X_
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M%R<G ''))-"V-HE])>I:P+=R((WG$8$C*.BENI ]*IRNK <KX?\ ^2E>,?\
M<LO_ $6U+\4?^2<:O_NQ_P#HQ:ZJ.TMH;F:YBMXDN)]OFRJ@#2;1A=QZG Z9
MHNK2VOK9[:[MXKB!_OQ3('5N<\@\'FE?6X'._$/_ ))IXA_[!TO_ *":\_\
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M-6$TZQCAN(DL[=8[EF:=%B4"4L,,6&/F)'7/6DY@>97^HGPMHOA3QJX9XQI
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M\U_WE^B-([!1117FC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *]&\ _\ ("G_ .OEO_05KSFO1O /_("G_P"OEO\
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MW46I@)M-&TTNZC=1:F FTT;32[J-U%J8";31M-+NHW46I@)M-&TTNZC=1:F
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M^,/_ 'T:/^%@W7_/C#_WT:.3*?YG^/\ D'O%3_A!-7_O6W_?P_X4?\()J_\
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M9_C_ )![Q4_X035_[UM_W\/^%'_"":O_ 'K;_OX?\*M_\+!NO^?&'_OHT?\
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MHH **X;X@Q'Q#/I?@R*1D_M.0S7K(>4MHN3]-S[%'XU%I6K7&J?"C58K\_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>C> ?\ D!3_ /7RW_H*UYS7HW@'_D!3_P#7RW_H*UZV2_[VO1DRV.JHHHK[
M$S"BBB@ HHHH **** "BBB@ HHHH ",TFT4-TIE8SE%/5 /VBC:*914\\>PQ
M^T4;13**.>/8!^T4;13**.>/8!^T4;13**.>/8!^T4;13**.>/8!^T4;13**
M.>/8!^T4;13**.>/8!^T4;13**.>/8!^T4;13**.>/8!^T4;13**.>/8!^T4
M;13**.>/8!^T4;13**.>/8!^T4;13**.>/8!^T4;17E.D>)=6TSXE:TFHW4L
MV@7>I?8(C(Y(LY_+1D')^57W$8'&X#UKH_#-]=3>.?&D$]U-);VT]L(8Y)"5
MB!AR=H/"Y/)Q5-Q701V>T4;17E7A[Q)JK^,H=9O;J9M!\13SVEA$['RX3%@0
ML > 9 LA]_EJQ\0I(9O&>@V%_P"*K_P_ITMI<R236NHBT#NICV@L>#U-%XWM
M8#TW:*-HKS_PMI.E6IO[_2/'>K^(-ENT;QW&KK=QQ$\AL*/E;Y>#]:V/A[=7
M%[\/=!N;N>6>XELT:265RS.<=23R32<H]@.HVBC:*\TU?1KKQ/\ $V_T]O$F
MOZ9:VNF6\J1Z9?&%2S/("2,$=A5G2X=7\&^--.T:?7+W5]'U:*40MJ+B2>":
M-=V-^!N5ESP?3\WS1[ >A;11M%<WXSNKB/1([*TGD@NM1NHK.*2)RKIO;YF!
M'((0.<CTK0US6;;P[H=UJMXLK6]JFYQ'@MC('&2!W]:7/'L,U-HHVBN$7XK:
M +R2WFMM6M\H7M))K)@M_P @8M^[DY&.!G-7=)^(>BZGI&J:C,E[I@TK_C]M
M]0@\N:$8R"5!/4=,<FCF7\HCKMHHVBN,T7XC:;K.J0V#Z9K6F/<Y^R2ZE9&&
M.ZP,XC;)R<<X.*Q_#?Q*$S^*KC7+;4K.QTVZ=DGN;38D48"*(LCDR;B3MY.&
M%.Z_E ]+VBC:*X[0OB%8ZUK,>E2:3K>E7,Z,]O\ VG9&%;@+RVPY.<#GM7*>
M%_BA::7X<C358=<U PW-P+S4(K9YXK4><^T2R$\87;P,X&*+K^4#US:*-HKE
MM?\ '6E:"+)!#?:G=7T9EMK73+<SRR1C!+@# V\]2:P/$/C:#6_AMK=]I$M_
MI]]9M'%-#,K07-LY=>& .1D'J#@\^])27\H'I&T4;17(KK^E:7K'B:YO-0OX
MTL(;>2Z%RX-O$"A(\I1SD]QCDXQ1X<\?Z?XCU+^SUT[5].NFB,\*:E:&'SXP
M0"R')!'(_.CFC_*!UVT4;13**7/'L,?M%&T4RBCGCV ?M%&T4RBCGCV ?M%&
MT4RBCGCV ?M%&T4RBCGCV ?M%&T4RBCGCV ?M%&T4RBCGCV ?M%&T4RBCGCV
M ?M%&T4RBCGCV ?M%&T4RBCGCV ?M%&T4RBCGCV ?M%&T4RBCGCV ?M%&T4R
MBCGCV ?M%&T4RBCGCV K:CI=IJMNL%VA>-7W@!B.<$=OJ:S/^$+T3_GV?_OZ
MW^-5?'$LD6BPM'(R,;A1E3C^%JX#[;=?\_,W_?PUX^-QN&IU>6=)2??3_(I)
MV/2?^$+T3_GV?_OZW^-'_"%Z)_S[/_W];_&O-OMMU_S\S?\ ?PT?;;K_ )^9
MO^_AKD_M+"?\^%^'^0^5]STG_A"]$_Y]G_[^M_C1_P (7HG_ #[/_P!_6_QK
MS;[;=?\ /S-_W\-'VVZ_Y^9O^_AH_M+"?\^%^'^0<K[GI/\ PA>B?\^S_P#?
MUO\ &C_A"]$_Y]G_ ._K?XUYM]MNO^?F;_OX:/MMU_S\S?\ ?PT?VEA/^?"_
M#_(.5]STG_A"]$_Y]G_[^M_C1_PA>B?\^S_]_6_QKS;[;=?\_,W_ '\-'VVZ
M_P"?F;_OX:/[2PG_ #X7X?Y!RON>D_\ "%Z)_P ^S_\ ?UO\:/\ A"]$_P"?
M9_\ OZW^->;?;;K_ )^9O^_AH^VW7_/S-_W\-']I83_GPOP_R#E?<])_X0O1
M/^?9_P#OZW^-'_"%Z)_S[/\ ]_6_QKS;[;=?\_,W_?PT?;;K_GYF_P"_AH_M
M+"?\^%^'^0<K[GI/_"%Z)_S[/_W];_&C_A"]$_Y]G_[^M_C7FWVVZ_Y^9O\
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M@NSG_P#A"]$_Y]G_ ._K?XT?\(7HG_/L_P#W];_&N@HH^HX;_GVON079S_\
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MZ;_"C^S-0_Y\;G_OTW^%'LI]F!5HJU_9FH?\^-S_ -^F_P */[,U#_GQN?\
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M/X&L[JWUN9YK::)3;, 70@9W+ZUVY=3FL5!M=12V._HHHK[<R"BBB@ HHHH
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MPHW"F44>UD _<*-PIE%'M9 /W"C<*911[60#]PHW"F44>UD _<*-PIE%'M9
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M):Y6NJ\ _P#(=G_Z]F_]"6NW+?\ >X>HI;'HU%%%?=&04444 %%%% !1110
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MKHKHP96&0P.012T<\NX&)XIU:ZTG3(Y[4J)&F"'<N>-K'^E<C_PF^L_WX?\
MOV*Z#QY_R X/^OE?_06KSROG<RQ=>G7Y83:5EU+BE8Z/_A-]9_OP_P#?L4?\
M)OK/]^'_ +]BN<HK@^OXK_GX_O'9'1_\)OK/]^'_ +]BC_A-]9_OP_\ ?L5S
ME%'U_%?\_']X61T?_";ZS_?A_P"_8H_X3?6?[\/_ '[%<Y11]?Q7_/Q_>%D=
M'_PF^L_WX?\ OV*/^$WUG^_#_P!^Q7.44?7\5_S\?WA9'1_\)OK/]^'_ +]B
MC_A-]9_OP_\ ?L5SE%'U_%?\_']X61T?_";ZS_?A_P"_8H_X3?6?[\/_ '[%
M<Y11]?Q7_/Q_>%D='_PF^L_WX?\ OV*/^$WUG^_#_P!^Q7.44?7\5_S\?WA9
M'1_\)OK/]^'_ +]BC_A-]9_OP_\ ?L5SE%'U_%?\_']X61T?_";ZS_?A_P"_
M8H_X3?6?[\/_ '[%<Y11]?Q7_/Q_>%D='_PF^L_WX?\ OV*/^$WUG^_#_P!^
MQ7.44?7\5_S\?WA9'1_\)OK/]^'_ +]BC_A-]9_OP_\ ?L5SE%'U_%?\_']X
M61T?_";ZS_?A_P"_8H_X3?6?[\/_ '[%<Y11]?Q7_/Q_>%D='_PF^L_WX?\
MOV*/^$WUG^_#_P!^Q7.44?7\5_S\?WA9'1_\)OK/]^'_ +]BC_A-]9_OP_\
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M^<;=N<[L\8ZUL5Y1+<ZB?!M_87-C9QZ)>:G>6TVH_:6=[97N9!YC0^6!@-@
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MWJ7:P'5T445(!1110 4444 %%%% !1110 4444 %%%% !1110!QBD#XS3DG
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MJ_\ 9GAW_GWL/_':/[,\._\ /O8?^.T?V'/_ )^(.8\HHKU?^S/#O_/O8?\
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M('-68/B1$WA5M3N='NXM36^.F_V4K!Y&N<_<5N 1CG=Z9K4.E7I^)::OY/\
MH(T@VQEW#_6>:&VXSGISG&*X[6OA[J6M:%K$$UE!))_PD$FI6]K/,52ZB*A=
MI9#E,@G'0Y SQ2]T#J=!\7:G=ZNFE>(O#4VA7L\;2VH-TEQ'.%QN =.C#.=I
M[<UST/Q9OY--AUF3P=>1Z%]H-O<W_P!K0B-O,V95,!G7.,GCG([53\"^!&L?
M%$&JGP):>&X[:-QN;5Y;R:1F&!MP^Q5P3G<#VQZUI?\ "+:S_P *8D\/_8_^
M)HQ;$'FIWN"_WL[?N\]:=HW GT+7/$%Q\6_$&G3Z7)_9D<4 $AO598% <HX3
MOYG<#D8YKH?%_B<^%=.M;M;"2^:XNX[588GVL6?.,<<G( QQUZUB3^'[^7QY
MJZ7>D+>>'M=L(H+FX%R$,)C5QM*Y#'=NZKTJ*\^'>GZ+9Z7;>%=+\F-=9MKR
MZ7[0S81,Y;]XQZ ]!^5+2X$]UXYUNW6RT^+PA+<>)+B%KB73([^/9;Q!MH9Y
ML;>>PQZBI?\ A84-KX6U;5=5TJYL+[22J7>GNZLRNV-FUQ\K*VX8;Z^E87Q&
M\!RZUXCM]=3P[!XCB%J+:2P>_:T="&)#HX(!^\00?08IWAGP5?:1X5UP6?A?
M1M-N=0V"/2[BYENXW1>JS.SE23EL%0 .,YHM&P'0>&?%VL:Q?+;:KX4GTR.:
M(R074-W'>0.!C(9X^$)SP#UYK M/'5KH7A#08]$\/;KC4YKA+33VOU1!L=MY
M,TGJ3D#WP*SO!O@K5K'QC;:I;>%E\)V<6_[9$NKFZ%X"I"J$'"@$YYZ=JL3>
M$]:3X>:5I=SX5T_6_)EG-SI]Q<B*8;I&*-%,#M4X//?!IVC<"SXM\7>(9?AC
MK-VGAZ^TG4X"(I@URH$2'!\V*4<2#D#Y><D^E:VH>,_$&GZ=8!?!ES-J4T!F
MN(GOHX[>W4'&#<,-A8]=HYQ7+:5X UY/ _BG3X[!=*AU&!18:,]^;D0NN2Q\
MP\#<<=/QJ37]"\2ZSJVFZUJ7@:WUA/L(A_LJ?5$46,P<[GS]QPR[>Q/&.,<E
MD!M+\5(G\(V^MQZ+/-,VI+ILUG!.LC+*>NQQ\LG;&,9SU%-E\>:W-9Z]IMQX
M6GTW7+2P-W;VYOHW$L1.W>)!P"O)QSTZUD:#X,\16>B06MSI%K;2IXHCU$Q6
MDJ>2D& 24&<@+R-O7CI76ZKH%_?>-;F\CB"V<V@R60F+# E:3(&,YZ<YQBE[
MJ F^'.H:GJ?@32KG5K1[>X-O&%=[@3-<)L7$I(Z%NN#R.]=37,^ 8M7M/!UA
MI^M:8-/NK&-;4*)UE$JHH D!7IGTZBNFJ7N 4444@"BBB@ HK&77L^-'\._9
MONZ>+WS_ #.N9"FW;CVSG/X5LT %%%4]0N;VV%M]BL/MADN$CF'G"/RHS]Z3
MG[V/[HY- %RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .6
M\>?\@.#_ *^5_P#06KSRO0_'G_(#@_Z^5_\ 06KSROE\U_WE^B-([!1117FC
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KJO /_ "'9_P#KV;_T):Y6NJ\ _P#(=G_Z]F_]"6NW+?\ >X>H
MI;'HU%%%?=&04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?D@EDBPA8GIA@RY[9[5H>.M6\3Z=82ZCHTOA=M$2U+S'56E+2-SE5VG:01@
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M3]LE/SLA4???;W[T[I[@=*GB#5;/4K&WUO2[&UM[TND4]KJ#3;'5#)APT4>
M55N03R.G.:V8M4T^=K58;ZUD-W&9+<),I\Y!C+)@_,!D<CU%<R/#MQH?B&QU
M*PAOM3MC&T,UO<WS3O;-@D2Q&>3C/W6 /(*XZ'+?"^BZEH^LM<W&GH(=1B9R
MD<@(TT[RPA&6Y5MV24'WP?X2NT:0'9T445(!1110 4444 %%%% !1110!#;W
M=M=F46UQ%-Y,ABE\MPVQQU4XZ$9Z&IJ\>M-9\6Z5_P )A=:!IFG365CJ]S<7
M3WLCAI@%4E(@O\0 SEN.1Q7:V7BR:X\1:7;S1PQ:;JND_;;5R#O$JX+H3G!
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M>_\ WTO^-'_"*ZW_ - ]_P#OI?\ &NG_ .%@VO\ SXS?]]"C_A8-K_SXS?\
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M_A%=;_Z![_\ ?2_XT?\ "*ZW_P! ]_\ OI?\:]8HH_L'#_S/\/\ (.=GD_\
MPBNM_P#0/?\ [Z7_ !H_X176_P#H'O\ ]]+_ (UZQ11_8.'_ )G^'^0<[/)_
M^$5UO_H'O_WTO^-'_"*ZW_T#W_[Z7_&O6**/[!P_\S_#_(.=GD__  BNM_\
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M\Q"KY5L=0<#@^E<U17F,ZRBN$UC^UO%OBV\\/6&KW.D:7IL,;7MQ9D+<32R
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MNG_]?,?_ *$*HU>T7_D.Z?\ ]?,?_H0K2C_$CZH#V*BBBOT,Q"BBB@ HHHH
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M,<>M>F    =!2T4FP"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444
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M'X\_Y <'_7RO_H+5YY7R^:_[R_1&D=@HHHKS1A1110 4444 %%%% !5[1?\
MD.Z?_P!?,?\ Z$*HU>T7_D.Z?_U\Q_\ H0K2C_$CZH#V*BBBOT,Q"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5HWN(U92>H+#(JJ>+R]S25)W_KS"S/4****^I,PHHHH **** "BBB@ HHHH
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M3HHE>Y;2C=RWDK+N8X VJO(]#GVJY%\0-8UOP/IMWH]]:'4GUM-+DN5A/E3
MYP^QQN4$%21P>"!1R,#UFBJ&BVFH6.DPV^J:H=3O$SYEV8%AWY)(^1>!@8'X
M5?J0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#EO'G_(#@_Z^5_]!:O/
M*]#\>?\ (#@_Z^5_]!:O/*^7S7_>7Z(TCL%%%%>:,**** "BBB@ HHHH *O:
M+_R'=/\ ^OF/_P!"%4:O:+_R'=/_ .OF/_T(5I1_B1]4![%1117Z&8A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 C=*P]?T'^W)-);[3Y']GZA'>X\O=YFP,-O48SNZ\].E;C=*97-4^
M(9R_B3P>VL:A#J^E:M<:-K4$?DK>0() \><[)(VX=<\C/>JVC>"+N'68-8\2
M>(+C7]0M01:EX$@A@R,%EC7C<1QNKL:*CF8&-HV@#2;W6[AK@3KJEW]I*&/
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M*051YA\S+QTP./2NMT_0!8^(]9U;[0)%U)8%\GR\>7Y:E>N><Y]!BMFBAR;
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MTH_Q(^J ]BHHHK]#,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *3(H;I3*QG4<78!^11D4RBI]J^PQ^
M11D4RBCVK[ /R*,BF44>U?8!^11D4RBCVK[ /R*,BF44>U?8!^11D4RBCVK[
M /R*,BF44>U?8!^11D4RBCVK[ /R*,BF44>U?8!^11D4RBCVK[ /R*,BF44>
MU?8!^11D4RBCVK[ /R*,BF44>U?8!^11D4RBCVK[ /R*,BF44>U?8!^11D4R
MBCVK[ /R*,BF44>U?8!^11D4RBCVK[ /R*,BF44>U?8!^11D4RBCVK[ /R*,
MBF44>U?8!^11D4RBCVK[ /R*,BF44>U?8!^11D4RBCVK[ /R*,BF44>U?8!^
M11D4RBCVK[ /R*,BF44>U?8!^11D4RBCVK[ /R*,BF44>U?8!^11D4RBCVK[
M /R*,BF44>U?8!^11D4RBCVK[ /R*,BF44>U?8!^11D4RBCVK[ /R*,BF44>
MU?8!^11D4RBCVK[ /R*,BF44>U?8"&]O+.SA62\ECCC+;07Z9Y_P-4/[>T#_
M )_+;\O_ *U9?CS_ ) <'_7RO_H+5YY7CXW-JE"KR1BF4HW1ZO\ V]H'_/Y;
M?E_]:C^WM _Y_+;\O_K5Y117)_;M7^1?B/D1ZO\ V]H'_/Y;?E_]:C^WM _Y
M_+;\O_K5Y111_;M7^1?B'(CU?^WM _Y_+;\O_K4?V]H'_/Y;?E_]:O***/[=
MJ_R+\0Y$>K_V]H'_ #^6WY?_ %J/[>T#_G\MOR_^M7E%%']NU?Y%^(<B/5_[
M>T#_ )_+;\O_ *U20ZUHDLT<<5U;M([!4 '))Z5Y)5[1?^0[I_\ U\Q_^A"J
MIYW5E-1Y%J'*>Q4445]29A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 C=*YWQ/KESHLNAK;1PN+_ %2*
MSE\P$X1@Q)7!'/RCKGZ5T3=*XKQ__K_"7_8P6_\ Z#)7//XP'^(?$VL#6QX>
M\*Z?;7>JK")[B>\<K;VJ$D+OV_,6.#A1SCFJVG>)_$NE:U9:5XST_3HQJ#F*
MTO\ 2W<P&7&1&ZO\RD@<'H:@;5[/PA\2=7DUN=;2RUN*"2UO9CB(/&I1HF8\
M*>C#/')J'Q#X@TSQ;KF@:'X?O(=2FAU&&_NI[1Q)';Q1$L2SCC+'"@9[FIL,
MN:)X\EO/B%J_AC4+>*%(I633YTR/.*(K.AR3E@'!XQQGTJ27QO-97'C1[NWC
M>UT!8GA6($/)NBWD,22.O&0!CWK$AT"37V\:1V<H@U.UUL7-A<?\\YUACV_@
M>5/L37.Z;XEN;[1/B1K*Z:$N6^S17-K/'Y@B81^7-E?X@N'/N!3Y4!V.G>*O
M&%AK6D0^*M-TB.QUF0Q6[:?*YDMY-I95D#<-D#&5X&*?KOB+QM'=:E<Z-I6E
M6^CZ82)9=7>2.2ZVC<QBQ@!>P9N">:XO3[;0=#\0>$I_#_B^?Q-=O<+;+8W-
MTMP(8G7YY(U S 5 SSVR/6NM\3ZQX \2_;]+\5S+9S:1,P$5Y<&"3.T$2Q!6
MRX(Y'4^W/);78"WJ/CC4;C1/#I\/:7'+J_B"+S;:*\<K% @0,[.1R0,C@8)S
MD>AT/#>N:X^KS:%XGM+&+4T@%U%-I[LT$\9;:<!_F4J< YZYS7"2W)N/ 7@W
M4=<UB^T;5?/=+'6GB1A"IW;//#$#:\:KGU/)XS5_P/&^H?$J[U%?$<GB(6>F
M?9;G41&B0&1Y RI$$^7 5<G!/+=:&E8#U:BBBLP"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH X;1/'DMY\0M7\,:A;Q0I%*R:?.F1YQ1%9T.2<L
M X/&.,^E:^AZ_=:GXJ\2Z7-'"L&ERP)"R*0S!X]QW9.#STP!7(PZ!)K[>-([
M.40:G:ZV+FPN/^><ZPQ[?P/*GV)K#T+QI,MGX_U];62WU*22UMTM6&66[,?E
M;/<"3]!5\J>P'::+XZGU/QW>Z/-;11Z8S2Q:=<@'=/+ 5$P/.#RW&!T4U<\5
M^(M9LM5T[0O#MC:W&JWZ22B6]=E@AC3&6;;RW+ 8'->>7GAGXA>'O#.ES/%X
M:>V\.2?;D-FT_P!ID R9 2PVG>"V[IFNK\4:[X6U.YT.+Q!;+'I%_;_:;#6/
MM#1>5,<?)O7'EDJ<YW8."".*+*^@&MH.K>+HM:32O%.DV1\^)I(=0TGS&MU*
MXRDF\94X/!)P>@J_X/UNY\0:$U]=I$DHN[B'$0(7;'*R#J3SA1FN.T#58K'Q
MYIVC^'O%=SXCT^[BFDO8Y[D7?V,*,HXF'(!;Y=I)Z_2J'@[P'_;FCW%__P )
M7XIT_P S4+L?9[#4?*A7$[CA=IQG&3[T-(#O?"&OW7B"UU66[CA1K34[BSC\
MI2 4C( )R3SZ_P JZ*N!^$UK]BT'6;7SYY_)UN[C\Z=]TCX(&YCW)[FN^J9;
M@%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .:\;>(;WP_H
MT1TFVBN=6O+A+:R@E!*LYR26P0<!58\&M+P]K4'B'P]8:O;\1W4*R;?[C?Q*
M?<'(_"N"UL^)_$'Q)>?PNNCM'X=B\@G5?,V>?,,L4\OG(3:.>FX^M5_#0O\
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M-?\ >7Z(TCL%%%%>:,**** "BBB@ HHHH *O:+_R'=/_ .OF/_T(51J]HO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
;!1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6883362672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes, Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 35,861<span></span>
</td>
<td class="nump">$ 438<span></span>
</td>
<td class="num">$ (7,460)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">14,329<span></span>
</td>
<td class="num">(1,442)<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">374<span></span>
</td>
<td class="nump">234<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax expense (benefit)</a></td>
<td class="nump">50,603<span></span>
</td>
<td class="num">(630)<span></span>
</td>
<td class="num">(5,980)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(7,096)<span></span>
</td>
<td class="num">(290,511)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred income benefit</a></td>
<td class="num">(7,096)<span></span>
</td>
<td class="num">(290,511)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 43,507<span></span>
</td>
<td class="num">$ (291,141)<span></span>
</td>
<td class="num">$ (5,980)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871107136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity, Restricted Stock Unit Activity (Details) - Restricted Stock Units [Member] - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested at beginning of period (in shares)</a></td>
<td class="nump">1,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled/forfeited (in shares)</a></td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested at end of period (in shares)</a></td>
<td class="nump">1,866<span></span>
</td>
<td class="nump">1,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 50.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">60.23<span></span>
</td>
<td class="nump">$ 51.06<span></span>
</td>
<td class="nump">$ 48.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">51.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled/forfeited (in dollars per share)</a></td>
<td class="nump">53.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested at end of period (in dollars per share)</a></td>
<td class="nump">$ 55.80<span></span>
</td>
<td class="nump">$ 50.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Unrecognized Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to non-vested RSUs</a></td>
<td class="nump">$ 56.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6863513376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes, Tax Act (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal corporate tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6885241920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies, Long-Lived Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Long-Lived Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Charges related to write-down of long-lived assets</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6885441728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies, Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6886873424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1,122,599<span></span>
</td>
<td class="nump">$ 599,674<span></span>
</td>
<td class="nump">$ 514,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">4,384<span></span>
</td>
<td class="nump">1,820<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_ResearchDevelopmentAndPatentExpense', window );">Research, development and patent</a></td>
<td class="nump">465,688<span></span>
</td>
<td class="nump">414,604<span></span>
</td>
<td class="nump">374,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">286,644<span></span>
</td>
<td class="nump">244,622<span></span>
</td>
<td class="nump">108,488<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">756,716<span></span>
</td>
<td class="nump">661,046<span></span>
</td>
<td class="nump">483,132<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">365,883<span></span>
</td>
<td class="num">(61,372)<span></span>
</td>
<td class="nump">31,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment income</a></td>
<td class="nump">52,205<span></span>
</td>
<td class="nump">30,187<span></span>
</td>
<td class="nump">8,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(48,768)<span></span>
</td>
<td class="num">(44,789)<span></span>
</td>
<td class="num">(44,752)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_GainLossOnExtinguishmentOfFinancingLiability', window );">Loss on extinguishment of financing liability for leased facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,689)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early retirement of debt</a></td>
<td class="num">(21,865)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expenses</a></td>
<td class="num">(686)<span></span>
</td>
<td class="num">(182)<span></span>
</td>
<td class="num">(3,548)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income tax benefit (expense)</a></td>
<td class="nump">346,769<span></span>
</td>
<td class="num">(76,156)<span></span>
</td>
<td class="num">(16,763)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit (expense)</a></td>
<td class="num">(43,507)<span></span>
</td>
<td class="nump">291,141<span></span>
</td>
<td class="nump">5,980<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">303,262<span></span>
</td>
<td class="nump">214,985<span></span>
</td>
<td class="num">(10,783)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net (income) loss attributable to noncontrolling interest in Akcea Therapeutics, Inc.</a></td>
<td class="num">(9,116)<span></span>
</td>
<td class="nump">58,756<span></span>
</td>
<td class="nump">11,129<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Ionis Pharmaceuticals, Inc. common stockholders</a></td>
<td class="nump">$ 294,146<span></span>
</td>
<td class="nump">$ 273,741<span></span>
</td>
<td class="nump">$ 346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share (in dollars per share)</a></td>
<td class="nump">$ 2.12<span></span>
</td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing basic net income per share (in shares)</a></td>
<td class="nump">139,998<span></span>
</td>
<td class="nump">132,320<span></span>
</td>
<td class="nump">124,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per share (in dollars per share)</a></td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="nump">$ 2.07<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing diluted net income per share (in shares)</a></td>
<td class="nump">142,872<span></span>
</td>
<td class="nump">134,056<span></span>
</td>
<td class="nump">126,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_CommercialMember', window );">Commercial Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 352,450<span></span>
</td>
<td class="nump">$ 254,922<span></span>
</td>
<td class="nump">$ 120,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_SPINRAZARoyaltiesMember', window );">SPINRAZA Royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">292,992<span></span>
</td>
<td class="nump">237,930<span></span>
</td>
<td class="nump">112,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Sales, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">42,253<span></span>
</td>
<td class="nump">2,237<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_LicensingAndOtherRoyaltiesMember', window );">Licensing and Other Royalty Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">17,205<span></span>
</td>
<td class="nump">14,755<span></span>
</td>
<td class="nump">7,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember', window );">Research and Development Revenue Under Collaborative Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 770,149<span></span>
</td>
<td class="nump">$ 344,752<span></span>
</td>
<td class="nump">$ 394,165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_GainLossOnExtinguishmentOfFinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the purchase price of the facility and the carrying value of our financing liability at the time of the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_GainLossOnExtinguishmentOfFinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_ResearchDevelopmentAndPatentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects. Also includes charges for amortization and write-downs of capitalized patent costs, as well as legal fees for patent litigation and patent defense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_ResearchDevelopmentAndPatentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_SPINRAZARoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_SPINRAZARoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_LicensingAndOtherRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_LicensingAndOtherRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6881009168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information and Concentration of Business Risk (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information and Concentration of Business Risk [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Segment Information</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The following tables show our segment revenue and income (loss) from operations for </span>2019, 2018 and 2017<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> (in thousands), respectively.</span></div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="ze030c5e389c640c2991886f2f6ba40f4" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Ionis Core</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Akcea Therapeutics</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Elimination of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intercompany Activity</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Revenue:</div></td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Commercial revenue:</div></td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SPINRAZA royalties</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">292,992</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">292,992</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Product sales, net</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">42,253</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">42,253</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Licensing and other royalty revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12,616</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,172</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5,583</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">17,205</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 43.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total commercial revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">305,608</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">52,425</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5,583</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">352,450</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue under collaborative agreements</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">553,038</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">436,118</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(219,007</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">770,149</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total segment revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">858,646</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">488,543</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(224,590</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,122,599</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total operating expenses</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">523,207</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">450,469</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(216,960</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">756,716</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) from operations</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">335,439</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">38,074</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(7,630</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">365,883</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zb93ba8fe3f024f1fa4d3f61c84b60bad" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Ionis Core</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Akcea Therapeutics</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Elimination of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intercompany Activity</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Revenue:</div></td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Commercial revenue:</div></td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SPINRAZA royalties</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">237,930</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">237,930</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">TEGSEDI product sales, net</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,237</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,237</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Licensing and other royalty revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,755</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12,000</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14,755</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 43.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total commercial revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">240,685</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14,237</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">254,922</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue under collaborative agreements</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">401,259</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">50,630</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(107,137</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">344,752</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total segment revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">641,944</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">64,867</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(107,137</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">599,674</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total operating expenses</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">380,212</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">295,683</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(14,849</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">661,046</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) from operations</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">261,732</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(230,816</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(92,288</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(61,372</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z4d329b28bc324ba3bbf9eb96d75066a3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Ionis Core</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Akcea Therapeutics</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Elimination of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intercompany Activity</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Revenue:</div></td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Commercial revenue:</div></td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SPINRAZA royalties</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">112,540</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">112,540</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Licensing and other royalty revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7,474</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7,474</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 43.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total commercial revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">120,014</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">120,014</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue under collaborative agreements</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">405,171</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">43,401</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(54,407</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">394,165</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total segment revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">525,185</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">43,401</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(54,407</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">514,179</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total operating expenses</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">373,788</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">163,871</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(54,527</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">483,132</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) from operations</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">151,397</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(120,470</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">120</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">31,047</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table shows our total assets by segment at December 31, 2019 and 2018 (in thousands), respectively.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z4b7b08804da24aa49b1b8bfdb2287736" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total Assets</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Ionis Core</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Akcea Therapeutics</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Elimination of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intercompany Activity</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,478,081</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">599,250</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(844,219</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,233,112</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,975,491</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">365,261</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(672,968</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,667,784</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8721-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6883840144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Long-Term Obligations and Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Long-Term Obligations</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The carrying value of our long-term obligations was as follows (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z3479120fb70c49dfbea272f920706f19" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.125 percent convertible senior notes</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">434,711</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1 percent convertible senior notes</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">275,333</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">568,215</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Long-term mortgage debt</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">59,913</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">59,842</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Principal balance of fixed rate note with Morgan Stanley (1)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12,500</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Leases and other obligations</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">17,569</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,163</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">787,526</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">646,720</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less: current portion</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2,026</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(13,749</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total Long-Term Obligations</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">785,500</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">632,971</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z2d1da80f1e1b4c8fb24d5d884387f78e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our $12.5 million fixed rate note with Morgan Stanley was included in our current portion of long-term obligations on our consolidated balance sheet at December 31, 2018. We paid off our fixed rate note in the third quarter of 2019.</div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Convertible Notes</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At December 31, 2019, we had the following <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.125%</span> Notes outstanding (amounts in millions except price per share data):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="za16edea38bc54e628301a72484af85b3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: top; padding-bottom: 2px; white-space: nowrap;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">0.125% <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Notes</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Outstanding principal balance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">548.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Maturity date</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: top; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 15, 2024</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Interest rate</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.125</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 88%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Conversion price per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">83.28</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total shares of common stock subject to conversion</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The following table summarizes information about the equity and liability components of our outstanding </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.125%</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes (in millions). We measured the fair values of the convertible notes outstanding based on quoted market prices, which is a Level 2 measurement at December 31, </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">:</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z7dc44d0a9b0443dda7f99ab1d70efbdf" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-indent: 3pt;">0.125% <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Notes</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Fair value of outstanding notes</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">558.7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Principal amount of convertible notes outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">548.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Unamortized portion of debt discount</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">105.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Long-term debt</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">434.7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Carrying value of equity component</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">105.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 27pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At December 31, 2019, we had the following 1% Notes outstanding (amounts in millions except price per share data):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zb43006877680441c81f9bc23fb14ec3e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: top; padding-bottom: 2px; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1% Notes</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Outstanding principal balance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">309.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Maturity date</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: top; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">November 30, 2021</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Interest rate</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: top; background-color: #CCEEFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1 percent</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 88%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Conversion price per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">66.81</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total shares of common stock subject to conversion</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The following table summarizes information about the equity and liability components of our outstanding </span>1%<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes (in millions). We measured the fair values of the convertible notes outstanding based on quoted market prices, which is a Level 2 measurement at December 31, </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">:</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zabdbc8437c344a2893cd480c7c4bf557" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-indent: 16pt;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Fair value of outstanding notes</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">354.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">725.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Principal amount of convertible notes outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">309.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">685.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Unamortized portion of debt discount</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">32.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">110.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Long-term debt</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">275.3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">568.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Carrying value of equity component</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">33.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">219.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We account for our convertible notes using an accounting standard that requires us to assign a value to our convertible debt equal to the estimated fair value of similar debt instruments without the conversion feature and to record the remaining portion in equity. As a result, we recorded our convertible notes at a discount, which we are amortizing as additional non-cash interest expense over the expected life of the respective debt. We determined our nonconvertible debt borrowing rate using a combination of the present value of the debt&#8217;s cash flows and a Black-Scholes valuation model. The following table summarizes the nonconvertible borrowing rate, effective interest rate and amortization period of our debt discount for our convertible notes:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z42f3873bea834b268c1005c0970cb12c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">
  <tr>
    <td style="width: 39.53%; vertical-align: bottom;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td style="width: 2.25%; vertical-align: bottom;">&#160;</td>
    <td style="width: 28.83%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1% Notes</div></td>
    <td style="width: 1.39%; vertical-align: top;">&#160;</td>
    <td style="width: 28%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">0.125%<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes</span></div></td>
  </tr>
  <tr>
    <td style="width: 39.53%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Nonconvertible debt borrowing rate</div></td>
    <td style="width: 2.25%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 28.83%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.4 percent</div></td>
    <td style="width: 1.39%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 28%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.4 percent</div></td>
  </tr>
  <tr>
    <td style="width: 39.53%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effective interest rate (1)</div></td>
    <td style="width: 2.25%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 28.83%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.5 percent</div></td>
    <td style="width: 1.39%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 28%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.9 percent</div></td>
  </tr>
  <tr>
    <td style="width: 39.53%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amortization period of debt discount</div></td>
    <td style="width: 2.25%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 28.83%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7 years</div></td>
    <td style="width: 1.39%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 28%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5 years</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z644a31acdd52488c97d7adc5c94171fd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For our 1% Notes, our effective interest rate represents our effective interest rate after our December 2019 debt exchange.&#160;</div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Maturity Schedules</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Annual debt and other obligation maturities, including fixed and determinable interest, at December 31, 2019 are as follows (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zbf1bb99a34ec45e78be045fb2e06c256" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,260</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2021</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">316,114</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2022</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,495</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2023</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,180</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2024</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">553,006</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Thereafter</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">64,429</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Subtotal</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">947,484</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less: current portion</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2,026</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less: fixed and determinable interest</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(28,014</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less: unamortized portion of debt discount</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(137,975</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Plus: lease liabilities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">17,235</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">796,704</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_LesseeOperatingLeaseInformationTableTextBlock', window );">Amounts Related to Operating Leases</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amounts related to our operating leases were as follows (dollar amounts in millions):</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z3d2e84cc75f74373b53127abdaff1269" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">At December 31, 2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Right-of-use operating lease assets (1)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating lease liabilities (2)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">17.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average remaining lease term</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.1 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average discount rate</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z49deda5f82f74fe1af4f88874881e5f9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Included in <span style="-sec-ix-hidden:Fact_f81ca57385a04657b8ecd0f06d505159">deposits and other assets</span> on our consolidated balance sheet.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z26af2e3421ce4117a512d5aa97d68ee7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Current portion of $2.0 million was included in <span style="-sec-ix-hidden:Fact_530181678e9244af8b37885d3ba85980">current portion of long-term obligations</span> on our consolidated balance sheet, with the difference included in <span style="-sec-ix-hidden:Fact_9c37cb3853f74a4f821bbe4ed37a06ba">long-term obligations</span>.</div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Payments for Operating Lease Liabilities</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As of December 31, 2019, the future payments for our operating lease liabilities are as follows (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z21d6f95567c944849963a4017490880d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Operating</span> <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Leases</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Year ending December 31,</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,285</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -0.2pt; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2021</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,022</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -0.2pt; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2022</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,781</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2023</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,520</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2024</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,396</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Thereafter</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,465</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total minimum lease payments</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23,469</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Imputed interest</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(6,234</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; margin-left: 36.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total operating lease liabilities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">17,235</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_LesseeOperatingLeaseInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information on lessee's operating leases, including carrying value of right-of-use assets and lease liabilities, weighted-average remaining term and weighted-average discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_LesseeOperatingLeaseInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph (a)<br> -Subparagraph (5)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6887987904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 303,262<span></span>
</td>
<td class="nump">$ 214,985<span></span>
</td>
<td class="num">$ (10,783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">12,540<span></span>
</td>
<td class="nump">10,706<span></span>
</td>
<td class="nump">6,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_OperatingLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use operating lease assets</a></td>
<td class="nump">1,542<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of patents</a></td>
<td class="nump">1,912<span></span>
</td>
<td class="nump">1,822<span></span>
</td>
<td class="nump">1,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium (discount) on investments, net</a></td>
<td class="num">(7,485)<span></span>
</td>
<td class="num">(1,013)<span></span>
</td>
<td class="nump">6,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">1,942<span></span>
</td>
<td class="nump">1,810<span></span>
</td>
<td class="nump">1,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of convertible senior notes discount</a></td>
<td class="nump">37,338<span></span>
</td>
<td class="nump">33,363<span></span>
</td>
<td class="nump">30,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfLeasedAsset', window );">Amortization of long-term financing liability for leased facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">146,574<span></span>
</td>
<td class="nump">131,312<span></span>
</td>
<td class="nump">85,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOnSaleOfInvestments', window );">Gain on investment in Regulus Therapeutics, Inc.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(374)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_GainLossOnExtinguishmentOfFinancingLiability', window );">Loss on extinguishment of financing liability for leased facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early retirement of debt</a></td>
<td class="nump">21,865<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes (including benefit from valuation allowance release)</a></td>
<td class="num">(7,096)<span></span>
</td>
<td class="num">(290,516)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments', window );">Non-cash losses related to patents, licensing, property, plant and equipment and investments</a></td>
<td class="nump">2,034<span></span>
</td>
<td class="nump">1,012<span></span>
</td>
<td class="nump">3,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Contracts receivable</a></td>
<td class="num">(47,674)<span></span>
</td>
<td class="nump">47,595<span></span>
</td>
<td class="nump">45,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(5,411)<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="num">(2,493)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other current and long-term assets</a></td>
<td class="num">(44,659)<span></span>
</td>
<td class="num">(29,348)<span></span>
</td>
<td class="num">(58,367)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Long-term income tax receivable</a></td>
<td class="nump">8,418<span></span>
</td>
<td class="num">(223)<span></span>
</td>
<td class="num">(9,114)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(16,343)<span></span>
</td>
<td class="num">(655)<span></span>
</td>
<td class="nump">1,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable', window );">Income taxes</a></td>
<td class="nump">31,656<span></span>
</td>
<td class="num">(710)<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="nump">8,089<span></span>
</td>
<td class="nump">4,117<span></span>
</td>
<td class="nump">965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities', window );">Accrued liabilities and deferred rent</a></td>
<td class="nump">16,499<span></span>
</td>
<td class="num">(17,023)<span></span>
</td>
<td class="nump">28,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred contract revenue</a></td>
<td class="num">(119,283)<span></span>
</td>
<td class="nump">494,254<span></span>
</td>
<td class="nump">30,182<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">345,720<span></span>
</td>
<td class="nump">602,888<span></span>
</td>
<td class="nump">174,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of short-term investments</a></td>
<td class="num">(1,946,726)<span></span>
</td>
<td class="num">(1,794,735)<span></span>
</td>
<td class="num">(877,810)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sale of short-term investments</a></td>
<td class="nump">1,951,734<span></span>
</td>
<td class="nump">882,824<span></span>
</td>
<td class="nump">557,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(30,905)<span></span>
</td>
<td class="num">(13,608)<span></span>
</td>
<td class="num">(34,764)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_PaymentsToAcquireLicensesAndOtherAssets', window );">Acquisition of licenses and other assets, net</a></td>
<td class="num">(5,377)<span></span>
</td>
<td class="num">(4,044)<span></span>
</td>
<td class="num">(3,093)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_PaymentsToAcquireCostMethodInvestments', window );">Purchase of strategic investments</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from the sale of Regulus Therapeutics, Inc.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,507<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(41,274)<span></span>
</td>
<td class="num">(929,563)<span></span>
</td>
<td class="num">(358,291)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from equity, net</a></td>
<td class="nump">119,657<span></span>
</td>
<td class="nump">27,900<span></span>
</td>
<td class="nump">22,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options</a></td>
<td class="num">(19,242)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from the issuance of 0.125 percent convertible senior notes</a></td>
<td class="nump">109,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">0.125 percent convertible senior notes issuance costs</a></td>
<td class="num">(10,428)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="nump">56,110<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForHedgeFinancingActivities', window );">Purchase of note hedges</a></td>
<td class="num">(108,684)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchases and retirements of common stock</a></td>
<td class="num">(34,392)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities', window );">Principal payments on debt and capital lease obligations</a></td>
<td class="num">(12,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,599)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock in Akcea Therapeutics, Inc. from its initial public offering, net of underwriters' discount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">110,438<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from building mortgage debt, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">59,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from the sale of Akcea Therapeutics, Inc. common stock to Novartis in a private placement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering costs paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_PaymentToSettleFinancingLiabilityForLeasedFacility', window );">Payment to settle financing liability for leased facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(80,133)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">100,021<span></span>
</td>
<td class="nump">475,865<span></span>
</td>
<td class="nump">229,087<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">404,467<span></span>
</td>
<td class="nump">149,190<span></span>
</td>
<td class="nump">44,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">278,820<span></span>
</td>
<td class="nump">129,630<span></span>
</td>
<td class="nump">84,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">683,287<span></span>
</td>
<td class="nump">278,820<span></span>
</td>
<td class="nump">129,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">9,870<span></span>
</td>
<td class="nump">9,592<span></span>
</td>
<td class="nump">8,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">9,041<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease liabilities</a></td>
<td class="nump">14,178<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NonCashCapitalAndPatentExpenditures', window );">Amounts accrued for capital and patent expenditures</a></td>
<td class="nump">3,126<span></span>
</td>
<td class="nump">4,428<span></span>
</td>
<td class="nump">1,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property, plant and equipment included in long-term obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,350<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesIssued1', window );">0.125 percent convertible senior notes principal issued related to our December 2019 debt exchange/issuance</a></td>
<td class="nump">439,326<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReduction', window );">1 percent convertible senior notes principal extinguished related to our December 2019 debt exchange</a></td>
<td class="nump">375,590<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ions_BiogenIncMember', window );">Biogen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">447,965<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ions_NovartisInternationalAGMember', window );">Novartis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 71,737<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill and an other than temporary decline in value that has been recognized against investments accounted for under the cost method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_GainLossOnExtinguishmentOfFinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the purchase price of the facility and the carrying value of our financing liability at the time of the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_GainLossOnExtinguishmentOfFinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and the change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NonCashCapitalAndPatentExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets and patents that have been incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NonCashCapitalAndPatentExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_OperatingLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_OperatingLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PaymentToSettleFinancingLiabilityForLeasedFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to settle financing liability for leased facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PaymentToSettleFinancingLiabilityForLeasedFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PaymentsToAcquireCostMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of investments accounted for under the cost method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PaymentsToAcquireCostMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PaymentsToAcquireLicensesAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of licenses and other assets not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PaymentsToAcquireLicensesAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfLeasedAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense charged against earnings for the periodic recognition of capitalized leases. This element may apply to energy companies that lease mineral producing properties and to other enterprises that capitalize property, plant, or equipment obtained through capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45031-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfLeasedAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying value and the sale price of an investment.  A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment.  This element refers to the Gain included in earnings and not to the cash proceeds of the sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in employer-related costs classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of notes issued in noncash investing and financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of notes retired (or transferred to another entity) in noncash investing or financing transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForHedgeFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3581-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForHedgeFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ions_BiogenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ions_BiogenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ions_NovartisInternationalAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ions_NovartisInternationalAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6863456672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies, Contracts Receivable (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractReceivablesAbstract', window );"><strong>Contracts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_PeriodAfterBillingWhenPaymentIsReceived', window );">Period of time after billing when payment is received</a></td>
<td class="text">3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PeriodAfterBillingWhenPaymentIsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The time period between billing a collaboration partner for goods delivered or services performed that are due unconditionally and payment is received from the collaboration partner, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PeriodAfterBillingWhenPaymentIsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6888007328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies, Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_AccruedClinicalExpenses', window );">Clincial expenses</a></td>
<td class="nump">$ 24,461<span></span>
</td>
<td class="nump">$ 22,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_AccruedInLicensingFeesCurrent', window );">In-licensing expenses</a></td>
<td class="nump">10,289<span></span>
</td>
<td class="nump">12,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other miscellaneous expenses</a></td>
<td class="nump">32,019<span></span>
</td>
<td class="nump">13,080<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 66,769<span></span>
</td>
<td class="nump">$ 47,503<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_AccruedClinicalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_AccruedClinicalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_AccruedInLicensingFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for in-licensing fees under collaboration agreements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_AccruedInLicensingFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6872900752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements and Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementsAndLicensingAgreementsAbstract', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangements and Licensing Agreements</a></td>
<td class="text">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">6. Collaborative Arrangements and Licensing Agreements</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Strategic Partnership</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Biogen</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We have several strategic collaborations with Biogen focused on using antisense technology to advance the treatment of neurological disorders. These collaborations combine our expertise in creating antisense medicines with Biogen&#8217;s expertise in developing therapies for neurological disorders. We developed and licensed to Biogen SPINRAZA, our approved medicine to treat people with spinal muscular atrophy, or SMA. In</span> December 2017, we entered into a collaboration with Biogen to identify <span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">new antisense medicines for the treatment of SMA</span>. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We and Biogen are currently developing </span>eight<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> medicines to treat neurodegenerative diseases under these collaborations, including medicines to treat people with ALS, Alzheimer&#8217;s disease</span><sub>&#160;</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">and Parkinson&#8217;s disease. In addition to these medicines, our collaborations with Biogen include a substantial research pipeline that addresses a broad range of neurological diseases. From inception through December 2019, we have received more than $</span>2.4<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> billion from our Biogen collaborations, including $</span>1<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> billion we received from Biogen in the second quarter of 2018 for our 2018 strategic neurology collaboration.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Spinal Muscular Atrophy Collaborations</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">SPINRAZA</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In January 2012, we entered into a collaboration agreement with Biogen to develop and commercialize SPINRAZA, an RNA-targeted therapy for the treatment of SMA. Biogen reported in </span>January 2020 that SPINRAZA was approved in over 50 countries around the world. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">From inception through December 2019, we earned more than $</span>1<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> billion in total revenue under our SPINRAZA collaboration, including more than $</span>640<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in revenue from SPINRAZA royalties and more than $</span>435<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in R&amp;D revenue. We are receiving tiered royalties ranging from </span>11 percent<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> to </span>15 percent<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> on net sales of SPINRAZA. We have exclusively in-licensed patents related to SPINRAZA from Cold Spring Harbor Laboratory and the University of Massachusetts. We pay Cold Spring Harbor Laboratory and the University of Massachusetts a low single digit royalty on net sales of SPINRAZA. Biogen is responsible for global development, regulatory and commercialization activities and costs for SPINRAZA.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We completed our performance obligations under our collaboration in 2016, including delivering the license to Biogen in July 2016. </span>We also earned additional milestone payments subsequent to delivering the license to Biogen that we recognized in full in the period each milestone payment became probable because we did not have a performance obligation related to each milestone payment. For example, we received $90 million of milestone payments for the approval of SPINRAZA in the EU and Japan in 2017 and recognized the full amounts into revenue in the period Biogen achieved the milestone events.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">New antisense medicines for the treatment of SMA</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In December 2017, we entered into a collaboration agreement with Biogen to </span>identify <span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">new antisense medicines for the treatment of SMA</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. </span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Biogen has the option to license therapies arising out of this collaboration following the completion of preclinical studies. Upon licensing, Biogen </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">will be responsible for all further global development, regulatory and commercialization activities and costs for such therapies</span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. Under the collaboration agreement, we received a </span>$25 million<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> upfront payment in December 2017. We will receive development and regulatory milestone payments from Biogen if new medicines advance towards marketing approval. </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In total over the term of our collaboration, we are eligible to receive up to $</span>1.2<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> billion in license fees, milestone payments and other payments, including up to $</span>80<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for the achievement of development milestones, up to $</span>180<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for the achievement of commercialization milestones and up to $</span>800<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for the achievement of sales milestones. In addition, we are eligible to receive tiered royalties </span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">from the mid-teens to </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">mid-</span>20 percent<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> range </span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">on net sales.</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> We will achieve the next payment of up to $</span>60<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">for the license of a medicine under this collaboration. </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of this collaboration, we identified one performance obligation, which was to perform R&amp;D services for Biogen. We determined the transaction price to be the $25 million upfront payment we received when we entered into the collaboration. We allocated the transaction price to our single performance obligation. In the fourth quarter of 2019, we completed our R&amp;D services performance obligation under this collaboration. We were recognizing revenue as we performed services based on our effort to satisfy our performance obligation relative to the total effort expected to satisfy our performance obligation. We completed our performance obligation earlier than we previously estimated, as a result, we recognized $8.3 million of additional revenue in the fourth quarter of 2019. We do not have any remaining performance obligations under this collaboration. We will receive development and regulatory milestone payments from Biogen if Biogen advances the development candidate under this collaboration toward marketing approval.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Neurology Collaborations</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">2018 Strategic Neurology</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In April 2018, we and Biogen entered into a strategic collaboration to develop novel antisense medicines for a broad range of neurological diseases and entered into a SPA. As part of the collaboration, Biogen gained exclusive rights to the use of our antisense technology to develop therapies for these diseases for </span>10<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> years. We are responsible for the identification of antisense drug candidates based on selected targets</span>. Biogen is responsible for conducting IND-enabling toxicology studies for the selected target. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Biogen will have the option to license the selected target </span>after it completes the IND-enabling toxicology study. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">If Biogen exercises its option to license a medicine, it will assume </span>all <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">further global development, regulatory and commercialization responsibilities and costs for that medicine.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In the second quarter of 2018, we received </span>$1 billion from Biogen, comprised of $625 million to purchase our stock at an approximately 25 percent cash premium and $375 million in an upfront payment. <span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We are eligible to receive up to $</span>270<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in milestone payments for each medicine that achieves marketing approval. </span>In addition, we are eligible to receive tiered royalties <span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">up to the </span>20 percent range <span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">on net sales.</span> From inception through December 2019, we have received over $1 billion in payments under this collaboration, excluding $15 million we generated in the fourth quarter of 2019 for advancing two targets under this collaboration. We will achieve the next payment of $7.5 million if Biogen designates another target<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> under this collaboration. </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">At the commencement of this collaboration, </span>we identified one performance obligation, which was to perform R&amp;D services for Biogen.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> We determined our transaction price to be $</span>552<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million, comprised of $</span>375<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million from the upfront payment and $</span>177<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for the premium paid by Biogen for its purchase of our common stock.</span> We determined the fair value of the premium we received by using the stated premium in the SPA and applying a lack of marketability discount. We included a lack of marketability discount in our valuation of the premium because Biogen received restricted shares of our common stock. We allocated the transaction price to our single performance obligation. From inception through December 2019, we have included $597 million in payments in the transaction price for our R&amp;D services performance obligation under this collaboration, including four $7.5 million milestone payments we achieved in 2019 for advancing four<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>targets under this collaboration. These milestone payments did not create new performance obligations because they are part of our original R&amp;D services performance obligation. Therefore, we included these amounts in our transaction price for our R&amp;D services performance obligation in the period we achieved the milestone payment. We are recognizing revenue for our R&amp;D services performance obligation as we perform services based on our effort to satisfy our performance obligation relative to our total effort expected to satisfy our performance obligation. We<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> currently estimate we will satisfy our performance obligation in </span>June 2028.</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">2013 Strategic Neurology</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In September 2013, we and Biogen entered into a long-term strategic relationship focused on applying antisense technology to advance the treatment of neurodegenerative diseases. As part of the collaboration, Biogen gained exclusive rights to the use of our antisense technology to develop therapies for neurological diseases and has the option to license medicines resulting from this collaboration. We will usually be responsible for drug discovery and early development of antisense medicines and Biogen will have the option to license antisense medicines after Phase 2 proof-of-concept. In October 2016, we expanded our collaboration to include additional research activities we will perform. If Biogen exercises its option to license a medicine, it will assume all further global development, regulatory and commercialization responsibilities and costs for that medicine. We are currently advancing five medicines in development under this collaboration, including a medicine for Parkinson&#8217;s disease, two medicines for ALS and two medicines for undisclosed targets. In December 2018, Biogen exercised its option to license one of our ALS medicines, tofersen, and as a result Biogen is now responsible for all further global development, regulatory and commercialization activities and costs for tofersen.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under the terms of the agreement, we received an upfront payment of $100 million and are eligible to receive milestone payments, license fees and royalty payments for all medicines developed under this collaboration, with the specific amounts dependent upon the modality of the molecule advanced by Biogen. For each antisense molecule that is chosen for drug discovery and development under this collaboration, we are eligible to receive up to approximately $260 million in a license fee and milestone payments per program. The $260 million per program consists of approximately $60 million in development milestones, including amounts related to the cost of clinical trials, and up to $130 million in milestone payments if Biogen achieves pre-specified regulatory milestones. In addition, we are eligible to receive tiered royalties up to the mid-teens on net sales from any antisense medicines developed under this collaboration. From inception through December 2019, we have received over $240 million in upfront fees, milestone payments and other payments under this collaboration. We will achieve the next payment of up to $10 million if we advance a program under this collaboration.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of our strategic neurology collaboration, we identified one performance obligation, which was to perform R&amp;D services for Biogen. At inception, we determined the transaction price to be the $100 million upfront payment we received and allocated it to our single performance obligation. As we achieve milestone payments for our R&amp;D services, we include these amounts in our transaction price for our R&amp;D services performance obligation. We are recognizing revenue for our R&amp;D services performance obligation based on our effort to satisfy our performance obligation relative to our total effort expected to satisfy our performance obligation<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. </span>In the third quarter of 2019, we updated our estimate of the total effort we expect to expend to satisfy our performance obligation. As of September 30, 2019, we had completed a<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> significant portion of the research and development services. We expect to complete the remainder of our services in 2020. </span>As a result, we recorded a cumulative catch up adjustment of $16.5 million to decrease revenue in the third quarter of 2019. We will recognize this amount over the estimated remaining period we will perform services. From inception through December <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2019</span>, we have included $145 million in total payments in the transaction price for our R&amp;D services performance obligation.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under this collaboration, we have also generated additional payments that we concluded were not part of our R&amp;D services performance obligation. We recognized each of these payments in full in the respective quarter we generated the payment because we did not have any performance obligations for the respective payment. The following are the payments we generated in 2018 and 2019:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zf702cef10ad9420fbb18fe4148806ca7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the third quarter of 2018, we earned a $10 million milestone payment when Biogen initiated a Phase 1 study of IONIS-C9<sub>Rx</sub>. </div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zd8bea4369b954832b61973bbc3eb6b4b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the fourth quarter of 2018, we earned a $35 million license fee when Biogen licensed tofersen from us because Biogen had full use of the licenses without any continuing involvement from us.</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z0d772d1d1a5a49d0bbf4e2f24aeb9608" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the fourth quarter of 2018, we earned <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">a $</span>5<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million milestone when Biogen initiated a Proof-of-Concept study for tofersen</span></div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z7067decd235e4169aa6e8ded911dd106" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the third quarter of 2019, we earned an $8 million milestone payment when Biogen initiated a Phase 1/2 study of ION859 (IONIS-LRRK2<sub>Rx</sub>) <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">for the treatment of people with Parkinson&#8217;s disease </span>under this collaboration. </div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze7ef725125ba4d91b9d7e95ae4eb1fa0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the fourth quarter of 2019, we earned a $10 million milestone payment when Biogen advanced IONIS-C9<sub>Rx</sub>. </div></td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">2012 Neurology</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In December 2012, we and Biogen entered into a collaboration agreement to develop and commercialize novel antisense medicines to up to three targets to treat neurodegenerative diseases. We are responsible for the development of each of the medicines through the completion of the initial Phase 2 clinical study for such medicine. Biogen has the option to license a medicine from each of the programs through the completion of the first Phase 2 study for each program. We are currently advancing IONIS-MAPT<sub>Rx</sub> for Alzheimer&#8217;s disease and ION581 for Angelman syndrome under this collaboration. If Biogen exercises its option to license a medicine, it will assume all further global development, regulatory and commercialization responsibilities and costs for that medicine. In December 2019, Biogen exercised its option to license IONIS-MAPT<sub>Rx</sub> and as a result Biogen is now responsible for all further global development, regulatory and commercialization activities and costs for IONIS-MAPT<sub>Rx</sub>.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Under the terms of the agreement, we received an upfront payment of $</span>30<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million. Over the term of the collaboration, we are eligible to receive up to $</span>210<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in a license fee and milestone payments per program, plus a mark-up on the cost estimate of the Phase 1 and 2 studies. The $</span>210<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million per program consists of up to $</span>10<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in development milestone payments, plus a mark-up on the cost estimate of the Phase 1 and 2 studies and up to $</span>130<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in milestone payments if Biogen achieves pre-specified regulatory milestones. In addition, we are eligible to receive tiered royalties up to the mid-teens on net sales of any medicines resulting from each of the </span>three<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> programs. From inception through December 2019, we have received $</span>130<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in payments under this collaboration, including $</span>45<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million we earned when Biogen licensed IONIS-MAPT</span><sub>Rx </sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">and $</span>10<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million when Biogen advanced ION581, both of which occurred in the fourth quarter of 2019. We also achieved a $</span>7.5<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million milestone payment in the first quarter of 2020 when we advanced IONIS-MAPT</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. We will achieve the next payment of $</span>12<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>million if we continue to advance IONIS-MAPT<sub>Rx</sub>.</div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under our collaboration, we determined we had a performance obligation to perform R&amp;D services. We allocated $40 million in total payments to the transaction price for our R&amp;D services performance obligation. In the third quarter of 2019, we completed our R&amp;D services performance obligation when we designated a development candidate and Biogen accepted the development candidate. Biogen&#8217;s decision to accept the development candidate was not within our control. We were recognizing revenue as we performed services based on our effort to satisfy our performance obligation relative to the total effort expected to satisfy our performance obligation. Because Biogen accepted the development candidate earlier than when we were previously estimating, we recognized $6.3 million of accelerated revenue in the third quarter of 2019.</div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">When we commenced development for IONIS-MAPT<sub>Rx</sub> we identified our development work as a separate performance obligation. We are recognizing for our IONIS-MAPT<sub>Rx</sub> development performance obligation based on the percentage of completion. From inception through December 2019, we have included $37.5 million in the transaction price for our IONIS-MAPT<sub>Rx</sub> development performance obligation. We currently estimate we will satisfy our performance obligation in September 2020. Our total transaction price for our IONIS-MAPT<sub>Rx </sub>development performance obligation includes the following payments we achieved in 2019 related to our development work:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zb049489b4a5f433bbe2ed2024d5f35c3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the second quarter of 2019, we achieved a $7.5 million milestone payment from Biogen when we advanced IONIS-MAPT<sub>Rx </sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">for Alzheimer&#8217;s disease</span> under this collaboration. </div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z635746e4788a4facb52952eeb34cfca2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the fourth quarter of 2019, we achieved a $12 million milestone payment from Biogen when we entered into an agreement to conduct a long-term extension study for IONIS-MAPT<sub>Rx</sub>. </div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the fourth quarter of 2019, we identified another performance obligation upon Biogen&#8217;s license of IONIS-MAPT<sub>Rx</sub> because the license we granted to Biogen is distinct from our other performance obligations. We recognized the $45 million license fee for IONIS-MAPT<sub>Rx</sub> as revenue at that time because Biogen had full use of the license without any continuing involvement from us. Additionally, we did not have any further performance obligations related to the license after we delivered it to Biogen.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the fourth quarter of 2019, we <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">earned a $</span>10<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million milestone payment when Biogen advanced ION581. We recognized this milestone payment in full in the fourth quarter of 2019 because we do not have any performance obligations related to this milestone payment.</span></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with Biogen (in millions, except percentage amounts):</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z0380747c43454884ab39653ff62a443c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SPINRAZA royalties (commercial revenue)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">293.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">237.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">112.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">180.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">137.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">150.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total revenue from our relationship with Biogen</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">473.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">375.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">263.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">42</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">63</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">51</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our </span>consolidated balance sheet at <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">December 31, </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and </span>2018<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> included deferred revenue of $</span>525.8<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million and $</span>580.9<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million, respectively, related to our relationship with Biogen.</span></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Research, Development and Commercialization Partners</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">AstraZeneca</div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Cardiovascular, Renal and Metabolic Diseases Collaboration</div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In July 2015, we and AstraZeneca formed a collaboration to discover and develop antisense therapies for treating cardiovascular, renal and metabolic diseases. Under our collaboration, AstraZeneca has licensed </span>three<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> medicines from us: IONIS-AZ4-2.5-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, a medicine we designed to treat cardiovascular disease and our first </span>medicine that combines our Generation 2.5 and<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> LICA technology, ION532, a medicine we designed to </span>treat a genetically associated form of kidney disease and <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">ION839, a medicine we designed to </span>inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis, or NASH<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. AstraZeneca is responsible for all further global development, regulatory and commercialization activities and costs for each of the medicines it has licensed and any medicines AstraZeneca licenses in the future.</span></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under the terms of the agreement, we received a $65 million upfront payment. We are eligible to receive license fees and milestone payments of up to more than $4 billion as medicines under this collaboration advance, including up to $1.1 billion for the achievement of development milestones and up to $2.9 billion for regulatory milestones. In addition, we are eligible to receive tiered royalties up to the low teens on net sales from any product that AstraZeneca successfully commercializes under this collaboration agreement. We will achieve the next payment of $10 million under this collaboration if we advance a medicine under this collaboration<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</span> From inception through December 2019, we have received over $175 million in upfront fees, license fees, milestone payments, and other payments under this collaboration, including a $10 million milestone payment we earned in the fourth quarter of 2019 when AstraZeneca initiated a Phase 1 trial for ION839.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of this collaboration, we identified one performance obligation, which was to perform R&amp;D services for AstraZeneca. We determined the transaction price to be the $65 million upfront payment we received and we allocated it to our single performance obligation. We are recognizing revenue for our R&amp;D services performance obligation as we perform services based on our effort to satisfy this performance obligation relative to our total effort expected to satisfy our performance obligation. We<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> currently estimate we will satisfy this performance obligation in</span> August 2021. As we achieve milestone payments for our R&amp;D services, we include these amounts in our transaction price for our R&amp;D services performance obligation. From inception through December<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> 2019</span>, we have included $90 million in payments in the transaction price for our R&amp;D services performance obligation.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under this collaboration, we have also generated additional payments that we concluded were not part of our R&amp;D services performance obligation. We recognized each of these payments in full in the respective quarter we generated the payment because the payments were distinct and we did not have any performance obligations for the respective payment. The following are the payments we have earned:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z4e81e175835f49a2a473992532fd14cc" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In the first quarter of 2018, we earned </span>two<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>$30 million license fees when AstraZeneca licensed ION532 and ION839 because AstraZeneca had full use of the licenses without any continuing involvement from us. </div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z984f9fae8d6743d1acd0c178a6cbc814" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the third quarter of 2018, we earned a $10 million milestone payment when AstraZeneca initiated a Phase 1 study of IONIS-AZ4-2.5-L<sub>Rx</sub>. </div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z6311690ca5444922891b858eebbeb95b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the fourth quarter of 2019, we earned a $10 million milestone payment when AstraZeneca initiated a Phase 1 study of ION839. </div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Oncology Collaboration</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In December 2012, we entered into a collaboration agreement with AstraZeneca to discover and develop antisense medicines to treat cancer. As part of the agreement, we granted AstraZeneca an exclusive license to develop and commercialize </span>danvatirsen <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">for the treatment of cancer. AstraZeneca is responsible for all global development, regulatory and commercialization activities for </span>danvatirsen<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. We and AstraZeneca have evaluated </span>danvatirsen<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in people with head and neck cancer, advanced lymphoma and advanced metastatic hepatocellular carcinoma. AstraZeneca is evaluating </span>danvatirsen<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in combination with durvalumab, AstraZeneca&#8217;s PD-L1, blocking medicine, in people with head and neck cancer, metastatic bladder cancer and metastatic non-small cell lung cancer. We and AstraZeneca also established an oncology research program. AstraZeneca has the option to license medicines resulting from the program, and if AstraZeneca exercises its option to license a medicine, it will be responsible for all further global development, regulatory and commercialization activities and costs for such medicine. In the fourth quarter of 2018, we added </span>ION736 (formerly IONIS-AZ7-2.5<sub>Rx</sub>) to our preclinical pipeline, a second medicine under our oncology collaboration.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Under the terms of this agreement, we received $</span>31<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in upfront payments. We are eligible to receive milestone payments and license fees from AstraZeneca as programs advance in development. If AstraZeneca successfully develops </span>danvatirsen<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and ION736 under the research program, we could receive license fees and milestone payments of up to more than $</span>450<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million, including up to $</span>152<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for the achievement of development milestones and up to $</span>275<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for the achievement of regulatory milestones. In addition, we are eligible to receive tiered royalties up to the mid-teens on net sales from any medicines resulting from these programs. From inception through December 2019, we have received over $</span>125<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in upfront fees, milestone payments, and other payments under this oncology collaboration, including nearly $</span>30<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million in milestone payments we achieved when AstraZeneca advanced </span>danvatirsen and ION736, in the fourth quarter of 2018. We <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">will achieve the next payment of up to $</span>25<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">if we advance a medicine under our cancer research program with AstraZeneca.</span></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of this collaboration, we identified four performance obligations, three of which we completed in March 2014 and we completed the remaining R&amp;D services performance obligation in February 2018. In the fourth quarter of 2018, we earned a $17.5 million milestone payment and a $10 million milestone payment when AstraZeneca advanced two programs under our collaboration. We recognized these milestone payments in full in the fourth quarter because we do not have any performance obligations related to these milestone payments.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with AstraZeneca (in millions, except percentage amounts):</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z3e98572cb7a74e948b59d5a9feec5657" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">28.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">120.7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our </span>consolidated balance sheet at <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">December 31, </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and </span>2018<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> included deferred revenue of $</span>25.0<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million and $</span>40.1<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million, respectively, related to our relationship with AstraZeneca.</span></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Bayer</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In May 2015, we entered into an exclusive license agreement with Bayer to develop and commercialize IONIS-FXI<sub>Rx</sub> for the prevention of thrombosis. We were responsible for completing a Phase 2 study of IONIS-FXI<sub>Rx</sub> in people with end-stage renal disease on hemodialysis. Under the terms of the agreement, we received a $100 million upfront payment in the second quarter of 2015. In February 2017, we amended our agreement with Bayer to advance IONIS-FXI<sub>Rx</sub> and to initiate development of IONIS-FXI-L<sub>Rx</sub>, which Bayer licensed. In conjunction with the decision to advance these programs, we received a $75 million payment from Bayer. In October 2019, Bayer decided it would advance IONIS-FXI-L<sub>Rx</sub> following positive clinical results. Bayer is now responsible for all global development, regulatory and commercialization activities and costs for the FXI program.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are eligible to receive up to $385 million in license fees, milestone payments and other payments, including up to $125 million for the achievement of development milestones and up to $110 million for the achievement of commercialization milestones. In addition, we are eligible to receive tiered royalties in the low to high 20 percent range on gross margins of both medicines combined. From inception through December 2019, we have received over $185 million from our Bayer collaboration, including a $10 million milestone payment we earned in the fourth quarter of 2019 when Bayer decided it would advance IONIS-FXI-L<sub>Rx</sub>. We will achieve the next payment of $20 million if Bayer initiates a Phase 3 study for the FXI program.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of this collaboration, we identified three performance obligations, the license of IONIS-FXI<sub>Rx</sub>, which we delivered in May 2016, R&amp;D services and delivery of API, both of which we completed in November 2016.</div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In February 2017, when we amended our collaboration with Bayer, we identified two new performance obligations<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, </span>one<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for the license of IONIS-FXI-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and </span>one<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for R&amp;D services</span>. We determined the transaction price to be the $75 million payment. We allocated $64.9 million to <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">the license of IONIS-FXI-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> based on its estimated relative stand-alone selling price and recognized the associated revenue upon our delivery of the license in the first quarter of 2017. We allocated $</span>10.1<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million to our R&amp;D services performance obligation based on an estimated relative stand-alone selling price. </span>We recognized revenue for our R&amp;D services performance obligation as we performed services based on our effort to satisfy our performance obligation relative to our total effort expected to satisfy our performance obligation which we completed in the third quarter of 2019.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the fourth quarter of 2019, we earned a $10 million milestone payment when Bayer decided it would advance IONIS-FXI-L<sub>Rx</sub>. We recognized this milestone payment in full in the fourth quarter of 2019 because we do not have any performance obligations related to this milestone payment.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with Bayer (in millions, except percentage amounts):</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zb1073dc32a5e4c66a2a664b0634da7c6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">67.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our </span>consolidated balance sheet at <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">December 31, 2019 and 2019 included deferred revenue of $</span>2.4<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million and $</span>4.3<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million, respectively, related to our relationship with Bayer.</span></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">GSK</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In March 2010, we entered into an alliance with GSK using our antisense drug discovery platform to discover and develop new medicines against targets for rare and serious diseases, including infectious diseases and some conditions causing blindness. Under the terms of the agreement, we received upfront payments of $35 million. Our collaboration with GSK currently includes two medicines targeting hepatitis B virus, or HBV: IONIS-HBV<sub>Rx</sub> and IONIS-HBV-L<sub>Rx</sub>, which we designed to reduce the production of viral proteins associated with HBV infection. In the third quarter of 2019, following positive Phase 2 results, GSK licensed our HBV program. GSK is responsible for all global development, regulatory and commercialization activities and costs for the HBV program.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under our agreement, if GSK successfully develops these medicines and achieves pre-agreed sales targets, we could receive license fees and milestone payments of up to $262 million, including up to $47.5 million for the achievement of development milestones, up to $120 million for the achievement of regulatory milestones and up to $70 million for the achievement of commercialization milestones. In addition, we are eligible to receive tiered royalties up to the mid-teens on net sales from any product that GSK successfully commercializes under this alliance. From inception through December 2019, we have received more than $189 million in payments under this alliance with GSK, including a $25 million license fee we earned in the third quarter of 2019 when GSK licensed the HBV program. We will achieve the next payment of $15 million when GSK initiates a Phase 3 study of a medicine under this program.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We completed our R&amp;D services performance obligations under our collaboration in March 2015. </span>We identified a new performance obligation when we granted GSK the license of the HBV program and assignment of related intellectual property rights in the third quarter of 2019 because the license is distinct from our other performance obligations. We recognized the $25 million license fee for the HBV program as revenue at that time because GSK had full use of the license without any continuing involvement from us. Additionally, we did not have any further performance obligations related to the license after we delivered it to GSK.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We do not have any remaining performance obligations under our collaboration with GSK; however, we can still earn additional payments and royalties as GSK advances the HBV program.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with GSK (in millions, except percentage amounts):</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zfc1697a2c45e4e5d9ba00caf3a13ead3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">25.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We did not have any deferred revenue from our relationship with GSK at December 31, 2019 and 2018.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Janssen Biotech, Inc.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In December 2014, we entered into a collaboration agreement with Janssen Biotech, Inc. to discover and develop antisense medicines that can be locally administered, including oral delivery, to treat autoimmune disorders of the GI tract. Janssen had the option to license medicines from us through the designation of development candidates for up to three programs. Under our collaboration, Janssen licensed ION253 in November 2017, which is currently in preclinical development. Prior Janssen&#8217;s license of ION253, we were responsible for the discovery activities to identify development candidates. Under the license, Janssen is responsible for the global development, regulatory and commercial activities for ION253.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under the terms of the agreement, we received $35 million in upfront payments. We are eligible to receive up to more than $285 million in license fees and milestone payments for these programs, including up to $65 million for the achievement of development milestones, up to $160 million for the achievement of regulatory milestones and up to $60 million for the achievement of commercialization milestones. From inception through December 2019, we have received over $75 million. In addition, we are eligible to receive tiered royalties up to the near teens on net sales from any medicines resulting from this collaboration. We will achieve the next payment of $5 million if Janssen continues to advance a target under this collaboration.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of this collaboration, we identified one performance obligation, which was to perform R&amp;D services for Janssen. We determined the transaction price to be the $35 million upfront payments we received. We allocated the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</span>35<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million</span> to our single performance obligation. As we achieved milestone payments for our R&amp;D services, we included these amounts in our transaction price for our R&amp;D services performance obligation. We recognized revenue for our R&amp;D services performance obligation over our period of performance, which ended in November 2017.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We identified separate performance obligation when Janssen licensed ION253 under our collaboration because the license we granted to Janssen was distinct from our other performance obligations. We recognized the $5 million license fee for ION253 in November 2017, because Janssen had full use of the licenses without any continuing involvement from us. Additionally, we did not have any further performance obligations related to the license after we delivered it to Janssen.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with Janssen (in millions, except percentage amounts):</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zf8941280a0a94e81bb425341b948878a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">36.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We did not have any deferred revenue from our relationship with Janssen at December 31, 2019 and 2018.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Roche</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Huntington&#8217;s Disease</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In April 2013, we formed an alliance with Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd., collectively Roche, to develop treatments for HD based on our antisense technology. Under the agreement, we discovered and developed tominersen, an antisense medicine targeting HTT protein. We developed tominersen through completion of our Phase 1/2 clinical study in people with early stage HD. In December 2017, upon completion of the Phase 1/2 study, Roche exercised its option to license tominersen<sub>&#160;</sub>and is now responsible for the global development, regulatory and commercialization activities and costs for tominersen.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under the terms of the agreement, we received an upfront payment of $30 million in April 2013 and an additional $3 million payment in 2017. We are eligible to receive up to $365 million in a license fee and milestone payments including up to $70 million for the achievement of development milestones, up to $170 million for the achievement of regulatory milestones and up to $80 million for the achievement of commercialization milestones. In addition, we are eligible to receive up to $136.5 million in milestone payments for each additional medicine successfully developed. We are also eligible to receive tiered royalties up to the mid-teens on any net sales of any product resulting from this alliance. From inception through December 2019, we have received over $145 million in upfront fees, milestone payments and license fees for advancing tominersen, including $35 million in milestone payments we earned in the first quarter of 2019 when Roche dosed the first patient in a Phase 3 study for tominersen. We will achieve the next payment of $15 million if Roche advances tominersen.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of this collaboration, we identified one performance obligation, which was to perform R&amp;D services for Roche. We determined the transaction price to be the $30 million upfront payment we received and allocated it to our single performance obligation. As we achieved milestone payments for our R&amp;D services, we included these amounts in our transaction price for our R&amp;D services performance obligation. We recognized revenue for our R&amp;D services performance obligation over our period of performance, which ended in September 2017.</div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under this collaboration, we have also generated additional payments that we concluded were not part of our R&amp;D services performance obligation. We recognized each of these payments in full in the respective quarter we generated the payment because the payments were distinct and we did not have any performance obligations for the respective payment. The following are the payments we have earned:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z2cb9bd0d8147431e8242225e5734bea8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the fourth quarter of 2017, we earned a $45 million license fee when Roche licensed tominersen because Roche had full use of the license without any continuing involvement from us. </div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z3ba97b8a23374e16b9cd8bc689285c53" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the first quarter of 2019, we earned $35 million in milestone payments when Roche dosed the first patient in the Phase 3 study of tominersen in the first quarter of 2019. </div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We do not have any remaining performance obligations related to tominersen under this collaboration with Roche; however, we can still earn additional payments and royalties as Roche advances tominersen.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">IONIS-FB-L</span><sub><span style="background-color: #FBFBFB;">Rx</span></sub><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for Complement-Mediated Diseases</span></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In October 2018, we entered into a collaboration agreement with Roche to</span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> develop IONIS-FB-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for the treatment of complement-mediated diseases. We are currently conducting Phase 2 studies in two disease indications for </span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">IONIS-FB-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, one for the treatment of patients with geographic atrophy, or GA, the advanced stage of dry age-related macular degeneration, or AMD, and a second for the treatment of patients with IgA nephropathy. </span>Roche<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> has the option to license IONIS-FB-L</span><sub><span style="background-color: #FBFBFB;">Rx</span></sub><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> at the completion of these studies. Upon licensing, </span>Roche <span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">will be responsible for all further global development, regulatory and commercialization activities and costs.</span></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Under the terms of this agreement, we received a </span>$75 million<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> upfront payment in October 2018. We are eligible to receive up to </span>$684 million<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in development, regulatory and sales milestone payments and license fees. In addition, we are also eligible to receive tiered royalties from the high teens to </span>20 percent<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> on net sales. We will achieve the next payment of $</span>20<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million when we advance </span>the Phase 2 study in patients with dry AMD<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</span></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of this collaboration, we identified one performance obligation, which was to perform R&amp;D services for Roche. We determined the transaction price to be the $75 million upfront payment we received and allocated it to our single performance obligation. We are recognizing revenue for our R&amp;D services performance obligation as we perform services based on our effort to satisfy our performance obligation relative to our total effort expected to satisfy our performance obligation. We<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> currently estimate we will satisfy our performance obligation in </span>December 2022.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with Roche (in millions, except percentage amounts):</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z3751bf5f787c451499c06571891a9800" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">57.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">55.7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our </span>consolidated balance sheet at <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">December 31, </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and 2018 included deferred revenue of $</span>52.3<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million and $</span>72.6<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million related to our relationship with Roche, respectively.</span></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Akcea Collaborations</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following collaboration agreements relate to Akcea, our majority owned affiliate. Akcea is responsible for the development activities under these collaborations. As such, Akcea recognizes the associated revenue earned, cash received and expenses incurred in its statement of operations, which we reflect in our consolidated results. We also reflect the noncontrolling interest attributable to other owners of Akcea&#8217;s common stock in a separate line on our statement of operations and a separate line within stockholders&#8217; equity on our consolidated balance sheet.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For each of Akcea's collaborations Akcea pays us sublicense fees for payments that it receives and we recognize those fees as revenue in our Ionis Core operating segment results and Akcea recognizes the fees as R&amp;D expense. In our consolidated results, we eliminate any sublicense revenue and expense.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Novartis</div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In January 2017, we and Akcea initiated a collaboration with Novartis to develop and commercialize AKCEA-APO(a)-L<sub>Rx</sub> and AKCEA-APOCIII-L<sub>Rx</sub>.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea received a $75 million upfront payment in the first quarter of 2017, of which it retained $60 million and paid us $15 million as a sublicense fee. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In February 2019, Novartis licensed AKCEA-APO(a)-L</span><sub>Rx</sub> and Akcea earned a $150 million license fee. Akcea paid us $75 million as a sublicense fee in 2.8 million shares of Akcea common stock. Novartis is responsible for conducting and funding all future development, regulatory and commercialization activities for AKCEA-APO(a)-L<sub>Rx</sub>, including a global Phase 3 cardiovascular outcomes study, which Novartis initiated in December 2019.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>In connection with Novartis&#8217; license of AKCEA-APO(a)-L<sub>Rx</sub>, Akcea and Novartis established a more definitive framework under which the companies would negotiate the co-commercialization of AKCEA-APO(a)-L<sub>Rx</sub> in selected markets. Included in this framework is an option by which Novartis could solely commercialize AKCEA-APO(a)-L<sub>Rx</sub> in exchange for Novartis paying Akcea increased commercial milestone payments based on sales of AKCEA-APO(a)-L<sub>Rx</sub>.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> When Novartis decided to not exercise its option for </span>AKCEA-APOCIII-L<sub>Rx</sub>, Akcea retained rights to develop and commercial AKCEA-APOCIII-L<sub>Rx</sub>.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under the collaboration, Akcea is eligible to receive up to $675 million in milestone payments, including $25 million for the achievement of a development milestone, up to $290 million for the achievement of regulatory milestones and up to $360 million for the achievement of commercialization milestones. Akcea is also eligible to receive tiered royalties in the mid-teens to low 20 percent range on net sales of AKCEA-APO(a)-L<sub>Rx</sub>. Akcea will pay 50 percent of these license fees, milestone payments and royalties to us as sublicense fees.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In conjunction with this collaboration, we entered into a SPA with Novartis. As part of the SPA, Novartis purchased 1.6 million shares of our common stock for $100 million in the first quarter of 2017. As part of the SPA, Novartis was required to purchase $50 million of Akcea&#8217;s common stock at the IPO price or our common stock at a premium if an IPO did not occur by April 2018. Under the SPA, in July 2017, Novartis purchased $50 million of Akcea&#8217;s common stock in a separate private placement concurrent with the completion of Akcea's IPO at a price per share equal to the IPO price.</div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of this collaboration, Akcea identified four separate performance obligations:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="za92dcc9ca554450dbde079edd52a748b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D services for AKCEA-APO(a)-L<sub>Rx</sub>;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z969c1fbd3a7d4bceb111d5b8034e0da7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D services for AKCEA-APOCIII-L<sub>Rx</sub>;<sub>&#160;</sub></div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z7a53186ffac14cde8f9dafbcae98b1ee" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">API for AKCEA-APO(a)-L<sub>Rx</sub>; and </div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z5c9cb7188be64f6fa8629693209b9498" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">API for AKCEA-APOCIII-L<sub>Rx</sub>. </div></td>
  </tr>
</table>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea determined that the R&amp;D services for each medicine and the API for each medicine were distinct from its other performance obligations.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea determined our transaction price to be $108.4 million, comprised of the following:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z95c64f6ac223413087c92b4e7148ad52" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$75 million from the upfront payment;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z5fda1af0585f4b50aece02928629da77" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$28.4 million for the premium paid by Novartis for its purchase of our common stock at a premium in the first quarter of 2017; and </div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zd1af860b61eb4d06adc195cc22f1eefa" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$5.0 million for the potential premium Novartis would have paid if they purchased our common stock in the future.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -36pt; margin-left: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea allocated the transaction price based on the estimated stand-alone selling price of each performance obligation as follows:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zf1ec8c14e9fd4097a634d42230b5ed2d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</span>64.0<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for the R&amp;D services for </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">AKCEA-APO(a)-L</span><sub style="font-family: 'Times New Roman';">Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">;</span></div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z4d65be2b97bf4dc992b6d7f8890d35fe" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$40.1 million for the R&amp;D services for <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">AKCEA-APOCIII-L</span><sub style="font-family: 'Times New Roman';">Rx</sub>; </div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z4a5a892931aa46dcbb360dd2c2da8d07" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1.5</span> million for the delivery of AKCEA-APO(a)-L<sub>Rx</sub> API; and</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z70a24658629e48879924f550d9d26261" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2.8</span> million for the delivery of AKCEA-APOCIII-L<sub>Rx</sub> API.</div></td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea recognized revenue related to each of the performance obligations as follows:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z4ad445a40aac4d02b766c98537df051b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea completed its R&amp;D services performance obligation for AKCEA-APO(a)-L<sub>Rx </sub>in second quarter of 2019. As such, Akcea recognized all revenue it allocated to its AKCEA-APO(a)-L<sub>Rx </sub>R&amp;D services as of the end of the second quarter of 2019;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z9bc63efdf0e1423fa47eb9c79e9a847f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea completed its R&amp;D services performance obligation for AKCEA-APOCIII-L<sub>Rx</sub> in the fourth quarter of 2019 because Novartis elected to terminate the strategic collaboration for AKCEA-APOCIII-L<sub>Rx</sub> during the period. As a result, Akcea was not required to provide any further R&amp;D services, as such, Akcea recognized all revenue it allocated to its AKCEA-APOCIII-L<sub>Rx</sub> L<sub>Rx </sub>R&amp;D services as of the end of the fourth quarter of 2019;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z2eb463986cc148edaab3f8c0fc340615" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea recognized the amount attributed to AKCEA-APO(a)-L<sub>Rx</sub> API when Akcea delivered it to Novartis in 2017; and</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zc57903c50d3a443fb4070a41db918de4" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea recognized the amount attributed to AKCEA-APOCIII-L<sub>Rx</sub> API when Akcea delivered it to Novartis in May 2018.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Akcea recognized revenue related to the R&amp;D services for the AKCEA-APO(a)-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and AKCEA-APOCIII-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> performance obligations as Akcea performed services </span>based on its effort to satisfy its performance obligation relative to Akcea's total effort expected to satisfy its performance obligation<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</span></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019 and 2018, Akcea earned the following revenue from its relationship with Novartis (in millions, except percentage amounts):</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z69ce748cda9640099c4155d9ea42f332" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">187.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">50.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">43.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">17</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our </span>consolidated balance sheet at <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">December 31, </span>2018<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> included deferred revenue of $</span>28.8<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million related to Akcea's relationship with Novartis. We did </span>no<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">t have any deferred revenue from our relationship with Novartis at December 31, 2019.</span></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Pfizer</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">AKCEA<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-ANGPTL3-L</span><sub>Rx</sub></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In October 2019, Akcea initiated a collaboration with Pfizer for the license of AKCEA</span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-ANGPTL3-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, a medicine to treat people with cardiovascular and metabolic diseases. Akcea recently completed a Phase 2 study of AKCEA</span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-ANGPTL3-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in patients</span> with elevated levels of triglycerides, or hypertriglyceridemia, type 2 diabetes and <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">non-alcoholic fatty liver disease, or NAFLD. Pfizer is responsible for all development and regulatory activities and costs beyond those associated with this study.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Under the terms of the agreement, Akcea received a $</span>250<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million upfront payment. Akcea is also eligible to receive development, regulatory and sales milestone payments of up to $</span>1.3<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> billion</span>, including up to $205 million for the achievement of development milestones, up to $250 million for the achievement of regulatory milestones and up to $850 million for the achievement of commercialization milestones. Akcea is<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> also eligible to earn tiered royalties in the mid-teens to low </span>20 percent<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> range on annual worldwide net sales. Akcea has retained the rights to co-commercialize AKCEA</span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">-ANGPTL3-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in the U.S. and certain additional markets. Akcea</span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> will achieve the next payment of $</span>75<span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million when Pfizer advances AKCEA-ANGPTL3-L</span><sub><span style="background-color: #FBFBFB;">Rx</span></sub><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of this collaboration, Akcea identified three separate performance obligations:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze99c6a33b95947ed81c68654c16d319e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">License of AKCEA-ANGPTL3-L<sub>Rx</sub>;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z9f82745b2a734ec181ae05f3d3c17dfb" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D services for AKCEA-ANGPTL3-L<sub>Rx</sub>; and</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze279fcd45eb041eab8e90392a384799d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">API for AKCEA-ANGPTL3-L<sub>Rx</sub>.</div></td>
  </tr>
</table>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea determined the transaction price to be $250 million, the upfront payment it received.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Akcea</span> allocated the transaction price based on the estimated stand-alone selling price of each performance obligation as follows:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze54e7b0fe6964ad482f1ea90cb1e8d4f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$245.6 million for the license of AKCEA-ANGPTL3-L<sub>Rx</sub>;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z8172b430e2874deb85b9c47a783a932f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</span>2.2<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for the R&amp;D services for </span>AKCEA-ANGPTL3-L<sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">; and</span></div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z7c560cb48d85427a9f66c095b4b29f24" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">$</span>2.2<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million for the delivery of </span>AKCEA-ANGPTL3-L<sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> API.</span></div></td>
  </tr>
</table>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea is recognizing revenue related to each of its performance obligations as follows:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zeb2eff08d272446d9de8fac3d324e9bb" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 22.5pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea recognized $245.6 million for the license of AKCEA-ANGPTL3-L<sub>Rx</sub> in the fourth quarter of 2019 because Akcea determined the license Akcea granted to Pfizer was distinct from its other performance obligations and Pfizer had full use of the license without any continuing involvement from Akcea. </div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z06340fd0be4446e4add1b4fab2760135" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 22.5pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea is<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> recognizing revenue related to the R&amp;D services for </span>AKCEA-ANGPTL3-L<sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> as Akcea performs services </span>based on Akcea's effort to satisfy its performance obligation relative to Akcea's total effort expected to satisfy its performance obligation<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. Akcea</span> expects to satisfy its R&amp;D services performance obligation by mid-2020<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. </span></div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z7f59c7ed1f0c4a5bb58495efb32b1f25" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 22.5pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> recognized the amount attributed to the API supply for </span>AKCEA-ANGPTL3-L<sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> when it delivered it to Pfizer in the fourth quarter of 2019. </span></div></td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">During the fourth quarter of 2019, we received </span>6.9 million shares of Akcea common stock for <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">payment of the </span>$125 million sublicense fee Akcea owed us.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the year ended December 31, 2019, Akcea earned the following revenue from its relationship with Pfizer (in millions, except percentage amounts):</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z6a52ad3f4f4548a28b37262fe935a7dc" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">248.7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">22</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our </span>consolidated balance sheet at <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">December 31, </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> included deferred revenue of $</span>1.3<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million related to Akcea&#8217;s relationship with Pfizer.</span></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">PTC Therapeutics</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In August 2018, Akcea entered into an exclusive license agreement with PTC Therapeutics to commercialize TEGSEDI and WAYLIVRA in Latin America. Under the license agreement, Akcea is eligible to receive up to $26 million in payments, including $12 million it received in the third quarter of 2018, $6 million it received in the second quarter of 2019 following European Medicines Agency, or EMA, approval of WAYLIVRA, $4 million it received in the fourth quarter of 2019 when PTC received approval for TEGSEDI in Brazil, and up to $4 million in an additional regulatory milestone payment. Akcea is eligible to receive royalties from PTC in the mid-20 percent range on net sales in Latin America for each medicine. PTC&#8217;s obligation to pay Akcea royalties begins on the earlier of 12 months after the first commercial sale of a product in Brazil or the date that PTC recognizes revenue of at least $10 million in Latin America. Consistent with the agreements between Ionis and Akcea, the companies will share all payments, including royalties.</div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At the commencement of this collaboration, Akcea identified two performance obligations, which were the licenses Akcea granted to PTC to commercialize TEGSEDI and WAYLIVRA in Latin America in the third quarter of 2018. Akcea recognized $12 million in license fee revenue at that time because PTC had full use of both licenses without any continuing involvement from Akcea. Akcea does not have any remaining performance obligations under its collaboration with PTC. Akcea can still earn additional payments and royalties as PTC commercializes the medicines.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the second quarter of 2019, Akcea earned a $6 million payment when WAYLIVRA was approved by the EMA. Akcea recognized this payment in full in the second quarter of 2019 because it does not have any performance obligations related to this payment. Additionally, in the fourth quarter of 2019, Akcea earned $4 million when TEGSEDI was approved in Brazil. Akcea recognized this payment in full in the fourth quarter of 2019 because it does not have any performance obligations related to this payment.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019 and 2018, Akcea earned the following revenue from its relationship with PTC (in millions, except percentage amounts):</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zf3ce81334bbb4ee983c75acc2b6feb6c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Licensing and other royalty revenue (commercial revenue)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our consolidated balance sheet at December 31, 2019 and 2018 did not include any deferred revenue related to Akcea&#8217;s relationship with PTC.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CollaborativeArrangementsAndLicensingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CollaborativeArrangementsAndLicensingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6885250512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">Investments</a></td>
<td class="text">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2. Investments</div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes the contract maturity of the available-for-sale securities we held as of December 31, 2019:</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z6c0f78857c00481b9a2fe8abae31c196" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">One year or less</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">70</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">After one year but within two years</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">After two years but within <span style="-sec-ix-hidden:Fact_5b50da2d62974df399b2ebfcfccf0c30">three and a half years</span></div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">100</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As illustrated above, at December 31, 2019, 90 percent of our available-for-sale securities had a maturity of less than two years.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">All of our available-for-sale securities are available to us for use in our current operations. As a result, we categorize all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At December 31, 2019, we had an ownership interest of less than 20 percent <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">in </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">five</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> private companies and </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">two</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> public companies with which we conduct business. The privately-held companies are </span>Atlantic Pharmaceuticals Limited, Dynacure SAS, Empirico, Inc., Seventh Sense Biosystems and Suzhou Ribo Life Science Co, Ltd.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The publicly traded companies are ATL and ProQR. </span></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following is a summary of our investments (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zf9b6c17e2c154c6ab71c1ee67da358d6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"/></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gross Unrealized</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Estimated</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Cost </span>(1)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gains</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Losses</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Available-for-sale securities:</div></td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities (2)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">669,665</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,451</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(43</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">671,073</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">188,216</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">303</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(43</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">188,476</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury (2)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">327,670</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">232</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(27</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">327,875</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21,065</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">26</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21,086</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total securities with a maturity of one year or less</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,206,616</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,012</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(118</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,208,510</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">428,627</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,911</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(43</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">431,495</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">140,988</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">57</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(117</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">140,928</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">35,822</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(12</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">35,819</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">19,309</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">19,321</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total securities with a maturity of more than one year</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">624,746</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,995</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(178</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">627,563</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total available-for-sale securities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,831,362</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,007</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(296</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,836,073</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Equity securities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total equity securities included in other current assets (3)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,712</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(870</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,842</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total equity securities included in deposits and other assets (4)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,000</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,000</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total equity securities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14,712</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(870</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,842</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total available-for-sale and equity securities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,846,074</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,007</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,166</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,849,915</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z13827f1de67a455a9892b6f4cd0857a7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gross Unrealized</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Estimated</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Cost </span>(1)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gains</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Losses</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Available-for-sale securities:</div></td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities (2)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">956,879</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,858</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">955,034</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">168,839</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(104</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">168,738</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">244,640</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(77</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">244,578</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states (2)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">63,572</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(323</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">63,249</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total securities with a maturity of one year or less</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,433,930</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">31</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2,362</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,431,599</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">299,018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">194</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,286</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">297,926</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">107,789</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">194</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(109</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">107,874</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15,600</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(24</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15,576</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">16,980</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(287</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">16,693</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total securities with a maturity of more than one year</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">439,387</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">388</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,706</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">438,069</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total available-for-sale securities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,873,317</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">419</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4,068</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,869,668</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Equity securities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total equity securities included in other current assets (3)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,212</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">137</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,349</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total available-for-sale and equity securities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,874,529</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">556</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4,068</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,871,017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z784ee7f1d4b643169b5db132e0df44a0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We hold our available-for-sale securities at amortized cost.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z0db8278eb43646f79139982440394852" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Includes investments classified as cash equivalents on our consolidated balance sheet.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z72201901808a45b9b3f1774f8add5ea2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our equity securities included in other current assets consisted of our investment in ProQR, which is a public company. We recognize our public company equity securities at</span> fair value.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z3d706207d5ac4b169c0cbd627c904d24" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our equity securities included in deposits and other assets consisted of our investment in Empirico, which is a private company. We recognize our private company equity securities at</span> cost minus impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> on our consolidated balance sheet.</span></div></td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investments we consider to be temporarily impaired at December 31, 2019 are as follows (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zc70ed2d8b7b040eaa431c9f6deed2462" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Less than 12 Months of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Temporary Impairment</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">More than 12 Months of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Temporary Impairment</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total Temporary</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Impairment</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Number of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Investments</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Estimated</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Unrealized</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Losses</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Estimated</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Unrealized</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Losses</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Estimated</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Unrealized</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Losses</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 16%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">49</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">131,702</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(75</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11,840</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(11</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">143,542</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(86</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 16%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">43</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">149,731</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(136</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">37,041</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(24</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">186,772</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(160</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 16%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">84,270</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(39</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">84,270</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(39</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 16%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,241</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,303</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20,544</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(11</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 16%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total temporarily impaired securities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">113</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">375,944</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(255</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">59,184</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(41</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">435,128</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(296</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We believe that the decline in value of our debt securities is temporary and primarily related to the change in market interest rates since purchase. We believe it is more likely than not that we will be able to hold these securities to maturity. Therefore, we anticipate full recovery of our debt securities&#8217; amortized cost basis at maturity.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI http://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI http://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6863468192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Data (Unaudited) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">10. Quarterly Financial Data (Unaudited)</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Summarized quarterly data for the years ended December 31, 2019 and 2018 are as follows (in thousands, except per share data).</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zbbded80230f54883844977a2db5dd5f5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019 Quarters</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">First</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Second</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Third</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fourth</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">297,214</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">163,813</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">167,892</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">493,680</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating expenses</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">175,679</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">182,640</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">165,369</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">233,028</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) from operations</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">121,535</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(18,827</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,523</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">260,652</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income (loss)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">90,884</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(10,012</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,432</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">203,957</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">84,443</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(876</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">26,163</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">184,415</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income (loss) per share (1) (2)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.63</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.01</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.19</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.31</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Diluted net income (loss) per share (1) (3)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.62</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.01</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.18</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.28</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z6dcd313bcba54fcbbfd2063358483afb" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018 Quarters</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">First</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Second</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Third</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fourth</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">144,419</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">117,747</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">145,395</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">192,113</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating expenses</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">147,720</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">168,028</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">163,967</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">181,331</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) from operations</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3,301</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(50,281</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(18,572</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,782</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income (loss)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(10,812</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(56,573</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(20,365</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">302,735</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,420</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(40,358</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4,559</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">320,078</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income (loss) per share (1) (2)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.01</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.29</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.03</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.32</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Diluted net income (loss) per share (1) (3)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.01</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.29</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.03</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.21</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">________________</div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z238c61f0c45341568e1fd63ba558f508" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We computed net income (loss) per share independently for each of the quarters presented. Therefore, the sum of the quarterly net income (loss) per share will not necessarily equal the total for the year.</div></td>
  </tr>
</table>

<div style="text-align: justify; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z4b10092c7ee94951986f14bc378411d6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As discussed in Note 1, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Organization and Significant Accounting Policies, </span>we compute basic net income (loss) per share by dividing the total net income (loss) attributable to our common stockholders by our weighted-average number of common shares outstanding during the period. Our basic net income (loss) per share calculation for each of the quarters in 2019 and 2018 considered our net income for Ionis on a stand-alone basis plus our share of Akcea&#8217;s net loss for the period. To calculate the portion of Akcea&#8217;s net loss attributable to our ownership, we multiplied Akcea&#8217;s loss per share by the weighted average shares we owned in Akcea during the period. As a result of this calculation, our total net income (loss) available to Ionis common stockholders for the calculation of net income (loss) per share is different than net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders in the consolidated statements of operations.</div></td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our basic net income (loss) per share for each quarter in 2019 was calculated as follows (in thousands, except per share amounts):</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z66d226e9f1e04c068da73924c4bbb872" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended March 31 , 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Income</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">68,582</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.35</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23,846</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net income attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23,846</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">63,697</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">87,543</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">138,582</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.63</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z0a7c3905d3e645b7bf1d61ed99b81aa3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended June 30 , 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">70,221</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.40</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(28,244</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(28,244</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">27,311</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net loss available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(933</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">140,247</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net loss per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.01</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z63a88a9296e2466eaad9bc93a89393ce" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended September 30 , 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">70,221</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.34</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(23,772</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(23,772</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">49,930</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">26,158</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">140,551</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.19</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zd25327371fce44efae3b5570b907c56d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended December 31 , 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Income</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">71,342</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.87</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">62,243</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net income attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">62,243</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">121,552</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">183,795</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">140,583</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.31</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our basic net income (loss) per share for each quarter in 2018 was calculated as follows (in thousands, except per share amounts):</div>

<div style="text-align: left; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zbbcbf397131340ad9566b5428b09a107" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended March 31 , 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">45,448</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.44</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(19,997</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(19,997</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,785</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net loss available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,212</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">125,330</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net loss per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.01</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>

<div style="text-align: justify; margin-left: 31.5pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z2b8e94f57db4490c82a68c1ff759a0e3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended June 30 , 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">60,832</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.72</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(43,814</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(43,814</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,882</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net loss available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(37,932</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">128,712</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net loss per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.29</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z2549de914d904e2a82162394a6946bc2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended September 30 , 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">65,538</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.73</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(47,789</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(47,789</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">43,226</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net loss available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4,563</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">137,346</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net loss per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.03</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z0b1244fa792d4e2f89c46e4a73ab2036" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended December 31 , 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">67,130</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.79</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(53,219</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(53,219</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">372,913</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">319,694</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">137,699</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.32</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zc5ec9a701b644f2192ef4fd51a353c9b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We had net income available to Ionis common stockholders for the following periods. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during those periods.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: justify; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Diluted common equivalent shares for each of the periods consisted of the following (in thousands except per share amounts):</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zf822f8c87ab4452683b2466a81529563" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended March 31, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">87,543</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">138,582</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.63</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -6pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,252</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">665</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our ESPP</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">38</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our 1 percent convertible notes</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">87,543</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">141,537</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.62</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zcafdd1c50c0b47bea13bfdef22787b0b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended September 30, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">26,158</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">140,551</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.19</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,993</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">844</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our ESPP</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our 1 percent convertible notes</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">26,158</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">143,408</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.18</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z43f9157d9e1242ac8e62d24c49d3a75f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended December 31, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">183,795</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">140,583</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.31</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,467</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">848</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our ESPP</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our 0.125 percent convertible notes</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">644</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">860</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our 1 percent convertible notes</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12,046</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,527</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">196,485</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">153,303</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.28</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z2edbbee13c264fed8062982b71bf6ef3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended December 31, 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">319,694</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">137,699</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.32</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,254</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">636</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our ESPP</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our 1 percent convertible notes</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,745</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,260</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">330,439</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">149,856</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.21</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -36pt; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For the three months ended March 31, 2019 and September 30, 2019, the calculation excluded the 1 percent notes because the effect on diluted earnings per share was anti-dilutive.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871277536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements and Licensing Agreements, Pfizer (Details)<br> $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($) </div>
<div>PerformanceObligation</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_ReceiptOfSharesInSubsidiary', window );">Additional shares of Akcea stock received (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_SublicenseFeePaidForLicenseOfDrug', window );">Sublicense fee paid in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,122,599<span></span>
</td>
<td class="nump">$ 599,674<span></span>
</td>
<td class="nump">$ 514,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember', window );">R&amp;D Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770,149<span></span>
</td>
<td class="nump">$ 344,752<span></span>
</td>
<td class="nump">$ 394,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember', window );">Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 246,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones', window );">Maximum amount of payments receivable for development, regulatory and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones', window );">Maximum amount of payments receivable for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones', window );">Maximum amount of payments receivable for regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones', window );">Maximum amount of payments receivable for commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="nump">$ 850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RoyaltyPercentageReceivedOnNetSalesOfDrug', window );">Royalty percentage received on net sales of drug</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NextPotentialMilestonePayment', window );">Next prospective milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations', window );">Number of separate performance obligations | PerformanceObligation</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_ReceiptOfSharesInSubsidiary', window );">Additional shares of Akcea stock received (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_SublicenseFeePaidForLicenseOfDrug', window );">Sublicense fee paid in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">248,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | Pfizer [Member] | Revenue [Member] | Strategic Partner [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | Pfizer [Member] | AKCEA-ANGPTL3-L [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="nump">245,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | Pfizer [Member] | R&amp;D Services for AKCEA-ANGPTL3-L [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | Pfizer [Member] | AKCEA-ANGPTL3-L API [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CollaborativeArrangementAndLicensingAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for commercialization milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for development milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for development, regulatory and sales milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for regulatory milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NextPotentialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The next potential milestone payment to be earned under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NextPotentialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_ReceiptOfSharesInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares received from the subsidiary during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_ReceiptOfSharesInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of separate performance obligations under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration the Company earned or is eligible to earn under the collaboration agreement, including any variable consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RoyaltyPercentageReceivedOnNetSalesOfDrug">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage received on the net sales of a drug by a collaboration partner under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RoyaltyPercentageReceivedOnNetSalesOfDrug</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_SublicenseFeePaidForLicenseOfDrug">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the sublicense fee paid in common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_SublicenseFeePaidForLicenseOfDrug</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payments received during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_AKCEAANGPTL3LMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_AKCEAANGPTL3LMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentServicesForMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentServicesForMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6771502592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes, Gross Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Gross Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance of unrecognized tax benefits</a></td>
<td class="nump">$ 68,301<span></span>
</td>
<td class="nump">$ 78,014<span></span>
</td>
<td class="nump">$ 66,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decrease for prior period tax positions</a></td>
<td class="num">(867)<span></span>
</td>
<td class="num">(12,814)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase for prior period tax positions</a></td>
<td class="nump">736<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase for current period tax positions</a></td>
<td class="nump">1,614<span></span>
</td>
<td class="nump">3,101<span></span>
</td>
<td class="nump">9,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance of unrecognized tax benefits</a></td>
<td class="nump">69,784<span></span>
</td>
<td class="nump">$ 68,301<span></span>
</td>
<td class="nump">$ 78,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that could impact effective tax rate, if recognized</a></td>
<td class="nump">21,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties on unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6970636016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information and Concentration of Business Risk, Segment Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,122,599<span></span>
</td>
<td class="nump">$ 599,674<span></span>
</td>
<td class="nump">$ 514,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">$ 233,028<span></span>
</td>
<td class="nump">$ 165,369<span></span>
</td>
<td class="nump">$ 182,640<span></span>
</td>
<td class="nump">$ 175,679<span></span>
</td>
<td class="nump">$ 181,331<span></span>
</td>
<td class="nump">$ 163,967<span></span>
</td>
<td class="nump">$ 168,028<span></span>
</td>
<td class="nump">$ 147,720<span></span>
</td>
<td class="nump">756,716<span></span>
</td>
<td class="nump">661,046<span></span>
</td>
<td class="nump">483,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">260,652<span></span>
</td>
<td class="nump">$ 2,523<span></span>
</td>
<td class="num">$ (18,827)<span></span>
</td>
<td class="nump">$ 121,535<span></span>
</td>
<td class="nump">10,782<span></span>
</td>
<td class="num">$ (18,572)<span></span>
</td>
<td class="num">$ (50,281)<span></span>
</td>
<td class="num">$ (3,301)<span></span>
</td>
<td class="nump">365,883<span></span>
</td>
<td class="num">(61,372)<span></span>
</td>
<td class="nump">31,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets as of current period</a></td>
<td class="nump">$ 3,233,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,667,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,233,112<span></span>
</td>
<td class="nump">2,667,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_CommercialMember', window );">Commercial Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">352,450<span></span>
</td>
<td class="nump">254,922<span></span>
</td>
<td class="nump">120,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_SPINRAZARoyaltiesMember', window );">SPINRAZA Royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,992<span></span>
</td>
<td class="nump">237,930<span></span>
</td>
<td class="nump">112,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product Sales, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,253<span></span>
</td>
<td class="nump">2,237<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_LicensingAndOtherRoyaltiesMember', window );">Licensing and Other Royalty Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,205<span></span>
</td>
<td class="nump">14,755<span></span>
</td>
<td class="nump">7,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember', window );">R&amp;D Revenue Under Collaborative Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 770,149<span></span>
</td>
<td class="nump">344,752<span></span>
</td>
<td class="nump">394,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage ownership</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Ionis Core [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 858,646<span></span>
</td>
<td class="nump">641,944<span></span>
</td>
<td class="nump">525,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">523,207<span></span>
</td>
<td class="nump">380,212<span></span>
</td>
<td class="nump">373,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,439<span></span>
</td>
<td class="nump">261,732<span></span>
</td>
<td class="nump">151,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets as of current period</a></td>
<td class="nump">$ 3,478,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,975,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,478,081<span></span>
</td>
<td class="nump">2,975,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Ionis Core [Member] | Commercial Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305,608<span></span>
</td>
<td class="nump">240,685<span></span>
</td>
<td class="nump">120,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Ionis Core [Member] | SPINRAZA Royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,992<span></span>
</td>
<td class="nump">237,930<span></span>
</td>
<td class="nump">112,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Ionis Core [Member] | Product Sales, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Ionis Core [Member] | Licensing and Other Royalty Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,616<span></span>
</td>
<td class="nump">2,755<span></span>
</td>
<td class="nump">7,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Ionis Core [Member] | R&amp;D Revenue Under Collaborative Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">553,038<span></span>
</td>
<td class="nump">401,259<span></span>
</td>
<td class="nump">405,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Akcea Therapeutics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">488,543<span></span>
</td>
<td class="nump">64,867<span></span>
</td>
<td class="nump">43,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,469<span></span>
</td>
<td class="nump">295,683<span></span>
</td>
<td class="nump">163,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,074<span></span>
</td>
<td class="num">(230,816)<span></span>
</td>
<td class="num">(120,470)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets as of current period</a></td>
<td class="nump">599,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599,250<span></span>
</td>
<td class="nump">365,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Akcea Therapeutics [Member] | Commercial Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,425<span></span>
</td>
<td class="nump">14,237<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Akcea Therapeutics [Member] | SPINRAZA Royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Akcea Therapeutics [Member] | Product Sales, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,253<span></span>
</td>
<td class="nump">2,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Akcea Therapeutics [Member] | Licensing and Other Royalty Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,172<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Akcea Therapeutics [Member] | R&amp;D Revenue Under Collaborative Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">436,118<span></span>
</td>
<td class="nump">50,630<span></span>
</td>
<td class="nump">43,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Elimination of Intercompany Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(224,590)<span></span>
</td>
<td class="num">(107,137)<span></span>
</td>
<td class="num">(54,407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(216,960)<span></span>
</td>
<td class="num">(14,849)<span></span>
</td>
<td class="num">(54,527)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,630)<span></span>
</td>
<td class="num">(92,288)<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets as of current period</a></td>
<td class="num">$ (844,219)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (672,968)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(844,219)<span></span>
</td>
<td class="num">(672,968)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Elimination of Intercompany Activity [Member] | Commercial Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,583)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Elimination of Intercompany Activity [Member] | SPINRAZA Royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Elimination of Intercompany Activity [Member] | Product Sales, Net [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Elimination of Intercompany Activity [Member] | Licensing and Other Royalty Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,583)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember', window );">Elimination of Intercompany Activity [Member] | R&amp;D Revenue Under Collaborative Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (219,007)<span></span>
</td>
<td class="num">$ (107,137)<span></span>
</td>
<td class="num">$ (54,407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_SPINRAZARoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_SPINRAZARoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_LicensingAndOtherRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_LicensingAndOtherRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ions_AkceaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ions_AkceaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ions_IonisCoreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ions_IonisCoreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ions_AkceaTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ions_AkceaTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_IntersegmentEliminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6870659664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements and Licensing Agreements, GSK (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2010 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Drug</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,122,599<span></span>
</td>
<td class="nump">$ 599,674<span></span>
</td>
<td class="nump">$ 514,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember', window );">R&amp;D Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 770,149<span></span>
</td>
<td class="nump">344,752<span></span>
</td>
<td class="nump">$ 394,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember', window );">GSK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfDrugsBeingDeveloped', window );">Number of drugs currently being developed | Drug</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones', window );">Maximum amount of payments receivable for license fees and milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones', window );">Maximum amount of payments receivable for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones', window );">Maximum amount of payments receivable for regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones', window );">Maximum amount of payments receivable for commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NextPotentialMilestonePayment', window );">Next prospective milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember', window );">GSK [Member] | Revenue [Member] | Strategic Partner [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember', window );">GSK [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CumulativePaymentsReceived', window );">Cumulative payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember', window );">GSK [Member] | R&amp;D Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,400<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 14,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CollaborativeArrangementAndLicensingAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CumulativePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative amount of payments received under the collaboration agreement as of the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CumulativePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for commercialization milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for development milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for license fees and substantive milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for regulatory milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NextPotentialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The next potential milestone payment to be earned under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NextPotentialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfDrugsBeingDeveloped">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of drugs currently being developed under the collaboration agreement(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfDrugsBeingDeveloped</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payments received during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871326336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity, Preferred and Common Stock (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized to issue (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">140,339,615<span></span>
</td>
<td class="nump">137,928,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">140,339,615<span></span>
</td>
<td class="nump">137,928,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Net proceeds from stock option exercises, vesting of restricted stock units, and ESPP purchases</a></td>
<td class="nump">$ 119,657<span></span>
</td>
<td class="nump">$ 27,900<span></span>
</td>
<td class="nump">$ 22,931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Junior Participating Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized to issue (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">140,300,000<span></span>
</td>
<td class="nump">137,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">140,300,000<span></span>
</td>
<td class="nump">137,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future issuance (in shares)</a></td>
<td class="nump">26,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Number of shares issued for stock option exercises, vesting of restricted stock units, and ESPP purchases (in shares)</a></td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Net proceeds from stock option exercises, vesting of restricted stock units, and ESPP purchases</a></td>
<td class="nump">$ 119,700<span></span>
</td>
<td class="nump">$ 27,900<span></span>
</td>
<td class="nump">$ 22,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6870906128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Commitments, Line of Credit Arrangement (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_FixedRateNoteWithMorganStanleyMember', window );">Fixed Rate Note with Morgan Stanley [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAbstract', window );"><strong>Line of Credit Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Payment of outstanding borrowings</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=ions_MorganStanleyPrivateBankNationalAssociationMember', window );">Morgan Stanley [Member] | Revolving Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAbstract', window );"><strong>Line of Credit Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_FixedRateNoteWithMorganStanleyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_FixedRateNoteWithMorganStanleyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=ions_MorganStanleyPrivateBankNationalAssociationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=ions_MorganStanleyPrivateBankNationalAssociationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6868181792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies, Deferred Revenue (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityAbstract', window );"><strong>Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from amounts in beginning deferred revenue balance</a></td>
<td class="nump">$ 159.5<span></span>
</td>
<td class="nump">$ 105.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6874751104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies, Noncontrolling Interest in Akcea Therapeutics, Inc. (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Noncontrolling Interest in Akcea Therapeutics, Inc. [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_SharesReceivedFromSubsidiaryForLicenseOfDrug', window );">Additional shares of Akcea stock received for license of drug</a></td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Noncontrolling Interest in Akcea Therapeutics, Inc. [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage ownership</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Noncontrolling Interest in Akcea Therapeutics, Inc. [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage ownership</a></td>
<td class="nump">68.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Noncontrolling Interest in Akcea Therapeutics, Inc. [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage ownership</a></td>
<td class="nump">77.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_SharesReceivedFromSubsidiaryForLicenseOfDrug">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of additional shares of stock received from Akcea Therapeutics, Inc. as a sublicense fee in connection with Pfizer licensing AKCEA-ANGPTL3-L.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_SharesReceivedFromSubsidiaryForLicenseOfDrug</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ions_AkceaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ions_AkceaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6863447456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Legal Proceedings [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Proceedings</a></td>
<td class="text">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">9. Legal Proceedings</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">From time to time, we are involved in legal proceedings arising in the ordinary course of our business. Periodically, we evaluate the status of each legal matter and assess our potential financial exposure. If the potential loss from any legal proceeding is considered probable and the amount can be reasonably estimated, we accrue a liability for the estimated loss. Significant judgment is required to determine the probability of a loss and whether the amount of the loss is reasonably estimable. The outcome of any proceeding is not determinable in advance. As a result, the assessment of a potential liability and the amount of accruals recorded are based only on the information available to us at the time. As additional information becomes available, we reassess the potential liability related to the legal proceeding, and may revise our estimates.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In November 2019, a purported stockholder of Akcea filed an action in the Delaware Court of Chancery, captioned <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">City of Cambridge Retirement System v. Crooke, et al.</span>, C.A. No. 2019-0905, or the Delaware Action. The plaintiff in the Delaware Action asserts claims against (i) current and former members of Akcea&#8217;s Board of Directors, and (ii) Ionis, or collectively, the Defendants. The plaintiff asserts derivative claims on behalf of Akcea, which is a nominal defendant in the Delaware Action, as well as putatively direct claims on behalf of a purported class of Akcea stockholders. The plaintiff in the Delaware Action asserts that the Defendants breached their fiduciary duties in connection with the licensing transaction that Akcea and Ionis entered into regarding TEGSEDI and AKCEA-TTR-<span style="background-color: #FFFFFF; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">L</span><sub><span style="background-color: #FFFFFF;">Rx</span></sub>. The plaintiff also asserts an unjust enrichment claim against Ionis. We and Akcea have moved to dismiss the plaintiff&#8217;s complaint. We believe that the claims asserted in the Delaware Action are without merit.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6863474528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">5. Income Taxes</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) before income taxes is comprised of (in thousands):</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z4092c9a5a2814eb28f48de6d2a9e9058" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">344,280</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(69,576</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5,289</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Foreign</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,489</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(6,580</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(11,474</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) before income taxes</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">346,769</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(76,156</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(16,763</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our income tax expense (benefit) was as follows (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z713025753cca4d42a8b28f2a7fba9d21" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Current:</div></td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Federal</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">35,861</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">438</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(7,460</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">State</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14,329</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,442</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,246</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Foreign</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">413</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">374</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">234</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total current income tax expense (benefit)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">50,603</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(630</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5,980</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deferred:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Federal</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(7,096</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(290,511</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">State</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total deferred income tax benefit</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(7,096</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(290,511</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total income tax expense (benefit)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">43,507</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(291,141</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5,980</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our expense (benefit) for income taxes differs from the amount computed by applying the U.S. federal statutory rate to income (loss) before taxes. The sources and tax effects of the differences are as follows (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zb11f654ab51c478685d3b34848ff0f2f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="22" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pre-tax income (loss)</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">346,769</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(76,156</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(16,763</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Statutory rate</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">72,822</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(15,993</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5,867</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">35.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">State income tax net of federal benefit</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">49,119</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2,202</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">820</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Foreign</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">340</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,735</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2.3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,299</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(25.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net change in valuation allowance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(37,765</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(10.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(277,924</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">364.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(86,296</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">514.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net operating loss expiration</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,864</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(11.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,987</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(23.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">TEGSEDI licensing gain</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">59,583</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(78.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Impact from outside basis differences</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(16,344</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4.7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Tax credits</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(22,296</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(6.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(73,362</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">96.3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(32,769</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">195.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deferred tax true-up</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">646</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,947</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(13.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,848</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(28.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Tax rate change</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,811</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,808</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">114,832</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(685.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-deductible compensation</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,361</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,154</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,575</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(9.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other non-deductible items</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">329</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(569</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,548</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(15.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea deconsolidation adjustment at IPO</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">469</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stock-based compensation</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4,837</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4,199</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(14,337</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">85.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Foreign-derived intangible income benefit</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2,071</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,608</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,633</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(89</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effective rate</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">43,507</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(291,141</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">382.3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5,980</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">35.7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Significant components of our deferred tax assets and liabilities as of December 31, 2019 and 2018 are as follows (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z6ce9a811fab143898ba48d74d51fe77e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deferred Tax Assets:</div></td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net operating loss carryovers</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20,191</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">89,717</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D credits</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">210,455</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">313,652</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deferred revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">127,763</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">27,381</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stock-based compensation</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">65,703</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">61,027</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Intangible and capital assets</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">77,861</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">49,007</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12,510</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,275</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total deferred tax assets</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">514,483</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">549,059</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deferred Tax Liabilities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Convertible debt</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(6,110</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(24,018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Fixed assets</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,958</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3,884</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net deferred tax asset</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">502,531</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">525,041</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Valuation allowance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(196,974</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(234,245</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total net deferred tax assets and liabilities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">305,557</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">290,796</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We evaluate our deferred tax assets regularly to determine whether adjustments to the valuation allowance are appropriate due to changes in facts or circumstances, such as changes in expected future pre-tax earnings, tax law, interactions with taxing authorities and developments in case law. In making this evaluation, we rely on our recent history of pre-tax earnings. Our material assumptions are our forecasts of future pre-tax earnings and the nature and timing of future deductions and income represented by the deferred tax assets and liabilities, all of which involve the exercise of significant judgment. Although we believe our estimates are reasonable, we are required to use significant judgment in determining the appropriate amount of valuation allowance recorded against our deferred tax assets.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We have historically recorded a valuation allowance against all our net deferred tax assets due to cumulative financial statement losses. However, in the fourth quarter of 2018, we reversed the valuation allowance previously recorded against Ionis&#8217; stand-alone U.S. federal net deferred tax assets, resulting in a one-time non-cash tax benefit of $</span>332.1<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million. </span>We reversed the valuation allowance in 2018 as<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> we expected to generate U.S. pre-tax income on an Ionis standalone basis in future periods at a level that would result in us fully utilizing our U.S. federal net operating loss carryforwards and our Research and Development and Orphan Drug tax credit carryforwards. </span>We utilized a significant portion of these carryforwards in 2019 to partially offset our estimated federal tax liability for the year.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our valuation allowance decreased by $37.3 million from December 31, 2018 to December 31, 2019. The decrease relates primarily to the current year utilization of a portion of our net deferred state tax assets, primarily California net operating loss carryovers, that had been fully reserved by the valuation allowance.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We continue to maintain a full valuation allowance of $197.0 million against all of Akcea&#8217;s net deferred tax assets and the net state deferred tax assets of Ionis at December 31, 2019 due to uncertainties related to our ability to realize the tax benefits associated with these assets.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We generated combined state taxable income and recognized a combined state tax liability in 2019. We utilized Ionis&#8217; state deferred tax assets, primarily California net operating loss carry forwards, to reduce our combined state tax liability for the year by $59.1 million, which resulted in a corresponding reduction to our combined state valuation allowance. We have historically generated combined state net operating losses due primarily to Akcea&#8217;s net operating losses. However, Akcea generated net income in 2019. This was due to an increase in their research and development and license revenue, primarily related to non-recurring transactions in the first and fourth quarter from Novartis&#8217; exercise of its option to license AKCEA-APO(a)-L<sub>Rx</sub> and Pfizer&#8217;s license of AKCEA-ANGPTL3-L<sub>Rx</sub>, respectively. Although Akcea generated net income in 2019, given their history of losses, there can be no assurance that they will achieve profitability in future periods. We expect Akcea to incur additional operating losses for the foreseeable future and therefore we continue to maintain a full valuation allowance against our remaining net deferred state tax assets.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At December 31, 2019, we had federal and state, primarily California, tax net operating loss carryforwards of $99.5 million and $117.9 million, respectively. Our federal tax loss carryforwards are available indefinitely. Our California tax loss carryforwards will begin to expire in 2033. At December 31, 2019, we also had federal and California research and development tax credit carryforwards of $198.8 million and $74.1 million, respectively. Our Federal research and development tax credit carryforwards will begin to expire in 2034. Our California research and development tax credit carryforwards are available indefinitely.</div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Utilization of the net operating loss and tax credit carryforwards may be subject to an annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization.</div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act of 2017, or the Tax Act. The Tax Act made broad and complex changes to the U.S. tax code, including, but not limited to, reducing the U.S. federal corporate income tax rate to 21 percent, imposing a mandatory one-time transition tax on certain unrepatriated earnings of foreign subsidiaries <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">subjecting certain foreign earnings to U.S. taxation through base erosion anti-abuse tax, or BEAT, and global intangible low-taxed income, or GILTI, </span>eliminating the corporate alternative minimum tax, or AMT, and changing how existing AMT credits can be realized. We were required to recognize the tax effect of the tax law changes in the year of enactment. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our accounting for the elements of the Tax Act is complete. We have made an accounting policy election to treat taxes due on the GILTI inclusion as a current period expense.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We analyze filing positions in all U.S. federal, state and foreign jurisdictions where we file income tax returns, and all open tax years in these jurisdictions to determine if we have any uncertain tax positions on any of our income tax returns. We recognize the impact of an uncertain tax position on an income tax return at the largest amount that the relevant taxing authority is more-likely-than not to sustain upon audit. We do not recognize uncertain income tax positions if they have less than 50 percent likelihood of the applicable tax authority sustaining our position.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes our gross unrecognized tax benefits (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z4b3b1be351044041904f4aadda12afa8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Beginning balance of unrecognized tax benefits</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">68,301</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">78,014</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">66,999</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Decrease for prior period tax positions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(867</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(12,814</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Increase for prior period tax positions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">736</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,520</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Increase for current period tax positions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,614</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,101</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,495</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ending balance of unrecognized tax benefits</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">69,784</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">68,301</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">78,014</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Included in the balance of unrecognized tax benefits at December 31, 2019, is $21.7 million that could impact our effective tax rate, subject to our remaining valuation allowance.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We do not foresee any material changes to our gross unrecognized tax benefits within the next twelve months.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We recognize interest and/or penalties related to income tax matters in income tax expense. We did not recognize any accrued interest and penalties related to gross unrecognized tax benefits during the year ended December 31, 2019.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are subject to taxation in the U.S. and various state and foreign jurisdictions. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our tax years for 1999 through 2018 are subject to examination by the U.S. federal, state and foreign tax authorities.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We do not provide for a U.S. income tax liability and foreign withholding taxes on undistributed foreign earnings of our foreign subsidiaries as we consider those earnings to be permanently reinvested. It is not practicable for us to calculate the amount of unrecognized deferred tax liabilities associated with these earnings.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( )1P8E ?(\\#P    !,"   +    7W)E;',O+G)E;'.MDD^+
MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V
M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F'
M.>RGGD7E2B.5^S3%":4A+<TXP)6E/S/WJVR;A5ND9T*YKCM+1[873T$7LF<;
M!I99-G\LCNVW<+ZT+/0:S>,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C
M-R."?S]PN -02P,$%     @ E'!B4"?HAPZ"    L0   !    !D;V-0<F]P
M<R]A<' N>&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(?
MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M#[^;L O&'NP_-KX*=BW\NHON"U!+ P04    " "4<&)0F5R<(Q &  "<)P
M$P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03
M<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS
M[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#
MW(*+"$MX%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S
M^!7+5(UEHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4
MPL3 :F<_5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:
MX./Q>#BVR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;
M:)P*C5M/TVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ
M$A6UY4#3( !8<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&
M<IV0!0X -\313%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD
M,WJ=?3K.:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z
M'&="?,_V]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S
M(M>41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(
MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU
M+,76>)7 \:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/
M:;,CIW0FS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:
MK<(1*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1
MDEXW0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*
MY \FIS_I,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_
MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R
MS<C'5*^3*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;
M)0G+5--E-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R
M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ
MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR
MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2
M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE
ML<%5'<]56_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_
M13.V$I<8O./FQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7G
MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5
M' 86%S+D4.Z2D 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2
M)1(4BK ,!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%
MV^)4S;L:OB9@2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODR
MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\
MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS
MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!
M4$L#!!0    ( )1P8E!\)-=@>0,  ,D0   8    >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL?5CM;ILP%'T5Q ,4?*_)1Y5$:AI-F[1)5:=MOVGB)*B ,W":
M[NUG#*6I[W7_!'#.\;%]?0YQ%A?=/+='I4ST6I5UNXR/QIQNDZ3='E65MS?Z
MI&K[S5XW56[L8W-(VE.C\ITC564":3I)JKRHX]7"M3TTJX4^F[*HU4,3M>>J
MRIM_:U7JRS(6\5O#8W$XFJXA62U.^4']5.;7Z:&Q3\G8RZZH5-T6NHX:M5_&
M=^)V@UE'<(C?A;JT5_=1-Y4GK9^[AV^[99QV(U*EVIJNB]Q>7M2]*LNN)SN.
MOT.G\:C9$:_OWWK_XB9O)_.4M^I>EW^*G3DNXUD<[=0^/Y?F45^^JF%"61P-
ML_^N7E1IX=U(K,96EZW[C+;GUNAJZ,4.I<I?^VM1N^NE_T;*@<838"# 2,#T
M4P(.!!P)XG,%.1#D.\$M?])/Q:W-)C?Y:M'H2]3TY3WEW2X2M]*N_K9K=(OM
MOK/+T]K6EU6Z2%ZZ;@;$ND? %4*,B,3V/0H )[ &0H>/ O<4@1\1&XJ0_!"0
MG2,Z.E[1,YXN6;IT='E%GWA+1!%37B!C!3)"GWD"%#'G!2:LP(30A5]E!A(H
M\Y25F%*^5^<U T%>8L9*S"A?>A(,)%#J.2LQIWR_U@PD, N1\HY+:0]3WW,,
M)J02\+6@/?B[BL,$]I5@S7TG@/0 )#\83&!K"=Z_ FD/_N9B,,&Y\#87U,6
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M,(2V9Q>T2/(LMSZ#R@.#$*$;GE6S\YZGP.,ZM0]4X#DG0)[9V]B#0QE.@'5
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M,WC3;/I#.;\[O5B6]_7NU[CY?7/XDMKA15T]ME_ &Y^^!7CU/U!+ P04
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M2'( 259F@T[#9,%\C9.+;Z!SF3A)YT#G$UW=YK%UC">G\>2L3 \=P E;F00
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MP8,O^7"H\I,,JZ<E#9 LG*%"4N4QZCQ"G4PJ_"3"ZFE) R2+9"R5'JQCU'F
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M]_OS0>SSA[Y[NQPR7WZ>='_X'U!+ P04    " "4<&)0O)BS$_0!   ,!@
M&    'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;(U5[8Z;,!!\%<0#G,/W)0*D
M7I*JE5HINJKM;P>6@,Y@:COA^O:UC0^1Q(WX@[WKF6%GL4TZ4/;&:P#AO+>D
MXYE;"]%O$.)%#2WF3[2'3JY4E+58R)"=$.\9X%*36H+\U2I&+6XZ-T]U[L#R
ME)X%:3HX,(>?VQ:SOR] Z)"YGON1>&U.M5 )E*<]/L$/$#_[ Y,1FE3*IH6.
M-[1S&%29^\G;[!.%UX!?#0Q\-G>4DR.E;RKX6F;N2A4$! JA%+ <+K %0I20
M+../T72G5RKB?/ZA_EE[EUZ.F,.6DM]-*>K,?7:=$BI\)N*5#E_ ^(E<QYC_
M!A<@$JXJD>\H*.'ZZ11G+FAK5&0I+7X?QZ;3XS"N)(&AV0F^(?@3P0L?$@)#
M")820D,(EQ(B0XAN"&CTKINYPP+G*:.#P\;MT&.UZ[Q-)#]7H9+ZZ^@UV4\N
MLY?<CZ(47920P;R,&'^.N49L[Q'>^OD:L[-AUM>8_3TF#B8(DD8F-[[5C:_Y
MX8R_3NS\P,H/-#^8.PW_(Q!:!<*[ KQ5?--.&R:Y:<1CS%4AD;60Z+X3:SL_
MMO+CY9U(K +)@D[8,#?;9KL LUN V3_&C(;0[-2H>_([9J>FX\Z1"GD ]3&I
M*!4@]59/LL.UO)JG@$ EU#21<S9>4&,@:&_N7C3] /)_4$L#!!0    ( )1P
M8E"MTZ3]M $  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;'U3
MVV[;, S]%4$?4"5*F@:!;:!I473 !@0MMCTK-GU!=7$E.>[^OI3L>-YF[$42
M*9[#0XI*>F/?7 W@R8>2VJ6T]KX],.;R&I1P-Z8%C3>EL4IX-&W%7&M!%!&D
M)..KU8XIT6B:)=%WLEEB.B\;#2=+7*>4L+^.($V?TC6].EZ:JO;!P;*D%16\
M@O_>GBQ:;&(I&@7:-483"V5*[]>'XS;$QX ?#?1N=B:ADK,Q;\'X4J1T%02!
MA-P'!H';!1Y RD"$,MY'3CJE#,#Y^<K^%&O'6L["P8.1/YO"URG=4U) *3KI
M7TS_#&,]MY2,Q7^%"T@,#THP1VZDBRO).^>-&EE0BA(?P][HN/?#S>X*6P;P
M$< GP#X"V) H*G\47F2)-3VQ0^];$9YX?>#8FSPX8ROB'8IWZ+UD_':7L$L@
M&F..0PR?Q:RG"(;L4PJ^E.+(_X'S9?AF4>$FPC=_*+Q;)M@N$FPCP?:_)2[%
M[/]*PF8]56"K.$V.Y*;3<9)GWFE@[WE\D]_AP[1_$[9JM"-GX_%E8_]+8SR@
ME-4-CE"-'VPR))0^'._P;(<Q&PQOVO$'L>D;9Y]02P,$%     @ E'!B4(S/
MM?BU 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL?5/;;MP@
M$/T5Q <$+[O9IBO;4C91U4J-M$K5Y)FUQS8*&!?P.OG[#MAQK-;*"S##.6<N
M#.E@[(MK #QYU:IU&6V\[PZ,N:(!+=R5Z:#%F\I8+3R:MF:NLR#*2-**\239
M,RUD2_,T^DXV3TWOE6SA9(GKM1;V[0C*#!G=T'?'HZP;'QPL3SM1PR_PO[N3
M18O-*J74T#II6F*ARNCMYG#<!7P$/$D8W.),0B5G8UZ"\:/,:!(2 @6%#PH"
MMPO<@5)!"-/X,VG2.60@+L_OZM]B[5C+63BX,^I9EK[)Z TE)52B5_[1#-]A
MJN>:DJGXGW !A?"0"<8HC')Q)47OO-&3"J:BQ>NXRS;NPWC#MQ-MG< G I\)
M-S$.&P/%S.^%%WEJS4#LV/M.A"?>'#CVI@C.V(IXA\D[]%YR?OTU99<@-&&.
M(X8O,)L9P5!]#L'70ASY?W2^3M^N9KB-].V2OD_6!7:K KLHL/NTQ!7,_M\B
MV:*G&FP=I\F1PO1MG.2%=Q[86Q[?Y ,^3ON#L+5L'3D;CR\;^U\9XP%32:YP
MA!K\8+.AH/+A^ 7/=ARST?"FFWX0F[]Q_A=02P,$%     @ E'!B4(N@BV>U
M 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL?5/;;M0P$/T5
MRQ]0[WI#*:LD4K<(@032JHCR[$TFB55?@NULRM\S=M(0(.+%]HSGG#DS'N>C
M=<^^ PCD12OC"]J%T!\9\U4'6O@;VX/!F\8Z+0*:KF6^=R#J!-**\=WNEFDA
M#2WSY#N[,K=#4-+ V1$_:"W<SQ,H.Q9T3U\=C[+M0G2P,N]%"U\A?.O/#BVV
ML-12@_'2&N*@*>C]_GC*8GP*>)(P^M69Q$HNUCY'XU-=T%T4! JJ$!D$;E=X
M *4B$<KX,7/2)64$KL^O[!]2[5C+17AXL.J[K$-7T#M*:FC$H,*C'3_"7,\;
M2N;B/\,5%(9')9BCLLJGE52##U;/+"A%BY=IER;MXW23O9MAVP ^ _@"N$MY
MV)0H*7\O@BAS9T?BIM[W(C[Q_LBQ-U5TIE:D.Q3OT7LM^2W/V342S3&G*8:O
M8O9+!$/V)07?2G'B_\#Y-ORPJ?"0X(<_%!ZV";)-@BP19/\M<2LF^RL)6_54
M@VO3-'E2V<&D25YYEX&]Y^E-?H=/T_Y%N%8:3RXVX,NF_C?6!D INQL<H0X_
MV&(H:$(\OL6SF\9L,H+MYQ_$EF]<_@)02P,$%     @ E'!B4%1Q.4ZU 0
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MJ'T\WH6S'<=L-#QVTP]B\S<N?@%02P,$%     @ E'!B4*1Q<VFV 0  T@,
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M (%"/L!U@$V3G+.)#Q HY -<"M@TSSF;^ "!0C[ U8!-4YVSB0\0*. #PO6
M0*HSWP<(1 $?$*X'!%*=?!] 4, 'A.L!@50GWP<0%/ !X7I (-7)]P$$!7Q
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M88)A'ISW"C59(0+QP@3#)+A)CIKDB$"Z,,$P&6ZR1DW6]P+ALA($DSSXNL(
MOT$!(I$OKQ &6C_P>7!3PWN)-%CZ8*#E;26SYL!!GEU;5%XE+JWKR;/HU'J?
M(]=<_L&'OOV=RG/3*N\@M&E1KI&<A-!@<@F>S/=>FZ=B6C X:3M=F;D<^N6P
MT*(;WP(R/4CE7U!+ P04    " "4<&)0W<CIN]$!  "<!   &0   'AL+W=O
M<FMS:&5E=',O<VAE970R,BYX;6QM5.N.G" 4?A7" RR*HSN9J,G.-DV;M,ED
MF[:_&3U>LB 6<-R^?0%=:Z?\$<[ANYR#0#Y+]:H[ (/>!!]T@3MCQA,ANNI
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M:J0T8$N)'FS#G7TJMH!#8]STT<[5<F&6P,AQ?0O(]B"5?P!02P,$%     @
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MF.N3#E(:86LA=_8?/ME.>)Q4XF"ZX<*.5=\.]A,CVZ'53<9^>_,/4$L#!!0
M   ( )1P8E#8GI8IN0$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#(W
M+GAM;&U3VVZ<,!#]%<L?$"^&;-(5(&535:W42*M439Z],( 57ZAMEN3O:QM"
M4,*+[1F?<^;B<3YJ\V([ (=>I5"VP)US_8$06W4@F;W2/2A_TV@CF?.F:8GM
M#; ZDJ0@=+?;$\FXPF4>?2=3YGIP@BLX&60'*9EY.X+08X$3_.YXY&WG@H.4
M><]:^ /N;W\RWB*+2LTE*,NU0@:: M\EAV,6\!'PQ&&TJS,*E9RU?@G&K[K
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M\?BRL?^-,1XPE=T-CE"''VPQ)#0^'#_AV4YC-AG>]/,/8LLW+O\"4$L#!!0
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M=/Y8*<%BY,*&42BX(PUMU%$<<9>T069!Q:BN;)0T57_$,O08K*BT9KJ\1JA
M:D8V 3"AB!]-0!6)$HIM\P[ (ADIYE09V.<!5<O*(;9R"-R26SD$5I91PJUL
MPXR5N9J&-NHHX:?,R ;%D;:L;*.D2,*$G;)CL*+2W/NN <KLT3HC 4P0C]$I
M4$426FO> 5@4QB%368;T'R6$[1QA.T=V-/-3:K#%A(?KJ$#'3.H+#-.,;0AA
MI)ASC0!,QCIF&KU"L"CDU=(8PB0/KVL HSCB9IP@F)96N8D631)>#]XA&$F>
M(3*TJ J$(ZQC;.X8A#639Q#;;I6$*N9A;<- 6(]L%(I8&V6TJ20O(,&2*'P
M#(4/V*<[?!*LSP3HDTN=V(;C+F!#F&=F-L)1LE;=.^RS A#I3'.#!M22M7)L
M'NH(9XKH@%L?X@PC"_8KB$MBS0LAB#,1RFLAA#/B<;X,X2@,#D*TK5M7#RN
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M_T+C(THOT?@5I5_1^)C2;VC\FM+O:'Q"Z0T:/Y-QFLD8[4PFYDF"GJ@@S50
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M*G7/@*M>\$!"DZ.':'_86KP#_.QA5(M]8)V<A'BQAR]UCD);$%"HM%4@9KG
M 2BU0J:,WY,FFE-:XG)_57]RWHV7$U%P$/177^LN1Q]14$-#SE0_B_$S3'Y2
M%$SFO\(%J(';2DR.2E#E?H/JK+1@DXHIA9%7O_;<K>.D?Z6M$^*)$,^$:/=?
M0C(1DC>"NTWL*W-6'XDF12;%&$C_6 .Q/1'M$W.9E0VZNW/?C%MEHI<B#<,,
M7ZS0A"D])EY@HAF!C?J<(EY+4<;OZ/%M@L-[Q"Y9SY"LFD@</[DQ\8\2MZL"
M6R>PO1&X*[+TF"AT(.ZO(?VT2>^\K,'"='/O!R\>B(%L72^KH!)GKNU5+*+S
MN#S$]H'OXJ49(]_U;S)^!K\1V?9<!2>A3?NX1VZ$T&"J##>FL3LS]O.!0J/M
M]H/92]_\_J#%,,TUGO]<BK]02P,$%     @ E'!B4#=$(I39 0  9 0  !D
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M2CU<J#%O6\]V(EG3M=5^W]NO_P)02P,$%     @ E'!B4,7J[H[^ 0  >P4
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MDIEY<V!,4J70?U+:3NK.,FQ*>I!Z.5-KW@WN;B-9TU]*O.%FM/P'4$L#!!0
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MI:H:<Q0S6:,5-Z$A74F'66D4XI]'X'Q@0#X0D<63P0PV+#WH!C/8  TEX1A
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MI%1>KX'*1H%>!M/+('J5"3^(3A,^E F/54HHK0Q&H4%E7IGPAI=P9(*GDO!
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M0GG@5K+PD!#]L)S%&BV:02[TB5$>22E/1K>A&!E0\?BY44S8*B+8%%1 #YE
MV7"FMQSF0I^8X%5$\"HFBU-<+?F%8E(Q<:F(3 7/C29VHLS@N1GD0I^8.%=$
MG/?*M+ -)BZ5_<+<,'&IB P#E< *9PXJ,1;/S2 7^L3$N2+B'-ZO6X4K+)$:
M=+_N"*Z!8M8G)LX554?!2H""%",HFA$#394^L!(@( $/2)9CH-48Z-L8Z&8
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M+W-H965T-34N>&ULC5;1CILP$/P5Q'L/KS$VG))(O515*[72J57;9U_B).@
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MV),8"S(&';4G&01YM$ \PB? A1T/!'DD0Z#Z'PEU713V;#:@9>(8]R8.JYL
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MJ^9M6+\O+@^R+A^J_-0]I//[)X7+_P!02P,$%     @ E'!B4-ETYCN1 P
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M&Q@DP(8 7Q!81HH!DQA,:S!QDLW2#'9=%(XSRZ^+N4DQN>(X 04G@&"KK,6
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M-^F.<\F4RO!6Z3NH;FR:U&PG]3!5XWYH28:)Y-W8;@53S[?Z!U!+ P04
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M;1! 3C)]GH.4I$4.I$+?/&,G5,CD)-N$D*)OY#'%TAVDZ)(.!N=.A:U>NT/
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M<SDVQ-'0HI^:/9F_..5_4$L#!!0    ( )1P8E 6BA]WZ@$  -T$   9
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MI3+;![T7X\2-AN*=>TSP]*)E_P!02P,$%     @ E'!B4"*64>&( @  =@@
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MU7[,* *PZ1RP:0XB%0H.-DEGO.*CR &HRJ2^U'8 -BV!+8 !,  (IA@QB@8
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MY'>6[LNKZ;:J#C//*U^V*DO*;_E![>M?7O,B2ZKZLGCSRD.ADDUKE*4>]_W
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M.;1%'.(>8MQ#/")WC::BNN<C]Y#'MJCY3L1<^KYO*04" Y_9L/4P;P^]WLP
M*6%GR/(0E!-<<*\9'Y-J0BB8P,HEL).#H)A@=FY<5 "6JT?<%5&?C- FAHF3
M$(030BB8'),_0BI8,*#0-<A86Y&S!!\0&.-^:.,>,7<L(-<@H5 ,DR@!A!-"
M+U@T)H>$9+ 88R+M<H]=';3S? EB]C"$\G!7>2"R.R[N:D!@2(4Y%:$!'-4
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M'E=/BL&*@>'(XPU:2="@N-WZSV )\M,+H: <::2:HEI E/<L2:JDFD,ZZBM
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MB 7S'G. !+&S_K@3B]\(!0L$AA2""CL4P'Z.IF/!U,80MV/G!1JY9=T(!6L
MCH&R0B=4[(2:;B"!I8*X4L$BYX7M2L#4K@!F-0%8'7$["GYDG1.8_(0 #XE8
MQ-T8U# 4LF3O)F2<"2PA!)(0/K'U(+ ^$/: E!&8^01@/A+.=LM%Q9C;/8%<
M1?:&"U(:'DWD#"L( 10$\XG="X&E@8A'>@=3GH"O<V;W+G*6BKBQ<&'*$XCR
M8L('A<E,T0,E4YBJU*6JLW=849>JTP53F*D48"J>3'9B;_[(YIS"'*/W;,\I
ML#]'MF0 (,YMU!9 4>XV+Q@<_7)9'MN#>^7MU*6HFXH'L_W'@2?2'!VM^16>
MK3$PO\&S;7?4_.^^^Q+Q-2F/:5%Y+ZK6!];V6'E0JI8Z>_1!YWV2R;X?9/)0
M-[="WY?=%X!N4*NS^;H1])]8EO\ 4$L#!!0    ( )1P8E"^S_AH3 0  (45
M   9    >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;)58V8[B.!3]E2@?T(F7
M; B0BEHHI!ZIU*V>>4Z!6=1)S"2AZ/[[R>)B$ON8AA<2FW-7WWOL>'J6Y<]J
M+T3M_,JSHIJY^[H^3CRO6N]%GE9?Y%$4S3];6>9IW0S+G5<=2Y%N.J$\\ZCO
MAUZ>'@IW/NWFWLKY5)[J[%"(M]*I3GF>EK\7(I/GF4O<SXEOA]V^;B>\^?28
M[L1W4?\XOI7-R+MHV1QR450'63BEV,[<!S)9<;\5Z!!_'\2Y&KP[;2CO4OYL
M!ZO-S/5;CT0FUG6K(FT>'^)19%FKJ?'C7Z74O=AL!8?OG]I?NN";8-[32CS*
M[)_#IM[/W-AU-F*;GK+ZFSR_"A50X#HJ^J_B0V0-O/6DL;&66=7].NM35<M<
M:6E<R=-?_?-0=,^STO\IA@6H$J 7 4ZO"C EP&X5X$J 7P0HN2H0*('@5H%0
M"82W"D1*(+I5(%8"\:T"B1)(- &O7[^N()[2.IU/2WEVRKZFCVG;.F22-"6W
M;B>["NO^:VJB:F8_YH1$=.I]M)H4:-&#Z #$0S;&/ $,B<>8I8DA%X37N'GQ
ME2)?%Q2XP<<F'DU,$X_N*P1IFIZ!-3TQ+P@3:4$CKY,QYO4&6ZOKMD;I8W"I
M6:> #:/V(\L"<*B!=QKX*&^:F\L>$W28XA-#@T0/V<0UF%!?A16 $4ZB!+L=
M0+<#TVU_D-Z1AA!J".](700U1#>DKL>$@UBCR"=<SYP)8YQ'@5XOD9$YEG 2
M!MCK&'H=&UYSWZ(@@0J2.Q)'?,Q0/E@^JB7E6:&&X48T]'V=@4Q80)D.>_VC
MMK'C%FHE8,TC2_H(I+P'0N])(.Y[PE#]AWIF (KHJ%>H2Z/Y%0;9 L=40Q#7
MV/B.X+XGP3W)PYU/PAL:5X%&517Y9E69L-BHO152UFJSN(WIAB"^B6*+#MS\
M)+XG?;C_26(R2*SOV0HTHBK?MT5,,4U00!/#?4+M_&9CL\!8J16"V1W"[4]!
M^_L)T4I'H49L'@9V6Y@F*$6V]#)5J-$&<R7/F$THX@EF''J888I<LX5)@ (2
M\!.FV^*&K?B**<P5%!P22*QO'PHU"JM;+HLMS"D4<4I@A!6:MJX4!N8!:O(
M'S"Q.C.;)PK;N1PS!07GA#C4K<1W=3GF$VKRB4''3Q3PB=GD+P#&[0EFF'88
MHIW8DCZ&F8*1.XB6809@B 'TT_22F0Q KL5L^9 P*8#'EKV%X<YF_)Z0<<LR
MLV6-O66A0*.3G%D+SW^$C1W"?<U 7YN,S\R^#F-NMX4;FZ$-WN 09GX$4'O/
M,=S=#'5WH.<YOI5#&.YLADX*H6[%;-DKR\1QRW+T0:$7SA*@0AYJAKS!-4LN
MREUW;U<Y:WDJZE9V,'NY&WSH+K.T^069/!(P_T0F+VA^22:K_KKG?[/]!>5?
M:;D[%)7S+NM:YMW5SE;*6C0Q^5^:Q.U%NKD,,K&MV]>H>2_[B\%^4,NCNO3T
M+C>O\_\ 4$L#!!0    ( )1P8E#!&Z@+V@0  '89   9    >&PO=V]R:W-H
M965T<R]S:&5E=#<W+GAM;)59VV[C-A#]%<,?$/$RU"5P#.3BN 5:(-A%VV?%
MIB]8R7(E)=[^?75AO#)YZ$0OL:2<X<R0/&=&U.Q4E#^JG=;UY&>>':J[Z:ZN
MC[=!4*UV.D^KF^*H#\U_-D69IW5S6VZ#ZECJ=-T9Y5D@& N#/-T?IO-9]^RE
MG,^*MSK;'_1+.:G>\CPM_WO067&ZF_+IQX-O^^VN;A\$\]DQW>KONO[K^%(V
M=\%YE/4^UX=J7QPFI=[<3>_Y[5*IUJ!#_+W7IVIP/6E3>2V*'^W-[^N[*6LC
MTIE>U>T0:?/SKA]UEK4C-7'\:P:=GGVVAL/KC]&?N^2;9%[32C\6V3_[=;V[
MF\;3R5IOTK>L_E:<?M,F(36=F.S_T.\Z:^!M)(V/59%5W=_)ZJVJB]R,TH22
MIS_[W_VA^SV9\3_,L($P!N)L(**K!M(8R%\&_*H!&0,Z&U!\U4 9 _55#Z$Q
M"+]J$!F#R#((^MGMENLIK=/YK"Q.D[+?<<>TW=C\-FHVQ*I]V*U_][]FQ:KF
MZ?N<\UC,@O=V) -ZZ$%B *)07F*> (;'EYB%B^%G1-"$>8Y5H%@?A&O.8RN.
M1P@B*U@(4E:T+HC"Y!+S##"1-7M+A(EPWA*ND>P&D,-H6>29.8(C4#<"7>8;
M6JO<@U0'.G2@2#'&L!\%_2CD)[+\]*!DX$?<Q-A+"+V$R(N]UT(G&V:MW:>(
MI8MH)\0S(Q&,-0*Q6AMDT6/"@9L&(U1B;S87UV#"R-K<2P#CQ*,$AQW#L&,W
M;#;8V!<C)'"$9,2FY0QK$_O"Y!G0,-TH8ISLR0,X210IFZT&-UQTF1 /E2=T
MCZQR-_300WH.U>Z>BS$SB)6#2T25Q)9NZ3"2WX0>1UA@.%*8A-F.7(GAS,\H
MCD6&NRI#MG@_&=!PN<GC!8L,=U6&;,E\XJY"<!:3-R&L$1R)1,)M7RZOQ157
MF-<<$)LGPG85NQ+B7R7,?YX "1&)S=[D4YD&$!''OF@$EA*!I"21GC$PIP4?
M04B!22T$$E9K6RT0BB>6SC]CE$6$Y6>HRZBQC @D(XE'(016"$%C9@\S7R#F
MVYP4+O-#\NY>@=DO4(^1> 1<8%J+:$S&F*_"Y2O(V*4K5]Z$,5T%H"M//&V9
MQ"23;$3"$I-,NH733=B +L2=<5_&$E-10F)XNB3IZ<S'M.82$T.ZI1-D3$#\
MO0EC]DC0G0OO&)@7,AR3,.:%_$I/;$ 7E36.AN6N%T& 4RRT84L (^DMGA*3
M48+B*9@O><PS.:8O)LPS<HL9.:^X!/IB?Q$GS$8";:Q@=KM +AU#?U='F(X$
MZ"B8?<I@4+;4^5QAUA(H9X)9$[C *$_A),][-VB+!;/)36Y;?.4]DS"[";Y[
M6V_%CP;U55=8! @41\$\Q9&P"-"8XDB8CX2:6?OLRH"4O6-\*6/:$BB/@GG*
MH\*T56/*H\*$5)"0=E=M4,.<PVMG.9B1"O6J]KO"0KF,%%=<848JU&#*R'8E
M75>)?RD5YJ0"G&2)M'VYG)171$UYSL-0R>7,]N6B0K*[ZV!PHIOK<ML=X%>3
M5?%VJ-M--7AZ_DAP+]H38>OY []]Y.#Y@M\N^Q/D7\/W7R3^3,OM_E!-7HNZ
M+O+NM'A3%+5N8F<W3>P[G:[/-YG>U.UEU%R7_9> _J8NCN8K1W#^U#+_'U!+
M P04    " "4<&)0!>NJLR\$  " %   &0   'AL+W=O<FMS:&5E=',O<VAE
M970W."YX;6R56-MNXS80_15!'Q!IAA0I&;:!./:F!5H@V$7;9\6F+UA=7$F.
MMW]?71A'(D>^O$02?6;F<#ASR'!ZSHN?Y5ZIROF5)EDY<_=5=9QX7KG>JS0N
MG_*CRNI?MGF1QE7]6>R\\EBH>-,:I8F'OB^\-#YD[GS:CKT5\VE^JI)#IMX*
MISRE:5S\MU!)?IZYX'X.?#_L]E4SX,VGQWBG?JCJK^-;47]Y%R^;0ZJR\I!G
M3J&V,_<9)J_<;PQ:Q-\'=2Y[[TXSE?<\_]E\_+Z9N7[#2"5J734NXOKQH5Y4
MDC2>:A[_:J?N)69CV'__]/ZMG7P]F?>X5"]Y\L]A4^UG;N@Z&[6-3TGU/3__
MIO2$ M?1L_]#?:BDAC=,ZACK/"G;O\[Z5%9YJKW45-+X5_<\9.WSK/U_FM$&
MJ WP8L#QJ@'3!NQB@/*J =<&_%Z#0!L$7P9PU4!H W&O@=0&TC#PNNRVR[6,
MJW@^+?*S4W05=XR;PH:)K MBW0RVZ]_^5J]868]^S $!IMY'XTF#%AT(>R N
MV!"S)# 0#C$K&_,5R:MI7K@BQ76!MCD"#F.\$" (3;*D)P.TLD%<1$/,-P(C
M#4:O%$;2\V;D&K'6 >NS]>5(YCCI@;<>^# ITLA<!XI:4-:"\"FDHP1DE("*
M(HPH'2CH19&![_MT'$'&$40<(^DK886I,1A$Y@+:N!HC)#?6D( !!QG1M"5)
M6]JT_5ZQ##R$I(?P@4*(2 _1':GK,**_0M(';F8NLE+".)>!6?T$+.(@ IHU
M^+1*^19O[H_4)HP('3R0/" %Z!GP=OJ6&M2?,7(Q6N) ]SPP.Q0"'_%!=SWP
M1Z9,]S383<U#;NX/=E-CT]1C4Z;;&HB^1@C,] JK/('Y@V!ZL[D-'+*BNQ:H
MMHVL19=6,/0#@M1-W) 3K0,0$G7(I,DIM&,%5*)NXH:<:&4!0EK\R#HEV.(2
MDIQLV0BO<$):-M"6#?#-ZET1*,'%2"!:7!"(!0FL4P?<V/LTGUNP(2-:JM"6
M*AX:O;30H/YJL)$HM$JAK5+<W/$7&G2O.B M9GC/&6:)]B%&/(WLTD@K'MYS
MC%FB+7F 5U:)ECR\XRBS1%O($.VJ(5 \E*.$:+5#2NTP,AG9*M9(J\E(VBEB
MHWQHI4-"Z1#&FI-6)HP>V 89K22,4A)I%,6*0B&,G?5I*6&$E"",G'48W?P,
M'YGQR#\=][2V!@V++A!CB\SHUF94:YM=H$'!O:'HYF9$<R.," 2CFY:)1[)+
M]QFS^XS(+G%8P-$)TPW$J ;",1]T [%'&HC3#<2)$[PU80T*KD_8Z]UMI*K8
MM5=9I;/.3UG5L.R-7J[+GML+(6-\ 9,7(,97,'GM[E*^W'=W<W_&Q>Z0E<Y[
M7E5YVMZ;;/.\4C5Y_ZFFO5?QYO*1J&W5O,KZO>CNQ+J/*C_J^S[O<NDX_Q]0
M2P,$%     @ E'!B4'*MPX_' P  ZA$  !D   !X;"]W;W)K<VAE971S+W-H
M965T-SDN>&ULE5C;CILP$/T5Q <4/#:W*(FTN>U6:J55J[;/;.(DJ(!3()OV
M[VO FR7VN"4O&_">.7,\9H[!TXNH?M9'SAOG=Y&7]<P]-LUIXGGU]LB+M/X@
M3KR4_]F+JD@;>5L=O/I4\737!16Y![X?>D6:E>Y\VHT]5_.I.#=Y5O+GRJG/
M19%6?Q8\%Y>92]RW@2_9X=BT ]Y\>DH/_"MOOIV>*WGG75EV6<'+.A.E4_']
MS'T@DR?*VH .\3WCEWIP[;13>1'B9WOS<3=S_581S_FV:2E2^?/*ESS/6R:I
MXY<B=:\YV\#A]1O[IIN\G,Q+6O.ER']DN^8X<V/7V?%]>LZ;+^+RQ-6$ M=1
ML__$7WDNX:T2F6,K\KK[ZVS/=2,*Q2*E%.GO_C<KN]^+XG\+PP- !< U ,@_
M Z@*H&,#F I@8P,"%1",#0A50#@V(%(!T=B 6 7$UP :="O>+T>WOJNT2>?3
M2ER<JG]$3VG;"602RR=HVPYV#TSW/[G$M1Q]G1, ,O5>6R8%6O0@&( 8B6\Q
M:Q/SSN))"5<=@.E8@)DB3&Y3+!%,I$E=F1CBAY&F=42R#98,;C&/&$;+]80(
M @"\-!1=(MHQT)LI19;B,I2!=0QLR$"TN:Q[3-!ARC<,!(E>%Q,G,6'$M-(@
M,,)(E."R U1V8,JF$4X0H@3A'96+4(9H1.5Z3#BL7 1^H-4-0;$HT%"/D5&V
MB UJ>Z,X1A7'AF)&?)P@00F2.XI&?-Q4?%-$K$WU28&&%;&T!;%8%S$7QX=$
M]RYBE-37K8L82C3(YI\LMV)1?WL@8(H%H!8.W C(/4Y <"L@B!< ,+UHS%R;
MT/>-POT/=JL([W*"M+DT'EU18*1BAJ"E0@V7R92]0E $[+)Q;R$A)CO498<C
M9*\5*K"A;O7@3D40JP+0=SX$%;+0D@@W&&(ZC$QDO Z8J)C9^ALW(I)@B1(]
M46(NIF\M'N"&!:9A$: V#MR.@-S1G8"[!" NX4?:0[5&4=H";# 0"6UR<,,!
MBI7%QH$;#K![RH);!" 686S#@'2U#WJO;3"8O?D!;W[ FI]:'F_ &Q:B>PJ#
M]R(@O:@79J5 8V>,-R-@S4@M^Q?%NXSZ=\R8XEU&D4U?G_&2FKNU?5NB>"M2
M;,.FEE<Q:GESOV?#IGC_T!$O[PMJOFXC&X@W^"@L>'7H#@UJ9RO.9=.J'(Q>
M#R8>H/VHU,879+(BR/B:3![[8X=W^OX4Y'-:';*R=EY$(S]ENP_.O1 -E^+]
M#U+VD:>[ZTW.]TU[&<GKJC]]Z&\:<5(G*][U>&?^%U!+ P04    " "4<&)0
MS_, 5F,(   \,@  &0   'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6R56]MR
MVS80_16-WET1EP5 C^V9V(D;6\I,IIVVSXI-7Z:2Z$IRW/Y](8E6Q-VS"OD2
MV\K!<K'8/=@#4&=O]?+OU5-5K0?_SF>+U?GP:;U^.1V-5G=/U7RZ^J5^J1;Y
M?Q[JY7RZSG\N'T>KEV4UO=\.FL]&MBC":#Y]7@POSK:??5U>G-6OZ]GSHOJZ
M'*Q>Y_/I\K_+:E:_G0_-\/V#WYX?G]:;#T879R_3Q^KW:OW'R]=E_FNTMW+_
M/*\6J^=Z,5A6#^?##^;T2UEL!FP1?SY7;ZN#WP>;J7RKZ[\W?]S<GP^+C4?5
MK+I;;TQ,\X_OU54UFVTL93_^:8P.]\_<##S\_=WZ]7;R>3+?IJOJJI[]]7R_
M?CH?IN'@OGJ8OL[6O]5OGZMF0C0<-+.?5-^K689O/,G/N*MGJ^V_@[O7U;J>
M-U:R*_/IO[N?SXOMS[?&_OLP/, V ^Q^@#5'![AF@.LZP#<#?-<!U R@K@-"
M,R!T'1"; ;'K@-0,2%T'E,V LNL 4[RO7/%C2#H^9+_8IO-3WI?;=%YO\[[@
MYL>*&[]-]UTN;I/[XW0]O3A;UF^#Y:X^7Z8;&C"G>50VOOET6R[;_\P)OLJ?
M?K\PUM'9Z/O&5 .ZW('L <B;U,;<2HS9(T;9A[TC%CIR:>4S0ME^QA7 Q**-
M^8@PIHWY)#'&1-\&72-#MHWY%1@J0FR#/D,0"]\- %D76(PAB#UNW,'O"<(P
M.U\ QI1X21W.+;>UX XLA,)B"QY;\%L+OCUAGGD[4-B"%EN0\A#"#Z'N;@9L
M(4@W#0OY[0Y#!UYFC*62Y?A8XC(F\.R< )CQ)BH+%+'?$?C-TN RB@=9YPK+
M%N%*PDP@QROX(X E&SPKXD\ %BE$9NT:63/.L7+_%?GF2E&G");$3&\ +!>/
M95.XC2(K-S,PK*3'$A:"*3R#323,)V><DJ8)+W<"R\UF=YED,84B$,OFJR2S
M@JQCBRU!)R8ER^+^2<*,-<0WH6OIF2EBXHP,GTF< #\#&.6E9IES V Y^1GJ
M5GKF J7$PC&6L)-@G.!F8"TG1,0K7>*5+A%OLNJY+,7D7"YMP5S7)4B)$&-B
ME'0K<=#>^.?V6E/<]%ZP<RGD))UF0^M^3'?N-[AQ^6!L!_9O0*W@D/7$6&,,
M<)9\:7F2 )S)<LUH\U=V:.- #$FQH>S1QO>(H;(%&^H20Y*Q*6U9\OQ".!=+
M5_ 82EQ^*!UL1FW?E<W?@-W_H'-KVU V8A-[Q%!A=X/H7<10LHO/70BG*@"S
MHM.< )06.X6G#" JIU"=57C %MUC9Q4>L*9#[!I0*U_ROL_VJ3&"^4@,-@&P
MZ*-2OU;A'@NXQVH);!42L#WZ=*N0@ 6=N@R@%SM.C)FS> ML94?O? ZA4#$
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M**(C=]ZT1=E^G$21E6,$*ZU-B;LN<<8JY1\5WHNHE1']6H-J7;TG[ZT1[X
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ML#UI-><*M,#@02ML]=NS!A1J9::/>B[F&S@'B@_+XX+6%Z[X!U!+ P04
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MY2+9;=-%O"I#V/>BUS+@.8"HB%?PRC+Y$OPU>:B^UX?_FTU'_6A<6_*N*!#
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MY((Z,R^9 (7T4>(,T;GLU/U )D$VY[3/\[!!4Q+@'=(=#!$3HQP<.'M:2W)
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MN>&UMPBU^A"JC-@:0^MJ6G-89,^*< <"M&U1YN(?MD>KG"89I4O%8EE&ZO:
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M(,8#+J+G"AB9<EQ.*J!,<V-F6]B>9-?)]CX!A-^55DJSH9AX@#EL-E[1/^Y
M_L4 EKBP$E>AJR8!68(3!9#9 7P>3F=K]NHL^29ZTYBNQ%:*%GE9.A#18+&*
MT[6Y<;#G?,%F4#H-FD=*R3_X\TA$"1ZEB8(PY0=<T*PGWK*H[^(ZB.7%VE/
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MG6[R-3H8$1& ;I(=@!1?T6_();D_!+.&IY(>8C#+(6>S :3$9F;5D)5975Y
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M"J.)A>AH#K@_?@R=G/VF='(^G@#9F=.>>;&S,3>WGX]A!\/1DR[F9 :X,P^
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M"\K&36C4,N5%%-KF(W*7]'63,C_X44<FDNEWB%W>8NFCXVW+]#9MWICJ37+
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MHH(YNV8B'0Y&$Z9L@[ZET1&FTV&.'?PZ//H;?W\R&@R8Y@+P)DWD.3B9RAM
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M\XF5ETXD?O79OA9LAVKCG OP_.AULB1=^9@:E4\BJY&?3,,1M5DD\&!?Z^$
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MAUI&H'@>RI;AXN.45T?X,!RV97K<2]W]*I34;*TXTL;RA/[.JC'ITY&^FW4
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MTRFFU!$X:5$A<Z1&%X@K *",6L8;,K -CT.L8Y)+'\0UBM.LRAKIG4BT!$K
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M37BVSU<11=OXZK&+FO&R@H_]@%%"^ K+I<";FB0"5'J=[M;<R?OZP5E0I:"
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M-0'RGDNM$OT0LG,37]^<!^6TH.UV1IXH^.&*F#;V298&LJBK/*%5.:F7"WC
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M_'122\4G*9AI%;23/0*>S3@DD\4VBJ+&[>5%[M]744<5&&K4G+&KOJE-.:@
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MY=19/*-6):=U :93N&9.T9JJBDR3ZW2R6CV*&0P3>*N5RJTE05Q\=01OR?A
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MI"WI2J1G+Z'<_6RJ[0HZP?9ZHT[PQZ[(DSYICBC[]K&6@D3JI-A]-()9Q&%
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MILQF5/NY9@^4&*ZL-ZT,!6W@P-:UD/72>X\+C:[;&0A "TYBL6+)I7WE[Y#
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M1\;*]NK5/HRZ@4-0&J>*4QFD?5@<5^Z44[Y#3O&DG](-VM!+OI3-[$"F^:9
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M@7?D-<T9 3WU7>(^1*J&6Z!7@VLK&<R96VN[5';KL"FH7>JN#=S18V.;FF7
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MY7'2_U,XK^*JBG6^9? K]';AW%&D,8&\+X]D/)3GB9V0=UO#P;2@>73 L1_
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M7IJARI\>O=<CQWOM!D/RZ>2D*,_'E*X""L.%JN9K@]MPX0<Z;-@VBRC 4FZ
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M_4Y(UT,2#<:[44:HM"6'7>$-0Z*4*'/&2"[YSBVLD;<JX9HBD"U,$?7 )\T
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M7ZQ*K-3:&-C.PWETZ4XMCR@?) J)IQZ'L&WCF')F^ L\%92PDQ(;9FJS*$)
M.M3"*:I*QJ ;@N[&//HX\J, CPW?;$44@)H('T_^H(]0G 3H^< +P<_C%(%P
M81@@NOC1>(P!8"#(P.,(M\%V?U1FNJIN'<<YS#0EIA90'YARA('D&&479PD-
MX;C(?,[\2,.$Q*H/K9K$'MDIN'UUKOCJ*6!1***-!N7%0.HY6C.@(1CCY[<_
M7+Y]<^X9+##$.6DTD0)S+N#LTV4-;3B_'DFA*REGML:04*F.9!,2;BKP>YQJ
M @)PLY5&FWB@N,H1&I0CF?XQB &T1AC>3>'ZXXR$100503K"O)V4Q*0W=KFR
M]6I3GF[N,?;*"VB3,2T:4Y-BV$7:N (Q::."]QE[)X*3W0.M'EA-0 ([IF$0
MRJW(!<!L"\P40[]T0+N^7)S.L)0:>\$<?1>''7I,K3%EAL-BT A"N/Z D,8T
M00%>6[@M500=A9R=:>\XI1FS.H$V+@R83VF'&$P76*D)QVK PDS6WOG%QVU[
MX"49TC*3R66?!G^,TV>(&-F;Q _'.*Y4E@LN(WJ@X(V1,P036U'Y":N>LYQ4
MS>PC/\B101\'3+K;"(97[!B3SPM^)>5E91P>7N3C@A>,Y&C-O&FG]=6 _@UH
MW;DAXH*567-3((O)VWF<FNJHHK6IM+:OC=_&6VC'C0PIP-Z3^VH@7)[*V(\Z
MYOJRBS%1N"GZZ F%, #J0,&E&/LY"MW_S^3N_D]O]%F/PL!/TA2Z0HBPR'2B
M"DV$44YW _P3%V$_76:IGX.XDH5^$.48-Z2(C+.OJ<*76CM@N"A-P340!+E0
M$D9Z8JBR'^5I4S"QEATMAPF(IV1>Q@;2L;LPULZ_/'K=](ZCX MWCR C$> I
MHDZ]8U>F<KOY8\K[4H*.D'KL%PA[K;_^T%FDD>R@,)>83-%1BD'<1W_MNHK"
M<>:/"<\=+@>XR9)4.U'ZZC\VB0ZC=%(RBB&6<.#GP+6;1\2DU^GJ-+A.(F,/
M.QX[3*9X1FZHFXW=C25('BS(M*'&!!JNNQ<,5_)C<@/D['TF-,SQ&*D$J]V+
M[1,T*_POQS"X!9"/6:0Y!H(L0GN_05,9U$ >9Q9^!WK>G#>UP[/K783'3?"F
M@BF,R8_?  #;-7MT6"0=R] .W+6KYYQ91?R$?RKIY.P&-/3M@?"?5$T:%$C<
MALGYCC.[K>Y;O)O1'_<UI3/$[62U*)LQE"M['%R#VO3. =BOJN5-Z<+2VIX3
M#'-!@]Y.P/4FF5Y>G'_X=/8?9]YJ^3B9LUO>0BB5D9W0,44+*_P;YQ1>%V+4
MN&;+FNL6> 6'9/@/4_BL8$T'3Q%]<O$HXTP)[C$#X>OHPLP2M0^GU20B"S *
MH&'[KCU#L_I_ *U->\U\WV5/[7$]^\8V-P:6$<,G,"P#Y4",3(3-V;:H9)0G
M\:Z]I*\FC]#M;VDQ>42_PC*&"8>"$FEF^0[*)-4/_Q^W%_&'RW_[32TACN?7
MH$,T5A-6-J]FL74!\623$M1>OS]/%B!=+)!QK$OTPL%U-?I-K:@:X:^PJ@$=
M[HP99X:ATUL6-1"J[%!,/BVG,,O?TB+RB'Z%)4QS.M,%G^\4$S:VK&&J3G;'
MC3-TF2PL47%J[URC2H7Y.6OT8?D5R^_5OPH#+/*1!)P0HF0\2K:S0+0Z%/S_
MYD)=7(,P./@BZ:>VIZV>C.+):R<1DFV.EQ0[B"F*.M;F\VL7<N^IA_+9J U'
M]HR$=F2$=A.9R?+HHQY.CU0:HI6.8DVW<SP\J1UK?%G>D)'KW,[.H33:!3:U
MTN;\5QC7C]GFZ/SK4R@&ZZ U0K ]<%R>C$ -5 )H+.,WLT:-P$VZ6#,JQT$B
MYI5E%_UK-.CS;CNT]'9>W5GI"90NI3 #5(08I\$?B9;TDHIYN3OPLDM_0%4!
MX8PBKP.YT_QZ=,$1-EQ'E'&Q-= I8IO&C3\'D4D8$:I5&/@A9IVG9(X^H?#-
M0)EGVI1$U@BT!Z:1GT2I>2_&+]*@=:8YKK)1EM8HG!2S'A? &]%H@_;BD$Q&
MT&*.!0LM)!IW]S&0I_ SBDI+BD+"$8^C" .!!-;(#Z.(<&>:<:M6#8\TBF'"
M!&N2!A@$2ZT@"DO&K>1IYN=AUG",-DD-TYA2/XFIL&(AF$C'N<^N/10TJ#[%
M$5T7WY/@,/8^#OH(CG_5'HS[?L(#0HMS]Z]!9!?Y>9HB\046K@["4J5;B"Y*
M C\K4GS.Z35-_'$4[4MS28 @MV-RO\)2'",P4$CV='2>YVG42W)9$@HB09:0
M7^R%_38&DX[]+$^VT5M<!()H$XWA)!4,0X7.$L;)S]"\FNPFMRA#/QF7C(P#
MOU#P[\ RHD)5# S]&$,MCR@^\3M278BFWZ2/ZN370>234YA"T]M-W_:3#RCR
M9"%K0>_R]_O33PH\,T3O!B+X'P,5)L2QXG'BASK4ODT^:"L."85:7GUAO<QF
M[S#?RJWB/*9P1XROC!&M2)I((XFY+F(@QF@G]80ID,:8Z1<6(5% <)1U%",%
MYMTI<[?HV,#;F(4&,5HC>(C,=CO(_?;;F"<N/IYG(]?V<!![+T&K*6%FXZ&-
M4HJ8*3!X)AP+/%\4PV*&40=$'>(TCW/@]^1W0=X>4>C(<98C=C8?OPAKMI"M
MMBE+_84A%^:/WCM=1OG-9#WQCG]:3#8S#.@YZ37%]KV\'=G4U&NVTZM7Y?6<
MHA0F5(4<OL9#HTH@6!565#0SE?D1^(CE?;60Y;^;+"9L6\9+ DLN(1;0-=62
MI^S9VJZ1(BFDF[D)CZ#PL.I.+.;UR+M4K@<-4#&G#/;)GJ4GMOKD^B+J12Z4
ME:YAH5?U6OV)\+M+:%W]^9E0--1?[[@H@ORI6"5Q>Q"L&, ;3RX!W(1 'P5)
M?\DXAKL@L!*#K$,? J5E#%I81 02B*^F?DS""E)I$!6[CWP4^BFAB1^#7E,(
MP\"\H9BNDX"<@U9Q01U1,@[(+49W'6&@$JLH0-JA:RR(_7&:=[S9+#/+)_H"
MUOD.!/\-80K58HOJ+EM8 '-DN:Z00+:(,&"H?_@M3-OE8*5SLZ68W,8)=*"&
M4V/!*. @I6!$W" <Q>'1FW8AU^ZF8FDJ:C9%;!GA0Z1NP#-23YC@;-F9 #PE
MR>D[(($Q8?["I1^&<0_U)#F"XQ#-%$@I0H)C$E_" BZ".-Q)/<<Q.9LXLBN@
M:@,G0DJI9'-@&>"BFX*0< HAG.,48_)C<<\&0,4,[10'$0;^?!,ZPK"]B&+L
M$JE"A#$5*94FBE$(R#MJAF\A)+/M\"D:JT\!SRH:P0V\'SGM:C *NQ'_OY0F
MH&U;3Q6PR7ODE8OUG!FS70WR'XI4)2N[G$F-'@QRXR3(>G/7>!K:V=;C0T57
MREK?!XCU)0 +B#U$5[W-RQDS\:RF!-5-77/N*":3@R+G?414)968CLS=#N<X
M,S 0%\MY-:4,[8]=Y<);P]1+H6"0)$6&XDRM4L\'%17_3,CE@J#'=IT?,0L&
MT5'EGCJ@M'BS</7VXN+\=*.\>,85#9%KT8T0(0!PUE$N7-69W5$P7-X_'U M
MG K-Y <5L46\KR0>6&.>9KBK6#BBB;7WZ,^;!=HYGK!%3ZS^G@.#I=JIP (2
M%<A2^!&&^AU<TUTW,&27,!0H#&F7N/6A>W0\CC'(=- >)0@8F%M[1%W9.R1L
ML6N3+N'0*22CW\9.888TJ^.$X_B$G5(-#-DI1-B.@\,J?V-X<#%XK](TW'6>
MPG'75EG2^?=E>SF"!C/;*U#XR2(@P/APMB?O#]DFDKY=^7J/XMU $.-T^$85
M\?:-0GGW:?=C\>O<C\5W.-(@52=)(<Q7CG0(AVR</^%(ZP8&T4H!@G1Z"/-E
ML.R![#="R,_@0/;KW)'?8YM 7RUB4<%$ 3E.8H[G.WB;= -#M@D-^M$ANT1&
M]N';5&#)AAW;%(V'WI+?9:]2/XWE2"G-+V%\_B?LE6I@T"T9PSV=';)9"=87
M&;I7L+,QR,$[CE3<O5>M:_*[;!4Z,P+9*M%#TYB-H@=OE6Y@R%;%:$(-XX-N
MRACX;#9.!F]6-AYOORE)E4<5_0LC>B[V'I12<8TI5MLXFQ!_6I.?M6T'9E ,
MFX=-/J@D=37+A<8!F3J;2@!>V"8Z,N0G4W2@:W%F*E!B69=FP,JFT=M$T[ @
M;[H(_NYJ.-+"@<*"")7*AO5A<U=2&?H3=5Z.WY2+)?D+\$LX':<"H4.M/T$9
M58JFTB8Y X8PS]1ZV[4P9#@(N4Y];.X)L$, ?A2JAV 3U;9W%43'SI=5=5Y8
M#7YW\H!IZ?00!I.K)K(L;370P$##=&Y36+;8]7@WJCBC43:S4,_W65S?NY]O
M,-NFAGV<65":]K(G:,S.Q1"[Z^;['O3!RI52G)1V]&WH(\2<S:?11Y$D>]%'
M%/PVZ4,O.SI8"['+[[AMOP=YB$ZG]#7EA/A6])%D^5/I8R=#<.@CW/EX?T$#
MII$,E*\B>Q*9891)DGEC=(\_(XUA5E>"T2AI3%4NQ.LS@,B*7Y?(1!Q2HHZ2
M9[X5D45IFX?L=TG%V5Y$UJ;I?8@C\/,DI:HE6?",U $Z-<6!8:V7@BI,D?OF
MG<B!7,U4L$C*+C&&O!NMVXO=,,KBPD!? K&)/YB9\NRNRND$<4<)PUGV>Z$%
M2PQG!>'+5DT(5V.QKDX53;0*0>SO@GE%&>M ,1?L5Y+TYC?E&E:Y/O%.E=PH
M_X H^*,$RC8[CYV#U<IOV"Q&:J7R=@9.URC^=G95$UAB*TCXS !D&VA[49N(
M>E=PJBG/&L5=3O*G<W'V;Z_?GIV>??CAXO/[^/1]*TK9"KI5VE'SF3P;!4$K
M]C8,@JZO73@F[[]A\1C<LR_\.2N&-3/Y96LS>=[5S&'D,:5'E6)AV7GOM0IK
MT\M/EV^\XQ>HE?[1(AK$P('VS!>?C?GQA?-W:T6VDA6<0DU6Q3:::_T(1WJD
MF7X704Z[Y]I/E0/<TPC<2RC%UKENA0_]+?Q/_V]1J_F]KY<>D)\M+^-P=C+0
MUA;LN Y<8+&+#7!2S,*]F$\XEXAIHKT*$:Q"W%H%^=K_6]+UTS:4VOZ<@RTS
MZ,5PW#+R3^8NY?[/\"[M[Y[WH.]78(F2@LZ-]3W7:U!Q#5%;QMWB,F)WVMYO
MZZVA ]9X8JL."*%.)FO5.Z&PE^;O(D$PO,;2K76"',\+7X:,T=)QY-J)ML\5
MYF#L1@.\.5>/'A9PFRD+TEI#$6R/N.&2!6T1$]K#GP8;HCI-3,I,-!KHDK)E
MH-Y(%A7&H>, 56'%4NI3F ZP#3XEM(VV69(A=XA7408*]:^D@;8A5-GZU'P^
M+XV+C']HV&'WM*72;M]MYNOJ?HX%1-TV&K9FJ13XT'-R'\KFX>W8$,M"R2M<
MU?;R^U8D< <1[6<@M;<5^MH:S61@D-9<J'(W">\;-"9!KD[M-1W%RK Q.CZN
M)2K__RDLJ\7-VM?F[\;Q-@ETB!#_-ZJ *H3U$^.9-!3 [<)YN%4X_SA=&Q%;
M] )0L2BX?3$M34G'UC:45R,O*EA9W.?%'R>/JL-TG_=L-2+>Y\4WY51/,3KT
MQ;&\N&U4?<_8.D[?,W9?Q8!VU#,:=6;;P-3^?)ZL;LJUU/S8UGHZ8)3C;4O9
MTX?]?M[3Q]G]JC7+0=O5=4CZ-4&#]G]O&G?JJ$R(,Y;WZBY5Q2=0?AXR'M.#
ME?7TWU[OCKF)6XRE]4FG?_6)Z'@:0(I' ?V&].'-:CE?WCSVOO#3_?5JB;!*
MO$7:#M,__+J\GQ 47=]*#5R0SZL)J&93KHJ%93CVG@OT=-@JG7_\<'YY^N[5
MZ7NZ+4%KNI_3)IS^6,XJ$DO>5#47+=JRTL5>*VU6\*Z:@\*)LK"N%0,22E6B
M^>N_O9[#\F/[)6TS8PC_&2O ZUWK:@:R*!^\-7$!+&'W%?<+1\",H6/"T8!I
M]CQV\%Z=S1>/\\G=TQO:_YY5I5^P&!:N-,E>^J+MT'7;3_=SG M="&Y=W:FR
M;%<5%6?P'F[+A3Z25=U[*F.1>)X^5PT&J/AFMX5PBS6YU4+_W-43%B ;9<=8
MA<"N-(#=K FM*)ANS[&_7&SC0A7;N,1B&WM/O+N9+3L/$ZE /$,E@5.*T%)5
MKZFJ)F>'EY[*%K<L6^JK=C+N<XB4JI;(FT8MD0NN)?)6)3_MO3S#F]Y&,-R&
ME,TSS:B<K-8:4]-;;'3J]]XNW^I2I2#O7V^XPE3;B2 ID^H@>G IS":/G332
MXFS3Z>9.A?I:-2+[1^)4DE2P[_U3P"IG'=^%'=]%'=_%'=\EW0O9NP\?5#74
MZ2U>*DZ-P(=5M2Y/9\N'UHP;*(M&7GH^W@Y?KC:E@WC;3]J]VE17*_W[\7I>
M<;IPWVJ=+TX-OG7?0WS?W54UEH":+$H86N^SG/P]D5'.>]%]#UA +J*ZAFN>
M;BQ=\5J;ONS4<K$)'>2E/*2C;^"(G*TV-\]PY<!9X/]2N3ZVA["]Y'R!!;L$
M,K1/R'!4KM><F]\BLV%]#%*&-B"^3^>/I[=80(2Q "K>+LY=1UHDV^%$55FV
MHE1U?1(L3HGH1616C-IN JO#%8QW77[S'O??.5RZ!4'\&U3B_1E&5RO]&V&>
M9EZYO+X>A/G4KKPW><!*NR!R3N:M,7U9KGX^K1:G('J@^;)EVL'*8+=P(&Z6
MR_:$5#4+&6@7RT.KL-?#N"VTD^?C[2"(@6ZZ?O3)9<FR!IX$%AGVW[3M[?5O
M'U;^1.:K;_D9EFB>5IVW_-9.?+CM56WD]_A+O^]1M7*O6RE5*QV+C^;?%0BL
MU^L'@J%XS]<N[*3O_3A9;*ZQ\N7*5;6LJ??OZO,T/"#^HD-.^]J^WV*6T[[I
M0'=$>"A9L16$L*GF,ZK(ISYYYW=P%K]:N-+ZE\O'FJHK]'7RI,8&K':8?H-)
M#%B\I&?QZ# X/?7;)7I:0#,/^DZ&-;/C\0%+V+." QK>L4;O-JM%1665<5'>
M5;_@Y_Z9['A\P$P&M+!CR%MYV?Z,GPL_'\#AY<4M"NCNNN.MX?=7=&ZQH78Q
M[RWUH-M7\'TU]8HD>LZ5Q*KA[TD.%NBHO?7^=A-;-*-MVJ&N;3YG8V?W:N\]
M12[)\8H"A5[;@4*ZGEJ?$/[I\J<MH4F[FNU?!2SV:_RU+1;8S3<.4GVU1,+W
M&8YS5=ZBX@GZ-F6[':0+[V[V;Y] C<.X70RPZHC'Z[3L4;$6:G'JM-@1']*6
MH*?-,FM2'YB"-/I:;7E)%JMR,B=#Y0^3"JM=X&Q*6!V,MM)QWOT'L&_T4O,,
MI,(YT#5M&SE1?%4##$;>6FBQDIJ7M/W4VH*A4V/>,WWTR!\C/O S4X"IUR[O
M%+R#D;[ PDI.>>7 JK>,?O A*[\G%%D#[8Y#.:BSQ=(=H"EPAST,ZKZG]_P9
M7/AVA9TW6&%GFUO!?;*??QS  SL B(?9'N3-MI^YW> 00X.Y[@3S\!GXG%64
M_4>X0T$V:1A7@+5]TL!\'-&N99>A7*^ODRUW'1IF3#!,IXE SAYT# K=7SZY
M,(T?1G]M4>#KY>I^25Y9HI$!+.E,11.=PDZ=(ABME;"R?_,8?(H3(_CJINFI
M-Z"TT1C&\Y9419(*1_Z U;@6M!)G-\"CMDWG;VG[J^PY.WSF">KJF)]71#;]
M#M6_Y<_2[#./7VKC2IP<=4DNG27*J&CPN=Q<85@L9_#(8_)27V]_V2SQYKI
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MP2XAGVB2YQDX<%0T$PX38>!DOS@*SDW%D5ME*XA]ZT-N88%,?SN@9^9CJW:
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M_XC*E^>RR.=.-(?F3D$8)\U.SO98%!-?-C/75C;E[3V>_GOMW3]02P,$%
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MF<^6?PI<_P%02P$"% ,4    " "4<&)0'R// \     3 @  "P
M    @ $     7W)E;',O+G)E;'-02P$"% ,4    " "4<&)0)^B'#H(   "Q
M    $               @ 'I    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0
M   ( )1P8E">X\3/[@   "L"   1              "  9D!  !D;V-0<F]P
M<R]C;W)E+GAM;%!+ 0(4 Q0    ( )1P8E"97)PC$ 8  )PG   3
M      "  ;8"  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ E'!B
M4'PDUV!Y P  R1   !@              ( !]P@  'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;%!+ 0(4 Q0    ( )1P8E"#&GW8N00  .(6   8
M      "  :8,  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M" "4<&)0UK9\'4("  "O!P  &               @ &5$0  >&PO=V]R:W-H
M965T<R]S:&5E=#,N>&UL4$L! A0#%     @ E'!B4&@'Q% F!0  -!D  !@
M             ( !#10  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4
M Q0    ( )1P8E#@/Z-1K0(   T)   8              "  6D9  !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " "4<&)0KM '<HT(   1
M.   &               @ %,'   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL
M4$L! A0#%     @ E'!B4%NNR4SV 0  # 8  !@              ( !#R4
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( )1P8E#F;&/_
M& @  /4N   8              "  3LG  !X;"]W;W)K<VAE971S+W-H965T
M."YX;6Q02P$"% ,4    " "4<&)0O)BS$_0!   ,!@  &
M@ &)+P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ E'!B
M4*W3I/VT 0  T@,  !D              ( !LS$  'AL+W=O<FMS:&5E=',O
M<VAE970Q,"YX;6Q02P$"% ,4    " "4<&)0C,^U^+4!  #2 P  &0
M        @ &>,P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0
M   ( )1P8E"+H(MGM0$  -(#   9              "  8HU  !X;"]W;W)K
M<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ E'!B4%1Q.4ZU 0  T@,
M !D              ( !=C<  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q0
M2P$"% ,4    " "4<&)0I'%S:;8!  #2 P  &0              @ %B.0
M>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( )1P8E"0-%^;
MM $  -(#   9              "  4\[  !X;"]W;W)K<VAE971S+W-H965T
M,34N>&UL4$L! A0#%     @ E'!B4*'^/?*U 0  T@,  !D
M ( !.CT  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " "4
M<&)0A=-Y;;4!  #2 P  &0              @ $F/P  >&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( )1P8E";>V;MM $  -(#   9
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M970R,BYX;6Q02P$"% ,4    " "4<&)0'0L13NP!  !F!0  &0
M    @ %M3   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    (
M )1P8E##-,:4(@(  /X&   9              "  9!.  !X;"]W;W)K<VAE
M971S+W-H965T,C0N>&UL4$L! A0#%     @ E'!B4+RDW&;M 0  9@4  !D
M             ( !Z5   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"
M% ,4    " "4<&)004.84*L"  !["P  &0              @ $-4P  >&PO
M=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( )1P8E#8GI8IN0$
M -(#   9              "  >]5  !X;"]W;W)K<VAE971S+W-H965T,C<N
M>&UL4$L! A0#%     @ E'!B4%%E[,VW 0  T@,  !D              ( !
MWU<  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " "4<&)0
M+TITRDD"  ">!P  &0              @ '-60  >&PO=V]R:W-H965T<R]S
M:&5E=#(Y+GAM;%!+ 0(4 Q0    ( )1P8E",B7*<1 <  (DH   9
M      "  4U<  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%
M  @ E'!B4!_IA*YG!0  "1\  !D              ( !R&,  'AL+W=O<FMS
M:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " "4<&)0LTQE7[8!  #2 P
M&0              @ %F:0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+
M 0(4 Q0    ( )1P8E!&[1S<W0$  &@$   9              "  5-K  !X
M;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ E'!B4#=$(I39
M 0  9 0  !D              ( !9VT  'AL+W=O<FMS:&5E=',O<VAE970S
M-"YX;6Q02P$"% ,4    " "4<&)0?65RX0(#  #G"P  &0
M@ %W;P  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( )1P
M8E#%ZNZ._@$  'L%   9              "  ;!R  !X;"]W;W)K<VAE971S
M+W-H965T,S8N>&UL4$L! A0#%     @ E'!B4+\ W1Y* @  G@<  !D
M         ( !Y70  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
M    " "4<&)0MM[]:Z@!  "[ P  &0              @ %F=P  >&PO=V]R
M:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( )1P8E"2EKH F (  "4)
M   9              "  45Y  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL
M4$L! A0#%     @ E'!B4-<YH+T-!   W10  !D              ( !%'P
M 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " "4<&)0HZ?1
MRPD"   U!@  &0              @ %8@   >&PO=V]R:W-H965T<R]S:&5E
M=#0Q+GAM;%!+ 0(4 Q0    ( )1P8E#7.P:>[0$  -X$   9
M  "  9B"  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @
ME'!B4&\%N5J_ 0  $P0  !D              ( !O(0  'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"% ,4    " "4<&)0NDH, #0#   B#0  &0
M            @ &RA@  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4
M Q0    ( )1P8E" V6;,] $   P&   9              "  1V*  !X;"]W
M;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ E'!B4$H%L_BY 0
MT@,  !D              ( !2(P  'AL+W=O<FMS:&5E=',O<VAE970T-BYX
M;6Q02P$"% ,4    " "4<&)0YB(1/T,&  #\)0  &0              @ $X
MC@  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( )1P8E!N
M?6=31@(  *T'   9              "  ;*4  !X;"]W;W)K<VAE971S+W-H
M965T-#@N>&UL4$L! A0#%     @ E'!B4.:\#.[G!P  VC$  !D
M     ( !+Y<  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )1P8E"39,8@Q (  )L*   9              "
M 7*O  !X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ E'!B
M4-RNO*6U @  V@D  !D              ( !;;(  'AL+W=O<FMS:&5E=',O
M<VAE970U-2YX;6Q02P$"% ,4    " "4<&)0AA=C'>(#  "$$@  &0
M        @ %9M0  >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0
M   ( )1P8E"7VKA=*0,  'X-   9              "  7*Y  !X;"]W;W)K
M<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ E'!B4')UQ-QZ @  :@@
M !D              ( !TKP  'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q0
M2P$"% ,4    " "4<&)0$;2<8.,$   U'   &0              @ &#OP
M>&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( )1P8E#9=.8[
MD0,  #8/   9              "  9W$  !X;"]W;W)K<VAE971S+W-H965T
M-C N>&UL4$L! A0#%     @ E'!B4,*L8##1 @  +@H  !D
M ( !9<@  'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"% ,4    " "4
M<&)0!?O7 ]D"  #1"@  &0              @ %MRP  >&PO=V]R:W-H965T
M<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( )1P8E"(6;)M% 0  *@7   9
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M970V-RYX;6Q02P$"% ,4    " "4<&)0T-^LIQ4"  !]!@  &0
M    @ ' X0  >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    (
M )1P8E 6BA]WZ@$  -T$   9              "  0SD  !X;"]W;W)K<VAE
M971S+W-H965T-CDN>&UL4$L! A0#%     @ E'!B4"*64>&( @  =@@  !D
M             ( !+>8  'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"
M% ,4    " "4<&)0"K_/OV *  !<1P  &0              @ 'LZ   >&PO
M=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( )1P8E K*A#]6@4
M $4>   9              "  8/S  !X;"]W;W)K<VAE971S+W-H965T-S(N
M>&UL4$L! A0#%     @ E'!B4)*FF6)D!   IQ8  !D              ( !
M%/D  'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4    " "4<&)0
M&!9?\6X#  #J#@  &0              @ &O_0  >&PO=V]R:W-H965T<R]S
M:&5E=#<T+GAM;%!+ 0(4 Q0    ( )1P8E ZV5+GP ,  &X1   9
M      "  50! 0!X;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L! A0#%
M  @ E'!B4+[/^&A,!   A14  !D              ( !2P4! 'AL+W=O<FMS
M:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    " "4<&)0P1NH"]H$  !V&0
M&0              @ '."0$ >&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+
M 0(4 Q0    ( )1P8E %ZZJS+P0  ( 4   9              "  =\. 0!X
M;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @ E'!B4'*MPX_'
M P  ZA$  !D              ( !11,! 'AL+W=O<FMS:&5E=',O<VAE970W
M.2YX;6Q02P$"% ,4    " "4<&)0S_, 5F,(   \,@  &0
M@ %#%P$ >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( )1P
M8E =&7[L[@$  .T$   9              "  =T? 0!X;"]W;W)K<VAE971S
M+W-H965T.#$N>&UL4$L! A0#%     @ E'!B4'F<Z]@5 @  N04  !D
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M='EL97,N>&UL4$L! A0#%     @ E'!B4.][>X_/!0  03<   \
M     ( !/RX" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( )1P8E#Y R27
MD@(  (XQ   :              "  3LT @!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( )1P8E!FJ5M;+0(  #$P   3
M  "  04W @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !< %P -AD  &,Y
$ @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6863517776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Significant Accounting Policies</a></td>
<td class="text">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1. Organization and Significant Accounting Policies</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Basis of Presentation</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In our consolidated financial statements we included the accounts of Ionis Pharmaceuticals, Inc. (&#8220;we&#8221;, &#8220;us&#8221; or &#8220;our&#8221;) and the consolidated results of our majority-owned affiliate, Akcea Therapeutics, Inc., which we formed in December 2014. In July 2017, Akcea completed an initial public offering, or IPO. Since Akcea&#8217;s IPO, our ownership has ranged from </span>68 percent<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> to </span>77 percent<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. At December 31, 2019, o</span>ur ownership was approximately 76 percent. We reflect changes in our ownership of Akcea in our financial statements in the period the change occurs. For example, we reflected an increase in our ownership when we received 6.9 million shares of Akcea common stock as payment for the sublicense fee Akcea owed us for Pfizer&#8217;s license of AKCEA-ANGPTL3-L<sub>Rx</sub> in the fourth quarter of 2019. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Refer to the section titled &#8220;Noncontrolling Interest in Akcea&#8221; in Note 2, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Significant Accounting Policies,</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for further information related to our accounting for our investment in Akcea.</span></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Organization and Business Activity</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We incorporated in California on January 10, 1989. In conjunction with our IPO, we reorganized as a Delaware corporation in April 1991. We were organized principally to develop human therapeutic medicines using antisense technology. In December 2015, we changed our name from Isis Pharmaceuticals, Inc. to Ionis Pharmaceuticals, Inc.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Basic and Diluted Net Income per Share</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Basic net income per share</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We compute basic net income per share by dividing the total net income attributable to our common stockholders by our weighted-average number of common shares outstanding during the period.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The calculation of total net income attributable to our common stockholders for each year considered our net income for Ionis on a stand-alone basis plus our share of Akcea&#8217;s net income (loss) for the period. To calculate the portion of Akcea&#8217;s net income (loss) attributable to our ownership for each year, we multiplied Akcea&#8217;s income (loss) per share by the weighted average shares we owned in Akcea during the period. As a result of this calculation, our total net income available to Ionis common stockholders for the calculation of net income per share is different than net income attributable to Ionis Pharmaceuticals, Inc. common stockholders in our consolidated statements of operations for each year.</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our basic net income per share, was calculated as follows (in thousands, except per share amounts):</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z104b454b266445eaac9eed834835145f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Portion of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Income</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">70,100</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.49</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">34,073</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net income attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">34,073</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">262,490</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">296,563</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">139,998</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.12</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zfe21e6fd0158439f854dad365e54a58d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Portion of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">59,812</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2.74</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(163,938</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(163,938</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">440,806</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">276,868</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">132,320</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.09</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We calculated our basic net income per share for 2017 as follows (in thousands, except per share amounts):</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z7f02aeb560ee40bd982c44713ab0a2ac" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2017</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Portion of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20,669</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3.08</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(63,638</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Preferred shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15,748</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1.80</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(28,346</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(91,984</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">110,776</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,792</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">124,016</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.15</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Prior to Akcea&#8217;s IPO in July 2017, we owned Akcea series A convertible preferred stock, which included a <span style="-sec-ix-hidden:Fact_814732dbfffb4dbbb487265b1d09e7b7">six percent</span> cumulative dividend. Upon completion of Akcea&#8217;s IPO in July 2017, our preferred stock was converted into common stock on a 1:1 basis. The preferred stock dividend was not paid at the IPO because the IPO was not a liquidation event or a change in control. During 2017, Akcea used a two-class method to compute its net loss per share because it had both common and preferred shares outstanding during the periods. The two-class method required Akcea to calculate its net loss per share for each class of stock by dividing total distributable losses applicable to preferred and common stock, including the six percent cumulative dividend contractually due to series A convertible preferred shareholders, by the weighted-average of preferred and common shares outstanding during the requisite period. Since Akcea used the two-class method, accounting rules required us to include our portion of Akcea&#8217;s net loss per share for both Akcea&#8217;s common and preferred shares that we owned in our calculation of basic and diluted net income per share for the year ended December 31, 2017.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Diluted net income per share</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We calculated our diluted net income per share as follows <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(in thousands except per share amounts):</span></div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zb0e4b49c2e274df0b9950bc8e8004fbd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">296,563</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">139,998</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.12</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -8.9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,090</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: 0.1pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">766</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our Employee Stock Purchase Plan</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">296,563</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">142,872</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.08</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z01b775cd675848508a1d52bc1c4cff37" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">276,868</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">132,320</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.09</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -8.9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,216</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: 0.1pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">514</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our Employee Stock Purchase Plan</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">276,868</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">134,056</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.07</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zd8deeaecb9c64cd89c8fc8806b7a193d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2017</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,792</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">124,016</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.15</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -8.9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,619</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: 0.1pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">459</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our Employee Stock Purchase Plan</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,792</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">126,098</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.15</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For each year presented, the calculation excluded our convertible senior notes because the effect on diluted earnings per share was anti-dilutive.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Revenue Recognition</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Our Revenue Sources</span></span></div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We generally recognize revenue when we have satisfied all contractual obligations and are reasonably assured of collecting the resulting receivable. We are often entitled to bill our customers and receive payment from our customers in advance of recognizing the revenue. In the instances in which we have received payment from our customers in advance of recognizing revenue, we include the amounts in deferred revenue on our consolidated balance sheet.</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Commercial Revenue: SPINRAZA royalties and Licensing and other royalty revenue</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We earn commercial revenue primarily in the form of royalty payments on net sales of SPINRAZA. We will also recognize as commercial revenue future sales milestone payments and royalties we earn under our partnerships.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Commercial Revenue: Product sales, net</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We added product sales from TEGSEDI to our commercial revenue in the fourth quarter of 2018 and we added product sales from WAYLIVRA to our commercial revenue in the third quarter of 2019. </span>In the U.S., we distribute TEGSEDI through an exclusive distribution agreement with a third-party logistics company, or 3PL, that takes title to TEGSEDI. The 3PL is our sole customer in the U.S. The 3PL then distributes TEGSEDI to a specialty pharmacy and a specialty distributor, which we collectively refer to as wholesalers, who then distribute TEGSEDI to health care providers and patients. In Europe, prior to the third quarter of 2019 we distributed TEGSEDI through a non-exclusive distribution model with a 3PL that took title to TEGSEDI. The 3PL was our sole customer in Europe. The 3PL in Europe then distributed TEGSEDI to hospitals and pharmacies. In the third quarter of 2019, we entered into a distribution arrangement with a 3PL and began to sell both TEGSEDI and WAYLIVRA directly to hospitals and pharmacies in Europe.</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Research and development revenue under collaborative agreements</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We often enter into collaboration agreements to license and sell our technology on an exclusive or non-exclusive basis. Our collaboration agreements typically contain multiple elements, or performance obligations, including technology licenses or options to obtain technology licenses, research and development, or R&amp;D, services, and manufacturing services.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our collaboration agreements are detailed in Note 6, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Collaborative Arrangements and Licensing Agreements.</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Under each collaboration note we discuss our specific revenue recognition conclusions, including our significant performance obligations under each collaboration.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Steps to Recognize Revenue</span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We use a five-step process to determine the amount of revenue we should recognize and when we should recognize it. The five step process is as follows:</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zb9f70b6bc634422f82831b9476ae8444" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">1.</td>
    <td style="width: auto; vertical-align: top; text-align: left;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Identify the contract</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Accounting rules require us to first determine if we have a contract with our partner, including confirming that we have met each of the following criteria:</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z32abea7f3b454dedb5d275fcd69bfc41" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: left;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We and our partner approved the contract and we are both committed to perform our obligations;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z2fef2cbf4007441595d4245add81d46d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: left;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have identified our rights, our partner&#8217;s rights and the payment terms;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze8401d5278b84ee1953ba4283b1f9851" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have concluded that the contract has commercial substance, meaning that the risk, timing, or amount of our future cash flows is expected to change as a result of the contract; and</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z7c8deb873be94db28e11c93fd5b094f0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: left;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We believe collectability is probable. </div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: -18pt; margin-left: 54pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zac78659984944d66a7d6f7f05a5a6181" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"><span style="background-color: #FFFFFF;">2.</span></td>
    <td style="width: auto; vertical-align: top; text-align: left;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"><span style="background-color: #FFFFFF; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Identify the performance obligations</span></div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We next identify the distinct goods and services we are required to provide under the contract. Accounting rules refer to these as our performance obligations. We typically have only one performance obligation at the inception of a contract, which is to perform R&amp;D services.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Often times we enter into a collaboration agreement in which we provide our partner with an option to license a medicine in the future. We may also provide our partner with an option to request that we provide additional goods or services in the future, such as active pharmaceutical ingredient, or API. We evaluate whether these options are material rights at the inception of the agreement. If we determine an option is a material right, we will consider the option a separate performance obligation. Historically, we have concluded that the options we grant to license a medicine in the future or to provide additional goods and services as requested by our partner are not material rights. These items are contingent upon future events that may not occur. When a partner exercises its option to license a medicine or requests additional goods or services, then we identify a new performance obligation for that item.</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In some cases, we deliver a license at the start of an agreement. If we determine that our partner has full use of the license and we do not have any additional material performance obligations related to the license after delivery, then we consider the license to be a separate performance obligation.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zf1f446d282dd4e1b832e3c09c5f82c88" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">3.</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Determine the transaction price</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We then determine the transaction price by reviewing the amount of consideration we are eligible to earn under the collaboration agreement, including any variable consideration. Under our collaboration agreements, consideration typically includes fixed consideration in the form of an upfront payment and variable consideration in the form of potential milestone payments, license fees and royalties. At the start of an agreement, our transaction price usually consists of only the upfront payment. We do not typically include any payments we may receive in the future in our initial transaction price because the payments are not probable and are contingent on certain future events. We reassess the total transaction price at each reporting period to determine if we should include additional payments in the transaction price.</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Milestone payments are our most common type of variable consideration. We recognize milestone payments using the most likely amount method because we will either receive the milestone payment or we will not, which makes the potential milestone payment a binary event. The most likely amount method requires us to determine the likelihood of earning the milestone payment. We include a milestone payment in the transaction price once it is probable we will achieve the milestone event. Most often, we do not consider our milestone payments probable until we or our partner achieve the milestone event because the majority of our milestone payments are contingent upon events that are not within our control and are usually based on scientific progress. For example, in the fourth quarter of 2019, we earned a $10 million milestone payment from AstraZeneca when AstraZeneca initiated a Phase 1 trial for ION839. We did not consider the milestone payments probable until AstraZeneca achieved the milestone event because the initiation of the Phase 1 trial was a contingent event that was not within our control. We recognized the milestone payments in full in the period the milestone event was achieved because we did not have any remaining performance obligations related to the milestone payment.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z61f3f8aec88b4866a2bbc6540840c7b9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">4.</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Allocate the transaction price</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Next, we allocate the transaction price to each of our performance obligations. When we have to allocate the transaction price to more than one performance obligation, we make estimates of the relative stand-alone selling price of each performance obligation because we do not typically sell our goods or services on a stand-alone basis. We then allocate the transaction price to each performance obligation based on the relative stand-alone selling price.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We may engage a third party, independent valuation specialist to assist us with determining a stand-alone selling price for collaborations in which we deliver a license at the start of an agreement. We estimate the stand-alone selling price of these licenses using valuation methodologies, such as the relief from royalty method. Under this method, we estimate the amount of income, net of taxes, for the license. We then discount the projected income to present value. The significant inputs we use to determine the projected income of a license could include:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zd0332dc311ad49d5aebb0b0dcec49da1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Estimated future product sales;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zbafbea8c82a44de19538caf8c4d34c17" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Estimated royalties on future product sales;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zc5914eb350eb4288913df6b658f90445" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Contractual milestone payments;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z23f53850cb2e499c87cc78fc51b878db" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expenses we expect to incur;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zba5b48ea375f49caad917f1f137ff6cf" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income taxes; and</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zc80b99fe0b894aecb56282f28ddea0a9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A discount rate.</div></td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We typically estimate the selling price of R&amp;D services by using our internal estimates of the cost to perform the specific services. The significant inputs we use to determine the selling price of our R&amp;D services include:</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z2a27bbd1916f4ee3b3441ed762a2c2b3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The number of internal hours we estimate we will spend performing these services;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z3d50f6d0709c44f89b5262ca45319fbe" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The estimated cost of work we will perform;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zf1df7de1efb647f3a758705c8216c76d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The estimated cost of work that we will contract with third parties to perform; and</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zcc18420c84464778ad67ecdb5155e530" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The estimated cost of API we will use. </div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For purposes of determining the stand-alone selling price of the R&amp;D services we perform and the API we will deliver, accounting guidance requires us to include a markup for a reasonable profit margin.</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We do not reallocate the transaction price after the start of an agreement to reflect subsequent changes in stand-alone selling prices.</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zaa2a29a440094a6385db6db34fe05178" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">5.</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Recognize revenue</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -54pt; margin-left: 54pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We recognize revenue in one of two ways, over time or at a point in time. We recognize revenue over time when we are executing on our performance obligation over time and our partner receives benefit over time. For example, we recognize revenue over time when we provide R&amp;D services. We recognize revenue at a point in time when our partner receives full use of an item at a specific point in time. For example, we recognize revenue at a point in time when we deliver a license or API to a partner.</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For R&amp;D services that we recognize over time, we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time we estimate it will take us to complete the activities, or costs we incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates and use significant judgement. If our estimates or judgements <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods. For example, </span>in the third quarter of 2019, we updated our estimate of the total effort we expected to expend to satisfy our performance obligation under our<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> 2013 Strategic Neurology collaboration with Biogen</span>. As of September 30, 2019, we had completed a<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> significant portion of the research and development services. We expect to complete the remainder of our services in 2020. As a result of our change in estimate, in the third quarter of 2019, we recorded a cumulative catch up adjustment of $</span>16.5<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million to decrease revenue. Refer to Note 7, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Collaborative Arrangements and Licensing Agreements</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, for further discussion of the cumulative catch up adjustment we made.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following are examples of when we typically recognize revenue based on the types of payments we receive.</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Commercial Revenue: SPINRAZA royalties and Licensing and other royalty revenue</span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We recognize royalty revenue, including royalties from SPINRAZA sales, in the period in which the counterparty sells the related product and recognizes the related revenue, which in certain cases may require us to estimate our royalty revenue.</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Commercial Revenue: Product sales, net</span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We recognize product sales in the period </span>when our customer obtains control of our products, which occurs at a point in time upon transfer of title to the customer. We classify payments to customers or other parties in the distribution channel for services that are distinct and priced at fair value as selling, general and administrative expenses in our consolidated statements of operations. Otherwise, payments to customers or other parties in the distribution channel that do not meet those criteria are classified as a reduction of revenue, as discussed further below. We exclude from revenues taxes collected from customers relating to product sales and remitted to governmental authorities.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Reserves for Product sales</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We record product sales at our net sales price, or transaction price. We include in our transaction price estimated reserves for discounts, returns, chargebacks, rebates, co-pay assistance and other allowances that we offer within contracts between us and our customers, wholesalers, health care providers and other indirect customers. We estimate our reserves using the amounts we have earned or what we can claim on the associated sales. We classify our reserves as a reduction of accounts receivable when we are not required to make a payment or as a current liability when we are required to make a payment. In certain cases, our estimates include a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, our reserves reflect our best estimates under the terms of our respective contracts. When calculating our reserves and related product sales, we only recognize amounts to the extent that we consider it probable that we would not have to reverse in a future period a significant amount of the cumulative sales we previously recognized. The actual amounts we receive may ultimately differ from our reserve estimates. If actual amounts in the future vary from our estimates, we will adjust these estimates, which would affect our net product sales in the respective period.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following are the components of variable consideration related to product sales:</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Chargebacks: </span>In the U.S., we estimate obligations resulting from contractual commitments with the government and other entities to sell products to qualified healthcare providers at prices lower than the list prices charged to our U.S. customer. Our U.S. customer charges us for the difference between what it pays for the product and the selling price to the qualified healthcare providers. We also estimate the amount of chargebacks related to our estimated product remaining in the distribution channel at the end of the reporting period that we expect our customer to sell to healthcare providers in future periods. We record these reserves as an accrued liability on our consolidated balance sheet for the chargebacks related to product sales to our U.S. customer during the reporting period.</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Government rebates</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">: We are subject t</span>o discount obligations under government programs, including Medicaid and Medicare programs in the U.S. and we record reserves for government rebates based on statutory discount rates and estimated utilization. We estimate Medicaid and Medicare rebates based on a range of possible outcomes that are probability-weighted for the estimated payer mix. We record these reserves as an accrued liability on our consolidated balance sheet with a corresponding offset reducing our product sales in the same period we recognize the related sale. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program. On a quarterly basis, we update our estimates and record any adjustments in the period that we identify the adjustments.</div>

<div style="text-align: justify; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Managed care rebates: </span>We are subject to rebates in connection with a value-based agreement with one of our commercial payer&#8217;s. We record these rebates as an accrual on our consolidated balance sheet in the same period we recognize the related revenue. We estimate our managed care rebates based on our estimated payer mix and the applicable contractual rebate rate.</div>

<div style="text-align: justify; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Trade discounts: </span>We provide customary invoice discounts on product sales to our U.S. customer for prompt payment. We record this discount as a reduction of product sales in the period in which we recognize the related product revenue.</div>

<div style="text-align: justify; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Distribution services</span>: We receive and pay for various distribution services from our U.S. and EU customers and wholesalers in the U.S.. We classify the costs for services we receive that are either not distinct from the sale of the product or for which we cannot reasonably estimate the fair value as a reduction of product sales. To the extent that the services we receive are distinct from the sale of the product, we classify the costs for such services as selling, general and administration, or SG&amp;A, expenses.</div>

<div style="text-align: justify; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Product returns: </span>Our U.S. customer has return rights and the wholesalers have limited return rights primarily related to the product&#8217;s expiration date. We estimate the amount of product sales that our customer may return. We record our return estimate as an accrued refund liability on our consolidated balance sheet with a corresponding offset reducing our product sales in the same period we recognize the related sale. Based on our distribution model for product sales, contractual inventory limits with our customer and wholesalers and the price of the product, we have had minimal returns to date and we believe we will continue to have minimal returns. Our EU customers only take title to the product after they receive an order from a hospital or pharmacy and therefore they do not maintain excess inventory levels of our products. Accordingly, we have limited return risk in the EU and we do not estimate returns in the EU.</div>

<div style="text-align: justify; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Other incentives: </span>In the U.S., we estimate reserves for other incentives including co-payment assistance we provide to patients with commercial insurance who have coverage and reside in states that allow co-payment assistance. We record a reserve for the amount we estimate we will pay for co-payment assistance. We base our reserve on the number of estimated claims and our estimate of the cost per claim related to product sales that we have recognized as revenue. We record our other incentive reserve estimates as an accrued liability on our consolidated balance sheet with a corresponding offset reducing our product sales in the same period we recognize the related sale.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Research and development revenue under collaboration agreements:</span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Upfront payments</span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">When we enter into a collaboration agreement with an upfront payment, we typically record the entire upfront payment as deferred revenue if our only performance obligation is for R&amp;D services we will provide in the future. We amortize the upfront payment into revenue as we perform the R&amp;D services. For example, under our <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">collaboration agreement with Roche to</span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> develop IONIS-FB-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for the treatment of complement-mediated diseases</span>, we received a $75 million upfront payment in the fourth quarter of 2018. We allocated the upfront payment to our single performance obligation, R&amp;D services. We are amortizing the $75 million upfront payment using an input method over the estimated period of time we are providing R&amp;D services.</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Milestone payments</span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are required to include additional consideration in the transaction price when it is probable. We typically include milestone payments for R&amp;D services in the transaction price when they are achieved. We include these milestone payments when they are achieved because there is considerable uncertainty in the research and development processes that trigger these payments. Similarly, we include approval milestone payments in the transaction price once the medicine is approved by the applicable regulatory agency. We will recognize sales-based milestone payments in the period in which we achieve the milestone under the sales-based royalty exception allowed under accounting rules.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We recognize milestone payments that relate to an ongoing performance obligation over our period of performance. For example, in the fourth quarter of 2019, we achieved two $7.5 million milestone payments from Biogen when we advanced two new targets for undisclosed neurological diseases under our 2018 strategic neurology collaboration. We added these payments to the transaction price and allocated it to our R&amp;D services performance obligation. We are recognizing revenue related to these milestone payments over our estimated period of performance.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Conversely, we recognize in full those milestone payments that we earn based on our partners&#8217; activities when our partner achieves the milestone event and we do not have a performance obligation. For example, in the fourth quarter of 2019, we recognized a $10 million milestone payment <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">when Biogen advanced the development candidate for an undisclosed target under our 2012 neurology collaboration agreement</span>. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We concluded that the milestone payment was not related to our R&amp;D services performance obligation. Therefore, we recognized the milestone payment in full in the fourth quarter of 2019.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">License fees</span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We generally recognize as revenue the total amount we determine to be the relative stand-alone selling price of a license when we deliver the license to our partner. This is because our partner has full use of the license and we do not have any additional performance obligations related to the license after delivery. </span>For example, in the fourth quarter of 2019, we earned a $45 million license fee when Biogen licensed IONIS-MAPT<sub>Rx</sub> from us. We also recognized $246 million of license fee revenue related to Akcea&#8217;s license of AKCEA-ANGPTL3-L<sub>Rx</sub> to Pfizer in the fourth quarter of 2019.</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Sublicense fees</span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We recognize sublicense fee revenue in the period in which a party, who has already licensed our technology, further licenses the technology to another party because we do not have any performance obligations related to the sublicense. </span>For example, in the second quarter of 2019, we earned a $20 million sublicense fee when Alnylam Pharmaceuticals sublicensed our technology to Regeneron Pharmaceuticals.</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Amendments to Agreements</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">From time to time we amend our collaboration agreements. When this occurs, we are required to assess the following items to determine the accounting for the amendment:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z4d3009374a5e478e8122026b5e139b45" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If the additional goods and/or services are distinct from the other performance obligations in the original agreement; and</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zf0f366c375b94c81a0b52ddbbfa1f51e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If the goods and/or services are at a stand-alone selling price. </div></td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If we conclude the goods and/or services in the amendment are distinct from the performance obligations in the original agreement and at a stand-alone selling price, we account for the amendment as a separate agreement. If we conclude the goods and/or services are not distinct and at their stand-alone selling price, we then assess whether the remaining goods or services are distinct from those already provided. If the goods and/or services are distinct from what we have already provided, then we allocate the remaining transaction price from the original agreement and the additional transaction price from the amendment to the remaining goods and/or services. If the goods and/or services are not distinct from what we have already provided, we update the transaction price for our single performance obligation and recognize any change in our estimated revenue as a cumulative adjustment.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">For example, in May 2015, we entered into an exclusive license agreement with Bayer to develop and commercialize IONIS-FXI</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for the prevention of thrombosis. As part of the agreement, Bayer paid us a $</span>100<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million upfront payment. At the onset of the agreement, we were responsible for completing a Phase 2 study of IONIS-FXI</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in people with end-stage renal disease on hemodialysis and for providing an initial supply of API. In February 2017, we amended our agreement with Bayer to advance IONIS-FXI</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and to initiate development of IONIS-FXI-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, which Bayer licensed. As part of the 2017 amendment, Bayer paid us $</span>75<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million. We are also eligible to receive milestone payments and tiered royalties on gross margins of IONIS-FXI</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and IONIS-FXI-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. Under the 2017 amendment, we concluded we had a new agreement with </span>three<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> performance obligations. These performance obligations were to deliver the license of IONIS-FXI-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, to provide R&amp;D services and to deliver API. We allocated the $</span>75<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million transaction price to these performance obligations. </span>Refer to <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Note 7, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Collaborative Arrangements and Licensing Agreements</span>, for further discussion <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">of our accounting treatment for our Bayer collaboration.</span></div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Multiple agreements</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">From time to time, we may enter into separate agreements at or near the same time with the same partner. We evaluate such agreements to determine whether we should account for them individually as distinct arrangements or whether the separate agreements should be combined and accounted for together. We evaluate the following to determine the accounting for the agreements:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z5a22915e59694cedaf8815e2feb45467" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Whether the agreements were negotiated together with a single objective;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z4c6b305fcd854a51950b2b0c8b9ff86f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Whether the amount of consideration in one contract depends on the price or performance of the other agreement; or</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z82b56ef158ea487c94fc2daddd0e9546" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Whether the goods and/or services promised under the agreements are a single performance obligation. </div></td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our evaluation involves significant judgment to determine whether a group of agreements might be so closely related that accounting guidance requires us to account for them as a combined arrangement.</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For example, in the second quarter of 2018, we entered into two separate agreements with Biogen at the same time: a new strategic neurology collaboration agreement and a stock purchase agreement, or SPA. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We evaluated the Biogen agreements to determine whether we should treat the agreements separately or combine them. We considered that the agreements were negotiated concurrently and in contemplation of one another. Based on these facts and circumstances, we concluded that we should evaluate the provisions of the agreements on a combined basis.</span></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: -54pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Contracts Receivable</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: -18pt; margin-left: 54pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our contracts receivable balance represents the amounts we have billed our partners or customers and that are due to us unconditionally for goods we have delivered or services we have performed. When we bill our partners or customers with payment terms based on the passage of time, we consider the contract receivable to be unconditional. We typically receive payment within one </span><span style="-sec-ix-hidden:Fact_5acf7b3d4ee04d009d32a31d9e4ded77">quarter</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> of billing our partner or customer</span>.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -54pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Unbilled SPINRAZA Royalties</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our unbilled SPINRAZA royalties represent our right to receive consideration from Biogen in advance of when we are eligible to bill Biogen for SPINRAZA royalties. We include these unbilled amounts in other current assets on our consolidated balance sheet.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: -54pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Deferred Revenue</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We are often entitled to bill our customers and receive payment from our customers in advance of our obligation to provide services or transfer goods to our partners. In these instances, we include the amounts in deferred revenue on our consolidated balance sheet.</span> During the years ended December 31, 2019 and 2018, we recognized $159.5 million and $105.3 million of revenue from amounts that were in our beginning deferred revenue balance for each respective period. For further discussion, refer to our revenue recognition policy above.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Cost of Products Sold</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our cost of products sold includes manufacturing costs, transportation and freight costs and indirect overhead costs associated with the manufacturing and distribution of our products. We also may include certain period costs related to manufacturing services and inventory adjustments in cost of products sold. Prior to obtaining regulatory approval of TEGSEDI in July 2018 and WAYLIVRA in May 2019, we expensed as research and development expenses a significant portion of the costs we incurred to produce the initial commercial launch supply for each medicine. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We previously expensed $</span>0.7<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million and $</span>0.1<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million of costs to produce our products related to the product sales revenue we recognized in 2019 and 2018, respectively.</span></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Research, Development and Patent Expenses</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our research and development expenses include wages, benefits, facilities, supplies, external services, clinical trial and manufacturing costs and other expenses that are directly related to our research and development operations. We expense research and development costs as we incur them. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. For the years ended December 31, 2019, 2018 and 2017, research and development expenses were $461.5 million, $411.9 million and $372.5 million, respectively. A portion of the costs included in research and development expenses are costs associated with our partner agreements. For the years ended December 31, 2019, 2018 and 2017, research and development costs of approximately $83.2 million, $58.7 million and $59.5 million, respectively, were related to our partner agreements.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We capitalize costs consisting principally of outside legal costs and filing fees related to obtaining patents. We amortize patent costs over the useful life of the patent, beginning with the date the U.S. Patent and Trademark Office, or foreign equivalent, issues the patent. The weighted average remaining amortizable life of our issued patents was 10.3 years at December 31, 2019.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The cost of our patents capitalized on our consolidated balance sheet at December 31, 2019 and 2018 was $34.0 million and $32.7 million, respectively. Accumulated amortization related to patents was $8.3 million and $8.7 million at December 31, 2019 and 2018, respectively.</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Based on our existing patents, we estimate amortization expense related to patents in each of the next five years to be the following:</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z3b4746089ec94fcf825148a7e478c941" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ending December 31,</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amortization</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(in millions)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2021</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2022</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2023</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2024</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We review our capitalized patent costs regularly to ensure that they include costs for patents and patent applications that have future value. When we identify patents and patent applications that we are not actively pursuing, we write off any associated costs. In 2019, 2018 and 2017, patent expenses were $4.2 million, $2.6 million and $2.1 million, respectively, and included non-cash charges related to the write-down of our patent costs to their estimated net realizable values of $2.2 million, $0.8 million and $0.4 million, respectively.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Accrued Liabilities</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our accrued liabilities consisted of the following (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z3a44c21e41964165973dff87ef753698" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Clinical expenses</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">24,461</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">22,125</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -18pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In-licensing expenses</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,289</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12,298</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -18pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other miscellaneous expenses</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">32,019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,080</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total accrued liabilities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">66,769</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">47,503</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Noncontrolling Interest in Akcea Therapeutics, Inc.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Prior to Akcea&#8217;s IPO in July 2017, we owned 100 percent of Akcea. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Since Akcea&#8217;s IPO, our ownership has ranged from </span>68 percent<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> to </span>77 percent<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. At December 31, </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, o</span>ur ownership was approximately 76 percent. We reflect changes in our ownership percentage in our financial statements as an adjustment to noncontrolling interest in the period the change occurs. During 2019, we received the following additional shares of Akcea common stock:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zb8e73bce7e5949779fde18c99941a249" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.8 million shares in the first quarter of 2019 as payment for the sublicense fee Akcea owed us for Novartis&#8217;s license of AKCEA-APO(a)-L<sub>Rx</sub>, and;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zb8be43d6e4c14352bda3fb7b936ad303" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.9 million shares in the fourth quarter of 2019 as payment for the sublicense fee Akcea owed us for Pfizer&#8217;s license of AKCEA-ANGPTL3-L<sub>Rx</sub>.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The shares third parties own represent an interest in Akcea&#8217;s equity that we do control. However, as we continue to maintain overall control of Akcea through our voting interest, we reflect the assets, liabilities and results of operations of Akcea in our consolidated financial statements. We reflect the noncontrolling interest attributable to other owners of Akcea&#8217;s common stock in a separate line on the statement of operations and a separate line within stockholders&#8217; equity in our consolidated balance sheet. In addition, we record a noncontrolling interest adjustment to account for the stock options Akcea grants, which if exercised, will dilute our ownership in Akcea. This adjustment is a reclassification within stockholders&#8217; equity from additional paid-in capital to noncontrolling interest in Akcea equal to the amount of stock-based compensation expense Akcea had recognized.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Concentration of Credit Risk</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, short-term investments and receivables. We place our cash equivalents and short-term investments with reputable financial institutions. We primarily invest our excess cash in commercial paper and debt instruments of the U.S. Treasury, financial institutions, corporations, and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1, P-1 or F-1 by Moody&#8217;s, Standard &amp; Poor&#8217;s, or S&amp;P, or Fitch, respectively. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Cash, Cash Equivalents and Investments</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We consider all liquid investments with maturities of three months or less when we purchase them to be cash equivalents. Our short-term investments have initial maturities of greater than three months from date of purchase. We classify our short-term debt investments as &#8220;available-for-sale&#8221; and carry them at fair market value based upon prices on the last day of the fiscal period for identical or similar items. We record unrealized gains and losses on debt securities as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments. We use the specific identification method to determine the cost of securities sold.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We also have equity investments of less than 20 percent ownership in publicly and privately held biotechnology companies that we received as part of a technology license or partner agreement. At December 31, 2019, we held equity investments in two publicly held companies, ProQR Therapeutics N.V., or ProQR, and Antisense Therapeutics Limited, or ATL. We also held equity investments in five privately-held companies, Atlantic Pharmaceuticals Limited, Dynacure SAS, Empirico, Inc., Seventh Sense Biosystems and Suzhou Ribo Life Science Co, Ltd.</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In January 2018, we adopted the amended accounting guidance related to the recognition, measurement, presentation, and disclosure of certain financial instruments. The amended guidance requires us to measure and record our equity investments at fair value. Additionally, the amended accounting guidance requires us to recognize the changes in fair value in our consolidated statement of operations, instead of through accumulated other comprehensive income. Prior to 2018, we accounted for our equity investments in privately held companies under the cost method of accounting. Under the amended guidance we account for our equity investments in privately held companies at their cost minus impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Our adoption of this guidance did not have an impact on our results.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Inventory Valuation</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We reflect our inventory on our consolidated balance sheet at the lower of cost or market value under the first-in, first-out method, or FIFO. We capitalize the costs of raw materials that we purchase for use in producing our medicines because until we use these raw materials, they have alternative future uses, which we refer to as clinical raw materials. We include in inventory raw material costs for medicines that we manufacture for our partners under contractual terms and that we use primarily in our clinical development activities and drug products. We can use each of our raw materials in multiple products and, as a result, each raw material has future economic value independent of the development status of any single medicine. For example, if one of our medicines failed, we could use the raw materials for that medicine to manufacture our other medicines. We expense these costs as R&amp;D expenses when we begin to manufacture API for a particular medicine if the medicine has not been approved for marketing by a regulatory agency.</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We obtained the first regulatory approval for TEGSEDI in July 2018 and for WAYLIVRA in May 2019. At December 31, 2019, our physical inventory for TEGSEDI and WAYLIVRA included API that we produced prior to when we obtained regulatory approval. As such, this API has no cost basis as we had previously expensed the costs as R&amp;D expenses.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We review our inventory periodically and reduce the carrying value of items we consider to be slow moving or obsolete to their estimated net realizable value based on forecasted demand compared to quantities on hand. We consider several factors in estimating the net realizable value, including shelf life of our inventory, alternative uses for our medicines in development and historical write-offs. We recorded an <span style="-sec-ix-hidden:Fact_1261d93c836d4d94bba4bd8c45f1e569">insignificant</span> amount of inventory write-offs during the year ended December 31, 2019. We did not record any inventory write-offs for the years ended December 31, 2018 or 2017.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our inventory consisted of the following (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z1ee494cca3ec409c868c744c6428df49" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Raw materials:</div></td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 19.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Raw materials- clinical</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,363</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,497</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -18pt; margin-left: 28.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Raw materials- commercial</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,520</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 28.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total raw materials</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15,883</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,497</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Work in process</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,039</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Finished goods</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">258</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">85</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; margin-left: 28.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total inventory</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,180</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,582</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Property, Plant and Equipment</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We carry our property, plant and equipment at cost and depreciate it on the straight-line method over its estimated useful life, which consists of the following (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z6b8fa4917b344088b2fa85d6aab08f8c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Estimated Useful Lives</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(in years)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Computer software, laboratory, manufacturing and other equipment</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3 to 10</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">60,965</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">53,496</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Building, building improvements and building systems</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15 to 40</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">119,830</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">97,528</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Land improvements</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,853</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,853</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Leasehold improvements</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5 to 15</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,600</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,981</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Furniture and fixtures</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5 to 10</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7,354</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,283</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">204,602</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">179,141</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less accumulated depreciation</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(74,013</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(61,474</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">130,589</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">117,667</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Land</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23,062</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14,493</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;Total</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">153,651</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">132,160</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We depreciate our leasehold improvements using the shorter of the estimated useful life or remaining lease term.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value of Financial Instruments</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have estimated the fair value of our financial instruments. The amounts reported for cash, accounts receivable, accounts payable and accrued expenses approximate the fair value because of their short maturities. We report our investment securities at their estimated fair value based on quoted market prices for identical or similar instruments.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Leases</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Topic 842 Adoption</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In February 2016, the Financial Accounting Standards Board, or FASB, issued amended accounting guidance related to lease accounting. This guidance supersedes the lease requirements we previously followed in Accounting Standards Codification, or ASC, Topic 840, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Leases</span>, or Topic 840, and created a new lease accounting standard, Topic 842, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Leases</span>, or Topic 842. Under Topic 842, an entity will record on its balance sheet all leases with a term longer than one year. Further, an entity will record a liability with a value equal to the present value of payments it will make over the life of the lease (lease liability) and an asset representing the underlying leased asset (right-of-use asset). The new accounting guidance requires entities to determine if its leases are operating or financing leases. Entities will recognize expense for operating leases on a straight-line basis as an operating expense. If an entity determines a lease is a financing lease, it will record both interest and amortization expense and generally the expense will be higher in the earlier periods of the lease. We adopted Topic 842 on January 1, 2019 and adjusted our opening balance sheet on that date for our right-of-use operating lease assets and operating lease liabilities. At adoption, we recorded $13.5 million in right-of-use operating lease assets and $18.5 million in operating lease liabilities, of which we classified $2 million as a current liability. We adopted Topic 842 using the available practical expedients<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification of those leases we had in place as of January 1, 2019. </span>The adoption did not have an impact on our consolidated statement of operations.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Leases</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We determine if an arrangement contains a lease at inception. We currently only have operating leases. We recognize a right-of-use operating lease asset and associated short- and long-term operating lease liability on our consolidated balance sheet for operating leases greater than one year. Our right-of-use assets represent our right to use an underlying asset for the lease term and our lease liabilities represent our obligation to make lease payments arising from the lease arrangement. We recognize our right-of-use operating lease assets and lease liabilities based on the present value of the future minimum lease payments we will pay over the lease term.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</span>We determined the lease term at the inception of the lease, and in certain cases our lease term could include renewal options if we concluded we were reasonably certain that we will exercise the renewal option.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As our current leases do not provide an interest rate implicit in the lease, we used our or Akcea&#8217;s incremental borrowing rate, based on the information available on the date we adopted Topic 842 or as of the lease inception date in determining the present value of future payments. Our right-of-use operating lease asset also includes any lease payments we made and excludes any tenant improvement allowances we received. We recognize rent expense for our minimum lease payments on a straight-line basis over the expected term of our lease. We recognize period expenses, such as common area maintenance expenses, in the period we incur the expense.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Long-Lived Assets</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We evaluate long-lived assets, which include property, plant and equipment and patent costs, for impairment on at least a quarterly basis and whenever events or changes in circumstances indicate that we may not be able to recover the carrying amount of such assets. We recorded charges of $2.2 million, $0.8 million and $0.8 million for the years ended December 31, 2019, 2018 and 2017, respectively, related primarily to the write-down of intangible assets.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Use of Estimates</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Stock-Based Compensation Expense</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We measure stock-based compensation expense for equity-classified awards, principally related to stock options, restricted stock units, or RSUs, and stock purchase rights under our ESPP based on the estimated fair value of the award on the date of grant. We recognize the value of the portion of the award that we ultimately expect to vest as stock-based compensation expense over the requisite service period in our consolidated statements of operations. We reduce stock-based compensation expense for estimated forfeitures at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We use the Black-Scholes model to estimate the fair value of stock options granted and stock purchase rights under our ESPP. On the grant date, we use our stock price and assumptions regarding a number of variables to determine the estimated fair value of stock-based payment awards. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors.</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We recognize compensation expense for option awards and RSUs using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award were in substance multiple awards, which results in the expense being front-loaded over the vesting period.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The fair value of RSUs is based on the market price of our common stock on the date of grant. The RSUs we have granted vest annually over a four-year period.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">See Note 4, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Stockholders&#8217; Equity,</span> for additional information regarding our stock-based compensation plans.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Accumulated Other Comprehensive Loss</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Accumulated other comprehensive loss is primarily comprised of unrealized gains and losses on investments, net of taxes and adjustments we made to reclassify realized gains and losses on investments from other accumulated comprehensive loss to our Consolidated Statement of Operations. The following table summarizes changes in accumulated other comprehensive loss for the years ended December 31, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2019</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2018</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2017</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> (in thousands):</span></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zf8dcaf0ca45440bba49fa3a29bc22bb5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Beginning balance accumulated other comprehensive loss</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(32,016</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(31,759</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(30,358</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Unrealized gains (losses) on securities, net of tax (1)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,633</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(280</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(960</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amounts reclassified from accumulated other comprehensive loss</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(374</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Currency translation adjustment</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">93</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(67</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net other comprehensive loss for the period</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,726</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(257</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,401</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ending balance accumulated other comprehensive loss</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(25,290</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(32,016</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(31,759</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>

<div style="text-align: justify;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z11d622af5d604f70bd2be3051942ec9a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A tax benefit of $1.4 million and $0.3 million was included in other comprehensive loss for the years ended December 31, 2019 and 2018, respectively. There was no tax benefit or expense for other comprehensive loss for the year ended December 31, 2017.&#160;</div></td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Convertible Debt</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At issuance, we accounted for our convertible debt instruments, including our 0.125 percent senior convertible notes, or 0.125% Notes and 1 percent senior convertible notes, or 1% Notes, that may be settled in cash upon conversion (including partial cash settlement) by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate on the date the notes were issued. In reviewing debt issuances, we were not able to identify any comparable companies that recently issued non-convertible debt instruments. Therefore, we estimated the fair value of the liability component of our notes by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We assigned a value to the debt component of our convertible notes equal to the estimated fair value of similar debt instruments without the conversion feature, which resulted in us recording our debt at a discount. We are amortizing our debt issuance costs and debt discount over the life of the convertible notes as additional non-cash interest expense utilizing the effective interest method. For additional information, see Note 3, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Long-Term Obligations and Commitments</span>.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Segment Information</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We have </span>two<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> operating segments, our Ionis Core segment and Akcea Therapeutics, our majority-owned affiliate. Akcea is </span>a biopharmaceutical company focused on developing and commercializing medicines to treat patients with serious and rare diseases<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. We provide segment financial information and results for our Ionis Core segment and our Akcea Therapeutics segment based on the segregation of revenues and expenses that our chief decision maker reviews to assess operating performance and to make operating decisions. We allocate a portion of Ionis&#8217; development, R&amp;D support and general and administrative expenses to Akcea for work Ionis performs on behalf of Akcea and we bill Akcea for these expenses.</span></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value Measurements</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We use a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets, which includes our money market funds and treasury securities classified as available-for-sale securities and our investment in equity securities in publicly-held biotechnology companies; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable, which includes our fixed income securities and commercial paper classified as available-for-sale securities; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring us to develop our own assumptions. We classify the majority of our securities as Level 2. We obtain the fair value of our Level 2 investments from our custodian bank or from a professional pricing service. We validate the fair value of our Level 2 investments by understanding the pricing model used by the custodian banks or professional pricing service provider and comparing that fair value to the fair value based on observable market prices.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following tables present the major security types we held at December 31, 2019 and 2018&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">that we regularly measure and carry at fair value</span>. At December 31, 2019, a portion of our ProQR investment was <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">subject to trading restrictions through the fourth quarter of 2020, as a result we</span> included a lack of marketability discount in valuing this investment, which is a Level 3 input. At December 31, 2018, our ProQR investment was <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">subject to trading restrictions through the fourth quarter of 2019, as a result we</span> included a lack of marketability discount in valuing this investment, which is a Level 3 input. The tables segregate each security type by the level within the fair value hierarchy of the valuation techniques we utilized to determine the respective securities&#8217; fair value (in thousands):</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z0cec2f41ef46437e96b40a502fd19a06" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 8pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">At</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quoted Prices in</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Active Markets</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 1)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Significant Other</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Observable Inputs</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 2)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Significant</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Unobservable Inputs</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 3)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cash equivalents (1)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">418,406</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">418,406</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities (2)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,102,568</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,102,568</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies (3)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">329,404</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">329,404</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury (4)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">363,694</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">363,694</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states (4)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">40,407</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">40,407</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div/><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investment in ProQR Therapeutics N.V. (5)</div></div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,506</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,506</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -8.9pt; margin-left: 22.55pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,258,985</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">782,100</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,472,379</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,506</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z6dbe183adeca4fdb81898fb0f23d867c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 8pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">At</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quoted Prices in</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Active Markets</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 1)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Significant Other</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Observable Inputs</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 2)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Significant</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Unobservable Inputs</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 3)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cash equivalents (1)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">146,281</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">146,281</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities (6)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,252,960</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,252,960</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies (4)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">276,612</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">276,612</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury (7)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">260,154</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">260,154</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states (4)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">79,942</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">79,942</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investment in ProQR Therapeutics N.V. (5)</div></div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,349</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,349</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -8.9pt; margin-left: 22.55pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,017,298</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">406,435</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,609,514</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,349</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">________________</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zcc6c856321964d22a7f08198e22558a3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Included in cash and cash equivalents on our consolidated balance sheet.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -36pt; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z3bb7cbd9edf34eea8445b9bb699f5225" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$19.0 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</div></td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z9302b49ff4924d45b72f0ef80173e32d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$0.8 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zcc7cb538270446d19a63ff93630b2e26" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Included in short-term investments.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z0a497b435bb34da0940d397a2ee925d1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Included in other current assets on our consolidated balance sheet.&#160;</div></td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze53e73690894408ba98ca5e5e87ae494" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(6)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$50.2 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z9da9f51ab1ce4cf8b13bf7b591532750" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(7)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$14.2 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</div></td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income Taxes</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We account for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. We record a valuation allowance when necessary to reduce our net deferred tax assets to the amount expected to be realized.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act of 2017, or the Tax Act. The Tax Act created a new requirement on global intangible low-taxed income, or GILTI, earned by foreign subsidiaries for tax years beginning on or after January 1, 2018. The GILTI provisions require foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#8217;s assets to be included in our U.S. income tax return. Under U.S. GAAP, we are permitted to make an accounting policy election to either treat taxes due on future inclusions in U.S. taxable income related to GILTI as a current-period expense when incurred or to factor such amounts into our measurement of deferred taxes. We have made the election to account for GILTI as a component of current taxes incurred rather than as a component of deferred taxes.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We apply the authoritative accounting guidance prescribing a threshold and measurement attribute for the financial recognition and measurement of a tax position taken or expected to be taken in a tax return. We recognize liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step requires us to estimate and measure the tax benefit as the largest amount that is more than 50 percent likely to be realized upon ultimate settlement.</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are required to use significant judgment in evaluating our uncertain tax positions and determining our provision for income taxes. Although we believe our reserves are reasonable, no assurance can be given that the final tax outcome of these matters will not be different from that which is reflected in our historical income tax provisions and accruals. We adjust these reserves for changing facts and circumstances, such as the closing of a tax audit or the refinement of an estimate. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences may impact the provision for income taxes in the period in which such determination is made.</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are also required to use significant judgment in determining any valuation allowance recorded against our deferred tax assets. In assessing the need for a valuation allowance, we consider all available evidence, including scheduled reversal of deferred tax liabilities, past operating results, the feasibility of tax planning strategies and estimates of future taxable income. We base our estimates of future taxable income on assumptions that are consistent with our plans. The assumptions we use represent our best estimates and involve inherent uncertainties and the application of our judgment. Should actual amounts differ from our estimates, the amount of our tax expense and liabilities we recognize could be materially impacted.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> We record a valuation allowance to reduce the balance of our net deferred tax assets to the amount we believe is more-likely-than-not to be realized.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We do not provide for a U.S. income tax liability and foreign withholding taxes on undistributed foreign earnings of our foreign subsidiaries.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Impact of Recently Issued Accounting Standards</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In June 2016, the FASB issued guidance that changes the measurement of credit losses for most financial assets and certain other instruments. If we have credit losses, this updated guidance requires us to record allowances for these instruments under a new expected credit loss model. This model requires us to estimate the expected credit loss of an instrument over its lifetime, which represents the portion of the amortized cost basis we do not expect to collect. The new guidance requires us to remeasure our allowance in each reporting period we have credit losses. We adopted this the new guidance on January 1, 2020. We do not expect this guidance will have an impact on our consolidated financial statements.</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In August 2018, the FASB issued clarifying guidance on how to account for implementation costs related to cloud-servicing arrangements. The guidance states that if these fees qualify to be capitalized and amortized over the service period, they need to be expensed in the same line item as the service expense and recognized in the same balance sheet category. The update can be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We adopted this guidance on January 1, 2020 on a prospective basis. We do not expect this guidance will have an impact on our consolidated financial statements.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In August 2018, the FASB updated its disclosure requirements related to Level 1, 2 and 3 fair value measurements. The update included deletion and modification of certain disclosure requirements and additional disclosure related to Level 3 measurements. The guidance is effective for fiscal years beginning after December 31, 2019 and early adoption is permitted. We adopted this updated guidance on January 1, 2019 and it did not have a significant impact on our disclosures.</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In November 2018, the FASB issued clarifying guidance of the interaction between the collaboration accounting guidance and the new revenue recognition guidance we adopted on January 1, 2018 (Topic 606). Below is the clarifying guidance and how we will implement it (in italics):</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z6b37abcc28844ec1995be6ea3287fde1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">When a participant is considered a customer in a collaborative arrangement, all of the associated accounting under Topic 606 should be applied</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z568b757cadfb43b88346ae2bdab57f19" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 72pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">We will apply all of the associated accounting under Topic 606 when we determine a participant in a collaborative arrangement is a customer </div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z729d51441c36453d9dd29ff6baaa5429" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Adds &#8220;unit of account&#8221; concept to collaboration accounting guidance to align with Topic 606. The &#8220;unit of account&#8221; concept is used to determine if revenue is recognized or if a contra expense is recognized from consideration received under a collaboration</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z36356b76546d4b1b9df6a54de364a594" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 72pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">We will use the &#8220;unit of account&#8221; concept when we receive consideration under a collaborative arrangement to determine when we recognize revenue or a contra expense</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze5669a8c7b084090bd8ad32061dcc5d9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The clarifying guidance precludes us from recognizing revenue under Topic 606 when we determine a transaction with a collaborative partner is not a customer and is not directly related to the sales to third parties</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze5279de5f245498da7e1f9b7cb96a4f7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 72pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">When we conclude a collaboration partner is not a customer and is not directly related to the sales to third parties, we will not recognize revenue for the transaction </div></td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We adopted this new guidance on January 1, 2020. We do not expect this guidance will have a significant impact on our consolidated financial statements.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In December 2019, the FASB issued guidance to simplify the accounting for income taxes. The update includes removing several exceptions under the existing guidance and includes several simplification updates, none of which apply to our current accounting for income taxes. The guidance is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted. We adopted this updated guidance in the fourth quarter of 2019 and it did not have an impact on our consolidated financial statements or disclosures.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6977255040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements and Licensing Agreements, Biogen (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="7">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Drug </div>
<div>Country</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>PerformanceObligation</div>
</th>
<th class="th">
<div>Sep. 30, 2013 </div>
<div>USD ($) </div>
<div>PerformanceObligation</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($) </div>
<div>Program </div>
<div>Target</div>
</th>
<th class="th">
<div>Feb. 26, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Drug </div>
<div>Country </div>
<div>Target</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>Payment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Drug </div>
<div>Payment </div>
<div>Target </div>
<div>Country</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>PerformanceObligation</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($) </div>
<div>PerformanceObligation</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,122,599<span></span>
</td>
<td class="nump">$ 599,674<span></span>
</td>
<td class="nump">$ 514,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_SPINRAZARoyaltiesMember', window );">SPINRAZA Royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,992<span></span>
</td>
<td class="nump">237,930<span></span>
</td>
<td class="nump">112,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_LicensingAndOtherRoyaltiesMember', window );">Licensing and Other Royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,205<span></span>
</td>
<td class="nump">14,755<span></span>
</td>
<td class="nump">7,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember', window );">R&amp;D Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 770,149<span></span>
</td>
<td class="nump">344,752<span></span>
</td>
<td class="nump">394,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember', window );">Biogen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfDrugsBeingDeveloped', window );">Number of drugs currently being developed | Drug</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CumulativePaymentsReceived', window );">Cumulative payments received</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473,600<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
<td class="nump">$ 263,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 525,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 580,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525,800<span></span>
</td>
<td class="nump">$ 580,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember', window );">Biogen [Member] | Revenue [Member] | Strategic Partner [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="nump">63.00%<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember', window );">Biogen [Member] | SPINRAZA Royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 293,000<span></span>
</td>
<td class="nump">$ 237,900<span></span>
</td>
<td class="nump">$ 112,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember', window );">Biogen [Member] | R&amp;D Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,600<span></span>
</td>
<td class="nump">$ 137,100<span></span>
</td>
<td class="nump">150,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember', window );">SPINRAZA [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfCountriesWhereDrugIsApprovedForUse', window );">Number of countries where SPINRAZA is approved for use | Country</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax', window );">Cumulative revenue earned</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RoyaltyPercentageReceivedOnNetSalesOfDrug', window );">Royalty percentage received on net sales of drug</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember', window );">SPINRAZA [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RoyaltyPercentageReceivedOnNetSalesOfDrug', window );">Royalty percentage received on net sales of drug</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember', window );">SPINRAZA [Member] | SPINRAZA Royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax', window );">Cumulative revenue earned</a></td>
<td class="nump">640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember', window );">SPINRAZA [Member] | R&amp;D Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax', window );">Cumulative revenue earned</a></td>
<td class="nump">435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 435,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember', window );">New Antisense Medicines for the Treatment of SMA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RoyaltyPercentageReceivedOnNetSalesOfDrug', window );">Royalty percentage received on net sales of drug</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones', window );">Maximum amount of payments receivable for license fees and milestones</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones', window );">Maximum amount of payments receivable for development milestones</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones', window );">Maximum amount of payments receivable for commercialization milestones</a></td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForSalesMilestones', window );">Maximum amount of payments receivable for sales milestones</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NextPotentialPayment', window );">Next prospective payment</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations', window );">Number of separate performance obligations | PerformanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember', window );">2018 Strategic Neurology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CumulativePaymentsReceived', window );">Cumulative payments received</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceivedIncludingPurchaseOfStock', window );">Upfront payment received, including purchase of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RoyaltyPercentageReceivedOnNetSalesOfDrug', window );">Royalty percentage received on net sales of drug</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NextPotentialPayment', window );">Next prospective payment</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations', window );">Number of separate performance obligations | PerformanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 552,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_TermOfCollaborationAgreement', window );">Term of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_PercentageCashPremiumPaidOnSharesPurchased', window );">Percentage cash premium paid on shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments', window );">Maximum amount of payments receivable per drug for substantive milestone payments</a></td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfTargetsAdvanced', window );">Number of targets advanced | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_PremiumPaidOnSharesPurchased', window );">Premium paid on shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfMilestonePaymentsAchieved', window );">Number of milestone payments achieved | Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation', window );">Cumulative payments included in transaction price for performance obligation</a></td>
<td class="nump">597,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 597,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 597,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_PaymentsIncludedInTransactionPriceForPerformanceObligation', window );">Payments included in transaction price for performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MilestonePaymentAchieved', window );">Milestone payment achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember', window );">2013 Strategic Neurology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CumulativePaymentsReceived', window );">Cumulative payments received</a></td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NextPotentialPayment', window );">Next prospective payment</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations', window );">Number of separate performance obligations | PerformanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfDrugsCurrentlyBeingAdvanced', window );">Number of drugs currently being advanced | Drug</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (16,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember', window );">2013 Strategic Neurology [Member] | Licensing and Other Royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember', window );">2013 Strategic Neurology [Member] | R&amp;D Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation', window );">Cumulative payments included in transaction price for performance obligation</a></td>
<td class="nump">$ 145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember', window );">2013 Strategic Neurology [Member] | Medicines for ALS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfDrugsCurrentlyBeingAdvanced', window );">Number of drugs currently being advanced | Drug</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement', window );">Number of drugs licensed under option | Drug</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember', window );">2013 Strategic Neurology [Member] | Medicines for Undisclosed Targets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfDrugsCurrentlyBeingAdvanced', window );">Number of drugs currently being advanced | Drug</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember', window );">2013 Strategic Neurology [Member] | Antisense Molecule [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments', window );">Maximum amount of payments receivable per program for license fee and milestone payments</a></td>
<td class="nump">$ 260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones', window );">Maximum amount of payments receivable per program for development milestones</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones', window );">Maximum amount of payments receivable per program for regulatory milestones</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember', window );">2013 Strategic Neurology [Member] | IONIS-C9 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember', window );">2013 Strategic Neurology [Member] | Tofersen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember', window );">2013 Strategic Neurology [Member] | ION859 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember', window );">2012 Neurology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CumulativePaymentsReceived', window );">Cumulative payments received</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NextPotentialPayment', window );">Next prospective payment</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments', window );">Maximum amount of payments receivable per program for license fee and milestone payments</a></td>
<td class="nump">210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones', window );">Maximum amount of payments receivable per program for development milestones</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones', window );">Maximum amount of payments receivable per program for regulatory milestones</a></td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfTargetsToBeDevelopedAndCommercialized', window );">Number of drugs to be developed and commercialized | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized', window );">Number of programs under which drugs are to be developed and commercialized | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember', window );">2012 Neurology [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember', window );">2012 Neurology [Member] | Licensing and Other Royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember', window );">2012 Neurology [Member] | R&amp;D Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation', window );">Cumulative payments included in transaction price for performance obligation</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember', window );">2012 Neurology [Member] | IONIS-MAPT [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation', window );">Cumulative payments included in transaction price for performance obligation</a></td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MilestonePaymentAchieved', window );">Milestone payment achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember', window );">2012 Neurology [Member] | ION581 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CollaborativeArrangementAndLicensingAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative payments received since inception of the collaboration agreement included in the transaction price for the performance obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CumulativePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative amount of payments received under the collaboration agreement as of the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CumulativePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for commercialization milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for development milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for license fees and substantive milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for sales milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable per drug for substantive milestone payments under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable per drug or program for development milestone payments under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable per drug or program for license fees and/or substantive milestone payments under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable per drug or program for regulatory milestone payments under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MilestonePaymentAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment achieved during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MilestonePaymentAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NextPotentialPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The next potential payment to be earned under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NextPotentialPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfCountriesWhereDrugIsApprovedForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of countries where the drug is approved for treatment in patients.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfCountriesWhereDrugIsApprovedForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfDrugsBeingDeveloped">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of drugs currently being developed under the collaboration agreement(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfDrugsBeingDeveloped</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfDrugsCurrentlyBeingAdvanced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of drugs currently being advanced under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfDrugsCurrentlyBeingAdvanced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of drugs licensed by the partner under option in the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfMilestonePaymentsAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of milestone payments achieved during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfMilestonePaymentsAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of programs under which drugs are to be developed and commercialized under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfTargetsAdvanced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of targets advanced under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfTargetsAdvanced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfTargetsToBeDevelopedAndCommercialized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of targets to be developed and commercialized under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfTargetsToBeDevelopedAndCommercialized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PaymentsIncludedInTransactionPriceForPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments received under the collaboration agreement during the period included in the transaction price for the performance obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PaymentsIncludedInTransactionPriceForPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PercentageCashPremiumPaidOnSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage cash premium paid per share of the Company's common stock under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PercentageCashPremiumPaidOnSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PremiumPaidOnSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash premium paid on the purchase of the Company's common stock under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PremiumPaidOnSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of separate performance obligations under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration the Company earned or is eligible to earn under the collaboration agreement, including any variable consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RoyaltyPercentageReceivedOnNetSalesOfDrug">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage received on the net sales of a drug by a collaboration partner under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RoyaltyPercentageReceivedOnNetSalesOfDrug</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_TermOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the collaboration agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_TermOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payments received during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_UpfrontPaymentReceivedIncludingPurchaseOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the upfront payment received, including the purchase of shares of the Company's stock, under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_UpfrontPaymentReceivedIncludingPurchaseOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_SPINRAZARoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_SPINRAZARoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_LicensingAndOtherRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_LicensingAndOtherRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_MedicinesForAmyotrophicLateralSclerosisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_MedicinesForAmyotrophicLateralSclerosisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_MedicinesForUndisclosedTargetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_MedicinesForUndisclosedTargetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_AntisenseMoleculeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_AntisenseMoleculeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_IONISC9Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_IONISC9Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_TofersenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_TofersenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ION859Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ION859Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_IONISMAPTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_IONISMAPTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ION581Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ION581Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6882244672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information and Concentration of Business Risk, Contracts Receivable from Significant Partners (Details) - Contracts Receivables [Member] - Credit Concentration [Member] - Significant Partners [Member] - Partner<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_SignificantPartnersAbstract', window );"><strong>Significant Partners [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfSignificantPartners', window );">Number of significant partners</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfSignificantPartners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of significant partners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfSignificantPartners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_SignificantPartnersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_SignificantPartnersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CreditConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ions_SignificantPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ions_SignificantPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6878983984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements and Licensing Agreements, Janssen Biotech, Inc. (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($) </div>
<div>Program </div>
<div>PerformanceObligation</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,122,599<span></span>
</td>
<td class="nump">$ 599,674<span></span>
</td>
<td class="nump">$ 514,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_LicensingAndOtherRoyaltiesMember', window );">Licensing and Other Royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,205<span></span>
</td>
<td class="nump">14,755<span></span>
</td>
<td class="nump">7,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember', window );">R&amp;D Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770,149<span></span>
</td>
<td class="nump">344,752<span></span>
</td>
<td class="nump">$ 394,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember', window );">Janssen Biotech, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized', window );">Number of programs under which drugs are to be developed and commercialized | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones', window );">Minimum amount of payments receivable for license fees and milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones', window );">Maximum amount of payments receivable for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones', window );">Maximum amount of payments receivable for regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones', window );">Maximum amount of payments receivable for commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NextPotentialMilestonePayment', window );">Next prospective milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations', window );">Number of separate performance obligations | PerformanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember', window );">Janssen Biotech, Inc. [Member] | Revenue [Member] | Strategic Partner [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember', window );">Janssen Biotech, Inc. [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CumulativePaymentsReceived', window );">Cumulative payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember', window );">Janssen Biotech, Inc. [Member] | IONIS-JBI2-2.5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember', window );">Janssen Biotech, Inc. [Member] | R&amp;D Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 6,600<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CollaborativeArrangementAndLicensingAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CumulativePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative amount of payments received under the collaboration agreement as of the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CumulativePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for commercialization milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for development milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for regulatory milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount of payments receivable for license fees and substantive milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NextPotentialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The next potential milestone payment to be earned under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NextPotentialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of programs under which drugs are to be developed and commercialized under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of separate performance obligations under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration the Company earned or is eligible to earn under the collaboration agreement, including any variable consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payments received during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_LicensingAndOtherRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_LicensingAndOtherRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_IONISJBI225Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_IONISJBI225Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0001140361-20-004500-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-20-004500-xbrl.zip
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MQ6%G)B2]8;"@#%DL?!&+T!6@(BR=BD6!L&V\_!I*EI'0^O.?[']:3A[AY5H
M;#%G3GQW1/HHP-$M<^JO8Q?-6N<1+EL*JJ];04]4YP%[G$IW6F*W#-T@\\!Y
M<LL6,)3 2$7YX'[CE*/D<$%0&INB )<T9_Q8S6#5A/5]S#> I\ ?%8*\;R&V
MS;A+3./!1MA&$R_L"2 \L SU!LQ$!"K"G;4P69J)V)5P[V\<@Q<Q>$'C6D81
MSH4K9J@)W<.6Y05HQ/Z"1NC=;?LJANF#.?L<JD>8.V&C9-FNM6PUPUZMX+3^
M6SU9@T.K,*=M8% _G#.71S3';YAABGB60)*2,D_XX$(]M,X4W4+=D"%P!H'E
MQY0_"&+T3/"0<LM$I$!EG$[U!!6^9F$@DH2)+U$,OX%3221<Z4M83<'0^%$F
MPA(X7KHV\-U5,\&$[PLWE4" TBL- D6Y[CF(#U6ULOHZB&25J^P: I_SDU7^
M.,W.!@ID@S+)SNP^;[,XR3AL#1P@C+C'+<%^]MH]'&6WL5+$UKZ @P)4T]6+
M)#BCOH,R5N2,#(V;7<$63=<BMZI974]G=4M9YP80O"@J3_.\&%" !5_FB@[:
MYJ(&4XBO;F&!#['@G_OP8ZN"#^W\$0S9<7#,#O=A=\<\>.3SI&F2,O!H+A:8
M.3515!U@':P05""B3N1WS#60G 49O36+"676U/+BE<AXC<3$ H@GH?G329_-
M[8";K+>2V&;%665+O=?8TJVB%(0'[$(%@7K<N0FI'(8\3\H6UD?](*T??A%N
M1N9U3F$)(MNO8&_&]/H(*+$J1H:W/?P"@3"1P+CYFP5O0NX;KVB_25\W^"MK
MF3-.9NEEL)@G$U<!>H48@MY+IA*"K0HMMSDZ9K.-EG:+,#<'W/&5L7!K8S-:
M1<!9@?04L1X@"IB(2IG,D:%G\=[==9_1& "!"@99-IA]LFW! 9XD&?PHN,)?
M%2Y7*<X"E$ YEZ4'D6O'!2X@<P"])F#*0!J.JGSC%;@#HU.QB56+6X75.E,.
MLU&L'J0GV&,L,?'&. U! %P=SN7/T;4C":A:)@;2BJL60P$8;(G<Q^$EL,0^
M10B"V)40*4ZG8I8H%<)@Z0/[5TX\!>23AW,(UD"O(10"_:;"\.X:KJ/B0-#2
M[VXNKA&DK-[' "YQ\/H$%2L.)24K3>6,H ?,PW,74\$@Z10BP&1*7P#HD7HJ
MZTQ*#H;=0GQ6WE>QP%?#2^*6(;!N'D:#P$):R H./\0.,<;A"'Z1R4^J(CAB
M ?RN*3?HIS:$6/PK$PFI(7D*?;64&Q&\L:9"$(=C/"Z$AW-9 \YM%JY95]S*
M+8FF'7Z) B73I_1\FPS:4OM*)E>4C=WI+;-KFGP)A/\4*9-[X#?=@Q/8FRMD
ME!H%LQQ9-74N0=QWX7=8*";P/>HPH/B)4A[SN4S)!YL4"M [@*M$A52DTV$0
MI6U<=7E)O,Q91!J$M&&608D Q36J5$/*-4]>GPE5MEJ@OFNS&R2F49%SS^LO
M\L/E(1(<DQH7Q1$OB[5&BAJ#%Q=KH8N0^=2>$CK3$E^0E> C,5O6IVZ@E 7K
M;1H+1$0\AJ5Y-&6[2\$&N%K@M&CV-I89)6-NX?6P+'7*YD+%_"PFW*$@\9_D
M%F3(7T+5(ZH'&%=D -73T0ZNQ5A5!;,'[R&^N )4E]<RR%)*]*[=:W<)FZ%P
M:E]4LJ4Z_K*;UZH-G']4\6>&$242%%9 F8$6U%/XGW:"#AY2T!B<#(_!06_K
MNH@5.>PZ)#O#<;8Z@HZG>MN;!;;@S<TH(6ZH3Z@G@VT&WP1+PHG6 I%L*N;N
MO2;FTHF!Q['4!S[<X(JD5E4KG'HYWIKLEB>T3S*4%G.RE$2)EPH];9$0:"F2
MQ>RI=1"8NK%T=,$#E<J="B\#E[9GE&W[-E:4)5SQ$)(@%%8.4G, OY@A;(KI
M^Z_*D?0>SS7XSHNLY6K"CPHB)F@KZAAI( 9A4:E0Z$E,=4$#>1B>:,_=0I/5
M0TP8PL*N)'WU:NO^>#M@VVCAZ!LP9.C,H%1O>J+2\2:O2:I @-$V61>("P-]
MBT6ER@I^$>#Q(U9&J-X,\BJYD*-V=XV"2[N$>V#Y*."N=N*;WS :2PXVG;S1
M8QE6RJN*->]:$U 3G;ESI"B :^8AR1A4.E5 6P2N&5A&22_>EYL8@3-/T1R
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MN'8BDK*D&,#)FJ6HX X?P1<IX2=-*&>:H%"RZ +*MQ7[B0/HN)F^:%21*7L
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M_U\):U_SJTORJ]S0+1KUS?_:"C3_W/\ 4$L#!!0    ( )1P8E#]-'M/30D
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M$58M2(!LTB+7I:[GE!AMLH- Z:'A>= B[5;3E0J.UW!?.@]GC9TACQQQ!I_
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M/MX2D_>E@8NMPWWZ<:S?Z'[^^P=02P,$%     @ E'!B4) W6+I*"0  _3L
M  \   !E>&AI8FET,S%?,BYH=&WMFUESVS@2Q]^W:KX#5JF92:HDF_<A.ZYR
M$B?CVDR2<KPO^P8"#0L;BM  I!7ETT\#I Y;<D:19V<SMOR0\,#13:)__'=3
M/![5X_+DAW\0<CP"RMT6;M>R+N'DIR=^XAT='[9[W:E_#@;DK610&>"D5D/R
ML1F/9=TGE+S0BG(M^160EVH\H=6L[>/^7BG6C*&J"=- :^S;&%E=D;-7;TXO
MA"QQVY /%^]Q$TAR$!_X!]Y*[Y=J,M/R:E03/\]C,B"!%WBK$PX&K1>'G1O'
MA>(S8NI9"<][0E7U0-"Q+&=#\O.E'(,A[V!*+M285C_WB3O2)P:T%$?$M3;R
M"PR)[TWJHUX[,I?71/+GO<N+-Q<?X<KZ,A1A$%,_R =YD4>#* KH@*9>/(B]
M/,NBS N]).G-KYP=H#.HAL_U@);RJAH2YU8WZ\XVM@>F8,<:DD*5',T^^SR2
MA:Q)Z!\$QX<X_8HE)\>%GN_>.K7)2+S?->C[6MD[>7EV<7G^^OSEZ>7Y^W?W
MM.F_C:FEF-W?J/,^.2OE%UI /2)O#\@OJKF"JH].:SL!J4>T'GZ#L2?SA7M<
MTP*7,X.R-!/*<(T_[WD]MS^AG,_W_Y152J:2UR.[X_UX1%:O4PD"3S-5*CTD
M3SSW=X16E-28Y[U7'S^\?BM-?6E-[;D5_@6"3(C,BZ,B3Z/ IQG/8\J2J,@*
MWX^\Q9*V?RM!BO[JD]5]>X3/W>OL"U)K[+6]M(R6<QMK-3DB-P*B=VNDN]=!
MZ]^8ZBM9#>S.D.23>T=4[\0_6+VQ"RL.:_Z'3M*F5IN=W-ZM/V]YDQ&]!J+A
M6L+40GLD#3FMJH:6Y (F2M=$5>2UTF/L,?@748*<JPK;?!A1/:8,&N<%3G%>
ML8.CK2X*'M ;%@D>MLOLKKAYP"$51 %//"_R1)!$,="<,YHE7I8&"4\R7CR.
MD H>2$B]H%;]8-2,9^13I:8EH ;IMY%%V\C2;61QA4-7"F4/#D)EA:=GI*EJ
MW0!:B$+(:2(,.8J7&Q^Q$KL*RO"0)@IU%7K8MEMK4 $#8ZC&YY.Z?0$(MOT$
M:,_*) :/<302;2B=DL));0,F-2HS;%;A>&@:!TVF(\E&Q#3VGV7_*6CH!K$>
MC:4I46Q9%3>5^.348"; G,5VW G:JCCZC?<,+U8QVW!Y]C#9"28\]'S*!8W#
MC$>I"#,:<I$52!3J)V'A/PZ8A \=)F"A850IN4N8A*PP1FW\+V,2TZX*^V);
MO7)>5@*?YK26.*BL6-EP[(YQOQZ ?62)U.6,3#!Z+8EDM<X26I9+]G11;IQ]
MRRG14B[MA/V;1F/SIL36"!N%1' V&6?TC6:,FA$1I9J:.98T7.&JUQ1MHO9@
MZRGZU5^ABYG;?9=_>\#L!I@L#I-(^)S%-/)80C/!8A%PI$Z8AMDC20"B!P*8
MRQOA]-.3+/#3(]-1HTMR[5-<"2%QUP7:.:$:7+!CF$J[B#'T"!B[H*49V>:V
MV1@EC94U=I]+PTIE&NVX56M5MH$^T8H!Q\.&/,50YH#4 +Z.&0S@L\]L1*LK
M(*>H(RZ:$KOX(1WX\5-XYL;R8][NM;O25B6J%C]V0F+%Q@J56@A8XU9F_OI$
MXL9$ B>RCM\F$K:P2=5PCY>=Z@LT+03-&>9#6>31- ]S$5.:0YP'49[']\%+
M%/\%>&D9=M^XI,\>!E]>@<$!,;!<PO#'&.C;Y(;1QFS?Q285!6 $=S.U:8IJ
M- Z 4N!:&B<]-F5"4+F!;1%OJ6)6%9*&DCI&=(G+,L[[G7JR)R6*F!N2Q32%
MD5Q2+:U'LDVOG("K[$B-L2F/8ZQQ^9'3)\H &E2C4K*=)M3>OZ:D5H&AG\Z(
M9>J$/=I$S.F:+J'$K0)L0U0^V!_X7N+LQ*"\B/,TR6F<Y4F4Y(SR#/*"BR@+
M>)KQ])$PJ'B0#-I:%ZRA:'M%<1>1U@ET"U$6:]>26]!0HRH7/KA,&VTK,)8^
M5/,Y"9!-DA:RE/7,)D:;[+"@=-!P/&B1=J/I2@7':;C/G8>31D^01\9RAC*F
M-'<&N%K.%528K)6()3P#$\L[VZ2IZA8]R$4Y0=6TA\].\/$%<)KXPH^9B'(&
M.6>V,AP%+,XP5X=' A_V0.!S=DW+QHD"&X@@!+!:7F,(F0WEC$7^M87J:7=O
M5S@Z)6#5#W9$@6+:HDJAFMI.MD$#;3)I&Z%&%ZW!UIG$URJ[G5G%O)SE> KM
MI4$#C^S@>USLE"\5?I;Z- PC5D1I# 7-_# ,BRSVLM"_7SGF;X0+_D!P\:H-
MO/6(MN^&NKJ$.[,1&]^@4&S*HQAKM W3E?QBPZAC9>IU;FBP/_S P0U>-?);
M@_D*SO7TCC$$$@FUPZW6G2<,L>#><U4W*[3/6C-'U"RR,ZLZ'+" .WWF+E G
ME6:DE)^@M"^]UMOW[WW-]I#:&5)A&GG@1SR.O32B@A?,YR)-(<_#(BCR1_)2
M*G[4-6/W0Q,^QUM_J06L5K&(F1-E*0LL$[9/U]81M5:T6=A*&RYKI<TB0W('
M< [[>\4:'(TV="L4YE_V')=HK!O@*4((18^Q*@O_MZ6C.4KAMT:B+XZ23<7<
MZZUG^[+P3@1A?IY&21)'20!1S/P":)Z%D8 T3@,$RR.1.0^E+'Q:EL061R02
MPKXTL:]?F 0,Z2ZS651CIT _V<RDK46XW,255=R/8.9OC;\)%%WAM'V'-9<.
MZ_!8:@G*<20#"REQ)U2Z8@QV03HHC9!S^9*Q5Z(9XW+ 2^"\ZS3=QK?R>YFQ
M^ZOI@+$<LJ*(:!0!38HTY!%C1<)29 4/'@DD'DK=]A13'J'QR=S'D 6G+C#H
MW<_+.CKTVP1!5M>JO :;)53TJOO9G.X$"8PGI9H!GIV.5*M"Z WV("N^):=:
M)\5=H-E.[NT4Q?_3Z]Y^VS'_PF-EXO\;%@J$*>@!LJ"D$X-MYEM;$<.Q(?$2
M/PZ LZ@04>R)K*"1* 10+V8>]?AR?2_OQ6TN;*""?Q"$/VX7,5_GP+T+![;&
M."2_4HW/MJ#O/H)97W_KJV_-I3@[2-/OPJ7U%;C1B5L!]'>Z:5MZN+]-:\_<
MC@B%JFLU7@0["2:?B7L-_Q=?@T-S2,[>GO_G],79Y2_N.Z'W_WYS]FY_9[_S
M -SP;=?^GGW7]ZP[8 <?$EGCR,Q^.SB2(,CKA09[WY:>'N&]G.O%&^KQKKQO
MOG5\:#^)=1O=1[^_ U!+ P04    " "4<&)0J#,5'\T&  #R(0  #P   &5X
M:&EB:70S,E\Q+FAT;>U:6W/;-A9^[\S^A[/*M+5G))F4*,F4%,\XLI)Z-HT]
MLO*R;R  FMB2! N 491?WP-0M"C+;ITZF]HSUA-Q.SBW[P-YH&EBLO3D7S\
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M]B'1&5OEZ4JG&6@!%L!V QG$,I-'[&V&+YD\^ 5V$N_B6[_F@+I(P0ZIA*@
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M&46I7M* A ?\OS-DA (#2GY]I76&]K/5UH[6< 4_%0"?%P#??T,_[)@"=0O
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MNFVIIN$JONQ@R[6>CM"J1VC)IB;_#KHI2Z*0X,^GPACB;/0]S'X???4PNGO
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MWME_IN&$C.W#K-Y^^0FC##\DD7\QGJ3)(P_YS19DS5WN9^CC@9%V:T9^F(9
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MMC$\+9<-<B6K=9[?V7F>7_BQC"JSH5KA/2E95:ZD ?Y25?/WVZF;X?],B8:
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MT/!0L.54](203MMN&76J%/X26!D$5A:,C-$^1TDO[<K([/K@Q@,'UXO3T1O
M]G6$8^\E_ )6.X95OVVR;PC519M@U.?)V@)!'2'HQ8&_^F!PAK IC"/3&-P.
M*9TV0!7^^5#\\P9"EESN@SFA2L!N2]BU,HY\%!'T=]ARO;@H:T)ULH?AG2Y]
MR5IGD:?>"YR$S\:$SZ8O(F5+%=1S0V^!&4:28'MK\,U-ZP'FH3G$@TC;\F*
M2]S]*E[A^^W=]]N/PFW53?#BZM+23)%?;KM3HYZL_6A)X5B\$N<?4?P(D]GC
MP0I# _N3&1.(9P;Q2^FBM5WJ-54D15NUJ:\FBE6,'U;6BI]-@\QC?Z\A&:N!
M[+9RP< >I&?UOJWUM5F<*[W/HDKNP%C5W!V<WE\^GT2@ES'T=@ L=H\%$0Z%
M<"@.JW'88#<U<R-%@]L>V:$L\[9'<E]"/-2F(CP+\6#:$^Q&GMGI4;"W$VT&
MVJ. 9R$6EIA32SR ;@7<R TOM3XL]2T0/-\YSSON1*#7G0C,'O*4GU&=F_N
M9I6Z'!(:7CL'O9D,XUC6V_<>,#O+3/:S-5P :!< ZFT3^%(L(-#!(SJ8\$@-
MV1  XA1 BWMOC<[4BR57[6[@+]7>9#&LO"([3U)Z9NSY_UY\ZJ[28 3_XY/Y
M/<=N6A[M9C$.LE<M.*V?1H;JS]IPH\\T7-M./?12U>XJE]Y"-@3T&43<MI+:
M5A Y1K; \RX PIG<;.>8+$%T:\>$)7>$0Y=WN-[(_GSO3B'NU'N5.LP;,PS(
M/AH;[R1<;[VQ9^@'DO.'N0/:';^C4&S?FQV$+ A98$(66#G!1,B"D(5]R\+>
MBFP&6K/.L.0,MD:ND\0B;]5QK!@Q(;A"<(7@<F!QA[K!A$_!'<S6DKYE6&PJ
M$3EFMN*GWMJ'"SZSRN=.]QK(LE8:8KF7OMZ?2?Z#/)U8CE]O_SX\'+QV#GHS
M#3+IG]+.-,A=MEKIJ[)8 *A_ .WL\+$P[O'P,8&5C;'RXFA7'3/69"(7*&1O
MK4. >5]@YK"7#RM9&B$W0FYXDIO]==ZHF@XZO30=%!#?>5#EM&\SZ R\S>!0
M\#G$X@WFY$:T(7SE M-0I(RM]>)!+'X)(1]*^<<!"+D0+T9TY%"2$$+(V1-R
M8<D9436\9DSZ.:>2+[GB%4!]E2;H?1\:K9,I^1N*LPS''\(DQ][#1>P=(DA:
M3DI/J-$[1DWI+@C\#!D_"V:+(JB=V=+W70TI(,8+Q(91%,,IFEY==R)PVED-
M,(]K3YS"G6U0MI)6#@L$6#E?1TB6D*QA2=:^$DF6,I<L19.?Z4[XMP\7JFH(
M6=FT7V%SWH03M@[]R@;H5[IK_<]CH?,P966@Y4/[EBRQ"MG;*B2G<BB6)0]0
M#;#205"H 0[4@!# H=8DB<)#H0:$&CAX-<#3X:R#ESPV@<Y079-6'_4)?_6P
M.W T2<.(/)W,TTT"(#A$P*R;A=Z4D-;^N$]Z:6<[!.OS'^"O'M31E9<GA>#9
M!PVH]?/0HWO;^LP(>FD/[FTO3:&$AMJ+AMK(3>JP,=1R[E3 :1!PXJD%I0 1
M.R#JMZQ2N#\\NS_#*+D5NN15NN3%\0ZA%YT(T@:EI9;BKJTS0R(?Q(HVV@X7
M2RF>;OM7"NW!L_9@8NF"P4K!;'5#]8&B\65JM_.3.*P99^7X-R$+HAQV6QGE
MM;+%JE>31*Z6;V=T>4-"VY6D;K?CL+?13:C6 U>MHG:XVS/O&)8<5AWTP]RS
MP*M/Q'VU+[^">U@"PJH^XS6PYW[3GA!<KN2$.87"JZO<X2FS',@*^]J<@U-F
M!9\9WO+0,,2TH!A4699$H0\:PC\CXPEQ1ID^^NIA=/> 4S3!TSSTLGIG1^>9
MR+^A>(K2&1D3T:B7R2,HMS!C$T(D!;1NTDH$K9^Z_=C1+3G ADWK\GA<6:V+
MZE75[AMAK_#1V[90I9>J=I>F_C4*864N>?3WT[/1Z/IJ]$FHC1<SQ\N3M=V*
ML]!/K+E7*Q)70LH&8YQW)MP#D3(F4E)=B.1!"QN+8-R3AN!5!I:C08%GQO#,
M:X@ED@L\^2\#07[#>5\"\[8Y,ZO6DI: ]3 T*Z>>@M7^]'-Z:;<*7:"8,10S
MI26U=66E'W$$TY'.8-;*4/CTXN)"9"Q>3AT\.W/"X.\>RJM+?,LKLO,D%0CO
MHF;Z^0D5P&=!AXN4\ZL4N,@"<Z"]!;99!=K.[,V+<LH0Y)<J&KI;7BQ8B(4P
M,+BV6$GG H\.WJJP44K#7D^'@4DCBVCMQS2);A ,=8,8F!0-<3\SJ[9(G' [
M5"EB$:VLBOY."QK$!L;!RQP;NQL'L2V95<.YMZV/O#<;.!R1WZ^PL:&#AB3R
MK$2<0N29%7EAY8<E\OL*C_LY.9!+*>,<3GUMF>^GT[= R(!V=]:M6AUZI@0+
M!>+S#NH.F=3K(/RC,CR'A:YG)F*[[!E[Q>%.^]ZR3J>G%#*S@5*@_B!0S_(V
M_0.&]""WK[U&DGC-?PCW1:!^IZA?5.3=G=_U>B"_KFY82 %[<&PEN-M4"@_4
MG6)6"HO*[,M?K^\^:9]&'@'1]0-*Q\BCMZ/H(@;P^"&0*N116*6.U,#&J#MT
MR12R-W A$'9O@WRP2",<BO@P >DM\L&=IA'Z['8I[ RK6]*ZMQ7LZ0)NA9*]
M<D9A%U]E%YFK0]IO>9:(=+E?=6#%21Y-[P&E:GGJ_/7=:?.U;"N%GH['?7E"
M6!-<II:3];HM@ZG) N)<N;GL2E8'BEYOWQ;!/-9D=N)"(0]"'H82DMEU8V%;
M=H1]$/+ B#S8[9L,PZ5.=_:!P?([(0]"'O:W'='N8><)AX@>%+06]BG)-E/%
MR\\T 233%_M7.=QWD\Q01!XG=&[+-9&7II"U),IA2203RKZW1=,[?)]A/Q2R
MVE)6%^9+""9#@KFOA=/ML[@K!?,W-(O"QQ0)R6PIF8L3)D23(='<3T)Y1;\6
MX?**- /+"YY]! D=Y/OVTWNE@_SW'MK6<RBKG L-4T6.F_7='U N7I0+"MD_
M"-EGHZYQU^6>O";.&&S:*#05Q^T>15PS=$TUK%Z3' LZ>UC?=CV7^;Z3 BW,
MH*736O/UJ5"8GXL<CPL'Y J>"E_%][?%F*M\YLHTRNWUQ>7-Z%^CY>3G;0XZ
MD-S]80KSBK.L>AB]ZR*)P^PT23&;:'HA";>&YNV-X[.35KY\:>JZ\F&:")C;
MX#50&)S575\7\WK)V/:\I"%+T-Y/#3MX2=M7)+[BD*2M)>W%E;CG1>E)I,:E
M2.VJ?*P;^'8JJ&L8V)OL,'3:T"K9N2"N:TG<612.PYA>\ HOCD41> F)SU+?
MV[KLIBXAK^J[CQ!B2_7-@2>T<^VY-UO1AW\E@HJYK)1?'H9?4X%I@6CAQW!O
M1+:, 0:!^CYQP65 RM"IO<*C84^/"H^&'UEY-@3C$<VOBRD'SN4=+!-Q8LMW
MO5PD'%E&)*6/".\T&8]QZH4H&H*O,)CUEFV5P#);!Q?4]2$+A[&PL_=0<#"K
M2@.7'>%7'SR7V_D,AX,%89;W$,R)RB91V<2N$=]7,+CETCC70B' M^>UYBXR
ML[TH>]:0RJKZ9M=='E(:6B37F-2ZW'CQ0THT;U)*Q+@@B!*B7:] ,YY#82B<
MY20)S:):YR*6%D5[AY"][,+Y$#% 7SF55X!NP2'@!W%[\&?V@[C]]1MD;H,+
M)QZ$6,8^]"1D'\ZY*!P4A8,'ZTP/<JV(>1 .O8J_#Q='E 1PGL9@>GV 5X>(
MG9T4'$@0:]E'+KI\\6J#V D5A&0(R6 I-.BO2OBE) B/T-]/U?"KTTF\@I*_
MD&$8&2 N0H>#:$\QI)SJL-M3#";J%5:* 2LUK(I1%F':7?T$BV$$X^O8HEQ'
M%$^PG>_<4 $/P^_?CTX\"$>>\8RGV*'%:DC,KKH?DK\]Z'J?P2GC;85YUVW3
MAY3%&:YCQ'1UT*Y+5P??H:2_2)6C4RU8JP(]K+BU"PBRB"K!Y=U$8&(S$=N(
M8[R60QQTP%/,PRL8^XC6!]1#0BP;;VH0>/4#^MO)SE' P69AW:[S09QNP1&.
M 8N*EU=]N&_'@!.\,A5'<94"Y54P^G,4>"S%9[:]@FB)<[B@9-.-W5OE[9!<
MB.&N;S)3G2B\"'9D0Q1^B<(O7B#=Z[J&R!/SD:[@M'>2V(O*E,? JM)GV9/9
M6PF[*([IPZ2',7 0KGVJ**M?7NEXBJ6% UY::*#*[A)5AUO)(B)JKG25B".$
M;AH\BIC726VARXLN$FXN<T+_-!GEP3A22L9-F'W],/N 8^]AC-*OA;OA><D4
M4'J#/1P^(C<JL;GJSKO9I%R-2+$?YD^N*._\C/Z=I*?3+$_&,)E%+5AX'P/;
M/"#L&N*S&+YG$R05$)ZA?HZ69Z=A.[OT= ZKHK!U,[F]!GL)*W/"UX%F<.FU
M%<L50IPX$Z<=P'O7(LWO4HE>62?9U.2^T?H*+:.WUC*R>:S)76D9J](RLL/>
MM !:K-9HD9T.IT6OIX5!M-CMT6)WBY;:)LF:IC X+>UUBZQUJ%NL6K<P*$1.
M>R%RNA2B1D! T/+[U3=B7Q["R>IDXT7LL>E)$ NZ,/9U:;Z: C:<T?X0SG>N
MAI&T"9,R*A@[$(FU%7DA?!2,[3R04>3]E#$N>.S"JG82D[(090A6=L+*O41&
M2^D%H6Y[L*-[29 XM1UUA!WMA[&M[6C'^?5%.RH8.U"K*A@[%!N[I(J%N\2Q
M\EU() M6[GAAK<M$PQ(KA;H="F.7,DA"1KG-&2VG[P4K.4[8+R8:!"OY32U0
M6?R(W?PBSO)T2D9?=ER('W&:AVZ$;W$<)NEEDN-,N<8IJ2)BDY^5Y7Q*3MU1
MX66BNF3Q0E7R@@!N6^9*O!S!M5UP3>MP1\)B["CXUP__F(@NEQ>U!;-WPNP]
ME::\5K)E136&R.\G= U0OA?#&2'?NY'OO00\RVD(P>P=,'M_B8I%RSWZAE*_
MWJQR@V&>0B_'_FV>>%_99NS"T.<;/%;2,#BCO"RTBWP\&T^B9(8QG8&K";O[
M-E_@Y5HZ#DPN!3]YD\]EIUGH64X]X6?Y*.22.WXN13:"G\,*7H2>Y=7_>4XN
M!1]9E<=I'!9,_ )R6'-DC%$V3?'[,$MT5;'>?;G]6-U?_51])@]8]3#UR<-*
M2AY0BK--GZ:M>=H$_MST67K]+#]\!, TK[F<CDD+HB1]Y4P\N9]\^1''">U6
M\_2Q;>=DX1%O%T?_ KG&4ZZ2[,DU3H,D':/8PU=N%-[3S@N;3J6YYMEH1E"_
MZ=.LU4^[0^D]WOAA]NJ'U7U7-WV>L_IYI\EX@N+9AD]3Y-5/*XNH-GW:"L&E
M]5?Q(^BLUSSPJ?#2!Q:>R*8/>RJ[Q<."(/0J#=K^:?HZ6D%%1M%KB%TC(!_3
MZ?VFCUHC#Z>D8TFZ,4C6R,-UFMRG:+SIT]8(1'$""#['F^I198U$E&U2GG]:
M^/U=BB.J<TAYBY2D/DY_>:.<R&\DE'II$BV:?7+O29+>OU7!%KPMKW@;("\_
M#I(DCY,<OY&"-!G?X"#[Y<TY_/"[[2$4^+IE(LW0%==!.+ \V;$]3]85[.AO
MI#PI+X='_*XKOJ?9BH\"PX/+74?%LNG+IFXK;F AXXT4A?'7F^='1H=%KH.Y
M>;M$Y&ZH=F37-'UDRY:"=*3H"%M N2ICS4"ZI1K#I-KU'&S)OF&XIJ5[GN.:
M+@:FZY;M Z>Q/4RJ9=/5K$#S+=-5=5,W7%VU$?9U&9!N*(X_3*H!THKI(D5!
M@:8;BF9K*/ L1P^ -ETUW&%2[6+9T&6 LN:9NJ;IMF59 7(45\:@VUPT3*JQ
M#ISU51O+OJ]KMF<[)I8]0]%MSW<1EH=)M:E:KJ_XON* #L<J0G(0>,C3P'II
MAF+@85*MF+*KFHKJ&4&@RYH/9+NJACT?^ \F;:!R[2/%U10%D V1J:(9KF%@
M#V/+Q0$R]*'J<()K,%V6JYB![A!/S7%<Q=$ Y(YE^<HPJ59-*]!-3;$"V=5E
M(%H-9,TR@?NR9B-EH'(=*!;PVO5U R$](&I;MU4+:3I"EH\\9YA4(P.(-@S%
M CSKIF_9FAIXAFEHMF,CWQQH]*&YAAQXFJF:M@?1AF=#Z*4AD/  W'((Q(9)
M=> H@0X#MAT#@P<*04@ BDTV#=W"LNX-E->>XRL6^.":9QC 7!UYEF;[@>N[
MNJT[NC=,J@'8CHQU$E=#M!$@9'C@E.FJ&F#30_) +5<@RZ[G6Q!ANK:N8@\$
MVO=D'6BR/=6PS&%2K9JFX?DJ4./J)/N/?!MB+Y))4I$)#NHPJ78MLE$9O!-?
M]W7;-N%?)3!=US.P*CO!0#-(-D:*XCBV[(,JDS7=<71DNI3E@0TH'R;5&^;-
M;!NTG(5LST.VKF"$(#"3%=/"V .3'V!.J-Y0FPV$Z@VUV4"HWE"N!T*U+P<^
M]N#_RX:C.Z;C&I:C:I:M^YZJ>OIRI.EY0*3JNIH,LJ_I&@3COJO:%OR!'$5#
MG%"M6V9@*JH?>#K2?=^S%4L!/\U2"/L,;3E;: 4.=EU#<71?!E.G@L)S-=^W
M%24(="?@A6I5 \OCN;YFF!!3R[IM(,5V<:#ZR-)D>9G7@8P5WP"QD&VLNX:!
M=,^R9*!;P9IC^1HO5"O(! ?<\FP+Z6"_;$/3 \-"BNJ8=F N:[.A4&THAJSJ
M1F ;NBY;MHL"4]=]U?$ [:HQ4*K=P%,4UY1=6X5P6E4=U7*-P%1EPPNPXR['
MUP.A6K.T /N.AS47Z;J&P#*YEFK#GW:@N^ZREX(5Q<>NH8'!<L#0!8ZK:J9I
M8PL#]? ,3JA&NNT&LF^Y2 %CC8&-NJ.9@6?(FN6Z3WPS( U$'R(4785)0J:-
M+,]T01(LQ71\Q>.$:L"WXV([\&P??#,5V]BV%-T#U\Q&BFLMKP) 2*89AN-I
MAA;HAHF19X'_:JD.TL'\F0$O5,N*@TT$D1,V=;C/D2T/@T;S? <^8W685(.O
MH5FZJ@$)@:Z!CXEMU]!5W_ U5U:5)SE2K > !P-B,A.<&LNQL(X@VE20YV*L
MJ9Q0C0)'-K"+'2L 8"NR[8./JFL!6>MTS6#9-U--&:#@!:9F>[H+*DT!9IN6
M#0H?O#J5E_A:]4&(-<T+ I7DPVU'MDTP7R#H&M#A+B-\(%3;"&AT#5<-2,P%
M010R/0?[ONN O/K*LKT>"-7@:+A8]17'-Y&N>J;M@#DR@<^ZB:P +_MF Z$:
M?"P%XF@#V N6"V$7]+)A>&"S/ /)QG*V<"!4*T E7.'9KNGIGFZZAJV ER*[
MINVJCF8-DVH(K'1P0S4?0FS=\@)DDWH<%2,%H&\9RRNY Z$Z<$Q'E147FZ8)
MY+O(]I%B^MAW_2 (GJQ?#X1JT_04%0/.#1SHX(*"=VIYJ@X^" X,W5[V4@9"
MM8TU%$!P+2N6KSO(LQ755%5;U53-U2#P&B;58+,0&"YPHAU9=VW7=5QPRQ!\
MHV'X)A@FU9H"WB?X9 8&1]34%4?5%* >D60!\KV!ZG"0:B^P$/C<)IAM5W<L
M3W'EP/>0!9I=68ZO!T(U$&$$@:,'KJ\!IWUPP3U?\V3?\2'Z0@/5X9:I&9;I
M68J'7%T)7,?P/==%AN:33(,[4!T.KHCODXHZT&>Z ?3:R#0<V75]B$-T9: Q
MUX;Q-9 +,:F##=,R]4 #!Q[^<PS;#0(-T.)P0O6&\?5 J-[0#Q\(U1OZX0.A
M>D.$:R1!Z,B*099* L]S#%-7/=5#M@;:S>8E1[HAPH="]68Q%[@SCJXH&*!M
MZ3 _8-E-!-X- J<]"%Q>UKDVC+D&0O6&,== J-XPYAH(U1O&7 .A>L.8:R!4
M;QAS#83J#6.N@5#M8("V"78*:R#7LN."=^(A+"/-,!1'>T*U&FC(E3'6#:3K
M9--N0$H6L [AIJ.2,A8NJ/9]U]1-9$!\J>BZY3K@9P5.(%L(#%C@+=<J:%I@
M6[)N:)KBDTHE)&N*H2F6;!BV+R.%$ZH]',A.8#J^C\&EU'SD8@P\\["&5<VR
MEG>G#H1JU=7 LU9]"+E<W?05Y)F!@]5 5C15!A]]N8Z4[.743,M70+X=7P?[
MYBB6Z@:Z[8$6X(5J#?F6C1603QOIA@_&"OL^,K 'LJL8_O*:YD"H]CP57%#=
ME655TRU09 8P'SP61Y8-#["\3+5B:;*A!:J"7=T.5!>!%Z> 3 2:&9BRR0G5
M@>YZ$&AYO@S2#$)MZZ13J.IA%_BM*LL>Z4"HAI&;EFU;CH,58HE<1=-U73,4
M70YLQ5ZN51@(U;XOZZ"O U<%.%M@LAVP7)YF! [P'+3SLKU&CB4[-G@GMJ7[
M,H@# M-MF$[@RA"N6!U077R3)=/4PUGQ\0$CGW80],/']__]7S^3?YH?I"R?
MD3>2+G['* KOXW<2:7B/TY^D((F!?#0.H]D[Z2]WX1AGTB7^)MTD8Q3_Y4BB
MWQQ)&4[#H+PZ"__ [R3%GN3E%]]P>/^0OY/<)/)_@D$_I-4;7<J3=U*<Q/@G
MJ?AT["9YGHSA"9/O4I9$H2^Y$?*^UK_GR>2=I"__^%"^1)$GWW^2O"1*X+G_
M$]#_X%:XYCY-IK%_O/S3*JK'*+T/X^,(!_!$-,V3^JNT> O][HWT]OV7RXN[
MLX_2[=WH[NQVCY-Z>W;ZY>;B[N+L5AI=?I3._O?TKZ/+7\^DTZO/GR]N;R^N
M+OL?G+QN<+\AP&9\GR?QD?3Q5%)E0W=:#@?@XJ8PS_7E.7(C#+]&T03Y/CSU
MES<@S^1S-D%>]9DT%/O#!^?*DL$U"B!(-BS5UI0 61:R%-T SP,N*]^[)<G?
M0C]_(!_D/]<@!91%:)+!-=5?BT@CT)K#5*;_ ;'__5^2]'.>TG_)7WXUQ/(=
MFG+B&/ 6>DR%AZ+J<2 3</?_^1_%E'_Z^6WNKW^ ?F)9:QZP+(#EL"2UDK66
MK]!.5+OM&.$/0BW\0_CZ"CSL7M3.KVX^2\2Z@-:BW3E#3XH1Z2KKX_#=Q\2C
MQXJ0=J\%#HM$K&59OJ5;I'V##GH'(E3+# +#<VW/1 B<_;*-*EB+)_W_21_C
M-^\5^?CO5)_/W]MV&MK.&D7EF\I&U-+6@YB\+ N2%Z$,#.?'V^OS3V&6WY&A
MO&DG^4@#>ZIX:D"2_3ZV;-+O"&))PT=@H$GCPA<%S21#7BDEY=_4$BP#[!;?
M)UCZ<B'=SL8 E[\\G88W[U^$SBB.IRBZP9,DS1L0(CTP9'"OL*4BW3%-" !=
M5]9EA,'CA$#A90A)M#]K_LN;$"8_P]X[-TDB%T51DKO)=R*;WTF[I)^>HNP9
M<2_,X\J96@&M)O)ZL#2CR\LOHT_2S=GUU<V==/WEYO;+Z/).NKN2P$#>@164
M%$VZNI$4XP?_1^GJ7+K[ZYG4L)VUW1R=WI&?%4?3"Z%Y1F-50K7@7^U(2ZV=
MB?,DE?('+ 5A!FR19ABE$HY][+^LNJYI?^>SHNMS X"*:RB^Y^HDOZ8'@$$%
M@Q6U/&2YX//*VF8 ?.>3\[[AA@<?S<CP</SF_4?L%5VT->5((K<]I_!:3O*_
MIUD>!K,AZ#49RR#RJNQKOJFKAF5CQ]8,S[%T3_$,UV=;K]VE*,Y"$JH\T6V&
M#GZ:&S@6LC7=D+&CR2IH; 5KLJ( PKK2;7(ONFV.L.[4&SP+V!\O/.R)S&_V
M]"4-<7<SNKR]N*.A 7E5[R^L7+^=O*QC$U",F75+,%?[>2UK4M&NGV8NI-_G
M_P&,FQ\[]B1[M&RGR7@<9N2$!3!NH,7C*;48:]7/&3TAX1PNO:17-M2.K:LF
M4F79=G5%-TW#,4DZW4%.X).%)J6%5PXZ_9C\;:RU5!M$K('F>[IKZ:J,3!V"
M5O#V9,]R-,]W/ V\/QXC5O7$UK>,6#6EYXAUDS&NC%CW'Y6^ /\;? ^^!BB%
M_!)^:8B 'UBNKYK8-C'69<^S%1N3GD..C#0K"/P6(G"1Q&$F73\@,, >GM(I
MA-%?Q-[)*^/5K=7@#V??@3@Z"U(22'/J)91)V01[Y$077PIC*<PSR8.APVM_
M[#<GQ9KH%BI'@^C80!C+I*)1U0P4.*!]@B#0D6K92@N74K=/'&VM].S!0+P@
M"H#+) 7_DR;-;W.(0LK3%$X3ORD9",F.;ENRCTU%5V33L4S+TY#K. %$/GH+
MX_#$)\W(VR9I\DC&5,0[$?J&R(DSJ^3D6:6EGBBK=%:A"MOI/=XX=X>^7Y3'
M,7F4>T\,NJM;FFO8MNHKANYX*G(L3<$&=G3-E*V@18CZ7M..94T#;FLO,*4T
M!.P*!ZA!"F\)?,($G,(4 I4TS/S0HWXAZ,6P*0KTLO0>Q>$?]/./PP<AS-#%
M#;C\Q>%XJ;2(+NDR.5F>A*WSU3S;"M]$LNH;LHIL3P^09>ND*ZMO>@'$Z2Z2
M6]@*YSFTL*=Q1KZ?XBPK__D4QEAIA@^:+BL*]FW?0[JA*JZO^;+L!HXG8W)D
M2@MMH]J&(?V*_@#^8PGL4)HO:YVCER*;<G"G\.=5>I=\BYO+#HZG8%53+2LP
M=*3 R%32P<BR%%/UD=HFP#E%:92YR'_MN*@*NDJOP>J!NEE8$S$QJ8]0=9A%
M74&**YNV;;J^#2-09-MH,[C1:RSGMAJ+3Q!?)^1 JW^%DR4_Q_=]+9!]32<+
M"89GNIX-T8"O^BJV=%]I@Q&RBT;NQ%RNFMH=68)RFHA=O$X!JN$$1=+9=^Q!
M1/.(I>)TL:R55>P#8#N:!<"'1 #2N>%C2"R(JARE&"T)@J;*LJGJ@:NHJF[X
MV T4S_<4Q7<4Y#ENBP6V]Y;Y1 R.UP[C4P+LO7Y(XJ>)*=DP2"-)<$(]T)&^
M[AA@5E3;<LE)#Y[?1C4ZFG(,<KE&+'<0@L^#[O_S/[:J6#]EX&A$>$((+I-V
M1\0#C:;$#9(@"D) 58V\5R56RBH=6B)$5SK*+ZH$D?G*Y/)+4+L%+9&&>0A/
M2BG9.,6^-)FFV90D'?)$@BNH3ZFH/[@_$AU#LK0C+W\W",\0? R$+# 7@>?I
M-@ 70F?-D0/L@9N!C#8+[L[JPI12;[;)]/6-Z+LPCV@Z"2/OH5C&:V$,E!-[
ME3UHG?]4C!-[57S$TL2DB(IP1A<'6\V)]JP/U<9&*B?*,\]@85HNR^PCA0O^
M[CV@^!Z^B*5O#R%\,U<4K_&4ULE+,RU.U> ^*%]K\DH].5-4ETI3,QK 2+7(
MV4VJ+NN6;R#7#TS3LDE+0B]PVB2BR<H03"\]3?M(^M.)+"O2-4JE?Z!H^IH4
M6U^BRP:/F@NP*^ICS^E_Z^Q?VQ>3>;)5=;[LNPX9I0XIZ@L68&%H2F#;LJ];
MNB6;KNG;'I)]I/EJX#MM8NR+J\O;)]S?)?7*3ZL7D#=0C:TQMTXOLH&YE_3"
M6:DEEQ:I-!\\<5?!V-9UW=8#9 "C?54)=,5 CF.](A5/]'&5A;\#5^P293[Z
M3Z$[I,\H_8ISZ=.GTW9![<M14>$\T6_"F&09R[6\C2HSMY[_C=S4^P4W5>J[
M8.,2PH(%,=FPV!O;EJ;(6J '-LE:.! V.3[2D:&2DY4P>YZS6#I_317?UC)P
M$?LDOX\E=R9Y#QBD'6+$KU)80+VQ4AQF$I*^ =:.O\;)-X ^1AE@U(<?LBF)
M75$F^3@(XV(A^68*4-5EHQ*:AJR!_)R\E"W]#5[T=_*>V_(U%_0MS?)+RRCS
MMZ:IFU;@(%\S/!>9@>>J"CG_[T5+^$^<+2NTDD4;"/>36L!YX7#Q,*D4X\MD
M(Z6Q]KGR3\MZX26,O%[/]@BSE0B+DQQ4\7^F(5'$H']I15-*RR.SU8I9(^MT
M]2=:Q#97TR<2L+BK65_DY@OX_4<23>,<I;30*LT:N,66CM3 \_5 0SHIN"(E
MZXJ%+),<$(.#%KB]3'J%[2#@1;78MP=,%WJ7@/:#\J/T .J*H,N74!35$&MB
MS\7E!?#,1;@MP*RAV"IWC4"/_$QJ)24??HWOZ:63%'N8I@845:*UWIGT SP/
MG#$IFT(,G#TDI/*FJE','U"^//9O*'LJ(?3FDH8?01/'OO2#6M (\2) 8NK^
M&R@@U]-+X28RBO(YI!@YHX.@@T19+CFRY*-9]J*:/IVF*=Q=%#"3>"5'^;2)
M=E5V+,/1=</0-1UCUS:=P ,X(]7T<+LU0:&E61*C= Y% B] UCC,<\ BC@!A
M:1(3MR>:21A<H)ET00(EP %9,?J(<B2=%PI]0<KFSVAJ^*8# ?B?%KMZI=OC
M.^D'PC+K)Q6\K=K#"&G=VH34K74B<NEZD2O&6TL2SGY\44X:\T"FH12;YMJY
M:P80S"'9,L%5)WW6% Q.C2T'JB.;EBSD9-N0<4]"0MWF"*5@%9 'H1K @""=
MX(;XS/'*;\D.\..5/V1CD"YX2UII7,#%&*9O=D0,$SP.M#E9XKF7[M/D6_Y0
M_7P"=@K3L5$?G9;"T[7=,A^U;H1EPJ:Z[,4+UH^ONI 8I_+B-6.MKJRB"/"+
MCM7*W#9M[(GTPREE  0(/[YKN2@VJ!(DV[>1J_FZJWB!#AZD[2JR$SB&C!Q7
M=E6#[7+5%TLUJ/-\"FB[3])90ULZAF<[R+ 4<"]T[")$VD4X0+KC6!HRVM0U
M?J* 'S7P3%^V.\=ZV(6$3R:V%VO19?%IBRGMG2NK$T0L"_#EDJ': :\'*2^W
MI=VL(RGIM#"&V\[E"QJ6OO?#- MCG#7CMD!3#<4SS<!W7%TSD8T#$ZE:0$XZ
M],W@-=7^K7>@#EC ^X;16>51_5IX5+L!4?76XJ7E.YO;F2'B1]@PL:7(NH8P
M0N1$=W*>JF,I+NYU.W.[G:K=%.]U%F)TN+@$\4KP3%Q 2LZ>6P!8"O=ID ]J
MGN1I(1*>9D5, 7-0-%-8L<\6PA+RKFA&7OXMA%<30,8PWH2$"8]A1F.)&,5>
MB"(2@I#M1[1^)H=8 :5^)I$]0J&_;FU.^P&MRL85RPR;;Z_>+%3='334'J"Q
M4=J4AK+9 P1&%7JD'U8L^BR$:\"$'\LL?"><>,F<D=$]54"!ZSBN9;KDT%L=
MVQ <*1[&JJEBE]3<J_TKH'54JRWQM[#TT"4$2!ZG0QEIO7K 3#J'5#N@"6B8
M[^&8B *ZOP>E1_X:%V4/CZ1<JL+S8U(E-4AI54;+(P!S=)& )FT"DEN'N[/J
MCKD '4DN(LIN.H%;R4\12;5G*")IRM"KW['P\"*1 G?!-XW"C%^C!- 'ZHXH
MY*I @R0J_U1*R#E--\)-RR)R/76CT#N/$K3034EVR)F_@>N11I6.;SNRY1J*
MZ9F!BTSDK9(04Y/?2-,X++[[(LL@)C[V8!JCK,B9@/^#Z5_-1C?Q=.PG>7GA
MF_?6D6YK1YJN'2FDL\3BZ-^35668EK]-8RQI<M$$Y^3_<@6NLB$#4)$]H+0
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MNX8_:0S>K'E_TE)\3UW#6\ZB%V&4TFSLP^+6QD+/+NUM+"=JKM-7/'S%2R8
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M4AAFY+HR1G>)CV:,J;B^#V*NP^S&6<QD!NOO?XBI1B7IM!\!-/_&=%\9E3W
M$TCE R;K:F2]E&9[LFGZ&!+3,4[(AC,:1,;':IFDN51)_5%:]."<9TL;JR ^
M62$BYG]5D'K[F5KL"5R.P+/WRJ6WIDO!6G3?4RX,9D*DK%Z?LF(-))\I=>10
M8>21,W7_*+(M45)4>-2RU&D,D))UV-(.E+E5#\(^*E11 CR5W)0L.)*2F*/2
MSRK=QHPXPH5/T\CM/$G-T@N^01Q*7+(3Z4N4E^>U@A] JJGRHASSB,K]8^A/
M%\X2+E::BC>1.IQ2 Y"K Z([(GP,%."<ZI8[<@%@AEY HG^Z=H6)7*!H]D>Y
MUDESD7Y(2C^!F!DY,Y;@I5K,<5$&2B4@00M=I(871F$ $A*%7^%7,MJ'*E&4
M?0/<)M_@XXGTL; DJ&(8'9&/ U)Z$,9']-FUC]#S =&@9)7NWP41(W&@CQ:<
M&0);/Z%',@,*_*E'5B5H, .#(%_EF%!?N"4$WV2ESJ/ZKU!V9#T;8HZJ\JAI
M,LIB2\K^L#A8GKP. )K2;<X-G* QD>OBBOJU])!HJIXH&JKQ@9)Z"+.W9 DP
M^1:?S(T_?5H!(OJBZ@9:^QN%>0Y$+SR>>.P%[57] QT+37O.Z+I.F-<GTV?3
M275&-5FB!W#.$J(,P6TGB^E9?2%1WR%8U03>6MZT/$A"?;J,?+7^2RM$()N2
MLY@+QSXB 5$I2/7Z%!EMG8 MBM!J?5X17Y0HI>4,9TM3#*$DC)B6_= BZ)#L
M*E_0!_.26Y)H+82D^=[.PTKC1.LD)4\X6<7 C:4#FFH')5%DCK/B&!6Z)DPT
M"O)F99T4F?0QT99$5.K:HWJQ<Q[4$0" K^HGI%8!]. D0AYV$U)V1;H!D@K
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MBF+N72091=GOJLCD/*/685#<'6F:)2BC1\V!A%S&4FV+E1X"3([XECGUPJ=
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MSNZ>MDEP+$X=QSVB9)%*=?@=9KFEB(A(5UQ!Z_WR7JUP1[,A:B4\US1Z)KN
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MULO;8O9+B?!Z=:6&I;L9ILUQP\:)7<BZ3S(-;T]AZ^+><9[]U_R:?N.B%.0
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M1/Z6Q#]W/:>CT5,(9YJ3;B;W7+^Z;E[/*PSE4^2-EPPQ6B-T<8BYABQ^)-I
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M@T'P;J?8%#_C4@0QEN1-\ABA42GU%'(D@,Y.']0-==3B48:H>4QQ4-%N/AF
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MY;]C$=WC^.67'.XPR'*=Y )P!VU'[/\"KD1R*JP=N<>H>8[FV]WP?'#KL:B
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MD3O2A5)QU:5N,%&6PJO@F3*/(1  ^;[T75F:1SD\WF.U(B'+0^ZN7DHEPPV
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M+*;9@FNK5DM'#/>.AR5&BQ*R2V;+3DEG8!33?/QIH9E*T<B4JXH>,"*>E(:
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M8]0.ELRL,)N!&X1KGS 7UI?(.!X^QP?3V\\9D3:&,H+=,S\@\$(IQB4!Y9L
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MU44W1K'D9W&PUN<H\AK6)]2_N+B3* $-"2Q&_ 2*[O.GDU'#X): /8A;!F_
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MJF>C9(Z5(W+YT0/&D] UIFPVI<)G J(GYM$EF(0B>WCYB>3%^S,D .IP<59
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M-=9&M0E]&^'$(2XC=3+B@N/3SRZ//EH?%"=3%=3/V&W?!!NTF^W6[HV'@Z6
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M9;%AW8'D#64#:!KID4X7,;8DA<<&.-F9YM5&$_C'L:7SE[@CE5HLLK9(<C6
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MZLQ\+9_%N%J#RCD1^N6BB'DD(1A"-9.LI"*Y-GZ/S%IN:Y'Y080R MM(*"R
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MT\69;!8GPCDP"'R3=G+C3X;XQ@?D55"#TG5Y _VP_UTF&]A)9V!9.!C]/?A
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M$Z0N?$:<1BT),MN%V_Q&1?3'E 77)X* OT\+"(WZD2;O6Q5=X,0//1V+FBS
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M;CZ%7ZAZ=)YUK2)'N%&NAI-- ODS< QI31RJ(%*B$'1]BHR:+M-CK6I[0W,
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M*3/Z;@JTEK!:*A*#\H,QQ#A';@9' L_4-:O7[M2U[)N5>2NVIA,=1TD!L7C
M@<=&8!K<-3JUG ^)SU@"K^(DK''">"@ ":?6B3*MCK8#*[01E[UGBY'MLL[F
MEQN?WOQK;E%5S,ZDI:JFO9+4>,XV-.-\M.3T\$3!+=C(7>[VO)' +*]'ENZO
MIXZ@#%#1VF8N?+. I>[2TR)NJ _<-%$T_.@0B'%P0FSUF->L*B1PA,.#)20
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M=#R\Q'06+\MHZ2TB<U*8>J?9',@':"L&ZK;"!%NYXXTW<WZ%6!^9688+]5%
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MW?L\ &8H+!HG'\"F8I]LUV,B6(-)(),/I.$-?2F$!%YR/'4NT/].H+"$D;H
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MG\QH:U%3I:22[^25!E()2_0Z?:,/[$?_SOVHP9EGM;[#KSNCW, 8V"-O'8%
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M/I%H+#8%O'GMP *12,JH?(CHB9^U-[+GI70]/\(F!.H2KEA_"?5Z@X]G&,M
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MR/\O<FQCX!]QE%))O8SC0-9^2M'5)(M4TI^XFJ1/C_1*2V8;@L7I9\^QS Y
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MH/!:!L^+7@D!"BX<#01RGHI),=_/D:'A6!<)/H72)\N)R%+177V)RR/@$*V
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M&4S+*D3WIS=UB\M@6E4A9UKI;K4#=7O+8%I36&K8QK#-_I3!/,5V;5D9C/P
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M(5A,PPAN(42E*3!24JEBE>^+JG14[ ^KT5M,&%9X-$GYVK^F5;PP4@L4;(N
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M!D/#AH:?9S*83 9#PWM.PX/.?C7(-31L:'B)AGN=[7:M,\'?1Y_1Z5*-OXD
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MGY.X#J,T2W*))Y?P\CT5V#S\*:G+*?>%N$1=/"V5<=BO&:>9WO!BCXK'%2O
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M8@$S)3]@&7>%><H.>(5<TX+3^(O"^:G=AFI(6M'.;PO,<<S1TBH/Z.'7!:W
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MP[UN?R%XT!>">E- GW?DV=\KYIY?9?U!@FBYX#M3WR,01R!> &(<@;A%(*:
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M3P5#SA*=2@V,L0(1Z)1V*6ZSQ2B2/<3$9O/3J[3T"Z&]X$Y][<;^VC%F/=9
M((,'L84#S07T<EH(1K26&D.MD9?2*32<IC6Y ,V-Y& ]SKHW0"":Z)&/GLY'
MDDDD"0; 2$T\]PCI(&!: <V MJS-4F3">Q2LN1P@&M9/'\01"N5"_;%;DT<^
M&@)=, 0J<)G53=:!"U!&<H10RC CE& OI#G%@/,4""U:'<^!48_"[C4-B09U
MY*.G\Y'T-K- QBC* .$""2$!-,PA+;'5KJ9%7G.S.FBTHC?,BIXF)5V-LH+>
M1FDRF#40&6F_H,(;'DWK=:/-&DR"T$GFS--!F*V[.[1[ZJH_5H-#IW)W/*>,
MFI[:V%H D7(40,(QT=C9U#I+./.2/6VSEPCJ =2]_@?1VHZLU0QK:88YQA)!
M01"Q/+3M1 C0U')D(%1M]MN&N,?)AGNRUM=;I%-F>8W0G_4*,]5HUB1SW]QP
MTJ:Y'B?^M%RFU[F)/W5S?Z<>Q^N:U#KKJ+3&A5:BQ*.;<L8AF!KN,+,(DS93
MZZ#H(=ZQLMTXLRMR\&9QL*:&"*,1-9)Y?<5(SC"V$E*C4JM)J^U(&.@ANF9C
M($[Q:F&*5XSXOV[;Z<&T/&N18,Y!B@!!*1?:P=0)9HBFV''=:L<RW . ;K:%
M%#GHM7,01L1JZQQ51!$$J108"H1TRK2@'(%6L^>]R);="\1M;92_K8;C*W0B
M=,?:Z(XMT7U+H;9WH>,L-!I%1&E#C),B)09HRW6P(ES=0*+&9#>1H <Z6+@3
M4P B6[V4K4B*E= 2*(TPD4)HC:$SE@@"$/1Z<8L"G;)0JM*]H,'6FMO--+QZ
MI F^'A\,\W$V"2/E#D(C+I>/OZBQ.QV'*H\3EX7V7.K<+= @LA!IS5)$F260
M @F U(9JBQ4P4-X7M_K7S9OM_NCG__(,4.RQ'KA3-^R/LJ/1V.4 (EK=^;.[
MU"Z[2;YXD7SIC'K?H0?)MX6-X!0 DFHH%:!>S]:2V10CQ!V7VCERWP#+-6\$
MV/%7K>'B6R\D5^6-PS-,E^;)+*S-<]<XNFO6+K#68&PND&D@XGH1Y90FW!J@
MH"4:&JFD,I8KC2F4#-Z7,=(85SQ3:<2DQV'W)L)&AT_DP:?S( +>TDHI=@1B
MPCB2)(4:@Y0ZZA2HR[]N5D0OR8._NVQD57[Q4]D4$_VRV>SWZKQ%+>A4Q+(T
M!=0Q(3D1R@A$J<2(*T<MD>X^C^7RE N75:C0&C5+B"5S *6$*N0E4Q"A A)*
MA$"8$5NC8C]1AC:_"W6BL]LJ9?2!=,0'\J@X2Y6TUJ0I8@X18IUF*B5IRB$W
MR%E^7]/_9MCAN0%$VL/KGGD4G9"1 1MA0"V@E5XD8VD 4<IYP1Q:?"@+I45>
M,K4JE9_KKA0]!+L7P8_NRN7BCPOU2CV_@CR?I0Q5F<[1__1Z;-] !;,ZBX6B
MBGH'E*&(I=PAFQ+"F5.$(FL(<D!8B6";:4.0]BCIGM"/3J3(2,]@)"J-,@9:
MC*3P=CF4@@J22LRI% S?:XLWXH[MR0X6\6]S?5(Y5["%48-SD7[I!?>Y.G>>
M(/0XUB+%2H;&2S /1VJ8?\Q&E^_5\.MB\1'0UCK)J"*2:&^U,&X8\V(?&BAT
M7;.CQE0"*CV4;<CLXUA[%#FV(QRK(9#8($D5=L0**8"!$!D+"5$*W)MDTA#'
M"K*-U8*;Y$UH<LQQK#%ZE;9.387$8O(6<ARE2G*%"1&"*$>HX1Y?:&@#3D6;
M7H(>):)'6?><D]%1$)EG&>9Q7AQ;Q*%+E2:*&&&PI=II#JP3LM4T9-@C O08
MBMZ!S<H5.1V/S->+T<!KIWDU C=Q_Y[TQ]=Q<.*Z<:5K6]()^=.U38ET\@K,
MGH9Z0HTN+T=AN+B'W%[RA\?B_^'#!3R?J.PX*]/2_DL-)N[$9:<7*EO,3 LM
M/W#*,7,($6Z1A$* U%D@C+".+1<3((N2?R[XP0O2[)[V%)@*9*6T*9+ ZR]*
M(Z:-HQ#H%#/DE@L1/NLIP(Y7?)9)E5-9H-")^R59^L&+I\QW)^.+4>;)P2XV
MDE7 /X$E5'!()'72TC351$#(M6!JN4:R:/&!0=/']L#JN4D1U@9H;!6Q"@LH
M4L7"D,84"&F6F\_TK-5C 'J@_&^)0\N+1TC4[!EZ3SV\X\DX'ZMA\/TL,IT&
M&&)&&-2& .9U;J>HE"9DA(;)>.T]_Q.7?Y#GDQLG)["DTG'LC$L)U=SSEX80
M4DY3Z<WM^S+W&E@Y)*"'L>RQVAR@VR?GM[R9HU).4*TX@]@ZXBE5&9MB2KB$
MVI]@JCK#:'>."CGN%)8>QJ''1& 4]5RG_#D9ZUD/+C>TZ7E'A7E/(M$3J*[E
M]#U,UB_67QS<:'X2B1HG'SRQA2RR!,->$BBJ^-#M5T4O\9>Y<OZJW]S@.CH&
M7Y]O8X$G"D5A,?4A)0(P[+F9, *Y$E11X+S2H+'T(K3-B8 >N#;;M1%YYW7S
MCB1(2<I3"Q4C2!,E/1-I2:#&7AT0]R4+-]/7N'M#"[;6+=C0Z#]K^^&<U,#;
M/'WK;YB8LH-V= MVQ=VSPJ$H,VHX\<1P,*R:J2^@S:(5GPH*L"02*4PXUPHQ
MI+5*H<-*2E+CBVAP-@$"N,=Y]^ FNE C3[V IQ30UF^1<C"TV91,,(DPM4!#
M29%RN,V.@3U > _1[JF_T=W\V/3>R>6D& N=C,87WL8VH\NKS%VX8>Z-ZV0P
MRF/BS;J!IQ4;X<VC(\ZFA'$<Z&)OD2S*P6>'GC:.W/@X/5,_%CV^*0.26&4%
M@,1"H4++,\FLLS3E$BSG-WP AO)BK]\]C$>TAV3WP.AA>Z+)TWT;F38R[1.8
M%CMIB@[=B(4T7>>U<H2TD!J&SL/ZQ0,"EF%:[+4(N&E3P]IDV@TK0UJ%CF)=
MVC?]6($4ZQD:A,TO;JSZ0V?W53;T1Y\O$-R'DMX6 [J2,.="8!1HPHR2&!&C
M#1?868'<?3WR&D5*#GB/XC6G4393Y[ I2D^$A0@+#\$"YEYW(IA#*B3AT@FM
MO(K$-4BELA0OESSP0EB0C'NS9RL*%C=+K=J,N4T'HV$_+S,+:Y.YH\FXC2;C
MPQBWF-J_7U#!8BM#IXT1F'L[4! !J':IAABE5E(AH&JWSHIPV .;/H0F\M!K
MYR$D($T!"A56F@B.=$BQL)H3"9VCNF:82H/E5H"('N#=F_NPYKR*5KT@4.Q
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MG="('MV_+F"E'4W">*$GG?5+S^P/31_"LY!W'4^^=!.QW:%]T-4M *1"&$2
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M$HJD1D*,4P53C6J2#=MH54Y8C[--2X.*&8?;R*2/5@&M@TLMUM:"%!% +(%
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M$R*P8-((3A!A@J5"22L\$A+ 4_%$*P@]RWD$L>Q)V;%QI-&!'-EZ8]F:<@4
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M4B07SLB8EO6(YW]?^B0'N7(]]%;W3DE*8Y\ _"" _XLNKWD=OQ K&BY9:[2
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MN8T>Z['7@!\I1_NWS"+HIR?H7U_T\>-H/)DVE_C6WB^[MFZM_G>\_'W5R+L
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M7LJ_PK%PW#>.*0=C&KDFZ018.J<W&(6QD"53\^8EHS,L 0O3PO0AF=8U!Q=
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M4_\JO7<[.L /V^,6JH5JH?J6ZF!J#48Q(SI(D2/;4L#6@C7IC!L?GS_W&K'
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MW:I"?.B#W>,9H,6*A9>SV367U7VIX+E4E4QQ""7K5&LUT<=NYPM16>?_'.I
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M#LEE/\S/INGEAT&W^67*MYYVMW9#<M>GF".X/T4PZP2#URBD;BAC105U^6I
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MQ]++(.">'KB%"AN??36J!?HMNH?*G(%UU &!]Y.ZT\/VLX;AZ/85"+@"[J'
M]:$6GTA!#19LBM&ZHI0BZ]$Y"FNFCW>0H8LA#*/L"3KK_>$_3R>9N<P&=3IY
M-YA?\&#6)*<OD47?0M(>Z+D#-$_=RLCW340ZK?9\7'ZD>:?8/KRJ7U9YJ_-?
M.3@;$Z14,K@<D_+69.<PH(MEW?S7;@(,UWP5V[_A$4F,"7+;1LY&#L&9C) L
M9 RDP3KVVG-R):V;<=Y!:!"C&48CP EPIP]<5*49-.L;>!4R:XS: QKO$@6
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M$,6"(>H'DF(<AP(P05^;&V60%(.D&"1%FZ3@@/J1EA.8$8)HX),(QRPDB),
MA: 5N^"BO3)[D12E[:;_89ILS%\-NA!C;:[8L=S7%M,LG9;[7GU3C:<DAN(1
M*T]J3E@H V[<W=[Z^>U_FG7^@?SGW^R_Q6:8N:R_?\KNU%N>*?;G6Q;KMW_'
MQH_L*3>T>Y]5%Q7SL0OK^69QJ\7W_06_E=_YWWOWRO!D:4-7BU]P8>N^5#\U
M5_6-][<?FN/=.HG]+V+QQ6,Y$9Z.I5Z1FX\?;CY[M_]]_>G7ZW?O?_MR\^[Z
ME\\C[^;#NZL3CNK=QP^?/_YR\]/UE_<_>9^_Z']^??_ARV?OX\_>N^O/_^W]
M_,O'WS^?<'Q_N9EXL_MTGK.)S/^ZO*<\:VZSY30]E/&XY.C_>F,\ROJSX=7J
MLQ%[_XH5%Y'^'X1AB  />10QQ"G!$,LPCOB;_4AP;UT>K1)MDQ7>='?VM/FA
M=GEQ.I]2>SZ>V^>P0_OQ7_R:G1[:S>MV0'+_'RW#O/<34X[XDQ(6GMZ#P>CP
M!V*K!_.(;DJG73\*;8$+(2WC#.HS'0V;VVUSR;"YE[NYN,^;NY<3H!=5-Y_G
MT^G8 EVSL2>37(S3?)[IAYCV?B;\%(_31R^9%#:M-E6_V[/VLW>2/HK?Z!@2
M8%B9U[<RYX2,'I!]""#;H$KELP$3_<R]R+W([JFHZ583TP>UU!<%X1AA)O7_
M"<048!$4(0><AD2%E!P(5''%_4M'!/>O/&A @1YX\B0\":,P@H@Q!N,0":0(
MYF%$@BCBR" EMF6^[[]HCXY""@:>''ARX$G;C11C$$3<%S26*& ^B8A$(1'(
M-#Z*R9%P#4<^[%]]WL7B=^Q+DQ?I@_)F[)LZ18>C_A467Y:4.D'"1T%17PQ!
MK0LJ)9B2OH\! B%"$A$<:JV>0(J$-'FB1U+H?71BA, ^I7@-;/GJV9)PYLN8
M<*T6"!1*RK$0*(:*0ZRU" Q?!=3YP),#3_:()U$LXM"/ 28P1+X*& ="&<@^
M0B43H(4G]Z'37QA/GI-K_N"A0;V+;VUX,)E\U6:DQ0^?R%8T\7T'#,_.67%R
M?*&^+4DOSL"^+<I )P.=#'0R..3VZ)#[9#;S;1J_G>?*8WFN9OKLYC.63)0T
M"+NJ!&I;M$*LVR,>M@O(8)*\!I/$DM_'^+=<71O:^UA2WLVD @C\.<T^3E7&
MC/IH^RS5C9>:@($QCY0?28H10-('5!G@#4DIL)&)XP#P!F@48'+>]LO P ,#
MGX*!8XI@Z/M4LZ9 *M!L*Y7D,<%8*<)\.3@$!^8=F+>GS*MYE,;*L*%"" 8Q
ME4&()(U#'BNL4 O\RN Y/&O/X7XLC^L'/3:#5R5$-C<-UK6!(=@T,9Y$XR><
MLIEIT*Z^3=5$)C/C57SM7L++$GA'3&FRK5P_I),"'<+2V/5$WEH*>]\@L";B
MK@JT=.(Q8U0@KCCQPXA@)BBF+$)$'<6F@*, 1+T3;(/K;6#2?C IC\(@#@16
MDH8HA(0*DR>L;8;0CT6,6P V#]$Q<(1 _^S^@4D')NT'DP:04Q#&E"J,44@"
MSBDD?AQ$/-2?PA8F/4"V<#"BY,1-T(?@Q$M)\':>:3LT+]()IEFJ3='9T\B;
MCIDV#(R-8'!OIR;[P'0%',]E$;,8IY.[MS.5/7@IUX.V)<E#J.*B)-Y)D.6L
MM&L*N9N)F&>9DC_.9Q_2V?\H6RK1D'Q"RSTB0QX%$""((!<$2R2P5(2AF!PH
M+G%AGI&!4P=./3BGPHCXF/,P8KZ/M#JON4\PY2.. ?##-@CI Q@2< 3#_E7^
M#LPZ,&N_F#6(S"$:,B8C@N+8YSYD""N$8A\S'[9$"X> PQ!PV$&'/RD^NYGD
MLVQN[(FJ]M7TI_P\T_^1MRHS8%;L3C4+64(.1.0CQ8((P1"3* AB$<I Q5)1
MVE((:]6Z?RR_[/I;DO_C73JQB\S'ZK.:)&FF25_E?@#"\LV_6MS#9=*%3=(-
M:\I]"[:>,_Z5?NH:]7K3XCUFR-5(]&*:H6@BFIEZS4Q;6<F4C;TDSTW()E-C
MLS3>+/72>;; 9C3SU /CLSI][&_F#C81:@CA7-)Y<8*J=,L6-Y;^@F:X)H(!
MT]R' (Y,L2<)?>13ID@00RC0<2H]$:0C. 1L!I8<6%*S)$,02H:8YL4(21E1
M0)"D^H.B NK3X;4F=0W<.'#C\;DQYHIH794&*A((8DP"&7/@8^5CZD,L7JO1
M-(1@CFTT^3''+)8D#!5 RH^H0"0F,@Z5I)%L,]]?:#0%S[68P',MIG7XCI=8
M2WHJR>1NGN3W+[*9AHC5)9T$)W"M66;XI.3<_MB,2RD%:.0C$8@0(6J.!A]#
M!A%5%("VC-U#Y+;A<!32P=\],.7 E-:7" (_C@#'OA2(2\@BK$0D35$;"?W7
M:RX-_#CPXRGXD3(D) Q\%<02\5!;20&6/HT#3 D@N,6C^#H,)I<HTW\N=?Q;
M[5'6_E7;N/?5S>^S4J;N)'W0:_9DH&BLRGZU8T1;!GD>S0OIT+SP%30O_/#Q
MR_O/WI>/WE(7PY]O/EQ_>'=S_4NCG^%.>B]$SP=M<&>)6!&<'[,[-DG^9;,K
MM1UNNP'9#S^R/,D_QK>9RHWM;[^:Y\E$Y?E/*A=9,C5?74_DM>; ^<38QK?Z
M9I&H_(M>H1_'J?BSD,/FXS](% >((ZX4HTA&/O6!$CCFF +&H[ % 'S-6-%O
M95.S =F\K-M))G,EKV?E*U#$(0H8541&"#&BGTU]RA$B0<0@ ,&;+3NYCWZ!
MK?L87'G--;8)KY_U*Y-8"^W)S%LLGU>MWX(GEG;.;F0Y[>)9]>KNGKK#>H%#
MKA<H#O5E:OW;R@0[S!BXS!B^V<XL2PQB=^NIC=8!#ZAI-@RBD".! JI?)%D$
M%1&$,OP<PWP7K5-M2L0DH#*,.)(0$@*%"!GV>02,(^ TM&YEALGR;DJ-C=2\
MQ]V&+KN-WFQYX^X%=MB5W1REAV3.]B6EN<$Q+]NT!7^MZ MK"[_'K4 N6Q%V
MV8JU595)/AVS)T-L:EW(;%C^/^;Y+(F?5CSR,-J+^WW3GOH.>WHSL2YG4<LB
M5:,QLK%^B?[">-9S[U$MZBEF]X6J;&NU-8/>I!/-J;?W3-LL0LVM :'?<3,1
M5]Y?C,T"_.\?E?TC^'[DE=_,\_(;+\VJ[_18RB__:L\V\Z:EL6E1,!\7;S7C
M?F!_I%DR>WJ;/AIP*A;'R3C1%XZ\ZS^%8MZ7>Z5M$#ND<D C8Z2(>S,?8V,5
MU2%-CSNZTM=Y_V<^?C*?</4D8QB,E1F"7OQ$&W%F?:9SKL6V'DRLEW-R-S(S
MN;G]>*7/Y(E0Q9W69L/?Y^:'D1VT&6N6WR=3[Y[E7F;\^GK1L_3!JWAKJW7Z
M:S*Q<ZY"*Q^KQRTB*S\^W;),_]E,D!0AB( F>Q8C%"'%_3#F,M8:E(RDSX)-
M$9;ZZ3:X8F?47%2]I$5(Y1^?S#SL17J R</\87^AEFB]E+**M>R5&4P YH!;
M$$D<!PJ$!&"%*-1"1S!]I(N(0$U_85L^DO,6L&_[W0*,C[,%5][U;*FALPV"
M:;XI]V6)?1XU^[#I-$OU9#73:XX]Q+:Q" O-X)@3K8#I]>/2IPS$B &]H4"V
MH""_;-OVLCWK"6;5]EQYORLM-N.Q$C.OB"+F1N8M2R(M3PLY5_[2>@8D$RN0
M]8.3M)3-!1!@*L0\RZ^\G[7\4]^8D90C(V'+UU9"4V06+'#MY8_W:E)<+E3R
M55^]I<[TLSYEC'.NN/)G+34_SWF>R(1E3_KUOR1ZSKGZ&/^4S>\:FVA"R<H7
M"'" $*" "D$B/P8REAARUF8Q!O[F\!98\MPMLFRC[7+LBJYOD^:,L9EC;B>V
MV A]X#R8KV?:'/"8Z8SR9*L:#2:*6?K<GCUFLIZ6XN5-Z:->O7EN+[J--1MF
M]?%376Q>\'_?O;]^>_WA[[=??H%O?_E/_:@?/GW3'*;_K38YUELTN_?^.6>9
M9A9SEUF)*V^OW*Z74S];2UT[(55L]BR9C?4L2HW@0SHQ.Y.E>I6T55NW?=3#
MK(]7HT/HS\9MZX%1+<+W-])2"S./^LXSI0F),![#[8;W:/_CT$>4V=G8;(U>
MN$9[W=4< K88C[G#?%5 ;I>5L<7B71U5F0]=E/GHG/T&D<N,\;89UX;% 0SN
M-<]2Y:+3U&U1V9\.L4;898U(CZVT0Q,5<5DPVN,%*\S:WZV!F6;3-+."3,NH
M=_JU6GI-$GVP:9.,Z:7*GO3U(R^@A%H[3:_$'_-)<7 \)OK ,I+.6EI6GT@+
MDC8*B%85M6(Y9H_ZF/6J]]B%U\)PFB5CS_C9K+;TJ(\8;W%KG;6E%4PM7J7Z
MJL:I-M[F>F+FY*I4.D];DUKR:X[Q#..8U@:S)+>'[DR)^TDZ3N^>[*B;]F9H
MAUHH4M(.WV@[A3UXDV^TJ_5 MIC=AZ [ZN0F]\]9?@>^TYR#'9[?]TS3].0N
MUV:'56>W.'\EPSQF-#1=B!F6G(.84NAC$L3<WX_S%] 0:A,41 %$&$J"4:10
M"$+D0Q"&;*OS]Y#'D?'_"GL._92,YT8D?% SK^P6J&T0SZ[=,1S"@5/$(P!;
M_9 [E]UAKP[NO#Q_CW+@%,L)8)>];'WEKIM@ST_L=INH8-J)LN@[%:/F:XQZ
MN.UU"MX$VZ,W.W?*87O1P*K/V!67O=P>_MFY+0Y[&?:<5:UR;0(8^A3U^$8.
M]?B3I\>62*.[&H_,+#7 NXU+V6R6)7QN$[<J3T/33W6O3VZ5Y>9!YJ?B0%?R
M+?NJE>0[Y4WF5NM-X_JNTNDUG^4S?=*;%\MY5KV_<#1N4V;W26U.[HD@ZD)M
MK:_<==.:1V20'"V[XK*7N,M>MKYRUTUKOI[>28XOQLO/QF(^+M9#\ZZS6#">
M2,7$O?>D6!%S3O3WE=6[>)ZYKC!NC2/*LZ)!SU4OB95>N3<=SW-[4R&W*I]Y
M[>MN/.LOXS3/_UI[S4N1XGU)ZUFIXH<TJ^:WZUEMTUT$,Y8F:6W[A_EXEDS'
MB9[H\J.7'[LDA\V0*O'I5>*SE);ZD46XNW+CMLA,[]KX.XIHN=VS>[ULC7TL
M(M'K._F5)>-J7L46;-K(V3IAM!XJ^A$R,0%RXWB>W6NYLH5RMF42M TD:4E?
M: 2L3)9 T:M 7["\,\<Z59S<FP'I(HE:7[GKIC6/Z@5F$P5.KM. [G#G?!;W
M2L['ZF.\ZMBQUM"/3^\LY;X;L[PUFU4 HO\7(R)$B+ **0W,1@E):,R1: '#
M?;&31R*?2HDCGP$? 1:1F&,1QHPB D--I$$7>FM=U5TW]=\A_5$+ELW*\LAF
M']1GB'4PQ^EXG#[FWE]L##6=Y_K<TF]0WX2:SAHBD15M+O[ZW0ZR/Y0[R\F3
M"_QM-+*;P!RHLI,#K762.[UN:^[JBU6N]YD>[>0F!UN%SF[:<""H3EZ\]F#
MSKL*_WFAX0@U'D^9-';N?[TQC].?3;54]=F,Y5^!CS@*$0>17K90,2:H4I)
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M@[>/:?C@5S'V]Z;5'93-G;SG<*M\?P;#NK Y.&<V![&*@> Q\GV,4!#24"*
M0GT;"22*Y,#F^V5SJT4EA>V5E*!+=NXFAV/!_K8[!OX^+W^S?&\$056_;32[
MXS+V(F.J,V]#IU@*W!K(?P:7NO V/&?>5@3Y@0P!)IP@I0(:0LX0() ',27A
M*S["&^E_!V#O(F0N[=EMTM.;!_C]<IEE/N<%:,-(FU9L4MM;%M\AR?\<>;/$
M6&$VQ6KA7C>2HJS,%"R_]V+C$S<><O5MJD2I#HA[D^E@G.:LA*RHK+9J--\;
MN7*.V@%TBIW!K?'\9\@"%PF"SEF"8$&DX@1#KBB2'! 5!(+"6(;<IRCV7Z\$
M.8QVP-4X45_KTAW&DW$R>S*,K8T!7N#,]-!'BYT"KKA3P!6Z(9;M)^#:U@*E
MH.*E#B@A>H4.&N@4OX1;<RF>04HN!!B=LVQF I,HI)0@BI",(H9E%./8#UG(
MHH"<EW;W[+#5$B]M0V\'BPS#'DK[?<]WPPN>+U:6PH$;DCF7A$Z_#B"GL#ON
M5)D&G=(+X&$KTWISV+AOI5.\%W>*]T*G>"_<3[SWP,E;$_W4RN%4<+<I.TXF
MVA:]2U.9E[5+15U.Y5LNPXF%5[FH^BXSN9OFXY77$H<LR\SU=;FU/:U3JUV>
M6"BB1763M9W3B?YK2\O,'9C458.=V\4;/RY>>&W:;"E;[/0QKFYO=-F@0:08
M"X.0DA#1F%& % 5A'$4RT%1&GX%;W>RR$3:[;-Q\^'E#GXVWN1*FU\9CFLE<
M3=[\H*EGK<_&AC7T2E]!4LW+F/B+&&^%!I#DS?A 6:IU[&HL[!3^QYW"_] I
M_ \/7JG8&SE]OFTRP- FXT7<YY0P03HE3$"GA EX\%K(SD3XT18)S^Q]%:Y'
MA>JQH1!N"92W.E.; =\"]&-2%N,N51=[#THFPF;RE-@[UO=KS\\']E0@^3WO
MF>9D5_FLSNJI[C+6IKF&C4NU(,T66L'26_6RS$T-L-8<++A,!2ZBYM:&TA?K
M*<NDJ@N^OKVQXU1?V5C3CT5GMG"CA890E1X;K4,?B":#:%P'O5K.-IMF7JWI
ME7=C,YL6F4Z+N9IT\94G6@P6"WVHB3)/*G6FO('I^>IU,T-L/VNOO/_6FE.:
M%>K*J,Z):G'W5[/2E]QEICSN&;OI%< Y&S=D24]C>;63!E?Y:3ES0#]KDLY6
ME]/FU><FPUX]%.M=L.:=(<[Y5*] .0ZC89FR<S,90UWF6:D0\TSOHTG;9_6;
MU#<3QC!%Y(E!G-Q&N'IRY8#SK;0V*K!W'M5"9V5:AWW<I/_$9M7,2,VTCJ3(
M$*=T(-*I$!DZI3W!M4+D#5&P?B@C[COBE+E!.M5WMK=MVXG(W__.43>:$DS'
M;<$LZH.5KV,MZ+5D67!V(>?RF98$UN28;)/*ED&;(LI$0>.Y%L2FM*B4ZDTL
M#7-W:@5/D;0Z>6H*C5JP;2HZSM28E4'0I2<;%;":S--"TBR=!M7%!KA?/>-0
M.!*!.Z4OD$XEK^V-U7;>=?"2U]Z(J^-ES+0W-=MY5Z=X-W&*=Y.SCG?'08Q0
M)#6[28E4P D$"@J?BC F0!!RF3$5N)=2ID/DU#Q["C\MU:'.M,Z=E[[#J=;7
M50]#%L0I9DXZQ<S;^P3NO.O@1<J]D>CNN^D4@":="H7;6_[MO&L_*)<'CEH4
M *S;F=K8O9GZFJC'JB/2(D&N4NF*)2VC&EKQN[.=3;5NUVA34(0T6ITVS9(H
MHX1^95KO-$]8>OZ5]UO=[V 3#-)H94B+L$?944DKQ,DW)5<N6^GRH'ED/HVS
MU #NE)G 1EUN'];JS=-T9BQJHT"O]7$8U7IOK-1*5X<K[WJ+ME^D+:]OSCR?
M5YAU>6*L?I.V:(([YDDKD[ .HE+A7UL8N_!UOXG'PN-5-<]:]J D1=.IQ$ 7
MZ6FV4$RCB^VBA47I+ZE2K.IF8 W_B %"T@>@@<9;\I+8D9NF8;D%1#!DFLY:
M7\W*PKE,3=/,1LRT09&D<AE%H:C4*U$1Z@58F#[UH"N,[-7W',L><0JXDV[-
M[)P"[F@MX-Z6V''NQX]3T)QT"IJW-Y?<>5?_@^:_MG2YR0J_^D.:SVSZ=B'!
MK>]BTYGPNVK FK1TSIGGU;%EGSI._C0X[>41]J!F]ZFLY57EMU9)T:FKE'[V
MYM4G&V]J=;T6:U4(^*% JS>";_,YX#&/)Q.6/17BK8!BV3R\,DT@+\N.E\]K
M>T=RGZ:VA6+9(;Q]R':Q:FG7,JQ-TD[+96$\VLT,V7KR6MK:9-KE5Y83^]5,
MRF*]CAK>IMH39#=[?<_J=YBDA[&Y,<V6?>^;W[ET^#RP/]+,I/:6R?QMG95:
M//1-UWQU;)D83U)W6YQEZ;@^P*HSF+/<E!II"2>2HO)(F*GH(SS7)YCM%/^-
M/4S':K2UN4,)8J]WTG33]/Y]2YK&;\4!?UM,YE/9?K*1:J&P$4TA$=JL1T@2
M&I @A@%A'$>$5 6W2ZD6^LI&JL4_OFC^^Q@W\!ROOR7Y/Y;0'IL_3F2-]%@#
M/;XO\/AO)K/T9O*3'J1)'M$O ":EY#K7Y/:_:J)W[5?[PW)R1]!,[G@;U;D=
MT5)NA\GKD.FLO/+-#X&_GMFA]WYLEF^=[&W#C,8X"MBDYA>%JC.S^W%[K[?9
M"S27&-XV@9&;CQ\(I(5VE<AE"F]EQ#4*;[ZKI&VYD[C+034B=LM#>[0E*0W:
M+AY1A"3U;^U4O2Q15T?15(RL9[DDY$K):AFR'48UIX:DK9:J=CUGZD$K?J7*
M]AR'\[J .Y(:X)1A0SIEV+2W-=YYUZO.L#F4E]@IW6)[K]MG$(\#R5'_G+W$
MD3ZI8L*4((0C$D4,<"ZB$/D$^0)S>IE>8G3^7N+K\3@5)I9W+DYBZI1I0#ME
M&K0W:=YYU\$ASWLCT-UWTRE+@7;*4FCOK[RS@WG_LQ0^Z$=:>X1M9>K"UUL
M5FU/12^3 :S69Q+Y=C[V(<UL:H/64B>;T@-&A</R3ZUSZJ4PB0MYI1-;G;%
M.=7VFEXR\Q331,0JFH5U&Q=CWY#[U-195YVG=3>2]6R^(M>M\=*R"4GE=G_F
M@FX:5&5K/F^.1]*,J5/^!.V4/]'>$7OG7:\G?\)]-YU2$V@GN.[VKM([[SHX
M7/<^HFTFHJ(F=\R@193M"VT+3.,.DFJJ[/N\(H'7+%K9>3+)9T5'21/@,3Y
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M RCCB$<AB:F/BLRE@77WQ[KOT@(68=Z: WFVW.H4@=W>EOT9?.?"K?2<N17
M6!^MH2\X4(A20; 0F,0B##C!1/*!6_=\T'Z;%NX9XT2QN*;&;Y%,Q#P[6U9U
MBM"'G2+TU"E"KQGJG'F5LY CHAC$88RH8$S2 ,=!'$ <QY&(!U[=+Z_>E'Y(
MX\4\.JKP/AG4*?@==NHN8EC-B4//NK^((#ZG-%8^)Q0Q)7@8 0)B0*14S&?G
ME41S!AQZO0@AF'+VJQYFNQB*=F*$3AD2H5.&1+26(7&!925F99TVI%/</'**
MFT?];[6]A':X'*Q<#5"N0O296L<B2ED4N,U49LK!UI)*1%K$9"NH/_MP$ZTU
M*?\UWM]+HX-KPS.#6!OB<>.#ALB<:+-3%D#DE 40K64!;)#W_9 7QU.W(J>
M:[15O#R' IP()SQG=0LP@#F7 0VB&"D%]611H"2.] \"<#BH6_M5MXR$G5@P
MVB+9HQ38]UIRYDM9(56U6F[2;"JY75;*Y:J6KN?J\8B<8O91IYB]854G#C_K
MJ#V4H1]'TL<^%0C%A/(01$ P%,* QEP-'+Y_#E=U+% 4]:3>8YK]6?-TR<UG
MR[M.$?RH4P3?,*$3[YYU##\.9(RE"E3,(X1CR'!(L!\* H)(X-?<A?'HO%L!
MXU8XL8U>V8O,6!/S7UA9Y^SPC)Q"_5&G4+]A5B<>/^]@OP@( KX@"&D>QX3)
M""LA>1B$H0KA*^ZE=DP>O[Z]J;E[GO>SG9HA="?^Z%3('3FE$42'+.0^RYYJ
M9](^ 0[M$U[&DVYA]*!3 X7(*5\@ZG\#!8,Y,YUGTS0O?-?-HJ'G5.^L>Y\?
MZQ+,NEEV4]:7Y40CCRU:%MW-$VG+%U=PC!I(1"S[<SZU53G,PKRE$ZM\3+,T
M3F8E+Q^IA-&0DA,%=JH&CYP"XM$KP9TWB^NT)YTBEI%3Q!+WOZ9[@0*I>6U[
M%7*!Y;ZQ'K!H=1*;)KJVQ[9I/:&_+5IBVT+#C1+F6.VP#!$XT4ZGX"IV"J[B
MM>!JK_GY>.8S=HH'XD[ [(8"G CGK*'9&0,,4(:0[U.]II"$DD=23SE6?AC@
M"X5F#\\?=.=3#8*9%;T;^VAQ!VXQX:!3N3%VBG[C@Y8;6_.ZSQ9WASUVBPH&
MG4#:L5/\$Y\%2'NVRMD6@'M2V&B/J6=\!2,O-2@.L^3!8J4:W%)OFB8EIJO^
M=@4HMWK2XJ['$IC'(KA_4V)N;;=TL@7.IW&WL06; *TE=&[N<351QH:K+UT!
M0GU\WJBJ=FUK/57;I[4^_^))K4-L=DC2K&<ZG!4/J#.Z5E9R]P0VO;\5<*/H
MWF<A/JK!'4TW=HL"!IT QK%3O!,/';UW[XK39G:")\=.@2W<?WARP^1KWJ\J
M:KG@^%I4%1!DBN7S$L2\0GXN$TJ-9#'IGS6,S1<+X;OXILX+-1)X"=Y+Q5KX
MSJKZ+"-I,QMHL7?80BTM/!Y95KCC<KV#>5Q:\5OAV-;1?!:X.:OO;+;HL*X"
M*],:MR>SP@,X,RALA8-/I$9$5H\V74R3F47Z61]_8L#2[K1@G)10PJ,%J%F)
M]KL(,A6]'\H1UL_2EQ53?ZH0B5NG_,7@!NE]F8\+%&-FKC1N?P/+5.WO@_XU
MF1I([Z?-\&S+R;N+I:L.@24ZJ;#<DF+K3=O4J::0HE7%DEO4PMA-Y@\J2_47
MB]1C<\0:\F@F%/\QEW>+9H!FIQNIRMGBY]S;*-U\!^E6^'=*VK?IT/-LT6%P
M"6W*MO][*MKGQK$M+BRHI^ )V;)NZTQ6@DQK0LFJ7BP5#H!=T55T]5+N5G#V
M-I^@#6-]/I66H)H+5\UBB<CJTL@"?+IDPP;%;5&2YE73FKUN@9D$]#[/3)')
MG591/JAY9I"TGE9:X]B,BA^3]$Y-RE6Y\JYM+."SFLXLX+H'_=%B3>Z9K!E7
M[\Y^!]VD7=N?98%=;G"U6&80P/3*2DT*XW1J78Q+JMZB0'5)N!30X;+87K,7
MS9[*P >^G30K^;ZZJ"1C?4FU^34P_V::,52928L$+^9:3A0R2K"9'OI\ZC%I
M#J6B043L_7NE ;1"^,_SMW>,3;_[5!#^SUGZ4)7.&V3\=_I!J18#[[^5@O?:
MMK]1\@O[UH#XAV',9!Q!3(A$2 :<$PR (H%/(TH#T0+Q[^,*XM^GT-\[Q']-
M689&S4P*^ML-[Q\VX?T-K>COMN/\1U?A&M+_?DFV:AM@!;XPP:E:S;_R]#24
M;2?](=64B&O)L\<AM#F #,1"8W.\QNX4YT2]05Z]0_G^A_;FAP))+S9-+$S+
MUR07\SQO,/4.#K&@K=(4R1U53W9+^P@ZI7U@I[0/_'KP^SOLIUO* .B4,H"=
M4@;P?E(&-AFQG8V>+[8GS7B<VEY_A2O(ZE168ZA<&(OJNG7/QY+A8GHWV3N;
M?>5*O\NQ7!S +9P/.H7SL5,X'V\-YU]*L2MPB^6#3K%\[!3+)_N)Y1^(7=LU
M@[V>[TL/LQ.01OVUB_]=8=F,$[L2[]('K:H:N&*O5&>_\S[?WGSX=/V_UPT$
MMV7EQ'J-BU9K)<9O';LJ*?*HA.F6*  Z)0H0IT0!LI\J[ MVA@*WX#WH5+9,
MG-(4R%F ES>.^F5>;7H&%XQND;MK 6!A&D<KS<)J&/+2A61,2(N';A.%:AQP
MZZ&I\!YMQ]QJ),N7U,,I'IHL6LD*9M(?BWZVUM56>MH6+I_YF@0ZFGKB%A$'
MG2+BQ"DB3O83$;]DH>,6^@:=0M_$*?1-^A[Z[KUV<]N$H+4-!DZCM;B%<$&G
M$"YQ"N&2_81P+]N; =RBN*!3%)<X17%)_Z.X>Y472UK0$@+UBF934DR=<B)*
M3[Z7<J.0Y'4'X2H\6SPKKW275 B#7]&216+;$]MH9%S$)6;);%R'2*OWV%")
M30+5Z[IPOIBH27F%#0\6IE=5:%M.06_A+$OXW!*0B9!,5-'E=CD(;GQ#YE*M
M^Q5:F0V+2C/FF"59T1_%=',ID[Y'WIV:J(R579.E*4(Q36^M;UA5$*2+5K1Y
M.DZ*X%P^T_\4$S#+-2T[?^=7WD<S_L<DUSK?'N9HIU7FQ3\H90*5J6G*DB5:
M+TU8T2BZ6-/$3+2()YE]*QW>M0*J?RI=X;;70.$<YVJ</I8QK*+NI6AN4]R4
M%YB.-GA7A!GMKXNI%-%P$WQ/5TBO4(D?DED9G+PS8=F)60VSV',]B\R&W8^F
MT;JYUT$G]SIQ<J^3P;W^K(UQV4_8R;U.G-SKI.\5>>U*[2=E9*LQFK7 6E(K
MC[3%T,U'#COYR-N[:.^\Z[64O$$W-SGLY"9O;S.]ZRYZ%B5O1>+&ZN$YLPJ'
MZ0Y7?&'5&)NAMI;S90_OJFBUU%36$\,6:6I9DZTK5-C<)+;-YME$_Z$UC^Q.
MF6)L^RTW:5OZV_3MU&1+V79_-IEHX28WU7J/YKM%*F(:&TW0I/D83U=:I(^8
MO.O9H]+JYSRO<[-K9<*HF:F>K)ZP^7"OV'AV[PF6U7G66=YXJ=Z))#-9-_4#
MEA,'K?>LFFN1[+A(B,OK9J^*91-E<Q<?RZ$+S:%:HTH>JGBAGG.JC6RK]9G=
M6-9CE]ZSKGZ5%<=Y&6"TY5?-I/:BWM'Z_V2=9\<JS=%FS><VJ:=(,ALGC"?C
M9/:T])#-#[CR;E8\CJ.5A+Q%O7-6I,_%6KG74S,#3><S@^S=4*[U3O!R!&6I
MCU$*4[,$8_75)%"9',]4[U35-]&\[5[3C-;WA$E=^V:L$34QY%Q-JJ*/>:F'
M&]UZKF^H/:-6B1XM,M__G*2/$UN?K3G$J*IE@LE,/TY:CZ[41*'OU[HZ*Q+S
M4KW^++=@()79P^=/5;BG6NXIFQFL/J/%?S5FP7BTO+]55:GYDNLU;*SCO.S_
MJ,T>E3WDE1&E;S6Y83;7I&*#LM^P7@XQ+_7G92JRNO.RB[GTYQC6FBR%N"N"
MKO)1O\UL!6Q%S-HD,9QC$F&+O1LO4AD?;6='0X%5WV.C]YN<29N!NI3,: H/
M&FERB_S(E82:0E[9V@CU-4GG>7.P97YQM=4+5BRC[]8;;I)<S9+J&V5BQ8@U
M.AHKM%AUFV"Z\KC2FBI'_Y5I,J@?4-\XJK$!BL2?$G"Q^7O1B]0N49DC6LGD
M5B.[L=%E0NVQCF2W "'L%"!L[TV_\Z[7T][X?+%AT( -\S+^<XOIPDXQ7>H4
MTZ7[B>D>,=&K",(^3/7P2E>;%NB)/<6JHZU8N>J\7'5$'0N0'+I%3&&GB&E[
M8_N==ZU%3"\QH0NZ13UAIZAG>V_ZG7>M13U;3[OU-M!]"D1LR A?&)/?50&(
MFT)A^NWJ\]5RC_1%>4I5"V7$0.%R;I@(6AX\)+,R<[. YE0-_W+#1M2?D@JN
MTWC\ZY"&^>*?^EF%T[PP-5<MS5F)".-I<60U>S8IN[/G]4^%K6RECE$.S90:
MX8Z/JU^5U]N:JJK9>Z'C&H.HMHZM)6H4=GVDUM<U<TW6VS*4VO_V.5G#E8WS
M=%-Y7</T;PK4IN:\L$B*ZA8SA&WQ"U:45MGZP*JDQM;8F*$7ED5ECI15-$NA
MJ6KC]+^MNY1,UFJN%DZ50J=?,LXGQB#/-',V+.FT);S#V=@Z.?)[$W.I]F##
M^BS; VVTX,EY5GD@5N=_-#O!+20/.X7DJ5-(GJZ%Y"_RA'*+J<-.,?7VEO8[
M[UJ+J5_,"?7WQ<%1.CL/49+TG16]6DSE<_Z'K14LWY(N.G,UC[_"F]0XU&S=
M-GO(FWF-ORJ9")9(>R84'PKA:*^LQ+(51.:*NDQPV0=\M[8 BW*)A2=NJ7]8
MX:):' E:Y(^3?['UZNWV$:Z]IJ/O<;D.6Y^:>ND>DF\'.0JLPL'T%9EQ^*03
MNQ%I'.=J5CA^*V]>JY,H9P^U0VVIEKB9,FKN*$J'JQ6S:M+ZP;UH,3+5:Z\:
MSJ^I'IS(DJF5#3*;W^D!&X>F7N,[5D!:/MYKM:IR@J7F^7I!I$S,+5K)6JS)
MPK%9;^"M =W[J:(TK>B8+2S+4DUY.LN3O%'*O.)QKK)E,T,63XW*N]6$E4HQ
M2(R-F905](W+CW9RNN4.P$ZY ]0I=X"NY0X\4U!?PGGJEA* .J4$M'>NWWG7
M6DK Q9RGO[(),R914]+7IM_J(9C69T$1)IPHL< '8$6ZUMOBF%B@>]H?2Z2I
M0EK7:;!6]O_'OQ$0X.];38'B90WQKV_:+?1?(KWK*NS58.1#R\(LCL 5&ZLZ
MPVISCTVG>GTKQU=M"Q?/:3;U/#B;(;>T#-0I+:.]Y?S.NYZ5EG&9TA"Y96J@
M3ID:[>W&=]U5M1N_1''X)6-2+?(LFI*P0H\KG 0F3IE,OJ;&FU-?[MD$CIW>
M!://Z<L>IK-%W+\I^Y)\H;^OIRALRQFNJZ$VRKN%.^BH%4K(+>J).D4]-S3K
MWGW;LQ"4+U0.N87'4*?PV(9FTKMO>U:OUK,41#\UO;-5UGQ)"M^5TL+F8)3Y
M,%:HF&";P?N2;3<OTBIJ%\/[WQK)X=;GL$CI:OHCEE.HJM[%^7)&?R,OI/8!
MJ,0Z]DW.2IWG;X=1Z&?C&BBK$DMI5EJ[I1 3;%)"S!?M'%9Z,2]7"6P3E%?>
ME_6,F\(QOS[^I;J$;>.U5O.FA3$95?73GU/$8(#.](V?_VX1 Z]'=4G#T:2T
M6U04=8J*;FA<OONVK7'1"Y?2;M%2U"E:NJ&+]^[;+C=>>EMK4S8;MU87UT.)
M]RPOKRI0Z?/:5&S*7)O8-TX>DL(T;5X^S;38RQ*;GU>'LAJBJ#*CC=!(RBP+
M8QQOP^=<T57OV4HXKZAV-Z-H*JA%:I\=6_W<90]MIN+YI*>.VA^;)OS20?F0
MRK)*;26+LVG!:YU?'Q_&Q6ZWJ0QI+ZW:ZD%:;?123Z3F 6)WW4 FFJ/@P;H)
M+#E9N#B[ND4X@*MQHM7VI8Z7B06[3(MGK-Q?A+27#GF;C6K159=J_NIH==6I
MY:FA7W@V]:LX!YEWG^930__FI)K>L^R!B:=JBGK?TR(+Z*DN@F/)Q&8SJV_"
MX-@VUL_ ,^:KU8M7WK4P5*:W>_RT6)TUGLC_K/9>SZ]<G_*5-5%6RUA?>+1S
MU"UVBSK%;HV<=1+/6Z.W%WZ.NL5T4:>8[H:6Y[MON]RH[L>R1L1DQQHX_=W)
M1TLQT73E]D;0M2B$*1*-%L4PC68 )B&D"L=96=[P3R>3?)X5-]R7(K8.S!5A
M,9/26':HFM7!3Y,1V?[BYC'*ZOSX*BA:'LS-:=;=R4L+;_-3C6MZ*>N^+(=9
M1!T;#59-O<RBIF<5M=CV7YV:_"=;5[,Y=:8,^-F%650->%;56;C5&VK#RD:M
M5PB<0:CW6*+)+8J).D4Q-W1TWWW;4 /]K*UQV=&P4\!S0__NW;?U&F2T5[@^
MGS:!CE=PID5*QC*D>AT?-2GO)T#\"=W"@F&GL."&9MF[;UL+# Z@86O[XK2=
MG<*'&_HL[[PM&!!1GRM;?IMJLWM2QPGST\@*M^!=V"UXU]Y">?=MKZ=HL<..
MND7YPFY1OO8&S+MO.P-HT[*ZWQ9W:I/"MF';<."7ALK$FR_S]F@=%;ULQF2,
M)8,WNGR]18@RK2.R11J3EQ3>-.OFV]!*)BELYK:F[(6I61K&2X7912W*@ZF$
M*&VBU='82=>MZY9ZO+?U@%]IME/WM]ESCZ%M6_ I%;9%3UL">4L!Z\\_FO_=
M=%Z\H!E(J2)Z-Q\_W'Q^^_./;W^I1S#G/WSZIC_I?_?;@*1R,<PRQ>K&,D7W
M&_/I[8.2!62&9BW3G:0Z:$:-L*AQ6?Q[>Q,:DP3_77E6W18$\:F\J=%D)H9&
MO&!,A40(8TZ5#!'E,*1$H0"V-)DA@5\VF2$!@,'>F\Q\%+.T:#%#3(L92Q&[
M.\Q$S0XS6QK+X/6V,G4GF'7V*;@M-4AO*SV#2%D)5C19EZWL5R8:F:F.-_4M
M&[5WOC31[I*UJZ*G3MLL,0NE%MY^3"F* LAYJ,^1 &(2L#@.XM>\S:UM_!8]
MT!HII84KRH(S%DWR%I5TYA%K.WDLS<$M12#LEB(0N*4(!&=4.GV^"!3A@$#Q
M,A9R2]X(NR5O!&[)&\$ \?T"<_W79*Q%N"EV.*W![A9_#KO%GP.W^',P 'H_
M:VN<=K1;H#IP"U0'_8?T_GT=B:]&UEM458HES)JJJ^<:6J/%]DMFQK*N0-NL
M8KTPYJMG/ZS)AW9;?/NK;'Z-U=K%O4D(DDN@DD7M5,N;VN_UN!+,M 2V^3MF
M#O6L3?72?%+"$<Z>&M!I[?$./7F3XU-%AF=9<G=7*+;Y8AA7WN=$#XYE97I/
MO>RFD_%7O>@M(]^X'*DQ<,Q/QGX5IHMRU1/9SNQIM18K4W<&^<ZD'VF%9"*>
M[,I9M\<BXFOCPF49V^;!M%1<E$M:#*B^<5&0VWQPU2G&I$45=;\V;<!49]OK
M2R!*VP]G/CZB?N\6=@Z[A9T#M[!S,(2=G[4U+CL:=0L[!VYAYZ#OX-LK#1Q:
MY(.5?47&B#E63/[DY"XM 63:'++6^B][?Y<V?^/*%4?I-C]1T5NZ%NQ;?#@?
M;%+0Q[C65TMO3GY=WMQPYX 8"2BTQALAB90^W3"*612 ",.(XHBLNW-PW1H:
M'Z0U]+46_N/*F;.Y+734].;<?/BY=N?X2^Z<M[D2QJ7SJ.W+7$W>_#![3-<=
M.ML\8CM:;W]9'%NWYM2Z+A6,O+'($>:1H$1(G_N((4HAI0IKCD"4*ZS\WB[R
MEM[;VUQF+1VW:Y]9FY)D<H^+02R0E.57PQ_/HG/-WU\,%I0F\/*NQMIKT1?&
M2OG:@ D0A)*#@*H $(RUA(0X[.W:XWT2^$2+P%FQ1E8GU6I(DHMQ:I25B9IG
MZ3B]LY#0582@$;,Q0_5L#9/2U]27/RV'P IGLY1*KJB$51;ZNGYG*Z1JOW=2
MN[G7%.9VT5J[MRN!;=6I,D:U7$;1KC+7HKG-,=L4TD<ZRR.WK)VH6]9.>Z_S
MW;?M)VOGLK6SR"UQ)^J6N-/>[7SG;:#_/1KT 6PQT4OK<J&I6>A! TUH&S)M
MTML>BQ8#RT ?IO'31#^T++$R".;)UP*ILN[.55Y3:5_YBA%H4>]7ZE1LVC3;
M*+I>J/8U\Z\W:2OS_.T=8]-="LO[;V7V_+4QYO5"?&'?FO$]X<<A"OP0$X$X
M%"R&2@(2Z\,PY*%L">/2.KY'#Q+?^TD)>SSJ%X"7J"O/C? %_@NTE?UF,%@"
M*S6?6N.Q\)T-QXO0A&5SXNW);5)+&H=W<:@OG]9@TQF]R)$HQ>#5?J?SN\7#
ML1X?N:C!7E_#1Y:7O3:68$V??>Y_J8K15GFC_765<-C*9E='/AG<LNZB;EEW
MP"WK#@Q9=\_:&J<=[99U!]RR[D#?L^YZ%?@K#B@M.90Z3<@O<LO+B+KE90"W
MO RPGR;@%RXMW-($HFYI L M30#T/4U@_UU\2Q27Y>Y.=>5CX=!(9W6G(ZOX
M*]-LRH2IM#[#&[6%MA733&MQ>B&,7K*,%F_ZDGGC4L)4[B^IQDF5-E;]5FI)
MI2UBM* D-Q&Q*L37-%0,((75>>P/\=)SVNP4"_U:1T;;]:Y\Q:FR>*#%%2B'
M_'155?>^T,0IF[\=V+P)?,U8 @F)]7\!]IFF=R0%43ABG%:-0[:9-R4JR,?L
M<Z&F6NMF8<),I"UW_F0C@-J(+.R4LS.*T!87[GAQ''I-"Z;\7I:YS[]>WWY9
M2GHN'+WS1NN#ANI^T%TG$$>A4A A%"/)  G#()8!" &77,8M2:N'-FH72:O4
MS.,VUHN0[6_[ (HV[Y_FNN86MKA,K_\4BM68,]7%^K[K__ON_?7;ZP]_O_WR
M"WS[R_+VZAN+>>RTM(YSQ+KE247=\J2 6YX4>!9.QR4H/FZY3E&W7"?@ENL$
M^I[KU"LSZ?.<CT]N*;EEN$3=,ER 6X8+&#)<GK4U+CN*NV6X +<,%]#_#)=]
M6TJ-U+HE_E]4+;:GU#%KK#R-2O2=7&N$F6+R::%&VN[92MQ/K"M[I V:S"+,
ME!?D98/?ZH(B'Z< H;&/KBVC%FOGF2;.8DI;S9I<KX&VJES,FN=57<%8^0Q0
MH'P<(\P!"R#$DG%(-;%#WF:V^*A28/T(^CTQ6WXUJ:7 ]Y%1>J_'DZ<Q>[@M
M<.;4?&8R$/*;B=BC'KPEMK-"KM:2*8?DK8RI<>TJ61I*^:2LNT _<^6^8ZFZ
MV"US '?+' !NF0/@68T +N#DPF[1?]PM^@_<HO^P[]'_-E6W^.ZQ+!7CZ5CJ
M@5YKJ2/KU*-:#N7'VG6WR![N%MF#;I$]^"PP_$O@1;?H'.X6G8-NT3G8]^C<
MFQ]^MKCIIGC9:$I5$?.#*D$'-\%A77F_%W4J2>ZE0LRSHC79:K4.LUZ\TH=4
MM:!.9NJA0,U=.-I- <BBEF(!M5A*@&,UG,9N\3G<+3X'W>)S\/7$YYXYA;JN
MNLMFN(76MG>>?PX%.1%>X=>:V;*IYBZYG\Y+U=S-12Z O%;*M-\4?17^Z\U/
MGV]__B7)9U_,4/2W:CR>FDC4Y,XF.IO/>MM%]=FLS+^0A+Y/(48L5 @310(
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M,O<SD(K8L6<VJ7JHMZ;^LI_AKJT=Q/#R9<O2&+_K]$?KU(*W#@<,7&/A,!8
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MXQ+'F*5&$)OJ).:.ZM2#P;>1^(\-;(GH,<'WP4=\)$$F&$Z](4R91!(K?,P
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M%<=<=5U3'C/@7"(3DC#*J+8)YR2R8'K 1ZZO-.RQG&X'_@YVOCJL\"%6V0,
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MLZ!K!SX^&+)'ES'T.R;]?,[@CI#!W4GJ7JJTJ9I[%9-;3/@!1C<O7#N$K].
M+%R+C1B:["',<:P?I+ ;A:GZ/U3WAJ$Z/N2>(>^8NT5KAPSW"'O>[D%U;_MI
MCO-AJS1*'(98SK/IQY#U=%, RQCEWL-S;KOEW6'%H9MN;ZEV_<:M.BB$;E(5
M(VZZT72M_-0I(G1B(X$I<T)'J;+2 W]F!+[9;R'.#KH/#"FU7@\1(+34&4D=
MPWKT2.I$H<=7,^X3'L<]I79W"ZN?%"*TQR+8)D-Z/5!BV)Q.J?/>>&:($8[8
M)$IH[&(*'*HGV'>W9OJ)@;+:ENR^ NFJ[6#=H %N.#.JO!R92S #W$I7L4#
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MPGH^JR+#<,&=LM!U8J'+(^M4DEJ.A4K4TG4>6H=.QB,]GX7J4HQ03#(P9X.
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MP<N[_++@VNVPG@]NFN7%+V HE22B2?WF/A]NW-6D%O;"&=U@,,!35W0I+&+
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MQ 9.;&  &XA3ZHV3G!*GF#=:4IXR)5/&HBA59!\FS*[]'2>EX,0-3MQ@)]S
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MJ'.(-0C0.&9$_?HWJQL 0;()@#@;8"D<'A)$=UV93YZ522,E 0B74E-+-@F
MG:4[ZU%-8%"LRY4IF%0PJ6#2J<TNP;4(7@6I0&ANF ^Y.Y,PR?(H5?&4G34>
MS3QE^$_.DZM^PC7F(^T-IG:VR T^>?!!13\?<)6_@G0<J#51!PE@M5/&Y,:
MH*FTG#'.9QV#\=$8WDTV?HR_6C%J3,*#85)R&X%[;QSE- K+'4,1:P-O&G/=
M0[!J1)WO8LH$DDF<I27:XU.66>$\51Q -8VX[B']*I_(&D\BSBK3VSW(F($
M>[;W$%_F1ITO\8CS.V<$?@JJ:#RA]8^M/*/U![P%58A=J$)O0Q6FHHJ*83L^
M]OLS8/C3JUP, '_/+#__/<_D=QE<I)I;1#,+*3A-M=')D<0XJIOY1LQ>Q$WG
M,:S-,:D6@7=P1L@?OGJUNX>^*7BP@>M]ZV7J6J@>F-WVIZ<T[\]J-9 ]>Y2U
M,<&GC\2CN(ZC72,<]0>?8];$\K3Z 8=\-WF<;GZDH;^-OE(\.IQV3S8)U,3T
MX?63QO#=<2RAETS<?Y\.)S%T?A[U?+XD/S@9E;U#1?A3[/S5COZ%IL3)IO%%
M93ATZ-;7_ O%MYSBW^, O83S'4PZ/TVNXNADM/:3PV]_JK2OVF@]-=5OWVVV
M4/WY4/W)J.R7P;!M%+]]_Z!C4'P[BO8<N1FV'5]UXEW7]\X7V\OB2[E]>\XN
M[%;XIS-1O1N$_,]W=Z2UVE_M*34NZN1U & LZJ@5!6\CTY8ZU9 2KEN7)D1!
M=IFFYWVCMK![8??#L[L$JSAW0))3X 35R3F:I#%:N6150VG$1^Q^"4D\!3$*
M8A3$V @Q;(@Q$(B$>@)*&.L0-X*),:D8=5-_A)T1HQ5)-BV[,U; HH!%^\&"
ML&2)M8@/+$%* G\)(@I/I?.<RT. 1>GFW1:(>8E=J!9$@0=^OQ+S%[+TG#IU
M.;6V%J@')9.D+"0/%D+PFBIJHU(452HO>$.3BOTZ78Z(<8]RE9E@72-/?'^B
M39?M"RN?,RLG;XPUFI' +0AI;4HN17 R4L$5'$+C.5KUY)>H\108*#"P3=LI
M3RVSN#E>2F",6L4 Y;MU4CDN5,-5I-9Y28I24-"@H,%^&E!Q:U3@N=("A9C#
M*]82D(8PZ0EMZI%2W" 7HQ2\Q'26I]M058VG/BXZN7?LK)5[Z3'5 OQL:PL*
M)J@@#$32 H H[6R2 ($9'[QF8A/\/%2!^+\L2/G=C)(/I14Q);N2LM:!80D[
M%9[>IJV,T,E18IV3#I052#9:Y\(Q4CH%T%"T^'P<)0>%A?:K1P41"B)L@0A.
M>R\B <^5RM6(K>'>>TDX) 4HZ<_99U(4A0(+!1:V"XYZHJ5GGGL>P5&JI4J.
MT:AEC,:ELW:>%$6AI)-LYT=9-/&>MW_O?*%*@LFI,;2M#FBN>(K!^,B=!>!6
MI^@4T_BC3H 6V D=*'/Z/8@F)$F7"F@=[I4P4N'B+;@XJLBCU%QH;\!*8V@R
MSALKE;/$LD,$E8_H,BE 4("@ ,%FGI((^?J-$51&D,$ZBKA@<Q<6B"3IL\XN
MV3,0M-\(*AA0,& +#*#1VH#L;IWEH+5W"@RQQFOA>5)TDYSQ%KM%"@:T/:&D
M7NZ)O2#CJCU[9YCN_"%V$#HW\V;MG?%2M_;YUV8/E823TX-K6WW.C!,9O M<
M2 Z6@!:6:A<3"U9Q0AKZVQW-7_*^HMYW@_#SG,C?+]'X'ON:F*Z!$D0J#'T1
M# U2&@J$$!\X1,.,)L9&;GF@ ;6H<ZAS<@I,:+_F5/"@X,$V'A3PSC$CC94"
M?-1&B4@$D>"D]E0W-"\[)P]*T1$*)A1,>#8F)(]ZOTV)20TT*"=]3, ))3(%
M+=)Y>U2*CM"6WM<;M7D_8!>.&<?\,/@4QY/J$DYOT/EY-/S[/SH?KI!L;^(4
MUX0O>_._;SI?B(67Y&C]K]=N4!L:L=U5MFZ3_WJGN1X/CW,!J<F2<_?[3W_K
M+;M?'%=&L2"E=" #M5XF$UDBE#.BTR9%%$Y?4K++H64=&-<0P.D[,!;&?^&,
M[X/6H!6#7#W%*:^3--H:[9,-,B9]!FZ:2]"A"G 4X#@OX!#4*B4M]QS!PXM@
M&27*!:4U*@PRG$-&3 &. AP%.(X-'"2*8)2%E".](+35,BIN=4C ;!+GD$93
MK)53>G.>U8]\@YM$^LWC+!K&W@BQCTR:#\.)[1_1D[-V<]H KZ=H+'_L"N+M
M6?D:1_UX'-<5%1?:2Z6"2SFD[V)RG'I!/>*U2";$38S$D^,MZQ*JNLSH=F'N
M&DHXO;Y6 *4 RMX!)49+E&5!1Q- 6F4(TY"\T4F%"-Q=JM?I 28!D5W@HB!2
M0:2"2*=%I. IS<6QN" (0(D804STRH;D(D_N$.F*K7!G/;)*)3%=04]\<;-@
M4L&D@DDQ>>4"IR9* MI9"YXRG#Z7T09M6?&4G34>S3QE^$_.DZM^PC7F(^T-
MIG:VR T^>?!!13\?<)6_@G0<J#51!PE@M5/&$., -)66,\;Y+*\#'XWAW63C
MQ\2K%:/&)#P8)B6W*$F]-XYR&H7ECC$=[#PR='_,=0_)52-J2GF0"223.$M+
MM,>G++/">:HX@&D:<=U#E+S*1[+R+MZN$/'K@_]JFCX%(30>ROK'5A[+^C/=
M@A#4+H0POZ/[3$J@:RD!)Y5QYY[HF)TT>[87&5_F1ITO\83S._^\(U',GU[C
M$Y\O<9?=I5OM+MN%AM0V-*17C;@)T6_%*ZK:X@KK]Z-B+ 04(7^XKQ?5Z#07
M2K4.]!7.NF_'*'B_??_S]S_VQI,/>2KX:>SW9_+M3Z](_7N67//?\\[\[KWT
M6DC.J)$0\ !5(IH:'1D30EO^JB'D,UOD?);ZID'63H8W7W7N:W.[@NH7](\/
MM(+[$['3R?")B30SQKZ5PC0<3@;#2:P5/?SE5QN "V$\%SR!0.W.J]SJEQF+
M[(',D]6C^IE_#/,LKB:3F[=??OGY\^<WO[E1_\UP]/%+1@C_<H1__G+^W5>=
MWZ[[;_LVGV,<O/[E?<Y ]OUIB"'G'WL[OJKN;E<_Q+L&HQUDA^%TE(F\BBW;
M2;[Z;?%%'BGW*L;)FPIGYN,\5,7VI=<L<.\.P7;BVT:L6/_82K18#S5;X)/9
M2<:QK5"8/Y1QH3>^Z=O;K'/')9&TF31Y$&'E\E& M?JHB,UZZ[<Y,-B%+!LU
MXG4/98UX%_YKY(7UCYESEIO<.>5=,#$D#C%:#2"<<4X:DP3*SC;)379V<E.I
MZ+0(R S,(O%(;967C@FKJ#2!^GW)S?MT6PU-4.LA7")#4H#HA6%(K!Z/EQ"M
ME7 TN[YVOR'G(RCB(PFX.$B>&)D[>KO@O,#_TPTWY$SE OJZ%M?OL[3^<>@K
M7JV;1S7V%&]]ZRJQ\!7)U;XB\Z:IA]T];:4)PC8]TPY2<+]Z:#^:5!?!:')5
M%<D)O93B*.8_+;]\?#4<35Y/XN@:?YO?']M81VL0:JW7TQJ%T]K'8*5TVD"V
M;2,1Z4Z:6J/W;>U38I4W8@E]BV9%&[U::Y_:R:G5[ 19^]1*)\@FM+\5R]!S
M5JT,)\R!20DW%@*J58HE$I,F>(J1L] FU8J?G6J5V\!0YAPGB%,<N#&H;S"M
M>&ZV3;D]H&JE"3*+]0+ $9")&@-:D*1=PG%5B'M2K0PD"2XEI9@ Z_(8CNB$
M:W:!"M4076NU:K6/QA:;:EGD35,6Y69*U@:G6Y2L@RM9T"BFUC^VD[.^V36U
M]BF^DY+5Z*U?^Y0ZI#NLECOWW&'51T5IJ[=^FP/;R4O;[();^]1*%]PFO+05
M"_)S5MJ\5]X)KIDBD.M,&"MY2H9+3AR+3+9):8.S4]I0_Z5!Z(C\$<$)8<$K
M17@(-/+<#OT@<:1FV7F6(2)HQ('UC^WDBV]V ZQ]:F4.S@9PN0W(FB(53R45
MM\IA8KOYQ+;*U%KM/MF$E[9B07'.4I%8,,H!%VAO0[#$  D(V);%:)@(M$U2
M49R=5$1RU9Y+%6@R8 )8I0U5S"70'BBC!Y&*0[0VT7)$TSV7>[-5MN^S$ROF
M":-G(3NW2R&$W;RM6^40TIV2"-E6281L91)A<=O?WZIM-G@WU\16B82KK<Y-
M:'\KECGK3,(H>%1<&J(- -$NUQJS(HJH%6ZR@3;).GEVLDXE$YT3U$ @$( 9
MB [M/V2>'"=)AW3;1V0B*R@5WGB(DFLI=4A*@18IQ*3VY;8GU'F-/,B2 (J$
MA$QJ=8@@DXI./5FILJ5N^X-G1 CRIJE>^&;.^@W.M#CK#Z]:;9>Y"KOY1+=*
M7:4[Y:ZRK7)7V2%S5U].GNJ!CW9E%&<36MZ*!<XZ>=0$:Y*@UE$?P2>-!^*2
M<L)0P9D2I$VJDCH[52E2&F*.14AI@/!D'.,HWJ**7JF8:Y <3%6B5%NDVVBL
M$$BK24O#/9(RT5H[R?>E*A%7*=6,*.3)H(15'D=%C9L$5)[HN:E*V_6H7-:3
M_DQA!V5H@U,KRM#AE:'MTD/%0:_SLAIG[NL9&PEKWX]V5-TYOUH$/Q 6Y])F
M]LG\WOD,T&:[^/1Z/!)!'.T.Z]^_KA2?/S/V2%MY/($;^S&^=LBB_WIM$P[_
MUO8_V]MQWIBKT?Q+]8*J&_0=DF_1WY.GL_(-L\_(5YVKF.73K#3E ]G:= %_
M_J?E;7WU0/E[@B0?*8F[4*G8+B-3T$7=B+\A\(UZ_@'N_S#PP^OXP?Z6>\KX
MV_S6K_M#_Z]7=W-30@5+%.$2K6%4%'*C8B8CB\'[9'E#868TJ0F=#.<9;J\Z
M$1'S)I/4:!J;UB$HX91Y1WCTN":=&_MI*Z/+#?\TR(U\G3L29_W!YQE]N&$_
M5!U6\O9T<'_B^!X?WFWH?B_.B^WRJ,1*9^7Z[=WB3-A9^9]W.)'MTFK$2OMD
M_>9N<2('-UMWAO]_QH[U'@%VDCU,6>_(W#7)W-69CE%CJS23*KA5*3C]GG6]
M?F]RV[F.DZMAZ.9"*/ZJDW7 W@@?RE\?13_\B.I:WN!A0E4-U9H1JB?XVGF<
M;/E=N?UT'CP_&G^[B3ZK,FDZ0>VQ>B2K.+6*6;>ECI\J!6AR92>=*_LI=ER,
M@_F@O\^"<Z@:I;F6V:FZ4\_4IE'USE'$UP_&;SH_##K92,MS[3;/=%0O:)35
ML?DT9[-S<1!3;Y(G-9W@4G[/&S; K1K>Q!$2&/[6'^)KZO7B]L1<H*?Z)>1:
M/,.;JE64QR'Q+=Z.1K<XPF<["CBS?\['[=A<Z69&L+;?'WZNE+S/5[CJ0<1-
M&=O1+5I:^/4PQ3_DM>=)-*T&OU4=Z'5UY(O=QH]='@XI#C?PS;$8>;MD'+$R
M&6<]3V[!R/!B_$\[G.9V>1UB99K3^H/9XC0?W:]J'2S_-.A\BYR=+=\.8]T.
MRY6-*\[]Y<W[-YV/BWL G3BP%0<C;M^,(D+"N/>IALU^_-@;]^O]Q+]>#P?]
M6V3Q.28,$1*J-Z(JU?EF.L/D_QFZ<>>=KR"M'G2&>/E;^/F;W,YN_DL&KLKN
MM(@WG^<RH)H6COFQ/T1[%,%X8@<?>]D]A\CU.HN6,),SU<O_\L./'W[H=A 9
M!]F"O<T8BRH?LL+4C7NA9T<+^8"CWN+WQHA5:&$,,KQF"3/J5,9(YW\LD@\B
M(:WV2]=3K5[?N1D-9TT9Y[-\/,QM-0=\Z3@+D/A;!M:\#78.NGD)M=S(PU9B
MX-$[JHXAZJOQ$MZZ^^9\1N?J$.]D[>RM;SJ_(!'-_OJ7=^]^1N$:*_F#TN2Z
M-YD!];7]5ZPF5<OMO LWE:G0B?U8>Y+P6[%7I:=,\@G-Y'F8QCSQF>RJYE1O
M"<ZJ&A._5BUR-K-1[-O9F/4N(L'8><++:YQ3;Q@J$8+BN99&^."THJY\6L-.
M0M+$G\;3+/,JB9/'PC_D/;B^\P\]5!)B+?TJV7YM0ZPU@Z7%+:LLRU-#'D .
MKE\X3\RIU[Z8&8KE:E^N\@X^>NC!+(Z%G-LEUHB5B37K07 +Y)1%#FYR+%N=
MYLJ4I?4'L\5I'O(*S/[,DYL;E%N5TCI%BV/40UT^B[@E^/LX[85*)48)./:C
MGLL?6GP&?[T:]D,EV9;QQDXF^*WI)-XI] M;8=EX>?A<E@858-\,Q_4W)@C&
ME0AZH$K7GR.PVGL _\]X9Z<\LG^FN(31Q/8&]X9 :6?'&5*K=WT>OAY/XDT6
M:%D^U3(N]4;C2:?ZO%>)G%C;"S5PWIMO'F=YA2AO0\R^Y5XE3GNI>J3VN53+
MG4<A\)V],/--AY[/?8]K"PP-%QST&B4A+NA?L3HK9.#!<%+_/;]O,?SG7K^?
MMV>,-(,+G2UKBM9/=R8D\RSPV(;]Z=Q\G(LA) 2T3RH++F_:QYI#9AN1J:B7
M9?5MO25C7.,@U'NRL$VG]>8@N5[GS5DZW<5&S2VZF6[4MZ./^/VYO50O>+;:
M:IF"9.&<G;&+U=\SI3I3%"Z=:7\V).H$DWY%2T>3+=ME%HB5F07K@64+--(O
MQ7VU7:!;K S.K]_<+4[DD)=!]B<?*O],Q>$5^$Y1&1WCP+V$*(5L^7_3\''>
MD'N&BY7A,'T:<&O_S!TJYN\N+(A'?K(WG7=]%$S3CU=977>QWXN?:B=,=OB,
M/L6Y#\F.AX,,I5T$QVP?3$>5T,)99L3XB$)M< >962#UJWD-IY-JL&&%S>.L
M$J,I@%90!:899]U=[!!UXM'PNGY-[9GK99,G]6OA-+,_KGIC5,QSG'[9"EDR
MDO(.H( =31%P*ZEE0S[&V006Z\I;X:^R>8>[E+7]^DG?&_GI-2)\]MAU9_I_
M#:BY!':UI7-)6H'_W,C$B:)06(C:P0*K$=2',__@) XFS]HFW("[W:E ^\X#
M-EZX]F;3O(O!(LK;VT[O^@:750NQ)RD@;VOUC=HDPM_JK:_?.".D&<..*XOF
M:.B_72A5KKQ5M!XVM@DHK8S>7A#\R^WBAG)E(:(-=G>;,WD4Y6NK $"8&FXL
M!9:A'17&1N?ZPN-O/Z)\0.3+L-G@4*\#"%G_7 1+!G$6*&ATVU<^G1S1Z&57
M#W[<H&(OZ\)C?Q7#M)\]%RA61F-$NX<AE24[HMNYL>/E\ -"-2J?X]IWF% $
M]6;AFPR3&?/[MG:DC2<Y1?EC;Q:KF -OY0&[B\4LN8<JL9!-DVIKUG^_TO11
MZ%W?U$*V@O!\=M5FC"M8KU)A*FF+TYH9-\O/X-9-*_F3#;U*2N!W75;0[\;/
ML^\-/@W[G_+(5S7L+R3]9+[ 2@:@:=FKDY_RM//+YG3RIO,>17HV'?T$A>!"
M7-3RH1:R]];=78ZKS%Z6-WCN'WL8\/J\; GZ:BA7R2RD=*2*N>3)P9BG$(]L
M@7AKHTIW8:2\GGE"T6Q!FT65EK2@F:WTNK:-7F?I^[JR#!_&FXZ*P-M%].5N
M$?VM0OKT44R_.-R:#F:K\]PI'^#P)[,/V1B&E8%0J:XASJ32P^C#74P_@]0\
MII&Q.#O/*K%6:;G9D3' 5<Y\9W=?7<1-9C#1%,$YEL;;'-]=_]BC".\)D@=W
M6/5VL5<IUB2CX?+>+?RL/X^&@V&6I%4F19V>]G22FO-<0TPR" L@O3#!"JU%
M\$(IZN;UJ7=*4G-:**:"-TE&H,B;S.66XQ&<=*"$7]_5XR 9:K7)B+SPCY@=
M@RC+?T =!OGE;BL[[]$X#CG/XR@Y;,W!GO6/K0PPK=_]+8ZLR+N-CF6KTUP9
M8%I_,%N<9OOSW]!Z^Y_I(.:$ 5FK\-^_>_\UZJT5PRX"2Y6Q4GFZ9BEN#Z)"
MLPRN6;)7%K/70[1*[J)*2VEO<Y]C73^BM[@!D6W)E)7G*NY][XUY9JA*3V_J
M-/_%M!Y$-N:*_5R97Z35C>/R.%F*9]NS2MI8Q*V6!L3)A]C/YE=O]O.3,91[
M.7O+KZC]=W>C=G+*2J>'H_=[*>+3\2YU<&;-C6>QHM'<()O9%/C[[U6&"^XH
M&IR]RGB::3;UV'E*?MC/3L[::,PK>WJ7YD&?K*O<63[9/VSK^>0A<UI%[<]K
M/)*95W1X4\7\\D9-'HZ+B[B7DL)(]="#F>='%X]4+MUJL+QY,T'2<-&C*;7Q
M:!K6=A$EN3*BM!Y)MH"?E3K=);D4MXLHR941I?6;N\6)M#_S#@7"N^G''.O(
M.62/18+OHSF3;N^E'>"V70T_/TQ,0O:M0[WS%+QQ%6Y8Y%3Y_G :7N=(2L]7
MKLC1*,N7F2C(*+88H&+R>;Q]'M]($3_Z]Q3W),VCSJ@N]R:SP',5PEF 9X6^
MDRHPGL>;QRJJ]=W6+LOZ%3-_59C'-,9H#R!DHXCL(<[,PSCSMRQ[M^XG8"^>
MO7<GK9,3!SX.1[,H?2W0YA&PRAV'3\]2UT9Q,AJ.,TCV/N7 ^K *PBU]D/<;
MX;)QGQ?Y7G5J8'6]+@^5Q5(&;?SF8P1?@=QU^L72^+4DN@Q WRY(I%8&B=8C
MP1;P4=+/-CJ6K4YS97QI_<%L<9KM3S][4AC,-?%>%1*8-W9>SH"^!_55X^4*
M2BJDY)UD>Z/*_7[/DAC?0\5%TC#JW_$N'6T8JIC67$>>6Q-/S:(2 [,++H@N
M][[V8'Z\82X+($-0BRG-L"^+M]3+EZX?)637>+M(7N=U,K:I@TIVA+ ]Q]_\
MRD5B\V,P?F3L/ 3EV4M1(P^]4"%PC;/WXG[W(?=N]4<#5[5=L$&M##:LYZPM
MV'%E_E7+>N">[2UK7FY9/X]]MHOMJ)6QG?6<L 7[M#]9#J79W] .J"\5;6[<
MU'Z87F:$6:$2%R>?8ZQU_.QVL2[7-ZLD5$-2]CS:7E\1^A1Q5^^E(-_IRG<2
MX!'6Z\X7'X8W/=^11/[Q3>?KV$>#JS?/*7L\ZSQHMLD^SU3PA9&0Y<47*"\K
M.\F/__CV6')@N[B46GG7<3U-;A,U>92)=;%:]OY*:VVPJ=L<Q4JE?!/BV8KF
MSKK2-JY.6><]TSJW>*3&"!=EQ)5IE:KF0^M*:LUI=%6UJZ.5W6ISJ_-_YCM_
MMG-C\^B]FTK?'B^2VZI[H1X''EY7<8[JKMU"6&1-_<[AU:T\.7.7_W@\]+WZ
MSL>=/*F#%@LAD,LBS9*F9GZC_10W>EHM.Q0R;!4GW;&=H-HN(*SD.2.#D+@B
MH;P-R0%W6G.0-C(7K!,JU:TO5B.#8JU!AMD'>>BW,V4&9_9?_V&D,E^U%3*:
M)_W/F8Y6W_1[-A!4-X]S1'"6UAL?0M)*Y,F(M013YPHB6X7G5_==VP0-M@*1
MLRYNKI@)N7DT]5R"X,&$P$Q*TEEK!; -0*15ZD6;.\*_"V'<R045&/DJ5W^L
M@C<U#E2?TGRR:.S=+.+_JPW1*EXT3VV\ Y#:T;G9.-DO.:Y]IG=PTTL+N[8W
M7@Z#Y2!@JL!G,!G91;#L_I>J5/*YSE1/'O\:$:;"(E'CWMK.%:*V"N'OV(%/
M;9>KH/0Y0Q277$BGI  9P%%G0I*(32$B8EFQ2?^%HN<<4L_)5U@F&T/.7+V9
M@<(#J&A B ?ZS3VH6GK9[.K)'+F&HT= =:Y LU5FRNIN>YL@QE9 <];5RZ.0
MTECME2,:B"$N:!LX(Y(&[T4X-UVHS2W</SSAY[Y!3LY1XBJYL5(EYJQ=W_ZK
MF7L3DPD9?S">.?@K!>DAJ&2;:I ].>,JV+ID-%5AV/K3T,/Q)U6AL45TN4X%
MZL?9/;'>*-3VV;R Z_DAS%;)*SNV353;9>EH<MX(PY0)420& HP.5D6:C%/>
M&6DAJ:+*G$B5F0%(5E(R_#RT40X!%MU%,"\_^UB#F9=R6@:R0P',+HRLMTO0
MTCLE:#6W45S[U*,4K?;FA.QP(-NEZ.B=4G2:VQ&N?>I1DD[KL@P>YG'M\4K$
MBLRNUB33ZNT25O1."2O-G;S6/G7PE)5+ (?=#N8LLH+N2@T3:E;=@ALB!U[?
MU!<.KNZ58'Q<%.MQ)FMV>UX//U751G(M$^3/7&5W5MNCME'J^V2H)3[*YEF\
M9/[L;"KS7-AZK'$NKC6HLI;JVV6S\I%US=E%L^9U$]\U[96*V;6!W=->>_-2
MP],1&F7_1NS,(]7EF9_(@'WV38/L_=DZ-W:#Y+\5S4[F#8V:KI!S[B JT,0;
M#8(%FVABG#K#D+G TCU<(2<I.<>=!4844,?QA\23\))311V+I[E"SG)9H46K
MIR>OB#\)2^M7M<56;-1>Y(1%$M;/?XM%\[7=>A;']$TV<Q&/8OCZ]IO*D5J5
M#OJKG>1.9K??(K-5IF\3I3.EHM&<6JH9:"6LU%8(PJ)EVL2Y>-^)TK5EWBI%
MB'(&=  3B15.4LF,$XX\IO362:JJU.TPW]>M:Y)4'HWI];4=X;=FJ:"S?<^%
ME*I=7Z02S(MLO480?YT-S%PB=M9BKKKA&W.QI^K>\J/+"V^?Y, ]DF=C>&S=
M0RNC8^M/? LRN9 F0^LW=HO36!E"V&QC:ZK>+-'1DZ0T*J">$%17G;$L16V=
MC9RBXHD&_WX<0&L]?/<<@DT>N4_5TW]Z5=^^6,SKH3^K_O/B=5K_H?%JPC??
M?/?=]]\_<'*MQZ#79ND>2%['VX[9!RHUBH>LT;[]J_VM=SV]GLN"N2#XN;IY
M^X\<H*-+K3PMX=HXYWSNZHZFB#4&A*4RL:24FS>(7BD"EGJ$OT9T>QNFH\_#
M41C'0>XH$BNE]2&$5>6TX_BA*[X^.-SRS'-_>H4OW^X0Z9HS_*__H)(\='YN
M,.QCHCS11)X:=GF",^_Q;";F&62])^)\T&*VHLZG^\OF/O4S8L7?_ME#NV2
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M&"%Y2)()(])3]1\N#RVRP8 ;<&:0\=+3<IYVJ.0*1953Y0,*S/%T=%L2=5H
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M:#FDHXA[+U,T7GJI(5KG'!?&"50-K>:GO[!0"C,7K"E8<REY/<DD95QD7(,
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MLQ8?>AJ5>HI9I&>#?G9N<U<W!=:80P:[*+WABG%)+$]Y-,V4DCXHU:U?<<S
MVB4"GAVB&@^:A-Z).ORUZHA*Y:W'EL-#43</G$'5 CZXU!9'DO+?0,[ &]XJ
MY-4&_ 3TKT> F;%8@)"K@)DW3@6.$2::4&&1%$TIA;9#E%>%O2[%B2MNX4$W
MWMS?!W#GAVF*4UG%1=%5+C:JQ+I<[B-(]1F,DC\_RZ:RI'OCQQ'E0\R7PT5Y
M)UCN<47YJ&'!@)#F2J?D-_->*A<\HAI$G E'PV75S)U$V!_[W-X/E?Y4@O]R
M%2%H'GP]"2C]F?HS^V_2Y?LSC[?6MA#/RR!4N-Y>S+WV#@LP@ RSCFDD/"'4
M1.%<8*Y;YZ855)40UZH!3NSKP;=_A+#/HX#>OQ^EMK^RD2[7W-?ZV6K@)@MT
MDJ> 4==O]Z7'>!8JZK<,/_<F%ECWBY_4T1.=8M8*@J5!BAF&C<=4"$Z<0SH@
MVJ0<C^46UM4D:3<'I DM] (C0(\%>4];M<4S=%#RM+$_=N=5G??'GDTJO&$)
M;A#,.#/<S?Q4@B.QRI"5GU2YF%))%+?80HSCY.>>_?#J>:;<#T2N+7?]!>[
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MS:EXM6"%EYD3Z@+DHQ,*/&#*#1,\:BJ<!:.?<(^B:.S*[N* :;D#3? B%6!
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MV/3+V77#".=+*OE\4@5/JN"XJ@!K+A6B)&+FF$"I8D6@5*S"+3.2-Z!BJB]
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MF,6-S]QYE7I"$=AC7]KLYF$#:EL-V\;Z 2@"QX$':,+U!>MN8.XF\)OJ7WO
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MJQG.(K!]H6!*_=D/G;A/HE6,56R-L<[I>\;\URK,*LX_S)HMS$&V1V1Q LV
MS?+XZZ0([:P_\,6Q9::]F]%L$HJDPMT8="_8,;__U=S>??]3+Y:G=CX,=QQ,
M;\MCZ?WHA<M=TC^63ZD'SIA!#I&$]\D=BQR.)RVC=I%;IQ C#>U$<GXBP;_
M"GD['MV%\?3^[<# @33T";0B"\V/]_-2W[?%,BKQ2D&\A7 M&RE'F>.BFXI^
MZQ'(1-O;)7D^.F61T)*!F\FB8"QP:XRSGD85")Q,VC1 E+6A[))2.CXE,6O
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M2VII,CP5XH@Q*2TVTCN:.E@,0WYWNOY9+\!#[]*.C&>A:9U24"6TEL(2S+Q
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M%C7_66'4U,O+@E/J68;(O$*$<:<)D]I93ARA5$8>"6-X(SS/.:LS<H7(^3G
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MV0H;3YX[-EX34/NS'UZ/AOU)E_S7"CY+?LVSJF0K*"=Y[K.JGOWPSPI*SM0
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M.!MC<F[/^+3;HH*[>'HH[7W(&0X6 \X_4_ZA>1F>/BXS:6>K@<^K^<$KS%E
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M+5?)5AH7NCRCJ\6%KV]\?MZK?+]3C.7O1--R9_F!LR5OE#L;OW"Y?OG1>&'
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M0A)/&HRW*#'8J+.R&IE5<H\U_<\H*4A;-;1JZ'EIZ(8"A)>KJ)&.Y4^1(1_
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M)=&WU*)TD%OFPQQ3] Z<GC\?JPQI;T_)MAEI_:3&I:1B\@$\E'FNF'UOH6U
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M!YZE:A_%: LK*$E%GFL%7B0;/",G X#'K.ZI%MW7LL"J@%V:5N;*,1Q7^?\
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MPG$<7(W0CZY&\U'^6L:.01J-<1Q&>)5_.5]Y7KYY?3.]GLQH\85RS=6E;LI
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MH9QU[X-MPG;%BNEB^08ZV4II2[],9B/7<Q#NX'A!S+YW#Q2\!XD&Y9$0!F"
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MWAA<W-S.76>FEY,")T+YS''%$:92:,,"\U9:DSGE@[!GN\Y'"'JU).N^^"6
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MB1%GE+64'Y]Q&H?)K*W+ZQA;<06G(X_L>C#1B+*Z1GJSK9#CF-!\HA,VMMC
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MA=YCE2@@2AX,M69..,P^>=0]VJE3'F4;K?)G=(\>W_CHU&J/,GG&BU88'SN
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M;0^;1P.;VEMDD6'/GM-^T@#02R,]2 7<XG3(9J50$I\R':126WY</;=@V$2
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M5"\7T1VU-]=35^&%+AXU*UK:S/ZLLCR-2"F/R1B=3G'*Q)O^Z7L7!G>FK70
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M!BG*EI=,K=[$WL5S.2I*T*STD*%+7D">"!6L ^8- NRUD5XAJHBF$H12;EA
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M<YMMQ;^]K=ZV18;'/4U(F>YW+LQ7%=X\T&7V<3ZSWKM%BI-_6I4L+6H4?44
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MT=?XVDL_N3_@2_YM/)W-HP/T/G,]%LL/\0KSM%VOP_/O[S_JN=]D_&-"$44
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MT)E0R"NDM47(I';AU/,:M'"!$:$!$*EC73@2A;+CKZ+JJW(BUP"+!E094&5
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M^A!5.@>(YQ@!=9^8.J6CO!MAF'?__NN[']Z/;G-[&2WB7,?O3_WRO FJ/G4
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M%R1Z_X #B@TH=A+)/E@JE3-4@0)/P5@K4,#2.VDUY^=&L0X3A1RN).]9Z#V
MV0!F+PS,.LT[2FD$<(XDMAHH-XIYY:TW+ BO ^^H%O#YIPB?WFS.F2(<0&\
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MY:$?\5=I+';D.O_[;K$<A_LT-<EL-N:F&.W']R['BYGYZ%_C<*=K%G;:^7Q
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MC&*"0_:#4D%BWA+/*.6>$^=U9/+$F<#'7=DYN#&$7^AY7J3GB5X19I1UP !
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MK12&.!>LE=#=T/R1R/Z>82[#^2=:**$]L] >1_9H[CTT]]VL74=N4]*"4!7
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M/G!/@@E1.]O1X_C1I,16[=O8!>_;R5\\38"]VO&<P.E R_T^E$1'JB&CEA
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MD4Q1=5%UL5Z]RBWM30#9<,6E4P F!%#&.>T2#9*E@H5MZ.R\=QL@'YT<%?B
M,7D.N=DZ3@/U(L>*[*@GYR.K$S6@F%%U477/4\S5#!#949$==4MV5!:="EQ'
MY6@$Z[TA%)RTDC)K-+>;3X7N-[$\$+(GQ[(PV5PC#D=RU!HBQ4H #(H951=5
M]SS%7,T ,=G<NV3SMN2HA$L:HE20N ,JG95$\U2Z=G&I2-A<Z; 7<E2N!APP
MOXSDJ$B.6M>0D6&RUFP<RA15MV8Q5S- )$<]&#2N1AP[EOMJST&!H &$ \Z8
MH<$*E9)@RKE(U#-!\*Y5O*2R=/'IY_?4Y*AF&S;.K!:[L'%V$K)NO$J_ '+4
M8F];3 ?=:3HZ"5DW7F6>2XY*'&4 R2K# D26M/$@(UC%K6,Y)D=RU%N#/@XY
MZO?1+[A1*7*C(C?J,8>!W*@OP@;.DQ<0N5&1&Q4-%[E1:Q$E<J-660V!W*C]
MW?6O\R1%W^@*#\&-RAA/+N@8HM<0&+/ :2!*).D(H[&K[6F.]1=)3<HX/2XW
MJAI03NK*>]:AR]4,\$P8U9 ;=;?-$M#$<N&CT]&#"]9)&V2(E&07HH/H*E_=
MBU_9F1L5N061&Q6Y4<_D-.26Y%3@I!.2.>H 0''M0!K)D[(N R2GNXX[[L5Y
M[5A#)/B 4?1?R(V*W*BGIEQ#TLJ*A(=JAFJ&:E8)@21RHVZ$G\&"%9PSH12'
M<JZ,IZ2 )NMU5!(TPL\Z51O+U9$;M?+ JH];*"CF>@9X1C)%U475Q7+U*K>T
M-P'D!-[[&" Y1B *HB757$21*"A%5-H,D(_.C<H5&QA:6<E.'XK7>T^..@>S
M2(]Z-N2'R#%9*W! F:+JUB#F:@:(]*CG3H]Z*'949PU8'Q1AWH,$;KF32F6H
M':RV <A&B+T7T$S-0!KH!VA^E@5C:AB93.L.ZRK!&BAF5%U4W?,4<S4#Q-1P
M[U+#VS*9&LZC)I$:RRGD_[/),0T\2<.53;R+Q.DQ7+L]DZDT9W%2%YE,MV R
M7:2$D<NTPB$C(62MJ3.4*:INS6*N9H#(97HP<%R-.':KSN6!"Q9E]#I9X""M
M!B49 #&@'-?P3!1\K^CV*;6V[(*SNA#P7JQT.]+1)2/FFH;X4;23=MR7*SR:
M ?*2=&;QR7+L"[68W^(1<L]]D?#\^+KEQ'DKZ#U2S_L#N,X1VFLWB?;WUS;E
MQ[^QHT_V\[2H\>5D^:/Y"[6ST)"6C&:-6G)ICXO/R+?-Y8)!IPU;EC.U9*7L
MF,3E5^MB?=5RDGX9;^=+[$)!2K>B(&4[49!VLM!NNJJPT/:%$;9#P=8'^Z^;
MZ6R8/G\QANUEV4TAN_&J1REDGS#[V^@,7Z.0W<L2<]O\-A+!YD&/[#2[_^\_
MO/_QK\/I[-<RE%=/H[/U(GIC%:%. B1&#8LIOZ6@E@ONC>LBEEV\Y'*4^KK#
MY[?YA-M+_,XE/?SK.ZO3[8'8F]GX@8%T*^F^04$:CV=7XUF<+_;Y'_],DJ?$
M3!129=WAH$7^CQ':I<2]=::LTO-K?AF745S.9M=OOOGFTZ=/%W^ZR>AB//GM
M&T8(_V:2O_YF^=M7S9\?1V]&MLQCO'K]CP]EXZZYM&$]P_&T0V\%)32SRYC_
M'(W&G[)JE-3(<!RF%\V[:6.;29S>C&:#YE,LEU_?E,W!,!RU?W;E4YIRJ/.W
M]I:?%GG"U\O-Q*LV4]B,TVHD\]U%>[6XY_"/N/PJ_OMFF %'7C([]B";<#.9
M/V4\C:L!M_YJ*:.[<&8W;+"G-8EOY5]@ES6I>QW<>!6[NR:%X?1Z9#\7Q!C7
MEI"GK0=W$GUSCW$KS]=^5,TRM_T,PU8S+'::X<Y5:^-5_#'4L9JX^Y.TLQO_
M?N$]'C3TXI*B]9?%410_LK#O\I+3O+KE2Q=??/%97PVOBC.XF6;_,&WBGSY>
MS]9\DOV8\>AL^O6;(VF!V$H+Y$Y:T.E;-EX%:.=;S;#<:H;53C/<Z5LV7B6>
MV^ @:<:2]EI9!R"8U-PQD-)J*I@1DI]O@X,Z>AG\S4ZR[^.T[6-@CM''X Q9
MG[N)FM=KFX__^*_^?O,Q ^'9>+(UKUMOV<9?BHJ=N!G%5]_'J_''X14JV3DK
MV?L\I/6F!2?HO=("ZIH5[$2G818G=JH@1:^Y G*C_*K<U.Z<W9[MKI[T70]5
M,@/62ZZ!BF D..T,]XPF$"DX8K3W]S=5#:&+355#^'Y*9K0:Y!BO'_NJU9PV
M[KDCJ/.\T EL=]M#P=X$:R05RE('W @C#>,F)4*]8X9U%+L]:KG;'@K6 Z%[
M<B0"37>/AZC.846OZ,UW.QJ5[3F 4A1TZ?(LM/.$*6 Z>D5DTN*9OF"KHU'D
M0I[C$GXTYNTJ(I\?4HI^5K:)5MO*T^AO)L/9,$[?G(1*NQJ>V7J8BZL124TD
MQ=4(!?4$]03UY(!Z<O@E>:MDI.S>L]]Y39Y'@LUP.KUI$Y$WU^7PQY]QXH?3
M6);J-A/9C*\+XCID*K*>B*6:O,*QPH.6=)I]>VI:\I-%T*AZ)U.]QR/3GZ[\
MI.4DM:-%LKGU5N_6.O+\.E[&K#&\MY_+C]]-)O;JM_:Z=8I43IVR*1JE- 7+
MI:%&<>JM85R!Z*)(O1/&_O/=)SL)OWZ^CBTEZ@\?KT?CSS&V"?"?6_^XO[:>
M;,#$B1-?:*&]M=!*1%(+X-I3#H3MA?.@$W#E3[)+\^40[1QOV>)JYC^Z\H=D
M0^@!;J_ LCHUZ$Q@%T;1+T_UC@B[:$K<)$-I4AR2$UJ)&+1S,7 JA.EH>_PX
M[/IEY2I;X+7'3NI25 >XT#;[89N5B*06P+6GXW:' 5R3.+(%:"U:N?[PX?U[
M3&O5$KF<(;["H/GEJ5XWOBH9]*>!J^\7^^/S'?.?TZU<T_N;B;_,P.O]R%ZM
M']E2!" 0II2W8+33D87DO+ L!$]3.,J1+:ZKPU!H?_VPOTI$4D4=PP9&_5X
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M)9R[2]A?G (A)<%%T@$\6)\<1.^I3X0G[PE[PCF-8S:SN.,=S$"P$Q^71>>
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MG0:$2'^0DEP!3M"1D-*10$T # !(R$A^?X#_^9"<(#U)=HK\-,492F*'\K/
M"1)2TA,G2<G(3IXDMOH1VX&3=&3G+@O*G3JO;4%^Q95>*"#ZTVD.^>(&!IV>
M34[AAT]>4)QAO'"1B?DJ%_>UZSPBHF+B$I*W%.XH*BFKJ*KIZND;(.X;&ED^
MLGIL;6-KY_;4W</3ZYGWRU>!0<&O0T)C8M_&O8M__R$A+?US1F96=DYN26E9
M>45E577-U\:FYF\MK6W?>_OZ!P:'AD=&IZ9G9N?F%Q:7EK>V=W;W]@^PN,.?
MO$@ 4I*_/?]+7G1$7B=.GB0]2?Z3%\D)SY\=Z$Z2718\=4Y.F]S"]?P5H8#3
M]/+1GXH;*#B$=389'C[I.</(*3)U=>LGM=^9_7O$7OP?,?L[L?_B-0I0D9(0
MG4=*!\"! 0@(K)^FQ>WTP3?Z4_&FL,W*.CD(D/6V/CZ,A8"PPA.AF#C81PBP
M^@$!"Z-2$( UGKP$ :DRPH1C50AH[H$ 2I\FV,Y")HC)@6-K?EQ+CR/?-Z,E
M^*6C_K5LR7O@?P3_=PF6$5?&9A3:,<^G6O$7IA2/F[2<?QO10/*>-"JU2'0E
M;L<\"#[KT(-:.:0]IK9?4NNRY9@O[1#E8;B4HS0DITBOQ\ZT4!,5N:<NH[,^
M*L'W74'X6T9TR>V'I_SM"H@ :0V(B'T$CJ:(\',;AN"S\!QPJ!]U2)?+L!7G
M1J66J.;LMF+[PV6=HHH_LI+ R$X<)+MO?M ( 5MZX-?& =3"9#L!"Q)XJGEX
MX6NLB)T2PJ<@PAUWU.9O>\ZX@Q((0,(@(#3]UZ'Z;=K*^Y&\N&$_!6K\ZQ5P
MRF(9L[-A!0&^< A@4,;SR1@3_%91&\$0,)T7DQ;U4_!OAT$L.+I!"/BCUBCL
M?>]*_-$(B*$EFAQQ51$V*E&T8+%');[-0=07&)P'HNOCCS<A *\/^Q52H5HH
MO,S5O*MQ^:+SK++QGXT!_Q6321P]:#.-2@[NOXEI_5>6N$;H:0:E:+,M4-%L
MSK^0R>U*GJG7V=$KJXBAO!E[-[I8S^'Y?=*HA*H$U"<(: 4U(* H&[5[V4BG
M0_"&K61]:TY 8[;8QPJ9S-!K1:6R*G.^UOGF2_"'1_0$1.*\,XZA-*)JF3:G
M$$$X3^U# %';9\ MT>JM\P0+U/X0!#PJ9$<JB#0-!=UP?35JY(!Y9$N?[P1^
MM2@"T0<$.2T"5Q3VKN@&CD!4?1T"F@;9&!KV.K3P^/C)ED=_T6_ F(U4K__C
MSAH_TW27..,9VCY.Z\U<X0;^LDZJK;(GEQMYJ>@0/-C69C6=&*V"84,6V.9[
M>\S.,02\T86 D/0_@DWUS)@<'FN0Z3@ED<44$48:';XO[;YAP%<GE;LLUNYF
M;S]_I^GYY,/(5%V]W)FD:OH,_R%/:LJ_$*BVH]COP!W*DF@0,2\1-7]2<+=5
M(L]YBM^=+FF8E22VX@[W]JF$%)F*V)1$O-S'C5^($=<L15 ]!, Q.#(X-J&S
MLJ]P/69JZM5OE:;;LP%E_G"U>*V><NI[PH:C9;E99"7TUGV< ;K,V!&1].M2
M:WF45S;P7,P'> @ 9^F)WK:!@%>-9L1)M8%_D8K7L#:QK7P7'V;KZM33T41F
ML)'R7N;ZP:@,(9%/VW3L_:1SE3BO];;LKH^OG<:.NL:>-UFTSQ^(B?S1'WE:
M4VL&D\N4MHX>G2XJ(;[-4L5#25O8@52LPAX&MT6DTT9<#_HYCZG+DG8AX*S-
M7QB,#16XEYCW-(5%IJ?J>V7"2XXM4:U[O45/<\Y)#?MFNE8K_1B!!8@*Y42&
M/YN=C_=34%#X9ZA*UW=KQUB\N*N?M]#/"!8_>"*8TA)9O]P<'^QNJC3BY.CH
MV_K^#4N'=M^RC;YKETFH#LJ^-B@PZJ]<@.X7J9VXH:@^YA'RWNJ)'/D6JWZB
M,_7R@<?7:19NF_=6JE9,[%^2$AA,W&)?O%VO,1T7X?[5Z+\2SU\Q%=K>7BNX
M%!"^2/'H(7VX^TIHSKVM^Y\+%P3J Z.K?U4.G[HYA%HX@H!+61!PWC"^XH*1
M;PY;OYEQ#;EV%>O+[BT$.,4TJ%@TZM_ '1\QH;0*UB81XNPJ)"O>9K@CBVYW
M)_XS2_VVM*7(N?U9^_(SUBE]9<Y!=:80I^^?D?N,2NB_FD&ZJ!Y1?B'.F.V!
M-&4)ZJJ;Z"SR4'1N"O<%\G;)-KC8U];QOR+_V?ST2F3 NQ:>QDNXG)_30V+7
M5,E4,?_< ++_)9?8@SKOV22#2"_LZ+HW!+P6N4$,M?\L O1Q;1:6GSRGP?]N
M>$:GP[=?@C1V,GO<-OY=A8MI)X7Q,P@80/YPP['#F75S(H.;YI&;W3U_Z9?V
M1,H\"<?Y%/[H\1O8R!^>M(U99KL'O1N6?9;]["?X'TD8BM-HR92F#,#O?S,M
MM+4MW'A0(O*K?Y1_L9R]D!1ECL/5>I52Y_-DGN,2W%EL/@-V\:'-O&9/ACK_
MA:OO/]4YG.<F^*MO6/P:!VO-3]LAO#-C^0YB<"5\<R2C%R)R?4B6[=OS>NI(
MB8.)MEF90^TR%&E=:S+("=%.&C/PJ;A^U3(WW_RBE/*/Y&<]H35+0V2&FJ=E
MC9_PVA5+6T/ %?'7\%46-PA(2T#F=V!3[,=>I2@:WB0]*ZN]<O?(#XW?@X 6
M1457"( )$7,7F*RLN6K =XQ<(!#=-),654ET.MH<_U3?3M_ 4T^1K\,%8.+L
M\9!BE,40A<J 6SW*8^O@0A'A%F\F$FLZ8RJNZ&BV<;LJLNU\A\=D8(^?(:G3
MQ8WH%N^F;FFI/*]T/5-QI3)QA$-@D\6 K'9_3!,)KL>#D<?O'Q6VPZF7#X-#
MX%/L%64"N;@BVI&.4-0M:Y=QS<F;/@-Y<#*O4.)<B3=CK^PS+#>^]\W>(XX^
MVRS+];*6=O=.RK5:2B:X,]$/*2CL8OK: 7R'F+'8&/*FT*>\@IM+-1B#,]4]
M+&!U#[Z_1C:_#TAUF/\<_P5Y]67S6:R=(X_*GFW0PX )P/7%$];DSP_8W<;H
M30/#G?^&37O_*!6W @&1H:N%LM1>A,%1XY RZN([@1/($9*O 3%>H%J8)E9Q
M)ME8HZ*?KPPN-C@OR*?C5T@V_OD1ZX63_B*F@9'J?\-$_W?NF8-/3=4;#Y-J
MG ILKQ:,WY]@F4')G_X1Y=I\+VV5S_#OWH+]C5=NO[8'HTSEOGO5._.+=B3C
M;QQ@'!\E8OA 8=Q0K_Z.\NH,!' $$7._V3EPL35OR?OB&\1W)#\$1*--(."W
MP!9"N-UA+E)_RQD?Z;UP_.H&?-<2H<3BX3-R88M[T;)'D6'0[YJV,8%I,Y]P
M15RWO-_ R"_!N;HN<?T;[6WR)W[PPY'Z'"\ALN[Y01$V.[:'7</3LWS45-'6
MGZZ-2!P09VO_#N>J!9^B!#JZ'BRL98UCP-BFG-S<+\B:F#3V:G_JH4WAA)HV
MO+0=1)M'M2LCW%NZY@O+6E8PCK\[A!QPS#2BC!88'I'N>Z$VE<@;[CX?+ZUZ
MO\9H(_,0OBW)S O>WD3OST<78(Z+6@D=E><=M@^>H7S"9RW7CP;1^,O,_)G!
M&<M&J%!DP_$GVD16<&3CQJU'5L85RA8*"48T7@GWXGF]UTK]!'H\)+QY2WKK
MF#+LD=RFW.I;L%%'0D=?_="PH=AO<$_+F]SAK OU]\LWN:+R^3N,R,.NH%!!
M'-<J?"Z\]&)SZ0 S6+?DW]UX:YH(NO4-:<A:4RK2ZR=?5J2_=ZJ37MO$VG7E
M8)3/>^/KFM#I37=*'SFW$P<//IXB73Z-=]56A(#+6L&I>ZN80R 74=.? NNK
MH\WF4KM:RY<+#Z'YTKA]?+M@S<$XBL5+?#71O^M. ?MDHLI)R]%262U,5 WA
MPAKS=J]J45L2H;0(+__2 &5\OYS$FK6+PR+KE.GS)+8QR8L;AH<?N'\0WFCI
M^D) EUKWX%/:UPCF^AVC]FP622ZW<Q%W>%8Y?SABOK38Y64-:TS#@VW3EN:Y
M^O.=C53Y4V[G?W=K1;-!@(*60@E-N(6FZYS!6^?V1<+E&<(=\U,0,*P" 8O?
M"E\B!GRM89'(-@MG-ZZ8QQ$NCB2O<T@]'HWU%7E_':"W939_A9=QY73,EO/B
M2I$8%W_+M$W2 B;N%MA'G6^SW!([4NWGCM$@(CDE[E8AU%K%T?UH)\ID_[.%
M1'7EM69UU7+_\7;]0_IXS5Y^:=WI9#LI&^N*WK<B-RUG=]Z[M7Q\X/]A/S>%
M;8L,'>&<V>V^%S0M]7Y\K/6*OKTG*8<M::;P8&K6L,*G%?9+FQ%[7U[P*UW>
M5P_1))%^VW;0)9L7JD6#]5YI$.];.=Q1<*8N<ZI8O&I@'\Q!:L,^L@L/LDU0
M[9N-FYBSV98M4K3WW0";,G+O=/MR_1987".CIBBQQ]+\&$NI6CX@>A!S*,A?
M\);6C=,Z?>T;.8H;'OA4];.=_U6LA15[J@-WU:U7L;>"];^T/\(W>8HJ-WI4
MFE%M,8]A0^FLG7.,Z\@Z0AOD6B1U7-&LASU^3-UY A8&258;DT;<A8<CSL4W
M(F:,ZWW,P]0&/E:DJM;'MAD[7[T=+'U=YY27Q(J.D>T]K)3&D/M+*D]QC\I4
MRQ*A[ ?)-'CO'X24W8D+#1<2:%#L!;EH1YK81P27FAV]$-<#^<AJ;C:0JJ]
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MF;0RJDQ=.3FJN0"7:YE9,=$;D/SZEFN@<&/I8U>8<5644:^[S15]_JR[5 _
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M)BE\)Q(QN7!1\FBRW\NS"3-\R[_4=E\+?J0V/+:^(X;S97=]F5(OD76MTJ5
M_G.<7GS3C'-<Y$(C!&R&0\!7V#0$8)4AH/S [^4!9I3=3##HVT1JI)MJ(;%1
ME+B'A!,GW"7"('J$I8V WH: D:XU" @2W#"1#9AV7I7A,/[MB#OY.,OI,F;>
M<1MY(-& GMPO2,5J[!K7TZKWN8-GCE%'LC >27@9.]]NV]<B7YKYC(8L<,7R
M^E3NMR(AC3R,.Q@T8;1L[RM)^ 8!@:\A8!CE?'1AF!,]YO$LL0H],<, JE1V
M/Q6@7F:_L?G9*'"OGZ=;VC/FDMC(\IS^LQ;R(BU-^[@^:>L,&W\.4UW53<S(
MPR/A+_L0X&0]WN&_/Z\;E<D3_TK:0B#0^<9(@>)<\KB29(&11D ]C8OWDUM/
MN8(I9.0+F?/'/\>.WA(K+U]/_M!Y3I5S3^0M+D$L12E(F%4QY Y_53::5-IZ
MY6Y!E![Q;&@I9D.T#X&!]C5\8><N!*!*P"UZ\.NG+7(\P3;U8%^+<*6J^@VJ
M_":XL\5*QH AVO*/;5%8/=F?Q>U.80*A#0*:M#M>'NF20P"<[HNV*03@>6!G
M0?3\!P@ 'T' ]#6B512F:7'X/OC&:BI>D;45_A_!_UV"BWZ]$+ M YMRJLY:
M2?!;K33R479V8RT\I\P9^$!35K,.46C@9ILJFO+0%I%#KH8H(1Y0/VZB&7^Y
M!C!F)TLV(""J7OM^H91"!'TER*.5+(0)9U>)Y^TT)OCSH38J?U9;9GCFL/%B
M_>P+@WTM%OWGW(Q9XQA^UNKK!E +T^V$(_!G!0F14(G'&X(8YY^U9G!DN&C6
MZABDQB_.9A=6$ACF"XA<&<T/QB#@9['LCR-75Q';-P\)++B>-FU3YU\TVQ#M
M\"P/1#?''Q,7$%X#]E.LQ1Y>?"<])JT&\XO.'@@XL_.SR!\F<$2,"=@$>&FQ
M>6OC"M9Y0?FJHCMJLTC4&8?]>4$ \WN1]$^0K!^BHH.'-C%=D6JA*^"4F1UF
M9\L* OQ0OQ>??@%%Z&H&.6B+IE#)_\H./<?)H00EF'DC>$N2Y]=+ ,:87P'E
MW?(,<%>7T>F=5UW]KB"DTF!:<IOH1Z/>=^8ANAH-ZXIW/=@:,D2+%_6T%?T^
M;"O3_O$>0+VS83>_.YIC3>ANBN8:4I<D:4:R538NCA@P:8@O^(74@U$B2]$=
MPR#$ZZ*0.!6CK@G?:#M5CBZ;(B4(>$6N]M-NZ*,U\&>QC*272&>'<&1.X*J"
M@&)7O_A)V4?/.AD6,9O/E\QWMIX1S5+TNUDNW4+@\68@QOYWKF%AJ\C->>6D
M'K.(/RDF>IPT@^C&A>-]%-&+PU7(]@V:_XC\C\C_1T5ZBS\'9\G@Q[Z5A!=E
MO_1QM&561(;9# ZB>=-5'G')4[0!'J2]M=OC%4AV5%F.O7%5!F?/IW\\WQCK
M% ?K]:[O'KWXRI)M1G&&E2T_0U-FTW[QM2PU<9%%?0 Q\*[THERMU:.I$ZKB
M1CG<.4**$/!M"3Z5*@TC(KY5=(P/)AYK^^BVZQGVE/'""R\A8&&!>'I#O2$R
MJ?ESOV[A.6_>Y2BL-9J89=!=><3,<AD"9IZ"C;)><(*_N_D1CA8"6#[2QBT6
MY?YY,#&64N%^0  .-P!NS,+Q3L]E$6G(;.).RW<3Q..740?;,(+X/X( <&:A
MA^D$IIT&"-C9R84 3"N(G8!MHE.(NE*3$02" I'3(NG_56C2$+#O2C1WXSUB
M:*6 [S[2WZUW-:/!6GS"<N@EWNM=J']F]>IKN]2G>QEO8P/ET-]YRS]_X9TS
M9R2&XX5"<%A^!@*41/WT#76]+!L/SJN*C#)^X"P1]/0L"R\5G(U1F4T8C%,\
MY<WD+R9AJ*:#J-Z.8]A#X*^8L4# )Q]5"/A"S-9?H[!WZL0A0'X_%@*>:Q/3
MEN->W/ >6&D+ 1RR^FE(HBU>J3>"NP*V<"P9#$OL<3H^" (6S7K!S3/PS?05
MWM] ISZ"DF^>HI_^GQL)= +4Q -U_6<(^$$/3BD/(AX0)K+PX3B#T,.\/S?^
M [+\PH;C6BT<TW;!OX,;9FCZ\L@C=5MXSHAWN>@?6C=#O)P)@6O<$ "D$Q.N
M;$DM^?X:?-;Z>QEBP/Q/C?"I<YN88\I1+0*),H'>S\J#=FT4;.T,O99639M
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M%_H+6 \B@V$Y13821W7/J(//.9/"^-&A7BIN<$,\X\K>:1T95FUD>"0_ NF
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MR'H&KBUZKHR_A@ *S6[OG-8*U=5TS&!VBP0JHE>]WQ# #OC9!UX$D'DD&HH
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M:K1"*:DFWO#<ZDH&.*UV]A+)CS/TX*UJR!-?2MT]6;HG?/#@__X*WS.QIU<
MK[ (=U)FM]#HA5/R>MZKW52%<8(E@X,K :T:WN/C:?,!-+2M7H'!W6RUF\S9
MSUE/4GNT.ILG+]];0SSAUO6Q"[+5(N(,RAO[$[=S""#DGMMB8X'AG$SNY 0+
MDM8\R*4HHYC9Y8[V24HJ*,PYL-,"[C RXJ1'UJNN<:;4YQ1JQR 0FT)GS3P3
MWV6')!*]# Q_V]OJ40\XJN>W!JN<YA=RWC$7[\=GP/JM>E0T[>=LL7-8]\?2
MQU=ZW4]$/?G75"Q4VE0VUFHJE)3QN/6Y'5.M/M1Z.7EXMA"G,$<>:.*[.7>>
M[S\^$5VVEX@J.=9OT':_]8U_[1Z#5;&A&I-])%IR?:HIQ/\A,=7,WCWQ2H^T
MZ@.TG?Z!)$M\@NFHJ<+FK* PI(K2]T=^07XQ&VP'OVZYS@#&N4WA)DT1^(="
MNS#%TZ%<75NU)D!=$]R]&2 Z;JN%;9'?:38'"$EZ<OBBE[ZYGX%NYK9P_*[=
M/C'3Y]/AL\J%'?'_E]3D?T-+T/H0P#E6(P*HNC-&,F$^[Y!_/+'5>Q*92LZ!
M1+)=/FQ]ID(::ZO<$BQ]?68I=7I]528B!:V8Q)'!B-#$[<],,K8/FW^87E1R
MME83)B0L&DUV3//,[^87F1M-5JE\WX+35JBSL%D5!]HP8>=-/(FO/Y1FX:P1
M2I$;6D4"9_W;('8&@;^XIB^)_4Y-&11,4@#2*#5@XE2 J3*+Y7-R*O<Q@9I*
MFHY>,#LI]Y$4."W8LX+UYNAK8RE%58+LW7RR%9]6WY@9!>OAFX-3A+#C].<,
M5#@6]21>UD/*PR"V/P!DU/TQ,]KM%!\JVFMAV5<;89LFKY#>"VEM=0ID=0>@
MV$]@[2$=2JSQ2>H!?Z0GZR!I@BGYF>?'GVL/T$TU.+;-C4^.J>W4NM"HFJNS
M;336Q7D+_FC.VKZ3<H=QD&QNQT 7G0;O96R6^US@U+5-]9G@I]:3/$GN5NJ>
MSRI&.[55W(W;.GY$_<PS65GIXP,M*Y3YW+UQ8+?0L]L5IW=^):W.A:< *XLS
M%5(WS:=-E1*,>Y]<.'TFIRB)53@]6!BC25,7?[ E]+:#]NNL@=;TB<PB$9'B
M$X6WQ:7?3QF=)E :7Y386/([ERT<,A=^Y5%YOF@SQ5XPS!N<5R_7D+[)#T04
M=:)34$%RZ.;2E.P)8F-;R.445(W>#5A8.'EP]JJ^G6J^4I6#:_9+%1\0+VE]
M;FQ4U&;JVI#6^_*#)?)(&: J+-Y;\NU*-3365.453%C>#HR!/%<CS#(Z\FG\
M2C3R!VR4-:#>4WKP.DZZ 5MD+("6VEH%[^7F-UL*E'NAS,)VU *?I8A*0VSH
MV6$IJROLR$YDBND'G 4+ ?C#.K5>F4#29"*YOTB3<>]M)CQ(*=D)K.KW"80_
M!KT6%I;YX5G%1ZJ2^'&D9._'@9%050X#2.V=C$G"HQ5VX5IZ2]L\?'*HV[?A
MK.^:%VH^@H$Z$U/5+0;+)/::9M_?)<#W3T318K19R67C!CM::D7=$, 4[;VG
M$P+P1<HMU(K4B[R7%BX!\F/?_JNE^O_M^IZ0,;)XAT%O$4#]WX4$#8_BC_]P
MAJI^Z,LJ)<_K]PIR"N]VNJ>FU&>1222N7"KQ7CD?M*'YQ73.O&A\COPNL?H8
M?-K)>*XJ>EHZ_0,WSE\@=6CZ_*IP(V34^9CSEO,&>K:B8T3&EW!'T92B3WRB
MC\S,4Z%?!?D%V:8P?7DW&F0JY>:;?E(&!:0S<^98=ZEC.Y8PJ3)WJ3YZ@YTX
M_!3;$92M46HOB(=:XS8*N6-_WU ?>.Q=,,D*L7G"1S";C "P7ZFOAZ@_$C68
M2Y*#,>4$5=:3%S);6X7@L7K0(T>?E _X"_]B3GT1NN2CY.O+M6IS+>9;N(4+
M8,IN@KO#%CP.O'A@LH;X;^'?GQD:*EVUJQ_BN;E*\YGE,L%!1B-_TF.5()-2
M "BY(/<317L3 OAL:7Q'<.,:H:X^5U3?/K2==Z6SG?10T=-4&0^K*+5.O.U/
M$PZ:>,&<1*H1+,&/6U2+BH(YHPT-J6<-^YRE.(.4WC8+3^.B.5YH7+]0V^OR
M0^<X%EMJKI3B@47#K(GDHB=)0=/J!$JT)9R<P:G6.ZDV,71XKS.MZ]^F[[1N
MX%":,G(&-6:$<=@U&Y[HN ;Y=#P'=F'?0O3FA5@Y&F9^))[W.#Y.7&433R^W
M N>7BPVI3;6CYJ:2["K%9IOPDQX4D0P*1S65J>]9L%BW5I!J*,W:NH49U^F^
M8QM\8_+&7"1<(%!C95G<"\)0_UV!C;!R/J)?$E_R^)U[T8_]B_W..B%1MJ\C
MA!^K>ZZO2M^;J4U>\[&-CBH5>L[(<-3,;RKH?8X@7!W(HM5^AW$X^.W-N.+T
M=D=O:>3+Z>GQG+E<-J=RI])\*X[2/!29;,H2*W2N8'527?.GSEC94SS8)19W
M:66MQAMXNS+P0R2#'0CT<[,O?>=WJ%J;54O\"1[.U5D*KQ^'A?#R;3D$9[%+
M[1CF)L:VN2S\TUJ#3A.T]IW^VL730:+Q._SSK,$?<*));= D>R^A! )PEV*!
MDDU,V9,=*@3(B<X]6F2\&W9<+^:=#TZ8EN%UJQBI4Y-R3492;['_8/_^Z:K&
MLG^?6B"4=BF0*@9F& +8(G!  ,97G;?\+&9S.6?0^P!V!' (G__;OU%::^8$
M$PI8V?8AH[X<+PBY+_S,C@S["L(^T(8LLY0^0_REI?E4)2J%$(S6N(RR<RY&
MRTQ+BD0+169"PXV[!4(";1=-]@O-1P!"&H>=N!7$XZ)$K$/4R!M5QB4C94%N
M=%\!*/Y $MLQO^A)7?)$=N!$X#+,G75L=_*C#EY&K[YMHS8R+P1CMN3]6SGQ
M'-)W UP&=C44\CS3#U)S C95&PT.[TBI/'<5Z5&I:]$Q!65-/ <4S7C38G)A
MPH!&5R7>\;T5KZ_*<.SN\/G)9\4IF:V:(P0@?3ZP1HAQU]=T. \K\7V_6>PJ
M&&IG?_FXDGB',>)^,#RR$*5=;A.;85PY\[-F,RC76Q;TBZ4]*M.6/6(IJ)GS
M56I.X_M??+C^W&->??K(^LC*K3]G-GF\V:ODXN.X9EB0;[F;\B <[\;FB5I[
M[U:ZNB_RM"-).=BZGC3IZ"JF*RA]\!X5N-B"$TEVN0N,&(A4_ RC(ZZGQ?H<
MQ5*M&R*E!7;TH*./&SI"CT_2L'P[65";:*B@GF#O%E: :AW_,:9*#61R(7X3
M-W2UF LS_==GM+Z=$04-MY'MI)#ZRO=2]+;Y%J*-]/K^&;[EH"IL+,XFT.^^
M7=:<_M%1&RWG(( I314R/W$+2X;]9H5 07O&H J_:=2JX-,/:2:U;*9RABY)
MF GT57?-9I'U^SN?O^5R*_+2%*;F2]+Q3*OP3&M_(;$NS+0N+"'L1ZI?SK@!
M[US%507UUQH+!I)/4W>NG,AHWF#[V\>,UU0=B)TJS?((XAGJ&DHE6F"-M7%3
MFRP_AN_3Q:R5["& ,]XYA_J>[X_36,$J[ ;7D:)K3E&YV*NY+V\_QRYF?FSP
MH_[UT7])8'6AFCS'CY;^Q/(],IC4Q-!B70Q?AOST%322TB7-:6&B6%9\W8$U
M2'?7LZ(]7=K")1 L36+Q/EHFI]+ Z)<Y6?!=&O%3(XM\=5U_<QI-SO>_@=(W
M:GW6KM<<6_$B>*V44IHS"6G*R47KX5YEEQI-4!9#@:6?8Z,FS1T^B\_A!K*?
M=*,^NMW.EF-LM%#A*>AH\X9!U(8/:5FK5DU(?/&(-.3I]QU9??>^A2* +CGC
M?>U13T)M=^&%UK(@!G8&.7'ER>61MHZ&/1RVPXOW@;<E]_OU%/0]%4NR O)1
M.'X&(?  J,!<8-WW,M;>M=S:HOFZ5J^/A6T1VY1F85P<R,)=J23ST$0"/U2<
MV:+JM%Q$ #D$AKLT95(64-MA# /I&7\$X(1_[JWR1[;<#+S/Z@8Y=;+=$STM
M-[O,QK-A(?<I\QF\'['^F2+:3AX,+E#Z?X<3?I?_X<10Z#_77"FB3U__BO%\
MV;H-)="&]A?B#%GF[@K"[R-YG7I!T-V,6KZ?WS'APS;Z07 [&^3L.Y,D79II
MZ!2(ZV/]9FV=>:\@RPS1H+%&ZHI@T($UC59*J)9:HJDC<,D[RO?EY64SV7)W
MM(P3"8/Y;"4*<77FG>#W]9/[CL*"5E#":(:!_G2=H+A+R;MRIM$&WF^6"9TM
M,'ZSHT=JTT5G&!6^1%L3$70*$O)+PSDG]F\VOQ\_/:VS:)?=5[<6(:V;KAS+
M<V)KB2S?Q(>Z!?R NF'*SB]"*>9^%,^>: <&6?P)TTZ2GMIL":"/E7MY?-S=
MX?2%09,Q\@<A1%6'?]/(]>&%Z,U^^>(KN!3FK7IBGXQ+<?]CJO@-N97I( 4R
M_E4'W<Y?.X6I$1-Z;8*T6">DSZX37V5=%H&]N=/YW/J]/[2\=8WEC7VM(XV2
M$+_UU/NIE;F.M(SJ< ]N.1?6!6]?"31D7N(U&_Q9QJ]P+P&#N D$,(VJ@OD'
MGU) O'#7[I^?"<&GCKRHZ_W')S7^&L\TGJQU<"I#3*IU4>K[LK?5_U*?V2S,
M/&-//%VW:FM\&V\_!\RMAOPB!G,C8UB5VP^UP7\$\/[0MML%?]%R!OWRLO+D
M8E_FZJ,#!+2'&9W?O+*2?FKRU,02 .N3[]&W9&P7Y!,3J^HMOQBDCC"+\ 7A
M8L=/I<K7R<;'UR5($,(,\R\PTFGM_Q 1EF"=].<QUC#O(P!6(YF'D40Z.#H:
M5+]9,6#1K*79M_>F0(XJF02>8,Y$6=970;^S)&RC7D=H3OUL@LSQ2X2L+DNB
M*9'8$/T/%+V)'KY0/^<I\7RJ9 :C(^_=TH';QJ^'3\,+CT)8&LBO!EI2*BZ*
MI59"W=N^+YN$WQ+#Z8Z:K_MT5? &7.HO(2'M)AY8(2<;&D>!5?=8J8O!3"9!
M[S\1OLDCUWH*@+Q-7$M86T!Y^!J/E=578#A6[*8$!CT4G)%A9$'@Z!)K%%PN
M+.H+VL1ZZK_,=:QYXN(NY>,IW5#3L7 SYQ"2\[Y\?&_3+-"1- :M9Y=1\T_"
M%I6"WKL^0#[ @ JS8@,;#J^&FA!5]YIH23H/W*)HWPB]\I$'QO&LXP9UWR15
MM4\<I'J8U^;&/XUGW&FS"@^,;;G$A8PM.P*I7-%W2?>&H5]4S/Y0/)4"K/X/
M6FSBQ/_68BLJ_D<V/?^"SM55=3$,29UUTW"0>\W/3$78XLI$LHE_W^59WRIP
M)67HJ(H$<R* 2.CE@7<0=(NY&-H)AONSV%SL?\0Z/[BW??3*6UQ!^P-]U';O
MZ<,LXWFYW$<M!^(,ANZE<=YNIF4[*FZ:?7\DM1T7-[ /T%UZ/3;W2%GX$,,!
M)^K&HYD:ZBXU?L#Z?4"!_+&TKGGJ06<95?"3-W*,%)+6%Q]X%V$W9BUG;D<N
M70.<5G/H=<AK#E9(5>9QCFR.UD2GV2K"V..'T%F[R#69*/W!PR40*HK.R%D]
M.KU!1]2^6*^K4KP?AMKPV9^I;W+EGJ,+!8H60K!UP]_-=S[1V1.X*)9P_UP9
M<6<<JN_6*_=JX22!PIR*^T:[H#&LKBS]F+M2X"2R:4'H49F> 1LG&Q?+UNXH
M*3^_<$B%[;[1TS:#%Y OQ(_#LJ(C>B@CQ7/K;4W#KM1:?\.C58,I1UDJ!P_9
M+R$X<:&5>6P^G$M0_<$S_Y4U<L6'!^>%!T?*S@)+I8T,:=&6F.^B"_90.JV&
M@T3<%)@;0</%D[0$@QE+:BH5VF9B2&A1(6V<$>3V01D!'"T]FPO2O,^ZO*4*
M9O[9MJEZ]J*$(2=T_&LM?LISB-,)*[^09#DC3O'X<>+X[RH='*,WJ7Y3Y%X)
MN)&U.L[&7P[=**K[G$#1\E_8[ OH(_QI/E$$"&-54=:=:7<6BW,V=]"\C2 C
M(?'_X:BB\BZJNVK_^>UG)1[M6I46"=*&C]]5%&^G>S4UF04JC%9AD4IJ/5D9
ME.X19M -7[%]A;2H)RVU2TKT@;Y?P.=]-<Y##],SKD(F<PGC7UQ';#^)IF_6
M28I6R6\%)Y2O-^P&;/R^UW@MFF&E_T=@?Y"/>^#IA3A2K@1YCH/#RPJPM7]#
MIR1N$XDSZTN-IV\MN7W/, U39705B4L?D[Q=@;ZN]-$\&P^U>ZO(R[_L0Q&Q
M[(B)Y'T#:K_<DXH.)J'6-C5L'O.HK J>9JMLY=X7F)^&&$G08B&Y8'PA'BUM
M ^(TZT$N^8$L_=L@[=2 :8VQN !O*H_GL#:)&I;""D<Y$XPCOM]$Q[(DM,'\
M)A@J)95>'W$VMA+H#5[@AI/X7;8$9NGO'0K,T@@ZEY&.R1VA_["<RFEH#3BG
M86\KHZ4Z\/:UD4/C42X5,\U']86,;T_4^V"N1 \ZW3N^AB;Q;FUR:G&<O.38
M,?P8F?Z2+,-UIFCXEBI(*59V0^*\)1>I  $_WEUI!* 7M@T)F[T2+"W,3LTX
MR1"4?[D=\=SG^8JF6?KO/F<9_O#\W.P3UW&6>-JMG3K!H8\J.=W+QAJ-@_!#
M>[AFWYE1P ":1LC9(#QAJ^'*@T_F@6K).N2!.[SQO#35+Z1J6<G5P?6PJ_Q&
MVVIA-VZZBF2@P+W\[5)[E& "U:%#L9Y1U(5!TXO3S]'/U%//'B@KRU\M_>2D
M)\S]P:GH=CMO"/EYE]_5',P?<IVT+;JA"X6H?7[(, 3_<)-\6:&=55=4,I_Z
MOM+^M%]UP.H4KR[X?42NHMUX!ZNPD->K^[II9"EK94;*W8L][2(CH8O52<[A
M:F<=U7NU13+K2C"<6$#!C;V<S*5\LG+GMQQ.^";U9JJM".O,KA?76:&C)IO)
M\:WE[4YEA:YZ8 F?^2>+-XW/&2C;)E=<EGFUQX:G%6H4#-Z8-31$":I) ^/T
M#W*G[][=)LP.W"ZGI"T,BMT'8^XKZ[I1*IT3>HV7C(EVMWDW'[,NA;_+6D4
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M[0.S^@"WO(K*:MA)&>HMOG2A)P&G2V^].O'N@\Y.17[%?H@I][61H8CMO:F
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MPJ]O3_?7??MVWYGYS<SS=,'B#VH_Y^RP]GK?=YVU#WH2O0"0JBFI*@%86%B
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M2T<#\V^:$#M,?W,9V)$VN 3:INS1A@JH9;I$)*&!J&$T<)T!1G*.NPX]77)
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M;# =H\)T3%$=T_M?V#;,5.96XR234O'%9'XO9+KWT\CXC!7HYB%!5)U+F4S
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M(-<D9QH)Z1A*UHZ6(_ZR<'_WO&U@,/&D[NM;/X'DEZ^M:1AD%*TQR*4!'<M
M _%\J'&S4VG26>,^C-9V4;A+B=':@K6Q&*U-JFR+*%OB"RU$\L!!CX>WIT5+
M>AG)@@Y8\[IS>]AVB&ZR'4:<II$\QJC"3QA5J(P&[II?YD4C;(K/WT,/LM#
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MQ)3\2ZC7V""QFYR@S"_UT7J7Z<A;EJ=DCXUMC8*^/+M#?HO^8>5,0.*M,>M
M-S=Q< 3\$X81%*C_8@2=$S081B T\Q+#"'Y6-9FLL69+ .>RX6<4>HAY6+_&
MKJAMZ62+Y(L#>Y[A>]>KI4P#'+W7W!2D(1&V/LQPZS<B<N%&(I_10)B(<9VA
M].7^H#=;V&3@O3^=0 '.4\+7D(8P#<(6(^<Y.P,_@Z1J!8([-K>M:&[I^H$X
M"/!I6%GJ[[>;E[OENJS>7]RY3<@Y^"%P::?^)YXT:S"U[I,)L,> 9$ W>/C(
MH/-38D<QHVWE%D[7FY?#5*=!MKDO?[;0E]MF1GE9,\C@&(SZ85B(6K7-#E(K
M5^K;"Y9-B&-UMS1WDK^T:Z?7^2?@0C,<$_!#T "]/5(OIR/#[L>0S?G[>@7A
M!SX?9]Z];K/,@ "6G[ND ^5EKXJ+];RW+F0$!S"@4LW# [D"%:6W<1A0P54%
MP=,(*0UB,1NCG"]8>,QJ>+'N!\<DC5IZ(/=NBSY&9(!22*/D!TT<$^?+Q=Z*
MJ/?P"&LP=L[OB(?_Q'9PDJP#<$=C"J:CY'^N\WO[^_(I^FQD;T*9CHW=4N:D
MRA5]7YL:&1E7.I(0LN2RIE1WF=\WA.Z'(%W00&HAY@^X#Z,@<D ;YUPK_>KM
M<K0^)!:EMD*;.D;WDOJ_ERBZY=%TTZU-(7?%L9*D T:I4K.1GO"5R#9U)U^;
MG%L:7[CR?_OUH->L+45@@CY%4AO\XY5!H(UY>3GW"7R+D2Z6XAE'RLBRP&Q5
M7F>SHW&I']:FT^!7A/F25K"TV09N?%[72:>B0^E ]AUGW5)MNE#F.P.MS9 B
M_N>@@C\SL(P4#WO[E>KJ!'&+-X0];!%4.O(];"D J,'3_ U*SL-8,<'.GO?.
M<5(.XCH^6?-C46K/T'?^@@3Y=[I;UIA!/SB+/XJ83XFU3_ YUC[[F#W9PF(?
M5FV3%;;3N?.30--9Z1$#%K@ADJ*=B0%YW^$D4FK''K?=-<Z.Z_$-Q2?QG):*
MQ'@,!C+*.6DDF>O%G_CJ1> P[?JX3;M(/38?2X7\^P1$@/AO,9P;DRX3A5:;
M1N#._KNSUM5)[;L1%T#%6,IB6:#GX]DP>M=.2:]PX+PH'+$TL93:S@,:+$'-
M-ZJ2ZY-G'=D)A\$",WL+^B)\Y[JDK44FG\^7NX?QB-XNSIS<),M4$+O7[\!:
MW370M6KFV4T@(6U!I T>.3(@63 /]V."?[_'Y>G7D1N!6U+C2MSU<@FR=AK.
M/^-/TA>'J^3]%^]7R3N=./&R2DY,/'4T,NJ*/-1BCKS)AI4@310'AIEI+<E-
MT;4962=\8B@X'XL,[#\T5LI(CJC=Y>87GXY@K*%.(['XTOB\\3*]WC#/3-7F
MR_,33'2T:=?O9O5^,SX)B"8'/YMQQAU4")J_UWEX$CC&#:L-YE"9%Z=HL2:,
M()=0Q@K5A*4T8 2[%]>J*I(#_F-UR7!NS9"$-?$)8P4M)]M:L*&\SC8 JGA4
M(T=;3U&+6O5U['SJO'M(B( IMCQ[\I%*X!(6)104,00>.SX =\Z?<4WM7=:A
M@?6PK;1AN>>IE)-G9)L_W"0S[]1]]\W&SQQP.N3KYE=93P[8=#&1:]<B-T34
M=7DEU#RAAT_->AJ3NV)U3L82R[.Y/IKSE_ Z(ODG!-(O4M<L9U-\%M^TLX>1
MLQ.#QT?@'1$T(%AUV8 &=FC/4'^I.KK@&IUU-HM]-4@1*YS=HCK90>QE;)_:
MD![NAIM.FY)^E%BEBAZX57#CI:Y0Z9/Q^EL0!R(ZG[[HTN_[1=N0T_P[]WM
M01-1%8-HX*_?+30$'CTR^/XW+[4IA_Z=9J\]O)>T.N8I?U:L1B_RW/76&;%^
MLZ2\'!V?8D&'HR+E$H4H:FJ=&NRP:R*;4E@R)]K0-[KO</';ODK6*%Z'(W;_
M>&54:#%,GC'V%U12M2 F]!"QD(*VFT%(N>Q-6L\J_3CCW&LEB2Y62E::HL$R
M4BG/0?5?ZH7,$:'PH%\ZH>GUT7/N\5;A/*)T_(TZR^6 %$&/'E N5<_?'=8
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M4+$+9TGDZ*+3W-24((#_4JZMQWXFG$L_3MT@Q\XH[=YX2K#W3Q42SC^+1S1
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MYZ*EJNH8V;S4<YKL,2SF&G B3E+N3T# A7=K51,SA7AD)&8V8P;&(:,NT"+
M#% ! -79.R5O\9KWS4PE>,W[-P5U^1?C>>E4Z9V:9%S-(WRYH1ZA,FW=;'-\
MH17QJB*\IAM:=N=: J]46(<0T;U]7Y=_=5R?K$."P&.N)/)"7P/;MU%*&W:F
MPYC _ 7EZQ+OC.-N9.4HE%5;C"N<T?;C/6_Q>S&QAV?:?KN(.+88:T$X4,Q(
MGD@W(5_F0CQL,>\&DWTX'*S@V>/G%S./8Y.Z*C'3IEI]>P+/#^9AWV!GR<,Z
M'@AK]L@@/'K9@R$%K9;4IAC3!>+25^.53M9/%;A)%M7O)=^!:4XP"VNNL&R9
M??;*I3E^0)UP?+/VJ\D-/\=,KYB[QC<B#/1GY:6&.R?N^7(P>'SK["-Y&T T
M@N^_BTZ;\!3!QA:J\AC2PER]N34^ #)3Y^;HLXA=3 X;&I0QO/ARZ[53H"KQ
MA)8W$/H/;4 "2^AH$^X]?@GAU(UF38PHEA AON[#$5+M'[WIU/&D?.%"5>]]
M@.M*]CN5"YFR' J;#;E_%;=49F;E^SZ*?6GNWPJ:V2GZ?N%P8U( 2[2DJ/[9
MQS6 "A-(67\;',NS&77^#6S;JD?Y".$8DC(:3))W?O6I'@G>, R&\<4%I0.L
MSA04_04Q K7O)7G$-JOCN"&LR_]24-RW-'*%JOE6Z9H8(47(V(Y%*8X1)2-+
MPL!<J,=J^U.G@*-#&&^QT$LK-% 7JY&U8<&V3)28#A,[Z_L9Q[4LQ0*<,-;4
M$9M,K2:4KZ/?3,DRN;:_ZJI(2@Z5?W)?E[DY.>[X2QYA^_JJ[A-+%I=/'/I=
MS5B>ATMB!2D.;\6=O-U@C/HZS!^;0V5Y !]&GH #' # W;8[+L777W=;R(T\
M!)="JFLS+J:P)V;W9T@% 81N^F.$<<A/7G^TT*))$DZ!Q1>83&QSE>6AY/O<
MXC $% >OM/'PJN2$=;CW/^E!)?Y[)<4E:HZ .[C_]$#43&M?Z*JM4'CY1S6V
M*D(^I7KK\,5@L%FPF$<I>K!M%I6,6:J8].Y.B*\=ESD:I%,865)A#W[6":KK
M.!I>VB58^_<A\LVQXKPY>7.:D^.+;TG&:K,!>;R+<!YGC[3'SC*=,CTDY^=R
MV,*0X541%4-]]Q.$>"9?35P1B@ECHVS:Z=%QUUR$::Y(%IX"+-18*"ZASJZ6
M *= '"XC*8WO0MMQ%"'W^R%P4/,;,F$8'&"/T7[M(,<S<[F/3IXA!#$I")<'
M^0>SBO8,L 1/7*W^%F?]^I\GW+/ (I#[!05F8Q;JRR;3-_J^9GX@7K2Z3I&@
MIJ+(3PA?^RVE]<5'UP70S^CJ@H^N>#4&-/5/-8:JGVH,N&1(W'!E"E+5VZ]P
MW8M@&'FR5%%-^VG W<@)$%Y$/'Z@X[9="H9;"D.DYY5:.>C;:R\5""?S5C >
ME"ILO_DN:U1%+;[9H"%032,7JNYWF/"?-ZW_($2Z'*=N^&"G3X'=&UY[)P$A
MZ"KLS7T<8' ^!0XOR@$[>'-(\.E?*.D[O[]KM+[WI00:Z)+O,"I] //UKBR5
M& 0/>+\,-9IS=R7XI@QB@"!;<E%1F,&[?:TYMMYEV&]=ML_&2+01A,L375D4
M]C(+-8=KX N0<BR]):NEH^AK]$3#V,:+#.UVF2% ,9U/\*XK.:?NG:X^ DN-
MH-X@B?IAP:T \4+S']W6=%KW.33=J+QKT[Y]TDP$MJ6M; &FY<-#W?T U*T)
M@W2OA?AK,QK%(GVJ=L6D2O;SL7N+\D[MRC+**BUZ))4_JUZ_JN3]E,O]EV*\
M'PD.,@E,_(1,T0*]ZWU@,FBGQ1^M"C<TE4&6_Y3I-(P(&NB;E8K/TV5).5(4
MYM5L2B%?+BM,%,C1&4XG8?<85#C*=H?2UC,WR*&\VI/*U,]/U/8Z"&96OGZ?
M9<\1DV81R58>JIQ''<M?R!?J:!KMM'D1QK+@#E._F&IKY:I"DJ2R<;N/9 2'
MDDJ*-K$,#A_AEWX(\>:PM ](R2:_)LQI%"A$CHY*?CN_S==,'46#H6\MI[S^
M%=LY1'N_AC_OV7/=SDNB,"9!4I)7]*'*).NU_]6%*;! S8$7[4-+GX0[-^XZ
M&D[^MCD\7'):]\BE52X'1P&5G.O2<!2PSNY J$J&I=TMZQS06_QJOBV^_05:
MH"5I K&L4?M$G+::@N<QCT?OR_>@ +=N][W=R":72,OQ$3=,E_[RVN8E4WY.
M068;/DYK0?&:X+D2-K;"Z6""C=W;1M@K:,K&< 61MX[I6K7R&K%/.CEM4I[<
M"G:KB8E#QBVBE9DDA4RU^XM&D'>'A 2M[,?*S&^57GY,'VP4DD6(*"WA^^F+
M1.6PB?=%FOFP-N<;%]1+?]D,]B8D("PD-*Q147R.DQ_M_0E)>7MK+W;\$N_X
MRV!16F4JL-&HS.UP2X\XF*YDI#+G\\* Q^A3(,J9<>#+FKRX:ZZ]J9/4Y'+R
ML^14H9J6K&"IY#Z;G$=MN2W4T5A9#=[AI;H$TOX)%LDNQ)?LIO.D/G(I<=MY
M-#6]MPX;X9:$J[6Z814;$%4'W_<6!3DN!'0_N#9OL[('/+E\9<ZCSI4G&-B[
M": IQ?<=^Q=VH)_J50*]LGRAMN%"^WL]/B[3D_FB8:,*WH?2S2#"AYFL0L3D
MA4^N78)A,N-/Q-HL^9F3A^]Z<5FQ&[JI KZ-;4?DN'LL+K>W=CC[YD.0VD]M
MD,RHSC_$04I@ O\3,/^E\:8DZ7^N&1/L\&U<4.A&%HE-OTF"<SXK3DZ3OY=A
M3$@C=^9:L6[@JX%ZYX97)WD*EZ6JYE8E,V]S][ZJDV^OD7\1^*('X+MRCTT6
MX'?W-^QZ"AA.!5$.FYJB#*(+NSPXOAXPWE;8?F$F4:?^_ !")#6GO*K"\7[^
MRP%UR"R]Y\:9'F1+SH6&(\GW-WE*,_3::)_-]V?R7%RAD#DGMIB#R[&@_]7P
MA$4(2@L7 <-/ 1?0X<6;.X=_;;G5(QG]YV0%Y)>6VH;@/_DH6"KU_<1#YP].
M_GL, WY\"V-O@SP1E&/>^/3>\^+(]P32]:7.A)OTL^]2DH<BMO[0H?^;$NL[
MU.^*_2782P'B^$H3!P6^TD3KZ*U.Y+6]B. EVQK6[%B['I#\[IOAQ*5"M_Q'
MW@.F%J8-G??=ON0NJC!S)9!R)5 "@4JHS(6O8+$J;9 19!Y-I EONE>O)_N
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MLV)=22]"D^HO7(B03B51=$NQT/R '4A/_"RA1 UG'-<9+\D7<TG,>D#O/*(
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M5/96N\794NPL[AU,H:[CTW#K[6ZBM_H:BWI?UM1(N5 J'.^;%&X?R9IUOE/
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M!"@>E+:C&^YAZ5]7T,$]+/T/<52D7-NDBN_DCG);P>?[Z@WM*FN7GY_][GA
M'LJID*0SROR@IS^+-LL*;7&[$-OMI]!@N*\;)5+DEBN^X?JF??-9^W2F_UZ/
MNYQ-$K4(RJ4=Q("YWEEYI+N?]NR99>ETJ5.,5)S:*>![]7VP[&V8=\;>"?U^
M-.K303)GD7W@FZ]']8@)O@@%>Y#8\0H7530<'";9K(NWN73F-0TT5(,!BVK;
MFE?$A2&\UVBHY&V10T/0_^$;>PJ@ZH(XH7TM.(AK"#IV?O6W9B\E/'BG#G3D
M"5&%TM$I('T*L!:WW#K)V(74SVZXT%B:VW-:CE_0"OSLD3UYX/TMSFJO%V#
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MG_E])?2V\MGSB0O9G#L6J*69Y];O=5]/:Y<_^,XRR\AAA*0H2")=DQM-GPW
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M)<L,JL'$?Z9ZBMYZEM__?7_/^[Z_/I^NS^=Q/]><\[VN^SKG.N<^USG7C]Z
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M&I-$^&?F.5D"8"8\ $KOCJ(T[T_L\4/=8,8/U5']RU 'TC[1P7U'!_H#.IO
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M#@JB8O:QEUT4,@!P\*1@"CK9[]TPZZRPQ;U^U_)3+^7:JLP"]%&[S+ )E'D
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ME!\T*F('%\1</3,5W33PDI*U/+PS7UZDIM]!WW(7[6F#1]2-Q]FN 39F/7>
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M$FL +**-,FJ2K_97A"X(+]K0:\!HXFS%T!&LFFE$>9GC4<@WH:E4W:$9,YL
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MCG%**:JE"!J6>E&$%.$SK9J]K6"-G!:G#,^YAR'42L0.I/)X*^2HX)1WT";
M>2%/_4H[$^1YX1']T6YNW:[P.RRW+*9 B"&=DHGQ S*Y=[F2V+*1"\(3\)2;
MX ;>RRQ&ZHU<8:0\98#"KP#*OR: DE7\^<OE+&M M6%_94E:Y!KH(UP.D.'U
M$:R2L\2$Z_06OK[(Z7S'U#E:P7FPB#WRIO3)-FGV!*<J047.T#'OX'A$0)>A
M[!Z-CX96.\(.4K'OIQX\JH3R3XYQ7$+--THN+UZ34WJ 3=:/.]X]N<P?':!3
MK5H6J78>.JH%W_/D[7.T2'4[+7)21[C4Y-Q+$@J3P53BLR66=)CU>F8;$'BB
MBH>'BSWI9KJ)E5MZ^>W[AG!'5[MU[NL0(>\(P#P*"= C&5=@-8L^SPY=4L[$
M%IB5EYH3/G.<-BR?PXVS'[4#>!8^CBR'L*X@(!XP]";@.X?+V=/G5&-#;]S&
MF!%!3]V%HA2A6/*!L-0[(/X>W^//M']2E18](Y3WM>(I7YN&5^>7\V?XZ,^\
M:@J-POC[^^GD#;KM5P8%KZDU; )D$B+LBX0#LUY/!B #HX<';B)K[BO:4(O7
MV)6B3'%5?Q"Q80"]0_AN<$]['<J'GHUKZC:[!G<TV^-2UT9-#3BUV\\6D6L)
M/LKUYTJR,KR&%W:DQ?4:O+#C-1M>V)4@9>Z;0$UN6*;CA*7Q@3CKUJCY&[JD
MF2P0N:,D1"@4"9B91[KJ'&@AYH0= J]4778MI74<]1V+.DCY*,T<[X?1#:7]
MTA+_+"W!N./-Q*/D2Q_T"D4'#.]+M4CXTCG8B2' 49 QQ9U].\=,KA?#_#_T
MX^W$]UDEB%=CUB7*CG$>M*6.80C!>FJK=CD73+S[X@H->9-D3D7K4V.Q'5'&
MJ61OF-@71IZ&EX1Y!/H<Q&F,OC"K*VQQRCZSFF0\0JE>8G9M9X( +E +#I@G
MG#KRD]!']D.T2(VG2T.<_YSHZJ'+#M<6;,?K&Y\W53;N?[5!]W&B2=O1!(%E
M&BD/0,D>>,_L,7]4_:J+U)*%1^DXROSJF4V =&-V/(\EA48::XMF$2[-,:RW
MMRD.,^JT].T9 RQNJS=Z)-"FC $V;4?#'7^>'O+-R?LW;8R_?RM0D0K@436&
M5XNL]WW+\7)G[)5]/]1G8,RS?V>5[$E%IS89]M WHNG9#6\7UY9AUV D^2;,
MO'UK;@WWK0R9'^8)Z&<X##P5\XV"OUD.\[J<^(K(1XZB<A-@<-H$P,W<?HA/
M66\V'/^0]7:_%#HV#Z[O3;*YZ?1LQ(5%*&/?TY1MX5":2!QB)/1X]:'Q?M5<
MR$U[Z+Z6YJ-!J7<7,J!WB8E(&5;*=->/=,__.%;CH_#V7JE))93CH1-OD";&
MC"]T]-Z]X4V@13#P3?@MT+4V4MZ/PZ5>.K[&G5L=A:XNSOP_]@VV?XJTW*OY
ME\Z*;?<,?GZ6>BOWH'2^O3-;>%Y,Z?PK(9_M1\?4+2VI_OA\&N!VW+(A_>"/
M-<KV;S7FRRK6Q-'MW"J4EXS&G<FS4LRC$(H0-XPW*^[R^GM"^1#SQ*-'<$?3
M;"J4BBKZ*Z>[04/(AM&#UU'8UN._)9*E=\\WBGG;:^E%1[<I2DLNMP=[6.=@
MR]^^Z'[D7%GB;'#X]-G#(!9R^&J17$*2?8+I*>*7&HX_"'I,>["@/*T:#%)?
MS="I$L/+K:XWZ=]E'[,'$J)$ >(DA*(Z,(7RL\J^EC,_&F4Y81?9P!IK<<X.
M $?!YXU'T.LHAKXFZLPQ,%]9R;VF78D[&6-PKVL;H%S[%&83AZ7XCHZ6(2HK
M*.1@J(M7GV$\"X]+"WL[!!MIO4E3:UCHGGA.G'R'.('2A0'$3JML98O76SHU
MQ.IXO:6=%4P" '8 1];1O_<KQE]ME&7>-?%JP5>>O73*9EZ8IPAZ59MYBH/\
M2<2)=RS$=NK3FAZ=& @J-G=$XHYN%ZOF<;50UM,F%^D'!&S'SN!0>XF?A+6J
M:\NL/0H&L$0EBR"<?I\<W9.7&X=9#RW"SD;ZS5^8$L#RN4ZQYPK7:UGU>_%Z
M,+PL/3DYZT;JK]4['M=Z.^%QX)@TU7/*>1OQ(C7>!#^MD675IW=GDSB[C6OT
M'B<USS@X'[LU".)Q2 HI@E"*44M+@-Z;!,J=3D56'-.8Y\3LV<&8?O5KIEN$
M9Y@8&7OO&X\#J6_=,H+>$5=TB60\+3I#A5&0HO0O"%(]XWM3!L(>O"92:<*>
M7^9^/NBZ7*B(CFSC\[86/7"$E#A]: @:*>LVX=<!>?3K[.=?/_NY-UJ3,9\>
M(9?)<"#3)?+5OBS\UB$/<$R#WKU UM2O(?SS9_:4WN8KW4>Y2WVL-28!-8;5
MXYJXU@#)K)1C"MV05+FP-#/$1"8WW1IEHGXWE=WL "6N@7\1^CD"<GAAZ:UV
ML7OVP.U'-E"VB?C#"Z^86?BC*\'H%.J@>@6Y7CF+*UZO16Z:1L45/@E?4*LG
MT1*;#YOJ1@'V9\ILD";5A_I")(\\[IQ+NQ5W,M8A306064V[?%:5L:Q-%"2G
M]W(3H/;::<E)6EA8]EQ]44Z1KK2E&J[_ 2"OS_ !QIREV L5G7UH1+&>Z%WK
MND@GV*Z'L0<OS;[-P&\\AE<'DA/\;P6J$WLNEBHH^YLHSQB<#+N>/C 3?S[?
MN==YYHE A%WJ:I06G#\*SA^M]_=+_O^X/<;IC' PU;,:OK+:I=-*+E8GK<WG
MD^#1^4PL8U]Y S-7F*!#,+ J_B<BH[GBN15O:S>X<#ORNJ.L$=4:'*&CJ;*6
MF\!2\\@'BW'>41X_1:C+0GB$>0<D 2>';<A"*G\$G]@Y&P]_]2!49%'8I_+C
M:_D3 NM!8"[37)DU0R4,=?2HYP$G#M9W^^<U8H92\+I,>2^0.6VGB/+O",:F
MGNS*S=?4)1A+:<]*"SWQQM)-6*.?J!([K1([:S+^YSDCH9J$G\_O]V,82A$]
M+Z^\EUATVDYI'-Q-#JR'1;S+%4%#ZA/YZVRI$[/W6<;7AN4=N7,]>")X$Z P
M&^?U^Q*^T?X5+?G2[0^B)<:(L>&04\6(V_>QUG?+2B\6E:O1,!"/L;E=9V-9
M]+%/''P +'IHCKZ 5I\2=,HV<O6Z0' ATF)\/[D0 *]Y2%\[IR3VSD-D@V<N
M#CFCF?\Q[.";Y[DR+I7"[=(HNU+S"T7R&KH_BX%8*:(G<T<3=0A9&AHE3P+>
M[R5G5--MK=W!00)GCS@4J<CB]#:9VHO4!'E_:%B_[WQ4C=IMEGMAXC>N!Y+T
M IGD0;SCXQ'2S*8],YL 33F9)>=.I).P46J/Y+4WYZ^_CV1\NF-C1WN;,KVR
MZ%S:#I[D$RF4']F4NW#R&7R!D6=WW,Q"S04<>.Y#,BE_^C&)_GB"@]7A?_(A
MS;^I@9,Q%GXK(JPS+18Y!J[EI\:(&^O, VZ9WCR+96?/Y#)G)U]U'(54YUA5
MQG%:TE]BA2O6: ?39P5Q,4:8S\E> _-#>" RX+G?O=':;<IG0^92_*X6&GK7
MM?L)4I'VB1_4$5PV%T!],J@E*:?J@$<UHS25 K9)UL>K)F7=@YRCC Z=HJ!;
M=;RFI7!8W[-7ULN&/*#.XX/G6=?[QG +;TOY]&[D,"7F%N$"Q..-C5P;>&-C
M(3QG)HGK9=<F "_W6WJ=MUS[NM^.NI?CY&/5$ZB0I7T?/31'DG=9*=!U=ZVK
MER+5G2S/"AT[[IL<J]+&;)ILG^!'([G24-,>W(\(M9Z?>\0A]&XT=-* ]G!3
M/F6^.5J)?;YM)'"69!0T+?'+)_F93R((K37F[_(0SI"?S':.!-)3K])-MJI*
MJ[2W.J@];H.#X\?E[#&.Q] M+6?O[[MT*$M<C=O\6LXKFE'IU3!UMA/O38]&
MFLC/%M>G/C*17,ATEWSS??88D8^L"+O'J9Y2W:77KY[.K&E-4K!?/@6/"'T>
MX]_( Q,8FZQZXV/5_E99M>,=@G9V[]DT?83[E5>RNX_-$_L6A:N<B8R5!LO%
MK\$JH4029>#SF\!UCU ]7;;*POKU(Q ?YR=^\R%+2+;B\\K:D%@/!4(2>-5(
M1?<N37&5H?3TFT=;#C&^N74BA%9U. &S;&Y3Q;BRX3OR@J>ZWV"F6#C$.=:W
M94Y7_REG^NWK0FZ444C@"E'!OX$A\,]N13!V#X5.#Z?TIATK=#5>M!2>2CPD
M^NI-8/G38@T"6M1:HG9JIU4 C[-CN8%KBSZ+- -WE_-?\QT8,&D(C<)$1D;I
MY.'XUW/\*B\\7UM?^(GFZ$$EP3XF;VS<156\!W6E1Z,OP(W*@ZR\"P*G\T&A
M*&A88;]5S7UL3M+[%XDZMIO 1$[Q?$,KT.K/1>_U80AVH#(W);],M\'@Y:=C
MI/LO+^STT,TX#+O%-4[K2DSKRHCN1FM:V0N7U>HJRVGIJH_K/@RA)N5:(I7/
M=J_:.-CK09-9MA#]XTB-HD)7VB.1*BB#! U;+;<?(N^2,N'CBG+> .'CRFB(
M%!=X:=PWTBC]EPNRQ80J76^ ,N8G4_ ^<Q:*#\PI\&M@(PEF@MCP<:&5VIME
M5NV<QUF!M^_*7(ZA)Q-LWUG5%CRCW.E.!#?K $"\[Z3!*?PIDLL?PA3V7_+:
M [\L4><I>]3IXO@Q?^'J:)P:5* 2?"EICLS4*@+#=/V=+<.LB&O6F]+/22+:
M6Y-$GLY=%I&4;9R;$^8O*8Z6W>TGSO,,Q$\N(PTD5_L(]J4@P2-[2L82XY*7
M:#KO(-<]'K YBC ?:11NJD<:LR6$0(\3O(H&376"5^'2%Q+\R:L0='F#]RJN
M:P'$GL.E"O;^QJ\)V>-7<4QWD8):5O*[7C8O.]^>=!;F;4T%GD)K46>5^ 'S
M/J5_@Y#HO["!:K!O"45_'.EB1T7R+IGQV<Y'XF4DGTP:+R,BQ/Y+*+KHY%MR
M9NA-H)834KI48&74.Y^OY@Y<\#NL)*L<(3HHU:PH9\%<!;/J<7]+(:_5IB&[
MKKY_WIR0WJX>ZD?:G$1-"D&GT'R+8%SX+H*AY^,E^\(\8B9I/XV]S;6\N@='
MTM.A!\4%VEL!&))J6&3W]1>R?RZ';9B0P]9 R&&C_#Z'[6T5E$ZR FP4_EL.
M6][7'+;G*V<"P8PK#7X*W!>39'X:A1$ Y_R?]SD8]72['ZZ$'O)4UGZNX:Z^
MM:X>1+().S#J'(J:?U^!^9CUJ.:]P(!-Q^#$,+$(^UAT,\8_?G6@=DBXU\/(
MH]"@K._VQ )M[8UGTKXRU>&-YN,1)/ ZP,58#EOGG8U02!QI,F[7/ 48W35/
MNKPSBMI+A9_=S!G":Y[C>A).O-/HC(JM+4,T0O!JF'3W4]F=/@![%.+2&GBD
MO?+4L^>%/;AS>7&AKZ/A;$9P8FM+=GIF)UD2I54'KZ4.R&U"B:MK<HX"L4,B
M>9;^A!)7?J)O""6NQBBE -\E5&1D<@:. [_::S8@3Y?R[QCU43V'NTN?2E)4
ME]7P$2T5:0;8+5B:Y'E_^LGR]Z\0_2]J@NTX;W3T84S;>OLJY*WP8\]R7N$B
MO9!#YB2H,3DIBC82FA0=12@M\FF5VZ)? >/3WARY7"E[/W/3SM8LNZ./<=34
MS$1B)"IGJPC9K8.&S>@7_X*,-67TXEC\F54#O1"^ 4="QIK?/V2L72%DK'$0
M,M;$MF>L714L0*O5?O2NHK^6$CU?;%EIQ19T+EC*9H^"MW.#<".QQVLNE#:D
MK_OF"Z1R0S$D-$?NS;ZWUM4+RT)37P(T,!'!92(UZ38'B,;_P>-9-YN1+0W%
M4O["B &^9=LA[O?O=3Y^2N:@<QQ<.PCB80!U&AOWS[S/=7)WI"HH-O-XJD['
MQ _F1<MP>4F.;$AC^X1'-3*0^G*TA_(=3-33S\N-':#$I8(7Z4HFI],NE*[7
M&4OUR9UUFIQUD34U*A'>+?3X+A!:]2453#P$Y/\S70' [\=.NO(GZ<5:,I=&
MR>ZR..< Y\_D+W-2@& ]<Y!O3X11,/,&5LHPL?K7']/V]5-U$Q\)I&5/"$&9
MAZOC;0MRJ_&@$QC?J*$WG>8WM*X'-WM='C4+CV"$.FDMWHE*MS=1>O7J]$RL
M_>M7!DJ65IS.RL3G),Y$:3'8B<%AH8##Q@ZL[5TD=:MG(%16-VHWQPO<[6$1
M&6F6W4RP:EAQD9"JU>-_ _G^.]J?"IN6FV-@@9((TK?1EJREG"=K/;)%]N[C
M# LJ3O"Z2DO*Y=E^VFT3")((9YBQOO_VU($W_4PT>==U'QYB/,^5.2M&BHKL
MB >PWAH](OE&6L.Z+VV,^Y?>?*C;QZFT<80N0@GEIX3JZU  86?,'J0=L@U^
M+93+R+AK$]@XK360MPP<8*DB3B[Y$-XL*AB$]4=KZ*'C-3,MJ?9DIM:'"N7F
MDUG'2&$>>=DQ^)U6N\ KP+YJ!'A.J'A$HV#!_<-^!PV\&S;"2MI?F9N6G"YJ
M5B S=FT0;+&/CE]SK%$0ZBPUNL_W/A(9Y1?<5:U/9LI/.-&:V:C0P$(<=A%\
MZ?^$P7%;HM-0B7>Y.5*9/BY*S12_K1+JYKD\I&%$#BNC/7/O9 XN)#Z;R[^:
M?0P5);6#UZ.44PO"W&9'TV9\$.N?C1U"]L[Q%80(&;"IP_NIM5BNK[>"ZI$<
M=B1:BO*0^F&VC8_A5RM>\>M&PN@SV7([;&S?/SXDB4S['!\5;)$(,89SW!#/
MD^&-[HX>NFW\FE!TXGT:>M9+^+30Y9Z>3T4G"LD*83*0 Y01I.O#2(\@$A^Y
M]FHOBCX/JP<%23<(F0S'EF5WA#&:^9P.'[43JP7[V%G-PH(V ?)\$R+#U12U
M!Y?J6C@.ZQ]^0DF[ZT#T8VM>=O:$A 13ZIJC70^O:.XGU,E(??:T4#/RB'\
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M[J4)/7*^9.FV4?$"][,('AE>=AKQ%"H.6^,>.;4'B<IZI>[947>E'@/[PGP
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M2F^7&NU#AA.<1OR)FWYFO*BQA%)JX->K!IJ/W@8.\I8E""*X>#G2*YF-F28
M:O&0\:2_WX#_3VN"P_JG9YT=3@_W*[E8[9&JD3MWY#*MZ@FTG2(LP .#84))
MUB=N CM%2.KD)W+;7KX2#XSB?$CI6N74T%(8UZ;P7DLA'&]A (\*JV"T[RK
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M<S'*, #L$5-G>OQZ>BBY562/UD'IZ?VU+[QSX4:=VC8M ><V@Y7O(99#TN)
MJP>)+86@)1TRHK9@&Z81T0#+0ON*#L822P3S=3-)27E;\TD>?!#_PN4,VX.B
MVN@WY]PU>M[)RT4\$*KT\'4D)FWX7D>7EZ1Y(;XGQS8)IN.X#-I#E(5T<SW>
M_U3MWM[J>-WD&F@OE<:P:2U]9'!J5$IQK";K4'%D:W[_)4.9[8*M4]A62-'/
MGD@G&#.V&U#TM8"S_XC?@OFMP[DXJY'D8RA+X?AI)Y;#)O$[423C9P#/QV;+
M'NN1;]R-1D?SPY^GIO.ON9*>/S(1&U=PB.X?T.E(K(.A<4 SWUW)2WP*ZSHU
M[FP1C6U[7)TXP)W!5I3ESN ->Q#[CO!B$N?J$/:-@6<S='(K?Y7U8&V,!TLX
M+ZE8"WBD9:$E&BYH5?4ZS'H)?TDW/E],%M1#.F\R+H,LN-H_H&UT=&7J>?HV
M?J/.Q>,#(88"'RQ]6P,.V*8:DMXXDCZRK.BE]NZIJ@V1; O:(=FY-MFLVT,H
M&#@NXMN\Z@@2YS2;F'8* 7:KH2^PIP=XD57/6R[<5=A'I,T_=/!7Y)H36!IW
M&LIRID&Q_\8TD-S6Y#Q+7>$F?0N/P(FPU>0+*@^2+O%$V=^*<H@2VZ7&OW:G
M@ZD(.!YP23K;>. !E\A^ M8<#[BN'F9UI9' *%*V"Y/YI<0Q]1JHE /AYB_Y
MXQ'/+%WF&JZ_?]0,?T:>'N\([,N=(K6.%,J %&_WAJ01?SN:*G9+:I7F8:@;
M;!T3[[GZ/7"BO\RAU2-DE6?Z]('/KF<)FJCP6:':>[/(V^X:2WUJ85FR!CU+
MT=C\<E8Z=M.KB YV@N%_=F_._R_&TX;E/GJ, Y[=VD0VC7+4O\I[\3S9F7.\
M] E00!TY*=*?OAY6.#FO^%&G-?W\V[K0V>P7M'>2Q+-%0?%1QB0AEX,]*&X^
M!NV!8P=\';9Z\2%J.2U5Q[7-2G?VZ+^( 7>P[Q7>Q$BCUJ?:DN8_5X6-/>T6
M[?)\H1&UE3A1"H(Z>\O%INPR.=;9&;0U\;](A$)*.S@$CM_>KAE-_/B>H5U_
M[2DG)M')7HU"26S:%Y*_;0-10>VF)%R0?W9>.R_@$W7K+,#P<N<)@MXDQJ$C
M__3WH\O(7@JWGG&I\/=M[#.BRA:<'3#X%<?G,2!C4?("-\*A_^@)>KSBS? %
MKF@W9W7=(&N3\*G<-=DD@:8S156OQ1ASP'Y+NG$:8%^WKET7'&#@.4/6JXWM
MK;;;BV"+Q>YK0,<3"PE^BU'AM6?(B3\V$+NB4M#8EMTB18K7YNBLL8!(J4NL
MQ KBSH]\F:7T U*X /KT8OZC;NG=)1Q0FC>U@I!^8K2?Y+/6CP.L=.K_4_\%
M)/]W3RE-#[O@ITQ/9O*W:^U4ZU+O>2I:/8WYJ.\70QT;%MU;D7'FULD5S5V[
M<YSVRHQC_GC\?$(1$M[?SB;? 3R.)&#WPPQ*'W%Z0W# ZT(Y'- 0)GVD!3RE
MUO)D.)14ZY'H(JNXLF;:TY$1I13N+]M$04'"ALK[6]'BWUVD!G$@32\.:'2=
MQ@$'%[:EC^B:<$"+=DOX<5JV&=-\X#BMRR<STSXE=H4&EIGG8$)*C 91R-^$
M&A0^%]RT3[3#(JD6^WK/Q<6(\\]J*X )S^JQ!(QF%J'-@G9.AM_ 9+,,?B0_
M/1DCA@E3N/XR_D;DYQN?^[>$#C7Q_WA^9Q2R02=-,7G&ZS+\E?;C39L$WH^+
M#,8,B6E:G[(KA(O>F>M*!>-1A>F2M@BS"ZSWDUZF'CK%S)R^5=WHGN[?>%@-
ML.S/V"S@WG1&+&?W;G -ZVN#5A;2\KL5@<&/1E@:TGQ!X<.<XJ,.06#$2@9Z
MZBA.^IS/L/8*#E H==H&;4"+Y<-KDB)?%([")N2HS[8>1G9&Z']L4[MML>^9
M=,!<0["+]^57V=@)Z=U2S^,?J6M';R&,TTPOTT610IN+$\W)%T\&3KY9!],W
MD%]'(9!.)H3?:QI]1M+.5\3G'^FPV]->NA:#D.!>\+VO!!+;\$N7-=R3!]RA
M@=)F.(#"//'4RH.*6+U4Z%,+=F]-,O_,QR"."-GE%B5KF@W#8*\9Z3/+KC&&
M1AB?6]55L0S?TSK%F3X"](\$[0%HH/4=&<;)>#P2:+S K9?__/FU 4^S*>I>
M($;+9LQO"\H?Y<&(;KU^>HF'^; EC>&'A"2:.-["F5FT27+5H6KNE&#F#Q')
MRG?+H[;%MD,7#%];>)VJ:XT9?!PO9\Q(E1DV'2'9 NC_53JS$@=@U(Z@.$#.
M$(\& ^A\,+F5[S")LH.V%Z94!K?'EKZ)EKB4*_,0M=.S*HMU,!Z&  /_ CG8
M?SLKY,=DH8*FVAB<)2]/?QK2L:R),55T# B3 K'Z+B*8B?M;3Q\$4H-0[^IG
MNHT:1]]:5'T+2TA\2+#ZB$XP+?"!,OGU,']W0F?B3RL;DBK*_<[)SN7?KAVJ
M+-+L?7#5^)#+0&A*3&A&N+5NU;&# T:&FI("2JJNO';-K!:3TH.4W,RE)>1Z
M!&6?GJO<:+L-P#L,OONA0UNQ4.>Q#\KO96NJY=Y_MV\ND-J70#">)0!%KSN9
M&&$XD%Y$%[3ZD0/3FN1?+7H>LR2T3CP#<[X6NRO@E$8!P[I=*JU(F)R]S)K&
M>9G=\?*/L\:=D'D M$T<?ZARH]>.N6BFDE+DD?O:%3FF,8\/UF"B:MIIYFS&
M/0_.UG0"*^\;/E;'_K,V4Y7U82W%](>]GTU83.$3B)46N)\\X+5AXF.6,]+F
M_M"5:.+#JY%K5*24'Y7$'C8T$'K3/*HC*:JOZ>=GJ_E8?:*DNII$2FY;2<@H
M,&=*)7UA^PP#,CWB:7@HW]&%N,MG@TWJ?$6NAETU'5T=9GH0X:C<\=U7JCQW
M;U?D("W5Z:$[])65\SDY05LV1P'6($4VEK1XI ?G&NN;B7%WW9Y0UVRVZ]PJ
MY&]F9#B_F\TH$01L!G&FB2U\@TG.YI.UN-@XOUZV-VRMA[.R(CM8;.6"]-?$
MVNE;%:E!1DU2I*B-@+IOQW[9QY%K>K"-*>5+:Y5C>\-(ADAUW<630WM34@X9
MX&/=_791BFS06?7&ESF5+D?-:QQTE]OBOZ\S?"*=?KJ2M-/)1;"@3GFDA\DZ
M$SBWT/C5/.%A@U[EM9%0F:S6/D/UJ-C&N?<];@"2V2X'KH:NR[,O'G=+OZNH
M.4STH77"(<;]_JZ_^TK8]C;-+OPWZIUY,[WG[X\MI0D.\?(B-]=LG$EG D7/
ME9Y7."WH+@8X9Y![[$)&VK"WF%_C .,<Z6UK+>3.@!N#(IK_A;!5+5L3_WRW
MN_FC&A/N5J*B:-%USM3*D:A*=E-C?UG@ #(+:9U@:[032<[D/9$D+KG[;O9$
MDKAU>+_]$4A+\B55IM/L!1S0RL^ \1MS*;J43HQ:H4A]>2JJXG!Z@V53B5=!
M_6-;$49TFB+PK;MH&FOBH>&^_:3:Z3&%J<NMDY^,@^BM>0@Z=7(MJM22W^J5
MUB5FC]Y']-:^+0U\='>8@)V+0(P@_:$,E$0=-J1#-:ZOPM[?.?_+UN+Z%7X]
MU&3HK(0/VX.O:_Q1;&_HWY!_":*S"?]&BIA7@D%N 9B[5:H\L^#0;9UR*PCE
MLE)"QR<N0R?V6]4N?O-U]X"G=,BPIS1K:=>/T[=7\H3<\1?<-L_[1]*+5$H]
MB;P4"DS#<=:F3O'2_!-S0SU.#<+YS65[E,KD:'%EMNA;GP3$6 +:678S(&ZH
MR#4: 4\5?AH+]"=:TBM9UK?B#3)LS3^Z,HUP6C RTX9!7;^6ZC'9J90/;'>]
M7/\QV_#U#[4O?PB+/^1B'7E!TTQ]1 $,//NBL!B69%U?75<:_'SC'A@,#N]4
MF^FO:"<W)U@]X*X-W*G+SM8S&NGXKCMQL_C&H=)X&.A>0'L[6_[]C%-Y4T8C
M2PF.AD83#196)P5=_VOZ4<3W48)*T/![:.9ZDQD[R*25;JP2'Y^&T+Y%Y<L8
M&DW(W68*>_$YOVZX'S+RQ?6AB%)ESKHT)6N" +OLS&<M)/0 \JT4W7Q[1T<K
M,0#L0JB]OY0)L#7,> FJY#1].GZ'L0X%!='?4?M.+NK,I<C(+._@4L>)J4>S
M]5ZXN=?ZC<-"R.335[%V')#PR"XN!0QE=51J$&^UE/8W@B2VI+'8&-WU%[_F
M)=R*>1<>,MXI.YKVC)\<$7O$XL\0F?-;LG,R4"FY0TFWV/LUE35H_I!I4?7R
M<RPQ:W.(ML\]&F% AO/1U>Y(S!.C@^3ZS60<,&8UM9@!210V&D&V["H[\ 7V
M)+^_*'4QG.-J%_<Z0LR>4DV<S<?$WZTW>07+^.V(+U<D.?]^AX7+6:E6UH#+
MBUIQ44WOVSFC%#6LUJO:T-)!U^IIS9U.N DV-2EY_)!S$1'/B\FQF6=E67SA
M[EEP&;1WR.[:PUE)9:H1$7FR'M-@'=L^6'FG,44 HT.$?ZU)HW2)9L,:;XU6
M=FN[/GM5?!&WEHM?Y9N&<5?3U$Q[-T,!^!5L*_+V@*TU/]OF>OYC\R>JB#5G
M=H'VZ>F KWE]X$D/[3R3_"67@[173DS=J8UV(9HP@9^8T7-:G9A_N)>L5@_P
MD+%F8S:RA<X;JC>F-S:JZ)EKR%;B4/):FX8 - YYZ3\!9B@K_WQ5ANE=<8&%
M-W-_&@[0J??O_.8H^ADS+L-I&?%A&'Q:4$V,9B8)!ZQQ7G6);$IBM/1K.+?,
M>__3VIR[N4)_]>M)-R9Q9/-.JI,FFN+-WD'MT5ZY:G2=64^?LH3F4ZT.L3N^
M0HB"K1EPDS!Z,$=X]YVIZOF6@5NY= R)L/V'50 QV5E'D,;5:GN@R&86$II.
M5<">K%0Q4//"\(848K:'9%,S;DOP]0LB>_I71;TY^2K0D866I*PY5X_)(A.[
MW90NQ^^*%:D&?ISV"&V;-L*-'7%);&31Q^)^7F3QQQ+_KX.PU2"29O-*]A2N
M:=,8GPM%,LP@'$#>A0/NN6+O^1S:F"W[%!L6T<8?Q\Z2,7Q8^'RHSV]7_NYJ
MN??ZL4,81>6/DO",\LQ@#=LLJ;&3:];RH.V=,$>ZN;#H"'KU&]GOQ5C045:9
M7^KXW19N#A=9]4_<X* J<47HVRW%\^[;9U*$-.6P$7ZO34=&-GGVTCP86SFX
M)N62]9 RPLJYPWVF9^:C&4-<@H1,ERTLAAJ:Q/^!_UI7!^_&&F=)523#3)H0
M0X$,&[<[/2&TU5?*%]6VQF0'^SCFEJY\*++.O-D1RL)1<8EMB^BT.^M+-&*!
M8'PZC2'/K8!O/L*<0P;=P4"L<U>0A,V?9,.(^/ZPH:5K],BPKKJK\R47.<(G
MBM:GU*@=[4'2@5YV*#.%H:?\S[7+=)?=!>D-]:Q< -C9,CJ>,/N6T#(*I7%0
M QW [*</C:R[O%0/66<KK?VZPQ.\SC>J9Q9,+;-*RD 6&R7;:I\-\FOHX:EY
MXPN3NX<I1C,;\1QRSF3M% A]]RKX.HMTO6UB^6[RV"DEXN5"UTYO:/W9@OG:
M3]6#G!\_?V O]R<J=R.Q7B4'HNT5Q*W1_NK".\?PF4.EQ4&7I.^A>8W)5PIG
M$WC" ()]/9$B1(>U%"D[*E>L!7";S,JSU.UN'+=,"IS87DX^KY*3I$T68T]&
MY1#CMB>L%L)%L'%P<J5O28<>T(;OA'I=,B(VF&A&P?*<:?+196;DM%;05W*@
MTN><;/:(E<C;;WREC'' ,U%D^M&Q53I&R@@KJ7C$6L^( Q96]/'1YB8.0"\?
M>(< &"'MH(.Q!W4!FH),-R2"J18[+NT*!K%NCDA$K&[%)F4;@"-PP-QK3#*V
ML=SH0#@O/8.B"5$E&N'L4XX/)VCYMKUU$G?K/QF%6B^X?)X?<E7<:9,J'?9I
M9$#W8KU+>X^@_#B N2#@E]$1O $'D-BU2>\?#$FCX/5''E6]05@:3,YCI*=$
M[[DI2SEE/W:+MU7?X#MQ<=RYE :?7 5L9:"7%\3 XXL9Y,=.VJID<K7?LLK2
M9AG$DBQ, FR/0[LH*^/L!3UVD9RG:E*Q8BL7:G3NNMU#7"]X:UD9P="J8_S)
M!KR@].4Y862<E%(;&\Q3GAJTN1#L+72D4E;A/[D^*@WI.5N?<&TSG#O65RG=
M <%MKR"QL[9P4!A6HYJ?U:R;5I^CWV!_..^WKM=I4NUZ4+,&,)X%$(BV6P=3
MLT_B3?+@XD,QV%'QEMJX(8UUQC9NA<\%V>]9L,91;NPZ+7& 3C\.*(X\BNV6
MPS9^\EE\G_?]).7F@ -BW-_C TWU8QH:P/,_TJCQ1P\PQ9  FRG%+Y/B-;+<
MCO;TU@,1],]OS#GF^DS"C 7 [K-0&G-#ZF*]?*=[_ITBAWX=_)=(P);DQ2;V
M/:!61[="ZB$<8"$>6N+-V(?4I"!)O_.H)=&.K>N&2.H$Q19BJ9<9FKM</CJ9
MXY"S["JH/ZDOM?_8J0LZ!] !% ! 0>21C=@(VO7FKJD8VGD)7Q-IO,,HLN8?
MVQW>YM;C\I[;)3IH7)Q%@(7^P+L2[3-[B>*53VXO4]GTXY*GQ9'25S2K5K5M
M-=?8HTA93(3[=+$]:>SU V;I^FB:,&_;I0MN\*Y7[%$IJ0V-SAT<G]0\G:*W
M]7^;-HV"_/R*A#XX3H'+6M1NA^NV:81?Y"][;.7.U.HM#Q7<:B5]V+$ /*E+
MQ&]^ZC0FJT8IE@2PJ(=A_I-YNC;6"*4.NIFX;6Z/ '\(/7&5*L/L7L13U=#S
MM9(#%^_P*,*)6K&O[O8FGI99_' ]1D#-ZIN4Q)%8W> 5OAK5C*5- WW"LT:R
MMLF9]I .%BUZ1T&M"&6 DXXP,O6W>O5DH(H8H]V0K_RI?$?*V1WOI%J(ET\]
M>5'67Q%/X'%*!L& W>,,&RJ1A8EJH_7UNAC[;ODA8T3("S)-SRH24D[6D1=]
MK!G88,-? &GKR[?Q%\#G'PF5N>E3/J</I6<&(W/-H9!M+WY=K[U=-"7+%KS;
MMYA&=6HU1POI5PY$AP#+_^P,Y[^7U=ECLM JK8:,F,@\B^MJQ;N>=+#T*_R?
M&@]=;X2YF[)O*L_U@;]L:TERWGW^X,L'9Q7G:./:\HA9X2B@P4 .L%?J@>3D
MQ0%:?S=^MIRG!GT_Z$7T$E@>CO*0;H^DW>-1-A'77Q#7**RD<?3@#C,&^;6X
M?R\_%+%4=JB6'>*[Y)?:T[5MGB3<VRG*8KQ W]&XO=0+E?\B Z6RP@)HH\ O
M6=^V)2I8-"GZ<X,?R>B93URDRE@(.Y>F^+[ M@X'%*@W0\_ 66?UW+_NW2R)
M<$_-M*J^WRRT_PR:4A56U'4NJ)V3,$ &>EXS2AT?-NB<W^P@1_]23_L^)@ E
M<MB8I#_:&NU^*?OAN6)5RN?696@7$W\Y7RDTR&&(KF>*+0-BC+)K6W-5V+0^
MDJ/=K0V9@:\&5H9[WTF=8$>0VP\_X4PLS-S.UV[3^[JV(RGX72)9XMD4]7NW
MAT<-X)/P)*"],(!G4-JLV^Q0>I;'HF=KWR,^,YK7W%ONHC=*B'Q7*XJ@@Z&6
M- .2LWB2/)^%,.& #CFTZ'&@;?VVE<[8#OJ7%]5[@O1"X^,4G[G7R]#=T[$X
M0*'%4-JPX5#LY&,#TJLTG-CP$%^I]/_,H)P]SH"1V3F_Q=]J#Y^P^"_W6[M.
M73[C&-;YPE%L/-.O?5[=*.[T[L'"D2L.8-]JGMH]784#OJC*0,_>P5\E.]!5
M=&[I1M-***FM2?0JOP';,YH):C6:5ID%HL\5G'T1XQ[S[CX(U0M;2AC+3Y.<
MB<>O7?:B7A,*A.5>C"%A<CE/U\[=Z=3M$0C T8=*F*#IY>OJ0?$NHYE&=E%S
MT*L=;D-E"GV%4ZG'8C33.ZOI)<_.\4>4= 6%R!(F/7JCI+GVY($I+VA1B;R2
MJ1RBBZX"=B#/H6 <,&/LYH'4QDX<@F-=!B=U1F#C,Y3E9AXXP(>NS7)5>N:5
MS[(M#NBTPP$V!?S3B>&O48EAND,:%1%G^#5EJ3>5;GRX>^6VK1IIJPJ_!O%1
M[.;0X%/0-!3UN7Y'U&=>% >4??D%#O4\IOXC?SQ4OJAKMLOYO*2;LV>KKLF"
MICRYW/;X!:V+H$.*&;VPD2%:.W FL@B_>$O[!UZ?C"Y!KJ6_JDZ[SM7>Q<C5
MWD%/DW,R7+O%P8[7298;_'.I!""F[NR0<'+OV97$JMK#C:KJ^"PXU8V%-P7*
MK#(( AA Y#5E1&PY:CTJ4NR5-7[-1C*^.6'SFFD\;YAF=!2%H"01<*\P'TMT
M?VP4SM7_Q%\RQJ +UI_:O.' I@"1E-*\TY9=8#47L@<9&6N9,AF\<G39<:JR
MKKL[F^F2UOY0()9=?RX*G.C7I8$_4'[1-*Y_7!@!$_:<#3X2MLEKN%1(,;T[
M+:I%__A,^(>F*G^E)E-X-L#T R2X@=>$<8!@^7$M/JJYL'> @HQ:81_;'7KB
M@-%KH*UC_.] ?;[\5Z4 A/XUD"L(://9U#A2Q0$/]0J/+WSK[0/W07]/800L
MC:S?YTR[A ,^:@UA0RPQ_G53Z*FCV-YS/L/<*SA 7A@N*T/D)?W#UV!X7^/A
MQ(:$U!D79N, ,^@^9]+SXT!3O._<T0!_/%D9XU:3E1U?2W,1_N[_A?[#C*K3
M@QHT1:5GWE3=85ZEKDX#^Q4/[KD8:G) " 'HC'N4)5,4OS6R<#USL<'3CJ,F
MG![D7Q7/;DJ9 I4S(M8 &9D<08,F(8$73NE.>+T3.E?IP_N.*=-Q*>!XD+=R
MHYPMP(A1YPNT>"$B1D\$]7AI[)J4Z>Z5!S*FG/QG&:D0"0Y#+.4R;UF8-WY6
M/P#)TW0MX@!*.%OA2N2;)8]Q6M&5>LK<"DCYAO6C4_6%G6HR[/9",DSR_P+<
MI'\;@_NAR[&W=JMQ /XP.KAX_0!;)X,9PP$<G@8XH-SGF)()L(1?PA2+!MB>
M4QQD5JZ1YD'9/_@PG/9 \>ZSS4[I2<8YT?Z#OY=LT&E,-Z[!]F"_'++CM_L6
M/+)DWZQKZVKUD_7DHI[KLP7F:>R#->(."XNC61.AB8H.Y%G:-[)Y:CW$Z&$"
M;+$K,E#G+T;7S*=*7%_PB5PJS!Q>ILR4%;W1;<=6T=;3]MW0O?VT.,R87,<L
MR_M+'7VEBO/ =O>M5G>H==:I;FHY%U';]D=7_>U?+0.2",F8D"T<@#&HAT@O
M/L3[!T\D5E3Q5[T(&1"9-S6]=S%;TQ(,S@F3!QL:CH>WM<LB/A!#/L.[ QA-
M"MP9G0ON/3C.XNWW,/>&IAE\82HVNLTVPBG6>6FM4TS:77G.8=!7LL=]IK0\
M87;V_HP_.S][C("6/ %[C!M L8,*RN<(&^W>KM(7E,VN;0ZWHG[.&WU>@GK3
MG<QOX%CU:=H53/)L^@7;T+MUFQ_TH(LBOFT0U X]Q[[&U%4Q\5;N^B I9K?L
MEJ]-QXF9/3:/YPP_OQ,[%33:YC[ST2FJTI8"U (X[FPKKAY/&]R[G6!WWBBR
M>&Q2EXZ/Q7E_7N&QW34<X.PM&[EA!B,_/X2R0S"1*6S:P>3X=VLW9VI2:,K"
MZ^Z%UYHVD L.:X/C"HW_PA2K8_EE4<ZKWNBLVP;V%C2X?I7'&0>\U?45/]CI
M'1ET>X@)?QK3=0$V:II#50P8U+2/D2V[Y#%2(-*^S3F_?FMDF:3V)JDLFATU
M<?^1G11-;YP@+=^8!2_U0D U6+P%\)J2=U,,P 'FR4)F=F:S7>)?EUP4AG9S
MZ=GG_-=3J!$-$JYF*2!$H6*_%+<;@\Z6=_>L%=W1!]M#/0;K!;&V)%I7M9$V
M^F4N@H]_J_S5.X#%?TIILZY_UHH>-KYVR,:08D+?&\=@9XCI%5LT)_A8>.[X
M]9'>F?3G:T=\A%_)NH940I]1^M>;W1TFBKQAJL5F)\W: Z)O1QNM7>C72_8Y
M;1$CL_[2JAJ5%175-!^N3 ^]3-X<D9&S8BB";&:^-G2EX!GM:%VVR).4)K);
MF&DSRPCJQS((P)Y8+(/<8UO]V13%$W3]"ZK9W5&YF4-%'* 2ZZY^M2B:*L4T
MQJ&:KG&/L, 30HCMU>G7E_6:W7];5JY(/OJ4OTX9X-NLSFDD")2^_$B6C=MJ
M:CN?N^WFU[63 6(25A)/1ZB5Q.X<=7">]"'$=F20G94]DU^CO8M6)*=D44*&
MW\CEH@- ", EA^N-+PP'S$[Y2L^(H^H/&#U+D\]\O?_=(&2$IY;";=\_S PJ
M8"C3XWWS[Y3]?9 XX%D2;83KI$^[] .;@#4TJTUGS<-^%E$P_4R%H;V C)1,
MH2;&"UVN@TJ2>[>\<C+Z.I1:N>)D]#5*1,J>.HHF\C'PGG$+RX71FL4!IR5*
M)Q,YOKUA$Z\I(C;WS_5O>4$O(_2M<5NLG;[@BJ]4%ZJ^Q8C$+9_21EAIS7;B
M&U$J^FSG@Y>!ITF;8B->Z+WO(6UQB4<165K4<0R56+F4?]VIO=5*[+7&E-_?
MG/616.DNL3U8JO''+"NN(DPDTD!J4^(]_$YN37 *Z;JNJ3BA8\2MM-HV)H\!
MIR-9='QW<W%]2&G4IK@+Y61["*GXC*;OVV$ ; D<&OZ6BW_'\F%F9M0IQCJ3
MG#][#&9$Y/*MZ;]H9^,(&[ME#%E?%T<@YB)?LJ<;H@US3JM<R?JP3)Y\4=NL
M(NY]UT./%,C+:<^D'76P=V]2]_%"\FP9]G.1 :*)L'VKW5XD2F%.JP,6H]X5
MYA0%ZEY,LGN!O78D>ZB6\549>"I:S#K"E%7G/>=.2!#>H,B>$IO^*F_%[3<4
M%;6\>&X5?;E6[25TNRQBM&="1)Z*@MI'4+D#'VZQ;UK. S1;"VW20>>\WMC1
M+FI'OSQM.Y _<Y=.1%D(^9K0Q 5H%66<?W% $0)@3F7ZN^?;7JPH3\#OCU\H
M\WE1(B-'T,Z2=U45&Q-=$BZZGN$(;_S4_#SU<UA&E%!DK"VQ&@G=G1EO5E1!
M]8Q*2^G0M8[53+L*_5,QQJ=<*CK+1,FG4\S 2< >Y!2VSV6SF;?F2=W-)I P
MF;FR LA=D*6#7&DY .PJ3\ YLFWCI(*F2$D\D#^B+<OWJZ/M^2HC<=]9NX'^
MGK]0>^$S;B7.I,%9GE!WTR"W%)BC0LL#.D9_DKFSGGW@J:<ZK1?,6M09EYCM
M1FI4O3B3PZ>L'CJ%F=%MR=FLC-$C)8G,?1K7,/AS1 Z"5=;# 7B4?X M.I*;
MS2=K3+!R+L!C8(4I>W&.N09@33;!VI8>(=:C3K.ID(V^UW:]/GXW_9R1XKR9
MW0B=GIE8#SRCNLJU1[SMWAV,T4QYR)%AL%1\EO*NB+-1F5HCU\?[.<9ZB4!.
M#Z+9Y)T]%T$?S P]I8,^]RYV>DROFC#UJ%X"5) ]_OK&Q0(7IN;I'%ZENZ<W
M(6^/6#!/)HF^?J\;^&R7;W0Q6.M&M'5 .J_H7>6&1Q2DIXE=UD6D&(\N?851
MVMEYVD=/NOFRN2<^BRE:!VC"U0%0ZZJMN*WO&G,P'A5H>V<7+!YPQA_GYPX/
MNX]L8H?LH^U:A<*;S>B9).4!<QU?[WZC+1Z?L2GLE\)[ W6<;FRWRA^LP]3?
M50FMGAI\:#_2 /O@^8+1N?6Z1\A^TVQO\TMO5LN$BZT]*EY2#8PWS-J2V:0F
MYGW909N^ .=K]BU?T,)3/ 3WPL-7=Y] K#A&4:?_PY!6/;9[8,KTGN(UBJ)7
M) :?/XARMU6DT!K+T(NM&&0R7T/EGU"#L!Q?WOT86#+5_'E5#0!$E#E+ =L[
M\O<&2FU$%<KUPN]IE!3YI3_J<!;$>[\:Z!&Q/82YU??*'?W:O68?(HM=1P/5
MV?#+R-NFLH[%XAT$SV[<WUD56_E:X7,.V^=]H7_U>V33BE0._,L3T@OG(X@<
M'9Y/E&(8I_EAY&$Q (S@5S#^"_XI0(>".. S'K?;IA_JUF+K8!@#-'T=\XJH
M8+<5QV"ZQXM$2H7.#UEZP<2*')H58_%@5TX_([DE(WHX.$^R1KF@S0;64=U5
M'3Q#F5K)W=-DS)8]V0 [Y<A%4//FXS0Z.]"VX&)Y.?I*^ ]*5 3VDMDC>P#T
M25DRS]'W-+?X M[9]4*#3?#.7A.CU(!W]A.Q9HE!Z%_U.S%+G.0_9^T.B0Q\
M%M\5ON!9@@1+,\ E'&9X:GF:G'PL#"RO*MOPU @J1"ETE;Y</_W@!3L@MNX!
M3(GV@8S4L3W2F^K"D,/3'3C@S9O"ESRC4F1'=_MJH)GCBQZSO7:,>S:.B2^"
M;NJW@K3O;$$J!&2LUQ< 4U\O?GG'76G*(YKW#]J<(2'7,L.W_"0[&Y&$$7?:
M'_97+!3>6N2U6]V1$-O@O3)=71HK<<E?]J((*9A<3(PELM&75^=S.B.6L?NM
ME9!;MDI9=$GUT)2;7.+F%?H(9;K.MU0"CC*/%.GO&*D..#6<^593MD>I>(WJ
MM3);M!Q/#AU+0 .A2P;$[S?/@J&^]+-2P''9YH(V*NRCS%?X6E:[R*55*OB[
MQ4H)F1NGPM)?DH-F/*:"=@HI]-TO]"2Z/IJ?.-M-J165TV1M&T&LR*TTY]$'
MKG'CW TL2IHD@](V<90VLF@//%1%M\O8O?JBH)'"M2]W2EGLCN'0W^F"0,G?
M_SM=$,#A9 BFZ38F!YG*UGTH&ER8N>50O69]Q2$,R6QN4^MI C/+R(?@<>Y9
M'/ 7H.N#%96!&@U)STHSNEDU&MX?$G;C8X\E>M2DS H6LWE!9K.O-!%F:B)>
M&".<_F+RZM!>N%RS3B]#\T.WU[$=X7T+K#&2N2,=8+;HMEN5,SZ!AOQHO;>Z
M%HZZH]=Y0KNF'[[(N\RM&9T(9M(0O9-"D 2LP4S08P9HFH5=G8"9M-9!KR*V
M%TV&MS^?CM>GHN7P9?"V?L\:9"\I/0-I\L'(EHA6#KSV72E/^;RT1<>&/!O4
M0T'2P>.K#A70$C9!0$FO\1-8G_ D@SY5MXW-WZC6JFB\I&1(+-3E.#X][4'T
M3^>:_SL9S7?L9<SEF7I:MX@-_?K:;R9552.U+ D" 9;<Y 3TDM2NA4IO?-G\
M26QL9LO+0\2,@T\I,EK2W,&#5@J H%19GAK4-0470VF_-N/X,$G[-4:T]?;Y
M+K*PLVY/0<_5VM)2>9('Z@C<* XF'I475?>/2R'Y\L>**0,VTX7<VL27TL"2
M5OU<&1 \*@]R0/D<$Y;V'N( _+%TX>VO.L!K_4, -![!FYUDTOI4]'% /0I_
M[>96OL/VUI&<\!"(L]ZSJK[AR8O*I5#\#"N52[LZQ)AV72?W=[;;_;S!$O.K
M;,SN,5P66;_/Y7V29LD?PH9; @LKP])FT'TNC^?'_IDXX$N13N301V_\$:BQ
M SDD4L:'0(\R($Z#6'J,4+,HU'P +FW>O^%JP3I!H/39L>7S8Y481>W>>\M6
ML77':7 :5W=V5%?NB,)P\UG]RS<1!/Z+W;V&RBM++1XMU" \GD;U2$%.6!SX
M&.9D'"=2TZ=)#".-]===.,8!>!02KO,1_YB&R:A$A(=6D[K=3)ZBB^HS Z'Q
M*X(0,C8!<$1%K]$]@\?A@6FOS)A2 S//)Q0MF HHL,EWL,\H$K#'8K[]JH?M
M@Z1.0QW]X.2L@;I,OZU9A6I,SV[7]X]CY<=/1$\1 RQSQB99MG=DF(URCD H
M81P0OVOEN2;ZQ-4K9K'\58J)E+GWR[6(;'$D_5^O76N56@,<B0-^_03*6? +
M*.:8W<UW@4R?4>^F!-=U7BJY3!>S,3U+JW<%-@%$P68(D/UNZ;IMN.W@@6&Z
MA0F!U&[$($VPBC%Y5 ;Y-(57H/ZO*@G('>E ;^)O1X4EF">MTCP2WNWOQL1;
MG>9I)OKK''JN)^%?[4P*'+_[9/F<L/@EX8#6O.&_N1_SDNQ6#Z=#&8(2IBUU
M_:E'+U95GO[!=]$41S(Y=""S/+*H01U+]>1PRBR]DO-8NGX#^KU89Y(*ZVF*
M"ZK-%-?-F+Q4G>/^(\GBA+V$4G\.-]DU6CN67DM_/#6'/5#:76_=J&@2'[U^
MH",K#[CC@*/+_,_3M_E]YM;:< #C6RQU8E/O 6W]I@M^V1$Z&?C7[X./CE1F
M%H[)IO8E''! &Q<.".1 ;6$#-XY2*_#O.GX1_Z[3\7L_!H/_OAM[6+5Q'W1G
MT4-4 "+IR5L;'[/7[J[:GS[TU8\N2!@H<=L;@0DI2L=_](5C&;_"[F65)>??
M;W,UUY=JY;CU<5$KSC_[?3N;O^(-J[LAP$GJY*X11'K1$'^CC$5BQ15_N>!"
MF1_1Y"^7?>=7*^;IP[]NZ5\M.\[GEPO>/LU%\/PC1G9:5>A.67UQ7TUUW@-M
M<Z,UI]2"3!HQ_@!_L.XZWF_9TDAL\^?Q4:EX1OQI?%1*;Z"$CTI)V$KM?5"9
M=<P^?;4X(+8<>N18>^K_Y>KCA\V3+J7.=#.?X50N/Y0,8ZBI*"]>&V^)Y%6&
MQ;@+O_X=@B2A W54&(A6!1Y$"YM'Y'PDT_9T;E6>-WE,N#5$O[3($_M7^[/0
M&+_<7]-F"BSJBS?\>6TOZ/GE6)+<,P]9GN,.B-Z"\&DLA#FW<4;$+\=I@$6S
MX-*HH)"$E8<SW<+,(WLM0@CV>#V7:7A;UQSS<YA#A'_5K?\2%O_3_@##@Q<L
MK1U^7]'Y;-["[ZOPH0P=!#5H>S+O4 'S9.0*[>U^89XEI%<1+1GYW?#AB6H.
MWU:E3K,,%I?]3]@#Y+T!6[L-]JTK!5D6[[PR;%W8BQ#3IK%?\[[($#FG0V .
MHKZP6Z,EVE<G,Q/6['CY6&]HQEOG&4^O:RU#Z)DVQ:]S$2Q[,>P&H%Q>%PG3
MU'V=VPRH5H6\HO,6##'I8LXF?-_.%$DS8)Y.7<,P*_D(OXD'O;]X26U<X?_T
M.;DLQZ2+A<!7_5*=0*$,AN,D+7P#!Y1''E-R %X^O\C-_VE_R\"XD?\%4$L#
M!!0    ( )5P8E"ZH!DY[E@  #UN   +    :6UA9V4Q,BYJ<&?LNG547%^;
M)GIP"!;<)4&#NVL(%D*0!'=W=[<@P25  L%="H*[NSN$*KQP+PANPZ]OWYG;
MW^K^IOOV]'?GKC7[K.>O?5;5>M[]VO.>_?3[:0UX^5Y&7@: @X,##)\?X D"
M2 &HR,@HR$BH*"@H:&BH+S#P,3'0T3%(</&P\2E(J2@I2,G)J6G9&*A?L]"0
MDS/ROV'AX.3AX:%B$!05X!)AX^;A^NM'X-#0T##0,8@Q,8FY7I&_XOH/KZ=.
M  <5G@G>$P'N-0"/ X>  _?4"U ! !P2W#\MX)\7'#P"(A(R"BK:"_3G%^I>
M O!P" CPB A(2(B(S[M^S_L (@X2[BM.260\%2.4UT[X7$$).:@T;ZNZ"%2G
M3FFYC9V#T5X0$A&3D-+1,S"^8>+AY>,7$!22>B<M(RLG__[39S5U#4TM;1-3
M,W,+2RMK%U<W=P]/+^^0+Z%AX1%?(Q.3OB6GI'[_D9:;EU]06%1<4EI=4UM7
MW]#8U-S=T]O7/S X-#P],SLWO_![$;R^ =W<VM[9W=N'G9W_N;B\NKZY_8L7
M'(  ]W^O?Y47SC,O>$1$!$24OWC!P7O\]0(.(M(K3F1<2144(R>\UUQ!J/AO
M$W*JNM!HN%5/"8R=IUX0TO*LT\'^HO9/S/Y]Q(+_7S'[[\3^!R\P@($ ]WQX
M"#B .'!URY@;^.)OP8S>E_FFYC0LPHVLL3 C4RUX!8RT3'O6L"Q-683X '<P
M_>N/ X4-MV?BPCL844C%'ZM*$RM6L]@M>ZA=AX^7!)\)385W]$:@<!KS!)L8
MK74#."4/Y4LKE5.EUEXU,9N#&#AEUXQDJ2H,<2@H5K88BHAGH'?=8U;D23_0
MF^:>S'L"=O#OH_M9?<,ER:A.I[-E+S,UT)B-K9#;NM#W!! =^7*NQZ!HA7S@
M']",&I<3F]KZ/F.=E%373(A0H. %(](/P%O:]28*":C+KZ\/V]!XG)'CH%7N
M"==?'$ .%"6,/-]M?P-I"*PSP%'*'T,Z_N%L>\RS\(WP3F8M!R%H@D5PP&2
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MUI!!TM(T?>D=S(PB>:H>NMY1]P28@YO3DW&J$M7CRTT$8A1PU9 _ A<5P9'
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M/*M PG"FW*Y\G;5QP.%%?_[MNL0VZ)_UGIFU&.E4G4Z"FU?1VRO)MU')9'2
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MQ-W8F;[C#CK!RP!=8(FF!+(;>'HHS+*KW^H8L-TX195Y6)IW[J+G(,9=RM.
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M5J(S887!>@GRWAZ7&#Q+RJ+G(G&B[A3H6A[@@9O;O=W8'_)K[]_OMF&.JYG
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M,B/LL\G/ I1M*EE)20V#2!>_"[NW[HH-6[2#2M[6F0-+.M5BNZY,J(+11Y>
M 6Z%SR4OJ)HN4:C@ZL*;XB7BA%J.296 ^3VXQGR90W>8J<,P5#H+5:G:.'IC
MQ$] (3_EO0#MQG@DM5,73Q*3'(86?K_UB?&$!D5RFX'CKHDK6]=Q?4*O0J/:
M]RQ*R)(U9%%(EM(IH(=XTG7XQX1PK.-N@3=MYA?OK$?@B98*RP,\=+.U2C)J
M7:HLHDT%J7)LS&S=LE ])N 4*C!9ILOTG&.6YE;_O NF^GZ);88@= @+5(B5
MDY0EY%42OV/,U_-1W6SJZ7W^^D. Q/Q%Y"*(SPNWZ[BUPEYJPEJ =*<]+-1/
M-&_KAMBPG)UX<X% I5@24K\[EZ+>7:CNDJSO6$9TMG=GVR,9Y;S%!Z/NI:MC
M<SXZAA+R#Z4<RR"P)X:D^:A(</AXFRD0_+ N_J%X7ZV#*U?PN-U+X;,![EB.
M?35I7"#-8P9I]\)]6Q8%3]V.S2KN'IN!^<P[Y2L;JE);V>^ 2;& .0<E#EN.
M%H>#CCX;E 3\&RC&#:6;EY2P9#-4>CA_Q?N:QULG/2=HM/NU)'',[I'T;?F;
M^/WFP3H)#QI3J*H@5EU<_CD.\>P'K2LV!%C@]J'MH72)'%.V@='V*XF/KX8%
M"U[4GIBJ)V !_KKO4OCC=?GV*2H1Y5F5PTY^S/SNZCY)-E]#5]728AI7>'F6
MHY8/EBK.U19!S-ZQ)G4CJP/7(W]R\MRSY!+'QW.+GWCU&%_./Z_+89E,7GMT
M,6GX*9],#WY85#<CZ:6,\P/4F$M[YNE-PY8+=_ %GD-6;-N<(,YM=.<?U"':
MA\5+YZ><RA2&@GLYVE-]NN5.MAP<M(?61X](R_>:&7H%1MJ9.-"692^ C3LR
MEP%D U]%"\IWR2'R-+\2,5*3M#L90U7%GZ%_.*.IH?=_U*Y\8CXE#S-$Z3F.
MKRD:0/:6(,BG_\!('O\/G!*VF!EUR1G3X0<9MSTX=<[' O_-!?X?-B42,=Q)
M^4+, ,24P_&SB*K-A:&(<Z,"N<EO@P6LLRBU_QLPL/_,^MVLZ06;\ZX6^#P6
ML-<RA)#*R19[^Q^]'W6<F\R_PM@FDCYQ(#J0J:6DSC3N7=MQ!:6NJG'/UTZ0
M>NW*3G2@-&?: 0;N:H9H/)P_PY_%O:6C>!Y'A58>UF*!\A4L,, .I?_ /HGK
MO5HT_FB+YB_.#4&+7ILMA\2-."^*-.55HJ?>8S;K**PN/OPZ?$A6OVM,\S4\
MS@:?MXSX[F,3/\NJKPU)8]OWFB*\4QTZ=[.*RA50S[  ]VSFQ<M4+*!4K;&4
MKF""(R9W1P5"3\:>Q3 Q4IUZW^-V6:%:5X0I)RQ]#%.*U4]H2^XIZ.5-9OUY
M&_@)NSMR*+?,JA--M230%4YO/>0G[O62DU,-DT#CU.]Z\O90O-.[<^M6,P?,
MSG&ZU/WB&7\6%O"4N@->FHY=-L@@&\8"U7)D2[Z@&D-#GU@G]':]7]TX.5@@
M. (XJI>[7ZYTM1MSI9$DPB!VV@F%CR$T/DY$6LN[/(YITQP07&N(HRE:[ZS_
MUK/ZEHW0)V0^**#'1AQVSH-A3OUQ#_-4$IV.$ UA\>$=RD/9X?2LKKUP_8N>
ME^0_FU$[(-J')(/+'Q;VD'KA<WPCXL'0_>A!EK7>,I064Q^))]75]2!4W2(Y
M*F>H;JRKJ%=/-<@-M>W767:\XO 9%1X9K:<Q\H/K9^'F%Y-'5\Q=.(,@=Y4"
M#WUQK6[<9J8UVCK8BV/*W.AMBU^8N], <GC#IUA&LKT'>I]/)<_;XG']K9./
MEHK%1Q:!()E]&!NDKQY7>M5=5NR[(LKRA\Z%%V?IAW0CQAP(F]*4)PYRXS*;
MMJ,L,C<58> Q#-<,REW9PXQL?KHD[#+&W3GWS%E;V?]S8EA'MP>HZB+V;F/"
MSH!X>TOSW1KQ3K#\JQAB\>6Q .Z6RH%R=W-M(Y8ODBHW!5:_2,^D(1S,OF4>
M"&.!"9KETU)ZZLU7>AT?CIKNR5+(*C:F;"D^+,AD7L?G3>)TIS.$1-/K#O<0
MG%U?>=G9P<:L1*BZ$&P*0?1$>"^-OE]\(WH% D_5B:51XHBH(D!:I=R$ACG*
M5-V4D51Z3Z6\AV/?8G@;S,D==>Z1L JS#<D7_=1F+NDL+]HX5VAD="]JPZL;
M>_6=S1'1TVTBI-3-T\"/^+@71N*X\**!K+BXG!T%X^P6L0%]LA@+_W#(EPF?
MI>ER3G#.T#F:?[\>])*(BO7H6(P<?M3REB& M3;"WZA-TA/Y TW=/'IU91G4
MJJ$WV'RC=XDI0X"O3?*$/].OY"V=OT@7$."QS+SV^B+4G&-J2O?3VCI&3M!O
M]D/7W(*%]/*&@U?;66B"_\(I5!+R62WWX;B9K=%K)N^U'\L6R_';,%J2PPN'
MI>OC83HL.HCJBP;IUI94ED\*J>_C,^V[<+EA/O^/D-W#8 1<3V0TZ[-0ZMJA
M_2>/QMS5HYO=IC6MT=+$UX)6G'B.%M#CQ(K_)J[QIW^]8Q(6XF?FLE3*O*X5
M-*9/0\HL$O,M(81B>MM,>+S6CQT+Q'/HX')&$>C0\+%PRR\))0?#$("+ $7?
M%C2J>LE=Z]D_O+;V&?(E&Q@.LAAP7D&+4;@*[<4Y1;LFP$QS7O_T5O)HQC&Z
MC[&8;\D</VV_L"?G^1G$&HUP?QFN(JLORR7X[(,L>R'B\YSXKDX!:M#*22X.
MG&VJPN^H-9C[^&D,B?@Z%B#_4! C8*#)>%^8&#-9K8_DT4(5*X+I#;(CNSW;
MBN\%Y[@;*!XZ8X$+"T7VUT5^1F&J4/1U3+ 7^2+=\>E@+;D(Y5WN/)=I[U0C
M:'7H&A7)+%24,YX%_H6\B(F8L-)4",F+43[&::X/.M3/62(^A]BV'!/78)0C
MR0\O+)8B;1GX7#Y[VV.FE)E,AJY1'#[[?DYQWP7YDJ5481?#1@0O+3GVV5OG
MG*Q;])9+BY^"HL&-F;HHB])I4[6ULH]B5PVKPOA3)XIO*GR [^E 05B !U>Y
MYX\WL4 .<Z#\9:IH>B_17/HSNL-*5<]<UR_6%AO M@D_YO88?&=J%TRTQ:Y=
MMERS=,,1TD"Y-P3U^OY2(O43*MDX\+6OG1/K8Y!W7WG5EQ,@H+I?W\$P-+VX
MZ[/1[$,AZI./3.%"6RPC[(?Z5"9_<BS;23\MF9B//H53WB_WC=2O?5RYJBQ!
M]4D:%.K0)BY[,BHNFWK*%7%+D$=$Y%XN)V]"H%JY_I"3!XABRMM!/4RUJ:ZZ
M@4+A\Z!191%-]&LU?)1> LP>J/Z31VR50C5*YPS;W(C?.,\QQ:E&'T\0/8T*
M#IHLS_13RNG)\@X]>93 VQT7PHMZOU^ )-#M:C,[Y7#?RVTYN[7Q)=9LS,\-
MLHCFJ-G*8&@,FJG#[6L?4B]/1!<.-X @:J]ANC&CF.^-:(;,8XAD/_CHPVR4
MQ^8\8_EE2/.\X1866'L'F7'! K81_,0Y!G[/:D><A\9ZVTY.&*A.+,*#A<\)
M7<Q0C?K#CE-;Z]_/ D.(]+ODM.G8<V_Q7-Z7IU]RHEKLS"N>J(\XVSWE]SN4
M\EXFA<+E*XW7(LO,-EY5&8:D[?-\7JB;<>6$W9[+&GR64=/"XKYN7IQC\DZ3
M>(^^W(&#CBC8_U@>W#:>=,)R/T24VY+]S155\=4YR>&%X0#.N>EI3M5'/;>S
M&,F@?%?D*S0\,0+ZYV;%#NP<YCEZPZG]PZF?/DK<\FYNPB4$_0&BJGGZQ>!'
M-2.Y \YC0ZN37 G]4;M\(Q;2'&\_9_X2I65D^MHMY.=R)23/O-Q)N NXZB_S
M<_\I :B<"UY(8@)/("=(A_:-[&_^=(M";X\S!$;GP4&MOEZJCZ977BCCX;-"
MFG3DE) XFTP=C24*IKJ*):W>=?< 5N]##!<#R"'=VZY8P%0("WS*LSC'F>9=
M>#&DB0,3^9#H54PX4AZJY'&])G%QNC$\!RR<#*?.9^"TX5?<Y7N^WMX +VV$
M"067_^#LV=_]A*,,S3KAH,#R:R@G._GSC&M5-1H'L-Q>5KLX26%.O(0.$\3X
MZW/P(A:X8K#5$-25-VFDRI.QI%Z(_.*_>JJ?$-\!N&.!7Q HI4-E&]UU<O1^
MB=@LYGUO<Y"SV/P1%E#7X9U?RO^J/-S%ZDO4A]VRV:Q'YG%]GE$!XMMJ^?-W
M"Z>]9=$BAQMA&A*5QJ6-C)@!+""=X"G<9NZ1A?]KYALU^A<9Q$S*U+#7PE<^
M=[O&EL=VYM65%PY#?O<7F>3N"H;QR(Q%.W#;>0Z6-LT.JNDO'#XNX%R/ '8\
M6L)%41[+&KB2,S9G,V,AYEAZ:,5C,U6R,2?3@J1(,+4+8&BLJ]433D8_O75
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M;'E8IX.Z[$>!,G>^#>OH&JCS%A/X$]V:H<ZAX<^.Q/RF\IZ"B0E.^DX^_^F
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M^A#V3U^@_OAO3I3=_/'WGG*K' OT$-3@<#(RNZ#@:W?8NH%D"$D9>3!5]GX
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MGDOMLDFX; UN[5X^VD_1@(B!BHXE<$?'61,#:#66VF$B?FRHN'P48;,@^SE
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MUY/7(F;IP<P.AXK_].:HOW$RXAR*$@WH],L&3^E?4!R-J3/OS:&>4W.AH&C
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M>Z]67^)9] <_*RL( U$0=\,CMX/($8:)6_WXZBG/'A&X%BSL!E',^N3KL]C
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ML>Y%IJB_TBW\__CK@3X>_1M02P,$%     @ E7!B4!HAOD$2NP  >O4   L
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M7ZR0*W\.S6.(X0'=84[6'>/@T_.EUXN8(!DP"V4/%2@?>.X4.W;&YW\*"A'
MRU%:^BXA>_=\&$,1J<W>C!S*@H</+8*1]D+#?IS )FUA9<*SZUWU0I!JX?,!
MCU)6]2.)\N(^RX<97I;>W"%DG>EERE*#4I/\99SMBV3].-$27Y<-GL9\>!*.
M=&J<'KA_UPJY8JAQ$!%\TMK!YM/KT%2[O4Y!G^0Z]_F4ZTG1943P."SRT9I
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MBV*^\J88?C'!Y]!Z5>> 9O(=SUV]1T=X'=';<."E@8T3AI(_Q& )W!0Q_7/
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M?%AZ'HJ^%]T"_LM,581$VHC\)KWRYT;:L@&$"/VK'.HO?7(WCPSP8&\F%Y/
M0>X5*C0]5*1_Z:$]S'$!76$;^5G#B!>&);T97QG]>P_17SEI>\L@_7<S=[X2
M;(,(R@SSVW-0[KZG'XLUBUQWIVNA,O:>(/T_2(S_;9@3VSZ[D,NR3BKY?*/[
M>;7'EN=980?7TP^28M[:EK<KZ;UXMQP<N\+NMJE9,^:0&>];'\.3+#N.C3!0
MB__+E$9\P[[<9X2]A8CC$[$]8GZF"G7/+)EHTI[.%DZD=5UH)LFJ:;DA\JH
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M4PCH^/D-(AP9$B*"UL-:WWO*H_R+^#9#'C$S,]MLI]?*Y3)NR(PJ?'0-(7A
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MDE&^O<G:ZX<N2^J\"4V[O9&;3KYN]2]')0;=WD1]$_P9A&2"Q0*^O:&U<#S
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MH8".8M@6" >0B<]QV_#;4")95P_^2<F:V50/_\#Q@'8@ @)=O1Q1E4==6%P
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MB"#5'0EM2+3]EC54X8VAF2?CO#N[#)H NL*KJ?/M\T NM5I4HX1R>M4M]&J
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M,+\H0LR]GWN;@8]$4T_'SY&J]9KJJ9F;A7Q/83BQ4V1^6=5"BS<ODL&Z,U0
M0: "G>"\8FQ)XINE ,9Z!7>/@5*4W3-\)*KDI$$8$_&5@KE&\78G/.=%R;HH
M<F/6NCJVG0CYLK.08PF"+K!J C$(1YK8+(\0D)_/BH/AC2GE"/='K?$?N?0'
MH1^3$9+6C\E(M3@JHZ;:]W#AX% _S,R(2)<7A_W;.?FQV3,>]W\;U88;>$?3
MH2[1+3'>LV 7B[GG,!Z7/?V4E8P +GJI]B*33_#KU!X<:,H?5SS4D)5YI.2J
M!;^+J.9HT4<CL3(Y+R_G\P%D\[N^(5=+M=][:><JH=J%C2HV=ND8PV0E ,:=
MTZ0DIR>S@,2NPDX5^(.:?ITZCI0:P-")(P3 ECSIY)/Z8R+%_UFQ,_^M@TWE
M%ZR),\SU%YKI]?^@CVW\[Y("H;\11M-;_+BWXL\J &Q5>N%WXS$*B(E?"\ H
M^J,N: 55:PFM-]U<$Y*42^3J0%>8T%<1I0',$C=A.$F/A?'9"S%Z?UFBG.[-
M#Y8_]GQHM :1;/@M-#85K*(FC#SG:!K#^U1HM>S9-9_VS>W9QR%S2$KJ=9A9
M5MVT126NN][33N":)E.Z9(8Z?P:GEJ )?&)4XG*B0XE=>L0PNY: L^IQ<P"G
MI^+B=W7F"S%P.;]QHD;7T$GF>HAOJR&2,VW:>GQ =QW2YR-^M2SS476MI=>6
M>;/!N)+K"["(Z)1\GS_+#R!N]4+S&TC!$]O9Y'^4.O[K*!;E@A_C!Q?U.H/R
M\(L-*D^-JL=SDHC,;)8XS5H,*8L<)^218LWC52:^>P5S)KB[T@1(E]5)4X58
MLPOTW?@H8]A]9$#D"""Q5UBX5M9:W"V?W1ZCBFB*Y4KHAC,V8@\7& ]O4!$[
MY27WF-R9JE*MDJ: :HE8E?6,]5"$T#E;%=I.)&_FI)J&@2 4!YN6'#)U#^/A
M*A.#D\O5-N$6'B<;-U_;83?8\'G17KZW,Y_0)6HJ'6DH8I&NJ8[::H>TG>B'
M=(WW%+],X_]PGA8I)NM:HEQ=55T1&@5%3A-SBB@TPWEN".%WIHJ2LS/7%';5
MN\36 W.#0&G#> %:&N+2&DQ0NK;[*-'(D'<P;YF4WWNC#"/QM^:8.<>+)8"<
M06DZ7'.@[YEJ6.D-<G38=+[<^OYD=#"\\#"GTT6CPJ0"IAEEV:7$\8:=V7U,
M5(' !@%V+8F^L8 S($%P#\P,$;[A)XOW5B5BQR'6F/Y RJ@>C0BCN2<9J:B;
MW&-8O6:M^/H$0N0OW%47_AE%[OH(^'R^=W,AA,7OY(P-E:@#)5&&!M;Z4-OS
M@\(;G+"?A$GP'&E4"9+JB&B/KT6_C7"QV7UIIZ4QK\DN3JS[QG/[JT>0"49?
M(1(/N4.)XH_?9="26 .?<8/S)9^WOP#-$ VZP14EO?T+%"IMSB#$A1Y!RTPR
MMWT'__KQ.P2;J3I]_PWX1X!QM3\*)9IT-:3_&?8H?<\KS 4DDH+"=)_$S:+,
M.:@+ Y!EGV-)$]K]!*?:+IJA2^TJ\F"][F 1L![I$R7,[W=0G.&*/MFA8.X6
MFE7XW2/8V3/[YF4890TF!0)61D]0,^L-!^0]"F]WGH)P.&UC&+KP4KOGREZ7
M_R- )=[LB)E3DIET$9/AJ<:S?H/BZ[9# 'IFLAK(<]H_%<0%;A02K8&==6C>
MSP&#GDO$$-B7V\QG EXZM]P43)IE<@P*E16G=!2%<N_=&E>",F/E3_$IU<M8
M1<_D^M1 H1X-Z^S1/E=Y_/36!005TNY@K6"B!'2X?;MASYP^?<E/$8?OC%\>
M%_D6A2TG8NG&B;+R,"8]ZW#F.VSD2BZQ-72Q *KRIE:)^FXJ;*Y_.-'V9D?J
MFR4JL^^TKRN..-/4!"9_S.O6)X'$855R'QJ])IDC>'H2]>948A?9ZA/AQ7<Z
MN'XE:=$H7I-1*ZTV6F6(Q/G2MU<62K#YM55S-;3Q5"^<;-2YV08==7%&N;?=
M!(:RK&WB_0I%#9Z]FUL)@4 _674YQ: G;ID-.84XXLB3_P+8Y/S6TOEUE/I'
MPJ;_3[07C,W_3$&Z5KL4\PAH4KK@5VWD:.7SF()RA42 U2YC"1O*,NF?9+SU
M@]EHATNIGW!7BYOV6DG!A8+B$1HSZR[30%3&PS^>S,ZP$;A<%CWD"=:P\ PS
M?1*=T2^CISN]?9>B12#(7EL9[Y+!USA4D"<V4(V'P=U1LV8!OA@60%?ZLV_4
MTF51NG^!4GK"JW).?OR04(YQH%)"A\2%%XKH]7TR<ME?Y:0X2MW(=?D##T]&
M&L[2+5K#EV8]:FMITHO?J#AL-_RT_<.I''EPEO@P;S8> 6%!/=<QM)8_-[S^
M$/!O"VW%/O#1D7'LJZ07N8YX#;/<.2ALO7X$\#>?C K;"_[<@$Q"NCM]!'2+
MDCJ0G?4_ DAPD/YC_1_K?[9N_568SDUS67+JG MK,,C*-'SI]&.*AD\4__%?
M1@T=OO_V"!@=G>Y7N6#YB\!V!O+#D%U&"-UWD7X,]S758AN Y,%6[_T\(P<:
M/;\3[BF2OW;GZB"I:)?J=T2"RQ^:04:Q%@ OR:Z&1,E&\Q71:4:_U^'+#47/
MK/OGX17-Z6,$9)!'P+QU7SCP$5"S%"-Y&7NN*3CV$"R,=6-]WW67>[IT&WJC
MG +R$LTX8-FN@/F/^7_,_S O:D,.?(W/A035&S5WF6G0#U<2@1?\G^ R=5-6
M]/-H_%;VW*7G7&+EXQWN-^)[-P[F9X=>\W;OZ>KKIBQ+W^2,+G^KF*A47_]4
M:^0[]#R(J927>:_+[?3G:N%DGO*MKBJ\)./4\YT<7G#_$N:.6]'%V3#E,#_J
MTU!%GK92,CJX)B3M*?$_B 7 SJO/,ZQY*LL#]**5773BIOM"%?E]1B.%:<\*
M6?[8F1VIPD6]%Y,I #%#QO6H;TAO?ULF_L"NBW=UO_\]GP HJ%2BWNHPRM8T
M-\;V55:']#(> "N%>WD T=>JED?!#EI(8;Q6-%'B'P]> 8N,DR#,0VU<!M[?
MJ_C(1(2++4<U@*N6N-85<T('R)J6,H32P%KC.&6CB/:-;4_7 Q7:D^: H@.(
M<Y.3:K*6H_I!5F1_9PH'<KX6ZD=(%U(1C(,#IYI0KLO<ZW&@87U=3>WS* J)
M6 7U82:FDM":R*<EO,2F_!/MG?$OIOPC+\<OVVFCPZDO71.<]\^X]Y>JDVJ'
M*V$<+/^@4_CGD:=G?DEHV9G4N-'6"=QODJF+D+TZ7[:]X"$@=Z3P9AY526VN
MJFVHJPB2&8?&:,2"B*295X9%6@]4S7[+ 0J ]P6[=J!^9JM5/UJ7RV2L8(;$
M->(O5AS)#(, '"7CR!>!&Q$K6-)LW<)\DV!TJ3DE'],*$"E>*)6X61+NY 1[
MA#K:L;AL$@8Z0.OO$HS?1E&NWAS(S>-J.NI&=>2%*QG(,M6YI3<5E5-!89A]
M;JZ7(X">,%:?D*,48.HG+TWV'H43AAHG2(1./Q$K68S>[(\[P4[^:KDM^-5_
M"R(^N_ZY\?[QOU>6:@NBRY;,65FZ(3A/^7X7\ @0P;U$&%[2R_+P^ALAC>*?
M<!T841%7#JU9[7?>S\.X;3#?^<2OG OA@W5I=&C&.D"7T]&@P%S=84X6*C/B
M&&6)]KQ>\D3(,L;-\D_2P&Z-ZZ1<,ZAQYNG.L:1 4P%-2CZ5_E?+T)<-D?81
MW"O?9KO)MPB*)#STW',UKX-.%Q\![RI+QW+08MDU&U8ET!AI;*CEOAXN?SP(
M ASF%B-NZ9UD5?L45?8>G'^V^C!PA8>%3VUA^G4<YO@C<7VYONL:(-YX*_S0
M:X6*T+$BWC%?&(C>#36$O+5_2?WVY"YR1>+) +*!2Q<ZP W][SA4?]L#SU)_
M$:7&(S%1;CABK[T8F><2+%\U[FCBWUEQNQQ%Q#,* ;LD&FOWZ8$CN#?>L"CY
MVIX!',[5@*YKP3K\\T0+C,I58:_ P;F9$"HR,PG;9O.C^1PT9 P\BLSPKBH3
MQA+N=GG?53B M 86?^_=ZELMUG6/#JPSW"Z,?1AA$B#NX+Q+&Z-++!]WX96N
M=M2@62EM')IM(@>W'H@XQ-($F RS6;BS2%,Y6>E::&%9;!*&GQ%SV/(:@TIX
M)Z1J+<*=!7^+V C.ZH^B^S\-QLAQ?@,CPLJI'&*;F==6TY=V;U'8H7F.3*Z\
MUA$O\5??'L4#]G*+I1X!G5??.G,J^!#N6&QS12TIM#\W3]8,;1A_R3M?3GR_
MCL%A,MRYIC">T5@VXNC^>2,F_1/#6[0$9T2+.( *@L1-WU8(G# )-6Z/N2[%
M!.WQ179]^H)F-\*$!'EYW3A48R,N#/Y]80_,,%(NOLD0HFB>AS)G8Q4TJ:%<
MSII8"/I2U=;'VN*4&.W0<L-^N _?QW<&!V9L5'NR.=2BF$O!R,(Z_?.BS/MJ
MNWSD=R?^3,U>SF^I2&H.$M>5R$\6XZBPY[6U=&=;+Y5<K:E.,,]K[!"WVTJM
M"E,8$:R37+:\,=*#VAX!G\*L:<,QP31[@Z>#);'/E[D/EYH'3JO60H[VNN5%
MS4"$F813D> \+:9@] $#40T\M-I=Y ND,':>(V$\LQ_3#L/__WW^:*F3KLH,
M$"A'DY_,Y(V$VJ>72M&)M],O1:W!*>ZJH7P%D/2Z,V['DF?FA'<VW6[ RPYI
MEAADV6:IZ/\5%3);D2S.\7@(;DS*^E]K<^HI2'_6YI"$UA)<#^]0BN?F1*C&
M^XT9NG',-1)C>  8DL7N8JYWC$7FSIIA*7G2&!E@$!6VYFPO+R+=&\YW6))O
M,"F=8.9=>[BV.>49P?:=U,<TU<YD_@=4_N!7>^[@O=R<SU;2K_SCC .E,6/G
MR+15FP.HZZNNO>Q!)=M\$XKFSLZA#)I:$ET4'=_@:8<KPX3)<06&, 7S1&$W
M^"^G9:=8C(\%$PIFOOCWS9:PO)7W\S,)53$0J;!41'T.Y>D[:2G0/)_FBPWF
M--MW*'IMS<3UE!JR.9-@:"$?&TGV]<H.0!X(T],"OU63[OV3<@?G7TCLVL#?
MN:M7=4R5N>W:3=&3ZK0T*Q<2>*/>%7:N6>YY$Q@0M*-U'^@LX* 4)"OEOBX
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M$Y"J7LR5  Z5&YRCSBIEIM"UT_AN-80(+3$N*KDF\C(<WUJ_C'\$^#T"XA9
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M\"EM9@/MX26POH4.4U"*$X;>!K_\FFH;<D'I*US'9\X8[460<^D7@FYU*7+
M(>*%NQK.#H <L/**,?K")OJVPU\-48=W/T<< ^643@!U](-<WL=S8FMG%E4)
M>+,1F+RPZ92@LH+UKN-S8_P2WC4UMB0.'Z$]XZJF.+= /<\@]:7Z+'"^["D
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MHB50=:R%XA3F B=:&JPQ)I+S8#WO%I%]Y]GJ@LKYH-3V I5LCI09#H4^_R.
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M!(0)]%Q@XCN-#=3;U$_Y1TC(9=%GEO!KG-J\D;LX:HG]J^AFV2G96L,%O;;
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MT;/="T!#NT&$@2C)S/)&9@^/?%>;L36E&9M[QYB8->LYG:\<'!"_D _2RJ+
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MURC^GY'_.YPR?R4!92@/8KYZ=N83\W<)TPT\D?],F(XWK]7F8DO7-, QB%P
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MEGB^]-0"+E_8%;NHV8MI_?*Y.'MK+R#%FS#0?&7!HQT>MW 0FF0\?1%8A>%
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M8"$B0J@F8Z$,G='C2JOR7Z432 ^S_P=02P,$%     @ E7!B4(G5 :J&Y0$
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M-!+J7'AYR88"Z/-!_NO%D_!PP=?!@X\S^F6P%'HMH,V5^W-7%!(<AQ$H('P
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MM$"-Q&*#P\H@+:US^T'KAI/0EY>:>QI@[IX)F/@:[O!0+0I 4B=?*2:?2Z"
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MG7V$^,:O5"#W#XJQZ5D8"G/E"G);$,F?&!"]#Y,AN+LN:[KLB5Z+VZ_6XM5
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M5_B?XD:^77^-%3).-_W3,$DMZ"E.QW*-,Z'&[F"KF@ PWXYG^:K,&CT.5%2
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MU)Y>"V9/N597LQB!B.;D0-8\1 %I\;6R?[KP@8D9G<&8ALT-AT+K#2=7),B
M>[-9*("5;@O9G(\"TFW$I*H#NEL]S&9:MOT)LK]&?E<>)<079CC.%8*=#D.&
MEE3#GT[6IYAK"R:I]_0YP#( -Q#I3NH!0W7^3IZQ"R>5*>40^ZJNHX_F1>'-
M2Q_*7H0T"OC0GH "C'+MKW 271:SM^N99[?B/;W3^JS&13\\5R)X_>/A6N2F
MJ)\J0FJ4OTZWE4<IO<>L)'R(7?6C6?N K*01"<,S3/7VR=.B+&LZ6RK1LI-2
M\(1K[TK3Z_6J*1BPF+NE60P/6=C)+,PV49+M@T_01TFZF]ZM?271"5Z+UG3Y
MNA_Q/JE]UY[:.U@K+]5O =D;^Y12#_3)I$A<)G=#,7T2 GW(IV!LSZ$BT--=
M5L#*3-MAA(N) O*C,+@10RJ782A@ATS#"^P\R[1/E5JH350=TS;_/=CKFK%2
MS7CH,5NF#?>E<C^2$G:JF8A,N,HYC>"P0@&:*W9]#N%U)?$)+:)CGYD2/%-L
MTHPS9T4[2YIY3P_#P\*7&"TQ[HL[?&O#7LG,X9\LBQE1HF]RX['+G_CXY</#
MM>#.@>,JEWS';J6WC##RMRRNC/WSO-#KFYP)3;.TX8N'4\_L20WY[1AKN5^:
M!/.VT'\!SW94H  ]"XBT9M$ M$Q )*,]+3:3 Z\YZ:4/P4M"HG08HR5FR4%&
MS&S90K["U-.J,B7B;0*P(([4:<8CQJ_AKS7=!F"?M#:KPV/U-L[.- *>V@L>
M\7L6#0N+PU06[&EG9/+Q:J6_S4YO"/&(4]\5'WJ2JNV06'OTQ9EV2R^L68ZQ
MIZB%/9[5D5P*CYBOJ6G98M97K($.$JA;3H?W1FOD-OGZZ:'"RG3UG@FQUORA
M2KX%A+KP/0K8QG= C.7 _WVB4UN04.Y_BIR\?#EK..E<E;]XKC##;-<X[S!P
M",G$C@"F="7+7+S=KO<S)9AQK@<%2!>;6H*#^A=4DT'P[$W#5\C):O)7_;&@
M,T,5[MVE_6\^M##P FA,8U<>NZTD7=H!0_B(V3@ M#94 2VN!<PO#1$L<5MV
M9_5-IW>.&F:.)/?.M^2OUTOX3UUJ=#PK\[NIK]S.T1&$0ZE?3 ]ZQ@>'F2U>
M6GHIVEU%,QA97]B]U=3X2FSQ/N6(^>SF(?C*92V)'1;X7N"-"P/(HBQ8P'^2
M8:T[3!:X.$/8J+=*LJK %?-<PNC6/'6F&BE/B\-^I/!^>.TP M(!Q%^@@-MQ
M;\%;0X97M'IAKO5@6*FW(R?-!NAV&\'GE,F6+C>[-D=9$I;CQ<IO1I09"WOG
MM,Z%%XA %"!-F:!CP(0"(N/0A%;8"3WFD6)*/.A'&H%/#U! Z5;'UKBD" KH
MP47.@D\3(5<L&+^1 JQLA[Y#LS=3:6'#/K;C4G3:A.#@^NY$?W>MIVN!1<=A
M3[DH96R.$^58E1VA_^'SU]O?=-E#6W(PP<GURIJA98H2FL^*8G_8"]P>GG_7
M-U3IHD?62=GW#',(@4N$#%P8@]GQ3R54%7*;5ES#TWG$.;(J[4O,=P:]OEQK
MD08B@1=<M-XEW3NZU0^9BCQW1G"@@\,91;)]Q=>BDS\MZA+V3695MXM%TCDP
MSD180@7J4;BH9-YON+\:XL0YI9 _Q:$[PQ' >1OSHV.KT5F_R*JO:%L)6AWI
M%_PRX9G#LBA [@/-Z@C=](^G@5C8EW-7'JE+U,GR^U'K=*O%\06EKV+-6O@#
M9L5!2\91*JD%]JUT&8E[@5XB-O:"YWD[RPHP*WJ:>JDN&G&/%[F]%BJP6DI"
MT;#&"+UAO/!)V;"@RC>7[WSG"VU1@+H4)>)6_N88\M;@MO'(GFF)S?C'J8R6
M]YU<O()OPAV=Y$+*>G6\H9I%"<_KH@;T.]-P*YV8,+\0?5W"O%9\3)!M6RN7
MJ3\MV7FS.EB!'FM'M3':K_^)P.4G>R^9''W=>KAY=93\%):9(CDQ"7_C,3=)
MOS%;2Z*0[$AS?D&.F_@U$Y$  T)[%.#]VJ<^)CC>I3UZ'DQI=695[.EYZ>QP
MS!:Y[1%AJBU4G?&E'F/HN'.U=YG:29'%4^5''@ZQ0\18A0L)C98U"B V+ZGV
MKMX2YZF:[.B7[_^QO$3;='-Y>?$#.82)HZJ6K) UMI XFJ>JHFT$=@=;[>BE
M/4/HJ,2K88/RP5W6RH.=@'0\5:8Q(N,5=XR;1K?F3_H'GC/15 ^R[F<6IF].
M=IS:Z*L01G:=6B3<<DJB1EC7S;Y;$+9=C9UJAUHFDI:^1@%F/Y),3=]-*^-X
M6V+*+10KW88'<>Z9%GTN721?57BJ2#;;P&/\X\HF<S"_+/'Z8YA+ _V4P7KD
MKL(SC@FNMQV@UW=I^C<Y_/?[<BRR-NIO!F_:<^X>'Q%B6HG-O1:>=QBN S=5
MGQ3$N4L$Y FM5_N[:UJ5EL_M5F)^R3E&0E*(7=T4N%BC^ \'O\0\1-Q,PI93
MGY7!HBZ1L7/D,I*[+>(?0UP7CH?E?>^Z$06\ 2:'W,]41]?5^J#+9E^)K"4H
MPJ^T\ *.5KM:Y;J2GTZCT+7S73^3#N0CJKF34>BG0NT#V7<'Y&MM0L,;?)OX
M6:6^+25J>'ZOP8&0QCY/S2B=Z@YWK/#7N;>CO &!PB7.1[ 7!SX9WF;<"7;\
M->G>&8X/<!]A?,6):-7]5"!P:<;7Y.1-]%'-4 4#^^47S,IEER7,_=."D#8D
M!1*&KL;1=?#-@;P2LVOG0A5)>F_P1*;>M+E[._L(C-X_L7M%'T);.QX[1--M
MQW%TSU?NIEL*D2&3-M3"TH"J]/)%&2S&AOTH_^4</>+\7+?."DY,?T72DE\P
M:54AY&1@T/$*B[3TK6Y.3R# 8+&+I.S>NDA,/ NL_6,"X7OY13V '/<:'I"$
MO'QS"7ZZ/Y;K1IQH:AWI'GNH0))X:V4\G$1];M:7%_%O,D+VL "^ !AOP\,\
M:-'&FWQS&#II%&]JMU9D&T!.4M=!TW^<!R:W$?1  8'\NI]?32J]FM"9W=#C
ML2)E2(]EQJUW[Q<PP=D/KTF?D(-")IDR;&@"%$Q*CDPJ,85-;N!"<\#Y %\[
M]R)DF_\23#;UU?]V^R0*</MTF+.S>DV:.##)QNUA14,EW,*ZG.E6^:">-6]L
MK.=8.3E1^@J6RTF;$23P^> .0L!JH9=NU_L1>P'=IFY5.H]_J]WU8'?,JGZ/
MLDS%A1W%QO(+V9Q"%&"N]]"3!7[)$/T*6PKDYG<^@ TEG[(1K%85JN<K&5UP
MOY9@XZVV2^Q^*SCI 0]L6O.6_IV<=(CUL'*4';@MV;Y:S[8"V1?%B3@ZNN'G
MU[^@-_, A!^J0OM9.XU0Z-L7<KY.G)HK4XTWS^$Z/EU9TL96.'F1+5@OBSH^
M=MSOB#5-*ELK&[R392[)V)U!VS"LJZ[K1S6,+.SF^++$Z&G!C]$W*$,!J,E0
M8(Q[<:* J(BO*&#*_HK\).,@&BGGC-84811P?"=O[EW#H=IQ\J4=NK0T**WG
MA7;N)I^L@9!O1WR/)HM,4< M ON+S8:>%Q[QHV-BG2Q.[[0IHM<Q,G'SX>F/
MX$%.BPD;QY]/L(8GI8PGLM]*58)::HTL)')#X2%.E.T-MID0+OO4XF".C?F;
M>=&^;@SAM48^3*.)_TX:Y-V3\@@,0=R]*OPVA>Y*FA^F:IO_P#ZTMQ>OPB%U
MJL -[CA8B3MU?;=@HU*FJ^^N41PA.J9TT-"?'%,SIAGFHBBAJQNPV&XOR%H:
MP#OU!/$CA:R3<1UV(B:V1P)Q')NU.]*>ZHPN&!(D/\=D,3K8B <VQ?^/")L0
M?^\C)95F48//:9#XN<?5I7.GG^Y\FG+?UKWU]LV>0SO?%0?SKV!LM2_TUF6&
MZ8?89?O "8=6*Z\B97("92-M"^DGL2N%*VMNTLUXB8: ?'&1=/W^;!G*%GU%
M-W[S!UIAJ6HJ-]U$]J3H+XCJKCI:Q%Y\/R J#UY2^UA:,EOV_8,=B)VYL("#
MH+5\LK?@(]%>Z/8)Q$ J<W+NN>>;)'F3K%!"ES-*TZ=Q+9-Q?G;'8>J&R)Y*
M_U.%@U.1.]/7?27W,(_R>M5E]T<S$UDFH2&2<\Z5$_97B2RZYVNK;)B8R<V^
M(M5UZ9N.ZY-E]>F$#[HY:^P??U;D<FBZ23:<?48I6R8N014C6&-=/=/T1HFH
MVOQZZP<<5T1*DC+NTE-B6'/\;)433GZ>S=E1?\I5DORJ8M;]:#&2&&;U]NT+
MYT+!0OD#PB0ZV+(:6W@4O3 .9U[JX*I6JD$CX<E9H9 $9/4#-KK#(GD%+T,!
M+%L*O_W/'O18'?8>5N&E@\X/%W1^P$; %W>W6JUN7F=/^\04-.^I9'W61'=,
MA_FTVJ^JXI[QE\?CYR5'+UW/<@^F( F/]T\KO2P@.V8.YH,/[=Q<V=S9A,?5
MHT.9/"Y/.Y>.KY[UD5RS$;6-MJNIJO1;C+ 2BU'HZGL OJ&W<E,L IA  996
M!FREETIU%0DO<]?TZCN'UQA*7"F+YN?P4<#+K7PW%("/\\:]?,QA>6+V/(HA
ME8$+V]& <?3^-K\*F>YT;[%NMTPX]J3R*2&Q,(/#EIP_&O_,K8;6]0D_ K>/
M[NQDU)L_ AJQ3O@Q/J=N.&[IK,0FX(D5L.+);XLE-[Y$4FX8\!?7C-4*Y(A9
MQ0GFI,[X6:PV=C*-9$N71O9=W[V@6T2 <L?7P9/Q7XJ7U!35*=\:Z]Z1FR^7
M:IR4D-_2%.=<$LLN2Z5^[Z([E7AGE<U_A2U>X3D'%U]%DE/X&PE+3+$FT8S8
ML,5<W1FI[7>8?MQQ#3],OG+L[/D[Z8<50V8)RD><"\ETX.$/:+^6AQ__R%!1
M'2BBN>"6C&FSU*Q6CBE\*D#O,N+<125/^];4=;@Q$I.8YK6<M#Y. JY_*:<&
MHPGHQJS^U6?$>-Y2,6391/2NT^$2+-,2D[JI1W<1)ZI=X'W"Z!T!+.SS:L";
MHV#$>8^T/,MU$"$WM"#-%Q-4UD61,OWZJVFH<YO#A6 )<+!37N:A,7O#^S3(
MU;\)PS8)ERW?QM!REJBVH:H:!;Q=LTCD4*BXO&,:&N7PY7( E^V;.PJ8K'BT
M>FS04TSI&?.QDY4YK"GB/K&PP+,"Z]A3U^K0[QMG<Z_*]&PK#Y_JPFG/59B3
MP->SGA*G/X2Y6!2_:;GPR;))?V3FGK23:4E0#@YKD@@  '2[$.1C-7+<$2>$
MN\T>J$;O:D#VI3J&A:R3J2'#8N,!1.798-3<L]HXN9%41Z7Q=VN*;R4P5'V>
MB3KXG6Q#<C6&UHJ&CO5IU^([E+1Y'!Y,FKG=+"(8=VB[*1*,1C2V+40%*<=)
M@FPFA:ZWY7F,[R<CPG5 5V]OHH#!$"F0^J ,)3/[9K5$0)79J<23B5><9[CC
MK>%RTDUY8+@&DA0%I-PW/$-W'_!O&UP-(TB!)_Y+Q&9.S$C*AK?@=0+J*P04
M>2_B3Y;-!PT!+/5E]6,F!Z#W_.><>3-1L^V7/]Y^)&R,Z5"?2QJE]O<2=][A
M[6BE]KD#VR,<X[C_?6[N_ /7"J'RD'"':;SIJ4<B-8(#B@<=H.*^A*, Q O0
M?C[B%@J0TFK86T(!!R_Z=1'/![FXC'L#2G"2Q?V%712V@W5$V#")51YY?KBW
M6[)TA:ZN=X^'C;\9S$[=$WMH:K=:PWS-#2"YSM,EO,D3CQGI)@!>T(5+(WV+
MH',=*& Q&P6\LU\@N;C6A@*@(!007.".Y( X>\=JI8U8%'U)ZX)2Y@B>]HPW
M=Z[1O)*5ZKO7NQ94VHN# EK/SFY81^7[ZPJTLL:D2;40+!?(\GTIMR0QKTGX
MT[*?0YLK]@.O,$Q00$,$"FC3, @YP%0<.RD;2B\9Y;P3S\>9%U<>1JY_<W,P
MNHMF[<.]KW,4_%KV9C)%8W>^!TA33.9I/!V+?" L I7R])7!V(8Y07^Y$_TP
M+R?CU,W7&^T=SQIJDC <"'6\KIG>CNU@"$]4V @_0?>9B^8QQE GC&&!JIU\
M%IX9PZGQSYSYX][S?23[9XW\N"7ZO7-_&O3GL'U+JEO2%WIXR0*UJ!]Y54C:
MC5V0^,H\9L"4.QQ@",],99(< B]0UL$F.5J#V_SU)[N(N]_K,J^\9#%"-)ZD
M2,3O6OTI)FHHX/I<,^@8.P2)!*, 2FT/[E8B;MTQV)/P_N>E\98]Y<4&D_P*
MSF]R95583).D"@K\OEF=\/[%9N9[L).8K;[\B[ETCE69NGLZ_WQS^D]!+EM/
MD8C['/FG6^5^QJO-H)0G-]^O\P26YGMJ8"[W:Z 7HK>YMN?/MXZ/E#)R:PZG
M#>_M4'EJ!1?+:OGB81$'2N!__8?&U#.O*'R8CI =&E8=32\:7AZVN%]!?8T]
M7FHC=-E7E[;#IQ0SZU7FVJ]'Z=6#)_6KPR,7:O1!>OZ[$ZDU0CS:,T&D'T(J
M(.H1>A:SY0T+O,,-"\3V-\Z%#$WT5B5R5QW8XH9=12^/4PQZW= EZJ]W0VNR
MH]6.3VYTC[]PN]?DXG207.%V4>F1CRSMS(?7P))(AP&?MDY_JWY\UCO6(4X!
ML5ZA9W/W R:'W6-<O^/Q]:T85_FNXU@2RTQO-?P:''DD\*?.4!*M33>8^N:P
ME$!LR8<>K,R[> PW<255MW%4V((;4B%;3\=V[?.38*K#7+9I1RN!ZA6']#]0
M0-(;%D2#GBI3KQO_7_&)%D)_8#3-=>ADM+0RQJ2\UI/S^S3Y:T$>XV0#AT8!
MP<]+BD%(9IMX@=ZD5,:P/+5/*YY&1=*E(FYN?8_J<88\ELHP.FL20?]/>+&]
MY(!::; LI)?C4DBKOJ[T<91\GIWX7&2 VTL&0+C/ 18ZP!!25?)K:#_SGX='
M;;54GT:Z.5Q]+K9BO?8HLC.O1LIYLX<^RSC@A#*!I(V(SF9$9?O*C/_\SJ'I
MJ$%GB)S)E"Q+_Z-I"XK?* 4-X5]Q2JY!,.Z_ ?I_980YX?[YKQBVC@*W^.@_
MQP[//WA)[N>7M6J2KA^P% D[&S/O-RXSE67]EI'M6Y+T0^+2RU#K"=;^R)KN
MZ1[!W78/LG7PO1__S:GGOWH7_L% 98"(Q6_C,<N$,$=>_KXPG=\6%I)G26?0
M0*%F'6OC&,GSDK#5"(FE ?[9;7>A5I)SQA/0I06Z'QZKBB\C(O&)(+G4<<C9
MX71.FD%:-/P541E@R# DF2=OSEU)H( NZ'P2"OCU%D&P*1S= R\J4( *]- 0
MSO:/S6",S$<!PW.(."3^'@KX=<0U?=7DV#Y!<Z''9RB %07X>Z+G_>5NSU.H
M=:V"_O_MPZ".O;^7R%?#-F_CC [L$>V)FVXL+TD]DA]9*^DVT^%40;A..$6X
MV/!(Q<1(/CHS@)P,A0?_#O-_!Q^2%3?CB>/RQF5,LW7NGPX^< [[A*ZH,)N.
M[Q2A@)\9KY$]/;H'/-IP@9[CMR]CH@?X)=?N7V=?/B(YL4>BX[3<L*\"_37'
MUUX+%A%ON=)% 5D-Y]R(&W-_FO]?T68AD!:N\@ %:*" C3VD(@K .OLK??V/
MNW"AW@(ZO+L^=[*$B_0MXPV+$.+Y49]!TYT<C]2XTH[Y]?Z[/'^>I/#CKS9=
M_P4%QC_12#T=[KV0J_B>R[8T.ZW2WW)%[@BT<J_QXE+S?WS_3=H%F77P[87K
MUI7*TO.<A&'XTSDR&18D[:A)L&"47$F,&NG+(O;7P*[-O3F%R@:X*7%X4_ZN
MQ1#5>!#&LW"3*7_14*:RX<&'KN+Q9\]A OVXW/ZPIOC\\G06LDDE\8'LDO=<
M&"[1PK88'W"W@K><=0E"H.^9F"NC\-^2ZVBSJ%>3%E-JS@2LRR\)GQ04!V.;
M=K='9Y/X%6\LJ511?RVZ?/"NMB4A:LZ-=J-_*+KU0CG54=SU]O!N!K6:%MZU
MYMXUN\LFR'G1'"/'B&6*B+**X??*RH/D=^;!L[+!H+*\XKR7>0_3&J<]7UZ<
M%-X/;-%)BC.9Q.ZM:+W[ZJ.X E,B)%TY1D&X)?*M!N-#7-K5.F0P1OO:C0S+
M,RHFD6$G.Y&*\OW#R?.](]]%F7/%=T Y;DJ_WO4E<87,?OM%I4?Z0H\.PC]_
MZ^43=UHOQK^_^^EJ@H4-PPFA./5EM2XS&*/U8._&NLZ%M8Y&34X$66U$1H>-
MQRSM9PWG3^0=CDNKSW0K@(@,06X20[!OK9JXJR1+E))4X^T(K4\J+KSIQ$_N
MK8A&^NOZ3=:%!V/_<*Q>^7((GVO6Y-&5/]!-*!1\$1H3RB]%U%&NDN_R7.WA
M0QD*U0?_WI=^"_AT!XS&))FM[+.M>.:L#C9* FQ"C.\KWG)N=\0C"EUJT-E>
M3U'2F]_UXK'(])+?G^F+2&VRLOT^$_+9=@?+$E^&H#:[HX!O3R^Q!>X/"H0A
MB0T)K*/TIYY.%8QQ3XO+>B]\\%<LPO)*<1B)#-4L59.J4M:4+JD,[/!AKXZ:
M?!X V<%Z5OKR?H*I[3N)?17A#3V7F,R,-$M)_ ;O&VJ)SEM3J0YV]J^>#N8E
MF>3:SB]]\(G9<E:E$J\Z3GSXUG?C[#&(EG.@APB9&S'K?-FPXYRO0KY.'0\+
M<:$Q#I9?JME?+@]Q5MTFY_]RU]94?(TI9G9$2&-@=E+)QHDF"G_)<EEZ\&,H
MV;DJ0]8'2$3K9"+LK>VQ8C*>=2SO5+\5XVCK('9YQ,ML/OJUM2X $ -9K[N(
M$6S46BQZ"VU3^S-Z/I&WVTM_7TK&R^(;1 ]7UC)RR[V MG#>:3^=M'*1>'4Q
M._:0M2QFYR!JELJP^L4#R3W;:/W\:PHG_U@^T./OU#HMNB]7Q!C'B@D$6SS"
MJC$U>NTY?]*1[_)158RAHJ5;+(0$4VM*;TK!GI=_(O@YNZR9(R_>4JCFY^Y,
MZUC1T$BXJ?1!0%#N^=?\TF?WXS46W5FG_+\Z#>\7NJ3Y.@Q8OSJ$^0C-O^IX
M.IR=YN__V[_=_.D@%M(]\*FR6'1W5KK1W#!%0E3J1MYUE1)[*1T+&,<EUXR/
M3.*&[.V=M*1MU3,ERXS083I<+VON9\C&(PHTX.45SF/4? ISX0[VB%KWN85L
MC^2O<6+V#N(2;ZI_2I*PNS0UEC ?XBT%;WDF>6]DE]M+R1@CG&:"7)BHYL/C
M2&R L150QF DPM*?/O[!T5ZZ1VA)M^?WRLLPUW ZS,UV6"'[*G\P;^79Z^":
M[ZD0@&QN^@4\W_1@M2QU8_:>E<'T.H\AP2V.QR5]'83+=[$^\'38#DB:-L#*
M^K=EAB,F$'OEAC(69Z?;LRJ] VLT&QUC95L]7@H9XRT+2@1R0RX)0?,1!@'8
ME=37M&^R)K#3.'-\(3P4_G9H500G:-4Y9F(X2GN' +/N5[@;O+A\Q(.!-%&6
M3^'R**,\FHE-SAW?*)>\7;R?%WOAQR/OLE&K<H,@-/+#9@]%P$;%F^'X"U+G
M9=-)7^4%=&JJJOW+(ZH_'A@+*( 4O.PV MU)1H;HK-IDPOU0 '-].@JP10''
M.C ^7<Z(VB844*..)GK$;[_IX?R.0DT*^Y]Y>-]=B#BG.+:_.'B#KAITS@OJ
M/^YW(((]A*X@Z)6D<%JHGO<Q(RDDE'38TTHDY=G3@H$_'P&_*\FWD^;8D.OX
M(CLOQ'/ E7,Q?!YV6LLG.0VEM6;IZ[AN$TMA91PQC*!N,ZV12WNQAOEK);;V
M,,4#N5;.AW&.DQFU;=ZN4Q:@#,M-TF[C VGYVDB\ &2S#:6]PHNW*3[W0(<Y
M_'O$,VBQ4UR<L,\G&1< W[IMUW(6?&L<@1G9S[#H-[WFG!PHJAGDG*MOTR:[
MICY:>%OWS=VJ2"JBEM?RH_( 882!K WX1=1A2U.]Z'[OS'9%T4;YM].2/B>V
MZ'M1E!&.&?*]MMJ%K237=>32IB".1#Y#,UXUNBOUBJYDX13RH2(WC<P\_+84
MG>9[/0QQ((F[K6X^M\:6NMLPIA@@^CGDL1V 132,__I6ZJ?J=Z,5+7OD<,,7
MG[JRK29?%F+EN5>5O934O9*;L7?8TYQ' 1]00 OT$F<:NOY^<ZX5A&/ML1>0
M'B<GJV0].9,J,TVA=*-@XK8)I(DA]/BF<RX9Q$U#W[2)+T&0;*-<7<9U"G9F
M.WC;#Y;T/)Q/2F^E5B5C_1!2H5YUL).4ZY+)&*@<R_HYWSB4?9HDRK% 5Z1S
M+513?U[,$\\Y-V"P;.F;Y9!BPF-SKK%T3)Y=EBB^3JQK?+/?].66DHEMJ/<R
MK9A;/<R6,R'I47!I@5Q2WL_1-[-H >>N[-+D:WHV=PMF(#5/_07&,M[-*97'
ME+?>OLQ(E.^.'@D7IKAFO>@E/;KMS&G8[)&4 8ZTP$8$* CRV?5PX5['WY2S
M;H%Y>2\D4]HD410/NH#+].3R6CC8(F\;2QE_*?8;"=[XNL]K13U+_:;EPD8F
M2\M0T4'T/*,<)R@.+$;N*#]O7@BI>3Q2IMA +)&8^Z3<HU23+[')59;2[Y5\
MOUKCJJ_M(L)A?ZGY]?1&7.2&<++JF''X"G*0>X]*EK5=R,ABBFET!-J<MV]Q
MJC"$ HH:!D)1@.4A<E3HHK?&*?%\8THX'T1M.1F0&<]>4FZE5)YK[\#=@S,^
MDM@1W2>!*S#H_@SJT' /=W?Z4 7;2W#_XUEU76N\\H;SE;E6ONX.;P2GNI7:
M65732:]'FQ%$17:$OP.FM%(BRU6F77#KW&^&'KMI_F!@W[T >]O64*%:8[\B
M)MO ND)5UZ:?XGK1TU<LX^U2L];SOKC=71AR:E+1"DPU>OEY.QE>TE5#'0@/
MZ]C,BUO)5;P/%- ]"(0"K.IM!8N?+;19A" DJ7KZ7;M8\[8#K:4#N%CTS[D/
M!:>-F)0E9;]Z6@F0!*O66D_QY_.\_4HLU+=D?>7:KK+(?K?4A5\=\7N>,CU/
MGK;_X3=#F):\HG#5CL@^_(I<\GF./?#C+O+WMR+NJ>P*K4CI_R<,5A!RB]WY
MW,_?R V6*I0EZFB%[KR*SKM+H=V^ZCK_<A_7BV[S7Q;AD'1S&%UE07+$Y5*L
MU#9G[3Z55!5[^F$:B9@YN]+L.I*4L]^PH+7/G9IN.L!5&W56Z/%Q^92LG*1^
M ^<Z-3VLW!W+A>:DH$3S8.:J(HB+7X*D)5 CJ9>LP E*6:7?\AHOO_M@8RZX
M+:ZYGGO$N9"V#OF9;LZZW_KT0/H>Y:UK*XXJ^W[^RKP/;V<<S+T]X335XN;V
MW7:Y= R^616  K:=6OPZ/T0?A2Z'.NP\I!Y8+U.A$TCZG%&7&>3M]&W3]RKA
MZ0<\,QI:^P<5TP331R/JI894T[/T4_JFTM5#98KRDD-CUHOSW=3"EA.2YYWM
M0)\\9<=F Y% 30,!Q,M:T,$&%F_QY<[W^(.E(^8/*R_,.\6BKV.(,WEC*RX4
M!E[$9&16.)@NY-H3Z,]H2>1GZ\OJYKRI..#;9<_]4-DX+>%)ZM6W&E/8FC!8
ML'&J4Q' ,LQ9AO]8XU#!^T9O5?TN'+<GZ7Q#)7F1*^6B/=7^*T3#^UFW<F)*
M=3S]>&M3W)ZM+Z)W9TLO(\ZO5JI"![\"[FW\-4P2B5_PZMGYG7@7]8![3A_J
MM/P5Q$T*(15-HGV%!3,B^ZQA,RU5@I.]F5_M"(VNQJ+$5Q(A76O"BWY.?$6P
M6D,G8T^;3,M)QO;";_VXDTK?8XS(9+Z8R]I7*\P3NN 40NQ;.0NDG1C'D@43
M<K0[F:M+8MY\ZJ+%>K#P,?RM!]T\0F5_ZGEUG,*(/;]6[0N)^D3&Q!%R0XG<
MSQ1K/0J\&'W*;DZ-)P71"["WYOLG98B]A4L[BIEJRM* 7<78%ZH^ER64;"Q7
M \(GVT2*ZJ4_8Y+:F3<8&L-V1G^8_B/Z,NQ<E5J:/>O\]\S^%]7"^"<8R& -
M;2^.9HZ2,QCTDK>PU$2P?XVAZ1.^[^F6J;=>[3U;:/&MUSYA2^!E@)GK,\KJ
M-_Z8)*:1.@8_Y19#S%R+/:[A%M&WZ77!(0,^>_-N+->3E[A6;/5R JF+)'CK
MDG?+ ^:TATVJPV]\JC>753'Z\1 SB[;C6H77']/<,_.^ ?6@T;"M\[HS?+'T
M^V>+\F#>'^0R(D1-R\O1?4YS K8;KDJY4.M/?)[+W@D]T]#1W9D*V@X#>*_A
MOX3P7WCPVOJR73T=7+1?BRZ__HUMG/7ER*Y)\,S[1Z[^$H&4H\-_Y!;?ZC^%
M"+.:5@;\>W#4_F5S"%(_JO]\QW_8(+U%\B:T<R\;!4R!KZC*>F N2_9$-F[U
MW/6594,%J^\0=061Y,3,JNX7P6LH8('T '2%P=VPUY4?K2&YA/\^[?OQ<-2$
MBWZH#H<-DHR$# 4,D%\B$?'@_V69MKY^T0M:,_3@L<POA#\6ET/72XI[EX>_
M_6*=="OT&*L>W8'?"4GYV^AOH[^-_AE&-ALJA-#.K'0H+!1T<0WFC^X&;BV"
M+ZX90N>B#2X7UE]6[(_%8'4.=C-^85]OP=:ZB447E"S12FDLJKH2Y1'_7$W&
MW.O[O]&8 3 'NET1Q#WNLH[UN1A.V$5R>XZJ#=Z=@C[[MGKQ?>5H=ZJX1;&Q
MX 5"-X>L2 [*>Q,:A+[S*RI058B Z4-XX@+WC4W#B0O)3)B0+F&2X<2RRD<7
M$3/,.I5%Z#G%2<3%80+:+X'$C$V.= 1/\4@B07[FAVA*4%OY38<+5;!Y@:NA
M3<1@P[VV,7&[%$OJ,0V=Q+-(%Z\%SD6RDI(H*09V85KAKL9"R<K:@]W(A>,#
ME]TJ,Z=711F]?>&Q3]X7,5#A<[E1 6=+DG7+\1V:T4OBFI%;4YS0$NS&P&UY
ME<A5=DNW&TDJO379&U)5:ILHX/?))&&@=)\71\->VM65Y)LM[:X:CAQ\,BGE
MT<RY[&S6M0N.-.'S2P)3LS9,-P^H@_BG&#$UE;CZCN24'F;8O$R,YA)6G5'
M(H9@BIO[KH1(B.TX7 BMR$TN'=O_J!72/ZAOR()G(B?/6KM2:"SNFEJX?_W,
MN;M$,[DCNN+[:IF80[T#1,HR?&('?A+2JA%/H:[-.5T=/"FP[MAQO8@=BZQ)
M1*(H&#.6K="[ "R+R+[4\PD[UPR91#QNJ-NG#F+]/G:S8<0YFC10+1SVXT9N
MI/^@\+EN &ZHA\9)&"S$V9YV0U!GML@F>]+ZH,<K.Q_K]MACU7'U+\6GW4YM
MF"M!&X9_B(!RL.FI ]?O\^0*E-;=.O9,9-WNUIHN#;LO$S3]TF3;Z<N;JJ#Y
M@RD:2@$*W)(@A5(BLOQ,OQUS8_'!?I8PAUL?:R'CL\9V2_2R#[R]E2QUVDS-
M6'MB]RFB-@U%S?L4ZX$NE@L 6 <6/\M@;"_J_>Z+VFGE%?WA-V=5IC[6_M]!
M!_I]25E_F_SW-;E#7'3 )CLHH%VZE6!S%L]8$R\\D/,C@*:;N!U=M33/[J,
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MS2<?[_WCB?F*7;SSK$T.^P5%=-O^:2*L%J4TN23E^-/+RXH'32EP)@':<\
MON4I:8A'^K\94PWVY[-BLRZ#-3N X?F>Y\L0<17P[&-P&/!2RC$97@5;Q\(
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M'XFV<&;Y]):6(,U_-B'AH[N&XA+D0RT7=)URFG[PY8CCF8RAN!5>%<6>%#_
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M+POY[Y39=U6"S4R!^QC OI@5FEP@$ 3SP@# @1<WM7\'6AN#)@7? /<YJ&$
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M7K_D:DE'D0WQ:CXF+BC&E\@Q]T&#3M29V6SE;4V40(@3" WI0Z3+/\[*K"6
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M39N==JO2_V'L%D+J.Q,8+3/;J/W %<NHB9@^&(B_3D6^33HC) 59[R0S%E.
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M]=%/N#&^MLN8>@8: JZ?7R !9J]:G*YYI7DM*J1 WIR !TB VU-!G[0Z.=&
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M7=[S?%.:W/GH0G9JJK\*3\M"AGXZTZ!VE"MA29&/G)0,DV1R 78$TT#4WTR
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M"@5,S1BN+^R0)G.P'?_6$18Y@GOX9DH\Y&?\':BM6BB\.1Z6O\9Z4($:?BD
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M^R6Y<86*!(AIMQ<V/0)UC[@C 0 D8)BHA&GEN4%7<O[54&$;")TR^/:T8\W
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MQ5 Y):N=9-R9N*E]([)Z2\5<M;?9A^M5=-!U,'V<;5:H"/%NX9I,FB_>6IX
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M-<%#@BM+08L?HA)^$[@_5 55^);CIM.^XRE\!3/7T%#:4JX8\RN[6S=>A,O
MD&_V_H['QJD\^+3>HSC\SJ[+^C0=EA0M,W'1[$H.^0HWN3;1-^RB5"!%Y90S
M"5W,EE?G]0I?&_E&"/BU<C]Y-MCJR#*);KQ>,'-V<Q3N.UW.: /INE32NI=I
MVT"+[_B8F!PG;L@C?OY,=_@*;]GJ(>IFS,09T4@;Z;;]?$]V!].=V'45+3$J
M=BP4DL7XXP&=%DJR2:Y\>5Z5T;3JBC)QBFK6EG0E0+.=A!.JT%&8Y5,A-F J
M_,61++0R.BM=@*+RS'* H'V1/7S#T<2!0V8/DLR!R>DW[D6R!,:$9[>4;3KT
M$)P)!!T$SI7[+KD\/WI%=XC#3TS%V^"(8!Z3JA>2668"<M.']2X;RVN\^3%'
M2@0.#6^C_.U]VQIVI,*]'9UY8BCVT!5=K?/!U6.>)!+?WI4]3KGKS-,:L[<%
MA \C\1RF::<\-*P\H4,MM6'%//FN*3-][L_II5B7-),R4@0=#T(VDLKU6RL&
M;14K*1]/[K)48'!<-[5L1]4YZ'@6*4XFC D)NHH&5H"P-F.]^I:F,K\I4X3
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MJ0T8JY@)=7SQ@VOKJF:?:TN^=B[\+@ZX"BMT$C7UZIE_S6GR7;?D-@V9;'B
M?F7Y]YJJ2//'O*HQIB&^>\U#&(?%,FG!?F".\2OC^+W!*+0+WN#R8&7/SV>0
M(9NC7'\50B%_UBD3%;&+)"8YR?&-J@#-<2?-$VPYJ<!.VJ#3957V"#G,T"07
MXW,Q@XB2&"QT3CWG_3CLD_G_P]YWAS79;/L&08HT4>E505$I%GH7^2 @)2!*
M;XK44*1W(B"]@X#2(KT36NA5NDB'A-Z+@ %"+R&YX'?.WG[[['W.N?N<Y][G
MWO/]D3SOK)E9L]Z9-3-KO3/S&Z@#ESQ+A[&XM'S+Z[!D]#"%NW&RAM/J^Q^;
MFUO9I\I35(;'$*M*_Q&@Y PJCL-&C\LH+/=2RH!VO"./\:DS0O&[$:G15JA"
M58R9-,9#GE%:I).3/95/!P[-7KMJ\7PZR>+V5;V>55)[8 (I:T,)7A0=INW-
MC@)==]&5O^Y5_<-/,Q$C7=M0CR:OC'[EL2#T!KZ;63[P],NZXBL#W0#AE\)L
M=YF#)?*R[(2,AW)A-\I&ZQ7=YCP4A49M"^%T]2J)YJD*[\LYW$[+'BX\Y>N3
MH^ R*78RQ-O0095MB$:46B8RKK\MSGJ0N':_5 _?9R=5F"[G*Z_Q2'[*N44^
M(<#5\Z!,O_/ *+ _1ER6=QX:W11*U[('NXO8XW&0WX8G!"$[&48.'7HMD6J,
M8;I='-&/V=7"_59^N $B]HL6**DL$Y57(SC@=6^W>=YK-()I(J:SCA7]Q<G,
M."/L>L^-PR19MY3-Z'Q7E@WYT==H@]*\T*0CZP<\ B1MT5]OBRF$V^U<59DC
MRG)@B&C*W]#!PL0[.[LJ$\ITQV&!17XZG\-0/=!C<P5ZMI.%"-45B;ZR80,X
MY(;"/)II%APQ8$#;O'- PQ6V*M*UAP'[>:FWL=PNWXX/=7+Q2M-;5P/=QI1V
M&-5(JA#>H-JAZ=N4HA =BA#K)W1%MEV7S),L1A@P\$TV+!)^N!L5%?.058@M
M>5%8<N3<6D-1SSDS; 45(88U?:6"JA(+Z&9<BQTQ:SN_W.Z M';+L?2^@YX-
MXH>C:0JRM71U)YX5& MVSGP]HUNU1'<!S,)2[RY3& _FPFB,%Q2PS)-'?1#J
M]5LGW;Z=UB0DMK>X&[5WU8_&2Q0X#M<T,<:2>86NV2?]BO7HE\AQ]G#9QN!;
MVJT$_BY4W-]4#MC\WA'BX1<QI3D@<HMUYSL*/(I<\16:1DP>3W>%<40M\L#'
MI86WWG'EY9G\O75M)NA8L>Y"X:'W;U]&*P3>JUS],;OZ:+(N^X=#R)+CF:;N
M]M;[S&UC5SZ-^A'V"%US7C9_Y>3U]LHZA61>Z6ZBO5[WT1N;7$Q$@?RDO:SM
M$^)\,AS1XT?6/"Q+-W<P+;>691S[Z3NS3)C9U2X]J74:(.H(=6HCQQ:$=0]O
MGOL90PW/SX<$<5!;[9L#[.T1DV%^5GJ+Q(IAOD[)X+LQ7]<BIV.>OJ65:FNH
MZ0,C':5SPZ\T6RY39/(,HV0?1?+ANZB(GMAI?D^K\]6X\N\8P92\OTZ%E9@_
M[#J%A;5#6+QANY)5Y!@Z]P==YQ/<JM _.UF)S@9"=UBAV 9='.#IL[W:7= ?
MPR>8I+-1]_+E<MO#A._G)@KLQ>Y_Q1$DK-W2,Z-FC9)J.%%?>IT7K7H,.]L:
M*H\-W^>]KS$ N:"K+5%N>7_H%\ !+G!AFPZ;GFD&OB[B7<3X7,#"LD$\]K+=
M8#\18G^F<'4F5:S& 2[H&5VL,V?W4L$XP 52+>2<BP&S[]"FU 7Y[@[1.2>S
M1!S@ J+6\'0VBS;0J*(N\B=9_(+UIY]EB2.QAVNR\V,\?Q9X02\V;).BM!*7
MSN_,PP$LUB=,UMN7Q"=,D#%#G<G^WA1/.)"*?V4*Y)>U8$I-VNZ4'2ID+ZVH
M;J1!6RKDI=>GE=Y_]RB&KV*1LZG!TE*2T5=9;E57/G%S]U3D!V)P6N/>AY1)
M!;:YV YWH[VBR%\:7B2=J4S\"BM)8ZF=<;;6=Q:!<E>;= B71A+V-N)*,>G'
M8"E) )N[7^*! H8^:UH/_'R:A%/YM?!"K7_7./Q&[N0[8O']?H./1="_X2E"
MSC7O')=MZ5PU;)F(R+2:=$IF\)^/YS(.NQ3J,_"6+]$Y;[M3:<1)>Y_4VE!W
M*'6M:EHV>^:C<;7-)Z>6I8CJ=J?&7YK@^(+CM,S\9K#7Y[$U8E[N].$^J]6*
MCYT"=4;A7\_L[1V25](&)1G7&%C2[#RKA ZK:#6:3&H\UG[K<)J.Z9/OMO$;
M!I!IJOVU(A43;_:P!U<=*:2WV-%9J^M!58);V[.4O7O-_55>6*T_84^[4^MA
M2#$Q 9Z(*&4J9PP]6HAX^5H0C\ZH3HX/ Q2Y SO^I3E[KRY']^, 7TBRS_\8
M9FA/96?'=$5B[8^3NU><)B,:I^]'P+9;GXWNAX8#3T':94*O9)<;XN9#N K)
M,[[I.70R4>F[_*)53(,4VO2-3-OM4/\]8?Y0$C,/+=*/F!6R9CZ:CB=,9&B=
MQB?GKZ#T,RW+SVI*1_\0D_\'??L!18N%"^M/LAO^>0Z^GU7Z4QM#6TMT]#N/
M+Z@L_X;E]@^:!#OL!1GX<S#Y70%_%[->['+6U)_E_6^7YY \6D_%DI?7ZX[L
MIX]EO1LIW(R/G#CO^%^J [&^(!S &W@TRDIUE*%=@BRV+H()/DURAGT(I%<%
M<;@G]EQ@RK:Q_@XI:WP!*;NZH=D3IW!OV*6N"3;CX9B[."U</:)15K5OG(X#
M^-M1GA% L9A(= :6NDUJ[QKD=$>JHV;V2.GB9M6?,+M2OZ/N_A(L/^G0Q $D
M9_=Q %L&#[).K/>#C25'P^WBFSC YU@<8#;ZXD+7OPJ+%+N L V2^AW!MO-?
M88;_0-@/@V&]FC:P,Y2O/N( _>UGGA&AOT@4>:1Y%0<84, !MKK.W;E5R#P?
MFNAWB%XZ'. G9N\?PI*E<>=<JLX@DRT_^%B/CYI@T8._BG1Q/^@"ZPF)U-DQ
MZZ+>%N:.-]N_ !&S_@LP\1_"B,=-QP<X .S452+@O%*E:/=W1!_\422I>3T9
M'$":$P=H8L> 4_ZV&<S_#>&72B0J^0997< V F5_%0N(X0J"?.?  0Z7(.$.
M3=N?COQ^!S*&_ YK_$M(ZRL.L#J);4+-'=!'8C"&R*[O3;_*8_YK2Q>[8*]+
M787\Q&J._!?LYE^#&_2&F%,(\JR>I?71>26$GAPST_XJ"NNO#2W0=ZZ79@N4
MOT,?GZ?_B87\A["7,=<Y&]L3'*#*;\Q4:A<-,63_9U4OLM $LHO" 0P/MO]4
MO/\!BM?H,\\_8#NS9LOP&DUW\/%@D8-I_Z XHAI">.3W8M0I^'-#[:ZQKOV\
M)]S Y6X_P#UQDVNJ^5E8[HQO!00FZ#HV-AJNJ^$"07Y6DZ6>L/_OW<9[;\JR
M4J,V)36%?])FZ[> &8G,+6(\FR?-S>QYU"D+#^A=/;X$,X+=,S4"#*O?\]51
MJN:3=#8^TG8_;]P/_400)-?6&4T<I6]1T9:X]$+*ZQ7^V!?ZSQ6?;.*9IX6_
MN 7[S+8:47.QMO+=D?6Z>>/=<G 1K6K(SFUAZT]D@6=9PNQH:M[HXK7$/;Z>
M;/VB+[K?$#OSSSY$N^<1X.OUP<"V.9CGV]/+,=R:.N]='AH0'^UFO)BA#[1G
M9#I%WIQ_[7F;P35/@<%D,\W.K(!7;@P'&&*2E9I3&?X!S!*[LII=%;(G.[0E
M(-C0GI+2#4\%W<,JR!!PA;W!?"-\TBEPIV%!F;&5YNFNSLBM<O^(&XT*QM_S
M'^MN4R\/)V-XT#ZL>X^Z<8"L1YK@!2]>CZ8;:SH1T9()DN4Y,NR\4*^;C.GV
M>-%V,6%7Y@2)ET*X?7^,;&^%82062CD/[N113\KV?-8 JFW WPD?=MQ?J2E>
M:V0<RAS9!T/+Q]M>B"?1;RLTSTM+@++L*]WK'Q]U=&.4YQ,&X?VW3,IJ%:/%
MU3L O'6Q],+T$SUC"Y6>(HLP\J/*!5=^"464?;//DN$M^0/?MY1]Z7&!#M>Q
MM,!6'."$\KSW)I\WBZR3()9]B!<>/W2S,1Q^V=_L5(3@4=@[&;((]XBXX,^0
M;GETX&F\X0E/00R2N.0(FN_J)R:7P)ML:GMB?+_G.I95M I#F!)5W*_4B'3L
M%<1^[=C9$2Z&)6=5<-[.9"\&H+:&2@0@(9+D T[:>[V*6CL/>+JN=1YH)UFP
M47U-(_(595AV2A"%M2E+:<RU6A=+9^L*G48_&XK>=^G$7,HN/W=&V1OYT9ZL
MVQ$;)] D".-QHDE"<O!I4 ?=)MW%1P;G ^]'VV<X0&"QP(:RRKV*21.SQ#<:
M=QX2JF@R^G0*=X )'X2E N)?AGL^2?LX1PO_!%QX9N0MT#\]::#G*K- %&3#
M_ZDB2$ 1-#6A=U=;7GZ,GADX;<J9MAK9\2GO:+)=U=S9W2!M3A%L[D2'&&(L
MF%81X=GI\5FYK ?P(J%'J73Q]BN/"$QS*0Q!X+:P.=].\U=B4E^;]SJ+/8R+
M3%PA"T3^]>J.B%K)4NKV9OJ=3RR"[(WX[T#S6BXSU\W%^>;UJ0681?;#[\7H
M:CV(W"R>X;\9,-O@4\?V[MF<G:)=?O>=A@Q86#W7 ?USE#IHI A&,$C2Q7:/
M"SXBI/20#9VH(>ULX^K7.4.S#1^:!(O6:QR2\2T3N#%1M+TGB.R Z1Y!9>H&
M=/7\7L"]'N$]<&BZ4OW#86!'6'Q7K[I\U!%V#>R.#+#>2W$6&W]7ZU^,*0@R
MD;UB?.U5 C[]Q!A;K%Y\@QO80P >%QG ,JL)U?6'Z]]:,+JF+9YC/E9R^\JU
M&@[*)(NN]/,Z4-S>"L<(+73?"?UME+TVGBHATKBCV7W^'8='!)>AV@B/8Y'H
MHFI#PE=X95@/=Y*BM>IC%0 'EKI91V^]4E)LJ#_,,?RF37: X_ ^^;WE+Y?U
M>YE"IJJ^DA#1$;P5R6AC$=V>#?7$7PCZJ=$MV5]W'D1S>$@_QSL>43-J#$QO
MOZ5\39'^JVB >L3GO9Q191'?[P=AKI>F27" 1ED3[:/AWQH]U&Y4!258T<Q8
M[)T&O8XJ^>K#_MG PZ'?,B;B#\L?9><#4_CU+P@+IZ)U*IW?4'"A2]]6QU]<
M@^"U@Y'XL'8WJ792T(^]"H\CQWM+Y:=&QM>>F4A7HY;L.H#\ Y\0YMYL0_6*
M.:1G+ =B=:\G%;.E-39\*8C%(XBW-$UJJWS-7\6[#FF/%<I_PXMZIW!%;)L$
MP]4G+@0;/_KMZ%.]^K6U*O14IY,'OT@\"4&&)?\K6C;/ZA:"U1CEY\A]&G1D
MB"=CGJMA6ZIR<@(ME1P.\&JZ3#8\M)(#D SK"3-RNG'L1-VO7#+*O<_GR+VR
MJUR(LA;Z*C=.2V\ E "RA]082!"C[647>62>CA8YGEI+O:RMWDD=-P57OGRN
M&G\:^@[ GARKB5%;Y%&=_/ZZW\ /"$9)V$R(Z4O BE."F(C1<'5HO8K"8FG&
M!UYWP;1\[;778S/*RZ2?AB8>?*A<8]R$ 18E<RZ*,5O@ ;9YTPXLCY)*C.:$
MO();</AUN5U*)>T0EEN-NL]*<S3;1E/;6.RX=<T?VQ?MNW9B$V$S;!F&/3$%
MW,1N/W<^DV5*^^8A0;W4R(NNK+&E\',XR^$,W"N8EN U&4D;EET(3F*M93L;
M](MR3Q[M::+=@&U_9597&K%VXHIUO E5&[96RK[[V.&>3VD@OHWJ-M\:D(OU
ML81HR,XL\=&. G^*S2;DAO91!".I7*U^94#?=VJ"L@K7"?7->9]UMV*#_H71
M]CI=RP1)H;)&-V:R$P:+:[]%%U!5<RS;:P,/(R@E1^Q+'=AG<F%2([SUVH5'
MG;J#COHVY(\GAD@MXEW@VI\4"SSS<_#)Y!1$.@B)!-[/<*"_S9!5H1,.LJ&V
MME9?8]:Z+>GT\3CC-X=85&-CJ('X3(-?Q5(S;/.UIRTU$SWY;&K+B<TB+1B%
MPF <1DL4H_;5/(KM#''AJV%=C66^/(*DFG#PP&^J">K5I;+<XQ)$',EXB!H<
M@/BH1S^AD\$[P:E('TS#\-X^6J C_(!:3G;ZM'STC +(I/:55L+Y[VQ6Q5.R
MK 1J6[,I8Y,K%Y;:*W"  IXJ9[N(#+H^RV6[-%_,ZY1(Z?D]3BP. #?2F3["
M ?0'WJ!- AI,S&QZ. YJ9;0*"J/OB<E\59EKHYC-,7NEM\^0DVL9[ZY5*13K
M]G3%L3)TF:=6[K2@6;@_;Z&:Q.G<T'/-,!BR]I3*E\F<,/P>"N'JL2ROX-:C
M_,#T9C="Y5%LV$*2V0+T:G&X"?G^DG*N[E$<?U)2T+PJ+SM1;%54IJ^H\8T?
MM!*"(6@O2*<H%KK0^W1FMVWPR*.[^DUI6?V04CS2+LS:--GDG<T2!==8$2>M
MH*H*"^<U.5@CS51X='+>I@3YG4*2J<1_<.#^?\RA^T+EGT9>V*% 0(=D6II7
M7=N$8/E!"G2\0/18TL"S7^#)1NJC2!FH93<"0^OD4*A8>.1A6#T Y_)_4>/H
M;Q;R-@-08=TQ)TQ8NWZQ3&C8VDAIS?4\5FL4#@XWTXF1XD0YW.HH[4Q&10C,
MXTE8]D7.@[W$6EU$;T^%>M@Z\+1VUTJDQ6N:<H6E)I4FSJ:'EI0VK^$ 9$C0
M-OFJO[J&BV)HJ7W5 T+M)XY&F39+F(]]0(.X\@5;DLH:)W">Q4E17W2A#A>'
M4-3=MVHEST19F.WQ6K;T>6[H^T=WF3>2-?GI^FFC:8,V!7HV7KR!]];JME/,
M!Q@%M[P6[L]RVE.3[3!>.Z$=\U0HM,0!+&;/TF^R:'QS\]:)VTAU@$J'9+C-
M?8?!/!7$#\4R$#\6X.;UL'U=ZHX?JRNGQZ@P36596E(FKP0?V=3H^0U6U)T8
MY3M[,SUB[;T]*:?ENYXUO"#ON-),<\-QG6*XUP%4Z%1EV4;0:G)Y04#)C%/*
M162QR$I-=JS0U#54'CNSO9*1Z88%3O+,L J9HI("^,+"L(Z&WS7<88$<@P($
MNT4F[YYBC)+Q EC>7R7>NU7Q/9,OJF9;:2(RP'%:\E2OVEI36:S(">RXDZ4!
M>"??/1TW[R,E!-<LWQ8LLLL;GSZ"MB<P3&D\#T:AXH?$S-O\-LO?GRXYT1?/
MA+B\+A-N +4P)!ST(O+FH3?TOMO/E'A4-WY+>-@UAU?/GLQUE5!^(^0-A+QH
M5K%.=]K@9%6[-E4L?K3LFM9RY*W'(<(O]:*K!B,KQ=SOUI&R1PQZTN;J;@QL
M&-Q"\W34N%F&Q5M:Q\S<%2+CL]+S;;.#RNQU' 951**V*"Q%@= EK[+I^5UG
MF_%J8^&N_E4=1[6WI<TM\U),.AQ/04'>3H5L-GZG--0S?OF;?7) ^L(&$3@7
MY(JK+#RI1W![XW:&V.0D__,G&Z5IN\R91JHE>!\OKS+C">_?OUNMM7LFI6J\
M$&0<JUYGC;=U6Y=DQKGM4'CEUFG9H-^*%9&O-.N7NH;SWF?T%]@-F"B:-\ZN
MP%.])*)'':I<'RH;+\^;ICK)V">]>W,>2; ,VJ7^7J&N\L5R560>0JKXN=?+
M*]>R;'T"?OI@X@%'L/'E%Z]>JKFJ/G;=YV^\MSW:U\";X/0JO_(3)$>//BWY
MR1V"QW$F]^69_!"U%P*N\GAR'5ASM=$86D^?E=J)3V(*W0PL_3OX=HU9Q@L]
M(@-/DOFT],T-[B4]J_,#A8*JH[0S>T2!ARH(J7M+N[%8B>D+16]9@U*PJ@PO
M5GC9@XL2ARQG'+=7@&QD&<Q3,=)B#2<O/?H#:I-_@GB'+_\KB'>A54LF1\DU
M:)(%9TX.\ZY!L"SMJS=V+BQDB,7ABFI'")V^!9+&V<*"RRO.-,!)+7Q&,9G+
MPV\X1-$0H/AJ_AC%72\+L<WO=SD8%Z"+T_0<ZWQ$=D^)LAHBBC)/_\$=P?EL
MF\ 7NZ6*YJTX65YNSQBG.;VOR^;?N#V1HK!_)[U\F[?)EH,FYFA7/5;6)Z&G
M0M$QXG6^''4Q[0I[& LAD'IZ4'9,FPZA0SN&42L &Y[WS+0;5.?CD7@3]\,^
MASX7=S+CAC<XP)=S-X8&C;EWEG$8C ,\VY$PV95<V6HM.N_9;TL[UV<N16K&
M&KB,9/G#0>7\UC=<P6YLR[H<F*FY1?R3466I9O<AUR1%)!Q*!\K7&Z.G-@9S
M!#R.R)*_DA/03>0BTOR[&.>NL/S?7CU/^'# ;I$3333A4 >B,0 FK-WTFBS?
M"C-&%[_$,JS;M=MEK<T\:BC;1K6*>(GP&)O)VBO>4G)[N>H3V2_PW5&]CCK:
MQV3>G!\'N#JQKE%V['PP832<43D^*$-(Y.Q%^"BRH[S?I[P.>T?*0Y^A\R12
MR7MKR\-K:ZCVY+R#,0G"YKQ<5&OK(B8[JN)/E!?YE(T%,ET("$^_QDC=;?0C
MHD:LZ5@WAF=.6,3[-/:#K[2R[,;"Y0A!17KIH?Z^_V,G/#R*1^?=:F^J$]O[
MEWMC-4PZA&23SRGTD6>)1;*\D%LUI"+GCWRLIP(Z(2(8OZCRCSC >,8C'*#\
M96X&M$ODS^@_HW^)OG+X_#N7_<*F,C^H8YX/6)=#WR_Q2/482X<#I-8"S_:I
MW5;_<-YK=[_<[$I,9+F.H(=C&5S4+D%LE!UY'DL&Z==GQYZ$1$JULNXBY<\=
MUW38S?1R[#AD%\4 >0,[/NHWV,6<EROA&'FZ?E_\KSGJ T*D*@TQI])G,4VK
MBQ(>_=N=F/TAJ:W<W%_2[S#<_<F*Z. 9#@ -V]_Z:S$9?\E0T&6><6J" _17
ML(YS8;WY_K%<D:@$'$!RX$^Y_B_+=1!*PN^2$I!Z0"XX(UOS=-)>JFY2N.C*
MWVZE.'Q(%UFHM@J/9&24&7NYU' ^9A</1_VS6QHO?A$_OPD77(<48"P;C"5Z
M7Y7ZY(-=! T>#O '#;';YF;U//M&L;\S^@PETNF0[*<MFA/L"<S=<'$'^OW@
M/]9I\=6?M53Y<CDJ[-CR^HHI8'?M.1@'V%$79\8!]&!->SH:WH'%:XW7T!1-
M&6"DG<6.WFQWKLZ4OG"$R$(4?FLR61X=N^2'  MSR=L(6CU#2M?\+Q/(Y_%W
M$B<6NL>+-N.\M_5G'Y?TO?5P>(DA7<SS5/;*LY@(K]= (H;E!XAW:#R<HC-F
M\#B6'D=!*'6*)QJ@H=ZWOC>-Q?(L9X>5][JXX4U?-5,.I;-KO1[CNE>HS_6L
M/J'EX4:MJ V"/USEP%R5R0W]:?;;>ZB<0>J<VAM:01-T7W8J&1+N<SEG@O],
MNS#]>7AIE%)P/&-Y'9G[5;X)>+WZ O/KGA?#%5*4VCI3E@G='.F*2!-?NF%Z
MT\D>^V8C!P,',(0F;QO<5OL>[[VFSMHG_+"K# NW^+9ZG;%"C=LXP $B*=LU
M>]"HY!.#HK)6WZ ;GY]O$O+RX_I59XJ'P'-?>* NS7*&)U1;^4';R<M/N^D6
M-YN&ZCO>47>H'8;EM<S%^@W!/5_F]Z<=@5Z.6L<(I0Z-KH2;$.3=?\SG2R'%
M,+^G_]+*T]HXX\BVG>\HY.LZ?69=Q,J2?JARP0>[ATN79GF'0(99H 7*(R4<
M8!X/#<3<9AV3!!U8-8(.S%+JG(=39LSH.K.X+&D'4DD:N:=TVT4I+U^.QG_G
M/9I,E9C0YBW:L%T55,'((S<S7EALW;,N1$6( P"MNY):.,\,5NF[^L@=--Q!
M_N1Q-9#0B1$KX^?&++>#+@NOA=E%/EL3(.9VB@S24:ZK<(FG=2?_&C_%;!*>
MRFLO+$)4]%!P7\)]I;^CEB+\VE/$1)@F)5?)[9;P%\7#R2ZK; C#D'H[29\%
M,"FQ=7I,._7M4<ZW#K9,,<2+;*OX*]TB_9=J>!ZO[ZH<0>=Q $K+;UMWPB^O
MQKG<[$H=C:*;@FX!LD"U(\[NH/!ZS9R-Q&(H;2!%TH*<==.$I$MJ">_SFSOD
M&0 ;9C>1]"Y>]\!@3VFB@ H1)_KT&&>RTE8"0V\+K?FK'C'@#]4(+,=:_%;!
M['=WIA-'\(KB*S/^;-3U1KKPL-9B(CT[;5#N[#HKQ=YD3VZJ%_#+2:;AQ%LY
M%[%C@H*2_6-Y][6M1LZC9Y.RUD]G=<H;HK)?5?BJ#G]=W<QNV;T$8HJXI\7K
M%+_+TUNA_MFHC,V)(DN>P"S*C6BBNN#,N!.9Z+_K"I$;6AC^L6S^9%0I3V#<
MH(CE81KH"8BH2*\&VHG4I*%E<((%HJR6 X1J?(]7W!8<>G+O7DHFPXM&"OC#
MCB:0.H@'XB)F"^1B<F55QN38#(DINV\@-/!2Z<98S9Q#6/13&2N4IT Q< %$
MH;5!]66@:,3CFY*]ZI(OWRP!"_C3B$ 3PSH+URA_/VGG/!J<':2A.?)^\M.T
MB]$-X68ZU$RM,L.J=/D0_Z3R_8/.']R-L@EQHF4]%4SOV3!M1JOTX@R[X8HJ
M1V OF&N (=6LOLZZFCZMZ]:6TF5&HTD.XC"A2VGR'(_FS(;\JU,[\RV:;+&]
M5=B14Z') TJI'W7U16<'FZNL.G #NWEE];;A[XV,PS$[TW=J2JNKP2E/1U==
MPCED0]GDDS^\5>! RF8>Q54I6Q3V &HCU02I^JU)"_D:V^U&*EL#)GT[5Y[C
MK=Y(9#!3E'U9,F+M)&9L9\:N0.S\9)E>AEI8N(N>?E-8(ESGC_9UL5D;]G;]
ML*U5A35-RX/]@KE^)OL:^;1P[[V8A]BK\G1,J:/#FJ0+S$\I23$R)4BXX",+
MEWCR''@W0>:UP)FZ!GRRL%/UI\9[9[8=[J;E)F8+*7Q*B8@3T'VQ!J:OOU'Z
M/HG6,R-B=7TKAM1)3'D?'ZO?Z66%&*"]KE26)__U;*Y3F*Y39$UO&=G&?'-?
M7TQQ8+42 8/=N3(X/D6H]1HKPOSA(1[0)KOF 56[0&I#GNMC\B^L-PQD'*C4
M#JF:%K?V(J4.AE**N<;V/)JHS)U9@),"*:*3J"LLK*)KU[^I#Q2#V*<TO.L6
M>82D$7O6@NL+XQ3IFV0Q4_>)/]R\&20A\_"*J#VX3]PB9TQF4?_9"E)].VF*
M+DUA;^M:2\5O^1_52:.[V,M2&W85R4X(T\#;&VJ-0X56A1K@T.>\'Q7I7@")
M"6+L7Y1<MG=?@-XG3<W+L7S,K_,!>9CX*F!BY3?-RH2@#%6*VQR88I'^5^TZ
MP_O*4AKO^K-G)V:^4 S?KNBYY;<6QV%:'ZE.LZHT(I<%_6&\R'Z6$>-\K$4W
M&SDW6R[E[V) :TO 6^.=2BW(:FEN#(;]F'DU04*: JTC[W$\SN,GB?-T6%0,
M)U4=VO.ZL_%;I'J#,_=$48M\VI-,WQ9YVX_;E+F8K!%QY?RU2C4%CEK9;V7@
MJ+75'UD?@=?+?%E3;].+.S+9O?34SK1(:*(2OW7H[I2)NE>CS:!%'>H?>9\"
MR,8"3"N6TJ?):77O:I@]D%D4V#VX7F>Z-!U>OTJ_ULL?)=AO6(K@;U!;499Z
M7EYGKC*N,>,4U>'%2+"(SIX$)\JBNBKAH]QFR1TF5+)OPR;Q6JSPD\W"D"E?
MQ._A *2TK9!M?W+A/G8H:G;<0[RIW&KQVWB'RX\.M_YY;<%:B2)8\R3JV5"O
M['+GQP>\KZ57&YHF'MW:W'CW#CT<HD&:6FX",S^)^Q:/8(#[3[=!O._RJHU[
M?V8*4=@_8T"J*4LN:I0$''>16M_^RAV>^O&YO8.!21X4G[2)]-PWIW,L+<0!
MS%N6< #3'[OBT&/P"FJ5D2]E"@OO=XT?5BY'B,O8D>, [P7D36KC%0LDK,EH
M!X70'*#6Z+,A"E%C?OO 1ZCLS57L-6FS@W"I'TUO'A^+]4]4;76@&L3K[: Z
MNCP0N9'B)7CI:"%OL7&WJU$-T*DSE^A6_2E*XZ2Q.H&OJ -J[32W8@;@CVD.
M6Q1>=+A*F:W"%3U@6C;@U$1Y#-D.W'@;FCM?63VDX*=Z.6!@Y]8^X'J<U>DN
M\*[>R;F3FG?W;^V>9GV;I2.L,M$;0Q-]'EO\N:T9DWMAJW3->QC+O0ELN&UN
M<8HD[!7U;A3-^*;:&Y$U?TZ!?O+9[>IBP447#/M:V,DQR@!RL1NN$0?P=X#@
M "24![88#KKJ4Y<)0:\JE%B2F,/N?H<@^F14*RFUQZW0(M'A\:REAG-A]'$A
M9XIJOAEC!$@)#=4I\,J/KQ@NKJ@[N]OBX,3@5G7=,Z;#(9I*/< !PY[EADU(
MERD^ZFPM6 #?W;)YM?U%@</%G,DMJ_GVAVW=6&1-OF!ER=H!B;&EKY@NA.F^
M#-WWT"CG2!OS$KW]?]BT.@)S++<KAJWV(Z].R4#FR9_3VV3%K/?KRES>4\8H
M7-]>@CCZ17SL]; -W)++FN\5W+=>JM0--5^ZVM7^"4_UK<+2&4B'H62X)DOV
MQHNP?V18[FS]\9.#[:_'=(Z^::)7SSUWOHVWLRV!Z1C?<SO6X>T_^3D O^CH
MO)B;QSC QFC3'@=,$<;_MP18=].T9H&DKB .X.8=="[>/NCA?X/5_/C>F^9<
MSYR],_"][/%,AE(=144+F[2:F!G.ZG</0S2>&$A,"0Z/F.$+;ZA9,FBD%#QA
M&RGDL7U%=$OLHX8L$9*,W& '.KR?\14"0N3$)3B^*"LM'[:.G^@8(M5U.BV5
MII-E?2*<HZNCJRVSK#/93F 2^B/X4GC;4C+%4HRR]E^R1FC0RKT==,PJC_]F
M$?\:82$^SG:5M]/3K[KXH<H3D7UJB>FXXC2K V3EP-1DTTR(>6N!E_1"D1MH
M[61P62IG0_:C/OV)<W2V!56%NVF*A0EC<MGDDU)?KR\^&KP\G^LK8R96Z%9]
M7W)Q//]L\M;=EY+@9>2],RD=\?/7-E]^Y>@PN^UWI(CUM[Z. UQ&0] ">31)
MKVPYKLF86#-.MB\][;[FQ^3I&>KS95N8Z>W]K0]8:!&+^HEWA8ZTHUKM4,7&
M6CRXCE0W6$,P2+RDH$2.SJ2;F7@N8E_\J@S8EKFA7JV5[-DUX475_!!A %XS
M_E#.KZ\MJ\5=Q).="O;0>AT_7_4-W4&=967,#52/6,EKG>^EF%05?<\@F$*]
MQI'T$:7VIGO=!2\1\9?\H0]KZ;5BCOB^#'_;59XO8E%X\[IORYC*E#-&@:N[
M:.LO[UA.FB%*SJ@(#T%P>0GVT:'H&FJ!EW+](^Q5\79B8Y/=$ZT/_#+6$ZBF
M+!F4PZ?0D(*8A7&.-R?72*AS+JH7>/'&-.?UY-[ICQ+HOSJFORZHH1DOB"AO
M>U43I+!;)_?R'5O$I8?]!N#'4B26).FL9+85V);K"R+X5:F5LZYRA%,VY#N!
MTRGU9YO@JK]*+Z\II^)CX9&S1J4UD^0,MFHE;6EV37C/78VG:_.8B'ZM$U\%
M^I?RF0I=9.[F'/]KDRO&!3ZFEY6ZX/.S+46T'&Y^4,=<O.W/ BZBU?H)A%3%
M::F _+R"]?9W35Y]E]Y0_PN'BSLL3==J66(SW*#C[OIQD9\.L3TVT38G*'R!
M4)//ZX<L_ EZB-525^MK\OS5UB];?K,7$O=OB@10"&\,U?;_:^5:C(=\_S;"
MS\.J&2,B('&_8W]A0;"F2N&*%RE^2/SNLV$XXPMX0PF\IBHL0#['7_]&Q/M+
M#XD+9B[TYZ?^FHJE)ZXAN,C;N$QL;M68N@W\5F=B.A=/=QR\E6@#S;*8^(V0
M7/ +XBN-=8>8N88 )_(*D8#'7UZ;^\OWHMM9%<BK4XJVU_L)/3_1XYGO/'1.
MS6#W"WF_)FJAH9XS<74X-(:,ZUMK9HHD#H"_LJ'Y2RWY#SYME1]V+'\TO+>A
M"!*I4CQPI9%Z>%(Y\-@;+@!/@:>43>I,MA*0)LM>NZP6&]N\^+>]UB3"+V,M
MX;&>Q8ER>.8.#E 8/S/.;K;5C7\G9J/UA&=_9U9_C8:6-CB\ZMHD>U?U6@"[
MN$;.7WJ0MO^@[H_X6:M3L_&%4\V$9;=)PK-/?=/3=JEV+WG$I=+'#!I0J=&O
MK!V/9\4%NR+&-^+Q.07R?M7)QR&0OW"K^3LZ\!^HR!^C;U6-\S1.V$KVTTZ$
M>:M!C6;+12;KBOGZ[F?6$H;;Y?%F"$:_NKVS:-TS>?.#<39=&!;^5UG$'M9R
M><5,HJ!6I^*&EE3'!LXM3:8.52YZ9LDOI,9%;:70#RI6(!70*=C)UO':\!8.
M $? ?E%&T@S>?UAAX;]*J4^6_M=>P:O!U&5R P?X93C[%J &^J6)_NOQ.W_S
MY1V.IO07\)+1KZFM\F'@G*SX=,-15<)+UA3RA:H8!^@O@\R.7L!2BZM04MT?
MMJ1 >HGWY[0NY-Y74P&;(+M6S8M#L5?#7;!>L5@L[&)#)K%<'0X@V8T#0#0Q
M8-:\UY#5R=-/,,0V#M#7N)N27OO@Z*G [/$!Z/2D:1&(N<FPA3GE/#LS1&>L
M:T&/#[ KK+JM.(#H:9]SR/>F>6(D9'5<:NM\8@YGW7X/;MK] 3W<AW1$_L[V
MHY<M)69C2V2"*_W<UF/7QP&@;W" IH*+?:N_"B^9%7RQ9W;SU7Z]U"ZL_M^7
MV?PDGA/KU503^*?(_Z^+S(,1QP&B,#C _OKLR37-+.3U.1R 8EU'#L;3OG0_
MNN(R'@6EV(>#$P94P?KC?(>< +7$\CI)![X\^@61SYN%%R?#Y'?_V56HGR?#
MZJST%@58H=C^#96?!Z@W1+ISTC)?)XXD]>, 9OL9/_]SS7-7H_6"_DC*2)7N
M"J[' 0X@.N(__P-"1):8_DST9Z+_\XE6!2!,$!/+6&V(F5NCP2RT?S(Y5T(0
MJI.% Y"R8].DCOEP@#&DQ*]PTYY]['SM3PLSZ+\G?:\[8965X6U]]N'-8H%B
MP;F/=5Z"?S0.H K%?,(!?IC_(03V2R_%(CH@4G--7<A3/E),4^A_G",2966V
MBR7%^/V9X<\,__<SC& D%F91J*>*AB7'C+<>V^RZF!&0&>,C:G7^S4ED\;*&
M9T?>[A&;/[;YKCS,,(Q)++L Z\!__]^[A-;Y-VM@2MZL\*/P(K"0)%N,VUX!
M*;*T8CC&-$*\@_"8U>+RQ]+%5$!QJ.80S*;>8;Y(CLY%1QOHS,LQ1?CE>YHK
M)R<'RSN$\G)DB#A/L24MEFF8#>&(>F98H6QT>&M&WK29K L5=W^,P&\VZV;4
MF(7B'(A^3=0@P4[J@*:X7(X[.RZ39E>NKE5.E^,2'H%I"99YG=: =81!;#S4
M_&3Y;&BRCH6M3CO9#0)4)<8!+$!%3J*""0O,9FV5V%MHG@H&^_'?T&-K)=_N
MW.UO%8\0YL0'4-SGX6H9FCZZM/MT- -LD557G<@)O)QNS"?^_)YZ"^N],W(Q
M_[!^LN_#8"P#FB*%)4T@S/XH9*/?%=B')F*,8@JO"Z1?#4._\*0B3,KTE$]2
M&;028"8">0CUQJ>_8;6.>GBV)-U-1SJRV4<IW6NXW>>WZ,7>0FM9IML"PP$L
MNUV[;\J%H$@8/T2G^-2PA5VU&X)9(+SOHA^$[/4:&PZF#: <H^\%3-L,+2@L
M13LOE85=!J2*KOBP.#=M^ZWK!)07ND);=7IQ@*2\*=J1HGGH#P2:RUKU6P21
M="K>AL&GA4CB(W:MX8"F8JW0) \N[LP>N_L^EWQ;&;7,\@Y%"B>11Q%66^+B
M$[(1Z54L;^X5=3M&?P[>P7,%$+U5QXA[>6R L?2U$/PU;_KA@?Y+"A;6]NV^
M.$!&!N^.O8=_!Y'XP!B'^I'V/)<AY7<D0[*&X>L$33MA^#6^H)OT.['<"IQ$
M'">ES 4-&9^;T[/JXN,N-OG\AXBQ!B"T(I8*=*2$D< !2"(QOHW=3CB ! 1A
M$VE[TI2$G&AX75-WQGM@&Z0CF,<D4E956A.B+409E]SQPEA$9,*=8@2QX,'B
M-.\S?WTQG DC1(O5<I.""YX[+68[SDRVNY!0Y^GJP^*ONYTZA8DI2RPLVW&(
M<K-7]P+643:+[XGHN$L+'&XR"W>*OT"Z4V-#%[F\P$\J=[FW)K^.%D:/TIXE
M^9,]F1(5%&&O!+]'>-/W$@4YW8OT0=4#F?>'IV3=SHH/PHD=8LKN_&"ZYF:0
M,5,@IY+[75QZD5QG57_;!!E8,0[CM@V+L3K5:5D5BF_)<)*X0E8E_L:X2,N6
M3OO(OO5%?=G G6AHF[()]\,I6K<L([Y; <P@?#/\F8RD+R=]_EFNDLKL\O#:
MZL'5Z)S2JAKS 1(U/RNWCS$WJASZK9PUMAO+//OW)!NY]7_SWI=:G(V$PM:0
M$^%$>3:L]%.65!NUP"!//L$D)^L<B=GQ1-0;W:"'TL?#FS&NB\*%X7QM#-WH
MV4"K"M2UWP9-!A9-WEOB6]F51CXVVFD75F)1<= ]P?KG&1Q!5>NK*F=MA0)7
MRH"[-TQ-/?U;1-9F<QK4*@:=SCCUME/V1'6FVFFB:DU.SM*HBB)4$Y8P<];B
M/ R$66 0D\YW[VL#&8.>4K6+S^/G>:P8SM3D.JV7>CGS1/!GJ<=<;74;$-9W
M1..#G3(-GIQR!)A>8W]SB4&$=MEI-7<K6H]_AAH1.W\0EZUWI M"U'_B%!+U
M:F\.4:N5NS^H1#$J+'[84F08D$H_*BXI<(_7*B(V9^K&*6_LP:+3@3U?3=7>
M<9DP2_*0<PG7U!":-:QXS_;JY/=X!K*3HN7>#+VGI4I7:<AHR>2_%).(!>_1
MB11Z 3L$)ZK\G+[OSU+TDL\D#O)LQO'T/:;WD=-6ST^MP2_-:$,R].:TBY&&
M7_M">AJTIQTZT2,48P(2$=9D>S?>LAJ&__)!_:,%:[ T6C +8DS&4%D8C]9=
M&U2!+;5?7R6_^25>Y+5=)_Z:LI: D%,DP[K@R=0$,-"33[+&SHRA88/GZY,H
M&_J79*TK5@X^J*.754?Q94?/>-SU:1;83J ''CH)W_)=K/L$S[8.O%Q[-6IB
MVUA8T-[P!X'\I\S.7(LWD!I-MA$DA5G$M+R,^67O@)"-R/E>(0T$YKKEQ@V^
MZ0<AWN-O!X2I4-H[/_PCOV4D&W,,OJ$UW?&407A/2\9*^<(RD&2OP8JW:\,1
MYF72SA\\2^>VI?LY*"R_L5*EVY(*YCAD3,OF\:P--Y6-^G4A14Y#IBX]ZO/B
MTPE4;)"ZIJZQ QF0B[$.JPL\Z><7G#*3$%ND[MR0HMQG-I,9G8OO(^' SL:J
M^2+<0K)&9)^BN /O1:F(,ODDZA#F@-)<JY[7C<8^0U,&WAG8X@S/@A.N\;)_
MY!4"K T&./A-)J[.'Q5YGCB*MJ52UBE3]N_P/L BWLO-F'[+-^(KMHOM%&'.
MS_'!D"$D.?U>2A)6;"\Y=RTZ6 X9*+,_;)X,'"OP=:AFM=4Y=R_?&VJ?3\U"
M=WP.I(X^Q8SY]:H<,F(/G,]FW(>'YG-K(<'PC]ZWCQ)Y9$"N>[J*YBFKX/8W
M5>$:<M<(ME:,EBCD1+) P>XQTH1%7G,;DU+DWWJJGGM\'!^D>U>\'?E),WE5
M0L+2XV(A'\GR /GJE#@6B*P8J8S?-U-%% ??>J>Z,SXEJO&R'=I&;MQ:,'?:
M2]B!( SG*1:(:]0$!AE=BS9^^YK(FV]-SB<O0ZK-ZZFRL6K5((9+LL X1V5
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MK'(<JC@!7+5-Y-T$UTO4XZ?H$TV=**26BV^.6!NX\YXI]&VQ1J"UN4SK0W$
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M\L20UOI$C\G72EV2,Y"S5V\/HT@:>];.9"YV0JU8BC>JA01XG3(V&K1<<F=
M6).=[,PB9%Z,U,>%R@$ 'O?J'E%Z_L<U>ZVP0(<BPST585+X5CAAAA.^%M#9
M.G%LZL$S)XO;%TS6Z')\:8Q>TPI:PJD6:XWHZM]EQ56#.NJ,%OP8U@FE0<PY
M]_U1Y$AL^8:%7JM<XQ2:J?JKCW$5A(DHC5EI$$9UY1KY-IDDY7NB?5CSFDOV
MW#,IX9Z\5BB2N>M,31G92S_X'0,^34VU_!9,"E.U:U*7%@!K&5. <Z32W:2#
M9&4EY[M5YCXOR4<S%=M_29?&YJBH2PI[/[Z!.KI=&/9X+P@*Q)PQ@^*CU(:Q
MXO(=+>"1V"W?Q]4XI?Y[6Q/_H:C2KPWJ*GT?+ZQ81#,,TIQDD6@L*"MPUKMW
M</66VC,?\EK&"&K*!?&+ )UM]=83XM5CHF[(!8ICXLY.G#[=AUG?62AQI $(
M$@KU,G9UW@21AJ92C ;0T'V9>2Q@02S1NVO]<$5)9%7_0N863^3B[AM2S8P$
M5%P/,_:U&T!DZQ'5CN NNQ3^T4_H0 F[)AK$LI\@':?\GDN%2OD['EHQ2JGN
MO _WO5K7$:KT"&%_BU5$B6S>/$M4'XEE]88:)=KKB:U@;+MW UAFC*CM'MSP
MK:"&U30SF\4*XF-\@ZX^'/=BE.[F=ZN5AR3@E*EAX,1)+!&#4Z'6%YA@Y@TL
M\^4R->^09O\G]&(U1VA"4*/G:2!CX+2;,FU,$T[S*$M+^60E+XWC3,Z [V2
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M>2TU5?FXA%!VM<#UQ']_6DJ2J)<]'R O0H>A)[=@D#2N?F!OY3=5S>K H;X
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MZ"X^X@NB=%UFK;KV7U$]NFAN)ZV*F]/N+*KLW,A*?%^V7Q6MYHO=P*:RP'&
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M>WE6AG+E2^;+'BA4Z.FQ*KGZ/CT,1$U5HU#S<\6R!_U_4*-\KB#\(N[0%T@
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M,S+>=#Q!TN]PE.-P!'7J-!9%S8>MUH<]FVA!'&]2:_Q0HA_Q\#ZBVD#"REV
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MJ 'F4U)J,+TQ3^$EX&Y&W>U2"'>ZOA 5)<JJNCD@%MWFM&<(";B!"@<M=;.
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ME  "NH93F !P1WUQ+9Q>/VMBNZ_.$I8[WM(S%6Z(?ZN>)M0G1[C<\Z]OO7*
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MTCIJBE;_Z*4AT)QC"%0MDGV8Q )>#C3J,&%7G-VO$[-7'S3.LC8#F;\33*@
M_MQ/SMO/N;&JZ%%M5L*@-<CQ#:GD2;>%;)O28%=<LVQWUIK W\39??RE 6?!
M  ]A0/)E<93A_ 'R!].FL(TM?ZS-T9TF&U(FMCD ^1>@R-Z@I95@"F==8 L+
M$MCYUJZ0*\<GAHFE'^?I,L"1W-6[VK@;M+A#KM[L.<W)H%[;Z+6706.N\/ZH
M'R<NQ?F4),K)0:*[)\[LR0DA<XH^9TR*-M[M4L4^@&_[(87AJ>]JBT3%2$U8
M%/%Z0H-=4"E3]+"HH56QSNC-[**OU\B4")FO'X1[I'2CI$)JR@FX(P5N"-!P
MG*FXVWRT4*L#@M_&Q/OHC7A]-C=SD_6S1KH0<ZA-[G2WY+VV]@38=' DZ<@1
M3-TB''P5=V4'$^X%JA*] *=KZ%./\>9RN?KQC)@OC_-_BB]M6SQ_4(2Q0JPN
M=V4PHHW]A8+WILC,-(+S<HUT""]M ;N>F<:P?G#Z:NJ2:S5G5\9-,)*0.!DM
MXQAX+7F Q>OC/<ZX*8$M!I0?1O8RP(@4"[B.AJ %/IS)C,(4'_B_''O/M?CQ
MS:-=SEBYJ'"OS_Z1$H]6=>OIA6P*H%FH X7Q\H+Q/>>?35JT#M",=V?"P96S
MU%0 5EE;6C*>D5,[*R2_ 6GX4>\YCQE=^ '&6%?Q_=(KXL>]SRI>\C2F'"+&
M2XTI'WB*N8;.3B[*DL6').[&4RY$=CD77,1.[[2^/Q,WL;KST_A#>^L[ISHW
M0XLTC2&"P03%^6^BNM_*)6FG#5FB:=QW5.''T7'V/<^*'+M0,IHB&Z&'*GFH
M.*_G:*'SAUC ]Q:[.-LGD)JO'_?%6U._SO>X[0[-.1D'W0\ZU!-X.)$]>HC9
M^Q8[I?3>3U/=L(7O=/R(CEP)(5Z^(\'[]>2K2-2.X,;#SIUZVI=K]E=>W]0'
MAA1X>RVUL\<S4)7LDP0A#W3J=J5\:#$^G%'LMOPX&X!$-#1U8:-.%=)]?)P2
M$7%X@[.2[!NP]#9YI>^WL#8JRMZM\*D"DPU1VY+WM<C(3)"[;>[3T"6*&!DZ
M$LH[*A9Y(*1G]7?0<>U0;V6U[,VLQZTN5WU"G.\T_Y>:BGOKV:'1_S_T06_O
MLS>J"J?=5)V;_#3!77CC%P[T[G&.&TRNZ(0R595&E6O/2LA3P\J[334_(C_1
M#4;37 B37'@X+C^NTHB,F)LPR+0G!^6 \F9WY/>L.-7K_YW"O8(9O%]8TFZ>
M&HW(,*W=:S;\-OR-S86S.U>T<013!%.,YB9LC[,GSGS^-Z/_I8QHV8*]>(HW
MJ7<&)YMNCDK.YO82R.'^#.V_<KCXKGKX3',LH+7D4F#<ZI+O\NODPZHS@M25
MG9_G.U^^^H^#CHI-4)52F_>Q@#B&BP@P1=';R-RT3;'9>>_+I;B8""R \%T=
M%B#9AP5 ='_MSO^#9#460$1^F07YR8,%?!O]_03Q <Y^]5P4&@OXH>!..8\*
MM(8<;&>>'$%ZHC"R JT_C]7/3EN7@5*_,6?XK4S_[]6?[?.T+MY"8 %KWZ7V
M-K& J^?^G5@M9/$-9((;"W@H=48M]5M9(E(+"Y!B6,8">@-^F$$ZJ,JP@.$J
MR/SD7R$!OY-[CP5T=&$!A2:7+R#'_)#?RIZT!9<?I.!80 Q1;\^?3>?_D^)W
M+" @! MXV7J>A 5L6_YY=BRB?GX.B<("F.[_1X%:5Z,2DEWR0)KMKKXLH'X?
M2GK!PIU#@;#?13FE\-E::CJ!U.D8PFR>+]%X8@&@7<-%-#J>@@D1S3?JN*4P
MYFR>5E:C<A1[M_^9^+3_F3BVZ3S>+\7GLC<Y(M $YY_V\"%3'%C Q;WX&(:@
ML@\LUAZ3P\'F]?5CSF=3%=7CL:Z1XCWX/QE UY,JES, >QJF$@]##P:EE$UP
MP%-*8S4E5\*J< E(X3'C+V.L31&8H^;MBB;$NY/2CG$JG 5[:EB6O^/,V4H)
M&)L6H^?<15C0FXQ.7)-":FVI?R)]G=UDL'RI9!$.V3:/PP*4LZ$Y2_+IK!?'
MT2X<-FH'G82L9RZUJ4V-B@X5O85N_*:V9\TDCU8F2&6RF\;;7(W)HHQ!XG>@
MXH(Q7?V>.8IOQ5*9W_N^?1#MWR[,N$:KJX2FN51J#;[ZC Q"EWX@(!!G?-28
M.%O/Z^;DPXJ*4"DAC7IVZORME=D';3U@W,R.1CN:+-2[/(8H_J.+F=><1YZF
MBQ_&<1YH]*C="E:$.Y+PJ<*!..O.NO<7(B2M#^-Z#$H4'A:4/+O%0;.GHF)<
M1)9Y[AZ\"4=FHDHNE3*NU,!P'@N0%WCHLVT)%>R\5+Z$80&F82875)RNKU(J
M_L<+HKI$2\%L:*F()TV/IN*F00[?!2[VIWO-/'U;WRC4.]X7"X$;D-7335)T
M;F !Q,Y7A[6.T.7=%",N@;C[B'P0:^@F+RD>'^U3X?:=P7<@29:@3FJ[4&Z6
MVI1-D)>20#.L%&"7H4-((0\A/\1/+Z^@3Y2S/X5$N@1.],27891M.#2^^"DY
M8P:WG12<>WG-#NZ^IMF:3EE@1 =%1/G6)+=6VAIE&KZZ+X4,IEZ^>-#JZ.D#
M/'$7-[7($\ G:!PU=G-9ZH>0]BW-OC[$I<]Z:_>6=2FLH^?-5L?AXT9>>>F?
MQ9=QRXUGY633(&IX(%>-<VO(:D6&]<>XP5=4IINMF]-XM&2J7#H$UG+NZ2?=
MJFJ<HGO \?/[[IZ+WX2V)SY,!)M/Q]3+^4WS2IX4_$)!>>O,S3]MW=&BET+Q
M">I4QTC[+C#EVB#%CQ9V]'%6*5C**&&X(W$,[ K47XC2(7^HMP#% MCVW-TO
MN=4<#$YURO-!;A[.)X+$QV$F-UG'YY[DQMS<><C#\,R1+Z.Y:+]"@B1TX5QH
M>0=HU%@-.F=VL,N;2P/.3\_!G?%E&+\6#9CA%JV#^;?VZ#?WBN>GP4X=]PTF
M:]/9_7;7C>#70@#]C_'['$5OBZ%5XGUG-0PY][H"1#_X.F6OCV_&;KW1KJL[
M>,X5R[A"P^CK7T^>1IQ[(#<?>1132"RDC/IXFI!E<\MQTP'N2<V:*CR<0!?(
MXN5*N8.A+279#-V'X&.JB&G:D2V%"%TG5?<EFN"=]]>N9R@9!9(39-&NC>,W
M-!-T(]/GH"FZP4T"@@&>XC:<A4)*#K2+#O4$:N%\Z05U_,(U!$ Y]\'R;IID
M+RG/)9K,6X-VV<BN;PUG!CP)KQG#Y8M\'.).A@#MAV606^!&?00W8EH;E7MJ
M[B1O[K=)4[_':,\3/<Q Z+Y WS3ZM6UK_;?XW[NZH>"MR]M2& ,W""H=4G39
M7W?&?8H%-+>HSF]^V8B$E:&09PIA&FC:EKL)FY";TS+D<G9G?91JN/?O,)]C
MF.WP'#V<BU?&%CS**-9T6LG+ YL+]+;H[R6JU$Z\T[/)B[UDRW3RGD61IDL<
MC,%^H"=<YQBN!KLN9BO#V3-]MHB.]\EZ9E_;IWLN^B-)^.82.7"AV?7IZCVG
M#58V>9;&%(EZ$YQ9D2I'P(E CG<.T1EFI,G-%<*K8?/!,4#PFW'=(*6&!/?R
M*?6$]B26D0&EZQZWU:3ATC($_(X58E:/ \/<"N<VGLY8-9B.<S-(OOU<KW_>
MHL@@ZD,B3TH/^_"?AN#_XREKR^51I.<^!5A >0(6,*+3M-I,TR:U?RWSLN6J
M;Y,Q.*HR.8&M]R7 M>7NZGY+_F=2T?X#^?N'+/3&RFV;W!;3E2G=#/057+E8
MYG)>.[]L(H^+)96V9MKO[):\.^5"<V6K-A).$:E%_<<AI?3KP+Y;WW"2Z:KR
M@(!HST/H<6B8;]=Z@VXPK)P<B(GJ.JX E;PEAYOERSY-RI'$[6..O-'6AANU
M=2]^H<].DL'84K3)QEJ\SHVO:X.1DYPJ>2E&.8/PI_JZ=6-VY#N"V&]@V6XI
M5#$LG>UEC;Y 2;/6CIBF'OK10<Z;A37 [5)[>^^2,K1$72BG0)BJ4^=K;H3P
MB_L&+TX>LB0K]3JSK>C2AL>,3 'E)$W%C^$OT-PAYR;Y6QZ70399P(W*%R$W
M9\NZ3O#ED#+.;80$PEN9H\B@3DYR!514L$T3>ZZ[T&F _W3 F4I=DJ(P54PO
M[<E2\[50PX&;QW?$15U*-8FA,4P5P\\ @XY3*<180$B3>=R68(<$KO*#[9WT
M^)8IAZBC 1QA;=K'&8Z.WAR5V;&NN)&HEI!B,%"_930K: @U\'GF6W^S3+6K
M%#\>>>R7%45:1^*WEJVWG-.UV@WHHL)JH@1/U".?WSA.-.%VBG6/:!-91C13
MAWH-D(I,E)VK+\[3#A>"(1T0Y#'91NWQ57]%3EEV7DTC A^.!;]^N264 JU-
M(41S^XE7">AHCW^8M',[#CCC+W ;T,8G%3:;WC!.UH:^YX3N<K)E2.P;*+[U
MK;M3&5I%#C>)3W+:4D\B(9*++[5I4BC&0-1J1G?*D )QR@W:X<S=]0,#E;6]
M_5FJ9;&$VF;MT.I.T>:>YH*^H@8X7>Y8!2SL-5DV.])K2'%&48H+?RXH;2(Q
M@WJ,>R^WJ1[&R9_-P_701=^K=B9UY':9_R9I@7*==;Z!WJRQX?1SL]A]&18L
M0(S"XN9]>TU[$L 08$AD\.'XM=F[&HI_,P[S"P.%)7)D<MM+:3'+CJL 1#X]
M"+)?T=S$9]R9/7]":4Z?=F#D<I?-5)C&%3T5<@2\4P2R7HS@&G/)< E[23[L
MK)N-'X7S,K.)U"#/89'.Z]NFKHY])WV>W9+09*E9ADR5<YLA&5^=/><4WFU1
MW;Q1[0$"'#.;I6%R3('2!&SG)O'-3B5>Y6AOF*UYALXSGQ5\"FFV>:E\)K!3
M=S18X#!^E,DS@EE?Y8SYN.O:A?AQM"\6(-Z+Y[UY5/QH%7? I9P8[*\#0WOE
MJ/"HELB8FGZ<D?_@C#M@N,; OLQ&M6,DV)QC;$7/@9J<L=^MJ3E[^<5[4Y @
MS JEIJ:>;UV8G<B'VPFCV:.X<GEO"1"3C,&5FD<68 F$+IBCN_MS)-(F3QS-
MX?WM/7L&QW3T?%?.[\Y'M9N95?*EA.T,C*4,&.W+FY=(T2^HH\HF[E4R_0'/
M9J^F[0L.:,'#C#;W)RGJ4358 ,$<YC'\>55]#1#TN6ZRY5N.EX+K[2Y[KPX2
MONC/:<=ETPRDUB^M!74Y;*[]-*8"$D_AB;]9>"I&I5VE&ZFX/->(O&IH-W_K
M-6N+;AVAV@_$M:CFKOOLK(@<4$EB*+C]YR@C'2[.R(+'E&(T9JI#-+ $E(UQ
MG3(8+R]G::Q+FW^"_SUW)4'N=0).E?S<?$'.J&RJJ?MJU,*.KE(#RBV%N=Z3
MG=MBPB+"1R[V+=L* 5[$H*_O=-JKJ>,,#M1:Z)&JBO1HV5&)A&'7OOQ)F.WQ
M6/9VWY.G?3["M&L"<Z,J2:0,J8NKC248IOUQG9J:5$TC#R.5[6%V1=O1>D9>
MP1]XY)&.3_FTP/?;(LR6@@6T%E34B>$V-!&#)?WN_.&=N+8,;Z WAA8\S1#-
M5J%>NVWV2$'_TF_GG)>]@O=XK:154E7.E6[YYKU#3JN):$VED?$9#OM[493H
M8;Y.O:I%56'4ACA7]UDG!T>:KBMJ$PJ_O#$L(:9;/JK !_A].]_!K#FX7 'C
M[UYJV4)QB80UC"_6<5YD4=3V*#B"W\>=!%F5DP0M[7B<&2)V2\O.13Q=<FLS
MK?'<GEGPDBG&*MTVB_2G#4\Y+'[\Q0?5SX!GW>^V>&"'.E,=PT\OE!&8'#/)
M'9]YG,:CE1:PV46FM$PQCHF2\YP//7V;7IU5W:*W!Q-.A-HH[7]O3DXG:&F_
M,AOZU":!_$8TFA,"=)(=PG8"-\3[BWS?@6A$=M7PU>R?LA_XKK;P8]PXA\.Y
M85D+&'&-ZYCP*R\>1OT5^$[[IGNOCB9 \LO#FBOMPIW?F*,<M>&L\501(3<.
M>IF!0*S\T'M#0,#-$3L H)KV49<QSI3C<C.]ZD]S_[- ['\&:U@W!TQP*7TU
M6IWJAZQS&#O]ATDEC^_<9\A#\WZSXNQ0CNT7'?]$N/C?'5;>(T<C1SR6&K>E
MKZ:A_@JW-E0PU%:]C$H21HO:YIF^NBG$A@C/-!!9_$9@<]?F[DRF :^WY5J0
M*5V-1HV6H[=EWU%.!IV/ZZC\J.I5D0T1"7;%^=_5_C]9#??^2U1":I&)DIN8
M&DL<36T]K@]! 4P;"_A(KGAY-'QQSK#X?[#WUF%Q-5N^\"98" 02W"&!X!+<
M/5@(EN"-!H(&=VT" 0+!"9!@C;N[2[ 0 @1W=Z?1!IKN2]XS9^[[OG/FSMPY
MY]KWG3_V\U3M6K76JK5+?F5KZV^&\2E++W:Y.\KX.A/:5-V->XJZ9M@^(7$^
M470+*D6&KA&+JX;H;^WN\='GR!WL97_YY1P"*QOLM8E X!UE(1XHTUU/2EP<
M@8,<(+-Z93=HAQ*'U^ (FM^%+<[@>/!+>(C%W"^'$6@C$BW.2 ","5._'5(8
M8FYV(=<PB:_UJOLEVH@ =\C%35M/U._#94O@S:$U8M_!P]\)HSD*L*)9^.6X
M.A#.^AXQ,P[>8O2\Y3H+M_Q#Y J!B?!!2/U?)%IK,#Y[UG*BQ-[:C&E0_U!(
MJ)UFI+GLVN;VLZ2G;MX@ 7MHZ44'B3:)%]N(_A#;( <I1DS_ _XRRDD[H["O
M8R7]SR&L!PRID0EA3&4>_O_%WUK\SSPH%#G<:?/,\0/:*V1?/$M!NC:-YC%L
MSA01LN:6NI)3K3KH=92;]3THQ64//4Z4CLZNK!;?C+DJ*\;]X-<SJ$C35#U\
M^@WP5=;\PV+3IZ$[GD:SXD]/*F[R;LH1;GY((*[&)ZUY?W:T3E]C6F_)VL.F
MQ\LH=,';VZ6IJJT.&#+QQ0KVZ-AZGK:PE 0.]C'*\:C@;*M*DHWM62_)"S-&
M+4(-7R(X3J&D,=69N66&!+!??36RF#T_9-C=I_"[F#YW;)KUXTJ[+!61CH +
M9'>OVCPS#Z/8;;(UI.\[85?N7WF!6T(FA 1<:L0U?E*'( &LB? DW(+B08N
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M5[CEAY=&OVU^Q33IIPK(Q7/)/AJ&KUR#SOO:JS#O%2IYH\JF"?E@6I!2=H/
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M'*6<G9[Q UOV&>B3R#5.37RF=B&ZBG:ADC8<FV&/Y,Y:KV9U4I\SD67V.(H
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M,J%4'=[#4\>B.)-U/7<'1%5XD&Q3@ 1,K+QX&SERB'J^K#R+U:6>NW22&U5
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MZG_;9RZQS]4G$5HD[!;_)GLZ68E)-)]</CIW9=KB]0]/Q@*&=TYILE1S)$@
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MD8K,5IQW=$X5C2Q8/KLMR?G61+*6,^5QX-Z,NUR[A_.>#Y9K-VS/)[FU)[W
M#;DG9FV7 P]6FWM4CLX;CWE$IE8F5#]4EG1O^")A:& FW9Q>S>[,2,O"6,VC
M\XS2R11XDO7%3$Y1HP.C(>Q*LQEG8\T6!^Q]C:B9TG&>?[Q)<$EDJ/;V523I
MLP:HB62,97D]? !ZZ+>BLO.CQL,3?_IJ(TMV3E_6<K/+//-967@!)%8V;2%L
M(52O2L)0.)](%LL=)>]! RDG>MS[2'HH/[1.K7B)V7>3.9T_21.*,=O&FC.
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ME4CU+Q2LGRY,<BW_$46T_AFOP).1?P-02P,$%     @ E7!B4+2&Y]+7;0
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MGQS!?H#&350.4_PL)P[MIXKWQ]J$#*)7G?4\1.Y^J1S9AP@??#)^,.>P79?
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MDZ\L5_<Q5E7DSMBL49%Y$+G5-&]IZ*!AZ>EC&K7E*\=%'^QH4O)(,\0&C7!
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M.3B5P ;;"I>!Y3,QDB>7\"DH>N'Z1___&Z>L]FP?I@T';(5@A^!/X#?1(CA
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M_+ZDZ$'>($(T O4VA0H#I*B#3BZ&_L .?A5+'1A.,4 -!FCL1_-#S#=!AQC
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M(E1&*QL1(2I"L40P)%-?.4_CE+BK;95]-DK(Q:\LI<]"OUV0GG6L@=DBP2F
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M4.U<-4[3Q3A M8R;1KJ0+1DI6/?AYKM>[ZJ<VWS!1\%!'**_JL1>?_L<YX#
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M])O<=!LJ(L%O6V;-E0;MO#FQ-"%P&8S%^!"*8(,B!3V7+2[#7$#'EZWGN+#
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M.Q/L]6:F=*=EP2OM-T_Y(G_^='\GP@!+U7B3]N?^\U=-BEEU2XHG6@TA8?Q
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M1];ED>P?!.8HE@W0W0WE%F</GKZNFW6X4W:1XSDF=AS4G(T2$[^Q5C9VI.7
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M6FBZGY<J?G!!=4F>Q,"]G=*TG-NK%2G??$D="'>OKIN[Y9TL:""U\SVMV+]
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MB8>^I4?D+C5O0*\C=;\@ /]8'/ OTA[7"R  _\#H1;XAHAD!2)M9[DLXV2,
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MO:C9%JZ.J&.G^H0_+-NN+!DWX,,5=JE03C1MUY#; ]9J8]]C# -V]+M3P@@
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M>USELH@>#OY6E 4<3<*@+GUFVB(LKZM3,U@U4IKX0U],ZXVYIA7:H/RR;F5
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ME8,E0ZP@*(J3JS+PO5!(2@-8OS+ZH-V+LNY31PHC&3PCIY4P.S7'0N_M,/U
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M#<HGCXR 6?Z-+/-.TQ5]S(5M-^M/&9K;9%YIKJSCQ,=S08-I,7&/I*7UL;Z
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ME/B'W_WO#?'S&T[Q5/\V;Y#YM.C>T(\5\9"P+Q[A!.U:/RX/[R7K.WO_A!:
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M_172D2N4]AI')L'+E:-[UB:\O/VWJ90C<?=?C[34+G(=\-\I<)'NUBZ!G$4
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MHW;]I@RR1W;PIJ&ZHNHYJH(M4Y<? RIMI."D9\ZG!AZP7=RD%S7$VIIBZ4G
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MXGL?/ML"KG>PC=2AN"@%G4]=%+AYJ1BC5\+9T^?(@6(#&9[^1B[T.FP[O04
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M*()#L@PD1=J5+2H'V+CGLL>RS%ESZ5HM#UC&]UEE'%%8^)!(8$L+HZ7:I!_
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MU?(B@&P[V2GXM)9I;6+!G3XB8'_7BRVM:(KW$UTC?<"%[,DC__'6+.B$K K
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MJQDK0@.7B907.\*[,&^-NUG-G_VMT=$]]UH/A=-*/!-6B2&S=^@%KNU<9>(
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MRT.2.<HD[T#QQ?SOA-8K3LO-2EF<=!2Z7Z8@XR6'9*RS]Y,>"C_*AX.?%C?
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MX +#('B=&#,)_VIE3>V(\2EG:?;K W*G-FB2H*VH3*P*;MIW/JR9(BY6TF@
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M8_KEM<"<;MPG9R_H[8?RIEU\)<J"C*I&MV^'96K$+%=)7*5:4"?SVA#&'AC
M#2-/=B]<AUH,BD/R)C2[67%Y4U9(4T7?IYBUMJ4;F0QR]*[4WM-ON\W\K>8D
MK)U:>/Z*G)"]&(7)MP2OW&RS >JCJ7.M"7%+;JU7):RB\4J29K00$I/*N)TW
MYGD3\F[Q,];D7;PAX54*]JV R:#VU;V6/%=>+C(=4WF#N[/1-G?"^9->W'W5
M1I#XVK>24THWL]!LV[(\C'MW=1$ZIUB:L#J%$KT=[F@<<C%/I ;+?L<6E_,-
M H5:GYAMZD$I&O3UK\^X=J^0R.'2/EY.<LS[Y']340*XJ:@MVQ]^SW>1SHUK
M<A'5011K-_/1F6,J/9*$;HE6C)XG]N8VI9 9&TAUK,!"6'GA@I,YL#&G;/&=
MOC-GQREA[5*AMJ^F[6:"1[&.#/U%7KO)=AQ1Z7V2DHOY-?!]^L:-%_@.*K+@
MU\/')@0(RXO\[5L[?Z)G=9QA6%+R%"14;=-:[CLW_"$98SO^@$AJ18SFI@JA
ME/80KSW5*)\6[0V6Z7.5)HF:C1^AHR.1=\,,PT8'_54^+9-N$@*"P:QI5_Y^
MJ_750 ,?5],Q_24W9%VRSNOO+M1J;\%MCT4\LI?BTE\&LQ:FB QD!+,"_[NV
M/ 0C,N!H#H$(00//R)\5KD,.&(<A6YM<%]=4RR!!C*^-U>!V1\9E@Q+DIVO-
M_\\,]+>-5/X4-%:[M:AE1E.RX75SL+54=Y.'>D4K?U8^DHC:=Z>SF;^Q75?"
MC1T-V'B:14Q8BLZ=H(&2QI-&QNB3"';71)[DFNJ=_L<;ZIU0R6*X_*-*:PH7
M^_83FO&@\><RLBIJ,I\VWBFDGYG$MR0?QH &1D"-XJVZ[+ /:TI5%55E#4';
M5P1V%W^0M#6IZBT*8_D.&%<MC5IMYW,MD,QJ-MN3Z"_<"Q7T!]V:/P75L?/'
MCAWTLE/ ))BW&8R?7S?4![I)1^:QHC=D/CL)(]" <@VLH3G?7/;\84"+ZFVE
M0WF<M1Y)(GY$GM^9O,<27[$E#-QX:)*I&*U=6MED%075N-+WP5&/:X^,F Y;
MA]OT1'&NTRLV=LOUSK79^><XH9D9L6TO3KZ5P.W%4Q5I0JLYD^_NZS>M["AT
M7%MW-GB2Y2#$TX<TR"$F-?$BJA\UJMJ?%M",M'\P$YCE+9S+7_E9[/J+=BN!
MMP7K_%Z4Q>,<++Z+X5FYKQ@MG)P%D<I2/ ^A-]-6JH2)M=4\<S9HK(JO-^=N
MC,4-,EF]KO(S5!'AQL;N50AHK*>L2'DROS\;<7.PR"%*B"HF)N"6#Z7/_;FG
M6LH^>(M[I/ &K?%:$0;ONSZ[0V]18X?2]ZDO%A2IVL;LW%*<(EY6S4\BY0T6
MS#&MRA0]%XI,A,PH3'1LB-;)&V5XJ[!'<J@+/$-=*%%:4C:<KSK6-D:KY="I
MGA9ZAU-.#EB*DDZWR"<[D1DM][-:?DK;QX0U*27!,>*](='^-L7OHNHB%KQP
M!]6'&IB>1/7/K5CNG)[UY[]!/L3, 1!,#]4 1H6[;6W2:LF8TSI6EE4&SU[M
MFU@4"^:VLP'12_,6@#@6P6>LHH1HP.L0#3P?90P2A)SDK_FQ>TTZ&Z^9U7@-
M&G/%/?!:%8^QH*/962ZK2%BD#;)<=)WOCV:ZQ<$@230\8FAC^WPL=IQ;G/D$
M]G(?'(\OB/NHXMKTEZ/'S(9N@S;%R^,IY/+X+L-2U3#<PN_F;@2EWZ:D<V;+
M0HP<D;A/![W7B:E$S,L"4#>L=_#W=O3@4FB@V$EFQ3.N[USRR63R')?<#R3;
ME]J2LA%+AC'$&&V>Z:-ZZB6B,-_(CR["[\UT@E;.W-7>/:JD,Q@*\8L [X-"
MD#Q&^YB(K*B&443CP#0R.F]6%N?=;G^&;T@S8JG<0CFNN;2!P,PCIMDR*VV<
M%E^B70Z49-N><K\7A>SN@]PPA>4#8Y/>$9M)*IP+$]I!W_,* ZJMLOC+^7:R
M/E955TE;% R1F^;[2- 4X-$GXTUUW#H<"7;#5Y;K;D580+75U$+'HFFO%:YX
M9]JIT$'PI@X/VRA9F&T[\I=MF<TVJ7"!L*[7J%L'HOX_=L2;H2<5[+N%<[+^
MYW)!1F4DI<)VVLMDAM/O U$*_*&1/U*^?7$BI29@?:>B\3)L,ZSJZ2[6+4/W
M>24#\?6,8/'KK!GO?VTD1WP+>0O)]%[79?(]_9F^X?5TNW01Y*BN 6R.^-ZA
M1&S3FZDGJLD720Y[V^=Z12D5LR_//.U/;<-K+TRSW_#9]_/%PL"!HG?*4-0T
MXBP!"R0WOKDF"I_%L2MWK]WF#W>S$BTW7]@RJR:JS'/1TZ60MF>CEQO1H#CP
MJ*(ERJWYB&T?<1+F7%'!'ZOK/,FA7WFXS-V](GFCQWXTD5X=D6*JVS4D,[&G
M.T91'?122D@2/R,E34"!.$OH")^N!M+Y)@+U4Q8-9+9:P#-1$AS&J-IWF.&5
MT,0S:FHGU>)<6,^,]$S7J;'AG7VEL[9QDO)*\),%EW=AAD$C>9FA_J <IA]9
M-@\]A-  \Z$,&BC2UD.PJGW>$ 5&"[VH-A)B0Q8+23FF-)GG)M$ E/VCX-+G
MCP"_H0U/Y);N.!U)LU4%3)Q&+)#40 5+1>PGX- FI*2EI36I)65ICJ/PE&PG
MG/7C@[0CP.8J99'Z&A*;,XS+YP@-;%,1UD7E*F-'Z=[G.<Q;2VXL39@_FH.+
M84:JN[!XF.*PZ!@?-7^86,2Q%N6%NO5BGWWEZL:.;JGY&V/#8;ZL+Q2KK@2E
M5)EXJT\V>\._(!+6> MQI^Z.%=\K-<J>XQC+.1W+>/&A7H$U6/0 F1\C(E+U
M]?-WU]&T8AK&]P%!W@PTAP7(A@HTD+?IU;VZ%FK1Q]->2)ZQAE'_(:Z%J0EW
M^!R,(IUL*,--K=R>M4:6M,W%>0D<[:2Z'8?4"&F=JY775O@OSK0QW/\H^/ 4
MY*L 74<8A85,3&Y4.)U$76&XIO\ZK'3\ 2Z1R2H^@Z6SF_#==!?E-EJ99PG/
M)G1R&%TU;\&\E#CGX/3//>Y;KB%%ALKS#*M-:38W#YY(JDI#P8\JB99L-W9T
M(('" KGF M56\3=,!UQT;]#%42SRWQ"2G(KE:^]B6O"$\PU+FUKRM0B03;4<
M-J;>DQ33% ZES\[IF%_$A#(MC"CY(M( QM#^S)O#\F3RQ4!3HL'S-^?#Y9+/
M=G"2G'H5!E4P_KZW/Z4QXR'B(U$CEOF4Y^*K>H?0X$^03U6GAYU@\"EO:47X
MHGG@3KI&-B![)XWP'B[NTLB\0^_KX@%>2^Y5F43">TU#KJ+(BI-.6H$1[VBI
MAW8I%O5,0[QA3(NXB1!/ LH=3X=!: TQOR*S>5'&L<6YPUXK^/G@T8Y!JQ>U
M[,L^VA_I^]^5F)73'&:JQ"RS?<18&#6/XLMT'JP>%QH/LZ]4F_1(.GMK=)'Z
MU 3V76,)CJ47;)LU6?7OFWUB\.$I[9>7U]L$;]VRJ9]A_:%^4"> (H'LR)-#
MFHPO8BX*+S*YXB^R2B&1$3.N6E5M/0;6X"R#B.VQ_;GF.?@+C8;BL)4!<;L6
M2.8",GGMO,;)6-ARJ]6=X\0W<S..=-J,1C9L&@;)BUJ<9#9$D.&1)Q? O734
M]/8O%B^2H!L'<N.D,JG)NO?$@$90=,?CQ>2F]BNG7G1%,-$Z]P4M<_<P3F+B
M+L0G38,/WLN@4WU>#[:8N:X#7'G-Y?QH^8HQ86J.BMP%19Y-_GF-]8KFGN<B
M'IU!G&[OQ>VD3PK3+'A[P3+EYYS)!I;&5M(&Y+5L-(;'CQ6NO@YH0C%6,#>F
MFT9:.7[<+@NSV[2C]1YA>)KY^8D\\PB'@[DU(5*RK-*_:TY!1PKKSG/IV"MO
MVAYUR$Z>]#K&,= ."8O 0(V]7R;$38;:'0EZR8!WBB2WJC;;1?KYH+WIII0"
M-Z;EL]2[19IP$J0Y!A,D<$BH(J.PL'W7'XS$Q@[+$[;$[M?N&W=&?J2(8 *9
M;G(_?IS50R'\;6Q6'B[-CF(D-S!_\TWTJ\O2M@%92_U2KTW#_O7CZI5:OK3-
M$T1;>H%+L#MUN<PG+9?6J*)P5I(H8*9/FCDUK>!KM,%3B9M*U#)J(_.##N:]
M<LN+M.J:QNU*-XVQI\<C)!; @=  7Z- +O_QG4.(63QU-J7YHSMB=K@#2UA2
M%@1JI;,:FF;\A>:>YH2CM9_G"& !DHT='<(,8GS@I]ZR0GAY*>*+]#)*L$\,
M^#4#5IDE(X6W:Q6VB7>_D"R,3RR3ILR8QL5IBHPWZQ%)CCUKEJP<?5LY9BEJ
M\>QUD>.G8Z8>J+2('5[AZP"IH9TO8?/#%HLNR<MA45>50M& IS_H:DW*Q49W
MUD8'9].$9D[MDZJ6!\*'H4;PLQ_'V;;J"Z<NBKQHX :7MVC[10'4U)A&H<<5
MJ[;6XF(6&?WS+*_[.Z9BOC&%O*V%.UL*2N/YF"O;7F0P3S_Z^$V[6)CD*=U1
MJ^>-[ U-IT@L7]FB\A*_1-MP*'F8]'&3=Z\XA7>F>"Y_%D7D&_IS,LT-CH\O
M[<<Y0E%E][&EHEPJ='@48!7UE6H,5$,I8X\S8Y?4/\QHRYS73?H+"#V;7[K.
M+<^24S"U0)=BW'1Q\RQQ/XH5+$WEQ?AR8_=(A$FA-OC@]&5Q575(X&K"#/UP
M X&DA'IY:7F1;T=IA?\L?6OM#X-K52S,\\[,J_Y'17?S.S$E-<KG_XBA@R!&
MAA5[+/T@=?@X=^:$8(F/,175OZ71*8F(8S WX>F"R(]%W+\ :T)^79;ZM7LY
M\." >@6<O27U"96:#^Y' \;'F7_L,P;P.XQ_76101GB5H0'P1>I8Q*]=B!C7
M[91?UUSE-Q##2#1P M$4_F// =3Z_[HX^$N@/*;SG+PP^=N^[,J_M?Q;R__9
M6LK7W.)\R_.2E79=\@?:F7<W/4:IKP;1;PW^3?$RE^@MSRC$XM0Y#R2:3:IF
MAZJ/B">L?&V5I*F+;:HSZ\*5IP9;^)7A1:@R9#SAR1[\&=_<V8G\.:)A20IY
MFV8/><YR<:$'RR^$:S >XZ&!SE146\2EX]H&@Q@TT-\.1P,'+)D[]ES+>@%G
MGQOV/Y@W'&ZGGAY#,'?_*5)+;[\$O'D##42#+\(8+QTSM+.A@=0(&!I8%H>N
MZG4T$!\^@BQ<&X>L38+W-M$ YN8_)58T+!A"1EC0P#W(.0WXTK%(N!K&0XQ+
M:* CH+RG(=*+<?4M&F@B+<!86 *9&_WC%2>7A%I"FCK00(X\ZA7&5[Q_.7&G
M*T1Y@=O10"2Q>3SD#A+<TXKIEYET,%8:8B;EO%]OJ;@L%XH&_"+1@$(J,O[7
M&Q+^>G;R1 ^)A$2@@3L,X]PH"3@D'I./KTG6H '13C0 4?OCO2R79/.5HP%\
M)E0Z^(P'#4P,_N5DVZ[A#.-L1M1SD0(C9 AF=N6A1)&$.:,\HU&HPC_>K7%)
ML+DYBD+JXAGDP!@S*&=>/IY8@1S"4&!DH+MV]QGE NH=UZ7ESKPD<6P<R1Z!
M^(!9&0PA#:3^<E+<A0;6EI"0,Y*3JK@#KF9DC]Y_E4 1?_+G]K_I\V_Z_&/Z
M%,H75YV_2[5T+#5.)NNL?-(F]KA_27D\K42;-V88,MZQX%I_6XBWH3!^!?Q/
MN*.;+P'>?B7@?%IX0'G2QE2"JC?^]+O%=2N_"7G[IJ:A#O(18O%6B&MKU57^
MGT <SU.4.KE'6W,^?@;Z'R6Z,@L.UJP8W2ZX6_F43CFSZO#U/"[.::%,1I*=
MMK#AE\3A7LC'K,3Q*-.L"X\F3#>K?=#TCY[$8[9+_UHM,&_3'%[7I:BMJ:0M
MI'].$?@H+KEO!!N\0^+U?HP''O:FN$["A@&HC&NJSC_UY7QG^MPFZR(IW$Z'
M[FK<P2=,P&,7.)VVD\*56Q@>5E8^CU:N&DD_0 [,RE9_SM#C?X>](O8"D7)?
M/2^E6<)&8(SE)P/>Z/%GXW/G0$[R5X@/6X>R/$422R7WW_C1 ?>#]@/$$D:-
M&Q(5JL:=C,H-W%D_2U^L-%M2B>#>U[@ZN<ZK%HU\7E%:NK_V@:/6W*4RMECO
M0\,/%<=#(/@5'4MOTM+C/14/#N+&(*2\?@J##K0HVK.H=_[L$T5__\$1*%_(
MA&W3G9Q\C4&DO!;VKHHQX*@SX0EOC=K(S$@XIZ#6?:2SP,#U;8]'^>V+7(03
M9H-A#2:!E/*[CQ?&]_6E%EY"B5;+R7V7.$R/N/!U=:;"QL,S\)]3=?>MF6&E
MG@2"Q<Q3]J_6UI./6M=2V_.\9/+CVEZVCUJ?9V_XE)8*IZ<8X,J=&]3EXPS
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M"L,P_+K0[+<EI"6AL.;7H1U$DB5W2&!5\S;TI.<FP;&AU]YAE291^;!QY6_
MGZ]2SAC59?'3<HP25KSND4L.IB8,]*$1;ZV*@C)TURF9DJ/-&K9/2G &JV\E
MT/0#EI.5:!2,FH[2L8??";M#;Z7K:V_&JI:/2.88>M=:?'I<D1*1_!# ZL W
MEWCR),O2$&/$J<=&BA8-4!_E+)X7'#&<FW$?"0P$LI:0 TR3DSQ6:Z#7XCV>
M">YLJ8/'QN4@= D)9C)^3#91V[=/G71F F!-_MPM-%+*@V*8V>L>W\881YUM
M="\9>-KL\PR^PDC$G[T%# S_2RDLM;@,B5?!E$WAZD?""._L%&(<,PE3V%HU
MR^2E=5G*/=K0%8IG*C\ISK)R@*;9/.E\K<$ MC/(=J40<VHBS?QE$$K_ 'Q[
M>*ET_*K)_<PBW8W#6C&80?D%4X%?N!X+UE/A=9R"@4!=)QXCR_!X[$!HOJ<C
M"66<OVE;+_"H-4MB%2 \4$ESR8<]?&5VSN;. S0 "T& VX"_-0[+]+M,"B]T
MB&HAG3ZK50ZNBOGIY#!?(>K-YBB'L,S:B%])+CNOKX;DZ-Z_+7Z\EOB2-X;%
MH<$URJUIP&.'^]K':=OL$1+[$C&7$?.F<)_H3"O=KZ,W/[5Q*W?9]DY5=B]1
M/>6([(!/6&98?E^'"<1^M4/EC9/X*>6HA%XJZ=;^THX,D/:K/CS&8TG_)2/@
M[[T2,I#V$6):[,S_].+B3@;CN(?-RK\L(/_^JAL+A_E[4=PO*H_WW182&"-'
MXLI6458B%84^D5_2JL8X>W?NT*8^ 9AO: (7<$<:%O#M<,\FC%Y;KUZYQI'Y
MZX2MR(534<2_V*S-U/'4!W_8;F6<=EN!=;/G3K\?_%XW^;./ $D:Q^C./%VN
MEAV@S-B#T>PQYT+=U6FZ4L%<CS=W35]])@<0/UD3&)\_OZK94C]U;I&\ND[)
MO);Z]90J8_Q75T/) C2@TU$9#2C^"CQB,&SXL&$H6_#\\?A>9UBG$"_D-FJ_
MF$I8:;)C]/A';/7*NKF*JOL]R  S&E"O0/MB[K +#=B+-@*^\:Q\X:2>_)<,
M4*00\@!RL3STANR?V?_=;-"/=<@!8 2R-<YU>5/C/#7M!C_-$R)?#N-.-.!=
M<(.1]Z\@W*KQWPW"@- F:=DVH3ZE/9_/DU=CZU'2Q*R1$OM@B]+5[-.&EV*C
MJ-,-C9S<D]"B%SJ':A=SF;16$,^CO%&5'7*'AP/Q*;.7++^R-=,B+%HB[WM=
MTX.NLUG+23REJ0-_*R8=QKTLE2( K#M7^95=*$4[%/"0_2SW<F\XXCI;PXKE
M)%28R/R7..[7V?DJH++7G2$2UUS3K[-C=(/%TPG^*<S_9<)H'[I5/J],EC&K
MGV*T5@GXO':3FG;L;Q;-D"TT:O@D\[%U:,!"_S;!G>2'"@IUA-=!<* %#3A$
M ZZH3=& 18N_R0%W611S73@2(4N0D-ZCAI(<5TC &6TY&G [)0 -6+NFH[]Z
M!EN'_B9G(FH(=++*<&:"0 .^0$R4=]$ P@-Q,.H>D! -&$ #4)+1:$!0^I_P
M8J:TB)U>T$''/AK C6I/G4'1+7M,(!_YT*$!*6@ \L-58WH/]"?<4$Z*;NI+
MQ$K$$NKU9=CS6B2P\[@8(8\$H@%7?V=82JA'$;^CT-A@8"4/70]=![+E@C+
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M>_#T"R%29"BPC'NNWWY4R^1W;G_2[LUB0V3 B3_56;](\#;D-V:_J;8]K77
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M>J5-Z$Y/J*.W#U.(V1%E!XMLE-G&C>,=!+F[?*0>]U=(IW&],?14'RU4/@+
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M]'QP_*ZR&SC<ET/5J>8>K_MEEVB'F%4-XL,%C8VU%T< 'XF_<NXD:+YKJ+7
M$R+@7BH=#47?3ZG9F"<> ?YD1=1_+TCM]WI\K\=_4#WFY4+&!<[77>',"'7F
M_133+')'&_;>T8E]O8,QJ?Y'C'R,E@<@(J*W;[.WVQC\U&=YQ-4QB/.NF>[_
M2O+R"4/J2<>MD3J\.MOMS!2."'W(@7BF+9,PX_D.\K5$)<"_=C/7GL+;9/,1
M6^9HLP]I2)6L)!^B<6X9"YBG=XM7&I(978"QITRY=@=/1<0-8'#;,(O/T.H$
M5&DQLXUVKW1"A\.6\NU"3=$YF]PD'I[)@"631WAO+JZ9/:-0>8,;4^J?,$%M
MA0Z*T,3!1[+*%SM04CST$C.041U^)[K^HF6\1VOG.>IZIT&5T)/0E=C6%<-V
MSI^PTT&U37C ]!:VUJT*6QFG4^XK.F4:_"H;66/6+VW>+(_P-;3\XB>B'/Z,
M?W7Y=5F';H,)Y5(I=A2Y 7T%HW24OJMW%%/H+]ES''EK,Q/\W,[TJ>MG6]*[
M[*_2-D/S>+VYNFC$,$N<0&DX2%.@JM*:4%G0>ZNJ.Y\;+@2?Z E817 0&Q/=
MAZNS<[6GF#V-NS05$B1SK'@"&W0GKG'3\?!!T/Y5<'-/M8O_\P$W%)BTE*BI
MHQX)2DW)A7L&W"V/6@[-$V/D!>9>.#,D_ L#W-(@M4_;:\W_0*^$QC^ +Q9P
M,M#7Z<:/26V!?UM-$/Y@J+L_?5U4-,^I+P=[H-7C$6G(1]\CGR*_ZK8-EN>[
MP>2IQ//%,2X._<Q%.PDFX,$UHS"NZ@OYF>+ZI)]VL:"DD' XUE#)^&-T4U+O
M;2&-)5FP\/%L\\#'F5-CLAR&JV;C#I-S)ZR&+X+%GBNDN@S6JZZS /CME98:
M'68>NC^_#Q%PF4JYNN?,\B0A;K%'QY.KK?\;E$ELWZ85&/+,/,+G+8K+C<9/
M^;A$X^]QDO<8<)2@#9G?<\":GW?M5O\".NCR.U6V%#,>?JU\40["]?[ L-M]
MY<[BZ )FK!WW)EBRZM;PEQ9'.IEQIMW.U@G @!UG#N@*\&=>1>.O]>_HHQWR
M5]7#)ED;QNB_WL"GX, (CD\PRP:[:LE;N9"=W+-T2IT\2J(+%O:0'A11QF1[
MO\,]P)T>H]XTO294V02C'2IT/99,S\!6;E5?<WC2I0J'K@];ZA5 Q]70@])@
M)3[N_,X\I4FA3 3"^IS[V 430H]AVH<):PN@4_^VPKC;IVL2SP#D=/XX=#H/
MMDT:_2F,:#W5^0I0A+E<+!G.\Q682(%R.#]MCP#B78*G;9FFBHY?=8+PO?-9
M<LV;*Q:FU6RAMJ7=*TPK[((1HWXWHBQ/Q/9,M%T'TLZY2\HP0Y'^XU/ZC*^#
M2MI<V"GE8N=:>L]I_@@P*L@E4:YVK^GUMY?$XRR>0'T+WCP8>\"9_!OYT]6Y
M^$Y+DA_R))O%L$DY5$@_!<FJV^<1#C.>@%V]&<UH-&&EG\_>);R8'<MZJGC3
M6G!!Y8LG[:GB,*PAT,JW'9_I]##^8JWJ]D8\J;3T_0D.-HSD'A6J\AB7 QTJ
M2<0-2A%'[-U\;1\%3Y.$16WGA&WM.=M-IISBLJS'1G2R$!#RD#)Z=;VQN>4G
M HNYZK1O5TOC[W\]'!<7KDTQ(7K,HBR6)QK,AX[(L!7ZFOEW,^0=X5&)R:=8
M[CM?V$;"UCN9D HD,[)5"AZ&W&A(V.$8SEUMNM]V>;!#]^&.SCN-2+G H24Y
M2"I<@^V"$?EY@ =.ZX4OZCTPA^U3*<N %-^Y,\8ZTM?N*,WEXZ3TI^2#4Z2J
M/LSOS:R^DZJP;'EH;S?;[A39T\93E_84 ZR;7W; 2]ZG?+5"WIHP)H\ $S%!
MP_#MUF=!/LE#^3X-BPQ^AFJO;$S%J"C\2-U B15H8,*<P=P7:XJ H(PDN!E>
M9G-:E%EN,DA^!6E.25#H@T B7IZYEO-L$];<SG.%A'V-!%,Q)L4X/\5LG^T/
MBAR#5)1Q=S9Y[HNOOF55ZAXWGV%9;^SNX\@D>J).BW]<V9[)S(7KRT7_JC?P
M3XJ9_VB0]CA0VDNM-J&T?LO4YH1T"L[_64'&D\_$BLH?]GK>._R]%N3AJ2@R
M:3[JU<<#L'?^\3)9Z]\]S^L?KU-73M2U^$@(_=?EE;*.N)DD+5PML!IZ?M#?
M&C@X?UI'HI]PY7=-R),-ZN5GPS7;>8$'#[RF& 4NS9GUR%].MQ@$?D:$V$:<
MP^<TDN]/1LR%X;9Q%DT5U0D:^1[,0MH]JPGK<'FE0!.CB_:/@%Y*/--Q"U9!
MV@9?"^K@-#[>.NJ(89_48_2 <2\X=(AAVNONU&TQMV!^ME$SF0"<#_R7:ME4
MQ.4)2]93(RUN?$#%:JCC:+:PSU>5 #^+-^YYIMCPH"A90J^'D< B1B##BJO/
M/3W;NL'+X\7[.E'S.OLK;!W6+B31TB?%7E/,6O45^ *XRZ3^ZR- R<]6XW.Z
MA<P"W6Q^TBRNW.YB<^I)>5K'<.C3(P9]!]?)3@ANJ6G?!U)VZRLKM=&-ZS?.
M?403%$EH=>C2IH&LP 6M@AZI7J!9OI@>?7[CRVR<];]SM%J> OD(4'_(]X"\
M^O$\X>V71(A*)''_=D*M]*ED\W3)& )WK4#(%M>"G$E9KI==8U3>DPD6#Q3]
MZ /="C2&@JND:$]KOV O<[]>HO Q^IK.XR7S/<%(CQQJE)X)_9?'^^+=1C<0
MB2$E79QSHE=].I"?&S47)8?GL]ND39J+7\",X>.@KM.A.:!2"'9O&+G2VB![
M/=#13,#<42SJIJ]DP;=<O AE+0R?61(ODJIZG1/'PWAI</!<=O79.0')7&Q\
MDTTKZ'K&$X7ZSX]@*HLBB$OOYH+]$UN8"4ZKZI:4B*T/&$=\SF% YGSW/.8-
MA-<Z]![8]H7;3 N?@>AN2/T'OSM&FC%65=KJOQ1,O13OD2BE2*=+)[^EMO[<
MEY6<JKP)OIT ^?GE<BR'7SE-?*7#S8J 9;[M8$8'N>PAXI3VY$J$5Q)?A<M
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M%PS0ELT1=<',N!_DEGL..C?\><YG8#]S@5V$V?5?>HQQ*+>EL8\Z*3(J8>G
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MP&Y?/]8]8\6:?HG#J*>&(A/>BPT/3W3VN4)V^%!>V]\,9E[;J_??CNMA<J+
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MQME452ZZATK0XXI_X[[6\^.X$Y]R?5HBF;.D0,=R$+2F][PDW 7W ((3)\D
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MP#,%S5$GCN=7ZZ+ZWB<$[QJ(WX;E+1X:""[VW43?(*.<TBJE"H!\E@"O)QU
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MLS&"TYDD-_Z:DDGP8:R[\0B0=$P?5F8V5'9[)I)[4PNR_]Y- 1WH?1,#7$5
M$'SMEKJ&EC\Y,BIJ*^P%& 7FA;ZJ-=Z)^@R(%3''=-VM?[W5M50SZ,PA72&Z
MK>]!:$=L[>RABIR'N8MJL-AXPR89ZM.5+<,4BZMB\8-^3 M6A?4$QM[#$T*=
MW@(%+KX56GS%LR$B=A:[I;HIP&/XY:I=VAQQ?N0G+_/C#%)[A2:$^M&^)0:P
M&H%S,@W#.3D5^^)^]CU*;B-+> 6Z*DZF,S0DIGYU/MW"^<%=_X.78#;H2L]*
MC::322?I7//-% ;4_<S1"\J<[5KD%]<"+>UY73UM:=M;G_RR@[]%EZC*]D9O
M^Y.Z(2F58*VUE459TQ:U#7VYDW#7UVLXG]^P'[0^I[A63U=,C1ON/2P-$IEA
M[W8F8K.#]WXR4]DP$'@BM>%2C.MS-_?[M.L,I&P1/:SKW$" VSH7)ELW]@ZG
MJV1S)*W"S.\JQ4O)?[W=U\,+G/6?+K-^6!PZ3M])+BK6KYKV^5%V49?Y VXG
M#$NW.A()A'*D[8I65844OE:-^:ER2UJH&S\/'\0\J8+/D8D"JU:.9XV+/5W6
M/JZK<YL65;%5G1=R]5Z;K.F]SIW^Q/I#Q1#<U@=_?DL@P8J+4ZS%W?$&F7C&
MN0R+_MS;ZPPB#@8#*C,ZNMHS'!70>A7)FO:73.K4PF*DPBR#O#^<>1<=7)<@
MJ*>D"?Q1\-MBZ3MSC>9Q&(##:ZX>9N98ESY>LW=#9[,RJ2F8\T[3?F0N<95J
MC[,Y]([_V7TT2PCJ';A6JNN%64-EUY.AH]X0SD=\R;3RJ]CN@X5JDQ;L(T?-
MEZB#%^'I537A(1W8L6QB<S##W%V]&<0LI@H:L%T?*O1A0MEKU(] H:;U@UZ3
M-U9?=9N1,700SY;[O</9#CWTUM#G@1!R?KNZ%_3H7L+2F]#.Z9L2&82)0K&N
M]Z6->UC].O%Q-8<%=6P#C\8/]:=T]11LSA?=7VM:)(_),SY8?"?^,,O-1-*]
M\+XMV0M+.ZF;->7AY37;U;"U"PO0@+U1606B***Q[6J!SDK2BW>;Y\Q2O-TF
MB9ZRLW&=<MN=UH%E,NC6872'Z_[!M%/L3=SQ'-CY,_EJDSNO:EZ[,?D+;X:>
M49?WB>\M-5K3FM4'"DB_-59CL=Z AOOU+'J,<F_0\(G$67%;4I$O<-\KU)C"
MS96 AJ/+<3X@V/LQ0*#G=YM# 7@4G$'#U5UTHJ]3^#RY#)Z4^P7<5LT_X[(_
M.9*L)F!'[M0O'VR4SFO>FQ*X>CKP?%<.UR@\X)73Y:WGPSH:(TZ]H@(?UY[:
M7NEJVBXG'B$_3,CG_ Q^G_C*_Z2-ZD;OV](.$UO"=!7<WA1YT;B[Q2MQS3"0
M/_L85$PP<[OIAI>F0'[.C"'?6QU9QFEFTNM\IK$X&VYTQ\MU>/N=OH=Z+Z89
M/@W/^K,Z6E);.DXX=/6AQC8*X$9IVDN50<(YUUABF'%2V%I7(JOI>8>C!VZ/
M:+[0)VKF1@5FBA#;NT4@L\ZC^+6"ZW]>-(!,Q#0&@@<^=+5!*&077:K(3_/L
M%3\Y OT#O+0^>NXF:P=G9!Y'0<-\72-*2=/.65IIE3E7N1D<3QPBZX^V5:<F
MIS:1899O+*]6E*[;/.XDQ_-8)&4#M?.I0U#R7D+CKH9D&3%VT6R#+S" 92P/
MZ9$1SF+A.T.ZR,RZIBL;9X[6!O?'#/JIN29TJB,XZ7'<)HA:XWY$*CE,\(]K
M6XA(?':\UQ<49V(IENZCQ1$K8/\-=!\J96EK]>9<O%[E=)C:]&"0\T1<"_8-
MV\OR4[Q\(25-H8+SOV^]MW,8@,C?NWKNTK=ZH"AM;'(4;%IY;EQ_+O:K>9/Q
M#O#YN6ZW6ST@E$%&.=*T9(B=S.N:L'/TAW/!<\@M1KMSF8'*RUQ'<SL?G^K.
M>;#.S/"1G// ;92SE^(;>OA/"6IYELA-4!1?-6YI&N'*\:[UT)M!)_=CRE&S
M81N61CW;&D]3GG"G-O+T<:AW++9KM/FEF/S4P*6ER<RQRE7//$65>D6CLGA2
MZUY$*0$<>F'WC=@DDU.J&;E6XB5OG3-MA6:J#L):)9+",Z=P;RRM/(AH(QD5
MR[K4C=[$I^=..F'<@8JFHQ*G#\'3RKN:EZX71YLG&&!Z^Z6^!0T__&!!?Y/J
MUJV0B+)>FZB[L)S;X0A)NOY #S'I98[[<-N5JM N6?EV'N[7L7IO<5ACG\BX
M8P#K^9JCVGV[$@=O1\_O?8N7WN:FC4$+KP1^ZBN3!+5V$P#K]L)K#?(<BZ&6
M9I&WA[6#>43RB%&WJ<7WA=:^+: @TF/FVL?T=UL/3&]K<W+$RH FB_F:#T[K
MGSJZ+\Z)OAHM3-IJ;6LO>>01U[%ZBOPQ>:.XF5X>UY<W=+06P16T)\&T,*_@
M;NG^5=?-.V%+*L38>,U?4^S#HI]?FI+(1):"N;5XLG:?+7%"03(-?C@%^V8Y
M(LHJ%P,0[ ;9HON=;,$]!_517#O?JGKGZLRX(VK6Z7G[F,066M@7SS' ==80
M&D/2S9,X,G:%8?@;/Y9 6M_AARF?D\7![^F<^TR+@LH#41R<94BVR#Q67@X8
M&\\7W10 .LJ)]UBH2+-J_T.0+2=S=>7^;@SQ4+%IK"C;V,?(]]=K\(HPP!O+
MA:EUY?.K19-1NO;WO!IKSJN[#'S*<=;5(*V/?.Y9KW<:3C6ZQMA?IE]^^Q_M
MO7=8D]_2*!H%09"B2).N@")5>B<B0D"D*Z$7J2'2>XV ] X"TGNOTCM*1Z3W
MWGL-4@*$Y*!^W]D__=J^>]_GWN<Y9_^Q5K)6WIE9,VMFUJSVIOSK(1]RFA]9
M.U\OB@9HM'BM?>UIZ7$W_=9$40E_:Z,A;5LFP(5!TG]@R19X? F2&JJT>SYR
MU",\&KQZX]LM.I7=&JI70VI3LF_>&E9Z[N*^?<*CUP$>MGSIJH@-X,T]+@F(
MM5Q,Z*'L\;<CE<XVYK!<.TM]IR[D&9'4R+VMZ-1$>W<&060JHL >1SRTQ0?!
MBQ=^D47\[5UB=Y>>RQT='VCF9A4^I?KF2<PNE<<+<OU7S'%]@YXMZXEVO7*V
M$'/7VX%;<X^7\8J)7N'Q/^X2$/T"\'Y)R  '>X7YK9:/V,O9M@GM^RJ_UI8:
M.KF<[\$,*0M_<N]:A]2U_?CYL2E^>./VL]?IEKC?%'.>B?1Q[FHC!]IM,<,5
MB&3Q I66[?$*<[QNBHKG#VY2O!5_[F*??L-[IZ>*A#P(Y1PJMG\A>N597B#H
M423RR:PW(N R@83E_J663>/1G1>NML- =L[0T9'N*V7H1[*Z.Z+N6N[,5[@G
M3^\ IUQ%4AZ9]*[NG]DV.[BB*C>>F J)5JXX.IS+!8.5I!Z$FNX.:M_&NX&'
M]10C6*62FE)VC(1,9?CMOBKW![(GK)X*50O6T@2@Q4Q5E4V*_(G4* DY#:EA
MC.#\U"F;.-2=ATLL-;XWS=/OB!-)DC.\E\2]]NB1Y[XLL=(7(DD\*)4I7_Z#
M!::CZRD_W1-VG)O-CV-N_:B6QVA ^DH)H 2&6/WQ'JF4R_<J:(!DM\ZU5^];
MKF;\OSFSOS?I*B/OHP&1VAFP:=@E-:-;Y1\5C]\J"[LPI:>F7LW5 /]@NBX8
M7J?OLI9ZR'!$FZ06@:SLX^Z5/"DY 6J\N;<BLP$4$@D0Q;ZR!O %;1&M&1I@
M<)RA.& 2\2@5N?$3!+BKN^-1X5YP&386(B&>_#S9^WM&5]2 AQT:4 G[=#[X
M$Q4O/I8SD0MA7]@#!?&S8=0HJG,;--4\<6DZPO,O(O\B\B\B_PR118_'3BI@
M.-#7O+ BETA]"&YD!"$14PSECG17 _]XJU \O/H2(PT-^)R+!G0TMG:*"5S%
M1=S/_910?1<F"3:ESAZPV. "/ML*-, Q6W@\!0UH?88&C%R-A-&$J'$Y+0TJ
M&/)Q"25L0(@6B1OVXPUC/KS+EN?8$FB IQ(:$.) >S#0?,R"!JQ>U50.H@'X
MM]  Y6;4*^"%MJB$1-B?S],>9#>8HP%/-V 'S$!X<2N*@@R5!4/FPD[J@(MI
ML"TP&O#5[RIZN>)M&0U8E'.:1GD.H $+KV#+H+\V!%J*!OCZH %Y5\$>,^UE
M<1C"5/<\&@TXO.)U:F.$YXI-A(H.'QJ0:@=$D-#^>.\%+K1C_HC@"OGU##2
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M@XM DQY@DOQA D6OU9EIYBCDYY=5UC1DH1^(&BR.1M:LT!.Q>/H"J)8Q<C0
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M:1%/[(<*ZYG0^,;]3^I+W.;P 4R=Z;3F;(\OU=JFP1!/TAM=,BT=N?H0[,U
M.M-@>&<XI4BE$N&35SVYOX^\[VJP>.$K3I-^REG.9'.]O$7,2"6Y5F#IG? 4
M2]@8TB1W:MMV4X/0MYBW=F?0L-&P1HWT=BMS:NG91*A#F&5+7\%2_;0<I4+]
M,)(_=VYVGGVU,MP]I6OY49_#F4&GO$ORAVO#@UK5WFY&5UY7L=G7]9J!N_Z#
MS(.L(2VZ&:Y,Z40:/_I*>YX_M\/^#]IKJY<S4^>AO+S[ C6<HM#\?6Y^%X<
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M'*ITD0KD)>;IGLFZ^4Z.;6'09=&'U(S&52/%JB=#NQ:*EF_>8'&]][J)*Z]
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MQ $JIT#;])3OG%7C."0G;GU36?LR4;CT&D/WF?S,DR^H4VJG_=Q44*BZ*8W
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MX4M# W#YM(4O^-9W?3X&6=YO:/$8TA2V3DX\.DUE[U=,]\$V73C*NM*P'J)
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MR0W_G[!4'7S (;.(ZFSM'\*?J];N#MHZB*AF*=TPL%AJ)5L@;;-1PA<FL?7
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M?I"H?8H7BS!AA/=7C^OG;PC6Z'-KOO[I5;8_.[ZBLUPN3A@O_QTGP8/8QDG
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M-Q@A;LP6;R-DBM#13I;ZA2#2X!F6:YF]V&%[$'7&R4K =YZ<'KC,1D%3QSZ
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M>3=1SX#8T**_38[('S)6?+BS)X277SPWLAY>:[^X%, "FIX!K_R&!,_'_@1
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M4M7OGEO[#?S:(\HS@.Y7C\@-ZHMLGY#7>^W\[Y*[?ZB&B%IJ5C]M"S,.\"@
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M.5,(0G4G=FT)0BMAS6EJ@+A:)OE$G+XO_?;X41;PS@LP/W6M)Z >7#A5 :T
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M>)"'N)MUW2 J<_ZN965_F!^8U1L2EW0F-\.9][>I3UE2--#S XC1'\C##\N
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M/R#P/XW#S+(L&>'77D*\*!#A%9:2)7R/#T^A 605F-;G=3J0JE*M75J_#:A
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MK#?DENF0UGW_>*2S4</IPSO.PVZCS12@Z$&.-:X^;Z-2X0KADM06'AU]R%#
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M RLT_0&T[#MO\+1-A5GU=*L"<N;Q"/W/25!M$D:5!K6MB@8 4W2;]&0]>BB
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M)C$#3EZUP/:*#-Y;$/#J]G0IGEUMH:689;<U\Y]!N.!UL_;I4[P?B6H1NNU
MZP6XF7D(#:<E63C=:6I?V;B/?:($5)>K>H8\].$K#NF+%KB&J(7@ %_MP2@4
M@$7FZG"0%/58W&\ZPAW/2+?ZMW_*WAEF1RBE,D23.H1::#%@VFXOWLPI_\-Z
M.9R ?EVC4_#?$GHTO&M>7[\2\A^%:S@<Q:233,^]@=X^ B*0@=')S6)$#USL
M48^ :EP :N=_J:@&.?E3G&/"TU(:P\3FLE=T%W]P5-675VW?QY?%7.C@GC>O
M/C!TVEV(OSZP-6F8>?5#MOI/EDG&CZ'CPQU!3L]+-;V?)8/\\W"*4^6W8!V1
MKWQZDTH4H>@4"$7D*1^49K1U3[REAG4@$T?]4TQ'@"1N-3)VX;*LW5EXA5]E
M4&W;35:2S$#9;G5)Q8MW#24*IB3^UM00+-1QZ&00$EI\U3RN';^,)!^=F"[_
MW>A ^\OVAP/G+D62RF)PC-".G! <;OVI)1D"Y5-$.X=<\BR@#T02MK'Y50=F
M.?DOM^%UW]!4A/(K^?#^K&&7^IXT9J3-S+[O54,,0GAKYGU>[']QB!3D:24K
MWFN $50U34-'YL:J4S]$;69V6:$Y-!0NA_[RG).:(\MS99<Q]Y7T%NY[^^!]
MSZ/-@N"+/>4@?03TBA0V@ O<PQD:)P1>^(Y9!+'PE+U\_H.F_A K,O3($ [+
M EN<RH,Q/O:-&0;9O"055Z5!C4?6>D59=VOTFFT*X+GJE[W%HFN7:9*^D'2^
MY2G/1-?YIC4)=<&6UH1Q]Q)^LEO3."20OM$FY9CONZ5U%94GO1#1@7=S:#4%
M/9O*:^XZ+V9NQ&JS%I9)'',J&O#0CC1-Z*;EK3FA*>4),?,^EYY)<J!_!/C+
M\9V'><Y]]M;/7>BIX*PRI:S$(&V2CKN>X=!E.F&JH@MA-XPSQ&A.ZJ*%'HQ3
M2>^?.N;]M!5 SE_I=]]XOI[?\71& P *2M'[V_ED10C*/Z57JG<KUKY,;T!Y
M;%6<$(R:AD@2CEJ7HC0,^I]I+81K+WI0A0)NG S)ND>-56:S?\R^BA#5SY0[
ME26JB3V5)R!2F72G-Q=:9UYN8:ZMCR.B76;2611Y(_6N<D<^A[8NM=1=6W8&
MCO'B5S\%B/)S00/MI\H!#\[H1M:><_';K98W:E'\;FHYE$K*NC4&?I%U985I
M=/B?I\C/E::7!+H> <.9#7()]^N7GSS_($M0(N-A=WB%B^,E4@_TD[^CTD0'
MWA7TZ%#C?,_C*O\V56)TYFZL'+],85=1J)2I\=%4?*F+NHS:NSAKGV753^(<
MQO2C.BKYR+PZ2<(-,5#<CCYA%D%7I0\R%<,F%BU[HT=1*:[K>_((\!(NH;0C
MW>6I-0;7GCQ->*,5</W^1=*.5)S<[/J,_&R+K/\'W?*%6G2!;=!L=W\:[^U8
M?LF,Z^>1*V,?\?[ WJ01XF[.5"?&Z$$=/@R91(QH'.PA7G&V6@3?:L=8*AST
M"! 7*,N[YC:^3VX1.=\=',)I+WJ9E#^)RY);'OOOT066V(@8%I9@1Z-X.Z47
M0H 4Y/L>=S8'+]$V)Z^<=(\72R=&B>K^D'TY+AX4'CK2^)G0(;8N$9([6VM<
M+5UHY-,,XJJCD/!^4>??Q^V0.6_"=^B^P]9RPC#R)2K,?^4 >T5(_=TZU@ZA
M=SR@4[S*R(2CCD*@;Z48![:P_6TPEI=^[/>G,_2FW4@?MN3<31^_@:$B]CTG
M35?5TJ/3H\7EV3NN-;*6@-/#6^4VG>E.DL1M$Y9?ST@:M_W'#;39\MWI'HC9
MRO)K27\.XCXY<FB:=[, B#L$CML*E7SO^5ZCW+[J.[.9Q75  %*?OY9G(&C#
M]#G1]!9?T[_'1*U]AN8VM1*ET/(D#Y"S3>U.NS$5PK6920_S&B!GNS^RUJRC
M"RCY(ED;+'Z(A]<=A=Z<M[7RR.?I+0^M:HS5R [2FW/J///QNM6\9^KN\<7V
MKQ 0Y[$,ZAO<ZNN2"Z7W[HEIB23P=-G*:[QJ65/@R->'H[$?&CH!/F<< HL[
M7V?\(*W3K%\2:(8B\03G+^FRK[\R9TGKK[$TV_ O[<.29XR'3ZUEQ0Q9)39,
M-_9A/^:<?HI1W:=[9#,N5??<+FQ?^ZX#,!?C?J%]:F5^!)#0A0G0D0V.UEAU
M*XZKUN1YGQ)>+M+Z-9<9;(Z'NQAJ@VJ/1V&IG.DN<%'I%^FN_CF!Y9,'?4+J
M#H$SR6T2?4,KRE,'^U @D;Y^7]7[P-S22+1KK5:$"&\6Q_V,A<Y?4_L_2XD
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MSLI@KZY2F!LL)L[9O+3^R,TFOR7X:!(O34$A1+YP-6>$2T)-_>JBX1$0\*5
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MEPG&ZE7*Q&6P:& W<9JYYB5/%NK:97%'3^]VH'K<&?9"2#Z6#;=.<D>&?G\
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M9)J(H2;>!^V=A\+=PC,>AVN4W8Y&Y$'0^''=&0M-VD:#AN3D'@:&$_PR3@E
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M,NJF".:5OP898L!U=:G^OOX>SWRFBA,!O3\9\O*_<X;06():V:D4(D^13B/
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M0N0 7KFS7D.(4-E=6$SRZXP<%SW5-@5[8ID'=1>LH('5]XD4!5Y # W#: W
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MMTP?VWCY C:<_X=9/#RCT3+>8"UR9AF>"6ORM?3#66O4R20D^3"X5<$R ;"
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MN@<QKZQ&U#"3SN5V(+EY3V^UJ=L^JYYO<!V$X&;@NV>8<#]4*K]T.4IHPW;
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MG85_O/8#2MNGLU= MY_H%3!;VA_TY_RY\,MS7#QW.],-]BM@5:Y>^-=L_(_
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MH<)OEQC3]P:9HMWHXU$V8=3Y3:3KUS2GP0RY$;W9V(88=MD'=\IC&K)'O1A
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MW'OM2&Y)YU;7JXP6V6551^=N6>ODDW="9;7+:I22R/P7P\H]M8A(U81_DYU
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M8$E%UW BSPO["5NQYKC)..M0$N$/HYHB,=A%,Q(YJ\]901WB]),>C<3V0?=
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M>F+'Y5S]\+F^<-1\Y4'Q(RY_>1$#5XC%?)\00I"JW0DZ]G&M2L(RPESQ[;<
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M=C(/R\3XL6&88%/E;J]0%1,$C(LKJT0I=N;I918'(HIU_3;7+5,&$JVEF.Q
M8NP6WSZS&RQRR$3!=*;ZY@)U>PV)!D?'E2JJ14W#Q@-77IPAN&W.HIS&:[#R
M=&UZ>-&;MF#]\2[WXDKGK@#BS7$)TAJ&=3D8K$4/1!EK1;3??S-[Y'M4U;Q\
M&M0Q:,,P@K@XK4SZ4Q==8?&H=P'M7LDWV,VO+XP 6DW*9!H7R;UMYJ<I]LD?
M(\9$DK8>086:-\?BN6^^QVSN\QP>W7%(,<AAL<5]BP3G*$3W:A#.0&Y6"?6R
MD,1'HMMH[<8"_0N/:OOD(4\=!)O7QC[&EF:[\)F8IJ:G%52Y?G;#UN#M)"/A
M-@.)CNRF9:&-9 I^FW\CWP@%0L*AAGDS\E[DZOY,Q;SJ'_4WY R\O\Y7T[%M
M'O@H%J]T!]N@6M6KL>>ZC6BJCP[PO)*BDQ7.'/BOS+6U[=*_)*@P,XD!/2?;
M?]IF#$Q:'C>XU.'=%%K$.:TI/;P@X31IGW?&:Z.U\!.G;99_/$EL%+WCJ^35
M3S$AI*%%XJF50=0 -EPC@8P\R^"(.Y9U-49S7HDZO.W>U;0N"WBM1^9G#9@D
M_JB#_J@H#V6E+%.2EL>^6QB9KXOKS+AAR_<YG3(7SS5F;U^2NI%(U,L^6VI)
MEB=4J!^R;Q_B+>M0/*W('*703SM"/5W%7^K#W+=8($25?V!(L VMWWO[LFOC
M%2MJ/+GCY!W6[.'OA-\J* T_C<_7K[3,X)8P#=%[9%&QJF ?P8EWR;*^;MRX
MKU6"D+AV\;4[^&T"XO15ED=Q'YZ2C4%CO*E&QFRY&7A0FR4[8 A+ "Z*#)_S
MW?R*($Z4>' @;"I71IBDAIGL3C&W2/VP95[!]<,B"?N(B*8:<)T4_0.DD1DE
M[A'BM(@_\#7:0L5MOC=?JR MTN(FZ$_6A;/XW*ML&KQT1$]?U+S(,9W$\&%;
MBHKC<SPI(]**U@M/Z2!GXZA"1)9)*FSJ$5NN\G\D3"G/4LBB;.I57,X'Y["_
MS@F@P6I9>ODPAD.Y*5]\<'LH\&Y/ZMFH0=_W3^ />?;O4:55I'((?.O'PD/J
MC%Z[=P[EA_(?\NVR_A_:WCL>KJ_;'Q\AI"%Z-X+H)7H=-7H9)&J4,+H@B-XC
MB#9:E R&Z'TBB-X[T9D1O8MNU%'"3S[/\]S[/+_[O=_O]][OZ_YW7F>?L_=:
M:Y^SW^^URUK#9F6"G0.OSG_;S;3A1)8T0L3R#)401CR,*!H7;="W7C'2X6<O
MD. TA"K-PZF8G?A$RE+O8YD?/XK=IFMDG]9/I*6(Y@K^[%9%(5V7L!W+FB2T
M!W.H9AZ!'#35O-;DXSB)MQ4S,J)MUIB04=#-3(DK4Q3Y#< T^?'YE+]#QH%9
MJ!4:[_,W_C;_N^[74ACOP@S-Y0/%'X22^OH'$FK"R2) .Y/8]?BP91AN+#G:
M+)Q'D.:(MN);T6:\EI>O29I"LPK$-8OV!%$0P("A<K^4YR(J<J=S6.<EPOCL
M*[0DL)N_Q=J&<D0/%_K=78ERM!YE\OXT /V,D,5C$D(#0Z^4>"(":1MZ9;P1
M18UD*P[<KOW,1R,JT U2K)E1Y7M,#*LZ_S:]@P>]'GFD%&H./)X*Y#B/99U
M(1<HJL2J,PE+79Y 6K(0N. PHX+Y9\UW 6\-I?*C,U^88#"08DO"I[595WR3
M C5]3K;807TG@I87L&/L@X&7.-=K=5E7_),4>'U.J5F$TG\O(L3HB6<!SKF[
M@ >E[AIUAZ_*;;&'#_TUJ*3RF["OR:"%LE)J;C(8JV)A<,(<GPQ]8.*6;=^)
MT"_LI>1"Y=\#+LI2E%N?9U9K2+%:;ZOC]]?PW%B"%F4TJ[FI!E#9!V7.U@AB
MM>:K;-D= !?N] 2;;%QQ<FLK2ZGYZ'*;M:*F-7(&N=Z0>F81@*Z]5>C8[P^\
M]LB#5!M*?Z2VOZJU!XC8,"!;PFQJPPUKGCG-U;XKK5WR_8P4C:ODZP8@7#&0
M@RUO%NCI,BW'T9$67JV7O:'U*/>TW_ZT0&:>P\1;N:]R%5FMV&1/_\O<Q=+K
M\T]!FGS3!L)#H95 O#<[Y>MU,/]\9[[ZWPZSU0]=W"""SVU<B2[T!PX'_1>=
MB7]TB^%HL 1H:0#\A5@^O_DU4.U-G[3L@_K RQ7 7+9;JO[$NI?!1=O SS1F
M7]O21I?9?XVQR5,%*3CH(6JM K&[MQD/ ]2C")V7]@5R<HU_.ZPA:#'%>RN=
MG0(D:\V!1A?=>Q-@RP.VRX[;<3.VD1YYS1&^!FSR<S_+(C3 Z"^+N0\"SP:3
M98,-+_:A:9J3&S7\0:1QN [9!X1A-!T7%GM:DEUXD0>(CXR&5TZGHY95B9!(
MP&85.$+_(C/J296*2D0N=FR9KQZBI"MO4T-RB/3#,.MTXTI[X,/UL9.'#N=$
M7M._%0PPU>:%9ARR-@T.;'BD6.L7B*X8+7MB[L;.+$@T];%SF!3(T4D$>JAE
MB1]-8EQ=T)YCE7]>X]K1X+2L%KG*-?6KF1?ZT!!W;$6"L G@_YI GZD6P8T>
MA@)E48PA@P^B\7R.2^Y+SDE1[$& _<W.F/%'-:;\WVNB)#[CW@48H:2X3+I\
MJ6>&#P/)\7U8.\!4F40R[7;R(IK5K;8M#YSVJ[!=N"#><HK*I9GA16Y+^W1*
M!2IUNKG=TM2 "_?OV<D@4NM&M5L0>*4Y\31LR.4P_:W#>*-#P!M) 4_&[\B?
M;0BX'^MBU#Z5ZMDM >Y<O66.VZ62[BR57U3(?F15\KKMFO2T6_U<^HCZG7_M
MOG(M<A!S%DI$1;KS0* &=G(#^, ?(?D4:S\$!C@6_S^-S/]VT+_I'^'T96@I
MVA#G=QT"3XG^JSEM%J7^.<C?GR/(-?_)$>3(9^QV@-8N /???2C\P-H%U8-8
MHEMANJ0OUYOFKI<N]-]C4F*)P,/Z8N4[A-WOM/C7_*Z%M*'SQYN9T9-*?D?P
MI)V\HE%F9;/U(7MEW,LL 61AQ;GLH,DXP>54SUB2/R,DTB/+QSJ$(K'@>1.G
MPO6I;"'7Q--<_]HB@2$W,] +3/C0@(6,_Z82W86;-@DT+ ,N/N[?13;QF?"'
MV/8+]AD:H'TQ@<3$(60GVFV(75[/4>.RY_Z[>:<O(B#:<9.*A3QY$ANM3%#Z
MN*53+8AS,A\6L:\X6X]-?[ZM@2>Y_H7?Y;U=Y/F*M-$HA<6B&,C^W3:R<O+
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M8'!]A!,W7!CPGD,ONJ"87U+ =^,GE_I/J[*+HSD>_3%).>2.<G3Z(U06IQ,
M&A91IH27GU.8'?F^_?]AYO:1-+%MW-;TFPK^.QZP_@./H'H=T8?1[\I;HZ.I
M%13,ZK/\V; F3;>V) R,E%X#"JOI-/&E\!+T'P;/-V+W9)*6F]J5[N:?\ROJ
M!0D%,&(.%(\4G'G?O'5H/Y&X =2HT#:_2Y!@L2((NNO8$^3J^<A13'0U'LIO
M7M<(O]B$VYE$T:\7UQXND&)59/UZL4U!;VRK/*S%N6D&P#R@XQD2RXNFX)S5
M9S\ :E36CZ_!;$=SC2&,37-$VG+%07BOV0WT& ]U.)4B%'''^##Z?3< LN.6
M"@='X5E<9GUDGL\E*OC*?12F$*;,-$!!U5HL_ZP9;\O*3P6_4AH?SKE9?_YJ
M23C4ES#2<<^03O<^HFA\CW<LCN#_:MTY(3FI]98,OR8E"1Z\]9&W!AP>XIC7
M)WK(J^ZU;\&R6T-)#[W*7Q#/S9(SQ\,4CISSCFAK6)'?7RM_B04\0O+HVQ@S
M9D=PES$IHX+NE7 +=TWA:]M]]9)\H<8CT)!9ANU2]ZY.=*.,LP4;EF7#3&#W
MO(<!_JEC2F2B9MU)=%#YF92.?4BO0",]GJH9G^4U+S+J%YA7;B&MN@+.OH*S
M-_<R.E*S-:"*_OYYK-1QXHC8&U,[11G<)##(/C))$4<XD-J-;VA1DPVLK4H^
MTFC5-@UNDF!(W]M^*5\:=42K\_Z>*.1\O*7I;8W<#>!S&.#%CS2.][TOCU!Y
MRI4B 7/L-44$U"E(];."D$1DY=EJ.G4\G=SA[-EZ\1,V"J2QBXYUY6C;EKT+
M RO5A?9$FH'C:1K^L:^A[$FYJ0;-):/% 7ZQYEO.$GW;&>BGR@ZZ":\W+\B[
MZ 1TU#X\[IOP05&@.=M&[3V(-1[)!\RWUSB7YH[O26(\+:J/&XY;0OIK'_3D
MW\M[6X%V*LG7R)]-S96K%5VO]A-99C\V460Q)!A1HD)88CH6!P2_^LNQ)1FX
M':+-) 'RB9D->A]M+Z7;Z=E"#,=?.ZZX:,?#MBY0W<V/T'E[H1X?61Q#*]\[
M;#D_\(+3>6I"S9Y1,*5K,>6\2+^D_OM>3QP1\LVWH99:2DTO35AFV>@-KDH4
M(P%??B<YWP D>]94_G;19:LM0W4#^*EW SCZH?WO]TBEOY7= #92<RXY%JZ]
M(UL4 %K7_35_4NLE_NW.2':0P W@7Q[Z3VX-)3DI752<Z]]'O](,X\53[\]Z
M1K;IOI%)217^P;HG#^ 7STHBC2*=O-LL(P9B'ZLX,@BL-LD,:F2Y?C*YO$#%
M%T:5A;\?.O_ 'ZP#7;8=ZF(XY-S<?DBY\YJH^XL,78E$QSQ]U2C7Z).(E[M4
M#'IK_ZU]1G0E$6C]][LG64=OJ'KR[#$E1IF*%=Y?@.YN8]_\\%<HK^0+"*5D
MK/IP @2Q5IN?89RY/_'UO0GWF#W@I&BMG]P+7@YDW$QE8'B-FG#M<.2P,(CO
M :=BFTGX&7ROJ4:[1CTU6(7TRD8"+EBZ;WG<HY6<0J$5,Y+<F>57 IL,U^Y;
M<%(>/]Z"\TPO.<Y^J:?B0-*9$OH$P@T9^L'\],WD@NO/O(>(C)-7YKQ=S\!,
MPT+'4C"E4ZMRZ0W8+1@?T.1RHF53CP5@@ MRK"BOGDOL<WWV%4=-E.8W;VO.
M6EZJ\F_ DUO K9=.\J+HVNZN1Y*/_-@J;7M+0_<+FT0';;57X2!(_J,'$!QB
M[!&%/U@3Z7@]0>/&#P^H/@9^D**VJP<U>M[%29O@FW<SM5KI<R3I.5"P+6PP
MD7T ^H7]JTD4HAET QCGNRKID QT8L5D%FS$A^(=(5S&^AQ99FO,N (YT&!:
M)[,('R^ZTQN .. TC5*'CIDQ.";\7/_C@!->%XU<2>P\=F9W4_\41 /[=^RF
MJ9 ; Y!HEQ3KNLH-,X)GA=;N/9@H)!#!T@T@-H@*).AB _H*>2[[T7N&/Y6>
M,T8ZM\V9.UWQD340-=U?OAW9F>TJYGZY*;<2E_SF"&_;DV0EOB"_=G=;UBS!
M3X[BEPCJ\J'..7"_6KC7[4N\,!0$8HF4;>WZSP(+*>.R8=G^C\4;Z#$3.KH!
M^/\MA4G+?TQA\F'1.AE:G5$V]SM<(WDQ'4?'%EN>:4([?HOS#WE(9,E"<Q50
M@;9N &'-3,U?"DM9Y#R%Q4?P&D8-8&7H[R.AW=X_TY'.[]V'=TO('7^R=0*'
M@L2G;PDA]=47!#9:$>^CD_2"&,+/N=ZAS<\TC-MIZ>/6>L-7::HF$GAZX?9+
MR]<%9)(Q=1^/UPO[&!@R5<\8J\7/2%7Y]4'B>F=AW%V#\R[IU&L?@B2D(6,-
M9N$8_M[=<9:O71),44 >(P\0]A.([C'MB/*,AO4==9\73P-2$;A&O>?G3?==
M^:Z*=,-50P+GZ*L.Y@B7-';TQ36[XF0IK[944A_J7;AIW>%3>S=5[6RNFM(I
MKE&73K#(ZP2:'6>.E\D7"&U,I=_1D!FZ+YWG.Z+M\&*3G5-)FZ[KF<H1=? Z
MS<?CPJM%?)-L6S-%O#*C6PM(J_8;M@FY4BEMJ.HIB],\%H=G<"I2X;H9C*B*
M"I6\V3*PKLO]L;X39=2T& N>BCEZUE8R37K?,;^TTT). +;.#/$LYI+/,C?Q
M6;Z'Y)DJMZ-7\"SBB^,;7M-271$CHU$Y1,^GEC^3+56?W0N/P!7+)1!C^<*%
MQ306GY8G&-$T<&^I)4]4=)A,_P=VL"HSCG74W8$!QHWSB1*&8;,R;0)^::,D
M8^LOV>.">K+='/VBE*5KYJTERHN1R9'JS>4<LX\$$C'(-V\D)FM7:2$U1LE1
MZN-Z;<ME.99Z?IH<BV]+8&$Q/&[T7!73"LN\/PA<.7WE&BE\+#72X[*H XH
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M&AT%NCSU%G>-$:2+"!HBWJC44\&X^V:Q/H<W@"ABP=$9Q18V9BCG:,B&PPW
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MMC6 Y'LB'E>_L#?!-0JWRHW^C;2<5P?PJ*L,28M++SD.]JW,_!-A^9LIFM\
M*:R'E[:5_TY[_D-7M=P*L"$)D:IJ.:AA$>M9&OPG0O27#D*Q46[1B;%#20$\
M&JA_,L&=4T:7VK_QM;[(TV%D,C#*DR;,Y:SIMJ?,Q4FB(\W$0+[+C<DS/6!0
M<7\C,<C^Q4JX09OH]K8,?<D&J^1QSA#8=')-^B!#@!<8*QC8_G9U)?JVFR<;
M5U?@57 ?B!B"VXRF;H4)5)=++^SZS.5\!*_X?AST7LZ0IO>FJ4&SL#M>_/D8
M;XQEWZQ2BV YWBV_3;?4WN"1Z5UO1%R3>)JJT,^>9H-I>F5>*]4(MIZ ;^49
M_=,P@N,6/*<U/O=>_;J]F.L_H=H?!/@@TN%-A4>)4!_4K9_9[OB$-7X<&8IN
M2(R.CO4!G)@)^2N(#*N[WS8LZ<;B&_".%YKF8(-"!H&T^K-L&&.%7";TDX"T
M?54;Y^.H'AY2&]K+$;PB[X$X?K&L'SFU""YGFF99RJO-\!YP-+SG]C6#OUZ[
M%4D_203Z,P4ZYYUW*\S23'#TV7KPU(DL1WQZY*-^":C# !Z46?*.M+CVB@U3
MNJ^;3*S.42(>_)-WWS"(<P O)A./.>!=2/>WQ=7;O@&]& )KC\6*B6Z4>>M@
MD,:'MXH7=(\]HI<6!_S17\E8^V\&D!)QG7UW,99)(_;B_9^?[^51(JJ:WM5E
MV.CPRXJ=H7CTV48U&[ICI;!W\]8T!>FIM"<Y0^HD\*2UP(,T9=+;^L 83:#7
M*J1%$&MK:>+LBQO48>B8EUS%-W"M@L;--(Q9^['K6SX88!B-DZB0HWE S(P=
MK=]_T9Q7,H!0X>Y0AAA^/W38YAY9D.F+Z_=BH%[R,[S%8'":<FW"SP>#M<VV
MV&I+\U_(4.'F"DP^4(?<NO%E^!*+U=W@[4@TXD/*F=X\<^-8_IO2YUBF:W\%
MGIE._A](ZBB-X0I<3O]'U)>2'\T/L?Y$?>GYUZ@OC6[+-A'.QW16S!&QGV@M
M/1"0<N R1>@22O!5^&&',FF<[WJ0D)_TLH2_O,+W>N^7 HKWUQM3EL.*ZU,B
M[G[ >=9+1;914NI0_\R7U%M.T2,XT22\HX7 &!/^TD3S2B*C=2TBB]#C(*^H
M\F#P RO&W*BE$!_IBH4B$R0J?9;K<*;U6J?1?#+X=OB3VCX]S+!_8X.#]*K^
M[-(GM(."$]?4U7E_QM60!88X?M!4=<4C->UX!9?ZVF@9QHHNJ.+E=\2!<V:A
M%=-A?I<O7[^\)AS+F2AO%^T%V<FKS#JX#?,X3HO=>P-U8-G@6L.3-2U;67CX
MD$8/3MH-XOS!C,6X<*5[/&64CI8H')#+RWVU%W0LM .3>S.V1'6-90K.[Y::
M[)%$E4\#OC\F/+WK"LGV\L[=?S*FS/"A%VS4\UUILIHN-Z/83B@M?RJ._6+Y
M^_%#H:J*2UF@@*=0VUU+YZ#V.?9*Z^E[QYCW0:#-L2&5Q4F1M!^KF7G/QQ9/
MBBNV"U,>3:V [,),!6##\9@A>P$>0M,J@SP2I:&^;666#:I-9*7D7N/HQN4D
ML]0+\)!8M]VV\"NJTDR)^?1$HJ& JG3Y3ZBCW[^+%5(1/GU'KGA";"E9@YS$
MRPX1'_=U<@M /DBM-*8R#=H<9%XVK: P3CA@O52)QQ<IWN\6/?EQM<=G,)M6
MP](MLVFLK(MGI;I>3TX95ZQ$3A9:M6,SD-<OQ3IB,;$KDKT4[F+ZBE_JL]=K
M"Y\5V.F -U9,R"%AF3<J]CC^/H5+N<"FOL+/U)?A51'#7.$>*H/*I6[12,?<
M:TO.8<8RIB-D_7P]7'"E_URML!,-^QJS_Y*L;AM9^J65]J30(B* ]6Q3;T4,
MY"!T#UMLO9P)X#,A\-*V<W9%*("EEQ9I*;H-:[J_ HN@5NS^Q!H_:!J]*Y1V
MOW?0-.:;5%*B2$0>45O!5L2Z'?][GR+I//WHJZ")B^"A1!;I!L,3#NF'4KY)
M+/ZFB^RB<^!+KH8ZW(9]0B]7SH&?N?$"R>OU;HL-&C]F[FKH%/FQQD1YJ-RS
M\,IJ[WFB4A[>56]A5V,@&ZV#D5?34-6AM<X:V2"?-X;@P<PJE27H':;PWI>]
M)6@;!!Z$&JU(W,66])OIC53IS?62TI)W,\U >&D^-.$PU!;3-K5L 2TKP$4L
M@F<AK]1J143S+B73::E/_"7:R5'D1!*L7%F3E8MIZOYM@UANW;R.UEZOJ"ZK
M5R]R'>F_<-24^0?XD=BL]AKBS3$VVV/B<^7S',KCHZUB^ 02(G_F69 FA@Z*
M["2@#^$.HP'D&"/"QPO*"3&M3_9-2Q?N'=]Z>R;^OXB.&*?[8FO]V2UKWL6Z
MX&"9J<5^\ F0GO0LA_0L$)0)FCTRGE.@?P!)'\$+):.1H;/7MF$'[(H6O9LB
M]]>Y!WZ2>Z<Y<CR ;&IV$[DWZG^,,X(WN(Z4DYWRSC+L=SN$<VXF'D2!<2QX
MD4G-Q':C74S>\J&L90"_SM$DU]SC/&6ZOJG[Y2'=1B]]]&JXZQ\!)J>NN ]"
M:SZ:@H4\[V81/KMDK@,4K:=SK5YO(O)7,4KYG^\3$0ZE9MX7O*+MNAC!^Q'C
M]"LOE2@RUMJ8;=]T$DW3J@<C".'N5*DJY^P[5GO9@"S+<I+OO6M254NF\*D@
MIH"T8DJ#Z?431&Z9%)F!&H2&,LQ$=EM_IYEL<U2:C\#?GF2",&.GD=7=-?14
MFBS6U_Y->6YP?=&^&80WY/@27\KQJ])AMZ^O?K^48 0$_71H-+CQN-CQ'5!^
MNOF.7#;2NH>9WF%Z/>.)<<6=1L+%ZRJ81YK(#RP LB7BFD$=8@DU)D*1_0QK
MG2@_YL]08QJK-B-N,W<R<TTTM5D._/C-V^S7#EXYYW U(8GI%E&2G5GBMD'"
MYTC+9/-],Y7W?3GW6;DU[71ME-Q7!N76Y:GB%I'/+SY4VKB1),)*;-[P()Y$
M/]I[S3EZ? ,(5WM'-D>#-XO*,UDZB)$@X$U=S(E403%)3F3^I'C4<&U_:B*Q
M-%@E*Z]TCI*Y?O@M;$B.T?B#T/JP: [595Z]S1"/.GBM8E5O+V5I4^@9E2=D
M^IO?BWM5J&G!)7GJT\Q0Y+/A?._HR)Y9?0\)LIVWUY-4<I+3M!173XB3K*9G
MQQ-;#]_SQYC)X(M/T9ZKG+\8C&D.G"CX?60F?E3D(7+*.G"Q![U0K7RLA*RL
MJM7\(MXI 9_<,B//BN3$Y8C,]7FPV$S[O'+[*]-A0X_16>%R^M?FB:Z>^8HJ
MO_NLR=_,H0IR\_=3/#Q$A(ZY/,B7GYJQB_OH9(C/7'O=-F'Z<*A@:DY'3\IE
M0I+[:5Z#6D78*&S5LR(]WR==?QPN\+7&C'"6OS/H ^BN7^>4AJD0G63;U?9\
M?\7\_*=<9#?9ZT3E[1U))NZYXI;!82'V@Y=MZ'"$W4'^9Z=I+N;NW"2\@FI'
M.D84XE-FDK>06P%UC,&8H%,LO&7I8>:/F?#R0+UQ,XW/\1&])XBBEF^.GC;]
MX/Y&FN6DTK=;Q)2ME,.J.P-N9L[Z2=GV2DG&JX(E%!.6T[GI/GJ77E*NN-B3
MPZ'"Z#E3"QG"P?FF[4MJU*U*:V"^05"HYO/WI.?Q1VT'?N>LA+J(1EY01M'G
MFM?ZHS> J>]UK/V:_B49Z.X41XJP<CJ(EAS\?>TO&QY=4L<ZG?PQ*>>%>EV9
M6_55"$,+X$_C/5]'H[BM6] BH6"&7ND,?X6EW^03FX\K(E38Q&/M3]S473NZ
MI-8%47Q+_%Z:*VNM/F:8Y^4/#^B;PZCO%DC7:_H7*8;:/@S8%*/<-!4YG0^[
M[CW7UZ[QO3\OS!H"M4=FY*L5/GZ9>%P&CGCVM+GZ;2%@>M7%1*D]ZIZS.:X"
M?LA\TT5M'BU'L472&N23\X,Y&^Q ([V#C.ZQ!9 _I1_(9KP/W/^E=J1TY7M<
M:F)!GA>O>+WMKP*E!4FS#NK G[H=OQ=]48I#*MMC7^""X3J?(:U4(/:\ U&A
M0Z_Z>61)_/Y83+:J2K> =C)#,,S<R>=R_*'GH"LL5]5@!6&DL?IL/7L69-?0
M$@7")[3(A@9V[^F,HR*=@Y_*0FH+N6'.,>E"F:9\6AA2Q)0FV ?)T[N:SBM@
MTS7M9U167%_^(&2LM@5O:VRS_D?R\ZN\C^M-) SGA;,AVZ8FY<_?93XNW1(.
M<ZI6U1_197($ZS5)+%GC!>4W#HVV+'^5AX=?H%SR%QX.$BUX:,YS!GV] <07
MB%WS;NM4<6CTBX"83+^_FB-XK318PS3=N*$V,3\]]$J%D)(!VQ3V]G2)4(D6
ME>!5/C%E/^;MK3ML_S9I+B*A22)#)$C@M.ZK%S^)8281K^&)P!V1V9),PK67
MD2HJ&RS?$*^I:R++[TNDO.UZ@4%,=:?]GFOX3&X$S[-Q8HI)Q1[4GW!"(+X>
M)DLXH/3;D8K(QQ#C7:I"=^!#0Z4"]3[JO2X"!]C*J:-<MW,'37?"V'./56'V
M .: PU<OG3[ V@_>;(!1:]_[=+F\REH^W@!$IGZ"?3@D^M=&S1IL6Y9B[T_-
MV<VL1I.\PFXS<DYMJ3>*:H^F4 +R;<S7\#\C.#H?_Q3Z0$0?2*JU6<&EQ8!=
M0 :)^U*)*M-_5"H%2=14XBH U>OYH<2?T#!V+Q.XZ2AN>!J5YQ*A"E1=X3YC
M)!$N9NO;+_"8TB=)W]!:Y^OMPDKBEFWQ9M.IDUGG&U2*'[0IX>9''+CINGHK
MSJ@[GM2.T#J)E2\?;VC$W0 J3 -=;@!/O(P]R[=V*[-[?UX_F/[<8PBD\]JL
M7)Y)/PIG.D%X8@B";#T?202;XJTP CM1EIGG]H$9_G@'W'>\[-"S#T9:3PPM
M5.)RH^K VJ8N*['A>N+550E=]U3XTB./BR&AEJ]E)#VS"",DP5G?@XO2/(9!
M @9V#U4O7Y*8YJ&[B*5)BHM#)01:2X?# FC"32?\ZO3= 6_SAW3]'"5U: P]
M_6]'DLP//BZ.\_JW#BZQW:JP!9TM]KIP3?Q+<AWVT&?BJ$:O\:7!_,]YGW-B
M\>P0Q#7?E2:><WDM1 (^&/8J/7AK9SJD*SKM8]T<>NM\=-#0S!',+^7T<<*K
M\Q?NOSL5.VSPN070;3L!HD.X/0F5(L.!@K\8:WL43E#\XU[<1M;NB^<^BE4C
M#*U= #>^YV/?28GMS2H&?H^;1AS,M.M-KTT1\VR=@#$O?0+ >RU&@//,'=<;
MP+LQ%7MT<06.=7/*#2!4S?P&(-EBM"KINZBF00,^(A*^JL):M@(1&J7MN*[L
MI5/7Y1HJ>18QL\89$%0?XV8<U'=O*[]_\9B[!F2+O<'[IS79JA0&1Z'C0HP:
M)/;$K$S)[2"[6\*.5J&_Z/:1]810+ZFJX^_> E4D1M<<X^,:DW"<Q3L.(\VT
M7OPSK\+?%34P!DEF[B2L7N5_,NQ7FA,Z'L&H%.SU?'HFE@O^\/W!CN27][?5
MB+WV"IK%%U1JH-PWK4'3M.E-,SK%\'6]E:(8ATRX*X36]6W*4*Z/:=5-VU[2
MYMK8_8T^&!L\WWT\-#O1<E!4"NA)D@$*T;"3XG+84Y@J(9L3D 'D4Z]L#W\P
M==P=-CK?-ZAZ!5+Y8AH< WBA9I,H(2O88I7B0J/A"^X8!DS;G]*_B]_K7V\
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M_;@"P.U!<V($!V2=<M VRW=D<W.=/I;;V.(:U"1IX]!R.C8R%G4QOK$ $+[
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M8"Z_RGJL%_/<(_>M-W'8YE>=_LJV$ KZWB(R;8VST)_/H&U/'4 ;&<C"Q2N
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MJ):G3GMH"78^X(LSK\1NFHO/J HD&\9W*"Q[IP?GO@UEU=YEB.IJ=%O:4^"
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M.=JL+Z2YCS-475%U$/_[/T$24DC^_;6Q\2R;W6.H/OH9(DY%@A/159UDVO,
MV/:>AQRH-&/^3)!3MI["H,4QG&G.0B)-(O[US?2)E'G)Y,\]V+]$DWD-H3U^
MM22:7I:P/Z:6_HV%#F-0YOX>?7G_K=2&])U$=C=W,<KN(C\Y!.-1R*_U /[O
M^)%%CB_5@\/2-<+:\C^ZF7!W';IL@F1((%,!XPP@224S4(=]=N(+\WQN5K#
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MAJV+1&KLQ2+2>-WE,;,J2+CS#2U%_\HX)OX!V8;!(-V<K$V][M*R,&7>9U[
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M#H;)QAU2>W$.SV:(J&VDG9_Z>B"S%M/IL8CIZ?]&:\C_5_17ZUM)#,?!P-/
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M^1@U%U8#IP_3]YQV 9V4NP!"P/I D+JL7$HFSD',8%0.MR1L1:P,,O/U# Y
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M-M_P=D6<GAP9R<6@":?CM[:=ZB/!97D 3N?BK"584;R:D1!:K--F  +ZVE"
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MH07F9C.N^!;53JR,11\L<;=Z5^T'NSJ/J" 8*]) ,%!Q0_A+"ILMKRIA,96
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M&"8KL1'AU'K;?)AF(C0 O0I(QWT@->'$$3D\DN7$-ESG5G4VMY=EZ#=-MXH
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MJM:,B2YD L,$OG@Z,)JD/6;;_,*8/$C^Y$L-C0E-%&Q",B:\C/*&Z,[&SY3
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M,Z;@BA(Z9%_XE.;R407M"5[Y**BZ>,TKQ@PERJ?'C.4)-#4H]7R#H=>Q8*Q
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M^.$I[/)TGL908L'3/]*'*9JV:S!:N@ZJ/9B)>PH<W#FMH19MT0,-<A]<^00
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MWU-UI:MO6%L:-%-5^: I*U?+BQ103V76L5V06G1.+^5%0L+(KM6Z+_F8T3U
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M#NT>X&-"' %#*]W3\KS(&=)B')18^;KCT31!_<DK)]M#[&H>%&"EZVXG6^7
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M(D$TM^+]]$'FM)JLQ?H90< 9_QQ!Z*<]:/-;O7G-!FN-^N#O6:P$#G6^>$S
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M$]W.^K> 1)TSZO[4_=[66MFIXVH(V-V/E&MU 6CN2II)',PIF^6@[!GS#FO
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M!+E%V7EXN?]\"0(:&AK&"PQ"3$Q";BI2*N[_[>NI$X"#BI"/T(>(0 UXAH.
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M($V<'X[J@58;[,5#V!6IQ%_?.]314YRD0&'RU90Q2CYM;@?G<?0)T+:0]01
MOS/AA4L!-,S=-"?Q:8,1P]_S_4^ *I;&_-39\IN'5[]1IFV\'DQ^9WKEK'%\
M,=%;PG0ZFIV5C<=[:_+-;5.LR;NJ/P4R7B2OZ1W?P,Q9"$6B ]9K$D> V("
M)/4)2;0_C;3"HCY@./R!VC-UC3)&!,:B_+C>_)2$('0%?29XMTDU9'G>6V)S
M4=!1%99>KF/4^_:,L^?%L>K3E<TMH2:O);8K$1T*]C^&W%)T%^77A^G)FM&I
M</.R-K H@U[HCU;IA*M$??Q1MO6>SZYE,9*1W<C"DX7[<:C K)9CXJ/$1P4/
M_? "T[YNDGLX2MEH$*S Q^TDIUW756DZ4?5^I.=%=#4_P%J5)T>>J.\6]5)
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M'D9SI@ARH9JZ>N,5O&Q*/_TN@8G<GEQ80!"6S'.;T6MUM,S;KBGIB9RL<5A
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MA/F93/F9S/&L+B7H;TO0)W '-"QVF"26)8:S)(D$K\HI.R<[MK#,GP"&>$\
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M]\5=Q=DT3LSG%7EF>05KTC;4ZD^X#X/%[>YNG\,2_"Q,BFXDS;E42"V^6;B
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MX/2(('_[\Y])__]Z2&/_ U!+ P04    " "5<&)0GQC)WVHC   4N0$ $0
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MLW!=7R-%40&)@['@0I%N$R K#HL-LSJ5_E!<_'P"#+OFDJ[(G_\?4$L#!!0
M   ( )5P8E!8TD.5S"0  'Q) @ 5    :6]N<RTR,#$Y,3(S,5]C86PN>&UL
M[5U9<R.YD7[?B/T/VO:S^II9VSWAL4.MHT<1ZJ8LL3V[3QL0"9+P% LTJJ@6
M_>L7J(.L T<"A6*AV!/A\+18F8G,Q(<$D+C^\K>7=73VC%E":/SSJW>OW[XZ
MP_&,SDF\_/G5-CE'R8R05W_[ZW_^QU_^Z_S\$XXQ0RF>GSWMSJZO/ET\+$C$
M29.S^X<)_R<^^^/K]Z_?OGY[]I%1-&=DOL3GYX*94_WVD_B_)Y3@,UYHG/ST
MDI"?7ZW2=//3FS??OGU[_>V'UY0MW[Q_^_;=F__Y?/<X6^$U.B=QDJ)XAE^=
M<?J?DNS'.SI#::9QA?WEB46E@!_>[,M24HB_SDNR<_'3^;OWYS^\>_V2S%\5
M*HK/@$)*\I<6?6'3NP\?/KS)ONY)N2"B$;TWFWOO["SW'Z,1?L"+,_'?KP^W
M>VZ2D&2S0FS]>D;7;\37-W_?(I9B%NUN2,S%$!1=H11]C=%V3GC]7>$4D2CA
MRF2"T]T&__PJ(>M-A,O?5@PO?G[%G9QPW[S[\.Y][ID_0"6_<5/\EJ-OC:?H
M!2=7>($9PW/^QT62X#2YB.=W!#UQR*5$?':VP:&0[N8\X!GE_HI(!MW)XC%%
MZ3:E;#>EUXL%GJ7D61 ^\/;EQS27 KN;N?_G]<L&QPG^R&/&@J1^3#()]Z7^
M'4V2CWA!&:Y!Q9\)^@(<S9AL1'3F\?@.\Z!4BKM$T>SM.Q>M]?(<E;RC\9+'
MC_7D*2++#)FBR5W2]9JD:QRGB;Q4%_V=B^K+M,^\ 3*2[D37-M]&_1JG+JPO
M\R0$?1JH*\XY$#SC))?^N%VO$=M-%I7?*BW@O5L8L!#?W83*/Z=XO:$,,1+M
M;M<;1%BG,8!]&;W61W]5X4/Q2QJG#,W2LCU.%A?/7#9ZBD3\3U"$'_%,?.DZ
MINE6HFN?PY8H)O_.FA]OGH]D&9,%F:$XO9C-Z#86T?6>1F3&R[KAF/@'BK;X
M,P^W6X:[UJ&_LH]@//]EN]Y&8O8T25>8\4"V87C%1S%\&":& T=R!%R/(SCE
MGE'>!:>[^TA\CN?7_]J2C:B:(SG#7/X1G"!:;BS&Y0*?&<>1K-<4?)P&P;;8
MTXS.4\%',/LC2LB,$UV1:,O;X!><YC. >\P>N=0N<[]>U'!T">^#$E[47,09
M,?', ^YD<8F2U4U$OSD9"!#J6]UJ=#Q,W;PJKRK"LRG%9(=_]:E]5:H'A3^B
M2&2]'E<8IYWU; BKJC?C8VS1"7(!=_SO6D'X)<7Q',_+HH22;OIG!99%1G16
M*R8224S*Z@85I62YP 5*GK*$X#8Y7R*T>2,,?8.C-"E_R4P_?_NNR%K^H?CY
M_RJA3<2!E,Y^6]%HCEDB.KAT5Y;)AX0X^OD5E#PEJ?"$F?S-4(:WE>$-*MK.
ML\#'LKB8IHP\;5,Q&)[2+Y2W-SY8II%(8]_&?#K)!]$-]_@56CC1E]" 7&UT
MF]$% YJC'18?HC+O)R>+*7IIV.K(73C"FKONI4HLNV!UAR$V*\OB_ZP%LO:2
M0T'Q)A'S82'MG/ P7_(O&%UK*Y5V=4/%CI_.V@6=I?3,N@#*N("?7_T@%K:^
M8;)<I<4JUW! F\^),!%%]XC,;^-+M"$IBD1>B\:9U4UL@1E*. $8@D60K;$0
MT !D%CAY'PY.'L0 /,;S:\1BL<1:@?X5YJ-ZTNRFX R%ZR ,H>+$VE@ 3B R
M"YS\& Y.*C#.\EL-5*@^%VYI?PZUQ@V& .JW+:&HS7>&VAS6"9T&FQ0P#C.X
MSJ5\X6Y9N87#WX;3?#Z3F++,2NG87_6Y<%W[\RDAQV!\3[AIEQI@,P5/F:4-
MT,/\L>9\DS;RYNBF17@CI8KUZL2&.H<Q:-^=+]3]2M+5Y39)^?2%E9KM1 5L
M&<-Q,R99<NU[>B!7$(VJWO.[V*MJ(/E( "@Q:+!?2M&A)FA#_U)>Y\=-NS36
M8N16&>D.J10571"X;FI-X::I %U0%^D1E:@ $R'YFE1RCW:BQU'6NX;H4.E2
MHH!KW&P4K+JE<H#CI6-&+1HOIYBMK_"36&8O,C#9KKO*[BU%0'/A+6.='6^H
M@.GB @".+,47\/KO<.!UO=Y$=(?Q \ZR-<;>!$Q?^!! 'RIT;$T%P 4@,KQQ
MDW;()T>)#0MDD!T\5AP,!L %)K5 S!_#04PQF*KLS]<.3=5T]:&IC"Y40$!-
M@P]-9:* .?4 9J+.T3/K9=5QTLM(K;T71ORR'WI5>G)E9@%$VQA:*6C#JSL+
MV[35J)<3W@)1J? =17%RPUWT$<7--68M3:/"&S3!5K3.%D@%-_C#ZZ!XQ_J,
M64KXU$^,W'7Y0CW=8?"BH@NNDJ$V&;* *AG ;$FH*P[JO+?ULD%-5'B)A?S,
M;G-$5ONQ''X5/PZLJF(,*?M64WSX5*UL')_I]@6G\ F4@D,S?VIQ#-<&Y=6D
MF#GI+:TUQ)I<U9RI)2^\E*[8AY\ED)*5B"#/*!*;Q"_22\38CL1+Z085&YX2
M)C">$('B8*T!*C")X87N_>DCCND&)F2?"F?4/P58PQK=]1599PQO'I%MN-5U
M8FJ"PGX908 U:+1#7X\R]O F#_L3P3>4/39.!#^EA[\4XQ4W[G)$8\L=($BZ
M>4"/(&O9P'3[\1U7\YA=B\H<(6U% ?5AE;:NG'YK:=J1,8QI=[OZ(&8HJE'!
M&EY05!X';P]1(*2%5_2D(=6QA5&*JM9+"&]9\(;$W#%WY%DL3:0H7HIL4 '5
M5IW#B L'F8A#JG<KPQ0U;Y(1WH"VO/IMOR:EJG<S8>$:'6%(]0TV2%'7.G[#
M[I"_O&G:?\?_/L+);,6A]:' M[]PH7J=0($WZ;>B1AK?!FL\-3T<#E4[\\O\
MX')4^I@M4%ZAM+L7:NVS)DPT4P?ILB'V^>"#L@5))<VD_>$PX-I_&#"]57I>
MK"&*A"Z)M]S7A]C3NO^Q>?*%CY_J4O)EF<\X7=%YY;ZO5O;LZ"7ODW-'+'FX
M25]Y:Z0R@&LHR@F?C&+ L\;/.-[BLM*:*P_7+\5!(='-\__-VQ<@=)"P/XWL
M(&&XD*ZK8NK#'[70+BDM/['L4$IXD[!+FF3W+A>7^C9;D^KS?LVP^7E00R:+
M3Y3.LP5US)[)#">/-)I+3-(35HQ3$0X'?F6-4 O3:@!O2LP70=62CK!Q[@$G
MF#MC=<4;642S) 97XY[/(N*T4+,5!,$<^Z 'X BSGNV--58X2&1XX>L19X/H
M_'&$B&M\,5^3F"2I"-G/6(X5.Z;RQB0@4YB(<3+9"!JHU "W=!G&$(9^#S)
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M2\EWKW_&Z8K.*T>8&@UB@)(+W!VUY,'"DH.55_P?24IFW6NJ*<G=\P=)PX7
M(:!*??J]%FF/:(T(UIVL"._(E(,Y-_Q/LFSN(>XNR+U1[07]WJ9<O3ZR)K4W
M(J2M$JTA$O_G]<L&QPG^B&.\(&D8PZ.66M*FK*2JM5,)U6"Q[ HO,&-X#K,2
M2+T_RFV@'MSJ&\Q; HKLC(<Q-7Q@8AKR>"RL3JFC!QI'8K6%Y9=YP@H)+PM0
M:OZ8HE0<[[WC15EBRX:U@3 8ZZAPYN -5[3!B@+N\SG^( KD3@</ CS7U5G'
MW.>;'X^$-4D8<;F?UT \M,DU> ,MA_'4'6#B&7 O,ZPZJ9OY]?W,VJ*RC<VP
M(H)M047?# 22B;H.(37UB, #--D--FKAX8V)2I7SN2<4, ;J!F"4U&,"#,QD
M1\ HA0/WB 8VH+'JFJ'C&9/00+,F#^(8\(Q$)),\68@^9<L;\VY*KQ<+/$O)
MLR!\X#W-T)F4O3Y[]856LMQ5(RS8,Y;745DP^KO(1UYJO:+$VPVS5.3N)MLT
M(7.<71!V13@K1^$,ER]-@SS13;365ZZBAXL?#F"AO3JV%H#@VF67@'G5RK 5
MZUC0_T)%J-MRLJ<(%U$VW^!Q2=?BKXS*'?].\BT:@:7\4VP)75S<<W.P5*WL
MU0,:,D.LO%RA>,D)RB0,)[I($IPFXEK;'%U11+\AWOX=6I"#=(OV8R7]%%N/
MNWM[;CM6BH5WO QB(O_QDEM&6GN1W)@M8%]E/D54*YW3,VBKY1:8_'.?K^%"
M=+H2?R4T(O.\5N?_W.9K]^+NU^T3'Z41Q'87Z>V&NH]SW NQ0*U+(:>([L[.
M[KD5N.A7CGU&%L*+;%:-HISNI 1%#DT)*M*BX9A%GF(SL71DSXW"K$UX*RRN
M<YSLTEA/L^6:K(XSXT+6*8(=ZKH!9KR%&F6$'QF^[QFAV1'"2I[; =HZ,1:H
MEHLY14 #'-8SEN4:%##^,"X49VWP,!!S0;!*A 5ZVR).$;D&1_6,VG;I9>#U
MDFL?=F#QN$),K"F(=VP."539$S&]%=!Q"*(KX!0;0R<G#S!8T>E6-J2 +F.!
MF"G?3NHTBC&)LF@<:E&GV R CNL9\&HMPMNL!;'GHMQ^MM]H4B-V #A0H@7.
MC1)/$>YV;NP9]49E?)[J[)*H9]OE'9GQ/H>;^0F1#ML.3*)LDNY*4:<(7*#C
M^DZ@*[4([](MF[7<ZQC-TFPIUS$\ZP4YK/LW!9TBID%..])J?E.'<MPQ=.SE
MHW^2FS19?,'IX487\7JS<QBVD&J!79#44P2RO3M[1C5((9\W>'9 >+'^=(49
MIYO?QBEOD&+>F[,4.\O=H>XBWGX%$RC^%,'?P<''6=D$:E9&_( N7-[;=I*W
M*AQJKLO.A8Y2FMX9S_X$4[537[Z!G@UR+LWG)LD.'1%L4[3T)LV^Q'O?<#_\
M_9L V/;L32B>_:OA-4_? >G&TS#.(+>4[/-4U<E V\V'/E$-UD"VE3B0(9.O
MHR#^!.J'&B,Y\.$^ZO!TH,-^ .)R8&/H"*V;P#L'9[A03TF?DPG)UI[S&8TA
MA8?W6)"B,4Y51XO ]/HP.@WB )%[E%3:VS$(3ML'@&H[!9T/ /6*%L/N0$LN
M/7)"V@/HCA^;/7[V*%+OX?.R[;3+&C7\:(]S_^E<1C]'R4ZF=^WJ5Y^=K8,N
M(2>.K8\,.'#JPVIH!P/<0ZOMQG_[\*K=V!_2^12%_L -G8[<>IR%N&W3'6LN
MVS+M\6;<=AD^Y!1&VVW [$6V'JZNLL<(9B]^[ AU5QW"VW]LR')IM[(Y\<+R
MEN%L6.N>HH1O2'//1JHVG 5TSX#"@D[GG[S*U"-S/*><W!'K[Q23/9)=3RD%
M=-S/PC+9U0&N[/:X'?R" +\0-5X X >-C0/^7C:G=\E1-7?/NV>B])*ZG*(X
MG:P2R$=><T>J$@.Y4Q2T'](9DP[2?>^S/1GLNOO2)YZMM"B#K&HOR%!7?[=6
M_46^HW@)EPS_KFQ+O8IN7[#J!20#=>/1(R6UO_!C*"I_9L^XUZ:C%)C9:BF#
MOXG%-:[H>D-BKA?O2BX8$W-&V0JH V?;2V;.X1_$<H4$[>(CZ3M9EII47X$"
M:2#;#3WPZGS+]$^,)AHH2HA4;;,@"L>TVO::2\38CM?K-\3F1GO-G"HGZ#@#
M:GKU"J5=7*!O65E!C89C+B"\5&U;?4D204^DA,S0"0$7=)AF_39 J$WM THI
MM33E_RA_*X;AU=08'XT6 ^D$G$/MLP@5WKP4,2JT^G>J*]:]:!+>!0TM.^N/
M99I +Z=6X;=)/2HH:DUU1553J,^=[_V%TGP3:ZWG?\ )YHY? :(D@%L3 +7<
MHP*4E2LZA"UM(>'M,6D;1^G\&XDB'F,/Z:_\DW'V8V95SHETK*/"&=P)KB#3
ME@ \%3'>?(9ZHMU#ZJ)66-"3K8IY]XSR*6.ZNX]0G'*07/]K2S;K]E4BCMS:
M9)J&^U0 Z."K?I-J&BUD_4TXB;6*#88L@8I2B\7P\@6^<&>?5>B*L7KNX4<3
MG@+RLK8;<5ILL?&TM#^!EAITAP,\2VY_]#GPT^!=X-8_M#0P4G8"1UVF_OL6
ML12S:%<L!:'H"J7H:XRV?-:$YT.O37._YLF![*3Q,]<%\<'UE%[2]5H<'J"S
MWU8TXOY,KDBT30]V%W!WYB\ X, _6#" ZRKNTI@Y>ZK&;>VG@GNX@.$."=K5
M2[5P8JV'"##6Y?N\O]E3GR6L(<_X$<^V+ N>^4:@29RI?(U83.*EN",RRR5+
M1Z(=1)2]FI.(D:+6@[^Z0]=-B?#&7+]F6N#YQ3-F:(F_;-=/F$T6A:69[HFX
MLRA%\9P;U("N(W=1"];<H7FII:*L*W+BU7M(Q3M<@W8% NWFGUH[MM1!M&++
MLL/K?GC@8MD^)Q05X2I3_2)-&7G:IGD@.ZQBWJ.=(-;L?_,G\' FH[/ 4>+:
MNR>[@MV'0CX[,,7.5Y":9?=;=+J+Z_4FHCN,L][Z?LMF*VZ"2%FZP-M:N W4
M+82?+NQ=/7R4)F"A7'@KKB ++VG,?980<0':%7Y*#X-8E^9BEF;3/G323K=!
M@'UXE!:@T\;GW=)^(+_?PGJ8Q35@K*$HW"JE&,RB!_R,XVVK-39_+G0__#Q<
M^]!YF"HUKX%9(D( ]L :WNA;; 04QY^*383-^E)]+JQO?PZV_@R60.JQ+4(V
ME@2M'!0?Q/\]\:[XK_\/4$L#!!0    ( )5P8E"YC5;JE*   *16#  5
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M2+F%HL0.2"*0><DEPW0;UN/87#I"Z [5MLSX$'J@9G#YMG\ Y:-4OJZ<:AP
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M^HH2O6B5YEO"\][2.4,K7*!.OK5A)F R=?6I- >FGU"UQDMZ\Z>L:O-I@*T
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MZ'OTG!1-*D^..6VV!X/1U-MVJ6A. %P^>L_3YDK%@Y]7E#6G1[MUSVZY.P;
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M47&^+0KJ3*BS$ G.=J 5=BN8NL*DT*+= ^80@31EN<]7XN("/>,RK7-2U4R
ML &I-,*'O-)$,:+1$RYP(F\NBDW^5Y%8#K![-T@3)]FP*Y.^A74$GI*^R15_
M2OIV2OIVY$G?@ 8FT*B*SIB$)7HS,!GE2=Z4AJ'S6Q5@<U##](G2](-IU-#
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M6T]2\.A641T[5@YX?*P\NHWC +FS\-5+WNGTV&^@XJZWF6;J7K]-WJAG0>-
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M]-H?_[TE\^>^B-R=K$- !2L)@0GB"]H=MD"3M,,0Y_RU%P$K^QESOB*H)WO
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M[64RW@& O!1;BD2E@CK_U4C 4 $YWHDQV7J9$9&+P\P=<\?U$2O+B?4>P4F
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M8.HPG.K]WVB^/[3\Y=NJH%%W] ><5^BU^IC5Y'[YMD1/](_34\/Q/5XB$_[
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M3)O)4TN\#FTR#=6TW4TH<$_6==YQ8IEE(IS)!?#<MVHW"L"KK3V@ #P*P*,
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M.R@?OY;N[?8[9D:8O]$-J/W??+$9,J9!*G9\E)'V-7UP61!KFL@/B/R (W[
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M]6@N$M(B(:V<D-;O:38DI$5"VDLCI/T>"6F1D!8):<_*%SJ(?*ALH4A(.U6
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M)%QN^5E]OZ^"LWQFH'.XQ"5O2=>W1"VGDW#X@#7S+>P@B'7>=GO/:%@WA][
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MQ%7-066>.>#H2-0UV29C4=6$UZ;D367\XTN%($C_,3"X:#U@1>EL]Q"$*;L
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M;9U7+60."L.#K B_(IV0I*1G&Y2PJ"MRP^.2Z\5?/^@]4U4]@K=4]:D':?^
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MG^BW_/HKC1[IQ\+F7O*X"TM'8U$8.CKCJIAJQA*A2#V.O-)@K&#\XBL[E>@
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M(!@DD:VP U[T89G:Q#YP*-BFUO+$M()-,FU*AWR%1!"Y"\\Z(VI12X1-4BS
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M2RWTA,&?'^;GS_XG010E7X.")B2E$7OVMV^\5"%&1TS-K!J(*7AJF2G-,@-
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M&\BV^K$,MA,IIXV.>6LL))&.:&;_=>?CLF\O/#;)[B&(G\KWNX;YDR<[)C
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MZZ1]Y4GU*IO.FVRDZT>4@-WZ.3$@AK!,&@+Z'?<8HS&*S_0DZ]*-A%FVYR>
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M3:QTB6_N?6:LHQ5X-HXQ@<Z*OR\TSRD]&<+ZI,7UZTF#_Q/"NK]9C$LJQKE
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MP1U:LND[3":<S@4NZ8#>U,0#&5DT[0C'=_O&$]FF6?'(GV:L6-_VGL&@S@N
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M C>M3TC5GO .QXQ)><)W $K/DP]QB'_-A!,20&-=/J@;NR)B:7Z^+-!U9\7
MO8$.]YY;[M&F7:!TZP\]A&FC 0)RK.P'HE?'@W.4N5?ZGJMI$-/K>]GT^*!F
MJN<66 M2Q;_$";TJZ!:LY*,..C7O='#%M=8%\M$-,&]6C.L;49..?.>M2=G<
M_\HK%!80^@D'#LC MB^(A0-/X1'QGOXL/FV$-^T .^B(V.G@BHBMB_G*JZ%+
M*S;VC:C9&"@!QW" $% X8$ "MGU!!!QXF@6![DNOD;OI\-.58.3[?;E:RCN1
MLE>H.0$!DJ9EV01,!EF>R<^QAK77Y03,4ZO5'N;+"&8G5 -LZ/@8SI&G0%!
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M,^7GL*$N28(=3:UO (Y\":XVM' J(&BH3E09YGS1_(ELXK7G)\$ST )#;XT
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MFFG-6.V#NTQ6,^TZ%(<[TQX<D?/%V>-C1A^C@I*X^;BJ&-_(UD$9B=SL@5'
MU=E.EX%/1QM:A-\L:)WP7R6"P_0G$"[WXK7NJB7'=TE!1_;Q:<I!UHCE__R=
MYD6</-[R?7_Y?K4&JSR$^)A:&:I]^!)[553AK"$"HG2B\EJ_B_I#7MC5?S]0
M)091 $.$H8A#DE^5.Q3EU7^?4+GMOX:#1.B%V#B56[7AMI&(RD^[JO<N%7@
M/A:M.,@"K2X]KW=%7D0)/W,/^'[&1ZSR;7H$2,M^5A%XGN=;Q!Q.83CY.[A<
M'+"-"O1J<KHW?F3KBU-HC+A*,)$7N*L'%L%@+BM8_Q:'J6W^"^/I\0<H;,C+
MH9THWM"KR8>MCHX65P]3'KU6^\LGNMIM:+K^S.(KZ)?XA:ZNV$0D>8P?-GQW
M*BWRS[MBE]&S;9H5\3_+WX1O54UR>L\7F&7'5KLPW=3GJ*:G)B?$8/ K:OS@
ME!D%V]VBVXS4[<@ZS5@Z*!C]/!_XYP3CJ7ML#607T4M/3]&C#XRJ> 6B@\#F
MY"DOZ6J3?/I9&?U06B5[LZ2R>T(JRT3([>^E]7!.0C\TBLM*JP/A> C%T/7Z
MGFZ?TRS*7J^VSU&<\4+O2\IO$+E*7FA>\'_GH.)GBJE!L6-G"DDQ;9P[*V8F
M! ,116OSBZ9?O'DE5==2_]H^82C9)$P*E&LJ-L1"96-5)$SVT7FF#GIQ,240
ME[P9% ^M$;*W0BHS)UTR!5LIA,(O327@FV!A9'KQFL\M"SN+^<NXY?L59\EJ
M\)=OK-;)SY9%_!(7K\!*P)VK4:7@PA6:'.('Y[#2<!8L3%$=N5_<WGTCS>>A
MJ*9#?@A5U2T.9:*+[U4LRJZ^7> RX*!J<A>H3PT8/(5KGZ[MGW:<D+W%ZE54
M$B6K\1^YHY-630(NRXY#8+1EW6$K3!AE(:]<$^;E]7R79>R_@"4>K-NH7--U
M0]-<M2.'913(,4P. :86;9M0I <(#*&,P =-I@AJ"V)V0[S.B$L'>1WF% N4
M@U6.ML,)J;L$G#C=HE>;T-S -XQ$4R;13\,-)66BK'>5\/?VJHTH^Z/"3%8<
MD(R+UQ@F&\>=3DP,Q_4Z DYX!K,&#(>+9B_3AV9/7:=]N16CF@;45D/1+%3L
MR\M[1,0IZ_F)?A05/,HW"([&KM8!D$*;E\.#VD.QJ[9'Y1/2FN]Q/MQ"Y7!(
M#YO%!\WZT JH[BI$]]O8/*:98%!1*)D:=*"J9B',4A!9A60JH!9.%ETQ#/-I
MR128:N3-'BAZ13.SK5,QFTB#8);3&L4N'/>T@CQWJ(P<SC.%H&AH4%GXYF%H
M%43O&I[M\R9]I;0Z8+,Y>I.1 WT]!L$3<'%FDB?'4[P)L<V^;#,]UBGSOZG>
M]0LZEW<W-^$)+#9G#.9W2. TF^M-<&HR\9O\W<(6AMD6@A#B]*@*\"6BQE&]
M5K0_O)SY.I85H\.2%\NUI,/0ES!JQ&])1I?I8Q+_DZ[NHY^?:$+7<9'?IIO-
MYS3C7Q-8 MH:&E5XYH;0=-K4M</ZS#(4F-!:&5_\-4OSG'3[$M:9-+U#$3YK
M( IU;0HD9*IE:E,L2G:1>>6*@Y+%-@QW1!D4'%*^$&Z%U&8"+B3\\TE;!O@C
M5!A)_#]V4<9RR^;U<YQ$R3*.-E<)F^YNRR($F+\M;(Q2MY$--"4R\.HP89M'
M 9,@4[N+M@-I>Y"+J(A"T1,;H FEQ'+<92)B8$ZL'\;Q^&* @S1L$8$3^)^*
M\=_I$W"F]<4,;7Z=FQIA9%7%N1]ER-)4"NTXRI_ZCFB2H7-EFBEA,@'T"I,&
MD#&#XWMJ90A&#L P$FJ R0#+>*^S(28[S', !+]*ENF6?J),B6CUWZSLOV#_
M)R_BY5FR8E4_C1^A!?0D:X(WIZRL(;ZX8N'?Z7M6]O% WW2Q];"HFI-?^.$0
MOY+*!*G_R(S08-;&IF%4\AK,1*#(7XZQ,"Q[9\8Z1O^$<O*"V(18'+-I]#I9
MR:*'(:=.2&.L?'>[-A=P<1\2]0 OIOGG7AB3@/-TPWZ=-&,SE1?:V<N7L]"_
MLG&7?'S/_BN/EOM'?]*R =O!J)+ <X"FA5@AN9FD($<'TTM4IST%[5GN;D?-
M2^5DQC\L94U(UWYH\R-TY@A%U@569;*+Y4NLQ+C?) AMWCZG"?\&39IAJ:4^
M@+5^>@.<NUE;$JBML25$637T[7"^9AL+5"UMK"_VY6-[*O,O=?-?PU$U6RA*
MY&L")N0Z96A4)DA6L?GEBX/IF'4<#LER.BPB&AN=29F01P%/P4*@EG;JY9-;
M84RY+NB:9EFY!Z-:-6;UR9<X>H@W<1%3Z"LI5E9&Z=S0"IHT&?EUF,9MXH"I
MDKGE1=.E%)[ZF0V?PG2ZA2(U=N@3RHPU%&0*8V10K"X6,?FCAH.,;16#(UX,
M,C6 ) &G:)^\T:9F'\0)(R6?+9?9CEID86C'4>+5=T03%)TKA^D5Z!JF'"!C
MB[I5B$D3#!8AWTV&4<9PG0TQJ6&>9\6K@YP'=8L'UD%F$R WX$SF'LS:?.4.
MS6%DI<LHXU>/YC<T:][0*Q\I7L2;74&A+ZY961GE*T,K:&)@Y-=A)K.) Z84
MYI8799.RZJT;D:^T:%:MF)WJ+>!0E,(.@$+9L$:#3$*,#(KUQ"(F?^QPD#>M
M8G!$C4%&;?KO.7%"QMP)-\?Z9(XV^_J@3B!Y>;VF_&BD_7Z?VZB@MY2/*2LI
M3-Y*LS<USM 6IO"$R-BYRUQM&PQ0E>S,+_HMRL,ZBJC8\;/..3U:L^7*%C<9
MC S9@U2L19/ (M4C8ZL24;*,SC.77&1VZT!<$FF8XUO:=)[:<CMDP+> TWP0
M_-(G?*\$"R/UGRV7N^UNP^)=71=/-../H3/Z1).\_3[\)0GXZK&]-=&2LHTU
MS'4[<_]N%Y^MXP$O\EEZ6)P_\?V'.8GY <6M%5*:(3T[Y16ZH4C5-,3*E@*G
MP4:Q/&AN6+IF:!NC?WJY62NWC\4QM\:KZDIV]=]M"[=("(EYD)5Y[]0+HV"X
MH _%59(7V:ZZ31NPKTO=0;"%2]8!<4N*V(73C5E*E]"])@HCBR]I\OCAGF9;
M<OVPB1_+NC.81*N%@61/B'Z@Y+L_Q'UE&SU4GF9!GI-]3VIWTV$WR$XE!@N.
M0=Z)='H%G(KPL0G8FH0%SC#2PF7"ONGK'_&*S7M?:+*CGUY_C_XKS<YW><$R
M6I9_>KVESVE6Q,GC'7VLOH;R/<O)%L<+RO86\=;";&-P\^KDU'" ZV*3O/3T
MI39 'EY):8*T-D[XWUHSI+$3VDN0TV$M7B+#P)5TH<S6N&2];%JL(:B=Z#G?
MIU=6RF_3Y'P3Y3IM,^L/V[PBZN_VP?S8HR.5,G(^X5&\Q";L&7PI0%5_4AHX
MX7/QS6[%Y>C^1UK]D?Q.BZ=T%9PL&2(2_DQ>#1*CA_%C4P:/X65QA" GS<'T
M-'N)EU1\D='9IHR%_=?U^K8]]Y9]Q3AE[7)M.87O8RQ+F#[PI LO*D?RAAX@
M4 *1_?9ELKV<H[+>N\BCZ^"$[%U4%5Y[^G;EA91N@A-,!WP2BZH;^$J%%\^=
M1)RQO\_Q"+A^=Y4;/ZZ$W,6^+-S(7&[:<A+IK,K>7UXNK\WY\&DDX,V1 D>F
MS,"M*>[PZ%BA-7M:7'ROD%7 Q78S-U%ZDP#(A;FU%JS*#>GGT7-<1!MNDU5Y
MVW3'6H?[%.#0=4._W^U A2.0)QSZ106[5]?4-FS6_N9Z;4WL=>Z7UI11H"T&
MBEY8Z[RD]GP0+ZEIH&:[J#?Y!36Q.>O%O3E?3I-[GNO5-'4$3@@ ?2W-9DD\
MR-+ $YGLWEESR*8P4O%-EC*]+5[YW:W%6;*Z_.]=_%P>?:I< H=U&R5<73<T
M?5$[<K/V#/()TQ" J473YJ2\I+DH9PEMN]"6>(%X$1(=/I8R:JLMB-D,\1H
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M]:R7?MB8AH#Q@:K/&D<O47CX!0Y.F/"F+UY"#TN5!M?3V9VY>$)J]_PJNSH
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MUM@)N\**._PQH[1).+ZN4_'ZMT;<M]ZC72Y0D,6/A9$IZ)., 0$.< @@XT&
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MZ]9>G$;<R1A[/L\<@LP&'14]UB6QTVHSIKVA'\DG,66)@_N+5N#O@1X@_RI
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M[__?/^?!Z%Y$EXBI6?0YVU!RZZ>,SR/P[@>.] QQPSJ_U7UKH#>_T&43=OV
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M\,"*ZA%]9=$57U.OY.62G-D=1QQ<E+*FT4S<L%3UA@QF9(]$:X:-_FDP0/>
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MU,3"'/%@C<8!W%2SOS@_!FQW-4V^-@]]5:OB7;+V%U"YI7!_X.Y2PCH"R)!
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M0I(=.F4 4HS#8U<+YC1G4/!1[EF$D$EX>7L6XF>=]BQL#0)F#J:JC/@I&."
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M-T"*4S\3).EW;[4.Z1D?=?';CU\NWE^_X2Y8T<,)./(_N1\F\KI^6NXFR"G
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MQ5B"-:5P?5L)Y%!-V((7%JD-9@J<Q6F]VX+!H[1:J485I"DE[-LB6(9H==[
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MF)H=%%LPH3HK5^4<]727HDZFT>PKBU1?/_!_)9XO%LWK(/%#EFQB^@"+8P7
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MI8+^UAUD.P[HF[WZR<MZ]2W9#LU7CVJ-\FQOWL!6U%G\8QGX2U%V,8WI _M
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MS//%N)-"E+2Y/ JDK)O&*^BC-HC7X&4.K/EK Y:TGSL*L(;H4GI'$^*'36]
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M3'(GW-!6XT)I-GJ9C%9S<;8%MF@]>F-@&VFYD0HSY'(GX= F88YK$B!".QL
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M67>XPW'JU3P,$7=1SNRVP>U$D"-Q):VA8^FR=1-'=+/4C P!-'\E )(X$=8
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M)I#,WI)9VW'(2+11F[S:C :$5;F?OP+HPT'<8#XKST?O*G2")B^J\TMV^I*
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MI80(8I3R$$0RW8?BB,%?/\F:$UZR8%; X.%59-8Z?2Z?U1RSY4HG6]D2@\7
MF:S]YTRYYTRYJBY<O>WW2-JQ:,Q5-9 &FZ[#K5Z0Z>:)"_JXY:9MF,';<2HU
MSV7?Z+Q/-^-].@^?/SCOTXV^3W<5I-N;"']-7=B1.PHCWXCCDO;WWQBD]MU"
M9[;=0,\X?0[^!R=7>9KA'>DCC*TV/D$=N\$@F%0%NOY:K%MB,/?7I'1U2"^?
M[OP\4'L8EYM4\3D@+D/1\S_.;'V]M^?"0,VO_SR8$ RPY\!\W<H2C+H8/I*U
MS=GG6=B1SVN.FUG2Z4SFA[,8G#>S'-G,ND<9]0D?$OP:$A?Z\O E1:O;>+%'
M"6G0>'.QS,+7,B\]VP_59W!ZJD.9@;U'PA.\#C/&8R3]#_4#X8T/]J8=_4;"
M MTZDX]R)<4SX@WF^J/"X"2/(UPWHI>NXV48H=9C*\]X6'\;LPK6A2-C55C<
MB2986H:L:R6L3\?=Y.8G:SUWU.;&0@NT>_<8@I1[RTT!7%N?'(6_HYNQC^%F
MFRW61*^+-$79Q8[&.__! I9RN?JI$'BYV4)2UW;3X%5!NC%65%-.9@UE%FNR
M:@SB#8V(*#3M78,%$=<3C(1XMM!6LM(T>):)I!_9[ :(E\L$%<AIZ?DI3)?T
M/>+T(EX])&@7YKOT-GY%E86[X![$I :])I/Y=@835IVHDVB*JO$XFV/)TEKZ
MWH1Q0"P:;ZYP*ID!V*3,\;]+.E_ PRUD8^SO"N3Y*V2=KHI>LKJ[5EU5B%\!
M/1/$3/IW@F2YK6S F2F5_MME#F*Z6(&L"D=-B&4&'1/#+;IW@EV^;6Q@MB6-
M_DMF3F 5GM<%E+G%I=PL8T-4(T7+6/B49&KQ]<TQ^@SK(GX*(D37O+QUGX2J
M:@@NU6SQ";/+- #ERJ+Q8IBIM1=G,[E^^W<17[]1A?(PW99A>4?7^RX,7L(H
MS+JI%W6*-N )+SIKS&I:<#H@PP7T_D4OJFY*]44,C1G/=8'I&["7T,\:ZRJV
MF@[@$JET'MMJP_K9!>_B4R5X:;#GX W1'4+RYQ7Y,>RY&5#RX\FTC'RVP%:T
MU%0GV#*A[#VTQ?%$BA7F[6X?A FUQQ5Q\C<H/>;Q*AY;>MX&\3/:[7$2)(<3
M[6U,MP<_HVQ+D^-Q3TQ&JZ#>N1BA@MEVF]%;8Z*]DA'4\/U!L?Y]P:,1JW3#
MG#@R]8+<*\C\@@Z9Y8KF("1"T42T=3 R:^M4HR37,(*2#EU EK8[\^(KU"JR
MR\>\VMF7806U:H2.N;4BZFM+1ZJ8U!;V7E,#T7)QV:+U'HE\S<UBKU6/1FR7
MZV@KYL_3%,R*\E(KQ)\PF(6\!R+ %F81R:Y0(V++=6@VEE;$GT3A*^/&L&(I
MP>#(+.4].B'6,#U@,FOT/BBJK^G%LHP#>P@.(&1RZ+F8[-%[CT:Q!<SBL%>7
MYY%-PIY6*4E6V_0\;."P"68&&4T!S+R']0#;C3;V @31#XNR?1V7XQ1=[_81
M/B#TB*)BQJ@.SB +*6!YL7,K*N\]R-4L-(++*ZK;6M049ZN=.1TE>4OJBWA5
M'R*H(%65D<B] #+R'KN:-C/ND "%\#S,"K:!QPMZT2RMM!WK0NC+F%NRL)B6
M,;9E^\$J1A\1G='QG/91S#3';BKBU=NB&D_U.-'4PQ)E3)";P43*C7'$]/RV
M,]R4G5E*O:!RXAMO.X2V;4S 7*7R ;><,1D ;0];XJS%@U,T01(7ZU1B+=O'
MJ$-&&5\R('<6@(%X"!$RL)<[*SA4<\[%\I]YF*"+UR",Z 84?1$XH$]M+/.D
MD)81_ZM9NL["I5K:M0$7@@D\U$J@45<@29'/2U4"[^,VB(&6"*W2&])^5$&R
MEO\<9%3'PV+-U[Z+[V%<3MGF]+CXBG<C5C.">UU)//>;>_V=&(+,^=GA(0KB
MC%B!9I'?4Q+9@"XMR!O+!05]A;6N;489P0656XPUX>RW]Z2_"Y<H3HLMUN+P
M@!G8I%B*AT1>J;G $&2543#(J]EB, D4@)#[$FJ%>/!S[5Z#8?2IWT0P!#[Q
MW0&5,!*W/=?%NGSR18I6U7(<[U10SE?,:EIF# ]44+=^O(<CB9;A%M+><M'>
M:O$6O-JV,8%>E<H'Q'AXNUL+WQ0<L%LKK,3SA2I'Y6-R!=W=6@ #\1 B9."$
M;W";ICD1D<PH13J@]$M,D' ;TS<?PU>ZT\'.$D37BZ?KF<7+<HL]_2#R)T:K
MB^&#C%"7:T,_!)UXVA8 S18"N;N^S@CR^OL\3;UVJ4(CG_%S\$:C<NB3CD1-
MNO\(R<LVE$UGA:K.QM=^9,9N1KJ(MBC>WVULC@Y7F/@T2493FK-.%>64C'FC
M1^DK6L':FQZS>[7I!V XLB*MNUN9RJB>DUB)L@&4G>&32>DKYL#:FQP$F;5Y
M?Q&1[07]&B1)(-ZTXQ,+O>03L:_@4['!>'[JJ4+/;R+6W8LX$[^@U08QK,$9
M_  E.H.@L(2O>%2VALE!45BKQA:Q8X/C2<M'M,^3Y99XNHLU<75W."Z6>WQH
M2@KTD<DMX#\P8;8PC$MNI1I;OV[!DFAV]$GN<+QY1LF.^B87\:JZ3<$-$=,I
M6C6/6E%/03O /B;@JU:]QLT^MX#,<FUN8Z)=$#WD+U&X7*R)4L1: #]46$[@
MDG+*>8I?7<N,Y:ARZA[C-I\EW-+N6>9%$*W7P0482.45F %$0;8PC4U>I1KY
MT%W9L6<N$05N*I1>N)2?A9.J:(GQ%O0L%U4IB;G36'Q(PE?B<3Q$P1*Q KF5
M"@E1V2\T*VA*;#(>/OL5#TA);AVD1R^[Z'"PK78^:6^OG47J*PSA^IO=;6=5
MIY-J>YI8[6?\A#)BA?Y#*S<X*=]DNPF6K!0E^@S:L%-BX#<8]6UE$*)*0N@D
MM7!KK0ZWE7;,FW:LF[=XUK:-"1RK5%[C5^>4R=MX67A8YH!X66$E W)*N+!/
M0O6E_Z>7"%Z#J PE(KJ%2S*@T0\7\:K]0X/R 24AO7/0SAQT_59%VY&_;(-X
M@QZ)K:_7:]2+M;53>06(J2MWM&-9;0-(IYQ:0(UX$>DPZDN'-MD_37:W>?:>
MJ3O#D$"4?=&1B%!)=D9X1?G;QS/&E6TT'<HU[CV6*+^.K2_EGO+]/BH,$T14
MOYL(?[V-USC9E7A@WUU2+%4_O XM93'!+/&527L_!.'JGO&6%_/K,4%LYZN]
M7J;8.EBF6J<KP=B7N3X[;#U/T=9*@\^&"(_@E$:X1^ 74"0*#L!*G_,8=T2=
MF>[T!E'(M ;F;"V[O3D'C>IVC^,E^>OING&\8FRE? K39833/$&<6<T4NX:3
M-HR=O:C"<+/-%NLO*2H2XRQ>LH#@BRQOZW7L#3X]%%;L;_.2KAO@5,<<#N%D
M;0@PABELTI;M062HC$6TXA#9K'D%G',\8HAR95"F(X]7#V24C;/KMSV*5V%&
M5.\=;,!+U"<:D!*S@*VZ;<S#$R2#YQDI*N6:.A&?*J=*7.;9/<[^@0I'O#?K
MJ14[SF[08K, L::5S",9+HCG!T9$%:):FN9H]:$WVO8_'8?5YJ=90$^@[1@#
M9;.R 4<4SD#H$:WR)2,G!?MC$T:-C_,!$D_CD:#4J&Z,RZG.+.8-KQVAF]?#
MJASC.3 ;+?+<>O\2"]M*:-^"4;&#PF"@[QXR0UQM&&JQKD'##$'B&%1H,@;+
ME@&?6T^"#@UB_X_O>[8C+?1[^8WYJ657]$:\_A4ZFJ=EV3 -T_TV2'9_6N)=
M6?<560WB*%S1H+NC1FE#Y8?"YEN4A<L@^M;:(0Z@?>N3&P@4JN,:(:F]$RLF
M2+OJL1#<_6A-A2)Y2$PLF5-I+M["[G8"GZ!2A47@B#KWP0Y]PKL@[#I<,C*F
M:DTR<QL\C7Q!3R@.<5+X*C]\^/CG!Y303&^?T>X%)1T%%$O5"V5H*6O3@[1A
ML*[N[3F#5T_AS$#YN[97R!;\@SJ.V$6$(.H6\1!!0JV'PJ?+W//C1,&L@,'#
MJ\BFE"6U)I^5X4R63BP6I).M;+' 8N!ORD_^VJGK8_$65RR"\QGQW,Z(VZBO
M(WUH@'/1_JMJ[ TV71]=O2#3,Q07G,6&G;:ES&_FJ8@RAHMVWN@SL-'G?8N<
M-_K.&WVC;/0MDDT0AW^4;12OGL)-'*[#)7V@;KG$>4R[VP..PB6] 6EKQFT*
M>=J9+"5^:%ACL:Z&A2 Z;5IR_!FC/"L &>)IS;/ARG\9$.30]!<G'2[SE P<
M:?H)I<LDW%=:]D'S3!!Y&?73[TQ2EZQ=S-1E;=0SBV$\;:.T1ULCJM!A>605
M3#H4$P_US9?+[-TC.,K &9<%%,>;! P*BS<C:FEX(YV HJ>1"Z.*J 4P1)UV
MSV:P*V\],-CXZ4/1)*6D=^\6+U&X*5C2YU5I+K/0<G>CBU?ISHZ8J+$%X=PN
MS"DC;!%8W5@!<MT.U6(-]6'%K&Z2RW=5-'3O;YSS=TI@[/6[.>N1DHE[>Y&2
MBS[^0^;S\F%0B^$/75'HZ0\W  )"?-S)%A-;W*1G"7:"&:_?*Y<3&H)9SN+F
M!ZAEL;X5NCLCHOK*O1%P/5X[U,>+FQ8=ZDH&Z30/H.Q>U75JPF=(Q?>XY:1\
M75WHTI#&PDJ*=IUR+O_6E63#7=:!Z?L*1P0EF-['>T47]/V@3;6)$*_NPB6*
M4WJHL$D0TG7=N?$R2A7SCF&'<3E&U6ARL7>:S9%8/AAHE)18R:VA8B@B\! 3
M=<Y;]40IXY@41/#89WA"F_(<^924@&X5%*_L)M4.9[TM^1BFO]M;6Y2"/J(]
M3HHS5\ZJ0D)6N]%<,GLKB8Y(@#4$O 1';;=&#FG;81V=.VL%3AW%*@'"V\\M
MP>O=/L)%AN1+%*-U:'$/L/DF<9'5*PN3SM#*]3642QYG3H62]A+@TPFI$'"1
M;5'R@(E$1TGK=I,/"T/9U!G,M=E8=#W4 8*-&:SK>X!E*?*7:\O@L?-QAS9!
M5+UL0<9;JV-2?392NC]T^$?Q$A2(JE/V-"ZIE+4V,A4-]3G(*&*Z@O*&(:4R
ME3V 96P.,!IMC?6,T1M/X%73$058I<?#QW_E04*$B ['$(Q/019\B8-\%6:$
MC:W>TI>KL;R2CB>:I2O0*)>V-J8()>4-*FJ%(#9Q85C1;7*L:9#VR*)8.QU;
MH+5Z/+BH!**> U+?24!J2^:BU0_\;5XYZ>E.J8!T/M&<"B89*1A3+('G.9&O
M@R2FJZ@'E#R1L0R)\0FDKMI#2CT?E*H99B2@2H4P?#5F0I@^HE<4YX@^9$G7
M)%3C7\-L>Y6G&=[1G0\1:O4*UXEK%0O/!].#S#82Q%5E\CR+XB-:HO"57LU*
M91"7$1[AS"><$W2!YA@-IOSZ/<_*^)P$*U3O.%>KFO2D[Y?X)8PBM.I9H /8
MH6RJ]M-G,Q^P&S+E2%U!7[HQ,DY.[[(0Q? F#N5K/S!]VS$1T<\'XZK&&=?]
M$(FA_ZJ4$ZBESW,OUD^!U..0$QXW*OB$\P$HV!RC;5+PZ_?\G9A'8@;2HO0U
MMT^D_T5X3[4O4JBGB.E<*)0X#J: $O-!J[J!1AM0 8*,D>AXTIC_+(@W-+E=
M\;A*2DP29N@N?$4K)GK!]*>GZV3T\T&NJG%&PBU C JU?_44M2WS/.4O:;@*
M@R1$Z2(I7/G&C>AFGN7K."OR&#&1;90GZQQ$G^=\>L@81I[B9$5?U*JG_>1O
M3SL%SM-P^2LB?I@5@?.]_B.C//4*/N6LL XTR'@(Y@M0'[>XD^VX_V R4;C1
MRR1+/LWB_&>O)<5G!-1AIAL+O<I2U9#V]94UJEM,>!_$2)>1-5+>L,GF@UR@
M*4;SLWFUUTCT]6CO(<%[E&2'AXA&A\4KV@>+Q:\8F:K%ZGL9X&+S0:ZFJ49"
M,ER:&MF^GA#>!&'R]R#*4<,FI^3#[)6A4IFJH8!EY@-H'2.-A&:@*#64?3W#
MNT-IBE"9!4H\+@,HC]=5!)3S 2O<("-!5"A #4Q?C^EN=WO2 XO$SLFG,-WC
M-(@6:YK#K]B#+#<E;^-EE-,[<MW=RM(<$A=XO!IJ[WF,&N;3@<9O@+%\]C$$
MKSNLKX>87U(R55ZG6;@C)NN^R<+^6+52]^-\$"Y4>R1P=NNL<>7KX6(1Z'U)
MYKA5\^[XHDX#?5ML3Y)N1Y<=;-=[ (<Z08@.A_G >+@!1\*ZEF!UA_#UW+*?
MM5'LYX#IN;DT9^R#J!IG+"#+Q:AAZ^LA(,T[+ :J@**1WWG&8)0;8"3X,2NN
M;Y;X>O&OF[<*LB94*L/)'C;[=9N.D<8:-V&BU%#V]5#ON!GY&04TZ<!I5UT,
M9^5RW8UG>;GYP%K76&-O0,O%J>'MZTGA,8^Q[,Q:3-;-%3UCK )-,=J9-:_V
M&HF^GNS=HZ^-/"8)CLE?EZAQXB-&J&[QJKG4B\\'T0---Q+2U:6J>X"1 T&'
MD_L4SVF>4_OP,3V/U#Y/RRU:Y1'=4N[DWJ /]2TO#S0!'U$M"E)NRL-!/.I%
MEAZ/^8R/)HPXUB),3S3/\PI)M*;WO<(HS]"J&"DU^X:,"ZQW\+F\F_X!-*2=
M'L(73C^?D5-]!*\;U\=Z-\ORC.91W-$=G-+6U>U(4,<QR;K3F\RPGE\7&\'D
M(_<[,Q)[GFKI- @1;S[)B>AA\!)&Q44SX!P%+=B;EN0%Y]=-E,TU^N0CE\?S
MU$TG58_7*J[RA+8\$."P8CUXRXK-$=Q*IAH=VC)I/$^UQ+U;H7R+1OG^S"QA
MK&R>J>_,S"??4FOZR7=Y1"^X%Y??:<Q6@K;TB9=75)XIW.%4P1?1Y\9R4'2X
MS:='F#7L%*Z,CI">)XHZG@F7*Y?J9'BUB!_1DLQ[8;RA^PG<C5C=XMVH '#Q
M^72/@:8;.T8 +)7)3%.3O^-]O+5O^?"I(0GW%6\N1>-F?8_":M: .@\-W:8/
MUR%:T8W[,@-U7CR9E"=A=OA$<"B<H4VPZMM(@Y7%5\'YC8^-&J@]K##JK3,,
MZ-?G^2G-ESA!013^@58_!V%,78)%W!U(>$C6*EO?:5(KZRI6AY@ !$[%"F9R
M'K)8/Z/='B=!<CC=):3*HQ0*3A.L>JL@'5:N0M>@@4!('E:?R;.%J9\KQ?&&
M"+%;O$3AIF!9/JQX?)C1LK=&+S=(GQ<4$S6NGSCU6. )<U2T1GH*^:@A*] ;
M&_@%K(T DD;#&OJVNSJ[@G9OYS/VW'4B#N(K2C)Z4$IU%,Y&(-I3YD81K<-H
M4M$2"B0)3V<>M$J3K $=\J\N;,A/OS76%*?9X(;H'43_0$%2KS/JSB.#U'!>
M)\@-X>4V)(U920&R0^JT%D81LG.&EFET%GM$<YS&FR*?3O/=5A%(M<JVTB2!
MRSH,PB%6@().L0[/ QE8VM9A&X>Z@RDC$\A!@$\I!\]0JF:1(5B5UF0R0F'B
M%6 _>X'E)5]?H'N<\99^,&)N<HPVL0-+0792E$+P,C-*>K',PE?9 &*.86\I
MJ<_0VO "! D>P6[M44<L2'MIJB^ YTO7C@E>NB9X1,1<X3)#J\(8%_&J\\N7
M.,RTNLDH5;$[D.&J_.M:8]IZ8*<S+-ILCCVN=_L('Q!Z0LEKN$3L >HB*F0I
M B"JAPC_0*L'E(1X15^!@UPT'*>>_G4KT_5XU0O'M;)^%S0NEVM;%FR-BE&C
MVR7DE,(<AQ7EU+N(O9>0+M[";DY1&5GO^:PNF76E/N%=$,8 M=J$ L5J0G-0
MN_A]B8+G+5G*[E&>A4N:U_8SVKV@I".WG+"26T1H;?@#6!TKZ-@>N_C,Z;@E
M8CJ&'V[9JJTNBA7P+K<I9=U^=:W/4M^BS .5*6=HP%#.L2=C6.S,KGS>/(.6
M/ V;T_RD>!?&Z#9#N^[L :063HX-:@=\ZY.,#\&!GD5?? V257.U3T.%2Z2F
M:;XK?U/> QK.7+ ?-(2Y8QVS#R7.YI Q@T*Z]%$JWD[1$&GFM6O4,\=Q64'-
M\I GRRVAH#>WC/<K S4!.]F@FN;0X\R9VGCW&R3:&%M&UENXY^RHS>)*/H^4
MM>\6AF_X@/<0E+=L1)SUC_ CBV>AQ]R8UE/D'261!K\"*+NY51T-@RWENT1K
MG*"3K.2/-"O2+-V0W\.-.*;'$#=&D@@M;A;CZ^6HP*;-U0VUYXK03?^@5?5L
M'%8Z?.*8QA_7MB#Z5VF,+E&,UB$T XHVIQ[>-3CY@_6A9M+$N4:U\SD[7*\1
M/1\]=?#'($/TZ"9>AE$H#]8TP:I_ JC!RA^8#S:4)LYUZIU->K9/E>Q$Z_)>
M/YG U'.U:7%AW/I1XN(/LH>81Q/4BE5Z'L)\TIO>\:W/UXGNU3R5/N(H(GX9
MW>D 0EJ740_5ZHS\ ?9 (VEB6[U6C^.=KXA6P0NFT=VOZ"))@GA3Y6:A'7I)
MDQ#%FXM-@M"P^Z^<@R[%ZCF+_H%<CD$(FES,G?N)1+BG"7;8GY_)WU(B"N5Q
M0C<KAF:\"@!&U*W VKC_3"I8K!MB,D)WA#2543@TUO3JMTO ;@IV=(Q>Z3ID
M1K7T-+V+T<$O0[Q!,=,$!CCI#3IM3M9F<ET(8).F:T_OBB*5H2 #1+&VWV9H
M)J63UW\3UV89F$ XEYWFW-IG]PZP+C/BU(!GR&-M!\[0D!X<4&)D1.\STAS0
MFXS> <;YAIM\.&]*XEI4/$\7IBK7,1&B> P"W\:?26MO"<,??@VS[<]/_ZF$
M]J'L)7U G_V<>H8A(X_67_3EL[;-9[P7?4++0B?"\U^IDO^7&)!8F[B &5IN
M>?<&)JMO<#\#U_>^.IY>,UCLB6"!K3T:8<9Q>\3++3+AN#$8Z3EN+49SZB7*
MAIO:<6M)8NU%">-3#NFZ>9 <",N_T)Y\CU^#) O96W CUS)X>I'4,J?N8M;D
M%J<2B9C6GILPWM$6RPR74^9/5-&'=?B'XJ: D3H&=S)A'>^KB\'-;;&#"84T
M^9B%W>YUD6_R-",<_UIH^7S5O ]LN)LIU#6XNX'J>E_=3MW\%KL?2-BJ&_[5
MTXLPXL-H//3LMMUZS,J*+ "JE?A[D7W$> H,BRWHIA(P+0]M4(X<#EV8-ZKW
M'>>>_;B5C!% <^?0K?Z4AOS'9(C.D@*LB_5CF/Y^>:#_O2&2XT06-:G!H1,N
MJ<1A'H-*'V?8A$5''';N6!>+E23U/M7,F)/*)*/8%+/26(IX?AEZ:#"L:8C(
M+U=K2FP< ^W+VD/=FJD35Z,-U:R11[YXN:@U9%[FQ)(H3>F@:3NM=2GN(]KC
MA"86YR6TEI#5\SN7S+K;LUAWA6LTT>6A^@C(KJ+#I9\Y18V+O8P.LG;'IFS3
MR?/ J;>3XT2M/C\'E/_*@X1,:-'A^'#OIR +OL1!O@HSM+(\?O2E:S2"-$N$
M9ND*,LJE'1B$A#(#[ZQI\.@-0$H\K T_NOC 9LS5'I,4A6D/54I"F%PW33Q:
M-=\A)X[/4[B)PW6X#.+L8KG$>4R'Z0<<A<L0I<5#XHOU0Z/^3R@+PLC><&;T
MD?>JXYI].+Y$IB&>U@;$SV&,Z8LUM\7)0)JQ[L@):2H[<&@F3<.\^!J37K<-
M]XQ;:<QO=1NVO]F1F9DOFO.U*_<Y,[3FM,:SKWXZZ ['F>> 9O<J+ ,NQV3U
M<5FOL+_'8>*A$XO'I;:9F*Q:YK)W"*4__CW2'2C&>-W[O;))X_?IY62.@(PO
M35D'W-K5EY9@)=SE.Z:\S&^G6;SYS5JW8=D4BT5O=Y8& ]I%.@7]ZB*?@S=^
M8[*^U8W9_N9<8PI$%S=FNZ#A5Y2G-DQWYN0/)PRCU#-FJ]",9TO>K "<*1O%
MG7E[>_"*[8X3G"&EXZS<[AP(D7A(\!*A57I#8'&;ICE9.*-%\A04Z>.*;,.<
M);YZP<H**@6=:?JCY_> $GJL%6S0Y>&AZ%X2, !*<N A+&EMY-!H=SS$*NT!
M!UY[Y8S :W4MJT:1U3M]1$L4OJ(55?@I?TG#51@DAQN<E*?3-!]>DF^Z^^8:
M19M/M("+>H;" 789 D.U:CV/ 9%/AGC Y"%V/^Z:X5LJ=7B^.23UYJ >"M"[
M$[#3SV9AVR4V>V;!,+H\&LF("*P&\CJ\2/5\C6:J_Q1&>896]R@K<V^2";\8
MA<^';>_CL*V1 SM(8@*0M$9 @9#+PQ7>[8AJ49"FS =?=<OW,YM#RUM_1_7\
M..SY<=@Q)]CSX[#GQV$=]P'UAWWM)V-5:W3O(5E#,W;M/A2J+M;%LV>,*4E*
M5\_ ?#IK.C9%84],7()Z0F(0V%.G@&8A"^=R/>?[<7;M?;<WC/(MC^6:=,;-
M'J^RT_9X^-M;R0CTBI(L) /20RVX" @@ZI/3):9V%B0J6L(@(^'H^5ZA?"S'
M@#&Q,Z'R>!8&9?!ZI]X*=!XUX*X(JO+W</BH5'VSK;I\PUI&@VB[?@N;UIZ^
MI1A,MX7YK7T_SORJ^1;'87J%$W:L&.=K_0!K]ZOMVV;]V42L //JV&GBZ!7V
M?)$+ZT!8C$3./,%B68Q:;5;O?9H #%TFIPIV=89/EZ9\]Z9XO(O4PI@>F-_J
MG;SV-WO#/_.-\>:U]\O#B>8A.!2Y>JCP)PWBU4,4Q/?!#K%GD1&K:$8W&*_"
M6J-<[_81/B!4.%2+/=6%.1E*Z2KS".CLC5YCH@+#;=,9W$:0BHY_ FGT)R"R
MAGS!]I^R?$1IEH3+3+13(*2I@_W9-+-%*,0FTZ"3(XGGNQ#LZ1=/,B%UDE(V
M)3E&CAF7X)VZLB(WRX#KVF&O_R");5>5J?,=)_8=1ES[%Q)BMU3FA-N :$4*
M.Q >T]Y-_A2^ABL4K^CC\*?(Z([:*D6.D?Z0(M8&$UA#8BW5V^.)L*8R5A52
MPPR/BYY1LBOS*Y+O*3$6].2(6U!VB,0HZ#X"M<V@B$.5>FQLW7.V@G]%X69+
MO-(+(ASI*?<Y]4L7ZS+NGE[Z6-W&IY#[#L3T"E?V52WL/M0&F4,1;JIU67LJ
M<40O ^)=0+P*'[ %44X10AR6UIX#-(.48]SZ'4Z['C?S6V6\SC?W$2%21A$)
M'5;67IT; 0$7KT$8%0G3<".*:(LCHF+*&D4T2[-0!"GM&<Z4#3($B9#*K+TD
M9P:KXFD\S](LB%?$8BRD:I4%.5^]LNZC=(@QC+I>O:JL/<$V]6A:71S3'D\[
MY95'U&-Y]]$ZU"BCC:K'Z@:\;(:S(+*-6J)N4NSR!U&E9-$[+[(L"5_RK%2_
MO_W?.!WH!D498UC'41E@Z#[0C9M-$?DFZM=_7<SX;@U(G=9!^$.>++=$-7J0
MI0-I*3,5. N8S03*4'.- 6-!W16$?_(V (+C<U735<_U@GG*LM)B7YE?VGTL
M#S.(&7^97UF]/:X3<NN"\]&U"-LQEE!Q-BP]<G)A"@[<M.PZK!]\#:4!1@/P
MMH)!27_$=7#WA&>3[&=0#(Q2N(:!H!A9??J[M+9#D8RG"QJ:<F2D5$(:8LT_
MS= C>D5QCA[1$A,J6N*<6.A])!;Z%*;!9I.@325EA016#B$(:645,:DU986/
M0%=:0AZ*YM#8NXRC]Q1Y?5UGT$/FRJ7'?ZE:_H#]$]IGA3B$Z8_T#?O+$&\0
M^[+)R+5(WJH>7(N],'1-6 D>335K\DZLNIJXHA=3!XOI6NI>?44_H66MYT>J
MYP6=\/X;Q6@9&.YLX)H&=SA 3>^KTZF:WF+' XBJ'P<Z>%O6>/=;+#-<:OM7
MJNTC)HL?P_U.7L7@#B>JXGWU-+"Q+78QD8S6 EZ-]ZR+?1)&M8ZC>(_2&@;W
M*T$-[ZM;04UML5<)1+06&SRZMSA*OX)48MQ'?,^]2\'@#GF&S#XV??3UB"[A
M3U3-AW7X!TI&\PFY=1AT"AEUO*\.!C>W$VXA0TAK >/&N]=G@I$M$>]?B]5E
M%!^B8/= #V:"99&I.XBXV="GK71P!U2K]'WUR $-8K&+JDEM+81>L<^F3,73
MR^"@.._!&4GZ%H21&V/9@;#[<^$-*5MK*'L#XQ.;O<67#0;C:N"@!+!W]\4$
M79&'CD1L4;T^&+G8%?$;M_$->DGR(*$J_L5@YU+AK].[8/S?4_?2L+BU_@63
MU??49^:=/>59?S0'#B+)@!MB+K2?./@&#XU5:3<-L[(B\YEJ)?XFH /%=&%8
M5%3;NB+.U,@<CL[DA *]T/:0X%6^S!;)$TI>2==DQ).)2$XOB#-(;"A"X5X)
MP7YI3DK75HE%9\[[.@V&\6J1;5'RB ]!1!^/8CI34/)*!3FYS=>B):V E=5M
M]UYN#;3KRCE[?B5!V&<QO!<P;=KB6CWLS.,V_XD%,#RJS2MLALZ\RP(:C3\'
M_X.3JSS-\(YT!\:DPB>H;,8BF%0%FI]WL6Z)P9Q0I'1UQ@D^G;D)I3SSX^W/
M<[Y6 O:^6NMZ<I-BF3+M+L=E2/M;CY'G8[^@:V$X7-L&[/,L$H#P><U_W)>.
M8&JC/HN=OX^K<+2]X^2LAI*++^?<.9"WNA+EAD#I"L?%W2BZ154W+.=>EV*I
MX[,+P%+FYA=)E?4E_ >4K'&R"^(E6KQ$8=E.Z05-%X3V99O5Q=4L,: "F-&T
M*K V5JGB!D]@X/:P!Y2P?,O"O&36CELF&4VNWY913I-;7*0I(O];/0=O:OU)
MQ '68=@<9M0C "8:"_+LJL<XX1@R)WS9$]/'697DZA$M4?C:2TLB)JKLR"/R
M"4T@1;4!P^/NVK6$>K#^'$:(:!&C2N+T@E@9]>$!IJ\7TW)ZGT"CJKXV?@ 5
MN1:,+]&N<9KUD-#=LM6J2/_076(,90.;#05L?,*C(6.--2\*ZG<MS+WN</?H
MZW.0;!#I::M7ZKOR1D ^86?H8Q'ZA#&PPH,'.U8-KL5K Q<_3XBT0?D($6,1
MI+>6AO%46S[+>/H$U#',./8B62:,:Z'/B@/^L+E]V)0^*_!*3#/5!#Y.V)>)
M>?L4I5;(?PIL(Y('21;WSMC4"W;F=4A!GQ"H;9#!\SZD1OTLW$Z<]8$/3N1#
M 2C5IZP^0-\WD?93E*?$OO5[1X6*QUMJ!X=RYH8?OO4YI:="!L"1LG>*)9A_
MHLYZ2$C+S4NJ]CE3Y_O(U%DW_:GE>=8#4)Y>E>53FG,'R3HJQ*N+-9GT+\.(
MT&]^W:*XVCR]33F''HJEZLAC:"F+%Y7DS8-UU>_>+^)65<1*0JOP/*;+^$0(
M[V$CS8-" 4RVEL-SX:=*L\H'.,^#[VL>;*Z*[L+@)8S"[""9$4%E.G.CI(R;
M=F@G=/^C-[?J%898AE'8^DP+:W8\T"SLJ5=8=W,HA]9YGHL5VLS.K"P1Y9W,
MSU<XS1;K^G;3$XY6YRGZO4S1M.5_QGC5O-1&$<"=GZ$%CE.0O(#)-!]=))-6
M> UQGD8'P12K4JBEE[R0Q2D5W%)8TP;=>51683GRPBHZ3YZL!E+H>*/-G'(Y
MWLFT^4CJI8G8/A'7+\+[*J'+ [%:G%V_[5&<TJ7O>2)]#Q/IZ;$R(E^8H3NZ
M'7=+A(XWX4N$:&![EK+>:E(O6%E,I>#Y'2?#>IW?<8(D/#*1M-%$OD;K%[VG
MRW;E1**KX1?,'0E\.&>YFMC@&K.A5LXK>#T^9,!2GKX$2E\>RAOZ]%55QF2M
M4;)J *62+EKF)"/-!\',D:)96FXA=FEK5BK7..SYG?FM/O)O?[,VS.BV$Q:K
MUQYC%"LICOG;S#W? ]$9*_#03@1N@ZX(U/[*5;^WF59_^!\R_RK5ZDP",9-S
MSQTGH8Q*$?DL<^=$8IER4XTXNHU]M6H[C9M61J',\38,J(R;=E#17T5OJS<N
M5-H0JRG=O6(!J*J,\!=6,<[R=E#X9N$_<'H)^V/+,W, ]_SAZ4N*UGET%ZZ[
M\%<I(AT$FT7LI35E-Y5P N;JVLEMVF(MGEV;+#W/,"28]7Y.<*HPK[;(Y7-J
M1>X5E)@ZZL.H9F<MH<_H$+I8+O-='A&;K"YV.,FJ@RPXJ"0,Y##C,O +># [
M#( BMP)KF85&!^=-GN4):FHK]J9-L)(#%L#*16,R!+Y';]GS5Q2]HL\XSK8*
M4XD",\ ( &'FXEX0'%22L4/9FN"](JF(LE$'(MI\/2R&^O\@"ZOGKWA07^GP
MT.HB1Q[OK&>P;6>S0QPEFK&;R-&:5 ]?TX*XZ/>%DLM[[ T,^UGO#Z5,\_5-
M.7K?X+Q[K#B,B79_*)F\P^[ L)[MWE"*9"UOI[7.0&B'=X8&$_W.4#!YCYVA
M;SWKG:$0:8PTH*[O$:EN0@S8+0)493CIT/#3G_KF ?/TI_NQ=?IS^N@@((3R
MRYJX6]A:]EPS<\CM;A^$"3V+7*Q[D"W0'#&RM"B6JDP++N4@9O0TEH$)S%4_
M]ZXCX<_*9_+"(V;-0_@N3\\?OE:*V)&%.8 L#:E1&NTPSN6^.<2]]5MMU("W
MNUZ^0U//IOE\.U;[%MU(MV15Y)E_+D3R2Y(3G:H$&^'Y6NQ[N1;;;_FK/$GX
M,6I@^OHNI)S>W/JJJNR*4!*@1YR%EH2J+7B?RMX=1;#I,53)SKU#607%73<>
M8VNGHV(PW,;'^X\WZ*@1&Q)BVC8P>+1>P0.DL#Y(>.P]/T!<9%N4<.W0G71
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MX08GY?$=4?M3DF\Z&-0I6F?&5BKJ&0H'V&4(#-6JU9\O'8E\E4^'>,#T(79
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M EC&.T3JV&(8*($U>KZA2G66 E%,5%F;1^0=U$#:#L,6KPK/-V#O4)"B+8X
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M._I#.,VVQYFS[S3=;)"\GC_!;-*F(WH=(WH;,^Z(([; -#W3K (:>37<>L-
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M2[RT!\KC6JISL!'6I'ZBS_,VP?EF^_P54\W2P> '\U4='N1\9]TA5.TZ7=<
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M8]7VP7I?9(D9H<4Y=I,7=_!NJ1I@&'<>%8T&O7<*DHMU/U(NSP#?;E@"DTE
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M71@<%S2V'X+I"WJ/,UZ$!XRX IV,V)J[\+3<HE4>H<6Z$/'R<!4%:<IZ( 9
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MRZLO[TM"5@6;/$E5WV6U,[A7W?Y\C!Z_OW@7=@Y]P084PW#H'$&IP(6U0M.
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ME/7'F;D5K?H'%:)6,4G'?>.B;">6,'AULQ%/_ <QLC9\V8)/,>HQH3#!1K%
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M627IQ%,5(1& %\&!^UL)>6X4QEVNT6P:<*<KY2;$*TM7,XNUBCX(RF+[( U
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MS]1=6'N:K(NS]36PWN/P-AF[B8,;>B@^H+T<\%95 ,))XKG?6"Y@44>16"X
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MD"3N/829K)!H.E,:JX"5:"!NL6P+EFTQ@ZO_:U;LLO*-D?RI.0[K=P&.:R>
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M!/'8$8\=@,=>KT]A>!&8'8'9$9@=@=D1F!V!V1&8'8'9$9@=@=D1F%WZ=<K
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M>&AI8FET,C%?,2YH=&U02P$"% ,4    " "4<&)05I,+&D\$  #"#P  #P
M            @ %#&   97AH:6)I=#(S7S$N:'1M4$L! A0#%     @ E'!B
M4/TT>T]-"0  !SP   \              ( !OQP  &5X:&EB:70S,5\Q+FAT
M;5!+ 0(4 Q0    ( )1P8E"0-UBZ2@D  /T[   /              "  3DF
M  !E>&AI8FET,S%?,BYH=&U02P$"% ,4    " "4<&)0J#,5'\T&  #R(0
M#P              @ &P+P  97AH:6)I=#,R7S$N:'1M4$L! A0#%     @
ME'!B4(1PSE/0%0  !F@   X              ( !JC8  &5X:&EB:70T7SDN
M:'1M4$L! A0#%     @ E7!B4*,L0S8VA04 ,-]&  L              ( !
MIDP  &9O<FTQ,&LN:'1M4$L! A0#%     @ E7!B4 3ICM),(P  32X   H
M             ( !!=(% &EM86=E,2YJ<&=02P$"% ,4    " "5<&)0R4;T
M=XM5  "Z8   "P              @ %Y]04 :6UA9V4Q,"YJ<&=02P$"% ,4
M    " "5<&)0_HA%'?P, 0!HMP$ "P              @ $M2P8 :6UA9V4Q
M,2YJ<&=02P$"% ,4    " "5<&)0NJ 9.>Y8   ];@  "P
M@ %26 < :6UA9V4Q,BYJ<&=02P$"% ,4    " "5<&)0OOP-M#.2   RT@
M"P              @ %IL0< :6UA9V4Q,RYJ<&=02P$"% ,4    " "5<&)0
M&B&^01*[  !Z]0  "P              @ '%0P@ :6UA9V4Q-"YJ<&=02P$"
M% ,4    " "5<&)0B=4!JH;E 0#\K@( "P              @ $ _P@ :6UA
M9V4Q-2YJ<&=02P$"% ,4    " "5<&)0M(;GTM=M  #JH@  "P
M    @ &OY H :6UA9V4Q-BYJ<&=02P$"% ,4    " "5<&)0R5+5.FK.  "7
M"@$ "P              @ &O4@L :6UA9V4Q-RYJ<&=02P$"% ,4    " "5
M<&)0%*,*N\&9  "XW@  "@              @ %"(0P :6UA9V4T+FIP9U!+
M 0(4 Q0    ( )5P8E "-I>];'P   :H   *              "  2N[# !I
M;6%G934N:G!G4$L! A0#%     @ E7!B4(M*T1G)FP  &K0   H
M     ( !OS<- &EM86=E-BYJ<&=02P$"% ,4    " "5<&)0K3Z< G ! 0#D
MF@$ "@              @ &PTPT :6UA9V4W+FIP9U!+ 0(4 Q0    ( )5P
M8E"I]&LEHG$  +5[   *              "  4C5#@!I;6%G93@N:G!G4$L!
M A0#%     @ E7!B4$D#ICRZ6P  "&0   H              ( !$D</ &EM
M86=E.2YJ<&=02P$"% ,4    " "5<&)0GQC)WVHC   4N0$ $0
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M&1( :6]N<RTR,#$Y,3(S,5]P<F4N>&UL4$L%!@     < !P ?P8  %?=$@
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871295248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements and Licensing Agreements, PTC Therapeutics (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2018 </div>
<div>PerformanceObligation</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,122,599<span></span>
</td>
<td class="nump">$ 599,674<span></span>
</td>
<td class="nump">$ 514,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_LicensingAndOtherRoyaltiesMember', window );">Licensing and Other Royalty Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,205<span></span>
</td>
<td class="nump">14,755<span></span>
</td>
<td class="nump">$ 7,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember', window );">PTC Therapeutics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations', window );">Number of separate performance obligations | PerformanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | PTC Therapeutics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumPaymentReceivableUnderLicenseAgreement', window );">Maximum payment receivable under license agreement</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Payment received under license agreement</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones', window );">Maximum amount of payments receivable per drug for regulatory milestones</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner', window );">Royalty percentage received on net sales of each drug in Latin America from PTC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil', window );">Period before PTC pays royalties on net sales of product after first commercial sale in Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties', window );">Minimum revenue recognized in Latin America by PTC before paying royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | PTC Therapeutics [Member] | Revenue [Member] | Strategic Partner [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | PTC Therapeutics [Member] | Licensing and Other Royalty Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | PTC Therapeutics [Member] | License Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | PTC Therapeutics [Member] | WAYLIVRA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | PTC Therapeutics [Member] | TEGSEDI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CollaborativeArrangementAndLicensingAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable per drug or program for regulatory milestone payments under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumPaymentReceivableUnderLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments expected to be received under the license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumPaymentReceivableUnderLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time before collaboration partner pays royalties on net sales of product after first commercial sale in Brazil, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of separate performance obligations under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount of revenue recognized in Latin America by the collaboration partner before paying royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage received on the net sales of each drug in Latin America from the collaboration partner under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_LicensingAndOtherRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_LicensingAndOtherRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_WaylivraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_WaylivraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_TegsediMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_TegsediMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871731968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Commitments, Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Option</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use operating lease assets</a></td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:OtherAssetsNoncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 17,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">7.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">ions:LongTermObligationsNoncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease cash payments</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Annual Future Payments for Operating Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2020</a></td>
<td class="nump">3,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">3,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">2,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">2,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td>
<td class="nump">2,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">9,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">23,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest</a></td>
<td class="num">(6,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">17,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 3,600<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember', window );">Office and Laboratory Space Adjacent to Manufacturing Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease', window );">Number of options to extend lease | Option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Term of lease extension</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember', window );">Office Space Subleased to Akcea [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease', window );">Number of options to extend lease | Option</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Term of lease extension</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | Office Space for Corporate Headquarters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Operating Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Term of lease extension</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of lease</a></td>
<td class="text">123 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_LesseeOperatingLeasePeriodOfFreeRent', window );">Period of free rent under lease</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_LesseeOperatingLeaseAllowanceForTenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation', window );">Initial amount of letter of credit</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate', window );">Letter of credit on third anniversary of rent commencement date</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate', window );">Letter of credit on fifth anniversary of rent commencement date</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of options to extend the lease under the lessee's operating leasing arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_LesseeOperatingLeaseAllowanceForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allowance for tenant improvements to the office space included in the lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_LesseeOperatingLeaseAllowanceForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial letter of credit provided to lessor to secure lease obligation under lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Letter of credit provided to lessor to secure lease obligation under lessee's operating lease on the fifth anniversary of the rent commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Letter of credit provided to lessor to secure lease obligation under lessee's operating lease on the third anniversary of the rent commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_LesseeOperatingLeasePeriodOfFreeRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time in which the rent is free under operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_LesseeOperatingLeasePeriodOfFreeRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_OfficeSpaceForCorporateHeadquartersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_OfficeSpaceForCorporateHeadquartersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6888285184">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Commitments, Convertible Notes (Details)<br> $ / shares in Units, $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CallSpread', window );">Cost of call spread</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 52,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForHedgeFinancingActivities', window );">Purchase of note hedges</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">108,700<span></span>
</td>
<td class="nump">$ 108,684<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from issuance of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 56,100<span></span>
</td>
<td class="nump">$ 56,110<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread', window );">Conversion price per share, including note hedges (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 123.38<span></span>
</td>
<td class="nump">$ 123.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early retirement of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (21,865)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,300<span></span>
</td>
<td class="nump">$ 35,200<span></span>
</td>
<td class="nump">$ 32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember', window );">0.125% Convertible Senior Notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 15,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.125%<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 83.28<span></span>
</td>
<td class="nump">$ 83.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Total shares of common stock subject to conversion (in shares) | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange', window );">Percentage of principal amount used as purchase price upon occurrence of fundamental change</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount of convertible notes outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 548,800<span></span>
</td>
<td class="nump">$ 548,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Unamortized portion of debt discount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">105,200<span></span>
</td>
<td class="nump">105,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">434,711<span></span>
</td>
<td class="nump">434,711<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying value of equity component</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 105,800<span></span>
</td>
<td class="nump">$ 105,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Amortization period of debt discount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember', window );">0.125% Convertible Senior Notes [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of outstanding notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 558,700<span></span>
</td>
<td class="nump">$ 558,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember', window );">0.125% Convertible Senior Notes [Member] | Borrowing Rate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Nonconvertible debt measurement input rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.044<span></span>
</td>
<td class="nump">0.044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember', window );">0.125 Percent Convertible Senior Notes Issued in Exchange for 1 Percent Notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 439,300<span></span>
</td>
<td class="nump">$ 439,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember', window );">0.125 Percent Convertible Senior Notes Issued under Subscription Agreements [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">109,500<span></span>
</td>
<td class="nump">109,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember', window );">1% Convertible Senior Notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Principal amount repurchased</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 375,600<span></span>
</td>
<td class="nump">$ 375,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount of offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,500<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price per share (in dollars per share) | $ / shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 66.81<span></span>
</td>
<td class="nump">$ 66.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Total shares of common stock subject to conversion (in shares) | shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange', window );">Percentage of principal amount used as purchase price upon occurrence of fundamental change</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount of convertible notes outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 309,900<span></span>
</td>
<td class="nump">$ 309,900<span></span>
</td>
<td class="nump">$ 685,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet', window );">Unamortized portion of debt discount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32,800<span></span>
</td>
<td class="nump">32,800<span></span>
</td>
<td class="nump">110,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">275,333<span></span>
</td>
<td class="nump">275,333<span></span>
</td>
<td class="nump">568,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Carrying value of equity component</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,500<span></span>
</td>
<td class="nump">$ 33,500<span></span>
</td>
<td class="nump">219,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early retirement of debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 21,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1', window );">Amortization period of debt discount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember', window );">1% Convertible Senior Notes [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Fair value of outstanding notes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 354,800<span></span>
</td>
<td class="nump">$ 354,800<span></span>
</td>
<td class="nump">$ 725,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember', window );">1% Convertible Senior Notes [Member] | Borrowing Rate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMeasurementInput', window );">Nonconvertible debt measurement input rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.074<span></span>
</td>
<td class="nump">0.074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes275PercentMember', window );">2 3/4 Percent Convertible Senior Notes [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract', window );"><strong>Convertible Notes [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Principal amount repurchased</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,100<span></span>
</td>
<td class="nump">$ 140,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2.75%<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">For our 1% Notes, our effective interest rate represents our effective interest rate after our December 2019 debt exchange.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CallSpread">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash outflow from payments for hedge transactions and proceeds from the issuance of warrants. The call spread transaction was entered into to minimize the impact of potential economic dilution upon conversion of the 0.125% notes issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CallSpread</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The computed conversion price per share of the debt instrument based on the the conversion feature embedded in the debt instrument and the impact of the purchased hedges in the call spread transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of the principal amount of the notes to be purchased, plus accrued and unpaid interest, upon the occurrence of certain fundamental changes, as set forth in the indenture governing the convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount (premium).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28567-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForHedgeFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 27<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3581-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForHedgeFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes275PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes275PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6771661120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes, Tax Credit Carryforwards (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 99.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal [Member] | Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">198.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember', window );">California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">117.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember', window );">California [Member] | Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 74.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6885277872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes, Income (Loss) Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="nump">$ 344,280<span></span>
</td>
<td class="num">$ (69,576)<span></span>
</td>
<td class="num">$ (5,289)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">2,489<span></span>
</td>
<td class="num">(6,580)<span></span>
</td>
<td class="num">(11,474)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income (loss) before income tax benefit (expense)</a></td>
<td class="nump">$ 346,769<span></span>
</td>
<td class="num">$ (76,156)<span></span>
</td>
<td class="num">$ (16,763)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6873472192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity, Stock Option Activity (Details) - Stock Options [Member] - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">11,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(2,617)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled/forfeited/expired (in shares)</a></td>
<td class="num">(236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">11,001<span></span>
</td>
<td class="nump">11,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">6,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 47.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">56.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">40.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled/forfeited/expired (in dollars per share)</a></td>
<td class="nump">50.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">51.48<span></span>
</td>
<td class="nump">$ 47.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share)</a></td>
<td class="nump">$ 50.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Average Remaining Contractual Term, Aggregate Intrinsic Value and Other [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Average remaining contractual term, outstanding at end of period</a></td>
<td class="text">4 years 4 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Average remaining contractual term, exercisable at end of period</a></td>
<td class="text">3 years 4 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, outstanding at end of period</a></td>
<td class="nump">$ 104,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable at end of period</a></td>
<td class="nump">$ 59,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 28.76<span></span>
</td>
<td class="nump">$ 25.49<span></span>
</td>
<td class="nump">$ 25.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 83,800<span></span>
</td>
<td class="nump">$ 34,800<span></span>
</td>
<td class="nump">$ 49,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received from exercise of stock options</a></td>
<td class="nump">$ 105,900<span></span>
</td>
<td class="nump">$ 18,900<span></span>
</td>
<td class="nump">$ 21,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue', window );">Weighted-average fair value of options exercised (in dollars per share)</a></td>
<td class="nump">$ 72.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract', window );"><strong>Unrecognized Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to non-vested stock options</a></td>
<td class="nump">$ 97,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options exercised during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6881124880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies, Stock-Based Compensation Expense (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6968577680">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies, Fair Value Measurements (Details) - Recurring Basis [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 418,406<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 146,281<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in ProQR Therapeutics N.V.</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">4,506<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,349<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,258,985<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,017,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,102,568<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">1,252,960<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Debt Securities [Member] | Cash and Cash Equivalents [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">50,200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Debt Securities issued by U.S. Government Agencies [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">329,404<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[5]</sup></td>
<td class="nump">276,612<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Debt Securities issued by U.S. Government Agencies [Member] | Cash and Cash Equivalents [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Debt Securities issued by the U.S. Treasury [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">363,694<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">260,154<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[7]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Debt Securities issued by the U.S. Treasury [Member] | Cash and Cash Equivalents [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14,200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Debt Securities issued by States of the U.S. and Political Subdivisions of the States [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[6]</sup></td>
<td class="nump">40,407<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">79,942<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets (Level 1) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">418,406<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">146,281<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in ProQR Therapeutics N.V.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">782,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">406,435<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets (Level 1) [Member] | Corporate Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities issued by U.S. Government Agencies [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities issued by the U.S. Treasury [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">363,694<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">260,154<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities issued by States of the U.S. and Political Subdivisions of the States [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in ProQR Therapeutics N.V.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,472,379<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,609,514<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) [Member] | Corporate Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,102,568<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,252,960<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) [Member] | Debt Securities issued by U.S. Government Agencies [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">329,404<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">276,612<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) [Member] | Debt Securities issued by the U.S. Treasury [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Other Observable Inputs (Level 2) [Member] | Debt Securities issued by States of the U.S. and Political Subdivisions of the States [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,407<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">79,942<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3) [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in ProQR Therapeutics N.V.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,506<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,349<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,506<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,349<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3) [Member] | Corporate Debt Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3) [Member] | Debt Securities issued by U.S. Government Agencies [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3) [Member] | Debt Securities issued by the U.S. Treasury [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Significant Unobservable Inputs (Level 3) [Member] | Debt Securities issued by States of the U.S. and Political Subdivisions of the States [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Available-for-sale securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Included in cash and cash equivalents on our consolidated balance sheet.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Included in other current assets on our consolidated balance sheet.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">$19.0 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">$50.2 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[5]</td>
<td style="vertical-align: top;" valign="top">$0.8 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[6]</td>
<td style="vertical-align: top;" valign="top">Included in short-term investments.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[7]</td>
<td style="vertical-align: top;" valign="top">$14.2 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6872846048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements and Licensing Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember', window );">Biogen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Revenue from Collaborative Relationship</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with Biogen (in millions, except percentage amounts):</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z0380747c43454884ab39653ff62a443c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SPINRAZA royalties (commercial revenue)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">293.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">237.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">112.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">180.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">137.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">150.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total revenue from our relationship with Biogen</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">473.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">375.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">263.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">42</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">63</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">51</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember', window );">AstraZeneca [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Revenue from Collaborative Relationship</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with AstraZeneca (in millions, except percentage amounts):</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z3e98572cb7a74e948b59d5a9feec5657" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">28.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">120.7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember', window );">Bayer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Revenue from Collaborative Relationship</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with Bayer (in millions, except percentage amounts):</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zb1073dc32a5e4c66a2a664b0634da7c6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">67.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember', window );">GSK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Revenue from Collaborative Relationship</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with GSK (in millions, except percentage amounts):</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zfc1697a2c45e4e5d9ba00caf3a13ead3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">25.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember', window );">Janssen Biotech, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Revenue from Collaborative Relationship</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with Janssen (in millions, except percentage amounts):</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zf8941280a0a94e81bb425341b948878a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">36.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember', window );">Roche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Revenue from Collaborative Relationship</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with Roche (in millions, except percentage amounts):</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z3751bf5f787c451499c06571891a9800" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">57.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">55.7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember', window );">Novartis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Revenue from Collaborative Relationship</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019 and 2018, Akcea earned the following revenue from its relationship with Novartis (in millions, except percentage amounts):</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z69ce748cda9640099c4155d9ea42f332" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">187.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">50.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">43.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">17</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember', window );">Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Revenue from Collaborative Relationship</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the year ended December 31, 2019, Akcea earned the following revenue from its relationship with Pfizer (in millions, except percentage amounts):</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z6a52ad3f4f4548a28b37262fe935a7dc" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">248.7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">22</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember', window );">PTC Therapeutics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems', window );"><strong>Collaborative Arrangements and Licensing Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Revenue from Collaborative Relationship</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019 and 2018, Akcea earned the following revenue from its relationship with PTC (in millions, except percentage amounts):</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zf3ce81334bbb4ee983c75acc2b6feb6c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Licensing and other royalty revenue (commercial revenue)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Percentage of total revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6885469728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAbstract', window );"><strong>Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Contract Maturity of Available-for-Sale Securities</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes the contract maturity of the available-for-sale securities we held as of December 31, 2019:</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z6c0f78857c00481b9a2fe8abae31c196" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">One year or less</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">70</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">After one year but within two years</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">After two years but within <span style="-sec-ix-hidden:Fact_5b50da2d62974df399b2ebfcfccf0c30">three and a half years</span></div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">100</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Summary of Investments</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following is a summary of our investments (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zf9b6c17e2c154c6ab71c1ee67da358d6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"/></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gross Unrealized</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Estimated</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Cost </span>(1)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gains</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Losses</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Available-for-sale securities:</div></td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities (2)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">669,665</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,451</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(43</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">671,073</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">188,216</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">303</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(43</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">188,476</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury (2)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">327,670</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">232</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(27</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">327,875</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21,065</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">26</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21,086</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total securities with a maturity of one year or less</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,206,616</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,012</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(118</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,208,510</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">428,627</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,911</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(43</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">431,495</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">140,988</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">57</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(117</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">140,928</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">35,822</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(12</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">35,819</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">19,309</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">19,321</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total securities with a maturity of more than one year</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">624,746</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,995</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(178</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">627,563</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total available-for-sale securities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,831,362</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,007</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(296</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,836,073</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Equity securities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total equity securities included in other current assets (3)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,712</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(870</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,842</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total equity securities included in deposits and other assets (4)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,000</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,000</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total equity securities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14,712</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">-</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(870</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,842</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total available-for-sale and equity securities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,846,074</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,007</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,166</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,849,915</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z13827f1de67a455a9892b6f4cd0857a7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gross Unrealized</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Estimated</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Cost </span>(1)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Gains</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Losses</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Available-for-sale securities:</div></td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities (2)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">956,879</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,858</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">955,034</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">168,839</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(104</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">168,738</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">244,640</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(77</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">244,578</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states (2)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">63,572</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(323</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">63,249</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total securities with a maturity of one year or less</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,433,930</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">31</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2,362</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,431,599</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">299,018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">194</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,286</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">297,926</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">107,789</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">194</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(109</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">107,874</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15,600</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(24</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15,576</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">16,980</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(287</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">16,693</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total securities with a maturity of more than one year</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">439,387</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">388</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,706</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">438,069</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total available-for-sale securities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,873,317</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">419</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4,068</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,869,668</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Equity securities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total equity securities included in other current assets (3)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,212</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">137</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,349</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total available-for-sale and equity securities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,874,529</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">556</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4,068</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,871,017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z784ee7f1d4b643169b5db132e0df44a0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We hold our available-for-sale securities at amortized cost.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z0db8278eb43646f79139982440394852" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Includes investments classified as cash equivalents on our consolidated balance sheet.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z72201901808a45b9b3f1774f8add5ea2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our equity securities included in other current assets consisted of our investment in ProQR, which is a public company. We recognize our public company equity securities at</span> fair value.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z3d706207d5ac4b169c0cbd627c904d24" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our equity securities included in deposits and other assets consisted of our investment in Empirico, which is a private company. We recognize our private company equity securities at</span> cost minus impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> on our consolidated balance sheet.</span></div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock', window );">Temporarily Impaired Investments</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investments we consider to be temporarily impaired at December 31, 2019 are as follows (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zc70ed2d8b7b040eaa431c9f6deed2462" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Less than 12 Months of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Temporary Impairment</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">More than 12 Months of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Temporary Impairment</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total Temporary</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Impairment</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Number of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Investments</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Estimated</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Unrealized</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Losses</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Estimated</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Unrealized</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Losses</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Estimated</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Unrealized</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Losses</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 16%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">49</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">131,702</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(75</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11,840</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(11</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">143,542</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(86</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 16%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">43</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">149,731</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(136</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">37,041</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(24</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">186,772</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(160</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 16%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">84,270</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(39</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">84,270</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(39</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 16%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,241</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,303</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20,544</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(11</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 16%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total temporarily impaired securities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">113</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">375,944</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(255</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">59,184</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(41</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">435,128</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(296</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investments in an unrealized loss position for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), including: (a) the aggregate related fair value of investments with unrealized losses, (b) the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6869427120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember', window );">0.125 Percent Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible senior notes</a></td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember', window );">1 Percent Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible senior notes</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6887198512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 20, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Ionis Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000874015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,483,343,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,219,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-19125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0336973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2855 Gazelle Court<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlsbad<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">931-9200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.001 Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IONS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871572048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 303,262<span></span>
</td>
<td class="nump">$ 214,985<span></span>
</td>
<td class="num">$ (10,783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gains (losses) on investments, net of tax</a></td>
<td class="nump">6,633<span></span>
</td>
<td class="num">(280)<span></span>
</td>
<td class="num">(960)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification adjustment for realized gains included in net income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(374)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Currency translation adjustment</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss)</a></td>
<td class="nump">309,988<span></span>
</td>
<td class="nump">214,728<span></span>
</td>
<td class="num">(12,184)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interest in Akcea Therapeutics, Inc.</a></td>
<td class="nump">9,118<span></span>
</td>
<td class="num">(58,781)<span></span>
</td>
<td class="num">(11,224)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders</a></td>
<td class="nump">$ 300,870<span></span>
</td>
<td class="nump">$ 273,509<span></span>
</td>
<td class="num">$ (960)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32157-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6863520528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information and Concentration of Business Risk<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information and Concentration of Business Risk [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information and Concentration of Business Risk</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">7. Segment Information and Concentration of Business Risk</div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We have </span>two<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> reportable segments Ionis Core and Akcea Therapeutics. </span>At December 31, 2019, we owned approximately 76 percent of Akcea.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Segment income (loss) from operations includes revenue less operating expenses attributable to each segment.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In our Ionis Core segment we are exploiting our antisense technology to generate a broad pipeline of first-in-class and/or best-in-class medicines for us and our partners. Our Ionis Core segment generates revenue from a multifaceted partnering strategy.</div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Akcea is </span>a biopharmaceutical company focused on developing and commercializing medicines to treat patients with serious and rare diseases<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. Akcea generates revenue from TEGSEDI and WAYLIVRA product sales and from its collaborations.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The following tables show our segment revenue and income (loss) from operations for </span>2019, 2018 and 2017<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> (in thousands), respectively.</span></div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="ze030c5e389c640c2991886f2f6ba40f4" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Ionis Core</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Akcea Therapeutics</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Elimination of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intercompany Activity</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Revenue:</div></td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Commercial revenue:</div></td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SPINRAZA royalties</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">292,992</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">292,992</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Product sales, net</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">42,253</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">42,253</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Licensing and other royalty revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12,616</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,172</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5,583</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">17,205</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 43.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total commercial revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">305,608</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">52,425</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5,583</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">352,450</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue under collaborative agreements</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">553,038</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">436,118</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(219,007</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">770,149</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total segment revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">858,646</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">488,543</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(224,590</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,122,599</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total operating expenses</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">523,207</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">450,469</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(216,960</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">756,716</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) from operations</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">335,439</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">38,074</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(7,630</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">365,883</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zb93ba8fe3f024f1fa4d3f61c84b60bad" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Ionis Core</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Akcea Therapeutics</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Elimination of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intercompany Activity</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Revenue:</div></td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Commercial revenue:</div></td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SPINRAZA royalties</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">237,930</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">237,930</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">TEGSEDI product sales, net</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,237</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,237</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Licensing and other royalty revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,755</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12,000</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14,755</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 43.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total commercial revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">240,685</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14,237</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">254,922</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue under collaborative agreements</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">401,259</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">50,630</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(107,137</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">344,752</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total segment revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">641,944</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">64,867</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(107,137</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">599,674</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total operating expenses</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">380,212</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">295,683</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(14,849</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">661,046</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) from operations</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">261,732</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(230,816</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(92,288</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(61,372</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z4d329b28bc324ba3bbf9eb96d75066a3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Ionis Core</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Akcea Therapeutics</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Elimination of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intercompany Activity</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Revenue:</div></td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Commercial revenue:</div></td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">SPINRAZA royalties</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">112,540</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">112,540</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Licensing and other royalty revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7,474</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7,474</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 43.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total commercial revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">120,014</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">120,014</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D revenue under collaborative agreements</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">405,171</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">43,401</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(54,407</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">394,165</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total segment revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">525,185</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">43,401</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(54,407</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">514,179</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total operating expenses</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">373,788</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">163,871</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(54,527</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">483,132</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) from operations</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">151,397</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(120,470</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">120</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">31,047</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table shows our total assets by segment at December 31, 2019 and 2018 (in thousands), respectively.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z4b7b08804da24aa49b1b8bfdb2287736" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total Assets</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Ionis Core</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Akcea Therapeutics</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Elimination of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intercompany Activity</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Total</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,478,081</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">599,250</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(844,219</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,233,112</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 31, 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,975,491</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">365,261</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(672,968</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,667,784</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Contracts receivables at December 31, 2019 and December 31, 2018 were comprised of approximately 75 percent and 99  percent for each year from one and four significant partners, respectively.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6863400016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Long-Term Obligations and Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock', window );">Long-Term Obligations and Commitments</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">3. Long-Term Obligations and Commitments</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The carrying value of our long-term obligations was as follows (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z3479120fb70c49dfbea272f920706f19" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.125 percent convertible senior notes</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">434,711</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1 percent convertible senior notes</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">275,333</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">568,215</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Long-term mortgage debt</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">59,913</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">59,842</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Principal balance of fixed rate note with Morgan Stanley (1)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12,500</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Leases and other obligations</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">17,569</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,163</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">787,526</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">646,720</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less: current portion</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2,026</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(13,749</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total Long-Term Obligations</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">785,500</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">632,971</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z2d1da80f1e1b4c8fb24d5d884387f78e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our $12.5 million fixed rate note with Morgan Stanley was included in our current portion of long-term obligations on our consolidated balance sheet at December 31, 2018. We paid off our fixed rate note in the third quarter of 2019.</div></td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Convertible Notes and Call Spread</div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">0.125 Percent</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Convertible Senior Notes</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In December 2019, we entered into privately negotiated exchange and/or subscription agreements with certain new investors and certain holders of our existing <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1%</span> Notes to exchange $375.6 million of our <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">1%</span> Notes for $439.3<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">&#160;</span>million of our 0.125% Notes, and to issue $109.5 million of our 0.125% Notes. We completed this exchange to reduce our cash interest payments, increase our conversion price and extend our maturity for a large portion of our debt. Additionally, i<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">n conjunction with the December 2019 exchange, we entered into a call spread transaction, which was comprised of purchasing note hedges and selling warrants, to minimize the impact of potential economic dilution upon conversion of our </span>0.125% Notes<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> by increasing the effective conversion price even further.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Interest is payable semi-annually on June 15 and December 15 of each year for the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.125%</span> Notes. The <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.125%</span> Notes are convertible at the option of the note holders prior to August 1, 2024 only under certain conditions. On or after August 1, 2024, the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.125%</span> Notes are initially convertible into approximately 6.6 million shares of common stock at a conversion price of approximately $83.28 per share. We will settle conversions of the notes, at our election, in cash, shares of our common stock or a combination of both. We may not redeem the <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.125%</span> Notes prior to maturity, and no sinking fund is provided for them. If we undergo a fundamental change, holders may require us to purchase for cash all or any portion of their <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.125%</span> Notes at a purchase price equal to 100 percent of the principal amount of the notes to be purchased, plus accrued and unpaid interest to, but excluding, the fundamental change purchase date.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At December 31, 2019, we had the following <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.125%</span> Notes outstanding (amounts in millions except price per share data):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="za16edea38bc54e628301a72484af85b3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: top; padding-bottom: 2px; white-space: nowrap;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">0.125% <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Notes</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Outstanding principal balance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">548.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Maturity date</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: top; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">December 15, 2024</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Interest rate</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.125</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 88%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Conversion price per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">83.28</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total shares of common stock subject to conversion</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The following table summarizes information about the equity and liability components of our outstanding </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.125%</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes (in millions). We measured the fair values of the convertible notes outstanding based on quoted market prices, which is a Level 2 measurement at December 31, </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">:</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z7dc44d0a9b0443dda7f99ab1d70efbdf" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-indent: 3pt;">0.125% <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Notes</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Fair value of outstanding notes</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">558.7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Principal amount of convertible notes outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">548.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Unamortized portion of debt discount</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">105.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Long-term debt</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">434.7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Carrying value of equity component</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">105.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 27pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Call Spread</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Additionally, i</span>n conjunction with the December 2019 exchange, we entered into a call spread transaction, which was comprised of purchasing note hedges and selling warrants, to minimize the impact of potential economic dilution upon conversion of our <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.125%</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes</span> by increasing the conversion price even further. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The call spread cost us $</span>52.6<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million, of which $</span>108.7<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million was for the note hedge purchase, offset by $</span>56.1<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million we received for selling the warrants. We increased our effective conversion price to $</span>123.38<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> with the same number of underlying shares as our </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.125%</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Similar to our </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.125%</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, our note hedges are subject to adjustment. Additionally, our note hedges are exercisable upon conversion of the </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.125%</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. The note hedges will expire upon maturity of </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.125%</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, or December 2024. The note hedges and warrants are separate transactions and are not part of the terms of our </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.125%</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. The holders of the </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.125%</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> do not have any rights with respect to the note hedges and warrants.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We recorded the aggregate amount paid for the note hedges and the aggregate amount received for the warrants in additional paid-in capital in our consolidated balance sheet. We excluded shares under the note hedges from our calculation of diluted earnings per share as they were antidilutive. We will include the shares issuable under the warrants in our calculation of diluted earnings per share when the average market price per share of our common stock for the reporting period exceeds the strike price of the warrants.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">1 Percent Convertible Senior Notes</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In November 2014, we completed a $500 million offering of convertible senior notes, which mature in 2021 and bear interest at 1 percent. We used a substantial portion of the net proceeds from the issuance of the 1% Notes to repurchase $140 million in principal of our 2&#190; percent convertible senior notes, or 2&#190;% Notes. In December 2016, we issued an additional $185.5 million of 1% Notes in exchange for the redemption of $61.1 million of our <span style="-sec-ix-hidden:Fact_5720e35e625f4851a419d661f07222c0">2&#190;</span>% Notes. In December 2019, we exchanged a portion of our 1% Notes for <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">0.125%</span> Notes. As a result, the principal balance of 1% Notes was $309.9 million. Additionally, we recorded a $21.9 million non-cash loss on early retirement of debt, reflecting the early retirement of a significant portion of our 1% Notes in December 2019.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At December 31, 2019, we had the following 1% Notes outstanding (amounts in millions except price per share data):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zb43006877680441c81f9bc23fb14ec3e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: top; padding-bottom: 2px; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1% Notes</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Outstanding principal balance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">309.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Maturity date</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: top; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">November 30, 2021</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Interest rate</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: top; background-color: #CCEEFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1 percent</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 88%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Conversion price per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">66.81</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total shares of common stock subject to conversion</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Interest is payable semi-annually in arrears on May 15 and November 15 of each year for the 1% Notes. The 1% Notes are convertible at the option of the note holders prior to July 1, 2021 only under certain conditions. On or after July 1, 2021, the 1% Notes are initially convertible into approximately 4.6 million shares of common stock at a conversion price of approximately $66.81 per share. We will settle conversions of the notes, at our election, in cash, shares of our common stock or a combination of both. We may not redeem the 1% Notes prior to maturity, and no sinking fund is provided for them. If we undergo a fundamental change, holders may require us to purchase for cash all or any portion of their 1% Notes at a purchase price equal to 100 percent of the principal amount of the notes to be purchased, plus accrued and unpaid interest to, but excluding, the fundamental change purchase date.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">The following table summarizes information about the equity and liability components of our outstanding </span>1%<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes (in millions). We measured the fair values of the convertible notes outstanding based on quoted market prices, which is a Level 2 measurement at December 31, </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">:</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zabdbc8437c344a2893cd480c7c4bf557" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-indent: 16pt;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Fair value of outstanding notes</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">354.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">725.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Principal amount of convertible notes outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">309.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">685.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Unamortized portion of debt discount</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">32.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">110.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Long-term debt</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">275.3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">568.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Carrying value of equity component</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">33.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">219.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We account for our convertible notes using an accounting standard that requires us to assign a value to our convertible debt equal to the estimated fair value of similar debt instruments without the conversion feature and to record the remaining portion in equity. As a result, we recorded our convertible notes at a discount, which we are amortizing as additional non-cash interest expense over the expected life of the respective debt. We determined our nonconvertible debt borrowing rate using a combination of the present value of the debt&#8217;s cash flows and a Black-Scholes valuation model. The following table summarizes the nonconvertible borrowing rate, effective interest rate and amortization period of our debt discount for our convertible notes:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z42f3873bea834b268c1005c0970cb12c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">
  <tr>
    <td style="width: 39.53%; vertical-align: bottom;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td style="width: 2.25%; vertical-align: bottom;">&#160;</td>
    <td style="width: 28.83%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">1% Notes</div></td>
    <td style="width: 1.39%; vertical-align: top;">&#160;</td>
    <td style="width: 28%; vertical-align: bottom; border-bottom: #000000 2px solid;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">0.125%<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> Notes</span></div></td>
  </tr>
  <tr>
    <td style="width: 39.53%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Nonconvertible debt borrowing rate</div></td>
    <td style="width: 2.25%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 28.83%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.4 percent</div></td>
    <td style="width: 1.39%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 28%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.4 percent</div></td>
  </tr>
  <tr>
    <td style="width: 39.53%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effective interest rate (1)</div></td>
    <td style="width: 2.25%; vertical-align: bottom; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 28.83%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.5 percent</div></td>
    <td style="width: 1.39%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
    <td style="width: 28%; vertical-align: bottom; background-color: #FFFFFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.9 percent</div></td>
  </tr>
  <tr>
    <td style="width: 39.53%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amortization period of debt discount</div></td>
    <td style="width: 2.25%; vertical-align: bottom; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 28.83%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7 years</div></td>
    <td style="width: 1.39%; vertical-align: top; background-color: #CCEEFF;">&#160;</td>
    <td style="width: 28%; vertical-align: bottom; background-color: #CCEEFF;"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5 years</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z644a31acdd52488c97d7adc5c94171fd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For our 1% Notes, our effective interest rate represents our effective interest rate after our December 2019 debt exchange.&#160;</div></td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our total interest expense for our outstanding senior convertible notes for the years ended December 31, 2019, 2018 and 2017 included $39.3 million, $35.2 million and $32.5 million, respectively, of non-cash interest expense related to the amortization of the debt discount and debt issuance costs for our convertible notes.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Financing Arrangements</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Line of Credit Arrangement</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In June 2015, we entered into a five-year revolving line of credit agreement with Morgan Stanley Private Bank, National Association, or Morgan Stanley, which we amended in February 2016. Under the amended credit agreement, Morgan Stanley provided a maximum of $30 million of revolving credit for general working capital purposes. During the third quarter of 2019, we paid off our total outstanding borrowings of $12.5 million under the agreement and subsequently terminated the agreement.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Research and Development and Manufacturing Facilities</div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In July 2017, we purchased the building that houses our primary R&amp;D facility for $79.4 million and our manufacturing facility for $14.0 million. We financed the purchase of these two facilities with mortgage debt of $60.4 million in total. Our primary R&amp;D facility mortgage has an interest rate of 3.88 percent. Our manufacturing facility mortgage has an interest rate of 4.20 percent. During the first five years of both mortgages, we are only required to make interest payments. Both mortgages mature in August 2027.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As a result of the purchase, we extinguished the financing liability we had previously recorded on our balance sheet for our primary R&amp;D facility. The difference between the purchase price of our primary R&amp;D facility and the carrying value of our financing liability at the time of the purchase was $7.7 million. We recognized this amount as a non-cash loss on extinguishment of financing liability for leased facility in our consolidated results of operations in the third quarter of 2017. We previously accounted for the lease of our manufacturing facility as an operating lease. We capitalized the purchase price of the manufacturing facility as a fixed asset in the third quarter of 2017.</div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Maturity Schedules</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Annual debt and other obligation maturities, including fixed and determinable interest, at December 31, 2019 are as follows (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zbf1bb99a34ec45e78be045fb2e06c256" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,260</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2021</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">316,114</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2022</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,495</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2023</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,180</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2024</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">553,006</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Thereafter</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">64,429</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Subtotal</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">947,484</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less: current portion</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2,026</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less: fixed and determinable interest</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(28,014</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less: unamortized portion of debt discount</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(137,975</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Plus: lease liabilities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">17,235</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">796,704</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Operating Leases</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Ionis Leases</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We lease a facility adjacent to our manufacturing facility that has laboratory and office space that we use to support our manufacturing facility. We lease this space under a non-cancelable operating lease with an initial term ending in June 2021 and an option to extend the lease for up to two&#160;five-year periods.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We also lease additional office spaces. We sublease a portion of one of these spaces to Akcea. We lease these spaces under non-cancelable operating leases with initial terms ending in 2023 with options to extend the leases for one&#160;five-year period. The sublease with Akcea is eliminated in our consolidated financial statements.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Akcea Lease</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea entered into an operating lease agreement for office space located in Boston, Massachusetts for its new corporate headquarters in the second quarter of 2018. The lease commencement date was in August 2018 and Akcea took occupancy in September 2018. Akcea is leasing this space under a non-cancelable operating lease with an initial term ending after 123 months and an option to extend the lease for an additional five-year term. Under the lease agreement, Akcea received a three-month free rent period, which commenced on August 15, 2018, and a tenant improvement allowance up to $3.8 million. Akcea provided the lessor with a letter of credit to secure its obligations under the lease in the initial amount of $2.4 million, to be reduced to $1.8 million on the third anniversary of the rent commencement date and to $1.2 million on the fifth anniversary of the rent commencement date if Akcea meets certain conditions set forth in the lease at each such time.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">When we determined our lease term for our operating lease right-of-use assets and lease liabilities for these leases, we did not include the extension options for these leases.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amounts related to our operating leases were as follows (dollar amounts in millions):</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z3d2e84cc75f74373b53127abdaff1269" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">At December 31, 2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Right-of-use operating lease assets (1)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating lease liabilities (2)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">17.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average remaining lease term</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8.1 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average discount rate</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z49deda5f82f74fe1af4f88874881e5f9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Included in <span style="-sec-ix-hidden:Fact_f81ca57385a04657b8ecd0f06d505159">deposits and other assets</span> on our consolidated balance sheet.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z26af2e3421ce4117a512d5aa97d68ee7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Current portion of $2.0 million was included in <span style="-sec-ix-hidden:Fact_530181678e9244af8b37885d3ba85980">current portion of long-term obligations</span> on our consolidated balance sheet, with the difference included in <span style="-sec-ix-hidden:Fact_9c37cb3853f74a4f821bbe4ed37a06ba">long-term obligations</span>.</div></td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the year ended December 31, 2019, we paid $3.9 million of lease payments, which was included in operating activities in our consolidated statement of cash flows.</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As of December 31, 2019, the future payments for our operating lease liabilities are as follows (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z21d6f95567c944849963a4017490880d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Operating</span> <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Leases</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Year ending December 31,</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,285</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -0.2pt; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2021</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,022</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -0.2pt; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2022</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,781</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2023</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,520</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2024</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,396</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Thereafter</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,465</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total minimum lease payments</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23,469</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Imputed interest</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(6,234</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; margin-left: 36.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total operating lease liabilities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">17,235</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Rent expense was $3.6 million, $2.6 million and $1.7 million for the years ended December 31, 2019, 2018 and 2017, respectively.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for debt and capital lease obligations can be reported. Information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. Also includes descriptions and amounts of capital leasing arrangements that consist of direct financing, sales type and leveraged leases. Disclosure may include the effect on the balance sheet and the income statement resulting from a change in lease classification for leases that at inception would have been classified differently had guidance been in effect at the inception of the original lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6870462320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies, Inventory Valuation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory Valuation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-off</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">15,883<span></span>
</td>
<td class="nump">8,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">2,039<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">258<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">18,180<span></span>
</td>
<td class="nump">8,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=ions_ClinicalRawMaterialsMember', window );">Clinical Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory Valuation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">9,363<span></span>
</td>
<td class="nump">8,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=ions_CommercialRawMaterialsMember', window );">Commercial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory Valuation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 6,520<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=ions_ClinicalRawMaterialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=ions_ClinicalRawMaterialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=ions_CommercialRawMaterialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=ions_CommercialRawMaterialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6972980336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies, Revenue Recognition (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="7">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>PerformanceObligation</div>
</th>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>USD ($) </div>
<div>PerformanceObligation</div>
</th>
<th class="th">
<div>May 31, 2015 </div>
<div>USD ($) </div>
<div>PerformanceObligation</div>
</th>
<th class="th">
<div>Sep. 30, 2013 </div>
<div>USD ($) </div>
<div>PerformanceObligation</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($) </div>
<div>PerformanceObligation</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($) </div>
<div>Agreement</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>Target </div>
<div>Payment</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>PerformanceObligation </div>
<div>Payment</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($) </div>
<div>PerformanceObligation</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract', window );">Number of performance obligations at inception of contract | PerformanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,122,599<span></span>
</td>
<td class="nump">$ 599,674<span></span>
</td>
<td class="nump">$ 514,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ions_BiogenIncMember', window );">Biogen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfAgreementsWithCollaborationPartner', window );">Number of agreements | Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_LicensingAndOtherRoyaltiesMember', window );">Licensing and Other Royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,205<span></span>
</td>
<td class="nump">$ 14,755<span></span>
</td>
<td class="nump">$ 7,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember', window );">2013 Strategic Neurology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (16,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations', window );">Number of separate performance obligations | PerformanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember', window );">2013 Strategic Neurology [Member] | Licensing and Other Royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember', window );">AstraZeneca [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations', window );">Number of separate performance obligations | PerformanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember', window );">IONIS-FB-L for Complement-Mediated Diseases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations', window );">Number of separate performance obligations | PerformanceObligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember', window );">2018 Strategic Neurology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfMilestonePaymentsAchieved', window );">Number of milestone payments achieved | Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPriceAdditions', window );">Milestone payments received and added to transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfNewTargetsAdvanced', window );">Number of new targets advanced | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations', window );">Number of separate performance obligations | PerformanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 552,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember', window );">2012 Neurology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember', window );">2012 Neurology [Member] | Licensing and Other Royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember', window );">Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">246,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember', window );">Alnylam [Member] | Licensing and Other Royalties [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember', window );">Bayer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations', window );">Number of separate performance obligations | PerformanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember', window );">Bayer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations', window );">Number of separate performance obligations | PerformanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember', window );">Bayer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfAgreementsWithCollaborationPartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of agreements entered into with the collaboration partner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfAgreementsWithCollaborationPartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfMilestonePaymentsAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of milestone payments achieved during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfMilestonePaymentsAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfNewTargetsAdvanced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new targets advanced during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfNewTargetsAdvanced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of performance obligations at the inception of a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of separate performance obligations under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration the Company earned or is eligible to earn under the collaboration agreement, including any variable consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerTransactionPriceAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The additional amount of consideration the Company earned under the collaboration agreement that is added to the transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerTransactionPriceAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payments received during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ions_BiogenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ions_BiogenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_LicensingAndOtherRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_LicensingAndOtherRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6874521856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies, Research, Development and Patent Expenses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research, Development and Patent Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 461.5<span></span>
</td>
<td class="nump">$ 411.9<span></span>
</td>
<td class="nump">$ 372.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_PatentAbstract', window );"><strong>Patents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful life</a></td>
<td class="text">10 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 34.0<span></span>
</td>
<td class="nump">32.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Estimated Amortization Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2020</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2021</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2022</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2023</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2024</a></td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_PatentExpenses', window );">Patent expenses</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Non-cash charges related to write-down</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsMember', window );">Collaborative Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research, Development and Patent Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">$ 83.2<span></span>
</td>
<td class="nump">$ 58.7<span></span>
</td>
<td class="nump">$ 59.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PatentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PatentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PatentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Includes charges for amortization and write-downs of capitalized patent costs as well as legal fees for patent litigation and patent defense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PatentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6885405856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Obligations and Commitments, Research and Development and Manufacturing Facilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipmentAbstract', window );"><strong>Research and Development and Manufacturing Facilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_GainLossOnExtinguishmentOfFinancingLiability', window );">Loss on extinguishment of financing liability for leased facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (7,689)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_LongTermMortgageDebtMember', window );">Long-term Mortgage Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipmentAbstract', window );"><strong>Research and Development and Manufacturing Facilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 60,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_PrimaryResearchAndDevelopmentFacilityMember', window );">Primary R&amp;D Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipmentAbstract', window );"><strong>Research and Development and Manufacturing Facilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBuildings', window );">Payment to acquire building</a></td>
<td class="nump">$ 79,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">3.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan', window );">Period to make interest only payments on mortgage loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_GainLossOnExtinguishmentOfFinancingLiability', window );">Loss on extinguishment of financing liability for leased facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipmentAbstract', window );"><strong>Research and Development and Manufacturing Facilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBuildings', window );">Payment to acquire building</a></td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan', window );">Period to make interest only payments on mortgage loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_GainLossOnExtinguishmentOfFinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the purchase price of the facility and the carrying value of our financing liability at the time of the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_GainLossOnExtinguishmentOfFinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time to make only payments of interest on the mortgage loan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBuildings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of buildings (properties) whether for investment or use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBuildings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_LongTermMortgageDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_LongTermMortgageDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_PrimaryResearchAndDevelopmentFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_PrimaryResearchAndDevelopmentFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871594672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments, Investments Temporarily Impaired (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Investment</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Temporarily Impaired Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1', window );">Number of investments | Investment</a></td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Estimated fair value, less than 12 months of temporary impairment</a></td>
<td class="nump">$ 375,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized losses, less than 12 months of temporary impairment</a></td>
<td class="num">(255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Estimated fair value, more than 12 months of temporary impairment</a></td>
<td class="nump">59,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized losses, more than 12 months of temporary impairment</a></td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue', window );">Estimated fair value, total temporary impairment</a></td>
<td class="nump">435,128<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss', window );">Unrealized losses, total temporary impairment</a></td>
<td class="num">$ (296)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Temporarily Impaired Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1', window );">Number of investments | Investment</a></td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Estimated fair value, less than 12 months of temporary impairment</a></td>
<td class="nump">$ 131,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized losses, less than 12 months of temporary impairment</a></td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Estimated fair value, more than 12 months of temporary impairment</a></td>
<td class="nump">11,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized losses, more than 12 months of temporary impairment</a></td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue', window );">Estimated fair value, total temporary impairment</a></td>
<td class="nump">143,542<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss', window );">Unrealized losses, total temporary impairment</a></td>
<td class="num">$ (86)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Debt Securities issued by U.S. Government Agencies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Temporarily Impaired Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1', window );">Number of investments | Investment</a></td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Estimated fair value, less than 12 months of temporary impairment</a></td>
<td class="nump">$ 149,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized losses, less than 12 months of temporary impairment</a></td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Estimated fair value, more than 12 months of temporary impairment</a></td>
<td class="nump">37,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized losses, more than 12 months of temporary impairment</a></td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue', window );">Estimated fair value, total temporary impairment</a></td>
<td class="nump">186,772<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss', window );">Unrealized losses, total temporary impairment</a></td>
<td class="num">$ (160)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">Debt Securities issued by the U.S. Treasury [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Temporarily Impaired Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1', window );">Number of investments | Investment</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Estimated fair value, less than 12 months of temporary impairment</a></td>
<td class="nump">$ 84,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized losses, less than 12 months of temporary impairment</a></td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Estimated fair value, more than 12 months of temporary impairment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized losses, more than 12 months of temporary impairment</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue', window );">Estimated fair value, total temporary impairment</a></td>
<td class="nump">84,270<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss', window );">Unrealized losses, total temporary impairment</a></td>
<td class="num">$ (39)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Debt Securities issued by States of the U.S. and Political Subdivisions of the States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Temporarily Impaired Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1', window );">Number of investments | Investment</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue', window );">Estimated fair value, less than 12 months of temporary impairment</a></td>
<td class="nump">$ 10,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Unrealized losses, less than 12 months of temporary impairment</a></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue', window );">Estimated fair value, more than 12 months of temporary impairment</a></td>
<td class="nump">10,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Unrealized losses, more than 12 months of temporary impairment</a></td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue', window );">Estimated fair value, total temporary impairment</a></td>
<td class="nump">20,544<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss', window );">Unrealized losses, total temporary impairment</a></td>
<td class="num">$ (11)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale that have been in a continuous loss position for twelve months or longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale in a continuous loss position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate fair value of investments in debt and equity securities in an unrealized loss position which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale that have been in a continuous loss position for less than twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for less than twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for twelve months or longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investment positions in available-for-sale investments in a continuous unrealized loss position for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6885818288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity, Share Repurchase Program (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 02, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Share Repurchase Program [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized amount of share repurchase program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Shares repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,400<span></span>
</td>
<td class="nump">$ 34,392<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockDisclosuresAbstract', window );"><strong>Share Repurchase Program [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Shares repurchased (in shares)</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Shares repurchased</a></td>
<td class="nump">$ 90,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6886860176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements and Licensing Agreements, Bayer (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2017 </div>
<div>USD ($) </div>
<div>PerformanceObligation</div>
</th>
<th class="th">
<div>May 31, 2015 </div>
<div>USD ($) </div>
<div>PerformanceObligation</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,122,599<span></span>
</td>
<td class="nump">$ 599,674<span></span>
</td>
<td class="nump">$ 514,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember', window );">R&amp;D Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770,149<span></span>
</td>
<td class="nump">344,752<span></span>
</td>
<td class="nump">$ 394,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember', window );">Bayer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations', window );">Number of separate performance obligations | PerformanceObligation</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember', window );">Bayer [Member] | Revenue [Member] | Strategic Partner [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember', window );">Bayer [Member] | R&amp;D Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,300<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 67,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember', window );">Bayer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones', window );">Maximum amount of payments receivable for license fees and milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones', window );">Maximum amount of payments receivable for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones', window );">Maximum amount of payments receivable for commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement', window );">Royalty percentage received on gross margins of both drugs combined</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CumulativePaymentsReceived', window );">Cumulative payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NextPotentialMilestonePayment', window );">Next prospective milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations', window );">Number of separate performance obligations | PerformanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember', window );">Bayer [Member] | R&amp;D Services for IONIS-FXI-L [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 10,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember', window );">Bayer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_PaymentReceivedForAdvancingPrograms', window );">Payment received for advancing programs</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations', window );">Number of new performance obligations | PerformanceObligation</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember', window );">Bayer [Member] | IONIS-FXI-L [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations', window );">Number of new performance obligations | PerformanceObligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 64,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember', window );">Bayer [Member] | R&amp;D Services for IONIS-FXI-L [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations', window );">Number of new performance obligations | PerformanceObligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CollaborativeArrangementAndLicensingAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CumulativePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative amount of payments received under the collaboration agreement as of the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CumulativePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for commercialization milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for development milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for license fees and substantive milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NextPotentialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The next potential milestone payment to be earned under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NextPotentialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PaymentReceivedForAdvancingPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payments received during the period for advancing programs under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PaymentReceivedForAdvancingPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new performance obligations identified under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of separate performance obligations under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration the Company earned or is eligible to earn under the collaboration agreement, including any variable consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The royalty percentage received on gross margins of drug(s) under the collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payments received during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentServicesForIONISFXILMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentServicesForIONISFXILMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_IONISFXILMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_IONISFXILMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6872540304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="16">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2019</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2019</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2018</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2018</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Quarterly Financial Data (Unaudited) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 493,680<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 167,892<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 163,813<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 297,214<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 192,113<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 145,395<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 117,747<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 144,419<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Operating expenses</a></td>
<td class="nump">233,028<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">165,369<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">182,640<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">175,679<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">181,331<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">163,967<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">168,028<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">147,720<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 756,716<span></span>
</td>
<td class="nump">$ 661,046<span></span>
</td>
<td class="nump">$ 483,132<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">260,652<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,523<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(18,827)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">121,535<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,782<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(18,572)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(50,281)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(3,301)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">365,883<span></span>
</td>
<td class="num">(61,372)<span></span>
</td>
<td class="nump">31,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">203,957<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,432<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(10,012)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">90,884<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">302,735<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(20,365)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(56,573)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(10,812)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">303,262<span></span>
</td>
<td class="nump">214,985<span></span>
</td>
<td class="num">(10,783)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders</a></td>
<td class="nump">$ 184,415<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 26,163<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (876)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 84,443<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 320,078<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (4,559)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (40,358)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1,420)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 294,146<span></span>
</td>
<td class="nump">$ 273,741<span></span>
</td>
<td class="nump">$ 346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share (in dollars per share)</a></td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 2.12<span></span>
</td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income (loss) per share (in dollars per share)</a></td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 0.62<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="nump">$ 2.07<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Income (Numerator) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Income (loss) available to Ionis common stockholders</a></td>
<td class="nump">$ 183,795<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 26,158<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (933)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 87,543<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 319,694<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (4,563)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (37,932)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1,212)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 296,563<span></span>
</td>
<td class="nump">$ 276,868<span></span>
</td>
<td class="nump">$ 18,792<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Income available to Ionis common shareholders, plus assumed conversions</a></td>
<td class="nump">$ 196,485<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 26,158<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 87,543<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 330,439<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 296,563<span></span>
</td>
<td class="nump">$ 276,868<span></span>
</td>
<td class="nump">$ 18,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Shares (Denominator) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing basic net income (loss) per share (in shares)</a></td>
<td class="nump">140,583<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">140,551<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">140,247<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">138,582<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">137,699<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">137,346<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">128,712<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">125,330<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">139,998<span></span>
</td>
<td class="nump">132,320<span></span>
</td>
<td class="nump">124,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of Diluted Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan', window );">Shares issuable related to our ESPP (in shares)</a></td>
<td class="nump">18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">20<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">38<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing diluted net income per share (in shares)</a></td>
<td class="nump">153,303<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">143,408<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">141,537<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">149,856<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">142,872<span></span>
</td>
<td class="nump">134,056<span></span>
</td>
<td class="nump">126,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember', window );">0.125 Percent Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Quarterly Financial Data (Unaudited) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible senior notes</a></td>
<td class="nump">0.125%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.125%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0.125%<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Income (Numerator) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther', window );">Shares issuable related to our convertible notes</a></td>
<td class="nump">$ 644<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of Diluted Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Shares issuable related to our convertible notes</a></td>
<td class="nump">860<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember', window );">1 Percent Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Quarterly Financial Data (Unaudited) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible senior notes</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Income (Numerator) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther', window );">Shares issuable related to our convertible notes</a></td>
<td class="nump">$ 12,046<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 10,745<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of Diluted Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Shares issuable related to our convertible notes</a></td>
<td class="nump">9,527<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">10,260<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of Diluted Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Shares issuable related to stock-based compensation (in shares)</a></td>
<td class="nump">1,467<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,993<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,252<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,254<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,090<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
<td class="nump">1,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of Diluted Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Shares issuable related to stock-based compensation (in shares)</a></td>
<td class="nump">848<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">844<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">665<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">636<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">766<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ions_IonisCoreMember', window );">Ionis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Quarterly Financial Data (Unaudited) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders</a></td>
<td class="nump">$ 121,552<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 49,930<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 27,311<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 63,697<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 372,913<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 43,226<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5,882<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 18,785<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 262,490<span></span>
</td>
<td class="nump">$ 440,806<span></span>
</td>
<td class="nump">$ 110,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Quarterly Financial Data (Unaudited) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders</a></td>
<td class="nump">$ 62,243<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (23,772)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (28,244)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 23,846<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (53,219)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (47,789)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (43,814)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (19,997)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per share (in dollars per share)</a></td>
<td class="nump">$ 0.87<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.34)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.40)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.73)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.72)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (0.44)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_WeightedAverageNumberOfSharesOwnedInSubsidiary', window );">Weighted average shares owned in Akcea (in shares)</a></td>
<td class="nump">71,342<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">70,221<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">70,221<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">68,582<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">67,130<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">65,538<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">60,832<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">45,448<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="20"></td></tr>
<tr><td colspan="20"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As discussed in Note 1, Organization and Significant Accounting Policies, we compute basic net income (loss) per share by dividing the total net income (loss) attributable to our common stockholders by our weighted-average number of common shares outstanding during the period. Our basic net income (loss) per share calculation for each of the quarters in 2019 and 2018 considered our net income for Ionis on a stand-alone basis plus our share of Akcea&#8217;s net loss for the period. To calculate the portion of Akcea&#8217;s net loss attributable to our ownership, we multiplied Akcea&#8217;s loss per share by the weighted average shares we owned in Akcea during the period. As a result of this calculation, our total net income (loss) available to Ionis common stockholders for the calculation of net income (loss) per share is different than net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders in the consolidated statements of operations.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">We computed net income (loss) per share independently for each of the quarters presented. Therefore, the sum of the quarterly net income (loss) per share will not necessarily equal the total for the year.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">We had net income available to Ionis common stockholders for the following periods. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during those periods.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">For the three months ended March 31, 2019 and September 30, 2019, the calculation excluded the 1 percent notes because the effect on diluted earnings per share was anti-dilutive.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of shares issuable under the Company's employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_WeightedAverageNumberOfSharesOwnedInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares owned in the subsidiary during the reporting period determined by relating the portion of time within a reporting period that shares have been owned to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_WeightedAverageNumberOfSharesOwnedInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1930-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelectedQuarterlyFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ions_IonisCoreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ions_IonisCoreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ions_AkceaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ions_AkceaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6888027312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements and Licensing Agreements, Novartis (Details)<br> $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>PerformanceObligation </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_SublicenseFeePaidForLicenseOfDrug', window );">Sublicense fee paid in stock</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_ReceiptOfSharesInSubsidiary', window );">Additional shares of Akcea stock received (in shares) | shares</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from sale of common stock to Novartis in a private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,122,599<span></span>
</td>
<td class="nump">599,674<span></span>
</td>
<td class="nump">514,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember', window );">R&amp;D Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770,149<span></span>
</td>
<td class="nump">344,752<span></span>
</td>
<td class="nump">$ 394,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember', window );">Novartis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid', window );">Proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations', window );">Number of separate performance obligations | PerformanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_PremiumReceivedOnSharesIssued', window );">Premium received on shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture', window );">Potential premium received if common stock is purchased in the future</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 28,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember', window );">Novartis [Member] | Revenue [Member] | Strategic Partner [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember', window );">Novartis [Member] | R&amp;D Services for AKCEA-APO(a)-L [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember', window );">Novartis [Member] | Delivery of AKCEA-APO(a)-L [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember', window );">Novartis [Member] | R&amp;D Services for AKCEA-APOCIII-L [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember', window );">Novartis [Member] | Delivery of AKCEA-APOCIII-L [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember', window );">Novartis [Member] | R&amp;D Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 187,400<span></span>
</td>
<td class="nump">$ 50,600<span></span>
</td>
<td class="nump">$ 43,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | Novartis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_PortionOfUpfrontPaymentRetained', window );">Portion of upfront payment retained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_PortionOfUpfrontPaymentPaidAsSublicenseFee', window );">Portion of upfront payment paid as sublicense fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee', window );">Percentage of license fees, milestone payments and royalties paid as sublicense fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_AdditionalAmountOfCommonStockRequiredToBePurchased', window );">Additional amount of common stock required to be purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from sale of common stock to Novartis in a private placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | Novartis [Member] | License Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | Novartis [Member] | AKCEA-APO(a)-L [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForMilestones', window );">Maximum amount of payments receivable for milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones', window );">Maximum amount of payments receivable for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones', window );">Maximum amount of payments receivable for regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones', window );">Maximum amount of payments receivable for commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RoyaltyPercentageReceivedOnSalesOfDrug', window );">Royalty percentage received on sales of drug</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_AdditionalAmountOfCommonStockRequiredToBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The additional amount of common stock the collaboration partner is required to purchase under a Stock Purchase Agreement (SPA) in conjunction with the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_AdditionalAmountOfCommonStockRequiredToBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CollaborativeArrangementAndLicensingAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for commercialization milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for development milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for regulatory milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of license fees, milestone payments and royalties paid as sublicense fee under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PortionOfUpfrontPaymentPaidAsSublicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the upfront payment received during the period under the collaboration agreement that was paid as a sublicense fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PortionOfUpfrontPaymentPaidAsSublicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PortionOfUpfrontPaymentRetained">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the upfront payment received during the period under the collaboration agreement that was retained by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PortionOfUpfrontPaymentRetained</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The potential premium received if common stock is purchased in the future under a Stock Purchase Agreement (SPA) in conjunction with the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PremiumReceivedOnSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the premium received over the trading price of common stock at the time of purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PremiumReceivedOnSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of common stock, including the premium paid for the purchase of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_ReceiptOfSharesInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares received from the subsidiary during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_ReceiptOfSharesInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of separate performance obligations under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration the Company earned or is eligible to earn under the collaboration agreement, including any variable consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RoyaltyPercentageReceivedOnSalesOfDrug">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage received on the sales of a drug by a collaboration partner under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RoyaltyPercentageReceivedOnSalesOfDrug</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_SublicenseFeePaidForLicenseOfDrug">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the sublicense fee paid in common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_SublicenseFeePaidForLicenseOfDrug</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payments received during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_DeliveryOfAKCEAAPOALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_DeliveryOfAKCEAAPOALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_DeliveryOfAKCEAAPOCIIILMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_DeliveryOfAKCEAAPOCIIILMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_AKCEAAPOALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_AKCEAAPOALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6971053712">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Investments, Summary of Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Summary of Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost', window );">Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,846,074<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,874,529<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,007<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">556<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,166)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,068)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,849,915<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,871,017<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Available-for-sale Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Summary of Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,831,362<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,873,317<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,007<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">419<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(296)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,068)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,836,073<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,869,668<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Available-for-sale Securities [Member] | Securities with Maturity of One Year or Less [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Summary of Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,206,616<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,433,930<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,012<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">31<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(118)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(2,362)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,208,510<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,431,599<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Available-for-sale Securities [Member] | Securities with Maturity of More than One Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Summary of Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">624,746<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">439,387<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,995<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">388<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(178)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,706)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">627,563<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">438,069<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member] | Securities with Maturity of One Year or Less [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Summary of Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">669,665<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">956,879<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,451<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(43)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,858)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">671,073<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">955,034<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member] | Securities with Maturity of More than One Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Summary of Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">428,627<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">299,018<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,911<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">194<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(43)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(1,286)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">431,495<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">297,926<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Debt Securities issued by U.S. Government Agencies [Member] | Securities with Maturity of One Year or Less [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Summary of Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">188,216<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">168,839<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">303<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(43)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(104)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">188,476<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">168,738<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Debt Securities issued by U.S. Government Agencies [Member] | Securities with Maturity of More than One Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Summary of Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">140,988<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">107,789<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">194<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(117)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(109)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">140,928<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">107,874<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">Debt Securities issued by the U.S. Treasury [Member] | Securities with Maturity of One Year or Less [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Summary of Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">327,670<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">244,640<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">232<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(27)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(77)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">327,875<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">244,578<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">Debt Securities issued by the U.S. Treasury [Member] | Securities with Maturity of More than One Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Summary of Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">35,822<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(12)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(24)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,819<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">15,576<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Debt Securities issued by States of the U.S. and Political Subdivisions of the States [Member] | Securities with Maturity of One Year or Less [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Summary of Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">21,065<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">63,572<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(323)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">21,086<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">63,249<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember', window );">Debt Securities issued by States of the U.S. and Political Subdivisions of the States [Member] | Securities with Maturity of More than One Year [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Summary of Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">19,309<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,980<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(287)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,321<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,693<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Summary of Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,712<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">137<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(870)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,842<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,349<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities [Member] | Other Current Assets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Summary of Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">4,712<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1,212<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities [Member] | Deposits and Other Assets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Summary of Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="nump">10,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities [Member] | Included in Other Current Assets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Summary of Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(870)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,842<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities [Member] | Included in Deposits and Other Assets [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Summary of Investments [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Gross unrealized gains</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Gross unrealized losses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Estimated fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">We hold our available-for-sale securities at amortized cost.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Includes investments classified as cash equivalents on our consolidated balance sheet.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Our equity securities included in other current assets consisted of our investment in ProQR, which is a public company. We recognize our public company equity securities at fair value.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">Our equity securities included in deposits and other assets consisted of our investment in Empirico, which is a private company. We recognize our private company equity securities at cost minus impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer on our consolidated balance sheet.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of (1) investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of (1) amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of (1) unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of (1) unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentSecondaryCategorizationAxis=ions_SecuritiesWithMaturityOfOneYearOrLessMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentSecondaryCategorizationAxis=ions_SecuritiesWithMaturityOfOneYearOrLessMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentSecondaryCategorizationAxis=ions_SecuritiesWithMaturityOfMoreThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentSecondaryCategorizationAxis=ions_SecuritiesWithMaturityOfMoreThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USStatesAndPoliticalSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ions_DepositsAndOtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ions_DepositsAndOtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentSecondaryCategorizationAxis=ions_IncludedInOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentSecondaryCategorizationAxis=ions_IncludedInOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentSecondaryCategorizationAxis=ions_IncludedInDepositsAndOtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentSecondaryCategorizationAxis=ions_IncludedInDepositsAndOtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6885295392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies, Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use operating lease assets</a></td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">17,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Topic 842 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6874061792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies, Convertible Debt (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember', window );">0.125 Percent Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible senior notes</a></td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember', window );">1 Percent Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract', window );"><strong>Convertible Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible senior notes</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6874611168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes, Reconciliation of Statutory to Effective Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Reconciliation Between Effective and Statutory Tax Rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Pre-tax income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 346,769<span></span>
</td>
<td class="num">$ (76,156)<span></span>
</td>
<td class="num">$ (16,763)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,822<span></span>
</td>
<td class="num">(15,993)<span></span>
</td>
<td class="num">(5,867)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income tax net of federal benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,119<span></span>
</td>
<td class="num">(2,202)<span></span>
</td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="nump">1,735<span></span>
</td>
<td class="nump">4,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Net change in valuation allowance</a></td>
<td class="nump">$ 332,100<span></span>
</td>
<td class="num">(37,765)<span></span>
</td>
<td class="num">(277,924)<span></span>
</td>
<td class="num">(86,296)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount', window );">Net operating loss expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,864<span></span>
</td>
<td class="nump">3,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount', window );">TEGSEDI licensing gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">59,583<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount', window );">Impact from outside basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,344)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,296)<span></span>
</td>
<td class="num">(73,362)<span></span>
</td>
<td class="num">(32,769)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Deferred tax true-up</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="nump">9,947<span></span>
</td>
<td class="nump">4,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Tax rate change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,811<span></span>
</td>
<td class="num">(1,808)<span></span>
</td>
<td class="nump">114,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount', window );">Non-deductible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,361<span></span>
</td>
<td class="nump">3,154<span></span>
</td>
<td class="nump">1,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other non-deductible items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="num">(569)<span></span>
</td>
<td class="nump">2,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount', window );">Akcea deconsolidation adjustment at IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,837)<span></span>
</td>
<td class="num">(4,199)<span></span>
</td>
<td class="num">(14,337)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount', window );">Foreign-derived intangible income benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,071)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,608)<span></span>
</td>
<td class="nump">1,633<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,507<span></span>
</td>
<td class="num">$ (291,141)<span></span>
</td>
<td class="num">$ (5,980)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation Between Effective and Statutory Tax Rate Percentage [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income tax net of federal benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.20%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="num">(4.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="num">(2.30%)<span></span>
</td>
<td class="num">(25.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Net change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10.90%)<span></span>
</td>
<td class="nump">364.90%<span></span>
</td>
<td class="nump">514.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent', window );">Net operating loss expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(11.60%)<span></span>
</td>
<td class="num">(23.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent', window );">TEGSEDI licensing gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(78.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent', window );">Impact from outside basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.70%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.40%)<span></span>
</td>
<td class="nump">96.30%<span></span>
</td>
<td class="nump">195.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Deferred tax true-up</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="num">(13.10%)<span></span>
</td>
<td class="num">(28.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Tax rate change</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="num">(685.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent', window );">Non-deductible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="num">(4.10%)<span></span>
</td>
<td class="num">(9.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other nondeductible items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="num">(15.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent', window );">Akcea deconsolidation adjustment at IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(2.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">85.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent', window );">Foreign-derived intangible income benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.60%<span></span>
</td>
<td class="nump">382.30%<span></span>
</td>
<td class="nump">35.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to an adjustment for the deconsolidation of a subsidiary from the consolidated federal income tax return on the date of the subsidiary's Initial Public Offering (IPO).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to an adjustment for the deconsolidation of a subsidiary from the consolidated federal income tax return on the date of the subsidiary's Initial Public Offering (IPO).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to licensing gain on TEGSEDI.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to licensing gain on TEGSEDI.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the expiration of net operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the expiration of net operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign-derived intangible income benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign-derived intangible income benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the impact from outside basis differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the impact from outside basis differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to compensation in excess of $1 million paid to any "covered employee" of the corporation under Section 162(m) of the Tax Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to compensation in excess of $1 million paid to any "covered employee" of the corporation under Section 162(m) of the Tax Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32059-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6874484544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity, Stock-based Compensation Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>Officer</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,574<span></span>
</td>
<td class="nump">$ 131,312<span></span>
</td>
<td class="nump">$ 85,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Products Sold [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">438<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ions_ResearchDevelopmentAndPatentMember', window );">Research, Development and Patent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,348<span></span>
</td>
<td class="nump">76,557<span></span>
</td>
<td class="nump">64,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,788<span></span>
</td>
<td class="nump">54,595<span></span>
</td>
<td class="nump">21,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="num">$ (19,100)<span></span>
</td>
<td class="nump">$ 37,100<span></span>
</td>
<td class="nump">$ 44,300<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfExecutiveOfficersTerminatingEmployment', window );">Number of executive officers terminating employment | Officer</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfExecutiveOfficersTerminatingEmployment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of executive officers terminating employment with the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfExecutiveOfficersTerminatingEmployment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ions_ResearchDevelopmentAndPatentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ions_ResearchDevelopmentAndPatentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6885505344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes the stock option activity under our stock plans for the year ended December 31, 2019 (in thousands, except per share and contractual life data):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z9b50c63317624dd0af7fdc21a2a7bfb8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Number</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">of Shares</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Exercise</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Price Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Remaining</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Contractual Term</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Years)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Aggregate</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intrinsic</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Value</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Outstanding at December 31, 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11,311</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">47.85</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Granted</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,543</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">56.19</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Exercised</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2,617</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">40.48</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cancelled/forfeited/expired</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(236</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">50.11</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Outstanding at December 31, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11,001</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">51.48</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.41</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104,029</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Exercisable at December 31, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,004</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">50.95</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.34</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">59,780</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">RSU Activity</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes the RSU activity for the year ended December 31, 2019 (in thousands, except per share data):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zc0f5e4e23b714ab09d3ea5e085c1013f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Number</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">of Shares</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted Average</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Grant Date Fair</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Value Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-vested at December 31, 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,246</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">50.20</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Granted</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,114</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">60.23</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Vested</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(422</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">51.36</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cancelled/forfeited</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(72</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">53.39</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-vested at December 31, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,866</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">55.80</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes stock-based compensation expense for the years ended December 31, 2019, 2018 and 2017 (in thousands), which was allocated as follows and includes $37.1 million, $44.3 million and $17.5 million of stock-based compensation expense for Akcea employees in 2019, 2018 and 2017, respectively:</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="ze0f1f82608a349d9975520506247db45" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cost of products sold</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">438</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">160</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Research, development and patent</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">95,348</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">76,557</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">64,521</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Selling, general and administrative</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">50,788</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">54,595</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21,454</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">146,574</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">131,312</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">85,975</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_ShareBasedCompensationLineItems', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-Average Assumptions for Stock Options</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Ionis Employee Stock Options:</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z1a22f5901f3944f2be1e317aad3cab4b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Risk-free interest rate</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dividend yield</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Volatility</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">60.3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">63.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">65.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expected life</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.8 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.6 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.5 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Ionis Board of Director Stock Options:</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zc7e20a324c544bf6af7f8bb69517a4b2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Risk-free interest rate</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dividend yield</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Volatility</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">60.7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">61.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">61.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expected life</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.6 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.6 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.6 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Weighted-Average Assumptions for ESPP</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Ionis ESPP:</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zaf6dcfd7dd86499dbd414c26e0657d2f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Risk-free interest rate</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dividend yield</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Volatility</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">45.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">47.3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">59.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expected life</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6 months</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6 months</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6 months</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_ShareBasedCompensationLineItems', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Weighted-Average Assumptions for Stock Options</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Akcea Employee Stock Options:</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z6d0f71f781114c2796697bdc6544ea2f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Risk-free interest rate</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dividend yield</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Volatility</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">75.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">77.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">79.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expected life</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.09 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.08 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.06 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Akcea Board of Director Stock Options:</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zbbe3118c00004f9f91eb04676b0aef23" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Risk-free interest rate</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dividend yield</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Volatility</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">73.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">78.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">79.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expected life</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.25 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.42 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.25 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Weighted-Average Assumptions for ESPP</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Akcea ESPP:</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z274cc299456642c993f118c12d22a0fd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Risk-free interest rate</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dividend yield</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Volatility</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">60.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">64.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">73.3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expected life</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6 months</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6 months</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6 months</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_ShareBasedCompensationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_ShareBasedCompensationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6872857424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Basis of Presentation</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">In our consolidated financial statements we included the accounts of Ionis Pharmaceuticals, Inc. (&#8220;we&#8221;, &#8220;us&#8221; or &#8220;our&#8221;) and the consolidated results of our majority-owned affiliate, Akcea Therapeutics, Inc., which we formed in December 2014. In July 2017, Akcea completed an initial public offering, or IPO. Since Akcea&#8217;s IPO, our ownership has ranged from </span>68 percent<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> to </span>77 percent<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. At December 31, 2019, o</span>ur ownership was approximately 76 percent. We reflect changes in our ownership of Akcea in our financial statements in the period the change occurs. For example, we reflected an increase in our ownership when we received 6.9 million shares of Akcea common stock as payment for the sublicense fee Akcea owed us for Pfizer&#8217;s license of AKCEA-ANGPTL3-L<sub>Rx</sub> in the fourth quarter of 2019. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Refer to the section titled &#8220;Noncontrolling Interest in Akcea&#8221; in Note 2, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Significant Accounting Policies,</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for further information related to our accounting for our investment in Akcea.</span></div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Income per Share</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Basic and Diluted Net Income per Share</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Basic net income per share</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We compute basic net income per share by dividing the total net income attributable to our common stockholders by our weighted-average number of common shares outstanding during the period.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The calculation of total net income attributable to our common stockholders for each year considered our net income for Ionis on a stand-alone basis plus our share of Akcea&#8217;s net income (loss) for the period. To calculate the portion of Akcea&#8217;s net income (loss) attributable to our ownership for each year, we multiplied Akcea&#8217;s income (loss) per share by the weighted average shares we owned in Akcea during the period. As a result of this calculation, our total net income available to Ionis common stockholders for the calculation of net income per share is different than net income attributable to Ionis Pharmaceuticals, Inc. common stockholders in our consolidated statements of operations for each year.</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our basic net income per share, was calculated as follows (in thousands, except per share amounts):</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z104b454b266445eaac9eed834835145f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Portion of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Income</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">70,100</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.49</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">34,073</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net income attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">34,073</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">262,490</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">296,563</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">139,998</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.12</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zfe21e6fd0158439f854dad365e54a58d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Portion of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">59,812</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2.74</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(163,938</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(163,938</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">440,806</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">276,868</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">132,320</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.09</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We calculated our basic net income per share for 2017 as follows (in thousands, except per share amounts):</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z7f02aeb560ee40bd982c44713ab0a2ac" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2017</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Portion of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20,669</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3.08</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(63,638</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Preferred shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15,748</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1.80</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(28,346</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(91,984</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">110,776</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,792</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">124,016</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.15</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Prior to Akcea&#8217;s IPO in July 2017, we owned Akcea series A convertible preferred stock, which included a <span style="-sec-ix-hidden:Fact_814732dbfffb4dbbb487265b1d09e7b7">six percent</span> cumulative dividend. Upon completion of Akcea&#8217;s IPO in July 2017, our preferred stock was converted into common stock on a 1:1 basis. The preferred stock dividend was not paid at the IPO because the IPO was not a liquidation event or a change in control. During 2017, Akcea used a two-class method to compute its net loss per share because it had both common and preferred shares outstanding during the periods. The two-class method required Akcea to calculate its net loss per share for each class of stock by dividing total distributable losses applicable to preferred and common stock, including the six percent cumulative dividend contractually due to series A convertible preferred shareholders, by the weighted-average of preferred and common shares outstanding during the requisite period. Since Akcea used the two-class method, accounting rules required us to include our portion of Akcea&#8217;s net loss per share for both Akcea&#8217;s common and preferred shares that we owned in our calculation of basic and diluted net income per share for the year ended December 31, 2017.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Diluted net income per share</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We calculated our diluted net income per share as follows <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(in thousands except per share amounts):</span></div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zb0e4b49c2e274df0b9950bc8e8004fbd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">296,563</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">139,998</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.12</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -8.9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,090</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: 0.1pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">766</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our Employee Stock Purchase Plan</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">296,563</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">142,872</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.08</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z01b775cd675848508a1d52bc1c4cff37" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">276,868</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">132,320</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.09</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -8.9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,216</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: 0.1pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">514</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our Employee Stock Purchase Plan</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">276,868</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">134,056</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.07</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zd8deeaecb9c64cd89c8fc8806b7a193d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2017</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,792</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">124,016</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.15</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -8.9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,619</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: 0.1pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">459</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our Employee Stock Purchase Plan</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,792</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">126,098</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.15</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For each year presented, the calculation excluded our convertible senior notes because the effect on diluted earnings per share was anti-dilutive.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Revenue Recognition</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Our Revenue Sources</span></span></div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We generally recognize revenue when we have satisfied all contractual obligations and are reasonably assured of collecting the resulting receivable. We are often entitled to bill our customers and receive payment from our customers in advance of recognizing the revenue. In the instances in which we have received payment from our customers in advance of recognizing revenue, we include the amounts in deferred revenue on our consolidated balance sheet.</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Commercial Revenue: SPINRAZA royalties and Licensing and other royalty revenue</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We earn commercial revenue primarily in the form of royalty payments on net sales of SPINRAZA. We will also recognize as commercial revenue future sales milestone payments and royalties we earn under our partnerships.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Commercial Revenue: Product sales, net</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We added product sales from TEGSEDI to our commercial revenue in the fourth quarter of 2018 and we added product sales from WAYLIVRA to our commercial revenue in the third quarter of 2019. </span>In the U.S., we distribute TEGSEDI through an exclusive distribution agreement with a third-party logistics company, or 3PL, that takes title to TEGSEDI. The 3PL is our sole customer in the U.S. The 3PL then distributes TEGSEDI to a specialty pharmacy and a specialty distributor, which we collectively refer to as wholesalers, who then distribute TEGSEDI to health care providers and patients. In Europe, prior to the third quarter of 2019 we distributed TEGSEDI through a non-exclusive distribution model with a 3PL that took title to TEGSEDI. The 3PL was our sole customer in Europe. The 3PL in Europe then distributed TEGSEDI to hospitals and pharmacies. In the third quarter of 2019, we entered into a distribution arrangement with a 3PL and began to sell both TEGSEDI and WAYLIVRA directly to hospitals and pharmacies in Europe.</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Research and development revenue under collaborative agreements</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We often enter into collaboration agreements to license and sell our technology on an exclusive or non-exclusive basis. Our collaboration agreements typically contain multiple elements, or performance obligations, including technology licenses or options to obtain technology licenses, research and development, or R&amp;D, services, and manufacturing services.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our collaboration agreements are detailed in Note 6, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Collaborative Arrangements and Licensing Agreements.</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Under each collaboration note we discuss our specific revenue recognition conclusions, including our significant performance obligations under each collaboration.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Steps to Recognize Revenue</span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We use a five-step process to determine the amount of revenue we should recognize and when we should recognize it. The five step process is as follows:</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zb9f70b6bc634422f82831b9476ae8444" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">1.</td>
    <td style="width: auto; vertical-align: top; text-align: left;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Identify the contract</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Accounting rules require us to first determine if we have a contract with our partner, including confirming that we have met each of the following criteria:</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z32abea7f3b454dedb5d275fcd69bfc41" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: left;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We and our partner approved the contract and we are both committed to perform our obligations;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z2fef2cbf4007441595d4245add81d46d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: left;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have identified our rights, our partner&#8217;s rights and the payment terms;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze8401d5278b84ee1953ba4283b1f9851" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have concluded that the contract has commercial substance, meaning that the risk, timing, or amount of our future cash flows is expected to change as a result of the contract; and</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z7c8deb873be94db28e11c93fd5b094f0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: left;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We believe collectability is probable. </div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: -18pt; margin-left: 54pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zac78659984944d66a7d6f7f05a5a6181" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"><span style="background-color: #FFFFFF;">2.</span></td>
    <td style="width: auto; vertical-align: top; text-align: left;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"><span style="background-color: #FFFFFF; font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Identify the performance obligations</span></div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We next identify the distinct goods and services we are required to provide under the contract. Accounting rules refer to these as our performance obligations. We typically have only one performance obligation at the inception of a contract, which is to perform R&amp;D services.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Often times we enter into a collaboration agreement in which we provide our partner with an option to license a medicine in the future. We may also provide our partner with an option to request that we provide additional goods or services in the future, such as active pharmaceutical ingredient, or API. We evaluate whether these options are material rights at the inception of the agreement. If we determine an option is a material right, we will consider the option a separate performance obligation. Historically, we have concluded that the options we grant to license a medicine in the future or to provide additional goods and services as requested by our partner are not material rights. These items are contingent upon future events that may not occur. When a partner exercises its option to license a medicine or requests additional goods or services, then we identify a new performance obligation for that item.</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In some cases, we deliver a license at the start of an agreement. If we determine that our partner has full use of the license and we do not have any additional material performance obligations related to the license after delivery, then we consider the license to be a separate performance obligation.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zf1f446d282dd4e1b832e3c09c5f82c88" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">3.</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Determine the transaction price</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We then determine the transaction price by reviewing the amount of consideration we are eligible to earn under the collaboration agreement, including any variable consideration. Under our collaboration agreements, consideration typically includes fixed consideration in the form of an upfront payment and variable consideration in the form of potential milestone payments, license fees and royalties. At the start of an agreement, our transaction price usually consists of only the upfront payment. We do not typically include any payments we may receive in the future in our initial transaction price because the payments are not probable and are contingent on certain future events. We reassess the total transaction price at each reporting period to determine if we should include additional payments in the transaction price.</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Milestone payments are our most common type of variable consideration. We recognize milestone payments using the most likely amount method because we will either receive the milestone payment or we will not, which makes the potential milestone payment a binary event. The most likely amount method requires us to determine the likelihood of earning the milestone payment. We include a milestone payment in the transaction price once it is probable we will achieve the milestone event. Most often, we do not consider our milestone payments probable until we or our partner achieve the milestone event because the majority of our milestone payments are contingent upon events that are not within our control and are usually based on scientific progress. For example, in the fourth quarter of 2019, we earned a $10 million milestone payment from AstraZeneca when AstraZeneca initiated a Phase 1 trial for ION839. We did not consider the milestone payments probable until AstraZeneca achieved the milestone event because the initiation of the Phase 1 trial was a contingent event that was not within our control. We recognized the milestone payments in full in the period the milestone event was achieved because we did not have any remaining performance obligations related to the milestone payment.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z61f3f8aec88b4866a2bbc6540840c7b9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">4.</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Allocate the transaction price</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Next, we allocate the transaction price to each of our performance obligations. When we have to allocate the transaction price to more than one performance obligation, we make estimates of the relative stand-alone selling price of each performance obligation because we do not typically sell our goods or services on a stand-alone basis. We then allocate the transaction price to each performance obligation based on the relative stand-alone selling price.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We may engage a third party, independent valuation specialist to assist us with determining a stand-alone selling price for collaborations in which we deliver a license at the start of an agreement. We estimate the stand-alone selling price of these licenses using valuation methodologies, such as the relief from royalty method. Under this method, we estimate the amount of income, net of taxes, for the license. We then discount the projected income to present value. The significant inputs we use to determine the projected income of a license could include:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zd0332dc311ad49d5aebb0b0dcec49da1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Estimated future product sales;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zbafbea8c82a44de19538caf8c4d34c17" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Estimated royalties on future product sales;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zc5914eb350eb4288913df6b658f90445" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Contractual milestone payments;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z23f53850cb2e499c87cc78fc51b878db" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expenses we expect to incur;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zba5b48ea375f49caad917f1f137ff6cf" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income taxes; and</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zc80b99fe0b894aecb56282f28ddea0a9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A discount rate.</div></td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We typically estimate the selling price of R&amp;D services by using our internal estimates of the cost to perform the specific services. The significant inputs we use to determine the selling price of our R&amp;D services include:</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z2a27bbd1916f4ee3b3441ed762a2c2b3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The number of internal hours we estimate we will spend performing these services;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z3d50f6d0709c44f89b5262ca45319fbe" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The estimated cost of work we will perform;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zf1df7de1efb647f3a758705c8216c76d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The estimated cost of work that we will contract with third parties to perform; and</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zcc18420c84464778ad67ecdb5155e530" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The estimated cost of API we will use. </div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For purposes of determining the stand-alone selling price of the R&amp;D services we perform and the API we will deliver, accounting guidance requires us to include a markup for a reasonable profit margin.</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We do not reallocate the transaction price after the start of an agreement to reflect subsequent changes in stand-alone selling prices.</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zaa2a29a440094a6385db6db34fe05178" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">5.</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Recognize revenue</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -54pt; margin-left: 54pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We recognize revenue in one of two ways, over time or at a point in time. We recognize revenue over time when we are executing on our performance obligation over time and our partner receives benefit over time. For example, we recognize revenue over time when we provide R&amp;D services. We recognize revenue at a point in time when our partner receives full use of an item at a specific point in time. For example, we recognize revenue at a point in time when we deliver a license or API to a partner.</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For R&amp;D services that we recognize over time, we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time we estimate it will take us to complete the activities, or costs we incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates and use significant judgement. If our estimates or judgements <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods. For example, </span>in the third quarter of 2019, we updated our estimate of the total effort we expected to expend to satisfy our performance obligation under our<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> 2013 Strategic Neurology collaboration with Biogen</span>. As of September 30, 2019, we had completed a<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> significant portion of the research and development services. We expect to complete the remainder of our services in 2020. As a result of our change in estimate, in the third quarter of 2019, we recorded a cumulative catch up adjustment of $</span>16.5<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million to decrease revenue. Refer to Note 7, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Collaborative Arrangements and Licensing Agreements</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, for further discussion of the cumulative catch up adjustment we made.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following are examples of when we typically recognize revenue based on the types of payments we receive.</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Commercial Revenue: SPINRAZA royalties and Licensing and other royalty revenue</span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We recognize royalty revenue, including royalties from SPINRAZA sales, in the period in which the counterparty sells the related product and recognizes the related revenue, which in certain cases may require us to estimate our royalty revenue.</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Commercial Revenue: Product sales, net</span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We recognize product sales in the period </span>when our customer obtains control of our products, which occurs at a point in time upon transfer of title to the customer. We classify payments to customers or other parties in the distribution channel for services that are distinct and priced at fair value as selling, general and administrative expenses in our consolidated statements of operations. Otherwise, payments to customers or other parties in the distribution channel that do not meet those criteria are classified as a reduction of revenue, as discussed further below. We exclude from revenues taxes collected from customers relating to product sales and remitted to governmental authorities.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Reserves for Product sales</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We record product sales at our net sales price, or transaction price. We include in our transaction price estimated reserves for discounts, returns, chargebacks, rebates, co-pay assistance and other allowances that we offer within contracts between us and our customers, wholesalers, health care providers and other indirect customers. We estimate our reserves using the amounts we have earned or what we can claim on the associated sales. We classify our reserves as a reduction of accounts receivable when we are not required to make a payment or as a current liability when we are required to make a payment. In certain cases, our estimates include a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, our reserves reflect our best estimates under the terms of our respective contracts. When calculating our reserves and related product sales, we only recognize amounts to the extent that we consider it probable that we would not have to reverse in a future period a significant amount of the cumulative sales we previously recognized. The actual amounts we receive may ultimately differ from our reserve estimates. If actual amounts in the future vary from our estimates, we will adjust these estimates, which would affect our net product sales in the respective period.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following are the components of variable consideration related to product sales:</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Chargebacks: </span>In the U.S., we estimate obligations resulting from contractual commitments with the government and other entities to sell products to qualified healthcare providers at prices lower than the list prices charged to our U.S. customer. Our U.S. customer charges us for the difference between what it pays for the product and the selling price to the qualified healthcare providers. We also estimate the amount of chargebacks related to our estimated product remaining in the distribution channel at the end of the reporting period that we expect our customer to sell to healthcare providers in future periods. We record these reserves as an accrued liability on our consolidated balance sheet for the chargebacks related to product sales to our U.S. customer during the reporting period.</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Government rebates</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">: We are subject t</span>o discount obligations under government programs, including Medicaid and Medicare programs in the U.S. and we record reserves for government rebates based on statutory discount rates and estimated utilization. We estimate Medicaid and Medicare rebates based on a range of possible outcomes that are probability-weighted for the estimated payer mix. We record these reserves as an accrued liability on our consolidated balance sheet with a corresponding offset reducing our product sales in the same period we recognize the related sale. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program. On a quarterly basis, we update our estimates and record any adjustments in the period that we identify the adjustments.</div>

<div style="text-align: justify; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Managed care rebates: </span>We are subject to rebates in connection with a value-based agreement with one of our commercial payer&#8217;s. We record these rebates as an accrual on our consolidated balance sheet in the same period we recognize the related revenue. We estimate our managed care rebates based on our estimated payer mix and the applicable contractual rebate rate.</div>

<div style="text-align: justify; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Trade discounts: </span>We provide customary invoice discounts on product sales to our U.S. customer for prompt payment. We record this discount as a reduction of product sales in the period in which we recognize the related product revenue.</div>

<div style="text-align: justify; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Distribution services</span>: We receive and pay for various distribution services from our U.S. and EU customers and wholesalers in the U.S.. We classify the costs for services we receive that are either not distinct from the sale of the product or for which we cannot reasonably estimate the fair value as a reduction of product sales. To the extent that the services we receive are distinct from the sale of the product, we classify the costs for such services as selling, general and administration, or SG&amp;A, expenses.</div>

<div style="text-align: justify; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Product returns: </span>Our U.S. customer has return rights and the wholesalers have limited return rights primarily related to the product&#8217;s expiration date. We estimate the amount of product sales that our customer may return. We record our return estimate as an accrued refund liability on our consolidated balance sheet with a corresponding offset reducing our product sales in the same period we recognize the related sale. Based on our distribution model for product sales, contractual inventory limits with our customer and wholesalers and the price of the product, we have had minimal returns to date and we believe we will continue to have minimal returns. Our EU customers only take title to the product after they receive an order from a hospital or pharmacy and therefore they do not maintain excess inventory levels of our products. Accordingly, we have limited return risk in the EU and we do not estimate returns in the EU.</div>

<div style="text-align: justify; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Other incentives: </span>In the U.S., we estimate reserves for other incentives including co-payment assistance we provide to patients with commercial insurance who have coverage and reside in states that allow co-payment assistance. We record a reserve for the amount we estimate we will pay for co-payment assistance. We base our reserve on the number of estimated claims and our estimate of the cost per claim related to product sales that we have recognized as revenue. We record our other incentive reserve estimates as an accrued liability on our consolidated balance sheet with a corresponding offset reducing our product sales in the same period we recognize the related sale.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Research and development revenue under collaboration agreements:</span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Upfront payments</span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">When we enter into a collaboration agreement with an upfront payment, we typically record the entire upfront payment as deferred revenue if our only performance obligation is for R&amp;D services we will provide in the future. We amortize the upfront payment into revenue as we perform the R&amp;D services. For example, under our <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">collaboration agreement with Roche to</span><span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> develop IONIS-FB-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for the treatment of complement-mediated diseases</span>, we received a $75 million upfront payment in the fourth quarter of 2018. We allocated the upfront payment to our single performance obligation, R&amp;D services. We are amortizing the $75 million upfront payment using an input method over the estimated period of time we are providing R&amp;D services.</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Milestone payments</span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are required to include additional consideration in the transaction price when it is probable. We typically include milestone payments for R&amp;D services in the transaction price when they are achieved. We include these milestone payments when they are achieved because there is considerable uncertainty in the research and development processes that trigger these payments. Similarly, we include approval milestone payments in the transaction price once the medicine is approved by the applicable regulatory agency. We will recognize sales-based milestone payments in the period in which we achieve the milestone under the sales-based royalty exception allowed under accounting rules.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We recognize milestone payments that relate to an ongoing performance obligation over our period of performance. For example, in the fourth quarter of 2019, we achieved two $7.5 million milestone payments from Biogen when we advanced two new targets for undisclosed neurological diseases under our 2018 strategic neurology collaboration. We added these payments to the transaction price and allocated it to our R&amp;D services performance obligation. We are recognizing revenue related to these milestone payments over our estimated period of performance.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Conversely, we recognize in full those milestone payments that we earn based on our partners&#8217; activities when our partner achieves the milestone event and we do not have a performance obligation. For example, in the fourth quarter of 2019, we recognized a $10 million milestone payment <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">when Biogen advanced the development candidate for an undisclosed target under our 2012 neurology collaboration agreement</span>. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We concluded that the milestone payment was not related to our R&amp;D services performance obligation. Therefore, we recognized the milestone payment in full in the fourth quarter of 2019.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">License fees</span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We generally recognize as revenue the total amount we determine to be the relative stand-alone selling price of a license when we deliver the license to our partner. This is because our partner has full use of the license and we do not have any additional performance obligations related to the license after delivery. </span>For example, in the fourth quarter of 2019, we earned a $45 million license fee when Biogen licensed IONIS-MAPT<sub>Rx</sub> from us. We also recognized $246 million of license fee revenue related to Akcea&#8217;s license of AKCEA-ANGPTL3-L<sub>Rx</sub> to Pfizer in the fourth quarter of 2019.</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"><span style="text-decoration: underline;">Sublicense fees</span></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We recognize sublicense fee revenue in the period in which a party, who has already licensed our technology, further licenses the technology to another party because we do not have any performance obligations related to the sublicense. </span>For example, in the second quarter of 2019, we earned a $20 million sublicense fee when Alnylam Pharmaceuticals sublicensed our technology to Regeneron Pharmaceuticals.</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Amendments to Agreements</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">From time to time we amend our collaboration agreements. When this occurs, we are required to assess the following items to determine the accounting for the amendment:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z4d3009374a5e478e8122026b5e139b45" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If the additional goods and/or services are distinct from the other performance obligations in the original agreement; and</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zf0f366c375b94c81a0b52ddbbfa1f51e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If the goods and/or services are at a stand-alone selling price. </div></td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">If we conclude the goods and/or services in the amendment are distinct from the performance obligations in the original agreement and at a stand-alone selling price, we account for the amendment as a separate agreement. If we conclude the goods and/or services are not distinct and at their stand-alone selling price, we then assess whether the remaining goods or services are distinct from those already provided. If the goods and/or services are distinct from what we have already provided, then we allocate the remaining transaction price from the original agreement and the additional transaction price from the amendment to the remaining goods and/or services. If the goods and/or services are not distinct from what we have already provided, we update the transaction price for our single performance obligation and recognize any change in our estimated revenue as a cumulative adjustment.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">For example, in May 2015, we entered into an exclusive license agreement with Bayer to develop and commercialize IONIS-FXI</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> for the prevention of thrombosis. As part of the agreement, Bayer paid us a $</span>100<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million upfront payment. At the onset of the agreement, we were responsible for completing a Phase 2 study of IONIS-FXI</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> in people with end-stage renal disease on hemodialysis and for providing an initial supply of API. In February 2017, we amended our agreement with Bayer to advance IONIS-FXI</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and to initiate development of IONIS-FXI-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, which Bayer licensed. As part of the 2017 amendment, Bayer paid us $</span>75<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million. We are also eligible to receive milestone payments and tiered royalties on gross margins of IONIS-FXI</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and IONIS-FXI-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. Under the 2017 amendment, we concluded we had a new agreement with </span>three<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> performance obligations. These performance obligations were to deliver the license of IONIS-FXI-L</span><sub>Rx</sub><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, to provide R&amp;D services and to deliver API. We allocated the $</span>75<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million transaction price to these performance obligations. </span>Refer to <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Note 7, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Collaborative Arrangements and Licensing Agreements</span>, for further discussion <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">of our accounting treatment for our Bayer collaboration.</span></div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;">Multiple agreements</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">From time to time, we may enter into separate agreements at or near the same time with the same partner. We evaluate such agreements to determine whether we should account for them individually as distinct arrangements or whether the separate agreements should be combined and accounted for together. We evaluate the following to determine the accounting for the agreements:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z5a22915e59694cedaf8815e2feb45467" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Whether the agreements were negotiated together with a single objective;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z4c6b305fcd854a51950b2b0c8b9ff86f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Whether the amount of consideration in one contract depends on the price or performance of the other agreement; or</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z82b56ef158ea487c94fc2daddd0e9546" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Whether the goods and/or services promised under the agreements are a single performance obligation. </div></td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our evaluation involves significant judgment to determine whether a group of agreements might be so closely related that accounting guidance requires us to account for them as a combined arrangement.</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For example, in the second quarter of 2018, we entered into two separate agreements with Biogen at the same time: a new strategic neurology collaboration agreement and a stock purchase agreement, or SPA. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We evaluated the Biogen agreements to determine whether we should treat the agreements separately or combine them. We considered that the agreements were negotiated concurrently and in contemplation of one another. Based on these facts and circumstances, we concluded that we should evaluate the provisions of the agreements on a combined basis.</span></div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Contracts Receivable</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: -54pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Contracts Receivable</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: -18pt; margin-left: 54pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Our contracts receivable balance represents the amounts we have billed our partners or customers and that are due to us unconditionally for goods we have delivered or services we have performed. When we bill our partners or customers with payment terms based on the passage of time, we consider the contract receivable to be unconditional. We typically receive payment within one </span><span style="-sec-ix-hidden:Fact_5acf7b3d4ee04d009d32a31d9e4ded77">quarter</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> of billing our partner or customer</span>.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy', window );">Unbilled SPINRAZA Royalties</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -54pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Unbilled SPINRAZA Royalties</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our unbilled SPINRAZA royalties represent our right to receive consideration from Biogen in advance of when we are eligible to bill Biogen for SPINRAZA royalties. We include these unbilled amounts in other current assets on our consolidated balance sheet.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Deferred Revenue</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: -54pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Deferred Revenue</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We are often entitled to bill our customers and receive payment from our customers in advance of our obligation to provide services or transfer goods to our partners. In these instances, we include the amounts in deferred revenue on our consolidated balance sheet.</span> During the years ended December 31, 2019 and 2018, we recognized $159.5 million and $105.3 million of revenue from amounts that were in our beginning deferred revenue balance for each respective period. For further discussion, refer to our revenue recognition policy above.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Products Sold</a></td>
<td class="text">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Cost of Products Sold</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our cost of products sold includes manufacturing costs, transportation and freight costs and indirect overhead costs associated with the manufacturing and distribution of our products. We also may include certain period costs related to manufacturing services and inventory adjustments in cost of products sold. Prior to obtaining regulatory approval of TEGSEDI in July 2018 and WAYLIVRA in May 2019, we expensed as research and development expenses a significant portion of the costs we incurred to produce the initial commercial launch supply for each medicine. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We previously expensed $</span>0.7<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million and $</span>0.1<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> million of costs to produce our products related to the product sales revenue we recognized in 2019 and 2018, respectively.</span></div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our research and development expenses include wages, benefits, facilities, supplies, external services, clinical trial and manufacturing costs and other expenses that are directly related to our research and development operations. We expense research and development costs as we incur them. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. For the years ended December 31, 2019, 2018 and 2017, research and development expenses were $461.5 million, $411.9 million and $372.5 million, respectively. A portion of the costs included in research and development expenses are costs associated with our partner agreements. For the years ended December 31, 2019, 2018 and 2017, research and development costs of approximately $83.2 million, $58.7 million and $59.5 million, respectively, were related to our partner agreements.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Patent Expenses</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We capitalize costs consisting principally of outside legal costs and filing fees related to obtaining patents. We amortize patent costs over the useful life of the patent, beginning with the date the U.S. Patent and Trademark Office, or foreign equivalent, issues the patent. The weighted average remaining amortizable life of our issued patents was 10.3 years at December 31, 2019.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The cost of our patents capitalized on our consolidated balance sheet at December 31, 2019 and 2018 was $34.0 million and $32.7 million, respectively. Accumulated amortization related to patents was $8.3 million and $8.7 million at December 31, 2019 and 2018, respectively.</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Based on our existing patents, we estimate amortization expense related to patents in each of the next five years to be the following:</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z3b4746089ec94fcf825148a7e478c941" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ending December 31,</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amortization</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(in millions)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2021</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2022</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2023</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2024</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We review our capitalized patent costs regularly to ensure that they include costs for patents and patent applications that have future value. When we identify patents and patent applications that we are not actively pursuing, we write off any associated costs. In 2019, 2018 and 2017, patent expenses were $4.2 million, $2.6 million and $2.1 million, respectively, and included non-cash charges related to the write-down of our patent costs to their estimated net realizable values of $2.2 million, $0.8 million and $0.4 million, respectively.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Noncontrolling Interest in Akcea Therapeutics, Inc.</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Noncontrolling Interest in Akcea Therapeutics, Inc.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Prior to Akcea&#8217;s IPO in July 2017, we owned 100 percent of Akcea. <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Since Akcea&#8217;s IPO, our ownership has ranged from </span>68 percent<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> to </span>77 percent<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. At December 31, </span>2019<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, o</span>ur ownership was approximately 76 percent. We reflect changes in our ownership percentage in our financial statements as an adjustment to noncontrolling interest in the period the change occurs. During 2019, we received the following additional shares of Akcea common stock:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zb8e73bce7e5949779fde18c99941a249" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.8 million shares in the first quarter of 2019 as payment for the sublicense fee Akcea owed us for Novartis&#8217;s license of AKCEA-APO(a)-L<sub>Rx</sub>, and;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zb8be43d6e4c14352bda3fb7b936ad303" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.9 million shares in the fourth quarter of 2019 as payment for the sublicense fee Akcea owed us for Pfizer&#8217;s license of AKCEA-ANGPTL3-L<sub>Rx</sub>.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The shares third parties own represent an interest in Akcea&#8217;s equity that we do control. However, as we continue to maintain overall control of Akcea through our voting interest, we reflect the assets, liabilities and results of operations of Akcea in our consolidated financial statements. We reflect the noncontrolling interest attributable to other owners of Akcea&#8217;s common stock in a separate line on the statement of operations and a separate line within stockholders&#8217; equity in our consolidated balance sheet. In addition, we record a noncontrolling interest adjustment to account for the stock options Akcea grants, which if exercised, will dilute our ownership in Akcea. This adjustment is a reclassification within stockholders&#8217; equity from additional paid-in capital to noncontrolling interest in Akcea equal to the amount of stock-based compensation expense Akcea had recognized.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Concentration of Credit Risk</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, short-term investments and receivables. We place our cash equivalents and short-term investments with reputable financial institutions. We primarily invest our excess cash in commercial paper and debt instruments of the U.S. Treasury, financial institutions, corporations, and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1, P-1 or F-1 by Moody&#8217;s, Standard &amp; Poor&#8217;s, or S&amp;P, or Fitch, respectively. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock', window );">Cash, Cash Equivalents and Investments</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Cash, Cash Equivalents and Investments</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We consider all liquid investments with maturities of three months or less when we purchase them to be cash equivalents. Our short-term investments have initial maturities of greater than three months from date of purchase. We classify our short-term debt investments as &#8220;available-for-sale&#8221; and carry them at fair market value based upon prices on the last day of the fiscal period for identical or similar items. We record unrealized gains and losses on debt securities as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments. We use the specific identification method to determine the cost of securities sold.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We also have equity investments of less than 20 percent ownership in publicly and privately held biotechnology companies that we received as part of a technology license or partner agreement. At December 31, 2019, we held equity investments in two publicly held companies, ProQR Therapeutics N.V., or ProQR, and Antisense Therapeutics Limited, or ATL. We also held equity investments in five privately-held companies, Atlantic Pharmaceuticals Limited, Dynacure SAS, Empirico, Inc., Seventh Sense Biosystems and Suzhou Ribo Life Science Co, Ltd.</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In January 2018, we adopted the amended accounting guidance related to the recognition, measurement, presentation, and disclosure of certain financial instruments. The amended guidance requires us to measure and record our equity investments at fair value. Additionally, the amended accounting guidance requires us to recognize the changes in fair value in our consolidated statement of operations, instead of through accumulated other comprehensive income. Prior to 2018, we accounted for our equity investments in privately held companies under the cost method of accounting. Under the amended guidance we account for our equity investments in privately held companies at their cost minus impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Our adoption of this guidance did not have an impact on our results.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory Valuation</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Inventory Valuation</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We reflect our inventory on our consolidated balance sheet at the lower of cost or market value under the first-in, first-out method, or FIFO. We capitalize the costs of raw materials that we purchase for use in producing our medicines because until we use these raw materials, they have alternative future uses, which we refer to as clinical raw materials. We include in inventory raw material costs for medicines that we manufacture for our partners under contractual terms and that we use primarily in our clinical development activities and drug products. We can use each of our raw materials in multiple products and, as a result, each raw material has future economic value independent of the development status of any single medicine. For example, if one of our medicines failed, we could use the raw materials for that medicine to manufacture our other medicines. We expense these costs as R&amp;D expenses when we begin to manufacture API for a particular medicine if the medicine has not been approved for marketing by a regulatory agency.</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We obtained the first regulatory approval for TEGSEDI in July 2018 and for WAYLIVRA in May 2019. At December 31, 2019, our physical inventory for TEGSEDI and WAYLIVRA included API that we produced prior to when we obtained regulatory approval. As such, this API has no cost basis as we had previously expensed the costs as R&amp;D expenses.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We review our inventory periodically and reduce the carrying value of items we consider to be slow moving or obsolete to their estimated net realizable value based on forecasted demand compared to quantities on hand. We consider several factors in estimating the net realizable value, including shelf life of our inventory, alternative uses for our medicines in development and historical write-offs. We recorded an <span style="-sec-ix-hidden:Fact_1261d93c836d4d94bba4bd8c45f1e569">insignificant</span> amount of inventory write-offs during the year ended December 31, 2019. We did not record any inventory write-offs for the years ended December 31, 2018 or 2017.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our inventory consisted of the following (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z1ee494cca3ec409c868c744c6428df49" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Raw materials:</div></td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 19.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Raw materials- clinical</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,363</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,497</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -18pt; margin-left: 28.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Raw materials- commercial</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,520</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 28.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total raw materials</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15,883</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,497</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Work in process</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,039</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Finished goods</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">258</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">85</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; margin-left: 28.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total inventory</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,180</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,582</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Property, Plant and Equipment</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We carry our property, plant and equipment at cost and depreciate it on the straight-line method over its estimated useful life, which consists of the following (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z6b8fa4917b344088b2fa85d6aab08f8c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Estimated Useful Lives</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(in years)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Computer software, laboratory, manufacturing and other equipment</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3 to 10</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">60,965</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">53,496</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Building, building improvements and building systems</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15 to 40</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">119,830</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">97,528</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Land improvements</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,853</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,853</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Leasehold improvements</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5 to 15</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,600</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,981</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Furniture and fixtures</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5 to 10</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7,354</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,283</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">204,602</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">179,141</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less accumulated depreciation</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(74,013</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(61,474</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">130,589</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">117,667</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Land</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23,062</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14,493</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;Total</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">153,651</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">132,160</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We depreciate our leasehold improvements using the shorter of the estimated useful life or remaining lease term.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value of Financial Instruments</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have estimated the fair value of our financial instruments. The amounts reported for cash, accounts receivable, accounts payable and accrued expenses approximate the fair value because of their short maturities. We report our investment securities at their estimated fair value based on quoted market prices for identical or similar instruments.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Leases</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Topic 842 Adoption</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In February 2016, the Financial Accounting Standards Board, or FASB, issued amended accounting guidance related to lease accounting. This guidance supersedes the lease requirements we previously followed in Accounting Standards Codification, or ASC, Topic 840, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Leases</span>, or Topic 840, and created a new lease accounting standard, Topic 842, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Leases</span>, or Topic 842. Under Topic 842, an entity will record on its balance sheet all leases with a term longer than one year. Further, an entity will record a liability with a value equal to the present value of payments it will make over the life of the lease (lease liability) and an asset representing the underlying leased asset (right-of-use asset). The new accounting guidance requires entities to determine if its leases are operating or financing leases. Entities will recognize expense for operating leases on a straight-line basis as an operating expense. If an entity determines a lease is a financing lease, it will record both interest and amortization expense and generally the expense will be higher in the earlier periods of the lease. We adopted Topic 842 on January 1, 2019 and adjusted our opening balance sheet on that date for our right-of-use operating lease assets and operating lease liabilities. At adoption, we recorded $13.5 million in right-of-use operating lease assets and $18.5 million in operating lease liabilities, of which we classified $2 million as a current liability. We adopted Topic 842 using the available practical expedients<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification of those leases we had in place as of January 1, 2019. </span>The adoption did not have an impact on our consolidated statement of operations.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Leases</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We determine if an arrangement contains a lease at inception. We currently only have operating leases. We recognize a right-of-use operating lease asset and associated short- and long-term operating lease liability on our consolidated balance sheet for operating leases greater than one year. Our right-of-use assets represent our right to use an underlying asset for the lease term and our lease liabilities represent our obligation to make lease payments arising from the lease arrangement. We recognize our right-of-use operating lease assets and lease liabilities based on the present value of the future minimum lease payments we will pay over the lease term.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">&#160;</span>We determined the lease term at the inception of the lease, and in certain cases our lease term could include renewal options if we concluded we were reasonably certain that we will exercise the renewal option.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As our current leases do not provide an interest rate implicit in the lease, we used our or Akcea&#8217;s incremental borrowing rate, based on the information available on the date we adopted Topic 842 or as of the lease inception date in determining the present value of future payments. Our right-of-use operating lease asset also includes any lease payments we made and excludes any tenant improvement allowances we received. We recognize rent expense for our minimum lease payments on a straight-line basis over the expected term of our lease. We recognize period expenses, such as common area maintenance expenses, in the period we incur the expense.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Long-Lived Assets</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We evaluate long-lived assets, which include property, plant and equipment and patent costs, for impairment on at least a quarterly basis and whenever events or changes in circumstances indicate that we may not be able to recover the carrying amount of such assets. We recorded charges of $2.2 million, $0.8 million and $0.8 million for the years ended December 31, 2019, 2018 and 2017, respectively, related primarily to the write-down of intangible assets.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Use of Estimates</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation Expense</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Stock-Based Compensation Expense</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We measure stock-based compensation expense for equity-classified awards, principally related to stock options, restricted stock units, or RSUs, and stock purchase rights under our ESPP based on the estimated fair value of the award on the date of grant. We recognize the value of the portion of the award that we ultimately expect to vest as stock-based compensation expense over the requisite service period in our consolidated statements of operations. We reduce stock-based compensation expense for estimated forfeitures at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We use the Black-Scholes model to estimate the fair value of stock options granted and stock purchase rights under our ESPP. On the grant date, we use our stock price and assumptions regarding a number of variables to determine the estimated fair value of stock-based payment awards. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors.</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We recognize compensation expense for option awards and RSUs using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award were in substance multiple awards, which results in the expense being front-loaded over the vesting period.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The fair value of RSUs is based on the market price of our common stock on the date of grant. The RSUs we have granted vest annually over a four-year period.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">See Note 4, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Stockholders&#8217; Equity,</span> for additional information regarding our stock-based compensation plans.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Accumulated Other Comprehensive Loss</a></td>
<td class="text">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Accumulated Other Comprehensive Loss</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Accumulated other comprehensive loss is primarily comprised of unrealized gains and losses on investments, net of taxes and adjustments we made to reclassify realized gains and losses on investments from other accumulated comprehensive loss to our Consolidated Statement of Operations. The following table summarizes changes in accumulated other comprehensive loss for the years ended December 31, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2019</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2018</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2017</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> (in thousands):</span></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zf8dcaf0ca45440bba49fa3a29bc22bb5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Beginning balance accumulated other comprehensive loss</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(32,016</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(31,759</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(30,358</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Unrealized gains (losses) on securities, net of tax (1)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,633</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(280</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(960</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amounts reclassified from accumulated other comprehensive loss</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(374</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Currency translation adjustment</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">93</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(67</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net other comprehensive loss for the period</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,726</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(257</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,401</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ending balance accumulated other comprehensive loss</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(25,290</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(32,016</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(31,759</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>

<div style="text-align: justify;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z11d622af5d604f70bd2be3051942ec9a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A tax benefit of $1.4 million and $0.3 million was included in other comprehensive loss for the years ended December 31, 2019 and 2018, respectively. There was no tax benefit or expense for other comprehensive loss for the year ended December 31, 2017.&#160;</div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible Debt</a></td>
<td class="text">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Convertible Debt</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At issuance, we accounted for our convertible debt instruments, including our 0.125 percent senior convertible notes, or 0.125% Notes and 1 percent senior convertible notes, or 1% Notes, that may be settled in cash upon conversion (including partial cash settlement) by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate on the date the notes were issued. In reviewing debt issuances, we were not able to identify any comparable companies that recently issued non-convertible debt instruments. Therefore, we estimated the fair value of the liability component of our notes by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We assigned a value to the debt component of our convertible notes equal to the estimated fair value of similar debt instruments without the conversion feature, which resulted in us recording our debt at a discount. We are amortizing our debt issuance costs and debt discount over the life of the convertible notes as additional non-cash interest expense utilizing the effective interest method. For additional information, see Note 3, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Long-Term Obligations and Commitments</span>.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Segment Information</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">We have </span>two<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> operating segments, our Ionis Core segment and Akcea Therapeutics, our majority-owned affiliate. Akcea is </span>a biopharmaceutical company focused on developing and commercializing medicines to treat patients with serious and rare diseases<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">. We provide segment financial information and results for our Ionis Core segment and our Akcea Therapeutics segment based on the segregation of revenues and expenses that our chief decision maker reviews to assess operating performance and to make operating decisions. We allocate a portion of Ionis&#8217; development, R&amp;D support and general and administrative expenses to Akcea for work Ionis performs on behalf of Akcea and we bill Akcea for these expenses.</span></div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fair Value Measurements</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We use a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets, which includes our money market funds and treasury securities classified as available-for-sale securities and our investment in equity securities in publicly-held biotechnology companies; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable, which includes our fixed income securities and commercial paper classified as available-for-sale securities; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring us to develop our own assumptions. We classify the majority of our securities as Level 2. We obtain the fair value of our Level 2 investments from our custodian bank or from a professional pricing service. We validate the fair value of our Level 2 investments by understanding the pricing model used by the custodian banks or professional pricing service provider and comparing that fair value to the fair value based on observable market prices.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following tables present the major security types we held at December 31, 2019 and 2018&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">that we regularly measure and carry at fair value</span>. At December 31, 2019, a portion of our ProQR investment was <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">subject to trading restrictions through the fourth quarter of 2020, as a result we</span> included a lack of marketability discount in valuing this investment, which is a Level 3 input. At December 31, 2018, our ProQR investment was <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">subject to trading restrictions through the fourth quarter of 2019, as a result we</span> included a lack of marketability discount in valuing this investment, which is a Level 3 input. The tables segregate each security type by the level within the fair value hierarchy of the valuation techniques we utilized to determine the respective securities&#8217; fair value (in thousands):</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z0cec2f41ef46437e96b40a502fd19a06" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 8pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">At</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quoted Prices in</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Active Markets</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 1)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Significant Other</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Observable Inputs</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 2)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Significant</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Unobservable Inputs</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 3)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cash equivalents (1)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">418,406</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">418,406</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities (2)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,102,568</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,102,568</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies (3)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">329,404</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">329,404</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury (4)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">363,694</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">363,694</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states (4)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">40,407</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">40,407</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div/><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investment in ProQR Therapeutics N.V. (5)</div></div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,506</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,506</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -8.9pt; margin-left: 22.55pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,258,985</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">782,100</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,472,379</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,506</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z6dbe183adeca4fdb81898fb0f23d867c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 8pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">At</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quoted Prices in</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Active Markets</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 1)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Significant Other</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Observable Inputs</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 2)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Significant</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Unobservable Inputs</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 3)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cash equivalents (1)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">146,281</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">146,281</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities (6)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,252,960</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,252,960</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies (4)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">276,612</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">276,612</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury (7)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">260,154</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">260,154</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states (4)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">79,942</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">79,942</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investment in ProQR Therapeutics N.V. (5)</div></div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,349</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,349</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -8.9pt; margin-left: 22.55pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,017,298</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">406,435</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,609,514</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,349</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">________________</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zcc6c856321964d22a7f08198e22558a3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Included in cash and cash equivalents on our consolidated balance sheet.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -36pt; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z3bb7cbd9edf34eea8445b9bb699f5225" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$19.0 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</div></td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z9302b49ff4924d45b72f0ef80173e32d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$0.8 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zcc7cb538270446d19a63ff93630b2e26" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Included in short-term investments.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z0a497b435bb34da0940d397a2ee925d1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Included in other current assets on our consolidated balance sheet.&#160;</div></td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze53e73690894408ba98ca5e5e87ae494" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(6)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$50.2 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z9da9f51ab1ce4cf8b13bf7b591532750" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(7)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$14.2 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income Taxes</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We account for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. We record a valuation allowance when necessary to reduce our net deferred tax assets to the amount expected to be realized.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act of 2017, or the Tax Act. The Tax Act created a new requirement on global intangible low-taxed income, or GILTI, earned by foreign subsidiaries for tax years beginning on or after January 1, 2018. The GILTI provisions require foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#8217;s assets to be included in our U.S. income tax return. Under U.S. GAAP, we are permitted to make an accounting policy election to either treat taxes due on future inclusions in U.S. taxable income related to GILTI as a current-period expense when incurred or to factor such amounts into our measurement of deferred taxes. We have made the election to account for GILTI as a component of current taxes incurred rather than as a component of deferred taxes.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We apply the authoritative accounting guidance prescribing a threshold and measurement attribute for the financial recognition and measurement of a tax position taken or expected to be taken in a tax return. We recognize liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step requires us to estimate and measure the tax benefit as the largest amount that is more than 50 percent likely to be realized upon ultimate settlement.</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are required to use significant judgment in evaluating our uncertain tax positions and determining our provision for income taxes. Although we believe our reserves are reasonable, no assurance can be given that the final tax outcome of these matters will not be different from that which is reflected in our historical income tax provisions and accruals. We adjust these reserves for changing facts and circumstances, such as the closing of a tax audit or the refinement of an estimate. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences may impact the provision for income taxes in the period in which such determination is made.</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are also required to use significant judgment in determining any valuation allowance recorded against our deferred tax assets. In assessing the need for a valuation allowance, we consider all available evidence, including scheduled reversal of deferred tax liabilities, past operating results, the feasibility of tax planning strategies and estimates of future taxable income. We base our estimates of future taxable income on assumptions that are consistent with our plans. The assumptions we use represent our best estimates and involve inherent uncertainties and the application of our judgment. Should actual amounts differ from our estimates, the amount of our tax expense and liabilities we recognize could be materially impacted.<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> We record a valuation allowance to reduce the balance of our net deferred tax assets to the amount we believe is more-likely-than-not to be realized.</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We do not provide for a U.S. income tax liability and foreign withholding taxes on undistributed foreign earnings of our foreign subsidiaries.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Impact of Recently Issued Accounting Standards</a></td>
<td class="text">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Impact of Recently Issued Accounting Standards</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In June 2016, the FASB issued guidance that changes the measurement of credit losses for most financial assets and certain other instruments. If we have credit losses, this updated guidance requires us to record allowances for these instruments under a new expected credit loss model. This model requires us to estimate the expected credit loss of an instrument over its lifetime, which represents the portion of the amortized cost basis we do not expect to collect. The new guidance requires us to remeasure our allowance in each reporting period we have credit losses. We adopted this the new guidance on January 1, 2020. We do not expect this guidance will have an impact on our consolidated financial statements.</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In August 2018, the FASB issued clarifying guidance on how to account for implementation costs related to cloud-servicing arrangements. The guidance states that if these fees qualify to be capitalized and amortized over the service period, they need to be expensed in the same line item as the service expense and recognized in the same balance sheet category. The update can be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We adopted this guidance on January 1, 2020 on a prospective basis. We do not expect this guidance will have an impact on our consolidated financial statements.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In August 2018, the FASB updated its disclosure requirements related to Level 1, 2 and 3 fair value measurements. The update included deletion and modification of certain disclosure requirements and additional disclosure related to Level 3 measurements. The guidance is effective for fiscal years beginning after December 31, 2019 and early adoption is permitted. We adopted this updated guidance on January 1, 2019 and it did not have a significant impact on our disclosures.</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In November 2018, the FASB issued clarifying guidance of the interaction between the collaboration accounting guidance and the new revenue recognition guidance we adopted on January 1, 2018 (Topic 606). Below is the clarifying guidance and how we will implement it (in italics):</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z6b37abcc28844ec1995be6ea3287fde1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">When a participant is considered a customer in a collaborative arrangement, all of the associated accounting under Topic 606 should be applied</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z568b757cadfb43b88346ae2bdab57f19" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 72pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">We will apply all of the associated accounting under Topic 606 when we determine a participant in a collaborative arrangement is a customer </div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z729d51441c36453d9dd29ff6baaa5429" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Adds &#8220;unit of account&#8221; concept to collaboration accounting guidance to align with Topic 606. The &#8220;unit of account&#8221; concept is used to determine if revenue is recognized or if a contra expense is recognized from consideration received under a collaboration</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z36356b76546d4b1b9df6a54de364a594" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 72pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">We will use the &#8220;unit of account&#8221; concept when we receive consideration under a collaborative arrangement to determine when we recognize revenue or a contra expense</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze5669a8c7b084090bd8ad32061dcc5d9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The clarifying guidance precludes us from recognizing revenue under Topic 606 when we determine a transaction with a collaborative partner is not a customer and is not directly related to the sales to third parties</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze5279de5f245498da7e1f9b7cb96a4f7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 72pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">When we conclude a collaboration partner is not a customer and is not directly related to the sales to third parties, we will not recognize revenue for the transaction </div></td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We adopted this new guidance on January 1, 2020. We do not expect this guidance will have a significant impact on our consolidated financial statements.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In December 2019, the FASB issued guidance to simplify the accounting for income taxes. The update includes removing several exceptions under the existing guidance and includes several simplification updates, none of which apply to our current accounting for income taxes. The guidance is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted. We adopted this updated guidance in the fourth quarter of 2019 and it did not have an impact on our consolidated financial statements or disclosures.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash, cash equivalents and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.3A-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355119-122828<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5033-111524<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21459-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for treatment of receivables that are billable but have not been billed as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -URI http://asc.fasb.org/topic&amp;trid=2196771<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6863576864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Data (Unaudited) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Quarterly Financial Data</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Summarized quarterly data for the years ended December 31, 2019 and 2018 are as follows (in thousands, except per share data).</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zbbded80230f54883844977a2db5dd5f5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019 Quarters</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">First</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Second</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Third</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fourth</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">297,214</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">163,813</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">167,892</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">493,680</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating expenses</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">175,679</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">182,640</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">165,369</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">233,028</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) from operations</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">121,535</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(18,827</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,523</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">260,652</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income (loss)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">90,884</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(10,012</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,432</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">203,957</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">84,443</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(876</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">26,163</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">184,415</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income (loss) per share (1) (2)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.63</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.01</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.19</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.31</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Diluted net income (loss) per share (1) (3)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.62</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.01</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.18</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.28</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z6dcd313bcba54fcbbfd2063358483afb" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018 Quarters</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">First</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Second</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Third</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Fourth</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quarter</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">144,419</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">117,747</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">145,395</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">192,113</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Operating expenses</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">147,720</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">168,028</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">163,967</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">181,331</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) from operations</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3,301</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(50,281</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(18,572</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,782</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income (loss)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(10,812</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(56,573</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(20,365</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">302,735</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,420</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(40,358</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4,559</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">320,078</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income (loss) per share (1) (2)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.01</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.29</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.03</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.32</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Diluted net income (loss) per share (1) (3)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.01</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.29</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.03</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.21</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">________________</div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z238c61f0c45341568e1fd63ba558f508" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We computed net income (loss) per share independently for each of the quarters presented. Therefore, the sum of the quarterly net income (loss) per share will not necessarily equal the total for the year.</div></td>
  </tr>
</table>

<div style="text-align: justify; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z4b10092c7ee94951986f14bc378411d6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">As discussed in Note 1, <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Organization and Significant Accounting Policies, </span>we compute basic net income (loss) per share by dividing the total net income (loss) attributable to our common stockholders by our weighted-average number of common shares outstanding during the period. Our basic net income (loss) per share calculation for each of the quarters in 2019 and 2018 considered our net income for Ionis on a stand-alone basis plus our share of Akcea&#8217;s net loss for the period. To calculate the portion of Akcea&#8217;s net loss attributable to our ownership, we multiplied Akcea&#8217;s loss per share by the weighted average shares we owned in Akcea during the period. As a result of this calculation, our total net income (loss) available to Ionis common stockholders for the calculation of net income (loss) per share is different than net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders in the consolidated statements of operations.</div></td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our basic net income (loss) per share for each quarter in 2019 was calculated as follows (in thousands, except per share amounts):</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z66d226e9f1e04c068da73924c4bbb872" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended March 31 , 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Income</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">68,582</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.35</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23,846</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net income attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23,846</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">63,697</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">87,543</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">138,582</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.63</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z0a7c3905d3e645b7bf1d61ed99b81aa3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended June 30 , 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">70,221</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.40</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(28,244</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(28,244</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">27,311</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net loss available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(933</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">140,247</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net loss per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.01</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z63a88a9296e2466eaad9bc93a89393ce" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended September 30 , 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">70,221</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.34</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(23,772</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(23,772</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">49,930</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">26,158</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">140,551</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.19</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zd25327371fce44efae3b5570b907c56d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended December 31 , 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Income</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">71,342</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.87</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">62,243</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net income attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">62,243</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">121,552</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">183,795</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">140,583</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.31</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our basic net income (loss) per share for each quarter in 2018 was calculated as follows (in thousands, except per share amounts):</div>

<div style="text-align: left; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zbbcbf397131340ad9566b5428b09a107" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended March 31 , 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">45,448</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.44</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(19,997</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(19,997</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,785</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net loss available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,212</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">125,330</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net loss per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.01</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>

<div style="text-align: justify; margin-left: 31.5pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z2b8e94f57db4490c82a68c1ff759a0e3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended June 30 , 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">60,832</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.72</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(43,814</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(43,814</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5,882</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net loss available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(37,932</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">128,712</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net loss per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.29</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z2549de914d904e2a82162394a6946bc2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended September 30 , 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">65,538</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.73</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(47,789</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(47,789</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">43,226</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net loss available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4,563</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">137,346</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net loss per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.03</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z0b1244fa792d4e2f89c46e4a73ab2036" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended December 31 , 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Portion of</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">67,130</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.79</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(53,219</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(53,219</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">372,913</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">319,694</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">137,699</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.32</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zc5ec9a701b644f2192ef4fd51a353c9b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We had net income available to Ionis common stockholders for the following periods. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during those periods.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: justify; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Diluted common equivalent shares for each of the periods consisted of the following (in thousands except per share amounts):</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zf822f8c87ab4452683b2466a81529563" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended March 31, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">87,543</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">138,582</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.63</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -6pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,252</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">665</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our ESPP</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">38</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our 1 percent convertible notes</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">87,543</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">141,537</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.62</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zcafdd1c50c0b47bea13bfdef22787b0b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended September 30, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">26,158</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">140,551</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.19</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,993</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">844</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our ESPP</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our 1 percent convertible notes</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">26,158</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">143,408</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.18</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z43f9157d9e1242ac8e62d24c49d3a75f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended December 31, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">183,795</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">140,583</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.31</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,467</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">848</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our ESPP</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our 0.125 percent convertible notes</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">644</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">860</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our 1 percent convertible notes</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12,046</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,527</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">196,485</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">153,303</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.28</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z2edbbee13c264fed8062982b71bf6ef3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Three Months Ended December 31, 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">319,694</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">137,699</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.32</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,254</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">636</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our ESPP</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our 1 percent convertible notes</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,745</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,260</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">330,439</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">149,856</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.21</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -36pt; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For the three months ended March 31, 2019 and September 30, 2019, the calculation excluded the 1 percent notes because the effect on diluted earnings per share was anti-dilutive.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118952077&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6885512208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">140,339,615<span></span>
</td>
<td class="nump">137,928,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">140,339,615<span></span>
</td>
<td class="nump">137,928,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember', window );">0.125 Percent Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible senior notes</a></td>
<td class="nump">0.125%<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember', window );">1 Percent Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>LIABILITIES AND STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible senior notes</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6870794640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember', window );">1 Percent Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible senior notes</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember', window );">0.125 Percent Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible senior notes</a></td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6876706944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies, Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">$ (74,013)<span></span>
</td>
<td class="num">$ (61,474)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">153,651<span></span>
</td>
<td class="nump">132,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_PropertyPlantAndEquipmentExcludingLandMember', window );">Property, Plant and Equipment, Excluding Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="nump">204,602<span></span>
</td>
<td class="nump">179,141<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">130,589<span></span>
</td>
<td class="nump">117,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_EquipmentAndComputerSoftwareMember', window );">Computer Software, Laboratory, Manufacturing and Other Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="nump">$ 60,965<span></span>
</td>
<td class="nump">53,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_EquipmentAndComputerSoftwareMember', window );">Computer Software, Laboratory, Manufacturing and Other Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_EquipmentAndComputerSoftwareMember', window );">Computer Software, Laboratory, Manufacturing and Other Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building, Building Improvements and Building Systems [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="nump">$ 119,830<span></span>
</td>
<td class="nump">97,528<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building, Building Improvements and Building Systems [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building, Building Improvements and Building Systems [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">40 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember', window );">Land Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="nump">$ 2,853<span></span>
</td>
<td class="nump">2,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="nump">18,981<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="nump">$ 7,354<span></span>
</td>
<td class="nump">6,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment</a></td>
<td class="nump">$ 23,062<span></span>
</td>
<td class="nump">$ 14,493<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_PropertyPlantAndEquipmentExcludingLandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_PropertyPlantAndEquipmentExcludingLandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_EquipmentAndComputerSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ions_EquipmentAndComputerSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7029772336">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies, Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Loss [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,187,160<span></span>
</td>
<td class="nump">$ 365,280<span></span>
</td>
<td class="nump">$ 39,613<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net other comprehensive loss for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,726<span></span>
</td>
<td class="num">(257)<span></span>
</td>
<td class="num">(1,401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,684,547<span></span>
</td>
<td class="nump">1,187,160<span></span>
</td>
<td class="nump">365,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Income tax expense included in other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Accumulated Other Comprehensive Loss [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Loss [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(32,016)<span></span>
</td>
<td class="num">(31,759)<span></span>
</td>
<td class="num">(30,358)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(25,290)<span></span>
</td>
<td class="num">(32,016)<span></span>
</td>
<td class="num">(31,759)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized Gains (Losses) on Securities [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Loss [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive loss before reclassifications, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,633<span></span>
</td>
<td class="num">(280)<span></span>
</td>
<td class="num">(960)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(374)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Currency Translation Adjustment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>Accumulated Other Comprehensive Loss [Roll Forward]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive loss before reclassifications, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 93<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="num">$ (67)<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">A tax benefit of $1.4 million and $0.3 million was included in other comprehensive loss for the years ended December 31, 2019 and 2018, respectively. There was no tax benefit or expense for other comprehensive loss for the year ended December 31, 2017.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17B<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724394-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6874722208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments, Contract Maturity of Available-for-Sale Securities (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>Company</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Contract Maturity of Available-for-Sale Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage', window );">One year or less</a></td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage', window );">After one year but within two years</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage', window );">After two years but within three and a half years</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage', window );">Total</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage', window );">Percentage of available-for-sale securities with a maturity of less than two years</a></td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumContractMaturityPeriodRange1', window );">Maximum contract maturity period, range 1</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumContractMaturityPeriodRange2', window );">Maximum contract maturity period, range 2</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumContractMaturityPeriodRange3', window );">Maximum contract maturity period, range 3</a></td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Ownership Interests in Private and Public Companies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment', window );">Number of privately-held companies in which there is an equity ownership interest of less than 20%</a></td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment', window );">Number of publicly-held companies in which there is an equity ownership interest of less than 20%</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of available-for-sale debt securities that mature beyond one year but within two years of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of available-for-sale debt securities that mature beyond two years but within three and one-half years of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate percentage of all available-for-sale debt securities, regardless of maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of available-for-sale debt securities that mature within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of available-for-sale debt securities that mature within two years of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumContractMaturityPeriodRange1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum contract maturity period for the first range of available-for-sale securities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumContractMaturityPeriodRange1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumContractMaturityPeriodRange2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum contract maturity period for the second range of available-for-sale securities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumContractMaturityPeriodRange2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumContractMaturityPeriodRange3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum contract maturity period for the third range of available-for-sale securities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumContractMaturityPeriodRange3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of privately-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of publicly-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871591696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes, Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred Tax Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryovers</a></td>
<td class="nump">$ 89,717<span></span>
</td>
<td class="nump">$ 20,191<span></span>
</td>
<td class="nump">$ 89,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D credits</a></td>
<td class="nump">313,652<span></span>
</td>
<td class="nump">210,455<span></span>
</td>
<td class="nump">313,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">27,381<span></span>
</td>
<td class="nump">127,763<span></span>
</td>
<td class="nump">27,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">61,027<span></span>
</td>
<td class="nump">65,703<span></span>
</td>
<td class="nump">61,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible and capital assets</a></td>
<td class="nump">49,007<span></span>
</td>
<td class="nump">77,861<span></span>
</td>
<td class="nump">49,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">8,275<span></span>
</td>
<td class="nump">12,510<span></span>
</td>
<td class="nump">8,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">549,059<span></span>
</td>
<td class="nump">514,483<span></span>
</td>
<td class="nump">549,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements', window );">Convertible debt</a></td>
<td class="num">(24,018)<span></span>
</td>
<td class="num">(6,110)<span></span>
</td>
<td class="num">(24,018)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,958)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,884)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance', window );">Net deferred tax asset</a></td>
<td class="nump">525,041<span></span>
</td>
<td class="nump">502,531<span></span>
</td>
<td class="nump">525,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(234,245)<span></span>
</td>
<td class="num">(196,974)<span></span>
</td>
<td class="num">(234,245)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total net deferred tax assets and liabilities</a></td>
<td class="nump">290,796<span></span>
</td>
<td class="nump">305,557<span></span>
</td>
<td class="nump">290,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">One-time non-cash tax benefit related to reversal of valuation allowance</a></td>
<td class="nump">$ 332,100<span></span>
</td>
<td class="num">(37,765)<span></span>
</td>
<td class="num">$ (277,924)<span></span>
</td>
<td class="num">$ (86,296)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease', window );">Decrease in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_IncreaseDecreaseInStateTaxLiability', window );">Decrease in combined state tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (59,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the net amount of deferred tax assets (before reduction for valuation allowance) and liabilities as of the balance sheet date, which result from applying the applicable enacted tax rate to net temporary differences and carryforwards pertaining to assets or liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_IncreaseDecreaseInStateTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in state tax liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_IncreaseDecreaseInStateTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesFinancingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesFinancingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>form10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:ions="http://isispharm.com/20191231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ions-20191231.xsd" xlink:type="simple"/>
    <context id="c20190101to20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="c20200220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <instant>2020-02-20</instant>
        </period>
    </context>
    <context id="c20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0125PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0125PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20170101to20171231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ProductOrServiceAxis_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ProductOrServiceAxis_SPINRAZARoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ProductOrServiceAxis_CommercialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ProductOrServiceAxis_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ProductOrServiceAxis_CommercialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ProductOrServiceAxis_CommercialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ProductOrServiceAxis_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ProductOrServiceAxis_SPINRAZARoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ProductOrServiceAxis_SPINRAZARoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20161231_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="c20161231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="c20161231_StatementEquityComponentsAxis_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="c20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="c20161231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="c20161231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="c20161231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_StatementEquityComponentsAxis_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_StatementEquityComponentsAxis_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_StatementEquityComponentsAxis_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:NovartisInternationalAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:NovartisInternationalAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:BiogenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:BiogenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:BiogenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:NovartisInternationalAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:BiogenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:BiogenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:NovartisInternationalAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:NovartisInternationalAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:BiogenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:NovartisInternationalAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:NovartisInternationalAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ions:BiogenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_StatementEquityComponentsAxis_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20171231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_StatementEquityComponentsAxis_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c20181231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c20181231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c20181231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c20171231_StatementEquityComponentsAxis_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c20181231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20181231_StatementEquityComponentsAxis_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20171231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c20191231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20170101to20171231_MajorCustomersAxis_BiogenIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ions:BiogenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_MajorCustomersAxis_NovartisInternationalAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ions:NovartisInternationalAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_MajorCustomersAxis_NovartisInternationalAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ions:NovartisInternationalAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_MajorCustomersAxis_NovartisInternationalAGMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ions:NovartisInternationalAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_MajorCustomersAxis_BiogenIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ions:BiogenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_MajorCustomersAxis_BiogenIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ions:BiogenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_OwnershipAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_OwnershipAxis_AkceaTherapeuticsIncMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_OwnershipAxis_AkceaTherapeuticsIncMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191001to20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20170630_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_StatementClassOfStockAxis_ConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20191001to20191231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190701to20190930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20181001to20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170201to20170228_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="c20150501to20150531_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-01</startDate>
            <endDate>2015-05-31</endDate>
        </period>
    </context>
    <context id="c20190401to20190630_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c20170701to20170930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="c20170228_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-28</instant>
        </period>
    </context>
    <context id="c20170228_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-28</instant>
        </period>
    </context>
    <context id="c20180401to20180630_MajorCustomersAxis_BiogenIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ions:BiogenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20181231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20170101to20171231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170630_OwnershipAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="c20190101to20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="c20181231_PublicUtilitiesInventoryAxis_ClinicalRawMaterialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">ions:ClinicalRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_PublicUtilitiesInventoryAxis_ClinicalRawMaterialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">ions:ClinicalRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_PublicUtilitiesInventoryAxis_CommercialRawMaterialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">ions:CommercialRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_PublicUtilitiesInventoryAxis_CommercialRawMaterialsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">ions:CommercialRawMaterialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20181231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20181231_PropertyPlantAndEquipmentByTypeAxis_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentExcludingLandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:PropertyPlantAndEquipmentExcludingLandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_PropertyPlantAndEquipmentByTypeAxis_LandImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_PropertyPlantAndEquipmentByTypeAxis_LandImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndComputerSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:EquipmentAndComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_PropertyPlantAndEquipmentByTypeAxis_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentExcludingLandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:PropertyPlantAndEquipmentExcludingLandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndComputerSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:EquipmentAndComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndComputerSoftwareMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:EquipmentAndComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndComputerSoftwareMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:EquipmentAndComputerSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_LandImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20181231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20161231_StatementEquityComponentsAxis_AociIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="c20171231_StatementEquityComponentsAxis_AociIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c20181231_StatementEquityComponentsAxis_AociIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_StatementEquityComponentsAxis_AociIncludingPortionAttributableToNoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_BalanceSheetLocationAxis_CashAndCashEquivalentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_BalanceSheetLocationAxis_CashAndCashEquivalentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_BalanceSheetLocationAxis_CashAndCashEquivalentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_BalanceSheetLocationAxis_CashAndCashEquivalentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20181231_InvestmentTypeAxis_DebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfMoreThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_DebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfMoreThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_DebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfMoreThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfMoreThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfMoreThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfMoreThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfMoreThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_InvestmentTypeAxis_DebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfMoreThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_DebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfMoreThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_DebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfMoreThanOneYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:SecuritiesWithMaturityOfOneYearOrLessMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_InvestmentTypeAxis_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_BalanceSheetLocationAxis_DepositsAndOtherAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ions:DepositsAndOtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_BalanceSheetLocationAxis_OtherCurrentAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_BalanceSheetLocationAxis_OtherCurrentAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20190101to20191231_InvestmentSecondaryCategorizationAxis_IncludedInOtherCurrentAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:IncludedInOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_InvestmentTypeAxis_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_InvestmentTypeAxis_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_InvestmentSecondaryCategorizationAxis_IncludedInDepositsAndOtherAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:IncludedInDepositsAndOtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_InvestmentSecondaryCategorizationAxis_IncludedInOtherCurrentAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:IncludedInOtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_InvestmentSecondaryCategorizationAxis_IncludedInDepositsAndOtherAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentSecondaryCategorizationAxis">ions:IncludedInDepositsAndOtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_InvestmentTypeAxis_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_InvestmentTypeAxis_USTreasurySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_InvestmentTypeAxis_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USStatesAndPoliticalSubdivisionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_DebtInstrumentAxis_LongTermMortgageDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:LongTermMortgageDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_DebtInstrumentAxis_FixedRateNoteWithMorganStanleyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:FixedRateNoteWithMorganStanleyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_DebtInstrumentAxis_FixedRateNoteWithMorganStanleyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:FixedRateNoteWithMorganStanleyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20181231_DebtInstrumentAxis_LeasesAndOtherObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:LeasesAndOtherObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_DebtInstrumentAxis_LeasesAndOtherObligationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:LeasesAndOtherObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_DebtInstrumentAxis_LongTermMortgageDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:LongTermMortgageDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20141130_DebtInstrumentAxis_ConvertibleSeniorNotes275PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes275PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-30</instant>
        </period>
    </context>
    <context id="c20161231_DebtInstrumentAxis_ConvertibleSeniorNotes275PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes275PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="c20161231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20141130_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-30</instant>
        </period>
    </context>
    <context id="c20191201to20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0125PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes275PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes275PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0125PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191201to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0125PercentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20190101to20191231_CreditFacilityAxis_RevolvingCreditFacilityMember_LineOfCreditFacilityAxis_MorganStanleyPrivateBankNationalAssociationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ions:MorganStanleyPrivateBankNationalAssociationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_CreditFacilityAxis_RevolvingCreditFacilityMember_LineOfCreditFacilityAxis_MorganStanleyPrivateBankNationalAssociationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ions:MorganStanleyPrivateBankNationalAssociationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20190701to20190930_DebtInstrumentAxis_FixedRateNoteWithMorganStanleyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:FixedRateNoteWithMorganStanleyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c20170701to20170731_PropertyPlantAndEquipmentByTypeAxis_PrimaryResearchAndDevelopmentFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:PrimaryResearchAndDevelopmentFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="c20170701to20170731_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="c20170731_DebtInstrumentAxis_LongTermMortgageDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:LongTermMortgageDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="c20170731_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="c20170731_PropertyPlantAndEquipmentByTypeAxis_PrimaryResearchAndDevelopmentFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:PrimaryResearchAndDevelopmentFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-07-31</instant>
        </period>
    </context>
    <context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_PrimaryResearchAndDevelopmentFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:PrimaryResearchAndDevelopmentFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170701to20170930_PropertyPlantAndEquipmentByTypeAxis_PrimaryResearchAndDevelopmentFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:PrimaryResearchAndDevelopmentFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:OfficeSpaceSubleasedToAkceaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceForCorporateHeadquartersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:OfficeSpaceForCorporateHeadquartersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_PropertyPlantAndEquipmentByTypeAxis_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:OfficeSpaceSubleasedToAkceaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceForCorporateHeadquartersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ions:OfficeSpaceForCorporateHeadquartersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_StatementClassOfStockAxis_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_StatementClassOfStockAxis_SeriesCPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_StatementClassOfStockAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_StatementClassOfStockAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20190101to20191231_StatementClassOfStockAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_StatementClassOfStockAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_StatementClassOfStockAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c20200101to20200302_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-02</endDate>
        </period>
    </context>
    <context id="c20150630_PlanNameAxis_EquityIncentivePlan2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EquityIncentivePlan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-06-30</instant>
        </period>
    </context>
    <context id="c20170531_PlanNameAxis_EquityIncentivePlan2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EquityIncentivePlan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="c20191231_PlanNameAxis_StockOptionPlan1989Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:StockOptionPlan1989Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20150531_PlanNameAxis_EquityIncentivePlan2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EquityIncentivePlan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-05-31</instant>
        </period>
    </context>
    <context id="c20190630_PlanNameAxis_EquityIncentivePlan2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EquityIncentivePlan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="c20150630_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:NonemployeeDirectorsStockOptionPlan2002Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-06-30</instant>
        </period>
    </context>
    <context id="c20150531_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:NonemployeeDirectorsStockOptionPlan2002Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-05-31</instant>
        </period>
    </context>
    <context id="c20191231_PlanNameAxis_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20190101to20191231_PlanNameAxis_StockOptionPlan1989Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:StockOptionPlan1989Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2011Member_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EquityIncentivePlan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EquityIncentivePlan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_AwardTypeAxis_StockOptionMember_PlanNameAxis_EquityIncentivePlan2011Member_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EquityIncentivePlan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_AwardTypeAxis_StockOptionMember_PlanNameAxis_StockOptionPlan1989Member_VestingAxis_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:StockOptionPlan1989Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_AwardTypeAxis_StockOptionMember_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member_VestingAxis_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:NonemployeeDirectorsStockOptionPlan2002Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:NonemployeeDirectorsStockOptionPlan2002Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:NonemployeeDirectorsStockOptionPlan2002Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_PlanNameAxis_EquityIncentivePlan2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EquityIncentivePlan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20190101to20191231_PlanNameAxis_EquityIncentivePlan2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EquityIncentivePlan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member_VestingAxis_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:NonemployeeDirectorsStockOptionPlan2002Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_PlanNameAxis_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20090601to20090630_PlanNameAxis_EmployeeStockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ions:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-06-01</startDate>
            <endDate>2009-06-30</endDate>
        </period>
    </context>
    <context id="c20181231_AwardTypeAxis_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20190101to20191231_AwardTypeAxis_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_AwardTypeAxis_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20170101to20171231_AwardTypeAxis_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_AwardTypeAxis_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20181231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20170101to20171231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_IncomeStatementLocationAxis_ResearchDevelopmentAndPatentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ions:ResearchDevelopmentAndPatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190701to20190930_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_IncomeStatementLocationAxis_ResearchDevelopmentAndPatentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ions:ResearchDevelopmentAndPatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_IncomeStatementLocationAxis_ResearchDevelopmentAndPatentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ions:ResearchDevelopmentAndPatentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_IncomeStatementLocationAxis_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_IncomeStatementLocationAxis_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_IncomeStatementLocationAxis_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_AwardTypeAxis_BoardOfDirectorStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ions:BoardOfDirectorStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ions:BoardOfDirectorStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_AwardTypeAxis_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ions:BoardOfDirectorStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_AwardTypeAxis_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ions:BoardOfDirectorStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_AwardTypeAxis_BoardOfDirectorStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ions:BoardOfDirectorStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_AwardTypeAxis_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_AwardTypeAxis_BoardOfDirectorStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ions:BoardOfDirectorStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20181001to20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_IncomeTaxAuthorityNameAxis_CaliforniaFranchiseTaxBoardMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_IncomeTaxAuthorityNameAxis_InternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_IncomeTaxAuthorityNameAxis_InternalRevenueServiceIRSMember_TaxCreditCarryforwardAxis_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_IncomeTaxAuthorityNameAxis_CaliforniaFranchiseTaxBoardMember_TaxCreditCarryforwardAxis_ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20180401to20180630_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="c20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_ProductOrServiceAxis_SPINRAZARoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_RangeAxis_MaximumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20130901to20130930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-09-01</startDate>
            <endDate>2013-09-30</endDate>
        </period>
    </context>
    <context id="c20121201to20121231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-12-01</startDate>
            <endDate>2012-12-31</endDate>
        </period>
    </context>
    <context id="c20171201to20171231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20180430_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="c20130930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-09-30</instant>
        </period>
    </context>
    <context id="c20171231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_ProductOrServiceAxis_IONISMAPTMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:IONISMAPTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_ProductOrServiceAxis_MedicinesForUndisclosedTargetsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:MedicinesForUndisclosedTargetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_ProductOrServiceAxis_MedicinesForAmyotrophicLateralSclerosisMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:MedicinesForAmyotrophicLateralSclerosisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191201to20191231_ProductOrServiceAxis_MedicinesForAmyotrophicLateralSclerosisMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:MedicinesForAmyotrophicLateralSclerosisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_ProductOrServiceAxis_AntisenseMoleculeMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:AntisenseMoleculeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20121231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-12-31</instant>
        </period>
    </context>
    <context id="c20190401to20190630_ProductOrServiceAxis_IONISMAPTMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:IONISMAPTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c20181001to20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20191001to20191231_ProductOrServiceAxis_IONISMAPTMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:IONISMAPTMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20181001to20181231_ProductOrServiceAxis_TofersenMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:TofersenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ProductOrServiceAxis_SPINRAZARoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20191001to20191231_ProductOrServiceAxis_ION581Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ION581Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180701to20180930_ProductOrServiceAxis_IONISC9Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:IONISC9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ProductOrServiceAxis_SPINRAZARoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20181001to20181231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20191001to20191231_ProductOrServiceAxis_IONISC9Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:IONISC9Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190701to20190930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20200101to20200226_SubsequentEventTypeAxis_SubsequentEventMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-02-26</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ProductOrServiceAxis_SPINRAZARoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190701to20190930_ProductOrServiceAxis_ION859Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ION859Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20150701to20150731_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-07-01</startDate>
            <endDate>2015-07-31</endDate>
        </period>
    </context>
    <context id="c20121201to20121231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-12-01</startDate>
            <endDate>2012-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_RangeAxis_MaximumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20121231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-12-31</instant>
        </period>
    </context>
    <context id="c20150731_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-31</instant>
        </period>
    </context>
    <context id="c20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20180101to20180331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="c20140331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-03-31</instant>
        </period>
    </context>
    <context id="c20181001to20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20181001to20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20181001to20181231_ProductOrServiceAxis_ION736Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ION736Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20181001to20181231_ProductOrServiceAxis_DanvatirsenMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:DanvatirsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20180331_ProductOrServiceAxis_ION532Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ION532Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20180331_ProductOrServiceAxis_ION839Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ION839Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="c20180701to20180930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20150401to20150630_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-04-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20150531_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-05-31</instant>
        </period>
    </context>
    <context id="c20170201to20170228_ProductOrServiceAxis_ResearchAndDevelopmentServicesForIONISFXILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentServicesForIONISFXILMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="c20170201to20170228_ProductOrServiceAxis_IONISFXILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:IONISFXILMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-02-28</endDate>
        </period>
    </context>
    <context id="c20170228_ProductOrServiceAxis_IONISFXILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:IONISFXILMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-28</instant>
        </period>
    </context>
    <context id="c20170228_ProductOrServiceAxis_ResearchAndDevelopmentServicesForIONISFXILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentServicesForIONISFXILMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-28</instant>
        </period>
    </context>
    <context id="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsBayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20100301to20100331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-03-01</startDate>
            <endDate>2010-03-31</endDate>
        </period>
    </context>
    <context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20190701to20190930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20141231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="c20141201to20141231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20171101to20171130_ProductOrServiceAxis_IONISJBI225Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:IONISJBI225Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20130401to20130430_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-04-01</startDate>
            <endDate>2013-04-30</endDate>
        </period>
    </context>
    <context id="c20181001to20181031_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="c20190101to20190331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181031_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="c20130430_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-04-30</instant>
        </period>
    </context>
    <context id="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20171001to20171231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementsAndLicensingAgreementsRocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20170101to20170331_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c20190201to20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:AKCEAAPOALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:AKCEAAPOALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20170331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c20170331_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="c20170701to20170731_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="c20170331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="c20170331_ProductOrServiceAxis_DeliveryOfAKCEAAPOCIIILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:DeliveryOfAKCEAAPOCIIILMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="c20170331_ProductOrServiceAxis_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="c20170331_ProductOrServiceAxis_DeliveryOfAKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:DeliveryOfAKCEAAPOALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="c20170331_ProductOrServiceAxis_ResearchAndDevelopmentServicesForAKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentServicesForAKCEAAPOALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="c20190201to20190228_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_LicenseMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20191001to20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="c20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_ResearchAndDevelopmentServicesForMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentServicesForMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="c20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAANGPTL3LActivePharmaceuticalIngredientMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:AKCEAANGPTL3LActivePharmaceuticalIngredientMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="c20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAANGPTL3LMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:AKCEAANGPTL3LMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="c20191001to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20191001to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAANGPTL3LMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:AKCEAANGPTL3LMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20190401to20190630_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c20191001to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180701to20180930_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180831_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20191001to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_TegsediMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:TegsediMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190401to20190630_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_WaylivraMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:WaylivraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20180701to20180930_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_LicenseMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ions:CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ProductMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_CommercialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ProductMember_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_CommercialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_CommercialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ProductMember_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:SPINRAZARoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ProductMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:LicensingAndOtherRoyaltiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:CommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ions:ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="c20191231_ConsolidationItemsAxis_IntersegmentEliminationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:AkceaTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20181231_ConsolidationItemsAxis_IntersegmentEliminationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:IntersegmentEliminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CreditConcentrationRiskMember_MajorCustomersAxis_SignificantPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ions:SignificantPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CreditConcentrationRiskMember_MajorCustomersAxis_SignificantPartnersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ions:SignificantPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190401to20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c20180701to20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="c20180401to20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="c20180101to20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="c20190701to20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c20190101to20190331_OwnershipAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="c20190701to20190930_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c20190101to20190331_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="c20181001to20181231_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20180701to20180930_OwnershipAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="c20180401to20180630_OwnershipAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="c20190401to20190630_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c20191001to20191231_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180701to20180930_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="c20180401to20180630_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="c20191001to20191231_OwnershipAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20180101to20180331_OwnershipAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="c20180101to20180331_StatementBusinessSegmentsAxis_IonisCoreMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ions:IonisCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="c20181001to20181231_OwnershipAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190701to20190930_OwnershipAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c20190401to20190630_OwnershipAxis_AkceaTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ions:AkceaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="c20190930_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="c20190331_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="c20191001to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20190331_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="c20191001to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes0125PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190701to20190930_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c20181001to20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ions:ConvertibleSeniorNotes1PercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20190331_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="c20181001to20181231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190101to20190331_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="c20191001to20191231_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20191001to20191231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c20190701to20190930_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c20181001to20181231_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c20190701to20190930_AwardTypeAxis_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000874015</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <unit id="U001">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U002">
        <measure>shares</measure>
    </unit>
    <unit id="U003">
        <measure>pure</measure>
    </unit>
    <unit id="U004">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U005">
        <measure>ions:PerformanceObligation</measure>
    </unit>
    <unit id="U006">
        <measure>ions:Payment</measure>
    </unit>
    <unit id="U007">
        <measure>ions:Target</measure>
    </unit>
    <unit id="U008">
        <measure>ions:Agreement</measure>
    </unit>
    <unit id="U009">
        <measure>ions:Company</measure>
    </unit>
    <unit id="U010">
        <measure>ions:Segment</measure>
    </unit>
    <unit id="U011">
        <measure>ions:Investment</measure>
    </unit>
    <unit id="U012">
        <measure>ions:Option</measure>
    </unit>
    <unit id="U013">
        <measure>ions:Officer</measure>
    </unit>
    <unit id="U014">
        <measure>ions:Installment</measure>
    </unit>
    <unit id="U015">
        <measure>ions:Drug</measure>
    </unit>
    <unit id="U016">
        <measure>ions:Country</measure>
    </unit>
    <unit id="U017">
        <measure>ions:Program</measure>
    </unit>
    <unit id="U018">
        <measure>ions:LicenseFee</measure>
    </unit>
    <unit id="U019">
        <measure>ions:Partner</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="c20190101to20191231"
      id="Fact_6104fbc79d0047928ce0530c29121038">0000874015</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="c20190101to20191231"
      id="Fact_f736aac1be9d44d8a7c970cdeb69b081">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="c20190101to20191231"
      id="Fact_8a77f6f4ebb346e7ac84078a365dacec">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="c20190101to20191231"
      id="Fact_51bbeb4c096d4ab2a5fb40142600a2e8">2019</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="c20190101to20191231"
      id="Fact_89ca9da358684bde912e758d7d33270c">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="c20170101to20170630_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_ConvertiblePreferredStockMember"
      decimals="INF"
      id="Fact_814732dbfffb4dbbb487265b1d09e7b7"
      unitRef="U003">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <ions:PeriodAfterBillingWhenPaymentIsReceived
      contextRef="c20190101to20191231"
      id="Fact_5acf7b3d4ee04d009d32a31d9e4ded77">P3M</ions:PeriodAfterBillingWhenPaymentIsReceived>
    <us-gaap:InventoryWriteDown
      contextRef="c20190101to20191231"
      id="Fact_1261d93c836d4d94bba4bd8c45f1e569"
      unitRef="U001"
      xsi:nil="true"/>
    <ions:MaximumContractMaturityPeriodRange3
      contextRef="c20190101to20191231"
      id="Fact_5b50da2d62974df399b2ebfcfccf0c30">P3Y6M</ions:MaximumContractMaturityPeriodRange3>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes275PercentMember"
      decimals="INF"
      id="Fact_5720e35e625f4851a419d661f07222c0"
      unitRef="U003">0.0275</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="c20191231"
      id="Fact_f81ca57385a04657b8ecd0f06d505159">us-gaap:OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="c20191231"
      id="Fact_530181678e9244af8b37885d3ba85980">us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="c20191231"
      id="Fact_9c37cb3853f74a4f821bbe4ed37a06ba">ions:LongTermObligationsNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="c20190101to20191231"
      id="Fact_6777d74751794fff96b76ff5cb8c6aab">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="c20190101to20191231"
      id="Fact_3626099ee72a4966a03bb040aef4b1f9">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="c20190101to20191231"
      id="Fact_1b51dcb448964fa491ed107ca7bfc303">2019-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="c20190101to20191231"
      id="Fact_5400abf97a83450e9302ff61e30117ca">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="c20190101to20191231"
      id="Fact_8426a2008b4146659670559a9fdbbda1">000-19125</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="c20190101to20191231"
      id="Fact_df7bd26e86ee40cc818e648190a37ffd">Ionis Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20190101to20191231"
      id="Fact_aa094870de6141069767c3ab99f91e41">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20190101to20191231"
      id="Fact_b473b5882d1549c2a9731e5e943607f3">33-0336973</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20190101to20191231"
      id="Fact_834011ed8dca4521bd3d00bf9c0e66da">2855 Gazelle Court</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20190101to20191231"
      id="Fact_69c1e23277f54a1f9c28e4b77162da21">Carlsbad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20190101to20191231"
      id="Fact_66e4abe2440141a1b06886bd81011085">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20190101to20191231"
      id="Fact_ddd3f0d34aef45c6bc8e86d2d2e74d11">92010</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20190101to20191231"
      id="Fact_3200624fb12245debf1cdc11d91ac9b9">760</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20190101to20191231"
      id="Fact_055ebb5973ce4ad4950bf287b17f0cd5">931-9200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="c20190101to20191231"
      id="Fact_6ea276f4924047d5abdf6678bee3cf9d">Common Stock, $.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20190101to20191231"
      id="Fact_6e531f880d474706b6d8ca0da3d2fd9a">IONS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20190101to20191231"
      id="Fact_3d1cdb1ee844484fa5c20d21f415a997">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="c20190101to20191231"
      id="Fact_175f9c28e466467f9ad35cba6fcb2164">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="c20190101to20191231"
      id="Fact_e74a2fcd4f3a4426a40ae17a7612bbef">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="c20190101to20191231"
      id="Fact_2097594455434eeb869fc101a26ce6da">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="c20190101to20191231"
      id="Fact_8b6f444a07694a15821e67f80f290670">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="c20190101to20191231"
      id="Fact_95c89a5712094ebaa070a91099973a53">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="c20190101to20191231"
      id="Fact_f3251c66fd9b436a8ef6a23f77e3d6f1">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20190101to20191231"
      id="Fact_5c10ae56e71043aeaa41bbc825971bea">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="c20190101to20191231"
      id="Fact_fb99b76b7ba14e8a9b1cee262ebe4ab2">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="c20190630"
      decimals="0"
      id="Fact_3093f45fbc13449d8907b516c6fba6ac"
      unitRef="U001">7483343134</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c20200220"
      decimals="INF"
      id="Fact_0fd2eda6fda6482ba4622abf15221ceb"
      unitRef="U002">139219800</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20191231"
      decimals="-3"
      id="Fact_bc9174e7fd1b46998715a48e884958d3"
      unitRef="U001">683287000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20181231"
      decimals="-3"
      id="Fact_7d7f77575df24801aeb6d430b5e2aea9"
      unitRef="U001">278820000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="c20191231"
      decimals="-3"
      id="Fact_f2286909ac5641e29bb72849f613afb8"
      unitRef="U001">1816257000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="c20181231"
      decimals="-3"
      id="Fact_a1df8a4ae5fb4f9d95e154d2c09e0e03"
      unitRef="U001">1805252000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="c20191231"
      decimals="-3"
      id="Fact_09ccd7c4554b495cb3b69ab0dd4c6353"
      unitRef="U001">63034000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="c20181231"
      decimals="-3"
      id="Fact_264161db8a37477daa1cb9fc9575e8fb"
      unitRef="U001">12759000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:InventoryNet
      contextRef="c20191231"
      decimals="-3"
      id="Fact_ef71bc5f67e14616981b9564f38cbdf9"
      unitRef="U001">18180000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="c20181231"
      decimals="-3"
      id="Fact_dac3eca6a6f24f2b88d7f80946b830f6"
      unitRef="U001">8582000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="c20191231"
      decimals="-3"
      id="Fact_ea0ef4e752a74ed2b3d6cfb2d9a33c46"
      unitRef="U001">139839000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="c20181231"
      decimals="-3"
      id="Fact_05664ce5755b408da83f5e1ff62a18ee"
      unitRef="U001">102473000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20191231"
      decimals="-3"
      id="Fact_c50a2906bf9c489fa10f03522ee0777f"
      unitRef="U001">2720597000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20181231"
      decimals="-3"
      id="Fact_37c6bfa1615e424e9cc12fd7d5941e85"
      unitRef="U001">2207886000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20191231"
      decimals="-3"
      id="Fact_e673fd22a5d44fc98ce04c462d2a135c"
      unitRef="U001">153651000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20181231"
      decimals="-3"
      id="Fact_d4aed8b852744ba8a28d733722dfa3e7"
      unitRef="U001">132160000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20191231"
      decimals="-3"
      id="Fact_35383fdfc944499d99481f4236a96589"
      unitRef="U001">25674000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20181231"
      decimals="-3"
      id="Fact_bd7406d09bb34cd38fa8036df5735589"
      unitRef="U001">24032000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="c20191231"
      decimals="-3"
      id="Fact_5f2a655af2b4494588eb9fd1c7927ce1"
      unitRef="U001">305557000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="c20181231"
      decimals="-3"
      id="Fact_d5da495aeeca4464978a569391184ebe"
      unitRef="U001">290796000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c20191231"
      decimals="-3"
      id="Fact_028d5e12b53d44efafc7fc6259a8c677"
      unitRef="U001">27633000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="c20181231"
      decimals="-3"
      id="Fact_0c76b4574810464783e04a0b5fcd3d22"
      unitRef="U001">12910000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="c20191231"
      decimals="-3"
      id="Fact_e7755fa54d8645189ca7a38afb274c32"
      unitRef="U001">3233112000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20181231"
      decimals="-3"
      id="Fact_bbc96043d6b84ad0a64609e7e45001dd"
      unitRef="U001">2667784000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20191231"
      decimals="-3"
      id="Fact_d2f4209896534c34b236247e2f014047"
      unitRef="U001">16067000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20181231"
      decimals="-3"
      id="Fact_4a77a0a95bc24ec9879730f3c54c5767"
      unitRef="U001">28660000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20191231"
      decimals="-3"
      id="Fact_6757e467d4ca4989a92e1b0146882726"
      unitRef="U001">37357000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="c20181231"
      decimals="-3"
      id="Fact_e13f67f862ed4bf9b0ccd8241eabef36"
      unitRef="U001">29268000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20191231"
      decimals="-3"
      id="Fact_70b781ca48864bb9b31bb2272f1c75fd"
      unitRef="U001">66769000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20181231"
      decimals="-3"
      id="Fact_969294300c9b472f89e106ba0b60bd69"
      unitRef="U001">47503000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="c20191231"
      decimals="-3"
      id="Fact_0ac97222f6364543b31753077f08b8f9"
      unitRef="U001">32514000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="c20181231"
      decimals="-3"
      id="Fact_924182cca560478288901c6e2b93dbec"
      unitRef="U001">858000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="c20191231"
      decimals="-3"
      id="Fact_c3dd012ae5014734b3edfded476645f1"
      unitRef="U001">2026000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="c20181231"
      decimals="-3"
      id="Fact_b637339218424d74ba82205fd72c11a5"
      unitRef="U001">13749000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="c20191231"
      decimals="-3"
      id="Fact_dde59dcefdfc41a5aece21fc7e36d234"
      unitRef="U001">118272000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="c20181231"
      decimals="-3"
      id="Fact_b5c48cb25c964d7c97633d915cafdb42"
      unitRef="U001">160256000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20191231"
      decimals="-3"
      id="Fact_6dd286ee152042f78be1fe86c4b53e7b"
      unitRef="U001">273005000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20181231"
      decimals="-3"
      id="Fact_324dbdee5a4a42159831822bf6b85720"
      unitRef="U001">280294000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="c20191231"
      decimals="-3"
      id="Fact_e76b53d24abc4ce98f4c0bd7bb5c4ee7"
      unitRef="U001">490060000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="c20181231"
      decimals="-3"
      id="Fact_4f3a8b90ab234988bb31ecd484021c4b"
      unitRef="U001">567359000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_2d12bb6f256d41509009bc5bd3a0c195"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_75004fb19a054dbb96df3227e79bee4c"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="-3"
      id="Fact_4eab47dc0a1d4b1c9a9acd7ab3519611"
      unitRef="U001">434711000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="-3"
      id="Fact_20d7bf53e413467294f1b30f5e5ea0f9"
      unitRef="U001">0</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_4d6ff05e689748ac82559327ae5d49e0"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_1396e02f45a24349a9a81454882364d5"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-3"
      id="Fact_fa9ddcff26e244deb6af4ff717c2ed72"
      unitRef="U001">275333000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-3"
      id="Fact_b81d968939c04aae8ac13f6ad19d2814"
      unitRef="U001">568215000</us-gaap:ConvertibleDebtNoncurrent>
    <ions:LongTermObligationsNoncurrent
      contextRef="c20191231"
      decimals="-3"
      id="Fact_4c526f7e2df4476ea452dc42e08d921b"
      unitRef="U001">15543000</ions:LongTermObligationsNoncurrent>
    <ions:LongTermObligationsNoncurrent
      contextRef="c20181231"
      decimals="-3"
      id="Fact_59cacc1d32984d6198584f93759863e0"
      unitRef="U001">4914000</ions:LongTermObligationsNoncurrent>
    <us-gaap:LongTermLoansFromBank
      contextRef="c20191231"
      decimals="-3"
      id="Fact_d0bdde965a494bd1967c669121c18b69"
      unitRef="U001">59913000</us-gaap:LongTermLoansFromBank>
    <us-gaap:LongTermLoansFromBank
      contextRef="c20181231"
      decimals="-3"
      id="Fact_b1093c295a3e4d8980c112cd144aa095"
      unitRef="U001">59842000</us-gaap:LongTermLoansFromBank>
    <us-gaap:Liabilities
      contextRef="c20191231"
      decimals="-3"
      id="Fact_72e72fa97a344884ae45c7d1457d4c58"
      unitRef="U001">1548565000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c20181231"
      decimals="-3"
      id="Fact_e80cd271efab4a4c8c3d5beb70de894b"
      unitRef="U001">1480624000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20181231"
      decimals="3"
      id="Fact_633d3f736e2247d291880fed08c8de60"
      unitRef="U004">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20191231"
      decimals="3"
      id="Fact_3582d99df2904a4ab26bce510bf362eb"
      unitRef="U004">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20181231"
      decimals="0"
      id="Fact_9a0912d45871495e9d5ffb48117b86ac"
      unitRef="U002">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20191231"
      decimals="0"
      id="Fact_7cf23bc0b3da4da3818fa69653f089c6"
      unitRef="U002">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20191231"
      decimals="0"
      id="Fact_6b03136461bc406ab4ea599c454895bc"
      unitRef="U002">140339615</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20191231"
      decimals="0"
      id="Fact_83959e73ecef45b7bf3b111575f95c72"
      unitRef="U002">140339615</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20181231"
      decimals="0"
      id="Fact_ae85ba7613de4a38acdf354791b136fa"
      unitRef="U002">137928828</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20181231"
      decimals="0"
      id="Fact_2e7ea39c8d104a0ca5cf2a5f9cdbc016"
      unitRef="U002">137928828</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="c20191231"
      decimals="-3"
      id="Fact_5f48063ae846417a85a50e82db398716"
      unitRef="U001">140000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="c20181231"
      decimals="-3"
      id="Fact_942a957fd1a642b4a9846b941b383984"
      unitRef="U001">138000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="c20191231"
      decimals="-3"
      id="Fact_3f85039492a3477ba262bbaf1e3a9940"
      unitRef="U001">2203778000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="c20181231"
      decimals="-3"
      id="Fact_a0bd160ae16c4b96869235d0b1952ae3"
      unitRef="U001">2047250000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="c20191231"
      decimals="-3"
      id="Fact_7f6094dad8014d18a90ab96ded5f7902"
      unitRef="U001">-25290000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="c20181231"
      decimals="-3"
      id="Fact_3e9ce1fe826144aea3422b89b11598b2"
      unitRef="U001">-32016000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20191231"
      decimals="-3"
      id="Fact_6946ee9e730b46ca9324cbc783ed82e1"
      unitRef="U001">-707534000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20181231"
      decimals="-3"
      id="Fact_37e824371589479e8ba1817b0f9ad53a"
      unitRef="U001">-967293000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="c20191231"
      decimals="-3"
      id="Fact_1ebcc837b8984805befb132fd95881a8"
      unitRef="U001">1471094000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20181231"
      decimals="-3"
      id="Fact_2815f025bebb4872b942adb7491ee5b7"
      unitRef="U001">1048079000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="c20191231"
      decimals="-3"
      id="Fact_15a602087f334617867a83b5dd1b29aa"
      unitRef="U001">213453000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="c20181231"
      decimals="-3"
      id="Fact_689780f0068e47e98756616aa52d94d0"
      unitRef="U001">139081000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20191231"
      decimals="-3"
      id="Fact_d61c237c2816416e9904b633d30916b8"
      unitRef="U001">1684547000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20181231"
      decimals="-3"
      id="Fact_0f68a4db9f9b47ad8afdba3a4483a05e"
      unitRef="U001">1187160000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20191231"
      decimals="-3"
      id="Fact_801588c240bd4ed6bb876453863968da"
      unitRef="U001">3233112000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20181231"
      decimals="-3"
      id="Fact_52b3ab3e91024ab988399c759f32bda8"
      unitRef="U001">2667784000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ProductOrServiceAxis_SPINRAZARoyaltiesMember"
      decimals="-3"
      id="Fact_fdaf4e7de3e14bc88036b45f358b0bc2"
      unitRef="U001">292992000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ProductOrServiceAxis_SPINRAZARoyaltiesMember"
      decimals="-3"
      id="Fact_7043d15f95394ffe96f0662fa9fad2fa"
      unitRef="U001">237930000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ProductOrServiceAxis_SPINRAZARoyaltiesMember"
      decimals="-3"
      id="Fact_ac6e240eca5848d5badb78f0ca60c1a3"
      unitRef="U001">112540000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ProductOrServiceAxis_ProductMember"
      decimals="-3"
      id="Fact_e82af709616c487887988783c2c8d9c7"
      unitRef="U001">42253000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ProductOrServiceAxis_ProductMember"
      decimals="-3"
      id="Fact_a83fa126a57b41d599f30e7cad218b6c"
      unitRef="U001">2237000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ProductOrServiceAxis_ProductMember"
      decimals="-3"
      id="Fact_ad9a698af9f24b05865de462af852631"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember"
      decimals="-3"
      id="Fact_573e884a4bdb425aa0b05fe6b144961b"
      unitRef="U001">17205000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember"
      decimals="-3"
      id="Fact_f85a761fec13470182f51d2856db9e79"
      unitRef="U001">14755000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember"
      decimals="-3"
      id="Fact_b54fd83200b746189af9f22a352eed08"
      unitRef="U001">7474000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ProductOrServiceAxis_CommercialMember"
      decimals="-3"
      id="Fact_fd9bb6ab6005461abb18649530165b23"
      unitRef="U001">352450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ProductOrServiceAxis_CommercialMember"
      decimals="-3"
      id="Fact_22602d3c8dbb4cce84585819b2a51d20"
      unitRef="U001">254922000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ProductOrServiceAxis_CommercialMember"
      decimals="-3"
      id="Fact_00a0f7dfe1fe42f2a3f0f34b4024aee6"
      unitRef="U001">120014000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember"
      decimals="-3"
      id="Fact_1620967f6acc42749745d5ae96e21c91"
      unitRef="U001">770149000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember"
      decimals="-3"
      id="Fact_0b96d8115fb4483dbc8311aafd1be7ec"
      unitRef="U001">344752000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember"
      decimals="-3"
      id="Fact_e3059784aae44cb6910ec96b251c7c0c"
      unitRef="U001">394165000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_00980b8be4a74f4fbdcc3edafc17198f"
      unitRef="U001">1122599000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_538efe69e72243699e94c3aa305b19c1"
      unitRef="U001">599674000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_32e9022328524875ac203ea1d35a74e1"
      unitRef="U001">514179000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_284d13f3b0c542e2be15e9d709d0fa47"
      unitRef="U001">4384000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_5c8f71079d0c4bab89afb5b5cd4f517d"
      unitRef="U001">1820000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_c74a16886992472e8e1ef9e3f198eae8"
      unitRef="U001">0</us-gaap:CostOfGoodsAndServicesSold>
    <ions:ResearchDevelopmentAndPatentExpense
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_deeed41a015f43ddb12f6865983ea8df"
      unitRef="U001">465688000</ions:ResearchDevelopmentAndPatentExpense>
    <ions:ResearchDevelopmentAndPatentExpense
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_9c3cab4b5389427ba74e69009ea765e5"
      unitRef="U001">414604000</ions:ResearchDevelopmentAndPatentExpense>
    <ions:ResearchDevelopmentAndPatentExpense
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_b91da5a5400f4a60b02409b9d698857d"
      unitRef="U001">374644000</ions:ResearchDevelopmentAndPatentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_45acc2391f3d437c94c32375af3fd727"
      unitRef="U001">286644000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_4b516d97f3e644e3bebe35a3e962a2d3"
      unitRef="U001">244622000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_91e5528c46124f72a2837c37daf9ab0b"
      unitRef="U001">108488000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_209b855f67a840c5adfd7d6d2132674f"
      unitRef="U001">756716000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_9583df6f11bd43278907171ed427d4ec"
      unitRef="U001">661046000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_710cbcd2ece544baa561093e1ebc3db4"
      unitRef="U001">483132000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_a29afc3ae1f74d74a4369f8ed00932b6"
      unitRef="U001">365883000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_a89db9808ad84853b7f4af5bb8f658a1"
      unitRef="U001">-61372000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_c14f627556d1404e9df00ec104e525ef"
      unitRef="U001">31047000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_8190f0450b994481b761b63a19fa2db0"
      unitRef="U001">52205000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_8c0f1b356e8a463e92d88c8d35f410bc"
      unitRef="U001">30187000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_4cafde1786854b4a831f3771fe519f13"
      unitRef="U001">8179000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpense
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_47eb0551e96b4a789a0b721ce64eef0f"
      unitRef="U001">48768000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_6c26daacbb594ef5a5eafb7e6d90e3cb"
      unitRef="U001">44789000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_97c245353bc447c096bb628d4d02557c"
      unitRef="U001">44752000</us-gaap:InterestExpense>
    <ions:GainLossOnExtinguishmentOfFinancingLiability
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_1b6947bfaba548758e64566b848f59cb"
      unitRef="U001">0</ions:GainLossOnExtinguishmentOfFinancingLiability>
    <ions:GainLossOnExtinguishmentOfFinancingLiability
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_a5937e22a494466284df196fbd0fcb71"
      unitRef="U001">0</ions:GainLossOnExtinguishmentOfFinancingLiability>
    <ions:GainLossOnExtinguishmentOfFinancingLiability
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_58a1a8d5100146e5ad352c095b159c25"
      unitRef="U001">-7689000</ions:GainLossOnExtinguishmentOfFinancingLiability>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_c3a4479d5bc24c12bbb3654f2b59fba2"
      unitRef="U001">-21865000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_1e981ccfec9e4e77bdb93b732ca6bb87"
      unitRef="U001">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_db456fea13e442f58dc87cedc52ba432"
      unitRef="U001">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_516792b864244fea81a047aaeb6a86f7"
      unitRef="U001">-686000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_df31a318f46e40c0bad155f92c7bffb9"
      unitRef="U001">-182000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_95a44b06b165497c90c92f0ecb837d5d"
      unitRef="U001">-3548000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_786ffe6ab1c44b428a4fc9133fa1fb21"
      unitRef="U001">346769000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_d3bdd0f2404d4109ab52a26b4122517d"
      unitRef="U001">-76156000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_abea68078429482298990eda2a273682"
      unitRef="U001">-16763000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_25eb94c1a44848a4ae8038f050bdb154"
      unitRef="U001">43507000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_5b1c8e20abb84c34b626e66d15f639fe"
      unitRef="U001">-291141000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_4e00bc85f9de44bc9fae3e310059dd54"
      unitRef="U001">-5980000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_eed2832b2f23443a8a7b6a11b3b5c8be"
      unitRef="U001">303262000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_17fba83bb5c645feab5192b45331713f"
      unitRef="U001">214985000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_1b16a95e7fa948b78f84194e8da4f693"
      unitRef="U001">-10783000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_39c266b37a4b4b75807a14eb73538310"
      unitRef="U001">9116000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_498b97278bb645e598fad5c547449f5f"
      unitRef="U001">-58756000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_2924ba1e6c0449e68559e8bfbf1fff33"
      unitRef="U001">-11129000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_d67d140ccc41433e809a30cd81e184e2"
      unitRef="U001">294146000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_41f8afe988ab4add8c88a8e7caefd925"
      unitRef="U001">273741000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_bb9a33cf051a47359fe47c04a4566435"
      unitRef="U001">346000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20190101to20191231"
      decimals="2"
      id="Fact_ad4c690aa177438c98b7e63bbcd61da7"
      unitRef="U004">2.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20180101to20181231"
      decimals="2"
      id="Fact_2c847af7934d4aee8d1e75c8c45eaaed"
      unitRef="U004">2.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20170101to20171231"
      decimals="2"
      id="Fact_dc69ad9fdaac456cb95135c896add9e4"
      unitRef="U004">0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_974483869c87424686f8a9d8ad9407f8"
      unitRef="U002">139998000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_57a007ce704b4b8e9d16bf5187758b1a"
      unitRef="U002">132320000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_24585fd306204e04ac047eefaae344a7"
      unitRef="U002">124016000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20190101to20191231"
      decimals="2"
      id="Fact_7912333792fd463c8e34f1de8bd9f9e6"
      unitRef="U004">2.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20180101to20181231"
      decimals="2"
      id="Fact_be3545ea33e8465ea31dcf5f8cde1413"
      unitRef="U004">2.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20170101to20171231"
      decimals="2"
      id="Fact_1c75266fa9c242d78bbf9c06298d1fe8"
      unitRef="U004">0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_2e175ab1f4b4430c94110075de726551"
      unitRef="U002">142872000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_2bfa48d5ab3a400f9f083d57c473a574"
      unitRef="U002">134056000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_5a8e2e89a8854d18b716d51e6be5e33a"
      unitRef="U002">126098000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_ca9d6b6e811d4d90a3511939ceaffd35"
      unitRef="U001">303262000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_0f152c7175c442d096186ccdac7163b8"
      unitRef="U001">214985000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_e9347ab362a94c8f9fec26b2321644a8"
      unitRef="U001">-10783000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_33ff3ee28c9b4c45b1a904711a9fffdb"
      unitRef="U001">6633000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_7ada2fcd89584f6e9d084b26c02bad37"
      unitRef="U001">-280000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_48783ec4c4a4439782c377df7893c03c"
      unitRef="U001">-960000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_3b86bd0eff5744bea0c1168aa475edc1"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_4956a7b49b104a6a89c4a25a21e22e91"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_5ebf1d568f17475db6e7caa910125a6d"
      unitRef="U001">374000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_0118d01a0fc0483d942b9e51407b4717"
      unitRef="U001">93000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_e0cf23c629544136a3b19d99634a49a6"
      unitRef="U001">23000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_107faab7668f4901940b3c076c0c0ec6"
      unitRef="U001">-67000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_88990aa910f44465b514db16de1b6797"
      unitRef="U001">309988000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_a94a014398884db3aad264a9afa0f0b9"
      unitRef="U001">214728000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_952a61bbba0241e4b821f51c3f0cbaf0"
      unitRef="U001">-12184000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_0a2ffbf7523a40bfb67425a2f824fdda"
      unitRef="U001">9118000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_835fc2d29a554273b86faf6556c423be"
      unitRef="U001">-58781000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_7354d55541b84356989b29706bcadb0e"
      unitRef="U001">-11224000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_c084b014906646ef8b8e0d1564259a56"
      unitRef="U001">300870000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_a5f2d997e0854eb2bac6beedf43dbdc0"
      unitRef="U001">273509000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_8a473722becb41bd9bc5a5fa8d670a5c"
      unitRef="U001">-960000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="c20161231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_fd68097e538c4b81b9bd4921620080f6"
      unitRef="U002">121636000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20161231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_64d1adea22c6400d899f50eacb6b29e2"
      unitRef="U001">122000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20161231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_92deefa3c28e47c5b979d2b7658c7619"
      unitRef="U001">1311229000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20161231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_c3741346678549d58e3408ca523e7a1c"
      unitRef="U001">-30358000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20161231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_ea62c55770e44c1daacc2df30d4795b7"
      unitRef="U001">-1241380000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20161231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_ad4ccb7a094841f58d036cd173beda7a"
      unitRef="U001">39613000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20161231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_a952a188c419434fb7ec7098f2b9950c"
      unitRef="U001">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20161231"
      decimals="-3"
      id="Fact_c686bc8629764f71b2253b35cf2412e0"
      unitRef="U001">39613000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_f57535e622164f339a6c82bba63e4428"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_1743253c1bf14efab032700eb36bdf42"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_020443c416a44ec388ce65759f2a445c"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_6c410bcb824948a88f2e5504a60e6c63"
      unitRef="U001">346000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_56d476ab6a104072b642175b9bd8b013"
      unitRef="U001">346000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_17081bb682174af2af61b2f9f5397c43"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_4afb0261ba344f83b0def222fca29e14"
      unitRef="U001">346000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_0e3bd928ac7848c387c696f2f40dbe60"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_a90097243bde4406b124f7551e1fc054"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_051ca26e3c29447889e52b45ae827ab0"
      unitRef="U001">-1334000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_7d3018f98130431dbce35431bd18a168"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_93d42dc646f3414ea4f28746f0f079c2"
      unitRef="U001">-1334000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_1ebfaf794acb4bc4859d0aa04832df0e"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_f36378ab4b5a4c85a76002fd8dbe422b"
      unitRef="U001">-1334000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_120b3e829cca4d3db38746d14dcea9cf"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_6ea42c0ff7e0453a95bed2efa16563d0"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_760886ee213a4f1086e1fa353c55ac27"
      unitRef="U001">-67000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_b2f243cad35940a69fd750813e0b9005"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_dc848cf7789b4c529df5f6778ad65a0c"
      unitRef="U001">-67000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_02e237697f4b43d69464b572b00bb889"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_5d654a3d46b34c72818ae5f97336adfc"
      unitRef="U001">-67000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_ab01054e09164a8b86ed8a056a2a40bc"
      unitRef="U002">1631000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_48f92edc119349c392868b97532a1a7e"
      unitRef="U001">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_a11acc6903c6429690c33297ae69a98b"
      unitRef="U001">71737000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_64057ec289eb4423b8dd2ef0ceb00709"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_5353448487fb4a49836e592fb3b985f1"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_95c240029be54d83a8e53b879da39f7b"
      unitRef="U001">71739000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_0eb705d35b9f467ab511c84f357ce263"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20170101to20171231_CounterpartyNameAxis_NovartisInternationalAGMember"
      decimals="-3"
      id="Fact_d7a6aabe82c747d9a58860a3f2d5280b"
      unitRef="U001">71739000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_e57de8a5f40049fb875ab0d99a0da99a"
      unitRef="U002">1709000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_074d7b5874874ed09f1da1463212087a"
      unitRef="U001">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_8d03d0db70d14bf9ac1b58473ad4c657"
      unitRef="U001">22931000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_a55a166958544405abb544f64c2dbc62"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_7d5c129eb6824cd9aa9d7fb088cdcddc"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_7edee4630923452abd6ae5450469a239"
      unitRef="U001">22932000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_33279df145c44dd2b8899acc707a2958"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_44948b5450a74c80b499a91d44ff8887"
      unitRef="U001">22932000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_e2b28030b5914cbf88c54ac00cc4576f"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_001c6ca7907842f98ac9aef5630fcf80"
      unitRef="U001">85975000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_5771dc32ee084269a6710bd19e393b9f"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_6604eb2d4df04aa6810504a074bfa450"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_99b5694fc4174f9781d435577fcd4f05"
      unitRef="U001">85975000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_8591421a040646408b49f831181765f5"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_a0e7f202280747dc8f747551ebd633bb"
      unitRef="U001">85975000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ions:StockIssuedDuringPeriodSharesNewIssuesBySubsidiary
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_2565e2b8fd63455e811028466b2e6f8b"
      unitRef="U002">0</ions:StockIssuedDuringPeriodSharesNewIssuesBySubsidiary>
    <ions:StockIssuedDuringPeriodValueNewIssuesBySubsidiary
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_ade3d650cd164279ab40871e21547b9b"
      unitRef="U001">0</ions:StockIssuedDuringPeriodValueNewIssuesBySubsidiary>
    <ions:StockIssuedDuringPeriodValueNewIssuesBySubsidiary
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_9a85d1991e2a4b7b8111903a160c684e"
      unitRef="U001">157270000</ions:StockIssuedDuringPeriodValueNewIssuesBySubsidiary>
    <ions:StockIssuedDuringPeriodValueNewIssuesBySubsidiary
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_0bf0f8a752094c6a802223a55b51f861"
      unitRef="U001">0</ions:StockIssuedDuringPeriodValueNewIssuesBySubsidiary>
    <ions:StockIssuedDuringPeriodValueNewIssuesBySubsidiary
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_d5894fd6fe8d4a0e8be4122b860d9dc9"
      unitRef="U001">0</ions:StockIssuedDuringPeriodValueNewIssuesBySubsidiary>
    <ions:StockIssuedDuringPeriodValueNewIssuesBySubsidiary
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_167168c44c79462c85f9a5954f3f40d5"
      unitRef="U001">157270000</ions:StockIssuedDuringPeriodValueNewIssuesBySubsidiary>
    <ions:StockIssuedDuringPeriodValueNewIssuesBySubsidiary
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_21434565ba214cbf8ebbdf2fd33571c0"
      unitRef="U001">0</ions:StockIssuedDuringPeriodValueNewIssuesBySubsidiary>
    <ions:StockIssuedDuringPeriodValueNewIssuesBySubsidiary
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_0c7fb6d2206c4f1bb29dba4c01188835"
      unitRef="U001">157270000</ions:StockIssuedDuringPeriodValueNewIssuesBySubsidiary>
    <ions:NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_c2efaca8fa6a45a7a69b6d8520c0f455"
      unitRef="U001">0</ions:NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary>
    <ions:NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_6cec2ceb83354bd7acbed0f8425163e5"
      unitRef="U001">-90351000</ions:NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary>
    <ions:NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_a7e9a2348e4f46198a4a5ebb155e570d"
      unitRef="U001">0</ions:NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary>
    <ions:NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_22e15779c5de4e7c8f4fef6cb91a190a"
      unitRef="U001">0</ions:NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary>
    <ions:NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_f303f512554042ce87e1f6f40a816984"
      unitRef="U001">-90351000</ions:NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary>
    <ions:NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_f461e3ac014041d788dd481fc6aed056"
      unitRef="U001">90381000</ions:NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary>
    <ions:NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_37f880c732844e9bad324aafba1a49d5"
      unitRef="U001">30000</ions:NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_35741777134841d7a1d294b1ff07b5c2"
      unitRef="U001">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_d001dff9df0e4f0b9610194daa5aa057"
      unitRef="U001">-5110000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_a041c2cab55e4ef899c87ce42e0cea35"
      unitRef="U001">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_4e9d2a3a7f454b9e8fcec454f09f4f63"
      unitRef="U001">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_cbb62b66e5fa4370989862794a4e53ee"
      unitRef="U001">-5110000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_5f98725aad6343fc92d3aa055a631ba0"
      unitRef="U001">-6114000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_9877998ce4fe403fbb49607c40dc5dd1"
      unitRef="U001">-11224000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:SharesIssued
      contextRef="c20171231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_6fe590d22b42475cb2ab499952418720"
      unitRef="U002">124976000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20171231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_0b2e87ee326e4b829343f9178b718248"
      unitRef="U001">125000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20171231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_71af73b6843e4908bff33ed3bb3f81dc"
      unitRef="U001">1553681000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20171231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_506ef91fee2e48aaae45a93b7ba31557"
      unitRef="U001">-31759000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20171231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_e7473abf9eef44dd831973c3e99d4a9c"
      unitRef="U001">-1241034000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20171231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_1df4c5d4bf1e4c5fbb614f3dfa6fcd49"
      unitRef="U001">281013000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20171231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_8ad5daed766d41658a6facb3d89a1cd8"
      unitRef="U001">84267000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20171231"
      decimals="-3"
      id="Fact_03abc9126e214857b1c975f0d8b154cb"
      unitRef="U001">365280000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_c84e3d7df2744ac490f2ece90238084c"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_a05d8d9d09c34d3aa0b85cc78675563d"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_0f5d62d23bc047e2a3dc1c0f774b9020"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_aecdfc9e7f3b4d8181fc8ead9202c0bf"
      unitRef="U001">273741000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_9e86184a3845435c956f280f8d01667b"
      unitRef="U001">273741000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_b254521696fb4e05a0eb787bdb22422a"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_8ff18ce23015476190e74edcd530b87d"
      unitRef="U001">273741000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_7ba08b22b1b540d6aeb73d182a28608d"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_9c3d7ef70b634be98d60773f8b79aaf0"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_3e64e9de93f64f50802c77e8a55ac347"
      unitRef="U001">-280000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_8de1eaa5c2ee4ab3b60cc78f1890b129"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_930a0caf475345729a1ee26892965811"
      unitRef="U001">-280000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_eb2f7611b4dc405193a092337b144d42"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_48c7584a84da4c90803e9757f9b399cc"
      unitRef="U001">-280000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_90ccf61964db4d16a531dc7d86992d0a"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_fd28d183cbe944178e688ea98f385c3c"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_d9b7477e2efe498582984e21cc3cbeb0"
      unitRef="U001">23000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_8d4fdd4f7f7f438cbb9dc1ad836fdec1"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_d68b268e678f471ab3112b50cbac1193"
      unitRef="U001">23000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_9929043870fc465fb02ef438606c0838"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_82fc623119a8449f8f2a8a7bb05278a1"
      unitRef="U001">23000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_422d1342431843698c70e9e3e6a7d970"
      unitRef="U002">11502000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_2815369ff411484dafeb907944063272"
      unitRef="U001">11000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_f81af2efa9704103bcb9323e1a5f10a0"
      unitRef="U001">447954000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_af988eeb5f914d178b4f60d05fcf8139"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_7999e83bb836472b9fb91450d2febc65"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_348f46d0add04c708f65b3df0bb57858"
      unitRef="U001">447965000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_5aeda03bfc9940e3979be51056cd44d1"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20180101to20181231_CounterpartyNameAxis_BiogenIncMember"
      decimals="-3"
      id="Fact_da1f3831ed924137a6c6e12ae46c56d6"
      unitRef="U001">447965000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_9d30603d6cfd4749bcdd89daaf10dd65"
      unitRef="U002">1451000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_f826cd8d24a94dcd96107584163a2fdc"
      unitRef="U001">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_2dc6f4f1933f49daaca7de2c77136413"
      unitRef="U001">27898000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_bcc4a6182a964efeac1f24893ac74c31"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_a243a22d6fc3446a8f3886c10c6effad"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_700a04df12a14eb6a230b1964cc684b2"
      unitRef="U001">27900000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_69b8eb05b0ef4453b060ffd6599f20a6"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_3783a73ce7344d1bbda2d31237e63c46"
      unitRef="U001">27900000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_db045d548f2240a286157e5143cd5467"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_78d7b7e3c1f74195a84f5fcc6da41363"
      unitRef="U001">131312000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_da8349e873094998b27c1da80326bb76"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_f03b2cdadbfd478cac32496466c3e7c5"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_f7b362873c854477ba81148bc17282ab"
      unitRef="U001">131312000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_9453fe6b0add4f3a99b3bb84b26f63dd"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_17be3f01639941beb54bf488fbc8f610"
      unitRef="U001">131312000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_666c40a4a122403cae72b21e8817611b"
      unitRef="U001">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_47a91296bf2945758c0363e1d81f40a4"
      unitRef="U001">-113595000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_94729224298b458b8079f3c8596d65ae"
      unitRef="U001">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_91c3d721cec84f3a8abc4a8a4938d37f"
      unitRef="U001">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_7d69dd60ea324bb889f6533ca7de9328"
      unitRef="U001">-113595000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_d388d05f36b24606903d69f5ffdc3ed4"
      unitRef="U001">54814000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_01d5d052ad874a94a27a0b66cccb1b73"
      unitRef="U001">-58781000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:SharesIssued
      contextRef="c20181231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_ddcaee8d8e4e415f99603d60fbe0130c"
      unitRef="U002">137929000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20181231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_b05da05da7fe41bda5bf6ada927a792d"
      unitRef="U001">138000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20181231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_6ab9978b577d43178d568aee326b7826"
      unitRef="U001">2047250000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20181231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_a41d9ba2c9a34eac96b94876d458700e"
      unitRef="U001">-32016000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20181231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_84f539e326a64ec0ab408c09645014b1"
      unitRef="U001">-967293000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20181231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_d7840211f9204d4e84bda2551d44d0c2"
      unitRef="U001">1048079000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20181231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_ec7256f1e9984d82a2ceccc0c5cc83d5"
      unitRef="U001">139081000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20181231"
      decimals="-3"
      id="Fact_12ff567b84a548acaed74dc483a0acc8"
      unitRef="U001">1187160000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_a67f9527449c47eeb32f69118f686b2f"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_8f3162784e6545a6924bc32c7733346c"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_a350a139c53d4d6fb396ed04590e6ce5"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_b3a2447b1d834cd0a3ceaa4817d99a93"
      unitRef="U001">294146000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_1a865e1176c546ef9bb829e8888bea17"
      unitRef="U001">294146000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_8ae3f201424a47eda14b0dc5e7c87f15"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_de8d2f53ac6d4d879added5a5aa1dcc9"
      unitRef="U001">294146000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_091acbdc3d82400b856fb543039fff06"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_cb0a0c71133844d3813cf48f84db8653"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_ccafcb363fac48a1894ab9d43abd6205"
      unitRef="U001">6633000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_783f4fab8a7a406b9f621eff4771df67"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_452ae92e05a247dd8ff31928b367fbc8"
      unitRef="U001">6633000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_a40693ecba5b4be18cf4bf78c9877442"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_1bb43560b5e5484e943ecb8f677e0578"
      unitRef="U001">6633000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_57e0d1697c8e4a479de822431d02ddcb"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_ac7228222b1b49dcb8f72098da3a2fc5"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_1fc757414d054332964615bbdf74bef5"
      unitRef="U001">93000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_f0d212544aec4c4a9786a02a41de4f60"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_ea09c80cfd634d45bab908ab4ec28c80"
      unitRef="U001">93000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_72802d9709534b28aab5c5cde6356875"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_87403d54e17c49d7b817a60049b06375"
      unitRef="U001">93000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_c24c54602c144726bfa552f8a73e19cb"
      unitRef="U002">3100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_8e7958f907ad494caf864e34d07a6a23"
      unitRef="U001">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_2147c10da0b64b7e9ecab30181a3380f"
      unitRef="U001">119654000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_f09f40a13c0a49e7bb263437412ae0fa"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_e64b1e9c032f43b69df459e05bc70d0d"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_50a3d26ac1f5441697cb3978958677f5"
      unitRef="U001">119657000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_35227d58ddcd4fd5a24c7e200027ed14"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_a9610c4a050040a1b9d134486721c73b"
      unitRef="U001">119657000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_83a3e2736f2143ada2faad90731539af"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ions:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_953662494e8042ca9a0656b07a91bf1c"
      unitRef="U001">0</ions:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption>
    <ions:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_d8369e5fb5e64dd88bad2b718fbc5a05"
      unitRef="U001">77331000</ions:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption>
    <ions:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_8b3a83dca8ec4f0989e5a8a7a373b923"
      unitRef="U001">0</ions:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption>
    <ions:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_69b685a069454aada5e59edce9c03386"
      unitRef="U001">0</ions:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption>
    <ions:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_ccc3b06011914242998f1f6fc5a86f5e"
      unitRef="U001">77331000</ions:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption>
    <ions:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_90b27e956e1341d88497f039672d94bf"
      unitRef="U001">0</ions:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption>
    <ions:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_724720b280a44a0ba9fb326d292189c3"
      unitRef="U001">77331000</ions:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_48a58ec03ee9478c94ed56dd8e46cc7d"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_65e36c24f0894b40853b9eeb75338a47"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_83f8530c6b384ae98925066d03454ef3"
      unitRef="U001">81877000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_dfeb6a4b1c284a3b93d79cf3a45a07ac"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_8888f84bb0a14310ae386fb181379ef5"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_49bc1c5ebc0548fcb8fcda6bac4779e5"
      unitRef="U001">81877000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_4e13fb008b184d2ca173a0e726662a02"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_69bcc9ef38b04a3f9c599f8d1788c1c8"
      unitRef="U001">81877000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_e50a4f4665d04c8c948a7c4ed8b11a23"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_9030e03e300141b7a4c3684d6640bb69"
      unitRef="U001">56110000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_69d1c1a3e263405db0d40fc651f9eee0"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_4d037abc26f04f29babe19cdcdf1e842"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_bdc639c44a0045d6aeb936229afd02b6"
      unitRef="U001">56110000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_6fd6745266c64d4ba944fd94daf65883"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_3d495ff92a534f91aa5cba742ef4998d"
      unitRef="U001">56110000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_e79a280b4f0648d4b31f376e0c7b6a73"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_b588eded63ab4563bbe0ece09adcb1a8"
      unitRef="U001">-85860000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_11e3e8eb23cc49358654b3257ee72ae0"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_b8fcdd9317c54a3faf946784ada255fd"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_888f566bee434121b979e85a24d8d253"
      unitRef="U001">-85860000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_d3315b42b16c424b8b2915ebba587dd6"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_3d45fdaeb6cb42af88cdd003e9d475c9"
      unitRef="U001">-85860000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_6d0509a3a49e4fd79186aba88fdfe7cc"
      unitRef="U002">535000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_3e2d452fbb8e42f6a34ac114784ab9a3"
      unitRef="U001">1000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_c2c06cb20c284344b197268932c18253"
      unitRef="U001">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_e4b1fe1d06444bfd96807b9c900fe8c4"
      unitRef="U001">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_c29b6427e7554a4180120463ed6cd6f4"
      unitRef="U001">34387000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_bb78398196024e879afbff00d3335ff8"
      unitRef="U001">34388000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_caf4b9bf5c8041a1a878141b4db37ad9"
      unitRef="U001">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_f181e719466440b694f0c0c4e9e5e3cf"
      unitRef="U001">34388000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_8814916665504ddc88722078a6a2074f"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_251a778792bc4574921239d96e2cc76b"
      unitRef="U001">146574000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_72ff720ee9954b8e8e3dd43fd9fb1c97"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_1d0ce5c99690477898d58d2270f91119"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_3bbe99e715fc4f75ad0ccd0a8564a13a"
      unitRef="U001">146574000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_aa9f51446a9947dfa4afad89a4c87329"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_ecddf625db5e4ae8b44436f78790413a"
      unitRef="U001">146574000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_a3235a69b98240b697dda8695b530e9b"
      unitRef="U002">-154000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_b6558edaae9a4bc19dc54b131b2b7dbd"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_4e435cadfcab475db76df4d24e337ba4"
      unitRef="U001">-19242000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_1dd896112023423b82db73b8a21630fa"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_f7f9adce2f554b4da4e8e972e171e084"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_4fc01f2664c9469caeed47d3bd7593a9"
      unitRef="U001">-19242000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_4d1d40b3aa7e4e0eba01947bddbee8e4"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_20b2a9e912cc45ad89b6a659c11d0af7"
      unitRef="U001">-19242000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_9019973e46e44654bc6d5693a64d8d54"
      unitRef="U001">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_fa0e947eab2649f98fdad98a4fc5b5cb"
      unitRef="U001">-65254000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_45ed5950a192470bb0c6f36e87ee64eb"
      unitRef="U001">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_b914f08f78a044f782f44be3ed9b15fd"
      unitRef="U001">0</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_fe58258522784128b04dece32d36d4c2"
      unitRef="U001">-65254000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_eec4affdb73243209fa0da61997ada6b"
      unitRef="U001">74372000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:MinorityInterestPeriodIncreaseDecrease
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_6a88f675be4b4fbdaa04b195da7e5eaf"
      unitRef="U001">9118000</us-gaap:MinorityInterestPeriodIncreaseDecrease>
    <us-gaap:SharesIssued
      contextRef="c20191231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_746edf0b2d594dc1bfff28688790aadb"
      unitRef="U002">140340000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20191231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_dd95823efc6d48629085e2df2a2df03f"
      unitRef="U001">140000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20191231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_7926590c4ac846588194c66ff4c2550a"
      unitRef="U001">2203778000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20191231_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="Fact_e2257cbf08d94c6bb70d24097bf49d5d"
      unitRef="U001">-25290000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20191231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_73eb2d116b2544438ca47b4bc3166000"
      unitRef="U001">-707534000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20191231_StatementEquityComponentsAxis_ParentMember"
      decimals="-3"
      id="Fact_2257e7f227984d2080fa75bfdcc1445e"
      unitRef="U001">1471094000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20191231_StatementEquityComponentsAxis_NoncontrollingInterestMember"
      decimals="-3"
      id="Fact_a6af661e63ee4803aa097fa82936e2c0"
      unitRef="U001">213453000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20191231"
      decimals="-3"
      id="Fact_f192a399801f4e43be246c6b0b0043d5"
      unitRef="U001">1684547000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_74418700e541478eadc5aced379a124b"
      unitRef="U001">303262000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_3fb9b4a0ea3c4f27a1399c4165b5801f"
      unitRef="U001">214985000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_39b8baae321b42f7a5f4fa01fd0016cc"
      unitRef="U001">-10783000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_9783424161d0448dad5051ce77601a96"
      unitRef="U001">12540000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_6e647886642547db938d5dd7ac6cb6ac"
      unitRef="U001">10706000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_c043d99cc86a49da958b7b3be663c1e1"
      unitRef="U001">6708000</us-gaap:Depreciation>
    <ions:OperatingLeaseRightOfUseAssetAmortization
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_187fd18217c9402ba4a18dc3da990453"
      unitRef="U001">1542000</ions:OperatingLeaseRightOfUseAssetAmortization>
    <ions:OperatingLeaseRightOfUseAssetAmortization
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_97e6d2268c574e3d8f29df4998aec6d6"
      unitRef="U001">0</ions:OperatingLeaseRightOfUseAssetAmortization>
    <ions:OperatingLeaseRightOfUseAssetAmortization
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_215c70afe4f549f890056ebd2c3be83f"
      unitRef="U001">0</ions:OperatingLeaseRightOfUseAssetAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_c4419687fb464fe5bdc6e0d2984bef36"
      unitRef="U001">1912000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_2510d199eca04ba290db4822e474a069"
      unitRef="U001">1822000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_dfcf2be324b646d9bb90e538cfcfa5d7"
      unitRef="U001">1641000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_19b1a8aca8b7454d8d920b65112f9717"
      unitRef="U001">7485000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_1d483a94eb99484aaf16db7faa11b937"
      unitRef="U001">1013000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_a3256c7afeb0459b896a0c3caee0e2f8"
      unitRef="U001">-6752000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_b85286437b974418ba977d6f06debc76"
      unitRef="U001">1942000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_a644e66590634fa5857536f88b90ec7a"
      unitRef="U001">1810000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_8299ca7b84184a219ca22bdd8885ded6"
      unitRef="U001">1616000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_c6a08bf487994614bcb0094e8c8ffdb8"
      unitRef="U001">37338000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_1705faed1556409b8a834d130ee3edae"
      unitRef="U001">33363000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_a26c3943aee0441994aee8f5be710103"
      unitRef="U001">30920000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfLeasedAsset
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_0f0686824c2d4ba5bbe71d8816dab0f9"
      unitRef="U001">0</us-gaap:AmortizationOfLeasedAsset>
    <us-gaap:AmortizationOfLeasedAsset
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_c63e45e30bb84c4ab3194b7e56e8eb76"
      unitRef="U001">0</us-gaap:AmortizationOfLeasedAsset>
    <us-gaap:AmortizationOfLeasedAsset
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_17752f9064a34f5b816cc4fae67422b9"
      unitRef="U001">3659000</us-gaap:AmortizationOfLeasedAsset>
    <us-gaap:ShareBasedCompensation
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_de86964f1c204681a24953a828812433"
      unitRef="U001">146574000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_b7ce371b025e4c42b0adacb5ab3929a4"
      unitRef="U001">131312000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_1639ac5ab8ad4f01b5b69c5287ccb579"
      unitRef="U001">85975000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainOnSaleOfInvestments
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_4d1595e63af04abea4966fe86708ced5"
      unitRef="U001">0</us-gaap:GainOnSaleOfInvestments>
    <us-gaap:GainOnSaleOfInvestments
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_6c6ff75931a54728a59ae998477a38a1"
      unitRef="U001">0</us-gaap:GainOnSaleOfInvestments>
    <us-gaap:GainOnSaleOfInvestments
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_4636e938136d4cdfa6bfecf49a1f916d"
      unitRef="U001">374000</us-gaap:GainOnSaleOfInvestments>
    <ions:GainLossOnExtinguishmentOfFinancingLiability
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_0c14da2f172b4616bda58edd7c204d69"
      unitRef="U001">0</ions:GainLossOnExtinguishmentOfFinancingLiability>
    <ions:GainLossOnExtinguishmentOfFinancingLiability
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_5938268a07c646f2b101d782daafc456"
      unitRef="U001">0</ions:GainLossOnExtinguishmentOfFinancingLiability>
    <ions:GainLossOnExtinguishmentOfFinancingLiability
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_9ef4a7dd516e42f787c64d7e55cc44ab"
      unitRef="U001">-7689000</ions:GainLossOnExtinguishmentOfFinancingLiability>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_e867493ef4ff4d3ebe904b6d5afd0509"
      unitRef="U001">-21865000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_746295e1c66f4d83896cdde464856584"
      unitRef="U001">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_92b9752085fc414faf69a3c81e0bfb45"
      unitRef="U001">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_1d37213306b346a2a2c697ca032c3d0e"
      unitRef="U001">-7096000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_5c2bc7d8b78d4b099c1e6ade218bd61f"
      unitRef="U001">-290516000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_2a9eba50a072476bbfd8481cf925c9b4"
      unitRef="U001">0</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <ions:AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_291cde2cb61241079f0d07a1773ddce6"
      unitRef="U001">2034000</ions:AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments>
    <ions:AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_41bc9d424e104261a082087cb455e2a0"
      unitRef="U001">1012000</ions:AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments>
    <ions:AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_3670e160c2544d3d9cbe6b16b6a00e35"
      unitRef="U001">3302000</ions:AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_f68a004f44a6458192f1daa14c3a54bb"
      unitRef="U001">47674000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_e61ccb4ba21a4ee397258365ed72f449"
      unitRef="U001">-47595000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_d476ac7c7da448f6a23a134d6afa1da6"
      unitRef="U001">-45088000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_085c28a5897b4fdc902bd3eb96b38cfe"
      unitRef="U001">5411000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_721b959345b1466b92ba324d3da7222a"
      unitRef="U001">-1400000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_f0c18d8f1c034754aa7043aeea9887ef"
      unitRef="U001">2493000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_864803efe0c94dcc8ef6304a526731c5"
      unitRef="U001">44659000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_9c22cd95e9714742b7353b0030bbba8e"
      unitRef="U001">29348000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_6e52fd98d6cb4429b89f68777b6ce49d"
      unitRef="U001">58367000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_f85089599ebd420ab0dfeb4f295cfc60"
      unitRef="U001">-8418000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_39986573e52c4b22a4e7523064d4a2b9"
      unitRef="U001">223000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_5e5b325268ae444f9a6564725f633244"
      unitRef="U001">9114000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_a2882fd1ebf24bd894bdd232be12bb88"
      unitRef="U001">-16343000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_19037c392df44ffaa87bb0e8fa58cb64"
      unitRef="U001">-655000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_fdf8edb884a5467dbfa35ec370b22a73"
      unitRef="U001">1784000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_cbe5d4f72a7b47b6bbf20a734efa0ff9"
      unitRef="U001">31656000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_928bf4ded5484066ada8046ae256e5bd"
      unitRef="U001">-710000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_35b11d3a61584178b39dbfdaa63e5d23"
      unitRef="U001">435000</us-gaap:IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInOtherEmployeeRelatedLiabilities
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_be8c0f046cfa423dbf8943de92eacba3"
      unitRef="U001">8089000</us-gaap:IncreaseDecreaseInOtherEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherEmployeeRelatedLiabilities
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_c2e1e6792bbf4d45bb9581a0838da942"
      unitRef="U001">4117000</us-gaap:IncreaseDecreaseInOtherEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherEmployeeRelatedLiabilities
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_1610f4d30b0d484693cb2ccb1dd531cd"
      unitRef="U001">965000</us-gaap:IncreaseDecreaseInOtherEmployeeRelatedLiabilities>
    <ions:IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_c2d76681eaf6401eb0820fac87914240"
      unitRef="U001">16499000</ions:IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities>
    <ions:IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_46fb0027cc774970b1e33fe73a8d0134"
      unitRef="U001">-17023000</ions:IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities>
    <ions:IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_fd2ee65b38e940ef8147608e66310a1d"
      unitRef="U001">28564000</ions:IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_6eed7a6f16674d629d60401fee845c19"
      unitRef="U001">-119283000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_860c87bb13ca432ab6413fcb41ab7d48"
      unitRef="U001">494254000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_9c03c531ef514d558aa7fca25bb6b718"
      unitRef="U001">30182000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_19c256c737ca49a4a82b43e1d4907fd7"
      unitRef="U001">345720000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_6ac8228472434c89928ff5906d8cdfa8"
      unitRef="U001">602888000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_39199cc3649f4be29630e4d9f60a5e3f"
      unitRef="U001">174149000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_e72b6b733f32469391537642ed9f915f"
      unitRef="U001">1946726000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_dade26c6f20f4b60a4feec4e181794e8"
      unitRef="U001">1794735000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_67fd6ba04f7343b8835d000a36955a72"
      unitRef="U001">877810000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_4c7538b4bbdc45c8b0632c5597958d34"
      unitRef="U001">1951734000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_38e7752c94b34c97a1435e616eb5db40"
      unitRef="U001">882824000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_80d5593638ef4ce1981649265ba744b9"
      unitRef="U001">557369000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_af7f2fbf99644b83883250b2765bc5ae"
      unitRef="U001">30905000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_28d3f3d53dd04a84a5b65fcacb820e59"
      unitRef="U001">13608000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_77a9b1f4ce9d4712ac162eef39cf7ca1"
      unitRef="U001">34764000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <ions:PaymentsToAcquireLicensesAndOtherAssets
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_c4ddbc47fdde42a994020ac78cea3e4d"
      unitRef="U001">5377000</ions:PaymentsToAcquireLicensesAndOtherAssets>
    <ions:PaymentsToAcquireLicensesAndOtherAssets
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_dff874e0a9d440f2b2291df63ce33c1c"
      unitRef="U001">4044000</ions:PaymentsToAcquireLicensesAndOtherAssets>
    <ions:PaymentsToAcquireLicensesAndOtherAssets
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_83d9fabba44a4c58856c75295f25be39"
      unitRef="U001">3093000</ions:PaymentsToAcquireLicensesAndOtherAssets>
    <ions:PaymentsToAcquireCostMethodInvestments
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_80fc4ad369ea4266aa819342e5a274f3"
      unitRef="U001">10000000</ions:PaymentsToAcquireCostMethodInvestments>
    <ions:PaymentsToAcquireCostMethodInvestments
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_2dd3f9b1b98e487c90386a8b5c2e7dbd"
      unitRef="U001">0</ions:PaymentsToAcquireCostMethodInvestments>
    <ions:PaymentsToAcquireCostMethodInvestments
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_62fe3844a7e8414ea863aff8f888c1ce"
      unitRef="U001">2500000</ions:PaymentsToAcquireCostMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_7edd2db69de6496994b65033d5aa0d88"
      unitRef="U001">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_e41dc87c481d4131aff70bf715ac57c7"
      unitRef="U001">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_27c69f80f41e411ba9543311f05e58f7"
      unitRef="U001">2507000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_f34b0cc23b5d447c95919927abae52a5"
      unitRef="U001">-41274000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_dc86ed420ba74326be5713c12aa09032"
      unitRef="U001">-929563000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_25c5a36f9c66441bbadcb049e1be0f09"
      unitRef="U001">-358291000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_9766979c83c547faaf9db39fd1ec8b13"
      unitRef="U001">119657000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_e8614ff277e9476fabd71fcec8d4876c"
      unitRef="U001">27900000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_847a8383a3104ae19857ffdfc7350136"
      unitRef="U001">22931000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_d0c63549a159422d8925dbeac4505a02"
      unitRef="U001">19242000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_4420366a0a5648d6bb96c8031145c0f8"
      unitRef="U001">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_0355270d749349ec8d585f6e041767cc"
      unitRef="U001">0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_d059c5d1572341c7b1665fabcbd30820"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_225e1862aa0445a6b71d0471dfa6b546"
      unitRef="U001">109500000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_b7eedb2ae11b4edb9d5e14441f8c7798"
      unitRef="U001">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_fc4f30f07d0c493098e146a7aead7848"
      unitRef="U001">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_70f588014d3e4b30baa726f0da2418a1"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_64ba705f156e4145a902a5899027210e"
      unitRef="U001">10428000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_f313f339843849879880343bb3a88792"
      unitRef="U001">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_9e7cba35e2b34b3294529c9f00b291fc"
      unitRef="U001">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_495d0e1c772f477aa4b69187144a2acc"
      unitRef="U001">56110000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_fd3083678ca946bc8c04d46f0ed04911"
      unitRef="U001">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_6a2730d1fb4e46bfbf665ffb2a8cec4f"
      unitRef="U001">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:PaymentsForHedgeFinancingActivities
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_93476033a0d54173bc9010c262c485d1"
      unitRef="U001">108684000</us-gaap:PaymentsForHedgeFinancingActivities>
    <us-gaap:PaymentsForHedgeFinancingActivities
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_f5757aa8a1b84931b13cb7b1821bd15a"
      unitRef="U001">0</us-gaap:PaymentsForHedgeFinancingActivities>
    <us-gaap:PaymentsForHedgeFinancingActivities
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_18ed7373cfed41688772a16bc1938cfc"
      unitRef="U001">0</us-gaap:PaymentsForHedgeFinancingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_4ea9107410344f6ea56e07ac99f40f7d"
      unitRef="U001">34392000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_a877c68b655745d9b6bc70655c9025d0"
      unitRef="U001">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_95cb066a3d5548738b8c9564f1c73b6c"
      unitRef="U001">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_557667a97fa84b1f8a6a354d828e462f"
      unitRef="U001">12500000</us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_06f41cbbdf604c0c83ffd872ca84b5a4"
      unitRef="U001">0</us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_15ae921ec787447894e64ba1af89992c"
      unitRef="U001">3599000</us-gaap:RepaymentsOfLongTermDebtAndCapitalSecurities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_33886d091bd74c3b81ba8a961010aafc"
      unitRef="U001">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_9e405ad35d8347d982a4eab76b7f513b"
      unitRef="U001">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_311cba869100479c9bc1af6662d37d2b"
      unitRef="U001">110438000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_40fecba1abf94eb3933e63602d8d200c"
      unitRef="U001">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_a737854ff328444db888566f0555afd4"
      unitRef="U001">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_64402f2028b048fc9a02f9274727ae4f"
      unitRef="U001">59750000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20190101to20191231_MajorCustomersAxis_BiogenIncMember"
      decimals="-3"
      id="Fact_31f2a6013f174a42875e8adb4bd9553d"
      unitRef="U001">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20180101to20181231_MajorCustomersAxis_BiogenIncMember"
      decimals="-3"
      id="Fact_a6d6cf7497d14ddabf086f00d2d6b9f7"
      unitRef="U001">447965000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20170101to20171231_MajorCustomersAxis_BiogenIncMember"
      decimals="-3"
      id="Fact_d21338aa254a4785a08c74f7957900df"
      unitRef="U001">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20190101to20191231_MajorCustomersAxis_NovartisInternationalAGMember"
      decimals="-3"
      id="Fact_b2a0da660cd14042b4297bcbdf082081"
      unitRef="U001">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20180101to20181231_MajorCustomersAxis_NovartisInternationalAGMember"
      decimals="-3"
      id="Fact_62098e4ea30d4e17870220459736b7ff"
      unitRef="U001">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20170101to20171231_MajorCustomersAxis_NovartisInternationalAGMember"
      decimals="-3"
      id="Fact_7356470850824c2ba37d8f507541acda"
      unitRef="U001">71737000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_2ce8896b663c496391a7345690647e9c"
      unitRef="U001">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_bb4d2886dfbe4912bae7a8e421b3bebe"
      unitRef="U001">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_8005a235884a48568575462880dd3388"
      unitRef="U001">50000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_b24671f684db4b548dd971d0d518995e"
      unitRef="U001">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_b29ef4a3029c4beab233a01aaa773f2f"
      unitRef="U001">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_8b71bc7ef66240c8bd938cb5a0e51095"
      unitRef="U001">2037000</us-gaap:PaymentsOfStockIssuanceCosts>
    <ions:PaymentToSettleFinancingLiabilityForLeasedFacility
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_5944b73e0a664cadad2799749f6cfce6"
      unitRef="U001">0</ions:PaymentToSettleFinancingLiabilityForLeasedFacility>
    <ions:PaymentToSettleFinancingLiabilityForLeasedFacility
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_d1f4073d220243ed9ca2c6c80e5df1da"
      unitRef="U001">0</ions:PaymentToSettleFinancingLiabilityForLeasedFacility>
    <ions:PaymentToSettleFinancingLiabilityForLeasedFacility
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_519835b941674b2f959525ccdeabc30f"
      unitRef="U001">80133000</ions:PaymentToSettleFinancingLiabilityForLeasedFacility>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_d0b81d4107734a99947e72b9ef08fd52"
      unitRef="U001">100021000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_695577047908479aa462291bcf511bc0"
      unitRef="U001">475865000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_51741218780e4456a9f34ed2578e6cb5"
      unitRef="U001">229087000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_424bfa231a4440118755b82c9de508d0"
      unitRef="U001">404467000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_95d8220f6f2d45ba950a407056745ec4"
      unitRef="U001">149190000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_9335e820abb445728b10d591aaa919e2"
      unitRef="U001">44945000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20181231"
      decimals="-3"
      id="Fact_2fe11c4a0552452c9ee5a7c3aac47705"
      unitRef="U001">278820000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20171231"
      decimals="-3"
      id="Fact_38e0d74e03924dde80c877dfd5b295d0"
      unitRef="U001">129630000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20161231"
      decimals="-3"
      id="Fact_f274cb6e3cd045b38892b34d9be46c38"
      unitRef="U001">84685000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20191231"
      decimals="-3"
      id="Fact_802558b256f940a8a9f59915d51c438b"
      unitRef="U001">683287000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20181231"
      decimals="-3"
      id="Fact_463b7126048f497ca4901d977f5c2ac9"
      unitRef="U001">278820000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20171231"
      decimals="-3"
      id="Fact_b29066047a884910867fa584b8145295"
      unitRef="U001">129630000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_b47f47ad7adc4ae2a63c5b2b958e5986"
      unitRef="U001">9870000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_365634aaa3f54c4e87b568166b422025"
      unitRef="U001">9592000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_777216b0c9fd41a0868d458c42358f8f"
      unitRef="U001">8035000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_ecaed007242544d4875e2a8394cda8a9"
      unitRef="U001">9041000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_8ba0df8b170c45d9b7cc4f3eb3758c73"
      unitRef="U001">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_4fcf50f2783540e1ab2ce456a89dac23"
      unitRef="U001">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_9fb6e06d97424d029e274cd992868d40"
      unitRef="U001">14178000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_f9435009c20c4e1286dedbf877ee8a0d"
      unitRef="U001">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_7ee9fe8123e4431f9d154d9f5bfe7e4b"
      unitRef="U001">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <ions:NonCashCapitalAndPatentExpenditures
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_2e1171bfaa9c4beb805687ac979a648e"
      unitRef="U001">3126000</ions:NonCashCapitalAndPatentExpenditures>
    <ions:NonCashCapitalAndPatentExpenditures
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_b651f1c7ed9545389caa3fee850fcf78"
      unitRef="U001">4428000</ions:NonCashCapitalAndPatentExpenditures>
    <ions:NonCashCapitalAndPatentExpenditures
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_13b925f99e774581bb9380f16b558158"
      unitRef="U001">1983000</ions:NonCashCapitalAndPatentExpenditures>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_c9258d5b61324343bc87d4c7de8a4f80"
      unitRef="U001">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_36807bb56a004428912cae04b722058b"
      unitRef="U001">3350000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_16d4c75aad684ff0b03a47e44f07a03d"
      unitRef="U001">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_85b2c604ea1643578611fc5d1efde99f"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesIssued1
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_2631a61142764254850409ae81f33c49"
      unitRef="U001">439326000</us-gaap:NotesIssued1>
    <us-gaap:NotesIssued1
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_a433da4a48564dd69284d9856e9c3deb"
      unitRef="U001">0</us-gaap:NotesIssued1>
    <us-gaap:NotesIssued1
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_fbe82c691e6c437781dfb207e079037c"
      unitRef="U001">0</us-gaap:NotesIssued1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_0fb7afd855e24e069c48f8df5ed96d3d"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesReduction
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_cee29604c1c5449fbe8073a349e9224b"
      unitRef="U001">375590000</us-gaap:NotesReduction>
    <us-gaap:NotesReduction
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_8210f62b70dc4bd3a67ec6dd974850eb"
      unitRef="U001">0</us-gaap:NotesReduction>
    <us-gaap:NotesReduction
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_9a4cd310e1fd4b579017d09f17982879"
      unitRef="U001">0</us-gaap:NotesReduction>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="c20190101to20191231"
      id="Text_86f14b4beea94d60902ec7fb792ab655">
&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;1. Organization and Significant Accounting Policies&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Basis of Presentation&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;In our consolidated financial statements we included the accounts of Ionis Pharmaceuticals, Inc. (&#x201c;we&#x201d;, &#x201c;us&#x201d; or &#x201c;our&#x201d;) and the consolidated results of our majority-owned affiliate, Akcea Therapeutics, Inc., which we formed in December 2014. In July 2017, Akcea completed an initial public offering, or IPO. Since Akcea&#x2019;s IPO, our ownership has ranged from &lt;/span&gt;68 percent&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; to &lt;/span&gt;77 percent&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;. At December 31, 2019, o&lt;/span&gt;ur ownership was approximately 76 percent. We reflect changes in our ownership of Akcea in our financial statements in the period the change occurs. For example, we reflected an increase in our ownership when we received 6.9 million shares of Akcea common stock as payment for the sublicense fee Akcea owed us for Pfizer&#x2019;s license of AKCEA-ANGPTL3-L&lt;sub&gt;Rx&lt;/sub&gt; in the fourth quarter of 2019. &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Refer to the section titled &#x201c;Noncontrolling Interest in Akcea&#x201d; in Note 2, &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Significant Accounting Policies,&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; for further information related to our accounting for our investment in Akcea.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Organization and Business Activity&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We incorporated in California on January 10, 1989. In conjunction with our IPO, we reorganized as a Delaware corporation in April 1991. We were organized principally to develop human therapeutic medicines using antisense technology. In December 2015, we changed our name from Isis Pharmaceuticals, Inc. to Ionis Pharmaceuticals, Inc.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Basic and Diluted Net Income per Share&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Basic net income per share&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We compute basic net income per share by dividing the total net income attributable to our common stockholders by our weighted-average number of common shares outstanding during the period.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The calculation of total net income attributable to our common stockholders for each year considered our net income for Ionis on a stand-alone basis plus our share of Akcea&#x2019;s net income (loss) for the period. To calculate the portion of Akcea&#x2019;s net income (loss) attributable to our ownership for each year, we multiplied Akcea&#x2019;s income (loss) per share by the weighted average shares we owned in Akcea during the period. As a result of this calculation, our total net income available to Ionis common stockholders for the calculation of net income per share is different than net income attributable to Ionis Pharmaceuticals, Inc. common stockholders in our consolidated statements of operations for each year.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our basic net income per share, was calculated as follows (in thousands, except per share amounts):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z104b454b266445eaac9eed834835145f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Portion of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;70,100&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.49&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;34,073&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net income attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;34,073&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;262,490&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;296,563&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;139,998&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net income per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.12&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zfe21e6fd0158439f854dad365e54a58d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Loss&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Portion of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;59,812&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2.74&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(163,938&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net loss attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(163,938&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;440,806&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;276,868&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;132,320&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net income per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.09&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We calculated our basic net income per share for 2017 as follows (in thousands, except per share amounts):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z7f02aeb560ee40bd982c44713ab0a2ac" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Loss&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Portion of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;20,669&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(3.08&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(63,638&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Preferred shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;15,748&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1.80&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(28,346&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net loss attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(91,984&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;110,776&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18,792&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;124,016&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net income per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.15&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Prior to Akcea&#x2019;s IPO in July 2017, we owned Akcea series A convertible preferred stock, which included a &lt;span style="-sec-ix-hidden:Fact_814732dbfffb4dbbb487265b1d09e7b7"&gt;six percent&lt;/span&gt; cumulative dividend. Upon completion of Akcea&#x2019;s IPO in July 2017, our preferred stock was converted into common stock on a 1:1 basis. The preferred stock dividend was not paid at the IPO because the IPO was not a liquidation event or a change in control. During 2017, Akcea used a two-class method to compute its net loss per share because it had both common and preferred shares outstanding during the periods. The two-class method required Akcea to calculate its net loss per share for each class of stock by dividing total distributable losses applicable to preferred and common stock, including the six percent cumulative dividend contractually due to series A convertible preferred shareholders, by the weighted-average of preferred and common shares outstanding during the requisite period. Since Akcea used the two-class method, accounting rules required us to include our portion of Akcea&#x2019;s net loss per share for both Akcea&#x2019;s common and preferred shares that we owned in our calculation of basic and diluted net income per share for the year ended December 31, 2017.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Diluted net income per share&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We calculated our diluted net income per share as follows &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;(in thousands except per share amounts):&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zb0e4b49c2e274df0b9950bc8e8004fbd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Numerator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Denominator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per-Share&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;296,563&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;139,998&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.12&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effect of dilutive securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -8.9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon exercise of stock options&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,090&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: 0.1pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon restricted stock award issuance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;766&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our Employee Stock Purchase Plan&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income available to Ionis common stockholders, plus assumed conversions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;296,563&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;142,872&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.08&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z01b775cd675848508a1d52bc1c4cff37" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Numerator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Denominator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per-Share&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;276,868&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;132,320&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.09&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effect of dilutive securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -8.9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon exercise of stock options&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,216&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: 0.1pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon restricted stock award issuance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;514&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our Employee Stock Purchase Plan&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income available to Ionis common stockholders, plus assumed conversions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;276,868&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;134,056&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.07&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zd8deeaecb9c64cd89c8fc8806b7a193d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Numerator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Denominator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per-Share&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18,792&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;124,016&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.15&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effect of dilutive securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -8.9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon exercise of stock options&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,619&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: 0.1pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon restricted stock award issuance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;459&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our Employee Stock Purchase Plan&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income available to Ionis common stockholders, plus assumed conversions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18,792&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;126,098&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.15&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;For each year presented, the calculation excluded our convertible senior notes because the effect on diluted earnings per share was anti-dilutive.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Revenue Recognition&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;span style="text-decoration: underline;"&gt;Our Revenue Sources&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We generally recognize revenue when we have satisfied all contractual obligations and are reasonably assured of collecting the resulting receivable. We are often entitled to bill our customers and receive payment from our customers in advance of recognizing the revenue. In the instances in which we have received payment from our customers in advance of recognizing revenue, we include the amounts in deferred revenue on our consolidated balance sheet.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Commercial Revenue: SPINRAZA royalties and Licensing and other royalty revenue&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We earn commercial revenue primarily in the form of royalty payments on net sales of SPINRAZA. We will also recognize as commercial revenue future sales milestone payments and royalties we earn under our partnerships.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Commercial Revenue: Product sales, net&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We added product sales from TEGSEDI to our commercial revenue in the fourth quarter of 2018 and we added product sales from WAYLIVRA to our commercial revenue in the third quarter of 2019. &lt;/span&gt;In the U.S., we distribute TEGSEDI through an exclusive distribution agreement with a third-party logistics company, or 3PL, that takes title to TEGSEDI. The 3PL is our sole customer in the U.S. The 3PL then distributes TEGSEDI to a specialty pharmacy and a specialty distributor, which we collectively refer to as wholesalers, who then distribute TEGSEDI to health care providers and patients. In Europe, prior to the third quarter of 2019 we distributed TEGSEDI through a non-exclusive distribution model with a 3PL that took title to TEGSEDI. The 3PL was our sole customer in Europe. The 3PL in Europe then distributed TEGSEDI to hospitals and pharmacies. In the third quarter of 2019, we entered into a distribution arrangement with a 3PL and began to sell both TEGSEDI and WAYLIVRA directly to hospitals and pharmacies in Europe.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Research and development revenue under collaborative agreements&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We often enter into collaboration agreements to license and sell our technology on an exclusive or non-exclusive basis. Our collaboration agreements typically contain multiple elements, or performance obligations, including technology licenses or options to obtain technology licenses, research and development, or R&amp;amp;D, services, and manufacturing services.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Our collaboration agreements are detailed in Note 6, &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Collaborative Arrangements and Licensing Agreements.&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Under each collaboration note we discuss our specific revenue recognition conclusions, including our significant performance obligations under each collaboration.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;span style="text-decoration: underline;"&gt;Steps to Recognize Revenue&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We use a five-step process to determine the amount of revenue we should recognize and when we should recognize it. The five step process is as follows:&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zb9f70b6bc634422f82831b9476ae8444" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;1.&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Identify the contract&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Accounting rules require us to first determine if we have a contract with our partner, including confirming that we have met each of the following criteria:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z32abea7f3b454dedb5d275fcd69bfc41" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We and our partner approved the contract and we are both committed to perform our obligations;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z2fef2cbf4007441595d4245add81d46d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We have identified our rights, our partner&#x2019;s rights and the payment terms;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze8401d5278b84ee1953ba4283b1f9851" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We have concluded that the contract has commercial substance, meaning that the risk, timing, or amount of our future cash flows is expected to change as a result of the contract; and&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z7c8deb873be94db28e11c93fd5b094f0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We believe collectability is probable. &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: -18pt; margin-left: 54pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zac78659984944d66a7d6f7f05a5a6181" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;&lt;span style="background-color: #FFFFFF;"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;&lt;span style="background-color: #FFFFFF; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Identify the performance obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We next identify the distinct goods and services we are required to provide under the contract. Accounting rules refer to these as our performance obligations. We typically have only one performance obligation at the inception of a contract, which is to perform R&amp;amp;D services.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Often times we enter into a collaboration agreement in which we provide our partner with an option to license a medicine in the future. We may also provide our partner with an option to request that we provide additional goods or services in the future, such as active pharmaceutical ingredient, or API. We evaluate whether these options are material rights at the inception of the agreement. If we determine an option is a material right, we will consider the option a separate performance obligation. Historically, we have concluded that the options we grant to license a medicine in the future or to provide additional goods and services as requested by our partner are not material rights. These items are contingent upon future events that may not occur. When a partner exercises its option to license a medicine or requests additional goods or services, then we identify a new performance obligation for that item.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In some cases, we deliver a license at the start of an agreement. If we determine that our partner has full use of the license and we do not have any additional material performance obligations related to the license after delivery, then we consider the license to be a separate performance obligation.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zf1f446d282dd4e1b832e3c09c5f82c88" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;3.&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Determine the transaction price&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We then determine the transaction price by reviewing the amount of consideration we are eligible to earn under the collaboration agreement, including any variable consideration. Under our collaboration agreements, consideration typically includes fixed consideration in the form of an upfront payment and variable consideration in the form of potential milestone payments, license fees and royalties. At the start of an agreement, our transaction price usually consists of only the upfront payment. We do not typically include any payments we may receive in the future in our initial transaction price because the payments are not probable and are contingent on certain future events. We reassess the total transaction price at each reporting period to determine if we should include additional payments in the transaction price.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Milestone payments are our most common type of variable consideration. We recognize milestone payments using the most likely amount method because we will either receive the milestone payment or we will not, which makes the potential milestone payment a binary event. The most likely amount method requires us to determine the likelihood of earning the milestone payment. We include a milestone payment in the transaction price once it is probable we will achieve the milestone event. Most often, we do not consider our milestone payments probable until we or our partner achieve the milestone event because the majority of our milestone payments are contingent upon events that are not within our control and are usually based on scientific progress. For example, in the fourth quarter of 2019, we earned a $10 million milestone payment from AstraZeneca when AstraZeneca initiated a Phase 1 trial for ION839. We did not consider the milestone payments probable until AstraZeneca achieved the milestone event because the initiation of the Phase 1 trial was a contingent event that was not within our control. We recognized the milestone payments in full in the period the milestone event was achieved because we did not have any remaining performance obligations related to the milestone payment.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z61f3f8aec88b4866a2bbc6540840c7b9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;4.&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Allocate the transaction price&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Next, we allocate the transaction price to each of our performance obligations. When we have to allocate the transaction price to more than one performance obligation, we make estimates of the relative stand-alone selling price of each performance obligation because we do not typically sell our goods or services on a stand-alone basis. We then allocate the transaction price to each performance obligation based on the relative stand-alone selling price.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We may engage a third party, independent valuation specialist to assist us with determining a stand-alone selling price for collaborations in which we deliver a license at the start of an agreement. We estimate the stand-alone selling price of these licenses using valuation methodologies, such as the relief from royalty method. Under this method, we estimate the amount of income, net of taxes, for the license. We then discount the projected income to present value. The significant inputs we use to determine the projected income of a license could include:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zd0332dc311ad49d5aebb0b0dcec49da1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Estimated future product sales;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zbafbea8c82a44de19538caf8c4d34c17" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Estimated royalties on future product sales;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zc5914eb350eb4288913df6b658f90445" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Contractual milestone payments;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z23f53850cb2e499c87cc78fc51b878db" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Expenses we expect to incur;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zba5b48ea375f49caad917f1f137ff6cf" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income taxes; and&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zc80b99fe0b894aecb56282f28ddea0a9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;A discount rate.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We typically estimate the selling price of R&amp;amp;D services by using our internal estimates of the cost to perform the specific services. The significant inputs we use to determine the selling price of our R&amp;amp;D services include:&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z2a27bbd1916f4ee3b3441ed762a2c2b3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The number of internal hours we estimate we will spend performing these services;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z3d50f6d0709c44f89b5262ca45319fbe" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The estimated cost of work we will perform;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zf1df7de1efb647f3a758705c8216c76d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The estimated cost of work that we will contract with third parties to perform; and&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zcc18420c84464778ad67ecdb5155e530" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The estimated cost of API we will use. &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 54pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;For purposes of determining the stand-alone selling price of the R&amp;amp;D services we perform and the API we will deliver, accounting guidance requires us to include a markup for a reasonable profit margin.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We do not reallocate the transaction price after the start of an agreement to reflect subsequent changes in stand-alone selling prices.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zaa2a29a440094a6385db6db34fe05178" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;5.&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Recognize revenue&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -54pt; margin-left: 54pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We recognize revenue in one of two ways, over time or at a point in time. We recognize revenue over time when we are executing on our performance obligation over time and our partner receives benefit over time. For example, we recognize revenue over time when we provide R&amp;amp;D services. We recognize revenue at a point in time when our partner receives full use of an item at a specific point in time. For example, we recognize revenue at a point in time when we deliver a license or API to a partner.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;For R&amp;amp;D services that we recognize over time, we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time we estimate it will take us to complete the activities, or costs we incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates and use significant judgement. If our estimates or judgements &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods. For example, &lt;/span&gt;in the third quarter of 2019, we updated our estimate of the total effort we expected to expend to satisfy our performance obligation under our&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; 2013 Strategic Neurology collaboration with Biogen&lt;/span&gt;. As of September 30, 2019, we had completed a&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; significant portion of the research and development services. We expect to complete the remainder of our services in 2020. As a result of our change in estimate, in the third quarter of 2019, we recorded a cumulative catch up adjustment of $&lt;/span&gt;16.5&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million to decrease revenue. Refer to Note 7, &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Collaborative Arrangements and Licensing Agreements&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;, for further discussion of the cumulative catch up adjustment we made.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following are examples of when we typically recognize revenue based on the types of payments we receive.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;span style="text-decoration: underline;"&gt;Commercial Revenue: SPINRAZA royalties and Licensing and other royalty revenue&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We recognize royalty revenue, including royalties from SPINRAZA sales, in the period in which the counterparty sells the related product and recognizes the related revenue, which in certain cases may require us to estimate our royalty revenue.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;span style="text-decoration: underline;"&gt;Commercial Revenue: Product sales, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We recognize product sales in the period &lt;/span&gt;when our customer obtains control of our products, which occurs at a point in time upon transfer of title to the customer. We classify payments to customers or other parties in the distribution channel for services that are distinct and priced at fair value as selling, general and administrative expenses in our consolidated statements of operations. Otherwise, payments to customers or other parties in the distribution channel that do not meet those criteria are classified as a reduction of revenue, as discussed further below. We exclude from revenues taxes collected from customers relating to product sales and remitted to governmental authorities.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Reserves for Product sales&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We record product sales at our net sales price, or transaction price. We include in our transaction price estimated reserves for discounts, returns, chargebacks, rebates, co-pay assistance and other allowances that we offer within contracts between us and our customers, wholesalers, health care providers and other indirect customers. We estimate our reserves using the amounts we have earned or what we can claim on the associated sales. We classify our reserves as a reduction of accounts receivable when we are not required to make a payment or as a current liability when we are required to make a payment. In certain cases, our estimates include a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, our reserves reflect our best estimates under the terms of our respective contracts. When calculating our reserves and related product sales, we only recognize amounts to the extent that we consider it probable that we would not have to reverse in a future period a significant amount of the cumulative sales we previously recognized. The actual amounts we receive may ultimately differ from our reserve estimates. If actual amounts in the future vary from our estimates, we will adjust these estimates, which would affect our net product sales in the respective period.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following are the components of variable consideration related to product sales:&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Chargebacks: &lt;/span&gt;In the U.S., we estimate obligations resulting from contractual commitments with the government and other entities to sell products to qualified healthcare providers at prices lower than the list prices charged to our U.S. customer. Our U.S. customer charges us for the difference between what it pays for the product and the selling price to the qualified healthcare providers. We also estimate the amount of chargebacks related to our estimated product remaining in the distribution channel at the end of the reporting period that we expect our customer to sell to healthcare providers in future periods. We record these reserves as an accrued liability on our consolidated balance sheet for the chargebacks related to product sales to our U.S. customer during the reporting period.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Government rebates&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;: We are subject t&lt;/span&gt;o discount obligations under government programs, including Medicaid and Medicare programs in the U.S. and we record reserves for government rebates based on statutory discount rates and estimated utilization. We estimate Medicaid and Medicare rebates based on a range of possible outcomes that are probability-weighted for the estimated payer mix. We record these reserves as an accrued liability on our consolidated balance sheet with a corresponding offset reducing our product sales in the same period we recognize the related sale. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program. On a quarterly basis, we update our estimates and record any adjustments in the period that we identify the adjustments.&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Managed care rebates: &lt;/span&gt;We are subject to rebates in connection with a value-based agreement with one of our commercial payer&#x2019;s. We record these rebates as an accrual on our consolidated balance sheet in the same period we recognize the related revenue. We estimate our managed care rebates based on our estimated payer mix and the applicable contractual rebate rate.&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Trade discounts: &lt;/span&gt;We provide customary invoice discounts on product sales to our U.S. customer for prompt payment. We record this discount as a reduction of product sales in the period in which we recognize the related product revenue.&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Distribution services&lt;/span&gt;: We receive and pay for various distribution services from our U.S. and EU customers and wholesalers in the U.S.. We classify the costs for services we receive that are either not distinct from the sale of the product or for which we cannot reasonably estimate the fair value as a reduction of product sales. To the extent that the services we receive are distinct from the sale of the product, we classify the costs for such services as selling, general and administration, or SG&amp;amp;A, expenses.&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Product returns: &lt;/span&gt;Our U.S. customer has return rights and the wholesalers have limited return rights primarily related to the product&#x2019;s expiration date. We estimate the amount of product sales that our customer may return. We record our return estimate as an accrued refund liability on our consolidated balance sheet with a corresponding offset reducing our product sales in the same period we recognize the related sale. Based on our distribution model for product sales, contractual inventory limits with our customer and wholesalers and the price of the product, we have had minimal returns to date and we believe we will continue to have minimal returns. Our EU customers only take title to the product after they receive an order from a hospital or pharmacy and therefore they do not maintain excess inventory levels of our products. Accordingly, we have limited return risk in the EU and we do not estimate returns in the EU.&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Other incentives: &lt;/span&gt;In the U.S., we estimate reserves for other incentives including co-payment assistance we provide to patients with commercial insurance who have coverage and reside in states that allow co-payment assistance. We record a reserve for the amount we estimate we will pay for co-payment assistance. We base our reserve on the number of estimated claims and our estimate of the cost per claim related to product sales that we have recognized as revenue. We record our other incentive reserve estimates as an accrued liability on our consolidated balance sheet with a corresponding offset reducing our product sales in the same period we recognize the related sale.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;span style="text-decoration: underline;"&gt;Research and development revenue under collaboration agreements:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;span style="text-decoration: underline;"&gt;Upfront payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;When we enter into a collaboration agreement with an upfront payment, we typically record the entire upfront payment as deferred revenue if our only performance obligation is for R&amp;amp;D services we will provide in the future. We amortize the upfront payment into revenue as we perform the R&amp;amp;D services. For example, under our &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;collaboration agreement with Roche to&lt;/span&gt;&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; develop IONIS-FB-L&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; for the treatment of complement-mediated diseases&lt;/span&gt;, we received a $75 million upfront payment in the fourth quarter of 2018. We allocated the upfront payment to our single performance obligation, R&amp;amp;D services. We are amortizing the $75 million upfront payment using an input method over the estimated period of time we are providing R&amp;amp;D services.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;span style="text-decoration: underline;"&gt;Milestone payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We are required to include additional consideration in the transaction price when it is probable. We typically include milestone payments for R&amp;amp;D services in the transaction price when they are achieved. We include these milestone payments when they are achieved because there is considerable uncertainty in the research and development processes that trigger these payments. Similarly, we include approval milestone payments in the transaction price once the medicine is approved by the applicable regulatory agency. We will recognize sales-based milestone payments in the period in which we achieve the milestone under the sales-based royalty exception allowed under accounting rules.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We recognize milestone payments that relate to an ongoing performance obligation over our period of performance. For example, in the fourth quarter of 2019, we achieved two $7.5 million milestone payments from Biogen when we advanced two new targets for undisclosed neurological diseases under our 2018 strategic neurology collaboration. We added these payments to the transaction price and allocated it to our R&amp;amp;D services performance obligation. We are recognizing revenue related to these milestone payments over our estimated period of performance.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Conversely, we recognize in full those milestone payments that we earn based on our partners&#x2019; activities when our partner achieves the milestone event and we do not have a performance obligation. For example, in the fourth quarter of 2019, we recognized a $10 million milestone payment &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;when Biogen advanced the development candidate for an undisclosed target under our 2012 neurology collaboration agreement&lt;/span&gt;. &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We concluded that the milestone payment was not related to our R&amp;amp;D services performance obligation. Therefore, we recognized the milestone payment in full in the fourth quarter of 2019.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;span style="text-decoration: underline;"&gt;License fees&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We generally recognize as revenue the total amount we determine to be the relative stand-alone selling price of a license when we deliver the license to our partner. This is because our partner has full use of the license and we do not have any additional performance obligations related to the license after delivery. &lt;/span&gt;For example, in the fourth quarter of 2019, we earned a $45 million license fee when Biogen licensed IONIS-MAPT&lt;sub&gt;Rx&lt;/sub&gt; from us. We also recognized $246 million of license fee revenue related to Akcea&#x2019;s license of AKCEA-ANGPTL3-L&lt;sub&gt;Rx&lt;/sub&gt; to Pfizer in the fourth quarter of 2019.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;span style="text-decoration: underline;"&gt;Sublicense fees&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We recognize sublicense fee revenue in the period in which a party, who has already licensed our technology, further licenses the technology to another party because we do not have any performance obligations related to the sublicense. &lt;/span&gt;For example, in the second quarter of 2019, we earned a $20 million sublicense fee when Alnylam Pharmaceuticals sublicensed our technology to Regeneron Pharmaceuticals.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Amendments to Agreements&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;From time to time we amend our collaboration agreements. When this occurs, we are required to assess the following items to determine the accounting for the amendment:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z4d3009374a5e478e8122026b5e139b45" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;If the additional goods and/or services are distinct from the other performance obligations in the original agreement; and&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zf0f366c375b94c81a0b52ddbbfa1f51e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;If the goods and/or services are at a stand-alone selling price. &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;If we conclude the goods and/or services in the amendment are distinct from the performance obligations in the original agreement and at a stand-alone selling price, we account for the amendment as a separate agreement. If we conclude the goods and/or services are not distinct and at their stand-alone selling price, we then assess whether the remaining goods or services are distinct from those already provided. If the goods and/or services are distinct from what we have already provided, then we allocate the remaining transaction price from the original agreement and the additional transaction price from the amendment to the remaining goods and/or services. If the goods and/or services are not distinct from what we have already provided, we update the transaction price for our single performance obligation and recognize any change in our estimated revenue as a cumulative adjustment.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;For example, in May 2015, we entered into an exclusive license agreement with Bayer to develop and commercialize IONIS-FXI&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; for the prevention of thrombosis. As part of the agreement, Bayer paid us a $&lt;/span&gt;100&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million upfront payment. At the onset of the agreement, we were responsible for completing a Phase 2 study of IONIS-FXI&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; in people with end-stage renal disease on hemodialysis and for providing an initial supply of API. In February 2017, we amended our agreement with Bayer to advance IONIS-FXI&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; and to initiate development of IONIS-FXI-L&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;, which Bayer licensed. As part of the 2017 amendment, Bayer paid us $&lt;/span&gt;75&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million. We are also eligible to receive milestone payments and tiered royalties on gross margins of IONIS-FXI&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; and IONIS-FXI-L&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;. Under the 2017 amendment, we concluded we had a new agreement with &lt;/span&gt;three&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; performance obligations. These performance obligations were to deliver the license of IONIS-FXI-L&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;, to provide R&amp;amp;D services and to deliver API. We allocated the $&lt;/span&gt;75&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million transaction price to these performance obligations. &lt;/span&gt;Refer to &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Note 7, &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Collaborative Arrangements and Licensing Agreements&lt;/span&gt;, for further discussion &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;of our accounting treatment for our Bayer collaboration.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Multiple agreements&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;From time to time, we may enter into separate agreements at or near the same time with the same partner. We evaluate such agreements to determine whether we should account for them individually as distinct arrangements or whether the separate agreements should be combined and accounted for together. We evaluate the following to determine the accounting for the agreements:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z5a22915e59694cedaf8815e2feb45467" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Whether the agreements were negotiated together with a single objective;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z4c6b305fcd854a51950b2b0c8b9ff86f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Whether the amount of consideration in one contract depends on the price or performance of the other agreement; or&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z82b56ef158ea487c94fc2daddd0e9546" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Whether the goods and/or services promised under the agreements are a single performance obligation. &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our evaluation involves significant judgment to determine whether a group of agreements might be so closely related that accounting guidance requires us to account for them as a combined arrangement.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;For example, in the second quarter of 2018, we entered into two separate agreements with Biogen at the same time: a new strategic neurology collaboration agreement and a stock purchase agreement, or SPA. &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We evaluated the Biogen agreements to determine whether we should treat the agreements separately or combine them. We considered that the agreements were negotiated concurrently and in contemplation of one another. Based on these facts and circumstances, we concluded that we should evaluate the provisions of the agreements on a combined basis.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: -54pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Contracts Receivable&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: -18pt; margin-left: 54pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Our contracts receivable balance represents the amounts we have billed our partners or customers and that are due to us unconditionally for goods we have delivered or services we have performed. When we bill our partners or customers with payment terms based on the passage of time, we consider the contract receivable to be unconditional. We typically receive payment within one &lt;/span&gt;&lt;span style="-sec-ix-hidden:Fact_5acf7b3d4ee04d009d32a31d9e4ded77"&gt;quarter&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; of billing our partner or customer&lt;/span&gt;.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -54pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Unbilled SPINRAZA Royalties&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 54pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our unbilled SPINRAZA royalties represent our right to receive consideration from Biogen in advance of when we are eligible to bill Biogen for SPINRAZA royalties. We include these unbilled amounts in other current assets on our consolidated balance sheet.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: -54pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Deferred Revenue&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We are often entitled to bill our customers and receive payment from our customers in advance of our obligation to provide services or transfer goods to our partners. In these instances, we include the amounts in deferred revenue on our consolidated balance sheet.&lt;/span&gt; During the years ended December 31, 2019 and 2018, we recognized $159.5 million and $105.3 million of revenue from amounts that were in our beginning deferred revenue balance for each respective period. For further discussion, refer to our revenue recognition policy above.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Cost of Products Sold&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our cost of products sold includes manufacturing costs, transportation and freight costs and indirect overhead costs associated with the manufacturing and distribution of our products. We also may include certain period costs related to manufacturing services and inventory adjustments in cost of products sold. Prior to obtaining regulatory approval of TEGSEDI in July 2018 and WAYLIVRA in May 2019, we expensed as research and development expenses a significant portion of the costs we incurred to produce the initial commercial launch supply for each medicine. &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We previously expensed $&lt;/span&gt;0.7&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million and $&lt;/span&gt;0.1&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million of costs to produce our products related to the product sales revenue we recognized in 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Research, Development and Patent Expenses&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our research and development expenses include wages, benefits, facilities, supplies, external services, clinical trial and manufacturing costs and other expenses that are directly related to our research and development operations. We expense research and development costs as we incur them. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. For the years ended December 31, 2019, 2018 and 2017, research and development expenses were $461.5 million, $411.9 million and $372.5 million, respectively. A portion of the costs included in research and development expenses are costs associated with our partner agreements. For the years ended December 31, 2019, 2018 and 2017, research and development costs of approximately $83.2 million, $58.7 million and $59.5 million, respectively, were related to our partner agreements.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We capitalize costs consisting principally of outside legal costs and filing fees related to obtaining patents. We amortize patent costs over the useful life of the patent, beginning with the date the U.S. Patent and Trademark Office, or foreign equivalent, issues the patent. The weighted average remaining amortizable life of our issued patents was 10.3 years at December 31, 2019.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The cost of our patents capitalized on our consolidated balance sheet at December 31, 2019 and 2018 was $34.0 million and $32.7 million, respectively. Accumulated amortization related to patents was $8.3 million and $8.7 million at December 31, 2019 and 2018, respectively.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Based on our existing patents, we estimate amortization expense related to patents in each of the next five years to be the following:&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z3b4746089ec94fcf825148a7e478c941" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ending December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amortization&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in millions)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2020&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2021&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2022&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2023&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2024&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We review our capitalized patent costs regularly to ensure that they include costs for patents and patent applications that have future value. When we identify patents and patent applications that we are not actively pursuing, we write off any associated costs. In 2019, 2018 and 2017, patent expenses were $4.2 million, $2.6 million and $2.1 million, respectively, and included non-cash charges related to the write-down of our patent costs to their estimated net realizable values of $2.2 million, $0.8 million and $0.4 million, respectively.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Accrued Liabilities&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our accrued liabilities consisted of the following (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z3a44c21e41964165973dff87ef753698" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Clinical expenses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;24,461&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;22,125&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -18pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In-licensing expenses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10,289&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;12,298&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -18pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Other miscellaneous expenses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;32,019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;13,080&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total accrued liabilities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;66,769&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;47,503&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Noncontrolling Interest in Akcea Therapeutics, Inc.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Prior to Akcea&#x2019;s IPO in July 2017, we owned 100 percent of Akcea. &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Since Akcea&#x2019;s IPO, our ownership has ranged from &lt;/span&gt;68 percent&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; to &lt;/span&gt;77 percent&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;. At December 31, &lt;/span&gt;2019&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;, o&lt;/span&gt;ur ownership was approximately 76 percent. We reflect changes in our ownership percentage in our financial statements as an adjustment to noncontrolling interest in the period the change occurs. During 2019, we received the following additional shares of Akcea common stock:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 54pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zb8e73bce7e5949779fde18c99941a249" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.8 million shares in the first quarter of 2019 as payment for the sublicense fee Akcea owed us for Novartis&#x2019;s license of AKCEA-APO(a)-L&lt;sub&gt;Rx&lt;/sub&gt;, and;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zb8be43d6e4c14352bda3fb7b936ad303" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.9 million shares in the fourth quarter of 2019 as payment for the sublicense fee Akcea owed us for Pfizer&#x2019;s license of AKCEA-ANGPTL3-L&lt;sub&gt;Rx&lt;/sub&gt;.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The shares third parties own represent an interest in Akcea&#x2019;s equity that we do control. However, as we continue to maintain overall control of Akcea through our voting interest, we reflect the assets, liabilities and results of operations of Akcea in our consolidated financial statements. We reflect the noncontrolling interest attributable to other owners of Akcea&#x2019;s common stock in a separate line on the statement of operations and a separate line within stockholders&#x2019; equity in our consolidated balance sheet. In addition, we record a noncontrolling interest adjustment to account for the stock options Akcea grants, which if exercised, will dilute our ownership in Akcea. This adjustment is a reclassification within stockholders&#x2019; equity from additional paid-in capital to noncontrolling interest in Akcea equal to the amount of stock-based compensation expense Akcea had recognized.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Concentration of Credit Risk&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, short-term investments and receivables. We place our cash equivalents and short-term investments with reputable financial institutions. We primarily invest our excess cash in commercial paper and debt instruments of the U.S. Treasury, financial institutions, corporations, and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1, P-1 or F-1 by Moody&#x2019;s, Standard &amp;amp; Poor&#x2019;s, or S&amp;amp;P, or Fitch, respectively. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Cash, Cash Equivalents and Investments&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We consider all liquid investments with maturities of three months or less when we purchase them to be cash equivalents. Our short-term investments have initial maturities of greater than three months from date of purchase. We classify our short-term debt investments as &#x201c;available-for-sale&#x201d; and carry them at fair market value based upon prices on the last day of the fiscal period for identical or similar items. We record unrealized gains and losses on debt securities as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments. We use the specific identification method to determine the cost of securities sold.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We also have equity investments of less than 20 percent ownership in publicly and privately held biotechnology companies that we received as part of a technology license or partner agreement. At December 31, 2019, we held equity investments in two publicly held companies, ProQR Therapeutics N.V., or ProQR, and Antisense Therapeutics Limited, or ATL. We also held equity investments in five privately-held companies, Atlantic Pharmaceuticals Limited, Dynacure SAS, Empirico, Inc., Seventh Sense Biosystems and Suzhou Ribo Life Science Co, Ltd.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In January 2018, we adopted the amended accounting guidance related to the recognition, measurement, presentation, and disclosure of certain financial instruments. The amended guidance requires us to measure and record our equity investments at fair value. Additionally, the amended accounting guidance requires us to recognize the changes in fair value in our consolidated statement of operations, instead of through accumulated other comprehensive income. Prior to 2018, we accounted for our equity investments in privately held companies under the cost method of accounting. Under the amended guidance we account for our equity investments in privately held companies at their cost minus impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Our adoption of this guidance did not have an impact on our results.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Inventory Valuation&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We reflect our inventory on our consolidated balance sheet at the lower of cost or market value under the first-in, first-out method, or FIFO. We capitalize the costs of raw materials that we purchase for use in producing our medicines because until we use these raw materials, they have alternative future uses, which we refer to as clinical raw materials. We include in inventory raw material costs for medicines that we manufacture for our partners under contractual terms and that we use primarily in our clinical development activities and drug products. We can use each of our raw materials in multiple products and, as a result, each raw material has future economic value independent of the development status of any single medicine. For example, if one of our medicines failed, we could use the raw materials for that medicine to manufacture our other medicines. We expense these costs as R&amp;amp;D expenses when we begin to manufacture API for a particular medicine if the medicine has not been approved for marketing by a regulatory agency.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We obtained the first regulatory approval for TEGSEDI in July 2018 and for WAYLIVRA in May 2019. At December 31, 2019, our physical inventory for TEGSEDI and WAYLIVRA included API that we produced prior to when we obtained regulatory approval. As such, this API has no cost basis as we had previously expensed the costs as R&amp;amp;D expenses.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We review our inventory periodically and reduce the carrying value of items we consider to be slow moving or obsolete to their estimated net realizable value based on forecasted demand compared to quantities on hand. We consider several factors in estimating the net realizable value, including shelf life of our inventory, alternative uses for our medicines in development and historical write-offs. We recorded an &lt;span style="-sec-ix-hidden:Fact_1261d93c836d4d94bba4bd8c45f1e569"&gt;insignificant&lt;/span&gt; amount of inventory write-offs during the year ended December 31, 2019. We did not record any inventory write-offs for the years ended December 31, 2018 or 2017.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our inventory consisted of the following (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z1ee494cca3ec409c868c744c6428df49" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Raw materials:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 19.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Raw materials- clinical&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;9,363&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;8,497&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 28.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Raw materials- commercial&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6,520&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 28.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total raw materials&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;15,883&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;8,497&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Work in process&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,039&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Finished goods&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;258&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;85&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; margin-left: 28.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total inventory&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18,180&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;8,582&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Property, Plant and Equipment&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We carry our property, plant and equipment at cost and depreciate it on the straight-line method over its estimated useful life, which consists of the following (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z6b8fa4917b344088b2fa85d6aab08f8c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Estimated Useful Lives&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in years)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Computer software, laboratory, manufacturing and other equipment&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3 to 10&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;60,965&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;53,496&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Building, building improvements and building systems&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;15 to 40&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;119,830&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;97,528&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Land improvements&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;20&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,853&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,853&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;5 to 15&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;13,600&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18,981&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;5 to 10&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;7,354&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6,283&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;204,602&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;179,141&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Less accumulated depreciation&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(74,013&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(61,474&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;130,589&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;117,667&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Land&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;23,062&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;14,493&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;153,651&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;132,160&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We depreciate our leasehold improvements using the shorter of the estimated useful life or remaining lease term.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fair Value of Financial Instruments&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We have estimated the fair value of our financial instruments. The amounts reported for cash, accounts receivable, accounts payable and accrued expenses approximate the fair value because of their short maturities. We report our investment securities at their estimated fair value based on quoted market prices for identical or similar instruments.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Leases&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Topic 842 Adoption&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In February 2016, the Financial Accounting Standards Board, or FASB, issued amended accounting guidance related to lease accounting. This guidance supersedes the lease requirements we previously followed in Accounting Standards Codification, or ASC, Topic 840, &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Leases&lt;/span&gt;, or Topic 840, and created a new lease accounting standard, Topic 842, &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Leases&lt;/span&gt;, or Topic 842. Under Topic 842, an entity will record on its balance sheet all leases with a term longer than one year. Further, an entity will record a liability with a value equal to the present value of payments it will make over the life of the lease (lease liability) and an asset representing the underlying leased asset (right-of-use asset). The new accounting guidance requires entities to determine if its leases are operating or financing leases. Entities will recognize expense for operating leases on a straight-line basis as an operating expense. If an entity determines a lease is a financing lease, it will record both interest and amortization expense and generally the expense will be higher in the earlier periods of the lease. We adopted Topic 842 on January 1, 2019 and adjusted our opening balance sheet on that date for our right-of-use operating lease assets and operating lease liabilities. At adoption, we recorded $13.5 million in right-of-use operating lease assets and $18.5 million in operating lease liabilities, of which we classified $2 million as a current liability. We adopted Topic 842 using the available practical expedients&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification of those leases we had in place as of January 1, 2019. &lt;/span&gt;The adoption did not have an impact on our consolidated statement of operations.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Leases&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We determine if an arrangement contains a lease at inception. We currently only have operating leases. We recognize a right-of-use operating lease asset and associated short- and long-term operating lease liability on our consolidated balance sheet for operating leases greater than one year. Our right-of-use assets represent our right to use an underlying asset for the lease term and our lease liabilities represent our obligation to make lease payments arising from the lease arrangement. We recognize our right-of-use operating lease assets and lease liabilities based on the present value of the future minimum lease payments we will pay over the lease term.&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;&#160;&lt;/span&gt;We determined the lease term at the inception of the lease, and in certain cases our lease term could include renewal options if we concluded we were reasonably certain that we will exercise the renewal option.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;As our current leases do not provide an interest rate implicit in the lease, we used our or Akcea&#x2019;s incremental borrowing rate, based on the information available on the date we adopted Topic 842 or as of the lease inception date in determining the present value of future payments. Our right-of-use operating lease asset also includes any lease payments we made and excludes any tenant improvement allowances we received. We recognize rent expense for our minimum lease payments on a straight-line basis over the expected term of our lease. We recognize period expenses, such as common area maintenance expenses, in the period we incur the expense.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Long-Lived Assets&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We evaluate long-lived assets, which include property, plant and equipment and patent costs, for impairment on at least a quarterly basis and whenever events or changes in circumstances indicate that we may not be able to recover the carrying amount of such assets. We recorded charges of $2.2 million, $0.8 million and $0.8 million for the years ended December 31, 2019, 2018 and 2017, respectively, related primarily to the write-down of intangible assets.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Use of Estimates&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Stock-Based Compensation Expense&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We measure stock-based compensation expense for equity-classified awards, principally related to stock options, restricted stock units, or RSUs, and stock purchase rights under our ESPP based on the estimated fair value of the award on the date of grant. We recognize the value of the portion of the award that we ultimately expect to vest as stock-based compensation expense over the requisite service period in our consolidated statements of operations. We reduce stock-based compensation expense for estimated forfeitures at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We use the Black-Scholes model to estimate the fair value of stock options granted and stock purchase rights under our ESPP. On the grant date, we use our stock price and assumptions regarding a number of variables to determine the estimated fair value of stock-based payment awards. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We recognize compensation expense for option awards and RSUs using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award were in substance multiple awards, which results in the expense being front-loaded over the vesting period.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The fair value of RSUs is based on the market price of our common stock on the date of grant. The RSUs we have granted vest annually over a four-year period.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;See Note 4, &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Stockholders&#x2019; Equity,&lt;/span&gt; for additional information regarding our stock-based compensation plans.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Accumulated Other Comprehensive Loss&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Accumulated other comprehensive loss is primarily comprised of unrealized gains and losses on investments, net of taxes and adjustments we made to reclassify realized gains and losses on investments from other accumulated comprehensive loss to our Consolidated Statement of Operations. The following table summarizes changes in accumulated other comprehensive loss for the years ended December 31, &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;2019&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;, &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;2018&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; and &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;2017&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zf8dcaf0ca45440bba49fa3a29bc22bb5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Beginning balance accumulated other comprehensive loss&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(32,016&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(31,759&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(30,358&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Unrealized gains (losses) on securities, net of tax (1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6,633&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(280&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(960&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(374&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Currency translation adjustment&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;93&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;23&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(67&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net other comprehensive loss for the period&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6,726&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(257&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,401&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ending balance accumulated other comprehensive loss&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(25,290&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(32,016&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(31,759&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z11d622af5d604f70bd2be3051942ec9a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;A tax benefit of $1.4 million and $0.3 million was included in other comprehensive loss for the years ended December 31, 2019 and 2018, respectively. There was no tax benefit or expense for other comprehensive loss for the year ended December 31, 2017.&#160;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Convertible Debt&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;At issuance, we accounted for our convertible debt instruments, including our 0.125 percent senior convertible notes, or 0.125% Notes and 1 percent senior convertible notes, or 1% Notes, that may be settled in cash upon conversion (including partial cash settlement) by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate on the date the notes were issued. In reviewing debt issuances, we were not able to identify any comparable companies that recently issued non-convertible debt instruments. Therefore, we estimated the fair value of the liability component of our notes by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We assigned a value to the debt component of our convertible notes equal to the estimated fair value of similar debt instruments without the conversion feature, which resulted in us recording our debt at a discount. We are amortizing our debt issuance costs and debt discount over the life of the convertible notes as additional non-cash interest expense utilizing the effective interest method. For additional information, see Note 3, &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Long-Term Obligations and Commitments&lt;/span&gt;.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Segment Information&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We have &lt;/span&gt;two&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; operating segments, our Ionis Core segment and Akcea Therapeutics, our majority-owned affiliate. Akcea is &lt;/span&gt;a biopharmaceutical company focused on developing and commercializing medicines to treat patients with serious and rare diseases&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;. We provide segment financial information and results for our Ionis Core segment and our Akcea Therapeutics segment based on the segregation of revenues and expenses that our chief decision maker reviews to assess operating performance and to make operating decisions. We allocate a portion of Ionis&#x2019; development, R&amp;amp;D support and general and administrative expenses to Akcea for work Ionis performs on behalf of Akcea and we bill Akcea for these expenses.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fair Value Measurements&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We use a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets, which includes our money market funds and treasury securities classified as available-for-sale securities and our investment in equity securities in publicly-held biotechnology companies; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable, which includes our fixed income securities and commercial paper classified as available-for-sale securities; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring us to develop our own assumptions. We classify the majority of our securities as Level 2. We obtain the fair value of our Level 2 investments from our custodian bank or from a professional pricing service. We validate the fair value of our Level 2 investments by understanding the pricing model used by the custodian banks or professional pricing service provider and comparing that fair value to the fair value based on observable market prices.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following tables present the major security types we held at December 31, 2019 and 2018&#160;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;that we regularly measure and carry at fair value&lt;/span&gt;. At December 31, 2019, a portion of our ProQR investment was &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;subject to trading restrictions through the fourth quarter of 2020, as a result we&lt;/span&gt; included a lack of marketability discount in valuing this investment, which is a Level 3 input. At December 31, 2018, our ProQR investment was &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;subject to trading restrictions through the fourth quarter of 2019, as a result we&lt;/span&gt; included a lack of marketability discount in valuing this investment, which is a Level 3 input. The tables segregate each security type by the level within the fair value hierarchy of the valuation techniques we utilized to determine the respective securities&#x2019; fair value (in thousands):&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z0cec2f41ef46437e96b40a502fd19a06" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 8pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;At&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quoted Prices in&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Active Markets&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Level 1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Significant Other&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Observable Inputs&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Level 2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Significant&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Unobservable Inputs&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Level 3)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Cash equivalents (1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;418,406&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;418,406&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Corporate debt securities (2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,102,568&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,102,568&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by U.S. government agencies (3)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;329,404&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;329,404&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by the U.S. Treasury (4)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;363,694&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;363,694&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by states of the U.S. and political subdivisions of the states (4)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;40,407&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;40,407&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div/&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Investment in ProQR Therapeutics N.V. (5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4,506&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4,506&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -8.9pt; margin-left: 22.55pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,258,985&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;782,100&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,472,379&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4,506&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z6dbe183adeca4fdb81898fb0f23d867c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 8pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;At&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quoted Prices in&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Active Markets&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Level 1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Significant Other&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Observable Inputs&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Level 2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Significant&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Unobservable Inputs&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Level 3)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Cash equivalents (1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;146,281&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;146,281&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Corporate debt securities (6)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,252,960&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,252,960&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by U.S. government agencies (4)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;276,612&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;276,612&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by the U.S. Treasury (7)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;260,154&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;260,154&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by states of the U.S. and political subdivisions of the states (4)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;79,942&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;79,942&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Investment in ProQR Therapeutics N.V. (5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,349&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,349&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -8.9pt; margin-left: 22.55pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,017,298&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;406,435&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,609,514&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,349&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;________________&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zcc6c856321964d22a7f08198e22558a3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Included in cash and cash equivalents on our consolidated balance sheet.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -36pt; margin-left: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z3bb7cbd9edf34eea8445b9bb699f5225" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$19.0 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z9302b49ff4924d45b72f0ef80173e32d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(3)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$0.8 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zcc7cb538270446d19a63ff93630b2e26" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Included in short-term investments.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z0a497b435bb34da0940d397a2ee925d1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Included in other current assets on our consolidated balance sheet.&#160;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze53e73690894408ba98ca5e5e87ae494" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(6)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$50.2 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z9da9f51ab1ce4cf8b13bf7b591532750" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(7)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$14.2 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Income Taxes&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We account for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. We record a valuation allowance when necessary to reduce our net deferred tax assets to the amount expected to be realized.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act of 2017, or the Tax Act. The Tax Act created a new requirement on global intangible low-taxed income, or GILTI, earned by foreign subsidiaries for tax years beginning on or after January 1, 2018. The GILTI provisions require foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#x2019;s assets to be included in our U.S. income tax return. Under U.S. GAAP, we are permitted to make an accounting policy election to either treat taxes due on future inclusions in U.S. taxable income related to GILTI as a current-period expense when incurred or to factor such amounts into our measurement of deferred taxes. We have made the election to account for GILTI as a component of current taxes incurred rather than as a component of deferred taxes.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We apply the authoritative accounting guidance prescribing a threshold and measurement attribute for the financial recognition and measurement of a tax position taken or expected to be taken in a tax return. We recognize liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step requires us to estimate and measure the tax benefit as the largest amount that is more than 50 percent likely to be realized upon ultimate settlement.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We are required to use significant judgment in evaluating our uncertain tax positions and determining our provision for income taxes. Although we believe our reserves are reasonable, no assurance can be given that the final tax outcome of these matters will not be different from that which is reflected in our historical income tax provisions and accruals. We adjust these reserves for changing facts and circumstances, such as the closing of a tax audit or the refinement of an estimate. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences may impact the provision for income taxes in the period in which such determination is made.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We are also required to use significant judgment in determining any valuation allowance recorded against our deferred tax assets. In assessing the need for a valuation allowance, we consider all available evidence, including scheduled reversal of deferred tax liabilities, past operating results, the feasibility of tax planning strategies and estimates of future taxable income. We base our estimates of future taxable income on assumptions that are consistent with our plans. The assumptions we use represent our best estimates and involve inherent uncertainties and the application of our judgment. Should actual amounts differ from our estimates, the amount of our tax expense and liabilities we recognize could be materially impacted.&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; We record a valuation allowance to reduce the balance of our net deferred tax assets to the amount we believe is more-likely-than-not to be realized.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We do not provide for a U.S. income tax liability and foreign withholding taxes on undistributed foreign earnings of our foreign subsidiaries.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Impact of Recently Issued Accounting Standards&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In June 2016, the FASB issued guidance that changes the measurement of credit losses for most financial assets and certain other instruments. If we have credit losses, this updated guidance requires us to record allowances for these instruments under a new expected credit loss model. This model requires us to estimate the expected credit loss of an instrument over its lifetime, which represents the portion of the amortized cost basis we do not expect to collect. The new guidance requires us to remeasure our allowance in each reporting period we have credit losses. We adopted this the new guidance on January 1, 2020. We do not expect this guidance will have an impact on our consolidated financial statements.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In August 2018, the FASB issued clarifying guidance on how to account for implementation costs related to cloud-servicing arrangements. The guidance states that if these fees qualify to be capitalized and amortized over the service period, they need to be expensed in the same line item as the service expense and recognized in the same balance sheet category. The update can be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We adopted this guidance on January 1, 2020 on a prospective basis. We do not expect this guidance will have an impact on our consolidated financial statements.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In August 2018, the FASB updated its disclosure requirements related to Level 1, 2 and 3 fair value measurements. The update included deletion and modification of certain disclosure requirements and additional disclosure related to Level 3 measurements. The guidance is effective for fiscal years beginning after December 31, 2019 and early adoption is permitted. We adopted this updated guidance on January 1, 2019 and it did not have a significant impact on our disclosures.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In November 2018, the FASB issued clarifying guidance of the interaction between the collaboration accounting guidance and the new revenue recognition guidance we adopted on January 1, 2018 (Topic 606). Below is the clarifying guidance and how we will implement it (in italics):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z6b37abcc28844ec1995be6ea3287fde1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;When a participant is considered a customer in a collaborative arrangement, all of the associated accounting under Topic 606 should be applied&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z568b757cadfb43b88346ae2bdab57f19" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 72pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;We will apply all of the associated accounting under Topic 606 when we determine a participant in a collaborative arrangement is a customer &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z729d51441c36453d9dd29ff6baaa5429" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Adds &#x201c;unit of account&#x201d; concept to collaboration accounting guidance to align with Topic 606. The &#x201c;unit of account&#x201d; concept is used to determine if revenue is recognized or if a contra expense is recognized from consideration received under a collaboration&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z36356b76546d4b1b9df6a54de364a594" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 72pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;We will use the &#x201c;unit of account&#x201d; concept when we receive consideration under a collaborative arrangement to determine when we recognize revenue or a contra expense&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze5669a8c7b084090bd8ad32061dcc5d9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The clarifying guidance precludes us from recognizing revenue under Topic 606 when we determine a transaction with a collaborative partner is not a customer and is not directly related to the sales to third parties&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze5279de5f245498da7e1f9b7cb96a4f7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 72pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;When we conclude a collaboration partner is not a customer and is not directly related to the sales to third parties, we will not recognize revenue for the transaction &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We adopted this new guidance on January 1, 2020. We do not expect this guidance will have a significant impact on our consolidated financial statements.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In December 2019, the FASB issued guidance to simplify the accounting for income taxes. The update includes removing several exceptions under the existing guidance and includes several simplification updates, none of which apply to our current accounting for income taxes. The guidance is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted. We adopted this updated guidance in the fourth quarter of 2019 and it did not have an impact on our consolidated financial statements or disclosures.&lt;/div&gt;
</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="c20190101to20191231"
      id="Text_2b199108265b4c4198b7da63e8c89a7b">
&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Basis of Presentation&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;In our consolidated financial statements we included the accounts of Ionis Pharmaceuticals, Inc. (&#x201c;we&#x201d;, &#x201c;us&#x201d; or &#x201c;our&#x201d;) and the consolidated results of our majority-owned affiliate, Akcea Therapeutics, Inc., which we formed in December 2014. In July 2017, Akcea completed an initial public offering, or IPO. Since Akcea&#x2019;s IPO, our ownership has ranged from &lt;/span&gt;68 percent&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; to &lt;/span&gt;77 percent&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;. At December 31, 2019, o&lt;/span&gt;ur ownership was approximately 76 percent. We reflect changes in our ownership of Akcea in our financial statements in the period the change occurs. For example, we reflected an increase in our ownership when we received 6.9 million shares of Akcea common stock as payment for the sublicense fee Akcea owed us for Pfizer&#x2019;s license of AKCEA-ANGPTL3-L&lt;sub&gt;Rx&lt;/sub&gt; in the fourth quarter of 2019. &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Refer to the section titled &#x201c;Noncontrolling Interest in Akcea&#x201d; in Note 2, &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Significant Accounting Policies,&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; for further information related to our accounting for our investment in Akcea.&lt;/span&gt;&lt;/div&gt;
</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c20191231_OwnershipAxis_AkceaTherapeuticsIncMember_RangeAxis_MinimumMember"
      decimals="2"
      id="Fact_1c52629d5af4464eb05fbdfeead6d0a1"
      unitRef="U003">0.68</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c20191231_OwnershipAxis_AkceaTherapeuticsIncMember_RangeAxis_MaximumMember"
      decimals="2"
      id="Fact_6d7f1e25827e4935a7cab4cc683ece59"
      unitRef="U003">0.77</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c20191231_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="2"
      id="Fact_a67cffe7b85b4003bd09a2f4a26d72d3"
      unitRef="U003">0.76</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ions:SharesReceivedFromSubsidiaryForLicenseOfDrug
      contextRef="c20191001to20191231"
      decimals="-5"
      id="Fact_df5ee0c42b2442929cc860f2dfd73ba5"
      unitRef="U002">6900000</ions:SharesReceivedFromSubsidiaryForLicenseOfDrug>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="c20190101to20191231"
      id="Text_2da7bfa9547f4a7dbb2f9930781fb07b">
&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Basic and Diluted Net Income per Share&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Basic net income per share&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We compute basic net income per share by dividing the total net income attributable to our common stockholders by our weighted-average number of common shares outstanding during the period.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The calculation of total net income attributable to our common stockholders for each year considered our net income for Ionis on a stand-alone basis plus our share of Akcea&#x2019;s net income (loss) for the period. To calculate the portion of Akcea&#x2019;s net income (loss) attributable to our ownership for each year, we multiplied Akcea&#x2019;s income (loss) per share by the weighted average shares we owned in Akcea during the period. As a result of this calculation, our total net income available to Ionis common stockholders for the calculation of net income per share is different than net income attributable to Ionis Pharmaceuticals, Inc. common stockholders in our consolidated statements of operations for each year.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our basic net income per share, was calculated as follows (in thousands, except per share amounts):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z104b454b266445eaac9eed834835145f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Portion of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;70,100&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.49&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;34,073&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net income attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;34,073&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;262,490&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;296,563&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;139,998&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net income per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.12&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zfe21e6fd0158439f854dad365e54a58d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Loss&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Portion of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;59,812&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2.74&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(163,938&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net loss attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(163,938&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;440,806&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;276,868&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;132,320&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net income per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.09&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We calculated our basic net income per share for 2017 as follows (in thousands, except per share amounts):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z7f02aeb560ee40bd982c44713ab0a2ac" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Loss&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Portion of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;20,669&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(3.08&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(63,638&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Preferred shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;15,748&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1.80&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(28,346&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net loss attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(91,984&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;110,776&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18,792&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;124,016&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net income per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.15&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Prior to Akcea&#x2019;s IPO in July 2017, we owned Akcea series A convertible preferred stock, which included a &lt;span style="-sec-ix-hidden:Fact_814732dbfffb4dbbb487265b1d09e7b7"&gt;six percent&lt;/span&gt; cumulative dividend. Upon completion of Akcea&#x2019;s IPO in July 2017, our preferred stock was converted into common stock on a 1:1 basis. The preferred stock dividend was not paid at the IPO because the IPO was not a liquidation event or a change in control. During 2017, Akcea used a two-class method to compute its net loss per share because it had both common and preferred shares outstanding during the periods. The two-class method required Akcea to calculate its net loss per share for each class of stock by dividing total distributable losses applicable to preferred and common stock, including the six percent cumulative dividend contractually due to series A convertible preferred shareholders, by the weighted-average of preferred and common shares outstanding during the requisite period. Since Akcea used the two-class method, accounting rules required us to include our portion of Akcea&#x2019;s net loss per share for both Akcea&#x2019;s common and preferred shares that we owned in our calculation of basic and diluted net income per share for the year ended December 31, 2017.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Diluted net income per share&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We calculated our diluted net income per share as follows &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;(in thousands except per share amounts):&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zb0e4b49c2e274df0b9950bc8e8004fbd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Numerator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Denominator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per-Share&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;296,563&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;139,998&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.12&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effect of dilutive securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -8.9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon exercise of stock options&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,090&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: 0.1pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon restricted stock award issuance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;766&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our Employee Stock Purchase Plan&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income available to Ionis common stockholders, plus assumed conversions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;296,563&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;142,872&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.08&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z01b775cd675848508a1d52bc1c4cff37" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Numerator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Denominator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per-Share&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;276,868&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;132,320&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.09&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effect of dilutive securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -8.9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon exercise of stock options&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,216&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: 0.1pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon restricted stock award issuance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;514&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our Employee Stock Purchase Plan&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income available to Ionis common stockholders, plus assumed conversions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;276,868&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;134,056&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.07&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zd8deeaecb9c64cd89c8fc8806b7a193d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Numerator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Denominator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per-Share&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18,792&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;124,016&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.15&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effect of dilutive securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -8.9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon exercise of stock options&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,619&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: 0.1pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon restricted stock award issuance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;459&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our Employee Stock Purchase Plan&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income available to Ionis common stockholders, plus assumed conversions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18,792&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;126,098&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.15&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;For each year presented, the calculation excluded our convertible senior notes because the effect on diluted earnings per share was anti-dilutive.&lt;/div&gt;
</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock
      contextRef="c20190101to20191231"
      id="Text_c28282748cc547e59916832cd89fb4c8">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our basic net income per share, was calculated as follows (in thousands, except per share amounts):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z104b454b266445eaac9eed834835145f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Portion of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;70,100&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.49&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;34,073&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net income attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;34,073&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;262,490&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;296,563&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;139,998&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net income per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.12&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zfe21e6fd0158439f854dad365e54a58d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Loss&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Portion of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;59,812&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2.74&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(163,938&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net loss attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(163,938&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;440,806&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;276,868&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;132,320&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net income per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.09&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We calculated our basic net income per share for 2017 as follows (in thousands, except per share amounts):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z7f02aeb560ee40bd982c44713ab0a2ac" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Loss&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Portion of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;20,669&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(3.08&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(63,638&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Preferred shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;15,748&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1.80&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(28,346&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net loss attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(91,984&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;110,776&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18,792&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;124,016&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net income per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.15&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock>
    <ions:WeightedAverageNumberOfSharesOwnedInSubsidiary
      contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember"
      decimals="-3"
      id="Fact_15287ca1da7a4e18a9ee8972a4823021"
      unitRef="U002">70100000</ions:WeightedAverageNumberOfSharesOwnedInSubsidiary>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember"
      decimals="2"
      id="Fact_9814ec36723d489dbd4e4c74f8b91687"
      unitRef="U004">0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember"
      decimals="-3"
      id="Fact_343d7b1e02e240df812b3efbadfc402c"
      unitRef="U001">34073000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_9de17ffd9b104577a708d4d8f1509e01"
      unitRef="U001">34073000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20190101to20191231_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_5c7b0518904e47418483341709852d64"
      unitRef="U001">262490000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_7e491f4aadd94c68abfd6a19ddac90ad"
      unitRef="U001">296563000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_683ae782f7fe4a82918f22dea02d9d01"
      unitRef="U002">139998000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20190101to20191231"
      decimals="2"
      id="Fact_025896a7df2b41838c7449c76fed8d09"
      unitRef="U004">2.12</us-gaap:EarningsPerShareBasic>
    <ions:WeightedAverageNumberOfSharesOwnedInSubsidiary
      contextRef="c20180101to20181231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember"
      decimals="-3"
      id="Fact_940b4a03fe6f4389949b2cdbec92c4e0"
      unitRef="U002">59812000</ions:WeightedAverageNumberOfSharesOwnedInSubsidiary>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20180101to20181231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember"
      decimals="2"
      id="Fact_0332420a922344dbb39388360df6e41d"
      unitRef="U004">-2.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="c20180101to20181231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember"
      decimals="-3"
      id="Fact_16fac149fc8a42eb8215243e61e0851d"
      unitRef="U001">-163938000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20180101to20181231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_3ee347bdde47445b90efca086e479676"
      unitRef="U001">-163938000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20180101to20181231_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_e9ea76d10eaf4d52892351487043b0f0"
      unitRef="U001">440806000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_cb1ed57e97fa41f88c3b82ffabc4e03c"
      unitRef="U001">276868000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_30220b3f42ac486f9c7b81691c93d62b"
      unitRef="U002">132320000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20180101to20181231"
      decimals="2"
      id="Fact_94e75adb0d50429696d61fb3a1db7bb4"
      unitRef="U004">2.09</us-gaap:EarningsPerShareBasic>
    <ions:WeightedAverageNumberOfSharesOwnedInSubsidiary
      contextRef="c20170101to20171231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember"
      decimals="-3"
      id="Fact_7f3e78d8ab30451e8241ca0e38eee153"
      unitRef="U002">20669000</ions:WeightedAverageNumberOfSharesOwnedInSubsidiary>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20170101to20171231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember"
      decimals="2"
      id="Fact_c8212e5603a14371bc8cfbb9954ade3f"
      unitRef="U004">-3.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="c20170101to20171231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_CommonStockMember"
      decimals="-3"
      id="Fact_f558eef64fe94b50b7701b347d41b454"
      unitRef="U001">-63638000</us-gaap:NetIncomeLoss>
    <ions:WeightedAverageNumberOfSharesOwnedInSubsidiary
      contextRef="c20170101to20171231_StatementClassOfStockAxis_ConvertiblePreferredStockMember"
      decimals="-3"
      id="Fact_4f96c03ae3ce4ff787733bc0b5ec5544"
      unitRef="U002">15748000</ions:WeightedAverageNumberOfSharesOwnedInSubsidiary>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20170101to20171231_StatementClassOfStockAxis_ConvertiblePreferredStockMember"
      decimals="2"
      id="Fact_746a8867994d42d29ca41bf1fef558d7"
      unitRef="U004">-1.80</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="c20170101to20171231_StatementClassOfStockAxis_ConvertiblePreferredStockMember"
      decimals="-3"
      id="Fact_63e92a44c759484cb7272d40998b6eeb"
      unitRef="U001">-28346000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20170101to20171231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_2ce538bf55324fddb82784f3b5823d97"
      unitRef="U001">-91984000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20170101to20171231_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_baffdf3fbb9c415ab2b08db707345d3f"
      unitRef="U001">110776000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_3e2e4d46fb4d4c759780855b07483e3f"
      unitRef="U001">18792000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_b84b45d5c04845a4b15143efc6c0dec6"
      unitRef="U002">124016000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20170101to20171231"
      decimals="2"
      id="Fact_aa49435657a645e0abbdf698dd72f613"
      unitRef="U004">0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:ConvertiblePreferredStockTermsOfConversion
      contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_StatementClassOfStockAxis_ConvertiblePreferredStockMember"
      id="Fact_ecb896b7a1c74750abf1bb5e217f0fe8">converted into common stock on a 1:1 basis</us-gaap:ConvertiblePreferredStockTermsOfConversion>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_c5b95a77a3674760bd9dde0a5ba42e29">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We calculated our diluted net income per share as follows &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;(in thousands except per share amounts):&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zb0e4b49c2e274df0b9950bc8e8004fbd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Numerator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Denominator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per-Share&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;296,563&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;139,998&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.12&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effect of dilutive securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -8.9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon exercise of stock options&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,090&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: 0.1pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon restricted stock award issuance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;766&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our Employee Stock Purchase Plan&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income available to Ionis common stockholders, plus assumed conversions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;296,563&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;142,872&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.08&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z01b775cd675848508a1d52bc1c4cff37" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Numerator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Denominator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per-Share&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;276,868&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;132,320&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.09&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effect of dilutive securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -8.9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon exercise of stock options&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,216&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: 0.1pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon restricted stock award issuance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;514&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our Employee Stock Purchase Plan&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income available to Ionis common stockholders, plus assumed conversions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;276,868&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;134,056&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.07&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zd8deeaecb9c64cd89c8fc8806b7a193d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Numerator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Denominator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per-Share&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18,792&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;124,016&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.15&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effect of dilutive securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -8.9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon exercise of stock options&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,619&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: 0.1pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon restricted stock award issuance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;459&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our Employee Stock Purchase Plan&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income available to Ionis common stockholders, plus assumed conversions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18,792&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;126,098&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.15&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_928ebff2305241a187a9702bd859ffdc"
      unitRef="U001">296563000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_8c42ec6f83704cb0b72cd914336afac6"
      unitRef="U002">139998000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20190101to20191231"
      decimals="2"
      id="Fact_db74783fdc8d4155ba634e6a502e8c66"
      unitRef="U004">2.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact_fb4b7906279d467fb31bf97c42314d00"
      unitRef="U002">2090000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockMember"
      decimals="-3"
      id="Fact_6fda8655aebe48fcb0075da625a15701"
      unitRef="U002">766000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <ions:IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_c0b638de467b4fa3899ed822f610c542"
      unitRef="U002">18000</ions:IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_48a3337692f14bbdad665c341beadbc3"
      unitRef="U001">296563000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_afcf6e9e7dd24cc4870bf41943d9e76d"
      unitRef="U002">142872000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20190101to20191231"
      decimals="2"
      id="Fact_1c2916338e004b83b9a89b2346d1a77d"
      unitRef="U004">2.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_a26ab11884634d9d8cbfbe2f762fd122"
      unitRef="U001">276868000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_82557aeb9c3c4b78bc24813f9172640c"
      unitRef="U002">132320000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20180101to20181231"
      decimals="2"
      id="Fact_5f9331686a4747708db2903e2436826a"
      unitRef="U004">2.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact_54681ee48ba34ad68a5424d80a225e34"
      unitRef="U002">1216000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c20180101to20181231_AwardTypeAxis_RestrictedStockMember"
      decimals="-3"
      id="Fact_91caa39b33724bef87c48867cfa27c77"
      unitRef="U002">514000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <ions:IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_63435561706d411bada0a6048a8b479f"
      unitRef="U002">6000</ions:IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_a61d1113740f4208a4f729d24f0e5aa6"
      unitRef="U001">276868000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_3fde4743a5254c2e9d1db7eaa0ba1e5d"
      unitRef="U002">134056000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20180101to20181231"
      decimals="2"
      id="Fact_c2d9fb4d375f42e6a6330aada4be5e62"
      unitRef="U004">2.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_7770bc95f08f4485a43bbc0a7ccb1d48"
      unitRef="U001">18792000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_16f6d335b2e94b91842456b8650b64e7"
      unitRef="U002">124016000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20170101to20171231"
      decimals="2"
      id="Fact_dac2ceb88209472f9ee8b0435b40e522"
      unitRef="U004">0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact_2bdc136d0eae478587248dd71970987b"
      unitRef="U002">1619000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c20170101to20171231_AwardTypeAxis_RestrictedStockMember"
      decimals="-3"
      id="Fact_16f130a3cbc4456fb8a66929f97a1363"
      unitRef="U002">459000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <ions:IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_b5b936017ef040e4a73ecb6f10bcccf2"
      unitRef="U002">4000</ions:IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_19cdca1d19fd4b0aaa3c90ca895f3626"
      unitRef="U001">18792000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_8f4199f02a7c4375b1908349b2e11384"
      unitRef="U002">126098000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20170101to20171231"
      decimals="2"
      id="Fact_6c4277c20e034a4c9fdf6030aba39c8c"
      unitRef="U004">0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="c20190101to20191231"
      id="Text_a7941b74efeb4884837e75cd6f25191b">
&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Revenue Recognition&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;span style="text-decoration: underline;"&gt;Our Revenue Sources&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We generally recognize revenue when we have satisfied all contractual obligations and are reasonably assured of collecting the resulting receivable. We are often entitled to bill our customers and receive payment from our customers in advance of recognizing the revenue. In the instances in which we have received payment from our customers in advance of recognizing revenue, we include the amounts in deferred revenue on our consolidated balance sheet.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Commercial Revenue: SPINRAZA royalties and Licensing and other royalty revenue&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We earn commercial revenue primarily in the form of royalty payments on net sales of SPINRAZA. We will also recognize as commercial revenue future sales milestone payments and royalties we earn under our partnerships.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Commercial Revenue: Product sales, net&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We added product sales from TEGSEDI to our commercial revenue in the fourth quarter of 2018 and we added product sales from WAYLIVRA to our commercial revenue in the third quarter of 2019. &lt;/span&gt;In the U.S., we distribute TEGSEDI through an exclusive distribution agreement with a third-party logistics company, or 3PL, that takes title to TEGSEDI. The 3PL is our sole customer in the U.S. The 3PL then distributes TEGSEDI to a specialty pharmacy and a specialty distributor, which we collectively refer to as wholesalers, who then distribute TEGSEDI to health care providers and patients. In Europe, prior to the third quarter of 2019 we distributed TEGSEDI through a non-exclusive distribution model with a 3PL that took title to TEGSEDI. The 3PL was our sole customer in Europe. The 3PL in Europe then distributed TEGSEDI to hospitals and pharmacies. In the third quarter of 2019, we entered into a distribution arrangement with a 3PL and began to sell both TEGSEDI and WAYLIVRA directly to hospitals and pharmacies in Europe.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Research and development revenue under collaborative agreements&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We often enter into collaboration agreements to license and sell our technology on an exclusive or non-exclusive basis. Our collaboration agreements typically contain multiple elements, or performance obligations, including technology licenses or options to obtain technology licenses, research and development, or R&amp;amp;D, services, and manufacturing services.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Our collaboration agreements are detailed in Note 6, &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Collaborative Arrangements and Licensing Agreements.&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Under each collaboration note we discuss our specific revenue recognition conclusions, including our significant performance obligations under each collaboration.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;span style="text-decoration: underline;"&gt;Steps to Recognize Revenue&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We use a five-step process to determine the amount of revenue we should recognize and when we should recognize it. The five step process is as follows:&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zb9f70b6bc634422f82831b9476ae8444" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;1.&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Identify the contract&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Accounting rules require us to first determine if we have a contract with our partner, including confirming that we have met each of the following criteria:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z32abea7f3b454dedb5d275fcd69bfc41" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We and our partner approved the contract and we are both committed to perform our obligations;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z2fef2cbf4007441595d4245add81d46d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We have identified our rights, our partner&#x2019;s rights and the payment terms;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze8401d5278b84ee1953ba4283b1f9851" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We have concluded that the contract has commercial substance, meaning that the risk, timing, or amount of our future cash flows is expected to change as a result of the contract; and&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z7c8deb873be94db28e11c93fd5b094f0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We believe collectability is probable. &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: -18pt; margin-left: 54pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zac78659984944d66a7d6f7f05a5a6181" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;&lt;span style="background-color: #FFFFFF;"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: left;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;&lt;span style="background-color: #FFFFFF; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Identify the performance obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We next identify the distinct goods and services we are required to provide under the contract. Accounting rules refer to these as our performance obligations. We typically have only one performance obligation at the inception of a contract, which is to perform R&amp;amp;D services.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Often times we enter into a collaboration agreement in which we provide our partner with an option to license a medicine in the future. We may also provide our partner with an option to request that we provide additional goods or services in the future, such as active pharmaceutical ingredient, or API. We evaluate whether these options are material rights at the inception of the agreement. If we determine an option is a material right, we will consider the option a separate performance obligation. Historically, we have concluded that the options we grant to license a medicine in the future or to provide additional goods and services as requested by our partner are not material rights. These items are contingent upon future events that may not occur. When a partner exercises its option to license a medicine or requests additional goods or services, then we identify a new performance obligation for that item.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In some cases, we deliver a license at the start of an agreement. If we determine that our partner has full use of the license and we do not have any additional material performance obligations related to the license after delivery, then we consider the license to be a separate performance obligation.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zf1f446d282dd4e1b832e3c09c5f82c88" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;3.&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Determine the transaction price&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We then determine the transaction price by reviewing the amount of consideration we are eligible to earn under the collaboration agreement, including any variable consideration. Under our collaboration agreements, consideration typically includes fixed consideration in the form of an upfront payment and variable consideration in the form of potential milestone payments, license fees and royalties. At the start of an agreement, our transaction price usually consists of only the upfront payment. We do not typically include any payments we may receive in the future in our initial transaction price because the payments are not probable and are contingent on certain future events. We reassess the total transaction price at each reporting period to determine if we should include additional payments in the transaction price.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Milestone payments are our most common type of variable consideration. We recognize milestone payments using the most likely amount method because we will either receive the milestone payment or we will not, which makes the potential milestone payment a binary event. The most likely amount method requires us to determine the likelihood of earning the milestone payment. We include a milestone payment in the transaction price once it is probable we will achieve the milestone event. Most often, we do not consider our milestone payments probable until we or our partner achieve the milestone event because the majority of our milestone payments are contingent upon events that are not within our control and are usually based on scientific progress. For example, in the fourth quarter of 2019, we earned a $10 million milestone payment from AstraZeneca when AstraZeneca initiated a Phase 1 trial for ION839. We did not consider the milestone payments probable until AstraZeneca achieved the milestone event because the initiation of the Phase 1 trial was a contingent event that was not within our control. We recognized the milestone payments in full in the period the milestone event was achieved because we did not have any remaining performance obligations related to the milestone payment.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z61f3f8aec88b4866a2bbc6540840c7b9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;4.&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Allocate the transaction price&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Next, we allocate the transaction price to each of our performance obligations. When we have to allocate the transaction price to more than one performance obligation, we make estimates of the relative stand-alone selling price of each performance obligation because we do not typically sell our goods or services on a stand-alone basis. We then allocate the transaction price to each performance obligation based on the relative stand-alone selling price.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We may engage a third party, independent valuation specialist to assist us with determining a stand-alone selling price for collaborations in which we deliver a license at the start of an agreement. We estimate the stand-alone selling price of these licenses using valuation methodologies, such as the relief from royalty method. Under this method, we estimate the amount of income, net of taxes, for the license. We then discount the projected income to present value. The significant inputs we use to determine the projected income of a license could include:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zd0332dc311ad49d5aebb0b0dcec49da1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Estimated future product sales;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zbafbea8c82a44de19538caf8c4d34c17" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Estimated royalties on future product sales;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zc5914eb350eb4288913df6b658f90445" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Contractual milestone payments;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z23f53850cb2e499c87cc78fc51b878db" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Expenses we expect to incur;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zba5b48ea375f49caad917f1f137ff6cf" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income taxes; and&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zc80b99fe0b894aecb56282f28ddea0a9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;A discount rate.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We typically estimate the selling price of R&amp;amp;D services by using our internal estimates of the cost to perform the specific services. The significant inputs we use to determine the selling price of our R&amp;amp;D services include:&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z2a27bbd1916f4ee3b3441ed762a2c2b3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The number of internal hours we estimate we will spend performing these services;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z3d50f6d0709c44f89b5262ca45319fbe" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The estimated cost of work we will perform;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zf1df7de1efb647f3a758705c8216c76d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The estimated cost of work that we will contract with third parties to perform; and&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zcc18420c84464778ad67ecdb5155e530" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The estimated cost of API we will use. &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 54pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;For purposes of determining the stand-alone selling price of the R&amp;amp;D services we perform and the API we will deliver, accounting guidance requires us to include a markup for a reasonable profit margin.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We do not reallocate the transaction price after the start of an agreement to reflect subsequent changes in stand-alone selling prices.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zaa2a29a440094a6385db6db34fe05178" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;5.&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Recognize revenue&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -54pt; margin-left: 54pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We recognize revenue in one of two ways, over time or at a point in time. We recognize revenue over time when we are executing on our performance obligation over time and our partner receives benefit over time. For example, we recognize revenue over time when we provide R&amp;amp;D services. We recognize revenue at a point in time when our partner receives full use of an item at a specific point in time. For example, we recognize revenue at a point in time when we deliver a license or API to a partner.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;For R&amp;amp;D services that we recognize over time, we measure our progress using an input method. The input methods we use are based on the effort we expend or costs we incur toward the satisfaction of our performance obligation. We estimate the amount of effort we expend, including the time we estimate it will take us to complete the activities, or costs we incur in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This results in a percentage that we multiply by the transaction price to determine the amount of revenue we recognize each period. This approach requires us to make numerous estimates and use significant judgement. If our estimates or judgements &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;change over the course of the collaboration, they may affect the timing and amount of revenue that we recognize in the current and future periods. For example, &lt;/span&gt;in the third quarter of 2019, we updated our estimate of the total effort we expected to expend to satisfy our performance obligation under our&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; 2013 Strategic Neurology collaboration with Biogen&lt;/span&gt;. As of September 30, 2019, we had completed a&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; significant portion of the research and development services. We expect to complete the remainder of our services in 2020. As a result of our change in estimate, in the third quarter of 2019, we recorded a cumulative catch up adjustment of $&lt;/span&gt;16.5&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million to decrease revenue. Refer to Note 7, &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Collaborative Arrangements and Licensing Agreements&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;, for further discussion of the cumulative catch up adjustment we made.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following are examples of when we typically recognize revenue based on the types of payments we receive.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;span style="text-decoration: underline;"&gt;Commercial Revenue: SPINRAZA royalties and Licensing and other royalty revenue&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We recognize royalty revenue, including royalties from SPINRAZA sales, in the period in which the counterparty sells the related product and recognizes the related revenue, which in certain cases may require us to estimate our royalty revenue.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;span style="text-decoration: underline;"&gt;Commercial Revenue: Product sales, net&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We recognize product sales in the period &lt;/span&gt;when our customer obtains control of our products, which occurs at a point in time upon transfer of title to the customer. We classify payments to customers or other parties in the distribution channel for services that are distinct and priced at fair value as selling, general and administrative expenses in our consolidated statements of operations. Otherwise, payments to customers or other parties in the distribution channel that do not meet those criteria are classified as a reduction of revenue, as discussed further below. We exclude from revenues taxes collected from customers relating to product sales and remitted to governmental authorities.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Reserves for Product sales&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We record product sales at our net sales price, or transaction price. We include in our transaction price estimated reserves for discounts, returns, chargebacks, rebates, co-pay assistance and other allowances that we offer within contracts between us and our customers, wholesalers, health care providers and other indirect customers. We estimate our reserves using the amounts we have earned or what we can claim on the associated sales. We classify our reserves as a reduction of accounts receivable when we are not required to make a payment or as a current liability when we are required to make a payment. In certain cases, our estimates include a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, our reserves reflect our best estimates under the terms of our respective contracts. When calculating our reserves and related product sales, we only recognize amounts to the extent that we consider it probable that we would not have to reverse in a future period a significant amount of the cumulative sales we previously recognized. The actual amounts we receive may ultimately differ from our reserve estimates. If actual amounts in the future vary from our estimates, we will adjust these estimates, which would affect our net product sales in the respective period.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following are the components of variable consideration related to product sales:&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Chargebacks: &lt;/span&gt;In the U.S., we estimate obligations resulting from contractual commitments with the government and other entities to sell products to qualified healthcare providers at prices lower than the list prices charged to our U.S. customer. Our U.S. customer charges us for the difference between what it pays for the product and the selling price to the qualified healthcare providers. We also estimate the amount of chargebacks related to our estimated product remaining in the distribution channel at the end of the reporting period that we expect our customer to sell to healthcare providers in future periods. We record these reserves as an accrued liability on our consolidated balance sheet for the chargebacks related to product sales to our U.S. customer during the reporting period.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Government rebates&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;: We are subject t&lt;/span&gt;o discount obligations under government programs, including Medicaid and Medicare programs in the U.S. and we record reserves for government rebates based on statutory discount rates and estimated utilization. We estimate Medicaid and Medicare rebates based on a range of possible outcomes that are probability-weighted for the estimated payer mix. We record these reserves as an accrued liability on our consolidated balance sheet with a corresponding offset reducing our product sales in the same period we recognize the related sale. For Medicare, we also estimate the number of patients in the prescription drug coverage gap for whom we will owe an additional liability under the Medicare Part D program. On a quarterly basis, we update our estimates and record any adjustments in the period that we identify the adjustments.&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Managed care rebates: &lt;/span&gt;We are subject to rebates in connection with a value-based agreement with one of our commercial payer&#x2019;s. We record these rebates as an accrual on our consolidated balance sheet in the same period we recognize the related revenue. We estimate our managed care rebates based on our estimated payer mix and the applicable contractual rebate rate.&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Trade discounts: &lt;/span&gt;We provide customary invoice discounts on product sales to our U.S. customer for prompt payment. We record this discount as a reduction of product sales in the period in which we recognize the related product revenue.&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Distribution services&lt;/span&gt;: We receive and pay for various distribution services from our U.S. and EU customers and wholesalers in the U.S.. We classify the costs for services we receive that are either not distinct from the sale of the product or for which we cannot reasonably estimate the fair value as a reduction of product sales. To the extent that the services we receive are distinct from the sale of the product, we classify the costs for such services as selling, general and administration, or SG&amp;amp;A, expenses.&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Product returns: &lt;/span&gt;Our U.S. customer has return rights and the wholesalers have limited return rights primarily related to the product&#x2019;s expiration date. We estimate the amount of product sales that our customer may return. We record our return estimate as an accrued refund liability on our consolidated balance sheet with a corresponding offset reducing our product sales in the same period we recognize the related sale. Based on our distribution model for product sales, contractual inventory limits with our customer and wholesalers and the price of the product, we have had minimal returns to date and we believe we will continue to have minimal returns. Our EU customers only take title to the product after they receive an order from a hospital or pharmacy and therefore they do not maintain excess inventory levels of our products. Accordingly, we have limited return risk in the EU and we do not estimate returns in the EU.&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Other incentives: &lt;/span&gt;In the U.S., we estimate reserves for other incentives including co-payment assistance we provide to patients with commercial insurance who have coverage and reside in states that allow co-payment assistance. We record a reserve for the amount we estimate we will pay for co-payment assistance. We base our reserve on the number of estimated claims and our estimate of the cost per claim related to product sales that we have recognized as revenue. We record our other incentive reserve estimates as an accrued liability on our consolidated balance sheet with a corresponding offset reducing our product sales in the same period we recognize the related sale.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;span style="text-decoration: underline;"&gt;Research and development revenue under collaboration agreements:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;span style="text-decoration: underline;"&gt;Upfront payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;When we enter into a collaboration agreement with an upfront payment, we typically record the entire upfront payment as deferred revenue if our only performance obligation is for R&amp;amp;D services we will provide in the future. We amortize the upfront payment into revenue as we perform the R&amp;amp;D services. For example, under our &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;collaboration agreement with Roche to&lt;/span&gt;&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; develop IONIS-FB-L&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; for the treatment of complement-mediated diseases&lt;/span&gt;, we received a $75 million upfront payment in the fourth quarter of 2018. We allocated the upfront payment to our single performance obligation, R&amp;amp;D services. We are amortizing the $75 million upfront payment using an input method over the estimated period of time we are providing R&amp;amp;D services.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;span style="text-decoration: underline;"&gt;Milestone payments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We are required to include additional consideration in the transaction price when it is probable. We typically include milestone payments for R&amp;amp;D services in the transaction price when they are achieved. We include these milestone payments when they are achieved because there is considerable uncertainty in the research and development processes that trigger these payments. Similarly, we include approval milestone payments in the transaction price once the medicine is approved by the applicable regulatory agency. We will recognize sales-based milestone payments in the period in which we achieve the milestone under the sales-based royalty exception allowed under accounting rules.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We recognize milestone payments that relate to an ongoing performance obligation over our period of performance. For example, in the fourth quarter of 2019, we achieved two $7.5 million milestone payments from Biogen when we advanced two new targets for undisclosed neurological diseases under our 2018 strategic neurology collaboration. We added these payments to the transaction price and allocated it to our R&amp;amp;D services performance obligation. We are recognizing revenue related to these milestone payments over our estimated period of performance.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Conversely, we recognize in full those milestone payments that we earn based on our partners&#x2019; activities when our partner achieves the milestone event and we do not have a performance obligation. For example, in the fourth quarter of 2019, we recognized a $10 million milestone payment &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;when Biogen advanced the development candidate for an undisclosed target under our 2012 neurology collaboration agreement&lt;/span&gt;. &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We concluded that the milestone payment was not related to our R&amp;amp;D services performance obligation. Therefore, we recognized the milestone payment in full in the fourth quarter of 2019.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;span style="text-decoration: underline;"&gt;License fees&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We generally recognize as revenue the total amount we determine to be the relative stand-alone selling price of a license when we deliver the license to our partner. This is because our partner has full use of the license and we do not have any additional performance obligations related to the license after delivery. &lt;/span&gt;For example, in the fourth quarter of 2019, we earned a $45 million license fee when Biogen licensed IONIS-MAPT&lt;sub&gt;Rx&lt;/sub&gt; from us. We also recognized $246 million of license fee revenue related to Akcea&#x2019;s license of AKCEA-ANGPTL3-L&lt;sub&gt;Rx&lt;/sub&gt; to Pfizer in the fourth quarter of 2019.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;span style="text-decoration: underline;"&gt;Sublicense fees&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We recognize sublicense fee revenue in the period in which a party, who has already licensed our technology, further licenses the technology to another party because we do not have any performance obligations related to the sublicense. &lt;/span&gt;For example, in the second quarter of 2019, we earned a $20 million sublicense fee when Alnylam Pharmaceuticals sublicensed our technology to Regeneron Pharmaceuticals.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Amendments to Agreements&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;From time to time we amend our collaboration agreements. When this occurs, we are required to assess the following items to determine the accounting for the amendment:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z4d3009374a5e478e8122026b5e139b45" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;If the additional goods and/or services are distinct from the other performance obligations in the original agreement; and&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zf0f366c375b94c81a0b52ddbbfa1f51e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;If the goods and/or services are at a stand-alone selling price. &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;If we conclude the goods and/or services in the amendment are distinct from the performance obligations in the original agreement and at a stand-alone selling price, we account for the amendment as a separate agreement. If we conclude the goods and/or services are not distinct and at their stand-alone selling price, we then assess whether the remaining goods or services are distinct from those already provided. If the goods and/or services are distinct from what we have already provided, then we allocate the remaining transaction price from the original agreement and the additional transaction price from the amendment to the remaining goods and/or services. If the goods and/or services are not distinct from what we have already provided, we update the transaction price for our single performance obligation and recognize any change in our estimated revenue as a cumulative adjustment.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;For example, in May 2015, we entered into an exclusive license agreement with Bayer to develop and commercialize IONIS-FXI&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; for the prevention of thrombosis. As part of the agreement, Bayer paid us a $&lt;/span&gt;100&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million upfront payment. At the onset of the agreement, we were responsible for completing a Phase 2 study of IONIS-FXI&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; in people with end-stage renal disease on hemodialysis and for providing an initial supply of API. In February 2017, we amended our agreement with Bayer to advance IONIS-FXI&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; and to initiate development of IONIS-FXI-L&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;, which Bayer licensed. As part of the 2017 amendment, Bayer paid us $&lt;/span&gt;75&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million. We are also eligible to receive milestone payments and tiered royalties on gross margins of IONIS-FXI&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; and IONIS-FXI-L&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;. Under the 2017 amendment, we concluded we had a new agreement with &lt;/span&gt;three&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; performance obligations. These performance obligations were to deliver the license of IONIS-FXI-L&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;, to provide R&amp;amp;D services and to deliver API. We allocated the $&lt;/span&gt;75&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million transaction price to these performance obligations. &lt;/span&gt;Refer to &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Note 7, &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Collaborative Arrangements and Licensing Agreements&lt;/span&gt;, for further discussion &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;of our accounting treatment for our Bayer collaboration.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Multiple agreements&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;From time to time, we may enter into separate agreements at or near the same time with the same partner. We evaluate such agreements to determine whether we should account for them individually as distinct arrangements or whether the separate agreements should be combined and accounted for together. We evaluate the following to determine the accounting for the agreements:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z5a22915e59694cedaf8815e2feb45467" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Whether the agreements were negotiated together with a single objective;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z4c6b305fcd854a51950b2b0c8b9ff86f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Whether the amount of consideration in one contract depends on the price or performance of the other agreement; or&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z82b56ef158ea487c94fc2daddd0e9546" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Whether the goods and/or services promised under the agreements are a single performance obligation. &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our evaluation involves significant judgment to determine whether a group of agreements might be so closely related that accounting guidance requires us to account for them as a combined arrangement.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;For example, in the second quarter of 2018, we entered into two separate agreements with Biogen at the same time: a new strategic neurology collaboration agreement and a stock purchase agreement, or SPA. &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We evaluated the Biogen agreements to determine whether we should treat the agreements separately or combine them. We considered that the agreements were negotiated concurrently and in contemplation of one another. Based on these facts and circumstances, we concluded that we should evaluate the provisions of the agreements on a combined basis.&lt;/span&gt;&lt;/div&gt;
</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <ions:RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract
      contextRef="c20190101to20191231"
      decimals="INF"
      id="Fact_916eaa51598549fa924e925f66d1a329"
      unitRef="U005">1</ions:RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract>
    <ions:UpfrontPaymentReceived
      contextRef="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"
      decimals="-6"
      id="Fact_e7341a58c10044d89181f318ab768870"
      unitRef="U001">10000000</ions:UpfrontPaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190701to20190930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"
      decimals="-5"
      id="Fact_35fadf63788d44d1bb8722e81096991c"
      unitRef="U001">-16500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:UpfrontPaymentReceived
      contextRef="c20181001to20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember"
      decimals="-6"
      id="Fact_f3341a779cd4477b9ed549b3598e413c"
      unitRef="U001">75000000</ions:UpfrontPaymentReceived>
    <ions:UpfrontPaymentReceived
      contextRef="c20181001to20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember"
      decimals="-6"
      id="Fact_d7a5d9320f994613bb599013781aff1f"
      unitRef="U001">75000000</ions:UpfrontPaymentReceived>
    <ions:NumberOfMilestonePaymentsAchieved
      contextRef="c20170701to20170930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="INF"
      id="Fact_2f4c3cdec64d4ebab74fa61267369768"
      unitRef="U006">2</ions:NumberOfMilestonePaymentsAchieved>
    <ions:RevenueFromContractWithCustomerTransactionPriceAdditions
      contextRef="c20170701to20170930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="-5"
      id="Fact_67b6c98cd0b04a499399e7c1949be7e0"
      unitRef="U001">7500000</ions:RevenueFromContractWithCustomerTransactionPriceAdditions>
    <ions:NumberOfNewTargetsAdvanced
      contextRef="c20170701to20170930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="INF"
      id="Fact_b795fee01141433db219e12877341375"
      unitRef="U007">2</ions:NumberOfNewTargetsAdvanced>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"
      decimals="-6"
      id="Fact_dc0f5410578c4b3caf3ed28f1705b5dc"
      unitRef="U001">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20191001to20191231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"
      decimals="-6"
      id="Fact_10644c4cd74c4270aa654dc8e76ab934"
      unitRef="U001">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"
      decimals="-6"
      id="Fact_83765ee3444f4da28551fd1252bdbdff"
      unitRef="U001">246000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:UpfrontPaymentReceived
      contextRef="c20190401to20190630_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember"
      decimals="-6"
      id="Fact_3fe0a292e07f47b2a1337dab39a323b4"
      unitRef="U001">20000000</ions:UpfrontPaymentReceived>
    <ions:UpfrontPaymentReceived
      contextRef="c20150501to20150531_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember"
      decimals="-6"
      id="Fact_6ea18e5a463d43b3b68db4829c2434ab"
      unitRef="U001">100000000</ions:UpfrontPaymentReceived>
    <ions:UpfrontPaymentReceived
      contextRef="c20170201to20170228_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember"
      decimals="-6"
      id="Fact_b224b3d9e0104fcb9d25e5b648e59cd5"
      unitRef="U001">75000000</ions:UpfrontPaymentReceived>
    <ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
      contextRef="c20170228_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"
      decimals="INF"
      id="Fact_a813007ed00d44ddb1de4e340c0c1d20"
      unitRef="U005">3</ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c20170228_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember"
      decimals="-6"
      id="Fact_aee59b0b43254954a5491abf5bd715ef"
      unitRef="U001">75000000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <ions:NumberOfAgreementsWithCollaborationPartner
      contextRef="c20180401to20180630_MajorCustomersAxis_BiogenIncMember"
      decimals="INF"
      id="Fact_794974dbb1c34381ac6981b5758714d7"
      unitRef="U008">2</ions:NumberOfAgreementsWithCollaborationPartner>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="c20190101to20191231"
      id="Text_70a8fbc7cd8d478a96621d57f162a36c">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: -54pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Contracts Receivable&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: -18pt; margin-left: 54pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Our contracts receivable balance represents the amounts we have billed our partners or customers and that are due to us unconditionally for goods we have delivered or services we have performed. When we bill our partners or customers with payment terms based on the passage of time, we consider the contract receivable to be unconditional. We typically receive payment within one &lt;/span&gt;&lt;span style="-sec-ix-hidden:Fact_5acf7b3d4ee04d009d32a31d9e4ded77"&gt;quarter&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; of billing our partner or customer&lt;/span&gt;.&lt;/div&gt;
</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy
      contextRef="c20190101to20191231"
      id="Text_faac8b93fbf747a0b879d9b6b5712192">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -54pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Unbilled SPINRAZA Royalties&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 54pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our unbilled SPINRAZA royalties represent our right to receive consideration from Biogen in advance of when we are eligible to bill Biogen for SPINRAZA royalties. We include these unbilled amounts in other current assets on our consolidated balance sheet.&lt;/div&gt;
</us-gaap:TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="c20190101to20191231"
      id="Text_823cc816d6d44936960102525ecec2ea">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: -54pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Deferred Revenue&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We are often entitled to bill our customers and receive payment from our customers in advance of our obligation to provide services or transfer goods to our partners. In these instances, we include the amounts in deferred revenue on our consolidated balance sheet.&lt;/span&gt; During the years ended December 31, 2019 and 2018, we recognized $159.5 million and $105.3 million of revenue from amounts that were in our beginning deferred revenue balance for each respective period. For further discussion, refer to our revenue recognition policy above.&lt;/div&gt;
</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="c20190101to20191231"
      decimals="-5"
      id="Fact_7a9ec3bea8ad464ca6e12c6aa16435cd"
      unitRef="U001">159500000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="c20180101to20181231"
      decimals="-5"
      id="Fact_ced6b030f6d146bb91eabbce81e6f413"
      unitRef="U001">105300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="c20190101to20191231"
      id="Text_254afeb786aa436f810cc6424e22ff9f">
&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Cost of Products Sold&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our cost of products sold includes manufacturing costs, transportation and freight costs and indirect overhead costs associated with the manufacturing and distribution of our products. We also may include certain period costs related to manufacturing services and inventory adjustments in cost of products sold. Prior to obtaining regulatory approval of TEGSEDI in July 2018 and WAYLIVRA in May 2019, we expensed as research and development expenses a significant portion of the costs we incurred to produce the initial commercial launch supply for each medicine. &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We previously expensed $&lt;/span&gt;0.7&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million and $&lt;/span&gt;0.1&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million of costs to produce our products related to the product sales revenue we recognized in 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;
</us-gaap:CostOfSalesPolicyTextBlock>
    <ions:CostOfProductsSoldPreviouslyRecognized
      contextRef="c20190101to20191231"
      decimals="-5"
      id="Fact_0bfe661a777b42c0be8e4a6111928739"
      unitRef="U001">700000</ions:CostOfProductsSoldPreviouslyRecognized>
    <ions:CostOfProductsSoldPreviouslyRecognized
      contextRef="c20180101to20181231"
      decimals="-5"
      id="Fact_6fbce6aca9464ccb92df280b96eebb3c"
      unitRef="U001">100000</ions:CostOfProductsSoldPreviouslyRecognized>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="c20190101to20191231"
      id="Text_28c5a2071783403e9a962d2e005cb136">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our research and development expenses include wages, benefits, facilities, supplies, external services, clinical trial and manufacturing costs and other expenses that are directly related to our research and development operations. We expense research and development costs as we incur them. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. For the years ended December 31, 2019, 2018 and 2017, research and development expenses were $461.5 million, $411.9 million and $372.5 million, respectively. A portion of the costs included in research and development expenses are costs associated with our partner agreements. For the years ended December 31, 2019, 2018 and 2017, research and development costs of approximately $83.2 million, $58.7 million and $59.5 million, respectively, were related to our partner agreements.&lt;/div&gt;
</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20190101to20191231"
      decimals="-5"
      id="Fact_d0c1565159a044b595630e050bb43a4e"
      unitRef="U001">461500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20180101to20181231"
      decimals="-5"
      id="Fact_0114d1a3cfd445bbb2a6b5bc9fba079f"
      unitRef="U001">411900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20170101to20171231"
      decimals="-5"
      id="Fact_203e9d3fa0b14eca9d0edbb437f4f325"
      unitRef="U001">372500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsMember"
      decimals="-5"
      id="Fact_802d7e1d88dd4400b573e6ee2246659a"
      unitRef="U001">83200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20180101to20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsMember"
      decimals="-5"
      id="Fact_216c3f8ce5e44d2c80d7b536e2b7febb"
      unitRef="U001">58700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20170101to20171231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsMember"
      decimals="-5"
      id="Fact_f19630c62fc04ac590d8f34e449d0135"
      unitRef="U001">59500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy
      contextRef="c20190101to20191231"
      id="Text_3d51b0b184354eea966e871ef92d8650">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We capitalize costs consisting principally of outside legal costs and filing fees related to obtaining patents. We amortize patent costs over the useful life of the patent, beginning with the date the U.S. Patent and Trademark Office, or foreign equivalent, issues the patent. The weighted average remaining amortizable life of our issued patents was 10.3 years at December 31, 2019.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The cost of our patents capitalized on our consolidated balance sheet at December 31, 2019 and 2018 was $34.0 million and $32.7 million, respectively. Accumulated amortization related to patents was $8.3 million and $8.7 million at December 31, 2019 and 2018, respectively.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Based on our existing patents, we estimate amortization expense related to patents in each of the next five years to be the following:&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z3b4746089ec94fcf825148a7e478c941" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ending December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amortization&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in millions)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2020&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2021&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2022&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2023&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2024&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We review our capitalized patent costs regularly to ensure that they include costs for patents and patent applications that have future value. When we identify patents and patent applications that we are not actively pursuing, we write off any associated costs. In 2019, 2018 and 2017, patent expenses were $4.2 million, $2.6 million and $2.1 million, respectively, and included non-cash charges related to the write-down of our patent costs to their estimated net realizable values of $2.2 million, $0.8 million and $0.4 million, respectively.&lt;/div&gt;
</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="c20190101to20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember"
      id="Fact_0743de364414479fa413c5d659ce3213">P10Y3M18D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember"
      decimals="-5"
      id="Fact_df1e6fe595054242bd56601d34e950e2"
      unitRef="U001">34000000.0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20181231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember"
      decimals="-5"
      id="Fact_421e79a98335467eb99a9cba6857377d"
      unitRef="U001">32700000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember"
      decimals="-5"
      id="Fact_414dd9c96ebb45a28f493a17da9dec2e"
      unitRef="U001">8300000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20181231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember"
      decimals="-5"
      id="Fact_91380e7cfc944a1e8053aef43d6d897f"
      unitRef="U001">8700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_369ccc0519494b209f2f7c69b835cf77">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Based on our existing patents, we estimate amortization expense related to patents in each of the next five years to be the following:&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z3b4746089ec94fcf825148a7e478c941" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ending December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amortization&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in millions)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2020&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2021&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2022&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2023&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2024&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="c20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember"
      decimals="-5"
      id="Fact_8b4595506d5b46448ab97fdee1240d0f"
      unitRef="U001">1800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="c20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember"
      decimals="-5"
      id="Fact_e44494ea589f4fd6bf584443ca16bfcc"
      unitRef="U001">1800000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="c20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember"
      decimals="-5"
      id="Fact_5f35096f0bcf43fb92b147de0bf72462"
      unitRef="U001">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="c20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember"
      decimals="-5"
      id="Fact_7b3245e6bc5b4426819c1fb6dc13148c"
      unitRef="U001">1600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="c20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember"
      decimals="-5"
      id="Fact_f6ccdf05d6a5463584227257d28f4a82"
      unitRef="U001">1400000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <ions:PatentExpenses
      contextRef="c20190101to20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember"
      decimals="-5"
      id="Fact_57ea08b5d1894948b17ad9f00140ea03"
      unitRef="U001">4200000</ions:PatentExpenses>
    <ions:PatentExpenses
      contextRef="c20180101to20181231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember"
      decimals="-5"
      id="Fact_9907ec92e4dd4419b5a9f4fb46f56330"
      unitRef="U001">2600000</ions:PatentExpenses>
    <ions:PatentExpenses
      contextRef="c20170101to20171231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember"
      decimals="-5"
      id="Fact_3201b72effcf4c0c8e0d51523e32d64f"
      unitRef="U001">2100000</ions:PatentExpenses>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="c20190101to20191231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember"
      decimals="-5"
      id="Fact_acdbb50a6f92446b87e379e817f900c3"
      unitRef="U001">2200000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="c20180101to20181231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember"
      decimals="-5"
      id="Fact_3029299725d54805be6165d35d2050b9"
      unitRef="U001">800000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="c20170101to20171231_FiniteLivedIntangibleAssetsByMajorClassAxis_PatentsMember"
      decimals="-5"
      id="Fact_1057b62f0867480b862004e4e8b9e9ed"
      unitRef="U001">400000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_87bf2c631a3c4ead881ada96127f2237">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our accrued liabilities consisted of the following (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z3a44c21e41964165973dff87ef753698" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Clinical expenses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;24,461&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;22,125&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -18pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In-licensing expenses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10,289&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;12,298&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -18pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Other miscellaneous expenses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;32,019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;13,080&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total accrued liabilities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;66,769&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;47,503&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <ions:AccruedClinicalExpenses
      contextRef="c20191231"
      decimals="-3"
      id="Fact_dd19e9b42ea648b5a66ad1c40729f204"
      unitRef="U001">24461000</ions:AccruedClinicalExpenses>
    <ions:AccruedClinicalExpenses
      contextRef="c20181231"
      decimals="-3"
      id="Fact_fac7f03b039f4f02a05228c036fc1f3c"
      unitRef="U001">22125000</ions:AccruedClinicalExpenses>
    <ions:AccruedInLicensingFeesCurrent
      contextRef="c20191231"
      decimals="-3"
      id="Fact_4a54e14632b04a9cb08ecbd7c4f7b264"
      unitRef="U001">10289000</ions:AccruedInLicensingFeesCurrent>
    <ions:AccruedInLicensingFeesCurrent
      contextRef="c20181231"
      decimals="-3"
      id="Fact_a1182bff6aa841d1b17861b49376378a"
      unitRef="U001">12298000</ions:AccruedInLicensingFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c20191231"
      decimals="-3"
      id="Fact_962c481f08204a1f938ac3ce6088c025"
      unitRef="U001">32019000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c20181231"
      decimals="-3"
      id="Fact_558a2514ca9d46d38ef6431a99ec3875"
      unitRef="U001">13080000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20191231"
      decimals="-3"
      id="Fact_d3d4336195b54976b7bcea8d3b30b7ac"
      unitRef="U001">66769000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c20181231"
      decimals="-3"
      id="Fact_e91e73e81dd74acab89c06a66144eab3"
      unitRef="U001">47503000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy
      contextRef="c20190101to20191231"
      id="Text_ece58b8638f04f80b592393388f33955">
&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Noncontrolling Interest in Akcea Therapeutics, Inc.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Prior to Akcea&#x2019;s IPO in July 2017, we owned 100 percent of Akcea. &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Since Akcea&#x2019;s IPO, our ownership has ranged from &lt;/span&gt;68 percent&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; to &lt;/span&gt;77 percent&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;. At December 31, &lt;/span&gt;2019&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;, o&lt;/span&gt;ur ownership was approximately 76 percent. We reflect changes in our ownership percentage in our financial statements as an adjustment to noncontrolling interest in the period the change occurs. During 2019, we received the following additional shares of Akcea common stock:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 54pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zb8e73bce7e5949779fde18c99941a249" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.8 million shares in the first quarter of 2019 as payment for the sublicense fee Akcea owed us for Novartis&#x2019;s license of AKCEA-APO(a)-L&lt;sub&gt;Rx&lt;/sub&gt;, and;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zb8be43d6e4c14352bda3fb7b936ad303" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.9 million shares in the fourth quarter of 2019 as payment for the sublicense fee Akcea owed us for Pfizer&#x2019;s license of AKCEA-ANGPTL3-L&lt;sub&gt;Rx&lt;/sub&gt;.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The shares third parties own represent an interest in Akcea&#x2019;s equity that we do control. However, as we continue to maintain overall control of Akcea through our voting interest, we reflect the assets, liabilities and results of operations of Akcea in our consolidated financial statements. We reflect the noncontrolling interest attributable to other owners of Akcea&#x2019;s common stock in a separate line on the statement of operations and a separate line within stockholders&#x2019; equity in our consolidated balance sheet. In addition, we record a noncontrolling interest adjustment to account for the stock options Akcea grants, which if exercised, will dilute our ownership in Akcea. This adjustment is a reclassification within stockholders&#x2019; equity from additional paid-in capital to noncontrolling interest in Akcea equal to the amount of stock-based compensation expense Akcea had recognized.&lt;/div&gt;
</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c20170630_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="2"
      id="Fact_769029e542944bf999e422df3b90efc5"
      unitRef="U003">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c20191231_OwnershipAxis_AkceaTherapeuticsIncMember_RangeAxis_MinimumMember"
      decimals="2"
      id="Fact_58b26cdf07c24edeadfa19650b871e33"
      unitRef="U003">0.68</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c20191231_OwnershipAxis_AkceaTherapeuticsIncMember_RangeAxis_MaximumMember"
      decimals="2"
      id="Fact_77ecfee62c304b829d327b3441b4f57e"
      unitRef="U003">0.77</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c20191231_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="2"
      id="Fact_6b6bb01bbc794527a344f19aa39625a5"
      unitRef="U003">0.76</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ions:SharesReceivedFromSubsidiaryForLicenseOfDrug
      contextRef="c20190101to20190331"
      decimals="-5"
      id="Fact_5c33394e61a94d3aa8de15383f87fe0d"
      unitRef="U002">2800000</ions:SharesReceivedFromSubsidiaryForLicenseOfDrug>
    <ions:SharesReceivedFromSubsidiaryForLicenseOfDrug
      contextRef="c20191001to20191231"
      decimals="-5"
      id="Fact_55cba755dbc541409905ee410a39c915"
      unitRef="U002">6900000</ions:SharesReceivedFromSubsidiaryForLicenseOfDrug>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="c20190101to20191231"
      id="Text_f2cb3c34c3c943679b79190d82dff1f7">
&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Concentration of Credit Risk&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash equivalents, short-term investments and receivables. We place our cash equivalents and short-term investments with reputable financial institutions. We primarily invest our excess cash in commercial paper and debt instruments of the U.S. Treasury, financial institutions, corporations, and U.S. government agencies with strong credit ratings and an investment grade rating at or above A-1, P-1 or F-1 by Moody&#x2019;s, Standard &amp;amp; Poor&#x2019;s, or S&amp;amp;P, or Fitch, respectively. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. We periodically review and modify these guidelines to maximize trends in yields and interest rates without compromising safety and liquidity.&lt;/div&gt;
</us-gaap:ConcentrationRiskCreditRisk>
    <ions:CashCashEquivalentsAndInvestmentsPolicyTextBlock
      contextRef="c20190101to20191231"
      id="Text_b61476ba09e2462e89e8f87c1ed0938a">
&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Cash, Cash Equivalents and Investments&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We consider all liquid investments with maturities of three months or less when we purchase them to be cash equivalents. Our short-term investments have initial maturities of greater than three months from date of purchase. We classify our short-term debt investments as &#x201c;available-for-sale&#x201d; and carry them at fair market value based upon prices on the last day of the fiscal period for identical or similar items. We record unrealized gains and losses on debt securities as a separate component of comprehensive income (loss) and include net realized gains and losses in gain (loss) on investments. We use the specific identification method to determine the cost of securities sold.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We also have equity investments of less than 20 percent ownership in publicly and privately held biotechnology companies that we received as part of a technology license or partner agreement. At December 31, 2019, we held equity investments in two publicly held companies, ProQR Therapeutics N.V., or ProQR, and Antisense Therapeutics Limited, or ATL. We also held equity investments in five privately-held companies, Atlantic Pharmaceuticals Limited, Dynacure SAS, Empirico, Inc., Seventh Sense Biosystems and Suzhou Ribo Life Science Co, Ltd.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In January 2018, we adopted the amended accounting guidance related to the recognition, measurement, presentation, and disclosure of certain financial instruments. The amended guidance requires us to measure and record our equity investments at fair value. Additionally, the amended accounting guidance requires us to recognize the changes in fair value in our consolidated statement of operations, instead of through accumulated other comprehensive income. Prior to 2018, we accounted for our equity investments in privately held companies under the cost method of accounting. Under the amended guidance we account for our equity investments in privately held companies at their cost minus impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. Our adoption of this guidance did not have an impact on our results.&lt;/div&gt;
</ions:CashCashEquivalentsAndInvestmentsPolicyTextBlock>
    <ions:NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment
      contextRef="c20191231"
      decimals="INF"
      id="Fact_b448547c88c7434cbc329f97a4b3ea28"
      unitRef="U009">2</ions:NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment>
    <ions:NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment
      contextRef="c20191231"
      decimals="INF"
      id="Fact_5091e6339b9e4e85943dd42b9d332383"
      unitRef="U009">5</ions:NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="c20190101to20191231"
      id="Text_7e9cc48265cd42a19ccef33d81370017">
&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Inventory Valuation&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We reflect our inventory on our consolidated balance sheet at the lower of cost or market value under the first-in, first-out method, or FIFO. We capitalize the costs of raw materials that we purchase for use in producing our medicines because until we use these raw materials, they have alternative future uses, which we refer to as clinical raw materials. We include in inventory raw material costs for medicines that we manufacture for our partners under contractual terms and that we use primarily in our clinical development activities and drug products. We can use each of our raw materials in multiple products and, as a result, each raw material has future economic value independent of the development status of any single medicine. For example, if one of our medicines failed, we could use the raw materials for that medicine to manufacture our other medicines. We expense these costs as R&amp;amp;D expenses when we begin to manufacture API for a particular medicine if the medicine has not been approved for marketing by a regulatory agency.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We obtained the first regulatory approval for TEGSEDI in July 2018 and for WAYLIVRA in May 2019. At December 31, 2019, our physical inventory for TEGSEDI and WAYLIVRA included API that we produced prior to when we obtained regulatory approval. As such, this API has no cost basis as we had previously expensed the costs as R&amp;amp;D expenses.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We review our inventory periodically and reduce the carrying value of items we consider to be slow moving or obsolete to their estimated net realizable value based on forecasted demand compared to quantities on hand. We consider several factors in estimating the net realizable value, including shelf life of our inventory, alternative uses for our medicines in development and historical write-offs. We recorded an &lt;span style="-sec-ix-hidden:Fact_1261d93c836d4d94bba4bd8c45f1e569"&gt;insignificant&lt;/span&gt; amount of inventory write-offs during the year ended December 31, 2019. We did not record any inventory write-offs for the years ended December 31, 2018 or 2017.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our inventory consisted of the following (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z1ee494cca3ec409c868c744c6428df49" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Raw materials:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 19.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Raw materials- clinical&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;9,363&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;8,497&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 28.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Raw materials- commercial&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6,520&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 28.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total raw materials&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;15,883&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;8,497&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Work in process&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,039&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Finished goods&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;258&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;85&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; margin-left: 28.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total inventory&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18,180&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;8,582&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryWriteDown
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_2004f9d82c16414ba69bf4dd2f384800"
      unitRef="U001">0</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_e7c66e14d5e9439da7f69eb299318ade"
      unitRef="U001">0</us-gaap:InventoryWriteDown>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_5fd58eb42e4748f1b0cb4bfcfebadc48">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our inventory consisted of the following (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z1ee494cca3ec409c868c744c6428df49" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Raw materials:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 19.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Raw materials- clinical&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;9,363&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;8,497&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 28.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Raw materials- commercial&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6,520&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 28.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total raw materials&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;15,883&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;8,497&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Work in process&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,039&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Finished goods&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;258&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;85&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; margin-left: 28.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total inventory&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18,180&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;8,582&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="c20191231_PublicUtilitiesInventoryAxis_ClinicalRawMaterialsMember"
      decimals="-3"
      id="Fact_607597dd540146e09e590486dfbfd332"
      unitRef="U001">9363000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="c20181231_PublicUtilitiesInventoryAxis_ClinicalRawMaterialsMember"
      decimals="-3"
      id="Fact_7cb2d5b100c4460fa603ceb958dfa363"
      unitRef="U001">8497000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="c20191231_PublicUtilitiesInventoryAxis_CommercialRawMaterialsMember"
      decimals="-3"
      id="Fact_7ce8ae9ab80f4c6b893833f04a2e1b3a"
      unitRef="U001">6520000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="c20181231_PublicUtilitiesInventoryAxis_CommercialRawMaterialsMember"
      decimals="-3"
      id="Fact_de29fe59994e4eedaaf0e505fe2fa8ce"
      unitRef="U001">0</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="c20191231"
      decimals="-3"
      id="Fact_128d62d036e2429290b412a68bb359e3"
      unitRef="U001">15883000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="c20181231"
      decimals="-3"
      id="Fact_2a47aa942a2943ed97036570c8b25890"
      unitRef="U001">8497000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="c20191231"
      decimals="-3"
      id="Fact_85d7f4970a574d26939ed8575266e7f1"
      unitRef="U001">2039000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="c20181231"
      decimals="-3"
      id="Fact_84044948dea84b95bf0906aa87b24ba3"
      unitRef="U001">0</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="c20191231"
      decimals="-3"
      id="Fact_e5ad76dbdb1441b68871a7035a59c0b3"
      unitRef="U001">258000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="c20181231"
      decimals="-3"
      id="Fact_518f7488f3314fafb99fe4a5c96254f0"
      unitRef="U001">85000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="c20191231"
      decimals="-3"
      id="Fact_ed1f9a6ae98d4c7cba25f90cb15577f3"
      unitRef="U001">18180000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="c20181231"
      decimals="-3"
      id="Fact_d2b4370b0072452b9c9faa8459b51794"
      unitRef="U001">8582000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="c20190101to20191231"
      id="Text_3ca961ffb1204250b6e485d9fbf46b51">
&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Property, Plant and Equipment&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We carry our property, plant and equipment at cost and depreciate it on the straight-line method over its estimated useful life, which consists of the following (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z6b8fa4917b344088b2fa85d6aab08f8c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Estimated Useful Lives&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in years)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Computer software, laboratory, manufacturing and other equipment&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3 to 10&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;60,965&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;53,496&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Building, building improvements and building systems&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;15 to 40&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;119,830&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;97,528&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Land improvements&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;20&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,853&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,853&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;5 to 15&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;13,600&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18,981&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;5 to 10&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;7,354&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6,283&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;204,602&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;179,141&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Less accumulated depreciation&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(74,013&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(61,474&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;130,589&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;117,667&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Land&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;23,062&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;14,493&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;153,651&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;132,160&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We depreciate our leasehold improvements using the shorter of the estimated useful life or remaining lease term.&lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="c20190101to20191231"
      id="Text_ec7145f67b8740268c4191ee25a68742">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We carry our property, plant and equipment at cost and depreciate it on the straight-line method over its estimated useful life, which consists of the following (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z6b8fa4917b344088b2fa85d6aab08f8c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Estimated Useful Lives&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(in years)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Computer software, laboratory, manufacturing and other equipment&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3 to 10&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;60,965&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;53,496&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Building, building improvements and building systems&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;15 to 40&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;119,830&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;97,528&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Land improvements&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;20&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,853&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,853&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;5 to 15&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;13,600&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18,981&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;5 to 10&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;7,354&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6,283&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;204,602&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;179,141&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Less accumulated depreciation&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(74,013&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(61,474&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;130,589&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;117,667&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Land&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;23,062&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;14,493&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#160;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;153,651&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;132,160&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndComputerSoftwareMember_RangeAxis_MinimumMember"
      id="Fact_bee2828c703f419991ca5e4f981c6bfb">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndComputerSoftwareMember_RangeAxis_MaximumMember"
      id="Fact_5570d89b49ca4d3bbc122f34e561c666">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20191231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndComputerSoftwareMember"
      decimals="-3"
      id="Fact_a358b86f59e5426781124e8c9288e3bd"
      unitRef="U001">60965000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20181231_PropertyPlantAndEquipmentByTypeAxis_EquipmentAndComputerSoftwareMember"
      decimals="-3"
      id="Fact_32583aa3a38b4549871afd68f63cda1e"
      unitRef="U001">53496000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember_RangeAxis_MinimumMember"
      id="Fact_af3476af11bf463db8625923d46c44ce">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember_RangeAxis_MaximumMember"
      id="Fact_86510f26269445ae8f1cd2bd97d35737">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20191231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember"
      decimals="-3"
      id="Fact_36283464a0474949b8398ef74fa87f78"
      unitRef="U001">119830000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20181231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember"
      decimals="-3"
      id="Fact_babb21fe699d4456ba2a90a494e8f764"
      unitRef="U001">97528000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_LandImprovementsMember"
      id="Fact_c74c578c9a114415ba62e9a933b22bc1">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20191231_PropertyPlantAndEquipmentByTypeAxis_LandImprovementsMember"
      decimals="-3"
      id="Fact_56a2f9f0147240f0bd015bba6bf7acb2"
      unitRef="U001">2853000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20181231_PropertyPlantAndEquipmentByTypeAxis_LandImprovementsMember"
      decimals="-3"
      id="Fact_48464f6662f34caab0d0adfeb2d1483a"
      unitRef="U001">2853000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember_RangeAxis_MinimumMember"
      id="Fact_8e57e819a7024b98844132cc9cdf317f">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember_RangeAxis_MaximumMember"
      id="Fact_09061fd932d049ef9bf84842b438b1c8">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20191231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact_9274143ded5b4f0ba33136edf1a5c107"
      unitRef="U001">13600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20181231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact_a69d39db65ac49c7a52d11122d390f52"
      unitRef="U001">18981000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember_RangeAxis_MinimumMember"
      id="Fact_c9e81d98bca94d41b8a299e5e0e5d8a8">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember_RangeAxis_MaximumMember"
      id="Fact_4ace8e2987224a629f4296698241a73c">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20191231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      decimals="-3"
      id="Fact_4cc9147a7cbc4ee49795347f0fb5a079"
      unitRef="U001">7354000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20181231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      decimals="-3"
      id="Fact_94b40916e0474421a05f751c4a6948c3"
      unitRef="U001">6283000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20191231_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentExcludingLandMember"
      decimals="-3"
      id="Fact_e24786e819c34f2797962439fcf6ce74"
      unitRef="U001">204602000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20181231_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentExcludingLandMember"
      decimals="-3"
      id="Fact_191a9c51a9564c86b6ddbb7016ec7e8d"
      unitRef="U001">179141000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c20191231"
      decimals="-3"
      id="Fact_c8c6a3d838c64434aeb0fd3c8a6f6727"
      unitRef="U001">74013000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c20181231"
      decimals="-3"
      id="Fact_35a3e65d6be441349ebb2cee7ffa8cd5"
      unitRef="U001">61474000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20191231_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentExcludingLandMember"
      decimals="-3"
      id="Fact_b19aa12690254ebfbb74e114f415ba73"
      unitRef="U001">130589000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20181231_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentExcludingLandMember"
      decimals="-3"
      id="Fact_43f79740c06f430d802eb80d4aee36c7"
      unitRef="U001">117667000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20191231_PropertyPlantAndEquipmentByTypeAxis_LandMember"
      decimals="-3"
      id="Fact_34379c34064b4008bd443f086b5b56d2"
      unitRef="U001">23062000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20181231_PropertyPlantAndEquipmentByTypeAxis_LandMember"
      decimals="-3"
      id="Fact_640721fc5bba475f8612db62b456d80b"
      unitRef="U001">14493000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20191231"
      decimals="-3"
      id="Fact_845ce990f2174f7bafb81c35eb3d8604"
      unitRef="U001">153651000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20181231"
      decimals="-3"
      id="Fact_c1ac0d6f145b41659e8c734c98f6f1c8"
      unitRef="U001">132160000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="c20190101to20191231"
      id="Text_c824b2789e934753b736b5a6841fbd43">
&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fair Value of Financial Instruments&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We have estimated the fair value of our financial instruments. The amounts reported for cash, accounts receivable, accounts payable and accrued expenses approximate the fair value because of their short maturities. We report our investment securities at their estimated fair value based on quoted market prices for identical or similar instruments.&lt;/div&gt;
</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="c20190101to20191231"
      id="Text_ae074b5998d54afa844354162eb3317e">
&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Leases&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Topic 842 Adoption&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In February 2016, the Financial Accounting Standards Board, or FASB, issued amended accounting guidance related to lease accounting. This guidance supersedes the lease requirements we previously followed in Accounting Standards Codification, or ASC, Topic 840, &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Leases&lt;/span&gt;, or Topic 840, and created a new lease accounting standard, Topic 842, &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Leases&lt;/span&gt;, or Topic 842. Under Topic 842, an entity will record on its balance sheet all leases with a term longer than one year. Further, an entity will record a liability with a value equal to the present value of payments it will make over the life of the lease (lease liability) and an asset representing the underlying leased asset (right-of-use asset). The new accounting guidance requires entities to determine if its leases are operating or financing leases. Entities will recognize expense for operating leases on a straight-line basis as an operating expense. If an entity determines a lease is a financing lease, it will record both interest and amortization expense and generally the expense will be higher in the earlier periods of the lease. We adopted Topic 842 on January 1, 2019 and adjusted our opening balance sheet on that date for our right-of-use operating lease assets and operating lease liabilities. At adoption, we recorded $13.5 million in right-of-use operating lease assets and $18.5 million in operating lease liabilities, of which we classified $2 million as a current liability. We adopted Topic 842 using the available practical expedients&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; permitted under the transition guidance within the new standard, which among other things, allowed us to carry forward the historical lease classification of those leases we had in place as of January 1, 2019. &lt;/span&gt;The adoption did not have an impact on our consolidated statement of operations.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Leases&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We determine if an arrangement contains a lease at inception. We currently only have operating leases. We recognize a right-of-use operating lease asset and associated short- and long-term operating lease liability on our consolidated balance sheet for operating leases greater than one year. Our right-of-use assets represent our right to use an underlying asset for the lease term and our lease liabilities represent our obligation to make lease payments arising from the lease arrangement. We recognize our right-of-use operating lease assets and lease liabilities based on the present value of the future minimum lease payments we will pay over the lease term.&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;&#160;&lt;/span&gt;We determined the lease term at the inception of the lease, and in certain cases our lease term could include renewal options if we concluded we were reasonably certain that we will exercise the renewal option.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;As our current leases do not provide an interest rate implicit in the lease, we used our or Akcea&#x2019;s incremental borrowing rate, based on the information available on the date we adopted Topic 842 or as of the lease inception date in determining the present value of future payments. Our right-of-use operating lease asset also includes any lease payments we made and excludes any tenant improvement allowances we received. We recognize rent expense for our minimum lease payments on a straight-line basis over the expected term of our lease. We recognize period expenses, such as common area maintenance expenses, in the period we incur the expense.&lt;/div&gt;
</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20181231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201602Member"
      decimals="-5"
      id="Fact_791b97c772ad4257ae769911c654eae9"
      unitRef="U001">13500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="c20181231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201602Member"
      decimals="-5"
      id="Fact_dafb303ce0f34188b19899dba00a8508"
      unitRef="U001">18500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20181231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201602Member"
      decimals="-6"
      id="Fact_cfa70eddbff644b78e96e7f036178408"
      unitRef="U001">2000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="c20190101to20191231"
      id="Text_ccc9e6e3414f4ec8a6fb102c6bd6da0b">
&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Long-Lived Assets&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We evaluate long-lived assets, which include property, plant and equipment and patent costs, for impairment on at least a quarterly basis and whenever events or changes in circumstances indicate that we may not be able to recover the carrying amount of such assets. We recorded charges of $2.2 million, $0.8 million and $0.8 million for the years ended December 31, 2019, 2018 and 2017, respectively, related primarily to the write-down of intangible assets.&lt;/div&gt;
</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="c20190101to20191231"
      decimals="-5"
      id="Fact_1f00325938654d8aaa92961967dd4fe1"
      unitRef="U001">2200000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="c20180101to20181231"
      decimals="-5"
      id="Fact_d4bb9e72c83944a891eb6db91aae4474"
      unitRef="U001">800000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="c20170101to20171231"
      decimals="-5"
      id="Fact_42a5e2e524a746bebd539b59be5602e1"
      unitRef="U001">800000</us-gaap:AssetImpairmentCharges>
    <us-gaap:UseOfEstimates
      contextRef="c20190101to20191231"
      id="Text_fa52b57cc0c34e458f80bc4eb239131d">
&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Use of Estimates&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.&lt;/div&gt;
</us-gaap:UseOfEstimates>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="c20190101to20191231"
      id="Text_ea6ca4b7f7044d6782f4b675d057249a">
&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Stock-Based Compensation Expense&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We measure stock-based compensation expense for equity-classified awards, principally related to stock options, restricted stock units, or RSUs, and stock purchase rights under our ESPP based on the estimated fair value of the award on the date of grant. We recognize the value of the portion of the award that we ultimately expect to vest as stock-based compensation expense over the requisite service period in our consolidated statements of operations. We reduce stock-based compensation expense for estimated forfeitures at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We use the Black-Scholes model to estimate the fair value of stock options granted and stock purchase rights under our ESPP. On the grant date, we use our stock price and assumptions regarding a number of variables to determine the estimated fair value of stock-based payment awards. These variables include, but are not limited to, our expected stock price volatility over the term of the awards, and actual and projected employee stock option exercise behaviors.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We recognize compensation expense for option awards and RSUs using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award were in substance multiple awards, which results in the expense being front-loaded over the vesting period.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The fair value of RSUs is based on the market price of our common stock on the date of grant. The RSUs we have granted vest annually over a four-year period.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;See Note 4, &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Stockholders&#x2019; Equity,&lt;/span&gt; for additional information regarding our stock-based compensation plans.&lt;/div&gt;
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      id="Fact_9c07a9a996a942cfa5196c4e73d65a5f">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:StockholdersEquityPolicyTextBlock
      contextRef="c20190101to20191231"
      id="Text_d27c5c60b02f4df9826e0031d2963802">
&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Accumulated Other Comprehensive Loss&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Accumulated other comprehensive loss is primarily comprised of unrealized gains and losses on investments, net of taxes and adjustments we made to reclassify realized gains and losses on investments from other accumulated comprehensive loss to our Consolidated Statement of Operations. The following table summarizes changes in accumulated other comprehensive loss for the years ended December 31, &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;2019&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;, &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;2018&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; and &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;2017&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zf8dcaf0ca45440bba49fa3a29bc22bb5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Beginning balance accumulated other comprehensive loss&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(32,016&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(31,759&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(30,358&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Unrealized gains (losses) on securities, net of tax (1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6,633&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(280&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(960&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(374&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Currency translation adjustment&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;93&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;23&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(67&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net other comprehensive loss for the period&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6,726&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(257&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,401&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ending balance accumulated other comprehensive loss&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(25,290&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(32,016&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(31,759&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z11d622af5d604f70bd2be3051942ec9a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;A tax benefit of $1.4 million and $0.3 million was included in other comprehensive loss for the years ended December 31, 2019 and 2018, respectively. There was no tax benefit or expense for other comprehensive loss for the year ended December 31, 2017.&#160;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_d8df1a2b2dc24317bc8c70d8750aae0c">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Accumulated other comprehensive loss is primarily comprised of unrealized gains and losses on investments, net of taxes and adjustments we made to reclassify realized gains and losses on investments from other accumulated comprehensive loss to our Consolidated Statement of Operations. The following table summarizes changes in accumulated other comprehensive loss for the years ended December 31, &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;2019&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;, &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;2018&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; and &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;2017&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; (in thousands):&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zf8dcaf0ca45440bba49fa3a29bc22bb5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Beginning balance accumulated other comprehensive loss&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(32,016&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(31,759&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(30,358&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Unrealized gains (losses) on securities, net of tax (1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6,633&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(280&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(960&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(374&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Currency translation adjustment&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;93&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;23&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(67&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net other comprehensive loss for the period&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6,726&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(257&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,401&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ending balance accumulated other comprehensive loss&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(25,290&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(32,016&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(31,759&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z11d622af5d604f70bd2be3051942ec9a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;A tax benefit of $1.4 million and $0.3 million was included in other comprehensive loss for the years ended December 31, 2019 and 2018, respectively. There was no tax benefit or expense for other comprehensive loss for the year ended December 31, 2017.&#160;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20181231_StatementEquityComponentsAxis_AociIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-3"
      id="Fact_6f30e6b32fc54ac29484f539ce291bdb"
      unitRef="U001">-32016000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20171231_StatementEquityComponentsAxis_AociIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-3"
      id="Fact_19707e9f0bad40fbb1dba6349904c9f1"
      unitRef="U001">-31759000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20161231_StatementEquityComponentsAxis_AociIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-3"
      id="Fact_1a98a410f1db4d8f8fc817d58996446f"
      unitRef="U001">-30358000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-3"
      id="Fact_cc2b624b002347aca5b376689005c704"
      unitRef="U001">6633000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-3"
      id="Fact_f4bc7becd02b4abe8419122ceb5ec217"
      unitRef="U001">-280000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-3"
      id="Fact_8f26788799e14b9bb1344435140f818a"
      unitRef="U001">-960000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-3"
      id="Fact_0b7e13fbfd214cd4a51d0949e3a3d4e3"
      unitRef="U001">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-3"
      id="Fact_a8d24fdb304f411ebbfbd80312597613"
      unitRef="U001">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-3"
      id="Fact_3e832d296129439b9c7c04d0ac7ce585"
      unitRef="U001">374000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="c20190101to20191231_StatementEquityComponentsAxis_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-3"
      id="Fact_0a2161241cf748ad98c7b5a37ef210e4"
      unitRef="U001">93000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="c20180101to20181231_StatementEquityComponentsAxis_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-3"
      id="Fact_ad85fd5199354df78b105b0532f640eb"
      unitRef="U001">23000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="c20170101to20171231_StatementEquityComponentsAxis_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-3"
      id="Fact_2cf95908fea8415aa5b562ff94646094"
      unitRef="U001">-67000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_2ce128cedcb64e06a3c8d4d1586e4c6e"
      unitRef="U001">6726000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_a2223b8bb7e44f6f89e44f7a99d65ec1"
      unitRef="U001">-257000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_15d14efe39a949dabe720e0cc4f8a8d2"
      unitRef="U001">-1401000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20191231_StatementEquityComponentsAxis_AociIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-3"
      id="Fact_47d26dc5eb544c51b35c31726e80cf7c"
      unitRef="U001">-25290000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20181231_StatementEquityComponentsAxis_AociIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-3"
      id="Fact_92c6a81d4cc548c79c16aa702d293bfc"
      unitRef="U001">-32016000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c20171231_StatementEquityComponentsAxis_AociIncludingPortionAttributableToNoncontrollingInterestMember"
      decimals="-3"
      id="Fact_d50f6f2316fb42a59ada44dcc1e3f6fc"
      unitRef="U001">-31759000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="c20190101to20191231"
      decimals="-5"
      id="Fact_94347ad5e6d2462b8cc18ca1ddce90e2"
      unitRef="U001">1400000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="c20180101to20181231"
      decimals="-5"
      id="Fact_b4c227fd58254a14b4a1aab9ae5a2738"
      unitRef="U001">300000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="c20170101to20171231"
      decimals="-6"
      id="Fact_d03ca52bed96438596b3ef0a600a4819"
      unitRef="U001">0</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:DebtPolicyTextBlock
      contextRef="c20190101to20191231"
      id="Text_da81473855ab4b1397ab41e0c02ea04c">
&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Convertible Debt&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;At issuance, we accounted for our convertible debt instruments, including our 0.125 percent senior convertible notes, or 0.125% Notes and 1 percent senior convertible notes, or 1% Notes, that may be settled in cash upon conversion (including partial cash settlement) by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate on the date the notes were issued. In reviewing debt issuances, we were not able to identify any comparable companies that recently issued non-convertible debt instruments. Therefore, we estimated the fair value of the liability component of our notes by using assumptions that market participants would use in pricing a debt instrument, including market interest rates, credit standing, yield curves and volatilities.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We assigned a value to the debt component of our convertible notes equal to the estimated fair value of similar debt instruments without the conversion feature, which resulted in us recording our debt at a discount. We are amortizing our debt issuance costs and debt discount over the life of the convertible notes as additional non-cash interest expense utilizing the effective interest method. For additional information, see Note 3, &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Long-Term Obligations and Commitments&lt;/span&gt;.&lt;/div&gt;
</us-gaap:DebtPolicyTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_9dac22281bdf451a940008eda1d7a823"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_21cdbefcddab46039805db2aaa0c4339"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_d2044d977d4a415c9cadeaa7e187ed54"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_b10b14bf0679415f909b7c584e5b9db5"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="c20190101to20191231"
      id="Text_6d9fef6cc7d04259a699ad6740c48d10">
&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Segment Information&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We have &lt;/span&gt;two&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; operating segments, our Ionis Core segment and Akcea Therapeutics, our majority-owned affiliate. Akcea is &lt;/span&gt;a biopharmaceutical company focused on developing and commercializing medicines to treat patients with serious and rare diseases&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;. We provide segment financial information and results for our Ionis Core segment and our Akcea Therapeutics segment based on the segregation of revenues and expenses that our chief decision maker reviews to assess operating performance and to make operating decisions. We allocate a portion of Ionis&#x2019; development, R&amp;amp;D support and general and administrative expenses to Akcea for work Ionis performs on behalf of Akcea and we bill Akcea for these expenses.&lt;/span&gt;&lt;/div&gt;
</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c20190101to20191231"
      decimals="INF"
      id="Fact_419f6aaf7f954198a58ab39bfb5080c8"
      unitRef="U010">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="c20190101to20191231"
      id="Text_d1e487930af14a5b9c0da0458c9a0a80">
&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fair Value Measurements&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We use a three-tier fair value hierarchy to prioritize the inputs used in our fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets, which includes our money market funds and treasury securities classified as available-for-sale securities and our investment in equity securities in publicly-held biotechnology companies; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable, which includes our fixed income securities and commercial paper classified as available-for-sale securities; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring us to develop our own assumptions. We classify the majority of our securities as Level 2. We obtain the fair value of our Level 2 investments from our custodian bank or from a professional pricing service. We validate the fair value of our Level 2 investments by understanding the pricing model used by the custodian banks or professional pricing service provider and comparing that fair value to the fair value based on observable market prices.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following tables present the major security types we held at December 31, 2019 and 2018&#160;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;that we regularly measure and carry at fair value&lt;/span&gt;. At December 31, 2019, a portion of our ProQR investment was &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;subject to trading restrictions through the fourth quarter of 2020, as a result we&lt;/span&gt; included a lack of marketability discount in valuing this investment, which is a Level 3 input. At December 31, 2018, our ProQR investment was &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;subject to trading restrictions through the fourth quarter of 2019, as a result we&lt;/span&gt; included a lack of marketability discount in valuing this investment, which is a Level 3 input. The tables segregate each security type by the level within the fair value hierarchy of the valuation techniques we utilized to determine the respective securities&#x2019; fair value (in thousands):&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z0cec2f41ef46437e96b40a502fd19a06" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 8pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;At&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quoted Prices in&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Active Markets&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Level 1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Significant Other&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Observable Inputs&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Level 2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Significant&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Unobservable Inputs&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Level 3)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Cash equivalents (1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;418,406&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;418,406&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Corporate debt securities (2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,102,568&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,102,568&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by U.S. government agencies (3)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;329,404&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;329,404&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by the U.S. Treasury (4)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;363,694&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;363,694&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by states of the U.S. and political subdivisions of the states (4)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;40,407&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;40,407&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div/&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Investment in ProQR Therapeutics N.V. (5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4,506&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4,506&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -8.9pt; margin-left: 22.55pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,258,985&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;782,100&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,472,379&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4,506&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z6dbe183adeca4fdb81898fb0f23d867c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 8pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;At&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quoted Prices in&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Active Markets&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Level 1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Significant Other&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Observable Inputs&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Level 2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Significant&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Unobservable Inputs&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Level 3)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Cash equivalents (1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;146,281&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;146,281&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Corporate debt securities (6)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,252,960&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,252,960&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by U.S. government agencies (4)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;276,612&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;276,612&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by the U.S. Treasury (7)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;260,154&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;260,154&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by states of the U.S. and political subdivisions of the states (4)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;79,942&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;79,942&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Investment in ProQR Therapeutics N.V. (5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,349&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,349&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -8.9pt; margin-left: 22.55pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,017,298&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;406,435&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,609,514&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,349&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;________________&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zcc6c856321964d22a7f08198e22558a3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Included in cash and cash equivalents on our consolidated balance sheet.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -36pt; margin-left: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z3bb7cbd9edf34eea8445b9bb699f5225" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$19.0 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z9302b49ff4924d45b72f0ef80173e32d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(3)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$0.8 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zcc7cb538270446d19a63ff93630b2e26" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Included in short-term investments.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z0a497b435bb34da0940d397a2ee925d1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Included in other current assets on our consolidated balance sheet.&#160;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze53e73690894408ba98ca5e5e87ae494" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(6)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$50.2 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z9da9f51ab1ce4cf8b13bf7b591532750" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(7)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$14.2 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="c20190101to20191231"
      id="Text_3b110457f29542f28d1e0eea27b2d971">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following tables present the major security types we held at December 31, 2019 and 2018&#160;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;that we regularly measure and carry at fair value&lt;/span&gt;. At December 31, 2019, a portion of our ProQR investment was &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;subject to trading restrictions through the fourth quarter of 2020, as a result we&lt;/span&gt; included a lack of marketability discount in valuing this investment, which is a Level 3 input. At December 31, 2018, our ProQR investment was &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;subject to trading restrictions through the fourth quarter of 2019, as a result we&lt;/span&gt; included a lack of marketability discount in valuing this investment, which is a Level 3 input. The tables segregate each security type by the level within the fair value hierarchy of the valuation techniques we utilized to determine the respective securities&#x2019; fair value (in thousands):&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z0cec2f41ef46437e96b40a502fd19a06" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 8pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;At&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quoted Prices in&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Active Markets&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Level 1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Significant Other&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Observable Inputs&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Level 2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Significant&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Unobservable Inputs&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Level 3)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Cash equivalents (1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;418,406&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;418,406&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Corporate debt securities (2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,102,568&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,102,568&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by U.S. government agencies (3)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;329,404&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;329,404&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by the U.S. Treasury (4)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;363,694&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;363,694&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by states of the U.S. and political subdivisions of the states (4)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;40,407&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;40,407&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div/&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Investment in ProQR Therapeutics N.V. (5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4,506&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4,506&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -8.9pt; margin-left: 22.55pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,258,985&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;782,100&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,472,379&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4,506&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z6dbe183adeca4fdb81898fb0f23d867c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 8pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;At&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quoted Prices in&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Active Markets&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Level 1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Significant Other&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Observable Inputs&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Level 2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Significant&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Unobservable Inputs&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Level 3)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Cash equivalents (1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;146,281&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;146,281&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Corporate debt securities (6)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,252,960&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,252,960&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by U.S. government agencies (4)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;276,612&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;276,612&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by the U.S. Treasury (7)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;260,154&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;260,154&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by states of the U.S. and political subdivisions of the states (4)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;79,942&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;79,942&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Investment in ProQR Therapeutics N.V. (5)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,349&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,349&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -8.9pt; margin-left: 22.55pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,017,298&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;406,435&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,609,514&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,349&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;________________&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zcc6c856321964d22a7f08198e22558a3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Included in cash and cash equivalents on our consolidated balance sheet.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -36pt; margin-left: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z3bb7cbd9edf34eea8445b9bb699f5225" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$19.0 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z9302b49ff4924d45b72f0ef80173e32d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(3)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$0.8 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zcc7cb538270446d19a63ff93630b2e26" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Included in short-term investments.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z0a497b435bb34da0940d397a2ee925d1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Included in other current assets on our consolidated balance sheet.&#160;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze53e73690894408ba98ca5e5e87ae494" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(6)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$50.2 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z9da9f51ab1ce4cf8b13bf7b591532750" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(7)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$14.2 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_c019e6ae06e64200907ceaf6cd9642e2"
      unitRef="U001">418406000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_e16b0ecf33a545d1b4a712e4f2efae2f"
      unitRef="U001">418406000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_eefa2800e09b4d348fe4eea3ed73e20e"
      unitRef="U001">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_3309e6a041b04ac8b0c2bc0e51a2b7af"
      unitRef="U001">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_a48bf0d7ba1349e58e4936fc5037bb76"
      unitRef="U001">1102568000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_0690adcb15b64af0b0c13842098e9b68"
      unitRef="U001">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_372fce9620ea4fcb92674a9744117a0f"
      unitRef="U001">1102568000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_dcdce4930680418c9c6723d59d0766bf"
      unitRef="U001">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_d0fdecfde0594969b57923784dc22c4e"
      unitRef="U001">329404000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_2d496c63e7fc4f4db6d3d96def177b93"
      unitRef="U001">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_94fd62b1449442d198bd1ba1536e68d9"
      unitRef="U001">329404000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_2265bd19815f4068a52086a7da4852fb"
      unitRef="U001">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_bfc11b60b8204c22927b5f6205cfe9b4"
      unitRef="U001">363694000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_929a4b0adc4b4b7e8aff38356715510b"
      unitRef="U001">363694000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_6e86df31823f42aaa223f9a0dce513f0"
      unitRef="U001">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_972a7f7ceab649b8beac4628d113d401"
      unitRef="U001">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_21a61427c87a455b8534f57a12968f6a"
      unitRef="U001">40407000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_dd6b67a198574e04be9fb121cc80987c"
      unitRef="U001">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_d9174d81bf52404fb4871b9adc8c39ad"
      unitRef="U001">40407000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_4e6f9b5b003344d79d80feeaea24381e"
      unitRef="U001">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_3ad78e1baf8a45d8baedda5ec0ee15d5"
      unitRef="U001">4506000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_be5ad974e87249c580a06f47230219d6"
      unitRef="U001">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_8c4ee761b3584039949879598e5ff4dd"
      unitRef="U001">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_0e852cc477c6465290c90b9918bf4e1e"
      unitRef="U001">4506000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_b383f6d599984bd3b51295d6cb0bc979"
      unitRef="U001">2258985000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_29f2efb673634f019fe1212835028f33"
      unitRef="U001">782100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_8c28d864022a4a0e91e10d4036681a05"
      unitRef="U001">1472379000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20191231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_b35385dc7d67458392cde51a59fa3e67"
      unitRef="U001">4506000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_c119be8fc8d4422e8e8714cae28a1b7d"
      unitRef="U001">146281000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_64a733b40fb74b518fbb1f69987bfa71"
      unitRef="U001">146281000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_adeed04e01c04759ab4b5d9eef7ee8b4"
      unitRef="U001">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_02fa0aa5d92f4ff5a0ad5e5c16bc3364"
      unitRef="U001">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_476f612dfc4a4ddc8171ae7717eec530"
      unitRef="U001">1252960000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_fc99a9820d3a456aaffbfe4b6e153744"
      unitRef="U001">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_6c1a2a160c664221a7242dfab67b3575"
      unitRef="U001">1252960000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_93a97d3b0bc14ef699aa0469026c016a"
      unitRef="U001">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_25150245f8544078baf644d29cdc825a"
      unitRef="U001">276612000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_d58fb10abb6b47a5ace8828f366b7446"
      unitRef="U001">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_b8cc5e04c3774039a93ccc6034f74cdc"
      unitRef="U001">276612000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_4c086c2c3c3e4b11867fb21e86ee9bfa"
      unitRef="U001">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_373fed9ce3ba443a8feb7284438f4bb6"
      unitRef="U001">260154000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_e7e3e68358c94a6991f9bc9a67ba0a25"
      unitRef="U001">260154000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_be401c09516e46dab13e6a290c4e0f85"
      unitRef="U001">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_1eaad4e0aba3488cb7490a9c85c3f710"
      unitRef="U001">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_2306dcbd35634a0485a18bef2da7300e"
      unitRef="U001">79942000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_466914000cd34e929809ae3a3d1dd4e1"
      unitRef="U001">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_b4cbb2969a654ce8975e05064b68c183"
      unitRef="U001">79942000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_bfc230aff26841d7b6cef430106fd85f"
      unitRef="U001">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_2b37972d666b46d1ac6f9e2f013208f4"
      unitRef="U001">1349000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_cd8848724d3a4b7c8f698a98cfad6ef8"
      unitRef="U001">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_51a776a3c3724c5da2107bd7882086d5"
      unitRef="U001">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_0e5d97a4f5634458a86e73a8df42af50"
      unitRef="U001">1349000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20181231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_58c677dbf6914befb31c51c42a5f9de8"
      unitRef="U001">2017298000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_eea07a2d8e9d46a790284fc98f7de43b"
      unitRef="U001">406435000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_dc11b10a350e43f09509ec7adfbe3fb1"
      unitRef="U001">1609514000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c20181231_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="Fact_efc7bd319e6048baa4c12bac36ead8a2"
      unitRef="U001">1349000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20191231_BalanceSheetLocationAxis_CashAndCashEquivalentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"
      decimals="-5"
      id="Fact_ce470ce0da684fc0965a0abdbc5bdb8f"
      unitRef="U001">19000000.0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20191231_BalanceSheetLocationAxis_CashAndCashEquivalentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-5"
      id="Fact_94f64bff77254ab4850b08f2bbbd1572"
      unitRef="U001">800000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20181231_BalanceSheetLocationAxis_CashAndCashEquivalentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_CorporateDebtSecuritiesMember"
      decimals="-5"
      id="Fact_901bc85a32f541369ef5a8de46f7eb74"
      unitRef="U001">50200000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="c20181231_BalanceSheetLocationAxis_CashAndCashEquivalentsMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FinancialInstrumentAxis_USTreasurySecuritiesMember"
      decimals="-5"
      id="Fact_0be87ae2076b4d75a7c41aba90d2f514"
      unitRef="U001">14200000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="c20190101to20191231"
      id="Text_757da07036b745328cb726e2edccfa35">
&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Income Taxes&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We account for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. We record a valuation allowance when necessary to reduce our net deferred tax assets to the amount expected to be realized.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act of 2017, or the Tax Act. The Tax Act created a new requirement on global intangible low-taxed income, or GILTI, earned by foreign subsidiaries for tax years beginning on or after January 1, 2018. The GILTI provisions require foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#x2019;s assets to be included in our U.S. income tax return. Under U.S. GAAP, we are permitted to make an accounting policy election to either treat taxes due on future inclusions in U.S. taxable income related to GILTI as a current-period expense when incurred or to factor such amounts into our measurement of deferred taxes. We have made the election to account for GILTI as a component of current taxes incurred rather than as a component of deferred taxes.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We apply the authoritative accounting guidance prescribing a threshold and measurement attribute for the financial recognition and measurement of a tax position taken or expected to be taken in a tax return. We recognize liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step requires us to estimate and measure the tax benefit as the largest amount that is more than 50 percent likely to be realized upon ultimate settlement.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We are required to use significant judgment in evaluating our uncertain tax positions and determining our provision for income taxes. Although we believe our reserves are reasonable, no assurance can be given that the final tax outcome of these matters will not be different from that which is reflected in our historical income tax provisions and accruals. We adjust these reserves for changing facts and circumstances, such as the closing of a tax audit or the refinement of an estimate. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences may impact the provision for income taxes in the period in which such determination is made.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We are also required to use significant judgment in determining any valuation allowance recorded against our deferred tax assets. In assessing the need for a valuation allowance, we consider all available evidence, including scheduled reversal of deferred tax liabilities, past operating results, the feasibility of tax planning strategies and estimates of future taxable income. We base our estimates of future taxable income on assumptions that are consistent with our plans. The assumptions we use represent our best estimates and involve inherent uncertainties and the application of our judgment. Should actual amounts differ from our estimates, the amount of our tax expense and liabilities we recognize could be materially impacted.&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; We record a valuation allowance to reduce the balance of our net deferred tax assets to the amount we believe is more-likely-than-not to be realized.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We do not provide for a U.S. income tax liability and foreign withholding taxes on undistributed foreign earnings of our foreign subsidiaries.&lt;/div&gt;
</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="c20190101to20191231"
      id="Text_bc384ef6d5a446c59da5885dc5771bd9">
&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Impact of Recently Issued Accounting Standards&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In June 2016, the FASB issued guidance that changes the measurement of credit losses for most financial assets and certain other instruments. If we have credit losses, this updated guidance requires us to record allowances for these instruments under a new expected credit loss model. This model requires us to estimate the expected credit loss of an instrument over its lifetime, which represents the portion of the amortized cost basis we do not expect to collect. The new guidance requires us to remeasure our allowance in each reporting period we have credit losses. We adopted this the new guidance on January 1, 2020. We do not expect this guidance will have an impact on our consolidated financial statements.&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In August 2018, the FASB issued clarifying guidance on how to account for implementation costs related to cloud-servicing arrangements. The guidance states that if these fees qualify to be capitalized and amortized over the service period, they need to be expensed in the same line item as the service expense and recognized in the same balance sheet category. The update can be applied either retrospectively or prospectively to all implementation costs incurred after the date of adoption. We adopted this guidance on January 1, 2020 on a prospective basis. We do not expect this guidance will have an impact on our consolidated financial statements.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In August 2018, the FASB updated its disclosure requirements related to Level 1, 2 and 3 fair value measurements. The update included deletion and modification of certain disclosure requirements and additional disclosure related to Level 3 measurements. The guidance is effective for fiscal years beginning after December 31, 2019 and early adoption is permitted. We adopted this updated guidance on January 1, 2019 and it did not have a significant impact on our disclosures.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In November 2018, the FASB issued clarifying guidance of the interaction between the collaboration accounting guidance and the new revenue recognition guidance we adopted on January 1, 2018 (Topic 606). Below is the clarifying guidance and how we will implement it (in italics):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z6b37abcc28844ec1995be6ea3287fde1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;When a participant is considered a customer in a collaborative arrangement, all of the associated accounting under Topic 606 should be applied&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z568b757cadfb43b88346ae2bdab57f19" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 72pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;We will apply all of the associated accounting under Topic 606 when we determine a participant in a collaborative arrangement is a customer &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z729d51441c36453d9dd29ff6baaa5429" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Adds &#x201c;unit of account&#x201d; concept to collaboration accounting guidance to align with Topic 606. The &#x201c;unit of account&#x201d; concept is used to determine if revenue is recognized or if a contra expense is recognized from consideration received under a collaboration&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z36356b76546d4b1b9df6a54de364a594" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 72pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;We will use the &#x201c;unit of account&#x201d; concept when we receive consideration under a collaborative arrangement to determine when we recognize revenue or a contra expense&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze5669a8c7b084090bd8ad32061dcc5d9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The clarifying guidance precludes us from recognizing revenue under Topic 606 when we determine a transaction with a collaborative partner is not a customer and is not directly related to the sales to third parties&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze5279de5f245498da7e1f9b7cb96a4f7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 72pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;When we conclude a collaboration partner is not a customer and is not directly related to the sales to third parties, we will not recognize revenue for the transaction &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We adopted this new guidance on January 1, 2020. We do not expect this guidance will have a significant impact on our consolidated financial statements.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In December 2019, the FASB issued guidance to simplify the accounting for income taxes. The update includes removing several exceptions under the existing guidance and includes several simplification updates, none of which apply to our current accounting for income taxes. The guidance is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted. We adopted this updated guidance in the fourth quarter of 2019 and it did not have an impact on our consolidated financial statements or disclosures.&lt;/div&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentTextBlock
      contextRef="c20190101to20191231"
      id="Text_33b4e7480c98452daf1f231b92b474a1">
&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2. Investments&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following table summarizes the contract maturity of the available-for-sale securities we held as of December 31, 2019:&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z6c0f78857c00481b9a2fe8abae31c196" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;One year or less&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;70&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;After one year but within two years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;20&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;After two years but within &lt;span style="-sec-ix-hidden:Fact_5b50da2d62974df399b2ebfcfccf0c30"&gt;three and a half years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;100&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;As illustrated above, at December 31, 2019, 90 percent of our available-for-sale securities had a maturity of less than two years.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;All of our available-for-sale securities are available to us for use in our current operations. As a result, we categorize all of these securities as current assets even though the stated maturity of some individual securities may be one year or more beyond the balance sheet date.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;At December 31, 2019, we had an ownership interest of less than 20 percent &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;in &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;five&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; private companies and &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;two&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; public companies with which we conduct business. The privately-held companies are &lt;/span&gt;Atlantic Pharmaceuticals Limited, Dynacure SAS, Empirico, Inc., Seventh Sense Biosystems and Suzhou Ribo Life Science Co, Ltd.&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;The publicly traded companies are ATL and ProQR. &lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following is a summary of our investments (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zf9b6c17e2c154c6ab71c1ee67da358d6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"/&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Gross Unrealized&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Estimated&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Cost &lt;/span&gt;(1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Gains&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Losses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fair Value&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Available-for-sale securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Corporate debt securities (2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;669,665&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,451&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(43&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;671,073&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by U.S. government agencies&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;188,216&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;303&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(43&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;188,476&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by the U.S. Treasury (2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;327,670&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;232&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(27&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;327,875&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by states of the U.S. and political subdivisions of the states&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;21,065&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;26&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;21,086&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total securities with a maturity of one year or less&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,206,616&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,012&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(118&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,208,510&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Corporate debt securities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;428,627&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,911&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(43&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;431,495&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by U.S. government agencies&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;140,988&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;57&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(117&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;140,928&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by the U.S. Treasury&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;35,822&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(12&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;35,819&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by states of the U.S. and political subdivisions of the states&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;19,309&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;19,321&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total securities with a maturity of more than one year&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;624,746&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,995&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(178&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;627,563&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total available-for-sale securities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,831,362&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;5,007&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(296&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,836,073&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Equity securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total equity securities included in other current assets (3)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4,712&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(870&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3,842&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total equity securities included in deposits and other assets (4)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10,000&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10,000&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total equity securities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;14,712&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(870&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;13,842&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total available-for-sale and equity securities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,846,074&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;5,007&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,166&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,849,915&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z13827f1de67a455a9892b6f4cd0857a7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Gross Unrealized&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Estimated&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31, 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Cost &lt;/span&gt;(1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Gains&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Losses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fair Value&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Available-for-sale securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Corporate debt securities (2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;956,879&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;13&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,858&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;955,034&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by U.S. government agencies&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;168,839&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(104&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;168,738&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by the U.S. Treasury&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;244,640&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;15&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(77&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;244,578&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by states of the U.S. and political subdivisions of the states (2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;63,572&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(323&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;63,249&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total securities with a maturity of one year or less&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,433,930&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;31&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2,362&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,431,599&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Corporate debt securities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;299,018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;194&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,286&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;297,926&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by U.S. government agencies&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;107,789&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;194&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(109&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;107,874&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by the U.S. Treasury&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;15,600&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(24&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;15,576&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by states of the U.S. and political subdivisions of the states&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;16,980&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(287&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;16,693&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total securities with a maturity of more than one year&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;439,387&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;388&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,706&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;438,069&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total available-for-sale securities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,873,317&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;419&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4,068&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,869,668&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Equity securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total equity securities included in other current assets (3)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,212&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;137&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,349&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total available-for-sale and equity securities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,874,529&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;556&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4,068&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,871,017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z784ee7f1d4b643169b5db132e0df44a0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We hold our available-for-sale securities at amortized cost.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z0db8278eb43646f79139982440394852" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Includes investments classified as cash equivalents on our consolidated balance sheet.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z72201901808a45b9b3f1774f8add5ea2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(3)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Our equity securities included in other current assets consisted of our investment in ProQR, which is a public company. We recognize our public company equity securities at&lt;/span&gt; fair value.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z3d706207d5ac4b169c0cbd627c904d24" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Our equity securities included in deposits and other assets consisted of our investment in Empirico, which is a private company. We recognize our private company equity securities at&lt;/span&gt; cost minus impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; on our consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Investments we consider to be temporarily impaired at December 31, 2019 are as follows (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zc70ed2d8b7b040eaa431c9f6deed2462" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Less than 12 Months of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Temporary Impairment&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;More than 12 Months of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Temporary Impairment&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total Temporary&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Impairment&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Number of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Investments&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Estimated&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fair Value&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Unrealized&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Losses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Estimated&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fair Value&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Unrealized&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Losses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Estimated&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fair Value&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Unrealized&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Losses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 16%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Corporate debt securities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;49&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;131,702&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(75&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;11,840&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(11&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;143,542&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(86&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 16%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by U.S. government agencies&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;43&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;149,731&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(136&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;37,041&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(24&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;186,772&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(160&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 16%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by the U.S. Treasury&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;84,270&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(39&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;84,270&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(39&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 16%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by states of the U.S. and political subdivisions of the states&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;11&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10,241&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10,303&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;20,544&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(11&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 16%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total temporarily impaired securities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;113&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;375,944&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(255&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;59,184&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(41&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;435,128&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(296&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We believe that the decline in value of our debt securities is temporary and primarily related to the change in market interest rates since purchase. We believe it is more likely than not that we will be able to hold these securities to maturity. Therefore, we anticipate full recovery of our debt securities&#x2019; amortized cost basis at maturity.&lt;/div&gt;
</us-gaap:InvestmentTextBlock>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_277e9831a1824875a68a5502ea289e18">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following table summarizes the contract maturity of the available-for-sale securities we held as of December 31, 2019:&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z6c0f78857c00481b9a2fe8abae31c196" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;One year or less&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;70&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;After one year but within two years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;20&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;After two years but within &lt;span style="-sec-ix-hidden:Fact_5b50da2d62974df399b2ebfcfccf0c30"&gt;three and a half years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;100&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <ions:MaximumContractMaturityPeriodRange1
      contextRef="c20190101to20191231"
      id="Fact_a0389bbbc04d444aa9945a16f2f77b47">P1Y</ions:MaximumContractMaturityPeriodRange1>
    <ions:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage
      contextRef="c20191231"
      decimals="2"
      id="Fact_e1a84f7ba1234915827448c633c10e96"
      unitRef="U003">0.70</ions:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage>
    <ions:MaximumContractMaturityPeriodRange1
      contextRef="c20190101to20191231"
      id="Fact_a9a809b245674eb5912c14df728dc0f0">P1Y</ions:MaximumContractMaturityPeriodRange1>
    <ions:MaximumContractMaturityPeriodRange2
      contextRef="c20190101to20191231"
      id="Fact_d1dd3aa1c3444cc8babea1f02c42cb74">P2Y</ions:MaximumContractMaturityPeriodRange2>
    <ions:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage
      contextRef="c20191231"
      decimals="2"
      id="Fact_54f16a3082454b16a1368f8660393627"
      unitRef="U003">0.20</ions:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage>
    <ions:MaximumContractMaturityPeriodRange2
      contextRef="c20190101to20191231"
      id="Fact_649df9025a904bcfad6dc6ab6bd4c304">P2Y</ions:MaximumContractMaturityPeriodRange2>
    <ions:AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage
      contextRef="c20191231"
      decimals="2"
      id="Fact_d60e9c8e586b428c886b9d9653ac0f6e"
      unitRef="U003">0.10</ions:AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage>
    <ions:AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage
      contextRef="c20191231"
      decimals="2"
      id="Fact_298fc5ad20a2442399af2cd8e8215ece"
      unitRef="U003">1</ions:AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage>
    <ions:AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage
      contextRef="c20191231"
      decimals="2"
      id="Fact_971b070bcf6846b8970847cdbaef1457"
      unitRef="U003">0.90</ions:AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage>
    <ions:MaximumContractMaturityPeriodRange2
      contextRef="c20190101to20191231"
      id="Fact_e4aa3be8fcd040d0bcd0def824af337d">P2Y</ions:MaximumContractMaturityPeriodRange2>
    <ions:NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment
      contextRef="c20191231"
      decimals="INF"
      id="Fact_c487d989afb240aaae9be0536d4b8656"
      unitRef="U009">5</ions:NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment>
    <ions:NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment
      contextRef="c20191231"
      decimals="INF"
      id="Fact_cc8fa179d30548a7b52fcdc75fe7eeee"
      unitRef="U009">2</ions:NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_25f9d7aa00504b8ca3d76245ab5a2ce0">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following is a summary of our investments (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zf9b6c17e2c154c6ab71c1ee67da358d6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"/&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Gross Unrealized&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Estimated&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Cost &lt;/span&gt;(1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Gains&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Losses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fair Value&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Available-for-sale securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Corporate debt securities (2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;669,665&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,451&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(43&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;671,073&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by U.S. government agencies&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;188,216&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;303&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(43&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;188,476&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by the U.S. Treasury (2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;327,670&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;232&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(27&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;327,875&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by states of the U.S. and political subdivisions of the states&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;21,065&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;26&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;21,086&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total securities with a maturity of one year or less&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,206,616&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,012&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(118&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,208,510&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Corporate debt securities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;428,627&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,911&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(43&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;431,495&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by U.S. government agencies&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;140,988&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;57&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(117&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;140,928&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by the U.S. Treasury&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;35,822&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(12&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;35,819&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by states of the U.S. and political subdivisions of the states&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;19,309&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;19,321&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total securities with a maturity of more than one year&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;624,746&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,995&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(178&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;627,563&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total available-for-sale securities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,831,362&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;5,007&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(296&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,836,073&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Equity securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total equity securities included in other current assets (3)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4,712&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(870&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3,842&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total equity securities included in deposits and other assets (4)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10,000&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10,000&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total equity securities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;14,712&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;-&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(870&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;13,842&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total available-for-sale and equity securities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,846,074&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;5,007&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,166&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,849,915&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z13827f1de67a455a9892b6f4cd0857a7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Gross Unrealized&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Estimated&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31, 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Cost &lt;/span&gt;(1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Gains&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Losses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fair Value&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Available-for-sale securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Corporate debt securities (2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;956,879&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;13&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,858&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;955,034&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by U.S. government agencies&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;168,839&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(104&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;168,738&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by the U.S. Treasury&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;244,640&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;15&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(77&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;244,578&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by states of the U.S. and political subdivisions of the states (2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;63,572&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(323&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;63,249&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total securities with a maturity of one year or less&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,433,930&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;31&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2,362&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,431,599&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Corporate debt securities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;299,018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;194&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,286&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;297,926&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by U.S. government agencies&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;107,789&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;194&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(109&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;107,874&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by the U.S. Treasury&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;15,600&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(24&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;15,576&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by states of the U.S. and political subdivisions of the states&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;16,980&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(287&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;16,693&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total securities with a maturity of more than one year&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;439,387&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;388&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,706&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;438,069&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total available-for-sale securities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,873,317&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;419&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4,068&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,869,668&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Equity securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total equity securities included in other current assets (3)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,212&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;137&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,349&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total available-for-sale and equity securities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,874,529&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;556&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4,068&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,871,017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z784ee7f1d4b643169b5db132e0df44a0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We hold our available-for-sale securities at amortized cost.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z0db8278eb43646f79139982440394852" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Includes investments classified as cash equivalents on our consolidated balance sheet.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z72201901808a45b9b3f1774f8add5ea2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(3)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Our equity securities included in other current assets consisted of our investment in ProQR, which is a public company. We recognize our public company equity securities at&lt;/span&gt; fair value.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: -18pt; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z3d706207d5ac4b169c0cbd627c904d24" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Our equity securities included in deposits and other assets consisted of our investment in Empirico, which is a private company. We recognize our private company equity securities at&lt;/span&gt; cost minus impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; on our consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_bc9e70d55b674cc9b6be541478de94e8"
      unitRef="U001">669665000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_0c24393396f14a5fadd7e6d9dd062834"
      unitRef="U001">1451000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_615e6981ef5c43e4afa6a302941c0754"
      unitRef="U001">43000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_0a185c2049a6469e81e8e4df671bb2f5"
      unitRef="U001">671073000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_c9d17af33c554c64ac738dfbdb48494c"
      unitRef="U001">188216000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_e61b3c1e7a7a45d7a7ce7d512404dfea"
      unitRef="U001">303000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_8cd5ebaff4ff47b59a6f49c94f90f5e4"
      unitRef="U001">43000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_dc66d2f463f54767abee4fc4f62595f6"
      unitRef="U001">188476000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_f00bcd75b4b842ec98fdc045c48c2576"
      unitRef="U001">327670000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_d6b1880a34fc425f848f593694e21d3b"
      unitRef="U001">232000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_52ee12eba4604cd6beb6d916ef074d49"
      unitRef="U001">27000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_93f61f2dcaf249fe8c2941b0bedb2ad6"
      unitRef="U001">327875000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_f17e37bd45aa4fdbae4827a34aa7dac9"
      unitRef="U001">21065000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_8da02b683fe94c99ae3334fe0583bcbf"
      unitRef="U001">26000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_f5548b5e22d64358b14bff13c4cde745"
      unitRef="U001">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_5215ece6e8674be582ac13fad8e0e02f"
      unitRef="U001">21086000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_06b37f3d76b24645b428aed40ef7519d"
      unitRef="U001">1206616000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_868aecd154b3411fad39ee7f067ae085"
      unitRef="U001">2012000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_27ce74de3a8d48ed86f8ce84429f7f33"
      unitRef="U001">118000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_7cbbbf68a23c4d05acea3eb703650eb7"
      unitRef="U001">1208510000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_68c90e44ae7142faa5c935422fe6ca01"
      unitRef="U001">428627000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_0ecb6c8cead3473f9be6b9fc2b15d79f"
      unitRef="U001">2911000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_4f2e99491c92483882c5013894e5a3b4"
      unitRef="U001">43000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_8078467ba1d947589f274b1470ccc8c7"
      unitRef="U001">431495000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_e4c79d28e0dd438c896e0c5148cdbae0"
      unitRef="U001">140988000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_c3fb53b35b5e4f0a801fb17377bbe452"
      unitRef="U001">57000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_f20247b6d2f84ccbbb1dbab68b9cd3d6"
      unitRef="U001">117000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_a656c02b450b4ae39000dbd1d10a2d67"
      unitRef="U001">140928000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_160b2612c5ff403daa0b23ecdd2866db"
      unitRef="U001">35822000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_b1272ac8ac42497ba65853e630ea020a"
      unitRef="U001">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_803581e2009f4b95bf2af6ab10413c74"
      unitRef="U001">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_32fdcfaa188c4467a9bc336b98ee4765"
      unitRef="U001">35819000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_4ae16ba11af3451383afc794f381425b"
      unitRef="U001">19309000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_fee237831c094d6db8d66deaea062f6b"
      unitRef="U001">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_b46d7b7d41284f92910e48dd0d37da98"
      unitRef="U001">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_072a76897a5042d8befaddf252441541"
      unitRef="U001">19321000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_b71803caad4d4886ad41f6bbc5e209f5"
      unitRef="U001">624746000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_8a0a49d9cc1e4c129249d0be27e415f2"
      unitRef="U001">2995000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_0ca92b9c73b2492aadcfbe4f82a50cb4"
      unitRef="U001">178000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_91167061047b48f4b8610c1a21447584"
      unitRef="U001">627563000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20191231_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_a5e37551797746d7832fc5653898ad64"
      unitRef="U001">1831362000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20191231_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_5784263002924b25aff1cb14f626bf7f"
      unitRef="U001">5007000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20191231_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_7654b51ce0a5448fa1c5723b77e4a3cd"
      unitRef="U001">296000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20191231_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_fb3ebfc0325446129501360d15bf62ff"
      unitRef="U001">1836073000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="c20191231_BalanceSheetLocationAxis_OtherCurrentAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember"
      decimals="-3"
      id="Fact_cef09f69ddec4b3dabee2b4ce3e2377b"
      unitRef="U001">4712000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="c20190101to20191231_InvestmentSecondaryCategorizationAxis_IncludedInOtherCurrentAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember"
      decimals="-3"
      id="Fact_3f654be6d96e41e4b4713c77ccf1c8e3"
      unitRef="U001">0</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="c20190101to20191231_InvestmentSecondaryCategorizationAxis_IncludedInOtherCurrentAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember"
      decimals="-3"
      id="Fact_3d2a388042994347ab5102d669861a7d"
      unitRef="U001">870000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_IncludedInOtherCurrentAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember"
      decimals="-3"
      id="Fact_2d87969d9ae34d49b910e43cebb1d676"
      unitRef="U001">3842000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="c20191231_BalanceSheetLocationAxis_DepositsAndOtherAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember"
      decimals="-3"
      id="Fact_9ebd36323e384809b15acae0a3551932"
      unitRef="U001">10000000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="c20190101to20191231_InvestmentSecondaryCategorizationAxis_IncludedInDepositsAndOtherAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember"
      decimals="-3"
      id="Fact_aed73c2c4de9479b940ffa549e9fedd0"
      unitRef="U001">0</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="c20190101to20191231_InvestmentSecondaryCategorizationAxis_IncludedInDepositsAndOtherAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember"
      decimals="-3"
      id="Fact_1f1394dc79044e9197f515e0b7bca042"
      unitRef="U001">0</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c20191231_InvestmentSecondaryCategorizationAxis_IncludedInDepositsAndOtherAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember"
      decimals="-3"
      id="Fact_acab1218ec2e41199e1b320128741143"
      unitRef="U001">10000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="c20191231_InvestmentTypeAxis_EquitySecuritiesMember"
      decimals="-3"
      id="Fact_1f62fdc7a62342f68a33d50b3bde0a58"
      unitRef="U001">14712000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="c20190101to20191231_InvestmentTypeAxis_EquitySecuritiesMember"
      decimals="-3"
      id="Fact_c2b1f14b00d941b6b317ee97742c8d96"
      unitRef="U001">0</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="c20190101to20191231_InvestmentTypeAxis_EquitySecuritiesMember"
      decimals="-3"
      id="Fact_9d1928afc7224324b66d25fddff38253"
      unitRef="U001">870000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c20191231_InvestmentTypeAxis_EquitySecuritiesMember"
      decimals="-3"
      id="Fact_594521b1bd6241bea5eaec95f58271c0"
      unitRef="U001">13842000</us-gaap:EquitySecuritiesFvNi>
    <ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost
      contextRef="c20191231"
      decimals="-3"
      id="Fact_afee4ce7ef954363a1010e810f1ae960"
      unitRef="U001">1846074000</ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost>
    <ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain
      contextRef="c20191231"
      decimals="-3"
      id="Fact_a346c4f456874316909407a757ecc1b7"
      unitRef="U001">5007000</ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain>
    <ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss
      contextRef="c20191231"
      decimals="-3"
      id="Fact_0bd6c064edff43c09905fc28e289473e"
      unitRef="U001">1166000</ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss>
    <ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi
      contextRef="c20191231"
      decimals="-3"
      id="Fact_f35d561e61484f2295cadeeb2d03bdbd"
      unitRef="U001">1849915000</ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_8ea119980dc64034994a6b7ad86f848c"
      unitRef="U001">956879000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_6df2fbe2752e4bd0bb77abf8abe0ae29"
      unitRef="U001">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_73421ff544c5487b9e733e95b060b569"
      unitRef="U001">1858000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_c85091a5a55a45a881f09b4c8c70a29c"
      unitRef="U001">955034000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_da1b311c89004135b55ecee7befa549d"
      unitRef="U001">168839000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_6c6ca7c3257b46848b5da442e9d2b424"
      unitRef="U001">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_f8696120bd5749f081186004728dcfec"
      unitRef="U001">104000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_ba83c8acf52443779871f0f7f21e0f69"
      unitRef="U001">168738000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_267f46317f0b40caa2f037611c038a1e"
      unitRef="U001">244640000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_2d25c6a792494377addd272a5b8dded6"
      unitRef="U001">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_f56cc4d0d90d4e7fbb8f72585969858c"
      unitRef="U001">77000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_0c7a5d61dae34de8a30b14b8802b8785"
      unitRef="U001">244578000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_2665cd241db44217ad8643b9ae2a63da"
      unitRef="U001">63572000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_5244a18f7849464e8277366dd5790037"
      unitRef="U001">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_703babc31466440681b56330914ed672"
      unitRef="U001">323000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_8732df0d6eac436fa8da11aab067289a"
      unitRef="U001">63249000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_f91f4bf7895e4255b6fb1606547e04c4"
      unitRef="U001">1433930000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_58f014330e0d46f68ac56681d9bcc775"
      unitRef="U001">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_4d687e924d2549c292e3b98c471a8b1c"
      unitRef="U001">2362000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfOneYearOrLessMember_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_5b653caa5875494f883c075c43b1bf5c"
      unitRef="U001">1431599000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_90b66da8071a4a14ae79ae20e35a4725"
      unitRef="U001">299018000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_6969869c8ab34390a5923698c47c72bb"
      unitRef="U001">194000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_fa5a358807714f81a4468c02e061a381"
      unitRef="U001">1286000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_c8341442a25e450b8c2a53f28afa5bbb"
      unitRef="U001">297926000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_627bd1dd191a4e2aa0ffcac3c093515e"
      unitRef="U001">107789000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_de7b01c6aeff4c67be7342b578227fe7"
      unitRef="U001">194000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_6dd609ef5c9d4c5abd47201f2f3c3971"
      unitRef="U001">109000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_01ade62c43ae4d1d9d121b813ab06110"
      unitRef="U001">107874000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_1a4e37f7b16f498caa99b193ac3977d1"
      unitRef="U001">15600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_9e774f36b3824b5da1f596ef542f70e8"
      unitRef="U001">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_fcf3826f90e44039b289f8286697222d"
      unitRef="U001">24000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_3834f60c806146fdb57604df4ca44d5f"
      unitRef="U001">15576000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_3b50fc36268c472c83543a498f74c6a3"
      unitRef="U001">16980000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_3cc6fe9c6c684eabbb359b5b57a83381"
      unitRef="U001">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_f9f79be238454b459039ee2cf29f6635"
      unitRef="U001">287000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_285a93f311de42a8b8b01192c7d0cee6"
      unitRef="U001">16693000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_be05404e83c643348777fa91b0e1b9ba"
      unitRef="U001">439387000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_80c5acbabb8c4f0bb30f07636779a6ef"
      unitRef="U001">388000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_2d2b1cb797c643148d37d334e933eeb2"
      unitRef="U001">1706000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20181231_InvestmentSecondaryCategorizationAxis_SecuritiesWithMaturityOfMoreThanOneYearMember_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_2bbc29a667a94cb99ff6c9f040ebeea6"
      unitRef="U001">438069000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="c20181231_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_8caafd476a3541b9aef7c098cc041e94"
      unitRef="U001">1873317000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="c20181231_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_609132a66d2f4130b140a88c2fb0c89d"
      unitRef="U001">419000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="c20181231_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_b09e4761e6054b25a622ed40b8db284e"
      unitRef="U001">4068000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="c20181231_InvestmentTypeAxis_DebtSecuritiesMember"
      decimals="-3"
      id="Fact_4de7d9b3be6d447db4b3c3fe0b8f036b"
      unitRef="U001">1869668000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="c20181231_BalanceSheetLocationAxis_OtherCurrentAssetsMember_InvestmentTypeAxis_EquitySecuritiesMember"
      decimals="-3"
      id="Fact_ddb646a5d0f1447b92caf9f07a627fcd"
      unitRef="U001">1212000</us-gaap:EquitySecuritiesFvNiCost>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="c20180101to20181231_InvestmentTypeAxis_EquitySecuritiesMember"
      decimals="-3"
      id="Fact_88ed4a2745c54e14a622755a003ef7d5"
      unitRef="U001">137000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="c20180101to20181231_InvestmentTypeAxis_EquitySecuritiesMember"
      decimals="-3"
      id="Fact_b4cdd38512ef47d9b5d3df0de25143e1"
      unitRef="U001">0</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="c20181231_InvestmentTypeAxis_EquitySecuritiesMember"
      decimals="-3"
      id="Fact_c71d4b805e374b9696b1907d0c3b8708"
      unitRef="U001">1349000</us-gaap:EquitySecuritiesFvNi>
    <ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost
      contextRef="c20181231"
      decimals="-3"
      id="Fact_fd07a2a1606f48d78bc5fb285d90a137"
      unitRef="U001">1874529000</ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost>
    <ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain
      contextRef="c20181231"
      decimals="-3"
      id="Fact_f166a5e138d3457b82d04bfee0b2aaa8"
      unitRef="U001">556000</ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain>
    <ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss
      contextRef="c20181231"
      decimals="-3"
      id="Fact_377148fd543d4bcd9b069e1883f63342"
      unitRef="U001">4068000</ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss>
    <ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi
      contextRef="c20181231"
      decimals="-3"
      id="Fact_250e88ec455a48818d6c542e743f1801"
      unitRef="U001">1871017000</ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi>
    <us-gaap:ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_cba310dfefea46e783635573366c8a41">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Investments we consider to be temporarily impaired at December 31, 2019 are as follows (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zc70ed2d8b7b040eaa431c9f6deed2462" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Less than 12 Months of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Temporary Impairment&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;More than 12 Months of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Temporary Impairment&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total Temporary&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Impairment&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Number of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Investments&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Estimated&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fair Value&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Unrealized&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Losses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Estimated&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fair Value&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Unrealized&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Losses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Estimated&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fair Value&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Unrealized&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Losses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 16%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Corporate debt securities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;49&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;131,702&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(75&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;11,840&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(11&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;143,542&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(86&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 16%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by U.S. government agencies&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;43&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;149,731&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(136&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;37,041&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(24&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;186,772&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(160&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 16%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by the U.S. Treasury&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;84,270&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(39&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;84,270&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(39&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 16%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Debt securities issued by states of the U.S. and political subdivisions of the states&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;11&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10,241&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10,303&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;20,544&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(11&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 16%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total temporarily impaired securities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;113&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;375,944&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(255&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;59,184&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(41&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;435,128&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(296&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock>
    <us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
      contextRef="c20191231_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="0"
      id="Fact_f9618b2492ae44b9b2470cf733ce4b89"
      unitRef="U011">49</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="c20191231_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_8a4ee48acfb249da93ed76eb27590389"
      unitRef="U001">131702000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="c20191231_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_c22fdf6c8a284c929edd1d1e31715069"
      unitRef="U001">75000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="c20191231_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_ae913f21594f4e35afd8a76532ae424d"
      unitRef="U001">11840000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c20191231_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_43ae0d4a4c054ce9ac7eda928a66f3ce"
      unitRef="U001">11000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="c20191231_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_ec87642bcf1e414893317ddf8e9a318b"
      unitRef="U001">143542000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
      contextRef="c20191231_InvestmentTypeAxis_CorporateDebtSecuritiesMember"
      decimals="-3"
      id="Fact_78ffaf6a2e0a4600a0863fb17ff1167b"
      unitRef="U001">86000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
      contextRef="c20191231_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="0"
      id="Fact_f0a1839edcc7432e98746bb64c9ee469"
      unitRef="U011">43</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="c20191231_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_b304ca8379be480192f74af7587a8091"
      unitRef="U001">149731000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="c20191231_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_301a9ca5e351446b9207bca35ae755e0"
      unitRef="U001">136000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="c20191231_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_9b1b03fbb4cf4eecac345367db167657"
      unitRef="U001">37041000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c20191231_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_9d6b816f7b4142c18af47ff9cfd9f58f"
      unitRef="U001">24000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="c20191231_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_3e15c3eb96834a428a8667e2fb4e22b1"
      unitRef="U001">186772000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
      contextRef="c20191231_InvestmentTypeAxis_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-3"
      id="Fact_6e0af781bd10431daa022f5cd9efe3b5"
      unitRef="U001">160000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
      contextRef="c20191231_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="0"
      id="Fact_c1029e647fba4541b4d7263304fd79cc"
      unitRef="U011">10</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="c20191231_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_d716f3ced7e84d1798d4c4fa34d6a57d"
      unitRef="U001">84270000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="c20191231_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_f5f5355986bb47ef8a1ca8923caf0a85"
      unitRef="U001">39000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="c20191231_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_9b9a73b628f344808c7ab85c6a75d8d1"
      unitRef="U001">0</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c20191231_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_174a3baf01714eeeb108a54a57ca43f7"
      unitRef="U001">0</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="c20191231_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_ed030e10b084484a9b80a80825ca4cb5"
      unitRef="U001">84270000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
      contextRef="c20191231_InvestmentTypeAxis_USTreasurySecuritiesMember"
      decimals="-3"
      id="Fact_58dcc7edf31940d68b9dd446115a1dfd"
      unitRef="U001">39000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
      contextRef="c20191231_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="0"
      id="Fact_6a4598e27cbb4ce3834c5c94e2c9c9ef"
      unitRef="U011">11</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="c20191231_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_d2cb2e04792f444ca946c37374eeb936"
      unitRef="U001">10241000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="c20191231_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_0766a8e2b98249298b9034c82546a6aa"
      unitRef="U001">5000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="c20191231_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_6be64d751387431f8ba145348542de66"
      unitRef="U001">10303000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c20191231_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_8324ced774214cbd90bb510a612d290b"
      unitRef="U001">6000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="c20191231_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_504113a73418469ebd7cef470ea4110b"
      unitRef="U001">20544000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
      contextRef="c20191231_InvestmentTypeAxis_USStatesAndPoliticalSubdivisionsMember"
      decimals="-3"
      id="Fact_ab7ea417914c4216add9d8b5bcfc1435"
      unitRef="U001">11000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
      contextRef="c20191231"
      decimals="0"
      id="Fact_38afc72bdce54d76994f6fb7a69caed9"
      unitRef="U011">113</us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
      contextRef="c20191231"
      decimals="-3"
      id="Fact_74871fb2d35c495cbb8413d5c53f03ee"
      unitRef="U001">375944000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="c20191231"
      decimals="-3"
      id="Fact_7c6e399d14d947288451729c35801e95"
      unitRef="U001">255000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
      contextRef="c20191231"
      decimals="-3"
      id="Fact_87f419c8d84b49258b687bc0e4069426"
      unitRef="U001">59184000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="c20191231"
      decimals="-3"
      id="Fact_093fdc7dd87f4ffb94e8b8f388a333f4"
      unitRef="U001">41000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
      contextRef="c20191231"
      decimals="-3"
      id="Fact_c04e62a976624d76bc5f1b3453b01bc4"
      unitRef="U001">435128000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue>
    <us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
      contextRef="c20191231"
      decimals="-3"
      id="Fact_80adec327e3b4b73825cd52dd312f579"
      unitRef="U001">296000</us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock
      contextRef="c20190101to20191231"
      id="Text_a58b6e796bad49fe998eefa2a578a4e7">
&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;3. Long-Term Obligations and Commitments&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The carrying value of our long-term obligations was as follows (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z3479120fb70c49dfbea272f920706f19" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.125 percent convertible senior notes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;434,711&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1 percent convertible senior notes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;275,333&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;568,215&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Long-term mortgage debt&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;59,913&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;59,842&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Principal balance of fixed rate note with Morgan Stanley (1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;12,500&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Leases and other obligations&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;17,569&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6,163&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;787,526&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;646,720&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Less: current portion&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2,026&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(13,749&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total Long-Term Obligations&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;785,500&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;632,971&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z2d1da80f1e1b4c8fb24d5d884387f78e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our $12.5 million fixed rate note with Morgan Stanley was included in our current portion of long-term obligations on our consolidated balance sheet at December 31, 2018. We paid off our fixed rate note in the third quarter of 2019.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Convertible Notes and Call Spread&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;0.125 Percent&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&#160;&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Convertible Senior Notes&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In December 2019, we entered into privately negotiated exchange and/or subscription agreements with certain new investors and certain holders of our existing &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;1%&lt;/span&gt; Notes to exchange $375.6 million of our &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;1%&lt;/span&gt; Notes for $439.3&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&#160;&lt;/span&gt;million of our 0.125% Notes, and to issue $109.5 million of our 0.125% Notes. We completed this exchange to reduce our cash interest payments, increase our conversion price and extend our maturity for a large portion of our debt. Additionally, i&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;n conjunction with the December 2019 exchange, we entered into a call spread transaction, which was comprised of purchasing note hedges and selling warrants, to minimize the impact of potential economic dilution upon conversion of our &lt;/span&gt;0.125% Notes&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; by increasing the effective conversion price even further.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Interest is payable semi-annually on June 15 and December 15 of each year for the &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;0.125%&lt;/span&gt; Notes. The &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;0.125%&lt;/span&gt; Notes are convertible at the option of the note holders prior to August 1, 2024 only under certain conditions. On or after August 1, 2024, the &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;0.125%&lt;/span&gt; Notes are initially convertible into approximately 6.6 million shares of common stock at a conversion price of approximately $83.28 per share. We will settle conversions of the notes, at our election, in cash, shares of our common stock or a combination of both. We may not redeem the &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;0.125%&lt;/span&gt; Notes prior to maturity, and no sinking fund is provided for them. If we undergo a fundamental change, holders may require us to purchase for cash all or any portion of their &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;0.125%&lt;/span&gt; Notes at a purchase price equal to 100 percent of the principal amount of the notes to be purchased, plus accrued and unpaid interest to, but excluding, the fundamental change purchase date.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;At December 31, 2019, we had the following &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;0.125%&lt;/span&gt; Notes outstanding (amounts in millions except price per share data):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="za16edea38bc54e628301a72484af85b3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;0.125% &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Outstanding principal balance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;548.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Maturity date&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: top; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;December 15, 2024&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Interest rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.125&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 88%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Conversion price per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;83.28&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total shares of common stock subject to conversion&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;The following table summarizes information about the equity and liability components of our outstanding &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;0.125%&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; Notes (in millions). We measured the fair values of the convertible notes outstanding based on quoted market prices, which is a Level 2 measurement at December 31, &lt;/span&gt;2019&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;:&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z7dc44d0a9b0443dda7f99ab1d70efbdf" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-indent: 3pt;"&gt;0.125% &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Fair value of outstanding notes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;558.7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Principal amount of convertible notes outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;548.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Unamortized portion of debt discount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;105.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Long-term debt&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;434.7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Carrying value of equity component&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;105.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 27pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Call Spread&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Additionally, i&lt;/span&gt;n conjunction with the December 2019 exchange, we entered into a call spread transaction, which was comprised of purchasing note hedges and selling warrants, to minimize the impact of potential economic dilution upon conversion of our &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;0.125%&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; Notes&lt;/span&gt; by increasing the conversion price even further. &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;The call spread cost us $&lt;/span&gt;52.6&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million, of which $&lt;/span&gt;108.7&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million was for the note hedge purchase, offset by $&lt;/span&gt;56.1&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million we received for selling the warrants. We increased our effective conversion price to $&lt;/span&gt;123.38&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; with the same number of underlying shares as our &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;0.125%&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; Notes&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Similar to our &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;0.125%&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; Notes&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;, our note hedges are subject to adjustment. Additionally, our note hedges are exercisable upon conversion of the &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;0.125%&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; Notes&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;. The note hedges will expire upon maturity of &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;0.125%&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; Notes&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;, or December 2024. The note hedges and warrants are separate transactions and are not part of the terms of our &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;0.125%&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; Notes&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;. The holders of the &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;0.125%&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; Notes&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; do not have any rights with respect to the note hedges and warrants.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We recorded the aggregate amount paid for the note hedges and the aggregate amount received for the warrants in additional paid-in capital in our consolidated balance sheet. We excluded shares under the note hedges from our calculation of diluted earnings per share as they were antidilutive. We will include the shares issuable under the warrants in our calculation of diluted earnings per share when the average market price per share of our common stock for the reporting period exceeds the strike price of the warrants.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;1 Percent Convertible Senior Notes&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In November 2014, we completed a $500 million offering of convertible senior notes, which mature in 2021 and bear interest at 1 percent. We used a substantial portion of the net proceeds from the issuance of the 1% Notes to repurchase $140 million in principal of our 2&#xbe; percent convertible senior notes, or 2&#xbe;% Notes. In December 2016, we issued an additional $185.5 million of 1% Notes in exchange for the redemption of $61.1 million of our &lt;span style="-sec-ix-hidden:Fact_5720e35e625f4851a419d661f07222c0"&gt;2&#xbe;&lt;/span&gt;% Notes. In December 2019, we exchanged a portion of our 1% Notes for &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;0.125%&lt;/span&gt; Notes. As a result, the principal balance of 1% Notes was $309.9 million. Additionally, we recorded a $21.9 million non-cash loss on early retirement of debt, reflecting the early retirement of a significant portion of our 1% Notes in December 2019.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;At December 31, 2019, we had the following 1% Notes outstanding (amounts in millions except price per share data):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zb43006877680441c81f9bc23fb14ec3e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;1% Notes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Outstanding principal balance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;309.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Maturity date&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: top; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;November 30, 2021&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Interest rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: top; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1 percent&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 88%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Conversion price per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;66.81&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total shares of common stock subject to conversion&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Interest is payable semi-annually in arrears on May 15 and November 15 of each year for the 1% Notes. The 1% Notes are convertible at the option of the note holders prior to July 1, 2021 only under certain conditions. On or after July 1, 2021, the 1% Notes are initially convertible into approximately 4.6 million shares of common stock at a conversion price of approximately $66.81 per share. We will settle conversions of the notes, at our election, in cash, shares of our common stock or a combination of both. We may not redeem the 1% Notes prior to maturity, and no sinking fund is provided for them. If we undergo a fundamental change, holders may require us to purchase for cash all or any portion of their 1% Notes at a purchase price equal to 100 percent of the principal amount of the notes to be purchased, plus accrued and unpaid interest to, but excluding, the fundamental change purchase date.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;The following table summarizes information about the equity and liability components of our outstanding &lt;/span&gt;1%&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; Notes (in millions). We measured the fair values of the convertible notes outstanding based on quoted market prices, which is a Level 2 measurement at December 31, &lt;/span&gt;2019&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;:&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zabdbc8437c344a2893cd480c7c4bf557" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-indent: 16pt;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Fair value of outstanding notes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;354.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;725.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Principal amount of convertible notes outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;309.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;685.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Unamortized portion of debt discount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;32.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;110.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Long-term debt&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;275.3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;568.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Carrying value of equity component&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;33.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;219.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We account for our convertible notes using an accounting standard that requires us to assign a value to our convertible debt equal to the estimated fair value of similar debt instruments without the conversion feature and to record the remaining portion in equity. As a result, we recorded our convertible notes at a discount, which we are amortizing as additional non-cash interest expense over the expected life of the respective debt. We determined our nonconvertible debt borrowing rate using a combination of the present value of the debt&#x2019;s cash flows and a Black-Scholes valuation model. The following table summarizes the nonconvertible borrowing rate, effective interest rate and amortization period of our debt discount for our convertible notes:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z42f3873bea834b268c1005c0970cb12c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 39.53%; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 2.25%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28.83%; vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;1% Notes&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 1.39%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28%; vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;0.125%&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width: 39.53%; vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Nonconvertible debt borrowing rate&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 2.25%; vertical-align: bottom; background-color: #CCEEFF;"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28.83%; vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;7.4 percent&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 1.39%; vertical-align: top; background-color: #CCEEFF;"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28%; vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4.4 percent&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width: 39.53%; vertical-align: bottom; background-color: #FFFFFF;"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effective interest rate (1)&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 2.25%; vertical-align: bottom; background-color: #FFFFFF;"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28.83%; vertical-align: bottom; background-color: #FFFFFF;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;7.5 percent&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 1.39%; vertical-align: top; background-color: #FFFFFF;"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28%; vertical-align: bottom; background-color: #FFFFFF;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4.9 percent&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width: 39.53%; vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Amortization period of debt discount&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 2.25%; vertical-align: bottom; background-color: #CCEEFF;"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28.83%; vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;7 years&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 1.39%; vertical-align: top; background-color: #CCEEFF;"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28%; vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;5 years&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z644a31acdd52488c97d7adc5c94171fd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;For our 1% Notes, our effective interest rate represents our effective interest rate after our December 2019 debt exchange.&#160;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our total interest expense for our outstanding senior convertible notes for the years ended December 31, 2019, 2018 and 2017 included $39.3 million, $35.2 million and $32.5 million, respectively, of non-cash interest expense related to the amortization of the debt discount and debt issuance costs for our convertible notes.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Financing Arrangements&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Line of Credit Arrangement&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In June 2015, we entered into a five-year revolving line of credit agreement with Morgan Stanley Private Bank, National Association, or Morgan Stanley, which we amended in February 2016. Under the amended credit agreement, Morgan Stanley provided a maximum of $30 million of revolving credit for general working capital purposes. During the third quarter of 2019, we paid off our total outstanding borrowings of $12.5 million under the agreement and subsequently terminated the agreement.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Research and Development and Manufacturing Facilities&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In July 2017, we purchased the building that houses our primary R&amp;amp;D facility for $79.4 million and our manufacturing facility for $14.0 million. We financed the purchase of these two facilities with mortgage debt of $60.4 million in total. Our primary R&amp;amp;D facility mortgage has an interest rate of 3.88 percent. Our manufacturing facility mortgage has an interest rate of 4.20 percent. During the first five years of both mortgages, we are only required to make interest payments. Both mortgages mature in August 2027.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;As a result of the purchase, we extinguished the financing liability we had previously recorded on our balance sheet for our primary R&amp;amp;D facility. The difference between the purchase price of our primary R&amp;amp;D facility and the carrying value of our financing liability at the time of the purchase was $7.7 million. We recognized this amount as a non-cash loss on extinguishment of financing liability for leased facility in our consolidated results of operations in the third quarter of 2017. We previously accounted for the lease of our manufacturing facility as an operating lease. We capitalized the purchase price of the manufacturing facility as a fixed asset in the third quarter of 2017.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Maturity Schedules&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Annual debt and other obligation maturities, including fixed and determinable interest, at December 31, 2019 are as follows (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zbf1bb99a34ec45e78be045fb2e06c256" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2020&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6,260&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2021&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;316,114&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2022&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3,495&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2023&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4,180&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2024&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;553,006&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;64,429&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Subtotal&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;947,484&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Less: current portion&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2,026&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Less: fixed and determinable interest&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(28,014&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Less: unamortized portion of debt discount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(137,975&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Plus: lease liabilities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;17,235&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;796,704&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Operating Leases&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Ionis Leases&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We lease a facility adjacent to our manufacturing facility that has laboratory and office space that we use to support our manufacturing facility. We lease this space under a non-cancelable operating lease with an initial term ending in June 2021 and an option to extend the lease for up to two&#160;five-year periods.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We also lease additional office spaces. We sublease a portion of one of these spaces to Akcea. We lease these spaces under non-cancelable operating leases with initial terms ending in 2023 with options to extend the leases for one&#160;five-year period. The sublease with Akcea is eliminated in our consolidated financial statements.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Akcea Lease&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea entered into an operating lease agreement for office space located in Boston, Massachusetts for its new corporate headquarters in the second quarter of 2018. The lease commencement date was in August 2018 and Akcea took occupancy in September 2018. Akcea is leasing this space under a non-cancelable operating lease with an initial term ending after 123 months and an option to extend the lease for an additional five-year term. Under the lease agreement, Akcea received a three-month free rent period, which commenced on August 15, 2018, and a tenant improvement allowance up to $3.8 million. Akcea provided the lessor with a letter of credit to secure its obligations under the lease in the initial amount of $2.4 million, to be reduced to $1.8 million on the third anniversary of the rent commencement date and to $1.2 million on the fifth anniversary of the rent commencement date if Akcea meets certain conditions set forth in the lease at each such time.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;When we determined our lease term for our operating lease right-of-use assets and lease liabilities for these leases, we did not include the extension options for these leases.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Amounts related to our operating leases were as follows (dollar amounts in millions):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z3d2e84cc75f74373b53127abdaff1269" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;At December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Right-of-use operating lease assets (1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;12.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Operating lease liabilities (2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;17.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average remaining lease term&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;8.1 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average discount rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;7.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z49deda5f82f74fe1af4f88874881e5f9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Included in &lt;span style="-sec-ix-hidden:Fact_f81ca57385a04657b8ecd0f06d505159"&gt;deposits and other assets&lt;/span&gt; on our consolidated balance sheet.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z26af2e3421ce4117a512d5aa97d68ee7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Current portion of $2.0 million was included in &lt;span style="-sec-ix-hidden:Fact_530181678e9244af8b37885d3ba85980"&gt;current portion of long-term obligations&lt;/span&gt; on our consolidated balance sheet, with the difference included in &lt;span style="-sec-ix-hidden:Fact_9c37cb3853f74a4f821bbe4ed37a06ba"&gt;long-term obligations&lt;/span&gt;.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;During the year ended December 31, 2019, we paid $3.9 million of lease payments, which was included in operating activities in our consolidated statement of cash flows.&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;As of December 31, 2019, the future payments for our operating lease liabilities are as follows (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z21d6f95567c944849963a4017490880d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Operating&lt;/span&gt; &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Year ending December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2020&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3,285&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -0.2pt; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2021&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3,022&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -0.2pt; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2022&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,781&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2023&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,520&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2024&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,396&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;9,465&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total minimum lease payments&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;23,469&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Less:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Imputed interest&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(6,234&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 36.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total operating lease liabilities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;17,235&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Rent expense was $3.6 million, $2.6 million and $1.7 million for the years ended December 31, 2019, 2018 and 2017, respectively.&lt;/div&gt;
</us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="c20190101to20191231"
      id="Text_208586d6f378473eabd791ddd2021443">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The carrying value of our long-term obligations was as follows (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z3479120fb70c49dfbea272f920706f19" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.125 percent convertible senior notes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;434,711&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1 percent convertible senior notes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;275,333&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;568,215&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Long-term mortgage debt&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;59,913&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;59,842&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Principal balance of fixed rate note with Morgan Stanley (1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;12,500&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Leases and other obligations&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;17,569&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6,163&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;787,526&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;646,720&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Less: current portion&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2,026&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(13,749&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total Long-Term Obligations&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;785,500&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;632,971&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z2d1da80f1e1b4c8fb24d5d884387f78e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our $12.5 million fixed rate note with Morgan Stanley was included in our current portion of long-term obligations on our consolidated balance sheet at December 31, 2018. We paid off our fixed rate note in the third quarter of 2019.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_e8724a5b059d4f8799a8feaa202dd539"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ions:LongTermDebtAndOtherObligations
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="-3"
      id="Fact_cc24fb43c0744f1c98325749d3d1c0eb"
      unitRef="U001">434711000</ions:LongTermDebtAndOtherObligations>
    <ions:LongTermDebtAndOtherObligations
      contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="-3"
      id="Fact_65be5fa6a2434040beb0d9ae2a2ca4aa"
      unitRef="U001">0</ions:LongTermDebtAndOtherObligations>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_678c9c8d08e84bc49b41f282f783fa1e"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_d0d025675d994c9489fb7c521ed3ca93"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ions:LongTermDebtAndOtherObligations
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-3"
      id="Fact_cab8c72e622844b2bff548c7151f9645"
      unitRef="U001">275333000</ions:LongTermDebtAndOtherObligations>
    <ions:LongTermDebtAndOtherObligations
      contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-3"
      id="Fact_263762c2879f49e19df48df907a46cf1"
      unitRef="U001">568215000</ions:LongTermDebtAndOtherObligations>
    <ions:LongTermDebtAndOtherObligations
      contextRef="c20191231_DebtInstrumentAxis_LongTermMortgageDebtMember"
      decimals="-3"
      id="Fact_7526ddee5b884532b24be01e4d495612"
      unitRef="U001">59913000</ions:LongTermDebtAndOtherObligations>
    <ions:LongTermDebtAndOtherObligations
      contextRef="c20181231_DebtInstrumentAxis_LongTermMortgageDebtMember"
      decimals="-3"
      id="Fact_1a31cb06bce14608b6b4bc53c537a2e8"
      unitRef="U001">59842000</ions:LongTermDebtAndOtherObligations>
    <ions:LongTermDebtAndOtherObligations
      contextRef="c20191231_DebtInstrumentAxis_FixedRateNoteWithMorganStanleyMember"
      decimals="-3"
      id="Fact_e8de7b5791e54d49b936fa0044b283a0"
      unitRef="U001">0</ions:LongTermDebtAndOtherObligations>
    <ions:LongTermDebtAndOtherObligations
      contextRef="c20181231_DebtInstrumentAxis_FixedRateNoteWithMorganStanleyMember"
      decimals="-3"
      id="Fact_dd04e3efb270478489cafc35f9191531"
      unitRef="U001">12500000</ions:LongTermDebtAndOtherObligations>
    <ions:LongTermDebtAndOtherObligations
      contextRef="c20191231_DebtInstrumentAxis_LeasesAndOtherObligationsMember"
      decimals="-3"
      id="Fact_4f4ce1cf534445a182bc4dc79c4da3ed"
      unitRef="U001">17569000</ions:LongTermDebtAndOtherObligations>
    <ions:LongTermDebtAndOtherObligations
      contextRef="c20181231_DebtInstrumentAxis_LeasesAndOtherObligationsMember"
      decimals="-3"
      id="Fact_14ee837947184542bf24c811e63d710b"
      unitRef="U001">6163000</ions:LongTermDebtAndOtherObligations>
    <ions:LongTermDebtAndOtherObligations
      contextRef="c20191231"
      decimals="-3"
      id="Fact_67f1e8de33db4b3ba71a251d6969a0e4"
      unitRef="U001">787526000</ions:LongTermDebtAndOtherObligations>
    <ions:LongTermDebtAndOtherObligations
      contextRef="c20181231"
      decimals="-3"
      id="Fact_0db6c0acf39c4704b8b7fb0682124be0"
      unitRef="U001">646720000</ions:LongTermDebtAndOtherObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="c20191231"
      decimals="-3"
      id="Fact_66f728e151b74fe99d367269b42506b7"
      unitRef="U001">2026000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="c20181231"
      decimals="-3"
      id="Fact_6b303576d07b435ebdc0b94cf229a5a7"
      unitRef="U001">13749000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <ions:LongTermDebtAndOtherObligationsNoncurrent
      contextRef="c20191231"
      decimals="-3"
      id="Fact_147209ef0e4d4ccf9a6541966995a76b"
      unitRef="U001">785500000</ions:LongTermDebtAndOtherObligationsNoncurrent>
    <ions:LongTermDebtAndOtherObligationsNoncurrent
      contextRef="c20181231"
      decimals="-3"
      id="Fact_85488b1118b143d68b8dce7fa49d282e"
      unitRef="U001">632971000</ions:LongTermDebtAndOtherObligationsNoncurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="c20181231_DebtInstrumentAxis_FixedRateNoteWithMorganStanleyMember"
      decimals="-5"
      id="Fact_85c8de06d6504ef7b8e7379132dfcceb"
      unitRef="U001">12500000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_4bea2f4a817c43a9a04ad1e23ed64460"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_1870776015794dfc8ef5f8b1e447336c"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-5"
      id="Fact_c20e03a6b29c48f297e64a4679fa9c5f"
      unitRef="U001">375600000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_b16e24609ee743c7bc4f5ff336547c52"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember"
      decimals="-5"
      id="Fact_712a7e9c20e2446687234da15c55574b"
      unitRef="U001">439300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_ee88310c4297461c9e36d233141d8e6d"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember"
      decimals="-5"
      id="Fact_4fb2d114d9054ec1ab34d5bc942df800"
      unitRef="U001">109500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_91e74186c76c4d6f9f3b0792c25a8126"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_b678b3b287184ce883f541de9b3318b0"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_243b14e84d1842d5a1561cbadfdc7501"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_aca37e6592634dfea9eef91832500545"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_93e447d776f44e03b6def90e87589945"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="-5"
      id="Fact_bdb0f6e71c464c07a7fcbc83441b7a3d"
      unitRef="U002">6600000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="2"
      id="Fact_11e47b80c0ea4c0b84c2b33098b7b371"
      unitRef="U004">83.28</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_1853ce4f8b7b48fd95ac8e504bc98be7"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_dfcecee6bd19487eaf70edea7c8f81ca"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ions:DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange
      contextRef="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="2"
      id="Fact_c714ec93e83942c5ab6d1b22a0ca3d32"
      unitRef="U003">1</ions:DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_a71fb8ccb76643209283717603f36b68">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;At December 31, 2019, we had the following &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;0.125%&lt;/span&gt; Notes outstanding (amounts in millions except price per share data):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="za16edea38bc54e628301a72484af85b3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;0.125% &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Outstanding principal balance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;548.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Maturity date&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: top; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;December 15, 2024&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Interest rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.125&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 88%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Conversion price per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;83.28&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total shares of common stock subject to conversion&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;The following table summarizes information about the equity and liability components of our outstanding &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;0.125%&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; Notes (in millions). We measured the fair values of the convertible notes outstanding based on quoted market prices, which is a Level 2 measurement at December 31, &lt;/span&gt;2019&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;:&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z7dc44d0a9b0443dda7f99ab1d70efbdf" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-indent: 3pt;"&gt;0.125% &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Fair value of outstanding notes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;558.7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Principal amount of convertible notes outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;548.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Unamortized portion of debt discount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;105.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Long-term debt&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;434.7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Carrying value of equity component&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;105.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 27pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;At December 31, 2019, we had the following 1% Notes outstanding (amounts in millions except price per share data):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zb43006877680441c81f9bc23fb14ec3e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;1% Notes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Outstanding principal balance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;309.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Maturity date&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: top; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;November 30, 2021&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Interest rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: top; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1 percent&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 88%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Conversion price per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;66.81&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total shares of common stock subject to conversion&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;The following table summarizes information about the equity and liability components of our outstanding &lt;/span&gt;1%&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; Notes (in millions). We measured the fair values of the convertible notes outstanding based on quoted market prices, which is a Level 2 measurement at December 31, &lt;/span&gt;2019&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;:&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zabdbc8437c344a2893cd480c7c4bf557" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold; text-indent: 16pt;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Fair value of outstanding notes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;354.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;725.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Principal amount of convertible notes outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;309.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;685.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Unamortized portion of debt discount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;32.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;110.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Long-term debt&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;275.3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;568.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Carrying value of equity component&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;33.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;219.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We account for our convertible notes using an accounting standard that requires us to assign a value to our convertible debt equal to the estimated fair value of similar debt instruments without the conversion feature and to record the remaining portion in equity. As a result, we recorded our convertible notes at a discount, which we are amortizing as additional non-cash interest expense over the expected life of the respective debt. We determined our nonconvertible debt borrowing rate using a combination of the present value of the debt&#x2019;s cash flows and a Black-Scholes valuation model. The following table summarizes the nonconvertible borrowing rate, effective interest rate and amortization period of our debt discount for our convertible notes:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z42f3873bea834b268c1005c0970cb12c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 39.53%; vertical-align: bottom;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 2.25%; vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28.83%; vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;1% Notes&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 1.39%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28%; vertical-align: bottom; border-bottom: #000000 2px solid;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;0.125%&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; Notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width: 39.53%; vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Nonconvertible debt borrowing rate&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 2.25%; vertical-align: bottom; background-color: #CCEEFF;"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28.83%; vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;7.4 percent&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 1.39%; vertical-align: top; background-color: #CCEEFF;"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28%; vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4.4 percent&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width: 39.53%; vertical-align: bottom; background-color: #FFFFFF;"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effective interest rate (1)&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 2.25%; vertical-align: bottom; background-color: #FFFFFF;"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28.83%; vertical-align: bottom; background-color: #FFFFFF;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;7.5 percent&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 1.39%; vertical-align: top; background-color: #FFFFFF;"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28%; vertical-align: bottom; background-color: #FFFFFF;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4.9 percent&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="width: 39.53%; vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Amortization period of debt discount&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 2.25%; vertical-align: bottom; background-color: #CCEEFF;"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28.83%; vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;7 years&lt;/div&gt;&lt;/td&gt;
    &lt;td style="width: 1.39%; vertical-align: top; background-color: #CCEEFF;"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 28%; vertical-align: bottom; background-color: #CCEEFF;"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;5 years&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z644a31acdd52488c97d7adc5c94171fd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;For our 1% Notes, our effective interest rate represents our effective interest rate after our December 2019 debt exchange.&#160;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_0e5fc93e472946cc9732114aaf09fe86"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_b355bf734b4d4619b79d46bb66e07d75"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="-5"
      id="Fact_57777fe91a8e4f29a6ef267206ee9a82"
      unitRef="U001">548800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      id="Fact_717eebd3862f421ca0587a6d283178c9">2024-12-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_f57c2bf3954e4b06bdb6e73d241258c0"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="2"
      id="Fact_a265121c183843bd982ee24779b2a3e1"
      unitRef="U004">83.28</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="-5"
      id="Fact_a8446d3306204ee4841e3d9e1f0b0e88"
      unitRef="U002">6600000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_6b7a3e820d8b4273b11b894d2ba67007"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_36c017cad1564114b1df3b506c8236f1"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"
      decimals="-5"
      id="Fact_2f64fb9997454976b38c6e2b417f5aec"
      unitRef="U001">558700000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="-5"
      id="Fact_3403814cbf0745fd98f50890c7c3cf9e"
      unitRef="U001">548800000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="-5"
      id="Fact_832aa30f085e43a8865c2e2d32fd5473"
      unitRef="U001">105200000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="-5"
      id="Fact_889e7ec833e44e569fb87f9f739bbe7b"
      unitRef="U001">434700000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="-5"
      id="Fact_63d1f0908e44402a9baa9b04f5053aab"
      unitRef="U001">105800000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_1eb86644c97d419d93743b0512053bf1"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ions:CallSpread
      contextRef="c20191201to20191231"
      decimals="-5"
      id="Fact_e9d4aad460e644458ec285d77482089c"
      unitRef="U001">52600000</ions:CallSpread>
    <us-gaap:PaymentsForHedgeFinancingActivities
      contextRef="c20191201to20191231"
      decimals="-5"
      id="Fact_0994e1dc04004d2382a34c5e13628fa1"
      unitRef="U001">108700000</us-gaap:PaymentsForHedgeFinancingActivities>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="c20191201to20191231"
      decimals="-5"
      id="Fact_129b374a00b44cc89defdbe6353d570e"
      unitRef="U001">56100000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <ions:DebtInstrumentConvertibleConversionPriceIncludingCallSpread
      contextRef="c20191231"
      decimals="2"
      id="Fact_47a59f154aa241e092e3cb2ff63ce803"
      unitRef="U004">123.38</ions:DebtInstrumentConvertibleConversionPriceIncludingCallSpread>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_d2c7414fb1da467f803bda3bed07ee1b"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_7b8ba4a02a954d6599d6024b18243e28"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_7a8ce4e67bd54f9a987fa4ed687d2240"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_3d6dde904f90445d93305af76cf6eda2"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_9bb8ca84262b41cdb2763e3d9fb4239f"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_4451c7a7d9d84d2780c91b575f56d194"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_a138942c9a354318adbd51f712f26e3a"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20141130_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-6"
      id="Fact_ae69fb3096d04ec386cf18bda382f2ac"
      unitRef="U001">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_5aa11ec0f17e45ff8bae60179009c497"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_eb07200e0d7e47e8980856189249c81b"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="c20141130_DebtInstrumentAxis_ConvertibleSeniorNotes275PercentMember"
      decimals="-6"
      id="Fact_a7cfea2321f84b2196ac4f1c44ae3c68"
      unitRef="U001">140000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20161231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-5"
      id="Fact_40b369e59fd54938a3c76d88c97539ee"
      unitRef="U001">185500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_8ed18eaff8004156b3c13189a20eab93"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="c20161231_DebtInstrumentAxis_ConvertibleSeniorNotes275PercentMember"
      decimals="-5"
      id="Fact_c377503f2bbe44b488a9c42e68e820e1"
      unitRef="U001">61100000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_72efeb8706804393b794e69da1859ca9"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_52a80f2cfee04eb587e3582cda96ceb8"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_7f4517d888a848e8aa549382b1f663fa"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-5"
      id="Fact_73cc83fd51084b739e29305c9bcf6432"
      unitRef="U001">309900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20191201to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-5"
      id="Fact_e56c4f7d46164e5682b05b11e5a76ff0"
      unitRef="U001">21900000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_21ae763200804eda89d695f565a9b421"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_351f7a4cc22d4c609a76582f7cafaced"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_d9759ef53cf341c89d402861e03cffa5"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-5"
      id="Fact_4c0a1cf7da584572b5539e94887de88d"
      unitRef="U001">309900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      id="Fact_e4ab161cf8e14dac8e510129236b076a">2021-11-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_3e00958972ef4dd78ced0398e546c3e7"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_95d9dc164aba4bc4906d223af6cce4cd"
      unitRef="U004">66.81</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-5"
      id="Fact_c84bb6217a084a41ad136652cc09e03d"
      unitRef="U002">4600000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_f0bd4c0c0e7f4e15a243cf31a30d5fe3"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_5195a53072b24193b8693cceb851285c"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_599a6c650ba949af823e3721d1dcc7ab"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-5"
      id="Fact_c3b8a56b35774f09a683069e7da23a49"
      unitRef="U002">4600000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_1e3f531b50ce45a78f352059a2aabe03"
      unitRef="U004">66.81</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_fef53aa8a8f64806813c1c9401c10e7c"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_8147e405f341494fba590f9fd7e1adbe"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ions:DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange
      contextRef="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_fdfc68a3935a465f936cbb5325d0f693"
      unitRef="U003">1</ions:DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_6957f3faaf5447e0a8c23e16d21eb4cd"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"
      decimals="-5"
      id="Fact_b112bc86a62a40879d379e5de93d9d13"
      unitRef="U001">354800000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member"
      decimals="-5"
      id="Fact_19578032f14c46009a660da235b4a752"
      unitRef="U001">725000000.0</us-gaap:LongTermDebtFairValue>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-5"
      id="Fact_77697145541a4cb3a1de5998960249dc"
      unitRef="U001">309900000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-5"
      id="Fact_37a87f48cea1468dbabf7142062c1fde"
      unitRef="U001">685500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-5"
      id="Fact_692ce55b49e842f39e92b6574d933927"
      unitRef="U001">32800000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet
      contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-5"
      id="Fact_927ea0104b9648739f8cadf26fe8c648"
      unitRef="U001">110800000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumNet>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-5"
      id="Fact_4eefe8c5ad4f45dab9f8431005a68c88"
      unitRef="U001">275300000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-5"
      id="Fact_394e50c3174b419995a848e3ad315d86"
      unitRef="U001">568200000</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-5"
      id="Fact_615b424156904461b65ab8fba56baf57"
      unitRef="U001">33500000</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
      contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-5"
      id="Fact_275ed98d8a534881b164a506f08888da"
      unitRef="U001">219000000.0</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_54d20492d3454961ab50976a25101d84"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_4b335b7942d14e2abc8562afa2e5f0ec"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"
      decimals="3"
      id="Fact_ad2c1bc1c1f846a1affa31c79be4b69c"
      unitRef="U003">0.074</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentMeasurementInput
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember_MeasurementInputTypeAxis_MeasurementInputDiscountRateMember"
      decimals="3"
      id="Fact_596bdc839a504047b97a479e25a26ff8"
      unitRef="U003">0.044</us-gaap:DebtInstrumentMeasurementInput>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="3"
      id="Fact_04d37423456f431eae8b542d5d3b0213"
      unitRef="U003">0.075</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="3"
      id="Fact_6ac68bb7b1894b778d0cc3db62132135"
      unitRef="U003">0.049</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      id="Fact_5e9b605d305346328ae877fed8602d67">P7Y</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1
      contextRef="c20190101to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      id="Fact_0958d84136bc4152acbe44cfeef2d965">P5Y</us-gaap:DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_e30378472c6741629087ed2375181d83"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="c20190101to20191231"
      decimals="-5"
      id="Fact_9c53099ee180469b94aa9696977d2880"
      unitRef="U001">39300000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="c20180101to20181231"
      decimals="-5"
      id="Fact_bdbef3ccc85649118ae89b354a641e27"
      unitRef="U001">35200000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="c20170101to20171231"
      decimals="-5"
      id="Fact_08ed41e893e1431f80a65f44ee96fab5"
      unitRef="U001">32500000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DebtInstrumentTerm
      contextRef="c20190101to20191231_CreditFacilityAxis_RevolvingCreditFacilityMember_LineOfCreditFacilityAxis_MorganStanleyPrivateBankNationalAssociationMember"
      id="Fact_a08d8b007c144c47ba522cd66c16754b">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="c20191231_CreditFacilityAxis_RevolvingCreditFacilityMember_LineOfCreditFacilityAxis_MorganStanleyPrivateBankNationalAssociationMember"
      decimals="-6"
      id="Fact_89fd661deb0b4c3fa02f86026008098b"
      unitRef="U001">30000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="c20190701to20190930_DebtInstrumentAxis_FixedRateNoteWithMorganStanleyMember"
      decimals="-5"
      id="Fact_df1b80118efc4ee18a12e9720dbc121d"
      unitRef="U001">12500000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:PaymentsToAcquireBuildings
      contextRef="c20170701to20170731_PropertyPlantAndEquipmentByTypeAxis_PrimaryResearchAndDevelopmentFacilityMember"
      decimals="-5"
      id="Fact_4a0c024b965c4f51b897f9cf5bc80424"
      unitRef="U001">79400000</us-gaap:PaymentsToAcquireBuildings>
    <us-gaap:PaymentsToAcquireBuildings
      contextRef="c20170701to20170731_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"
      decimals="-5"
      id="Fact_06974c574f644e5baacbd3f8e2c599a6"
      unitRef="U001">14000000.0</us-gaap:PaymentsToAcquireBuildings>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c20170731_DebtInstrumentAxis_LongTermMortgageDebtMember"
      decimals="-5"
      id="Fact_1c1b0d341f0d4a39b8dd7164eab2e39d"
      unitRef="U001">60400000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20170731_PropertyPlantAndEquipmentByTypeAxis_PrimaryResearchAndDevelopmentFacilityMember"
      decimals="4"
      id="Fact_2e21e0a6347e447a8991607c0227050a"
      unitRef="U003">0.0388</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20170731_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"
      decimals="4"
      id="Fact_b8df62c274f14f0499a84c79aa3dd4f9"
      unitRef="U003">0.0420</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ions:PeriodToMakeInterestOnlyPaymentsOnMortgageLoan
      contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"
      id="Fact_cec9dfdd051e4462bf766547d85be9b4">P5Y</ions:PeriodToMakeInterestOnlyPaymentsOnMortgageLoan>
    <ions:PeriodToMakeInterestOnlyPaymentsOnMortgageLoan
      contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_PrimaryResearchAndDevelopmentFacilityMember"
      id="Fact_885a5330a5d64c1ca25849873c2df457">P5Y</ions:PeriodToMakeInterestOnlyPaymentsOnMortgageLoan>
    <ions:GainLossOnExtinguishmentOfFinancingLiability
      contextRef="c20170701to20170930_PropertyPlantAndEquipmentByTypeAxis_PrimaryResearchAndDevelopmentFacilityMember"
      decimals="-5"
      id="Fact_91f1c941f9ad432eb652599a51fbba84"
      unitRef="U001">-7700000</ions:GainLossOnExtinguishmentOfFinancingLiability>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_73b31c6480504477b1a7dc3c319a40db">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Annual debt and other obligation maturities, including fixed and determinable interest, at December 31, 2019 are as follows (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zbf1bb99a34ec45e78be045fb2e06c256" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2020&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6,260&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2021&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;316,114&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2022&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3,495&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2023&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4,180&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2024&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;553,006&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;64,429&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Subtotal&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;947,484&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Less: current portion&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2,026&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Less: fixed and determinable interest&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(28,014&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Less: unamortized portion of debt discount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(137,975&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Plus: lease liabilities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;17,235&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;796,704&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember"
      decimals="-3"
      id="Fact_d2eb54062a6d4f188ef1dbae3b8653d3"
      unitRef="U001">6260000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember"
      decimals="-3"
      id="Fact_c42e928b65cd45aa923675e567769ac7"
      unitRef="U001">316114000</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember"
      decimals="-3"
      id="Fact_6b7eb3455bef4825bec5934f0ca8a9f2"
      unitRef="U001">3495000</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInFourthYear
      contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember"
      decimals="-3"
      id="Fact_5163088d8dfb4bd8afb6a945c3e15b83"
      unitRef="U001">4180000</us-gaap:ContractualObligationDueInFourthYear>
    <us-gaap:ContractualObligationDueInFifthYear
      contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember"
      decimals="-3"
      id="Fact_04194527fb664e52a3ac79595e34b654"
      unitRef="U001">553006000</us-gaap:ContractualObligationDueInFifthYear>
    <us-gaap:ContractualObligationDueAfterFifthYear
      contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember"
      decimals="-3"
      id="Fact_74f3f2a83bb64af5b0b4b21df7d35ef0"
      unitRef="U001">64429000</us-gaap:ContractualObligationDueAfterFifthYear>
    <us-gaap:ContractualObligation
      contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember"
      decimals="-3"
      id="Fact_41f58f8c96774a38af7b7c1cc41eabb9"
      unitRef="U001">947484000</us-gaap:ContractualObligation>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent
      contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember"
      decimals="-3"
      id="Fact_6f4d80245c92479cb52c2337f5f2441b"
      unitRef="U001">2026000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:InterestPayableCurrentAndNoncurrent
      contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember"
      decimals="-3"
      id="Fact_53dcce35c24c453fbe6ca8ac55743624"
      unitRef="U001">28014000</us-gaap:InterestPayableCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember"
      decimals="-3"
      id="Fact_dd49b690e0844ab6ae886462d160f033"
      unitRef="U001">137975000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredRentCredit
      contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember"
      decimals="-3"
      id="Fact_59ceb438da8a4afa9f9b8d13af3dfa2f"
      unitRef="U001">17235000</us-gaap:DeferredRentCredit>
    <ions:LongTermDebtAndOtherObligationsNoncurrent
      contextRef="c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember"
      decimals="-3"
      id="Fact_e4222f3c3fbf48189f3454e1d53ce42c"
      unitRef="U001">796704000</ions:LongTermDebtAndOtherObligationsNoncurrent>
    <ions:LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease
      contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember"
      decimals="INF"
      id="Fact_1404db7a5a0e4be8b2654e7362b1b46b"
      unitRef="U012">2</ions:LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="c20191231_PropertyPlantAndEquipmentByTypeAxis_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember"
      id="Fact_3fa1c2318c4d4b2f8088992fbf02bb6d">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <ions:LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease
      contextRef="c20190101to20191231_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember"
      decimals="INF"
      id="Fact_cb77855b95994f0488becac7637cd2b1"
      unitRef="U012">1</ions:LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="c20191231_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember"
      id="Fact_5cb70db62bdc4486992b4feba32be9c4">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceForCorporateHeadquartersMember"
      id="Fact_1cf767bfa2604645b03665b44c8069bb">P123M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceForCorporateHeadquartersMember"
      id="Fact_a817cf4e10ab4fdc88a9eaaa0d2f61a5">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <ions:LesseeOperatingLeasePeriodOfFreeRent
      contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceForCorporateHeadquartersMember"
      id="Fact_ba6fa8c8bcc140258a36c6828c2ab217">P3M</ions:LesseeOperatingLeasePeriodOfFreeRent>
    <ions:LesseeOperatingLeaseAllowanceForTenantImprovements
      contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceForCorporateHeadquartersMember"
      decimals="-5"
      id="Fact_4d5ed2a157b248b29eab88a7bb6399b9"
      unitRef="U001">3800000</ions:LesseeOperatingLeaseAllowanceForTenantImprovements>
    <ions:LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation
      contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceForCorporateHeadquartersMember"
      decimals="-5"
      id="Fact_4ea76f481ee94befba9ffed4fb541c89"
      unitRef="U001">2400000</ions:LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation>
    <ions:LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate
      contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceForCorporateHeadquartersMember"
      decimals="-5"
      id="Fact_5cd8770ef41646968466e8170f8df26c"
      unitRef="U001">1800000</ions:LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate>
    <ions:LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate
      contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_PropertyPlantAndEquipmentByTypeAxis_OfficeSpaceForCorporateHeadquartersMember"
      decimals="-5"
      id="Fact_1ff3895264114d1abecd3d9873549a39"
      unitRef="U001">1200000</ions:LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate>
    <ions:LesseeOperatingLeaseInformationTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_617aaf4bea8246bc99dc65dcafe47f72">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Amounts related to our operating leases were as follows (dollar amounts in millions):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z3d2e84cc75f74373b53127abdaff1269" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;At December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Right-of-use operating lease assets (1)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;12.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Operating lease liabilities (2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;17.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average remaining lease term&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;8.1 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average discount rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;7.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z49deda5f82f74fe1af4f88874881e5f9" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Included in &lt;span style="-sec-ix-hidden:Fact_f81ca57385a04657b8ecd0f06d505159"&gt;deposits and other assets&lt;/span&gt; on our consolidated balance sheet.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z26af2e3421ce4117a512d5aa97d68ee7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Current portion of $2.0 million was included in &lt;span style="-sec-ix-hidden:Fact_530181678e9244af8b37885d3ba85980"&gt;current portion of long-term obligations&lt;/span&gt; on our consolidated balance sheet, with the difference included in &lt;span style="-sec-ix-hidden:Fact_9c37cb3853f74a4f821bbe4ed37a06ba"&gt;long-term obligations&lt;/span&gt;.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</ions:LesseeOperatingLeaseInformationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20191231"
      decimals="-5"
      id="Fact_23749203f9514c17a3eb9047effcbc3f"
      unitRef="U001">12600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="c20191231"
      decimals="-5"
      id="Fact_0bcc1def02bf4a9fae57dfb5f4021412"
      unitRef="U001">17200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="c20191231"
      id="Fact_ccfd1bbd8568445fb43b6a1d85973cc7">P8Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="c20191231"
      decimals="3"
      id="Fact_0f6726aa9c174130a3010b4dad4799ef"
      unitRef="U003">0.076</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20191231"
      decimals="-5"
      id="Fact_9b0c762d64a740078d7920512d9fd9e9"
      unitRef="U001">2000000.0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeasePayments
      contextRef="c20190101to20191231"
      decimals="-5"
      id="Fact_0b0968d7b6d44d43b94d14127e7b0391"
      unitRef="U001">3900000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_2cefc4cc8d6748129c33abcec77c053a">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;As of December 31, 2019, the future payments for our operating lease liabilities are as follows (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z21d6f95567c944849963a4017490880d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Operating&lt;/span&gt; &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Year ending December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2020&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3,285&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -0.2pt; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2021&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3,022&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -0.2pt; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2022&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,781&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2023&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,520&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2024&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,396&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Thereafter&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;9,465&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total minimum lease payments&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;23,469&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Less:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 18.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Imputed interest&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(6,234&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 36.7pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total operating lease liabilities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;17,235&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="c20191231"
      decimals="-3"
      id="Fact_46f76b117a04494ca6a17beb53f570c7"
      unitRef="U001">3285000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="c20191231"
      decimals="-3"
      id="Fact_a0c5aec014324c7cb0c840fa0ba4f4fd"
      unitRef="U001">3022000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="c20191231"
      decimals="-3"
      id="Fact_60d8f92c9a0245da92a6e5b3703538f4"
      unitRef="U001">2781000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="c20191231"
      decimals="-3"
      id="Fact_06719e85aaa649a793c4a758dc24108b"
      unitRef="U001">2520000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="c20191231"
      decimals="-3"
      id="Fact_a234894a94604af3851d9a9b9a7e0368"
      unitRef="U001">2396000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="c20191231"
      decimals="-3"
      id="Fact_9dfbcc29769149b7a7275bc1e34d886d"
      unitRef="U001">9465000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="c20191231"
      decimals="-3"
      id="Fact_1c01baaf54874ba59a14a7ef68852b77"
      unitRef="U001">23469000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="c20191231"
      decimals="-3"
      id="Fact_f5bf1724933445328ccdc1f5bcee5d01"
      unitRef="U001">6234000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="c20191231"
      decimals="-3"
      id="Fact_4b3b9da6657742a4adb29f8c455266b5"
      unitRef="U001">17235000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="c20190101to20191231"
      decimals="-5"
      id="Fact_c4dae47efc26426db76344c3495d0867"
      unitRef="U001">3600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="c20180101to20181231"
      decimals="-5"
      id="Fact_3fece8ea1f464d25a5ccc06fa0fb6da2"
      unitRef="U001">2600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="c20170101to20171231"
      decimals="-5"
      id="Fact_aa216fc8e41f4f6586b6e1b074494d8d"
      unitRef="U001">1700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="c20190101to20191231"
      id="Text_6d42e24e9e4a40f2b1346af8b0d12a02">
&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;4. Stockholders&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt; Equity&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Preferred Stock&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We are authorized to issue up to 15 million shares of &#x201c;blank check&#x201d; Preferred Stock. As of December 31, 2019, there were no shares of Preferred Stock outstanding. We have designated Series C Junior Participating Preferred Stock but have no issued or outstanding shares as of December 31, 2019.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Common Stock&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;At December 31, 2019 and 2018, we had 300 million shares of common stock authorized, of which 140.3 million and 137.9 million were issued and outstanding, respectively. As of December 31, 2019, total common shares reserved for future issuance were 26.2 million.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;During the years ended December 31, 2019, 2018 and 2017, we issued 3.1 million, 1.5 million and 1.7 million shares of common stock, respectively, for stock option exercises, vesting of restricted stock units, and ESPP purchases. We received net proceeds from these transactions of $119.7 million, $27.9 million and $22.9 million in 2019, 2018 and 2017, respectively.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Share Repurchase Program&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In September 2019, our board of directors approved an initial share repurchase program of up to $125 million of our common stock. Our stock repurchase program has no expiration date. Through December 31, 2019, we repurchased 535,000 shares for $34.4 million. In the first quarter of 2020, we repurchased an additional 1.5 million shares for $90.6 million.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Stock Plans&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;1989 Stock Option Plan&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In June 1989, our Board of Directors adopted, and the stockholders subsequently approved, a stock option plan that, as amended, provides for the issuance of non-qualified and incentive stock options for the purchase of up to 20.0 million shares of common stock to our employees, directors, and consultants. The plan expires in January 2024. The 1989 Plan does not allow us to grant stock bonuses or restricted stock awards and prohibits us from repricing any options outstanding under the plan unless our stockholders approve the repricing. Options vest over a four-year period, with 25 percent exercisable at the end of one year from the date of the grant and the balance vesting ratably, on a monthly basis, thereafter and have a term of seven years. At December 31, 2019, a total of 0.1 million options were outstanding, of which options to purchase 0.1 million shares were exercisable, and 0.04 million shares were available for future grant under the 1989 Plan.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;2011 Equity Incentive Plan&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In March 2011, our Board of Directors adopted, and the stockholders subsequently approved, a stock option plan that provides for the issuance of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and performance cash awards to our employees, directors, and consultants. In June 2015, May 2017 and June 2019, after receiving approval from our stockholders, we amended our 2011 Equity Incentive Plan to increase the total number of shares reserved for issuance. We increased the shares available under our 2011 Equity Incentive Plan from 5.5 million to 11.0 million in June 2015, from 11.0 million to 16.0 million in May 2017 and from 16.0 million to 23.0 million in June 2019. The plan expires in June 2021. The 2011 Plan does not allow us to reduce the exercise price of any outstanding stock options or stock appreciation rights or cancel any outstanding stock options or stock appreciation rights that have an exercise price or strike price greater than the current fair market value of the common stock in exchange for cash or other stock awards unless our stockholders approve such action. Currently we anticipate awarding only options and restricted stock unit awards to our employees, directors and consultants. Under the 2011 Plan, stock options cannot vest in a period of less than two years and restricted stock unit awards cannot vest in a period of less than three years. We have granted restricted stock unit awards to our employees under the 2011 Plan which vest annually over a four-year period. At December 31, 2019, a total of 10.0 million options were outstanding, of which 5.4 million were exercisable, 1.7 million restricted stock unit awards were outstanding, and 7.4 million shares were available for future grant under the 2011 Plan.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Under the 2011 Plan, we may issue a stock award with additional acceleration of vesting and exercisability upon or after a change in control. In the absence of such provisions, no such acceleration will occur. The stock options and restricted stock unit awards we issue to Dr. Stanley T. Crooke in his former role as chief executive officer and issued to B. Lynne Parshall in her former role as chief operating officer will accelerate upon a change of control, as defined in the 2011 Plan. In addition, we implemented a change of control and severance benefit plan that provides for change of control and severance benefits to our executive officers, including our chief executive officer and chief financial officer. If we terminate one of our executive officers or if an executive officer resigns for good reason during the period that begins three months before and ends twelve months following a change in control of the company, the impacted executive officers&#x2019; stock options and RSUs vesting will accelerate for options and RSUs outstanding as of the termination date.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Corporate Transactions and Change in Control under 2011 Plan&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In the event of certain significant corporate transactions, our Board of Directors has the discretion to take one or more of the following actions with respect to outstanding stock awards under the 2011 Plan:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zcb34c7d1e4c048899e93ebb5a7d68318" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;arrange for assumption, continuation, or substitution of a stock award by a surviving or acquiring entity (or its parent company);&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z6e451eac07ec40ea8f4b2469d382252a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;arrange for the assignment of any reacquisition or repurchase rights applicable to any shares of our common stock issued pursuant to a stock award to the surviving or acquiring corporation (or its parent company);&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z1804c283807648828a63435f4451acd3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;accelerate the vesting and exercisability of a stock award followed by the termination of the stock award;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z5f80dab3f5b546fd8cc4ecce3150f3af" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;arrange for the lapse of any reacquisition or repurchase rights applicable to any shares of our common stock issued pursuant to a stock award;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="za9fb373834d54a3a900c0043acd5e180" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;cancel or arrange for the cancellation of a stock award, to the extent not vested or not exercised prior to the effective date of the corporate transaction, in exchange for cash consideration, if any, as the Board, in its sole discretion, may consider appropriate; and&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z166bbc44488d4829b2be0e17a4e293e6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;arrange for the surrender of a stock award in exchange for a payment equal to the excess of (a) the value of the property the holder of the stock award would have received upon the exercise of the stock award, over (b) any exercise price payable by such holder in connection with such exercise.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;2002 Non-Employee Directors&#x2019; Stock Option Plan&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In September 2001, our Board of Directors adopted, and the stockholders subsequently approved, an amendment and restatement of the 1992 Non-Employee Directors&#x2019; Stock Option Plan, which provides for the issuance of non-qualified stock options and restricted stock units to our non-employee directors. The name of the resulting plan is the 2002 Non-Employee Directors&#x2019; Stock Option Plan, or the 2002 Plan. In June 2015, after receiving approval from our stockholders, we amended our 2002 Non-Employee Directors Stock Option Plan to increase the total number of shares reserved for issuance. We increased the shares available under our 2002 Non-Employee Directors Stock Option Plan from 1.2 million to 2.0 million. Options under this plan expire 10 years from the date of grant. Options granted become exercisable in four equal annual installments beginning one year after the date of grant. At December 31, 2019, a total of 0.9 million options were outstanding, of which 0.5 million were exercisable, 0.1 million restricted stock unit awards were outstanding, and 0.1 million shares were available for future grant under the 2002 Plan.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Employee Stock Purchase Plan&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In June 2009, our Board of Directors adopted, and the stockholders subsequently approved, the amendment and restatement of the ESPP and we reserved an additional 150,000 shares of common stock for issuance thereunder. In each of the subsequent years, we reserved an additional 150,000 shares of common stock for the ESPP resulting in a total of 3.7 million shares authorized under the plan as of December 31, 2019. The ESPP permits full-time employees to purchase common stock through payroll deductions (which cannot exceed 10 percent of each employee&#x2019;s compensation) at the lower of 85 percent of fair market value at the beginning of the purchase period or the end of each purchase period. Under the amended and restated ESPP, employees must hold the stock they purchase for a minimum of six months from the date of purchase. During 2019, employees purchased and we issued to employees 0.05 million shares under the ESPP at a weighted average price of $40.95 per share. At December 31, 2019, there were 0.7 million shares available for purchase under the ESPP.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Stock Option Activity&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following table summarizes the stock option activity under our stock plans for the year ended December 31, 2019 (in thousands, except per share and contractual life data):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z9b50c63317624dd0af7fdc21a2a7bfb8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Number&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;of Shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Exercise&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Price Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Remaining&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Contractual Term&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Years)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Aggregate&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Intrinsic&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Value&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Outstanding at December 31, 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;11,311&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;47.85&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,543&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;56.19&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2,617&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;40.48&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Cancelled/forfeited/expired&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(236&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;50.11&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Outstanding at December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;11,001&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;51.48&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4.41&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;104,029&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Exercisable at December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6,004&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;50.95&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3.34&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;59,780&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The weighted-average estimated fair values of options granted were $28.76, $25.49 and $25.42 for the years ended December 31, 2019, 2018 and 2017, respectively. The total intrinsic value of options exercised during the years ended December 31, 2019, 2018 and 2017 were $83.8 million, $34.8 million and $49.5 million, respectively, which we determined as of the date of exercise. The amount of cash received from the exercise of stock options was $105.9 million, $18.9 million and $21.2 million for the years ended December 31, 2019, 2018 and 2017, respectively. For the year ended December 31, 2019, the weighted-average fair value of options exercised was $72.52. As of December 31, 2019, total unrecognized compensation cost related to non-vested stock options was $97.5 million. We will adjust the total unrecognized compensation cost for future changes in estimated forfeitures. We expect to recognize this cost over a weighted average period of 1.3 years.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Restricted Stock Unit Activity&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following table summarizes the RSU activity for the year ended December 31, 2019 (in thousands, except per share data):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zc0f5e4e23b714ab09d3ea5e085c1013f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Number&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;of Shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted Average&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Grant Date Fair&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Value Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Non-vested at December 31, 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,246&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;50.20&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,114&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;60.23&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Vested&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(422&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;51.36&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Cancelled/forfeited&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(72&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;53.39&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Non-vested at December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,866&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;55.80&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;For the years ended December 31, 2019, 2018 and 2017, the weighted-average grant date fair value of RSUs granted was $60.23, $51.06 and $48.88 per RSU, respectively. As of December 31, 2019, total unrecognized compensation cost related to RSUs was $56.5 million. We will adjust the total unrecognized compensation cost for future changes in estimated forfeitures. We expect to recognize this cost over a weighted average period of 1.5 years.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Stock-based Compensation Expense and Valuation Information&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following table summarizes stock-based compensation expense for the years ended December 31, 2019, 2018 and 2017 (in thousands), which was allocated as follows and includes $37.1 million, $44.3 million and $17.5 million of stock-based compensation expense for Akcea employees in 2019, 2018 and 2017, respectively:&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="ze0f1f82608a349d9975520506247db45" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Cost of products sold&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;438&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;160&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Research, development and patent&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;95,348&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;76,557&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;64,521&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Selling, general and administrative&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;50,788&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;54,595&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;21,454&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;146,574&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;131,312&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;85,975&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In the third quarter of 2019, three Akcea executive officers terminated their employment and entered into separation agreements with Akcea. As a result, in the third quarter of 2019, Akcea reversed $19.1 million of stock-based compensation expense it had previously recognized related to the executive officers&#x2019; stock options and RSUs that were no longer going to vest. In the fourth quarter of 2019, Akcea adjusted its stock-based compensation expense for an additional executive officer who will terminate his employment in April 2020.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Determining Fair Value&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Valuation.&lt;/span&gt; We measure stock-based compensation expense for equity-classified awards, principally related to stock options, RSUs, and stock purchase rights under the ESPP at the grant date, based on the estimated fair value of the award and we recognize the expense over the employee&#x2019;s requisite service period. We value RSUs based on the market price of our common stock on the date of grant.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We use the Black-Scholes model to estimate the fair value of stock options granted and stock purchase rights under our ESPP. The expected term of stock options granted represents the period of time that we expect them to be outstanding. We estimate the expected term of options granted based on actual and projected exercise patterns. We recognize compensation expense for stock options granted, RSUs, and stock purchase rights under the ESPP using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award were in substance multiple awards, which results in the expense being front-loaded over the vesting period.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;For the years ended December 31, 2019, 2018 and 2017, we used the following weighted-average assumptions in our Black-Scholes calculations:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Ionis Employee Stock Options:&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z1a22f5901f3944f2be1e317aad3cab4b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;60.3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;63.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;65.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Expected life&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4.8 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4.6 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4.5 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Ionis Board of Director Stock Options:&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zc7e20a324c544bf6af7f8bb69517a4b2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;60.7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;61.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;61.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Expected life&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.6 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.6 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.6 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Ionis ESPP:&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zaf6dcfd7dd86499dbd414c26e0657d2f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;45.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;47.3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;59.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Expected life&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6 months&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6 months&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6 months&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Risk-Free Interest Rate.&lt;/span&gt; We base the risk-free interest rate assumption on observed interest rates appropriate for the term of our stock option plans or ESPP.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Dividend Yield.&lt;/span&gt; We base the dividend yield assumption on our history and expectation of dividend payouts. We have not paid dividends in the past and do not expect to in the future.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Volatility.&lt;/span&gt; We use an average of the historical stock price volatility of our stock for the Black-Scholes model. We computed the historical stock volatility based on the expected term of the awards.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Expected Life. &lt;/span&gt;The expected term of stock options we have granted represents the period of time that we expect them to be outstanding. We estimated the expected term of options we have granted based on actual and projected exercise patterns.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Forfeitures.&lt;/span&gt; We reduce stock-based compensation expense for estimated forfeitures. We estimate forfeitures at the time of grant and revise, if necessary, in subsequent periods if actual forfeitures differ from those estimates. We estimate forfeitures based on historical experience.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In addition to our stock plans, Akcea has its own stock plan under which it grants options and RSUs and under which it derives its stock-based compensation expense. The following are the weighted-average Black-Scholes assumptions Akcea used under its plan for the years ended December 31, 2019, 2018 and 2017:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Akcea Employee Stock Options:&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z6d0f71f781114c2796697bdc6544ea2f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;75.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;77.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;79.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Expected life&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.09 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.08 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.06 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Akcea Board of Director Stock Options:&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zbbe3118c00004f9f91eb04676b0aef23" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;73.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;78.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;79.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Expected life&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.25 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.42 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.25 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Akcea ESPP:&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z274cc299456642c993f118c12d22a0fd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;60.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;64.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;73.3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Expected life&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6 months&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6 months&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6 months&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following summarizes the Black-Scholes input methodology for Akcea options that differs from the methodology we use for Ionis options:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Volatility.&lt;/span&gt; Since Akcea does not have sufficient history to estimate the volatility of its common stock, Akcea calculates its expected volatility based on a blend of its historical volatility and reported data from selected publicly traded peer companies for which historical information is available. Akcea plans to continue to use this blend to calculate its volatility until the historical volatility of its common stock is sufficient to measure expected volatility for future option grants.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Expected Life. &lt;/span&gt;Since Akcea does not have sufficient historical information, it uses the simplified method for estimating its expected term. Under the simplified method Akcea calculates its expected term as the average time-to-vesting and the contractual life of the options. As Akcea gains additional historical information, it will transition to calculating its expected term based on its exercise patterns.&lt;/div&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20191231_StatementClassOfStockAxis_PreferredStockMember"
      decimals="-6"
      id="Fact_cdf2c784100f453c85b910f7ffa74a1e"
      unitRef="U002">15000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20191231_StatementClassOfStockAxis_PreferredStockMember"
      decimals="INF"
      id="Fact_9e3c83d35b1a4ad9bb5804db20a70950"
      unitRef="U002">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20191231_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact_56071bcb2d56480397a630e97def5c32"
      unitRef="U002">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20191231_StatementClassOfStockAxis_SeriesCPreferredStockMember"
      decimals="INF"
      id="Fact_5fe1b66991274e8cbc8b7286eae05354"
      unitRef="U002">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20181231_StatementClassOfStockAxis_CommonStockMember"
      decimals="-6"
      id="Fact_292edcba897f40209ed42c14feed0f2e"
      unitRef="U002">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20191231_StatementClassOfStockAxis_CommonStockMember"
      decimals="-6"
      id="Fact_10c668f50b664401a30c1bb6a51edb5a"
      unitRef="U002">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20191231_StatementClassOfStockAxis_CommonStockMember"
      decimals="-5"
      id="Fact_6d69412111c94f649e3bc6185a645456"
      unitRef="U002">140300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20191231_StatementClassOfStockAxis_CommonStockMember"
      decimals="-5"
      id="Fact_5f23b4a620974ffa9ac1338867c08a09"
      unitRef="U002">140300000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20181231_StatementClassOfStockAxis_CommonStockMember"
      decimals="-5"
      id="Fact_eba69077d17e4204b64b00ee384f8ab0"
      unitRef="U002">137900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20181231_StatementClassOfStockAxis_CommonStockMember"
      decimals="-5"
      id="Fact_7461dbbf5e58485bbd613618075e0ee5"
      unitRef="U002">137900000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20191231_StatementClassOfStockAxis_CommonStockMember"
      decimals="-5"
      id="Fact_47e88bfdb1664c48a2b1ff64f80389f5"
      unitRef="U002">26200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="c20190101to20191231_StatementClassOfStockAxis_CommonStockMember"
      decimals="-5"
      id="Fact_0ee4b00a77834001bc604428d95159c5"
      unitRef="U002">3100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="c20180101to20181231_StatementClassOfStockAxis_CommonStockMember"
      decimals="-5"
      id="Fact_6d8eb059ce834187b603ca07d5abb207"
      unitRef="U002">1500000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross
      contextRef="c20170101to20171231_StatementClassOfStockAxis_CommonStockMember"
      decimals="-5"
      id="Fact_edd10ce23a74492e8176afb94a7abdb0"
      unitRef="U002">1700000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="c20190101to20191231_StatementClassOfStockAxis_CommonStockMember"
      decimals="-5"
      id="Fact_d6943984a2cd41b0a8cb3b1deb1f9fc2"
      unitRef="U001">119700000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="c20180101to20181231_StatementClassOfStockAxis_CommonStockMember"
      decimals="-5"
      id="Fact_5fbad294b6304ae4a8a72a7d07384a09"
      unitRef="U001">27900000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="c20170101to20171231_StatementClassOfStockAxis_CommonStockMember"
      decimals="-5"
      id="Fact_4af5fbc849034e59b7d2901adc45af29"
      unitRef="U001">22900000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="c20190930"
      decimals="-6"
      id="Fact_44310671d1664bfca3445b963a157027"
      unitRef="U001">125000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c20191001to20191231"
      decimals="0"
      id="Fact_a0ec8c80989241c28567434e9da68f95"
      unitRef="U002">535000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="c20191001to20191231"
      decimals="-5"
      id="Fact_b3c70b4e95ca4205b78bd5e2e50aeeab"
      unitRef="U001">34400000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c20200101to20200302_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="-5"
      id="Fact_e459a3912815439c8077106b57fb5880"
      unitRef="U002">1500000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="c20200101to20200302_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="-5"
      id="Fact_2b769cf5ebe543ef91ba7139fec3a4d2"
      unitRef="U001">90600000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20191231_PlanNameAxis_StockOptionPlan1989Member"
      decimals="-5"
      id="Fact_2a82263b39a7474ba2b3298ff2f3a349"
      unitRef="U002">20000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20190101to20191231_PlanNameAxis_StockOptionPlan1989Member"
      id="Fact_300b6e73bf984f4ba7b411e09fd8ac0a">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember_PlanNameAxis_StockOptionPlan1989Member_VestingAxis_ShareBasedCompensationAwardTrancheOneMember"
      decimals="2"
      id="Fact_f9de77fe0ed4406e89bc6cca403c951f"
      unitRef="U003">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember_PlanNameAxis_StockOptionPlan1989Member_VestingAxis_ShareBasedCompensationAwardTrancheOneMember"
      id="Fact_8c42e3e31eb04afc9a1a6d089d774313">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="c20190101to20191231_PlanNameAxis_StockOptionPlan1989Member"
      id="Fact_7077ae6833184dee85f5278742d25b56">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20191231_PlanNameAxis_StockOptionPlan1989Member"
      decimals="-5"
      id="Fact_add8de5b32ae49bb87473e4eddedffb6"
      unitRef="U002">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c20191231_PlanNameAxis_StockOptionPlan1989Member"
      decimals="-5"
      id="Fact_803cbfb1dea74d34930f47cade7a9b19"
      unitRef="U002">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c20191231_PlanNameAxis_StockOptionPlan1989Member"
      decimals="-4"
      id="Fact_8c931ba74e0d4e5c8d57ed4b294c4a22"
      unitRef="U002">40000.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20150531_PlanNameAxis_EquityIncentivePlan2011Member"
      decimals="-5"
      id="Fact_5882aa832aa646c6b635e3bfe41d5f81"
      unitRef="U002">5500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20150630_PlanNameAxis_EquityIncentivePlan2011Member"
      decimals="-5"
      id="Fact_1f00ba80dcbf4591a6c03449d0ff3e6e"
      unitRef="U002">11000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20150630_PlanNameAxis_EquityIncentivePlan2011Member"
      decimals="-5"
      id="Fact_b4182e47d22e4ab1b6c25c3beae739b7"
      unitRef="U002">11000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20170531_PlanNameAxis_EquityIncentivePlan2011Member"
      decimals="-5"
      id="Fact_73b32b7412144ae2844353056c2328ce"
      unitRef="U002">16000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20170531_PlanNameAxis_EquityIncentivePlan2011Member"
      decimals="-5"
      id="Fact_67f1d774e8d34fbbbdcb82cbb830d91a"
      unitRef="U002">16000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20190630_PlanNameAxis_EquityIncentivePlan2011Member"
      decimals="-5"
      id="Fact_dd1127c8a7ec4eedb63afb7ca6169e93"
      unitRef="U002">23000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember_PlanNameAxis_EquityIncentivePlan2011Member_RangeAxis_MinimumMember"
      id="Fact_0537bd173d9041859f6644b1acb57f77">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2011Member_RangeAxis_MinimumMember"
      id="Fact_a9447454bff64390b3b86709206cd065">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlan2011Member"
      id="Fact_323dc3ca223441ed8cae26677d80920d">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20191231_PlanNameAxis_EquityIncentivePlan2011Member"
      decimals="-5"
      id="Fact_f6eb4ef69d9549b79f43b5ca7f3d3f65"
      unitRef="U002">10000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c20191231_PlanNameAxis_EquityIncentivePlan2011Member"
      decimals="-5"
      id="Fact_c37dd0f781d649a5bc97d2c87bbaeacf"
      unitRef="U002">5400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c20191231_PlanNameAxis_EquityIncentivePlan2011Member"
      decimals="-5"
      id="Fact_f19dff70c85e4b53ab5b44f7e4b872f2"
      unitRef="U002">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c20191231_PlanNameAxis_EquityIncentivePlan2011Member"
      decimals="-5"
      id="Fact_f121d278af9942b4ba6d23912dbef6db"
      unitRef="U002">7400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <ions:NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers
      contextRef="c20190101to20191231_PlanNameAxis_EquityIncentivePlan2011Member"
      decimals="INF"
      id="Fact_8f959a059fb340fc9f6dfdc4cbdfc6d9"
      unitRef="U013">1</ions:NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers>
    <ions:PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers
      contextRef="c20190101to20191231_PlanNameAxis_EquityIncentivePlan2011Member"
      id="Fact_5cf8f8a57af249d4a6cce115597f8861">P3M</ions:PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers>
    <ions:PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers
      contextRef="c20190101to20191231_PlanNameAxis_EquityIncentivePlan2011Member"
      id="Fact_4b4db5c64d7f42eca6f341535cd62db4">P12M</ions:PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20150531_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member"
      decimals="-5"
      id="Fact_0e9dea3a9bb44f258d4a6a1eeffbb1b0"
      unitRef="U002">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20150630_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member"
      decimals="-5"
      id="Fact_e55c20e37dc6464eb74bde99a3d220dc"
      unitRef="U002">2000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="c20190101to20191231_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member"
      id="Fact_e6b00753880241348e596a82fa22bab2">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <ions:NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable
      contextRef="c20190101to20191231_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member_VestingAxis_ShareBasedCompensationAwardTrancheOneMember"
      decimals="INF"
      id="Fact_ecf5143f6da4476497ba61d7ea1d3cf7"
      unitRef="U014">4</ions:NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member_VestingAxis_ShareBasedCompensationAwardTrancheOneMember"
      id="Fact_21760feab1df457580b254deda24e758">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20191231_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member"
      decimals="-5"
      id="Fact_28beff5bd3d14e0c9936c3a0e4bfd184"
      unitRef="U002">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c20191231_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member"
      decimals="-5"
      id="Fact_5c3c554e640546a481c2968b37014870"
      unitRef="U002">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="c20191231_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member"
      decimals="-5"
      id="Fact_d025b834777346cfa313dfb503dafd03"
      unitRef="U002">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c20191231_PlanNameAxis_NonemployeeDirectorsStockOptionPlan2002Member"
      decimals="-5"
      id="Fact_03da27efb55141628520731fb9e70ab8"
      unitRef="U002">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c20090601to20090630_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="0"
      id="Fact_3b40f4cda8e040fdba6be624573711c9"
      unitRef="U002">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c20190101to20191231_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="0"
      id="Fact_627f300828104f14b873bf05eda50f67"
      unitRef="U002">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c20191231_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="Fact_e19efe7ddb5143df982e961a832ee9c5"
      unitRef="U002">3700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="c20191231_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="2"
      id="Fact_ad7d5d970b7445cb891d0cfb579417b5"
      unitRef="U003">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c20190101to20191231_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="2"
      id="Fact_f1124fb149ea4ba28036505d69fad8f3"
      unitRef="U003">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod
      contextRef="c20190101to20191231_PlanNameAxis_EmployeeStockPurchasePlanMember"
      id="Fact_f085e44a32534bbd8486ce10fc828657">P6M</ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c20190101to20191231_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="-4"
      id="Fact_36267c2abcb644b69eb45aceda22f69b"
      unitRef="U002">50000.00</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased
      contextRef="c20190101to20191231_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="2"
      id="Fact_2c284719dc094a59851d962ad33aacae"
      unitRef="U004">40.95</us-gaap:EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c20191231_PlanNameAxis_EmployeeStockPurchasePlanMember"
      decimals="-5"
      id="Fact_9bcf03b844ab41c1a8fbd64333e01f0e"
      unitRef="U002">700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_7b10324fbe6d4c7b8c7ce61a7cf34482">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following table summarizes the stock option activity under our stock plans for the year ended December 31, 2019 (in thousands, except per share and contractual life data):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z9b50c63317624dd0af7fdc21a2a7bfb8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Number&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;of Shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Exercise&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Price Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Remaining&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Contractual Term&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Years)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Aggregate&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Intrinsic&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Value&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Outstanding at December 31, 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;11,311&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;47.85&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,543&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;56.19&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2,617&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;40.48&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Cancelled/forfeited/expired&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(236&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;50.11&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Outstanding at December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;11,001&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;51.48&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4.41&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;104,029&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Exercisable at December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6,004&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;50.95&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3.34&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;59,780&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20181231_AwardTypeAxis_StockOptionMember"
      decimals="-3"
      id="Fact_de361e6a303f48689eff997a4c7a9e18"
      unitRef="U002">11311000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20181231_AwardTypeAxis_StockOptionMember"
      decimals="2"
      id="Fact_013443363d8b4eb7aa061c464dc7a3dd"
      unitRef="U004">47.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember"
      decimals="-3"
      id="Fact_c363e628c500466b86c02f00df87e45d"
      unitRef="U002">2543000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember"
      decimals="2"
      id="Fact_147bf3d775c544d39301adb1493fa05e"
      unitRef="U004">56.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember"
      decimals="-3"
      id="Fact_65fe49e661654c6fadd66c3158cb37e5"
      unitRef="U002">2617000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember"
      decimals="2"
      id="Fact_645eac997a48446a8364fedf6f9b00a2"
      unitRef="U004">40.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember"
      decimals="-3"
      id="Fact_d7093d8852d44af280644f5b3f4724f8"
      unitRef="U002">236000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember"
      decimals="2"
      id="Fact_b2d99eaaf66c4310b3826984e917430d"
      unitRef="U004">50.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c20191231_AwardTypeAxis_StockOptionMember"
      decimals="-3"
      id="Fact_ac7cb8c9588948168b54c219f469e752"
      unitRef="U002">11001000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c20191231_AwardTypeAxis_StockOptionMember"
      decimals="2"
      id="Fact_3a779dec16434ab39ded18c995252583"
      unitRef="U004">51.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember"
      id="Fact_8a97634ee0de48ab9bba7815890a31ce">P4Y4M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c20191231_AwardTypeAxis_StockOptionMember"
      decimals="-3"
      id="Fact_c25c76c1a9f94691b856964b458fadef"
      unitRef="U001">104029000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c20191231_AwardTypeAxis_StockOptionMember"
      decimals="-3"
      id="Fact_f87605af70314ee88af627c71f1097ba"
      unitRef="U002">6004000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c20191231_AwardTypeAxis_StockOptionMember"
      decimals="2"
      id="Fact_385eca89102d4e9587c5000cc39964b4"
      unitRef="U004">50.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember"
      id="Fact_7314f310e53045fd9d6e985a8a4eb55d">P3Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20191231_AwardTypeAxis_StockOptionMember"
      decimals="-3"
      id="Fact_bb850db7a9184d57b61549c6a8eeacca"
      unitRef="U001">59780000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember"
      decimals="2"
      id="Fact_bd436c790ccc47e68cd7e2153d0e63dd"
      unitRef="U004">28.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20180101to20181231_AwardTypeAxis_StockOptionMember"
      decimals="2"
      id="Fact_4dd2a593ab554175bbb0a93d55390a88"
      unitRef="U004">25.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20170101to20171231_AwardTypeAxis_StockOptionMember"
      decimals="2"
      id="Fact_a3befa246b7c4d03aced2b483085120f"
      unitRef="U004">25.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember"
      decimals="-5"
      id="Fact_1218d40eea68418bb4f00f1ad78f4cff"
      unitRef="U001">83800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="c20180101to20181231_AwardTypeAxis_StockOptionMember"
      decimals="-5"
      id="Fact_bde2c92764604d8497b0668d13fb888b"
      unitRef="U001">34800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="c20170101to20171231_AwardTypeAxis_StockOptionMember"
      decimals="-5"
      id="Fact_8cc0e16daa8e4b2382fc554cc98ddf99"
      unitRef="U001">49500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember"
      decimals="-5"
      id="Fact_83423df31a3f436fab220d64f20b3ada"
      unitRef="U001">105900000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20180101to20181231_AwardTypeAxis_StockOptionMember"
      decimals="-5"
      id="Fact_9199ba163c904e0aaa3d539cccdda650"
      unitRef="U001">18900000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20170101to20171231_AwardTypeAxis_StockOptionMember"
      decimals="-5"
      id="Fact_6cc972e2025849d8a6820145ab793c87"
      unitRef="U001">21200000</us-gaap:ProceedsFromStockOptionsExercised>
    <ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue
      contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember"
      decimals="2"
      id="Fact_2b17593a26f3421991429bedce8b1c41"
      unitRef="U004">72.52</ions:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="c20191231_AwardTypeAxis_StockOptionMember"
      decimals="-5"
      id="Fact_72c37b7b47114b45a9abf8d6722faa52"
      unitRef="U001">97500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20190101to20191231_AwardTypeAxis_StockOptionMember"
      id="Fact_b3913cf410e541fe90a6f1003271ba18">P1Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_079cd073de4a49889e073e44695cbbe1">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following table summarizes the RSU activity for the year ended December 31, 2019 (in thousands, except per share data):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zc0f5e4e23b714ab09d3ea5e085c1013f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Number&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;of Shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted Average&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Grant Date Fair&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Value Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Non-vested at December 31, 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,246&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;50.20&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,114&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;60.23&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Vested&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(422&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;51.36&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Cancelled/forfeited&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(72&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;53.39&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Non-vested at December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,866&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;55.80&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20181231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact_9b79ad26dfed4644a99778a07c2788e7"
      unitRef="U002">1246000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20181231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_7b0c381469384de4a83c2d06c591c7e0"
      unitRef="U004">50.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact_1bdc071fcc1b43c49a958a8b0de0d593"
      unitRef="U002">1114000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_029b251fe1ed4825bb24ef350c208693"
      unitRef="U004">60.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact_32f1bead9c704269b614ad1cd037ad04"
      unitRef="U002">422000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_df38f96941f0458f9ca876b79bbed1b6"
      unitRef="U004">51.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact_22694e1383774415bf4c78c2ec3ee1f6"
      unitRef="U002">72000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_d3684b8ecd434d79a0c627293baaf219"
      unitRef="U004">53.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="Fact_28559434ff5b402683a66fe056752875"
      unitRef="U002">1866000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_5d0497b5899240c48adeef1f11e34ed4"
      unitRef="U004">55.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_6c1a06db93094900a762b6eb164c546f"
      unitRef="U004">60.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20180101to20181231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_43f43b5a78cc4be1918b46bdde39a8d8"
      unitRef="U004">51.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20170101to20171231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_57cca4b8f1044664988a96c292d978d1"
      unitRef="U004">48.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="c20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact_87ca3f2ec59f473aaf7df5ff01d27232"
      unitRef="U001">56500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      id="Fact_18e1a1c706d54df78d64da3820fb50b9">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="c20190101to20191231"
      id="Text_73294d497dea4c4fbe6e3dffff002cbe">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following table summarizes stock-based compensation expense for the years ended December 31, 2019, 2018 and 2017 (in thousands), which was allocated as follows and includes $37.1 million, $44.3 million and $17.5 million of stock-based compensation expense for Akcea employees in 2019, 2018 and 2017, respectively:&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="ze0f1f82608a349d9975520506247db45" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Cost of products sold&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;438&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;160&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Research, development and patent&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;95,348&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;76,557&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;64,521&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Selling, general and administrative&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;50,788&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;54,595&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;21,454&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;146,574&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;131,312&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;85,975&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="-5"
      id="Fact_f10b8b42e6244f988aaf4fd5de10cafc"
      unitRef="U001">37100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20180101to20181231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="-5"
      id="Fact_1f1c1f94efad47beb6afa69146eccaa6"
      unitRef="U001">44300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20170101to20171231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="-5"
      id="Fact_afb09cb91b5c4c60ac3218bdcff80a83"
      unitRef="U001">17500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20190101to20191231_IncomeStatementLocationAxis_CostOfSalesMember"
      decimals="-3"
      id="Fact_c65bd9300b1849b09ce0cf552755ec1d"
      unitRef="U001">438000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20180101to20181231_IncomeStatementLocationAxis_CostOfSalesMember"
      decimals="-3"
      id="Fact_5192811678f84304b2c63cedee948433"
      unitRef="U001">160000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20170101to20171231_IncomeStatementLocationAxis_CostOfSalesMember"
      decimals="-3"
      id="Fact_a370ff2076d840e78591c1b614a65c61"
      unitRef="U001">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20190101to20191231_IncomeStatementLocationAxis_ResearchDevelopmentAndPatentMember"
      decimals="-3"
      id="Fact_082a856e25ff4c6c87bb43e07011a3a0"
      unitRef="U001">95348000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20180101to20181231_IncomeStatementLocationAxis_ResearchDevelopmentAndPatentMember"
      decimals="-3"
      id="Fact_fbf019d0d38c4d20951785656bdfb76e"
      unitRef="U001">76557000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20170101to20171231_IncomeStatementLocationAxis_ResearchDevelopmentAndPatentMember"
      decimals="-3"
      id="Fact_590dd7d3580e4ce79e0bd853a27c60e2"
      unitRef="U001">64521000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20190101to20191231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact_faf4608623c94854a015ec45e8a2e44a"
      unitRef="U001">50788000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20180101to20181231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact_e2891cabb204471380d6c8707ca7c311"
      unitRef="U001">54595000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20170101to20171231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact_1d43b8c463a34284a11803d822ccf283"
      unitRef="U001">21454000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_e526ced9a8ee48df88cdbb0fe414de86"
      unitRef="U001">146574000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_e09ed4e35f1149ffade548f4d1e3dd6a"
      unitRef="U001">131312000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_14e48c9e15754897b6ddb6e8ce984ffb"
      unitRef="U001">85975000</us-gaap:AllocatedShareBasedCompensationExpense>
    <ions:NumberOfExecutiveOfficersTerminatingEmployment
      contextRef="c20190701to20190930_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="INF"
      id="Fact_cb6c6555dd4d4b54a68986c39eb04125"
      unitRef="U013">3</ions:NumberOfExecutiveOfficersTerminatingEmployment>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20190701to20190930_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="-5"
      id="Fact_e366f8294e7a416091e1112d5e7b1895"
      unitRef="U001">-19100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_eed5d49b2291458dab9b93c467ee0710">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Ionis Employee Stock Options:&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z1a22f5901f3944f2be1e317aad3cab4b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;60.3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;63.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;65.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Expected life&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4.8 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4.6 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4.5 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Ionis Board of Director Stock Options:&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zc7e20a324c544bf6af7f8bb69517a4b2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;60.7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;61.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;61.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Expected life&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.6 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.6 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.6 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="3"
      id="Fact_39e4c82810704489bfbb65ee776e5a18"
      unitRef="U003">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="3"
      id="Fact_a907f9f67ed94038aa87ea5dbd343610"
      unitRef="U003">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="3"
      id="Fact_d5a55e05e6ab431680a0d9086b9e0bb9"
      unitRef="U003">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="3"
      id="Fact_ac7a468c8e8141e5a6b44a4226e17623"
      unitRef="U003">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="3"
      id="Fact_6f0bd71680af49fe8c31973636909b08"
      unitRef="U003">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="3"
      id="Fact_467f22edbb03445faa1bf91c44625ca8"
      unitRef="U003">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="3"
      id="Fact_e343e701b7bb4973a553dcb0d627618e"
      unitRef="U003">0.603</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="3"
      id="Fact_cf083492bd334305a8d635507396630c"
      unitRef="U003">0.630</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="3"
      id="Fact_b479bbaa6e5942498c2c6ef23bade12e"
      unitRef="U003">0.659</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_aeba017ee0304164a606372e31b4d36e">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_4ff009d529b14f28a67b413d0aa72b8a">P4Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_17b6c1af49ea4548aea7024e13340b1f">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20190101to20191231_AwardTypeAxis_BoardOfDirectorStockOptionMember"
      decimals="3"
      id="Fact_59c5b44210f64e2ba5300762080b28cb"
      unitRef="U003">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20180101to20181231_AwardTypeAxis_BoardOfDirectorStockOptionMember"
      decimals="3"
      id="Fact_5cd81543aca54eeaa0061cb4901bcea7"
      unitRef="U003">0.028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20170101to20171231_AwardTypeAxis_BoardOfDirectorStockOptionMember"
      decimals="3"
      id="Fact_b27308a354da40f7bb7eb1590023fe41"
      unitRef="U003">0.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20190101to20191231_AwardTypeAxis_BoardOfDirectorStockOptionMember"
      decimals="3"
      id="Fact_836ca23d34bf40d1ad317bbd7b996732"
      unitRef="U003">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20180101to20181231_AwardTypeAxis_BoardOfDirectorStockOptionMember"
      decimals="3"
      id="Fact_dd7841189e61468984dd257450ed86fa"
      unitRef="U003">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20170101to20171231_AwardTypeAxis_BoardOfDirectorStockOptionMember"
      decimals="3"
      id="Fact_f6175c15b7104058bdf6a42169341ab4"
      unitRef="U003">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c20190101to20191231_AwardTypeAxis_BoardOfDirectorStockOptionMember"
      decimals="3"
      id="Fact_570fb2702c0c4104ab71032ea3a96785"
      unitRef="U003">0.607</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c20180101to20181231_AwardTypeAxis_BoardOfDirectorStockOptionMember"
      decimals="3"
      id="Fact_71af5aa64f46473c820a7539b3bcc84e"
      unitRef="U003">0.615</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c20170101to20171231_AwardTypeAxis_BoardOfDirectorStockOptionMember"
      decimals="3"
      id="Fact_9d88dfeaff20416a8bed01fc37947c33"
      unitRef="U003">0.612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20190101to20191231_AwardTypeAxis_BoardOfDirectorStockOptionMember"
      id="Fact_bdcda0ba9a7942588e74e26d29bbb33b">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20180101to20181231_AwardTypeAxis_BoardOfDirectorStockOptionMember"
      id="Fact_42adbfd09267470aaddb1b451dd3ec51">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20170101to20171231_AwardTypeAxis_BoardOfDirectorStockOptionMember"
      id="Fact_a0b7e9b5bba44f52abc599d09c3c6813">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_ad4e550d1cc64418b2227fa2fb6f6a90">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Ionis ESPP:&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zaf6dcfd7dd86499dbd414c26e0657d2f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;45.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;47.3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;59.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Expected life&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6 months&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6 months&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6 months&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockMember"
      decimals="3"
      id="Fact_3c0b7d8f83f04a1eb86c0d26a34847de"
      unitRef="U003">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockMember"
      decimals="3"
      id="Fact_d445da93ea354d4a8bd3403324c38b1b"
      unitRef="U003">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockMember"
      decimals="3"
      id="Fact_7e683d90439c433b952d511d85e1a926"
      unitRef="U003">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockMember"
      decimals="3"
      id="Fact_99b71834e6e0477dbdfc7e3f693daeaa"
      unitRef="U003">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockMember"
      decimals="3"
      id="Fact_0eb7e7fbc4304fdf9099a8b950d12dde"
      unitRef="U003">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockMember"
      decimals="3"
      id="Fact_34e237d15deb4d56bee7e4f7c1e34d34"
      unitRef="U003">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockMember"
      decimals="3"
      id="Fact_6518e8ff94e84bee8887d5c801654559"
      unitRef="U003">0.456</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockMember"
      decimals="3"
      id="Fact_9ae61ebbc4da40a487b4fb949bf8e04a"
      unitRef="U003">0.473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockMember"
      decimals="3"
      id="Fact_46d7ebf746c644dbab44800478c4bf2c"
      unitRef="U003">0.599</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockMember"
      id="Fact_6cb5a0bf099e40cc864c264a7ce21cef">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockMember"
      id="Fact_f4dc66b6347f46f7b1f589a4102dcbc3">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockMember"
      id="Fact_b50f67a3f15a4f28a7f815371d6feb14">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      id="Text_9a47228854db40e58bb10bf8df4c7de5">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Akcea Employee Stock Options:&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z6d0f71f781114c2796697bdc6544ea2f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;75.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;77.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;79.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Expected life&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.09 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.08 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.06 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Akcea Board of Director Stock Options:&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zbbe3118c00004f9f91eb04676b0aef23" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;73.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;78.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;79.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Expected life&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.25 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.42 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.25 years&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_9427990941124c8d84b21942b7851dc1"
      unitRef="U003">0.022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_7f37e862c77a4dfa88dbb42f1f7df3b5"
      unitRef="U003">0.028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_65f69e859fe64c2f8567e04d83d27ad2"
      unitRef="U003">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_ad69dda9779c4411a946438aa548dc66"
      unitRef="U003">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_63f6046c55da44619e30077b4b23e13d"
      unitRef="U003">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_8afdde2a0f4d4c508212cbba4de5d73f"
      unitRef="U003">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_a81b171ee24a461b80fe013b4fafde03"
      unitRef="U003">0.754</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_e1c6279157a942a5a72f291eb095018e"
      unitRef="U003">0.771</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_14142d560c124e338be9ccae1fc251d6"
      unitRef="U003">0.795</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      id="Fact_e33d45f84350409ca60b5e11bee0862b">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      id="Fact_32a1e1728de345a992537bc600ef3217">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      id="Fact_d7baac71895f4870b794ceabe6ec6861">P6Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20190101to20191231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_32bfb362dea94deaabe530ccc1ebb41b"
      unitRef="U003">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20180101to20181231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_787fd132ce504f22badee12fa1cd9add"
      unitRef="U003">0.029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20170101to20171231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_598e1a9e2c4f479297eac501bde974c7"
      unitRef="U003">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20190101to20191231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_7d00f24631834ad59d867d14e7f8f474"
      unitRef="U003">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20180101to20181231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_b92024a4a63c4472980707f550677db7"
      unitRef="U003">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20170101to20171231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_310662f660c1405196f21feb60d767ad"
      unitRef="U003">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c20190101to20191231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_20e6c9e5c43d4b0abfb9f1f0f43fdd00"
      unitRef="U003">0.738</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c20180101to20181231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_a2007326872f4bdcbd5f3bd17302d57b"
      unitRef="U003">0.782</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c20170101to20171231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_ff076db6ae4745cbbeb3c378e621b02d"
      unitRef="U003">0.794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20190101to20191231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      id="Fact_d65dbad630614b6686dc737ed2dbf318">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20180101to20181231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      id="Fact_33083c5e681a431aa5caf47692ebc8cd">P6Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20170101to20171231_AwardTypeAxis_BoardOfDirectorStockOptionMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      id="Fact_5e855268ef484ae090049da9c0a5494c">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      id="Text_ac97a0fcee594c8c8f377c30d4f5daf1">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Akcea ESPP:&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z274cc299456642c993f118c12d22a0fd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Dividend yield&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Volatility&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;60.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;64.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;73.3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Expected life&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6 months&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6 months&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6 months&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_bf5ecf8a64054fae95c4804511ce6aec"
      unitRef="U003">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_72db8e8c6e314a68b21ff5ca9daa8795"
      unitRef="U003">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_441c829cbbd14005ae76633c08dbb58d"
      unitRef="U003">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_410ad5b69a2248319707dd8c8030cb6e"
      unitRef="U003">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_d4a69058792f4aafa70899b5b9ee410b"
      unitRef="U003">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_300a88498bfa41528eaf68769e20db52"
      unitRef="U003">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_637662f604f74eff9088c6c132d5f729"
      unitRef="U003">0.600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_b2759e0179794c4ea710cb01fde6ffad"
      unitRef="U003">0.642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      decimals="3"
      id="Fact_e83cd4f6e0e542deaa111fc2184cb9c3"
      unitRef="U003">0.733</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20190101to20191231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      id="Fact_6867f5f4f3d6472898e752108981a60e">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20180101to20181231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      id="Fact_ecab4ddbcf9d44d2bd9ac9d2163912b1">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20170101to20171231_AwardTypeAxis_EmployeeStockMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember"
      id="Fact_c36b27cba34d4c6e9e05233761bbebdb">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="c20190101to20191231"
      id="Text_c0b4f25af9504e6a8c2960620b85c78d">
&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;5. Income Taxes&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income (loss) before income taxes is comprised of (in thousands):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z4092c9a5a2814eb28f48de6d2a9e9058" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;United States&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;344,280&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(69,576&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5,289&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,489&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(6,580&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(11,474&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income (loss) before income taxes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;346,769&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(76,156&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(16,763&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our income tax expense (benefit) was as follows (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z713025753cca4d42a8b28f2a7fba9d21" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Current:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Federal&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;35,861&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;438&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(7,460&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;State&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;14,329&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,442&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,246&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;413&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;374&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;234&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total current income tax expense (benefit)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;50,603&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(630&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5,980&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Deferred:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Federal&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(7,096&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(290,511&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;State&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total deferred income tax benefit&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(7,096&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(290,511&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total income tax expense (benefit)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;43,507&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(291,141&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5,980&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our expense (benefit) for income taxes differs from the amount computed by applying the U.S. federal statutory rate to income (loss) before taxes. The sources and tax effects of the differences are as follows (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zb11f654ab51c478685d3b34848ff0f2f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Pre-tax income (loss)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;346,769&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(76,156&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(16,763&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Statutory rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;72,822&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(15,993&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5,867&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;35.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;State income tax net of federal benefit&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;49,119&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;14.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2,202&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;820&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;340&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,735&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2.3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4,299&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(25.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net change in valuation allowance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(37,765&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(10.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(277,924&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;364.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(86,296&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;514.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net operating loss expiration&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;8,864&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(11.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3,987&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(23.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;TEGSEDI licensing gain&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;59,583&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(78.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Impact from outside basis differences&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(16,344&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4.7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Tax credits&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(22,296&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(6.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(73,362&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;96.3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(32,769&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;195.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Deferred tax true-up&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;646&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;9,947&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(13.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4,848&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(28.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Tax rate change&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,811&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,808&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;114,832&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(685.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Non-deductible compensation&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3,361&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3,154&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,575&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(9.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Other non-deductible items&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;329&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(569&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,548&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(15.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea deconsolidation adjustment at IPO&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;469&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Stock-based compensation&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4,837&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4,199&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;5.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(14,337&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;85.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Foreign-derived intangible income benefit&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2,071&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Other&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,608&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,633&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(89&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effective rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;43,507&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;12.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(291,141&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;382.3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5,980&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;35.7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Significant components of our deferred tax assets and liabilities as of December 31, 2019 and 2018 are as follows (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z6ce9a811fab143898ba48d74d51fe77e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Deferred Tax Assets:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net operating loss carryovers&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;20,191&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;89,717&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D credits&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;210,455&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;313,652&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;127,763&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;27,381&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Stock-based compensation&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;65,703&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;61,027&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Intangible and capital assets&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;77,861&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;49,007&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Other&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;12,510&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;8,275&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;514,483&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;549,059&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Deferred Tax Liabilities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Convertible debt&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(6,110&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(24,018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Fixed assets&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,958&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Other&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(3,884&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net deferred tax asset&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;502,531&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;525,041&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Valuation allowance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(196,974&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(234,245&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total net deferred tax assets and liabilities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;305,557&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;290,796&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We evaluate our deferred tax assets regularly to determine whether adjustments to the valuation allowance are appropriate due to changes in facts or circumstances, such as changes in expected future pre-tax earnings, tax law, interactions with taxing authorities and developments in case law. In making this evaluation, we rely on our recent history of pre-tax earnings. Our material assumptions are our forecasts of future pre-tax earnings and the nature and timing of future deductions and income represented by the deferred tax assets and liabilities, all of which involve the exercise of significant judgment. Although we believe our estimates are reasonable, we are required to use significant judgment in determining the appropriate amount of valuation allowance recorded against our deferred tax assets.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We have historically recorded a valuation allowance against all our net deferred tax assets due to cumulative financial statement losses. However, in the fourth quarter of 2018, we reversed the valuation allowance previously recorded against Ionis&#x2019; stand-alone U.S. federal net deferred tax assets, resulting in a one-time non-cash tax benefit of $&lt;/span&gt;332.1&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million. &lt;/span&gt;We reversed the valuation allowance in 2018 as&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; we expected to generate U.S. pre-tax income on an Ionis standalone basis in future periods at a level that would result in us fully utilizing our U.S. federal net operating loss carryforwards and our Research and Development and Orphan Drug tax credit carryforwards. &lt;/span&gt;We utilized a significant portion of these carryforwards in 2019 to partially offset our estimated federal tax liability for the year.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our valuation allowance decreased by $37.3 million from December 31, 2018 to December 31, 2019. The decrease relates primarily to the current year utilization of a portion of our net deferred state tax assets, primarily California net operating loss carryovers, that had been fully reserved by the valuation allowance.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We continue to maintain a full valuation allowance of $197.0 million against all of Akcea&#x2019;s net deferred tax assets and the net state deferred tax assets of Ionis at December 31, 2019 due to uncertainties related to our ability to realize the tax benefits associated with these assets.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We generated combined state taxable income and recognized a combined state tax liability in 2019. We utilized Ionis&#x2019; state deferred tax assets, primarily California net operating loss carry forwards, to reduce our combined state tax liability for the year by $59.1 million, which resulted in a corresponding reduction to our combined state valuation allowance. We have historically generated combined state net operating losses due primarily to Akcea&#x2019;s net operating losses. However, Akcea generated net income in 2019. This was due to an increase in their research and development and license revenue, primarily related to non-recurring transactions in the first and fourth quarter from Novartis&#x2019; exercise of its option to license AKCEA-APO(a)-L&lt;sub&gt;Rx&lt;/sub&gt; and Pfizer&#x2019;s license of AKCEA-ANGPTL3-L&lt;sub&gt;Rx&lt;/sub&gt;, respectively. Although Akcea generated net income in 2019, given their history of losses, there can be no assurance that they will achieve profitability in future periods. We expect Akcea to incur additional operating losses for the foreseeable future and therefore we continue to maintain a full valuation allowance against our remaining net deferred state tax assets.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;At December 31, 2019, we had federal and state, primarily California, tax net operating loss carryforwards of $99.5 million and $117.9 million, respectively. Our federal tax loss carryforwards are available indefinitely. Our California tax loss carryforwards will begin to expire in 2033. At December 31, 2019, we also had federal and California research and development tax credit carryforwards of $198.8 million and $74.1 million, respectively. Our Federal research and development tax credit carryforwards will begin to expire in 2034. Our California research and development tax credit carryforwards are available indefinitely.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Utilization of the net operating loss and tax credit carryforwards may be subject to an annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;On December 22, 2017, the U.S. government enacted comprehensive tax legislation commonly referred to as the Tax Cuts and Jobs Act of 2017, or the Tax Act. The Tax Act made broad and complex changes to the U.S. tax code, including, but not limited to, reducing the U.S. federal corporate income tax rate to 21 percent, imposing a mandatory one-time transition tax on certain unrepatriated earnings of foreign subsidiaries &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;subjecting certain foreign earnings to U.S. taxation through base erosion anti-abuse tax, or BEAT, and global intangible low-taxed income, or GILTI, &lt;/span&gt;eliminating the corporate alternative minimum tax, or AMT, and changing how existing AMT credits can be realized. We were required to recognize the tax effect of the tax law changes in the year of enactment. &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Our accounting for the elements of the Tax Act is complete. We have made an accounting policy election to treat taxes due on the GILTI inclusion as a current period expense.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We analyze filing positions in all U.S. federal, state and foreign jurisdictions where we file income tax returns, and all open tax years in these jurisdictions to determine if we have any uncertain tax positions on any of our income tax returns. We recognize the impact of an uncertain tax position on an income tax return at the largest amount that the relevant taxing authority is more-likely-than not to sustain upon audit. We do not recognize uncertain income tax positions if they have less than 50 percent likelihood of the applicable tax authority sustaining our position.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following table summarizes our gross unrecognized tax benefits (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z4b3b1be351044041904f4aadda12afa8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Beginning balance of unrecognized tax benefits&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;68,301&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;78,014&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;66,999&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Decrease for prior period tax positions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(867&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(12,814&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Increase for prior period tax positions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;736&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,520&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Increase for current period tax positions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,614&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3,101&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;9,495&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ending balance of unrecognized tax benefits&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;69,784&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;68,301&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;78,014&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Included in the balance of unrecognized tax benefits at December 31, 2019, is $21.7 million that could impact our effective tax rate, subject to our remaining valuation allowance.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We do not foresee any material changes to our gross unrecognized tax benefits within the next twelve months.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We recognize interest and/or penalties related to income tax matters in income tax expense. We did not recognize any accrued interest and penalties related to gross unrecognized tax benefits during the year ended December 31, 2019.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We are subject to taxation in the U.S. and various state and foreign jurisdictions. &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Our tax years for 1999 through 2018 are subject to examination by the U.S. federal, state and foreign tax authorities.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We do not provide for a U.S. income tax liability and foreign withholding taxes on undistributed foreign earnings of our foreign subsidiaries as we consider those earnings to be permanently reinvested. It is not practicable for us to calculate the amount of unrecognized deferred tax liabilities associated with these earnings.&lt;/div&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_c607f452c64f473bb9c5dde69c499108">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income (loss) before income taxes is comprised of (in thousands):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z4092c9a5a2814eb28f48de6d2a9e9058" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;United States&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;344,280&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(69,576&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5,289&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,489&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(6,580&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(11,474&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income (loss) before income taxes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;346,769&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(76,156&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(16,763&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_1154d9477ea5403c89bcaba61b591e79"
      unitRef="U001">344280000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_74d3abad4f744e0aa68801acc3a6ed6b"
      unitRef="U001">-69576000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_8977ca2c8272434794efd8259c5f22b7"
      unitRef="U001">-5289000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_70ca994a31be49619caefe5e71de1587"
      unitRef="U001">2489000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_8425f2adaf6948cdb4db61cdf7def1fc"
      unitRef="U001">-6580000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_15eeca6092a14a5c9b839eb716ea8ae4"
      unitRef="U001">-11474000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_317564d38d3f4684aaa47f65a5d386e8"
      unitRef="U001">346769000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_9fd05fd89e164623ad7d51c758cf30c6"
      unitRef="U001">-76156000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_225bd758b4d047a9b56b2a1266e8768e"
      unitRef="U001">-16763000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_75ef1dbd0a5841a5acf583bb7ca67f64">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our income tax expense (benefit) was as follows (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z713025753cca4d42a8b28f2a7fba9d21" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Current:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Federal&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;35,861&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;438&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(7,460&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;State&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;14,329&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,442&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,246&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;413&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;374&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;234&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total current income tax expense (benefit)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;50,603&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(630&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5,980&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Deferred:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Federal&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(7,096&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(290,511&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;State&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total deferred income tax benefit&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(7,096&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(290,511&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total income tax expense (benefit)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;43,507&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(291,141&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5,980&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_f7d1c022ad9f48ddaa94094db5e10a09"
      unitRef="U001">35861000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_3b8dd023e1f647b8a3ac8d6daa73c20c"
      unitRef="U001">438000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_7390edee7ebc486d8f38622d5c52bcc1"
      unitRef="U001">-7460000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_29cdf46cccf847508b045e7ee750b157"
      unitRef="U001">14329000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_18598915ff304ad69c4f603530fa17ba"
      unitRef="U001">-1442000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_b16b487bd08b4f16b0833b9f760c9124"
      unitRef="U001">1246000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_ca5d84cba52a406991333d46438a92be"
      unitRef="U001">413000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_7ac2061535c24653b193dc9c25179163"
      unitRef="U001">374000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_94c31631758a4c52bc819107405e16bf"
      unitRef="U001">234000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_273269185dee42eb91195045f6449fc7"
      unitRef="U001">50603000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_33a16e765b9c499ba27c595254ef3547"
      unitRef="U001">-630000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_2d44830595d442f082fda176f5b4c723"
      unitRef="U001">-5980000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_87cec1e54272412b8aa84293213da2a9"
      unitRef="U001">-7096000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_3fdf75baf2f34ebb8e8ae479ea28b0dc"
      unitRef="U001">-290511000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_c00a5eec073e447cab0567a91678c321"
      unitRef="U001">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_e78064ae2d4443f18407baa35f73bf2f"
      unitRef="U001">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_989cd3ae4b8346399913987c81866608"
      unitRef="U001">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_d254df8f11b14f8594ca47e6a7f95134"
      unitRef="U001">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_be2ed18e2072458bba8c88d0a45981b5"
      unitRef="U001">-7096000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_499db25413694d1996ce63465160cf19"
      unitRef="U001">-290511000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_b02665644bb848b5b79ed1b9b7aba937"
      unitRef="U001">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_39aa3556afa54b90a94840a97eb5b995"
      unitRef="U001">43507000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_d3a17d5cbd604f2eaffbec171dab238a"
      unitRef="U001">-291141000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_72e6d39ff1da4d90b52e886f5e5ff672"
      unitRef="U001">-5980000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_2c8e7d31275c4be7ad6a80198f6bab7d">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our expense (benefit) for income taxes differs from the amount computed by applying the U.S. federal statutory rate to income (loss) before taxes. The sources and tax effects of the differences are as follows (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zb11f654ab51c478685d3b34848ff0f2f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="22" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Pre-tax income (loss)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;346,769&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(76,156&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(16,763&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Statutory rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;72,822&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(15,993&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;21.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5,867&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;35.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;State income tax net of federal benefit&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;49,119&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;14.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2,202&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;820&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Foreign&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;340&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,735&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2.3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4,299&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(25.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net change in valuation allowance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(37,765&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(10.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(277,924&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;364.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(86,296&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;514.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net operating loss expiration&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;8,864&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(11.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3,987&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(23.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;TEGSEDI licensing gain&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;59,583&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(78.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Impact from outside basis differences&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(16,344&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4.7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Tax credits&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(22,296&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(6.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(73,362&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;96.3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(32,769&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;195.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Deferred tax true-up&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;646&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;9,947&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(13.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4,848&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(28.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Tax rate change&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,811&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,808&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;114,832&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(685.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Non-deductible compensation&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3,361&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3,154&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,575&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(9.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Other non-deductible items&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;329&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(569&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,548&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(15.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea deconsolidation adjustment at IPO&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;469&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Stock-based compensation&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4,837&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4,199&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;5.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(14,337&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;85.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Foreign-derived intangible income benefit&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2,071&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Other&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,608&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,633&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(89&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 28%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effective rate&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;43,507&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;12.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(291,141&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;382.3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5,980&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;35.7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_48c8db752dd847f894945e665263db28"
      unitRef="U001">346769000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_d90962261a1d4e50b88595c178ff0d7d"
      unitRef="U001">-76156000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_82f7c2373f9d4876bd0497532436a6c4"
      unitRef="U001">-16763000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_b85170cf40184efb99422514dde69ba0"
      unitRef="U001">72822000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c20190101to20191231"
      decimals="3"
      id="Fact_ba5c266bc6c041669acb634b40fe9801"
      unitRef="U003">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_a4b904e0d10e47ab8481b786c1abe1ef"
      unitRef="U001">-15993000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c20180101to20181231"
      decimals="3"
      id="Fact_a77137cc5cdc428e9742bd1fec8ff6f2"
      unitRef="U003">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_9224cc00ae254362861b845404083000"
      unitRef="U001">-5867000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c20170101to20171231"
      decimals="3"
      id="Fact_0e74348c85d9419b92dc858bfbfb8651"
      unitRef="U003">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_2b7c3633170a40ae9be93f62ef0241a6"
      unitRef="U001">49119000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="c20190101to20191231"
      decimals="3"
      id="Fact_0598ed64f7924d5fbe52079c56929f59"
      unitRef="U003">0.142</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_e3b34f93e7f9416ca458d23851dae3c9"
      unitRef="U001">-2202000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="c20180101to20181231"
      decimals="3"
      id="Fact_196a7e14a0f4404891352f10b96f74b4"
      unitRef="U003">0.029</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_69b8ebd3294b4be8ba8b457bfcaa8715"
      unitRef="U001">820000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="c20170101to20171231"
      decimals="3"
      id="Fact_35da4fb5e1034b3e8483e03f47ce73c3"
      unitRef="U003">-0.049</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_7f4040ef5d7b4da7a7f650bc5150bcee"
      unitRef="U001">340000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="c20190101to20191231"
      decimals="3"
      id="Fact_f0ada95d66be46c484ea33c6988ff8cf"
      unitRef="U003">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_bb56315ea61941fa9334b20db313a392"
      unitRef="U001">1735000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="c20180101to20181231"
      decimals="3"
      id="Fact_1b666959322542018da1ab6a3fcdd0d0"
      unitRef="U003">-0.023</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_a8b08aa07f334b19ae749ec79bb4c2f8"
      unitRef="U001">4299000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="c20170101to20171231"
      decimals="3"
      id="Fact_3073dd31dd784f6199bcbd4645c6a2c9"
      unitRef="U003">-0.256</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_9efc559699e843b7949b61578198c52e"
      unitRef="U001">-37765000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20190101to20191231"
      decimals="3"
      id="Fact_44c537cfa23648abad9df1629e8ef953"
      unitRef="U003">-0.109</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_3089c505758644759fb7e8c5ad5478fe"
      unitRef="U001">-277924000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20180101to20181231"
      decimals="3"
      id="Fact_110d265d3b7b40408f9b513e9a9ba4c6"
      unitRef="U003">3.649</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_add03b8c1f5c42b8ae930d79a66e2d9b"
      unitRef="U001">-86296000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20170101to20171231"
      decimals="3"
      id="Fact_6ec22dc5b4fd41c6ad55f9ed00a9676e"
      unitRef="U003">5.148</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <ions:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_037b68149f514240b571e4b057b7d37d"
      unitRef="U001">0</ions:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount>
    <ions:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent
      contextRef="c20190101to20191231"
      decimals="3"
      id="Fact_892196abe1a5452f8f1fadd574e7d5b0"
      unitRef="U003">0.000</ions:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent>
    <ions:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_a63a31c01b6f498aa2504bf9fa0220ff"
      unitRef="U001">8864000</ions:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount>
    <ions:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent
      contextRef="c20180101to20181231"
      decimals="3"
      id="Fact_3994e2dcfb154b47a855adea0299a9fc"
      unitRef="U003">-0.116</ions:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent>
    <ions:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_cd496ddabe66446f915c56d43b20262d"
      unitRef="U001">3987000</ions:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount>
    <ions:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent
      contextRef="c20170101to20171231"
      decimals="3"
      id="Fact_5574c2ce2b434d8c849853df85a0f198"
      unitRef="U003">-0.238</ions:EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent>
    <ions:EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_e91cdb5920254d0b9c8644ea0bd6b31e"
      unitRef="U001">0</ions:EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount>
    <ions:EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent
      contextRef="c20190101to20191231"
      decimals="3"
      id="Fact_7baff2ad883145ecacbb955908ebe106"
      unitRef="U003">0.000</ions:EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent>
    <ions:EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_f125a9429aed4ba59cb4535943b4d39f"
      unitRef="U001">59583000</ions:EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount>
    <ions:EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent
      contextRef="c20180101to20181231"
      decimals="3"
      id="Fact_c9f5186ca7d84f9f98618eeb48a5a9b9"
      unitRef="U003">-0.782</ions:EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent>
    <ions:EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_9c59a15f67874cbf89823f5147894005"
      unitRef="U001">0</ions:EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount>
    <ions:EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent
      contextRef="c20170101to20171231"
      decimals="3"
      id="Fact_b1173bf1f8de49f08e0e02bf8437d58c"
      unitRef="U003">0.000</ions:EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent>
    <ions:EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_9fb2790ff3c94f178f4d09b6102d0adf"
      unitRef="U001">-16344000</ions:EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount>
    <ions:EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent
      contextRef="c20190101to20191231"
      decimals="3"
      id="Fact_9f26347de83849108790ac9dfef08ef7"
      unitRef="U003">-0.047</ions:EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent>
    <ions:EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_f59a48753b43436a810d954a9d62028a"
      unitRef="U001">0</ions:EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount>
    <ions:EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent
      contextRef="c20180101to20181231"
      decimals="3"
      id="Fact_170526424df144d6b3a5c7ad2df709ad"
      unitRef="U003">0.000</ions:EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent>
    <ions:EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_b0ac595eec344cd89ecac62ed010fd34"
      unitRef="U001">0</ions:EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount>
    <ions:EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent
      contextRef="c20170101to20171231"
      decimals="3"
      id="Fact_79be2841c00041e7af11e17a17380101"
      unitRef="U003">0.000</ions:EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_8a24b678d3fe4184bb737b9b5173599f"
      unitRef="U001">22296000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="c20190101to20191231"
      decimals="3"
      id="Fact_4a7a563d6d234cd58bc7137fba77ff75"
      unitRef="U003">0.064</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_ba2fef410ac44e2f8481b601dcf4397d"
      unitRef="U001">73362000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="c20180101to20181231"
      decimals="3"
      id="Fact_3fbd7800b7924295bc76f61b343a21a8"
      unitRef="U003">-0.963</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_c945210ff20b45cd8c7dba081d43d2d5"
      unitRef="U001">32769000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="c20170101to20171231"
      decimals="3"
      id="Fact_d1bcf2d2993f400c81d80c35f297056d"
      unitRef="U003">-1.955</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_fdfb05c1990c464695261107a860feeb"
      unitRef="U001">646000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="c20190101to20191231"
      decimals="3"
      id="Fact_b964d6aa6a524c4b8d521e92d44ddf1c"
      unitRef="U003">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_ba7b1884b12a4e2abb5526f4674a1b50"
      unitRef="U001">9947000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="c20180101to20181231"
      decimals="3"
      id="Fact_7b8114439ec74d04b71a3c5bf7cc21bb"
      unitRef="U003">-0.131</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_ad3c883eceee40a88935de84f632b61b"
      unitRef="U001">4848000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="c20170101to20171231"
      decimals="3"
      id="Fact_37390301d0c64a41907cda1fe77196a4"
      unitRef="U003">-0.289</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_d8e127114141478db3fce29187653ab8"
      unitRef="U001">1811000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="c20190101to20191231"
      decimals="3"
      id="Fact_ff5dfbc4b41e4ba2b6268cabc8800f1d"
      unitRef="U003">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_aa8f48cff99340d4a3fed8f3b3cbf779"
      unitRef="U001">-1808000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="c20180101to20181231"
      decimals="3"
      id="Fact_52d9c63f1ecc41e1a17a8fbee6d6d2b0"
      unitRef="U003">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_120334d23e2248fa94f0a8b3a47a38ec"
      unitRef="U001">114832000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="c20170101to20171231"
      decimals="3"
      id="Fact_ff0c8b5e461b4e889743179d12b8fc63"
      unitRef="U003">-6.850</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <ions:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_b9e8226b9cd642a1885a669f1e3ff8e8"
      unitRef="U001">3361000</ions:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount>
    <ions:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent
      contextRef="c20190101to20191231"
      decimals="3"
      id="Fact_8a1f4cfd47914ffdbf619fcbc8052f31"
      unitRef="U003">0.010</ions:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent>
    <ions:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_c63d7e7b9487406bac497ca46a6fc820"
      unitRef="U001">3154000</ions:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount>
    <ions:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent
      contextRef="c20180101to20181231"
      decimals="3"
      id="Fact_d641767da49f48b0857103834131b687"
      unitRef="U003">-0.041</ions:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent>
    <ions:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_c2fa1635eae94d73911269398d313a08"
      unitRef="U001">1575000</ions:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount>
    <ions:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent
      contextRef="c20170101to20171231"
      decimals="3"
      id="Fact_5755b6fed27041f187a7d0f88f7107ea"
      unitRef="U003">-0.094</ions:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_bce0197e78cd4cc7ba3eb11921c32b36"
      unitRef="U001">329000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="c20190101to20191231"
      decimals="3"
      id="Fact_d3f365ea019845c7bf004cde11c47f07"
      unitRef="U003">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_28cb54a2c81c4c359a6868e4d9ab80be"
      unitRef="U001">-569000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="c20180101to20181231"
      decimals="3"
      id="Fact_b6b2ce59821f49c5809c638e96706e58"
      unitRef="U003">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_6a6dcd4f9b944b1e858d646ec40c72b7"
      unitRef="U001">2548000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="c20170101to20171231"
      decimals="3"
      id="Fact_be635adead3e46bd8c975057753892db"
      unitRef="U003">-0.152</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <ions:EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_14125e9710be4f4990c31c44ce937c5d"
      unitRef="U001">0</ions:EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount>
    <ions:EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent
      contextRef="c20190101to20191231"
      decimals="3"
      id="Fact_f46ab7265f39434b85df84146b99602c"
      unitRef="U003">0.000</ions:EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent>
    <ions:EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_67cc5470c2dd4915bb82242964974990"
      unitRef="U001">0</ions:EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount>
    <ions:EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent
      contextRef="c20180101to20181231"
      decimals="3"
      id="Fact_cc5abb17ae784ef596f7eb9f04c0a0fd"
      unitRef="U003">0.000</ions:EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent>
    <ions:EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_d6efdf4265814896844d64b589018989"
      unitRef="U001">469000</ions:EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount>
    <ions:EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent
      contextRef="c20170101to20171231"
      decimals="3"
      id="Fact_146b3877cfb84c5c905ff82c19d29d16"
      unitRef="U003">-0.028</ions:EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_f07a2c7215d74a90a5f9d4a42053e134"
      unitRef="U001">-4837000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="c20190101to20191231"
      decimals="3"
      id="Fact_896722cf23bd46bd892c4514b440f82b"
      unitRef="U003">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_4ace56cd661941dda164a7b4d1dbc5d5"
      unitRef="U001">-4199000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="c20180101to20181231"
      decimals="3"
      id="Fact_883950498a674a698da46bd68262d2a9"
      unitRef="U003">0.055</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_72b2dcbbe49449748e7c9c75562444f6"
      unitRef="U001">-14337000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="c20170101to20171231"
      decimals="3"
      id="Fact_9e38310d67c54659ba2147167a59a001"
      unitRef="U003">0.855</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <ions:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_dfb8b37eb49f4805811f12f4b8c7ce05"
      unitRef="U001">-2071000</ions:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount>
    <ions:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent
      contextRef="c20190101to20191231"
      decimals="3"
      id="Fact_17e44038245847de86fe6b3f39ef47bd"
      unitRef="U003">-0.006</ions:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent>
    <ions:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_282ef35eb1654b2f8cb0e93c44ba382f"
      unitRef="U001">0</ions:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount>
    <ions:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent
      contextRef="c20180101to20181231"
      decimals="3"
      id="Fact_09164a15a1544ccf853826dd0b3550ba"
      unitRef="U003">0.000</ions:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent>
    <ions:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_7e6cff3559a04bcb99869ca1d4ef489c"
      unitRef="U001">0</ions:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount>
    <ions:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent
      contextRef="c20170101to20171231"
      decimals="3"
      id="Fact_417843ce4b3c41b7a5882fd6f8e31e98"
      unitRef="U003">0.000</ions:EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_579c7a65442043da929eea96c26a5f30"
      unitRef="U001">-1608000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="c20190101to20191231"
      decimals="3"
      id="Fact_d4daf54210844f62bbb1a04059ef74aa"
      unitRef="U003">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_a992f73d15204a0081e6aa41357a8de5"
      unitRef="U001">1633000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="c20180101to20181231"
      decimals="3"
      id="Fact_4c434cf931ee4c45825ee90aa9c5caf0"
      unitRef="U003">-0.021</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_bc52c68679ef48cab49f85908463be0f"
      unitRef="U001">-89000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="c20170101to20171231"
      decimals="3"
      id="Fact_4d88b363955f43e1a07814eb57337204"
      unitRef="U003">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_deca3f5e839941f4a90d3b8031b558aa"
      unitRef="U001">43507000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20190101to20191231"
      decimals="3"
      id="Fact_5b3403b4768d4be492d67b3c92d9483d"
      unitRef="U003">0.126</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_9706d35248bb454c8a3a3c80240bc33f"
      unitRef="U001">-291141000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20180101to20181231"
      decimals="3"
      id="Fact_f0cc7188c05e4808b694a7a38a1291cc"
      unitRef="U003">3.823</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_05f18d362e2441e2a636fa371d9e87f0"
      unitRef="U001">-5980000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20170101to20171231"
      decimals="3"
      id="Fact_b6d022290a824526a58ab495c81c8422"
      unitRef="U003">0.357</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_7bc059be0d5b40b885611b777029a315">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Significant components of our deferred tax assets and liabilities as of December 31, 2019 and 2018 are as follows (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z6ce9a811fab143898ba48d74d51fe77e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Deferred Tax Assets:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net operating loss carryovers&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;20,191&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;89,717&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D credits&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;210,455&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;313,652&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Deferred revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;127,763&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;27,381&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Stock-based compensation&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;65,703&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;61,027&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Intangible and capital assets&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;77,861&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;49,007&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Other&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;12,510&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;8,275&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;514,483&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;549,059&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Deferred Tax Liabilities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Convertible debt&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(6,110&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(24,018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Fixed assets&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,958&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Other&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(3,884&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net deferred tax asset&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;502,531&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;525,041&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Valuation allowance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(196,974&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(234,245&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total net deferred tax assets and liabilities&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;305,557&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;290,796&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="c20191231"
      decimals="-3"
      id="Fact_f6113dec90244be7a15feeec0e7f99b3"
      unitRef="U001">20191000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="c20181231"
      decimals="-3"
      id="Fact_de531fc8054a467eb0d8ebe192e75809"
      unitRef="U001">89717000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="c20191231"
      decimals="-3"
      id="Fact_6e4434c808b24cdd8e98c8c527eccd87"
      unitRef="U001">210455000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="c20181231"
      decimals="-3"
      id="Fact_8cae73daf0c14e699722d8495d504e3f"
      unitRef="U001">313652000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="c20191231"
      decimals="-3"
      id="Fact_3161a0571c2d40cfa484d6df3f0587b3"
      unitRef="U001">127763000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="c20181231"
      decimals="-3"
      id="Fact_8e7b04eb5d41408cb9a2aae8c76b704c"
      unitRef="U001">27381000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="c20191231"
      decimals="-3"
      id="Fact_cf4d0af63f314ebebc4008a2387ff7ba"
      unitRef="U001">65703000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="c20181231"
      decimals="-3"
      id="Fact_616f9b6b59aa4b9b83a42abbfc396399"
      unitRef="U001">61027000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="c20191231"
      decimals="-3"
      id="Fact_1eb4e0ee7798484c84a06c938cd4969a"
      unitRef="U001">77861000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="c20181231"
      decimals="-3"
      id="Fact_5dbb3a06f1ce4e86bcf8b0b23175d4c6"
      unitRef="U001">49007000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="c20191231"
      decimals="-3"
      id="Fact_68255c3bd980428f8ac1596cf0f40278"
      unitRef="U001">12510000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="c20181231"
      decimals="-3"
      id="Fact_8fd4dba767ea4fb1ad2e077d22dd1144"
      unitRef="U001">8275000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="c20191231"
      decimals="-3"
      id="Fact_db490d6be6234997ab204f135fae4219"
      unitRef="U001">514483000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="c20181231"
      decimals="-3"
      id="Fact_0e07da67ce43444f913fc9c18171c638"
      unitRef="U001">549059000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="c20191231"
      decimals="-3"
      id="Fact_33b89af7fd6c46f9863e3c4ca73a50d0"
      unitRef="U001">6110000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesFinancingArrangements
      contextRef="c20181231"
      decimals="-3"
      id="Fact_0c45383ac12549f6ae51268c42c2cd6f"
      unitRef="U001">24018000</us-gaap:DeferredTaxLiabilitiesFinancingArrangements>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="c20191231"
      decimals="-3"
      id="Fact_e25b4841ea8643daaead657546cec52e"
      unitRef="U001">1958000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="c20181231"
      decimals="-3"
      id="Fact_9878485dcb08467684a2d157588eeafd"
      unitRef="U001">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="c20191231"
      decimals="-3"
      id="Fact_1b5703c2c4764515a3e8ad2afeea59cf"
      unitRef="U001">3884000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="c20181231"
      decimals="-3"
      id="Fact_1b2f279a0c764ac6861cf53127c15459"
      unitRef="U001">0</us-gaap:DeferredTaxLiabilitiesOther>
    <ions:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
      contextRef="c20191231"
      decimals="-3"
      id="Fact_2aed2e8242ea4d2a953befcd5fd869ee"
      unitRef="U001">502531000</ions:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance>
    <ions:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance
      contextRef="c20181231"
      decimals="-3"
      id="Fact_079ce9450c7a4660ba7391c5cb7a50dc"
      unitRef="U001">525041000</ions:DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c20191231"
      decimals="-3"
      id="Fact_972868dc5873412980ceca72fd836c11"
      unitRef="U001">196974000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c20181231"
      decimals="-3"
      id="Fact_2c9b12b4481545a7ba60367cdb421919"
      unitRef="U001">234245000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c20191231"
      decimals="-3"
      id="Fact_57658da53796431d95347a5ae91df615"
      unitRef="U001">305557000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c20181231"
      decimals="-3"
      id="Fact_b0ad9b5a1bcf4171839877e1f6c48962"
      unitRef="U001">290796000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20181001to20181231"
      decimals="-5"
      id="Fact_5822bb0dcd3341c7a8c11324ef6b029b"
      unitRef="U001">332100000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease
      contextRef="c20190101to20191231"
      decimals="-5"
      id="Fact_54269da909f44affbb474d26a98ef345"
      unitRef="U001">-37300000</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c20191231"
      decimals="-5"
      id="Fact_79bb4d4f42da4e4cb9634ca58cbeb45a"
      unitRef="U001">197000000.0</us-gaap:DeferredTaxAssetsValuationAllowance>
    <ions:IncreaseDecreaseInStateTaxLiability
      contextRef="c20190101to20191231"
      decimals="-5"
      id="Fact_32218318699447e786a482dfc0bf3f88"
      unitRef="U001">-59100000</ions:IncreaseDecreaseInStateTaxLiability>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20191231_IncomeTaxAuthorityNameAxis_InternalRevenueServiceIRSMember"
      decimals="-5"
      id="Fact_d9f8be4484bf4eb29dfdbd375c201523"
      unitRef="U001">99500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20191231_IncomeTaxAuthorityNameAxis_CaliforniaFranchiseTaxBoardMember"
      decimals="-5"
      id="Fact_ad3cae48e06445f7aefbd80a218590f4"
      unitRef="U001">117900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="c20191231_IncomeTaxAuthorityNameAxis_InternalRevenueServiceIRSMember_TaxCreditCarryforwardAxis_ResearchMember"
      decimals="-5"
      id="Fact_895e697c597d405a96e760deb75e2c01"
      unitRef="U001">198800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="c20191231_IncomeTaxAuthorityNameAxis_CaliforniaFranchiseTaxBoardMember_TaxCreditCarryforwardAxis_ResearchMember"
      decimals="-5"
      id="Fact_8191e961253a4f2faaff06f7920ca14f"
      unitRef="U001">74100000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c20180101to20181231"
      decimals="2"
      id="Fact_5d85031df258433ba61dbc8dc13d4b85"
      unitRef="U003">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_6436d4f50bda4b63bd641448eb6cb0d4">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following table summarizes our gross unrecognized tax benefits (in thousands):&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z4b3b1be351044041904f4aadda12afa8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Beginning balance of unrecognized tax benefits&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;68,301&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;78,014&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;66,999&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Decrease for prior period tax positions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(867&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(12,814&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Increase for prior period tax positions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;736&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,520&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Increase for current period tax positions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,614&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3,101&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;9,495&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ending balance of unrecognized tax benefits&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;69,784&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;68,301&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;78,014&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20181231"
      decimals="-3"
      id="Fact_6f5ba375963f47a19fbb04fed7232165"
      unitRef="U001">68301000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20171231"
      decimals="-3"
      id="Fact_0f12ba3f88584d21bf0b87b613d47847"
      unitRef="U001">78014000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20161231"
      decimals="-3"
      id="Fact_67e334d942db4ea29c0cbe3ffcea2715"
      unitRef="U001">66999000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_3f06e5d0f5b747c280280e9fcf69a448"
      unitRef="U001">867000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_39287cd4b49c44a4a617144fa53df1bf"
      unitRef="U001">12814000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_0bb19795798b4cca8d22978a26340bd0"
      unitRef="U001">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_ecf1724d9d65437ab5ccd486d8ab6ebd"
      unitRef="U001">736000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_0ad407c0955648c48850ba2d8d052462"
      unitRef="U001">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_7d0ea3f6a325421b85ab3cbb04eb12fa"
      unitRef="U001">1520000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_6119186f5d854118b836ddc5c481ef2d"
      unitRef="U001">1614000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_f3e7b13433a84e72a642c54ecc6a02b3"
      unitRef="U001">3101000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_809af95107674a60b9a6aa50165e5ba7"
      unitRef="U001">9495000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20191231"
      decimals="-3"
      id="Fact_c2747640a25a483791181f56caf8bc45"
      unitRef="U001">69784000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20181231"
      decimals="-3"
      id="Fact_58382ea6463045ef8f7cefb3fdbf3dd7"
      unitRef="U001">68301000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20171231"
      decimals="-3"
      id="Fact_ed1574437d194d92b955e24fdec9efce"
      unitRef="U001">78014000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="c20191231"
      decimals="-5"
      id="Fact_d79b3530a3b2429e9ee130d62e49ab36"
      unitRef="U001">21700000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_f621fb3495a94bc1ae99ec0bc3395bdf"
      unitRef="U001">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="c20190101to20191231"
      id="Text_6e702f22370b442ca4e36ca2335e2018">
&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;6. Collaborative Arrangements and Licensing Agreements&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Strategic Partnership&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Biogen&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We have several strategic collaborations with Biogen focused on using antisense technology to advance the treatment of neurological disorders. These collaborations combine our expertise in creating antisense medicines with Biogen&#x2019;s expertise in developing therapies for neurological disorders. We developed and licensed to Biogen SPINRAZA, our approved medicine to treat people with spinal muscular atrophy, or SMA. In&lt;/span&gt; December 2017, we entered into a collaboration with Biogen to identify &lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;new antisense medicines for the treatment of SMA&lt;/span&gt;. &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We and Biogen are currently developing &lt;/span&gt;eight&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; medicines to treat neurodegenerative diseases under these collaborations, including medicines to treat people with ALS, Alzheimer&#x2019;s disease&lt;/span&gt;&lt;sub&gt;&#160;&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;and Parkinson&#x2019;s disease. In addition to these medicines, our collaborations with Biogen include a substantial research pipeline that addresses a broad range of neurological diseases. From inception through December 2019, we have received more than $&lt;/span&gt;2.4&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; billion from our Biogen collaborations, including $&lt;/span&gt;1&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; billion we received from Biogen in the second quarter of 2018 for our 2018 strategic neurology collaboration.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Spinal Muscular Atrophy Collaborations&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;SPINRAZA&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;In January 2012, we entered into a collaboration agreement with Biogen to develop and commercialize SPINRAZA, an RNA-targeted therapy for the treatment of SMA. Biogen reported in &lt;/span&gt;January 2020 that SPINRAZA was approved in over 50 countries around the world. &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;From inception through December 2019, we earned more than $&lt;/span&gt;1&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; billion in total revenue under our SPINRAZA collaboration, including more than $&lt;/span&gt;640&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million in revenue from SPINRAZA royalties and more than $&lt;/span&gt;435&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million in R&amp;amp;D revenue. We are receiving tiered royalties ranging from &lt;/span&gt;11 percent&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; to &lt;/span&gt;15 percent&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; on net sales of SPINRAZA. We have exclusively in-licensed patents related to SPINRAZA from Cold Spring Harbor Laboratory and the University of Massachusetts. We pay Cold Spring Harbor Laboratory and the University of Massachusetts a low single digit royalty on net sales of SPINRAZA. Biogen is responsible for global development, regulatory and commercialization activities and costs for SPINRAZA.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We completed our performance obligations under our collaboration in 2016, including delivering the license to Biogen in July 2016. &lt;/span&gt;We also earned additional milestone payments subsequent to delivering the license to Biogen that we recognized in full in the period each milestone payment became probable because we did not have a performance obligation related to each milestone payment. For example, we received $90 million of milestone payments for the approval of SPINRAZA in the EU and Japan in 2017 and recognized the full amounts into revenue in the period Biogen achieved the milestone events.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;New antisense medicines for the treatment of SMA&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;In December 2017, we entered into a collaboration agreement with Biogen to &lt;/span&gt;identify &lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;new antisense medicines for the treatment of SMA&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;. &lt;/span&gt;&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Biogen has the option to license therapies arising out of this collaboration following the completion of preclinical studies. Upon licensing, Biogen &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;will be responsible for all further global development, regulatory and commercialization activities and costs for such therapies&lt;/span&gt;&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;. Under the collaboration agreement, we received a &lt;/span&gt;$25 million&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; upfront payment in December 2017. We will receive development and regulatory milestone payments from Biogen if new medicines advance towards marketing approval. &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;In total over the term of our collaboration, we are eligible to receive up to $&lt;/span&gt;1.2&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; billion in license fees, milestone payments and other payments, including up to $&lt;/span&gt;80&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million for the achievement of development milestones, up to $&lt;/span&gt;180&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million for the achievement of commercialization milestones and up to $&lt;/span&gt;800&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million for the achievement of sales milestones. In addition, we are eligible to receive tiered royalties &lt;/span&gt;&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;from the mid-teens to &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;mid-&lt;/span&gt;20 percent&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; range &lt;/span&gt;&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;on net sales.&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; We will achieve the next payment of up to $&lt;/span&gt;60&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;for the license of a medicine under this collaboration. &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;At the commencement of this collaboration, we identified one performance obligation, which was to perform R&amp;amp;D services for Biogen. We determined the transaction price to be the $25 million upfront payment we received when we entered into the collaboration. We allocated the transaction price to our single performance obligation. In the fourth quarter of 2019, we completed our R&amp;amp;D services performance obligation under this collaboration. We were recognizing revenue as we performed services based on our effort to satisfy our performance obligation relative to the total effort expected to satisfy our performance obligation. We completed our performance obligation earlier than we previously estimated, as a result, we recognized $8.3 million of additional revenue in the fourth quarter of 2019. We do not have any remaining performance obligations under this collaboration. We will receive development and regulatory milestone payments from Biogen if Biogen advances the development candidate under this collaboration toward marketing approval.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Neurology Collaborations&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;2018 Strategic Neurology&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;In April 2018, we and Biogen entered into a strategic collaboration to develop novel antisense medicines for a broad range of neurological diseases and entered into a SPA. As part of the collaboration, Biogen gained exclusive rights to the use of our antisense technology to develop therapies for these diseases for &lt;/span&gt;10&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; years. We are responsible for the identification of antisense drug candidates based on selected targets&lt;/span&gt;. Biogen is responsible for conducting IND-enabling toxicology studies for the selected target. &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Biogen will have the option to license the selected target &lt;/span&gt;after it completes the IND-enabling toxicology study. &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;If Biogen exercises its option to license a medicine, it will assume &lt;/span&gt;all &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;further global development, regulatory and commercialization responsibilities and costs for that medicine.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;In the second quarter of 2018, we received &lt;/span&gt;$1 billion from Biogen, comprised of $625 million to purchase our stock at an approximately 25 percent cash premium and $375 million in an upfront payment. &lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We are eligible to receive up to $&lt;/span&gt;270&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million in milestone payments for each medicine that achieves marketing approval. &lt;/span&gt;In addition, we are eligible to receive tiered royalties &lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;up to the &lt;/span&gt;20 percent range &lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;on net sales.&lt;/span&gt; From inception through December 2019, we have received over $1 billion in payments under this collaboration, excluding $15 million we generated in the fourth quarter of 2019 for advancing two targets under this collaboration. We will achieve the next payment of $7.5 million if Biogen designates another target&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; under this collaboration. &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;At the commencement of this collaboration, &lt;/span&gt;we identified one performance obligation, which was to perform R&amp;amp;D services for Biogen.&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; We determined our transaction price to be $&lt;/span&gt;552&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million, comprised of $&lt;/span&gt;375&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million from the upfront payment and $&lt;/span&gt;177&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million for the premium paid by Biogen for its purchase of our common stock.&lt;/span&gt; We determined the fair value of the premium we received by using the stated premium in the SPA and applying a lack of marketability discount. We included a lack of marketability discount in our valuation of the premium because Biogen received restricted shares of our common stock. We allocated the transaction price to our single performance obligation. From inception through December 2019, we have included $597 million in payments in the transaction price for our R&amp;amp;D services performance obligation under this collaboration, including four $7.5 million milestone payments we achieved in 2019 for advancing four&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&#160;&lt;/span&gt;targets under this collaboration. These milestone payments did not create new performance obligations because they are part of our original R&amp;amp;D services performance obligation. Therefore, we included these amounts in our transaction price for our R&amp;amp;D services performance obligation in the period we achieved the milestone payment. We are recognizing revenue for our R&amp;amp;D services performance obligation as we perform services based on our effort to satisfy our performance obligation relative to our total effort expected to satisfy our performance obligation. We&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; currently estimate we will satisfy our performance obligation in &lt;/span&gt;June 2028.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;2013 Strategic Neurology&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In September 2013, we and Biogen entered into a long-term strategic relationship focused on applying antisense technology to advance the treatment of neurodegenerative diseases. As part of the collaboration, Biogen gained exclusive rights to the use of our antisense technology to develop therapies for neurological diseases and has the option to license medicines resulting from this collaboration. We will usually be responsible for drug discovery and early development of antisense medicines and Biogen will have the option to license antisense medicines after Phase 2 proof-of-concept. In October 2016, we expanded our collaboration to include additional research activities we will perform. If Biogen exercises its option to license a medicine, it will assume all further global development, regulatory and commercialization responsibilities and costs for that medicine. We are currently advancing five medicines in development under this collaboration, including a medicine for Parkinson&#x2019;s disease, two medicines for ALS and two medicines for undisclosed targets. In December 2018, Biogen exercised its option to license one of our ALS medicines, tofersen, and as a result Biogen is now responsible for all further global development, regulatory and commercialization activities and costs for tofersen.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Under the terms of the agreement, we received an upfront payment of $100 million and are eligible to receive milestone payments, license fees and royalty payments for all medicines developed under this collaboration, with the specific amounts dependent upon the modality of the molecule advanced by Biogen. For each antisense molecule that is chosen for drug discovery and development under this collaboration, we are eligible to receive up to approximately $260 million in a license fee and milestone payments per program. The $260 million per program consists of approximately $60 million in development milestones, including amounts related to the cost of clinical trials, and up to $130 million in milestone payments if Biogen achieves pre-specified regulatory milestones. In addition, we are eligible to receive tiered royalties up to the mid-teens on net sales from any antisense medicines developed under this collaboration. From inception through December 2019, we have received over $240 million in upfront fees, milestone payments and other payments under this collaboration. We will achieve the next payment of up to $10 million if we advance a program under this collaboration.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;At the commencement of our strategic neurology collaboration, we identified one performance obligation, which was to perform R&amp;amp;D services for Biogen. At inception, we determined the transaction price to be the $100 million upfront payment we received and allocated it to our single performance obligation. As we achieve milestone payments for our R&amp;amp;D services, we include these amounts in our transaction price for our R&amp;amp;D services performance obligation. We are recognizing revenue for our R&amp;amp;D services performance obligation based on our effort to satisfy our performance obligation relative to our total effort expected to satisfy our performance obligation&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;. &lt;/span&gt;In the third quarter of 2019, we updated our estimate of the total effort we expect to expend to satisfy our performance obligation. As of September 30, 2019, we had completed a&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; significant portion of the research and development services. We expect to complete the remainder of our services in 2020. &lt;/span&gt;As a result, we recorded a cumulative catch up adjustment of $16.5 million to decrease revenue in the third quarter of 2019. We will recognize this amount over the estimated remaining period we will perform services. From inception through December &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;2019&lt;/span&gt;, we have included $145 million in total payments in the transaction price for our R&amp;amp;D services performance obligation.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Under this collaboration, we have also generated additional payments that we concluded were not part of our R&amp;amp;D services performance obligation. We recognized each of these payments in full in the respective quarter we generated the payment because we did not have any performance obligations for the respective payment. The following are the payments we generated in 2018 and 2019:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zf702cef10ad9420fbb18fe4148806ca7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In the third quarter of 2018, we earned a $10 million milestone payment when Biogen initiated a Phase 1 study of IONIS-C9&lt;sub&gt;Rx&lt;/sub&gt;. &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zd8bea4369b954832b61973bbc3eb6b4b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In the fourth quarter of 2018, we earned a $35 million license fee when Biogen licensed tofersen from us because Biogen had full use of the licenses without any continuing involvement from us.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z0d772d1d1a5a49d0bbf4e2f24aeb9608" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In the fourth quarter of 2018, we earned &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;a $&lt;/span&gt;5&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million milestone when Biogen initiated a Proof-of-Concept study for tofersen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z7067decd235e4169aa6e8ded911dd106" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In the third quarter of 2019, we earned an $8 million milestone payment when Biogen initiated a Phase 1/2 study of ION859 (IONIS-LRRK2&lt;sub&gt;Rx&lt;/sub&gt;) &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;for the treatment of people with Parkinson&#x2019;s disease &lt;/span&gt;under this collaboration. &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze7ef725125ba4d91b9d7e95ae4eb1fa0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In the fourth quarter of 2019, we earned a $10 million milestone payment when Biogen advanced IONIS-C9&lt;sub&gt;Rx&lt;/sub&gt;. &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;2012 Neurology&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In December 2012, we and Biogen entered into a collaboration agreement to develop and commercialize novel antisense medicines to up to three targets to treat neurodegenerative diseases. We are responsible for the development of each of the medicines through the completion of the initial Phase 2 clinical study for such medicine. Biogen has the option to license a medicine from each of the programs through the completion of the first Phase 2 study for each program. We are currently advancing IONIS-MAPT&lt;sub&gt;Rx&lt;/sub&gt; for Alzheimer&#x2019;s disease and ION581 for Angelman syndrome under this collaboration. If Biogen exercises its option to license a medicine, it will assume all further global development, regulatory and commercialization responsibilities and costs for that medicine. In December 2019, Biogen exercised its option to license IONIS-MAPT&lt;sub&gt;Rx&lt;/sub&gt; and as a result Biogen is now responsible for all further global development, regulatory and commercialization activities and costs for IONIS-MAPT&lt;sub&gt;Rx&lt;/sub&gt;.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Under the terms of the agreement, we received an upfront payment of $&lt;/span&gt;30&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million. Over the term of the collaboration, we are eligible to receive up to $&lt;/span&gt;210&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million in a license fee and milestone payments per program, plus a mark-up on the cost estimate of the Phase 1 and 2 studies. The $&lt;/span&gt;210&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million per program consists of up to $&lt;/span&gt;10&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million in development milestone payments, plus a mark-up on the cost estimate of the Phase 1 and 2 studies and up to $&lt;/span&gt;130&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million in milestone payments if Biogen achieves pre-specified regulatory milestones. In addition, we are eligible to receive tiered royalties up to the mid-teens on net sales of any medicines resulting from each of the &lt;/span&gt;three&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; programs. From inception through December 2019, we have received $&lt;/span&gt;130&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million in payments under this collaboration, including $&lt;/span&gt;45&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million we earned when Biogen licensed IONIS-MAPT&lt;/span&gt;&lt;sub&gt;Rx &lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;and $&lt;/span&gt;10&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million when Biogen advanced ION581, both of which occurred in the fourth quarter of 2019. We also achieved a $&lt;/span&gt;7.5&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million milestone payment in the first quarter of 2020 when we advanced IONIS-MAPT&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;. We will achieve the next payment of $&lt;/span&gt;12&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&#160;&lt;/span&gt;million if we continue to advance IONIS-MAPT&lt;sub&gt;Rx&lt;/sub&gt;.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Under our collaboration, we determined we had a performance obligation to perform R&amp;amp;D services. We allocated $40 million in total payments to the transaction price for our R&amp;amp;D services performance obligation. In the third quarter of 2019, we completed our R&amp;amp;D services performance obligation when we designated a development candidate and Biogen accepted the development candidate. Biogen&#x2019;s decision to accept the development candidate was not within our control. We were recognizing revenue as we performed services based on our effort to satisfy our performance obligation relative to the total effort expected to satisfy our performance obligation. Because Biogen accepted the development candidate earlier than when we were previously estimating, we recognized $6.3 million of accelerated revenue in the third quarter of 2019.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;When we commenced development for IONIS-MAPT&lt;sub&gt;Rx&lt;/sub&gt; we identified our development work as a separate performance obligation. We are recognizing for our IONIS-MAPT&lt;sub&gt;Rx&lt;/sub&gt; development performance obligation based on the percentage of completion. From inception through December 2019, we have included $37.5 million in the transaction price for our IONIS-MAPT&lt;sub&gt;Rx&lt;/sub&gt; development performance obligation. We currently estimate we will satisfy our performance obligation in September 2020. Our total transaction price for our IONIS-MAPT&lt;sub&gt;Rx &lt;/sub&gt;development performance obligation includes the following payments we achieved in 2019 related to our development work:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zb049489b4a5f433bbe2ed2024d5f35c3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In the second quarter of 2019, we achieved a $7.5 million milestone payment from Biogen when we advanced IONIS-MAPT&lt;sub&gt;Rx &lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;for Alzheimer&#x2019;s disease&lt;/span&gt; under this collaboration. &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z635746e4788a4facb52952eeb34cfca2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In the fourth quarter of 2019, we achieved a $12 million milestone payment from Biogen when we entered into an agreement to conduct a long-term extension study for IONIS-MAPT&lt;sub&gt;Rx&lt;/sub&gt;. &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In the fourth quarter of 2019, we identified another performance obligation upon Biogen&#x2019;s license of IONIS-MAPT&lt;sub&gt;Rx&lt;/sub&gt; because the license we granted to Biogen is distinct from our other performance obligations. We recognized the $45 million license fee for IONIS-MAPT&lt;sub&gt;Rx&lt;/sub&gt; as revenue at that time because Biogen had full use of the license without any continuing involvement from us. Additionally, we did not have any further performance obligations related to the license after we delivered it to Biogen.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In the fourth quarter of 2019, we &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;earned a $&lt;/span&gt;10&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million milestone payment when Biogen advanced ION581. We recognized this milestone payment in full in the fourth quarter of 2019 because we do not have any performance obligations related to this milestone payment.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with Biogen (in millions, except percentage amounts):&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z0380747c43454884ab39653ff62a443c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;SPINRAZA royalties (commercial revenue)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;293.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;237.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;112.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;180.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;137.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;150.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total revenue from our relationship with Biogen&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;473.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;375.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;263.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Percentage of total revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;42&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;63&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;51&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Our &lt;/span&gt;consolidated balance sheet at &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;December 31, &lt;/span&gt;2019&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; and &lt;/span&gt;2018&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; included deferred revenue of $&lt;/span&gt;525.8&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million and $&lt;/span&gt;580.9&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million, respectively, related to our relationship with Biogen.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Research, Development and Commercialization Partners&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;AstraZeneca&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Cardiovascular, Renal and Metabolic Diseases Collaboration&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;In July 2015, we and AstraZeneca formed a collaboration to discover and develop antisense therapies for treating cardiovascular, renal and metabolic diseases. Under our collaboration, AstraZeneca has licensed &lt;/span&gt;three&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; medicines from us: IONIS-AZ4-2.5-L&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;, a medicine we designed to treat cardiovascular disease and our first &lt;/span&gt;medicine that combines our Generation 2.5 and&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; LICA technology, ION532, a medicine we designed to &lt;/span&gt;treat a genetically associated form of kidney disease and &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;ION839, a medicine we designed to &lt;/span&gt;inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis, or NASH&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;. AstraZeneca is responsible for all further global development, regulatory and commercialization activities and costs for each of the medicines it has licensed and any medicines AstraZeneca licenses in the future.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Under the terms of the agreement, we received a $65 million upfront payment. We are eligible to receive license fees and milestone payments of up to more than $4 billion as medicines under this collaboration advance, including up to $1.1 billion for the achievement of development milestones and up to $2.9 billion for regulatory milestones. In addition, we are eligible to receive tiered royalties up to the low teens on net sales from any product that AstraZeneca successfully commercializes under this collaboration agreement. We will achieve the next payment of $10 million under this collaboration if we advance a medicine under this collaboration&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;.&lt;/span&gt; From inception through December 2019, we have received over $175 million in upfront fees, license fees, milestone payments, and other payments under this collaboration, including a $10 million milestone payment we earned in the fourth quarter of 2019 when AstraZeneca initiated a Phase 1 trial for ION839.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;At the commencement of this collaboration, we identified one performance obligation, which was to perform R&amp;amp;D services for AstraZeneca. We determined the transaction price to be the $65 million upfront payment we received and we allocated it to our single performance obligation. We are recognizing revenue for our R&amp;amp;D services performance obligation as we perform services based on our effort to satisfy this performance obligation relative to our total effort expected to satisfy our performance obligation. We&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; currently estimate we will satisfy this performance obligation in&lt;/span&gt; August 2021. As we achieve milestone payments for our R&amp;amp;D services, we include these amounts in our transaction price for our R&amp;amp;D services performance obligation. From inception through December&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; 2019&lt;/span&gt;, we have included $90 million in payments in the transaction price for our R&amp;amp;D services performance obligation.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Under this collaboration, we have also generated additional payments that we concluded were not part of our R&amp;amp;D services performance obligation. We recognized each of these payments in full in the respective quarter we generated the payment because the payments were distinct and we did not have any performance obligations for the respective payment. The following are the payments we have earned:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z4e81e175835f49a2a473992532fd14cc" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;In the first quarter of 2018, we earned &lt;/span&gt;two&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&#160;&lt;/span&gt;$30 million license fees when AstraZeneca licensed ION532 and ION839 because AstraZeneca had full use of the licenses without any continuing involvement from us. &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z984f9fae8d6743d1acd0c178a6cbc814" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In the third quarter of 2018, we earned a $10 million milestone payment when AstraZeneca initiated a Phase 1 study of IONIS-AZ4-2.5-L&lt;sub&gt;Rx&lt;/sub&gt;. &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z6311690ca5444922891b858eebbeb95b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In the fourth quarter of 2019, we earned a $10 million milestone payment when AstraZeneca initiated a Phase 1 study of ION839. &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Oncology Collaboration&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;In December 2012, we entered into a collaboration agreement with AstraZeneca to discover and develop antisense medicines to treat cancer. As part of the agreement, we granted AstraZeneca an exclusive license to develop and commercialize &lt;/span&gt;danvatirsen &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;for the treatment of cancer. AstraZeneca is responsible for all global development, regulatory and commercialization activities for &lt;/span&gt;danvatirsen&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;. We and AstraZeneca have evaluated &lt;/span&gt;danvatirsen&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; in people with head and neck cancer, advanced lymphoma and advanced metastatic hepatocellular carcinoma. AstraZeneca is evaluating &lt;/span&gt;danvatirsen&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; in combination with durvalumab, AstraZeneca&#x2019;s PD-L1, blocking medicine, in people with head and neck cancer, metastatic bladder cancer and metastatic non-small cell lung cancer. We and AstraZeneca also established an oncology research program. AstraZeneca has the option to license medicines resulting from the program, and if AstraZeneca exercises its option to license a medicine, it will be responsible for all further global development, regulatory and commercialization activities and costs for such medicine. In the fourth quarter of 2018, we added &lt;/span&gt;ION736 (formerly IONIS-AZ7-2.5&lt;sub&gt;Rx&lt;/sub&gt;) to our preclinical pipeline, a second medicine under our oncology collaboration.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Under the terms of this agreement, we received $&lt;/span&gt;31&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million in upfront payments. We are eligible to receive milestone payments and license fees from AstraZeneca as programs advance in development. If AstraZeneca successfully develops &lt;/span&gt;danvatirsen&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; and ION736 under the research program, we could receive license fees and milestone payments of up to more than $&lt;/span&gt;450&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million, including up to $&lt;/span&gt;152&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million for the achievement of development milestones and up to $&lt;/span&gt;275&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million for the achievement of regulatory milestones. In addition, we are eligible to receive tiered royalties up to the mid-teens on net sales from any medicines resulting from these programs. From inception through December 2019, we have received over $&lt;/span&gt;125&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million in upfront fees, milestone payments, and other payments under this oncology collaboration, including nearly $&lt;/span&gt;30&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million in milestone payments we achieved when AstraZeneca advanced &lt;/span&gt;danvatirsen and ION736, in the fourth quarter of 2018. We &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;will achieve the next payment of up to $&lt;/span&gt;25&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;if we advance a medicine under our cancer research program with AstraZeneca.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;At the commencement of this collaboration, we identified four performance obligations, three of which we completed in March 2014 and we completed the remaining R&amp;amp;D services performance obligation in February 2018. In the fourth quarter of 2018, we earned a $17.5 million milestone payment and a $10 million milestone payment when AstraZeneca advanced two programs under our collaboration. We recognized these milestone payments in full in the fourth quarter because we do not have any performance obligations related to these milestone payments.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with AstraZeneca (in millions, except percentage amounts):&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z3e98572cb7a74e948b59d5a9feec5657" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;28.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;120.7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;21.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Percentage of total revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;20&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Our &lt;/span&gt;consolidated balance sheet at &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;December 31, &lt;/span&gt;2019&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; and &lt;/span&gt;2018&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; included deferred revenue of $&lt;/span&gt;25.0&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million and $&lt;/span&gt;40.1&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million, respectively, related to our relationship with AstraZeneca.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Bayer&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In May 2015, we entered into an exclusive license agreement with Bayer to develop and commercialize IONIS-FXI&lt;sub&gt;Rx&lt;/sub&gt; for the prevention of thrombosis. We were responsible for completing a Phase 2 study of IONIS-FXI&lt;sub&gt;Rx&lt;/sub&gt; in people with end-stage renal disease on hemodialysis. Under the terms of the agreement, we received a $100 million upfront payment in the second quarter of 2015. In February 2017, we amended our agreement with Bayer to advance IONIS-FXI&lt;sub&gt;Rx&lt;/sub&gt; and to initiate development of IONIS-FXI-L&lt;sub&gt;Rx&lt;/sub&gt;, which Bayer licensed. In conjunction with the decision to advance these programs, we received a $75 million payment from Bayer. In October 2019, Bayer decided it would advance IONIS-FXI-L&lt;sub&gt;Rx&lt;/sub&gt; following positive clinical results. Bayer is now responsible for all global development, regulatory and commercialization activities and costs for the FXI program.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We are eligible to receive up to $385 million in license fees, milestone payments and other payments, including up to $125 million for the achievement of development milestones and up to $110 million for the achievement of commercialization milestones. In addition, we are eligible to receive tiered royalties in the low to high 20 percent range on gross margins of both medicines combined. From inception through December 2019, we have received over $185 million from our Bayer collaboration, including a $10 million milestone payment we earned in the fourth quarter of 2019 when Bayer decided it would advance IONIS-FXI-L&lt;sub&gt;Rx&lt;/sub&gt;. We will achieve the next payment of $20 million if Bayer initiates a Phase 3 study for the FXI program.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;At the commencement of this collaboration, we identified three performance obligations, the license of IONIS-FXI&lt;sub&gt;Rx&lt;/sub&gt;, which we delivered in May 2016, R&amp;amp;D services and delivery of API, both of which we completed in November 2016.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In February 2017, when we amended our collaboration with Bayer, we identified two new performance obligations&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;, &lt;/span&gt;one&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; for the license of IONIS-FXI-L&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; and &lt;/span&gt;one&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; for R&amp;amp;D services&lt;/span&gt;. We determined the transaction price to be the $75 million payment. We allocated $64.9 million to &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;the license of IONIS-FXI-L&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; based on its estimated relative stand-alone selling price and recognized the associated revenue upon our delivery of the license in the first quarter of 2017. We allocated $&lt;/span&gt;10.1&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million to our R&amp;amp;D services performance obligation based on an estimated relative stand-alone selling price. &lt;/span&gt;We recognized revenue for our R&amp;amp;D services performance obligation as we performed services based on our effort to satisfy our performance obligation relative to our total effort expected to satisfy our performance obligation which we completed in the third quarter of 2019.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In the fourth quarter of 2019, we earned a $10 million milestone payment when Bayer decided it would advance IONIS-FXI-L&lt;sub&gt;Rx&lt;/sub&gt;. We recognized this milestone payment in full in the fourth quarter of 2019 because we do not have any performance obligations related to this milestone payment.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with Bayer (in millions, except percentage amounts):&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zb1073dc32a5e4c66a2a664b0634da7c6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;14.3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;5.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;67.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Percentage of total revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;13&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Our &lt;/span&gt;consolidated balance sheet at &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;December 31, 2019 and 2019 included deferred revenue of $&lt;/span&gt;2.4&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million and $&lt;/span&gt;4.3&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million, respectively, related to our relationship with Bayer.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;GSK&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In March 2010, we entered into an alliance with GSK using our antisense drug discovery platform to discover and develop new medicines against targets for rare and serious diseases, including infectious diseases and some conditions causing blindness. Under the terms of the agreement, we received upfront payments of $35 million. Our collaboration with GSK currently includes two medicines targeting hepatitis B virus, or HBV: IONIS-HBV&lt;sub&gt;Rx&lt;/sub&gt; and IONIS-HBV-L&lt;sub&gt;Rx&lt;/sub&gt;, which we designed to reduce the production of viral proteins associated with HBV infection. In the third quarter of 2019, following positive Phase 2 results, GSK licensed our HBV program. GSK is responsible for all global development, regulatory and commercialization activities and costs for the HBV program.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Under our agreement, if GSK successfully develops these medicines and achieves pre-agreed sales targets, we could receive license fees and milestone payments of up to $262 million, including up to $47.5 million for the achievement of development milestones, up to $120 million for the achievement of regulatory milestones and up to $70 million for the achievement of commercialization milestones. In addition, we are eligible to receive tiered royalties up to the mid-teens on net sales from any product that GSK successfully commercializes under this alliance. From inception through December 2019, we have received more than $189 million in payments under this alliance with GSK, including a $25 million license fee we earned in the third quarter of 2019 when GSK licensed the HBV program. We will achieve the next payment of $15 million when GSK initiates a Phase 3 study of a medicine under this program.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We completed our R&amp;amp;D services performance obligations under our collaboration in March 2015. &lt;/span&gt;We identified a new performance obligation when we granted GSK the license of the HBV program and assignment of related intellectual property rights in the third quarter of 2019 because the license is distinct from our other performance obligations. We recognized the $25 million license fee for the HBV program as revenue at that time because GSK had full use of the license without any continuing involvement from us. Additionally, we did not have any further performance obligations related to the license after we delivered it to GSK.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We do not have any remaining performance obligations under our collaboration with GSK; however, we can still earn additional payments and royalties as GSK advances the HBV program.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with GSK (in millions, except percentage amounts):&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zfc1697a2c45e4e5d9ba00caf3a13ead3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;25.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;14.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Percentage of total revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We did not have any deferred revenue from our relationship with GSK at December 31, 2019 and 2018.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Janssen Biotech, Inc.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In December 2014, we entered into a collaboration agreement with Janssen Biotech, Inc. to discover and develop antisense medicines that can be locally administered, including oral delivery, to treat autoimmune disorders of the GI tract. Janssen had the option to license medicines from us through the designation of development candidates for up to three programs. Under our collaboration, Janssen licensed ION253 in November 2017, which is currently in preclinical development. Prior Janssen&#x2019;s license of ION253, we were responsible for the discovery activities to identify development candidates. Under the license, Janssen is responsible for the global development, regulatory and commercial activities for ION253.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Under the terms of the agreement, we received $35 million in upfront payments. We are eligible to receive up to more than $285 million in license fees and milestone payments for these programs, including up to $65 million for the achievement of development milestones, up to $160 million for the achievement of regulatory milestones and up to $60 million for the achievement of commercialization milestones. From inception through December 2019, we have received over $75 million. In addition, we are eligible to receive tiered royalties up to the near teens on net sales from any medicines resulting from this collaboration. We will achieve the next payment of $5 million if Janssen continues to advance a target under this collaboration.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;At the commencement of this collaboration, we identified one performance obligation, which was to perform R&amp;amp;D services for Janssen. We determined the transaction price to be the $35 million upfront payments we received. We allocated the &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/span&gt;35&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million&lt;/span&gt; to our single performance obligation. As we achieved milestone payments for our R&amp;amp;D services, we included these amounts in our transaction price for our R&amp;amp;D services performance obligation. We recognized revenue for our R&amp;amp;D services performance obligation over our period of performance, which ended in November 2017.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We identified separate performance obligation when Janssen licensed ION253 under our collaboration because the license we granted to Janssen was distinct from our other performance obligations. We recognized the $5 million license fee for ION253 in November 2017, because Janssen had full use of the licenses without any continuing involvement from us. Additionally, we did not have any further performance obligations related to the license after we delivered it to Janssen.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with Janssen (in millions, except percentage amounts):&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zf8941280a0a94e81bb425341b948878a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;36.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Percentage of total revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We did not have any deferred revenue from our relationship with Janssen at December 31, 2019 and 2018.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Roche&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="text-align: left; margin-left: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Huntington&#x2019;s Disease&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In April 2013, we formed an alliance with Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd., collectively Roche, to develop treatments for HD based on our antisense technology. Under the agreement, we discovered and developed tominersen, an antisense medicine targeting HTT protein. We developed tominersen through completion of our Phase 1/2 clinical study in people with early stage HD. In December 2017, upon completion of the Phase 1/2 study, Roche exercised its option to license tominersen&lt;sub&gt;&#160;&lt;/sub&gt;and is now responsible for the global development, regulatory and commercialization activities and costs for tominersen.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Under the terms of the agreement, we received an upfront payment of $30 million in April 2013 and an additional $3 million payment in 2017. We are eligible to receive up to $365 million in a license fee and milestone payments including up to $70 million for the achievement of development milestones, up to $170 million for the achievement of regulatory milestones and up to $80 million for the achievement of commercialization milestones. In addition, we are eligible to receive up to $136.5 million in milestone payments for each additional medicine successfully developed. We are also eligible to receive tiered royalties up to the mid-teens on any net sales of any product resulting from this alliance. From inception through December 2019, we have received over $145 million in upfront fees, milestone payments and license fees for advancing tominersen, including $35 million in milestone payments we earned in the first quarter of 2019 when Roche dosed the first patient in a Phase 3 study for tominersen. We will achieve the next payment of $15 million if Roche advances tominersen.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;At the commencement of this collaboration, we identified one performance obligation, which was to perform R&amp;amp;D services for Roche. We determined the transaction price to be the $30 million upfront payment we received and allocated it to our single performance obligation. As we achieved milestone payments for our R&amp;amp;D services, we included these amounts in our transaction price for our R&amp;amp;D services performance obligation. We recognized revenue for our R&amp;amp;D services performance obligation over our period of performance, which ended in September 2017.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Under this collaboration, we have also generated additional payments that we concluded were not part of our R&amp;amp;D services performance obligation. We recognized each of these payments in full in the respective quarter we generated the payment because the payments were distinct and we did not have any performance obligations for the respective payment. The following are the payments we have earned:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z2cb9bd0d8147431e8242225e5734bea8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In the fourth quarter of 2017, we earned a $45 million license fee when Roche licensed tominersen because Roche had full use of the license without any continuing involvement from us. &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z3ba97b8a23374e16b9cd8bc689285c53" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In the first quarter of 2019, we earned $35 million in milestone payments when Roche dosed the first patient in the Phase 3 study of tominersen in the first quarter of 2019. &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We do not have any remaining performance obligations related to tominersen under this collaboration with Roche; however, we can still earn additional payments and royalties as Roche advances tominersen.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;IONIS-FB-L&lt;/span&gt;&lt;sub&gt;&lt;span style="background-color: #FBFBFB;"&gt;Rx&lt;/span&gt;&lt;/sub&gt;&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; for Complement-Mediated Diseases&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;In October 2018, we entered into a collaboration agreement with Roche to&lt;/span&gt;&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; develop IONIS-FB-L&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; for the treatment of complement-mediated diseases. We are currently conducting Phase 2 studies in two disease indications for &lt;/span&gt;&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;IONIS-FB-L&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;, one for the treatment of patients with geographic atrophy, or GA, the advanced stage of dry age-related macular degeneration, or AMD, and a second for the treatment of patients with IgA nephropathy. &lt;/span&gt;Roche&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; has the option to license IONIS-FB-L&lt;/span&gt;&lt;sub&gt;&lt;span style="background-color: #FBFBFB;"&gt;Rx&lt;/span&gt;&lt;/sub&gt;&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; at the completion of these studies. Upon licensing, &lt;/span&gt;Roche &lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;will be responsible for all further global development, regulatory and commercialization activities and costs.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Under the terms of this agreement, we received a &lt;/span&gt;$75 million&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; upfront payment in October 2018. We are eligible to receive up to &lt;/span&gt;$684 million&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; in development, regulatory and sales milestone payments and license fees. In addition, we are also eligible to receive tiered royalties from the high teens to &lt;/span&gt;20 percent&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; on net sales. We will achieve the next payment of $&lt;/span&gt;20&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million when we advance &lt;/span&gt;the Phase 2 study in patients with dry AMD&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;At the commencement of this collaboration, we identified one performance obligation, which was to perform R&amp;amp;D services for Roche. We determined the transaction price to be the $75 million upfront payment we received and allocated it to our single performance obligation. We are recognizing revenue for our R&amp;amp;D services performance obligation as we perform services based on our effort to satisfy our performance obligation relative to our total effort expected to satisfy our performance obligation. We&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; currently estimate we will satisfy our performance obligation in &lt;/span&gt;December 2022.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with Roche (in millions, except percentage amounts):&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z3751bf5f787c451499c06571891a9800" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;57.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;8.3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;55.7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Percentage of total revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;11&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Our &lt;/span&gt;consolidated balance sheet at &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;December 31, &lt;/span&gt;2019&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; and 2018 included deferred revenue of $&lt;/span&gt;52.3&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million and $&lt;/span&gt;72.6&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million related to our relationship with Roche, respectively.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic; font-weight: bold;"&gt;Akcea Collaborations&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following collaboration agreements relate to Akcea, our majority owned affiliate. Akcea is responsible for the development activities under these collaborations. As such, Akcea recognizes the associated revenue earned, cash received and expenses incurred in its statement of operations, which we reflect in our consolidated results. We also reflect the noncontrolling interest attributable to other owners of Akcea&#x2019;s common stock in a separate line on our statement of operations and a separate line within stockholders&#x2019; equity on our consolidated balance sheet.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;For each of Akcea's collaborations Akcea pays us sublicense fees for payments that it receives and we recognize those fees as revenue in our Ionis Core operating segment results and Akcea recognizes the fees as R&amp;amp;D expense. In our consolidated results, we eliminate any sublicense revenue and expense.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Novartis&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In January 2017, we and Akcea initiated a collaboration with Novartis to develop and commercialize AKCEA-APO(a)-L&lt;sub&gt;Rx&lt;/sub&gt; and AKCEA-APOCIII-L&lt;sub&gt;Rx&lt;/sub&gt;.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea received a $75 million upfront payment in the first quarter of 2017, of which it retained $60 million and paid us $15 million as a sublicense fee. &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;In February 2019, Novartis licensed AKCEA-APO(a)-L&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt; and Akcea earned a $150 million license fee. Akcea paid us $75 million as a sublicense fee in 2.8 million shares of Akcea common stock. Novartis is responsible for conducting and funding all future development, regulatory and commercialization activities for AKCEA-APO(a)-L&lt;sub&gt;Rx&lt;/sub&gt;, including a global Phase 3 cardiovascular outcomes study, which Novartis initiated in December 2019.&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;&#160;&lt;/span&gt;In connection with Novartis&#x2019; license of AKCEA-APO(a)-L&lt;sub&gt;Rx&lt;/sub&gt;, Akcea and Novartis established a more definitive framework under which the companies would negotiate the co-commercialization of AKCEA-APO(a)-L&lt;sub&gt;Rx&lt;/sub&gt; in selected markets. Included in this framework is an option by which Novartis could solely commercialize AKCEA-APO(a)-L&lt;sub&gt;Rx&lt;/sub&gt; in exchange for Novartis paying Akcea increased commercial milestone payments based on sales of AKCEA-APO(a)-L&lt;sub&gt;Rx&lt;/sub&gt;.&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; When Novartis decided to not exercise its option for &lt;/span&gt;AKCEA-APOCIII-L&lt;sub&gt;Rx&lt;/sub&gt;, Akcea retained rights to develop and commercial AKCEA-APOCIII-L&lt;sub&gt;Rx&lt;/sub&gt;.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Under the collaboration, Akcea is eligible to receive up to $675 million in milestone payments, including $25 million for the achievement of a development milestone, up to $290 million for the achievement of regulatory milestones and up to $360 million for the achievement of commercialization milestones. Akcea is also eligible to receive tiered royalties in the mid-teens to low 20 percent range on net sales of AKCEA-APO(a)-L&lt;sub&gt;Rx&lt;/sub&gt;. Akcea will pay 50 percent of these license fees, milestone payments and royalties to us as sublicense fees.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In conjunction with this collaboration, we entered into a SPA with Novartis. As part of the SPA, Novartis purchased 1.6 million shares of our common stock for $100 million in the first quarter of 2017. As part of the SPA, Novartis was required to purchase $50 million of Akcea&#x2019;s common stock at the IPO price or our common stock at a premium if an IPO did not occur by April 2018. Under the SPA, in July 2017, Novartis purchased $50 million of Akcea&#x2019;s common stock in a separate private placement concurrent with the completion of Akcea's IPO at a price per share equal to the IPO price.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;At the commencement of this collaboration, Akcea identified four separate performance obligations:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="za92dcc9ca554450dbde079edd52a748b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D services for AKCEA-APO(a)-L&lt;sub&gt;Rx&lt;/sub&gt;;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z969c1fbd3a7d4bceb111d5b8034e0da7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D services for AKCEA-APOCIII-L&lt;sub&gt;Rx&lt;/sub&gt;;&lt;sub&gt;&#160;&lt;/sub&gt;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z7a53186ffac14cde8f9dafbcae98b1ee" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;API for AKCEA-APO(a)-L&lt;sub&gt;Rx&lt;/sub&gt;; and &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z5c9cb7188be64f6fa8629693209b9498" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;API for AKCEA-APOCIII-L&lt;sub&gt;Rx&lt;/sub&gt;. &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea determined that the R&amp;amp;D services for each medicine and the API for each medicine were distinct from its other performance obligations.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea determined our transaction price to be $108.4 million, comprised of the following:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z95c64f6ac223413087c92b4e7148ad52" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$75 million from the upfront payment;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z5fda1af0585f4b50aece02928629da77" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$28.4 million for the premium paid by Novartis for its purchase of our common stock at a premium in the first quarter of 2017; and &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zd1af860b61eb4d06adc195cc22f1eefa" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$5.0 million for the potential premium Novartis would have paid if they purchased our common stock in the future.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -36pt; margin-left: 72pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea allocated the transaction price based on the estimated stand-alone selling price of each performance obligation as follows:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zf1ec8c14e9fd4097a634d42230b5ed2d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/span&gt;64.0&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million for the R&amp;amp;D services for &lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;AKCEA-APO(a)-L&lt;/span&gt;&lt;sub style="font-family: 'Times New Roman';"&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z4d65be2b97bf4dc992b6d7f8890d35fe" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$40.1 million for the R&amp;amp;D services for &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;AKCEA-APOCIII-L&lt;/span&gt;&lt;sub style="font-family: 'Times New Roman';"&gt;Rx&lt;/sub&gt;; &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z4a5a892931aa46dcbb360dd2c2da8d07" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;1.5&lt;/span&gt; million for the delivery of AKCEA-APO(a)-L&lt;sub&gt;Rx&lt;/sub&gt; API; and&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z70a24658629e48879924f550d9d26261" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;2.8&lt;/span&gt; million for the delivery of AKCEA-APOCIII-L&lt;sub&gt;Rx&lt;/sub&gt; API.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea recognized revenue related to each of the performance obligations as follows:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z4ad445a40aac4d02b766c98537df051b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea completed its R&amp;amp;D services performance obligation for AKCEA-APO(a)-L&lt;sub&gt;Rx &lt;/sub&gt;in second quarter of 2019. As such, Akcea recognized all revenue it allocated to its AKCEA-APO(a)-L&lt;sub&gt;Rx &lt;/sub&gt;R&amp;amp;D services as of the end of the second quarter of 2019;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z9bc63efdf0e1423fa47eb9c79e9a847f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea completed its R&amp;amp;D services performance obligation for AKCEA-APOCIII-L&lt;sub&gt;Rx&lt;/sub&gt; in the fourth quarter of 2019 because Novartis elected to terminate the strategic collaboration for AKCEA-APOCIII-L&lt;sub&gt;Rx&lt;/sub&gt; during the period. As a result, Akcea was not required to provide any further R&amp;amp;D services, as such, Akcea recognized all revenue it allocated to its AKCEA-APOCIII-L&lt;sub&gt;Rx&lt;/sub&gt; L&lt;sub&gt;Rx &lt;/sub&gt;R&amp;amp;D services as of the end of the fourth quarter of 2019;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z2eb463986cc148edaab3f8c0fc340615" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea recognized the amount attributed to AKCEA-APO(a)-L&lt;sub&gt;Rx&lt;/sub&gt; API when Akcea delivered it to Novartis in 2017; and&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zc57903c50d3a443fb4070a41db918de4" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea recognized the amount attributed to AKCEA-APOCIII-L&lt;sub&gt;Rx&lt;/sub&gt; API when Akcea delivered it to Novartis in May 2018.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Akcea recognized revenue related to the R&amp;amp;D services for the AKCEA-APO(a)-L&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; and AKCEA-APOCIII-L&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; performance obligations as Akcea performed services &lt;/span&gt;based on its effort to satisfy its performance obligation relative to Akcea's total effort expected to satisfy its performance obligation&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;During the years ended December 31, 2019 and 2018, Akcea earned the following revenue from its relationship with Novartis (in millions, except percentage amounts):&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z69ce748cda9640099c4155d9ea42f332" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;187.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;50.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;43.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Percentage of total revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;17&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Our &lt;/span&gt;consolidated balance sheet at &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;December 31, &lt;/span&gt;2018&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; included deferred revenue of $&lt;/span&gt;28.8&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million related to Akcea's relationship with Novartis. We did &lt;/span&gt;no&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;t have any deferred revenue from our relationship with Novartis at December 31, 2019.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;Pfizer&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;AKCEA&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;-ANGPTL3-L&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;In October 2019, Akcea initiated a collaboration with Pfizer for the license of AKCEA&lt;/span&gt;&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;-ANGPTL3-L&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;, a medicine to treat people with cardiovascular and metabolic diseases. Akcea recently completed a Phase 2 study of AKCEA&lt;/span&gt;&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;-ANGPTL3-L&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; in patients&lt;/span&gt; with elevated levels of triglycerides, or hypertriglyceridemia, type 2 diabetes and &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;non-alcoholic fatty liver disease, or NAFLD. Pfizer is responsible for all development and regulatory activities and costs beyond those associated with this study.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Under the terms of the agreement, Akcea received a $&lt;/span&gt;250&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million upfront payment. Akcea is also eligible to receive development, regulatory and sales milestone payments of up to $&lt;/span&gt;1.3&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; billion&lt;/span&gt;, including up to $205 million for the achievement of development milestones, up to $250 million for the achievement of regulatory milestones and up to $850 million for the achievement of commercialization milestones. Akcea is&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; also eligible to earn tiered royalties in the mid-teens to low &lt;/span&gt;20 percent&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; range on annual worldwide net sales. Akcea has retained the rights to co-commercialize AKCEA&lt;/span&gt;&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;-ANGPTL3-L&lt;/span&gt;&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; in the U.S. and certain additional markets. Akcea&lt;/span&gt;&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; will achieve the next payment of $&lt;/span&gt;75&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million when Pfizer advances AKCEA-ANGPTL3-L&lt;/span&gt;&lt;sub&gt;&lt;span style="background-color: #FBFBFB;"&gt;Rx&lt;/span&gt;&lt;/sub&gt;&lt;span style="background-color: #FBFBFB; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;At the commencement of this collaboration, Akcea identified three separate performance obligations:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze99c6a33b95947ed81c68654c16d319e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;License of AKCEA-ANGPTL3-L&lt;sub&gt;Rx&lt;/sub&gt;;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z9f82745b2a734ec181ae05f3d3c17dfb" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D services for AKCEA-ANGPTL3-L&lt;sub&gt;Rx&lt;/sub&gt;; and&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze279fcd45eb041eab8e90392a384799d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;API for AKCEA-ANGPTL3-L&lt;sub&gt;Rx&lt;/sub&gt;.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea determined the transaction price to be $250 million, the upfront payment it received.&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; Akcea&lt;/span&gt; allocated the transaction price based on the estimated stand-alone selling price of each performance obligation as follows:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze54e7b0fe6964ad482f1ea90cb1e8d4f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$245.6 million for the license of AKCEA-ANGPTL3-L&lt;sub&gt;Rx&lt;/sub&gt;;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z8172b430e2874deb85b9c47a783a932f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/span&gt;2.2&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million for the R&amp;amp;D services for &lt;/span&gt;AKCEA-ANGPTL3-L&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z7c560cb48d85427a9f66c095b4b29f24" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;$&lt;/span&gt;2.2&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million for the delivery of &lt;/span&gt;AKCEA-ANGPTL3-L&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; API.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea is recognizing revenue related to each of its performance obligations as follows:&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zeb2eff08d272446d9de8fac3d324e9bb" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 22.5pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea recognized $245.6 million for the license of AKCEA-ANGPTL3-L&lt;sub&gt;Rx&lt;/sub&gt; in the fourth quarter of 2019 because Akcea determined the license Akcea granted to Pfizer was distinct from its other performance obligations and Pfizer had full use of the license without any continuing involvement from Akcea. &lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z06340fd0be4446e4add1b4fab2760135" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 22.5pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea is&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; recognizing revenue related to the R&amp;amp;D services for &lt;/span&gt;AKCEA-ANGPTL3-L&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; as Akcea performs services &lt;/span&gt;based on Akcea's effort to satisfy its performance obligation relative to Akcea's total effort expected to satisfy its performance obligation&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;. Akcea&lt;/span&gt; expects to satisfy its R&amp;amp;D services performance obligation by mid-2020&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z7f59c7ed1f0c4a5bb58495efb32b1f25" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 36pt;"/&gt;
    &lt;td style="width: 22.5pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x25cf;&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; recognized the amount attributed to the API supply for &lt;/span&gt;AKCEA-ANGPTL3-L&lt;sub&gt;Rx&lt;/sub&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; when it delivered it to Pfizer in the fourth quarter of 2019. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;During the fourth quarter of 2019, we received &lt;/span&gt;6.9 million shares of Akcea common stock for &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;payment of the &lt;/span&gt;$125 million sublicense fee Akcea owed us.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;During the year ended December 31, 2019, Akcea earned the following revenue from its relationship with Pfizer (in millions, except percentage amounts):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z6a52ad3f4f4548a28b37262fe935a7dc" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;248.7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Percentage of total revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;22&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Our &lt;/span&gt;consolidated balance sheet at &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;December 31, &lt;/span&gt;2019&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; included deferred revenue of $&lt;/span&gt;1.3&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; million related to Akcea&#x2019;s relationship with Pfizer.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;"&gt;PTC Therapeutics&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In August 2018, Akcea entered into an exclusive license agreement with PTC Therapeutics to commercialize TEGSEDI and WAYLIVRA in Latin America. Under the license agreement, Akcea is eligible to receive up to $26 million in payments, including $12 million it received in the third quarter of 2018, $6 million it received in the second quarter of 2019 following European Medicines Agency, or EMA, approval of WAYLIVRA, $4 million it received in the fourth quarter of 2019 when PTC received approval for TEGSEDI in Brazil, and up to $4 million in an additional regulatory milestone payment. Akcea is eligible to receive royalties from PTC in the mid-20 percent range on net sales in Latin America for each medicine. PTC&#x2019;s obligation to pay Akcea royalties begins on the earlier of 12 months after the first commercial sale of a product in Brazil or the date that PTC recognizes revenue of at least $10 million in Latin America. Consistent with the agreements between Ionis and Akcea, the companies will share all payments, including royalties.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;At the commencement of this collaboration, Akcea identified two performance obligations, which were the licenses Akcea granted to PTC to commercialize TEGSEDI and WAYLIVRA in Latin America in the third quarter of 2018. Akcea recognized $12 million in license fee revenue at that time because PTC had full use of both licenses without any continuing involvement from Akcea. Akcea does not have any remaining performance obligations under its collaboration with PTC. Akcea can still earn additional payments and royalties as PTC commercializes the medicines.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In the second quarter of 2019, Akcea earned a $6 million payment when WAYLIVRA was approved by the EMA. Akcea recognized this payment in full in the second quarter of 2019 because it does not have any performance obligations related to this payment. Additionally, in the fourth quarter of 2019, Akcea earned $4 million when TEGSEDI was approved in Brazil. Akcea recognized this payment in full in the fourth quarter of 2019 because it does not have any performance obligations related to this payment.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;During the years ended December 31, 2019 and 2018, Akcea earned the following revenue from its relationship with PTC (in millions, except percentage amounts):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zf3ce81334bbb4ee983c75acc2b6feb6c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Licensing and other royalty revenue (commercial revenue)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;12.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Percentage of total revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our consolidated balance sheet at December 31, 2019 and 2018 did not include any deferred revenue related to Akcea&#x2019;s relationship with PTC.&lt;/div&gt;
</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ions:NumberOfDrugsBeingDeveloped
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"
      decimals="INF"
      id="Fact_7af8e6ccc5734a52b212b2cb39251c85"
      unitRef="U015">8</ions:NumberOfDrugsBeingDeveloped>
    <ions:CumulativePaymentsReceived
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"
      decimals="-8"
      id="Fact_2c7f6368c67b460ea001466f23a85954"
      unitRef="U001">2400000000</ions:CumulativePaymentsReceived>
    <ions:UpfrontPaymentReceivedIncludingPurchaseOfStock
      contextRef="c20180401to20180630_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="-9"
      id="Fact_1d11244e9c01430c90e4f6051ed9a9c0"
      unitRef="U001">1000000000</ions:UpfrontPaymentReceivedIncludingPurchaseOfStock>
    <ions:NumberOfCountriesWhereDrugIsApprovedForUse
      contextRef="c20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember"
      decimals="0"
      id="Fact_36f52e68092e46448c21ed2babef24c8"
      unitRef="U016">50</ions:NumberOfCountriesWhereDrugIsApprovedForUse>
    <ions:CumulativeRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember"
      decimals="-9"
      id="Fact_80c48219eb9e4393b8569e87d9780e38"
      unitRef="U001">1000000000</ions:CumulativeRevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:CumulativeRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20191231_ProductOrServiceAxis_SPINRAZARoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember"
      decimals="-6"
      id="Fact_6cef645a43bf4562909cf1040246fa31"
      unitRef="U001">640000000</ions:CumulativeRevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:CumulativeRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember"
      decimals="-6"
      id="Fact_4f6bdc7d5939403c952ca9aeb8c58deb"
      unitRef="U001">435000000</ions:CumulativeRevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:RoyaltyPercentageReceivedOnNetSalesOfDrug
      contextRef="c20190101to20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember"
      decimals="2"
      id="Fact_61c6432e61694a50bab0c763baf066d7"
      unitRef="U003">0.11</ions:RoyaltyPercentageReceivedOnNetSalesOfDrug>
    <ions:RoyaltyPercentageReceivedOnNetSalesOfDrug
      contextRef="c20190101to20191231_RangeAxis_MaximumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember"
      decimals="2"
      id="Fact_1823d09bb3e44264ad0c1a26037d2ae5"
      unitRef="U003">0.15</ions:RoyaltyPercentageReceivedOnNetSalesOfDrug>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember"
      decimals="-6"
      id="Fact_d2b23e45f5f74edbb0a88c4534bcf757"
      unitRef="U001">90000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:UpfrontPaymentReceived
      contextRef="c20171201to20171231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember"
      decimals="-6"
      id="Fact_d0f059efca0b4cb78eead790f4fa19ae"
      unitRef="U001">25000000</ions:UpfrontPaymentReceived>
    <ions:MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember"
      decimals="-8"
      id="Fact_8fa42de141e3407c99bbfa2f29113c53"
      unitRef="U001">1200000000</ions:MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember"
      decimals="-6"
      id="Fact_e38aa26f41814546bda50548960b0e5e"
      unitRef="U001">80000000</ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForCommercializationMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember"
      decimals="-6"
      id="Fact_6b3fbb9794124e4184ca605383c0149b"
      unitRef="U001">180000000</ions:MaximumAmountOfPaymentsReceivableForCommercializationMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForSalesMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember"
      decimals="-6"
      id="Fact_322a430335cd4f42adcade119ecaa19b"
      unitRef="U001">800000000</ions:MaximumAmountOfPaymentsReceivableForSalesMilestones>
    <ions:RoyaltyPercentageReceivedOnNetSalesOfDrug
      contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember"
      decimals="2"
      id="Fact_febbc9e4755e4074b3a325f2dacf1e28"
      unitRef="U003">0.20</ions:RoyaltyPercentageReceivedOnNetSalesOfDrug>
    <ions:NextPotentialPayment
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember"
      decimals="-6"
      id="Fact_7d01c2380f624d1fb49986067438d3ed"
      unitRef="U001">60000000</ions:NextPotentialPayment>
    <ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
      contextRef="c20171231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember"
      decimals="INF"
      id="Fact_d072d638eb714ba6a26876ea2bbbb72a"
      unitRef="U005">1</ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c20171231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember"
      decimals="-6"
      id="Fact_e3683f7ee88940418d4cb28dad798342"
      unitRef="U001">25000000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember"
      decimals="-5"
      id="Fact_4edfbf91e3db4c149d8f7c6de6cfd7f2"
      unitRef="U001">8300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:TermOfCollaborationAgreement
      contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      id="Fact_3d01100b8b54487eb5650d892b0313da">P10Y</ions:TermOfCollaborationAgreement>
    <ions:UpfrontPaymentReceivedIncludingPurchaseOfStock
      contextRef="c20180401to20180630_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="-9"
      id="Fact_976237d61b074e5e9b91af22b9df351f"
      unitRef="U001">1000000000</ions:UpfrontPaymentReceivedIncludingPurchaseOfStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20180401to20180630_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="-6"
      id="Fact_271dd8aced544c41be19b5a818ba4058"
      unitRef="U001">625000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ions:PercentageCashPremiumPaidOnSharesPurchased
      contextRef="c20180401to20180630_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="2"
      id="Fact_c96d0cb6c7e643c7b9c75b57384aa601"
      unitRef="U003">0.25</ions:PercentageCashPremiumPaidOnSharesPurchased>
    <ions:UpfrontPaymentReceived
      contextRef="c20180401to20180630_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="-6"
      id="Fact_755b026d1fee41558d1dc2c5b62ee556"
      unitRef="U001">375000000</ions:UpfrontPaymentReceived>
    <ions:MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="-6"
      id="Fact_62648637171d42169a691df96b84fa12"
      unitRef="U001">270000000</ions:MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments>
    <ions:RoyaltyPercentageReceivedOnNetSalesOfDrug
      contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="2"
      id="Fact_210a08ece63647968230838a5127deb6"
      unitRef="U003">0.20</ions:RoyaltyPercentageReceivedOnNetSalesOfDrug>
    <ions:CumulativePaymentsReceived
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="-9"
      id="Fact_da56d1dc03c24e66a27cff951a361cbb"
      unitRef="U001">1000000000</ions:CumulativePaymentsReceived>
    <ions:MilestonePaymentAchieved
      contextRef="c20181001to20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="-6"
      id="Fact_5f11f4f0f6ca486ba3c59c4c2ec9f3a8"
      unitRef="U001">15000000</ions:MilestonePaymentAchieved>
    <ions:NumberOfTargetsAdvanced
      contextRef="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="INF"
      id="Fact_dad6ba19467e4eae98084a3e57d833ca"
      unitRef="U007">2</ions:NumberOfTargetsAdvanced>
    <ions:NextPotentialPayment
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="-5"
      id="Fact_2ccf74adb28c46398e26d42924be60cb"
      unitRef="U001">7500000</ions:NextPotentialPayment>
    <ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
      contextRef="c20180430_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="INF"
      id="Fact_5e47f934a68347d89f25d91842517b61"
      unitRef="U005">1</ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c20180430_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="-6"
      id="Fact_295623a84e6d476bb91ebff3bfed5858"
      unitRef="U001">552000000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <ions:UpfrontPaymentReceived
      contextRef="c20180401to20180630_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="-6"
      id="Fact_141e7593cbf740c7a6acd7c7ace28ee3"
      unitRef="U001">375000000</ions:UpfrontPaymentReceived>
    <ions:PremiumPaidOnSharesPurchased
      contextRef="c20180401to20180630_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="-6"
      id="Fact_90cf8273bd7a479187f0efa5fa9c8263"
      unitRef="U001">177000000</ions:PremiumPaidOnSharesPurchased>
    <ions:CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="-6"
      id="Fact_20ba18c7432f48b692b7d780c2e643aa"
      unitRef="U001">597000000</ions:CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation>
    <ions:NumberOfMilestonePaymentsAchieved
      contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="INF"
      id="Fact_0a1037bc6a4143f29676e6da2baeec61"
      unitRef="U006">4</ions:NumberOfMilestonePaymentsAchieved>
    <ions:PaymentsIncludedInTransactionPriceForPerformanceObligation
      contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="-5"
      id="Fact_c2e9e0d69612487ab5f5ec8cb0d9ef7c"
      unitRef="U001">7500000</ions:PaymentsIncludedInTransactionPriceForPerformanceObligation>
    <ions:NumberOfTargetsAdvanced
      contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember"
      decimals="INF"
      id="Fact_dedcae59a32644a79cca2aa4b477e4b2"
      unitRef="U007">4</ions:NumberOfTargetsAdvanced>
    <ions:NumberOfDrugsCurrentlyBeingAdvanced
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"
      decimals="INF"
      id="Fact_eb09908f5c9a48cc93d43f56069f13ca"
      unitRef="U015">5</ions:NumberOfDrugsCurrentlyBeingAdvanced>
    <ions:NumberOfDrugsCurrentlyBeingAdvanced
      contextRef="c20191231_ProductOrServiceAxis_MedicinesForAmyotrophicLateralSclerosisMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"
      decimals="INF"
      id="Fact_996f95d3d4dd49e39ee68fd344ce391e"
      unitRef="U015">2</ions:NumberOfDrugsCurrentlyBeingAdvanced>
    <ions:NumberOfDrugsCurrentlyBeingAdvanced
      contextRef="c20191231_ProductOrServiceAxis_MedicinesForUndisclosedTargetsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"
      decimals="INF"
      id="Fact_d29b91083ea1419fb33ff60bf441130f"
      unitRef="U015">2</ions:NumberOfDrugsCurrentlyBeingAdvanced>
    <ions:NumberOfDrugsLicensedUnderOptionInCollaborationAgreement
      contextRef="c20191201to20191231_ProductOrServiceAxis_MedicinesForAmyotrophicLateralSclerosisMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"
      decimals="INF"
      id="Fact_45b8fdc1551143b7b267f69ae4b242c5"
      unitRef="U015">1</ions:NumberOfDrugsLicensedUnderOptionInCollaborationAgreement>
    <ions:UpfrontPaymentReceived
      contextRef="c20130901to20130930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"
      decimals="-6"
      id="Fact_df6e4e7a86a541f1926d3e828e7efea5"
      unitRef="U001">100000000</ions:UpfrontPaymentReceived>
    <ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments
      contextRef="c20191231_ProductOrServiceAxis_AntisenseMoleculeMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"
      decimals="-6"
      id="Fact_e29891c91d1a456e9cb73201cb58d5f4"
      unitRef="U001">260000000</ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments>
    <ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments
      contextRef="c20191231_ProductOrServiceAxis_AntisenseMoleculeMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"
      decimals="-6"
      id="Fact_0dfbd8128b624f969b95f7ef71d4d44f"
      unitRef="U001">260000000</ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments>
    <ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones
      contextRef="c20191231_ProductOrServiceAxis_AntisenseMoleculeMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"
      decimals="-6"
      id="Fact_245f4587f74e4be8b4a2a97ac77ea0f6"
      unitRef="U001">60000000</ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones>
    <ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones
      contextRef="c20191231_ProductOrServiceAxis_AntisenseMoleculeMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"
      decimals="-6"
      id="Fact_c1d1f25511534235862a7aa4449afd2d"
      unitRef="U001">130000000</ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones>
    <ions:CumulativePaymentsReceived
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"
      decimals="-6"
      id="Fact_43252364b31243cf9fe665618b7d0d4d"
      unitRef="U001">240000000</ions:CumulativePaymentsReceived>
    <ions:NextPotentialPayment
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"
      decimals="-6"
      id="Fact_531e5e06da924c38a4eddf832276baff"
      unitRef="U001">10000000</ions:NextPotentialPayment>
    <ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
      contextRef="c20130930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"
      decimals="INF"
      id="Fact_5f22f24c59d44580af822992d7804572"
      unitRef="U005">1</ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c20130930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"
      decimals="-6"
      id="Fact_bcce97a700fa470ea25912768f89b9f3"
      unitRef="U001">100000000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190701to20190930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"
      decimals="-5"
      id="Fact_b62f5dd4cf444635b5e8c1a45181319c"
      unitRef="U001">-16500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation
      contextRef="c20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"
      decimals="-6"
      id="Fact_8e6bac473c9a4873a7bb0e87fa0b76df"
      unitRef="U001">145000000</ions:CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180701to20180930_ProductOrServiceAxis_IONISC9Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"
      decimals="-6"
      id="Fact_63dec559cce845c6b0ef765a3708692b"
      unitRef="U001">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20181001to20181231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"
      decimals="-6"
      id="Fact_81e42ca6272446b1b4943add62dab9b1"
      unitRef="U001">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20181001to20181231_ProductOrServiceAxis_TofersenMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"
      decimals="-6"
      id="Fact_006f69b7a4444911a0f6769b45a080a9"
      unitRef="U001">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190701to20190930_ProductOrServiceAxis_ION859Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"
      decimals="-6"
      id="Fact_ccce677ba0b14a499d2ffb36507cc46d"
      unitRef="U001">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20191001to20191231_ProductOrServiceAxis_IONISC9Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember"
      decimals="-6"
      id="Fact_c73bcf5effca436fa5cef751e9a6c8ca"
      unitRef="U001">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:NumberOfTargetsToBeDevelopedAndCommercialized
      contextRef="c20121231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"
      decimals="INF"
      id="Fact_150fabe1273b434dbedbd63b5b43038c"
      unitRef="U007">3</ions:NumberOfTargetsToBeDevelopedAndCommercialized>
    <ions:UpfrontPaymentReceived
      contextRef="c20121201to20121231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"
      decimals="-6"
      id="Fact_96e0bfc66c13486cb77a67ff0bc02893"
      unitRef="U001">30000000</ions:UpfrontPaymentReceived>
    <ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"
      decimals="-6"
      id="Fact_ca3ece52a6764f27b53aa658420e1e3c"
      unitRef="U001">210000000</ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments>
    <ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"
      decimals="-6"
      id="Fact_0bbe193efceb411386581d3674a65290"
      unitRef="U001">210000000</ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments>
    <ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"
      decimals="-6"
      id="Fact_75f24e61b9f94c949ecc39419626d788"
      unitRef="U001">10000000</ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones>
    <ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"
      decimals="-6"
      id="Fact_12ca19bdf13e48ffb87ff55a87528661"
      unitRef="U001">130000000</ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones>
    <ions:NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized
      contextRef="c20121231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"
      decimals="INF"
      id="Fact_a9dc5fc90fff488ab419c13f5bd3df17"
      unitRef="U017">3</ions:NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized>
    <ions:CumulativePaymentsReceived
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"
      decimals="-6"
      id="Fact_7a4c67230f974ba9bfd049a2c63e615a"
      unitRef="U001">130000000</ions:CumulativePaymentsReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20191001to20191231_ProductOrServiceAxis_IONISMAPTMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"
      decimals="-6"
      id="Fact_975c2c7408d7426c81c8a83cec34024b"
      unitRef="U001">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20191001to20191231_ProductOrServiceAxis_ION581Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"
      decimals="-6"
      id="Fact_b3c0f29705e748919da1c85bbb7a6e6f"
      unitRef="U001">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20200101to20200226_SubsequentEventTypeAxis_SubsequentEventMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"
      decimals="-5"
      id="Fact_820c16ce7d3640a1a6c86987f712b3ab"
      unitRef="U001">7500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:NextPotentialPayment
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"
      decimals="-6"
      id="Fact_7bc80b0e8adf47ca8dd64914ace6d170"
      unitRef="U001">12000000</ions:NextPotentialPayment>
    <ions:CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation
      contextRef="c20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"
      decimals="-6"
      id="Fact_1381ecc294394ea081d42cec69196f2b"
      unitRef="U001">40000000</ions:CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190701to20190930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"
      decimals="-5"
      id="Fact_6edc31f3d40d48f3944b9cbb4ebd25f4"
      unitRef="U001">6300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation
      contextRef="c20191231_ProductOrServiceAxis_IONISMAPTMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"
      decimals="-5"
      id="Fact_65c25865c5cb46d88f766f99f72dcb07"
      unitRef="U001">37500000</ions:CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation>
    <ions:MilestonePaymentAchieved
      contextRef="c20190401to20190630_ProductOrServiceAxis_IONISMAPTMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"
      decimals="-5"
      id="Fact_501adc29c4e44efd9ab1593ae3a999b3"
      unitRef="U001">7500000</ions:MilestonePaymentAchieved>
    <ions:MilestonePaymentAchieved
      contextRef="c20191001to20191231_ProductOrServiceAxis_IONISMAPTMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"
      decimals="-6"
      id="Fact_e3916157cd464b41935844d1547678d0"
      unitRef="U001">12000000</ions:MilestonePaymentAchieved>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20191001to20191231_ProductOrServiceAxis_IONISMAPTMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"
      decimals="-6"
      id="Fact_15e8499c99b84633ab63c1a97bb470f3"
      unitRef="U001">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20191001to20191231_ProductOrServiceAxis_ION581Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember"
      decimals="-6"
      id="Fact_68b4f122e6a446cf9ecf4f8f9556c677"
      unitRef="U001">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"
      id="Text_d8f9c34f572b4ed39b43785ed86e06a1">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with Biogen (in millions, except percentage amounts):&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z0380747c43454884ab39653ff62a443c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;SPINRAZA royalties (commercial revenue)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;293.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;237.9&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;112.5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;180.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;137.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;150.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total revenue from our relationship with Biogen&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;473.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;375.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;263.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Percentage of total revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;42&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;63&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;51&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ProductOrServiceAxis_SPINRAZARoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"
      decimals="-5"
      id="Fact_146a11e1cc3848fa846dfa10b6ca4fac"
      unitRef="U001">293000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ProductOrServiceAxis_SPINRAZARoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"
      decimals="-5"
      id="Fact_14a41acf19b5433ca4e106a13b3a92ec"
      unitRef="U001">237900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ProductOrServiceAxis_SPINRAZARoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"
      decimals="-5"
      id="Fact_ebf6a7c4d4d642cb8445cc41028dbc4f"
      unitRef="U001">112500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"
      decimals="-5"
      id="Fact_d521219505d14ed8ba28900af2b4eef0"
      unitRef="U001">180600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"
      decimals="-5"
      id="Fact_9cfd5dd6b460430ca49c4c87b102810e"
      unitRef="U001">137100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"
      decimals="-5"
      id="Fact_0be9c7e59ca144e3bbe8fe61671d767b"
      unitRef="U001">150600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"
      decimals="-5"
      id="Fact_1fd9f9b2ff4242a8ba5d5dc97a5064da"
      unitRef="U001">473600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"
      decimals="-5"
      id="Fact_73c0a219d58348498ce8dc987fd9d27e"
      unitRef="U001">375000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"
      decimals="-5"
      id="Fact_542df45308ad4ee9a37c56efe7fa18d1"
      unitRef="U001">263100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"
      decimals="2"
      id="Fact_b18b889b350941048d2231c689a9f351"
      unitRef="U003">0.42</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"
      decimals="2"
      id="Fact_33938ec04f5e40b889d8fcae645d637a"
      unitRef="U003">0.63</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"
      decimals="2"
      id="Fact_6c809afdaa814005b1f6b0887bff71f2"
      unitRef="U003">0.51</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"
      decimals="-5"
      id="Fact_f8f7b974cb2a433882a0fd53fe341a83"
      unitRef="U001">525800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember"
      decimals="-5"
      id="Fact_35c30aecc55949b1afd1112082165450"
      unitRef="U001">580900000</us-gaap:ContractWithCustomerLiability>
    <ions:NumberOfLicensedDrugs
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"
      decimals="INF"
      id="Fact_b682e7d57d3a45c18d753ca8d347beeb"
      unitRef="U015">3</ions:NumberOfLicensedDrugs>
    <ions:UpfrontPaymentReceived
      contextRef="c20150701to20150731_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"
      decimals="-6"
      id="Fact_afe0e303f52c47de8fef2665adbb52f3"
      unitRef="U001">65000000</ions:UpfrontPaymentReceived>
    <ions:MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"
      decimals="-9"
      id="Fact_681cbdadca67472d9b022f4711037c7f"
      unitRef="U001">4000000000</ions:MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"
      decimals="-8"
      id="Fact_8bf17f1115c642a893b55340a0970cea"
      unitRef="U001">1100000000</ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForRegulatoryMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"
      decimals="-8"
      id="Fact_efb4704088a04a6e826d67ea5c2f326d"
      unitRef="U001">2900000000</ions:MaximumAmountOfPaymentsReceivableForRegulatoryMilestones>
    <ions:NextPotentialPayment
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"
      decimals="-6"
      id="Fact_cf47c653ca844b46ba8588a2a589a194"
      unitRef="U001">10000000</ions:NextPotentialPayment>
    <ions:CumulativePaymentsReceived
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"
      decimals="-6"
      id="Fact_b46d3be360f94ea788b2b83ce6c73f6f"
      unitRef="U001">175000000</ions:CumulativePaymentsReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180701to20180930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"
      decimals="-6"
      id="Fact_48047624f3d64ef8ab735f9f354d1afb"
      unitRef="U001">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
      contextRef="c20150731_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"
      decimals="INF"
      id="Fact_12852f4c3cee4a69b4f4fee5d29498e6"
      unitRef="U005">1</ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c20150731_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"
      decimals="-6"
      id="Fact_321f6d91fea64a57a4103c135ba57bd1"
      unitRef="U001">65000000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <ions:CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation
      contextRef="c20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"
      decimals="-6"
      id="Fact_ec77e25e50654249ba1ef8f5f9e4a1d1"
      unitRef="U001">90000000</ions:CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation>
    <ions:NumberOfLicenseFeesEarned
      contextRef="c20180101to20180331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"
      decimals="INF"
      id="Fact_cae7641b707f452289941fceefd520c1"
      unitRef="U018">2</ions:NumberOfLicenseFeesEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20180331_ProductOrServiceAxis_ION839Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"
      decimals="-6"
      id="Fact_e5a7b501073741939fc54a02add83b3a"
      unitRef="U001">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20180331_ProductOrServiceAxis_ION532Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"
      decimals="-6"
      id="Fact_e85c6c9e30914bd0a8087a5b903ad7e9"
      unitRef="U001">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180701to20180930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"
      decimals="-6"
      id="Fact_b354e861c2bd46999901a4505b256e38"
      unitRef="U001">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20181001to20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember"
      decimals="-6"
      id="Fact_344416977fa842688cb3eb2ccbfc49f5"
      unitRef="U001">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:UpfrontPaymentReceived
      contextRef="c20121201to20121231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"
      decimals="-6"
      id="Fact_2cd1bc1d00e14c1d84b80c4ee6e222db"
      unitRef="U001">31000000</ions:UpfrontPaymentReceived>
    <ions:MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"
      decimals="-6"
      id="Fact_7408146d87de4593b6dc9b03dacc64e6"
      unitRef="U001">450000000</ions:MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"
      decimals="-6"
      id="Fact_484e8f6f1dd242f5996c00b362124558"
      unitRef="U001">152000000</ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForRegulatoryMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"
      decimals="-6"
      id="Fact_20c0e0a8259e44148a7d32d9c9881c8c"
      unitRef="U001">275000000</ions:MaximumAmountOfPaymentsReceivableForRegulatoryMilestones>
    <ions:CumulativePaymentsReceived
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"
      decimals="-6"
      id="Fact_ec695803788a443b8addc8655e99aaa7"
      unitRef="U001">125000000</ions:CumulativePaymentsReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20181001to20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"
      decimals="-6"
      id="Fact_546bc7b5d7b641e0842361b086374c17"
      unitRef="U001">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:NextPotentialPayment
      contextRef="c20191231_RangeAxis_MaximumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"
      decimals="-6"
      id="Fact_9d85706b0d4c4c5dbc82e0700a25253c"
      unitRef="U001">25000000</ions:NextPotentialPayment>
    <ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
      contextRef="c20121231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"
      decimals="INF"
      id="Fact_9659e33cf0f045a18ddfbc6af3bd7186"
      unitRef="U005">4</ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations>
    <ions:NumberOfPerformanceObligationsCompleted
      contextRef="c20140331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"
      decimals="INF"
      id="Fact_98902606606a46b192b6aa219b7c20cb"
      unitRef="U005">3</ions:NumberOfPerformanceObligationsCompleted>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20181001to20181231_ProductOrServiceAxis_DanvatirsenMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"
      decimals="-5"
      id="Fact_2c2750daedb84d4285c346d6c1676448"
      unitRef="U001">17500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20181001to20181231_ProductOrServiceAxis_ION736Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"
      decimals="-6"
      id="Fact_c12e1cf9eef04dedbdefabddee95ccee"
      unitRef="U001">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:NumberOfProgramsAdvanced
      contextRef="c20181001to20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember"
      decimals="INF"
      id="Fact_869d672b0b0d4547ab0774a9a808f2d8"
      unitRef="U017">2</ions:NumberOfProgramsAdvanced>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember"
      id="Text_f400bcb381b745faa5a030abbe973471">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with AstraZeneca (in millions, except percentage amounts):&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z3e98572cb7a74e948b59d5a9feec5657" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;28.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;120.7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;21.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Percentage of total revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;20&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember"
      decimals="-5"
      id="Fact_77009387bc654006989ae141c96c8496"
      unitRef="U001">28100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember"
      decimals="-5"
      id="Fact_b4bc1487977543468f0c2592f732bfb0"
      unitRef="U001">120700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember"
      decimals="-5"
      id="Fact_6f993bce8b8f4c7aa2348aedba4438cf"
      unitRef="U001">21600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember"
      decimals="2"
      id="Fact_146be9f3b2bd4a1390bcfa5173d38d88"
      unitRef="U003">0.03</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember"
      decimals="2"
      id="Fact_dd338796e71247f6bc131ed50f37ef36"
      unitRef="U003">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember"
      decimals="2"
      id="Fact_aa247af696394bd6806e0b89dffcff91"
      unitRef="U003">0.04</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember"
      decimals="-5"
      id="Fact_c0d98582c04c40f885040e43e3e95697"
      unitRef="U001">25000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember"
      decimals="-5"
      id="Fact_29e93280d0e245d79babbeeaf1bba43f"
      unitRef="U001">40100000</us-gaap:ContractWithCustomerLiability>
    <ions:UpfrontPaymentReceived
      contextRef="c20150401to20150630_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember"
      decimals="-6"
      id="Fact_1ecc831150824141bd76a92d58b3f591"
      unitRef="U001">100000000</ions:UpfrontPaymentReceived>
    <ions:PaymentReceivedForAdvancingPrograms
      contextRef="c20170201to20170228_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember"
      decimals="-6"
      id="Fact_27a5975c2c5d4ed98e446e999c953f35"
      unitRef="U001">75000000</ions:PaymentReceivedForAdvancingPrograms>
    <ions:MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember"
      decimals="-6"
      id="Fact_1ea7b17e0fd54a53ba9ea212e481602c"
      unitRef="U001">385000000</ions:MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember"
      decimals="-6"
      id="Fact_e03c5e12d8dc4479948a18adba98b88c"
      unitRef="U001">125000000</ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForCommercializationMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember"
      decimals="-6"
      id="Fact_ab70c484782f41e4acf44792bd373694"
      unitRef="U001">110000000</ions:MaximumAmountOfPaymentsReceivableForCommercializationMilestones>
    <ions:RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement
      contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember"
      decimals="2"
      id="Fact_fb2e5156c6b544b98419218e7a28691b"
      unitRef="U003">0.20</ions:RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement>
    <ions:CumulativePaymentsReceived
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember"
      decimals="-6"
      id="Fact_55c7b99eec38441eb299ea5fe41b3ea2"
      unitRef="U001">185000000</ions:CumulativePaymentsReceived>
    <ions:NextPotentialMilestonePayment
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember"
      decimals="-6"
      id="Fact_abb5e5bfab0742a594537d03e99e580c"
      unitRef="U001">20000000</ions:NextPotentialMilestonePayment>
    <ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
      contextRef="c20150531_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember"
      decimals="INF"
      id="Fact_1279bd3e4793428181ec1aad1e8b44ba"
      unitRef="U005">3</ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations>
    <ions:RevenueFromContractWithCustomerNumberOfNewPerformanceObligations
      contextRef="c20170201to20170228_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember"
      decimals="INF"
      id="Fact_88bf8c1f8dfc4704bd5e5ef69d1688f0"
      unitRef="U005">2</ions:RevenueFromContractWithCustomerNumberOfNewPerformanceObligations>
    <ions:RevenueFromContractWithCustomerNumberOfNewPerformanceObligations
      contextRef="c20170201to20170228_ProductOrServiceAxis_IONISFXILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember"
      decimals="INF"
      id="Fact_036ca3d6a65a45808b611cf2f29cf18c"
      unitRef="U005">1</ions:RevenueFromContractWithCustomerNumberOfNewPerformanceObligations>
    <ions:RevenueFromContractWithCustomerNumberOfNewPerformanceObligations
      contextRef="c20170201to20170228_ProductOrServiceAxis_ResearchAndDevelopmentServicesForIONISFXILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember"
      decimals="INF"
      id="Fact_84ed394b95dc4b689089483bec9ee81d"
      unitRef="U005">1</ions:RevenueFromContractWithCustomerNumberOfNewPerformanceObligations>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c20170228_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember"
      decimals="-6"
      id="Fact_c9e8f99e0b5547cfa910d6da0c7fa156"
      unitRef="U001">75000000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c20170228_ProductOrServiceAxis_IONISFXILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember"
      decimals="-5"
      id="Fact_671c15f958d449e1b0996ae26fb02f7f"
      unitRef="U001">64900000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c20170228_ProductOrServiceAxis_ResearchAndDevelopmentServicesForIONISFXILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember"
      decimals="-5"
      id="Fact_66e51b39565d4d5491b40a7ff56ff227"
      unitRef="U001">10100000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20191001to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"
      decimals="-6"
      id="Fact_9fa6b92a37764bc4ad97b1ac44dab174"
      unitRef="U001">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"
      id="Text_3e44851f40134046bc9f808677661e83">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with Bayer (in millions, except percentage amounts):&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zb1073dc32a5e4c66a2a664b0634da7c6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;14.3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;5.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;67.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Percentage of total revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;13&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"
      decimals="-5"
      id="Fact_f99969488acc436791df63a07499be6d"
      unitRef="U001">14300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"
      decimals="-5"
      id="Fact_9fe9de20486147f8955d5c734eb9d8b3"
      unitRef="U001">5000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"
      decimals="-5"
      id="Fact_59362cd04b3741fd938d03dcb0e698f6"
      unitRef="U001">67100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"
      decimals="2"
      id="Fact_4046e641eafa4ddcb89c308b055c2ce2"
      unitRef="U003">0.01</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"
      decimals="2"
      id="Fact_babedde018f446ab8478453fdfd8dcc9"
      unitRef="U003">0.01</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"
      decimals="2"
      id="Fact_abdecb8fff3747c8aca189e9a145033d"
      unitRef="U003">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"
      decimals="-5"
      id="Fact_739fa714d0af4d74849dd6f1cadcd0d8"
      unitRef="U001">2400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember"
      decimals="-5"
      id="Fact_64e74248337d43bd85c81ec53ac919fa"
      unitRef="U001">4300000</us-gaap:ContractWithCustomerLiability>
    <ions:UpfrontPaymentReceived
      contextRef="c20100301to20100331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"
      decimals="-6"
      id="Fact_7283fa5013cc4c8f8847969829246bd2"
      unitRef="U001">35000000</ions:UpfrontPaymentReceived>
    <ions:NumberOfDrugsBeingDeveloped
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"
      decimals="INF"
      id="Fact_34359473758b4342a786a2bfd26d9b28"
      unitRef="U015">2</ions:NumberOfDrugsBeingDeveloped>
    <ions:MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"
      decimals="-6"
      id="Fact_4efd385d112840afad0e4faa46214870"
      unitRef="U001">262000000</ions:MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"
      decimals="-5"
      id="Fact_229776738d884ce8aee54ac341784a2d"
      unitRef="U001">47500000</ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForRegulatoryMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"
      decimals="-6"
      id="Fact_131e23080dcc40398152b2bd4d048056"
      unitRef="U001">120000000</ions:MaximumAmountOfPaymentsReceivableForRegulatoryMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForCommercializationMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"
      decimals="-6"
      id="Fact_a5c67dd2e09b4b708ea1ffa029688a59"
      unitRef="U001">70000000</ions:MaximumAmountOfPaymentsReceivableForCommercializationMilestones>
    <ions:CumulativePaymentsReceived
      contextRef="c20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"
      decimals="-6"
      id="Fact_80b40aad4e4f428d854cce06e968dea2"
      unitRef="U001">189000000</ions:CumulativePaymentsReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190701to20190930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"
      decimals="-6"
      id="Fact_157814dcf79c45a780af9420a88abc80"
      unitRef="U001">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:NextPotentialMilestonePayment
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"
      decimals="-6"
      id="Fact_5f7e1c8f371048a4aa050ce4806c0edf"
      unitRef="U001">15000000</ions:NextPotentialMilestonePayment>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190701to20190930_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"
      decimals="-6"
      id="Fact_eaf6203cfa224f3791cb9bffe7977090"
      unitRef="U001">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"
      id="Text_4f8ce91d37794e73ae312862eb75a78e">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with GSK (in millions, except percentage amounts):&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zfc1697a2c45e4e5d9ba00caf3a13ead3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;25.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;14.8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Percentage of total revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"
      decimals="-5"
      id="Fact_1efa0cc60e004562b4e6a6c7879c789d"
      unitRef="U001">25400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"
      decimals="-5"
      id="Fact_56e66bccc3624645bcb22750e41916dd"
      unitRef="U001">1600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"
      decimals="-5"
      id="Fact_ec6cf4febb2f49e683915746e6801969"
      unitRef="U001">14800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"
      decimals="2"
      id="Fact_fcadd36b6cbc4c4796ae789c7805b00f"
      unitRef="U003">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"
      decimals="2"
      id="Fact_ff3be5276ecf4d51a2514c2feff18233"
      unitRef="U003">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"
      decimals="2"
      id="Fact_64cbaaeaf4c249c28f7644f151cd8a75"
      unitRef="U003">0.03</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"
      decimals="-6"
      id="Fact_b211069271df4c4a802417ef5e7b0d32"
      unitRef="U001">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember"
      decimals="-6"
      id="Fact_59e8ee0b0973416987e4c07862acaea5"
      unitRef="U001">0</us-gaap:ContractWithCustomerLiability>
    <ions:NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized
      contextRef="c20141231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"
      decimals="INF"
      id="Fact_26aef289b10143debb8dca041c8ee779"
      unitRef="U017">3</ions:NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized>
    <ions:UpfrontPaymentReceived
      contextRef="c20141201to20141231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"
      decimals="-6"
      id="Fact_7f98b32d298b42688c37d988ab2909b8"
      unitRef="U001">35000000</ions:UpfrontPaymentReceived>
    <ions:MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"
      decimals="-6"
      id="Fact_a564066b38e84d2595cdfbfc276b1eba"
      unitRef="U001">285000000</ions:MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"
      decimals="-6"
      id="Fact_c2e87dcc7db149c7bef875e445a5c48c"
      unitRef="U001">65000000</ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForRegulatoryMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"
      decimals="-6"
      id="Fact_8be6f9afea8a40139feecb8a0aa84941"
      unitRef="U001">160000000</ions:MaximumAmountOfPaymentsReceivableForRegulatoryMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForCommercializationMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"
      decimals="-6"
      id="Fact_e21d01127a2247a9ba21d6eafa2cdea6"
      unitRef="U001">60000000</ions:MaximumAmountOfPaymentsReceivableForCommercializationMilestones>
    <ions:CumulativePaymentsReceived
      contextRef="c20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"
      decimals="-6"
      id="Fact_9ad34bef7ccb4d00b82f1650470dc23d"
      unitRef="U001">75000000</ions:CumulativePaymentsReceived>
    <ions:NextPotentialMilestonePayment
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"
      decimals="-6"
      id="Fact_608263f8b813452282c49861d04ce4b7"
      unitRef="U001">5000000</ions:NextPotentialMilestonePayment>
    <ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
      contextRef="c20141231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"
      decimals="INF"
      id="Fact_f68fbf09b9ae48f4837c1876e49a8d0f"
      unitRef="U005">1</ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c20141231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"
      decimals="-6"
      id="Fact_6b929259ee5b4b7da8a05540eca83d56"
      unitRef="U001">35000000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c20141231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"
      decimals="-6"
      id="Fact_a00a77fdd643486b8ca7e353ece96e57"
      unitRef="U001">35000000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20171101to20171130_ProductOrServiceAxis_IONISJBI225Member_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"
      decimals="-6"
      id="Fact_a198ddc9a96f4e258029eddad08021db"
      unitRef="U001">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"
      id="Text_f54f5d999716490c9cb36e7ed99e0d8d">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with Janssen (in millions, except percentage amounts):&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zf8941280a0a94e81bb425341b948878a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;6.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;36.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Percentage of total revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"
      decimals="-5"
      id="Fact_e6fb7a6986bb4a6dabf275cd43de3142"
      unitRef="U001">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"
      decimals="-5"
      id="Fact_d2a35f12eb3c4819acf4b38b9b44e610"
      unitRef="U001">6600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"
      decimals="-5"
      id="Fact_fb1097993d3640f5978bde9ecba258fb"
      unitRef="U001">36000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"
      decimals="2"
      id="Fact_fba485fa0402455c87b77af7362e351f"
      unitRef="U003">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"
      decimals="2"
      id="Fact_84de48daf8514dcaa02ab54da0a048a0"
      unitRef="U003">0.01</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"
      decimals="2"
      id="Fact_d89ed37737544e2aac9c1cd3c8d8ab99"
      unitRef="U003">0.07</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"
      decimals="-6"
      id="Fact_e6090aaddd3944d880fb682755e83a3b"
      unitRef="U001">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember"
      decimals="-6"
      id="Fact_365ae9af3d38401eb562eea4ba20c9d2"
      unitRef="U001">0</us-gaap:ContractWithCustomerLiability>
    <ions:UpfrontPaymentReceived
      contextRef="c20130401to20130430_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember"
      decimals="-6"
      id="Fact_9f09a173393d49bc818e79aacee84764"
      unitRef="U001">30000000</ions:UpfrontPaymentReceived>
    <ions:MilestonePaymentsReceived
      contextRef="c20170101to20171231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember"
      decimals="-6"
      id="Fact_8432cd12b85e48c6b111a7bdcb5f2ac8"
      unitRef="U001">3000000</ions:MilestonePaymentsReceived>
    <ions:MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember"
      decimals="-6"
      id="Fact_d8d42ebb32dc46b7895c83156cf73607"
      unitRef="U001">365000000</ions:MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember"
      decimals="-6"
      id="Fact_70a5f7bc239446719e9285ed2ff78c07"
      unitRef="U001">70000000</ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForRegulatoryMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember"
      decimals="-6"
      id="Fact_884490256579410c93629768255d304a"
      unitRef="U001">170000000</ions:MaximumAmountOfPaymentsReceivableForRegulatoryMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForCommercializationMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember"
      decimals="-6"
      id="Fact_a9fce437f8684220b259d8408d43875f"
      unitRef="U001">80000000</ions:MaximumAmountOfPaymentsReceivableForCommercializationMilestones>
    <ions:MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember"
      decimals="-5"
      id="Fact_67793d8d7c8843aba2b236e8d909758e"
      unitRef="U001">136500000</ions:MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped>
    <ions:CumulativePaymentsReceived
      contextRef="c20191231_RangeAxis_MinimumMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember"
      decimals="-6"
      id="Fact_3aa74885781e415aa4fe5dd8e04e1eda"
      unitRef="U001">145000000</ions:CumulativePaymentsReceived>
    <ions:MilestonePaymentsReceived
      contextRef="c20190101to20190331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember"
      decimals="-6"
      id="Fact_18ad29df344a4c9e9dc00cbac3e23532"
      unitRef="U001">35000000</ions:MilestonePaymentsReceived>
    <ions:NextPotentialMilestonePayment
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember"
      decimals="-6"
      id="Fact_cb403b59db80408fb4a9b96e8393b762"
      unitRef="U001">15000000</ions:NextPotentialMilestonePayment>
    <ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
      contextRef="c20130430_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember"
      decimals="INF"
      id="Fact_efae3e04708b4937bacd7fa2bb5963f7"
      unitRef="U005">1</ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c20130430_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember"
      decimals="-6"
      id="Fact_872b6a5c29be484ca3beb5fa683f1784"
      unitRef="U001">30000000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20171001to20171231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember"
      decimals="-6"
      id="Fact_bc4e255dadbd4cddaaf6cf364d7f60a2"
      unitRef="U001">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20190331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember"
      decimals="-6"
      id="Fact_7314f04e9d0e40a49fbaacf4f47109de"
      unitRef="U001">35000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:UpfrontPaymentReceived
      contextRef="c20181001to20181031_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember"
      decimals="-6"
      id="Fact_dc2c32a9c1124cddb9ed5ff336ece731"
      unitRef="U001">75000000</ions:UpfrontPaymentReceived>
    <ions:MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember"
      decimals="-6"
      id="Fact_06d83477fcf046bbabd2d4017da3a520"
      unitRef="U001">684000000</ions:MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones>
    <ions:RoyaltyPercentageReceivedOnNetSalesOfDrug
      contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember"
      decimals="2"
      id="Fact_63fb5f4decbb426a9cd241023b3ecd39"
      unitRef="U003">0.20</ions:RoyaltyPercentageReceivedOnNetSalesOfDrug>
    <ions:NextPotentialMilestonePayment
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember"
      decimals="-6"
      id="Fact_5128247561064475b51c4c5bf62130be"
      unitRef="U001">20000000</ions:NextPotentialMilestonePayment>
    <ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
      contextRef="c20181031_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember"
      decimals="INF"
      id="Fact_468a8db7e8de46a69b5ee7a0575f664d"
      unitRef="U005">1</ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c20181031_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember"
      decimals="-6"
      id="Fact_64f9009b51e54bc8a818455d38bda2ae"
      unitRef="U001">75000000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember"
      id="Text_468e27558b254e0daccd0fff5ff71edd">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;During the years ended December 31, 2019, 2018 and 2017, we earned the following revenue from our relationship with Roche (in millions, except percentage amounts):&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z3751bf5f787c451499c06571891a9800" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;57.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;8.3&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;55.7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Percentage of total revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;5&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;11&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember"
      decimals="-5"
      id="Fact_fb8913807e664ded9db727de95b93bfc"
      unitRef="U001">57000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember"
      decimals="-5"
      id="Fact_43d5265cf6164fce9ca88f18b5897dc3"
      unitRef="U001">8300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember"
      decimals="-5"
      id="Fact_20872827ad6c4817bcf759078e23498f"
      unitRef="U001">55700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember"
      decimals="2"
      id="Fact_50cff48cda6946bc87457fee3925e81c"
      unitRef="U003">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember"
      decimals="2"
      id="Fact_cf5ca05dc07c4448bdda2353f8ed8769"
      unitRef="U003">0.01</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember"
      decimals="2"
      id="Fact_6490dfcad60e494083f50ae6646f73e4"
      unitRef="U003">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember"
      decimals="-5"
      id="Fact_5ff4d7b8efd14d4a81981ea0cfa0cf58"
      unitRef="U001">52300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember"
      decimals="-5"
      id="Fact_a38902f403274142aedd7c7ed42e8214"
      unitRef="U001">72600000</us-gaap:ContractWithCustomerLiability>
    <ions:UpfrontPaymentReceived
      contextRef="c20170101to20170331_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-6"
      id="Fact_f101e92127dd43ef9f460e172673d2f2"
      unitRef="U001">75000000</ions:UpfrontPaymentReceived>
    <ions:PortionOfUpfrontPaymentRetained
      contextRef="c20170101to20170331_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-6"
      id="Fact_22075448bf51400dbf0c07e88efac495"
      unitRef="U001">60000000</ions:PortionOfUpfrontPaymentRetained>
    <ions:PortionOfUpfrontPaymentPaidAsSublicenseFee
      contextRef="c20170101to20170331_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-6"
      id="Fact_658dc7b342f34e4fb8aea7a4183d5bd5"
      unitRef="U001">15000000</ions:PortionOfUpfrontPaymentPaidAsSublicenseFee>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190201to20190228_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_LicenseMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-6"
      id="Fact_0515b2fff4b64bc6b94f554c3b656d06"
      unitRef="U001">150000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:SublicenseFeePaidForLicenseOfDrug
      contextRef="c20190201to20190228"
      decimals="-6"
      id="Fact_7496596603f7476a91badebb2a672dea"
      unitRef="U001">75000000</ions:SublicenseFeePaidForLicenseOfDrug>
    <ions:ReceiptOfSharesInSubsidiary
      contextRef="c20190201to20190228"
      decimals="-5"
      id="Fact_e7462e9427f94afe949ed71375352f81"
      unitRef="U002">2800000</ions:ReceiptOfSharesInSubsidiary>
    <ions:MaximumAmountOfPaymentsReceivableForMilestones
      contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-6"
      id="Fact_d2d27d33e1b24ff79741dbb8504b3a12"
      unitRef="U001">675000000</ions:MaximumAmountOfPaymentsReceivableForMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones
      contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-6"
      id="Fact_b0160b60708f4f9cac5ee7648f0ee321"
      unitRef="U001">25000000</ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForRegulatoryMilestones
      contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-6"
      id="Fact_788a557118454c209aecf3914c029c91"
      unitRef="U001">290000000</ions:MaximumAmountOfPaymentsReceivableForRegulatoryMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForCommercializationMilestones
      contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-6"
      id="Fact_b32f437673cc4aac8bfcce020d51b7b0"
      unitRef="U001">360000000</ions:MaximumAmountOfPaymentsReceivableForCommercializationMilestones>
    <ions:RoyaltyPercentageReceivedOnSalesOfDrug
      contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="2"
      id="Fact_016f76af44eb49289c02150198f2a523"
      unitRef="U003">0.20</ions:RoyaltyPercentageReceivedOnSalesOfDrug>
    <ions:PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee
      contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="2"
      id="Fact_2f358346f22a4389b8b1dd0527408054"
      unitRef="U003">0.50</ions:PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20170101to20170331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-5"
      id="Fact_21e55b070897453d838adbfcb2e0f867"
      unitRef="U002">1600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <ions:ProceedsFromSaleOfCommonStockIncludingPremiumPaid
      contextRef="c20170101to20170331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-6"
      id="Fact_3a1b3a249b30451fa1ce1c491bcb7999"
      unitRef="U001">100000000</ions:ProceedsFromSaleOfCommonStockIncludingPremiumPaid>
    <ions:AdditionalAmountOfCommonStockRequiredToBePurchased
      contextRef="c20170331_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-6"
      id="Fact_f8120f81bc5b4216ac3b0e47eb07b856"
      unitRef="U001">50000000</ions:AdditionalAmountOfCommonStockRequiredToBePurchased>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="c20170701to20170731_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-6"
      id="Fact_47ca08bac8744acbb92fb035975c1a5d"
      unitRef="U001">50000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
      contextRef="c20170331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="INF"
      id="Fact_45dfae68b384426d9e7f35800c5ee5da"
      unitRef="U005">4</ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c20170331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-5"
      id="Fact_6dbe3e18253b42678289e91bfc07aa2b"
      unitRef="U001">108400000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <ions:UpfrontPaymentReceived
      contextRef="c20170101to20170331_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-6"
      id="Fact_5578c7a91e964f86994ba7891b038b6c"
      unitRef="U001">75000000</ions:UpfrontPaymentReceived>
    <ions:PremiumReceivedOnSharesIssued
      contextRef="c20170101to20170331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-5"
      id="Fact_a374896a5baf4a14a92524dbf907cb65"
      unitRef="U001">28400000</ions:PremiumReceivedOnSharesIssued>
    <ions:PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture
      contextRef="c20170331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-5"
      id="Fact_844ad8b58c81489eb92908f6d9b9a1e0"
      unitRef="U001">5000000.0</ions:PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c20170331_ProductOrServiceAxis_ResearchAndDevelopmentServicesForAKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-5"
      id="Fact_40c2b997e5d94404a5664d9c274e413e"
      unitRef="U001">64000000.0</ions:RevenueFromContractWithCustomerTransactionPrice>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c20170331_ProductOrServiceAxis_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-5"
      id="Fact_051befe7d00048df8a2b3cb0405d5ae3"
      unitRef="U001">40100000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c20170331_ProductOrServiceAxis_DeliveryOfAKCEAAPOALMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-5"
      id="Fact_b3744373869c4288908b09e14ce88277"
      unitRef="U001">1500000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c20170331_ProductOrServiceAxis_DeliveryOfAKCEAAPOCIIILMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-5"
      id="Fact_060f939deb0d4433a9dd740934afd81c"
      unitRef="U001">2800000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      id="Text_a6f89095bf0e47fc874b96fd205b9809">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;During the years ended December 31, 2019 and 2018, Akcea earned the following revenue from its relationship with Novartis (in millions, except percentage amounts):&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z69ce748cda9640099c4155d9ea42f332" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;187.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;50.6&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;43.4&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Percentage of total revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;17&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;8&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-5"
      id="Fact_34a7cbc53ddb475aaaa8bcec238b44ce"
      unitRef="U001">187400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-5"
      id="Fact_cd2c4f63152b45998731917ab0309ed1"
      unitRef="U001">50600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-5"
      id="Fact_4ff5f9c394c349349b7bc24fd95d7574"
      unitRef="U001">43400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="2"
      id="Fact_1f40d9d87ee4435c83ab9656d281b655"
      unitRef="U003">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="2"
      id="Fact_130e18fe0f0c441186a0e17a58f664d9"
      unitRef="U003">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20170101to20171231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="2"
      id="Fact_3cbf0264fff04ba19d7c857cee72d9f4"
      unitRef="U003">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-5"
      id="Fact_c157a7a68eec446e886b129749c3f931"
      unitRef="U001">28800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember"
      decimals="-6"
      id="Fact_4a63767109a742c69dad59da07813ba7"
      unitRef="U001">0</us-gaap:ContractWithCustomerLiability>
    <ions:UpfrontPaymentReceived
      contextRef="c20191001to20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"
      decimals="-6"
      id="Fact_cb6f652ab8d440198d3fd9d76dec5102"
      unitRef="U001">250000000</ions:UpfrontPaymentReceived>
    <ions:MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones
      contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"
      decimals="-8"
      id="Fact_6b53e3b0d55a43dc810b7552f975ad24"
      unitRef="U001">1300000000</ions:MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones
      contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"
      decimals="-6"
      id="Fact_4843a345b1a94a5c9754fd3131d466f1"
      unitRef="U001">205000000</ions:MaximumAmountOfPaymentsReceivableForDevelopmentMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForRegulatoryMilestones
      contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"
      decimals="-6"
      id="Fact_65c6ae0a577449888f0854e765cc3fca"
      unitRef="U001">250000000</ions:MaximumAmountOfPaymentsReceivableForRegulatoryMilestones>
    <ions:MaximumAmountOfPaymentsReceivableForCommercializationMilestones
      contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"
      decimals="-6"
      id="Fact_1e2a222db3b0433380bd4a8b285d7a81"
      unitRef="U001">850000000</ions:MaximumAmountOfPaymentsReceivableForCommercializationMilestones>
    <ions:RoyaltyPercentageReceivedOnNetSalesOfDrug
      contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"
      decimals="2"
      id="Fact_087ef4b100ca43ee9a37508169ca8d55"
      unitRef="U003">0.20</ions:RoyaltyPercentageReceivedOnNetSalesOfDrug>
    <ions:NextPotentialMilestonePayment
      contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"
      decimals="-6"
      id="Fact_ba59193a12cb4ecfa5c7841f81370632"
      unitRef="U001">75000000</ions:NextPotentialMilestonePayment>
    <ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
      contextRef="c20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"
      decimals="INF"
      id="Fact_a8154dd63afb404880837533d573e4e5"
      unitRef="U005">3</ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"
      decimals="-6"
      id="Fact_0a949aa4d4bd4639afc9cb68a2386c63"
      unitRef="U001">250000000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAANGPTL3LMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"
      decimals="-5"
      id="Fact_3df59de76eec44fb982aa66ddb7bf65b"
      unitRef="U001">245600000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_ResearchAndDevelopmentServicesForMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"
      decimals="-5"
      id="Fact_2ee33180ebd4466188789fc4e1ca515e"
      unitRef="U001">2200000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20191001to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"
      decimals="-5"
      id="Fact_ccb177feb237400896c77bdba3d1032a"
      unitRef="U001">2200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:RevenueFromContractWithCustomerTransactionPrice
      contextRef="c20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAANGPTL3LActivePharmaceuticalIngredientMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"
      decimals="-5"
      id="Fact_faca94cd7ae3413ba6ba103ff64de86a"
      unitRef="U001">2200000</ions:RevenueFromContractWithCustomerTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20191001to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_AKCEAANGPTL3LMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"
      decimals="-5"
      id="Fact_a58f0662a0494f9fbe63a6f7245c7574"
      unitRef="U001">245600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ions:ReceiptOfSharesInSubsidiary
      contextRef="c20191001to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"
      decimals="-5"
      id="Fact_931ab7e2e5ce499b803bf647570b165c"
      unitRef="U002">6900000</ions:ReceiptOfSharesInSubsidiary>
    <ions:SublicenseFeePaidForLicenseOfDrug
      contextRef="c20191001to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"
      decimals="-6"
      id="Fact_09e1434df8f644f6b9c95d432101ab61"
      unitRef="U001">125000000</ions:SublicenseFeePaidForLicenseOfDrug>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"
      id="Text_a4a2e7f817664c90a16e230b1467d77c">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;During the year ended December 31, 2019, Akcea earned the following revenue from its relationship with Pfizer (in millions, except percentage amounts):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z6a52ad3f4f4548a28b37262fe935a7dc" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;248.7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Percentage of total revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;22&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"
      decimals="-5"
      id="Fact_1d17b5c018944937b8cbeb29dd0891c5"
      unitRef="U001">248700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"
      decimals="2"
      id="Fact_a3245c2e2713458bb84324eb997a0b67"
      unitRef="U003">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember"
      decimals="-5"
      id="Fact_cd5471bf55444af8bd2d42a2cd8ec423"
      unitRef="U001">1300000</us-gaap:ContractWithCustomerLiability>
    <ions:MaximumPaymentReceivableUnderLicenseAgreement
      contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"
      decimals="-6"
      id="Fact_7e14ae5c11c740c6831238a4f01ae711"
      unitRef="U001">26000000</ions:MaximumPaymentReceivableUnderLicenseAgreement>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="c20180701to20180930_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"
      decimals="-6"
      id="Fact_7f4ceca23bae42a69715fca5095f560d"
      unitRef="U001">12000000</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="c20190401to20190630_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"
      decimals="-6"
      id="Fact_b2771ded298b402da7a83f7e5fa44114"
      unitRef="U001">6000000</us-gaap:ProceedsFromLicenseFeesReceived>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="c20191001to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"
      decimals="-6"
      id="Fact_11672b26a18f4223bfa5b297211ae00b"
      unitRef="U001">4000000</us-gaap:ProceedsFromLicenseFeesReceived>
    <ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones
      contextRef="c20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"
      decimals="-6"
      id="Fact_e9b4a2226bef410b9424e419209f30ed"
      unitRef="U001">4000000</ions:MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones>
    <ions:RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner
      contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"
      decimals="2"
      id="Fact_570d071a48d248dbb4cd460b720cd572"
      unitRef="U003">0.20</ions:RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner>
    <ions:PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil
      contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"
      id="Fact_bccc4622e6f241879d241b2230aae36c">P12M</ions:PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil>
    <ions:RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties
      contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"
      decimals="-6"
      id="Fact_bc71f4a0dda144cc9da7727f9004032f"
      unitRef="U001">10000000</ions:RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties>
    <ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
      contextRef="c20180831_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"
      decimals="INF"
      id="Fact_7cdf5da28b2f42cbb5b3b1e421c304b3"
      unitRef="U005">2</ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180701to20180930_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_LicenseMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"
      decimals="-6"
      id="Fact_cca90ebf4c4e4f7eb1bd74a11a6216ea"
      unitRef="U001">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190401to20190630_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_WaylivraMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"
      decimals="-6"
      id="Fact_9adc484ca5df48ce9cc85dc768b8a6da"
      unitRef="U001">6000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20191001to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_TegsediMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"
      decimals="-6"
      id="Fact_444bcde53d3e43399eefaef07d545127"
      unitRef="U001">4000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"
      id="Text_06f7674d78514b5abc8204e089e60c94">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;During the years ended December 31, 2019 and 2018, Akcea earned the following revenue from its relationship with PTC (in millions, except percentage amounts):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zf3ce81334bbb4ee983c75acc2b6feb6c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31,&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -27pt; margin-left: 27pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Licensing and other royalty revenue (commercial revenue)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10.2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;12.0&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Percentage of total revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"
      decimals="-5"
      id="Fact_9891ac1c164742aa9f336a16f8769e38"
      unitRef="U001">10200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"
      decimals="-5"
      id="Fact_6133400e71034c1d812fdb9519ceeeb6"
      unitRef="U001">12000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"
      decimals="2"
      id="Fact_9a2a82c451d248319bd6f1123ba4776c"
      unitRef="U003">0.01</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"
      decimals="2"
      id="Fact_a7a775b1695d4dfbb7cc3ab3a3a9eae7"
      unitRef="U003">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c20181231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"
      decimals="-6"
      id="Fact_dd80a9f419024a63bbffa3c2e2888698"
      unitRef="U001">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="c20191231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember"
      decimals="-6"
      id="Fact_81d977bc02a14b74be1bb00b1a4c83a5"
      unitRef="U001">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="c20190101to20191231"
      id="Text_e344b0f2337949b4b280461dffbd966f">
&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;7. Segment Information and Concentration of Business Risk&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;We have &lt;/span&gt;two&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; reportable segments Ionis Core and Akcea Therapeutics. &lt;/span&gt;At December 31, 2019, we owned approximately 76 percent of Akcea.&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; Segment income (loss) from operations includes revenue less operating expenses attributable to each segment.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In our Ionis Core segment we are exploiting our antisense technology to generate a broad pipeline of first-in-class and/or best-in-class medicines for us and our partners. Our Ionis Core segment generates revenue from a multifaceted partnering strategy.&lt;/div&gt;

&lt;div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;Akcea is &lt;/span&gt;a biopharmaceutical company focused on developing and commercializing medicines to treat patients with serious and rare diseases&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;. Akcea generates revenue from TEGSEDI and WAYLIVRA product sales and from its collaborations.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;The following tables show our segment revenue and income (loss) from operations for &lt;/span&gt;2019, 2018 and 2017&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; (in thousands), respectively.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="ze030c5e389c640c2991886f2f6ba40f4" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Ionis Core&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Akcea Therapeutics&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Elimination of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Intercompany Activity&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Revenue:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Commercial revenue:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;SPINRAZA royalties&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;292,992&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;292,992&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Product sales, net&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;42,253&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;42,253&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Licensing and other royalty revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;12,616&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10,172&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5,583&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;17,205&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 43.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total commercial revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;305,608&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;52,425&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5,583&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;352,450&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue under collaborative agreements&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;553,038&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;436,118&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(219,007&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;770,149&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total segment revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;858,646&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;488,543&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(224,590&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,122,599&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total operating expenses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;523,207&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;450,469&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(216,960&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;756,716&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income (loss) from operations&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;335,439&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;38,074&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(7,630&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;365,883&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zb93ba8fe3f024f1fa4d3f61c84b60bad" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Ionis Core&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Akcea Therapeutics&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Elimination of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Intercompany Activity&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Revenue:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Commercial revenue:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;SPINRAZA royalties&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;237,930&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;237,930&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;TEGSEDI product sales, net&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,237&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,237&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Licensing and other royalty revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,755&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;12,000&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;14,755&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 43.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total commercial revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;240,685&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;14,237&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;254,922&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue under collaborative agreements&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;401,259&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;50,630&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(107,137&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;344,752&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total segment revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;641,944&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;64,867&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(107,137&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;599,674&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total operating expenses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;380,212&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;295,683&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(14,849&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;661,046&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income (loss) from operations&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;261,732&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(230,816&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(92,288&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(61,372&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z4d329b28bc324ba3bbf9eb96d75066a3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Ionis Core&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Akcea Therapeutics&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Elimination of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Intercompany Activity&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Revenue:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Commercial revenue:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;SPINRAZA royalties&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;112,540&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;112,540&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Licensing and other royalty revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;7,474&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;7,474&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 43.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total commercial revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;120,014&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;120,014&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue under collaborative agreements&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;405,171&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;43,401&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(54,407&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;394,165&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total segment revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;525,185&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;43,401&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(54,407&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;514,179&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total operating expenses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;373,788&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;163,871&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(54,527&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;483,132&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income (loss) from operations&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;151,397&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(120,470&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;120&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;31,047&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following table shows our total assets by segment at December 31, 2019 and 2018 (in thousands), respectively.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z4b7b08804da24aa49b1b8bfdb2287736" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total Assets&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Ionis Core&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Akcea Therapeutics&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Elimination of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Intercompany Activity&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3,478,081&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;599,250&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(844,219&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3,233,112&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;December 31, 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,975,491&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;365,261&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(672,968&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,667,784&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Contracts receivables at December 31, 2019 and December 31, 2018 were comprised of approximately 75 percent and 99  percent for each year from one and four significant partners, respectively.&lt;/div&gt;
</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c20190101to20191231"
      decimals="INF"
      id="Fact_7b6216c3ebc44b518de52c3d575b97de"
      unitRef="U010">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="c20191231_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="2"
      id="Fact_7579292414fd4edcae095d48a9e69f1b"
      unitRef="U003">0.76</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="c20190101to20191231"
      id="Text_22aa02140d1544bb91cfa2bb9e2b5708">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;The following tables show our segment revenue and income (loss) from operations for &lt;/span&gt;2019, 2018 and 2017&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt; (in thousands), respectively.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="ze030c5e389c640c2991886f2f6ba40f4" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Ionis Core&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Akcea Therapeutics&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Elimination of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Intercompany Activity&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Revenue:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Commercial revenue:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;SPINRAZA royalties&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;292,992&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;292,992&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Product sales, net&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;42,253&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;42,253&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Licensing and other royalty revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;12,616&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10,172&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5,583&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;17,205&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 43.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total commercial revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;305,608&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;52,425&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(5,583&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;352,450&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue under collaborative agreements&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;553,038&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;436,118&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(219,007&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;770,149&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total segment revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;858,646&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;488,543&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(224,590&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,122,599&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total operating expenses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;523,207&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;450,469&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(216,960&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;756,716&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income (loss) from operations&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;335,439&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;38,074&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(7,630&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;365,883&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zb93ba8fe3f024f1fa4d3f61c84b60bad" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Ionis Core&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Akcea Therapeutics&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Elimination of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Intercompany Activity&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Revenue:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Commercial revenue:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;SPINRAZA royalties&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;237,930&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;237,930&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;TEGSEDI product sales, net&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,237&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,237&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Licensing and other royalty revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,755&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;12,000&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;14,755&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 43.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total commercial revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;240,685&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;14,237&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;254,922&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue under collaborative agreements&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;401,259&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;50,630&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(107,137&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;344,752&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total segment revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;641,944&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;64,867&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(107,137&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;599,674&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total operating expenses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;380,212&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;295,683&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(14,849&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;661,046&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income (loss) from operations&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;261,732&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(230,816&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(92,288&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(61,372&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z4d329b28bc324ba3bbf9eb96d75066a3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Ionis Core&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Akcea Therapeutics&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Elimination of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Intercompany Activity&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Revenue:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Commercial revenue:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;SPINRAZA royalties&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;112,540&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;112,540&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Licensing and other royalty revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;7,474&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;7,474&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 43.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total commercial revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;120,014&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;120,014&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 7.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;R&amp;amp;D revenue under collaborative agreements&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;405,171&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;43,401&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(54,407&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;394,165&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; margin-left: 25.2pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total segment revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;525,185&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;43,401&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(54,407&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;514,179&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Total operating expenses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;373,788&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;163,871&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(54,527&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;483,132&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income (loss) from operations&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;151,397&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(120,470&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;120&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;31,047&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following table shows our total assets by segment at December 31, 2019 and 2018 (in thousands), respectively.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z4b7b08804da24aa49b1b8bfdb2287736" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total Assets&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Ionis Core&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Akcea Therapeutics&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Elimination of&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Intercompany Activity&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Total&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3,478,081&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;599,250&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(844,219&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;3,233,112&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 52%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -10pt; margin-left: 10pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;December 31, 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,975,491&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;365,261&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(672,968&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,667,784&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;
</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_6afe8e8668b04c5fb57325d4b93bb23d"
      unitRef="U001">292992000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_4f418fb55533484c9b94b8ee10ef7898"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember"
      decimals="-3"
      id="Fact_e90aac00ba9f4b74bfa7df527a4402e7"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ProductOrServiceAxis_SPINRAZARoyaltiesMember"
      decimals="-3"
      id="Fact_33b6132cd6d149bcb21f15b948504473"
      unitRef="U001">292992000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ProductMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_825dd68f3b244ab980fcb381b502335e"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ProductMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_4253d66893b544a0b98945eeff82e360"
      unitRef="U001">42253000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_ProductMember"
      decimals="-3"
      id="Fact_48b2d3d7430c48faa4f514df069b8308"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ProductOrServiceAxis_ProductMember"
      decimals="-3"
      id="Fact_236e4517c52741819047698a87bd8f57"
      unitRef="U001">42253000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_b9dfeeef44b447bdb8495f56c12d23ae"
      unitRef="U001">12616000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_3628beb8cd0440aa9c4e2b743f6115fc"
      unitRef="U001">10172000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember"
      decimals="-3"
      id="Fact_5eeb113cac5e42f9aa002efebb601358"
      unitRef="U001">-5583000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember"
      decimals="-3"
      id="Fact_b42c7a2cbe7c4bdeac16fe7876deace0"
      unitRef="U001">17205000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_c44a9fae3b504834badbba6952229a72"
      unitRef="U001">305608000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_00ea3970f91f4a2ca51524fd6e5d8c5a"
      unitRef="U001">52425000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_CommercialMember"
      decimals="-3"
      id="Fact_21b636a466964e9a96a4e4276b023022"
      unitRef="U001">-5583000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ProductOrServiceAxis_CommercialMember"
      decimals="-3"
      id="Fact_c262df0828a44f0ca600f2d34ecf59cd"
      unitRef="U001">352450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_4a04a60c9cea4630a3974e9237779741"
      unitRef="U001">553038000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_c500cc672e4e4a61bdc98605f5ad035f"
      unitRef="U001">436118000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember"
      decimals="-3"
      id="Fact_30890e9b395041aab244b05eaa9bfc1c"
      unitRef="U001">-219007000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember"
      decimals="-3"
      id="Fact_49f0bd2b45984a46a61dd06f40a3a248"
      unitRef="U001">770149000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_780e562acba94b9db1a44fb8db4d391a"
      unitRef="U001">858646000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_17dccbb558b94ce893b8e12b7a220935"
      unitRef="U001">488543000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember"
      decimals="-3"
      id="Fact_7133b18e64924d3f97f374bef01929e8"
      unitRef="U001">-224590000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_5938281f23ba489da69fb9de8ddb93c4"
      unitRef="U001">1122599000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostsAndExpenses
      contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_fd90bb8f1c014004a60938ffe5512b22"
      unitRef="U001">523207000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_b608e9a60f0746ba87e457b693f95589"
      unitRef="U001">450469000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember"
      decimals="-3"
      id="Fact_18e0bbe264124c5da106c621ebd8b0de"
      unitRef="U001">-216960000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_2f29c1009e9f454eaa686cf5f03a4f1f"
      unitRef="U001">756716000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_c70bdd1280d04e33928f8f67b27d342d"
      unitRef="U001">335439000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20190101to20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_97c27fd2cd8746c4bff11763fab60a9c"
      unitRef="U001">38074000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20190101to20191231_ConsolidationItemsAxis_IntersegmentEliminationMember"
      decimals="-3"
      id="Fact_13c0b92f5c334cd79fe21d76465bbe72"
      unitRef="U001">-7630000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20190101to20191231"
      decimals="-3"
      id="Fact_1e7c02d8f21b4997a7d5799940f1f5c7"
      unitRef="U001">365883000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_318542b6e43041b7a35f38b86729d651"
      unitRef="U001">237930000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_ce8a3e7546c743fd992f9ed83ba36bc1"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember"
      decimals="-3"
      id="Fact_5716fcd14cd247f0af30c52d8a2c8746"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ProductOrServiceAxis_SPINRAZARoyaltiesMember"
      decimals="-3"
      id="Fact_aca9c4384cb2417fb4477bb426020a57"
      unitRef="U001">237930000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ProductMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_a8cad1b246414eae888b966f9439fd96"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ProductMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_a472da0eb90b474fb01235eab69bc338"
      unitRef="U001">2237000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_ProductMember"
      decimals="-3"
      id="Fact_569d3f5cedb341479573c9f00ad5065a"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ProductOrServiceAxis_ProductMember"
      decimals="-3"
      id="Fact_bc0c5a8aed6242cf9507f59667b0b095"
      unitRef="U001">2237000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_108299dc3f78432cbeda93345157c390"
      unitRef="U001">2755000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_4198a0c44e4d4c119e3bba3f27762740"
      unitRef="U001">12000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember"
      decimals="-3"
      id="Fact_44436caf046a4b41a0411d5af56dfd9d"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember"
      decimals="-3"
      id="Fact_86539ea247ab47c58125baeeffd8bf77"
      unitRef="U001">14755000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_a74b1519a21d4f6392d89d778544c1d7"
      unitRef="U001">240685000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_3d84626bae4f4617b6271858829afef2"
      unitRef="U001">14237000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_CommercialMember"
      decimals="-3"
      id="Fact_d09fd63c25564e329244f14aa77aa9a0"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ProductOrServiceAxis_CommercialMember"
      decimals="-3"
      id="Fact_389f7e0d63054fb39d19dc6da506f8e7"
      unitRef="U001">254922000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_8270d7f5f6c744bb92a2004a7c28da0b"
      unitRef="U001">401259000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_7e3dbc256f6c48fabac7999367080c21"
      unitRef="U001">50630000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember"
      decimals="-3"
      id="Fact_110d4a8b116f419b977be52cd7010d44"
      unitRef="U001">-107137000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember"
      decimals="-3"
      id="Fact_2904d0e875bc4fea942e1a7a98101b32"
      unitRef="U001">344752000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_4398da70003540029d0d7605e03b67dc"
      unitRef="U001">641944000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_c4c389db39494e34bcc70f18ed8ca66c"
      unitRef="U001">64867000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember"
      decimals="-3"
      id="Fact_88b7466081ca436b95e9eceb5f7eaf60"
      unitRef="U001">-107137000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_2abe38c85e084b75a9fea72a3d7a0970"
      unitRef="U001">599674000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostsAndExpenses
      contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_df004b537cda4ce88886e4777d7ee02a"
      unitRef="U001">380212000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_a885c7bc128e4998a6d7e9c76b52ddb6"
      unitRef="U001">295683000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember"
      decimals="-3"
      id="Fact_8954dd602fd8409282de2096ddd23aa4"
      unitRef="U001">-14849000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_3ab6506defab44cc8c1a14f909cdc1a9"
      unitRef="U001">661046000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_9f1ec2a8feac4ffb8941b0d7e2a02108"
      unitRef="U001">261732000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20180101to20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_b8ae4f5fab1b4c8fafcc8d016c245441"
      unitRef="U001">-230816000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20180101to20181231_ConsolidationItemsAxis_IntersegmentEliminationMember"
      decimals="-3"
      id="Fact_cce557a5eabd4144bab77f9bcdca4655"
      unitRef="U001">-92288000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20180101to20181231"
      decimals="-3"
      id="Fact_81b2472c287a477cb0cbfdf02ba82947"
      unitRef="U001">-61372000</us-gaap:OperatingIncomeLoss>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_643bfff6e6454546a0eafa6003d06593"
      unitRef="U001">112540000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_48d5fd71182c4dec9a297759f5cc32c9"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_SPINRAZARoyaltiesMember"
      decimals="-3"
      id="Fact_a7072df96aa24aecbf3b3f722277f21e"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ProductOrServiceAxis_SPINRAZARoyaltiesMember"
      decimals="-3"
      id="Fact_efeda3f0d1e84d4cbf7c9d49e2f64bcf"
      unitRef="U001">112540000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_509142df716d47c0b8878dd24fd11c1c"
      unitRef="U001">7474000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_400c68af61a142ad9505e01a2a1bcb4f"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember"
      decimals="-3"
      id="Fact_40dc99a7994848b491aacc3da206e693"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ProductOrServiceAxis_LicensingAndOtherRoyaltiesMember"
      decimals="-3"
      id="Fact_83ce62cd8a594ab0a0fa82f5001c8135"
      unitRef="U001">7474000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_e3523e77e4d5401d9e93bf5f4b6f5d0e"
      unitRef="U001">120014000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_CommercialMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_341d4848206f4e3cbec9234fb7359cfc"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_CommercialMember"
      decimals="-3"
      id="Fact_2d85ea774425454f8294e974309e0f99"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ProductOrServiceAxis_CommercialMember"
      decimals="-3"
      id="Fact_d0c68b66db7b4a07a14ec99c249724a3"
      unitRef="U001">120014000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_df95ee27ac7f462cb96345455905d8f8"
      unitRef="U001">405171000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_472a27771e2c41b1952c38b51a763990"
      unitRef="U001">43401000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember"
      decimals="-3"
      id="Fact_1fa27f1eb4b54d72bb91032b29ffb598"
      unitRef="U001">-54407000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ProductOrServiceAxis_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember"
      decimals="-3"
      id="Fact_b4ea2826218e4568bef4c392942b28dc"
      unitRef="U001">394165000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_24a4a2bacce9474ca9a3cd3ce053902e"
      unitRef="U001">525185000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_f3149f9bfb8a4644bb11a55b9d5abd25"
      unitRef="U001">43401000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember"
      decimals="-3"
      id="Fact_15cdc207e58b4f26bc58ff17b1e5c225"
      unitRef="U001">-54407000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_537a36a3fb2c4240830bf14f1fc0e530"
      unitRef="U001">514179000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostsAndExpenses
      contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_1b8dc8f1f1354498ac3cb49477328548"
      unitRef="U001">373788000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_eeb2dc8a1acc47b3bee47d336d5e9f2b"
      unitRef="U001">163871000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember"
      decimals="-3"
      id="Fact_25a14b8a961e4d22b16608d8fbd24489"
      unitRef="U001">-54527000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_3e4d0b646d914517b93860165a8d9dd7"
      unitRef="U001">483132000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_b6f49d0ddfea4cae8b24ef0506b19dd5"
      unitRef="U001">151397000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20170101to20171231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_feefc7d2d3b94cfaa86963033e8da9a4"
      unitRef="U001">-120470000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20170101to20171231_ConsolidationItemsAxis_IntersegmentEliminationMember"
      decimals="-3"
      id="Fact_0972534fc7674f2ca0c2113c30bc8e26"
      unitRef="U001">120000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20170101to20171231"
      decimals="-3"
      id="Fact_ec70297ab4244463a24824848df2246f"
      unitRef="U001">31047000</us-gaap:OperatingIncomeLoss>
    <us-gaap:Assets
      contextRef="c20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_4393e21bf23041519f08cf012a684ef4"
      unitRef="U001">3478081000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20191231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_41da19f8f16940fc8503d30961a583e9"
      unitRef="U001">599250000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20191231_ConsolidationItemsAxis_IntersegmentEliminationMember"
      decimals="-3"
      id="Fact_e878b5b1327943bf9fe8329a61b7ca25"
      unitRef="U001">-844219000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20191231"
      decimals="-3"
      id="Fact_bd3cd73399c64f20b57693c66dc37ab9"
      unitRef="U001">3233112000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_165a2783f8ad4636aa05337476ec6f11"
      unitRef="U001">2975491000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20181231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_AkceaTherapeuticsMember"
      decimals="-3"
      id="Fact_0c0f2ea58e66476ea656ccf108f71566"
      unitRef="U001">365261000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20181231_ConsolidationItemsAxis_IntersegmentEliminationMember"
      decimals="-3"
      id="Fact_474f897008694a98a304e7242c4bd91b"
      unitRef="U001">-672968000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20181231"
      decimals="-3"
      id="Fact_72af7c7066294da4883e92aa73bfecde"
      unitRef="U001">2667784000</us-gaap:Assets>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CreditConcentrationRiskMember_MajorCustomersAxis_SignificantPartnersMember"
      decimals="2"
      id="Fact_28f0adbb41bc491dba19be13a5d7e43d"
      unitRef="U003">0.75</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CreditConcentrationRiskMember_MajorCustomersAxis_SignificantPartnersMember"
      decimals="2"
      id="Fact_65b613fed44d4106b07531e197665bfb"
      unitRef="U003">0.99</us-gaap:ConcentrationRiskPercentage1>
    <ions:NumberOfSignificantPartners
      contextRef="c20190101to20191231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CreditConcentrationRiskMember_MajorCustomersAxis_SignificantPartnersMember"
      decimals="INF"
      id="Fact_f77b5cfe2f944a15983b965d2dedff4b"
      unitRef="U019">1</ions:NumberOfSignificantPartners>
    <ions:NumberOfSignificantPartners
      contextRef="c20180101to20181231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CreditConcentrationRiskMember_MajorCustomersAxis_SignificantPartnersMember"
      decimals="INF"
      id="Fact_4c28cf57e67b421f9e33d6b9fe701b2c"
      unitRef="U019">4</ions:NumberOfSignificantPartners>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="c20190101to20191231"
      id="Text_4828029eb0b0493f99454748bc595924">
&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;8. Employment Benefits&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We have an employee 401(k) salary deferral plan, covering all employees. Employees could make contributions by withholding a percentage of their salary up to the IRS annual limit $19,000 and $25,000 in 2019 for employees under 50 years old and employees 50 years old or over, respectively. We made approximately $6.4 million, $5.7 million and $3.0 million in matching contributions for the years ended December 31, 2019, 2018 and 2017, respectively.&lt;/div&gt;
</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <ions:DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge
      contextRef="c20190101to20191231"
      decimals="0"
      id="Fact_06c142c7ec1040e0b05c4b2596dfe112"
      unitRef="U001">19000</ions:DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge>
    <ions:DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge
      contextRef="c20190101to20191231"
      decimals="0"
      id="Fact_2703ad6213db4e249c38d0794a2c6418"
      unitRef="U001">25000</ions:DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="c20190101to20191231"
      decimals="-5"
      id="Fact_345fd7748408424580894d7cb0e0e108"
      unitRef="U001">6400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="c20180101to20181231"
      decimals="-5"
      id="Fact_47a2898dc66b4221ba3a2d92c2c0643a"
      unitRef="U001">5700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="c20170101to20171231"
      decimals="-5"
      id="Fact_0c0b367e1550466b886c0390a13e1e0f"
      unitRef="U001">3000000.0</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="c20190101to20191231"
      id="Text_8889b34573874aeeb1e3093442528ca9">
&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;9. Legal Proceedings&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;From time to time, we are involved in legal proceedings arising in the ordinary course of our business. Periodically, we evaluate the status of each legal matter and assess our potential financial exposure. If the potential loss from any legal proceeding is considered probable and the amount can be reasonably estimated, we accrue a liability for the estimated loss. Significant judgment is required to determine the probability of a loss and whether the amount of the loss is reasonably estimable. The outcome of any proceeding is not determinable in advance. As a result, the assessment of a potential liability and the amount of accruals recorded are based only on the information available to us at the time. As additional information becomes available, we reassess the potential liability related to the legal proceeding, and may revise our estimates.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;In November 2019, a purported stockholder of Akcea filed an action in the Delaware Court of Chancery, captioned &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;City of Cambridge Retirement System v. Crooke, et al.&lt;/span&gt;, C.A. No. 2019-0905, or the Delaware Action. The plaintiff in the Delaware Action asserts claims against (i) current and former members of Akcea&#x2019;s Board of Directors, and (ii) Ionis, or collectively, the Defendants. The plaintiff asserts derivative claims on behalf of Akcea, which is a nominal defendant in the Delaware Action, as well as putatively direct claims on behalf of a purported class of Akcea stockholders. The plaintiff in the Delaware Action asserts that the Defendants breached their fiduciary duties in connection with the licensing transaction that Akcea and Ionis entered into regarding TEGSEDI and AKCEA-TTR-&lt;span style="background-color: #FFFFFF; font-size: 10pt; font-family: 'Times New Roman', Times, serif;"&gt;L&lt;/span&gt;&lt;sub&gt;&lt;span style="background-color: #FFFFFF;"&gt;Rx&lt;/span&gt;&lt;/sub&gt;. The plaintiff also asserts an unjust enrichment claim against Ionis. We and Akcea have moved to dismiss the plaintiff&#x2019;s complaint. We believe that the claims asserted in the Delaware Action are without merit.&lt;/div&gt;
</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="c20190101to20191231"
      id="Text_c2c3e6e9a4d542cf8c6f1350eb5450ef">
&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;10. Quarterly Financial Data (Unaudited)&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Summarized quarterly data for the years ended December 31, 2019 and 2018 are as follows (in thousands, except per share data).&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zbbded80230f54883844977a2db5dd5f5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019 Quarters&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;First&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quarter&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Second&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quarter&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Third&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quarter&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fourth&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quarter&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;297,214&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;163,813&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;167,892&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;493,680&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Operating expenses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;175,679&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;182,640&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;165,369&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;233,028&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income (loss) from operations&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;121,535&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(18,827&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,523&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;260,652&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;90,884&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(10,012&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18,432&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;203,957&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;84,443&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(876&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;26,163&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;184,415&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net income (loss) per share (1) (2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.63&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.01&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.19&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.31&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Diluted net income (loss) per share (1) (3)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.62&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.01&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.18&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.28&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z6dcd313bcba54fcbbfd2063358483afb" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018 Quarters&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;First&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quarter&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Second&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quarter&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Third&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quarter&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fourth&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quarter&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;144,419&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;117,747&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;145,395&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;192,113&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Operating expenses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;147,720&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;168,028&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;163,967&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;181,331&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income (loss) from operations&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(3,301&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(50,281&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(18,572&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10,782&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(10,812&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(56,573&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(20,365&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;302,735&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,420&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(40,358&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4,559&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;320,078&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net income (loss) per share (1) (2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.01&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.29&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.03&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.32&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Diluted net income (loss) per share (1) (3)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.01&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.29&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.03&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.21&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;________________&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z238c61f0c45341568e1fd63ba558f508" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We computed net income (loss) per share independently for each of the quarters presented. Therefore, the sum of the quarterly net income (loss) per share will not necessarily equal the total for the year.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify; margin-left: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z4b10092c7ee94951986f14bc378411d6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;As discussed in Note 1, &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Organization and Significant Accounting Policies, &lt;/span&gt;we compute basic net income (loss) per share by dividing the total net income (loss) attributable to our common stockholders by our weighted-average number of common shares outstanding during the period. Our basic net income (loss) per share calculation for each of the quarters in 2019 and 2018 considered our net income for Ionis on a stand-alone basis plus our share of Akcea&#x2019;s net loss for the period. To calculate the portion of Akcea&#x2019;s net loss attributable to our ownership, we multiplied Akcea&#x2019;s loss per share by the weighted average shares we owned in Akcea during the period. As a result of this calculation, our total net income (loss) available to Ionis common stockholders for the calculation of net income (loss) per share is different than net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders in the consolidated statements of operations.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our basic net income (loss) per share for each quarter in 2019 was calculated as follows (in thousands, except per share amounts):&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z66d226e9f1e04c068da73924c4bbb872" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended March 31 , 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt; Portion of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;68,582&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.35&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;23,846&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net income attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;23,846&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;63,697&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;87,543&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;138,582&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net income per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.63&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z0a7c3905d3e645b7bf1d61ed99b81aa3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended June 30 , 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Loss&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt; Portion of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;70,221&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.40&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(28,244&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net loss attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(28,244&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;27,311&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net loss available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(933&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;140,247&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net loss per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.01&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z63a88a9296e2466eaad9bc93a89393ce" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended September 30 , 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Loss&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt; Portion of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;70,221&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.34&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(23,772&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net loss attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(23,772&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;49,930&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;26,158&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;140,551&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net income per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.19&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zd25327371fce44efae3b5570b907c56d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended December 31 , 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt; Portion of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;71,342&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.87&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;62,243&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net income attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;62,243&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;121,552&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;183,795&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;140,583&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net income per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.31&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our basic net income (loss) per share for each quarter in 2018 was calculated as follows (in thousands, except per share amounts):&lt;/div&gt;

&lt;div style="text-align: left; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zbbcbf397131340ad9566b5428b09a107" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended March 31 , 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Loss&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt; Portion of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;45,448&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.44&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(19,997&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net loss attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(19,997&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18,785&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net loss available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,212&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;125,330&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net loss per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.01&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify; margin-left: 31.5pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z2b8e94f57db4490c82a68c1ff759a0e3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended June 30 , 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Loss&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt; Portion of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;60,832&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.72&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(43,814&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net loss attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(43,814&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;5,882&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net loss available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(37,932&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;128,712&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net loss per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.29&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z2549de914d904e2a82162394a6946bc2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended September 30 , 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Loss&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt; Portion of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;65,538&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.73&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(47,789&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net loss attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(47,789&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;43,226&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net loss available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4,563&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;137,346&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net loss per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.03&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z0b1244fa792d4e2f89c46e4a73ab2036" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended December 31 , 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Loss&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt; Portion of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;67,130&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.79&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(53,219&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net loss attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(53,219&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;372,913&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;319,694&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;137,699&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net income per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.32&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zc5ec9a701b644f2192ef4fd51a353c9b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(3)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We had net income available to Ionis common stockholders for the following periods. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during those periods.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Diluted common equivalent shares for each of the periods consisted of the following (in thousands except per share amounts):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zf822f8c87ab4452683b2466a81529563" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended March 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Numerator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Denominator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per-Share&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;87,543&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;138,582&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.63&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effect of dilutive securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -6pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon exercise of stock options&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,252&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon restricted stock award issuance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;665&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our ESPP&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;38&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our 1 percent convertible notes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income available to Ionis common stockholders, plus assumed conversions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;87,543&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;141,537&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.62&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zcafdd1c50c0b47bea13bfdef22787b0b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended September 30, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Numerator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Denominator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per-Share&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;26,158&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;140,551&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.19&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effect of dilutive securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon exercise of stock options&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,993&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon restricted stock award issuance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;844&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our ESPP&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;20&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our 1 percent convertible notes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income available to Ionis common stockholders, plus assumed conversions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;26,158&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;143,408&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.18&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z43f9157d9e1242ac8e62d24c49d3a75f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Numerator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Denominator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per-Share&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;183,795&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;140,583&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.31&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effect of dilutive securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon exercise of stock options&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,467&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon restricted stock award issuance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;848&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our ESPP&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our 0.125 percent convertible notes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;644&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;860&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our 1 percent convertible notes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;12,046&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;9,527&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income available to Ionis common stockholders, plus assumed conversions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;196,485&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;153,303&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.28&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z2edbbee13c264fed8062982b71bf6ef3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended December 31, 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Numerator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Denominator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per-Share&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;319,694&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;137,699&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.32&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effect of dilutive securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon exercise of stock options&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,254&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon restricted stock award issuance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;636&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our ESPP&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our 1 percent convertible notes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10,745&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10,260&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income available to Ionis common stockholders, plus assumed conversions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;330,439&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;149,856&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.21&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -36pt; margin-left: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;For the three months ended March 31, 2019 and September 30, 2019, the calculation excluded the 1 percent notes because the effect on diluted earnings per share was anti-dilutive.&lt;/div&gt;
</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="c20190101to20191231"
      id="Text_b65c0b3c5ab243bd949bc3d66e4ac1df">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;The following financial information reflects all normal recurring adjustments, which are, in the opinion of management, necessary for a fair statement of the results of the interim periods. Summarized quarterly data for the years ended December 31, 2019 and 2018 are as follows (in thousands, except per share data).&lt;/div&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zbbded80230f54883844977a2db5dd5f5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2019 Quarters&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;First&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quarter&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Second&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quarter&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Third&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quarter&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fourth&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quarter&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;297,214&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;163,813&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;167,892&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;493,680&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Operating expenses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;175,679&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;182,640&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;165,369&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;233,028&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income (loss) from operations&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;121,535&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(18,827&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,523&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;260,652&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;90,884&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(10,012&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18,432&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;203,957&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;84,443&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(876&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;26,163&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;184,415&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net income (loss) per share (1) (2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.63&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.01&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.19&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.31&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Diluted net income (loss) per share (1) (3)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.62&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.01&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.18&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.28&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z6dcd313bcba54fcbbfd2063358483afb" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;2018 Quarters&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;First&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quarter&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Second&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quarter&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Third&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quarter&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Fourth&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Quarter&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Revenue&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;144,419&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;117,747&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;145,395&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;192,113&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Operating expenses&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;147,720&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;168,028&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;163,967&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;181,331&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income (loss) from operations&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(3,301&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(50,281&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(18,572&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10,782&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income (loss)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(10,812&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(56,573&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(20,365&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;302,735&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,420&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(40,358&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4,559&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;320,078&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net income (loss) per share (1) (2)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.01&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.29&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.03&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.32&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Diluted net income (loss) per share (1) (3)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.01&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.29&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.03&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.21&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;________________&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z238c61f0c45341568e1fd63ba558f508" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We computed net income (loss) per share independently for each of the quarters presented. Therefore, the sum of the quarterly net income (loss) per share will not necessarily equal the total for the year.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify; margin-left: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z4b10092c7ee94951986f14bc378411d6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(2)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;As discussed in Note 1, &lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;"&gt;Organization and Significant Accounting Policies, &lt;/span&gt;we compute basic net income (loss) per share by dividing the total net income (loss) attributable to our common stockholders by our weighted-average number of common shares outstanding during the period. Our basic net income (loss) per share calculation for each of the quarters in 2019 and 2018 considered our net income for Ionis on a stand-alone basis plus our share of Akcea&#x2019;s net loss for the period. To calculate the portion of Akcea&#x2019;s net loss attributable to our ownership, we multiplied Akcea&#x2019;s loss per share by the weighted average shares we owned in Akcea during the period. As a result of this calculation, our total net income (loss) available to Ionis common stockholders for the calculation of net income (loss) per share is different than net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders in the consolidated statements of operations.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our basic net income (loss) per share for each quarter in 2019 was calculated as follows (in thousands, except per share amounts):&lt;/div&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z66d226e9f1e04c068da73924c4bbb872" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended March 31 , 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt; Portion of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;68,582&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.35&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;23,846&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net income attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;23,846&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;63,697&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;87,543&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;138,582&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net income per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.63&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z0a7c3905d3e645b7bf1d61ed99b81aa3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended June 30 , 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Loss&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt; Portion of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;70,221&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.40&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(28,244&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net loss attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(28,244&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;27,311&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net loss available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(933&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;140,247&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net loss per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.01&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z63a88a9296e2466eaad9bc93a89393ce" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended September 30 , 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Loss&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt; Portion of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;70,221&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.34&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(23,772&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net loss attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(23,772&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;49,930&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;26,158&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;140,551&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net income per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.19&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zd25327371fce44efae3b5570b907c56d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended December 31 , 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt; Portion of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;71,342&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.87&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;62,243&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net income attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;62,243&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;121,552&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;183,795&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;140,583&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net income per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.31&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Our basic net income (loss) per share for each quarter in 2018 was calculated as follows (in thousands, except per share amounts):&lt;/div&gt;

&lt;div style="text-align: left; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zbbcbf397131340ad9566b5428b09a107" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended March 31 , 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Loss&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt; Portion of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;45,448&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.44&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(19,997&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net loss attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(19,997&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18,785&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net loss available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(1,212&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;125,330&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net loss per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.01&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: justify; margin-left: 31.5pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z2b8e94f57db4490c82a68c1ff759a0e3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended June 30 , 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Loss&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt; Portion of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;60,832&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.72&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(43,814&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net loss attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(43,814&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;5,882&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net loss available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(37,932&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;128,712&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net loss per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.29&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z2549de914d904e2a82162394a6946bc2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended September 30 , 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Loss&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt; Portion of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;65,538&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.73&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(47,789&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net loss attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(47,789&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;43,226&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net loss available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(4,563&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;137,346&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net loss per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.03&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z0b1244fa792d4e2f89c46e4a73ab2036" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended December 31 , 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Average Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Owned in Akcea&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Net Loss&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per Share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Ionis&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt; Portion of&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;Akcea&lt;/span&gt;&#x2019;&lt;span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"&gt;s Net Loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Common shares&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;67,130&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(0.79&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(53,219&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Akcea&#x2019;s net loss attributable to our ownership&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(53,219&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Ionis&#x2019; stand-alone net income&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;372,913&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;319,694&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Weighted average shares outstanding&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;137,699&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Basic net income per share&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.32&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zc5ec9a701b644f2192ef4fd51a353c9b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;
  &lt;tr&gt;
    &lt;td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;(3)&lt;/td&gt;
    &lt;td style="width: auto; vertical-align: top; text-align: justify;"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;We had net income available to Ionis common stockholders for the following periods. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during those periods.&lt;/div&gt;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: justify; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Diluted common equivalent shares for each of the periods consisted of the following (in thousands except per share amounts):&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zf822f8c87ab4452683b2466a81529563" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended March 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Numerator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Denominator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per-Share&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;87,543&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;138,582&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.63&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effect of dilutive securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -6pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon exercise of stock options&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2,252&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon restricted stock award issuance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;665&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our ESPP&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;38&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our 1 percent convertible notes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income available to Ionis common stockholders, plus assumed conversions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;87,543&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;141,537&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.62&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="zcafdd1c50c0b47bea13bfdef22787b0b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended September 30, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Numerator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Denominator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per-Share&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;26,158&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;140,551&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.19&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effect of dilutive securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon exercise of stock options&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,993&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon restricted stock award issuance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;844&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our ESPP&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;20&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our 1 percent convertible notes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income available to Ionis common stockholders, plus assumed conversions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;26,158&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;143,408&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;0.18&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z43f9157d9e1242ac8e62d24c49d3a75f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended December 31, 2019&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Numerator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Denominator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per-Share&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;183,795&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;140,583&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.31&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effect of dilutive securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon exercise of stock options&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,467&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon restricted stock award issuance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;848&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our ESPP&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;18&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our 0.125 percent convertible notes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;644&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;860&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our 1 percent convertible notes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;12,046&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;9,527&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income available to Ionis common stockholders, plus assumed conversions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;196,485&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;153,303&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1.28&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="text-align: left;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" id="z2edbbee13c264fed8062982b71bf6ef3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"&gt;&lt;div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Three Months Ended December 31, 2018&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Income&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Numerator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;(Denominator)&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Per-Share&lt;/div&gt;&lt;div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;"&gt;Amount&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Net income available to Ionis common stockholders&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;319,694&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;137,699&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.32&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Effect of dilutive securities:&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon exercise of stock options&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;1,254&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable upon restricted stock award issuance&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;636&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our ESPP&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;7&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9pt; margin-left: 21pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Shares issuable related to our 1 percent convertible notes&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10,745&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;10,260&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
  &lt;tr&gt;
    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;Income available to Ionis common stockholders, plus assumed conversions&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;330,439&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;149,856&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;$&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;&lt;div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;2.21&lt;/div&gt;&lt;/td&gt;
    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;
  &lt;/tr&gt;
&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: justify; text-indent: -36pt; margin-left: 36pt;"&gt;&lt;span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"&gt;For the three months ended March 31, 2019 and September 30, 2019, the calculation excluded the 1 percent notes because the effect on diluted earnings per share was anti-dilutive.&lt;/div&gt;
</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:Revenues
      contextRef="c20190101to20190331"
      decimals="-3"
      id="Fact_405935fc1a234f9693c9e050d5d1faf6"
      unitRef="U001">297214000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="c20190401to20190630"
      decimals="-3"
      id="Fact_e1ea1a2285c44c159fc7940b53b1eca8"
      unitRef="U001">163813000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="c20190701to20190930"
      decimals="-3"
      id="Fact_b0f53fcdeb5149d4a00f45cc69091373"
      unitRef="U001">167892000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="c20191001to20191231"
      decimals="-3"
      id="Fact_e4523a99204b47479a6578ee1ea5c227"
      unitRef="U001">493680000</us-gaap:Revenues>
    <us-gaap:CostsAndExpenses
      contextRef="c20190101to20190331"
      decimals="-3"
      id="Fact_aa23b0f93153488597551e03eb288034"
      unitRef="U001">175679000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="c20190401to20190630"
      decimals="-3"
      id="Fact_ba0545722fa749958bc91a3467210be7"
      unitRef="U001">182640000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="c20190701to20190930"
      decimals="-3"
      id="Fact_b19b91ad3aed407aabf139e529e9fa66"
      unitRef="U001">165369000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="c20191001to20191231"
      decimals="-3"
      id="Fact_ef90677def3140d98ac71d198d622906"
      unitRef="U001">233028000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20190101to20190331"
      decimals="-3"
      id="Fact_01f1a808e8df4e62a878cf07afa7ed37"
      unitRef="U001">121535000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20190401to20190630"
      decimals="-3"
      id="Fact_deef4502b31f41688adecd82c0c515de"
      unitRef="U001">-18827000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20190701to20190930"
      decimals="-3"
      id="Fact_0a8576bd68274551b54937a3c64dfcd7"
      unitRef="U001">2523000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20191001to20191231"
      decimals="-3"
      id="Fact_923dc71a6c8946569992db56c25448e0"
      unitRef="U001">260652000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="c20190101to20190331"
      decimals="-3"
      id="Fact_ef4e35c29e504ecda7c36c96c1aee8e8"
      unitRef="U001">90884000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20190401to20190630"
      decimals="-3"
      id="Fact_4a9a55aede9e4d679715875d6e3584b3"
      unitRef="U001">-10012000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20190701to20190930"
      decimals="-3"
      id="Fact_28285e71fbae42529e40f2f9e7c6ac1c"
      unitRef="U001">18432000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20191001to20191231"
      decimals="-3"
      id="Fact_c6bc921d748440ee8a2149a0046d16dd"
      unitRef="U001">203957000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20190101to20190331"
      decimals="-3"
      id="Fact_70191f1596d046aab1549b8741bbb263"
      unitRef="U001">84443000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20190401to20190630"
      decimals="-3"
      id="Fact_c32a43869a1b46e2a6d4c6675431dd9c"
      unitRef="U001">-876000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20190701to20190930"
      decimals="-3"
      id="Fact_fb7803ccdeda4e7199d2a1be79da9830"
      unitRef="U001">26163000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20191001to20191231"
      decimals="-3"
      id="Fact_33e716eff34a4b7b8689e954b0810f18"
      unitRef="U001">184415000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20190101to20190331"
      decimals="2"
      id="Fact_c12cf7abb66848b497c1b0fdca78f316"
      unitRef="U004">0.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20190401to20190630"
      decimals="2"
      id="Fact_ab7ddc03812d45bba8a6590bbdaa6412"
      unitRef="U004">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20190701to20190930"
      decimals="2"
      id="Fact_8e3aff85017d49ac81262282323b3438"
      unitRef="U004">0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20191001to20191231"
      decimals="2"
      id="Fact_d19a2d112d904b8bb9b627ad113e904f"
      unitRef="U004">1.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20190101to20190331"
      decimals="2"
      id="Fact_68f4a8f3d2df47cfa8896e2ea15ab759"
      unitRef="U004">0.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20190401to20190630"
      decimals="2"
      id="Fact_16eafacc8b6c4c46b58136f0b68b2937"
      unitRef="U004">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20190701to20190930"
      decimals="2"
      id="Fact_2d4ca33cff2c472890862928fc3e81b2"
      unitRef="U004">0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20191001to20191231"
      decimals="2"
      id="Fact_af905ebe97f14c108dd0f43f627bb6f0"
      unitRef="U004">1.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:Revenues
      contextRef="c20180101to20180331"
      decimals="-3"
      id="Fact_5204880f63b443bd81fa12e49662e39e"
      unitRef="U001">144419000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="c20180401to20180630"
      decimals="-3"
      id="Fact_5691cb1907b145f6b282b80ef5adf3e7"
      unitRef="U001">117747000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="c20180701to20180930"
      decimals="-3"
      id="Fact_580cdc588a9a45d787156f145dfd6e74"
      unitRef="U001">145395000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="c20181001to20181231"
      decimals="-3"
      id="Fact_d0af4ac96aec47cfb0e22e39e38be43d"
      unitRef="U001">192113000</us-gaap:Revenues>
    <us-gaap:CostsAndExpenses
      contextRef="c20180101to20180331"
      decimals="-3"
      id="Fact_faeea64b036241e0b02cf5560667b6d0"
      unitRef="U001">147720000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="c20180401to20180630"
      decimals="-3"
      id="Fact_b89203e619464a8a8d711634dd2a54a4"
      unitRef="U001">168028000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="c20180701to20180930"
      decimals="-3"
      id="Fact_6e09fbd1ee99419186761cf8063c181c"
      unitRef="U001">163967000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="c20181001to20181231"
      decimals="-3"
      id="Fact_2ef12b0b1e934c82b2b4fd872862b4b8"
      unitRef="U001">181331000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20180101to20180331"
      decimals="-3"
      id="Fact_ddde75d1e32c4bc8ad8f3d53e587dd94"
      unitRef="U001">-3301000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20180401to20180630"
      decimals="-3"
      id="Fact_c88f114e993d41aaac8521254f951167"
      unitRef="U001">-50281000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20180701to20180930"
      decimals="-3"
      id="Fact_78f6c5253c2c44d7a296c84d2dd8ba33"
      unitRef="U001">-18572000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20181001to20181231"
      decimals="-3"
      id="Fact_08ef991a056947b487e3906f5e0841c0"
      unitRef="U001">10782000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="c20180101to20180331"
      decimals="-3"
      id="Fact_e61281c101e64429aca3f789e110d674"
      unitRef="U001">-10812000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20180401to20180630"
      decimals="-3"
      id="Fact_5b34ea9293b84685a8158429326c6f14"
      unitRef="U001">-56573000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20180701to20180930"
      decimals="-3"
      id="Fact_a32ea718553e43b19f110a461acdad46"
      unitRef="U001">-20365000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c20181001to20181231"
      decimals="-3"
      id="Fact_6d0055893f9641e3866eed897c5a7c63"
      unitRef="U001">302735000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20180101to20180331"
      decimals="-3"
      id="Fact_4a0c58ce78ec4910902158c4525e452d"
      unitRef="U001">-1420000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20180401to20180630"
      decimals="-3"
      id="Fact_8c845df7689446e29d1c1bf0a37fab2e"
      unitRef="U001">-40358000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20180701to20180930"
      decimals="-3"
      id="Fact_12dac20c747c4975a7f4f1577e69ec61"
      unitRef="U001">-4559000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20181001to20181231"
      decimals="-3"
      id="Fact_ba9e92a5bd4e4e859856117256f50207"
      unitRef="U001">320078000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20180101to20180331"
      decimals="2"
      id="Fact_763576c71cab41fb95dcbba53d8fc8b3"
      unitRef="U004">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20180401to20180630"
      decimals="2"
      id="Fact_66c12e16e5ef41b7be87c24864ef5483"
      unitRef="U004">-0.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20180701to20180930"
      decimals="2"
      id="Fact_313f67285e0f464192314b8ac770adc7"
      unitRef="U004">-0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20181001to20181231"
      decimals="2"
      id="Fact_0ce5ff94fbd3419d928cd3c0d9de8ba9"
      unitRef="U004">2.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20180101to20180331"
      decimals="2"
      id="Fact_08e18485edd442aeb6ea55cb7dc5a055"
      unitRef="U004">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20180401to20180630"
      decimals="2"
      id="Fact_8a292b5b2fc640eaaa6c9eddb9c04d14"
      unitRef="U004">-0.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20180701to20180930"
      decimals="2"
      id="Fact_55abe2d19d6a42c689a6863e846a7fea"
      unitRef="U004">-0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20181001to20181231"
      decimals="2"
      id="Fact_f969201be6664a8ba8da16dedbdfffc9"
      unitRef="U004">2.21</us-gaap:EarningsPerShareDiluted>
    <ions:WeightedAverageNumberOfSharesOwnedInSubsidiary
      contextRef="c20190101to20190331_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_1216b48327b7477bb2f422d217a18307"
      unitRef="U002">68582000</ions:WeightedAverageNumberOfSharesOwnedInSubsidiary>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20190101to20190331_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="2"
      id="Fact_799d1133f85c49f39362cc2c835becca"
      unitRef="U004">0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="c20190101to20190331_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_e604af170ed04b548deb692cc50b66fc"
      unitRef="U001">23846000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20190101to20190331_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_26f856a46c2b4e5fb50866b8cb04b29a"
      unitRef="U001">23846000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20190101to20190331_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_c81e9f3e122941018b434df23f66b4c5"
      unitRef="U001">63697000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20190101to20190331"
      decimals="-3"
      id="Fact_e87ae36d3520424eab9b68ccefbc3f46"
      unitRef="U001">87543000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20190101to20190331"
      decimals="-3"
      id="Fact_58327dafdbed4b9eab67dcc9582fe38c"
      unitRef="U002">138582000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20190101to20190331"
      decimals="2"
      id="Fact_cded1266b5a742518086dee9fdfb3f1b"
      unitRef="U004">0.63</us-gaap:EarningsPerShareBasic>
    <ions:WeightedAverageNumberOfSharesOwnedInSubsidiary
      contextRef="c20190401to20190630_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_88c7772a2b124614b9620340a1db2410"
      unitRef="U002">70221000</ions:WeightedAverageNumberOfSharesOwnedInSubsidiary>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20190401to20190630_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="2"
      id="Fact_ce8420ec05674c74b45524f8397e6947"
      unitRef="U004">-0.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="c20190401to20190630_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_6fc555d704cc45e083ec6dcb21be4625"
      unitRef="U001">-28244000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20190401to20190630_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_f1532d4f7130494696c9301fe4a4605c"
      unitRef="U001">-28244000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20190401to20190630_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_9d2998f4fb82407fb38c3c6cae74551e"
      unitRef="U001">27311000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20190401to20190630"
      decimals="-3"
      id="Fact_5d807d32331041009e14eaf1335c36f7"
      unitRef="U001">-933000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20190401to20190630"
      decimals="-3"
      id="Fact_a97a88f6b028439b8b03672135ee2b40"
      unitRef="U002">140247000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20190401to20190630"
      decimals="2"
      id="Fact_9ded035640c84b8089eeec1dac09cd5f"
      unitRef="U004">-0.01</us-gaap:EarningsPerShareBasic>
    <ions:WeightedAverageNumberOfSharesOwnedInSubsidiary
      contextRef="c20190701to20190930_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_83edf38f53a24b64b8b6bd94a8ca5658"
      unitRef="U002">70221000</ions:WeightedAverageNumberOfSharesOwnedInSubsidiary>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20190701to20190930_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="2"
      id="Fact_368309363def4642ac46f2434cabc9d0"
      unitRef="U004">-0.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="c20190701to20190930_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_087e07deab0440bebdc73de289324d1a"
      unitRef="U001">-23772000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20190701to20190930_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_20b89649d34e48249b8e5adb928d2712"
      unitRef="U001">-23772000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20190701to20190930_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_72a432341a4d489ea5258e3ad45a4601"
      unitRef="U001">49930000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20190701to20190930"
      decimals="-3"
      id="Fact_8ec47d7cc67d4462b0ba87428e68c1d1"
      unitRef="U001">26158000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20190701to20190930"
      decimals="-3"
      id="Fact_b4532452076740d5a6203a0b217e9329"
      unitRef="U002">140551000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20190701to20190930"
      decimals="2"
      id="Fact_46edfb3c0a6b49ffb1bbef370451f895"
      unitRef="U004">0.19</us-gaap:EarningsPerShareBasic>
    <ions:WeightedAverageNumberOfSharesOwnedInSubsidiary
      contextRef="c20191001to20191231_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_2e9fe85ccab349ca8d5506c348e2a62a"
      unitRef="U002">71342000</ions:WeightedAverageNumberOfSharesOwnedInSubsidiary>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20191001to20191231_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="2"
      id="Fact_a903c30771cf4bd5b62eebe86cd6fd6d"
      unitRef="U004">0.87</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="c20191001to20191231_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_caa5b7b2a4a24544990e8d31e09125a6"
      unitRef="U001">62243000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20191001to20191231_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_884e7d77348346b49e5227d5ed057f9b"
      unitRef="U001">62243000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20191001to20191231_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_46f6f7a9b6234ec19d304e746c55815c"
      unitRef="U001">121552000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20191001to20191231"
      decimals="-3"
      id="Fact_f9a948d9257f437e994aec65b62081e8"
      unitRef="U001">183795000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20191001to20191231"
      decimals="-3"
      id="Fact_815dfe6768684e6290e270f2d79702f8"
      unitRef="U002">140583000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20191001to20191231"
      decimals="2"
      id="Fact_2977dc798d184957ade439c2afeb14e0"
      unitRef="U004">1.31</us-gaap:EarningsPerShareBasic>
    <ions:WeightedAverageNumberOfSharesOwnedInSubsidiary
      contextRef="c20180101to20180331_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_8db77bf79d71403d84e4278b7edb8914"
      unitRef="U002">45448000</ions:WeightedAverageNumberOfSharesOwnedInSubsidiary>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20180101to20180331_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="2"
      id="Fact_4c9782a2610c438fb25085c943cc0693"
      unitRef="U004">-0.44</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="c20180101to20180331_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_6dd56f27f2784d41868ec6fb9bf431fc"
      unitRef="U001">-19997000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20180101to20180331_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_bf06aa234c5341cdb35faf00ae495b70"
      unitRef="U001">-19997000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20180101to20180331_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_475d550bccca407f9b58b0755d00eb46"
      unitRef="U001">18785000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20180101to20180331"
      decimals="-3"
      id="Fact_9a795de9784940e9aad1ae90b4114c56"
      unitRef="U001">-1212000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20180101to20180331"
      decimals="-3"
      id="Fact_e6d6605951b845078ca1ce96ceea6a96"
      unitRef="U002">125330000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20180101to20180331"
      decimals="2"
      id="Fact_93036c39f03143c9a31348e606869fed"
      unitRef="U004">-0.01</us-gaap:EarningsPerShareBasic>
    <ions:WeightedAverageNumberOfSharesOwnedInSubsidiary
      contextRef="c20180401to20180630_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_52794ae9c4b2481d805373d5dcf5b4b3"
      unitRef="U002">60832000</ions:WeightedAverageNumberOfSharesOwnedInSubsidiary>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20180401to20180630_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="2"
      id="Fact_5cbce9b960094b6ca3b5dfc348800e11"
      unitRef="U004">-0.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="c20180401to20180630_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_35b7599a33924bd29ec74c40b127eed0"
      unitRef="U001">-43814000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20180401to20180630_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_7ce183bea5544ce99568eb14a97b35d2"
      unitRef="U001">-43814000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20180401to20180630_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_58af2114d636404e96f20c6fc372e1d9"
      unitRef="U001">5882000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20180401to20180630"
      decimals="-3"
      id="Fact_9e438608dee94fc99a32689cd2d5a726"
      unitRef="U001">-37932000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20180401to20180630"
      decimals="-3"
      id="Fact_607e907eaed84e20a757c60b736ce5b9"
      unitRef="U002">128712000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20180401to20180630"
      decimals="2"
      id="Fact_2b07a0dfa1f546f480946f41747c98e2"
      unitRef="U004">-0.29</us-gaap:EarningsPerShareBasic>
    <ions:WeightedAverageNumberOfSharesOwnedInSubsidiary
      contextRef="c20180701to20180930_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_fe01f2e6ba89433c8ebe0f79d8de626e"
      unitRef="U002">65538000</ions:WeightedAverageNumberOfSharesOwnedInSubsidiary>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20180701to20180930_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="2"
      id="Fact_cf9cf896ab094238bfb8de8a475025f3"
      unitRef="U004">-0.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="c20180701to20180930_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_57bdfb4cd4bb4987930f793ddf853745"
      unitRef="U001">-47789000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20180701to20180930_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_c42298ded5ea4e20aa09715c73219c96"
      unitRef="U001">-47789000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20180701to20180930_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_93736b7449dd479bb8bf1d62fc201ad1"
      unitRef="U001">43226000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20180701to20180930"
      decimals="-3"
      id="Fact_2eb7d38e7b1e4acc9014b6a612a983ae"
      unitRef="U001">-4563000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20180701to20180930"
      decimals="-3"
      id="Fact_0361de674f3b416ba6083f36403670d3"
      unitRef="U002">137346000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20180701to20180930"
      decimals="2"
      id="Fact_8c347451d45b432291da57ff527bbe07"
      unitRef="U004">-0.03</us-gaap:EarningsPerShareBasic>
    <ions:WeightedAverageNumberOfSharesOwnedInSubsidiary
      contextRef="c20181001to20181231_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_223fbd8edec84d22a431d075f6b021e9"
      unitRef="U002">67130000</ions:WeightedAverageNumberOfSharesOwnedInSubsidiary>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20181001to20181231_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="2"
      id="Fact_480a35ceb8ec4bdab6ad6de10c208d51"
      unitRef="U004">-0.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="c20181001to20181231_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_4b6b562b1b444738b46963f7ab22ab83"
      unitRef="U001">-53219000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20181001to20181231_OwnershipAxis_AkceaTherapeuticsIncMember"
      decimals="-3"
      id="Fact_da4a53325773454293ff741fac8e7648"
      unitRef="U001">-53219000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20181001to20181231_StatementBusinessSegmentsAxis_IonisCoreMember"
      decimals="-3"
      id="Fact_f4ccced4fb204e50861835e5f147707f"
      unitRef="U001">372913000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20181001to20181231"
      decimals="-3"
      id="Fact_ba94acd702cc4643a3b677508da8ad40"
      unitRef="U001">319694000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20181001to20181231"
      decimals="-3"
      id="Fact_933e80e19a314141afb2843f6937af37"
      unitRef="U002">137699000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20181001to20181231"
      decimals="2"
      id="Fact_3d352e6ec8fa4346a84762440947b384"
      unitRef="U004">2.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20190101to20190331"
      decimals="-3"
      id="Fact_4ac638415d964b8b93c21f45fdb098cc"
      unitRef="U001">87543000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20190101to20190331"
      decimals="-3"
      id="Fact_c9da96157a1b4395969239ff01cb2920"
      unitRef="U002">138582000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20190101to20190331"
      decimals="2"
      id="Fact_903d4771485b4358bc027428ec706f85"
      unitRef="U004">0.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c20190101to20190331_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact_31b7afe977814a36919731ca9237457f"
      unitRef="U002">2252000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c20190101to20190331_AwardTypeAxis_RestrictedStockMember"
      decimals="-3"
      id="Fact_1ff39f911f734fb5875ed8bbed315591"
      unitRef="U002">665000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <ions:IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan
      contextRef="c20190101to20190331"
      decimals="-3"
      id="Fact_c7044d0277ca498b8e2dfbc5a2ddc1fd"
      unitRef="U002">38000</ions:IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20190331_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_7a05d15db4e54c92a623574937d6183e"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="c20190101to20190331_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-3"
      id="Fact_936ef83a91964ac3aa661bb2b577b835"
      unitRef="U001">0</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="c20190101to20190331_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-3"
      id="Fact_4437f69579374ad38f076343b0900c91"
      unitRef="U002">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="c20190101to20190331"
      decimals="-3"
      id="Fact_0587e06300254e20a4d0a0207ac53329"
      unitRef="U001">87543000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20190101to20190331"
      decimals="-3"
      id="Fact_eb9d746b433448fd88352d2be3f4668f"
      unitRef="U002">141537000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20190101to20190331"
      decimals="2"
      id="Fact_acf19f9f2a2d454f806cb8c67c3f1221"
      unitRef="U004">0.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20190701to20190930"
      decimals="-3"
      id="Fact_a2e7db14af714d97b8fcb9e454ffad59"
      unitRef="U001">26158000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20190701to20190930"
      decimals="-3"
      id="Fact_37c357f8a90640b0835dd699bddc6b7c"
      unitRef="U002">140551000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20190701to20190930"
      decimals="2"
      id="Fact_5dc13a1ebb204497a09727c28e16985a"
      unitRef="U004">0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c20190701to20190930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact_380ff50e306d4522903deb7f48356023"
      unitRef="U002">1993000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c20190701to20190930_AwardTypeAxis_RestrictedStockMember"
      decimals="-3"
      id="Fact_9bd54d740942472a961376ed64002fab"
      unitRef="U002">844000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <ions:IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan
      contextRef="c20190701to20190930"
      decimals="-3"
      id="Fact_a76a0ba8954044e2bfd6db1397a2240b"
      unitRef="U002">20000</ions:IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20190930_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_04e82bb0d1424192a81e9920608ff298"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="c20190701to20190930_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-3"
      id="Fact_de2d5c0a4048495cb76d4a395a2b5599"
      unitRef="U001">0</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="c20190701to20190930_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-3"
      id="Fact_0bc2c40501dd48c2a51a6f433946a3f4"
      unitRef="U002">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="c20190701to20190930"
      decimals="-3"
      id="Fact_c443cf59a91a4df2961be7e6bd2e98ed"
      unitRef="U001">26158000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20190701to20190930"
      decimals="-3"
      id="Fact_280a96ed03d247af953c06d965812719"
      unitRef="U002">143408000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20190701to20190930"
      decimals="2"
      id="Fact_c6bda12260a24486afece5222821d5c7"
      unitRef="U004">0.18</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20191001to20191231"
      decimals="-3"
      id="Fact_cceaef2c22204a908414bc2f28045442"
      unitRef="U001">183795000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20191001to20191231"
      decimals="-3"
      id="Fact_b83d923230294453aea541f0cd433d52"
      unitRef="U002">140583000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20191001to20191231"
      decimals="2"
      id="Fact_26fc347439824bad93dea56901589229"
      unitRef="U004">1.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c20191001to20191231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact_261405a64e7b42a2864075242c35b9fd"
      unitRef="U002">1467000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c20191001to20191231_AwardTypeAxis_RestrictedStockMember"
      decimals="-3"
      id="Fact_81007694e2e844bd86c089aa743141ba"
      unitRef="U002">848000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <ions:IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan
      contextRef="c20191001to20191231"
      decimals="-3"
      id="Fact_a73965154bf34010a7ae7aff58d873a7"
      unitRef="U002">18000</ions:IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="5"
      id="Fact_1fcaca39a2db4ce499e9fb5e7b7659cb"
      unitRef="U003">0.00125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="c20191001to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="-3"
      id="Fact_cbef44e0f5a9433baad60d1521f098d0"
      unitRef="U001">644000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="c20191001to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember"
      decimals="-3"
      id="Fact_2a64057c1222473ba4bddd213c182709"
      unitRef="U002">860000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_65762f29027f42468a0a3c7099b3f5c1"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="c20191001to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-3"
      id="Fact_02848174582845b899cba8c3ac468ebf"
      unitRef="U001">12046000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="c20191001to20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-3"
      id="Fact_4dff535f8d4c4acfb4ecc1cf03fcc02a"
      unitRef="U002">9527000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="c20191001to20191231"
      decimals="-3"
      id="Fact_ce3cbc4dcd6347a28e0ee3cc46fa7443"
      unitRef="U001">196485000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20191001to20191231"
      decimals="-3"
      id="Fact_984bf13bbf9044a691a42dd3eb008c11"
      unitRef="U002">153303000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20191001to20191231"
      decimals="2"
      id="Fact_92fcf919d3694b338ecfefc170097220"
      unitRef="U004">1.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="c20181001to20181231"
      decimals="-3"
      id="Fact_a711b3e4209a4addafefd5ba790e3924"
      unitRef="U001">319694000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20181001to20181231"
      decimals="-3"
      id="Fact_dcae11cbbf09411c82064edb89209cc1"
      unitRef="U002">137699000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20181001to20181231"
      decimals="2"
      id="Fact_d607a38fcd0f417c91a9e8770288fd33"
      unitRef="U004">2.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c20181001to20181231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="-3"
      id="Fact_66c0753e21d048c1916338f168e89337"
      unitRef="U002">1254000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c20181001to20181231_AwardTypeAxis_RestrictedStockMember"
      decimals="-3"
      id="Fact_7ee0340cd65a4528bbced1df496993e7"
      unitRef="U002">636000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <ions:IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan
      contextRef="c20181001to20181231"
      decimals="-3"
      id="Fact_03b69728caff4c708fea2f9df8ab9c22"
      unitRef="U002">7000</ions:IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_9e657f6f4338497084c4f62d902e54e3"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther
      contextRef="c20181001to20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-3"
      id="Fact_6ae71e31117549879ba639a42ec356ca"
      unitRef="U001">10745000</us-gaap:DilutiveSecuritiesEffectOnBasicEarningsPerShareOther>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="c20181001to20181231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="-3"
      id="Fact_04589a9e03a84687950244aecc7e00f3"
      unitRef="U002">10260000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="c20181001to20181231"
      decimals="-3"
      id="Fact_43f2a0fff211482c90108a69c1a23e52"
      unitRef="U001">330439000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20181001to20181231"
      decimals="-3"
      id="Fact_79d79ed66e074edfb7ef753c4bf456b7"
      unitRef="U002">149856000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20181001to20181231"
      decimals="2"
      id="Fact_8779796f76214f59b2a0c11ee7a79cac"
      unitRef="U004">2.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20190930_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_02416fb2919c4c8b9c6e5dc81b9d57d7"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20190331_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember"
      decimals="2"
      id="Fact_f11ae7226fa64dc9adde56548c8d6e8e"
      unitRef="U003">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_8caafd476a3541b9aef7c098cc041e94"
          xlink:label="Fact_8caafd476a3541b9aef7c098cc041e94"
          xlink:type="locator"/>
        <link:footnote id="Foot_41dc381daf5c41bb92e06d06481bf7a5" xlink:label="Foot_41dc381daf5c41bb92e06d06481bf7a5" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">We hold our available-for-sale securities at amortized cost.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_8caafd476a3541b9aef7c098cc041e94"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_90b66da8071a4a14ae79ae20e35a4725"
          xlink:label="Fact_90b66da8071a4a14ae79ae20e35a4725"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_90b66da8071a4a14ae79ae20e35a4725"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_bc9e70d55b674cc9b6be541478de94e8"
          xlink:label="Fact_bc9e70d55b674cc9b6be541478de94e8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_bc9e70d55b674cc9b6be541478de94e8"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_06b37f3d76b24645b428aed40ef7519d"
          xlink:label="Fact_06b37f3d76b24645b428aed40ef7519d"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_06b37f3d76b24645b428aed40ef7519d"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_4ae16ba11af3451383afc794f381425b"
          xlink:label="Fact_4ae16ba11af3451383afc794f381425b"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_4ae16ba11af3451383afc794f381425b"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_be05404e83c643348777fa91b0e1b9ba"
          xlink:label="Fact_be05404e83c643348777fa91b0e1b9ba"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_be05404e83c643348777fa91b0e1b9ba"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_e4c79d28e0dd438c896e0c5148cdbae0"
          xlink:label="Fact_e4c79d28e0dd438c896e0c5148cdbae0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_e4c79d28e0dd438c896e0c5148cdbae0"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_627bd1dd191a4e2aa0ffcac3c093515e"
          xlink:label="Fact_627bd1dd191a4e2aa0ffcac3c093515e"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_627bd1dd191a4e2aa0ffcac3c093515e"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_160b2612c5ff403daa0b23ecdd2866db"
          xlink:label="Fact_160b2612c5ff403daa0b23ecdd2866db"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_160b2612c5ff403daa0b23ecdd2866db"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_da1b311c89004135b55ecee7befa549d"
          xlink:label="Fact_da1b311c89004135b55ecee7befa549d"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_da1b311c89004135b55ecee7befa549d"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_1a4e37f7b16f498caa99b193ac3977d1"
          xlink:label="Fact_1a4e37f7b16f498caa99b193ac3977d1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_1a4e37f7b16f498caa99b193ac3977d1"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_267f46317f0b40caa2f037611c038a1e"
          xlink:label="Fact_267f46317f0b40caa2f037611c038a1e"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_267f46317f0b40caa2f037611c038a1e"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_f17e37bd45aa4fdbae4827a34aa7dac9"
          xlink:label="Fact_f17e37bd45aa4fdbae4827a34aa7dac9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_f17e37bd45aa4fdbae4827a34aa7dac9"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_a5e37551797746d7832fc5653898ad64"
          xlink:label="Fact_a5e37551797746d7832fc5653898ad64"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_a5e37551797746d7832fc5653898ad64"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_3b50fc36268c472c83543a498f74c6a3"
          xlink:label="Fact_3b50fc36268c472c83543a498f74c6a3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_3b50fc36268c472c83543a498f74c6a3"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_f91f4bf7895e4255b6fb1606547e04c4"
          xlink:label="Fact_f91f4bf7895e4255b6fb1606547e04c4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_f91f4bf7895e4255b6fb1606547e04c4"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_c9d17af33c554c64ac738dfbdb48494c"
          xlink:label="Fact_c9d17af33c554c64ac738dfbdb48494c"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_c9d17af33c554c64ac738dfbdb48494c"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_68c90e44ae7142faa5c935422fe6ca01"
          xlink:label="Fact_68c90e44ae7142faa5c935422fe6ca01"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_68c90e44ae7142faa5c935422fe6ca01"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_f00bcd75b4b842ec98fdc045c48c2576"
          xlink:label="Fact_f00bcd75b4b842ec98fdc045c48c2576"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_f00bcd75b4b842ec98fdc045c48c2576"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_2665cd241db44217ad8643b9ae2a63da"
          xlink:label="Fact_2665cd241db44217ad8643b9ae2a63da"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_2665cd241db44217ad8643b9ae2a63da"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_b71803caad4d4886ad41f6bbc5e209f5"
          xlink:label="Fact_b71803caad4d4886ad41f6bbc5e209f5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_b71803caad4d4886ad41f6bbc5e209f5"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_8ea119980dc64034994a6b7ad86f848c"
          xlink:label="Fact_8ea119980dc64034994a6b7ad86f848c"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_8ea119980dc64034994a6b7ad86f848c"
          xlink:to="Foot_41dc381daf5c41bb92e06d06481bf7a5"
          xlink:type="arc"/>
        <link:footnote id="Foot_88fe67a8cca841eaa8660167eec626fe" xlink:label="Foot_88fe67a8cca841eaa8660167eec626fe" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Includes investments classified as cash equivalents on our consolidated balance sheet.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_bc9e70d55b674cc9b6be541478de94e8"
          xlink:to="Foot_88fe67a8cca841eaa8660167eec626fe"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_f00bcd75b4b842ec98fdc045c48c2576"
          xlink:to="Foot_88fe67a8cca841eaa8660167eec626fe"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_2665cd241db44217ad8643b9ae2a63da"
          xlink:to="Foot_88fe67a8cca841eaa8660167eec626fe"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_8ea119980dc64034994a6b7ad86f848c"
          xlink:to="Foot_88fe67a8cca841eaa8660167eec626fe"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_d0fdecfde0594969b57923784dc22c4e"
          xlink:label="Fact_d0fdecfde0594969b57923784dc22c4e"
          xlink:type="locator"/>
        <link:footnote id="Foot_cc6012bb3041434399bdb287399a913a" xlink:label="Foot_cc6012bb3041434399bdb287399a913a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">$0.8 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_d0fdecfde0594969b57923784dc22c4e"
          xlink:to="Foot_cc6012bb3041434399bdb287399a913a"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_476f612dfc4a4ddc8171ae7717eec530"
          xlink:label="Fact_476f612dfc4a4ddc8171ae7717eec530"
          xlink:type="locator"/>
        <link:footnote id="Foot_7f9ebb5194d04d4294eb3dd811ff49fa" xlink:label="Foot_7f9ebb5194d04d4294eb3dd811ff49fa" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">$50.2 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_476f612dfc4a4ddc8171ae7717eec530"
          xlink:to="Foot_7f9ebb5194d04d4294eb3dd811ff49fa"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_2306dcbd35634a0485a18bef2da7300e"
          xlink:label="Fact_2306dcbd35634a0485a18bef2da7300e"
          xlink:type="locator"/>
        <link:footnote id="Foot_f0e1d58ea08e4b55a4c7703dd1e397d3" xlink:label="Foot_f0e1d58ea08e4b55a4c7703dd1e397d3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in short-term investments.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_2306dcbd35634a0485a18bef2da7300e"
          xlink:to="Foot_f0e1d58ea08e4b55a4c7703dd1e397d3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_21a61427c87a455b8534f57a12968f6a"
          xlink:label="Fact_21a61427c87a455b8534f57a12968f6a"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_21a61427c87a455b8534f57a12968f6a"
          xlink:to="Foot_f0e1d58ea08e4b55a4c7703dd1e397d3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_25150245f8544078baf644d29cdc825a"
          xlink:label="Fact_25150245f8544078baf644d29cdc825a"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_25150245f8544078baf644d29cdc825a"
          xlink:to="Foot_f0e1d58ea08e4b55a4c7703dd1e397d3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_bfc11b60b8204c22927b5f6205cfe9b4"
          xlink:label="Fact_bfc11b60b8204c22927b5f6205cfe9b4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_bfc11b60b8204c22927b5f6205cfe9b4"
          xlink:to="Foot_f0e1d58ea08e4b55a4c7703dd1e397d3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_373fed9ce3ba443a8feb7284438f4bb6"
          xlink:label="Fact_373fed9ce3ba443a8feb7284438f4bb6"
          xlink:type="locator"/>
        <link:footnote id="Foot_e11deb538669403f9b23668e7ec77e3b" xlink:label="Foot_e11deb538669403f9b23668e7ec77e3b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">$14.2 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_373fed9ce3ba443a8feb7284438f4bb6"
          xlink:to="Foot_e11deb538669403f9b23668e7ec77e3b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_a48bf0d7ba1349e58e4936fc5037bb76"
          xlink:label="Fact_a48bf0d7ba1349e58e4936fc5037bb76"
          xlink:type="locator"/>
        <link:footnote id="Foot_77eb85d4142a44a68a7c6b25a7169d1c" xlink:label="Foot_77eb85d4142a44a68a7c6b25a7169d1c" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">$19.0 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_a48bf0d7ba1349e58e4936fc5037bb76"
          xlink:to="Foot_77eb85d4142a44a68a7c6b25a7169d1c"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_c119be8fc8d4422e8e8714cae28a1b7d"
          xlink:label="Fact_c119be8fc8d4422e8e8714cae28a1b7d"
          xlink:type="locator"/>
        <link:footnote id="Foot_ad43559c353f456eac7c04729a412d6f" xlink:label="Foot_ad43559c353f456eac7c04729a412d6f" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in cash and cash equivalents on our consolidated balance sheet.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_c119be8fc8d4422e8e8714cae28a1b7d"
          xlink:to="Foot_ad43559c353f456eac7c04729a412d6f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_c019e6ae06e64200907ceaf6cd9642e2"
          xlink:label="Fact_c019e6ae06e64200907ceaf6cd9642e2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_c019e6ae06e64200907ceaf6cd9642e2"
          xlink:to="Foot_ad43559c353f456eac7c04729a412d6f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_04d37423456f431eae8b542d5d3b0213"
          xlink:label="Fact_04d37423456f431eae8b542d5d3b0213"
          xlink:type="locator"/>
        <link:footnote id="Foot_4e4fe8e547864dd797e4a2e01acbee32" xlink:label="Foot_4e4fe8e547864dd797e4a2e01acbee32" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">For our 1% Notes, our effective interest rate represents our effective interest rate after our December 2019 debt exchange.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_04d37423456f431eae8b542d5d3b0213"
          xlink:to="Foot_4e4fe8e547864dd797e4a2e01acbee32"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_af905ebe97f14c108dd0f43f627bb6f0"
          xlink:label="Fact_af905ebe97f14c108dd0f43f627bb6f0"
          xlink:type="locator"/>
        <link:footnote id="Foot_260ceacf638c4b6691c7c678cfe81725" xlink:label="Foot_260ceacf638c4b6691c7c678cfe81725" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">We computed net income (loss) per share independently for each of the quarters presented. Therefore, the sum of the quarterly net income (loss) per share will not necessarily equal the total for the year.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_af905ebe97f14c108dd0f43f627bb6f0"
          xlink:to="Foot_260ceacf638c4b6691c7c678cfe81725"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_2d4ca33cff2c472890862928fc3e81b2"
          xlink:label="Fact_2d4ca33cff2c472890862928fc3e81b2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_2d4ca33cff2c472890862928fc3e81b2"
          xlink:to="Foot_260ceacf638c4b6691c7c678cfe81725"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_8a292b5b2fc640eaaa6c9eddb9c04d14"
          xlink:label="Fact_8a292b5b2fc640eaaa6c9eddb9c04d14"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_8a292b5b2fc640eaaa6c9eddb9c04d14"
          xlink:to="Foot_260ceacf638c4b6691c7c678cfe81725"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_55abe2d19d6a42c689a6863e846a7fea"
          xlink:label="Fact_55abe2d19d6a42c689a6863e846a7fea"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_55abe2d19d6a42c689a6863e846a7fea"
          xlink:to="Foot_260ceacf638c4b6691c7c678cfe81725"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_08e18485edd442aeb6ea55cb7dc5a055"
          xlink:label="Fact_08e18485edd442aeb6ea55cb7dc5a055"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_08e18485edd442aeb6ea55cb7dc5a055"
          xlink:to="Foot_260ceacf638c4b6691c7c678cfe81725"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_16eafacc8b6c4c46b58136f0b68b2937"
          xlink:label="Fact_16eafacc8b6c4c46b58136f0b68b2937"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_16eafacc8b6c4c46b58136f0b68b2937"
          xlink:to="Foot_260ceacf638c4b6691c7c678cfe81725"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_68f4a8f3d2df47cfa8896e2ea15ab759"
          xlink:label="Fact_68f4a8f3d2df47cfa8896e2ea15ab759"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_68f4a8f3d2df47cfa8896e2ea15ab759"
          xlink:to="Foot_260ceacf638c4b6691c7c678cfe81725"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_f969201be6664a8ba8da16dedbdfffc9"
          xlink:label="Fact_f969201be6664a8ba8da16dedbdfffc9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_f969201be6664a8ba8da16dedbdfffc9"
          xlink:to="Foot_260ceacf638c4b6691c7c678cfe81725"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_66c12e16e5ef41b7be87c24864ef5483"
          xlink:label="Fact_66c12e16e5ef41b7be87c24864ef5483"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_66c12e16e5ef41b7be87c24864ef5483"
          xlink:to="Foot_260ceacf638c4b6691c7c678cfe81725"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_8e3aff85017d49ac81262282323b3438"
          xlink:label="Fact_8e3aff85017d49ac81262282323b3438"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_8e3aff85017d49ac81262282323b3438"
          xlink:to="Foot_260ceacf638c4b6691c7c678cfe81725"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_d19a2d112d904b8bb9b627ad113e904f"
          xlink:label="Fact_d19a2d112d904b8bb9b627ad113e904f"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_d19a2d112d904b8bb9b627ad113e904f"
          xlink:to="Foot_260ceacf638c4b6691c7c678cfe81725"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_313f67285e0f464192314b8ac770adc7"
          xlink:label="Fact_313f67285e0f464192314b8ac770adc7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_313f67285e0f464192314b8ac770adc7"
          xlink:to="Foot_260ceacf638c4b6691c7c678cfe81725"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_c12cf7abb66848b497c1b0fdca78f316"
          xlink:label="Fact_c12cf7abb66848b497c1b0fdca78f316"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_c12cf7abb66848b497c1b0fdca78f316"
          xlink:to="Foot_260ceacf638c4b6691c7c678cfe81725"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_0ce5ff94fbd3419d928cd3c0d9de8ba9"
          xlink:label="Fact_0ce5ff94fbd3419d928cd3c0d9de8ba9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_0ce5ff94fbd3419d928cd3c0d9de8ba9"
          xlink:to="Foot_260ceacf638c4b6691c7c678cfe81725"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_763576c71cab41fb95dcbba53d8fc8b3"
          xlink:label="Fact_763576c71cab41fb95dcbba53d8fc8b3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_763576c71cab41fb95dcbba53d8fc8b3"
          xlink:to="Foot_260ceacf638c4b6691c7c678cfe81725"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_ab7ddc03812d45bba8a6590bbdaa6412"
          xlink:label="Fact_ab7ddc03812d45bba8a6590bbdaa6412"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_ab7ddc03812d45bba8a6590bbdaa6412"
          xlink:to="Foot_260ceacf638c4b6691c7c678cfe81725"
          xlink:type="arc"/>
        <link:footnote id="Foot_f63ff29e56764f3485555958bff3cab9" xlink:label="Foot_f63ff29e56764f3485555958bff3cab9" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">We had net income available to Ionis common stockholders for the following periods. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during those periods.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_af905ebe97f14c108dd0f43f627bb6f0"
          xlink:to="Foot_f63ff29e56764f3485555958bff3cab9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_2d4ca33cff2c472890862928fc3e81b2"
          xlink:to="Foot_f63ff29e56764f3485555958bff3cab9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_68f4a8f3d2df47cfa8896e2ea15ab759"
          xlink:to="Foot_f63ff29e56764f3485555958bff3cab9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_f969201be6664a8ba8da16dedbdfffc9"
          xlink:to="Foot_f63ff29e56764f3485555958bff3cab9"
          xlink:type="arc"/>
        <link:footnote id="Foot_3d79790158204fcc95642c2ca83c4b8f" xlink:label="Foot_3d79790158204fcc95642c2ca83c4b8f" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">For the three months ended March 31, 2019 and September 30, 2019, the calculation excluded the 1 percent notes because the effect on diluted earnings per share was anti-dilutive.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_2d4ca33cff2c472890862928fc3e81b2"
          xlink:to="Foot_3d79790158204fcc95642c2ca83c4b8f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_68f4a8f3d2df47cfa8896e2ea15ab759"
          xlink:to="Foot_3d79790158204fcc95642c2ca83c4b8f"
          xlink:type="arc"/>
        <link:footnote id="Foot_94f9411e48574896ba56a419ae90ffb3" xlink:label="Foot_94f9411e48574896ba56a419ae90ffb3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">As discussed in Note 1, Organization and Significant Accounting Policies, we compute basic net income (loss) per share by dividing the total net income (loss) attributable to our common stockholders by our weighted-average number of common shares outstanding during the period. Our basic net income (loss) per share calculation for each of the quarters in 2019 and 2018 considered our net income for Ionis on a stand-alone basis plus our share of Akcea&#x2019;s net loss for the period. To calculate the portion of Akcea&#x2019;s net loss attributable to our ownership, we multiplied Akcea&#x2019;s loss per share by the weighted average shares we owned in Akcea during the period. As a result of this calculation, our total net income (loss) available to Ionis common stockholders for the calculation of net income (loss) per share is different than net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders in the consolidated statements of operations.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_66c12e16e5ef41b7be87c24864ef5483"
          xlink:to="Foot_94f9411e48574896ba56a419ae90ffb3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_8e3aff85017d49ac81262282323b3438"
          xlink:to="Foot_94f9411e48574896ba56a419ae90ffb3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_d19a2d112d904b8bb9b627ad113e904f"
          xlink:to="Foot_94f9411e48574896ba56a419ae90ffb3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_313f67285e0f464192314b8ac770adc7"
          xlink:to="Foot_94f9411e48574896ba56a419ae90ffb3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_c12cf7abb66848b497c1b0fdca78f316"
          xlink:to="Foot_94f9411e48574896ba56a419ae90ffb3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_0ce5ff94fbd3419d928cd3c0d9de8ba9"
          xlink:to="Foot_94f9411e48574896ba56a419ae90ffb3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_763576c71cab41fb95dcbba53d8fc8b3"
          xlink:to="Foot_94f9411e48574896ba56a419ae90ffb3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_ab7ddc03812d45bba8a6590bbdaa6412"
          xlink:to="Foot_94f9411e48574896ba56a419ae90ffb3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_9ebd36323e384809b15acae0a3551932"
          xlink:label="Fact_9ebd36323e384809b15acae0a3551932"
          xlink:type="locator"/>
        <link:footnote id="Foot_92f3ab0ee45a44b9baf44a6e4c6792b4" xlink:label="Foot_92f3ab0ee45a44b9baf44a6e4c6792b4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Our equity securities included in deposits and other assets consisted of our investment in Empirico, which is a private company. We recognize our private company equity securities at cost minus impairments, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer on our consolidated balance sheet.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_9ebd36323e384809b15acae0a3551932"
          xlink:to="Foot_92f3ab0ee45a44b9baf44a6e4c6792b4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_ddb646a5d0f1447b92caf9f07a627fcd"
          xlink:label="Fact_ddb646a5d0f1447b92caf9f07a627fcd"
          xlink:type="locator"/>
        <link:footnote id="Foot_33f87045331d4d29a03153170558d0a1" xlink:label="Foot_33f87045331d4d29a03153170558d0a1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Our equity securities included in other current assets consisted of our investment in ProQR, which is a public company. We recognize our public company equity securities at fair value.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_ddb646a5d0f1447b92caf9f07a627fcd"
          xlink:to="Foot_33f87045331d4d29a03153170558d0a1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_cef09f69ddec4b3dabee2b4ce3e2377b"
          xlink:label="Fact_cef09f69ddec4b3dabee2b4ce3e2377b"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_cef09f69ddec4b3dabee2b4ce3e2377b"
          xlink:to="Foot_33f87045331d4d29a03153170558d0a1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_2b37972d666b46d1ac6f9e2f013208f4"
          xlink:label="Fact_2b37972d666b46d1ac6f9e2f013208f4"
          xlink:type="locator"/>
        <link:footnote id="Foot_c498c367d1f949d4a789172bf48c4121" xlink:label="Foot_c498c367d1f949d4a789172bf48c4121" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in other current assets on our consolidated balance sheet.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_2b37972d666b46d1ac6f9e2f013208f4"
          xlink:to="Foot_c498c367d1f949d4a789172bf48c4121"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_3ad78e1baf8a45d8baedda5ec0ee15d5"
          xlink:label="Fact_3ad78e1baf8a45d8baedda5ec0ee15d5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_3ad78e1baf8a45d8baedda5ec0ee15d5"
          xlink:to="Foot_c498c367d1f949d4a789172bf48c4121"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_cc2b624b002347aca5b376689005c704"
          xlink:label="Fact_cc2b624b002347aca5b376689005c704"
          xlink:type="locator"/>
        <link:footnote id="Foot_c173053f21eb48f2baac71e2bf36f606" xlink:label="Foot_c173053f21eb48f2baac71e2bf36f606" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">A tax benefit of $1.4 million and $0.3 million was included in other comprehensive loss for the years ended December 31, 2019 and 2018, respectively. There was no tax benefit or expense for other comprehensive loss for the year ended December 31, 2017.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_cc2b624b002347aca5b376689005c704"
          xlink:to="Foot_c173053f21eb48f2baac71e2bf36f606"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_f4bc7becd02b4abe8419122ceb5ec217"
          xlink:label="Fact_f4bc7becd02b4abe8419122ceb5ec217"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_f4bc7becd02b4abe8419122ceb5ec217"
          xlink:to="Foot_c173053f21eb48f2baac71e2bf36f606"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_8f26788799e14b9bb1344435140f818a"
          xlink:label="Fact_8f26788799e14b9bb1344435140f818a"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_8f26788799e14b9bb1344435140f818a"
          xlink:to="Foot_c173053f21eb48f2baac71e2bf36f606"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_dd04e3efb270478489cafc35f9191531"
          xlink:label="Fact_dd04e3efb270478489cafc35f9191531"
          xlink:type="locator"/>
        <link:footnote id="Foot_9a970986ba874d05b3ae45569fb070a7" xlink:label="Foot_9a970986ba874d05b3ae45569fb070a7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Our $12.5 million fixed rate note with Morgan Stanley was included in our current portion of long-term obligations on our consolidated balance sheet at December 31, 2018. We paid off our fixed rate note in the third quarter of 2019.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_dd04e3efb270478489cafc35f9191531"
          xlink:to="Foot_9a970986ba874d05b3ae45569fb070a7"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6887811040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity, Stock-based Valuation Information (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-Average Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">60.30%<span></span>
</td>
<td class="nump">63.00%<span></span>
</td>
<td class="nump">65.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ions_BoardOfDirectorStockOptionMember', window );">Board of Director Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-Average Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">60.70%<span></span>
</td>
<td class="nump">61.50%<span></span>
</td>
<td class="nump">61.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-Average Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">45.60%<span></span>
</td>
<td class="nump">47.30%<span></span>
</td>
<td class="nump">59.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | Employee Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-Average Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">75.40%<span></span>
</td>
<td class="nump">77.10%<span></span>
</td>
<td class="nump">79.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 21 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | Board of Director Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-Average Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">73.80%<span></span>
</td>
<td class="nump">78.20%<span></span>
</td>
<td class="nump">79.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 5 months 1 day<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-Average Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">64.20%<span></span>
</td>
<td class="nump">73.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ions_BoardOfDirectorStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ions_BoardOfDirectorStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>652</ContextCount>
  <ElementCount>620</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>150</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>19</UnitCount>
  <MyReports>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>030000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>040000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>040100 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>050000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>050100 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>060100 - Disclosure - Organization and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>060200 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>060300 - Disclosure - Long-Term Obligations and Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/LongtermObligationsAndCommitments</Role>
      <ShortName>Long-Term Obligations and Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>060400 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>060500 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>060600 - Disclosure - Collaborative Arrangements and Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreements</Role>
      <ShortName>Collaborative Arrangements and Licensing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>060700 - Disclosure - Segment Information and Concentration of Business Risk</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRisk</Role>
      <ShortName>Segment Information and Concentration of Business Risk</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>060800 - Disclosure - Employment Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/EmploymentBenefits</Role>
      <ShortName>Employment Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>060900 - Disclosure - Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/LegalProceedings</Role>
      <ShortName>Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>061000 - Disclosure - Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/QuarterlyFinancialDataUnaudited</Role>
      <ShortName>Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>070100 - Disclosure - Organization and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://isispharm.com/role/OrganizationAndSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>080100 - Disclosure - Organization and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://isispharm.com/role/OrganizationAndSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>080200 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://isispharm.com/role/Investments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>080300 - Disclosure - Long-Term Obligations and Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/LongtermObligationsAndCommitmentsTables</Role>
      <ShortName>Long-Term Obligations and Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://isispharm.com/role/LongtermObligationsAndCommitments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>080400 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://isispharm.com/role/StockholdersEquity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>080500 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://isispharm.com/role/IncomeTaxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>080600 - Disclosure - Collaborative Arrangements and Licensing Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables</Role>
      <ShortName>Collaborative Arrangements and Licensing Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>080700 - Disclosure - Segment Information and Concentration of Business Risk (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskTables</Role>
      <ShortName>Segment Information and Concentration of Business Risk (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRisk</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>081000 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/QuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://isispharm.com/role/QuarterlyFinancialDataUnaudited</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>090100 - Disclosure - Organization and Significant Accounting Policies, Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails</Role>
      <ShortName>Organization and Significant Accounting Policies, Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>090102 - Disclosure - Organization and Significant Accounting Policies, Basic and Diluted Net Income per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails</Role>
      <ShortName>Organization and Significant Accounting Policies, Basic and Diluted Net Income per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>090104 - Disclosure - Organization and Significant Accounting Policies, Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails</Role>
      <ShortName>Organization and Significant Accounting Policies, Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>090106 - Disclosure - Organization and Significant Accounting Policies, Contracts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesContractsReceivableDetails</Role>
      <ShortName>Organization and Significant Accounting Policies, Contracts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>090108 - Disclosure - Organization and Significant Accounting Policies, Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesDeferredRevenueDetails</Role>
      <ShortName>Organization and Significant Accounting Policies, Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>090110 - Disclosure - Organization and Significant Accounting Policies, Cost of Products Sold (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesCostOfProductsSoldDetails</Role>
      <ShortName>Organization and Significant Accounting Policies, Cost of Products Sold (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>090112 - Disclosure - Organization and Significant Accounting Policies, Research, Development and Patent Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails</Role>
      <ShortName>Organization and Significant Accounting Policies, Research, Development and Patent Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>090114 - Disclosure - Organization and Significant Accounting Policies, Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails</Role>
      <ShortName>Organization and Significant Accounting Policies, Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>090116 - Disclosure - Organization and Significant Accounting Policies, Noncontrolling Interest in Akcea Therapeutics, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails</Role>
      <ShortName>Organization and Significant Accounting Policies, Noncontrolling Interest in Akcea Therapeutics, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>090118 - Disclosure - Organization and Significant Accounting Policies, Cash, Cash Equivalents and Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndInvestmentsDetails</Role>
      <ShortName>Organization and Significant Accounting Policies, Cash, Cash Equivalents and Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>090120 - Disclosure - Organization and Significant Accounting Policies, Inventory Valuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails</Role>
      <ShortName>Organization and Significant Accounting Policies, Inventory Valuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>090122 - Disclosure - Organization and Significant Accounting Policies, Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Organization and Significant Accounting Policies, Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>090124 - Disclosure - Organization and Significant Accounting Policies, Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLeasesDetails</Role>
      <ShortName>Organization and Significant Accounting Policies, Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>090126 - Disclosure - Organization and Significant Accounting Policies, Long-Lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLonglivedAssetsDetails</Role>
      <ShortName>Organization and Significant Accounting Policies, Long-Lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>090128 - Disclosure - Organization and Significant Accounting Policies, Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesStockbasedCompensationExpenseDetails</Role>
      <ShortName>Organization and Significant Accounting Policies, Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>090130 - Disclosure - Organization and Significant Accounting Policies, Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Organization and Significant Accounting Policies, Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>090132 - Disclosure - Organization and Significant Accounting Policies, Convertible Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesConvertibleDebtDetails</Role>
      <ShortName>Organization and Significant Accounting Policies, Convertible Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>090134 - Disclosure - Organization and Significant Accounting Policies, Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesSegmentInformationDetails</Role>
      <ShortName>Organization and Significant Accounting Policies, Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>090136 - Disclosure - Organization and Significant Accounting Policies, Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails</Role>
      <ShortName>Organization and Significant Accounting Policies, Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>090200 - Disclosure - Investments, Contract Maturity of Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Investments, Contract Maturity of Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>090202 - Disclosure - Investments, Summary of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails</Role>
      <ShortName>Investments, Summary of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>090204 - Disclosure - Investments, Investments Temporarily Impaired (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails</Role>
      <ShortName>Investments, Investments Temporarily Impaired (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>090300 - Disclosure - Long-Term Obligations and Commitments, Long-Term Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails</Role>
      <ShortName>Long-Term Obligations and Commitments, Long-Term Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>090302 - Disclosure - Long-Term Obligations and Commitments, Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails</Role>
      <ShortName>Long-Term Obligations and Commitments, Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>090304 - Disclosure - Long-Term Obligations and Commitments, Line of Credit Arrangement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails</Role>
      <ShortName>Long-Term Obligations and Commitments, Line of Credit Arrangement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>090306 - Disclosure - Long-Term Obligations and Commitments, Research and Development and Manufacturing Facilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails</Role>
      <ShortName>Long-Term Obligations and Commitments, Research and Development and Manufacturing Facilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>090308 - Disclosure - Long-Term Obligations and Commitments, Maturity Schedules (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails</Role>
      <ShortName>Long-Term Obligations and Commitments, Maturity Schedules (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>090310 - Disclosure - Long-Term Obligations and Commitments, Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails</Role>
      <ShortName>Long-Term Obligations and Commitments, Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>090400 - Disclosure - Stockholders' Equity, Preferred and Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails</Role>
      <ShortName>Stockholders' Equity, Preferred and Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>090402 - Disclosure - Stockholders' Equity, Share Repurchase Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/StockholdersEquityShareRepurchaseProgramDetails</Role>
      <ShortName>Stockholders' Equity, Share Repurchase Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>090404 - Disclosure - Stockholders' Equity, Stock Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/StockholdersEquityStockPlansDetails</Role>
      <ShortName>Stockholders' Equity, Stock Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>090406 - Disclosure - Stockholders' Equity, Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity, Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>090408 - Disclosure - Stockholders' Equity, Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stockholders' Equity, Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>090410 - Disclosure - Stockholders' Equity, Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/StockholdersEquityStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity, Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>090412 - Disclosure - Stockholders' Equity, Stock-based Valuation Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails</Role>
      <ShortName>Stockholders' Equity, Stock-based Valuation Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>090500 - Disclosure - Income Taxes, Income (Loss) Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes, Income (Loss) Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>090502 - Disclosure - Income Taxes, Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes, Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>090504 - Disclosure - Income Taxes, Reconciliation of Statutory to Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes, Reconciliation of Statutory to Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>090506 - Disclosure - Income Taxes, Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes, Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>090508 - Disclosure - Income Taxes, Tax Credit Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/IncomeTaxesTaxCreditCarryforwardsDetails</Role>
      <ShortName>Income Taxes, Tax Credit Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>090510 - Disclosure - Income Taxes, Tax Act (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/IncomeTaxesTaxActDetails</Role>
      <ShortName>Income Taxes, Tax Act (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>090512 - Disclosure - Income Taxes, Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes, Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>090600 - Disclosure - Collaborative Arrangements and Licensing Agreements, Biogen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails</Role>
      <ShortName>Collaborative Arrangements and Licensing Agreements, Biogen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>090602 - Disclosure - Collaborative Arrangements and Licensing Agreements, AstraZeneca (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails</Role>
      <ShortName>Collaborative Arrangements and Licensing Agreements, AstraZeneca (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>090604 - Disclosure - Collaborative Arrangements and Licensing Agreements, Bayer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails</Role>
      <ShortName>Collaborative Arrangements and Licensing Agreements, Bayer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>090606 - Disclosure - Collaborative Arrangements and Licensing Agreements, GSK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails</Role>
      <ShortName>Collaborative Arrangements and Licensing Agreements, GSK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>090608 - Disclosure - Collaborative Arrangements and Licensing Agreements, Janssen Biotech, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails</Role>
      <ShortName>Collaborative Arrangements and Licensing Agreements, Janssen Biotech, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>090610 - Disclosure - Collaborative Arrangements and Licensing Agreements, Roche (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails</Role>
      <ShortName>Collaborative Arrangements and Licensing Agreements, Roche (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>090612 - Disclosure - Collaborative Arrangements and Licensing Agreements, Novartis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails</Role>
      <ShortName>Collaborative Arrangements and Licensing Agreements, Novartis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>090614 - Disclosure - Collaborative Arrangements and Licensing Agreements, Pfizer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails</Role>
      <ShortName>Collaborative Arrangements and Licensing Agreements, Pfizer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>090616 - Disclosure - Collaborative Arrangements and Licensing Agreements, PTC Therapeutics (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails</Role>
      <ShortName>Collaborative Arrangements and Licensing Agreements, PTC Therapeutics (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>090700 - Disclosure - Segment Information and Concentration of Business Risk, Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails</Role>
      <ShortName>Segment Information and Concentration of Business Risk, Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>090702 - Disclosure - Segment Information and Concentration of Business Risk, Contracts Receivable from Significant Partners (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails</Role>
      <ShortName>Segment Information and Concentration of Business Risk, Contracts Receivable from Significant Partners (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>090800 - Disclosure - Employment Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/EmploymentBenefitsDetails</Role>
      <ShortName>Employment Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://isispharm.com/role/EmploymentBenefits</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="form10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>091000 - Disclosure - Quarterly Financial Data (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://isispharm.com/role/QuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="form10k.htm">form10k.htm</File>
    <File>exhibit10_70.htm</File>
    <File>exhibit21_1.htm</File>
    <File>exhibit23_1.htm</File>
    <File>exhibit31_1.htm</File>
    <File>exhibit31_2.htm</File>
    <File>exhibit32_1.htm</File>
    <File>exhibit4_9.htm</File>
    <File>ions-20191231.xsd</File>
    <File>ions-20191231_cal.xml</File>
    <File>ions-20191231_def.xml</File>
    <File>ions-20191231_lab.xml</File>
    <File>ions-20191231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image1.jpg</File>
    <File>image10.jpg</File>
    <File>image11.jpg</File>
    <File>image12.jpg</File>
    <File>image13.jpg</File>
    <File>image14.jpg</File>
    <File>image15.jpg</File>
    <File>image16.jpg</File>
    <File>image17.jpg</File>
    <File>image4.jpg</File>
    <File>image5.jpg</File>
    <File>image6.jpg</File>
    <File>image7.jpg</File>
    <File>image8.jpg</File>
    <File>image9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6874736656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies, Basis of Presentation (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_SharesReceivedFromSubsidiaryForLicenseOfDrug', window );">Additional shares of Akcea stock received for license of AKCEA-ANGPTL3-L</a></td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage ownership</a></td>
<td class="nump">76.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage ownership</a></td>
<td class="nump">68.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage ownership</a></td>
<td class="nump">77.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_SharesReceivedFromSubsidiaryForLicenseOfDrug">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of additional shares of stock received from Akcea Therapeutics, Inc. as a sublicense fee in connection with Pfizer licensing AKCEA-ANGPTL3-L.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_SharesReceivedFromSubsidiaryForLicenseOfDrug</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ions_AkceaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ions_AkceaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6892968864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 683,287<span></span>
</td>
<td class="nump">$ 278,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">1,816,257<span></span>
</td>
<td class="nump">1,805,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contracts receivable</a></td>
<td class="nump">63,034<span></span>
</td>
<td class="nump">12,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">18,180<span></span>
</td>
<td class="nump">8,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">139,839<span></span>
</td>
<td class="nump">102,473<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">2,720,597<span></span>
</td>
<td class="nump">2,207,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">153,651<span></span>
</td>
<td class="nump">132,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Patents, net</a></td>
<td class="nump">25,674<span></span>
</td>
<td class="nump">24,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Long-term deferred tax assets</a></td>
<td class="nump">305,557<span></span>
</td>
<td class="nump">290,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Deposits and other assets</a></td>
<td class="nump">27,633<span></span>
</td>
<td class="nump">12,910<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">3,233,112<span></span>
</td>
<td class="nump">2,667,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">16,067<span></span>
</td>
<td class="nump">28,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">37,357<span></span>
</td>
<td class="nump">29,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">66,769<span></span>
</td>
<td class="nump">47,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="nump">32,514<span></span>
</td>
<td class="nump">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term obligations</a></td>
<td class="nump">2,026<span></span>
</td>
<td class="nump">13,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred contract revenue</a></td>
<td class="nump">118,272<span></span>
</td>
<td class="nump">160,256<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">273,005<span></span>
</td>
<td class="nump">280,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term deferred contract revenue</a></td>
<td class="nump">490,060<span></span>
</td>
<td class="nump">567,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_LongTermObligationsNoncurrent', window );">Long-term obligations, less current portion</a></td>
<td class="nump">15,543<span></span>
</td>
<td class="nump">4,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansFromBank', window );">Long-term mortgage debt</a></td>
<td class="nump">59,913<span></span>
</td>
<td class="nump">59,842<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,548,565<span></span>
</td>
<td class="nump">1,480,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 300,000,000 shares authorized, 140,339,615 and 137,928,828 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,203,778<span></span>
</td>
<td class="nump">2,047,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(25,290)<span></span>
</td>
<td class="num">(32,016)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(707,534)<span></span>
</td>
<td class="num">(967,293)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Ionis stockholders' equity</a></td>
<td class="nump">1,471,094<span></span>
</td>
<td class="nump">1,048,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest in Akcea Therapeutics, Inc.</a></td>
<td class="nump">213,453<span></span>
</td>
<td class="nump">139,081<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders' equity</a></td>
<td class="nump">1,684,547<span></span>
</td>
<td class="nump">1,187,160<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">3,233,112<span></span>
</td>
<td class="nump">2,667,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember', window );">0.125 Percent Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">434,711<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember', window );">1 Percent Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible senior notes</a></td>
<td class="nump">$ 275,333<span></span>
</td>
<td class="nump">$ 568,215<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_LongTermObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_LongTermObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansFromBank">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the operating cycle if longer, excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansFromBank</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6970120064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Novartis [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Biogen Inc. [Member]</div>
</th>
<th class="th"><div>Additional Paid In Capital [Member]</div></th>
<th class="th">
<div>Additional Paid In Capital [Member] </div>
<div>Novartis [Member]</div>
</th>
<th class="th">
<div>Additional Paid In Capital [Member] </div>
<div>Biogen Inc. [Member]</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
<th class="th">
<div>Accumulated Other Comprehensive Loss [Member] </div>
<div>Novartis [Member]</div>
</th>
<th class="th">
<div>Accumulated Other Comprehensive Loss [Member] </div>
<div>Biogen Inc. [Member]</div>
</th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th">
<div>Accumulated Deficit [Member] </div>
<div>Novartis [Member]</div>
</th>
<th class="th">
<div>Accumulated Deficit [Member] </div>
<div>Biogen Inc. [Member]</div>
</th>
<th class="th"><div>Total Ionis Stockholders' Equity [Member]</div></th>
<th class="th">
<div>Total Ionis Stockholders' Equity [Member] </div>
<div>Novartis [Member]</div>
</th>
<th class="th">
<div>Total Ionis Stockholders' Equity [Member] </div>
<div>Biogen Inc. [Member]</div>
</th>
<th class="th"><div>Noncontrolling Interest in Akcea Therapeutics, Inc. [Member]</div></th>
<th class="th">
<div>Noncontrolling Interest in Akcea Therapeutics, Inc. [Member] </div>
<div>Novartis [Member]</div>
</th>
<th class="th">
<div>Noncontrolling Interest in Akcea Therapeutics, Inc. [Member] </div>
<div>Biogen Inc. [Member]</div>
</th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Novartis [Member]</div></th>
<th class="th"><div>Biogen Inc. [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2016</a></td>
<td class="nump">$ 122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,311,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (30,358)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,241,380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2016</a></td>
<td class="nump">121,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in unrealized gains (losses), net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of common stock in connection with employee stock plans</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in connection with employee stock plans (in shares)</a></td>
<td class="nump">1,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary', window );">Issuance of Akcea Therapeutics, Inc. common stock in conjunction with intial public offering</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary', window );">Issuance of Akcea Therapeutics, Inc. common stock in conjunction with intial public offering (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary', window );">Noncontrolling interest in Akcea Therapeutics, Inc. in conjunction with initial public offering</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,351)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,351)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Noncontrolling interest in Akcea Therapeutics, Inc.</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,110)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,110)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,114)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,224)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,553,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,759)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,241,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="nump">124,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in unrealized gains (losses), net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 447,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 447,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 447,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of common stock in connection with employee stock plans</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in connection with employee stock plans (in shares)</a></td>
<td class="nump">1,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Noncontrolling interest in Akcea Therapeutics, Inc.</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113,595)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(113,595)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,814<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,781)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,047,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,016)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(967,293)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,048,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,187,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">137,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in unrealized gains (losses), net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Issuance of common stock in connection with employee stock plans</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock in connection with employee stock plans (in shares)</a></td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption', window );">1 percent convertible senior notes retirement, equity portion, net of tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,331)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,331)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77,331)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">0.125 percent convertible senior notes, equity portion, net of issuance costs and tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Purchase of note hedges, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85,860)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85,860)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85,860)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Repurchases and retirements of common stock</a></td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,388)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchases and retirements of common stock (in shares)</a></td>
<td class="num">(535)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,242)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,242)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,242)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options (in shares)</a></td>
<td class="num">(154)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestPeriodIncreaseDecrease', window );">Noncontrolling interest in Akcea Therapeutics, Inc.</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,254)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,254)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,203,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (25,290)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (707,534)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,471,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,684,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">140,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the redemption of convertible debt instruments as two separate components - a debt component and an equity component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders in an initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued by subsidiary during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period by a subsidiary. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32157-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6869496384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Income (Loss) Before Income Taxes</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) before income taxes is comprised of (in thousands):</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z4092c9a5a2814eb28f48de6d2a9e9058" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">United States</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">344,280</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(69,576</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5,289</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Foreign</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,489</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(6,580</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(11,474</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income (loss) before income taxes</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">346,769</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(76,156</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(16,763</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our income tax expense (benefit) was as follows (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z713025753cca4d42a8b28f2a7fba9d21" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Current:</div></td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Federal</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">35,861</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">438</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(7,460</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">State</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14,329</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,442</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,246</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Foreign</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">413</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">374</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">234</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total current income tax expense (benefit)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">50,603</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(630</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5,980</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deferred:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Federal</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(7,096</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(290,511</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">State</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total deferred income tax benefit</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(7,096</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(290,511</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total income tax expense (benefit)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">43,507</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(291,141</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5,980</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Statutory to Effective Tax Rate</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our expense (benefit) for income taxes differs from the amount computed by applying the U.S. federal statutory rate to income (loss) before taxes. The sources and tax effects of the differences are as follows (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zb11f654ab51c478685d3b34848ff0f2f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="22" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Pre-tax income (loss)</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">346,769</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(76,156</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(16,763</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Statutory rate</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">72,822</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(15,993</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5,867</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">35.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">State income tax net of federal benefit</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">49,119</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2,202</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">820</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Foreign</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">340</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,735</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2.3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,299</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(25.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net change in valuation allowance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(37,765</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(10.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(277,924</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">364.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(86,296</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">514.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net operating loss expiration</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,864</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(11.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,987</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(23.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">TEGSEDI licensing gain</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">59,583</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(78.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Impact from outside basis differences</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(16,344</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4.7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Tax credits</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(22,296</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(6.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(73,362</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">96.3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(32,769</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">195.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deferred tax true-up</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">646</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,947</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(13.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,848</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(28.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Tax rate change</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,811</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,808</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">114,832</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(685.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-deductible compensation</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,361</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,154</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,575</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(9.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other non-deductible items</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">329</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(569</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,548</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(15.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea deconsolidation adjustment at IPO</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">469</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stock-based compensation</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4,837</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4,199</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(14,337</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">85.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Foreign-derived intangible income benefit</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2,071</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,608</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(0.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,633</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(89</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 28%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effective rate</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">43,507</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(291,141</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">382.3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5,980</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">35.7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred Tax Assets and Liabilities</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Significant components of our deferred tax assets and liabilities as of December 31, 2019 and 2018 are as follows (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z6ce9a811fab143898ba48d74d51fe77e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deferred Tax Assets:</div></td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net operating loss carryovers</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20,191</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">89,717</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">R&amp;D credits</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">210,455</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">313,652</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deferred revenue</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">127,763</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">27,381</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Stock-based compensation</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">65,703</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">61,027</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Intangible and capital assets</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">77,861</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">49,007</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12,510</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,275</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total deferred tax assets</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">514,483</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">549,059</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Deferred Tax Liabilities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Convertible debt</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(6,110</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(24,018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Fixed assets</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,958</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3,884</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net deferred tax asset</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">502,531</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">525,041</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Valuation allowance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(196,974</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(234,245</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total net deferred tax assets and liabilities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">305,557</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">290,796</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Gross Unrecognized Tax Benefits</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes our gross unrecognized tax benefits (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z4b3b1be351044041904f4aadda12afa8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Beginning balance of unrecognized tax benefits</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">68,301</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">78,014</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">66,999</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Decrease for prior period tax positions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(867</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(12,814</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Increase for prior period tax positions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">736</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,520</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Increase for current period tax positions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,614</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3,101</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,495</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ending balance of unrecognized tax benefits</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">69,784</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">68,301</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">78,014</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=117331294&amp;loc=d3e36027-109320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6885731504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock', window );">Basic Net Income per Share</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our basic net income per share, was calculated as follows (in thousands, except per share amounts):</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z104b454b266445eaac9eed834835145f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Portion of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Income</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">70,100</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.49</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">34,073</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net income attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">34,073</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">262,490</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">296,563</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">139,998</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.12</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zfe21e6fd0158439f854dad365e54a58d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Portion of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">59,812</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2.74</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(163,938</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(163,938</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">440,806</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">276,868</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">132,320</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.09</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We calculated our basic net income per share for 2017 as follows (in thousands, except per share amounts):</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z7f02aeb560ee40bd982c44713ab0a2ac" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid; white-space: nowrap;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2017</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Owned in Akcea</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s</span></div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Net Loss</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Ionis</span>&#8217;</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Portion of</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Akcea</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">s Net Loss</span></div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Common shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20,669</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3.08</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(63,638</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Preferred shares</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15,748</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1.80</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(28,346</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Akcea&#8217;s net loss attributable to our ownership</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(91,984</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ionis&#8217; stand-alone net income</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">110,776</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,792</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Weighted average shares outstanding</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">124,016</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Basic net income per share</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.15</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Income Per Share</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We calculated our diluted net income per share as follows <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">(in thousands except per share amounts):</span></div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zb0e4b49c2e274df0b9950bc8e8004fbd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">296,563</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">139,998</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.12</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -8.9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,090</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: 0.1pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">766</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our Employee Stock Purchase Plan</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">296,563</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">142,872</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.08</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z01b775cd675848508a1d52bc1c4cff37" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">276,868</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">132,320</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.09</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -8.9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,216</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: 0.1pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">514</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our Employee Stock Purchase Plan</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">276,868</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">134,056</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.07</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zd8deeaecb9c64cd89c8fc8806b7a193d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2017</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Income</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Numerator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Shares</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Denominator)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Per-Share</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amount</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net income available to Ionis common stockholders</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,792</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">124,016</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.15</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Effect of dilutive securities:</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -8.9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon exercise of stock options</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,619</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: 0.1pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable upon restricted stock award issuance</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">459</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Shares issuable related to our Employee Stock Purchase Plan</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9.1pt; margin-left: 9.1pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Income available to Ionis common stockholders, plus assumed conversions</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,792</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">126,098</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.15</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Amortization Expense for Patents</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Based on our existing patents, we estimate amortization expense related to patents in each of the next five years to be the following:</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z3b4746089ec94fcf825148a7e478c941" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; border-bottom: #000000 2px solid;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ending December 31,</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Amortization</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(in millions)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2020</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2021</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2022</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2023</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2024</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our accrued liabilities consisted of the following (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z3a44c21e41964165973dff87ef753698" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Clinical expenses</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">24,461</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">22,125</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -18pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In-licensing expenses</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">10,289</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">12,298</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -18pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Other miscellaneous expenses</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">32,019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,080</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total accrued liabilities</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">66,769</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">47,503</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Our inventory consisted of the following (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z1ee494cca3ec409c868c744c6428df49" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Raw materials:</div></td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 19.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Raw materials- clinical</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">9,363</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,497</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -18pt; margin-left: 28.4pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Raw materials- commercial</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,520</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 28.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total raw materials</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15,883</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,497</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Work in process</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,039</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Finished goods</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">258</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">85</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; margin-left: 28.45pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total inventory</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,180</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">8,582</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We carry our property, plant and equipment at cost and depreciate it on the straight-line method over its estimated useful life, which consists of the following (in thousands):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z6b8fa4917b344088b2fa85d6aab08f8c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Estimated Useful Lives</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(in years)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Computer software, laboratory, manufacturing and other equipment</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3 to 10</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">60,965</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">53,496</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Building, building improvements and building systems</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">15 to 40</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">119,830</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">97,528</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Land improvements</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">20</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,853</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,853</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Leasehold improvements</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5 to 15</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">13,600</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">18,981</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Furniture and fixtures</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">5 to 10</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">7,354</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,283</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">204,602</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">179,141</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Less accumulated depreciation</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(74,013</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(61,474</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">130,589</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">117,667</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Land</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23,062</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">14,493</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#160;Total</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">153,651</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">132,160</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Changes in Accumulated Other Comprehensive Loss</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Accumulated other comprehensive loss is primarily comprised of unrealized gains and losses on investments, net of taxes and adjustments we made to reclassify realized gains and losses on investments from other accumulated comprehensive loss to our Consolidated Statement of Operations. The following table summarizes changes in accumulated other comprehensive loss for the years ended December 31, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2019</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">, </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2018</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> and </span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">2017</span><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;"> (in thousands):</span></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zf8dcaf0ca45440bba49fa3a29bc22bb5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Beginning balance accumulated other comprehensive loss</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(32,016</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(31,759</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(30,358</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Unrealized gains (losses) on securities, net of tax (1)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,633</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(280</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(960</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Amounts reclassified from accumulated other comprehensive loss</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(374</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Currency translation adjustment</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">93</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">23</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(67</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Net other comprehensive loss for the period</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,726</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(257</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1,401</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Ending balance accumulated other comprehensive loss</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(25,290</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(32,016</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(31,759</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
  </tr>
</table>

<div style="text-align: justify;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z11d622af5d604f70bd2be3051942ec9a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">A tax benefit of $1.4 million and $0.3 million was included in other comprehensive loss for the years ended December 31, 2019 and 2018, respectively. There was no tax benefit or expense for other comprehensive loss for the year ended December 31, 2017.&#160;</div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following tables present the major security types we held at December 31, 2019 and 2018&#160;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">that we regularly measure and carry at fair value</span>. At December 31, 2019, a portion of our ProQR investment was <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">subject to trading restrictions through the fourth quarter of 2020, as a result we</span> included a lack of marketability discount in valuing this investment, which is a Level 3 input. At December 31, 2018, our ProQR investment was <span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">subject to trading restrictions through the fourth quarter of 2019, as a result we</span> included a lack of marketability discount in valuing this investment, which is a Level 3 input. The tables segregate each security type by the level within the fair value hierarchy of the valuation techniques we utilized to determine the respective securities&#8217; fair value (in thousands):</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z0cec2f41ef46437e96b40a502fd19a06" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 8pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">At</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31, 2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quoted Prices in</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Active Markets</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 1)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Significant Other</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Observable Inputs</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 2)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Significant</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Unobservable Inputs</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 3)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cash equivalents (1)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">418,406</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">418,406</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities (2)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,102,568</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,102,568</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies (3)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">329,404</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">329,404</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury (4)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">363,694</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">363,694</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states (4)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">40,407</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">40,407</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div/><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investment in ProQR Therapeutics N.V. (5)</div></div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,506</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,506</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -8.9pt; margin-left: 22.55pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,258,985</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">782,100</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,472,379</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4,506</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z6dbe183adeca4fdb81898fb0f23d867c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 8pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">At</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Quoted Prices in</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Active Markets</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 1)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Significant Other</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Observable Inputs</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 2)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Significant</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Unobservable Inputs</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Level 3)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cash equivalents (1)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">146,281</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">146,281</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Corporate debt securities (6)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,252,960</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,252,960</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by U.S. government agencies (4)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">276,612</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">276,612</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by the U.S. Treasury (7)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">260,154</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">260,154</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: left; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Debt securities issued by states of the U.S. and political subdivisions of the states (4)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">79,942</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">79,942</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Investment in ProQR Therapeutics N.V. (5)</div></div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,349</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,349</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -8.9pt; margin-left: 22.55pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,017,298</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">406,435</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,609,514</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,349</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">________________</div>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zcc6c856321964d22a7f08198e22558a3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(1)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Included in cash and cash equivalents on our consolidated balance sheet.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -36pt; margin-left: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z3bb7cbd9edf34eea8445b9bb699f5225" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$19.0 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</div></td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z9302b49ff4924d45b72f0ef80173e32d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(3)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$0.8 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zcc7cb538270446d19a63ff93630b2e26" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(4)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Included in short-term investments.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 18pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z0a497b435bb34da0940d397a2ee925d1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(5)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Included in other current assets on our consolidated balance sheet.&#160;</div></td>
  </tr>
</table>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="ze53e73690894408ba98ca5e5e87ae494" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(6)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$50.2 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z9da9f51ab1ce4cf8b13bf7b591532750" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(7)</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$14.2 million included in cash and cash equivalents on our consolidated balance sheet, with the difference included in short-term investments on our consolidated balance sheet.</div></td>
  </tr>
</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on basic earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6863405056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employment Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employment Benefits</a></td>
<td class="text">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">8. Employment Benefits</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We have an employee 401(k) salary deferral plan, covering all employees. Employees could make contributions by withholding a percentage of their salary up to the IRS annual limit $19,000 and $25,000 in 2019 for employees under 50 years old and employees 50 years old or over, respectively. We made approximately $6.4 million, $5.7 million and $3.0 million in matching contributions for the years ended December 31, 2019, 2018 and 2017, respectively.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6885395984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">
<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;">4. Stockholders</span>&#8217;<span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-weight: bold;"> Equity</span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Preferred Stock</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We are authorized to issue up to 15 million shares of &#8220;blank check&#8221; Preferred Stock. As of December 31, 2019, there were no shares of Preferred Stock outstanding. We have designated Series C Junior Participating Preferred Stock but have no issued or outstanding shares as of December 31, 2019.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Common Stock</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">At December 31, 2019 and 2018, we had 300 million shares of common stock authorized, of which 140.3 million and 137.9 million were issued and outstanding, respectively. As of December 31, 2019, total common shares reserved for future issuance were 26.2 million.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">During the years ended December 31, 2019, 2018 and 2017, we issued 3.1 million, 1.5 million and 1.7 million shares of common stock, respectively, for stock option exercises, vesting of restricted stock units, and ESPP purchases. We received net proceeds from these transactions of $119.7 million, $27.9 million and $22.9 million in 2019, 2018 and 2017, respectively.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Share Repurchase Program</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In September 2019, our board of directors approved an initial share repurchase program of up to $125 million of our common stock. Our stock repurchase program has no expiration date. Through December 31, 2019, we repurchased 535,000 shares for $34.4 million. In the first quarter of 2020, we repurchased an additional 1.5 million shares for $90.6 million.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Stock Plans</div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">1989 Stock Option Plan</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In June 1989, our Board of Directors adopted, and the stockholders subsequently approved, a stock option plan that, as amended, provides for the issuance of non-qualified and incentive stock options for the purchase of up to 20.0 million shares of common stock to our employees, directors, and consultants. The plan expires in January 2024. The 1989 Plan does not allow us to grant stock bonuses or restricted stock awards and prohibits us from repricing any options outstanding under the plan unless our stockholders approve the repricing. Options vest over a four-year period, with 25 percent exercisable at the end of one year from the date of the grant and the balance vesting ratably, on a monthly basis, thereafter and have a term of seven years. At December 31, 2019, a total of 0.1 million options were outstanding, of which options to purchase 0.1 million shares were exercisable, and 0.04 million shares were available for future grant under the 1989 Plan.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">2011 Equity Incentive Plan</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In March 2011, our Board of Directors adopted, and the stockholders subsequently approved, a stock option plan that provides for the issuance of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and performance cash awards to our employees, directors, and consultants. In June 2015, May 2017 and June 2019, after receiving approval from our stockholders, we amended our 2011 Equity Incentive Plan to increase the total number of shares reserved for issuance. We increased the shares available under our 2011 Equity Incentive Plan from 5.5 million to 11.0 million in June 2015, from 11.0 million to 16.0 million in May 2017 and from 16.0 million to 23.0 million in June 2019. The plan expires in June 2021. The 2011 Plan does not allow us to reduce the exercise price of any outstanding stock options or stock appreciation rights or cancel any outstanding stock options or stock appreciation rights that have an exercise price or strike price greater than the current fair market value of the common stock in exchange for cash or other stock awards unless our stockholders approve such action. Currently we anticipate awarding only options and restricted stock unit awards to our employees, directors and consultants. Under the 2011 Plan, stock options cannot vest in a period of less than two years and restricted stock unit awards cannot vest in a period of less than three years. We have granted restricted stock unit awards to our employees under the 2011 Plan which vest annually over a four-year period. At December 31, 2019, a total of 10.0 million options were outstanding, of which 5.4 million were exercisable, 1.7 million restricted stock unit awards were outstanding, and 7.4 million shares were available for future grant under the 2011 Plan.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Under the 2011 Plan, we may issue a stock award with additional acceleration of vesting and exercisability upon or after a change in control. In the absence of such provisions, no such acceleration will occur. The stock options and restricted stock unit awards we issue to Dr. Stanley T. Crooke in his former role as chief executive officer and issued to B. Lynne Parshall in her former role as chief operating officer will accelerate upon a change of control, as defined in the 2011 Plan. In addition, we implemented a change of control and severance benefit plan that provides for change of control and severance benefits to our executive officers, including our chief executive officer and chief financial officer. If we terminate one of our executive officers or if an executive officer resigns for good reason during the period that begins three months before and ends twelve months following a change in control of the company, the impacted executive officers&#8217; stock options and RSUs vesting will accelerate for options and RSUs outstanding as of the termination date.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Corporate Transactions and Change in Control under 2011 Plan</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the event of certain significant corporate transactions, our Board of Directors has the discretion to take one or more of the following actions with respect to outstanding stock awards under the 2011 Plan:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="zcb34c7d1e4c048899e93ebb5a7d68318" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">arrange for assumption, continuation, or substitution of a stock award by a surviving or acquiring entity (or its parent company);</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z6e451eac07ec40ea8f4b2469d382252a" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">arrange for the assignment of any reacquisition or repurchase rights applicable to any shares of our common stock issued pursuant to a stock award to the surviving or acquiring corporation (or its parent company);</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z1804c283807648828a63435f4451acd3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">accelerate the vesting and exercisability of a stock award followed by the termination of the stock award;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z5f80dab3f5b546fd8cc4ecce3150f3af" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">arrange for the lapse of any reacquisition or repurchase rights applicable to any shares of our common stock issued pursuant to a stock award;</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="za9fb373834d54a3a900c0043acd5e180" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">cancel or arrange for the cancellation of a stock award, to the extent not vested or not exercised prior to the effective date of the corporate transaction, in exchange for cash consideration, if any, as the Board, in its sole discretion, may consider appropriate; and</div></td>
  </tr>
</table>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" id="z166bbc44488d4829b2be0e17a4e293e6" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">
  <tr>
    <td style="width: 36pt;"/>
    <td style="width: 18pt; vertical-align: top; align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#9679;</td>
    <td style="width: auto; vertical-align: top; text-align: justify;"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">arrange for the surrender of a stock award in exchange for a payment equal to the excess of (a) the value of the property the holder of the stock award would have received upon the exercise of the stock award, over (b) any exercise price payable by such holder in connection with such exercise.</div></td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">2002 Non-Employee Directors&#8217; Stock Option Plan</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In September 2001, our Board of Directors adopted, and the stockholders subsequently approved, an amendment and restatement of the 1992 Non-Employee Directors&#8217; Stock Option Plan, which provides for the issuance of non-qualified stock options and restricted stock units to our non-employee directors. The name of the resulting plan is the 2002 Non-Employee Directors&#8217; Stock Option Plan, or the 2002 Plan. In June 2015, after receiving approval from our stockholders, we amended our 2002 Non-Employee Directors Stock Option Plan to increase the total number of shares reserved for issuance. We increased the shares available under our 2002 Non-Employee Directors Stock Option Plan from 1.2 million to 2.0 million. Options under this plan expire 10 years from the date of grant. Options granted become exercisable in four equal annual installments beginning one year after the date of grant. At December 31, 2019, a total of 0.9 million options were outstanding, of which 0.5 million were exercisable, 0.1 million restricted stock unit awards were outstanding, and 0.1 million shares were available for future grant under the 2002 Plan.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Employee Stock Purchase Plan</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In June 2009, our Board of Directors adopted, and the stockholders subsequently approved, the amendment and restatement of the ESPP and we reserved an additional 150,000 shares of common stock for issuance thereunder. In each of the subsequent years, we reserved an additional 150,000 shares of common stock for the ESPP resulting in a total of 3.7 million shares authorized under the plan as of December 31, 2019. The ESPP permits full-time employees to purchase common stock through payroll deductions (which cannot exceed 10 percent of each employee&#8217;s compensation) at the lower of 85 percent of fair market value at the beginning of the purchase period or the end of each purchase period. Under the amended and restated ESPP, employees must hold the stock they purchase for a minimum of six months from the date of purchase. During 2019, employees purchased and we issued to employees 0.05 million shares under the ESPP at a weighted average price of $40.95 per share. At December 31, 2019, there were 0.7 million shares available for purchase under the ESPP.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Stock Option Activity</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes the stock option activity under our stock plans for the year ended December 31, 2019 (in thousands, except per share and contractual life data):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z9b50c63317624dd0af7fdc21a2a7bfb8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Number</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">of Shares</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average Exercise</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Price Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Average</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Remaining</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Contractual Term</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">(Years)</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Aggregate</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Intrinsic</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Value</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Outstanding at December 31, 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11,311</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">47.85</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Granted</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2,543</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">56.19</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Exercised</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(2,617</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">40.48</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cancelled/forfeited/expired</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(236</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">50.11</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Outstanding at December 31, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">11,001</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">51.48</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.41</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">104,029</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Exercisable at December 31, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6,004</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">50.95</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">3.34</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">59,780</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The weighted-average estimated fair values of options granted were $28.76, $25.49 and $25.42 for the years ended December 31, 2019, 2018 and 2017, respectively. The total intrinsic value of options exercised during the years ended December 31, 2019, 2018 and 2017 were $83.8 million, $34.8 million and $49.5 million, respectively, which we determined as of the date of exercise. The amount of cash received from the exercise of stock options was $105.9 million, $18.9 million and $21.2 million for the years ended December 31, 2019, 2018 and 2017, respectively. For the year ended December 31, 2019, the weighted-average fair value of options exercised was $72.52. As of December 31, 2019, total unrecognized compensation cost related to non-vested stock options was $97.5 million. We will adjust the total unrecognized compensation cost for future changes in estimated forfeitures. We expect to recognize this cost over a weighted average period of 1.3 years.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Restricted Stock Unit Activity</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes the RSU activity for the year ended December 31, 2019 (in thousands, except per share data):</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zc0f5e4e23b714ab09d3ea5e085c1013f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Number</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">of Shares</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Weighted Average</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Grant Date Fair</div><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Value Per Share</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-vested at December 31, 2018</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,246</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">50.20</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Granted</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,114</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">60.23</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Vested</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(422</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">51.36</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 18pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cancelled/forfeited</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">(72</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">)</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">53.39</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Non-vested at December 31, 2019</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1,866</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">55.80</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For the years ended December 31, 2019, 2018 and 2017, the weighted-average grant date fair value of RSUs granted was $60.23, $51.06 and $48.88 per RSU, respectively. As of December 31, 2019, total unrecognized compensation cost related to RSUs was $56.5 million. We will adjust the total unrecognized compensation cost for future changes in estimated forfeitures. We expect to recognize this cost over a weighted average period of 1.5 years.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 12pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif;">Stock-based Compensation Expense and Valuation Information</span></div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following table summarizes stock-based compensation expense for the years ended December 31, 2019, 2018 and 2017 (in thousands), which was allocated as follows and includes $37.1 million, $44.3 million and $17.5 million of stock-based compensation expense for Akcea employees in 2019, 2018 and 2017, respectively:</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="ze0f1f82608a349d9975520506247db45" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">Year Ended December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Cost of products sold</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">438</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">160</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">&#8212;</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Research, development and patent</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">95,348</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">76,557</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">64,521</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Selling, general and administrative</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">50,788</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">54,595</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">21,454</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Total</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">146,574</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">131,312</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">$</div></td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">85,975</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In the third quarter of 2019, three Akcea executive officers terminated their employment and entered into separation agreements with Akcea. As a result, in the third quarter of 2019, Akcea reversed $19.1 million of stock-based compensation expense it had previously recognized related to the executive officers&#8217; stock options and RSUs that were no longer going to vest. In the fourth quarter of 2019, Akcea adjusted its stock-based compensation expense for an additional executive officer who will terminate his employment in April 2020.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Determining Fair Value</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: -18pt; margin-left: 54pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Valuation.</span> We measure stock-based compensation expense for equity-classified awards, principally related to stock options, RSUs, and stock purchase rights under the ESPP at the grant date, based on the estimated fair value of the award and we recognize the expense over the employee&#8217;s requisite service period. We value RSUs based on the market price of our common stock on the date of grant.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">We use the Black-Scholes model to estimate the fair value of stock options granted and stock purchase rights under our ESPP. The expected term of stock options granted represents the period of time that we expect them to be outstanding. We estimate the expected term of options granted based on actual and projected exercise patterns. We recognize compensation expense for stock options granted, RSUs, and stock purchase rights under the ESPP using the accelerated multiple-option approach. Under the accelerated multiple-option approach (also known as the graded-vesting method), we recognize compensation expense over the requisite service period for each separately vesting tranche of the award as though the award were in substance multiple awards, which results in the expense being front-loaded over the vesting period.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">For the years ended December 31, 2019, 2018 and 2017, we used the following weighted-average assumptions in our Black-Scholes calculations:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Ionis Employee Stock Options:</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z1a22f5901f3944f2be1e317aad3cab4b" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Risk-free interest rate</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dividend yield</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Volatility</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">60.3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">63.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">65.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expected life</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.8 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.6 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">4.5 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Ionis Board of Director Stock Options:</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zc7e20a324c544bf6af7f8bb69517a4b2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Risk-free interest rate</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dividend yield</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Volatility</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">60.7</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">61.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">61.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expected life</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.6 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.6 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.6 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Ionis ESPP:</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zaf6dcfd7dd86499dbd414c26e0657d2f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Risk-free interest rate</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dividend yield</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Volatility</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">45.6</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">47.3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">59.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expected life</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6 months</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6 months</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6 months</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Risk-Free Interest Rate.</span> We base the risk-free interest rate assumption on observed interest rates appropriate for the term of our stock option plans or ESPP.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Dividend Yield.</span> We base the dividend yield assumption on our history and expectation of dividend payouts. We have not paid dividends in the past and do not expect to in the future.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Volatility.</span> We use an average of the historical stock price volatility of our stock for the Black-Scholes model. We computed the historical stock volatility based on the expected term of the awards.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Expected Life. </span>The expected term of stock options we have granted represents the period of time that we expect them to be outstanding. We estimated the expected term of options we have granted based on actual and projected exercise patterns.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Forfeitures.</span> We reduce stock-based compensation expense for estimated forfeitures. We estimate forfeitures at the time of grant and revise, if necessary, in subsequent periods if actual forfeitures differ from those estimates. We estimate forfeitures based on historical experience.</div>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">In addition to our stock plans, Akcea has its own stock plan under which it grants options and RSUs and under which it derives its stock-based compensation expense. The following are the weighted-average Black-Scholes assumptions Akcea used under its plan for the years ended December 31, 2019, 2018 and 2017:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Akcea Employee Stock Options:</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z6d0f71f781114c2796697bdc6544ea2f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Risk-free interest rate</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dividend yield</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Volatility</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">75.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">77.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">79.5</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expected life</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.09 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.08 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.06 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Akcea Board of Director Stock Options:</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="zbbe3118c00004f9f91eb04676b0aef23" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Risk-free interest rate</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dividend yield</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Volatility</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">73.8</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">78.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">79.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expected life</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.25 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.42 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6.25 years</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: italic;">Akcea ESPP:</div>

<div style="text-align: justify;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div>

<table cellpadding="0" cellspacing="0" id="z274cc299456642c993f118c12d22a0fd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><div style="text-align: justify; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 12pt; font-family: 'Times New Roman', Times, serif;"><br/></span></div></td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">December 31,</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2019</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2018</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-weight: bold;">2017</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Risk-free interest rate</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">2.4</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.9</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">1.1</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Dividend yield</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">0.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Volatility</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">60.0</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">64.2</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">73.3</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><div style="font-family: 'Times New Roman', Times, serif; font-size: 10pt;">%</div></td>
  </tr>
  <tr>
    <td style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: justify; text-indent: -9pt; margin-left: 9pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">Expected life</div></td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6 months</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6 months</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
    <td colspan="1" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom">&#160;</td>
    <td colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;" valign="bottom"><div style="text-align: right; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">6 months</div></td>
    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #FFFFFF; white-space: nowrap;" valign="bottom">&#160;</td>
  </tr>
</table>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">The following summarizes the Black-Scholes input methodology for Akcea options that differs from the methodology we use for Ionis options:</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Volatility.</span> Since Akcea does not have sufficient history to estimate the volatility of its common stock, Akcea calculates its expected volatility based on a blend of its historical volatility and reported data from selected publicly traded peer companies for which historical information is available. Akcea plans to continue to use this blend to calculate its volatility until the historical volatility of its common stock is sufficient to measure expected volatility for future option grants.</div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 12pt;"><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman', Times, serif; font-style: italic;">Expected Life. </span>Since Akcea does not have sufficient historical information, it uses the simplified method for estimating its expected term. Under the simplified method Akcea calculates its expected term as the average time-to-vesting and the contractual life of the options. As Akcea gains additional historical information, it will transition to calculating its expected term based on its exercise patterns.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6887653936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies, Basic and Diluted Net Income per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="16">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2019</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2019</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2019</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2018</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2018</div></th>
<th class="th" colspan="2"><div>Jun. 30, 2018</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic Net Income per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (loss) per share (in dollars per share)</a></td>
<td class="nump">$ 1.31<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.12<span></span>
</td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 184,415<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 26,163<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (876)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 84,443<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 320,078<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (4,559)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (40,358)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1,420)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 294,146<span></span>
</td>
<td class="nump">$ 273,741<span></span>
</td>
<td class="nump">$ 346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income available to Ionis common stockholders</a></td>
<td class="nump">$ 183,795<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 26,158<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (933)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 87,543<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 319,694<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (4,563)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (37,932)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (1,212)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 296,563<span></span>
</td>
<td class="nump">$ 276,868<span></span>
</td>
<td class="nump">$ 18,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing basic net income per share (in shares)</a></td>
<td class="nump">140,583<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">140,551<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">140,247<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">138,582<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">137,699<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">137,346<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">128,712<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">125,330<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,998<span></span>
</td>
<td class="nump">132,320<span></span>
</td>
<td class="nump">124,016<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Income available to Ionis common shareholders, plus assumed conversions</a></td>
<td class="nump">$ 196,485<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 26,158<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 87,543<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 330,439<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 296,563<span></span>
</td>
<td class="nump">$ 276,868<span></span>
</td>
<td class="nump">$ 18,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan', window );">Shares issuable related to our Employee Stock Purchase Plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing diluted net income per share (in shares)</a></td>
<td class="nump">153,303<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">143,408<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">141,537<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">149,856<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,872<span></span>
</td>
<td class="nump">134,056<span></span>
</td>
<td class="nump">126,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per share (in dollars per share)</a></td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 0.62<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3],[4]</sup></td>
<td class="nump">$ 2.21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="nump">$ 2.07<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic Net Income per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Shares issuable related to stock-based compensation (in shares)</a></td>
<td class="nump">1,467<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,993<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,252<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,254<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,090<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
<td class="nump">1,619<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic Net Income per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Shares issuable related to stock-based compensation (in shares)</a></td>
<td class="nump">848<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">844<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">665<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">636<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ions_IonisCoreMember', window );">Ionis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic Net Income per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 121,552<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 49,930<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 27,311<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 63,697<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 372,913<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 43,226<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 5,882<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 18,785<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262,490<span></span>
</td>
<td class="nump">$ 440,806<span></span>
</td>
<td class="nump">$ 110,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic Net Income per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_WeightedAverageNumberOfSharesOwnedInSubsidiary', window );">Weighted average shares owned in Akcea (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (loss) per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.80)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (28,346)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic Net Income per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,073<span></span>
</td>
<td class="num">$ (163,938)<span></span>
</td>
<td class="num">$ (91,984)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic Net Income per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_WeightedAverageNumberOfSharesOwnedInSubsidiary', window );">Weighted average shares owned in Akcea (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,100<span></span>
</td>
<td class="nump">59,812<span></span>
</td>
<td class="nump">20,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (loss) per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.49<span></span>
</td>
<td class="num">$ (2.74)<span></span>
</td>
<td class="num">$ (3.08)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,073<span></span>
</td>
<td class="num">$ (163,938)<span></span>
</td>
<td class="num">$ (63,638)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember', window );">Akcea [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic Net Income per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">converted into common stock on a 1:1 basis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="21"></td></tr>
<tr><td colspan="21"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As discussed in Note 1, Organization and Significant Accounting Policies, we compute basic net income (loss) per share by dividing the total net income (loss) attributable to our common stockholders by our weighted-average number of common shares outstanding during the period. Our basic net income (loss) per share calculation for each of the quarters in 2019 and 2018 considered our net income for Ionis on a stand-alone basis plus our share of Akcea&#8217;s net loss for the period. To calculate the portion of Akcea&#8217;s net loss attributable to our ownership, we multiplied Akcea&#8217;s loss per share by the weighted average shares we owned in Akcea during the period. As a result of this calculation, our total net income (loss) available to Ionis common stockholders for the calculation of net income (loss) per share is different than net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders in the consolidated statements of operations.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">We computed net income (loss) per share independently for each of the quarters presented. Therefore, the sum of the quarterly net income (loss) per share will not necessarily equal the total for the year.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">We had net income available to Ionis common stockholders for the following periods. As a result, we computed diluted net income per share using the weighted-average number of common shares and dilutive common equivalent shares outstanding during those periods.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top">For the three months ended March 31, 2019 and September 30, 2019, the calculation excluded the 1 percent notes because the effect on diluted earnings per share was anti-dilutive.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of shares issuable related to employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_WeightedAverageNumberOfSharesOwnedInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares owned in the subsidiary during the reporting period determined by relating the portion of time within a reporting period that shares have been owned to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_WeightedAverageNumberOfSharesOwnedInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific terms relevant to convertibility. Includes class of preferred stock and number of shares convertible into, exercise (or conversion) price or rates, dates relevant to conversion timing and events relevant to conversion. Describe also any beneficial conversion features. where convertible preferred stock with a nondetachable conversion feature is in-the-money at commitment date. For contingently convertible preferred stock, discuss the circumstances of the contingency, including the events or changes in circumstance that would cause the contingency to be met and any of the significant features necessary to understand the conversion rights and the timing of those rights. Include also an events or changes in circumstance, if any, that could adjust or change the contingency, conversion price, or number of shares, including significant terms of those changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1500-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ions_IonisCoreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ions_IonisCoreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ions_AkceaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6885468576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies, Cost of Products Sold (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAbstract', window );"><strong>Cost of Products Sold [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CostOfProductsSoldPreviouslyRecognized', window );">Previously expensed costs to produce TEGSEDI related to TEGSEDI commercial revenue</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CostOfProductsSoldPreviouslyRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs related to goods produced and sold that were previously recognized as expense and are related to the commercial revenue recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CostOfProductsSoldPreviouslyRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6885253296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies, Cash, Cash Equivalents and Investments (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>Company</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents and Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment', window );">Number of publicly-held companies in which there is an equity ownership interest of less than 20%</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment', window );">Number of privately-held companies in which there is an equity ownership interest of less than 20%</a></td>
<td class="nump">5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of privately-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of publicly-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6888396336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity, Stock Plans (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2009 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>Officer </div>
<div>Installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2015 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,001,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,004,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ions_StockOptionPlan1989Member', window );">1989 Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ions_StockOptionPlan1989Member', window );">1989 Stock Option Plan [Member] | Stock Options [Member] | One Year from Date of Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Period before options are exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ions_EquityIncentivePlan2011Member', window );">2011 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000,000.0<span></span>
</td>
<td class="nump">11,000,000.0<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers', window );">Number of executive officers terminated before change in control when vesting will accelerate for executive officers | Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers', window );">Period before change in control when vesting will accelerate for executive officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers', window );">Period after change in control when vesting will accelerate for executive officers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ions_EquityIncentivePlan2011Member', window );">2011 Equity Incentive Plan [Member] | Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ions_EquityIncentivePlan2011Member', window );">2011 Equity Incentive Plan [Member] | Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ions_EquityIncentivePlan2011Member', window );">2011 Equity Incentive Plan [Member] | Restricted Stock Units [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ions_NonemployeeDirectorsStockOptionPlan2002Member', window );">2002 Non-Employee Directors' Stock Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ions_NonemployeeDirectorsStockOptionPlan2002Member', window );">2002 Non-Employee Directors' Stock Option Plan [Member] | One Year from Date of Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable', window );">Number of equal annual installments over which options become exercisable | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ions_NonemployeeDirectorsStockOptionPlan2002Member', window );">2002 Non-Employee Directors' Stock Option Plan [Member] | Stock Options [Member] | One Year from Date of Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Period before options are exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ions_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract', window );"><strong>Stock Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares reserved for issuance (in shares)</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum percentage of employee compensation used to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of fair market value used to determine purchase price of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod', window );">Holding period for purchased stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares purchased and issued under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased', window );">Purchase price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equal annual installments over which options become exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of executive officers terminated by the Company during the period that begins three months before and ends twelve months following a change in control of the Company when vesting will accelerate for options and RSUs outstanding as of the termination date for executive officers</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time after a change in control of the Company when vesting will accelerate for options and RSUs outstanding as of the termination date for executive officers, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time before a change in control of the Company when vesting will accelerate for options and RSUs outstanding as of the termination date for executive officers, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the holding period from the date of purchase for stock purchased under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average purchase price of capital shares purchased through an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ions_StockOptionPlan1989Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ions_StockOptionPlan1989Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ions_EquityIncentivePlan2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ions_EquityIncentivePlan2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ions_NonemployeeDirectorsStockOptionPlan2002Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ions_NonemployeeDirectorsStockOptionPlan2002Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ions_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ions_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6874327936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Obligations and Commitments, Maturity Schedules (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Annual Debt and Other Obligation Maturities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Less: current portion</a></td>
<td class="num">$ (2,026)<span></span>
</td>
<td class="num">$ (13,749)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_LongTermDebtAndOtherObligationsNoncurrent', window );">Total</a></td>
<td class="nump">785,500<span></span>
</td>
<td class="nump">$ 632,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember', window );">Long-Term Obligations, Excluding Financing Liability for Leased Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract', window );"><strong>Annual Debt and Other Obligation Maturities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2020</a></td>
<td class="nump">6,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2021</a></td>
<td class="nump">316,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2022</a></td>
<td class="nump">3,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">2023</a></td>
<td class="nump">4,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">2024</a></td>
<td class="nump">553,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="nump">64,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Subtotal</a></td>
<td class="nump">947,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Less: current portion</a></td>
<td class="num">(2,026)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Less: fixed and determinable interest</a></td>
<td class="num">(28,014)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: unamortized portion of debt discount</a></td>
<td class="num">(137,975)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Plus: lease liabilities</a></td>
<td class="nump">17,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_LongTermDebtAndOtherObligationsNoncurrent', window );">Total</a></td>
<td class="nump">$ 796,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_LongTermDebtAndOtherObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt, capital lease and other obligations due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_LongTermDebtAndOtherObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6885763312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Obligations and Commitments, Long-Term Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract', window );"><strong>Long-Term Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_LongTermDebtAndOtherObligations', window );">Total long-term obligations, including current portion</a></td>
<td class="nump">$ 787,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 646,720<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Less: current portion</a></td>
<td class="num">(2,026)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,749)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_LongTermDebtAndOtherObligationsNoncurrent', window );">Total Long-Term Obligations</a></td>
<td class="nump">785,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">632,971<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember', window );">0.125 Percent Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract', window );"><strong>Long-Term Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_LongTermDebtAndOtherObligations', window );">Total long-term obligations, including current portion</a></td>
<td class="nump">$ 434,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible senior notes</a></td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember', window );">1 Percent Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract', window );"><strong>Long-Term Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_LongTermDebtAndOtherObligations', window );">Total long-term obligations, including current portion</a></td>
<td class="nump">$ 275,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 568,215<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on convertible senior notes</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_LongTermMortgageDebtMember', window );">Long-term Mortgage Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract', window );"><strong>Long-Term Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_LongTermDebtAndOtherObligations', window );">Total long-term obligations, including current portion</a></td>
<td class="nump">$ 59,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,842<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_FixedRateNoteWithMorganStanleyMember', window );">Fixed Rate Note with Morgan Stanley [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract', window );"><strong>Long-Term Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_LongTermDebtAndOtherObligations', window );">Total long-term obligations, including current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Less: current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,500)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ions_LeasesAndOtherObligationsMember', window );">Leases and Other Obligations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract', window );"><strong>Long-Term Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_LongTermDebtAndOtherObligations', window );">Total long-term obligations, including current portion</a></td>
<td class="nump">$ 17,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,163<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Our $12.5 million fixed rate note with Morgan Stanley was included in our current portion of long-term obligations on our consolidated balance sheet at December 31, 2018. We paid off our fixed rate note in the third quarter of 2019.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_LongTermDebtAndOtherObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of long-term debt, capital lease and other obligations (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_LongTermDebtAndOtherObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_LongTermDebtAndOtherObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt, capital lease and other obligations due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_LongTermDebtAndOtherObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes0125PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_ConvertibleSeniorNotes1PercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_LongTermMortgageDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_LongTermMortgageDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_FixedRateNoteWithMorganStanleyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_FixedRateNoteWithMorganStanleyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ions_LeasesAndOtherObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ions_LeasesAndOtherObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>119
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10k.htm": {
   "axisCustom": 0,
   "axisStandard": 34,
   "contextCount": 652,
   "dts": {
    "calculationLink": {
     "local": [
      "ions-20191231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ions-20191231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "form10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ions-20191231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ions-20191231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ions-20191231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 908,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 6,
    "http://isispharm.com/20191231": 2,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 13
   },
   "keyCustom": 137,
   "keyStandard": 483,
   "memberCustom": 86,
   "memberStandard": 56,
   "nsprefix": "ions",
   "nsuri": "http://isispharm.com/20191231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000100 - Document - Document and Entity Information",
     "role": "http://isispharm.com/role/DocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060100 - Disclosure - Organization and Significant Accounting Policies",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPolicies",
     "shortName": "Organization and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060200 - Disclosure - Investments",
     "role": "http://isispharm.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060300 - Disclosure - Long-Term Obligations and Commitments",
     "role": "http://isispharm.com/role/LongtermObligationsAndCommitments",
     "shortName": "Long-Term Obligations and Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060400 - Disclosure - Stockholders' Equity",
     "role": "http://isispharm.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060500 - Disclosure - Income Taxes",
     "role": "http://isispharm.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060600 - Disclosure - Collaborative Arrangements and Licensing Agreements",
     "role": "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreements",
     "shortName": "Collaborative Arrangements and Licensing Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060700 - Disclosure - Segment Information and Concentration of Business Risk",
     "role": "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRisk",
     "shortName": "Segment Information and Concentration of Business Risk",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060800 - Disclosure - Employment Benefits",
     "role": "http://isispharm.com/role/EmploymentBenefits",
     "shortName": "Employment Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060900 - Disclosure - Legal Proceedings",
     "role": "http://isispharm.com/role/LegalProceedings",
     "shortName": "Legal Proceedings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061000 - Disclosure - Quarterly Financial Data (Unaudited)",
     "role": "http://isispharm.com/role/QuarterlyFinancialDataUnaudited",
     "shortName": "Quarterly Financial Data (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "010000 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://isispharm.com/role/ConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "070100 - Disclosure - Organization and Significant Accounting Policies (Policies)",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080100 - Disclosure - Organization and Significant Accounting Policies (Tables)",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesTables",
     "shortName": "Organization and Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080200 - Disclosure - Investments (Tables)",
     "role": "http://isispharm.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080300 - Disclosure - Long-Term Obligations and Commitments (Tables)",
     "role": "http://isispharm.com/role/LongtermObligationsAndCommitmentsTables",
     "shortName": "Long-Term Obligations and Commitments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080400 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://isispharm.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080500 - Disclosure - Income Taxes (Tables)",
     "role": "http://isispharm.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080600 - Disclosure - Collaborative Arrangements and Licensing Agreements (Tables)",
     "role": "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables",
     "shortName": "Collaborative Arrangements and Licensing Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080700 - Disclosure - Segment Information and Concentration of Business Risk (Tables)",
     "role": "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskTables",
     "shortName": "Segment Information and Concentration of Business Risk (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "081000 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)",
     "role": "http://isispharm.com/role/QuarterlyFinancialDataUnauditedTables",
     "shortName": "Quarterly Financial Data (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191001to20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ions:SharesReceivedFromSubsidiaryForLicenseOfDrug",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090100 - Disclosure - Organization and Significant Accounting Policies, Basis of Presentation (Details)",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails",
     "shortName": "Organization and Significant Accounting Policies, Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://isispharm.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U004",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191001to20191231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "U004",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090102 - Disclosure - Organization and Significant Accounting Policies, Basic and Diluted Net Income per Share (Details)",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
     "shortName": "Organization and Significant Accounting Policies, Basic and Diluted Net Income per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "lang": null,
      "name": "ions:IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ions:RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U005",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090104 - Disclosure - Organization and Significant Accounting Policies, Revenue Recognition (Details)",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails",
     "shortName": "Organization and Significant Accounting Policies, Revenue Recognition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ions:RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U005",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090106 - Disclosure - Organization and Significant Accounting Policies, Contracts Receivable (Details)",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesContractsReceivableDetails",
     "shortName": "Organization and Significant Accounting Policies, Contracts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090108 - Disclosure - Organization and Significant Accounting Policies, Deferred Revenue (Details)",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesDeferredRevenueDetails",
     "shortName": "Organization and Significant Accounting Policies, Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ions:CostOfProductsSoldPreviouslyRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090110 - Disclosure - Organization and Significant Accounting Policies, Cost of Products Sold (Details)",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesCostOfProductsSoldDetails",
     "shortName": "Organization and Significant Accounting Policies, Cost of Products Sold (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ions:CostOfProductsSoldPreviouslyRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:ResearchAndDevelopmentExpensePolicy",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090112 - Disclosure - Organization and Significant Accounting Policies, Research, Development and Patent Expenses (Details)",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails",
     "shortName": "Organization and Significant Accounting Policies, Research, Development and Patent Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:ResearchAndDevelopmentExpensePolicy",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ions:AccruedClinicalExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090114 - Disclosure - Organization and Significant Accounting Policies, Accrued Liabilities (Details)",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails",
     "shortName": "Organization and Significant Accounting Policies, Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ions:AccruedClinicalExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191001to20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ions:SharesReceivedFromSubsidiaryForLicenseOfDrug",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090116 - Disclosure - Organization and Significant Accounting Policies, Noncontrolling Interest in Akcea Therapeutics, Inc. (Details)",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails",
     "shortName": "Organization and Significant Accounting Policies, Noncontrolling Interest in Akcea Therapeutics, Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ions:NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment",
      "reportCount": 1,
      "unitRef": "U009",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090118 - Disclosure - Organization and Significant Accounting Policies, Cash, Cash Equivalents and Investments (Details)",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndInvestmentsDetails",
     "shortName": "Organization and Significant Accounting Policies, Cash, Cash Equivalents and Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryWriteDown",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20180101to20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090120 - Disclosure - Organization and Significant Accounting Policies, Inventory Valuation (Details)",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails",
     "shortName": "Organization and Significant Accounting Policies, Inventory Valuation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryWriteDown",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20180101to20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090122 - Disclosure - Organization and Significant Accounting Policies, Property, Plant and Equipment (Details)",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails",
     "shortName": "Organization and Significant Accounting Policies, Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090124 - Disclosure - Organization and Significant Accounting Policies, Leases (Details)",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLeasesDetails",
     "shortName": "Organization and Significant Accounting Policies, Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20181231_AdjustmentsForNewAccountingPronouncementsAxis_AccountingStandardsUpdate201602Member",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090126 - Disclosure - Organization and Significant Accounting Policies, Long-Lived Assets (Details)",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLonglivedAssetsDetails",
     "shortName": "Organization and Significant Accounting Policies, Long-Lived Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090128 - Disclosure - Organization and Significant Accounting Policies, Stock-Based Compensation Expense (Details)",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesStockbasedCompensationExpenseDetails",
     "shortName": "Organization and Significant Accounting Policies, Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090130 - Disclosure - Organization and Significant Accounting Policies, Accumulated Other Comprehensive Loss (Details)",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails",
     "shortName": "Organization and Significant Accounting Policies, Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtInstrumentInterestRateStatedPercentage",
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "U003",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090132 - Disclosure - Organization and Significant Accounting Policies, Convertible Debt (Details)",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesConvertibleDebtDetails",
     "shortName": "Organization and Significant Accounting Policies, Convertible Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U010",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090134 - Disclosure - Organization and Significant Accounting Policies, Segment Information (Details)",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesSegmentInformationDetails",
     "shortName": "Organization and Significant Accounting Policies, Segment Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U010",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090136 - Disclosure - Organization and Significant Accounting Policies, Fair Value Measurements (Details)",
     "role": "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails",
     "shortName": "Organization and Significant Accounting Policies, Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ions:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U003",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090200 - Disclosure - Investments, Contract Maturity of Available-for-Sale Securities (Details)",
     "role": "http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails",
     "shortName": "Investments, Contract Maturity of Available-for-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ions:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U003",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090202 - Disclosure - Investments, Summary of Investments (Details)",
     "role": "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails",
     "shortName": "Investments, Summary of Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ions:DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "030000 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "role": "http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U011",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090204 - Disclosure - Investments, Investments Temporarily Impaired (Details)",
     "role": "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails",
     "shortName": "Investments, Investments Temporarily Impaired (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U011",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ions:LongTermDebtAndOtherObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090300 - Disclosure - Long-Term Obligations and Commitments, Long-Term Obligations (Details)",
     "role": "http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails",
     "shortName": "Long-Term Obligations and Commitments, Long-Term Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ions:LongTermDebtAndOtherObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191201to20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ions:CallSpread",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090302 - Disclosure - Long-Term Obligations and Commitments, Convertible Notes (Details)",
     "role": "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails",
     "shortName": "Long-Term Obligations and Commitments, Convertible Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191201to20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ions:CallSpread",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190701to20190930_DebtInstrumentAxis_FixedRateNoteWithMorganStanleyMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfLongTermLinesOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090304 - Disclosure - Long-Term Obligations and Commitments, Line of Credit Arrangement (Details)",
     "role": "http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails",
     "shortName": "Long-Term Obligations and Commitments, Line of Credit Arrangement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190701to20190930_DebtInstrumentAxis_FixedRateNoteWithMorganStanleyMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfLongTermLinesOfCredit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ions:GainLossOnExtinguishmentOfFinancingLiability",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090306 - Disclosure - Long-Term Obligations and Commitments, Research and Development and Manufacturing Facilities (Details)",
     "role": "http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails",
     "shortName": "Long-Term Obligations and Commitments, Research and Development and Manufacturing Facilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20170731_DebtInstrumentAxis_LongTermMortgageDebtMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090308 - Disclosure - Long-Term Obligations and Commitments, Maturity Schedules (Details)",
     "role": "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails",
     "shortName": "Long-Term Obligations and Commitments, Maturity Schedules (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231_DebtInstrumentAxis_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090310 - Disclosure - Long-Term Obligations and Commitments, Operating Leases (Details)",
     "role": "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails",
     "shortName": "Long-Term Obligations and Commitments, Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090400 - Disclosure - Stockholders' Equity, Preferred and Common Stock (Details)",
     "role": "http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails",
     "shortName": "Stockholders' Equity, Preferred and Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231_StatementClassOfStockAxis_PreferredStockMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190930",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090402 - Disclosure - Stockholders' Equity, Share Repurchase Program (Details)",
     "role": "http://isispharm.com/role/StockholdersEquityShareRepurchaseProgramDetails",
     "shortName": "Stockholders' Equity, Share Repurchase Program (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190930",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231_AwardTypeAxis_StockOptionMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090404 - Disclosure - Stockholders' Equity, Stock Plans (Details)",
     "role": "http://isispharm.com/role/StockholdersEquityStockPlansDetails",
     "shortName": "Stockholders' Equity, Stock Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231_PlanNameAxis_StockOptionPlan1989Member",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20161231_StatementEquityComponentsAxis_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "040000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20161231_StatementEquityComponentsAxis_CommonStockMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20181231_AwardTypeAxis_StockOptionMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090406 - Disclosure - Stockholders' Equity, Stock Option Activity (Details)",
     "role": "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails",
     "shortName": "Stockholders' Equity, Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231_AwardTypeAxis_StockOptionMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20181231_AwardTypeAxis_RestrictedStockUnitsRSUMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090408 - Disclosure - Stockholders' Equity, Restricted Stock Unit Activity (Details)",
     "role": "http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails",
     "shortName": "Stockholders' Equity, Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231_AwardTypeAxis_RestrictedStockUnitsRSUMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090410 - Disclosure - Stockholders' Equity, Stock-based Compensation Expense (Details)",
     "role": "http://isispharm.com/role/StockholdersEquityStockbasedCompensationExpenseDetails",
     "shortName": "Stockholders' Equity, Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U003",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090412 - Disclosure - Stockholders' Equity, Stock-based Valuation Information (Details)",
     "role": "http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails",
     "shortName": "Stockholders' Equity, Stock-based Valuation Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231_AwardTypeAxis_EmployeeStockOptionMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U003",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090500 - Disclosure - Income Taxes, Income (Loss) Before Income Taxes (Details)",
     "role": "http://isispharm.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails",
     "shortName": "Income Taxes, Income (Loss) Before Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090502 - Disclosure - Income Taxes, Income Tax Expense (Benefit) (Details)",
     "role": "http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails",
     "shortName": "Income Taxes, Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090504 - Disclosure - Income Taxes, Reconciliation of Statutory to Effective Tax Rate (Details)",
     "role": "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails",
     "shortName": "Income Taxes, Reconciliation of Statutory to Effective Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090506 - Disclosure - Income Taxes, Deferred Tax Assets and Liabilities (Details)",
     "role": "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes, Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231_IncomeTaxAuthorityNameAxis_InternalRevenueServiceIRSMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090508 - Disclosure - Income Taxes, Tax Credit Carryforwards (Details)",
     "role": "http://isispharm.com/role/IncomeTaxesTaxCreditCarryforwardsDetails",
     "shortName": "Income Taxes, Tax Credit Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231_IncomeTaxAuthorityNameAxis_InternalRevenueServiceIRSMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "U003",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090510 - Disclosure - Income Taxes, Tax Act (Details)",
     "role": "http://isispharm.com/role/IncomeTaxesTaxActDetails",
     "shortName": "Income Taxes, Tax Act (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtInstrumentInterestRateStatedPercentage",
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes1PercentMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "U003",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "040100 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "role": "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20181231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090512 - Disclosure - Income Taxes, Gross Unrecognized Tax Benefits (Details)",
     "role": "http://isispharm.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes, Gross Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20161231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090600 - Disclosure - Collaborative Arrangements and Licensing Agreements, Biogen (Details)",
     "role": "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
     "shortName": "Collaborative Arrangements and Licensing Agreements, Biogen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBiogenMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090602 - Disclosure - Collaborative Arrangements and Licensing Agreements, AstraZeneca (Details)",
     "role": "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
     "shortName": "Collaborative Arrangements and Licensing Agreements, AstraZeneca (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U003",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090604 - Disclosure - Collaborative Arrangements and Licensing Agreements, Bayer (Details)",
     "role": "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
     "shortName": "Collaborative Arrangements and Licensing Agreements, Bayer (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20181231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsBayerMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090606 - Disclosure - Collaborative Arrangements and Licensing Agreements, GSK (Details)",
     "role": "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
     "shortName": "Collaborative Arrangements and Licensing Agreements, GSK (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20100301to20100331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember",
      "decimals": "-6",
      "lang": null,
      "name": "ions:UpfrontPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090608 - Disclosure - Collaborative Arrangements and Licensing Agreements, Janssen Biotech, Inc. (Details)",
     "role": "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
     "shortName": "Collaborative Arrangements and Licensing Agreements, Janssen Biotech, Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20141231_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember",
      "decimals": "INF",
      "lang": null,
      "name": "ions:NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U017",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090610 - Disclosure - Collaborative Arrangements and Licensing Agreements, Roche (Details)",
     "role": "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails",
     "shortName": "Collaborative Arrangements and Licensing Agreements, Roche (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231_TypeOfArrangementAxis_CollaborativeArrangementsAndLicensingAgreementsRocheMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190201to20190228",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "ions:SublicenseFeePaidForLicenseOfDrug",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090612 - Disclosure - Collaborative Arrangements and Licensing Agreements, Novartis (Details)",
     "role": "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
     "shortName": "Collaborative Arrangements and Licensing Agreements, Novartis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20170101to20170331_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U002",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190201to20190228",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ions:ReceiptOfSharesInSubsidiary",
      "reportCount": 1,
      "unitRef": "U002",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090614 - Disclosure - Collaborative Arrangements and Licensing Agreements, Pfizer (Details)",
     "role": "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
     "shortName": "Collaborative Arrangements and Licensing Agreements, Pfizer (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191001to20191031_ConsolidatedEntitiesAxis_AkceaTherapeuticsIncMember_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember",
      "decimals": "-6",
      "lang": null,
      "name": "ions:UpfrontPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090616 - Disclosure - Collaborative Arrangements and Licensing Agreements, PTC Therapeutics (Details)",
     "role": "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
     "shortName": "Collaborative Arrangements and Licensing Agreements, PTC Therapeutics (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20180831_TypeOfArrangementAxis_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember",
      "decimals": "INF",
      "lang": null,
      "name": "ions:RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U005",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "050000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U010",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090700 - Disclosure - Segment Information and Concentration of Business Risk, Segment Information (Details)",
     "role": "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails",
     "shortName": "Segment Information and Concentration of Business Risk, Segment Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U010",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CreditConcentrationRiskMember_MajorCustomersAxis_SignificantPartnersMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U003",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090702 - Disclosure - Segment Information and Concentration of Business Risk, Contracts Receivable from Significant Partners (Details)",
     "role": "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails",
     "shortName": "Segment Information and Concentration of Business Risk, Contracts Receivable from Significant Partners (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CreditConcentrationRiskMember_MajorCustomersAxis_SignificantPartnersMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U003",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ions:DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "090800 - Disclosure - Employment Benefits (Details)",
     "role": "http://isispharm.com/role/EmploymentBenefitsDetails",
     "shortName": "Employment Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20190101to20191231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ions:DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191001to20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "091000 - Disclosure - Quarterly Financial Data (Unaudited) (Details)",
     "role": "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails",
     "shortName": "Quarterly Financial Data (Unaudited) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191001to20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U001",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtInstrumentInterestRateStatedPercentage",
       "div",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10k.htm",
      "contextRef": "c20191231_DebtInstrumentAxis_ConvertibleSeniorNotes0125PercentMember",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unitRef": "U003",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "050100 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)",
     "role": "http://isispharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 150,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ions_AKCEAANGPTL3LActivePharmaceuticalIngredientMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The active pharmaceutical ingredient, or API, for AKCEA-ANGPTL3-L, a LIgand-Conjugated Antisense, or LICA, medicine designed to inhibit the production of the angiopoietin-like 3, or ANGPTL3, protein.",
        "label": "AKCEA-ANGPTL3-L Active Pharmaceutical Ingredient [Member]",
        "terseLabel": "AKCEA-ANGPTL3-L API [Member]"
       }
      }
     },
     "localname": "AKCEAANGPTL3LActivePharmaceuticalIngredientMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_AKCEAANGPTL3LMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AKCEA-ANGPTL3-L is a LIgand-Conjugated Antisense, or LICA, medicine designed to inhibit the production of the angiopoietin-like 3, or ANGPTL3, protein.",
        "label": "AKCEA-ANGPTL3-L [Member]"
       }
      }
     },
     "localname": "AKCEAANGPTL3LMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_AKCEAAPOALMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An antisense therapy with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of the lipoprotein Lp(a).",
        "label": "AKCEA-APO(a)-L [Member]",
        "terseLabel": "AKCEA-APO(a)-L [Member]"
       }
      }
     },
     "localname": "AKCEAAPOALMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_AKCEAAPOCIIILMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An antisense therapy with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of the lipoprotein ApoCIII.",
        "label": "AKCEA-APOCIII-L [Member]",
        "terseLabel": "AKCEA-APOCIII-L [Member]"
       }
      }
     },
     "localname": "AKCEAAPOCIIILMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_AccruedClinicalExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued clinical expenses",
        "terseLabel": "Clincial expenses"
       }
      }
     },
     "localname": "AccruedClinicalExpenses",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_AccruedInLicensingFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for in-licensing fees under collaboration agreements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued in-licensing fees, Current",
        "terseLabel": "In-licensing expenses"
       }
      }
     },
     "localname": "AccruedInLicensingFeesCurrent",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_AdditionalAmountOfCommonStockRequiredToBePurchased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The additional amount of common stock the collaboration partner is required to purchase under a Stock Purchase Agreement (SPA) in conjunction with the collaboration agreement.",
        "label": "Additional amount of common stock required to be purchased",
        "terseLabel": "Additional amount of common stock required to be purchased"
       }
      }
     },
     "localname": "AdditionalAmountOfCommonStockRequiredToBePurchased",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the redemption of convertible debt instruments as two separate components - a debt component and an equity component.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Redemption",
        "negatedLabel": "1 percent convertible senior notes retirement, equity portion, net of tax"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtRedemption",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_AkceaTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Akcea Therapeutics, Inc. is a subsidiary of the Company and was formed to develop and commercialize drugs for cardiometabolic disorders.",
        "label": "Akcea Therapeutics, Inc. [Member]",
        "terseLabel": "Akcea [Member]"
       }
      }
     },
     "localname": "AkceaTherapeuticsIncMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails",
      "http://isispharm.com/role/StockholdersEquityStockbasedCompensationExpenseDetails",
      "http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails",
      "http://isispharm.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_AkceaTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reportable segment which includes the operations of the Company's wholly-owned subsidiary, Akcea Therapeutics, Inc., which was formed to develop and commercialize drugs for cardiometabolic disorders.",
        "label": "Akcea Therapeutics [Member]"
       }
      }
     },
     "localname": "AkceaTherapeuticsMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_AntisenseMoleculeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Each antisense molecule that is chosen for drug discovery and development to advance the treatment of neurological diseases.",
        "label": "Antisense Molecule [Member]"
       }
      }
     },
     "localname": "AntisenseMoleculeMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill and an other than temporary decline in value that has been recognized against investments accounted for under the cost method of accounting.",
        "label": "Asset Impairment Charges, including other than temporary impairment in Cost-method Investments",
        "terseLabel": "Non-cash losses related to patents, licensing, property, plant and equipment and investments"
       }
      }
     },
     "localname": "AssetImpairmentChargesIncludingOtherThanTemporaryImpairmentInCostMethodInvestments",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of available-for-sale debt securities that mature beyond one year but within two years of the balance sheet date.",
        "label": "Available-for-sale Securities, Debt Maturities, after One Through Two Years, Percentage",
        "terseLabel": "After one year but within two years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsPercentage",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ions_AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of available-for-sale debt securities that mature beyond two years but within three and one-half years of the balance sheet date.",
        "label": "Available-for-sale Securities, Debt Maturities, after Two Through Three and One Half Years, Percentage",
        "terseLabel": "After two years but within three and a half years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTwoThroughThreeAndOneHalfYearsPercentage",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate percentage of all available-for-sale debt securities, regardless of maturity.",
        "label": "Available-for-sale Securities, Debt Maturities, Total, Percentage",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ions_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "ions_AvailableForSaleSecuritiesDebtMaturitiesTotalPercentage",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of available-for-sale debt securities that mature within one year of the balance sheet date.",
        "label": "Available-for-sale Securities, Debt Maturities, within One Year, Percentage",
        "terseLabel": "One year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearPercentage",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ions_AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of available-for-sale debt securities that mature within two years of the balance sheet date.",
        "label": "Available-for-sale Securities, Debt Maturities, within Two Years, Percentage",
        "terseLabel": "Percentage of available-for-sale securities with a maturity of less than two years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ions_BiogenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biogen Inc. is an American multinational biotechnology company.",
        "label": "Biogen Inc. [Member]",
        "terseLabel": "Biogen [Member]"
       }
      }
     },
     "localname": "BiogenIncMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_BoardOfDirectorStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby a member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement, as a form of compensation.",
        "label": "Board of Director Stock Option [Member]",
        "terseLabel": "Board of Director Stock Options [Member]"
       }
      }
     },
     "localname": "BoardOfDirectorStockOptionMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CallSpread": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net cash outflow from payments for hedge transactions and proceeds from the issuance of warrants. The call spread transaction was entered into to minimize the impact of potential economic dilution upon conversion of the 0.125% notes issued.",
        "label": "Call Spread",
        "terseLabel": "Cost of call spread"
       }
      }
     },
     "localname": "CallSpread",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_CashCashEquivalentsAndInvestmentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash, cash equivalents and investments.",
        "label": "Cash, Cash Equivalents and Investments [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndInvestmentsPolicyTextBlock",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ions_ClinicalRawMaterialsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Raw materials purchased for use in producing medicines that have alternative future uses until they are used.",
        "label": "Clinical Raw Materials [Member]",
        "terseLabel": "Clinical Member]"
       }
      }
     },
     "localname": "ClinicalRawMaterialsMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementAndLicensingAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Collaborative Arrangement and Licensing Agreement [Abstract]"
       }
      }
     },
     "localname": "CollaborativeArrangementAndLicensingAgreementAbstract",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to collaborative arrangement with Bayer HealthCare amended in February 2017 to advance IONIS-FXIRx for the prevention of thrombosis and to initiate development of IONIS-FXI-LRx.",
        "label": "Collaborative Arrangement and Licensing Agreement Amended in February 2017 with Bayer [Member]",
        "terseLabel": "Bayer [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the collaborative arrangement entered into with Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd., collectively Roche, in April 2013 to develop treatments for Huntington's disease, or HD, based on the Company's antisense technology.",
        "label": "Collaborative Arrangement and Licensing Agreement Entered Into in April 2013 with Roche [Member]",
        "terseLabel": "Huntington's Disease [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the expanded collaborative arrangement entered into with Biogen Inc. in April 2018 to develop novel antisense drug candidates for a broad range of neurological diseases.",
        "label": "Collaborative Arrangement and Licensing Agreement Entered Into in April 2018 with Biogen [Member]",
        "terseLabel": "2018 Strategic Neurology [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the collaborative arrangement entered into with PTC Therapeutics by Akcea Therapeutics, Inc. in August 2018 to commercialize TEGSEDI and WAYLIVRA in Latin America.",
        "label": "Collaborative Arrangement and Licensing Agreement Entered Into in August 2018 with PTC Therapeutics [Member]",
        "terseLabel": "PTC Therapeutics [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the collaborative arrangement entered into with AstraZeneca PLC in December 2012 and amended in January 2016 to discover and develop antisense drugs for cancer.",
        "label": "Collaborative Arrangement and Licensing Agreement Entered Into in December 2012 with AstraZeneca [Member]",
        "terseLabel": "Oncology [Member]",
        "verboseLabel": "AstraZeneca [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the collaborative arrangement entered into with Biogen Inc. in December 2012. This agreement is focused on developing and commercializing novel antisense drugs for up to three targets to treat neurological or neuromuscular diseases (Neurology).",
        "label": "Collaborative Arrangement and Licensing Agreement Entered Into in December 2012 with Biogen [Member]",
        "terseLabel": "2012 Neurology [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the collaborative arrangement entered into with Janssen Biotech, Inc. in December 2014 to discover and develop antisense drugs that can be locally administered, including oral delivery, to treat autoimmune disorders of the gastrointestinal tract.",
        "label": "Collaborative Arrangement and Licensing Agreement Entered Into in December 2014 with Janssen Biotech, Inc. [Member]",
        "terseLabel": "Janssen Biotech, Inc. [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2014WithJanssenBiotechIncMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the collaborative arrangement entered into with Biogen Inc. in December 2017 to identify new antisense oligonucleotide drug candidates for the treatment of spinal muscular atrophy, or SMA.",
        "label": "Collaborative Arrangement and Licensing Agreement Entered Into in December 2017 with Biogen [Member]",
        "terseLabel": "New Antisense Medicines for the Treatment of SMA [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2017WithBiogenMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the collaborative arrangement entered into with Biogen Inc. in January 2012 to develop and commercialize nusinersen for the treatment of spinal muscular atrophy, or SMA, a severe motor-neuron disease that is the leading genetic cause of infant mortality.",
        "label": "Collaborative Arrangement and Licensing Agreement Entered Into in January 2012 with Biogen [Member]",
        "terseLabel": "SPINRAZA [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2012WithBiogenMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the collaborative arrangements and licensing agreements entered into with Novartis to develop and commercialize AKCEA-APO(a)-L and AKCEA-APOCIII-L.",
        "label": "Collaborative Arrangement and Licensing Agreement Entered Into in January 2017 with Novartis [Member]",
        "terseLabel": "Novartis [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementAndLicensingAgreementEnteredIntoInJanuary2017WithNovartisMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the collaborative arrangement entered into with AstraZeneca PLC in July 2015 to discover and develop antisense therapies for treating cardiovascular and metabolic diseases primarily focused on targets in the kidney and renal diseases.",
        "label": "Collaborative Arrangement and Licensing Agreement Entered Into in July 2015 with AstraZeneca [Member]",
        "terseLabel": "Cardiovascular, Renal and Metabolic Diseases [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the collaborative arrangement entered into with Alnylam Pharmaceuticals, Inc. in March 2004 to develop and commercialize RNAi therapeutics.",
        "label": "Collaborative Arrangement and Licensing Agreement Entered Into in March 2004 with Alnylam Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Alnylam [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the collaborative arrangement and licensing agreement entered into with GlaxoSmithKline (GSK) in March 2010 to discover and develop new drugs against targets for rare and serious diseases, including infectious diseases and some conditions causing blindness.",
        "label": "Collaborative Arrangement and Licensing Agreement Entered Into in March 2010 with GSK [Member]",
        "terseLabel": "GSK [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2010WithGSKMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to collaborative arrangement entered into with Bayer HealthCare in May 2015 to develop and commercialize IONIS-FXI for the prevention of thrombosis.",
        "label": "Collaborative Arrangement and Licensing Agreement Entered Into in May 2015 with Bayer [Member]",
        "terseLabel": "Bayer [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the collaborative arrangement entered into with Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd., collectively Roche, in October 2018 to develop IONIS-FB-LRx for the treatment of complement-mediated diseases.",
        "label": "Collaborative Arrangement and Licensing Agreement Entered Into in October 2018 with Roche [Member]",
        "terseLabel": "IONIS-FB-L for Complement-Mediated Diseases [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the collaborative arrangements and licensing agreements entered into with Pfizer for the license of AKCEA-ANGPTL3-LR to treat people with cardiovascular and metabolic diseases..",
        "label": "Collaborative Arrangement and Licensing Agreement Entered Into in October 2019 with Pfizer [Member]",
        "terseLabel": "Pfizer [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the collaborative arrangement entered into with Biogen Inc. in September 2013. This agreement is a long-term strategic relationship focused on applying antisense technology to advance the treatment of neurodegenerative diseases (Strategic Neurology).",
        "label": "Collaborative Arrangement and Licensing Agreement Entered Into in September 2013 with Biogen [Member]",
        "terseLabel": "2013 Strategic Neurology [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementsAndLicensingAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Collaborative Arrangements and Licensing Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndLicensingAgreementsAbstract",
     "nsuri": "http://isispharm.com/20191231",
     "xbrltype": "stringItemType"
    },
    "ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the collaborative arrangements and licensing agreements entered into with AstraZeneca PLC.",
        "label": "Collaborative Arrangements and Licensing Agreements, AstraZeneca [Member]",
        "terseLabel": "AstraZeneca [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the collaborative arrangements and licensing agreements entered into with Bayer HealthCare.",
        "label": "Collaborative Arrangements and Licensing Agreements, Bayer [Member]",
        "terseLabel": "Bayer [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndLicensingAgreementsBayerMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementsAndLicensingAgreementsBiogenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the collaborative arrangements and licensing agreements entered into with Biogen Inc.",
        "label": "Collaborative Arrangements and Licensing Agreements, Biogen [Member]",
        "terseLabel": "Biogen [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndLicensingAgreementsBiogenMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementsAndLicensingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents collaborative arrangements and licensing agreements to which the entity is party.",
        "label": "Collaborative Arrangements and Licensing Agreements [Member]",
        "verboseLabel": "Collaborative Agreements [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndLicensingAgreementsMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to the collaborative arrangements and licensing agreements entered into with Hoffman-La Roche Inc. and F. Hoffmann-La Roche Ltd., collectively Roche.",
        "label": "Collaborative Arrangements and Licensing Agreements, Roche [Member]",
        "terseLabel": "Roche [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndLicensingAgreementsRocheMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions Disclosure [Line Items]",
        "terseLabel": "Collaborative Arrangements and Licensing Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureLineItems",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ions_CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangements and non-collaborative arrangement transactions.",
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions Disclosure [Table]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNonCollaborativeArrangementTransactionsDisclosureTable",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ions_CommercialMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commercial [Member]",
        "terseLabel": "Commercial Revenue [Member]"
       }
      }
     },
     "localname": "CommercialMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CommercialRawMaterialsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Raw materials purchased for manufacturing medicines for commercial production.",
        "label": "Commercial Raw Materials [Member]",
        "terseLabel": "Commercial [Member]"
       }
      }
     },
     "localname": "CommercialRawMaterialsMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "0.125 percent convertible senior notes due December 2024 that were issued in exchange for 1 percent notes in December 2019.",
        "label": "Convertible Senior Notes 0.125 Percent, Issued in Exchange for 1 Percent Notes [Member]",
        "terseLabel": "0.125 Percent Convertible Senior Notes Issued in Exchange for 1 Percent Notes [Member]"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes0125PercentIssuedInExchangeFor1PercentNotesMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "0.125 percent convertible senior notes due December 2024 that were issued under subscription agreements in December 2019.",
        "label": "Convertible Senior Notes 0.125 Percent, Issued under Subscription Agreements [Member]",
        "terseLabel": "0.125 Percent Convertible Senior Notes Issued under Subscription Agreements [Member]"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes0125PercentIssuedUnderSubscriptionAgreementsMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_ConvertibleSeniorNotes0125PercentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "0.125 percent convertible senior notes due December 2024.",
        "label": "Convertible Senior Notes 0.125 Percent [Member]",
        "terseLabel": "0.125 Percent Convertible Senior Notes [Member]",
        "verboseLabel": "0.125% Convertible Senior Notes [Member]"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes0125PercentMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets",
      "http://isispharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesConvertibleDebtDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_ConvertibleSeniorNotes1PercentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "1 percent convertible senior notes due November 2021.",
        "label": "Convertible Senior Notes 1 Percent [Member]",
        "terseLabel": "1 Percent Convertible Senior Notes [Member]",
        "verboseLabel": "1% Convertible Senior Notes [Member]"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes1PercentMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets",
      "http://isispharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesConvertibleDebtDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_ConvertibleSeniorNotes275PercentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2 3/4 percent convertible senior notes due October 2019.",
        "label": "Convertible Senior Notes 2.75 Percent [Member]",
        "terseLabel": "2 3/4 Percent Convertible Senior Notes [Member]"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes275PercentMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_CostOfProductsSoldPreviouslyRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The costs related to goods produced and sold that were previously recognized as expense and are related to the commercial revenue recognized during the period.",
        "label": "Cost of Products Sold Previously Recognized",
        "terseLabel": "Previously expensed costs to produce TEGSEDI related to TEGSEDI commercial revenue"
       }
      }
     },
     "localname": "CostOfProductsSoldPreviouslyRecognized",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesCostOfProductsSoldDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cumulative payments received since inception of the collaboration agreement included in the transaction price for the performance obligation.",
        "label": "Cumulative payments included in transaction price for performance obligation",
        "terseLabel": "Cumulative payments included in transaction price for performance obligation"
       }
      }
     },
     "localname": "CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_CumulativePaymentsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cumulative amount of payments received under the collaboration agreement as of the end of the reporting period.",
        "label": "Cumulative payments received",
        "terseLabel": "Cumulative payments received"
       }
      }
     },
     "localname": "CumulativePaymentsReceived",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_CumulativeRevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cumulative amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Cumulative Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Cumulative revenue earned"
       }
      }
     },
     "localname": "CumulativeRevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_DanvatirsenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Danvatirsen (formerly IONIS-STAT3-2.5, also known as AZD9150) was designed to treat cancer by inhibiting the production of a gene critical for tumor cell growth and survival. Signal transducer and activator of transcription 3, or STAT3, is over-active in a variety of cancers, including brain, lung, breast, bone, liver and multiple myeloma and promotes tumor cell growth and prevents cell death.",
        "label": "Danvatirsen [Member]",
        "terseLabel": "Danvatirsen [Member]"
       }
      }
     },
     "localname": "DanvatirsenMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_DebtInstrumentConvertibleConversionPriceIncludingCallSpread": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The computed conversion price per share of the debt instrument based on the the conversion feature embedded in the debt instrument and the impact of the purchased hedges in the call spread transaction.",
        "label": "Debt Instrument, Convertible, Conversion Price including call spread",
        "terseLabel": "Conversion price per share, including note hedges (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPriceIncludingCallSpread",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ions_DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of the principal amount of the notes to be purchased, plus accrued and unpaid interest, upon the occurrence of certain fundamental changes, as set forth in the indenture governing the convertible notes.",
        "label": "Debt Instrument, Convertible, Percentage of principal amount used as purchase price upon occurrence of fundamental change",
        "terseLabel": "Percentage of principal amount used as purchase price upon occurrence of fundamental change"
       }
      }
     },
     "localname": "DebtInstrumentConvertiblePercentageOfPrincipalAmountUsedAsPurchasePriceUponOccurrenceOfFundamentalChange",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of (1) investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Available-for-sale and Equity Securities, FV-NI",
        "totalLabel": "Estimated fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of (1) amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Available-for-sale and Equity Securities, FV-NI, Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails": {
       "order": 0.0,
       "parentTag": "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of (1) unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Available-for-sale and Equity Securities, FV-NI, Gross Unrealized Gain",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedGain",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of (1) unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and (2) unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Available-for-sale and Equity Securities, FV-NI, Gross Unrealized Loss",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiGrossUnrealizedLoss",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the net amount of deferred tax assets (before reduction for valuation allowance) and liabilities as of the balance sheet date, which result from applying the applicable enacted tax rate to net temporary differences and carryforwards pertaining to assets or liabilities.",
        "label": "Deferred Tax Assets (Liabilities), Net, before Valuation Allowance",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The limit of annual employee contributions to the plan per calendar year by eligible employees who are over 50 years of age.",
        "label": "Defined Contribution Plan, Employee Contribution Limit by Plan Participants over Fifty Years Age",
        "terseLabel": "Employee contribution limit per calendar year for employees over 50 years of age"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/EmploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The limit of annual employee contributions to the plan per calendar year by eligible employees who are under 50 years of age.",
        "label": "Defined Contribution Plan, Employee Contribution Limit by Plan Participants under Fifty Years Age",
        "terseLabel": "Employee contribution limit per calendar year for employees under 50 years of age"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/EmploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_DeliveryOfAKCEAAPOALMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Delivery of AKCEA-APO(a)-L, an antisense therapy with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of the lipoprotein Lp(a).",
        "label": "Delivery of AKCEA-APO(a)-L [Member]",
        "terseLabel": "Delivery of AKCEA-APO(a)-L [Member]"
       }
      }
     },
     "localname": "DeliveryOfAKCEAAPOALMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_DeliveryOfAKCEAAPOCIIILMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Delivery of AKCEA-APOCIII-L, an antisense therapy with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of the lipoprotein ApoCIII.",
        "label": "Delivery of AKCEA-APOCIII-L [Member]",
        "terseLabel": "Delivery of AKCEA-APOCIII-L [Member]"
       }
      }
     },
     "localname": "DeliveryOfAKCEAAPOCIIILMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_DepositsAndOtherAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing deposits and other noncurrent assets.",
        "label": "Deposits and Other Assets [Member]"
       }
      }
     },
     "localname": "DepositsAndOtherAssetsMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 16.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to an adjustment for the deconsolidation of a subsidiary from the consolidated federal income tax return on the date of the subsidiary's Initial Public Offering (IPO).",
        "label": "Effective Income Tax Rate Reconciliation, Deconsolidation Adjustment for Subsidiary at IPO, Amount",
        "terseLabel": "Akcea deconsolidation adjustment at IPO"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoAmount",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to an adjustment for the deconsolidation of a subsidiary from the consolidated federal income tax return on the date of the subsidiary's Initial Public Offering (IPO).",
        "label": "Effective Income Tax Rate Reconciliation, Deconsolidation Adjustment for Subsidiary at IPO, Percent",
        "terseLabel": "Akcea deconsolidation adjustment at IPO"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeconsolidationAdjustmentForSubsidiaryAtIpoPercent",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to licensing gain on TEGSEDI.",
        "label": "Effective Income Tax Rate Reconciliation, Drug Licensing Gain, Amount",
        "terseLabel": "TEGSEDI licensing gain"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDrugLicensingGainAmount",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to licensing gain on TEGSEDI.",
        "label": "Effective Income Tax Rate Reconciliation, Drug Licensing Gain, Percent",
        "terseLabel": "TEGSEDI licensing gain"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDrugLicensingGainPercent",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the expiration of net operating loss carryforwards.",
        "label": "Effective Income Tax Rate Reconciliation, Expiration of Net Operating Loss, Amount",
        "terseLabel": "Net operating loss expiration"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossAmount",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the expiration of net operating loss carryforwards.",
        "label": "Effective Income Tax Rate Reconciliation, Expiration of Net Operating Loss, Percent",
        "terseLabel": "Net operating loss expiration"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingLossPercent",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 18.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign-derived intangible income benefit.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign-derived intangible income benefit, Amount",
        "terseLabel": "Foreign-derived intangible income benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitAmount",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 16.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign-derived intangible income benefit.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign-derived intangible income benefit, Percent",
        "terseLabel": "Foreign-derived intangible income benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignDerivedIntangibleIncomeBenefitPercent",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the impact from outside basis differences.",
        "label": "Effective Income Tax Rate Reconciliation, Impact from outside basis differences, Amount",
        "terseLabel": "Impact from outside basis differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesAmount",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the impact from outside basis differences.",
        "label": "Effective Income Tax Rate Reconciliation, Impact from outside basis differences, Percent",
        "terseLabel": "Impact from outside basis differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationImpactFromOutsideBasisDifferencesPercent",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to compensation in excess of $1 million paid to any \"covered employee\" of the corporation under Section 162(m) of the Tax Act.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Excess Compensation, Amount",
        "verboseLabel": "Non-deductible compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationAmount",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to compensation in excess of $1 million paid to any \"covered employee\" of the corporation under Section 162(m) of the Tax Act.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Excess Compensation, Percent",
        "terseLabel": "Non-deductible compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseExcessCompensationPercent",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ions_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the 2009 Employee Stock Purchase Plan, as amended and restated, which permits full-time employees to purchase common stock through payroll deductions at a percentage of the fair market value.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_EquipmentAndComputerSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems and purchased software applications and internally developed software for long-term internal use. Includes other tangible personal property, nonconsumable in nature, with finite lives used to produce goods and services, such as laboratory, manufacturing and other equipment.",
        "label": "Equipment and Computer Software [Member]",
        "terseLabel": "Computer Software, Laboratory, Manufacturing and Other Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentAndComputerSoftwareMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_EquityIncentivePlan2011Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the stock option plan that provides for the issuance of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and performance cash awards to employees, directors, and consultants.",
        "label": "Equity Incentive Plan 2011 [Member]",
        "terseLabel": "2011 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlan2011Member",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_FixedRateNoteWithMorganStanleyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fixed rate note with Morgan Stanley Private Bank, National Association under a five-year revolving credit agreement dated June 16, 2015 and amended February 24, 2016.",
        "label": "Fixed Rate Note with Morgan Stanley [Member]",
        "terseLabel": "Fixed Rate Note with Morgan Stanley [Member]"
       }
      }
     },
     "localname": "FixedRateNoteWithMorganStanleyMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_GainLossOnExtinguishmentOfFinancingLiability": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the purchase price of the facility and the carrying value of our financing liability at the time of the purchase.",
        "label": "Gain (Loss) on Extinguishment of Financing Liability",
        "negatedLabel": "Loss on extinguishment of financing liability for leased facility",
        "terseLabel": "Loss on extinguishment of financing liability for leased facility"
       }
      }
     },
     "localname": "GainLossOnExtinguishmentOfFinancingLiability",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_ION532Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A drug designed to treat a genetically associated form of kidney disease.",
        "label": "ION532 [Member]",
        "terseLabel": "ION532 [Member]"
       }
      }
     },
     "localname": "ION532Member",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_ION581Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ION581 is an antisense oligonucleotide (ASO) that targets Ubiquitin Protein Ligase E3A-Antisense Transcript (UBE3A-ATS), which is a long non-coding ribonucleic acid (lncRNA). ION581 reduces the levels of UBE3A-ATS and is being developed as a potential therapy for Angelman Syndrome (AS).",
        "label": "ION581 [Member]",
        "terseLabel": "ION581 [Member]"
       }
      }
     },
     "localname": "ION581Member",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_ION736Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ION736, formerly known as IONIS-AZ7-2.5, is a Generation 2.5 antisense drug.",
        "label": "ION736 [Member]",
        "terseLabel": "ION736 [Member]"
       }
      }
     },
     "localname": "ION736Member",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_ION839Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A drug designed to inhibit an undisclosed target to treat patients with nonalcoholic steatohepatitis, or NASH.",
        "label": "ION839 [Member]",
        "terseLabel": "IOIN839 [Member]"
       }
      }
     },
     "localname": "ION839Member",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_ION859Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ION859 (BIIB094) is an antisense medicine designed to inhibit the production of the Leucine Rich Repeat Kinase 2, or LRRK2, protein as a potential therapy for Parkinson's disease, or PD.",
        "label": "ION859 [Member]",
        "terseLabel": "ION859 [Member]"
       }
      }
     },
     "localname": "ION859Member",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_IONISC9Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "IONIS-C9Rx is an antisense medicine designed to selectively inhibit the production of the mutated chromosome 9 open reading frame 72, or C9ORF72, gene.",
        "label": "IONIS-C9 [Member]",
        "terseLabel": "IONIS-C9 [Member]"
       }
      }
     },
     "localname": "IONISC9Member",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_IONISFXILMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "IONIS-FXI-L [Member]",
        "terseLabel": "IONIS-FXI-L [Member]"
       }
      }
     },
     "localname": "IONISFXILMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_IONISJBI125Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "IONIS-JBI1-2.5 [Member]",
        "terseLabel": "IONIS-JBI1-2.5 [Member]"
       }
      }
     },
     "localname": "IONISJBI125Member",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_IONISJBI225Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "IONIS-JBI2-2.5 [Member]",
        "terseLabel": "IONIS-JBI2-2.5 [Member]"
       }
      }
     },
     "localname": "IONISJBI225Member",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_IONISMAPTMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "IONIS-MAPT is an antisense drug designed to selectively reduce the production of microtubule-associated protein tau (MAPT), or tau protein, in the brain, for the treatment of Alzheimer's disease.",
        "label": "IONIS-MAPT [Member]",
        "terseLabel": "IONIS-MAPT [Member]"
       }
      }
     },
     "localname": "IONISMAPTMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_IncludedInDepositsAndOtherAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount related to amortized cost balance included in Deposits and other assets on the statement of financial position.",
        "label": "Included in Deposits and Other Assets [Member]",
        "terseLabel": "Included in Deposits and Other Assets [Member]"
       }
      }
     },
     "localname": "IncludedInDepositsAndOtherAssetsMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_IncludedInOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount related to amortized cost balance included in Other current assets on the statement of financial position.",
        "label": "Included in Other Current Assets [Member]",
        "terseLabel": "Included in Other Current Assets [Member]"
       }
      }
     },
     "localname": "IncludedInOtherCurrentAssetsMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 24.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and the change during the period in carrying value for all deferred liabilities due within one year or operating cycle.",
        "label": "Increase (Decrease) in Accrued Liabilities and Deferred Liabilities",
        "terseLabel": "Accrued liabilities and deferred rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndDeferredLiabilities",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_IncreaseDecreaseInStateTaxLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in state tax liability.",
        "label": "Increase (Decrease) in State Tax Liability",
        "terseLabel": "Decrease in combined state tax liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInStateTaxLiability",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of shares issuable under the Company's employee stock purchase plan (ESPP).",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Employee Stock Purchase Plan",
        "terseLabel": "Shares issuable related to our ESPP (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfEmployeeStockPurchasePlan",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ions_IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of shares issuable related to employee stock purchase plan.",
        "label": "Incremental Common Shares Attributable to Employee Stock Purchase Plan",
        "verboseLabel": "Shares issuable related to our Employee Stock Purchase Plan (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToEmployeeStockPurchasePlan",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ions_IonisCoreMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reportable segment in which the Company is exploiting a novel drug discovery platform created to generate a broad pipeline of first-in-class or best-in-class drugs for the Company and its partners. This segment generates revenue from a multifaceted partnering strategy. This strategy includes revenue from collaborations with preferred partners, traditional alliances and working with a consortium of companies that can exploit the Company's drugs and technology. Revenue from collaborations with preferred partners and traditional alliances may consist of upfront payments, milestone payments, licensing fees and royalties.",
        "label": "Ionis Core [Member]",
        "terseLabel": "Ionis [Member]"
       }
      }
     },
     "localname": "IonisCoreMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_LeasesAndOtherObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Details pertaining to leases and other obligations not separately disclosed in the financial statements.",
        "label": "Leases and Other Obligations [Member]"
       }
      }
     },
     "localname": "LeasesAndOtherObligationsMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of options to extend the lease under the lessee's operating leasing arrangement.",
        "label": "Lessee, Leasing Arrangements, Operating Leases, Number of options to extend lease",
        "terseLabel": "Number of options to extend lease"
       }
      }
     },
     "localname": "LesseeLeasingArrangementsOperatingLeasesNumberOfOptionsToExtendLease",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_LesseeOperatingLeaseAllowanceForTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allowance for tenant improvements to the office space included in the lessee's operating lease.",
        "label": "Lessee, Operating Lease, Allowance for Tenant Improvements",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAllowanceForTenantImprovements",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_LesseeOperatingLeaseInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information on lessee's operating leases, including carrying value of right-of-use assets and lease liabilities, weighted-average remaining term and weighted-average discount rate.",
        "label": "Lessee, Operating Lease Information [Table Text Block]",
        "terseLabel": "Amounts Related to Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseInformationTableTextBlock",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ions_LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Initial letter of credit provided to lessor to secure lease obligation under lessee's operating lease.",
        "label": "Lessee, Operating Lease, Initial Letter of Credit to Secure Lease Obligation",
        "terseLabel": "Initial amount of letter of credit"
       }
      }
     },
     "localname": "LesseeOperatingLeaseInitialLetterOfCreditToSecureLeaseObligation",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Letter of credit provided to lessor to secure lease obligation under lessee's operating lease on the fifth anniversary of the rent commencement date.",
        "label": "Lessee, Operating Lease, Letter of Credit to Secure Lease Obligation on Fifth Anniversary of Rent Commencement Date",
        "terseLabel": "Letter of credit on fifth anniversary of rent commencement date"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnFifthAnniversaryOfRentCommencementDate",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Letter of credit provided to lessor to secure lease obligation under lessee's operating lease on the third anniversary of the rent commencement date.",
        "label": "Lessee, Operating Lease, Letter of Credit to Secure Lease Obligation on Third Anniversary of Rent Commencement Date",
        "terseLabel": "Letter of credit on third anniversary of rent commencement date"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLetterOfCreditToSecureLeaseObligationOnThirdAnniversaryOfRentCommencementDate",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_LesseeOperatingLeasePeriodOfFreeRent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time in which the rent is free under operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Period of Free Rent",
        "terseLabel": "Period of free rent under lease"
       }
      }
     },
     "localname": "LesseeOperatingLeasePeriodOfFreeRent",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ions_LicensingAndOtherRoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from license fees and other royalties, excluding royalties from the sale of SPINRAZA.",
        "label": "Licensing and Other Royalties [Member]",
        "terseLabel": "Licensing and Other Royalties [Member]",
        "verboseLabel": "Licensing and Other Royalty Revenue [Member]"
       }
      }
     },
     "localname": "LicensingAndOtherRoyaltiesMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_LongTermDebtAndOtherObligations": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of long-term debt, capital lease and other obligations (with maturities initially due after one year or beyond the operating cycle if longer).",
        "label": "Long-term Debt and Other Obligations",
        "totalLabel": "Total long-term obligations, including current portion"
       }
      }
     },
     "localname": "LongTermDebtAndOtherObligations",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_LongTermDebtAndOtherObligationsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails": {
       "order": 1.0,
       "parentTag": "ions_LongTermDebtAndOtherObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt, capital lease and other obligations due after one year or beyond the normal operating cycle, if longer.",
        "label": "Long-term Debt and Other Obligations, Noncurrent",
        "terseLabel": "Total Long-Term Obligations",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebtAndOtherObligationsNoncurrent",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_LongTermMortgageDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two loan agreements with UBS AG entered into on July 18, 2017 to partially finance the purchase of the Company's research and development and manufacturing facilities.",
        "label": "Long-term Mortgage Debt [Member]",
        "terseLabel": "Long-term Mortgage Debt [Member]"
       }
      }
     },
     "localname": "LongTermMortgageDebtMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the aggregate of all long-term obligations of the entity, including capital leases and other financing arrangements, excluding the long-term financing liability for the entity's leased research and development facility.",
        "label": "Long-Term Obligations, Excluding Financing Liability for Leased Facility [Member]"
       }
      }
     },
     "localname": "LongTermObligationsExcludingFinancingLiabilityForLeasedFacilityMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_LongTermObligationsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-term Obligations, Noncurrent",
        "terseLabel": "Long-term obligations, less current portion"
       }
      }
     },
     "localname": "LongTermObligationsNoncurrent",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount of payments receivable for each additional drug developed under the collaboration agreement.",
        "label": "Maximum amount of payment receivable for each additional drug developed",
        "terseLabel": "Maximum amount of payment receivable for each additional drug developed"
       }
      }
     },
     "localname": "MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount of payments receivable for commercialization milestones under the collaboration agreement.",
        "label": "Maximum amount of payments receivable for commercialization milestones",
        "terseLabel": "Maximum amount of payments receivable for commercialization milestones"
       }
      }
     },
     "localname": "MaximumAmountOfPaymentsReceivableForCommercializationMilestones",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount of payments receivable for development milestones under the collaboration agreement.",
        "label": "Maximum amount of payments receivable for development milestones",
        "terseLabel": "Maximum amount of payments receivable for development milestones"
       }
      }
     },
     "localname": "MaximumAmountOfPaymentsReceivableForDevelopmentMilestones",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount of payments receivable for development, regulatory and sales milestones under the collaboration agreement.",
        "label": "Maximum amount of payments receivable for development, regulatory and sales milestones",
        "terseLabel": "Maximum amount of payments receivable for development, regulatory and sales milestones"
       }
      }
     },
     "localname": "MaximumAmountOfPaymentsReceivableForDevelopmentRegulatoryAndSalesMilestones",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount of payments receivable for license fees and substantive milestones under the collaboration agreement.",
        "label": "Maximum amount of payments receivable for license fees and substantive milestones",
        "terseLabel": "Maximum amount of payments receivable for license fees and milestones"
       }
      }
     },
     "localname": "MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_MaximumAmountOfPaymentsReceivableForMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount of payments receivable for milestones under the collaboration agreement.",
        "label": "Maximum amount of payments receivable for milestones",
        "terseLabel": "Maximum amount of payments receivable for milestones"
       }
      }
     },
     "localname": "MaximumAmountOfPaymentsReceivableForMilestones",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount of payments receivable for regulatory milestones under the collaboration agreement.",
        "label": "Maximum amount of payments receivable for regulatory milestones",
        "terseLabel": "Maximum amount of payments receivable for regulatory milestones"
       }
      }
     },
     "localname": "MaximumAmountOfPaymentsReceivableForRegulatoryMilestones",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_MaximumAmountOfPaymentsReceivableForSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount of payments receivable for sales milestones under the collaboration agreement.",
        "label": "Maximum amount of payments receivable for sales milestones"
       }
      }
     },
     "localname": "MaximumAmountOfPaymentsReceivableForSalesMilestones",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount of payments receivable per drug for substantive milestone payments under the collaboration agreement.",
        "label": "Maximum amount of payments receivable per drug for substantive milestone payments",
        "terseLabel": "Maximum amount of payments receivable per drug for substantive milestone payments"
       }
      }
     },
     "localname": "MaximumAmountOfPaymentsReceivablePerDrugForSubstantiveMilestonePayments",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount of payments receivable per drug or program for development milestone payments under the collaboration agreement.",
        "label": "Maximum amount of payments receivable per drug or program for development milestones",
        "terseLabel": "Maximum amount of payments receivable per program for development milestones"
       }
      }
     },
     "localname": "MaximumAmountOfPaymentsReceivablePerDrugOrProgramForDevelopmentMilestones",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount of payments receivable per drug or program for license fees and/or substantive milestone payments under the collaboration agreement.",
        "label": "Maximum amount of payments receivable per drug or program for license fees and substantive milestone payments",
        "terseLabel": "Maximum amount of payments receivable per program for license fee and milestone payments"
       }
      }
     },
     "localname": "MaximumAmountOfPaymentsReceivablePerDrugOrProgramForLicenseFeesAndSubstantiveMilestonePayments",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount of payments receivable per drug or program for regulatory milestone payments under the collaboration agreement.",
        "label": "Maximum amount of payments receivable per drug or program for regulatory milestones",
        "terseLabel": "Maximum amount of payments receivable per program for regulatory milestones",
        "verboseLabel": "Maximum amount of payments receivable per drug for regulatory milestones"
       }
      }
     },
     "localname": "MaximumAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestones",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_MaximumContractMaturityPeriodRange1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum contract maturity period for the first range of available-for-sale securities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Maximum contract maturity period, range 1",
        "terseLabel": "Maximum contract maturity period, range 1"
       }
      }
     },
     "localname": "MaximumContractMaturityPeriodRange1",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ions_MaximumContractMaturityPeriodRange2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum contract maturity period for the second range of available-for-sale securities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Maximum contract maturity period, range 2",
        "terseLabel": "Maximum contract maturity period, range 2"
       }
      }
     },
     "localname": "MaximumContractMaturityPeriodRange2",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ions_MaximumContractMaturityPeriodRange3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum contract maturity period for the third range of available-for-sale securities, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Maximum contract maturity period, range 3",
        "terseLabel": "Maximum contract maturity period, range 3"
       }
      }
     },
     "localname": "MaximumContractMaturityPeriodRange3",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ions_MaximumPaymentReceivableUnderLicenseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount of payments expected to be received under the license agreement.",
        "label": "Maximum payment receivable under license agreement",
        "terseLabel": "Maximum payment receivable under license agreement"
       }
      }
     },
     "localname": "MaximumPaymentReceivableUnderLicenseAgreement",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_MedicinesForAmyotrophicLateralSclerosisMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medicines to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, a nervous system disease that weakens muscles and impacts physical function.",
        "label": "Medicines for Amyotrophic Lateral Sclerosis [Member]",
        "terseLabel": "Medicines for ALS [Member]"
       }
      }
     },
     "localname": "MedicinesForAmyotrophicLateralSclerosisMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_MedicinesForUndisclosedTargetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medicines to treat undisclosed targets under the collaboration agreement.",
        "label": "Medicines for Undisclosed Targets [Member]",
        "terseLabel": "Medicines for Undisclosed Targets [Member]"
       }
      }
     },
     "localname": "MedicinesForUndisclosedTargetsMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_MilestonePaymentAchieved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Milestone payment achieved during the period.",
        "label": "Milestone payment achieved"
       }
      }
     },
     "localname": "MilestonePaymentAchieved",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_MilestonePaymentsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of milestone payments received during the period under the collaboration agreement.",
        "label": "Milestone payments received",
        "terseLabel": "Milestone payments received"
       }
      }
     },
     "localname": "MilestonePaymentsReceived",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum amount of payments receivable for license fees and substantive milestones under the collaboration agreement.",
        "label": "Minimum amount of payments receivable for license fees and substantive milestones",
        "terseLabel": "Minimum amount of payments receivable for license fees and milestones"
       }
      }
     },
     "localname": "MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_MorganStanleyPrivateBankNationalAssociationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Morgan Stanley Private Bank, National Association offers banking and credit products and services. The company was founded in 1996 and is based in Purchase, New York. Morgan Stanley Private Bank, National Association operates as a subsidiary of Morgan Stanley.",
        "label": "Morgan Stanley Private Bank, National Association [Member]",
        "terseLabel": "Morgan Stanley [Member]"
       }
      }
     },
     "localname": "MorganStanleyPrivateBankNationalAssociationMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_NextPotentialMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The next potential milestone payment to be earned under the collaboration agreement.",
        "label": "Next potential milestone payment",
        "terseLabel": "Next prospective milestone"
       }
      }
     },
     "localname": "NextPotentialMilestonePayment",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_NextPotentialPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The next potential payment to be earned under the collaboration agreement.",
        "label": "Next potential payment",
        "terseLabel": "Next prospective payment"
       }
      }
     },
     "localname": "NextPotentialPayment",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_NonCashCapitalAndPatentExpenditures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets and patents that have been incurred.",
        "label": "Non-cash Capital and Patent Expenditures",
        "terseLabel": "Amounts accrued for capital and patent expenditures"
       }
      }
     },
     "localname": "NonCashCapitalAndPatentExpenditures",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders in an initial public offering.",
        "label": "Noncontrolling Interest, Increase from New Issues by Subsidiary",
        "terseLabel": "Noncontrolling interest in Akcea Therapeutics, Inc. in conjunction with initial public offering"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromNewIssuesBySubsidiary",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_NonemployeeDirectorsStockOptionPlan2002Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the 2002 Non-Employee Directors Stock Option Plan, which provided for the issuance of stock options to the entity's non-employee directors for the purchase of common stock.",
        "label": "Nonemployee Directors' Stock Option Plan 2002 [Member]",
        "terseLabel": "2002 Non-Employee Directors' Stock Option Plan [Member]"
       }
      }
     },
     "localname": "NonemployeeDirectorsStockOptionPlan2002Member",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_NovartisInternationalAGMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland.",
        "label": "Novartis International AG [Member]",
        "terseLabel": "Novartis [Member]"
       }
      }
     },
     "localname": "NovartisInternationalAGMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_NumberOfAgreementsWithCollaborationPartner": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of agreements entered into with the collaboration partner.",
        "label": "Number of agreements with collaboration partner",
        "terseLabel": "Number of agreements"
       }
      }
     },
     "localname": "NumberOfAgreementsWithCollaborationPartner",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_NumberOfCountriesWhereDrugIsApprovedForUse": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of countries where the drug is approved for treatment in patients.",
        "label": "Number of countries where drug is approved for use",
        "terseLabel": "Number of countries where SPINRAZA is approved for use"
       }
      }
     },
     "localname": "NumberOfCountriesWhereDrugIsApprovedForUse",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_NumberOfDrugsBeingDeveloped": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of drugs currently being developed under the collaboration agreement(s).",
        "label": "Number of drugs being developed",
        "terseLabel": "Number of drugs currently being developed"
       }
      }
     },
     "localname": "NumberOfDrugsBeingDeveloped",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_NumberOfDrugsCurrentlyBeingAdvanced": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of drugs currently being advanced under the collaboration agreement.",
        "label": "Number of drugs currently being advanced",
        "terseLabel": "Number of drugs currently being advanced"
       }
      }
     },
     "localname": "NumberOfDrugsCurrentlyBeingAdvanced",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_NumberOfDrugsLicensedUnderOptionInCollaborationAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of drugs licensed by the partner under option in the collaboration agreement.",
        "label": "Number of drugs licensed under option in collaboration agreement",
        "terseLabel": "Number of drugs licensed under option"
       }
      }
     },
     "localname": "NumberOfDrugsLicensedUnderOptionInCollaborationAgreement",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of equal annual installments over which options become exercisable.",
        "label": "Number of equal annual installments over which options become exercisable"
       }
      }
     },
     "localname": "NumberOfEqualAnnualInstallmentsOverWhichOptionsBecomeExercisable",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of executive officers terminated by the Company during the period that begins three months before and ends twelve months following a change in control of the Company when vesting will accelerate for options and RSUs outstanding as of the termination date for executive officers",
        "label": "Number of executive officers terminated before change in control when vesting will accelerate for executive officers",
        "terseLabel": "Number of executive officers terminated before change in control when vesting will accelerate for executive officers"
       }
      }
     },
     "localname": "NumberOfExecutiveOfficersTerminatedBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_NumberOfExecutiveOfficersTerminatingEmployment": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of executive officers terminating employment with the company.",
        "label": "Number of executive officers terminating employment",
        "terseLabel": "Number of executive officers terminating employment"
       }
      }
     },
     "localname": "NumberOfExecutiveOfficersTerminatingEmployment",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_NumberOfLicenseFeesEarned": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of license fees earned during the period under the collaboration agreement.",
        "label": "Number of license fees earned",
        "terseLabel": "Number of license fees earned"
       }
      }
     },
     "localname": "NumberOfLicenseFeesEarned",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_NumberOfLicensedDrugs": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of drugs that have been licensed under the collaboration agreement.",
        "label": "Number of licensed drugs",
        "terseLabel": "Number of licensed drugs"
       }
      }
     },
     "localname": "NumberOfLicensedDrugs",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_NumberOfMilestonePaymentsAchieved": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of milestone payments achieved during the period under the collaboration agreement.",
        "label": "Number of milestone payments achieved",
        "terseLabel": "Number of milestone payments achieved"
       }
      }
     },
     "localname": "NumberOfMilestonePaymentsAchieved",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_NumberOfNewTargetsAdvanced": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of new targets advanced during the period under the collaboration agreement.",
        "label": "Number of new targets advanced",
        "terseLabel": "Number of new targets advanced"
       }
      }
     },
     "localname": "NumberOfNewTargetsAdvanced",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_NumberOfPerformanceObligationsCompleted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of performance obligations completed under the collaboration agreement.",
        "label": "Number of performance obligations completed",
        "terseLabel": "Number of performance obligations completed"
       }
      }
     },
     "localname": "NumberOfPerformanceObligationsCompleted",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of privately-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for under the cost method.",
        "label": "Number of Privately-Held Companies in which Entity has Equity Investment",
        "terseLabel": "Number of privately-held companies in which there is an equity ownership interest of less than 20%"
       }
      }
     },
     "localname": "NumberOfPrivatelyHeldCompaniesInWhichEntityHasEquityInvestment",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_NumberOfProgramsAdvanced": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of programs advanced under the collaboration agreement.",
        "label": "Number of programs advanced",
        "terseLabel": "Number of programs advanced"
       }
      }
     },
     "localname": "NumberOfProgramsAdvanced",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of programs under which drugs are to be developed and commercialized under the collaboration agreement.",
        "label": "Number of programs under which drugs are to be developed and commercialized",
        "terseLabel": "Number of programs under which drugs are to be developed and commercialized"
       }
      }
     },
     "localname": "NumberOfProgramsUnderWhichDrugsAreToBeDevelopedAndCommercialized",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of publicly-held companies, in which the entity has an equity ownership interest of less than 20%, with which it conducts business. These are accounted for at fair value.",
        "label": "Number of Publicly-Held Companies in which Entity has Equity Investment",
        "terseLabel": "Number of publicly-held companies in which there is an equity ownership interest of less than 20%"
       }
      }
     },
     "localname": "NumberOfPubliclyHeldCompaniesInWhichEntityHasEquityInvestment",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_NumberOfSignificantPartners": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of significant partners.",
        "label": "Number of Significant Partners",
        "terseLabel": "Number of significant partners"
       }
      }
     },
     "localname": "NumberOfSignificantPartners",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_NumberOfTargetsAdvanced": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of targets advanced under the collaboration agreement.",
        "label": "Number of targets advanced",
        "terseLabel": "Number of targets advanced"
       }
      }
     },
     "localname": "NumberOfTargetsAdvanced",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_NumberOfTargetsToBeDevelopedAndCommercialized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of targets to be developed and commercialized under the collaboration agreement.",
        "label": "Number of targets to be developed and commercialized",
        "terseLabel": "Number of drugs to be developed and commercialized"
       }
      }
     },
     "localname": "NumberOfTargetsToBeDevelopedAndCommercialized",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Office and laboratory space in a facility adjacent to the Company's manufacturing facility leased under non-cancelable operating leases.",
        "label": "Office and Laboratory Space Adjacent to Manufacturing Facility [Member]",
        "terseLabel": "Office and Laboratory Space Adjacent to Manufacturing Facility [Member]"
       }
      }
     },
     "localname": "OfficeAndLaboratorySpaceAdjacentToManufacturingFacilityMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_OfficeSpaceForCorporateHeadquartersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Office space located in Boston, Massachusetts for Akcea Therapeutics, Inc.'s corporate headquarters leased under non-cancelable operating leases.",
        "label": "Office Space for Corporate Headquarters [Member]"
       }
      }
     },
     "localname": "OfficeSpaceForCorporateHeadquartersMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_OfficeSpaceSubleasedToAkceaTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Office space subleased to Akcea Therapeutics, Inc. (Akcea) leased under non-cancelable operating leases.",
        "label": "Office Space Subleased to Akcea Therapeutics, Inc. [Member]",
        "terseLabel": "Office Space Subleased to Akcea [Member]"
       }
      }
     },
     "localname": "OfficeSpaceSubleasedToAkceaTherapeuticsIncMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_OperatingLeaseRightOfUseAssetAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of right-of-use operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortization",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_PatentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Patent [Abstract]",
        "terseLabel": "Patents [Abstract]"
       }
      }
     },
     "localname": "PatentAbstract",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ions_PatentExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Includes charges for amortization and write-downs of capitalized patent costs as well as legal fees for patent litigation and patent defense.",
        "label": "Patent Expenses",
        "terseLabel": "Patent expenses"
       }
      }
     },
     "localname": "PatentExpenses",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_PaymentReceivedForAdvancingPrograms": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of payments received during the period for advancing programs under the collaboration agreement.",
        "label": "Payment received for advancing programs",
        "terseLabel": "Payment received for advancing programs"
       }
      }
     },
     "localname": "PaymentReceivedForAdvancingPrograms",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_PaymentToSettleFinancingLiabilityForLeasedFacility": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow paid to settle financing liability for leased facility.",
        "label": "Payment to settle financing liability for leased facility",
        "negatedLabel": "Payment to settle financing liability for leased facility"
       }
      }
     },
     "localname": "PaymentToSettleFinancingLiabilityForLeasedFacility",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_PaymentsIncludedInTransactionPriceForPerformanceObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments received under the collaboration agreement during the period included in the transaction price for the performance obligation.",
        "label": "Payments included in transaction price for performance obligation",
        "terseLabel": "Payments included in transaction price for performance obligation"
       }
      }
     },
     "localname": "PaymentsIncludedInTransactionPriceForPerformanceObligation",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_PaymentsToAcquireCostMethodInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of investments accounted for under the cost method of accounting.",
        "label": "Payments to Acquire Cost Method Investments",
        "negatedLabel": "Purchase of strategic investments"
       }
      }
     },
     "localname": "PaymentsToAcquireCostMethodInvestments",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_PaymentsToAcquireLicensesAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for acquisition of licenses and other assets not otherwise defined in the taxonomy.",
        "label": "Payments to Acquire Licenses and Other Assets",
        "negatedLabel": "Acquisition of licenses and other assets, net"
       }
      }
     },
     "localname": "PaymentsToAcquireLicensesAndOtherAssets",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_PercentageCashPremiumPaidOnSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage cash premium paid per share of the Company's common stock under the collaboration agreement.",
        "label": "Percentage cash premium paid on shares purchased",
        "terseLabel": "Percentage cash premium paid on shares purchased"
       }
      }
     },
     "localname": "PercentageCashPremiumPaidOnSharesPurchased",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ions_PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of license fees, milestone payments and royalties paid as sublicense fee under the collaboration agreement.",
        "label": "Percentage of license fees, milestone payments and royalties paid as sublicense fee",
        "terseLabel": "Percentage of license fees, milestone payments and royalties paid as sublicense fee"
       }
      }
     },
     "localname": "PercentageOfLicenseFeesMilestonePaymentsAndRoyaltiesPaidAsSublicenseFee",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ions_PeriodAfterBillingWhenPaymentIsReceived": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The time period between billing a collaboration partner for goods delivered or services performed that are due unconditionally and payment is received from the collaboration partner, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period after billing when payment is received",
        "terseLabel": "Period of time after billing when payment is received"
       }
      }
     },
     "localname": "PeriodAfterBillingWhenPaymentIsReceived",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesContractsReceivableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ions_PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time after a change in control of the Company when vesting will accelerate for options and RSUs outstanding as of the termination date for executive officers, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period after change in control when vesting will accelerate for executive officers",
        "terseLabel": "Period after change in control when vesting will accelerate for executive officers"
       }
      }
     },
     "localname": "PeriodAfterChangeInControlWhenVestingWillAccelerateForExecutiveOfficers",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ions_PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time before a change in control of the Company when vesting will accelerate for options and RSUs outstanding as of the termination date for executive officers, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period before change in control when vesting will accelerate for executive officers",
        "terseLabel": "Period before change in control when vesting will accelerate for executive officers"
       }
      }
     },
     "localname": "PeriodBeforeChangeInControlWhenVestingWillAccelerateForExecutiveOfficers",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ions_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time before collaboration partner pays royalties on net sales of product after first commercial sale in Brazil, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period before collaboration partner pays royalties on net sales of product after first commercial sale in Brazil",
        "terseLabel": "Period before PTC pays royalties on net sales of product after first commercial sale in Brazil"
       }
      }
     },
     "localname": "PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ions_PeriodToMakeInterestOnlyPaymentsOnMortgageLoan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time to make only payments of interest on the mortgage loan, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Period to make interest only payments on mortgage loan",
        "terseLabel": "Period to make interest only payments on mortgage loan"
       }
      }
     },
     "localname": "PeriodToMakeInterestOnlyPaymentsOnMortgageLoan",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ions_PortionOfUpfrontPaymentPaidAsSublicenseFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of the upfront payment received during the period under the collaboration agreement that was paid as a sublicense fee.",
        "label": "Portion of upfront payment paid as sublicense fee",
        "terseLabel": "Portion of upfront payment paid as sublicense fee"
       }
      }
     },
     "localname": "PortionOfUpfrontPaymentPaidAsSublicenseFee",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_PortionOfUpfrontPaymentRetained": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of the upfront payment received during the period under the collaboration agreement that was retained by the entity.",
        "label": "Portion of upfront payment retained",
        "terseLabel": "Portion of upfront payment retained"
       }
      }
     },
     "localname": "PortionOfUpfrontPaymentRetained",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The potential premium received if common stock is purchased in the future under a Stock Purchase Agreement (SPA) in conjunction with the collaboration agreement.",
        "label": "Potential premium received if common stock is purchased in future",
        "terseLabel": "Potential premium received if common stock is purchased in the future"
       }
      }
     },
     "localname": "PotentialPremiumReceivedIfCommonStockIsPurchasedInFuture",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_PremiumPaidOnSharesPurchased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash premium paid on the purchase of the Company's common stock under the collaboration agreement.",
        "label": "Premium paid on shares purchased",
        "terseLabel": "Premium paid on shares purchased"
       }
      }
     },
     "localname": "PremiumPaidOnSharesPurchased",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_PremiumReceivedOnSharesIssued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of the premium received over the trading price of common stock at the time of purchase.",
        "label": "Premium received on shares issued",
        "terseLabel": "Premium received on shares issued"
       }
      }
     },
     "localname": "PremiumReceivedOnSharesIssued",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_PrimaryResearchAndDevelopmentFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility constructed for the entity's primary research and development activities under a lease agreement with an affiliate of BioMed Realty, L.P.",
        "label": "Primary Research and Development Facility [Member]",
        "terseLabel": "Primary R&amp;D Facility [Member]"
       }
      }
     },
     "localname": "PrimaryResearchAndDevelopmentFacilityMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_ProceedsFromSaleOfCommonStockIncludingPremiumPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the sale of common stock, including the premium paid for the purchase of common stock.",
        "label": "Proceeds from sale of common stock, including premium paid",
        "terseLabel": "Proceeds from sale of common stock"
       }
      }
     },
     "localname": "ProceedsFromSaleOfCommonStockIncludingPremiumPaid",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_PropertyPlantAndEquipmentExcludingLandMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business and not intended for resale, excluding land. Examples include, but are not limited to, buildings, land and leasehold improvements, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Excluding Land [Member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentExcludingLandMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_ReceiptOfSharesInSubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares received from the subsidiary during the period.",
        "label": "Receipt of shares in subsidiary",
        "terseLabel": "Additional shares of Akcea stock received (in shares)"
       }
      }
     },
     "localname": "ReceiptOfSharesInSubsidiary",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from research and development services performed under a collaboration agreement.",
        "label": "Research and Development Revenue Under Collaborative Agreements [Member]",
        "terseLabel": "R&amp;D Revenue [Member]",
        "verboseLabel": "R&amp;D Revenue Under Collaborative Agreements [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails",
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_ResearchAndDevelopmentServicesForAKCEAAPOALMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and development (R&amp;D) services for AKCEA-APO(a)-L, an antisense therapy with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of the lipoprotein Lp(a).",
        "label": "Research and Development Services for AKCEA-APO(a)-L [Member]",
        "terseLabel": "R&amp;D Services for AKCEA-APO(a)-L [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentServicesForAKCEAAPOALMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and development (R&amp;D) services for AKCEA-APOCIII-L, an antisense therapy with the potential to significantly reduce cardiovascular risk in patients suffering from high levels of the lipoprotein ApoCIII.",
        "label": "Research and Development Services for AKCEA-APOCIII-L [Member]",
        "terseLabel": "R&amp;D Services for AKCEA-APOCIII-L [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentServicesForAKCEAAPOCIIILMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_ResearchAndDevelopmentServicesForIONISFXILMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and development (R&amp;D) services for IONIS-FXI-L.",
        "label": "Research and Development Services for IONIS-FXI-L [Member]",
        "terseLabel": "R&amp;D Services for IONIS-FXI-L [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentServicesForIONISFXILMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_ResearchAndDevelopmentServicesForMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and development (R&amp;D) services for AKCEA-ANGPTL3-L, a LIgand-Conjugated Antisense, or LICA, medicine designed to inhibit the production of the angiopoietin-like 3, or ANGPTL3, protein.",
        "label": "Research and Development Services for AKCEA-ANGPTL3-L [Member]",
        "terseLabel": "R&amp;D Services for AKCEA-ANGPTL3-L [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentServicesForMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_ResearchDevelopmentAndPatentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects. Also includes charges for amortization and write-downs of capitalized patent costs, as well as legal fees for patent litigation and patent defense.",
        "label": "Research, Development and Patent Expense",
        "terseLabel": "Research, development and patent"
       }
      }
     },
     "localname": "ResearchDevelopmentAndPatentExpense",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_ResearchDevelopmentAndPatentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing research, development and patent expenses.",
        "label": "Research, Development and Patent [Member]",
        "terseLabel": "Research, Development and Patent [Member]"
       }
      }
     },
     "localname": "ResearchDevelopmentAndPatentMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_RevenueFromContractWithCustomerNumberOfNewPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of new performance obligations identified under the collaboration agreement.",
        "label": "Revenue from Contract with Customer, Number of new performance obligations",
        "terseLabel": "Number of new performance obligations"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerNumberOfNewPerformanceObligations",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of performance obligations at the inception of a contract.",
        "label": "Revenue from Contract with Customer, Number of performance obligations at inception of contract",
        "terseLabel": "Number of performance obligations at inception of contract"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of separate performance obligations under the collaboration agreement.",
        "label": "Revenue from Contract with Customer, Number of separate performance obligations",
        "terseLabel": "Number of separate performance obligations"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ions_RevenueFromContractWithCustomerTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of consideration the Company earned or is eligible to earn under the collaboration agreement, including any variable consideration.",
        "label": "Revenue from Contract with Customer, Transaction Price",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTransactionPrice",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_RevenueFromContractWithCustomerTransactionPriceAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The additional amount of consideration the Company earned under the collaboration agreement that is added to the transaction price.",
        "label": "Revenue from Contract with Customer, Transaction Price, Additions",
        "terseLabel": "Milestone payments received and added to transaction price"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTransactionPriceAdditions",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum amount of revenue recognized in Latin America by the collaboration partner before paying royalties.",
        "label": "Revenue recognized by collaboration partner in Latin America before paying royalties",
        "terseLabel": "Minimum revenue recognized in Latin America by PTC before paying royalties"
       }
      }
     },
     "localname": "RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The royalty percentage received on gross margins of drug(s) under the collaborative arrangement.",
        "label": "Royalty percentage received on gross margins of drugs under collaboration agreement",
        "terseLabel": "Royalty percentage received on gross margins of both drugs combined"
       }
      }
     },
     "localname": "RoyaltyPercentageReceivedOnGrossMarginsOfDrugsUnderCollaborationAgreement",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ions_RoyaltyPercentageReceivedOnNetSalesOfDrug": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty percentage received on the net sales of a drug by a collaboration partner under the collaboration agreement.",
        "label": "Royalty percentage received on net sales of drug",
        "terseLabel": "Royalty percentage received on net sales of drug"
       }
      }
     },
     "localname": "RoyaltyPercentageReceivedOnNetSalesOfDrug",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ions_RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty percentage received on the net sales of each drug in Latin America from the collaboration partner under the collaboration agreement.",
        "label": "Royalty percentage received on net sales of each drug in Latin America from collaboration partner",
        "terseLabel": "Royalty percentage received on net sales of each drug in Latin America from PTC"
       }
      }
     },
     "localname": "RoyaltyPercentageReceivedOnNetSalesOfEachDrugInLatinAmericaFromCollaborationPartner",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ions_RoyaltyPercentageReceivedOnSalesOfDrug": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty percentage received on the sales of a drug by a collaboration partner under the collaboration agreement.",
        "label": "Royalty percentage received on sales of drug",
        "terseLabel": "Royalty percentage received on sales of drug"
       }
      }
     },
     "localname": "RoyaltyPercentageReceivedOnSalesOfDrug",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ions_SPINRAZARoyaltiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty revenues from the sale of SPINRAZA (nusinersen).",
        "label": "SPINRAZA Royalties [Member]",
        "terseLabel": "SPINRAZA Royalties [Member]"
       }
      }
     },
     "localname": "SPINRAZARoyaltiesMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_SecuritiesWithMaturityOfMoreThanOneYearMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents investment securities with an expected maturity of more than one year.",
        "label": "Securities with Maturity of More than One Year [Member]"
       }
      }
     },
     "localname": "SecuritiesWithMaturityOfMoreThanOneYearMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_SecuritiesWithMaturityOfOneYearOrLessMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents investment securities with an expected maturity of one year or less.",
        "label": "Securities with Maturity of One Year or Less [Member]"
       }
      }
     },
     "localname": "SecuritiesWithMaturityOfOneYearOrLessMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the holding period from the date of purchase for stock purchased under the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Holding Period",
        "terseLabel": "Holding period for purchased stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardHoldingPeriod",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ions_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options exercised during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Fair Value",
        "terseLabel": "Weighted-average fair value of options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageFairValue",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ions_ShareBasedCompensationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation [Line Items]",
        "terseLabel": "Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationLineItems",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ions_ShareBasedCompensationTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based compensation.",
        "label": "Share-based Compensation [Table]"
       }
      }
     },
     "localname": "ShareBasedCompensationTable",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ions_SharesReceivedFromSubsidiaryForLicenseOfDrug": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of additional shares of stock received from Akcea Therapeutics, Inc. as a sublicense fee in connection with Pfizer licensing AKCEA-ANGPTL3-L.",
        "label": "Shares received from subsidiary for license of drug",
        "terseLabel": "Additional shares of Akcea stock received for license of AKCEA-ANGPTL3-L",
        "verboseLabel": "Additional shares of Akcea stock received for license of drug"
       }
      }
     },
     "localname": "SharesReceivedFromSubsidiaryForLicenseOfDrug",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ions_SignificantPartnersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Significant Partners [Abstract]"
       }
      }
     },
     "localname": "SignificantPartnersAbstract",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ions_SignificantPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Significant corporate partners and leading global pharmaceutical companies that are working alongside the Company to develop the Company's drugs, advance the Company's technology, and prepare to commercialize and sell the Company's drugs under collaborative arrangement and licensing agreements.",
        "label": "Significant Partners [Member]",
        "terseLabel": "Significant Partners [Member]"
       }
      }
     },
     "localname": "SignificantPartnersMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_StockIssuedDuringPeriodSharesNewIssuesBySubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued by subsidiary during the period.",
        "label": "Stock Issued During Period, Shares, New Issues by Subsidiary",
        "terseLabel": "Issuance of Akcea Therapeutics, Inc. common stock in conjunction with intial public offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssuesBySubsidiary",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "ions_StockIssuedDuringPeriodValueNewIssuesBySubsidiary": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period by a subsidiary. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues by Subsidiary",
        "terseLabel": "Issuance of Akcea Therapeutics, Inc. common stock in conjunction with intial public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssuesBySubsidiary",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_StockOptionPlan1989Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the 1989 Stock Option Plan, which provides the issuance of non-qualified and incentive stock options for the purchase of common stock to the entity's employees, directors and consultants.",
        "label": "Stock Option Plan 1989 [Member]",
        "terseLabel": "1989 Stock Option Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlan1989Member",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_SublicenseFeePaidForLicenseOfDrug": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of the sublicense fee paid in common stock.",
        "label": "Sublicense fee paid for license of drug",
        "terseLabel": "Sublicense fee paid in stock"
       }
      }
     },
     "localname": "SublicenseFeePaidForLicenseOfDrug",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_TegsediMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "TEGSEDI (inotersen) is a Generation 2+ antisense drug to treat people with hereditary TTR amyloidosis, or hATTR, a rare, progressive, fatal disease.",
        "label": "TEGSEDI [Member]",
        "terseLabel": "TEGSEDI [Member]"
       }
      }
     },
     "localname": "TegsediMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_TermOfCollaborationAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of the collaboration agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Term of collaboration agreement",
        "terseLabel": "Term of collaboration agreement"
       }
      }
     },
     "localname": "TermOfCollaborationAgreement",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ions_TofersenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tofersen (IONIS-SOD1Rx or BIIB067) is an antisense medicine designed to inhibit the production of superoxide dismutase 1, or SOD1, which is a well understood genetic cause of familial amyotrophic lateral sclerosis, or ALS.",
        "label": "Tofersen [Member]",
        "terseLabel": "Tofersen [Member]"
       }
      }
     },
     "localname": "TofersenMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_UpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of upfront payments received during the period under the collaboration agreement.",
        "label": "Upfront payment received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "UpfrontPaymentReceived",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_UpfrontPaymentReceivedIncludingPurchaseOfStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of the upfront payment received, including the purchase of shares of the Company's stock, under the collaboration agreement.",
        "label": "Upfront payment received, including purchase of stock",
        "terseLabel": "Upfront payment received, including purchase of stock"
       }
      }
     },
     "localname": "UpfrontPaymentReceivedIncludingPurchaseOfStock",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ions_WaylivraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "WAYLIVRA is a drug designed to treat two severe and rare, genetically defined diseases, familial chylomicronemia syndrome, or FCS, and familial partial lipodystrophy, or FPL.",
        "label": "WAYLIVRA [Member]",
        "terseLabel": "WAYLIVRA [Member]"
       }
      }
     },
     "localname": "WaylivraMember",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ions_WeightedAverageNumberOfSharesOwnedInSubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares owned in the subsidiary during the reporting period determined by relating the portion of time within a reporting period that shares have been owned to the total time in that period.",
        "label": "Weighted average number of shares owned in subsidiary",
        "terseLabel": "Weighted average shares owned in Akcea (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOwnedInSubsidiary",
     "nsuri": "http://isispharm.com/20191231",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r490",
      "r499"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by consolidated entity or group of entities.",
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/StockholdersEquityStockbasedCompensationExpenseDetails",
      "http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails",
      "http://isispharm.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity or group of entities consolidated into reporting entity.",
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/StockholdersEquityStockbasedCompensationExpenseDetails",
      "http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails",
      "http://isispharm.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r171",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.",
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Maturity Schedules"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r53",
      "r126",
      "r500"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r181",
      "r273",
      "r277",
      "r472"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails",
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.",
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r180",
      "r273",
      "r276",
      "r470",
      "r471"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Products and Services [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails",
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails",
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails",
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails",
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Topic 842 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "verboseLabel": "Contracts Receivables [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premium (discount) on investments, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r15",
      "r444",
      "r460"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accrued Liabilities [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r31",
      "r233"
     ],
     "calculation": {
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r54",
      "r63",
      "r66",
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Currency Translation Adjustment [Member]"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r56",
      "r57",
      "r58",
      "r63",
      "r66"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), including portion attributable to noncontrolling interest.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Including Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized Gains (Losses) on Securities [Member]"
       }
      }
     },
     "localname": "AccumulatedNetInvestmentGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r60",
      "r62",
      "r63"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r59",
      "r63",
      "r66",
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Loss [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "0.125 percent convertible senior notes, equity portion, net of issuance costs and tax"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "terseLabel": "Purchase of note hedges, net of tax"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Recognition and Exercise",
        "terseLabel": "Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r285",
      "r287",
      "r324",
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r241",
      "r255",
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Issuance of warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r287",
      "r318",
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r87",
      "r110",
      "r412"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of convertible senior notes discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r79",
      "r110",
      "r414"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r110",
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r110",
      "r221",
      "r226"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of patents"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfLeasedAsset": {
     "auth_ref": [
      "r110",
      "r418"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The expense charged against earnings for the periodic recognition of capitalized leases. This element may apply to energy companies that lease mineral producing properties and to other enterprises that capitalize property, plant, or equipment obtained through capital leases.",
        "label": "Amortization of Leased Asset",
        "terseLabel": "Amortization of long-term financing liability for leased facility"
       }
      }
     },
     "localname": "AmortizationOfLeasedAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r59",
      "r63",
      "r66",
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss [Member]"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r110",
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "verboseLabel": "Charges related to write-down of long-lived assets"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLonglivedAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetImpairmentChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Asset Impairment Charges [Abstract]",
        "terseLabel": "Long-Lived Assets [Abstract]"
       }
      }
     },
     "localname": "AssetImpairmentChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLonglivedAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r174",
      "r442",
      "r459"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Total assets as of current period",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r52"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r391"
     ],
     "calculation": {
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r194"
     ],
     "calculation": {
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r192",
      "r210"
     ],
     "calculation": {
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetailsCalc2": {
       "order": 0.0,
       "parentTag": "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-sale Securities",
        "verboseLabel": "Available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Temporarily Impaired Investments [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale that have been in a continuous loss position for twelve months or longer.",
        "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "Unrealized losses, more than 12 months of temporary impairment"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r198"
     ],
     "calculation": {
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale in a continuous loss position.",
        "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Unrealized losses, total temporary impairment"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the aggregate fair value of investments in debt and equity securities in an unrealized loss position which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value",
        "totalLabel": "Estimated fair value, total temporary impairment"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale that have been in a continuous loss position for less than twelve months.",
        "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "Unrealized losses, less than 12 months of temporary impairment"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for less than twelve months.",
        "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value",
        "terseLabel": "Estimated fair value, less than 12 months of temporary impairment"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the aggregate fair value of investments in debt and equity securities categorized neither as held-to-maturity nor trading securities that have been in a continuous unrealized loss position for twelve months or longer.",
        "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Twelve Months or Longer, Fair Value",
        "terseLabel": "Estimated fair value, more than 12 months of temporary impairment"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Available-for-sale Securities, Debt Maturities [Abstract]",
        "terseLabel": "Contract Maturity of Available-for-Sale Securities [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r189",
      "r193",
      "r210"
     ],
     "calculation": {
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r191",
      "r210"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Summary of Investments [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of investment positions in available-for-sale investments in a continuous unrealized loss position for which an other-than-temporary impairment (OTTI) has not been recognized in the income statement.",
        "label": "Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions",
        "terseLabel": "Number of investments"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r288",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesStockbasedCompensationExpenseDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails",
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails",
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails",
      "http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r388",
      "r389"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Building, Building Improvements and Building Systems [Member]"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the government of the state of California.",
        "label": "California Franchise Tax Board [Member]",
        "terseLabel": "California [Member]"
       }
      }
     },
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r114",
      "r115",
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property, plant and equipment included in long-term obligations"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r28",
      "r112"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-term Investments [Abstract]",
        "terseLabel": "Cash, Cash Equivalents and Investments [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesCashCashEquivalentsAndInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r104",
      "r112",
      "r117"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r104",
      "r406"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Class of Stock Disclosures [Abstract]",
        "terseLabel": "Share Repurchase Program [Abstract]"
       }
      }
     },
     "localname": "ClassOfStockDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityShareRepurchaseProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityShareRepurchaseProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r365",
      "r366",
      "r368"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Arrangements and Licensing Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Legal Proceedings [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Common Stock [Abstract]"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)",
        "verboseLabel": "Common stock, shares authorized to issue (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.001 par value; 300,000,000 shares authorized, 140,339,615 and 137,928,828 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Employment Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r69",
      "r71",
      "r72"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r69",
      "r71",
      "r372",
      "r373",
      "r383"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "verboseLabel": "Comprehensive income (loss) attributable to noncontrolling interest in Akcea Therapeutics, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r69",
      "r71",
      "r371",
      "r383"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r162",
      "r163",
      "r403",
      "r404"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r162",
      "r163",
      "r403",
      "r404",
      "r474"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r162",
      "r163",
      "r403",
      "r404",
      "r474"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r157",
      "r456"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r162",
      "r163",
      "r403",
      "r404"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r162",
      "r163",
      "r403",
      "r404"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r119",
      "r374",
      "r384",
      "r385"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "auth_ref": [
      "r119",
      "r122",
      "r374",
      "r384",
      "r385",
      "r386"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "terseLabel": "Noncontrolling Interest in Akcea Therapeutics, Inc."
       }
      }
     },
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Contracts Receivable [Abstract]",
        "terseLabel": "Contracts Receivable [Abstract]"
       }
      }
     },
     "localname": "ContractReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesContractsReceivableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r269",
      "r271",
      "r274"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, Net, Current",
        "terseLabel": "Contracts receivable"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r269",
      "r270",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Contract with Customer, Liability [Abstract]",
        "terseLabel": "Deferred Revenue [Abstract]"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r269",
      "r270",
      "r274"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion of deferred contract revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r269",
      "r270",
      "r274"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term deferred contract revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized from amounts in beginning deferred revenue balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueAfterFifthYear": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Contractual Obligation, Due after Fifth Year",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "ContractualObligationDueAfterFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInFifthYear": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Contractual Obligation, Due in Fifth Year",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "ContractualObligationDueInFifthYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInFourthYear": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Contractual Obligation, Due in Fourth Year",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "ContractualObligationDueInFourthYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Contractual Obligation, Due in Next Fiscal Year",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInSecondYear": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Contractual Obligation, Due in Second Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "ContractualObligationDueInSecondYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligationDueInThirdYear": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contractual obligation due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Contractual Obligation, Due in Third Year",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "ContractualObligationDueInThirdYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Convertible Debt, Noncurrent",
        "terseLabel": "Convertible senior notes",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "ConvertibleDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.",
        "label": "Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Convertible Notes [Abstract]"
       }
      }
     },
     "localname": "ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockTermsOfConversion": {
     "auth_ref": [
      "r17",
      "r18",
      "r256",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Specific terms relevant to convertibility. Includes class of preferred stock and number of shares convertible into, exercise (or conversion) price or rates, dates relevant to conversion timing and events relevant to conversion. Describe also any beneficial conversion features. where convertible preferred stock with a nondetachable conversion feature is in-the-money at commitment date. For contingently convertible preferred stock, discuss the circumstances of the contingency, including the events or changes in circumstance that would cause the contingency to be met and any of the significant features necessary to understand the conversion rights and the timing of those rights. Include also an events or changes in circumstance, if any, that could adjust or change the contingency, conversion price, or number of shares, including significant terms of those changes.",
        "label": "Conversion ratio"
       }
      }
     },
     "localname": "ConvertiblePreferredStockTermsOfConversion",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r280",
      "r282",
      "r473"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails",
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cost of Goods and Services Sold [Abstract]",
        "terseLabel": "Cost of Products Sold [Abstract]"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesCostOfProductsSoldDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of Products Sold [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Products Sold"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      },
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "terseLabel": "Operating expenses",
        "totalLabel": "Total operating expenses",
        "verboseLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditConcentrationRiskMember": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.",
        "label": "Credit Concentration [Member]"
       }
      }
     },
     "localname": "CreditConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r125",
      "r353",
      "r358"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r131",
      "r355"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r125",
      "r353",
      "r358"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current income tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current [Abstract]"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r125",
      "r353",
      "r358"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Strategic Partner [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtAndCapitalLeasesDisclosuresTextBlock": {
     "auth_ref": [
      "r250",
      "r419"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for debt and capital lease obligations can be reported. Information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. Also includes descriptions and amounts of capital leasing arrangements that consist of direct financing, sales type and leveraged leases. Disclosure may include the effect on the balance sheet and the income statement resulting from a change in lease classification for leases that at inception would have been classified differently had guidance been in effect at the inception of the original lease.",
        "label": "Debt and Capital Leases Disclosures [Text Block]",
        "verboseLabel": "Long-Term Obligations and Commitments"
       }
      }
     },
     "localname": "DebtAndCapitalLeasesDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Long-Term Obligations and Commitments [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r13",
      "r15",
      "r16",
      "r443",
      "r445",
      "r457"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets",
      "http://isispharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesConvertibleDebtDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r16",
      "r244",
      "r445",
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Principal amount of convertible notes outstanding"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "auth_ref": [
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.",
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Carrying value of equity component"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Conversion price per share (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": {
     "auth_ref": [
      "r40",
      "r256",
      "r259",
      "r261"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.",
        "label": "Debt Instrument, Convertible, Number of Equity Instruments",
        "terseLabel": "Total shares of common stock subject to conversion (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Amortization period of debt discount"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r413",
      "r416"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount",
        "verboseLabel": "Face amount of offering"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r38",
      "r247",
      "r413"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Interest rate",
        "terseLabel": "Interest rate on convertible senior notes"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesConvertibleDebtDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesConvertibleDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r39",
      "r396"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.",
        "label": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentMeasurementInput": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of input used to measure debt instrument, including, but not limited to, convertible and non-convertible debt.",
        "label": "Debt Instrument, Measurement Input",
        "terseLabel": "Nonconvertible debt measurement input rate"
       }
      }
     },
     "localname": "DebtInstrumentMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets",
      "http://isispharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesConvertibleDebtDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Principal amount repurchased"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r41",
      "r128",
      "r256",
      "r260",
      "r261",
      "r262",
      "r412",
      "r413",
      "r416",
      "r455"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesConvertibleDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r412",
      "r416"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedLabel": "Less: unamortized portion of debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumNet": {
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r415",
      "r416"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount (premium).",
        "label": "Debt Instrument, Unamortized Discount (Premium), Net",
        "terseLabel": "Unamortized portion of debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r119",
      "r240"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "terseLabel": "Available-for-sale Securities [Member]"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails",
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r125",
      "r354",
      "r358"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Long-term deferred tax assets"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r110",
      "r125",
      "r354",
      "r358"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred income benefit"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred [Abstract]"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred income taxes (including benefit from valuation allowance release)"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCredit": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.",
        "label": "Deferred Rent Credit",
        "verboseLabel": "Plus: lease liabilities"
       }
      }
     },
     "localname": "DeferredRentCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r125",
      "r354",
      "r358"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r328",
      "r351",
      "r352"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible and capital assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r345"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred Tax Assets [Abstract]"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r347"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Total net deferred tax assets and liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r327",
      "r351",
      "r352"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryovers"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r328",
      "r351",
      "r352"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r349",
      "r351",
      "r352"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "R&amp;D credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r327",
      "r351",
      "r352"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r346"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred Tax Liabilities [Abstract]"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesFinancingArrangements": {
     "auth_ref": [
      "r328",
      "r351",
      "r352"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from financing arrangements.",
        "label": "Deferred Tax Liabilities, Financing Arrangements",
        "negatedLabel": "Convertible debt"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFinancingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r328",
      "r351",
      "r352"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r328",
      "r351",
      "r352"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "ions_DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r283"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Matching contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/EmploymentBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r110",
      "r231"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units.",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities",
        "terseLabel": "Shares issuable related to our convertible notes"
       }
      }
     },
     "localname": "DilutiveSecuritiesEffectOnBasicEarningsPerShareOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r78",
      "r135",
      "r141",
      "r145",
      "r146",
      "r147",
      "r151",
      "r453",
      "r468"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic net income per share (in dollars per share)",
        "terseLabel": "Basic net income (loss) per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic Net Income per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r78",
      "r135",
      "r141",
      "r145",
      "r146",
      "r147",
      "r151",
      "r453",
      "r468"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Diluted net income (loss) per share (in dollars per share)",
        "terseLabel": "Diluted net income per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r119",
      "r148",
      "r149",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Basic and Diluted Net Income per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r130",
      "r334",
      "r335"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Reconciliation Between Effective and Statutory Tax Rate Percentage [Abstract]"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r334",
      "r335",
      "r357"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "U.S. federal corporate tax rate",
        "verboseLabel": "Statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails",
      "http://isispharm.com/role/IncomeTaxesTaxActDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r334",
      "r335",
      "r357"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Net change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r334",
      "r335",
      "r357"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Tax rate change"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r334",
      "r335",
      "r357"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r334",
      "r335",
      "r357"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Other nondeductible items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r334",
      "r335",
      "r357"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 14.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r334",
      "r335",
      "r357"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 17.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r334",
      "r335",
      "r357"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent",
        "verboseLabel": "Deferred tax true-up"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r334",
      "r335",
      "r357"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State income tax net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r334",
      "r335",
      "r357"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Unrecognized Compensation Expense [Abstract]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails",
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period for recognition",
        "verboseLabel": "Weighted average period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails",
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost related to non-vested RSUs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense related to non-vested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP [Member]"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Options [Member]",
        "verboseLabel": "Stock Options [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average purchase price of capital shares purchased through an employee stock ownership plan.",
        "label": "Employee Stock Ownership Plan (ESOP), Weighted Average Purchase Price of Shares Purchased",
        "terseLabel": "Purchase price (in dollars per share)"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPWeightedAveragePurchasePriceOfSharesPurchased",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Major Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityShareRepurchaseProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r401"
     ],
     "calculation": {
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNi",
       "weight": 1.0
      },
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Investment in ProQR Therapeutics N.V.",
        "verboseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetailsCalc2": {
       "order": 1.0,
       "parentTag": "ions_DebtSecuritiesAvailableForSaleAndEquitySecuritiesFvNiCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI, Cost",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGain": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r10",
      "r14",
      "r200",
      "r449",
      "r458",
      "r488"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity Securities [Member]"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r391",
      "r392",
      "r393",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r391",
      "r392"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Assets Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r392",
      "r436"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value, Hierarchy [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r391",
      "r392",
      "r395",
      "r396",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r392",
      "r437"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets (Level 1) [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r392",
      "r438"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2) [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r392",
      "r439"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3) [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r397",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring Basis [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value, Net Asset (Liability) [Abstract]",
        "terseLabel": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "localname": "FairValueNetAssetLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r119",
      "r400",
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r213",
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r225"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r222",
      "r223",
      "r225",
      "r228",
      "r441"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Estimated Amortization Expense [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r225",
      "r441"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r222",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r225"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Patents, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainOnSaleOfInvestments": {
     "auth_ref": [
      "r80",
      "r81",
      "r110",
      "r451",
      "r469"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the carrying value and the sale price of an investment.  A gain would be recognized when the sale price of the investment is greater than the carrying value of the investment.  This element refers to the Gain included in earnings and not to the cash proceeds of the sale.",
        "label": "Gain on Sale of Investments",
        "negatedLabel": "Gain on investment in Regulus Therapeutics, Inc."
       }
      }
     },
     "localname": "GainOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r110",
      "r248",
      "r249"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on early retirement of debt",
        "terseLabel": "Loss on early retirement of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r110",
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "verboseLabel": "Non-cash charges related to write-down"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://isispharm.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "terseLabel": "Pre-tax income (loss)",
        "totalLabel": "Income (loss) before income tax benefit (expense)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails",
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r125",
      "r173",
      "r360"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax benefit (expense)",
        "totalLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails",
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Reconciliation Between Effective and Statutory Tax Rate [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r119",
      "r332",
      "r333",
      "r343",
      "r344",
      "r348",
      "r362",
      "r489"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r331",
      "r334",
      "r335"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Net change in valuation allowance",
        "verboseLabel": "One-time non-cash tax benefit related to reversal of valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails",
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r330",
      "r334",
      "r335"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Tax rate change"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r123",
      "r334",
      "r335"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r124",
      "r334",
      "r335"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 15.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "terseLabel": "Other non-deductible items"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 17.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r334"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 19.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount",
        "terseLabel": "Deferred tax true-up"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r124",
      "r334",
      "r335"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State income tax net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "calculation": {
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedLabel": "Tax credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesReconciliationOfStatutoryToEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "negatedLabel": "Contracts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 26.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred contract revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.",
        "label": "Income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Long-term income tax receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 23.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in employer-related costs classified as other and current.",
        "label": "Increase (Decrease) in Other Employee-Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other current and long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "auth_ref": [
      "r144",
      "r149"
     ],
     "calculation": {
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Shares issuable related to our convertible notes"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r142",
      "r149"
     ],
     "calculation": {
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      },
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Shares issuable related to stock-based compensation (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r119",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Patent Expenses"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r75",
      "r172",
      "r411",
      "r414",
      "r454"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r102",
      "r106",
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r450",
      "r466"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.",
        "label": "Interest Payable",
        "negatedLabel": "Less: fixed and determinable interest"
       }
      }
     },
     "localname": "InterestPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Federal [Member]"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntersegmentEliminationMember": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eliminating entries used in operating segment consolidation.",
        "label": "Elimination of Intercompany Activity [Member]"
       }
      }
     },
     "localname": "IntersegmentEliminationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r49",
      "r216"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "terseLabel": "Inventory Valuation [Abstract]"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r50",
      "r119",
      "r152",
      "r217",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory Valuation"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-off"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentHoldingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Investment Holdings [Line Items]"
       }
      }
     },
     "localname": "InvestmentHoldingsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails",
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentHoldingsTable": {
     "auth_ref": [
      "r476",
      "r481",
      "r485",
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The investment holdings table is used for any listing of investments. The \"Investment [Axis]\" identifies the investment for which the line items apply. The other axes are used for categorizing the investments and creating useful subtotals. These axes cover different categorizations. The appropriate axes are expected to be used. Additional axes can be added for alternative categorizations.",
        "label": "Investment Holdings [Table]"
       }
      }
     },
     "localname": "InvestmentHoldingsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails",
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r86",
      "r87",
      "r88"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Net",
        "terseLabel": "Investment income"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentSecondaryCategorizationAxis": {
     "auth_ref": [
      "r479",
      "r480",
      "r482",
      "r483"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by second categorization of investments, which may include, but is not limited to industry.",
        "label": "Investment Secondary Categorization [Axis]"
       }
      }
     },
     "localname": "InvestmentSecondaryCategorizationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTextBlock": {
     "auth_ref": [
      "r200",
      "r202",
      "r203",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for investment.",
        "label": "Investments"
       }
      }
     },
     "localname": "InvestmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r475",
      "r478",
      "r484",
      "r487"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails",
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r475",
      "r478",
      "r484",
      "r487"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails",
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]",
        "terseLabel": "Ownership Interests in Private and Public Companies [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsContractMaturityOfAvailableforsaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsBySecondaryCategorizationDomain": {
     "auth_ref": [
      "r477",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments in the \"Investment Holdings [Table]\" and the \"Summary of Investment Holdings [Table]\" are often categorized at two levels. The first categorization is the investment type. The second categorization can vary. The usual secondary categorizations are industry, country or geography.",
        "label": "Investments by Secondary Categorization [Domain]"
       }
      }
     },
     "localname": "InvestmentsBySecondaryCategorizationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Contract Maturity of Available-for-Sale Securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandImprovementsMember": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to real estate held.",
        "label": "Land Improvements [Member]",
        "terseLabel": "Land Improvements [Member]"
       }
      }
     },
     "localname": "LandImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "Legal Proceedings"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LegalProceedings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Operating Leases [Abstract]"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Future Payments for Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://isispharm.com/role/OperatingLeasesDetailsCalc01": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://isispharm.com/role/OperatingLeasesDetailsCalc01": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Term of lease extension"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r447",
      "r464"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets",
      "http://isispharm.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License Fees [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Line of Credit Facility [Abstract]",
        "terseLabel": "Line of Credit Arrangement [Abstract]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r34",
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r34",
      "r128"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails": {
       "order": 0.0,
       "parentTag": "ions_LongTermDebtAndOtherObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "LongTermDebtAndCapitalLeaseObligationsCurrent",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Current portion of long-term obligations"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Fair value of outstanding notes"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermLoansFromBank": {
     "auth_ref": [
      "r16",
      "r445",
      "r461"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the operating cycle if longer, excluding current portion.",
        "label": "Long-term mortgage debt"
       }
      }
     },
     "localname": "LongTermLoansFromBank",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Convertible Debt [Abstract]",
        "terseLabel": "Convertible Debt [Abstract]"
       }
      }
     },
     "localname": "LongtermConvertibleDebtCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesConvertibleDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Long-Term Obligations [Abstract]"
       }
      }
     },
     "localname": "LongtermDebtCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLongtermObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ManufacturingFacilityMember": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure used in the manufacturing of goods.",
        "label": "Manufacturing Facility [Member]"
       }
      }
     },
     "localname": "ManufacturingFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Annual Debt and Other Obligation Maturities [Abstract]"
       }
      }
     },
     "localname": "MaturitiesOfLongtermDebtAndCapitalLeaseObligationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsMaturitySchedulesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Borrowing Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r45",
      "r446",
      "r463"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Noncontrolling interest in Akcea Therapeutics, Inc."
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Percentage ownership"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestPeriodIncreaseDecrease": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net Increase or Decrease in balance of noncontrolling interest in the subsidiary during the reporting period.",
        "label": "Noncontrolling Interest, Period Increase (Decrease)",
        "terseLabel": "Noncontrolling interest in Akcea Therapeutics, Inc."
       }
      }
     },
     "localname": "MinorityInterestPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r45",
      "r83",
      "r370",
      "r380"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r104",
      "r107",
      "r111"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r67",
      "r70",
      "r77",
      "r111",
      "r149",
      "r452",
      "r467"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net income",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income attributable to Ionis Pharmaceuticals, Inc. common stockholders",
        "verboseLabel": "Net income (loss) attributable to Ionis Pharmaceuticals, Inc. common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r67",
      "r70",
      "r376",
      "r382"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedLabel": "Net (income) loss attributable to noncontrolling interest in Akcea Therapeutics, Inc."
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r135",
      "r139"
     ],
     "calculation": {
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      },
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net income available to Ionis common stockholders",
        "verboseLabel": "Income (loss) available to Ionis common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r139",
      "r140"
     ],
     "calculation": {
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Income available to Ionis common shareholders, plus assumed conversions"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income (Numerator) [Abstract]"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r134",
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Impact of Recently Issued Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]",
        "terseLabel": "Segment Information [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest in Akcea Therapeutics, Inc. [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesIssued1": {
     "auth_ref": [
      "r114",
      "r115",
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value of notes issued in noncash investing and financing activities.",
        "label": "Notes Issued",
        "terseLabel": "0.125 percent convertible senior notes principal issued related to our December 2019 debt exchange/issuance"
       }
      }
     },
     "localname": "NotesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReduction": {
     "auth_ref": [
      "r114",
      "r115",
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value of notes retired (or transferred to another entity) in noncash investing or financing transactions.",
        "label": "Notes Reduction",
        "terseLabel": "1 percent convertible senior notes principal extinguished related to our December 2019 debt exchange"
       }
      }
     },
     "localname": "NotesReduction",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      },
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations",
        "verboseLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r424"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Annual Future Payments for Operating Lease Liabilities [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r422"
     ],
     "calculation": {
      "http://isispharm.com/role/OperatingLeasesDetailsCalc01": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r425",
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease cash payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r421"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r432",
      "r434"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r431",
      "r434"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Abstract]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r171",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization and Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r133",
      "r137",
      "r168",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization and Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r36"
     ],
     "calculation": {
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other miscellaneous expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "OtherAssetsNoncurrent",
        "terseLabel": "Deposits and other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r371",
      "r372",
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Change in unrealized gains (losses), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r55",
      "r60",
      "r407",
      "r408",
      "r409",
      "r410"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Currency translation adjustment",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r63",
      "r74"
     ],
     "calculation": {
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive loss before reclassifications, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r68",
      "r71",
      "r74",
      "r255"
     ],
     "calculation": {
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Net other comprehensive loss for the period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r60",
      "r64",
      "r65",
      "r199"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedLabel": "Reclassification adjustment for realized gains included in net income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r61",
      "r359",
      "r361"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "terseLabel": "Income tax expense included in other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r56",
      "r60"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "verboseLabel": "Unrealized gains (losses) on investments, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r388",
      "r390"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other Current Assets [Member]"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other expenses"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Total Ionis Stockholders' Equity [Member]"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "terseLabel": "Patents [Member]"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForHedgeFinancingActivities": {
     "auth_ref": [
      "r101",
      "r108"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.",
        "label": "Payments for Hedge, Financing Activities",
        "negatedLabel": "Purchase of note hedges",
        "terseLabel": "Purchase of note hedges"
       }
      }
     },
     "localname": "PaymentsForHedgeFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchases and retirements of common stock",
        "terseLabel": "Shares repurchased"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://isispharm.com/role/StockholdersEquityShareRepurchaseProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "0.125 percent convertible senior notes issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Offering costs paid"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r90",
      "r93",
      "r190"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBuildings": {
     "auth_ref": [
      "r94"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for acquisition of buildings (properties) whether for investment or use.",
        "label": "Payment to acquire building"
       }
      }
     },
     "localname": "PaymentsToAcquireBuildings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Research and Development and Manufacturing Facilities [Abstract]"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Employment Benefits"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/EmploymentBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r288",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Dividend rate"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Preferred Stock [Abstract]"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "verboseLabel": "Proceeds from the issuance of 0.125 percent convertible senior notes"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from building mortgage debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from issuance of common stock in Akcea Therapeutics, Inc. from its initial public offering, net of underwriters' discount"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from the issuance of common stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from the sale of Akcea Therapeutics, Inc. common stock to Novartis in a private placement",
        "terseLabel": "Proceeds from sale of common stock to Novartis in a private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r95",
      "r321"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds from equity, net",
        "verboseLabel": "Net proceeds from stock option exercises, vesting of restricted stock units, and ESPP purchases"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from issuance of warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Proceeds from Issuance or Sale of Equity [Abstract]",
        "terseLabel": "Basis of Presentation [Abstract]",
        "verboseLabel": "Noncontrolling Interest in Akcea Therapeutics, Inc. [Abstract]"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasisOfPresentationDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesNoncontrollingInterestInAkceaTherapeuticsIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received from licensees for license fees during the current period.",
        "label": "Proceeds from License Fees Received",
        "terseLabel": "Payment received under license agreement"
       }
      }
     },
     "localname": "ProceedsFromLicenseFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r90",
      "r91",
      "r190"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sale of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Proceeds from Sale of Equity Method Investments",
        "verboseLabel": "Proceeds from the sale of Regulus Therapeutics, Inc."
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r95",
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash received from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product Sales, Net [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r67",
      "r70",
      "r103",
      "r174",
      "r179",
      "r371",
      "r375",
      "r377",
      "r382",
      "r383"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://isispharm.com/role/ConsolidatedStatementsOfComprehensiveIncomeLoss",
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r31",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r30",
      "r232"
     ],
     "calculation": {
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r234",
      "r465"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r29",
      "r119",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsOperatingLeasesDetails",
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "auth_ref": [
      "r25"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of inventory held.",
        "label": "Inventory [Axis]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.",
        "label": "Inventory [Domain]"
       }
      }
     },
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesInventoryValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Quarterly Financial Data (Unaudited) [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/QuarterlyFinancialDataUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r119",
      "r183",
      "r185",
      "r186",
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Contracts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r63",
      "r66",
      "r74"
     ],
     "calculation": {
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedLabel": "Amounts reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "Accumulated Other Comprehensive Loss [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Gross Unrecognized Tax Benefits [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.",
        "label": "Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security",
        "negatedLabel": "Principal payments on debt and capital lease obligations"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebtAndCapitalSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-term Lines of Credit",
        "terseLabel": "Payment of outstanding borrowings"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r326",
      "r491"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Research and Development Expense [Abstract]",
        "terseLabel": "Research, Development and Patent Expenses [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r119",
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and Development [Member]"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock Awards [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units [Member]",
        "verboseLabel": "RSUs [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesStockbasedCompensationExpenseDetails",
      "http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails",
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r263",
      "r462"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "verboseLabel": "Revenue Recognition [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r272",
      "r273"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails",
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "verboseLabel": "Revenue [Member]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r120",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r120",
      "r121"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r76",
      "r170",
      "r171",
      "r177"
     ],
     "calculation": {
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Line of Credit [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsLineOfCreditArrangementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r430",
      "r434"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Changes in Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r41",
      "r128",
      "r256",
      "r260",
      "r261",
      "r262",
      "r412",
      "r413",
      "r416",
      "r455"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Long-Term Obligations"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Net Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r141",
      "r143",
      "r147",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": {
     "auth_ref": [
      "r141",
      "r143",
      "r147",
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]",
        "terseLabel": "Basic Net Income per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Statutory to Effective Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r287",
      "r317",
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r287",
      "r317",
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure about the extent of the entity's reliance on its major customers.",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskContractsReceivableFromSignificantPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r222",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Income (Loss) Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r25",
      "r26",
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r31",
      "r234"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/LongtermObligationsAndCommitmentsResearchAndDevelopmentAndManufacturingFacilitiesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Quarterly Financial Data"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r169",
      "r174",
      "r175",
      "r176",
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r169",
      "r174",
      "r175",
      "r176",
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Segment Information"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r288",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesStockbasedCompensationExpenseDetails",
      "http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails",
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails",
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails",
      "http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r294",
      "r306",
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Weighted-Average Assumptions for ESPP"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Weighted-Average Assumptions for Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r42",
      "r127",
      "r251",
      "r252",
      "r254",
      "r256",
      "r257",
      "r258",
      "r260",
      "r261",
      "r262",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of investments in an unrealized loss position for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), including: (a) the aggregate related fair value of investments with unrealized losses, (b) the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value).",
        "label": "Schedule of Temporary Impairment Losses, Investments [Table Text Block]",
        "terseLabel": "Temporarily Impaired Investments"
       }
      }
     },
     "localname": "ScheduleOfTemporaryImpairmentLossesInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r342",
      "r356"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Gross Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Amortization Expense for Patents"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r160",
      "r162",
      "r163",
      "r164",
      "r403",
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Revenue from Collaborative Relationship"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Information and Concentration of Business Risk [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]",
        "terseLabel": "Segment Information [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesSegmentInformationDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting, Disclosure of Other Information about Entity's Reportable Segments [Abstract]",
        "terseLabel": "Segment Information [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingDisclosureOfOtherInformationAboutEntitysReportableSegmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Information and Concentration of Business Risk"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRisk"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SelectedQuarterlyFinancialInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Selected Quarterly Financial Information [Abstract]",
        "terseLabel": "Quarterly Financial Data (Unaudited) [Abstract]"
       }
      }
     },
     "localname": "SelectedQuarterlyFinancialInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r85",
      "r215"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series C Junior Participating Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement, Disclosure [Abstract]",
        "terseLabel": "Stock Plans [Abstract]"
       }
      }
     },
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]",
        "terseLabel": "Stock-Based Compensation [Abstract]",
        "verboseLabel": "Stock-Based Compensation Expense [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesStockbasedCompensationExpenseDetails",
      "http://isispharm.com/role/StockholdersEquityStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Period before options are exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesStockbasedCompensationExpenseDetails",
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Cancelled/forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled/forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-vested at end of period (in shares)",
        "periodStartLabel": "Non-vested at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Non-vested at end of period (in dollars per share)",
        "periodStartLabel": "Non-vested at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value per Share [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted-Average Assumptions [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesStockbasedCompensationExpenseDetails",
      "http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails",
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails",
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails",
      "http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum percentage of employee compensation used to purchase shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r295",
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "terseLabel": "Number of awards outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Average Remaining Contractual Term, Aggregate Intrinsic Value and Other [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "periodEndLabel": "Exercisable at end of period (in shares)",
        "terseLabel": "Number of options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails",
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Exercisable at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Cancelled/forfeited/expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, outstanding at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r296",
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "terseLabel": "Number of options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails",
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price Per Share [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r286",
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesStockbasedCompensationExpenseDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://isispharm.com/role/StockholdersEquityRestrictedStockUnitActivityDetails",
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails",
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails",
      "http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled/forfeited/expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "One Year from Date of Grant [Member]"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r119",
      "r288",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Award term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r312",
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockbasedValuationInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value, exercisable at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Average remaining contractual term, exercisable at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Average remaining contractual term, outstanding at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percentage of fair market value used to determine purchase price of stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "terseLabel": "Payments of tax withholdings related to vesting of employee stock awards and exercise of employee stock options (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r0",
      "r174",
      "r220",
      "r236",
      "r237",
      "r238",
      "r470"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails",
      "http://isispharm.com/role/SegmentInformationAndConcentrationOfBusinessRiskSegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r44",
      "r255"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets",
      "http://isispharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets",
      "http://isispharm.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows",
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r18",
      "r19",
      "r255",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares purchased and issued under ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r255",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock purchase (in shares)",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r255",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Issuance of common stock in connection with employee stock plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture",
        "verboseLabel": "Number of shares issued for stock option exercises, vesting of restricted stock units, and ESPP purchases (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityPreferredAndCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r19",
      "r255",
      "r263",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r18",
      "r19",
      "r255",
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock purchase"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture",
        "terseLabel": "Issuance of common stock in connection with employee stock plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "verboseLabel": "Stock Options [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockOptionActivityDetails",
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Authorized amount of share repurchase program"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityShareRepurchaseProgramDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r18",
      "r19",
      "r255",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedLabel": "Repurchases and retirements of common stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "auth_ref": [
      "r18",
      "r19",
      "r255",
      "r263"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).",
        "label": "Stock Repurchased and Retired During Period, Value",
        "negatedLabel": "Repurchases and retirements of common stock"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r18",
      "r19",
      "r255",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "terseLabel": "Shares repurchased (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityShareRepurchaseProgramDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r22",
      "r23",
      "r184"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Ionis stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets",
      "http://isispharm.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r369",
      "r370",
      "r381"
     ],
     "calculation": {
      "http://isispharm.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedBalanceSheets",
      "http://isispharm.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r118",
      "r119",
      "r253"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/StockholdersEquityShareRepurchaseProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/StockholdersEquityShareRepurchaseProgramDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/StockholdersEquityShareRepurchaseProgramDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r349"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforwards [Abstract]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesTaxCreditCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for treatment of receivables that are billable but have not been billed as of the balance sheet date.",
        "label": "Trade and Other Accounts Receivable, Unbilled Receivables, Policy [Policy Text Block]",
        "terseLabel": "Unbilled SPINRAZA Royalties"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivableUnbilledReceivablesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "verboseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsAstrazenecaDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBayerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsBiogenDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsGskDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsJanssenBiotechIncDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsNovartisDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPfizerDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsPtcTherapeuticsDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsRocheDetails",
      "http://isispharm.com/role/CollaborativeArrangementsAndLicensingAgreementsTables",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesResearchDevelopmentAndPatentExpensesDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r280",
      "r448"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Debt Securities issued by U.S. Government Agencies [Member]"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails",
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USStatesAndPoliticalSubdivisionsMember": {
     "auth_ref": [
      "r280",
      "r473"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bonds or similar securities issued by state, city, or local US governments or the agencies operated by state, city, or local governments. Debt securities issued by state governments may include bond issuances of US state authorities including, for example, but not limited to, housing authorities, dormitory authorities, and general obligations while debt securities issued by political subdivisions of US states would include, for example, debt issuances by county, borough, city, or municipal governments.",
        "label": "US States and Political Subdivisions Debt Securities [Member]",
        "terseLabel": "Debt Securities issued by States of the U.S. and Political Subdivisions of the States [Member]"
       }
      }
     },
     "localname": "USStatesAndPoliticalSubdivisionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails",
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r280",
      "r282",
      "r448"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "Debt Securities issued by the U.S. Treasury [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsInvestmentsTemporarilyImpairedDetails",
      "http://isispharm.com/role/InvestmentsSummaryOfInvestmentsDetails",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Summary of Investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r329",
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance of unrecognized tax benefits",
        "periodStartLabel": "Beginning balance of unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Decrease for prior period tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest and penalties on unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increase for current period tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increase for prior period tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized tax benefits that could impact effective tax rate, if recognized"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r155",
      "r156",
      "r158",
      "r159",
      "r165",
      "r166",
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)",
        "terseLabel": "Decrease in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/StockholdersEquityStockPlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Effect of Diluted Securities [Abstract]"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r140",
      "r147"
     ],
     "calculation": {
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Shares used in computing diluted net income per share (in shares)",
        "totalLabel": "Shares used in computing diluted net income per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r138",
      "r147"
     ],
     "calculation": {
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      },
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Shares used in computing basic net income (loss) per share (in shares)",
        "terseLabel": "Shares used in computing basic net income per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/ConsolidatedStatementsOfOperations",
      "http://isispharm.com/role/OrganizationAndSignificantAccountingPoliciesBasicAndDilutedNetIncomePerShareDetails",
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Shares (Denominator) [Abstract]"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://isispharm.com/role/QuarterlyFinancialDataUnauditedDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 19
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3581-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(d),(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1278-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1930-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=118952077&loc=d3e1280-108306"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "310",
   "URI": "http://asc.fasb.org/topic&trid=2196771"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117546-209714"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "321",
   "URI": "http://asc.fasb.org/topic&trid=75115024"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "325",
   "URI": "http://asc.fasb.org/topic&trid=2197064"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031898-161870"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21459-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32059-109318"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e39076-109324"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-04)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355119-122828"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32157-110900"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28567-108399"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902458&loc=d3e39896-112707"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=84164758&loc=d3e45031-112735"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918631-209977"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12.2(ii))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(b))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C.1(b),2)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12C(2))-",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r492": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r493": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r494": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r495": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r496": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r497": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "303",
   "Subparagraph": "(5)"
  },
  "r498": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r499": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6871275664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements and Licensing Agreements, AstraZeneca (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2015 </div>
<div>USD ($) </div>
<div>PerformanceObligation</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($) </div>
<div>PerformanceObligation</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Drug</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>Program</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($) </div>
<div>LicenseFee</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Drug</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2014 </div>
<div>PerformanceObligation</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,122,599<span></span>
</td>
<td class="nump">$ 599,674<span></span>
</td>
<td class="nump">$ 514,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember', window );">R&amp;D Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770,149<span></span>
</td>
<td class="nump">344,752<span></span>
</td>
<td class="nump">$ 394,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember', window );">AstraZeneca [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 40,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 40,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember', window );">AstraZeneca [Member] | Revenue [Member] | Strategic Partner [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember', window );">AstraZeneca [Member] | R&amp;D Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,100<span></span>
</td>
<td class="nump">$ 120,700<span></span>
</td>
<td class="nump">$ 21,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember', window );">Cardiovascular, Renal and Metabolic Diseases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfLicensedDrugs', window );">Number of licensed drugs | Drug</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones', window );">Minimum amount of payments receivable for license fees and milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones', window );">Maximum amount of payments receivable for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones', window );">Maximum amount of payments receivable for regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NextPotentialPayment', window );">Next prospective payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CumulativePaymentsReceived', window );">Cumulative payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations', window );">Number of separate performance obligations | PerformanceObligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfLicenseFeesEarned', window );">Number of license fees earned | LicenseFee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember', window );">Cardiovascular, Renal and Metabolic Diseases [Member] | ION532 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember', window );">Cardiovascular, Renal and Metabolic Diseases [Member] | IOIN839 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember', window );">Cardiovascular, Renal and Metabolic Diseases [Member] | R&amp;D Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation', window );">Cumulative payments included in transaction price for performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember', window );">Oncology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones', window );">Minimum amount of payments receivable for license fees and milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones', window );">Maximum amount of payments receivable for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones', window );">Maximum amount of payments receivable for regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CumulativePaymentsReceived', window );">Cumulative payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations', window );">Number of separate performance obligations | PerformanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfPerformanceObligationsCompleted', window );">Number of performance obligations completed | PerformanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NumberOfProgramsAdvanced', window );">Number of programs advanced | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember', window );">Oncology [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NextPotentialPayment', window );">Next prospective payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember', window );">Oncology [Member] | Danvatirsen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember', window );">Oncology [Member] | ION736 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CollaborativeArrangementAndLicensingAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative payments received since inception of the collaboration agreement included in the transaction price for the performance obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CumulativePaymentsIncludedInTransactionPriceForPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CumulativePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative amount of payments received under the collaboration agreement as of the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CumulativePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for development milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for regulatory milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount of payments receivable for license fees and substantive milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MinimumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NextPotentialPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The next potential payment to be earned under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NextPotentialPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfLicenseFeesEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of license fees earned during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfLicenseFeesEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfLicensedDrugs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of drugs that have been licensed under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfLicensedDrugs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfPerformanceObligationsCompleted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of performance obligations completed under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfPerformanceObligationsCompleted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NumberOfProgramsAdvanced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of programs advanced under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NumberOfProgramsAdvanced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of separate performance obligations under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration the Company earned or is eligible to earn under the collaboration agreement, including any variable consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payments received during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsAstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInJuly2015WithAstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ION532Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ION532Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ION839Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ION839Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_DanvatirsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_DanvatirsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ION736Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ION736Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6881681232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employment Benefits (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge', window );">Employee contribution limit per calendar year for employees under 50 years of age</a></td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge', window );">Employee contribution limit per calendar year for employees over 50 years of age</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Matching contributions</a></td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The limit of annual employee contributions to the plan per calendar year by eligible employees who are over 50 years of age.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsOverFiftyYearsAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The limit of annual employee contributions to the plan per calendar year by eligible employees who are under 50 years of age.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_DefinedContributionPlanEmployeeContributionLimitByPlanParticipantsUnderFiftyYearsAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7043669344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative Arrangements and Licensing Agreements, Roche (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($) </div>
<div>PerformanceObligation</div>
</th>
<th class="th">
<div>Apr. 30, 2013 </div>
<div>USD ($) </div>
<div>PerformanceObligation</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,122,599<span></span>
</td>
<td class="nump">$ 599,674<span></span>
</td>
<td class="nump">$ 514,179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember', window );">R&amp;D Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770,149<span></span>
</td>
<td class="nump">344,752<span></span>
</td>
<td class="nump">$ 394,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember', window );">Roche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,300<span></span>
</td>
<td class="nump">$ 72,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember', window );">Roche [Member] | Revenue [Member] | Strategic Partner [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember', window );">Roche [Member] | R&amp;D Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,000<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="nump">$ 55,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember', window );">Huntington's Disease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones', window );">Maximum amount of payments receivable for license fees and milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones', window );">Maximum amount of payments receivable for development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones', window );">Maximum amount of payments receivable for regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones', window );">Maximum amount of payments receivable for commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped', window );">Maximum amount of payment receivable for each additional drug developed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NextPotentialMilestonePayment', window );">Next prospective milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations', window );">Number of separate performance obligations | PerformanceObligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember', window );">Huntington's Disease [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CumulativePaymentsReceived', window );">Cumulative payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember', window );">IONIS-FB-L for Complement-Mediated Diseases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract', window );"><strong>Collaborative Arrangement and Licensing Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones', window );">Maximum amount of payments receivable for license fees and milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">684,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_NextPotentialMilestonePayment', window );">Next prospective milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations', window );">Number of separate performance obligations | PerformanceObligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RevenueFromContractWithCustomerTransactionPrice', window );">Transaction price</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ions_RoyaltyPercentageReceivedOnNetSalesOfDrug', window );">Royalty percentage received on net sales of drug</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CollaborativeArrangementAndLicensingAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CollaborativeArrangementAndLicensingAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_CumulativePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative amount of payments received under the collaboration agreement as of the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_CumulativePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for each additional drug developed under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentReceivableForEachAdditionalDrugDeveloped</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for commercialization milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for development milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for license fees and substantive milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForLicenseFeesAndSubstantiveMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of payments receivable for regulatory milestones under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_MilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments received during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_MilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_NextPotentialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The next potential milestone payment to be earned under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_NextPotentialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of separate performance obligations under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RevenueFromContractWithCustomerTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration the Company earned or is eligible to earn under the collaboration agreement, including any variable consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RevenueFromContractWithCustomerTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_RoyaltyPercentageReceivedOnNetSalesOfDrug">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty percentage received on the net sales of a drug by a collaboration partner under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_RoyaltyPercentageReceivedOnNetSalesOfDrug</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ions_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payments received during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ions_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ions_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ions_ResearchAndDevelopmentRevenueUnderCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsRocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2013WithRocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
